<SEC-DOCUMENT>0001193125-23-012061.txt : 20230120
<SEC-HEADER>0001193125-23-012061.hdr.sgml : 20230120
<ACCEPTANCE-DATETIME>20230120163122
ACCESSION NUMBER:		0001193125-23-012061
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20230120
DATE AS OF CHANGE:		20230120

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scilex Holding Co
		CENTRAL INDEX KEY:			0001820190
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-269205
		FILM NUMBER:		23541442

	BUSINESS ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303
		BUSINESS PHONE:		(650) 516-4310

	MAIL ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Scilex Holding Company/DE
		DATE OF NAME CHANGE:	20221117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vickers Vantage Corp. I
		DATE OF NAME CHANGE:	20200804
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d428534d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-269205 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 28,128,422 Shares of Common Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">This prospectus relates to the resale from time to time of up to 28,128,422 shares of common stock, par value $0.0001 per share (the
&#147;Common Stock&#148;), of Scilex Holding Company, a Delaware corporation (&#147;Scilex&#148;), by B. Riley Principal Capital II, LLC, a Delaware limited liability company (the &#147;Selling Securityholder&#148;). The shares included in this
prospectus consist of shares of Common Stock that we have issued or that we may, in our discretion, elect to issue and sell to the Selling Securityholder, from time to time after the date of this prospectus, pursuant to a standby equity purchase
agreement we entered into with the Selling Securityholder on January 8, 2023 (the &#147;B. Riley Purchase Agreement&#148;), in which the Selling Securityholder has committed to purchase from us, at our direction, up to $500,000,000 of our Common
Stock, subject to terms and conditions specified in the B. Riley Purchase Agreement. As consideration for the Selling Securityholder&#146;s irrevocable commitment to purchase shares of our Common Stock at our election and in our discretion from time
to time after the date of this prospectus and prior to the first day of the month next following <FONT STYLE="white-space:nowrap">the&nbsp;36-month&nbsp;anniversary</FONT> of the date on which this registration statement has been declared effective
by the Securities and Exchange Commission, upon the terms and subject to the satisfaction of the conditions set forth in the B. Riley Purchase Agreement, we have agreed to issue to the Selling Securityholder 250,000 shares of Common Stock pursuant
to the terms of the B. Riley Purchase Agreement (the &#147;Commitment Shares&#148;). See the section of this prospectus titled &#147;<I>Committed Equity Financing</I>&#148; for a description of the B. Riley Purchase Agreement and the section titled
&#147;<I>Selling Securityholder</I>&#148; for additional information regarding the Selling Securityholder. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">Our registration of the
securities covered by this prospectus does not mean that the Selling Securityholder will offer or sell any of the shares of Common Stock. The Selling Securityholder may offer, sell, or distribute all or a portion of its shares of Common Stock
publicly or through private transactions at prevailing market prices or at negotiated prices. We will not receive any proceeds from the sale of shares of Common Stock by the Selling Securityholder pursuant to this prospectus. However, we may receive
up to $500,000,000 in aggregate gross proceeds from sales of our Common Stock to the Selling Securityholder that we may, in our discretion, elect to make, from time to time after the date of this prospectus, pursuant to the B. Riley Purchase
Agreement. We provide more information about how the Selling Securityholder may sell or otherwise dispose of the shares of our Common Stock in the section titled &#147;<I>Plan of Distribution</I>.&#148; We will bear all costs, expenses and fees in
connection with the registration of the shares of Common Stock offered hereby. The Selling Securityholder will bear all commissions and discounts, if any, attributable to its sales of the shares of Common Stock offered hereby. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">The Selling Securityholder is an &#147;underwriter&#148; within the meaning of Section&nbsp;2(a)(11) of the U.S. Securities Act of 1933, as
amended (the &#147;Securities Act&#148;), and any profits on the sales of shares of our Common Stock by the Selling Securityholder and any discounts, commissions or concessions received by the Selling Securityholder are deemed to be underwriting
discounts and commissions under the Securities Act. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">Our Common Stock is listed on the Nasdaq Capital Market under the symbol
&#147;SCLX&#148;. On January&nbsp;19, 2023, the last reported sales price per share of our Common Stock was $10.62. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">We are an
&#147;emerging growth company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;) and, as such, we have elected to comply with certain reduced public company reporting requirements for this
prospectus and future filings with the Securities and Exchange Commission. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">We may amend or supplement this prospectus from time to time
by filing amendments or supplements as required. You should read this prospectus, together with additional information described under the heading &#147;<I>Where You Can Find More Information</I>&#148;, and any amendments or supplements carefully
before you invest in any of our securities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:5%; font-size:10.5pt; font-family:Times New Roman"><B>INVESTING IN OUR COMMON STOCK INVOLVES SUBSTANTIAL RISKS. YOU SHOULD REVIEW CAREFULLY THE
RISKS AND UNCERTAINTIES DESCRIBED UNDER THE HEADING &#147;<A HREF="#rom428534_11">RISK FACTORS</A>&#148; BEGINNING ON PAGE 13 OF THIS PROSPECTUS. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus
is January 20, 2023 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_1">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">v</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_2">CERTAIN DEFINED TERMS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">vii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_3">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_4">The Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_5">Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_5a">Recent Developments </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_6">Committed Equity Financing</A>s</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_7">Emerging Growth Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_8">Summary Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_9">Corporate Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_10">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_11">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_12">Risks Related to our Limited Operating History, Financial Condition and Capital
 Requirements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_13">Risks Related to our Commercial Operations and Product
Development</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_14">Risks Related to our Business and Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_15">Risks Related to Scilex&#146;s Intellectual Property</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_16">Risks Related to Government Regulations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_17">Risks Related to our Relationship with Sorrento</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_18">Risks Related to this Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_19">Risks Related to Ownership of our Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_20">COMMITTED EQUITY FINANCING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_201">Advances of Common Stock Under B. Riley Purchase Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_202">Additional Advances of Common Stock under B. Riley Purchase
Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_203">Conditions to Each Advance and Additional Advance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_204">Termination of the B. Riley Purchase Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_205">No Short-Selling by Securityholder</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_206">Effect of Sales of our Common Stock under the B. Riley Purchase Agreement on
our Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_21">MARKET AND INDUSTRY DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_22">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_23">DETERMINATION OF OFFERING PRICE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_24">MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_25">Market Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_26">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_27">Securities Authorized for Issuance under Equity Compensation
Plans</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_28">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_29">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_30">Overview</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_31">Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_32">Recent Developments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_33">Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on Our
Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_34">Comparability of Our Results and Our Relationship with
Sorrento</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_35">Components of Our Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_36">Operating Costs and Expenses</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_37">Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_38">Comparison of Nine Months Ended September&nbsp;30, 2022 and
2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_39">Comparison of Years Ended December&nbsp;31, 2021 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_40">Comparison of Years Ended December&nbsp;31, 2020 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_41">Liquidity and Capital Resources</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_42">Debt Financings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_43">Critical Accounting Policies and Estimates</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_44">Recent Accounting Pronouncements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_45">Quantitative and Qualitative Disclosures About Market Risk</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_46">Emerging Growth Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_47">Smaller Reporting Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_48">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_49">The Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_50">Our Marketed Product and Pipeline</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_51">Our Strategy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_52">Our Management Team</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_53">Our Product Portfolio</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_54">Commercialization and Market Access</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_55">Clinical Development Overview</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_56">Medical Affairs</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_57">Manufacturing and Supply Chain</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_58">Competition</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_59">Material Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_60">Intellectual Property</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_61">Government Regulation and Product Approval</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_62">Employees and Human Capital Resources</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_63">Facilities and Properties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_64">Legal Proceedings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_65">Our Corporate History</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_66">Website</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_67">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_68">Executive Officers and Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_69">Family Relationships</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_70">Board Composition</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_71">Controlled Company Exemption</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_72">Director Independence</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_73">Role of Board in Risk Oversight Process</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_74">Board Leadership Structure</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_75">Board Diversity</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_76">Committees of our Board</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_77">Code of Business Conduct and Ethics</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_78">Compensation Committee Interlocks and Insider Participation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_79">Limitation of Liability and Indemnification of Directors and
Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_80">EXECUTIVE AND DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_81">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_82">Summary Compensation Table</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_83">Narrative Disclosure to Summary Compensation Table</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_84">Potential Payments upon Termination or Change in Control</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_85">Perquisites, Health, Welfare and Retirement Benefits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_86">Pension Benefits and Nonqualified Deferred Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_87">Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End
</FONT> 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_88">Equity-Based Incentive Plans</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_89">Emerging Growth Company Status</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_90">Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_91">Director Compensation Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_92">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_93">Certain Relationships of Vickers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_94">Certain Relationships of Legacy Scilex</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_95">PRINCIPAL SECURITYHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_96">SELLING SECURITYHOLDER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_97">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_98">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_207">U.S. Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_208">Non-U.S. Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_209">Foreign Account Tax Compliance Act</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_99">DESCRIPTION OF OUR SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_100">General</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_101">Authorized and Outstanding Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_210">Our Common Stock </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_102">Our Preferred Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_103">Registration Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_104">Anti-Takeover Matters in our Governing Documents and Under Delaware
Law</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_105">Conflicts of Interest</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_106">Rights of Appraisal and Payment</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_107">Stockholders&#146; Derivative Actions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_108">Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_109">Transfer Agent and Registrar</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_110">Listing</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_111">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_112">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_113">CHANGE IN AUDITORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_114">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom428534_115">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information we have provided in this prospectus, any applicable prospectus
supplement and any related free writing prospectus. Neither we nor the Selling Securityholder have authorized anyone to provide you with information different from that contained in this prospectus, any applicable prospectus supplement or any
related free writing prospectus. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. You
must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the
information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the document, regardless of the time of delivery of this prospectus or any sale of a
security. Since the date of this prospectus and the documents incorporated by reference into this prospectus, our business, financial condition, results of operations and prospects may have changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Investors Outside the United States</B>: The Selling Securityholder is offering to sell, and seeking offers to buy, the securities offered by this
prospectus only in jurisdictions where offers and sales are permitted. Neither we nor the Selling Securityholder have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action
for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities
offered by this prospectus and the distribution of this prospectus outside the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> that we filed with the Securities
and Exchange Commission (the &#147;SEC&#148;) using the &#147;shelf&#148; registration process. Under this shelf registration process, the Selling Securityholder may, from time to time, sell the securities offered by it described in this prospectus.
We will not receive any proceeds from the sale by such Selling Securityholder of the securities offered by it described in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the Selling Securityholder have authorized anyone to provide you with any information or to make any representations other than
those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling Securityholder take responsibility for, and can
provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the Selling Securityholder will make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or
change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you
in the section of this prospectus titled &#147;<I>Where You Can Find More Information</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, we
consummated the previously-announced business combination (the &#147;Business Combination&#148;) pursuant to that certain Agreement and Plan of Merger, dated as of March&nbsp;17, 2022 (as amended, restated or supplemented from time to time,
including by Amendment No.&nbsp;1 to Agreement and Plan of Merger, dated as of September&nbsp;12, 2022) (the &#147;Merger Agreement&#148;), by and among us, Vantage Merger Sub Inc., our then-wholly owned subsidiary (the &#147;Merger Sub&#148;), and
the <FONT STYLE="white-space:nowrap">pre-Business</FONT> Combination Scilex Holding Company (&#147;Legacy Scilex&#148;). Pursuant to the terms of the Merger Agreement, we effected a deregistration under the Cayman Islands Companies Act (as revised)
and a domestication under Section&nbsp;388 of the Delaware General Corporation Law, as amended (the &#147;DGCL&#148;), pursuant to which our jurisdiction of incorporation was changed from the Cayman Islands to the State of Delaware (the
&#147;Domestication&#148;), and, on the terms and subject to the conditions set forth in the Merger Agreement and in accordance with the DGCL, Merger Sub merged with and into Legacy Scilex (the &#147;Merger&#148; or the &#147;Business
Combination&#148;), with Legacy Scilex surviving as our wholly owned subsidiary. In connection with the Business Combination, we changed our name from Vickers Vantage Corp. I to Scilex Holding Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, references in this prospectus to the &#147;Company,&#148; &#147;Scilex,&#148; &#147;we,&#148;
&#147;us,&#148; &#147;our,&#148; and similar terms refer to Scilex Holding Company, a Delaware corporation formerly known as Vickers Vantage Corp. I, and its consolidated subsidiaries. References to &#147;Legacy Scilex&#148; refer to the private
Delaware corporation that is now our wholly owned subsidiary, named Scilex, Inc. (formerly known as Scilex Holding Company). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual
documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those
documents as described below under &#147;<I>Where You Can Find More Information</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_1"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain statements contained in this prospectus may constitute &#147;forward-looking statements&#148; for purposes of federal securities laws.
Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements appear in a number of places in this prospectus including, without limitation, in the sections titled
&#147;<I>Business</I>&#148; and &#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>.&#148; In addition, any statements that refer to projections, forecasts or other characterizations of future
events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as &#147;plan,&#148; &#147;believe,&#148; &#147;expect,&#148; &#147;anticipate,&#148;
&#147;contemplate,&#148; &#147;intend,&#148; &#147;outlook,&#148; &#147;estimate,&#148; &#147;forecast,&#148; &#147;project,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;may,&#148; &#147;might,&#148; &#147;possible,&#148;
&#147;potential,&#148; &#147;predict,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; and other similar words and expressions (including the negative of any of the foregoing), but the absence of these words does not mean that a
statement is not forward-looking. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on information available as of the date of this prospectus
and our managements&#146; current expectations, forecasts and assumptions, and involve a number of judgments, known and unknown risks and uncertainties and other factors, many of which are outside the control of the Company and our directors,
officers and affiliates. There can be no assurance that future developments will be those that have been anticipated. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to
be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in &#147;<I>Risk Factors,</I>&#148; our periodic filings with the SEC
and the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain the listing of our Common Stock on the Nasdaq Capital Market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our public securities&#146; liquidity and trading; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise financing in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of any legal proceedings that may be instituted against us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain qualified directors, officers, employees and key personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to compete effectively in a highly competitive market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the competition from larger pharmaceutical companies that have greater resources, technology, relationships
and/or expertise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to protect and enhance our corporate reputation and brand; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact from future regulatory, judicial and legislative changes in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of any of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to research, discover and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to grow and manage growth profitably; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain intellectual property protection and not infringe on the rights of others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to execute our business plans and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and other similar disruptions in the
future; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors detailed under the section of this prospectus titled &#147;<I>Risk Factors</I>.&#148;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should one or more of these risks or uncertainties materialize or should any of the
assumptions made by our management prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the continuing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. We do not undertake any obligation to update, add or
to otherwise correct any forward-looking statements contained herein to reflect events or circumstances after the date they were made, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or
otherwise, except as may be required under applicable securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vi </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_2"></A>CERTAIN DEFINED TERMS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Board</I>&#148; means the board of directors of the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Business Combination</I>&#148; means the merger contemplated by the Merger Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Bylaws</I>&#148; means the Bylaws of Scilex Holding Company, effective as of November&nbsp;10, 2022.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Certificate of Designations</I>&#148; means the Certificate of Designations of the Company, designating
the series of preferred stock, par value $0.0001 per share, of the Company as &#147;Series A Preferred Stock&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Certificate of Incorporation</I>&#148; means the Restated Certificate of Incorporation of Scilex Holding
Company, filed with Secretary of State of the State of Delaware on November&nbsp;10, 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Closing</I>&#148; means the closing of the Business Combination. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Closing Date</I>&#148; means date of the Closing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Code</I>&#148; means the Internal Revenue Code of 1986, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Common Stock</I>&#148; means the common stock, par value $0.0001 per share, of Scilex.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Continental</I>&#148; means Continental Stock Transfer&nbsp;&amp; Trust Company, our transfer agent.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Debt Exchange Agreement</I>&#148; means the Contribution and Satisfaction of Indebtedness Agreement,
dated as of September&nbsp;12, 2022, by and among Sorrento, Legacy Scilex and Scilex Pharmaceuticals, Inc. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>DGCL</I>&#148; means the General Corporation Law of the State of Delaware, as amended.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Domestication</I>&#148; means the change of our domicile pursuant to a transfer by way of continuation
of an exempted company out of the Cayman Islands and a domestication into the State of Delaware as a corporation, and our <FONT STYLE="white-space:nowrap">de-registration</FONT> in the Cayman Islands. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Effective Time</I>&#148; means the time at which the Business Combination became effective.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Equity Incentive Plan</I>&#148; means the Scilex Holding Company 2022 Equity Incentive Plan.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>ESPP</I>&#148; means the Scilex Holding Company 2022 Employee Stock Purchase Plan.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Exchange Act</I>&#148; means the Securities Exchange Act of 1934, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>founder shares</I>&#148; means the 3,450,000 outstanding Vickers Ordinary Shares held by the Sponsors
and the following directors of Vickers: Pei Wei Woo, Suneel Kaji and Steve Myint, which were converted into 3,450,000 shares of Common Stock in connection with the Domestication. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Funding Commitment Letter</I>&#148; means that certain letter agreement, dated as of October&nbsp;17,
2022, between Sorrento and Legacy Scilex. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>GAAP</I>&#148; means accounting principles generally accepted in the United States of America.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Initial Shareholders</I>&#148; means the Sponsors, Pei Wei Woo, Suneel Kaji and Steve Myint, each as the
holders of founder shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>IPO</I>&#148; refers to the initial public offering of 13,800,000 Units of Vickers consummated on
January&nbsp;11, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>IRS</I>&#148; means the United States Internal Revenue Service. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Legacy Scilex Board</I>&#148; means the board of directors of Legacy Scilex. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Legacy Scilex Common Stock</I>&#148; means the common stock of Legacy Scilex, par value $0.0001 per
share, prior to the Effective Time. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Legacy Scilex Preferred Stock</I>&#148; means the Series A Preferred Stock, par value $0.0001 per share,
of Legacy Scilex issued to Sorrento prior to the Effective Time pursuant to the Debt Exchange Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Maxim</I>&#148; means Maxim Group LLC, the representative of the underwriters in the IPO.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Merger Agreement</I>&#148; means that certain Agreement and Plan of Merger, dated as of March&nbsp;17,
2022, by and among us, Merger Sub and Legacy Scilex, as it may be amended or restated from time to time, including by the Merger Agreement Amendment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Merger Agreement Amendment</I>&#148; means that Amendment No.&nbsp;1 to Agreement and Plan of Merger,
dated as of September&nbsp;12, 2022, by and among us, Merger Sub and Legacy Scilex. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Merger Sub</I>&#148; means Vantage Merger Sub Inc., a Delaware corporation that was a wholly owned
subsidiary of Vickers prior to the Closing and that, pursuant to the Business Combination, was merged with and into Legacy Scilex, with Legacy Scilex continuing as our wholly owned subsidiary. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Nasdaq</I>&#148; means The Nasdaq Stock Market LLC. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Nasdaq Listing Rules</I>&#148; means the rules and listing standards of Nasdaq. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Private Placement Warrants</I>&#148; means the 6,840,000 warrants sold in a private placement to Vickers
Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd consummated on January&nbsp;11, 2021 (of which 2,736,000 were forfeited pursuant to the Sponsor Support Agreement and 3,104,000 were transferred to Sorrento pursuant to the Warrant
Transfer Agreement, in each case in connection with the Business Combination). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>public shareholders</I>&#148; means the holders of the public shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>public shares</I>&#148; means the Vickers Ordinary Shares which were sold as part of the IPO, whether
they were purchased in the IPO or in the aftermarket, including any of our Initial Shareholders to the extent that they purchase such public shares (except that our Initial Shareholders will not have conversion or tender rights with respect to any
public shares they own). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Public Warrants</I>&#148; means the redeemable warrants that were included in the Units that entitle the
holder of each whole warrant to purchase one Vickers Ordinary Share at a price of $11.50 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>SEC</I>&#148; means the U.S. Securities and Exchange Commission. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Securities Act</I>&#148; means the Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Series A Preferred Stock</I>&#148; means the preferred stock, par value $0.0001 per share, of the
Company, designated as Series A Preferred Stock pursuant to the Certificate of Designations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Sorrento</I>&#148; means Sorrento Therapeutics, Inc. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Sorrento Group</I>&#148; means Sorrento together with its affiliates, subsidiaries, successors and
assigns (other than us and our subsidiaries). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Sorrento Trigger Event</I>&#148; means the time that the Sorrento Group first ceases to beneficially own
more than 50% in voting power of the then-outstanding shares of our stock entitled to vote generally in the election of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Sponsors</I>&#148; means Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Sponsor Support Agreement</I>&#148; means that certain Sponsor Support Agreement, dated March&nbsp;17,
2022, by and among the Initial Shareholders and with Scilex, Inc. (f/k/a Scilex Holding Company). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Stockholder Agreement</I>&#148; means the Stockholder Agreement, dated as of September&nbsp;12, 2022,
between Vickers and Sorrento. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">viii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Trust Account</I>&#148; means the Trust Account of Vickers that held the proceeds from Vickers&#146;s
IPO and the private placement of the Private Placement Warrants. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Units</I>&#148; means the units of Vickers, each of which consisted of one Vickers Ordinary Share and <FONT
STYLE="white-space:nowrap">one-half</FONT> of one redeemable warrant upon the consummation of an initial business combination, which units, if not separated into its component securities as of immediately prior to the Effective Time were, without
any action on the part of the holder, separated automatically into its component securities, comprised of one share of Common Stock and <FONT STYLE="white-space:nowrap">one-half</FONT> of one warrant to purchase one share of Common Stock.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Vickers</I>&#148; means Vickers Vantage Corp. I, our predecessor company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Vickers Debt Agreement</I>&#148; means that certain Debt Contribution Agreement, dated as of
October&nbsp;17, 2022, by and among Vickers and the Sponsors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Vickers Ordinary Shares</I>&#148; means (i)&nbsp;the ordinary shares, par value $0.0001 per share, of
Vickers prior to the Domestication and (ii)&nbsp;the Common Stock following the Domestication. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Warrant Transfer Agreement</I>&#148; means that certain Warrant Transfer Agreement, dated as of
October&nbsp;17, 2022, by and among Sorrento, the Sponsors, Vickers and Maxim. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ix </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information that is presented in greater detail elsewhere in this prospectus. Because it is only a
summary, it does not contain all of the information you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in this
prospectus. Before you decide whether to purchase our securities, you should read this entire prospectus carefully, including the section of this prospectus titled &#147;Risk Factors&#148;. You should also carefully read the information in this
prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_4">
</A>The Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing <FONT
STYLE="white-space:nowrap">non-opioid</FONT> pain management products for the treatment of acute and chronic pain. We believe that our innovative <FONT STYLE="white-space:nowrap">non-opioid</FONT> product portfolio has the potential to provide
effective pain management therapies that can have a transformative impact on patients&#146; lives. We target indications with high unmet needs and large market opportunities with <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapies for the
treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our first commercial product in October 2018 and are developing our late-stage pipeline, which includes a pivotal Phase 3
candidate, a Phase 2 candidate and a Phase 1 candidate that is expected to enter into Phase 2 studies in the first half of 2023. Our commercial product, ZTlido (lidocaine topical system) 1.8% (&#147;ZTlido&#148;) is a prescription lidocaine topical
product approved by the U.S. Food and Drug Administration, for the relief of neuropathic pain associated with postherpetic neuralgia (&#147;PHN&#148;) which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion
technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration
period. Scilex licenses the rights to ZTlido from and relies exclusively on Oishi Koseido Co., Ltd. (&#147;Oishi&#148;) and Itochu Chemical Frontier Corporation (&#147;Itochu,&#148; and together with Oishi, the &#147;Developers&#148;) pursuant to
the Product Development Agreement and Commercial Supply Agreement (both as defined below). The Developers have the right to terminate the Product Development Agreement and the Commercial Supply Agreement under certain circumstances as more fully
described in the sections titled &#147;<I>Business &#151; Material Agreements &#151; Itochu and Oishi Product Development Agreement&#148; and &#147;Business &#151; Material Agreements &#151; Itochu and Oishi Commercial Supply Agreement,</I>&#148;
including, among other things, if our total net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> are equal to or less than five percent of its net sales of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> for a period
of four or more consecutive quarters. As of the date of this prospectus, our net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to
terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our three product candidates are <FONT STYLE="white-space:nowrap">(i)&nbsp;SP-102</FONT> (10 mg, dexamethasone sodium phosphate viscous gel)
(&#147;SEMDEXA&#148;), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, <FONT STYLE="white-space:nowrap">(ii)&nbsp;SP-103</FONT> (lidocaine topical
system) 5.4%, <FONT STYLE="white-space:nowrap">(&#147;SP-103&#148;),</FONT> a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of low back pain (&#147;LBP&#148;), and
<FONT STYLE="white-space:nowrap">(iii)&nbsp;SP-104</FONT> (4.5 mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release capsules) <FONT STYLE="white-space:nowrap">(&#147;SP-104&#148;),</FONT> a novel <FONT
STYLE="white-space:nowrap">low-dose</FONT> delayed-release naltrexone hydrochloride formulation for treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence
in the first half of 2023. If these product candidates are approved by the FDA, we believe each of them could become the treatment option for their respective indications in the United States. In addition, on June&nbsp;14, 2022, we entered into a
License and Commercialization Agreement (the &#147;Romeg Agreement&#148;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#147;Romeg&#148;). Pursuant to the Romeg Agreement, among other things, Romeg granted us (1)&nbsp;the right to
manufacture, promote, market, distribute and sell pharmaceutical products comprising </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liquid formulations of colchicine for the prophylactic treatment of gout (a painful arthritic disorder) in adult humans in the United States and (2)&nbsp;an exclusive, transferable license to use
the trademark &#147;GLOPERBA&#148;. GLOPERBA is an <FONT STYLE="white-space:nowrap">FDA-approved,</FONT> oral medication for the treatment of gout in adults and we are planning to commercialize GLOPERBA in 2023 and believe we are well-positioned to
market and distribute the product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Marketed Product and Innovative <FONT STYLE="white-space:nowrap">Non-Opioid</FONT> Pipeline </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on developing and commercializing innovative <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapies that will provide
safe, substantial and localized pain relief for large market opportunities. The following chart illustrates our current commercial product and novel product candidates, for which we have worldwide commercialization rights, except with respect to
Japan for ZTlido and <FONT STYLE="white-space:nowrap">SP-103.</FONT> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g428534g56j49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 960 San Antonio Road, Palo Alto, California 94303, and our
telephone number is (650) <FONT STYLE="white-space:nowrap">516-4310.</FONT> For additional information about us, please see the sections of this prospectus titled &#147;<I>Business</I>&#148; and &#147;<I>Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section titled &#147;<I>Risk Factors</I>&#148; in this prospectus for a
discussion of some of the risks related to the execution of our business strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_5"></A>Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022 (the &#147;Closing Date&#148;), Vickers consummated the previously announced Business Combination pursuant to the
terms of the Merger Agreement, by and among Vickers, Merger Sub and Legacy Scilex. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, (i)&nbsp;prior to
the Closing, Vickers changed its jurisdiction of incorporation by deregistrating as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware (the
&#147;Domestication&#148;) and (ii)&nbsp;at the Closing, and following the Domestication, Merger Sub merged with and into Legacy Scilex (the &#147;Merger&#148;), with Legacy Scilex as the surviving company in the Merger, and, after giving effect to
such Merger, Legacy Scilex became a wholly owned subsidiary of Vickers. The Merger was approved by Vickers&#146;s shareholders at a meeting held on November&nbsp;9, 2022. In connection with the Business Combination, Vickers changed its name to
&#147;Scilex Holding Company.&#148; </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms and subject to the conditions of the Merger Agreement, at the
Effective Time, (i)&nbsp;each outstanding share of Legacy Scilex Common Stock outstanding immediately prior to the Effective Time was automatically cancelled in exchange for the right to receive 0.673498 shares of our Common Stock, (ii)&nbsp;each
share of Legacy Scilex Preferred Stock outstanding immediately prior to the Effective Time was cancelled in exchange for the right to receive (a)&nbsp;one share of Series A Preferred Stock and
<FONT STYLE="white-space:nowrap">(b)&nbsp;one-tenth</FONT> of one share of our Common Stock, and (iii)&nbsp;each option to purchase shares of Legacy Scilex Common Stock outstanding as of immediately prior to the Effective Time was converted into the
right to receive a comparable option to purchase shares of our Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock and Public Warrants are currently listed on
the Nasdaq Capital Market under the symbols &#147;SCLX&#148; and &#147;SCLXW,&#148; respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of holders of our Common
Stock and Warrants are governed by the Certificate of Incorporation, the Bylaws and the DGCL, and, in the case of the Warrants, the Warrant Agreement, dated January&nbsp;6, 2021, between Vickers and Continental (the &#147;Warrant Agreement&#148;).
See sections of this prospectus titled &#147;<I>Description of Our Securities</I>&#148; and &#147;<I>Certain Relationships and Related Party Transactions</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_5a"></A>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;3, 2023, we filed a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> providing certain preliminary unaudited
financial results for the one and twelve months ended December&nbsp;31, 2022, and as of December&nbsp;31, 2022, based on then-currently available information. Our independent auditor has not reviewed or audited these preliminary estimated financial
results. Our actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges. This preliminary financial data has been prepared by and is the responsibility of the Company. We have not fully
completed our review of these preliminary financial results for the one and twelve months ended December&nbsp;31, 2022, and as of December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In such Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> we estimated that: ZTlido gross sales for December 2022 were in
the range of $10.0&nbsp;million to $12.0&nbsp;million; the gross sales for ZTlido in 2022 were in the range of $93.0&nbsp;million to $98.0&nbsp;million, compared to $63.9&nbsp;million in 2021, representing growth in the range of 45% to 53%; net
sales for 2022 were in the range of $37.0&nbsp;million to $42.0&nbsp;million, compared to net sales of $31.3&nbsp;million in 2021, representing growth in the range of 18% to 34%; and, as of December&nbsp;31, 2022, our cash and cash equivalents were
in the range of $1.8&nbsp;million to $2.5&nbsp;million, and our accounts receivables were in the range of $18.0&nbsp;million to $22.0&nbsp;
million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_6"></A>Committed Equity Financings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. Riley Purchase Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
January 8, 2023, we entered into the B. Riley Purchase Agreement with the Selling Securityholder. Pursuant to the B. Riley Purchase Agreement, we have the right to sell to the Selling Securityholder up to $500,000,000 of shares of our Common Stock,
subject to certain limitations and conditions set forth in the B. Riley Purchase Agreement, from time to time during the term of the B. Riley Purchase Agreement. Sales of Common Stock to the Selling Securityholder under the B. Riley Purchase
Agreement, and the timing of any such sales, are at our option, and we are under no obligation to sell any securities to the Selling Securityholder under the B. Riley Purchase Agreement. In accordance with our obligations under the B. Riley Purchase
Agreement, we have filed the registration statement of which this prospectus forms a part with the SEC to register under the Securities Act the resale by the Selling Securityholder of up to 28,128,422 shares of Common Stock, consisting of an
aggregate amount of 250,000 Commitment Shares and up to 27,878,422 shares of Common Stock that we may elect, in our sole discretion, to issue and sell to the Selling Securityholder, from time to time under the B. Riley Purchase Agreement. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the satisfaction of the conditions to the Selling Securityholder&#146;s purchase
obligation set forth in the B. Riley Purchase Agreement, including that the registration statement of which this prospectus forms a part be declared effective by the SEC and the final form of this prospectus is filed with the SEC, we will have the
right, but not the obligation, from time to time at our discretion until the first day of the month next following the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date on which this registration statement has been declared
effective by the SEC, to direct the Selling Securityholder to purchase a specified amount of shares of Common Stock (each such sale, an &#147;Advance&#148;) by delivering an irrevocable written notice to the Selling Securityholder (each, an
&#147;Advance Notice&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock, if any, that we elect to sell to the Selling Securityholder pursuant to an
Advance will be purchased at a price equal to 98% of the VWAP (as defined below) during the period (such period, the &#147;Pricing Period&#148;) beginning at 9:30:01 a.m., New York City time, on the date of purchase of shares of Common Stock issued
and sold to the Selling Stockholder pursuant to an Advance Notice (such shares, the &#147;Advance Shares&#148;) or such later time publicly announced as the official open of the primary (or &#147;regular&#148;) trading session on the Nasdaq Capital
Market on such purchase date (the &#147;Purchase Commencement Time&#148;) and ending at the earliest of (i) 3:59 p.m., New York City Time, on the purchase date or such earlier time publicly announced as the official close of the primary (or
&#147;regular&#148;) trading session on the Nasdaq Capital Market on such purchase date, (ii)&nbsp;immediately at such time following the Purchase Commencement Time for such purchase that the total number (or volume) of shares of Common Stock traded
on the Nasdaq Capital Market during such period has exceeded the Advance Share Volume Maximum (as defined below) for such purchase and (iii)&nbsp;if we so elect in the applicable Advance Notice for such Advance (such election, a &#147;Limit Order
Discontinue Election&#148;), such time the sale price of the shares of Common Stock traded on the Nasdaq Capital Market during such Pricing Period is less than the applicable minimum price threshold determined in accordance with the B. Riley
Purchase Agreement. &#147;VWAP&#148; means, for the Common Stock for a specified period, the dollar volume-weighted average price of the Common Stock on the Nasdaq Capital Market for such period as reported by Bloomberg through its &#147;AOR&#148;
function, subject to certain exceptions, qualifications and limitations. &#147;Advance Share Volume Maximum&#148; means, with respect to an Advance, if such Advance is designated in the Advance Notice as a (i)&nbsp;purchase-Type A, a number of
shares of Common Stock that is equal to the quotient obtained by dividing (a)&nbsp;the Advance Share amount to be purchased by the Selling Securityholder, by (b) 0.10, or (ii)&nbsp;purchase-Type B, a number of shares of Common Stock that is equal to
the quotient obtained by dividing (a)&nbsp;the Advance Share amount to be purchased by the Selling Securityholder, by (b) 0.25 (in each case, subject to certain adjustments). We may also specify a certain minimum acceptable price per share in each
Advance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there is no mandatory minimum amount for any Advance, subject to the terms and conditions of the B. Riley Purchase
Agreement, an Advance may be for a number of shares of Common Stock not to exceed (i)&nbsp;with respect to an Advance, purchase-Type A, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000, and (b)&nbsp;the product of
(1) 0.10, multiplied by (2)&nbsp;the total number (or volume) of shares of Common Stock traded on the Nasdaq Capital Market during the Pricing Period for such purchase-Type A, and (ii)&nbsp;with respect to an Advance, purchase-Type B, such number of
shares of Common Stock that is equal to the lesser of: (a) 1,000,000 and (b)&nbsp;the product of (1) 0.25, multiplied by (2)&nbsp;the total number (or volume) of shares of Common Stock traded on the Nasdaq Capital Market during the Pricing Period
for such purchase-Type B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The B. Riley Purchase Agreement also provides that we have the right, but not the obligation, to sell to the
Selling Securityholder, from time to time subject to certain limitations, at our sole and absolute discretion an additional number of shares of Common Stock (each such additional sale, an &#147;Additional Advance&#148;) at a purchase price per share
equal to 98% of the VWAP during the Additional Pricing Period (as defined in the B. Riley Purchase Agreement) by delivering an irrevocable written notice to the Selling Securityholder (each, an &#147;Additional Advance Notice&#148;). The purpose of
the Additional Advance is to allow us to execute more than one advance request on a purchase date with the Selling Stockholder as each prior advance has been completed under the terms of the B. Riley Purchase Agreement. Each Additional Advance is
generally subject to terms and </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions consistent with those of an Advance, except for, among other things, the time period of the pricing period for such Additional Advance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no upper limit on the price per share that the Selling Securityholder could be obligated to pay for the Common Stock we may elect to
sell to the Selling Securityholder in any Advance or Additional Advance. We will control the timing and amount of any sales of Common Stock to the Selling Securityholder. Actual sales of shares of our Common Stock to the Selling Securityholder under
the B. Riley Purchase Agreement will depend on a variety of factors to be determined by us from time to time, which may include, among other things, market conditions, the trading price of our Common Stock, and determinations by us as to the
appropriate sources of funding for our company and its operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the B. Riley Purchase Agreement, we may not
sell any shares of Common Stock thereunder and the Selling Securityholder shall not have the obligation to purchase shares of Common Stock thereunder to the extent (but only to the extent) that after giving effect to such purchase and sale, the
aggregate number of shares of Common Stock issued thereunder would exceed 28,128,422 shares of Common Stock, which number of shares is equal to 19.9% of the aggregate amount of Common Stock issued and outstanding as of the date of the B. Riley
Purchase Agreement (the &#147;Exchange Cap&#148;), unless (i)&nbsp;we obtain stockholder approval to issue shares of Common Stock in excess of the Exchange Cap in accordance with the applicable Nasdaq Listing Rules or (ii)&nbsp;the average price of
all applicable sales of shares of Common Stock under the B. Riley Purchase Agreement equals or exceeds $4.87, which represents the &#147;Minimum Price&#148; (as such term is defined in Rule 5635 of the Nasdaq Listing Rules). Moreover, we may not
issue or sell any shares of Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by the Selling Securityholder and its affiliates (as
calculated pursuant to Section&nbsp;13(d) of the U.S. Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated thereunder), would result in the Selling
Securityholder beneficially owning more than 4.99% of the outstanding voting power or number of shares of Common Stock (the &#147;Beneficial Ownership Limitation&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net proceeds under the B. Riley Purchase Agreement to us will depend on the frequency and prices at which we sell shares of our Common
Stock to the Selling Securityholder. We expect that any proceeds received by us from such sales to the Selling Securityholder will be used for working capital and general corporate purposes, which may include capital expenditures, research and
development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital
stock. The Selling Securityholder has agreed that it and its affiliates will not engage in any short sales of the Common Stock nor enter into any transaction that establishes a net short position in the Common Stock during the term of the B. Riley
Purchase Agreement. The B. Riley Purchase Agreement will automatically terminate on the earliest to occur of (i)&nbsp;the first day of the month next following the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date on which
this registration statement has been declared effective by the SEC or (ii)&nbsp;the date on which the Selling Securityholder shall have purchased from us under the B. Riley Purchase Agreement shares of our Common Stock for an aggregate gross
purchase price of $500,000,000. We have the right to terminate the B. Riley Purchase Agreement at no cost or penalty upon five trading days&#146; prior written notice to the Selling Securityholder; provided that there are no outstanding Advance
Notices or Additional Advance Notices and all outstanding amounts owed to the Selling Securityholder have been paid. We and the Selling Securityholder may also agree to terminate the B. Riley Purchase Agreement by mutual written consent. Neither we
nor the Selling Securityholder may assign or transfer our respective rights and obligations under the B. Riley Purchase Agreement, and no provision of the B. Riley Purchase Agreement may be modified or waived by us or the Selling Securityholder
other than by an instrument in writing signed by both parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the Selling Securityholder&#146;s commitment to
purchase shares of Common Stock at our direction upon the terms and subject to the conditions set forth in the B. Riley Purchase Agreement, we issued </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
250,000 Commitment Shares to the Selling Securityholder. The B. Riley Purchase Agreement contains customary representations, warranties, conditions, and indemnification obligations of the
parties. The representations, warranties, and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements, and may be subject to
limitations agreed upon by the contracting parties. We do not know what the purchase price for our Common Stock will be and therefore cannot be certain as to the number of shares we might issue to the Selling Securityholder under the B. Riley
Purchase Agreement. Although the B. Riley Purchase Agreement provides that we may sell up to $500,000,000 of our Common Stock to the Selling Securityholder, only 28,128,422 shares of our Common Stock are being registered for resale by the Selling
Securityholder under the registration statement of which this prospectus forms a part, which represents (i)&nbsp;the 250,000 Commitment Shares that we issued to the Selling Securityholder under the B. Riley Purchase Agreement in consideration of its
commitment to purchase shares of Common Stock at our election under the B. Riley Purchase Agreement and (ii)&nbsp;up to 27,878,422 shares of Common Stock that may be issued to the Selling Securityholder from time to time, if and when we elect to
sell shares to the Selling Securityholder under the B. Riley Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when we elect to issue and sell shares to the
Selling Securityholder under the B. Riley Purchase Agreement, we may need to register for resale under the Securities Act additional shares of our Common Stock in order to receive aggregate gross proceeds equal to the $500,000,000 available to us
under the B. Riley Purchase Agreement, depending on market prices for our Common Stock. If all of the 28,128,422 shares offered by the Selling Securityholder for resale under the registration statement of which this prospectus forms a part were
issued and outstanding as of the date hereof (without taking into account the 4.99% Beneficial Ownership Limitation or the 19.9% Exchange Cap limitation), such shares would represent approximately 16.6% of the total number of shares of our Common
Stock outstanding and approximately 82.7% of the total number of outstanding shares held by <FONT STYLE="white-space:nowrap">non-affiliates,</FONT> in each case as of January&nbsp;11, 2023 (and assuming we have not otherwise issued any shares to YA
II pursuant to the Yorkville Purchase Agreement which is more fully described elsewhere in this prospectus). If we elect to issue and sell more than the 28,128,422 shares offered under this prospectus to the Selling Securityholder, which we have the
right, but not the obligation, to do, we must first register for resale under the Securities Act any such additional shares, which could cause substantial additional dilution to our stockholders. The number of shares ultimately offered for resale by
the Selling Securityholder is dependent upon the number of shares we may elect to sell to the Selling Securityholder under the B. Riley Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are substantial risks to our stockholders as a result of the sale and issuance of Common Stock to the Selling Securityholder under the
B. Riley Purchase Agreement. These risks include the potential for substantial dilution and significant declines in our stock price. See the section titled &#147;<I>Risk Factors</I>&#148; for details. Issuances of our Common Stock in this offering
will not affect the rights or privileges of our existing stockholders, except that the economic and voting interests of each of our existing stockholders will be diluted as a result of any such issuance. Although the number of shares of Common Stock
that our existing stockholders own will not decrease as a result of sales, if any, under the B. Riley Purchase Agreement, the shares owned by our existing stockholders will represent a smaller percentage of our total outstanding shares after any
such issuance to the Selling Securityholder. For more detailed information regarding the B. Riley Purchase Agreement, see the section titled &#147;<I>Committed Equity Financing</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Yorkville Purchase Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
November&nbsp;17, 2022, we entered into a standby equity purchase agreement (the &#147;Yorkville Purchase Agreement&#148;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#147;YA II&#148;), pursuant to which we will have the
right, but not the obligation, to sell to YA II up to $500,000,000 of our Common Stock. YA II is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the satisfaction of the conditions to YA II&#146;s purchase obligations set forth in the Yorkville Purchase Agreement, we will have the
right, but not the obligation, from time to time at our discretion until the first day of </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the month following <FONT STYLE="white-space:nowrap">the&nbsp;36-month&nbsp;anniversary</FONT> of the date on which the initial registration statement filed with respect to the Yorkville Purchase
Agreement has been declared effective by the SEC, to direct YA II to purchase a specified amount of shares of Common Stock (each such sale, a &#147;Yorkville Advance&#148;) by delivering written notice to YA II (each, a &#147;Yorkville Advance
Notice&#148;). The registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268607)</FONT> related to the Yorkville Purchase Agreement was filed with the SEC on November&nbsp;30,
2022, was declared effective by the SEC on December&nbsp;9, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there is no mandatory minimum amount for any Yorkville Advance, a
Yorkville Advance may be for a number of shares of Common Stock not to exceed 200% of the average of the daily trading volume of the Common Stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the five
trading days immediately preceding the date of the Yorkville Advance Notice. The shares of Common Stock, if any, that we elect to sell to YA II pursuant to a Yorkville Advance will be purchased at a price equal to 98% of the lowest daily VWAP (as
defined below) during the two consecutive trading days commencing on the date of delivery of a Yorkville Advance Notice. &#147;VWAP&#148; means, for any trading day, the daily volume weighted average price of the Common Stock for such trading day on
the Nasdaq Capital Market as reported by Bloomberg L.P. during regular trading hours. See the section of this prospectus titled &#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations &#151; Recent
Developments</I>&#148; for addition information regarding the Yorkville Purchase Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_7"></A>Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart Our Business
Startups Act of 2012 (the &#147;JOBS Act&#148;). As an emerging growth company, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth
companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended (the &#147;Sarbanes-Oxley Act&#148;), reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not
previously approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with
new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required
to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
<FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any such election to opt out is irrevocable. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will
be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new
guidance or the application of existing guidance to changes in our business could significantly affect our business, financial condition and results of operations. In addition, we are in the process of evaluating the benefits of relying on the other
exemptions and reduced reporting requirements provided by the JOBS Act, as more fully described in the section of this prospectus titled &#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations &#151;
Emerging Growth Company</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of: (i)&nbsp;the last day of the fiscal
year (a)&nbsp;following the fifth anniversary of the closing of the IPO, (b)&nbsp;in which we have total annual gross revenue of at least $1.235&nbsp;billion, or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the market
value of our common equity that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> equals or exceeds $700&nbsp;million as of the last business day of our most recently completed second fiscal quarter; and (ii)&nbsp;the date on which
we have issued more than </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. References herein to &#147;emerging growth company&#148; have the
meaning associated with it in the JOBS Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_8"></A>Summary Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to our Limited Operating History, Financial Condition and Capital Requirements </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are currently a single commercial product company that is heavily dependent on the commercial success of
ZTlido and we may be unable to generate sufficient revenue to support our operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history and have incurred significant losses since our inception. We anticipate that
we will incur continued losses for the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise substantial
doubt about our ability to continue as a going concern. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to our Commercial Operations and Product Development
</I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We obtain our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw
materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer to comply with FDA regulations, we
may not be able to find an alternative source on commercially reasonable terms, or at all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our
future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product
candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interim <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary data from our clinical
trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ZTlido and GLOPERBA may have undesirable properties that could result in significant negative consequences, and
our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to
our Business and Operations </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to retain our key executives, it may delay our development efforts and harm our business,
financial condition and results of operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any disruption in our research and development facilities could adversely affect our business, financial
condition and results of operations. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to our Intellectual Property </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are substantially dependent on the intellectual property we <FONT STYLE="white-space:nowrap">in-license</FONT>
from Oishi and Itochu, and if we lose the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize <FONT
STYLE="white-space:nowrap">SP-103</FONT> would be harmed. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We recently entered into the Romeg Agreement for the <FONT STYLE="white-space:nowrap">in-licensing</FONT> of
certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such intellectual property or if the Romeg Agreement is terminated for any reason, our ability to commercialize
GLOPERBA would be harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to maintain patent protection for ZTlido, GLOPERBA and our product candidates, or if the scope
of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks
Related to Government Regulations </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The regulatory approval processes of the FDA are lengthy, time-consuming and inherently unpredictable, and if we
are ultimately unable to obtain regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any approved product candidate will be subject to ongoing and continued regulatory review, which may result in
significant expense and limit our ability to commercialize such products. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to our Relationship with Sorrento
</I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Certain of our directors and officers may have actual or potential conflicts of interest because of their
positions with Sorrento. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are controlled by Sorrento, whose interests may differ from those of our public shareholders.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to this Offering and Ownership of our Common Stock </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is not possible to predict the actual number of shares we will sell under the B. Riley Purchase Agreement to
the Selling Securityholder, or the actual gross proceeds resulting from those sales. Further, we may not have access to the full amount available under the B. Riley Purchase Agreement with the Selling Securityholder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The sale and issuance of our Common Stock to the Selling Securityholder will cause dilution to our existing
stockholders, and the sale of the shares of Common Stock acquired by the Selling Securityholder, or the perception that such sales may occur, could cause the price of our Common Stock to fall. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Investors who buy shares of Common Stock at different times will likely pay different prices.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our management team will have broad discretion over the use of the net proceeds from our sale of shares of Common
Stock to the Selling Securityholder, if any, and you may not agree with how we use the proceeds and the proceeds may not be invested successfully. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If our operations and performance do not meet the expectations of investors or securities analysts, the market
price of our securities may decline. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to
emerging growth companies will make our Common Stock less attractive to investors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a controlled company within the meaning of the Nasdaq Listing Rules and, as a result, will qualify for,
and may rely on, exemptions from certain corporate governance requirements. Our stockholders may not have the same protection afforded to stockholders of companies that are subject to such governance requirements. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_9"></A>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the name &#147;Vickers Vantage Corp. I&#148; on February&nbsp;21, 2020 as a Cayman Islands exempted company for the
purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. On November&nbsp;9, 2022, we changed our jurisdiction of incorporation by
deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware. On November&nbsp;9, 2022, we changed our name to &#147;Scilex Holding Company&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 960 San Antonio Road, Palo Alto, California 94303, and our telephone number is (650) <FONT
STYLE="white-space:nowrap">516-4310.</FONT> Our website address is <I>www.scilexholding.com</I>. Any information contained on, or that can be accessed through, our website is not incorporated by reference into, nor is it in any way part of this
prospectus and should not be relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. You
may obtain any of the documents filed by us with the SEC at no cost from the SEC&#146;s website at <I>http://www.sec.gov.</I> </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_10"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Issuer </P></TD>
<TD>Scilex Holding Company </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock Offered by the Selling Securityholder </P></TD>
<TD>28,128,422 shares of Common Stock, consisting of (i) 250,000 Commitment Shares and (ii)&nbsp;up to 27,878,422 shares of Common Stock we may elect, in our discretion, to issue and sell to the Selling Securityholder under the B. Riley Purchase
Agreement from time to time. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Terms of the Offering </P></TD>
<TD>The Selling Securityholder will determine when and how it will dispose of any shares of Common Stock registered under this prospectus for resale. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; padding-bottom:3pt; margin-top:-2pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock Outstanding Before this Offering<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>
</P></TD>
<TD>141,598,856 shares of Common Stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock Outstanding After this Offering </P></TD>
<TD>169,727,278 shares of Common Stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>We will not receive any proceeds from the resale of shares of Common Stock included in this prospectus by the Selling Securityholder. However, we may receive up to $500,000,000 in aggregate gross proceeds under the B. Riley Purchase Agreement
from sales of Common Stock that we may elect to make to the Selling Securityholder pursuant to the B. Riley Purchase Agreement, if any, from time to time in our discretion. We expect to use the net proceeds that we receive under the B. Riley
Purchase Agreement for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures,
acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. However, we have not designated any specific uses and have no current agreement with
respect to any acquisition or strategic transaction. See &#147;<I>Use of Proceeds</I>.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Market for our Common Stock </P></TD>
<TD>Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#147;SCLX&#148;. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See &#147;<I>Risk Factors</I>&#148; beginning on page&nbsp;13 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in the securities being offered by this
prospectus. </TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares of Common Stock outstanding is based on an aggregate of 141,598,856 shares outstanding as
of January&nbsp;11, 2023, assumes that we have not otherwise issued any shares of Common Stock to YA&nbsp;II pursuant to the Yorkville Purchase Agreement (other than the 250,000 shares of Common
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Stock issued to YA II in connection with the signing of such agreement) which is more fully described elsewhere in this prospectus, and excludes: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">744,201 shares of Common Stock issuable upon the exercise of stock options outstanding under the Scilex Pharma
2017 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">16,195,178 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2019 Stock
Option Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11,003,988 shares of Common Stock issuable upon the exercise of the Warrants, with an exercise price of $11.50
per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 20,276,666 shares of Common Stock available for future issuance under the Equity Incentive Plan (which
number includes the annual increase on January&nbsp;1, 2023 (but does not include a possible increase in any subsequent year) pursuant to the provisions of such plan which provides for a possible annual increase on January&nbsp;1 of each year
beginning on January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to up to 4% of the total number of shares of our Common Stock outstanding on December&nbsp;31 of the immediately preceding year); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 2,875,759 shares of Common Stock available for future issuance under the ESPP (which number includes the
annual increase on January&nbsp;1, 2023 (but does not include a possible increase in any subsequent year) pursuant to the provisions of such plan which provides for a possible annual increase on January&nbsp;1 of each year beginning on
January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to up to 1% of the total number of shares of our Common Stock outstanding on December&nbsp;31 of the immediately preceding year). </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_11"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. Before making an investment decision, you should consider carefully the
following risk factors, as well as the other information set forth in this prospectus, including matters addressed in the section titled &#147;Cautionary Note Regarding Forward-Looking Statements&#148;. If any of these risks actually occur, it may
materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. Additionally, the risks and uncertainties
described in this prospectus, any prospectus supplement, any post-effective amendment or in any document incorporated by reference herein or therein are not the only risks and uncertainties that we face. We may face additional risks and
uncertainties that are not presently known to us, or that we currently deem immaterial. The following discussions should be read in conjunction with our financial statements and the notes to the financial statements included therein. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_12"></A>Risks Related to our Limited Operating History, Financial Condition and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are currently a single commercial product company that is heavily dependent on the commercial success of ZTlido and we may be unable to generate
sufficient revenue to support our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido is our only product approved for commercial sale and we are entirely
dependent upon its sales to generate revenue. In February 2018, we obtained regulatory approval for ZTlido for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and we began commercializing ZTlido in
the United States in October 2018. As a result, it is difficult to evaluate our current business and predict our future prospects. We cannot assure that ZTlido will gain market acceptance among physicians, health care payors, patients and the
medical community, which is critical to our commercial success. We have limited experience engaging in commercial activities and limited relationships with physicians, hospitals and payors. Market acceptance of ZTlido depends on a number of factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance by physicians, major operators of clinics and patients of the drug as a safe and effective treatment
for the relief of neuropathic pain associated with PHN; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability, cost and potential advantages of alternative treatments, including less expensive generic
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of coverage, adequacy of reimbursement and favorability of pricing policies by third-party
payors and government authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of other competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product labeling or any product inserts required by the U.S. Food and Drug Administration (the
&#147;FDA&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of adverse side effects. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to successfully commercialize ZTlido, we will need to expand our marketing efforts to develop new relationships and expand existing
relationships. Physicians may decide not to prescribe ZTlido for a variety of reasons, including changes in available offerings, adverse publicity, perceived safety issues, inadequate coverage or reimbursement for ZTlido or the utilization of
products developed by other parties, all of which are circumstances outside of our control. Demand for ZTlido may not increase as quickly as we predict, and we may be unable to increase our revenue to the level that we currently expect. Even if we
succeed in increasing market acceptance of ZTlido, maintaining and creating relationships with physicians, we may be unable to reach or sustain a level of profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to effectively promote ZTlido will also depend on pricing and cost-effectiveness, including our ability to produce at a
competitive price. In addition, our efforts to educate the medical community and third-party payors on the benefits of ZTlido may require significant resources, may be constrained by FDA rules and policies on product promotion and may never be
successful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited operating history and have incurred significant losses since our inception. We
anticipate that we will incur continued losses for the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a limited operating history. Prior to March
2019, our operations were conducted through Scilex Pharmaceuticals Inc. (&#147;Scilex Pharma&#148;), which was formed in September 2012 and is now our wholly owned subsidiary. In March 2019, we effected a corporate reorganization and acquired Semnur
Pharmaceuticals, Inc. (&#147;Semnur&#148;), which was formed in June 2013. Since our inception, we have focused on organizing and staffing our company, business planning, raising capital, identifying potential
<FONT STYLE="white-space:nowrap">non-opioid</FONT> pain therapy candidates, undertaking preclinical studies and clinical trials of our product candidates and establishing research and development and manufacturing collaborations. All of our revenue
to date is attributable to sales of ZTlido, and we expect that sales of ZTlido will account for all of our revenue for at least the near term. Our relatively short operating history as a company makes any assessment of our future success and
viability subject to significant uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in biopharmaceutical product development is highly speculative because it
entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We will
encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to overcome such risks and difficulties successfully. Our ability to execute
on our business model and generate revenues depends on a number of factors including our ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully complete ongoing <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials
and obtain regulatory approvals for our current and future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify new acquisition or <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully identify new product candidates and advance those product candidates into <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">raise additional funds when needed and on terms acceptable to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract and retain experienced management and advisory teams; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial and management information systems and personnel, including personnel to support
clinical, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> manufacturing and planned future commercialization efforts and operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launch commercial sales of our product candidates, whether alone or in collaboration with others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate and continue relationships with third-party suppliers and manufacturers and have commercial quantities
of product candidates manufactured at acceptable cost and quality levels and in compliance with the FDA, and other regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">set acceptable prices for product candidates and obtain coverage and adequate reimbursement from third-party
payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve market acceptance of product candidates in the medical community and with third-party payors and
consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cannot successfully execute any one of the foregoing, our business may not succeed or become profitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant net losses, with net losses of $88.4&nbsp;million, $47.5&nbsp;million, and
$178.6&nbsp;million for the years ended December&nbsp;31, 2021, 2020, and 2019, respectively. As of December&nbsp;31, 2021, we had an accumulated deficit of approximately $352.6&nbsp;million. For the foreseeable future, we expect to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continue to incur significant expenses related to the commercialization of ZTlido and GLOPERBA and the research and development of our product candidates,
<FONT STYLE="white-space:nowrap">SP-102</FONT> (10 mg dexamethasone sodium phosphate viscous gel) (&#147;SEMDEXA&#148;), <FONT STYLE="white-space:nowrap">SP-103</FONT> (lidocaine topical system) 5.4%
<FONT STYLE="white-space:nowrap">(&#147;SP-103&#148;),</FONT> and <FONT STYLE="white-space:nowrap">SP-104</FONT> (4.5mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release capsules) <FONT
STYLE="white-space:nowrap">(&#147;SP-104&#148;).</FONT> We anticipate that our expenses will increase substantially due to the completion of the pivotal Phase 3 trial for SEMDEXA, commencement of the Phase 2 clinical trial for <FONT
STYLE="white-space:nowrap">SP-103</FONT> and multiple Phase 1 trials for <FONT STYLE="white-space:nowrap">SP-104.</FONT> Consequently, we expect to incur substantial losses for the foreseeable future and may never become profitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to risks incidental to the development of new biopharmaceutical products, and we may encounter unforeseen expenses,
difficulties, complications, delays and other unknown factors that may adversely affect our business. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and
remain profitable could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be required to make milestone payments to the former stockholders of Semnur in connection with our development and commercialization of SEMDEXA,
which could adversely affect the overall profitability of SEMDEXA, if approved. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Agreement and Plan of
Merger we entered into with Semnur, Sigma Merger Sub, Inc., our prior wholly owned subsidiary, Fortis Advisors LLC, solely as representative of the holders of Semnur equity, or the Semnur Equityholders, and Sorrento, for limited purposes, we are
obligated to pay the Semnur Equityholders up to an aggregate of $280.0&nbsp;million in contingent cash consideration based on the achievement of certain milestones. A $40.0&nbsp;million payment will be due upon obtaining the first approval of a new
drug application by the FDA (&#147;NDA&#148;) of any Semnur product, which includes SEMDEXA. Additional payments will be due upon the achievement of certain cumulative net sales of Semnur products, as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $20.0&nbsp;million payment upon the achievement of $100.0&nbsp;million in cumulative net sales of a Semnur
product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $20.0&nbsp;million payment upon the achievement of $250.0&nbsp;million in cumulative net sales of a Semnur
product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $50.0&nbsp;million payment upon the achievement of $500.0&nbsp;million in cumulative net sales of a Semnur
product; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $150.0&nbsp;million payment upon the achievement of $750.0&nbsp;million in cumulative net sales of a Semnur
product. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These milestone obligations could impose substantial additional costs on us, divert resources from other
aspects of our business, and adversely affect the overall profitability of SEMDEXA, if approved. We may need to obtain additional financing to satisfy these milestone payments, and cannot be sure that any additional funding, if needed, will be
available on terms favorable to us, or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require substantial additional funding, which may not be available to us on acceptable
terms, or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have consumed substantial amounts of cash since inception. We expect to significantly increase
our spending to continue our commercialization efforts for ZTlido and GLOPERBA, advance development of our current product candidates and launch and commercialize any product candidates for which we receive regulatory approval. Furthermore, we
expect to incur additional costs associated with operating as a public company. We will also require additional capital to fund our other operating expenses and capital expenditures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, our cash and cash equivalents were approximately
$2.5&nbsp;million and we had an accumulated deficit of approximately $358.0&nbsp;million. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and expenses associated with our ongoing commercialization efforts for ZTlido and GLOPERBA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the degree of success we experience in commercializing ZTlido and GLOPERBA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue generated by sales of ZTlido, GLOPERBA and other products that may be approved, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of conducting studies and clinical trials for our product candidates,
SEMDEXA, <FONT STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of manufacturing ZTlido, GLOPERBA and our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current
or future collaboration or license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements
and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which ZTlido, GLOPERBA or any of our product candidates, if approved for commercialization, is
adopted by the physician community; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to expand our research and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of acquiring, licensing or investing in businesses, product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing products and product candidates and other market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and types of future products we develop and commercialize; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any product liability or other lawsuits related to our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses needed to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with being a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of public shares that are redeemed by our public shareholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending
intellectual property-related claims; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent and scope of our general and administrative expenses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we are able to generate significant revenue, if ever, we expect to finance our operations through a combination of equity offerings,
debt financings, collaborations, government contracts or other strategic transactions. We cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at all. Any additional fundraising efforts may divert our
management from their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize our product candidates. Furthermore, any additional
equity or equity-related financing may be dilutive to our stockholders, and debt or equity financing, if available, may subject us to restrictive covenants and significant interest costs. If we raise additional funds through collaborations or
strategic alliances with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or technologies, or grant licenses on terms that may not be favorable to us. If we are
unsuccessful in our efforts to raise additional financing on acceptable terms, we may be required to significantly reduce or cease our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise
substantial doubt about our ability to continue as a going concern. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Note 2 titled &#147;<I>Liquidity and Going
Concern</I>&#148; of our consolidated financial statements included elsewhere in this prospectus, we disclose that there is substantial doubt about our ability to continue as a going concern. In addition, our independent registered public accounting
firm included an explanatory paragraph in its report on our consolidated financial statements as of and for the year ended December&nbsp;31, 2021, which stated that substantial doubt existed about our ability to continue as a going concern. We have
negative working capital and have incurred significant operating losses and negative cash flows from operations and expect to continue incurring losses for the foreseeable future. Further, we had an accumulated deficit of approximately
$352.6&nbsp;million as of December&nbsp;31, 2021 and approximately $264.1&nbsp;million as of December&nbsp;31, 2020. These conditions raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do
not include any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to become a profitable operating company
is dependent upon our ability to generate revenue and obtain financing adequate to fulfill our development and commercialization activities, and achieving a level of revenue adequate to support our cost structure. We have plans to obtain additional
resources to fund our currently planned operations and expenditures through additional debt and equity financing. Our plans are substantially dependent upon the success of future sales of ZTlido, which is still in the early stages of
commercialization, and are dependent upon, among other things, the success of our marketing of ZTlido and our ability to secure additional payor contracts with terms that are consistent with our business plan. If we are unable to obtain sufficient
funding, our financial condition and results of operations will be materially and adversely affected and we may be unable to continue as a going concern. Future financial statements may disclose substantial doubt about our ability to continue as a
going concern. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide
additional funding to us on commercially reasonable terms or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have identified a material weakness in our internal control over financial
reporting. Any material weakness may cause us to fail to timely and accurately report our financial results or result in a material misstatement of our financial statements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the audit of our consolidated financial statements for the years ended December&nbsp;31, 2021 and 2020, we identified
control deficiencies in the design and operation of our internal control over financial reporting that constituted a material weakness. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial
reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2021 and 2020, the material weakness identified in our internal control over financial reporting related
to ineffective control activities in the areas of revenue, debt, derivative liabilities, cash flows and leases caused by a lack of sufficient accounting resources. As a result of the material weakness, we hired additional accounting personnel and
are implementing remediation measures including, but not limited to, performing a comprehensive assessment of accounting and finance resource requirements and hiring other personnel with sufficient accounting expertise at Sorrento to improve the
operating effectiveness of our review controls and monitoring activities, and utilizing external accounting experts as appropriate. Any potential material misstatements were identified and corrected as audit adjustments in the applicable periods and
are properly reflected in our financial statements included in this prospectus. We hired a new Chief Financial Officer in May 2022 at Legacy Scilex and she became Chief Financial Officer of the Company in connection with the closing of the Business
Combination. In addition, we expect to hire additional personnel with accounting expertise and utilize external accounting experts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the future, in order to properly manage our internal control over financial reporting, we may need to take additional measures to further augment our finance resources, and we cannot be certain that the measures we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have taken, and expect to take, to improve our internal controls will be sufficient to ensure that our internal controls will remain effective and eliminate the possibility that other material
weaknesses or deficiencies may develop or be identified in the future. If we experience future material weaknesses or deficiencies in internal controls and we are unable to correct them in a timely manner, our ability to record, process, summarize
and report financial information accurately and within the time periods specified in the rules and forms of the SEC, will be adversely affected. Any such failure could negatively affect the market price and trading liquidity of our Common Stock,
lead to delisting, cause investors to lose confidence in our reported financial information, subject us to civil and criminal investigations and penalties, and generally materially and adversely impact our business and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we identify future material weaknesses in our internal controls over financial reporting or fail to meet the demands that will be placed
upon us as a public company, including the requirements of the Sarbanes-Oxley Act as, we may be unable to accurately report our financial results or report them within the timeframes required by law or stock exchange regulations. Failure to comply
with Section&nbsp;404 of the Sarbanes-Oxley Act could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. If additional material weaknesses exist or are discovered in the future, and we are unable
to remediate any such material weakness, our business, financial condition and results of operations could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_13"></A>Risks
Related to our Commercial Operations and Product Development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We obtain our commercial supply of ZTlido, clinical supply of our product
candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer
to comply with FDA regulations, we may not be able to find an alternative source on commercially reasonable terms, or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
rely on a number of sole or single source suppliers and manufacturers, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturer and supplier for the commercial supply of ZTlido; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturer and supplier for the clinical supply of <FONT STYLE="white-space:nowrap">SP-103;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturer and supplier for the clinical supply of <FONT STYLE="white-space:nowrap">SP-104;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supplier of sodium hyaluronate, one of the excipients for SEMDEXA; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturer for the clinical supply of SEMDEXA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Product Development Agreement, dated as of May&nbsp;11, 2011, by and among Scilex Pharmaceuticals, Inc. (as successor to Stason
Pharmaceuticals, Inc.), Oishi Koseido Co., Ltd. (&#147;Oishi&#148;) and Itochu Chemical Frontier Corporation (&#147;Itochu&#148;) (as amended, the &#147;Product Development Agreement&#148;), and the Commercial Supply Agreement, dated as of
February&nbsp;16, 2017, by and among Scilex Pharma and Oishi and Itochu (as amended, the &#147;Commercial Supply Agreement&#148;), we license the rights to ZTlido from and rely exclusively on Oishi and Itochu for the manufacturing and supply of
ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> (collectively, the &#147;Products&#148;). Oishi and Itochu have the right to terminate the Product Development Agreement and the Commercial Supply Agreement under certain circumstances,
including, among other things: (1)&nbsp;if we are in material breach of the agreement and the breach is not curable or if the breach is curable and we fail to cure such material breach within 180 days after notice requesting to cure; (2)&nbsp;if, at
any time during the term of the Product Development Agreement and the Commercial Supply Agreement, the market conditions are such that (a)&nbsp;our total net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> are equal to or less
than five percent of our net sales of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> for a period of four or more consecutive quarters, or (b)&nbsp;the economic viability of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> is
affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us, on the one hand, and Oishi and Itochu, on the other hand, and the parties are unable
to resolve the concerns under the foregoing clauses (a)&nbsp;and (b)&nbsp;after 30&nbsp;days of good-faith discussion; and (3)&nbsp;in the event of our bankruptcy or assignment for the benefit of creditors. As of the date of this
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospectus, our net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate
the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. If the Product Development Agreement and the Commercial Supply Agreement are
terminated, we would lose access to the intellectual property and proprietary manufacturing process upon which ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> depend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our exclusive Supply Agreement, dated December&nbsp;17, 2015 (the &#147;Genzyme Supply Agreement&#148;), with Genzyme Corporation
(&#147;Genzyme&#148;), we depend on Genzyme to fulfill our clinical and commercial supply requirements for sodium hyaluronate, one of the excipients for SEMDEXA. Genzyme has the right to terminate the Supply Agreement under certain circumstances,
including, but not limited to: (1)&nbsp;if we are in material breach of the agreement and fail to cure such breach within 30 days of written notice of such breach, (2)&nbsp;if our development of SEMDEXA is ceased or we do not file for regulatory
approval for SEMDEXA by January&nbsp;1, 2020, or (3)&nbsp;if Genzyme decides to discontinue manufacturing the product at its facility for economic or strategic reasons and provides us with 24 months&#146; notice. We did not file for regulatory
approval for SEMDEXA by January&nbsp;1, 2020 and we are only aware of a limited number of suppliers of the excipient. In accordance with the preceding clause&nbsp;(3), Genzyme has notified us of its intention to terminate the Genzyme Supply
Agreement, effective as of May&nbsp;31, 2024. Although we are currently in the process of identifying and certifying new suppliers to fulfill our clinical and commercial supply requirements for sodium hyaluronate we may not be able to find an
alternative supplier of sodium hyaluronate on commercially reasonable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Master Services Agreement, dated January&nbsp;27,
2017 (as amended, the &#147;Lifecore Master Services Agreement&#148;), with Lifecore Biomedical, LLC (&#147;Lifecore&#148;), we depend on Lifecore to manufacture clinical supplies of SEMDEXA. Lifecore has the right to terminate the Lifecore Master
Services Agreement under certain circumstances, including, but not limited to: (1)&nbsp;if we are in material breach of the agreement and fail to cure such breach within 30 days of written notice; (2)&nbsp;if we (a)&nbsp;become insolvent,
(b)&nbsp;cease to function as a going concern, (c)&nbsp;become convicted of or plead guilty to a charge of violating any law relating to either party&#146;s business, or (d)&nbsp;engage in any act which materially impairs goodwill associated with
SEMDEXA or materially impairs the terminating party&#146;s trademark or trade name; (3)&nbsp;if we fail to pay past due invoices upon 30 days&#146; written notice, or (4)&nbsp;if we reject or fail to respond to a major change proposed by Lifecore
that does not change Semnur&#146;s written and approved acceptance criteria in its product specifications. In the event that Lifecore decides to terminate the Lifecore Master Services Agreement, finding an alternative manufacturer may be difficult.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Master Services Agreement (the &#147;Tulex Master Services Agreement&#148;) and statement of work with Tulex Pharmaceuticals
Inc. (&#147;Tulex&#148;), we depend on Tulex to develop, test and manufacture clinical supplies of <FONT STYLE="white-space:nowrap">SP-104.</FONT> Tulex has the right to terminate the Tulex Master Services Agreement under certain circumstances,
including, but not limited to: (1)&nbsp;if we are in material breach of the agreement or a statement of work and fail to cure such breach within 15 days after receipt of notice of such breach (or such other time period expressly stated in the
applicable statement of work) or (2)&nbsp;in the event of our insolvency, bankruptcy, reorganization, liquidation or receivership, or a failure to remove any insolvency, bankruptcy, reorganization, liquidation or receivership proceedings within ten
days from the date of institution of such proceedings. In addition, we may terminate the agreement or any statement of work (a)&nbsp;without cause upon 30 days prior written notice to Tulex or (b)&nbsp;immediately upon written notice in the event
Tulex is dissolved or undergoes a change in control. In the event that the Tulex Master Services Agreement or a statement of work is terminated, we may not be able to find an alternative manufacturer and supplier on commercially reasonable terms.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the manufacturing facilities used by our third-party suppliers and manufacturers must continue to comply with FDA
regulations and are subject to periodic announced or unannounced inspections. We have limited control over the ability of our third-party suppliers and manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If
our third-party suppliers and manufacturers fail to comply with FDA regulations, the FDA may not authorize the manufacture of our products and product candidates at these facilities, and we may be unable to find alternative manufacturing facilities
in a timely manner or at all. The failure by such third parties to comply with applicable regulations could result in sanctions being imposed on us, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including clinical holds, fines, injunctions, import detention, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of our product, operating restrictions and
criminal prosecutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our product candidates may compete with other product candidates and products for access to
manufacturing facilities and other supplies. There are a limited number of manufacturers that operate under current Good Manufacturing Practices (&#147;cGMP&#148;) regulations and that might be capable of manufacturing for us. Also, prior to the
approval of our product candidates, we would need to identify a contract manufacturer that could produce our products at a commercial scale and that could successfully complete FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection and
inspections by other health authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates
are disrupted or delayed, there can be no assurance that alternative sources can serve as adequate replacements or that supplies will be available on terms that are favorable to us, if at all. Any disruption in supply could affect the profitability
of ZTlido and the development of SEMDEXA, <FONT STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
rely on a single third-party logistics distribution provider, Cardinal Health 105, which until recently had also been our only customer. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on Cardinal Health 105, LLC (&#147;Cardinal Health 105&#148;) as our third-party logistics distribution provider for ZTlido
in the United States. Cardinal Health 105 also performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks, distributor fee for service, government reporting, customer returns, accounts receivable,
inventory control, product security (DSCSA serialization) inquiries and recall assistance. In the years ended December&nbsp;31, 2019, 2020 and 2021, and in the first quarter of 2022, Cardinal Health 105 was our only customer and sales to Cardinal
Health 105 represented all of our net revenue for such periods. Beginning on April&nbsp;1, 2022, we began selling ZTlido directly to three large distributors, McKesson Corporation (&#147;McKesson&#148;), Cardinal Health 110, LLC (&#147;Cardinal
Health 110&#148;) and AmerisourceBergen Corporation (&#147;AmerisourceBergen&#148;), as well as to numerous pharmacies. If we are unable to maintain a favorable relationship with Cardinal Health 105 (or with any of our other two distributors), we
expect that our revenue would decline and our business would be harmed as a result. We may be unable to control the timing of the delivery of ZTlido to distributors, and any financial uncertainty or loss of key logistic employees of Cardinal Health
105, as our only third-party logistics provider, may negatively impact our sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we continue to expand the commercialization of
ZTlido, we expanded our direct distribution network to national and regional distributors and pharmacies in the second quarter of 2022. We currently hold wholesaler licenses and commenced selling directly to our main distributor customers as well as
pharmacies. We discontinued our use of &#147;title model&#148; services provided by Cardinal Health 105, but expect that Cardinal Health 105 will continue to perform other third-party logistics services for us. Any disruption in the abovementioned
distribution channel would adversely affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to achieve certain milestones
in our Product Development Agreement with Itochu and Oishi, we could lose rights that are important to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of
our existing license and supply agreements impose various milestone and other obligations on us. For example, under our Product Development Agreement with Itochu and Oishi, if our total net profits for ZTlido and
<FONT STYLE="white-space:nowrap">SP-103</FONT> are equal to or less than five percent of our net sales of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> for a period of four or more consecutive quarters, Itochu and Oishi have the right to
terminate the Product Development Agreement if the parties are unable to resolve the concerns after 30 days of good-faith negotiation. As of the date of this prospectus, our net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT>
have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its
right of termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to achieve the milestones under the Product Development Agreement, we may lose
our exclusivity rights or the counterparty may have the right to terminate the agreement, any of which could adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our future clinical trials. If these third
parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not have the ability to independently conduct any clinical trials. The FDA and regulatory authorities in other jurisdictions
require us to comply with regulations and standards, commonly referred to as good clinical practice (&#147;GCP&#148;) requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data
and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and
other third parties, such as contract research organizations (&#147;CROs&#148;), to conduct <FONT STYLE="white-space:nowrap">GCP-compliant</FONT> clinical trials of our product candidates properly and on time. While we have agreements governing
their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our <FONT STYLE="white-space:nowrap">GCP-compliant</FONT>
clinical trials play a significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third
parties, we have limited ability to control the amount and timing of resources that they devote to our programs. Although we rely on these third parties to conduct our <FONT STYLE="white-space:nowrap">GCP-compliant</FONT> clinical trials, we remain
responsible for ensuring that each of our clinical trials is conducted in accordance with our investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities.
For any violations of laws and regulations in the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement actions that may include civil penalties up to and including criminal prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for
whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. We face the risk of potential unauthorized disclosure or infringement, misappropriation or other violation of our
intellectual property by CROs, which may reduce our trade secret and intellectual property protection and allow our potential competitors to access and exploit our proprietary technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If the
third parties conducting our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us
or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GCPs, or for any other reason, we may need to enter into new arrangements with alternative third
parties. This could be difficult, costly or impossible, and our clinical trials may need to be extended, delayed, terminated or repeated. As a result, we may not be able to obtain regulatory approval or successful commercialization in a timely
fashion, or at all, for the applicable product candidate. Our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may in the future enter into collaborations, <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements, joint ventures, or strategic
alliances with third-parties that may not result in the development of commercially viable products or the generation of significant future revenues. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is substantially dependent upon the intellectual property licensed from Oishi and Itochu. In the ordinary course of our business,
we may enter into collaborations, additional <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements (such as, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for example, the Romeg Agreement), joint ventures, or strategic alliances to develop proposed products and to pursue new markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proposing, negotiating and implementing collaborations, <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements, joint ventures,
strategic alliances or partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these opportunities or
arrangements. We may not identify, secure or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms, or at all, and may not realize the anticipated benefits of any such transactions or
arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, with respect to current and future collaborations, we may not be in a position to exercise sole
decision-making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our collaborators may have economic or business interests or goals that are, or that may become,
inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any
agreement, such as those related to financial obligations or the ownership or control of intellectual property developed during the collaboration. If any conflicts arise with our current or future collaborators, they may act in their self-interest,
which may be adverse to our best interest, and they may breach their obligations to us. In addition, we have limited control over the amount and timing of resources that our current collaborators or any future collaborators devote to our
collaborators&#146; or our future products. Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements
are contractual in nature and may be terminated or dissolved under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such
rights at a premium. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delays in clinical trials could result in increased costs to us and delay our ability to obtain commercial approval and
generate additional revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval for the sale of our product candidates, we must conduct extensive
clinical trials to demonstrate the safety and efficacy of our product candidates for their intended indications. Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be
conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining regulatory authorizations to commence a clinical trial or reaching a consensus with
regulatory authorities on trial design; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in identifying prospective clinical investigators or clinical trial sites that have necessary
qualifications, interest and capacity to perform a requested protocol; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of
which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining approval from one or more institutional review boards (&#147;IRBs&#148;);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IRBs refusing to approve, suspending or terminating the trial at the investigational site, precluding enrollment
of additional subjects, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to the clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in recruiting suitable subjects to participate in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to perform in accordance with GCPs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites,
including delays by third parties with whom we have contracted to perform certain of those functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in subjects completing participation in a trial or returning for post-treatment <FONT
STYLE="white-space:nowrap">follow-up,</FONT> including, for example, as a result of reluctance to visit medical facilities as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial sites or subjects dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of adequate funding to continue the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the
resulting data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjects experiencing severe or unexpected drug-related adverse effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, after an
inspection of our clinical trial operations, trial sites or manufacturing facilities, or for other reasons; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events in our trials or in trials of the same class of agents conducted by other
sponsors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements or guidance that require amending or submitting new clinical protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a facility manufacturing our product candidates or any of their components being ordered by the FDA to
temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any changes to our manufacturing process that may be necessary or desired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not
performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCP, or other regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party contractors not performing data collection or analysis in a timely or accurate manner; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or
regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by subcontractors in support of our marketing applications.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in
which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in
accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, participants
being exposed to unacceptable health risks, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in
regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs,
timing or successful completion of a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development costs will increase if we experience delays in testing or
marketing approvals. The FDA and other regulatory agencies may impose new or refined testing expectations based on experience and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increased knowledge over time. In addition, if we make manufacturing or other changes to our product candidates, we may need to conduct additional studies to bridge our modified product
candidates to earlier versions. We do not know whether any of our clinical trials, including our planned clinical trials of <FONT STYLE="white-space:nowrap">SP-103,</FONT> <FONT STYLE="white-space:nowrap">SP-104</FONT> and SEMDEXA, will begin or
continue as planned, will need to be restructured or will be completed on schedule, or at all. We may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of any clinical trials we
initiate in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize
our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face potential business disruptions and related risks resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which could have
a material adverse effect on our business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, a novel strain of
coronavirus, or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> was reported to have surfaced in Wuhan, China. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> is
the virus that causes <FONT STYLE="white-space:nowrap">COVID-19.</FONT> The <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak has grown into a global pandemic that has impacted countries throughout the world. Financial markets have been
experiencing extreme fluctuations that may cause a contraction in available liquidity globally as important segments of the credit markets react to the development. The pandemic may lead to a decline in business and consumer confidence. The global
outbreak of <FONT STYLE="white-space:nowrap">COVID-19</FONT> continues to rapidly evolve. As a result, businesses have closed or limited operations and limits have been placed on travel. The extent to which
<FONT STYLE="white-space:nowrap">COVID-19</FONT> may impact our business, clinical trials and sales of ZTlido will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic
spread of the disease and variants, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United
States and other countries to contain and treat the disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are monitoring the potential impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, and if <FONT STYLE="white-space:nowrap">COVID-19</FONT> or variants of concern continue to spread globally, including in the United States, we may experience disruptions that could severely
impact the development of our product candidates, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in enrolling patients in our clinical trials as patients may be reluctant, or unable, to
visit clinical sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site
investigators, clinical site staff and potential closure of clinical facilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreases in patients seeking treatment for chronic pain; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including
interruption in global shipping that may affect the transport of clinical trial materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in local regulations as part of a response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
outbreak, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or cause us to discontinue the clinical trials altogether; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals
serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risk that participants enrolled in our clinical trials will acquire
<FONT STYLE="white-space:nowrap">COVID-19</FONT> while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and
contractors due to limitations in employee resources or forced furlough of government employees; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on
travel imposed or recommended by federal or state governments, employers and others. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quarantines, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related
to <FONT STYLE="white-space:nowrap">COVID-19</FONT> or other infectious diseases could impact personnel at third-party suppliers in the United States and other countries, or the availability or cost of materials, which would disrupt our supply
chain. Any manufacturing supply interruption of materials could adversely affect our ability to conduct ongoing and future research and testing activities. For example, we obtain our commercial supply of ZTlido and our clinical supply of <FONT
STYLE="white-space:nowrap">SP-103</FONT> exclusively from Oishi and Itochu in Japan. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may result in delays in the procurement and shipping of ZTlido, which may have an adverse impact on
our operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;24, 2021, the Safer Federal Workforce Task Force issued written guidance to implement Executive
Order 14042, which was signed by President Biden on September&nbsp;9, 2021. A number of federal courts have issued orders enjoining enforcement of the Executive Order, including one on a nationwide basis. As a result, the government stated that it
will take no action to enforce the requirements of the Executive Order at this time. As a federal contractor, we have mandated that all of our employees and, in addition, contractors that enter our U.S. buildings and certain other locations, be
fully vaccinated against <FONT STYLE="white-space:nowrap">COVID-19,</FONT> subject to disability and religious exemptions, by December&nbsp;8, 2021. Despite the government&#146;s <FONT STYLE="white-space:nowrap">no-action</FONT> position, we
continue to comply with the Executive Order. We may experience workforce constraints due to shortages of vaccinated personnel, strains on the labor market, limitations on hiring new employees and difficulty retaining and securing employees who are
vaccinated, all of which could negatively affect our business and operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The spread of
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> which has caused a broad impact globally, may materially affect the Company economically. While the potential economic impact brought by, and the duration of,
<FONT STYLE="white-space:nowrap">COVID-19</FONT> may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, which could in the future negatively affect our liquidity. In addition,
a recession or market correction resulting from the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> could materially affect our business and the value of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the continued spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> globally could materially and adversely impact our
operations, including without limitation, our manufacturing and supply chain, sales and marketing efforts, sales of ZTlido, travel and employee health and availability, which may have a material and adverse effect on our business, financial
condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory
approval for our product candidates and the approval may be for a more narrow indication than we seek. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot commercialize our
product candidates until the appropriate regulatory authorities have reviewed and approved the product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and local statutes and
regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals. Even if our product candidates meet the safety and efficacy endpoints in clinical trials, the
regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA advisory committee, if convened, recommends
<FONT STYLE="white-space:nowrap">non-approval</FONT> or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in
regulatory authority policy or data requirements during the period of product development, clinical trials and the regulatory review process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we receive regulatory approval, the FDA may approve a product candidate for more limited indications than requested or they may impose
significant limitations in the form of narrow indications, warnings or a Risk Evaluation and Mitigation Strategy (&#147;REMS&#148;). The FDA may require labeling that includes precautions or contra-indications with respect to conditions of use, or
may grant approval subject to the performance of costly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
post-marketing clinical trials. In addition, the FDA may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the
foregoing scenarios could materially harm the commercial prospects for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if the results of any
clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be delayed or fail in obtaining marketing approval for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval for indications or patient populations that are not as broad as we intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be subject to changes in the way the products are administered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be required to perform additional clinical trials to support approval or be subject to additional post-marketing
testing requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its
distribution in the form of a modified REMS; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be sued and held liable for harm caused to patients; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience damage to our reputation. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may find it difficult to enroll or maintain patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of
our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying and qualifying patients to participate in any clinical trials of our product candidates is
critical to our success. The timing of any clinical trials depends on our ability to recruit patients and to complete required <FONT STYLE="white-space:nowrap">follow-up</FONT> periods. If patients are unwilling to participate in our clinical trials
due to negative publicity from adverse events, competitive clinical trials for similar patient populations, or for other reasons, the timeline for recruiting patients, conducting trials and potentially obtaining regulatory approval may be delayed.
We may also experience delays if patients withdraw from a clinical trial or do not complete the required monitoring period. These delays could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness
of our product candidates or termination of clinical trials altogether. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment is affected by many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and nature of the patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to clinical sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the eligibility and exclusion criteria for the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that enrolled patients will not complete a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including
difficulties in initiating clinical sites, enrolling and retaining participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies that may be implemented and other factors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages of the product candidate in
relation to other available products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conditions for which we currently plan to evaluate our product candidates are
common but the eligibility criteria of our clinical trials limit the pool of available trial participants. For example, we experienced a delay in the enrollment of our now completed SEMDEXA Phase 3 clinical trial in sciatica due to the selective
eligibility criteria in place to reduce the placebo effect and the impacts of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and may experience similar issues with enrollment of our other planned clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our
product candidates, and this competition will reduce the number and types of patients available to it, because some patients who have opted to enroll in our trials may instead opt to enroll in a trial being conducted by a competitor. We may conduct
some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The incidence and prevalence for target patient populations of our product candidates are based on estimates and third-party sources. If the market
opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely
affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodically, we make estimates regarding the incidence and prevalence of target patient populations of our product
candidates based on various third-party sources and internally generated analyses and use such estimates in making decisions regarding our product development strategy, including acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT>
product candidates and determining indications on which to focus in preclinical studies or clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These estimates may be
inaccurate or based on imprecise data. For example, the total addressable market opportunities will depend on, among other things, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the
addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify or gain access to, all of which may
significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition and our competitors may
discover, develop or commercialize products faster or more successfully than us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries
are characterized by intense competition and rapid technological advances. In addition, the competition in the pain management market, and other relevant markets, is intense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido and our product candidate, <FONT STYLE="white-space:nowrap">SP-103,</FONT> face and will likely face competition from prescription and
generic topical lidocaine patches, including Lidoderm<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (a branded, prescription 5% lidocaine patch product) (&#147;Lidoderm&#148;) and generic lidocaine patches manufactured by Mylan N.V.,
Teva Pharmaceutical Industries Limited (&#147;Teva&#148;) and Par Pharmaceutical, Inc. Additionally, <FONT STYLE="white-space:nowrap">SP-103,</FONT> if approved, will likely compete with various opioid pain medications, nonsteroidal
anti-inflammatory drugs (&#147;NSAIDs&#148;), muscle relaxants, antidepressants and anticonvulsants particularly as we seek approval for the treatment of acute LBP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEMDEXA, if approved, has the potential to become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> epidural steroid product for
the treatment of sciatica. While there are currently no FDA approved epidural steroid injections indicated for the treatment of sciatica, we are aware of certain <FONT STYLE="white-space:nowrap">non-steroid</FONT> product candidates in development.
SEMDEXA, if approved, also will compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants, anticonvulsants and surgical procedures. Procedures may include nerve blocks and transcutaneous electrical nerve stimulations.
We may also face indirect competition from the <FONT STYLE="white-space:nowrap">off-label</FONT> and unapproved use of branded and generic injectable steroids. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there are currently no formulations containing naltrexone in clinical development for
the treatment of fibromyalgia, we are aware of certain <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapeutics currently in a late-stage phase 3 pipeline containing two 505(b)(2) development programs. Our product candidate, <FONT
STYLE="white-space:nowrap">SP-104,</FONT> will likely face direct competition from these candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the market will
become increasingly competitive in the future. Many of our competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as
well as significantly greater experience in developing product candidates and technologies, undertaking preclinical studies and clinical trials, obtaining FDA and other regulatory approvals of product candidates, formulating and manufacturing
product candidates, and launching, marketing and selling product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional mergers and acquisitions in the biotechnology and
pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their
products as well. Smaller or early-stage companies or generic or biosimilar pharmaceutical manufacturers may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These
competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or
necessary for, our programs. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our commercial opportunity could be reduced
or eliminated if our competitors succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we are currently developing or that we may develop. If approved,
our product candidates will face competition from commercially available drugs as well as drugs that are in the development pipelines of our competitors and later enter the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to <FONT
STYLE="white-space:nowrap">in-license</FONT> novel compounds that could make our product candidates less competitive. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and
commercializing medicines before we do, which would have a material adverse impact on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The third-party payor coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain coverage and adequate
reimbursement for ZTlido, GLOPERBA or our product candidates, if approved, could decrease our ability to generate product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the third-party coverage and reimbursement of existing and newly approved products. Market
acceptance and sales of ZTlido, GLOPERBA and our product candidates, if approved, in domestic markets will depend significantly on the availability of coverage and adequacy of reimbursement from third-party payors, including government programs
(such as Medicare and Medicaid) and private payor healthcare and insurance programs. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Coverage and reimbursement for ZTlido can differ
significantly from payor to payor, and we may not be able to maintain adequate coverage and reimbursement in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further,
obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use
of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be obtained or applied consistently. We may not be able to provide data sufficient to gain acceptance with respect to coverage and
reimbursement. Additionally, coverage may be more limited than the purposes for which the product is approved by the FDA or similar regulatory authorities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outside of the United States. Assuming that coverage is obtained for a given product, the resulting reimbursement rates might not be adequate or may require
<FONT STYLE="white-space:nowrap">co-payments</FONT> or <FONT STYLE="white-space:nowrap">co-insurance</FONT> that patients find unacceptably high. Patients, physicians, and other healthcare providers may be less likely to prescribe, dispense or use,
as applicable, any approved product unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market for our products will depend significantly on access to third-party payors&#146; drug formularies for which third-party payors
provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded product in
their formularies or otherwise restrict patient access to a branded product when a less costly generic equivalent or other alternative is available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if we obtain adequate levels of reimbursement, third-party payors carefully review and increasingly question the coverage
of, and challenge the prices charged for, products. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Increasingly, third-party payors are requiring that pharmaceutical companies provide them with predetermined
discounts from list prices and are challenging the prices for products. We cannot be sure that coverage and reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, what the level of
reimbursement will be. If coverage and reimbursement of our product candidates are unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability. Furthermore, the
requirements governing medical product pricing vary widely from country to country. In some foreign countries, the proposed pricing for a prescription device must be approved before it may be lawfully marketed. Historically, products launched in the
European Union do not follow price structures of the United States and generally prices tend to be significantly lower. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product
candidate SEMDEXA is expected to be a physician-administered injectable viscous gel and as such, separate reimbursement for the product itself may not be available. Instead, if SEMDEXA receives regulatory approval, the administering physician may be
reimbursed only for providing the treatment or procedure in which SEMDEXA is used. To the extent separate coverage and reimbursement should become available for SEMDEXA, we anticipate that it will be sold to physicians on a &#147;buy and bill&#148;
basis. Buy and bill products must be purchased by healthcare providers before they can be administered to patients. Healthcare providers subsequently must seek reimbursement for the product from the applicable third-party payor, such as Medicare or
a health insurance company. Healthcare providers may be reluctant to administer our product candidates, if approved, because they would have to fund the purchase of the product and then seek reimbursement, which may be lower than their purchase
price, or because they do not want the additional administrative burden required to obtain reimbursement for the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the
codes used by providers to bill for SEMDEXA, if approved, could also affect reimbursement. <FONT STYLE="white-space:nowrap">J-Codes</FONT> are codes maintained by the Centers for Medicare and Medicaid Services (&#147;CMS&#148;), which are a
component of the Healthcare Common Procedure Coding System and are typically used to report injectable drugs that ordinarily cannot be self-administered. We do not have a specific <FONT STYLE="white-space:nowrap">J-Code</FONT> for any of our product
candidates. If our product candidates are approved, we may apply for one but cannot guarantee that a <FONT STYLE="white-space:nowrap">J-Code</FONT> will be granted. To the extent separate coverage or reimbursement is available for any product
candidate, if approved, and a specific <FONT STYLE="white-space:nowrap">J-Code</FONT> is not available, physicians would need to use a <FONT STYLE="white-space:nowrap">non-specific</FONT> miscellaneous <FONT STYLE="white-space:nowrap">J-Code</FONT>
to bill third-party payors for these physician-administered drugs. Because miscellaneous <FONT STYLE="white-space:nowrap">J-Codes</FONT> may be used for a wide variety of products, health plans may have more difficulties determining the actual
product used and billed for the patient. These claims must often be submitted with additional information and manually processed, which can create delays in claims processing times as well as increasing the likelihood for claim denials and claim
errors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we have multiple programs and product candidates in our development pipeline and are pursuing
a variety of target indications and treatment approaches, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on development opportunities or product candidates that may be more profitable or for which
there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Apart from our <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product, ZTlido, we
currently have several product candidates that are at various stages of development. We have limited financial and management resources. As a result, we may forego or delay pursuit of opportunities with potential target indications or product
candidates that later prove to have greater commercial potential than our current and planned development programs and product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to progress product candidates that can address unmet or underserved medical needs and favor those candidates with large market
opportunities. However, our resource allocation decisions may cause us to fail to capitalize on viable commercial product candidates or profitable market opportunities. Our spending on current and future research and development programs and other
future product candidates for specific indications may not yield any commercially viable future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may be required to
relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such future
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may pursue additional <FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions of product
candidates or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual
acquisition or license of a successful product candidate, potentially resulting in a diversion of our management&#146;s time and the expenditure of our resources with no resulting benefit. For example, if we are unable to identify programs that
ultimately result in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products that ultimately do not provide a return on our investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of
future trial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, difficult to design and implement, and can take many years to complete, in
part because it is subject to rigorous regulatory requirements. The FDA or other regulatory authorities may not agree with the proposed analysis plans or trial design for the clinical trials of our product candidates. They may also not agree with
the scope of our proposed investigational plan. In addition, the outcome of our clinical trials is risky and uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials may
not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical
trials. It is not uncommon for companies in the pharmaceutical industry to suffer significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Our future
clinical trial results may not be successful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This product candidate development risk is heightened by any changes in the planned
clinical trials compared to the completed clinical trials. As product candidates are developed through preclinical to early and late stage clinical trials towards approval and commercialization, it is customary that various aspects of the
development program, such as manufacturing and methods of administration, are altered along the way in an effort to optimize processes and results. While these types of changes are common and are intended to optimize the product candidates for late
stage clinical trials, approval and commercialization, such changes carry the risk that they will not achieve their intended objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Phase 3 trial was completed for SEMDEXA for the treatment of sciatica, a Phase 2 trial commenced in the second quarter of 2022 for <FONT
STYLE="white-space:nowrap">SP-103,</FONT> and multiple Phase 1 trials were initiated in the first quarter of 2022 for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">SP-104.</FONT> We may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of such clinical
trials in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all. Our clinical trials may produce negative or inconclusive results, and, in the future, we may decide, or regulators may require
us, to conduct additional clinical trials and preclinical studies in addition to those we have planned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2022, we announced final
results from our Phase 3 trial for SEMDEXA, which results reflect achievement of primary and secondary endpoints, and we intend to use the results to support an NDA submission seeking approval for the treatment of sciatica. However, the FDA may
disagree with our assumptions and require us to conduct an additional Phase 3 trial before submitting an NDA. Our failure to adequately demonstrate the safety and effectiveness of our product candidates would prevent receipt of regulatory clearance
or approval and, ultimately, the commercialization of that product or indication for use. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim
<FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification
procedures that could result in material changes in the final data. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publish interim <FONT
STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> or preliminary data from our clinical trials, which are based on a preliminary analysis of then-available data. Preliminary or interim data from clinical trials that we may complete are subject
to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or interim data also remain subject to audit and verification procedures that may result
in the final data being materially different from the preliminary data we previously published. In some instances, there can be significant variability in safety or efficacy results between different clinical trials or clinical trial sites for the
same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial
procedures and the rate of dropout among clinical trial participants. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data
could significantly harm our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may
not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization
of the particular product candidate or product and our company in general. Data disclosures must be carefully managed to conform to limitations on preapproval promotion and laws related to clinical trial registration and posting of results. In
addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and stockholders may not agree with what we determine is the material or otherwise
appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug,
product, product candidate or our business. If the <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached,
our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for
their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining
regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies,
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials that the applicable product candidate is both safe and effective for use in each target indication. Each product candidate must demonstrate an adequate risk versus
benefit profile in its intended patient population and for its intended use. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and its outcome is
inherently uncertain. Failure can occur at any time during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety
concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business,
financial condition and results of operations. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities will
interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or comparable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities for support of a marketing approval, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential
approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize any of them in
any other jurisdiction, which would limit our ability to realize their full market potential. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any products in
any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis regarding safety and efficacy.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However,
the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory
approval in one country does not guarantee regulatory approval in any other country. In cases where data from United States clinical trials are intended to serve as the basis for marketing approval in the foreign countries, the standards for
clinical trials and approval may be different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval processes vary among countries and can involve additional product testing and
validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials, which could be costly and
time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. If we fail to comply with regulatory requirements in international markets or to obtain
and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be impeded. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business may suffer reputational harm due to failures of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure of any of our product candidates could have a lasting negative impact on our reputation, which could, in turn, impact our ability
to successfully enter into future licensing arrangements or other transactions with potential counterparties, raise future capital or attract key personnel to join us. As a result, our business and prospects would be materially harmed and our
results of operations and financial condition would likely suffer materially. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido and GLOPERBA may have undesirable properties that could result
in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with ZTlido, GLOPERBA
and our product candidates. In the event that ZTlido or GLOPERBA is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
identified to have undesirable side effects, a number of potentially significant negative consequences could occur. Regulatory authorities may withdraw their approval of the product or seize the
product. Restrictions may be imposed on the manufacturing or marketing of ZTlido or GLOPERBA or any component thereof, including the imposition of a REMS plan that may require creation of a Medication Guide outlining the risks of such side effects
for distribution to patients, as well as elements to assure safe use of the product, such as a patient registry and training and certification of prescribers. Any of these events could damage our reputation and prevent us from achieving or
maintaining market acceptance of ZTlido or GLOPERBA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the clinical trials we conduct with our product candidates, patients may
experience changes in their health, including illnesses, injuries, discomforts or a fatal outcome. Often, it is not possible to determine whether the product candidate being studied caused or was associated with these conditions. In addition, it is
possible that as we test our clinical products in larger, longer and more extensive clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other
adverse events that were observed in earlier clinical trials, as well as conditions that did not occur or went undetected in previous clinical trials, will be reported by subjects. Many times, side effects are only detectable after investigational
products are tested in large-scale, Phase 3 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that our product candidates reveal an unacceptable severity and
prevalence of these or other side effects, the clinical trials could be suspended or terminated and the FDA could order us to cease further development of or deny approval of our product candidates, for any or all targeted indications. The
drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and results of
operations significantly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido, GLOPERBA and our product candidates are complex and difficult to manufacture. We could experience delays in
satisfying regulatory authorities or manufacturing problems that result in delays in our development or commercialization programs, limit the supply of our product candidates, or otherwise harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently depend on contract manufacturers to conduct the manufacturing and supply activities for ZTlido, GLOPERBA and our product
candidates. Manufacturing these product candidates require facilities specifically designed for and validated for this purpose and sophisticated quality assurance and quality control procedures are necessary. Several factors could cause production
interruptions, including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions in the operations of our suppliers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If contaminations are discovered in our supply of ZTlido, GLOPERBA or our product candidates or in the manufacturing facilities, such
manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We may not be successful in securing additional sources at all or on a timely basis, which could materially harm our
development timelines. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay,
require us to begin new clinical trials at additional expense or terminate clinical trials completely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are risks
associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process <FONT STYLE="white-space:nowrap">scale-up,</FONT> process reproducibility, stability issues,
compliance with cGMP, lot consistency and timely availability of raw materials. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could
result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our manufacturers may encounter problems hiring and retaining the experienced
scientific, quality assurance, quality-control and manufacturing personnel needed to operate our complex manufacturing processes, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory
requirements. Any problems in our manufacturing process or facilities could make us a less attractive collaborator for potential partners, including larger biotechnology companies and academic research institutions, which could limit our access to
additional attractive development programs. Problems in our manufacturing process could restrict our ability to meet potential future market demand for products, which could harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_14"></A>Risks Related to our Business and Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to retain our key executives, it may delay our development efforts and harm our business, financial condition and results of operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract,
retain and motivate key executives to accomplish our business objectives, we may experience constraints that will significantly impede our ability to raise additional capital and our ability to implement our overall business strategy. In particular,
we are highly dependent upon our executive officers, including Jaisim Shah, our President and Chief Executive Officer, Henry Ji, Ph.D., our Executive Chairperson, and Elizabeth Czerepak, our Executive Vice President, Chief Financial Officer and
Chief Business Officer. The loss of services of these executive officers could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials and the successful commercialization of ZTlido and
GLOPERBA. We do not carry &#147;key person&#148; insurance on any of our executive officers or other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition for key
executives in the biotechnology and pharmaceuticals field is intense, due to the limited number of individuals who possess the skills and experience required by our industry. Many of the pharmaceutical companies against which we compete for
qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They may also provide more diverse opportunities and better chances for career advancement. Some of these
characteristics may be more appealing to qualified candidates than what we have to offer. In addition, we may experience employee turnover as a result of the ongoing &#147;great resignation&#148; occurring throughout the U.S. economy, which has
impacted job market dynamics. New hires require training and take time before they achieve full productivity. New employees may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified
individuals. Moreover, we conduct our operations in the San Francisco Bay Area, a region that is home to many other biopharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified
personnel. As such, we could have difficulty attracting and retaining experienced executives and may be required to expend significant financial resources in our recruitment and retention efforts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may need to increase the size of our company and may not effectively manage our growth. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, we had approximately 85 full-time employees. We may need to continue to expand our managerial, operational,
sales and marketing, finance and other resources in order to manage our operations, clinical trials, research and development activities, regulatory filings, manufacturing and supply activities, and any marketing and commercialization activities,
including <FONT STYLE="white-space:nowrap">co-promotion</FONT> activities. Future growth would impose significant added responsibilities on members of management, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, recruiting, integrating, maintaining and motivating additional employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing our internal development efforts effectively, including the clinical, FDA and internal regulatory review
process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">improving our operational, financial and management controls, reporting systems and procedures.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future financial performance and our ability to commercialize our product candidates
will depend, in part, on our ability to effectively manage any future growth, if any, which may cause a significant strain on our management, and our operational, financial and other resources. Our ability to manage our growth effectively will
require us to implement and improve our operational, financial and management systems and to expand, train, manage and motivate our employees. These demands may require the hiring of additional management personnel and the development of additional
expertise by management. Any increase in resources devoted to research and product development without a corresponding increase in our operational, financial and management systems could have a material adverse effect on our business, financial
condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to
significant uninsured liabilities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we endeavor to obtain appropriate insurance coverage for insurable risks that we
identify, we do not carry insurance for all categories of risk that our business may encounter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insurance coverage is becoming
increasingly expensive. We have observed rapidly changing conditions in the insurance markets relating to nearly all areas of traditional corporate insurance. Such conditions have resulted in higher premium costs, higher policy deductibles and lower
coverage limits. We may not be able to maintain insurance coverage at a reasonable cost, or in sufficient amounts to protect us against losses due to liability. While we maintain property, casualty and general liability coverage, we do not carry
specific biological or hazardous waste insurance coverage and our insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination
or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not know if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may
require us to pay substantial amounts, which would adversely affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If product
liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing and marketing of ZTlido and clinical testing of our product candidates may expose us to individual product liability claims,
class action lawsuits or actions, and other individual or mass tort claims. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or
sale. In addition, physicians may misuse our products with their patients if they are not adequately trained, potentially leading to injury and increased risk of product liability. Any such product liability claims may include allegations of defects
in manufacturing, defects in design, a failure to warn of risks inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend
ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates, if approved. Even successful defense would require significant financial and management resources.
Regardless of the merits or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue from product sales; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our product candidates or products that we develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiation of investigations by regulators; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on labeling, the marketing or manufacturing of the product, withdrawal of the product from the
market or voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a diversion of management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize our product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against
potential product liability claims could prevent or inhibit the commercialization of any products we develop. We currently carry product liability insurance covering use in our clinical trials in the amount of $10.0&nbsp;million in the aggregate.
Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance
coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that
exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable
cost or in sufficient amounts to protect us against losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any disruption in our research and development facilities could adversely affect our
business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are in the San Francisco Bay Area,
California. Our facilities may be affected by natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters. Earthquakes are of particular significance since our facilities are located in an earthquake-prone area. We are also vulnerable to
damage from other types of disasters, including power loss, attacks from extremist organizations, fires, floods and similar events. If our facilities are affected by a natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disaster, we may be
forced to curtail our operations and/or rely on third-parties to perform some or all of our research and development activities. Although we believe we possess adequate insurance for damage to our property and the disruption of our business from
casualties, such insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. In the future, we may choose to expand our operations in either our existing facilities
or in new facilities. If we expand our worldwide manufacturing locations, there can be no assurance that this expansion will occur without implementation difficulties, or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to grow our business through acquisitions and may fail to realize the anticipated benefits of any acquisition, and acquisitions can be
costly and dilutive. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends on our ability to continually enhance and broaden our product offerings in response to
changing customer demands, competitive pressures, technologies and market pressures. Accordingly, from time to time we may expand our business and intellectual property portfolio through the acquisition of new businesses and technologies. We cannot
assure that we will achieve anticipated benefits from any acquisition to justify the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition within our industry for
acquisitions of businesses, technologies and assets may become intense. Even if we are able to identify an acquisition that we would like to consummate, we may not be able to complete the acquisition on commercially reasonable terms or the target
may be acquired by another company. We may enter into negotiations for acquisitions that are not ultimately consummated. Those negotiations could result in diversion of management time and significant <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of any acquisition depends on, among other things, our ability
to combine our business with an acquired business in a manner that does not materially disrupt existing relationships and that allows us to achieve </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development and operational synergies. If we are unable to achieve these objectives, the anticipated benefits of an acquisition may not be realized fully, or at all, or may take longer to realize
than expected. In particular, if we undertake such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large <FONT STYLE="white-space:nowrap">one-time</FONT> expenses or acquire intangible assets that could
result in significant future amortization expenses. As a result, an acquisition may not be accretive to our stock value or development pipeline in the near or long term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to incur higher development and regulatory costs, and additional costs integrating the operations and personnel of any companies we
acquire, which cannot be estimated accurately at this time. If the total costs of the integration of our companies and advancement of acquired product candidates and technologies exceed the anticipated benefits of the acquisition, our business,
financial condition and results of operations could be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>International components of our business expose us to business, legal,
regulatory, political, operational, financial and economic risks associated with conducting business outside of the United States. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently collaborate with international manufacturing partners and may potentially expand our business internationally in the future. The
purchase and shipment of components from international sources subjects us to U.S. and foreign governmental trade, import and export, and customs regulations and laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with these regulations and laws is costly and exposes us to penalties for <FONT STYLE="white-space:nowrap">non-compliance.</FONT>
Other laws and regulations that can significantly impact us include various anti-bribery laws, including the U.S. Foreign Corrupt Practices Act (the &#147;FCPA&#148;), as well as export controls laws. Any failure to comply with applicable legal and
regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges,
seizure of shipments, restrictions on certain business activities and exclusion or debarment from government contracting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting
business internationally involves a number of risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">multiple, sometimes conflicting and changing laws and regulations such as tax laws, export and import
restrictions, employment laws, anti-bribery and anti-corruption laws, regulatory requirements and other governmental approvals, permits and licenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in enforcing our intellectual property rights and in defending against third-party threats and
intellectual property enforcement actions against us, our distributors or any of our third-party suppliers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by us or our distributors to obtain appropriate licenses or regulatory approvals for the sale or use of
our product candidates, if approved, in various countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in managing foreign operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency exchange rate fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in duties and tariffs, license obligations and other <FONT STYLE="white-space:nowrap">non-tariff</FONT>
barriers to trade; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the imposition of new trade restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complexities associated with managing multiple payor-reimbursement regimes or
<FONT STYLE="white-space:nowrap">self-pay</FONT> systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak
of disease, boycotts, curtailment of trade and other business restrictions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to comply with the FCPA, including its books and records provisions and its anti-bribery provisions, and
similar anti-bribery and anti-corruption laws in other jurisdictions, for example by failing to maintain accurate information and control over sales or distributors&#146; activities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these risks, if encountered, could significantly harm our future international
expansion and operations and, consequently, negatively impact our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The increasing use of
social media platforms presents new risks and challenges. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Social media is increasingly being used to communicate about our
research, product candidates, investigational medicines and the diseases our product candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations
relating to such use are not always clear. This evolution creates uncertainty and risk of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulations applicable to our business, resulting in potential regulatory actions against us. For
example, patients may use social media channels to comment on their experience in an ongoing blinded clinical study or to report an alleged adverse event. When such disclosures occur, there is a risk that we may fail to monitor and comply with
applicable adverse event reporting obligations or we may not be able to defend our business or the public&#146;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say
about our product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. Furthermore, our employees, affiliates and/or business
partners may use social media for their personal use, and their activities on social media or in other forums could result in adverse publicity for us. Any negative publicity as a result of social media posts, whether or not such claims are
accurate, could adversely impact us. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business, financial condition and
results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business and operations would suffer in the event of system failures. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are
vulnerable to damage from computer viruses, unauthorized access, cybersecurity attacks or hacking, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system failure, accident or
security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs or a loss of our trade secrets or other proprietary information. For
example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any
disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur material legal claims and liability, damage to our reputation,
suffer loss or harm to our intellectual property rights and the further research, development and commercial efforts of ZTlido, GLOPERBA and our product candidates, if approved, could be delayed. If we are held liable for a claim against which we
are not insured or for damages exceeding the limits of our insurance coverage, whether arising out of cybersecurity matters, or from some other matter, that claim could have a material adverse effect on our business, financial condition and results
of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, a cybersecurity attack, data breach or privacy violation that leads to disclosure or modification of, or prevents
access to, patient information, including personally identifiable information or protected health information, could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us
to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. Our ability to
effectively manage and maintain our internal business information, and to ship products to customers and invoice them on a timely basis, depends significantly on our enterprise resource planning system and other information systems. Portions of our
information technology systems may experience interruptions, delays or cessations of service or produce errors in connection with ongoing systems implementation work. Cybersecurity attacks in particular are evolving and include, but are not limited
to, threats, malicious software, ransom ware, attempts to gain unauthorized access to data and other electronic security breaches that could lead to disruptions in systems, misappropriation of confidential or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise protected information and corruption of data. If we are unable to prevent such cybersecurity attacks, data security breaches or privacy violations or implement satisfactory remedial
measures, our operations could be disrupted, and we may suffer loss of reputation, governmental investigations, claims or litigation that may not be covered by insurance, financial loss and other regulatory penalties because of lost or
misappropriated information, including sensitive patient data. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and results of operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As widely reported, global credit and financial markets have experienced volatility and disruptions in the past several years and
especially in 2020 and 2021 due to the impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases
in unemployment rates and uncertainty about economic stability. For example, an overall decrease in or loss of insurance coverage among individuals in the United States as a result of unemployment, underemployment or the repeal of certain provisions
of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the &#147;ACA&#148;), may decrease the demand for healthcare services and pharmaceuticals. If fewer patients seek medical care
because they do not have insurance coverage, we may experience difficulties in any eventual commercialization of our product candidates and our business, results of operations, financial condition and cash flows could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurances that further deterioration in credit and financial markets and confidence in economic conditions will not occur.
Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any
necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance
and price of our Common Stock, and could require us to delay or abandon clinical development plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to effectively monitor and respond
to the rapid and ongoing developments and expectations relating to the environmental, social and governance matters, including related social expectations and concerns, may impose unexpected costs or results in reputational or other harm that could
have a material adverse effect on our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is an increasing focus from certain investors, employees, regulators,
listing exchanges and other stakeholders concerning corporate responsibility and sustainability matters, specifically related to environmental, social and governance (&#147;ESG&#148;) factors. Some investors and investor advocacy groups may use
these factors to guide investment strategies and, in some cases, investors may choose not to invest in us if they believe our policies relating to corporate responsibility are inadequate. Third-party providers of corporate responsibility ratings and
reports on companies have increased to meet growing investor demand for measurement of corporate responsibility performance, and a variety of organizations currently measure the performance of companies on such ESG topics, and the results of these
assessments are widely publicized. Investors, particularly institutional investors, use these ratings to benchmark companies against their peers, and major institutional investors have publicly emphasized the importance of ESG measures to their
investment decisions. Topics taken into account in such assessments include, among others, companies&#146; efforts and impacts on climate change and human rights, ethics and compliance with law, diversity and the role of companies&#146; board of
directors in supervising various sustainability issues. In light of investors&#146; increased focus on ESG matters, if we are perceived as lagging with respect to ESG initiatives, these investors may engage with us to improve ESG disclosures or
performance and may also make voting decisions, or take other actions, to hold us and our Board accountable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are rapid
and ongoing developments and changing expectations relating to ESG matters, and the criteria by which our corporate responsibility practices are assessed may change, which could result in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. If we elect not to or are unable to adequately recognize and respond to such developments and
governmental, societal, investor and consumer expectations relating to such ESG matters, we may miss corporate opportunities, become subject to additional scrutiny or incur unexpected costs. We may face risk of litigation or reputational damage in
the event that our corporate responsibility procedures or standards do not meet the standards set by various constituencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also
face reputational damage if we are unable to achieve an acceptable ESG or sustainability rating from third-party rating services. A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our Common
Stock from consideration by certain investors who may elect to invest with our competitors instead. Ongoing focus on corporate responsibility matters by investors and other parties as described above may impose additional costs or expose us to new
risks. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, financial condition or results of operations, including the sustainability of our business over time, and could
cause the market value of our Common Stock to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our emphasis on ESG issues may not maximize short-term financial results
and may yield financial results that conflict with the market&#146;s expectations. We may in the future make business decisions that may reduce our short-term financial results if we believe that the decisions are consistent with our ESG goals,
which we believe will improve our financial results over the long-term. These decisions may not be consistent with the short-term expectations of our stockholders and may not produce the long-term benefits that we expect, in which case our business,
financial condition and results of operations could be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_15"></A>Risks Related to Scilex&#146;s Intellectual Property
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are substantially dependent on the intellectual property we <FONT STYLE="white-space:nowrap">in-license</FONT> from Oishi and Itochu, and if
we lose the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize <FONT STYLE="white-space:nowrap">SP-103</FONT> would be
harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is substantially dependent upon the intellectual property licensed from Oishi and Itochu. Pursuant to the
Product Development Agreement, we have been granted an exclusive, worldwide license (except with respect to Japan) under current and future intellectual property rights relating to ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> lidocaine
tape products and the lidocaine in such products, including, among other things: (1)&nbsp;any patent applications, continuation applications, any issued or issuing patents, as well as any foreign patent applications, (2)&nbsp;all <FONT
STYLE="white-space:nowrap">know-how,</FONT> work product, trade secrets, invents, data, processes, techniques, procedures, compositions, devices, methods, formulas, protocols and information, whether patentable or not, (3)&nbsp;copyrightable works,
copyrights and applications, registrations and renewals, (4)&nbsp;logos, trademarks, service marks, and all applications and registrations relating thereto, (5)&nbsp;other proprietary rights, (6)&nbsp;abbreviated new drug applications or other
applications to market, and (7)&nbsp;any regulatory exclusivities or supplemental protection certificates. Our ability to commercialize ZTlido and develop <FONT STYLE="white-space:nowrap">SP-103</FONT> depends on the effectiveness and continuation
of the Product Development Agreement. If we lose the right to license the intellectual property rights granted by the Product Development Agreement, our ability to develop ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> as well as new
product candidates based on the licensed intellectual property would be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Product Development Agreement imposes various
development, regulatory and/or commercial diligence obligations, payments and other obligations. Oishi and Itochu have the right to terminate the Product Development Agreement under certain circumstances, including, among other things: (1)&nbsp;if
we are in material breach of the agreement and the breach is not curable or if the breach is curable and we fail to cure such material breach within 180 days after notice requesting to cure; (2)&nbsp;if, at any time during the term of the Product
Development Agreement, the market conditions are such that (a)&nbsp;our total net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> are equal to or less than five percent of our net sales of ZTlido and <FONT
STYLE="white-space:nowrap">SP-103</FONT> for a period of four or more consecutive quarters, or (b)&nbsp;the economic viability of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> is affected significantly as evidenced by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us, on the one hand, and Oishi and Itochu, on the other hand, and the
parties are unable to resolve the concerns under the foregoing clauses (a)&nbsp;and (b)&nbsp;after 30 days of good-faith discussion; and (3)&nbsp;in the event of our bankruptcy or assignment for the benefit of creditors. As of the date of this
prospectus, Scilex&#146;s net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and
Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. If the Product Development Agreement is terminated for certain reasons, such as our material breach of the agreement,
our bankruptcy, or lack of economic viability, we will be required to transfer all licensed intellectual property rights, including those relating to ZTlido and <FONT STYLE="white-space:nowrap">SP-103,</FONT> to Oishi and Itochu or their designee,
at our own cost and expense. The loss of such licenses could materially harm our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
recently entered into the Romeg Agreement for the <FONT STYLE="white-space:nowrap">in-licensing</FONT> of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such
intellectual property or if the Romeg Agreement is terminated for any reason, our ability to commercialize GLOPERBA would be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently entered into the Romeg Agreement for the <FONT STYLE="white-space:nowrap">in-licensing</FONT> of certain intellectual property
rights from Romeg with respect to the commercialization of GLOPERBA. Pursuant to the Romeg Agreement, we have been granted (1)&nbsp;the right to manufacture, promote, market, distribute and sell pharmaceutical products comprising liquid formulations
of colchicine for the prophylactic treatment of gout in adult humans in the United States and (2)&nbsp;an exclusive, transferable license to use the trademark &#147;GLOPERBA.&#148; Under the Romeg Agreement, among other things, Romeg granted us
(1)&nbsp;a transferable license, with the right to sublicense, under the patents and <FONT STYLE="white-space:nowrap">know-how</FONT> specified therein to (a)&nbsp;commercialize the pharmaceutical product comprising liquid formulations of colchicine
for the prophylactic treatment of gout in adult humans (the &#147;Initial Licensed Product&#148;) in the United States (including its territories) (the &#147;Territory&#148;), (b) develop other products comprising the Initial Licensed Product as an
active pharmaceutical ingredient (together with the Initial Licensed Product, the &#147;Licensed Products&#148;) and commercialize any such products and (c)&nbsp;manufacture Licensed Products anywhere in the world, solely for commercialization in
the Territory; and (2)&nbsp;an exclusive, transferable license, with right to sublicense, to use the trademark &#147;GLOPERBA&#148; and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial
Licensed Product solely in the Territory. The license to <FONT STYLE="white-space:nowrap">know-how</FONT> is exclusive for purposes of developing and commercializing Licensed Products in the Territory during the royalty term, but is otherwise <FONT
STYLE="white-space:nowrap">non-exclusive.</FONT> The license to patents is exclusive for purposes of developing and commercializing Licensed Products in the Territory until July&nbsp;1, 2027 and, thereafter, is
<FONT STYLE="white-space:nowrap">co-exclusive</FONT> with Granules Pharmaceuticals, Inc. for the royalty term for such purposes. The royalty term begins on the date of the agreement and ends on the later of (i)&nbsp;expiration of the last to expire
of the patents that covers the manufacture or commercialization of the Licensed Products in the Territory or (ii)&nbsp;the tenth anniversary of the date of the Romeg Agreement. Our ability to commercialize GLOPERBA and develop Licensed Products
depends on the effectiveness and continuation of the Romeg Agreement. If we lose the right to license the intellectual property rights granted by the Romeg Agreement, our ability to develop GLOPERBA as well as new product candidates based on the
licensed intellectual property would be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Romeg Agreement imposes various development, regulatory and/or commercial diligence
obligations, payments and other obligations. Romeg has the right to terminate the Romeg Agreement under certain circumstances, including, among other things: (a)&nbsp;in the event we are in material breach of the Romeg Agreement, unless we have
cured any such breach within 60 days after any notice thereof was provided; (b)&nbsp;upon notice to us, if we fail to timely pay any milestone payment, percentage royalties or minimum quarterly royalties or fail to timely deliver the requisite
quarterly report, which termination will be effective 30 days after the date of such notice, unless we have made such payment in full or delivered such quarterly report within such 30 day period; (c)&nbsp;immediately, if we challenge the licensed
patents under any court action or proceeding or before any patent office or assist any third party to conduct any of these activities; (d)&nbsp;by written notice to us if sales of Licensed Products do not commence or continue within specified
periods agreed to by the parties; or (e)&nbsp;in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
event of our bankruptcy or assignment for the benefit of creditors. If the Romeg Agreement is terminated for certain reasons, such as our material breach of the agreement, our bankruptcy, or our
failure to timely pay milestone payments, we will be required upon Romeg&#146;s request to transfer all licensed intellectual property rights, including those relating to the GLOPERBA and the Licensed Products, to Romeg or their designee, within
thirty days after the termination of the Romeg Agreement at a price to be agreed upon by the parties. The loss of such licenses could materially harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential disputes over intellectual property rights that we have licensed may prevent or impair our ability to maintain our current licensing
arrangements on acceptable terms. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property rights is of high importance to our business and involves
complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial or other obligations under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property rights of the
licensor that are not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense intellectual property rights to third parties under collaborative development
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our product candidates, and what activities satisfy those diligence obligations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual
property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, our business, financial condition and results of operations may be adversely affected. We may enter into
additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if our licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third
parties would have the freedom to seek regulatory approval of, and to market, products identical or competitive to ours and we may be required to cease our development and commercialization of certain of our product candidates, if approved.
Moreover, if disputes over intellectual property that we license prevent or impair our ability to maintain other licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product
candidates. Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are
unable to maintain patent protection for ZTlido, GLOPERBA and our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trademarks, trade secret protection, and confidentiality agreements to protect the intellectual property
related to ZTlido, GLOPERBA and our product candidates. Our success depends in part on our ability to obtain and maintain patent protection in the United States, for GLOPERBA, and in the United States and other countries with respect to ZTlido and
our product candidates. We seek to protect our proprietary position by filing and/or <FONT STYLE="white-space:nowrap">in-licensing</FONT> patent applications in the United States and abroad related to our development programs and product candidates.
The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patents and patent applications that we own or
<FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with claims that protect ZTlido, GLOPERBA and our product candidates in the United States or in other foreign countries. There is no assurance that all of the
potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. Even if patents do successfully issue and
even if such patents cover ZTlido, GLOPERBA and our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful
opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory
approvals, the period of time during which we could market a product candidate under patent protection could be reduced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent
application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These
risks and uncertainties include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Patent and Trademark Office (&#147;PTO&#148;) and various foreign governmental patent agencies require
compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the <FONT STYLE="white-space:nowrap">non-compliance</FONT> with which can result in abandonment or lapse of a patent or patent
application, and partial or complete loss of patent rights in the relevant jurisdiction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications may not result in any patents being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise
may not provide any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors, many of whom have substantially greater resources than we do and many of whom have made
significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope
of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S.
courts, allowing foreign competitors a better opportunity to create, develop and market competing products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other parties may have designed around our claims or developed technologies that may be related or competitive to
our platform, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could
dominate our patent position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the
practice of our technologies or the successful commercialization of any products or product candidates that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">because patent applications in the United States and most other countries are confidential for a period of time
after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an interference proceeding can be provoked by a third party or instituted by the PTO to determine who was the
first to invent any of the subject matter covered by the patent claims of our applications for any application with an effective filing date before March&nbsp;16, 2013. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is also expensive and time-consuming, and we and our licensors may not be able to file and prosecute all
necessary or desirable patent applications at a reasonable cost or in a timely manner </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or in all jurisdictions where protection may be commercially advantageous. It is also possible that we and our licensors will fail to identify patentable aspects of our research and development
output before it is too late to obtain patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the patent applications we hold or
<FONT STYLE="white-space:nowrap">in-license</FONT> with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for ZTlido,
GLOPERBA and our product candidates, it could dissuade other companies from collaborating with us to develop product candidates, and threaten our ability to commercialize ZTlido, GLOPERBA and our product candidates. Any such outcome could have a
materially adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or maintaining necessary rights to product components and
processes and brands for our development pipeline through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Presently we have intellectual property rights, through licenses from third parties related to ZTlido,
<FONT STYLE="white-space:nowrap">SP-103,</FONT> and GLOPERBA. Because our programs for ZTlido, GLOPERBA, <FONT STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104</FONT> may require the use of additional proprietary
rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use these proprietary rights. In addition, our product candidates may require
specific formulations to work effectively and efficiently and these rights may be held by others. It may also be commercially advantageous to use trademarks held by others. We may be unable to acquire or
<FONT STYLE="white-space:nowrap">in-license</FONT> proprietary rights related to any compositions, formulations, methods of use, processes or other intellectual property rights from third parties that we identify as being necessary for our product
candidates. Even if we are able to obtain a license to such proprietary rights, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be
required to expend significant time and resources to develop or license replacement technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where we obtain licenses from or
collaborate with third parties, we may not have the right to control the preparation, filing and prosecution of patent and trademark applications, or to maintain the patents covering technology that we license from third parties and associated
trademark registrations, or such activities, if controlled by us, may require the input of such third parties. We may also require the cooperation of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not
be provided. Therefore, these patents, trademarks and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business, in compliance with applicable laws and regulations, which may affect the validity
and enforceability of such patents and trademarks, or any patents and trademark registrations that may issue from such applications. Moreover, if we do obtain necessary licenses, we will likely have obligations under those licenses, including making
royalty and milestone payments, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications, or loss of
trademark rights, could have a material adverse impact on our business. Our business would suffer if any such licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents or
trademarks against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any licenses terminate, or if
the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours. Moreover, our licensors may own or control
intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#146;s rights. In addition, while we cannot currently
determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we
use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party proprietary rights is a competitive area, and companies, which may be more established, or have
greater resources than we do, may also be pursuing strategies to license or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acquire third-party proprietary rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage
over us due to their size, cash resources and greater clinical development and commercialization capabilities. We may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do
so, the third-party may offer, on an exclusive basis, their proprietary rights to other parties, potentially blocking our ability to pursue our program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or
at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required
third-party intellectual property rights on commercially reasonable terms, our ability to commercialize our products, and our business, financial condition and results of operations could suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees (including former employees of our licensors), collaborators or other third parties have an
interest in our patents or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> The failure to name the proper inventors on a patent application can result in the patents issuing thereon being
unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter
of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding <FONT STYLE="white-space:nowrap">co-ownership</FONT> of potential joint inventions. Litigation may be
necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business.
Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Claims that we infringe, misappropriate, or violate the intellectual property rights of third parties may give rise to costly and lengthy litigation,
and we could be prevented from selling products, forced to pay damages, and defend against litigation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert
patent or other intellectual property infringement or misappropriation claims against us or our strategic partners, licensors or licensees with respect to ZTlido, GLOPERBA and our product candidates. If ZTlido, GLOPERBA or any of our product
candidates, methods, processes and other technologies are alleged to infringe on or be improperly based on the proprietary rights of other parties, we could face adverse consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants,
including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. We cannot assure that any of our current or future
product candidates will not infringe existing or future patents. We may not be aware of patents that have already issued that a third party might assert are infringed by one of our current or future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods
for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be currently pending third-party patent
applications which may later result in issued patents that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our product candidates or our technologies may infringe, or which such third parties claim are infringed by the use of our technologies. Parties making claims against us for infringement or
misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these
claims, regardless of their merit, could involve substantial expenses and could be a substantial diversion of our valuable management and employee resources from our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our
intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability.
Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. In the future, we may agree to indemnify our commercial collaborators against certain intellectual
property infringement claims brought by third parties. Any claims of patent infringement asserted by third parties would be time-consuming and could: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">result in costly litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">divert the time and attention of our technical personnel and management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cause development delays; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevent us from commercializing our product candidates until the asserted patent expires or is held finally
invalid or not infringed in a court of law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, which may not be
possible on a cost-effective basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which
may include treble damages if we are found to have been willfully infringing such intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to pay the attorney&#146;s fees and costs of litigation to the party whose intellectual property
rights we may be found to be infringing; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable
terms, or at all. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are sued for patent infringement, we would need to demonstrate that our products or methods
either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do either. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of
clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#146;s time and attention in pursuing these
proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the
validity of the patents in court. Patent litigation is costly and time-consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain <FONT
STYLE="white-space:nowrap">non-infringing</FONT> technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our
product candidates to market and be precluded from manufacturing or selling our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that others have
not filed patent applications for technology covered by our pending applications, or that we were the first to invent the technology, because: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">some patent applications in the United States may be maintained in secrecy until the patents are issued;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications in the United States and elsewhere can be pending for many years before issuance, or
unintentionally abandoned patents or applications can be revived; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pending patent applications that have been published can, subject to certain limitations, be later amended in a
manner that could cover our technologies, our product candidates or the use of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identification of third-party patent rights that may be relevant to our technology is difficult because patent
searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications in the United States are typically not published until 18 months after the priority date; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publications in the scientific literature often lag behind actual discoveries. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the
patent&#146;s prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to
market our products. Further, we may incorrectly determine that our technologies, products, or product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#146;s pending patent application will issue
with claims of relevant scope. Our determination of the expiration date of any patent in the United States or internationally that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products or
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours,
and others may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and future approved products or impair our competitive position. Numerous third-party U.S.
and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or
methods for treatment related to the use or manufacture of our product candidates. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such
technologies. If another party has filed a U.S. patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the PTO to determine priority of invention in the United States. The costs of
these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of
our U.S. patent position with respect to such inventions. Other countries have similar laws that permit secrecy of patent applications, and may be entitled to priority over our applications in such jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have
substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we were to prevail, any litigation or administrative proceeding could be costly and time-consuming and would divert the attention of
our management and key personnel from our business operations. Furthermore, as a result of a patent infringement suit brought against us or our strategic partners or licensees, we or our strategic partners or licensees may be forced to stop or delay
developing, manufacturing or selling technologies, product candidates or potential products that are claimed to infringe a third party&#146;s intellectual property unless that party grants us or our strategic partners&#146; or licensees&#146; rights
to use its intellectual property. Ultimately, we may be unable to develop some of our product candidates or may have to discontinue development of a product candidate or cease some of our business operations as a result of patent infringement
claims, which could severely harm our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patents or other intellectual property,
which could be expensive, time-consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents, trademarks, copyrights or other
intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and key personnel. For example, on
June&nbsp;22, 2022, we filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp. and Apotex, Inc. (together, &#147;Aveva&#148;) in the U.S. District Court for the Southern District of Florida alleging infringement of certain Orange
Book patents covering ZTlido. See the section titled &#147;<I>Business &#151; Legal Proceedings</I>&#148; for additional information regarding such proceedings. Any claims we assert against perceived infringers could provoke these parties to assert
counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a
patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will
construe the patent&#146;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or
proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any
of these occurrences could adversely affect our business, financial condition and results of operations. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or
that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only
monetary damages, which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be
compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims,
which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we
receive as a result of the proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the expense and uncertainty of litigation, we may conclude that even if a third party
is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high
or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other
<FONT STYLE="white-space:nowrap">non-litigious</FONT> action or solution. Any of the foregoing may have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our intellectual property rights are invalidated or circumvented, our business, financial condition and results of operations will be adversely
affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our long-term success depends on our ability to continually discover, develop and commercialize innovative new
pharmaceutical products. Without strong intellectual property protection, we would be unable to generate the returns necessary to support the enormous investments in research and development and capital as well as other expenditures required to
bring new product candidates to the market and for commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intellectual property protection varies throughout the world and is
subject to change over time. In the United States, for small molecule drug products, such as ZTlido and GLOPERBA, the Hatch-Waxman Act provides </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generic companies powerful incentives to seek to invalidate our pharmaceutical patents. As a result, we expect that our U.S. patents on major pharmaceutical products will be routinely challenged,
and there can be no assurance that our patents will be upheld. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a distraction to management and other employees. We face generic
manufacturer challenges to our patents outside the United States as well. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims
could result in our being unable to market a product in a particular territory or being required to pay damages for past infringement or royalties on future sales. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition and our business, financial condition
and results of operations may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have registered trademarks with the PTO for the mark &#147;ZTlido,&#148;
&#147;SCILEX&#148; and &#147;RESPONSIBLE BY DESIGN,&#148; and we have filed trademark applications for the marks &#147;SEMNUR PHARMACEUTICALS&#148; and &#147;SEMDEXA&#148; in the United States. We also have trademark registrations for ZTlido in the
UK and Greece, we have a pending trademark application for ZTlido in China and we are appealing a decision refusing to register a trademark application for ZTlido in China. In China, we detected a third-party trademark registration for ZTlido and
filed an invalidation proceeding &#151; Invalidation of TM Registration No.&nbsp;36299669 &#147;ZTlido&#148; in Class&nbsp;5 in the name of


<IMG SRC="g428534g73e11.jpg" ALT="LOGO">
 (Qinhuangdao Hengjun Trading Co., Ltd.) (the &#147;China ZTlido Trademark Invalidation Proceeding&#148;). The China ZTlido Trademark Invalidation Proceeding is pending. Our trademarks or trade names may be challenged,
infringed, diluted, tarnished, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential
partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In
addition, there could be potential trade name or trademark infringement, dilution or tarnishment claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade
names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely
affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product
candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual
property, particularly patents. Obtaining and enforcing patents in the biotechnology and pharmaceutical industries involve both technological and legal complexity. Therefore, obtaining and enforcing biotechnology and pharmaceutical patents is
costly, time-consuming and inherently uncertain. In addition, the America Invents Act (the &#147;AIA&#148;), which was passed in September 2011, resulted in significant changes to the U.S. patent system. An important change introduced by the AIA is
that, as of March&nbsp;16, 2013, the United States transitioned from a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> to a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the
same invention. Under a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, assuming the other requirements for patentability are met, the first inventor to file a patent application
generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the PTO after that date but before us could therefore be awarded a patent
covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application and diligent in filing patent
applications, but circumstances could prevent us from promptly filing patent applications on our inventions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among some of the other changes introduced by the AIA are changes that limit where a
patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the PTO. This applies to all of our U.S. patents, even those issued before March&nbsp;16, 2013. Because of a lower
evidentiary standard in PTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a PTO proceeding sufficient for the PTO to hold a claim
invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, a third party may attempt to use the PTO procedures to invalidate our patent claims that would not have been invalidated if first
challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs
surrounding the prosecution of our or our licensors&#146; patent applications and the enforcement or defense of our or our licensors&#146; issued patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may become involved in opposition, interference, derivation, <I>inter partes </I>review or other proceedings challenging our or our
licensors&#146; patent rights, and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent
rights, allow third parties to commercialize ZTlido, GLOPERBA and our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent
rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent
protection available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with
regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the PTO, the laws and
regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, the Biden administration recently
indicated its support for a proposal at the World Trade Organization to waive patent rights with respect to <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines. Any waiver of our patent or other intellectual property protection by the U.S. and
other foreign governments could have a material adverse effect on our competitive position, business, financial condition and results of operations. In addition, the European patent system is relatively stringent in the type of amendments that are
allowed during prosecution, but, the complexity and uncertainty of European patent laws has also increased in recent years. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important
for our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment
and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions to
maintain patent applications and issued patents. For example, periodic maintenance fees on any issued patent are due to be paid to the PTO and other foreign patent agencies in several stages over the lifetime of the patent. The PTO and various
foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by
payment of a late fee or by other means in accordance with the applicable rules, there are situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely
file national and regional stage patent applications based on our international patent application, failure to respond to official actions within </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees, and failure to properly legalize and submit formal documents. If we or any of our licensors fail to maintain
the patents or patent applications covering ZTlido, GLOPERBA and our product candidates, our competitors may be able to enter the market, which would have an adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Confidentiality agreements with employees may not adequately prevent disclosure of our trade secrets and other proprietary information and may not
adequately protect our intellectual property, which could limit our ability to compete. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To help protect our proprietary <FONT
STYLE="white-space:nowrap">know-how</FONT> and our inventions for which patents may be unobtainable or difficult to obtain, or prior to seeking patent protection, we rely on trade secret protection and confidentiality agreements. To this end, we
require all our employees to enter into agreements that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our
business. These agreements typically limit the rights of the third parties to use or disclose our confidential information. We also typically obtain agreements from these parties that provide that inventions conceived by the party in the course of
rendering services to us will be our exclusive property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, current or former employees may unintentionally or willfully disclose
our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. The need to share trade secrets and other confidential information
increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our competitive position is based, in
part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our
business, financial condition and results of operations. Enforcing a claim that a third party obtained illegally, and is using, trade secrets and/or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> is expensive, time-consuming and
unpredictable, and the enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our trade
secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> or other proprietary information is disclosed, the value of our trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and other proprietary rights would be significantly impaired
and our business and competitive position would suffer. Moreover, our third-party licensing partners may retain rights in some of our proprietary or joint trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> patented inventions or other
proprietary information, including rights to sublicense and rights of publication, which may adversely impact our ability to obtain patents and protect trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> or other proprietary information.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their
current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our
employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors, as well as our academic partners. Although we try
to ensure that our employees, consultants and advisors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that these individuals or we have used or
disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#146;s current or former employer. We may also be subject to claims that patents and applications that we may file to protect
inventions of our employees or consultants are rightfully owned by their former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary
damages, we may lose valuable intellectual property rights or personnel. An inability to incorporate such technologies or features would have a material adverse effect on our business, financial condition and results of operations and may prevent us
from successfully commercializing ZTlido, GLOPERBA and our product candidates, if approved. Moreover, any such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
litigation or the threat of such litigation may adversely affect our ability to hire employees or contract with independent contractors. A loss of key personnel or their work product could hamper
or prevent our ability to commercialize ZTlido, GLOPERBA and our product candidates, if approved. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of
intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own.
Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third
parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. In addition, individuals executing agreements with us may have preexisting or competing obligations to a third
party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our position as a relatively small company may cause us to be at a significant disadvantage in defending our intellectual property rights
and in defending against infringement claims by third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation relating to the ownership and use of intellectual
property is expensive, and our position as a relatively small company in an industry dominated by very large companies may cause us to be at a significant disadvantage in defending our intellectual property rights and in defending against claims
that ZTlido, GLOPERBA or any of our product candidates infringes or misappropriates third-party intellectual property rights. However, we may seek to use various post-grant administrative proceedings, including new procedures created under the AIA,
to invalidate potentially overly-broad third-party rights. Even if we can defend our position, the cost of doing so may adversely affect our ability to grow, generate revenue or become profitable. In the course of the ongoing litigation or any
future additional litigation to which we may be subject, we may not be able to protect our intellectual property at a reasonable cost, or at all. The outcome of litigation is always uncertain, and in some cases could include judgments against us
that require us to pay damages, enjoin us from certain activities or otherwise affect our legal, contractual or intellectual property rights, which could have a significant adverse effect on our business, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical
industries, including PTO administrative proceedings, such as <I>inter partes </I>reviews, and reexamination proceedings before the PTO or oppositions and revocations and other comparable proceedings in foreign jurisdictions. Numerous U.S. and
foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the
risk increases that ZTlido, GLOPERBA or our product candidates may give rise to claims of infringement of the patent rights of others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite safe harbor provisions, third parties may assert that we are employing their proprietary technology without authorization. There may
be third-party patents, of which we are currently unaware, with claims to materials, formulations, methods of doing research, methods of manufacture or methods for treatment related to the use or manufacture of ZTlido, GLOPERBA or our product
candidates. Because patent applications can take many years to issue, there may be currently pending unpublished patent applications which may later result in issued patents that ZTlido, GLOPERBA or our product candidates may infringe. In addition,
third parties may obtain patents in the future and claim that the use of our technologies infringes these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of ZTlido, GLOPERBA or
any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidate unless we obtain a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for
manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license,
limit our uses, or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further
commercialize ZTlido and GLOPERBA, or develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee
resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses from third
parties, cease marketing ZTlido or GLOPERBA, or developing our product candidates, limit our uses, pay royalties or redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. We cannot
predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research
or allow commercialization of ZTlido, GLOPERBA or our product candidates, if approved. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further commercialize
ZTlido or GLOPERBA, or develop and commercialize one or more of our product candidates, which could harm our business, financial condition and results of operations significantly. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed
alleged confidential information or trade secrets of their former employers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology and pharmaceutical
industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously
provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used
or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying
monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a
distraction to our management team and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The requirements for patentability and the patent enforcement differ in many countries. Filing, prosecuting and defending patents
on ZTlido and all of our product candidates throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United
States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other
jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but
enforcement in some countries is not as strong as that in the United States. These products may compete with ZTlido and our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates, if approved, in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent
them from so competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ongoing conflict in Ukraine and related sanctions could significantly devalue our Ukrainian and Russian,
patent applications. Recent Russian decrees may significantly limit our ability to enforce Russian patents. We cannot predict when or how this situation will change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign
jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals and methods of
treatment of the human body, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign
jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and
could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, many countries have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant
licenses to third parties. Furthermore, many countries limit the enforceability of patents against government agencies or government contractors. In those countries, we may have limited remedies if patents are infringed or if we are compelled to
grant a license to a third party, which could materially diminish the value of those patents and limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to
obtain a significant commercial advantage from the intellectual property that we develop or license, which could adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or
obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors, and inventions agreements with
employees, consultants and advisors, to protect our trade secrets and other proprietary information. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and
technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and these agreements may not effectively prevent disclosure of confidential information and may not provide an
adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. For example, in 2010, the FDA, as part of its Transparency Initiative,
recommended steps that the FDA could take to increase transparency, including with respect to making additional information publicly available on a routine basis, which may include information that we may consider to be trade secrets or other
proprietary information, and it is not clear at the present time how the FDA&#146;s disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our
proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of
misappropriation of a trade secret by an employee, consultant, customer or third party with authorized access. Our security measures may not prevent an employee, consultant or customer from misappropriating our trade secrets and providing them to a
competitor, and any recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse
engineer certain aspects of our products that we consider proprietary. Competitors and other third parties could attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our
intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the
outcome is unpredictable. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions. In addition, some courts inside and outside the United States are less willing or
unwilling to protect trade secrets. Moreover, trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel skilled in the art from company to
company or academic to industry scientific positions. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to
compete with us, which could harm our competitive position. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If
we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our
trade secret information may be jeopardized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reliance on third parties may require us to share our trade secrets, which increases the
possibility that our trade secrets will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we rely on third parties to help manufacture and
supply our products and product candidates, and we expect to collaborate with third parties on the continuing development of future product candidates, we must, at times, share trade secrets with them. We also expect to conduct research and
development programs that may require us to share trade secrets under the terms of our partnerships or agreements with CROs. We seek to protect our proprietary technology in part by entering into agreements containing confidentiality and use
restrictions and obligations, including, material transfer agreements, consulting agreements, confidentiality agreements or other similar agreements with our advisors, contractors, service providers and consultants prior to disclosing proprietary
information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to
share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these
agreements. Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or disclosure would impair our
competitive position and may have an adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, these
agreements typically restrict the ability of our advisors, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts
to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A
competitor&#146;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights and regulatory exclusivity rights do not necessarily address all
potential threats to our competitive advantage. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is uncertain because
legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors may be
able to use our product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations. For example: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Others may be able to make products that are similar to ZTlido, GLOPERBA or our product candidates but that are
not covered by the claims of the patents that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We or our licensors or strategic partners might not have been the first to make the inventions covered by the
issued patent or pending patent application that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We or our licensors or strategic partners might not have been the first to file patent applications covering
certain of our inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our pending patent applications may not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may
be held invalid or unenforceable, as a result of legal challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not develop additional proprietary technologies that are patentable; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The patents of others may have an adverse effect on our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could significantly harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future,
for example with respect to proper priority claims, inventorship, claim scope or requests for patent term adjustments. If we or our partners, collaborators, licensees or licensors, whether current or future, fail to establish, maintain or protect
such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, licensees or licensors, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of
any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such
applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition and results of operations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual
questions, and has been and will continue to be the subject of litigation and new legislation. Publications in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are
typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our own patents or pending patent applications, or that we were
the first to file for patent protection of such inventions. As a result of these and other factors, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent
applications may not result in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patents being issued that protect ZTlido, GLOPERBA and our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of
our patents or narrow the scope of our patent protection. If these changes were to occur, they could have a material adverse effect on our ability to generate revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, we may be subject to a third-party <FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the PTO or become
involved in opposition, derivation, reexamination, <I>inter partes </I>review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of defending our patents or enforcing our
proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate,
our patent rights, allow third parties to commercialize ZTlido, GLOPERBA and our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing
third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or
future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our
owned and potentially licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in
whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of ZTlido, GLOPERBA or our product candidates. Generally,
patents are granted a term of 20 years from the earliest claimed <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. In certain instances, patent term can be adjusted and increased to recapture a portion of delay incurred by the PTO
in examining the patent application. The scope of patent protection may also be limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount
of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not
provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_16"></A>Risks
Related to Government Regulations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the FDA are lengthy, time-consuming and inherently unpredictable, and if
we are ultimately unable to obtain regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The time required to obtain approval from the FDA is unpredictable but typically takes many years following the commencement of clinical trials
and depends upon numerous factors, including the substantial discretion of the regulatory authorities, and its outcome is inherently uncertain. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain
approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. For example, we believe that the data from our Phase 3 CLEAR trial will be sufficient to support a 505(b)(2) NDA submission
for SEMDEXA. However, the FDA may disagree and may require us to conduct additional clinical studies before we are able to submit the NDA, even though we believe the data from the CLEAR trial are adequate. Our future success depends on our ability
to develop, receive regulatory approval for, and introduce new products or product enhancements that will be accepted by the market in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA can delay, limit or deny approval of a product candidate for many reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may disagree with the design or implementation of our clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to such authorities&#146; satisfaction that a product candidate is safe and
effective for its proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or ambiguous results from our clinical trials may not meet the level of statistical significance
required for approval by the FDA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may disagree with our interpretation of data from preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may not agree that the data collected from clinical trials of our product candidates are acceptable or
sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States, and such authorities may impose requirements for additional preclinical studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may disagree regarding the formulation, labeling and/or the specifications of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may decline to approve the manufacturing processes or facilities of third-party manufacturers
with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data
insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage successfully complete
the FDA regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates,
which would significantly harm our business, financial condition and results of operations. In addition, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the
price we intend to charge for our product candidates, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or
desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than an NDA submitted for ZTlido in the United States, which was approved by the FDA in February 2018, we have not previously submitted
an NDA to the FDA for any product candidate, and we cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even
if our clinical trials are successful. If we do not receive regulatory approvals for our product candidates, our business, financial condition and results of operations will be substantially harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the FDA does not conclude that certain of our product candidates satisfy the requirements for the Section&nbsp;505(b)(2) regulatory approval pathway,
or if the requirements for such product candidates under Section&nbsp;505(b)(2) are not as we expect, the approval pathway for those product candidates will likely take significantly longer, cost significantly more and entail significantly greater
complications and risks than anticipated, and in either case may not be successful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our product candidates SEMDEXA, <FONT
STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104,</FONT> we may seek FDA approval through the Section&nbsp;505(b)(2) regulatory pathway. The Hatch-Waxman Act added Section&nbsp;505(b)(2) to the Federal Food, Drug
and Cosmetic Act (the &#147;FDCA&#148;). Section&nbsp;505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials that were not conducted by or for the applicant and for which the applicant
has not obtained a right of reference. Section&nbsp;505(b)(2) allows an NDA we submit to the FDA to rely in part on data in the public domain or the FDA&#146;s prior conclusions regarding the safety and effectiveness of approved compounds, which
could expedite the development program for our product candidates by potentially </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
decreasing the amount of data that we would need to generate in order to obtain FDA approval. If the FDA does not agree that the Section&nbsp;505(b)(2) regulatory pathway is acceptable as we
anticipated, we may need to conduct additional clinical trials, provide additional data and information and meet additional standards for regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if FDA accepts our plan to pursue the Section&nbsp;505(b)(2) regulatory pathway, we cannot assure that our product candidates will
receive the requisite approvals for commercialization. In addition, the pharmaceutical industry is highly competitive, and Section&nbsp;505(b)(2) NDAs are subject to special requirements designed to protect the patent and market exclusivity rights
of sponsors of previously approved drugs that are referenced in a Section&nbsp;505(b)(2) NDA. These requirements may give rise to patent litigation against us and mandatory delays in approval of our NDAs for up to 30 months or longer depending on
the outcome of any litigation. Further, a manufacturer of an approved product may file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. FDA imposes strict
requirements on such petitions in part to dissuade companies from improperly using these petitions to delay approval of competing drug products. Nonetheless, if successful, such petitions can significantly delay, or even prevent, the approval of the
new product. However, even if the FDA ultimately denies such a petition, the FDA may delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section&nbsp;505(b)(2) regulatory pathway, there is
no guarantee this would ultimately lead to accelerated product development or earlier approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any approved product candidate will be subject to
ongoing and continued regulatory review, which may result in significant expense and limit our ability to commercialize such products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even after a product is approved, we will remain subject to ongoing FDA and other regulatory requirements governing the manufacturing, testing,
labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, import, export, record-keeping and reporting of safety and other post-market information. The holder of an approved NDA is obligated to monitor and report
adverse events and, among other things, any failure of a distributed product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the
approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. In addition, the FDA may
impose significant restrictions on the approved indicated uses for which the product may be marketed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These requirements include
submissions of safety and other post-marketing information and reports, registration and listing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. The future discovery of previously unknown
problems with a product, including adverse events of unanticipated type, severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investigation or additional study obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">communications to prescribers or patients about specific information or issues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or
voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning or untitled letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or
suspension or revocation of product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of any event or penalty described above may inhibit our ability to successfully commercialize our product candidates and
generate revenue and could require us to expend significant time and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
resources in response and could generate negative publicity. We may not be able to regain compliance, or we may only be able to regain compliance after a lengthy delay, significant expense, lost
revenues and damage to our reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s and other regulatory authorities&#146; policies may change, and additional laws or
government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we
are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our ability to generate revenue and achieve or sustain profitability. Changes in law or government regulations
may also alter the competitive landscape, potentially to our disadvantage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain manufacturers in the market in which we compete
distribute certain products without completing the FDA approval process. For example, we believe certain lidocaine topical patches, plaster or poultice products marketed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> (&#147;OTC&#148;) and without FDA approval, require approval and compete inappropriately with ZTlido. In December 2018, we filed a citizen&#146;s
petition asking the FDA to clarify its requirements and take enforcement action against such products. The FDA has not responded with a decision or action. The FDA has generally held the position that requests for enforcement action via citizen
petition are not allowed, which may reduce the likelihood of the FDA taking action explicitly in response to our December 2018 petition. Furthermore, we believe the labeling and marketing of certain OTC lidocaine patches products are false and
deceptive, which could cause significant damages to our business and a diminution of goodwill in our intellectual property. In February 2021, we filed a complaint against such manufacturers to seek an award of damages and the entry of injective
relief enjoining further dissemination of such false and deceptive advertisement. In addition, on March&nbsp;7, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#147;CARES Act&#148;) was signed into law, which included statutory
provisions reforming FDA&#146;s mechanisms for regulating OTC drugs. Under the CARES Act, the FDA considers a drug to be generally recognized as safe and effective (&#147;GRASE&#148;) if it meets certain requirements, including items such as the
active ingredient, indication for use, dosage, route of administration, and labeling set forth in the OTC monograph and related rulemakings. Historically, the FDA was required to establish, revise, and amend an OTC monograph by <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">notice-and-comment</FONT></FONT> rulemaking, which was lengthy and resource-intensive. The CARES Act replaces the rulemaking process with a final administrative order process.
Administrative orders may be initiated by the FDA or at the request of a drug manufacturer or any other person. After a period for public comment on the administrative order, the FDA is able to issue a final administrative order, rather than a
regulation, permitting the drug to be marketed over the counter. As this process is much more streamlined and less burdensome, this may benefit the manufacturers of lidocaine topical patches to obtain GRASE status from the FDA and thereby legally
market these products <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> and compete with ZTlido. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or
executive action, either in the United States or abroad. For example, certain policies of the current U.S. administration may impact our business and industry. Namely, recent U.S. administrations have taken several executive actions, including the
issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#146;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking,
issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions, including the Executive Orders, will be implemented, and the extent to which they will impact the FDA&#146;s ability to
exercise its regulatory authority. If these executive actions impose constraints on FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our business, financial condition and results of operations may be
negatively affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A fast track product designation, breakthrough therapy designation or other designation to facilitate
product candidate development may not lead to faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product sponsor may apply for fast track designation from the FDA if a product is intended for the treatment of a serious or life-threatening
condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition. The FDA has broad discretion whether or not to grant this designation. We have received fast track designation for SEMDEXA for
the treatment of sciatica and <FONT STYLE="white-space:nowrap">SP-103</FONT> for the treatment of acute LBP. Even though SEMDEXA and <FONT STYLE="white-space:nowrap">SP-103</FONT> have received fast track designation, we may not experience a faster
process, review or approval compared to conventional FDA procedures. A fast track designation does not expedite clinical trials, or mean that regulatory requirements are less stringent or provide assurance of ultimate marketing approval by the FDA.
Instead, fast track designation provides opportunities for frequent interactions with FDA review staff, as well as eligibility for priority review, if relevant criteria are met, and rolling review of individual sections of an NDA submitted to the
FDA as they become finalized. The FDA may rescind the fast track designation if it believes that the designation is no longer supported by data from our clinical development program. The FDA may also withdraw any fast track designation at any time.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied for breakthrough therapy designation and expect to seek priority review for SEMDEXA for the treatment of sciatica. A
breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough
therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in potentially less efficacious control
regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a
product candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to provide such designation. In any event, the receipt of a breakthrough therapy designation may not result in a faster
development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if SEMDEXA qualifies as a breakthrough therapy for sciatica,
the FDA may later decide that SEMDEXA no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If approved, our products candidates regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (the &#147;BPCIA&#148;), which
created an abbreviated approval pathway under section 351(k) of the Public Health Service Act (the &#147;PHSA&#148;) for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT>
reference biological product. Under the BPCIA, a section 351(k) application for a biosimilar or interchangeable product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In
addition, the approval of a biosimilar or interchangeable product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period
of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full Biologics License Application (&#147;BLA&#148;) for the competing product submitted under section 351(a) of the PHSA containing
the competing sponsor&#146;s own <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#146;s biological product. The
law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether approval of a biological product qualifies for reference product exclusivity turns
on whether FDA consider the approval a &#147;first licensure&#148;. Not every licensure of a biological product is considered a &#147;first licensure&#148; that gives rise to its own exclusivity period. Other aspects of the BPCIA, some of which may
impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our product candidates in a way that is similar to traditional
generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain marketing
approval for biosimilars referencing our product candidates, our product candidates may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in funding for the FDA could hinder its ability to hire and retain key leadership and other personnel, or otherwise prevent new products and
services from being developed or commercialized in a timely manner, which could negatively impact our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of
other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other regulatory authorities may also slow the time necessary for new drugs to be reviewed and/or approved by
necessary government agencies, which would adversely affect our business, financial condition and results of operations. For example, over the last several years, including for 35 days beginning on December&nbsp;22, 2018, the U.S. government has
shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely
review and process our regulatory submissions, which could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Separately, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on March&nbsp;10, 2020, the FDA announced its
intention to postpone most inspections of foreign manufacturing facilities, and on March&nbsp;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July&nbsp;10, 2020, the FDA
announced its intention to resume certain <FONT STYLE="white-space:nowrap">on-site</FONT> inspections of domestic manufacturing facilities subject to a risk-based prioritization system. Increased cases associated with a <FONT
STYLE="white-space:nowrap">COVID-19</FONT> variant led the FDA to again pause inspections, although the FDA announced in February 2022 that it would resume routine domestic surveillance inspections and that it would proceed with certain foreign
surveillance inspections where country conditions permit. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a
prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the
ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to comply with health and data protection laws and regulations could lead to government enforcement actions and civil or criminal penalties,
private litigation or adverse publicity and could negatively affect our operating results and business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our collaborators
are subject to federal, state and foreign data protection laws and regulations which address privacy and data security. In the United States, such laws may include, but are not limited to, numerous federal and state laws and regulations, including
the U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;) and its implementing regulations, state data breach notification laws, state health information privacy laws and federal and state consumer protection
laws, including Section&nbsp;5 of the Federal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Trade Commission Act, which govern the collection, use, disclosure and protection of health-related and other personal information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we are not subject to HIPAA, as we are neither a Covered Entity nor Business Associate (as defined in HIPAA), we may have access to
very sensitive data regarding patients who participate, or whose tissue samples or other biospecimens are used, in our clinical trials. The maintenance of this data imposes upon us administrative and financial burdens, and litigation risks. In
addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data that are subject to privacy and security requirements under HIPAA and other privacy and data security and
consumer protection laws. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly receive individually identifiable health information maintained by a HIPAA-Covered Entity in a manner that is not
authorized or permitted by HIPAA, and subject to other civil and/or criminal penalties if we obtain, use, or disclose information in a manner not permitted by other privacy and data security and consumer protection laws. Our ability to use or
disclose information may be limited by the scope of an authorization signed by clinical trial subjects or the terms of the contract that we enter into with providers or other data sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, states are constantly adopting new laws or amending existing laws relating to the data privacy and security and consumer
protection, requiring attention to frequently changing regulatory requirements. For example, California enacted the California Consumer Privacy Act (the &#147;CCPA&#148;), which creates new individual privacy rights for California consumers and
places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide new disclosure to consumers about such companies&#146; data collection, use and sharing
practices, provide such consumers new ways to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain sales or transfers of personal information, and provide consumers with a private right of action in connection with certain types of incidents.
The CCPA has been amended several times, and will be significantly updated from the California Privacy Rights Act (the &#147;CPRA&#148;), a ballot initiative that passed in November 2020 and which will go into effect on January&nbsp;1, 2023. The
CPRA introduced significant amendments to the CCPA and also created a new state agency vested with authority to implement and enforce the CCPA and the CPRA, the California Privacy Protection Agency (the &#147;CPPA&#148;). New implementing
regulations are expected to be introduced by the CPPA. Virginia also recently enacted a CCPA/CPRA-like law, the Virginia Consumer Data Privacy Act (the &#147;VDCPA&#148;), to provide its residents with similar rights, and Colorado, Connecticut and
Utah have passed similar laws. New legislation enacted in various other states will continue to shape the data privacy environment nationally. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with
respect to confidential, sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. The effects on our business of the CCPA, CPRA, VDCPA and
other similar state laws and general consumer protection authorities are potentially significant, and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. Privacy
laws and regulations are constantly evolving and there are a number of legislative proposals at both the state and federal level that could impose new obligations or limitations in areas affecting our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Federal Trade Commission (the &#147;FTC&#148;) also sets expectations for failing to take appropriate steps to keep consumers&#146;
personal information secure, or failing to provide a level of security commensurate to promises made to individual about the security of their personal information (such as in a privacy notice) may constitute unfair or deceptive acts or practices in
violation of Section&nbsp;5(a) of the Federal Trade Commission Act (the &#147;FTC Act&#148;). The FTC expects a company&#146;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it
holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. With respect
to privacy, the FTC also sets expectations that companies honor the privacy promises made to individuals about how the company handles consumers&#146; personal information. Any failure to honor promises, such as the statements made in a privacy
policy or on a website, may also constitute unfair or deceptive acts or practices in violation of the FTC Act. While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce promises as it
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interprets them, and events that we cannot fully control, such as data breaches, may be result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or
enforcement actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">International data protection laws, including Regulation 2016/679, known as the General Data Protection Regulation
(the &#147;GDPR&#148;), may also apply to health-related and other personal information obtained outside of the United States. The GDPR imposes several data protection requirements in the European Union, as well as imposes potential fines for
noncompliant companies of up to the greater of &#128;20&nbsp;million or 4% of annual global revenue. The regulation imposes numerous requirements for the collection, use, storage and disclosure of personal information, including more stringent
requirements relating to consent and the information that must be shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals of personal data breaches, extensive new internal
privacy governance obligations and obligations to honor expanded rights of individuals in relation to their personal information, including the right to access, correct and delete their data. In addition, the GDPR includes restrictions on
cross-border data transfers. The GDPR increased our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure
compliance with the GDPR, including as implemented by individual European Union countries. Further, the United Kingdom&#146;s decision to leave the European Union, often referred to as Brexit, has led and could also lead to legislative and
regulatory changes and may increase our compliance costs. As of January&nbsp;1, 2021 and the expiry of transitional arrangements agreed to between the United Kingdom and the European Union, data processing in the United Kingdom is governed by a
United Kingdom version of the GDPR (combining the GDPR and the Data Protection Act 2018), exposing us to two parallel regimes, each of which authorizes similar fines and other potentially divergent enforcement actions for certain violations. On
June&nbsp;28, 2021, the European Commission adopted an Adequacy Decision for the United Kingdom, allowing for the relatively free exchange of personal information between the European Union and the United Kingdom, however, the European Commission
may suspend the Adequacy Decision if it considers that the United Kingdom no longer provides for an adequate level of data protection. Other jurisdictions outside the European Union are similarly introducing or enhancing privacy and data security
laws, rules and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with U.S. and international data protection laws and regulations could require us to take on more
onerous obligations in our contracts, increase our compliance costs, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. We cannot guarantee that we are, or will be, in
compliance with all applicable international regulations as they are enforced now or as they evolve. Claims that we have violated individuals&#146; privacy rights, failed to comply with data protection laws or breached our contractual obligations,
even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business involves the use of hazardous materials and we and third-parties with whom we contract must comply with environmental laws and regulations,
which can be expensive and restrict how we do business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development activities involve the controlled storage,
use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and manufacturers and suppliers with whom we may contract are subject to laws and regulations governing the use,
manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our manufacturers&#146; facilities pending their use and disposal. We cannot
eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly
<FONT STYLE="white-space:nowrap">clean-up</FONT> and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. We cannot guarantee that the safety procedures
utilized by third-party manufacturers and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. We do not carry
specific biological or hazardous waste insurance coverage, and our property, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the
event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our
business operations. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production
efforts. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements, which could have a material adverse effect on our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud, illegal activity or other misconduct by our employees, independent contractors, consultants, commercial
partners and vendors. Misconduct by employees could include intentional, reckless and/or negligent conduct that fails to comply with the laws and regulations of the FDA, EU Member States, EMA and other similar foreign regulatory bodies, provide
true, complete and accurate information to the FDA, EMA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with federal and state health-care fraud and abuse laws and regulations, comply with
laws and regulations, including, but not limited to the FCPA and internal policies restricting payments to government agencies and representatives, report financial information or data accurately or disclose unauthorized activities to us. In
particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict
or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by employees, independent contractors, consultants, commercial partners and vendors
could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees,
independent contractors, consultants, commercial partners and vendors, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental
investigations or FDA debarment or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our
rights, those actions could have a significant impact on our business, financial condition and results of operations, including the imposition of significant fines or other sanctions and serious harm to our reputation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, transparency and disclosure, or
sunshine, laws, government price reporting, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and future arrangements with healthcare professionals, clinical sites and clinical investigators, consultants, customers, patient
organizations and third-party payors may subject us to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act. These laws may impact, among other things, our
current activities with clinical study investigators and research subjects, as well as our current and future sales, marketing, patient assistance and education programs. In addition, we may be subject to physician payment transparency laws and
patient privacy regulation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by both the federal government and the states and foreign jurisdictions in which we conduct our business. The laws that may affect our ability to operate include, but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully
soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual, or the furnishing, recommending, or arranging for an item or service for which payment may be made
under a federal healthcare program, such as the Medicare and Medicaid programs &#151; a person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or special intent to violate the law in order to have committed a
violation; in addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal civil and criminal false claims laws, including the False Claims Act, which prohibit, among other things,
individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used a false statement material to a false or fraudulent
claim, or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. The False Claims Act has been used to assert liability on the basis of kickbacks and other improper referrals,
improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, and improper promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses (i.e., uses not expressly approved by the FDA in a drug&#146;s label);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, which imposes criminal liability for, among other things, knowingly and willfully executing, or attempting
to execute, a scheme to defraud any healthcare benefit program, including private third party payors, or falsifying or covering up a material fact or making any materially false or fraudulent statement in connection with the delivery of or payment
for health care benefits, items or services &#151; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA and its implementing regulations, which imposes certain requirements relating to the privacy, security and
transmission of individually identifiable health information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and
medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to
physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), teaching hospitals and, beginning in 2022, certain other healthcare professionals, as well as ownership and investment interests held by the physicians
described above and their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical
devices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal government price reporting laws, which require drug manufacturers to calculate and report complex pricing
metrics to government agencies, including CMS and Department of Veterans Affairs (&#147;VA&#148;), where such reported prices may be used in the calculation of reimbursement and/or discounts on marketed products paid by government healthcare
programs. Participation in these programs and compliance with the applicable requirements may result in potentially significant discounts on products subject to reimbursement under federal healthcare programs and increased infrastructure costs, and
may potentially limit a drug manufacturer&#146;s ability to offer certain marketplace discounts; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Prescription Drug Marketing Act, which restricts the manner in which manufacturers may disseminate
complimentary drug samples to healthcare practitioners, requires physical and accounting controls, and establishes penalties for improper sample distribution; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">state law equivalents of each of the above federal laws, such as licensing, anti-kickback, false claims, consumer
protection and unfair competition laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s
voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug
manufacturers to file reports with states regarding pricing information and marketing expenditures, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and
entities, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any future research and development of our product candidates outside the United States, and any future
sales of our product or product candidates once commercialized outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of
our business activities could be subject to challenge under one or more of such laws. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or
the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business practices and arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs.
Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we
may be subject to, without limitation, civil, criminal, and administrative penalties, damages, monetary fines, disgorgement, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries
or jurisdictions, integrity oversight and reporting obligations to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> imprisonment, contractual damages, reputational harm, diminished profits and future earnings and
curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition and results of operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is
found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our business,
financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the
promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to have improperly promoted <FONT
STYLE="white-space:nowrap">off-label</FONT> uses of ZTlido, GLOPERBA or our product candidates, if approved, or if we are found to have improperly engaged in <FONT STYLE="white-space:nowrap">pre-approval</FONT> promotion prior to the approval of
such product candidates, we may become subject to significant liability. Such enforcement has become more common in the industry. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription
products, such as ZTlido, GLOPERBA and our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#146;s approved
labeling. If we receive marketing approval for our product candidates for our proposed indications, physicians may nevertheless use our product for their patients in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a manner that is inconsistent with the approved label, if the physicians believe in their professional medical judgment it could be used in such manner. However, if we are found to have promoted
our product for any <FONT STYLE="white-space:nowrap">off-label</FONT> uses, the federal government could levy civil, criminal and/or administrative penalties, and seek fines against us. The FDA, Department of Justice or other regulatory authorities
could also request that we enter into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the
promotion of ZTlido, GLOPERBA or our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare reform measures could hinder or prevent our product candidates&#146; commercial success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been, and we expect there will continue to be, a number of legislative and regulatory changes to health care systems in the United
States and abroad that could impact our ability to sell our products profitably. The United States government and other governments have shown significant interest in pursuing healthcare reform. For example, in 2010, the ACA was enacted, which
substantially changed the way healthcare is financed by both governmental and private insurers in the United States. Healthcare reform measures like the ACA may adversely impact the pricing of healthcare products and services in the United States or
internationally and the amount of reimbursement available from governmental agencies or other third-party payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment,
there have been ongoing efforts to modify the ACA and its implementing regulations. For example, tax legislation enacted at the end of 2017 includes provisions that, effective January&nbsp;1, 2019, eliminated the tax penalty for individuals who do
not maintain sufficient health insurance coverage, or the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;individual mandate.&#148; It is unclear how healthcare reform measures enacted by Congress or implemented by the Biden administration
or efforts, if any, to modify the ACA or its implementing regulations, or portions thereof, will impact our business. Litigation and legislation over the ACA and other healthcare reform measures are likely to continue, with unpredictable and
uncertain results. Further, additional legislative changes to and regulatory changes under or related to the ACA remain possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of,
on average, 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May&nbsp;1, 2020,
through May&nbsp;31, 2022, due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the
temporary suspension during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. The American Taxpayer Relief Act of 2012
further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop
new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S.
Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the
relationship between pricing and manufacturer patient programs, as addressed further in the risk factor below titled &#147;<I>If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other
governmental pricing programs once our products come to market, we could be subject to additional reimbursement requirements, penalties, sanctions, and fines, which could have a material adverse effect on our business, financial condition, results
of operations, and future prospects</I>.&#148; While any proposed measures may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
require authorization through additional legislation to become effective, Congress and the Biden administration have each indicated that it will continue to seek new legislative and/or
administrative measures to control drug costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal health care programs and commercial payers will pay for
healthcare products and services, which could result in reduced demand for ZTlido, GLOPERBA and our product candidates, if approved, or additional pricing pressures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control
pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage
importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition and results of operations. In addition, regional
healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Furthermore, there has
been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These or other reforms could reduce the ultimate demand for ZTlido, GLOPERBA and our product
candidates, if approved, or put pressure on our product pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict the likelihood, nature or extent of government
regulation that may arise from future legislation or administrative action in the United States. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or
policies, or if we or such third parties are not able to maintain regulatory compliance, ZTlido may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs applicable
to our product or product candidates, if approved, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations
and future prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to
interpretation by manufacturers, governmental or regulatory agencies and the courts. Such interpretation can change and evolve over time. In the case of Medicaid pricing data, if a manufacturer becomes aware that its reporting for a prior quarter
was incorrect, or has changed as a result of recalculation of the pricing data, the manufacturer is obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase
costs for complying with the laws and regulations governing the Medicaid Drug Rebate Program and could result in an overage or underage in rebate liability for past quarters. Price recalculations also may affect the ceiling price at which a
manufacturer is required to offer its products under the 340B program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A failure to comply with reporting and payment obligations under
the Medicaid Drug Rebate program and other governmental programs could negatively affect financial results. CMS issued a final regulation, which became effective on April&nbsp;1, 2016, to implement the changes under the ACA to the Medicaid Drug
Rebate Program. The final regulation has increased and will continue to increase costs and the complexity of compliance, has been and will continue to be time-consuming to implement, and could have a material adverse effect on the results of
operations, particularly if CMS challenges the approach a manufacturer has taken in the implementation of the final regulation. Other regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate Program
may have a similar impact. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers have obligations to report the average sales price for certain of drugs to the Medicare program
as a part of the agreement to participate in the Medicaid Drug Rebate program. For calendar quarters beginning January&nbsp;1, 2022, manufacturers are required to report the average sales price for certain drugs under
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Medicare program regardless of whether they participate in the Medicaid Drug Rebate program. Statutory or regulatory changes or CMS guidance could affect the average sales price calculations
for products and the resulting Medicare payment rate, and could negatively affect results of operations. Starting in 2023, manufacturers must pay refunds to Medicare for single source drugs or biologics, or biosimilar biological products, reimbursed
under Medicare Part B and packaged in single-dose containers or <FONT STYLE="white-space:nowrap">single-use</FONT> packages, for units of discarded drug reimbursed by Medicare Part B in excess of 10% of total allowed charges under Medicare Part B
for that drug. Manufacturers that fail to pay refunds could be subject to civil monetary penalties of 125&nbsp;percent of the refund amount. Congress further could enact a Medicare Part B inflation rebate, under which manufacturers would owe
additional rebates if the average sales price of a drug were to increase faster than the pace of inflation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health Resources and Services
Administration (&#147;HRSA&#148;) issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which
became effective on January&nbsp;1, 2019. Implementation of this regulation has affected manufacturer obligations and potential liability under the 340B program. Manufacturers are also required to report the 340B ceiling prices for covered
outpatient drugs to HRSA, which then publishes them to 340B covered entities. Any charge by HRSA that a manufacturer has violated the requirements of the program or the regulation could negatively affect financial results. Moreover, under a final
regulation effective January&nbsp;13, 2021, HRSA newly established an administrative dispute resolution (&#147;ADR&#148;) process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered
entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that can be appealed to a federal court. An ADR proceeding could subject a
manufacturer to onerous procedural requirements and could result in additional liability. Further, any additional future changes to the definition of average manufacturer price and the Medicaid rebate amount under the ACA or otherwise could affect
our 340B ceiling price calculations and negatively affect results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Civil monetary penalties can be applied if a
manufacturer (i)&nbsp;is found to have knowingly submitted any false price or product information to the government, (ii)&nbsp;is found to have made a misrepresentation in the reporting of its average sales price, (iii)&nbsp;fails to submit the
required price data on a timely basis, or (iv)&nbsp;is found to have knowingly and intentionally charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also decide to terminate the Medicaid Drug Rebate Agreement,
or HRSA, or to terminate the 340B program participation agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for the manufacturer&#146;s covered outpatient drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, manufacturers are required to provide to CMS a 70% discount on brand name prescription drugs utilized by Medicare Part D
beneficiaries when those beneficiaries are in the coverage gap phase of the Part D benefit design. Congress could enact legislation that sunsets this discount program and replaces it with a new manufacturer discount program. Under either program,
civil monetary penalties could be applied if a manufacturer fails to provide these discounts in the amount of 125&nbsp;percent of the discount that was due. Furthermore, Congress could enact a Medicare Part D inflation rebate, under which
manufacturers would owe additional rebates if the average manufacturer price of a drug were to increase faster than the pace of inflation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Congress could also enact additional changes that affect our overall rebate liability and the information we report to the government as part
of price reporting calculations. In addition, Congress could enact a drug price negotiation program under which the prices for certain high Medicare spend single source drugs would be capped by reference to the
<FONT STYLE="white-space:nowrap">non-federal</FONT> average manufacturer price. This or any other legislative change could impact the market conditions for our products. We expect continued scrutiny on government price reporting and pricing more
generally from Congress, agencies, and other bodies and are seeing an increase in state interest in price reporting, transparency and other policies to address drug pricing concerns. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to applicable law, knowing provision of false information in connection with price
reporting or contract-based requirements under the VA Federal Supply Schedule and/or Tricare programs can subject a manufacturer to civil monetary penalties. These programs and contract-based obligations also contain extensive disclosure and
certification requirements. If a manufacturer overcharges the government in connection with its arrangements with Federal Supply Schedule or Tricare, the manufacturer may be required to refund the difference to the government. Failure to make
necessary disclosures or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and/or response to a government investigation or
enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and future prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to obtain prior FDA authorization for any proposed product brand names, and any failure or delay associated with such approval may
adversely impact our business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any brand names we intend to use for our product
candidates will require authorization from the FDA regardless of whether we have secured a formal trademark registration from the PTO. The FDA typically conducts a review of proposed product brand names, including an evaluation of potential for
confusion with other product names. The FDA may also object to a product brand name if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed product brand names, we may be required to adopt an
alternative brand name for our product candidates. If we adopt an alternative brand name, we would lose the benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in
an effort to identify a suitable product brand name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new
trademark in a timely manner, or at all, which would limit our ability to successfully commercialize our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to the
U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal
penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations are subject to certain anti-corruption laws, including the FCPA, and other anti-corruption laws that apply in countries where we
conduct business, including performing clinical trials. The FCPA and other anti-corruption laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or
other persons to obtain or retain business or gain some other business advantage. We, our commercial partners and our affiliates operate in a number of jurisdictions that pose a risk of potential FCPA violations and we participate in collaborations
and relationships with third parties whose actions could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our
international operations might be subject or the manner in which existing laws might be administered or interpreted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no
assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA or other legal requirements, such as trade control laws. Any investigation of potential violations of the FCPA,
other anti-corruption laws or trade control laws by U.S., European Union or other authorities could have an adverse impact on our reputation, our business, financial condition and results of operations. Furthermore, should we be found not to be in
compliance with the FCPA, other anti-corruption laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, as well as the accompanying legal expenses, any of which could
have a material adverse effect on our reputation and liquidity, as well as on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_17"></A>Risks Related to our Relationship with Sorrento </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain of our directors and officers may have actual or potential conflicts of interest because of their positions with Sorrento. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Jaisim Shah, Dr.&nbsp;Henry Ji, Mr.&nbsp;Dorman Followwill, Ms.&nbsp;Laura&nbsp;J. Hamill,
<FONT STYLE="white-space:nowrap">Dr.&nbsp;Tien-Li</FONT> Lee, Mr.&nbsp;David Lemus and Mr.&nbsp;Tommy Thompson serve on our Board. Mr.&nbsp;Jaisim Shah and Dr.&nbsp;Henry Ji, who are our executive officers, are also members of the board of directors
of Sorrento (and in the case of Dr.&nbsp;Henry Ji, the positions of President, Chief Executive Officer and Chairman of the board of directors of Sorrento). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our Board has determined that Mr.&nbsp;Dorman Followwill, Ms.&nbsp;Laura&nbsp;J. Hamill,
<FONT STYLE="white-space:nowrap">Dr.&nbsp;Tien-Li</FONT> Lee, Mr.&nbsp;David Lemus and Mr.&nbsp;Tommy Thompson are &#147;independent directors&#148; within the meaning of applicable regulatory and stock exchange requirements in the United States,
both Mr.&nbsp;David Lemus and Mr.&nbsp;Dorman Followwill have served, and continue to serve, as directors of Sorrento (and in the case of Mr.&nbsp;Dorman Followwill, the Lead Independent Director of Sorrento) and Tommy Thompson has served, and
continues to serve, as special consultant to the Chief Executive Officer of Sorrento, Dr.&nbsp;Henry Ji. Further, <FONT STYLE="white-space:nowrap">Dr.&nbsp;Tien-Li</FONT> Lee is the founder, the Chief Executive Officer and a director of Aardvark,
which has been involved in an asset purchase transaction with Sorrento in connection with Sorrento&#146;s acquisition of Aardvark&#146;s delayed burst release low dose naltrexone formulation asset and intellectual property rights. As part of
Sorrento&#146;s investment in Aardvark relating to such asset purchase transaction, Sorrento paid cash for shares of Aardvark&#146;s Series B Preferred Stock, resulting in Sorrento holding approximately 8% of Aardvark&#146;s ownership interest as of
December&nbsp;31, 2021. Also as part of such investment, Dr.&nbsp;Henry Ji joined the board of directors of Aardvark in May 2021. Sorrento and Aardvark may enter into more commercial arrangements in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, such directors and officers may own shares of Sorrento common stock, options to purchase shares of Sorrento common stock or other
Sorrento equity awards. These individuals&#146; holdings of Sorrento common stock, options to purchase shares of Sorrento common stock or other equity awards of Sorrento may be significant for some of these persons compared to these persons&#146;
total assets. Their position at Sorrento and the ownership of any Sorrento equity or equity awards creates, or may create the appearance of, conflicts of interest when these directors and officers are faced with decisions that could have different
implications for Sorrento than the decisions have for us. For example, potential conflicts of interest could arise in connection with the resolution of any dispute that may arise between Sorrento and us regarding the terms of the agreements
governing the transition services and the relationship thereafter between the companies. Potential conflicts of interest may also arise if we enter into commercial arrangements with Sorrento in the future. As a result of these actual or apparent
conflicts, we may be precluded from pursuing certain growth initiatives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sorrento currently performs or supports many of our important corporate
functions. Our financial statements may not necessarily be indicative of the conditions that would have existed or our results of operations if we had been operated as an unaffiliated company of Sorrento, and we will incur incremental costs as a
stand-alone public company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are in the process of replicating and replacing certain functions, systems and infrastructure to
which we no longer have the same access after the Business Combination. We are also making investments and hiring additional employees to operate without the same access to Sorrento&#146;s existing operational and administrative infrastructure.
These initiatives are costly to implement. Due to the scope and complexity of the underlying projects relative to these efforts, the amount of total costs could be materially higher than our estimate, and the timing of the incurrence of these costs
is subject to change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sorrento currently performs or supports many important corporate functions for our company. Our financial
statements reflect charges for these services on an allocation basis. As a result, our historical financial statements may not be reflective of conditions that would have existed or what our results of operations would have been had we been a
stand-alone public company and no longer a majority-owned subsidiary of Sorrento. Pursuant to agreements we expect to enter into with Sorrento, we expect that Sorrento will continue to provide us with some
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the services related to these functions on a transitional basis in exchange for agreed-upon fees, and we expect to incur other costs to replace the services and resources that will not be
provided by Sorrento. We are also incurring additional costs as a stand-alone public company. As a stand-alone public company, our total costs related to certain support functions may differ from the costs that were historically allocated to us from
Sorrento. In addition, in the future, we expect to incur internal costs to implement certain new systems, including infrastructure and an enterprise resource planning system, while our legacy systems are currently being fully supported by Sorrento.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to replace these services or enter into appropriate third-party agreements on terms and conditions, including costs,
comparable to those that we will receive from Sorrento under our agreements with Sorrento. Additionally, after the agreements terminate, we may be unable to sustain the services at the same levels or obtain the same benefits as when we were
receiving such services and benefits from Sorrento. When we begin to operate these functions separately, if we do not have our own adequate systems and business functions in place, or are unable to obtain them from other providers, we may not be
able to operate our business effectively or at comparable costs, and our profitability may decline. In addition, we have historically received informal support from Sorrento, which may not be addressed in our agreements with Sorrento. The level of
this informal support will diminish or cease following the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are controlled by Sorrento, whose interests may differ from
those of our public shareholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, Sorrento controls approximately 96.6% of our voting power,
which means that, based on its percentage voting power, Sorrento controls the vote of all matters submitted to a vote of our stockholders. This control will enable Sorrento to control the election of the members of our Board and all other corporate
decisions. In particular, for so long as Sorrento continues to own a majority of our Common Stock, Sorrento will be able to cause or prevent a change of control of the Company or a change in the composition of our Board and could preclude any
unsolicited acquisition of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement and the Certificate of Incorporation, Sorrento has
certain rights, and the ability to take certain actions, that are not otherwise available to all of our stockholders. For example, the Registration Rights Agreement provides Sorrento the right, subject to certain conditions, to demand that we file a
registration statement or request that their shares of our Common Stock be covered by a registration statement that we are otherwise filing. See the section titled &#147;<I>Description of Our Securities &#151; Registration Rights</I>&#148; for
additional information regarding these rights. We have filed the registration statement of which this prospectus forms a part in order to satisfy these obligations. In addition, until such time as Sorrento first ceases to own greater than 50% of the
outstanding voting power of our Common Stock, the Certificate of Incorporation effectively provides Sorrento with the ability to fill vacancies on our Board, remove directors (with or without cause), call a special meeting of our stockholders, amend
the Certificate of Incorporation (subject to approval of our Board) and amend the Bylaws. The directors so elected will have the authority, subject to the terms of our indebtedness and applicable rules and regulations, to issue additional stock,
implement stock repurchase programs, declare dividends and make other decisions. See the section titled &#147;<I>Description of Our Securities &#151; Anti-Takeover Matters in our Governing Documents and Under Delaware Law</I>&#148; for additional
information regarding Sorrento&#146;s ability to take such actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even when Sorrento ceases to control a majority of the total voting
power of Scilex, for so long as Sorrento continues to own a significant percentage of our Common Stock and for so long as the Sorrento Group owns any shares of Series A Preferred Stock, Sorrento will still be able to significantly influence the
composition of our Board and the approval of actions requiring stockholder approval. Accordingly, for such period of time, Sorrento will have significant influence with respect to our management, business plans and policies. Because of the
significant ownership position held by Sorrento, our classified board structure and the rights granted to Sorrento under the Stockholder Agreement, new investors may not be able to effect a change in our business or management. The concentration of
ownership and availability of the foregoing rights could deprive our stockholders of an opportunity to receive a premium for their shares of common stock as part of a sale of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company and ultimately might affect the market price of our Common Stock. See the risk factor below titled &#147;<I>Sorrento, as the holder of Series A Preferred Stock, will have rights,
preferences and privileges that are not held by, and are preferential to, the rights of holders of our Common Stock.</I>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the interests of Sorrento may not be aligned with those of our other stockholders and this could lead to actions that may not be
in the best interests of our other stockholders. For example, Sorrento may have different tax positions or strategic plans for the Company, which could influence its decisions regarding whether and when we should dispose of assets or incur new or
refinance existing indebtedness. Additionally, Sorrento&#146;s significant ownership in the Company may discourage someone from making a significant equity investment in the Company, or could discourage transactions involving a change in control.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Sorrento and its affiliates engage in a broad spectrum of activities, including investments in our industry generally. In
the ordinary course of their business activities, Sorrento and its affiliates may engage in activities where their interests conflict with our interests or those of our other stockholders, such as investing in or advising businesses that directly or
indirectly compete with certain portions of our business or those businesses that are suppliers or customers of ours. The Certificate of Incorporation provides that, to the fullest extent permitted by law, none of Sorrento and its affiliates and any
person or entity who, while a stockholder, director, officer or agent of us or any of our affiliates, is a director, officer, principal, partner, member, manager, employee, agent and/or other representative of Sorrento and its affiliates (each an
&#147;Identified Person&#148;) will have any duty to refrain from (i)&nbsp;engaging in a corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be
competing with us or any of our affiliates or (ii)&nbsp;otherwise investing in or providing services to any person that competes with us or our affiliates engaging, directly or indirectly, in the same or similar business activities or lines of
business in which we operate. In addition, to the fullest extent permitted by law, no Identified Person will have any obligation to offer us or our subsidiaries or affiliates the right to participate in any corporate opportunity in the same or
similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates. This means that Sorrento may pursue acquisition opportunities that may be complementary
to our business and, as a result, those acquisition opportunities may not be available to us. In addition, Sorrento may have an interest in pursuing acquisitions, divestitures and other transactions that, in its judgment, could enhance its
investment, even though such transactions might involve risks to our stockholders or may not prove beneficial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on
December&nbsp;30, 2022, Sorrento announced that its board of directors has authorized Sorrento to dividend to Sorrento equityholders of record as of January&nbsp;9, 2023 an aggregate of 76,000,000 shares of our Common Stock that are currently held
by Sorrento. Provided that the board of directors of Sorrento does not revoke the dividend prior to January&nbsp;19, 2023, the scheduled payment date therefor, following such dividend Sorrento will still continue to hold approximately 53.3% of our
voting power, including shares of our Series A Preferred Stock and shares issuable upon exercise of warrants to purchase shares of our Common Stock, which shares have the rights, preferences and privileges described below, and Sorrento would still
have significant rights that are not otherwise available to holders of our Common Stock.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sorrento, as the holder of Series
A Preferred Stock, has rights, preferences and privileges that are not held by, and are preferential to, the rights of holders of our Common Stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock is issued only to Sorrento and is not convertible into shares of our Common Stock. The holders of Series A
Preferred Stock have rights, preferences and privileges that are senior, or in addition, to the rights, preferences and privileges of the holders of our Common Stock, including the right to receive, in the event of a change of control, liquidation
dissolution or winding up of the Company, a preference amount out of the assets available for distribution to stockholders before any distribution can be made to holders of our Common Stock. The preference amount is $10.00 per share (subject to
adjustment as set forth in the Certificate of Designations). If our Board declares or pays a dividend on our Common Stock, the holders of Series A Preferred Stock will participate, on a deemed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-converted-to-common</FONT></FONT></FONT> stock basis, in such dividend with the holders of our Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Series A Preferred Stock will have certain voting rights over our corporate
actions (including, among others, any change to the shares of Series A Preferred Stock into cash or other property, the issuance of equity securities that rank on a parity with or senior to Series A Preferred Stock with respect to dividend rights or
rights upon liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company and the amendment of the Certificate of Incorporation in a manner that adversely affects the holders of shares of Series A Preferred Stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, from and after the Effective Time, and for so long as the Sorrento Group beneficially
owns any shares of Series A Preferred Stock, among other things, (i)&nbsp;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to our Board (each, a &#147;Stockholder Designee&#148;
and collectively, the &#147;Stockholder Designees&#148;), regardless of whether such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or
appointed by our Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of our Board, or the size of our Board and (ii)&nbsp;we are required to take all actions reasonably
necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to our Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate
a replacement director for any Stockholder Designee that has been removed from our Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of our Board. Notwithstanding the foregoing, the parties have
agreed to ensure that our Board complies with all applicable requirements of the stock exchange, including independence requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Stockholder Agreement also provides that we are prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, amendments to the Certificate of Designations, increases or decreases in the size of
our Board, the incurrence of certain amounts of indebtedness and the payment of dividends on our Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information on
the terms of Series A Preferred Stock, see the section titled &#147;<I>Description of Our Securities &#151; Our Preferred Stock</I>&#148; and the section titled &#147;<I>Certain Relationships and Related Party Transactions &#151; Certain
Relationships of Vickers &#151; Stockholder Agreement with Sorrento.</I>&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to recently enacted state laws in California that
require gender and diversity quotas for boards of directors of public companies headquartered in California. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2018,
California enacted Senator Bill 826 (&#147;SB 826&#148;), which generally requires public companies with principal executive offices in California to have at least two female directors on its board of directors if the company has at least five
directors, and at least three female directors on its board of directors if the company has at least six directors. SB 826 has been challenged in legal proceedings and on May&nbsp;13, 2022, the Superior Court of California for the County of Los
Angeles entered an order striking down SB 826, holding that the statute violates the Equal Protection Clause of the California Constitution. The California Secretary of State has appealed the order and such appeal is currently pending. On
September&nbsp;16, 2022, the appellate court ruled to temporarily stay enforcement of the trial court&#146;s order, which prevented the California Secretary of State from collecting diversity data on corporate disclosure forms pursuant to
SB&nbsp;826, pending a further order of the appellate court. To the extent that this ruling of the appellate court permits the Secretary of State of California to collect and report diversity data, we may be required to comply with additional
disclosure requirements. However, ultimate enforceability of SB 826 remains uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, on September&nbsp;30, 2020,
California enacted Assembly Bill 979 (&#147;AB 979&#148;), which generally requires public companies with principal executive offices in California to include specified numbers of directors from &#147;underrepresented communities&#148;. A director
from an &#147;underrepresented community&#148; means a director who self-identifies as Black, African American, Hispanic, Latino, Asian, Pacific Islander, Native American, Native Hawaiian, Alaska Native, gay, lesbian, bisexual or transgender. By
December&nbsp;31, 2021, each public company with principal executive offices in California was required to have at least one director from an underrepresented </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
community. By December&nbsp;31, 2022, a public company with more than four but fewer than nine directors will be required to have a minimum of two directors from underrepresented communities, and
a public company with nine or more directors will need to have a minimum of three directors from underrepresented communities. On April&nbsp;1, 2022, the Superior Court of California for the County of Los Angeles entered an order striking down AB
979, holding that the statute violates the Equal Protection Clause of the California Constitution. On June&nbsp;6, 2022, a notice of appeal was filed. On September&nbsp;16, 2022, the appellate court ruled to temporarily stay enforcement of the trial
court&#146;s order, which prevented the California Secretary of State from collecting diversity data on corporate disclosure forms pursuant to AB&nbsp;979, pending a further order of the appellate court. To the extent that this ruling of the
appellate court permits the Secretary of State of California to collect and report diversity data, we may be required to comply with additional disclosure requirements. Litigation regarding AB&nbsp;979 will continue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure that we can recruit, attract and/or retain qualified members of our Board and meet gender and diversity quotas under Nasdaq
Listing Rules or any California law that may become applicable to the Company, which may expose us to financial penalties and adversely affect our reputation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_18"></A>Risks Related to this Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>It is not possible to predict the actual number of shares we will sell under the B. Riley Purchase Agreement to the Selling Securityholder, or the actual
gross proceeds resulting from those sales. Further, we may not have access to the full amount available under the B. Riley Purchase Agreement with the Selling Securityholder. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 8, 2023, we entered into the B. Riley Purchase Agreement with the Selling Securityholder, pursuant to which the Selling
Securityholder has committed to purchase up to $500,000,000 of our Common Stock, subject to certain limitations and conditions set forth in the B. Riley Purchase Agreement. The shares of our Common Stock that may be issued under the B. Riley
Purchase Agreement may be sold by us to the Selling Securityholder at our discretion from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally have the right to
control the timing and amount of any sales of our shares of Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement. Sales of our Common Stock, if any, to the Selling Securityholder under the B. Riley Purchase Agreement will
depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to the Selling Securityholder all, some or none of the shares of our Common Stock that may be available for us to sell to the Selling
Securityholder pursuant to the B. Riley Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the purchase price per share to be paid by the Selling Securityholder
for the shares of Common Stock that we may elect to sell to the Selling Securityholder under the B. Riley Purchase Agreement, if any, will fluctuate based on the market prices of our Common Stock prior to each Advance or Additional Advance made
pursuant to the B. Riley Purchase Agreement, if any, it is not possible for us to predict, as of the date of this prospectus and prior to any such sales or additional sales, the number of shares of Common Stock that we will sell to the Selling
Securityholder under the B. Riley Purchase Agreement, the purchase price per share that the Selling Securityholder will pay for shares purchased from us under the B. Riley Purchase Agreement, or the aggregate gross proceeds that we will receive from
those purchases by the Selling Securityholder under the B. Riley Purchase Agreement, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, although the B. Riley Purchase
Agreement provides that we may sell up to an aggregate of $500,000,000 of our Common Stock to the Selling Securityholder, only 28,128,422 shares of our Common Stock (including the aggregate amount of 250,000 Commitment Shares issued to the Selling
Securityholder pursuant to the B. Riley Purchase Agreement) are being registered for resale under the registration statement of which this prospectus forms a part. If we elect to sell to the Selling Securityholder all of the 28,128,422 shares of
Common Stock being registered for resale under this prospectus, depending on the market price of our Common Stock prior to each Advance or Additional Advance made pursuant to the B. Riley Purchase Agreement, the actual
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
gross proceeds from the sale of all such shares may be substantially less than the $500,000,000 available to us under the B. Riley Purchase Agreement, which could materially adversely affect our
liquidity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If it becomes necessary for us to issue and sell to the Selling Securityholder under the B. Riley Purchase Agreement more than
the 28,128,422 shares being registered for resale under this prospectus in order to receive aggregate gross proceeds equal to $500,000,000 under the B. Riley Purchase Agreement, we must file with the SEC one or more additional registration
statements to register under the Securities Act the resale by the Selling Securityholder of any such additional shares of our Common Stock we wish to sell from time to time under the B. Riley Purchase Agreement, which the SEC must declare effective.
Additionally, we would need to obtain stockholder approval to issue shares of Common Stock in excess of the Exchange Cap under the B. Riley Purchase Agreement in accordance with applicable Nasdaq Listing Rules, unless the average price of all
applicable sales of shares of Common Stock under the B. Riley Purchase Agreement equals or exceeds the &#147;Minimum Price&#148; (as such term is defined in Rule 5635 of the Nasdaq Listing Rules), in which case the Exchange Cap limitation would not
apply to issuances and sales of Common Stock under the B. Riley Purchase Agreement. Any issuance and sale by us under the B. Riley Purchase Agreement of shares of Common Stock in addition to the 28,128,422 shares of Common Stock being registered for
resale by the Selling Securityholder under the registration statement of which this prospectus forms a part could cause additional dilution to our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not required or permitted to issue any shares of Common Stock under the B. Riley Purchase Agreement if such issuance would breach our
obligations under the rules or regulations of Nasdaq. In addition, the Selling Securityholder will not be required to purchase any shares of our Common Stock if such sale or additional sale would result in the Selling Securityholder&#146;s
beneficial ownership exceeding 4.99% of the then outstanding voting power or number of Common Stock. Our inability to access a part or all of the amount available under the B. Riley Purchase Agreement, in the absence of any other financing sources,
could have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The sale and issuance of our Common Stock to the Selling Securityholder will cause dilution
to our existing stockholders, and the sale of the shares of Common Stock acquired by the Selling Securityholder, or the perception that such sales may occur, could cause the price of our Common Stock to fall. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price for the shares that we may sell to the Selling Securityholder under the B. Riley Purchase Agreement will fluctuate based on
the price of our Common Stock. Depending on a number of factors, including market liquidity, sales of such shares may cause the trading price of our Common Stock to fall. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when we do sell shares to the Selling Securityholder, the Selling Securityholder may resell all, some, or none of those shares at its
discretion, subject to the terms of the B. Riley Purchase Agreement. Therefore, sales to the Selling Securityholder by us could result in substantial dilution to the interests of other holders of our Common Stock. Additionally, the sale of a
substantial number of shares of our Common Stock to the Selling Securityholder, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a desirable time and price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investors who buy shares of Common Stock at different times will likely pay different prices. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the B. Riley Purchase Agreement, we control the timing and amount of any sales of Common Stock to the Selling Securityholder. If
and when we do elect to sell shares of our Common Stock to the Selling Securityholder pursuant to the B. Riley Purchase Agreement, the Selling Securityholder may resell all, some, or none of such shares in its discretion and at different prices,
subject to the terms of the B. Riley Purchase Agreement. As a result, investors who purchase shares from the Selling Securityholder in this offering at different times will likely pay different prices for those shares, and so may experience
different levels of dilution and, in some cases, substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from the Selling Securityholder in this offering as
a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
result of future sales made by us to the Selling Securityholder at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number
of shares to the Selling Securityholder under the B. Riley Purchase Agreement, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangement with the Selling Securityholder may make it more difficult
for us to sell equity or equity-related securities in the future at a desirable time and price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our management team will have broad discretion over
the use of the net proceeds from our sale of shares of Common Stock to the Selling Securityholder, if any, and you may not agree with how we use the proceeds and the proceeds may not be invested successfully. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team will have broad discretion as to the use of the net proceeds from our sale of shares of Common Stock to the Selling
Securityholder, if any, and we could use such proceeds for purposes other than those contemplated at the time of commencement of this offering. Accordingly, you will be relying on the judgment of our management team with regard to the use of those
net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending their use, we may invest those net proceeds in a way that does not
yield a favorable, or any, return for us. The failure of our management team to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_19"></A>Risks Related to Ownership of our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our operations and performance do not meet the expectations of investors or securities analysts, the market price of our securities may decline.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the factors listed below could have a negative impact on your investment in our securities, and our securities may trade at
prices significantly below the price you paid for them. In such circumstances, the trading price of our securities may not recover and may experience a further decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors affecting the trading price of our securities may include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize ZTlido, GLOPERBA or our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the status and cost of our marketing commitments for ZTlido, GLOPERBA and our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements regarding results of any clinical trials relating to our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated serious safety concerns related to the use of ZTlido, GLOPERBA or any of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory decisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in laws or regulations applicable to ZTlido, GLOPERBA or our product candidates, including but not
limited to clinical trial requirements for approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">legal disputes or other developments relating to proprietary rights, including patents, litigation matters and
our ability to obtain patent protection for ZTlido, GLOPERBA or our product candidates, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our decision to initiate a clinical trial, not initiate a clinical trial or to terminate an existing clinical
trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our dependence on third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of the introduction of new products by our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions and trends in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements concerning product development results or intellectual property rights of others;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future issuances of common stock or other securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to meet or exceed any financial guidance or expectations regarding product development milestones that we
may provide to the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated variations in quarterly operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to meet or exceed the estimates and projections of the investment community; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overall performance of the equity markets and other factors that may be unrelated to our operating performance or
the operating performance of our competitors, including changes in market valuations of similar companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or
our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates by the Company or by any securities analysts who might cover our stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuation of the market values of any of our potential strategic investments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuances of debt or equity securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with our contractual obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our Common Stock by us or our stockholders in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ineffectiveness of our internal controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports about the Company or its industry or positive or negative recommendations or
withdrawal of research coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to effectively integrate the operations of Semnur; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general political and economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effects of natural or <FONT STYLE="white-space:nowrap">man-made</FONT> catastrophic events;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effects of public health crises, pandemics and epidemics, such as the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events or factors, many of which are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the equity markets in general have recently experienced extreme price and volume fluctuations. Continued market fluctuations could
result in extreme volatility in the price of our Common Stock, which could cause a decline in the value of our Common Stock. Price volatility of our Common Stock might worsen if the trading volume of our Common Stock is low. In the past,
stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies&#146; stock. Such litigation, if instituted against the Company, could cause
us to incur substantial costs and divert management&#146;s attention and resources from our business. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#147;<I>Risk
Factors</I>&#148;, could have a dramatic and material adverse impact on the market price of our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legacy Scilex has not paid cash
dividends in the past and we do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the capital appreciation, if any, of our Common Stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex has not paid cash dividends on its common stock and we do not anticipate paying cash dividends on our Common Stock in the
foreseeable future. Should we decide in the future to do so, as a holding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company, our ability to pay dividends on our capital stock and meet other obligations depends upon the receipt of dividends or other payments from our operating subsidiaries, including Legacy
Scilex. In addition, our ability to pay dividends may be limited by covenants in future outstanding indebtedness that we or our subsidiaries may incur. Since we do not intend to pay dividends, a stockholder&#146;s ability to receive a return on such
stockholder&#146;s investment will depend on any future appreciation in the market value of our Common Stock. There is no guarantee that our Common Stock will appreciate or even maintain the price at which our stockholders have purchased it. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of a substantial number of shares of our Common Stock may cause the price of our Common Stock to decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our Common Stock, the trading price of our Common
Stock could decline and it could impair our ability to raise capital through the sale of additional equity securities. Unless otherwise waived by the Company and the applicable parties to the Registration Rights Agreement, Sorrento and certain
directors and equityholders of Vickers, including the Sponsors, are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions that restrict their ability to transfer certain of their shares of our Common Stock or any security convertible
into or exercisable or exchanged for our Common Stock until 180 days from the Effective Time, subject to certain exceptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operating results
may fluctuate significantly. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our operating results to be subject to quarterly, and possibly annual, fluctuations. Our
net loss and other operating results will be affected by numerous factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in the level of expenses related to our development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the addition or termination of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any intellectual property infringement lawsuit in which we may become involved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments affecting ZTlido, GLOPERBA or our product candidates, regulatory approvals of our product
candidates, and the level of underlying demand for such products and purchasing patterns; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or
receive under these arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our quarterly or annual operating results fall below the expectations of investors
or securities analysts, the price of our Common Stock could decline substantially. Furthermore, any quarterly or annual fluctuations in our operating results may, in turn, cause the price of our Common Stock to fluctuate substantially. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse opinion regarding our stock, our
stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our Common Stock will be influenced by the research and
reports that industry or securities analysts publish about the Company or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. Since we became public through a merger, securities analysts
of major brokerage firms may not provide coverage of the Company since there is no incentive to brokerage firms to recommend the purchase of our Common Stock. If no or few securities or industry analysts commence coverage of the Company, the trading
price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover it issues an adverse opinion regarding the Company, our business model, our intellectual property or
our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of the Company or fail to publish reports on us
regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our existing stockholders, restrict our operations or
require us to relinquish rights to ZTlido or our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue additional equity securities to fund future
expansion and pursuant to equity incentive or employee benefit plans. We may also issue additional equity for other purposes. These securities may have the same rights as our Common Stock or, alternatively, may have dividend, liquidation or other
preferences to our Common Stock. The issuance of additional equity securities, whether pursuant to the B. Riley Purchase Agreement, the Yorkville Purchase Agreement (pursuant to which may also sell up to $500,000,000 of shares of our Common Stock,
as more fully described elsewhere in this prospectus) or otherwise, will dilute the holdings of existing stockholders and may reduce the share price of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Equity Incentive Plan, which became effective on November&nbsp;9, 2022, we are authorized to grant equity awards to our
employees, directors and consultants. In addition, pursuant to the ESPP, which became effective on November&nbsp;9, 2022, we are authorized to sell shares to our employees. A total of 20,276,666 and 2,875,759 shares of our Common Stock have been
reserved for future issuance under the Equity Incentive Plan and the ESPP, respectively. In addition, the Equity Incentive Plan and ESPP provide for annual automatic increases in the number of shares reserved thereunder, in each case, beginning on
January&nbsp;1, 2023. As a result of such annual increases, our stockholders may experience additional dilution, which could cause the price of our Common Stock to fall. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement entered into in connection with the Business Combination, certain stockholders of Vickers and
Legacy Scilex can each demand that we register their registrable securities under certain circumstances and will each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective
registration statement under the Securities Act covering such securities and certain of our other securities. We have filed the registration statement of which this prospectus forms a part in order to satisfy the foregoing obligations. The
registration of these securities will permit the public sale of such securities, subject to certain contractual restrictions imposed by the Registration Rights Agreement and the Merger Agreement. The presence of these additional shares of our Common
Stock trading in the public market may have an adverse effect on the market price of our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through
collaboration, licensing or other similar arrangements, we may have to relinquish valuable rights to ZTlido or our product candidates, or grant licenses on terms unfavorable to the Company. If adequate funds are not available, our ability to achieve
profitability or to respond to competitive pressures would be significantly limited and we may be required to delay, significantly curtail or eliminate the development of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal stockholders, directors and executive officers will own a significant percentage of our capital stock, and have significant influence over
our management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors, executive officers, holders of 5% or more of our capital stock and their respective beneficially
own, in the aggregate, approximately 97% of our outstanding voting stock (and following the dividend of 76,000,000 shares of our Common Stock by Sorrento to certain of its equityholders, approximately 60% of our outstanding voting stock). This
concentration of voting power may make it less likely that any other holder of our Common Stock will be able to affect the way we are managed and could delay or prevent an acquisition of the Company on terms that other stockholders may desire. This
could prevent transactions in which stockholders might otherwise recover a premium for their shares over current market prices. See &#147;<I>Risk Factors &#151; We are</I> <I>controlled by Sorrento, whose interests may differ from those of our
public shareholders</I>&#148; above for additional information regarding Sorrento&#146;s influence and control in the Company. See &#147;<I>Security Ownership of Certain Beneficial Owners and Management</I>&#148; for information regarding the
ownership of our outstanding Common Stock by our directors, executive officers, and current beneficial owners of 5% or more of our voting securities and their respective affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating loss and tax credit carryforwards may be subject to limitation.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, a change of more than 50% in the ownership of a company&#146;s stock, by value, over a three-year period constitutes an
ownership change for U.S. federal income tax purposes. An ownership change may limit our ability to use our net operating loss carryforwards attributable to the period prior to the change. We have experienced a corporate reorganization in the past,
some ownership changes as a result of the Business Combination and/or some subsequent changes in the future in our stock ownership (some of which shifts are outside our control). As a result, if we earn net taxable income, our ability to use our <FONT
STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards to offset U.S. federal taxable income may become subject to limitations, which could potentially result in increased future tax liability for the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tax Cuts and Jobs Act of 2017 (the &#147;TCJA&#148;), as amended by the CARES Act, includes changes to U.S. federal tax rates and the
rules governing net operating loss (&#147;NOL&#148;) carryforwards. Under the TCJA, as modified by the CARES Act, limits a taxpayer&#146;s ability to utilize NOL carryforwards to 80% of taxable income (as calculated before taking the NOLs, and
certain other tax attributes, into account) for taxable years beginning after December&nbsp;31, 2020. In addition, NOLs arising in tax years ending after December&nbsp;31, 2017 and before January&nbsp;1, 2021 may be carried back to each of the five
taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December&nbsp;31, 2020 and before January&nbsp;1, 2026 may not be carried back. NOLs arising in tax years beginning after December&nbsp;31, 2017 can
be carried forward indefinitely. NOLs generated in tax years beginning before January&nbsp;1, 2021 will not be subject to the taxable income limitation, and NOLs generated in tax years ending before January&nbsp;1, 2018 will continue to have a <FONT
STYLE="white-space:nowrap">two-year</FONT> carryback and <FONT STYLE="white-space:nowrap">20-year</FONT> carryforward period. Deferred tax assets for NOLs will need to be measured at the applicable tax rate in effect when the NOL is expected to be
utilized. The changes in the carryforward/carryback periods, as well as the new limitation on use of NOLs may significantly impact our ability to utilize our NOLs to offset taxable income in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating
results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates
and assumptions that affect the amounts reported in our combined consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions change or if actual
circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of
our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in the Certificate of Incorporation and the Bylaws and under Delaware law could make an acquisition of
our Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws and the DGCL contains provisions that could make it more difficult for a third party to acquire
the Company, even if doing so might be beneficial to our stockholders. Among other things, these provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow our Board to authorize the issuance of undesignated preferred stock, the terms of which may be established
and the shares of which may be issued without stockholder approval, and which may include supermajority voting, special approval, dividend, or other rights or preferences superior to the rights of other stockholders; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for a classified board of directors with staggered three-year terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, at any time after the Sorrento Group first ceases to beneficially own more than 50% in voting power
of the then-outstanding shares of our Common Stock entitled to vote generally in the election of directors (the &#147;Sorrento Trigger Event&#148;), directors may only be removed for cause, and only by the affirmative vote of holders of at least 66
2/3% in voting power of all the then-outstanding shares of our Common Stock entitled to vote thereon, voting together as a single class; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit stockholder action by written consent from and after the Sorrento Trigger Event; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, at any time after the Sorrento Trigger Event, special meetings may only be called by or at the
direction of the Chairperson of the Board, the Board or the Chief Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, at any time after the Sorrento Trigger Event, any alteration, amendment or repeal, in whole or in
part, of any provision of the Bylaws by our stockholders will require the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our Common Stock entitled to vote thereon, voting together as a
single class; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish advance notice requirements for nominations for elections to the Board and for proposing matters that
can be acted upon by stockholders at stockholder meetings. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL generally prohibits a Delaware
corporation from engaging in any of a broad range of business combinations with any interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder. We have expressly elected not to be
governed by Section&nbsp;203 of the DGCL until the occurrence of a Sorrento Trigger Event. At that time, such election shall be automatically withdrawn and we will thereafter be governed by Section&nbsp;203 of the DGCL, except that the restrictions
on business combinations of Section&nbsp;203 of the DGCL will not apply to Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) regardless of its percentage ownership of our Common Stock. These provisions
could discourage, delay or prevent a transaction involving a change in control of the Company. These provisions could also discourage proxy contests and make it more difficult for our stockholders to elect directors of their choosing and cause us to
take other corporate actions they desire, including actions that our stockholders may deem advantageous. In addition, because our Board is responsible for appointing the members of our management team, these provisions could in turn affect any
attempt by our stockholders to replace current members of our management team. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These anti-takeover provisions and other provisions in the
Certificate of Incorporation, the Bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of the Board or initiate actions that are opposed by our then-current board of directors and could also
delay or impede a merger, tender offer or proxy contest involving the Company. The existence of these provisions could negatively affect the price of our Common Stock and limit opportunities for a stockholder to realize value in a corporate
transaction. For information regarding these and other provisions, see the section titled &#147;<I>Description of Our Securities.</I>&#148; In addition, if prospective takeovers are not consummated for any reason, we may experience negative
reactions from the financial markets, including negative impacts on the price of our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Certificate of Incorporation designates the
Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders and the federal district courts of the United States as the exclusive forum for litigation arising under the
Securities Act, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with the Company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Certificate of Incorporation, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of
the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter
jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom, will, to the fullest extent permitted by law, be the sole and exclusive forum for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers,
employees or stockholders to us or our stockholders; (iii)&nbsp;any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of the DGCL, the Certificate of
Incorporation or the Bylaws; (iv)&nbsp;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws; (v)&nbsp;any action or proceeding asserting a claim against us or
any of our current or former directors, officers, employees or stockholders as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware and (vi)&nbsp;any action asserting an &#147;internal corporate claim,&#148; as
that term is defined in Section&nbsp;115 of the DGCL; <I>provided that</I>, for the avoidance of doubt, the foregoing forum selection provision will not apply to claims arising under the Exchange Act or any other claim for which the federal courts
have exclusive jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that, unless we consent in writing to the selection of an
alternative forum, to the fullest extent permitted by law, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The
Certificate of Incorporation further provides that any person or entity purchasing or otherwise acquiring any interest in shares of our Common Stock is deemed to have notice of and consented to the provisions of the Certificate of Incorporation
described above. See the section titled &#147;<I>Description of Our Securities &#151; Anti-Takeover Measures in our Governing Documents and Under Delaware Law &#151; Exclusive Forum</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forum selection provisions in the Certificate of Incorporation may have the effect of discouraging lawsuits against our directors and
officers. The enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In
addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. If the enforceability of our forum selection provisions were to be challenged, it may incur additional costs associated with
resolving such challenge. While we currently have no basis to expect any such challenge would be successful, if a court were to find its forum selection provisions to be inapplicable or unenforceable with respect to one or more of these specified
types of actions or proceedings, we may incur additional costs associated with having to litigate in other jurisdictions, which could result in a diversion of the time and resources of our employees, management and board of directors, and could have
an adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company, and we cannot be certain if
the reduced reporting requirements applicable to emerging growth companies will make our Common Stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take
advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of
the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and
stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our Common Stock less attractive because we may rely on these exemptions. If some investors find our Common Stock less attractive
as a result, there may be a less active trading market for our Common Stock and our stock price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an
emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the closing of the IPO, (b)&nbsp;in which we have total annual gross revenue of at least $1.235&nbsp;billion, or
(c)&nbsp;in which we are deemed to be a large accelerated filer, which requires the market value of our Common Stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> to equal or exceed $700&nbsp;million as of the last business
day of the second fiscal quarter of such year, and (2)&nbsp;the date on which we have issued more than $1&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can also delay adopting new or revised
accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or
revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of
existing guidance to changes in our business could significantly affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a
controlled company within the meaning of the Nasdaq Listing Rules and, as a result, will qualify for, and may rely on, exemptions from certain corporate governance requirements. Our stockholders may not have the same protection afforded to
stockholders of companies that are subject to such governance requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sorrento controls a majority of the voting power of
our outstanding shares of Common Stock. As a result, we are a &#147;controlled company&#148; within the meaning of the corporate governance standards of Nasdaq. Under these corporate governance standards, a company of which more than 50% of the
voting power for the election of directors is held by an individual, group or another company is a &#147;controlled company&#148; and may elect not to comply with certain corporate governance requirements. For example, controlled companies, within
one year of the date of the listing of their common stock: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are not required to have a board that is composed of a majority of &#147;independent directors&#148; as defined
under the Nasdaq Listing Rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are not required to have a compensation committee that is composed entirely of independent directors or have a
written charter addressing the committee&#146;s purpose and responsibilities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are not required to have director nominations be made, or recommended to the full board of directors, by its
independent directors or by a nominating and corporate governance committee that is composed entirely of independent directors, and to adopt a written charter or a board resolution addressing the nominations process. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we do not presently intend to rely on these exemptions, we may opt to utilize these exemptions in the future as long as we remain a
controlled company. Accordingly, our stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cease to be a &#147;controlled company&#148; in the future, we will be required to comply with the Nasdaq listing standards, which may
require replacing a number of our directors and will require development of certain other governance-related policies and practices. These and any other actions necessary to achieve compliance with such rules may increase our legal and
administrative costs, will make some activities more difficult, time-consuming and costly and may also place additional strain on our personnel, systems and resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs as a result of operating as a public company, and our management will devote substantial time to related compliance
initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incur significant legal, accounting and other expenses that Legacy Scilex did not incur as a private company, and
these expenses may increase even more after we are no longer an &#147;emerging growth company.&#148; We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection
Act (the &#147;Dodd-Frank Act&#148;), as well as rules and regulations adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, we
expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly, which will increase our operating expenses. For example, we expect these rules and
regulations to make it more difficult and more expensive for the Company to obtain directors&#146; and officers&#146; liability insurance and we may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required to incur substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The
impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on the Board, our board committees or as executive officers. Advocacy efforts by stockholders and third parties may also prompt
additional changes in governance and reporting requirements, which could further increase costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we expect that we will need
to implement an enterprise resource planning (&#147;ERP&#148;) system. An ERP system is intended to combine and streamline the management of our financial, accounting, human resources, sales and marketing and other functions, enabling it to manage
operations and track performance more effectively. However, an ERP system would likely require us to complete many processes and procedures for the effective use of the system or to run our business using the system, which may result in substantial
costs. Any disruptions or difficulties in implementing or using an ERP system could adversely affect our controls and harm our business, financial condition and results of operations, including our ability to forecast or make sales and collect our
receivables. Moreover, such disruption or difficulties could result in unanticipated costs and diversion of management attention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a
public company, we are required to incur additional costs and obligations in order to comply with SEC rules that implement Section&nbsp;404 of the Sarbanes-Oxley Act. Under these rules, we are required to make a formal assessment of the
effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company, we will be required to include an attestation report on internal control over financial reporting issued by our independent
registered public accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaging in a process to document and evaluate its internal control over financial reporting, which is both costly and
challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting,
continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively, and implement a continuous reporting and improvement process for internal control over financial reporting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and
require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of our testing, our management may identify material weaknesses or deficiencies which may not be remedied in time
to meet the deadline imposed by the Sarbanes-Oxley Act. See &#147;<I>Risk Factors &#151; We have identified a material weakness in our internal control over financial reporting. Any material weakness may cause us to fail to timely and accurately
report our financial results or</I> <I>result in a material misstatement of our financial statements.</I>&#148; above for additional information regarding a previously identified material weakness. These reporting and other obligations place
significant demands on our management and administrative and operational resources, including accounting resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, changing
laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws,
regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies.
This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and
standards, and this investment may result in increased general and administrative expenses and a diversion of our management&#146;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new
laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and there could be a
material adverse effect on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to meet Nasdaq&#146;s continued listing requirements could result in a delisting of our
Common Stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to satisfy Nasdaq&#146;s continued listing requirements, such as the corporate governance requirements or
the minimum closing bid price requirement, Nasdaq may take steps to delist our Common Stock. Such a delisting would likely have a negative effect on the price of our Common Stock and would impair a stockholder&#146;s ability to sell or purchase our
Common Stock when a stockholder wishes to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our Common Stock to become listed again, stabilize the
market price or improve the liquidity of our Common Stock, prevent our Common Stock from dropping below the Nasdaq minimum bid price requirement or prevent future <FONT STYLE="white-space:nowrap">non-compliance</FONT> with Nasdaq&#146;s listing
requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive U.S. federal income tax reform could adversely affect the Company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes to tax laws, which changes may have retroactive application, could adversely affect the Company or holders of our Common Stock. In
recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The TCJA,
which was enacted in 2017, included changes to U.S. federal tax rates, imposed significant additional limitations on the deductibility of interest, allowed for the expensing of capital expenditures, and put into effect the migration from a
&#147;worldwide&#148; system of taxation to a modified territorial system. On March&nbsp;27, 2020, President Trump signed into law the CARES Act, which included certain changes in tax law (including to the TCJA) intended to stimulate the U.S.
economy in light of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including temporary beneficial changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. On August&nbsp;16, 2022,
President Biden signed into law the Inflation Reduction Act of 2022, which contained certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations, an excise tax of 1% on certain corporate stock <FONT
STYLE="white-space:nowrap">buy-backs,</FONT> and an excise tax with respect to certain drug sales for failing to offer a price that is not equal to or less than the negotiated &#147;maximum fair price&#148; under the law or for taking price
increases that exceed inflation. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. The impact of these tax reforms on holders of our Common Stock is uncertain
and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our Common Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Warrants will become exercisable for our Common Stock, which would increase the number of shares eligible for future resale in the public market and
result in dilution to our stockholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outstanding warrants to purchase an aggregate of 11,003,988 shares of our Common Stock are
exercisable in accordance with the terms of the Warrant Agreement governing those securities. The exercise price of these Warrants is $11.50 per share. To the extent such Warrants are exercised, additional shares of our Common Stock will be issued,
which will result in dilution to the holders of our Common Stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market, or the fact that such Warrants may be
exercised, could adversely affect the prevailing market prices of our Common Stock. However, there is no guarantee that the Warrants will ever be in the money prior to their expiration, and as such, the Warrants may expire worthless. See below risk
factor, &#147;<I>The Warrants may never be in the money, and they may expire worthless and the terms of the Warrants may be amended in a manner adverse to a holder if holders of a majority of the then-outstanding Warrants approve of such
amendment</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Warrants may never be in the money, they may expire worthless and the terms of the Warrants may be amended in a manner
adverse to a holder if holders of a majority of the then-outstanding Warrants approve of such amendment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Warrants were issued
in registered form under the Warrant Agreement between Continental, as warrant agent, and Vickers. The Warrant Agreement provides that the terms of the Warrants may be amended without the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consent of any holder to cure any ambiguity or correct any defective provision or correct any mistake, but requires the approval by the holders of a majority of the then-outstanding Warrants to
make any change that adversely affects the interests of the registered holders of Warrants. Accordingly, we may amend the terms of the Warrants in a manner adverse to a holder if holders of a majority of the then-outstanding Warrants approve of such
amendment. Although our ability to amend the terms of the Warrants with the consent of majority of the then-outstanding Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the
Warrants, convert the Warrants into cash, shorten the exercise period, or decrease the number of shares of our Common Stock purchasable upon exercise of a Warrant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may redeem any unexpired Warrants prior to their exercise at a time that is disadvantageous to you, thereby making the Warrants worthless.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the ability to redeem outstanding Warrants at any time after they become exercisable and prior to their expiration, at a
price of $0.01 per Warrant, provided that the closing price of our Common Stock equals or exceeds $18.00 per share (as adjusted for share subdivisions, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like)
on each of the 20 trading days within any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">30-trading-day</FONT></FONT> period commencing after the Warrants become exercisable and ending on the third trading day prior to the date on
which notice of redemption is given. If and when the Warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws.
Redemption of the outstanding Warrants could force the holders thereof to: (i)&nbsp;exercise such Warrants and pay the exercise price therefor at a time when it may be disadvantageous for a holder to do so; (ii)&nbsp;sell such Warrants at the
then-current market price when a holder might otherwise wish to hold such Warrants; or (iii)&nbsp;accept the nominal redemption price that, at the time the outstanding Warrants are called for redemption, is likely to be substantially less than the
market value of such Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may redeem the Warrants at any time after they become exercisable and prior to their
expiration for a number of shares of our Common Stock determined based on the fair market value of our Common Stock. The value received upon exercise of the Warrants (1)&nbsp;may be less than the value the holders would have received if they had
exercised their Warrants at a later time where the underlying share price is higher and (2)&nbsp;may not compensate the holders for the value of the Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_20"></A>COMMITTED EQUITY FINANCING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 8, 2023, we entered into the B. Riley Purchase Agreement with the Selling Securityholder. Pursuant to the B. Riley Purchase
Agreement, we have the right to sell to the Selling Securityholder up to $500,000,000 of shares of our Common Stock, subject to certain limitations and conditions set forth in the B. Riley Purchase Agreement, from time to time during the term of the
B. Riley Purchase Agreement. Sales of Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement, and the timing of any such sales, are at our option, and we are under no obligation to sell any securities to the Selling
Securityholder under the B. Riley Purchase Agreement. In accordance with our obligations under the B. Riley Purchase Agreement, we have filed the registration statement of which this prospectus forms a part with the SEC to register under the
Securities Act the resale by the Selling Securityholder of up to 28,128,422 shares of Common Stock, consisting of an aggregate amount of 250,000 Commitment Shares and up to 27,878,422 shares of Common Stock that we may elect, in our sole discretion,
to issue and sell to the Selling Securityholder, from time to time under the B. Riley Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have the right to
commence any sales of our Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement until the date on which all of the conditions to the Selling Securityholder&#146;s purchase obligation set forth in the B. Riley Purchase
Agreement have been satisfied, including that the registration statement of which this prospectus forms a part be declared effective by the SEC and the final form of this prospectus is filed with the SEC. From and after such date, we will have the
right, but not the obligation, from time to time at our discretion until the first day of the month next following <FONT STYLE="white-space:nowrap">the&nbsp;36-month&nbsp;anniversary</FONT> of the date on which this registration statement has been
declared effective by the SEC, to purchase a number of shares of Common Stock not to exceed the Maximum Advance Amount as described further below under the heading &#147;&#151;<I>Advances and Payments of Common Stock Under the B. Riley Purchase
Agreement</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will control the timing and amount of any sales of Common Stock to the Selling Securityholder. Actual sales of
shares of our Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement will depend on a variety of factors to be determined by us from time to time, which may include, among other things, market conditions, the trading price
of our Common Stock, and determinations by us as to the appropriate sources of funding for our company and its operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to
the terms of the B. Riley Purchase Agreement, we may not sell any shares of Common Stock thereunder and the Selling Securityholder shall not have the obligation to purchase shares of Common Stock thereunder to the extent (but only to the extent)
that after giving effect to such purchase and sale, the aggregate number of shares of Common Stock issued thereunder would exceed 28,128,422 shares of Common Stock, which number of shares is equal to 19.9% of the aggregate amount of Common Stock
issued and outstanding as of the date of the B. Riley Purchase Agreement, unless (i)&nbsp;we obtain stockholder approval to issue shares of Common Stock in excess of the Exchange Cap in accordance with the applicable Nasdaq Listing Rules or
(ii)&nbsp;the average price of all applicable sales of shares of Common Stock under the B. Riley Purchase Agreement equals or exceeds $4.87 which represents the &#147;Minimum Price&#148; (as such term is defined in Rule 5635 of the Nasdaq Listing
Rules). Moreover, we may not issue or sell any shares of Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by the Selling
Securityholder and its affiliates (as calculated pursuant to Section&nbsp;13(d) of the Exchange Act and Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated thereunder), would result in the Selling Securityholder beneficially owning shares
of Common Stock in excess of the 4.99% Beneficial Ownership Limitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the Selling Securityholder may assign or transfer
any of our respective rights and obligations under the B. Riley Purchase Agreement, and no provision of the B. Riley Purchase Agreement may be modified or waived by the parties other than by an instrument in writing signed by both parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net proceeds from sales, if any, under the B. Riley Purchase Agreement, will depend on the frequency and prices at which we sell shares of
Common Stock to the Selling Securityholder. To the extent we sell shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the B. Riley Purchase Agreement, we currently plan to use any proceeds therefrom for working capital and general corporate purposes, which may include capital expenditures, research and
development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the Selling Securityholder&#146;s commitment to purchase shares of Common Stock at our direction upon the
terms and subject to the conditions set forth in the B. Riley Purchase Agreement, we issued 250,000 Commitment Shares to the Selling Securityholder and paid $10,000 to B. Riley Principal Investments, LLC, a subsidiary of the Selling Securityholder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The B. Riley Purchase Agreement contains customary representations, warranties, conditions and indemnification obligations of the
parties. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to
limitations agreed upon by the contracting parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_201"></A>Advances of Common Stock Under the B. Riley Purchase Agreement
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will have the right, but not the obligation, from time to time at our discretion, until the first day of the month next following <FONT
STYLE="white-space:nowrap">the&nbsp;36-month&nbsp;anniversary</FONT> of the date on which this registration statement has been declared effective by the SEC, to direct the Selling Securityholder to purchase up to a specified maximum amount of shares
of Common Stock as set forth in the B. Riley Purchase Agreement by delivering an irrevocable written notice to the Selling Securityholder (each, an &#147;Advance Notice&#148;) on any trading day (each, an &#147;Advance Notice Date&#148;), so long
as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares be issued under any single Advance does not exceed (i)&nbsp;with respect to an Advance,
purchase-Type A, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000, and (b)&nbsp;the product of (1) 0.10, multiplied by (2)&nbsp;the total number (or volume) of shares of Common Stock traded on Nasdaq during the
Pricing Period (as defined below) for such purchase-Type A, and (ii)&nbsp;with respect to an Advance, purchase-Type B, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000 and (b)&nbsp;the product of (1) 0.25,
multiplied by (2)&nbsp;the total number (or volume) of shares of Common Stock traded on Nasdaq during the Pricing Period for such purchase-Type B (such amount in clause (i)&nbsp;and (ii), the &#147;Maximum Advance Amount&#148;), unless otherwise
agreed by the parties. &#147;Pricing Period&#148; means the period beginning at 9:30:01 a.m., New York City time, on the date of purchase of Advance Shares or such later time publicly announced as the official open of the primary (or
&#147;regular&#148;) trading session on Nasdaq on such purchase date (the &#147;Purchase Commencement Time&#148;) and ending at the earliest of (i) 3:59 p.m., New York City Time, on the purchase date or such earlier time publicly announced as the
official close of the primary (or &#147;regular&#148;) trading session on Nasdaq on such purchase date, (ii)&nbsp;immediately at such time following the Purchase Commencement Time for such purchase that the total number (or volume) of shares of
Common Stock traded on Nasdaq during such period has exceeded the Advance Share Volume Maximum for such purchase and (iii)&nbsp;if we so elect in the applicable Advance Notice for such Advance (such election, a &#147;Limit Order Discontinue
Election&#148;), such time the sale price of the shares of Common Stock traded on Nasdaq during such Pricing Period is less than the applicable minium price threshold determined in accordance with the B. Riley Purchase Agreement. &#147;Advance Share
Volume Maximum&#148; means, with respect to an Advance, if such Advance is designated in the Advance Notice as a (i)&nbsp;purchase-Type A, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a)&nbsp;the Advance
Share amount to be purchased by the Selling Securityholder, by (b) 0.10, and (ii)&nbsp;purchase-Type B, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a)&nbsp;the Advance Share amount to be purchased by the
Selling Securityholder, by (b) 0.25 (in each case, subject to certain adjustments); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicable Pricing Period for all prior Advances has been completed and all shares of Common Stock subject to
all prior Advances have been received by the Selling Securityholder. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_202"></A>Additional Advances of Common Stock Under the B. Riley Purchase Agreement
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The B. Riley Purchase Agreement also provides that we have the right, but not the obligation, to sell to the Selling Securityholder,
from time to time subject to certain limitations, at our sole and absolute discretion an additional number of shares of Common Stock (each such additional sale, an &#147;Additional Advance&#148;) by delivering an irrevocable written notice to the
Selling Securityholder (each, an &#147;Additional Advance Notice&#148;) on any trading day (each, an &#147;Additional Advance Notice Day&#148;). The purpose of the Additional Advance is to allow us to execute more than one advance request on a
purchase date with the Selling Stockholder as each prior advance has been completed under the terms of the B. Riley Purchase Agreement. Each Additional Advance is generally subject to terms and conditions consistent with those of an Advance, except
for, among other things, the time period of the pricing period for such Additional Advance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_203"></A>Conditions to Each Advance and
Additional Advance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder&#146;s obligation to accept Advance Notices and Additional Advance Notices that are
timely delivered by us under the B. Riley Purchase Agreement and to purchase shares of our Common Stock in Advances and Additional Advances under the B. Riley Purchase Agreement are subject to the satisfaction, at the applicable Advance Notice Date
or Additional Advance Notice Date, of the conditions precedent thereto set forth in the B. Riley Purchase Agreement, all of which are entirely outside of the Selling Securityholder&#146;s control, which conditions include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy in all material respects of our representations and warranties included in the B. Riley Purchase
Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there being an effective registration statement pursuant to which the Selling Securityholder is permitted to
utilize the prospectus thereunder to resell all of the Common Stock that we shall issue and sell to the Selling Securityholder (the &#147;Advance Shares&#148; or &#147;Additional Advance Shares&#148;, as the case may be) pursuant to such Advance
Notice or Additional Advance Notice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sale and issuance of such Advance Shares or Additional Advance Shares being legally permitted by all laws and
regulations to which we are subject; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no Material Outside Event (as such term is defined in the B. Riley Purchase Agreement) shall have occurred and be
continuing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">us having performed, satisfied, and complied in all material respects with all covenants, agreements, and
conditions required by the B. Riley Purchase Agreement to be performed, satisfied, or complied with by us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no statute, rule, regulation, executive order, decree, ruling, or injunction having been enacted, entered,
promulgated, or endorsed by any court or governmental authority of competent jurisdiction that prohibits or directly, materially, and adversely affects any of the transactions contemplated by the B. Riley Purchase Agreement; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Common Stock being quoted for trading on Nasdaq and us having not received any written notice that is then
still pending threatening the continued quotation of the Common Stock on Nasdaq. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_204"></A>Termination of the B.
Riley Purchase Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated as provided in the B. Riley Purchase Agreement, the B. Riley Purchase Agreement
will terminate automatically on the earliest to occur of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the first day of the month next following
<FONT STYLE="white-space:nowrap">the&nbsp;36-month&nbsp;anniversary</FONT> of the date on which this registration statement has been declared effective by the SEC; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the Selling Securityholder shall have purchased shares of Common Stock under the B. Riley
Purchase Agreement for an aggregate gross purchase price equal to $500,000,000. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have the right to terminate the B. Riley Purchase Agreement at any time, at no cost
or penalty, upon five trading days&#146; prior written notice to the Selling Securityholder; <I>provided</I> that there are no outstanding Advance Notices or Additional Advance Notices under which we are yet to issue Common Stock. We and the Selling
Securityholder may also terminate the B. Riley Purchase Agreement at any time by mutual written consent.<I></I><I>&nbsp;</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_205"></A>No Short-Selling by the Selling Securityholder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder has agreed that it and its affiliates will not engage in any short sales during the term of the B. Riley Purchase
Agreement and will not enter into any transaction that establishes a net short position with respect to the Common Stock, provided that nothing shall restrict the Selling Securityholder from selling a number of shares of Common Stock that it is
obligated to purchase under a pending Advance Notice or Additional Advance Notice but has not yet received from us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_206"></A>Effect
of Sales of our Common Stock under the B. Riley Purchase Agreement on our Stockholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shares of Common Stock that may be issued
or sold by us to the Selling Securityholder under the B. Riley Purchase Agreement that are being registered under the Securities Act for resale by the Selling Securityholder in this offering are expected to be freely tradable. The shares of Common
Stock being registered for resale in this offering may be issued and sold by us to the Selling Securityholder from time to time at our discretion over the term of the B. Riley Purchase Agreement. The resale by the Selling Securityholder of a
significant amount of shares registered for resale in this offering at any given time, or the perception that these sales may occur, could cause the market price of our Common Stock to decline and to be highly volatile. Sales of our Common Stock, if
any, to the Selling Securityholder under the B. Riley Purchase Agreement will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to the Selling Securityholder all, some, or none of the shares of
our Common Stock that may be available for us to sell to the Selling Securityholder pursuant to the B. Riley Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and
when we do elect to sell shares of our Common Stock to the Selling Securityholder pursuant to the B. Riley Purchase Agreement, the Selling Securityholder may resell all, some, or none of such shares in its discretion and at different prices subject
to the terms of the B. Riley Purchase Agreement. As a result, investors who purchase shares from the Selling Securityholder in this offering at different times will likely pay different prices for those shares, and so may experience different levels
of dilution and, in some cases, substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from the Selling Securityholder in this offering as a result of
future sales made by us to the Selling Securityholder at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares to the Selling Securityholder under the B. Riley
Purchase Agreement, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangement with the Selling Securityholder may make it more difficult for us to sell equity or equity-related securities in the
future at a desirable time and price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the purchase price per share to be paid by the Selling Securityholder for the shares of
Common Stock that we may elect to sell to the Selling Securityholder under the B. Riley Purchase Agreement, if any, will fluctuate based on the market prices of our Common Stock during the applicable Pricing Period, as of the date of this prospectus
we cannot reliably predict the number of shares of Common Stock that we will sell to the Selling Securityholder under the B. Riley Purchase Agreement, the actual purchase price per share to be paid by the Selling Securityholder for those shares, or
the actual gross proceeds to be raised by us from those sales, if any. As of January&nbsp;11, 2023, there were 141,598,856 shares of our Common Stock outstanding, of which 5,872,266 shares were held by
<FONT STYLE="white-space:nowrap">non-affiliates.</FONT> If all of the 28,128,422 shares offered for resale by the Selling Securityholder under the registration statement that includes this prospectus were issued and outstanding as of
January&nbsp;11, 2023, such shares would represent approximately 16.6% of the total number of shares of our Common Stock outstanding and approximately 82.7% of the total number of outstanding shares held by
<FONT STYLE="white-space:nowrap">non-affiliates.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the B. Riley Purchase Agreement provides that we may, in our discretion, from time
to time after the date of this prospectus and during the term of the B. Riley Purchase Agreement, direct the Selling Securityholder to purchase shares of our Common Stock from us in one or more Advances or Additional Advances under the B. Riley
Purchase Agreement, for a maximum aggregate purchase price of up to $500,000,000, only 28,128,422 shares of Common Stock (250,000 of which represent the aggregate amount of Commitment Shares we issued to the Selling Securityholder pursuant to the B.
Riley Purchase Agreement as payment for the Selling Securityholder&#146;s commitment to purchase shares of our Common Stock under the B. Riley Purchase Agreement) are being registered for resale under the registration statement that includes this
prospectus. Assuming all of such 28,128,422 shares were sold to the Selling Securityholder at the maximum 98% discount to the per share price of $4.87 (which represents the lower of the official closing price of our Common Stock on Nasdaq on January
6, 2023, the trading day immediately preceding the date of the B. Riley Purchase Agreement, and the average official closing price of our Common Stock on Nasdaq for the five consecutive trading days ending on January 6, 2023, the trading day
immediately preceding the date of the B. Riley Purchase Agreement), such number of shares would be insufficient to enable us to receive aggregate gross proceeds from the sale of such shares to the Selling Securityholder equal to the Selling
Securityholder&#146;s $500,000,000 total aggregate purchase commitment under the B. Riley Purchase Agreement. While the market price of our Common Stock may fluctuate from time to time after the date of this prospectus and, as a result, the actual
purchase price to be paid by the Selling Securityholder under the B. Riley Purchase Agreement for shares of our Common Stock, if any, may also fluctuate, in order for us to receive the full amount of the Selling Securityholder&#146;s commitment
under the B. Riley Purchase Agreement, it is possible that we may need to issue and sell more than the number of shares being registered for resale under the registration statement that includes this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If it becomes necessary for us to issue and sell to the Selling Securityholder more shares than are being registered for resale under this
prospectus in order to receive aggregate gross proceeds equal to $500,000,000 under the B. Riley Purchase Agreement, we must first (i)&nbsp;to the extent necessary, obtain stockholder approval prior to issuing shares of the Common Stock in excess of
the Exchange Cap in accordance with applicable Nasdaq Listing Rules, and (ii)&nbsp;file with the SEC one or more additional registration statements to register under the Securities Act the resale by the Selling Securityholder of any such additional
shares of our Common Stock, which the SEC must declare effective, in each case, before we may elect to sell any additional shares of our Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement. The number of shares of our
Common Stock ultimately offered for resale by the Selling Securityholder depends upon the number of shares of Common Stock, if any, we ultimately sell to the Selling Securityholder under the B. Riley Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance, if any, of shares of our Common Stock to the Selling Securityholder pursuant to the B. Riley Purchase Agreement would not affect
the rights or privileges of our existing stockholders, except that the economic and voting interests of each of our existing stockholders would be diluted. Although the number of shares of our Common Stock that our existing stockholders own would
not decrease as a result of sales, if any, under the B. Riley Purchase Agreement, the shares of our Common Stock owned by our existing stockholders would represent a smaller percentage of our total outstanding shares of our Common Stock after any
such issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the amount of gross proceeds we would receive from the
Selling Securityholder from our sale of shares of Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement at varying purchase prices: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Assumed<BR>Average<BR>Purchase<BR>Price<BR>Per<BR>Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Registered<BR>Shares to be<BR>Issued if<BR>Full Purchase<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage of<BR>Outstanding<BR>Shares<BR>After Giving<BR>Effect to<BR>the Issuance to<BR>the<BR>Selling<BR>Securityholder<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross Proceeds<BR>from the<BR>Sale of Shares to the<BR>Selling<BR>Securityholder<BR>Under&nbsp;the&nbsp;B.&nbsp;Riley&nbsp;Purchase<BR>Agreement</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$2.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63.80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$3.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,666,666.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54.02</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">499,999,998.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$4.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46.84</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$4.87<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,669,404.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">499,999,997.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$5.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41.35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$6.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,333,333.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37.01</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">499,999,998.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$7.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,428,571.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33.49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">499,999,997.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$7.87<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,934,404.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32.06</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">499,999,997.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$8.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,500,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30.58</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Does not include the aggregate amount of 250,000 Commitment Shares that we issued to the Selling Securityholder
as consideration for its commitment to purchase shares of Common Stock under the B. Riley Purchase Agreement. The number of shares of Common Stock offered by this prospectus may not cover all the shares we ultimately sell to the Selling
Securityholder under the B. Riley Purchase Agreement, depending on the purchase price per share. We have included in this column only those shares being offered for resale by the Selling Securityholder under this prospectus (excluding the 250,000
Commitment Shares), without regard for the Beneficial Ownership Limitation. The assumed average purchase prices are solely for illustration and are not intended to be estimates or predictions of future stock performance. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The denominator is based on 141,598,856 shares outstanding as of January&nbsp;11, 2023 (which includes the
aggregate amount of 250,000 Commitment Shares we issued to the Selling Securityholder), adjusted to include the issuance of the number of shares set forth in the second column that we would have sold to the Selling Securityholder, assuming the
average purchase price in the first column. The numerator is based on the number of shares of Common Stock set forth in the second column. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the average Nasdaq Official Closing Price for the five trading days immediately preceding the date
of the B. Riley Purchase Agreement) on January&nbsp;6, 2023, the trading day prior to execution of the B. Riley Purchase Agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the closing price of the Common Stock on Nasdaq on January&nbsp;11, 2023, the trading day prior to
the filing of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_21"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain information contained in this prospectus relates to or is based on studies, publications, surveys and other data obtained from
third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this prospectus, we have not independently verified the market and industry data contained in this
prospectus or the underlying assumptions relied on therein. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. Notwithstanding the foregoing, we are liable for the
information provided in this prospectus. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section of this prospectus titled &#147;<I>Risk
Factors</I>&#148;. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_22"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the shares of our Common Stock offered by the Selling Securityholder pursuant to this prospectus will be sold by the Selling
Securityholder for its own account. We will not receive any of the direct proceeds from these sales. However, we may receive up to $500,000,000 aggregate gross proceeds from any sales we make to the Selling Securityholder pursuant to the B. Riley
Purchase Agreement. The net proceeds from sales, if any, under the B. Riley Purchase Agreement, will depend on the frequency and prices at which we sell shares of Common Stock to the Selling Securityholder after the date of this prospectus. See the
section titled &#147;<I>Plan of Distribution</I>&#148; elsewhere in this prospectus for more information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to use the net
proceeds that we receive under the B. Riley Purchase Agreement for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs
expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. However, we have not designated any
specific uses and have no current agreement with respect to any acquisition or strategic transaction. As of the date of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts we may allocate to those
uses, for any net proceeds we receive. Accordingly, we will retain broad discretion over the use of these proceeds. Pending our use of the net proceeds as described above, we intend to invest the net proceeds pursuant to the B. Riley Purchase
Agreement in interest-bearing instruments. Our expected use of the net proceeds from this offering represents our current intentions based upon our present plans and business condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although it is difficult to predict our liquidity requirements, we anticipate that we will continue to incur net losses into the foreseeable
future as we support our commercializations activities, clinical development to expand approved indications, continue our development of, and seek regulatory approvals for, our product candidates, and expand our corporate infrastructure. As a
result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. See Note 2 titled &#147;Liquidity and Going
Concern&#148; to our consolidated financial statements included elsewhere in this prospectus for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date
of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts we may allocate to those uses, for any net proceeds we receive. The costs and timing of development activities, particularly conducting
clinical trials and preclinical studies, are highly uncertain, subject to substantial risks and can often change. Due to the many variables inherent to the development of our drug candidates, we cannot currently predict the stage of development we
expect the net proceeds of this offering to achieve for our clinical trials, preclinical studies and drug candidates. Accordingly, we will retain broad discretion over the use of these proceeds. For example, if we identify opportunities that we
believe are in the best interests of our stockholders, we may use a portion of the net proceeds from this offering to acquire, invest in or license complementary products, technologies or businesses, although we have no current understandings,
agreements or commitments to do so. In addition, the amounts and timing of our actual expenditures will depend upon numerous factors, including the results of our research and development efforts, the timing and success of preclinical studies, our
ongoing clinical trials or clinical trials we may commence in the future and the timing of regulatory submissions. Depending on the outcome of these activities and other unforeseen events, our plans and priorities may change and we may apply the net
proceeds of this offering toward different uses and in different proportions than we currently anticipate. Pending our use of the net proceeds as described above, we intend to invest the net proceeds from this offering in interest-bearing
instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_23"></A>DETERMINATION OF OFFERING PRICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot currently determine the price or prices at which shares of our Common Stock may be sold by the Selling Securityholder under this
prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_24"></A>MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_25"></A>Market Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock and Public Warrants are currently listed on Nasdaq under the symbols &#147;SCLX&#148; and &#147;SCLXW,&#148; respectively.
Prior to the consummation of the Business Combination, Vickers&#146;s Ordinary Shares, units and warrants were each listed on Nasdaq under the symbols &#147;VCKA,&#148; &#147;VCKAU&#148; and &#147;VCKAW,&#148; respectively. At the Effective Time,
without any action on the part of the holder, each Unit then outstanding separated automatically into its component securities, comprised of one share of Common Stock and <FONT STYLE="white-space:nowrap">one-half</FONT> of one warrant to purchase
one share of Common Stock. As of November&nbsp;10, 2022, there were eleven holders of record of our Common Stock and four holders of record of our Warrants, which amount does not include participants of The Depository Trust Company or beneficial
owners holding shares through nominee names. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_26"></A>Dividend Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividend on shares of our Common Stock. We anticipate that we will retain all of our future earnings, if
any, to fund the development and growth of our business. Any future determination to pay dividends on our capital stock will be at the discretion of our Board. It is the present intention of our Board to retain all earnings, if any, for use in our
business operations and, accordingly, our Board does not anticipate declaring any dividend in the foreseeable future. Should we decide in the future to do so, as a holding company, our ability to pay dividends on our capital stock and meet other
obligations depends upon the receipt of dividends or other payments from our operating subsidiaries, including Legacy Scilex. Further, our ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or
our subsidiaries incur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_27"></A>Securities Authorized for Issuance under Equity Compensation Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January 1, 2023, there were up to 20,276,666 shares of Common Stock authorized for future issuance under our Equity Incentive Plan and
2,875,759 shares of Common Stock authorized for future issuance under our ESPP. Our stockholders approved the Equity Incentive Plan and the ESPP on November&nbsp;9, 2022 in connection with the Business Combination and became effective upon the
Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities
Act to register the shares of Common Stock issued or issuable under the Equity Incentive Plan, the ESPP and the assumed Legacy Scilex options and other awards outstanding under the Scilex Pharma 2017 Plan and the 2019 Stock Option Plan. Any such
Form <FONT STYLE="white-space:nowrap">S-8</FONT> registration statement will become effective automatically upon filing. Once these shares are registered, they can be sold in the public market upon issuance, subject to applicable restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_28"></A>UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma condensed combined balance sheet as of September&nbsp;30, 2022 and the unaudited pro forma
condensed combined statements of operations for the year ended December&nbsp;31, 2021 and nine months ended September&nbsp;30, 2022 present the combined financial information of Vickers and Legacy Scilex after giving effect to the Business
Combination and related adjustments described in the accompanying notes. Vickers and Legacy Scilex are collectively referred to herein as the &#147;Companies,&#148; and the Companies, subsequent to the Business Combination, are referred to herein as
&#147;New Scilex.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11
of Regulation <FONT STYLE="white-space:nowrap">S-X,</FONT> Pro Forma Financial Information, as amended by the final rule, Release 33 10786. The following unaudited pro forma condensed combined statements of operations for the year ended
December&nbsp;31, 2021 and nine months ended September&nbsp;30, 2022 give pro forma effect to the Business Combination as if it had occurred on January&nbsp;1, 2021. The unaudited pro forma condensed combined balance sheet as of September&nbsp;30,
2022 gives pro forma effect to the Business Combination as if it was completed on September&nbsp;30, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma
condensed combined financial information are based on and should be read in conjunction with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accompanying notes to the unaudited pro forma condensed combined financial information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the audited historical financial statements and the unaudited historical financial statements of each of Vickers
and Legacy Scilex as of and for the year ended December&nbsp;31, 2021, and as of and for the nine months ended September&nbsp;30, 2022, respectively, and the related notes thereto, and; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other information relating to Vickers and Legacy Scilex contained in this prospectus, including the Merger
Agreement, which is filed as an exhibit to the registration statement of which this prospectus forms a part, and the disclosures contained in the section of this prospectus titled &#147;<I>Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations.</I>&#148;. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements have
been presented for illustrative purposes only and do not necessarily reflect what the combined company&#146;s financial condition or results of operations would have been had the Business Combination occurred on the dates indicated. Further, the
unaudited pro forma condensed combined financial information also may not be useful in predicting the future financial condition and results of operations of the combined company. The actual financial position and results of operations may differ
significantly from the pro forma amounts reflected herein due to a variety of factors. The unaudited pro forma adjustments represent management&#146;s estimates based on information available as of the date of these unaudited pro forma condensed
combined financial statements and are subject to change as additional information becomes available and analyses are performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;17, 2022, Vickers Vantage Corp. I (&#147;Vickers&#148;) entered into the Agreement and Plan of Merger (as amended on September&nbsp;12, 2022, the &#147;Merger Agreement&#148;) with Vantage Merger Sub Inc., a Delaware corporation and
wholly owned subsidiary of Vickers (&#147;Merger Sub&#148;), and Scilex Holding Company, a Delaware corporation (&#147;Legacy Scilex&#148;) under which Merger Sub was merged with and into Legacy Scilex with Legacy Scilex continuing as the surviving
corporation and a wholly owned subsidiary of Vickers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing of the Business Combination occurred on November&nbsp;10, 2022 (the
&#147;Closing&#148;), in which Vickers was renamed &#147;Scilex Holding Company&#148; (&#147;New Scilex&#148;). At the Closing, each outstanding share of Legacy Scilex Common Stock as of immediately prior to the time in which the Business
Combination became effective as stated in the Merger Agreement (&#147;Effective Time&#148;) was exchanged for shares of Common Stock and each outstanding share of Legacy Scilex Preferred Stock as of immediately prior to the Effective Time was
exchanged for the right to receive (a)&nbsp;one share of Series A Preferred Stock and <FONT STYLE="white-space:nowrap">(b)&nbsp;one-tenth</FONT> of one share of Common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock. Each Legacy Scilex stock option outstanding immediately prior to the Effective Time was converted into a stock option to acquire a share of Common Stock upon substantially the same terms
and conditions with respect to existing vesting and termination-related provisions. On November&nbsp;11, 2022, shares of Common Stock and Public Warrants started trading on the Nasdaq Capital Market under the ticker symbols &#147;SCLX&#148; and
&#147;SCLXW,&#148; respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate consideration paid to the equityholders of Legacy Scilex upon the Closing of the Business
Combination was 133,060,532 shares of Common Stock. The unaudited pro forma condensed combined financial information contained herein incorporates the results of Vickers&#146;s public shareholders having elected to redeem 8,576,838 shares of their
public shares for $89,884,677 in cash based upon actual redemptions as of the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As of September&nbsp;30, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As of September&nbsp;30, 2022</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">(Note 2)<BR>Vickers<BR>Vantage<BR>Corp. I<BR>(Adjusted)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Scilex<BR>Holding<BR>Company<BR>(Historical)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Pro Forma<BR>Adjustments</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Pro&nbsp;Forma<BR>Combined</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(B)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(C)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(E)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(K)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(E)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangibles, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(89,246</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(A)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,047</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(B)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(105,438</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities and Stockholders&#146; Equitv</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,862</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(G)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(E)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(G)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(G)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(174,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(H)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(H)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">251,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(219,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, net of discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(62,717</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(H)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,007</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(465</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(J)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting fee payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(C)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">318,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(293,332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As of September&nbsp;30, 2022</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">(Note 2)<BR>Vickers<BR>Vantage<BR>Corp. I<BR>(Adjusted)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Scilex<BR>Holding<BR>Company<BR>(Historical)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Pro Forma<BR>Adjustments</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Pro&nbsp;Forma<BR>Combined</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares subject to possible redemption 9,726,395 and 13,800,000 as of September&nbsp;30,
2022 and December&nbsp;31, 2021 at redemption value of approximately $10.41 and $10.00, respectively per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(101,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(A)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares $0.0001 par value; 1,000,000 shares authorized; none issued or
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 3,450,000 <FONT
STYLE="white-space:nowrap">non-redeemable</FONT> shares issued and outstanding at September&nbsp;30, 2022 and December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Scilex Preferred stock, $0.0001 par value; 45,000,000 shares authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(H)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Scilex Common stock, $0.0001 par value; 740,000,000 shares authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(A)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(D)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value, 20,000,000 shares authorized; none issued or outstanding at
September&nbsp;30, 2022 and December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value, 350,000,000 shares authorized 197,566,338 and 197,266,338 shares
issued and outstanding at September&nbsp;30, 2022 and December&nbsp;31, 2021 respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(D)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(A)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">407,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(D)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(E)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(F)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">284,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(H)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(J)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,003</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(358,030</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,025</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(E)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(359,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(K)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3(F)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,003</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(229,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">289,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(105,438</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Nine Months Ended September&nbsp;30, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For the Nine Months Ended September&nbsp;30, 2022</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">(Note 2)<BR>Vickers<BR>Vantage<BR>Corp. I<BR>(Adjusted)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Scilex Holding<BR>Company<BR>(Historical)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Pro Forma<BR>Adjustments</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Pro Forma<BR>Combined</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating and formation costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4(BB)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,615</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(878</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4(CC)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on debt extinguishment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on foreign currency exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income on mandatorily redeemable ordinary shares liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4(FF)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4(AA)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,434</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,516</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,181</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to Vickers ordinary
shares, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,862,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net loss per share of Vickers ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to Vickers ordinary
shares, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,862,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net loss per share of Vickers ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to Scilex common stock,
basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,549,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share of Scilex common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to New Scilex common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141,098,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share of New Scilex common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Year Ended December&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For the Year Ended December&nbsp;31, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">(Note 2)<BR>Vickers<BR>Vantage<BR>Corp. I<BR>(Adjusted)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Scilex Holding<BR>Company<BR>(Historical)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Pro Forma<BR>Adjustments</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Pro Forma<BR>Combined</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4(BB)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4(DD)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4(EE)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating and formation costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4(BB)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35,838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,015</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4(CC)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on debt extinguishment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on foreign currency exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4(AA)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (income) expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(89,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(89,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net income per share attributable to Vickers ordinary
shares, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,820,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income per share of Vickers ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net income per share attributable to Vickers ordinary
shares, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,834,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income per share of Vickers ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per <BR>share attributable to Scilex common
stock, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,266,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share of Scilex common <BR>stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to New Scilex common
stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141,098,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share of New Scilex common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1 &#151; Description of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;17, 2022, Vickers entered into the Merger Agreement with Merger Sub and Legacy Scilex. Pursuant to the Merger Agreement, subject
to the terms and conditions set forth therein, Merger Sub merged with and into Legacy Scilex and with Legacy Scilex becoming a wholly owned subsidiary of Vickers. After giving effect to the Business Combination, Vickers owned all of the issued and
outstanding equity interests of Legacy Scilex and its subsidiaries. In connection with the consummation of the Business Combination, Vickers was renamed as &#147;Scilex Holding Company&#148; (&#147;New Scilex&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Closing, each outstanding share of Legacy Scilex Common Stock as of immediately prior to the time the Business Combination became
effective as stated in the Merger Agreement was exchanged for shares of Common Stock and each outstanding share of Legacy Scilex Preferred Stock as of immediately prior to the Effective Time was exchanged for the right to receive (a)&nbsp;one share
of Series A Preferred Stock and <FONT STYLE="white-space:nowrap">(b)&nbsp;one-tenth</FONT> of one share of Common Stock. Each Legacy Scilex stock option outstanding immediately prior to the Effective Time was converted into a number of options
exercisable for newly issued shares of Common Stock based upon the Exchange Ratio and on substantially the same terms and conditions with respect to existing vesting and termination-related provisions. The exercise price per share for each option
for Common Stock is equal to (i)&nbsp;the existing exercise price per Legacy Scilex stock option, divided by (ii)&nbsp;the Exchange Ratio (defined below) (rounded up to the nearest whole cent). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Common Stock issuable to Legacy Scilex stockholders and optionholders is equal to (i) $1,500,000,000, minus
(ii)&nbsp;the Specified Indebtedness Amount (defined below), divided by $10 (&#147;Merger Consideration&#148;). The &#147;Specified Indebtedness Amount&#148; had pertained to the aggregate amount owed by Legacy Scilex in respect of senior secured
notes due 2026 issued under Scilex Pharmaceuticals Inc. (&#147;Scilex Pharma&#148;) and with Sorrento as the parent guarantor. On September&nbsp;28, 2022, Scilex Pharma repurchased all of the outstanding aggregate principal amount of the Scilex
Pharma Notes. As of immediately prior to the repurchase, the aggregate principal amount of the Scilex Pharma Notes was approximately $67.7&nbsp;million, and Scilex Pharma repurchased the Scilex Pharma Notes for an aggregate cash payment of
$39.7&nbsp;million as the holders of the Scilex Pharma Notes forgave and discharged an aggregate of $28.0&nbsp;million of principal amount of the Scilex Pharma Notes in connection with the repurchase. This repurchase reduced the Specified
Indebtedness Amount to $0, resulting in Merger Consideration transferred to Legacy Scilex common stockholders and optionholders at Closing of 150,000,000 shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Legacy Scilex Common Stock and Legacy Scilex stock options were converted into shares of Common Stock and options to acquire shares
of Common Stock, respectively, in each case based on the &#147;Exchange Ratio,&#148; which is equal to (a)&nbsp;the number of shares constituting the Merger Consideration, divided by (b)&nbsp;the sum of (i)&nbsp;issued and outstanding Legacy Scilex
Common Stock and (ii)&nbsp;issued and outstanding Legacy Scilex stock options as of immediately prior to the Effective Time. As there were 197,566,338 and 25,151,428 shares of Legacy Scilex Common Stock and Legacy Scilex stock options, respectively,
the Exchange Ratio was calculated to be 0.673498. Upon the Effective Time, 133,060,532 shares of Common Stock were transferred to Legacy Scilex stockholders as part of the Merger Consideration. The remaining portion of the Merger Consideration,
equal to 16,939,379 shares of Common Stock, is reserved for the Legacy Scilex optionholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2022, Legacy Scilex
and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement (the &#147;Debt Exchange Agreement&#148;) with Sorrento, pursuant to which (i)&nbsp;Sorrento contributed to Legacy Scilex all amounts (including accrued
interest thereon, if any) for certain loans and other amounts provided by Sorrento to Legacy Scilex and Scilex Pharma that remained outstanding as of immediately prior to the Closing of the Business Combination (the &#147;Aggregate Outstanding
Amount&#148; or &#147;Outstanding Indebtedness,&#148;) in exchange for the issuance by Legacy Scilex to Sorrento of preferred stock of Legacy Scilex, (ii)&nbsp;Legacy Scilex contributed to Scilex Pharma the portion of such Outstanding Indebtedness
that is owed by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Scilex Pharma to Sorrento as a contribution of capital for no consideration, and (iii)&nbsp;upon the occurrence of the events described in clauses (i)&nbsp;and (ii), the Aggregate Outstanding
Amount and the Outstanding Indebtedness was deemed satisfied in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Debt Exchange Agreement effective as
of immediately prior to, and contingent upon, the Closing of the Business Combination, Sorrento elected to contribute the Outstanding Indebtedness to Legacy Scilex in exchange for the issuance by Legacy Scilex to Sorrento of that number of shares of
preferred stock, par value $0.0001 per share, of Legacy Scilex (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#147;Exchange Shares&#148; and such transaction, the &#147;Debt
Contribution&#148;) that was equal to (i)&nbsp;the Aggregate Outstanding Amount plus the amount equal to 10% of the Aggregate Outstanding Amount divided by (ii) $11.00 (rounded up to the nearest whole share). In addition, prior to the Closing,
Legacy Scilex entered into agreements with certain creditors and Sorrento in which Legacy Scilex was legally released from being the primary obligor under certain liabilities from the creditors. The obligations to these creditors were transferred to
Sorrento. Immediately prior to the Closing, the total amount of liabilities transferred from Legacy Scilex to Sorrento was $11,880,945, which were also subject to the Debt Exchange Agreement. The Aggregate Outstanding Amount subject to this
conversion at Closing was $290,570,964 which was converted to aggregate number of shares of Legacy Scilex Preferred Stock issued to Sorrento prior to the Effective Time pursuant to the Debt Exchange Agreement of 29,057,097 shares and then at the
Effective Time such shares were exchanged for 29,057,097 shares of Series A Preferred Stock and 2,905,710 shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
October&nbsp;17, 2022, Sorrento and Legacy Scilex entered into a letter agreement (the &#147;Funding Commitment Letter&#148;). Pursuant to the terms of the Funding Commitment Letter, to the extent necessary to satisfy the closing condition in the
Merger Agreement that requires the combined company to have $5,000,001 in net tangible assets as of immediately following the time in which the Business Combination becomes effective (the &#147;Net Tangible Assets Condition&#148;), Sorrento would
fund one or more loans to Legacy Scilex up to (a)&nbsp;$10,000,000 and (b)&nbsp;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $310,000,000. At Closing, New
Scilex was able to achieve the Net Tangible Assets Condition without requiring a loan from Sorrento under the Funding Commitment Letter. As such, no amount was requested by Legacy Scilex under the Funding Commitment Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below illustrates the number of shares of Series A Preferred Stock and Common Stock held by Legacy Scilex stockholders at the
Closing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Series&nbsp;A<BR>Preferred&nbsp;Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Common<BR>Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(a) Merger Consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,060,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(b) Aggregate Outstanding Amount converted under the Debt Exchange Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,057,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,905,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,057,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,966,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the then-outstanding Public Warrants and Private Placement Warrants has an exercise price of $11.50
per share (the &#147;Exercise Price&#148;) to acquire one share of Vickers Ordinary Shares. The exercise price of the warrants is subject to a down-round provision that is only effective prior to the Closing of the Business Combination and is
therefore not, on its own, considered to have an impact to the classification of warrant on Legacy Scilex&#146;s Unaudited Pro Forma Condensed Combined Balance Sheet. Concurrently with the execution of the Merger Agreement, Vickers also entered into
the Sponsor Support Agreement. In the event that Vickers&#146;s public shareholders exercise redemption rights that results in the redemption of 75% or more of the issued and outstanding Vickers Ordinary Shares as were outstanding as of
March&nbsp;17, 2022, the Sponsors agreed to be subject to a 40% forfeiture of Private Placement Warrants held by each Sponsor immediately prior to Closing. At Closing, actual redemption was 91.7% and therefore 40% of the Private Placement Warrants
were forfeited pursuant to the Sponsor Support Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, as consideration for Sorrento agreeing to provide funding, as
necessary, under the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim entered into the Warrant Transfer Agreement pursuant to which, if, prior to the consummation of the Business Combination, the public shareholders have redeemed
50% or more of the public Vickers Ordinary Shares as were outstanding as of March&nbsp;17, 2022, then in addition to the forfeiture of Warrants by the Sponsors contemplated by the Sponsor Support Agreement, the Sponsors will transfer to Sorrento,
and Sorrento will acquire all rights, title and interest in and to all or a portion of the Private Placement Warrants (as equitably adjusted from time to time in respect of any change in the outstanding Vickers Ordinary Shares into a different
number, class or series, including by reason of any reclassification, recapitalization, share split (including a reverse share split), or combination, exchange, readjustment of shares, or similar transaction, or any share dividend or distribution
paid in shares) pursuant to the Warrant Transfer Agreement. Actual redemptions were 91.7% at Closing, which resulted in 3,104,000 Private Placement Warrants being transferred to Sorrento and 1,000,000 Private Placement Warrants being retained by
Sponsors pursuant to the Warrant Transfer Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on October&nbsp;17, 2022, Vickers and the Sponsors entered into the
Vickers Debt Agreement, pursuant to which the Working Capital Loans will be cancelled in exchange for the issuance of common stock, par value $0.0001, of Vickers prior to the consummation of the Business Combination. Pursuant to the terms of the
Vickers Debt Agreement, the aggregate amount of Working Capital Loans at Closing of $5,330,557 was converted to 533,057 shares of New Scilex Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes the pro forma ownership and voting power of Common Stock and Series A Preferred Stock, excluding the potentially
dilutive effect of all the Public Warrants, the Private Placement Warrants, any Working Capital Warrants and all outstanding New Scilex stock options issued to Legacy Scilex option holders in connection with the Business Combination: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares of<BR>Common<BR>Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;of<BR>Ownership</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares of<BR>Preferred<BR>Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;of<BR>Ownership</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%&nbsp;of<BR>Voting<BR>Power</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vickers public shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,149,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vickers initial shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,983,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legacy Scilex common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,966,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legacy Scilex preferred stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,057,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Shares at the Closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141,098,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,057,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected Accounting Treatment for the Business Combination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a reverse recapitalization, with no goodwill or other intangible assets recorded in accordance
with GAAP. Under this method of accounting, Vickers was treated as the &#147;acquired&#148; company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of Scilex issuing stock for the net assets of
Vickers, accompanied by a recapitalization. The net assets of Vickers will be recognized at historical cost, with no goodwill or other intangible assets recorded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex was determined to be the accounting acquirer based on evaluation of the following facts and circumstances: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Legacy Scilex stockholders have the majority of the voting power; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Legacy Scilex appointed the majority of the board of directors of New Scilex; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Legacy Scilex&#146;s existing management comprise the management of New Scilex; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Legacy Scilex comprise the ongoing operations of New Scilex; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Legacy Scilex is the larger entity based on historical revenues and business operations; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New Scilex assumes Legacy Scilex&#146;s name. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2&nbsp;&#151;&nbsp;Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of preparing these unaudited pro forma condensed combined financial statements, certain reclassifications were made to align Vickers
and Legacy Scilex&#146;s financial statement presentation. Following the consummation of the Business Combination, we are performing a comprehensive review of the two entities&#146; accounting policies. As a result of the review, we may identify
differences between the accounting policies of the two entities which, when conformed, could have a material impact on the financial statements of the post-combination company. Based on our initial analysis, we did not identify any differences that
would have a material impact on the unaudited pro forma condensed combined financial information. As a result, the unaudited pro forma condensed combined financial information does not assume any differences in accounting policies. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As of September&nbsp;30, 2022</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Vickers&nbsp;Vantage<BR>Corp. I<BR>(Historical)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Reclassification<BR>Adjustments</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Vickers&nbsp;Vantage<BR>Corp. I<BR>(Adjusted)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangibles, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities and Stockholders&#146; Equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mandatorily redeemable ordinary shares liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, net of discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible note&nbsp;&#151; related party, net of debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,007</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,163</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting fee payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As of September&nbsp;30, 2022</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Vickers&nbsp;Vantage<BR>Corp. I<BR>(Historical)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Reclassification<BR>Adjustments</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Vickers&nbsp;Vantage<BR>Corp. I<BR>(Adjusted)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares subject to possible redemption 9,726,395 and 13,800,000 as <BR>of
September&nbsp;30, 2022 and December&nbsp;31, 2021 at redemption value of approximately $10.41 and $10.00, respectively, per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares. $0.0001 par value; 1,000,000 shares authorized; none issued or
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 3,450,000 <FONT
STYLE="white-space:nowrap">non-redeemable</FONT> shares issued and outstanding at September&nbsp;30, 2022 and December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Scilex Preferred stock, $0.0001 par value; 45,000,000 shares <BR>authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Scilex Common stock, $0.0001 par value; 740,000,000 shares <BR>authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value, 350,000,000 shares authorized; 197,566,338 and 197,266,338 shares
issued and outstanding at September&nbsp;30, 2022 and December&nbsp;31, 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,003</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,003</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,003</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,003</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For the Nine Months ended September&nbsp;30, 2022</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Vickers&nbsp;Vantage<BR>Corp. I<BR>(Historical)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Reclassification<BR>Adjustments</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Vickers&nbsp;Vantage<BR>Corp. I<BR>(Adjusted)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating and formation costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on debt extinguishment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on foreign currency exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on initial issuance of private warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of conversion option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense &#151; debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs allocated to warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income on mandatorily redeemable ordinary shares liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to Vickers ordinary
shares, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,862,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,862,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net loss per share of Vickers ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to Vickers ordinary
shares, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,862,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,862,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net loss per share of Vickers ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For the Year Ended December&nbsp;31, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Vickers&nbsp;Vantage<BR>Corp. I<BR>(Historical)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Reclassification<BR>Adjustments</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Vickers&nbsp;Vantage<BR>Corp. I<BR>(Adjusted)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating and formation costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on debt extinguishment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on foreign currency exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on initial issuance of private warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of conversion option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense &#151; debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs allocated to warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net income per share attributable to Vickers ordinary
shares, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,820,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,820,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income per share of Vickers ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net income per share attributable to Vickers ordinary
shares, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,834,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,834,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income per share of Vickers ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3 &#151; Transaction Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet as of September&nbsp;30, 2022
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information does not give effect to any anticipated synergies, operating
efficiencies, tax savings, or cost savings that may be associated with the Business Combination. No tax adjustment has been computed for the pro forma New Scilex financial results, as it expects to maintain a full valuation allowance against its
U.S. deferred tax assets. The unaudited pro forma information does not purport to project the future financial position or operating results of New Scilex. The pro forma transaction adjustments included in the unaudited pro forma condensed combined
balance sheet as of September&nbsp;30, 2022 are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects reclassification of Vickers Ordinary Shares to permanent equity upon consummation of the Business
Combination, after final redemption. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects release of the restricted investments and cash held in the Trust Account upon consummation of the
Business Combination. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the settlement in cash of all deferred underwriting fees payable to Maxim. A reduction of
$5.2&nbsp;million was reflected in cash and cash equivalents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the conversion of Legacy Scilex Common Stock into Common Stock pursuant to the Merger Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents transaction costs incurred by Vickers and Legacy Scilex that are allocated between the instruments
issued and assumed in the Business Combination and recorded as a reduction to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital or expense. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(F)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the elimination of Vickers&#146;s historical accumulated deficit. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(G)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects $8,337,491 of Legacy Scilex liabilities assumed by Sorrento as of September&nbsp;30, 2022. Such amount
was included in the Outstanding Indebtedness which was contributed to Legacy Scilex as a capital contribution in exchange for the issuance of Legacy Scilex Common Stock pursuant to the Debt Exchange Agreement and at the Effective Time such shares of
Legacy Scilex Common Stock were exchanged for shares of Series A Preferred Stock and Common Stock in Note (H). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(H)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the conversion of Outstanding Indebtedness of $284.3&nbsp;million as of September&nbsp;30, 2022 into
shares of Common Stock and Series A Preferred Stock pursuant to the Debt Exchange Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(I)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the conversion of the Working Capital Loans of $5.0&nbsp;million as of September&nbsp;30, 2022 to
Common Stock pursuant to the Vickers Debt Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(J)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the forfeiture of 40% of the value of the outstanding Private Placement Warrants. Pursuant to the
Sponsor Support Agreement, 40% of the Private Placement Warrants are forfeited if 75% or more of the Vickers&#146;s public shareholders exercise their right to redeem their Vickers Ordinary Shares. A reduction of $0.5&nbsp;million was reflected
against derivative liabilities with an offset to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(K)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects a cash payment of $1.2&nbsp;million made in conjunction with the Closing for costs associated with
directors&#146; and officers&#146; (&#147;D&amp;O&#148;) insurance policies covering current or former directors and officers of Vickers and Legacy Scilex, which are required to be maintained for a period of six (6)&nbsp;years from the effective
date pursuant to the Merger Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4 &#151; Transaction Adjustments to Unaudited Pro Forma Condensed Combined Statement of
Operations for the nine months ended September&nbsp;30, 2022 and the year ended December&nbsp;31, 2021. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(AA)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the elimination of interest earned on investment held in the Trust Account. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(BB)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an adjustment to reflect previously expensed transaction costs as a reduction to additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital (see Note (E)) as part of the Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(CC)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the 40% of Private Placement Warrants forfeited, which resulted in a gain from derivative liabilities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(DD)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects an incremental amount of transaction costs expensed that are allocated to the Private Placement
Warrants. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(EE)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the immediate expense of costs incurred on D&amp;O insurance policies obtained in connection with
the Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(FF)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the elimination of interest income on mandatorily redeemable ordinary shares liability related to the
redemption of 4,073,605 Vickers Ordinary Shares made in connection with the Extension Proposal. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5 &#151; Net Income (Loss) per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net income (loss) per share is calculated based on the weighted average of Common Stock outstanding and the issuance of additional shares in
connection with the Business Combination, assuming the shares were outstanding since January&nbsp;1, 2021. As the Business Combination is being reflected as if it had occurred at the beginning of the period presented, the calculation of weighted
average shares outstanding for basic and diluted net income (loss) per share assumes that the shares issuable relating to the Business Combination have been outstanding for the entire periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following potential outstanding securities were excluded from the computation of pro forma net loss per share, basic and diluted, because
their effect would have been anti-dilutive or issuance of such shares is contingent upon the satisfaction of certain conditions which were not satisfied by the end of the period: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared using the actual redemptions at Closing related to Common
Stock for the nine months ended September&nbsp;30, 2022 and the year ended December&nbsp;31, 2021 (in thousands, except number of shares and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nine&nbsp;Months<BR>Ended<BR>September&nbsp;30,&nbsp;2022</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average shares of common stock outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141,098,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year ended<BR>December&nbsp;31, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(89,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average shares of common stock outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141,098,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_29"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the section
of this prospectus titled &#147;Unaudited Pro Forma Condensed Combined Financial Statements&#148; and the consolidated financial statements and related notes thereto included elsewhere in this prospectus. In addition to historical information, this
discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from these forward-looking statements as a result of certain factors. We discuss factors that we
believe could cause or contribute to these differences below and elsewhere in this prospectus, including those set forth in the sections of this prospectus titled &#147;Risk Factors&#148; and &#147;Cautionary Note Regarding Forward-Looking
Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_30"></A>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing
<FONT STYLE="white-space:nowrap">non-opioid</FONT> management products for the treatment of acute and chronic pain. According to the Centers for Disease Control and Prevention, an estimated 51.4&nbsp;million adults in the United States suffered from
chronic pain in 2019. We target indications with high unmet needs and large market opportunities with <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapies for the treatment of patients with acute and chronic pain. We launched our first
commercial product in October 2018 and are developing our late-stage pipeline. Our commercial product, ZTlido is a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of
post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief
throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. We market ZTlido through a dedicated sales force of <FONT STYLE="white-space:nowrap">60-70</FONT> sales representatives, targeting 10,000 primary care physicians,
pain specialists, neurologists and palliative care physicians who we believe treat the majority of PHN patients. We <FONT STYLE="white-space:nowrap">in-licensed</FONT> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> prophylactic treatment for painful gout flares in adults, in the U.S. We are planning to commercialize GLOPERBA in 2023 and believe we are well-positioned to market and distribute the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our development pipeline consists of three product candidates, <FONT STYLE="white-space:nowrap">(i)&nbsp;SP-102</FONT> (&#147;SEMDEXA&#148;)
(10 mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica,
<FONT STYLE="white-space:nowrap">(ii)&nbsp;SP-103</FONT> (lidocaine topical system) 5.4%, a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of acute LBP, and
<FONT STYLE="white-space:nowrap">(iii)&nbsp;SP-104</FONT> (4.5 mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release capsules), a novel <FONT STYLE="white-space:nowrap">low-dose</FONT> delayed-release
naltrexone hydrochloride formulation for treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in the first half of 2023. SEMDEXA has been granted fast
track designation by the FDA and, if approved, could become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> alternative to <FONT STYLE="white-space:nowrap">off-label</FONT> ESIs, which are administered over 12&nbsp;million times
annually in the United States. <FONT STYLE="white-space:nowrap">Top-line</FONT> results from the completed Phase 3 study have been received in November 2021 and reflected achievement of primary and secondary endpoints.
<FONT STYLE="white-space:nowrap">SP-103</FONT> has also been granted fast track designation by the FDA and, if approved, could become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> lidocaine topical product for the treatment of acute
LBP. <FONT STYLE="white-space:nowrap">SP-103</FONT> is a triple-strength lidocaine topical system designed to deliver a dose of lidocaine threefold higher than any lidocaine topical product that we are aware of, either approved or in development. We
are examining <FONT STYLE="white-space:nowrap">SP-103</FONT> as a treatment for acute LBP, a condition with high unmet need which, as of 2019, affected over 22&nbsp;million patients in the United States. According to the CDC in 2020, LBP was the
most common type of pain reported by patients, with 25% of U.S. adults reporting LBP in the prior 3 months. We initiated a Phase 2 trial of <FONT STYLE="white-space:nowrap">SP-103</FONT> in acute LBP in the second quarter of our fiscal year 2022.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently contract with third parties for the manufacture, assembly, testing, packaging, storage and distribution of our product. We
obtain our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and manufacturers. Prior to April 2022, we relied on a single third-party logistics distribution provider, Cardinal Health, for ZTlido distribution in the United States. Cardinal Health purchased
and shipped ZTlido to customer wholesale distribution centers. Cardinal Health also performed order management services on our behalf. On April&nbsp;2, 2022, we announced the expansion of our direct distribution network to national and regional
wholesalers and pharmacies. Cardinal Health will continue to provide traditional third-party logistics functions for us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our
inception, we have invested substantial efforts and financial resources on acquiring product and technology rights while building our intellectual property portfolio and infrastructure. We acquired Semnur and its lead product candidate, SEMDEXA, in
the first quarter of 2019, and we intend to continue to explore and evaluate additional opportunities such as these to grow our business. We have incurred significant operating losses as a result of such investment efforts, including the development
of SEMDEXA, conducting of Phase 3 trials for SEMDEXA, and the development of <FONT STYLE="white-space:nowrap">SP-103.</FONT> Our ability to generate revenue sufficient to achieve profitability will depend on the successful commercialization of our
product, ZTlido, and the development of our product candidates. For the years ended December&nbsp;31, 2021, 2020 and 2019, our net loss was $88.4&nbsp;million, $47.5&nbsp;million and $178.6&nbsp;million, respectively. For the nine months ended
September&nbsp;30, 2022 and 2021, we had a net loss of $5.5&nbsp;million and $46.5&nbsp;million, respectively. As of September&nbsp;30, 2022, we had an accumulated deficit of $358.0&nbsp;million. As of September&nbsp;30, 2022, we had cash and cash
equivalents of $2.5&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to make investments in our sales and marketing organization and expand digital
marketing efforts to broaden awareness of ZTlido and GLOPERBA and in research and development, clinical trials and regulatory affairs to develop our product candidates, SEMDEXA, <FONT STYLE="white-space:nowrap">SP-103,</FONT> and <FONT
STYLE="white-space:nowrap">SP-104</FONT> (which product candidate we acquired from Sorrento in May 2022). As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can
generate significant revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. We may be unable to raise additional funds
or enter into such agreements or arrangements when needed on favorable terms, or at all. If adequate funds on acceptable terms are not available when needed, we may be required to reduce the scope of the commercialization of ZTlido and GLOPERBA or
delay, scale back or discontinue the development of one or more of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_31"></A>Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;17, 2022, Vickers Vantage Corp. I (&#147;Vickers&#148;) entered into an Agreement and Plan of Merger (the &#147;BCA&#148;) with
Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#147;Vickers Merger Sub&#148;), and Scilex Holding Company, a Delaware corporation (&#147;Legacy Scilex&#148;). Pursuant to the terms of the BCA, Vickers Merger Sub merged with and
into Legacy Scilex, with Legacy Scilex surviving the merger and becoming a wholly- owned subsidiary of Vickers (collectively, the &#147;Business Combination&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, Vickers consummated the Business Combination pursuant to the terms of the BCA, with Legacy Scilex and Vickers
Merger Sub. Pursuant to the BCA, Vickers acquired all of the outstanding equity interests of Legacy Scliex. As a result of the Business Combination, New Scilex (as defined below) received gross proceeds of approximately $12.0&nbsp;million, prior to
the settlement of transaction-related costs and expenses. Additionally, all existing related party indebtedness and payables between Legacy Scilex, Scilex Pharma, and Sorrento, totaling $290.6&nbsp;million, was converted into equity interests of New
Scilex in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note 10 titled &#147;Related Party Transactions&#148; to our consolidated financial statements included elsewhere in
this prospectus for additional information). In connection with the Business Combination (as more fully described in the notes to these financial statements), Scilex Holding Company was renamed to Scilex, Inc. These financial statements are those of
Scilex Holding Company (now known as Scilex, Inc.) prior to the completion of such Business Combination. Additionally, in connection with the completion of the Business Combination, Vickers was renamed to, and will operate as, &#147;Scilex Holding
Company&#148; and the Company began trading on Nasdaq </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the new ticker symbol &#147;SCLX&#148; on November&nbsp;11, 2022. Scilex Holding Company following the completion of the Business Combination is sometimes referred to herein as &#147;New
Scilex.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this
method of accounting, Vickers is treated as the &#147;acquired&#148; company for accounting purposes and the Business Combination is treated as the equivalent of Legacy Scilex issuing stock for the net assets of Vickers, accompanied by a
recapitalization. The net assets of Vickers are stated at historical cost, with no goodwill or other intangible assets recorded. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_32">
</A>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;3, 2023, we filed a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT>
providing certain preliminary unaudited financial results for the one and twelve months ended December&nbsp;31, 2022, and as of December&nbsp;31, 2022, based on then-currently available information. Our independent auditor has not reviewed or
audited these preliminary estimated financial results. Our actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges. This preliminary financial data has been prepared by and is the
responsibility of the Company. We have not fully completed our review of these preliminary financial results for the one and twelve months ended December&nbsp;31, 2022, and as of December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In such Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> we estimated that: ZTlido gross sales for December 2022 were in
the range of $10.0&nbsp;million to $12.0&nbsp;million; the gross sales for ZTlido in 2022 were in the range of $93.0&nbsp;million to $98.0&nbsp;million, compared to $63.9&nbsp;million in 2021, representing growth in the range of 45% to 53%; net
sales for 2022 were in the range of $37.0&nbsp;million to $42.0&nbsp;million, compared to net sales of $31.3&nbsp;million in 2021, representing growth in the range of 18% to 34%; and, as of December&nbsp;31, 2022, our cash and cash equivalents were
in the range of $1.8&nbsp;million to $2.5&nbsp;million, and our accounts receivables were in the range of $18.0&nbsp;million to $22.0&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. Riley Purchase Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
January 8, 2023, we entered into the B. Riley Purchase Agreement with the Selling Securityholder. The Selling Securityholder is a wholly-owned subsidiary of B. Riley Principal Investments, LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the B. Riley Purchase Agreement, we have the right, but not the obligation, to sell to the Selling Securityholder up to
$500,000,000 of shares of Common Stock at any time during the 36 months following the date on which this registration statement has been declared effective by the SEC, subject to the terms of the B. Riley Purchase Agreement. To request a purchase,
we would submit an Advance Notice to the Selling Securityholder specifying the number of shares we intend to sell to the Selling Securityholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock, if any, that we elect to sell to the Selling Securityholder pursuant to an Advance will be purchased at a price
equal to 98% of the VWAP (as defined below) during the period (such period, the &#147;Pricing Period&#148;) beginning at 9:30:01 a.m., New York City time, on the date of purchase of Advance Shares or such later time publicly announced as the
official open of the primary (or &#147;regular&#148;) trading session on Nasdaq on such purchase date (the &#147;Purchase Commencement Time&#148;) and ending at the earliest of (i) 3:59 p.m., New York City Time, on the purchase date or such earlier
time publicly announced as the official close of the primary (or &#147;regular&#148;) trading session on Nasdaq on such purchase date, (ii)&nbsp;immediately at such time following the Purchase Commencement Time for such purchase that the total
number (or volume) of shares of Common Stock traded on Nasdaq during such period has exceeded the Advance Share Volume Maximum (as defined below) for such purchase and (iii)&nbsp;if we so elect in the applicable Advance Notice for such Advance (such
election, a &#147;Limit Order Discontinue Election&#148;), such time the sale price of the shares of Common Stock traded on the Nasdaq Capital Market during such Pricing Period is less than the applicable minimum price threshold determined in
accordance with the B. Riley Purchase Agreement. &#147;VWAP&#148; means, for the Common Stock for a specified period, the dollar volume-weighted average price of the Common Stock on Nasdaq for such period as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reported by Bloomberg through its &#147;AOR&#148; function, subject to certain exceptions, qualifications and limitations. &#147;Advance Share Volume Maximum&#148; means, with respect to an
Advance, if such Advance is designated in the Advance Notice as a (i)&nbsp;purchase-Type A, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a)&nbsp;the Advance Share amount to be purchased by the Selling
Securityholder, by (b) 0.10, and (ii)&nbsp;purchase-Type B, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a)&nbsp;the Advance Share amount to be purchased by the Selling Securityholder, by (b) 0.25 (in each
case, subject to certain adjustments). We may also specify a certain minimum acceptable price per share in each Advance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there is
no mandatory minimum amount for any Advance, subject to the terms and conditions of the B. Riley Purchase Agreement, an Advance may be for a number of shares of Common Stock not to exceed (i)&nbsp;with respect to an Advance, purchase-Type A, such
number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000, and (b)&nbsp;the product of (1) 0.10, multiplied by (2)&nbsp;the total number (or volume) of shares of Common Stock traded on Nasdaq during the Pricing Period for such
purchase-Type A, and (ii)&nbsp;with respect to an Advance, purchase-Type B, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000 and (b)&nbsp;the product of (1) 0.25, multiplied by (2)&nbsp;the total number (or volume)
of shares of Common Stock traded on Nasdaq during the Pricing Period for such purchase-Type B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The B. Riley Purchase Agreement also
provides that we have the right, but not the obligation, to sell to the Selling Securityholder, from time to time subject to certain limitations, at our sole and absolute discretion an Additional Advance. To request an additional purchase, we would
submit an Additional Advance Notice to the Selling Securityholder specifying the number of shares we intend to sell to the Selling Securityholder. The purpose of the Additional Advance is to allow us to execute more than one advance request on a
purchase date with the Selling Stockholder as each prior advance has been completed under the terms of the B. Riley Purchase Agreement. Each Additional Advance is generally subject to terms and conditions consistent with those of an Advance, except
for, among other things, the time period of the pricing period for such Additional Advance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also specify a certain minimum
acceptable price per share in each Advance or Additional Advance. In no event is the Selling Securityholder obligated to purchase any shares that would result in it owning more than 4.99% of the then-outstanding voting power or number of shares of
Common Stock. Moreover, under the applicable Nasdaq Listing Rules, in no event will we issue to the Selling Securityholder shares that, in the aggregate, would exceed the 19.9% Exchange Cap, unless we have received stockholder approval for such
issuance or such issuance is otherwise permitted by applicable Nasdaq Listing Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder&#146;s obligation to
purchase shares of Common Stock pursuant to the B. Riley Purchase Agreement is subject to a number of conditions, including that a registration statement be filed with the SEC registering the resale of the Commitment Shares and the shares to be
issued pursuant to any Advance or Additional Advance under the Securities Act, and that the registration statement is declared effective by the SEC. As consideration for the Selling Securityholder&#146;s commitment to purchase shares of Common Stock
at our direction upon the terms and subject to the conditions set forth in the B. Riley Purchase Agreement, we issued to the Selling Securityholder 250,000 shares of Common Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Yorkville Purchase Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
November&nbsp;17, 2022, we entered into the Yorkville Purchase Agreement with YA II. YA II is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Yorkville Purchase Agreement, we have the right, but not the obligation, to sell to YA II up to $500,000,000 of shares of
Common Stock at any time during the 36 months following the date on which the initial registration statement filed with respect to the Yorkville Purchase Agreement has been declared effective by the SEC, subject to the terms of the Yorkville
Purchase Agreement. The registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268607)</FONT> related to the the Yorkville Purchase Agreement was filed with the SEC on
November&nbsp;30, 2022, was declared effective by the SEC on December&nbsp;9, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To request a purchase, we would submit a Yorkville Advance Notice to YA II specifying the
number of shares we intend to sell to YA II. While there is no mandatory minimum amount for any Yorkville Advance, a Yorkville Advance may not be for a number of shares of Common Stock exceeding 200% of the average of the daily trading volume of the
Common Stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the five trading days immediately preceding the Yorkville Advance Notice Date. The shares of Common Stock, if any, that we elect to sell to
YA II pursuant to a Yorkville Advance will be purchased at a price equal to 98% of the lowest daily VWAP (as defined below) during the two consecutive trading days commencing on the date of delivery of a Yorkville Advance Notice. &#147;VWAP&#148;
means, for any trading day, the daily volume weighted average price of the Common Stock for such trading day on the Nasdaq Capital Market as reported by Bloomberg L.P. during regular trading hours. We may also specify a certain minimum acceptable
price per share in each Yorkville Advance. In no event is YA II obligated to purchase any shares that would result in it owning more than 4.99% of the then-outstanding voting power or number of shares of Common Stock. Moreover, under the applicable
Nasdaq Listing Rules, in no event will we issue to YA II shares that, in the aggregate, would exceed the 19.9% Exchange Cap, unless we have received stockholder approval for such issuance or such issuance is otherwise permitted by applicable Nasdaq
Listing Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">YA II&#146;s obligation to purchase shares of Common Stock pursuant to the Yorkville Purchase Agreement is subject to a
number of conditions, including that a registration statement be filed with the SEC registering the resale of the Commitment Shares and the shares to be issued pursuant to any Yorkville Advance under the Securities Act, and that the registration
statement is declared effective by the SEC. As consideration for YA II&#146;s commitment to purchase shares of Common Stock at our direction upon the terms and subject to the conditions set forth in the Yorkville Purchase Agreement, we issued to YA
II 250,000 shares of Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_33"></A>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are closely monitoring the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and its potential impact on our business. In an effort
to protect the health and safety of our employees, we took proactive action from the earliest signs of the outbreak, including implementing social distancing policies at our facilities, facilitating remote working arrangements and imposing employee
travel restrictions. The extent to which <FONT STYLE="white-space:nowrap">COVID-19</FONT> may impact our business, clinical trials and sales of ZTlido will depend on future developments, which are highly uncertain and cannot be predicted with
confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of
actions taken in the United States and other countries to contain and treat the disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_34"></A>Comparability of Our Results and
Our Relationship with Sorrento </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently operate as a majority-owned subsidiary of Sorrento. As a result, our historical financial
statements may not be reflective of what our results of operations would have been had we been a stand-alone public company and no longer a majority-owned subsidiary of Sorrento. In particular, certain legal, finance, human resources and other
functions have historically been provided to us by Sorrento at cost plus an agreed-upon markup. We expect that Sorrento will continue to provide us with some of the services related to these functions on a transitional basis in exchange for
agreed-upon fees, and we expect to incur other costs to replace the services and resources that will not be provided by Sorrento. We will also incur additional costs as a stand-alone public company. As a stand-alone public company, our total costs
related to certain support functions may differ from the costs that were historically allocated to us from Sorrento. In addition, in the future, we expect to incur internal costs to implement certain new systems, including infrastructure and an
enterprise resource planning system, while our legacy systems are currently being fully supported by Sorrento. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_35"></A>Components
of Our Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue consists solely of product sales of ZTlido in the United States. For product sales of ZTlido, we record <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT> sales adjustments for government and commercial rebates, chargebacks, wholesaler and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distributor fees, sales returns, special marketing programs, and prompt payment discounts. We expect that any net revenue we generate will fluctuate from year to year as a result of the
unpredictability of the demand for our product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_36"></A>Operating Costs and Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cost of Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue consists
of the cost of purchasing ZTlido from our manufacturing partners and inventory write-downs related to expiration dates for <FONT STYLE="white-space:nowrap">on-hand</FONT> inventory. We expect the cost of revenue to fluctuate with related sales
revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses are expensed when incurred and consist primarily of costs incurred for our research activities, including
the development of our product candidates, and include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">salaries, benefits and other related costs, including stock-based compensation expense for personnel engaged in
research and development functions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to outside consultants. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase, as we will incur incremental expenses associated with our product candidates that
are currently under development and in clinical trials. Product candidates in later stages of clinical development generally have higher development costs, primarily due to the increased size and duration of later-stage clinical trials. Accordingly,
we expect to incur significant research and development expenses in connection with our ongoing Phase 3 clinical trial for SEMDEXA, our planned Phase 2 and Phase 3 clinical trials for <FONT STYLE="white-space:nowrap">SP-103,</FONT> and initiation of
Phase 2 trials for <FONT STYLE="white-space:nowrap">SP-104.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Acquired <FONT STYLE="white-space:nowrap">In-process</FONT> Research and
Development </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acquired and may continue to acquire the rights to develop and commercialize new product candidates. The <FONT
STYLE="white-space:nowrap">up-front</FONT> payments to acquire a new drug compound or drug delivery device, as well as future milestone payments associated with asset acquisitions that do not meet the definition of a derivative and are deemed
probable to achieve the milestones, are immediately expensed as acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such
approval, have no alternative future use. Intangible assets acquired in a business combination that are used for <FONT STYLE="white-space:nowrap">in-process</FONT> research and development (&#147;IPR&amp;D&#148;) activities are considered
indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, we amortize the acquired IPR&amp;D over its estimated useful life.
Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Selling, General and Administrative </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses consist primarily of costs related to our contract sales force, salaries and other related costs,
including stock-based compensation, for personnel in our executive, marketing, finance, corporate and business development and administrative functions. Selling, general and administrative expenses also include professional fees for legal, patent,
accounting, auditing, tax and consulting services, travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses from Sorrento for rent and maintenance of facilities and other operating costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our selling, general and administrative expenses will vary year over year in
the future as we adapt our commercial strategies to changes in the business environment. We also expect to incur increased expenses as a result of the Business Combination and operating as a public company, including expenses related to compliance
with the rules and regulations of the SEC, and listing standards applicable to companies listed on a national securities exchange, additional insurance expenses, investor relations activities and other administrative and professional services. We
also expect to adjust the size of our administrative, finance and legal functions to adapt to the changes above and the anticipated growth of our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Intangible Amortization Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense consists of the amortization expense of intangible assets recognized on a straight-line basis over the
estimated useful lives of the assets. Our intangible assets, excluding goodwill, are composed of patent rights, acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development and assembled workforce. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Gain on Derivative Liability
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain on derivative liability consists of the changes to fair value of derivative liabilities between reporting periods relating to
certain embedded derivative features within the Scilex Pharma Notes, and is recorded as other income or expense. See Note 6 titled &#147;Debt&#148; to our consolidated financial statements appearing elsewhere in this prospectus and the section
titled &#147;Certain Relationships and Related Party Transactions &#151; Certain Relationships of Legacy Scilex &#151; Indenture and Letter of Credit&#148; for a description of the Scilex Pharma Notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(Gain) loss on Debt Extinguishment, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net consists of gains earned or losses incurred as a result of exercising our optional prepayment rights,
which are treated as partial extinguishments, and the Early Paydown Provision, which is treated as a debt extinguishment, under the Scilex Pharma Notes, offset, for the year ended December&nbsp;31, 2021, by a gain on debt extinguishment as a result
of the forgiveness of the loan in the amount of $1.6&nbsp;million received from Bank of America in May 2020 pursuant to the Paycheck Protection Program of the CARES Act (the &#147;PPP Loan&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Expense </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense
consists of interest related to the Scilex Pharma Notes and related party note payables to Sorrento. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(Gain) loss on Foreign Currency Exchange </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on foreign currency exchange relates to foreign exchange losses on payments made to our foreign supplier, Itochu, a manufacturer
and supplier of lidocaine tape products, including ZTlido and <FONT STYLE="white-space:nowrap">SP-103.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_37"></A>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our results of operations for the years ended December&nbsp;31, 2021, 2020 and 2019 and the nine months ended
September&nbsp;30, 2022 and 2021 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nine Months Ended<BR>September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands, except for per share amounts)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statements of Operations Data:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on foreign currency exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (income) expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,516</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares during the period &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands, except for per share amounts)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">2019</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statements of Operations Data:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35,838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(138,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (gain) on derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on debt extinguishment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (gain) on foreign currency exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(178,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(178,594</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_38"></A>Comparison of Nine Months Ended September&nbsp;30, 2022 and 2021 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue for the
nine months ended September&nbsp;30, 2022 and 2021 was $26.1&nbsp;million and $23.1&nbsp;million, respectively. The increase of $3.0&nbsp;million primarily driven by an increase in gross revenues by approximately 37% offset by increase in rebates.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of
revenue for the nine months ended September&nbsp;30, 2022 and 2021 was $6.3&nbsp;million and $2.5&nbsp;million, respectively, and relate to product sales. The increase of $3.8&nbsp;million was primarily due to an approximately 37% increase in gross
revenue for the nine months ended September&nbsp;30, 2022, compared to the nine months ended September&nbsp;30, 2021, royalty payments to our manufacturer beginning in the second quarter of 2022, and a $0.5&nbsp;million inventory reserve reversal in
May 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes research and development expenses by project for the nine months ended September&nbsp;30, 2022 and 2021 (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nine Months Ended<BR>September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Increase<BR>(Decrease)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-103</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(617</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-103</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-104</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-104</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Research and Development Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(574</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the nine months ended September&nbsp;30, 2022 and 2021 were
$6.5&nbsp;million and $7.0&nbsp;million, respectively. The $0.5&nbsp;million decrease in research and development expenses was primarily attributed to the completion of the Phase 3 <FONT STYLE="white-space:nowrap">SP-102</FONT> trial in November
2021, and was partially offset by clinical <FONT STYLE="white-space:nowrap">start-up</FONT> costs in the development of Phase 2 <FONT STYLE="white-space:nowrap">SP-103</FONT> in the fourth quarter of 2021, the Phase 1
<FONT STYLE="white-space:nowrap">SP-104</FONT> study in the fourth quarter of 2021, and an additional Phase 1 <FONT STYLE="white-space:nowrap">SP-104</FONT> study in the second quarter of 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses for the nine months ended September&nbsp;30, 2022 and 2021 were $41.4&nbsp;million and
$36.1&nbsp;million, respectively. The increase of approximately $5.3&nbsp;million was primarily due to a $7.7&nbsp;million increase in legal expenses related to the ZTlido patent infringement in which we were the plaintiff in September 2022,
$0.9&nbsp;million increase in travel and entertainment expenses, $0.2&nbsp;million increase in consulting expenses, and a $0.4&nbsp;million increase in insurance expense, offset by a $1.2&nbsp;million decrease in commercial operations caused by
fluctuation in fleet and electronics expenses, $2.0&nbsp;million decrease in personnel expense caused by $1.0&nbsp;million increase in personnel compensation that was offset by $3.0&nbsp;million decrease in bonus, a $0.5&nbsp;million decrease in
marketing expense, and a $0.2&nbsp;million decrease in other expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intangible Amortization Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense for each of the nine months ended September&nbsp;30, 2022 and 2021 was $2.9&nbsp;million and $2.8&nbsp;million,
respective. The increase of $0.1 is related to the amortization of acquired licenses for the exclusive license of GLOPERBA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gain on Derivative
Liability </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain on derivative liability for the nine months ended September&nbsp;30, 2022 and 2021 was $5.3&nbsp;million and
$0.1&nbsp;million, respectively. The gain recognized during the nine months ended September&nbsp;30, 2022 and 2021 was attributed to changes in the fair value of our derivative liability pertaining to the Scilex Pharma Notes due to revised sales
forecasts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(Gain) Loss on Debt Extinguishment, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net for the nine months ended September&nbsp;30, 2022 and 2021 was $(28.6) million and $12.5&nbsp;million,
respectively. The gain and loss incurred during the nine months ended September&nbsp;30, 2022 and 2021, respectively, was attributed to Scilex Pharma&#146;s repurchase of the Scilex Pharma Notes of $20.0&nbsp;million and $41.4&nbsp;million in
February 2022 and June 2022, respectively, as well as the Early Paydown Provision of $39.7&nbsp;million in September 2022 (see Note 6 titled &#147;Debt&#148; to our consolidated financial statements included elsewhere in this prospectus for
additional information) and $20.0&nbsp;million in each of February 2021 and April 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the nine months ended September&nbsp;30, 2022 and 2021 remained consistent and was $8.6&nbsp;million for each period </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Tax (Benefit) Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense for the nine months ended September&nbsp;30, 2022 and 2021 was $(36.0) thousand and $10.0&nbsp;thousand,
respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_39"></A>Comparison of Years Ended December&nbsp;31, 2021 and 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue for the
years ended December&nbsp;31, 2021 and 2020 was $31.3&nbsp;million and $23.6&nbsp;million, respectively. The increase of $7.7&nbsp;million was due to increased product sales of ZTlido. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue
for the years ended December&nbsp;31, 2021 and 2020 was $3.6&nbsp;million and $2.1&nbsp;million, respectively, and relate to product sales. The increase of $1.5&nbsp;million is mainly due to the temporary switch of shipping method from ocean to air
shipment in 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes research and development expenses by project for the years ended December&nbsp;31, 2021 and 2020 (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Increase<BR>(Decrease)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(529</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-103</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(919</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-103</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Research and Development Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the years ended December&nbsp;31, 2021 and 2020 were
$9.2&nbsp;million and $10.0&nbsp;million, respectively. The $0.8&nbsp;million decrease in research and development expenses was attributed to the completion of Phase 3 <FONT STYLE="white-space:nowrap">SP-102</FONT> trials in November 2021 as well as
CMC and regulatory related expenses incurred in 2020 to prepare for <FONT STYLE="white-space:nowrap">SP-103</FONT> clinical trials in 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses for the years ended December&nbsp;31, 2021 and 2020 were $50.6&nbsp;million and
$43.0&nbsp;million, respectively. The increase of approximately $7.6&nbsp;million was primarily due to $4.0&nbsp;million in additional expenses in marketing and commercial operations, $7.6&nbsp;million in legal and audit fees, and $1.2&nbsp;million
in additional other administrative expenses, offset by $5.2&nbsp;million of savings in sales expenses as a result of realigning our &#147;sales force&#148; territories resulting in the significant reduction of salesforce. The $7.6&nbsp;million
increase in legal and audit fees was primarily due to a $6.6&nbsp;million increase in litigation expenses related to the ZTlido patent infringement in which we were the plaintiff and $1.0&nbsp;million increase in legal intellectual property and
other legal corporate matters. The $4.0&nbsp;million increase in marketing and commercial operations was due to $1.4&nbsp;million increase in product promotion expenses, $1.0&nbsp;million increase in dues and subscriptions, $1.0&nbsp;million
increase in consulting expenses and $0.6&nbsp;million increase in personnel cost. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intangible Amortization Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense for each of the years ended December&nbsp;31, 2021 and 2020 was $3.7&nbsp;million, which is related to the
amortization of developed technology upon commercialization of ZTlido. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Loss (Gain) on Derivative Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loss (gain) on derivative liability for the years ended December&nbsp;31, 2021 and 2020 was $0.3&nbsp;million and $(0.8) million, respectively.
The loss incurred during the year ended December&nbsp;31, 2021 was attributed to changes in the fair value of our derivative liability pertaining to the Scilex Pharma Notes due to revised probabilities related to marketing approval timing for <FONT
STYLE="white-space:nowrap">SP-103</FONT> and revised sales forecasts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Loss on Debt Extinguishment, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loss on debt extinguishment net for the years ended December&nbsp;31, 2021 was $12.5&nbsp;million. The loss incurred was attributed to our
exercise of the optional principal repurchase payments on the Scilex Pharma Notes, offset by a gain on debt extinguishment of $1.5&nbsp;million related to the forgiveness on the entire PPP Loan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Pharma Notes Principal Increase </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal increase on the Scilex Pharma Notes for the years ended December&nbsp;31, 2021 was $28.0&nbsp;million. Actual cumulative net
sales of ZTlido from the issue date of the Scilex Pharma Notes through December&nbsp;31, 2021 did not equal or exceed $481.0&nbsp;million. As a result, we recorded the increase of $28.0&nbsp;million in principal as
<FONT STYLE="white-space:nowrap">non-operating</FONT> expense at December&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the years ended December&nbsp;31, 2021 and 2020 was $11.8&nbsp;million and $13.1&nbsp;million, respectively. The
$1.3&nbsp;million decrease in interest expense was primarily due to the $2.8&nbsp;million decrease in interest expense incurred on the Scilex Pharma Notes partially offset by a $1.1&nbsp;million increase in interest expense related to related party
notes with Sorrento and $0.4&nbsp;million increase in interest expense related to the CNH Revolving Loan during the year ended December&nbsp;31, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Tax Expense (Benefit) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit) for the years ended December&nbsp;31, 2021 and 2020 was $5.0&nbsp;thousand and $(53.0) thousand, respectively.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_40"></A>Comparison of Years Ended December&nbsp;31, 2020 and 2019 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue for the
years ended December&nbsp;31, 2020 and 2019 was $23.6&nbsp;million and $21.0&nbsp;million, respectively. The increase of $2.6&nbsp;million was due to product sales of ZTlido, which was commercially launched in October 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue
for the years ended December&nbsp;31, 2020 and 2019 was $2.1&nbsp;million and $5.8&nbsp;million, respectively, and relate to product sales. The decrease of $3.7&nbsp;million is mainly due to establishing an E&amp;O inventory provision in 2019 for
short-dated products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes research and development expenses by project for the years ended December&nbsp;31, 2020 and 2019 (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Increase<BR>(Decrease)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-103</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-103</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Research and Development Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the years ended December&nbsp;31, 2020 and 2019 were $10.0&nbsp;million
and $10.2&nbsp;million, respectively. The $0.2&nbsp;million decrease was primarily due to a slow down of clinical activities in the development of <FONT STYLE="white-space:nowrap">SP-102</FONT> due to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquired <FONT STYLE="white-space:nowrap">In-process</FONT> Research and Development
Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acquired IPR&amp;D expenses for the years ended December&nbsp;31, 2020 and 2019 were $0 and $75.3&nbsp;million,
respectively. The decrease was due to acquired IPR&amp;D expenses associated with our acquisition of Semnur&#146;s assets in March 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling,
General and Administrative Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses for the years ended December&nbsp;31, 2020 and
2019 were $43.0&nbsp;million and $64.7&nbsp;million, respectively. The decrease of approximately $21.7&nbsp;million was primarily due to $16.6&nbsp;million of savings in sales and marketing as a result of realigning our &#147;sales force&#148;
territories resulting in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the significant reduction of salesforce as well as achieving cost-saving within our marketing programs, a reduction of $2.4&nbsp;million in third-party services within the market access
department, and $2.7&nbsp;million in savings from lower legal and audit fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intangible Amortization Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense remained the same at $3.7&nbsp;million between the years ended December&nbsp;31, 2020 and 2019, which is
related to the amortization of developed technology upon commercialization of ZTlido. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(Gain) Loss on Derivative Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liability for the years ended December&nbsp;31, 2020 and 2019 was a gain of $0.8&nbsp;million and a loss of
$23.3&nbsp;million, respectively. The gain incurred during the year ended December&nbsp;31, 2020 and loss incurred during the year ended December&nbsp;31, 2019 was attributed to changes in the fair value of our derivative liability pertaining to the
Scilex Pharma Notes due to revised probabilities related to marketing approval timing for <FONT STYLE="white-space:nowrap">SP-103</FONT> and revised sales forecasts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense
for the years ended December&nbsp;31, 2020 and 2019 was $13.1&nbsp;million and $16.9&nbsp;million, respectively. The decrease in interest expense was primarily due to the $4.4&nbsp;million decrease in interest expense incurred on the Scilex Pharma
Notes issued in September 2018 partially offset by a $0.6&nbsp;million increase in interest expense related to related party notes with Sorrento during the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income
for the years ended December&nbsp;31, 2020 and 2019 was $0 and $0.5&nbsp;million, respectively. The decrease in interest income was primarily due to lower cash balances during the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Tax (Benefit) Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense for the years ended December&nbsp;31, 2020 and 2019 was $(53.0) thousand and $2.0&nbsp;thousand, respectively.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_41"></A>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, we had cash and cash equivalents of $2.5&nbsp;million. In connection with the completion of the Business
Combination, we received approximately $3.4&nbsp;million from the balance of the Trust Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have funded our operations primarily
through the issuance of the Scilex Pharma Notes, related party notes with Sorrento, and the 2020 revolving credit facility. The following table summarizes the aggregate indebtedness of these issuances as of September&nbsp;30, 2022, December&nbsp;31,
2021, and December&nbsp;31, 2020 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">September&nbsp;30,<BR>2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,<BR>2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,<BR>2020</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related Party Notes with Sorrento</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020 Revolving Credit Facility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred Consideration with Romeg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total indebtedness</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_42"></A>Debt Financings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Pharma Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
June&nbsp;2, 2022, Sorrento and the Company entered into a Consent Under and Amendment No.&nbsp;4 with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee (the &#147;Trustee&#148;)
and collateral agent (the &#147;Agent&#148;), and the beneficial owners of those certain senior secured notes due 2026 issued by Scilex Pharma in September 2018 (the &#147;Scilex Pharma Notes&#148;) listed on the signature pages thereto (the
&#147;Holders&#148;), which amended that certain Indenture, dated September&nbsp;7, 2018, by and among Scilex Pharma, Sorrento, the Trustee and the Agent, as amended (the &#147;Indenture&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the amendment to the Indenture (1)&nbsp;on June&nbsp;3, 2022, Scilex Pharma repurchased $41.4&nbsp;million of the aggregate
principal amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof, (2)&nbsp;the Holders agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before
September&nbsp;30, 2022 for $41.4&nbsp;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Holders will forgive and discharge $28.0&nbsp;million of the aggregate principal amount of the Scilex Pharma Notes,
(3)&nbsp;the minimum cash requirement under the Indenture was reduced to $5.0&nbsp;million in aggregate unrestricted cash equivalents at the end of each calendar month, and (4)&nbsp;the maximum aggregate principal amount of that certain intercompany
promissory note issued by Scilex Pharma to Sorrento on October&nbsp;5, 2018 was increased from up to $25.0&nbsp;million to up to $50.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $1.7&nbsp;million. On
September&nbsp;28, 2022, Scilex Pharma repurchased all of the outstanding aggregate principal amount of the Scilex Pharma Notes. As of immediately prior to the repurchase, the aggregate principal amount of the Scilex Pharma Notes was approximately
$67.7&nbsp;million, and Scilex Pharma repurchased the Scilex Pharma Notes for an aggregate cash payment of $39.7&nbsp;million as the holders of the Scilex Pharma Notes forgave and discharged an aggregate of $28.0&nbsp;million of principal amount of
the Scilex Pharma Notes in connection with the repurchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quarterly principal payments, based on a percentage of projected net sales of
ZTlido, optional and contingently accelerated repurchases, and the Early Paydown Provision under the Scilex Pharma Notes since January&nbsp;1, 2021 are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>Three Months Ended,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Prinicipal<BR>Payments</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;31, 2021*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;30, 2021*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;30, 2022*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;30, 2022*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total payments since January&nbsp;1, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes repurchase or Early Paydown Provision during the period (see Note 6 titled &#147;Debt&#148; to our
consolidated financial statements elsewhere in this prospectus). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ZTlido Royalties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the quarterly royalty payment of net sales of ZTlido associated with the Indenture, Scilex Pharma is a party to the Product
Development Agreement with the Developers, pursuant to which the Developers will manufacture and supply lidocaine tape products, including the Products, for Scilex Pharma. Pursuant to the Product Development Agreement, Scilex Pharma is required to
make aggregate royalty payments between 25% </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and 35% to the Developers based on net profits. During the nine months ended September&nbsp;30, 2022, Scilex Pharma made the first royalty payments in the amount of $0.2&nbsp;million. As of
September&nbsp;30, 2022, Scilex Pharma had ending balances of accrued royalty payables of $2.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Scilex
Pharma is in a net profit position, as defined in the Product Development Agreement, Scilex Pharma will first attempt to make aggregate royalty payments with cash generated from its operations. If these sources are insufficient, Scilex Pharma may
seek to raise additional funds through equity offerings, debt financings, collaborations, government contracts or other strategic transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingent Consideration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
$280.0&nbsp;million, $13.0&nbsp;million, and $23.0&nbsp;million in aggregate contingent consideration obligations in connection with the Merger of Semnur, Romeg license, and <FONT STYLE="white-space:nowrap">SP-104</FONT> acquisitions (see Note 3
titled &#147;Acquisitions&#148; to our consolidated financial statements included elsewhere in this prospectus for additional information), respectively, that are contingent upon achieving certain specified milestones or the occurrence of certain
events. Contingent consideration obligations are comprised of regulatory milestones and additional payments that will be due upon the achievement of certain amounts of net sales (see Note 3 titled &#147;Acquisitions&#148; to our consolidated
financial statements included elsewhere in this prospectus for additional information). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Consideration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have $3.7&nbsp;million of deferred consideration related to minimum royalty payments that were included in the initial measurement of
consideration transferred for the GLOPERBA license (see Note 3 titled &#147;Acquisitions&#148; to our consolidated financial statements included elsewhere in this prospectus for additional information). Deferred consideration minimum royalty
payments begin the first full quarter following June&nbsp;14, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Standby Equity Purchase Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;17, 2022, we entered into the Yorkville Purchase Agreement with YA II, whereby we have the right, but not the obligation, to
sell to YA II up to $500.0&nbsp;million of shares of Common Stock at our request during the 36 months following the date on which the initial registration statement filed with respect to the shares of Common Stock issuable pursuant thereto has been
declared effective by the SEC, subject to the terms therein. The registration statement filed with the SEC in connection with the Yorkville Purchase Agreement was declared effective by the SEC on December&nbsp;9, 2022 and we are now able to offer
and sell shares of our Common Stock under that agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 8, 2023, we entered into the B. Riley Purchase Agreement with the
Selling Securityholder, whereby we have the right, but not the obligation, to sell to the Selling Securityholder up to $500.0&nbsp;million of shares of Common Stock at our request during the 36 months following the date on which the initial
registration statement filed with respect to the shares of Common Stock issuable pursuant thereto has been declared effective by the SEC, subject to the terms therein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future Liquidity Needs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
discussed above, we have principally financed our operations through debt financings, and other debt arrangements. We have based our anticipated operating capital requirements on assumptions that may prove to be incorrect and we may use all our
available capital resources sooner than we expect. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and expenses associated with our ongoing commercialization efforts for ZTlido and GLOPERBA;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the degree of success we experience in commercializing ZTlido and GLOPERBA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue generated by sales of ZTlido, GLOPERBA, and other products that may be approved, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of conducting studies and clinical trials for our product candidates,
SEMDEXA, <FONT STYLE="white-space:nowrap">SP-103,</FONT> and <FONT STYLE="white-space:nowrap">SP-104;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of manufacturing ZTlido, GLOPERBA and our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current
or future collaboration or license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements
and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which ZTlido, GLOPERBA, or any of our product candidates, if approved for commercialization, is
adopted by the physician community; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to expand our research and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of acquiring, licensing or investing in businesses, product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing products and product candidates and other market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and types of future products we develop and commercialize; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any product liability or other lawsuits related to our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses needed to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with being a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending
intellectual property-related claims; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent and scope of our general and administrative expenses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should our sales of ZTlido, GLOPERBA and other product candidates not materialize at the anticipated rate contemplated in our business plan,
we will need to raise additional capital in order to continue to fund our research and development, including our plans for clinical and preclinical trials and new product development, as well as to fund operations generally. We will seek to raise
additional funds through various potential sources, such as equity and debt financings and license agreements. As discussed above, following the completion of the Business Combination, we entered into the Yorkville Purchase Agreement and the B.
Riley Purchase Agreement. The registration statement filed with the SEC in connection with the Yorkville Purchase Agreement was declared effective by the SEC on December&nbsp;9, 2022 and we are now able to offer and sell shares of our Common Stock
under that agreement, which will provide us with an additional source of liquidity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the liquidity provided by revenue
generating products, Advances under the Yorkville Purchase Agreement and Advances and Additional Advances under the B. Riley Purchase Agreement, we will receive up to an aggregate of approximately $126.5&nbsp;million from the exercise of the
Warrants (at an exercise price of $11.50 per share of Common Stock), assuming the exercise in full of all of the Warrants for cash, but will not receive any proceeds from the sale of the shares of our Common Stock issuable upon such exercise.
However, our ability to generate proceeds will depend on the market price of our Common Stock. On January 11, 2023, the closing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
price for our Common Stock was $7.47 per share. If the price of our Common Stock remains below $11.50 per share, we believe warrantholders will be unlikely to cash exercise their Warrants,
resulting in little or no cash proceeds to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities held by Sorrento and the Sponsors that were previously registered for
resale on a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268603)</FONT> filed with the SEC on November&nbsp;30, 2022, which was declared effective by the SEC on
December&nbsp;27, 2022 represent a substantial percentage of our outstanding Common Stock. After the restrictions on resale end, the Sponsors and Sorrento (who holds 140,217,207 shares of our Common Stock representing approximately 95.3% of the
shares of our Common Stock outstanding as of January&nbsp;11, 2023 (assuming the full exercise of all outstanding Warrants held by Sorrento and the Sponsors), will be able to sell all of the shares of our Common Stock and any Warrants registered for
resale thereunder for so long as such registration statement is available for use. The sale, or indication of an intention to sell, substantial amounts of our Common Stock or Warrants could result in a significant decline in the public trading price
of our securities and impair our ability to raise capital through the sale of additional equity securities. Even if the current trading price of our Common Stock is at or significantly below the price at which the units were issued in Vickers&#146;s
IPO, the Sponsors and Sorrento may have an incentive to sell because they will still profit on sales due to the lower price at which they purchased their shares compared to the public securityholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can give no assurances that we will be able to secure additional sources of funds to support our operations on acceptable terms, or at all,
or, if such funds are available to us, that such additional financing will be sufficient to meet our needs. These conditions, among others, raise substantial doubt about our ability to continue as a going concern. If we raise additional funds by
issuing equity or convertible debt securities, including pursuant to the Yorkville Purchase Agreement and the B. Riley Purchase Agreement, it could result in dilution to our existing stockholders or increased fixed payment obligations. In addition,
as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. If we incur additional indebtedness, we could become subject to covenants that would restrict our
operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could
adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but we may have to relinquish valuable rights to ZTlido, GLOPERBA, or our product
candidates or grant licenses on terms that are not favorable to us. Any of the foregoing could significantly harm our business, financial condition and results of operations. If we are unable to raise additional capital in sufficient amounts or on
terms acceptable to us, we may be required to reduce the scope of the commercialization of ZTlido and GLOPERBA or delay, scale back or discontinue the development of one or more of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also need to take certain other actions to allow us to maintain our projected cash and projected financial position including but not
limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for <FONT STYLE="white-space:nowrap">SP-102</FONT> and
<FONT STYLE="white-space:nowrap">SP-103,</FONT> and other discretionary costs. Although we believe such plans, if executed and coupled with the above described sources of liquidity, should provide us with financing to meet our needs, successful
completion of such plans is dependent on factors outside of our control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that we will continue to incur net losses into the
foreseeable future as we support our clinical development to expand approved indications, continue our development of, and seek regulatory approvals for, our product candidates, and expand our corporate infrastructure. As a result, we have concluded
that there is substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. See Note 2 titled &#147;Liquidity and Going Concern&#148; to our consolidated
financial statements included elsewhere in this prospectus for additional information. Proceeds from the Business Combination are dependent on the amount of redemptions by Vickers&#146;s public shareholders. Net proceeds from the Trust Account in
connection with the Business Combination, together with our existing cash and cash equivalents and proceeds from any Yorkville Advances made under the Yorkville Purchase Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or any Advances or Additional Advances made under the B. Riley Purchase Agreement, may be insufficient to enable us to fund our operating expenses and capital expenditure requirements for at
least the next 12 months. If these sources are insufficient to satisfy our liquidity requirements, we may seek to raise additional funds through equity offerings, debt financings, collaborations, government contracts or other strategic transactions.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table summarizes our cash flows for each of the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nine Months Ended<BR>September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash Flow Data:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,664</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(60,421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used for) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,656</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(62,269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,855</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Flows from Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2021, net cash used for operating activities was approximately $28.7&nbsp;million, primarily from our net
loss of $88.4&nbsp;million offset by other <FONT STYLE="white-space:nowrap">non-cash</FONT> reconciling items of $46.1&nbsp;million related to depreciation and amortization, principal increase to the Scilex Pharma Notes, stock-based compensation, <FONT
STYLE="white-space:nowrap">non-cash</FONT> operating lease cost, <FONT STYLE="white-space:nowrap">non-cash</FONT> interest for debt issuance costs and debt discount, interest payments related to the debt discount on the Scilex Pharma Notes, net loss
on debt extinguishment, and a loss on derivative liabilities, and by changes in operating assets and liabilities that provided $13.6&nbsp;million of cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2020, net cash used for operating activities was approximately $31.5&nbsp;million, primarily from our net
loss of $47.5&nbsp;million, offset by other <FONT STYLE="white-space:nowrap">non-cash</FONT> reconciling items of $9.0&nbsp;million related to depreciation and amortization, stock based compensation, <FONT STYLE="white-space:nowrap">non-cash</FONT>
operating lease cost, amortization of debt issuance costs and debt discount, interest on the Scilex Pharma Notes, and a gain on derivative liabilities, and changes in operating assets and liabilities of $7.0&nbsp;million of cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2019, net cash used for operating activities was approximately $60.4&nbsp;million, primarily from our net
loss of $178.6&nbsp;million, which was offset by charges related to acquired IPR&amp;D of $75.3&nbsp;million, a loss on derivative liability of $23.3&nbsp;million, other <FONT STYLE="white-space:nowrap">non-cash</FONT> reconciling items of
$23.6&nbsp;million related to depreciation and amortization, stock based compensation, <FONT STYLE="white-space:nowrap">non-cash</FONT> operating lease cost and amortization of debt issuance costs and debt discount, and changes in operating assets
and liabilities that used $4.0&nbsp;million of cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2022, net cash used for operating
activities was approximately $20.5&nbsp;million, primarily from our net loss of $5.5&nbsp;million, other <FONT STYLE="white-space:nowrap">non-cash</FONT> reconciling items of $44.7&nbsp;million related to depreciation and amortization, stock-based
compensation, <FONT STYLE="white-space:nowrap">non-cash</FONT> operating lease cost, <FONT STYLE="white-space:nowrap">non-cash</FONT> interest for debt issuance costs and debt discount, interest payments related to the debt discount on the Scilex
Pharma Notes, net gain on debt extinguishment, and a gain on derivative liabilities and offset by changes in operating assets and liabilities that provided $29.7&nbsp;million of cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2021, net cash used for operating activities was approximately $22.7&nbsp;million, primarily from
our net loss of $46.5&nbsp;million, offset by other <FONT STYLE="white-space:nowrap">non-cash</FONT> reconciling items of $14.0&nbsp;million related to depreciation and amortization, stock based compensation,
<FONT STYLE="white-space:nowrap">non-cash</FONT> operating lease cost, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amortization of debt issuance costs and debt discount, interest on the Scilex Pharma Notes, net loss on debt extinguishment, and a net loss on derivative liabilities, and changes in operating
assets and liabilities of $9.8&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Flows from Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2021, no cash was used for investing activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2020, net cash used for investing activities was approximately $25.0&nbsp;thousand, attributed to
property and equipment purchases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2019, net cash used for investing activities was approximately
$17.6&nbsp;million, primarily attributed to approximately $17.0&nbsp;million of cash paid for the acquisition of Semnur-related IPR&amp;D expenses and $0.6&nbsp;million of property and equipment purchases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2022, net cash used for investing activities was approximately $2.1&nbsp;million attributed to
cash paid for the acquisition of GLOPERBA licenses from Romeg and $7.0&nbsp;thousand attributed to cash paid for property, plant, and equipment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2021, no cash was used for investing activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Flows from Financing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
the year ended December&nbsp;31, 2021, net cash provided by financing activities was approximately $28.2&nbsp;million and was primarily related to $47.9&nbsp;million in proceeds from related party payables, $47.8&nbsp;million in proceeds from the
CNH Revolving Loan, $14.7&nbsp;million in proceeds from related party note payable with Sorrento, and offset by $48.8&nbsp;million repayment of the CNH Revolving Loan and $33.4&nbsp;million repayment of the Scilex Pharma Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2020, net cash used by financing activities was approximately $19.2&nbsp;million and is primarily related
to $58.9&nbsp;million repayment of the Scilex Pharma Notes, offset by $18.4&nbsp;million in proceeds from related party payables, $11.0&nbsp;million in proceeds from other loans, and $10.3&nbsp;million in proceeds from related party notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2019, net cash provided by financing activities was approximately $15.8&nbsp;million and is primarily
related to $16.6&nbsp;million of related party note proceeds, which were utilized to finance the acquisition of Semnur, plus $5.0&nbsp;million of promissory note proceeds offset by repayment of the related party note payable of $3.5&nbsp;million and
$2.3&nbsp;million repayment of the Scilex Pharma Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2022, net cash provided by financing
activities was approximately $20.7&nbsp;million and is primarily related to $51.9&nbsp;million in proceeds from related party payables, $62.5&nbsp;million in proceeds from related party note payables, $9.9&nbsp;million in proceeds from the CNH
Revolving loan, $96.0&nbsp;thousand in proceeds from the exercise of stock options, offset by $18.8&nbsp;million repayment on CNH Revolving Loan and $84.8&nbsp;million repayment of the Scilex Pharma Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2021, net cash provided by financing activities was approximately $22.1&nbsp;million and is
primarily related to $45.1&nbsp;million in proceeds from related party payables, $34.8&nbsp;million in proceeds from the CNH Revolving Loan, and $11.5&nbsp;million in proceeds from related party notes, offset by a $32.4&nbsp;million repayment of the
Scilex Pharma Notes and a $36.9&nbsp;million repayment on CNH Revolving Loan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_43"></A>Critical Accounting Policies and Estimates
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This management&#146;s discussion and analysis of our financial condition and results of operations are based upon our consolidated
financial statements which are prepared in accordance with GAAP. The preparation of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses during the
reporting period. We continually evaluate our estimates and judgments, the most critical of which are those related to derivative liabilities, income taxes and stock-based compensation and others listed below. We base our estimates and judgments on
historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in greater detail in the audited financial statements for the years ended
December&nbsp;31, 2021 and 2020 included elsewhere in this prospectus, we believe the following accounting policies and estimates are most critical to aid in understanding and evaluating our reported financial results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue
to date has been generated from product sales of ZTlido. We do not have significant costs associated with obtaining contracts with our customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue when control of the products is transferred to the customers in an amount that reflects the consideration we expect to
receive from the customers in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct
performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer
either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the
customer, meaning the customer has the ability to use and obtain the benefit of the good or service. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of
control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue from product sales relates solely to sales of ZTlido. Our performance obligations with respect to sales of ZTlido are
satisfied at a certain point in time, and we consider control to have transferred upon delivery to the customer. We consider control to have transferred upon delivery to the customer because, upon delivery, the customer has legal title to the asset,
physical possession of the asset has been transferred to the customer, the customer has significant risks and rewards in connection with ownership of the asset, and we have a present right to payment from the customer at that time. Invoicing
typically occurs upon shipment and the length of time between invoicing and the date on which payment is due is not significant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
product sales, we record <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT> sales adjustments for commercial and government rebates, fees, and chargebacks, wholesaler and distributor fees, sales returns and
prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in our customer contracts, customary industry practices and
current government regulations. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Gross-to-net</FONT></FONT> adjustments are generally recorded as contract liabilities under accrued expenses within our consolidated balance sheet.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rebates </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rebates are discounts that
we pay under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate
to contractual agreements with commercial healthcare providers, under which we pay rebates and fees for access to and position on that provider&#146;s patient drug formulary. Rebates and chargebacks paid under government programs are generally
mandated under law, whereas private rebates and fees are generally contractually negotiated with commercial healthcare providers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Both types of rebates vary over time. We record a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. We monitor the
sales trends and adjust for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Service Fees
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We compensate our customers and others in the distribution chain for wholesaler and distribution services. We have determined such
services received to date are not distinct from our sale of products to the customers, and therefore, these payments have been recorded as a reduction of revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Product Returns </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are obligated to
accept the return of products sold that are damaged or do not meet certain specifications. We may authorize the return of products sold in accordance with the term of its sales contracts, and estimate allowances for such amounts at the time of sale.
We estimate the amount of our product sales that may be returned by our customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate our product returns using historical
trends and product return rates typically experienced in the industry. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Co-payment</FONT> Assistance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive
<FONT STYLE="white-space:nowrap">co-</FONT> payment assistance. We accrue for <FONT STYLE="white-space:nowrap">co-payment</FONT> assistance based on actual program participation and estimates of program redemption using data provided by third-party
administrators. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Derivative Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Derivative liabilities are recorded on our consolidated balance sheets at their fair value on the date of issuance and are revalued on each
balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Derivative liabilities result from the Scilex Pharma Notes. For the Scilex Pharma Notes, interest payments and repayments of the principal are
based on a percentage of net sales of ZTlido and could be accelerated if certain net sales targets are not met or if marketing approval of <FONT STYLE="white-space:nowrap">SP-103,</FONT> or a similar product with a lidocaine concentration of not
less than 5%, is delayed or in the event of a qualified initial public offering. In estimating the fair value of such financial instruments, we may apply significant assumptions and estimates, including estimates involving future net product sales
and timing and probability of marketing approvals and the probability of a qualified initial public offering event, which could be impacted in the future based on market conditions. As of December&nbsp;31, 2021, the fair value of the derivative
liabilities associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a Monte Carlo simulation model including consideration of the terms of Amendment No.&nbsp;4 (see Debt note). Significant
Level&nbsp;3 assumptions used in the measurement included a 6.2% risk adjusted net sales forecast and an effective debt yield of 15.0% on December&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We perform a Level&nbsp;3 based assessment to identify the embedded derivatives that require bifurcation from the Scilex Pharma Notes and
separate accounting as a single compound derivative. Certain of these embedded features include default interest provisions, contingent rate increases, contingent put options, optional and automatic acceleration provisions and indemnified taxes. The
Scilex Pharma Notes were fully extinguished in September 2022 and, as such, there were no remaining derivative liabilities as of September&nbsp;30, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
account for stock-based compensation in accordance with FASB ASC Topic 718 &#147;Compensation &#150; Stock Compensation&#148;, which establishes accounting for equity instruments exchanged for employee and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under
the straight-line-method, over the employee&#146;s requisite service period (generally the vesting period of the equity grant) or <FONT STYLE="white-space:nowrap">non-employee&#146;s</FONT> vesting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of determining the inputs used in the calculation of stock-based compensation, we use historical data in estimating the expected
terms of options and determine an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. We use these estimates as variables in the Black-Scholes option
pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legacy Scilex Common Stock Valuation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As there has been no public market for the Legacy Scilex Common Stock to date, the estimated fair value of the Legacy Scilex Common Stock was
determined by the Legacy Scilex Board, considering our most recently available third-party valuations of the Legacy Scilex Common Stock and the Legacy Scilex Board&#146;s assessment of additional objective and subjective factors that it believed
were relevant, and factors that may have changed from the date of the most recent valuation through the date of the stock option grant. Prior to the Business Combination, given the absence of a public trading market for the Legacy Scilex Common
Stock, the valuations of the Legacy Scilex Common Stock were determined in accordance with the &#147;American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as
Compensation.&#148; The Legacy Scilex Board exercised its reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of fair value of the Legacy Scilex Common Stock, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Independent valuations of the Legacy Scilex Common Stock performed at periodic intervals by an independent
third-party valuation firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The likelihood of achieving a liquidity event, such as an initial public offering or sale of the company and the
potential value of a strategic merger or sale at different time points, given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our historical operating and financial performance as well as our estimates of future financial performance,
including the regulatory status of ZTlido and GLOPERBA and the timing and probability of continuing growth since commercialization of ZTlido and GLOPERBA under different operational scenarios; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The status of research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our stage of development and commercialization and our business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Industry information such as market trends and macro-economic events; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Valuations of comparable companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adjustments to recognize a relative lack of marketability of the Legacy Scilex Common Stock; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Additional objective and subjective factors relating to our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dates of our valuations have not always coincided with the dates of our stock option grants. In determining the exercise prices of the
stock options at each grant date, the Legacy Scilex Board considered, among other things, the most recent valuations of the Legacy Scilex Common Stock and the Legacy Scilex Board&#146;s assessment of additional objective and subjective factors we
believed were relevant as of the grant date. The additional factors considered when determining any changes in fair value between the most recent valuation and the grant dates included our operating and financial performance and current business
conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying the valuations represented management&#146;s best estimate, which
involved inherent uncertainties and the application of management&#146;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of the Legacy Scilex Common Stock and Legacy Scilex&#146;s stock-based
compensation expense could have been materially different. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>March&nbsp;17 and March&nbsp;31, 2019 Valuations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the valuation performed on March&nbsp;17, 2019 and March&nbsp;31, 2019, the fair value of the Legacy Scilex Common Stock was estimated
using the market and income approaches. Legacy Scilex weighted a guideline public company method, a market approach that uses comparable company data and applies to the subject company, equally with a discounted cash flow method, an income approach
that derives value by estimating reasonable future cash flows to the equityholders and discounting them to present value using a risk-adjusted discount rate. Legacy Scilex then used the Option Pricing Method (&#147;OPM&#148;) to allocate the
concluded equity value amongst the different equity classes and determine the value of Legacy Scilex Common Stock. These valuations resulted in a valuation of Legacy Scilex Common Stock of $1.16 per share as of March&nbsp;17, 2019 and March&nbsp;31,
2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>May&nbsp;31, 2019 Valuation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the valuation performed on May&nbsp;31, 2019, the fair value of the Legacy Scilex Common Stock was estimated using a hybrid Probability
Weighted Expected Return Method (&#147;PWERM&#148;), which estimates the value by probability-weighting different scenarios. Legacy Scilex used three going public scenarios and one stay-private scenario. For the three public scenarios, Legacy Scilex
utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, Legacy Scilex utilized the income and market
approaches in line with the March&nbsp;31, 2019 valuation and allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. Legacy Scilex then probability weighted (based on Legacy Scilex&#146;s best
estimates at the time) each scenario&#146;s common stock value to arrive at the concluded value of the Legacy Scilex Common Stock. This valuation resulted in a valuation of Legacy Scilex Common Stock of $1.16 per share as of May&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>December&nbsp;31, 2019 Valuation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the
valuation performed on December&nbsp;31, 2019, the fair value of the Legacy Scilex Common Stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. Legacy Scilex used three going public scenarios and
one stay-private scenario. For the three public scenarios, Legacy Scilex utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the
stay-private scenario, Legacy Scilex utilized the income approach in line with the March&nbsp;31, 2019 valuation and allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. Legacy Scilex then
probability weighted (based on Legacy Scilex&#146;s best estimates at the time) each scenario&#146;s common stock value to arrive at the concluded value of the Legacy Scilex Common Stock. This valuation resulted in a valuation of the Legacy Scilex
Common Stock of $1.16 per share as of December&nbsp;31, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>July&nbsp;31, 2020 Valuation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the valuation performed on July&nbsp;31, 2020, the fair value of the Legacy Scilex Common Stock was estimated using PWERM, which estimates
the value by probability-weighting different scenarios. Legacy Scilex used three going public scenarios and one stay-private scenario. For the three public scenarios, Legacy Scilex utilized recent comparable initial public offerings to estimate
value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, Legacy Scilex utilized the income approach in line with the March&nbsp;31, 2019, May&nbsp;31, 2019 and
December&nbsp;31, 2019 valuations and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. Legacy Scilex then probability weighted (based on Legacy Scilex&#146;s best
estimates at the time) each scenario&#146;s common stock value to arrive at the concluded value of the Legacy Scilex Common Stock. This valuation resulted in a valuation of the Legacy Scilex Common Stock of $1.16 per share as of July&nbsp;31, 2020.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since a public trading market for our Common Stock has been established in connection with the Closing of the Business Combination, it is
no longer be necessary for our Board to estimate the fair value of our Common Stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our Common Stock will be determined based on the
quoted market price of our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Debt </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for debt as liabilities measured at amortized cost and amortize the resulting debt discount from the allocation of proceeds to
interest expense using the effective interest method over the expected term of the debt instrument. We consider whether there are any embedded features in the debt instruments that require bifurcation and separate accounting as derivative financial
instruments pursuant to FASB, ASC, Topic 815, &#147;Derivatives and Hedging.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may enter financing arrangements, the terms of
which involve significant assumptions and estimates, including future net product sales, in determining interest expense, as well as the classification between current and long-term portions. In estimating future net product sales, we assessed
prevailing market conditions using various external market data against our anticipated sales and planned commercial activities as well as actual ZTlido sales as of the Scilex Pharma Note extinguishment. See Note 6 titled &#147;Debt&#148; to our
consolidated financial statements appearing elsewhere in this prospectus and the section titled &#147;Certain Relationships and Related Party Transactions &#151; Certain Relationships of Legacy Scilex &#151; Indenture and Letter of Credit&#148; for
a description of the Scilex Pharma Notes, which provide for repayments based on a percentage of net sales of ZTlido. Consequently, we imputed interest on the carrying value of the debt and recorded interest expense using an imputed effective
interest rate. We reassessed the expected payments each reporting period and accounted for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of our current and
long-term portions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning January&nbsp;1, 2019, at the inception of a contractual agreement and at transition to the new lease standard, we determine whether
the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, we
calculate the associated lease liability and corresponding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing
rate commensurate with the term of the lease. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line
basis over the lease term. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of ASC Topic <FONT STYLE="white-space:nowrap">740-10,</FONT> Income Taxes &#151; Overall, address the determination of whether
tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic <FONT STYLE="white-space:nowrap">740-10,</FONT> we may recognize the tax benefit from an uncertain tax position only if it
is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. We have determined that we have immaterial uncertain tax positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities
and the related financial amounts, using currently enacted tax rates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have deferred tax assets, which are subject to periodic recoverability assessments.
Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely will not be realized. As of September&nbsp;30, 2022 and December&nbsp;31, 2021, we maintained a full valuation allowance against our
deferred tax assets, with the exception of an amount equal to our deferred tax liabilities that are scheduled to reverse against Legacy Scilex&#146;s deferred tax assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intangible Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible
assets are carried at their initial valuation or acquisition price and amortized on a straight-line basis over the estimated useful lives of the assets. If the useful life is indefinite, we will <FONT STYLE="white-space:nowrap">re-evaluate</FONT>
the asset annually for impairment and make adjustments as necessary. Our patents were initially valued using the multi- period excess earnings method and the useful life of 15 years was determined by management based on the patent expiration date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our developed technology was valued based on a <FONT STYLE="white-space:nowrap">15-year</FONT> projection using the excess earnings
approach. We commenced amortization of IPR&amp;D upon commercialization of ZTlido in October 2018. We review our long-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset
may not be recoverable. Recoverability is measured by comparison of the assets&#146; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If
such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. There have not been any impairment losses of long-lived assets through September&nbsp;30, 2022.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Goodwill </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goodwill, which has
an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for
impairment. We have determined that only one reporting unit exists for examination under impairment review. During our goodwill impairment review, we may assess qualitative factors to determine whether it is more likely than not that the fair value
of our reporting units are less than their carrying amounts, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of our
company. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting units are less than their carrying amounts, then no additional assessment is deemed
necessary. Otherwise, we perform a quantitative goodwill impairment test. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test. We performed our annual
assessment for goodwill impairment in the fourth quarters of 2021, 2020, and 2019 and determined there was no impairment as of December&nbsp;31, 2021, 2020 and 2019, respectively. No interim impairment test was considered necessary during the nine
months ended September&nbsp;30, 2022 as we believe that it is more likely than not that the fair value of our goodwill was in excess of the carrying value </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquired <FONT STYLE="white-space:nowrap">In-Process</FONT> Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acquired and may continue to acquire the rights to develop and commercialize new product candidates. The
<FONT STYLE="white-space:nowrap">up-front</FONT> payments to acquire a new drug compound or drug delivery device, as well as future milestone payments associated with asset acquisitions that do not meet the definition of derivative and are deemed
probable to achieve the milestones, are immediately expensed as acquired IPR&amp;D provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. The acquired IPR&amp;D
related to the asset acquisition of IPR&amp;D from Semnur in March 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Material Cash Commitments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, our contractual obligations are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Payments Due by Period</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Less than<BR>1 year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="white-space:nowrap">1-3</FONT> years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="white-space:nowrap">3-5&nbsp;years</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">More&nbsp;than<BR>5 years</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related Party Notes Payable<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on Related Party Notes
Payable<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred Consideration with Romeg<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note 8 titled &#147;Commitments and Contingencies&#148; of the notes to our unaudited consolidated
financial statements included elsewhere in this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The related party notes payable and interest on related party notes payable were eliminated at the close of the
Business Combination under the terms of the Debt Exchange Agreement. See Note 10 titled &#147;Related Party Transactions&#148; of the notes to our unaudited consolidated financial statements included elsewhere in this prospectus.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note 3 titled &#147;Acquisitions&#148; of the notes to our unaudited consolidated financial statements
included elsewhere in this prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_44"></A>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2021, the FASB issued ASU <FONT STYLE="white-space:nowrap">2021-08,</FONT> Business Combinations (Topic 805): Accounting for
Contract Assets and Contract Liabilities from Contracts with Customers, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU <FONT
STYLE="white-space:nowrap">2021-08</FONT> is effective for fiscal years beginning after December&nbsp;15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> Income Taxes (Topic 740): Simplifying the
Accounting for Income Taxes. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740. The amendments also improve consistent application of and simplify U.S.
GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. The amendments in this update were effective for interim and annual periods for the Company beginning after December&nbsp;15, 2020. The Company adopted the standard
on January&nbsp;1, 2021. The adoption of the standard had no impact on its consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_45"></A>Quantitative
and Qualitative Disclosures About Market Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our exposure to market risk is confined to our cash and cash equivalents and debt securities. We have cash and cash equivalents and invest
primarily in high-quality money market funds, which we believe are subject to limited credit risk. Due to the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of
our portfolio. Additionally, all interest rates associated with our related party notes outstanding as of September&nbsp;30, 2022 are capped, therefore we are not subject to interest rate risk. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to
April&nbsp;2, 2022, sales to our sole customer and third-party logistics distribution provider, Cardinal Health, represented 100% of our net revenue. On April&nbsp;2, 2022, we announced the expansion of our direct
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distribution network to national and regional wholesalers and pharmacies. Cardinal Health will continue to provide traditional third-party logistics functions for us. Additionally, during the
nine months ended September&nbsp;30, 2022 and 2021, we purchased inventory from our sole supplier, Itochu. This exposes us to concentration of customer and supplier risk. We monitor the financial condition of our customers, limit our credit exposure
by setting credit limits, and have not experienced any credit losses for the nine months ended September&nbsp;30, 2022 and 2021. As we continue to expand the commercialization of our product, we are not limited to the current customer and have
elected to expand our distribution network. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning on April&nbsp;1, 2022, we began selling ZTlido directly to three large
distributors, McKesson Corporation, Cardinal Health, and AmerisourceBergen Corporation, as well as to numerous pharmacies. If we are unable to maintain a favorable relationship with Cardinal Health (or with any of our other two distributors), we
expect that our revenue would decline and our business would be harmed as a result. We may be unable to control the timing of the delivery of ZTlido to distributors, and any financial uncertainty or loss of key logistic employees of Cardinal Health,
as our only third- party logistics provider, may negatively impact our sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet
Arrangements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not have, during the periods presented, and we do not currently have, any
<FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined under applicable SEC rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Transactions
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a description of our related party transactions, see the section of this prospectus titled &#147;Certain Relationships and
Related Party Transactions&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_46"></A>Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#147;emerging growth company&#148; as defined in the JOBS Act is eligible to take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies. Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised
financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any
such election to opt out is irrevocable. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public
companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business
could significantly affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are in the process of evaluating
the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an emerging growth company we may take advantage of certain exemptions from
various reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirement to obtain an attestation and report from our auditors on the
assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board
requiring mandatory audit firm rotation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and
registration statements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on
executive compensation or golden parachute arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will qualify and will remain as an emerging growth company
until the earlier of (i)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the closing of the IPO, (b)&nbsp;in which we have total annual gross revenue of at least $1.235&nbsp;billion, or (c)&nbsp;in which we are
deemed to be a large accelerated filer, which means the market value of our common equity of that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> equals or exceeds $700&nbsp;million as of the last business day of our most recently
completed second fiscal quarter; and (ii)&nbsp;the date on which we have issued more than $1.00&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. References herein to
&#147;emerging growth company&#148; have the meaning associated with it in the JOBS Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_47"></A>Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two
years of audited financial statements. We expect that we will not be a smaller reporting company to the extent we remain a majority-owned subsidiary of Sorrento. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_48"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_49"></A>The Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing
<FONT STYLE="white-space:nowrap">non-opioid</FONT> pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with
<FONT STYLE="white-space:nowrap">non-opioid</FONT> therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our first commercial product in October 2018 and are
developing our late-stage pipeline, which includes a pivotal Phase 3 candidate, a Phase 2 candidate, and a Phase 1 candidate that is expected to enter Phase 2 studies in the first half of 2023. Our commercial product, ZTlido (lidocaine topical
system) 1.8% is a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with postherpetic neuralgia (&#147;PHN&#148;), which is a form of post-shingles nerve pain. ZTlido possesses novel delivery
and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT>
administration period. Scilex licenses the rights to ZTlido from and relies exclusively on Oishi Koseido Co., Ltd. (&#147;Oishi&#148;) and Itochu Chemical Frontier Corporation (&#147;Itochu,&#148; and together with Oishi, the &#147;Developers&#148;)
pursuant to the Product Development Agreement and Commercial Supply Agreement. The Developers have the right to terminate the Product Development Agreement and the Commercial Supply Agreement under certain circumstances as more fully described in
the sections titled &#147;<I>Business &#151; Material Agreements &#151; Itochu and Oishi Product Development Agreement</I>&#148; and &#147;<I>Business &#151; Material Agreements &#151; Itochu and Oishi Commercial Supply Agreement,</I>&#148;
including, among other things, if Scilex&#146;s total net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> are equal to or less than five percent of our net sales of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> for
a period of four or more consecutive quarters. As of the date of this prospectus, Scilex&#146;s net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have
the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our three product candidates are <FONT STYLE="white-space:nowrap">(i)&nbsp;SP-102</FONT> (10 mg, dexamethasone sodium phosphate viscous gel)
(&#147;SEMDEXA&#148;), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; <FONT STYLE="white-space:nowrap">(ii)&nbsp;SP-103</FONT> (lidocaine topical
system) 5.4%, <FONT STYLE="white-space:nowrap">(&#147;SP-103&#148;),</FONT> a Phase&nbsp;2, next-generation, triple-strength formulation of ZTlido, for the treatment of LBP; and <FONT STYLE="white-space:nowrap">(iii)&nbsp;SP-104</FONT> (4.5 mg, <FONT
STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release capsules) <FONT STYLE="white-space:nowrap">(&#147;SP-104&#148;),</FONT> a novel <FONT STYLE="white-space:nowrap">low-dose</FONT> delayed-release naltrexone
hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in the first half of 2023. If these product candidates are
approved by the FDA, we believe each of them could become the treatment option for their respective indications in the United States. Most recently, on June&nbsp;14, 2022, Scilex entered into a License and Commercialization Agreement (the
&#147;Romeg Agreement&#148;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.). Pursuant to the Romeg Agreement, among other things, Romeg granted Scilex (1)&nbsp;the right to manufacture, promote, market, distribute and sell
pharmaceutical products comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States and (2)&nbsp;an exclusive, transferable license to use the trademark &#147;GLOPERBA&#148;. GLOPERBA is
an <FONT STYLE="white-space:nowrap">FDA-approved,</FONT> oral medication for the treatment of gout in adults. Gout is a painful arthritic disorder affecting an estimated 8.7&nbsp;million people in the United States. Gout pain can be excruciating and
is a form of inflammatory arthritis that develops in some people who have high levels of uric acid in their blood. It can cause sudden severe episodes of pain and can be disabling with tenderness, warmth and swelling.
<FONT STYLE="white-space:nowrap">Non-steroidal</FONT> anti-inflammatory drugs, colchicine and corticosteroids are used a majority of time as the first line to treat acute gout. The U.S. is observed to have a high prevalence of gout, owing to
lifestyle issues such as high alcohol intake, obesity, and smoking. Scilex is planning to commercialize GLOPERBA in 2023 and believes it is well-positioned to market and distribute the product. Scilex has a direct distribution network to national
and regional wholesalers and pharmacies throughout all U.S. states. For more information on Scilex, please see the sections titled &#147;<I>Business &#151; Material Agreements &#151; Romeg License and Commercialization Agreement</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on identifying treatment options for pain management with established
mechanisms that have deficiencies in safety, efficacy or patient experience. We believe this approach allows us to potentially leverage the regulatory approval pathway available under Section&nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic
Act for each of these pipeline product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our marketed product, ZTlido, has multiple advantages over currently
available prescription and OTC lidocaine patches, of which over 147&nbsp;million and 136&nbsp;million of such patches were sold in the United States in 2021 and 2020, respectively, according to Symphony Healthcare. We have sold 6,336,032 and
7,011,112 ZTlido patches in the United States in 2020 and 2021, respectively. We acquired <FONT STYLE="white-space:nowrap">SP-102</FONT> from Semnur in March 2019 and are developing it to be an injectable viscous gel formulation of a widely used
corticosteroid designed to address the serious risks posed by <FONT STYLE="white-space:nowrap">off-label</FONT> epidural steroid injections (&#147;ESI&#148;), which are administered over 12&nbsp;million times annually in the United States. See the
section titled &#147;<I>Business &#151; Material Agreements &#151; Semnur Merger Agreement</I>&#148; for a description of our acquisition of Semnur and our ongoing obligations to Semnur&#146;s former equityholders. SEMDEXA has been granted fast
track designation by the FDA and, if approved, could become the only <FONT STYLE="white-space:nowrap">FDA-approved</FONT> ESI for the treatment of sciatica. According to a report by Decision Resources Group, it is estimated that over
4.8&nbsp;million patients will suffer from sciatica in the United States in 2022. <FONT STYLE="white-space:nowrap">SP-103</FONT> has also been granted fast track designation by the FDA and, if approved, could become the first <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> lidocaine topical product for the treatment of acute LBP. We are developing <FONT STYLE="white-space:nowrap">SP-104</FONT> as a novel delayed-release formulation of
<FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride for the treatment of fibromyalgia, which remains a largely unmet medical need given the low response rates of commercially available therapies. Naltrexone is routinely used <FONT
STYLE="white-space:nowrap">off-label</FONT> to treat fibromyalgia. There are no <FONT STYLE="white-space:nowrap">low-dose</FONT> formulations commercially available in the United States. Our patented formulation is designed to overcome undesirable
effects of immediate release naltrexone, such as hyperalgesia, dysphoria, nausea, anxiety and insomnia. We believe our currently approved product and future product candidates, if approved, could uniquely address what we believe are the significant
unmet needs of the targeted populations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_50"></A>Our Marketed Product and Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart illustrates our current commercial product and novel product candidates, for which we have worldwide commercialization
rights, except with respect to Japan for ZTlido and <FONT STYLE="white-space:nowrap">SP-103.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g428534g56j49.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_51"></A>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our vision is to become the leading pain management company delivering novel <FONT STYLE="white-space:nowrap">non-opioid</FONT> and <FONT
STYLE="white-space:nowrap">non-addictive</FONT> treatments to provide safe, effective and durable relief of multiple pain conditions. To accomplish this, the principal elements of our strategy are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Maximize the commercial potential of ZTlido</B>. We have assembled an integrated commercial organization using
a dedicated sales force and sales management, marketing and managed care capabilities to support continued uptake of ZTlido. We leverage a sales force of approximately <FONT STYLE="white-space:nowrap">60-70</FONT> people, targeting over 10,000
primary care physicians, pain specialists, neurologists, and palliative care physicians who we believe treat the majority of PHN patients. Additionally, we are utilizing
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-patient</FONT></FONT> marketing strategies to expand awareness and utilization of ZTlido. Our managed healthcare account executives have extensive experience in negotiating
contracts and have already achieved significant uptake by adding ZTlido to key formularies such as Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and Medicare plans), United Healthcare Commercial, Anthem Blue Cross
Blue Shield (&#147;BCBS&#148;), BCBS of Massachusetts, Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Select Health and Medicaid in California, Florida, Connecticut, Idaho, and North Dakota. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Develop and commercialize SEMDEXA as a novel epidural injection for the first approved treatment of
sciatica</B>. We are developing SEMDEXA to address the limitations associated with the available corticosteroid epidural injectable products that are used <FONT STYLE="white-space:nowrap">off-label.</FONT> Many of these products contain potentially
neurotoxic preservatives and particulates, and are administered over 12&nbsp;million times annually despite a warning on the label of serious neurologic complications, including loss of vision, stroke, paralysis and death. These products carry
warnings required by the FDA that the safety and efficacy of epidural administration has not been established. SEMDEXA has received fast track designation from the FDA and, if approved, could become the first
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> epidural steroid product with long-term patent protection, which we also believe would create significant barriers to entry. Due to the novelty of our formulation as well as the associated patents
and trade secrets, future potential competitors could be required to conduct extensive preclinical studies and costly comparative clinical trials. A full <FONT STYLE="white-space:nowrap">6-month</FONT> data analysis was completed in February 2022
and we have recently completed a pivotal Phase 3 study with final results received in March 2022, which results reflect achievement of primary and secondary endpoints. We believe these final results are supportive of a breakthrough therapy
designation for sciatica that, in addition to the fast track designation, is expected to allow the FDA to further expedite the overall development program leading to market approval. We have extensive clinical and
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> data (including those obtained from multiple Phase 2 clinical trials) with the novel viscous gel formulation of <FONT STYLE="white-space:nowrap">SP-102.</FONT> We expect to present the robust data
collected over the course of our multi-year clinical development program to the FDA as part of a NDA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Pursue clinical development of <FONT STYLE="white-space:nowrap">SP-103</FONT> for the first approved topical
treatment in patients with acute LBP</B>. We are developing <FONT STYLE="white-space:nowrap">SP-103</FONT> as a triple-strength lidocaine topical system for the treatment of acute LBP, to be used where we believe a high-dose strength and superior
adhesive qualities of a topical system may provide a greater therapeutic benefit than currently available therapies. <FONT STYLE="white-space:nowrap">SP-103</FONT> is designed to use ZTlido&#146;s delivery and adhesion technology to deliver a dose
of lidocaine that is threefold higher than any other approved lidocaine topical products. We initiated a Phase 2 trial in acute LBP in the second quarter of 2022. <FONT STYLE="white-space:nowrap">SP-103</FONT> has been granted fast track designation
by the FDA and, if approved, could become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> lidocaine topical product for the treatment of acute LBP. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Pursue clinical development of <FONT STYLE="white-space:nowrap">SP-104</FONT> for the treatment of
fibromyalgia, which has very few approved therapies that are marginally effective and have unpleasant side-effects</B>. We are developing <FONT STYLE="white-space:nowrap">SP-104</FONT> for fibromyalgia.
<FONT STYLE="white-space:nowrap">Low-dose</FONT> naltrexone hydrochloride delayed-release capsules are routinely used <FONT STYLE="white-space:nowrap">off-label</FONT> to treat fibromyalgia and other chronic pain conditions such as complex regional
pain. <FONT STYLE="white-space:nowrap">SP-104</FONT> addresses the shortcomings of using the high-dose commercial products and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
pharmacy-compounded products by delivering a <FONT STYLE="white-space:nowrap">low-dose</FONT> of naltrexone hydrochloride (approximately 11 times less than the commercial product) in a
delayed-release formulation that bypasses the stomach and releases the drug in the gut (upper intestine). These product characteristics mitigate against the known safety issues associated with the high-dose commercial products and immediate release
pharmacy-compounded products, and the overall reliability issues associated with pharmacy-compounded products. <FONT STYLE="white-space:nowrap">SP-104</FONT> has completed two Phase 1 studies to characterize the pharmacokinetics and safety of the
product, and we expect to commence Phase 2 studies in the first half of 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand our product portfolio by developing or acquiring <FONT STYLE="white-space:nowrap">non-opioid</FONT>
assets that leverage our novel delivery and adhesion technologies or our existing commercial infrastructure</B>. We are continuously evaluating opportunities to leverage our research and development experience to develop <FONT
STYLE="white-space:nowrap">non-opioid</FONT> therapeutics for pain management indications that are not adequately served with existing treatment options. We also seek to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire <FONT
STYLE="white-space:nowrap">non-opioid</FONT> therapeutics that can both complement our existing product portfolio and benefit from our existing commercial infrastructure. In evaluating marketed and clinical-stage expansion opportunities, Scilex
intends to pursue therapeutics that address markets served by our established target physician audience and that can be commercialized by our existing sales force. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Leverage our management team&#146;s experience to further develop and commercialize its current and future
product portfolio</B>. Our management team has held senior positions at leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Novartis Pharmaceuticals, Cephalon, Inc.,
Roche AG, PDL BioPharma, Inc., Xenoport, Inc. and Chiron Corp. Our team has substantial experience in rapidly progressing new drugs to clinical proof of concept, completing successful pivotal registration programs and successfully commercializing
products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our innovative <FONT STYLE="white-space:nowrap">non-opioid</FONT> product portfolio has the
potential to provide effective pain management therapies that can have a transformative impact on patients&#146; lives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_52"></A>Our
Management Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assembled a management team of experienced biopharma industry veterans, who have deep scientific, business and
leadership expertise in pharmaceutical industry, in addition to strong transactional and business development track records. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
management team is led by our Chief Executive Officer and President, Jaisim Shah, with strategic guidance from our Executive Chairperson, Henry Ji, Ph.D. They collectively have over 40 years of global biopharmaceutical and biotechnology experience.
Mr.&nbsp;Shah served as the Chief Executive Officer of Semnur from its inception in 2013 until our acquisition of Semnur in March 2019. He also has over 15 years of senior management experience in leading business development, commercial operations,
investor relations, marketing and medical affairs. Dr.&nbsp;Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of Sorrento&#146;s intellectual property. Our Chief Financial Officer,
Elizabeth Czerepak, has more than 35 years of finance and operational expertise across pharmaceuticals, biotechnology and venture capital. Our research efforts are guided by highly experienced scientists and experts. Our management team contributes
a diverse range of experiences from leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Novartis Pharmaceuticals, Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport,
Inc. and Chiron Corp. With this leadership, we believe we are well positioned to achieve our vision of becoming the leading pain management company delivering novel <FONT STYLE="white-space:nowrap">non-opioid</FONT> and <FONT
STYLE="white-space:nowrap">non-addictive</FONT> treatments to provide safe, effective and durable relief of multiple pain conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, we are supported by impressive teams across all levels of the organization. We hire and develop world-class talent from diverse backgrounds in biopharma, academia, technology and finance to ensure we have all of the capabilities to design
and deliver effective first-class pain management therapies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_53"></A>Our Product Portfolio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our marketed product,
ZTlido, is a lidocaine topical system approved for the relief of neuropathic pain associated with PHN. ZTlido was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved
adhesion and continuous pain relief throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. We launched ZTlido in October 2018 with an integrated commercial organization and we believe its differentiated therapeutic
profile, combined with our competitive pricing strategy and our active direct marketing efforts have driven, and will continue to drive, accelerated sales growth and increased market uptake. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prescription Lidocaine Patch Market Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prescription lidocaine patches are approved by the FDA as a local anesthetic and are generally used as a first-line treatment for the relief of
neuropathic pain associated with PHN. PHN is a chronic neuropathic pain syndrome that results as a complication following an infection of herpes zoster, also known as shingles. Herpes zoster symptoms resolve after a few weeks, but the pain caused by
the nerve injury can persist for months to years surrounding the affected area. According to Evaluate Ltd., there were over 3.5&nbsp;million people living with PHN conditions in the United States in 2021. Lidocaine patches have also been used in
patients with other types of pain, such as diabetic neuropathy, osteoarthritis and pain associated with surgery, cancer or trauma, and often in patients with LBP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2021, there were more than 147&nbsp;million prescription lidocaine patches sold in the United States, according to Symphony Healthcare. Of
this, five lidocaine patch manufacturers accounted for approximately 92% of the total prescriptions, according to Symphony Healthcare. We believe that the PHN market will continue to expand with the introduction of our lidocaine topical system,
ZTlido, which is supported by our commercial organization, by prescribing trends away from opioid use, and by continued growth in the population of patients aged 45 years and older who are at greater risk of suffering from PHN. Unlike Lidoderm, the
FDA has not determined that any other products are therapeutically equivalent to ZTlido, and accordingly, a prescription for ZTlido may not be able to be substituted by a generic product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current Treatment Landscape and Limitations of Existing Treatments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recommended first-line treatment for the relief of neuropathic pain associated with PHN includes topical lidocaine, gabapentinoids (which have
been associated with the potential for abuse as well as numerous adverse events), antidepressants and a multi-modal approach. Topical lidocaine and gabapentinoids are preferred for combination therapies due to their low propensity for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">drug-to-drug</FONT></FONT> interactions. For example, an eight-week combination use with pregabalin (Lyrica) has been proven to reduce pain in half for patients who had inadequate relief on
monotherapy, despite titration of pregabalin to effect. This efficacy boost was achieved without tolerability issues or adding to side effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A survey analyzing treatment patterns for neuropathic pain associated with PHN found that recommended first-line therapeutics were used in
only 29% of patients examined from 2010 to 2014, while the remaining patients were started on various <FONT STYLE="white-space:nowrap">off-label</FONT> treatments, including NSAIDS and opioids. These drugs can have adverse effects, especially on
elderly patients, which represent the majority of PHN patients. For example, opioids carry a well-characterized risk of abuse and misuse and the potential for serious side effects, such as respiratory depression, constipation and others, including
death. According to the Centers for Disease Control and Prevention, over 75% of the 100,306 drug overdose deaths during the <FONT STYLE="white-space:nowrap">12-month</FONT> period ending in April 2021 involved opioids. Similarly, tricyclic
antidepressants, which can be effective in managing the neuropathic pain associated with PHN, can result in significant systemic side effects and cardiotoxicity, posing risks to the elderly and patients with heart disease, epilepsy or glaucoma.
These side effects make topical lidocaine products an attractive first-line treatment option from a safety perspective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safety of lidocaine patches is well-supported in medical literature. Unlike transdermal
medications that are designed to achieve systemic drug levels via absorption through the skin or mucosal membrane, leading to effects away from the application site, topical lidocaine has a local effect at the site of application. Because drug
application is localized to the immediate area surrounding the patch, systemic absorption from a topical patch is low, reducing the risk of systemic side effects and lowering the potential for drug interactions relative to other systemic
pharmacologic therapies. Due to the low systemic exposure and minimal systemic side effects reported in clinical trials, we believe a topical lidocaine patch is well-suited for patients being treated with multiple medications or at a higher risk of
side effects, including the elderly or those with chronic conditions. As a localized treatment, lidocaine patches have been used concomitantly with other medications in patients for whom monotherapy is inadequate. Furthermore, we believe medication
administered topically rather than orally can improve patient compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While lidocaine patches have certain advantages over the
treatment alternatives discussed above, certain patches have limitations that may impact efficacy. For example, poor adhesion of the patch is a leading problem for topical lidocaine patches cited in the FDA Adverse Event Reporting System
(&#147;FAERS&#148;). Because the drug is incorporated in the adhesive for these products, patches must maintain adhesion or risk compromising the ability to deliver their full drug dose. As a result, establishing strong adhesion is a key factor for
patient compliance and satisfaction. In draft guidance issued in July 2021, the FDA recommended that developers of topical and transdermal delivery systems (&#147;TDSs&#148;) conduct studies to characterize the adhesion performance of the product
with suggested data requirements. Likewise, the FDA issued a draft guidance in October 2018 outlining the adhesion data requirements for generic TDSs. This guidance, along with Scilex&#146;s past experience with regulatory agencies, shows the
FDA&#146;s interest and the importance of adhesion performance of these products. There are also dermal safety requirements that force developers to carefully balance adhesion performance against dermal safety. ZTlido is the first TDS product
approved by the FDA that was able to demonstrate the targeted adhesion performance with an overall benign dermal safety profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following figure depicts data derived from FAERS as of December&nbsp;31, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g428534g00a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For many of the competing lidocaine patches, a common drawback is the usage of hydrogel technology that
limits the overall pharmaceutical efficiency of the product, requiring more total drug to be loaded into the patch </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to deliver sufficient drug to achieve a therapeutic effect. For example, Lidoderm has a drug load of 700 mg drug but only delivers 3&plusmn; 2% of that drug load. Consequently, adhesive thickness
must be increased in order to have a drug load sufficient to deliver a therapeutic dose of drug to the skin. As adhesive thickness increases, the product&#146;s pliability can be compromised to the extent that the patch loses adhesion as the skin
moves and wrinkles through normal patient activity. The weight of the hydrogel patches (largely due to high water content) further contributes to the challenge in maintaining adhesion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The greater drug load also poses a risk of accidental exposure. For example, with a bioavailability of 3 &plusmn; 2% of the 700 mg drug load
for Lidoderm, there is over 650 mg of drug remaining on the patch at the end of the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period, as captured in a bolded warning on the product label. If improperly disposed of, the residual
drug poses the potential risk to children, pets and others of accidental exposure to a toxic amount of lidocaine, although we believe the risk with this formulation has not been evaluated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to prescription lidocaine patches, there are commercially-available OTC topical lidocaine products in the market, but none of
these OTC products have been reviewed or approved by the FDA. Notably in 2003, the FDA proposed amending the tentative final monograph for OTC external analgesic drug products to clarify the status of patches (and poultices and plasters), noting
that the dosage forms had not been determined to be generally recognized as safe and effective for any analgesia at that time. Therefore, the FDA would likely not consider these OTC products to be compliant with the monograph and do not have legal
marketing status. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Solution </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
novel adhesion and delivery technology provides significantly improved adhesion compared to Lidoderm, manufactured by Endo Pharmaceuticals, and generic alternatives marketed by Mylan N.V. (&#147;Mylan&#148;), while providing bioequivalent delivery
of lidocaine via an efficient drug delivery system. Our product is lighter, thinner and provides for a better patient experience without compromise to dermal safety and with no presentation of dermal sensitization. Below is a comparison of the key
advantages of ZTlido to Lidoderm and generic lidocaine patches manufactured by Teva and by Mylan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Key Advantages of ZTlido vs. Lidoderm and Associated Generics </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g428534g00a03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: DIA = <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Drug-in-adhesive</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">* Source: A Scilex-sponsored <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> comparative adhesion study <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(SCI-LIDO-ADH-003)</FONT></FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido has been strategically designed to address poor adhesion, a leading complaint associated with other currently marketed topical
lidocaine products. ZTlido uses an advanced <FONT STYLE="white-space:nowrap">hot-melt</FONT> technology, which uses premixing and <FONT STYLE="white-space:nowrap">hot-melt</FONT> mixing of various excipients and lidocaine, followed by cGMP compliant
coating, lining, cutting and filling processes. In clinical studies, the technology provided significantly improved adhesion over Lidoderm and Mylan&#146;s generic lidocaine patch at 12 hours after application. In a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">head-to-head</FONT></FONT> study of 44 subjects, ZTlido showed statistically significant adhesion at <FONT STYLE="white-space:nowrap">all-time</FONT> points compared to Lidoderm. Further, ZTlido maintained greater than 90%
mean adhesion over the labeled <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period while Lidoderm fell below this benchmark within 3 hours. ZTlido also showed superior adhesion when compared to Mylan&#146;s generic lidocaine patch.
In this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> study, ZTlido maintained greater than 90% mean adhesion throughout the labeled <FONT STYLE="white-space:nowrap">12-hour</FONT> administration
period, while Mylan&#146;s generic product had a mean adhesion score of only 80% immediately after application, which progressively worsened over time. The formulation components are also carefully selected to achieve the target adhesion profile
without creating dermal sensitization and maintaining a benign irritation profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In two separate studies, adhesion performance of
ZTlido was compared to Lidoderm (with 44 subjects) and to Mylan&#146;s generic lidocaine patch (with 24 subjects), as depicted in the diagrams below. Both studies were performed with healthy volunteers using a standard clinical adhesion protocol
where adhesion could not be enhanced (<I>i.e.</I>, no reinforcement, pressing or reattaching). The level of adhesion was measured immediately after application (Time 0), and at 3, 6, 9 and 12 hours after application. ZTlido was the only lidocaine
product to achieve over 90% adhesion over 12 hours after application in these studies. Maintaining 90% adhesion was a requirement for ZTlido&#146;s NDA approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g428534g03v30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proprietary adhesive system utilized for ZTlido allows for a more efficient delivery of the drug from
the patch to the skin. This was supported by a clinical study in which our product achieved a bioequivalent dose of lidocaine while using a reduced drug load (36 mg for ZTlido versus 700 mg for Lidoderm). The drug delivery efficiency of ZTlido
lessens the danger of accidental exposure. After 12 hours after application, ZTlido contains approximately 18 mg of residual lidocaine. In comparison, each Lidoderm patch leaves over 650 mg in the patch at the end of the <FONT
STYLE="white-space:nowrap">12-hour</FONT> administration period. If improperly disposed of, the residual drug poses a risk of accidental exposure to a toxic amount of lidocaine to children, pets and others, although the risk with this formulation
has not been evaluated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The drug delivery efficiency of ZTlido also enables it to be manufactured as a thinner product relative to
Lidoderm and Teva&#146;s generic lidocaine patch. We strategically leveraged this property of ZTlido by utilizing a thin patch design with a nonwoven backing cloth that allows for better adhesion of the product. The improved adhesion performance,
thinner profile and incorporation of a flexible backing material allows for a product that maintains contact with the skin in contoured areas of the body, when encountering torsional strains arising from normal body movements and during contact with
clothing and bedding. While Mylan&#146;s generic lidocaine patch is also thinner than Lidoderm, it incorporates a film backing material that makes the product inflexible with body movements, contributing to its rapid loss in adhesion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adhesion profile of ZTlido allows the product to be used under moderate exercise conditions (tested in 4&nbsp;sessions of <FONT
STYLE="white-space:nowrap">30-minutes</FONT> of stationary bike exercise, cumulatively 2 hours) as captured in the ZTlido label. No ZTlido patches fell off during the entire <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period.
Lidoderm and the associated generics have not produced any public data on the use of their products by active pain patients under such conditions. ZTlido is also labeled to allow patients to shower and bathe while wearing the patch, which is
supported by an adhesion or pharmacokinetic study showing that while some degree of lifting is observed in these environments, the patches were able to be pressed back down or reattached in the cases where the product completely detached, with no
clinically meaningful change in pharmacokinetics. In contrast, Lidoderm and the associated generics are labeled with the effects of water exposure being unknown. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although ZTlido, Lidoderm and the associated generics are all labeled to not be used with heat (<I>e.g.</I>, heating pad or blanket), the <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> ZTlido label states that users may apply ZTlido to a treatment site after moderate heat exposure, such as after 15 minutes of heating pad use on a medium setting. This authorized use of ZTlido is of
value as heat therapy is widely used in treating pain. In contrast, Lidoderm and the associated generics are not labeled for use with heat. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe ZTlido has other favorable features compared to Lidoderm and associated generic
lidocaine patches such as the inclusion of a perforated release liner and the absence of cold flow. The perforated release liner allows for easier removal of the liner before application, which we believe provides convenience to patients who have
dexterity challenges. In contrast, Lidoderm and generic lidocaine patches incorporate a single-sheet release liner, requiring patients to pick at the corners and edges to breach and remove before application. Cold flow is the propensity of the
adhesive to migrate from the edges of the product under normal conditions, either in the product envelope or while on the skin. This can lead to difficulties in removing the product from the envelope and/or movement of the product, while on the
skin, away from the intended administration site. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched ZTlido in October 2018 with support from an integrated commercial
organization using a dedicated sales force and sales management, marketing and managed care capabilities. We market ZTlido through a dedicated <FONT STYLE="white-space:nowrap">65-person</FONT> sales force, targeting over 10,000 primary care
physicians, pain specialists, neurologists and palliative care physicians who we believe treat the majority of PHN patients. We are utilizing a multi-channel marketing strategy to expand awareness and utilization of ZTlido. Our managed healthcare
account executives have achieved success in adding ZTlido to key formularies, including Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and Medicare plans), United Healthcare Commercial, Anthem BCBS, BCBS of
Massachusetts, Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Select Health and Medicaid in California, Florida, Connecticut, Idaho, and North Dakota. We believe the benefits of ZTlido, combined with our competitive pricing
strategy and our active direct marketing efforts have driven, and will continue to drive, accelerated sales growth and increased market uptake. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to support several investigator-initiated research studies to explore the clinical benefits of using ZTlido in patients with carpal
tunnel syndrome, neck pain, intercostal neuralgia and other possible indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA)
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA) is a Phase 3, novel, injectable viscous gel formulation of a widely used
corticosteroid for epidural injections to treat sciatica. No ESIs are currently approved by the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sciatica Market Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A particularly debilitating complication of back pathology is sciatica, which is a condition caused by mechanical compression of the nerve
root, or by the effects of inflammatory mediators arising from a degenerative disc that results in inflammation and damage to the nerve roots. This nerve root compression in the lumbar segment of the spine causes shock-like or burning LBP combined
with pain radiating down along the sciatic nerve through the buttocks and down one leg, sometimes reaching the foot. This often severe and debilitating leg pain is usually associated with symptoms of neuropathy-like numbness and tingling. The
estimated lifetime incidence of sciatica ranges from 10% to 40% of the U.S. population, and about <FONT STYLE="white-space:nowrap">one-third</FONT> of these cases will develop symptoms lasting over a year. According to a report by Decision Resources
Group, it is estimated that over 4.8&nbsp;million patients will suffer from sciatica in the United States in 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current Treatment Landscape and
Limitations of Existing Treatments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the U.S. population ages, the incidence of sciatica and the need for interventions are expected
to continue to increase. For example, from 2000 to 2018, ESIs in Medicare beneficiaries increased by more than 125%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although there are
numerous etiologies of sciatica, and therapies may differ based on the etiology, pain management interventions for sciatica are usually multi-modal. Among the pain management interventions, ESI is considered to be efficacious and has been widely
used by physicians across multiple specialties, including anesthesiology, physical medicine and rehabilitation and pain medicine. However, there is no ESI therapy approved by the FDA for sciatica to date, and particulate formulations of
glucocorticoids have been associated with severe adverse events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with sciatica have a wide range of invasive and
<FONT STYLE="white-space:nowrap">non-invasive</FONT> treatment options. Surgical intervention options include such as vertebroplasy, spinal laminectomy, discectomy, microdiscectomy, foraminotomy, intradiscal electrothermal therapy, nucleoplasty,
radiofrequency denervation, spinal fusion and artificial disc replacement. These options are generally the last line of treatment because they can result in prolonged recovery time, may not be successful in reducing pain or addressing the underlying
cause, and may result in permanent loss of flexibility. For these reasons, less invasive interventions are usually implemented first. Less invasive interventions may include (i)&nbsp;nonpharmacological therapies such as physical therapy, stretching
exercises, spinal manipulations or chiropractic therapy, traction, acupuncture, transcutaneous electrical nerve stimulation, and biofeedback; (ii)&nbsp;oral pharmaceutical therapies such as NSAIDs, muscle relaxants, opiates, antidepressants, and
anticonvulsants; and (iii)&nbsp;injectable pharmaceutical therapies such as <FONT STYLE="white-space:nowrap">off-label</FONT> use of ESIs or nerve blocks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ESIs for various back pain syndromes are one of the most common procedures performed in the United States and lumbosacral radicular ESI
procedures represent 88% of total ESI procedures. ESIs are used when a patient&#146;s pain is inadequately controlled with oral pain medications, topical systems or interventions such as physical therapy. ESIs have demonstrated efficacy in reducing
pain, restoring function, reducing the need for other health care and avoiding back surgery. However, in addition to not being <FONT STYLE="white-space:nowrap">FDA-approved</FONT> for the treatment of lumbosacral radicular pain, currently-used ESIs
also present various risks and challenges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When administering an ESI, many physicians use a particulate steroid (including
methylprednisolone acetate, triamcinolone acetonide, or betamethasone sodium phosphate or betamethasone sodium acetate) instead of a <FONT STYLE="white-space:nowrap">non-particulate</FONT> steroid (dexamethasone sodium phosphate) because early
studies suggested that the duration of pain relief was longer with the particulates and fewer repeat injections were required, even though dexamethasone is considered an otherwise potent and therapeutically beneficial therapy. Particulate in
injectable products is defined as extraneous undissolved particles present in injectable solution products. An example of such particulate is precipitate of insoluble drug form, or suspended drug particle. These steroid particles or their aggregates
have at least two mechanisms for neurological damage: (1)&nbsp;they can act as emboli if injected into an artery and are of sufficient size to block small terminal arterioles supplying the brain or spinal cord; and (2)&nbsp;several particulate
steroids have an immediate and massive effect on microvascular perfusion because of formation of red blood cell aggregates. These emboli can cause rare but catastrophic neurologic injuries including stroke and spinal cord injury that can result in
increased pain, severe permanent disability or death. In addition, fungal meningitis has occurred from the injection of steroids manufactured in a compounding pharmacy that did not adhere to sterility standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has been evaluating serious neurologic events with ESIs since 2009, and in 2014, the FDA required a class warning on the currently <FONT
STYLE="white-space:nowrap">off-label</FONT> use of injectable corticosteroids to include information about the risk of serious neurologic events with ESIs. The warning on product labels for all injectable glucocorticoids states that the product is
to be used for intramuscular or intravenous purposes only, and specifically includes a warning for serious neurologic adverse reactions with epidural administration. These serious neurologic events have been reported with and without use of
fluoroscopy. The class warning also includes a statement that safety and effectiveness of epidural administration of these corticosteroids have not been established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain third-party payors have also provided limited coverage of ESIs to date. Based on coverage criteria established by different health
care plans and certain Medicare Administrative Contractors, an ESI is considered medically necessary and therefore reimbursable only when certain specific criteria are met. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Solution </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT
STYLE="white-space:nowrap">SP-102</FONT> to address problems associated with currently available corticosteroid products that are used in practice but not approved for epidural injection or the treatment of lumbosacral radicular pain. <FONT
STYLE="white-space:nowrap">SP-102</FONT> is a Phase 3 sterile dexamethasone sodium phosphate viscous gel formulation of 10 mg dexamethasone at a 5 mg/mL concentration in a <FONT STYLE="white-space:nowrap">pre-filled</FONT> glass syringe for delivery
via an epidural injection. <FONT STYLE="white-space:nowrap">SP-102</FONT> allows for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
use of the potent dexamethasone and provides for longer residency time at the site of injection through the use of a viscous excipient in lieu of particulates. The product is also formulated
without the use of preservatives and packaged in a <FONT STYLE="white-space:nowrap">pre-filled</FONT> syringe, so as to confer greater physician convenience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently-used steroids carry a class warning and are not approved to be administered epidurally for the treatment of sciatica. In fact, there
are further warnings that the safety and efficacy of the use of these products following epidural administration has not been established. Their formulations include neurotoxic preservatives, surfactants, suspensions or particulates that carry risks
of serious neurologic complications. Unlike currently-used steroids, <FONT STYLE="white-space:nowrap">SP-102</FONT> does not contain neurotoxic preservatives, surfactants, suspensions or particulates that carry risk of serious neurologic
complications, which we believe may improve safety and the extent of pain relief. By using dexamethasone sodium phosphate, the soluble form of the potent dexamethasone, we believe <FONT STYLE="white-space:nowrap">SP-102</FONT> may substantially
reduce the risk of embolic events in case of inadvertent intra-arterial administration and enable repeat injections. We expect the injectable viscous gel product, <FONT STYLE="white-space:nowrap">SP-102,</FONT> which uses a biocompatible,
biodegradable, novel excipient and is protected by multiple patents and patent applications and trade secrets, to prolong the residence time at the injection site and result in extended local activity. We believe
<FONT STYLE="white-space:nowrap">SP-102,</FONT> if successfully developed and approved, has the potential to reduce the disability related to lumbosacral radicular pain and help delay or avoid spine surgery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved, <FONT STYLE="white-space:nowrap">SP-102</FONT> could become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> ESI
product. We believe an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapy for the treatment of sciatica could potentially benefit from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-market</FONT></FONT>
advantage if it can be shown to reduce or delay the need for expensive and potentially risky interventions such as spinal surgery and decrease the use of opioids. <FONT STYLE="white-space:nowrap">SP-102</FONT> benefits from our substantial
intellectual property portfolio and other technical barriers to entry for potential competitors. Further, we are a party to an exclusive supply agreement for a proprietary biocompatible viscosity-enhancing excipient sodium hyaluronate in <FONT
STYLE="white-space:nowrap">SP-102.Our</FONT> complex manufacturing process, specialized equipment and <FONT STYLE="white-space:nowrap">know-how</FONT> for sterile viscous product candidates are also key to our competitive edge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently evaluating data on <FONT STYLE="white-space:nowrap">SP-102</FONT> from a pivotal Phase 3 CLEAR trial, which was designed to
evaluate the safety and efficacy in the proposed indication. The CLEAR clinical trial is a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 401 patients with sciatica at over 40 sites across the United States, with a primary
objective to evaluate the analgesic effect on average leg pain (as measured by the Numeric Pain Rating Scale in the affected leg) following a single epidural injection of <FONT STYLE="white-space:nowrap">SP-102,</FONT> compared to an intramuscular
injection of placebo over four weeks. A full <FONT STYLE="white-space:nowrap">6-months</FONT> data analysis was completed in February 2022 and we announced final results from the study in March 2022, which results reflect achievement of primary and
secondary endpoints. We believe these final results are supportive of a breakthrough therapy designation for sciatica that, in addition to the fast track designation, is expected to allow the FDA to further expedite the overall development program
leading to market approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 3 CLEAR trial summary results, which results reflect achievement of primary and secondary
endpoints, are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">SP-102</FONT>
(SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in Radiculopathy) experienced a rapid onset of pain relief, measured by Numeric
Pain Rating Scale of average daily pain in the affected leg, with improvement against placebo over the first 4 weeks, following a single transforaminal injection, LS Mean (SEM) difference <FONT STYLE="white-space:nowrap">-1.08</FONT> (0.17), with a <FONT
STYLE="white-space:nowrap">p-value</FONT> &lt; 0.001. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">SP-102</FONT>
(SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>) showed continued reduction of pain beyond one month, and the median time to open-label repeat injection was 99 days (95% CI: 78, 129 days) according to a Kaplan-Meier estimation.
By contrast, <FONT STYLE="white-space:nowrap">off-label</FONT> injectable steroids typically provide pain relief for periods ranging from less than a week and up to one month, and then a repeat injection may be required. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The key secondary endpoint of Oswestry Disability Index, the gold standard for measuring degree of disability and
estimating quality of life, showed a 28% improvement at 4 weeks on <FONT STYLE="white-space:nowrap">SP-102</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
(SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>) compared to baseline (minimal clinically meaningful improvement <FONT STYLE="white-space:nowrap">8%-12%)15.</FONT> The LS Mean
(SEM) difference as compared to placebo was <FONT STYLE="white-space:nowrap">-6.28</FONT> (1.49), with a <FONT STYLE="white-space:nowrap">p-value</FONT> &lt; 0.001. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There were no adverse events (&#147;AEs&#148;) of special interest reported, such as paraplegia, hematoma, or
infection at the injection site, which events are associated with the <FONT STYLE="white-space:nowrap">off-label</FONT> use of <FONT STYLE="white-space:nowrap">non-approved</FONT> injectable steroid preparations. Of the 354 patients receiving at
least a single injection of <FONT STYLE="white-space:nowrap">SP-102,</FONT> there were 125 (35.3%) patients experiencing treatment emergent adverse events (&#147;TEAEs&#148;), with 32 (9.0%) patients experiencing treatment-related AEs, 16 (4.5%)
patients experiencing medication-related AEs, 23 (6.5%) patients experiencing procedure-related AEs, four (1.1%) patients experiencing serious AEs, and one (0.3%) patients experiencing AEs related to early withdrawal. Of the 47 patients only
receiving a single placebo injection (and no repeat injection of <FONT STYLE="white-space:nowrap">SP-102),</FONT> there were 14 (29.8%) patients experiencing TEAEs with (i)&nbsp;two (4.3%) patients experiencing treatment-related AEs, (ii)&nbsp;two
(4.3%) patients experiencing medication-related AEs, (iii)&nbsp;one (2.1%) patient experiencing procedure-related AEs, (iv)&nbsp;one (2.1%) patient experiencing serious AEs, (v)&nbsp;one (2.1%) patient experiencing AEs related to early withdrawal,
and (vi)&nbsp;one (2.1%) patient death. TEAEs occurring in &#8805; two percent of patients were headache <FONT STYLE="white-space:nowrap">(SP-102:</FONT> 13 (6.4%), 17 events; placebo: 11 (5.5%), 11 events), injection site pain <FONT
STYLE="white-space:nowrap">(SP-102:</FONT> 4 (2.0%), four events; placebo: zero (0.0%), 0 events), upper respiratory tract infection <FONT STYLE="white-space:nowrap">(SP-102:</FONT> two (1.0%), 2 events; placebo: four (2.0%) events), sinusitis <FONT
STYLE="white-space:nowrap">(SP-102:</FONT> 4 (2.0%), four events; placebo zero (0.0%), 0 events) and hypertension <FONT STYLE="white-space:nowrap">(SP-102:</FONT> four (2.0%), four events; placebo: one (0.5%), two events). The C.L.E.A.R trial also
established the safety of repeat injections, as patients who experienced <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> radicular pain between 4 and 23 weeks were allowed to receive open-label
additional <FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>) injection. The safety analysis was comparable between treatment groups through 4, 12 and 24 weeks of study period.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Phase 3 <FONT STYLE="white-space:nowrap">SP-102</FONT> C.L.E.A.R Trial &#150; Primary Endpoint </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g428534g07q47.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g428534g00a02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-103</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SP-103</FONT> to be a triple-strength, <FONT STYLE="white-space:nowrap">non-aqueous</FONT>
lidocaine topical system for the treatment of acute LBP. <FONT STYLE="white-space:nowrap">SP-103</FONT> leverages the same adhesive drug delivery formulation and manufacturing as ZTlido along with comparable backing material, perforated release
liner and container-closure system. The increase in drug load is offset by a corresponding decrease in the adhesive diluent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Acute LBP Market Overview
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safe and effective treatment of acute LBP represents a high unmet needs and creates large market opportunities. LBP affects about
70% of people in resource-rich countries at some point in their lives. Acute LBP can be self-limiting, however. One year after an initial episode, as many as 33% of people still have moderate-intensity pain and 15% have severe pain. Acute LBP has a
high recurrence rate with 75% of those with a first episode having a recurrence. Although acute episodes may resolve completely, they may increase in severity and duration over time. Americans spent approximately $134.5&nbsp;billion in 2016 on
treating LBP and neck pain, which was the highest expenditure among 154 conditions studied by the Department of Institute for Health Metrics and Evaluation at the University of Washington. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current Treatment Landscape and Limitations of Existing Treatments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Centers for Disease Control and Prevention, in 2018, 28.0% of men and 31.6% of women aged 18 years old and older had lower
back pain in the past three months. The percentage of women who had lower back pain increased as age increased. Among men, the percentage increased with age through age 74 years and then decreased. Women in the age groups 18 &#150; 44, 45 &#150; 64,
and 75 years and older were more likely to have lower back pain in the past three months than were men in the same age groups, but percentages were similar between men and women in the age group <FONT STYLE="white-space:nowrap">65-74</FONT> years.
Although most patients recover quickly with minimal treatment, proper evaluation is imperative to identify rare cases of serious underlying pathology. Certain red flags should prompt aggressive treatment or referral to a spine specialist, whereas
others are less concerning. Serious red flags include significant trauma related to age (i.e., injury related to a fall from a height or motor vehicle crash in a young patient, or from a minor fall or heavy lifting in a patient with osteoporosis or
possible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
osteoporosis), major or progressive motor or sensory deficit, <FONT STYLE="white-space:nowrap">new-onset</FONT> bowel or bladder incontinence or urinary retention, loss of anal sphincter tone,
saddle anesthesia, history of cancer metastatic to bone and suspected spinal infection. Without clinical signs of serious pathology, diagnostic imaging and laboratory testing often are not required. Although there are numerous treatments for
nonspecific acute LBP, most have little evidence of benefit. Patient education and medications such as nonsteroidal anti-inflammatory drugs, acetaminophen and muscle relaxants are beneficial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Solution </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our triple-strength <FONT
STYLE="white-space:nowrap">SP-103</FONT> is an investigational, <FONT STYLE="white-space:nowrap">non-aqueous</FONT> lidocaine topical system undergoing clinical development in acute LBP conditions. If approved, we believe that <FONT
STYLE="white-space:nowrap">SP-103</FONT> could become the lidocaine topical product for acute LBP indications. All current uses of topical lidocaine products for LBP are <FONT STYLE="white-space:nowrap">off-label.</FONT> This program builds on the
learnings from ZTlido because both products share the same adhesive drug delivery formulation and manufacturing technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
developing <FONT STYLE="white-space:nowrap">SP-103</FONT> to deliver a dose of lidocaine that is at least threefold higher than any approved lidocaine topical products (including the approved ZTlido, which has a drug load of 36 mg lidocaine). We
manufacture <FONT STYLE="white-space:nowrap">SP-103</FONT> to have a drug load of 108 mg lidocaine in a similar adhesive formulation as ZTlido, along with comparable backing material, perforated release liner and container-closure system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-103</FONT> has demonstrated delivery of threefold the level of drug of ZTlido, and consequently delivers
threefold the level of drug of Lidoderm and associated generics by extrapolation. <FONT STYLE="white-space:nowrap">SP-103</FONT> has been granted fast track designation by the FDA and, if approved, could become the first <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> lidocaine topical product for the treatment of acute LBP. We believe <FONT STYLE="white-space:nowrap">SP-103,</FONT> if successfully developed and approved, may be able to address the limitations of
prescription lidocaine patches in treating acute LBP by delivering a higher dose of lidocaine to the application site, but with systemic exposure of drug remaining well below established safety thresholds.
<FONT STYLE="white-space:nowrap">SP-103</FONT> has three times the drug load of ZTlido (108 mg versus 36 mg) in the adhesive system and can potentially deliver threefold the level of the drug within a targeted area, with the convenience of a single
topical system. This level of dosage for <FONT STYLE="white-space:nowrap">SP-103</FONT> is comparable to the maximum approved daily dosage of ZTlido, or three topical systems for up to 12 hours during a <FONT STYLE="white-space:nowrap">24-</FONT>
hour period. By contrast, delivering higher levels of drug with other lidocaine patches is encumbered by the underlying hydrogel technology that constrains the level of drug that can be loaded into the adhesive of those products. The level of drug
product in such patches can be increased only with a thicker adhesive layer, which can result in a loss of adhesion performance and flexibility. Further, increasing product dimensions can allow delivery of the drug over a larger area, but does not
increase drug delivery to a localized area under the topical system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the acute LBP market presents an attractive commercial
opportunity due to the large patient population, lack of any approved drugs and high level of unmet medical need. We believe developing and commercializing a topical <FONT STYLE="white-space:nowrap">non-opioid</FONT> product targeting this segment
of the pain population represents a commercially attractive strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend initially to evaluate
<FONT STYLE="white-space:nowrap">SP-103</FONT> in a Phase 2 trial in subjects who have acute LBP. The study design is planned as an enriched-enrollment, randomized, double-blind, <FONT STYLE="white-space:nowrap">two-period</FONT> cross-over,
multicenter study of <FONT STYLE="white-space:nowrap">SP-103</FONT> and placebo in subjects with acute LBP. The study consists of a <FONT STYLE="white-space:nowrap">7-day</FONT> open-label <FONT STYLE="white-space:nowrap">run-in</FONT> period where
all subjects receive active treatment. Responders to treatment then will be randomized to blinded Treatment A, consisting of 30 days treatment with <FONT STYLE="white-space:nowrap">SP-103</FONT> or Treatment B, consisting of 30 days treatment with
placebo patch with no lidocaine. Scilex initiated the Phase 2 trial in the second quarter of 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-104</FONT>
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SP-104</FONT> for the treatment of fibromyalgia.
<FONT STYLE="white-space:nowrap">Low-dose</FONT> naltrexone hydrochloride delayed-release capsules is routinely used <FONT STYLE="white-space:nowrap">off-label</FONT> to treat fibromyalgia and other chronic pain conditions such as complex regional
pain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fibromyalgia Market Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fibromyalgia affects an estimated 10&nbsp;million people in the United States and an estimated 3% to 6% of the world population. While it is
most prevalent in women, it also occurs in men and children of all ethnic groups. Fibromyalgia is the second most common disorder that rheumatologists encounter, seen in 15% of evaluated patients. Approximately 8% of patients cared for in primary
care clinics have fibromyalgia. Prominent fibromyalgia researchers and specialists estimate the economic burden of fibromyalgia in the United States to be between $12&nbsp;billion to $14&nbsp;billion each year and the condition accounts for a loss
of 1% to 2% of the national overall productivity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Potential Complications of Fibromyalgia </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a <FONT STYLE="white-space:nowrap">non-exhaustive</FONT> list of complications of fibromyalgia: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extreme allodynia with high levels of distress; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">opioid or alcohol dependence; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">marked functional impairment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">severe depression and anxiety; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obesity and physical deconditioning; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">metabolic syndrome. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although fibromyalgia is frequently grouped with arthritis-related conditions, there is no apparent inflammation or damage to the joints,
muscles or other tissues. The diagnostic criteria for fibromyalgia is detailed in the chart below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g428534g89q11.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently approved products for pain in fibromyalgia, including duloxetine, pregabalin and
milnacipran, have limited efficacy. Responders applying such products can only demonstrate a 27% to 40% reduction of symptoms, which is far below the commonly accepted threshold of 50% to prove efficacy in treating fibromyalgia. In light of this, we
believe new treatments with higher efficacy are needed to improve management of fibromyalgia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Solution </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-104</FONT> has key clinical data supporting its use in fibromyalgia. There are investigational trials that
support use and development of <FONT STYLE="white-space:nowrap">SP-104</FONT> for fibromyalgia. Currently there are no <FONT STYLE="white-space:nowrap">low-dose</FONT> formulations (i.e., less than 5&nbsp;mg) available. Physicians currently use the
commercially available high-dose tablets (50 mg) and have compounding pharmacies aliquot lower doses for patients. Pharmacy-compounding is inherently inaccurate and does not involve analyses to confirm that the aliquoted product has the target level
of drug, and there is no assurance as to content uniformity within a batch as well as other quality attributes critical for pharmaceutical product performance. This can lead to errors in dosing and challenges with titration. The commercial products
and pharmacy-compounded products also allow for the immediate release of the drug in the stomach, which can lead to compliance challenges due to severe side effects. Common side effects for naltrexone include hyperalgesia, dysphoria, insomnia and
anxiety. All these issues culminate into patient compliance issues and result in the eventual abandonment of an otherwise viable therapy to treat this debilitating disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">SP-104</FONT> uses delayed burst release technology that bypasses the stomach and releases the drug in
the gut (upper intestine). When taking <FONT STYLE="white-space:nowrap">SP-104</FONT> at night before bed, peak drug levels are achieved at night during sleep, allowing the patient to avoid conscious perception of hyperalgesia and other side
effects. The combination of the delayed-release and administration at night may also maximize efficacy as most endorphin/ enkephalin release is during sleep, which maximizes the product&#146;s potential to elicit compensatory response. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to develop <FONT STYLE="white-space:nowrap">SP-104</FONT> for fibromyalgia. Phase 1 studies are to characterize the
pharmacokinetic and safety profile of <FONT STYLE="white-space:nowrap">SP-104,</FONT> and Scilex intends to initiate a Phase 2 study in the first half of 2023. If successful, we believe <FONT STYLE="white-space:nowrap">SP-104</FONT> can become a
pivotal treatment for management of fibromyalgia, which represents a large commercial opportunity with high unmet demands. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_54"></A>Commercialization and Market Access </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales&nbsp;&amp; Marketing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
built a robust and integrated commercial infrastructure using a dedicated sales force and sales management, marketing and managed care capabilities, to maximize the potential of our marketed product, ZTlido, and to commercialize our product
candidates, if approved. We are focused on achieving accelerated sales growth and increased market uptake for ZTlido in the topical lidocaine product market, where we believe we have the only actively promoted product. Our dedicated <FONT
STYLE="white-space:nowrap">65-person</FONT> sales force has broad experience in pain management and is exclusively focused on promoting ZTlido. Our sales representatives leverage their established relationships to call on over 10,000 target pain
specialists, neurologists, select primary care providers and palliative care physicians who Scilex believes treat the majority of PHN patients. We believe these same call points provide treatment for the sciatica and acute LBP patients that could
benefit from SEMDEXA and <FONT STYLE="white-space:nowrap">SP-103,</FONT> if approved. Our sales representatives typically have over 10 years of experience in promoting a broad scope of pain management products that Scilex intends to leverage as our
product candidates are commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, ZTlido had gained approximately 11.6% market share of the lidocaine
patch prescription market across the territories we cover in the United States. The total prescriptions of ZTlido for the nine months ended September&nbsp;30, 2022 grew by more than 47.9% over the nine months ended September&nbsp;30, 2021, according
to Symphony Healthcare&#146;s national prescription data. Our experienced sales representatives and managers are supported by our marketing team, whose members have successfully launched over 20 products
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with large pharmaceutical, biotechnology and specialty pharmaceutical companies. Our marketing team has developed a multi-channel marketing strategy to promote the continued uptake of ZTlido by
highlighting its significantly improved adhesion and continuous pain relief throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. We are also promoting ZTlido with a marketing campaign that engages patients seeking
relief for neuropathic pain associated with PHN through social media and medical and consumer journals. Further, our marketing function is supported by an experienced analytics team that leverages its experience in forecasting and analytics to draw
insights from healthcare databases to inform our marketing strategy. As part of our broader commercial strategy, our marketing analytics team is conducting market research to support the launch of <FONT STYLE="white-space:nowrap">SP-102,</FONT> <FONT
STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104,</FONT> if any of these candidates is approved. We believe that our sales force, supporting commercial infrastructure and established relationships with our
targeted physician audience will provide a strategic advantage in pursuing potential partnerships to commercialize other <FONT STYLE="white-space:nowrap">non-opioid</FONT> pain management therapeutics. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Market Access </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established
a patient-centric market access function with robust capabilities across the market access continuum, including payor sales, contracting and marketing strategies, supplemental patient assistance programs and responsible drug pricing to support
patients&#146; access to ZTlido. Our team of managed healthcare account executives has demonstrated experience in establishing products on formularies and have currently prioritized and targeted select payor accounts representing approximately
275&nbsp;million of the over 300&nbsp;million lives, with the remaining 25&nbsp;million to be considered in the future. Currently, ZTlido is covered for over 200&nbsp;million lives in the United States and coverage continues to improve. As of
January 2021, we have secured coverage for ZTlido on Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and Medicare plans), United Healthcare Commercial, Anthem BCBS, BCBS of Massachusetts, Louisiana and Kansas,
Lifetime/Excellus BCBS, MedImpact, CareFirst, Select Health and Medicaid in California, Florida, Connecticut, Idaho, and North Dakota. We continue to negotiate coverage with large payors and pharmacy benefit managers in all books of business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ZTlido Formulary Coverage &#151; Over 90% of Lives Covered or In Negotiation </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g428534g30m75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We utilize an outside vendor to administer a patient assistance program directed at patients with commercial
insurance or those paying <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket.</FONT></FONT> With the copay assistance program, qualifying patients do not have to pay any copayment for their ZTlido prescription. We
utilize an external vendor and train the sales force to work proactively with clinician office managers in completing required forms for prior authorization for ZTlido. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_55"></A>Clinical Development Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Trial Highlights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated ZTlido in over 600 subjects in clinical trials to support marketing approval and promotional campaigns for the relief of
neuropathic pain associated with PHN in the United States. Our studies sought to investigate the bioequivalence of ZTlido compared to Lidoderm, adhesion performance and the dermal safety and tolerability of ZTlido under a range of application times
and settings. Based on these studies, we concluded that ZTlido: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrated bioequivalence to Lidoderm in study
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-PK-002A;</FONT></FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">showed greater than or equal to 90% adhesion in over 90% of the subjects at the end of the <FONT
STYLE="white-space:nowrap">12-hour</FONT> administration period in study <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-ADH-001;</FONT></FONT></FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">showed superior adhesion to Lidoderm and Mylan&#146;s generic lidocaine patch in studies <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-AHD-002</FONT></FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-ADH-003;</FONT></FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">was not meaningfully impacted by heat or exercise in study <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-HEX-001;</FONT></FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">was able to be used under showering and bathing conditions in study <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-ADH-004;</FONT></FONT></FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">did not show clinically meaningful dermal irritation in study <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SCI-LIDO-DERM-001.</FONT></FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ZTlido Study Details </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pivotal Bioequivalence Study</I> &#151;
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-PK-002A</FONT></FONT></FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a comparative single-dose pharmacokinetic (&#147;PK&#148;) study between ZTlido and Lidoderm designed as a <FONT
STYLE="white-space:nowrap">two-way</FONT> cross-over in 54 healthy subjects. In this trial design, each subject received a single dose of three ZTlido or three Lidoderm patches followed by a washout period and the administration of the other
product. The purpose of this study was to establish bioequivalence between the products, which was determined by the statistical comparability of Cmax and AUC as shown in the figure below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This was considered the pivotal clinical trial for ZTlido, as it provided the pharmaceutical bridge between the two products and showed that
ZTlido had comparable safety and efficacy to Lidoderm. As a result of successfully establishing the pharmaceutical bridge, no stand-alone clinical efficacy studies were required by the FDA to determine ZTlido&#146;s analgesic effects for
ZTlido&#146;s approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mean Lidocaine Plasma Concentration Time Profiles &#151; Semilog Scale </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g428534g47j55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pivotal Adhesion Study</I> &#151; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SCI-LIDO-ADH-001</FONT></FONT></FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, single-treatment, single-period,
single-application adhesion performance study in 54 healthy, human subjects to assess the adhesion performance of ZTlido over the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period of the product. The study also investigated
whether ZTlido met an FDA established adhesion performance benchmark of greater than or equal to 90% adhesion in greater than or equal to 90% of subjects in the study at the end of the administration period. At the end of the <FONT
STYLE="white-space:nowrap">12-hour</FONT> administration period, over 90% of the subjects (49&nbsp;out of the 54 subjects) maintained greater than or equal to 90% adhesion, with no adverse events reported during the study. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ZTlido Maintained Greater Than 90% Adhesion Over the <FONT STYLE="white-space:nowrap">12-Hour</FONT> Time
Period </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g428534g47l56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This study was considered the pivotal adhesion study for marketing approval and is summarized in the
product label. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Head-to-Head</FONT></FONT> Adhesion Study versus Lidoderm</I> &#151; <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-ADH-002</FONT></FONT></FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
conducted an open label, single-treatment, three-period, single-application adhesion performance study in 44 healthy, human subjects to evaluate the adhesion performance of ZTlido compared to the adhesion performance of Lidoderm over a <FONT
STYLE="white-space:nowrap">12-hour</FONT> administration period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, ZTlido demonstrated significantly superior mean adhesion
scores compared to Lidoderm at 3, 5, 9 and 12 hours after application. ZTlido maintained a mean percent adhesion performance greater than 90% over the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period, while Lidoderm fell below
90% mean adhesion within three hours. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ZTlido Demonstrated Superior Adhesion Compared to Lidoderm </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g428534g04a04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Head-to-Head</FONT></FONT> Adhesion Study versus
Mylan&#146;s Generic</I> &#151; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-ADH-003</FONT></FONT></FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, single-treatment, <FONT STYLE="white-space:nowrap">two-period,</FONT> single-application adhesion performance study
in 24 healthy, human subjects to evaluate the adhesion performance of ZTlido compared to the adhesion performance of a generic lidocaine patch 5% manufactured by Mylan over a <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. The
purpose of this study was to compare the adhesion performance of ZTlido against a topical lidocaine product involving a <FONT STYLE="white-space:nowrap">non-aqueous</FONT> formulation. We selected Mylan&#146;s generic lidocaine patch as a comparator
because it has similar product characteristics, including a <FONT STYLE="white-space:nowrap">non-aqueous</FONT> polymer <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">drug-in-adhesive</FONT></FONT> system allowing for a thinner
patch and a lower drug load as compared to Lidoderm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, ZTlido demonstrated significantly superior adhesion performance
compared to Mylan&#146;s generic lidocaine patch. ZTlido maintained a mean adhesion greater than 90% over the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period, while the generic product had a mean adhesion score of only 80%
immediately after application, which declined to a mean adhesion score of 27% at 12 hours after application. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ZTlido Demonstrated Superior Adhesion Compared to Mylan&#146;s Generic Lidocaine Patch </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g428534g05a05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PK and Adhesion Study under Exercise and Heat Conditions</I> &#151; <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-HEX-001</FONT></FONT></FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, randomized,
three-treatment, three-sequence, three-period, cross-over, PK and adhesion performance study of three ZTlido topical systems applied to separate areas in 12 healthy, human subjects during physical exercise, exposure to heat and under normal
conditions, respectively. The three treatment periods were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Treatment A sought to assess the PK and adhesion performance of ZTlido under physical exercise conditions. In
this treatment period, subjects were instructed to perform exercise for 30 minutes on a stationary bike achieving a heart rate of 108 beats per minute, with continuous heart monitoring during exercise. Subjects were instructed to perform exercise
immediately after the application of the topical system and at 2.5, 5.5 and 8.5 hours following application of the topical system. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Treatment B sought to assess the PK and adhesion performance of ZTlido under heat conditions. In this treatment
period, a heating pad adjusted to the medium setting was applied for 20 minutes immediately after application of the topical system and at 8.5 hours following application of the topical system. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Treatment C sought to assess the PK and adhesion performance of ZTlido under normal conditions. In this treatment
period, topical systems were applied to the <FONT STYLE="white-space:nowrap">mid-lower</FONT> back and worn for 12 hours. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In treatment A, adhesion and PK performance were not compromised by exercise, as reflected
in the product label. In treatment B, heat had an effect on PK but had no effect on adhesion. In Treatment C, normal PKs were observed and greater than 90% of subjects showed greater than 90% adhesion. No meaningful irritation was observed across
all treatments across all time points in any of the subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The impact of heat and exercise on PK is presented in the figure below. It
was observed that heat had an effect on Cmax, but the drug returned to normal levels after removal of heat and there was no clinically meaningful observed effect on AUC. Heat did not appear to have a deleterious or catastrophic effect on topical
system performance, either as a dose-dump (i.e., immediate and complete release of all drug from the product), or as reduced drug delivery (i.e., much lower systemic exposure). There was no significant effect on PK observed with exercise when
compared to subjects under normal conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ZTlido Demonstrated Consistent* PK Performance under Exercise and Heat Conditions </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g428534g43v59.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Defined as no clinically meaningful changes by meeting bioequivalence criteria </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dermal Sensitization and Irritation Study</I> &#151; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-DERM-001</FONT></FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a provocative dermal sensitization and irritation human clinical trial, also referred to as a repeat insult topical system test,
intended to elicit the worst-case dermal safety of ZTlido by extended wearing of the product over multiple days. In this trial, we compared the sensitization potential, and the overall irritation profiles of ZTlido and Lidoderm in 218 normal and
healthy subjects. We used a <FONT STYLE="white-space:nowrap">7-point</FONT> scale where a score of 0&nbsp;indicated no irritation and a score of 7 was considered a strong reaction spreading beyond the application site. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, results showed that the adhesion quality of ZTlido did not compromise dermal
safety. The study reported that ZTlido did not show potential for dermal sensitization and showed an overall benign irritation profile. Both ZTlido and Lidoderm had a mean irritation score well below 1, which is defined as barely perceptible
erythema. This study allowed for the ZTlido label to adopt the same local tolerance language as labeled for Lidoderm. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Photoallergy and Phototoxicity
Studies &#151; </I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-PHOT0-001</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-PHOTO-002</FONT></FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a <FONT STYLE="white-space:nowrap">6-week</FONT> randomized study,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-PHOTO-001,</FONT></FONT> to evaluate the potential of ZTlido and its comparator, Lidoderm, to induce a photoallergic skin reaction in 54 healthy volunteers. In this study, we
observed that ZTlido was not photoallergenic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a <FONT STYLE="white-space:nowrap">4-day,</FONT> randomized study, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-PHOTO-002,</FONT></FONT> to evaluate the irritation potential of ZTlido and its comparator, Lidoderm, when application to skin is followed by light exposure in 32 healthy
volunteers, using a phototoxicity patch test. In this study, we observed that ZTlido was not phototoxic. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-Approval Studies for ZTlido </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Water Stress Study (Shower and Swimming) &#151;
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-ADH-004</FONT></FONT></FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a single-dose study in 24 subjects to examine the adhesion and lidocaine delivery (pharmacokinetics) of ZTlido when it is exposed
to two separate water stress conditions of (1)&nbsp;showering (10&nbsp;minutes) and (2)&nbsp;swimming (15 minutes). The study showed that while some degree of product lifting was observed, the product could be pressed back down or reattached with no
further diminished adhesion performance or drug delivery. This study led to a change in the product label indicating that patients may use the product while showering or bathing. This provides significant patient convenience as Lidoderm and the
associated generics are labeled to avoid contact with water such as bathing, swimming or showering, as these products may not stick if they get wet. With ZTlido, patients can engage in these activities within the
<FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investigator-Sponsored Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to support several investigator-initiated research studies to evaluate the clinical benefits of using ZTlido in patients with carpal
tunnel syndrome, neck pain, intercostal neuralgia and other possible indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA)
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently conducted a Phase 3 pivotal study of <FONT STYLE="white-space:nowrap">SP-102.</FONT> The Corticosteroid Lumbar
Epidural Analgesia for Radiculopathy (&#147;CLEAR&#148;) study is a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 401 patients with sciatica to compare the epidural administration of
<FONT STYLE="white-space:nowrap">SP-102</FONT> to placebo. We announced final results from this study in March 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Trial Highlights
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT> has been evaluated in a number of preclinical studies and clinical trials as a
potential treatment for sciatica. Key findings from the preclinical studies and clinical trials include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Repeat injections of <FONT STYLE="white-space:nowrap">SP-102</FONT> showed continued pain reduction with no
unexpected adverse events based on preliminary results from the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SP-102-03</FONT></FONT> study; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">SP-102</FONT> showed an extended local activity with epidural administration in
the <FONT STYLE="white-space:nowrap">ES-1504</FONT> study; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">SP-102</FONT> showed an extended residence time and tolerability in the
1014-1512 and the 1014-2847, preclinical studies; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The introduction of <FONT STYLE="white-space:nowrap">SP-102</FONT> into blood vessels did not result in
neurological complications in the UPD003-IS21 preclinical toxicology study. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA)
Study Details Phase 3 Pivotal Clinical Trial &#151; CLEAR </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently conducted a pivotal, randomized, double-blind,
placebo-controlled Phase 3 trial, CLEAR, that enrolled 401 patients with sciatica at over 40 sites across the United States. The study includes an open-label extension where subjects will be followed for up to 24 weeks after treatment to evaluate
the safety of administering <FONT STYLE="white-space:nowrap">SP-102</FONT> in a larger patient population. After week 4, subjects who met certain pain criteria received open-label <FONT STYLE="white-space:nowrap">SP-102</FONT> to investigate the
safety of repeat injections and the duration of pain relief following injection. This well-controlled, randomized trial was designed to demonstrate evidence of the analgesic effect and safety of <FONT STYLE="white-space:nowrap">SP-102.</FONT> The
schematic of this Phase 3 trial is demonstrated in the flowchart below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary objective of this study was to evaluate the analgesic
effect of <FONT STYLE="white-space:nowrap">SP-102</FONT> on average leg pain, measured using the Numeric Pain Rating Scale (&#147;NPRS&#148;) following a single transforaminal injection. These results were compared to an intra-muscular injection of
placebo over a four-week period. The secondary objectives of this study include (i)&nbsp;evaluation of the degree of disability over time as measured by the Oswestry Disability Index; (ii)&nbsp;characterization of the change of the subject&#146;s
radiculopathy symptoms and overall condition, using a combination of PainDETECT, modified Brief Pain Inventory, Clinical Global Impression of Change, and Patient Global Impression of Change and (iii)&nbsp;evaluation of the safety of a single and
repeat <FONT STYLE="white-space:nowrap">SP-102</FONT> injections. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Schematic of CLEAR &#151; <FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA)
Phase 3 Pivotal Trial </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g428534g64p61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enrollment was completed in the second half of 2021. We announced final data from this study in March 2022.
The Pivot Phase 3 trial has met the primary efficacy and key secondary efficacy endpoints: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the primary endpoint of change in average daily pain (as measured by the Numeric Pain Rating Scale) in the
affected leg over four weeks following the initial injection, the LS Mean (SE) group difference of <FONT STYLE="white-space:nowrap">-1.08</FONT> (0.17) compared to placebo with a <FONT STYLE="white-space:nowrap">p-value</FONT> less than 0.001.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The two key secondary endpoints assessing Oswestry Disability Index (&#147;ODI&#148;) and Time to open-label
repeat injection have been demonstrated for <FONT STYLE="white-space:nowrap">SP-102.</FONT> The LS Mean (SE) group difference in ODI compared to placebo at week 4 was <FONT STYLE="white-space:nowrap">-6.28</FONT> (1.49) with a <FONT
STYLE="white-space:nowrap">p-value</FONT> less than 0.001. A Cox proportional hazard model showed significantly longer duration of initial <FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA) treatment compared to placebo Hazard Ratio (95% CI)
0.49 (0.36, 0.65), with a <FONT STYLE="white-space:nowrap">p-value</FONT> less than 0.001. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2 Repeat Dose Study</I> &#151;
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SP-102-03</FONT></FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, <FONT
STYLE="white-space:nowrap">single-arm,</FONT> pharmacodynamics (&#147;PD&#148;) and safety study of repeat epidural injections of <FONT STYLE="white-space:nowrap">SP-102</FONT> in patients with sciatica. We conducted this study to characterize
repeat dose PD with respect to hypothalamic-pituitary-adrenal suppression using plasma cortisol levels, white blood cell count and blood glucose levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The study enrolled 19 subjects, of which 15 received repeat <FONT STYLE="white-space:nowrap">SP-102</FONT> epidural injections 4 to 8 weeks
after the initial injection. Four of the subjects did not experience recurrent pain and thus did not require a repeat injection. The daily average, current and worst pain in the affected leg and back showed continuous reduction throughout the <FONT
STYLE="white-space:nowrap">28-day</FONT> observation period for both treatments. Based on a preliminary review of the results, <FONT STYLE="white-space:nowrap">SP-102</FONT> injections were generally well-tolerated and there were no new unexpected
adverse events observed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mean Percentage Change in Sciatica-Related Leg Pain as Measured by NPRS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g428534g42x62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 1 Trial of <FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA) Compared to Reference Listed Drug </I>&#151; <FONT
STYLE="white-space:nowrap">ES-1504</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, <FONT STYLE="white-space:nowrap">single-arm,</FONT> <FONT
STYLE="white-space:nowrap">two-period,</FONT> fixed sequential-dose study to evaluate the PK, PD and safety of <FONT STYLE="white-space:nowrap">SP-102</FONT> when administered by epidural injection. <FONT STYLE="white-space:nowrap">SP-102</FONT> was
compared to intravenous dexamethasone sodium phosphate injection in subjects with lumbosacral radiculopathy. There were 12 subjects enrolled in this study, all of whom received <FONT STYLE="white-space:nowrap">SP-102</FONT> followed by the
intravenous dexamethasone sodium phosphate injection (Reference Listed Drug) administered one month later. A Reference Listed Drug is an approved drug product to which new versions are compared to show that they are bioequivalent. The purpose of
this study was to establish the pharmaceutical bridge between <FONT STYLE="white-space:nowrap">SP-102</FONT> and the Reference Listed Drug. The Tmax observed with the administration of <FONT STYLE="white-space:nowrap">SP-102</FONT> was four hours,
compared to 15 minutes observed with intravenous dexamethasone. The PD parameters and safety results of both products were similar, and <FONT STYLE="white-space:nowrap">SP-102</FONT> did not prolong cortisol suppression time. <FONT
STYLE="white-space:nowrap">SP-102</FONT> also maintained analgesic effects throughout a <FONT STYLE="white-space:nowrap">one-month</FONT> observation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The overall systemic exposure of dexamethasone was similar, whether administered as <FONT STYLE="white-space:nowrap">SP-102</FONT> or injected
intravenously, with a mean AUCinf of 0.916 &micro;g*h/mL (observed with <FONT STYLE="white-space:nowrap">SP-102)</FONT> compared to 0.943 &micro;g*h/mL (observed with intravenously-administered dexamethasone). Notably, there was a <FONT
STYLE="white-space:nowrap">16-fold</FONT> increase in the time to maximum serum concentration (&#147;Tmax&#148;) following epidural injection of <FONT STYLE="white-space:nowrap">SP-102.</FONT> The median Tmax was 4.00&nbsp;hours for <FONT
STYLE="white-space:nowrap">SP-102</FONT> compared to 0.25 hours for the comparison group. All 12 subjects with sciatica showed continuous reduction in back and leg pain during the <FONT STYLE="white-space:nowrap">one-month</FONT> observation period
following a single epidural injection of <FONT STYLE="white-space:nowrap">SP-102.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This study demonstrated that at an equivalent initial dose of dexamethasone, the systemic
exposure to dexamethasone following epidural injection of <FONT STYLE="white-space:nowrap">SP-102</FONT> did not exceed the exposure following intravenous injection of the Reference Listed Drug. The PD effects, measured as white blood cell count,
cortisol levels and glucose levels, as well as the safety profile, were similar between the two treatments. <FONT STYLE="white-space:nowrap">SP-102</FONT> injections were generally well-tolerated and did not result in new unexpected side effects.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Toxicology Studies</I> &#151; Study Nos. 1014-1512 and 1014-2847 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted PK and toxicology studies in two <FONT STYLE="white-space:nowrap">non-rodent</FONT> animal species to assess <FONT
STYLE="white-space:nowrap">SP-102</FONT> administered via epidural and intrathecal routes with single and multiple dose regimens. Pharmacokinetically, a prolonged increase in the active dexamethasone metabolite was consistent with the extended
residence time of the viscous gel formulation of <FONT STYLE="white-space:nowrap">SP-102</FONT> at the site of injection. There were no new unexpected toxicology findings apart from well-characterized toxicity findings commonly observed with
administration of dexamethasone sodium phosphate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Toxicology Study</I> &#151; UPD003-IS21 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a preclinical toxicology study designed to simulate the accidental introduction of epidural steroids into arterial blood vessels
providing blood supply to the spinal cord, which is a major cause of neurological complications associated with current administration of suspension steroids containing particulates.A2 mL (10 mg of dexamethasone) injection of <FONT
STYLE="white-space:nowrap">SP-102</FONT> was injected over <FONT STYLE="white-space:nowrap">1-2</FONT> minutes into the vertebral artery of large animal species. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-</FONT> and post-dose angiography showed no remarkable changes and all animals survived for approximately
24 hours until euthanasia. The veterinary animal health report and the pathology report concluded there were no vascular, spinal cord or brain injuries associated with injection into the vertebral artery of the animals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hydrodynamic Study</I> &#151; <FONT STYLE="white-space:nowrap">SP-PC002</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a hydrodynamic study of <FONT STYLE="white-space:nowrap">SP-102</FONT> in <FONT STYLE="white-space:nowrap">non-rodent</FONT>
animal species, which showed that epidural administration of <FONT STYLE="white-space:nowrap">SP-102</FONT> demonstrated an increased local residence half-life and a decreased flow from the injection site. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Intravascular Injection Study</I> &#151; <FONT STYLE="white-space:nowrap">SEM-005</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a study to evaluate the accidental intravascular injection of <FONT STYLE="white-space:nowrap">SP-102</FONT> into the vertebral
artery of <FONT STYLE="white-space:nowrap">non-rodent</FONT> animals. There were no adverse clinical signs associated with the accidental intra-arterial injection of <FONT STYLE="white-space:nowrap">SP-102</FONT> following a <FONT
STYLE="white-space:nowrap">24-hour</FONT> survival period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-103</FONT> (lidocaine topical system) 5.4%
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-103</FONT> is an investigational, <FONT STYLE="white-space:nowrap">non-aqueous</FONT>
lidocaine topical system undergoing clinical development in acute LBP. As a higher strength topical lidocaine system, <FONT STYLE="white-space:nowrap">SP-103</FONT> will build on the learnings from ZTlido because both products share the same
adhesive drug delivery formulation and manufacturing technology. The clinical program involves evaluating the safety and efficacy of <FONT STYLE="white-space:nowrap">SP-103</FONT> for the treatment of acute LBP. A Phase 1 study was completed that
demonstrated bioequivalent pharmacokinetics between the administration of a single <FONT STYLE="white-space:nowrap">SP-103</FONT> and the administration of three commercial ZTlido. The study also showed linear kinetics among multiple applications of
<FONT STYLE="white-space:nowrap">SP-103</FONT> (i.e., 1, 2 or 3 patches) over a <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. Adhesion performance was assessed and found to be comparable between <FONT
STYLE="white-space:nowrap">SP-103</FONT> and ZTlido. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, we plan to evaluate <FONT STYLE="white-space:nowrap">SP-103</FONT> in
the following studies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SP-103-02</FONT></FONT> is a Phase 2 study of <FONT
STYLE="white-space:nowrap">SP-103</FONT> in subjects with acute LBP. The study design is planned as an enriched-enrollment, randomized, double-blind, <FONT STYLE="white-space:nowrap">two-period,</FONT> cross-over, multicenter study of <FONT
STYLE="white-space:nowrap">SP-103</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
versus placebo. The study is expected to consist of a <FONT STYLE="white-space:nowrap">7-day</FONT> open-label <FONT STYLE="white-space:nowrap">run-in</FONT> period where all subjects receive
active treatment. Responders to treatment will then be randomized to receive blinded treatment of either <FONT STYLE="white-space:nowrap">SP-103</FONT> or placebo. This study will inform on the pivotal Phase 3 study design to support market
approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In addition to a pivotal Phase 3 program, we intend to perform a <FONT STYLE="white-space:nowrap">3-day</FONT> PK
study of <FONT STYLE="white-space:nowrap">SP-103,</FONT> an adhesion performance study of <FONT STYLE="white-space:nowrap">SP-103</FONT> and an investigational study to evaluate the effects of heat and exercise on the PK and adhesion of <FONT
STYLE="white-space:nowrap">SP-103</FONT> to support the NDA submission. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 2 trial of <FONT
STYLE="white-space:nowrap">SP-103</FONT> was initiated in the second quarter of 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-104</FONT> (4.5mg, <FONT
STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release capsules) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two Phase 1 trials have been
completed for <FONT STYLE="white-space:nowrap">SP-104</FONT> at investigative sites in New Zealand: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SP-104-01</FONT></FONT> is a food effect and
bridging pharmacokinetic study comparing <FONT STYLE="white-space:nowrap">SP-104</FONT> to Naltrexone HCL Tablets conducted on approximately 18 healthy adult subjects. The study is designed to be an open-label, three-period, three-treatment,
randomized study to characterize the PK and safety and tolerability of <FONT STYLE="white-space:nowrap">SP-104</FONT> under fasting and fed conditions. Subjects are randomly administered a single dose of one of three treatments and followed for PK
and safety for a period of time followed by a washout period before receiving one of the other treatments. All subjects receive all three treatments. The study characterize the single-dose clinical studies and ultimately the commercial label. The
study also serves as a &#147;pharmaceutical bridge&#148; between <FONT STYLE="white-space:nowrap">SP-104</FONT> and the commercial reference listed drug (the &#147;RLD&#148;) (Naltrexone HCI tablets, USP 50 mg) to support the eventual
Section&nbsp;505(b)(2) NDA. Assuming that the rate and extent of drug exposure for <FONT STYLE="white-space:nowrap">SP-104</FONT> will be lower than that observed for the RLD, this study allows us to rely upon the FDA&#146;s findings of safety for
the RLD instead of having to perform extensive nonclinical animal safety toxicology studies and establish an extensive clinical safety database. Our development program can focus on establishing efficiacy of
<FONT STYLE="white-space:nowrap">SP-104</FONT> in the treatment of fibromyalgia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SP-104-02</FONT></FONT> is a Phase 1 study of <FONT
STYLE="white-space:nowrap">SP-104</FONT> conducted on approximately 52 healthy human subjects. The study is designed to be a double-blind, randomized, <FONT STYLE="white-space:nowrap">two-period,</FONT>
<FONT STYLE="white-space:nowrap">two-treatment</FONT> crossover study to evaluate the safety of <FONT STYLE="white-space:nowrap">SP-104,</FONT> compared to immediate release naltrexone capsules. The primary purpose of the study is to test the
hypothesis that, when taken at night, the delayed release of 4.5 mg Naltrexone mitigates against adverse events known for the drug and could affect patient compliance in maintaining treatment for their fibromyalgia. In a small (n=52) cross-over
trial in healthy volunteers comparing <FONT STYLE="white-space:nowrap">SP-104</FONT> (naltrexone hydrochloride delayed-release 4.5 mg) to naltrexone hydrochloride immediate release 4.5 mg (the &#147;compared drug&#148;), there were no serious
adverse effects, no AEs leading to discontinuation, no meaningful differences in physical examinations, vital signs, or laboratory parameters between treatments, no severe AEs for either treatment. Of the 52 patients receiving at least a single
injection of <FONT STYLE="white-space:nowrap">SP-104,</FONT> there were 21 (40%) patients experiencing at least one TEAE, 14 (27%) patients experiencing at least one treatment-related TEAE, 12 (23%) patients experiencing at least one
treatment-related TEAE within 72 hours after first administration of <FONT STYLE="white-space:nowrap">SP-104.</FONT> Notable AEs of special interest were nausea and headache within 72 hours after first administration of <FONT
STYLE="white-space:nowrap">SP-104.</FONT> <FONT STYLE="white-space:nowrap">SP-104</FONT> administered at night before bed resulted in a lower number of subjects with at least one AE (p = 0.0414), and an even lower number of subjects with at least
one AE within 72 hours after the first administration of <FONT STYLE="white-space:nowrap">SP-140</FONT> when compared to the compared drug. There was a lower number of subjects with AEs of special interest within 72 hours after administration of <FONT
STYLE="white-space:nowrap">SP-104</FONT> (n=9; 12 events) versus the compared drug (n=15; 20 events). Notable AEs of special interest observed within 72 hours after administration of the applicable drug are nausea
<FONT STYLE="white-space:nowrap">(SP-104:</FONT> n=0; the compared drug: n=3) and headache <FONT STYLE="white-space:nowrap">(SP-104:</FONT> n=6; the compared drug: n=12). The study randomized subjects to one of two treatments followed by a washout
period and then receipt of the other treatment, which allows all subjects to act as their own control. The study will support intellectual property, inform on clinical study design and contribute to safety characterization to support market
applications. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We completed both studies in the second quarter of 2022. We plan to use data collected from
these studies to support an Investigational New Drug application with the FDA, which is expected to enable further clinical development and initiation of a planned multi-center placebo-controlled registration trial in the field of fibromyalgia. The
registration trial is designed to be a Phase 3, randomized double-blind, placebo-controlled, parallel group, multicenter study that meets the regulatory requirements of an &#147;adequate and well-controlled&#148; study to establish the efficacy of <FONT
STYLE="white-space:nowrap">SP-104</FONT> in the treatment of fibromyalgia. Depending on the outcomes, this registration trial alone may be efficient in supporting market approval of <FONT STYLE="white-space:nowrap">SP-104</FONT> or as an additional
Phase 3 study may be required. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_56"></A>Medical Affairs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Medical Affairs team includes <FONT STYLE="white-space:nowrap">in-house</FONT> medical expertise, health economics and third-party payor
support. The Medical Affairs team works with our clinical team to identify sites for clinical trials, support the investigator teams and develop publication plans for clinical and real-world ZTlido data and our product candidates. Our Medical
Affairs team also works with Key Opinion Leaders, professional societies and patient advocacy groups to educate on and support the appropriate use of pain therapeutics, including topical pain products. Further, our Medical Affairs team provides our
sales organization with therapeutic knowledge and product training. The Medical Affairs team and Promotional Review Committee review all promotional materials for scientific accuracy. Medical Affairs team also develops lifecycle planning and works
with our clinical team to determine registration or supportive studies, oversee post-approval studies and support investigator-sponsored trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_57">
</A>Manufacturing and Supply Chain </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently contract with third parties for the manufacture, assembly, testing, packaging, storage
and distribution of our product. Our technical team has extensive pharmaceutical development, manufacturing, analytical, quality and distribution experience and is qualified and capable of managing manufacturing and supply chain operations. Our
Quality System, Standard Operating Procedures and contract manufacturing organizations (&#147;CMOs&#148;) comply with cGMP and regulatory requirements. We selected our CMOs for specific competencies having met our development, manufacturing, quality
and the FDA regulatory requirements. These CMOs manufacture our clinical supplies and commercial batches. We currently have no plans to build our own manufacturing or distribution infrastructure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido is a single-layer, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">drug-in-adhesive</FONT></FONT> topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a
polyethylene terephthalate film release liner. ZTlido is commercially manufactured for us by Oishi Koseido Co., Ltd. (&#147;Oishi&#148;) in Japan. We have exclusive worldwide rights to Oishi&#146;s proprietary formulation and manufacturing
technologies except with respect to Japan. ZTlido is manufactured using premixing and <FONT STYLE="white-space:nowrap">hot-melt</FONT> mixing of various excipients and lidocaine, followed by cGMP compliant coating, lining, cutting and filling
processes. ZTlido is packaged as a carton of 30 topical systems, into individual child-resistant envelopes. See the section of this prospectus titled &#147;<I>Business &#151; Material Agreements &#151; Itochu and Oishi Product Development
Agreement</I>&#148; and &#147;<I>Business &#151; Material Agreements &#151; Itochu and Oishi Commercial Supply Agreement</I>&#148; for additional information regarding the manufacturing and supply chain of ZTlido. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once production is complete, commercial product shipments are sent to the United States, where our exclusive third-party logistics
distribution provider, Cardinal Health 105, ships them to temperature-controlled customer distribution centers, which are generally able to deliver finished product to retail pharmacies on the same day, or within 24 hours. We currently contract with
multiple pharmaceutical distributors throughout the United States, including McKesson, Cardinal Health 110 and AmerisourceBergen. Distributors have agreements in place that provide us with access to large retail chains, including CVS, Walgreens,
Rite Aid and Walmart, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
well as independent pharmacies. In addition to all order fulfillment, Cardinal Health 105 performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks,
distributor fee for service, government reporting, customer returns, accounts receivable, inventory control, product security (DSCSA serialization) inquiries and recall assistance. In the years ended December&nbsp;31, 2019, 2020, and 2021, and in
the first quarter of 2022, Cardinal Health 105 was our only customer and sales to Cardinal Health 105 represented all of our net revenue for such periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we continue to expand the commercialization of ZTlido, we expanded our direct distribution network to national and regional distributors
and pharmacies in the second quarter of 2022. We currently hold wholesaler licenses and commenced selling directly to our main distributor customers as well as pharmacies in the second quarter of 2022. In April 2022, we discontinued our use of
&#147;title model&#148; services provided by Cardinal Health 105, but expect that Cardinal Health 105 will continue to perform other third-party logistics services for us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT> is a Phase 3 sterile dexamethasone sodium phosphate injectable viscous gel drug product
containing dexamethasone sodium phosphate equivalent to 10 mg dexamethasone in a <FONT STYLE="white-space:nowrap">pre-filled</FONT> glass syringe with a 2 mL deliverable volume. <FONT STYLE="white-space:nowrap">SP-102</FONT> also contains sodium
hyaluronate, which is a novel, biocompatible, viscosity-enhancing excipient and is listed in the European Pharmacopeia. We have an exclusive supply agreement for sodium hyaluronate for <FONT STYLE="white-space:nowrap">SP-102</FONT> from the
manufacturer and supplier. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT> is manufactured by a single-source manufacturer, which supports
the clinical development, including the completed Phase 3 clinical trial of <FONT STYLE="white-space:nowrap">SP-102.</FONT> In March 2022, we announced final results of the Phase&nbsp;3 clinical trial, satisfying the primary efficacy and key
secondary efficacy endpoints. The manufacturing process is proprietary and includes trade secrets. We plan to engage our existing contract manufacturer, Lifecore, for the commercial production of <FONT STYLE="white-space:nowrap">SP-102,</FONT> if
approved. We plan to use the biocompatible proprietary excipient supplied by Sanofi-Aventis U.S. LLC (&#147;Sanofi&#148;) sodium hyaluronate, pursuant to the Genzyme Supply Agreement, and engage Sanofi for commercial supply of dexamethasone sodium
phosphate for <FONT STYLE="white-space:nowrap">SP-102,</FONT> if approved. See the section of prospectus titled &#147;<I>Business &#151; Material Agreements &#151; Genzyme Supply Agreement</I>&#148; and &#147;<I>Business &#151; Material Agreements
&#151; Lifecore Master Services Agreement</I>&#148; for additional information regarding the manufacturing and supply of the proprietary excipient and contact manufacturing of <FONT STYLE="white-space:nowrap">SP-102</FONT> product, respectively.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-103</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-103</FONT> contains 5.4% lidocaine (108 mg lidocaine) and is manufactured for clinical supply by Oishi,
using the same manufacturing processes as used for ZTlido. If our Phase 2 and Phase 3 trials are successful, we plan to submit the <FONT STYLE="white-space:nowrap">SP-103</FONT> manufacturing protocols in a supplemental new drug application. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-104</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SP-104,</FONT> a novel <FONT STYLE="white-space:nowrap">low-dose,</FONT> naltrexone
hydrochloride delayed release formulation for treating fibromyalgia. <FONT STYLE="white-space:nowrap">SP-104</FONT> is 4.5 mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed release capsule product in clinical
development, currently undergoing Phase 1 studies. It is manufactured by a contract manufacturer, Tulex, located in Cranbury, NJ. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_58">
</A>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry is highly competitive and subject to rapid and significant technological change. The large size and
expanding scope of the pain management market makes it an attractive therapeutic area for biopharmaceutical businesses. Our potential competitors include pharmaceutical, biotechnology and specialty pharmaceutical companies. Many of these companies
have drug pipelines, readily available capital, and established research and development organizations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido and our product candidate, <FONT STYLE="white-space:nowrap">SP-103,</FONT> if
approved, face and will likely face competition from prescription, generic, and OTC topical lidocaine patches, including Lidoderm and generic lidocaine patches manufactured by Teva, Mylan and Par Pharmaceutical, Inc. Additionally, <FONT
STYLE="white-space:nowrap">SP-103,</FONT> if approved, will likely compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants and anticonvulsants, particularly as we seek approval for the treatment of acute LBP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102,</FONT> if approved, has the potential to become the first
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> epidural steroid product for the treatment of sciatica. While there are currently no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> ESIs indicated for the treatment of sciatica, we are aware
of certain <FONT STYLE="white-space:nowrap">non-steroid</FONT> product candidates in development. <FONT STYLE="white-space:nowrap">SP-102,</FONT> if approved, will compete with various opioid pain medications, NSAIDs, muscle relaxants,
antidepressants, anticonvulsants and surgical procedures. Procedures may include nerve blocks and transcutaneous electrical nerve stimulations. We may also face indirect competition from the <FONT STYLE="white-space:nowrap">off-label</FONT> and
unapproved use of branded and generic injectable steroids. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there are currently no formulations containing naltrexone in clinical
development for the treatment of fibromyalgia, we are aware of certain <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapeutics currently in a late-stage phase 3 pipeline containing two 505(b)(2) development programs. Our product candidate, <FONT
STYLE="white-space:nowrap">SP-104,</FONT> will likely face direct competition from these candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the market will
become increasingly competitive in the future. Many of our competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as
well as significantly greater experience in: developing product candidates and technologies, undertaking preclinical studies and clinical trials, obtaining the FDA and other regulatory approvals of product candidates, formulating and manufacturing
product candidates and launching, marketing and selling product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional mergers and acquisitions in the biotechnology and
pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their
products as well. Smaller or early-stage companies or generic or biosimilar pharmaceutical manufacturers may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These
competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or
necessary for, our programs. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our commercial opportunity could be reduced
or eliminated if our competitors succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we are currently developing or that we may develop. If approved,
our product candidates will face competition from commercially available drugs as well as drugs that are in the development pipelines of our competitors and later enter the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to <FONT
STYLE="white-space:nowrap">in-license</FONT> novel compounds that could make our product candidates less competitive. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and
commercializing medicines before we do. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of ZTlido,
<FONT STYLE="white-space:nowrap">SP-102,</FONT> <FONT STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104</FONT> are likely to be their efficacy, durability, safety, price and the availability of reimbursement from
government and other third-party payors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_59"></A>Material Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Itochu and Oishi Product Development Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to the Product Development Agreement with Oishi Koseido Co., Ltd. (&#147;Oishi&#148;) and Itochu Chemical Frontier Corporation
(&#147;Itochu,&#148; and together with Oishi, the &#147;Developers&#148;). Pursuant to the Product Development Agreement, the Developers agreed to develop, exclusively for us, lidocaine tape products, including ZTlido and <FONT
STYLE="white-space:nowrap">SP-103</FONT> (the &#147;Products&#148;). Pursuant to the Product Development Agreement, we obtained the rights to market, sell and distribute the Products in global markets outside of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In carrying out the development responsibilities, the Developers agreed to, among other things, (1)&nbsp;source and provide the active
pharmaceutical ingredient for the Products for manufacturing, (2)&nbsp;develop a stable final dosage form of the Products suitable for regulatory approvals, (3)&nbsp;conduct product development activities necessary to support the filing of
applications for regulatory approvals for the Products and (4)&nbsp;conduct manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT> activities and preclinical studies for the Products. We are responsible for, among other things,
(a)&nbsp;conducting all pivotal human clinical trials for the Products, (b)&nbsp;completing all regulatory filings, correspondence and meetings with the FDA or other applicable governmental authorities with respect to the Products and
(c)&nbsp;commercially launching the Products. We maintain the ultimate responsibility and decision-making control with regard to the marketing and pricing of the Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties agreed to cooperate in good faith to determine whether to seek or maintain patent protection with respect to the Products, the
active pharmaceutical ingredient, any associated method of use, method of manufacturing, or any other invention that could reasonably be expected to affect the commercialization or value of the Products. The Developers have the first right to pursue
patent protection for any invention by them. All parties will jointly agree on the appointment of the patent representatives in each country outside of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the expiration or termination of the Product Development Agreement, the Developers granted us an exclusive, royalty-free, sublicensable,
worldwide license (except with respect to Japan) under its current and future intellectual property rights relating to the Products and the lidocaine in such Products. As consideration for the Developers&#146; development obligations under the
Product Development Agreement, we agreed to pay a contingent quarterly royalty between 25% and 35% to the Developers based on the net quarterly profits of the Products. In the event that the net profits of any of the first four calendar quarters
after the commercial launch equals a negative amount (a &#147;Net Loss&#148;), we are allowed to carry over such Net Loss to apply against all future calendar quarters until such Net Loss is covered, all calculated in accordance with GAAP. Under the
Product Development Agreement, if our total net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> are equal to or less than five percent of our net sales of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> for a period
of four or more consecutive quarters, the Developers have the right to terminate the Product Development Agreement and the Commercial Supply Agreement. As of the date of this prospectus, our net profits for ZTlido and
<FONT STYLE="white-space:nowrap">SP-103</FONT> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this
prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, if we receive any licensing fees from any third-party sublicensees, we are obligated to pay the same proportions of such licensing fee to the Developers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current term of the Product Development Agreement will continue until October&nbsp;2, 2028, which is the 10th anniversary of the first
commercial sale of ZTlido. Afterwards, the agreement will renew automatically for subsequent successive <FONT STYLE="white-space:nowrap">one-year</FONT> renewal periods unless we or the Developers terminate it upon
<FONT STYLE="white-space:nowrap">six-month</FONT> written notice. In addition, we or the Developers may terminate the Product Development Agreement if (1)&nbsp;the other party is in material breach of the agreement and the breach is not curable, or
if the breach is curable and the breaching party has not cured such material breach within 180 days after notice requesting to cure; (2)&nbsp;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the
absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; (3)&nbsp;the market conditions are such that (a)&nbsp;our total net profits of the Products are equal to or less than
five percent of our net sales of the Products for a period of four or more consecutive quarters, or (b)&nbsp;the Products&#146; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
economic viability is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us and the
Developers, and the parties are unable to resolve the concerns under the foregoing clauses (a)&nbsp;and (b)&nbsp;after 30 days of good-faith discussion; (4)&nbsp;the parties fail to reach mutual agreement as to who will conduct the clinical studies
and how the costs will be allocated; or (5)&nbsp;we or either one of the Developers are bankrupt or make assignment for the benefit of creditors. Additionally, we may terminate the Product Development Agreement if (i)&nbsp;any of the pivotal human
clinical trials for any of the Products fail, or (ii)&nbsp;the FDA issues a &#147;Refusal to File&#148; for any of the Products&#146; regulatory approval application and, after reasonable consultation with the Developers, we believe that it is
commercially unreasonable to <FONT STYLE="white-space:nowrap">re-file.</FONT> The Developers may terminate the Product Development Agreement if we fail to file for regulatory approval for any of the Products within three months of the date on which
all required components of the regulatory approval application are received by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Product Development Agreement, we and the
Developers have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (1)&nbsp;any breach of our respective representations, warranties or obligations under the Product Development
Agreement, (2)&nbsp;any failure by either of us to comply with all applicable laws, or (3)&nbsp;our respective negligence or willful misconduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Product Development Agreement and its amendments in the forms filed as exhibits to the
registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendments for a complete understanding of all of their respective terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Itochu and Oishi Commercial Supply Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;16, 2017, Scilex Pharma entered into the Commercial Supply Agreement with Itochu and Oishi. Pursuant to the Itochu and
Oishi Commercial Supply Agreement, Oishi agreed to manufacture, store, handle and perform quality control testing of the Products (as defined in the Product Development Agreement) at its facility in Japan. Itochu agreed to purchase Products from
Oishi and handle the shipping of the Products. Both Oishi and Itochu agreed to provide us with certain technical support regarding the Products as reasonably requested by us, including but not limited to analytical test methods, method development,
physical and chemical properties, and use of the Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Itochu and Oishi Commercial Supply Agreement, we pay per item
transfer prices for ZTlido, ZTlido professional samples and ZTlido placebo samples, in each case subject to certain minimum order quantities. We are required to provide a <FONT STYLE="white-space:nowrap">12-month</FONT> rolling purchase forecast of
the estimated quantities of the Products in writing on a monthly basis. Oishi is required to promptly notify us and Itochu if it lacks the capacity to meet the forecast. All Products ordered by us will be in the form of a firm written purchase
order. During the year ended December&nbsp;31, 2020, under the Itochu and Oishi Commercial Supply Agreement, we purchased inventory in the amount of $0.8&nbsp;million. During the year ended December&nbsp;31, 2021, we purchased inventory in the
amount of approximately $5.7&nbsp;million. The significant increase in inventory purchased was largely due to an excess of in stock inventory in fiscal year 2020 that was sold throughout fiscal year 2020 and the early part of fiscal year 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Itochu and Oishi Commercial Supply Agreement will remain in effect until the termination of the Product Development Agreement.
Additionally, either we or the Developers may terminate the Itochu and Oishi Commercial Supply Agreement (1)&nbsp;if the other party is in material breach of the agreement and the breach is not substantially cured within 60 days after receiving
written notice specifying the nature of the breach, or (2)&nbsp;in the event of any of the parties&#146; insolvency, bankruptcy or assignment for the benefit of creditors. Any third-party claim arising out of a breach by a party of any
representation, warranty or obligation under the Itochu and Oishi Commercial Supply Agreement, or a failure by a party to comply with applicable laws, or the negligence or willful misconduct of a party, will be subject to and governed by the Product
Development Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Itochu and Oishi Commercial Supply
Agreement and its amendments in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendments for a complete understanding of all of their respective
terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Genzyme Supply Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;17, 2015, through our wholly owned subsidiary, Semnur, we entered into the Genzyme Supply Agreement with Genzyme, an affiliate
of Sanofi-Aventis U.S. LLC. Pursuant to the Genzyme Supply Agreement, Genzyme agreed to produce and provide sodium hyaluronate, one of the excipients for SEMDEXA, and we agreed to purchase 100% of our clinical and commercial requirements for sodium
hyaluronate in specified territories, including the United States and all countries of the European Union (&#147;EU), exclusively from Genzyme. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Genzyme Supply Agreement, we agreed to pay a per gram price for clinical supply of sodium hyaluronate. For commercial supply,
the price will depend on the quantity of order. The pricing for both the clinical supply and the commercial supply of sodium hyaluronate is subject to readjustments each year on January&nbsp;1, provided that in no case will the price be increased by
more than 5% each year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Genzyme Supply Agreement provides for a five year exclusivity period in favor of us and will remain in effect
until 10 years after the effective date unless earlier terminated in accordance with the terms thereof, with automatic renewal for additional five year periods (on an exclusive basis), if the respective requirements for exclusivity are met by us as
set forth therein, and for additional <FONT STYLE="white-space:nowrap">two-year</FONT> periods thereafter unless either party gives notice of a termination not less than 18 months prior to the expiration of the then-current term. Either party may
terminate the Genzyme Supply Agreement if (1)&nbsp;the other party is in material breach of the agreement and fails to cure within 30 days, or (2)&nbsp;if the development of SEMDEXA is ceased or we do not file for regulatory approval for SEMDEXA by
January&nbsp;1, 2020. Additionally, Genzyme may terminate the Genzyme Supply Agreement if it decides to discontinue manufacturing the product at its facility for economic or strategic reasons and provides us with 24 months&#146; notice. We did not
file for regulatory approval for SEMDEXA by January&nbsp;1, 2020 and we are only aware of a limited number of suppliers of the excipient. In accordance with Genzyme&#146;s right terminate the Genzyme Supply Agreement if it decides to discontinue
manufacturing the product at its facility for economic or strategic reasons, Genzyme has notified us of its intention to terminate the Genzyme Supply Agreement, effective as of May&nbsp;31, 2024. Although we are currently in the process of
identifying and certifying new suppliers to fulfill our clinical and commercial supply requirements for sodium hyaluronate we may not be able to find an alternative supplier of sodium hyaluronate on commercially reasonable terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Genzyme Supply Agreement, we and Genzyme have agreed, subject to certain exceptions, to indemnify each other against any third-party
liabilities arising out of (1)&nbsp;any material breach of our respective representations, warranties and obligations thereunder, or (2)&nbsp;our respective gross negligence or willful misconduct. In addition, we have agreed to indemnify Genzyme
against any third-party liabilities arising out of the development, manufacture, storage, handling, use, marketing, distribution, offer for sale, sale, promotion or other commercialization of sodium hyaluronate by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Genzyme Supply Agreement in the form filed as an exhibit to the registration statement
of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lifecore Master
Services Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;27, 2017, through our wholly owned subsidiary, Semnur, we entered into the Lifecore Master
Services Agreement. Pursuant to the Lifecore Master Services Agreement, Lifecore is responsible for clinical trial material manufacturing and development services for SEMDEXA as set forth in each separate statement of work (each a &#147;Lifecore
Statement of Work&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties entered into a Lifecore Statement of Work on January&nbsp;27, 2017, pursuant to
which Lifecore agreed to provide, among other things, (1)&nbsp;project management support, (2)&nbsp;development services, (3)&nbsp;clinical trial materials, and (4)&nbsp;stability studies. We paid Lifecore for the development and clinical trial
material manufacturing services, which was invoiced at the completion of each service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of Lifecore&#146;s development
and clinical trial material manufacturing obligations, we granted Lifecore a nonexclusive, worldwide and royalty-free license under our owned or controlled intellectual property rights necessary to manufacture SEMDEXA, without additional right,
title or interest in our intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lifecore Master Services Agreement expires on December&nbsp;31, 2022, unless the
parties negotiate and execute a renewal of the agreement. Either party may terminate the Lifecore Master Services Agreement (1)&nbsp;if the other party is in material breach of the agreement and fails to cure such breach within 30 days of written
notice, subject to certain exceptions; or (2)&nbsp;immediately upon written notice to the other party if the other party (a)&nbsp;becomes insolvent, (b)&nbsp;ceases to function as a going concern, (c)&nbsp;is convicted of or pleads guilty to a
charge of violating any law relating to either party&#146;s business, or (d)&nbsp;engages in any act which materially impairs goodwill associated with SEMDEXA or materially impairs the terminating party&#146;s trademark or trade name. In addition,
Lifecore may terminate the agreement if (i)&nbsp;we fail to pay past due invoices upon 30 days&#146; written notice, or (ii)&nbsp;we reject or fail to respond to a major change proposed by Lifecore that does not change Semnur&#146;s written and
approved acceptance criteria in its product specifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lifecore Master Services Agreement contains customary reciprocal
indemnification obligations for Lifecore and Semnur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Lifecore Master Services
Agreement and the amendment thereto in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendment for a complete understanding of all of their
respective terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Semnur Merger Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;18, 2019, Legacy Scilex acquired Semnur pursuant to an Agreement and Plan of Merger with Semnur (as amended, the &#147;Semnur
Merger Agreement&#148;), Sigma Merger Sub, Inc., a wholly owned subsidiary of Legacy Scilex (&#147;Sigma Merger Sub&#148;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#147;Semnur Equityholders&#146;
Representative&#148;), and for limited purposes, Sorrento. Pursuant to the Semnur Merger Agreement, Sigma Merger Sub merged with and into Semnur (the &#147;Semnur Merger&#148;), with Semnur surviving as Legacy Scilex&#146;s wholly owned subsidiary.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with transactions contemplated by the Semnur Merger Agreement, Sorrento and each of the other holders of outstanding shares
of capital stock of Scilex Pharma, contributed each share of Scilex Pharma capital stock it owned to Legacy Scilex in exchange for one share of Legacy Scilex Common Stock (the &#147;Contribution&#148;). As a result of the Contribution, and prior to
the consummation of the Semnur Merger, Scilex Pharma became a wholly owned subsidiary of Legacy Scilex and Sorrento became the owner of approximately 77% of Legacy Scilex&#146;s issued and outstanding capital stock. As a result of the Semnur Merger,
Scilex Pharma and Semnur became wholly owned subsidiaries of Legacy Scilex. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the closing of the Semnur Merger, Legacy Scilex issued to
the holders of Semnur&#146;s capital stock (the &#147;Semnur Equityholders&#148;) and options to purchase Semnur&#146;s common stock, upfront consideration with a value of $70.0&nbsp;million. The upfront consideration was comprised of the following:
(i)&nbsp;a cash payment of approximately $15.0&nbsp;million, and (ii) $55.0&nbsp;million of shares of Legacy Scilex Common Stock (47,039,315 shares issued and 352,972 shares issuable, valued at $1.16 per share) (the &#147;Stock Consideration&#148;).
A portion of the cash consideration otherwise payable to the Semnur Equityholders was set aside for expenses incurred by the Semnur Equityholders&#146; Representative, and 4,749,095 shares of Legacy Scilex Common Stock otherwise issuable to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Semnur Equityholders were placed in escrow with a third party as security for the indemnification obligations of the Semnur Equityholders under the Semnur Merger Agreement. The expense fund and
escrow have since been released per the terms of the escrow agreement. The Semnur Equityholders that received the Stock Consideration were required to sign an exchange and registration rights agreement with Legacy Scilex, which is further described
below. Following the issuance of the Stock Consideration, Sorrento ownership in Legacy Scilex was diluted to approximately 58% of Legacy Scilex&#146;s issued and outstanding capital stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Semnur Merger Agreement, and upon the terms and subject to the conditions contained therein, Legacy Scilex also agreed to pay
the Semnur Equityholders up to $280.0&nbsp;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $40.0&nbsp;million payment that will be due upon obtaining the first approval of a NDA of a
Semnur product by the FDA and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: (i)&nbsp;a $20.0&nbsp;million payment upon the achievement of $100.0&nbsp;million in cumulative
net sales of a Semnur product, (ii)&nbsp;a $20.0&nbsp;million payment upon the achievement of $250.0&nbsp;million in cumulative net sales of a Semnur product, (iii)&nbsp;a $50.0&nbsp;million payment upon the achievement of $500.0&nbsp;million in
cumulative net sales of a Semnur product, and (iv)&nbsp;a $150.0&nbsp;million payment upon the achievement of $750.0&nbsp;million in cumulative net sales of a Semnur product. As of the date of this prospectus, none of the foregoing payments have
been triggered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Semnur Merger Agreement also provided that following the consummation of Legacy Scilex&#146;s first bona fide equity
financing with one or more third-party financing sources on an arms&#146; length basis with gross proceeds to Legacy Scilex of at least $40.0&nbsp;million, certain of the former Semnur optionholders will be paid cash in lieu of: (i)&nbsp;the 352,972
shares of Legacy Scilex Common Stock otherwise issuable to such former Semnur optionholders pursuant to the Semnur Merger Agreement, and (ii)&nbsp;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares
held in escrow pursuant to the Semnur Merger Agreement, with such shares in each case valued at $1.16 per share. The Semnur optionholders subsequently agreed, under the terms of the Exchange Agreement (as defined and described below) to forego the
foregoing right to any such payment in exchange for the right to participate in the Share Exchange (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2019, the
Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with Legacy Scilex (as amended, the &#147;Exchange Agreement&#148;). Pursuant to the Exchange Agreement, and upon the
terms and subject to the conditions contained therein, if within 18 months following the closing of the Semnur Merger, 100% of the outstanding equity of Legacy Scilex had not been acquired by a third party or Legacy Scilex had not entered into a
definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of Legacy Scilex capital stock on a major stock exchange that met certain requirements, then holders of the Stock Consideration could collectively elect
to exchange, during the <FONT STYLE="white-space:nowrap">60-day</FONT> period commencing the date that was the 18 month anniversary of the closing of the Semnur Merger (the &#147;Share Exchange&#148;), the Stock Consideration for shares of
Sorrento&#146;s common stock with a value of $55.0&nbsp;million based on a price per share of Sorrento&#146;s common stock equal to the greater of (a)&nbsp;the <FONT STYLE="white-space:nowrap">30-day</FONT> trailing volume weighted average price of
one share of Sorrento&#146;s common stock as reported on Nasdaq as of the consummation of the Share Exchange and (b) $5.55 (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the
&#147;Exchange Price&#148;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento and the Semnur Equityholders&#146; Representative on September&nbsp;28, 2020, on October&nbsp;9, 2020, Sorrento paid $55.0&nbsp;million in cash
to the Semnur Equityholders in lieu of issuing $55.0&nbsp;million of shares of Sorrento&#146;s common stock at the Exchange Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
foregoing is a summary of the material terms of the Semnur Merger Agreement (including the amendment thereto) in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the Semnur Merger
Agreement (including the amendment thereto) for a complete understanding of all of their respective terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Aardvark Asset Purchase Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2021, Sorrento entered into an asset purchase agreement (the &#147;Aardvark Asset Purchase Agreement&#148;) with Aardvark
Therapeutics, Inc. (&#147;Aardvark&#148;), pursuant to which, among other things, Sorrento acquired Aardvark&#146;s Delayed Burst Release Low Dose Naltrexone <FONT STYLE="white-space:nowrap">(DBR-LDN)</FONT> asset and intellectual property rights,
for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Assets&#148;), which includes a Statement of Work dated November&nbsp;18, 2020 (the &#147;Tulex
Statement of Work&#148;), pursuant to which Tulex agreed to, among other things, develop, test and manufacture clinical supplies of <FONT STYLE="white-space:nowrap">SP-104</FONT> for Sorrento. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to the acquisition, Sorrento designated Legacy Scilex to lead all development efforts related to
<FONT STYLE="white-space:nowrap">SP-104</FONT> and on May&nbsp;12, 2022, Legacy Scilex and Sorrento entered into a bill of sale and assignment and assumption agreement (the &#147;Bill of Sale&#148;), pursuant to which Sorrento sold, conveyed,
assigned and transferred to Legacy Scilex all of its rights, title and interest in and to the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets (including PCT/US2021/053645 and all patents and patent applications that claim priority rights
thereto) and Legacy Scilex assumed all of Sorrento&#146;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the <FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Acquisition&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the <FONT STYLE="white-space:nowrap">SP-104</FONT> Acquisition, Legacy Scilex issued a promissory note in the aggregate
principal amount of $5,000,000 to Sorrento (the &#147;Promissory Note&#148;). The Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66% simple interest per annum and
(b)&nbsp;the maximum interest rate permitted under law. The Promissory Note is payable in cash, shares of Common Stock (any shares so issued, the &#147;Consideration Shares&#148;) or any combination thereof, at Legacy Scilex&#146;s sole discretion,
and may be prepaid in whole or in part at any time without penalty. Legacy Scilex also agreed to file with the SEC, a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento,
within 60 days of the issuance of such Consideration Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the successor to the Aardvark Asset Purchase Agreement, Legacy Scilex is
obligated to pay Aardvark (i) $3,000,000, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in the Aardvark Asset Purchase Agreement) (which amount may be paid in shares of Common Stock or cash, in Legacy
Scilex&#146;s sole discretion) (the &#147;Development Milestone Payment&#148;) and (ii) $20,000,000, in cash, upon achievement of certain net sales by Legacy Scilex of a commercial product that uses the LDN Formulation (the &#147;Commercial
Product&#148;). Legacy Scilex will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by Legacy Scilex of a commercial product that uses the LDN Formulation. The royalty percentage is subject to
reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer. As of
the date of this prospectus none of the foregoing payments have been triggered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its acquisition of the <FONT
STYLE="white-space:nowrap">SP-104</FONT> Assets, Legacy Scilex has agreed that if it issues any shares of Common Stock in respect of the Development Milestone Payment, Legacy Scilex will prepare and file one or more registration statements with the
SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within 60 days following the date on which any such shares are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, MD, a member of our Board, is the founder, chief executive officer and a member of the
board of directors of Aardvark. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Aardvark Asset Purchase Agreement, Bill of Sale
and Promissory Note in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the forms of these agreements for a complete understanding of all of their respective terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tulex Master Services Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above, in connection with the <FONT STYLE="white-space:nowrap">SP-104</FONT> Acquisition, Legacy Scilex acquired the Tulex
Statement of Work, pursuant to which Tulex, among other things, develops, tests and manufactures clinical supplies of <FONT STYLE="white-space:nowrap">SP-104</FONT> for Legacy Scilex. The Tulex Statement of Work is governed by the terms of a master
services agreement (the &#147;Tulex Master Services Agreement&#148;). The Tulex Master Services Agreement was novated to Legacy Scilex on June&nbsp;15, 2022 and will remain in effect until five years after the effective date, unless terminated early
by either party. Either party may terminate the Tulex Master Services Agreement or a Tulex Statement of Work by written notice (1)&nbsp;if the other party is in material breach of the agreement or a Tulex Statement of Work and fails to cure such
breach within 15 days after receipt of notice of such breach (or such other time period expressly stated in the applicable Tulex Statement of Work) or (2)&nbsp;in the event of the other party&#146;s insolvency, bankruptcy, reorganization,
liquidation or receivership, or a failure to remove any insolvency, bankruptcy, reorganization, liquidation or receivership proceedings within ten days from the date of institution of such proceedings. In addition, we may terminate the agreement or
any Tulex Statement of Work (1)&nbsp;without cause upon 30 days prior written notice to Tulex or (2)&nbsp;immediately upon written notice in the event Tulex is dissolved or undergoes a change in control. A termination or expiration of a single Tulex
Statement of Work will not cause the automatic termination of the agreement or of any other Tulex Statement of Work. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party under the
Tulex Master Services Agreement agreed to indemnify the other party, its affiliates and each of their respective officers, directors, employees, contractors and agents against any third-party liabilities arising out of (1)&nbsp;such party&#146;s
breach of the Tulex Master Services Agreement or a Tulex Statement of Work or (2)&nbsp;the negligence or willful misconduct on the part of such party, its officers, directors, employees, agents or other representatives in connection with the Tulex
Master Services Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Tulex Master Services Agreement in the form filed as
an exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shah Investor LP Assignment Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;6, 2013, through Semnur, we entered into an Assignment Agreement with Shah Investor LP (&#147;Shah Investor&#148;). Mahendra
Shah, Ph.D., who served on our board of directors from March 2019 to October 2020, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned to us certain intellectual property related to pharmaceutical
compositions of corticosteroids (the &#147;Assigned IP&#148;). As consideration for the Assigned IP, we agreed to pay a contingent quarterly royalty in the <FONT STYLE="white-space:nowrap">low-single</FONT> digits to Shah Investor based on the
quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed utilizing the Assigned IP (a &#147;Royalty Product&#148;). We expect that SEMDEXA, if approved, will constitute a Royalty Product. The
royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as a Royalty Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the first Royalty
Product in the United States, whichever is longer. We also agreed to use commercially reasonable efforts to maximize the scope and coverage of the patents contained in the Assigned IP. As of the date of this prospectus, no royalty payments have been
made as we have not yet commercialized any applicable products and therefore such payments have not been triggered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Assignment
Agreement will remain in effect on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis
until royalties are no longer due on any Royalty Product. Either party may terminate the Assignment Agreement upon sixty days&#146; prior written notice, in the event the other party seeks to avoid a provision of the Assignment Agreement by
asserting that such provision is invalid, illegal or otherwise unenforceable, unless such assertion is eliminated and the effect of such assertion cured within such sixty day period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Assignment Agreement in the form filed as an exhibit to the registration statement of
which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Romeg License and Commercialization Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective June&nbsp;14, 2022, we entered into a License and Commercialization Agreement (the &#147;Romeg Agreement&#148;) with RxOmeg
Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.). Pursuant to the Romeg Agreement, Romeg granted to us (1)&nbsp;the right to manufacture, promote, market, distribute and sell the Licensed Products (as defined below) in the United States and
(2)&nbsp;an exclusive, transferable license to use the trademark &#147;GLOPERBA&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Romeg Agreement, among other things,
Romeg granted us (1)&nbsp;a transferable license, with the right to sublicense, under the patents and <FONT STYLE="white-space:nowrap">know-how</FONT> specified therein to (a)&nbsp;commercialize the pharmaceutical product comprising liquid
formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#147;Initial Licensed Product&#148;) in the United States (including its territories) (the &#147;Territory&#148;), (b) develop other products comprising the
Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#147;Licensed Products&#148;) and commercialize any such products and (c)&nbsp;manufacture Licensed Products anywhere in the world,
solely for commercialization in the Territory; and (2)&nbsp;an exclusive, transferable license, with right to sublicense, to use the trademark &#147;GLOPERBA&#148; and logos, designs, translations, and modifications thereof in connection with the
commercialization of the Initial Licensed Product solely in the Territory. The license to <FONT STYLE="white-space:nowrap">know-how</FONT> is exclusive for purposes of developing and commercializing Licensed Products in the Territory during the
royalty term, but is otherwise <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> The license to patents is exclusive for purposes of developing and commercializing Licensed Products in the Territory until July&nbsp;1, 2027 and, thereafter, is <FONT
STYLE="white-space:nowrap">co-exclusive</FONT> with Granules Pharmaceuticals, Inc. for the royalty term for such purposes. The royalty term begins on the date of the agreement and ends on the later of (i)&nbsp;expiration of the last to expire of the
patents that covers the manufacture or commercialization of the Licensed Products in the Territory or (ii)&nbsp;the tenth anniversary of the date of the Romeg Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the license under the Romeg Agreement, we agreed to pay Romeg (1)&nbsp;an
<FONT STYLE="white-space:nowrap">up-front</FONT> payment of $2.0&nbsp;million, (2)&nbsp;upon our achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $13.0&nbsp;million and (3)&nbsp;certain
royalties, at rates that do not exceed ten percent, based on annual net sales of the Licensed Products by us during the royalty term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Romeg Agreement will remain in effect until it is terminated in accordance with the terms thereof. We may terminate the Romeg Agreement (1)&nbsp;upon written notice to Romeg, if we elect (or are required) to withdraw the Initial Licensed Product
from the market as a result of serious adverse reactions from use of such product, which termination will be effective 30 days following the date of such notice or (2)&nbsp;at any time, without cause, upon written notice to Romeg, which termination
will be effective 120 days following the date of such notice, provided that a termination fee of up to $2.0&nbsp;million shall be paid to Romeg depending on when during the 10&nbsp;year period following the date of the agreement any such termination
notice set forth in the immediately preceding clause (2)&nbsp;has been provided. Romeg may terminate the Romeg Agreement (a)&nbsp;upon notice to us, if we fail to timely pay any milestone payment, percentage royalties or minimum quarterly royalties
or fail to timely deliver the requisite quarterly report, which termination will be effective 30 days after the date of such notice, unless we has made such payment in full or delivered such quarterly report within such 30 day period;
(b)&nbsp;immediately, if we challenge the licensed patents under any court action or proceeding or before any patent office or assist any third party to conduct any of these activities; or (c)&nbsp;by written notice to us if sales of Licensed
Products do not commence or continue within specified periods agreed to by the parties. In addition, either party may terminate the Romeg Agreement (1)&nbsp;in the event the other party materially breaches the agreement, unless the breaching party
has cured any such breach within 60 days after any notice thereof was provided or (2)&nbsp;in the event the other party (a)&nbsp;files in any court or agency a petition in bankruptcy or insolvency, (b)&nbsp;is served with an involuntary petition
against it in any insolvency proceeding and such involuntary petition has not been stayed or dismissed within 90 days after its filing, or (c)&nbsp;makes an assignment of substantially all of its assets for the benefit of its creditors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Romeg Agreement contains customary reciprocal indemnification obligations for Romeg and us. Additionally, we agreed, subject to certain
exceptions, to indemnify Romeg against any loss arising out of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacture or commercialization of any Licensed Product by or on behalf of us or our affiliates, marketing partners, sublicensees or subcontractors on or after the date of the license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Romeg Agreement, which is in the form filed as an exhibit to the registration
statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_60">
</A>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our ability to obtain and maintain proprietary protection for our product
candidates, technology and <FONT STYLE="white-space:nowrap">know-how,</FONT> to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our
proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our novel adhesion and delivery technology, inventions, improvements and product
candidates that are important to the development and implementation of our business. Our patent portfolio is intended to cover our product candidates, their methods of use and processes for their manufacture, and any other inventions that are
commercially important to our business. We also rely on trade secret protection of our confidential information and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to our novel adhesion and delivery technology, platforms and product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, patents are granted a term of 20 years from the earliest claimed
<FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. In certain instances, patent term can be adjusted to recapture a portion of delay by the PTO in examining the patent application or extended to account for term effectively lost as
a result of the FDA regulatory review period, or both. We cannot provide any assurance that any patents will be issued from our pending or future applications or that any patents will adequately protect our product or product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio, consisting of owned and/or licensed IP as of November&nbsp;23, 2022 contains approximately sixteen issued and unexpired
U.S. patents, six pending U.S. patent applications, and one pending Patent Cooperation Treaty (PCT) application. Our portfolio also includes certain foreign counterparts of these patents and patent applications including Australia, Brazil, Canada,
China, Hong Kong, India, Indonesia, Israel, Japan, Korea, Malaysia, Mexico, New Zealand, Panama, Peru, Philippines, Russian Federation, Singapore, South Africa, Taiwan, Ukraine, and certain countries within the European Patent Convention. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to ZTlido and <FONT STYLE="white-space:nowrap">SP-103,</FONT> our patents and patent applications cover compositions and methods
of treatment. With respect to our product candidate SEMDEXA, our patents and patent applications include formulations and methods of treatment. The patents are U.S. Pat. Nos. 10,500,284, 10,117,938, and 11,020,485, all of which expire in 2036. With
respect to <FONT STYLE="white-space:nowrap">SP-104,</FONT> our pending Patent Cooperation Treaty application is WO 2022/076470 (and all patents and patent applications that claim priority rights thereto), which covers oral delayed burst formulations
of <FONT STYLE="white-space:nowrap">low-dose</FONT> naloxone or naltrexone and related methods of treatment. We continue to seek to maximize the scope of our patent protection for all our programs. We have five issued U.S. patents and two pending
U.S. patent applications relating to lidocaine topical system compositions and methods of treating pain with lidocaine topical system compositions. The patents are U.S. Pat. Nos. 9,283,174, 9,925,264, 9,931,403, 10,765,749, 10,765,640 and 11,278,623
all of which expire in 2031. Related to GLOPERBA, our licensed patents include U.S. Pat. Nos. 9,907,751, 10,226,423, 10,383,820, and 10,383,821, which relate to liquid colchicine formulations for oral administration and associated methods of use.
U.S. Pat. No.&nbsp;10,226,423 expires in 2037. The remaining patents related to GLOPERBA expire in 2036. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that we have certain <FONT
STYLE="white-space:nowrap">know-how</FONT> and trade secrets relating to our technology and product candidates. We rely on trade secrets to protect certain aspects of our technology related to our current and future product candidates. However,
trade secrets can be difficult to protect. We seek to protect our trade secrets, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, service providers, and contractors. We also seek to preserve
the integrity and confidentiality of our data and trade secrets </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by maintaining physical security of our premises and physical and electronic security of our information technology systems. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks, Trade Secrets and Other Proprietary Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file trademark applications and pursue registrations in the United States and abroad when appropriate. We own registered U.S. trademarks for
the marks &#147;SCILEX,&#148; &#147;ZTlido&#148; and &#147;RESPONSIBLE BY DESIGN.&#148; We also own pending trademark applications for &#147;SEMNUR PHARMACEUTICALS&#148; and &#147;SEMDEXA&#148; in the United States. We also license the GLOPERBA
trademark as discussed in relation to the Romeg Agreement described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also depend upon the skills, knowledge and experience of
our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> we rely on trade secret protection and confidentiality
agreements to protect our interests. Our policy is to require each of our employees, consultants and advisors to execute a confidentiality and inventions assignment agreement before beginning their employment, consulting or advisory relationship
with us. The agreements generally provide that the individual must keep confidential and not disclose to other parties any confidential information developed or learned by the individual during the course of the individual&#146;s relationship with
us except in limited circumstances. These agreements generally also provide that we will own all inventions conceived by the individual in the course of rendering services to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEMDEXA benefits from our substantial intellectual property portfolio and other technical barriers to entry for potential competitors.
Further, we are a party to an exclusive supply agreement for a proprietary biocompatible excipient with no generic equivalent. Our complex manufacturing process, specialized equipment and <FONT STYLE="white-space:nowrap">know-how</FONT> for sterile
viscous product candidates are also key to our competitive edge. We believe that our competitors will be required to conduct lengthy and costly preclinical and clinical trials to establish products with comparable safety and efficacy to SEMDEXA.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_61"></A>Government Regulation and Product Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States at the federal, state and local levels, and in other countries and jurisdictions, extensively
regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and
reporting, marketing and export and import of products such as those we are marketing and developing. <FONT STYLE="white-space:nowrap">SP-102,</FONT> <FONT STYLE="white-space:nowrap">SP-103,</FONT> <FONT STYLE="white-space:nowrap">SP-104</FONT> and
any other product candidate that we develop must be approved by the FDA or otherwise authorized for marketing before they may be legally marketed in the United States and by the corresponding foreign regulatory agencies before they may be legally
marketed in foreign countries. The processes for obtaining marketing approvals, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial
resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Drug Development Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the FDCA and implementing regulations. Drugs are also subject to other federal, state and
local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial
resources. Failure to comply with the applicable requirements at any time during the product development process, approval process or after approval, may subject an applicant or its products to a variety of administrative or judicial sanctions, such
as inspection scrutiny, the FDA&#146;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or
distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits or civil or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
criminal penalties. The process required by the FDA before a drug may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory
Practices (&#147;GLPs&#148;) or other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an Investigational New Drug Application (&#147;IND&#148;), which must become effective
before human clinical trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an IRB covering each clinical site before each trial may be initiated; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials according to the laws and regulations
pertaining to the conduct of human clinical trials, collectively referred to as GCP requirements to establish the safety and efficacy of the proposed drug for its intended use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an NDA or other marketing application (collectively, an &#147;NDA&#148;), for a proposed
new drug, including its specific formulation and labeling; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug is
produced to assess compliance with the FDA&#146;s cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential FDA audit of the preclinical study and clinical trial sites that generated the data in support of the
NDA; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA prior to any commercial marketing, sale or shipment of the drug.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing novel compounds with potential therapeutic value in humans, the drug candidate enters the preclinical
testing stage, also referred to as preclinical studies. Preclinical studies include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the drug candidate.
The conduct of the preclinical studies must comply with federal laws and requirements including GLPs. The IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, and any available
clinical data or literature, to the FDA as part of the IND. The sponsor will also include a protocol detailing, among other things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the
effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical studies may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA,
unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold within that <FONT STYLE="white-space:nowrap">30-day</FONT> time period. In such a case, the IND
sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns, <FONT
STYLE="white-space:nowrap">non-compliance,</FONT> or for additional reasons. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend
or terminate such trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the drug candidate to healthy subjects or patients with the target
disease under the supervision of qualified investigators, generally physicians not employed by the trial sponsor. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the clinical trial,
subject selection and exclusion criteria, dosing procedures, and the parameters to be used to collect data and to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND, and timely safety reports must be submitted to
the FDA and investigators for suspected adverse reactions that are serious and unexpected. Clinical trials must be conducted in accordance with applicable statutes, the FDA&#146;s regulations and GCP requirements. Further, each clinical trial must
be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to
individuals participating in the clinical trials </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal
representative and must monitor the clinical trial until it is completed. In some instances, additional oversight boards, such as a data safety monitoring board, are required to evaluate interim data and determine whether a study should continue or
be modified or terminated. Information about many clinical trials is required to be publicly reported on www.ClinicalTrials.gov or similar databases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Phase 1</I></B>. The drug is initially introduced into healthy human subjects and tested for safety, dosage
tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently
toxic to ethically administer to healthy volunteers, the initial human testing may be conducted only in patients having the specific disease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Phase 2</I></B>. The drug is evaluated in a limited patient population to identify possible adverse effects
and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule for patients having the specific disease. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Phase 3</I></B>. The drug is administered to an expanded patient population in adequate and well-controlled
clinical trials to generate sufficient data to statistically confirm the safety and efficacy of the product for potential approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of
the product. Generally, at least two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA. In some cases, the FDA may approve a drug based on the results of a single adequate and well-controlled Phase 3
trial for excellent design and which provided highly reliable and statistically strong evidence of important clinical benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval studies, also referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used
to gain additional experience from the treatment of patients in the intended therapeutic indication and may be required by the FDA as part of the approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the status of drug development and results of the clinical trials must be submitted at least annually to the FDA,
and written IND safety reports must be submitted to the FDA and the investigators for suspected adverse reactions that are serious and unexpected (including increased rate of occurrence of such adverse reactions), findings from other studies that
suggest a significant risk in humans exposed to the drug, or any findings from tests in laboratory animals that suggests a significant risk for human subjects or patients. Phase&nbsp;1, Phase 2 and Phase 3 clinical trials may not yield positive
results, or may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research
subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if
the drug has been associated with unexpected serious harm to study subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the development of a new drug, sponsors are given
opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for
the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end of Phase 2 meeting to discuss their
Phase 2 clinical results and present their plans for the Phase 3 clinical trials that they believe will support approval of the new drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the
chemistry and physical characteristics of the drug as well as finalize a process </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug
candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be
conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA Review and Approval Processes
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of product development, preclinical studies and clinical trials for the claimed indications are incorporated into an
NDA. The FDA may grant deferrals for the development and submission of pediatric data or full or partial waivers after the initial submission of a pediatric study plan following an end of Phase 2 meeting. In addition, descriptions of the
manufacturing process and controls, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are also submitted to the FDA as part of an NDA requesting approval to market the product. The submission
of an NDA is subject to the payment of substantial user fees and a waiver of such fees may be obtained under certain limited circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether
the product is being manufactured in accordance with cGMP to assure and preserve the product&#146;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act (&#147;PDUFA&#148;) guidelines that are currently in effect, the FDA
has a goal of ten months from the date of &#147;filing&#148; of a standard, original NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to the FDA because
the FDA has approximately two months to make a &#147;filing&#148; decision after the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to
determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accepting an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The
resubmitted application also is subject to review before the FDA accepts it for filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer applications for novel drug
products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application
should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the drug approval process, the FDA also will determine
whether a REMS is necessary to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without a REMS, if required. A REMS could include medication
guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial
promotion, distribution, prescription or dispensing of products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA will generally inspect the facilities
at which the product is to be manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the
product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP requirements. If the FDA determines that the application, manufacturing process or
manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial
marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as
an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of
the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for
use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require
post-approval studies, referred to as Phase 4 testing, which involves clinical trials designed to further assess a product&#146;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products
that have been commercialized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA administers a number of different programs that enable the agency and sponsors in various ways to expedite the development or agency
review of a new drug product. Among these, the FDA has a fast track designation that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. New drugs are eligible for fast track designation if
they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. As an example of the modified processes available to a fast track product, the
FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and
determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA
programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy
exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority
review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six&nbsp;months of the filing date as compared to ten months for review of other NDAs under its current PDUFA review
goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening
diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier
than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability
or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform additional adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently
requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-use</FONT> submission of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast track designation, priority
review and accelerated approval do not change the standards for approval but may expedite the development or approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Food
and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#147;breakthrough therapies&#148; that may be eligible to receive breakthrough therapy designation. A sponsor may seek the FDA designation of a product
candidate as a &#147;breakthrough therapy&#148; if the product is intended, alone or in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more
intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated
as breakthrough therapy, the FDA will work with the sponsor to expedite the development and review of such drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With passage of the 21st
Century Cures Act in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is
intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The
benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval
based on surrogate or intermediate endpoints. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have obtained fast track designation for SEMDEXA for the treatment of lumbosacral
radicular pain and have applied for breakthrough therapy designation for the treatment of lumbosacral radicular pain based on the <FONT STYLE="white-space:nowrap">top-line</FONT> results obtained from the pivotal Phase 3 trial, which results reflect
achievement of primary and secondary endpoints. We have also obtained fast track designation for <FONT STYLE="white-space:nowrap">SP-103</FONT> for the treatment of acute LBP. We may seek additional designations for SEMDEXA, <FONT
STYLE="white-space:nowrap">SP-103</FONT> or our other product candidates. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the
time period for FDA review or approval will not be shortened. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur
after the product reaches the market. Later discovery of previously unknown risks or problems with a product may result in labeling changes, restrictions on the product or even complete withdrawal of the product from the market. After approval, most
changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Drug manufacturers and other entities involved in the manufacture and
distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and
other laws and regulations. In addition, the FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to
further assess and monitor the product&#146;s safety and effectiveness after commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any drug products for which we receive
FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences or quality issues with the product, providing the FDA with updated safety and efficacy
information, satisfaction of post-approval requirements or commitments, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements. These promotion and advertising requirements include, among other
things, standards for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, prohibitions against promoting drugs for uses, or in patient populations, that are not described in the drug&#146;s
approved labeling, which is known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> use,&#148; rules for conducting industry-sponsored scientific and educational activities, and promotional activities involving the internet. Failure to
comply with post-approval requirements can have negative consequences, including adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties. Although
physicians may prescribe legally available drugs for <FONT STYLE="white-space:nowrap">off-label</FONT> uses, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturers may not market or promote such <FONT STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with the applicable U.S. requirements at any time during the product
development process, approval process or after approval, may subject an applicant, manufacturer or product to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending
applications, withdrawal of an approval, clinical holds on post-approval clinical trials, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of
government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hatch-Waxman Amendments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;505 of the FDCA describes three types of NDAs that may be submitted to request marketing authorization for a new drug, the first
being a 505(b)(1) NDA. A 505(b)(1) NDA is an application that contains full reports of investigations of safety and effectiveness. A 505(b)(2) NDA likewise contains full reports of investigations of safety and effectiveness relevant to a product,
but some of the data are not owned by or licensed to the applicant. Section&nbsp;505(j) establishes an abbreviated approval process for generic versions of approved drug products through the submission of an abbreviated new drug application
(&#147;ANDA&#148;). An ANDA generally provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form, and with the same labeling and route of administration as the listed drug and has been shown
to be bioequivalent to the listed drug. ANDA applicants are required to conduct bioequivalence testing to confirm chemical and therapeutic equivalence to the branded reference drug. Generic versions of drugs can often, and sometimes must, be
substituted by pharmacists under prescriptions written for the branded reference drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A 505(b)(2) NDA is an application that contains
full reports of investigations of safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by or for the applicant, and for which the applicant has not obtained a right of reference.
This regulatory pathway enables the applicant to rely, in part, on the FDA&#146;s findings of safety and efficacy for an existing product, or published literature, in support of its application. Additional preclinical and clinical data may also be
submitted. The FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved, or for any new indication sought by the 505(b)(2) applicant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon submission of an ANDA or a 505(b)(2) NDA, an applicant must certify to the FDA at least one of the following (1)&nbsp;no patent
information on the drug product that is relied upon by the ANDA or 505(b)(2) NDA (known as the reference drug) has been submitted to the FDA; (2)&nbsp;such patent has expired; (3)&nbsp;the date on which such patent expires; or (4)&nbsp;such patent
is invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the drug product for which the ANDA or 505(b)(2) NDA is submitted. This last certification is known as a Paragraph IV Certification. If the NDA holder for the
reference drug or patent owner(s) asserts a patent challenge to the Paragraph IV Certification, the FDA may not approve that application until the earlier of 30&nbsp;months from the receipt of the notice of the Paragraph IV Certification, the
expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#146;s favor or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the <FONT
STYLE="white-space:nowrap">30-month</FONT> stay. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#146;s or patent
owner&#146;s decision to initiate patent litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to, and distinct from the patent protection provisions, the Hatch-Waxman
Amendments establish periods of regulatory exclusivity for certain approved drug products, during which the FDA cannot approve (or in some cases accept) an ANDA or 505(b)(2) application that relies on the branded reference drug. For example, the
holder of an NDA may obtain five years of exclusivity upon approval of a new drug containing a new chemical entity that has not been previously approved by the FDA. The Hatch-Waxman Amendments also provide three years of marketing exclusivity to the
holder of an NDA (including a 505(b)(2) NDA) for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or more new clinical trials (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. This three-year
exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for drugs that include the innovation that required the new clinical data, but generally allows the approval for <FONT STYLE="white-space:nowrap">non-protected</FONT>
characteristics and labeling. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation and Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition,
which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making
the product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA for the drug for the rare disease or condition. After
the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review
and approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or
condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such
approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug
supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication not protected by the exclusive approval, but that could be used <FONT
STYLE="white-space:nowrap">off-label</FONT> in the orphan indication. The FDA also has authority to withdraw exclusive marketing rights if the holder of an approved orphan drug cannot assure the availability of sufficient quantities of the drug
within a reasonable time to meet the needs of patients with the disease or condition for which the drug was designated. Once withdrawn under such circumstances, exclusive approval may not be reinstated for that drug. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-Party Payor Coverage, Pricing and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the
prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, sales of a product will depend, in part, on the extent to which third-party payors provide coverage and establish adequate
reimbursement levels for the product. Third-party payors include government payor programs at the federal and state levels, including Medicare and Medicaid, managed care providers, private health insurers and other organizations. In the United
States, no uniform policy of coverage and reimbursement for products exists among third-party payors. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or
reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
products for a particular indication, and which can change over time. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety
and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or other comparable regulatory approvals.
Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs, in order to be considered as a formulary option. Nonetheless, product candidates may not be considered by individual
payors to be medically necessary or cost-effective. A payor&#146;s decision to provide coverage for a product does not imply that a preferred formulary position or an adequate reimbursement rate will be approved. Further, one payor&#146;s
determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
level of coverage and reimbursement can differ significantly from payor to payor. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to
realize an appropriate return on our investment in product development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of pharmaceuticals continues to generate substantial
governmental and third-party payor interest. We expect that the pharmaceutical industry will experience pricing pressures due to the trend toward managed healthcare, the increasing influence of managed care organizations and additional legislative
proposals. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on
reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit
payments for pharmaceuticals such as our products and the product candidates that we are developing and could adversely affect our net revenue and results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Different pricing and reimbursement schemes exist in other countries. In the European Economic Area (&#147;EEA&#148;) (which is currently
comprised of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein), governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a
large part of the cost of those products to consumers. Some EEA countries operate positive and negative list systems under which some medicinal products are selected for coverage (positive list) and others are explicitly listed as excluded from
reimbursement (negative list). To obtain reimbursement or pricing approval, some of these EEA countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product to currently available therapies. Other
EEA countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result,
increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from <FONT STYLE="white-space:nowrap">low-priced</FONT> markets exert a commercial pressure on pricing within a country.
There can be no assurance that any country that has price controls or reimbursement limitations for products will allow favorable reimbursement and pricing arrangements for any of our products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Healthcare Reform </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
United States there have been, and continue to be, proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of healthcare and, more generally, to reform the U.S. healthcare
system. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the ACA was enacted, which is intended to broaden access to health
insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and
impose additional health policy reforms, and which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impact the U.S. pharmaceutical industry. The ACA, among other things,
(1)&nbsp;subjected therapeutic biologics to potential competition by lower-cost biosimilars by creating a licensure framework for <FONT STYLE="white-space:nowrap">follow-on</FONT> biologic products, (2)&nbsp;prescribed a new methodology by which
rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, (3)&nbsp;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug
Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, (4)&nbsp;established annual nondeductible fees and taxes on manufacturers of certain branded prescription drugs, apportioned among these
entities according to their market share in certain government healthcare programs, (5)&nbsp;established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered
under Medicare Part D, (6)&nbsp;expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability, (7)&nbsp;expanded
the entities eligible for discounts under the 340B Public Health Service Act program, (8)&nbsp;created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research,
along with funding for such research, and (9)&nbsp;established a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug
spending. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial, Congressional and Administrative challenges to certain aspects of the ACA, and
we expect there will be additional challenges and amendments to the ACA in the future. For example, legislation affecting the implementation of certain taxes under the ACA has been signed into law. The TCJA included a provision that repealed,
effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly
referred to as the &#147;individual mandate&#148;. Further, the Bipartisan Budget Act of 2018 (the &#147;BBA&#148;), among other things, amended the ACA, effective January&nbsp;1, 2019, to increase from 50% to 70% the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount that is owned by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans,
commonly referred to as the &#147;donut hole&#148;. On June&nbsp;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148; was
repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January&nbsp;28, 2021, President Biden issued an executive order that initiated a special enrollment period for
purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including
among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, on
August&nbsp;16, 2022, President Biden signed the Inflation Reduction Act of 2022 into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The
Inflation Reduction Act also eliminates the &#147;donut hole&#148; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost through a newly established manufacturer discount program. It is unclear how additional healthcare reform measures of the Biden administration or
other efforts, if any, to modify or invalidate the ACA or its implementing regulations, or portions thereof, will impact our business. Any health care reform measures will likely take time to unfold, and could have an impact on coverage and
reimbursement for healthcare items and services. We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or other policy or the impact of potential legislation or other policy on us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative and administrative changes have been proposed and adopted in the United States since the ACA was enacted to reduce
healthcare expenditures. For example, the Budget Control Act of 2011, among other things, in connection with subsequent legislation, reduced Medicare payments to providers, on average, by 2% per fiscal year. These reductions went into effect on
April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030, with the exception of a temporary suspension from May&nbsp;1, 2020, through May&nbsp;31, 2022, due to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. Moreover, on January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was
signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to
recover overpayments to providers from three to five years. If federal spending is further reduced, anticipated budgetary shortfalls may impact the ability of relevant agencies to continue to function at current levels. Amounts allocated to federal
grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approve research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which
has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient
programs, and reform government program reimbursement methodologies for drug products. At the federal level, these include proposed measures to permit Medicare to negotiate the price of certain drugs, to establish rebates under Medicare Part B and
Part D where the average sales price or the average manufacturer price of a drug respectively increases faster than the pace of inflation and to eliminate the existing manufacturer coverage gap discount program under Part D and replace it with a new
program that would require manufacturer discounts in both the initial and catastrophic phases of the program. On May&nbsp;16, 2019, CMS adopted a final rule that, among other things, will require Part D plans to adopt Real Time Benefit Tools that
are capable of integrating with electronic prescribing or electronic health record systems and have the capability to inform prescribers when lower-cost alternative therapies are available under a beneficiary&#146;s prescription drug benefit.
Similarly, since 2021, Part D Explanation of Benefits transmittals to members are required to inform Part D beneficiaries about drug prices and lower cost therapeutic alternatives. On August&nbsp;16, 2022, President Biden signed into law the
Inflation Reduction Act of 2022, which among other things, contains two specific provisions affecting pricing for drugs and biologics. The first provision allows for CMS to negotiate prices for certain single-source drugs and biologics reimbursed
under Medicare Part&nbsp;B and Part&nbsp;D, beginning with ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part&nbsp;D drugs in 2027, 15 Part&nbsp;B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and
beyond. The legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#147;maximum fair price&#148;
under the law or for taking price increases that exceed inflation. The legislation also caps Medicare beneficiaries&#146; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">annual&nbsp;out-of-pocket&nbsp;drug</FONT></FONT> expenses at
$2,000. The second provision imposes a requirement that pharma manufacturers provide a rebate to Medicare, if the manufacturer increases price at a rate higher than the measured inflation rate. Medicaid has had a rebate program for several years,
but Medicare did not. The intent is to limit price increases. The new rebate applies to drugs covered by Medicare under Part&nbsp;B or Part&nbsp;D . The rebate obligation applies if the average sales price (for Part&nbsp;B) or average manufacturers
price (for Part&nbsp;D) of a single source drug or biologic increases more than the rate of inflation (as measured by the index for urban consumers). The rebate amount is the total number of units sold in Medicare coverage multiplied by the amount
by which the price exceeds the inflation adjusted price. The base year against which the inflation adjustment is measured is 2021. If the price exceeds the inflation adjusted price, the difference is multiplied by the units sold in Medicare and that
amount is to be rebated. A failure to pay the rebate is subject to a penalty of 125% of the original rebate amount. The provision for Part&nbsp;D takes effect in 2022, with rebates to be paid beginning in 2023. The provision for Part&nbsp;B takes
effect in 2023. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts,
restrictions on certain product access and marketing cost disclosure and transparency measures. In some cases, states appear interested in public policy designed to encourage drug importation from other countries and bulk purchasing. Furthermore,
there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in
additional downward pressure on the price that we receive for any approved product, and could seriously harm our future revenue. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments
from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other U.S. Healthcare Laws and Compliance Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the
FDA, including the Centers for Medicare and Medicaid Services, other divisions of the United States Department of Health and Human Services (<I>e.g.</I>, the Office of Inspector General), the United States Department of Justice and individual United
States Attorney offices within the Department of Justice, and state and local governments. For example, various activities, including but not limited to sales, marketing and scientific/educational grant programs, must comply with the anti-fraud and
abuse provisions of the Social Security Act, the federal Anti-Kickback Statute, the federal False Claims Act and similar state laws, each as amended. Failure to comply with such requirements could potentially result in substantial penalties to us.
Even if we structure our programs with the intent of compliance with such laws, there can be no certainty that we would not need to defend against enforcement or litigation, in light of the fact that there is significant enforcement interest in
pharmaceutical companies in the United States, and some of the applicable laws are quite broad in scope. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback
Statute prohibits any person, including a pharmaceutical manufacturer (or a party acting on its behalf), from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce or reward either the
referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. This statute has been interpreted to apply
to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. The term &#147;remuneration&#148; is not defined in the federal Anti-Kickback Statute and has been broadly interpreted
to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests and providing anything at less than its fair market
value. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain business arrangements from prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve remuneration intended to
induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from federal Anti-Kickback
Statute liability. The government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of this statute or specific intent to violate it. In addition, the ACA provides that the government
may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below) or the civil monetary
penalties statute, which imposes fines against any person who is determined to have presented or caused to be presented claims to a federal healthcare program that the person knows or should know is for an item or service that was not provided as
claimed or is false or fraudulent. Additionally, many states have adopted laws similar to the federal Anti-Kickback Statute, and some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any
third-party payor, not only the Medicare and Medicaid programs in at least some cases, and do not contain safe harbors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal False
Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment of government funds, or knowingly makes, uses, or causes to be made or used a false
statement material to a false or fraudulent claim, or knowingly conceals or knowingly and improperly avoids, or decreases an obligation to pay money to the government. The qui tam provisions of the False Claims Act allow a private individual to
bring civil actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government and to share in any monetary recovery. In recent years, the number of suits brought by private individuals has
increased dramatically. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payor and not merely a federal healthcare program.
There are many potential bases for liability under the False Claims Act. Liability arises, primarily, when an entity knowingly submits, or causes another to submit, a false claim for reimbursement to the federal government. The False Claims Act has
been used to assert liability on the basis of inadequate care, kickbacks and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, improper promotion of <FONT STYLE="white-space:nowrap">off-label</FONT>
uses (<I>i.e.</I>, uses not expressly approved by the FDA in a drug&#146;s label), and allegations as to misrepresentations with respect to the services rendered. Our activities relating to the reporting of discount and rebate information and other
information affecting federal, state and third-party reimbursement of our products, and the sale and marketing of our products and our service arrangements or data purchases, among other activities, may be subject to scrutiny under these laws. We
are unable to predict whether we would be subject to actions under the False Claims Act or a similar state law, or the impact of such actions. However, the cost of defending such claims, as well as any sanctions imposed, could adversely affect our
financial performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The healthcare fraud provisions under the HIPAA impose criminal liability for, among other things, knowingly and
willfully executing, or attempting to execute, a scheme to defraud any health care benefit program, including private third-party payors, or falsifying or covering up a material fact or making any materially false or fraudulent statement in
connection with the delivery of or payment for health care benefits, items or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to, or our marketing activities
may be limited by, data privacy and security regulation by both the federal government and the states in which we conduct our business. For example, HIPAA and its implementing regulations, impose privacy, security and breach reporting obligations
with respect to individually identifiable health information upon &#147;covered entities&#148; (healthcare providers, health plans and healthcare clearinghouses), and their respective business associates, certain individuals or entities that create,
receive, maintain or transmit protected health information in connection with providing a specified service or performing a function for or on behalf of a covered entity. The FTC also sets expectations that failing to take appropriate steps to keep
consumers&#146; personal information secure, or failing to provide a level of security commensurate to promises made to an individual about the security of their personal information (such as in a privacy notice) may constitute unfair or deceptive
acts or practices in violation of Section&nbsp;5(a) of the FTC Act. The FTC expects a company&#146;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and
complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. With respect to privacy, the FTC
also sets expectations that companies honor the privacy promises made to individuals about how the company handles consumers&#146; personal information; any failure to honor promises, such as the statements made in a privacy policy or on a website,
may also constitute unfair or deceptive acts or practices in violation of the FTC Act. While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce promises as it interprets them, and events that we
cannot fully control, such as data breaches, may be result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions. Further, various states have implemented similar privacy laws and
regulations that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. California has also recently adopted the CCPA. The CCPA established a new privacy framework for
covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the State of California, imposing special rules on the collection of consumer data from minors, and creating a new
and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches of certain personal information. Penalties for violations
of the CCPA include civil penalties. In addition, a new California privacy law, CPRA, was passed by California votes on November&nbsp;3, 2020, introduced significant amendments to the CCPA and established and funded a dedicated California privacy
regulator, the CPPA. The amendments introduced by the CPRA are scheduled to take effect on January&nbsp;1, 2023 (with certain provisions having retroactive effect to January&nbsp;1, 2022). Further, a new Virginia privacy law, the VCDPA, was signed
into law on March&nbsp;2, 2021 and is also scheduled to take effect on January&nbsp;1, 2023, and the Colorado Privacy Act (&#147;CPA&#148;) will take effect on July&nbsp;1, 2023. The VCDPA and CPA will impose many similar obligations regarding the
processing and storing of personal information as the CCPA and the CPRA. Other states in the United States are considering omnibus privacy legislation, and industry organizations regularly adopt and advocate for new standards in these areas. The
uncertainty, ambiguity, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
complexity and potential inconsistency surrounding the implementation and interpretation of CCPA and other enacted or potential laws in other states exemplify the vulnerability of our business to
the evolving regulatory environment related to the privacy, security and confidentiality of personal information and protected health information. We may be subject to fines, penalties, or private actions in the event of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with such laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our activities outside of the U.S. implicate local and national data
protection standards, impose additional compliance requirements and generate additional risks of enforcement for <FONT STYLE="white-space:nowrap">non-compliance.</FONT> The European Union&#146;s GDPR which imposes fines of up to EUR 20&nbsp;million
or 4% of the annual global revenue of a noncompliant company, whichever is greater, and other data protection, privacy and similar national, state/ provincial and local laws may also restrict the access, use and disclosure of patient health
information abroad. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws, to protect against security breaches and hackers, or to alleviate problems caused
by such breaches. Compliance with these laws is difficult, constantly evolving, time consuming, and requires a flexible privacy framework and substantial resources. Compliance efforts will likely be an increasing and substantial cost in the future.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for
which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments or other transfers of value made to physicians and teaching
hospitals, as well as ownership and investment interests held by physicians and their immediate family members. In addition to this federal requirement, a number of individual states and foreign jurisdictions require detailed reporting and often
public disclosures concerning transfers of value to physicians, other health care providers and family members. Effective January&nbsp;1, 2022, these reporting obligations are extended to include transfers of value made to certain <FONT
STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants and nurse practitioners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with such
requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these laws result in the public disclosure of various types of payments and relationships. Several states have enacted legislation
requiring pharmaceutical companies to, among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, or
register their sales representatives, as well as prohibiting pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and prohibiting certain other sales
and marketing practices. These laws may affect our sales, marketing and other promotional activities by imposing administrative and compliance burdens on us. If we fail to track and report as required by these laws or otherwise comply with these
laws, we could be subject to the penalty provisions of the pertinent state and federal authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where our activities involve foreign
government officials, they may also potentially be subject to the FCPA. If we seek to have a product paid for with federal funds under the Medicaid programs or Medicare Part B, various obligations, including government price reporting, are required
under the Medicaid rebate provisions of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Health Care Act of 1992, each as amended, which generally require products to be offered at substantial rebates/discounts to such programs and
certain purchasers. Government price reporting may also be required with respect to average sales price, which serves as the basis of reimbursement under Medicare Part B. In order to distribute products commercially, we must comply with state laws
that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors
have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to
adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Many of our current as well as possible future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
activities are potentially subject to federal and state consumer protection and unfair competition laws. We must also comply with laws that require clinical trial registration and reporting of
clinical trial results on the publicly available clinical trial databank maintained by the National Institutes of Health at <U>www.ClinicalTrials.gov</U>. We are subject to various environmental, health and safety regulations, including those
governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous substances. From time to time, and in the future, our operations may involve the use of hazardous materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our
business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be
subject to penalties, including criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare programs, injunctions, recall or seizure of products, total or partial suspension
of production, denial or withdrawal of <FONT STYLE="white-space:nowrap">pre-marketing</FONT> product approvals, private &#147;qui tam&#148; actions brought by individual whistleblowers in the name of the government or refusal to allow us to enter
into supply contracts, including government contracts, integrity oversight and reporting obligations to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> and the curtailment or restructuring of our operations, any of
which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for
instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Hatch-Waxman Exclusivity</I>. Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain
applications of other companies seeking to reference another company&#146;s NDA. If the new drug is a new chemical entity subject to an NDA, the FDCA provides a five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing
exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is
the molecule or ion responsible for the action of the drug substance. This definition is currently under FDA review. During the exclusivity period, the FDA may not accept for review an ANDA or a Section&nbsp;505(b)(2) NDA submitted by another
company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, such an application may be submitted after four years if it contains a certification of
patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement</FONT> to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing
NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, such as new indications, dosages or strengths of an
existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year
exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical
trials necessary to demonstrate safety and effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pediatric Exclusivity</I>. Pediatric exclusivity is another type of
regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to any existing exclusivity period or patent term. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity may be granted by the FDA
based on the completion of a pediatric clinical trial in accordance with provisions of the FDCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Europe/Rest of World Government Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other
things, clinical trials, pricing and reimbursement, anti-bribery, advertising and promotion, data privacy and security and any commercial sales and distribution of our future products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries
prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior
to the commencement of human clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, for example, a clinical trial application (&#147;CTA&#148;) must be submitted
to each country&#146;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with the EU Clinical Trials Directive 2001/20/EC (the &#147;Clinical Trials
Directive&#148;) and the related national implementing provisions of the relevant individual EEA country&#146;s requirements, the clinical trial described in that CTA may proceed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (the &#147;Clinical Trials Regulation&#148;) was adopted. The Clincial
Trials Regulation entered into force on January&nbsp;31, 2022. The Clinical Trials Regulation is directly applicable in all the EEA countries, repealing the current Clinical Trials Directive. The new Clinical Trials Regulation allows a sponsor to
start and conduct a clinical trial in accordance with the Clinical Trials Directive during a transitional period of one year after the application date, i.e. January&nbsp;31, 2022. The transition period for the trials ongoing at the moment of
applicability will be a maximum of 3 years after the date of application of the Clinical Trials Regulation. Clinical trials authorized under the current Clinical Trials Directive before January&nbsp;31, 2023 can continue to be conducted under the
Clinical Trials Directive until January&nbsp;31, 2025. An application to transition ongoing trials from the current Clinical Trials Directive to the new Clinical Trials Regulation will need to be submitted and authorized in time before the end of
the transitional period. The new Clinical Trials Regulation is intended to simplify and streamline the approval of clinical trials in the EEA. The main characteristics of the regulation include: a streamlined application procedure through a single
entry point, the &#147;EU portal&#148;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications
for clinical trials, which is divided into two parts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other countries outside of the EEA, such as countries in Eastern Europe, Latin
America or Asia, the requirements governing the conduct of clinical trials vary from country to country. Internationally, clinical trials are generally required to be conducted in accordance with GCP, applicable regulatory requirements of each
jurisdiction and the medical ethics principles that have their origins in the Declaration of Helsinki. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, medicinal products can
be commercialized only after obtaining a Marketing Authorization (&#147;MA&#148;). There are several procedures for requesting marketing authorization which can be more efficient than applying for authorization on a
<FONT STYLE="white-space:nowrap">country-by-country</FONT> basis. There is a &#147;centralized&#148; procedure allowing submission of a single marketing authorization application to the European Medicines Agency (the &#147;EMA&#148;). If the EMA
issues a positive opinion, the European Commission will grant a centralized marketing authorization that is valid in all EEA countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The &#147;centralized&#148; procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal
products, and medicinal products containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The &#147;centralized&#148; procedure is optional for products
containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EEA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is also a &#147;decentralized&#148; procedure allowing companies to file identical applications to several EEA countries simultaneously
for product candidates that have not yet been authorized in any EEA country and a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;mutual recognition&#148; procedure allowing companies that have a product already authorized in one EEA country to apply for that authorization to be recognized by the competent authorities
in other EEA countries. Under the &#147;decentralized&#148; procedure, an identical dossier is submitted to the competent authorities of each of the EEA countries in which the MA is sought, one of which is selected by the applicant as the Reference
Member State (&#147;RMS&#148;). If the RMS proposes to authorize the product, and the other EEA countries do not raise objections, the product is authorized in all the EEA countries where the authorization was sought. Before granting the MA, the EMA
or the competent authorities of the EEA countries make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In many countries outside the United States, procedures to obtain price approvals, coverage and reimbursement can take considerable time after
the receipt of a MA. Many EEA countries periodically review their reimbursement of medicinal products, which could have an adverse impact on reimbursement status. In addition, we expect that legislators, policymakers and healthcare insurance funds
in the EEA countries will continue to propose and implement cost-containing measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative to branded
products, and/or branded products available through parallel import to keep healthcare costs down. Moreover, in order to obtain reimbursement for our products in some EEA countries, including some EU Member States, we may be required to compile
additional data comparing the cost-effectiveness of our products to other available therapies. Health Technology Assessment (&#147;HTA&#148;) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures
in some EEA countries, including those representing the larger markets. The HTA process, which is currently governed by national laws in each EEA country, is the procedure to assess therapeutic, economic and societal impact of a given medicinal
product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EEA countries. The
extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EEA countries, although the HTA Regulation, which aims to harmonize the clinical benefit assessment of HTA
across the EEA, will apply from January&nbsp;12, 2025. If we are unable to maintain favorable pricing and reimbursement status in EEA countries that represent significant markets, our anticipated revenue from and growth prospects for our products in
the EEA could be negatively affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, interactions between pharmaceutical companies and physicians are also
governed by strict laws, such as national anti-bribery laws of EEA countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#146; codes of professional conduct. Failure to comply with these
requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, the
advertising and promotion of our products are subject to laws governing promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. For example, applicable laws require that
promotional materials and advertising in relation to medicinal products comply with the product&#146;s Summary of Product Characteristics (&#147;SmPC&#148;), as approved by the competent authorities in connection with a marketing authorization
approval. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered <FONT STYLE="white-space:nowrap">off-label</FONT>
and is prohibited in the EEA. Other applicable laws at the EEA level and in the individual EU Member States also apply to the advertising and promotion of medicinal products, including laws that prohibit the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising of prescription-only medicinal products and further limit or restrict the advertising and promotion of our products to the general public and to health care professionals.
Violations of the rules governing the promotion of medicinal products in the EEA could be penalized by administrative measures, fines and imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to data privacy and security regulations in the United States, we may be subject to, or our marketing activities may be limited
by, data privacy and security regulations in the EEA where the legislative and regulatory landscape continues to evolve. There has been increased attention to privacy and data security issues that could potentially affect our business, including the
GDPR which imposes strict obligations on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
processing of personal data, including relating to the transfer of personal data from the EEA to third countries such as the United States. If we act in violation of the GDPR we may face
significant penalties of up to 10,000,000 Euros or up to 2% of our total worldwide annual turnover for certain violations, or up to 20,000,000 Euros or up to 4% of our total worldwide annual turnover for more serious violations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These data privacy and security regulations, including the GDPR, generally restrict the transfer of personal data from Europe, including the
EEA, United Kingdom and Switzerland, to the United States and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data. One of the primary safeguards allowing U.S.
companies to import personal data from Europe had been certification to the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield and <FONT STYLE="white-space:nowrap">Swiss-U.S.</FONT> Privacy Shield frameworks administered by the U.S.
Department of Commerce. However, the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union (the &#147;CJEU&#148;) in a case known colloquially as &#147;Schrems
II.&#148; Following this decision, the Swiss Federal Data Protection and Information Commissioner (the &#147;FDPIC&#148;) announced that the <FONT STYLE="white-space:nowrap">Swiss-U.S.</FONT> Privacy Shield does not provide adequate safeguards for
the purposes of personal data transfers from Switzerland to the United States. While the FDPIC does not have authority to invalidate the <FONT STYLE="white-space:nowrap">Swiss-U.S.</FONT> Privacy Shield regime, the FDPIC&#146;s announcement casts
doubt on the viability of the <FONT STYLE="white-space:nowrap">Swiss-U.S.</FONT> Privacy Shield as a future compliance mechanism for <FONT STYLE="white-space:nowrap">Swiss-U.S.</FONT> data transfers. The CJEU&#146;s decision in Schrems II also
raised questions about whether one of the primary alternatives to the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield, namely, the European Commission&#146;s Standard Contractual Clauses, can lawfully be used for personal data
transfers from Europe to the United States or other third countries that are not the subject of an adequacy decision of the European Commission. While the CJEU upheld the adequacy of the Standard Contractual Clauses in principle in Schrems&nbsp;II,
it made clear that reliance on those Clauses alone may not necessarily be sufficient in all circumstances. Use of the Standard Contractual Clauses must now be assessed on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis taking into account the legal regime applicable in the destination country, in particular regarding applicable surveillance laws and relevant rights
of individuals with respect to the transferred data. In the context of any given transfer, where the legal regime applicable in the destination country may or does conflict with the intended operation of the Standard Contractual Clauses and/or
applicable European law, the decision in Schrems II and subsequent draft guidance from the European Data Protection Board (the &#147;EDPB&#148;) would require the parties to that transfer to implement certain supplementary technical, organizational
and/or contractual measures to rely on the Standard Contractual Clauses as a compliant &#147;transfer mechanism.&#148; However, the draft guidance from the EDPB on such supplementary technical, organizational and/or contractual measures appears to
conclude that no combination of such measures could be sufficient to allow effective reliance on the Standard Contractual Clauses in the context of transfers of personal data &#147;in the clear&#148; to recipients in countries where the power
granted to public authorities to access the transferred data goes beyond that which is &#147;necessary and proportionate in a democratic society&#148; &#151; which may, following the CJEU&#146;s conclusions in Schrems II on relevant powers of United
States public authorities and commentary in that draft EDPB guidance, include the United States in certain circumstances (e.g., where Section&nbsp;702 of the US Foreign Intelligence Surveillance Act applies). At present, there are few, if any,
viable alternatives to the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield and the Standard Contractual Clauses. However, the CJEU recently invalidated the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield. The decision
in Schrems II also affects transfers from the United Kingdom to the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such, if we are unable to implement a valid
solution for personal data transfers from Europe, including, for example, obtaining individuals&#146; explicit consent to transfer their personal data from Europe to the United States or other countries, we will face increased exposure to regulatory
actions, substantial fines and injunctions against processing personal data from Europe. Inability to import personal data from Europe may also restrict our clinical trials activities in Europe; limit our ability to collaborate with contract
research organizations as well as other service providers, contractors and other companies subject to European data privacy and security laws; and require us to increase our data processing capabilities in Europe at significant expense.
Additionally, other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services
and operating our business. The types of challenges we face in Europe will likely also arise in other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
jurisdictions that adopt laws similar in construction to the GDPR or regulatory frameworks of equivalent complexity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or
withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_62"></A>Employees and Human Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, we had approximately 85 full-time employees, including five employees who have M.D.s or Ph.D.s. Within our
workforce, six employees were primarily engaged in research and development, 70 were primarily engaged in sales and marketing and nine were primarily engaged in general management and administration. None of our employees are represented by labor
unions or covered by collective bargaining agreements. We believe that we maintain good relationships with our employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We focus on
identifying, attracting, incentivizing, developing and retaining an exceptional team of highly talented and motivated employees to support our current product pipeline and future business goals. In order to drive innovation, we continuously improve
our human capital management strategies and find ways to foster engagement and growth within our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We regularly benchmark total
rewards we provide against our industry peers to ensure we offer competitive compensation and benefits packages to our employees and potential new hires. The principal purposes of our equity and cash incentive plans are to attract, retain and reward
selected personnel through the granting of stock-based and cash-based compensation awards, as well as provide our employees with the opportunity to participate in our employee stock purchase plan, in order to increase stockholder value and the
success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. We strive to build a diverse environment where our employees can thrive and one that inspires exceptional contributions and
professional and personal development in order to achieve our vision to become the leading pain management company that can have a transformative impact on patients&#146; lives. The success of our business is fundamentally connected to the
well-being, health and safety of our employees. In an effort to protect the health and safety of our employees, we took proactive action from the earliest signs of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, which included
implementing social distancing policies at our facilities, facilitating remote working arrangements, requiring proof of vaccination or acceptable exemption, and imposing employee travel restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to continue to develop our efforts related to attracting, retaining and motivating our workforce as we grow and develop. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_63"></A>Facilities and Properties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive office is currently located in Palo Alto, California, and consists of approximately 6,000 square feet of leased office
space. The lease term expires in October 2024. We also sublease office space in San Diego, California. We believe our facilities are adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate
space for our operations. We believe appropriate additional or alternative space will be available on commercially reasonable terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_64">
</A>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we may become involved in various legal proceedings, including those that may arise in the
ordinary course of business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;23, 2021, we filed an action in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S.
LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC
patch products (the &#147;Sanofi-Aventis&nbsp;&amp; Hisamitsu Litigation&#148;). This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their
respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly our claims, but which motions the court has largely rejected. Discovery is proceeding. The case is currently scheduled for trial to
begin on July&nbsp;24, 2023. We cannot make any predictions about the outcome in this matter or the timing thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Former Employee Litigation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;12, 2021, we filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex
Pharma, and Virpax Pharmaceuticals, Inc. (&#147;Virpax&#148;), a company now headed by Mr.&nbsp;Mack, alleging, among other things, breach by Mr.&nbsp;Mack of his <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement with us, breach of
fiduciary duty, and tortious interference by Virpax with that <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement (the &#147;Former Employee Litigation&#148;). This lawsuit seeks, among other relief, damages and an injunction enjoining
Mr.&nbsp;Mack from further violating his <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement and enjoining Virpax from tortiously interfering with Mr.&nbsp;Mack&#146;s <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement. The case
was tried from September&nbsp;12, 2022 to September&nbsp;14, 2022. Post-trial briefing is underway and closing arguments remain to be concluded. We cannot make any predictions about the outcome in this matter or the timing thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido Patent Litigation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
June&nbsp;22, 2022, we filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc. (together, &#147;Aveva&#148;) in the U.S. District Court for the Southern District of Florida (the &#147;Aveva Patent
Litigation&#148;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#147;ZTlido Patents&#148;). The Aveva Patent Litigation was initiated following the submission by Aveva, in accordance with the procedures set out in
the Hatch-Waxman Act, of an ANDA. Aveva&#146;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. We are
seeking, among other relief, an order that the effective date of any FDA approval of Aveva&#146;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&nbsp;10, 2031, and such
further and other relief as the court may deem appropriate. Aveva is subject to a <FONT STYLE="white-space:nowrap">30-month</FONT> stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than
November&nbsp;11, 2024. Trial in the Aveva Patent Litigation has not yet been scheduled. We cannot make any predictions about the final outcome of this matter or the timing thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_65"></A>Our Corporate History </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex was incorporated in Delaware in February 2019 for the purpose of effecting a corporate reorganization. On March&nbsp;18, 2019,
Legacy Scilex entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharma pursuant to which Legacy Scilex acquired 100% of the outstanding shares of capital stock of Scilex
Pharma in exchange for shares of Legacy Scilex Common Stock (such transaction, the &#147;Contribution&#148;). Pursuant to the Contribution and Loan Agreement, Sorrento provided Legacy Scilex with a loan with an initial principal amount of
$16.5&nbsp;million in the form of a note payable, which loan was used to fund the acquisition of Semnur. Concurrently therewith, Legacy Scilex entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., Legacy Scilex&#146;s
prior wholly owned subsidiary, Fortis Advisors LLC, solely as representative of the holders of Semnur equity, and Sorrento, for limited purposes (as amended, the &#147;Semnur Merger Agreement&#148;). Pursuant to the Semnur Merger Agreement, Sigma
Merger Sub, Inc. merged with and into Semnur (such transaction, the &#147;Semnur Merger&#148;), with Semnur surviving the Semnur Merger as Legacy Scilex&#146;s wholly owned subsidiary. As a result of the Contribution and the Semnur Merger, Scilex
Pharma and Semnur became Legacy Scilex&#146;s wholly owned subsidiaries. Prior to the Contribution and the Semnur Merger, operations of Legacy Scilex were conducted through Scilex Pharma, which was formed in September 2012. Semnur was formed in June
2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the JOBS Act. As an emerging
growth company, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation
requirements of Section&nbsp;
404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_66"></A>Website </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our website address is <I>www.scilexholding.com</I>. We do not incorporate the information on, or accessible through, our website into this
prospectus, and you should not consider any information on, or accessible through, our website as part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_67"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth certain information, as of the date of this prospectus, concerning the persons who are serving as our directors and
executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_68"></A>Executive Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the name, age and position of each of our directors and executive officers, as of December&nbsp;31, 2022. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="60%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Position(s)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Officers</I>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer, President and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Executive Chairperson and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth A. Czerepak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> Directors</I>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura J. Hamill<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D.<SUP
STYLE="font-size:75%; vertical-align:top">(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lemus<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy Thompson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Jaisim
Shah. </I></B>Mr.&nbsp;Shah has served as our Chief Executive Officer and President and a member of our Board since November&nbsp;10, 2022. Mr.&nbsp;Shah has also served as Legacy Scilex&#146;s President, Chief Executive Officer and a board member
since March 2019. He has more than 25 years of global biopharma experience, including over 15&nbsp;years in senior management leading business development, commercial operations, investor relations, marketing and medical affairs. He also served as
the Chief Executive Officer and a board member of Semnur from its inception in 2013 until its acquisition by Scilex in March 2019. Mr.&nbsp;Shah has served on the board of directors of Scilex Pharma since November 2016. Prior to Semnur,
Mr.&nbsp;Shah was a consultant to several businesses, including Sorrento Therapeutics, Inc., a publicly traded company, and was the Chief Business Officer of Elevation Pharmaceuticals, Inc., where Mr.&nbsp;Shah led a successful sale of Elevation to
Sunovion Pharmaceuticals Inc. in September 2012. Prior to Elevation, Mr.&nbsp;Shah was president of Zelos Therapeutics, Inc., where he focused on financing and business development. Prior to Zelos, Mr.&nbsp;Shah was the Senior Vice President and
Chief Business Officer at CytRx Corporation, a biopharmaceutical company. Previously, Mr.&nbsp;Shah was Chief Business Officer at Facet Biotech Corporation and PDL BioPharma, Inc., where he completed numerous licensing/ partnering and strategic
transactions with pharmaceutical and biotech companies. Prior to PDL, Mr.&nbsp;Shah was at Bristol-Myers Squibb, most recently as Vice President of Global Marketing where he received the &#147;President&#146;s Award&#148; for completing one of the
most significant collaborations in the company&#146;s history. Previously, Mr.&nbsp;Shah was at F. <FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche AG in international marketing and was global business leader for corporate alliances with
Genentech, Inc. and IDEC Corporation. Mr.&nbsp;Shah previously served as a director of Celularity Inc. from June 2017 to July 2021. He has served as a director of Sorrento Therapeutics, Inc., a publicly traded company, since September 2013.
Mr.&nbsp;Shah holds a M.A. in Economics from the University of Akron and a M.B.A. from Oklahoma University. We believe that Mr.&nbsp;Shah&#146;s extensive operational, executive and business development experience qualifies him to serve on our
Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Henry Ji, Ph.D. </I></B>Dr.&nbsp;Ji has served as our Executive Chairperson and a
member of our Board since November&nbsp;10, 2022. Prior to that, he served as Legacy Scilex&#146;s Executive Chairperson and a board member from March 2019 to November 2022. Dr.&nbsp;Ji has served on the board of directors of Scilex Pharma since
November 2016 and he served as the Chief Executive Officer of Scilex Pharma from November 2016 to March 2019. He <FONT STYLE="white-space:nowrap">co-founded</FONT> and has served as a director of Sorrento Therapeutics, Inc., a publicly traded
company, since January&nbsp;2006, served as its Chief Scientific Officer from November 2008 to September 2012, as its Interim Chief Executive Officer from April 2011 to September 2012, as its Secretary from September 2009 to June 2011, as its Chief
Executive Officer and President since September 2012 and as Chairman of its board of directors since August 2017. In 2002, Dr.&nbsp;Ji founded BioVintage, Inc., a research and development company focusing on innovative life sciences technology and
product development, and has served as its President since 2002. From 2001 to 2002, Dr.&nbsp;Ji served as Vice President of CombiMatrix Corporation, a publicly-traded biotechnology company that develops proprietary technologies, including products
and services in the areas of drug development, genetic analysis, molecular diagnostics and nanotechnology. During his tenure at CombiMatrix, Dr.&nbsp;Ji was responsible for strategic technology alliances with biopharmaceutical companies. From 1999
to 2001, Dr.&nbsp;Ji served as Director of Business Development, and in 2001 as Vice President of Stratagene Corporation (later acquired by Agilent Technologies, Inc.) where he was responsible for novel technology and product licensing and
development. In 1997, Dr.&nbsp;Ji <FONT STYLE="white-space:nowrap">co-founded</FONT> Stratagene Genomics, Inc., a wholly owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until
1999. Dr.&nbsp;Ji previously served as a director of Celularity Inc. from June 2017 to July 2021. Dr.&nbsp;Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of Sorrento&#146;s
intellectual property. Dr.&nbsp;Ji has a Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University. Dr.&nbsp;Ji has demonstrated significant leadership skills as President and Chief Executive
Officer of Stratagene Genomics, Inc. and Vice President of CombiMatrix Corporation and Stratagene Corporation and brings more than 20 years of biotechnology and biopharmaceutical experience to his position on the Scilex Board. We believe that
Dr.&nbsp;Ji&#146;s extensive knowledge of the industry in which we operate allows him to bring to our Board a broad understanding of the operational and strategic issues we face. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Elizabeth A. Czerepak</I></B>. Ms.&nbsp;Czerepak has served as our Executive Vice President, Chief Business Officer, Chief Financial
Officer and Secretary since November&nbsp;10, 2022. Prior to that, she served on the Legacy Scilex Board from September 2019 to October 2020 and on the board of directors of Sorrento from October 2021 to May 2022. Ms.&nbsp;Czerepak has over 35 years
of experience in big pharma, biotechnology and venture capital. Since September 2020, she has served as the Chief Financial Officer of BeyondSpring Inc., a global biopharmaceutical company focused on developing innovative immuno-oncology cancer
therapies. From May&nbsp;2018 to January 2020, Ms.&nbsp;Czerepak served as the Chief Financial Officer and the Chief Business Officer of Genevant Sciences, Inc., a technology-focused lipid nanoparticle delivery company, From 2015 to 2018 she served
as the Chief Financial Officer and Executive Vice President of Corporate Development of Altimmune, Inc., a clinical stage vaccines company, and from 2014 to 2015, she served as the Chief Financial Officer and the Chief Business Officer of Isarna
Therapeutics Inc., which develops selective transforming growth factor beta inhibitors for cancer, ophthalmic and fibrotic diseases. From 2011 to 2014, Ms.&nbsp;Czerepak served as the Chief Financial Officer, Secretary, Principal Accounting Officer
and Head of Human Resources at Cancer Genetics, Inc., a company that develops and commercializes molecular diagnostics. Prior to that, she served as a Managing Director at JPMorgan Chase&nbsp;&amp; Co. and Bear, Stearns&nbsp;&amp; Co., a General
Partner at Bear Stearns Health Innoventures L.P., a venture capital fund and as a NASD (now FINRA) Registered Representative (Series 7 and Series 63). Since February 2020, Ms.&nbsp;Czerepak has served as a director and chair of the audit committee
of Delcath Systems, Inc., an interventional oncology company focused on the treatment of liver cancer. Ms.&nbsp;Czerepak previously served on the board of directors of Spectrum Pharmaceuticals, Inc. from June 2019 to December 2020. She holds a B.A.
magna cum laude in Spanish and Mathematics Education from Marshall University and a M.B.A. from Rutgers University in 1982. In 2020, Ms.&nbsp;Czerepak earned a Corporate Director Certificate from Harvard Business School. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dorman Followwill</I></B>. Mr.&nbsp;Followwill has served as a member of our Board since November&nbsp;10, 2022. Prior to that, he served
as a director of Legacy Scilex from April 2022 to November 2022, as a director of Sorrento since October 2017 and as its lead independent director since August 2020. Mr.&nbsp;Followwill was Senior Partner of Transformational Health at
Frost&nbsp;&amp; Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, from 2016 to September 2020. Prior to that time, he served in various roles
at Frost&nbsp;&amp; Sullivan, including Partner on the Executive Committee managing the P&amp;L of the business in Europe, Israel and Africa, and Partner overseeing the Healthcare and Life Sciences business in North America, since initially joining
Frost&nbsp;&amp; Sullivan to help found the Consulting practice in January 1988. Mr.&nbsp;Followwill has more than 30 years of organizational leadership and management consulting experience, having worked on hundreds of consulting projects across
all major regions and across multiple industry sectors, each project focused around the strategic imperative of growth. He holds a B.A. from Stanford University in The Management of Organizations. We believe that Mr.&nbsp;Followwill&#146;s extensive
knowledge and understanding of the healthcare and life sciences industries qualify him to serve on our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Laura J. Hamill.
</I></B>Ms.&nbsp;Hamill has served as a member of our Board since November&nbsp;10, 2022. Prior to that, she served as a director of Legacy Scilex from April 2022 to November 2022 and has extensive experience in the biopharmaceutical industry, with
over 30 years of global commercial operational roles in a variety of executive leadership positions. Since <FONT STYLE="white-space:nowrap">mid-2019,</FONT> Ms.&nbsp;Hamill has served as the founder and a consultant at Hamill Advisory Group, LLC.
From September 2018 to July 2019, Ms.&nbsp;Hamill served as the Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc., a research-based biopharmaceutical company, where she was responsible for leading the company&#146;s
global commercial strategic direction and delivering annual revenue of $20&nbsp;billion. Prior to joining Gilead, Ms.&nbsp;Hamill held a number of U.S. and international executive positions at Amgen Corporation, a biotechnology company focused on
discovering and delivering innovative human therapeutics, from July 2000 to August 2018, most recently as Senior Vice President, U.S. Commercial Operations. During her time at Amgen, Ms.&nbsp;Hamill established the company&#146;s intercontinental
region and managed the company&#146;s international marketing and business operations while living abroad in Switzerland for three years. She also served as a member of the company&#146;s corporate governance team, such as business development,
global commercial operations, the Amgen foundation and chair for the company&#146;s Senior Women&#146;s Leadership Council. In addition, Ms.&nbsp;Hamill previously held a variety of executive roles in the biopharmaceutical industry, including
positions at Klemtner Inc. and F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche AG. Ms.&nbsp;Hamill has served on the board of directors of a number of public companies, including AnaptysBio, Inc. since September 2019, <FONT
STYLE="white-space:nowrap">Y-mAbs</FONT> Therapeutics, Inc. since April 2020, Pardes Biosciences, Inc. since August 2021 and BB Biotech AG since March 2022. She previously served as a director at Acceleron Pharma Inc. (acquired by Merck) from
September 2020 to December 2021. Ms.&nbsp;Hamill holds a B.A. in business administration from the University of Arizona. We believe that Ms.&nbsp;Hamill is qualified to serve on our Board because of her extensive leadership experience in the
biopharmaceutical industry and her global commercial operations and strategic planning expertise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D. </I></B>Dr.&nbsp;Lee has served as a member of our Board since
November&nbsp;10, 2022. Prior to that, Dr.&nbsp;Lee had served as a director of Legacy Scilex from March 2019 to November 2022 and as a director of Scilex Pharma since November 2018. Dr.&nbsp;Lee has over 20 years of experience as a biotechnology
innovator and executive who has been integrally involved with the founding or advancement of several biopharmaceutical companies. He is the founder and has served as the Chief Executive Officer of Aardvark Therapeutics, Inc. since March 2017. Prior
to that, Dr.&nbsp;Lee joined NantKwest, Inc., a publicly-traded immunotherapy company in 2014 and served as its Chief Strategy Officer until March 2017. His experience includes therapeutics for immunology, cardiovascular, oncology, neurology, and
infectious disease indications. Dr.&nbsp;Lee is also an inventor or <FONT STYLE="white-space:nowrap">co-inventor</FONT> of multiple biomedical and biotechnology innovations, licensed or assigned to several companies for development including
NantKwest, Inc., Simcere Pharmaceutical Group, Cellics Therapeutics, Inc., Sorrento and Aardvark Therapeutics, Inc. Dr.&nbsp;Lee earned his M.D. degree from the University of California, San Diego and his B.A. degree from the University of
California, Berkeley in Molecular Biology. We believe that Dr.&nbsp;Lee is qualified to serve on our Board because of his experience in management roles at life sciences companies and extensive academic and professional background in the field of
biotechnology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>David Lemus. </I></B>Mr.&nbsp;Lemus has served as a member of our Board since
November&nbsp;10, 2022. Prior to that, he served as a director of Legacy Scilex from April 2022 to November 2022 and as a director of Sorrento since October 2017. Mr.&nbsp;Lemus has served as Chief Executive Officer of IronShore Pharmaceuticals Inc.
since January&nbsp;2020 as well as the founder and Chief Executive Officer of LEMAX LLC since 2017. He also currently serves as a <FONT STYLE="white-space:nowrap">non-executive</FONT> board member of Silence Therapeutics, plc and BioHealth
Innovation, Inc. and served previously on several other boards of public and private companies as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director. He served from November 2017 to September 2018 as the Chief Operating Officer and
Chief Financial Officer of Proteros biosciences GmbH. Previously, from January 2016 to May 2017, he served as Interim Chief Financial Officer and Chief Operating Officer of Medigene AG. Prior to that time, at Sigma Tau Pharmaceuticals, Inc., he
served as Chief Executive Officer from January 2013 to July 2015, as Chief Operating Officer from March 2012 to December 2012, and as V.P. Finance from July 2011 to February 2012. Mr.&nbsp;Lemus previously served as Chief Financial Officer and
Executive V.P. of MorphoSys AG from January 1998 to May 2011. Prior to his role at MorphoSys AG, he held various positions, including Operations Manager and Controller (Pharma International Division) and Global IT Project Manager (Pharma Division)
at F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche AG, Group Treasurer of Lindt&nbsp;&amp; Spruengli AG and Treasury Consultant for Electrolux AB. Mr.&nbsp;Lemus received a M.S. from the Massachusetts Institute of Technology Sloan
School of Management in 1988 and a B.S. in Accounting from the University of Maryland in 1984. Mr.&nbsp;Lemus is also a certified public accountant licensed in the State of Maryland. We believe that Mr.&nbsp;Lemus&#146; extensive accounting and
financial background and business experience in the life sciences industry qualify him to serve on our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Tommy Thompson.
</I></B>Mr.&nbsp;Thompson has served as a member of our Board since November&nbsp;10, 2022. Prior to that, Mr.&nbsp;Thompson served on the Legacy Scilex Board from July 2022 to November 2022. Mr.&nbsp;Thompson currently serves as the Chief Executive
Officer of Thompson Holdings, a consulting firm. From July 2020 to March 2022, Mr.&nbsp;Thompson served as University of Wisconsin System President. From 2005 to 2012, Mr.&nbsp;Thompson was a partner in the law firm of Akin Gump Strauss
Hauer&nbsp;&amp; Feld LLP in Washington, D.C, and as an Adjunct Senior Advisor from 2017 to 2020. February 2005 to January 2011, Mr.&nbsp;Thompson served as President of Logistics Health, Inc., a provider of medical readiness and homeland security
solutions. Prior to entering the private sector in 2005, Mr.&nbsp;Thompson enjoyed a long and distinguished career in public service. From February 2001 to January 2005, Mr.&nbsp;Thompson served as the former Secretary of the U.S. Department of
Health&nbsp;&amp; Human Services, where he served as the nation&#146;s leading advocate for the health and welfare of all Americans. Prior to that, Mr.&nbsp;Thompson served four terms as Governor of Wisconsin from January 1987 to February 2001,
where he was best known for his efforts to revitalize the Wisconsin economy, for his national leadership on welfare reform, and for his work toward expanding health care access across all segments of society. Mr.&nbsp;Thompson currently serves as
Chairman of the board of directors of Physicians Realty Trust (NYSE: DOC) and of TherapeuticsMD, Inc. and also serves as a member of the board of directors of United Therapeutics Corporation (Nasdaq: UTHR). He previously served on the boards of
directors of various other companies, including Logistics Health, Inc. Health Solutions, a health care consulting company, C. R. Bard, Inc. (NYSE: BCR), Centene Corporation (NYSE: CNC), Plus Therapeutics, Inc. (formerly Cytori Therapeutics, Inc.)
(Nasdaq: PSTV), CareView Communications, Inc. (OTCQB: CRVW), Vyant Bio, Inc. (formerly Cancer Genetics, Inc.) (Nasdaq: VYNT), and Pure Bioscience, Inc. (Nasdaq: PURE). Mr.&nbsp;Thompson received both his B.S. and J.D. from the University of
Wisconsin-Madison. We believe that Mr.&nbsp;Thompson is qualified to serve on our Board because of his experience in public service, particularly his services and knowledge related to the health care industry as a whole, and extensive board
experience. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_69"></A>Family Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of the individuals who serve as our directors or executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_70"></A>Board Composition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and affairs are managed under the direction of our Board, which currently consists of seven members. Dr.&nbsp;Ji serves as
Executive Chairperson of our Board. The primary responsibilities of our Board are to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provide oversight, strategic guidance, counseling and direction to our management. Our Board meets on a regular basis and on an <I>ad hoc </I>basis as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the Certificate of Incorporation and the Bylaws, our Board is divided into three classes with staggered
three-year terms, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;I directors are Dorman Followwill, David Lemus, and Tommy Thompson, and their term will expire at
the annual meeting of stockholders to be held in 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;II directors are <FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D. and Laura J. Hamill and
their term will expire at the annual meeting of stockholders to be held in 2024; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;III directors are Henry Ji, Ph.D. and Jaisim Shah and their term will expire at the annual meeting
of stockholders to be held in 2025. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each annual meeting of stockholders to be held after the initial classification,
the successors to directors whose terms will then expire will be elected to serve from the time of election and qualification until the third annual meeting following their election. The authorized number of directors that shall constitute our Board
will be determined exclusively by our Board; <I>provided </I>that, at any time the Sorrento Group beneficially owns, in the aggregate, at least 50% in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the
election of directors, the stockholders may also fix the number of directors by resolutions adopted by the stockholders. Any increase or decrease in the number of directors will be apportioned among the three classes so that, as nearly equal as
practicable, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. No decrease in the number of directors constituting our Board will shorten the term of any incumbent director. Our directors may be removed
with or without cause by the affirmative vote of the holders of a majority in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the election of such directors; <I>provided, however</I>, that, from and
after the Sorrento Trigger Event any such director or all such directors may be removed only for cause and only by the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our capital stock
entitled to vote thereon, voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable law and the Certificate of Incorporation and subject
to the rights of the holders of any series of our preferred stock (including pursuant to the Stockholder Agreement), any vacancy on our Board may be filled by our Board or our stockholders; <I>provided, however</I>, that from and after the Sorrento
Trigger Event, any such vacancy shall be filled only by our Board and not by our stockholders. Any director elected in accordance with the preceding sentence shall hold office until the annual meeting of stockholders for the election of directors of
the class to which he or she has been appointed and until his or her successor has been duly elected and qualified, subject, however, to such director&#146;s earlier death, resignation, retirement, removal or disqualification. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_71"></A>Controlled Company Exemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sorrento controls a majority of the voting power for the election of directors. As a result, we are a &#147;controlled company&#148; within the
meaning of the Nasdaq Listing Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Nasdaq Listing Rules, a company of which more than 50% of the voting power is held by an
individual, group or another company is a &#147;controlled company&#148; and may elect not to comply with certain corporate governance standards, including, but not limited to, the requirements (i)&nbsp;that a majority of its board of directors
consist of independent directors, (ii)&nbsp;that its board of directors have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee&#146;s purpose and responsibilities and
(iii)&nbsp;that director nominees must be selected or recommended for the board&#146;s selection, either by independent directors constituting a majority of the board&#146;s independent directors in a vote in which only independent directors
participate, or a nominating and corporate governance committee comprised solely of independent directors with a written charter addressing the committee&#146;s purpose and responsibilities. While we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
do not presently intend to rely on these exemptions, we may opt to utilize these exemptions in the future as long as it remains a controlled company. Accordingly, our stockholders may not have
the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. If we cease to be a &#147;controlled company&#148; and our shares of Common Stock continue to be listed on Nasdaq,
we will be required to comply with these standards and, depending on our Board&#146;s independence determination with respect to its then-current directors, we may be required to add additional directors to our Board in order to achieve such
compliance within the applicable transition periods. See the section titled &#147;<I>Risk Factors &#151; We are a controlled company within the meaning of the Nasdaq Listing Rules and, as a result, qualify for, and may rely on, exemptions from
certain corporate governance requirements. Our stockholders may not have the same protection afforded to stockholders of companies that are subject to such governance requirements.</I>&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_72"></A>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Nasdaq Listing Rules, a majority of the members of our Board must satisfy Nasdaq&#146;s criteria for &#147;independence.&#148; As a
&#147;controlled company&#148;, we are largely exempted from such requirements. Our Board has determined that each of the directors on our Board, other than Dr.&nbsp;Ji and Mr.&nbsp;Shah (as a result of their positions as our Executive Chairperson
and our Chief Executive Officer, respectively), qualifies as an independent director, as defined by Rule 5605(a)(2) of the Nasdaq Listing Rules and our Board consists of a majority of &#147;independent directors&#148; as defined under the rules of
the SEC and Nasdaq relating to director independence requirements. In addition, we are subject to the rules of the SEC and Nasdaq relating to the membership, qualifications and operations of the audit committee, as discussed below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_73"></A>Role of Board in Risk Oversight Process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Risk assessment and oversight are an integral part of our governance and management processes. Our Board encourages management to promote a
culture that incorporates risk management into its corporate strategy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business operations. Management discusses strategic and operational (including
cybersecurity) risks at regular management meetings, and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks facing the Company. Throughout the year, senior management
reviews these risks with our Board at regular board meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board is responsible for overseeing our overall risk management process. The responsibility for managing risk rests with executive
management while the committees of our Board and our Board as a whole participate in the oversight process. Our Board&#146;s risk oversight process builds upon management&#146;s risk assessment and mitigation processes, which include reviews of
long-term strategic and operational planning, executive development and evaluation, regulatory and legal compliance and financial reporting and internal controls with respect to areas of potential material risk, including operations, finance, legal,
regulatory, cybersecurity, strategic and reputational risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_74"></A>Board Leadership Structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide our Board with the discretion to combine or separate the positions of Chief Executive Officer and Executive Chairperson of
our Board. Our Board is chaired by Dr.&nbsp;Ji. Our Board believes that separation of the positions of Chief Executive Officer and Executive Chairperson of our Board creates an environment that encourages objective oversight of management&#146;s
performance and enhances the effectiveness of our Board as a whole. We believe that this separation of responsibilities provides a balanced approach to managing our Board and overseeing the Company. However, our Board will continue to periodically
review its leadership structure and may make such changes in the future as it deems appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_75"></A>Board Diversity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In evaluating a director candidate&#146;s qualifications, our Board assesses whether a candidate possesses the integrity, judgment, knowledge,
experience, skills and expertise that are likely to enhance our ability, as well as the ability of the committees of our Board, to manage and direct our affairs and business. Our Board may consider many factors, such as personal and professional
integrity, ethics and values; experience in corporate management, such as serving as an officer or former officer of a publicly-held company; and experience as a board member or executive officer of another publicly-held company. In addition, our
Board may consider diversity in identifying potential director nominees, including diversity of expertise and experience in substantive matters pertaining to our business relative to other board members and diversity of background and perspective,
including, but not limited to, with respect to age, gender, race, place of residence and specialized experience. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_76"></A>Committees
of our Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has an audit committee, compensation committee and nominating and corporate governance committee. Our Board has
adopted a new charter for each of these committees, which complies with the applicable requirements of current Nasdaq Listing Rules. Copies of the charters for each committee are available on the investor relations portion of our website. The
composition and responsibilities of each of the committees of our Board are as set forth below. Members will serve on these committees until their resignation or removal or until otherwise determined by our Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit
committee consists of David Lemus, Laura J. Hamill and Dorman Followwill, with David Lemus serving as the chairperson of the committee. Each of the members of the audit committee satisfies the independence requirements under the applicable Nasdaq
Listing Rules and SEC rules. Each member of the audit committee can read and understand fundamental financial statements under the applicable rules and regulations of the SEC and Nasdaq Listing Rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The responsibilities of the audit committee are included in a written charter. The audit committee assists our Board in fulfilling our
Board&#146;s oversight responsibilities with respect to our accounting and financial reporting processes, the systems of internal control over financial reporting and audits of financial statements and reports, the performance of our internal audit
function, the quality and integrity of our financial statements and reports, the qualifications, independence and performance of our independent registered public accounting firm, and our compliance with legal and regulatory requirements. For this
purpose, the audit committee performs several functions. The audit committee&#146;s responsibilities include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing, determining the compensation of, retaining, overseeing and evaluating our independent registered
public accounting firm and any other registered public accounting firm engaged for the purpose of performing other review or attest services for the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to commencement of the audit engagement, reviewing and discussing with the independent registered public
accounting firm a written disclosure by the prospective independent registered public accounting firm of all relationships between the Company, or persons in financial oversight roles with the Company, and such independent registered public
accounting firm or their affiliates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining and approving engagements of the independent registered public accounting firm, prior to commencement
of the engagement, and the scope of and plans for the audit; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring the rotation of partners of the independent registered public accounting firm on our audit engagement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with management and the independent registered public accounting firm any fraud that includes
management or other employees who have a significant role in our internal control over financial reporting and any significant changes in internal controls; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and overseeing procedures for the receipt, retention and treatment of complaints regarding
accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the results of management&#146;s efforts to monitor compliance with our programs and policies designed
to ensure compliance with laws and rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing our programs, policies and procedures related to our information technology systems, including
information asset security and data protection; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management and the independent registered public accounting firm the results of the
annual audit and the independent registered public accounting firm&#146;s assessment of the quality and acceptability of our accounting principles and practices and all other matters required to be communicated to the audit committee by the
independent registered public accounting firm under generally accepted accounting standards, the results of the independent registered public accounting firm&#146;s review of our quarterly financial information prior to public disclosure and our
disclosures in our periodic reports filed with the SEC. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">David Lemus qualifies as an audit committee financial expert
within the meaning of SEC regulations and each of David Lemus, Laura J. Hamill and Dorman Followwill meet the financial sophistication requirements under the Nasdaq Listing Rules. Our independent registered public accounting firm and our management
periodically meet separately with the audit committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee reviews, discusses and assesses its own performance and
composition at least annually. The audit committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommends any proposed changes to our Board for its
consideration and approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the audit committee complies with all applicable requirements of the
Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
compensation committee consists of <FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D., Dorman Followwill and Laura J. Hamill, with <FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D. serving as the chairperson of the committee. <FONT
STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D., Dorman Followwill and Laura J. Hamill each satisfy the independence requirements under the Nasdaq Listing Rules. Each of the members of the compensation committee is be a <FONT
STYLE="white-space:nowrap">non-employee</FONT> director as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act and satisfies Nasdaq independence requirements. The compensation committee acts on behalf of
our Board to fulfill our Board&#146;s responsibilities in overseeing our compensation policies, plans and programs; and in reviewing and determining the compensation to be paid to our executive officers and
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors. The responsibilities of the compensation committee are included in its written charter. The compensation committee&#146;s responsibilities include, among others: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, modifying and approving (or, if it deems appropriate, making recommendations to our Board regarding)
our overall compensation strategy and policies, and reviewing, modifying and approving corporate performance goals and objectives relevant to the compensation of our executive officers and other senior management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining and approving (or, if it deems appropriate, recommending to our Board for determination and approval)
the compensation and terms of employment of our Chief Executive Officer, including seeking to achieve an appropriate level of risk and reward in determining the long-term incentive component of the compensation of the Chief Executive Officer;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining and approving (or, if it deems appropriate, recommending to our Board for determination and approval)
the compensation and terms of employment of our executive officers and other members of senior management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving (or, if it deems appropriate, making recommendations to our Board regarding) the terms of
employment agreements and severance agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> protections and
other compensatory arrangements for our executive officers and other members of senior management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conducting periodic reviews of the base compensation levels of all of our employees generally;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the type and amount of compensation to be paid or awarded to <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the adoption, amendment and termination of our equity incentive plans, stock appreciation
rights plans, pension and profit sharing plans, incentive plans, stock bonus plans, stock purchase plans, bonus plans, deferred compensation plans, 401(k) plans, supplemental retirement plans and similar programs, if any; and administering all such
plans, establishing guidelines, interpreting plan documents, selecting participants, approving grants and awards and exercising such other power and authority as may be permitted or required under such plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our incentive compensation arrangements to determine whether such arrangements encourage excessive
risk-taking, reviewing and discussing at least annually the relationship between our risk management policies and practices and compensation and evaluating compensation policies and practices that could mitigate any such risk. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, once we cease to be an &#147;emerging growth company,&#148; as defined in the JOBS Act, the responsibilities of the compensation
committee will also include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our Board for approval the frequency with which we conduct a vote on executive
compensation, taking into account the results of the most recent stockholder advisory vote on the frequency of the vote on executive compensation, and reviewing and approving the proposals regarding the frequency of the vote on executive
compensation to be included in our annual meeting proxy statements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management our Compensation Discussion and Analysis, and recommending to our Board
that the Compensation Discussion and Analysis be approved for inclusion in our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> registration statements and our annual meeting proxy statements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under its charter, the compensation committee may form, and delegate authority to, subcommittees as appropriate. The compensation committee
reviews, discusses and assesses its own performance and composition at least annually. The compensation committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter,
and recommends any proposed changes to our Board for its consideration and approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the compensation
committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominating and corporate governance committee consists of <FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D., Dorman Followwill and
Laura J. Hamill, with Dorman Followwill serving as the chairperson of the committee. <FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D., Dorman Followwill and Laura J. Hamill each satisfy the independence requirements under the Nasdaq Listing
Rules. The responsibilities of the nominating and corporate governance committee are included in its written </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
charter. The nominating and corporate governance committee acts on behalf of our Board to fulfill our Board&#146;s responsibilities in overseeing all aspects of our nominating and corporate
governance functions. The responsibilities of the nominating and corporate governance committee include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making recommendations to our Board regarding corporate governance issues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, reviewing and evaluating qualified candidates to serve as directors (consistent with criteria
approved by our Board); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining the minimum qualifications for service on our Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating incumbent directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">instituting and overseeing director orientation and director continuing education programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">serving as a focal point for communication between candidates,
<FONT STYLE="white-space:nowrap">non-committee</FONT> directors and our management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to our Board for selection candidates to serve as nominees for director for the annual meeting of
stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making other recommendations to our Board regarding matters relating to the directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing succession plans for our Chief Executive Officer and our other executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and overseeing matters of corporate responsibility and sustainability, including potential <FONT
STYLE="white-space:nowrap">long-and</FONT> short-term trends and impacts to our business of environmental, social and governance issues, and our public reporting on these topics; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering any recommendations for nominees and proposals submitted by stockholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee periodically reviews, discusses and assesses the performance of our Board and the committees
of our Board. In fulfilling this responsibility, the nominating and corporate governance committee seeks input from senior management, our Board and others. In assessing our Board, the nominating and corporate governance committee evaluates the
overall composition of our Board, our Board&#146;s contribution as a whole and its effectiveness in serving our best interests and the best interests of our stockholders. The nominating and corporate governance committee reviews, discusses and
assesses its own performance and composition at least annually. The nominating and corporate governance committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter,
and recommend any proposed changes to our Board for its consideration and approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the nominating and
corporate governance committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to the
Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_77"></A>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing of the Business Combination, on November&nbsp;10, 2022, our Board approved and adopted a written code of business conduct
and ethics, applicable to directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of our code of
business conduct and ethics is posted on our website at <I>www.scilexholding.com</I>. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of the website address in this prospectus is an
inactive textual reference only. We intend to disclose any amendments to our code of business conduct and ethics, or any waivers of its requirements, on our website to the extent required by the applicable rules and exchange requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_78"></A>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of our compensation committee is currently, or has been at any time in the past year, one of our officers or employees.
Other than Dr.&nbsp;Ji and Mr.&nbsp;Shah, none of our executive officers currently serves, or has served during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers
serving as a member of our Board or compensation committee. Please see the section of this prospectus titled &#147;<I>Executive and Director Compensation</I>&#148; for information regarding the compensation of Dr.&nbsp;Ji and Mr.&nbsp;Shah. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_79"></A>Limitation of Liability and Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws contain provisions that limit the liability of our directors for monetary damages to the
fullest extent permitted by the DGCL. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of their duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal
liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide that we shall indemnify any person who is or was a director or officer of the Company or who is or was serving at our
request as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (a &#147;Covered Person&#148;), and who is or was a party to,
is threatened to be made a party to, or is otherwise involved (including as a witness) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative based on such person&#146;s actions
in his or her official capacity as a director or officer of the Company or as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other
enterprise (to the extent serving in such position at our request), in each case against all liability and loss suffered (including, without limitation, any judgments, fines, excise taxes or penalties arising under the Employee Retirement Income
Security Act of 1974 and amounts paid in settlement consented to in writing by us) and expenses (including attorneys&#146; fees), actually and reasonably incurred by such person in connection therewith, subject to certain conditions. In addition,
the Bylaws provide that we may, to the fullest extent permitted by law, (i)&nbsp;advance costs, fees or expenses (including attorneys&#146; fees) incurred by a Covered Person defending or participating in any proceeding in advance of the final
disposition of such proceeding, subject to certain exceptions, and (ii)&nbsp;purchase and maintain insurance, at our expense, to protect us and any person who is or was our director, officer, employee or agent or is or was our director, officer,
employee or agent serving at our request as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability, expense or
loss, whether or not we would have the power or obligation to indemnify such person against such liability, expense or loss under the DGCL or the provisions of the Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers as determined by our Board. These
agreements, among other things, require us to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to advance all expenses actually
and reasonably incurred by the directors and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
executive officers in connection with any proceeding. We believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. We
also maintain directors&#146; and officers&#146; liability insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of the
Certificate of Incorporation, the Bylaws and the indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus
is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through their relationships with their
employers, be insured or indemnified against certain liabilities incurred in their capacity as members of our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of
liability and indemnification provisions in the Certificate of Incorporation and the Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the
likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. In addition, a stockholder&#146;s investment may be adversely affected to the extent we pay the
costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we
have been informed that in the opinion of the SEC, such indemnification is against public policy and is therefore unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
present, there is no pending litigation or proceeding involving any of our directors or executive officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a
claim for indemnification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_80"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_81"></A>Executive Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vickers Executive Officers and Director Compensation Prior to Completion of the Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Closing of the Business Combination, none of Vickers&#146;s executive officers or directors received any cash compensation for
services rendered to Vickers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex and Current Executive Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To achieve our goals, we have designed, and intend to modify as necessary, our compensation and benefits programs to attract, retain,
incentivize and reward deeply talented and qualified executives who share our philosophy and desire to work towards achieving our goals. We believe our compensation programs should promote the success of the Company and align executive incentives
with the long-term interests of our stockholders. This section provides an overview of the material components of our executive compensation programs, including a narrative description of the material factors necessary to understand the information
disclosed in the summary compensation table below. The following is a discussion and analysis of the material components of the compensation arrangements of Scilex&#146;s named executive officers in 2022. As an &#147;emerging growth company&#148; as
defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board or the compensation committee of our Board, with input from our Executive Chairperson and Chief Executive Officer, historically
determined the compensation for Scilex&#146;s named executive officers. Our named executive officers for the year ended December&nbsp;31, 2022, were Jaisim Shah, our Chief Executive Officer and President, Henry Ji, our Executive Chairperson and
Elizabeth Czerepak, our Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_82"></A>Summary
Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the compensation paid or accrued to
Scilex&#146;s named executive officers for the fiscal years ended December&nbsp;31, 2022 and December&nbsp;31, 2021:<B><I> </I></B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and principal position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-equity</FONT><BR>incentive<BR>plan<BR>compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-qualified</FONT><BR>deferred<BR>compensation<BR>earnings ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All other<BR>compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Jaisim Shah</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">773,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<B></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,435<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">785,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer, President and Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">579,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<B></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290,509<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<B></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,600<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">881,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Henry Ji, Ph.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">626,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">626,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Chairperson</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Elizabeth Czerepak</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<B></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Vice President, Chief Business Officer, Chief Financial Officer and
Secretary</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Does not include for 2022 the amount of any bonuses that may be awarded to our named executive officers as our
compensation committee has not, as of the date of the filing of this prospectus, yet determined bonus </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
amounts, if any, that may be awarded to our named executive officers for 2022. If any such bonus amounts are determined, we will, in accordance with Securities and Exchange Commission rules and
regulations, file a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or otherwise disclose the 2022 bonus amounts within four business days after our compensation committee has assessed 2022 performance and determined any bonus
awards for 2022 for our named executive officers. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents matching contributions made to Mr.&nbsp;Shah under the Company&#146;s 401(k) plan.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents discretionary bonus amount awarded to Mr.&nbsp;Shah by the Legacy Scilex Board.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents a signing bonus awarded to Ms.&nbsp;Czerepak in connection with her becoming our Executive Vice
President, Chief Business Officer, Chief Financial Officer and Secretary. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_83"></A>Narrative Disclosure to Summary
Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Arrangements with Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex has entered into an offer letter with each of Mr.&nbsp;Shah and Ms.&nbsp;Czerepak. The material terms of the offer letters are described
below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shah Offer Letter and Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex entered into an offer letter with Mr.&nbsp;Shah (the &#147;Shah Offer Letter&#148;) dated April&nbsp;19, 2019, pursuant to which
Mr.&nbsp;Shah serves as the Chief Executive Officer of Scilex Pharma. Under the Shah Offer Letter, Mr.&nbsp;Shah&#146;s annual base salary was initially set at $407,925, which was increased to $579,280 in 2020 and to $792,000 on November&nbsp;11,
2022 (but became effective as of March&nbsp;17, 2022). Mr.&nbsp;Shah&#146;s employment with Scilex is <FONT STYLE="white-space:nowrap">at-will,</FONT> and either Scilex or Mr.&nbsp;Shah may terminate the terms and conditions of the employment
relationship at any time, with or without cause and with or without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;6, 2019, Scilex issued to Mr.&nbsp;Shah an
option to purchase 8,126,836 shares of Scilex Common Stock, with an exercise price equal to $1.73 per share, whereby 25% of the shares vested on March&nbsp;18, 2020, and 1/48th of the total amount of the shares vested and shall vest each month
thereafter, subject to Mr.&nbsp;Shah providing continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. On December&nbsp;21, 2020, Scilex issued to Mr.&nbsp;Shah an additional option to purchase 1,626,497
shares of Scilex Common Stock, with an exercise price equal to $1.73 per share, whereby 25% of the shares vested on December&nbsp;21, 2021, and 1/48th of the total amount of the shares vested and shall vest each month thereafter, subject to
Mr.&nbsp;Shah providing continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. The foregoing number of shares and exercise prices for Mr.&nbsp;Shah&#146;s options reflect the application of the Exchange
Ratio in the Business Combination. Each of the foregoing options also vest in full if there is a Change in Control (as defined in the 2019 Stock Option Plan) and Mr.&nbsp;Shah&#146;s continuous service terminates due to an involuntary termination of
employment without &#147;cause&#148; or due to a voluntary termination of employment with &#147;good reason&#148; (each, as defined in the applicable option agreement) within 13 months after the effective time of such Change in Control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ji Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex has not
entered into an offer letter or employment agreement in connection with Dr.&nbsp;Ji&#146;s service as our Executive Chairperson. On November&nbsp;11, 2022, our compensation committee approved Dr.&nbsp;Ji&#146;s annual base salary of $792,000 and
bonus of $554,400, effective as of March&nbsp;17, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;20, 2019, Scilex issued to Dr.&nbsp;Ji, in connection with his
service as a director, an option to purchase 2,031,708 shares of Scilex Common Stock, with an exercise price equal to $1.73 per share, whereby 25% of the shares vested on March&nbsp;18, 2020, and 1/48th of the total amount of the shares vested and
shall vest each month thereafter, subject to Dr.&nbsp;Ji providing continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. The foregoing number of shares and exercise price for Dr.&nbsp;Ji&#146;s option
reflects the application of the Exchange Ratio in the Business Combination. Each of the foregoing options also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vest in full if there is a Change in Control (as defined in the 2019 Stock Option Plan) and Dr.&nbsp;Ji&#146;s continuous service terminates due to an involuntary termination of employment
without &#147;cause&#148; or due to a voluntary termination of employment with &#147;good reason&#148; (each, as defined in the applicable option agreement) within 13&nbsp;months after the effective time of such Change in Control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Czerepak Offer Letter and Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex entered into an offer letter with Ms. Czerepak (the &#147;Czerepak Offer Letter&#148;) dated April&nbsp;27, 2022, pursuant to which Ms.
Czerepak serves as our Executive Vice President, Chief Business Officer, and Chief Financial Officer. Under the Czerepak Offer Letter, Ms. Czerepak&#146;s annual base salary is $300,000 and she was awarded a $50,000 signing bonus. Following the
closing of the Business Combination and Scilex&#146;s filing of a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-8,</FONT> subject to the Board&#146;s approval, Scilex shall grant Ms. Czerepak an incentive stock option to purchase
350,000 shares of Scilex Common Stock, which shall vest over a four year period, whereby 1/4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of the shares subject to the option shall vest on the date that is one year after the vesting
commencement date and an additional 1/48<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of the shares subject to the option shall vest on the same date of each month thereafter, subject to Ms. Czerepak providing continuous service (as
defined in the equity incentive plan pursuant to which the option will be granted) on each such vesting date, inclusive. In addition, all of the shares subject to the option will vest upon the occurrence of a change in control (as defined in the
Equity Incentive Plan) that occurs prior to the termination of her continuous service. Ms. Czerepak&#146;s employment with Scilex is <FONT STYLE="white-space:nowrap">at-will,</FONT> and either Scilex or Ms. Czerepak may terminate the terms and
conditions of the employment relationship at any time, with or without cause and with or without notice. However, if Scilex terminates Ms. Czerepak&#146;s employment other than for cause or Ms. Czerepak resigns from her employment with Scilex for
good reason (each, as defined in the Czerepak Offer Letter), subject to Ms. Czerepak&#146;s execution and delivery of a release of claims in a form prescribed by Scilex, and so long as Ms. Czerepak has not been offered a full-time position at
Sorrento with a base salary and annual bonus potential of not less than the combined base salary and target bonus she received from both Scilex and Sorrento, if any, as of immediately prior to the termination of her employment, Scilex will continue
to pay Ms.&nbsp;Czerepak her base salary for a period of twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;14, 2019, Scilex issued to Ms.&nbsp;Czerepak, in
connection with her service as a director, an option to purchase 404,098 shares of Scilex Common Stock, with an exercise price equal to $1.73 per share, whereby 1/48th of the shares vested on September&nbsp;23, 2019<B>, </B>and 1/48th of the total
amount of the shares vested and shall vest each month thereafter, subject to Ms.&nbsp;Czerepak providing continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. The foregoing number of shares and exercise
price for Ms.&nbsp;Czerepak&#146;s option reflects the application of the Exchange Ratio in the Business Combination. Each of the foregoing options also vest in full if there is a Change in Control (as defined in the 2019 Stock Option Plan) and
Ms.&nbsp;Czerepak&#146;s continuous service terminates due to an involuntary termination of employment without &#147;cause&#148; or due to a voluntary termination of employment with &#147;good reason&#148; (each, as defined in the applicable option
agreement) within 13 months after the effective time of such Change in Control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Arrangements with Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the information provided by Compensia, a national compensation consulting firm engaged by our compensation committee to review and
advise on our compensation practices, on November&nbsp;11, 2022, our compensation committee approved the following base salaries and target bonuses (on terms and conditions determined by our Board) of our executive officers, effective as of
March&nbsp;17, 2022. As noted above, however, our compensation committee has not, as of the date of the filing of this prospectus, yet determined bonus amounts, if any, that may be awarded to our named executive officers for 2022: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target<BR>Bonus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">792,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">792,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the filing of the Company&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> with respect to the 2022 Equity Incentive Plan, we anticipate that our compensation committee will approve the following stock option grants thereunder, subject to the continued service of the individuals: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_84"></A>Potential Payments upon Termination or Change in Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2022, Scilex did not have any arrangement with any of its named executive officers providing for
potential payments, compensation or other benefits upon termination or the occurrence of a change of control, other than the severance provision for Ms.&nbsp;Czerepak and the accelerated vesting provisions pursuant to previously granted options as
described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_85"></A>Perquisites, Health, Welfare and Retirement Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive officers, during their employment with us, are eligible to participate in our employee benefit plans, including our medical,
vision and dental insurance plans, in each case on the same basis as all of our other employees. We generally do not provide perquisites or personal benefits to our named executive officers, except in limited circumstances. We do, however, pay the
premiums for medical, vision and dental insurance for all of our employees, including our named executive officers. Our Board may elect to adopt qualified or nonqualified benefit plans in the future if it determines that doing so is in our best
interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_86"></A>Pension Benefits and Nonqualified Deferred Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Shah participates in our <FONT STYLE="white-space:nowrap">tax-qualified</FONT> Section&nbsp;401(k) plan and we provide a 4% matching
contribution up to an annual compensation limit ($305,000 in 2022). We do not provide any other pension plan for our employees, and none of Scilex&#146;s named executive officers participated in a nonqualified deferred compensation plan during the
year ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_87"></A>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT>
2022 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents certain information concerning outstanding equity awards held by each of Scilex&#146;s named
executive officers as of December&nbsp;31, 2022. Following the Business Combination, each outstanding equity award with respect to our Common Stock reflected in the table below was equitably adjusted in accordance with the terms of the Merger
Agreement and the 2019 Stock Option Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option awards<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>securities<BR>underlying<BR>unexercised<BR>options (#)<BR>exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>securities<BR>underlying<BR>unexercised<BR>options (#)<BR>unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>exercise<BR>price<BR>per<BR>share($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>expiration<BR>date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/6/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/18/2019<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,618,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">507,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/6/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/21/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/21/2020<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">813,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">813,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/21/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9/20/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/18/2019<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,904,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9/20/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/14/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9/23/2019<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">328,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/14/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the terms of the Merger Agreement, effective as of the closing of the Business Combination on
November&nbsp;10, 2022, outstanding equity awards were adjusted as follows: (i)&nbsp;each option to purchase Legacy Scilex Common Stock that was outstanding as of immediately prior to the Effective Time was converted
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
into the right to receive an option relating to our Common Stock upon substantially the same terms and conditions as were in effect with respect to such option immediately prior to the Effective
Time (the &#147;Option&#148;) except that (x)&nbsp;such Option relates to that whole number of shares of Common Stock (rounded down to the nearest whole share) equal to the number of shares of Legacy Scilex Common Stock subject to such Option,
multiplied by the Exchange Ratio of 0.673498:1, and (y)&nbsp;the exercise price per share for each such share of Common Stock equals the exercise price per share of such Option in effect immediately prior to the Effective Time, divided by the
Exchange Ratio (rounded up to the nearest whole cent). The numbers in the table reflect the share numbers outstanding and exercise prices as of December&nbsp;31, 2022, in each case after giving effect to the Exchange Ratio. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each option was granted under the 2019 Stock Option Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each option vested as to 1/4th of the shares subject to the option on the one year anniversary of the vesting
commencement date and 1/48th of the shares subject to the option vested and shall vest on each monthly anniversary thereafter, subject to full acceleration in the event of an involuntary termination of employment without &#147;cause&#148; or due to
a voluntary termination of employment with &#147;good reason&#148; (each, as defined in the applicable option agreement) within 13 months following a Change in Control (as defined in the 2019 Stock Option Plan). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option vested and shall vest as to 1/48th of the shares subject to the option on each monthly anniversary
commencing on September&nbsp;23, 2019, subject to full acceleration in the event of an involuntary termination of employment without &#147;cause&#148; or due to a voluntary termination of employment with &#147;good reason&#148; (each, as defined in
the applicable option agreement) within 13 months following a Change in Control (as defined in the 2019 Stock Option Plan). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_88">
</A>Equity-Based Incentive Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors of Scilex Pharma originally adopted and its stockholders approved the 2017 Scilex Pharmaceuticals Inc. Equity Incentive
Plan (the &#147;Scilex Pharma 2017 Plan&#148;) on June&nbsp;26, 2017. The Scilex Pharma 2017 Plan was amended and restated on July&nbsp;5, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Scilex Pharma 2017 Plan, as amended and restated, provided that Scilex Pharma could grant incentive stock options, <FONT
STYLE="white-space:nowrap">non-statutory</FONT> stock options, stock awards, stock unit awards, stock appreciation rights and other stock awards. The only form of equity award granted under the Scilex Pharma 2017 Plan was options to purchase shares
of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of immediately prior to the corporate reorganization that was effected in March 2019, the maximum number of shares of
common stock of Scilex Pharma that could be issued under the Scilex Pharma 2017 Plan was 24,000,000, of which 18,099,000 remained available for future grants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no
additional awards were granted under the Scilex Pharma 2017 Plan. Each option to purchase shares of common stock of Scilex Pharma outstanding and unexercised immediately prior to the Contribution was cancelled and substituted for an option to
purchase the equivalent number of shares of Legacy Scilex Common Stock. Each new option was subject to the same terms and conditions as were in effect immediately prior to the Contribution. No stock options of Scilex Pharma were outstanding
following the reorganization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, options to purchase 744,201 shares of our Common Stock were outstanding
pursuant to options previously granted under the Scilex Pharma 2017 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2019 Stock Option Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Legacy Scilex Board adopted the Scilex Holding Company 2019 Stock Option Plan (the &#147;2019 Stock Option Plan&#148;) on May&nbsp;28,
2019. The 2019 Stock Option Plan was approved by Legacy Scilex&#146;s stockholders on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
June&nbsp;24, 2019. Upon adoption, 30,000,000 shares of Legacy Scilex Common Stock were authorized for issuance under the 2019 Stock Option Plan. The Legacy Scilex Board and Legacy Scilex&#146;s
stockholders approved an amendment to the 2019 Stock Option Plan on December&nbsp;21, 2020 to increase the number of shares authorized thereunder by 15,000,000 shares. As of December&nbsp;31, 2022, options to purchase 16,195,178 shares of our Common
Stock were outstanding under the 2019 Stock Option Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Stock Option Plan has terminated at the Closing, and no further awards
has been granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material terms of the 2019 Stock Option Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. Under the 2019 Stock Option Plan, an aggregate of 30,000,000 shares of Legacy Scilex Common Stock were initially
reserved for future issuance, which number was increased to 45,000,000 in December 2020. The authorized shares are subject to adjustment in the event of a change that occurs with respect to the common stock without the receipt of consideration by
Scilex, including a merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination
of shares, exchange of shares, recapitalization, reincorporation, reorganization, change in corporate structure, or similar equity restructuring transaction. Additionally, shares issued pursuant to awards under the 2019 Stock Option Plan that are
repurchased or that are forfeited, as well as shares reacquired as consideration for the exercise or purchase price of an award or to satisfy tax withholding obligations related to an award, will become available for future grant under the 2019
Stock Option Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Types of Awards</I>. The 2019 Stock Option Plan provided for the granting of (1)&nbsp;incentive stock options
intended to qualify as incentive stock options under the Code, (2)&nbsp;nonstatutory stock options that do not qualify as an incentive stock option, (3)&nbsp;stock appreciation rights, (4)&nbsp;restricted stock awards, (5)&nbsp;restricted stock unit
awards and (6)&nbsp;other stock awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility. </I>Incentive stock options could only be granted to Legacy Scilex&#146;s
employees or employees of its affiliates, and stock awards other than incentive stock options may be granted to employees, directors and consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options and Stock Appreciation Rights</I>. The Legacy Scilex Board determined the exercise price for stock options and stock
appreciation rights, provided that the exercise price generally could not be less than 100% of the fair market value of Legacy Scilex Common Stock on the date of grant, subject to certain exceptions relating to the assumption or substitution of
options or stock appreciation rights in connection with a corporate transaction in a manner consistent with Section&nbsp;409A or, if applicable, Section&nbsp;424(a) of the Code. Unless an award agreement provides otherwise, the termination date
shall be: (1)&nbsp;the earlier of 18 months or upon the expiration of the option or stock appreciation right, if termination is due to death; (2)&nbsp;the earlier of 12 months or upon the expiration of the option or stock appreciation right, if
termination is due to disability; or (3)&nbsp;three months, if termination is due to reasons other than for death, disability or cause. If the termination of service is due to cause, the stock option or stock appreciation right will terminate
immediately upon such termination of service, and the participant will be prohibited from exercising the option or stock appreciation right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock and Restricted Stock Unit Awards</I>. Each restricted stock and restricted stock unit award agreement is in the form and
contains such terms and conditions as the Legacy Scilex Board deemed appropriate. Unless otherwise provided in the award agreement, the Legacy Scilex Board held certificates or, if not certificated, other indicia representing the restricted shares.
If a recipient&#146;s service terminates, Legacy Scilex could receive through a forfeiture condition or a repurchase right, any or all of the shares of common stock held by the recipient as of the date of termination. Restricted stock units not yet
vested shall be forfeited upon termination of the recipient&#146;s employment unless otherwise set forth in the award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. Stock options or stock appreciation rights are generally not
transferable except by will or by the laws of descent and distribution or as otherwise provided under the 2019 Stock Option Plan. Restricted stock awards could be transferable by the participant only upon such terms and conditions as are set forth
in the restricted stock award agreement, as the Legacy Scilex Board determines in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. The 2019
Stock Option Plan is administered by our Board, although our Board may delegate the administration of the 2019 Stock Option Plan to a committee. The administrator has full power to determine, among other things: (1)&nbsp;who will be granted awards;
(2)&nbsp;when and how each award will be granted; (3)&nbsp;what type of award will be granted; (4)&nbsp;the provisions of each award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or
shares of common stock under the award; (5)&nbsp;the number of shares of common stock subject to an award; and (6)&nbsp;the fair market value applicable to an award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Change in Control/Corporate Transactions</I>. The 2019 Stock Option Plan provides that in the event of a change in control transaction (as
defined in the 2019 Stock Option Plan), a stock award may be subject to additional acceleration of vesting and exercisability as may be provided in the stock award agreement for such stock award or as may be provided in any other written agreement
between us or our affiliate and the participant, but in the absence of such provision, no such acceleration will occur. In addition, the 2019 Stock Option Plan provides that in the event of a corporate transaction (as defined in the 2019 Stock
Option Plan), our Board has the discretion to take a number of actions with respect to awards contingent upon the closing of the transaction, including arranging for the assumption or substitution of awards, arranging for the assignment of
repurchase rights in respect of awards, accelerating the vesting of awards, canceling awards or making payments in respect of awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment</I>. Our Board generally has the authority to amend awards, subject to the award recipient&#146;s consent if the amendment is not
favorable to the participant, except in connection with a capitalization adjustments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2022 Equity Incentive Plan
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, our Board adopted, subject to the approval by our stockholders, the Equity Incentive Plan. On
November&nbsp;9, 2022, our stockholders approved the Equity Incentive Plan. The Equity Incentive Plan became effective on November&nbsp;9, 2022, the day immediately preceding the date on which the Closing occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material terms of the Equity Incentive Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose of the Equity Incentive Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
purpose of the Equity Incentive Plan is to secure and retain the services of employees, directors and consultants, to provide incentives for such persons to exert maximum efforts for our success and to provide a means by which such persons may be
given an opportunity to benefit from increases in value of our Common Stock through the granting of awards under the Equity Incentive Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Awards
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Equity Incentive Plan provides for the grant of incentive stock options (&#147;ISOs&#148;) within the meaning of Section&nbsp;422
of the Code, to our employees and our parent and subsidiary corporations&#146; employees, and for the grant of nonstatutory stock options (&#147;NSOs&#148;), stock appreciation rights, restricted stock awards, restricted stock unit awards,
performance awards and other forms of awards to our employees, directors and consultants and any of our affiliates&#146; employees and consultants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the maximum number of shares of our Common Stock that may be issued under the Equity Incentive Plan after it becomes effective will
not exceed (i) 14,622,712 shares of our Common Stock, plus (ii)&nbsp;an additional number of shares of Common Stock equal to the number of shares subject to outstanding awards granted under the 2019 Stock Option Plan, that, following the effective
date of the Equity Incentive Plan, (a)&nbsp;are not issued because the award or any portion of the award expires or otherwise terminates without all of the shares covered by the award having been issued, (b)&nbsp;are not issued because the award or
any portion thereof is settled in cash, (c)&nbsp;are forfeited back to or repurchased by us because of the failure to meet a contingency or condition required for the vesting of such shares, (d)&nbsp;are withheld or reacquired to satisfy the
exercise, strike or purchase price or (e)&nbsp;are withheld or reacquired to satisfy a tax withholding obligation. In addition, the number of shares of our Common Stock that will be reserved for issuance under the Equity Incentive Plan will
automatically increase on January&nbsp;1 of each year for a period of ten years, beginning on January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to the lesser of (1) 4% of the total number of shares of our
Common Stock outstanding on December&nbsp;31 of the immediately preceding year, (2) 7,311,356 shares of Common Stock, and (3)&nbsp;such number of shares of our Common Stock determined by our Board or the compensation committee of our Board prior to
January&nbsp;1 of a given year. On January&nbsp;1, 2023, the authorized number of shares of our Common Stock referenced in the preceding clause (i)&nbsp;was increased to 20,276,666 based on the foregoing provisions. Notwithstanding anything to the
contrary in the foregoing sentence, the aggregate maximum number of shares of our Common Stock that may be issued on the exercise of ISOs under the Equity Incentive Plan is 14,622,712 shares, which amount will be increased commencing on
January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to the lesser of (i) 4% of the total number of shares of Common Stock outstanding on December&nbsp;31 of the preceding year, (ii) 7,311,356 shares of Common
Stock, and (iii)&nbsp;such number of shares of our Common Stock determined by our Board or the compensation committee of our Board prior to January&nbsp;1 of a given year. On January&nbsp;1, 2023, the authorized number of shares of our Common Stock
referenced in the preceding clause (i)&nbsp;regarding ISOs was increased to 20,276,666 based on the foregoing provisions. All of the foregoing share numbers are subject to adjustment as necessary to implement any changes in our capital structure (as
described below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares subject to awards that will be granted under the Equity Incentive Plan that expire or terminate without being
exercised in full will not reduce the number of shares available for issuance under the Equity Incentive Plan. The settlement of any portion of an award in cash will not reduce the number of shares available for issuance under the Equity Incentive
Plan. Shares of Common Stock withheld under an award to satisfy the exercise, strike or purchase price of an award or to satisfy a tax withholding obligation will not reduce the number of shares that will be available for issuance under the Equity
Incentive Plan. With respect to a stock appreciation right, only shares of common stock that are issued upon settlement of the stock appreciation right will count towards reducing the number of shares available for issuance under the Equity
Incentive Plan. If any shares of our Common Stock issued pursuant to an award are forfeited back to or repurchased or reacquired by us (i)&nbsp;because of a failure to meet a contingency or condition required for the vesting of such shares;
(ii)&nbsp;to satisfy the exercise, strike or purchase price of an award; or (iii)&nbsp;to satisfy a tax withholding obligation in connection with an award, the shares that are forfeited or repurchased or reacquired will revert to and again become
available for issuance under the Equity Incentive Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Administration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board, or a duly authorized committee of our Board, will administer the Equity Incentive Plan. Our Board, or a duly authorized committee of
our Board, may, in accordance with the terms of the Equity Incentive Plan, delegate to one or more of our officers the authority to (i)&nbsp;designate employees (other than officers) to be recipients of specified awards, and to the extent permitted
by applicable law, the terms of such awards; and (ii)&nbsp;determine the number of shares of Common Stock to be subject to such awards granted to such employees. Under the Equity Incentive Plan, our Board, or a duly authorized committee of our
Board, will have the authority to determine: award recipients; how and when each award will be granted; the types of awards to be granted; the provisions of each award, including the period of exercisability and the vesting schedule applicable to an
award; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the number of shares of Common Stock or cash equivalent subject to each award; the fair market value applicable to an award; and the terms of any performance award that is not valued in whole or
in part by reference to, or otherwise based on, Common Stock, including the amount of cash payment or other property that may be earned and the timing of payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Equity Incentive Plan, (i)&nbsp;our Board will not, without stockholder approval, (a)&nbsp;reduce the exercise or strike price of an
option or stock appreciation right (other than in connection with a capitalization adjustment), and (b)&nbsp;at any time when the exercise or strike price of an option or stock appreciation right is above the fair market value of a share of our
Common Stock, cancel and <FONT STYLE="white-space:nowrap">re-grant</FONT> or exchange such option or stock appreciation right for a new award with a lower (or no) purchase price or for cash, and (ii)&nbsp;a participant&#146;s rights under any award
will not be materially adversely impaired by any amendment without the participant&#146;s written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also designate a plan
administrator to administer the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of the Equity Incentive Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options will be granted
under stock option agreements adopted by our Board. Each option will be designated in writing as an ISO or an NSO. Our Board will determine the exercise price for stock options, within the terms and conditions of the Equity Incentive Plan, except
the exercise price of a stock option generally will not be less than 100% (or 110% in the case of ISOs granted to a person who owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or
subsidiary corporations, or a ten percent stockholder) of the fair market value of our Common Stock on the date of grant. Options granted under the Equity Incentive Plan will vest at the rate specified in the stock option agreement as will be
determined by our Board. The terms and conditions of separate options need not be identical. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No option will be exercisable after the
expiration of ten years (or five years in the case of ISOs granted to a ten percent stockholder) or a shorter period specified in the applicable award agreement. Unless the terms of an optionholder&#146;s stock option agreement, or other written
agreement between us and the recipient, provide otherwise, if an optionholder&#146;s service relationship with us or any of our affiliates ceases for any reason other than disability, death or cause, the optionholder may generally exercise any
vested options for a period of three months following the cessation of service. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation
of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 18 months following the date of death. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to disability,
the optionholder may generally exercise any vested options for a period of 12 months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. An optionholder may not exercise
an option at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the optionholder&#146;s stock option agreement or other written agreement between an optionholder and us, if an
optionholder&#146;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period: (i)&nbsp;the exercise of the
optionholder&#146;s option would be prohibited solely because the issuance of shares of common stock upon such exercise would violate applicable law, or (ii)&nbsp;the immediate sale of any shares of common stock issued upon such exercise would
violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the exercise period
to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no event may an
option be exercised beyond the expiration of its term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acceptable consideration for the purchase of common stock issued upon the exercise
of a stock option will be determined by our Board and may include (i)&nbsp;cash or check, bank draft or money order payable to us; (ii)&nbsp;a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
broker-assisted cashless exercise; (iii)&nbsp;subject to certain conditions, the tender of shares of our Common Stock previously owned by the optionholder; (iv)&nbsp;a net exercise of the option
if it is an NSO; or (v)&nbsp;other legal consideration acceptable to our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless our Board provides otherwise, options or stock
appreciation rights generally will not be transferable except by will or the laws of descent and distribution. Subject to approval of our Board or a duly authorized officer, an option may be transferred pursuant to a domestic relations order. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limitations on ISOs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate fair
market value, determined at the time of grant, of our Common Stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans or plans of our affiliates may not exceed
$100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting
power or that of any of our parent or subsidiary corporations unless (i)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant; and (ii)&nbsp;the term of the ISO does not
exceed five years from the date of grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Unit Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the Equity Incentive Plan, each restricted stock unit award will have such terms and conditions as determined by our
Board. A restricted stock unit award represents a participant&#146;s right to be issued on a future date the number of shares of our Common Stock that is equal to the number of restricted stock units subject to the award. A participant will not have
voting or any other rights as a stockholder of ours with respect to any restricted stock unit award (unless and until shares are actually issued in settlement of a vested restricted stock unit award). A restricted stock unit award will be granted in
consideration for a participant&#146;s services to us or an affiliate, such that the participant will not be required to make any payment to us (other than such services) with respect to the grant or vesting of the restricted stock unit award, or
the issuance of any shares of common stock pursuant to the restricted stock unit award. Our Board may determine that restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our Board
and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock (or any combination of our Common Stock and cash), or in any other form of consideration determined by our Board and set forth in the
restricted stock unit award agreement. At the time of grant, our Board may impose such restrictions or conditions on the award of restricted stock units that delay delivery to a date following the vesting of the award. Additionally, dividend
equivalents may be paid or credited in respect of shares of Common Stock covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, or other written agreement between us and the recipient, restricted
stock unit awards that have not vested will be forfeited once the participant&#146;s continuous service ends for any reason. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock awards will be granted under restricted stock award agreements adopted by our Board. A restricted stock award may be
awarded in consideration for cash, check, bank draft or money order, past services to us or any of our affiliates, or any other form of legal consideration that may be acceptable to our Board and permissible under applicable law. Our Board will
determine the terms and conditions of restricted stock awards, including vesting and forfeiture terms. Dividends may be paid or credited with respect to shares subject to a restricted stock award, as determined by our Board and specified in the
applicable restricted stock award agreement. If a participant&#146;s service relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the
participant terminates service with us through a forfeiture condition or a repurchase right. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock appreciation rights will be granted under stock appreciation right agreements adopted by our Board and denominated in shares of Common
Stock equivalents. The terms of separation stock appreciation rights need not be identical. Our Board will determine the purchase price or strike price for a stock appreciation right, which generally will not be less than 100% of the fair market
value of our Common Stock on the date of grant. A stock appreciation right granted under the Equity Incentive Plan will vest at the rate specified in the stock appreciation right agreement as will be determined by our Board. Stock appreciation
rights may be settled in cash or shares of our Common Stock (or any combination of our Common Stock and cash) or in any other form of payment, as determined by our Board and specified in the stock appreciation right agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will determine the term of stock appreciation rights granted under the Equity Incentive Plan, up to a maximum of ten years. If a
participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may generally exercise any vested stock appreciation right for a period of three months following
the cessation of service. If a participant&#146;s service relationship with us or any of our affiliates ceases due to death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally
exercise any vested stock appreciation rights for a period of 18 months following the date of death. If a participant&#146;s service relationship with us or any of our affiliates ceases due to disability, the participant may generally exercise any
vested stock appreciation rights for a period of 12 months following the cessation of service. In the event of a termination for cause, stock appreciation rights generally terminate upon the termination date. A holder of a stock appreciation right
may not exercise a stock appreciation right at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the stock appreciation right agreement or other written agreement between the
participant and us, if a participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period:
(i)&nbsp;the exercise of the participant&#146;s stock appreciation right would be prohibited solely because the issuance of shares upon such exercise would violate applicable law, or (ii)&nbsp;the immediate sale of any shares issued upon such
exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the
exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no
event may a stock appreciation right be exercised beyond the expiration of its term. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance Awards</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Equity Incentive Plan will permit the grant of performance awards that may be settled in stock, cash or other property. Performance awards
may be structured so that the stock or cash will be issued or paid only following the achievement of certain <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals during a designated performance period. Performance awards that
are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, our Common Stock. The performance goals may be based on any measure of performance selected by our Board. The performance
goals may be based on company-wide performance or performance of one or more business units, divisions, affiliates, or business segments, and may be either absolute or relative to the performance of one or more comparable companies or the
performance of one or more relevant indices. Unless specified otherwise by our Board at the time the performance award is granted, our Board will appropriately make adjustments in the method of calculating the attainment of performance goals for a
performance period as follows: (i)&nbsp;to exclude restructuring and/or other nonrecurring charges; (ii)&nbsp;to exclude exchange rate effects; (iii)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (iv)&nbsp;to
exclude the effects of any statutory adjustments to corporate tax rates; (v)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting principles;
(vi)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (vii)&nbsp;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such
divestiture; (viii)&nbsp;to exclude the effect of any change in the outstanding shares of our Common Stock by reason </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or
other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (ix)&nbsp;to exclude the effects of stock based compensation and the award of bonuses under our bonus plans; (x)&nbsp;to exclude costs
incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and (xi)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be
recorded under generally accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board retains the discretion to reduce or eliminate the compensation or
economic benefit due upon attainment of performance goals and to define the manner of calculating the performance criteria it selects to use for the performance period. Partial achievement of the specified criteria may result in the payment or
vesting corresponding to the degree of achievement as specified in the performance award agreement or the written terms of a performance cash award. Our Board will determine the length of any performance period, the performance goals to be achieved
during a performance period and the other terms and conditions of such awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Stock Awards</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will be permitted to grant other awards, based in whole or in part by reference to, or otherwise based on, our Common Stock, either
alone or in addition to other awards. Our Board will have the sole and complete discretion to determine the persons to whom and the time or times at which other stock awards will be granted, the number of shares under the other stock award (or cash
equivalent) and all other terms and conditions of such awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit</I>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate value of all compensation granted or paid following the effective date of the Equity Incentive Plan to any individual for
service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director with respect to any fiscal year, including awards granted under the Equity Incentive Plan (valued based on the grant date fair value for financial reporting purposes) and
cash fees paid by us to such <FONT STYLE="white-space:nowrap">non-employee</FONT> director, will not exceed $750,000 in total value, except such amount will increase to $1,000,000 for the year in which a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director is first appointed or elected to our Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, our
Board will appropriately and proportionately adjust (i)&nbsp;the class(es) and maximum number of shares subject to the Equity Incentive Plan and the maximum number of shares by which the share reserve may annually increase pursuant to the Equity
Incentive Plan; (ii)&nbsp;the class(es) and maximum number of shares that may be issued on the exercise of ISOs; and (iii)&nbsp;the class(es) and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding
awards granted under the Equity Incentive Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction (as defined below), unless otherwise provided in a participant&#146;s award agreement or other written
agreement with us or one of our affiliates or unless otherwise expressly provided by our Board at the time of grant, any awards outstanding under the Equity Incentive Plan may be assumed, continued or substituted for, in whole or in part, by any
surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to our Common Stock issued pursuant to awards may be assigned to the successor (or its parent company). If the surviving
or acquiring corporation (or its parent company) does not assume, continue or substitute for such awards, then (i)&nbsp;with respect to any such awards that are held by participants whose continuous service has not terminated prior to the effective
time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of such awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels depending on the level of performance, unless provided otherwise in the applicable
award agreement, vesting will accelerate at 100% of the target level) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate transaction) as our board of directors determines (or, if
our board of directors does not determine such a date, to the date that is five days prior to the effective time of the corporate transaction), and such awards will terminate if not exercised (if applicable) at or prior to the effective time of the
corporate transaction, and any reacquisition or repurchase rights held by us with respect to such awards will lapse (contingent upon the effectiveness of the corporate transaction); and (ii)&nbsp;any such awards that are held by persons other than
current participants will terminate if not exercised (if applicable) prior to the occurrence of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such awards will not terminate and may continue
to be exercised notwithstanding the corporate transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event an award will terminate if not exercised prior to the effective
time of a corporate transaction, our Board may provide, in its sole discretion, that the holder of such award may not exercise such award but instead will receive a payment, in such form as may be determined by our Board, equal in value to the
excess (if any) of (i)&nbsp;the value of the property the participant would have received upon the exercise of the award, over (ii)&nbsp;any per share exercise price payable by such holder, if applicable. As a condition to the receipt of an award, a
participant will be deemed to have agreed that the award will be subject to the terms of any agreement under the Equity Incentive Plan governing a corporate transaction involving us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Equity Incentive Plan, a &#147;corporate transaction&#148; generally will be the consummation, in a single transaction or in a
series of related transactions, of (i)&nbsp;a sale or other disposition of all or substantially all, as determined by our board of directors, of the consolidated assets of us and our subsidiaries; (ii)&nbsp;a sale or other disposition of at least
50% of our outstanding securities; (iii)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&nbsp;a merger, consolidation or similar transaction following which we are the surviving
corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transferability</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly
provided in the Equity Incentive Plan or the form of award agreement, awards granted under the Equity Incentive Plan may not be transferred or assigned by a participant. After the vested shares subject to an award have been issued, or in the case of
a restricted stock award and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in
compliance with the provisions herein, the terms of our trading policy and applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clawback/Recovery</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All awards granted under the Equity Incentive Plan will be subject to recoupment in accordance with any clawback policy that we are required to
adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Act or other applicable law and any clawback policy that we otherwise adopt,
to the extent applicable and permissible under applicable law. In addition, our Board may impose such other clawback, recovery or recoupment provisions in an award agreement as our Board determines necessary or appropriate, including but not limited
to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of cause. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment or
Termination</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may accelerate the time at which an award granted under the Equity Incentive Plan may first be exercised or the
time during which an award grant under the Equity Incentive Plan or any part thereof will vest, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
notwithstanding the provisions in the award agreement stating the time at which it may first be exercised or the time during which it will vest. Our Board will have the authority to amend,
suspend, or terminate the Equity Incentive Plan at any time, provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments will also require
the approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our Board adopts the Equity Incentive Plan. No awards may be granted under the Equity Incentive Plan while it is suspended or after it is terminated.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2022 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, our Board adopted, subject to the approval by our stockholders, the ESPP. On November&nbsp;9, 2022, our stockholders
approved the ESPP. The ESPP became effective on November&nbsp;9, 2022, the day immediately preceding the date on which the Closing occurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the ESPP is to secure and retain the services of new employees, to retain the services of existing employees, and to
provide incentives for such individuals to exert maximum efforts toward our success and that of our related corporations. The ESPP includes two components. One component is designed to allow eligible U.S. employees to purchase our Common Stock in a
manner that may qualify for favorable tax treatment under Section&nbsp;423 of the Code (the &#147;423 Component&#148;) and accordingly, it will be construed in a manner that is consistent with the requirements of Section&nbsp;423 of the Code. We
intend (but make no undertaking or representation to maintain) the 423 Component to qualify as an employee stock purchase plan, as that term is defined in Section&nbsp;423(b) of the Code. The other component will permit the grant of purchase rights
that do not qualify for such favorable tax treatment (the <FONT STYLE="white-space:nowrap">&#147;Non-423</FONT> Component&#148;) in order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or
employed outside of the U.S. while complying with applicable foreign laws, and except as otherwise provided in the ESPP or determined by our Board, it will operate and be administered in the same manner as the 423 Component. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share Reserve </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the maximum
number of shares of our Common Stock that may be issued under the ESPP will not exceed&nbsp;1,462,271 shares of our Common Stock. On January&nbsp;1, 2023, the maximum number of shares of our Common Stock that may be issued under the ESPP was
increased to 2,875,759 based on the following provisions of the ESPP. The ESPP provides that the number of shares of our Common Stock that will be reserved for issuance will automatically increase on January&nbsp;1 of each year for a period of up to
ten years, commencing on January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to the lesser of (i) 1% of the total number of shares of our Common Stock outstanding on December&nbsp;31 of the immediately
preceding calendar year; (ii) 1,827,839 shares of our Common Stock; and (iii)&nbsp;such number of shares of our Common Stock determined by our Board or the compensation committee of our Board prior to January&nbsp;1 of a given year, provided
however, that our Board may act prior to January&nbsp;1 of a given calendar year to provide that there will be no increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses
(i)&nbsp;to (iii)&nbsp;above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, up to the maximum number of shares of our Common Stock reserved may be used to
satisfy purchases of our Common Stock under the 423 Component and any remaining portion of such maximum number of shares may be used to satisfy the purchases of our Common Stock under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any purchase right granted under the ESPP terminates without having been exercised in full, the shares of our Common Stock not
purchased under such purchase right will again become available for issuance under the ESPP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Common Stock purchasable under the ESPP will be shares of authorized but unissued or
reacquired Common Stock, including shares repurchased by us on the open market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board administers the ESPP. Our Board may delegate some or all of the administration of the ESPP to a committee or committees of our Board.
All references to our Board in summary of the ESPP will include a duly authorized committee of our Board except where the context dictates otherwise. Further, to the extent not prohibited by applicable law, our Board may, from time to time, delegate
some or all of its authority under the ESPP to one or more of our officers or other persons or groups of persons as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the time of the delegation.
Our Board will have the authority to determine how and when purchase rights are granted and the provisions of each offering; to designate, from time to time, which of our related corporations will be eligible to participate in the 423 Component or
the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, or which related corporations will be eligible to participate in each separate offering; to construe and interpret the ESPP and purchase rights thereunder, and to establish, amend and
revoke rules and regulations for the ESPP&#146;s administration; to settle all controversies regarding the ESPP and purchase rights granted thereunder; to amend, suspend or terminate the ESPP; to exercise such powers and to perform such acts as it
deems necessary or expedient to promote the best interests of us and our related corporations and to carry out the intent of the ESPP to be treated as an employee stock purchase plan with respect to the 423 Component; and to adopt such rules,
procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit or facilitate participation in the ESPP by employees who are foreign nationals or employed or located outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All determinations, interpretations and constructions made by our Board in good faith will not be subject to review by any person and will be
final, binding and conclusive on all persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Offerings </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may grant or provide for the grant of purchase rights to eligible employees under an offering (consisting of one or more purchase
periods) on an offering date or offering dates selected by our Board. Each offering will be in the form and will contain those terms and conditions as our Board deems appropriate, and, with respect to the 423 Component, will comply with the
requirements of Section&nbsp;423(b)(5) of the Code. The provisions of separate offerings do not need to be identical, but each offering will include the period during which the offering will be effective, which period will not exceed 27 months
beginning with the offering date, and the substance of the applicable provisions contained in the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a participant has more than
one purchase right outstanding under the ESPP, unless he or she otherwise indicates in forms delivered to us or a third party designee of ours: (i)&nbsp;each form will apply to all of his or her purchase rights under the ESPP, and (ii)&nbsp;a
purchase right with a lower exercise price (or an earlier-granted purchase right, if different purchase rights have identical exercise prices) will be exercised to the fullest possible extent before a purchase right with a higher exercise price (or
a later-granted purchase right if different purchase rights have identical exercise prices) will be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will have the
discretion to structure an offering so that if the fair market value of a share of our Common Stock on the first trading day of a new purchase period within that offering is less than or equal to the fair market value of a share of our Common Stock
on the first day of that offering, then (i)&nbsp;that offering will terminate immediately as of that first trading day, and (ii)&nbsp;the participants in such terminated offering will be automatically enrolled in a new offering beginning on the
first trading day of such new purchase period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, purchase rights may only be granted to employees, including executive officers, employed by us (or by any of our affiliates or
related corporations as designated by our Board) on the first day of an offering if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such employee has been employed by us or by one of our designated affiliates or related corporations for such continuous period preceding such date (not to exceed two years) as our Board may
require. Our Board may (unless prohibited by applicable law) require that employees have to satisfy one or both of the following service requirements with respect to the 423 Component: (i)&nbsp;being customarily employed by us, or any of our related
corporations or affiliates, for more than 20 hours per week and more than five months per calendar year; or (ii)&nbsp;such other criteria as our Board may determine consistent with Section&nbsp;423 of the Code with respect to the 423 Component. Our
Board may provide that each person who, during the course of an offering, first becomes an eligible employee will, on the date or dates specified in the offering which coincides with the day on which the person becomes an eligible employee or which
occurs thereafter, receive a purchase right under that offering, and the purchase right will thereafter be deemed to be part of the offering with substantially identical characteristics. No employee will be eligible for the grant of any purchase
rights under the ESPP if immediately after such rights are granted, such employee owns stock possessing five percent or more of the total combined voting power or value of all classes of our outstanding capital stock (or the stock of any related
corporation) determined in accordance with the rules of Section&nbsp;424(d) of the Code. As specified by Section&nbsp;423(b)(8) of the Code, an eligible employee may be granted purchase rights only if such purchase rights, together with any other
rights granted under all employee stock purchase plans of ours or any of our related corporations, do not permit such eligible employee&#146;s rights to purchase our stock or the stock of any of our related corporations to accrue at a rate which,
when aggregated, exceeds $25,000 (based on the fair market value per share of such common stock on the date that the purchase right is granted) for each calendar year such purchase rights are outstanding at any time. Our Board may also exclude from
participation in the ESPP or any offering employees of ours, or of any of our related corporation, who are highly compensated employees, as within the meaning of Section&nbsp;423(b)(4)(D) of the Code, or a subset of such highly compensated
employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in the foregoing paragraph to the contrary, in the case of an offering under the <FONT
STYLE="white-space:nowrap">Non-423</FONT> Component, an eligible employee (or a group of eligible employees) may be excluded from participation in the ESPP or an offering if our Board has determined, in its sole discretion, that participation of
such eligible employee is not advisable or practical for any reason. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase Rights; Purchase Price </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the first day of each offering, each eligible employee, pursuant to an offering made under the ESPP, will be granted a purchase right to
purchase up to that number of shares of our Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by our Board, which will not exceed 15% of such employee&#146;s earnings (as defined by our Board) during
the period that begins on the first day of the offering (or such later date as our Board determines for a particular offering) and ends on the date stated in the offering, which date will be no later than the end of the offering. Our Board will
establish one or more purchase dates during an offering on which purchase rights granted for that offering will be exercised and shares of Common Stock will be purchased in accordance with such offering. Each eligible employee may purchase of up to
10,000 shares of our Common Stock in an offering (or such lesser number of shares determined by our Board prior to the start of the offering). Our Board may also specify (i)&nbsp;a maximum number of shares of our Common Stock that may be purchased
by any participant on any purchase date during an offering, (ii)&nbsp;a maximum aggregate number of shares of our Common Stock that may be purchased by all participants in an offering and/or (iii)&nbsp;a maximum aggregate number of shares of our
Common Stock that may be purchased by all participants on any purchase date under an offering. If the aggregate number of shares of our Common Stock issuable upon exercise of purchase rights granted under the offering would exceed any such maximum
aggregate number, then, in the absence of any action by our Board otherwise, a pro rata allocation of the shares of our Common Stock (rounded down to the nearest whole share) available, based on each participant&#146;s accumulated contributions,
will be made in as nearly a uniform manner as will be practicable and equitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price of shares of our Common Stock
acquired pursuant to purchase rights will not be less than the lesser of (i) 85% of the fair market value of a share of our Common Stock on the first day of an offering; or (ii) 85% of the fair market value of a share of our Common Stock on the date
of purchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Participation; Withdrawal; Termination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An eligible employee may elect to participate in an offering and authorize payroll deductions as the means of making contributions by
completing and delivering to us or our designee, within the time specified in the offering, an enrollment form provided by us or our designee. The enrollment form will specify the amount of contributions not to exceed the maximum amount specified by
our Board. Each participant&#146;s contributions will be credited to a bookkeeping account for the participant under the ESPP and will be deposited with our general funds except where applicable law requires that contributions be deposited with a
third party. If permitted in the offering, a participant may begin such contributions with the first payroll occurring on or after the first day of the applicable offering (or, in the case of a payroll date that occurs after the end of the prior
offering but before the first day of the next new offering, contributions from such payroll will be included in the new offering). If permitted in the offering, a participant may thereafter reduce (including to zero) or increase his or her
contributions. If required under applicable law or if specifically provided in the offering, in addition to or instead of making contributions by payroll deductions, a participant may make contributions through payment by cash, check or wire
transfer prior to a purchase date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During an offering, a participant may cease making contributions and withdraw from the offering by
delivering to us or our designee a withdrawal form provided by us. We may impose a deadline before a purchase date for withdrawing. Upon such withdrawal, such participant&#146;s purchase right in that offering will immediately terminate and we will
distribute as soon as practicable to such participant all of his or her accumulated but unused contributions and such participant&#146;s purchase right in that offering shall then terminate. A participant&#146;s withdrawal from that offering will
have no effect upon his or her eligibility to participate in any other offerings under the ESPP, but such participant will be required to deliver a new enrollment form to participate in subsequent offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise required by applicable law, purchase rights granted pursuant to any offering under the ESPP will terminate immediately if the
participant either (i)&nbsp;is no longer an employee for any reason or for no reason (subject to any post-employment participation period required by applicable law) or (ii)&nbsp;is otherwise no longer eligible to participate. We will distribute the
individual&#146;s accumulated but unused contributions as soon as practicable to such individual. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise determined by our
Board, a participant whose employment transfers or whose employment terminates with an immediate rehire (with no break in service) by or between us and one of our designated companies designated to participate in an offering (or between such
designated companies) will not be treated as having terminated employment for purposes of participating in the ESPP or an offering. However, if a participant transfers from an offering under the 423 Component to an offering under the <FONT
STYLE="white-space:nowrap">Non-423</FONT> Component, the exercise of the participant&#146;s purchase right will be qualified under the 423 Component only to the extent such exercise complies with Section&nbsp;423 of the Code. If a participant
transfers from an offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component to an Offering under the 423 Component, the exercise of the purchase right will remain <FONT STYLE="white-space:nowrap">non-qualified</FONT> under the <FONT
STYLE="white-space:nowrap">Non-423</FONT> Component. Our Board may establish different and additional rules governing transfers between separate offerings within the 423 Component and between offerings under the 423 Component and offerings under the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component. Unless otherwise specified in the offering or as required by applicable law, we will have no obligation to pay interest on contributions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase of Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On each purchase
date, each participant&#146;s accumulated contributions will be applied to the purchase of shares of our Common Stock, up to the maximum number of shares of our Common Stock permitted by the ESPP and the applicable offering, at the purchase price
specified in the offering. Unless otherwise provided in the offering, if any amount of accumulated contributions remains in a participant&#146;s account after the purchase of shares on the final purchase date of an offering, then such remaining
amount will not roll over to the next offering and will instead be distributed in full to such participant after the final purchase date of such offering without interest (unless otherwise required by applicable law). No purchase rights may be
exercised to any extent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unless the shares of our Common Stock to be issued upon such exercise under the ESPP are covered by an effective registration statement pursuant to the Securities Act and the ESPP is in material
compliance with all applicable U.S. federal and state, foreign and other securities, exchange control and other laws applicable to the ESPP. If on a purchase date the shares of our Common Stock are not so registered or the ESPP is not in such
compliance, no purchase rights will be exercised on such purchase date, and the purchase date will be delayed until the shares of our Common Stock are subject to such an effective registration statement and the ESPP is in material compliance, except
that the purchase date will in no event be more than 27 months from the first day of an offering. If, on the purchase date, as delayed to the maximum extent permissible, the shares of our Common Stock are not registered and the ESPP is not in
material compliance with all applicable laws, as determined by us in our sole discretion, no purchase rights will be exercised and all accumulated but unused contributions will be distributed to the ESPP participants without interest (unless the
payment of interest is otherwise required by applicable law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant will not be deemed to be the holder of, or to have any of the
rights of a holder with respect to, shares of our Common Stock subject to purchase rights unless and until the participant&#146;s shares of our Common Stock acquired upon exercise of purchase rights are recorded in our books (or the books of our
transfer agent). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP provides that in the event of a change in our capital structure through actions such as a merger, consolidation, reorganization,
recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or similar
transaction, our Board will appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the ESPP; (ii)&nbsp;the class(es) and maximum number of securities by which the share reserve is to increase
automatically each year; (iii)&nbsp;the class(es) and number of shares subject to, and purchase price applicable to, outstanding offerings and purchase rights; and (iv)&nbsp;the class(es) and number of securities that are subject to purchase limits
under each ongoing offering. Our Board will make these adjustments, and its determination will be final, binding and conclusive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate
Transactions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP provides that in the event of a corporate transaction (as defined below), any then-outstanding rights to
purchase our Common Stock under the ESPP may be assumed, continued, or substituted for by any surviving or acquiring corporation (or its parent company). If the surviving or acquiring corporation (or its parent company) elects not to assume,
continue, or substitute for such purchase rights, then (i)&nbsp;the participants&#146; accumulated payroll contributions will be used to purchase shares of our Common Stock (rounded down to the nearest whole share) within ten business days (or such
other period specified by our Board) before such corporate transaction under the outstanding purchase rights, and such purchase rights will terminate immediately after such purchase, or (ii)&nbsp;our Board, in its discretion, may terminate
outstanding offerings, cancel the outstanding purchase rights and refund the participants&#146; accumulated contributions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
ESPP, a &#147;corporate transaction&#148; is generally the consummation, in a single transaction or in a series of related transactions, of: (i)&nbsp;a sale or other disposition of all or substantially all, as determined by our Board, of the
consolidated assets of us and our subsidiaries; (ii)&nbsp;a sale or other disposition of at least 50% of our outstanding securities; (iii)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation; or
(iv)&nbsp;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue
of the transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transferability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During a participant&#146;s lifetime, purchase rights will be exercisable only by a participant. Purchase rights are not transferable by a
participant, except by will, by the laws of descent and distribution, or, if permitted by us, by a beneficiary designation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tax Withholding </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each participant must make arrangements, satisfactory to us and any applicable related corporation, to enable us or our related corporation to
fulfill any withholding obligation for taxes arising out of or in relation to a participant&#146;s participation in the ESPP. In our sole discretion and subject to applicable law, such withholding obligation may be satisfied in whole or in part by
(i)&nbsp;withholding from the participant&#146;s salary or any other cash payment due to the participant from us or any related corporation; (ii)&nbsp;withholding from the proceeds of the sale of shares of our Common Stock acquired under the ESPP,
either through a voluntary sale or a mandatory sale arranged by us; or (iii)&nbsp;any other method deemed acceptable by our Board. We will not be required to issue any shares of our Common Stock under the ESPP until such obligations are satisfied.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment, Suspension or Termination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will have the authority to amend, suspend or terminate the ESPP. Any benefits, privileges, entitlements and obligations under any
outstanding purchase right granted before an amendment, suspension or termination of the ESPP will not be materially impaired by any such amendment, suspension or termination except (i)&nbsp;with the consent of the person to whom such purchase
rights were granted, (ii)&nbsp;as necessary to facilitate compliance with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section&nbsp;423 of the Code), or (iii)&nbsp;as necessary to
obtain or maintain favorable tax, listing, or regulatory treatment. Except with respect to certain changes in our capital structure, stockholder approval is required for any amendment to the ESPP if such approval is required by applicable law or
listing requirements. No purchase rights may be granted under the ESPP while it is suspended or after it is terminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_89"></A>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the JOBS Act. As an emerging growth company, we are exempted from certain
requirements related to executive compensation, including the requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief Executive Officer to the
median of the annual total compensation of all of our employees, each as required by the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_90"></A>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2022, our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors received the following
compensation: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees<BR>Earned&nbsp;or<BR>Paid&nbsp;in<BR>Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura J. Hamill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87,588</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lemus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy Thompson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Ji, our Executive Chairperson, and Mr.&nbsp;Shah, our Chief Executive Officer and President, are not
included in this table, as each of them was an employee of Scilex and therefore receives no compensation for his service as a director. Dr.&nbsp;Ji&#146;s and Mr.&nbsp;Shah&#146;s compensation as named executive officers are included in the section
titled &#147;&#151; <I>Summary Compensation Table</I>&#148; above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2022, Dr.&nbsp;Lee held options to purchase an aggregate of 404,098 shares of Scilex
Common Stock (which number of options gives effect to the Exchange Ratio) and none of Mr.&nbsp;Followwill, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Ms.&nbsp;Hamill, Mr.&nbsp;Lemus and Mr.&nbsp;Thompson held any options or other equity awards to acquire shares of Scilex Common Stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Between January&nbsp;1, 2022 through April&nbsp;24, 2022, the fees earned by Dr.&nbsp;Lee were pursuant to a
consulting agreement dated October&nbsp;27, 2020, as amended on March&nbsp;17, 2021. Between April&nbsp;25, 2022 through December&nbsp;31, 2022, the fees earned by Dr.&nbsp;Lee were for his service as a member of our board of directors.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_91"></A>Director Compensation Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has determined the following compensation for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Annual Cash Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairs of the Audit Committee, Compensation Committee and Nominating and Corporate Governance
Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members of the Audit Committee, Compensation Committee and Nominating and Corporate Governance
Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Equity Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All annual cash compensation amounts for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
are payable in equal quarterly installments in arrears, following the end of each quarter in which the service occurred, <FONT STYLE="white-space:nowrap">pro-rated</FONT> for any partial months of service. The equity compensation paid to our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors will vest monthly over a period of 48 months from the date of grant with respect to the initial stock option grants and over a period of 12 months from the date of grant with respect to the
annual stock option grants, in each case, subject to continued service through each vesting date. Additionally, we will reimburse each outside director for reasonable travel expenses related to such director&#146;s attendance at Board and committee
meetings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_92"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of transactions since January&nbsp;1, 2020 and any currently proposed transactions to which Vickers or Legacy
Scilex was or is to be a participant in which the amount involved exceeded or will exceed $120,000, and in which any of Vickers&#146;s or Legacy Scilex&#146;s directors, executive officers or, to Vickers&#146;s or Legacy Scilex&#146;s knowledge,
beneficial owners of more than 5% of Vickers&#146;s or Legacy Scilex&#146;s capital stock, or their immediate family members have had or will have a direct or indirect material interest, other than compensation and other arrangements that are
described under the section of this prospectus titled &#147;<I>Executive and Director Compensation</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_93"></A>Certain
Relationships of Vickers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Founder Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2020, Vickers issued an aggregate of 3,593,750 Vickers Ordinary Shares to an affiliate of the Sponsors for an aggregate
purchase price of $25,000. In August 2020, the affiliate transferred his founder shares to the Sponsors for the same price paid for such shares. On October&nbsp;8, 2020, Vickers effected a share capitalization of 0.2 shares for each share
outstanding, on December&nbsp;7, 2020, the Sponsors forfeited 1,437,500 Vickers Ordinary Shares, which were cancelled by Vickers, and on January&nbsp;6, 2021, Vickers effected a share capitalization of 0.2 shares for each share outstanding,
resulting in 3,450,000 Vickers Ordinary Shares issued and outstanding. All share and <FONT STYLE="white-space:nowrap">per-share</FONT> amounts have been retroactively restated to reflect the share transactions. The founder shares included an
aggregate of up to 450,000 shares that were subject to forfeiture depending on the extent to which the underwriters&#146; over-allotment option is exercised, so that the number of founder shares will equal, on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis, approximately 20% of the issued and outstanding Vickers Ordinary Shares after the IPO. As a result of the underwriters&#146; election to partially exercise their over-allotment option, no
founder shares are currently subject to forfeiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or
sell any of their founder shares until six months after the consummation of the Business Combination or earlier if we consummates a liquidation, merger, share exchange or other similar transaction that results in all of the public shareholders
having the right to exchange their Vickers Ordinary Shares for cash, securities or other property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Promissory Note </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2020, Vickers issued an unsecured promissory note (the &#147;Promissory Note&#148;) to an affiliate of the Sponsors, pursuant
to which Vickers may borrow up to an aggregate principal amount of $125,000. The Promissory Note is <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable on the earlier of (i)&nbsp;December&nbsp;31, 2020 or (ii)&nbsp;the
completion of the IPO. The outstanding balance under the Promissory Note of $125,000 was repaid subsequent to the closing of the IPO on January&nbsp;14, 2021. Borrowings under the Promissory Note are no longer available to Vickers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Loans </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;20, 2021, the Sponsors loaned Vickers an aggregate of $500,000 for working capital purposes. On January10, 2022, the Sponsors deposited an aggregate of $1,035,000 into the Trust Account, to provide Vickers with an additional
three&nbsp;months to consummate an initial business combination pursuant to Vickers&#146;s Amended and Restated Memorandum and Articles of Association (&#147;Vickers&#146;s Charter&#148;). On January&nbsp;27, 2022, the Sponsors loaned Vickers an
additional aggregate principal amount of $500,000 for working capital purposes. On April&nbsp;10, 2022, the Sponsors deposited an aggregate of $1,035,000 into the Trust Account to provide Vickers with an additional three&nbsp;months to consummate an
initial business combination pursuant to Vickers&#146;s Charter. On June&nbsp;30, 2022, Vickers&#146;s shareholders approved an amendment (the &#147;Extension Amendment&#148;) to its amended and restated memorandum and articles of association to
extend the deadline by which it must complete an initial business combination from July&nbsp;11, 2022 to January&nbsp;11, 2023. Each extension </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
was made on a monthly basis and was conditioned on the deposit into the Trust Account of a payment equal to $0.0333 per public share outstanding. In connection with the shareholder vote on the
Extension Amendment, Vickers was required to provide its shareholders with the right to redeem their public shares. Holders of 4,073,605 public shares elected to redeem their shares at a per share redemption price of $10.27 thereby reducing the
amount in the Trust Account by an aggregate of approximately $41.8&nbsp;million. On July&nbsp;8, 2022, the Sponsors deposited an aggregate of $323,888.95 into the Trust Account to provide Vickers with an additional calendar month to consummate an
initial business combination pursuant to Vickers&#146;s Charter. After the redemption of the 4,073,605 public shares, there were 9,726,395 public shares remaining. On each of August&nbsp;11, 2022, September&nbsp;9, 2022 and October&nbsp;10, 2022,
the Sponsors deposited an additional payment of $323,888.95 into the Trust Account to provide Vickers with an additional calendar month to consummate an initial business combination pursuant to Vickers&#146;s Charter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, the Sponsors and Vickers entered into the Vickers Debt Agreement, which provides that, effective as of immediately
prior to the Effective Time, all of the issued and outstanding loans made by the Sponsors to Vickers prior to such Effective Time shall be contributed by the Sponsors to Vickers in exchange for a number of shares of our Common Stock determined by
dividing the aggregate amount of such indebtedness by $10.00. As of immediately prior to the Effective Time, the outstanding indebtedness was $5.3&nbsp;million, which resulted in the issuance of an additional 533,057 shares of our Common Stock to
the Sponsors, in accordance with the Vickers Debt Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advances from Related Party </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2020, an affiliate of the Sponsors advanced Vickers an aggregate of $30,000 to fund expenses in connection with the IPO. The advances
are <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable upon demand. As of June&nbsp;30, 2022 and December&nbsp;31, 2021, there were no advances outstanding. The outstanding amount of $30,000 as of December&nbsp;31, 2020 was
repaid on February&nbsp;26, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Service Fee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing on the effective date of the registration statement of the IPO through the acquisition of a target business, the Sponsors have
provided Vickers with office space and certain office and secretarial services at no cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No compensation of any kind, including any
finder&#146;s fee, reimbursement, consulting fee or monies in respect of any payment of a loan, will be paid by us to the Sponsors, officers and directors, or any of their affiliates, prior to, or in connection with any services rendered in order to
effectuate, the consummation of an initial business combination (regardless of the type of transaction that it is). However, these individuals will be reimbursed for any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable
business combinations. Our audit committee will review on a quarterly basis all payments that were made to the Sponsors, officers, directors or our or their affiliates and will determine which expenses and the amount of expenses that will be
reimbursed. There is no cap or ceiling on the reimbursement of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by such persons in connection with activities on our behalf. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Agreement with Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2022, Vickers entered into the Stockholder Agreement with Sorrento. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, from and after the Effective Time, and for so long as the Sorrento Group beneficially owns
any shares of Series A Preferred Stock, among other things, (i)&nbsp;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to our Board (each, a &#147;Stockholder Designee&#148; and
collectively, the &#147;Stockholder Designees&#148;), regardless of whether </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by our Board in
order to fill any vacancy created by the departure of any director or increase in the authorized number of members of our Board or the size of our Board and (ii)&nbsp;we are required to take all actions reasonably necessary, and not otherwise
prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to our Board as more fully described in the Stockholder Agreement. Notwithstanding the foregoing, the parties have agreed that our Board will
continue to satisfy all applicable stock exchange requirements applicable to directors, including with respect to director independence. Sorrento also have the right to designate a replacement director for any Stockholder Designee that has been
removed from our Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Stockholder Agreement also provides that we shall not, and shall cause our subsidiaries not to, among others, without the prior written consent of Sorrento: (i)&nbsp;amend, alter, modify or repeal (whether by merger, consolidation, by operation of
law or otherwise) any provisions of the Certificate of Incorporation (including the Certificate of Designations) or our Bylaws that increase or decrease the authorized number of directors constituting our Board; (ii)&nbsp;take any action that would
have the effect of increasing or decreasing the number of directors constituting our Board; (iii)&nbsp;amend, alter, modify or repeal (whether by merger, consolidation, reclassification, by operation of law or otherwise) any provisions of the
respective charters (and any related organizational documents) of any of the committees of our Board; (iv)&nbsp;file any voluntary petition under any applicable federal or state bankruptcy or insolvency law on behalf of us or any of our
subsidiaries; (v)&nbsp;(A) incur or permit any of our subsidiaries to incur any indebtedness in an aggregate principal amount in excess of $10,000,000) (with &#147;principal amount&#148; for purposes of this definition to include undrawn committed
or available amounts) or (B)&nbsp;enter into, modify, amend or renew (or permit any of our subsidiaries enter into, modify, amend or renew) any contract or other agreement in respect of indebtedness in an aggregate principal amount in excess of
$10,000,000 (with &#147;principal amount&#148; for purposes of this definition to include undrawn committed or available amounts); (vi) consummate or otherwise enter into any other contract or agreement to effect any change of control, joint venture
or corporate reorganization by the Company or any of our subsidiaries; (vii)&nbsp;declare or pay any dividend or distribution on our Common Stock, other Junior Security or Parity Security; or (viii)&nbsp;purchase, redeem or otherwise acquire for
consideration by us, directly or indirectly, any Common Stock, other Junior Security or Parity Security (except as necessary to effect (A)&nbsp;a reclassification of any Junior Security for or into other Junior Securities, (B)&nbsp;a
reclassification of any Parity Security for or into other Parity Securities with the same or lesser aggregate liquidation preference, (C)&nbsp;a reclassification of any Parity Security into a Junior Security, (D)&nbsp;the exchange or conversion of
any Junior Security for or into another Junior Security, (E)&nbsp;the exchange or conversion of any Parity Security for or into another Parity Security with the same or lesser per share liquidation amount, (F)&nbsp;the exchange or conversion of any
Parity Security for or into any Junior Security or (G)&nbsp;the settlement of incentive equity awards (including any applicable withholdings and the net exercise of options) in accordance with the terms thereof). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement will terminate and be of no further force and effect upon the earlier of (i)&nbsp;mutual written agreement of the
parties thereto and (ii)&nbsp;the date upon which Sorrento (together with its affiliates, subsidiaries, successors and assigns (other than us and our subsidiaries)) ceases to own any shares of Series A Preferred Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrant Transfer Agreement with Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with the execution of the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim entered into the Warrant Transfer
Agreement pursuant to which, if, prior to the consummation of the Business Combination, the public shareholders had redeemed 50% or more of the public Vickers Ordinary Shares as were outstanding as of March&nbsp;17, 2022, then in addition to the
forfeiture of Warrants by the Sponsors contemplated by the Sponsor Support Agreement, the Sponsors would transfer to Sorrento, and Sorrento would acquire all rights, title and interest in and to all or a portion of the Private Placement Warrants (as
equitably adjusted from time to time in respect of any change in the outstanding Vickers Ordinary Shares into a different </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number, class or series, including by reason of any reclassification, recapitalization, share split (including a reverse share split), or combination, exchange, readjustment of shares, or similar
transaction, or any share dividend or distribution paid in shares) as determined in accordance with the following schedule: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Redemptions</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Private<BR>Placement<BR>Warrants to be<BR>Transferred to<BR>Sorrento</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Private<BR>Placement<BR>Warrants to be<BR>Retained by<BR>Sponsors</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Private<BR>Placement<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">90% or greater</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,104,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,104,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">85% to 89.99%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,504,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,104,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">75% to 84.99%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,052,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,052,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,104,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">50% to 74.99%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,440,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,840,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Below 50%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,840,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,840,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the public shareholders redeemed an aggregate of 8,576,838
Vickers Ordinary Shares, which redeemed shares, together with the shares redeemed in connection with the Extension Proposal, represented an aggregate of 91.67% of the public Vickers Ordinary Shares outstanding as of March&nbsp;17, 2022. Accordingly,
the Sponsors transferred 3,104,000 Private Placement Warrants to Sorrento pursuant to the Warrant Transfer Agreement and forfeited 2,736,000 Private Placement Warrants pursuant to the Sponsor Support Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_94"></A>Certain Relationships of Legacy Scilex </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Reorganization </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;18, 2019, Legacy Scilex completed a corporate reorganization. In connection with the corporate reorganization, the existing stockholders of Scilex Pharma exchanged their shares for the same number of newly issued shares of Legacy Scilex
Common Stock, pursuant to a Contribution and Loan Agreement. As a result, Scilex Pharma and Semnur became Legacy Scilex&#146;s wholly owned subsidiaries. In connection with the reorganization, each option issued by Scilex Pharma to acquire shares of
common stock granted under the Scilex Pharma 2017 Plan was cancelled and substituted for an option to purchase an equivalent number of shares of Legacy Scilex Common Stock. See the section of this prospectus titled &#147;<I>Business &#151; Our
Corporate History</I>&#148; for further information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Relationship with Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, Legacy Scilex was a majority-owned subsidiary of Sorrento. Following the Closing of the Business
Combination, Sorrento continues to beneficially own a significant percentage of our outstanding Common Stock. In connection with the Business Combination, Legacy Scilex and Sorrento entered into certain agreements that relate to Legacy Scilex&#146;s
relationship with Sorrento prior to the Business Combination and provides a framework for our ongoing relationship with Sorrento. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;1, 2017, Scilex Pharma entered into a transition services agreement with Sorrento. Pursuant to this transition services agreement, Sorrento agreed to provide, directly or indirectly, certain administrative, financial, legal, tax,
insurance, facility, information technology and other services to Scilex Pharma. In addition to the services provided under this transition services agreement, Sorrento retains insurance coverage on behalf of Scilex Pharma. For the years ended
December&nbsp;31, 2021 and 2020, the total cost of services and insurance, including an agreed-upon markup, provided to Scilex Pharma was $4.0&nbsp;million and $2.3&nbsp;million, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Itochu and Oishi Product Development Agreement and Commercial Supply Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to the Product Development Agreement with Oishi and Itochu, who are responsible for supplying ZTlido and <FONT
STYLE="white-space:nowrap">SP-103</FONT> for development and commercialization purposes. We are also a party to the Itochu </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Oishi Commercial Supply Agreement, pursuant to which Itochu agreed to purchase Products (as defined in the Itochu and Oishi Commercial Supply Agreement) from Oishi and handles the shipping of
the Products. As of December&nbsp;31, 2020, Itochu held approximately 14.7% of Legacy Scilex&#146;s outstanding capital stock, representing a noncontrolling interest. Itochu ceased to be a shareholder of Legacy Scilex on January&nbsp;13, 2021. Its
Managing Executive Officer, Kenji Hakoda, served on the Legacy Scilex Board from March 2019 to October 2020. During the years ended December&nbsp;31, 2021 and 2020, pursuant to the aforementioned Product Development Agreement and the Itochu and
Oishi Commercial Supply Agreement, Legacy Scilex purchased inventory from Itochu in the amount of $5.7&nbsp;million and $1.0&nbsp;million, respectively, on terms Legacy Scilex considers to be arms&#146; length between the parties. See the sections
of this prospectus titled &#147;<I>Business &#151; Material Agreements &#151; Itochu and Oishi Product Development Agreement</I>&#148; and &#147;<I>Business &#151; Material Agreements &#151; Itochu and Oishi Commercial Supply Agreement</I>&#148; for
additional information regarding such agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indenture and Letter of Credit </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;7, 2018, Scilex Pharma entered into the Purchase Agreements with the Purchasers and Sorrento, which is a beneficial owner of
more than 5% of Legacy Scilex&#146;s capital stock. Pursuant to the Purchase Agreements, on September&nbsp;7, 2018, Scilex Pharma, among other things, issued and sold to the Purchasers the Scilex Pharma Notes for an aggregate purchase price of
$140.0&nbsp;million. The Scilex Pharma Notes are governed by the Indenture with Scilex Pharma, as issuer, U.S. Bank National Association, a national banking association, as the Trustee and Collateral Agent, and Sorrento, as guarantor. The Indenture
provides that the holders of the Scilex Pharma Notes will be entitled to receive quarterly payments in an amount equal to a fixed percentage, ranging from 15% to 25%, of the net sales of ZTlido for the prior fiscal quarter on each February&nbsp;15,
May&nbsp;15, August&nbsp;15 and November 15. As security for the Scilex Pharma Notes, Scilex Pharma has granted to the Collateral Agent, for the benefit of the Purchasers, a continuing security interest in and lien on Scilex Pharma&#146;s right,
title, and interest in and to ZTlido and all property and assets of Scilex Pharma that are necessary for, or otherwise relevant to, now or in the future, the manufacture and sale of ZTlido, on a worldwide basis (exclusive of Japan). Pursuant to the
Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture. Pursuant to the terms of the Indenture,
Sorrento issued an irrevocable standby letter of credit to Scilex Pharma (as amended, the &#147;Letter of Credit&#148;) which provides that, in the event that (1)&nbsp;Scilex Pharma does not hold at least $29.0&nbsp;million in unrestricted cash
(inclusive of cash equivalents in the collateral account) as of any calendar month ending March&nbsp;31, 2020 through and including the month ending March&nbsp;31, 2021 or at least $35.0&nbsp;million in unrestricted cash (inclusive of cash
equivalents in the collateral account) at the end of any calendar month after March&nbsp;31, 2021, (2) actual cumulative net sales of ZTlido from September&nbsp;7, 2018 through December&nbsp;31, 2021 are less than a specified sales threshold for
such period, or (3)&nbsp;actual cumulative net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes, beginning with the 2022 calendar year, are less than a specified sales threshold for such calendar year, Scilex Pharma,
as beneficiary of the Letter of Credit, will draw, and Sorrento will pay to Scilex Pharma, $35.0&nbsp;million in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount as a subordinated loan. The Letter of Credit will terminate upon the
earliest to occur of: (a)&nbsp;the repayment of the Scilex Pharma Notes in full, (b)&nbsp;the actual net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes exceeding a certain threshold, (c)&nbsp;the consummation of an
initial public offering on a major international stock exchange by us that satisfies certain valuation thresholds, and (d)&nbsp;the replacement of the Letter of Credit with another letter of credit in form and substance, including as to the identity
and creditworthiness of issuer, reasonably acceptable to the holders of at least 80% in principal amount of outstanding Scilex Pharma Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2020, the parties entered into a Consent Under and Amendment No.&nbsp;3 to Indenture and Letter of Credit
(&#147;Amendment No.&nbsp;3&#148;), which amended: (i)&nbsp;the Indenture, and (ii)&nbsp;the Letter of Credit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2020,
and in connection with Amendment No.&nbsp;3, the aggregate $45.0&nbsp;million in restricted funds held in previously established reserve and collateral accounts were released and Scilex Pharma utilized such funds to repurchase an aggregate of
$45.0&nbsp;million in principal amount of the Scilex Pharma Notes. Scilex </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Pharma also repurchased an aggregate of $20.0&nbsp;million in principal amount of the Scilex Pharma Notes on December&nbsp;16, 2020. Pursuant to the foregoing repurchases, the aggregate principal
amount of the Scilex Pharma Notes was reduced by an aggregate of $65.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further related to Amendment No.&nbsp;3, the
Purchasers also consented to Scilex Pharma incurring up to $10.0&nbsp;million of indebtedness in connection with an accounts receivable revolving loan facility with another lender and the incurrence of liens and the pledge of collateral to such
lender in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of
Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&nbsp;31, 2021 were less than a specified sales threshold for such period. As a result
of the draw notice being issued, Sorrento paid to Scilex Pharma $35.0&nbsp;million in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount as a subordinated loan. Per the terms of the Amendment No.&nbsp;3, in February 2022, Scilex Pharma
repurchased Scilex Pharma Notes in an aggregate amount equal to $20.0&nbsp;million at a purchase price in cash equal to 100% of the principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;15, 2022, in accordance with the Indenture, the principal amount of the Scilex Pharma Notes was increased by
$28.0&nbsp;million as actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&nbsp;31, 2021 did not equal or exceed a $481.0&nbsp;million sales threshold for such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;2, 2022, Sorrento and Scilex Pharma, entered into a Consent Under and Amendment No.&nbsp;4 to Indenture (&#147;Amendment
No.&nbsp;4&#148;) with the Trustee, Collateral Agent, and the Purchasers, which amended the Indenture. Pursuant to Amendment No.&nbsp;4, (1) on June&nbsp;3, 2022, Scilex Pharma repurchased approximately $41.4&nbsp;million of the aggregate principal
amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof (the &#147;Repurchase&#148;), (2) the Purchasers agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on
or before September&nbsp;30, 2022 for $41.4&nbsp;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Purchasers will forgive and discharge $28.0&nbsp;million of the aggregate principal amount of the Scilex
Pharma Notes, and (3)&nbsp;the minimum cash requirement under the Indenture was reduced to $5.0&nbsp;million in aggregate unrestricted cash equivalents at the end of each calendar month. Scilex Pharma funded the Repurchase with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cash-on-hand</FONT></FONT> and $15.0&nbsp;million received from Sorrento on June&nbsp;2, 2022. We paid off all the amounts outstanding under the Scilex Pharma Notes as of immediately prior
to the Closing of the Business Combination, which payment was funded by Sorrento and treated as intercompany debt in exchange for Series A Preferred Stock pursuant to the terms of the Debt Exchange Agreement described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;28, 2022, we repurchased the remaining outstanding principal balance of the Scilex Pharma Notes with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cash-on-hand</FONT></FONT> and $34.0&nbsp;million received from Sorrento. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Oaktree
Guaranty </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;7, 2018, Sorrento and certain of its domestic subsidiaries entered into a Term Loan Agreement, as
amended on May&nbsp;3, 2019 and December&nbsp;6, 2019 (as amended, the &#147;Oaktree Loan Agreement&#148;) with certain funds and accounts managed by Oaktree Capital Management, L.P. and Oaktree Fund Administration, LLC, as administrative and
collateral agent, for an initial term loan of $100.0&nbsp;million and a delayed draw term loan of $20.0&nbsp;million that was provided to Sorrento on May&nbsp;3, 2019. On April&nbsp;12, 2019, Legacy Scilex and Semnur entered into a Joinder Agreement
to the Oaktree Loan Agreement whereby each entity became a guarantor under the Oaktree Loan Agreement and pledged all of their respective assets (other than equity of Scilex Pharma) as collateral for the loans made to Sorrento under the Oaktree Loan
Agreement. All obligations owed under the Oaktree Loan Agreement were paid off in full on June&nbsp;12, 2020 and both Legacy Scilex and Semnur ceased to be a guarantor under the Oaktree Loan Agreement as of such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intercompany Promissory Note and Sale of Shares to Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;5, 2018, Scilex Pharma issued to Sorrento an intercompany promissory note in the amount of approximately $21.7&nbsp;million for
certain amounts previously advanced to Scilex Pharma by Sorrento (the &#147;Intercompany Note&#148;). On October&nbsp;22, 2018, Sorrento purchased from Legacy Scilex 24,117,608 shares of Legacy Scilex Common Stock in exchange for the cancellation of
$21.7&nbsp;million of indebtedness under the Intercompany Note. During 2021 and 2020, Sorrento made advances to Scilex Pharma in the amount of $8.1&nbsp;million and $10.3&nbsp;million, respectively, under the Intercompany Note. As of
December&nbsp;31, 2021 and 2020, the outstanding principal balance under the Intercompany Note was approximately $23.5&nbsp;million and $15.4&nbsp;million, respectively. In connection with Amendment No.&nbsp;4 to the Indenture, the maximum aggregate
principal amount of the Intercompany Note was increased from up to $25.0&nbsp;million to up to $50.0&nbsp;million. As of immediately prior to the Closing of the Business Combination, the outstanding principal balance under the Intercompany Note was
$23.5&nbsp;million, which amount was treated as Outstanding Indebtedness (as defined in the Debt Exchange Agreement discussed below) and contributed to Legacy Scilex in exchange for preferred stock as more fully described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note Payable to Sorrento </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;18, 2019, Legacy Scilex entered into a note payable with Sorrento with an initial principal amount of $16.5&nbsp;million. Legacy Scilex may borrow up to an aggregate of $20.0&nbsp;million of principal amount under the note payable. The
note is interest bearing at the lesser of (i) 10% simple interest per annum, and (ii)&nbsp;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in
part at any time without penalty or premium. The outstanding principal balance of the note as of December&nbsp;31, 2021 and 2020 was $19.6&nbsp;million and $13.0&nbsp;million, respectively. Accrued interest of $3.9&nbsp;million and $2.6&nbsp;million
was recognized under related party payable in Legacy Scilex&#146;s consolidated balance sheet as of December&nbsp;31, 2021 and 2020, respectively. During the six months ended June&nbsp;30, 2022 and 2021, Sorrento made advances to Legacy Scilex in
the amount of $27.5&nbsp;million and $0, respectively, under the note payable. The outstanding principal balance of the note on June&nbsp;30, 2022 and December&nbsp;31, 2021 was $47.1&nbsp;million and $19.6&nbsp;million, respectively, which was
recorded under the current related party note payable in Legacy Scilex&#146;s consolidated balance sheets. As of June&nbsp;30, 2022 and December&nbsp;31, 2021, Legacy Scilex had ending balances resulting from the accrued interest on the note payable
of $5.6&nbsp;million and $3.9&nbsp;million, respectively, which was recorded under the related party payable in Legacy Scilex&#146;s consolidated balance sheets. The proceeds from the note payable were used to finance the acquisition of Semnur and
to finance Legacy Scilex&#146;s operations. As of immediately prior to the Closing of the Business Combination, the outstanding principal balance under the foregoing notes was $54.3&nbsp;million, which amount was treated as Outstanding Indebtedness
(as defined in the Debt Exchange Agreement discussed below) and contributed to Legacy Scilex in exchange for preferred stock as more fully described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Debt Exchange Agreement and Related Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2022, Legacy Scilex and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement with
Sorrento (the &#147;Debt Exchange Agreement&#148;), pursuant to which (i)&nbsp;Sorrento shall contribute to Legacy Scilex all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to Legacy
Scilex and Scilex Pharma that remain outstanding as of immediately prior to the Closing of the Business Combination (the &#147;Aggregate Outstanding Amount&#148; or &#147;Outstanding Indebtedness&#148;), including with respect to the Scilex Pharma
Notes, the Intercompany Note, and the other notes payable to Sorrento described above, in exchange for the issuance by Legacy Scilex to Sorrento of preferred stock of Legacy Scilex, (ii)&nbsp;Legacy Scilex shall contribute to Scilex Pharma the
portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a contribution of capital for no consideration, and (iii)&nbsp;upon the occurrence of the events described in clauses (i)&nbsp;and (ii), the Aggregate Outstanding
Amount and the Outstanding Indebtedness shall be satisfied in full. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Debt Exchange Agreement effective as of immediately prior to,
and contingent upon, the Closing of the Business Combination, Sorrento has elected to contribute the Outstanding Indebtedness to Legacy Scilex in exchange for the issuance by Legacy Scilex to Sorrento of that number of shares of Legacy Scilex
Preferred Stock (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#147;Exchange Shares&#148; and such transaction, the &#147;Debt Contribution&#148;) that is equal to (i)&nbsp;the Aggregate
Outstanding Amount plus the amount equal to 10% of the Aggregate Outstanding Amount divided by (ii) $11.00 (rounded up to the nearest whole share); provided, that in no event shall the Aggregate Outstanding Amount exceed $310,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, Sorrento and Legacy Scilex entered into the Funding Commitment Letter. Pursuant to the terms of the Funding
Commitment Letter, upon the written request of Legacy Scilex (which request Legacy Scilex shall make to the extent necessary to satisfy the closing condition in the Merger Agreement that requires the combined company to have $5,000,001 in net
tangible assets as of immediately following the Effective Time) (the &#147;Net Tangible Assets Condition&#148;), Sorrento shall fund one or more loans to Legacy Scilex in the amount set forth in such written request (a &#147;Loan Request&#148;),
provided, that any amounts funded by Sorrento in respect of any Loan Request shall be treated as Outstanding Indebtedness for all purposes under the Debt Exchange Agreement and included in the calculation of the Aggregate Outstanding Amount
thereunder. The Funding Commitment Letter also provides that in no event shall the aggregate amount of loans made and funded by Sorrento pursuant to Loan Requests exceed the lesser of (a)&nbsp;$10,000,000 and (b)&nbsp;an amount that, when taken
together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $310,000,000. As consideration for the execution of the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim entered into the
Warrant Transfer Agreement, which is more fully described elsewhere in this prospectus. No Loan Requests were made under the Funding Commitment Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Debt Contribution, Legacy Scilex filed, with the Secretary of State of the State of Delaware, (i)&nbsp;a Certificate of Amendment
to its Amended and Restated Certificate of Incorporation to increase the authorized number of shares of preferred stock of Legacy Scilex from 20,000,000 to 45,000,000 and (ii)&nbsp;a certificate of designation setting forth the designations, powers,
rights and preferences and qualifications, limitations and restrictions of the Exchange Shares. Following the issuance thereof to Sorrento and in connection with the Closing of the Business Combination, such shares were converted into the right to
receive (i)&nbsp;one share of Series A Preferred Stock and <FONT STYLE="white-space:nowrap">(ii)&nbsp;one-tenth</FONT> of one share of our Common Stock, which shares of Series A Preferred Stock shall then have the rights set forth in the Certificate
of Designations. Sorrento is entitled to the rights set forth in the Stockholder Agreement as a result of Sorrento&#146;s ownership thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of immediately prior to the Closing, the Outstanding Indebtedness (including amounts related to the transfer of certain liabilities to
Sorrento and repayment of Scilex Pharma Notes) was $290,570,964, which was contributed by Sorrento, in accordance with the Debt Exchange Agreement, in exchange for 29,057,097 shares of Legacy Scilex Preferred Stock, which were in turn converted into
the right to receive 29,057,097 shares of Series&nbsp;A Preferred Stock and 2,905,710 shares of our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shah Investor LP Assignment
Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex, through Semnur, is a party to the Assignment Agreement with Shah Investor LP, pursuant to which Shah
Investor LP assigned Legacy Scilex certain intellectual property and Legacy Scilex agreed to pay Shah Investor LP a contingent quarterly royalty in the <FONT STYLE="white-space:nowrap">low-single</FONT> digits based on the quarterly net sales of any
pharmaceutical formulations for local delivery of steroids by injection developed utilizing such intellectual property, which would include SEMDEXA. Mahendra Shah, Ph.D., who served on the Legacy Scilex Board from March 2019 to October 2020, is the
managing partner of Shah Investor LP. See the section of this prospectus titled &#147;<I>Business &#151; Material Agreements &#151; Shah Investor LP Assignment Agreement</I>&#148; for additional information regarding the Assignment Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquisition of <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets from Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2021, Sorrento entered into an asset purchase agreement (the &#147;Aardvark Asset Purchase Agreement&#148;) with Aardvark
Therapeutics, Inc. (&#147;Aardvark&#148;), pursuant to which, among other things, Sorrento acquired Aardvark&#146;s Delayed Burst Release Low Dose Naltrexone <FONT STYLE="white-space:nowrap">(DBR-LDN)</FONT> asset and intellectual property rights,
for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Assets&#148;), which includes a Statement of Work dated November&nbsp;18, 2020 (the &#147;Tulex
Statement of Work&#148;), pursuant to which Tulex agreed to, among other things, develop, test and manufacture clinical supplies of <FONT STYLE="white-space:nowrap">SP-104.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to the acquisition, Sorrento designated Legacy Scilex to lead all development efforts related to
<FONT STYLE="white-space:nowrap">SP-104</FONT> and on May&nbsp;12, 2022, Legacy Scilex and Sorrento entered into a bill of sale and assignment and assumption agreement, pursuant to which Sorrento sold, conveyed, assigned and transferred to Legacy
Scilex all of its rights, title and interest in and to the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets (including PCT/US2021/053645 and all patents and patent applications that claim priority rights thereto) and Legacy Scilex assumed all
of Sorrento&#146;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the <FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Acquisition&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the <FONT STYLE="white-space:nowrap">SP-104</FONT> Acquisition, Legacy Scilex issued a promissory note in the aggregate
principal amount of $5,000,000 to Sorrento (the &#147;Promissory Note&#148;). The Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66% simple interest per annum and
(b)&nbsp;the maximum interest rate permitted under law. The Promissory Note is payable in cash, shares of Common Stock (any shares so issued, the &#147;Consideration Shares&#148;) or any combination thereof, at Legacy Scilex&#146;s sole discretion,
and may be prepaid in whole or in part at any time without penalty. Legacy Scilex also agreed to file with the SEC, a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento,
within 60 days of the issuance of such Consideration Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the successor to the Aardvark Asset Purchase Agreement, Legacy Scilex is
obligated to pay Aardvark (i) $3,000,000, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in the Aardvark Asset Purchase Agreement) (which amount may be paid in shares of Common Stock or cash, in Legacy
Scilex&#146;s sole discretion) (the &#147;Development Milestone Payment&#148;) and (ii) $20,000,000, in cash, upon achievement of certain net sales by Legacy Scilex of a commercial product that uses the LDN Formulation (the &#147;Commercial
Product&#148;). Legacy Scilex will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by Legacy Scilex of a commercial product that uses the LDN Formulation. The royalty percentage is subject to
reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer. As of
the date of this prospectus none of the foregoing payments have been triggered </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its acquisition of the <FONT
STYLE="white-space:nowrap">SP-104</FONT> Assets, Legacy Scilex has agreed that if it issues any shares of Common Stock in respect of the Development Milestone Payment, Legacy Scilex will prepare and file one or more registration statements with the
SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within 60 days following the date on which any such shares are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, MD, a member of our Board, is the founder, chief executive officer and a member of the
board of directors of Aardvark. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Guaranty of Lease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;8, 2019, Legacy Scilex entered into a new office lease for approximately 6,000 square feet for its executive offices in Palo
Alto, California, as amended on September&nbsp;15, 2019. The term of the lease commenced on September&nbsp;15, 2019 and will expire on November&nbsp;30, 2024. We will be obligated to pay an average of approximately $0.5&nbsp;million in annual rent
over the term of the lease. In connection with the lease, on August&nbsp;8, 2019, Sorrento executed a Guaranty of Lease, guaranteeing the performance of our obligations under the lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officer and Director Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the section of this prospectus titled &#147;<I>Executive and Director Compensation</I>&#148; for information regarding the
compensation of our executive officers and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an offer letter agreement with our named executive officer that, among other things, provides for certain compensatory and
change in control benefits, as well as severance benefits. For a description of such agreement, see the section of this prospectus titled &#147;<I>Executive and Director Compensation &#151; Arrangements with Executive Officers.</I>&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitation of Liability and Indemnification of Officers and Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the section of this prospectus titled &#147;<I>Management &#151; Limitation of Liability and Indemnification of Directors and
Officers</I>&#148; for information regarding our arrangements to provide indemnification to our officers and directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Combination
Related Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Merger Agreement, Vickers, Legacy Scilex and Sorrento entered into a
Company Stockholder Support Agreement, pursuant to which Sorrento agreed to vote all Legacy Scilex Common Stock beneficially owned by it, including any additional shares of Legacy Scilex it acquires ownership of or the power to vote, in favor of the
Business Combination and related transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, in connection with the closing of the Business Combination,
Scilex, Sorrento, the Sponsors, and Vickers&#146;s former directors Pei Wei Woo, Suneel Kaji and Steve Myint, entered into the Registration Rights Agreement, whereby, subject to certain exceptions, the parties agreed, among other things, not to
transfer any of our Common Stock or any security convertible into or exercisable or exchanged for our Common Stock beneficially owned or owned of record by such holder until the date that is the earlier of (i)&nbsp;one hundred eighty (180)&nbsp;days
from the date of the Registration Rights Agreement or (ii)&nbsp;the date on which we complete a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of our stockholders having the right to exchange
their shares of our Common Stock for cash, securities or other property. The Registration Rights Agreement governs the registration of certain shares of our Common Stock for resale and includes certain customary demand and &#147;piggy-back&#148;
registration rights with respect to shares of our Common Stock held by the parties thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Person Transaction Policy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval
or ratification of related person transactions. For purposes of our policy, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related
person are, were or will be participants in which the amount involved exceeds $120,000. Transactions involving compensation for services provided to us as an employee or director are not covered by this policy. A related person is any executive
officer, director or beneficial owner of more than 5% of any class of our voting securities and any of their respective immediate family members and any entity owned or controlled by such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related
person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to our audit
committee, or, if audit committee approval would be inappropriate, to another independent body of our Board, for review, consideration and approval or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the
transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem
reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition,
under our code of conduct and ethics, our employees and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person
transactions, our audit committee, or other independent body of our Board, will take into account the relevant available facts and circumstances including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks, costs and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact on a director&#146;s independence in the event that the related person is a director, immediate family
member of a director or an entity with which a director is affiliated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our audit
committee, or other independent body of our Board, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our audit committee, or other
independent body of our Board, determines in the good faith exercise of our discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_95"></A>PRINCIPAL SECURITYHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of our Common Stock as of January&nbsp;11, 2023 by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person or &#147;group&#148; known to be the beneficial owner of more than 5% of our outstanding Common
Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our current executive officers and directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a
security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. Shares subject to options and warrants that are currently
exercisable or exercisable within 60 days of the Closing Date are considered outstanding and beneficially owned by the person holding such options or warrants for the purpose of computing the percentage ownership of that person, but are not treated
as outstanding for the purpose of computing the percentage ownership of any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The beneficial ownership of our Common Stock is
based on 141,598,856 shares of such common stock outstanding as of January&nbsp;11, 2023. Voting power is based on 141,598,856 shares of Common Stock and 29,057,097 shares of Series A Preferred Stock outstanding as of January&nbsp;11, 2023. Shares
of Series&nbsp;A Preferred Stock are held solely by Sorrento. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, we believe, based on information available to
us, that all persons and entities named in the table have sole voting and investment power with respect to all shares shown as beneficially owned by them. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Common<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of<BR>Total<BR>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of<BR>Total<BR>Vote</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Directors and Executive Officers</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,838,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,989,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">345,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D.<SUP
STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">427,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura J. Hamill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lemus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy Thompson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All Directors and Executive Officers as a Group (8 individuals)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,600,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>5% Beneficial Owners</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sorrento Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,217,207</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise indicated, the business address of each of the following individuals is 4955 Directors Place,
San Diego, CA 92121. None of the following individuals own shares of Series A Preferred Stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 8,838,544 shares subject to options exercisable within 60 days of January&nbsp;11, 2023.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 1,989,380 shares subject to options exercisable within 60 days of January&nbsp;11, 2023.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 345,167 shares subject to options exercisable within 60 days of January&nbsp;11, 2023.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 427,670 shares subject to options exercisable within 60 days of January&nbsp;11, 2023.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 3,104,000 shares subject to Private Warrants and 1,386,617 shares subject to Public Warrants
exercisable within 60 days of January&nbsp;11, 2023. The business address of Sorrento Therapeutics, Inc. is 4955 Directors Place, San Diego, CA 92121. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_96"></A>SELLING SECURITYHOLDER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and sale by the Selling Securityholder of up to 28,128,422 shares of Common Stock that have been and may
be issued by us to the Selling Securityholder under the B. Riley Purchase Agreement. For additional information regarding the shares of Common Stock included in this prospectus, see the section titled &#147;<I>Committed Equity Financing</I>&#148;
above. We are registering the shares of Common Stock included in this prospectus pursuant to the provisions of the B. Riley Purchase Agreement we entered into with the Selling Securityholder on January 8, 2023 in order to permit the Selling
Securityholder to offer the shares included in this prospectus for resale from time to time. Except for the transactions contemplated by the B. Riley Purchase Agreement, and as set forth in the section titled &#147;<I>Plan of Distribution</I>&#148;
in this prospectus, the Selling Securityholder has not had any material relationship with us within the past three years. As used in this prospectus, the term &#147;Selling Securityholder&#148; mean B. Riley Principal Capital II, LLC, a Delaware
limited liability company, and the pledgees, donees, transferees, assignees, successors, designees, and others who later come to hold any of the Selling Securityholder&#146;s interest in the Common Stock other than through a public sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below presents information regarding the Selling Securityholder and the shares of Common Stock that may be resold by the Selling
Securityholder from time to time under this prospectus. This table is prepared based on information supplied to us by the Selling Securityholder, and reflects holdings as of January 11, 2023. The number of shares in the column titled &#147;Maximum
Number of Shares of Common Stock to be Offered Pursuant to this Prospectus&#148; represents all of the shares of Common Stock being offered for resale by the Selling Securityholder under this prospectus. The Selling Securityholder may sell some,
all, or none of the shares being offered for resale in this offering. We do not know how long the Selling Securityholder will hold the shares before selling them, and we are not aware of any existing arrangements between the Selling Securityholder
and any other stockholder, broker, dealer, underwriter, or agent relating to the sale or distribution of the shares of our Common Stock being offered for resale by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with Rule <FONT STYLE="white-space:nowrap">13d-3(d)</FONT> promulgated by the SEC under the
Exchange Act, and includes shares of our Common Stock with respect to which the Selling Securityholder has sole or shared voting and investment power. The percentage of shares of our Common Stock beneficially owned by the Selling Securityholder
prior to the offering shown in the table below is based on an aggregate of 141,598,856 shares of our Common Stock outstanding on January 11, 2023. Because the purchase price to be paid by the Selling Securityholder for shares of Common Stock, if
any, that we may elect to sell to the Selling Securityholder in one or more Advances or Additional Advances from time to time under the B. Riley Purchase Agreement will be determined on the applicable Advance Notice Dates or Additional Advance
Notice Dates for such Advances or Additional Advances, the actual number of shares of Common Stock that we may sell to the Selling Securityholder under the B. Riley Purchase Agreement may be fewer than the number of shares being offered for resale
under this prospectus. The fourth column in the table below assumes the resale by the Selling Securityholder of all of the shares of Common Stock being offered for resale pursuant to this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based
on the information furnished to us, that the Selling Securityholder has sole voting and investment power with respect to all shares of Common Stock that it beneficially owns, subject to applicable community property laws. Except as otherwise
described below, based on the information provided to us by the Selling Securityholder, the Selling Securityholder is not a broker-dealer or an affiliate of a broker-dealer. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Selling Securityholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of Shares<BR>of&nbsp;Common<BR>Stock&nbsp;Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Number of<BR>Shares of<BR>Common<BR>Stock Being<BR>Offered<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of Common&nbsp;Stock<BR>Beneficially Owned<BR>After&nbsp;the&nbsp;Offered<BR>Shares&nbsp;of&nbsp;Common&nbsp;Stock&nbsp;Are<BR>Sold</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">B. Riley Principal Capital II,
LLC<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,128,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than one percent. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the Commitment Shares we issued to the Selling Securityholder in consideration for entering into the
B. Riley Purchase Agreement with us. In accordance with Rule <FONT STYLE="white-space:nowrap">13d-3(d)</FONT> under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares that the
Selling Securityholder may be required to purchase under the B. Riley Purchase Agreement, because the issuance of such shares is at our discretion and is subject to conditions contained in the B. Riley Purchase Agreement, the satisfaction of which
are entirely outside of the Selling Securityholder&#146;s control, including the registration statement that includes this prospectus becoming and remaining effective. Furthermore, the Advances and Additional Advances of Common Stock under the B.
Riley Purchase Agreement are subject to certain agreed upon maximum amount limitations set forth in the B. Riley Purchase Agreement. Also, the B. Riley Purchase Agreement prohibits us from issuing and selling any shares of our Common Stock to the
Selling Securityholder to the extent such shares, when aggregated with all other shares of our Common Stock then beneficially owned by the Selling Securityholder, would cause the Selling Securityholder&#146;s beneficial ownership of our Common Stock
to exceed the 4.99% Beneficial Ownership Limitation. The B. Riley Purchase Agreement also prohibits us from issuing or selling shares of our Common Stock under the B. Riley Purchase Agreement in excess of the 19.9% Exchange Cap, unless we obtain
stockholder approval to do so or all applicable sales of shares of Common Stock under the B. Riley Purchase Agreement equal or exceed the &#147;Minimum Price&#148; (as such term is defined in Rule 5635 of the Nasdaq Listing Rules).
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes the 250,000 Commitment Shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes the sale of all shares being offered pursuant to this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of B. Riley Principal Capital II, LLC (&#147;BRPC II&#148;) is 11100 Santa Monica Blvd.,
Suite 800, Los Angeles, California 90025. BRPC II&#146;s principal business is that of a private investor. BRPC II is a wholly-owned subsidiary of B. Riley Principal Investments, LLC (&#147;BRPI&#148;). As a result, BRPI may be deemed to indirectly
beneficially own the securities of the company held of record by BRPC II. B. Riley Financial, Inc. (&#147;BRF&#148;) is the parent company of BRPC II and BRPI. As a result, BRF may be deemed to indirectly beneficially own the securities of the
company held of record by BRPC II and indirectly beneficially owned by BRPI. Bryant R. Riley is the <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer and Chairman of the Board of Directors of BRF. As a result, Bryant R. Riley may be
deemed to indirectly beneficially own the securities of the company held of record by BRPC II and indirectly beneficially owned by BRPI. Each of BRF, BRPI and Bryant R. Riley expressly disclaims beneficial ownership of the securities of the company
held of record by BRPC II, except to the extent of its/his pecuniary interest therein. We have been advised that none of BRF, BRPI or BRPC II is a member of the Financial Industry Regulatory Authority, Inc. (&#147;FINRA&#148;) or an independent
broker-dealer; however, each of BRF, BRPI, BRPC II and Bryant R. Riley is an affiliate of B. Riley Securities, Inc. (&#147;BRS&#148;), a registered broker-dealer and FINRA member, and Bryant R. Riley is an associated person of BRS. BRS will act as
an executing broker that will effectuate resales of our Ordinary shares that may be acquired by BRPC II from us pursuant to the B. Riley Purchase Agreement to the public in this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">250 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_97"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock offered by this prospectus are being offered by the Selling Securityholder. The shares may be sold or distributed
from time to time by the Selling Securityholder directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market
prices, at negotiated prices, or at fixed prices, which may be changed. We will not receive any of the proceeds from the sale of the securities by the Selling Securityholder. We may receive up to $500,000,000 aggregate gross proceeds under the B.
Riley Purchase Agreement from any sales we make to the Selling Securityholder pursuant to the B. Riley Purchase Agreement. The net proceeds from sales, if any, under the B. Riley Purchase Agreement, will depend on the frequency and prices at which
we sell shares of Common Stock to the Selling Securityholder after the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sale of the shares of our Common
Stock offered by this prospectus could be effected in one or more of the following methods: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokers&#146; transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transactions involving cross or block trades; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through brokers, dealers, or underwriters who may act solely as agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;at the market&#148; into an existing market for our Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in other ways not involving market makers or established business markets, including direct sales to purchasers
or sales effected through agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in privately negotiated transactions; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any combination of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of certain states, if applicable, the shares may be sold only through registered or licensed
brokers or dealers. In addition, in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from the state&#146;s registration or qualification requirement is available and
complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder is an &#147;underwriter&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder has informed us that it intends to use one or more registered broker-dealers to effectuate all sales, if
any, of our Common Stock that it may acquire from us pursuant to the B. Riley Purchase Agreement. Such sales will be made at prices and at terms then prevailing or at prices related to the then-current market price. Such registered broker-dealer
may, in some circumstances (for instance if such registered broker-dealer&#146;s involvement is not limited to receiving commission not in excess of the usual and customary distributors&#146; or sellers&#146; commissions), be considered to be an
underwriter within the meaning of Section&nbsp;2(a)(11) of the Securities Act. The Selling Securityholder has informed us that each such broker-dealer may receive commissions from the Selling Securityholder for executing such sales for the Selling
Securityholder and, if so, such commissions will not exceed customary brokerage commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brokers, dealers, underwriters, or agents
participating in the distribution of the shares of our Common Stock offered by this prospectus may receive compensation in the form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the
shares sold by the Selling Securityholder through this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of shares of our Common Stock sold by the Selling Securityholder may be less than or in excess of
customary commissions. Neither we nor the Selling Securityholder can presently estimate the amount of compensation that any agent will receive from any purchasers of shares of our Common Stock sold by the Selling Securityholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">251 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We know of no existing arrangements between the Selling Securityholder or any other
stockholder, broker, dealer, underwriter, or agent relating to the sale or distribution of the shares of our Common Stock offered by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time file with the SEC one or more supplements to this prospectus or amendments to the registration statement of which
this prospectus forms a part to amend, supplement, or update information contained in this prospectus, including, if and when required under the Securities Act, to disclose certain information relating to a particular sale of shares offered by this
prospectus by the Selling Securityholder, including with respect to any compensation paid or payable by the Selling Securityholder to any brokers, dealers, underwriters, or agents that participate in the distribution of such shares by the Selling
Securityholder, and any other related information required to be disclosed under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay the expenses incident to
the registration under the Securities Act of the offer and sale of the shares of our Common Stock covered by this prospectus by the Selling Securityholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for its irrevocable commitment to purchase our Common Stock under the B. Riley Purchase Agreement, we issued to the Selling
Securityholder 250,000 shares of our Common Stock as Commitment Shares in connection with the execution of the B. Riley Purchase Agreement. In addition, we have paid an affiliate of the Selling Securityholder a structuring fee of $10,000 in
connection with the structuring of the transactions by the Selling Securityholder under the B. Riley Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have
agreed to indemnify the Selling Securityholder and certain other persons against certain liabilities in connection with the offering of shares of our Common Stock offered hereby, including liabilities arising under the Securities Act, or, if such
indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. The Selling Securityholder has agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information
furnished to us by the Selling Securityholder specifically for use in this prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised that, in the opinion of the SEC, this indemnification is against public policy as expressed in the Securities Act, and is therefore
unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder has represented to us that at no time prior to the date of the B. Riley Purchase Agreement has
the Selling Securityholder or any entity managed or controlled by the Selling Securityholder engaged in or effected, in any manner whatsoever, directly or indirectly, for its own account or for the account of any of its affiliates, any short sale or
any transaction that establishes a net short position with respect to our Common Stock. The Selling Securityholder has agreed that, during the term of the B. Riley Purchase Agreement, none of the Selling Securityholder, its officers, its sole
member, or any entity managed or controlled by the Selling Securityholder will enter into or effect, directly or indirectly, any of the foregoing transactions for its own account or for the account of any other such person or entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the Selling Securityholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain
exceptions, Regulation M precludes the Selling Securityholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to induce any person to bid for or
purchase, any security that is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution of
that security. All of the foregoing may affect the marketability of the securities offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This offering will
terminate on the date that all shares of our Common Stock offered by this prospectus have been sold by the Selling Securityholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">252 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_98"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a discussion of certain material U.S. federal income tax considerations generally applicable to the purchase, ownership and
disposition of our Common Stock. This discussion is based on provisions of the Code, the Treasury Regulations promulgated thereunder (whether final, temporary, or proposed), administrative rulings of the IRS, and judicial decisions, all as in effect
on the date hereof, and all of which are subject to differing interpretations or change, possibly with retroactive effect. This discussion does not purport to be a complete analysis or listing of all potential U.S. federal income tax consequences
relating to the purchase, ownership and disposition of our Common Stock. In addition, this discussion does not address all aspects of U.S. federal income tax consequences to particular holders nor does it take into account the individual facts and
circumstances of any particular holder that may affect the U.S. federal income tax consequences to such holder, and accordingly, is not intended to be, and should not be construed as, tax advice. This discussion does not address the U.S. federal
3.8% Medicare tax imposed on certain net investment income or any aspects of U.S. federal taxation other than those pertaining to the income tax (such as the gift or estate tax), nor does it address any tax consequences arising under any U.S. state
and local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. Holders should consult their own tax advisors regarding such tax consequences in light of their particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No ruling has been requested or will be obtained from the IRS with respect to the U.S. federal income tax consequences to a holder of the
purchase, ownership or disposition of our Common Stock; thus, there can be no assurance that the IRS will not challenge the U.S. federal income tax treatment described below or that, if challenged, such treatment will be sustained by a court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary is limited to considerations relevant to holders that hold our Common Stock as &#147;capital assets&#148; within the meaning of
Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be important to holders in light of their individual circumstances, including holders
subject to special treatment under the U.S. tax laws, such as, for example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks or other financial institutions, underwriters, or insurance companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities who elect to apply a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts and regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, qualified retirement plans, individual
retirement accounts, or other <FONT STYLE="white-space:nowrap">tax-</FONT> deferred accounts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expatriates or former long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subchapter S corporations, partnerships or other pass-through entities or investors in such entities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers or traders in securities, commodities or currencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grantor trusts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. persons whose &#147;functional currency&#148; is not the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who received our Common Stock through the issuance of restricted stock under an equity incentive plan or
through a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan or otherwise as compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who own (directly or through attribution) 5% or more (by vote or value) of the outstanding securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our Common Stock as a position in a &#147;straddle,&#148; as part of a &#147;synthetic
security&#148; or &#147;hedge,&#148; as part of a &#147;conversion transaction,&#148; or other integrated investment or risk reduction transaction; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">253 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controlled foreign corporations, passive foreign investment companies, or foreign corporations with respect to
which there are one or more United States shareholders within the meaning of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.367(b)-3(b)(1)(ii);</FONT> or </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this discussion, the term &#147;U.S. Holder&#148; means a beneficial owner of our Common Stock that is, for U.S. federal income tax
purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (or other entity that is classified as a corporation for U.S. federal income tax purposes) that is
created or organized in or under the laws of the United States or any State thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (i)&nbsp;if a court within the United States is able to exercise primary supervision over the
administration of the trust and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (ii)&nbsp;that has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person for
U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; means a
beneficial owner of our Common Stock, that is neither a U.S. Holder nor a partnership (or an entity or arrangement treated as a partnership) for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership, including for this purpose any entity or arrangement that is treated as a partnership for U.S. federal income tax purposes,
holds our Common Stock, the U.S. federal income tax treatment of a partner in such partnership will generally depend on the status of the partner and the activities of the partnership. A holder that is a partnership and the partners in such
partnership should consult their own tax advisors with regard to the U.S. federal income tax consequences of the ownership and disposition of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS SUMMARY DOES NOT PURPORT TO BE A COMPREHENSIVE ANALYSIS OR DESCRIPTION OF ALL POTENTIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE
OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK. IN ADDITION, THE U.S. FEDERAL INCOME TAX TREATMENT OF THE BENEFICIAL OWNERS OF OUR COMMON STOCK MAY BE AFFECTED BY MATTERS NOT DISCUSSED HEREIN AND DEPENDS IN SOME INSTANCES ON DETERMINATIONS OF FACT
AND INTERPRETATIONS OF COMPLEX PROVISIONS OF U.S. FEDERAL INCOME TAX LAW FOR WHICH NO CLEAR PRECEDENT OR AUTHORITY MAY BE AVAILABLE. HOLDERS OF OUR COMMON STOCK SHOULD CONSULT WITH THEIR TAX ADVISORS REGARDING THE PARTICULAR TAX CONSEQUENCES TO THEM
OF THE OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK INCLUDING THE APPLICABILITY AND EFFECTS OF U.S. FEDERAL, STATE, LOCAL, AND OTHER TAX LAWS. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_207">
</A>U.S. Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we pay distributions or make constructive distributions (other than certain distributions of our stock or rights to acquire our stock) to
U.S. Holders of shares of our Common Stock, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income
tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#146;s adjusted tax basis in our Common
Stock. Any remaining excess will be treated as gain realized on the sale or other disposition of the Common Stock and will be treated as described under &#147;<I>U.S. Holders-Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of
Common Stock</I>&#148; below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">254 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a U.S. Holder that is a taxable corporation will generally qualify for
the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period
requirements are met, dividends we pay to a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder will generally constitute &#147;qualified dividends&#148; that will be subject to tax at the preferential tax rate accorded to long-term
capital gains. <FONT STYLE="white-space:nowrap">Non-corporate</FONT> U.S. Holders that do not meet a minimum holding period requirement or that elect to treat the dividend income as &#147;investment income&#148; pursuant to Section&nbsp;163(d)(4) of
the Code (dealing with the deduction for investment interest expense) will not be eligible for the reduced rates of taxation applicable to qualified dividends. In addition, the rate reduction will not apply to dividends if the recipient of a
dividend is obligated to make related payments with respect to positions in substantially similar or related property. This disallowance applies even if the minimum holding period has been met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the holding period requirements are not satisfied, a corporation may not be able to qualify for the dividends received deduction and would
have taxable income equal to the entire dividend amount, and <FONT STYLE="white-space:nowrap">non-corporate</FONT> holders may be subject to tax on such dividend at ordinary income tax rates instead of the preferential rates that apply to qualified
dividend income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder generally will recognize gain or loss on the sale, taxable exchange or other taxable disposition of our Common Stock, including
on a redemption that is treated as a sale or exchange under Section&nbsp;302 of the Code. Any such gain or loss will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder&#146;s holding period for the Common Stock so
disposed of exceeds one year. The amount of gain or loss recognized will generally be equal to the difference between (1)&nbsp;the sum of the amount of cash and the fair market value of any property received in such disposition and (2)&nbsp;the U.S.
Holder&#146;s adjusted tax basis in its Common Stock so disposed of. A U.S. Holder&#146;s adjusted tax basis in its Common Stock will generally equal the U.S. Holder&#146;s acquisition cost for such Common Stock, less any prior distributions treated
as a return of capital. The deductibility of capital losses is subject to limitations. Long-term capital gains recognized by <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders are generally eligible for reduced rates of tax. If the
U.S. Holder&#146;s holding period for the Common Stock so disposed of is one year or less, any gain on a sale or other taxable disposition of the shares would be subject to short-term capital gain treatment and would be taxed at ordinary income tax
rates. The deductibility of capital losses is subject to limitations. Any gain or loss recognized by a U.S. Holder on the sale or exchange of our Common Stock will generally be treated as U.S. source gain or loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_208"></A><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Distributions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
general, any distributions (including constructive distributions) we make to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of shares of our Common Stock, to the extent paid out of our current or accumulated earnings and profits (as
determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes and, provided such dividends are not effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s
conduct of a trade or business within the United States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is eligible for a reduced rate
of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> as applicable). Special certification and other requirements apply to certain <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that are pass-through entities rather than corporations or
individuals. Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its shares of our Common Stock and, to the
extent such distribution exceeds the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis, as gain realized from the sale or other disposition of the Common Stock, which will be treated as described under &#147;<I><FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders-Gain on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock</I>&#148; below. In addition, if we determine that we are likely to be classified as a &#147;United States real property
holding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">255 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation&#148; (see &#147;<I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders-Gain on Sale, Exchange or Other Taxable Disposition of Common Stock</I>&#148; below), we will withhold 15%
of any distribution that exceeds our current and accumulated earnings and profits </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that are effectively connected with such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (or if a tax treaty applies are
attributable to a U.S. permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder) will generally not be subject to U.S. withholding tax, provided such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder complies with certain certification and disclosure requirements (generally by providing an IRS Form <FONT STYLE="white-space:nowrap">W-8ECI).</FONT> Instead, such dividends generally will be
subject to U.S. federal income tax, net of certain deductions, at the same graduated individual or corporate rates applicable to U.S. Holders. If the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a corporation, dividends that are
effectively connected income may also be subject to a &#147;branch profits tax&#148; at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal income or withholding tax in respect of
gain recognized on a sale, taxable exchange or other taxable disposition of our Common Stock, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the conduct of a trade or business by the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S. permanent establishment or fixed base maintained by the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is an individual who is present in the United States
for 183 days or more in the taxable year of disposition and certain other conditions are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are or have been a &#147;United States real property holding corporation&#148; for U.S. federal income tax
purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder held our Common Stock and, in the case where shares of our Common Stock
are regularly traded on an established securities market, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has owned, directly or constructively, more than 5% of our Common Stock at any time within the shorter of the five-year period
preceding the disposition or such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period for the shares of our Common Stock. There can be no assurance that our Common Stock will be treated as regularly traded on an established
securities market for this purpose. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above will be subject to tax at generally
applicable U.S. federal income tax rates as if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder were a U.S. resident. Any gains described in the first bullet point above of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is
a foreign corporation may also be subject to an additional &#147;branch profits tax&#148; at a 30% rate (or lower applicable treaty rate). Gain described in the second bullet point above will generally be subject to a flat 30% U.S. federal income
tax. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are urged to consult their tax advisors regarding possible eligibility for benefits under income tax treaties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the third bullet point above applies to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder and applicable exceptions are not
available, gain recognized by such holder on the sale, exchange or other disposition of our Common Stock will be subject to tax at generally applicable U.S. federal income tax rates. In addition, a buyer of our Common Stock from such holder may be
required to withhold U.S. income tax at a rate of 15% of the amount realized upon such disposition. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are urged to consult their tax advisors regarding the application of these rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_209"></A>Foreign Account Tax Compliance Act </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Sections 1471 to 1474 of the Code and the Treasury Regulations and administrative guidance promulgated thereunder (commonly referred to
as the &#147;Foreign Account Tax Compliance Act&#148; or &#147;FATCA&#148;) a 30% withholding tax generally applies with respect to certain dividends in respect of and, subject to the proposed Treasury Regulations described below, gross proceeds
from a sale or disposition of, securities which are held by or through certain foreign financial institution (including investment funds), unless any such institution (a)&nbsp;enters into, and complies with, an agreement with the IRS to report, on
an annual basis, information with respect to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">256 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and by certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities that are wholly or
partially owned by U.S. persons and to withhold on certain payments, or (b)&nbsp;if required under an intergovernmental agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which
will exchange such information with the U.S. authorities. An intergovernmental agreement between the United States and the applicable foreign country may modify these requirements. Accordingly, the entity through which our Common Stock are held will
affect the determination of whether such withholding is required. Similarly, dividends in respect of, and (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, Common Stock held by an
investor that is a <FONT STYLE="white-space:nowrap">non-financial</FONT> <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity that does not qualify under certain exceptions will generally be subject to withholding at a rate of 30%, unless such
entity either (i)&nbsp;certifies to the applicable withholding agent that such entity does not have any &#147;substantial United States owners&#148; or (ii)&nbsp;provides certain information regarding the entity&#146;s &#147;substantial United
States owners,&#148; which will in turn be provided to the U.S. Department of Treasury. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the applicable Treasury Regulations and
administrative guidance, withholding under FATCA generally applies to payments of dividends. While withholding under FATCA generally would also apply to payments of gross proceeds from the sale or other disposition of securities (including Common
Stock), proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. All holders should consult
their tax advisors regarding the possible implications of FATCA on their investment in our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup
Withholding. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information returns will be filed with the IRS in connection with payments of dividends and the proceeds from a sale
or other disposition of our shares of Common Stock. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may have to comply with certification procedures to establish that it is not a United States person in order to avoid information reporting
and backup withholding requirements. The certification procedures required to claim a reduced rate of withholding under a treaty generally will satisfy the certification requirements necessary to avoid the backup withholding as well. Backup
withholding is not an additional tax. The amount of any backup withholding from a payment to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be allowed as a credit against such holder&#146;s U.S. federal income tax liability and may
entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT
DOES NOT COVER ALL TAX MATTERS THAT MAY BE IMPORTANT TO YOU. EACH PROSPECTIVE PURCHASER SHOULD CONSULT ITS TAX ADVISOR ABOUT THE TAX CONSEQUENCES OF AN INVESTMENT IN OUR COMMON STOCK BASED ON YOUR CIRCUMSTANCES. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">257 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_99"></A>DESCRIPTION OF OUR SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_100"></A>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following description summarizes the most important terms of our securities. The following summary does not purport to be complete and is subject to the Certificate of Incorporation, the Bylaws and the provisions of applicable law. A copy of the
Certificate of Incorporation and a copy of the Bylaws are attached as exhibits to the registration statement of which this prospectus forms a part. The stockholders are encouraged to read the applicable provisions of the DGCL, the Certificate of
Incorporation and the Bylaws in their entirety for a complete description of the rights and preferences of our securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_101"></A>Authorized and Outstanding Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation authorizes the issuance of (i) 740,000,000 shares of Common Stock, $0.0001 par value per share and (ii)
45,000,000 shares of preferred stock, $0.0001 par value per share (the &#147;Preferred Stock&#148;), of which 29,057,097 shares have been designated as Series A Preferred Stock. As of January&nbsp;11, 2023, there were 141,598,856 shares of Common
Stock and 29,057,097 shares of Series&nbsp;A Preferred Stock issued and outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_210"></A>Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides the following with respect to the rights, powers, preferences and privileges of our Common Stock.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders
of our Common Stock are entitled to receive ratably those dividends, if any, that may be declared from time to time by our Board upon the shares of our capital stock, which dividends may be paid either in cash, in property or in shares of our
capital stock, subject to preferences that may be applicable to preferred stock, if any, then outstanding. Subject to applicable law and the Certificate of Incorporation, our Board will have full power to determine whether any dividends shall be
declared and paid to stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of our Common Stock will be entitled to one vote for each share of our Common Stock held of record by such holder on all matters on
which stockholders generally are entitled to vote, except for any amendment to the Certificate of Incorporation that relates solely to the terms of one or more outstanding classes or series of our Preferred Stock if the holders of such affected
classes or series are entitled, either separately or together with the holders of one or more other such classes or series, to vote thereon pursuant to the Certificate of Incorporation or the DGCL. Any action or matter presented to the stockholders
at a duly called or convened meeting, at which a quorum is present, will be decided by the affirmative vote of the holders of a majority of the votes cast affirmatively or negatively (excluding abstentions) at the meeting by the holders entitled to
vote thereon, except that our directors will be elected by a plurality of the votes cast. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Right to Receive Liquidation Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a liquidation, dissolution or winding up of the Company, the holders of our Common Stock will be entitled to share ratably in
all assets remaining after payment of liabilities, subject to prior distribution rights of our Preferred Stock, if any, then outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No
Preemptive or Similar Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock have no preemptive or conversion rights or other subscription rights. There are no
redemption or sinking fund provisions applicable to our Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">258 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fully Paid and <FONT STYLE="white-space:nowrap">Non-Assessable</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding Vickers Ordinary Shares and the shares of our Common Stock issued in the Business Combination are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_102"></A>Our Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation authorizes our Board, subject to limitations prescribed by Delaware law, to issue up to 45,000,000 shares of
preferred stock in one or more series, to determine and fix from time to time the number of shares to be included in each such series and to fix the designations, powers, rights and preferences of the shares of each such series, and the
qualifications, limitations and restrictions thereof, including voting rights (if any), dividend rights, dissolution rights, conversion rights, exchange rights and redemption rights, in each case without further vote or action by our stockholders.
The number of authorized shares of our Common Stock and our Preferred Stock may be increased or decreased (but not below the number of the shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of our
outstanding stock entitled to vote thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may authorize the issuance of preferred stock with voting or conversion rights that
could adversely affect the voting power or other rights of the holders of our Common Stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other
things, have the effect of delaying, deferring or preventing a change in control and may adversely affect the market price of our Common Stock and the voting and other rights of the holders of our Common Stock. Other than the Series A Preferred
Stock issued to Sorrento in connection with the Closing of the Business Combination, there are no other Preferred Stock outstanding and we have no current plans to issue any other shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Number and Designation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We filed
the Certificate of Designations, designating 29,057,097 shares of our preferred stock as &#147;Series A Preferred Stock&#148;. As of the date of this prospectus, 29,057,097 shares of the Series A Preferred Stock have been issued to Sorrento pursuant
to the terms of the Merger Agreement and such shares have all of the rights, preferences and privileges set forth in the Certificate of Designations as more fully described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rank </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock
shall rank (i)&nbsp;senior to all of our Common Stock, and to all other classes or series of our capital stock, except for any such other class or series, the terms of which expressly provide that it ranks on parity with the Series A Preferred Stock
as to dividend rights and rights on liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company (&#147;Junior Securities&#148;); and (ii)&nbsp;on parity with each class or series of our capital stock, created
specifically ranking by its terms on parity with the Series A Preferred Stock as to dividend rights and rights on liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company (&#147;Parity Securities&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the
Series A Preferred Stock shall not be entitled to dividends unless we pay dividends to holders of the Common Stock and shall be entitled to receive, when, as and if declared by our Board, such dividends (whether in cash or other property) as are
paid to holders of our Common Stock to the same extent as if such holders of Series A Preferred Stock had been deemed to convert their shares of Series A Preferred Stock into Common Stock and had held such shares of Common Stock on the record date
for such dividends and distributions. Such payments will be made concurrently with the dividend or distribution to the holders of the Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">259 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Preference </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a change of control, liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, whether
voluntary or involuntary, before any payment or distribution of our property or assets (whether capital or surplus) shall be made to or set apart for the holders of Junior Securities, the holders of Series A Preferred Stock shall be entitled to
receive an amount per share of Series A Preferred Stock equal to the greater of (i)&nbsp;the sum of $10.00 (which amount shall be appropriately adjusted in the event of any stock split, stock combination or other similar recapitalization of the
Series A Preferred Stock) and all accrued and unpaid dividends and (ii)&nbsp;the amount such share of Series A Preferred Stock would be entitled to receive pursuant to the change of control, liquidation, dissolution or
<FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company assuming that such share had been converted into shares of Common Stock in a Deemed Conversion (as defined below). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion and Redemption Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Series A Preferred Stock will not be convertible into Common Stock or any of our other securities and will not be redeemable by
the Company; provided, however, a number of the rights, preferences and privileges of the Series A Preferred Stock set forth in the Certificate of Designations will be determined based on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-converted-to-</FONT></FONT></FONT> Common Stock basis or otherwise assume that the shares of Series A Preferred Stock are converted into shares of Common Stock. Accordingly, the number
of shares of Common Stock that each share of Series A Preferred Stock is deemed to be (or otherwise being treated as) converted into for the purpose of affecting the various rights, preferences and privileges of the Series A Preferred Stock set
forth in the Certificate of Designation (a &#147;Deemed Conversion&#148;), whether in connection with a change of control or otherwise, shall be equal to the result obtained by dividing (i)&nbsp;stated value by (ii) $10.00 (subject to anti-dilution
adjustments). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting and Other Preferred Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law or as set forth in the Certificate of Designations, the holders of shares of Series A Preferred Stock will
be entitled to vote, together with the holders of shares of Common Stock and not separately as a class, on all matters upon which holders of shares of Common Stock have the right to vote. The holders of shares of Series A Preferred Stock will be
entitled to one vote for each share of Common Stock that such share of Series A Preferred Stock would otherwise be convertible into pursuant to a Deemed Conversion on the record date for the determination of the stockholders entitled to vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As long as any shares of Series A Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of at least a
majority of the outstanding shares of Series A Preferred Stock (a)&nbsp;change the Series A Preferred Stock (whether by merger, consolidation, reclassification or otherwise) into cash, securities or other property except in accordance with the terms
of the Certificate of Designations; (b)&nbsp;create, authorize or issue any Parity Security or other equity security the terms of which provide that it ranks senior to the Series A Preferred Stock with respect to dividend rights or rights upon
liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, or increase the authorized amount of any such other class or series; or (c)&nbsp;amend the Certificate of Incorporation or the Certificate of Designations
in any manner that adversely affects the holders of Series A Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Agreement with Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, from and after the Effective Time, and for so long as the Sorrento Group beneficially owns
any shares of New Scilex Series A Preferred Stock, among other things, (i)&nbsp;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to our Board (each, a &#147;Stockholder
Designee&#148; and collectively, the &#147;Stockholder Designees&#148;), regardless of whether such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu
of meeting) or appointed by the Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of the Board, or the size of the Board and (ii)&nbsp;we will be required to take all actions
reasonably necessary, and not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">260 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to the Board as more fully described in the Stockholder Agreement. Sorrento
shall also have the right to designate a replacement director for any Stockholder Designee that has been removed from the Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the Board.
Notwithstanding the foregoing, the parties have agreed to ensure that the Board complies with all applicable requirements of the stock exchange, including independence requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement also provides that we will be prohibited from taking certain actions without the consent of Sorrento. Such actions
include, among other things, amendments to the Certificate of Designations, increases or decreases in the size of the Board, the incurrence of certain amounts of indebtedness and the payment of dividends on our Common Stock. For more information on
the Stockholder Agreement, see the section titled &#147;<I>Certain Relationships and Related Party Transactions</I><I></I><I>&nbsp;&#151; Certain Relationships of Vickers</I><I></I><I>&nbsp;&#151; Stockholder Agreement with Sorrento</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_103"></A>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement entered into in connection with the Closing of the Business Combination, certain of our
stockholders are able to demand that we register their registrable securities under certain circumstances and each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective
registration statement under the Securities Act covering the resale of all such registrable securities. We have filed the registration statement of which this prospectus forms a part in order to satisfy the foregoing obligations. The registration of
these securities will enable the public sale of such securities, subject to certain contractual restrictions imposed by the Registration Rights Agreement and the Merger Agreement. The presence of these additional shares of common stock trading in
the public market may have an adverse effect on the market price of our securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_104"></A>Anti-Takeover Matters in our Governing
Documents and Under Delaware Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of Delaware law, along with the Certificate of Incorporation and the Bylaws, all
of which are summarized below, may have the effect of delaying, deferring or discouraging another person from acquiring control of the Company. These provisions are expected to discourage coercive takeover practices and inadequate takeover bids.
These provisions are also designed, in part, to encourage persons seeking to acquire control of the Company to first negotiate with our Board. However, these provisions could have the effect of delaying, discouraging or preventing attempts to
acquire the Company, which could deprive our stockholders of opportunities to sell their shares of our Common Stock at prices higher than prevailing market prices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Authorized but Unissued Capital Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The authorized but unissued shares of our Common Stock and our Preferred Stock are available for future issuance without stockholder approval,
subject to any limitations imposed by the rules of the Nasdaq Listing Rules. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and
unreserved Common Stock and Preferred Stock could make more difficult or discourage an attempt to obtain control of the Company by means of a proxy contest, tender offer, merger or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified Board of Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Certificate of Incorporation provides that our Board are divided into three classes, with the classes as nearly equal in number as practical and each class serving three-year staggered terms. The directors in each class serve for a three-year term
(except that the term of our current Class&nbsp;I directors shall expire at the first annual meeting of stockholders following the Closing of the Business Combination and the term of our current Class&nbsp;II directors shall expire at the second
annual meeting of stockholders following the Closing of the Business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">261 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Combination), with one class being elected each year by the stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or
otherwise attempting to obtain control of the Company, because it generally makes it more difficult for stockholders to replace a majority of the directors. See the section of this prospectus titled &#147;<I>Management</I>&#148; for more information
on the classified board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that the total number of directors shall be determined from time
to time exclusively by our Board; provided that, at any time prior to a Sorrento Trigger Event, the stockholders may also fix the number of directors by resolution adopted by the stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Removal of Directors; Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, except as otherwise required by law or the Certificate of Incorporation, directors may be
removed with or without cause by the affirmative vote of the holders of a majority in voting power of the then-outstanding shares of our stock entitled to vote generally in the election of such directors; provided, however, that, from and after the
Sorrento Trigger Event, any such director or all such directors may be removed only for cause and only by the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our stock entitled to vote
thereon, voting together as a single class, in each case subject to the rights of holders of any series of Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
the Certificate of Incorporation provides that, except as otherwise provided therein or by law, any vacancy resulting from the death, resignation, removal or disqualification of a director or other cause, or any newly created directorship in our
Board, may be filled by a majority of the directors then in office, although less than a quorum, or by our stockholders; provided, however, that from and after the Sorrento Trigger Event, any vacancy resulting from the death, resignation, removal or
disqualification of a director or other cause, or any newly created directorship in our Board, shall be filled only by a majority of the directors then in office, although less than a quorum, and shall not be filled by our stockholders, in each case
subject to the rights of the holders of any series of Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may have the effect of deferring, delaying, or
discouraging hostile takeovers, changes in control of the Company or changes in our management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that we will opt out of Section&nbsp;203 of the DGCL until the occurrence of a Sorrento Trigger
Event, at which time we shall immediately and automatically become governed by Section&nbsp;203 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL
prohibits persons deemed to be &#147;interested stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly held Delaware corporation for three years following the date such persons become interested stockholders, unless
the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who,
together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a &#147;business combination&#148; includes a
merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions that are not approved in advance by our
Board, including discouraging attempts that might result in a premium over the market price for the shares of Common Stock held by stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that the restrictions on business combination of Section&nbsp;203 of the DGCL will not apply to
Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) regardless of the percentage of ownership of the total voting power of all the then-outstanding shares of our capital stock entitled to vote generally in
the election of directors beneficially owned by them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">262 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Cumulative Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative
voting. The Certificate of Incorporation does not authorize cumulative voting. Therefore, stockholders holding a majority of the shares of our capital stock entitled to vote generally in the election of directors will be able to elect all of our
directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special Stockholder Meetings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that special meetings of stockholders may only be called by order of the Chairperson of our Board,
our Board or the Chief Executive Officer; provided, however, that at any time prior to the Sorrento Trigger Event, special meetings of our stockholders shall also be called by or at the direction of our Board or the Chairperson of our Board at the
request of Sorrento, in each case subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. The Bylaws prohibits the conduct of any business at a special meeting other than as specified in
the notice for such meeting. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers or changes in control or management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Nominations and Stockholder Proposals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws establishes advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as
directors, other than nominations made by or at the direction of our Board or a committee of our Board. In order for any matter to be &#147;properly brought&#148; before a meeting, a stockholder will have to comply with advance notice requirements
and provide us with certain information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, to be timely, a stockholder&#146;s notice must be delivered to our secretary at our
principal executive offices not earlier than the close of business on the 120th day nor later than the close of business on the 90th day prior to the first anniversary of the preceding year&#146;s annual meeting (in the case of the first annual
meeting of stockholders held after January&nbsp;1, 2023, the date of the preceding year&#146;s annual meeting of the stockholders shall be deemed to be June&nbsp;30, 2022); provided, however, that, if the date of the annual meeting is advanced more
than 30 days prior to or delayed by more than 60 days after the anniversary of the preceding year&#146;s annual meeting, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely must be so delivered not earlier
than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting and the 10th day following the day on which public announcement of the date
of such meeting is first made by us. The Bylaws also specifies requirements as to the form and content of a stockholder&#146;s notice. The Bylaws allows any previously scheduled stockholders meeting to be postponed, adjourned or canceled by
resolution of our Board; provided, however, that with respect to any special meeting of stockholders scheduled at the request of Sorrento, our Board is not allowed to postpone, reschedule or cancel without the prior written consent of Sorrento. In
addition, the Bylaws allows the chair of a meeting of the stockholders to adopt rules and regulations for the conduct of that meeting that may have the effect of precluding the conduct of certain business at that meeting if the rules and regulations
are not followed. These provisions may also defer, delay, or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise attempting to influence or obtain control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;228 of the DGCL and the terms of the Certificate of Incorporation , any action required or permitted to be taken by
our stockholders must be effected by a duly called annual or special meeting of such stockholders; provided, however, that prior to the Sorrento Trigger Event, any action required or permitted to be taken at any annual or special meeting of our
stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents, setting forth the action so taken, is signed by or on behalf of the holders of record of outstanding stock having not less than the
minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">263 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and voted, is delivered to us in accordance with the DGCL, in each case subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Certificate of Incorporation or Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a
corporation&#146;s certificate of incorporation or bylaws, unless a corporation&#146;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, upon the occurrence of the Sorrento Trigger Event, the affirmative vote of the holders of at
least 66 2/3% of the voting power of the then-outstanding shares of stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the following provisions of the Certificate of Incorporation: Article V
(Board of Directors), Article VI (Consent of Stockholders in Lieu of Meeting; Special Meetings of Stockholders), Article VII (Limitation of Liability), Article&nbsp;VIII (Corporate Opportunities and Competition), Article IX (Exclusive Forum),
Article X (Section 203 of the DGCL) and Article XI (Amendment of Certificate of Incorporation and Bylaws), and no other provision may be adopted, amended or repealed that would have the effect of modifying or permitting the circumvention of the
provisions set forth in any of such Articles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws provide that, our Board is authorized to
make, alter and repeal the Bylaws, without the consent or vote of the stockholders, by an approval of a majority of the total authorized number of directors. Upon the occurrence of the Sorrento Trigger Event, the affirmative vote of the holders of
at least 66 2/3% of the voting power of the then-outstanding shares of stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of the DGCL, the Certificate of Incorporation and the Bylaws could have the effect of discouraging others from attempting
hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our Common Stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing
changes in the composition of our Board and our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Forum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate
of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter
jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall, to the
fullest extent permitted by law, be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of the Company, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our current or
former directors, officers, employees or stockholders to us or our stockholders, (iii)&nbsp;any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of
the DGCL or of the Certificate of Incorporation or the Bylaws, (iv)&nbsp;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws, (v)&nbsp;any action or proceeding
asserting a claim against us or any of our current or former directors, officers, employees or stockholders as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware, or (vi)&nbsp;any action asserting an
&#147;internal corporate claim,&#148; as that term is defined in Section&nbsp;115 of the DGCL. The foregoing exclusive forum provisions will not apply to claims arising under the Exchange Act or any other claim for which the federal courts have
exclusive jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Certificate of Incorporation provides that, unless we consent in writing to
the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe these provisions benefit us by providing increased consistency in the application of applicable law
in the types of lawsuits to which they apply, the provisions may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#146; certificates of
incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations
thereunder. It is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in the Certificate of Incorporation to be inapplicable or unenforceable in such action. We may
incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition. Any person or entity purchasing or otherwise acquiring any interest in shares of our
capital stock shall be deemed to have notice of and consented to the forum provisions in the Certificate of Incorporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitation of Liability
and Indemnification of Directors and Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws contain provisions that limit the
liability of our directors for monetary damages to the fullest extent permitted by the DGCL. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors,
except liability for the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of their duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal
liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide that we shall indemnify any person who is or was a director or officer of the Company or who is or was serving at our
request as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (a &#147;Covered Person&#148;) and who is or was a party to,
is threatened to be made a party to, or is otherwise involved (including as a witness) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative based on such person&#146;s actions
in his or her official capacity as a director or officer of the Company or as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other
enterprise (to the extent serving in such position at our request), in each case against all liability and loss suffered (including, without limitation, any judgments, fines, excise taxes or penalties arising under the Employee Retirement Income
Security Act of 1974 and amounts paid in settlement consented to in writing by us) and expenses (including attorneys&#146; fees), actually and reasonably incurred by such person in connection therewith, subject to certain conditions. In addition,
the Bylaws provide that we may, to the fullest extent permitted by law, (i)&nbsp;advance costs, fees or expenses (including attorneys&#146; fees) incurred by a Covered Person defending or participating in any proceeding in advance of the final
disposition of such proceeding, subject to certain exceptions, and (ii)&nbsp;purchase and maintain insurance, at our expense, to protect us and any person who is or was a director, officer, employee or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">265 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agent of the Company or is or was a director, officer, employee or agent of the Company serving at our request as a director, officer, employee or agent of another corporation, limited liability
company, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability, expense or loss, whether or not we would have the power or obligation to indemnify such person against such liability, expense or loss under
the DGCL or the provisions of the Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors, executive officers
and certain other employees as determined by our Board. These agreements, among other things, require us to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification
agreements also require us to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. Our Board believes that these agreements are necessary to attract and retain qualified
individuals to serve as directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of the Certificate of
Incorporation, the Bylaws and the indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through their relationships with their employers, be
insured or indemnified against certain liabilities incurred in their capacity as members of our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and
indemnification provisions in the Certificate of Incorporation and the Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of
derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. In addition, a stockholder&#146;s investment may be adversely affected to the extent we pay the costs of
settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been
informed that in the opinion of the SEC, such indemnification is against public policy and is therefore unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_105"></A>Conflicts of Interest </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the
corporation or its officers, directors or stockholders. The Certificate of Incorporation provides that, to the fullest extent permitted by law, no Identified Person (as defined therein) will have any duty to refrain from (i)&nbsp;engaging in a
corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates or (ii)&nbsp;otherwise investing in or providing
services to any person that is engaged in the same or similar business activities as we or our affiliates or competes with us or our affiliates. In addition, to the fullest extent permitted by law, no Identified Person will have any obligation to
offer to us or our subsidiaries or affiliates the right to participate in any corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us
or any of our affiliates. Subject to the preceding sentences and to the fullest extent permitted by applicable law, neither we nor any of our subsidiaries shall have any rights in any business interests, activities or ventures of any Identified
Person, and we waive and renounce any interest or expectancy therein, except with respect to opportunities offered solely and expressly to our officers in their capacity as such. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_106"></A>Rights of Appraisal and Payment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, with certain exceptions, our stockholders will have appraisal rights in connection with a merger or consolidation of the
Company. Pursuant to Section&nbsp;262 of the DGCL, stockholders who properly demand and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined
by the Delaware Court of Chancery. However, appraisal rights are not available in all circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">266 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_107"></A>Stockholders&#146; Derivative Actions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, any of our stockholders may bring an action in the Company&#146;s name to procure a judgment in its favor, also known as a
derivative action, provided that the stockholder bringing the action is a holder of our capital stock at the time of the transaction to which the action relates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_108"></A>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
the effective time of the Domestication, each warrant to purchase Vickers Ordinary Shares that was issued and outstanding immediately prior to the effective time of the Domestication and not terminated pursuant to its terms was converted into a
warrant to purchase shares of our Common Stock on the same terms and conditions as are in effect with respect to such warrant immediately prior to the effective time of the Domestication. As of the date of this prospectus, there are 6,899,988
outstanding Public Warrants and 4,104,000 outstanding Private Placement Warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Public Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Public Warrant entitles the registered holder thereof to purchase one share of our Common Stock at a price of $11.50 per share, subject to
adjustment as described in this prospectus. We may, in our sole discretion, lower the warrant exercise price at any time prior to the expiration date for a period of not less than 20 business days and any such reduction will be applied consistently
to all of the warrants, provided that we will provide at least 20 days&#146; prior written notice to registered holders of the warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, no Public Warrants will be exercisable for cash unless we have an effective and current registration statement covering the issuance
of the Common Stock issuable upon exercise of the warrants and a current prospectus relating to such Common Stock. Notwithstanding the foregoing, if a registration statement covering the issuance of the Common Stock issuable upon exercise of the
Public Warrants is not effective within 90 days from the consummation of the Business Combination, warrantholders may, from the 91st day after the consummation of the Business Combination until such time as there is an effective registration
statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from
registration is not available, holders will not be able to exercise their warrants on a cashless basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants will expire five
years from the consummation of the Business Combination (i.e., November&nbsp;10, 2027) at 5:00 p.m., New York City time or earlier upon redemption or liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may call the warrants for redemption (excluding the Private Placement Warrants), in whole and not in part, at a price of $0.01 per warrant:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at any time while the warrants are exercisable, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon not less than 30 days&#146; prior written notice of redemption to each warrantholder, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the closing price of the Common Stock equals or exceeds $18.00 per share (as adjusted for share <FONT
STYLE="white-space:nowrap">sub-divisions,</FONT> share dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period commencing after the warrants become exercisable and ending on the third trading day
prior to the date on which notice of redemption is given, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, there is an effective registration statement covering the Common Stock issuable upon exercise of
the Public Warrants, and a current prospectus relating thereto, available throughout the <FONT STYLE="white-space:nowrap">30-day</FONT> redemption. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not exercise such redemption right if the issuance of the Common Stock upon exercise of the warrants is not exempt from registration or
qualification under applicable state blue sky laws or we are unable to effect such registration or qualification. The right to exercise will be forfeited unless the warrants are exercised </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">267 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prior to the date specified in the notice of redemption. On and after the redemption date, a record holder of a warrant will have no further rights except to receive the redemption price for such
holder&#146;s warrant upon surrender of such warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redemption criteria for our warrants have been established at a price which is
intended to provide warrantholders a reasonable premium to the initial exercise price and provide a sufficient differential between the then-prevailing per share price of our Common Stock and the warrant exercise price so that if the per share price
of our Common Stock declines as a result of our redemption call, the redemption will not cause the per share price of our Common Stock to drop below the exercise price of the warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we call the warrants for redemption as described above, our management will have the option to require all holders of warrants to exercise
their warrants on a &#147;cashless basis.&#148; In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x)&nbsp;the product of the
number of shares of Common Stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the fair market value by (y)&nbsp;the fair market value. The &#147;fair market value&#148; for this purpose shall
mean the average reported closing price of the shares of our Common Stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. For example, if a holder held
150 warrants to purchase 150 shares of our Common Stock and the fair market value on the trading date prior to exercise was $15.00, that holder would receive 35 shares of our Common Stock without the payment of any additional cash consideration.
Whether we will exercise our option to require all holders to exercise their warrants on a &#147;cashless basis&#148; will depend on a variety of factors including the price of our Common Stock at the time the warrants are called for redemption, our
cash needs at such time and concerns regarding dilutive share issuances. Requiring a cashless exercise in this manner will reduce the number of shares of our Common Stock to be issued and thereby lessen the dilutive effect of a warrant redemption.
We believe this feature is an attractive option to use if we do not need the cash from the exercise of the Public Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants
are issued in registered form under a warrant agreement (the &#147;Warrant Agreement&#148;) between Continental, as warrant agent, and us. The Warrant Agreement provides that the terms of the warrants may be amended without the consent of any holder
to cure any ambiguity or correct any defective provision, but requires the approval, by written consent or vote, of the registered holders of a majority of the then-outstanding warrants (including the Private Placement Warrants) in order to make any
change that adversely affects the interests of the registered holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price and number of shares of Common Stock issuable
on exercise of the warrants may be adjusted in certain circumstances including in the event of (i)&nbsp;a stock dividend or split up, (ii)&nbsp;a consolidation, combination, reverse stock split or reclassification of the Common Stock,
(iii)&nbsp;extraordinary dividend or (iv)&nbsp;reclassification or reorganization of the outstanding Common Stock or an merger or consolidation of us with or into another corporation. However, the warrants will not be adjusted for issuances of
shares of Common Stock at a price below the par value per share issuable upon exercise of the warrants. Whenever the number of shares of Common Stock purchasable upon the exercise of the warrants is adjusted, the warrant exercise price will be
adjusted by multiplying such warrant exercise price immediately prior to such adjustment by a fraction (x)&nbsp;the numerator of which will be the number of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to
such adjustment, and (y)&nbsp;the denominator of which will be the number of shares of Common Stock so purchasable immediately thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant
agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified check or bank draft payable to
the order of the warrant agent or wire transfer, for the number of warrants being exercised. The warrantholders do not have the rights or privileges of holders of shares of Common Stock and any voting rights until they exercise their warrants and
receive shares of Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">268 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
After the issuance of shares of Common Stock upon exercise of the warrants, each holder will be entitled to one vote for each share of Common Stock held of record on all matters to be voted on by
stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described above, no Public Warrants will be exercisable for cash and we will not be obligated to issue shares of
Common Stock upon exercise of a warrant unless the shares of Common Stock issuable upon such warrant exercise have been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the
warrants. Under the terms of the Warrant Agreement, we have agreed to use our best efforts to meet these conditions and to maintain a current prospectus relating to the Common Stock issuable upon exercise of the warrants until the expiration of the
warrants. However, we cannot assure you that we will be able to do so and, if we do not maintain a current prospectus relating to the Common Stock issuable upon exercise of the warrants, holders will be unable to exercise their warrants and we will
not be required to settle any such warrant exercise. If the prospectus relating to the Common Stock issuable upon the exercise of the warrants is not current or if the Common Stock is not qualified or exempt from qualification in the jurisdictions
in which the holders of the warrants reside, we will not be required to net cash settle or cash settle the warrant exercise, the warrants may have no value, the market for the warrants may be limited and the warrants may expire worthless. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrantholders may elect to be subject to a restriction on the exercise of their warrants such that an electing warrantholder would not be
able to exercise their warrants to the extent that, after giving effect to such exercise, such holder (together with such holder&#146;s affiliates) would beneficially own in excess of 9.8% of the Common Stock outstanding immediately after giving
effect to such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder
would be entitled to receive a fractional interest in a share, we will, upon exercise, round up to the nearest whole number of shares of Common Stock to be issued to the warrantholder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Private Placement Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Private Placement Warrants are identical to the Public Warrants except that such Private Placement Warrants are exercisable for cash (even if a registration statement covering the issuance of the Common Stock issuable upon exercise of such warrants
is not effective) or on a cashless basis, at the holder&#146;s option, and will not be redeemable by us, in each case so long as they are still held by the initial purchasers or their affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the terms and conditions of the warrants does not purport to be complete and is qualified in its entirety by
reference to the copy of the Warrant Agreement that is filed as an exhibit to the registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_109">
</A>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our Common Stock is Continental. The transfer agent&#146;s
address is 1 State Street, 30th Floor, New York, New York 10004. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom428534_110"></A>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of our Common Stock and Public Warrants are listed on Nasdaq under the symbols &#147;SCLX&#148; and &#147;SCLXW&#148; respectively. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_111"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities being offered by this prospectus will be passed upon for us by Paul Hastings LLP, Palo Alto, California. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">269 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_112"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Vickers Vantage Corp. I as of December&nbsp;31, 2021 and 2020, for the year then ended December&nbsp;31, 2021, and
for the period from February&nbsp;21, 2020 (inception) through December&nbsp;31, 2020, and for the period from January&nbsp;1, 2021 through December&nbsp;31, 2021, appearing in this prospectus have been audited by WithumSmith+Brown, PC, independent
registered public accounting firm, as set forth in their report thereon (which includes explanatory paragraphs relating to the correction of certain misstatements related to the January&nbsp;11, 2021 financial statement and Vickers Vantage Corp.
I&#146;s ability to continue as a going concern), appearing elsewhere in this prospectus and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Scilex Holding Company at December&nbsp;31, 2021 and 2020, and for the years then ended, appearing in
this prospectus, have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about
our ability to continue as a going concern as described in Note 2 to the consolidated financial statements) appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and
auditing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Scilex Holding Company for the period ended December&nbsp;31, 2019, included in this prospectus
have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are included in reliance upon the report of such firm given upon their authority as experts
in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_113"></A>CHANGE IN AUDITORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon the Closing, on November&nbsp;10, 2022, the Board dismissed WithumSmith+Brown, PC (&#147;Withum&#148;), which served as
Vickers&#146;s independent registered public accounting firm prior to the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The report of Withum on the financial
statements of Vickers as of December&nbsp;31, 2020 and 2021 did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope or accounting principles except for an explanatory paragraph
in such report regarding substantial doubt about Vickers&#146;s ability to continue as a going concern and emphasized the restatement of Vickers&#146;s financial statement as of January&nbsp;11, 2021 due to its change in accounting for warrants and
Vickers Ordinary Shares subject to possible redemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fiscal years ended December&nbsp;31, 2020 and 2021 and the subsequent
interim period through November&nbsp;10, 2022, there were no disagreements (as defined in Item 304(a)(1)(iv) of Regulation <FONT STYLE="white-space:nowrap">S-K)</FONT> with Withum on any matter of accounting principles or practices, financial
statement disclosure or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Withum, would have caused Withum to make reference to the subject matter of the disagreements in its reports covering such periods. In
addition, no &#147;reportable events,&#148; as defined in Item 304(a)(1)(v) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K,&nbsp;occurred</FONT> within the period of Withum&#146;s engagement and the subsequent interim period preceding
Withum&#146;s dismissal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company provided Withum with a copy of the disclosures made by us in response to Item&nbsp;304(a) of <FONT
STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> and has requested that Withum furnish the Company with a letter addressed to the SEC stating whether it agrees with the statements made by us in response to Item&nbsp;304(a) of <FONT
STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> and, if not, stating the respects in which it does not agree. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10,
2022, the Board approved the engagement of Ernst&nbsp;&amp; Young LLP (&#147;EY&#148;) as the Company&#146;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2022. EY
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">270 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
audited the consolidated balance sheets of Scilex as of December&nbsp;31, 2020 and December&nbsp;31, 2021 and the related consolidated statements of operations, stockholders&#146; deficit and
cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2020 and 2021 and the subsequent interim period through November&nbsp;10, 2022,
neither the Company nor anyone on its behalf consulted with EY regarding (i)&nbsp;the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the
Company&#146;s financial statements, and no written report or oral advice was provided to the Company that EY concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting
issue, or (ii)&nbsp;any matter that was the subject of a disagreement within the meaning of Item&nbsp;304(a)(1)(iv) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K&nbsp;or</FONT> any reportable event within the meaning of
Item&nbsp;304(a)(1)(v) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_114"></A>WHERE YOU CAN FIND
MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> including exhibits,
under the Securities Act, with respect to the securities offered by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our securities, you
should refer to the registration statement of which this prospects is a part and the exhibits to such registration statement. The descriptions in this prospectus of the provisions of documents filed as exhibits to this prospectus are only summaries
of those documents&#146; material terms. You can read copies of such documents, along with copies of reports, proxy statements and other information filed by us with the SEC at the SEC&#146;s website at<I></I><I>&nbsp;http://www.sec.gov</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain a website at www.scilexholding.com. Through our website, we make available, free of charge, annual, quarterly and current
reports, proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may be accessed through, our website is not part of, and is
not incorporated into, this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">271 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom428534_115"></A>VICKERS VANTAGE CORP. I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_3">Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_4">Statements of Changes in Shareholders&#146; (Deficit) Equity</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_7">Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-25</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_8">Unaudited Condensed Consolidated Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_9">Unaudited Condensed Consolidated Statements of Changes in Shareholders&#146; Equity
 (Deficit)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-27</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_10">Unaudited Condensed Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-28</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_11">Notes to Unaudited Condensed Consolidated Financial
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-29</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4" ALIGN="center"><B>SCILEX HOLDING COMPANY</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CONSOLIDATED FINANCIAL STATEMENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_12">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-56</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_13">Consolidated Balance Sheets as of December&nbsp;31, 2021 and
2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-58</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_14">Consolidated Statements of Operations for the Years Ended December&nbsp;
31, 2021, 2020 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-59</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_15">Consolidated Statements of Stockholders&#146; Deficit for the Years Ended December&nbsp;31,
 2021, 2020 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-60</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_16">Consolidated Statements of Cash Flows for the Years Ended December&nbsp;
31, 2021, 2020 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-61</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_17">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-62</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_18">Consolidated Balance Sheets as of September&nbsp;
30, 2022 and December&nbsp;31, 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-90</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_19">Consolidated Statements of Operations as of September&nbsp;
30, 2022 and December&nbsp;31, 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-91</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_20">Consolidated Statements of Stockholders&#146; Deficit as of September&nbsp;
30, 2022 and December&nbsp;31, 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-92</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_21">Consolidated Statements of Cash Flows for the Nine Months Ended September&nbsp;30,
 2022 and 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-93</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin428534_22">Notes to Unaudited Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-94</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Shareholders and the Board of Directors of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vickers
Vantage Corp. I </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheet of Vickers Vantage Corp. I (the &#147;Company&#148;) as of December&nbsp;31, 2021 and 2020, the related
statements of operations, changes in shareholders&#146; (deficit) equity and cash flows for the year ended December&nbsp;31, 2021 and for the period from February&nbsp;21, 2020 (inception) through December&nbsp;31, 2020, and the related notes
(collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2021 and 2020, and the results of
its operations and its cash flows for the year ended December&nbsp;31, 2021 and for the period from February&nbsp;21, 2020 (inception) through December&nbsp;31, 2020, in conformity with accounting principles generally accepted in the United States
of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Going Concern </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying
financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, if the Company is unable to raise additional funds to alleviate liquidity needs as well as
complete a Business Combination by the close of business on April&nbsp;11, 2022, then the Company will cease all operations except for the purpose of liquidating. This date for mandatory liquidation and subsequent dissolution raises substantial
doubt about the Company&#146;s ability to continue as a going concern. Management&#146;s plans regarding these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this
uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restatement of Previously Issued Financial Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in Note 10 to the financial statements, the Company&#146;s previously issued January&nbsp;11, 2021 financial statement has ben restated herein to
correct certain misstatements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance with the
U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The
Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the
purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ WithumSmith+Brown, PC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s
auditor since 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;24,
2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PCAOB ID Number 100 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_2"></A>BALANCE SHEETS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">507,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Current Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>512,457</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>30,511</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments held in Trust Account&nbsp;&#151;&nbsp;US Treasury Securities Money Market
Fund</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139,410,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>139,923,196</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>199,484</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES AND SHAREHOLDERS&#146; (DEFICIT) EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advances from related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Promissory note&nbsp;&#151;&nbsp;related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Current Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>208,704</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>180,760</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible promissory note&nbsp;&#151;&nbsp;related party, net of discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">483,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion option liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,351,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting fee payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,190,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,240,295</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>180,760</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and Contingencies</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares subject to possible redemption 13,800,000 as of December&nbsp;31, 2021 and no
shares as of December&nbsp;31, 2020 at redemption value of $10.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139,380,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; (Deficit) Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 3,450,000 <FONT
STYLE="white-space:nowrap">non-redeemable</FONT> shares issued and outstanding at December&nbsp;31, 2021 and 2020<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,697,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Shareholders&#146; (Deficit) Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(8,697,099</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>18,724</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL LIABILITIES AND SHAREHOLDERS&#146; (DEFICIT) EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>139,923,196</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>199,484</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At December&nbsp;31, 2020, includes an aggregate of up to 450,000 ordinary shares that are subject to
forfeiture depending on the extent to which the underwriters&#146; over-allotment option is exercised (see Note 6). On January&nbsp;6, 2021, the Company effected a share capitalization of 0.2 shares for each share outstanding, resulting in 3,450,000
ordinary shares issued and outstanding (see Note 6). All share and per share amounts have been retroactively restated to reflect the share capitalization. As a result of the underwriters&#146; full exercise of their overallotment option on
January&nbsp;11, 2021, no shares were forfeited. </P></TD></TR></TABLE> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of the financial
statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_3"></A>STATEMENTS OF OPERATIONS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the<BR>Period from<BR>February&nbsp;21,<BR>2020<BR>(Inception)<BR>Through<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating and formation costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,005,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,005,498</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,276</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,377,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on initial issuance of private warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,599,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of conversion option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense&nbsp;&#151;&nbsp;debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,826</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs allocated to warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,788,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>783,438</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,276</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average shares outstanding, ordinary shares<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,820,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic net income (loss) per share, ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted weighted average shares outstanding, ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,834,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Diluted net income (loss) per share, ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At December&nbsp;31, 2020, excludes an aggregate of up to 450,000 ordinary shares that were subject to
forfeiture. </P></TD></TR></TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an
integral part of the financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_4"></A>STATEMENTS OF CHANGES IN SHAREHOLDERS&#146; (DEFICIT) EQUITY </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid in<BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Shareholders&#146;<BR>Equity<BR>(Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&nbsp;&#151;&nbsp;February&nbsp;21, 2020 (inception)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of ordinary shares to Sponsor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancellation of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of ordinary shares to Sponsor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,450,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&nbsp;&#151;&nbsp;December&nbsp;31, 2020 (audited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,450,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>24,655</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,276</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>18,724</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of ordinary shares subject to redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,655</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,474,606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,499,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">783,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">783,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&nbsp;&#151;&nbsp;December&nbsp;31, 2021 (audited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,450,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(8,697,444</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(8,697,099</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of the financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_5"></A>STATEMENTS OF CASH FLOWS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the<BR>Period from<BR>February&nbsp;21,<BR>2020<BR>(Inception)<BR>Through<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Operating Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">783,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income (loss) to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Formation cost paid through advances from affiliate of Sponsor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,377,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on initial issuance of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,599,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of conversion option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs allocated to private warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(801,330</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,276</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Investing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment of cash in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(139,380,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(139,380,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of Units, net of underwriting discounts paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of Private Placement Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,130,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advances from related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of advances from related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from promissory note &#151; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of promissory note &#151; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(125,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from convertible promissory note &#151; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(416,260</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(118,213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>140,658,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>31,787</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net Change in Cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>477,410</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>30,511</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash&nbsp;&#151;&nbsp;Beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash&nbsp;&#151;&nbsp;End of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>507,921</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>30,511</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Cash</FONT> investing and financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting fee payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,190,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs included in accrued offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs paid through promissory note&nbsp;&#151;&nbsp;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of the financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_6"></A>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE
1&nbsp;&#151;&nbsp;DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vickers Vantage Corp. I (the &#147;Company&#148;) is a blank check company
incorporated as a Cayman Islands exempted company on February&nbsp;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or
more businesses or entities (a &#147;Business Combination&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is not limited to a particular industry or sector for purposes of
consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021, the Company had not commenced any operations. All activity for the period from February&nbsp;21, 2020 (inception) through
December&nbsp;31, 2021 relates to the Company&#146;s formation and the initial public offering (&#147;Initial Public Offering&#148;), which is described below, and, subsequent to the Initial Public Offering, identifying a target company for a
Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate <FONT STYLE="white-space:nowrap">non-operating</FONT> income in the form of
interest income from the proceeds derived from the Initial Public Offering. The Company has selected December&nbsp;31 as its fiscal year end. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
registration statement for the Company&#146;s Initial Public Offering was declared effective on January&nbsp;6, 2021. On January&nbsp;11, 2021 the Company consummated the Initial Public Offering of 13,800,000&nbsp;Units (the &#147;Units&#148; and,
with respect to the ordinary shares included in the Units sold, the &#147;Public Shares&#148;), which includes the full exercise by the underwriter of its over-allotment option in the amount of 1,800,000&nbsp;Units, at $10.00 per Unit, generating
gross proceeds of $138,000,000 which is described in Note 3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the
sale of 6,840,000 warrants (the &#147;Private Placement Warrants&#148;) at a price of $0.75 per Private Placement Warrant in a private placement to Vickers Venture Fund&nbsp;VI Pte Ltd and Vickers Venture Fund&nbsp;VI (Plan) Pte Ltd, (the
&#147;Sponsor&#148;), generating gross proceeds of $5,130,000, which is described in Note 4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transaction costs amounted to $8,149,473, consisting of
$2,400,000 in cash underwriting fees, $5,190,000 in deferred underwriting fees, and $559,473 of other offering costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the closing of the
Initial Public Offering on January&nbsp;11, 2021, an amount of $139,380,000 ($10.10 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account
(the &#147;Trust Account&#148;), and invested in U.S. government securities, within the meaning set forth in Section&nbsp;2(a)(16) of the Investment Company Act, with a maturity of 185&nbsp;days or less, or in any open-ended investment company that
holds itself out as a money market fund investing solely in U.S. Treasuries and meeting certain conditions under <FONT STYLE="white-space:nowrap">Rule&nbsp;2a-7</FONT> of the Investment Company Act, as determined by the Company, until the earliest
of: (i)&nbsp;the completion of a Business Combination and (ii)&nbsp;the distribution of the funds in the Trust Account to the Company&#146;s shareholders, as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of
the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The stock exchange listing rules require that the Business Combination must be with one
or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust
Account). The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise
acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#147;Investment Company Act&#148;). There is no assurance
that the Company will be able to successfully effect a Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will provide the holders of the public shares (the &#147;Public
Shareholders&#148;) with the opportunity to redeem all or a portion of their public shares upon the completion of the Business Combination, either (i)&nbsp;in connection with a general meeting called to approve the Business Combination or
(ii)&nbsp;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be
entitled to redeem their Public Shares, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination (initially anticipated to be $10.10 per Public
Share), including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding public shares, subject to certain limitations as described in the prospectus. The
<FONT STYLE="white-space:nowrap">per-share</FONT> amount to be distributed to the Public Shareholders who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as
discussed in Note 6). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 and, if the
Company seeks shareholder approval, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the
Company. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the
redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (&#147;SEC&#148;), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to
completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Company&#146;s Sponsors have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during
or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a
proposed Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does
not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#147;group&#148; (as defined under
Section&nbsp;13 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)), will be restricted from redeeming its shares with respect to more than an aggregate of 20% of the Public Shares without the Company&#146;s prior
written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsors have agreed (a)&nbsp;to waive their redemption rights with respect to any Founder Shares and Public Shares held by them in
connection with the completion of a Business Combination and (b)&nbsp;not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i)&nbsp;to modify the substance or timing of the Company&#146;s obligation to allow
redemption in connection with the Company&#146;s initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&nbsp;with respect
to any other provision relating to shareholders&#146; rights or <FONT STYLE="white-space:nowrap">pre-initial</FONT> business combination activity, unless the Company provides the Public Shareholders with the opportunity to redeem their Public Shares
upon approval of any such amendment at a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of
taxes payable), divided by the number of then issued and outstanding Public Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;10, 2022, the Company extended the period of time to
consummate a Business Combination from January&nbsp;11, 2022 to April&nbsp;11, 2022. In connection with the extension, the Sponsors deposited $1,035,000 into the trust account in the form of a <FONT STYLE="white-space:nowrap">non-interest</FONT>
bearing loan. The Company will have until April&nbsp;11, 2022 to consummate a Business Combination. However, if the Company anticipates that it may not be able to consummate a Business Combination by April&nbsp;11, 2022, the Company may extend the
period of time to consummate a Business Combination by an additional three&nbsp;months (until July&nbsp;11, 2022 to complete a Business Combination (the &#147;Combination Period&#148;). In order to extend the time available for the Company to
consummate a Business Combination, the Sponsor or its affiliate or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share), on or prior to the date of the applicable deadline, for the three-month extension. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company has not completed a Business Combination within the Combination Period, the Company will (i)&nbsp;cease all operations except for the purpose
of winding up, (ii)&nbsp;as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the Public Shares, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate
amount then on deposit in the Trust Account, including interest (less up to $50,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which
redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii)&nbsp;as promptly as reasonably possible following such redemption,
subject to the approval of the Company&#146;s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company&#146;s obligations under Cayman Islands law to provide for claims of creditors and
the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#146;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the
Combination Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares
if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsors or any of their respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the
Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the
Company does not complete a Business Combination within the Combination Period, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In
the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the amount of funds deposited into the Trust Account ($10.10 per share). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to protect the amounts held in the Trust Account, the Sponsors have agreed that it will be liable to the Company if and to the extent any claims by a
third party (other than the Company&#146;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction
agreement, reduce the amount of funds in the Trust Account to below (1)&nbsp;$10.10 per Public Share or (2)&nbsp;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions
in the value of trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims
under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company&#146;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#147;Securities
Act&#148;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsors will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility
that the Sponsors will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#146;s independent registered public accounting firm), prospective target businesses
or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern and Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2021, the Company had $507,921 in its operating bank accounts, and working capital of $303,753. As of December&nbsp;31, 2021, approximately $31,000 of the amount on deposit in the Trust Account represented interest income, which is
available to pay the Company&#146;s tax obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company is unable to raise additional capital, it may be required to take additional measures
to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if
at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the above, in connection with the Company&#146;s assessment of going concern considerations in accordance with Financial
Accounting Standard Board&#146;s Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2014-15,</FONT> &#147;Disclosures of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern,&#148; management has
determined that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company&#146;s ability to continue as a going concern through July&nbsp;11, 2022 (extension date), the scheduled liquidation
date of the Company if it does not complete a Business Combination prior to such date. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be
necessary should the Company be unable to continue as a going concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company is unable to raise additional capital, it may be required to take
additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially
acceptable terms, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 2&nbsp;&#151;&nbsp;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial
statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;) and pursuant to the rules and regulations of the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth Company </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is an
&#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;), and it may take advantage of certain exemptions from various
reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registered public accounting firm attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports
and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised
financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any
such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the
Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#146;s financial statement with another public company which is
neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the financial
statements in conformity with GAAP requires the Company&#146;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant
judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could
change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be
subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Offering Costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offering costs consist of legal,
accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public
Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued
were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261 were charged to temporary equity upon the completion of
the Initial Public Offering, and $30,212 of the offering costs were related to the warrant liabilities and charged to the statements of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Shares Subject to Possible Redemption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification
(&#147;ASC&#148;) Topic 480 &#147;Distinguishing Liabilities from Equity.&#148; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares
(including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#146;s control) is classified as temporary
equity. At all other times, ordinary shares are classified as shareholders&#146; equity. The Company&#146;s ordinary shares, sold in the IPO, features certain redemption rights that are considered to be outside of the Company&#146;s control and
subject to occurrence of uncertain future events. Accordingly, at December&nbsp;31, 2021 and 2020, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#146; (deficit) equity section of the
Company&#146;s balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">480-10-S99,</FONT></FONT> the Company has
elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares subject to possible redemption to equal the redemption value at the end of each reporting period. This method
would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value.
The change in the carrying value of redeemable ordinary shares resulted in charges against additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital and accumulated deficit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2021, the ordinary shares reflected in the balance sheets are reconciled in the following table: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,119,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of carrying value to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,499,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ordinary shares subject to possible redemption</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139,380,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrant Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#146;s specific terms
and applicable authoritative guidance in Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) 480, Distinguishing Liabilities from Equity (&#147;ASC 480&#148;) and ASC 815, Derivatives and
Hedging (&#147;ASC 815&#148;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#146;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is
conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance
contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as
liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to <FONT STYLE="white-space:nowrap">re-measurement</FONT> at each balance sheet date until exercised, and any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
change in fair value is recognized in our statements of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for income
taxes under ASC Topic 740, &#147;Income Taxes,&#148; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For
those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#146;s management determined that the Cayman Islands is the Company&#146;s major tax jurisdiction. The
Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December&nbsp;31, 2021 and 2020, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The
Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income
taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#146;s tax provision was zero for the periods presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net income (Loss) per Ordinary Share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
complies with accounting and disclosure requirements of FASB ASC Topic 260, &#147;Earnings Per Share&#148;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding
for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&nbsp;Initial Public
Offering, and (ii)&nbsp;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 13,740,000 ordinary shares in the aggregate. As of December&nbsp;31, 2021
and 2020, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company, except for the 450,000 founder shares in
December&nbsp;31, 2021 which are no longer forfeitable and thus included for dilutive purposes. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table reflects the calculation of basic and diluted net income per ordinary share (in dollars,
except per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Period<BR>from&nbsp;February&nbsp;21,<BR>2020 (Inception)<BR>Through<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Basic net income (loss) per ordinary share</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of net income (loss), as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">783,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average ordinary shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,820,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Diluted net income (loss) per ordinary share</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of net income (loss), as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">783,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted weighted average ordinary shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,834,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income (loss) per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at
times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair
value of the Company&#146;s assets and liabilities, which qualify as financial instruments under ASC Topic&nbsp;820, &#147;Fair Value Measurement,&#148; approximates the carrying amounts represented in the accompanying balance sheets, primarily due
to their short-term nature, other than the derivative warrant liability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Standards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material
effect on the Company&#146;s condensed financial statements. In August&nbsp;2020, the FASB issued Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">No.&nbsp;2020-06,</FONT> Debt&nbsp;&#151;&nbsp;Debt with Conversion and
Other Options (Subtopic <FONT STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and Hedging&nbsp;&#151;&nbsp;Contracts in Entity&#146; Own Equity (Subtopic <FONT STYLE="white-space:nowrap">815-40):</FONT> Accounting for Convertible
Instruments and Contracts in an Entity&#146; Own Equity (&#147;ASU <FONT STYLE="white-space:nowrap">2020-06&#148;),</FONT> which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The
ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. ASU <FONT
STYLE="white-space:nowrap">2020-06</FONT> is effective for fiscal&nbsp;years beginning after December&nbsp;15, 2023, including interim periods within those fiscal&nbsp;years, with early adoption permitted. Management is currently evaluating the new
guidance but does not expect the adoption of this guidance to have a material impact on the Company&#146;s condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management does not believe that any other recently issued, but not yet effective, accounting standard if
currently adopted would have a material effect on the accompanying condensed financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 3&nbsp;&#151;&nbsp;PUBLIC OFFERING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Initial Public Offering, the Company sold to 13,800,000&nbsp;Units which includes a full exercise by the underwriters of their over-allotment
option in the amount of 1,800,000&nbsp;Units, at a purchase price of $10.00 per Unit. Each Unit consists of one ordinary share and <FONT STYLE="white-space:nowrap">one-half</FONT> of one redeemable warrant (&#147;Public Warrant&#148;). Each whole
Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE
4&nbsp;&#151;&nbsp;PRIVATE PLACEMENT </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Sponsors purchased an aggregate of 6,840,000
Private Placement Warrants at a price of $0.75 per Private Placement Warrant, for an aggregate purchase price of $5,130,000, in a private placement. Each Private Placement Warrant is exercisable to purchase one ordinary share at a price of $11.50
per share, subject to adjustment (see Note 9). A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business
Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will
expire worthless. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 5&nbsp;&#151;&nbsp;RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Founder Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2020, the Company
issued an aggregate of 3,593,750 ordinary shares to an affiliate of the Sponsors for an aggregate purchase price of $25,000. In August&nbsp;2020, the affiliate transferred his Founder Shares to the Sponsors for the same price paid for such shares.
On October&nbsp;8, 2020, the Company effected a share capitalization of 0.2 shares for each share outstanding, on December&nbsp;7, 2020, the Sponsors forfeited 1,437,500 ordinary shares, which were cancelled by the Company, and on January&nbsp;6,
2021, the Company effected a share capitalization of 0.2 shares for each share outstanding, resulting in 3,450,000 ordinary shares issued and outstanding (the &#147;Founder Shares&#148;). All share and
<FONT STYLE="white-space:nowrap">per-share</FONT> amounts have been retroactively restated to reflect the share transactions. The Founder Shares included an aggregate of up to 450,000 shares that were subject to forfeiture depending on the extent to
which the underwriters&#146; over-allotment option is exercised, so that the number of Founder Shares will equal, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, approximately 20% of the Company&#146;s issued and outstanding
ordinary shares after the Initial Public Offering. As a result of the underwriters&#146; election to partially exercise their over-allotment option, no Founder Shares are currently subject to forfeiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until six&nbsp;months after the
consummation of a Business Combination or earlier if, subsequent to a Business Combination, the Company consummates a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to
exchange their ordinary shares for cash, securities or other property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advances from Related Party </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2020, an affiliate of the Sponsors advanced the Company an aggregate of $30,000 to fund expenses in connection with the Initial Public Offering. The
advances are <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable upon demand. As </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of December&nbsp;31, 2021 and 2020, there was $0 and $30,000 advances outstanding, respectively. The outstanding amount of $30,000 was repaid on February&nbsp;26, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Promissory Note&nbsp;&#151;&nbsp;Related Party </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
July&nbsp;16, 2020, the Company issued an unsecured promissory note (the &#147;Promissory Note&#148;) to an affiliate of the Sponsors, pursuant to which the Company may borrow up to an aggregate principal amount of $125,000. The Promissory Note is <FONT
STYLE="white-space:nowrap">non-interest</FONT> bearing and payable on the earlier of (i)&nbsp;December&nbsp;31, 2020 or (ii)&nbsp;the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $125,000 was repaid
subsequent to the closing of the Initial Public Offering on January&nbsp;14, 2021. Borrowings under the Promissory Note are no longer available to the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Loans </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to finance
transaction costs in connection with a Business Combination, the Sponsors or an affiliate of the Sponsors, or certain of the Company&#146;s officers and directors may, but are not obligated to, loan the Company funds as may be required
(&#147;Working Capital Loans&#148;). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#146;s discretion, up to $1,500,000 of
notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant. Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company
may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of December&nbsp;31, 2021 and 2020, there were no amounts
outstanding under the Working Capital Loans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;20, 2021, the Company entered into two convertible promissory notes with the Sponsors
pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $500,000 (the &#147;Convertible Promissory Notes&#148;). The Convertible Promissory Notes are <FONT STYLE="white-space:nowrap">non-interest</FONT>
bearing and payable upon Business Combination. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will&nbsp;be forgiven except to the extent
that the Company has funds available to it outside of its Trust Account. Up to $500,000 of the Convertible Promissory Notes may be converted into warrants at a price of $0.75 per warrant at the option of the Sponsors. The warrants would be identical
to the Private Placement Warrants. As of December&nbsp;31, 2021, the outstanding principal balance under the Convertible Promissory Notes amounted to an aggregate of $500,000. Subsequent to December&nbsp;31, 2021, on January&nbsp;10, 2022, the
Company borrowed an additional $1,035,000, as discussed below. On January&nbsp;27, 2022, Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to&nbsp;loan&nbsp;the Company up to an
aggregate principal amount of $500,000. Subsequent to December&nbsp;31, 2021, the&nbsp;principal balance of the Convertible Promissory Notes amounted to an aggregate of $2,035,000 (see Note 11). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assessed the provisions of the Convertible Promissory Notes under ASC <FONT STYLE="white-space:nowrap">470-20.</FONT> The derivative component of
the obligation is initially valued and classified as a derivative liability (see Note 9). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The debt discount is being amortized to interest expense as a <FONT
STYLE="white-space:nowrap">non-cash</FONT> charge over the term of the Convertible Promissory Notes, which is assumed to mature in April&nbsp;2022, the Company&#146;s expected Business Combination date. During the year ended December&nbsp;31, 2021,
the Company recorded $1,826 of interest expense related to the amortization of the debt discount. The remaining balance of the debt discount at December&nbsp;31, 2021&nbsp;amounted to $16,901. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Extension Loans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 1, the Company may extend the period of time to consummate a Business Combination up to two times, each by an additional three&nbsp;months
(until July&nbsp;11, 2022 to complete a Business Combination). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000
($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension, providing a total possible Business Combination period up until July&nbsp;11, 2022 for a total payment value of $2,070,000
($0.15 per unit in either case). Any such deposits would be made in the form of <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing loans. Such notes would either be paid upon consummation of a Business Combination, or, at the relevant
insider&#146;s discretion, converted upon consummation of a Business Combination into additional Private Placement Warrants at a price of $0.75 per Private Placement Warrant. The Sponsor and its affiliates or designees intend, but are not obligated,
to fund the Trust Account to extend the time for the Company to complete a Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;10, 2022, the Company extended the
period of time to consummate a Business Combination to April&nbsp;11, 2022. The Sponsors deposited $1,035,000 into the Trust Account made in the form of <FONT STYLE="white-space:nowrap">non-interest-bearing</FONT> loans. If the Company completes an
initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the total amount into warrants at a price of $0.75 per warrant, which
warrants are identical to the Private Placement Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except
to the extent that the Company has funds available to it outside of its Trust Account. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 6&nbsp;&#151;&nbsp;COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks and Uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management continues to
evaluate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#146;s financial position, results of its
operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this
uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration and Shareholder Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a registration rights agreement entered into on January&nbsp;6, 2021, the holders of the Founder Shares, Private Placement Warrants and underlying
ordinary shares and any securities issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement requiring the Company to register such securities for resale. The holders of these
securities will be entitled to demand that the Company register such securities at any time after the Company consummates a Business Combination. In addition, the holders have certain &#147;piggy-back&#148; registration rights with respect to
registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Underwriting Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters are
entitled to a deferred fee of (i)&nbsp;3.5% of the gross proceeds of the initial 12,000,000&nbsp;Units sold in the Initial Public Offering, or $4,200,000, and (ii)&nbsp;5.5% of the gross proceeds from the Units sold
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to the over-allotment option, or $990,000. The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the
terms of the underwriting agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 7&nbsp;&#151;&nbsp;SHAREHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preference Shares</I></B>&nbsp;&#151;&nbsp;The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share, with
such designations, voting and other rights and preferences as may be determined from time to time by the Company&#146;s board of directors. At December&nbsp;31, 2021 and 2020, there were no preference shares issued or outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Shares</I></B>&nbsp;&#151;&nbsp;The Company is authorized to issue 200,000,000 ordinary shares with a par value of $0.0001 per share. Holders
of ordinary shares are entitled to one vote for each share. At December&nbsp;31, 2021, there were 3,450,000 shares of ordinary shares issued and outstanding, excluding 13,800,000 ordinary shares subject to possible redemption which are presented as
temporary equity. At December&nbsp;31, 2020, there were 3,450,000 ordinary shares issued or outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 8&nbsp;&#151;&nbsp;WARRANTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021 and 2020, there were 6,900,000 and 0 Public Warrants outstanding, respectively. Public Warrants may only be exercised for a whole
number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&nbsp;the completion of a Business Combination and (b)&nbsp;12&nbsp;months from the closing of
the Initial Public Offering. The Public Warrants will expire five&nbsp;years from the completion of a Business Combination or earlier upon redemption or liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the issuance of the ordinary
shares issuable upon exercise of the warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the issuance of the ordinary shares issuable upon exercise of the Public
Warrants is not effective within 90&nbsp;days from the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an
effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their
warrants on a cashless basis. The Public Warrants will expire five&nbsp;years after the completion of a Business Combination or earlier upon redemption or liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may redeem the Public Warrants: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01 per warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at any time while the warrants become exercisable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon not less than 30&nbsp;days&#146; prior written notice of redemption to each warrant holder;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the reported last sale price of the Company&#146;s ordinary shares equals or exceeds $18.00 per
share (subject to adjustment) for any 20 trading days within a <FONT STYLE="white-space:nowrap">30-trading</FONT> day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of
redemption to the warrant holders; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary
shares underlying such warrants at the time of redemption and for the entire <FONT STYLE="white-space:nowrap">30-day</FONT> trading period referred to above and continuing each day thereafter until the date of redemption. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to
do so on a &#147;cashless basis,&#148; as described in the warrant agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price and number of ordinary shares issuable upon exercise of
the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of
ordinary shares at a price below its exercise price. The Company has agreed to use its best efforts to have declared effective a prospectus relating to the ordinary shares issuable upon exercise of the warrants and keep such prospectus current until
the expiration of the warrants. However, if the Company does not maintain a current prospectus relating to the ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants for cash and the Company will
not be required to net cash settle or cash settle the warrant exercise. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#146;s warrants. If the Company is unable to complete a Business
Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the
Company&#146;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition,
if (x)&nbsp;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary
share (with such issue price or effective issue price to be determined in good faith by the Company&#146;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares
held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#147;Newly Issued Price&#148;), (y)&nbsp;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest
thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&nbsp;the volume weighted average trading price of its ordinary shares during the 20 trading day
period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#147;Market Value&#148;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest
cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued
Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2021 and 2020, there were 6,840,000 and 0 Private Placement Warrants outstanding, respectively. The Private Placement
Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants will be exercisable for cash (even if a registration statement covering the issuance of the ordinary
shares issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#146;s option and will not be redeemable by the Company, in each case so long as they are held by the initial purchasers or their affiliates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 9&nbsp;&#151;&nbsp;FAIR VALUE MEASUREMENTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair
value of the Company&#146;s financial assets and liabilities reflects management&#146;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to
maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value
hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;1:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide
pricing information on an ongoing basis.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;2:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Observable inputs other than Level&nbsp;1 inputs. Examples of Level&nbsp;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are
not active.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;3:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2021, assets held in the Trust Account were comprised of $139,410,739 in money market funds which are
invested primarily in U.S. Treasury Securities. Through December&nbsp;31, 2021, the Company did not withdraw any of interest earned on the Trust Account. At December&nbsp;31, 2020, there were no assets in the Trust Account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents information about the Company&#146;s assets and liabilities that are measured at fair value on a recurring basis at
December&nbsp;31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments held in Trust Account&nbsp;&#151;&nbsp;U.S. Treasury Securities Money Market
Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139,410,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant Liability&nbsp;&#151;&nbsp;Private Placement Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,351,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion Option Liability (see Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrant Liability Measurement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company established the initial fair value for the private warrants on January&nbsp;11, 2021, the date of the Company&#146;s Initial Public Offering, using
a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include
the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#146;s
ordinary shares and the Company&#146;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the
expected business combination and 20% after the expected business combination. The ordinary share price was determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
warrant price to equate to the observed price of the outstanding&nbsp;units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the
remaining expected life of the private warrants. The dividend yield&nbsp;percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants
is assumed to be equivalent to their remaining contractual term. Inputs are <FONT STYLE="white-space:nowrap">re-evaluated</FONT> each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no transfers between Levels 1, 2 or 3 during the year ended December&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides quantitative information regarding Level&nbsp;3 fair value measurements: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Strike price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term (in&nbsp;years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the changes in the fair value of warrant liabilities: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Private<BR>Placement</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of January&nbsp;1, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial measurement on January&nbsp;11, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,729,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation inputs or other assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,377,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,351,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion Option Liability Measurement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assessed the provisions of the Convertible Promissory Notes under ASC <FONT STYLE="white-space:nowrap">470-20.</FONT> The derivative component of
the obligation is initially valued and classified as a derivative liability. The conversion option was valued using the compound option pricing model, which is considered to be a Level&nbsp;3 fair value measurement (See Note 6). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;20,<BR>2021<BR>(Initial<BR>Measurement)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underlying warrant value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Holding period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate %</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.19</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield %</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the change in the fair value of conversion option liability: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of January&nbsp;1, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial measurement on December&nbsp;20, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 10&nbsp;&#151;&nbsp;RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restatement 1 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company previously accounted for its
outstanding Private Placement Warrants (the &#147;Warrants&#148;) issued in connection with its Initial Public Offering as components of equity instead of as derivative liabilities. The warrant agreement governing the Warrants includes a provision
that provides for potential changes to the settlement amounts dependent upon the characteristics of the holder of the warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;12, 2021,
the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the Securities and Exchange Commission together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose
acquisition companies titled &#147;Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (&#147;SPACs&#148;)&#148; (the &#147;SEC Statement&#148;). Specifically, the SEC Statement
focused on certain settlement terms and provisions related to certain tender offers following a business combination, which terms are similar to those contained in the warrant agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In further consideration of the SEC Statement, the Company&#146;s management further evaluated the Warrants under Accounting Standards Codification
(&#147;ASC&#148;) Subtopic <FONT STYLE="white-space:nowrap">815-40,</FONT> Contracts in Entity&#146;s Own Equity. ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Section&nbsp;815-40-15</FONT></FONT> addresses equity versus
liability treatment and classification of equity-linked financial instruments, including warrants, and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer&#146;s ordinary
shares. Under ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Section&nbsp;815-40-15,</FONT></FONT> a warrant is not indexed to the issuer&#146;s ordinary shares if the terms of the warrant require an adjustment to the exercise
price upon a specified event and that event is not an input to the fair value of the warrant. Based on management&#146;s evaluation, the Company&#146;s audit committee, in consultation with management, concluded that the Company&#146;s Private
Placement Warrants are not indexed to the Company&#146;s ordinary shares in the manner contemplated by ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Section&nbsp;815-40-15</FONT></FONT> because the holder of the instrument is
not an input into the pricing of a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fixed-for-fixed</FONT></FONT> option on equity shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with ASC Topic 340, Other Assets and Deferred Costs, as a result of the classification of the private warrants as derivative liabilities, the
Company expensed a portion of the offering costs originally recorded as a reduction in equity. The portion of offering costs that was expensed was determined based on the relative fair value of the Private Warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restatement 2 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in connection with the
preparation of the Company&#146;s financial statements as of September&nbsp;30, 2021, the Company concluded it should restate its financial statements to classify all Public Shares in temporary equity. The September&nbsp;30, 2021 <FONT
STYLE="white-space:nowrap">10-Q/A,</FONT> filed with the SEC on December&nbsp;8, 2021, includes the restatement of the unaudited March&nbsp;31, 2021 and June&nbsp;30, 2021 financial information. Included in the table below is the restatement
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the audited IPO Balance Sheet as of January&nbsp;11, 2021 originally filed on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on January&nbsp;15, 2021. In accordance with
ASC 480, paragraph <FONT STYLE="white-space:nowrap">10-S99,</FONT> redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. The Company previously
determined the ordinary shares subject to possible redemption to be equal to the redemption value of $10.10 per ordinary share while also taking into consideration a redemption cannot result in net tangible assets being less than $5,000,001.
Previously, the Company did not consider redeemable shares classified as temporary equity as part of net tangible assets. Effective with these financial statements, the Company revised this interpretation to include temporary equity in net tangible
assets. Accordingly, effective with this filing, the Company presents all redeemable ordinary shares as temporary equity and recognizes accretion from the initial book value to redemption value at the time of its Initial Public Offering and in
accordance with ASC 480. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, management has noted a reclassification adjustment related to temporary equity and permanent equity. This resulted
in an adjustment to the initial carrying value of the ordinary shares subject </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to possible redemption with the offset recorded to additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital (to the extent available), accumulated deficit and ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the change in
presentation for the ordinary shares subject to redemption, the Company also revised its income (loss) per ordinary share calculation to allocate net income (loss) to ordinary shares. This presentation contemplates a Business Combination as the most
likely outcome, in which case, ordinary shares share pro&nbsp;rata in the income (loss) of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The impact of these adjustments to the financial
statement, as previously reported, is presented below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As Previously<BR>Reported</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Adjustments<BR>Restatement&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Adjustments<BR>Restatement 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance sheet as of January&nbsp;11, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant Liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,729,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,729,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,345,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,729,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,074,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary Shares Subject to Possible Redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,999,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,729,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,110,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139,380,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">Paid-in</FONT> Capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,006,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,629,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,635,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated Deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,629,412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,474,606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,110,508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Shareholders&#146; Equity (Deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,110,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,110,163</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 11&nbsp;&#151;&nbsp;SUBSEQUENT EVENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued.
The Company did not identify any subsequent events, other than noted below, that would have required adjustment or disclosure in the financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;10, 2022, the Company extended the period of time to consummate a Business Combination to April&nbsp;11, 2022. The Sponsors deposited
$1,035,000 into the Trust Account made in the form of <FONT STYLE="white-space:nowrap">non-interest-bearing</FONT> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts
evidenced by the Convertible Promissory Notes or convert a portion or all of the total amount into warrants at a price of $0.75 per warrant, which warrants are identical to the Private Placement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven
except to the extent that the Company has funds available to it outside of its Trust Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;27, 2022, the Company entered into two
additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an additional aggregate principal amount of $500,000. The aggregate principal balance of the Convertible Promissory Notes
amounted to $2,035,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_7"></A>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Audited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">507,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Current Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>165,749</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>512,457</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments held in Trust Account &#151; U.S. Treasury Securities Money Market Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,293,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139,410,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>101,458,835</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>139,923,196</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS&#146;
DEFICIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">809,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Current Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>809,292</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>208,704</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible promissory notes&nbsp;&#151;&nbsp;related party, net of discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,035,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">483,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Simple promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,971,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mandatorily redeemable ordinary shares liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,162,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,351,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting fee payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,190,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,190,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>12,168,759</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,240,295</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and Contingencies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares subject to possible redemption&nbsp;9,726,395&nbsp;and&nbsp;13,800,000 as of
September&nbsp;30, 2022 and December&nbsp;31, 2021, respectively, at redemption value of $10.41&nbsp;and $10.00, respectively, per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,293,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139,380,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares, $0.0001&nbsp;par value;&nbsp;1,000,000&nbsp;shares
authorized;&nbsp;none&nbsp;issued or outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, $0.0001&nbsp;par value;&nbsp;200,000,000&nbsp;shares authorized;&nbsp;3,450,000 <FONT
STYLE="white-space:nowrap">non-redeemable</FONT> shares issued and outstanding at September&nbsp;30, 2022 and December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,003,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,697,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Shareholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(12,003,010</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,697,099</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS&#146;
DEFICIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>101,458,835</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>139,923,196</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_8"></A>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Nine Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating and formation costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">657,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">283,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,412,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">620,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(657,746</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(283,346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,412,297</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(620,642</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,162,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,188,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,872,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on initial issuance of private warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,599,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs allocated to warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of conversion option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on mandatorily redeemable ordinary shares liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">192,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense &#151; debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,901</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income earned on investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">459,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">664,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">526,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,161,006</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,035,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">271,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net (loss) income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(131,387</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,444,352</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>623,516</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(349,248</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding, ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,176,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,862,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,675,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net (loss) income per share, ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(0.01</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(0.08</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.04</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(0.02</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_9"></A>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#146; EQUITY (DEFICIT) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;<BR>Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Shareholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; January&nbsp;1, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,450,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,697,444</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,697,099</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of Ordinary shares subject to possible redemption amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,035,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,035,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(806,222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(806,222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; March&nbsp;31, 2022 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,450,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,538,666</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,538,321</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mandatorily redeemable ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(192,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(192,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of Ordinary shares subject to possible redemption amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,595,486</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,595,486</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,561,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,561,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; June&nbsp;30, 2022 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,450,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,765,076</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,764,731</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of Ordinary shares subject to possible redemption amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,106,892</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,106,892</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(131,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(131,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; September&nbsp;30, 2022 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,450,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(12,003,355</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(12,003,010</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER&nbsp;30, 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp;<BR>Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Shareholders&#146;<BR>Equity<BR>(Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,450,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,655</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,276</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,724</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of Ordinary shares subject to possible redemption amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,474,606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,499,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,328,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,328,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; March&nbsp;31, 2021 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,450,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,152,029</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,151,684</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(233,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(233,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; June&nbsp;30, 2021 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,450,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,385,778</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,385,433</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,444,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,444,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; September&nbsp;30, 2021 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,450,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,830,130</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,829,785</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_10"></A>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Nine months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Operating Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">623,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(349,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income (loss) to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income earned on investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(664,973</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,006</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on mandatorily redeemable ordinary shares liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(192,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,188,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,872,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on initial issuance of private warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,599,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of conversion option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,892</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs allocated to warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(126,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(116,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,937,961</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(693,609</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Investing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment of cash in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,041,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(139,380,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash withdrawn from Trust Account in connection with redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,824,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by (used in) investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>38,782,626</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(139,380,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of Units, net of underwriting discounts paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of Private Placement Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,130,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advances from related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of advances from related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from convertible promissory note&nbsp;&#150;&nbsp;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,535,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from simple promissory note&nbsp;&#150;&nbsp;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,971,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of promissory note&nbsp;&#150;&nbsp;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(125,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(416,260</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redemption of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,824,292</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash (used in) provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(37,317,625</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>140,158,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net Change in Cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(472,960</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85,131</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash &#151; Beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">507,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash &#151; End of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34,961</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>115,642</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Cash</FONT> investing and financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting fee payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,190,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_11"></A>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 1.
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vickers Vantage Corp. I (the &#147;Company&#148;) is a blank check company incorporated as a
Cayman Islands exempted company on February&nbsp;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or
entities (a &#147;Business Combination&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has one wholly owned subsidiary which was formed on February&nbsp;2, 2022, Vantage Merger Sub
Inc., a Delaware corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The
Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, the Company had not commenced any operations. All activity for the period from February&nbsp;21, 2020 (inception) through
September&nbsp;30, 2022 relates to the Company&#146;s formation and the initial public offering (&#147;Initial Public Offering&#148;), which is described below, and, subsequent to the Initial Public Offering, identifying a target company for a
Business Combination and in connection therewith entering into the Merger Agreement, which is described below in Note 6. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The
Company will generate <FONT STYLE="white-space:nowrap">non-operating</FONT> income in the form of interest income from the proceeds derived from the Initial Public Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registration statement for the Company&#146;s Initial Public Offering was declared effective on January&nbsp;6, 2021. On January&nbsp;11, 2021 the Company
consummated the Initial Public Offering of&nbsp;13,800,000&nbsp;Units (the &#147;Units&#148; and, with respect to the ordinary shares included in the Units sold, the &#147;Public Shares&#148;), which includes the full exercise by the underwriter of
its over-allotment option in the amount of&nbsp;1,800,000&nbsp;Units, at $10.00&nbsp;per Unit, generating gross proceeds of $138,000,000&nbsp;which is described in Note 3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of&nbsp;6,840,000 warrants (the &#147;Private Placement
Warrants&#148;) at a price of $0.75&nbsp;per Private Placement Warrant in a private placement to Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd, (the &#147;Sponsor&#148;), generating gross proceeds of $5,130,000, which is
described in Note 4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transaction costs amounted to $8,149,473, consisting of $2,400,000&nbsp;in cash underwriting fees, $5,190,000&nbsp;in deferred
underwriting fees, and $559,473&nbsp;of other offering costs </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the closing of the Initial Public Offering on January&nbsp;11, 2021, an amount of
$139,380,000&nbsp;($10.10&nbsp;per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#147;Trust Account&#148;), and invested in U.S.
government securities, within the meaning set forth in Section&nbsp;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in
U.S.&nbsp;Treasuries and meeting certain conditions under Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> of the Investment Company Act, as determined by the Company, until the earliest of: (i)&nbsp;the completion of a Business Combination and
(ii)&nbsp;the distribution of the funds in the Trust Account to the Company&#146;s shareholders, as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;10, 2022, the
Company extended the period of time to consummate a Business Combination from January&nbsp;11, 2022 to April&nbsp;11, 2022. On April&nbsp;11, 2022, the Company extended the period of time to consummate a Business Combination to July&nbsp;11, 2022.
On July&nbsp;11, 2022, the Company extended the period of time to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consummate a Business Combination to August&nbsp;11, 2022 and without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to five
times by an additional one month each time after, upon five days&#146; advance notice prior to the applicable deadlines, until January&nbsp;11, 2023. As of the date of this filing, the Company has extended the period of time to consummate a Business
Combination to November&nbsp;11, 2022. In connection with the extensions, the Sponsors deposited an aggregate of $3,365,554 into the trust account in the form of a <FONT STYLE="white-space:nowrap">non-interest-bearing</FONT> loans as of the date of
this filing. The Company will have until November&nbsp;11, 2022 to consummate a Business Combination. As a result, an aggregate of $101,293,086&nbsp;as of September&nbsp;30, 2022 is held in the Trust Account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of
the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.&nbsp;The stock exchange listing rules require that the Business Combination must be with
one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust
Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the
target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#147;Investment Company Act&#148;). There is no assurance that the Company will be able to
successfully effect a Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will provide the holders of the public shares (the &#147;Public Shareholders&#148;) with the
opportunity to redeem all or a portion of their public shares upon the completion of the Business Combination, either (i)&nbsp;in connection with a general meeting called to approve the Business Combination or (ii)&nbsp;by means of a tender offer.
The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares,
equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination (anticipated to be $10.38&nbsp;per Public Share as of the date of this filing), including
interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding public shares, subject to certain limitations as described in the prospectus. The <FONT STYLE="white-space:nowrap">per-share</FONT> amount
to be distributed to the Public Shareholders who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001&nbsp;and, if the Company seeks
shareholder approval, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company. If a
shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions
pursuant to the tender offer rules of the Securities and Exchange Commission (&#147;SEC&#148;), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing
a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Company&#146;s Sponsors have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after
the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed
Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the
Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#147;group&#148; (as defined
under Section&nbsp;13 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)), will be restricted from redeeming its shares with respect to more than an aggregate of&nbsp;20% of the Public Shares without the Company&#146;s
prior written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsors have agreed (a)&nbsp;to waive their redemption rights with respect to any Founder Shares and Public Shares held by
them in connection with the completion of a Business Combination and (b)&nbsp;not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i)&nbsp;to modify the substance or timing of the Company&#146;s obligation
to allow redemption in connection with the Company&#146;s initial Business Combination or to redeem&nbsp;100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or
(ii)&nbsp;with respect to any other provision relating to shareholders&#146; rights or <FONT STYLE="white-space:nowrap">pre-initial</FONT> business combination activity, unless the Company provides the Public Shareholders with the opportunity to
redeem their Public Shares upon approval of any such amendment at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest
shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company has not completed a Business
Combination within the Combination Period and shareholders do not further extend such period, the Company will (i)&nbsp;cease all operations except for the purpose of winding up, (ii)&nbsp;as promptly as reasonably possible but not more than ten
business days thereafter, redeem&nbsp;100% of the Public Shares, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to
$50,000&nbsp;of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public
Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#146;s remaining Public
Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company&#146;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no
redemption rights or liquidating distributions with respect to the Company&#146;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to
complete a Business Combination within the Combination Period. However, if the Sponsors or any of their respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the
Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not
complete a Business Combination within the Combination Period, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such
distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the amount of funds deposited into the Trust Account ($10.38&nbsp;per share). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to protect the amounts held in the Trust Account, the Sponsors have agreed that it will be liable to the Company if and to the extent any claims by a
third party (other than the Company&#146;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction
agreement, reduce the amount of funds in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Trust Account to below (1) $10.10&nbsp;per Public Share or (2)&nbsp;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to
reductions in the value of trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to
any claims under the Company&#146;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). In the event that an
executed waiver is deemed to be unenforceable against a third party, the Sponsors will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsors will have to
indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#146;s independent registered public accounting firm), prospective target businesses or other entities with which
the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2022, the Company held an extraordinary general meeting of its shareholders (the &#147;Meeting&#148;), to amend the Company&#146;s Amended
and Restated Memorandum and Articles of Association (the &#147;Extension Amendment&#148;) to (i)&nbsp;extend the date by which the Company has to consummate an initial business combination from July&nbsp;11, 2022 (the &#147;Original Termination
Date&#148;) to August&nbsp;11, 2022 (the &#147;Extended Date&#148;) and (ii)&nbsp;allow the Company without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to five times by an
additional one month each time after the Extended Date, upon five days&#146; advance notice prior to the applicable deadlines, until January&nbsp;11, 2023 or a total of up to nine months after the Original Termination Date (the &#147;Extension
Proposal&#148;). The Company&#146;s shareholders approved the Extension Amendment at the Meeting. On July&nbsp;5, 2022, the Company filed the Extension Amendment with the Cayman Islands Registrar of Companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with its solicitation of proxies in connection with the Extension Proposal, the Company was required to permit its public shareholders to redeem
their ordinary shares. Of the 13,800,000 ordinary shares outstanding with redemption rights, the holders of 4,073,605 ordinary shares elected to redeem their shares at a per share redemption price of $10.25. As a result, approximately
$41.8&nbsp;million was removed from the Trust Account to pay such holders and approximately $99.8&nbsp;million remained in the Trust Account. Following the redemptions, the Company has 9,726,395 ordinary shares with redemption rights outstanding and
the Company will deposit $323,888 (or approximately $0.0333 per ordinary share that remains outstanding) for each calendar month, or portion thereof, that is needed by the Company to complete an initial business combination from July&nbsp;11, 2022.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has deposited an aggregate of $1,295,556&nbsp;into the Trust Account to extend the date to consummate a business combination to
November&nbsp;11, 2022 (the &#147;Combination Period&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Going Concern and Liquidity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, the Company had $34,961&nbsp;in its operating bank accounts, and working capital deficit of $643,543. As of September&nbsp;30,
2022, approximately $696,000&nbsp;of the amount on deposit in the Trust Account represented interest income, which is available to pay the Company&#146;s tax obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not
necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the above, in connection with the Company&#146;s assessment of going concern considerations in
accordance with Financial Accounting Standard Board&#146;s Accounting Standards Codification Subtopic <FONT STYLE="white-space:nowrap">205-40,</FONT> &#147;Presentation of Financial Statements &#151; Going Concern,&#148; management has determined
that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company&#146;s ability to continue as a going concern through November&nbsp;11, 2022 (extension date), the scheduled liquidation date
of the Company if it does not complete a Business Combination prior to such date. These condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the
liabilities that might be necessary should the Company be unable to continue as a going concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company is unable to raise additional capital, it
may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be
available to it on commercially acceptable terms, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited
condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) for interim financial information and in accordance with the instructions
to Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Article 8 of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> of the SEC. Certain information or footnote disclosures normally included in condensed financial statements prepared in
accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of
financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for
a fair presentation of the financial position, operating results and cash flows for the periods presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed
consolidated financial statements should be read in conjunction with the Company&#146;s Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> as filed with the SEC on February&nbsp;24, 2022. The interim results for the three and
nine months ended September&nbsp;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&nbsp;31, 2022 or for any future periods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Principles of Consolidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying
unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth Company </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is an
&#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;), and it may take advantage of certain exemptions from various
reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements
of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of
securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued
or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make
comparison of the Company&#146;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because
of the potential differences in accounting standards used. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company&#146;s management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the
reporting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the
effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future
confirming events. One of the more significant accounting estimates included in these condensed consolidated financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more
current information because available and accordingly, the actual results could differ significantly from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash
Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash
equivalents. The Company did not have any cash equivalents as of September&nbsp;30, 2022 and December&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investments Held in Trust
Account </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At September&nbsp;30, 2022 and December&nbsp;31, 2021, the majority of the assets held in the Trust Account were held in money market
funds, which are invested primarily in U.S. Treasury securities. The Company presents its investments in money market funds on the condensed consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting
from the change in fair value of these securities is included in interest income in the accompanying unaudited condensed consolidated statements of operations. The estimated fair value of investments held in the Trust Account are determined using
available market information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Offering Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial
Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities
were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the
Initial Public Offering. Offering costs amounting to $8,119,261&nbsp;were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212&nbsp;of the offering costs were related to the warrant liabilities and charged to
the condensed consolidated statement of operations for the period ended September&nbsp;30, 2021. The Company classifies deferred underwriting commissions as <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities as their liquidation is not
reasonably expected to require the use of current assets or require the creation of current liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Shares Subject to Possible
Redemption </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards
Codification (&#147;ASC&#148;) Topic 480 &#147;Distinguishing Liabilities from Equity.&#148; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary
shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#146;s control) is classified as
temporary equity. At all other times, ordinary shares are classified as shareholders&#146; equity. The Company&#146;s ordinary shares features certain redemption rights that are considered to be outside of the Company&#146;s control and subject to
occurrence of uncertain future events. Accordingly, at September&nbsp;30, 2022 and December&nbsp;31, 2021, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#146; deficit section of the
Company&#146;s condensed consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under ASC
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">480-10-S99,</FONT></FONT> the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares to
equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company
recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital and
accumulated deficit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At September&nbsp;30, 2022 and December&nbsp;31, 2021, the ordinary shares reflected in the condensed
consolidated balance sheets are reconciled in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,119,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of carrying value to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,499,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ordinary shares subject to possible redemption as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>139,380,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mandatorily redeemable ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,824,292</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of carrying value to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,737,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ordinary shares subject to possible redemption as of September&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>101,293,086</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrant Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#146;s specific terms
and applicable authoritative guidance in Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) 480, Distinguishing Liabilities from Equity (&#147;ASC 480&#148;) and ASC 815,&nbsp;Derivatives and
Hedging&nbsp;(&#147;ASC 815&#148;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the
requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#146;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the
guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private
warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to <FONT STYLE="white-space:nowrap">re-measurement</FONT> at each balance sheet date until exercised, and
any change in fair value is recognized in our statement of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for income
taxes under ASC Topic 740, &#147;Income Taxes,&#148; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For
those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#146;s management determined that the Cayman Islands is the Company&#146;s major tax jurisdiction. The
Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September&nbsp;30, 2022 and December&nbsp;31, 2021, there were no unrecognized tax benefits and no amounts accrued for interest and
penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable
jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#146;s tax provision was zero for the periods presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Income (Loss) per Ordinary Share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
complies with accounting and disclosure requirements of FASB ASC Topic 260, &#147;Earnings Per Share&#148;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding
for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. Mandatorily redeemable ordinary shares are excluded from the weighted average
number of ordinary shares outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in
connection with the (i)&nbsp;Initial Public Offering, and (ii)&nbsp;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase&nbsp;13,740,000&nbsp;ordinary
shares in the aggregate. As of September&nbsp;30, 2022 and 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the
Company. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Basic and diluted net income (loss) per ordinary share</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(131,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,444,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">623,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(349,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average ordinary shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,176,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,862,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,675,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income (loss) per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.08</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at
times may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of September&nbsp;30, 2022 and December&nbsp;31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not
exposed to significant risks on such account. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s assets and liabilities, which qualify as financial instruments under ASC Topic&nbsp;820, &#147;Fair Value
Measurement,&#148; approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature, other than the derivative warrant liability and conversion option liability (Note
9). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Standards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August
2020, the FASB issued Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2020-06,</FONT> Debt &#151; Debt with Conversion and Other Options (Subtopic <FONT STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and
Hedging &#151; Contracts in Entity&#146; Own Equity (Subtopic <FONT STYLE="white-space:nowrap">815-40):</FONT> Accounting for Convertible Instruments and Contracts in an Entity&#146; Own Equity (&#147;ASU
<FONT STYLE="white-space:nowrap">2020-06&#148;),</FONT> which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for
equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. Management is currently evaluating the new guidance but does not expect the adoption of this
guidance to have a material impact on the Company&#146;s condensed consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management does not believe that any other recently
issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 3. PUBLIC OFFERING </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Initial Public
Offering, the Company sold to&nbsp;13,800,000&nbsp;Units which includes a full exercise by the underwriters of their over-allotment option in the amount of&nbsp;1,800,000&nbsp;Units, at a purchase price of $10.00 per Unit. Each Unit consists of one
ordinary share and <FONT STYLE="white-space:nowrap">one-half</FONT> of one redeemable warrant (&#147;Public Warrant&#148;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share
(see Note 7). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 4. PRIVATE PLACEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Sponsors purchased an aggregate of&nbsp;6,840,000 Private Placement Warrants at a price of
$0.75&nbsp;per Private Placement Warrant, for an aggregate purchase price of $5,130,000, in a private placement. Each Private Placement Warrant is exercisable to purchase one ordinary share at a price of $11.50&nbsp;per share, subject to adjustment
(see Note 7). A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period,
the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 5. RELATED PARTY TRANSACTIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Founder Shares
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2020, the Company issued an aggregate of&nbsp;3,593,750&nbsp;ordinary shares to an affiliate of the Sponsors for an aggregate
purchase price of $25,000. In August 2020, the affiliate transferred his Founder Shares to the Sponsors for the same price paid for such shares. On October 8. 2020, the Company effected a share </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capitalization of 0.2&nbsp;shares for each share outstanding, on December&nbsp;7, 2020, the Sponsors forfeited 1,437,500 ordinary shares, which were cancelled by the Company, and on
January&nbsp;6, 2021, the Company effected a share capitalization of&nbsp;0.2&nbsp;shares for each share outstanding, resulting in&nbsp;3,450,000&nbsp;ordinary shares issued and outstanding (the &#147;Founder Shares&#148;). All share and <FONT
STYLE="white-space:nowrap">per-share</FONT> amounts have been retroactively restated to reflect the share transactions. The Founder Shares included an aggregate of up to&nbsp;450,000&nbsp;shares that were subject to forfeiture depending on the
extent to which the underwriters&#146; over-allotment option is exercised, so that the number of Founder Shares will equal, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, approximately&nbsp;20% of the Company&#146;s issued and
outstanding ordinary shares after the Initial Public Offering. As a result of the underwriters&#146; election to partially exercise their over-allotment option, no Founder Shares are currently subject to forfeiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until six months after the consummation of
a Business Combination or earlier if, subsequent to a Business Combination, the Company consummates a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their
ordinary shares for cash, securities or other property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advances from Related Party </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2020, an affiliate of the Sponsors advanced the Company an aggregate of $30,000&nbsp;to fund expenses in connection with the Initial Public Offering.
The advances were <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable upon demand. Such advances were repaid in connection with the closing of the Initial Public Offering. Accordingly, as of September&nbsp;30, 2022 and
December&nbsp;31, 2021, there were no advances outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Promissory Note &#151; Related Party </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2020, the Company issued an unsecured promissory note (the &#147;Promissory Note&#148;) to an affiliate of the Sponsors, pursuant to which the
Company may borrow up to an aggregate principal amount of $125,000. The Promissory Note is <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable on the earlier of (i)&nbsp;December&nbsp;31, 2020 or (ii)&nbsp;the completion of the
Initial Public Offering. The outstanding balance under the Promissory Note of $125,000&nbsp;was repaid subsequent to the closing of the Initial Public Offering on January&nbsp;14, 2021. Borrowings under the Promissory Note are no longer available to
the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Loans </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to
finance transaction costs in connection with a Business Combination, the Sponsors or an affiliate of the Sponsors, or certain of the Company&#146;s officers and directors may, but are not obligated to, loan the Company funds as may be required
(&#147;Working Capital Loans&#148;). Such Working Capital Loans would be evidenced by promissory notes.&nbsp;The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#146;s discretion, up to $1,500,000
of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.&nbsp;Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the
Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;20, 2021, the Company entered issued two convertible promissory notes to the Sponsors to evidence Working Capital Loans pursuant to which the
Sponsors agreed to loan the Company up to an aggregate principal amount of $500,000&nbsp;(the &#147;Convertible Promissory Notes&#148;). The Convertible Promissory Notes are <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable
upon Business Combination. If a Business Combination is not consummated, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it
outside of its Trust Account. Up to $500,000&nbsp;of the Convertible Promissory Notes may be converted into warrants at a price of $0.75&nbsp;per warrant at the option of the Sponsors. The warrants would be identical to the Private Placement
Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;10, 2022, the Company borrowed an additional $1,035,000, as discussed below. On January&nbsp;27, 2022, Company entered into two
additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $500,000. As of September&nbsp;30, 2022 and December&nbsp;31, 2021, the principal balance of
the Convertible Promissory Notes amounted to an aggregate of $2,035,000&nbsp;and $500,000, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assessed the provisions of the
Convertible Promissory Notes under ASC <FONT STYLE="white-space:nowrap">470-20.</FONT> The derivative component of the obligation is initially valued and classified as a derivative liability (see Note 9). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The debt discount is being amortized to interest expense as a <FONT STYLE="white-space:nowrap">non-cash</FONT> charge over the term of the Convertible
Promissory Notes, which is assumed to mature in at Business Combination. During the three and nine months ended September&nbsp;30, 2022, the Company recorded $1,155&nbsp;and $16,901&nbsp;of interest expense related to the amortization of the debt
discount. The remaining balance of the debt discount at September&nbsp;30, 2022 and December&nbsp;31, 2021 amounted to $0&nbsp;and $16,901, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;11, 2022, the Company entered into two simple promissory notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to
an aggregate principal amount of $1,500,000&nbsp;(the &#147;Simple Promissory Notes&#148;). The Simple Promissory Notes are <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable upon Business Combination. If a Business Combination
is not consummated, the Simple Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. On
April&nbsp;18, 2022, the Company entered into two additional Simple Promissory Notes with the Sponsor pursuant to which the Sponsor agreed to loan the Company up to an aggregate principal amount of $500,000. As of September&nbsp;30, 2022 and
December&nbsp;31, 2021, the principal balance of the Simple Promissory Notes amounted to an aggregate of $2,971,667&nbsp;and $0, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Extension Loans </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in
Note 1, the Company may extend the period of time to consummate a Business Combination by an additional three months.&nbsp;In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or
designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension., </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;10, 2022, the Company extended the period of time to consummate a Business Combination to April&nbsp;11, 2022. The Sponsors deposited
$1,035,000&nbsp;into the Trust Account made in the form of <FONT STYLE="white-space:nowrap">non-interest-bearing</FONT> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the
amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the total amount into warrants at a price of $0.75&nbsp;per warrant, which warrants are identical to the Private Placement Warrants issued. If a Business
Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust
Account. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;11, 2022, the Company extended the period of time to consummate a Business Combination to
July&nbsp;11, 2022. The Sponsors deposited $1,035,000&nbsp;into the Trust Account made in the form of <FONT STYLE="white-space:nowrap">non-interest-bearing</FONT> loans. If the Company completes an initial business combination, the Company will, at
the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be
forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;11, 2022, the Company extended the
period of time to consummate a Business Combination to August&nbsp;11, 2022. The Sponsors deposited $323,889&nbsp;into the Trust Account made in the form of <FONT STYLE="white-space:nowrap">non-interest-bearing</FONT> loans. If the Company completes
an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and
all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;10, 2022, the Company extended the period of time to consummate a Business Combination to&nbsp;September&nbsp;11, 2022. The Sponsors deposited
$323,889&nbsp;into the Trust Account made in the form of <FONT STYLE="white-space:nowrap">non-interest-bearing</FONT> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts
evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company
has funds available to it outside of its Trust Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;9, 2022, the Company extended the period of time to consummate a Business
Combination to October&nbsp;11, 2022. The Sponsors deposited $323,889&nbsp;into the Trust Account made in the form of <FONT STYLE="white-space:nowrap">non-interest-bearing</FONT> loans. If the Company completes an initial business combination, the
Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the
Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;10, 2022, the
Company extended the period of time to consummate a Business Combination to November&nbsp;11, 2022. The Sponsors deposited $323,889&nbsp;into the Trust Account made in the form of <FONT STYLE="white-space:nowrap">non-interest-bearing</FONT> loans.
If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be
repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 6. COMMITMENTS AND CONTINGENCIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks and
Uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management continues to evaluate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and has concluded that
while it is reasonably possible that the virus could have a negative effect on the Company&#146;s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of
these condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration and Shareholder Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a registration rights agreement entered into on January&nbsp;6, 2021, the holders of the Founder Shares, Private Placement Warrants and underlying
ordinary shares and any securities issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement requiring the Company to register such securities for resale. The holders of these
securities will be entitled to demand that the Company register such securities at any time after the Company consummates a Business Combination. In addition, the holders have certain &#147;piggy-back&#148; registration rights with respect to
registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Underwriting Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters are
entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000&nbsp;Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or
$990,000.&nbsp;The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Combination Merger Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
March&nbsp;17, 2022, the Company entered into an agreement and plan of merger (the &#147;Merger Agreement&#148;) by and among Scilex Holding Company (&#147;Scilex&#148;), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE)
(&#147;Sorrento&#148;), VCKA, and Vantage Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of VCKA (&#147;Merger Sub&#148;). Parent and Merger Sub are sometimes referred to collectively as the &#147;Parent Parties.&#148;
Pursuant to the Merger Agreement, VCKA will, prior to the closing of the Merger, migrate to and domesticate as a Delaware corporation in accordance with Section&nbsp;388 of the Delaware General Corporation Law, as amended and the Cayman Islands
Companies Law (the &#147;Domestication&#148;). Thereafter, a business combination between VCKA and Scilex will be effected through the merger of Merger Sub with and into Scilex with Scilex surviving the merger as a wholly owned subsidiary of VCKA
(the &#147;Merger&#148;). Upon the closing of the Merger (the &#147;Closing&#148;), it is anticipated that VCKA will change its name to &#147;Scilex Holding Company&#148;. The board of directors of VCKA has (i)&nbsp;approved and declared advisable
the Merger Agreement, the Additional Agreements (as defined in the Merger Agreement) and the transactions contemplated thereby and (ii)&nbsp;resolved to recommend approval of the Merger Agreement and related transactions by the shareholders of VCKA.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2022, Vickers, Merger Sub and Scilex entered into Amendment No.&nbsp;1 to the Merger Agreement (the &#147;Amendment&#148;). The
Amendment amends the Merger Agreement to, among other things, provide that: (i)&nbsp;the Plan of Domestication attached to the Merger Agreement shall constitute a plan of domestication for purposes of Section&nbsp;388 of the DGCL and shall include
the corporate acts identified therein and any act or transaction contemplated by the Merger Agreement; (ii)&nbsp;at the Effective Time, each Domesticated Parent Unit shall separate automatically into its component parts, comprised of one share of
Domesticated Parent Common Share and <FONT STYLE="white-space:nowrap">one-half</FONT> of one Domesticated Parent Warrant (provided that no fractional Domesticated Parent Warrants shall be issued and any holder who would be entitled to receive a
fractional Domesticated Parent Warrant will have such fraction rounded down to the nearest whole number of Domesticated Parent Warrants); (iii) immediately after Closing, New Scilex&#146;s board of directors shall consist of seven directors, five of
whom will be designated by Scilex (including one director who shall satisfy the independence requirements of the applicable Stock Exchange (which shall be Nasdaq, unless the parties otherwise agree to list on another national securities exchange,
which may include the New York Stock Exchange, prior to the Closing)) and two of whom </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will be independent directors to be designated by Scilex and agreed to by Vickers prior to the Closing; (iv)&nbsp;at the Effective Time, by virtue of the Merger, each share of Series A Preferred
Stock of Scilex issued and outstanding immediately prior to the Effective Time shall be canceled and automatically converted into the right to receive, without interest, one Domesticated Parent Preferred Share and
<FONT STYLE="white-space:nowrap">one-tenth</FONT> of one Domesticated Parent Common Share; (v)&nbsp;Vickers shall use its reasonable best efforts to ensure that Vickers remains listed as a public company, and that the Parent Ordinary Shares and
public Parent Warrants remain listed on Nasdaq through the Closing and Scilex shall use its reasonable best efforts to prepare and file an initial listing application with the Stock Exchange in connection with the transactions contemplated by the
Merger Agreement; (vi)&nbsp;each party shall use its reasonable best efforts to, among other things, obtain approval for the listing of the Domesticated Parent Common Shares and Domesticated Parent Warrants issued pursuant to the Merger Agreement on
the Stock Exchange; (vii)&nbsp;following the consummation of the Domestication, and the filing of the Parent Certificate of Incorporation, but prior to the Effective Time, Vickers shall file with the Secretary of State of Delaware a certificate of
designations, in the form attached to the Merger Agreement as a new Exhibit F, which provides for, among other things, the designations, powers, rights and preferences and qualifications, limitations and restrictions of certain preferred stock of
Vickers; (viii)&nbsp;as a condition of Scilex to the Closing, that the shares of Domesticated Parent Common Shares and Domesticated Parent Warrants shall remain listed on Nasdaq through the Effective Time, the listing application for the listing of
the Domesticated Parent Common Shares and Domesticated Parent Warrants following the Effective Time shall have been approved by the applicable Stock Exchange, and, as of the Closing Date, Vickers shall not have received any written notice from
Nasdaq of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with Nasdaq&#146;s applicable continued listing requirements for any reason, where such notice has not been subsequently withdrawn by Nasdaq or the underlying failure appropriately
remedied or satisfied; and (ix)&nbsp;extend the Outside Date to November&nbsp;11, 2022. The Amendment also sets forth the agreement of Vickers and Scilex to amend the Parent Certificate of Incorporation to increase the number of authorized shares of
preferred stock set forth therein from&nbsp;20,000,000&nbsp;to&nbsp;45,000,000&nbsp;and, as a result, increase the total number of shares of all classes of stock that Vickers shall have authority to issue
from&nbsp;750,000,000&nbsp;to&nbsp;785,000,000&nbsp;and, in connection with the Domestication, to name the initial incorporator and initial board of directors of Vickers for the period between the Domestication and the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger is expected to be consummated by the fourth quarter of 2022, following the receipt of the required approval by the shareholders of VCKA and Scilex
and the satisfaction of certain other customary closing conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Merger Consideration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total consideration to be paid to the holders of Scilex common stock at Closing (the &#147;Merger Consideration&#148;) by VCKA twill be an amount equal to
the quotient of (a)&nbsp;the sum of (i) $1,500,000,000 minus (ii)&nbsp;the aggregate amount of Scilex long term debt excluding intercompany debt owed to Sorrento existing as of immediately prior to the date of the closing of the transaction (the
&#147;Closing Date&#148;); divided by (b) $10.00, and will be payable in shares of common stock, par value $0.0001 per shares, of VCKA upon its domestication in Delaware (&#147;VCKA Common Stock&#148;).&nbsp;The number of shares of VCKA Common Stock
to be paid as Merger Consideration will be determined in accordance with the terms of the Business Combination Agreement. In addition, each outstanding share of Scilex Preferred Stock as of immediately prior to the Effective Time of the Business
Combination will be cancelled in exchange for the right to receive (a)&nbsp;one&nbsp;share of Series A Preferred Stock of Vickers (following the Domestication), par value $0.0001&nbsp;per share (the &#147;New Scilex Series A Preferred Stock&#148;),
and <FONT STYLE="white-space:nowrap">(b)&nbsp;one-tenth</FONT> of one share of New Scilex Common Stock, and (iii)&nbsp;each option to purchase Scilex Common Stock that is outstanding as of immediately prior to the Effective Time will be exchanged
for a number of options exercisable for newly issued shares of New Scilex Common Stock based upon the Exchange Ratio. The total consideration to be received by holders of Scilex Common Stock and Scilex options at the Closing will be newly issued
shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
New Scilex Common Stock with an aggregate value equal to $1.5&nbsp;billion, subject to adjustments for certain debt obligations of Scilex (the &#147;Merger Consideration&#148;).&nbsp;The maximum
number of shares of New Scilex Series A Preferred Stock and New Scilex Common Stock to be issued to the holders of Scilex Preferred Stock at the Closing shall not exceed 31,000,000 and 3,100,000, respectively, such newly issued shares being
collectively referred to herein as the &#147;Preferred Consideration&#148;. It is anticipated that upon completion of the Business Combination, if none of the 9,726,395 VCKA Ordinary Shares are redeemed, VCKA&#146;s public shareholders would retain
an ownership interest of approximately 5.6% in New Scilex, the Sponsors, officers, directors and other holders of founder shares will retain an ownership interest of approximately 2.2% of New Scilex, and the Scilex stockholders will own
approximately (i) 77.2% of New Scilex in the form of New Scilex Common Stock and (ii) 15.0% of New Scilex in the form of New Scilex Series A Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the Effective Time, each Scilex stock option that is then outstanding shall be converted into the right to receive an option relating to VCKA Common
Stock upon substantially the same terms and conditions as are in effect with respect to such option immediately prior to the Effective Time; provided that the exercise price per share for each such Scilex stock option shall be equal to the exercise
price per share of such Scilex stock option in effect immediately prior to the Effective Time, divided by the Exchange Ratio. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Representations and
Warranties </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement contains customary representations and warranties of Scilex with respect to, among other things: (i)&nbsp;corporate
existence and power; (ii)&nbsp;authorization to enter into the Merger Agreement and related transactions; (iii)&nbsp;governmental authorization; <FONT STYLE="white-space:nowrap">(iv)&nbsp;non-contravention;</FONT> (v)&nbsp;capital structure;
(vi)&nbsp;organizational documents; (vii)&nbsp;assumed names; (viii)&nbsp;subsidiaries; (ix)&nbsp;financial statements; (x)&nbsp;absence of certain changes; (xi)&nbsp;properties and title to assets; (xii)&nbsp;litigation; (xiii)&nbsp;contracts;
(xiv)&nbsp;licenses and permits; (xv)&nbsp;compliance with laws; (xvi)&nbsp;intellectual property; (xvii)&nbsp;customers and suppliers; (xviii)&nbsp;employees and employee benefits; (xix)&nbsp;employment matters; (xx)&nbsp;withholding;
(xxi)&nbsp;real property; (xxii)&nbsp;tax matters; (xxiii)&nbsp;environmental laws; (xiv)&nbsp;finders&#146; fees; (xv)&nbsp;directors and officers; (xvi)&nbsp;certain business practices; (xvii)&nbsp;international trade matters and anti-bribery
compliance; (xviii)&nbsp;that Scilex is not an investment company; (xvix) compliance with health care laws and certain contracts; (xxx)&nbsp;insurance; (xxxi)&nbsp;related party transactions; (xxxii)&nbsp;privacy and data security and
(xxxiii)&nbsp;exclusivity of representations and warranties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement contains customary representations and warranties of the Parent Parties
with respect to, among other things: (i)&nbsp;corporate existence and power; (ii)&nbsp;authorization to enter into the Merger Agreement and related transactions; (iii)&nbsp;governmental authorization;
<FONT STYLE="white-space:nowrap">(iv)&nbsp;non-contravention;</FONT> (v)&nbsp;finders&#146; fees; (vi)&nbsp;issuance of shares; (vii)&nbsp;capitalization; (viii)&nbsp;information supplied; (ix)&nbsp;amount in the trust account; (x)&nbsp;listing of
VCKA securities; (xi)&nbsp;that VCKA is a reporting company; (xii)&nbsp;no market manipulation; (xiii)&nbsp;board approval; (xiv)&nbsp;SEC documents and financial statements; (xv)&nbsp;absence of changes; (xvi)&nbsp;litigation;
(xvii)&nbsp;compliance with laws; (xviii)&nbsp;money laundering laws; (xix)&nbsp;OFAC; (xx)&nbsp;that VCKA is not an investment company; (xxi)&nbsp;tax matters; (xxii)&nbsp;contracts; (xxiii)&nbsp;investigation; and (xiv)&nbsp;exclusivity of
representations and warranties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All representations and warranties by all parties shall terminate upon the Effective Time, and no representations,
warranties, covenants, obligations or other agreements contained in the Merger Agreement shall survive the Effective Time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Covenants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement includes customary covenants of the parties with respect to operation of their respective businesses prior to consummation of the Merger
and efforts to satisfy conditions to consummation of the Merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The Merger Agreement also contains additional covenants of the parties, including, among others, access to information, cooperation in the preparation of the Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> (the &#147;Registration Statement&#148;) and Proxy Statement (as each such term is defined in the Merger Agreement) required to be filed in connection with the Merger and to obtain all requisite approvals of
each party&#146;s respective stockholders. VCKA has also agreed to include in the Proxy Statement the recommendation of its board that its stockholders approve all of the proposals to be presented at the special meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conduct between Signing and Closing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of VCKA, Merger
Sub and Scilex has agreed that from the date of the Merger Agreement until the Closing Date or, if earlier, the valid termination of the Merger Agreement in accordance with its terms, it will not initiate, encourage or engage in any negotiations
with any party relating to an Alternative Transaction (as defined in the Merger Agreement), take any action intended to facilitate an Alternative Transaction or approve, recommend or enter into any agreement relating to an Alternative Transaction.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conditions to Closing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consummation of the
Merger is conditioned upon, among other things, (i)&nbsp;the absence of any applicable law or order that makes the transactions contemplated by the Merger Agreement illegal or otherwise prohibits consummation of such transactions; (ii)&nbsp;the
Registration Statement shall have become effective under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;); (iii) approval by VCKA&#146;s shareholders of the Merger and related transactions; (iv)&nbsp;approval by Scilex&#146;s
stockholders of the Merger and related transactions; and (v)&nbsp;all required filings under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and with any other governmental authority shall have been completed and cleared. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solely with respect to the Parent Parties, the consummation of the Merger is conditioned upon, among other things: (i)&nbsp;Scilex having duly performed or
complied with all of its obligations under the Merger Agreement in all material respects; (ii)&nbsp;the representations and warranties of Scilex being true and correct in all respects unless failure to be true and correct would not have or
reasonably be expected to have a Company Material Adverse Effect (as defined in the Merger Agreement) on Scilex&#146;s ability to consummate the Merger and related transactions; (iii)&nbsp;no event having occurred that would result in a Company
Material Adverse Effect; (iv)&nbsp;Scilex providing VCKA a certificate from the chief executive officer and chief financial officer of Scilex as to the accuracy of the foregoing conditions; (v)&nbsp;Scilex providing VCKA a certificate from the
secretary which has attached true and complete copies of (a)&nbsp;Scilex&#146;s organizational documents, (b)&nbsp;Scilex&#146;s board resolutions approving the Merger Agreement and the transactions contemplated thereby, (c)&nbsp;Scilex&#146;s
stockholder written consent approving the Merger Agreement and the transactions contemplated thereby and (d)&nbsp;certified certificate of good standing; (vi)&nbsp;Scilex shall have executed and delivered to VCKA each Additional Agreement to which
it is a party; (vi)&nbsp;Sorrento shall have executed the Registration Rights Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solely with respect to Scilex, the
consummation of the Merger is conditioned upon, among other things: (i)&nbsp;the Parent Parties having duly performed or complied with all of their obligations under the Merger Agreement in all material respects; (ii)&nbsp;the representations and
warranties of the Parent Parties being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a Parent Material Adverse Effect (as defined in the Merger Agreement) on the ability of
VCKA or Merger Sub to consummate the Merger and related transactions; (iii)&nbsp;no event having occurred that would result in a Parent Material Adverse Effect; (iv)&nbsp;each of the Parent Parties providing Scilex a certificate from an authorized
officer as to the accuracy of the foregoing conditions; (v)&nbsp;VCKA having been in material compliance with reporting requirements under the Securities Act and the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;);
(vi)&nbsp;each of VCKA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Parent Parties shall have executed and delivered to Scilex each Additional Agreement to which it is a party; (vii)&nbsp;the directors designated by Scilex shall have been appointed to the
board of directors of VCKA in accordance with the terms of the Merger Agreement, effective as of the Closing Date; (viii)&nbsp;VCKA shall remain listed on Nasdaq and the additional listing application for the VCKA Common Stock issued in connection
with the Merger shall have been approved by Nasdaq, and VCKA not having received any written notice from Nasdaq that it has failed, or would reasonably be expected to fail to meet the Nasdaq listing requirements as of the Closing Date for any
reason, where such notice has not been subsequently withdrawn by Nasdaq or the underlying failure appropriately remedied or satisfied; (ix)&nbsp;after giving effect to the Merger, VCKA shall have at least $5,000,001 in net tangible assets (as
determined in accordance with <FONT STYLE="white-space:nowrap">Rule&nbsp;3a51-1(g)(1)&nbsp;of</FONT> the Exchange Act); (x) the Domestication shall have been completed as provided in the Merger Agreement and a time-stamped copy of the certificate
issued by the Secretary of State of the State of Delaware in relation thereto shall have been delivered to the Company; and (xi)&nbsp;the Investment Management Trust Agreement (as defined in the Merger Agreement) shall have been amended solely to
the extent necessary to enable the intended effects of the Amended Underwriting Agreement (as defined in the Merger Agreement) without breach of, or other conflict with, the Investment Management Trust Agreement as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex, Scilex Pharmaceuticals, Inc. and Sorrento entered into a Contribution and Satisfaction of Indebtedness Agreement dated September&nbsp;12, 2022 (the
&#147;Debt Exchange Agreement&#148;), in order to facilitate the satisfaction of the closing condition under the Merger Agreement that requires Vickers to have at least $5,000,001&nbsp;in net tangible assets (as determined in accordance with Rule <FONT
STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the United States Securities and Exchange Act of 1934) (the &#147;Net Tangible Assets Condition&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement may be terminated as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By the mutual consent of VCKA and Scilex; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by VCKA, if any of the representations or warranties of Scilex set forth in the Merger Agreement shall not be
true and correct, or if Scilex has failed to perform any covenant or agreement set forth in the Merger Agreement (including an obligation to consummate the Merger), in each case such that the conditions to closing would not be satisfied and the
breach or breaches causing such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are not cured (or waived by VCKA) by the earlier of (i)&nbsp;the Outside Date (as defined
below) or (ii) 30 days after written notice thereof is delivered to Scilex; provided, however that VCKA is not then in material breach of any representation, warranty, covenant, or obligation in the Merger Agreement, which breach has not been cured;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Scilex, if any of the representations or warranties of VCKA or Merger Sub set forth in the Merger Agreement
shall not be true and correct, or if VCKA or Merger Sub has failed to perform any covenant or agreement set forth in the Merger Agreement (including an obligation to consummate the Merger), in each case such that the conditions to closing would not
be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are not cured (or waived by Scilex) by the earlier of (i)&nbsp;the
Outside Date or (ii) 30 days after written notice thereof is delivered to VCKA; provided, however that Scilex is not then in material breach of any representation, warranty, covenant, or obligation in the Merger Agreement, which breach has not been
cured; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either VCKA or Scilex </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on or after November&nbsp;11, 2022 (the &#147;Outside Date&#148;), if the Merger shall not have been
consummated prior to the Outside Date; provided that if an Extension Amendment (as defined in the Merger Agreement) shall be in effect, the Outside Date shall be the Extension Date (as defined in the Merger Agreement); provided, however, that the
right to terminate this Agreement under Section&nbsp;9.1(d)(i) of the Merger Agreement shall not be available to a party if the failure of the Merger to have been consummated before the Outside Date (or the Extension Date if applicable) was due to
such party&#146;s breach of or failure to perform any of its covenants or agreements set forth in the Merger Agreement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if any applicable law or order that makes the transactions contemplated by the Merger Agreement illegal or
otherwise prohibits consummation of such transactions shall have become final and <FONT STYLE="white-space:nowrap">non-appealable;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">v.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Scilex if VCKA has not received approval from its stockholders of the Merger and related transactions at the
Parent Special Meeting (as defined in the Merger Agreement), unless such meeting has been adjourned or postponed, in which case at the final adjournment or postponement thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">vi.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by VCKA if the Scilex stockholder written consent approving the Merger and related transactions shall not have
been obtained within five business days following the Registration Statement being declared effective by the Securities and Exchange Commission (the &#147;SEC&#148;), provided that upon Scilex receiving such stockholder approval, prior to the
termination by VCKA of the Merger Agreement, VCKA will no longer have this right to so terminate; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">vii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by VCKA, in the event that Scilex&#146;s audited financial statements for 2020 and 2021 have not been delivered
to the Parent Parties on or before March&nbsp;31, 2022 and remain undelivered prior to the termination of the Merger Agreement </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sponsor Support Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the
execution of the Merger Agreement, VCKA, Scilex and certain stockholders of VCKA entered into a certain Sponsor Support Agreement dated March&nbsp;17, 2022 (the &#147;Sponsor Support Agreement&#148;) pursuant to which those certain VCKA shareholders
who are parties thereto agreed to vote all shares of VCKA Ordinary Shares beneficially owned by them, including any additional shares of VCKA they acquire ownership of or the power to vote, in favor of the Merger and related transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2022, Vickers and Scilex entered into Amendment No.&nbsp;1 to the Original Support Agreement with the Vickers Shareholders (the
&#147;Support Agreement Amendment&#148;). The Support Agreement Amendment amends the Original Support Agreement to, among other things, provide that if, as of immediately prior to the Closing, the holders of more than seventy-five percent (75%) of
the aggregate amount of Parent Ordinary Shares issued and outstanding as of March&nbsp;17, 2022 shall have exercised redemption rights in conjunction with the shareholder vote on the Extension Amendment or the Parent Shareholder Approval Matters,
then automatically and without any further action by any other Person, such Vickers Shareholder shall forfeit a number of Parent Warrants equal to forty percent (40%) of all Parent Warrants held by such Vickers Shareholder immediately prior to
Closing, and all such Parent Warrants shall be cancelled and forfeited for no consideration, and shall cease to exist. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Company Stockholder Support Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Merger Agreement, VCKA, Scilex and Sorrento entered into a certain Company Stockholder Support Agreement dated
March&nbsp;17, 2022 (the &#147;Company Stockholder Support Agreements&#148;), pursuant to which Sorrento agreed to vote all Scilex Common Stock beneficially owned by it, including any additional shares of Scilex it acquires ownership of or the power
to vote, in favor of the Merger and related transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2022, Vickers entered into a Stockholder Agreement with Sorrento (the
&#147;Stockholder Agreement&#148;). Pursuant to the Stockholder Agreement, from and after the Effective Time, and for so long as Sorrento beneficially owns any shares of Vickers Series A Preferred Stock, par value $0.0001&nbsp;per share (&#147;New
Scilex Series A Preferred Stock&#148;), among other things, (i)&nbsp;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to the Board of Directors of New Scilex (each, a
&#147;Stockholder Designee&#148; and collectively, the &#147;Stockholder Designees&#148;), regardless of (i)&nbsp;whether such Stockholder Designee is to be elected to the Board of Directors of New Scilex (&#147;New Scilex Board&#148;) at a meeting
of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by the New Scilex Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of
members of the New Scilex Board, or (ii)&nbsp;the size of the New Scilex Board and New Scilex will be required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee to be so
nominated, elected or appointed to the New Scilex Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for any Stockholder Designee that has been removed from the New
Scilex Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the New Scilex Board. The Stockholder Agreement also provides that New Scilex will be prohibited from taking certain actions without the
consent of Sorrento. Such actions include, among other things, amendments to the certificate of designations designating the New Scilex Series A Preferred Stock, increases or decreases in the size of the New Scilex Board, the incurrence of certain
amounts of indebtedness and the payment of dividends on New Scilex Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Underwriting Agreement Amendment </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;17, 2022, VCKA and Maxim Group, LLC, the representative of the underwriters for the VCKA initial public offering (&#147;Maxim&#148;) entered into
an amendment (the &#147;UWA Amendment&#148;) of the underwriting agreement between VCKA and Maxim dated January&nbsp;6, 2021. The UWA Amendment provides for a potential deferral of the Deferred Underwriting Commission&nbsp;(as defined in the UWA
Amendment) as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If in connection with the consummation of a business combination, after redemptions of Ordinary Shares by VCKA&#146;s
shareholders, the balance in the trust account is $25,000,000&nbsp;or less, then the Deferred Underwriting Commission will be payable as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">50% of the Deferred Underwriting Commission will be payable to Maxim directly from the trust account; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the remaining 50% of the Deferred Underwriting Commission will be payable to Maxim in the form of a Promissory
Note on or before the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the effective date of a Business Combination. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maxim has also agreed to enter into any such amendment to the Investment Management Trust Agreement (as defined in the Merger Agreement) as may be required to
effectuate the intent of the UWA Amendment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Agreements to be Executed at Closing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement contemplates that, at or prior to the Closing, VCKA and Sorrento will enter into an Amended and Restated Registration Rights Agreement
(the &#147;Registration Rights Agreement&#148;), whereby, subject to certain customary exceptions, the parties will agree, among other things, not to transfer any shares of VCKA Common Stock or any security convertible into or exercisable or
exchanged for VCKA Common Stock beneficially owned or owned of record by such holder until the date that is the earlier of (i)&nbsp;one hundred eighty (180)&nbsp;days from the date of the Registration Rights Agreement or (ii)&nbsp;the date on which
the Company completes a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of the Company&#146;s stockholders having the right to exchange their shares of VCKA Common Stock for cash, securities or
other property. The Registration Rights Agreement will govern the registration of certain shares of VCKA Common Stock for resale and be effective as of the Closing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 7. SHAREHOLDERS&#146; DEFICIT </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preference
Shares</I></B><B></B><B>&nbsp;&#151;</B>&nbsp;The Company is authorized to issue&nbsp;1,000,000&nbsp;preference shares with a par value of $0.0001&nbsp;per share, with such designations, voting and other rights and preferences as may be determined
from time to time by the Company&#146;s board of directors. At September&nbsp;30, 2022 and December&nbsp;31, 2021, there were&nbsp;no&nbsp;preference shares issued or outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Shares</I></B>&nbsp;&#151; The Company is authorized to issue&nbsp;200,000,000&nbsp;ordinary shares with a par value of $0.0001&nbsp;per share.
Holders of ordinary shares are entitled to one vote for each share. At September&nbsp;30, 2022, there were&nbsp;3,450,000&nbsp;shares of ordinary shares issued and outstanding, excluding&nbsp;9,726,395&nbsp;ordinary shares subject to possible
redemption which are presented as temporary equity. At December&nbsp;31, 2021, there were&nbsp;3,450,000&nbsp;shares of ordinary shares issued and outstanding, excluding&nbsp;13,800,000&nbsp;ordinary shares subject to possible redemption which are
presented as temporary equity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 8. WARRANTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
of September&nbsp;30, 2022 and December&nbsp;31, 2021, there were&nbsp;6,900,000&nbsp;Public Warrants outstanding. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public
Warrants. The Public Warrants will become exercisable on the later of (a)&nbsp;the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will expire five years from the completion
of a Business Combination or earlier upon redemption or liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Public Warrants will be exercisable for cash unless the Company has an effective
and current registration statement covering the issuance of the ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the
issuance of the ordinary shares issuable upon exercise of the Public Warrants is not effective within 90 days from the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during
any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is
not available, holders will not be able to exercise their warrants on a cashless basis. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may redeem the Public Warrants: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01 per warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at any time while the warrants become exercisable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon not less than 30 days&#146; prior written notice of redemption to each warrant holder;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the reported last sale price of the Company&#146;s ordinary shares equals or exceeds
$18.00&nbsp;per share (subject to adjustment) for any 20 trading days within a <FONT STYLE="white-space:nowrap">30-trading</FONT> day period commencing after the warrants become exercisable and ending on the third trading business day prior to the
notice of redemption to the warrant holders; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary
shares underlying such warrants at the time of redemption and for the entire <FONT STYLE="white-space:nowrap">30-day</FONT> trading period referred to above and continuing each day thereafter until the date of redemption. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to
do so on a &#147;cashless basis,&#148; as described in the warrant agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price and number of ordinary shares issuable upon exercise of
the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of
ordinary shares at a price below its exercise price. The Company has agreed to use its best efforts to have declared effective a prospectus relating to the ordinary shares issuable upon exercise of the warrants and keep such prospectus current until
the expiration of the warrants. However, if the Company does not maintain a current prospectus relating to the ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants for cash and the Company will
not be required to net cash settle or cash settle the warrant exercise. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#146;s warrants. If the Company is unable to complete a Business
Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the
Company&#146;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition,
if (x)&nbsp;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary
share (with such issue price or effective issue price to be determined in good faith by the Company&#146;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares
held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#147;Newly Issued Price&#148;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon,
available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&nbsp;the volume weighted average trading price of its ordinary shares during the 20 trading day period
starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#147;Market Value&#148;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to
be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At September&nbsp;30, 2022 and December&nbsp;31, 2021, there were&nbsp;6,840,000&nbsp;Private Placement Warrants outstanding. The Private Placement
Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants will be exercisable for cash (even if a registration
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statement covering the issuance of the ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#146;s option and will not be redeemable by
the Company, in each case so long as they are held by the initial purchasers or their affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 9. FAIR VALUE MEASUREMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s financial assets and liabilities reflects management&#146;s estimate of amounts that the Company would have received in
connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and
liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and
liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Level&nbsp;1:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability
is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Level&nbsp;2:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Observable inputs other than Level&nbsp;1 inputs. Examples of Level&nbsp;2 inputs include quoted prices in
active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Level&nbsp;3:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing
the asset or liability. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At September&nbsp;30, 2022 and December&nbsp;31, 2021, assets held in the Trust Account were comprised of
$101,293,086&nbsp;and $139,410,739, respectively, in money market funds which are invested primarily in U.S. Treasury Securities.&nbsp;Through September&nbsp;30, 2022, the Company did not withdraw any interest earned on the Trust Account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents information about the Company&#146;s assets and liabilities that are measured at fair value on a recurring basis at
September&nbsp;30, 2022 and December&nbsp;31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments held in Trust Account &#151; U.S. Treasury Securities Money Market Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,293,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139,410,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant Liability &#151; Private Placement Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,162,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,351,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion Option Liability (see Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants were accounted for as liabilities in accordance with ASC
<FONT STYLE="white-space:nowrap">815-40</FONT> and are presented within warrant liabilities on our accompanying September&nbsp;30, 2022 unaudited condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception
and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the unaudited condensed consolidated statements of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrant Liability Measurement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company established the initial fair value for the private warrants on January&nbsp;11, 2021, the date of the Company&#146;s Initial Public Offering, using
a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include
the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#146;s
ordinary shares and the Company&#146;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the
expected business combination and 20% after the expected business combination. The ordinary share price was determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional warrant price to equate to
the observed price of the outstanding units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield percentage is zero
because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. Inputs are <FONT
STYLE="white-space:nowrap">re-evaluated</FONT> each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no transfers between Levels 1, 2 or 3 during the three and nine months ended September&nbsp;30, 2022 and 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides quantitative information regarding Level&nbsp;3 fair value measurements: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>September&nbsp;30,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Strike price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.03</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the changes in the fair value of warrant liabilities: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Private<BR>Placement</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of January&nbsp;1, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial measurement on January&nbsp;11, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,729,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation inputs or other assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,104,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,625,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation inputs or other assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of as of June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,693,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation inputs or other assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,162,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of as of September&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,856,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation inputs or other assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,504,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,351,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation inputs or other assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of March&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,762,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation inputs or other assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,530,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of June&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,231,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation inputs or other assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(68,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of September&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,162,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion Option Liability Measurement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assessed the provisions of the Convertible Promissory Notes under ASC <FONT STYLE="white-space:nowrap">470-20.</FONT> The derivative component of
the obligation is initially valued and classified as a derivative liability. The conversion option was valued using the compound option pricing model, which is considered to be a Level&nbsp;3 fair value measurement (See Note 6). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>September&nbsp;30,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underlying warrant value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Holding period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.03</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the change in the fair value of conversion option liability: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Conversion<BR>Option<BR>Liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of January&nbsp;1, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial measurement on December&nbsp;20, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation inputs or other assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial measurement on January&nbsp;10, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial measurement on January&nbsp;27, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation inputs or other assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of March&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation inputs or other assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(76,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of June&nbsp;30, 2022 and September&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 10. SUBSEQUENT EVENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed consolidated
financial statements were issued. Based upon this review, other than as described below and elsewhere in these unaudited condensed consolidated financial statements, the Company did not identify any subsequent events that would have required
adjustment or disclosure in the unaudited condensed consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;10, 2022, the Company extended the period of time
to consummate a Business Combination to November&nbsp;11, 2022. The Sponsors deposited $323,889&nbsp;into the Trust Account made in the form of <FONT STYLE="white-space:nowrap">non-interest-bearing</FONT> loans. If the Company completes an initial
business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all
amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
October&nbsp;17, 2022, the Company and its Sponsors entered into a Debt Contribution Agreement (the &#147;Debt Contribution Agreement&#148;). The Debt Contribution Agreement relates to certain amounts owed by the Company to the Sponsors for payment
of certain outstanding loans (the &#147;Company Obligations&#148;) as set forth in the Debt Contribution Agreement. Pursuant to the Debt Contribution Agreement, the Sponsors have agreed to contribute the Company Obligations to the Company in
exchange for the issuance of that number of shares of shares of common stock, par value $0.0001&nbsp;per share, of the Company, determined by dividing the Company Obligations by $10.00&nbsp;(the &#147;Contribution Shares&#148;) to the Sponsors
immediately prior to the consummation of the Business Combination but after the Domestication (as defined in the Merger Agreement). Upon the occurrence of the debt contribution and issuance of the Contribution Shares to the Sponsors pursuant to the
Debt Contribution Agreement, the Company Obligation owed to the Sponsors shall be extinguished in its entirety and shall be of no further force or effect and shall be deemed satisfied in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Debt Exchange Agreement, on October&nbsp;17, 2022, Sorrento and Scilex entered into a letter agreement (the &#147;Funding Commitment
Letter&#148;) pursuant to which, upon the written request of the Company (which request the Company shall make to the extent necessary to satisfy Net Tangible Asset Condition), Sorrento shall fund one or more loans to the Company in the amount set
forth in such written request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VICKERS VANTAGE CORP. I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTEMBER&nbsp;30, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, as consideration for Sorrento agreeing to provide for funding under the Funding
Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim Group LLC, entered into the Warrant Transfer Agreement (the &#147;Warrant Transfer Agreement&#148;) for the transfer of certain private placement warrants held by the Sponsors to Sorrento
in the event redemptions exceed certain thresholds specified in the Warrant Transfer Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, the Company entered into a
Letter Agreement with Sorrento and the Sponsors (the &#147;Letter Agreement&#148;) to provide that certain shares held by the Sponsors will be released from the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions only in an amount necessary
to help satisfy the minimum public float requirement under the Listing Standards of the Nasdaq Stock Market LLC, which amount shall not exceed&nbsp;1,500,000&nbsp;shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;28, 2022, the proxy statement/prospectus was declared effective and the Company commenced with mailing the proxy materials to the
Company&#146;s shareholders ahead of the extraordinary general meeting of the Company&#146;s shareholders on November&nbsp;9, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_12"></A>Report of Independent Registered Public Accounting Firm
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Stockholders of Scilex Holding Company </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have audited the accompanying consolidated balance sheets of Scilex Holding Company (the Company) as of December&nbsp;31, 2021 and 2020, the related consolidated statements of operations, stockholders&#146; deficit and cash flows for each of the two
years in the period ended December&nbsp;31, 2021, and the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial statements present fairly, in all material respects,
the financial position of the Company at December&nbsp;31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Company&#146;s Ability to Continue as a Going Concern </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 2 to the financial statements, the Company has suffered recurring losses from operations, has a working capital deficiency, and has stated that substantial doubt exists about the Company&#146;s ability to continue as a going concern.
Management&#146;s evaluation of the events and conditions and management&#146;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of
this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the
Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in
accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the
United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included
performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial
statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San
Diego, California </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;13, 2022 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the stockholders and the Board of Directors of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex
Holding Company </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated statements of operations, stockholders&#146; equity, and cash flows of Scilex Holding Company and
subsidiaries (the &#147;Company&#148;) for the year ended December&nbsp;31, 2019, and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material
respects, the results of the Company&#146;s operations and cash flows for the year ended December&nbsp;31, 2019, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Going Concern </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered negative working capital, recurring losses from operations, recurring negative
cash flows from operations and cumulative net losses that raise substantial doubt about its ability to continue as a going concern. Management&#146;s plans in regard to these matters are also described in Note 2. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the
Company&#146;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in
accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the
United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Matter </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in Note 1 to
the financial statements, the accompanying financial statements have been prepared from the separate records maintained by the Company and may not necessarily be indicative of the conditions that would have existed or the results of operations if
the Company had been operated as an unaffiliated company of Sorrento Therapeutics, Inc. Portions of certain income and expenses represent allocations made from home-office items applicable to the Company as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;23, 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We began serving as the Company&#146;s
auditor in 2018. In 2020 we became the predecessor auditor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_13"></A>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS OF DECEMBER&nbsp;31, 2021 AND 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except for par value and share amounts) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheets as of December&nbsp;31, 2021 and 2020 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangibles, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIABILITIES AND STOCKHOLDERS&#146; DEFICIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, net of discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">223,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and contingencies (See Note 11)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; Deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $ 0.0001 par value, 20,000,000 shares authorized; no shares issued or outstanding
at December&nbsp;31, 2021 and 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $ 0.0001 par value, 350,000,000 shares authorized; 197,266,338 shares issued and
outstanding at December&nbsp;31, 2021 and 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(352,550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(264,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(223,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(141,683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_14"></A>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2021, 2020 AND 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except for net loss per share amounts) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Operations for the Years Ended December&nbsp;31, 2021, 2020 and 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating costs and expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating costs and expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35,838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(138,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other expense</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (gain) on derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on debt extinguishment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (gain) on foreign currency exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(178,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88.424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(178,594</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares during the period &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:200pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_15"></A>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2021, 2020 AND 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Operations for the Years Ended December&nbsp;31, 2021, 2020 and 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,013</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued related to Semnur Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distribution to Sorrento</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(178,594</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(178,594</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(216,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options excercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distribution to Sorrento</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancellation of shares held in escrow related to Semnur Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(264,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(141,683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustment to shares issued in Semnur Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(352,550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(223,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:265pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_16"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2021, 2020 AND 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Operations for the Years Ended December&nbsp;31, 2021, 2020 and 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(178,594</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used for operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Amortization of debt issuance costs and debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt
discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,487</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,866</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Loss on debt extinguishment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Loss (gain) on derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Semnur-related IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Trade receivables, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(598</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,417</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Prepaid expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Long-term deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accrued payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(604</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Net cash used for operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,664</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(60,421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Acquisition of Semnur, net of cash acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Net cash used for investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Repayment of principal on the Scilex Pharma Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(58,927</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Repayment on other loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(48,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Proceeds from other loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Proceeds from stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Proceeds from related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Proceeds from related party note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Repayment of related party note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,518</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Net cash provided by (used for) financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Net change in cash, cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,656</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(62,269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Cash, cash equivalents and restricted cash at beginning of year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Cash, cash equivalents and restricted cash at end of year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Supplemental disclosures:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Supplemental disclosures of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and
financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> consideration in Semnur acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Semnur acquisition costs incurred but not paid in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Other loan forgiveness</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> distribution to Sorrento</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Reconciliation of cash, cash equivalents and restricted cash within the Company&#146;s balance
sheet</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_17"></A>Notes to Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Nature of Operations and Basis of Presentation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Organization and Principal Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex Holding Company (&#147;Scilex Holding&#148; and together with its wholly owned subsidiaries, the &#147;Company&#148;) was incorporated
in Delaware in February 2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (&#147;Sorrento&#148;). The Company is a commercial-stage, <FONT STYLE="white-space:nowrap">non-opioid</FONT> pain management company focused on the
development and commercialization of topical and injectable therapies. The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#147;ZTlido&#148;), a prescription lidocaine topical system that is
designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT>
administration period. The Company is currently developing two product candidates, <FONT STYLE="white-space:nowrap">SP-102</FONT> (10 mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used
corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica <FONT STYLE="white-space:nowrap">(&#147;SP-102&#148;),</FONT> and <FONT STYLE="white-space:nowrap">SP-103</FONT> (lidocaine topical system) 5.4% <FONT
STYLE="white-space:nowrap">(&#147;SP-103&#148;),</FONT> for the treatment of acute low back pain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;18, 2019, the Company
entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharmaceuticals Inc. (&#147;Scilex Pharma&#148;) pursuant to which the Company acquired 100% of the outstanding shares
of capital stock of Scilex Pharma in exchange for shares of the Company&#146;s common stock (the &#147;Contribution&#148;), which was accounted for as a reorganization of entities under common control. Pursuant to the Contribution and Loan
Agreement, Sorrento provided the Company with a loan with an initial principal amount of $16.5&nbsp;million in the form of a note payable, which was used by the Company to fund the acquisition of Semnur Pharmaceuticals, Inc. (&#147;Semnur&#148;).
Concurrently therewith, the Company entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., the Company&#146;s prior wholly owned subsidiary (&#147;Merger Sub&#148;), Fortis Advisors LLC, solely as representative of the
holders of Semnur equity (the &#147;Semnur Equityholders&#146; Representative&#148;), and Sorrento, for limited purposes (the &#147;Merger Agreement&#148;), which was accounted for as an asset acquisition. Pursuant to the Merger Agreement, Merger
Sub merged with and into Semnur (the &#147;Merger&#148;), with Semnur surviving as the Company&#146;s wholly owned subsidiary. As a result of the Contribution and the Merger, Scilex Pharma and Semnur became wholly owned subsidiaries of the Company.
Upon completion of the Contribution and the Merger, the historical consolidated financial statements of Scilex Pharma became the historical consolidated financial statements of Scilex Holding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, the Company had devoted substantially all of its efforts to the product development of
<FONT STYLE="white-space:nowrap">SP-102</FONT> and <FONT STYLE="white-space:nowrap">SP-103</FONT> and the commercialization of ZTlido. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis of
Presentation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in
the United States of America (&#147;U.S. GAAP&#148;) and include all adjustments necessary for the fair presentation of the Company&#146;s financial position for the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the accounts of the Company&#146;s subsidiaries. All intercompany balances and
transactions have been eliminated in consolidation. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Liquidity and Going Concern </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which
contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#146;s ability to continue as a going concern at least one year after the date the financial statements are
issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021, the Company&#146;s negative working capital was
$146.4&nbsp;million, including cash and cash equivalents of approximately $4.3&nbsp;million. During the year ended December&nbsp;31, 2021, the Company had operating losses of $35.8&nbsp;million and negative cash flows from operations of
$28.7&nbsp;million. The Company had an accumulated deficit of approximately $352.6&nbsp;million as of December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
September 2018, Scilex Pharma issued $224.0&nbsp;million of the Scilex Pharma Notes (see Note 8) for a purchase price of $140.0&nbsp;million. Pursuant to the Indenture, as amended (see Note 8), Scilex Pharma is required to maintain a minimum
unrestricted cash balance of $4.0&nbsp;million at the end of each month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2020, Scilex Pharma repurchased an aggregate of
$65.0&nbsp;million of the Scilex Pharma Notes (see Note 8) and amended the terms of the Scilex Pharma Notes to release $45.0&nbsp;million in restricted funds held in the Reserve Account (see Note 8) and Collateral Account (see Note 8) for the
purpose of consummating the repurchase of an aggregate of $45.0&nbsp;million of principal amount. In February 2021 and April 2021, Scilex Pharma effected specified principal repurchases totaling $40.0&nbsp;million of the principal amount of the
Scilex Pharma Notes. On December&nbsp;31, 2021, Scilex Pharma triggered a cumulative sales-related contingency that triggered an increase in the principal amount of the Scilex Pharma Notes by $28.0&nbsp;million. In February 2022, Scilex Pharma drew
down on the Letter of Credit (see Note 8) with Sorrento, which also triggered Scilex Pharma&#146;s obligation to repurchase $20.0&nbsp;million of the outstanding principal amount of the Scilex Pharma Notes and to maintain a minimum unrestricted cash
balance of $10.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;18, 2019, the Company acquired Semnur and the acquisition was accounted for as an asset
acquisition (See Note 4). The Company anticipates the cash needed for the development of Semnur&#146;s primary product candidate in development, <FONT STYLE="white-space:nowrap">SP-102,</FONT> as well in the development of <FONT
STYLE="white-space:nowrap">SP-103,</FONT> will be in excess of the Company&#146;s cash available within one year after the date these consolidated financial statements are issued. Semnur has no historical revenue and the Company will be responsible
for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least twelve months from
the issuance of these consolidated financial statements through debt and equity financing. The Company&#146;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are
dependent upon, among other things, the success of the Company&#146;s marketing of ZTlido. Should the Company&#146;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#146;s business plan, due to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to,
additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for <FONT STYLE="white-space:nowrap">SP-102</FONT> and <FONT STYLE="white-space:nowrap">SP-103,</FONT>
and other discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#146;s control. As
such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among
other things, raise substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date the financial statements are issued. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Significant Accounting Policies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation
of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date
of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The
Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. Although the balance at times may exceed federally-insured limits, the Company has not
experienced any losses on such accounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for
certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Level&nbsp;1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Level&nbsp;2: Quoted prices for similar instruments that are directly or indirectly observable in the
marketplace. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Level&nbsp;3: Significant unobservable inputs which are supported by little or no market activity and that are
financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that
is significant to the fair value measurement. The Company&#146;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or
liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the
Company or holders of the instruments could realize in a current market exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021 and 2020, the carrying
amount of cash equivalents approximates their fair value based upon quoted market prices. Certain of the Company&#146;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their
fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts
Receivable, Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounts receivable are presented net of allowances for expected credit losses and consist of trade receivables
from product sales to one customer, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts
receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by
reducing the allowance for expected credit losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inventory </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines inventory cost on a <FONT STYLE="white-space:nowrap">first-in,</FONT> <FONT STYLE="white-space:nowrap">first-out</FONT>
basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow-moving. The Company reserves for excess and obsolete inventory based upon
historical experience, sales trends, and specific categories of inventory and expiration dates for <FONT STYLE="white-space:nowrap">on-hand</FONT> inventory. As of December&nbsp;31, 2021 and 2020, the Company&#146;s inventory was primarily comprised
of finished goods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the
straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line
basis. The cost of repairs and maintenance is expensed as incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Goodwill and Other Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment
at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has determined that only one reporting unit exists for examination under impairment review. During its goodwill
impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are
not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than
not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the
qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates its
long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated
future entry of <FONT STYLE="white-space:nowrap">non-generic</FONT> and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a
periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#146; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the
recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Debt </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may enter
financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as
determining the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#146;s anticipated sales and
planned commercial activities as well as actual ZTlido sales up to the date the financial statements were issued. See Note 8 for discussion of the Scilex Pharma Notes, which include repayments based on a percentage of net sales of ZTlido.
Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments each reporting period and accounts for any changes
through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#146;s current and long-term portions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in
performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
license fees and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is
performed or when the goods have been received, rather than when payment is made, in accordance with Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) Topic 730, <I>Research and
Development</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquired <FONT STYLE="white-space:nowrap">In-Process</FONT> Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. The <FONT
STYLE="white-space:nowrap">up-front</FONT> payments to acquire a new drug compound or drug delivery device, as well as future milestone payments associated with asset acquisitions that do not meet the definition of a derivative and are deemed
probable to achieve the milestones, are immediately expensed as acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such
approval, have no alternative future use. Intangible assets acquired in a business combination that are used for <FONT STYLE="white-space:nowrap">in-process</FONT> research and development (&#147;IPR&amp;D&#148;) activities are considered
indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful
life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of
the FASB ASC Topic 740, <I>Income Taxes</I>, addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic
<FONT STYLE="white-space:nowrap">740-10,</FONT> the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the
technical merits of the position. The Company has determined that it has uncertain tax positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes
using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when
necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&nbsp;31, 2021 and 2020, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an
amount equal to its deferred tax liabilities that are scheduled to reverse against the Company&#146;s deferred tax assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. Operating lease <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#146;s leases do not provide an
implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced
by lease incentives. The Company&#146;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line
basis over the lease term in selling, general and administrative expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Derivative Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Derivative liabilities are recorded on the Company&#146;s consolidated balance sheets at their fair value on the date of issuance and are
revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s revenue is generated from product sales within the United States. The Company does not have significant costs associated
with costs to obtain a contract with its customer. All of the Company&#146;s revenue and accounts receivable result from a sole customer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue from product sales is fully comprised of sales of ZTlido. The Company&#146;s performance obligation with respect to sales of ZTlido is
satisfied at a point in time, which transfers control upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product
has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time. Invoicing typically occurs upon shipment and the length of time between
invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&nbsp;31, 2021 and 2020 were not material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For product sales, the Company records <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT> sales
adjustments for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most
likely amount approach based primarily upon provisions included in the Company&#146;s customer contract, customary industry practices and current government regulations.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Gross-to-net</FONT></FONT> adjustments are generally recorded as contract liabilities under accrued expenses within the Company&#146;s consolidated balance sheet. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rebates </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rebates are discounts which the
Company pays under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs
relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#146;s patient drug formulary. Rebates and chargebacks paid under government programs
are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product
sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjust for these rebates on a regular basis to reflect the most recent rebate experience and
contractual obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Service Fees </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined
such services received up to the date the financial statements were issued are not distinct from the Company&#146;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Product Returns </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is obligated
to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates
allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Co-Payment</FONT> Assistance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive
<FONT STYLE="white-space:nowrap">co-payment</FONT> assistance. The Company accrues for <FONT STYLE="white-space:nowrap">co-payment</FONT> assistance based on actual program participation and estimates of program redemption using data provided by
third-party administrators. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Customer Concentration Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fiscal years ended December&nbsp;31, 2021, 2020 and 2019, sales to the Company&#146;s sole distributor represented 100% of net
revenue. This exposes the Company to concentration of customer risk. The Company monitors the financial condition of its sole customer, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the years
ended December&nbsp;31, 2021, 2020 and 2019. As the Company continues to expand the commercialization of its product, the Company is not limited to the current customer and has the option of expanding its distribution network with additional
distributors through establishing its own affiliates, by acquiring existing third-party business or product rights or by partnering with additional third parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, <I>Compensation &#151; Stock Compensation </I>which establishes accounting for equity instruments exchanged for employee and consulting services. Under such
provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#146;s requisite service period (generally
the vesting period of the equity grant) or <FONT STYLE="white-space:nowrap">non-employee&#146;s</FONT> vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of
determining the inputs used in the calculation of stock-based compensation, the Company uses historical data in estimating the expected term of options and determines an estimate of option volatility based on an assessment of historical volatilities
of comparable companies whose share prices are publicly available. The Company uses these estimates as inputs in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could
have a material effect on the results presented in the Company&#146;s consolidated statement of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing net loss for the period by the weighted average number of shares of common stock outstanding
during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options. The treasury stock method is used to calculate the potential
dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive
securities are anti-dilutive and are excluded from the computation of diluted net loss per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the
chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions
regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of <FONT STYLE="white-space:nowrap">non-opioid</FONT> products focused on pain
management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2021, the FASB issued ASU <FONT STYLE="white-space:nowrap">2021-08,</FONT> <I>Business Combinations (Topic 805): Accounting for
Contract Assets and Contract Liabilities from Contracts with Customers</I>, which requires an acquirer in a business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU <FONT STYLE="white-space:nowrap">2021-08</FONT> is effective for fiscal years
beginning after December&nbsp;15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> <I>Income Taxes (Topic 740): Simplifying the
Accounting for Income Taxes</I>. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740. The amendments also improve consistent application of and simplify
U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. The amendments in this update were effective for interim and annual periods for the Company beginning after December&nbsp;15, 2020. The Company adopted the
standard on January&nbsp;1, 2021. The adoption of the standard had no impact on its consolidated financial statements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Semnur Acquisition </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;18, 2019, the Company completed the Merger. At the closing of the Merger, the Company issued to the holders of Semnur&#146;s
capital stock and options to purchase Semnur&#146;s common stock, upfront consideration with a value of $70.0&nbsp;million. The upfront consideration was comprised of the following: (a)&nbsp;a cash payment of approximately $15.0&nbsp;million, and
(b) $55.0&nbsp;million of shares of the Company&#146;s common stock (47,039,315 shares issued and 352,972 shares issuable, valued at $1.16 per share) (the &#147;Stock Consideration&#148;). Following the issuance of the Stock Consideration, Sorrento
ownership in the Company diluted to approximately 58% of the Company&#146;s issued and outstanding capital stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger
Agreement, and upon the terms and subject to the conditions contained therein, the Company also agreed to pay the Semnur Equityholders up to $280.0&nbsp;million in aggregate contingent cash consideration based on the achievement of certain
milestones, comprised of a $40.0&nbsp;million payment that will be due upon obtaining the first approval of a New Drug Application (&#147;NDA&#148;) of a Semnur product by the U.S. Food and Drug Administration (the &#147;FDA&#148;) and additional
payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: (1)&nbsp;a $20.0&nbsp;million payment upon the achievement of $100.0&nbsp;million in cumulative net sales of a Semnur product, (2)&nbsp;a
$20.0&nbsp;million payment upon the achievement of $250.0&nbsp;million in cumulative net sales of a Semnur product, (3)&nbsp;a $50.0&nbsp;million payment upon the achievement of $500.0&nbsp;million in cumulative net sales of a Semnur product, and
(4)&nbsp;a $150.0&nbsp;million payment upon the achievement of $750.0&nbsp;million in cumulative net sales of a Semnur product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
August&nbsp;7, 2019, the Company entered into an amendment to the Merger Agreement to provide that, following the consummation of the Company&#146;s first bona fide equity financing with one or more third-party financing sources on an arms&#146;
length basis with gross proceeds to the Company of at least $40.0&nbsp;million, certain of the former Semnur optionholders will be paid cash in lieu of: (1)&nbsp;the 352,972 shares of the Company&#146;s common stock otherwise issuable to such former
Semnur optionholders pursuant to the Merger Agreement, and (2)&nbsp;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Merger Agreement, with such shares in each case
valued at $1.16 per share. The amendment resulted in a reclassification of $0.4&nbsp;million from additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital to accrued liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2019, the Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights
Agreement with the Company (the &#147;Exchange Agreement&#148;).Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within 18 months following the closing of the Merger, 100% of the outstanding
equity of the Company has not been acquired by a third party or the Company has not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of the Company capital stock on a major stock exchange
that meets certain requirements, then holders of the Stock Consideration may collectively elect to exchange, during the <FONT STYLE="white-space:nowrap">60-day</FONT> period commencing the date that is the 18 month anniversary of the Closing (the
&#147;Share Exchange&#148;), the Stock Consideration for shares of Sorrento&#146;s common stock with a value of $55.0&nbsp;million based on a price per share of Sorrento&#146;s common stock equal to the greater of (a)&nbsp;the <FONT
STYLE="white-space:nowrap">30-day</FONT> trailing volume weighted average price </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of one share of Sorrento&#146;s common stock as reported on The Nasdaq Stock Market LLC as of the consummation of the Share Exchange and (b) $5.55 (subject to adjustment for any stock dividend,
stock split, stock combination, reclassification or similar transaction) (the &#147;Exchange Price&#148;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento on September&nbsp;28, 2020, on October&nbsp;9, 2020, Sorrento paid
$55.0&nbsp;million in cash to the Semnur Equityholders in lieu of issuing $55.0&nbsp;million of shares of Sorrento&#146;s common stock at the Exchange Price. Following the completion of the Share Exchange and as of December&nbsp;31, 2020, Sorrento
held approximately 82.3% of the outstanding common stock of the Company. On January&nbsp;29, 2021, Sorrento acquired additional shares of the Company, resulting in Sorrento holding approximately 99.97% of the outstanding common stock of the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the
single asset, <FONT STYLE="white-space:nowrap">SP-102.</FONT> As a result, approximately $75.3&nbsp;million was expensed as a component of acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development during the year ended
December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No contingent consideration was recorded as of December&nbsp;31, 2021 and 2020 since the related regulatory
approval milestones are not deemed probable until they actually occur. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Fair Value Measurements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#146;s financial assets and liabilities that are measured at fair value (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair value measurements at December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices<BR>in&nbsp;Active<BR>Markets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs<BR>(Level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Unobservable<BR>Inputs<BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair value measurements at December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices<BR>in&nbsp;Active<BR>Markets<BR>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs<BR>(Level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Unobservable<BR>Inputs<BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and
cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Derivative liabilities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recorded a loss of $0.3&nbsp;million, a gain of $0.8&nbsp;million and a loss of $23.3&nbsp;million on derivative liabilities for
the years ended December&nbsp;31, 2021, 2020 and 2019, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes. The compound derivative liabilities consist of the fair value of various embedded
features as further described in Note 8. The fair value of the derivative liabilities associated with the Scilex Pharma Notes was estimated using the discounted cash flow method under the income approach combined with a Monte Carlo simulation model.
This involves significant Level&nbsp;3 inputs and assumptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key assumptions for the compound derivative liabilities associated
with the Scilex Pharma Notes for the year ended December&nbsp;31, 2021 included a 6.2% risk-adjusted net sales forecast and an effective debt yield of 15.0%. The key assumptions for the compound derivative liabilities associated with the Scilex
Pharma Notes for the year ended December&nbsp;31, 2020 included a 7% risk-adjusted net sales forecast, an effective debt yield of 15% and an estimated probability of 100% of not obtaining marketing approval before March&nbsp;31, 2021. The key
assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&nbsp;31, 2019 included an 8% risk adjusted net sales forecast, an effective debt yield of 19.7% and estimated probabilities of
100% and 55% of not obtaining marketing approval before March&nbsp;31, 2021 and July&nbsp;1, 2023, respectively, and an estimated high probability of an initial public offering of the Company that satisfies certain valuation thresholds occurring
prior to October&nbsp;1, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table includes a summary of the derivative liabilities measured at fair value using
significant unobservable inputs (Level 3) during the years ended December&nbsp;31, 2021, 2020 and 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Re-measurement</FONT> of fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Re-measurement</FONT> of fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Re-measurement</FONT> of fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Property and Equipment </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consisted of the following as of December&nbsp;31, 2021 and 2020 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers&nbsp;&amp; equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense for each of the years ended December&nbsp;31, 2021, 2020 and 2019 was $39&nbsp;thousand,
$40&nbsp;thousand and $40&nbsp;thousand, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Goodwill and Intangible Assets </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021 and 2020, the Company had recorded goodwill of $13.5&nbsp;million. The Company performed a qualitative test for
goodwill impairment during the fourth quarter of 2021. Based upon the results of the qualitative testing, the Company concluded that it is <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> that the fair value of the Company&#146;s
goodwill was in excess of the carrying value and therefore performing the first step of the <FONT STYLE="white-space:nowrap">two-step</FONT> impairment test was unnecessary. No goodwill impairment was recognized for the years ended December&nbsp;31,
2021, 2020, and 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s intangible assets, excluding goodwill, are composed of patent rights, acquired technology and
assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. A summary of the Company&#146;s identifiable intangible assets as of December&nbsp;31,
2021 and 2020 is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>carrying<BR>amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>amortization</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Intangibles,<BR>net</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assembled workforce</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>carrying<BR>amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>amortization</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Intangibles,<BR>net</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assembled workforce</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021, the weighted average remaining life for identifiable intangible assets is 10.6
years. Aggregate amortization expense was $3.7&nbsp;million for each of the years ended December&nbsp;31, 2021, 2020, and 2019. Patent rights and acquired technology are amortized over a <FONT STYLE="white-space:nowrap">15-year</FONT> period.
Assembled workforce is amortized over a <FONT STYLE="white-space:nowrap">5-year</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimated future amortization expense
related to intangible assets at December&nbsp;31, 2021 is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Year Ending December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No impairment charges related to intangible assets were recorded during the years ended December&nbsp;31, 2021
and 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Debt </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018 Purchase Agreements and Indenture </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;7, 2018, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#147;2018 Purchase Agreements&#148;) with certain
investors (collectively, the &#147;Scilex Pharma Note Purchasers&#148;). Pursuant to the 2018 Purchase Agreements, on September&nbsp;7, 2018, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured
notes due 2026 in an aggregate principal amount of $224.0&nbsp;million (the &#147;Scilex Pharma Notes&#148;) for an aggregate purchase price of $140.0&nbsp;million (the &#147;Offering&#148;). The Scilex Pharma Notes are governed by an indenture (as
amended, the &#147;Indenture&#148;) with Scilex Pharma, as issuer, U.S. Bank National Association, a national banking association, as trustee (the &#147;Trustee&#148;) and collateral agent (the &#147;Collateral Agent&#148;), and Sorrento, as
guarantor. Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the
&#147;Guarantee&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net proceeds of the Offering were approximately $89.3&nbsp;million, after deducting the Offering expenses
payable by Scilex Pharma and funding a segregated reserve account with $20.0&nbsp;million (the &#147;Reserve Account&#148;) and a segregated collateral account with $25.0&nbsp;million (the &#147;Collateral Account&#148;) pursuant to the terms of the
Indenture. Funds in the Reserve Account were to be released to Scilex Pharma upon receipt by the Trustee of an officer&#146;s certificate under the Indenture from Scilex Pharma confirming receipt of a marketing approval letter from the FDA with
respect to <FONT STYLE="white-space:nowrap">SP-103</FONT> or a similar product with a concentration of not less than 5% (the &#147;Marketing Approval Letter&#148;) on or prior to July&nbsp;1, 2023. Funds in the Collateral Account were to be released
to Scilex Pharma only upon receipt of a written consent authorizing such release from the holders of a majority in principal amount of the Scilex Pharma Notes issued, upon the occurrence and during the continuance of an event of default at the
direction of the holders of a majority in principal amount of the Scilex Pharma Notes issued or upon the repayment in full of all amounts owed under the Scilex Pharma Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On each February&nbsp;15, May&nbsp;15, August&nbsp;15 and November&nbsp;15, beginning with February&nbsp;15, 2019, the holders of the Scilex
Pharma Notes were initially entitled to receive quarterly payments of the principal of the Scilex Pharma Notes equal to a fixed percentage, ranging from 10% to 20%, of the net sales of ZTlido for the prior fiscal quarter. However, because Scilex
Pharma did not receive the Marketing Approval Letter by March&nbsp;31, 2021, the percentage of net sales payable was increased to be in the range of 15% to 25%. If actual cumulative net sales of ZTlido from October&nbsp;1, 2022 through
September&nbsp;30, 2023 are less than approximately $218.1&nbsp;million, then Scilex Pharma will be obligated to pay an additional installment of the principal of the Scilex Pharma Notes each quarter in an amount between approximately
$10.1&nbsp;million and approximately $30.6&nbsp;million, with the amount of the additional installment of principal to be determined by reference to the amount by which cumulative net sales of ZTlido from October&nbsp;1, 2022 through
September&nbsp;30, 2023 are less than approximately $218.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Indenture, the aggregate principal amount
due under the Scilex Pharma Notes was to be increased by $28.0&nbsp;million on February&nbsp;15, 2022 if actual cumulative net sales of ZTlido from September&nbsp;7, 2018 through December&nbsp;31, 2021 were less than approximately
$481.0&nbsp;million. As actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&nbsp;31, 2021 did not equal or exceed the $481.0&nbsp;million threshold for such period, the Company recorded the increase
of $28.0&nbsp;million in the debt principal balance with an offset to Scilex Pharma Notes principal increase at December&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If actual cumulative net sales of ZTlido for the period from October&nbsp;1, 2022 through September&nbsp;30, 2023 are less than approximately
$290.7&nbsp;million, then the aggregate principal amount due under the Scilex Pharma Notes will be increased on November&nbsp;15, 2023 by between approximately $2.6&nbsp;million and approximately $84.8&nbsp;million, with the amount of the principal
increase to be determined by reference to the amount by which the cumulative net sales of ZTlido from October&nbsp;1, 2022 through September&nbsp;30, 2023 is less than approximately $290.7&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The final maturity date of the Scilex Pharma Notes is August&nbsp;15, 2026. The Scilex
Pharma Notes may be redeemed in whole at any time upon 30 days&#146; written notice at Scilex Pharma&#146;s option prior to August&nbsp;15, 2026 at a redemption price equal to 100% of the then-outstanding principal amount of the Scilex Pharma Notes.
In addition, upon a change of control of Scilex Pharma (as defined in the Indenture), each holder of a Scilex Pharma Note shall have the right to require Scilex Pharma to repurchase all or any part of such holder&#146;s Scilex Pharma Note at a
repurchase price in cash equal to 101% of the then-outstanding principal amount thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 Purchase Agreements include the terms
and conditions of the offer and sale of the Scilex Pharma Notes, representations and warranties of the parties, indemnification and contribution obligations and other terms and conditions customary in agreements of this type. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Indenture governing the Scilex Pharma Notes contains customary events of default with respect to the Scilex Pharma Notes (including a
failure to make any payment of principal on the Scilex Pharma Notes when due and payable), and, upon certain events of default occurring and continuing, the Trustee by notice to Scilex Pharma, or the holders of at least 25% in principal amount of
the outstanding Scilex Pharma Notes by notice to Scilex Pharma and the Trustee, may (subject to the provisions of the Indenture) declare 100% of the then-outstanding principal amount of the Scilex Pharma Notes to be due and payable. Upon such a
declaration of acceleration, such principal will be due and payable immediately. In the case of certain events, including bankruptcy, insolvency or reorganization involving Sorrento or Scilex Pharma, the Scilex Pharma Notes will automatically become
due and payable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Indenture, the Company and Scilex Pharma must also comply with certain covenants with respect to the
commercialization of ZTlido, as well as customary additional affirmative covenants, such as furnishing financial statements to the holders of the Scilex Pharma Notes, minimum cash requirements and net sales reports; and negative covenants, including
limitations on the following: the incurrence of debt; the payment of dividends, the repurchase of shares and under certain conditions making certain other restricted payments; the prepayment, redemption or repurchase of subordinated debt; a merger,
amalgamation or consolidation involving Scilex Pharma; engaging in certain transactions with affiliates; and the making of investments other than those permitted by the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Scilex Pharma Notes and related Guarantee have not been, and will not be, registered under the Securities Act or the securities laws of
any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements. The holders of the Scilex Pharma Notes do not have any registration rights. Pursuant to a
Collateral Agreement by and among Scilex Pharma, the Trustee and the Collateral Agent (the &#147;Collateral Agreement&#148;), the Scilex Pharma Notes will be secured by ZTlido and all of the existing and future property and assets of Scilex Pharma
necessary for, or otherwise relevant to, now or in the future, the manufacture and sale of ZTlido, on a worldwide basis (exclusive of Japan), including, but not limited to, the intellectual property related to ZTlido, the marketing or similar
regulatory approvals related to ZTlido, any licenses, agreements and other contracts related to ZTlido, and the current assets related to ZTlido such as inventory, accounts receivable and cash and any and all future iterations, improvements or
modifications of such product made, developed or licensed (or <FONT STYLE="white-space:nowrap">sub-licensed)</FONT> by Scilex Pharma or any of its affiliates or licensees (or <FONT STYLE="white-space:nowrap">sub-licensees)</FONT> (including <FONT
STYLE="white-space:nowrap">SP-103).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Indenture, Sorrento issued an irrevocable standby letter of
credit to Scilex Pharma (the &#147;Letter of Credit&#148;), which provides that, in the event that (1)&nbsp;Scilex Pharma did not hold at least $4.0&nbsp;million in unrestricted cash as of the end of any calendar month during the term of the Scilex
Pharma Notes, (2)&nbsp;actual cumulative net sales of ZTlido from September&nbsp;7, 2018 through December&nbsp;31, 2021 were less than a specified sales threshold for such period, or (3)&nbsp;actual cumulative net sales of ZTlido for any calendar
year during the term of the Scilex Pharma Notes, beginning with the 2022 calendar year, were less than a specified sales threshold for such calendar year, Scilex Pharma as beneficiary of the Letter of Credit, would be required to draw, and Sorrento
would be required to pay to Scilex Pharma, $35.0&nbsp;million in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount as a subordinated loan. The Letter of Credit was to terminate upon the earliest to occur of: (a)&nbsp;the repayment of
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Scilex Pharma Notes in full, (b)&nbsp;the actual net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes exceeding a certain threshold, (c)&nbsp;the consummation of
an initial public offering on a major international stock exchange by the Company that satisfies certain valuation thresholds, and (d)&nbsp;the replacement of the Letter of Credit with another letter of credit in form and substance, including as to
the identity and creditworthiness of issuer, reasonably acceptable to the holders of at least 80% in principal amount of outstanding Scilex Pharma Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2020, Scilex, Sorrento, the Trustee and the Agent, and the beneficial owners of the Scilex Pharma Notes and the Scilex
Note Purchasers entered into a Consent Under and Amendment No.&nbsp;3 to Indenture and Letter of Credit (&#147;Amendment No.&nbsp;3&#148;), which amended: (i)&nbsp;the Indenture, and (ii)&nbsp;the Letter of Credit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Amendment No.&nbsp;3, the Holders agreed to release all of the aggregate $45.0&nbsp;million in restricted funds held in the
Reserve Account and the Collateral Account for the purpose of consummating the repurchase of an aggregate of $45.0&nbsp;million of principal amount of the Scilex Pharma Notes from the Holders on a pro rata basis at a purchase price equal to 100% of
the principal amount thereof (such repurchase, the &#147;Scilex Repurchase&#148;). In connection with the Scilex Repurchase, the parties also agreed to remove (i)&nbsp;Sorrento&#146;s obligations under the Indenture to repurchase $25.0&nbsp;million
of Scilex Pharma Notes from the Holders if the Letter of Credit is drawn on and (ii)&nbsp;Scilex Pharma&#146;s obligation to repurchase $20.0&nbsp;million of Scilex Pharma Notes from the Holders if Scilex Pharma did not receive the Marketing
Approval Letter on or prior to July&nbsp;1, 2023. On December&nbsp;14, 2020, the restricted funds in the Reserve Account and the Collateral Account were released and the Scilex Repurchase was effected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amendment No.&nbsp;3 also revised the minimum cash covenant in the Indenture to provide that the amount of cash equivalents in bank accounts
that Scilex Pharma is required to have as of the end of any calendar month shall, commencing with the month ending December&nbsp;31, 2020, be equal to at least $4.0&nbsp;million in the aggregate, provided that if Scilex Pharma did not effectuate
(i)&nbsp;the December Optional Repurchase (as defined below) and (ii)&nbsp;at least one of either (x)&nbsp;the February Optional Repurchase (as defined below) or (y)&nbsp;the April Optional Repurchase (as defined below), then, commencing with the
month ending April&nbsp;30, 2021, and for each month thereafter, such amount would have been required to be at least $10.0&nbsp;million in the aggregate. If Scilex Pharma fails to meet the foregoing minimum cash requirements, then Scilex Pharma will
be required to draw on the Letter of Credit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amendment No.&nbsp;3 also provided Scilex Pharma with the option, in its sole and absolute
discretion, to repurchase Scilex Pharma Notes from the holders thereof on a pro rata basis on each of December&nbsp;16, 2020 (the &#147;December Optional Repurchase&#148;), February&nbsp;12, 2021 (the &#147;February Optional Repurchase&#148;) and
April&nbsp;13, 2021 (the &#147;April Optional Repurchase&#148;), in each case in an aggregate amount equal to the lesser of $20.0&nbsp;million or the then-outstanding principal amount of the Scilex Pharma Notes, at a purchase price in cash equal to
100% of the principal amount thereof. Scilex Pharma effectuated the December Optional Repurchase, the February Optional Repurchase, and the April Optional Repurchase, which reduced the aggregate principal amount of the Scilex Pharma Notes by
$60.0&nbsp;million and resulted in the minimum unrestricted requirement remaining at $4.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amendment No.&nbsp;3 further
provided that in the event that the Letter of Credit is drawn upon by Scilex Pharma, then Scilex Pharma had to, within five business days of such draw, repurchase the Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate
amount equal to the lesser of $20.0&nbsp;million or the then-outstanding principal amount of Scilex Pharma Notes, at a purchase price in cash equal to 100% of the principal amount thereof. In addition, upon the Letter of Credit being drawn on,
Scilex Pharma is required to have minimum cash of $10.0&nbsp;million at all times thereafter. In February 2022, Scilex Pharma drew upon the Letter of Credit with Sorrento and, as such, repaid $20.0&nbsp;million of the principal amount of the Scilex
Pharma Notes and became subject to a minimum cash requirement of $10.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Amendment No.&nbsp;3, the Holders also
consented to Scilex Pharma incurring up to $10.0&nbsp;million of indebtedness in connection with an accounts receivable revolving loan facility (discussed below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounted for Amendment No.&nbsp;3 as a debt modification under ASC Topic <FONT
STYLE="white-space:nowrap">470-50</FONT> as modified terms were not substantially different than the <FONT STYLE="white-space:nowrap">pre-modified</FONT> terms. The execution of Amendment No.&nbsp;3 resulted in an additional derivative liability of
$2.8&nbsp;million, which pertains to a $9.6&nbsp;million distribution to Sorrento with respect to a contingent accelerated repayment on the Scilex Pharma Notes in connection with the Letter of Credit and $6.8&nbsp;million reduction to the debt
discount on the Scilex Pharma Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To estimate the fair value of the Scilex Pharma Notes, the Company uses the discounted cash flow
method under the income approach, which involves significant Level&nbsp;3 inputs and assumptions, combined with a Monte Carlo simulation, as appropriate. The value of the debt instrument is based on the present value of future principal payments and
the discounted rate of return reflective of the Company&#146;s credit risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrowings of the Scilex Pharma Notes are as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carrying value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long term portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future minimum payments under the Scilex Pharma Notes, based on a percentage of projected net sales of ZTlido
are estimated as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Year Ending December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total minimum future payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company made principal payments of $45.9&nbsp;million, $69.8&nbsp;million, and $2.3&nbsp;million during
the fiscal years ended December&nbsp;31, 2021, 2020, and 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt discount and debt issuance costs, which are presented
as a direct reduction of the Scilex Pharma Notes in the consolidated balance sheets, are amortized as interest expense using the effective interest method. As principal repayments on the Scilex Pharma Notes are based on a percentage of net sales of
ZTlido and <FONT STYLE="white-space:nowrap">SP-103,</FONT> if the Marketing Approval Letter is received, the Company has elected to account for changes in estimated cash flows from future net sales prospectively. Specifically, a new effective
interest rate will be determined based on revised estimates of remaining cash flows and changes in expected cash flows will be recognized prospectively. The imputed effective interest rate at December&nbsp;31, 2021 and 2020 was 7.7% and 9.15%,
respectively. The amount of debt discount and debt issuance costs included in interest expense for the years ended December&nbsp;31, 2021, 2020 and 2019 was approximately $7.9&nbsp;million, $10.7&nbsp;million and $15.0&nbsp;million, respectively.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company identified a number of embedded derivatives that require bifurcation from the Scilex Pharma Notes and separate accounting in
the consolidated financial statements as derivative liabilities. Certain of these embedded features included default interest provisions, contingent rate increases, contingent put options, optional and automatic acceleration provisions and
indemnified taxes. The Company recorded this derivative within its consolidated financial statements (See Note 5). The Company <FONT STYLE="white-space:nowrap">re-evaluates</FONT> this assessment each reporting period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Scilex Pharma Notes also provide that, upon the occurrence of an event of default, the
holders of at least 25% in principal amount of the outstanding Scilex Pharma Notes may, by written notice to Scilex Pharma, declare all of the outstanding principal and premium under such Scilex Pharma Notes immediately due and payable. For purposes
of the Scilex Pharma Notes, an event of default includes, among other things, (i)&nbsp;Scilex Pharma&#146;s failure to pay outstanding material indebtedness, including the Scilex Pharma Notes, when due (ii)&nbsp;Scilex Pharma&#146;s breach of its
representations and warranties or failure to comply with its covenants and obligations under the Scilex Pharma Notes or (iii)&nbsp;the occurrence of certain insolvency or bankruptcy events (both voluntary and involuntary) involving Scilex Pharma.
The Company is in compliance with event of default clauses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Notes Payable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;5, 2018, Scilex Pharma issued to Sorrento a promissory note (see Note 13). On March&nbsp;18, 2019, the Company entered into a
note payable with Sorrento (see Note 13). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 Revolving Credit Facility </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2020, Scilex Pharma entered into the Credit and Security Agreement (the &#147;Credit Agreement&#148;) with CNH Finance
Fund I, L.P. (&#147;CNH&#148;) which provides Scilex Pharma with the ability to incur indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $10.0&nbsp;million and the incurrence of liens and the pledge of
collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus 1.75%. All
indebtedness incurred and outstanding will be due and payable in full on January&nbsp;1, 2024; unless the Credit Agreement is earlier terminated. As of December&nbsp;31, 2021 and 2020, the outstanding balance was $8.8&nbsp;million and
$9.5&nbsp;million, respectively. On February&nbsp;16, 2022, the Company notified CNH that it was terminating the Credit Agreement, effective March&nbsp;18, 2022. Upon termination, all principal balances and interest accrued were settled. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Paycheck Protection Program </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
May 2020, the Company received the proceeds from a loan in the amount of $1.6&nbsp;million (the &#147;PPP Loan&#148;) from Bank of America, as the lender, pursuant to the Paycheck Protection Program (&#147;PPP&#148;) of the Coronavirus Aid, Relief,
and Economic Security Act (the &#147;CARES Act&#148;). The PPP Loan matures on May 05, 2022 and bears interest at a rate of 1.0% per annum. The PPP Loan is evidenced by a promissory note dated May&nbsp;03, 2020 (the &#147;Note&#148;), which contains
customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the twenty-four-week period, beginning on the date of loan approval. For purposes of the
CARES Act, payroll costs exclude compensation of an individual employee in excess of $100,000, prorated annually. Not more than 25% of the forgiven amount may be for <FONT STYLE="white-space:nowrap">non-payroll</FONT> costs. Forgiveness is reduced
if full-time headcount declines, or if salaries and wages for employees with salaries of $100,000 or less annually are reduced by more than 25%. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven
is applied to outstanding principal. The Company used all of the proceeds from the PPP Loan to retain employees and maintain payroll. In May 2021, the Company received confirmation from the SBA that the entire PPP Loan was forgiven and recorded a
gain on debt extinguishment of $1.6&nbsp;million, which is included in loss on debt extinguishment, net, on the consolidated statements of operations for the year ended December&nbsp;31, 2021. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Stockholders&#146; Equity </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total number of authorized shares of preferred stock of Scilex Holding is 20,000,000, of which no shares were issued and outstanding at
December&nbsp;31, 2021 and 2020. The total number of authorized shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock of Scilex Holding is 350,000,000, of which 197,266,338 shares were issued and outstanding at December&nbsp;31, 2021 and 2020. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Stock Incentive and Employee Benefit Plans </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June
2017, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#147;Scilex Pharma 2017 Plan&#148;). The Scilex Pharma 2017 Plan reserved 24.0&nbsp;million shares of Scilex Pharma common stock. Stock options granted
under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter. The Scilex Pharma 2017 Plan was amended and restated on
July&nbsp;5, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the Merger Closing, the Scilex Pharma 2017 Equity Incentive Plan was terminated, and each option to purchase
Scilex Pharma&#146;s common stock outstanding and unexercised immediately prior to the Merger Closing was cancelled and substituted for that number of options to acquire common stock of Scilex Holding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2019 Stock Option Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#147;2019 Stock Option Plan&#148;) on
May&nbsp;28, 2019. The 2019 Stock Option Plan was approved by the Company&#146;s stockholders on June&nbsp;7, 2019. As of December&nbsp;31, 2019, 30.0&nbsp;million shares of common stock of the Company were reserved for issuance pursuant to the 2019
Stock Option Plan. On December&nbsp;21, 2020, the board of directors approved an amendment to the 2019 Stock Option Plan to reserve an additional 15.0&nbsp;million shares of common stock for issuance under the 2019 Stock Option Plan. As of
December&nbsp;31, 2020, 45.0&nbsp;million shares of common stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the
shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021, options to purchase 28,163,510 shares of the common stock of Scilex Holding were outstanding, which is comprised
of options to purchase 26,743,510 shares of common stock that were outstanding under the 2019 Stock Option Plan and options to purchase 1,420,000 shares of common stock that were outstanding pursuant to options previously granted under the Scilex
Pharma 2017 Plan. As of December&nbsp;31, 2021, 18,256,490 shares of the Company&#146;s common stock were reserved for awards available for future issuance under the 2019 Stock Option Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded within operating expenses was $5.8&nbsp;million, $5.4&nbsp;million and $4.3&nbsp;million for the years
ended December&nbsp;31, 2021, 2020 and 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total unrecognized compensation costs related to unvested employee and
nonemployee stock option grants as of December&nbsp;31, 2021 was $8.8&nbsp;million and the weighted average period over which these grants are expected to vest is 1.8 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Option Valuation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
calculates the fair value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions, including stock
price volatility, the expected life of stock options, risk free interest rate and the fair value per share of the underlying common stock on the date of grant. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the years ended 2020 and 2019 is set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average grant date fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$0.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$0.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected stock-price volatility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90.00%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">89.00%&nbsp;-&nbsp;104.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.53%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.63%&nbsp;-&nbsp;2.50%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term of options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.76&nbsp;-&nbsp;6.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per share of common stock on date of grant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$1.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$1.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$1.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$1.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected dividend yield</I>. The Company bases the expected dividend yield assumption on the fact that the
Company has never paid cash dividends and has no present intention to pay cash dividends on the Company&#146;s common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected
stock-price volatility</I>. The expected stock-price volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the transdermal
patch industry. In selecting the peer group, management considered publicly-traded transdermal patch companies with existing clinical stage branded and generic transdermal patches. Management further considered the development stage of the peer
group companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Risk-free interest rate</I>. The Company bases the risk-free interest rate assumption on the U.S. Treasury&#146;s
rates for U.S. Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> bonds with maturities similar to those of the expected term of the award being valued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected term of options</I>. The expected term of options represents the period of time when options are expected to be outstanding.
Because the Company does not have historic exercise behavior, the Company determines the expected life assumption for options issued to directors and employees using the simplified method, which is an average of the contractual term of the option
and its ordinary vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2020 and December&nbsp;31, 2019, Scilex Holding issued stock
options to certain employees and nonemployees. Significant inputs utilized in determining the fair value of the common shares are as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>March&nbsp;17 and March&nbsp;31, 2019 Valuations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the valuation performed on March&nbsp;17, 2019 and March&nbsp;31, 2019, the fair value of the Company&#146;s common stock was estimated
using the market and income approaches. The Company weighted a guideline public company method, a market approach that uses comparable company data and applies to the subject company, equally with a discounted cash flow method, an income approach
that derives value by estimating reasonable future cash flows to the equityholders and discounting them to present value using a risk-adjusted discount rate. The Company then used the Option Pricing Method (&#147;OPM&#148;) to allocate the concluded
equity value amongst the different equity classes and determine the common stock value. These valuations resulted in a valuation of the Company&#146;s common stock of $1.16 per share as of March&nbsp;17, 2019 and March&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>May&nbsp;31, 2019 Valuation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the
valuation performed on May&nbsp;31, 2019, the fair value of the Company&#146;s common stock was estimated using a hybrid Probability Weighted Expected Return Method (&#147;PWERM&#148;), which estimates the value by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the Company utilized recent comparable
initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income and market approaches in line with the
March&nbsp;31, 2019 valuation then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#146;s best estimates at the time) each
scenario&#146;s common stock value to arrive at the Company&#146;s concluded common stock value. This valuation resulted in a valuation of the Company&#146;s common stock of $1.16 per share as of May&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>December&nbsp;31, 2019 Valuation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the
valuation performed on December&nbsp;31, 2019, the fair value of the Company&#146;s common stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. The Company used three going public scenarios and one
stay-private scenario. For the three public scenarios, the Company utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the
stay-private scenario, the Company utilized the income approach in line with the March&nbsp;31, 2019 valuation then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then
probability weighted (based on the Company&#146;s best estimates at the time) each scenario&#146;s common stock value to arrive at the Company&#146;s concluded common stock value. This valuation resulted in a valuation of the Company&#146;s common
stock of $1.16 per share as of December&nbsp;31, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>July&nbsp;31, 2020 Valuation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the valuation performed on July&nbsp;31, 2020, the fair value of the Company&#146;s common stock was estimated using PWERM, which estimates
the value by probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the Company utilized recent comparable initial public offerings to estimate value,
which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income approach in line with the March&nbsp;31, 2019, May&nbsp;31, 2019 and December&nbsp;31, 2019
valuations then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#146;s best estimates at the time) each scenario&#146;s
common stock value to arrive at the Company&#146;s concluded common stock value. This valuation resulted in a valuation of the Company&#146;s common stock of $1.16 per share as of July&nbsp;31, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents a summary of the options outstanding at December&nbsp;31, 2021,
2020, and 2019 changes during the years then ended (in thousands, other than weighted-average exercise price): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>average<BR>exercise&nbsp;price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(745</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Benefit Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains a defined contribution 401(k) plan available to eligible employees, which is administered by Sorrento. Employee
contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $0.3&nbsp;million for each of the years
ended December&nbsp;31, 2021, 2020 and 2019. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commitments and Contingencies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product Development Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#147;Product Development Agreement&#148;) with two parties (the &#147;Developers&#148;), one of which is ITOCHU CHEMICAL FRONTIER Corporation
(&#147;Itochu&#148;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> (the &#147;Products&#148;), for Scilex Pharma. The Developers initially
developed, and have intellectual property rights relating to, the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers
are responsible for sourcing and supplying lidocaine for development and commercialization purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Product Development
Agreement, Scilex Pharma is required to make aggregate royalty payments between 25% and 35% to the Developers based on net profits. Up to the date the financial statements were issued, the Company made no aggregate royalty payments. Net profits are
defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the
sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The
Product Development Agreement will continue in full force and effect until October&nbsp;2, 2028, the date that is ten years from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for
subsequent successive <FONT STYLE="white-space:nowrap">one-year</FONT> renewal periods unless Scilex Pharma or the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Developers terminate it upon <FONT STYLE="white-space:nowrap">6-month</FONT> written notice. In addition, Scilex Pharma or the Developers may terminate the Product Development Agreement if
(1)&nbsp;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within 180 days after notice requesting to cure; (2)&nbsp;the FDA
determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; (3)&nbsp;the market
conditions are such that (a)&nbsp;commencing with the quarter ending March&nbsp;31, 2023, Scilex Pharma&#146;s total net profits of the Products are equal to or less than 5% of Scilex Pharma&#146;s net sales of the Products for a period of four or
more consecutive quarters, or (b)&nbsp;the Products&#146; economic viability is affected by documented external circumstances deemed detrimental to all parties as agreed to by Scilex Pharma and the Developers, and the parties are unable to resolve
the economic viability concerns under the foregoing clauses (a)&nbsp;and (b)&nbsp;after 30 days of good-faith discussion; (4)&nbsp;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be
allocated; or (5)&nbsp;Scilex Pharma or either one of the Developers are bankrupt or make assignment for the benefit of creditors. Up to the date the financial statements were issued, Scilex&#146;s net profits for ZTlido and <FONT
STYLE="white-space:nowrap">SP-103</FONT> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus,
neither Oishi nor Itochu has exercised its right of termination. Additionally, Scilex Pharma may terminate the Product Development Agreement if (i)&nbsp;any of the pivotal human clinical trials for any of the Products fail, or (ii)&nbsp;the FDA
issues a &#147;Refusal to File&#148; for any of the Products&#146; regulatory approval application and, after reasonable consultation with the Developers, Scilex Pharma believes that it is commercially unreasonable to
<FONT STYLE="white-space:nowrap">re-file.</FONT> The Developers may terminate the Product Development Agreement if Scilex Pharma fails to file for regulatory approval for any of the Products within three months of the date on which all required
components of the regulatory approval application are received by Scilex Pharma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;16, 2017, Scilex Pharma entered into a
Commercial Supply Agreement (as amended, the &#147;Supply Agreement&#148;) with the two Developers to provide commercial supply of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> to Scilex Pharma. The Supply Agreement contains standard
terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining
the amount of net profit under the Product Development Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Distribution Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2015, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#147;Distribution Agreement&#148;) to appoint an exclusive
third-party logistics distribution provider (the &#147;Distributor&#148;) and as an authorized distributor of record of ZTlido (&#147;Product&#148;) in the United States, its territories, possessions and commonwealths for an agreed schedule of fees,
subject to a 3% annual adjustment. The Distribution Agreement has an initial term of three years following the first shipment of <FONT STYLE="white-space:nowrap">FDA-approved</FONT> Product to a commercial customer and shall automatically renew for
additional terms of one year each, unless written notice of termination is given by either party at least 30 days prior to the end of the initial term or any renewal term. In the event of Product recalls, Scilex Pharma is solely responsible for all
product recalls, except in the event where the recalls arise from the Distributor&#146;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the
Distributor&#146;s facility, including all costs, expenses and risk of loss associated with such delivery. From late 2018 to early 2022, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a
fee of between 1% to 2% which was recorded as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT> sales adjustment. Beginning in April 2022, Scilex Pharma began directly selling and transferring title to
distributors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales Operations Services </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2016, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services,
which was subsequently superseded by a new project agreement entered into in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
September 2018 (the &#147;Project Agreement&#148;). In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales
representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the
vendor. In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2020, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the
sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor will continue to provide sales operations services and fleet management services and sample accountability services. The work order will
remain in effect until June&nbsp;30, 2022, and may be extended for additional periods of one year upon the mutual agreement of both parties. Either party may terminate the work order with 90 days&#146; notice. Scilex Pharma paid an implementation
fee of $59.0&nbsp;thousand and will pay fixed monthly fees of $63.7&nbsp;thousand to $65.8&nbsp;thousand for ongoing services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company recognized an expense of $1.9&nbsp;million, $10.5&nbsp;million, and $25.3&nbsp;million within selling, general and administrative expenses for services performed for the years ended December&nbsp;31, 2021, 2020, and 2019, respectively,
including implementation fees, fixed monthly fees and pass-through costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following two lawsuits, the
Company is not a party to any outstanding material litigation and management is currently not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#146;s financial condition or results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2021, the Company filed a lawsuit in the U.S. District Court for the Northern District of California against
Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> (OTC) lidocaine patch products, alleging, among other things, false and
deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding those patch products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021, the Company filed a lawsuit in the Delaware Court of Chancery against Anthony Mack, former President of the Company, and Virpax
Pharmaceuticals, Inc., a company now headed by Mr.&nbsp;Mack, alleging, among other things, breach by Mr.&nbsp;Mack of his <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement with the Company and his fiduciary duties to the Company, and
tortious interference by Virpax with that <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement. Both lawsuits are ongoing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating
Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases administrative and research and development facilities under various
<FONT STYLE="white-space:nowrap">non-cancelable</FONT> lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of December&nbsp;31, 2021, the Company&#146;s leases have remaining lease
terms of approximately 2.7 to 2.9 years. The term of the Company&#146;s leases does not include extension options that were not reasonably certain to be exercised from its lease terms, ranging from 3 to 5 years. Many of the Company&#146;s leases are
subject to variable lease payments. Variable lease payments are recognized in the period in which the obligation for those payments are incurred, are not included in the measurement of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets or lease liabilities and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income is recognized on a straight-line basis and is immaterial.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the Company&#146;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information
available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of
December&nbsp;31, 2021, the Company has no finance leases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of lease expense were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods
presented. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Supplemental quantitative information related to leases includes the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of lease liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating cash flows from operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining lease term in years &#151; operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average discount rate &#151; operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Maturities of lease liabilities were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liabilities as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating lease expense totaled approximately $0.7&nbsp;million, $1.1&nbsp;million and $0.8&nbsp;million for
the years ended December&nbsp;31, 2021, 2020 and 2019, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Income Taxes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total loss before income taxes for the years ended December&nbsp;31, 2021, 2020 and 2019 did not include a foreign component. The components of
benefits for income taxes were as follows for the period ended December&nbsp;31 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net tax effects of temporary differences between the
carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components
of the Company&#146;s net deferred tax liabilities and related valuation allowance are as follows at December&nbsp;31 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense limitations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Deferred Tax Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>58,939</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>46,412</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(56,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Deferred Tax Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,296</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,898</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred Tax Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangibles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,486</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(319</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Deferred Tax Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,296</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,898</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the available evidence supporting the realization of its gross deferred tax assets,
including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the domestic deferred tax
assets, the Company maintains a valuation allowance of $56.6&nbsp;million and $43.5&nbsp;million against its deferred tax assets as of December&nbsp;31, 2021 and 2020, respectively. Realization of the deferred tax assets will be primarily dependent
upon the Company&#146;s ability to generate sufficient taxable income prior to the expiration of its net operating losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
reconciliation between U.S. federal income taxes at the statutory rate and the Company&#146;s benefit from income taxes are as follows for the year ended December 31: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statutory Federal Income Tax Rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes, net of federal tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt discount and interest limitation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Return to provision adjustments and carryback</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.6</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14.8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.80em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income Tax Benefit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021, the Company had net operating loss carryforwards of approximately
$167.5&nbsp;million for federal and $81.7&nbsp;million for state income tax purposes, respectively. These may be used to offset future taxable income and will begin to expire in 2034 for state and 2035 for federal, except for $154.8&nbsp;million of
the federal net operating losses that have an indefinite carryforward period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internal Revenue Code Section&nbsp;382 rules apply to limit a corporation&#146;s ability to
utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section&nbsp;382. For the years ended December&nbsp;31, 2021, 2020, and 2019, there was no impact of such limitations
on the Company&#146;s income tax provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also has research and development and orphan drug credits of approximately
$2.0&nbsp;million for federal income taxes purposes. The federal credits may be used to offset future income tax and will begin to expire in 2035. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in the U.S., various state tax jurisdictions and various foreign tax jurisdictions. All of the
Company&#146;s tax years will remain open for three year for examination by the Federal and state tax authorities from the date of utilization of the net operating loss. The Company does not have any tax audits pending. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies the accounting guidance for uncertainty in income taxes pursuant to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ASC-740-10.</FONT></FONT> Under ASC 740, the impact of an uncertain income tax position taken on a tax return must be recognized at the largest amount that is cumulatively &#147;more likely than not&#148; to be sustained
upon audit by relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unrecognized tax benefits balances as of December&nbsp;31, 2021, 2020 and 2019 and the related increases and decreases to the balances
were immaterial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s policy is to recognize interest and penalties related to income tax matters in income tax expense. No
interest and penalties have been recognized as of and for the periods ended December&nbsp;31, 2021, 2020 and 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company believes
that no material amount of liabilities for uncertain tax positions will expire within 12&nbsp;months of December&nbsp;31, 2021. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Related Party Transactions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;18, 2019, the Company entered into a merger agreement with Sorrento, Semnur, Merger Sub, and Fortis Advisors LLC. Jaisim Shah, a
member of Sorrento&#146;s board of directors, was Semnur&#146;s Chief Executive Officer, a member of its board of directors and a stockholder of Semnur prior to the acquisition transaction. The upfront consideration was comprised of the following:
(a)&nbsp;a cash payment of approximately $15.0&nbsp;million, and (b) $55.0&nbsp;million of shares of the Company&#146;s common stock (47,039,315 shares issued and 352,972 shares issuable, valued at $1.16 per share) (i.e., the Stock Consideration).
Following the issuance of the Stock Consideration, Sorrento was the owner of approximately 58% of the Company&#146;s issued and outstanding capital stock as of December&nbsp;31, 2019. Following the completion of the Semnur Share Exchange and as of
December&nbsp;31, 2020, Sorrento held approximately 82.3% of the outstanding common stock of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended
December&nbsp;31, 2021, 2020 and 2019, the Company purchased approximately $5.7&nbsp;million, $1.0&nbsp;million, and $8.4&nbsp;million, respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the
aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#146;s statement of operations. As of December&nbsp;31, 2020, approximately 14.7% of the
outstanding capital stock of the Company was held by Itochu. On January&nbsp;13, 2021, 34,889,868 shares of the Company representing all outstanding capital stock of the Company held by Itochu were acquired by
<FONT STYLE="white-space:nowrap">non-related</FONT> minority shareholders. Thus, Itochu is not a shareholder subsequent to January&nbsp;13, 2021. On January&nbsp;29, 2021, Sorrento acquired 34,889,868 shares of the Company, resulting in Sorrento
holding approximately 99.97% of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Semnur is party to an Assignment Agreement, dated August&nbsp;6, 2013 (the &#147;Assignment
Agreement&#148;), with Shah Investor LP (&#147;Shah Investor&#148;). Mahendra Shah, Ph.D., who has served on the Company&#146;s board of directors since March 2019, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah
Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the <FONT STYLE="white-space:nowrap">low-single</FONT> digits based on quarterly net sales of any pharmaceutical
formulations for local delivery of steroids by injection developed using such intellectual property, which would include <FONT STYLE="white-space:nowrap">SP-102.</FONT> To date, the Company has made no royalty payments pursuant to the Assignment
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2017, a Transition Services Agreement (&#147;TSA&#148;) was executed between Scilex Pharma and Sorrento.
Pursuant to the TSA, Sorrento agreed, at the Company&#146;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services
provided under the TSA, Sorrento retains insurance coverage on behalf of the Company. During the years ended December&nbsp;31, 2021, 2020, and 2019, the total cost of services and insurance, including an agreed-upon markup, provided to the Company
and recognized in general and administrative expenses was $4.0&nbsp;million, $2.3&nbsp;million, and $0.9&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $16.5&nbsp;million. The note is interest bearing at the lesser of (a) 10% simple interest per annum, and (b)&nbsp;the maximum interest
rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. The outstanding principal balance of the note on December&nbsp;31,
2021 and 2020 was $19.6&nbsp;million and $13.0&nbsp;million, respectively, which was recorded under the current related party notes payable in the Company&#146;s consolidated balance sheets. As of December&nbsp;31, 2021 and 2020, the Company had
ending balances resulting from the accrued interest on the note payable of $3.9&nbsp;million and $2.6&nbsp;million, respectively, which was recorded under related party payable in the Company&#146;s consolidated balance sheets. The proceeds from the
note payable were used to finance the acquisition of Semnur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;5, 2018, Scilex Pharma issued to Sorrento a promissory note
in the amount of approximately $21.7&nbsp;million for certain amounts previously advanced to Scilex Pharma by Sorrento (the &#147;Intercompany Note&#148;). Scilex Pharma may borrow up to an aggregate of $25.0&nbsp;million of principal amount under
the note payable. The promissory note is interest bearing at the lesser of (a) 10% simple interest per annum, and (b)&nbsp;the maximum interest rate permitted under law. All outstanding principal amounts and accrued interest are due upon maturity on
August&nbsp;31, 2026. On October&nbsp;22, 2018, Sorrento purchased from the Company 24,117,608 shares of the Company&#146;s common stock in exchange for the repayment of $21.7&nbsp;million of indebtedness under this promissory note. During 2021 and
2020, Sorrento made advances to Scilex Pharma in the amount of $8.1&nbsp;million and $10.3&nbsp;million, respectively, under the promissory note. As of December&nbsp;31, 2021 and 2020, the Company had ending balances resulting from the accrued
interest on the promissory note of $3.1&nbsp;million and $1.0&nbsp;million, respectively, which was recorded under related party payable in the Company&#146;s consolidated balance sheets. As of December&nbsp;31, 2021 and 2020, Scilex Pharma&#146;s
outstanding principal balance under the promissory note was $23.5&nbsp;million and $15.4&nbsp;million, respectively, which was recorded under the <FONT STYLE="white-space:nowrap">non-current</FONT> related party note payable in the Company&#146;s
consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received $17.3&nbsp;million and $20.0&nbsp;million, in February 2021 and April 2021,
respectively, from Sorrento to fund the payment of Scilex Pharma Notes in February 2021 and April 2021, totaling $40.0&nbsp;million, as described in Note 8. The $37.3&nbsp;million received in February 2021 and April 2021 is due on demand to Sorrento
and was recorded under the related party payables in the Company&#146;s consolidated balance sheets. As of December&nbsp;31, 2021, related party payables due to Sorrento included $35.7&nbsp;million to cover working capital requirements,
$51.0&nbsp;million for repurchases of Scilex Pharma Notes, and $6.0&nbsp;million to pay litigation fees (see Note 11). As of December&nbsp;31, 2020, related party payables due to Sorrento consisted of $13.0&nbsp;million to cover working capital
requirements and $13.7&nbsp;million for repurchases of Scilex Pharma Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Loss Per Share </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2021, 2020 and 2019, basic loss per common share is computed by dividing net loss by the weighted average
number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the reconciliation of basic and diluted loss per share for the years ended December&nbsp;31, 2021, 2020, and
2019 (in thousands except per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(178,594</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator for Basic Loss Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of Dilutive Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator for Diluted Loss per Share &#151; Adjusted for Dilutive Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic Loss Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilutive Loss Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stock options that could potentially dilute basic earnings per share in the future were excluded from the
computation of diluted net loss per share because the effect would have been anti-dilutive due to the net loss for the years ended December&nbsp;31, 2021, 2020, and 2019 of 28.2&nbsp;million, 30.8&nbsp;million, and 25.4&nbsp;million, respectively.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Subsequent Events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following events were identified subsequent to the balance sheet date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>SPAC Transaction </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended, the &#147;Merger Agreement&#148;) with Vickers Vantage Corp. I (&#147;Vickers&#148;), a SPAC, and Vantage Merger Sub, Inc., a wholly owned subsidiary of
Vickers (&#147;Merger Sub&#148;). Pursuant to the terms of the Merger Agreement, (i)&nbsp;Merger Sub will merge with and into the Company, with the Company surviving the merger (&#147;combined company&#148;) and (ii)&nbsp;become a wholly owned
subsidiary of Vickers (collectively, the &#147;SPAC Transaction&#148;). The Merger is expected to close during the fourth quarter of 2022, and the Combined Company is expected to be listed on the Nasdaq Capital Market under the new ticker symbol
&#147;SCLX&#148;. Completion of the SPAC Transaction is subject to the approval of Vickers and Company shareholders and the satisfaction or waiver of certain other closing conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Pharma Note </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective
February&nbsp;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through
December&nbsp;31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, the Company paid to Scilex Pharma $35.0&nbsp;million in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount
as a subordinated loan. Per the terms of the Amendment No.&nbsp;3, in February 2022, Scilex Pharma repurchased Scilex Pharma Notes in an aggregate amount equal to $20.0&nbsp;million at a purchase price in cash equal to 100% of the principal amount.
In addition, the draw down of the Letter of Credit triggered a requirement for Scilex Pharma to maintain a minimum cash balance of $10.0&nbsp;million at all times going forward. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;15, 2022, in accordance with the Indenture, the principal amount of the Scilex Pharma Notes was increased by
$28.0&nbsp;million as actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&nbsp;31, 2021 did not equal or exceed a $481.0&nbsp;million sales threshold for such period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advances on Related Party Note Payable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;30, 2022, Sorrento made advances to the Company in the amount of $23.0&nbsp;million under the related party note payable entered
into on March&nbsp;18, 2019 with Sorrento. See Note 13 for further discussion of the related party note payable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-104</FONT> Acquisition from Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2022, the Company and Sorrento entered into a bill of sale and assignment and assumption agreement (the &#147;Bill of
Sale&#148;), pursuant to which Sorrento sold, conveyed, assigned and transferred to Scilex all of its rights, title and interest in and to Sorrento&#146;s Delayed Burst Release Low Dose Naltrexone <FONT STYLE="white-space:nowrap">(DBR-LDN)</FONT>
asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Assets&#148;) and the Company is currently analyzing the
accounting treatment for the transaction. These assets had previously been acquired by Sorrento from Aardvark Therapeutics, Inc. (&#147;Aardvark&#148;) in April 2021 pursuant to an asset purchase agreement (the &#147;Aardvark Asset Purchase
Agreement&#148;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#146;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the <FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Acquisition&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the <FONT STYLE="white-space:nowrap">SP-104</FONT> Acquisition, the Company issued a promissory note in the
aggregate principal amount of $5.0&nbsp;million to Sorrento (the &#147;2022 Promissory Note&#148;). The 2022 Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66% simple
interest per annum and (b)&nbsp;the maximum interest rate permitted under law. The 2022 Promissory Note is payable in cash, shares of the Company common stock (any shares so issued, the &#147;Consideration Shares&#148;) or any combination thereof,
at the Company&#146;s sole discretion, and may be prepaid in whole or in part at any time without penalty. The Company also agreed to file with the SEC, a resale registration statement, relating to the resale by Sorrento of any Consideration Shares
that may be issued to Sorrento, within 60 days of the issuance of such Consideration Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the successor to the Aardvark Asset
Purchase Agreement, the Company is obligated to pay Aardvark (i)&nbsp;$3,000,000, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in the Aardvark Asset Purchase Agreement) (which amount may be paid in
shares of the Company&#146;s common stock or cash, in the Company&#146;s sole discretion) (the &#147;Development Milestone Payment&#148;) and (ii) $20,000,000, in cash, upon achievement of certain net sales by the Company of a commercial product
that uses the LDN Formulation (the &#147;Commercial Product&#148;). The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the LDN
Formulation. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the
Commercial Product, whichever is longer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its acquisition of the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets,
the Company has agreed that if it issues any shares of the Company&#146;s common stock in respect of the Development Milestone Payment, the Company will prepare and file one or more registration statements with the SEC for the purpose of registering
for resale such shares and is required to file such registration statement with the SEC within 60 days following the date on which any such shares are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, MD, a member of the board of directors of the Company, is the founder, chief executive
officer and a member of the board of directors of Aardvark. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_18"></A>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS OF SEPTEMBER&nbsp;30, 2022 AND DECEMBER&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except for par value and share amounts; unaudited) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheets as of September&nbsp;30, 2022 and December&nbsp;31, 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">September&nbsp;30,<BR>2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,<BR>2021</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">ASSETS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Prepaid expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Intangibles, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Long-term deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">LIABILITIES AND STOCKHOLDERS&#146; DEFICIT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accrued payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Current portion of deferred consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Current portion of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Related party note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Current portion of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">251,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Long-term deferred consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Long-term debt, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Related party note payable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">318,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Commitments and contingencies (See Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Stockholders&#146; Deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Preferred stock, $0.0001 par value, 20,000,000 shares authorized; none issued or outstanding at
September&nbsp;30, 2022 and December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Common stock, $0.0001 par value, 350,000,000 shares authorized; 197,566,338 and 197,266,338
shares issued and outstanding at September&nbsp;30, 2022 and December&nbsp;31, 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(358,030</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(352,550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(229,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(223,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total liabilities and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to unaudited consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_19"></A>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE NINE MONTHS ENDED SEPTEMBER&nbsp;30, 2022 AND 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except for net loss per share amounts; unaudited) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheets as of September&nbsp;30, 2022 and December&nbsp;31, 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on foreign currency exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (income) expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,516</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares during the period &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to unaudited consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_20"></A>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE NINE MONTHS ENDED SEPTEMBER&nbsp;30, 2022 AND 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands; unaudited) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheets as of September&nbsp;30, 2022 and December&nbsp;31, 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Accumulated<BR>Deficit</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amount</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(352,550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(223,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aardvark <FONT STYLE="white-space:nowrap">SP-104</FONT> license transfer from Sorrento, net of
discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aardvark <FONT STYLE="white-space:nowrap">SP-104</FONT> discount amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, September&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(358,030</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(229,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Accumulated<BR>Deficit</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amount</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(264,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(141,683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustment to shares issued in Semnur Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, September&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(310,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(183,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to unaudited consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_21"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE NINE MONTHS ENDED SEPTEMBER&nbsp;30, 2022 AND 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands; Unaudited) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Cash Flows for the Nine Months Ended September&nbsp;30, 2022 and 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nine Months Ended<BR>September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used for operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Amortization of debt issuance costs and debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt
discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,813</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Gain on derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accounts receivables, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Prepaid expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Long-term deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,784</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accrued payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net cash used for operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Acquisition consideration paid in cash for Romeg intangible asset acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Purchase of property, plant, and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net cash used for investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Repayment of principal on the Scilex Pharma Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(84,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,376</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Repayment on other loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Proceeds from other loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Proceeds from stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Proceeds from related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Proceeds from related party note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,855</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Supplemental disclosures:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Supplemental disclosures of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and
financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Deferred consideration for Romeg intangible asset acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> consideration in Semnur acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Other loan forgiveness</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Promissory Note issued to Sorrento in exchange for the
<FONT STYLE="white-space:nowrap">SP-104</FONT> license, net of discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Fair value adjustment to derivative liability in troubled debt restructuring</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Live Action
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset in Palo Alto</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to unaudited consolidated financial statement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin428534_22"></A>Notes to Unaudited Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In connection with the business combination with Vickers Vantage Corp. I (as more fully described in these notes to the financial statements), Scilex
Holding Company was renamed Scilex, Inc. These financial statements are those of Scilex Holding Company (now known as Scilex, Inc.) prior to the completion of such business combination. </I></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Nature of Operations and Basis of Presentation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Organization and Principal Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex Holding Company (&#147;Scilex Holding&#148; (now known as Scilex, Inc.) and together with its wholly owned subsidiaries, the
&#147;Company&#148;) was incorporated in Delaware in February 2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, &#147;Sorrento&#148;). The Company is a commercial biopharmaceutical company focused on acquiring,
developing and commercializing <FONT STYLE="white-space:nowrap">non-opioid</FONT> management products for the treatment of acute and chronic pain. The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system)
1.8% (&#147;ZTlido&#148;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief
throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. The Company <FONT STYLE="white-space:nowrap">in-licensed</FONT> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> prophylactic treatment for painful gout flares in adults, in the U.S. (see Note 2). The Company is planning to commercialize GLOPERBA in 2023. The Company is currently developing three product
candidates, <FONT STYLE="white-space:nowrap">SP-102</FONT> (10&nbsp;mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular
pain, or sciatica <FONT STYLE="white-space:nowrap">(&#147;SP-102&#148;</FONT> or &#147;SEMDEXA&#148;) and <FONT STYLE="white-space:nowrap">SP-103</FONT> (lidocaine topical system) 5.4% <FONT STYLE="white-space:nowrap">(&#147;SP-103&#148;),</FONT>
for the treatment of acute low back pain, and <FONT STYLE="white-space:nowrap">SP-104</FONT> (4.5 mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release capsules)
<FONT STYLE="white-space:nowrap">(&#147;SP-104&#148;),</FONT> a novel formulation for the treatment of fibromyalgia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;18,
2019, the Company entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharmaceuticals Inc. (&#147;Scilex Pharma&#148;) pursuant to which the Company acquired 100% of the
outstanding shares of capital stock of Scilex Pharma in exchange for shares of the Company&#146;s common stock (the &#147;Contribution&#148;), which was accounted for as a reorganization of entities under common control. Pursuant to the Contribution
and Loan Agreement, Sorrento provided the Company with a loan with an initial principal amount of $16.5&nbsp;million in the form of a note payable, which was used by the Company to fund the acquisition of Semnur Pharmaceuticals, Inc.
(&#147;Semnur&#148;). Concurrently therewith, the Company entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., the Company&#146;s prior wholly-owned subsidiary (&#147;Merger Sub&#148;), Fortis Advisors LLC, solely as
representative of the holders of Semnur equity (the &#147;Semnur Equityholders&#146; Representative&#148;), and Sorrento, for limited purposes (the &#147;Merger Agreement&#148;), which was accounted for as an asset acquisition. Pursuant to the
Merger Agreement, Merger Sub merged with and into Semnur (the &#147;Merger of Semnur&#148;), with Semnur surviving as the Company&#146;s wholly-owned subsidiary. As a result of the Contribution and the Merger of Semnur, Scilex Pharma and Semnur
became wholly-owned subsidiaries of the Company. Upon completion of the Contribution and the Merger of Semnur, the historical consolidated financial statements of Scilex Pharma became the historical consolidated financial statements of Scilex
Holding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, the Company had devoted substantially all of its efforts to the product development of <FONT
STYLE="white-space:nowrap">SP-102</FONT> and <FONT STYLE="white-space:nowrap">SP-103</FONT> and the commercialization of ZTlido. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Business Combination
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended on September&nbsp;12, 2022, the
&#147;BCA&#148;) with Vickers Vantage Corp. I (&#147;Vickers&#148;), a special purpose acquisition </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company, and Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#147;Vickers Merger Sub&#148;). Pursuant to the terms of the BCA, Vickers Merger Sub merged with and into the
Company, with the Company surviving the merger (&#147;Legacy Scilex&#148;) and becoming a wholly-owned subsidiary of Vickers (collectively, the &#147;Business Combination&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, Vickers consummated the Business Combination pursuant to the terms of the BCA. Vickers acquired all of the
outstanding equity interests of Legacy Scilex. As a result of the Business Combination, New Scilex (as defined below) received gross proceeds of approximately $12.0&nbsp;million, prior to the settlement of transaction-related costs and expenses.
Additionally, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento totaling $290.6&nbsp;million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and
pursuant to the terms of the Debt Exchange Agreement (see Note 10). In connection with the Business Combination (as more fully described in the notes to these financial statements), Scilex Holding Company was renamed to Scilex, Inc. These financial
statements are those of Scilex Holding Company (now known as Scilex, Inc.) prior to the completion of such Business Combination. Additionally, in connection with the completion of the Business Combination, Vickers was renamed to, and will operate
as, &#147;Scilex Holding Company&#148; and the Company began trading on the Nasdaq Capital Market under the new ticker symbol &#147;SCLX&#148; on November&nbsp;11, 2022. Scilex Holding Company following the completion of the Business Combination is
sometimes referred to herein as &#147;New Scilex.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination will be accounted for as a reverse recapitalization in
accordance with U.S. GAAP. Under this method of accounting, Vickers is treated as the &#147;acquired&#148; company for accounting purposes and the Business Combination is treated as the equivalent of the Company issuing stock for the net assets of
Vickers, accompanied by a recapitalization. The net assets of Vickers are stated at historical cost, with no goodwill or other intangible assets recorded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s legal, accounting and other fees directly attributable to the Business Combination were capitalized within prepaid expenses
and other current assets on the consolidated balance sheets. As of September&nbsp;30, 2022, the Company had capitalized $7.3&nbsp;million of costs incurred in relation to the Business Combination. There were no capitalized costs in relation to the
Business Combination as of December&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis of Presentation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of
America (&#147;U.S. GAAP&#148;) and include all adjustments necessary for the fair presentation of the Company&#146;s financial position for the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the accounts of the Company&#146;s subsidiaries. All intercompany balances and
transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These consolidated financial statements should be read in conjunction with the
consolidated financial statements for the fiscal year ended December&nbsp;31, 2021. Operating results for quarter periods are not expected to be indicative of operating results for the Company&#146;s 2022 fiscal year, or any subsequent period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Use of Estimates </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of
these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Significant Accounting Policies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2022, there have been no changes to the Company`s significant accounting policies as described
in the notes to the audited financial statements for the years ended December&nbsp;31, 2021 and 2020 included in the proxy statement/prospectus filed by Vickers with the SEC on October&nbsp;28, 2022 beginning on page
<FONT STYLE="white-space:nowrap">F-48</FONT> thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Segments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the
chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions
regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of <FONT STYLE="white-space:nowrap">non-opioid</FONT> products focused on pain
management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Liquidity and Going Concern </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which
contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#146;s ability to continue as a going concern for at least one year after the date the financial statements
are issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, the Company&#146;s negative working capital was $219.6&nbsp;million, including cash and cash
equivalents of approximately $2.5&nbsp;million. During the nine months ended September&nbsp;30, 2022, the Company had operating losses of $30.9&nbsp;million and cash flows used for operations of $20.5&nbsp;million. The Company had an accumulated
deficit of approximately $358.0&nbsp;million as of September&nbsp;30, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2022, the Company exercised the Early Paydown
Provision to fully extinguish the Scilex Pharma Notes (see Note 6). In August 2022 and September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $41.4&nbsp;million. Pursuant to Amendment No.&nbsp;4, a
principal balance of $28.0&nbsp;million was forgiven by the Scilex Pharma Note Purchasers (see Note 6) upon the Company&#146;s exercise of the Early Paydown Provision. The Company funded the principal payments with
<FONT STYLE="white-space:nowrap">cash-on</FONT> hand and $34.0&nbsp;million received from Sorrento on September&nbsp;28, 2022 (see Note 10). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2022, the Company and Scilex Pharma entered into a Debt Exchange Agreement with Sorrento, pursuant to which all related
party payables and related party note payables that remain outstanding as of immediately prior to, and contingent upon, the closing of the Business Combination were contributed by Sorrento to the Company in exchange for the issuance by the Company
to Sorrento of preferred stock of the Company and such shares were subsequently converted into shares of New Scliex common stock and preferred stock (see Note 10). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, Sorrento and Scilex entered into a Funding Commitment Letter (see Note 10). Pursuant to the terms of the Funding
Commitment Letter, upon the written request of the Company, Sorrento shall fund one or more loans to the Company in the amount to achieve $5,000,001 in net tangible assets immediately following the effective time of the Business Combination. Such
related party payables or related party note payables will be converted into shares of preferred stock pursuant to the Debt Exchange Agreement. Any loans made under the Funding Commitment Letter will not exceed the lesser of (a) $10,000,000 and
(b)&nbsp;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $310,000,000 (see Note 10). The Company did not draw funds from the Funding Commitment Letter at the
effective time of the Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;18, 2019, the Company acquired Semnur and the acquisition was accounted for as
an asset acquisition (see Note 3). The Company anticipates the cash needed for the development of Semnur&#146;s primary product candidate in development, <FONT STYLE="white-space:nowrap">SP-102,</FONT> as well in the development of <FONT
STYLE="white-space:nowrap">SP-103,</FONT> will be in excess of the Company&#146;s cash available within one year after the date these consolidated financial statements are issued. Semnur has no historical revenue and the Company will be responsible
for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2022, the Company entered into a Bill of Sale (see Note 3), with Sorrento to acquire rights, title and interest in the <FONT
STYLE="white-space:nowrap">SP-104</FONT> Assets (see Note 3). <FONT STYLE="white-space:nowrap">SP-104</FONT> has not been approved for commercialization and, as such, no revenues have been generated to date by the asset. The Company will be
responsible for funding all development and commercialization efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;14, 2022, the Company entered into a license and
commercialization agreement with Romeg (see Note 3). The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, acquired licenses. The Company anticipates
incurring costs related to the commercial launch and marketing of the acquired licenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has plans to obtain additional
resources to fund its currently planned operations and expenditures for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government
contracts or other strategic transactions. The Company&#146;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of
the Company&#146;s marketing of ZTlido. Should the Company&#146;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#146;s business plan, due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or other
factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs,
sales and marketing costs, suspension or winding down of clinical development programs for <FONT STYLE="white-space:nowrap">SP-102,</FONT> <FONT STYLE="white-space:nowrap">SP-103,</FONT> and <FONT STYLE="white-space:nowrap">SP-104,</FONT> and other
discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#146;s control. As such,
management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other
things, raise substantial doubt about the Company&#146;s ability to continue as a going concern for one year after the date the financial statements are issued. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acquisitions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Semnur Acquisition </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;18,
2019, the Company completed the Merger of Semnur. At the closing of the Merger of Semnur, the Company issued to the holders of Semnur&#146;s capital stock and options to purchase Semnur&#146;s common stock, upfront consideration with a value of
$70.0&nbsp;million. The upfront consideration was comprised of the following: (a)&nbsp;a cash payment of approximately $15.0&nbsp;million, and (b) $55.0&nbsp;million of shares of the Company&#146;s common stock (47,039,315 shares issued and 352,972
shares issuable, valued at $1.16 per share) (the &#147;Stock Consideration&#148;). Following the issuance of the Stock Consideration, Sorrento ownership in the Company diluted to approximately 58% of the Company&#146;s issued and outstanding capital
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, and upon the terms and subject to the conditions contained therein, the Company also agreed to
pay the holders of Semnur equity (the &#147;Semnur Equityholders&#148;) up to $280.0&nbsp;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $40.0&nbsp;million payment that will be due
upon obtaining the first approval of a New Drug Application (&#147;NDA&#148;) of a Semnur product by the U.S. Food and Drug Administration (the &#147;FDA&#148;) and additional payments that will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
due upon the achievement of certain amounts of net sales of Semnur products, as follows: (1)&nbsp;a $20.0&nbsp;million payment upon the achievement of $100.0&nbsp;million in cumulative net sales
of a Semnur product, (2)&nbsp;a $20.0&nbsp;million payment upon the achievement of $250.0&nbsp;million in cumulative net sales of a Semnur product, (3)&nbsp;a $50.0&nbsp;million payment upon the achievement of $500.0&nbsp;million in cumulative net
sales of a Semnur product, and (4)&nbsp;a $150.0&nbsp;million payment upon the achievement of $750.0&nbsp;million in cumulative net sales of a Semnur product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;7, 2019, the Company entered into an amendment to the Merger Agreement to provide that, following the consummation of the
Company&#146;s first bona fide equity financing with one or more third-party financing sources on an arms&#146; length basis with gross proceeds to the Company of at least $40.0&nbsp;million, certain of the former Semnur optionholders will be paid
cash in lieu of: (1)&nbsp;the 352,972 shares of the Company&#146;s common stock otherwise issuable to such former Semnur optionholders pursuant to the Merger Agreement, and (2)&nbsp;any shares that would otherwise be issued to such former Semnur
optionholders upon release of shares held in escrow pursuant to the Merger Agreement, with such shares in each case valued at $1.16 per share. The amendment resulted in a reclassification of $0.4&nbsp;million from additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital to accrued liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2019, the Semnur Equityholders that received the Stock
Consideration were required to sign an Exchange and Registration Rights Agreement with the Company (the &#147;Exchange Agreement&#148;). Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if
within 18 months following the closing of the Merger, 100% of the outstanding equity of the Company has not been acquired by a third party or the Company has not entered into a definitive agreement with respect to, or otherwise consummated, a firmly
underwritten offering of the Company capital stock on a major stock exchange that meets certain requirements, then holders of the Stock Consideration may collectively elect to exchange, during the <FONT STYLE="white-space:nowrap">60-day</FONT>
period commencing the date that is the 18 month anniversary of the Closing (the &#147;Share Exchange&#148;), the Stock Consideration for shares of Sorrento&#146;s common stock with a value of $55.0&nbsp;million based on a price per share of
Sorrento&#146;s common stock equal to the greater of (a)&nbsp;the <FONT STYLE="white-space:nowrap">30-day</FONT> trailing volume weighted average price of one share of Sorrento&#146;s common stock as reported on The Nasdaq Stock Market LLC as of the
consummation of the Share Exchange and (b) $5.55 (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#147;Exchange Price&#148;). Pursuant to an amendment to the Exchange
Agreement entered into by Sorrento on September&nbsp;28, 2020, on October&nbsp;9, 2020, Sorrento paid $55.0&nbsp;million in cash to the Semnur Equityholders in lieu of issuing $55.0&nbsp;million of shares of Sorrento&#146;s common stock at the
Exchange Price. Following the completion of the Share Exchange and as of December&nbsp;31, 2020, Sorrento held approximately 82.3% of the outstanding common stock of the Company. On January&nbsp;29, 2021, Sorrento acquired additional shares of the
Company, resulting in Sorrento holding approximately 99.97% of the outstanding common stock of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The March 2019 transaction
was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, <FONT STYLE="white-space:nowrap">SP-102.</FONT> As a result, approximately $75.3&nbsp;million was expensed as a
component of acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development during the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No contingent consideration was recorded as of September&nbsp;30, 2022 and December&nbsp;31, 2021 since the related regulatory approval
milestones are not deemed probable until they actually occur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">SP-104</FONT> Acquisition </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2022, the Company entered into a bill of sale and assignment and assumption agreement (the &#147;Bill of Sale&#148;), with
Sorrento. Pursuant to the Bill of Sale, Sorrento sold, conveyed, assigned and transferred to the Company all of its rights, title and interest in and to Sorrento&#146;s Delayed Burst Release Low Dose Naltrexone
<FONT STYLE="white-space:nowrap">(&#147;DBR-LDN&#148;)</FONT> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post- COVID syndrome (collectively, the
<FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Assets&#148;). These assets had previously been acquired by Sorrento from Aardvark Therapeutics, Inc. (&#147;Aardvark&#148;) in April 2021 pursuant to an asset purchase agreement (the
&#147;Aardvark Asset Purchase Agreement&#148;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#146;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the
<FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Acquisition&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the <FONT STYLE="white-space:nowrap">SP-104</FONT> Acquisition, the
Company issued a promissory note in the aggregate principal amount of $5.0&nbsp;million to Sorrento (the &#147;2022 Promissory Note&#148;). Upon issuance of the note, the Company recorded a related party note payable liability of $4.1&nbsp;million,
net of discount, with an offset to additional paid in capital, given the common control relationship between Sorrento and the Company. The 2022 Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the
lesser of (a) 2.66% simple interest per annum and (b)&nbsp;the maximum interest rate permitted under law. The 2022 Promissory Note is payable in cash, shares of the Company&#146;s common stock or any combination thereof, at the Company&#146;s sole
discretion, and may be prepaid in whole or in part at any time without penalty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the successor to the Aardvark Asset Purchase
Agreement, the Company is obligated to pay Aardvark (i) $3,000,000, upon initial approval by the FDA of a new drug application for the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets (which amount may be paid in shares of the Company&#146;s
common stock or cash, in the Company&#146;s sole discretion) (the &#147;Development Milestone Payment&#148;) and (ii) $20,000,000, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the <FONT
STYLE="white-space:nowrap">SP-104</FONT> Assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will also pay Aardvark certain royalties in the single digits based on
percentages of annual net sales by the Company of a commercial product that uses the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets. The transaction was accounted for as an asset acquisition as substantially all the value of the gross assets
was concentrated in a single asset, <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets. The contingent milestones and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic 815, Derivatives and
Hedging, and will not be recognized until the contingencies are realized in accordance with the Company&#146;s accounting policy for contingent consideration in an asset acquisition. No contingent consideration was recognized at September&nbsp;30,
2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, MD, a member of the board of directors of the Company, is the founder and
chief executive officer of Aardvark. Kim D. Janda, Ph.D., a member of the Board of Directors of Sorrento, is a member of the advisory board of Aardvark. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GLOPERBA License Agreement </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
June&nbsp;14, 2022, the Company entered into a license agreement (the &#147;Romeg License Agreement&#148;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#147;Romeg&#148;). Pursuant to the Romeg License Agreement, among other
things, Romeg granted the Company (a)&nbsp;a transferable license, with the right to sublicense, under the patents and <FONT STYLE="white-space:nowrap">know-how</FONT> specified therein (with such license to
<FONT STYLE="white-space:nowrap">know-how</FONT> being exclusive for the limited purposes specified therein) to (i)&nbsp;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in
adult humans (the &#147;Initial Licensed Product&#148; or &#147;GLOPERBA&#148;) in the United States of America (including its territories) (the &#147;Territory&#148;), (ii) develop other products comprising the Initial Licensed Product as an active
pharmaceutical ingredient (the &#147;Licensed Products&#148;) and commercialize any such products and (iii)&nbsp;manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory and (b)&nbsp;an exclusive,
transferable license, with right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The Initial
Licensed Product, GLOPERBA, was approved and made available in the United States in 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the license under the
Romeg License Agreement, the Company paid Romeg an <FONT STYLE="white-space:nowrap">up-front</FONT> license fee of $2.0&nbsp;million, and has agreed to pay Romeg (a)&nbsp;upon the Company&#146;s achievement of certain net sales milestones, certain
milestone payments in the aggregate amount of up to $13.0&nbsp;million, (b)&nbsp;certain royalties in the <FONT STYLE="white-space:nowrap">mid-single</FONT> digit to <FONT STYLE="white-space:nowrap">low-double</FONT> digit percentages based on
annual net sales of the Licensed Product by the Company during the applicable royalty term under the Romeg License Agreement, and (c)&nbsp;minimum quarterly royalty payments totaling $7.1&nbsp;million commencing on the first year anniversary of the
effective date of the Romeg License Agreement and ending on the later of (i)&nbsp;expiration of the last to expire of the licensed patents covering the Licensed Products in the Territory or (ii)&nbsp;the tenth anniversary of the effective date of
the Romeg License Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction was accounted for as an asset acquisition since substantially all the value
of the gross assets was concentrated in a single asset, which is the Initial Licensed Product. In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $5.7&nbsp;million, which is comprised of
the upfront license fee of $2.0&nbsp;million and a deferred consideration of $3.7&nbsp;million that is the present value of the future minimum royalty payments and immaterial transaction costs. The contingent sales milestones and sales volume-based
future royalties were determined to meet a scope exception for derivative under ASC Topic 815, and will not be recognized until the contingencies are realized. No contingent consideration was recognized as a liability or included in the fair value
of the asset as of September&nbsp;30, 2022. The Company determined the useful life of the intangible asset to be approximately 15 years, which approximates the life of the licensed patents covering the Initial Licensed Product. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Fair Value Measurements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#146;s financial assets and liabilities that are measured at fair value (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Fair value measurements at September&nbsp;30, 2022</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Balance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Quoted&nbsp;Prices&nbsp;in<BR>Active Markets<BR>(Level&nbsp;1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Significant&nbsp;Other<BR>Observable&nbsp;Inputs<BR>(Level&nbsp;2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Significant<BR>Unobservable&nbsp;Inputs<BR>(Level&nbsp;3)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Fair value measurements at December&nbsp;31. 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Balance</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Quoted&nbsp;Prices&nbsp;in<BR>Active Markets<BR>(Level&nbsp;1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Significant&nbsp;Other<BR>Observable&nbsp;Inputs<BR>(Level&nbsp;2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Significant<BR>Unobservable&nbsp;Inputs<BR>(Level&nbsp;3)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and
cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Derivative liabilities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
recorded a gain of $5.3&nbsp;million and $0.1&nbsp;million on derivative liabilities for the nine months ended September&nbsp;30, 2022 and 2021, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma
Notes (see Note 6). The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $30.4&nbsp;million immediately after the entry into Amendment No.&nbsp;4 (see Note 6) associated with the Scilex Pharma Notes on
June&nbsp;2, 2022 (see Note 6). Amendment No.&nbsp;4 was accounted for as troubled debt restructuring; therefore, the carrying amount of the Scilex Pharma Notes, net, was adjusted to reflect the aforementioned change in fair value of the derivative
liability. The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Monte Carlo simulation model including consideration of the terms of Amendment No.&nbsp;4. Significant Level&nbsp;3 assumptions used in the measurement included a 6.1% risk adjusted net sales
forecast and an effective debt yield of 21.5% as of June&nbsp;30, 2022. The Scilex Pharma Notes were fully extinguished in September 2022 (see Note 6) and, as such, there were no remaining derivative liabilities as of September&nbsp;30, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3)
during the nine months ended September&nbsp;30, 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value measurement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at September&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Goodwill and Intangible Assets </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022 and December&nbsp;31, 2021, the Company had recorded goodwill of $13.5&nbsp;million. The Company performed a
qualitative test for goodwill impairment during the fourth quarter of 2021. Based upon the results of the qualitative testing, the Company concluded that it is <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> that the fair value of the
Company&#146;s goodwill was in excess of the carrying value and therefore performing the first step of the <FONT STYLE="white-space:nowrap">two-step</FONT> impairment test was unnecessary. The conclusion has not changed as of September&nbsp;30, 2022
and no goodwill impairment was recognized for the nine months ended September&nbsp;30, 2022 and 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s intangible
assets, excluding goodwill, are composed of patent rights, acquired technology, acquired licenses, and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their
useful lives. A summary of the Company&#146;s identifiable intangible assets as of September&nbsp;30, 2022 and December&nbsp;31, 2021 is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nine months ended September&nbsp;30, 2022</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Gross&nbsp;carrying<BR>amount</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Accumulated<BR>amortization</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Intangibles,&nbsp;net</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired licenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assembled workforce</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December 31. 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Gross&nbsp;carrying<BR>amount</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Accumulated<BR>amortization</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Intangibles,&nbsp;net</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assembled workforce</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;14, 2022, the Company entered into Romeg License Agreement to acquire an exclusive license to use
GLOPERBA from Romeg (see Note 3). The Company determined the acquisition of licenses to be an asset acquisition. The fair value of consideration transferred of $5.7&nbsp;million was assigned to acquired licenses with an amortization period of
approximately 15 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, the weighted average remaining life for identifiable intangible assets was
10.6&nbsp;years. Aggregate amortization expense was $2.9&nbsp;million and $2.8&nbsp;million for the nine months ended September&nbsp;30, 2022 and 2021, respectively. Patent rights and acquired technology are amortized over a <FONT
STYLE="white-space:nowrap">15-year</FONT> period. Assembled workforce is amortized over a <FONT STYLE="white-space:nowrap">5-year</FONT> period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimated future amortization expense related to intangible assets at September&nbsp;30,
2022 is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Year ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Amount</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022 (remaining three months)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Debt </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2018 Purchase Agreements and Indenture </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;7, 2018, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#147;2018 Purchase Agreements&#148;) with certain investors (collectively, the &#147;Scilex Pharma Note Purchasers&#148;). Pursuant to the 2018 Purchase
Agreements, on September&nbsp;7, 2018, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due 2026 in an aggregate principal amount of $224.0&nbsp;million (the &#147;Scilex Pharma
Notes&#148;) for an aggregate purchase price of $140.0&nbsp;million (the &#147;Offering&#148;). The Scilex Pharma Notes are governed by an indenture (as amended, the &#147;Indenture&#148;) with Scilex Pharma, as issuer, U.S. Bank National
Association, a national banking association, as trustee (the &#147;Trustee&#148;) and collateral agent (the &#147;Collateral Agent&#148;), and Sorrento, as guarantor. Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally
guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#147;Guarantee&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&nbsp;31, 2021 did not equal or exceed
$481.0&nbsp;million, which resulted in a $28.0&nbsp;million increase in the principal amount of the Scilex Pharma Notes, effective February&nbsp;15, 2022. As a result, the Company recorded the increase of $28.0&nbsp;million in principal and <FONT
STYLE="white-space:nowrap">non-operating</FONT> expense at December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;14, 2022, Scilex Pharma issued
to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&nbsp;31, 2021 were less than a specified
sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma $35.0&nbsp;million in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount as a subordinated loan and Scilex Pharma became
subject to a minimum cash requirement of $10.0&nbsp;million. In February 2022, Scilex Pharma repurchased Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate amount equal to $20.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;2, 2022, Sorrento and Scilex Pharma entered into a Consent Under and Amendment No.&nbsp;4 to Indenture (the &#147;Amendment
No.&nbsp;4&#148;) with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association) and the Scilex Note Purchasers. Pursuant to Amendment No.&nbsp;4, (1)&nbsp;on June&nbsp;3, 2022, Scilex Pharma
repurchased approximately $41.4&nbsp;million of the aggregate principal amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof, (2)&nbsp;the Scilex Note Purchasers agreed that Scilex Pharma can repurchase the remaining
principal amount of the Scilex Pharma Notes at any time on or before September&nbsp;30, 2022 for $41.4&nbsp;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Scilex Note Purchasers will forgive and
discharge $28.0&nbsp;million of the aggregate principal amount of the Scilex Pharma Notes (the &#147;Early Paydown Provision&#148;), (3) the minimum cash requirement under the Indenture was reduced to $5.0&nbsp;million in aggregate unrestricted cash
equivalents at the end of each calendar month, and (4)&nbsp;the maximum aggregate principal amount on the promissory note issued by Scilex Pharma to Sorrento on October&nbsp;5, 2018 was increased from up to $25.0&nbsp;million to up to
$50.0&nbsp;million. The Company funded the repurchase with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cash-on-hand</FONT></FONT> and $15.0&nbsp;million received from Sorrento on June&nbsp;2, 2022,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which was recorded under the current related party notes payable in the Company&#146;s consolidated balance sheets (see Note 10). The Company concluded that the Amendment No.&nbsp;4 was a
troubled debt restructuring for accounting purposes. The future undiscounted cash flows of the Scilex Pharma Notes were higher than the carrying value of the Scilex Pharma Notes at the time of the entry into the Amendment No.&nbsp;4, and
accordingly, no gain was recognized in the quarter ended June&nbsp;30, 2022. Due to a decrease of $30.4&nbsp;million in the fair value of the Scilex Notes Derivative caused by the Amendment No.&nbsp;4, the carrying value of the Scilex Notes was
increased by $30.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2022, the Company exercised the Early Paydown Provision to fully extinguish the Scilex
Pharma Notes. In August and September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $1.7&nbsp;million and $39.7&nbsp;million, respectively. Pursuant to Amendment No.&nbsp;4, $28.0&nbsp;million of
principal amount on the Scilex Pharma Notes was forgiven by the Scilex Pharma Note Purchasers and the Scilex Pharma Notes were fully extinguished in September 2022. The Company recorded a gain on debt extinguishment of $33.4&nbsp;million as a result
of the extinguishment. There are no derivative liabilities as of September&nbsp;30, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Borrowings of the Scilex Notes consisted of the
following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">September&nbsp;30,<BR>2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,<BR>2021</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carrying value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long term portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company made principal payments of $106.0&nbsp;million and $44.2&nbsp;million during the nine months ended
September&nbsp;30, 2022 and 2021, respectively. The imputed effective interest rate at December&nbsp;31, 2021 was 7.7%. The amount of debt discount and debt issuance costs included in interest expense for the nine months ended September&nbsp;30,
2022 and 2021 was approximately $3.1&nbsp;million and $5.9&nbsp;million, respectively. The Company recorded a gain on debt extinguishment of $28.6&nbsp;million and a loss on debt extinguishment of $14.0&nbsp;million in connection with its repayments
of principal made during the nine months ended September&nbsp;30, 2022 and 2021, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Related Party Notes Payable </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;5, 2018, Scilex Pharma issued to Sorrento a promissory note (see Note 10). On March&nbsp;18, 2019, the Company entered into a
note payable with Sorrento (see Note 10). On February&nbsp;14, 2022, Sorrento paid to Scilex Pharma $35.0&nbsp;million in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount as a subordinated loan (see Note 10). On May&nbsp;12, 2022,
the Company issued Sorrento a promissory note of $5.0&nbsp;million in exchange for the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets (see Note 3). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2020 Revolving Credit Facility </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;14, 2020, Scilex Pharma entered into the Credit and Security Agreement (the &#147;Credit Agreement&#148;) with CNH Finance Fund I, L.P. (&#147;CNH&#148;) which provides Scilex Pharma with the ability to incur indebtedness under an
accounts receivable revolving loan facility in an aggregate amount of $10.0&nbsp;million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement,
interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus 1.75%. All indebtedness incurred and outstanding will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
due and payable in full on January&nbsp;1, 2024; unless the Credit Agreement is earlier terminated. As of December&nbsp;31, 2021, the outstanding balance was $8.8&nbsp;million. On
February&nbsp;16, 2022, the Company notified CNH that it was terminating the Credit Agreement, effective March&nbsp;18, 2022. Upon termination, all principal balances and interest accrued were settled. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Stock Incentive and Employee Benefit Plans </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2017 Equity Incentive Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2017,
Scilex Pharma adopted the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#147;Scilex Pharma 2017 Plan&#148;). The Scilex Pharma 2017 Plan reserved 24.0&nbsp;million shares of Scilex Pharma common stock. Stock options granted under the
Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter. The Scilex Pharma 2017 Plan was amended and restated on July&nbsp;5,
2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of the Merger of Semnur, the Scilex Pharma 2017 Plan was terminated, and each option to purchase Scilex
Pharma&#146;s common stock outstanding and unexercised immediately prior to the closing of the Merger of Semnur was cancelled and substituted for that number of options to acquire common stock of Scilex Holding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Scilex Holding Company 2019 Stock Option Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#147;2019 Stock Option Plan&#148;) on
May&nbsp;28, 2019. The 2019 Stock Option Plan was approved by the Company&#146;s stockholders on June&nbsp;7, 2019. As of December&nbsp;31, 2019, 30.0&nbsp;million shares of common stock of the Company were reserved for issuance pursuant to the 2019
Stock Option Plan. On December&nbsp;21, 2020, the board of directors approved an amendment to the 2019 Stock Option Plan to reserve an additional 15.0&nbsp;million shares of common stock for issuance under the 2019 Stock Option Plan. As of
December&nbsp;31, 2020, 45.0&nbsp;million shares of common stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the
shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2022, options to purchase 25,159,760 shares of the common stock of Scilex Holding were outstanding, which is
comprised of options to purchase 24,054,760 shares of common stock that were outstanding under the 2019 Stock Option Plan and options to purchase 1,105,000 shares of common stock that were outstanding pursuant to options previously granted under the
Scilex Pharma 2017 Plan. As of September&nbsp;30, 2022, 20,945,240 shares of the Company&#146;s common stock were reserved for awards available for future issuance under the 2019 Stock Option Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded within operating expenses was $4.0&nbsp;million and $4.4&nbsp;million for the nine months ended
September&nbsp;30, 2022 and 2021, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total unrecognized compensation costs related to unvested employee and <FONT
STYLE="white-space:nowrap">non-employee</FONT> stock option grants as of September&nbsp;30, 2022 was $3.9&nbsp;million and the weighted average period over which these grants are expected to vest is 1.4 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employee Benefit Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
maintains a defined contribution 401(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal
tax regulations. The Company made matching contributions to the 401(k) plan totaling $0.3&nbsp;million and $0.2&nbsp;million for each of the nine months ended September&nbsp;30, 2022 and 2021, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commitments and Contingencies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Product Development Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February
2013, Scilex Pharma became a party to a product development agreement (as amended, the &#147;Product Development Agreement&#148;) with two parties (the &#147;Developers&#148;), one of which is ITOCHU CHEMICAL FRONTIER Corporation
(&#147;Itochu&#148;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> (the &#147;Products&#148;), for Scilex Pharma. The Developers initially
developed, and have intellectual property rights relating to, the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers
are responsible for sourcing and supplying lidocaine for development and commercialization purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Product Development
Agreement, Scilex Pharma is required to make aggregate royalty payments between 25% and 35% to the Developers based on net profits. During the nine months ended September&nbsp;30, 2022, Scilex Pharma made the first royalty payments in the amount of
$0.2&nbsp;million. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary
course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any
sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until October&nbsp;2, 2028, the date that is ten years from the date of the first commercial sale of ZTlido. The Product Development
Agreement will renew automatically for subsequent successive <FONT STYLE="white-space:nowrap">one-year</FONT> renewal periods unless Scilex Pharma or the Developers terminate it upon <FONT STYLE="white-space:nowrap">6-month</FONT> written notice. In
addition, Scilex Pharma or the Developers may terminate the Product Development Agreement if (1)&nbsp;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not
cured such material breach within 180 days after notice requesting to cure; (2)&nbsp;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to
address the efficacy study requirements despite good faith efforts; (3)&nbsp;the market conditions are such that (a)&nbsp;commencing with the quarter ending March&nbsp;31, 2023, Scilex Pharma&#146;s total net profits of the Products are equal to or
less than 5% of Scilex Pharma&#146;s net sales of the Products for a period of four or more consecutive quarters, or (b)&nbsp;the Products&#146; economic viability is affected by documented external circumstances deemed detrimental to all parties as
agreed to by Scilex Pharma and the Developers, and the parties are unable to resolve the economic viability concerns under the foregoing clauses (a)&nbsp;and (b)&nbsp;after 30 days of good-faith discussion; (4)&nbsp;the parties fail to reach mutual
agreement as to who will conduct the clinical studies and how the costs will be allocated; or (5)&nbsp;Scilex Pharma or either one of the Developers are bankrupt or make assignment for the benefit of creditors. Up to the date the financial
statements were issued, the Company&#146;s net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development
Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, Scilex Pharma may terminate the Product Development Agreement if (i)&nbsp;any of the pivotal
human clinical trials for any of the Products fail, or (ii)&nbsp;the FDA issues a &#147;Refusal to File&#148; for any of the Products&#146; regulatory approval application and, after reasonable consultation with the Developers, Scilex Pharma
believes that it is commercially unreasonable to <FONT STYLE="white-space:nowrap">re-file.</FONT> The Developers may terminate the Product Development Agreement if Scilex Pharma fails to file for regulatory approval for any of the Products within
three months of the date on which all required components of the regulatory approval application are received by Scilex Pharma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
February&nbsp;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#147;Supply Agreement&#148;) with the two Developers to provide commercial supply of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> to
Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be
deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusive Distribution Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2015, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#147;Distribution Agreement&#148;) to appoint an exclusive
third-party logistics distribution provider (the &#147;Distributor&#148;) and as an authorized distributor of record of ZTlido (&#147;Product&#148;) in the United States, its territories, possessions and commonwealths for an agreed schedule of fees,
subject to a 3% annual adjustment. The Distribution Agreement has an initial term of three years following the first shipment of <FONT STYLE="white-space:nowrap">FDA-approved</FONT> Product to a commercial customer and shall automatically renew for
additional terms of one year each, unless written notice of termination is given by either party at least 30 days prior to the end of the initial term or any renewal term. In the event of Product recalls, Scilex Pharma is solely responsible for all
Product recalls, except in the event where the recalls arise from the Distributor&#146;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the
Distributor&#146;s facility, including all costs, expenses and risk of loss associated with such delivery. From late 2018 to early 2022, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a
fee of between 1% to 2% which was recorded as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT> sales adjustment. Beginning in April 2022, Scilex Pharma began directly selling and transferring title to
distributors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sales Operations Services </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2016, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services,
which was subsequently superseded by a new project agreement entered into in September 2018 (the &#147;Project Agreement&#148;). In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma
with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be
provided by the vendor. In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2020, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the
sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor will continue to provide sales operations services, fleet management services and sample accountability services. The work order was in
effect until June&nbsp;30, 2022 and was extended for one year upon the mutual agreement of both parties. Either party may terminate the work order with 90 days&#146; notice. Scilex Pharma paid an implementation fee of $59.0&nbsp;thousand and will
pay fixed monthly fees of $63.7&nbsp;thousand to $65.8&nbsp;thousand for ongoing services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized an expense of
$0.5&nbsp;million and $1.6&nbsp;million within selling, general and administrative expenses for services performed for the nine months ended September&nbsp;30, 2022 and 2021, respectively, including implementation fees, fixed monthly fees and
pass-through costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Litigation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following three lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal
proceedings that, individually or in the aggregate, are deemed to be material to the Company&#146;s financial condition or results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;23, 2021, the Company filed an action in the U.S. District Court for the Northern District of California against
Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those
companies regarding their respective OTC patch products (the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;Sanofi- Aventis&nbsp;&amp; Hisamitsu Litigation&#148;). This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or
misleading statements of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly our claims, but which motions the court has largely rejected. Discovery is proceeding. The
case is currently scheduled for trial to begin on July&nbsp;24, 2023. The Company cannot make any predictions about the outcome in this matter or the timing thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Former Employee Litigation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;12, 2021, the Company filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc. (&#147;Virpax&#148;), a company now headed by Mr.&nbsp;Mack, alleging, among
other things, breach by Mr.&nbsp;Mack of his <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement with us, breach of fiduciary duty, and tortious interference by Virpax with that <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement
(the &#147;Former Employee Litigation&#148;). This lawsuit seeks, among other relief, damages and an injunction enjoining Mr.&nbsp;Mack from further violating his <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement and enjoining Virpax
from tortiously interfering with Mr.&nbsp;Mack&#146;s <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement. The case was tried from September <FONT STYLE="white-space:nowrap">12-14,</FONT> 2022. Post-trial briefing is completed and closing
arguments remain. The Company cannot make any predictions about the outcome in this matter or the timing thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ZTlido Patent Litigation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc. (together,
&#147;Aveva&#148;) in the U.S. District Court for the Southern District of Florida (the &#147;Aveva Patent Litigation&#148;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#147;ZTlido Patents&#148;). The Aveva
Patent Litigation was initiated following the submission by Aveva, in accordance with the procedures set out in the Hatch-Waxman Act, of an ANDA. Aveva&#146;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the
ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief, an order that the effective date of any FDA approval of Aveva&#146;s ANDA be no earlier than the
expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&nbsp;10, 2031, and such further and other relief as the court may deem appropriate. Aveva is subject to a
<FONT STYLE="white-space:nowrap">30-month</FONT> stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November&nbsp;11, 2024. Trial in the Aveva Patent Litigation has not yet been
scheduled. The Company cannot make any predictions about the final outcome of this matter or the timing thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating Leases </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Supplemental quantitative information related to leases includes the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of lease liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating cash flows from operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ROU assets obtained in exchange for new operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining lease term in years &#151; operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average discount rate &#151; operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2022, the Company entered into a new
<FONT STYLE="white-space:nowrap">non-cancelable</FONT> lease agreement for an administrative facility in Palo Alto. The lease includes annual rent increases and the option to extend. The term of the new lease is 26 months and the Company expects to
exercise the extension option at the end of the lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Maturities of lease liabilities were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Year Ending December&nbsp;31,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amount</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022 (Remaining three months)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liabilities as of September&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Income Taxes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and
liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and temporary differences. In assessing the Company&#146;s ability to
realize deferred tax assets, management considers, on a periodic basis, whether it is more likely than not that some portion or all the deferred tax assets will not be realized. As such, management has determined that it is appropriate to maintain a
valuation allowance against the Company&#146;s deferred tax assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s income tax (benefit) expense of $(36.4) thousand
and $10.0&nbsp;thousand reflect effective tax rates of 0.7% and 0.02% for the nine months ended September&nbsp;30, 2022 and 2021, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The difference between the expected statutory federal tax rate of 21.0% and the 0.7% effective tax rate for the nine months ended
September&nbsp;30, 2022 was primarily attributable to income tax expense associated with changes in a valuation allowance. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Related Party Transactions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;18, 2019, the Company entered into a merger agreement with Sorrento, Semnur, Merger Sub, and Fortis Advisors LLC. Jaisim Shah, a
member of Sorrento&#146;s board of directors, was Semnur&#146;s Chief Executive Officer, a member of its board of directors and a stockholder of Semnur prior to the acquisition transaction. The upfront consideration was comprised of the following:
(a)&nbsp;a cash payment of approximately $15.0&nbsp;million, and (b) $55.0&nbsp;million of shares of the Company&#146;s common stock (47,039,315 shares issued and 352,972 shares issuable, valued at $1.16 per share) (i.e., the Stock Consideration).
Following the issuance of the Stock Consideration, Sorrento was the owner of approximately 58% of the Company&#146;s issued and outstanding capital stock as of December&nbsp;31, 2019. Following the completion of the Share Exchange and as of
December&nbsp;31, 2020, Sorrento held approximately 82.3% of the outstanding common stock of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020,
approximately 14.7% of the outstanding capital stock of the Company was held by Itochu. On January&nbsp;13, 2021, 34,889,868 shares of the Company representing all outstanding capital stock of the Company held by Itochu were acquired by <FONT
STYLE="white-space:nowrap">non-related</FONT> minority shareholders. Thus, Itochu is not a shareholder subsequent to January&nbsp;13, 2021. On January&nbsp;29, 2021, Sorrento acquired 34,889,868 shares of the Company, resulting in Sorrento holding
approximately 99.97% of the Company. During the nine months ended September&nbsp;30, 2022 and 2021, the Company purchased approximately $4.0&nbsp;million and $4.8&nbsp;million, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of
revenues and selling, general and administrative expenses in the Company&#146;s statement of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Semnur is party to an Assignment
Agreement, dated August&nbsp;6, 2013 (the &#147;Assignment Agreement&#148;), with Shah Investor LP (&#147;Shah Investor&#148;). Mahendra Shah, Ph.D., who served on the Company&#146;s board of directors from March 2019 through September 2020, is the
managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the
<FONT STYLE="white-space:nowrap">low-single</FONT> digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed using such intellectual property, which would include <FONT
STYLE="white-space:nowrap">SP-102.</FONT> Through September&nbsp;30, 2022, the Company has made no royalty payments pursuant to the Assignment Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2017, a Transition Services Agreement (&#147;TSA&#148;) was executed between Scilex Pharma and Sorrento. Pursuant to the
TSA, Sorrento agreed, at the Company&#146;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services provided under the TSA,
Sorrento retains insurance coverage on behalf of the Company. During the nine months ended September&nbsp;30, 2022 and 2021, the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general
and administrative expenses was $3.2&nbsp;million and $3.0&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;18, 2019, the Company entered into a
note payable with Sorrento with an initial principal amount of $16.5&nbsp;million for the acquisition of Semnur. The note is interest bearing at the lesser of (a) 10% simple interest per annum, and (b)&nbsp;the maximum interest rate permitted under
law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. During the nine months ended September&nbsp;30, 2022 and 2021, Sorrento made advances
to the Company in the amount of $27.5&nbsp;million and $3.4&nbsp;million, respectively, under the note payable. The outstanding principal balance of the note on September&nbsp;30, 2022 and December&nbsp;31, 2021 was $47.1&nbsp;million and
$19.6&nbsp;million, respectively, which was recorded under the current related party note payable in the Company&#146;s consolidated balance sheets. As of September&nbsp;30, 2022 and December&nbsp;31, 2021, the Company had ending balances resulting
from the accrued interest on the note payable of $6.8&nbsp;million and $3.9&nbsp;million, respectively, which was recorded under related party payable in the Company&#146;s consolidated balance sheets. During the nine months ended September&nbsp;30,
2022, the proceeds from the note payable were used to finance the operations of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;5, 2018, Scilex Pharma
issued to Sorrento a promissory note in the amount of approximately $21.7&nbsp;million for certain amounts previously advanced to Scilex Pharma by Sorrento. Scilex Pharma may borrow up to an aggregate of $25.0&nbsp;million of principal amount under
the note payable. The promissory note is interest bearing at the lesser of (a) 10% simple interest per annum, and (b)&nbsp;the maximum interest rate permitted under law. All outstanding principal amounts and accrued interest are due upon maturity on
August&nbsp;31, 2026. On October&nbsp;22, 2018, Sorrento purchased from the Company 24,117,608 shares of the Company&#146;s common stock in exchange for the repayment of $21.7&nbsp;million of indebtedness under this promissory note. During the nine
months ended September&nbsp;30, 2022 and 2021, Sorrento made advances to Scilex Pharma in the amount of $0 and $8.1&nbsp;million, respectively, under the promissory note. As of September&nbsp;30, 2022 and December&nbsp;31, 2021, the Company had
ending balances resulting from the accrued interest on the note payable of $4.9&nbsp;million and $3.1&nbsp;million, respectively, which was recorded under related party payable in the Company&#146;s consolidated balance sheets. As of
September&nbsp;30, 2022 and December&nbsp;31, 2021, Scilex Pharma&#146;s outstanding principal balance under the promissory note was $23.5&nbsp;million, which was recorded under the <FONT STYLE="white-space:nowrap">non-current</FONT> related party
note payable in the Company&#146;s consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received $35.0&nbsp;million in February 2022 to fund the
payment of Scilex Pharma Notes in February 2022 totaling $20.0&nbsp;million, as described in Note 6. The $35.0&nbsp;million received in February 2022 is due no earlier than February 2030 and was recorded under the
<FONT STYLE="white-space:nowrap">non-current</FONT> related party note payable in the Company&#146;s consolidated balance sheets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional funding received from Sorrento is due on demand and recorded under the related
party payable in the Company&#146;s consolidated balance sheets. As of September&nbsp;30, 2022, related party payables due to Sorrento included $48.7&nbsp;million to cover working capital requirements, $100.0&nbsp;million for repurchases of Scilex
Pharma Notes, and $17.5&nbsp;million for litigation fees (see Note 8). As of December&nbsp;31, 2021, related party payables due to Sorrento consisted of $35.7&nbsp;million to cover working capital requirements, $51.0&nbsp;million for repurchases of
Scilex Pharma Notes, and $6.0&nbsp;million to pay litigation fees (see Note 8). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2022, the Company entered into the Bill
of Sale, with Sorrento (see Note 3). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#146;s rights, liabilities and obligations under Aardvark Asset Purchase Agreement. The Company issued the 2022 Promissory Note to Sorrento as
consideration transferred. The 2022 Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66% simple interest per annum and (b)&nbsp;the maximum interest rate permitted under law.
As of September&nbsp;30, 2022, the outstanding balance, net of discount, under the 2022 Promissory Note was $4.2&nbsp;million, which was recorded under the <FONT STYLE="white-space:nowrap">non-current</FONT> related party note payable in the
Company&#146;s consolidated balance sheets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Debt Exchange Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2022, the Company and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement (the
&#147;Debt Exchange Agreement&#148;) with Sorrento, pursuant to which (i)&nbsp;Sorrento shall contribute to the Company all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to the Company
and Scilex Pharma that remain outstanding as of immediately prior to the closing of the Business Combination (the &#147;Aggregate Outstanding Amount&#148; or &#147;Outstanding Indebtedness), including with respect to the Scilex Pharma Notes, an
intercompany promissory note issued by Scilex Pharma to Sorrento in the amount of approximately $27.5&nbsp;million for certain amounts previously advanced to Scilex Pharma by Sorrento, and the other notes payable to Sorrento described above (see
Note 6), in exchange for the issuance by the Company to Sorrento of preferred stock of the Company, (ii)&nbsp;the Company shall contribute to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a
contribution of capital for no consideration, and (iii)&nbsp;upon the occurrence of the events described in clauses (i)&nbsp;and (ii), the Aggregate Outstanding Amount and the Outstanding Indebtedness shall be satisfied in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Debt Exchange Agreement effective as of immediately prior to, and contingent upon, the closing of the Business
Combination, Sorrento has elected to contribute the Outstanding Indebtedness to the Company in exchange for the issuance by the Company to Sorrento of that number of shares of preferred stock, par value $0.0001 per share, of the Company (subject to
adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#147;Exchange Shares&#148; and such transaction, the &#147;Debt Contribution&#148;) that is equal to (i)&nbsp;the Aggregate Outstanding Amount plus the
amount equal to 10% of the Aggregate Outstanding Amount divided by (ii) $11.00 (rounded up to the nearest whole share); provided, that in no event shall the Aggregate Outstanding Amount exceed $310,000,000. As of September&nbsp;30, 2022, the
Aggregate Outstanding Amount was $276.8&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, pursuant to the terms of the Debt Exchange Agreement,
all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento, totaling $290.6&nbsp;million, was contributed by Sorrento to the Company in exchange for 29,057,097 shares of the Company&#146;s preferred stock. At the
Effective Time, such shares were then exchanged for 29,057,097 shares of New Scilex preferred stock and 2,905,710 shares of New Scilex common stock. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Loss Per Share </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2022 and 2021, basic loss per common share is computed by dividing net loss by the weighted
average number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the reconciliation of basic and diluted loss per share for
the nine months ended September&nbsp;30, 2022 and 2021 (in thousands except per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2021</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator for Basic Loss Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of Dilutive Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator for Diluted Loss per Share &#151; Adjusted for Dilutive Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic Loss Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilutive Loss Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stock options that could potentially dilute basic earnings per share in the future were excluded from the
computation of diluted net loss per share because the effect would have been anti-dilutive due to the net loss for the nine months ended September&nbsp;30, 2022 and 2021 were 25.2&nbsp;million and 30.3&nbsp;million, respectively. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Subsequent Events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events for recognition and disclosure purposes in the unaudited consolidated financial statements as of
September&nbsp;30, 2022, and the nine months then ended, through November&nbsp;17, 2022, the date the financial statements were available to be issued and, for disclosure purpose, through January&nbsp;12, 2023. Except as described below, or as
otherwise indicated in the footnotes, the Company has concluded that no events or transactions have occurred that require disclosure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Funding
Commitment Letter </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, Sorrento and the Company entered into a letter agreement (the &#147;Funding Commitment
Letter&#148;). Pursuant to the terms of the Funding Commitment Letter, upon the written request of the Company (which request the Company shall make to the extent necessary to satisfy the closing condition in the BCA that requires the combined
company to have $5,000,001 in net tangible assets as of immediately following the effective time of the Business Combination (the &#147;Effective Time&#148;) under the BCA (the &#147;Net Tangible Assets Condition&#148;)), Sorrento agreed to fund one
or more loans to the Company in the amount set forth in such written request (a &#147;Loan Request&#148;); provided, that any amounts funded by Sorrento in respect of any Loan Request were to be treated as Outstanding Indebtedness for all purposes
under the Debt Exchange Agreement and included in the calculation of the Aggregate Outstanding Amount thereunder with such amount to be contributed to the Company in exchange for shares of Legacy Scilex preferred stock. The Funding Commitment Letter
also provides that, in no event shall the aggregate amount of loans made and funded by Sorrento pursuant to Loan Requests exceed the lesser of (a) $10,000,000 and (b)&nbsp;an amount that, when taken together with all other Outstanding Indebtedness,
will result in the Aggregate Outstanding Amount equaling $310,000,000. The Company did not draw funds from the Funding Commitment Letter at the Effective Time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment to Amended and Restated Certificate of Incorporation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, the Company filed with the Secretary of State of the State of Delaware (i)&nbsp;a Certificate of Amendment to its
Amended and Restated Certificate of Incorporation to increase the authorized number of shares of preferred stock of the Company from 20,000,000 to 45,000,000 and (ii)&nbsp;a certificate of designation setting forth the designations, powers, rights
and preferences and qualifications, limitations and restrictions of the Series A Preferred Stock, par value $0.0001 per share, of Legacy Scilex. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sorrento Absorbed Liabilities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October and November 2022, Sorrento entered into agreements with certain of the Company&#146;s third party professional service providers to
assume $11.9&nbsp;million of liabilities accrued by the Company, of which $10.0&nbsp;million and $1.9&nbsp;million were recorded under accounts payable and accrued expenses, respectively, within the consolidated balance sheet. The liabilities
assumed by Sorrento were reclassified under related party payable within the consolidated balance sheet and subsequently exchanged on November&nbsp;10, 2022 under the terms of the Debt Exchange Agreement (see Note 10). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Committed Equity Financings </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
November&nbsp;17, 2022, the Company entered into a standby equity purchase agreement (the &#147;Yorkville Purchase Agreement&#148;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#147;YA II&#148;). Pursuant to the Yorkville
Purchase Agreement, the Company has the right to sell to YA II, from time to time during the term of the Yorkville Purchase Agreement, up to $500,000,000 of shares of New Scilex common stock, subject to certain limitations and conditions set forth
therein. Upon the satisfaction of the conditions to YA II&#146;s purchase obligation set forth in the Yorkville Purchase Agreement, including that a registration statement with respect to the shares to be issued to YA II thereunder be declared
effective by the SEC, the Company will have the right, but not the obligation, from time to time at its discretion until the first day of the month next following the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date on which
such registration statement has been declared effective by the SEC, to direct the YA II to purchase a specified amount of shares of Common Stock (each such sale, a &#147;Yorkville Advance&#148;) by delivering written notice to YA II (each, a
&#147;Yorkville Advance Notice&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there is no mandatory minimum amount for any Yorkville Advance, Yorkville Advance may be for
a number of shares of New Scilex common stock not to exceed 200% of the average of the daily trading volume of the New Scilex common stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the five
trading days immediately preceding the date of the Yorkville Advance Notice. The shares of New Scilex common stock, if any, that the Company elects to sell to YA II pursuant to a Yorkville Advance will be purchased at a price equal to 98% of the
lowest daily VWAP (as defined below) during the two consecutive trading days commencing on the date of delivery of a Yorkville Advance Notice. &#147;VWAP&#148; means, for any trading day, the daily volume weighted average price of the New Scilex
common stock for such trading day on the Nasdaq Capital Market as reported by Bloomberg L.P. during regular trading hours. The Company may also specify a certain minimum acceptable price per share in each Yorkville Advance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for YA II&#146;s commitment to purchase shares of New Scilex common stock at the Company&#146;s direction upon the terms and
subject to the conditions set forth in the Yorkville Purchase Agreement, the Company issued 250,000 shares of New Scilex common stock to YA II in connection with the execution of the Yorkville Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 8, 2023, the Company entered into a standby equity purchase agreement (the &#147;B. Riley Purchase Agreement&#148;) with B. Riley
Principal Capital II, LLC, a Delaware limited liability company (&#147;B.&nbsp;Riley&#148;). Pursuant to the B. Riley Purchase Agreement, the Company has the right to sell to B. Riley, from time to time during the term of the B. Riley Purchase
Agreement, up to $500,000,000 of shares of New Scilex common stock, subject to certain limitations and conditions set forth therein. Upon the satisfaction of the conditions to B. Riley&#146;s purchase obligation set forth in the B. Riley Purchase
Agreement, including that a registration statement with respect to the shares to be issued to B. Riley thereunder be declared effective by the SEC, the Company will have the right, but not the obligation, from time to time at its discretion until
the first day of the month next following the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date on which such registration statement has been declared effective by the SEC, to direct the B. Riley to purchase a specified amount
of shares of New Scilex common stock (each such sale, an &#147;Advance&#148;) by delivering an irrevocable written notice to B. Riley (each, an &#147;Advance Notice&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of New Scilex common stock, if any, that the Company elects to sell to B. Riley pursuant to an Advance will be purchased at a price
equal to 98% of the VWAP (as defined below) during the period (such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period, the &#147;Pricing Period&#148;) beginning at 9:30:01 a.m., New York City time, on the date of purchase of Advance Shares or such later time publicly announced as the official open of the
primary (or &#147;regular&#148;) trading session on the Nasdaq Capital Market on such purchase date (the &#147;Purchase Commencement Time&#148;) and ending at the earliest of (i) 3:59 p.m., New York City Time, on the purchase date or such earlier
time publicly announced as the official close of the primary (or &#147;regular&#148;) trading session on the Nasdaq Capital Market on such purchase date, (ii)&nbsp;immediately at such time following the Purchase Commencement Time for such purchase
that the total number (or volume) of shares of New Scilex common stock traded on the Nasdaq Capital Market during such period has exceeded the Advance Share Volume Maximum (as defined below) for such purchase and (iii)&nbsp;if the Company so elects
in the applicable Advance Notice for such Advance (such election, a &#147;Limit Order Discontinue Election&#148;), such time the sale price of the shares of New Scilex common stock traded on the Nasdaq Capital Market during such Pricing Period is
less than the applicable minimum price threshold determined in accordance with the B. Riley Purchase Agreement. &#147;VWAP&#148; means, for the New Scilex common stock for a specified period, the dollar volume-weighted average price of the New
Scilex common stock on the Nasdaq Capital Market for such period as reported by Bloomberg through its &#147;AOR&#148; function, subject to certain exceptions, qualifications and limitations. &#147;Advance Share Volume Maximum&#148; means, with
respect to an Advance, if such Advance is a (i)&nbsp;purchase-Type A, a number of shares of New Scilex common stock that is equal to the quotient obtained by dividing (a)&nbsp;the Advance Share amount to be purchased by B. Riley, by (b) 0.10, and
(ii)&nbsp;purchase-Type B, a number of shares of New Scilex common stock that is equal to the quotient obtained by dividing (a)&nbsp;the Advance Share amount to be purchased by B. Riley, by (b) 0.25 (in each case, subject to certain adjustments).
The Company may also specify a certain minimum acceptable price per share in each Advance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there is no mandatory minimum amount for
any Advance, subject to the terms and conditions of the B. Riley Purchase Agreement, an Advance may be for a number of shares of New Scilex common stock not to exceed (i)&nbsp;with respect to an Advance, purchase-Type A, such number of shares of New
Scilex common stock that is equal to the lesser of: (a) 1,000,000, and (b)&nbsp;the product of (1) 0.10, multiplied by (2)&nbsp;the total number (or volume) of shares of New Scilex common stock traded on the Nasdaq Capital Market during the Pricing
Period for such purchase-Type A, and (ii)&nbsp;with respect to an Advance, purchase-Type B, such number of shares of New Scilex common stock equal to the lesser of: (a) 1,000,000 and (b)&nbsp;the product of (1) 0.25, multiplied by (2)&nbsp;the total
number (or volume) of shares of New Scilex common stock traded on the Nasdaq Capital Market during the Pricing Period for such purchase-Type B. The Company may also specify a certain minimum acceptable price per share in each Advance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The B. Riley Purchase Agreement also provides that the Company has the right, but not the obligation, to sell to B. Riley, from time to time
subject to certain limitations, at the Company&#146;s sole and absolute discretion an additional number of shares of New Scilex common stock (each such additional sale, an &#147;Additional Advance&#148;) by delivering an irrevocable written notice
to B. Riley. The purpose of the Additional Advance is to allow the Company to execute more than one advance request on a purchase date with B. Riley as each prior advance has been completed under the terms of the B. Riley Purchase Agreement. Each
Additional Advance is generally subject to terms and conditions consistent with those of an Advance, except for, among other things, the time period of the pricing period for such Additional Advance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for B. Riley&#146;s commitment to purchase shares of New Scilex common stock at the Company&#146;s direction upon the terms
and subject to the conditions set forth in the B. Riley Purchase Agreement, the Company issued 250,000 shares of New Scilex common stock to B. Riley in connection with the execution of the B. Riley Purchase Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-113 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g428534g00a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g00a01.jpg
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M(&-H87)A8W1E<G,@8VAA;F=E9"!T;R!G<F%Y<V-A;&4N)B-X03LF(WA!.^*
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ME'::]C:N*C:MRH[[4NI+5-;UAKIFIV74M2+>Z]U!-3*]'U<=/&R5\>O/.+D
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M'U,C(8%1S6Q-A266>5LDTO'"^&0UKN3-C\+VT2!MB\(US"]C"TXF)>VEMM8
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M>6#2@G%3)<80LV#)??IV&LNN,C0")80&:R@\6=EYI+(!9<1K^?O!8R1P,?M
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MK=TU'RH3$)0/($!!L;)A*C9@BY8(RT"I%I(7BMU'94:)E[YI[_?Q&..<6>C
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MLJN0< 9@'(R\I+A. ATW !7$HAC.4 J9<?+GP:LN+YUY>).4N>GN)N.[:>1
M:S8(-7,M=\4 YB\9E+$13YSPN;R'Z.DST,Z[S;>$A,G)OKR,$\QMA9,1ACAE
M=WDI9S8,O1]J9G9VA!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MD"X7M?ZYV*TV:"+2U>0-<-\W40)O 3@>^><1>V!.W]AD7V2$=:%EG=CL<BP
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MYM<?SM!FJ)E\^?E.!GPL:W:,IN-P-;29,9WLG'9Y!.&[6G6H70TLVA4>UX+
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MVH>/S1?IIU-[1H?^LT[17OP-=>KJOU([LL(>-6&^O+7[4/'YHOTTZF]HT/\
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M_P!&,._OY_\ +ZD^?NN^CQ:* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M * 4 H!0"@% * 4 H!0"@% * 4!W4^3N_P!<C3'_ ,U-?=O,:X;N@?HA>/\
MZ:+^8T9VMN(?\Z.%?]I=OY%=#Z-Y]"3\KVCJDZJQ9D()K09LF9*#[N4$B13:
M12/--?PELDBXQLW7"X0.9;@;EK/EF[;$J1B[BW.V:K9-_,)^B1#=< =\K-=J
MG99H: Q;8>YBR+>3DC&SF,[C38:QUK)0L;2>!6$5'KE81%7XB(1A>-X/4"4F
M6FTVF6>(/'!40]%X/GR3WY5R_N0@NC.!^4Z^UD9C11%^[(Q\W&I!I=&9R]K(
M9!!Y.8T@AH[930Q+ .#1S*=,C@I(LUU_$2;N\I P5%:&QQU#0K2#QR* J\_S
M\6:9YIR\/+\_*N:KVSX7M6;.U8$D@G8TE<G\\I%*L V:AC$BV<A\]ASDE%BB
M+)%DR:L'Z^OR<+;RHFHBE(IA/D)C*):J5(OVIE^(6'<'1+M'JZFW9HG5;K3G
M3:1VI>9=A1:A10"@% * 4 H!0"@% * 4 H!0"@% * 4!Z]OE!-#33B*C6J]?
M01W'V9RTP,F^>DKYZ/'=Z#HT]Q7PLNP&%5^?RNXPNGAWKW&5K9=TIA>UK9<X
MP+B*@PW7UM5<&5+XYZ1*=B4T<<CT?OT<F;DDEB1&Z+%X4<JYY)EEPG3V[)@.
M]8_LUIM]DFM\,]%<W5DRW&>>"-85I)H,HW04M4YS].1OYJL:FCFNEFF1ZS?)
M,<37V@U!^:9/\$5V=WU,-_L+MYK3>VGGGX-N/OEV&.L+C^$#R3'$U]H-0?FF
M3_!%.^IAO]A=O-:;VT?!MQ]\NPQUA<?P@>28XFOM!J#\TR?X(IWU,-_L+MYK
M3>VCX-N/OEV&.L+C^$#R3'$U]H-0?FF3_!%.^IAO]A=O-:;VT?!MQ]\NPQUA
M<?P@>28XFOM!J#\TR?X(IWU,-_L+MYK3>VCX-N/OEV&.L+C^$#R3'$U]H-0?
MFF3_  13OJ8;_87;S6F]M'P;<??+L,=87'\(,*?^2VXC8XQ0(/SNJ,T'!J-
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M#\TR?X(IWU,-_L+MYK3>VCX-N/OEV&.L+C^$#R3'$U]H-0?FF3_!%.^IAO\
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MP;<??+L,=87'\('DF.)K[0:@_-,G^"*=]3#?["[>:TWMH^#;C[Y=ACK"X_A
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M6+\2'DV^,CT4-O:!K;XNIWQ,(>%7>87'V0=XC=1\7(^NK%^)#R;?&1Z*&WM
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MUYDVN*74** 4 H!0"@)M*>D'5OKYEV<O62?%=]':8K\9OTMA2:Q,A0"@% *
M4!-=K>;(CK*TY[W(3537Y';%(NKRMVH4JH44 H!0"@% 3K<'1+M'JZFW9HG5
M;K3G3:1VI>9=A1:A10"@% * 4 H!0"@% * 4 H!0"@% * 4!ZI_E7Y-)(GK#
M516+2 Y&B?C"?-O"4?+/PS_O=6,DKJH=^#G#9QS*M\,+J)<YW&=\<;Y8W[FW
M)V=N74E+5W6XLJZ:GJF-MZ.:RHACF:UW9,*:36R-<B.R54S1$7)53/)3SO\
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MF]*D36[G]"%*J%% * 4 H!0$T&],4SZM-9=J=M5>).==C2<:\R;7%+J%% *
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MU^1VQ2+J\K=J%*J%% * 4 H!0$ZW!T2[1ZNIMV:)U6ZTYTVD=J7F7846H44
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MQQL8JIKR56M153/AR4T/:_FN*ZRM,>^&"UBFOR.V*?1=7E;M0I50HH!0"@%
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MJ*5ERCJ98F1)2RSZ4;:6JI'I)IQ-3-SW-T57\W/)4];GE=>(G[":6_Y%.?\
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M<0_$V];IJLA3F4-78%F^<(.RC5PS151S\F8H_22_?O>X?Q4I^FVYW^@6"_\
MNO8OY;3$VUYL#B0VGP0,9/ >\W?$SFUD4+));*4!:P?BIM -H%];[+8F'0"%
M[8@3'8$7QC,I8C"HB%2?4TEGHMB48C4M<F$N]]B.:<&?'ET\7!R<"\'SY?.0
M5]Q/;P!:@#[9,%)1%(#'-2(N"THV2*U,I('^[ $ZVL#WS']M-X,.\',(SI*/
MZX'D6IO3T6[Q.!3<DV%FN:BL!,M5PR15R3A7/BY.+7RJNI5SXN!5/8_J>5KR
MR$AW3]*4IFAK$4+/Y30,'CTF=%[ A))4B7"Q]T\"B7Y5L2:E'@A@JG8([>+A
M7;(81'/!C,8^_O\ WG\VOYKBNLK3'OA@M5-?D=L4BZO*W:A2JA10"@% * 4!
M.MP=$NT>KJ;=FB=5NM.=-I':EYEV% 0_@(^J3_DQJ%.6@% * 4 H!0$UU!T>
M /6&^T!6JNOR-V("E5 * 4 H!0"@)K!?.C<_64*]SVJ*JZF\WI4B:W<_H0I5
M0HH!0"@% * F@WIBF?5IK+M3MJKQ)SKL:3C7F3:XI=0HH!0"@% * FTIZ0=6
M^OF79R]9)\5WT=IBOQF_2V%)K$R% * 4 H!0$UVMYLB.LK3GO<A-5-?D=L4B
MZO*W:A2JA10"@% * 4!.MP=$NT>KJ;=FB=5NM.=-I':EYEV%%J%% * 4 H!0
M"@% * 4 H!0"@% * \=VT:$&CI@_:MWK%ZW6:/63M%-RT=M'*>2+AJZ;K8YH
MN&[A'/-)9%7#--5//)-3'+'*]K@:>_UEK8JF'1*:]@Y)&/#,@H!)_$P+Q,&'
MR[VMD)#X.&"F(P9E9FTMDP960:W[U;<J7^@2[D#*"(;$(^[S?@8I&PCY1!5J
MH\$ A8UWFV75066;YN&35%;)!99JV551RSNFHJW04SQOFDG?$#U7_*_]$.JN
MLAUV8*5VMN3?UQ<_W:G\5">:?RF_T8P[^_G_ ,OJ3Y^Z[Z/%HH#ZV= Q*.S?
MA-T+'I0-P*"5M4ZE(W;W<.V:J)$&(CYL.0:/6#AJ^8OAA8>R(L7C-R@Y;.FR
M2J2N.6-KUY,Q1^DE^_>]P_BI3]-MSO\ 0'!?_=>Q?RVF*08T9J$[=GF1U]'+
MKCFP9F->LF=Q1(:WC\A6E@; :3%*,B _)A)7+HVBJS<H*W(NG3A3//-ROSFQ
M',C826M=>F +**%H1%245'!BD>8Q=Z"&N8TU!&@CJ,EA"0!9OF)Q'D(X^(1]
MTU[SYI4(1)"LL>\"#U!<#9 X84 '-Q(5@U&#6O/709M$L4D<5'*ZKITOE;']
MZKEX[77>/72M\W#QXNN[<JJN%E5<P-'VOYKBNLK3'OA@M5-?D=L4BZO*W:A2
MJA10"@% * 4!.MP=$NT>KJ;=FB=5NM.=-I':EYEV% 0_@(^J3_DQJ%.6@% *
M 4 H!0$UU!T> /6&^T!6JNOR-V("E5 * 4 H!0"@)K!?.C<_64*]SVJ*JZF\
MWI4B:W<_H0I50HH!0"@% * F@WIBF?5IK+M3MJKQ)SKL:3C7F3:XI=0HH!0"
M@% * FTIZ0=6^OF79R]9)\5WT=IBOQF_2V%)K$R% * 4 H!0$UVMYLB.LK3G
MO<A-5-?D=L4BZO*W:A2JA10"@% * 4!.MP=$NT>KJ;=FB=5NM.=-I':EYEV%
M%J%% * 4 H!0"@% * 4 H!0"@% * 4 H!0$0VI"X=.Y=JP'.(G&ID%[^ESSP
M/*P0N1"^^T([G9!UX/+M7C3OA&V>=DE^9YU.V>=L,K=U?EU=)75M Y\E#655
M%(]$8^2DJ)J=[V9J[0<Z%['.;I(BZ*JJ9HBY9HAMESLUGO4<4%YM-MNT,+W2
MQ0W.AI:^**71T-\CCJHI6,DT'.;IM1':+E;GDJH/V9>&[_X?-(>RB!_H%:[N
MCQ#X=O/6E=Z\V;N"P+XEX3__ !RS^QC]F7AN_P#A\TA[*('^@4[H\0^';SUI
M7>O'<%@7Q+PG_P#CEG]C+ *$BP0P>%!C1X8,)9MAPH2*9MQPP8/9I8-VC$>P
M9IHM63-J@G@BV:MDDT$$L,$TL,<,;8VVJ666>22::22::5[I)997NDDDD>JN
M>^1[U5SWN<JJYSE5SE555553DU/34]'3PTE)!#2TM-%'!3TU/$R"G@AB:C(H
M888FMCBBC8B,CC8UK&-1&M1$1$//KYGV% * FNU_-<5UE:8]\,%JIK\CMBD7
M5Y6[4*54** 4 H!0"@)UN#HEVCU=3;LT3JMUISIM([4O,NPH"'\!'U2?\F-0
MIRT H!0"@% * FNH.CP!ZPWV@*U5U^1NQ 4JH!0"@% * 4!-8+YT;GZRA7N>
MU1574WF]*D36[G]"%*J%% * 4 H!0$T&],4SZM-9=J=M5>).==C2<:\R;7%+
MJ%% * 4 H!0$VE/2#JWU\R[.7K)/BN^CM,5^,WZ6PI-8F0H!0"@% * FNUO-
MD1UE:<][D)JIK\CMBD75Y6[4*54** 4 H!0"@)UN#HEVCU=3;LT3JMUISIM(
M[4O,NPHM0HH!0"@% * 4 H!0"@% * 4 H!0"@% * Z-<;?$*XX9AVJ]D-8JC
M,5;R@\!\$+F% >'<DXTZRNY[]3&E<N5'O:UK)=Z\F?=\MU,.Y_?RW"&&6XHK
M*JD=6.HDIZ9*E)&P)/IKOK(M!6K+#DF3\\])=667"=8[J.Z')N=6NVW*.TLN
MRU]>ZA6%]:ZB2)$IY9]\1[:6J5ZYQ(W1T6IDJKI<&1T5\L:9] (SVD.O@FN?
M]Z*+P])U<WVTZ2^%#4^)<'7TGX0=\."_B_><6338;EW FT&O!7$803P;2-60
M6)6D21Y3++/)4*'[T[T\"XVQMC9QSW?%[WNES5K*<'QCA)F%7V]K:YU;V:VI
M<JNITI][['6!$1$2:;3T]^7/A;EH\>?!W%N5[ILFZ1%>Y9+,RT=J)*"-&LKG
M5V_]FMJW*JJZDI=[WOL5$1$1^EIKPMT>'N_7"SMD4 H!0$UVOYKBNLK3'OA@
MM5-?D=L4BZO*W:A2JA10"@% * 4!.MP=$NT>KJ;=FB=5NM.=-I':EYEV% 0_
M@(^J3_DQJ%.6@% * 4 H!0$UU!T> /6&^T!6JNOR-V("E5 * 4 H!0"@)K!?
M.C<_64*]SVJ*JZF\WI4B:W<_H0I50HH!0"@% * F@WIBF?5IK+M3MJKQ)SKL
M:3C7F3:XI=0HH!0"@% * FTIZ0=6^OF79R]9)\5WT=IBOQF_2V%)K$R% * 4
M H!0$UVMYLB.LK3GO<A-5-?D=L4BZO*W:A2JA10"@% * 4!.MP=$NT>KJ;=F
MB=5NM.=-I':EYEV%%J%.@FV>.-MIS8D]A\WA(J+!(64UNNQDDPEQ:-XS+74R
MV1H+7,IVK$5<X(^B1R,ZS*;@D[2=#&,T6DL2+P6/-I<*CP?:T7/,Q43/[>G)
M5R\N6LI9+C!UC'),1B\J2D HDWDP:/HM6T?-D'0Y,K'-/'%7DIS3'IBQ6([/
M<\7[ZN**'VO>*N>>#O(LT+!AH9>_3]WNAL4MXE8A#=^PG1!5OC9Y-(G*"S8_
M@6'YW0EX86ZE077Z,>2NJ6=EY! 8OLB9YO<K-60IA#V+53OMS*1MD1/?W]^,
MFB?'/JZ2"0+W6[ U+2)*>:&C!L,49O8H\BL:W[+]3 XC-"UGS!UEBV)QO<$8
MEL>$63P>ET[N@Y#, 2&FL!(NBO'\_P!B+P?9DO\ PSS#CBU& -X2_4$[BBT,
M2#/XHRAY)^[,K&-ELIQ,]-:TCDKA0VT50BYZ)-]E[;3@\Z<A9R3.ZP+#0"TZ
M "&,]C[C ,N#/W37K\B9IR\/(:[ N//54S./QC@;( X\U(8,'U 9R'/W#/:.
M.PM2\/6SHZ-36<L!K&*S5TIQ" Q5HJ8?Y(8C1+Z3*G4V+4ZWCX9+]_S<*IZ/
M0;DYXR-4)&X]&6XV>.I%(9,-BZ01:*K!28MX\+102^6-L9$Z$.AW@+*:QUP6
M&9HYGD[/<V;42Z),B+)F&2]']Z^A3#Y\>?#DW0;O7TB/CQ?>90@7+NHH9\&1
MED*^<N*ZT@<MT''>N:BD6?))-6F#U[BHX98N6S?NW-VH9+]N6M/FU<NM#*F^
M-/249&%2DG4FT;2CZ)W.1-3D&/CB(%T!";0DZC @Q<-L7&69>,:;G\BC))C@
M] 24./".@IAY>;0?"1ADO!\^K5PZOO\ ?)3>8MQ%Z^GTG/0"#O/"6P P/8!=
M.-&L[QWOO/7.SY5IF0)8N5TG;M4>UV/#RX1T<$"S(UFWLS?YJ9V)"T'PF7O]
MOI(B#XRG++(V1VQ#(KK^+!9_N77V9@+.I/-G+A_I)O(GLI)KH*ZJB@@&&R%@
M[&$R1L^S:-!MBKDDJS;AU'#D7+DX>#/[<N5>,W4SQL:!!,#Y)Y(WJS6,,,"1
MOP:Q3*N63-32LSX@TG&;$>[</KM'6JX!*I"*(V;^#)!X.P:QUZ67>L<7 9*O
M![Z\MIR3_BNCH#2^[=O0:,F9DEIH.^+8-#;4[!XS.$F#AVV45BLY7C9P:3'W
M<#2C7-X+8%7#1=JV5?,&PXN&?OQ.?[.'TFLK<:,6BT_V#KW:@=E!2FL5"JLF
M),SA&11A4(D U')1<F9RAQ%HX&#AVP_;#).<JSE>(8PGP4]/N5B4%36EZ(N7
MV\GEU_/R<IM;GC+T@@\C(]N0DI5Y."4D#05$-%R93YXE81)T(3/6(55KAFA@
MK!YD\8QF2*%E1C9$D_9Y,%R#%:SRP9+Z>GA]TUFJ1+CBUM)3<@89!)5<7@;C
M?S$(QL ?F3Z8:_D>N=)3IOM%^!!!52,6BR#K>T/$O.^L7[@,-<?.B36 "V$K
MPB@9?WY\&6OEYO1K+%J;B)UMN=YD-ASHLD4QBH*;W#R(7G'SGS1E**#N+26X
M$@JF;3 R5BY3<@S2H],4160,!T'F4@C,I$!!,LMG0>O_ .5_Z(=5=9#KLP4K
MM;<F_KBY_NU/XJ$\T_E-_HQAW]_/_E]2?/W7?1XM/>9\CC_W5Q _^8:S_P#I
MIU72>Z[_ )6P_P"SN7_JHCUY^2]_R3&?_:+%_P#KNI[$-<S#?+C?>QH'/K:V
M/:Y&P2*RX$;@D9E$>)0*4'STA:9:OE9L],9,,V04SC0X?)<)$# ZX="VN;=P
M;A3-C+XNI;IL]6^_/S<!%BFWN+*(RO:,?=>*;;*47MH1BTRUKI+:0M>!%-R;
M+?A)0M)T&^Y=E&=E-]0:N:-MB'!<<CNOBA]N=C*RF<4"%7Q,&&2<&M->M4VY
M(G#PH5#APXAU-NE)B!/&XV\/1X@T&H#8O#I6(;L5F,<CI8\F>//C<IC")QXO
M)610#$FI_,RKKUQ&-AHV*1B<!2"8*F7*G.J?/[KR+P*=M:$)KM?S7%=96F/?
M#!:J:_([8I%U>5NU"E5"B@% * 4 H"=;@Z)=H]74V[-$ZK=:<Z;2.U+S+L*
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M:JZ_(W8@*54 H!0"@% * FL%\Z-S]90KW/:HJKJ;S>E2)K=S^A"E5"B@% *
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M:ST%3+/GR3Y_?@X/G.\]""@)KM?S7%=96F/?#!:J:_([8I%U>5NU"E5"B@%
M* 4 H"=;@Z)=H]74V[-$ZK=:<Z;2.U+S+L* A_ 1]4G_ "8U"G+0"@% * 4
MH":Z@Z/ 'K#?: K577Y&[$!2J@% * 4 H!0$U@OG1N?K*%>Y[5%5=3>;TJ1-
M;N?T(4JH44 H!0"@% 30;TQ3/JTUEVIVU5XDYUV-)QKS)M<4NH44 H!0"@%
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MM2\R["@(?P$?5)_R8U"G+0"@% * 4 H":Z@Z/ 'K#?: K577Y&[$!2J@% *
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MKF[).#/-.ZM<..UA0"@% * FNU_-<5UE:8]\,%JIK\CMBD75Y6[4*54** 4
MH!0"@)UN#HEVCU=3;LT3JMUISIM([4O,NPH"'\!'U2?\F-0IRT H!0"@% *
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M:1VI>9=A0$/X"/JD_P"3&H4Y: 4 H!0"@% 374'1X ]8;[0%:JZ_(W8@*54
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M@*U5U^1NQ 4JH!0"@% * 4!-8+YT;GZRA7N>U1574WF]*D36[G]"%*J%% *
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7N#HEVCU=3;LT3JMUISIM([4O,NP__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g428534g00a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g00a02.jpg
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MU+U7:Z[$UKPP)>+S8A8+)#D_J7JNUUV)K7A@2\7FQ"P62')_4O5=KKL36O#
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ML.Z;_*'57NWHWTQ%C8I7OO?B;]&Y=R\"2!"@
M
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M4.JO=O1OIB+&Q2O?>_$WZ-R[EX$D"%
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MIVV=;?AMNNFZV/05\1"MZOU_7&Z=AO)&DU
M         %:\9!CE@C3?Y0ZJ]V]&^F(L;%*]][\3?HW+N7@20(4
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M#)*R^7LWM.V80@92P+3*LG85YA.3R6QYO_RQ6'>:9\ZY_>Q=OV[MYO-&DU@
M                    5KQD&.6"--_E#JKW;T;Z8BQL4KWWOQ-^C<NY>!)
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MZJ]V]&^F(L;%*]][\3?HW+N7@20(4
M
M                         "M>,@QRP1IO\H=5>[>C?3$6-BE>^]^)OT;E
MW+P)($*
M
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MS6V=[PKI]220ZE5_W=7?C=9^>IG]3G0W^B'17^[>H_\ :ZJ1Z,0_2
M             %L/_IU_R=XCO>74?I9T.;/)7[WZU^.:'YAGCK_":?TW\F']
MU==?[OHBQ:.5#S)                           K7C(,<L$:;_*'57NWH
MWTQ%C8I7OO?B;]&Y=R\"2!"@                                !\\C
M;7YJ[-]X-S^HY(>B^I_>G5?R=4OHVB.J->]VUSXU6/GJ9'P^B8H
M          !9\\@5^5?$)[P*A]./AU:]D%[[='?DZN?2:!S-Y+O<6MOC57^9
MIF_P=?#E(   /FH[<_-;9WO"NGU))#J57_=U=^-UGYZF?U.=#?Z(=%?[MZC_
M -KJI'HQ#](                    6P_\ IU_R=XCO>74?I9T.;/)7[WZU
M^.:'YAGCK_":?TW\F']U==?[OHBQ:.5#S)
M K7C(,<L$:;_ "AU5[MZ-],18V*5[[WXF_1N7<O D@0H
M                 ?/(VU^:NS?>#<_J.2'HOJ?WIU7\G5+Z-HCJC7O=M<^-
M5CYZF1\/HF*                    6?/(%?E7Q">\"H?3CX=6O9!>^W1WY
M.KGTF@<S>2[W%K;XU5_F:9O\'7PY2   #YJ.W/S6V=[PKI]220ZE5_W=7?C=
M9^>IG]3G0W^B'17^[>H_]KJI'HQ#](                    6P_P#IU_R=
MXCO>74?I9T.;/)7[WZU^.:'YAGCK_":?TW\F']U==?[OHBQ:.5#S)
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MC&3%3RNH3!\EQG&38+G.<8SC.?\ N /0]IZUTA@_BS#O  >T]:Z0P?Q9AW@
M/:>M=(8/XLP[P 'M/6ND,'\68=X #VGK72&#^+,.\ ![3UKI#!_%F'>  ]IZ
MUTA@_BS#O  >T]:Z0P?Q9AW@ /:>M=(8/XLP[P 'M/6ND,'\68=X #VGK72&
M#^+,.\ ![3UKI#!_%F'>  ]IZUTA@_BS#O  >T]:Z0P?Q9AW@ /:>M=(8/XL
MP[P /GQ;8,4^T]EG(8IR'O\ <C$.7.#%,4UBDLE,4V,YP8IL9QG&<9SC.,XS
MC/F'HOJ?WIU7\G5+Z-HCJC7O=M<^-5CYZF= 'T3%
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MC&,8QC ZDU_W=7?C=9^>IG]3O0W^B'17^[>H_P#:ZJ1^,0_2
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MS5V;[P;G]1R0]%]3^].J_DZI?1M$=4:][MKGQJL?/4R/A]$Q0
M        "SYY K\J^(3W@5#Z<?#JU[(+WVZ._)U<^DT#F;R7>XM;?&JO\S3-
M_@Z^'*0   ?-1VY^:VSO>%=/J22'4JO^[J[\;K/SU,_J<Z&_T0Z*_P!V]1_[
M752/1B'Z0                    MA_].O^3O$=[RZC]+.AS9Y*_>_6OQS0
M_,,\=?X33^F_DP_NKKK_ '?1%BT<J'F2                          !6
MO&08Y8(TW^4.JO=O1OIB+&Q2O?>_$WZ-R[EX$D"%
M             #YY&VOS5V;[P;G]1R0]%]3^].J_DZI?1M$=4:][MKGQJL?/
M4R/A]$Q0                   "SYY K\J^(3W@5#Z<?#JU[(+WVZ._)U<^
MDT#F;R7>XM;?&JO\S3-_@Z^'*0   ?-1VY^:VSO>%=/J22'4JO\ NZN_&ZS\
M]3/ZG.AO]$.BO]V]1_[752/1B'Z0                    MA_].O\ D[Q'
M>\NH_2SH<V>2OWOUK\<T/S#/'7^$T_IOY,/[JZZ_W?1%BT<J'F2
M                 !6O&08Y8(TW^4.JO=O1OIB+&Q2O?>_$WZ-R[EX$D"%.
MH)WZG+7IQK-&P,%;XTK)+B[K*1U%)%K659$D2E+.L$3,@W06D%"MT$UEB.%O
M]RJ2)T2'4*!P==W%K2V21HF!MC)X[S&V"99F5;R,>QF86J3*-?L\W6Y629LX
MNT0M=F73&/FY>NO)2.BUY.)^VN422T:=U89)1Q\'O?4ME5KR$%=&$DYMSQDT
MJC5!I*X=V9&2BG\Y'3=>:*L$W$S4I"%BY.6872.2<U%Y'1S]ZVFU6[-PHG"D
MM@                           /GD;:_-79OO!N?U')#T7U/[TZK^3JE]
M&T1U1KWNVN?&JQ\]3(^'T3%                    +/GD"ORKXA/>!4/IQ
M\.K7L@O?;H[\G5SZ30.9O)=[BUM\:J_S-,W^#KX<I   !65M_P#T\LS:;;:+
M.7BPC&);'8IN>*RSI9TXRTQ+R3F0PURXQM)'"^6^''JLK812PKDGI^J3]+T,
M<15CR7:33Z?3Z;_O="C_ !VFTNEZO_;Z3ZO\93I4^K/_ %BF)B84Q,*X]6-2
M_P )94=4ZGU3JI^1VM:=ZLU94-7O3KIWH=&M,ZE5=%5GI5HWT1IO1K2/1==4
M.O3ZO6ZO6I1+Z[_IR)K_ )<Q?R0=_P#E8;/M4Z3X<H?FZE^VGT_YSRH_B8K?
M^OM#_P /'^G(FO\ ES%_)!W_ .5@]JG2?#E#\W4OVT?SGE1_$Q6_]?:'_AX_
MTY$U_P N8OY(._\ RL'M4Z3X<H?FZE^VC^<\J/XF*W_K[0_\/'^G(FO^7,7\
MD'?_ )6#VJ=)\.4/S=2_;1_.>5'\3%;_ -?:'_AX_P!.1-?\N8OY(.__ "L'
MM4Z3X<H?FZE^VC^<\J/XF*W_ *^T/_#Q_IR)K_ES%_)!W_Y6#VJ=)\.4/S=2
M_;1_.>5'\3%;_P!?:'_AX_TY$U_RYB_D@[_\K![5.D^'*'YNI?MH_G/*C^)B
MM_Z^T/\ P\?Z<B:_Y<Q?R0=_^5@]JG2?#E#\W4OVT?SGE1_$Q6_]?:'_ (>/
M].1-?\N8OY(._P#RL'M4Z3X<H?FZE^VC^<\J/XF*W_K[0_\ #Q_IR)K_ )<Q
M?R0=_P#E8/:ITGPY0_-U+]M'\YY4?Q,5O_7VA_X>/].1-?\ +F+^2#O_ ,K!
M[5.D^'*'YNI?MH_G/*C^)BM_Z^T/_#Q_IR)K_ES%_)!W_P"5@]JG2?#E#\W4
MOVT?SGE1_$Q6_P#7VA_X>/\ 3D37_+F+^2#O_P K![5.D^'*'YNI?MH_G/*C
M^)BM_P"OM#_P\VV^3BX!7? /3-DU-WM)MM$VP+/#V(CYM3E:<6*+%12L;EH9
MLK9K-E[E?*OKL+X7:X3P7U?JC^?T\?N.BG1FET9J];T%*N*N?]3IJ&E5):!Z
M#J=2@Z'5ZKTVFZTWS*BZ-ITT]D_[(O0^R*UYT6USH>B.EZ)+HWJFNZLI5?2Z
M[H:[=<=;KE"M+3+2T-5:J6@6C5'J/1O1Z7K3UNO1^]-CX_5G5\
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M7C(,<L$:;_*'57NWHWTQ%C8I7OO?B;]&Y=R\"2!"@
M             !\\C;7YJ[-]X-S^HY(>B^I_>G5?R=4OHVB.J->]VUSXU6/G
MJ9'P^B8H                   !9\\@5^5?$)[P*A]./AU:]D%[[='?DZN?
M2:!S-Y+O<6MOC57^9IF_P=?#E(
M                      "M>,@QRP1IO\H=5>[>C?3$6-BE>^]^)OT;EW+P
M)($*                                 'SR-M?FKLWW@W/ZCDAZ+ZG]
MZ=5_)U2^C:(ZHU[W;7/C58^>ID?#Z)B@                   %GSR!7Y5\
M0GO J'TX^'5KV07OMT=^3JY])H',WDN]Q:V^-5?YFF;_  =?#E(
M                                               "M>,@QRP1IO\
M*'57NWHWTQ%C8I7OO?B;]&Y=R\"2!"@
M   !\\C;7YJ[-]X-S^HY(>B^I_>G5?R=4OHVB.J->]VUSXU6/GJ9'P^B8H
M                 !9\\@5^5?$)[P*A]./AU:]D%[[='?DZN?2:!S-Y+O<6
MMOC57^9IF_P=?#E(
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M\1^+_P"FMOWM'\!YG:X#S^SQ'XO_ *:V_>T?P'F=K@//[/$?B_\ IK;][1_
M>9VN \_L\1^+_P"FMOWM'\!YG:X#S^SQ'XO_ *:V_>T?P'F=K@//[/$?B_\
MIK;][1_ >9VN \_L\1^+_P"FMOWM'\!YG:X#S^SQ'XO_ *:V_>T?P'F=K@//
M[/$?B_\ IK;][1_ >9VN \_L\1^+_P"FMOWM'\!YG:X#S^SQ'XO_ *:V_>T?
MP'F=K@//[/$?B_\ IK;][1_ >9VN \_L\1^+_P"FMOWM'\!YG:X#S^SQ'XO_
M *:V_>T?P'F=K@//[/$H&[5];S0V1]H]7Z_V]N'KO4^EZKUOM#(^L]5Z?^_U
M?I^EZ'I_[O1\WI?W\X]%=3^].J_DZI?1M$=4Z][MKGQJL?/4SH0^B8H
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M/,[7 >?V>(_%_P#36W[VC^ \SM<!Y_9XC\7_ --;?O:/X#S.UP'G]GB/Q?\
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M.QBCV'8NU6,O:GZ\I97[55PBJHBM/2+E5Y*^@;!'SC*:C@IS((Y3"%@=V
M                         ?/(VU^:NS?>#<_J.2'HOJ?WIU7\G5+Z-HCJ
MC7O=M<^-5CYZF1\/HF*                    6?/(%?E7Q">\"H?3CX=6O
M9!>^W1WY.KGTF@<S>2[W%K;XU5_F:9O\'7PY2
M                                  K7C(,<L$:;_*'57NWHWTQ%C8I7
MOO?B;]&Y=R\"2!"@                                !\\C;7YJ[-]X
M-S^HY(>B^I_>G5?R=4OHVB.J->]VUSXU6/GJ9'P^B8H
M  !9\\@5^5?$)[P*A]./AU:]D%[[='?DZN?2:!S-Y+O<6MOC57^9IF_P=?#E
M(                                                        "M>
M,@QRP1IO\H=5>[>C?3$6-BE>^]^)OT;EW+P)($*
M            'SR-M?FKLWW@W/ZCDAZ+ZG]Z=5_)U2^C:(ZHU[W;7/C58^>I
MD?#Z)B@                   %GSR!7Y5\0GO J'TX^'5KV07OMT=^3JY])
MH',WDN]Q:V^-5?YFF;_!U\.4@
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M:QS-I'L4$FK)@V09LVJ)<$1;-6J1$&Z"1,?V(DBB0B:9<?V*4N,8_P"P%/9
M                         'SR-M?FKLWW@W/ZCDAZ+ZG]Z=5_)U2^C:(Z
MHU[W;7/C58^>ID?#Z)B@                   %GSR!7Y5\0GO J'TX^'5K
MV07OMT=^3JY])H',WDN]Q:V^-5?YFF;_  =?#E(
M                                   "M>,@QRP1IO\ *'57NWHWTQ%C
M8I7OO?B;]&Y=R\"2!"@                                !\\C;7YJ[
M-]X-S^HY(>B^I_>G5?R=4OHVB.J->]VUSXU6/GJ9'P^B8H
M     !9\\@5^5?$)[P*A]./AU:]D%[[='?DZN?2:!S-Y+O<6MOC57^9IF_P=
M?#E(
M"M>,@QRP1IO\H=5>[>C?3$6-BE>^]^)OT;EW+P)($*
M               'SR-M?FKLWW@W/ZCDAZ+ZG]Z=5_)U2^C:(ZHU[W;7/C58
M^>ID?#Z)B@                   %GSR!7Y5\0GO J'TX^'5KV07OMT=^3J
MY])H',WDN]Q:V^-5?YFF;_!U\.4@
M                        *UXR#'+!&F_RAU5[MZ-],18V*5[[WXF_1N7<
MO D@0IC;,<04E7-N4+7UAU+<HFG[.N%BUQ2MHJOZZK'/K[7*O;+BK&R532D3
M6J)@)F"HUK5KMH69*M9):+347:,(J4B95[8L;F[9Z8Y9DFV(OV^B>>6\ZI0>
M,*C7\VY++'(01=.:2979W;MLQVRM?6MJV]@UWA9DDA2ZC-S=QK?IL(B<FV6+
M-&Q*[N'C4W2+<YW[9'*+M_?R\)$V3A/#P],;X.[5C?;NR3=,KBFK;E!S-T3;
M2R325D*F8]9K*U>)97<E<&\=.OI*(E89L[A(B;AFL=)MXZRVNIQBDR9I/-I0
ML+Z^/KZ49#@#BI6>@X(B*DW,Q4.FX,<C<\K(LX\BYT\8,<B)G:R)53$*8N3E
M)DV2X-C.<8QG L-W)LC:5[2[SA>8-"Z;U#M+#=]"'@\F)6*S0Y@T+IO4.TL-
MWT(>#R8E8K-#F#0NF]0[2PW?0AX/)B5BLT.8-"Z;U#M+#=]"'@\F)6*S0Y@T
M+IO4.TL-WT(>#R8E8K-#F#0NF]0[2PW?0AX/)B5BLT.8-"Z;U#M+#=]"'@\F
M)6*S0Y@T+IO4.TL-WT(>#R8E8K-#F#0NF]0[2PW?0AX/)B5BLT.8-"Z;U#M+
M#=]"'@\F)6*S0Y@T+IO4.TL-WT(>#R8E8K-#F#0NF]0[2PW?0AX/)B5BLT.8
M-"Z;U#M+#=]"'@\F)6*S0Y@T+IO4.TL-WT(>#R8E8K-#F#0NF]0[2PW?0AX/
M)B5BLT?/TVNH17:6R54CD424OUQ4343-@Y%"'L4B8AR'+G)3$,7.#%,7.<&Q
MG&<9SC(]%M3^].J_DZI?1M$=4J][MKGQJL?/4SH(^B8H
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M8QC&,8QC&/-C^P]%]3^].J_DZI?1M$=4:][MKGQJL?/4SH ^B8H
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MXA/>!4/IQ\.K7L@O?;H[\G5SZ30.9O)=[BUM\:J_S-,W^#KX<I
M                                               5KQD&.6"--_E#
MJKW;T;Z8BQL4KWWOQ-^C<NY>!) A0
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MJQWFV<<1'[H
M       "M>,@QRP1IO\ *'57NWHWTQ%C8I7OO?B;]&Y=R\"2!"D=)[<U@KL
MNJR7NL&V*HU>NT:?][-<3:Z4:W;O))-LTR?&7+R-8NVDA(QZ!E'[".=-I!VV
M19KI+G$E3&TY"!V/1;/*O(2OVJ&EI1DG)KJ-&CLAS+MH26/ 3CN.4SZ*,JR@
MI],\!./(M1XUAITAX:36:R9<M<"G$Q.Y]23Z\8U@MET>:=S<@C%PK2(LT1).
MYEZX:+R"*42U9.UW$DFK&M74H1RR37;9BFCN3]=]@:KN$T-7J"2G=;L]?7?<
M26!0
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M(1WYOZV2*(4 "M>,@QRP1IO\H=5>[>C?3$6-BE>^]^)OT;EW+P)($*
M
M                                                  !6O&08Y8(T
MW^4.JO=O1OIB+&Q2O?>_$WZ-R[EX$D"%
M
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M6=RZG&#*(3DF^7$E(U@WHVB+B39-A"6E:N;'HV:+C574A7C?VF6S+(A3OH
M                                            K7C(,<L$:;_*'57N
MWHWTQ%C8I7OO?B;]&Y=R\"2!"@
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MI#1T\+?'^MI:3C+Q0)ZHMT6"TE799"Q0$A9V^7<*J^9X6K:LPB)BVR=_HO\
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MF'L[GF?F+V _4EG\9(QL._7CE'B]L5;5M9;OW6+Q]%W-;]N/A;MROEQL$$*
M                                            5KQD&.6"--_E#JKW
M;T;Z8BQL4KWWOQ-^C<NY>!) A0
M
M                      *UXR#'+!&F_P H=5>[>C?3$6-BE>^]^)OT;EW+
MP)($*
M
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M:FQ^W%F\4"%@LD)>+S8YQ[=ZU-C]N+-XH$+!9(2\7FS W[]F_P#]S*_$7?\
%_84A_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g428534g00a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g00a03.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2604&AO=&]S:&]P(#,N,  X0DE-! 0
M    )72^E8@X0DE-! 0      !X< 5H  QLE1QP"   "   < E  "E-T97!H
M96X@36$X0DE-!"4      ! B)R.S>.0!+UE6301,F3\].$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  @"4S,P  0 ".$))300F       .             #^    X
M0DE- _(       H  /_______P  .$))300-       $    6CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))301$       0     @   D    )
M #A"24T$'@      !      X0DE-!!H      T$    &              ',
M   "N@    8 9P P #  80 P #,    !                          $
M             KH   ',                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ',     %)G:'1L;VYG   "N@    9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
MS     !29VAT;&]N9P   KH    #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M    3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N
M9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L
M;VYG       X0DE-!"@       P    "/_         X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46
MHK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A
M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8U
MPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U5)8=^7G#(M#<E[6A[@UH
M;7  W,V^ZHN_E(?VS/\ ^Y5G^;5X;?\ 0_V_Z_\ P?Z-&O%%^!>@0;\K'QMO
MKV"L/)#2[02!N^E]%O"Q?MF?_P!RK/\ -J\-O^A_ZY_7_P"#_1J>'E9-F3>S
M*Z@:ZFMK](#T0\.<'ML=8#2=C=*_1W_3L_S$@/%!D=-#J:=,=3Z>[?&1616-
MSB"(C][=^=RD_JF#7/J6AD=W @:2.X_DJ#&>L7"GJ-CR)G9Z#HD;6_X!WT7-
M4;C538*[>I.ILLW;6DT ZC\T.I_,VNVI:*]7;\/_ $)CU6VO9B;K'-HMN_2&
MM^W<STKK/IL<RS;[&O\ T/Z3^PF8.E6V^@VZSU3N]ANN:[D.=S8W]WV_^=JO
MU%X'H/KS+;]F0994,=[VS7:YK:V.JW.>W;[&L_3)#J-;R]K+^H2P$NC%XDL]
MONQ/I,:[V?Z2O_2I@C$F5T?-E,\D8PX;CH3IU/%+^LZ!Z=C$DS;[IG]-;W._
M_2>WW! S\*FK!R;&/N:]M3W-<+[)!$VAS=]NSZ;?SO\ SVGQM^6U[Z\K*8 X
MM_25,KU.VS]'ZV,WU&-;[&V>]G_7%4SLBQOVK$=9F&*WCU755>@98;_Y\T^F
MUFW]!^F_]2)2A'A.@V/1./+DXXZRW'Z7_H3H.ZI@,]ME[&N D@F#SM1J<K&O
M+A1:RTL@/#"#$\;H67]O:RUE+KL\6%VW;]F:08=[K-]>*YCJ_<QNZI_\U_VX
MBXMYR+12W(S6O(W$V4-8T;3[FNM=BMJWNW_0W_S?\W_I$_3NP^KJ/Y?XSJ(%
MN2:K"WTK'@-W;F#=^][?^BJ.7=;AV,8ZW.O!;N+J:JK&^T_1=Z=&[?9]%*[$
MPGW!F3FO=: QWO-;3#=^WBIC?=N>D*[J)ET!_!TFV2S<X%D3(=IP@/SMCRPX
M]Q@D M9N!CON'[RJU=(P[6E]>0^UKH:YTUN! &U['#TO3]_YZC51T^C(=Z>>
M67L:&V#=3,>[Z>ZO\^QOJ?UT?3W5<NS>=E$55VBFP[S!9'O;S[GLGR2IRS:_
M9Z-M<:$O; [GG\[Z*I9;*OL]5EF1DY5+G:/I979'L>W?^KT;]C_Y'^$_D*E6
M.F65-<PYVQKMK'"AP_-VMV_J_N8Z-_\ 7_1_\"EZ>ZO7T#M7Y?HD159:TB=U
M;=VLQ'M3U97J,>_TK6>F)AS8+M)]C?SE2HZ7C7L9DLLO9N][ ]C:W!WTMYJL
MH:]C_5_3_I&?SGT_T?Z-0QLQ]K;;"_/;Z5;K/3MIK;N$1%1]':^QOTV,]3_H
M(:*'%>HT?__0[3(_I%W_ !C_ /JBH*>1_2+O^,?_ -45!%2E#%Q&YF;E5->*
M7,;CNM-C&7,>TC(:QC:K6_HGU_2]3?[U-/AWNIR,E[JG9M0;4/L]</?5[;B^
MWT'[6[<CZ'Z-WZ3TTAL?+]JT[Q\_^YDV:.D9F-)Q\ZBESMHL=7BULW!IW'Z+
MOY3EHW8?3LA_J9%%-SX WV,:XPWCW.'YLJHW.K>'$]+R&P"3NJKUU#-H_2?2
M<HLZ@'U@NZ3D->=',]-D D-W>XO'L_E(+]6/5<7'JKH&'2VNRV\!PI<S'<XB
MN^-UX;O]O_!_I4)M'4O2;BNI<VI[]S\@9]AL9KKL<^MSW;)_F]VQZL]2=74S
M"M>UM&ZZ;6D@#6JY[V/V@^O[F_0;^YZGYBH?M2&/K=?TUV08#&.#ZX<X-L&Y
MKM[[/4K>U_\ @_\ TDT;R\_V+Y7PP\C_ -*2?!HSZ;ZWOI>&@^_U,^RZ ?;8
M756,V/\ 3_,1;^F8V/C9%[<C(L>RFV/4R'/&K73+;G/J_P"W&[%*AG5;!78Z
MC!-=GN>YI?):[W;F;JOZK_<AVU=29BYC\RO$94*+'5OH+FO:X#<-S[6[/^$]
M;]__  :4OE/D48_GCYAKV874#:]VRQS2Y^V.H6L&T_0VUL;_ *_\'7_-ZG3;
M<LTQF5MH+0T,;ZOK.B-?4M,;W?Z_RUGW=2IIR3ZE^#72UQVLL:YCB&;/5_2N
M]C7U/LW_ $/?_P '_.*6)9U3)K?937TZU@,-<PV1/TP#^B]VW=])J<M+?R\+
M'RGA[KK:W;2R:;GU2#_Q3F^[]QRK=0Z6[,N]1N14UH:UK66T5W007Z^I;^D]
M[7[=JEZ'5?7K(IPA1[1:/?O[%[JW;-OZ/W^G^_\ \$B6V-JR12,!UE9#?TU;
M6D ^X^YKMGT(_-_?24CPL#)Q+&AN94,8$N=17176"YW\IA5AW3NDN>;'8V.Y
M[B27&MA))]SCNV_G*K7G-?:RO]E7UASFMW/KK#6R=I<\L>_VUM_=6C]GQ_\
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M-D?TB[_C'_\ 5%#117BNB])?4,_-&_T;!52YUA<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M          #_XO__24-#7U!23T9)3$4  0F^S/[^'@ (@'!!1$)% A   '!R
M=')#35E+3&%B( ?0  < &@ % "D -6%C<W!!4%!,     $%$0D4
M           !  #VU@ !     -,M041"10
M                                    "F1E<V,   #\    =&-P<G0
M  %P    *W=T<'0   &<    %$$R0C    &P  "B!D$R0C(   &P  "B!D$R
M0C$  *.X  "B!D(R03   47   (XM$(R03$  WYT  (XM$(R03( !;<H  (X
MM&=A;70 !^_<  "0D61E<V,         &E4N4RX@5V5B($-O871E9" H4U=/
M4"D@=C(
M                                                    =&5X=
M  !#;W!Y<FEG:'0@,C P,"!!9&]B92!3>7-T96US+"!);F,N  !865H@
M    M5H  +QG  "2,&UF=#(     ! ,)   !                     0
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MCJ%\HFJC5Z1%I3.F(*<.I_RHZJG7JL6KLZRAK8^N?:]KL%FQ1[(VLR2T$K4
MM>VVVK?(N+6YH[J0NWZ\:[U9OD>_-< BP1#!_L+LP]K$Q\6UQJ/'D<A^R6S*
M6<M$S"[-&,X!SNO/U="^T:?2D--YU&'52=8QUQC8 -CFV<W:LMN8W'W=8MY'
MWRS@$.#TX=CBN^.>Y'OE5^8SYP[GZ.C!Z9KJ<>M([!WL\.W#[I;O=O!5\3/R
M#_+J\\/TG/5S]DGW'O?S^,;YE?IA^RG[Z_RG_5S^"_ZT_UK__P   >@#IP4L
M!H0'OPCG"@0+%@P<#1X.' \9$!<1%!(0$PL4!!3\%?,6YA?8&,P9UAK>&^$<
MX1W?'ML?UB#1(<LBQ".^)+@ELR:N)ZHHIBFB*J KGBR=+9HNE2^1,(TQB3*&
M,X,T@35_-G\W?SB .8(Z?SM^/'P]?#Y\/WU ?T&"0H5#B42-19)&F$>:2)M)
MG4J?2Z-,IDVJ3J]/M%"Z4<!2QU/.5-55UU;95]M8WEG@6N-;YUSJ7>U>\5_U
M8/AA_&, 9 -E 67_9OQG^FCX:?5J\VOP;.YMZV[H;^5PX7'><MISUG3-=<-V
MN7>O>*5YFWJ0>X5\>GUO?F1_6(!-@4&"-8,IA!R%$(7^ANV'VXC*B;B*IHN5
MC(.-<8Y@CTZ0/9$LDAN3"I/ZE.F5V9;)E[J8IYF3FH";;9Q:G4B>-I\EH!2A
M!*'UHN:CV*3*I;VFL:>FJ)NID:J'JW^L=ZUOKF>O8+!:L52R3[-,M$FU1K9%
MMT2X1;E&NDB[2KQ.O5*^5[]=P&/!:L)RPWO$A,6*QI#'ELB=R:7*K<NVS+_-
MR,[2S]S0YM'QTOO4!M42UA[7*M@WV43:4=M>W&O=>=Z&WY3@G.&BXJCCK>2R
MY;;FNN>]Z,#IP^K4Z^7L]>X$[Q+P(/$L\CCS0_1.]5GV8_=J^&[Y;_IL^V3\
M5OU$_B__%___   "!0/8!6@&Q@@&"3(*4@ME#'(-> YZ#WH0>A%Y$G43<!1H
M%5X64A=%&#<9*1HT&ST<0!T_'CH?-" L(2,B&2,/) 0D^27N)N,GV"C,*<$J
MMBNK+)\MDRZ'+WPP<#%D,EDS331!-38V*S<A.!8Y"SH .O8[[3SC/=L^TS_+
M0,1!O4*W0[)$K$6F1J%'G$B7291*D$N.3(M-BDZ)3XA0B%&)4HA3B%2(58A6
MB5>*6(M9C5J/6Y%<DUV67IA?FV"=89]BH&.A9*-EI&:F9Z=HJ&FI:JIKJFRK
M;:MNJV^K<*EQJ'*E<Z-TH'6==IEWE7B1>8QZAWN"?'Q]=GYO?VF 88%:@E&#
M2(0^A36&*X<AB!>)#(H"BO>+[8SBC=B.S8_#D+F1KY*EDYR4DI6)EH"7>)AP
MF6J:8YM>G%F=59Y2GU"@3Z%/HE"C4J15I5FF7Z=FJ&ZI>*J"JXZLG*VKKKNO
MS+#?L?.S";0@M3BV4;=LN(>YI+K"N^&] ;XAOT/ 9<&'PJK#SL3QQA7'.<A>
MR8+*ILO*S.W.$,\RT%31=-*4T[+4S]7KUP;8'MDVVDS;8=QTW8?>F-^GX+/A
MON+'X\WDT>72YM#GS.C$Z;KJK.N;[(?M;^Y8[USP6_%6\DSS/?0J]1+U]O;6
M][/XC?EB^B_Z]/NQ_&;]$?VS_DW^X?]Q__\   '9 XT%"094!W\(E@FA"J0+
MGPR3#8(.< ]?$$P1-Q(A$PD3\!36%;L6GQ>#&($9?1IT&V8<51U!'BP?%R
M(.HATR*](Z8DD"5Z)F0G3B@Y*24J$"K]*^HLURW$+K$OGC",,7DR9S-5-$0U
M,C8B-Q$X 3CQ.>(ZTSO$/+4]ICZ8/XI ?4%O0F)#541)13Q&,$<C2!=)"TG_
M2O-+Z$S<3=!.Q4^Y4*U1H5*54XA4>E5M5E]745A#635:)EL87 E<^EWK7MQ?
MS&"]8:QBFV.)9'AE9F949T)H,&D>:@MJ^&OE;-)MOFZJ;Y9P@G%L<E9S0'0I
M=1)U^W;D=\UXMGF>>H9[;GQ6?3Y^)7\-?_2 VX'"@JB#C81RA5>&.X<@B 6(
MZHG/BK.+F(Q]C6*.1X\MD!*0^)'>DL23JI21E7B68)='F"^9&)H!FNJ;U)R_
MG:J>EI^#H'&A7Z)/HS^D,*4BIA6G"*?]J/.IZJKBJ]NLU:W0KLNOQ[#$L<*R
MP;/!M,*UQ;;(M\VXT[G;NN.[[;SXO@2_$< @P3#"0,-2Q&;%>L:/QZ;(OLG6
MRO',#,TJSD?/8]" T9_2O]/@U0/6)]=,V'/9F]K$V^_=&MY&WW/@H>'/XP+D
M3>69YN?H-NF&ZMCL*^V [M?P,?&0\N_T3?6J]P3X6OFK^O;\.OU[_KO___\
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ME*)\"B?SD_-\_02JDW]_IKNSI.*#E*DJH5J"G)85G@J!T()@FOV!/FW;F#J
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MN;:!I(Y"M,* O7UBL 6 #6OSJXQ_GEFXIV1_<D9LHZY_@S%LH-Y_P1>PH3N
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M+3?/IIV%U2/RI%N&& L7I0>%40  A2F  (<^O J28'BEMQ:08FF$LD&.IEG
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MR1*!V6V7PYZ V%]'OCV #U!.N0M_H$!]M#I_;2]0L$=_=QM]KI)_JP27K$F
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M\P  AW*  *7UES:*0)7"E.J)'X3&DL>(#7+VD,V'#V ;CQ.&04PYC9:%E3;
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MK=Y[! "CI]-]+@  @ "  '*5P>V"VF6 O2:!^%?GN&J!0DFHL]* S#IFKZV
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M><1X(GA">EUXRF&O>O]Y>DG9>Z)Z&B[U?$EZD IK?;%ZJ,=E=BJ Y+2N=N:
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M@@<[=O:$Y+MN@I1JG*HQ@CAL>)?K@?EN*H1Y@=%OOV_\@;EQ35IP@;ARV4.
M@=UT1RD$@H%U4P4\@[MVC;I,@+UTLZD0@(UUC9:S@&5V5H-/@$MW%V[E@$)W
MW5EP@%!XID*3@'AY6B@N@/QYR 3(@@QZTKD<?PY^S:?"?OE^MY68?M]^G((D
M?MA^AFW/?MQ^@UAY?OA^C4&Z?R=^DB=N?XY^? 1B@)%^DK>\?92(U:9<?8:'
M[I0.?7R&_H#)?8&&%6R0?9^%3%=A?<R$F$#,??^#]B:H?D2#A 0)?TB!U+9M
M?%F2X:4+?%"1.)*_?%"/?W^$?%V-R&MW?(",+59H?+Z*QS_^?/2)D"7_?1B)
M!@.^?B^"B+55>V*=#*/S>UZ:HY&H>UZ8'GYU>VZ5FVIY>Y63/%6*>\^1'C]&
M? F/=25H? ^/  -^?4&"7+1U>IZG2:,->IVD)I"\>IF@U7V*>J>=B&F@>M2:
M=53.>Q*7OSZL>SZ5QB3L>RJ4( -)?'V".;/,>@NQH*)8>@RMQH_X>?^IKWS"
M>@2EF6C<>C&AW50:>GF>NCX9>J.<Y"1_>FJ84@,>>]V"'+-<>:>\(*'2>:>W
MF(]6>8VROGP4>8.MZ6@Y>:BIEU.,>>ZF03V7>AJC?"0+><V87P+\>UZ"!*S8
MB[UIVISYBH!KNXO]B7YM<'G B*EO"&9IA_%PF%'LAV)R)#OHAR!SA2&QA_5T
M3@  AX%W)*OSB@)S99P'B/AT58KNB QU,GBYAS]V"&5QAHUVXE$'A@9WO#L1
MA<!X>"#VAFIXQP  A95[%:KPB&I\VYK5AWM\^8G9AIA]"W>=A=I](61QA31]
M1E IA+A]=3I1A')]F2!5A/1]D   @^9^BJG1AO:&6IFDA@^%MXB0A3Z% ':+
MA(:$4V-Y@^V#PT]<@WF#23FF@SB"XQ_&@YB"N   @F^  *BEA<./VYB8A.".
MBH>#A!>-(G5B@V>+MF)O@M:*9$YK@G6)2CCA@C*(;A\R@F:(>P  @2Z  *>K
MA->9?I>6@_J7?H:!@S"57'1O@H"3,V&,@?&1,$VJ@8:/>#A%@46.4AZU@5B-
MW0  @""  *;BA!RC,I;(@T6@B(6M@G:=K'.9@<*:RF#$@3>8)DT @,V5\C?'
M@':4NAY1@&R25P  @ "  *9*@X^M")8C@KZINH3X@>>F)G+A@2:BC& 2@)>?
M5DQ3@#F<V3<W?]^;M1WX?Z>41   @ "  *7C@RVW&I6D@F"S,X1>@7RNZW(\
M@*FJH%]\@!"F[TO7?Z^D>C;-?UBA>1V>?PV4!P  @ "  )ZFE1YI3H_4DR9K
M(W_ND7ELU&[,D -N:ER-CK!O]DD/C9UQ=#/6C1!RLAF'CJ)R]@  @Q9ZO)WL
MDY1R6H\6D<AS37\4D"=T,VWZCJQU%%O$C5AU^4A5C$5VV3,HBZUWBAC]C0!W
M@P  @:%^'YT8DA-[3HX0D&)[?7XACL9[IVT C5A[V%K@C U\&$>.BP%\7S)^
MBF-\D1A^BWQ\;   @%J  )P9D+>$*XS]CPN#LWSVC7Z#-6P)C!""N%GZBM:"
M6$;.B=.""3'EB3"!S1@1BA*!V0  @ "  )LFCX2-+(P C>*,$'OXC%Z*Z6L(
MBO:)OUDMB;6(LD8<B+Z'W#%9B!>'4!>PB,:'6   @ "  )I2CJ"648L_C0:4
MF'LWBWZ2Q&HUBA20\%A>B-6/1D5MA]2-\3#+ARF-31=)AZR,!0  @ "  )FD
MC>^?@HJ'C%J=,'IYBLV:M6EZB5Z8/5>MB"&6"D35AQR46S!>AE>3]!;_AK*/
MC0  @ "  )D<C6BHS(GUB]BEZ7G<BD2BS6C<B,F?MU<2AXB=#T1 AHN;22_F
MA;V:*1:^A>&/80  @ "  )B]C0BR5HF$BWNN\7E6B=RK.6A.B%*GD%:1AP:D
ME$/5A@2B]B^&A3B?'19KA4B/*   @ "  )#8GN%HS(+7G$QJC7/?F@)L-&/$
ME^]MQ5*'E@MO23_LE(9PL2M*D^AQLQ!LEMYQ+P  @ !]T)! G8UQ8X)(FQ!R
M47,\F,-S.F,FEJ-T(E'PE+9U##]EDRIUZ2K3DG5V>A XE/5U\@  @ "  (^8
MG"%YV8%UF;IZ$G)]EVUZ36)@E5-ZE5$]DVIZZ3[+D>%[0"I9D1Q[<1 &DR][
M)0  @ "  ([/FLR"/8"2F&Z!VW&$EBV!>6&0E!.!)E![DC> ZCXJD+. PBG>
MC^* J0_2D9* J@  @ "  (X F;2*J'_&EUF)N7"TE1V(QV"TDP>'WD_6D1R'
M##V;CZ"&>BEWCL&&/@^MD!:%>P  @ "  (U5F,:31W\7EGB1RW !E#R00& *
MDA^.ND\SD#.-8#TECI^,:BDBC;:,70^+CL")D0  @ "  (S&F!B;]WZ:E<^9
M^&^"DXF7U%]ZD6"5N4Z>CW63\3REC>*2S2C/C-B2Q0]IC9V*:P  @ "  (Q5
MEYFDOWXBE5*B0V\ DP.?DU[VD,V<\4X=CMR:U#PFC4^9W"AKC#B8&@]+C*R*
M5P  @ "  (P!ESVMQ'W#E/2JW&Z1DIJGJ%Z"D%:DD4VTCENB43O/C,:@]2@?
MBZ^;(0\<B_F*-P  @ "  (.)J1-H-W8\I?9IX&@5HQYK>%CBH'AL_DB+G@YN
M<C:RG#5OMR)>F^-P6@A8G:]P(   @ "  (,2I_)P9W7>I-9Q1V>MH>=R+%B!
MGR=S%D@PG*MS_C9GFL-TRR(KFD=U'@B FW1U,0  @ "  (*6II9X:'4_HXAX
MHF<BH)-XY5?OG=)Y/4>PFU1YH#8 F6=Y_B'KF,QZ%0B=F6=ZIP  @ "  ((
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MN3R*NUT>M1R)R5!$L0"(W$*>K0V($#/\J9&'DB.=ISJ'P _FIZN&N   F9"
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M.YE:='5R<(6V=79SF'$.=G-TO5MJ=W%UWT1V>%UVY"HX>05WD ;U>UMX%+O
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M=Q""9YQS=YB")8LW>!:!SWCZ>):!<F6N>2>!)E%:>;R Y3N/>CJ HR'F>F2
M5@%+?=%_NJMF=9>,0)L@=BJ+0(GE=K2*)7>Q=S^) &2<=]>'ZU!F>'V&^SK'
M>/J&*R%)>.B%S $@?AB PZI/=&F6,IH)=0.4>(C1=9&2EG:D=B.0J6.A=L&.
MUD^2=V.--SH9=]^+^2"_=YB+M@#]?E6 JZEP<WB@+YDE=!>=OH?J=*.;%G7!
M=36896+,==J5XD[;=H"3L3F*=NN2*"!1=G.0S #??H> EZC*<L&J.9AS<V*G
M%H<K<^BCK'3_='*@.6(.=1B=$TXK=<>:>#C]=BR9$!_O=7J4] #'?K" AJA<
M<D2T6)?P<N*PBH:/<UNL8G1:<]>H.&%S=':D@4VE=2*AL#A\=8.?AA]W=*B5
M1@"T?M& >:)_A<5D&9.@A19FB8.7A)QHPG(_A$=JT5^XA MLRDOQ@_)NK#:!
MA"!P2!QEA6%PY@  @$QVNJ&8@[AM@Y*G@T5O"8* @NAP;7$U@I]QOE[#@FMS
M!$L7@EIT.S7 @GUU.!O(@V]U9@  @ !ZN:"+@=EVU9%F@8AWBX%=@3MX*W 2
M@0-XP%W @-YY54HX@-=YY#4%@/-Z3QLW@9IZ+   @ !^.I]F@!F )9 S?]V
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ME&=[,01TD<!\3   @ "  '@;G+^![VN(FG*!N5X>F#6!=D_(EA.!+4!HE#2
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M]R<VHA=J&Q(JI']IIP  F--N8@  @ "  &V#K!!I/V&ZJ1MJCU3]ID9KX4=
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MI*&=XU]6H:2<J%*9GIB:]T38FZ*95C8SF1>8SR7\EVJ6YQ*JEZF,G@ +CXJ
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MLO5\TE3IKZQ\OTB^K%U\K3NYJ31\G"V.II5\HAT9I8Y\F0GJI8A]&0  CL&
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MDD^+)V'UD-6*H554CT6)Y$>SC;^)%3D&C':(=BC/BYV(415UB^.(! $#A]^
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MG%Z/*U;,FDJ.FTK3F!R-OCW8E?V,VR^NE$2,=A^+DWZ,KPR)DR6(>@  A2&
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MIS22?DP,I'J2(D"GH;J1530NGR.0I"9GG2^0F18FG/:-Y 5JF'"#J0  @8"
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MB>)\\%GNB3!]2TX B&=]>T$)AY]]C3+>AP1]F2+9ALQ]HP\+AQ)]M0  @!N
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MDVN!$TZ6DCZ!.T-,D.J!(S;MCY> ["DNCJ6 SAD@CJF ZP=0C!R X   @ "
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M/   @ "  $['I MHIT2CHEEIWCFDH+9K 2VAGTEL !_ GK]LD0[&H#]L*
MF'=O*P  @ !]_P  @ "  $Y+H@MO<40KH&MP3CDSGL5Q$2TKG4QQI!^,G*5Q
M]@[ G=EQC@ UE@!U"0  @ "     @ "  $W7H&IV8$/*GM-V\#CDG2AW52SK
MFYYWD1]8FM=WG [8FZEW7@!QD]IZ5   @ "     @ "  $USGQ-]54-_G8-]
MHCBKF\]]L"RWFC=]GA\FF5U]C [1F>5]M0"PD@E^S@  @ "     @ "  $TD
MG@.$64-*G'.$<3B!FK:$,BR9F0B#WQ\*F!*#Y ZJF'>#>P"UD)F >P  @ "
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M<!:1AEJ^<2B0ZD[K<>"/VT(3<DN.LS0+<GZ. B0O<B&.-A$1<S^*\   @ "
M    @ "  &"FC&]1F%8'B^U4W$IWBZE7_3V<BY5:Y"\:B]==91X(C2E>^@F
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MB:MS@$:9B6=T7#O2B/UU#2_JB(QUCR)IB&AUUQ'BB1]UB )%AE5X2@  @ "
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M40  @ "  $:;G0U;G3TTG"U=K#+"FV]?CB;;FOEA)!C#F[UAZ@B7F\YB4
MC$-I40  @ !YJ0  @ "  $8'FCQB.CR$F6]CW#'VF+QE5B9 F$=FBQA'F.UG
M!@B F$QG7P  B=YN?   @ !]@   @ "  $5DE[AHZ#O=EPQJ*3%>EEAK0"6H
ME=)L"A?[EDQL2PAUE0]LKP  A\9T+P  @ "     @ "  $3%E9-OOCM*E0IP
MIS#DE%MQ7R5,D[YQTQ>XE !QT B2DBER9   AA!Y9P  @ "     @ "  $0[
MD\)VG#K/DUIW.3""DJYWEB3XD@%WO!=HDAYWF0B"C])XFP  A+)]R@  @ "
M    @ "  $/)DD%]D#IMD?9][3 RD4]]^"3#D(A]VA="D'-]R A2C?!^>
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M8DJ#,E*D9&V#04=]9B&#!SM#9TR"LRVK9[."BAWL9NJ"MPN*;ER">P  @ "
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M:C^&\D=O; &&Z3S<;4&&>#$Y;<Z%\R01;62%VQ00;J2%N 11>+6"ZP  @ "
M    @ "  $SOC:!*UT-@C6I.-CC5C8-1:2R]C?]41!Y5CU]65PR D=U6]@
MB8I<-   @ !LK0  @ "  $N3B<M1E$(XB>94BS>UBA=74"O%BG]9OAV9BYA;
M; PYC15;U@  ADY@WP  @ !QC@  @ "  $J%A?I89T$<ADM:Z3:\AI1=/"K7
MAO-?.QS<A]1@A ODB)Y@OP  @U1EN@  @ !VB   @ "  $F-@E1?1T 7@LAA
M3S6K@R-C*RH!@X%DOQP@A#%EJPN(A+=EP@  @*IJW@  @ !ZZP  @ "  $B;
M?O%F/#\G?X]GSC3"?_YI-RD>@$]J5QN5@,%J^ L[@6!J_0  @ !P>0  @ !^
MO@  @ "  $>Z>^)M3#Y-?+!N<#/^?39O:"AQ?7UP(AK[?:9P; L3?H9PAP
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M#0  @ "  #\WE;Q/!#94E8Y1V2PLE9E48B!+ED!69A%NF*%7+P,)E159/P
M@:YD0   @ !U 0  @ "  #Y!DA95>#4ZDAE7X2L>DCY: A\ZDM=;H!"@E,-<
M'P+2D,]>+@  @ !I(P  @ !Y=   @ "  #UOCGU;_310CI]=]BH8CM5?J1YG
MCV1@Z __D-=A*@*JC09C.@  @ !N5@  @ !]6   @ "  #R:BQ1BFC-TBVED
M)BE$BZUE=!V9C")F2P^GC1!F9P*9B<5HAP  @ !T!   @ "     @ "  #O+
MA_)I73*FB(=J@2B0B.5K:QT&B4)K\0\_B:1KU@*FAP-N,   @ !Y.P  @ "
M    @ "  #L5A2EP*3'TA?YP[R?XAG=Q>1R-AK]QM [GAJYQA@*6A,5T4P
M@ !]F   @ "     @ "  #I\@KMW"C%=@\]W?"=VA&5WKAPNA)=WJ ZCA$EW
MD@)N@P)Z*P  @ "     @ "     @ "  #H-@*I^)S#G@?9^3R<+@JQ^,1OC
M@LQ^ 0Z1@EQ^+@*)@8A^_P  @ "     @ "     @ "     __\  /__  #_
M_P  ;69T,@     $ PD   $                    !
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MZM3KY>SU[@3O$O @\2SR./-#]$[U6?9C]VKX;OEO^FS[9/Q6_43^+_\7__\
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MYGU5DE*%*GUU>P>$AGW&8\2#\7XU3(^#>'[I-9*#*(  [#V'?8C+UA2&<(=
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MNI6\842?I)*)4=6:?H]50OF5.(P4-.V/OXC!*&F)]X5NGRZSNJ>PC]:N>J-
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M,N"!6H!)WU&!08U!RL& V8MNM9: @HFXG\6 38@^B;* +H;P<Y2 *86^78^
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M>GYR>(6,HGYY936*V7ZE4A2)#W[G/SN'1W];+2N%=( ,P5F3HHA_KZ*1;X=
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M9Z^SPIF[6QRM-98.3K.FEY*!0K*?UX[Z-WR8RHMY+5B1D(@.)-J*583O@(?
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M9B>!.(;.4N*! X5>/]Z [H/8+9V ]H(>PPZ"I)A L4Z!]I6^GN"!99,VB]N
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M++.!V'N;O$F MG4;J\F AW8 FF. 7W;:B$N 1G>V=;* .WBB8NZ 1'FG4%N
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M%HIQ:JV">HC<6;^" X=522.!EH6\..:!2H0$*;F!%H(<JG:$G9?QFSF#P)7
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MSJ@_@R^37J2&=6>0T:!+9T:.19O+62J+X)=)2T2)H9+!/?N'8XXM,6.%0(F
M)C2#)83TB("F;&FG?%&B^&N!;Z.?I6U=8G:<26]'5068RG%01Y65*7.%.J&1
M9G7B+CN-?WB0(R&)@'N3B!*E5W%L>_RAZ')S;T>>@G.-8B.;%G3#5+R7E'8<
M1U^3^W>=.H200WD^+D^,;WL<(WF(A'TQAZ"D"GCR>VN@JGE%;LR=1'FK8:B9
MW7HR5%>69GK91Q>2WGNB.F"/.'R +ER+>GV'(\:'J'ZLAQ:BQ(!*>LV?;(
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M)H^ J8,,DT>%7YZ!AC*$>9OB>&B#@9C3:A^"DY5^6[F!U)(A36Z!1HZ\/[B
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M+&Y[6?^#NG"J2]&#6'+Z/@^# W5L,-""T7@@)-:"PWLAC>F#P'!1@:R#5G'
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M?H+\:KF/OH+/7^F-XX)[5,6+]H(029F*#H&J/J*(+X%5-"N&9($+*G6$KH#
M(C6#%(!W=)N0AHG*:D..U(D+7W>,_8@,5%F+%(;G23V)-H7#/F>'9X2J-"N%
MGX.;*HB$"8*!(F."DH%J=#R/T9!L:@B.*8\H7S^,2HUT5!Z*3XM]20F(;XF2
M/BV&MX>V- .%!H7I*I2#@80+(HB"*((U<_*/29;6:<&-GI4(7O6+N9*:4]F)
MN8_72-.'V(TB/@N&)8I_,_:$AH?L*IN#&852(J:!TX+;;4*B;UZP8WB?I&&
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M(DV!KGUJ> >!(GB=;8Z ^GED8IN QWH65T6 DWJ]2]F ;'MM0%6 ;'PO-7*
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M46[81A2(_7$?.WR'KW.,,8&&9W8;*$*%.WCB(&J$,7O&;CN+\&^"9).*YG$
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MLX!N)DB$%(!I(#>"J8!?8BJ/SX;P68Z.4X:$4)N,CH7!1WV*F(37/FZ(J(0
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M']^"/7R(9<> QW$L7/& XW*@4\* X'0-2E> RG5Z0-^ OG< -W. RWB>+KN
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M?GA.0(!4<#Q3UX!"8:A9IX T4OQ?R8 T1+=F-X \-Q5L^H!3*NASS8!YE^)
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MZ76/)0V ''B['QR!27OG7G!V3VP?5DYWF&X&3>-XP6_S149YW''J/*5[!G0
M-!=\3G8V+$)]HWB!)3!_$7KJ'VN ;GU'7:5SY'++59=U;'0A34=VSG5N1,)X
M(7;!/$%Y?G@H,_IZ]'FN+$5\@7M&)5-^*'SI'ZU_MWYZ7/1QR7E$5/)SCWH(
M3+=U*'JR1$YVJWM9.^IX-7P4,]!YV'SF+%U[A7W*)7E]7WZO'^-_'W^ 7&9P
M G^,5(AR!W_'3&=ST7_&1!EU<W^R.\=W''^[,Z9X['_=+$)ZP8 4)8]\O(!
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M'=""MGO'51%_*6H-3<%_JVPF1CE__FY,/I> ,7""-PJ 87+A+YN I'5?*.B
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M_P  __\  /__  !M9G0Q      ,$(0   0                    $
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M@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,7_J#0J_Z8^/_^Q-TKYOC!2Y\\O5='B+&C
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MY)EGA]R6<9+5DWN<SY"$I,N.C*O(BI"PQ8>4M,.$F+?"@9NYP7^>NL%]HKO
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M&+?V*2NI]S,\G?8\2Y'W1%B&]DUB??!6:G;K7G%NYV1V:N1K>F;B<GUDX'>
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M9W*PK6U^IZ=SB9ZA>I*6G8"9CYJ(GXF7D*2$E)BH?Y.BJGR2K:MZDKJL>Y'
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MJ9]S>Z&:>H2:EH&+E)*(D8Z/D):)C)F:A(JBG8&*K9]_BKN??HK(GG^)R9V
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M2CW_E4L\_YQ,//^?3#S_GTP\_Y],//^?3#S_GTP\_Y],//^?3#S_GTRWO ,
MJ<L" )S; P"2_Q "B?\="(#_*A!U_S$8:_\X'V+_/B1;_T0I5/]*+%#_42],
M_U<R2?]<,T;_8#5$_V4V0O]I-T'_;C@__W,Y/?]W.CS_?#L[_X(\.?^'/3C_
MC#TW_Y,^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3ZJQ   G-(
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M7T/RNU]"\\Q@0?/G8$'SZ&!!\^A@0?/H8$'SZ&!!\^A@0?/H8$'SZ&#>IP(
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MV[PY$<ZW12##LD\PN*Q7/J^G7TJFH655GIUL7I>9<V:0E7ILBI*!<H60B7>
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M23G\XTDY_.-).?SC23G\XTDY_.-).?SC23G\XTG'K0  M[<" *K# @">T 0
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M0T'IND1 ZLU$0.KD1$#H]41 Y_A#0.?X0T#G^$- Y_A#0.?X0T#G^$/-HP
MO:X! +"X 0"DQ ( F= % (_A"@")\1H!@?$H!7CR,@QP\CL3:?)#&6+R2A]<
M\U C5O-7)U+S7BM/\V4M3/1L,$GT<S)&]'LT0_2$-D'UCC<^]9DY/?:D.COV
ML#LZ][\\.?C//#CWZ#PX]^P\./?L/#CW[#PX]^P\./?L/#CW[#R_J@  L;,
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M&B+_JALA_ZT;(?^M&R'_K1LA_ZT;(?^M&R'_K1N:O@  B\H  '[7  !PXP
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M5$RXOU1+N=A42[?M5$JV^55*L_Y62K/^5DJS_E9*L_Y62K/^5DJS_E;ZAP(
MUI@  ,FE P"]KP, L[@! *G"! "AS0@ FM 6 )+0* 2*SS8,@<Y!%7G,2AYR
MRU(F;,I:+6;)83)AR&@W7,=O/%C&=C]5QG]#4<6)14[%E$A+Q:!*2<6N2TC%
MOTM'QMA+1\7M2T;#^4U%PO].1<+_3D7"_TY%PO].1<+_3D7"_T[?D   S)\
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M+S?SYR\V\?,O-O'S+S;Q\R\V\?,O-O'S+S;Q\R^YIP  J[   )^[  "2Q@
MAM ! 'O=!0!T]Q$ ;?<< 6;X)@-?^"\&6ODX"E3Y0 Y0^D<13/I.%$C[519%
M^UL80OMB&D#\:!P]_' =.OUX'SC]@B V_8TB-/Z8(S+^I"0Q_[$E,/^_)B__
MSR8N_^,F+O_C)B[_XR8N_^,F+O_C)B[_XR:MK0  G[<  )+"  "&S0  >=H
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M5X)O_5>";_U7@F_]5X)O_5?_8!4!_VX1 ?][$P#_AA0 ]H\6 .>6& #;G!P
MSYLM!,67.PV\DT<8M(Y1(ZV*62RGAF$TH8)I.YQ_<$&7?'=&DWE^2X]WAD^+
M=8Y2B'.7581RH5B"<:Q:?W&Z7'YQS%Q]<N=;?7+V6GQR_%E\<OQ7?'+]5WQR
M_5=\<OU7?'+]5WQR_5?_8A0!_W$1 ?]]$0#_B!( \I(2 ..:$@#5GQD RIXK
M!,&;.0RXET47L))/(JF.6"NBBE\SG(9G.I>#;D"2@'5%C7Y\2HE\A$Z%>HQ2
M@GB55GYWGUA[=JI;>76X7'=UREQW=N5<=W?U6G=V^UEW=OQ8=W;\5W=V_%=W
M=OQ7=W;\5W=V_%?_9!(!_W,0 /^ $ #_BQ  [Y4. -^>#0#0HA< QJ$I [V>
M-PNTFD,6K)9-(*225BJ=CEXREXME.9*(;$"-A7-%B(-Z2H2 @4Z ?XI2?'V3
M57A\G5AU>ZA;<WJV7'%ZQUQQ>N)<<7OS6G%[^UER>OQ8<GK\6')Z_%AR>OQ8
M<GK\6')Z_%C_9Q$!_W4/ /^##@#TC@T VYD* -2A"P#,I!4 PJ0G [BB-@JP
MGD(5IYI,'Z"75"F9DUPQDY!C.(V-:C^(BG%$@XAX27Z&?TUZA(A1=H*157.!
MFUAO@*9:;7^T7&M_Q5QK@-]<:X#R6FN ^UEL?OQ8;7[\6&U^_%AM?OQ8;7[\
M6&U^_%C_:1 !_W@. /^%# #BD@@ U9L) ,ZC"0#'J!( O:@E K2F- FKHD 3
MHY]*'IN;4B>4F%HPCI5A-XB2:#V"D&]#?HYV2'F,?4QUBH50<8B.5&V'F5=J
MAJ199X6Q6V6%PEMEA=Q;987P6F:%^UEG@_Q89X/\5V>#_%=G@_Q79X/\5V>#
M_%?_; X _WL, /*)"0#9E08 SYX( ,FF" #!JQ  N*LB J^J,@BFISX2GJ1(
M'):A426/GE@NB)M?-8*99CQ]EFU!>)1T1G.2>TMOD(-/:X^,4F>.EE5DC:)8
M88RO65^,P%I?C-E97XSN65^,^UAABOU788G]5V&)_5=AB?U788G]5V&)_5?_
M;PP _W\) -^- P#2F 8 RJ(& ,*I!@"ZKPX LK @ :FN+P:AK#P0F*E&&I&G
M3R.)I%8L@Z)=,WV?9#EWG6L_<IMQ1&Z:>4AIF(%,99>*4&&5E%->E:!56Y2M
M5UJ4O5A9E-17693L5UF3^59;D?Y56Y#^55N0_E5;D/Y56Y#^55N0_E7_<PD
M]80$ -B1 P#,G 4 PZ4% +NM! "SLPP J[4< :.T+ 6;LCD.DK!$%XJM32"#
MJU0I?:E<,'>G8C9QI6D\;*1O06BB=T5DH7])7Y^(3%R>DD]8GIY25IVK4U2=
MO%13G=%44YWK4U.<^%-4FO]35)G_4U29_U-4F?]35)G_4U29_U/_> 8 X8D
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M/T2^]D%#O?]"0[S_0T.\_T-#O/]#0[S_0T.\_T/6C0  QIL  +BE  "MK@
MHK8  )B_ @"-R 8 @]$+ '_2&@!YTBH#<M(W"&S10@]FT4L58=!3&ES/6Q]8
MSV(C5,YI)U'.<2I-SGHM2LZ#,$C.CC)%SIHT0\ZH-4+.N#9!S\TU0<[H-4#-
M]3<_R_XY/LO_.3[+_SD^R_\Y/LO_.3[+_SG*E@  O*(  *^J  "CLP  F+P
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M&RO[ZQLK^^L;*_OK&RO[ZQNHJ@  FK0  (V_  " R0  =-,  &?>  !>\@@
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M3VE[OE!H?-50:'SM3VE\^TYI?/]-:GO_3&I[_TQJ>_],:GO_3&I[_TS_9@H
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M2%&7]4A1E_]'49;_1U&6_T=1EO]'49;_1U&6_T?V=P  V(4  ,F1  "_FP$
MM*(  *NH  "AL   FK(1 )2S(@&-LC %A;$\#'ZO1A1XKDX;<JQ6(6VK7"=H
MJ6,L9*AJ,&"G<31<IGDX6*6".U6DC#Y1HYA 3Z.E0DVCM$-,H\A#3*/D0TNA
M]$-+H/]$2Z#_1$N@_T1+H/]$2Z#_1$N@_T3C?0  SXL  ,*6  "WGP  K:8
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M+CS%_RX\Q?\N/,7_+CS%_R[$DP  MI\  *FF  "=K@  DK<  (:_  ![QP,
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M"1S_W0F8L   BKH  'S$  !OS0  8M@  %7>  !)Y   1/L% #__#@ [_Q4
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M3"8"_T\O _]0.07_3D,'_TQ/"_]*6P__2&83_T5Q%OQ#?!GZ0H8;^$&.'/9
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M0WAJOT1V:M1%=FOM0W9K^T)V:_]!=FS_0'9L_T!V;/] =FS_0'9L_T#_70H
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M0V!]]D)@??]!87W_0&%]_T!A??] 87W_0&%]_T#_9P  XW0  -)_  #'B $
MOH\" +:5 0"NF 8 IIH5 )^:)@*8F3,&D9<_#(N52!2%DU :?Y%8('J/7R5V
MC64J<HML+FZ*<S)JB'LV9H>$.6.&CCQ@A9D_782F05N$M$):A,=#6H3C0EJ#
M]$%;@_] 6X/_0%N#_S];@_\_6X/_/UN#_S__:@  WG@  ,V#  #"C   N9,
M +"8  "GG0( H)\2 )F?(P&3GC$%C)T\"X6;1A)_F4X8>I=6'G6672-PE&,H
M;))J+&B1<3!ED'DT88Z"-UZ-C#I:C)<]6(RD/U:+LD!4B\5 5(OA0%2*\S]5
MBOX_58G_/E6)_SY5B?\^58G_/E6)_S[O;P  UGP  ,B'  "]D0  M)@  *J<
M  "@H@  F:00 ).E( &,I"X#A:,Y"7^B0P]YH$P6=)]3&V^=6B!JG&$E9IIH
M*6.9;RU?F'<P6Y> -%B6BC=5E94Y4I6B.U"4L#U/E,,]3Y3?/$^3\CQ/DOT\
M3Y+_/$^1_SQ/D?\\3Y'_/$^1_SSD=   SX$  ,*,  "XE@  K9P  *.A  "8
MJ   D*H- (NK&P"%JRH"?JHV!GBI00QRJ$D2;:=1&&FF6!QDI%\A8*-F)5VB
M;2E9H74L5J%^+U.@B#)/GY,U39^@-TN>KSA*GL$X29[=.$F=\#A)G/PX29O_
M.4F;_SE)F_\Y29O_.4F;_SG;>@  R(<  +R2  "QF@  IJ   )RF  "1K
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M&C/._QJSF0  IJ$  )JI  ".L0  @;D  '7   !JQP  7LT# %34" !,W0T
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M QO^B009_I@$&/^H!!?_MP06_\@$%O_@!!;_Y 06_^0$%O_D!!;_Y 23K@
MA;<  'C   !JR0  7=(  %#9  !$WP  .N0  #7W P R_PP +O\2 "O_&@ H
M_R$ )O\G "/_+0 @_S, 'O\Y 1S_/P$9_T4!%_]- 17_50$3_U\!$?]J A#_
M> (._X<"#O^6 @W_I (,_[ "#/^^ @S_P@(,_\("#/_" @S_P@*'M@  >;\
M &O)  !>TP  4-L  $/@   XY0  +_   "O_   G_P@ )/\. "'_$P >_QD
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M-8E:P3:'6M8VAEOM-H5;^S6%7/\TA%S_,X1<_S.$7/\SA%S_,X1<_S/_4PH
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M.FUK]3AM:_\W;6O_-FUK_S9M:_\V;6O_-FUK_S;_6P  ZV<  -EQ  #,>0
MPWX" +N" P"TA D K848 *:%* &?A#4%F8) "I-_21"-?5(6B7M9&X1Y8!^
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M-5A^_S58?O\U6'[_-5A^_S7I:   U'0  ,9^  "[AP  LHT  *B1  ">E
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M*4"@_RG)?@  NHL  *^4  "CF@  F*   (VE  ""J@  =;   &RS# !IM!@
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M#3++H@XQR[(/,,S'#S#+Y0XOR?4/+LC]$2['_Q(NQ_\2+L?_$B['_Q*NEP
MH9X  )6E  ")K0  ?+0  '"[  !DP0  6<8  $[+ P!%T @ /M4. #W5&@ \
MUB8 .]<Q #G8.P XV44!-ME- 3795@(SVEX",=IH S#;<P0NVW\%+-N-!2K<
MG08IW*T&*-W!!BC=W@8GV^\')MGY"";8_@DFV/X))MC^"2;8_@FDG0  F*4
M (NM  !^M   <;P  &7#  !9R0  3<T  $/3 0 ZV08 ->0- #/D%@ QY"
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M 07_H $$_ZX!!/^\ 0/_QP$#_\<! __' 0/_QP&#M   =;T  &?&  !:SP
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M(Z%)QB2?2MXDG4KP))M*_2692_\DF4O_))A+_R282_\DF$O_))A+_R3_2 P
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M+GI;]2UZ7/\L>5S_*WI<_RIZ7/\J>ES_*GI<_RK_40  \EL  -YD  #/:@
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M+65K_RQE:_\L96O_+&5K_RST6P  W68  ,MO  # =@  MWL  *]^  "F?@$
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M*4^ _RG;:@  QW4  +I_  "PAP  IHP  )R/  "/D0  AI,% ("4$@![E2$
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M'$"?HAT^G[(>/9_&'CV?XQT]G?0>/9S_'SR;_Q\\F_\@/)O_(#R;_R#"?
MM8@  *F0  ">E@  DYL  (>?  ![I   ;Z@  &.L! !?K1$ 7*T? %JN*P!7
MKC8!5*Y  U&M2 5.K4\'2ZU7"4FM7@M&K&8-1*QN#T&L>!$_JX03/*N1%3JK
MH!8YJ[ 7.*O#%SBJX1<WJ?,8-Z?^&3:F_QHVIO\:-J;_&C:F_QJZA   KH\
M **6  "7FP  BZ$  '^F  !SJP  9Z\  %JT  !3M@P 4;<7 $^W) !-N#
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M B'5T@(@T^L"(-+V Q_1_P0?T?\$']'_!!_1_P2?FP  E*(  (>I  !YL0
M;;@  &"^  !4PP  2<<  #[+   UT $ +=4& "7;"P DWA( (]X< "+?)0 A
MX"X (. W !_A0  >X4H '>)3 !SC7@ ;XVH &N1X !CDB $7Y9H!%N:L 17F
MP $4Y]T!$^7O 1/C^@$3X_H!$^/Z 1/C^@&6H@  B:D  'NQ  !NN0  8<
M %3&  !(R@  /<\  #/3   JV0  (MX" ![K"@ <[!  &^T7 !GM'P 7[B8
M%>XM !3O-0 3\#T $?!& !#Q4  /\EL #O)I  WS>  ,](H "_6<  KUK@ )
M]L( "?;9  CU[0 (]>T "/7M  CU[0"+J0  ?;(  &^Z  !BP@  5<D  $?.
M   [T@  ,=@  "?=   ?X0  &>@  !;X!@ 4^@T $OL2 !#\%P ._!T #?TC
M  S]*0 *_C  "/\X  ;_00 #_TP  /]8  #_9@  _W<  /^)  #_FP  _ZL
M /^[  #_S@  _\\  /_/  #_SP!_L@  <;H  &/#  !6RP  2-$  #K6   O
MW0  )>$  !SE   4Z0  $?<   __ 0 -_PD "_\-  C_$  &_Q0  _\8  #_
M'@  _R,  /\J  #_,@  _SP  /]'  #_5   _V,  /]S  #_A0  _Y<  /^D
M  #_L@  _[(  /^R  #_L@#_(BD!_R,G ?\C* '_("L!_QPQ ?\:/0'_&$D!
M_Q96 O\48@+_$VX"_Q)X O\2@@+_$HL"_Q*2 O\2F0+_$IX"_Q*D O\2J0+_
M$J\"_Q*V O\2O0+_$L<"_Q+4 OT2Y0+Z$O$"]Q+Z O43_P+T$_\#]!/_ _03
M_P/T$_\#]!/_ _03_P/_)"<!_R8D ?\F) '_)"<!_R(O ?\@.@'_'D8!_QQ3
M O\:7P+_&&H"_Q=U O\7?P+_%X@"_Q>/ O\7E@+_%YP"_Q>A O\7IP+_%ZT"
M_Q>S _X7NP/]%\4#^A?1 _<7Y +T%^\"\1CZ N\8_P/N&/\$[AC_!.T8_P7M
M&/\%[1C_!>T8_P7_)R,!_RD@ /\I( #_*", _RDM ?\G-P'_)4,!_R-/ O\A
M6P+_'V8"_QUQ O\=>P/_'80#_QV, _X=DP/\')D#^QR? _H<I /Y'*H#]QRQ
M _8<N0/U'<(#\QW. _ =X0/L'>X#Z1[Y!.@>_P7F'O\&Y1[_!N4>_P?E'O\'
MY1[_!^4>_P?_*Q\ _RT< /\M&P#_+B  _R\I /\O- '_+#\!_RI+ O\H5P+_
M)F("_25M _HD=P/X(X #]B.( _4CCP/S(Y4$\B.;!/$CH03O(Z@$[B.N!.TC
MM@3K([\$ZB/,!.<CX 3C).T$X"3Y!MXD_P?<)/\(VR3_"=HD_PG:)/\)VB3_
M"=HD_PG_+AL _S$7 /\R%@#_-1P _S8E /\V+P'_-#H!_S%& ?LO4@+W+5T"
M\RQH _ K<@/N*GL$["J$!.HJBP3H*I(%YRF8!>8IG@7D*:4%XRFL!>$IM 7@
M*KT%WBK*!=LJW@76*NT'TBKX"<\K_PK-*O\+S"K_#,LJ_PS+*O\,RRK_#,LJ
M_PS_,A< _S42 /\X$@#_.Q@ _ST@ /\\*@#^.S4!]SE! ?$V30+L-%@"Z#-C
M ^4R;03C,G8$X#%_!=XQAP7<,(X&VC"5!M@PFP?6+Z('U"^I"-(OL0C0+[H)
MSS#&"<TPV G),>H*QC'W#,,Q_P[!,?\/P#'_#[\Q_P^_,?\0OS'_$+\Q_Q#_
M-A, _SD/ /\^$ #_010 _T,: /]"(P#U02X [3XZ ><]1@'A/%,"W3I> ]DY
M: 34.'$&T3AZ!\\W@0C--X@)RS:/"LHVE@K(-IT+QC6D#,4UK S#-;4-P37
M#< VSPZ]-N8.N3;T$+<V_Q&U-O\2M#;_$[,V_Q.S-O\3LS;_$[,V_Q/_.1
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M'HU*]AZ+2_\>BTO_'8I+_QV*2_\=BDO_'8I+_QW_10  _TT  .54  #960
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M(F];_R)O6_\A;UO_(6];_R'Z3P  X5H  ,]B  #$9P  NVL  +-L  "L:@0
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M(EQJ_R+C6P  SF8  ,!N  "V=   K'D  *-[  "8>0  D'H+ (I[%@"%?"0
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M'TU^HB!+?;$A2GW$(DI]X2%+?/0A2WO_($M[_R!+>_\@2WO_($M[_R#09P
MP'(  +1[  "J@@  H(8  )6(  "'B   ?(H  ':,#@!RC1H ;HXG &J.,@%F
MC3P#8XU$!6",3 A<BU,*6HM:#5>*81!4B6@248AQ%4^(>A=,AX4:2H:2'$B&
MH!U&AJ\>187"'D6%WQY%A/(>18/^'D6"_QY%@O\>18+_'D6"_Q[*;0  NG@
M *^!  "EAP  FHL  (^-  "!C@  =)$  &Z3"@!IE!4 9I4B &.5+@%@E3@"
M7)5!!%F42096E% (5)-7"E&37@Q.DF8/3))N$4F1>!1&D(,61)"0&$*/GAE
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M#S.EU \SI.X/,J+[$#*A_Q$RH?\1,J'_$3*A_Q&T@@  J(P  )V2  "2EP
MAIP  'FA  !MI0  8:D  %6L  !+KP4 1[ 0 $6P' !$L2< 0K$R $&R.P _
MLD,!/;)+ 3NR4P(YLEL#-[)D!#6R;@4SLGD&,;*'!R^QE@@NLJ8(+;*X"2RR
MT @LL.P)*Z_Y"BNN_PLJK?\+*JW_"RJM_PNMBP  H)(  )68  ")G0  ?:,
M '&H  !DK0  6;$  $VT  !"N   .[H* #B[$P WO!X -;PI #2],@ SO3L
M,KU$ #&^3  OOE4!+KY> 2R^: $JOG0"*;Z" B>_D0,FOZ(#)+^T R._RP,C
MON@#([SW!"*[_P4BN_\%(KO_!2*[_P6DD@  F)@  (R>  " I0  <ZL  &>P
M  !;M0  3[D  $2\   ZP   ,,0$ "K'"P HR!, )\D= ";))P ER3  ),HY
M "/*0@ BRTL (<M5 "#,7P ?S&P '<UZ !S-B@ ;S9P &<ZN 1C.Q0 8S>0
M&,ST 1C*_ $8RO\"&,K_ AC*_P*;F0  CY\  (*F  !UK0  :+,  %RY  !0
MO0  1,$  #G$   PR   *,P! "#0!@ 9U0L %M<0 !78&0 5V2( %-DK !/:
M-  3VCT $MM( !'<4P 1W5\ $-UM !#>?@ .WY$ #N"D  W@N  ,X-( "]_M
M  S>]P ,W?L #-W[  S=^P"2GP  A:<  '>N  !JM0  7;P  %#!  !$Q0
M.,D  "[-   ET0  'M4  !;: 0 1W@8 $.<-  [G$@ -Z!D #.@A  OI*0 *
MZC$ ">H[  ?K10 %ZU$ !.M>  /K;@ !ZX   .J4  #JIP  Z[P  .O2  #K
MZ0  [.\  .SO  #L[P"'IP  >:\  &NW  !>O@  4<4  $/)   WS0  +=$
M "/6   ;VP  $]\   [C   ,[@( "O8*  ?V#@ %]A(  _88  #U'@  ]24
M /4N  #U-P  ]D(  /9.  #V70  ]FX  /:!  #VE0  ]Z<  />W  #XQP
M^-   /C0  #XT ![KP  ;;@  &#   !2R   1,T  #?1   KUP  (=P  !C@
M   1Y   #.<   ?O   $^@   ?\#  #_"   _PT  /X0  #^%   _QH  /\A
M  #_*0  _S,  /\^  #_2P  _UL  /]L  #_@   _Y(  /^A  #_K0  _[,
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M >,9U0'?&N@!W!OU M@;_P+5'/\#U!S_ ],<_P32'/\$TAS_!-(<_P3_*1<
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M#*8V^ VE-O\.HS?_#J(W_PZB-_\.HC?_#J(W_P[_-P< _SL" /]  P#R0@4
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M%WU+_Q=]2_\6?4O_%GU+_Q;_0P  YDP  -93  #)6   P%D  +I8 0"T5@D
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M&65:_QGH3P  TUD  ,1A  "Y9@  L&@  *=I  ">90  EV8- )%G&0",:"<
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M&EEFHAM79K <5F;#'59FWQU69O,<5V;_&U=F_QI79O\:5V;_&E=F_QK;60
MQV(  +IJ  "O<   IG,  )IS  "/<   AW$% (%R$0!\<QX >',J '1S-0%P
M<S\#;7)'!6IQ3@=G<54)9'!<"V)O8PY?;VH076YR$EIM?!58;8875FR3&51L
MH!M2:Z\<46O!'%%KW!Q1:_$;4FO^&E)J_QI2:O\94FK_&5)J_QG47   PV8
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M%D" TA9!?^T607[[%D%]_Q9!??\607W_%D%]_Q;":@  M74  *I]  "?@@
MDH,  (6$  !YA0  :HD  &2* P!@C!  78T; %N.)P!8CC( 58X[ 5..0P)0
MCDH#3HU2!4R-609)C& (1XQH"D6+<@Q"BWT.0(J)#SZ*F!$\BJ<2.XJX$CJ*
MSQ([B.L2.X?Z$SN&_Q,[AO\3.X;_$SN&_Q.\<0  KWL  *6#  "9AP  C(@
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M!"6H_P4EI_\%):?_!26G_P6GB0  FX\  )&4  "$F0  >)X  &NB  !?I@
M4ZH  $BM   ]L   -+,# "^U#@ MM18 ++4@ "NV*0 JMC( *;<Z "BW0P G
MMTP )KA5 "2X7P CN&L (KAX 2"XB $?N)D!';FK 1RYP $<N-\!'+;R 1NU
M_ (;M/\"&[3_ ANT_P*?CP  E)4  (B;  ![H0  ;J8  &*K  !6L   2K,
M #^V   UN0  ++P  "2_!@ ?P@T '<(4 !S"'@ ;PR8 &L,O !G$.  8Q$$
M%\1* !;%50 5Q6$ %,9O !/&?P 2QI$ $<>D !#'N0 /Q]0 $,;N !#$^@ 0
MP_\ $,/_ !##_P"7E@  BYP  'ZB  !QJ0  9*\  %BT  !+N   0+L  #6^
M   KP0  (\4  !O) 0 4S 8 $- +  [1$0 -T1D #=$A  S1*@ ,T30 "](^
M  K220 )TU4 "=-B  C3<@ &U(0 !=28  34JP #U<   =7<  '5[0 !U?8
M =7V  '5]@".G0  @*0  '.K  !FL0  6;@  $R]   _P   -,,  "K'   A
MR@  &<X  !+2   -U@$ "=L%  ;<#0 $W!$  ]T8  '>(   WB@  -\Q  #@
M/   X4<  .)4  #C8P  XW0  .2(  #DFP  Y:X  .7!  #EU0  YN<  .;G
M  #FYP"#I   =:P  &BS  !:NP  3<$  $#$   SR   *,P  !_0   7U
M$-D   O=   %X0   .0   #E!P  Y@T  .<1  #H%@  Z1T  .HE  #K+@
M[3D  .]%  #P4P  \60  /%V  #RB@  \YP  /.M  #TNP  ],@  /3(  #T
MR !WK0  :K4  %R]  !/Q   0,D  #/-   GT0  '=8  !3<   .X   ".,
M  'F    Z@   .X   #N    [P0  / *  #Q#@  \Q(  /08  #V(   ^"H
M /HU  #]0P  _E(  /]C  #_=@  _XD  /^:  #_I@  _[   /^P  #_L #_
M%B, _Q4A /\1(0#_#20 _PDK /\&-P#_ T0 _P!1 /\ 70#_ &@ _P!R /\
M>P#_ (, _P"* /\ D0#_ )8 _P"< /\ H0#] *8 ^P"L /D LP#W +L ]0#%
M /, T0#R .0 \0#Q .\ ^@#N /\ [@#_ .T _P#M /\ [0#_ .T _P#_&2
M_Q@= /\5'0#_$!\ _PXI /\,- #_"D$ _P=- /\%60#_!&0 _P1N /\#=P#_
M X  _P.' /\#C0#] I, ^P*9 /D"G@#W J0 ]0*J /,!L #Q ;@ [P'" .T!
MSP#K >, Z@'O .@"^P#G!/\ Y@7_ .8&_P#F!O\ Y@;_ .8&_P#_'!L _QL9
M /\7& #_%1T _Q,E /\1, #_$#T _PY) /\,50#_"V  _PMJ /T+<P#["WP
M^0J# /<*B@#U"I  ] J6 /,*FP#Q"J$ [PFG .T)K@#K";8 Z G  .8)S0#D
M">( X@KP -\+^P#>#/\ W W_ -P-_P#;#?\!VPW_ =L-_P'_'Q< _QX3 /\;
M$@#_'!D _QLB /\8+ #_%3@ _Q-$ /X24 #Y$5L ]1!F /,0;P#P$'< [A!_
M .P0A@#J$(P Z1"2 .@0F #F#YX Y0^E .,/K #A#[0 X ^^ -X/S #:$.$
MU1'P -(2^P#/$O\!SA/_ <T3_P'-$_\!S!/_ <P3_P'_(A( _R(/ /\A#P#_
M(A0 _R(< /\@)P#_'3( ^!L^ /(92P#N&%8 ZA=@ .<6:@#D%G( XA9Z . 6
M@@#>%H@ W!:/ -L6E0#9%IL UA:B -06J0#2%K$ T!>[ ,X7R0#,&-X R!GN
M <4:^P'#&O\"P1O_ L ;_P+ &_\"P!O_ L ;_P+_)@X _R4+ /\H# #_*1
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M"I(W_PJ2-_\*DC?_"I(W_PK_,P  ]CH  .0_  #80@  SD(! ,D^!@#$.P\
MNSX= +4_+ "Q/SH K3]% :D_3P&F/E@"HSU? Z$]9P2?/&T%G3QT!IP[>P::
M.X('F#N*")8[DPF5.IP*DSJF"Y$ZL@N0.\ ,CCO5#(P\[ V*//L-B3S_#8D\
M_PR(//\,B#S_#(@\_PS_-P  ZC\  -Q%  #.20  Q4D  +]& @"Z0PP LT09
M *U%)P"H1C4 I$5! :!%2P*=1%,"FD-; YA#8@660FD&E$%P!Y)!=@B00'X)
MCD"&"HU C@N+0)@,B4"B#8= K@Z%0+P/A$#/#X)!Z0^!0?D/@$'_#X!"_PZ
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M$'%+_Q#L0P  V4P  ,A3  "]5P  M%@  *Q7  "E4@$ GE,/ )A4' "35"D
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M$F-5H11B5:\5857!%F!5VQ9@5O$58%;^%&!6_Q-A5O\285;_$F%6_Q+@30
MRU8  +U=  "R80  J&,  )UA  "570  C5X) (=>$P"#7R  ?U\L 'M?-P%W
M7D "=%Y( W%=3P1O7%8%;%Q<!VI;8PEH6VL+9EIS#61:? ]B6H<18%F3$EY9
MH!1=6:X56UF_%EM9V!9;6>\56UG]%%Q9_Q-<6?\27%G_$EQ9_Q+<4   QUD
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M%$QGSQ1,9NL436;[$TUF_Q).9?\23F7_$DYE_Q+,6@  O&,  +!J  "E;P
MF&X  (QM  " ;   =VT  '%N"P!M;Q0 :7 A &9Q+ !D<38!87$^ 5YQ1@)<
M<$T#67!4!5=P6P95;V((4V]J"E!N<PQ.;GX.3&V*$$IMF!%);*<22&RX$T=L
MS1-';.H32&OZ$DAK_Q)(:O\12&K_$4AJ_Q''7@  N&<  *QN  "A<@  DW(
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M"S:!_PPV@/\,-H#_##: _PRV;P  JG@  )]_  "0?@  @W\  '>   !K@@
M7H<  %6*  !.C 8 2HX0 $B/&@!'CR4 19 O $20. !"D$  0)!' 3^03P$]
MD%8".Y!? CF0: ,WCW,$-8^ !3./C@8QCYX',(ZO!R^.PP<OCN$'+XST""^+
M_P@OBO\(+XK_"2^*_PFP=@  I7\  )B$  "*A   ?84  '"'  !EB@  6HX
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M 1.N_P&:C0  D)(  (27  !UF@  :)\  %NC  !0J   1:P  #NP   QL@
M)[4  ""X   8N@< %+P. !.\%0 2O!X $;TF !&]+@ 0O3< $+Y!  Z^3  .
MOE< #;YE  R_=  +OX8 "KZ9  B^K  'OL( ![[?  B^\  (O?H "+W\  B]
M_ "3E   AYD  'J?  !LI0  8*H  %.O  !'LP  /+8  #&X   GNP  '[X
M !?!   1Q $ #,@(  C)#@ 'R10 !LD<  7))  $RBP  \HV  +*0   RTP
M ,M9  #+:   RWD  ,R,  #+GP  R[,  ,O(  #,X@  S.\  ,SQ  #,\0"*
MF@  ?*$  &^G  !BK0  5;,  $BX   [NP  ,+X  ";!   =Q   %<@   _+
M   *S@  !-("  #3"@  TP\  -04  #5&@  UB(  -<J  #9-   VC\  -Q+
M  #<6@  W6H  -U]  #=D0  W:0  -ZV  #>R   WMX  -[B  #>X@!_H@
M<:D  &2P  !6MP  2;P  #S    OQ   ),<  !O+   3SP  #=(   ?6
MVP   -X   #? P  X D  .$.  #B$@  XQ<  .4>  #F)P  Z#$  .H]  #L
M2P  [%H  .UL  #N@   [I0  .ZE  #NM   [L(  .[&  #NQ@!TJ@  9K(
M %BY  !+P   /<4  "_)   DS0  &=$  !'6   +VP   ]X   #A    Y0
M .@   #I    Z@   .L&  #M"P  [P\  / 3  #R&@  ]",  /<N  #Y.P
M^TH  /Q;  #];0  _8   /Z3  #^H@  _JT  /ZO  #^KP#_$!\ _PX= /\*
M'0#_ 2  _P H /\ -0#_ $$ _P!. /\ 6@#_ &4 _P!N /\ =P#_ '\ _@"&
M /P C #[ )( ^0"7 /@ G #W *( ]@"G /4 K0#S +4 \@"] /$ R0#O -P
M[@#K .T ]P#L /\ ZP#_ .H _P#J /\ Z@#_ .H _P#_$QP _Q$9 /\-&0#_
M!AP _P,E /\ ,0#_ #X _P!* /\ 5@#_ &$ _P!K /T <P#Z 'L ]P"# /4
MB0#T (\ \@"4 /$ F0#P )\ [@"D .T JP#L +( Z@"Z .@ Q@#G -8 Y0#H
M .0 ]0#C /X X@#_ .$ _P#A /\ X0#_ .$ _P#_%1@ _Q,4 /\/% #_#1D
M_PLB /\(+0#_!#D _P%& /\ 40#^ %P ^@!F /8 ;P#R '< [P!^ .T A0#K
M (L Z@"1 .@ E@#G )P Y@"A .0 J #C *\ X0"X -\ PP#= -$ VP#F -D
M\P#7 /T U0+_ -0"_P#4 _\ U /_ -0#_P#_&!, _Q40 /\2#P#_$A4 _Q$=
M /\.* #_##0 _PI! /D(3 #U!E< \09A .T&:@#I!7( Y@5Z .0%@0#B!8<
MX :- -\&D@#=!I@ VP:> -D&I0#7!JT U :U -(&P #0!\\ S@CE ,P)] #*
M"_\ R S_ ,<,_P#'#/\ Q@S_ ,8,_P#_&PX _QD, /\8#0#_&!$ _Q<8 /\4
M(@#[$2X \Q Z .T.1@#H#5( Y0U< .$-90#>#6T VPUU -@-? #5#8( TPV)
M -$-CP#0#94 S@V< ,T.HP#+#JL R0ZT ,@.P #&#L\ PQ#F , 1]0"]$O\
MO!+_ +L2_P"Z$O\!NA+_ ;H2_P'_'PH _QP$ /\?" #_'PT _QT2 /@:&P#N
M%B8 YA0S . 3/P#:$TL U!-6 - 37P#.%&@ RQ1O ,D4=P#'%7T QA6$ ,05
MB@##%9$ P1:8 , 6GP"^%J< O!>P +L7O "Y%\L MQCB +,9\@&Q&O\!KQO_
M :X;_P&N&_\!K1O_ :T;_P'_(@0 _R(  /\E @#\) < ]R$, .P=$@#A&AP
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M!X(W_P?T,@  XSL  -)!  #&1   O4,  +<_  "Q.PD JCL4 *4\(@"@/3
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M"G!$H@MO1*\,;D3 #&U%V0UL1>\,:T7]"VM&_PMK1O\*:T;_"FM&_PKE0
MSTD  ,%/  "U4@  JU(  *%/  ";2@  E$H, (]+%P"+3"0 ATPO (1,.@"!
M3$,!?DM+ 7M+4@)Y2E@#=TI?!'5)9@5S26T&<4EU!V])?@AM2(@):TB3"VI(
MGPQH2*T-9TF]#69)U YE2>T-94K\#&5*_PME2O\+94K_"V5*_PO@1   RTT
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M#U95S ]65>D.5E7Y#595_PU75/\,5U3_#%=4_PS130  P%8  +-<  "G7@
MFET  (]<  "&6   ?UD  'E:#0!T6Q< <5LC &Y;+@!K6S< :%M  65;1P%C
M6DX"85I5 U]:7 1=6F,%7%IK!EI9= A867\*5EF+"U19F U36*8.4EFV#E%9
MR@]16><.45CX#5)8_PU26/\,4EC_#%)8_PS-40  O%D  +!?  "C80  EF
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M#$-F_PM#9?\+0V7_"T-E_PN_7   L60  *9J  "6:0  B6D  'UI  !Q:0
M9VH  &)L 0!=;0T 66X6 %=O(0!5<"L 4W U %%P/0!0<$4!3G!, 4QP4P)*
M<%H#2'!B!$9O:P5$;W4&0F^"!T!NCPD_;IX*/6ZO"CUNP@H\;N */6WT"CUL
M_PH]:_\*/FO_"CYK_PJZ8   K6D  *!N  "1;0  A&T  'AM  !L;@  87
M %MR  !6= H 4G42 %!V'0!.=R< 3'<Q $MX.0!)>$$ 2'A) 49X4 %$=U<"
M0G=? T!W: ,^=W,$/'9_!CIVC0<Y=IP(-W6M"#=UP @V==X(-W3R"#=S_@@W
M<O\(-W+_"#=R_PBU9@  J6\  )IQ  "+<0  ?G$  '-R  !H<P  7'8  %1Y
M  !.>P4 2GT/ $A^& !&?R, 17\L $. -0!"@#T 08!% #^ 3 $]@%0!/(!<
M CI_90(X?V\#-G]\!#1_B@0R?YH%,7ZJ!C!^O08P?MH&,'WP!C![_08P>_\&
M,'K_!C!Z_P:P;   I'4  )1U  "&=0  >78  &YW  !C>0  5WT  $^!  !'
MA   0H8, #^'$P ]B!T /(@G #N),  ZB3@ .(E  #>)2  VB4\ -(E8 3.)
M80$QB6P!+XEX BV)AP(LB9<#*HBG RF(N@,IB-0#*8;N RF%_ 0IA/\$*83_
M!"F$_P2J=   GGL  (YZ  " >@  ='L  &A^  !=@0  4H4  $F)  !!C
M.9 % #61#P SDA< ,I(A #&2*0 PDS( +I,Z "V300 LDTH *Y12 "J47  H
ME&< )Y1S 264@@$DE),!(I.D 2&3MP$@D\\!(9+L 2"0^@(@C_\"((__ B"/
M_P*D?   EX   (=_  ![@   ;H(  &*%  !7B0  38X  $*2   ZE@  ,ID
M "J<"0 HG1$ )IT9 "6=(@ DGBH (YXR "*>.@ AGD( ()Y+ !^?50 >GV
M')]M !N??  :GXT &)^? !>?L@ 6G\D %I[H !:<]P 6F_\!%YO_ 1>;_P&=
M@P  CX8  (*&  !TAP  9XL  %N/  !0DP  1I@  #R<   SH   *Z,  ".F
M   <J L &JD1 !BI&  7J2$ %JHI !6J,0 4JCD $ZI# !.K30 2JU@ $:ME
M !"K=  .JX8 #JN9  VKK  ,J\$ #*K?  RI\@ -J/P #:C_  VH_P"6B@
MB8P  'J-  !LD0  8)4  %2:  !)GP  /Z,  #6G   KJ@  (ZX  !NP   4
MLP$ #[4*  VV$  ,MA8 "[8?  JV)P )MB\ "+8Y  >W0P &MT\ !+=;  .W
M:@ "MWL  +>.  "WH0  MK0  +;+  "VY0  M?$  +7W  "U]P"/D0  @90
M '*7  !EG   6*$  $RF  !!JP  -Z\  "RR   CM0  &K@  !.[   .O0
M"< %  /!#0  P1$  ,$7  #"'@  PB8  ,(O  ##.0  Q$0  ,10  #$7@
MQ6\  ,6!  #%E0  Q:@  ,6\  #$T0  Q.8  ,3N  #$[@"&F   >9X  &NC
M  !=J0  4*X  $2S   WM@  ++D  "*\   9OP  $<(   S%   &R    ,L
M  #,!P  S T  ,T1  #-%@  SAT  ,\D  #0+0  TC@  -1$  #44@  U6$
M -5S  #6AP  UIL  -:M  #7OP  V,X  -C=  #8W0![H   ;J8  &"M  !3
MLP  1;@  #B\   KOP  (<(  !?&   0R0  "LP   +0    U    -<   #8
M    V@4  -L+  #<#@  WA,  -\9  #A(0  XRH  .4V  #G0P  YU,  .AD
M  #I=P  Z8P  .J?  #JK@  ZKH  .K#  #JPP!PJ   8J\  %6V  !'O
M.<   "S$   @R   %LP   [0   'U    -D   #=    X0   .,   #D
MY@   .<!  #I!P  ZPP  .P0  #N%0  \!T  /,G  #V,P  ]T,  /A4  #Y
M9@  ^7H  /J.  #ZG@  ^ZD  /NP  #[L #_"QL _P<9 /\ &0#_ !P _P E
M /\ ,@#_ #\ _P!+ /\ 5P#_ &( _P!K /\ <P#] 'L ^P"" /H B #X (T
M]P"2 /8 F #U )T ] "B /, J0#Q +  [P"X .X PP#L -$ ZP#F .D \P#H
M /X Z #_ .@ _P#H /\ Z #_ .@ _P#_#A@ _PH5 /\!% #_ !@ _P B /\
M+@#_ #L _P!' /\ 4P#] %X ^@!G /< ;P#U '< \P!^ /( A #P (D [P"/
M .X E #L )H ZP"? .D I0#H *P Y@"T .0 OP#C ,P X0#B -\ \ #> /L
MW@#_ -T _P#= /\ W #_ -P _P#_$!, _PT1 /\&$ #_ A4 _P > /\ *0#_
M #8 _P!" /H 3@#T %D \0!B .X :P#L '( Z@!Y .@ ?P#G (4 Y0"+ .0
MD #B )8 X0"< -\ H@#= *D V@"Q -@ NP#5 ,@ T@#= -$ [0#0 /D SP#_
M ,X _P#- /\ S0#_ ,T _P#_$0\ _PX- /\,#0#_"Q( _P<9 /\") #_ #
M]@ \ .\ 20#J %, YP!= .0 9@#A &T WP!T -T >P#; ($ V0"& -8 C #4
M )( T@"8 -  G@#. *8 S "N ,H N #( ,0 Q@#7 ,4 Z@## /< P@#_ ,$!
M_P#  O\ P +_ , "_P#_% L _Q & /\0"0#_$ X _PX4 /\*'@#U!BD ZP0V
M .,#0@#? TX VP17 -8$8 #3!&@ T 1O ,X%=@#,!7P R@6" ,D%B #'!8X
MQ@64 ,0%FP#"!:, P :K +X&M0"]!L( NPC4 +H)Z0"W"_@ M0S_ +0,_P"T
M#/\ M S_ +0,_P#_%P0 _Q0  /\6 P#_% D _Q$. /(.%0#H#"$ W@HN -8+
M.P#0#$< S Q1 ,D,6@#&#6( Q UJ ,(-<0# #7< OPU] +T.@P"\#HH N@Z1
M +D.F "W#J  M@ZI +0/M "R#\$ L1#4 *X1ZP"K$OH J1+_ *@3_P"G$_\
MIQ/_ *<3_P#_&@  _QL  /D;  #K&0  Y10& .40#@#9#A< SQ$F ,@2- #$
M$T  OQ1+ +P45 "Y%5T MQ5D +45:P"T%7$ LA5X +$6?@"O%H4 KA:, *P6
ME "K%YP J1>F *<8L "F&+T I!C/ *(:YP"?&O< G1O_ 9P;_P&<&_\!FQO_
M 9L;_P'_'0  ]R$  .@D  #=)0  U"$! ,\;" #*%Q$ PAH@ +P<+0"W'3H
MLQY% + >3P"M'E< JQY? *D?9@"H'VP IA]S *4?>0"C'X  HA^' * @CP"?
M()@ G2"B )L@K &:(;D!F"'* 98BY &4(_4!DB/_ 9$C_P&0(_\!D"/_ 9 C
M_P'_(@  ZRD  -TN  #/+P  QRT  ,$G P"](@T MB,: + E* "L)C0 J"9
M *4G20"B)U( H"=: )XG80"<)V< FR=M )DG= "8)WL!EB>" 94GBP&3)Y0!
MD2B> 9 HJ0&.*+4"C2G& HLIWP*)*O("ARK_ H8J_P*&*O\"ABK_ H8J_P+T
M*   XS$  -$V  #%.   O#8  +8P  "R*PD JRP4 *8M(@"B+B\ GBXZ )LN
M1 "8+TT EB]5 )0N7 "2+F( D"YI 8\N;P&-+G8!C"Y^ 8HNA@*(+H\"ARZ:
M H4OI0.#+[(#@B_" X$PV@-_,.\#?3'^ WTQ_P-\,?\#?#'_ WPQ_P/M+P
MVS<  ,D]  "^/@  LSP  *PX  "G,P0 HC(1 )TT'0"9-2H E34U )(U0 "/
M-4D C350 (LU5P")-5X!AS5D 84T:P&$-'("@C1Y H T@@)^-(L#?326 WLU
MH01Y-:X$>#6^!7<VU 5V-NT%=#?\!70W_P1T-_\$=#?_!'0W_P3G-0  TCT
M ,-"  "X1   K$(  *0^  "?.0  FC@. )0Z&0"0.B8 C3LQ (H[.P"'.T0
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M"&!$R@A@1.8(7T7X!U]%_P=@1?\&8$3_!F!$_P;600  PTD  +9.  "G3P
MFTT  ))+  ",1P  A4<$ (!'$ !\2!H >$@F '5), !S23H <$E" &Y)20%L
M2% !:DA6 6A(70)F2&0"94AL V-(=01A1W\%8$>*!EY(EP==2*4(6TBT"%M(
MQPE:2.0(6DGV"%I)_P=:2/\&6DC_!EI(_P;110  OTP  +)2  "C40  EU
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M"$Q3_P=,4_\'35/_!DU3_P;%3@  ME8  *=:  "860  BU@  (%7  !W5
M<%4  &I6!@!F5Q  8E<: &!8) !=6"X 6UDW %E9/P!7648 5EE- 5195 %3
M65L"45EC D]8; -.6'8$3%B"!4I8CP9)6)X'2%BN"$=8P A'6-T(1UCR"$=7
M_P=(5_\'2%?_!DA7_P;!40  LED  *-<  "46P  AUL  'U:  !R6   :UD
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M!3AF_P6T7@  IV4  )5E  "&9   >F4  &]E  !D9@  66@  %)J  !-; 0
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M ":"?P$E@H\!)(*@ 2."L@$B@LD!(H'G 2)_]P$B?O\"(GW_ B)]_P*E<0
MDW$  (-Q  !V<0  ;'(  &!U  !6>   3'P  $.    [@P  ,X8  "V)"@ J
MBA$ *8L9 ">+(@ FBRH )8PQ "2,.0 CC$( (HU* "&-5  @C5X 'XUK !V-
M>0 <C8H &XV< !F-K@ 8C,0 &(SC !F*]0 9B?\!&8C_ 1F(_P&==P  C'8
M 'UV  !R=P  97D  %I\  !0@   1H0  #R)   TC   +9   "63 @ ?E0P
M'982 !R6&@ ;ER( &I<J !F7,@ 8F#H %YA# !:830 5F%@ %)AD !.8<P 1
MF(0 $)B6 !"8J0 .F+\ #I?=  ^6\@ 0E?P $)3_ !"4_P"5?0  A7P  'A\
M  !K?@  7X$  %2&  !*B@  0(\  #:3   MEP  )IH  !Z=   7H , $J(,
M !"C$@ 0HQD #Z,A  ZD*0 .I#$ #:0Z  RD10 +I%  "J1<  FD:@ 'I'L
M!J..  2CH0 "H[0  Z++  .BY@ #H?,  Z'[  .A^P"-@P  ?X(  '&$  !D
MAP  6(P  $V1  !"E@  .)H  "^>   FH@  'J4  !>H   1JP  #*X'  >O
M#0 #KQ(  J\9  &O(0  KRD  + R  "P/   L$<  +!3  "P80  L'$  +"#
M  "OEP  KZH  *^_  "NV0  KNL  *[T  "N] "'B0  >(H  &J.  !=DP
M49@  $6=   [H@  ,*8  ">J   >K@  %K$  !"T   +M@  !;D#  "Z"@
MN@X  +H3  "[&0  NR$  +PH  "\,0  O3P  +Y(  "^5@  OF4  +YW  "^
MC   OI\  +VS  "^QP  OMX  +WK  "]ZP!_D@  <)4  &*:  !5GP  2:4
M #VK   RKP  *+0  !ZV   5N0  #KP   F_   "P@   ,0   #%!   Q@H
M ,8.  #'$@  R!@  ,D?  #*)P  S#   ,X\  #.20  SUD  ,]J  #/?@
MSY,  ,^F  #/N   S\@  ,_;  #/VP!WG   :*$  %NG  !.K@  0;0  #2W
M   HN@  ';T  !/    -Q   !L<   #*    S@   -    #1    T@(  -,(
M  #5#   UA   -D5  #;'   W20  . O  #B/   XTL  .1<  #D;P  Y8,
M .68  #EJ0  Y;8  .7#  #EPP!LI0  7ZP  %&R  !$N0  -;P  "C    <
MQ   $L@   S+   #SP   -,   #8    W    -\   #?    X0   .,   #D
M P  Y@@  .@-  #I$0  [!@  .XB  #Q+@  \SP  /1-  #U7P  ]G,  />'
M  #WF0  ^*4  /BP  #XL #_ Q< _P 5 /\ %0#_ !@ _P C /\ +P#_ #P
M_P!( /\ 5 #_ %X _P!G /T ;P#[ '8 ^0!] /@ @P#V (@ ]0". /0 DP#R
M )@ \0"> /  I #N *L [0"S .L O0#J ,L Z #A .< \0#F /T Y0#_ .0
M_P#D /\ Y #_ .0 _P#_!Q, _P 1 /\ $0#_ !4 _P ? /\ *P#_ #< _P!$
M /X 3P#Z %H ]P!C /0 :P#R '( \ !Y .\ ?P#M (0 ZP"* .H CP#H )0
MYP": .4 H #D *< X@"O .  N0#> ,8 W #: -H [ #8 /D U@#_ -8 _P#7
M /\ V #_ -@ _P#_"A  _P,. /\ #0#_ !( _P : /\ )@#\ #( ]P _ /0
M2@#Q %4 [0!> .H 9@#H &X Y0!T ., >@#B (  X "% -X BP#< )  VP"6
M -@ G #5 *, TP"K -$ M0#. ,$ S #1 ,L YP#) /4 R #_ ,@ _P#( /\
MR #_ ,@ _P#_# P _P8( /\""@#_  \ _P 5 /P ( #Q "P [  Y .D 10#E
M $\ X0!9 -X 80#; &@ UP!O -0 =0#2 'L T "  ,X A@#, (P RP"2 ,D
MF #' *  Q0"H ,, L0#! +P OP#+ +T XP"\ /( NP#] +L _P"Z /\ N@#_
M +H _P#_#@4 _PD  /\)!0#_!@L _P$0 /  &0#F "4 X0 R -P /P#6 $D
MT0!3 ,X 6P#+ &, R !J ,8 < #% '8 PP![ ,$ @0#  (< O@". +P E "[
M )P N0"D +< K@"U +D LP#( +$ WP"P >\ KP'[ *X"_P"M _\ K0/_ *T#
M_P#_$   _PX  /\-  #V"P, \@<* .(!$0#; AT T@,K ,P#-P#(!$, Q 1-
M ,$$5@"^!5T O 5D +H%:P"X!7$ MP5V +4%? "S!H, L@:) + &D0"O!YD
MK0>A *L'JP"I"+< J G& *8*W0"E"_  HPS] *(-_P"A#?\ H0W_ * -_P#_
M$0  _!(  .P3  #B$P  VP\# -8)"P#."!0 Q@HB , ,, "\#3P N U& +4-
M3P"R#E< L Y? *X.90"M#FL JPYQ *H.> "H#GX IP^% *4/C0"D#Y8 HA"?
M * 0J0"?$+4 G1'% )L1W@"9$O$ EQ/_ )84_P"5%/\ E13_ )04_P#_%0
M[1L  . ?  #2'P  R1L  ,04!0#!$ X NA(; +03*0"P%#4 K!5  *D520"F
M%5( I!99 *(68 "A%F8 GQ9L )X6<@"<%GD FQ>  )D7B "8%Y$ EAB; )08
MI@"3&;( D1G! ) :V "-&^X BQS] (H<_P"*'/\ B1S_ (D<_P#T'0  Y"4
M -,I  #'*@  O"8  +8@  "T&0L KAH5 *@<(P"D'2\ H1XZ )X>1 ";'DP
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M G PR0)O,.4";C'W FTQ_P)M,?\";3'_ FTQ_P+?,@  R3D  +L^  "L/0
MH3H  )HW  "5,P  D#$* (PQ% "',B  A#,K ($S-0!_,SX ?3-& 'LS30!Y
M,U0 =S-: '8S80!T,V<!<C1O 7$T=P%O-($!;C2, FPTF )J-:4":36S V@U
MQ@-G-N(#9C;U V8V_P)F-O\"9C;_ F8V_P+8-P  Q#X  +5"  "F00  FS\
M ),\  "-.   B#8' (0W$0" -QP ?#@G 'HX,0!W.3H =3E" ',Y20!Q.5
M<#E7 &XY70!L.60!:SEK 6DY= %H.7X"9CF) F0YE0-C.J(#8CJQ V$ZPP-@
M.^ $7SOS U\[_P-?._\#7SO_ E\[_P+1.P  P$(  +!%  "A1   E4,  (U
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M!%1#_@-40_\#5$/_ U1#_P/(0@  N$D  *=+  "82@  C4D  (-'  !]0P
M=D,  '%$"@!M1!( :D4= &=%)P!D13  8D4X &!%/P!?14< 745- %M%5 !:
M1EL!649C 5=&; %61G8"5$:! U-&C@-21YP$4$>K!%!'O01/1]8%3T?O!$]'
M_01/1_\#3T?_ U!'_P/$10  M4T  *--  "53   B4L  ']*  !X1@  <4<
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M T)1_P.Z3P  JE0  )A4  ")5   ?5,  '-3  !I40  8E(  %Q3  !85 H
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M 35C@0$S8Y$",F.A C%CLP(Q8\@",6+G C%A^ (Q8?\",F#_ C)@_P*N7
MFUT  (I=  !\70  <%T  &9=  !<7@  4F   $QB  !%90  068* #YG$0 \
M:!H .V@B #EI*P X:3( -VHZ #9J00 U:DD -&I2 #-J6P Q:F4 ,&IP 2YJ
M?@$M:HX!+&J? 2MJL $J:L8!*FGE 2IH]@(K9_\"*V?_ BMG_P*I80  E6
M (1@  !W8   ;&$  &)A  !88P  3F8  $=H  ! :P  .FX% #9O#@ T<!4
M,W > #)Q)@ P<2X +W$U "YR/0 M<D4 +')- "MR5P J<F$ *7)M "=R>P F
M<HL )'*< 2-RK@$C<L,!(W'B 2-P] $C;_\!(V[_ 2-N_P&A90  CF0  ']D
M  !R9   :&4  %YF  !4:0  26P  $)O   [<@  -'4  "YX"@ K>1$ *GD8
M "EZ(0 G>B@ )GHP "5[.  D>T  (WM( ")[4@ A>UP ('MH !]\=@ =?(8
M''N8 !M[J@ :>[\ &GO> !IY\@ ;>/X &W?_ 1MW_P&9:0  B&D  'EI  !M
M:0  8VH  %EL  !/;P  17,  #UW   U>@  +GT  ">! P B@PT ((02 !^$
M&@ =A"( '(4J !N%,0 :A3D &85" !B&3  7AE8 %H9C !6&<0 4AH$ $H:3
M !&&I@ 1A;L $(76 !&#[P 1@OL $H+_ !*!_P"1;@  @6T  '1N  !I;@
M77   %-S  !)=P  0'P  #>    O@P  )X<  "&*   :C08 %8\- !.0$P 2
MD!H $I B !&0*@ 0D3( $)$[  ^11  .D4\ #9%<  R1:@ +D7H "I&-  B0
MGP 'D+, !X_)  >/Y@ 'CO0 "(W\  B-_P")<P  >W,  &]S  !C=0  5W@
M $U]  !#@0  .88  #"*   HC@  (9$  !J5   3EP  #IH(  N<#@ )G!,
M")P:  ><(@ &G"H !)PS  .</0 "G4@  )U4  "=8@  G'(  )R$  "<EP
MFZH  )N_  ":VP  FNP  )KU  "9^ "">0  =GD  &AZ  !<?@  48(  $:'
M   \C   ,I$  "F5   AF0  &9T  !*@   .HP  ":8%  .G#   IQ   *<5
M  "H'   J",  *@K  "I-   J3\  *E+  "I60  J6@  *EZ  "IC@  J:$
M *BU  "HRP  I^0  *?O  "G\P!]@   ;X$  &&$  !5B0  28X  #Z4   T
MF0  *IX  "&B   9I@  $JD   VL   'KP   +(   "S!P  LPP  +,0  "T
M%0  M!L  +4B  "V*P  MS4  +=   "X3@  N%T  +AN  "X@@  N)<  +BJ
M  "WO@  M](  +?F  "WZ@!VB   9XL  %J0  !.E@  0IP  #>B   LIP
M(JL  !FO   1LP  "[8   2Y    O    +X   "^    OP8  , +  #!#P
MPA,  ,,9  #$(   Q2D  ,<T  #(0@  R5$  ,EB  #)=0  R8H  ,F?  #*
ML0  RL$  ,G1  #)V0!NDP  8)@  %.>  !&I   .JL  "^P   DM0  &;@
M !"\   *OP   <$   #$    R    ,H   #*    S    ,T#  #."   T T
M -$0  #3%@  UAX  -HH  #=-   WD,  -]4  #?9P  X'P  ."1  #@I
MX+(  ."^  #@PP!FGP  6:8  $RM   _M   ,K@  "2\   8OP  $,,   C'
M    R@   ,T   #1    U0   -@   #9    VP   -T   #?    X00  .,*
M  #E#@  YQ,  .H<  #M)P  \#4  /%&  #R6   \VL  /.   #TE   ]*,
M /2N  #TL@#_ !, _P 1 /\ $0#_ !4 _P ? /\ + #_ #D _P!% /\ 4 #_
M %H _@!C /L :P#Y '( ]P!X /4 ?@#T (0 \@") /$ C@#P ), [@"9 .T
MGP#L *8 Z@"N .@ N #F ,4 Y0#; ., [0#B /L X@#_ .$ _P#A /\ X0#_
M .$ _P#_ !  _P . /\ #0#_ !( _P ; /\ * #_ #0 _@!! /L 3 #W %8
M] !? /$ 9@#O &T [ !T .H >@#I '\ YP"% .8 B@#E (\ XP"5 .$ FP#@
M *( W@"J -L M #9 ,  U@#0 -, Z #2 /< T0#_ -$ _P#0 /\ T #_ -
M_P#_  T _P ) /\ "@#_  \ _P 6 /L (@#W "\ ]  [ /  1P#M %$ Z0!:
M .4 8@#B &D X !O -X =0#< 'H V@"  -@ A0#5 (L TP"1 -$ EP#/ )X
MS0"F ,L KP#) +H QP#) ,4 X@#$ /( PP#^ ,( _P#! /\ P@#_ ,( _P#_
M P8 _P ! /\ !@#_  P ^0 1 /$ '0#K "D YP V ., 00#? $L VP!4 -4
M7 #2 &, SP!J ,T < #+ '4 R0![ ,@ @ #& (8 Q0", ,, DP#! )H OP"B
M +T JP"[ +8 N0#$ +< V@"V .T M #Z +0 _P"T /\ M #_ +0 _P#_!
M_P   /\   #_  8 [  - .4 %@#> "( UP O -$ .P#- $4 R@!. ,8 5P#$
M %X P0!D +\ :@"] '  O !U +H >P"Y ($ MP"' +4 C@"S )4 L@"> +
MIP"N +( K "_ *H T0"H .@ J #W *< _P"G /\ I@#_ *8 _P#_!@  _P4
M /$#  #H    X0 ' -4 $ #- !L QP G ,, ,P"_ #X O !( +D 40"V %@
MM !? +( 90"P &H KP!P *T =@"L 'P J@"" *D B0"G )$ I0": *, I "A
M *X H "[ )X!S0"= N8 G 3T )L$_P":!?\ F@7_ )D%_P#_"@  \0X  .00
M  #9#P  S@L  ,@#"P#" !, O (? +<#+ "S!#< L 5" *T&2@"J!E( J =9
M *8'7P"E!V4 HP=K *((<0"@"'< GPA^ )T(A0";"8X F@F7 )@*H0"6"JP
ME0NZ ),+S "2#.4 D WV (\._P".#O\ C@[_ (T._P#V$0  YA<  -8;  #'
M&0  OA4  +D0  "W"@T L0L7 *P-) "H#C  I0X[ *(.1 "?#TP G0]3 )L/
M6@":#V  F!!F )<0; "5$'( DQ!Y )(0@0"0$(H CQ&4 (T1GP"+$:H BA*X
M (@2RP"&$^8 A13W (,5_P"#%?\ @A7_ ((5_P#M&@  W"$  ,HE  "[(@
ML1\  *L:  "I% 8 I1(1 * 4'@"<%2H F14U )86/@"4%D< DA9. ) 650".
M%UL C!=A (L79P")%VT B!=T (88? "%&(8 @QF0 ($9FP" &J< ?AJU 'T;
MQP!\'.( >AWU 'D=_P!X'?\ >!W_ '@=_P#E(@  T"D  +\L  "P*@  IR<
M * C  "='P  FAH. )4<& "1'20 CAXO (P>.0")'D$ AQ]) (4?4 "#'U8
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M 5\P_0%?,/\!7S#_ 5\P_P'--   O#L  *DZ  ";.@  D#@  (DU  "#,@
M?S ! 'LO#@!W,!8 =# A '$Q*P!O,30 ;3$\ &LQ0P!J,4H :#)0 &<R5P!E
M,ET 9#)E &(R;0!A,W< 7S." 5XSC@%=-)P!6S2J 5HUNP%:-=(!637M 5DU
M_ %8-?\!6#7_ 5DU_P'(.   MSX  *0^  "6/0  BSP  (,Z  !]-P  >#0
M '0T"P!P-1, ;34= &HU)P!H-C  9C8X &0V/P!C-D8 839- & V4P!>-UH
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M/0X 83X7 %X^(0!</BD 6CXQ %@^.0!7/D  53]& %0_30!3/U4 4D!< %!
M90!/0&\!3D%Z 4U!AP%+098!2D&E DE"M0))0LL"24+H DE"^0))0?\"24'_
M 4E!_P&]0P  JD4  )A%  "*10  ?T4  '9#  !O0   :$   &-! 0!?00T
M7$$4 %E"'0!70B8 54(N %-"-@!10CT 3T)# $]#2P!.0U( 341: $Q$8P!*
M1&T!245X 4A%A0%'190!146C D5&M )$1LD"1$;G D1%^ )$1?\"147_ D5%
M_P&Z1@  ID@  )1(  "&2   >T<  ')&  !J0@  8T,  %Y$  !:10L 5D42
M %1&&P!11B, 3T8K $Y&,P!,1SH 2T=! $I'20!)2%  2$A8 $=(80!&26L
M1$EV 4-)@P%"29(!04FB D!)LP(_2L<"/TKE C])]P) 2?\"0$C_ D!(_P&V
M20  HDH  )%*  "#2@  =TH  &Y)  !E10  7D<  %E(  !520@ 44H0 $]*
M& !,2B$ 2DLI $E+,0!'2S@ 1DP_ $5,1@!$3$X 0TU6 $)-7P!!36@ 0$UT
M 3Y-@0$]39 !/$V@ 3M.L0(Z3L8".D[D CM-]@([3?\!.TS_ 3Q,_P&S30
MGDP  (U,  !_3   =$P  &I,  !@2@  64L  %1,  !0304 3$X. $E/%0!'
M3QX 14\F $10+@!"4#4 05 ] $!11  _44L /E%3 #U27  \4F8 .E)R #E2
M?P$X4HX!-U*> 392KP$U4L0!-5+B 392]0$V4?\!-E#_ 3=0_P&N3P  F4\
M (E/  ![3P  <$\  &9/  !<3@  5$\  $]1  !*4@$ 1E,, $-4$@!!5!L
M0%4C #Y5*P ]5C( /%8Z #M600 Z5DD .5=1 #A76@ V5V, -5=O #17? $S
M5XP!,5>< 3!7K0$P5\(!,%?@ 3!6] $Q5O\!,57_ 3%5_P&H4@  E5(  (12
M  !W4@  ;%(  &)2  !84P  3U0  $E6  !$5P  0%D( #U:$  [6A< .5L@
M #A;)P W7"\ -EPV #5</@ T7$8 ,UU. #%=5P P76$ +UUL "Y=>@ L78D
M*UV: 2I=JP$J7;\!*5W> 2I<\@$J6_X!*UO_ 2M:_P&C50  CU4  ']5  !R
M50  9U8  %Y6  !45P  3%D  $5;   _70  .E\$ #9@#0 T81, ,F(< #%B
M(P P8BL +V,R "YC.@ M8T( +&-* "ID4P I9%T *&1I "=D=@ F9(8 )627
M "1DJ0 C9+T (F3: "-C\0 C8OT!)&'_ 21A_P&<6   B5@  'I9  !N60
M8UD  %I:  !07   2%X  $%@   Z8P  -&8  "]H"@ L:1  *FD7 "EJ'P H
M:B8 )VHN "9K-0 E:ST )&M& "-K3P B;%D (&QE !]L<@ >;(( '6R4 !QL
MI@ ;:[H &FO4 !MJ[@ <:?P '&C_ !QH_P"57   @UP  '5<  !I70  7UT
M %9>  !,80  0V0  #QG   U:@  +VT  "AP!  C<@T (7(2 "!S&@ ?<R$
M'G,H !UT,  <=#@ &W1  !IT2@ 9=%0 %W5@ !9U;@ 5=7X %'60 !-TH@ 2
M=+8 $73/ !)S[  2<OH $W'_ !-Q_P".8   ?6   &]A  !E80  6V(  %%D
M  !(9P  /FL  #=N   P<0  *74  ")X   <>P< %WT. !9]$P 5?1L %'XB
M !-^*@ 2?C$ $7XZ !%^1  0?TX #W]:  Y_:  -?W@ #'^*  M^G0 *?K
M"7W&  I]Y  *?/0 "WO]  MZ_P"&90  =V4  &IE  !A9@  5F@  $QK  !"
M;P  .7,  #%W   J>@  (WX  !R!   5A   $(<(  V)#@ ,B10 #(D;  N)
M(P *B2L "8DS  B)/0 &B4@ !8E4  2)80 "B7$  8F#  ")E@  B*D  (>^
M  "'V@  ANP  (;U  "&^@!^:@  <6H  &=K  !;;   4'   $9T   \>
M,WT  "J!   CA0  '(@  !6,   0CP  #)(&  :3#  "DQ$  )06  "4'0
ME"0  )4L  "5-0  E4   )5,  "660  EFD  )5Z  "5C@  E*$  )2U  "3
MS   DN8  )+R  "2]P!X<   ;7   &!R  !4=0  27D  #]^   U@P  +(@
M ".-   ;D0  %)0   ^7   *F@  !)T#  ">"0  GPX  )\2  "@%P  H!T
M *$E  "B+0  HC<  *-#  "C4   HU\  *-Q  "CA   HID  **M  "AP@
MH=P  *'K  "@\@!S=@  9G<  %E[  !-@   0H4  #B+   ND   ))4  !N:
M   4G@  #J$   FD   "IP   *H   "K!   JPH  *P-  "M$0  K18  *X<
M  "O)   L"T  +$Y  "Q1@  LE4  +)F  "R>0  LHX  +&C  "RMP  L<H
M +'@  "QZ0!L?@  7X(  %*'  !&C0  .Y,  #"9   FG@  '*,  !.G   -
MJP  !ZX   "R    M0   +<   "X    N0(  +D(  "Z#   NQ   +P4  "]
M&P  OR,  ,$M  #".@  PDD  ,-:  ##;   Q((  ,27  #$JP  Q+P  ,3+
M  #$V@!EB0  6(X  $N5   _FP  ,Z(  "BH   =K0  %+$   VV   &N0
M +P   "_    PP   ,0   #%    Q@   ,<   #)!   R@D  ,L-  #-$0
MSQ@  -(A  #5+0  UCP  -A-  #97P  VG,  -J*  #;G@  VZX  -NZ  #<
MPP!>E@  49P  $2C   XJ@  ++$  ""W   5NP  #;X   3"    Q0   ,D
M  #-    T    -(   #2    U0   -8   #9    VP   -X%  #@"@  X@\
M .46  #H(   ["T  .T^  #M40  [F4  .]Z  #OCP  \)\  /"K  #PLP#_
M !  _P . /\ #@#_ !( _P = /\ *0#_ #4 _P!! /\ 30#^ %8 ^P!? /@
M9@#V &T ] !T /( >0#Q '\ \ "$ .X B0#M (\ ZP"5 .H FP#H *( Y@"J
M .4 LP#C ,  X0#2 .  Z@#? /D W0#_ -T _P#= /\ W@#_ -X _P#_  T
M_P * /\ "0#_  \ _P 8 /\ ) #^ #$ ^P ] /@ 2 #T %( \ !: .T 8@#K
M &D Z0!O .< =0#E 'H XP!_ .( A0#@ (H W@"0 -P E@#: )T V "E -4
MKP#2 +H T #* ,X XP#- /0 RP#_ ,L _P#+ /\ RP#_ ,L _P#_  @ _P #
M /\ !0#_  P _  4 /< 'P#R "L [P W .L 0@#G $P Y !5 .  70#= &0
MV@!J -@ < #5 '4 T@!Z -  @ #/ (4 S0"+ ,L D@#) )D QP"A ,4 J@##
M +4 P0## +\ V@"^ .X O0#\ +P _P"\ /\ O #_ +P _P#_    _P   /\
M  #Y  < \0 0 .H &@#D "4 WP Q -L / #7 $< T@!0 ,X 5P#+ %X R0!E
M ,8 :@#% '  PP!U ,$ >@#  (  O@"& +P C0"Z )0 N0"< +< I0"U +
MLP"] +$ SP"O .@ K@#X *X _P"M /\ K0#_ *T _P#_    _P   /T   #N
M  $ XP , -H % #1 !\ S  K ,@ -@#% $  P@!* +\ 4@"\ %D N@!? +@
M90"V &H M !O +, =0"Q 'H L "! *X B "M (\ JP"8 *D H0"G *L I0"X
M *, R "B .( H0#S *  _@"@ /\ H #_ *  _P#_    ]@   .H   #@
MTP & ,D #P#" !@ O0 D +D +P"V #H M !# +$ 3 "N %, K !9 *H 7P"I
M &0 IP!J *8 ;P"D '4 HP![ *$ @@"@ (H G@"3 )P G0": *< F "T )8
MPP"5 -P E #O ), ^P"3 /\ DP#_ )( _P#Y!0  Z@L  -P-  #+"@  P@4
M +P "@"V !$ L0 < *X * "J #, IP ] *0 10"B $T H !3 )X 60"< %\
MFP!D )H :@"8 '  EP!V )4 ?@"3 (8 D@&/ ) !F0". J0 C *Q (L#P ")
M!=8 B ;M (@'^@"'"/\ A@C_ (8(_P#O#P  WA0  ,H5  "\$@  LQ   *X,
M  "K!@T IP,5 *(%( "?!RP G @V )D(/P"7"4< E0E. ),)5 "1"EH D I?
M (X*90"-"FL BPIR (H+>0"("X( APN, (4,EP"##*( @0VP ( -P !_#=@
M?0[O 'P/_0![#_\ >Q#_ 'L0_P#F%P  T1X  +T=  "O'   IAD  *$5  ">
M$ 0 G0T/ )@.&0"4#B4 D0\O (\0.0",$$$ BA!( (@03P"'$%4 A1!; (01
M80""$6< @!%N '\1=0!]$7X ?!*( 'H2E !X$J  =Q.N '43O@!T%-4 <Q7N
M '$6_0!Q%O\ <1;_ ' 6_P#<'P  QB4  +,E  "E(P  G"$  )8>  "2&0
MD10+ (T4% ")%1\ AA8I (,6,P"!%SP @!=# 'X72@!\%U  >A=6 'D87 !W
M&&( =AAI '08<0!S&7H <1F$ &\:D !N&IT ;!NK &L<NP!J'-  :1WL &@>
M^P!H'O\ 9Q[_ &<>_P#1)@  O2H  *LJ  "=*@  DR@  (TE  "((@  AAT&
M (,;$ !_'!H ?!TD 'H=+@!W'C8 =AX^ '0>10!R'TL <1]1 &\?6 !N'UX
M;!]E &L@;0!I('8 :"&! &8AC0!E(IH 8R*H &(CN !A(\T 8"3I & D^@!?
M)/\ 7R3_ %\D_P#*+   MB\  *0O  "6+P  C"T  (4J  " *   ?20  'HB
M#0!V(Q4 <R,@ '$D*0!O)#( ;20Z &LE00!J)4< :"5- &8E5 !E)5H 9"9A
M &(F:0!A)G( 7R=] %XGB@!=*)< 6RFE %HIM0!:*LH 62KG %@J^ !8*O\
M6"K_ %@J_P#%,0  KS,  )XS  "0,P  AC(  '\O  !Y+0  =2H  '(H"@!O
M*!( :RD; &DI)0!G*BT 92HU &,J/0!B*D, 8"I* %\K4 !>*U< 7"M> %LL
M9@!9+&\ 6"UZ %<MAP!6+I4 5"ZC %,OLP!3+\< 4B_E %(O]P!2+_\ 4B__
M %(O_P#!-@  JC8  )DV  "+-@  @34  'DS  !S,0  ;R\  &LN!@!H+1
M9"X8 &(N(0!@+RH 7B\Q %PO.0!;+T  62]& %@O30!7,%, 5C!; %0Q8P!3
M,6P 4C)W %$RA !/,Y( 3C.A $TSL0!--,4!3#3C 4PT]@!,-/\ 3#3_ $PS
M_P"[.0  ICD  )4Y  "'.0  ?#D  '0W  !N-   :3,  &4R @!A,@T 7C(4
M %PS'@!:,R8 6#,N %8S-0!5-#P 4S1# %(T2@!1-%  4#58 $XU8 !--FH
M3#9U $LW@@!*-Y  23B? $@XL %'.,,!1SCA 4<X]0%'./\!1SC_ 4<X_P&W
M.P  HCP  )$\  "#/   >#P  ' Z  !J-P  9#8  & V  !<-@L 63<2 %8W
M&@!4-R, 4C<K % W,@!/.#D 33A  $PX1P!+.$X 2CE5 $DY7@!(.F@ 1SIS
M $8[@ !%.XX 1#R> $,\K@%"/,(!0CW? 4(\\P%"//\!0CS_ 4([_P&S/0
MGCX  (T^  !_/@  =3X  &P]  !F.@  8#D  %LZ  !7.@@ 4SL0 %$[& !.
M.R  3#LH $L[+P!)/#8 1SP] $<\1 !&/4L 13U3 $0^7 !#/F8 0C]Q $$_
M?@! /XT /T"< #Y K0$]0, !/4#= 3U \@$]0/\!/C__ 3X__P&N0   FD
M (E!  !\00  <4$  &A   !A/   6ST  %8^  !2/@4 3C\. $P_%0!)/QT
M1T E $9 + !$0#, 0T Z $)!0@!!04D 0$%1 #]"6@ ^0F, /4-O #Q#?  [
M0XL .D2; #E$JP$Y1+X!.$3; 3E$\0$Y0_X!.4/_ 3E#_P&J0@  ED,  (9#
M  !X0P  ;D,  &5#  !=0   5D   %%"  !-0@( 24,, $9#$@!$1!H 0D0B
M $%$*@ _13$ /D4X #U%/P \1D< .T9/ #I&5P Y1V$ .$=L #='>@ V2(D
M-4B9 #1(J@ T2+T ,TC9 #1(\  T1_T -$?_ #5&_P"F1   DD4  ()&  !U
M1@  :D8  &%%  !91   440  $Q&  !(1P  1$<* $%($  _21@ /4D@ #Q)
M)P Z2BX .4HV #A*/0 W2T0 -DM, #5+50 T3%\ ,TQJ #),=P Q3(8 ,$R7
M "]-J  N3;L +DW5 "Y,[P O3/T +TO_ #!+_P"A1P  CD@  'Y(  !Q2
M9DD  %U(  !52   3$D  $=*  !"2P  /TP& #M-#@ Y3A4 -TX= #9/)  U
M3RL ,T\S #)0.@ Q4$( ,%!* "]14@ N45P +5%G "Q1=0 K480 *E*5 "E2
MI@ I4KD *%+2 "E1[@ I4/P *E#_ "I/_P"<2@  B4H  'I+  !M2P  8TP
M %I,  !13   2$T  $-/   ]4   .5(" #53#  S5!( ,509 #!5(0 N52@
M+54O "Q6-P K5CX *E9& "E63P H5UD )U=D "97<@ E5X$ )%>2 "-7I  B
M5[< (E?/ ")7[  C5OH (U7_ "15_P"630  A$X  '5.  !I3@  7T\  %9/
M  !-4   15(  #]3   Y5@  ,U@  "]:"  K6P\ *EL5 "A<'0 G7"0 )EPK
M "5<,P D73H (UU# ")=3  A758 (%YA !]>;@ >7GX '5Z/ !Q>H0 ;7K0
M&EW, !M=Z0 ;7/D '%O_ !Q;_P"040  ?E$  '!1  !D4@  6U(  %)3  !*
M5   05<  #M9   U6P  +EX  "A@ P D8@P (F,1 "%C&  ?9"  'F0G !UD
M+@ <9#8 &V4^ !IE1P 995$ &&5= !=E:@ 697H %66+ !1EG@ 39;$ $F7(
M !)DYP 38_< %&+_ !1B_P")5   >%4  &M5  !@5@  5U8  $]7  !&60
M/5P  #9?   P8@  *60  "-G   =:@< &6P. !AL$P 6;1H %6TA !1M*0 4
M;3  $VTY !)N0@ 1;DP $&Y8  ]N90 .;G4 #6Z'  UNF@ ,;:T "VW"  ML
MX  ,:_, #6O]  UJ_P""60  <ED  &99  !<6@  5%H  $I<  !!7P  .6,
M #%F   J:0  )&P  !UO   7<@  $G4)  ]W#P .=Q0 #G<;  UW(P ,=RH
M"W<S  IW/  )=T< "'=2  =W7P %=V\ !'>   -WE  !=J<  ':[  %UU0 !
M=.L  G3V  )T_ ![70  ;5T  &)>  !97@  3F   $5C   \9P  ,VL  "MN
M   D<@  'G4  !=Y   2?   #7\&  F!#  %@1$  X$6  *!'0 !@20  ($M
M  ""-@  @D   (),  ""60  @F@  ()Y  ""C0  @:   ("T  " RP  ?^<
M '[R  !^^0!T8@  :&(  %YB  !39   26<  #]K   V<   +70  "5X   >
M?   %X   !&#   -A@  "(D$  *+"@  BPX  (L3  ",&   C!\  (TF  "-
M+P  CCD  (Y$  ".40  CF   (YQ  ".A0  CID  (VM  ",PP  C-\  (ON
M  "+]@!N:   9&<  %AI  !-;   0G$  #AV   O>P  )G\  !Z$   6B
M$(P   R/   &D@   )4   "6!P  EPP  )</  "8$P  F1@  )H?  ";)@
MFS   )P[  "<2   G%<  )QH  "<>P  G)   )NE  ";N@  FM   )KG  ":
M\0!J;0  7F\  %%R  !&=P  .WP  #&"   GAP  'HP  !:1   0E0  "ID
M  2<    H    *(   "C 0  HP8  *0+  "E#@  IA(  *<7  "H'@  JB8
M *LQ  "K/@  K$T  *Q=  "L<   K(4  *R;  "KKP  J\,  *O9  "JZ !D
M=0  5WD  $M^   _A   -(H  "F0   ?E@  %IL  !"?   )HP   :<   "J
M    K@   +    "P    L0   +(#  "T"   M0T  +80  "W%0  N1T  +LF
M  "\,P  O4$  +U2  "]9   OGD  +Z0  "]I   O;<  +W&  "]UP!<?P
M4(4  $2+   XD@  +)D  "&?   7I   $*D   FN    L@   +8   "Y
MO0   +\   "_    P    ,$   ##    Q 4  ,8*  #'#@  R1,  ,L<  #.
M)@  T#4  -%%  #25P  TFL  -."  #3EP  TZD  -*X  #2Q !5C   29,
M #V:   PH@  ):@  !JN   1M   ";D   "]    P0   ,0   #(    RP
M ,T   #-    SP   -    #2    U    -@   #:!@  W0P  . 1  #C&@
MYB<  .<X  #H2@  Z5T  .IR  #KB   ZYL  .RH  #LL@#_  T _P + /\
M"P#_ !  _P : /\ )@#_ #( _P ] /\ 2 #[ %( ^ !: /8 8@#S &D \0!O
M /  =0#N 'H [ !_ .L A #I (H Z "0 .8 E@#D )T X@"E .$ KP#? +L
MW0#+ -L Y@#9 /< V #_ -@ _P#7 /\ UP#_ -0 _P#_  @ _P $ /\ ! #_
M  T _P 5 /X (0#Z "P ]P X /0 0P#P $T [0!5 .H 70#G &0 Y !J .(
M< #@ '4 W@!Z -T ?P#; (4 V0"+ -4 D0#3 )D T0"@ ,\ J@#- +4 RP#$
M ,D W0#( /$ QP#_ ,8 _P#& /\ Q@#_ ,< _P#_    _P   /\   #_  H
M^  1 /$ ' #L "< Z0 R .8 /0#B $< W0!0 -D 6 #5 %\ T@!E -  :@#.
M '  S !U ,H >@#) '\ QP"% ,4 C ## )0 P0"< +\ I0"] +  NP"] +H
MT "X .L MP#[ +8 _P"V /\ M@#_ +8 _P#_    _P   /T   #S  4 Z0 .
M .$ %@#; "$ U0 M -$ -P#. $$ R@!* ,< 4@#$ %D P@!? ,  90"^ &H
MO !O +L = "Y 'H MP"  +8 AP"T (X L@"7 +  H "N *H K0"W *L R "I
M ., J #U *< _P"G /\ IP#_ *8 _P#_    _@   /$   #E    UP * ,T
M$0#' !P P@ F +\ ,0"\ #L N@!$ +< 3 "T %, L@!9 +$ 7P"O &0 K0!I
M *P ;P"J '0 J0!Z *< @0"F (D I "1 *( FP"@ *4 G@"R )T P0"; -H
MF@#O )D _0"8 /\ F #_ )@ _P#]    \    .$   #1    Q@ $ +T #0"W
M !4 LP @ +  *P"M #4 JP ^ *@ 1@"F $T I !4 *, 60"A %\ H !D )X
M:0"= &X FP!U )H >P"8 (, E@", )4 E@"3 *$ D0"M (\ NP"- ,\ C #I
M (L ^ ", /\ C #_ (P _P#S @  X@<  ,P'  "_!   MP   +$ " "K !
MIP 9 *0 ) "@ "X G@ W )P 0 ": $< F !. )8 5 "5 %D DP!> )( 9 "0
M &D CP!O (T =@"+ 'X B@"( (@ D@"& )T A0"I (, N "! ,H @ #E (
M]0!_ /\ ?P#_ '\ _P#H#0  T!   +X0  "Q#@  J T  *,(  "@ @P G  3
M )@ '0"5 "< D@ Q )  .0". 4$ C %( (H"3@") E0 AP)9 (8"7P"$ V0
M@P-K ($#<@" !'H ?@2$ 'T%C@![!9H >0:G '@&M0!V!\@ =0CC '4)] !T
M"O\ <PK_ ',*_P#=%0  Q!<  +$7  "E%@  G!,  )81  "4#00 DP@- (X'
M%0"+"2  B DJ (4*,P"#"SL @0M" ( +20!^"T\ ?0Q4 'L,6@!Z#&  > QG
M '<,;@!U#78 = V  '(-C !P#9D ;PZF &T.M0!L#LD :P_F &H0]P!I$/\
M:1#_ &D0_P#0'0  N1X  *@>  ";'0  DAL  (L9  "(%0  AQ$' (4.$ "!
M#QH ?A D 'L0+0!Y$#8 =Q$] '811 !T$4H <Q%0 '$15@!P$5P ;A)B &T2
M:@!K$G, :1-] &@3B0!F$Y8 912C &,5LP!B%<8 8A;C &$6]@!@%_\ 8!?_
M & 7_P#'(@  L",  )\D  "2(P  B2(  ((@  !^'0  ?!D  'H5#0!W%14
M=!8? '$6* !O%S  ;A<X &P7/P!K%T4 :1A+ &@840!F&%@ 91A> &,99@!B
M&6\ 8!EY %\:A0!=&Y( 7!NA %L<L !:',, 61W@ %@>] !8'O\ 6![_ %@>
M_P"_)P  J2@  )DH  "+*   @B<  'LE  !V(P  <R   '$<"0!N'!$ :QP:
M &D=(P!G'2P 91TS &,>.@!B'D$ 8!Y' %\>30!>'E0 7!]; %L?8@!9(&L
M6"!V %8A@@!5(9  5"*> %,BK@!2(\  42/= %$D\@!1)/\ 423_ %$C_P"Y
M*P  HRP  ),L  "&+0  ?"P  '0J  !O*   :R4  &DB!0!F(0X 8R(6 &$B
M'P!?(R< 72,O %PC-@!:(ST 621# %<D2@!6)%  5217 %,E7P!2)6@ 429S
M $\F?P!.)XT 32B< $PHK !+*;X 2RG: $HI\0!**?\ 2RG_ $LI_P"S+@
MGB\  (XP  "!,   =R\  &\N  !J*P  92H  &,G 0!?)PP 7"<3 %HG&P!8
M*"0 5B@K %4H,@!3*#D 4BE  % I1@!/*4T 3BE4 $TJ7 !,*F4 2BMP $DK
M? !(+(L 1RV: $8MJ@!%+KP 12[6 $4N[P!%+OX 12[_ $4M_P"N,0  FC(
M (DS  !\,P  <C,  &LQ  !E+P  8"T  %TL  !9+ D 5BP0 %0L& !2+"
M4"PH $XM+P!-+38 3"T\ $HM0P!)+4H 2"Y1 $<N60!&+V, 13!M $,P>@!"
M,8D 03&8 $$RJ ! ,KL /S+3 #\R[@! ,OT 0#+_ $ R_P"J,P  EC4  (8U
M  !Y-@  ;C4  &8U  !A,@  7#   %<P  !4, 8 43 . $XP%0!,,1T 2C$E
M $@Q+ !',3( 1C$Y $0Q0 !#,D< 0C)/ $$S5P! ,V  /S1K #XU>  ]-8<
M/#:6 #LVIP [-KD .C;1 #HV[0 [-OP .S;_ #LV_P"F-@  DC<  ((X  !U
M.   :S@  &,W  !=-@  5S,  %,T  !/- , 2S0, $DT$@!&-1H 134B $,U
M*0!!-2\ 0#4V #\V/0 ^-D0 /3=, #PW50 [.%X .CAI #DY=@ X.84 -SJ5
M #<ZI0 V.K@ -3K/ #8Z[  V.OL -CG_ #<Y_P"B.   CCD  'XZ  !R.P
M:#L  %\Z  !9.0  4S8  $XW  !*.   1C@* $0Y$ !!.1< /SD? #XY)@ \
M.2T .SHT #HZ.P Y.T( .#M* #<[4P V/%P -3QG #0]=  S/8, ,SZ3 #(^
MI  Q/K8 ,3[- #$^Z@ Q/OH ,CW_ #(]_P">.P  BSP  'L\  !N/0  9#T
M %P]  !5/   3CH  $D[  !%/   03T' #X]#@ \/14 .CX< #D^(P W/BH
M-C\Q #4_.  T/T  ,T!( #) 4  Q0%H ,$%E "]!<@ N0H$ +4*1 "U"H@ L
M0K4 *T++ "Q"Z0 L0OD +4'_ "U!_P"9/0  ASX  '<_  !K/P  84   %D_
M  !2/P  23X  $0_  ! 0   /$$$ #E"#0 W0A( -4,9 #-#(0 R0R@ ,40O
M #!$-@ O1#T +D5% "U%3@ L15@ *T9C "I&;P I1GX *$:/ "='H0 F1[,
M)D?) "9&YP G1O@ *$7_ "A%_P"50   @D$  '-"  !G0@  7D(  %5"  !.
M0@  14(  #]$   [10  -T8  #1'"@ Q2!  +T@6 "Y)'@ L224 *TDL "I)
M,P I2CH *$I" "=*2P F2U4 )4M@ "1+;0 C2WP (DN- "%,GP A3+$ ($S'
M "!+Y@ A2_< (DK_ ")*_P"00P  ?D0  &]$  !D10  6D4  %)%  !*1@
M04<  #Q(   W20  ,DL  "Y-!P K3@X *4X3 "=/&@ F3R$ )4\H "1/,  C
M4#< (E _ "%02  @4%( 'U%= !Y1:@ =47D '%&* !M1G  :4:\ &5'% !E1
MY  :4/8 &T__ !Q/_P"*1@  >4<  &M'  !@2   5D@  $Y(  !'20  /DL
M #E,   S3@  +E   "A3 @ D5 L (E40 "!5%@ ?5AX 'E8D !U6+  <5C,
M&U<[ !I71  95TX &%=9 !=89@ 56'4 %%B' !18F@ 35ZP $E?" !)7X0 3
M5O0 %%7_ !15_P"$20  =$H  &9+  !<2P  4TL  $M,  !$30  /$\  #51
M   O5   *58  "19   >6P< &ET- !A=$@ 771D %EX@ !5>)P 47BX $UXW
M !)>0  17TH $5]5 !!?8@ /7W$ #E^#  U?E@ -7ZD #%Z^  Q>V@ -7?
M#5S\  Y<_P!^30  ;DX  &).  !83P  3T\  $A0  ! 4@  .%0  #!7   J
M6@  )%T  !]?   98@$ $V4) !%F#P 09A0 #V8;  YG(@ -9RD #6<R  QG
M.P +9T4 "F=0  EG70 '9VP !F=]  5GD  $9J,  F:W  -ESP $9>D !&3U
M  1D_ !W40  :5(  %U2  !44@  3%,  $-5   [6   ,UL  "M>   E80
M'V0  !EG   3:@  #VT&  MP#  (<!$ !W 6  5P'0 $<"0  W L  )P-0
M<#\  '!*  !P5P  <&4  '!V  !PB@  ;YX  &^R  !NR   ;>4  &WR  !M
M^0!P5@  8U8  %E6  #_XO__24-#7U!23T9)3$4 ! E15P  1U@  #Y;   V
M7P  +F(  "9F   ?:@  &6T  !-P   .<P  "W8$  5X"P !> \  'D3  !Y
M&0  >1\  'HF  !Z+P  >CD  'I$  !Z4   >E\  'IP  !Z@P  >I@  'JL
M  !YP@  >-\  'CO  !W]P!J6P  7UL  %9;  !,7   0F   #EC   P:
M*&P  "!P   9=   $W<   Y[   )?@  !($"  """   @PT  (,0  "$%
MA1D  (8@  "&*   AS$  (<\  "'20  AU<  (=H  "'>P  AY   (:E  "%
MN@  A=,  (3J  "$] !E8   7&   %%A  !&9   /&D  #)M   I<@  (7<
M !E[   2@   #8,   B'   "B@   (T   ".!   C@D  (\-  "0$   D10
M )(9  "3(   E"D  )4S  "50   EDX  )9?  "5<@  E8@  )6=  "4L@
ME,@  )/B  "3[@!A90  5F8  $IJ   _;@  -70  "MY   A?P  &80  !&)
M   ,C0  !I$   "4    F    )H   ";    G (  )T'  ">"P  GPX  *$2
M  "B&   HR   *4I  "F-@  ID0  *95  "F:   IGT  *:4  "EJ0  I+T
M *31  "DY !;;   3W   $-U   X>P  +8$  ".'   9C0  $9(   N7   $
MG    *    "C    I@   *@   "I    J@   *P   "M!   K@D  + -  "Q
M$0  LQ<  +4@  "V*P  MSH  +=+  "X7   N'$  +B(  "XG0  N+$  +?"
M  "WT !4=@  2'P  #R"   QB0  )I   !N7   2G0  #*(   .G    JP
M *X   "R    M@   +@   "X    N@   +L   "]    O@   , %  #!"P
MPQ   ,86  #)(   RBX  ,L^  #,4   S&0  ,UZ  #-D0  S:0  ,VT  #-
MP !-@P  08H  #61   IF0  'J   !.F   ,K    [$   "V    N@   +X
M  #"    Q@   ,@   #(    R@   ,L   #-    S@   -    #2 0  U0@
M -D.  #=%0  X2$  .(Q  #D0P  Y58  .9K  #F@@  YY8  .>E  #FL #_
M  D _P % /\ !@#_  X _P 6 /\ (0#_ "T _P X /T 0P#Y $T ]0!5 /(
M70#P &, [@!I .P ;P#J '0 Z0!Z .< ?P#F (4 Y "+ ., D0#A )D WP"A
M -P J@#: +8 UP#& -4 X0#3 /0 T@#_ -$ _P#1 /\ SP#_ ,H _P#_  $
M_P   /\  0#_  P _P 2 /H '0#V "@ \P S /  /@#L $@ Z !0 .4 6 #B
M %X WP!D -T :@#; &\ V0!T -8 >@#4 '\ T@"% -  C #. ), S "< ,D
MI0#' +  Q@"^ ,0 U #" .X P0#^ ,  _P#  /\ OP#_ +X _P#_    _P
M /\   #Z  < \0 / .L & #F ", X@ N .  . #; $( U0!+ -$ 4@#. %D
MRP!? ,D 90#' &H Q@!O ,0 = #" 'H P0"  +\ A@"] (X NP"6 +D H "W
M *H M@"W +0 R@"R .8 L0#X +  _P"O /\ KP#_ +  _P#_    _P   /<
M  #J  ( X0 , -< $P#0 !T S  H ,D ,@#& #P P@!% +\ 30"\ %, N@!9
M +@ 7P"W &0 M0!I +0 ;@"R '0 L0!Z *\ @ "M (@ K "1 *H F@"H *4
MI@"Q *0 P0"C -P H0#R *$ _P"@ /\ H #_ *$ _P#_    ]P   .@   #9
M    RP ( ,, $ "] !@ N0 B +8 + "T #8 L@ _ *\ 1P"L $T JP!4 *D
M60"G %X I@!C *4 : "C &X H@!T *  >@"> (( G "+ )L E0"9 )\ F "L
M )8 N@"4 ,\ DP#K )( ^P"2 /\ D@#_ )$ _P#W    YP   -,   #&
MNP " +, # "M !( J@ < *< )@"D #  HP X *  0 "> $< G !. )H 4P"9
M %@ EP!= )8 8P"5 &@ DP!N )( = "0 'P CP"% (T CP"+ )H B@"G (@
MM0"& ,< A0#D (0 ]0"$ /\ @P#_ (, _P#L    TP   ,$!  "T    K
M *8 !P"@  X G0 6 )H ( "7 "D E0 R ), .@"1 $$ CP!( (T 30", %,
MBP!8 (D 70"( &, AP!I (4 ;P"# '< @@"  (  B@!^ )8 ?0"C 'L L !Z
M ,( >0#= '@ \0!W /T > #_ '@ _P#>"@  Q L  +(,  "F"P  G0@  )D$
M  "5  H D0 1 (X &0"+ ", B0 L (< - "% #L @P!" (( 2 "  $X ?P!3
M 'T 6 !\ %X >P!D 'D :@!X '( =@![ '0 A@!S )( <0"? '  K0!N +X
M;0'6 &T"[0!L _H ; /_ &P#_P#.$   MQ$  *82  ":$0  D1   (L.  ")
M"P, AP4, (0!$P"! 1P ?@(E 'P#+@!Z S8 > 0\ '<$0P!U!4@ = 5. ',%
M5 !Q!5D < 9? &X&9@!M!FX :P=X &H'@P!H")  9PF= &4)K !D";P 8PK4
M &,+[ !B#/H 8@S_ &(,_P##%@  K1<  )T8  "0&   AQ8  ($4  !]$0
M? X& 'P*#@!X"A8 =0L? '(+* !P##  ;PPW &T,/@!L#$0 :PU* &D-3P!H
M#54 9PU< &4-8P!C#FL 8@YU & .@0!?#HX 70^< %P0JP!;$+T 6A#6 %D1
M\ !9$?T 61'_ %D1_P"Y&P  I1T  )0>  "('@  ?AT  '@;  !T&   <14
M '$1"0!O$!$ ;! 9 &D0(@!G$2H 9A$R &01.0!C$3\ 8A%% & 22P!?$E$
M71)8 %P27P!:$V@ 61-R %<4?0!6%(L 5!69 %,5J0!2%KH 41;2 %$7[0!1
M%_T 41?_ %$7_P"R(   GB(  (XB  "!(P  =R(  ' A  !L'@  :1L  &<8
M! !F%0X 8Q85 &$6'@!?%B8 718M %P7- !:%SL 61=! %@81P!6&$T 51A4
M %,87 !2&60 41EN $\:>@!.&X@ 31N7 $L<I@!*'+@ 2AW/ $D=ZP!)'?L
M21W_ $H=_P"L)   F"4  (@F  ![)P  <28  &HE  !F(P  8B$  & >  !>
M' L 6QL2 %D<&@!7'"( 51PI %0<, !3'3< 41T] % =0P!/'4H 31Y1 $P>
M6 !+'V$ 21]K $@@=P!'((4 1B&4 $0BI !$(K8 0R+, $,CZ0!#(_H 0R/_
M $,B_P"F)P  DRD  (,J  !V*@  ;2H  &4I  !@)P  7"4  %DC  !7(0<
M52$/ %(A%@!0(1X 3B$E $TB+ !,(C, 2B(Y $DB0 !((D8 1R-- $4C50!$
M)%X 0R1I $(E=0! )H, /R:2 #XGHP ^)[0 /2?* #THZ  ]*/D /2?_ #XG
M_P"B*@  CBL  '\M  !R+0  :"T  &$L  !<*P  6"@  %0F  !1)@0 3B4-
M $PE$P!*)AH 2"8B $<F*0!%)B\ 1"8V $,G/ !!)T, 0"=+ #\H4P ^*5P
M/2EF #PJ<@ [*H$ .BN0 #DKH0 X++( -RS( #<LY@ X+/@ ."S_ #@L_P"=
M+   BBX  'LO  !O,   93   %TO  !8+@  4RL  % J  !,*@  22H+ $8J
M$0!$*A< 0BH? $$J)0 _*BP /BLS #TK.0 \*T  .RQ( #HL4  Y+5D ."YD
M #<N<  V+W\ -2^/ #0PGP S,+$ ,C#' #(PY0 S,/< ,S#_ #0O_P"9+P
MAS$  '<R  !K,@  8C(  %HR  !4,0  3R\  $LM  !'+@  1"X( $$N#@ _
M+A0 /2X< #LN(@ Y+RD ."\O #<O-@ V,#X -3!& #4Q3@ T,5< ,S)B #(R
M;@ Q,WT ,#.- "\TG@ N-+  +33% "TTXP N-/8 +S/_ "\S_P"5,0  @S,
M '0T  !H-0  7C4  %<T  !1-   2S(  $8Q  !",@  /S(% #PR#0 Y,Q(
M.#,9 #8S(  T,R8 ,S,M #(T-  Q-#L ,#5# # U3  O-E4 +C9@ "TW;  L
M-WL *S>+ "HXG  I.*X *#C# "@XX@ I./4 *C?_ "HW_P"2-   ?S4  '$V
M  !E-P  6S<  %0W  !--@  1S8  $(U   ]-@  .C8" #<W"P T-Q  ,C<6
M #$X'0 O."0 +C@K "TY,@ L.3D *SE! "HZ20 J.E, *3M> "@[:@ G.WD
M)CR) "4\FP D/*T (SS" ",\X  D//0 )3O_ "4[_P"--@  ?#@  &TY  !B
M.0  6#H  %$Y  !*.0  1#D  #TY   Y.@  -3L  #(["  O/ X +3T4 "P]
M&@ J/2$ *3TH "@^+P G/C8 )CX^ "4_1P D/U  (T!; ") :  A0'8 ($"'
M !]!F0 ?0:L 'D'  !Y!W@ ?0/, 'T#^ " __P").0  >#H  &D[  !>/
M53P  $T\  !'/   0#P  #@]   T/@  ,$   "U!!0 J0@P )T(1 "9#&  D
M0QX (T,E ")#+  A1#, ($0[ !]$1  >14X '459 !Q%90 ;170 &D6% !E&
MEP 91JD &$:^ !=%W  81?$ &43] !I$_P"$/   <ST  &8^  !;/P  4C\
M $H_  !$/P  /4   #9!   Q0P  +$0  "=& 0 D1PH (4@/ "!)%  >21L
M'4DB !Q)*0 ;2C  &DHX !E*00 82DL %TM5 !9+8@ 52W$ %$N" !-+E  2
M2Z< $DN\ !%+V0 22O  $TK\ !1)_P!_/P  ;T   &%!  !70@  3D(  $="
M  !!0@  .D,  #)%   M1P  *$D  "-+   >308 &T\- !A0$0 74!< %E >
M !50)0 44"P $U$T !)1/0 144< $5%2 !!17P /4FT #E)^  U1D0 -4:0
M#%&X  Q1T0 -4.P #5#Z  Y/_P!Y0P  :D0  %U$  !310  2T4  $1%   ^
M1@  -D@  "]*   I3   )$\  !]1   :4P  %%8) !%7#@ 06!, $%@9  ]8
M(  .6"@ #5@P  U8.0 ,6$, "UA.  I86@ (6&@ !UAY  98C  %6)\ !%BS
M  17R@ %5^8 !5?S  96_ !S1@  9$<  %E(  !02   2$@  $%)   Z2@
M,DT  "M0   E4@  (%4  !I8   56@  $%T&  Q@#  *8!  "6 5  A@'  '
M8", !6 K  1@-  #8#T  6!)  !@50  8&,  &!S  !@A@  7YH  %^N  !?
MQ   7N(  %[P  !>^ !L2@  7TL  %5+  !,3   14P  #U.   U4   +E,
M "=6   @60  &EP  !5?   08@  #64$  AG"P #9PX  &@3  !H&   :!\
M &DF  !I+@  :3@  &E#  !I3P  :5T  &EM  !I@   :90  &BI  !HOP
M9]P  &;N  !F]P!F3P  6D\  %%/  !*3P  05$  #A4   P5P  *%L  "%>
M   :8@  %&4  !!H   ,:P  !VX#  %P"0  < T  '$0  !Q%   <AH  ',A
M  !S*   <S$  ',\  !T2   <U8  '-F  !S>0  <XX  '.C  !RN0  <=(
M ''K  !P] !A4P  5E,  $]3  !%50  .U@  #)<   J8   (F0  !MH   4
M;   #V\   MR   &=@   'D   !Z!@  >@H  'L.  !\$0  ?14  'X;  !_
M(@  @"H  ( U  " 00  @$\  (!?  " <0  @(8  ("=  !_L@  ?LH  '[E
M  !]\0!<6   5%@  $E:   _70  -6$  "QE   C:@  &V\  !1S   .=P
M"7L   -_    @@   (0   "& 0  A@8  (@*  ")#0  BA   (L5  ",&P
MCB(  (\L  "/.   CT8  (]6  "/:   CWX  (^5  ".JP  C<$  (W<  ",
MZP!970  3E\  $-B   X9@  +FP  "1Q   <=P  %'P   Z!   (A0   (D
M  "-    D    )(   "3    E    )8#  "7"   F P  )H/  ";$P  G1H
M )\C  "@+@  H#P  *!,  "@7@  H'0  )^,  "?H@  G[<  )[+  ">X !3
M9   1V@  #QM   Q<P  )WD  !U_   4A0  #8L   :0    E    )@   "<
M    GP   *$   "B    I    *4   "G    J 0  *H)  "L#0  K1(  + 9
M  "R(P  LC$  +)"  "R5   LFD  +*   "RF   L:P  +*_  "QS@!,;@
M0',  #5Z   J@0  'X@  !6.   .E0  !IH   "?    I    *@   "L
MKP   +$   "Q    LP   +4   "V    N    +H   "\!@  O@P  , 1  ##
M&0  Q28  ,4W  #&20  QET  ,=R  #'B@  R)\  ,BO  #(O !&>@  .8$
M "Z)   BD   %Y@   ^?   'I0   *H   "O    LP   +<   "\    OP
M ,$   #"    Q    ,4   #'    R0   ,L   #-    SP,  -(*  #6$
MW!H  -TJ  #>/   WU   .!E  #A>P  X9$  .*B  #BK0#_  ( _P   /\
M P#_  P _P 3 /\ '0#_ "@ _@ S /L /@#W $@ \P!0 /  5P#M %X ZP!D
M .@ :0#G &\ Y0!T ., >0#B '\ X "% -X C #< ), V0"< -8 I@#3 +$
MT0#  ,\ V@#. /$ S #_ ,L _P#+ /\ Q@#_ ,$ _P#_    _P   /\   #_
M  @ ^P 0 /8 &0#R "0 [P N .T .0#H $( XP!+ .  4@#= %D V0!? -8
M9 #3 &D T0!N ,\ = #. 'D S !_ ,H A@#( (X Q@"6 ,0 H #" *L P "Y
M +X S0"\ .H NP#\ +H _P"Z /\ N@#_ +8 _P#_    _P   /X   #T  0
MZP - .0 % #? !\ VP I -@ ,P#3 #T S@!% ,H 30#' %, Q0!9 ,, 7P#!
M &0 OP!I +T ;@"[ ', N@!Y +@ @ "V (@ M "0 +( F@"Q *4 KP"R *T
MQ "L .$ JP#V *H _P"J /\ J@#_ *H _P#_    _0   .X   #B    U0 *
M ,T $0#' !D Q  C ,$ +0"_ #< NP _ +< 1P"U $X L@!3 +  60"O %X
MK0!C *P : "K &T J0!S *@ >@"F ($ I "* *, E "A )\ GP"L )X NP"<
M -( FP#N )H _P": /\ F0#_ )D _P#^    [@   -X   #+    P0 % +D
M#0"T !0 L0 > *X )P"K #  J@ Y *< 00"D $@ H@!- *$ 4P"? %@ G@!=
M )T 8@"; &< F@!M )@ <P"7 'L E0"$ )0 C@"2 )D D "F (X M "- ,@
MC #F (L ^0"* /\ B@#_ (L _P#P    VP   ,<   "Z    L    *@ "@"D
M !  H  8 )T (0"; "H F@ S )@ .P"6 $$ E !( )( 30"1 %( CP!7 (X
M7 ", &$ BP!G (H ;@"( '4 AP!^ (4 B "# )0 @@"@ (  KP!_ ,  ?@#=
M 'T \@!] /\ ?0#_ 'T _P#@    Q@   +4   "J    H@   )L !0"5  T
MD@ 3 )  ' "- "0 BP M (H - "( #L A@!" (4 1P"# $T @@!2 ($ 5P!_
M %P ?@!B 'T : ![ '  >@!Y '@ @P!V (\ =0"< '0 J@!R +H <0#1 '
M[ !P /L < #_ '  _P#-!   MP8  *<'  ";!@  DP0  (X   "*  @ A@ /
M (0 %@"! !X ?P G 'T +@!\ #8 >@ \ 'D 0@!W $< =@!, '4 4@!S %<
M<@!= '$ 8P!O &L ;@!T &P ?@!K (H :0"8 &@ I@!G +8 9@#+ &4 YP!E
M /< 90#_ &4 _P# #   JPT  )L.  "/#@  A@T  ($+  !^!P$ ? $+ 'D
M$0!W !@ =0 A ', *0!Q #  ;P V &X / !L $( :P!' &H 30!I %( : !8
M &8 7P!E &< 8P!P &(!>@!@ 8< 7P*5 %X"HP!< [, 7 /' %L$Y !;!?0
M6P;^ %L&_P"U$   H1(  )$3  "%$P  ?!(  '81  !S#@  <@P$ '$'#0!N
M!!( ; 0; &D%(P!G!2H 9@8Q &0&-P!C!CT 8@=# &$'20!?!TX 7@A5 %T(
M7 !;"6, 6@EM %@*> !7"H4 5@N3 %0+H@!3"[, 4@S' %(,Y !1#?4 40W_
M %$-_P"M%0  F1<  (D8  !]&0  =!@  &T7  !J%   9Q$  &<.!P!F# X
M8PP5 &$,'0!?#"4 70TL %P-,P!;#3D 6@T_ %@-10!7#4L 5@Y1 %4.60!3
M#F$ 4@YK % /=@!.$(, 31"2 $P0H@!+$+( 2A'( $D1Y0!)$?< 21+_ $D1
M_P"E&0  DAP  (,=  !V'@  ;1T  &8<  !B&@  7Q<  %X4 0!>$0H 6Q 1
M %D1& !7$2  51$G %01+@!3$30 41$[ % 200!/$D< 3A). $P250!+$UX
M21-G $@4<P!&%(  116/ $05GP!#%K  0A;% $(7XP!"%_8 0A?_ $(7_P"?
M'0  C"   'TA  !Q(@  :"(  &$A  !<'P  61P  %<9  !5%@8 5!4. %$5
M% !/%AP 3A8C $P6*@!+%C  2A8W $D7/0!'%T, 1A=* $484@!#&%H 0AED
M $$9<  _&GT /AN- #T;G0 \'*X .QS# #L<X0 ['?4 .QS_ #P<_P":(0
MAR,  '@D  !L)0  8R4  %PD  !7(P  4R   %$>  !/' ( 31L, $L:$0!(
M&Q@ 1QL@ $4;)@!$&RT 0QPS $(<.0! '$  /QU' #X=3P ]'E@ /!YB #H?
M;0 Y'WL .""+ #<AFP V(:T -2'! #4AWP U(?, -B'_ #8A_P"6(P  @R8
M '0G  !H*   7R@  %@G  !3)@  3R0  $PB  !)(   1R ) $0?#P!"'Q4
M0" < #\@(P ^("D /" O #LA-@ Z(3T .2%$ #@B3  W(E4 -B-? #0C:P S
M)'D ,B6) #$EF@ P):L ,":_ "\FW  P)O( ,";_ #$E_P"1)@  ?R@  '$J
M  !E*@  7"H  %4J  !/*0  2R@  $@E  !$)   020% #\D#0 ])!( .R09
M #DD'P W)"8 -B0L #4E,P T)3H ,R9! #(F2@ Q)U, ,"== "\H:0 N*7<
M+2F' "PIF  K*JH *BJ] "HJV@ K*O$ *RK^ "PI_P"-*   ?"H  &TL  !B
M+0  62T  %$M  !,+   1RL  $,H   _*   /"@" #DH"P W*!  -2@6 #,H
M'  R*", ,"@I "\I,  O*C< +BH_ "TK1P L*U$ *RQ; "HL9P I+74 *"V%
M "<MEP F+J@ )2Z\ "4NV  F+O  )B[] "<M_P"**P  >"T  &HN  !?+P
M5B\  $XO  !(+@  0RT  #\L   [+   -RP  #0L"0 R+ X ,"T3 "XM&@ M
M+2  *RTG "HN+0 J+C4 *2\] "@O10 G,$X )C!9 "4Q90 D,7, (S&# "(R
ME0 A,J< (3*[ " RU  A,N\ (C'\ "(Q_P"&+0  =2\  &<P  !<,0  4S$
M $LQ  !%,0  0#   #LP   V,   ,S   # Q!@ M,0T *S$1 "DR%P H,AX
M)S(D "4S*P E,S( )#,Z ",T0P B-$P (357 " U8P ?-7$ 'C:! !TVDP <
M-J4 &S:Y !LVT@ <-NT '3;[ !TU_P"",   <3(  &,S  !9-   4#0  $DT
M  !",P  /3,  #<S   Q-   +C4  "LU @ H-@L )3<0 "0W%0 B-QL (3@B
M " X*  ?.#  'C@W !TY0  <.4D &SI4 !HZ8  9.FX &#I_ !<[D0 7.Z0
M%CNW !4[T  6.NP %SKZ !@Y_P!],@  ;30  & U  !5-@  338  $8V  !
M-@  .C8  #0V   N.   *CD  "8Z   C.P@ (#P. !X]$@ =/1@ '#T? !L^
M)0 :/BT &3XT !<^/0 6/T< %3]1 !0_7@ 4/VP $T!\ !) CP 10*( $4"V
M !! S@ 1/^L $C_Y !(^_P!Y-0  :3<  %PX  !2.0  2CD  $,Y   ].0
M-SD  #$Z   K/   )ST  "(_   >000 &D(+ !A#$  70Q4 %40; !1$(@ 3
M1"D $T0Q !)$.@ 114, $$5. !!%6P .16D #D5Y  U%C  -19\ #$6R  M%
MR0 ,1>4 #43V  U$_P!T.0  93H  %@[  !/.P  1SP  $ \   Z/   -#P
M "X^   H0   (T(  !]$   :1@  %4@( !)*#0 12A( $$H8  ]+'@ .2R4
M#4LM  U+-@ ,2T  "TM*  I+5@ )2V0 "$MT  =+AP %2YH !$NN  1*Q  %
M2N  !4KP  9)^@!N/   8#T  %0^  !+/@  1#X  #T^   W/P  ,4   "I"
M   D10  'T<  !I)   53   $4X%  Y1"P +41  "E$4  E1&P (42( !U$I
M  51,@ $4CL  U)&  %24@  4E\  %)O  !2@0  498  %&I  !1OP  4-P
M %#N  !0]P!H0   6T$  %!!  !(00  04$  #M"   T0P  +44  "9(   @
M2P  &TT  !90   14P  #E4$  I8"@ &6 X  E@2  !9%P  61T  %DE  !9
M+0  638  %E!  !930  6EH  %II  !9?   69   %FE  !8N@  6-4  %?L
M  !7]@!C1   5D4  $U%  !%10  /T4  #='   O20  *$P  ")/   ;4@
M%E4  !%8   -6@  "5T#  1?"0  8 T  & 0  !A%   81D  &(@  !B)P
M8C$  &([  !B1P  8E4  &-D  !B=@  8HL  &*@  !AM@  8<\  &#J  !@
M]0!=2   4DD  $I(  !#2   .DH  #)-   J4   (U,  !Q7   66@  $5T
M  U@   (8P   V8!  !G!@  : L  &D.  !J$0  :Q4  &P;  !M(@  ;2H
M &TT  !M0   ;4X  &U=  !M;P  ;80  &R:  !LL   :\@  &OF  !J\P!8
M30  3DT  $A,   ^3@  -5$  "Q4   D6   '5P  !9@   09   #&<   =K
M   !;@   '    !R P  <@<  ',+  !U#@  =A$  '<6  !X'   >2,  'HM
M  !Z.0  >D<  'I6  !Y:   >GP  'F4  !XJ@  >,$  '??  !W[P!440
M3%$  $)2   X50  +UD  "9>   >8@  %F<  !!K   +;P  !7,   !W
M>@   'P   !^    ?P(  ( &  "!"@  @PT  (01  "&%0  B!P  (DE  "*
M,   BCX  (E-  ")7P  B7,  (B+  "(H@  A[D  (?1  "&Z !25@  1U<
M #Q:   R7P  *&0  !]I   6;P  $'0   IY   "?0   ($   "%    B
M (H   ",    C0   (\   "0!   D@@  ),,  "5$   EQ4  )D=  ";)P
MFS0  )M$  ":5@  FFH  )F"  ":F@  F+   )C'  "7W@!+7   0&   #5E
M   K:@  (7$  !=W   0?0  "8,   &(    C    )$   "5    F    )H
M  ";    G0   )\   "@    H@   *0%  "F"@  J X  *H4  "M'0  K2H
M *TY  "M2P  K5\  *UW  "LD   JZ<  *NZ  "KRP!%9@  .6L  "YQ   C
M>   &7\  !"&   )C0   ),   "8    G0   *$   "E    J    *L   "K
M    K@   *\   "Q    LP   +4   "W 0  N0<  +P-  "_$P  PA\  ,(N
M  #"0   PE0  ,%K  #!@P  P)L  ,&M  #!O  ^<@  ,G@  ">    <B
M$I    J7    G0   *,   "H    K0   +(   "V    N0   +L   "\
MO@   ,    #"    Q    ,8   #(    RP   ,X%  #1#0  UA0  -<C  #8
M-0  V4D  -I>  #;=0  VXP  -R?  #<JP#_    _P   /\   #_  D _P 0
M /\ &0#^ "0 _  O /D .0#T $, \ !+ .T 4@#J %D YP!? .0 9 #B &D
MX !N -X <P#< 'D V@!_ -< A@#4 (X T0"6 ,\ H0#, *P R@"[ ,@ T@#&
M .X Q@#_ ,4 _P#% /\ OP#_ +H _P#_    _P   /\   #^  4 ]P . /(
M%0#N !\ ZP J .D - #C #T W@!% -D 30#4 %, T0!9 ,X 7@#, &, R@!H
M ,D ;0#' ', Q0!Y ,, @ #! (@ OP"0 +T FP"[ *8 N0"T +< R "V .8
MM0#[ +0 _P"T /\ LP#_ *X _P#_    _P   /@   #M    Y0 + -T $0#7
M !H T@ D ,\ +@#+ #< QP!  ,, 1P#  $X O@!3 +P 60"Z %X N !C +8
M: "U &T LP!S +$ >0"O ($ K0"* *L E "I *  J "M *8 O@"E -L I #T
M *0 _P"C /\ HP#_ *( _P#_    ]@   .8   #7    RP & ,0 #@"^ !4
MNP ? +D * "W #$ M  Z +  00"M $@ JP!. *D 4P"G %@ I@!< *0 80"C
M &< H0!L *  <P"> 'H G0"# )L C@"9 )D EP"F )8 M@"5 ,P E #K ),
M_0"3 /\ DP#_ ), _P#W    Y    -    #!    MP " *\ "P"K !$ IP 9
M *4 (@"C "L H@ S )\ .P"< $( FP!( )D 30"7 %( E@!7 )4 6P"3 &$
MD@!F )  ;0"/ '0 C0!] (P AP"* ), B "@ (< KP"% ,( A0#B (0 ]P"$
M /\ A #_ (0 _P#E    S0   +P   "O    I@   )X !P":  X E@ 4 )0
M'0"2 "4 D0 M )  -0"- #P C !" (H 1P"( $P AP!1 (8 5@"$ %L @P!@
M ($ 9P"  &X ?@!W 'T @0![ (T >@": '@ J0!W +H =@#3 '8 [P!V /X
M=0#_ '4 _P#0    NP   *L   "?    EP   )   @"+  L B  0 (8 %P"$
M "  @@ G ($ +P!_ #4 ?0 \ 'P 00![ $8 >0!+ '@ 4 !W %4 =@!; '0
M80!S &D <0!Q '  >P!N (< ;0"5 &L HP!J +0 :@#) &D Z !I /D :0#_
M &D _P#     K    )P"  "0 @  B    (,   !_  8 >P - 'D $@!W !H
M=@ B '0 *0!S #  <0 V '  / !O $$ ;0!& &P 2P!K %  :@!6 &@ 7 !G
M &0 90!L &0 =@!C (( 80"0 &  GP!? *\ 7@## %X X0!> /0 70#_ %T
M_P"T!P  H D  ) +  "$"P  ? H  '<'  !T!   <0 ) &\ #P!M !4 :P <
M &D (P!H "H 9P Q &4 -@!D #P 8P!! &( 1@!@ $P 7P!2 %X 6 != %\
M6P!H %H <@!8 'X 5P", %8 FP!5 *L 5 "^ %0 V@!3 .\ 5 #[ %0 _P"I
M#0  E@X  (<0  !Z$   <A   &P.  !I#   9PD# &8$"P!D !  8@ 7 &
M'@!> "4 70 K %P ,0!: #< 60 \ %@ 0@!7 4< 5@%. %4"5 !3 EP 4@-E
M %$#;P!/!'L 3@2* $T%F0!,!:D 2P6\ $H&U !*!^T 2@?Y $H'_P"A$
MCA(  'X4  !S%   :A0  &03  !@$0  7@\  %T-!0!="0T 6@82 %@'&0!6
M!R  50<G %,'+0!2"#, 40@X % (/@!/"40 3@E* $P)40!+"ED 2@IB $@+
M;0!'"WH 1@R( $0,F !##*D 0@V\ $(-U0!"#>X 0@W[ $(-_P":%   AQ8
M '@8  !L&0  8QD  %T8  !9%@  5A,  %01  !4#@@ 4PT. %$-% !/#1L
M30TB $P-* !+#2X 2@TT $D-.@!'#D$ 1@Y' $4.3P!$#E< 0@]A $$0;  _
M$'D /A"( #T1F  [$:D .Q&\ #H1U@ Z$?  .A+] #L1_P"3&   @1H  ',<
M  !G'0  7AT  %@<  !3&P  4!@  $X6  !,$P, 3!$+ $H0$ !($1< 1A$>
M $41) !$$2H 0A$P $$1-P! $CT /Q)$ #T23  \$U0 .Q-> #D4:0 X%'8
M-Q6% #85E@ T%J< -!:Z #,6TP S%NX -!;\ #06_P".&P  ?!T  &X?  !C
M(   6B   %,@  !.'@  2AT  $@:  !&&   118' $,5#@!!%1, /Q4: #X5
M(  ]%2< .Q4M #H6,P Y%CH .!9! #<720 U%U$ -!A; #,99@ R&7, ,!J#
M "\:E  N&Z4 +1NX "T;T  M&^P +AO[ "X;_P"*'@  >"   &HB  !?(P
M5B,  $\B  !*(0  1B   $,>  !!&P  /QH# #T:#  [&1$ .1D6 #<:'0 V
M&B, -1HI #0:,  S&S8 ,1L^ # <1@ O'$\ +AU9 "T=9  L'G$ *Q^! "H?
MD@ I'Z0 *""W "<@S@ G(.L *"#Z "D?_P"&(   =",  &<D  !<)0  4R4
M $PE  !')   0B,  #\A   ]'P  .AX  #<>"0 U'@X ,QX3 #$>&@ P'B
M+QXF "X?+0 M'S, +" [ "L@0P J(4P *2%6 "@B8@ F(F\ )2-_ "0CD  C
M(Z( (B2U "(DS  B).D (R3Y "0C_P""(P  <24  &,F  !9)P  4"@  $DG
M  !#)P  /R8  #LD   X(@  -2(  #(B!@ P(@T +B(1 "PB%P J(AT *2(C
M "@C*@ G(S$ )B0X "4E00 D)4H (R94 "(F8  A)VT ("=] !\GCP >**$
M'BBT !THR@ =*.@ 'BCX !\G_P!^)0  ;B<  & I  !6*0  32H  $8J  !!
M*0  /"@  #<G   T)@  ,"8  "TF P K)PL *"<0 "<G%  E)QH )"<A ",H
M)P B*"X (2DV " I/@ ?*D@ 'BI2 !TK7@ <*VL &RM[ !HLC0 9+)\ &"RR
M !@LR0 8+.< &2OW !HK_P!Z)P  :BH  %TK  !3+   2BP  $,L   ^*P
M.2L  #0J   P*@  *RH  "DK   F*P@ (RP. "(L$@ @+!@ 'RP> !XM)0 =
M+2P '"TS !LN/  :+D4 &2]0 !@O7  7+VD %C!Y !4PBP 4,)X %#"Q !,P
MQP 3,.4 %##V !4O_P!V*@  9RP  %HM  !0+@  2"X  $$N   [+@  -BT
M #$M   L+0  )R\  "0O   A, 4 'S$, !PQ$  ;,A4 &C(< !DR(@ 8,BD
M%S,Q !8S.0 5,T, %#1- !,T60 2-&< $35W !$UB0 0-9P $#6P  XUQ@ /
M-.0 $#3U ! T_P!R+   8RX  %<P  !-,   13   #XP   X,   ,S   "\P
M   I,0  )#(  "$S   =-0( &C8) !<W#@ 5-Q, %#@9 !,X'P 2."8 $C@N
M !$Y-@ 0.4  $#E+  XY5P ..F0 #3IT  PZA@ ,.ID "SFL  HYP0 *.=X
M"SGQ  PX_ !N+P  7S$  %,R  !*,P  0C,  #LS   V,P  ,3(  "PS   G
M-   (38  !TX   9.0  %3L& !(]#  0/A  $#X5  X^'  ./B, #3XJ  P^
M,P ,/CP "S]'  H_4@ (/V  !S]O  8_@0 %/Y0 !#^H  ,^O  $/M< !3[L
M  4^]P!I,P  6S0  % U  !'-0  /S4  #DU   T-0  +C4  "DW   C.
M'CL  !H\   6/P  $D$$  Y#"@ ,1 X "D03  E$&0 (1"  !T0G  9$+P %
M1#@  T5"  )%3@  15L  $5J  !%?   19   $2D  !$N0  1-$  $3J  !#
M]0!D-@  5S<  $PX  !#.   /#@  #<X   Q.   *SD  "4[   @/0  &D
M !9"   21   #D<$  M)"0 '2@T !$L1  %+%@  2QP  $LC  !+*P  2S0
M $L^  !,20  3%<  $QF  !,=P  2XP  $NA  !+M0  2LX  $KI  !*]0!?
M.@  4CL  $@[  ! .P  .CL  #0[   N/   )SX  ")!   <0P  %D8  !))
M   .2P  "TX#  =0"  "40P  %$0  !2$P  4Q@  %,?  !3)@  4R\  %,Y
M  !310  4U(  %-A  !3<@  4X<  %*<  !2L0  4<H  %'G  !1] !9/@
M3CX  $4^   ^/@  .#X  #!    I0@  (T0  !U'   72@  $DT   Y0   +
M4P  !E4"  !7!P  6 L  %D.  !:$0  6A4  %L:  !<(0  7"H  %PT  !<
M/P  7$T  %Q;  !<;   7($  %N7  !;K0  6L4  %KD  !9\P!40@  2D(
M $)"   \0@  -$,  "Q&   E20  'DP  !=/   24P  #E8   I9   %6P
M %X   !@!   80@  &(,  !C#@  9!$  &46  !F'   9R,  &<M  !G.0
M9T8  &=5  !G9@  9WH  &:1  !EJ   9<   &3>  !D\ !/1@  1T8  $!%
M   W1P  +TH  "9-   ?40  &%4  !)9   -7   "&    )C    9@   &@
M  !J    :P0  &P(  !M#   ;PX  ' 2  !R%P  <QT  '0F  !T,@  =#\
M '1.  !S7P  ='(  '.*  !RH0  <;@  ''4  !P[ !,2@  14H  #M+   R
M3@  *5(  "!6   86P  $E\   UD   ':    &L   !O    <@   '4   !V
M    =P   'D"  !Z!@  ? H  'X.  " $0  @A8  (0>  "$*0  A#8  (1%
M  "$5@  @VH  (.!  ""F0  @;$  (#)  " Y0!*3@  /U   #53   K5P
M(EP  !EB   29P  #&P   5Q    =0   'D   !]    @0   (,   "%
MA@   (@   ")    BP0  (T(  "/#0  DA   )06  "6(   EBP  )8[  "6
M3   E6   )5V  "4D   DZ<  )*]  "2U0!$50  .5D  "]=   D8P  &FD
M !)O   ,=0  !'L   "     A0   (D   "-    D0   ),   "4    E@
M )@   ":    G    )X   "@!@  H@L  *40  "H%P  J2,  *DQ  "I0P
MJ58  *AM  "FAP  IYX  *:S  "EQP ^7@  ,F,  "=J   =<   $W@   Q_
M   #A0   (L   "1    E@   )L   "?    H@   *0   "E    IP   *D
M  "K    K0   +    "R    M0(  +<)  "[$   OA@  +XF  "^.   ODL
M +UA  "\>@  NY0  +JI  "ZN0 W:@  *W   "!X   6@   #8@   6/
ME@   )P   "B    IP   *P   "P    LP   +8   "W    N0   +L   "]
M    OP   ,(   #%    R    ,H   #."   TA   -4;  #5+   U$   -17
M  #3;@  U(8  -2;  #3JP#_    _P   /\   #_  4 _P . /\ %0#\ "
M^0 J /8 - #Q #T [0!& .D 30#F %, Y !9 .$ 7@#> &, W !H -D ;@#5
M ', TP!Y -  @ #. (@ RP"1 ,D G #& *< Q "W ,( S #  .P OP#_ +X
M_P"] /\ MP#_ +( _P#_    _P   /\   #Z  $ \P + .T $@#H !L Y0 E
M .0 +@#? #@ V !  -( 1P#. $X RP!4 ,@ 60#& %X Q !C ,( 9P#  &T
MOP!S +T >@"[ ($ N0"+ +8 E0"T *$ L@"O +  P@"N ., K@#Z *P _P"M
M /\ J0#_ *8 _P#_    _P   /(   #F    W0 ' -( #@#- !8 R@ @ ,@
M*0#% #( P  Z +P 0@"Y $@ MP!. +4 4P"S %@ L0!= +  8@"N &< K !L
M *H <P"I 'L IP"$ *4 C@"C )H H0"H )\ N0"> -( G0#R )P _P"= /\
MG #_ )D _P#\    [@   -T   #,    P0 " +H # "V !( L@ : +  (P"O
M "P K0 T *D / "F $( I !( *( 30"@ %( G@!7 )T 6P"< &  F@!F )D
M; "7 '0 E0!] ), AP"1 ), D "A (X L0"- ,8 C #H (L _0", /\ C #_
M (P _P#M    V    ,4   "W    K    *8 " "A  X GP 5 )T '@"; "8
MF@ N )< -0"5 #P DP!" )$ 1P"0 $P C@!1 (T 50"+ %H B@!@ (D 9@"'
M &T A0!V (0 @ "" (P @ ": '\ J0!] +P ? #< 'P ]0!\ /\ ? #_ 'P
M_P#9    P0   +$   "D    G    )0  P"0  P C0 1 (L & ") "  B0 H
M (< +P"% #8 @P \ (( 00"  $8 ?P!+ 'T 3P!\ %0 >P!: 'D 8 !X &<
M=@!P '4 >@!S (8 <0"3 '  H@!O +0 ;@#, &X [0!N /X ;@#_ &X _P#$
M    KP   *    "4    C    (8   "!  @ ?@ . 'P % ![ !L >0 B '@
M*0!W #  =0 V '0 .P!R $  <0!% '  2@!O $\ ;0!4 &P 6P!K &( :0!J
M &@ = !F (  90". &, G0!B *T 80#" &$ Y !A /@ 80#_ &$ _P"T
MH    )$   "&    ?@   'D   !U  , <0 + &\ $ !M !8 ;  = &L ) !K
M "H :0 P &@ -@!F #L 90!  &0 10!C $H 80!/ &  5@!? %T 70!E %P
M;P!: 'H 60"( %@ F !7 *@ 5@"[ %8 V !6 /$ 5@#_ %8 _P"H 0  E 4
M (4'  !Z!P  <@8  &P$  !I 0  9P ' &0 #0!C !$ 80 8 &  'P!? "4
M7@ K %T , !; #8 6@ [ %D 0 !8 $4 5P!+ %8 40!5 %@ 4P!A %( :@!0
M '8 3P"$ $X DP!- *0 3 "V $P S0!, .L 3 #Z $P _P"="0  BPL  'P-
M  !P#0  : T  &(,  !?"@  708! %P!"0!:  X 6  3 %< &0!6 "  50 F
M %, *P!2 #$ 40 V %  .P!/ $$ 3@!' $T 30!+ %4 2@!= $D 9P!' ',
M1@"  $4 D !$ *$ 0P"R $, R !# .8 0P#U $, _P"5#0  @P\  '00  !I
M$0  8!$  %H0  !6#@  5 T  %,*! !3!@L 40,0 $\!%0!. 1L 3 $A $L!
M)P!* BP 20(R $@"-P!' ST 10-# $0#2@!#!%$ 0@1: $ %9  _!7  /@9^
M #T&C@ \!Y\ .P>Q #H'Q@ Z!^, .@?S #H(_ ".$   ?!(  &X4  !B%0
M6A4  %04  !0$P  31$  $L.  !+#08 2@H, $D($0!'"!8 10@= $0((P!"
M""@ 00DN $ ),P _"3D /@I  #T*1P \"D\ .@M8 #D+8P X#&\ -@Q^ #4,
MC@ T#9\ ,PVQ #(-QP R#>, ,@WT #(-_@"($P  =Q4  &D7  !>&   51@
M $\8  !*%@  1Q4  $43  !#$ ( 0PX( $(-#@! #1( /PT8 #T-'P \#20
M.PTJ #D-,  X#C< -PX] #8.10 U#DT ,P]7 #(/8@ Q$&X +Q!] "X0C@ M
M$:  +!&R "L1R  K$>8 *Q'V "P1_P"#%@  <AD  &0:  !9&P  41L  $L;
M  !&&@  0A@  #\7   ^%   /!($ #L1"@ Z$!  .! 5 #<0&P U$2$ -!$G
M #,1+0 R$3, ,!$Z "\20@ N$DL +1-4 "L37P J%&P *11[ "@4C  G%9X
M)A6P "45Q@ E%>0 )17V "85_P!^&0  ;AL  & =  !6'@  31X  $<>  !"
M'0  /AP  #H:   X&   -Q8  #45!P T% T ,A02 # 4%P O%!T +10C "P5
M*@ K%3  *A4W "D6/P H%D@ )Q=2 "8870 D&&H (QEY "(9B@ A&9P (!FO
M !\9Q  ?&>( (!GT " 9_P!Z&P  :AX  %T?  !3(   2B   $0@   ^'P
M.AX  #<=   T'   ,AD  # 9!  N& L +!@0 "H8%  I&!H )Q@@ "89)@ E
M&2T )!HU ",:/0 B&T8 (1M0 " <6P ?'6@ 'AUW !T=B  <'IL &QZM !H>
MPP :'N  &AWS !L=_P!W'0  9R   %HA  !0(@  2"(  $$B   [(@  -R$
M #,@   P'P  +1T  "L=   H'0@ )AT. "4=$@ C'1< (1T= "$=)  @'BH
M'QXR !X?.@ ='T, '"!- !LA60 :(68 &2%U !@BAP 7(ID %B*L !4BP0 5
M(M\ %2'R !8A_@!S(   9"(  %<C  !-)   124  #XD   Y)   -",  # B
M   L(@  *2$  "8A   D(08 (B$, " A$  >(14 '2(; !LB(0 ;(B@ &B,O
M !DC.  8)$$ %R1+ !8E5P 5)60 %"9S !,FA0 2)I@ $2:K !$FP  0)MT
M$27Q !(E_0!P(@  820  %0F  !*)@  0B<  #PF   V)@  ,24  "TE   I
M)   )B0  "(E   ?)0, '28* !LF#@ 9)Q( &"<8 !<G'P 6)R4 %2@M !0H
M-0 3*3X $BE) !$I50 1*F( $"IQ  \J@P .*I8 #BJI  TJO0 -*M< #2KN
M  XI^P!L)   728  %$H  !(*   0"D  #DH   T*   +R@  "LG   G)P
M(B@  !XI   ;*@  &"L' !8K#0 4+!$ $RP6 !(L'  1+2, $"TJ ! M,@ /
M+CP #BY&  TN4@ -+E\ #"]N  LO?P *+Y( "2^E  DNN0 (+M  "2[I  HN
M]P!H)P  6BD  $XJ  !%*P  /2L  #<K   Q*@  +2H  "DJ   D*@  ("L
M !LM   8+@  %2\$ !(Q"@ 0,@X #S(3  XR&0 -,B  #3(G  PR+P +,S@
M"C-"  DS3@ (,UL !C1J  4T>P $,XX  S.B  (SM@ ",\T  S/G  0R\P!D
M*@  5BP  $LM  !"+0  .BT  #0M   O+   *RP  "8L   B+0  '2\  !DQ
M   5,@  $C0#  \V"0 ,. T "C@1  DX%@ (.!T !S@D  8X+  $.#0  S@^
M  (Y2@  .5<  #EE   Y=P  .8L  #B?   XLP  .,H  #CF   W\@!?+0
M4BX  $@O   _,   ."\  #(O   M+P  *2\  "0P   ?,0  &C,  !4U   2
M-P  #SD#  P["  (/0T !3X0  ,^%   /AH  #XA   ^*   /C$  #\[   _
M1@  /U,  #]A   _<P  /X<  #Z<   ^L   /<<  #WD   ]\@!:,   3C(
M $0R   \,@  -3(  # Q   K,0  )C(  " T   ;-@  %C@  !([   //0
M##\#  A!"  $0PP  $,.  !$$@  118  $4=  !%)   12T  $8V  !&0@
M1DX  $9=  !&;@  18(  $68  !$K0  1,0  $/C  !#\@!5-   2C4  $$U
M   Y-0  ,S0  "XT   H-0  (C<  !TZ   7/   $C\   ]!   ,1   "$8!
M  -(!@  20H  $H-  !+$   3!0  $T9  !.(   3B@  $XR  !-/0  3DH
M $Y8  !-:0  37T  $R4  !,J@  2\$  $OA  !*\@!0.   1C@  #TX   W
M.   ,3<  "HY   D.P  'CT  !A    30P  #T8   M)   '2P   DX   !0
M!   40@  %(+  !3#@  5!$  %45  !6&P  5R,  %<L  !7.   5T0  %=2
M  !68P  5G<  %:.  !5I0  5+T  %/=  !3\ !+/   0CP  #L[   U.P
M+3P  "8_   ?0@  &44  !-(   .2P  "T\   51    5    %<   !8 0
M6@4  %L(  !<#   70X  %\1  !@%@  8AT  &(F  !B,0  8CX  &%,  !A
M70  87   &"(  !@H   7[<  %[4  !=[@!'0   /S\  #H_   Q0   *4,
M "%&   :2@  $TX   Y1   *50  !%@   !;    7@   &$   !C    9 $
M &4$  !G"   : L  &H.  !L$@  ;A<  &\@  !O*@  ;S8  &Y%  !N50
M;F@  &U_  !MF   ;+   &O*  !JZ !$1   /D,  #5$   K1P  (TL  !M/
M   35   #E@   A<   "8    &0   !G    :P   &T   !O    <    '(
M  !T @  =08  '<*  !Y#@  ?!(  'X8  !_(@  ?RX  '\]  !^30  ?6$
M 'UW  !\D   >Z@  'K   !YWP!#1P  .4D  "],   E4   '%4  !1;   .
M8   !V4   !J    ;@   '(   !V    >0   'P   !^    ?P   ($   "#
M    A0   (<#  "*"   C T  (\1  "2&0  DB4  )(S  "21   D5<  )!M
M  "/A@  CI\  (VU  ",S0 ]3@  ,E$  "A6   >7   %6(   YH   ';@
M '0   !Y    ?@   ((   "&    B0   (P   ".    D    )(   "4
ME@   )@   ";    G@8  *$,  "D$0  IAL  *8I  "F.@  I4T  *5B  "D
M>P  HY0  *&K  "AOP V5P  +%P  "%B   7:0  #W    =W    ?@   (0
M  "*    CP   )0   "8    FP   )X   "?    H@   *0   "F    J
M *L   "M    L    +,$  "W#   NQ(  +L?  "[,   NT,  +I8  "Y<
MMXL  +>A  "WLP P8@  )6D  !IP   0>   "8    "(    CP   )8   ";
M    H0   *8   "J    K@   +    "Q    M    +8   "X    NP   +T
M  #     PP   ,<   #+ P  SPP  -,5  #2)0  TC@  -%.  #090  SWX
M ,V6  #,J0#_    _P   /\   #_  , _P + /P $0#Y !L ]P E /, +P#N
M #@ Z0!  .8 2 #B $X WP!4 -P 60#9 %X U0!C -, : #0 &T S@!S ,L
M>@#( (( Q@", ,, EP#  *, O@"R +P R "Z .H N0#_ +@ _P"Q /\ J@#_
M *< _P#_    _P   /L   #V    [0 ' .< #P#B !8 WP @ -X *0#9 #,
MT0 [ ,P 0@#( $@ Q0!. ,( 4P#  %@ O@!= +P 8@"Z &< N0!M +< = "U
M 'L L@"% +  D "N )P K "J *D O0"G -X I@#Y *4 _P"C /\ G0#_ )L
M_P#]    ]@   .L   #?    T0 # ,H # #% !( PP ; ,  ) "^ "P N0 U
M +8 / "S $, L !( *X 3@"L %( JP!7 *D 7 "G &$ I@!G *0 ;0"B '0
MH !] )X B "< )4 F@"C )@ M "6 ,T E0#Q )0 _P"5 /\ D #_ (X _P#S
M    Y@   -$   #"    N    +$ " "M  \ J@ 6 *@ '@"H "< I@ O *(
M-@"? #P G0!" )L 1P"9 $P EP!1 )8 50"4 %H DP!@ )$ 9@"0 &X C@!V
M (P @0"* (T B "; (8 K "% ,$ A #F (, _0"$ /\ @P#_ ($ _P#D
MRP   +H   "L    H@   )P ! "8  P E@ 1 )0 &0"3 "$ D@ H (\ , "-
M #8 BP \ (D 00"( $8 A@!+ (4 3P"$ %0 @@!: ($ 8 !_ &< ?@!O 'P
M>@!Z (8 > "4 '< I !U +< = #4 ', ] !T /\ = #_ '0 _P#+    M@
M *8   ":    D@   (H   "&  @ @P . ($ % "! !L @  C '\ *@!] #
M>P V 'H .P!X $  =P!% '4 20!T $X <P!4 '$ 6@!P &$ ;@!I &T <P!K
M '\ :0"- &@ G0!G *X 9@#' &4 Z@!F /\ 9@#_ &< _P"X    I    )4
M  "*    @0   'P   !V  0 =  , '( $ !Q !8 <  = '  ) !N "H ;0 P
M &L -0!J #H :0 _ &@ 1 !G $D 90!. &0 5 !C %L 80!C &  ;0!> 'D
M70"' %L E@!: *@ 60"] %D WP!9 /@ 6@#_ %H _P"H    E0   (<   ![
M    <P   &X   !J  $ 9P ( &4 #@!D !( 8P 8 &, 'P!B "4 80 J %\
M, !> #4 70 Z %P /@!; $0 60!) %@ 3P!7 %8 5@!> %0 : !3 ', 40"!
M %  D0!/ *( 3@"U $X T !. /  3@#_ $\ _P"<    B0   'L#  !P P
M: ,  &(!  !?    70 $ %L "P!9  \ 6  4 %< &0!7 "  5@ E %4 *@!3
M #  4@ T %$ .0!0 #\ 3P!$ $X 2P!- %( 2P!: $H 8P!) &\ 1P!\ $8
MC !% )T 10"P $0 QP!$ .@ 1 #Z $4 _P"2!   @ <  '$*  !F"@  7@H
M %D)  !5!P  5 0  %( !P!0  P 3P 0 $X %0!- !L 3  @ $L )@!* "L
M20 P $@ -0!' #H 1@!  $4 1@!# $X 0@!6 $$ 7P!  &L /@!X #T B  \
M )D / "K #P P0 [ .  .P#T #L _P")"@  > P  &H.  !?#@  5PX  %$.
M  !-#   2PL  $H( @!)! D 2  - $8 $0!% !8 1  < $, (0!" "8 00 K
M #\ ,0 ^ #8 /0 \ #P 0P [ $H .@!2 #D 7  X &@ -@!U #4 A0 T )8
M- "H #, O  S -@ ,P#O #, ^P""#0  <0\  &00  !9$0  41$  $L1  !'
M$   1 X  $(-  !!"P4 00<+ #\%#@ ^ Q( / (8 #L"'0 Z R( .0,H #@#
M+0 W S( -@0Y #4$/P T!4< ,P50 #$&6@ P!F8 +P=S "X'@P M!Y4 + >G
M "L'N@ K!]( *P?K "L']P!]$   ;!$  %\3  !4%   3!0  $84  !"$P
M/A(  #P0   Z#@$ .@T& #H*#  X"1  -@@4 #4(&0 T"1\ ,@DD #$)*0 P
M"2\ +PHV "X*/0 M"D4 + M. "L+60 I#&4 * QS "<,@P F#94 )0VG "0-
MNP C#=( (PWK ",-]P!X$@  :!0  %L6  !1%P  2!<  $(6   ]%@  .14
M #<3   U$0  ,Q # #,."  R#0T , T1 "\-%@ M#1L + TA "L-)P J#2T
M*0XT "@..P G#D0 )0Y. "0/60 C$&4 (1!S " 0A  ?$)8 'A"I !T0O0 <
M$-@ '1#N !T0^0!S%   9!8  %<8  !-&0  11D  #\9   Z&   -1<  #(6
M   P%0  +A,  "T1!  L$ H *Q . "D0$@ H$!@ )A > "40)  D$"H (Q$Q
M "(1.0 A$4( (!)+ !X25@ =$V, '!-Q !H3@@ 9%)4 &!2G !<4NP 7$]0
M%Q/N !@3^@!P%@  8!D  %0:  !*&P  0AP  #P;   V&P  ,AH  "\9   L
M&   *A8  "@4 0 F$P< )1,, ",3$  B$Q4 (!,: !\3(0 >%"< '10N !P5
M-@ ;%3\ &A9) !D65  8%V$ %A=P !48@0 4&), $QBF !(8N@ 2%]( $A?L
M !,7^@!L&0  71L  %$=  !''0  /QX  #D=   T'0  +QP  "L;   H&@
M)AD  "08   B%P0 (!<* !X7#@ <%Q( &A<7 !D8'@ 9&"0 &!DL !<9-  6
M&CT %1I' !0;4@ 3&U\ $AQN !$<?P 0')( $!RE  \<N0 .'-  #AOJ  \;
M^ !I&P  6AT  $X?  !%'P  /2   #8?   Q'P  +1X  "D=   E'0  (QP
M " ;   =&P$ &QL' !D<#0 7'!  %AP5 !4<&P 4'2( $QTI !(>,0 1'CH
M$1]% ! ?4  /(%T #B!L  T@?  -((\ #""B  L@M0 +(,H "R#E  P?] !E
M'0  5Q\  $PA  !"(0  .B$  #0A   O(0  *B   "8?   C'P  (!X  !T>
M   9(   %B $ !0@"P 2(0X $2$3 !$B&0 0(A\ #R(F  XC+P .(S< #2-!
M  PD30 +)%D "B1G  DD>  ()(L !R2>  <DL0 &),< !B/C  <C\0!B'P
M5"$  $DC  ! (P  .",  #(C   L(P  *"(  "0A   A(0  'B$  !HA   6
M(P  $R0# !$E"  /)@T #B<1  TG%@ ,)QT "R<C  HG*P )*#0 ""@^  <H
M20 &*%4 !2ED  0I=  #*8<  BF;  $HKP  *,4  2CA  $G\ !>(@  420
M $8E   ])0  -24  "\E   J)   )B0  "(C   ?(P  &R0  !@E   4)@
M$2@#  \I"  ,+ P "BP0  @L%  '+!H !BPA  4L*  #+3   BTZ  $M10
M+5(  "Y@   N<0  +80  "V9   MK0  +,(  "S@   L\ !:)   328  $,G
M   Z)P  ,R<  "TG   H)@  )"8  "$F   =)@  &2<  !4I   1*P  #RP#
M  TN!P ), P !C$.  ,Q$@ !,A<  #(>   R)0  ,BT  #(V   S0@  ,TX
M #-=   S;0  ,X$  #*6   RJP  ,<$  #'?   Q\ !6)P  2BD  #\J   W
M*@  ,"H  "LI   G*   (R@  !XI   :*@  %BP  !(N   /,   #3$"  HT
M!P %-0L  C8.   W$   .!0  #@:   X(@  ."H  #DS   Y/@  .4H  #E9
M   Y:0  .7T  #B3   XJ   -[\  #?>   V\ !1*P  1BP  #PL   T+
M+BP  "HK   E*P  ("P  !LM   7+P  $S$  ! S   --0  "3<"  4Z!@ !
M.PH  #P-   ]#P  /A(  #\7  ! '@  0"4  $ O  ! .@  0$8  $!4  !
M90  /W@  #^/   ^I@  /KT  #W<   ]\ !-+@  0B\  #DO   R+P  +2X
M "@N   B+P  '3   !@R   3-0  $#<   PZ   )/   !3X   !!!   0@@
M $,+  !$#0  1A   $<4  !(&0  2"$  $@J  !(-0  2$$  $A/  !(8
M1W,  $>*  !&H@  1;D  $79  !$\ !(,@  /C(  #8R   P,0  *S$  "4R
M   ?-   &38  !,Y   0/   ##\   A"   #1    $8   !( @  2@4  $L(
M  !,"P  3@X  $\1  !1%0  4AP  %(E  !2,   4CP  %%*  !16@  46T
M %"$  !/G0  3K4  $W2  !-[@!#-@  .S8  #0U   O-   )S4  "$X   :
M.P  %#X  !!!   ,1   !T<   )*    30   $\   !1    4P(  %0%  !5
M"   5PL  %D.  !;$0  71<  %T?  !=*@  738  %Q$  !<5   6V<  %M^
M  !:EP  6:\  %C+  !7Z@ _.0  .#D  #,X   K.0  (SP  !P_   50P
M$$<   M*   %3@   %$   !4    5P   %H   !<    70   %\   !@!
M8@<  &0+  !F#@  :!(  &L9  !K(P  :BX  &H\  !J30  :5\  &AU  !G
MCP  9J@  &7"  !DXP ]/0  -SP  "X]   E0   '40  !9)   030  "E$
M  15    6@   %T   !@    8P   &8   !H    :@   &L   !M    ;P(
M '$&  !T"@  =@X  'D3  ![&P  >R<  'HU  !Y10  >%D  'AM  !WA@
M=I\  '6W  !TT@ \00  ,D(  "A%   @2@  %TX  !!4   *60   EX   !C
M    9P   &L   !O    <@   '4   !W    >0   'L   !]    ?P   ((
M  "$ P  APD  (H.  ".$P  CQX  (XK  "..P  C4X  (MC  "*?   BI4
M (BM  "'Q0 V1P  +$L  ")/   950  $%L   IA   !9P   &T   !R
M=P   'L   !_    @P   (8   "(    B@   (T   "/    D0   )0   "7
M    F@$  )T'  "A#0  I10  *0A  "D,0  HT0  *)9  "@<   GXL  )VB
M  "=MP P4   )54  !M;   28@  "VD   %P    =P   'T   "#    B
M (T   "1    E0   )@   ":    G    )\   "A    HP   *8   "I
MK    +    "T!P  N X  +H8  "Z)P  N3D  +A.  "W90  MGX  +66  "S
MJP I6P  'F(  !1I   ,<0   GD   "!    B0   (\   "6    FP   *
M  "D    J    *L   "L    KP   +(   "T    M@   +D   "\    P
M ,0   #(    S0<  -(0  #2'0  T2\  -!$  #/6P  S7,  ,N-  #*H0#_
M    _P   /L   #Z    _  ( /@ #P#U !< ]  @ /$ *@#K #, Y@ [ .(
M0P#> $D V@!/ -8 5 #3 %D T !> ,X 8P#+ &@ R0!N ,8 =0## 'T P0"&
M +X D@"[ )X N0"N +8 PP"T .@ LP#_ *\ _P"E /\ G@#_ )L _P#]
M]P   /(   #P    YP # .$ # #< !( V  ; -8 ) #2 "T S  V ,8 /0#"
M $, OP!) +P 3@"Z %, N !8 +8 70"U &( LP!G +$ ;@"O '8 K !_ *H
MB@"H )< I0"F *, N0"A -D H #Y )X _P"8 /\ D@#_ (\ _P#S    [
M .,   #3    R    ,$ "0"]  \ NP 6 +D 'P"W "< LP O *\ -P"L #T
MJ@!# *@ 2 "F $T I !2 *, 5@"A %L GP!A )X 9P"< &\ F@!X )< @P"5
M )  DP"> )$ L "0 ,@ C@#P (T _P"* /\ A0#_ (( _P#G    W0   ,8
M  "X    K@   *@ ! "E  P H0 2 *$ &0"@ "( GP I )L , "8 #< E@ ]
M ), 0@"2 $< D !+ (\ 4 "- %4 C !: (H 80"( &@ AP!P (4 >P"# (@
M@0"6 '\ IP!] +P ? #C 'P _0!\ /\ > #_ '8 _P#6    P    *\   "C
M    F0   ),   "/  D C0 . (L % "* !P B@ C (@ *@"% #  @P V ((
M.P"  $  ?P!% 'X 2@!\ $\ >P!4 'H 6@!X &$ =@!I '4 <P!S (  <0".
M &\ GP!N +( ;0#/ &P ] !L /\ :P#_ &D _P#     JP   )L   "/
MAP   (    !\  0 >@ , '@ $0!X !< >  > '< ) !U "H <P P '$ -0!P
M #H ;@ _ &T 1 !L $D :P!. &H 5 !H %L 9P!C &4 ;0!D '@ 8@"' &
MEP!? *H 7@#" %X Z0!> /\ 7@#_ %T _P"L    F0   (H   !_    =P
M '$   !M    :@ ( &D #@!H !( 9P 8 &< 'P!G "4 90 J &, +P!B #0
M80 Y &  /@!? $, 7@!( %T 3@!; %4 6@!= %@ 9P!7 '( 50"! %0 D0!3
M *, 4@"X %$ W !1 /D 4@#_ %( _P"=    BP   'P   !Q    :0   &0
M  !@    7@ % %P "P!;  \ 6P 4 %H &0!: !\ 60 E %< *@!6 "\ 50 T
M %0 . !3 #T 4@!# %  20!/ %  3@!8 $T 8@!+ &T 2@!Z $D BP!( )T
M1P"Q $< S !& /  1P#_ $< _P"0    ?@   '    !F    7@   %D   !6
M    4P ! %( " !0  T 3P 0 $\ %0!. !H 3@ @ $T )0!, "H 2@ N $D
M,P!( #@ 1P ^ $8 1 !% $L 1 !3 $, 70!! &@ 0 !U #\ A0 ^ )< /0"K
M #T PP ] .8 /0#[ #X _P"'    =0,  &@&  !=!P  508  % &  !,!
M2@$  $D ! !'  H 1@ . $4 $0!% !8 1  ; $, ( !" "4 00 J $  +P _
M #0 /@ Z #T 0  [ $< .@!/ #D 60 X &0 -P!Q #8 @0 U ), - "F #0
MNP T -T - #U #4 _P!^!@  ;0D  & +  !6#   3@P  $@+  !$"@  0@@
M $ % 0 _ 0< /@ + #T #@ \ !( .P 7 #L '  Z "$ .0 E #< *@ V #
M-0 U #0 /  S $, ,@!, #$ 50 P &  +P!M "X ?0 M (\ + "B "P M@ L
M -  + #N "P _ !W"@  9PP  %H.  !0#@  20X  $,.   ^#0  .PP  #D+
M   X"0, -P4( #8"#0 U 1  -  3 #, &  R !T ,0 B #  )P O "P +@ R
M "T .  L $  *P!) "H 4@ I %T * !K "<!>@ F 8P )0"? "4 L@ E ,H
M)0#H "4 ]P!R#0  8@X  %80  !,$0  1!$  #X1   Y$   -@\  #,.   Q
M#0$ , L% # ("@ O!@T +@41 "P$%  K QD *@,> "D#(P H!"D )P0O "8%
M-0 E!3T ) 5& ",&4  B!EP (0=I " '>0 ?!XL '@>= !X'L  =!L8 '0;C
M !T%\P!M#@  7A$  %(2  !($P  0!,  #H3   U$@  ,1$  "X0   L#P
M*@X# "H-!P I"PL * D. "<)$0 E"!8 ) @; ",)(  B"28 (0DL " *,P ?
M"CL '@M$ !T+3P <#%L &PQI !H,>0 8#(L & R> !<,L  6#,4 %@SA !8+
M\ !I$   6A(  $X4  !%%0  /14  #<5   Q%   +1,  "H2   H$0  )A !
M "00!  C#@@ (PT, "(,#P @#!, 'PP8 !X-'0 =#2, ' TJ !L-,@ :#CH
M& Y$ !<.4  6#UP %0]J !,0>P 2$(T $1"@ !$0LP 0#\D $ _D !$/\@!E
M$@  5Q0  $L6  !"%P  .A<  #07   O%@  *A4  "<4   D$P  (A,  " 2
M P >$08 '1 ) !P0#0 ;#Q  &1 5 !@0&P 7$"$ %A H !41,  4$3D $Q%#
M !(23@ 1$EH $!)I ! 3>0 .$XP #A.>  T3L0 -$L4 #!+A  T2\0!B%
M5!8  $D8   _&0  -QD  #$9   L&   *!<  "06   A%@  'Q4  !P4 @ :
M$P0 &1(& !<2"P 5$@X %!(2 !,3&  2$Q\ $1,F !$4+0 0%#8 #Q5!  X5
M3  .%E< #19E  P7=0 +%X< "A>:  D6K0 (%L$ "!;=  D5[@!?%@  41@
M $8:   ]&@  -1L  "\:   J&@  )1D  "(8   ?&   '!<  !D6 0 7%@,
M%18$ !,6"0 1%@T $!<1  \7%@ .%QP #A@C  T8*@ ,&3, #!D\  L:1P *
M&E, "1IA  <;<0 &&X, !1N7  0:J@ #&K\  QG:  09[ !<&   3AH  $,<
M   Z'   ,QP  "P<   G'   (QL  " :   =&0  &AD  !<8 0 5& ( $AD$
M ! ;!P .&PP #1P0  P<$P +'!D "AP?  D=)P ('2\ !QXY  8>0P $'E
M Q]>  (?;@ !'X   !^5   >J0  'KT  !W8   =[ !8&@  2QP  $$>   X
M'@  ,!X  "H>   E'0  (1P  !X<   ;&P  &!L  !8; 0 3&P( $1P$  X>
M!P ,'PL "B .  @@$@ &(1< !2$=  0A)  "(BP  2(U   B0   (TT  "-:
M   C:P  (WX  ".3   BIP  (KP  "'7   A[0!5'0  2!\  #X@   U(
M+B   "@@   C'P  (!X  !T=   :'0  %AT  !,>   1'P( #B $  TB!P *
M) L !B4-  0E$  ")A0  "8:   F(0  )RD  "<R   G/0  )TD  "A7   H
M9P  )WL  ">0   GI0  )KL  ";6   E[0!1(   12$  #LB   R(@  +"(
M "8A   B(0  'B   !L?   8(   %"   !$B   /(P  #24#  HF!@ &* H
M RD-   K#P  +!(  "P7   L'@  +"8  "TO   M.0  +48  "U4   M9
M+7<  "R-   LI   *[H  "O6   J[@!-(@  020  #@D   P)   *20  "0C
M   A(@  '2(  !DB   5(P  $B0   \F   -*   "BH"  8L!0 "+@D  "\+
M   P#@  ,A   #,5   S&P  ,R(  #,K   S-@  ,T(  #-0   S8   ,W,
M #**   RH0  ,;@  ##6   P[P!))0  /B8  #0G   M)P  *"8  ",E   ?
M)   &R4  !8F   2*   $"H   TL   *+@  !C !  (R!   - <  #4*   W
M#   . X  #H2   Z%P  .A\  #HG   Z,@  .CX  #I,   Z7   .F\  #F&
M   XG@  .+8  #?4   V[P!$*0  .BD  #$I   K*0  )B@  "(G   =*
M&"D  !,K   0+@  #3    DR   %-0   3<    Y @  .P4  #P(   ^"P
M/PT  $$0  !#%   0QL  $,C  !#+@  0SD  $-'  !"5P  0FH  $&!  !
MF@  /[(  #[/   ^[P _+   -BP  "\L   J*P  )2H  !\K   9+0  %"\
M ! R   --0  "#@   0Z    /    #\   !!    0P(  $4%  !&"   2 L
M $H.  !,$0  318  $T>  !-*   330  $Q"  !,40  2V0  $M[  !*E
M2:T  $C*  !'[  [,   ,R\  "TO   H+0  (B\  !LQ   5-   $#<   TZ
M   (/0   D    !#    1@   $@   !*    3    $X!  !/!   40<  %,+
M  !5#@  6!(  %D9  !8(@  6"X  %<\  !72P  5EX  %9S  !5C0  5*<
M %+"  !2Y@ X,P  ,3(  "PQ   E,@  '34  !8X   1/   #$    =$
M1P   $H   !-    4    %,   !5    5P   %D   !:    7 ,  %X'  !A
M"P  9 X  &83  !G'   9B<  &8T  !E1   9%<  &1K  !BA0  89\  &"Y
M  !>W  U-P  ,#4  "@W   @.@  &#T  !%"   ,1@  !DH   !/    4P
M %8   !9    7    %\   !A    9    &4   !G    :0   &P!  !N!@
M<0L  '0/  !W%0  =R   '8M  !V/0  =4\  '1C  !S>P  <I4  '"O  !O
MR0 U.@  *SL  "(_   :0P  $D@   Q-   %4@   %<   !<    8    &0
M  !H    :P   &X   !Q    <P   '4   !W    >@   'P   !_    @@0
M (8*  "*#P  C!<  (LD  "*,P  B44  (=;  "&<@  A8L  (.E  ""O  O
M0   )40  !Q)   33@  #50   1:    80   &8   !K    ;P   '0   !Y
M    ?0   (    "#    A0   (<   "*    C    (\   "2    E@   )D"
M  ">"0  HA   *(:  "A*0  H#L  )]0  "=9P  FH$  )J9  "9KP I20
M'TX  !54   .6P  !6(   !I    <    '<   !]    @@   (8   "+
MCP   ),   "5    EP   )H   "=    H    *,   "F    J@   *X   "R
M    MPH  +L1  "Z'P  N3   +=%  "U7   M'0  +&.  "OI  B5   &%L
M !!B   ':@   ',   ![    @@   (D   "0    E0   )H   "?    HP
M *8   "H    JP   *X   "P    LP   +8   "Z    O0   ,(   #'
MS $  -,+  #4%0  TR8  -$Z  #040  S6@  ,N!  #*E@#\    ]@   /(
M  #Q    \P % /0 # #R !, \  < .T )0#H "X X@ V -X /@#9 $0 U !*
M -$ 3P#. %0 RP!9 ,D 7@#& &, Q !I ,$ < "^ '@ O "! +D C0"V )H
MLP"K +$ P "O .8 K@#_ *4 _P": /\ E #_ (\ _P#T    [    .@   #G
M    WP   -D "0#2 !  SP 7 ,\ ( #, "@ Q@ P ,  -P"\ #X N0!$ +<
M20"U $X LP!3 +$ 5P"O %T K0!B *L :0"I '$ IP!Z *4 A0"B ), H "B
M )T M@"; -0 F0#Y )8 _P"- /\ B #_ (0 _P#H    WP   -D   #)
MOP   +@ ! "U  T LP 2 +$ &@"P "( K0 J *D ,0"F #@ I  ] *( 0P"@
M $@ G@!, )P 40"; %8 F0!< )< 8@"5 &D DP!R )$ ?0"/ (L C0": (L
MK ") ,4 B #N (8 _P!_ /\ >@#_ '@ _P#9    S0   +L   "N    I0
M )\   "<  D F0 / )D %0"9 !T F  D )0 *P"1 #$ C@ W (P / "+ $$
MB0!& (@ 2P"& %  A0!5 (, 6P"" &( @ !K 'X =0!\ (( >@"2 '@ HP!W
M +D =@#@ '4 _P!R /\ ;@#_ &P _P#'    M0   *4   "9    CP   (D
M  "%  0 A  , (( $0"" !< @@ > (  )0!^ "L ?  Q 'H -@!Y #L =P!
M '8 1 !U $D <P!/ '( 50!P %P ;P!D &T ;@!L 'H :@"* &@ FP!G *\
M9@#, &4 ]0!D /\ 80#_ &  _P"T    H    )    "%    ?0   '<   !S
M    <  ( &\ #@!O !( ;P 8 &\ 'P!M "4 :P J &D , !H #0 9P Y &8
M/@!E $, 8P!( &( 3@!A %4 7P!> %X 9P!< ', 6P"" %D DP!8 *8 5P"_
M %< Z@!7 /\ 5@#_ %0 _P"A    C@   '\   !U    ;    &@   !D
M80 $ &  "P!?  \ 7P 3 %\ &0!? !\ 70 E %P *@!; "\ 60 S %@ . !7
M #T 5@!# %4 20!3 %  4@!8 %$ 80!0 &T 3@![ $T C !, )\ 2P"U $H
MW !* /H 2@#_ $H _P"2    @    '(   !G    7P   %H   !7    50 !
M %, !P!2  P 4@ 0 %( % !2 !H 40 ? $\ ) !. "D 30 N $P ,P!+ #@
M2@ ] $D 0P!( $H 1@!2 $4 7 !$ &< 0P!U $( A@!! )@ 0 "N $  RP _
M /( 0 #_ $  _P"%    =    &<   !=    50   $\   !,    2@   $@
M! !'  H 1P - $8 $0!& !4 1@ : $4 'P!$ "0 0P I $( +0!! #, /P X
M #X /@ ] $4 / !. #L 5P Z &( .0!O #@ @  W ), -@"G #8 P  V .@
M-@#^ #8 _P!\    :P   %X"  !4 P  30,  $<#  !# 0  00   #\  0 ^
M  < /0 + #T #@ \ !$ /  6 #P &@ Z !\ .0 D #@ *0 W "X -@ S #4
M.@ T $$ ,P!) #( 4P Q %X , !K "\ >P N (X +0"B "T N  M -T +0#X
M "X _P!S 0  9 4  %<'  !-"   1@@  $ (   [!P  . 4  #<#   V  0
M-0 ( #0 #  T  \ -  2 #, %@ R !L ,0 @ #  )  O "D +@ O "T -@ L
M #T *P!% "H 3P I %H * !G "< =P F (D )@"= "4 LP E ,\ )0#P "8
M_P!M!@  7@D  %(+  !(#   0 P  #H+   V"P  ,@H  # (   N!@( +@,&
M "T "@ L  T +  0 "L $P J !< *0 < "@ (  G "4 )@ K "4 ,@ D #D
M(P!" "( 2P B %< (0!D "  <P ? (4 'P"9 !X K@ > ,< '@#I !\ ^@!H
M"0  60P  $T-  !##@  / X  #8.   Q#0  +0T  "H,   H"P  )PD$ "8&
M"  F! L )0,. "0!$  D 10 (@$8 "$!'0 A "( (  H !\ +@ > 38 '0$_
M !P!20 ; 50 &@%A !H!<  9 8( & "6 !@ J@ 8 ,$ & #A !@ ] !C#
M50X  $D/  ! $   .!   #(0   M#P  *0X  "8.   C#0  (@P# " +!@ @
M"0D 'P<, !X&#@ >!1$ ' 45 !L%&@ :!1\ &@4E !D%*P 8!3, %P8\ !8&
M1@ 6!E( %0=? !0';@ 3!X  $@>4 !(&IP 2!;P $@39 !(#[P!?#@  40\
M $80   \$0  -1$  "\1   J$0  )A   "(0   @#P  '0X" !P-!0 :#0<
M&@L* !D*#0 8"1  %PD2 !8)%P 5"1P % DB !0**0 3"C$ $@HZ !(+10 1
M"U$ $ Q?  \,;@ .#(  #@R4  T+IP -"[H #0K2  T*Z@!<#P  3A$  $,2
M   Z$P  ,A,  "P3   G$@  (Q$  !\1   <$   &A " !@/!  6#@< %0X)
M !0-"P 3# T $@P0 !(,%  1#!H $0T@ ! -*  /#3  #@X[  T.1@ -#E$
M# ]>  L/;0 *#W\ "0^3  D/I@ (#KD " [0  <.Z !8$0  2Q(  $ 3   W
M%   ,!0  "D4   E%   (1,  !T2   :$@  %Q$" !41!0 3$ < $A ) !$/
M"@ 0#@P #@X.  X/$@ -$!@ #1 >  P0)0 ,$"T "Q$V  H100 )$4T "!):
M  <2:@ &$GP !1*0  02I  #$;@  Q'/  (1Z !5$@  210  #X5   U%@
M+18  "<6   B%0  'A0  !L4   8$P  %1(# !,2!0 2$0< $!$)  \1"@ -
M$0L #!(.  L2$0 *$A4 "1,;  D3(@ ($RH !Q0S  44/@ $%4H  Q58  (5
M9P !%7H  !6.   5HP  %+<  !3/   3Z0!2%   1A8  #L7   R%P  *Q<
M "47   A%@  '!8  !D5   6% $ %!,$ !(3!@ 1$@@ #Q((  X3"0 ,% H
M"A4-  @6$  &%A, !189  07'P #%R<  A@P  $8.P  &4<  !E5   99
M&7<  !F,   8H@  &+<  !?/   7Z@!/%@  0Q@  #D9   P&0  *1D  ",9
M   ?&   &Q<  !@6   5%0( $Q4% !$4!@ 0% 8 #A4'  P6"  *%PH !QD,
M  0:#@ "&Q(  1L6   ;'0  '"0  !PM   <.   '40  !U2   =8@  '74
M !V*   <H   '+8  !O0   :ZP!,&   0!H  #8;   M&P  )AL  "$:   =
M&0  &1D  !<8   4%P, $A8$ ! 7!  .%P0 #!D%  H:!P '' D  QT+   ?
M#0  (!   " 4   A&@  (2(  "$J   A-0  (D$  ")/   B7P  (G(  "&(
M   AGP  (+8  !_1   ?[0!(&@  /1P  #,=   K'0  )!T  " <   <&P
M&!H  !89 0 3&0$ $1D!  X: 0 ,' ( "AT#  <?!0 #(0@  "(*   D#
M)@X  "82   F&   )Q\  "<G   G,@  )SX  "=+   G7   )VX  ":%   F
MG0  );0  "31   C[@!$'0  .1\  # ?   H'P  (QX  !X=   ;'   &!L
M !0<   1'   #AT   T?   *(0  !B(!  ,D!   )@8  "@(   J"P  *PT
M "T0   M%0  +1P  "TD   N+@  +CH  "Y(   M6   +6H  "V!   LF@
M*[(  "K0   I[P! (   -B$  "TA   F(0  (2   !T?   :'@  %AX  !(?
M   /(0  #2(   HD   &)@   B@    K @  +00  "\&   P"0  ,@P  #0.
M   U$@  -1@  #4@   U*@  -38  #5#   U4P  -&8  #1\   SE@  ,J\
M #'-   P[P \(P  ,B0  "HD   D(P  ("(  !PA   7(0  $R,  ! E   -
M)P  "2D   4K   !+@   #     R    - $  #8$   X!@  .@D  #P-   ^
M$   /A0  #X<   ^)@  /C$  #X_   ]3@  /6$  #QW   [D0  .JL  #G)
M   X[0 W)P  +R<  "@F   C)0  'R0  !DE   4)@  $"@   TK   )+@
M!3     S    -0   #@    Z    /    #X!  !  P  0@<  $0*  !&#0
M21$  $D7  !((0  2"P  $<Z  !'20  1EL  $5Q  !$BP  0Z4  $+#  !!
MZ  T*@  +"H  "<H   B)P  '"@  !8J   1+0  #3    DS   #-@   #D
M   \    /@   $$   !#    1@   $@   !*    3 ,  $X&  !0"@  4PX
M %03  !4'   4R<  %,T  !30P  4E4  %%J  !0@P  3YX  $VY  !,X  P
M+0  *RP  "8K   ?+   &"X  !(R   --0  "#D   (]    0    $,   !&
M    20   $P   !.    40   %,   !5    5P   %D!  !<!@  7PH  &(.
M  !C%0  8Q\  &(L  !A/   8$X  %]B  !>>P  7)8  %NP  !9SP O,
M*B\  "(P   :,P  $S<   X[   (/P   40   !(    3    $\   !2
M50   %@   !;    70   &    !B    9    &8   !I    ;04  ' +  !T
M$   =!@  ',E  !R-   <D4  '!9  !O<0  ;8L  &NF  !JP  N,P  )34
M !TX   4/   #D$   ='    3    %$   !5    60   %T   !A    90
M &@   !K    ;0   &\   !R    =    '<   !Z    ?@   (($  "&"P
MBA$  (D<  "(*P  ACT  (12  "#9P  @8$  '^;  !^L@ I.@  (#T  !9"
M   /2   "$X   !4    6@   &    !D    :0   &X   !R    =@   'H
M  !]    @    ((   "%    B    (L   ".    D@   )8   "; P  H P
M *(3  "@(0  GS,  )U'  ":7@  F'<  )>/  "5IP C0P  &4@  !%.   )
M50   %P   !C    :@   '$   !V    >P   (    "&    B@   (X   "1
M    DP   )8   "9    G    *    "C    IP   *L   "P    M@0  +P-
M  "Z%P  N2@  +<\  "T4@  LFH  *^%  "MG  <3@  $U0   M<   !9
M &P   !T    ?    (,   ")    CP   )0   ":    GP   *(   "D
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M_/[______________________________________________________P
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ 0%?C
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M@ZB)SH&GC,^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^
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M@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,*
ML8S"SLH(!L[1"AS&UPI!K^H.89WF''B0VC*(B]),E(G+7YR(QFZCB,-XJ(7
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M@Z.,U(&CD=2 I)G3@*:AT8"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=&
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MEU]^W)-ND\^2>*7&DH*TQ)*)ML.1CKC!CI"ZP(J2O+^'E+V^A):_OH*9P+V
MF\&]?I[!O'VAPKQ[I,*\>JC#O'FMP[AYK\*X>:_"N'FOPKAYK\*X>:_"N'FO
MPKAYK\*X>:_"N'FOPKAYK\*X>:_"_ZH<!?^J)Q?_IS8O_Z)$2OJ=4F7JEU]^
MW)-ND\^2>*7&DH*TQ)*)ML.1CKC!CI"ZP(J2O+^'E+V^A):_OH*9P+V F\&]
M?I[!O'VAPKQ[I,*\>JC#O'FMP[AYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAY
MK\*X>:_"N'FOPKAYK\*X>:_"_ZH<!?^J)Q?_IS8O_Z)$2OJ=4F7JEU]^W)-N
MD\^2>*7&DH*TQ)*)ML.1CKC!CI"ZP(J2O+^'E+V^A):_OH*9P+V F\&]?I[!
MO'VAPKQ[I,*\>JC#O'FMP[AYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X
M>:_"N'FOPKAYK\*X>:_"_ZH<!?^J)Q?_IS8O_Z)$2OJ=4F7JEU]^W)-ND\^2
M>*7&DH*TQ)*)ML.1CKC!CI"ZP(J2O+^'E+V^A):_OH*9P+V F\&]?I[!O'VA
MPKQ[I,*\>JC#O'FMP[AYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"
MN'FOPKAYK\*X>:_"_ZH;!?^J)Q?_IS4O_Z-$2OJ=467IEUY^VY1ME,^2=Z;%
MDH&TQ).(ML.2C;C!CX^ZP(N1O+^(D[Z^A9:_O8*8P;R F\*\?I["O'VAP[M[
MI,2[>JG$NGFMQ+5YKL.U>:[#M7FNP[5YKL.U>:[#M7FNP[5YKL.U>:[#M7FN
MP[5YKL.U>:[#_ZL;!?^K)A?_J#0O_Z1#2OF>4&7IF%U_VI5IE<V4=*C%E'ZT
MQ)6&ML*5C+G!D8Z[OXV0O;Z)DK^]AI3!O(.7P[N!FL2Z?IW%NGVAQKI[I<:Y
M>JK&M7JLQK%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$L7JMQ+%Z
MK<2Q>JW$_ZL:!?^K)1?_J30O_Z1"2OF?3V;HF5R VI9FELR5<:G%E7RTQ):#
MM\*7B[K DXR\OH^.O[V+D,&\AY/#NH26Q;F!F<:Y?YW'N'VAR+A\ILFU>JK)
ML'NKQZQ[K<6L>ZW%K'NMQ:Q[K<6L>ZW%K'NMQ:Q[K<6L>ZW%K'NMQ:Q[K<6L
M>ZW%_ZP9!?^L)!;_J3,O_Z5!2OF?3V;HF5N!V9ACELR6;ZK%EGFTPY>!M\&8
MB;J_E8N]OI&-P+R-C\*ZB)+%N865Q[B"F,FW?YW*MGVBR[9\J,NP>ZG*K'RJ
MR*A]K,6H?:S%J'VLQ:A]K,6H?:S%J'VLQ:A]K,6H?:S%J'VLQ:A]K,6H?:S%
M_ZP9!?^L)!;_JC(O_Z5!2_F@3F?GFEF!V9EAE\N7;:O%EW>TPYE_M\&:A[N_
MEXJ^O9.,P;N.CL2YBI#'N(:3R;:"F,NU?YW-M'ZCSK%\ILZL?:C+J'VJR:5^
MK,:E?JS&I7ZLQJ5^K,:E?JS&I7ZLQJ5^K,:E?JS&I7ZLQJ5^K,:E?JS&_ZP9
M!?^M(Q;_JC(O_Z9 2_B@36?GG%>!V9I>E\N8:JS%F72TPYI]M\&;A;N^F8F_
MO)6*PKJ0C,6XC(_(MH>2R[2#E\ZS@)W0LG^DT:Q^I<^H?J?,I'^IR:& K,:A
M@*S&H8"LQJ& K,:A@*S&H8"LQJ& K,:A@*S&H8"LQJ& K,:A@*S&_ZT8!?^M
M(Q;_JS$O_Z8_2_B@36?GG56!V9Q<E\J9:*S%FG*TPYQZN,"<@[N^G(F_NY>)
MP[F3B\>WCHW+M(F0SK*$EM&Q@9W3K("BTZ> I="D@*?-H(&IRIZ!J\:>@:O&
MGH&KQIZ!J\:>@:O&GH&KQIZ!J\:>@:O&GH&KQIZ!J\:>@:O&_ZT8!?^M(A;_
MJS$O_Z<_2_BA3&?GGE.!V9U9E\J;9:S%G&^TPYUXN,">@;R]GHC NYJ(Q+B5
MB<FUD(O-LHN/T;"&E=6NA)[7IX*AU*."I-&?@J?-G(.IRIJ#J\>:@ZO'FH.K
MQYJ#J\>:@ZO'FH.KQYJ#J\>:@ZO'FH.KQYJ#J\>:@ZO'_ZT7!?^N(A;_JS O
M_Z<^2_BA2VCGGU&!V9]6E\J<8JS%G6RTPY]UN,"@?KR]H(?!NIV(QK>8B,NS
MDXG/L(Z-U*V)E-FHAIW:HH6AU9Z%I-&;A:;.F86IRI>%J\>7A:O'EX6KQY>%
MJ\>7A:O'EX6KQY>%J\>7A:O'EX6KQY>%J\>7A:O'_ZX7!/^N(A;_K# O_Z<^
M2_BB2VCHH4^!V:!3E\J>7ZS&GVFTPZ%RN,"B?+R]HH3!N:"'Q[6<A\VREXC2
MKI.+V*J.D]^BBYS<G(F@UIF(H]*7B*;.E8BIRI2(J\>4B*O'E(BKQY2(J\>4
MB*O'E(BKQY2(J\>4B*O'E(BKQY2(J\>4B*O'_ZX7!/^N(1;_K"\O_Z@]2_BB
M2FCHHDV V:)0E\N@7*S&H66SPZ1NM\"E>+R\I8+"N*2'R+2@A\ZPG8C5JYF*
MW:67D^:;D9O=EH^@UY2-H].2C*;/D8NHRY"*J\B0BJO(D(JKR)"*J\B0BJO(
MD(JKR)"*J\B0BJO(D(JKR)"*J\B0BJO(_ZX6!/^O(1;_K2\O_Z@\2_>B26CH
MI$J V:1-ELNB6*O&I&&SQ*=JM\"I=+R\J7["N*B'R+.FA\^LHH?7I)V)W9J:
MC>&5FIO>D96?V(^3HM..D*70CH^HS(V.JLF-CJK)C8ZJR8V.JLF-CJK)C8ZJ
MR8V.JLF-CJK)C8ZJR8V.JLF-CJK)_Z\6!/^O(1;_K2XO_ZD\2_>C26GHIDA_
MVJ=(E<RE4ZK'J%RRQ*QDML&N;KN]KWC MJR$R:ZGA]"FHX;5G:"&V9.=B=V-
MG93=C9V?V(N9H=2+EJ30BI.GS8J1J<F*D:G)BI&IR8J1J<F*D:G)BI&IR8J1
MJ<F*D:G)BI&IR8J1J<F*D:G)_Z\5!/^P(!;_KBXO_ZD[2_>D1VGIJ$1^VZM#
ME,VI3*G(K52PQK-<L\*W9KFWL'?"L*N$R:FGAL^AI(33EZ*$UHZ@A]F(GX_:
MAZ&:V(>@H=2'FZ31AYBFSH>5J<J'E:G*AY6IRH>5J<J'E:G*AY6IRH>5J<J'
ME:G*AY6IRH>5J<J'E:G*_[ 5!/^P(!7_KBTO_ZHZ2_BF1&CJJT!]W*\\DL^O
M0J;*M4FMQKQ2L;FU9[NPL'C#JZR$R:2IA,V<IH/0DZ2$TXNCAM6%HHS6@J*4
MUH.DG=2#HJ31@YZFSH2:J,N$FJC+A)JHRX2:J,N$FJC+A)JHRX2:J,N$FJC+
MA)JHRX2:J,N$FJC+_[ 4!/^Q'Q7_KRPN_ZLY2_BI0&?KKSM[WK8SC]*Z-*',
MPCFJN[I5M;"T:KVJL'G#IZV$QY^JA,N8J(/-D*>$T(FEAM*$I(K3@*20TW^E
ME])_IJ#0?Z6FSH"@J,N H*C+@*"HRX"@J,N H*C+@*"HRX"@J,N H*C+@*"H
MRX"@J,N H*C+_[$3!/^R'A7_L"LN_ZPW3/JL.V7MM31XXK\IB=C,()B^OSVN
ML+A9N*FS;+ZEL'K"HJZ$Q9NL@\B4JH3*CJF$S(BHALZ#IXG/@*>-SWZGD\]\
MJ)K.?*FBS7RGJ,M\IZC+?*>HRWRGJ,M\IZC+?*>HRWRGJ,M\IZC+?*>HRWRG
MJ,M\IZC+_[(2!/^S'17_L2DN_ZTV3/RQ-6+QO2IRYLT?@,C,(9NQO$6RJ+=>
MN:.S;[Z@L7O!GJ^$PY>NA,:1K(3'C*N%R8>JA\J#JHG+@*J,S'VID,Q\JI7+
M>JJ<RGFKI,IYJZ3*>:NDRGFKI,IYJZ3*>:NDRGFKI,IYJZ3*>:NDRGFKI,IY
MJZ3*_[,1!/^T&Q3_LR8N_Z\S3/VY*UWKRA]ITM\1?[G,)YRGO4RQH+=BN9VT
M<;V;LGR_FK&$P92PA,./KX7%BJZ&QH:MA\>#K(G'@*R+R'ZLCLA\K)+(>ZR7
MR'FMGL=YK9['>:V>QWFMGL=YK9['>:V>QWFMGL=YK9['>:V>QWFMGL=YK9['
M_[40 _^V&13_M20M_[0L2?+%'U36W1)BP=\3@:S-+IJ?P$^KFKAEMY>U<KN6
MM'R]E;*#OY&QA<&-L8;"B;"'PX:OB,.#KXG$@:^+Q'^NC<5]KI#%>ZZ4Q7JO
MF<1ZKYG$>J^9Q'JOF<1ZKYG$>J^9Q'JOF<1ZKYG$>J^9Q'JOF<1ZKYG$_[<.
M _^X%A/_MR M^;\?0=S9$43$ZQ)FL=\8@:#0,Y67QE"CD\!CK9&[<;.1N'NX
MD+:"NXZTA;V+LX:_B+*'P(:RB<"$L8K!@K&+P8"QC<%^L8_"?+&2PGNQE<%[
ML97!>[&5P7NQE<%[L97!>[&5P7NQE<%[L97!>[&5P7NQE<%[L97!]+H+ _V[
M$A+^NQLLY= /,LCI#TJT\A5GHN(B?9;6-XV/SD^8C,AAH(K$;J:*P7BJA[]]
MK82^@+"!O(*Q?[N$LWV[A;1[NH>U>KF)M7FYB[9WN8VV=KB/MW2XD[=TN).W
M=+B3MW2XD[=TN).W=+B3MW2XD[=TN).W=+B3MW2XD[=TN).WW+X& OC #A'N
MR XBR]L++K;X$4RE]1UCE^@L=8W?/8&'V%"+@]-@DH+/;)=_S7.;?,MWG7G)
M>J!WR'VA=<=_HW/&@J1RQ82E<,6&I6_$B*9NQ(JG;<.-IVO#D*AKPY"H:\.0
MJ&O#D*AKPY"H:\.0J&O#D*AKPY"H:\.0J&O#D*AKPY"HU\ & =O&" [+TPH5
MN.@,,J;_%4J8^B9<C? W:87I1G1_Y%-[?-]@@7C<:(5TVFV)<-AQBV[6=8UL
MU7B/:M1[D&G3?I%GTX"29M*#DV72A91DT8>48]"*E6+0CI9BT(Z68M".EF+0
MCI9BT(Z68M".EF+0CI9BT(Z68M".EF+0CI9BT(Z6T<(& <W+"06ZV@<9J/X.
M,9G_'4.._R]1A?H_7'[T361Y\%AJ<^Q?;VWJ8W-IYVEV9^5N>67D<GMCXW9]
M8N)Y?F#A?']?X'Z 7M^!@5W?@X)<WH:#6]V)A%K=C85:W8V%6MV-A5K=C85:
MW8V%6MV-A5K=C85:W8V%6MV-A5K=C85:W8V%R\0& +O1!@>IYP8:FO\3*X[_
M)#F%_S9$?O]$37G_455Q^U=;:_==8&7T8F1B\FAG7_!M:EWO<6Q;[75M6NUX
M;UGL>W!8ZWYQ5^J!<E;JA')5Z8=S5.F*=%/HCG53Z(YU4^B.=5/HCG53Z(YU
M4^B.=5/HCG53Z(YU4^B.=5/HCG53Z(YUO,D% *O; 0B:_PL6C_\9(X7_*RU^
M_SDW>/]&0'#_3D=I_U1-8O]:4E[^859:_&996/MK6U7Y<%U4^'1>4O=X7U'W
M>V!0]GYA3_6!8D_UA&-.](=D3?2+94SSD&9,\Y!F3/.09DSSD&9,\Y!F3/.0
M9DSSD&9,\Y!F3/.09DSSD&9,\Y!F_Z 8 _^B+!#_H#LE_YQ)//^75U/XDF1G
M[)!L>>*/=8G9CGZ7T8V'HLR,C:K'BI&QQ(B4ML.%EKC"@YFYPH&;N<%_GKK!
M?:&[P7NDN\!ZI[O >:J\P'BNO,!WM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QX
MM+N\>+2[O'BTN[QXM+N\>+2[_Z 8 _^B+!#_H#LE_YQ)//^75U/XDF1G[)!L
M>>*/=8G9CGZ7T8V'HLR,C:K'BI&QQ(B4ML.%EKC"@YFYPH&;N<%_GKK!?:&[
MP7NDN\!ZI[O >:J\P'BNO,!WM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\
M>+2[O'BTN[QXM+N\>+2[_Z 8 _^B+!#_H#LE_YQ)//^75U/XDF1G[)!L>>*/
M=8G9CGZ7T8V'HLR,C:K'BI&QQ(B4ML.%EKC"@YFYPH&;N<%_GKK!?:&[P7ND
MN\!ZI[O >:J\P'BNO,!WM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[
MO'BTN[QXM+N\>+2[_Z 8 _^B+!#_H#LE_YQ)//^75U/XDF1G[)!L>>*/=8G9
MCGZ7T8V'HLR,C:K'BI&QQ(B4ML.%EKC"@YFYPH&;N<%_GKK!?:&[P7NDN\!Z
MI[O >:J\P'BNO,!WM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BT
MN[QXM+N\>+2[_Z 8 _^B+!#_H#LE_YQ)//^75U/XDF1G[)!L>>*/=8G9CGZ7
MT8V'HLR,C:K'BI&QQ(B4ML.%EKC"@YFYPH&;N<%_GKK!?:&[P7NDN\!ZI[O
M>:J\P'BNO,!WM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QX
MM+N\>+2[_Z$8 _^C*Q#_H#HE_YQ(//^75E/XDV-H[))I>N&1<XK8CWR8T(Z$
MI,J.C*W&C9"TQ(J3M\.&E;C"A)BYP8&;NL%_G;O ?:"\P'NDO,!ZI[W >:R]
MP'BPO;UXL[RX>+.\N'BSO+AXL[RX>+.\N'BSO+AXL[RX>+.\N'BSO+AXL[RX
M>+.\_Z$8 _^C*A#_H3DE_YU(/?^8553WE&%IZY1F>^"2;XS6D7B:SI""ILB/
MB;#$CX^VPXN1M\*(E+G!A)>ZP(*:O,!_G;V_?:"^OWNDOKYZJ+^^>*V_O7BQ
MOKAXLKZT>;.]M'FSO;1YL[VT>;.]M'FSO;1YL[VT>;.]M'FSO;1YL[VT>;.]
M_Z(8 _^D*1#_H3@E_YU'/?^9553WEEYIZY5C>^"4;(W5DG6<S9%_J,>1A[+$
MD8ZVPXV0N,&)D[K AI:\OX*9O;]_G+Z^?:"_O7NEP+UYJL"]>+# N'FPP+1Y
ML;^O>K*]KWJRO:]ZLKVO>K*]KWJRO:]ZLKVO>K*]KWJRO:]ZLKVO>K*]_Z,8
M _^D*1#_HC@E_YY&/?^95%7WEUQIZY=@?-^6:8W5DW*=S))\JL62A;3$DHRV
MPH^/N<&+DKO AY6]OH.8O[V G,"]?:#!O'NEPKQYJ\*Y>:_"M'FOP;!ZL,"L
M>[*^K'NROJQ[LKZL>[*^K'NROJQ[LKZL>[*^K'NROJQ[LKZL>[*^_Z,8 O^E
M*!#_HC<E_Y]&/?^:4U7WF5IIZYE>?-^798[4E6^=RY1YJ\63@K3$E(JWPI&.
MN<",D+R_B).^O827P+R F\*[?:##NWNFQ+IZK<6T>J[$KWJOPJQ[L,"H?+&_
MJ'RQOZA\L;^H?+&_J'RQOZA\L;^H?+&_J'RQOZA\L;^H?+&__Z08 O^E*!#_
MHS8E_Y]%/?^:4U7WFE=IZYM;?-^98H[4EVN>RY5VK,64@+3#E8BWP9.-NL".
MC[V^B9+ O(65PKN!FL2Y?:#&N7NHQ[1ZJ\>O>ZW%JWNNPZ=\K\&D?;&_I'VQ
MOZ1]L;^D?;&_I'VQOZ1]L;^D?;&_I'VQOZ1]L;^D?;&__Z08 O^F)Q#_HS8E
M_Z!$/?^;4E;WG%5IZYQ8?-^;7H[4F6>>RI=SK,66?+3#EX6WP9:+N[^1C;Z]
MBY#!NX:4Q+F!F<>W?J#)MGRIRJY[JLBJ?*S&IGVMQ*-^K\&@?K&_H'ZQOZ!^
ML;^@?K&_H'ZQOZ!^L;^@?K&_H'ZQOZ!^L;^@?K&__Z48 O^F)@__I#4E_Z!$
M/?^<45;WGE-IZYY5>]^>6HW4FV2>RIEOK,68>;3#F8*XP9F*N[Z4C+^\CH[#
MN8B2Q[>"F,NU?J'-KWRGS:E]J<JE?JO'HG^MQ)]_K\*=@+&_G8"QOYV L;^=
M@+&_G8"QOYV L;^=@+&_G8"QOYV L;^=@+&__Z88 O^G)@__I#4E_Z!#/O^=
M4%7WGU%HZZ!3>^"@5XW4GE^>RIMKK,6;=;3#FWZXP)N'O+V7BL"ZD8S%MXJ0
MRK2$E\^R@*/2J'^ESZ. J,N@@*O'G8&MQ9N!K\*9@K&_F8*QOYF"L;^9@K&_
MF8*QOYF"L;^9@K&_F8*QOYF"L;^9@K&__Z88 O^G)0__I30E_Z%#/O^>3E7X
MH4YH[*)0>N"C4HS5H5N=RYYFK,:=<;3#GGJXP)Z$O+R;B,*YE8K'M8V-SK"&
MEM2I@J#6H8*DT)V"J,N:@ZK(F8.MQ9>$K\*6A+# EH2PP):$L,"6A+# EH2P
MP):$L,"6A+# EH2PP):$L,"6A+# _Z88 O^G)0__I30E_Z%"/O^?3%7XHDQG
M[*5->>&F3HO5I%:<S*%AJL:A;+/#HG:WP** O;R@A\.WFHC*LI.*TJR+E-N@
MAY_8FH:DT9>&I\R5AJK(E(>LQ9.'KL.2A[# DH>PP)*'L,"2A[# DH>PP)*'
ML,"2A[# DH>PP)*'L,"2A[# _Z<8 O^H) __IC,E_Z)"/O^@2E3YI$IF[:=*
M>.*I2XK6J%&:S:9;J<>E9;+$IW"VP*=ZO+RF@\.VHH?+KYV(UJ67E>:7CY[:
MDXVCTI&+I\V0BZK)D(JLQH^*KL./B;#!CXFPP8^)L,&/B;#!CXFPP8^)L,&/
MB;#!CXFPP8^)L,&/B;#!_Z<8 O^H) __IC,E_Z)!/O^B2%3YID=F[JI'=^.M
M1XC9K4N8SZQ4ILBL7J_&KVBSPK%SN;ZR?<"RJH?+I:*&U92<B]Z/FIW:C96B
MTXR2ILZ+D*G*BXZKQXN-K<2,C*_!C(ROP8R,K\&,C*_!C(ROP8R,K\&,C*_!
MC(ROP8R,K\&,C*_!_Z@8 O^I) __IS(E_Z-!/O^D1E/ZJ41D[ZU#=>2Q0H7;
MM$24TK5*H<NW4ZO*OE^MO;=NN+*P?,*IJH;+G*6$THV@A]B&H)?9AYZBTX>8
MI<^'E:C+AY.JR(B1K<6(D*_"B)"OPHB0K\*(D*_"B)"OPHB0K\*(D*_"B)"O
MPHB0K\*(D*_"_Z@8 O^I(P__IS(E_Z- /O^F0U+[JT%C\+$_<^>W/8+>OCN/
MUL0_FLS%2J:\O%VRL;5ONZJP?<.CJX3)EJ>#SHJDAM.!HY#5@:6?TH*AI<^"
MG*C,@YFJR826K,:%E*[#A92NPX64KL.%E*[#A92NPX64KL.%E*[#A92NPX64
MKL.%E*[#_ZD8 O^J(P__J#$E_Z0_/O^H0%'\KSQA\[8Y<.J_-WWCRC6'U-$W
ME;["2ZFPN6"UJ+1PO:.P?L*=K83'DJJ$RXBGALZ IHW0?:>8T'VHI,Y^I*C+
M?Y^JR8";J\:!F*W$@9BMQ(&8K<2!F*W$@9BMQ(&8K<2!F*W$@9BMQ(&8K<2!
MF*W$_ZH7 O^J(@__J# E_Z4^/O^K.T__M#==]KTS:NO*,77<VBF"Q,XXF;+!
M3ZNGN&.WH;1SO)ZQ?\&8KX3$CZR$R(>JA\J J8S,?*F3S'JJG,MYJZ;*>J>J
MR'RBJ\=]GJW$?9ZMQ'V>K<1]GJW$?9ZMQ'V>K<1]GJW$?9ZMQ'V>K<1]GJW$
M_ZH6 O^K(0[_J2XE_Z<\/O^P-DS\NC!9[\@L8M[9)VW+W":&MLP\FZC!5*N?
MN6:VF[5TO)FR?[^5L(3"C:^%Q(:MA\:!K(O(?:R0R'NLF,AYK9_'=ZVGQW>J
MK,9YI:W$>:6MQ'FEK<1YI:W$>:6MQ'FEK<1YI:W$>:6MQ'FEK<1YI:W$_ZL5
M O^L( [_JRTD_ZLV._^V+TCSQ"A1X-8F5LSD(G&[VBB(JLQ!FY_#5ZF9O&FR
MEK=VN92T@+V1LH7 B[&&P8:PB,.!KXO$?JZ/Q7NNE,5ZKYK$>*^@Q'6OI\1T
MK:[#=*VNPW2MKL-TK:[#=*VNPW2MKL-TK:[#=*VNPW2MKL-TK:[#_ZP4 O^M
M'P[_K"LD_[ O-_J_)4'DT2!%SN0=6[WI(G2MVBR)G\Y%F9?&6J23P&JMD;MV
MLY"X?[>-MH2[B;2&O86RB+^"L8O!?[&.P7RQDL)ZL9;!>;&;P7BRH<!TL:?!
M=+&GP72QI\%TL:?!=+&GP72QI\%TL:?!=+&GP72QI\%TL:?!_ZX2 ?^O'0W_
MKB@D_[@D,>K+&C70XA=#O_ =7J_H)76@VS&'EM%(E)#*7)Z-Q6JEB\%VJHF^
M?:^%O("R@KJ#M'ZYAK9\N(FW>;>,N'>WC[EVMI.Z=;:7NG2VG;ISMZ2Y<[>D
MN7.WI+ESMZ2Y<[>DN7.WI+ESMZ2Y<[>DN7.WI+ESMZ2Y_[ 0 ?^Q&@W_L24C
M\\07)]3?$"O![Q=(L/<@8*'J*W.5WSF"C==,C8C1796&S&J;A,ETH(#&>:1]
MQ'VF>L* J7?!@ZIUP(:L<[^*K7&_C:YOOI"O;KZ4KVR^F:]KOJ"O:[Z@KVN^
MH*]KOJ"O:[Z@KVN^H*]KOJ"O:[Z@KVN^H*]KOJ"O_[,. ?^T%@S\O!<:UM8+
M%L/M$#"R_!E*HODE7I;M,VZ,Y4%ZA=Y/@X'97HI_U6J/>M)PDW;/=9=SSGF9
M<<Q]FV_+@)UMRH2>:\F'GVG)BJ!HR(ZA9\>2HF7'EJ)DQYRC9,><HV3'G*-D
MQYRC9,><HV3'G*-DQYRC9,><HV3'G*-DQYRC]+8* ?^X$@O5S H+Q-L*&;+\
M$3.C_QU(EOPL6(SS.V6$[$EO?N=5=GKC8'QUWV>!<=UMA&W;<H=JV7:):-AZ
MBV;7?8UDUH&.8]6$CV'4B)!@TXN17]./DE[2E))<TIF37-*9DUS2F9-<TIF3
M7-*9DUS2F9-<TIF37-*9DUS2F9-<TIF3W+L$ -C#!P3$T0@'L^@*'*/_%#&6
M_R1#C/\T4(3[0EI]]D]B>/%::''N7VUKZV1Q9^EI=&3G;G9BYG-X8.5W>5_D
M>GM=XWY\7.*!?5OBA7Y:X8A_6>"+@%?@D(!6WY6!5M^5@5;?E8%6WY6!5M^5
M@5;?E8%6WY6!5M^5@5;?E8%6WY6!U+T% ,3(!P"TV04*H_X-');_&BR+_RLZ
M@_\Z1'S_2$UU_U)3;OU76&?Z75QC]V)?8/9G8EWT:V1;\V]E6?)S9U?Q=VA6
M\7II5?!]:E3O@&M3[X1K4NZ';%#NBVU/[9!N3^V0;D_MD&Y/[9!N3^V0;D_M
MD&Y/[9!N3^V0;D_MD&Y/[9!NQL % +30! &CXP(*EO\0&(O_("2"_S O>O\_
M-W+_2#YJ_TY#9/]42%[_64Q;_U]/6/]D4E7_:513_VU54OYQ5U#]=%A/_'A9
M3OM[6DW[?UM,^H-<2_F&74GYBUY(^)!?2/B07TCXD%](^)!?2/B07TCXD%](
M^)!?2/B07TCXD%](^)!?M<<" *3:  &6_P8'BO\4$8'_)!IY_S,B</\[*FC_
M0C%A_THV7/]1.U?_5S]3_UU"4/]B1$[_9T9,_VQ(2O]P24G_=$I(_W=+1O][
M3$7_?TU$_X-.0_^'3D+_BT]!_Y%00?^14$'_D5!!_Y%00?^14$'_D5!!_Y%0
M0?^14$'_D5!!_Y%0_Y$2 ?^5)PO_E3L<_Y-++_^/64/_C&14^XQK8_**<G'J
MB'Q]XX:$A]Z"BH_:?X^6UGV4F]-ZF)_1>)RBT'>?I,YUHJ;-=*:HS7*IJ<QQ
MK:K,<+*KRW"VJ\MOO*O(<,"KQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MG%)4^YU58_&=6G/GFU^!WIEIC]:6<IK/DWRERI&%K<60C;3#BY*XP866N[^
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M/4-Z_TE+<_]246S^5U=E^UU;8?EC7E[W:&!;]6UB6/1R9%;S=V95\GMG4_&
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MKTU$[;%43>6S6U7<L&5ASJAL<<.?=("XEGR-KH^&F*6(D:&=@YVGEX"MJY.
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M@5RFWX%<IM^!7*;?@5RFWX%<IM^!_X / ?^.#@'_H@T V[4( ,[!" #&T D
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MAAD?_Y$:'O^<&Q[_I1P=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!T=_[ =G,
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M4K22;UVLC'=GI(> ;YZ"BG>8?I1]DGN@@8UZK82*><"%B'K<A(=ZW8*&>M^
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M>&V,Y7AMC.5X;8SE>&V,Y7AMC.5X_VX3 ?][$0'_C1  _YT0 /JL$0#:NPL
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MMC<O_] X+O_O.2W__SDQ__\Y,_S_.3/\_SDS_/\Y,_S_.3/\_SDS_/\YP:@
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M$!/_K1$3_[H1$__#$A/_PQ(3_\,2$__#$A/_PQ(3_\,2E[X  (;,  !WVP
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M:7A\\&EX?/!I>'SP:7A\\&EX?/!I_V 7 ?]N$@'_?A  _XP1 /^9$0#QI!,
MXZX6 -:V' '+M# (P; _%[>K2R6MIE0SI*%=0)R=94J4F&Q3C)5T6X:1?6)_
MCH=H>8R2;72*GG%PB*UT;8C!=&V)Y'-OA^IQ<(3L;W*#[6US@>YK=(#P:72
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MVT=$V/1)0M/_343)_T]%PO]01[O_4D>[_U)'N_]21[O_4D>[_U)'N_]2YHH
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M*BS__RHL__\J+_G_*B_Y_RHO^?\J+_G_*B_Y_RHO^?\JN:8  *JN  "<N0
MCL4  ('1  !UW@  ;?H) &7_$0%>_QH"5_\C U+_+ 5,_S0'2/\\"D/_1 P_
M_TP.//]3$#C_6Q(U_V,4,O]L%B__=Q<L_X09*?^3&B?_HAPE_[0=)/_,'B/_
M[1XB__T?(O__'R+__Q\B__\?(O__'R+__Q\B__\?K*L  )VV  "/P@  @,X
M '/<  !GZ0  7_\& %C_#@!1_Q4!2_\= D;_)@-!_RT$//\U!3C_/ 8T_T('
M,?])""[_4 DK_U<**/]?"B7_:0PC_W0-(/^"#AW_D@\;_Z(0&O^R$1G_R!(8
M_^43%__Z%!?_^A07__H4%__Z%!?_^A07__H4G[,  )"_  " S   <MH  &3D
M  !8]0  4?\! $K_"P!$_Q !/O\7 3G_'@(T_R4",/\L RS_,@0H_S@$)?\^
M!2+_1 4?_TH%'/]1!AK_6087_V,'%/]N!Q+_? @0_XP(#_^<" [_K D._[L)
M#?_3"0W_TPD-_],)#?_3"0W_TPD-_],)D;P  (')  !RUP  9.0  %3K  !+
M_P  1/\  #W_!  W_PP ,?\0 2S_%@$H_QP!)/\B B#_)P(<_RP"&?\Q Q;_
M-@,3_SP#$?]" P__200-_U$$"_]:! G_9@0&_W,% _^!!0+_D 4!_YP% ?^K
M!0'_JP4!_ZL% ?^K!0'_JP4!_ZL%_T0D O\_+@/_/#8$_T X!/]!/0;_044(
M_T%1#?] 71/_/VH8_SQW'/\ZA"#_-Y$C_S:;)?\UI"?_-*PH_S2U*O\SOBO_
M,L@K_S+5+/\QY2W_,?$M_S'[+?\P_RW_,/\M_S/_+?\V_RS^./\M^3K_+O8[
M_R[V._\N]CO_+O8[_R[V._\N_T4C O\_+@/_/C0#_T(V!/]$.P;_1$,(_T5/
M#?]$6Q/_06@9_S]U'?\\@B'_.H\D_SB:)_\WHRG_-JPJ_S:T+/\UO2W_-,@N
M_S36+O\SYB__,_(O_S+\,/\R_S#_,_\O_S;_+_\Y_R_Y._\P]#W_,?$]_S'Q
M/?\Q\3W_,?$]_S'Q/?\Q_T8C O] +0/_03(#_T8S!/](. ;_2$ (_TE,#O](
M6!3_164:_T)R'_] ?R/_/8PF_SN8*?\ZH2O_.:HM_SBS+O\WO2__-L<P_S;5
M,?\VYC+_-?$R_S7[,O\U_S+_-O\R_SK_,?H]_S/S/O\T[4#_-.I!_S3J0?\T
MZD'_-.I!_S3J0?\T_T<B O]!+ /_12\#_TDP!/],-0;_33T(_TY(#O]-5!7_
M2V$;_TAN(/]%>R7_0H@H_S^4*_\^GB[_/:<O_SRO,?\\N#+_.\,S_SK/-/\Z
MX37_.NXU_SKX-?\Z_S7_.O\U^S[_-?)!_S?K0O\XY43_..%%_SCA1?\XX47_
M..%%_SCA1?\X_T@B O]#+ /_2"P#_TXM!/]1,07_4SD(_U5%#O]3417_45T<
M_TYJ(?]+=R;_2(,K_T6/+O]$F3#_0J(S_T&K-/]!M#;_0+TW_S_)./\_VSC_
M/^HY_S_U.?\__SG[0/\X\4/_.NA%_SSA1_\\VDC_/=5)_SW52?\]U4G_/=5)
M_SW52?\]_TDA O]$*@/_32@#_U,I!/]7+07_638(_UQ"#O];3A7_6%D<_U5E
M(O]2<BC_3WXM_TR*,/]*E#/_2)XV_T>F./]&KSG_1;@[_T7$//]$TCS\1.4]
M^$3R/?5%_CSQ1?\^YDC_0-Q*_T'22_]!S$W_0<E-_T')3?]!R4W_0<E-_T')
M3?]!_TH@ O]()P+_424#_U@E _]=*@3_8#,'_V,_#O]B2A7_8%4<_UQA(_]9
M;2G_57DN_U*$,_]0CS;]3IDY^TRB._I+JCWX2K0_]TJ^0/5)S$#Q2>%![4KP
M0>I*_$+D2O]$V$S_1<Q/_T;&4/]&P%'_1KY1_T:^4?]&OE'_1KY1_T:^4?]&
M_TP@ O],) +_52$"_UTA _]C)P3_9S$&_VH\#/]J1Q3_9U(;_V-<(_]?:"K[
M7'0P]UE_-?56BCGR5)0\\%*=/^Y1ID'L4*]#ZD^Z1.A.QT3F3]U%X4_N1=U.
M^TC43_])R%'_2L!3_TJZ5/]*ME7_2K16_TJT5O]*M%;_2K16_TJT5O]*_TT?
M O]0(0+_6AX"_V(> O]I)0/_;2T%_W$Y"_]Q1!+_;TX:^VM8(O5F8RGQ8V\P
M[6!Z-NE<A3OF6H\_Y%B80N%6HD3?5:M&W%.V2-I2PTK64MA*T5/L2\Q3^DW%
M5/].O%;_3[57_T^P6/].K%G_3:I:_TVJ6O]-JEK_3:I:_TVJ6O]-_TX> O]3
M'@+_7AL"_V<; O]N(@/_<RH$_W<U"?]X0!#Y=TH8\G-4(.QO7BCG:VHPXF=U
M-MYC@#S97XI!U%V31M%;G4G.6:9,RUBP3LA7O%#&5LU1PU?F4;Y7]U*X6/]3
ML%K_4ZM<_U*G7?]2HUW_4:)=_U"B7?]0HEW_4*)=_U"B7?]0_T\> O]7&P+_
M8A<!_VP9 O]T( +_>2<#_WXR!_F / WQ?T85ZGM0'>1W6R;=<V8NU6UP-]!I
M>C[+981$QV*.2<1@ETW 7J!0O5VJ4[M;ME6X6\56M5O?5K)<\U>L7?U7IE[]
M5J%@_E6>8/]4G&'_4YIA_U.:8?]3FF'_4YIA_U.:8?]3_U = O]:&0'_914!
M_W 7 ?]X'0'_?R0"_80N!?.&. KJAD(1XX1+&=M_5R/1>6(ORW1L.,5O=D#
M;']&O&B(2[AFD5"U8YM3L6&E5JY@L%FK7[]:J5_46Z9@[UNB8?I:G6/[69ED
M_%B69/U7E67^591E_E649?Y5E&7^591E_E649?Y5_U = O]=%P'_:1(!_W05
M ?]]&@'_A"$!]XDJ ^V-- ?DC3T-W(M(%M&%5"/)?UXNPGIH.+QU<4"W<7I'
MLFZ$3:YKC5*J:)96IV:@6:-EJUR@9+E>GF3-7IMDZEZ89OA=E&?Y7))H^UJ0
M:/Q9CFC]5XYH_5:.:/U6CFC]5HYH_5:.:/U6_U(< ?]?% '_;!$!_W@3 ?^!
M%P'_B!T!\H\E N>3+P3>E3@)TY!%%<J+42+"A5LNNX!E.+1[;D&O=W=(JG1_
M3J5PB%.A;I)7G6N<6YEJIUZ6:;5@E&C(89)IYF"/:O=?C6OX78MK^5R);/M:
MB&S\6(AK_%B(:_Q8B&O\6(AK_%B(:_Q8_U0: ?]B$P'_;Q !_WL2 /^%% #Z
MC1D [9,? >*9* +8F3,(S)5"%,203B&\BUDMM(5B-ZZ!:T"H?'-(HGE\3IUV
MA529<XY8E7&87)%OI&"-;K%BBVW#8XENXF*';_9AAF_W7X5O^5V$;_I;@V_[
M68-O_%B#;_Q8@V_\6(-O_%B#;_Q8_U88 ?]D$0'_<@X _WX0 /^($0#UD10
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M/C[+_T! P_]"0;W_0T*Y_T1"N?]$0KG_1$*Y_T1"N?]$W8@  ,>8  "XHP
MJZL  *"T  "5O@  B\@# (#1!P!XX0T =.$= 6[A*P-HX#<(8>!"#ES@3117
MX%894^!?'4_@:2)+X',E1^!^*$3@BRM"X)HM/^&K+S[BP2\^XN4O/-_Z,3G>
M_S0YV?\V.M#_.#O,_SD[S/\Y.\S_.3O,_SD[S/\YS9(  +R@  "MJ   H;$
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M$Q[__Q,>__\3'O__$Q[__Q,>__\3IJD  )BS  "*OP  >\H  &[5  !@WP
M5.<  $[_! !)_PX 0_\4 #__'0$Z_R4"-O\L C+_,P,O_SH#*_]!!"C_2 0E
M_T\%(O]7!2#_8 8=_VP'&O]Y!QC_B@@6_YL(%?^M"13_PPD3_^,)$__X"1/_
M_PH3__\*$___"A/__PH3__\*FK$  (N]  !\R   ;=0  %_@  !1Y@  1_4
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M2)%@_T>18/]'D6#_1Y%@_T>18/]'_TX8 ?]:$0'_9 X _V\0 /]V$P#\?1<
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M24Z?_TE0F?])4I;_2%22_T=4DO]'5)+_1U22_T=4DO]'_VX  -Y_  #*C0
MOI@  +.@  "JIP  H:X  )>V  "1NA  C+HC 86Y,@9^N#X.=[9)%W&U4AYK
MLUHE9;)B*V"Q:C!;L',U5Z]].5.NB3U/K99 3*VE0DJMN4-)KMA"2*OU0T>J
M_T1)I?]$2Z#_1$V<_T1-G/]$39S_1$V<_T1-G/]$ZG4  -*&  ##DP  MYT
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M*S;*_RTVRO\M-LK_+3;*_RTVRO\MQ9   +:=  "HI0  G*T  (^V  "#O@
M=\<  &S/ @!BU@< 6N0. %CD' !4Y"D!4.0U TSE/P5(Y4D'1>53"D+F7 T_
MYF8//.9Q$CKG?A0WYXP6->><%S/HKADRZ<89,NCJ&3'E_ADOY/\<+N3_'BWB
M_R MXO\@+>+_("WB_R MXO\@NIH  *JC  "=JP  D+0  (.]  !WQ@  :\\
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M!0[__P4.__\%E:\  (:Z  !WQ0  :-   %K;  !,X0  0.<  #?S   R_P
M+O\' "K_#@ F_Q, (_\: !__(  ;_R8 &/\K 17_,@$2_S@!$/]  0[_2 $,
M_U(!"?]= @;_:P($_WT" O^0 @'_HP( _[8" /_- P#_[ , _^P# /_L P#_
M[ , _^P#B+D  'C$  !IT   6]T  $OC   ^Z0  ,NX  "O_   F_P  (?\
M !W_"  :_PT %O\1 !/_%@ 0_QH #O\?  O_)  )_RH !O\P  +_-P$ _T !
M /]* 0#_5@$ _V0! /]U 0#_B $ _YH! /^J 0#_NP$ _[L! /^[ 0#_NP$
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M^V8G ?)F,0/J93T&XV-*"]Q@5Q+576(9T%IM'\Q7=R/(58 GQ52)*\)2DB[
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M1E^!_T1@?_]"87W_06)[_S]C>O\_8WK_/V-Z_S]C>O\__UX  .EM  #6>0
MR(0  +Z,  "VDP  KI<  *:;! "@G1< FITI I.<-PB,FD,0AIA-&("651]Z
ME%TF=9)E+'"0;#%LCG4V9XU^.F.+B3Y?BI5!7(FC1%J)M$58B<M%6(CM1%B(
M_T-9AO]!6X/_0%V!_SY=@/\^78#_/EV _SY=@/\^_V(  .1Q  #/?@  PX@
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M-TB<_S=)FO\W29K_-TF:_S=)FO\WXG0  ,J#  "\CP  L)@  *6>  ";I
MD*L  (6Q  !ZN 0 =KD4 '*Y)0%MN3,$:+@_"&.X20Y>MU(36K9:&%:V8AQ2
MM6L@3K1U)$NT@"=(LXXJ1;.=+$*SKBU!L\4N0;/I+4"P_B\_K_\Q/JW_,D"H
M_S)!IO\R0:;_,D&F_S)!IO\RU7P  ,**  "UE@  J)T  )VC  "2J@  A[$
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M%BC:_Q8HVO\6LY@  *6@  "9IP  B[   'ZX  !QP   9<@  %G.  !.TP
M1-L$ #_I#0 ]Z1< .^HC #GJ+@ VZS@!-.M" 3'L2P(O[54#+>U? RKN:P0H
M[G@%)N^(!B7OF@<C\*X'(O'(!R+P[0<A[/\'(>O_""#K_PH?ZO\+'^K_"Q_J
M_PL?ZO\+J)\  )NF  "-KP  ?[@  ''!  !DR@  6-   $S6  !!W0  ..0
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M8@$ _W,! /^' 0#_G0$ _[(! /_* 0#_Z@$ __,! /_S 0#_\P$ __,!A+<
M '3!  !ES   5M@  $??   YY0  +>H  "/N   <_0  &/\  !7_   1_P0
M#_\+  W_#@ )_Q$ !O\5  /_&@  _R   /\F  #_+@  _S<  /]!  #_30
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M.VUL_CEM;/\W;FS_-6YK_S1N:O\R;FK_,FYJ_S)N:O\R_U,  /1?  #>:@
MS7,  ,-Z  "[?@  M8$  *Z#"0"HA1H HH4K IN$.@>5@D4.D']/%8I]6!N&
M>U\@@7EG)7UW;RIZ=G<N=G2 ,G-SBS5O<I8X;'&C.FEPLCQH<,8\9W#G.V=Q
M_#EH<?\W:'#_-6EO_S1I;O\S:6[_,VEN_S-I;O\S_U8  .MB  #8;@  R78
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M-%A__S-9??\R67W_,EE]_S)9??\R[V   -MN  #'>@  NX,  +*+  "HD
MGY,  )26  "-F0X B9H> (2:+@)^F3H'>9=%#7263A-OE588:I->'6:292%B
MD6TF7H]V*EN.@2U7C8TP5(R:,U&,JC5/C+TU3XS>-4^+]S1/BO\S4(G_,E&&
M_S%2A/\Q4H3_,5*$_S%2A/\QZF4  -)S  #"?P  MH@  *R0  "BE   F)@
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M)CND_R8[I/\FS'H  +N(  "ND@  HID  )>>  ",I   @*H  '6O  !IM
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MD (=Z:0"&^F\ AKJX@(:YOP"&>7_ QGD_P08X_\%&./_!1CC_P48X_\%HYT
M ):D  "(K   >K4  &R]  !?Q   4\H  $?.   \TP  ,MH  "K?   E[@D
M(_ 1 "'Q&0 ?\2( '?(K !OS-  9]#X %_1( !7U4@ 3]E\ $O9N 1'W@ $0
M^)0!#_FJ 0[YQ@$.^>T!#?;_ 0WT_P$-\_\!#?/_ 0WS_P$-\_\!F:,  (NL
M  !\M0  ;;X  %_&  !2S0  1=(  #G8   OW@  )N(  !_J   <^P8 &?\.
M !?_$P 4_QH $O\A !#_*  ._S  #?\Y  O_0P )_TX !O]<  3_;  "_X
M ?^6  #_K0  _\H  /_P  #__P  __\  /__  #__P  __\ C:L  'VU  !N
MOP  8,@  %+0  !#UP  -]T  "OB   BY@  &>H  !7Y   2_P  $/\(  [_
M#@ ,_Q$ "?\6  ;_'  #_R(  /\J  #_,P  _ST  /])  #_5P  _VD  /]^
M  #_E0  _ZP  /_'  #_Z   __H  /_Z  #_^@  __H @+4  '"_  !AR0
M4M,  $/;   UX0  *>8  ![J   5[@  $/@   [_   +_P  "/\   3_!@
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M+7Q:^BQ[6O\J>UO_*'M;_R=[6O\F>EK_)7I:_R5Z6O\E_TD  /M2  #C7
MTF,  ,=H  # :P  NFL" +5K#0"N;1T J&XN :-M/ 6=:T@*F6I1#Y1H6A20
M9F(8C65J'(IC<B"'8GHCA&&#)H%@C"E^7Y<K>UZC+7E>L2]W7<0O=5[B+W5>
M^2UU7_\K=5__*75?_RAU7O\F=5[_)G5>_R9U7O\F_TL  /!5  #>7P  S6<
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M*V1K_REE:O\H96K_*&5J_RAE:O\H_5,  .-?  #.:0  P7$  +=W  "O>P
MIWT  )Y]  "8?A$ DX B (Z ,0*)?SX&A'U(#']\41%[>ED6=WE@&G-W:!YO
M=G A;'5X)6ET@BAF<XXK8W*:+F!QJ"]><;HP77'4,%UQ\BY><?\L7G#_*U]P
M_RE@;_\H8&[_*&!N_RA@;O\H\54  -YB  #*;0  O74  +-[  "K@   HH(
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M)DZ!_R9.@?\FX6,  ,EP  "[>P  L(0  *:*  ";C@  D9$  (23  !ZE0(
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MF@\SLZT0,K/%$#*RZ1 QL/X2,*[_%"^M_Q4OK/\6+ZS_%B^L_Q8OK/\6NX$
M *Z.  "AE0  EIH  (F@  !]I@  <:L  &6O  !9M   3K<  $.\!0! O1$
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M !+CSP 2X/0 $M[_ 1'=_P$1V_\"$=O_ A';_P(1V_\"GIH  )*A  "$J0
M=K$  &BX  !;OP  3L0  $+(   WS   +=   "35   <VP  %=\% !3I#@ 2
MZA0 $>L= !#K)@ .[#  #NTZ  WN1@ +[E, "N]B  GP=  (\8D !_*@  7R
MN@ $\>0  O']  +O_P #[?\  ^W_  /M_P #[?\ E:$  (:I  !XL@  :;H
M %O"  !-R   0,P  #31   JU@  (=L  !G@   2Y   #_ !  WY"@ +^@\
M"?L5  ?['  $_"0  ?PL  #\-P  _$(  /Q0  #\80  _74  /R,  #\I
M_,$  /SK  #\_P  _?\  /W_  #]_P  _?\ B:D  'FR  !JNP  7,0  $[,
M   _T0  ,M<  "?=   =X0  %>4   [H   *\0  "/T   7_ P !_PD  /\.
M  #_$@  _Q<  /\?  #_)P  _S$  /\^  #_30  _U\  /]U  #_C0  _Z8
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M *\ _P"V /\ O@#_ ,@ _P#7 /\ YP#_ /, _P#] /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _QLI /\=)@#_'"4 _QDG /\3+ #_#C0 _PM
M ?\(3@'_!5L!_P-H ?\"= '_ G\!_P*( ?\"D0'_ I@!_P*? ?\!I0#_ :P
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M&Y%'^1N/1_\:CD?_&8Y'_QB-1_\8C4?_%XU'_Q>-1_\7_SX" /]#  #K2P
MW5$  -%4  #*5 $ QE(% ,%1$0"Y4R( LU4S :Y400*J5$P%IE-6"*)17PR?
M4&</G4]O$9I.=Q283G\6EDV(&)-,D1F13)L;CTNF'8U+LQZ+2\4>B4OB'H=,
M]QZ&3/\=A4S_'(5-_QJ%3/\9A4S_&85,_QF%3/\9_T   /Q'  #E4   U58
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M('!:_QYP6O\=<%K_''!:_QQP6O\<_T@  .=2  #36P  Q6(  +MF  "S:
MK&@  *5F!0"?9Q0 FFDE )5I- *0:$ $C&=*"(AF4PR$95L0@61B$WYC:A9[
M8G(9>&%Z''9@A!YS7XXA<%Z:(VY>J"5L7;@E:E[.)FE>[B1I7O\B:E[_(&I>
M_Q]J7O\>:E[_'6I>_QUJ7O\=^4H  .-5  #/7P  P64  +=J  "O;   IVP
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M'EMJ_QY;:O\>ZU,  --@  #":0  MG$  *QV  "C>0  F7D  (UW  "'>0L
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MF1I#BJH;0HJ_&T&*X1M!B/D;08;_&T&%_QM"A?\:0H3_&D*$_QI"A/\:S6<
M +QT  "O?@  I88  )J*  ".C   @HT  '60  !GE   894( %Z7% !<ER,
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M"2RLV0@LJO4**ZC_"RJF_PPJI?\-*J7_#2JE_PTJI?\-M8   *B+  "<D0
MD98  (6<  !XH   :Z4  %^H  !3K   2*\  #VR   VM0L -+45 #.V(0 R
MMBP ,;<W #"W00 ON$L +KA5 "RX8 $JN&T!*;E[ B>YC0(EN9\#)+FT R.Y
MT@,CM_0$(K7_!2&T_P8AL_\'(;+_!R&R_P<ALO\'K8H  *"1  "5EP  B)T
M 'NC  !NJ   8:T  %6Q  !*M   /[<  #2[   KO@, ),(, "+"%  BPQ\
M(<,J "#$-  ?Q#\ 'L5* !W&5@ <QF, &\=S !K'A0 9QYD &,BN !?(RP 7
MQO$!%\3_ 1;#_P(6P?\#%L'_ Q;!_P,6P?\#HY$  )B8  "+G@  ?:4  '"K
M  !BL0  5K8  $JY   ^O0  -,   "K$   BR   &<P$ !/0"@ 1TA$ $-(:
M !#3)0 /TS  #M0\  [42  -U58 #=5E  S6>  ,UHT "]BD  K8O@ )V>8
M"M;^  O4_P +TO\ "]+_ 0O2_P$+TO\!FI@  (Z?  " I@  <JT  &2T  !7
MN@  2;\  #W"   RQ@  *,D  !_-   7T0  $=8   S;!0 (W@L !M\1  7?
M&@ $X"0  N$N  'B.@  XT<  .16  #D9P  Y7L  .:2  #FJ@  Y\@  .?P
M  #H_P  Z/\  .C_  #H_P  Z/\ D9\  (*G  !TKP  9;<  %>^  !)PP
M/,<  ##+   ESP  '-0  !39   .W0  ">$   +E    Z08  .D-  #I$0
MZA@  .LA  #M*P  [S<  /%%  #R5@  \V@  /-^  #TEP  ];   /;0  #W
M\P  ]_\  /?_  #W_P  ]_\ A:<  ':P  !FN   6,$  $K(   [S   +M$
M "/6   9W   $>    SC   $YP   .H   #U    ]    /4%  #U"P  ]@\
M /84  #X'0  ^B<  /PT  #_0P  _U4  /]I  #_@0  _YH  /^R  #_SP
M_^T  /_Y  #_^0  __D >+   &BZ  !9PP  2\L  #O1   MV   (=T  !;B
M   .Y@  ".H   #M    \    /@   #_    _P   /\   #_    _P8  /\,
M  #_$   _Q@  /\B  #_,   _T   /]3  #_:0  _X$  /^9  #_KP  _\,
M /_5  #_U0  _]4 _Q,H /\3)0#_$24 _PTG /\&+0#_ #4 _P!! /\ 3P#_
M %P _P!I /\ = #_ 'X _P"( /\ D #_ )< _P"= /\ I #_ *H _P"P /\
MMP#_ ,  _P#, /\ WP#_ .P _P#X /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _Q8E /\6(@#_%"$ _Q C /\** #_ #  _P ] /\ 2P#_ %@
M_P!D /\ < #_ 'H _P"$ /\ C #_ ), _P": /\ H #_ *8 _P"M /\ M #_
M +P _@#( /T V0#[ .D ^@#V /D _P#X /\ ^ #_ /@ _P#X /\ ^0#_ /D
M_P#Y /\ _QHB /\:'@#_&!T _Q,> /\.(@#_"BP _P<Y /\#1@#_ %, _P!@
M /\ :P#_ '8 _P!_ /\ B #_ (\ _P"6 /\ G0#_ *, _@"I /P L #Z +D
M]P#$ /4 T@#S .8 \@#T /$ _P#P /\ [P#_ .\ _P#O /\ \ #_ /  _P#P
M /\ _QX= /\>&0#_'!< _Q<8 /\3'@#_$2@ _PXT /\,00#_"DX _PA; /\'
M9@#_!G$ _P9Z /\&@P#^!HL _ :2 /H&F0#X!I\ ]@:F /0&K0#R!K4 \ 7
M .T%S@#K!>0 Z0;S .8(_P#E"O\ Y O_ .0+_P'D"_\!Y O_ >0+_P'D"_\!
M_R$8 /\A$P#_(!$ _QL2 /\<&@#_&B0 _Q8O /\3/ #_$4D _Q!5 /P.80#Y
M#FL ]@YU /0.?@#R#H8 \ Z. .X.E0#M#IL ZPZB .H.J@#H#K, Y@^] .4/
MS #A#^, W1#S -D1_P'6$O\!U!/_ =,3_P+2$_\"TA/_ M(3_P+2$_\"_R43
M /\E$ #_) T _R,. /\C% #_(AX _Q\I /\<-0#Y&4, ]!A/ .\76P#L%V8
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M!JXN^P>K+O\(J2[_"*@N_PBH+?\(J"W_"*@M_PBH+?\(_R\( /\Q  #_-0
M]C<  .HV @#G,P@ Y"\/ -DN&P#/,2P R3,\ ,0T20# -54!O#5? KHU: *W
M-7 #M31X!+,T@ 6Q-(@&L#20!JXTF0>L-*((JS2L":DTN0FG-,H*I37E"J$U
M^ N?-?\,G37_#)TU_PN<-?\+G#7_"YPU_PN<-?\+_S," /\U  #V.@  Y3X
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MB$+_$8A"_Q"'0O\0AT+_#X="_P^'0O\/_S@  /,]  #C1P  TDP  ,A.  #
M30  NTH" +9'#@"P21T JTLM *9,.P&B3$<"GDM1!)M+6@:92F((EDEJ"I1)
M<0R22'D.CTB"#XU'BQ&+1Y42B4:@%(=&K!6%1KL6A$;1%H)'[A: 1_\5?T?_
M%']'_Q)_1_\1?T?_$7]'_Q%_1_\1_SL  .Y#  #<3   S%$  ,%4  "Y5
MM%$  *Y-"P"H3QD HU$I )Y2-P&:4D,"EU%.!)115@:14%X)CD]F"XQ.;0V)
M3G4/ATU^$85-AQ."3)$5@$R<%GY+J1=\2[@8>TO-&'E,ZQAX3/X7=TS_%7=,
M_Q1W3/\3=TS_$G=,_Q)W3/\2_SX  .A'  #54   QE8  +Q8  "T60  K58
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M%&59_Q1E6?\4[T8  -I2  #&6P  NF$  +!E  "F9@  G6,  )5A  "/8@X
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MF1E1;:@:3VV[&TYMV1I.;/093VO_&$]K_Q=0:O\64&K_%5!J_Q50:O\5W54
M ,5A  "W:@  K'$  *)U  "4=   B70  'QS  !V=0  <7<0 &]X'0!L>2L
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M$SR$SQ,\@O 2/('_$CV _Q(]?_\2/7[_$3U^_Q$]?O\1Q68  +5Q  "J>P
MGX(  )*"  "%@@  >8,  &V&  !?B@  6(T! %2.#P!2CQL 4(\G $^0,P!-
MD#T!2Y!% DF03@-&D%8$1(]?!4*/: <_CW,)/8Z "SJ.CPPXCJ --XZS#C:.
MS XVC>\.-8O_#C6)_P\UB/\/-H?_#S:'_P\VA_\/OFT  +!Y  "E@@  F8<
M (R(  !_B   <HH  &:-  !:D0  4)4  $F7"0!'F!, 19@@ $29*P!#F38
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M AJM_P(:K/\#&JO_ QJK_P,:J_\#J(@  )N/  "1E   A)H  ':?  !HH@
M6Z4  $^I  !$K0  .;   "^S   FM@  'KD% !B[#@ 7NQ8 %[P@ !:\*@ 5
MO34 %+U  !.^2P 2OE@ $KYG !&_>  0OXP $,"B  [ N@ .P.$ #[W[  ^\
M_P 0NO\!$+K_ 1"Z_P$0NO\!GX\  )25  "'FP  >:$  &NG  !>K   4K$
M $6T   ZM@  +[D  "6\   =OP  %<,   _&!0 +R@T "<H4  C*'0 'RB<
M!\HR  ;+/@ %RTL !,Q:  /,:@ "S'X  <R4  #,JP  S<@  ,SM  #,_P
MR_\  <K_  '*_P !RO\ EY8  (J<  !\HP  ;JH  &"P  !2M@  1;D  #F\
M   NOP  (\,  !O&   3R@  #<T   C1   !U D  -0.  #5%0  UAX  -@G
M  #9,0  VSX  -Q+  #=6P  WFX  -Z$  #?FP  W[0  -[9  #?]P  W_\
M -__  #?_P  W_\ C9T  '^E  !PK   8;,  %.Z  !%OP  .,(  "S&   A
MR0  &,T  !#1   +U0  !-H   #>    X $  .$)  #B#@  Y!,  .4;  #G
M)   Z2\  .L\  #M2P  [ET  .YQ  #OB0  \*(  /"\  #PXP  [_D  /#_
M  #P_P  \/\ @:4  '*M  !CM0  5+T  $;$   WR   *LP  !_0   5U0
M#MH   ?>    X@   .8   #I    Z@   .P   #N!0  [PP  /$0  #S%P
M]2   /@K  #[.0  _4H  /Y>  #_=   _XT  /^F  #_P   _^$  /_U  #_
M]0  __4 =*X  &6W  !6P   1\@  #C-   JT@  '=@  !/=   ,X@   ^8
M  #I    [    /    #S    ]    /8   #X    ^@   /T'  #_#0  _Q(
M /\;  #_*   _S<  /]*  #_7@  _W8  /^/  #_I@  _[H  /_1  #_T0
M_]$ _P\D /\.(@#_"R$ _P,D /\ *0#_ #( _P ^ /\ 3 #_ %D _P!E /\
M< #_ 'H _P"$ /\ C #_ )( _P"9 /\ GP#_ *4 _P"K /\ L@#_ +H _P#%
M /\ TP#_ .< _P#T /\ _P#^ /\ _P#_ /X _P#^ /\ _@#_ /X _P#^ /\
M_Q$A /\0'@#_#1T _P<? /\ (P#_ "T _P Z /\ 2 #_ %4 _P!A /\ ; #_
M '8 _P!_ /\ AP#_ (X _P"5 /\ FP#_ *$ _P"G /X K@#] +8 _ #  /L
MS0#Y .( ^ #P /< _ #V /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#U /\ _Q4=
M /\3&@#_$!D _PL9 /\ '0#_ "D _P V /\ 0P#_ %  _P!< /\ 9P#_ '$
M_P!Z /X @P#\ (H ^@"1 /D EP#X )T ]P"C /4 J@#T +( \@"[ /$ R #O
M -P [@#L .T ^@#K /\ Z@#_ .H _P#J /\ Z@#_ .H _P#J /\ _Q@9 /\6
M%0#_$Q, _PX3 /\+&@#_!R0 _P(P /\ /@#_ $L _P!7 /\ 8@#\ &P ^ !U
M /4 ?@#R (4 \0", .\ DP#N )D [ "@ .L I@#I *X YP"W .8 PP#D -0
MX@#I .$ ]P#? /\ W0#_ -T _P#= /\ W0#_ -T _P#= /\ _QL3 /\:$ #_
M%@X _Q(. /\2%0#_#Q\ _PPK /\). #_!D4 ^P-1 /<"7 #R F8 [@)P .H"
M> #G H  Y@.' .0#C@#B Y4 X0.< -\$HP#=!*L VP2T -@%P #6!=  TP;G
M - (^ #."O\ S O_ ,L,_P#+#/\ RPO_ ,L+_P#+"_\ _Q\0 /\>"P#_&@<
M_QD+ /\8$0#_%AD _Q(D /H0, #S#CX [@U* .D,5@#E#&$ X@QJ -X-<P#;
M#7L V0V# -8-B@#4#9$ T@V9 - .H #/#JD S0ZS ,L.OP#*#]  QA'I ,(2
M^0"_$_\ O1/_ ;P3_P&\$_\!O!/_ ;L3_P&[$_\!_R(, /\A! #_(   _R$%
M /\?# #_'!$ ]A@< .P5* #E$S8 WQ)# -D33P#3%%H T!5D ,T6;0#+%G4
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M!I8O_P:5+O\%E2[_!94N_P65+O\%_RP  /\N  #J-0  W3D  -$Y  #*-@
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M"W%&_PMQ1O\+\SD  .!$  #,3   OE$  +13  "J4@  HDX  )U* 0"72Q$
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MF!)<6*<46UBX%%E9T!196/ 365C_$5I8_Q!:6/\.6E?_#5I7_PU:5_\-XT@
M ,M3  "[6P  L&$  *1B  "780  CE\  (5<  !_7@< >U\3 'AA(0!U8BX
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M$DEGR1))9^L226;_$$IF_P]*9?\.2V7_#4MD_PU+9/\-T50  +Y>  "Q9P
MIFT  )=L  "*:P  ?VL  '-K  !M;0  :&X, &5P%P!B<20 8'$P %YQ.@%<
M<4,"67%+ U=Q4P15<%H&4G!B!U!P:PE.;W4+2V^"#4ENCP]';I\016ZP$41N
MQQ%#;>H01&S_#T1K_PY%:_\-16K_#45J_PU%:O\-RU@  +IC  "M;   H7$
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M"#"#_P@P@O\(,('_"#"!_P@P@?\(MVL  *IV  "@?P  D'X  ()^  !V?P
M:H   %Z#  !3AP  2HL  $&. @ ]D X .Y 8 #J1(P YD2T .)(W #>20  V
MDDD -)-2 #.37 $QDV<!+Y-T BV2@P,KDI0#*I*G RB2O00HDN$#)Y#Z!">.
M_P4GC?\%)XS_!2>,_P4GC/\%L70  *5^  "9A0  BH0  'V$  !OA0  8X@
M %B+  !-CP  0Y,  #J7   RF@< +IL0 "V;&@ LG"0 *YPN "J=.  IG4$
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M  FR_P )LO\ FHT  )"3  "$F   =)P  &6@  !7I   2Z@  $"L   UL
M*K,  "&U   8N   $;L   R^ @ &P L  L 1  '!&0  P2(  ,(K  #"-@
MPT(  ,-0  #$7P  Q'$  ,2'  #$G0  Q+4  ,3:  #$]@  P_\  ,/_  ##
M_P  P_\ DY0  (>:  !XH   :J8  %RL  !/L0  0;4  #6W   IN@  '[T
M !;    0PP  "L8   /*    S 4  ,P,  #-$0  SA@  ,XA  #0*@  T34
M --#  #44@  U&,  -5X  #5CP  U:<  -;"  #6Z0  UOT  -;_  #6_P
MUO\ BIL  'NB  !LJ0  7K   %"V  !"N@  -+T  "C!   =Q   %,<   W+
M   &S@   -(   #7    V0   -H%  #<"P  W1   -\5  #A'0  XR<  .4S
M  #G0@  Z%0  .AG  #I?@  Z9<  .JO  #JS@  Z^\  .O^  #K_P  Z_\
M?:,  &ZK  !?L@  4;H  $+    TPP  )\<  !O+   2SP  "],   +8
MW0   .$   #D    Y0   .<   #I    ZP<  .T-  #O$0  \1D  /0D  #W
M,0  ^4$  /I5  #Z:@  ^X0  /N=  #\M@  _-(  /WM  #]]   _?0 <:P
M &&U  !2O0  1,0  #3)   FS0  &M(  !#8   (W0   .$   #E    Z
M .P   #O    \0   /,   #U    ]P   /D!  #["   _@X  /\5  #_(0
M_R\  /]!  #_5@  _VT  /^'  #_H   _[8  /_*  #_U   _]0 _PL@ /\'
M'@#_ !T _P @ /\ )0#_ "X _P [ /\ 20#_ %8 _P!B /\ ;0#_ '8 _P!_
M /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K0#_ +4 _P"^ /\ RP#_ .$
M_P#P /X _0#] /\ _0#_ /T _P#] /\ _ #_ /D _P#Y /\ _PT= /\+&@#_
M!!D _P : /\ 'P#_ "H _P W /\ 10#_ %$ _P!> /\ : #_ '( _P!Z /\
M@@#_ (D _P"0 /\ E@#_ )P _@"B /P J0#[ +  ^0"Y /@ Q@#V -D ]0#K
M /0 ^0#S /\ \@#_ /, _P#S /\ \P#_ /, _P#S /\ _Q 9 /\.%0#_"!0
M_P 4 /\ &0#_ "4 _P R /\ 0 #_ $P _P!9 /\ 8P#^ &T _ !U /H ?0#Y
M (0 ]P"+ /8 D0#T )< \P"> /( I #P *P [@"T .T P #K ,\ Z0#F .@
M]0#F /\ YP#_ .8 _P#E /\ Y0#_ .4 _P#E /\ _Q(4 /\0$ #_# \ _P,0
M /\ %0#_ "  _P L /\ .@#_ $< ^@!3 /< 7@#T &< \0!P .\ > #M '\
MZP"& .H C #H ), YP"9 .4 H #C *< X0"P -\ N@#= ,D VP#@ -@ \ #7
M /X U0#_ -0 _P#3 /\ TP#_ -, _P#3 /\ _Q40 /\2# #_#@D _PL, /\)
M$@#_ QH _P F /T ,P#T $  [P!- .L 6 #H &$ Y0!J .( <@#@ 'H W@"
M -P AP#: (X V "5 -0 G #2 *, T "L ,X M@#, ,0 R@#9 ,@ [0#' /L
MQ0#_ ,0!_P## ?\ Q '_ ,0!_P#$ ?\ _Q@+ /\5!0#_$   _Q & /\/#0#_
M#!0 _ <? /$#*P#G #D X@!& -X!40#: EL U0)D -(#; #/ W0 S01[ ,L$
M@@#*!(D R 60 ,8%F #$!:  P@:I ,$&M "_!L$ O0C5 +L)[ "X"_T M@S_
M +4-_P"T#?\ M W_ +0-_P"T#?\ _QL% /\8  #_%P  _Q8  /L3!@#Z$ X
M[@P6 .,)(@#:"3  TPH^ ,X+2@#*#%4 QPU> ,4-9P#"#F\ P0YV +\.?@"]
M#X4 O ^- +H0E0"X$)T MQ"G +41L@"S$<  LA'5 *X3[@"K%/X J17_ *<5
M_P"G%?\ IA3_ :84_P&F%/\!_Q\  /\<  #Z'@  ZQX  .,<  #?%04 W@X-
M -,.& #+$2@ Q1,W , 41 "\%D\ N1=9 +<780"T&&D LQEQ +$9> "O&H
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M X,O_P.#+_\#^RD  .LQ  #9.   R3P  +\\  "V.0  L#(  *PM"P"G+Q<
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MF II1J8+9T:V"V9&S ME1NP+9$?_"61&_PAD1O\'9$;_!F1%_P9D1?\&Z#L
M -!&  "_30  LU$  *51  ":3@  DDL  (U'  "'2 L @TH6 ']+) !]3#$
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M#513Q0U34^8,4U/\"U-3_PE44O\(5%+_"%12_P=44O\'VD8  ,-0  "U6
MJ%L  )E:  "-6   A%<  'M4  !V5@$ <5</ &Y9&P!L6B@ :5HS &=;/0%E
M6T4!8UM- F%:50-?6EP$75ID!5M9; 98678(5EF""518CPM26)X,4%BN#4]8
MPPU.6.0,3EC["T]7_PE/5_\(3U;_"%!6_P=05O\'TTH  ,!4  "R7   HUX
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M1&'Y"D1@_PE$8/\(15__!T5?_P=%7_\'R%(  +A<  "K9   FV0  (QC  "
M8P  =F,  &IB  !C9   7V8& %MG$0!9:!T 5VDI %9J,P!4:CP 4FI% 5!J
M3 %.:E0"3&I< TIJ901(:6\%1FEZ!T1IB A":)@)0&BI"C]HO0H^:-X)/F?W
M"3YF_P@_9?\'/V7_!S]D_P<_9/\'PU<  +-A  "G:0  EF@  (=G  ![9P
M<6<  &5H  !<:@  6&P! %1N#@!2;Q@ 4&\D $YP+@!-<#@ 2W%! $IQ20%(
M<5$!1G%9 D1P8@-"<&P$0'!X!3YPA@8\;Y4'.F^F"#AONP@X;]L'.&[V!SAM
M_P<X;/\&.6O_!CEJ_P8Y:O\&O5P  *]F  "B;0  D6P  ()K  !W:P  ;&P
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M B&%_P(AA?\"JW(  *%\  "/>P  @'H  '-Z  !F?   6W\  %""  !&A@
M/(H  #2-   LD0  )I,, "24$P CE!P (I4F "&5+P @E3@ 'Y9" !Z63  =
MEE@ ')9D !J7=  9EX8 &)>9 !>7K@ 5E\D %I7N !:3_P$6DO\!%I'_ 1:0
M_P$6D/\!I7L  )F#  ")@0  >X   &R"  !?A   5(@  $F+   _D   -90
M "V7   EF@  '9X! !:@#  4H1( %*$; !.A)0 2H2X $:(X !&B0P 0HD\
M#Z)<  ZC:P -HWT #:.2  RCIP *HL  "Z+F  R@_@ -G_\ #9[_  V=_P -
MG?\ GH0  )*)  "#B   <X@  &6+  !8C@  3)(  $&7   WFP  +IX  "2B
M   <I0  %:@   ^K!  *K@P !ZT2  :M&P %K20 !*XN  *N.0 !KD4  *Y2
M  "N80  KG,  *Z'  "NG0  KK0  *[5  "M]   K?\  *S_  "K_P  J_\
MEHL  (R0  ![D   :Y(  %V6  !0F@  1)\  #FC   OIP  ):L  !RN   4
ML0  #K0   FW   !N D  +@.  "Y%   N1P  +HE  "Z+P  NSH  +Q'  "\
M5@  O&<  +Q[  "\D0  O*D  +S$  "\ZP  N_X  +O_  "[_P  N_\ D)(
M (.8  !SFP  8Y\  %6C  !'J   .ZT  #"Q   EM   &[<  !*Z   ,O0
M!;\   ##    Q (  ,4*  #%#@  QA0  ,<;  #()   RBX  ,PZ  #-20
MS5D  ,UL  #.@P  SIL  ,VU  #.V@  SO8  ,W_  #-_P  S?\ AID  '>@
M  !II@  6JP  $RR   ^M@  ,+D  "2\   9OP  $<(   K%   "R0   ,P
M  #0    T0   -(!  #3"   U0T  -<1  #:&   W"$  -\L  #A.@  XDH
M .-=  #D<@  Y(L  .6E  #EP   Y>8  .7X  #E_P  Y?\ >J$  &NI  !<
MKP  3;8  #^\   POP  (\,  !?'   /R@  !\X   #1    U@   -P   #?
M    X    .(   #D    Y@,  .@)  #I#@  [!4  .X>  #Q*P  ]#H  /5-
M  #V80  ]WD  /B3  #XK0  ^<8  /GD  #Y\P  ^?, ;:H  %ZR  !/N@
M0,$  #'%   BR0  %LX   W2   $V    -T   #A    Y    .@   #K
M[0   .\   #Q    \P   /8   #X P  ^@L  /T1  #_&P  _RD  /\[  #_
M3P  _V8  /]_  #_F0  _Z\  /_#  #_U@  _]8 _P0< /\ &0#_ !D _P <
M /\ (@#_ "L _P X /\ 1@#_ %, _P!> /\ :0#_ '( _P!Z /\ @@#_ (D
M_P"/ /\ E0#_ )L _P"A /\ J #_ *\ _P"Y /\ Q0#_ -D _@#L /T ^P#[
M /\ ^P#_ /L _P#Z /\ ] #_ /  _P#P /\ _P<8 /\!%0#_ !0 _P 6 /\
M&P#_ "8 _P T /\ 0@#_ $X _P!: /\ 9 #_ &T _P!U /\ ?0#_ (0 _P"*
M /T D #\ )8 ^@"= /D HP#X *L ]P"T /4 OP#T ,X \P#F /$ ]@#P /\
M[P#_ .\ _P#N /\ [@#_ .H _P#J /\ _PL4 /\&$0#_ !  _P 0 /\ %@#_
M "( _P N /\ / #_ $D _P!4 /X 7P#[ &@ ^0!P /< > #U '\ \P"% /(
MBP#P )( [P"8 .T GP#L *8 Z@"N .@ N0#G ,< Y0#> ., \ #B /X X #_
M .  _P#A /\ X0#_ .$ _P#A /\ _PT0 /\)#0#_ 0P _P , /\ $@#_ !P
M_P H /P -@#Y $, ]@!. /( 60#O &( [ !K .H <@#H 'D Y@"  .0 A@#B
M (P X0"3 -\ F@#= *$ VP"J -@ M #5 ,  T@#3 -  Z@#. /H S0#_ ,T
M_P#- /\ S #_ ,P _P#, /\ _Q , /\,!P#_ P( _P ( /\ #@#_ !8 ]@ B
M /  +P#L #P Z0!( .4 4P#A %P W@!E -L ; #7 ', U !Z -( @ #0 (<
MS@". ,P E0#* )T R "E ,8 KP#$ +L P@#+ ,  Y0"^ /4 O0#_ +P _P"\
M /\ O #_ +P _P"\ /\ _Q$% /\.  #_"@  _P@! /\$"@#X !  Z0 : .,
M* #> #4 V0!! -, 3 #/ %8 RP!? ,D 9@#& &X Q !T ,( >P#! (( OP")
M +T D "\ )@ N@"A +@ JP"V +< M #' +( X "Q ?( KP+_ *X#_P"M!/\
MK03_ *T$_P"M!/\ _Q0  /\0  #_#P  \@T  .H*  #I PD W0 2 -0 'P#-
M 2T R (Z ,0#10#  U  O019 +L%80"Y!6@ MP9O +4&=@"T!WT L@>$ +$(
MC "O")4 K0F> *L)J "J"K4 J K% *8+WP"D#?0 H@[_ * ._P"?#O\ GP[_
M )\._P"?#O\ _Q<  /\3  #O&   Y!D  -L6  #2$ ( SPD+ ,@(%@#!"B0
MO PR +<-/@"T#DD L0Y3 *\06P"M$&, JQ!J *D1<0"H$7@ IA&  *41B "C
M$I$ H1*; * 3I@">$[, G!/# )L4W@"7%O0 E1;_ )07_P"3%_\ DA?_ )(6
M_P"2%O\ _QH  /0=  #E(P  U24  ,HD  #"'0  OA8$ +L0$ "T$QT KQ4K
M *L6. "G&$, I1E- *(95@"@&ET GAME )T;; ";'', FAQ[ )@<@P"7'8T
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MF@)[+Z<">B^W G@OS )V,.H"=3#^ G,P_P)S,/\"<R__ G,O_P)S+_\"\"H
M -PU  #'.P  NC\  *P\  "B.   G#,  )@O  "5+A  D# < (PR*0"),S4
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M!F!!P@9>0>(&7D'Y!5U!_P1=0/\#74#_ UU _P-=0/\#WSD  ,A#  "Y2@
MJ4L  )M)  "01P  B$0  (-!  !^008 >D(1 '9#'@!T12H <44U &]&/P!M
M1D< :T9/ 6I&5@%H1ET"9D9E F1&;0-B1G8$8$:"!%Y&C@5<19P&6T6L!EE&
MOP=81M\&6$;W!5=%_P171?\$5T3_ UA$_P-81/\#VCT  ,1'  "U3@  I$X
M )9,  "+2P  @TD  'U%  !X1@( =$<0 '!(&P!N22< :THR &I+/ !H2T0
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M!DA2_P5(4?\$25'_!$E0_P-)4/\#RD@  +E2  "J5P  F%8  (I5  !_5
M=E,  &Q1  !G4P  8E0( %]6$@!=5QX 6U<I %E8,P!86#P 5EE$ %593 %3
M65,!45E; D]89 )-6&T#2UAX!$E8A@5'5Y4&15>E!D17N 9#6-(&0U?R!D-6
M_P5#5?\$1%7_!$14_P-$5/\#QDP  +56  "E6@  E%D  (98  ![6   <5<
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M S)D_P,R9/\#MUL  *ED  "69   AF,  'AC  !M8P  9&0  %EE  !0:
M26L  $-M! ! ;@X /F\8 #UO(@ \<"L .G T #EQ/0 X<44 -W%. #9Q5P T
M<6$!,G%M 3%Q>@$O<8H"+7&< BMQKP(J<<@"*G#K BIO_P(J;?\"*FS_ BML
M_P(K;/\"L6$  *1I  "0:   @&<  '1G  !I9P  7V@  %5K  !+;@  0W$
M #QT   W=@H -'<2 #-X'  R>"4 ,7DN #!Y-P O>3\ +GE( "QZ4@ K>EP
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M:@ 1CWL $(^/  ^/I  .C[L #8_@  Z-^@ /B_\ $(K_ !")_P 0B?\ H7H
M (YY  !^=P  <G<  &1X  !8>P  37X  $*"   YA@  +XH  ">.   @D0
M&)4  !*8!0 .F@X #9H4  R:'0 +FB8 "YHP  J:.P )FD8 ")I3  :;80 %
MFG( !)J&  *:FP  FK$  9G/  *9\  "F/\ !)?_  66_P %EO\ F8$  (=_
M  !Z?@  :WX  %V!  !0A0  18D  #N-   QD@  *)8  !^9   8G0  $:
M  RC @ &I0H  :40  "E%@  IA\  *8H  "F,@  IST  *=*  "G6   IV@
M *=\  "GD0  IJ@  *;#  "EZ0  I?P  *7_  "D_P  I/\ D8<  (*&  !R
MA@  8X@  %6,  !)D0  /98  #*:   HG@  'Z(  !>F   0J0  "ZP   2O
M    L08  +$,  "R$0  LA<  +,?  "S*   M#(  +4_  "U30  M5T  +5P
M  "UA@  M9T  +6V  "UW   M/<  +3_  "T_P  M/\ BX\  'J.  !JD0
M6Y4  $V:  ! GP  -:0  "JH   @K   %K    ^T   )MP   ;D   "]
MO@   +X&  "_#   P!   ,$6  #"'0  PR<  ,4R  #&0   QE$  ,=C  #'
M>   QY$  ,>I  #'QP  Q^P  ,?^  #'_P  Q_\ @Y<  '&:  !AG@  4J,
M $6I   XK@  ++,  ""W   6N@  #KT   ;     PP   ,<   #)    R@
M ,P   #- P  S@D  - .  #2$P  U!L  -@E  #;,@  W4(  -U4  #>:0
MWH$  -Z<  #?M0  W]D  -_S  #?_P  W_\ =Y\  &BF  !9K0  2K,  #NX
M   MNP  '[\  !3"   ,Q@   \D   #,    T    -4   #9    V@   -P
M  #>    X    .(%  #D"P  YQ   .H8  #M)   \#(  /%$  #R6   \V\
M /2*  #TI   ]+\  /3?  #T\P  ]/0 :J@  %NO  !,MP  /;T  "W!   ?
MQ@  $\H   O.    T@   -<   #<    X    .4   #G    Z0   .L   #M
M    [P   /$   #S    ]@<  /D.  #\%@  _R(  /\S  #_1P  _UT  /]V
M  #_D0  _ZD  /^^  #_V   _]L _P 8 /\ %@#_ !4 _P 8 /\ '@#_ "<
M_P V /\ 0P#_ $\ _P!: /\ 9 #_ &T _P!U /\ ?0#_ (0 _P"* /\ D #_
M )8 _P"< /\ HP#_ *L _P"T /X OP#] ,\ ^P#G /H ^ #Y /\ ^0#_ /D
M_P#U /\ [@#_ .D _P#G /\ _P 4 /\ $0#_ !$ _P 2 /\ %P#_ ", _P Q
M /\ /@#_ $H _P!6 /\ 8 #_ &@ _P!P /\ > #] 'X _ "% /H BP#Y )$
M^ "8 /< G@#U *8 ] "N /( N0#Q ,< [P#@ .X \@#L /\ [ #_ .P _P#K
M /\ Y0#_ .  _P#> /\ _P,0 /\ #@#_  T _P - /\ $P#_ !X _P K /\
M. #_ $4 _@!0 /L 6@#X &, ]0!K /, <@#Q 'D [P!_ .X A@#L (P Z@"2
M .D F0#G *  Y@"I .0 LP#A ,  X #3 -X ZP#< /L VP#_ -H _P#: /\
MV0#_ -0 _P#2 /\ _P<- /\ "0#_  8 _P ) /\ #P#_ !@ ^P E /@ ,@#U
M #\ \@!* .T 5 #J %T YP!E .0 ; #B ', X !Z -X @ #< (8 V@"- -<
ME #4 )L T@"D ,\ K0#- +D RP#) ,D Y #( /8 Q@#_ ,4 _P#& /\ QP#_
M ,< _P#' /\ _PH& /\!  #_    _P $ /\ "P#T !( [P ? .H + #E #@
MX@!# -T 3@#9 %< U !? -$ 9P#. &T S !T ,H >@#( (  Q@"' ,4 C@##
M )8 P0"> +\ J "] +, N@#" +D VP"W /  M0#_ +8 _P"U /\ M0#_ +4
M_P"U /\ _PP  /\$  #_    _@   /8  P#H  T X  7 -D ) #1 #$ S0 \
M ,H 1P#& %$ PP!9 ,  8 "^ &< O !N +H = "Y 'L MP"" +4 B0"S )$
ML@": +  I "N *\ K "] *H T "H .L IP#[ *8 _P"F /\ I0#_ *4 _P"E
M /\ _PT  /\'  #T"0  Z@D  .($  #:  < SP 1 ,@ ' #" "D O@ U +L
M0 "W $H M !3 +( 6P"P &( K@!H *P ;P"K '4 J0!] *@ A "F (T I "6
M *, H "A *L GP&Y )T#S "<!.@ F@;Y )D'_P"8"/\ EPC_ )<(_P"7"/\
M_Q   /<0  #H%   W!4  ,X1  #&#0  P@0+ +P % "W 2$ L@,N *X%.@"K
M!D0 J A- *8(50"D"5P H@IC * *:@"?"W$ G0MX )P+@ ":#(D F0R3 )<,
MG@"5#:H E VX )(-S "0#NH CA#\ (P0_P"+$/\ BQ#_ (L0_P"*$/\ ^Q,
M .T:  #=(   S"$  +\=  "W%P  LQ$  +(+#0"K#1D IPXF *,/,P"?$#X
MG1%' )H14 "8$E< EA)> )4390"3$VP DA-S ) 4? "/%(4 C16/ (L5F@"*
M%:< B!:U (86R0"$%^< @AC[ ( 9_P!_&?\ ?QG_ '\8_P!_&/\ ]1H  .0C
M  #/*0  P"H  +,F  "J(@  I1P  *05" "@%!, FQ8A )<8+0"4&3@ D1I"
M (\;2P"-'%( BQQ9 (D=8 "('6< AAYO (4>=P"#'X  @A^+ ( ?EP!^(*,
M?2"R 'L@Q0!Y(>0 =R+Y '8B_P!U(O\ ="'_ '0A_P!T(?\ [R$  -LK  #'
M,0  MC$  *DN  "@*@  FR8  )@A 0"5'A  D" ; (TA* ")(S, AR0] (4D
M1@"#)4X @295 '\F7 !^)F, ?"=K 'LG<P!Y)WP >"B' '8HDP!T** !<BBO
M 7$IP0%O*> !;2GW 6PI_P%K*?\!:RG_ 6LH_P%K*/\!Z"@  - R  # .
MKC<  *$U  "8,@  DBT  (XI  "+)PP AR@7 (,J(P" *R\ ?BPY 'PL0@!Z
M+4H >"Y1 '<N6 !U+F  <R]G '(O;P!P+WD!;R^# 6TOD %K+YT!:2^L 6@P
MO@%G,-L!93#U 60P_P%C,/\!8R__ 6,O_P%C+_\!XBX  ,HX  "Z/0  J#P
M )HZ  "1-P  BC,  (8P  "#+@D ?R\3 'LP'P!X,BL =C,U '0S/@!R-$8
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M0   ?CX  'D[  !T.@  <3H. &T\& !K/20 :3XO &<_. !E/T  9$!( &)
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M TA)LP-'2<H#1DGL T9(_P)&2/\"1T?_ D=&_P)'1O\"QD,  +9,  "B3
MD4P  (1+  !Y2@  <$D  &E&  !D1P  7TD& %Q*$ !:2QL 6$PE %9,+P!5
M33@ 4TU  %)-2 !13D\ 3TY7 $Y.7P%,3FD!2DYS DA-@ )&38\#14V? T--
ML0-"3<@#04WJ T%,_P)!3/\"0DO_ D)*_P)"2O\"PD<  +-/  ">3P  C4X
M (!.  !U30  ;$P  &-*  !>3   6DT" %9.#@!43Q@ 4E B %%1+ !/434
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M C%;_ (Q6O\",5G_ C)9_P$R6/\!ME0  *19  "06   @%@  '-7  !I5P
M8%@  %19  !.6P  2%T  $-?! ! 8 X /F$7 #UA(  [8BD .F(R #EB.@ X
M8T( -V-+ #9C5  T8UT ,V-H #%C=@$O8X4!+F.6 2QCJ0$K8[\!*F/C 2IB
M^P$J8/\!*U__ 2M?_P$K7O\!L5D  )Y<  "+7   >UL  &];  !E6P  7%P
M %%>  !)8   0V(  #QE   X9PH -6@2 #1H&P S:20 ,FDM #%I-0 O:CT
M+FI& "UJ3P L:ED *VME "EK<@ H:X( )FN3 "1KIP C:[T (FK@ "-I^0$C
M9_\!(V;_ 2-F_P$D9?\!K&   )A@  "%8   =E\  &I?  !A8   5V   $UC
M  !$9@  /6@  #9K   P;@0 +' . "IQ%0 I<1X *'$F "=R+P F<C< )7)
M "1R2@ B<E0 (7-@ "!S;0 ><WT '7.0 !MSHP :<[D &7/< !IQ]P :</\
M&V__ !MN_P$;;?\!IF8  )%E  !_9   <60  &9D  !=9   4F8  $AI   _
M;   -V\  #!S   I=@  (GD( !][$  >>Q< ''L? !M[*  :>S  &7PY !A\
M0P 7?$X %GQ: !5\9P 4?7@ $GV+ !%]GP 0?;4 #WW5 !![]0 1>?\ $7C_
M !)W_P 2=_\ GFL  (IJ  !Z:0  ;6D  &)I  !7:@  3&T  $-P   Y=
M,7@  "E[   B?P  &X(  !2%"0 1AA  $887 !"''P 0AR@ #H<Q  Z'.P -
MAT8 #(=3  N'80 *AW$ "8>$  >'F  &AJX !8;)  :%[  'A/\ "(/_  F"
M_P )@O\ E7$  (-O  !T;@  :6X  %QO  !0<@  1G4  #QY   R?0  *H$
M "*%   ;B0  %(P   ^/ P *D@L !I(1  22&  "DB   9(I  "2,P  DSX
M )-+  "360  DVD  )-[  "2D   DJ8  )&_  "1Y0  D/H  (__  "/_P
MC_\ C7<  'UU  !P=   8G4  %5X  !)?   /X   #2$   KB0  (HT  !J1
M   3E   #I<   F;   !G0@  )T.  "=$P  GAH  )XB  "?*P  GS4  *!"
M  "@4   H%\  *!Q  "@AP  GYT  )^U  ">V@  G?8  )W_  "<_P  G/\
MAGT  'A\  !I?   6W\  $Z#  !!B   -HP  "R1   CE@  &IH  !*>   -
MH0  !J0   "G    J0,  *D*  "J#@  JQ,  *P9  "M(@  KBL  *\W  "O
M10  KU0  *]F  "O>P  KI0  *ZK  "NR0  KN\  *W_  "M_P  K?\ @80
M '&$  !AAP  4XL  $:0   YE@  +IL  ".@   :I   $J@   RL   $KP
M +(   "V    MP   +<"  "X"   N0T  +H2  "[&   O2$  +XK  # .
MP$@  ,!:  #!;@  P88  ,&@  #!N@  P>,  ,#Y  # _P  P/\ >8T  &B0
M  !9E   2YH  #V@   QI0  ):L  !JO   1LP  "[@   *[    O@   ,$
M  #$    Q0   ,8   #'    R 4  ,H+  #,#P  SA4  - ?  #3*P  U3H
M -5,  #68   V'<  -B2  #8K   V<D  -GL  #9^P  V/\ <)D  &">  !1
MI   0ZH  #6P   HM@  '+H  !&^   )P0   ,4   #(    RP   ,\   #2
M    TP   -8   #8    VP   -T   #?!P  X@T  .43  #H'0  ["H  .T\
M  #M40  [F<  .^!  #OG   \+<  /#3  #P[   \/0 9Z8  %BM  !)M
M.KH  "J^   <P@  $,8   ?*    S@   -(   #6    W    .    #C
MY    .8   #H    ZP   .T   #O    \@(  /4*  #X$0  _!P  /\L  #_
M/P  _U4  /]N  #_B@  _Z0  /^Z  #_T0  _^$ _P 4 /\ $@#_ !( _P 4
M /\ &0#_ "4 _P R /\ /P#_ $L _P!6 /\ 8 #_ &@ _P!P /\ > #_ '\
M_P"% /\ BP#_ )$ _P"8 /\ G@#^ *8 _0"N /P N0#Z ,@ ^0#B /@ ] #W
M /\ ]@#_ /8 _P#O /\ YP#_ .( _P#> /\ _P 1 /\ #@#_  X _P / /\
M% #_ "  _P M /\ .@#_ $8 _P!1 /\ 6P#_ &, _@!K /P <P#Z 'D ^0"
M /< A@#V (P ]0"2 /, F0#R *  \ "I .X LP#M ,$ ZP#6 .H [@#I /X
MYP#_ .< _P#E /\ W0#_ -4 _P#1 /\ _P - /\ "@#_  @ _P ) /\ $ #_
M !L _P H /\ -0#_ $  ^@!+ /8 50#S %X \0!F .X ;0#L '0 ZP!Z .D
M@ #G (8 Y@"- .0 DP#B )L X "C -X K0#< +D V@#* -< Y@#4 /@ T@#_
M -( _P#2 /\ S@#_ ,D _P#& /\ _P ( /\  P#_    _P # /\ #0#\ !8
M]P B /, +@#O #H [ !% .@ 3P#D %@ X0!@ -X 9P#; &T V0!T -4 >@#3
M (  T0"' ,\ C@#- )4 RP"> ,D IP#' +, Q0#" ,, W #! /$ OP#_ +\
M_P"^ /\ O@#_ +T _P"[ /\ _P   /\   #_    _P   /8 " #N !$ YP ;
M .$ )P#= #, V0 ^ -, 20#/ %( RP!9 ,@ 80#& &< Q !M ,( <P#  'H
MOP"  +T B "[ )  N0"8 +@ H@"U *T LP"[ +$ S@"P .H KP#\ *T _P"M
M /\ K@#_ *X _P"N /\ _P(  /\   #]    \@   .@   #>  P TP 5 ,P
M(0#( "P Q  X ,$ 0@"] $L N@!3 +@ 6@"V &$ M !G +( ;0"P '0 KP!Z
M *T @@"L (H J@"3 *@ G0"F *@ I "U *( Q@"A ., GP#V )X _P"> /\
MG@#_ )X _P"> /\ _P8  /L   #N!0  X@0  -4   #+  8 PP / +T &0"X
M "4 M  Q +$ .P"N $4 K !- *D 50"G %L I0!B *0 : "B &X H0!U )\
M? "> (4 G ". )H F "8 *0 E@"P )4 P0"3 -P D@#R )$ _P"0 /\ D #_
M (\ _P"/ /\ _0H  / .  #A$0  SA   ,(-  "[!P  MP * +$ $@"L !X
MJ  I *4 - "B #X GP!' )T 3P"; %8 F0%< )<!8P"6 FD E )P ),#> "1
M X  D 2* (X$E0",!:$ B@6N (D&O@"'"-@ A@GP (0*_P"#"_\ @PO_ (,+
M_P"#"_\ ]A   .87  #2'   P!H  +,6  "L$@  J T  *8'#0"B!18 G0<B
M )D)+@"6"C@ E M! )(,2@"0#%$ C@U8 (P-7@"+#64 B0UL (@.= "&#GT
MA0Z' (,.DP"!#Y\ @!"M 'X0O@!]$-L >A'T '@2_P!W$O\ =Q+_ '<2_P!W
M$O\ [Q<  -LA  #&)   M",  *@@  "@'   FQ<  )D1! "8#A  DQ ; (\1
M)P",$C( B1,\ (<31 "%%$P @Q13 ($56@" %6  ?A9H 'T6;P![%G@ >1>#
M '@7CP!V&)P =!BJ ',9NP!R&=0 ;QKQ &X;_P!M&_\ ;1K_ &T:_P!M&O\
MYR   - I  "\*P  JRH  )XH  "6)   D"   (T<  ",%PP B!@6 (0:(@"!
M&RT ?APW 'P=0 !Z'4@ >1Y/ '<>50!V'UP =!]C ',?:P!Q('0 <"!_ &XA
MBP!L(9@ :R&G &DBN !H(L\ 9B+N &4C_P!D(_\ 9"+_ &0B_P!D(?\ X"8
M ,@O  "T,0  HS   )8N  "-*P  AR@  (0D  ""( @ ?B 2 'LB'@!X(RD
M=20S ',E/ !Q)4, <"9+ &XF4@!M)UD :R=@ &HG: !I*'$ 9RA[ &4HB !D
M*94 8BFD & IM0!?*<L 7BKL %PJ_P!<*?\ 7"G_ %PI_P!<*/\ V"P  ,,U
M  "M-0  G30  ) S  "&,0  @"T  'PK  !Y* , =B<0 '(I&@!P*B4 ;2LO
M &LL. !J+$  :"U' &<M3@!E+E4 9"Y= &,N90!A+VX 7R]X %XOA !<+Y(
M6B^A 5DOL@%8,,@!5C#I 54P_@%5+_\ 52__ %4N_P!5+O\ T#$  +TZ  "H
M.0  ES@  (HW  " -@  >C(  '4P  !R+@  ;BX- &LO%@!I,"$ 9C$K &0R
M- !C,CT 83-$ & S2P!?-%( 731: %PT8@!:-&L 635U %<U@@!5-9 !5#6?
M 5(UL %1-<8!4#7G 4\U_0%/-?\!3S3_ 4\T_P%/,_\!RS8  +@]  "C/
MDCP  (4[  ![.@  =#<  &\U  !L,P  :#0* &4U$P!B-AX 8#<H %XW,0!=
M.#H 6SA! %HY2 !9.5  5SE7 %8Z7P!4.F@ 4SIS %$Z?P%/.HT!3CJ= 4PZ
MK@%+.L,!2CKE 4DZ_ %).?\!23G_ 4DX_P%*./\!QSH  +-   ">/P  CC\
M ($^  !W/0  <#L  &HX  !F.   8CD' %\Z$0!<.QL 6CLE %D\+@!7/3<
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M 3I'^ $Z1O\!.D7_ 3M%_P$[1/\!NT4  *9(  "21P  @D<  '9'  !K1P
M8T8  %M#  !610  4D<  $Y("@!,21( 2DD< $A*)0!'2BX 1DLV $5+/@!#
M2T8 0DQ- $%,5@! 3%\ /DQJ #Q,=@ [3(4!.4R5 3=,IP$V3+P!-4S= 35+
M]P$U2_\!-4K_ 39)_P$V2?\!N$D  *)+  ".2@  ?DH  ')*  !H2@  7TD
M %5(  !02@  3$L  $E,!P!&31  1$X9 $)/(@!!3RL 0% S #]0.P ^4$,
M/%%* #M14P Z45P .%%G #=1<P U48( ,U&3 3)1I0$P4;H!+U': 2]0]@$O
M3_\!,$[_ 3!._P$P3?\!M$T  )U-  "*30  >DT  &Y-  !D30  6TT  %%-
M  !+3P  1E   $)2 P _4PT /505 #Q4'@ Z52< .54O #A5-P W5C\ -E9'
M #564  S5ED ,E=D #!7<0 O5X  +5>1 "M7HP J5[@ *5?6 "E6]0 I5?\
M*E3_ 2I3_P$J4O\!KU$  )A1  "%40  =E   &I0  !@4   6%$  $Y2  !'
M4P  054  #M8   X60H -5H1 #1:&@ S6R( ,ELK #%;,P O7#L +EQ# "U<
M3  L7%8 *UU@ "E=;0 H77P )EV. "1=H0 C7;4 (EW2 ")<\P B6_\ (UK_
M "-9_P D6/\ J%4  ))4  " 5   <50  &94  !<5   5%4  $I6  !#6
M/%L  #9=   P8 4 +6$. "MA%0 J8AT *6(E "AB+@ G8S8 )F,^ "5C1P C
M8U$ (F1< "%D:0 ?9'D 'F2* !QDG@ ;9+, &63. !IC\0 ;8?\ &V#_ !Q@
M_P <7_\ H5D  (Q8  ![6   ;5@  &)8  !96   4%D  $=;   ^7@  -V
M #%C   J9@  )&D) "%J$  @:A< 'VH@ !YK*  =:S  '&LY !MK0@ :;$P
M&6Q8 !=L90 6;'0 %&R& !-LF@ 2;*\ $6S* !%K[P 2:?\ $VC_ !-H_P 3
M9_\ F5T  (5=  !U7   :%P  %Y<  !57   2UX  $)A   Y9   ,F<  "MJ
M   D;0  'G ! !=S"P 5=!$ %'08 !-T(0 2=2D $74R !%U.P 0=48 #W52
M  YU7P -=6X #'6!  MUE0 *=:H "'3#  ETYP *<_T "W'_  QQ_P ,</\
MD6(  ']A  !P80  9&$  %IA  !/8@  164  #QH   S;   *V\  "1R   =
M=@  %WD  !%\!  -?PP "W\2  I_&0 )?R( "'\J  9_-  %?S\ !']+  )_
M6  !?V<  ']Y  !_C@  ?Z,  'Z[  !]X   ??<  'S_  ![_P  >_\ B6<
M 'AG  !K9@  868  %1G  !):0  /VT  #5Q   L=0  )'D  !U\   6@
M$(,   R& @ &B0H  8D/  ")%   BAL  (HC  "++   BS<  (M#  "+4
MBU\  (MQ  "+A@  BYP  (JS  ")TP  B/,  (C_  "'_P  A_\ @FT  '-L
M  !H;   6FT  $YO  !"<P  .'<  "Y[   E@   '80  !6(   0C   "X\
M  22    E 8  )4,  "5$   EA4  )<<  "8)   F"X  )DY  "91P  F58
M )EH  "9?0  F90  )BK  "7R   ENX  );_  "5_P  E?\ >W0  &]S  !A
M<P  4W8  $9Z   [?P  ,(0  ":(   =C0  %)(   Z6   )F0   9P   "@
M    H0   *(&  "B#   I!   *44  "E'   IR0  *@O  "H/0  J4P  *E>
M  "I<@  J(D  *BB  "HO   I^4  *;[  "F_P  I?\ =WL  &A[  !9?@
M2X(  #Z'   RC0  )Y(  !V7   4G   #J    >D    J    *L   "N
MKP   +    "Q!   LPH  +0.  "U$P  MAL  +@D  "Z,0  ND   +I2  "[
M90  NWT  +J7  "ZL0  NM(  +KS  "Y_P  N?\ ;X,  %^&  !1BP  0Y
M #:7   JG0  'Z(  !6G   -K   !;    "T    MP   +L   "^    OP
M ,    #!    PP$  ,0'  #%#0  QQ$  ,H9  #-)   SC,  ,]$  #06
MT&X  -&(  #0I   T,$  -'F  #1^   T?\ 9X\  %>4  !)F@  .Z$  "ZG
M   AK0  %K,   ZX   &O    ,    ##    Q@   ,L   #-    S@   -
M  #1    U    -8   #: @  W D  -\/  #C%P  YB0  .<V  #H20  Z5\
M .IX  #KE   ZZ\  .O,  #LZ   [/8 7YX  %"D  !"JP  -+(  ":Y   9
MO@  #L(   3%    R@   ,T   #1    V    -L   #?    X    .(   #D
M    Y@   .D   #K    [@   /$%  #U#0  ^18  /PE  #].0  _D\  /]G
M  #_@@  _YT  /^U  #_RP  _^0 _P 1 /\ #P#_  \ _P 1 /\ %@#_ "(
M_P O /\ .P#_ $< _P!2 /\ 6P#_ &0 _P!L /\ <P#_ 'H _P"  /\ A@#_
M (P _@"3 /T F0#[ *$ ^@"I /@ M #W ,( ]@#: /4 \0#T /\ \P#_ /,
M_P#I /\ X #_ -@ _P#3 /\ _P . /\ "P#_  H _P + /\ $0#_ !T _P J
M /\ -@#_ $$ _P!, /\ 5@#^ %\ ^P!F /D ;0#W '0 ]0!Z /0 @ #R (8
M\ "- .\ E #M )L [ "D .H K@#I +H YP#- .4 Z0#D /L XP#_ .( _P#>
M /\ T0#_ ,P _P#( /\ _P ) /\ ! #_  $ _P $ /\ #@#_ !@ _P D /T
M, #[ #L ]P!& /, 4 #O %D [ !@ .H 9P#G &X Y@!T .0 >@#B (  X "'
M -X C@#< )4 V@"> -8 J #4 +, T0## ,\ WP#. /0 S #_ ,L _P#+ /\
MQ0#_ +\ _P"\ /\ _P " /\   #_    _P   /T "P#W !, \0 > .T *@#J
M #4 YP!  .( 2@#= %( V0!: -4 80#2 &< T !M ,X <P#, 'H R@"  ,@
MAP#& (\ Q "8 ,( H0#  *T O@"[ +P T "Z .T N0#^ +@ _P"X /\ MP#_
M +, _P"P /\ _P   /\   #_    ^0   .X !0#E  X W@ 8 -@ (P#2 "X
MSP Y ,L 0P#' $P Q !4 ,$ 6P"_ &$ O !G +L ;0"Y ', MP!Z +4 @0"T
M (D L@"2 +  FP"O *< K "T *L Q@"I .0 IP#X *8 _P"F /\ I0#_ *4
M_P"D /\ _P   /\   #U    Z@   -X   #0  H R  2 ,( '0"^ "@ NP S
M +D /0"U $8 L@!- +  50"M %L K !A *H 9P"H &T IP!S *4 >@"D ((
MH@", *  E@"? *$ G0"N )L O@"9 -@ EP#Q )8 _P"6 /\ EP#_ )< _P"7
M /\ _P   /4   #G 0  U    ,D   #   0 N  . +, %@"O "$ JP L *@
M-@"F #\ HP!' *$ 3P"? %4 G0!; )L 80": &< F !N )< =0"5 'T E "&
M )( D0"0 )P C@"I (P N "+ ,T B0#K (@ _0"( /\ B #_ (@ _P"( /\
M^08  .D,  #4#@  PPP  +<)  "P @  JP ) *8 $ "B !H G@ E )L , "8
M #D E@!! )0 20"2 %  D !6 (X 7 "- &( BP!I (H < "( '@ AP"! (4
MC "$ )@ @@"E (  M !^ ,@ ?0'G 'P"^0![ _\ >P3_ 'L$_P![!/\ \0X
M -X5  #%%0  M!0  *D1  "A#@  G@H  )L## "7 !, DP > ) !*0"- C,
MB@,\ (@$0P"&!4L A091 (,&5P""!UX @ =D '\(; !]"'0 ? A^ 'H)B0!X
M"98 =PJC '4*LP!S"\< <@SF ' -^P!P#?\ ;PW_ &\-_P!O#?\ Z!8  - >
M  "Y'0  J1P  )T:  "5%@  D!,  (\. P"."@X B0L7 (8,(P"##2T @ TV
M 'X./@!\#D8 >PY- 'D/4P!X$%H =A!A '40: !S$'$ <1%[ ' 1AP!N$90
M;!&B &L2L@!I$L< :!/G &83_0!E%/\ 913_ &43_P!E$_\ WQX  ,8D  "P
M)   H",  )0A  "+'P  AAL  (,7  ""$@@ ?Q$2 'P2'0!Y%"@ =A0Q '05
M.@!R%D$ <19( &\73P!N%U8 ;!== &L89 !I&&T :!EW &89@P!D&9  8QJ?
M &$:KP!@&L0 7AOD %T<^P!<'/\ 7!O_ %P;_P!<&_\ U24  +TJ  "H*0
MF"D  (PH  "#)0  ?2(  'D?  !X&P, =AD/ '(:& !O'", ;1TM &L=-0!I
M'CT :!Y$ &8?2P!E'U( 8R!9 &(@80!A(&D 7R%S %TA?P!<(8T 6B*< %DB
MK !7(L  5B/A %4C^0!4(_\ 5"+_ %0B_P!4(O\ S2L  +8N  "B+@  DBX
M (4M  !\*P  =B@  '(F  !O(P  ;2$, &HB%0!G(Q\ 920I &,D,0!B)3D
M8"9! %\F2 !=)D\ 7"=6 %LG70!9)V8 6"AP %8H? !4*(H 4RF9 %$IJ@!0
M*;X 3RG> $XI]P!-*?\ 32G_ $TH_P!.*/\ R#   + R  "<,@  C#(  ( Q
M  !V,   <"T  &LK  !H*0  9B@) &,H$0!@*1P 7BHE %PK+@!;*S8 62P]
M %@L1 !7+4P 52U3 %0M6P!3+6, 42YN % N>@!.+H@ 3"^7 $LOJ !)+[L
M2"_; $@O]@!'+_\ 1R[_ $<M_P!(+?\ Q#0  *LU  "7-0  AS4  'LU  !R
M-   :S(  &8O  !B+@  7RT% %PN$ !:+Q@ 6# B %8P*P!5,3, 4S$Z %(R
M0@!1,DD 4#)0 $XS6 !-,V$ 2S-K $HS=P!(-(4 1S25 $4TI@!#-+D 0C36
M $(T] !"-/\ 0C/_ $(R_P!",O\ P#@  *<X  "3.   @S@  '<X  !M-P
M9C8  &$S  !=,@  63(" %<S#0!4-!4 4C4? %$U* !/-C  3C8X $PW/P!+
M-T8 2C=. $DX5@!'.%\ 1CAI $0X=0!#.(, 03F3 $ YI  ^.;@ /3G3 #PY
M\P \./\ /3?_ #TW_P ]-O\ NSL  *([  "/.P  ?SL  ',[  !J.@  8CD
M %TW  !8-@  5#<  %$X"P!/.1, 33D< $LZ)0!*.BT 2#LU $<[/ !&/$0
M13Q+ $0\4P!"/%P 03UG #\]<P ^/8$ /#V1 #H]HP Y/;8 .#W1 #<]\@ W
M//\ .#O_ #@[_P X.O\ MCT  )X^  "+/@  ?#X  &\^  !F/0  7CT  %@[
M  !3.@  3SL  $P\" !)/1$ 1SX9 $8_(@!$/RH 0S\R $) .@!!0$$ 0$!)
M #Y!40 ]05H /$%D #I!<  X07\ -T&/ #5"H0 T0K0 ,D+. #)!\  R0/\
M,T#_ #,__P T/O\ L4   )I   "'0   >$$  &Q!  !B0   6T   %0_  !.
M/P  2D   $9!!0!$0@X 0D,6 $!#'P _1"< /D0O #Q$-P [13X .D5& #E%
M3@ X1E@ -D9B #5&;@ S1GP ,4:- #!&GP N1K, +4;, "U&[P M1?\ +D3_
M "Y#_P N0_\ K$,  )9#  "#0P  =$,  &A#  !?0P  5T,  %!#  !(0P
M1$4  $%& 0 ^1PP /$@3 #I('  Y220 .$DL #9)-  U2CL -$I# #-*3  R
M2E4 ,$M? "]+:P M2WH +$N+ "I+G0 H2[$ )TO* "=+[0 G2O\ *$G_ "A(
M_P I1_\ IT8  )%&  !_1@  <$8  &5&  !;1@  5$8  $Q'  !$2   /TH
M #M+   W3 D -4T0 #-.&  R3B  ,4\H #!/,  O3S@ +D]  "Q02  K4%(
M*E!< "A0:  G4'< )5"( "10FP B4*\ (5#( "!0ZP A3_\ (D[_ ")-_P C
M3?\ H4D  (Q)  !Z20  ;$H  &%*  !82@  4$H  $E+  ! 3   .TX  #50
M   Q4@0 +5,- "Q4%  J5!P *54D "A5+  G53, )E4\ "5610 D5DX (E99
M "%690 ?5G0 'E:% !Q6F  ;5JP &5;% !E6Z0 :5?\ &U3_ !M3_P <4O\
MFTT  (9-  !U30  :$T  %U-  !430  34X  $5/   \40  -E,  #%5   K
M6   )EH) "-;$  B6Q< (5P? "!<)P ?7"X '5PW !Q=0  ;74H &EU5 !A=
M80 777  %5V! !1=E0 37:H $5W" !%=YP 26_X $UK_ !-:_P 46?\ E%$
M (!1  !P40  9%$  %E1  !140  25(  $%3   X5@  ,ED  "M;   E7@
M'V$# !IC#  89!$ %V09 !9D(0 59"D %&4Q !-E.@ 2940 $650 !!E70 /
M96L #F5]  UED0 ,9:4 "F2\  IDX  +8_D #&+_  UA_P -8?\ C54  'I5
M  !K50  7U4  %95  !.50  1%<  #Q9   T7   +%\  "9B   ?90  &6@
M !-K!0 0;0T #FX2  UN&@ ,;B( #&XK  MN-  *;CX "&Y*  =N5P &;F4
M!&YV  )NB@  ;9\  &VV  !LU@  ;/,  6O_  )J_P #:O\ A5H  '1:  !F
M6@  7%D  %-9  !(6@  /UT  #9@   N8P  )F<  !]J   9;0  $W$   YT
M P *=PH !7<0  %W%0  =QP  '<D  !X+0  >#<  'A#  !X4   >%X  'AO
M  !XA   >)D  '>P  !VS0  =?   '7_  !T_P  =/\ ?E\  &Y?  !B7@
M65X  $U?  !"8@  .64  #!H   G;   'W   !AT   2=P  #7L   A^   "
M@ @  ($-  "!$0  @A<  (,>  "#)@  A#   (0[  "$2   A%<  (1H  "$
M?   A),  (.J  ""Q0  @>L  ('^  " _P  @/\ =V4  &ED  !?8P  4F0
M $=G   \:P  ,6\  "AS   @=P  &'P  !%_   ,@P  !H<   "*    C ,
M (P)  "-#@  CA$  (\7  "0'@  D2<  )(R  "2/P  DDX  ))?  "2<P
MDHL  )&B  "1O   D.4  (_\  "._P  CO\ <6L  &9J  !8:P  2VT  #]Q
M   T=@  *GL  ""    7A0  $(D   N-   $D0   )4   "8    F0   )H#
M  ";"   G T  )X1  "?%@  H!X  *(H  "B-0  HT0  *-5  "C:0  HH
M **:  "ALP  H-@  *#V  "?_P  G_\ ;G$  %]R  !1=0  1'D  #=^   L
MA   (8H  !>/   0E   "ID   &=    H    *0   "G    J    *D   "J
M    K 8  *T+  "O$   L!4  +(>  "T*0  M#D  +1*  "U70  M7,  +6.
M  "UJ   M,8  +/M  "R_P  LO\ 9GH  %=]  !)@@  /(<  "^.   CE
M&)H  !"?   )I    *D   "M    L    +0   "W    N    +D   "[
MO    +X"  # "   P@X  ,04  #''@  R"P  ,D]  #*4   RF8  ,I_  #*
MFP  RK@  ,K=  #*]0  RO\ 7H8  $^+  !!D0  ,Y@  ">?   ;I0  $:L
M  FP    M0   +D   "]    P0   ,8   #(    R0   ,L   #,    S@
M -    #2    U 4  -D,  #=$@  X1X  .(N  #C0@  Y%<  .5O  #FC
MYJ@  .7%  #EYP  YO8 5I0  $B;   ZH@  +*D  !^P   3M@  "[P   #!
M    Q0   ,D   #-    T@   -8   #:    VP   -X   #@    X@   .0
M  #G    Z0   .T   #P"@  ]!$  /@?  #Y,@  ^D@  /M?  #\>@  _9<
M /VO  #]QP  _>0 _P . /\ #0#_  P _P . /\ $P#_ !X _P J /\ -@#_
M $( _P!- /\ 5P#_ %\ _P!G /\ ;@#_ '0 _P!Z /\ @0#] (< _ "- /H
ME #Y )P ]P"E /4 KP#T +P \P#/ /$ [ #P /X [P#_ .\ _P#C /\ UP#_
M ,X _P#* /\ _P * /\ !@#_  0 _P ( /\ $ #_ !D _P E /\ ,0#_ #T
M_P!' /X 40#[ %D ^0!A /8 : #T &X \P!T /$ >@#O ($ [@"' .P C@#J
M )8 Z "? .8 J0#C +4 X@#& .  XP#? /@ W0#_ -T _P#4 /\ R0#_ ,(
M_P"^ /\ _P # /\   #_    _P ! /\ #0#_ !0 _0 @ /H *P#W #8 \P!!
M .\ 2P#L %0 Z !; .8 8@#C &@ X0!N -\ = #< 'H V@"! -@ B #4 )
MT@"8 ,\ H@#- *X RP"\ ,D TP#' /  Q@#_ ,0 _P#$ /\ NP#_ +8 _P"S
M /\ _P   /\   #_    _P   /< " #P !  ZP : .< )0#D #  X0 [ -P
M10#5 $T T0!5 ,X 6P#+ &( R0!G ,< ;0#% ', PP!Z ,$ @0"_ (D O0"2
M +L G "Y *< MP"U +4 R "S .8 L@#[ +$ _P"P /\ K@#_ *H _P"G /\
M_P   /\   #^    \0   .4  @#<  T TP 4 ,T 'P#* "H QP T ,0 /@#
M $< O !. +H 50"W %L M0!A +, 9P"R &T L !S *X >@"L (( J@"+ *@
ME0"G *  I0"M *, O@"A -L H #T )\ _P"> /\ GP#_ )T _P"; /\ _P
M /P   #N    X    -    #%  @ O@ 0 +D &0"U ", LP N +  -P"M $
MJ@!( *@ 3P"E %4 HP!; *( 8 "@ &8 GP!L )T <P"; 'L F@"$ )@ C@"6
M )H E0"G ), MP"1 ,P D #L (\ _P". /\ C@#_ (X _P"/ /\ _    .\
M  #;    R0   +T   "U  ( K@ , *D $P"E !T H@ G *  ,0"= #H F@!"
M )@ 20"6 $\ E !5 ), 6P"1 &  D !G (X ;0"- '4 BP!^ (D B0"( )4
MA@"B (4 L0"# ,0 @0#D (  ^0!_ /\ @ #_ (  _P"  /\ ] (  . )  #'
M"   MP<  *P#  "F    H  ' )L #P"8 !< E0 A )( *@"/ #, C0 \ (L
M0P") $D AP!0 (8 50"$ %L @P!A ($ : "  '  ?@!Y 'P A ![ )  >0"=
M '@ K !V +X =0#= ', ] !S /\ <P#_ ', _P!S /\ Z0T  ,\0  "Y$
MJ1   )X.  "7"P  DP8  )  "P", !$ B0 : (8 ) "# "X @0 V '\ /@!]
M $0 ? !+ 'H 40!Y %< =P!= '8 9 !T &P <P%U '$!@ !O HT ;@*: &P#
MJ@!K [L :036 &@&\0!H!_\ 9P?_ &<'_P!G!_\ WQ0  ,,7  "N%P  GA8
M ),5  "+$@  AA   (0, @"#!@T @ ,4 'P%'@!Y!R@ =P@P '4(. !S"4
M<@E& ' *3 !O"E, ;0M9 &P+80!J"VD :0QR &<,?@!F#(L 9 V9 &(-J0!A
M#;L 8 W8 %X.\P!=#O\ 70[_ %T._P!=#O\ U!P  +D=  "D'@  E1T  (D<
M  "!&@  >Q<  '@3  !X$ 8 =PT/ ',.& !P#B( ;@\K &P0,P!J$#L :1!"
M &<120!F$4\ 9!%6 &,270!A$F8 8!)O %X2>P!<$X@ 6Q.7 %D3IP!7%+H
M5A35 %45\P!4%?\ 5!7_ %05_P!4%/\ RB(  + B  "=(P  C2,  ($B  !Y
M(0  <QX  &\;  !N%P  ;1,, &H4% !G%1X 918G &,6+P!A%S< 8!<^ %X8
M10!=&$L 7!E2 %H96@!9&6( 5QIL %8:=P!4&H4 4AN4 %$;I !/&[< 3AO0
M $T<\0!,'/\ 3!S_ $T<_P!-&_\ PR8  *HG  "6)P  AR@  'LG  !R)@
M;"0  &@A  !F'@  9!L( &(;$0!?'!H 71TC %L>*P!:'C, 6!\Z %<?00!6
M($@ 5"!/ %,@5P!1(5\ 4"%I $XA= !-(8( 2R*1 $DBH@!((K0 1R+- $8C
M[P!%(_\ 12+_ $8B_P!&(?\ O"H  *0K  "1*P  @BP  '8K  !M*@  9BD
M &(F  !?)   72($ %LA#@!8(A8 5B,? %0D* !3)#  4B4W % E/@!/)D4
M3B9, $PF5 !+)UP 22=F $@G<0!&)W\ 12B/ $,HH !!*+( 0"C+ #\H[0 _
M*/\ /RC_ $ G_P! )_\ MRT  )\N  ",+P  ?2\  '$O  !H+@  82T  %TK
M  !:*   5R<  %0G# !2*!, 4"D< $XI)0!-*BP 2RHT $HK.P!)*T( 2"Q)
M $8L40!%+%H 1"QD $(M;P! +7T /RV- #TMG@ \+;  .BW( #HMZP Z+?\
M.BW_ #HL_P Z+/\ LC   )LQ  "(,@  >3(  &TR  !D,@  73$  %@O  !5
M+   42P  $\M"0!,+1$ 2BX9 $DO(@!'+RH 1C Q $4P. !#,#\ 0C%' $$Q
M3P! ,5< /C%A #TR;0 [,GL .3*+ #@RG  V,J\ -3+' #0RZ0 T,O\ -3'_
M #4Q_P U,/\ K3,  )8T  "$-0  =34  &DU  !@-0  630  %0S  !0,
M3#$  $DQ!@!',@\ 13,6 $,S'P!"-"< 0#0N #\U-@ ^-3T /35$ #PV3  Z
M-E4 .39? #<V:P V-G@ -#>) #(WF@ Q-ZT +S?% "\WZ  O-OX ,#7_ # U
M_P P-/\ J38  )(V  " -P  <C@  &8X  !=-P  5C<  % V  !+-   1S4
M $0V P!!-PT /S@4 #XX'  \.20 .SDL #HY,P Y.CH .#I" #8Z2@ U.E,
M-#M= #([:  P.W8 +SN' "T[F0 L.ZP *CO# "D[Y@ J.OT *CK_ "LY_P L
M./\ I#@  (XY  !\.@  ;CH  &,Z  !:.@  4SH  $TZ  !&.   0CH  #\[
M   \/ L .CP1 #@]&0 W/2$ -CXI #0^,  S/C< ,C\_ #$_1P P/U  +C]:
M "U 9@ K0'0 *4"$ "A EP F0*H )4#! "1 Y0 D/_P )3[_ "8]_P F/?\
MGSL  (H\  !X/0  :CT  %\]  !6/0  3ST  $D]  !"/0  /#X  #D_   V
M00@ -$$/ #)"%@ Q0AX +T,E "Y#+0 M0S0 +$0\ "M$1  J1$T *$18 "=%
M8P E17$ (T6" ")%E0 @1:@ 'T6_ !Y$XP ?1/L 'T/_ "!"_P A0?\ FCX
M (4_  !T0   9T   %Q   !30   3$   $9    ^00  .$,  #1%   P1@,
M+4<- "M($@ J2!H *4@B "A)*0 G23$ )4DY "1)00 C2DH (DI5 "!*80 ?
M2F\ '4I_ !M*D@ :2J8 &$J] !=*X  82?H &4C_ !I'_P :1_\ E4(  (!"
M  !P0P  8T,  %A#  !00P  24,  $)$   [10  -4<  #!)   K2P  )DT)
M "1.$  B3A8 (4\= "!/)0 ?3RP 'D\U !U//0 <4$< &E!1 !E070 74&L
M%E!\ !10CP 34*0 $5"Z !%0W@ 13_@ $D[_ !--_P 43?\ CT4  'M&  !K
M1@  7T<  %5'  !-1P  1D<  #]'   W2@  ,4P  "M.   F4   (%,# !Q5
M#  :5A$ &588 !=6(  65B< %58P !16.0 35T( $E=- !%760 05V@ #U=Y
M  Y7C  -5Z  "U>V  M6U  +5O0 #%7_  U4_P .4_\ B$D  '9*  !G2@
M6TH  %%*  !*2@  0TH  #M,   S3@  +%$  "94   A5@  &UD  !5<!P 1
M7@T $%X3 !!>&@ .7B( #EXJ  U>,P ,7CT "UY(  I>5  (7F( !UYS  5>
MA@ #7IL  EZQ  )=S  "7>X  US_  1;_P %6_\ @4X  '!.  !B3@  5TX
M $Y.  !'3@  /D\  #91   N5   )U<  "%:   ;70  %6   !!C P ,9@L
M"&<0  9G%0 %9QP !&<D  )G+0 !9S<  &="  !G3@  9UP  &=M  !G@
M9I4  &:L  !EQP  9>L  &3\  !D_P  8_\ >E(  &I3  !=4@  5%(  $M2
M  !"4P  .54  #!8   H6P  (5\  !IB   490  $&@   QK 0 &;@D  &\.
M  !O$@  ;Q@  ' ?  !P)P  <3   '$[  !Q2   <58  '%F  !Q>0  <8\
M '"G  !OP0  ;^<  &[\  !M_P  ;?\ <U@  &57  !:5P  458  $97   \
M6@  ,ET  "IA   B9   &F@  !1L   .;P  "G(   1V    > 4  '@+  !Y
M#@  >A,  'L9  !\(   ?2D  'TS  !]0   ?4X  'U>  !]<@  ?8@  'RA
M  !\N@  >^(  'KZ  !Y_P  >/\ ;5T  &!<  !77   2UT  $!?   U8P
M*V<  "-K   :;P  $W,   YW   (>P   GX   ""    @P$  (0&  "%"P
MA@\  (@3  ")&0  BB$  (LK  "+-P  C$8  (M6  "+:0  BX   (N9  "*
MLP  B=@  (CW  "(_P  A_\ :&,  %YB  !18@  1&4  #AI   N;@  )',
M !IX   3?0  #8$   :%    B0   (T   "0    D@   )(   "4!0  E0H
M )<.  "8$@  FA@  )LA  "<+0  G3P  )U,  "<7P  G'8  )N1  ";JP
MFLD  )KP  "9_P  F/\ 96D  %=I  !);   /7$  #!V   E?   &X$  !*'
M   ,C   !)$   "5    F0   )T   "@    H0   *(   "D    I0$  *<'
M  "I#   JA$  *T8  "O(@  KS   *]!  "O5   KVL  *Z%  "NH0  KKX
M *WF  "L_   K/\ 7G$  $]T  !">0  -7\  "B%   =C   $Y(   R8   #
MG0   *(   "F    J@   *X   "P    L0   +,   "T    M@   +@   "Z
M!   O H  +X0  #!%P  PR0  ,,U  #$20  Q%X  ,5W  #%DP  Q:\  ,71
M  ##\@  P_\ 5GP  $>"   ZB   +(\  ""6   4G0  #:,   .I    K@
M +(   "W    NP   +\   #"    P@   ,4   #&    R    ,H   #-
MSP   -((  #5#@  VQ@  -TG  #>.@  WU   .!H  #@A   X:$  .&]  #A
MX@  X/0 3HL  $"2   RF0  ):$  !BH   .KP  !;4   "Z    OP   ,0
M  #(    S@   -$   #4    U0   -@   #:    W0   -\   #B    Y
M .<   #K!0  [PX  /09  #U*P  ]D$  /=8  #X<@  ^9   /FK  #XQ
M^.$ _P + /\ " #_  D _P , /\ $@#_ !H _P F /\ ,@#_ #X _P!( /\
M4@#_ %H _P!B /\ :0#_ &\ _P!U /X >P#\ ($ ^P"( /D CP#W )< ]0"@
M /, J@#R +< [P#) .T Y@#L /L ZP#_ .L _P#= /\ S@#_ ,8 _P#" /\
M_P $ /\   #_    _P % /\ #0#_ !4 _P A /\ + #_ #@ _P!# /T 3 #Y
M %0 ]P!< /0 8P#R &D \ !O .X =0#L 'L Z@"" .@ B0#G )$ Y ": .(
MI #@ +  W0#  -H W #8 /0 U0#_ -, _P#+ /\ P0#_ +L _P"W /\ _P
M /\   #_    _P   /\ "@#] !$ ^0 ; /8 )P#T #( \  \ .P 1@#H $X
MY !6 .$ 7 #> &, W !H -D ;@#5 '0 T@![ -  @@#- (H RP"3 ,@ G0#&
M *@ Q "W ,$ S #  .L O@#_ +T _P"] /\ M #_ *X _P"K /\ _P   /\
M  #_    ^@   /( !0#J  X Y0 6 .  (0#= "L VP V -, /P#. $@ R@!/
M ,< 5@#$ %P P@!A ,  9P"^ &T O !S +H >@"X (( M@"+ +0 E@"R *$
ML "O *X P0"M .  JP#W *H _P"I /\ I@#_ *$ _P"? /\ _P   /\   #W
M    Z    -P   #0  H R@ 1 ,4 &P#" "4 OP O +P . "X $$ M0!( +(
M3P"P %4 K@!; *P 80"J &8 J !L *< <P"E 'L HP"$ *$ C@"? )H G0"G
M )L N ": -  F0#O )@ _P"7 /\ E@#_ )0 _P"2 /\ _P   /8   #D
MT@   ,4   "[  4 M0 . +  %0"L !\ J@ I *@ ,@"E #H H@!" *  20">
M $\ G !5 )H 6@"8 &  E@!F )4 ; "3 '0 D@!] )  AP". ), C "A (L
ML "* ,4 B #F (< ^P"& /\ AP#_ (< _P"& /\ ^    .4   #-    O0
M +,   "J    HP * )\ $0"; !D F0 C )< + "5 #0 D@ \ )  0P". $D
MC !/ (H 5 ") %H AP!@ (8 9@"$ &X @P!W ($ @0!_ (T ?@"; 'P J@![
M +P >@#; '@ ]0!X /\ > #_ '@ _P!X /\ [0   -$"  "[ @  K $  *(
M  ";    E@ % )$ #0"- !0 BP = (@ )@"& "X A  V (( /0"  $, ?@!)
M 'T 3P!\ %4 >@!; 'D 80!W &D =0!Q '0 ? !R (@ <0"6 &\ I0!N +8
M;0#. &P [@!K /\ :P#_ &L _P!K /\ WPL  ,(,  "N#   G@P  ),+  ",
M!P  B (  (4 "0"! !  ?P 7 'P ( !Z "@ >  P '8 . !T #X <P!$ '$
M2@!P %  ;@!6 &T 70!L &0 :@!M &@ =P!G (0 90"2 &0 H0!C +( 80#)
M &  Z0!@ /P 8 #_ &  _P!@ /\ T!   +81  "B$@  DQ(  (@1  " #P
M? T  'D) 0!X PL =0 1 ', &@!P ", ;@$K &P!,P!J CD :0-  &<#1@!F
M!$P 9012 &,%60!B!6$ 8 5J %\&= !=!H$ 7 >/ %H'GP!9![  5P?& %8)
MYP!6"OL 50K_ %4*_P!6"O\ QA4  *T7  "9&   BA@  '\7  !V%@  <1,
M &X0  !M#04 ;0D- &H)% !G"AT 90HF &,++@!B##4 8 P\ %\,0@!>#4@
M7 U/ %L-5@!9#5X 6 YH %8.<P!5#H  4PZ/ %$.GP!0#K$ 3@[( $T0Z@!-
M$/T 31#_ $T0_P!-$/\ O!L  *4<  "2'0  @QX  '<=  !O'   :1H  &87
M  !D%   9! ( &(/$ !?$!@ 71 A %L1*0!:$3$ 6!(X %<2/@!6$D4 5!),
M %,34P!1$UL 4!-E $X4< !,%'T 2Q2, $D4G !'%:X 1A7% $45Z !%%OX
M11;_ $45_P!%%?\ M1\  )XA  "+(@  ?"(  '$B  !H(0  8A\  %\=  !<
M&@  6Q<" %H5#0!7%A0 518= %07)0!2&"T 41@T $\8.P!.&4( 31E( $L:
M4 !*&E@ 2!IB $<:;0!%&WH 0QN) $(;F@! &ZP /QO" #X<Y0 ]'/P /AS_
M #X;_P ^&_\ KR,  )@D  "&)0  =R8  &PF  !C)0  720  %DB  !6'P
M5!T  %,<"P!1'!( 3AT: $T=(@!+'BD 2AXQ $D?-P!''SX 1B!% $4@30!#
M(%4 0B!? $ A:@ _(7< /2&' #LAF  Y(:H ."+  #<BXP W(OL -R+_ #@A
M_P X(?\ JB8  )0G  "!*0  <RD  &<I  !?*0  6"@  %0F  !1(P  3R(
M $PB!P!*(A  2"(7 $<C'P!%)"8 1"0N $(D- !!)3L 0"5# #\E2@ ])E,
M/"9< #HF9P Y)G4 -R>$ #4GE@ T)Z@ ,B>^ #$GX0 Q)_D ,B;_ #(F_P S
M)?\ I2D  (\J  !]+   ;RP  &0M  !;+   52L  % J  !,*   2B8  $<G
M! !$)PT 0B@4 $$H'  _*2, /BDK #TI,@ \*CD .RI  #DJ2  X*U  -BM:
M #4K90 S*W( ,2N" # LE  N+*< +"R\ "LLW@ L+/@ +"O_ "TJ_P M*O\
MH2P  (LM  !Y+@  :R\  & O  !8+P  42X  $PN  !(+   12L  $$K   _
M+ L /2P1 #LM&0 Z+B$ .2XH #<N+P V+S8 -2\^ #0O10 S+TX ,3!8 # P
M8P N,'  +#"  "HPD@ I,*4 )S"Z "8PW  F,/< )R__ "@O_P H+O\ G"X
M (<P  !V,0  :#(  %TR  !5,@  3C$  $@Q  !$,   0"\  #PP   Z,0D
M-S$0 #8R%@ U,AX ,S,E #(S+  Q,S, ,#0[ "\T0P M-$P +#16 "HU80 I
M-6X )S5^ "4UD  C-:, (C6Y "$UV0 A-/8 (C3_ ",S_P C,O\ F#$  (,S
M  !R-   930  %HU  !1-0  2S0  $4T  ! -   .C,  #<T   T-08 ,C8.
M # W$P O-QL +C<B "TX*0 K.#$ *C@X "DY0  H.4D )CE3 "4Y7P C.6P
M(3I\ " ZC@ >.J( '#JW !LYU0 <.?4 '3C_ !TX_P >-_\ DS0  '\V  !N
M-P  83<  %<W  !.-P  2#<  $(W   \-P  -3@  #(Y   O.@( +#L+ "H\
M$0 I/!@ *#T? "8])@ E/2X )#TU ",^/0 B/D8 (#Y0 !\^7  =/VD &S]Y
M !H_C  8/Z  %C^U !4^T@ 6/O, %SW_ !@\_P 8//\ CC<  'HX  !J.0
M7CH  %,Z  !+.@  13H  #\Z   Y.@  ,CP  "X^   I0   )D$( "1"#@ B
M0A0 (4(; "!#(P ?0RH 'D,R !Q#.@ ;1$, &D1- !A$60 71&< %41W !-$
MB@ 21)X $42S !!$T  00_( $4+_ !)"_P 30?\ B3L  '8\  !F/0  6CT
M % ]  !(/0  0CT  #P]   V/@  +T   "I"   E1   (48# !U(#  ;21$
M&4D7 !A)'@ 7228 %DDN !5*-@ 42D  $TI* !%*5@ 02F0 #TIT  Y*AP -
M2IL #$JP  I*R@ +2>P #$C_  U'_P -1_\ @SX  '$_  !B0   5D   $U
M  !%0   /T   #E!   R0@  *T4  "9'   A20  '$L  !9.!P 34 X $E 3
M !%0&0 04"$ #U I  Y0,0 -4#L #5%&  M140 *45\ "5%O  =0@0 %4)8
M U"K  )0Q0 #3^@  T_[  5._P &3?\ ?4(  &M#  !=1   4D0  $I$  !#
M0P  /$0  #5%   N1P  )TH  "%,   <3P  %U$  !)4 P .5PH "U@0  I8
M%0 (6!P !U@D  98+  %6#8  UA   %83   6%H  %AI  !8?   6)$  %>G
M  !7P   5N4  %;Y  !5_P  5?\ =D<  &9'  !92   3T<  $='  ! 1P
M.$@  #!*   I30  (E   !Q3   650  $5@   U; @ )7@D !%\.  !?$@
M7Q@  & ?  !@)P  8#   & [  !@1P  8%0  &!C  !@=@  8(L  %^B  !?
MNP  7^(  %[Y  !=_P  7?\ ;TL  &%,  !53   3$L  $1+   [3   ,DX
M "M1   C5   '%<  !9;   17@  #6    AC   "9@<  &<,  !G#P  :!,
M &D9  !J(0  :BD  &HT  !J0   :DT  &I=  !J;P  :H4  &J=  !IM@
M:-T  &CW  !G_P  9O\ :5$  %Q0  !24   2D\  #]0   U4P  +58  "19
M   =70  %F   !!D   ,9P  !FH   !N    ;P,  ' (  !Q#0  <A   '04
M  !U&P  =B,  '<L  !W.   =D8  '96  !V:   =GX  ':7  !UL0  =-,
M '/U  !S_P  <O\ 8U8  %A5  !05   1%4  #E8   O6P  )E\  !UC   5
M9P  $&P   IP   $<P   '8   !Z    ?    'P#  !^"   ?PP  ($0  ""
M%   A!L  (4D  "&+P  ACT  (9-  "%7P  A74  (6/  "$J0  @\D  (+Q
M  "!_P  @/\ 7UL  %9:  !)6P  /5X  #)A   G9@  'FL  !5P   .=0
M"7D   %^    @0   (4   "(    B@   (L   "- 0  C@8  ) +  "1#P
MDQ0  )4;  "7)@  ES0  )=$  "75@  EFP  )6&  "5H@  E,$  )/J  "2
M_P  DO\ 76$  $]A  !"9   -FD  "IN   ?=   %7D   Y_   'A    (D
M  ".    D@   )8   "8    F@   )L   "=    GP   *$#  "C"   I0T
M *<3  "I'   JB@  *HY  "J2P  JF$  *EZ  "HF0  J+4  *?=  "G^
MIO\ 5F@  $AL   Z<   +G8  ")]   7A   #HH   >0    E@   )H   "?
M    HP   *<   "J    JP   *T   "O    L0   +,   "U    N 4  +H,
M  "]$@  P!P  , M  # 0   OU4  +]N  "^BP  OJ@  +[)  "][P  O/X
M3G0  $!Y   R?P  )8<  !F.   0E0  !YP   "B    IP   *P   "P
MM0   +D   "\    O0   +\   #!    PP   ,8   #(    R@   ,T"  #0
M"P  U1(  -8A  #7-   V$D  -E@  #:?   VIH  -NU  #;V0  V_( 1H(
M #B)   KD   '9@  !*@   *IP   *X   "T    N0   +X   #"    R
M ,L   #.    SP   -(   #4    U@   -H   #=    WP   .(   #F
MZ@H  .\3  #P)0  \CH  /-1  #T:P  ](D  /6E  #UOP  ]=T _P & /\
M P#_  4 _P + /\ $ #_ !< _P B /\ +0#_ #D _P!$ /\ 30#_ %4 _P!=
M /\ 9 #_ &H _P!P /T =@#[ 'P ^0"# /< B@#U )( \P"; /  I@#N +,
MZP#$ .D Y #G /D Y@#_ .4 _P#3 /\ QP#_ +\ _P"[ /\ _P   /\   #_
M    _P " /\ "P#_ !( _P = /\ * #_ #, _P ^ /P 1P#X $\ ] !7 /$
M70#N &, [ !I .H ;P#H '4 Y@!\ .0 @P#B (L WP"5 -P GP#9 *L U0"[
M -( U #/ /( S0#_ ,P _P#% /\ N@#_ +0 _P"P /\ _P   /\   #_
M_P   /\ !@#Y  \ ]0 7 /, (@#Q "T [0 W .< 0 #B $D WP!0 -L 5P#7
M %T U !C -$ : #/ &X S !U ,H ? #( (0 Q0"- ,( F #  *0 O0"R +L
MQ@"Y .@ N #] +< _P"V /\ K0#_ *< _P"C /\ _P   /\   #_    ]0
M .L  0#D  P W@ 3 -D ' #3 "8 T0 P ,P .@#( $( Q !* ,  4 "] %8
MNP!< +D 80"W &< M0!M +, = "Q 'P KP"% *T D "J )P J "J *8 NP"E
M -H HP#U *, _P"B /\ G@#_ )H _P"7 /\ _P   /X   #O    WP   -
M  #'  < P0 / +P %P"Y "  MP J +4 ,P"P #L K0!# *L 20"H $\ I@!5
M *0 6@"C &  H0!F )\ ;0"= '0 G !] )H B "8 )0 E@"B )0 L@"2 ,D
MD0#K )$ _P"0 /\ D #_ (P _P"* /\ _    .P   #9    QP   +H   "Q
M  ( JP , *< $@"D !L H0 D *  + "> #4 FP \ )@ 0P"6 $D E !/ )(
M5 "0 %H CP!? (T 9@"+ &T B0!V (@ @ "& (P A ": (( J@"! +X @ #@
M (  ^0!_ /\ ?P#_ '\ _P!^ /\ \0   -@   #"    LP   *@   "@
MF0 ' )4 #@"2 !4 D  > (X )@"- "X B@ V (< /0"% $, A !) (( 3@"!
M %0 ?P!9 'X 8 !\ &< >@!O 'D >@!W (8 =0"4 '0 HP!R +4 <@#/ '$
M\0!P /\ < #_ '  _P!Q /\ X0   ,0   "P    H@   )<   "1    BP "
M (8 "P"# !$ @0 8 '\ (0!] "D ?  P 'D -P!X #T =@!# '0 20!S $X
M<@!4 '  6@!O &( ;0!J &L = !J (  : ". &< G0!E *\ 90#& &0 Z !D
M /T 8P#_ &, _P!D /\ SP4  +8'  "C"   E @  (D'  "" P  ?@   'L
M!@!W  X =0 3 '( &P!Q ", ;P K &T ,@!L #@ :@ ^ &D 1 !G $D 9@!/
M &4 5@!C %T 8@!E &  ;P!? 'L 70") %P F0!; *H 60"_ %D X0!8 /@
M6 #_ %@ _P!9 /\ P@P  *H-  "7#@  B0X  'T.  !V#0  <0H  &\&  !M
M  H :P 0 &D %@!G !X 90 F &, +0!A #, 8  Y %\ /P!= $4 7 !+ %L
M4@!: %D 6 !B %< ; !5 '@ 4P"& %( E@!1 *< 4 "[ $\!VP!. O0 3@/_
M $X$_P!. _\ N!   *$2  ".$P  ?Q,  '03  !L$@  9Q   &4.  !C"P,
M8P8, &$$$0!> QD 7 0A %L%* !9!B\ 6 8U %8'.P!5!T( 5 =( %,(3P!1
M"%8 4 E? $X):0!-"78 2PJ$ $D*E !("J8 1PJZ $8*V !%"_, 10S_ $4,
M_P!%#/\ L!0  )D6  "'&   >!D  &T8  !E%P  7Q8  %P3  !:$0  6@X&
M %H,#0!7#!0 50P< %,-) !2#2L 4 TQ $\.. !.#CX 30Y% $L.30!*#E4
M2 ]> $</: !%#W4 0Q"$ $$0E0! $*8 /A"[ #T0W  ]$?8 /1'_ #T0_P ^
M$/\ J1D  )(;  "!'   <AT  &<=  !?'   61L  %49  !3%@  4A,  %(1
M"@!0$!  3A$8 $P1( !*$B< 21(N $@3- !'$SL 11-" $0320!#%%( 011;
M #\490 ^%7( /!6! #H5D@ X%:0 -Q6Y #45V  U%O4 -A;_ #86_P W%?\
MHQP  (T>  ![(   ;2$  &(A  !:(0  5!\  % >  !-&P  3!D  $L6!@!)
M%@X 1Q<5 $47' !$&"0 0A@J $$8,0! &3@ /QD_ #T91@ \&D\ .AI8 #D:
M8P W&V\ -1M^ #,;D  R&Z( ,!NW "\;TP O'/, +QO_ # ;_P P&_\ G1\
M (@B  !W(P  :20  %XD  !6)   4",  $LB  !((   1AT  $4< @!#' P
M01P2 #\=&0 ^'2$ /!XG #L>+@ Z'S4 .1\\ #<?1  V'TP -"!6 #,@8  Q
M(&T +R!\ "TAC@ L(:  *B&U "DAT  I(?( *2'_ "H@_P K(/\ F2(  (0E
M  !S)@  92<  %LG  !3)P  3"8  $<E  !$)   0B$  #\A   ](0D .R$0
M #DB%@ X(AX -B,E #4C*P T)#( ,R0Y #(D00 P)$H +R53 "TE7@ K)6L
M*B5Z "@EC  F)9\ )"6S ",ES@ C)?  )"7_ "4D_P E)/\ E"4  ( G  !O
M*0  8BH  %<J  !/*@  22D  $0H  ! )P  /28  #HE   W)@8 -28. #0G
M%  R)QL ,2@B # H*0 O*#  +2DW "PI/P K*4< *2E1 "@J7  F*FD )"IX
M ",JB@ A*IT 'RJR !XJS  >*N\ 'RG_ " I_P A*/\ D"@  'PJ  !L*P
M7RP  %0L  !,+   1BP  $$K   \*P  ."H  #4J   R*P, ,"L, "XL$0 M
M+!@ +"P? "HM)@ I+2T *"TT "<N/  F+D4 )"Y/ ",N6@ A+V< 'R]V !TO
MB  <+YL &B^P !@OR@ 8+NT &2[_ !LM_P ;+?\ C"L  '@M  !H+@  6R\
M %$O  !)+P  0R\  #XN   Y+@  -"X  # N   M+P  *S * "DQ$  G,14
M)C$< "4R(P D,BH (S(Q "$S.0 @,T( 'S-, !TS5P ;,V0 &C1T !@TA@ 6
M-)H %#.N !,SR  3,^P %#/_ !4R_P 6,?\ ARX  '0O  !E,0  6#$  $XR
M  !&,@  0#$  #LQ   V,0  ,3$  "LS   H-   )34& ",V#0 A-A( (#<9
M !\W(  >-R< '3@N !LX-@ :.#\ &3A) !<Y50 5.6( %#EQ !(YA  1.9@
M$#FM  XXQP ...L $#C_ ! W_P 1-O\ @S$  ' R  !A-   530  $LT  !$
M-   /30  #@T   S-   +34  "@W   D.0  (#H" !T["P ;/!  &3T5 !@]
M'  7/2, %CTK !4^,P 4/CP $CY& !$^4@ 0/E\ #SYO  X^@0 ,/I4 "SZI
M  H^P0 */>0 "SW[  P\_P -._\ ?30  &LV  !=-P  43<  $@W  !!-P
M.S<  #4W   P-P  *CD  "4[   @/0  '#\  !=!!@ 40PT $D,2 !%#&  1
M0Q\ $$0G  ]$+P .1#D #41#  Q$3@ +1%L "41J  =$?  &1)  !$.E  )#
MO0 #0^   T/V  1"_P &0?\ >#@  &<Y  !9.@  3CH  $4Z   ^.@  .#H
M #,Z   M.P  )ST  "%    <0@  %T0  !-& P /20H #4H/  Q*%  +2AL
M"4HC  A**P '2C0 !4H^  1*20 "2E8  $IE  !*=P  2HL  $JA  !)N0
M2=T  $GU  !(_P  2/\ <CP  &(]  !5/@  2CX  $(]   \/0  -CT  "\^
M   I0   (T(  !U%   71P  $TH   ], @ +3PD !U -  -1$0  41<  %$>
M  !1)@  42\  %$Y  !11   4E$  %)@  !1<@  48<  %&=  !1M0  4-@
M %#U  !/_P  3_\ ;$   %U!  !100  1T$  $!    Y0   ,D$  "I#   D
M1@  'D@  !=+   23@  #E$   M3 0 &5@<  %<,  !8$   6!,  %D9  !:
M(0  6BD  %HS  !:/P  6DP  %I:  !:;   6H$  %F9  !9L0  6-$  %CT
M  !7_P  5_\ 944  %A%  !-10  140  #Y$   U10  +4<  "5*   >30
M&%   !)3   .5@  "ED   1<    7@0  %\)  !@#0  81   &(5  !C&P
M9",  &0M  !D.   9$4  &14  !D9@  9'L  &.3  !CK0  8LP  &'R  !A
M_P  8/\ 7TH  %-*  !*20  0T@  #E)   O3   )T\  !]2   850  $ED
M  U=   (8    F,   !F    : $  &D%  !J"@  :PT  &T1  !N%@  <!T
M '$F  !Q,0  <#X  '!.  !P7P  <',  &^-  !OIP  ;L8  &WO  !L_P
M;/\ 6D\  %!.  !(30  /4X  #-1   I5   (%@  !A<   18   #&0   9H
M    :P   &\   !R    =    '4   !W!   > D  'H-  !\$   ?18  '\>
M  " *   @#4  (!%  !_5@  ?VL  '^$  !^H   ?;X  'SI  ![_P  >O\
M5E0  $Y3  !"5   -U8  "Q:   B7P  &&,  !%H   +;0   W(   !V
M>@   'T   "     @P   (0   "&    AP(  (D'  "+#   C1   ) 6  "2
M'P  DBP  )([  "230  D6(  )%Z  "/EP  C[0  ([A  ",^P  C/\ 55D
M $A:   [70  +V$  "1F   9;   $7(   IW   "?0   ((   "&    BP
M (X   "1    DP   )4   "7    F0   )L   "=!   GPH  *(/  "D%@
MIB$  *8Q  "F0P  I5<  *1P  "CC@  HZL  *'0  "@]0  G_\ 3F$  $!D
M   S:0  )VX  !MU   1?   "X,   ")    C@   ),   "8    G0   *$
M  "D    I0   *<   "I    JP   *T   "P    L@   +4(  "X#@  O!8
M +PE  "\-P  NTP  +ID  "Y@0  MZ(  +?   "WZ@  M_P 1FL  #EP   K
M=P  'W\  !.&   +C@   94   ";    H0   *8   "K    L    +,   "W
M    MP   +H   "\    OP   ,$   #$    QP   ,H   #-!0  T0X  -09
M  #4*P  U$   --8  #3=   TY(  -*P  #2TP  TO( /GD  #&    CB
M%Y$   V9   #H    *<   "N    LP   +@   "]    P@   ,8   #*
MR@   ,T   #/    T@   -4   #9    W0   -\   #C    YP4  .L/  #L
M'P  [3,  .Y+  #O9   [X(  /"?  #QN0  \=@ _P   /\   #_  0 _P )
M /\ #@#_ !4 _P > /\ *0#_ #0 _P _ /\ 2 #_ %  _P!8 /\ 7@#_ &4
M_0!K /L <0#Y '< ^ !^ /8 A0#S (T \0"7 .X H@#K *\ Z #  .8 X #C
M /@ X@#_ -L _P#+ /\ P0#_ +D _P"T /\ _P   /\   #_    _P   /\
M"0#_ !  _P 9 /\ (P#_ "X _0 Y /D 0@#U $H \@!2 .X 6 #K %X Z0!D
M .8 :@#D '  X@!V -\ ?0#= (8 V0"/ -4 F@#1 *< S@"V ,L S@#) /
MQP#_ ,4 _P"[ /\ M #_ *T _P"I /\ _P   /\   #_    _P   /L  @#V
M  T \0 3 .T '@#L "@ Z0 R ., .P#= $0 V !+ -, 40#0 %@ S0!= ,L
M8P#) &@ Q@!O ,0 =@#" 'X OP"' +P D@"Z )\ MP"M +4 P0"R .0 L0#]
M *\ _P"L /\ I0#_ *  _P"< /\ _P   /\   #[    [@   .0   #<  @
MTP 0 ,\ & #+ "( R0 K ,8 - #! #T O0!$ +H 2P"W %$ M0!6 +( 7 "P
M &$ K@!G *P ;@"J '8 J !_ *8 B@"C )8 H0"E )\ M@"= -$ G #S )L
M_P"< /\ E@#_ ), _P"0 /\ _P   /8   #G    TP   ,8   "]  , N  -
M +, $P"Q !P KP E *X +@"I #8 I@ ] *, 1 "A $H GP!/ )T 50"; %H
MF@!@ )@ 9@"6 &X E !W )( @0"0 (X C@"< (P K0"* ,, B0#H (@ _P")
M /\ AP#_ (4 _P"" /\ \P   .,   #,    O    +    "G    H0 ( )X
M#P"; !8 F0 ? )@ )P"6 "\ DP W )$ /0". $, C !) (L 3@") %0 AP!9
M (4 8 "$ &< @@!O (  >@!^ (8 ? "4 'H I !Y +@ > #8 '< ]P!X /\
M> #_ '< _P!U /\ Y@   ,L   "W    J    )X   "6    CP $ (L # "(
M !( AP 9 (4 (0"$ "D @@ P '\ -P!] #T ? !# 'H 2 !Y $T =P!3 '8
M60!T &$ <@!I '$ <P!O '\ ;0"- &P G0!J *\ :0#( &@ [0!I /\ :0#_
M &D _P!I /\ T@   +@   "E    EP   (T   "&    @0   'P " !Y  X
M=P 4 '8 ' !T ", <P K '$ ,0!O #< ;@ ] &P 0P!K $@ :@!. &@ 5 !G
M %L 90!C &, ;0!B '@ 8 "' %\ E@!= *@ 70"^ %P Y !< /L 7 #_ %P
M_P!< /\ P@   *H!  "8 P  B00  '\"  !X    =    '  ! !M  P :P 1
M &D %P!H !X 9@ E &4 + !C #( 8@ X &  /0!? $, 7@!) %P 3P!; %8
M6@!> %@ : !7 ', 50"! %0 D0!2 *, 40"W %$ U@!1 /4 40#_ %$ _P!2
M /\ M@<  )\)  "-"P  ?@P  ',+  !L"@  : <  &4#  !C  < 80 - %\
M$P!= !H 7  A %L )P!9 "T 6  S %8 .0!5 #\ 5 !% %, 2P!1 %( 4 !:
M $\ 9 !- &\ 3 !] $H C0!) )\ 2 "R $< S !' .\ 1@#_ $< _P!' /\
MK P  )4.  "#$   =1   &L0  !C#P  7@X  %L,  !:"0( 600* %< #P!5
M !4 4P < %( (P!1 "D 3P O $X -0!- 3L 3 %! $H"2 !) D\ 2 )7 $8#
M80!% VT 0P-Z $(#BP!  YP /P.O #X#R  ]!.H /07\ #T&_P ^!O\ I!
M (X2  !\$P  ;A0  &04  !<$P  5A(  %,1  !1#@  4 P% % )# !/!Q$
M30<7 $L('P!)""4 2 DK $<),0!&"3@ 1 H^ $,*10!""DT 0 M5 #\+7P ]
M"VL / MY #H,B@ X#)P -PRO #4,QP U#.D -0W] #4-_P V#/\ G1,  (<5
M  !V%P  :1@  %X8  !6&   4!<  $T5  !*$P  21$  $D.!P!(#0X 1@T3
M $0-&@!##B$ 0@XH $ .+@ _#C4 /@\\ #T/0P [$$L .A!4 #@07@ V$&L
M-!!Y #(0B@ Q$)P +Q"P "T0R0 M$>P +1'_ "X1_P O$/\ EQ8  ((9  !Q
M&P  9!P  %D<  !1'   3!L  $<:  !$&   0Q4  $(3 @!!$@L 0!$0 #X2
M%P \$AX .Q,E #H3*P X$S( -Q,Y #840  T%$@ ,Q11 #$47  P%6@ +A5W
M "P5B  J%9H *!6N "<5QP F%>H )Q7_ "@5_P I%?\ D1H  'T<  !M'@
M8!\  %8?  !.'P  2!X  $,=  ! '   /AH  #T8   [%P< .18. #@7%  V
M%QL -1@B #,8*  R&"\ ,1DV # 9/0 N&48 +1I/ "L:60 J&F8 *!IT "8:
MA@ D&ID (AJM "$:Q0 @&N@ (1K^ "(:_P C&O\ C1T  'D?  !I(0  7"(
M %(B  !*(@  1"$  #\A   \(   .1X  #@;   U' 0 -!P- #(<$@ P'1@
M+QT? "X=)0 M'BP *QXS "H>.P I'T, )Q]- "8?5P D'V0 (A]R " ?A  ?
M'Y< '1^K !L?PP ;'^< &Q_] !T?_P >'O\ B2   '4B  !E(P  620  $\E
M  !')0  020  #PC   X(P  -2(  #,@   P( $ +B$* "PA$  K(14 *B(<
M "@B(P G(BD )B,P "4C.  C(T$ (B1* "$D50 ?)&$ '21P !LD@@ 9))4
M%R2J !8DP0 5).4 %B3\ !<C_P 9(_\ A2(  '$D  !B)@  5B<  $PG  !$
M)P  /B<  #DF   U)@  ,24  "XD   K)0  *24' "<F#@ E)A, )"<9 ",G
M(  B)R< (2@N " H-@ >*#X '2A( !LI4P 9*5\ &"EN !8I@  4*90 $BFH
M !$IP  1*.0 $2C[ !,H_P 4)_\ @"4  &XG  !?*   4RD  $DJ  !"*0
M.RD  #8I   R*   +B@  "HH   F*0  )"H$ "(K#  @*Q$ 'RP6 !TL'0 <
M+"0 &RTK !HM,P 8+3P %RU% !8N4  4+ET $BYL !$N?@ 0+I( #BZG  TM
MO0 -+=\ #2WY  XL_P 0+/\ ?"@  &HJ  !;*P  4"P  $8L   _+   .2P
M #0K   O*P  *RL  "8L   B+@  'R\  !PP"0 :,0X &3$3 !<Q&@ 6,B$
M%3(H !0R,  3,CD $C-# !$S3@ 0,UL #C-I  TS>@ ,,XX "C.B  @RN0 (
M,MD "#+T  HQ_P +,?\ =RL  &8M  !8+@  32\  $,O   \+@  -BX  #$N
M   M+@  *2X  ",P   ?,@  &S,  !<U!0 4-@P $C<1 !$W%@ 1-QT $#@D
M  \X+  ..#4 #3@_  PX2@ +.%< "3AE  <X=@ %.(H  SB?  $WM0 !-],
M C?Q  ,V_P %-O\ <RX  &(P  !4,0  23$  $$Q   Y,0  -#$  "\P   K
M,   )3(  " S   ;-@  %S@  !,Z @ 0/ D #3T.  P]$P +/1D "CTA  D]
M*0 (/3$ !CX[  4^1@ #/E(  3YA   ^<@  /H8  #V<   ]L@  /=   #SP
M   \_P  //\ ;3(  %TS  !0-   1C0  #XT   W-   ,C,  "TS   G-
M(C8  !TX   8.@  %#T  ! _ @ -00@ "4,-  9$$0 #1!8  D0=  !$)
M1"T  $0V  !$00  1$X  $1<  !$;0  1($  $28  !#KP  0\T  $+P  !"
M_P  0O\ :#8  %@W  !,.   0S@  #LW   U-@  ,#8  "DW   C.0  'CL
M !@]   30   $$(   U% 0 (1P<  TD,  !)#P  2A,  $L9  !+(   2R@
M $LR  !+/0  3$D  $Q7  !+:   2WT  $N4  !*K   2LH  $GO  !)_P
M2?\ 8CH  %0[  !).P  0#L  #DZ   S.0  +#H  "4\   ?/P  &4$  !-$
M   01P  #$D   A,   "3P4  % *  !0#0  41   %(5  !4&P  5",  %0L
M  !4-P  5$0  %12  !48P  5'<  %2/  !3J   4L8  %+M  !1_P  4?\
M7#\  $\_  !%/P  /CX  #<]   O/@  )T   "!#   91@  $TD   ],   +
M3P  !E(   !4    5P(  %@'  !9"P  6@X  %L1  !=%@  7AT  %\F  !?
M,0  7CT  %Y,  !>70  7G$  %V)  !=HP  7,$  %OK  !:_P  6O\ 5D0
M $M#  !#0@  /$$  #)"   I10  (4@  !I+   33@  #E(   I5   #60
M %L   !>    8    &("  !C!@  90H  &8.  !H$0  :A<  &L?  !K*0
M:S8  &M%  !K5@  :FH  &J"  !IG0  :+L  &?G  !F_P  9?\ 44@  $A(
M  !!1@  -T<  "Q*   C30  &U$  !-5   .60  "%T   %A    9    &<
M  !J    ;    &X   !P    <@4  ',)  !U#0  =Q$  'H8  ![(0  >RX
M 'H]  !Z3@  >6(  'EY  !XE@  =[,  '7@  !T_   <_\ 3DT  $=,   [
M30  ,$\  "93   <6   $UP   UA   &9@   &H   !O    <@   '8   !Y
M    ?    'T   !_    @0   (,"  "&!P  B P  (L1  ".&   CB0  (XS
M  "-1   C%@  (MO  "*C   B:H  (C/  "&]P  A?\ 35$  $%3   T50
M*5H  !Y?   490  #6H   5P    =@   'L   !_    @P   (<   "*
MC0   (X   "1    DP   )4   "8    F@4  )T,  "@$0  HQH  *,H  "B
M.@  H4X  *!E  "@@0  GJ   )W!  ";[@  FO\ 1ED  #E<   M80  (6<
M !9N   .=0  !7L   "!    AP   (T   "2    E@   )H   "=    GP
M *$   "D    I@   *@   "K    K@   +$#  "T"P  N!$  +D>  "Y+P
MN$,  +=:  "U=@  M)<  +2U  "QX@  L/P /V0  #%I   E;P  &'<   ]_
M   &AP   (X   "4    F@   *    "E    J@   *X   "Q    L@   +4
M  "W    N@   +P   "_    PP   ,8   #)    S@H  -(3  #2(P  T3<
M -!/  #.:@  S8H  ,JK  #+RP  R^\ -W$  "EX   =@   $8D   B1
MF@   *$   "G    K0   +,   "Y    O@   ,(   #%    Q@   ,D   #,
M    S@   -(   #5    V@   -X   #A    Y0   .H+  #K%P  ZBL  .I#
M  #J7@  ZGH  .N9  #KM0  Z]4 _P   /\   #_  $ _P ' /\ #0#_ !(
M_P ; /\ )0#_ "\ _P Z /\ 0P#_ $L _P!3 /\ 6@#] &  ^P!F /H :P#X
M '( ]@!X /0 @ #Q (D [P"2 .P G0#I *H Y@"\ ., W #? /< W0#_ ,P
M_P"^ /\ M0#_ +  _P"M /\ _P   /\   #_    _P   /\ !@#_  T _P 4
M /\ 'P#_ "D ^P S /< /0#S $4 [P!- .P 4P#H %D Y0!? ., 90#@ &H
MW0!Q -H > #6 (  T@"* ,\ E0#, *( R "R ,4 R0#" .T P #_ +L _P"P
M /\ J #_ *0 _P"A /\ _P   /\   #]    ^@   /@   #P  D [  1 .@
M&0#G ", Y0 M -X -@#6 #X T0!& ,T 3 #* %( R !8 ,4 70## &, P !I
M +X < "\ '@ N0"! +< C0"T )H L0"I *X O "L .$ J@#\ *@ _P"@ /\
MF0#_ )8 _P"4 /\ _P   /D   #R    YP   -L   #1  0 R@ - ,< % #$
M !T P@ F +\ +P"[ #< MP _ +0 10"Q $L K@!1 *P 5@"J %P J !A *8
M: "C '  H0!Y )\ A "= )$ F@"@ )@ L0"6 ,P E0#Q )0 _P"1 /\ BP#_
M (@ _P"& /\ ]P   .P   #>    R0   +P   "T    KP * *L $ "I !<
MJ  @ *< * "B #  GP X )P /@": $0 F !* )8 3P"4 %4 DP!: )$ 80"/
M &@ C0!Q (L >P") (@ AP"7 (4 J "# +X @0#D (  _P"  /\ ? #_ 'L
M_P!Y /\ Z0   -<   #!    L0   *8   "=    EP % )0 #0"2 !( D  :
M (\ (@". "H BP Q (D . "' #X A0!# (, 2 "! $X ?P!4 'X 6@!\ &$
M>@!I '@ <P!V '\ =0". ', GP!Q +, < #0 &\ ]@!O /\ ;P#_ &T _P!L
M /\ V@   +\   "L    G@   ),   ",    A0   (( "0!_  \ ?@ 5 'T
M' !\ "0 >@ K '< ,0!U #< =  ] '( 0@!Q $@ ;P!- &X 4P!L %H :P!B
M &D ; !G '@ 9@"& &0 EP!B *H 80#" &  ZP!A /\ 80#_ &$ _P!@ /\
MQ0   *T   ";    C0   (,   !\    =P   '( !0!P  P ;@ 1 &P %P!L
M !X :P E &D + !G #$ 9@ W &0 /0!C $( 8@!( &  3@!? %4 70!= %P
M9@!: '( 60"  %< D !6 *, 50"Y %0 W@!4 /L 5 #_ %4 _P!5 /\ M@
M )\   "-    ?P   '4   !N    :0   &8  0!C  D 80 . &  $P!? !D
M7@ @ %T )@!; "P 6@ R %@ -P!7 #T 5@!# %4 20!3 %  4@!8 %$ 80!/
M &P 3@!Z $P B@!+ )P 2@"Q $D S@!) /, 20#_ $D _P!* /\ J@$  )0%
M  ""!P  = @  &H(  !C!@  7@0  %L   !9  4 5P , %8 $ !4 !4 4P ;
M %( (@!1 "@ 4  M $X ,P!- #@ 3  ^ $L 10!* $P 2 !4 $< 70!& &@
M1 !U $, A0!! )@ 0 "K $  Q0 _ .H /P#_ $  _P!  /\ H @  (H+  !Y
M#0  ; T  &$-  !:#0  50L  %()  !0!@  3P(( $X #0!, !( 2P 7 $H
M'@!) ", 1P I $8 +P!% #0 1  Z $( 00!! $@ 0 !0 #X 6@ ] &0 / !R
M #H @@ Y )0 . "G #< O@ V ., -@#Y #8 _P W /\ F T  (,.  !R$
M91$  %L1  !3$   3A   $H.  !(#0  1PH# $<'"@!%! X 1 (3 $("&@!!
M B  0 ,E #X#*P ]!#$ / 0W #L$/@ Z!44 .05. #<%5P V!6( - 9P #(&
M@  Q!I( , :E "\%NP N!=T +@;U "T'_P N!_\ D1   'T1  !L$P  7Q0
M %44  !.%   2!,  $02  !!$   0 X  $ -!@! "@P /@D0 #P)%@ ["AP
M.0HB #@**  W"RX -@LU #4+.P S"T, ,@Q, # ,5@ O#&$ +0QO "L,?P J
M#)( * RE "<,NP E#-T )0WU "8-_P G#?\ BQ(  '<4  !G%@  6Q<  %$8
M  !)%P  0Q<  #\5   \%   .A(  #D1 0 Y#P@ . X- #<.$@ U#A@ - X?
M #(.)0 Q#RP , \R "\0.@ M$$( +!!+ "H050 H$&$ )A!O "00@  C$),
M(1"G !\0O0 >$.  'A'W !\0_P @$/\ AA0  ',7  !C&0  5QH  $T;  !%
M&@  0!H  #L9   X&   -18  #04   S$@0 ,A(+ #$2$  O$A4 +1(< "P3
M(@ K$RD *A,P "@3-P G%#\ )A1( "044P B%%\ (!5M !\5?@ =%9$ &Q6E
M !D5NP 8%=X &!7X !D4_P :%/\ @A<  &\:  !?'   4QT  $H=  !"'0
M/!T  #<<   T&P  ,1H  "\9   N%@  +!<( "L6#@ I%Q, *!<9 "<8(  E
M&"8 )!@M ",8-  B&3T (!E& !X940 =&5T &QIK !D:?  7&H\ %1JC !09
MN@ 2&=L $QGV !09_P 5&/\ ?1H  &L=  !<'P  4"   $<@   _(   .1\
M #0?   Q'@  +1T  "L<   I&P  )QL% "4;#  D'!$ (AP6 "$<'0 @'2,
M'QTJ !X=,@ <'CH &QY$ !D>3@ 7'EL %AYI !0?>@ 2'HT $1ZB ! >N  .
M'M@ #Q[U ! =_P 1'?\ >AT  &<?  !9(0  32(  $0B   \(@  -B(  #(A
M   N(0  *B   "<@   D'P  (B " " @"@ >(0\ '2$4 !PA&@ ;(B$ &2(G
M !@B+P 7(C@ %2-! !0C3  2(U@ $2-G ! C>  .(XL #2.?  PCM  +(]
M"R+P  PB_P -(?\ =A\  &0B  !6(P  2R0  $$D   Z)   -"0  "\C   K
M(P  *",  "0C   @(P  '20  !LE!P 9)@T %R81 !8F%P 5)QX %"<E !,G
M+  2)S4 $2@_ ! H2@ .*%8 #2AD  PH=  **(< "2B;  <GL0 %)\P !B?L
M  <F_@ ()O\ <2(  & D  !3)@  2"<  #\G   W)@  ,28  "TF   I)0
M)24  "(E   =)P  &2@  !8J!  4*PL $BP0 !$L%  0+!L $"PB  XL*0 .
M+3( #2T[  LM1@ *+5( ""U@  8M<  $+8,  BV8   LK@  +,D  "SK  $K
M_  "*_\ ;24  %TG  !/*   12D  #PI   U*0  +R@  "LH   G)P  (R<
M !\H   ;*@  %RP  !,N @ 0, @ #C$-  TQ$@ ,,1< "S$>  HQ)@ (,BX
M!S(W  4R0@ #,DX  3)<   R;   ,G\  #*5   QK   ,<<  ##J   P_
M,/\ :"D  %@J  !,*P  02P  #DL   R*P  +2L  "DJ   E*@  ("L  !PL
M   7+@  $S   ! R @ .- < "C<,  <W$  %-Q0  S<;  (W(@  -RH  #@S
M   X/@  .$H  #A8   X:   .'P  #>2   WJ0  -L4  #;J   V_0  -?\
M8RP  %0N  !(+P  /B\  #8N   P+@  *RT  "<M   B+0  '2\  !@Q   4
M,P  $#4   XW 0 *.@< !CL+  (\#@  /1(  #X7   ^'@  /B8  #XO   ^
M.@  /D8  #Y4   ^9   /G<  #Z/   ]IP  /<,  #SI   \_0  ._\ 7C
M % Q  !$,@  .S(  #0Q   N,   *2\  "0P   >,@  &30  !0V   0.0
M#3L   H]   %0 4  $$*  !"#0  0Q   $04  !%&@  1B(  $8K  !&-0
M1D$  $9/  !&7P  1G,  $6*  !%I   1,   $/H  !#_@  0O\ 6#0  $LU
M  !!-0  .34  #(T   M,P  )C0  " U   :.   %#H  ! ]   -0   "4(
M  1%    1P,  $@'  !*"P  2PX  $P1  !.%0  3QP  $\E  !/+P  3SP
M $]*  !/6@  3FT  $Z%  !-H   3+P  $OG  !+_@  2O\ 4SD  $<Y   ^
M.0  -S@  #$W   I-P  (3D  !L\   5/P  $$(   Q%   '2    DH   !-
M    3P   %$$  !2!P  5 L  %4.  !7$0  61<  %H?  !9*0  638  %E$
M  !95   6&<  %A_  !7F@  5K<  %7C  !4_0  5/\ 3CT  $,]   \/
M-3L  "P\   D/@  '$$  !5$   02   "TL   5.    40   %0   !7
M60   %L   != @  7@8  & +  !B#@  9!(  &<8  !G(@  9BX  &8\  !F
M30  96   &5W  !DDP  8[$  &'=  !@_   7_\ 24(  $%!   Z/P  ,$
M "9#   >1@  %4H  !!.   *4@   U8   !:    70   &    !C    90
M &<   !I    :P$  &T%  !O"@  <@X  '42  !W&P  =B8  '8U  !U1@
M=%D  '1O  !SBP  <JD  '#-  !O]P  ;O\ 1D8  $!%   U1@  *D@  "!,
M   740  $%8   E:   !7P   &,   !H    :P   &\   !R    =0   '<
M  !Y    >P   'T   "  P  @P@  (8-  ")$P  BAT  (HK  ")/   B$\
M (9F  "%@0  A*   (+"  "!\   ?_\ 1DL  #I,   N3P  (U,  !A8   0
M7@  "60   !I    ;P   '0   !X    ?    ($   "$    AP   (@   "+
M    C@   )    "3    E@   )D'  "=#0  H10  * A  "@,0  GD0  )U;
M  "<=@  F98  )FU  "6Y0  E?X /U(  #)5   F6@  &V   !%G   );0
M '0   ![    @0   (8   "+    D    )0   "7    F0   )P   "?
MH0   *0   "G    J@   *T   "Q!@  M0T  +@6  "W)@  MCD  +50  "T
M:@  LHD  +"J  "NSP  K?4 -UP  "MA   >:   $W    MX    @    (<
M  ".    E0   )H   "?    I    *@   "L    K0   +    "S    M0
M +@   "[    OP   ,,   #'    RP4  -$.  #1&P  T"X  ,]%  #-7P
MRWX  ,F>  #(O@  Q>D +VD  "-P   6>0  #8$   &+    DP   )L   "B
M    J    *X   "T    N    +T   #     P@   ,4   #(    RP   ,X
M  #1    U@   -L   #?    Y    .@&  #K$0  ZB,  .HZ  #I5   YW(
M .63  #CLP  X]0 _P   /\   #_    _P $ /\ "P#_ !  _P 7 /\ (0#_
M "L _P U /\ /@#_ $< _P!. /\ 50#\ %L ^@!A /@ 9@#V &T ] !S /(
M>P#O (0 [0". .H F0#F *< XP"Y -\ U0#; /< U@#_ ,  _P"R /\ J@#_
M *4 _P"B /\ _P   /\   #^    _    /P  P#^  L _P 1 /\ &@#] "0
M^0 N /0 . #P $  [ !( .D 3@#F %0 X@!: -\ 7P#< &4 V !K -0 <@#0
M 'L S0"% ,H D0#' )X PP"N ,  Q0"] .L NP#_ +  _P"D /\ G #_ )@
M_P"5 /\ _P   /H   #T    \0   /(   #J  4 YP . .( %0#A !X X0 H
M -@ ,0#0 #D RP!  ,@ 1P#% $T P@!3 +\ 6 "] %X NP!D +D :P"V ',
MM !\ +$ B "N )4 JP"D *@ N "F -P HP#[ )\ _P"5 /\ CP#_ (L _P")
M /\ ^0   .\   #G    WP   ,\   #(    P0 * +\ $0"\ !@ NP A +D
M*@"T #( L0 Z *X 0 "K $8 J !, *8 40"C %8 H0!< )\ 8P"= &H FP!S
M )D ?@"6 (P E "; )( K0"0 ,< C@#P (T _P"& /\ @ #_ 'T _P!\ /\
M[0   .    #1    OP   +,   "J    I@ % *( #0"A !, H  ; )\ (P";
M "L F  R )4 .0"3 #\ D0!$ (\ 2@". $\ C !5 (H 6P"( &, A@!K (0
M=@"" (( @ "2 'X HP!\ +H >@#A 'D _P!W /\ <@#_ '  _P!O /\ W0
M ,L   "V    IP   )T   "4    C@ ! (L "@") !  B  5 (< '0"' "4
MA  L (( ,@!_ #@ ?0 ] 'L 0P!Y $@ > !. '8 5 !U %L <P!C '$ ;@!O
M 'H ;0") &P F@!J *X :0#, &@ ]@!G /\ 90#_ &0 _P!C /\ R@   +0
M  "A    DP   (D   ""    >P   '@ !0!V  P =0 1 '0 & !S !\ <@ E
M '  + !N #( ;  W &H / !I $( : !( &8 3@!E %4 8P!= &( 9@!@ '(
M7@"  %T D@!; *4 6@"^ %D Z0!9 /\ 60#_ %@ _P!8 /\ N0   *(   "0
M    @P   'D   !Q    ;0   &D  0!F  D 90 . &0 $P!C !D 8P @ &$
M)@!@ "P 7@ Q %P -P!; #P 6@!" %@ 2 !7 $\ 5@!7 %0 8 !3 &P 40!Y
M %  B@!/ )X 3@"T $T V@!- /L 30#_ $T _P!- /\ J@   )0   ""
M=0   &L   !D    8    %T   !:  4 6  , %< $ !6 !4 5@ ; %4 (0!3
M "< 4@ L %$ ,0!/ #< 3@ ] $T 0P!, $H 2@!2 $D 6P!( &8 1@!S $4
MA !$ )< 0P"L $( R0!" /$ 0@#_ $, _P!# /\ G@   (D   !X P  :@0
M &$$  !: P  50$  %(   !0  ( 3@ ) $T #0!, !$ 2P 7 $H ' !) "(
M2  G $< +0!% #( 1  X $, /@!" $4 00!- #\ 5@ ^ &$ /0!N #L ?@ Z
M )$ .0"F #@ OP X .@ . #_ #D _P Y /\ E0,  ( '  !O"0  8@H  %@+
M  !1"@  3 @  $D&  !' P  1@ & $0 "P!#  \ 0@ 3 $$ & !! !X /P C
M #X *0 ] "X .P T #H .@ Y $$ . !) #< 4@ V %T - !J #, >@ R (P
M,0"A #  N  O -X +P#Y "\ _P P /\ C D  '@,  !H#0  7 X  %(.  !+
M#@  10T  $$,   _"@  /@@" #T$"  \ 0T .P 0 #H %0 Y !H .  @ #8
M)0 U "L -  P #, -P R #X ,0!& "\ 4  N %H +0!G "L =P J (D *0"=
M "@ LP G -$ )P#R "< _P G /\ A@P  '(.  !C$   5A$  $T1  !%$0
M0!   #P/   Y#@  -PT  #8+!  V" H -08. #0%$@ R!!< ,04< # %(@ O
M!2@ +@8N "T&-  K!CP *@9$ "D'3@ G!UD )@=E "0'=0 C!X< (@>; " &
ML  @!LL 'P7M !\&_@ ?!_\ @ X  &T1  !>$@  4A,  $@3  !!$P  .Q,
M #<2   T$0  ,A   # / 0 P#08 , L+ "\*$  M"A0 + L9 "H+'P I"R4
M* PK "<,,@ F##H ) Q# ",,30 A#5@ ( UE !X-=0 <#8@ &@V< !D-L0 8
M#,H %PSK !<-_  8#/\ >Q$  &D3  !:%0  3A8  $46   ]%@  .!4  #,5
M   P%   +1,  "L2   J$ , *@\( "D.#0 H#A$ )@X6 "4/'0 D#R, (P\I
M "$0,0 @$#D 'A!" !T03  ;$%@ &1!F !<0=@ 5$(D %!"> !(0LP 1$,X
M$1#N !(0_@ 2$/\ =Q,  &45  !7%P  2Q@  $(9   Z&0  -!@  # 7   L
M%P  *18  "<5   F% $ )1($ ",2"P B$@\ (1(4 " 2&@ >$R  '1,G !P3
M+@ :$S8 &11  !<42@ 6%%8 %!1D !(4=  1%(< $!2<  X4L0 -%,H #13K
M  X3_@ .$_\ <Q4  &$8  !3&@  2!L  #\;   W&P  ,AH  "T:   I&0
M)A@  "08   B%P  (!8! !X6"  =%@T &Q<2 !H7%P 9%QT &!@D !88*P 5
M&#0 %!@] !(92  1&50 $!EB  X9<@ -&80 #!F8  H9K0 )&,8 "1CG  D8
M^@ *%_\ ;Q@  %X:  !0'   11T  #P=   U'0  +QT  "H<   F&P  (QL
M "$:   >&@  '!H  !H;!0 8&PP %AP0 !4<%0 4'!L $QPB !(=*0 1'3$
M$!T[  X=10 -'E$ #!Y>  H>;0 )'H  !QZ4  4=J@ #'<(  QWF  0<^  %
M'/\ :QH  %L=  !-'@  0A\  #H?   R'P  +1\  "@>   D'@  (1T  !X=
M   <'0  &!X  !4? @ 3( D $B$. ! A$@ 0(1@ #B$?  XB)@ -(BX #"(W
M  HB00 )(DT !R):  4B:0 #(GP  2*1   BJ   (<   "'E   @^   (/\
M9QT  %<?  !*(0  0"$  #<B   P(0  *B$  "8@   B(   'Q\  !P?   9
M(   %B$  !(C @ 0) < #B8,  PF$  +)A4 "B8<  DF(@ ()BH !B<S  0G
M/0 #)TD  2=6   G9@  )WD  ">/   FI@  )K\  "7D   E^0  )/\ 8R
M %0B  !'(P  /20  #0D   N(P  *",  "0B   A(@  'B$  !HB   7(P
M$R0  ! F @ .* < "RH+  @K#@ &*Q, !"L8  (K'P !+"<  "PP   L.@
M+$4  "Q3   L8P  +'8  "R,   KI   *[X  "KD   J^@  *?\ 7R,  % E
M  !$)@  .B8  #(F   K)@  )B4  ",D   ?)   &R0  !<E   4)P  $2D
M  XK @ ++08 !R\+  0P#@  ,!$  #$5   Q'   ,2,  #(L   R-@  ,D(
M #)/   R7P  ,G(  #&)   QH@  ,+P  ##D   O^P  +_\ 6B<  $PH  !
M*0  -RD  "\I   I*   )2<  "$F   <)P  &"@  !0J   1+   #BX   LP
M 0 ',@4  S0)   U#   -@\  #<2   X&   ."   #@H   X,@  .3T  #E+
M   Y6P  .&X  #B%   WGP  -[H  #;D   U_   -?\ 52H  $@L   ]+
M-"P  "TK   H*@  )"D  !XJ   9*P  %"T  !$O   -,0  "C0   <V   "
M. 0  #H'   ["@  /0T  #X0  ! %   0!L  $ D  ! +@  0#D  $!'  !
M5@  0&D  $"    _FP  /K<  #WC   \_   //\ 4"\  $,O   Y+P  ,B\
M "PM   G+   ("T  !HO   5,0  $3,   TV   ).   !3L    ]    0 $
M $$$  !#!P  10L  $8.  !($0  2A8  $H>  !**   2C0  $E"  !)40
M260  $A[  !(EP  1[0  $;@  !%_   1/\ 2C,  #\S   V,P  ,#$  "HP
M   C,0  '#,  !8U   1.   #3L   @^   #00   $,   !&    2    $H
M  !,!   3@<  $\+  !1#@  5!(  %49  !5(@  5"X  %0\  !42P  4UX
M %-T  !2D   4:X  %#7  !/^P  3O\ 13<  #PW   U-@  +S0  "8U   >
M-P  %SH  !$]   ,00  !T0   !(    2@   $T   !0    4P   %4   !7
M    6 (  %L&  !="P  7PX  &(3  !B&P  8B<  &(T  !A10  8%<  &!M
M  !?B0  7:<  %S,  !:^   6?\ 03P  #H[   T.0  *CH  "$\   80
M$4,   Q'   &2P   $\   !3    5@   %D   !<    7P   &$   !C
M90   &<!  !J!0  ;0H  ' .  !S%0  <B   '(M  !Q/0  <$\  &]E  !N
M@   ;9\  &O!  !I\0  :/\ /T   #D^   N/P  )$(  !I&   22@  #$\
M  14    6    %T   !A    90   &@   !K    ;@   '$   !S    =0
M '@   ![    ?@,  ($*  "%#P  AQ<  (8D  "%-   A$8  ()=  "!=@
M?Y8  'ZV  !\YP  >O\ /T0  #-%   H2   '4P  !-2   ,5P   UT   !C
M    :    &T   !Q    =@   'H   !^    @0   (,   "&    B0   (L
M  ".    D@   )4!  "9"0  GA   )X:  "=*0  G#P  )I2  "8;   EHL
M )2J  "2U   D/H .$L  "Q.   @4P  %5D   U@   #9P   &X   !T
M>@   (    "$    B@   (X   "2    E0   )<   ":    G0   *    "C
M    IP   *L   "O    M D  +@0  "W'@  M3   +-&  "Q8   KWX  *R@
M  "KP0  J>X ,54  "1;   880  #FD   5Q    >0   ($   "(    CP
M )0   ":    GP   *0   "H    J0   *P   "O    LP   +4   "Y
MO0   ,$   #&    RP   -$*  #3%   T24  - [  #-5   RG$  ,B2  #%
MLP  P]X *6(  !QI   1<0  !WL   "$    C0   )4   "=    HP   *D
M  "O    M    +D   "\    O@   ,(   #%    R    ,P   #0    U
M -H   #?    Y    .H   #N#   [1H  .PO  #J20  Z&4  .:&  #DI0
MXL8 _P   /\   #_    _  ! /P " #^  X _P 4 /\ '0#_ "8 _P P /\
M.@#_ $( _P!) /X 4 #[ %8 ^0!< /8 8@#T &@ \@!O /  =@#M '\ Z@")
M .< E0#D *, X "U -L T #5 /8 R@#_ +8 _P"H /\ GP#_ )H _P"6 /\
M_P   /L   #V    \P   /,   #V  D ^@ . /T %@#[ "  ]P J /( ,P#M
M #L Z0!# .8 20#B $\ W@!5 -L 6P#6 &  T@!G ,\ ;@#, '8 R0"  ,8
MC #" )H OP"J +L P0"X .D M@#_ *< _P": /\ D@#_ (T _P"* /\ ^@
M /$   #J    YP   .<   #D  $ X  + -L $0#: !H VP C -$ + #* #0
MQ@ [ ,( 0@"_ $@ O !. +H 4P"X %D M@!? +, 9@"Q &X K@!W *P @P"I
M )$ I@"A *, M0"@ -@ G@#[ )4 _P"+ /\ A0#_ (  _P!^ /\ [P   .,
M  #:    TP   ,8   "_    N0 & +< #@"T !0 M  = +, )0"N "T JP T
M *< .P"D $$ H0!& )\ 3 "= %$ FP!7 )D 7@"7 &4 E0!N ), >0"0 (<
MC@"7 (P J0") ,0 B #O (4 _P!\ /\ =@#_ ', _P!R /\ X    -    #&
M    M@   *D   "A    G0 ! )D "@"8 !  F  6 )< '@"4 "8 D0 M (\
M- ", #H B@ _ (@ 10"' $H A0!0 (, 5@"! %X @ !F 'X <0!\ 'T >0"-
M '< H !U +8 <P#? '( _P!N /\ :0#_ &< _P!E /\ S    +X   "K
MG0   ),   "*    A0   (( !0"   T ?P 1 '\ & "  "  ?0 F 'H +0!W
M #, =0 X '0 /@!R $, < !) &\ 3P!M %8 ; !> &H : !H '4 9P"$ &4
ME@!D *L 8@#) &$ ]@!@ /\ 7 #_ %L _P!: /\ O0   *D   "7    B0
M 'X   !X    <P   &\  0!M  D ;  . &L $P!K !D :@ @ &@ )@!F "P
M90 R &, -P!B #P 8 !" %\ 2 != $\ 7 !7 %H 80!9 &T 5P![ %8 C@!5
M *( 4P"[ %( Z0!2 /\ 4 #_ $\ _P!/ /\ K0   )@   "&    >    &X
M  !G    8P   &    !=  4 7  + %L $ !; !4 6P ; %H (0!8 "8 5@ L
M %0 ,0!3 #8 4@ \ %$ 0@!/ $D 3@!1 $T 6P!+ &8 2@!T $D A0!( )D
M1P"Q $8 V !& /P 10#_ $4 _P!% /\ GP   (D   !X    ;    &(   !;
M    5@   %,   !1  ( 3P ( $\ #0!. !$ 3@ 6 $T ' !, "$ 2@ F $D
M+ !( #$ 1P W $4 /0!$ $0 0P!, $( 50!  &  /P!N #X ?@ ] )( / "I
M #L QP [ /, .P#_ #L _P \ /\ DP   'X   !N    80   %@   !1
M3    $D   !'    10 % $0 "P!#  X 0P 2 $, %P!" !T 0  B #\ )P ^
M "P /0 R #L .  Z #\ .0!' #@ 4  W %L -0!H #0 >  S (P ,@"B #$
MO  Q .< ,0#_ #( _P S /\ B0   '8#  !F!0  60<  % '  !)!@  0P4
M $ #   ^ 0  /  # #L "  Z  T .@ 0 #D %  Y !D -P > #8 (P U "@
M-  N #, -  R #L , !# "\ 3  N %< +0!D "P <P K (< *@"< "D M0 I
M -P *0#[ "D _P J /\ @00  &X(  !?"@  4PL  $H+  !""P  /0H  #D)
M   V"   -04  #0"!@ S  H ,@ . #$ $0 Q !4 ,  : "\ 'P N "0 +  J
M "L ,  J #< *0 _ "@ 20 G %0 )@!@ "0 ;P C (( (@"7 "$ K@ A ,P
M(0#S "$ _P B /\ >PD  &@,  !:#0  3@X  $4.   ]#@  . T  #,-   P
M#   +@L  "T) P M!@@ + 0, "L"#P J 1( *0$7 "@!'  G "$ )@ G "4
M+0 D #0 (P$] "(!1@ A 5$ 'P%= !X!;  < 7\ &P"4 !H J@ : ,4 &@#K
M !D _P : /\ =0P  &0.  !5#P  2A   $ 0   Y$   ,Q   "\/   L#@
M*0X  "<- 0 G# 4 )PH* "8(#0 E!Q  ) 84 "(&&0 A!A\ ( <D !\'*P >
M!S( '0<Z !P(1  :"$\ &0A< !<(:P 6"'T %0>1 !0'IP 3!K\ $@7D !(%
M^@ 2!?\ <0X  %\0  !1$0  1A(  #T2   V$@  ,!(  "L1   H$0  )1
M ",0   B#@0 (0T' "$,"P @"PX 'PL2 !T+%P <#!P &PPB !H,*0 9##$
M& PY !8-0P 5#4\ $PU< !(-:P 0#7X #PV2  X-IP -#+X #0S@  T,]0 -
M#/\ ;1   %P1  !.$P  0Q0  #H4   R%   +10  "@3   E$P  (A(  " 1
M   >$0, '! % !P/"  ;#PP &@X0 !D/%  7#QH %@\A !40*  4$#  $A Y
M !$01  0$%  #A!=  T0:P ,$'P "Q"0  D0I0 ($+P !Q#?  <0]  '#_\
M:1$  %@4  !+%0  0!8  #<6   P%@  *A8  "85   B%0  'Q0  !T3   :
M$P( &1($ !<2!@ 6$@H %1(. !02$@ 2$A@ $1,> !$3)0 0$RX #A,W  T4
M0  ,%$L "Q18  D49P '%'@ !A2-  04HP #$[L  A/=  $2]  "$O\ 91,
M %46  !(%P  /1@  #08   M&   *!@  ",7   @%P  '18  !H5   8%0(
M%A4$ !05!0 2%@@ $18- ! 7$  .%Q4 #A<;  T7(@ ,%RD "Q@R  D8/  '
M&$< !1A4  088P "&'4  1B+   7H0  %[D  !?=   6]0  %O\ 818  %(8
M  !%&@  .QH  #(:   K&@  )1H  "$9   >&   &Q@  !@7   6%P( %!<#
M !(8!0 0&0< #AL+  P;#P +&Q, "AL8  @<'P ''"8 !1PO  0<.  "'$0
M !U1   =8   '7(  !R(   <H   &[D  !O>   :]@  &O\ 7A@  $\:  !"
M'   .!P  "\=   I'   (QP  !\;   <&@  &1D  !<9 0 4&0( $AH# ! ;
M!  .'0< #!X+  D?#@ &(!$ !2 6  ,@'  !(2,  "$K   A-0  (4   "%.
M   A70  (6\  "&&   @G@  (+@  !_>   >^   'O\ 6AL  $L=   _'@
M-1\  "T?   G'@  (AT  !X=   ;'   &!L  !4;   2'   $!T"  X?!  ,
M(08 "2(*  4C#0 ")!   "43   E&0  )B   "8H   F,@  )CT  "9*   F
M6@  )FP  ":#   EG   );<  "3?   C^0  (_\ 51X  $<@   \(0  ,B$
M "LA   E(   (!\  !T>   :'0  %AX  !,>   0(   #B$   PC @ ()04
M!2<)   H"P  *@X  "L1   L%@  +!T  "PE   L+@  +#H  "Q'   L5@
M+&D  "R    KF@  *K4  "G?   I^P  */\ 42(  $0C   X)   +R0  "@C
M   C(@  'R$  !P@   7(   $R$  ! C   .)   "R8   @H   $*@0  "P'
M   N"0  , P  #$/   S$P  ,QD  #,A   S*@  ,S4  #-#   S4@  ,V4
M #)[   REP  ,;,  ##>   O^P  +O\ 3"4  #\F   U)P  +28  "<E   B
M)   'B,  !DC   4)   $28   XH   +*@  !RP   ,O    ,0(  #,$   U
M!P  -PH  #D-   Z$   .Q4  #L=   [)@  .S$  #L^   [3@  .V   #IW
M   YD@  .+   #?;   V_   -?\ 1RD  #LJ   R*@  *RD  "4G   A)@
M&R<  !4H   1*@  #BP   HO   &,0   30    V    .    #L!   ]!
M/P<  $$*  !##@  11$  $48  !%(0  12P  $0Y  !$2   1%L  $-Q  !"
MC0  0:L  $#2   _^@  /O\ 0BT  #@N   O+0  *2L  "0J   =*@  %RP
M !$N   -,0  "30   0W    .@   #P    _    00   $0   !&    2 ,
M $H'  !,"P  3@X  % 3  !0'   4"<  $\T  !/0P  3U4  $YJ  !-A@
M3*0  $K*  !)^   2/\ /C(  #4Q   N+P  *2X  " N   9,0  $C,   XW
M   ).@   CT   !     1    $<   !)    3    $\   !1    4P   %4!
M  !8!@  6@L  %T.  !?%0  7B   %XL  !=/   7$X  %MC  !:?@  6)T
M %?   !5\@  5/\ .C8  #,T   M,@  )#,  !LV   3.0  #CT   A!
M10   $D   !,    4    %,   !6    60   %L   !=    8    &(   !E
M    : 4  &L+  !O$   ;Q@  &XE  !M-   ;48  &M;  !J=0  :)0  &:V
M  !DZ0  8O\ .#D  #(W   H.0  'CL  !4_   .1   !TD   !-    4@
M %8   !:    7@   &(   !E    :    &L   !M    <    ',   !V
M>0   'T$  "!"P  A1$  (0=  ""+   @#X  'Y4  !^:P  >XH  'JJ  !W
MU@  =?T .#T  "P^   B00  %T8   ]+   '40   %<   !<    8@   &8
M  !K    ;P   '0   !X    >P   'X   "     @P   (8   "*    C0
M )$   "6 P  FPP  )T3  ";(0  FC,  )=)  "48@  DW\  )"@  ".Q0
MC/, ,40  "5(   :30  $%,   A:    80   &@   !N    =    'D   !_
M    A    (D   "-    D0   ),   "6    F0   )T   "@    I    *@
M  "L    L@,  +<-  "W%P  M2@  +(^  "P5@  K',  *J4  "IM   I>4
M*D\  !Y4   26P  "F(   !J    <P   'L   ""    B0   (X   "4
MF@   )\   "D    I@   *D   "M    L    +,   "W    NP   ,    #%
M    RP   -$$  #5#@  TQT  - R  #-2P  RF8  ,:'  #"J0  P<L (EL
M !9B   ,:P   70   !]    AP   )    "7    G@   *0   "K    L0
M +8   "Z    O    ,    #$    R    ,L   #/    U    -H   #@
MY@   .L   #Q!@  \!,  .XG  #L/P  ZEL  .=Z  #DFP  X+L _P   /L
M  #V    \P   /0 !0#V  P ^@ 1 /\ &0#_ "( _P L /\ -0#_ #T _P!%
M /P 3 #Z %( ]P!8 /4 7@#S &0 \0!J .X <@#L 'H Z0"% .4 D0#A *
MW0"R -@ S@#2 /8 P0#_ *T _P"> /\ E@#_ )  _P", /\ ^@   /(   #L
M    Z0   .D   #L  4 \@ , /@ $@#W !L ]0 E /  +@#K #< Y@ ^ .(
M10#= $L V !0 -, 5@#0 %P S0!B ,H :@#( '( Q0!\ ,( B "^ )8 N@"H
M +< OP"T .@ K@#_ )T _P"0 /\ B #_ (, _P"  /\ \    .4   #>
MV@   -L   #<    V  ' -$ #@#1 !4 T@ > ,L )P#% "\ P  W +T /0"Z
M $0 MP!) +4 3P"R %4 L !; *X 80"L &D J0!S *< ?P"D (T H0"> )X
ML@"; -4 F0#\ (P _P"" /\ >P#_ '8 _P!T /\ X@   -,   #*    QP
M +P   "V    L  ! *\ "P"L !$ K0 8 *T ( "H "@ I  O *  -@"= #P
MFP!" )D 1P"7 $T E0!3 ), 60"1 &$ CP!J (P =0"* (, B "4 (8 IP"#
M ,( @@#P 'P _P!S /\ ;0#_ &H _P!H /\ SP   ,$   "Y    K0   *
M  "8    E    )$ !@"0  T D  2 (\ &0". "$ BP H (@ +P"& #4 A  Z
M (( 0 "  $4 ?@!+ 'P 4@!Z %D > !B '8 ; !T 'D <@") '$ G0!O +0
M;0#? &P _P!E /\ 8 #_ %X _P!< /\ O@   +$   "@    D@   (D   ""
M    ?    'H  0!X  D =P . '@ % !W !H =  A '( )P!P "T ;@ S &P
M. !K #X :0!$ &@ 2@!F %$ 9 !: &, 9 !A '  7P!_ %X DP!= *D 7 #(
M %L ]P!7 /\ 5 #_ %( _P!1 /\ L    )\   "-    ?P   '0   !N
M:@   &8   !E  0 8P + &, $ !C !4 8P ; &$ (0!? "< 70 L %P ,@!:
M #< 60 ] %< 0P!6 $L 50!3 %, 7 !2 &@ 4 !W $\ B0!. )\ 30"Z $P
MZ0!+ /\ 20#_ $< _P!' /\ H@   (T   !\    ;@   &4   !>    60
M %<   !5  $ 5  ' %, #0!3 !$ 5  6 %( &P!1 "$ 3P F $X *P!, #$
M2P W $H /0!) $0 1P!, $8 5@!$ &$ 0P!P $( @0!! )< 0 "O #\ UP _
M /\ /@#_ #T _P ^ /\ E    '\   !O    8P   %D   !1    30   $H
M  !(    1P $ $< "@!&  X 1@ 1 $< %@!% !P 1  A $( )@!! "L 0  Q
M #X -P ] #X / !' #H 4  Y %L . !I #< >@ V (\ -0"G #4 Q@ T /4
M- #_ #0 _P U /\ B    '0   !E    6    $\   !(    0P   #\    ]
M    /  " #P !P [  P .P / #L $@ Z !< .0 < #< (0 V "8 -0 L #0
M,@ S #D ,0!! #  2P O %8 +@!C "T <P L (@ + "@ "L NP K .H *P#_
M "L _P L /\ ?P   &P   != 0  40(  $@#  !  P  .P(  #<    T
M,P   #( !0 R  D ,@ - #$ $  Q !, ,  8 "\ '0 M "( +  H "L +@ J
M #4 *0 ] "@ 1@ G %$ )@!> "4 ;@ D (( (P"9 ", LP B -X (@#_ ",
M_P D /\ =P   &4$  !6!@  2P<  $((   Z"   -0<  # &   M!0  + ,
M "L  P J  < *0 + "D #@ I !$ *  5 "< &0 F !X )0 D "0 *@ C #$
M(@ Y "$ 0P @ $X 'P!: !X :0 = 'P ' "3 !L K  ; ,T &P#V !L _P <
M /\ < 4  %\(  !1"@  1@L  #T+   U"P  , L  "L*   H"0  )0@  "0'
M @ C! 8 (P() "(!#  B  \ (0 2 "  %@ ? !L '@ @ !T )@ < "X &P V
M !H /P 9 $H & !7 !< 9@ 6 '@ %0"/ !4 I@ 4 ,, % #N !0 _P 5 /\
M:P@  %L+  !-#   0@T  #D-   Q#0  + T  "<-   C#   (0P  !\+ 0 >
M"@4 '0@( !T&"P <!0T ' 00 !L$%  9!!@ &00> !@$(P 7!"L %@0S !4$
M/  4!$< $P-4 !(#8P 1 W4 $ ** ! !H@ / +P #P#E  \ _@ 0 /\ 9PL
M %<-  !)#@  /@\  #4/   N#P  * \  "0.   @#@  '0X  !L- 0 9#00
M& P' !@+"0 7"0P %PD. !8)$@ 5"18 % D; !,)(0 2"2@ $@DP !$).@ 0
M"44 #PE2  X)80 -"7, # B(  L(GP *![< "@;;  H%]@ *!/\ 8PT  %,.
M  !&$   .Q$  #(1   K$0  )1   "$0   =$   &@\  !@/ 0 6#@0 %0X'
M !0-"0 3#0L $PP- !(,$  1#!0 $ P9 ! ,'P /#"< #@TO  T-.0 ,#44
M"PU1  D-8  (#7$ !@V&  4-G0 $#+0  PS2  (,\0 ""_\ 7PX  % 0  !#
M$0  .!(  "\2   H$@  (Q(  !X1   ;$0  &!$  !40 @ 4$ 4 $A ' !$/
M"0 0#PH $ X,  X.#@ .#Q( #0\7  P0'0 ,$"0 "A L  D0-@ ($$$ !A!.
M  4070 #$&\  1"$   0G   #[0   [4   .\P  #O\ 7!   $T2  ! $P
M-A0  "T4   F%   (1,  !P3   9$@  %A(  !01 P 2$08 $1$( ! 0"@ .
M$ L #1$+  P1#0 +$A$ "A(5  D2&@ ($B$ !A,I  43,P #$SX  A-+   3
M6@  $VP  !."   2FP  $K0  !'7   1]0  $?\ 6!(  $D4   ]%0  ,Q8
M "L6   D%0  'Q4  !H4   7%   %!,! !,2!  1$@< $!()  X2"0 -$@D
M"Q,*  D4#0 '%0\ !A83  06&  #%A\  A8G   7,   %SL  !=(   76
M%VH  !:    6F0  %;0  !79   4]P  $_\ 510  $86   Z%P  ,!@  "@8
M   B%P  '18  !D6   6%0  $Q0# !(3!@ 0$P< #Q,'  T4!P +%0@ "18)
M  88#  #&@X  1H1   :%@  &QP  !LD   ;+0  &S@  !M&   <50  &V<
M !M]   ;EP  &K,  !G;   8^0  %_\ 418  $,8   W&0  +AH  "8:   @
M&0  &Q@  !@7   5%@$ $Q4% !$5!  /%00 #18$  L7!0 )&08 !AH(  (<
M"@  '@T  " 0   @$P  (!D  " A   A*@  (34  "%"   A4@  (&0  "!Z
M   ?E0  '[$  ![;   =^@  '/\ 31D  #\;   T'   *QP  "0<   >&P
M&AH  !<8   4%P( $A<" ! 8 0 -&0$ "QH"  @< P %'00  A\&   A"
M(PL  "4.   F$0  )A8  "8>   G)P  )S(  "<_   F3@  )F   "9W   E
MD@  )*\  "/:   B^P  (?\ 2!T  #P>   Q'P  *!X  "(>   ='   &1L
M !8:   2&@  $!L   T<   +'0  "!\   0A   !(P(  "4$   G!@  *0D
M "P,   N#P  +A,  "X:   N(P  +BX  "X[   N2@  +5P  "UR   LC@
M*ZP  "K4   I^P  */\ 1"   #@A   N(0  )B$  " @   <'@  &!T  !0=
M   0'@  #A\   LA   '(P   R4    G    *0   "P!   N P  , 8  #,*
M   U#0  -A$  #87   V'P  -BD  #8V   V10  -5<  #5M   TB0  ,J@
M #'/   P^@  +_\ /R0  #0D   K)   )",  !\A   ;(   %B   !$A   .
M(P  "B4   8H   "*@   "T    O    ,@   #0    W    .0,  #L&   ^
M"@  0 X  $$2  !!&@  0"4  $ Q  ! 0   /U(  #YG   ]@@  /*(  #K'
M   Y^   ./\ .B@  # H   I)P  (R4  !\C   8)   $B4   XH   **@
M!2T    P    ,P   #8    X    .P   #X   !     0@   $4"  !'!@
M2@H  $T.  !-%0  3!\  $PK  !+.@  2DP  $EA  !(?   1YL  $6_  !#
M\P  0O\ -BP  "TK   G*0  (R<  !LH   4*@  #BT   HP   $,P   #<
M   Z    /0   $    !#    1@   $@   !+    30   %    !3 0  5@8
M %D+  !;$   6QD  %HE  !9-   6$8  %=:  !5=   5),  %*U  !0Z@
M3_\ ,S   "PN   G+   'BT  !8O   0,@  "C8   ,Z    /P   $(   !&
M    20   $P   !/    4@   %4   !8    6@   %T   !@    8P   &<&
M  !K#   ;!(  &L>  !K+   :3T  &=2  !F:@  9(D  &&K  !?W   7?\
M,3,  "PQ   B,@  &34  !$Y   */0   D(   !'    3    %    !4
M6    %L   !?    8@   &4   !H    :P   &X   !Q    =0   'D   !]
M!@  @@T  ((6  " )   ?C4  'Q)  ![80  >'\  ':?  !SQ@  </< ,38
M "8X   <.P  $D    M%   "2P   %$   !6    6P   &    !E    :0
M &X   !R    =@   'D   !\    ?@   ((   "%    B0   (X   "3
MF 8  )P.  ";&@  F"L  )9   "260  D7,  (V5  "+M0  B.@ *SX  "!!
M   51P  #4T   )4    6P   &$   !H    ;@   ',   !Y    ?@   (,
M  "(    C    (\   "2    E0   )D   "=    H0   *4   "J    L
M +<'  "X$0  M2$  +(U  "O30  JFD  *B(  "FJ   HM$ (T@  !A.   .
M5   !%P   !D    ;0   '4   !\    @P   (D   "/    E0   )L   "@
M    HP   *8   "I    K0   +$   "U    N0   +X   #$    R@   -(
M  #:"@  UA8  -(I  #.00  REP  ,5\  #"G0  P;T '%4  !%<   '90
M &X   !W    ?P   (@   "0    F    )\   "E    K0   +,   "X
MN@   +X   #"    Q@   ,H   #.    TP   -H   #@    YP   .T   #S
M    ] X  /(>  #O-@  [%$  .AN  #DD   W[$
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M[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$      P0A   !
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M/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/KW%!0"PUP4
MH_\0 YG_(@F+_RD/?O\P%7/_.!II_T ?8O])(UO_4297_UHH5?]B*E+_:2M1
M_V\L4/]S+4__=RY._WHN3O]]+TW_@"],_X0P2_^(,$O_BS!+_XLP2_^+,$O_
MBS!+_XLP2_^+,$O_BS!+_XLP2_^+,$O_BS!+_XLP2_^+,/^+' 3_B"@(_X0T
M#O^/.A3_ET(<_YY+)_^>5S3_G6)"_YEM3_^3>%SXC8)G\HB+<>R"DWGH?)F
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M+4/_FBU#_YHM0_^:+4/_FBU#_YHM0_^:+4/_FBU#_YHM0_^:+;'" 0"CT@
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M<<N;I'/0DZ)TU(ZB=-2.HG34CJ)TU(ZB=-2.HG34CJ)TU(ZB=-2.HG34CO^
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M4$__PU%/_\-13__#44__PU%/_\-13__#44__PU%/_\-13__#4=JO @#&O 4
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M6?%?Y5GQ7^59\5_E6?%?Y5GQ7_]P'@/_;"D&_VDS"?]R-PW_>3X2_WU'&?^
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MB(V1FH65EI:"GIJ2@*>=CW^SGHV PIZ+@,R:BX'2DHJ V(F)@-N&B8#;AHF
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M>$_6Y75/T^=T3]/G=$_3YW1/T^=T3]/G=$_3YW1/T^=T3]/G=/^/#P'_I X
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ML4,<Y;1+*=JO53K-J%Y*PJ!F6+F:;62QDW5NJHY\=J.*@WV>AHN"F8*3AY2
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M7$KC\UQ*X_-<2N/S7$KC\UQ*X_-<2N/S7/F9 P#4K ( Q;<$ +G#!0"PT@@
MI_81 9[U) :5]3(.BO4Z%X'U02!X]4@G</50+FKT6C1E]&,X8/1K/%WU=#]9
M]7Q"5_6$1%3UC491]I=(3_:A2DWVK$M+][E,2O?(34GXX$U(]_--2/?T34CW
M]$U(]_1-2/?T34CW]$U(]_1-2/?T3=JC  #'L0( N+L# *W)! "CV0< FOT4
M I+])P>'_B\-??XW%'3_/QML_T<@9O].)6#_5RE<_V M6?]I,%;_<3)3_W@T
M4?^ -D__B3=-_Y(Y2_^<.DG_ICM(_[$\1O^]/47_S#U$_^8^1/_G/D3_YSY$
M_^<^1/_G/D3_YSY$_^<^1/_G/LNL  "YM@$ K,(! *#0 @"5Y0< CO\8 X3_
M) 9Z_RP+</\T$&C_/!5A_T096_]+'5;_4R!3_ULB4/]C)$W_:R9+_W,G2?]Z
M*4C_@BI&_XHK1/^4+$+_GBU!_Z<N0/^Q+C__O"\^_\TP/O_-,#[_S3 ^_\TP
M/O_-,#[_S3 ^_\TP/O_-,+NQ  "LO   G\D  )/9  ")_ L!@/\7 G;_( 5L
M_R@)9/\P#5W_.!!7_T 34?]'%DW_3AA*_U891_]<&D3_8QQ"_VD=0/]P'C__
M>!X]_X ?._^((#K_D2$X_YLB-_^D(C;_K2,U_[@C-?^Y(S7_N2,U_[DC-?^Y
M(S7_N2,U_[DC-?^Y(ZVV  "?Q   DM(  (3A  !]_PT!<O\3 FC_&P1?_R,&
M6/\K"5'_,PM,_SH-1_]!#T/_2!% _TX2/?]4$SO_6A0Y_U\4-_]E%37_:Q8S
M_W(6,?]Z%R__@A<N_XL8+/^3&"O_G!DJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_
MIQDJ_Z<9*O^G&:&_  "2S   A-P  'CW  !N_PH!8_\0 EK_%0-2_QT$2_\D
M!D;_+ A!_S,)//\Z"CG_0 LU_T4,,O]*#3#_4 TN_U0.+/]9#BK_7@\H_V0/
M)O]J#R7_<1 C_W@0(O^ $2#_B!$?_Y$1'_^1$1__D1$?_Y$1'_^1$1__D1$?
M_Y$1'_^1$?]<(@/_5RT%_U@S!_]?-@G_8ST-_V5&$O]F4!?_95X<_V1N(O]A
M?"?_7XHK_UZ6+O]<H3'_6ZHS_UJR-?]9NC;_6,,W_UC-.?]7V#G_5N Z_U7F
M._]4[#S_4_$\_%+U/?A2^3WU4?T]\U'_/?-1_SWS4?\]\U'_/?-1_SWS4?\]
M\U'_/?]<(@/_5RP%_UHR!_]A-0G_93P-_V=%$O]H3Q?_:%P=_V9M(O]C>RC_
M88@L_U^4+_]>GS+_7:DU_UNQ-_]:N3C_6L$Z_UG+._]8U3S_5]\]_U;F/O]5
MZS[]5/ _^5/U/_92^4#S4OU \%+_/O!2_S[P4O\^\%+_/O!2_S[P4O\^\%+_
M/O]=(0/_6"P%_UPP!_]D,PG_:#H-_VM#$O]L3A?_;%H=_VIJ)/]G>"G_9(4N
M_V*1,O]AG#;_7Z8X_UZN.O]=MCS_7+X^_UO(/_]:TD'_6=U"_U?E0_U6ZD3Y
M5?!$]53U1?%4^D7N5/Y$[%3_0NQ4_T+L5/]"[%3_0NQ4_T+L5/]"[%3_0O]>
M(0/_62P%_U\N!O]F,@G_;#@,_V]!$?]O3!?_<5<>_VYG)?]K=2O_:((P_V6.
M-?]DF3G_8J,\_V"K/O]?LT'_7KM"_UW$1/]<SD;_6MQ'_EGD2/I7ZDGU5O!*
M\%7V2NU5^DKI5OY'YU;_1>=6_T7G5O]%YU;_1>=6_T7G5O]%YU;_1?]>(0/_
M62L%_V(M!O]J, C_;S8,_W) $?]T2AC_=54>_W)D)O]O<BW_;'\S_VF+./]F
MECS_9:! _V.H0_]AL$;_8+A(_U[!2O]=RTO_7-I-^EKC3O59ZD_P5_%0ZU;V
M4>=7^T[D6/]+X5G_2>%9_TGA6?])X5G_2>%9_TGA6?])X5G_2?]?( /_6BL%
M_V4K!O]M+@C_<S4,_W<^$?]X2!?_>5(?_W=@)_]T;B[_<'LU_VV'._]JDD'_
M9YM%_V6D2?YCK$S]8;1.^V"\4?I>QE/Y7=15]5OC5N]:ZECI6/)9Y5GW5N!:
M^U/;6_]/UUO_3==;_TW76_]-UUO_3==;_TW76_]-UUO_3?]@( /_72D%_V@I
M!O]Q*P?_>#,+_WP\$/]]1A?_?E ?_WU=*/]Y:C#_=78X_W&"/_QMC47Z:I=+
M^&>?3_9EIU/T8J]6\V"X6?%?P5SP7<U>[5S@8.A:[&'A6O)@VEOV6]-<^E?/
M7?U3S%[_4<Q>_U',7O]1S%[_4<Q>_U',7O]1S%[_4?]A'P/_8"<$_VLF!?]U
M*0?_?#$*_X$Z$/^#1!?_A$T?_X-9*/]_9C+\>G([^'5^0_5QB$OR;9)1[VF:
M5NUFHEOJ8ZI?Z&"R8^9>O&;D7,AIX5O::]U:ZFO37/!FS5[U8<A?^5S$8/Q8
MP6'^5<%A_E7!8?Y5P6'^5<%A_E7!8?Y5P6'^5?]B'P/_8R4$_V\D!?]Y* ;_
M@3 *_X4Y#_^(0A;_B4L>_XE6*/J%8C/U@&X]\'IY1^QU@U#I<(Q8Y6N57N%F
MG63>8Z1IVV"M;==?MV_47L-PT5[2<<U=YW''7^YKPF'R9KYB]F&Z8_E<MV/\
M6+=C_%BW8_Q8MV/\6+=C_%BW8_Q8MV/\6/]C'P/_9B,$_W(B!/]])P;_A2X)
M_XHW#O^-0!7_CTD>^H]3*/2,7S3NAFH_Z7]T2^-X?E7><H9>V&V/9=-JF&K/
M9Z!MS&6H<,ECL7/&8KQTQ&')=<%AX':\8^IQMV3O:K1E\V6P9O9@KF?Y7*YG
M^5RN9_E<KF?Y7*YG^5RN9_E<KF?Y7/]C'@/_:"$$_W4@!/^!)07_B2T(_X\U
M#/^2/A3\E$<=]99/*.Z16S3GBV9!X(1O3ME]>5C1=X)@S'.*9\=ODVS$;)MP
MP&FC<[UGK':Z9K9XN&7">;9EU7FR9N9VKFCL;ZII\&FH:?1CIFKW7Z9J]U^F
M:O=?IFKW7Z9J]U^F:O=?IFKW7_]D'@/_:R #_W@>!/^$) 7_C2P'_Y,T"_^7
M/!+XF44;\)M-)^B7633AD&)"UXEL3LZ#=5C(?7YAPWB&:+YTCFVY<)9RMFZ>
M=;)LIWBO:K%[K6F]?*IIS7VH:N-ZI6SI<J)L[6R@;?)FGF[U8IYN]6*>;O5B
MGF[U8IYN]6*>;O5BGF[U8O]E'0+_;1X#_WL= _^'(P3_D"H&_Y<R"OV<.Q#T
MGT,9[*%+)>.<5C/:EF!!SXYI3L>(<EC @GIANGV":+5YBFZQ=9)SK'*:=ZEP
MHWJF;JQ]HVVX?J%MQW^?;N!^G'#G=9IPZV^9<?!HEW'S9)=Q\V27<?-DEW'S
M9)=Q\V27<?-DEW'S9/]E'0+_;QT#_WX< _^*(@3_DRD%_YLQ"?F@.0_PHT$8
MYZ9)(]ZA5#'2FEY R)-G3<",;UBYAW=ALX)_:*Y]AVZI>HYSI'>6>*!TGWN=
M<ZA^FG&T@)AQPH&6<MB!E73E>)-TZG&2=>]KD77R9I%U\F:1=?)FD77R9I%U
M\F:1=?)FD77R9O]F'0+_<1L#_X ; _^,(0/_EB@%_YXO"/:D-PWLJ#\5XZM(
M(-BF4C#,GEQ PY=E3;N1;5>SBW1AK89\:*>"@VZB?HMTG7N3>)EYG'R5=Z5_
MDG:P@9!UOH*.=M&"CGCC>HUXZ'.,>.ULBWCQ:(MX\6B+>/%HBWCQ:(MX\6B+
M>/%HBWCQ:/]G' +_<QH"_X(: O^/( /_F28$_J(N!O.H-0OIK3T3WZ]&'M*I
M42_'HEH_OIMC3+65:E>NCW)@IXMY:*&'@6Z<@XATEX"0>))]F7R.?** BWJM
M@HAZNX.'>LV#AWSB?(=\YW6&?.QNAGSP:89\\&F&?/!IAGSP:89\\&F&?/!I
MAGSP:?]G' +_=1D"_X49 O^2'P+_G"4#^Z4L!?"L- GFLCL0V[-$'<VM3R[#
MIED^N9]A2["9:%:HE'!?H8]W9YN+?FZ6B(9SD(6.>(R"EGR(@*" A'^K@H%_
MN(-_?\J$@8'A?8&!YG:!@.MO@(#O:H" [VJ @.]J@(#O:H" [VJ @.]J@(#O
M:O]H' +_>!<"_X<8 O^4'0+_GR,#^*DJ!.RQ,0?BMSD-U;="',FP3BV^JE<]
MM*-?2JN>9U6CF&Y?G)1U9I:0?&V0C8-SBXJ+>(:(E'R!AIZ ?82H@GN$M81Y
MA,>$>H;@?WN%YG=[A>MP>X3N:WN$[FM[A.YK>X3N:WN$[FM[A.YK>X3N:_]I
M&P+_>A8"_XH7 O^7' +_HR$"]*TG ^BU+@7>O34*T+I &\2T3"RZKE8[KZA>
M2::B952>G6Q=EYES9I"5>6R*DH%RA9")=W^-DGQ[BYM_=XJF@G2)LX-RBL2#
M=(S@?W2+Y7AUB>IQ=HCM;':([6QVB.UL=HCM;':([6QVB.UL=HCM;/]K&@+_
M?10"_XT6 ?^:&@'_IAX!\+$C N2[*0/9PC )R[T_&<"X2BJULE0ZJJQ<1Z&G
M8U*9HVI<D9]Q9(J;=VN$F']Q?I:&=GF3CWMTDIE^<)"D@6V0L8)KD,&";9+=
M?VZ1Y7AOC^IQ<([M;'".[6QPCNUL<([M;'".[6QPCNUL<([M;/]N& +_@!(!
M_Y 5 ?^>%P'[JQH![+<> >##(0'2QBT(QL$]&+J\22BOMU(XI;):19RM85&3
MJ6A:BZ5O8H2B=6E^GWQO>)V$='.;C7ENF99\:IBB?V>7KH!EF+^!99G8?VB8
MY7AIENIQ:I3M;&J4[6QJE.UL:I3M;&J4[6QJE.UL:I3M;/]Q%@+_@Q$!_Y03
M ?^B% #UL!0 YKX4 -G,%0#,RBL'P,8[%K7!1R:JO%$VG[A80Y:S8$Z-L&98
MA:QM8'ZJ<V=WIWIL<J6"<FRCBW9HHI1Y9*&@?&"@K7U?H;U^7J+4?6&AYG9B
MG>MP8YON;&.;[FQCF^YL8YON;&.;[FQCF^YL8YON;/]T$P'_AQ !_Y@0 /ZG
M$ #GMPT UL4+ -#0$0#%SR@%N<LY%*['12.CPT\SF;]70(^[7DN&N&14?K5K
M7'>R<6-QL'AI:ZZ ;6:MB7)AJY-U7:N>>%NJK'E9J[QY6*S2>5JKZ'-<I^QN
M7:3O:EVD[VI=I.]J7:3O:EVD[VI=I.]J7:3O:O]Y$0'_C X _YX- -RN" #2
MNPD S,@) ,?6#@"]U24$LM(V$:?.0B"<RDPODL=4/(C#7$=_P6)0=[YI5W"\
M<%YJNW=C9;E_:&"XB&Q<MY)O6+:><56VJW-3M[MS4K?2<U2WZV]6LN]J5Z_Q
M9U>O\6=7K_%G5Z_Q9U>O\6=7K_%G5Z_Q9_]_#@'_DPL X:4% -*S!P#)O@<
MPLL( +S=#@"TW2,#JMHS#9_60!R4TTHJBM!2-X#-6D%XRV%*<,EH46K(;U=D
MQG9<7\5_8%K%B&16Q))G4\2>:5#$K&I/Q+QK3L73:D_%[6A0P/-D4;WU85&]
M]6%1O?5A4;WU85&]]6%1O?5A4;WU8?^&"@#PF@0 U*H$ ,BV!@"^P04 M\\)
M +#C$0"HXR4$G^(U#97@/AF+WD@E@=Q0,'C:6#IPV%]":=9G26/5;D]>U'93
M6=-_5U73B5I2TY-=3].@7TW3K6!+U+Y@2M788$O4[5Y,T?=<3,SY6DS,^5I,
MS/E:3,SY6DS,^5I,S/E:3,SY6O^/ P#:H@  RJ\# +VY! "TQ@4 J]0) *3J
M% &<Z2@&D^DT#HGH/1A_YT0B=^9.*F_F5S)IY5\X8^5G/5_D;T):Y'=%5N2
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M8&B2]U]HDO=?:)+W7VB2]U]HDO=?:)+W7_]O$0'_@0X _Y$. /*@# #:K0D
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M55"Z_E50NOY54+K^5?^% @#=F   S:8" ,&Q P"WN@, KL8& *?3"@"@W14
MF=TH!)#;-PZ&V4(9?=9+)'745"UMTEPU9]%C/&'0:T%<SW)&6,][253.A$U0
MSH]03<Z;4DO.J5-)SKE42,_/5$C.ZU-)SOA02LO_3DK*_TU*RO]-2LK_34K*
M_TU*RO]-2LK_3>>/  #1GP  PZL! +>T @"MOP, H\L& )O9"@"4Y1H!C>4K
M!H3D-0U[XS\6<^)('FSA4B9FX5HL8.!B,EO@:C97X'(Z4]][/5#?A4!-WX]#
M2N";14C@J$9&X+A'1>',1T7@Z$=%W_9&1=[_1$7>_T1%WO]$1=[_1$7>_T1%
MWO]$1=[_1-F7  #'I@  N+   *RY 0"BQ0( F-$& (_K#0")[A\"@.XK!GCM
M- QP[3T3:.U&&6+M3AY=[5<C6>U@)U7M:"I2[7$M3^UY+TSM@S)*[HTT1^Z8
M-47NI3=#[[,X0O#$.$'PWSE![^\X0.W].$#L_SA [/\X0.S_.$#L_SA [/\X
M0.S_.,N@  "ZJP  K;0  *'   "6S $ B]D% (3X$0%\^!\"=/@I!FSX,@ID
M^#L/7OE#$UCY2Q=3^5,:4/E;'4WZ9!]*^FPA2/IT(T;Z?B5$^X@F0?N3*$#[
MGBD^_*LJ/?RY*SO]RRL[_>(K.OST*SK\]RLZ_/<K.OSW*SK\]RLZ_/<K.OSW
M*[VH  "NL   H;P  )7(  ")U   ?N@% '?_$@%O_QP"9_\F!6#_+PA9_S<+
M5/\_#D__1Q%+_TX31_]6%43_719"_V080/]L&3W_=1H[_WX;.?^)'#?_E!TV
M_Z >-?^L'S/_N1\S_\@?,O_B(#+_YR R_^<@,O_G(#+_YR R_^<@,O_G(+"M
M  "BMP  E<0  (?0  ![W0  <OT) &K_$0%A_QD"6O\B U3_*@5._S('2?\Z
M"47_00M!_T@,/O].#CO_50\X_UL0-O]B$33_:1$R_W(2+_][$RW_AA0K_Y(5
M*O^>%2G_J18H_[,6)__"%B?_QQ8G_\<6)__'%B?_QQ8G_\<6)__'%J2T  "6
MP   A\P  'K:  !MZP  9/\% %S_#@%4_Q0!3?\< DC_) 1"_RP%/O\S!CK_
M.0<V_T (,_]%"##_2PDN_U$**_]7"BG_70LG_V0+)/]L#"+_=@T@_X -'O^,
M#AW_EPX<_Z$.&_^L#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/&_^N#Y>\  "(R0
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M5GF!_U%Y@?]1>8'_47F!_U%Y@?]1>8'_4?]E$P'_=0X _X,. /^0#@#UFPX
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M4F&8_U)AF/]289C_4O]R"P#_@P4 WY,! -&?! #)J@8 P;(% +N]! "TOQ@
MJ[XL!:*[.A&9N$4=D+5/*(>R5S* KUXZ>:UE0G.K;$ANJ7--::=Z462F@U9?
MI(U97*.87%BCI%Y6H[-?5:/&7U6DY%U8I/986J/_5%NA_U!;H?]06Z'_4%NA
M_U!;H?]06Z'_4/]W!P#PB0  UI@  ,ND P#!K00 N;8# ++ ! "KQ10 H\4H
M!)O"-PZ1P$,9B;U,)("Z52YYN%PV<K9C/6VT:D-GLW%(8K%Y3%ZP@5!:KXM4
M5J^75E.NHUA0KK)93Z[&64^NY%A1KO944Z[_4%2L_TU4K/]-5*S_352L_TU4
MK/]-5*S_3?]]  #?CP  SIT  ,.H @"YL ( L+H" *C$!0"AS \ F\PC I+*
M,PJ)R#\5@<9)'WG$4BARPEHP:\%A-V:_:#QAOG!!7+UX15B\@4E4O(M,4;N6
M3TZ[HU%,N[-22KO&4DJ[Y%%,N_9.3;K_2TZY_TE.N?])3KG_24ZY_TE.N?])
M3KG_2>^%  #4E0  QZ,  +JL 0"PM   I[\# )[)!@"5U L D-4= 8G4+@:
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M(C?YR"(V^>,B-OCS(C;W_"(V]_PB-O?\(C;W_"(V]_PB-O?\(K>F  "IK@
MG+D  )#$  "#SP  =]L  &_V"@!G_Q,!8/\= EK_)P-4_S %3_\X"$K_0 I&
M_T@,0_]/#D#_5@\]_UX0._]E$CC_;A,V_W<4-/^"%3+_CQ8P_YL7+_^I%R[_
MMQ@M_\@8+/_A&"S_[Q@L_^\8+/_O&"S_[Q@L_^\8+/_O&*NK  ">M0  D,$
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M_QG_/?\9_SW_&?\]_QG_/?\9_SW_&?] *@+_02X#_T<N _]*,03_3#<&_TM
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M28ET_T2(=/]#B'3_0XAT_T.(=/]#B'3_0_]=$@'_:PX _W@. /^##P#]C!
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M1W*$_T=RA/]'<H3_1_]F#0#_=0< ]H,% -R/ P#2F 8 S*$' ,BH" "_J1H
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M/$/%WSQ$Q/,[1,/_.47"_S=%P?\W1<'_-T7!_S=%P?\W1<'_-]6+  #%F@
MMZ0  *NL  "@M   EKX  (O'! "!T @ >-D. '79( %OV"\$:=@\"6/61A!>
MUE 56=58&E748!]1U&@B3M1Q)DO3>RE(TX4K1=.2+D+4GR]!U*\P/]7",3_5
MX3 _T_(P/]+]+S_1_RX_T/\N/]#_+C_0_RX_T/\N/]#_+LJ4  "[H0  K:D
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M$2;_\A$F__81)O_V$2;_]A$F__81)O_V$:>I  "9LP  B[X  '[)  !PTP
M9-X  %CG  !2_PD 3?\1 $?_&0%#_R(!/O\J CK_,@,W_SD#,_\_!##_1@4M
M_TT%*_]4!BC_6P<F_V,'(_]M""'_>0D?_X<)'O^5"AW_HPH<_[$*&__ "QK_
MU@L:_]\+&O_?"QK_WPL:_]\+&O_?"YNQ  "-O   ?L<  '#2  !CW@  5>0
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M.9ME_S:;9?\SFV7_,YME_S.;9?\SFV7_,_]5$P'_8 X _VL. /]T$ #_>Q(
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M.H!U_SJ =?\Z@'7_.O]=#@#_:@8 _W8& .2  P#9B08 TH\( ,^4"@#%EAL
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M1U";T4=1F^Y$4YO\0%6;_SQ6F_\Z5IO_.E:;_SI6F_\Z5IO_.O%T  #9@P
MR)   +Z:  "SH0  JJ<  *&N  "7M08 DK88 (RU*@.%M#<)?K)"$7>P3!AQ
MKE0?;*U;)6>K8BIBJFDO7JEQ,UJH>C=6IX,Z4Z:./5"FFT!-I:E!2Z6Z0DNF
MT4)+I>T_3:7\/$ZD_SE/I/\W3Z3_-T^D_S=/I/\W3Z3_-^1Z  #/B0  PI4
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M)3O+_R4[RO\E.\K_)3O*_R4[RO\E.\K_)<.3  "UG@  J*8  )VN  "1M@
MA;\  'G'  !OS@0 9-8) %[>$0!;WB  5]XM E/?.@10WT0&3-]."4G?5PQ&
MWU\/0]]H$4'?<1,^WWP5/-^)%SK@EADXX*4:-^"W&C;AS1HVW^P:-=[Y&C3=
M_QLTW/\;--S_&S3<_QLTW/\;--S_&[F<  "JI   GJL  )*U  "%O@  ><<
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M!A/_Z083_^D&$__I!I>O  "(N@  >L4  &S/  !>V@  4.   $3F   \]0
M-_\$ #/_#0 O_Q, *_\: "C_(0 E_R<!(?\M 1[_,@$;_S@!&?\_ 1;_1@(4
M_TT"$?]6 A#_8 (._VP"#/][ PO_BP,*_YH#"O^H PG_M0,(_\(#"/_" PC_
MP@,(_\(#"/_" XJX  ![PP  ;,X  %[;  !/X@  0N<  #;L   Q_P  +/\
M "?_!P C_PX (/\2 !S_&  8_QT %?\A !+_)@ 0_RP!#O\Q 0W_-P$*_SX!
M"/]& 07_3P$!_UD! /]F 0#_= $ _X(" /^0 @#_G ( _Z8" /^F @#_I@(
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M0XP7]$*4&/-!G!GQ0:,;[T"J&^Y LASM/[L=ZS_&'ND_U1[E/^@?XD#T'M]
M_AW=0?\;VT+_&ME"_QC80O\7V$+_%]A"_Q?80O\7V$+_%_] 'P'_2!H!_TX8
M ?]2&P'_5B,"_U@L _]7-P3_54('_U)-"_E06@[U36<2\4QR%NY*?1CK2(8;
MZ4>/'>=&EQ_E19X@XT2F(N%$KB/@0[<DWD/")=Q#T";70^4FTT3S)-!%_B+-
M1O\@S$?_'LI'_QS)2/\;R4C_&\E(_QO)2/\;R4C_&_]$&P'_3!8!_U(4 ?]8
M& '_71\!_U\H O]>,@/]73T&]EI)"O!750_J56(3YE)M&.)0=QS?3H$?W$R*
M(ME+DB352IHFTTFA*-%)J2G/2+(JS4B\*\M(R2S(2-\LQ4CO*\)*_"C 2_\E
MOTS_(KY-_R"]3?\?O4W_'KU-_QZ]3?\>O4W_'O]'& '_3Q,!_U81 /]>%0#_
M8AP!_V4D ?YE+0+T9#@%[6%#">9?40[@7%T4VEAH&M16<A[05'LBS%*$)LI0
MC"C'3Y0JQ4Z;+,-.HR[!3:POOTRV,+U,PC&[3-,RN$SI,;9.^"VT4/\JLU'_
M)[-2_R2R4O\BLE+_(K)2_R*R4O\BLE+_(O]*%0'_4Q$ _UL/ /]B$@#_:!<
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M+(YE_RR.9?\LCF7_+/]5#@#_7P8 _VD& /1R!@#B> 8 VWP) -E_# #-@1T
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M1%]^ST1@?^Q 8H#\.F2 _S9E@?\S9H'_,F:!_S)F@?\R9H'_,O]D  #E<@
MTWX  ,>'  "^CP  MI4  *Z9  "FFPP H)P> )F;+@22F3L*BY9&$H643QE_
MD5<?>H]>)76.92IQC&PN;8IS,FF)>S9FB(0Y8H://5^%FC]<A:A!6H6W0EF%
MS$):A>H_7(;[.EZ&_S9?A_\R7X?_,E^'_S)?A_\R7X?_,OUH  #@=@  S8(
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M,DJ?_S!+G_\N2Y__+4N?_RU+G_\M2Y__+=UY  #)A@  O)(  +&:  "FH
MG*8  )&L  "&L@  ?;8- 'FV'0!UMBP";[4Y!FJT0PMELTP18+)4%ERQ6QI8
ML&,>5:]K(5&O<R5.KGTH2ZV(*DBME2U%K:,N1*VS+T.MR"]"K.<O0ZOY+42K
M_RM$JO\I1*K_*42J_RE$JO\I1*K_*=&   #!C0  M9@  *F?  ">I0  DZP
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M$R_4_Q,OU/\3+]3_$[.:  "FH0  FJD  (VQ  " N@  =,$  &C)  !<SP
M4M4# $C<" !%Y1( 0^4> $'F*@ ^YC4!.^<^ 3GG1P(WYU #-.A9!#+H8@4P
MZ&T&+NEY!RSIAP@KZI8)*>JG"BCJN@HGZ]8*)^GP"B?G_0DFYO\*)N;_"B;F
M_PHFYO\*)N;_"JB@  "<IP  C[   (*Y  !TP@  :,H  %O1  !/UP  1=T
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M 8:W  !WP0  :,P  %K7  !+W@  /N0  #+I   G[0  (_\  !__   ;_P4
M%_\, !3_$  1_Q0 #_\8  W_'0 +_R( "/\H  7_+@ "_S4  /\]  #_1P
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M+O\+[B[_"^TN_POL+O\*["[_"NPN_PKL+O\*["[_"O\U(@'_.QX!_S\= ?]
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M':)2_QVB4O\=HE+_'?]*#P#_4@H _UH) /]@"P#_90X ]6<1 .AH& #=9R0
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M.FUJSCIM:^LW;VW\,7!N_RUQ;O\J<6__*'%O_RAQ;_\H<6__*/]9  #K90
MVW   ,UX  #$?@  O((! +:$ 0"NA0X IX8@ *"%, .:@CT(DX!(#XY]416)
M>UD:A'E@'X!W9R-\=6XG>71U*G9S?2YS<H8Q<'&0-&UPG#=J;Z@Y:&^W.F=O
MRSIG<.DW:7'Z,FMR_RUL<_\J;'/_*&QS_RAL<_\H;'/_*/]<  #G:   U7,
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M,5F!_RU;@O\J6X+_*5N"_RE;@O\I6X+_*>QF  #8<P  QWX  +R'  "SC@
MJ9(  *"5  "6F $ D)D3 (J9) &%F#($?Y8^"7F42 YTDU 4;Y%7&6N07AUH
MCF4A9(UM)6",=2A=BWXK6HJ(+E>)E#%4B:$S4HBP-%&(PS50B.(T4HCV,%.(
M_RQ4B/\I58C_*%6(_RA5B/\H58C_*.9K  #0>   PH,  +>,  "MD@  HY8
M )J:  ".G@  AY\0 (.?( !^GR\">)T[!W.<10QNFTT1:9E5%F687!IAEV,>
M7I9J(5N5<B57E'PH5).&*U&2DBY.DJ P3)*O,4N2PC%*D> Q3)'U+4V1_RI.
MD/\H3I#_)DZ0_R9.D/\F3I#_)MYP  #)?0  O(D  +*2  "GEP  G9L  ).?
M  "&I   ?J8, 'JF&P!UIBH!<*8W!&RE00EGHTH-8Z)2$E^A619;H6$96*!H
M'52?<"!1GGHC3IV$)DN=D2E(G)XJ1IRN+$6<P2Q%G-\K19OT*4::_R='FO\E
M1YK_)$>:_R1'FO\D1YK_)-1W  #"A   MH\  *N6  "AG   EJ   (NE  !_
MJ@  =*X% &^O% !LKR0 :*\R F2N/05?K48)6ZQ/#5BL5A%4JUX44:IF%TZJ
M;AI+J7@=2*F#($6HCR)#J)TD0:BM)4"HP"4_J-\E/Z;T(T"E_R) I?\A0*3_
M($"D_R! I/\@0*3_(,I^  "[BP  KY4  *2;  "9H0  CJ8  (*L  !WL0
M:K8  &.X#@!AN!T 7K@L 5JX. )7N$(%4[A+"%"W4PM-MUL.2K9C$$>V:Q-$
MM7460K6!&#^UCAH]M9P<.[6L'#JUP!TYM=\<.;/T'#FR_QPYL?\;.;#_&SFP
M_QLYL/\;.;#_&\&&  "TDP  IYH  )R@  "1IP  A:T  'FS  !MN   8KT!
M %;"!P!3PQ0 4L,C %#$, %-Q#L"2L1% T?$3@5%Q%<'0L-?"4##: L]PW(-
M.\-^#SC#C!$VPYL2-<.K$S/#P!,SP^ 3,\'U$S+ _Q0RO_\4,;[_%#&^_Q0Q
MOO\4,;[_%+B0  "KF0  GZ   ).G  "'K@  >[0  &Z[  !CP   6,4! $W*
M!0!$SPP 0] 7 $+0)0! T#( /]$] 3W11P$[T5 ".=)9 S;28P0TTFX%,M)Z
M!S#2B @NTI@)+=.I"2S3O@HLT]\)*]'S"BK/_@LISO\,*<W_#2G-_PTIS?\-
M*<W_#:Z8  "BGP  EJ8  (FN  !\M@  ;[T  &/#  !7R   3,T  $+2 P Y
MV0D -=\0 #3?&P RX"< ,>$R ##A/0 NXD< +>)0 2OB6@$JXV4"*.-Q B;D
M?P,EY(\#(^6A!"+EM 0AY<T$(.3L!"#B^P0?X?\%'^#_!1_@_P4?X/\%'^#_
M!:2>  "8I0  BZX  'VV  !PO@  8\8  %;+  !+T   0-4  #;<   OY0<
M+>T0 "ON&  I[B( )^\K "7O-  C\#P (?!% !_Q3@ =\E@!&_)D 1GS<0$8
M\X$!%_22 A7TI0(4];H"$_76 A/T[P(2\OP"$O#_ A+P_P(2\/\"$O#_ IJD
M  "-K0  ?[8  '&_  !CQP  5LX  $G3   ]V@  ,]\  "KC   F] 4 )/L-
M "'\$P >_1L '/TB !G^*0 7_C$ %?\Y !/_00 1_TH $/]5  [_80 ,_V\!
M#/^  0K_DP$)_Z8!"/^Z 0?_U $'_^L!!O_V 0;_]@$&__8!!O_V 8^L  "
MM@  <K\  &/)  !6T0  2-@  #O=   PX@  )N8  !_P   <_P  &?\) !;_
M#@ 4_Q, $?\9  __'@ -_R0 "_\K  G_,@ &_SL  _]$  #_3P  _UP  /]K
M  #_?0  _Y   /^C  #_M   _\8  /_6  #_U@  _]8  /_6 (*U  !SOP
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M+/\(W2S_"-TL_PC=+/\(W2S_"/\U&@#_.A8 _ST4 /\_%P#_01\ _T$I ?]
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M+7Q:SRY[6^PK?%S\)GQ=_R)]7O\??5[_'7U>_QU]7O\=?5[_'?]0  #U60
MX6,  -)J  #);@  PG ! +UP P"V<!  KG$B *AP,@*A;C\&G&Q*"Y=J4Q"2
M:%L4CF9B&(ME:1N(8W >A6)X(8)A@"2 8(DF?5^2*7M>G2MX7JDM=EZX+G5>
MS"]T7NDM=6#Z)W9A_R-W8O\@=V+_'G=B_QYW8O\>=V+_'O]2  #L7   W&8
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M*F9M_R9F;?\C9V[_(&=N_R!G;O\@9V[_(/99  #@90  SF\  ,)V  "Y?
ML7\  *F   "@@ < F8$7 )2!* &.@#4#B'Y!"(-\2@U^>E(1>GA9%79W8!ES
M=F<<<'1N'VUS=B-J<G\F9W&)*61QE2MB<*$M8'"P+UYPPB]=<-\O7W'U*F!Q
M_R9A<O\C8G+_(&)R_R!B<O\@8G+_(.]<  #<:0  RG(  +YZ  "U@   K80
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M'U"#_Q]0@_\?4(/_']YI  #)=0  O(   +*(  "HC0  G9$  ).3  "%E@
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M%+N%  "OD   HY<  )B=  ",HP  @*@  '2M  !HL@  7+8  %"Z 0!)O T
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M 1K?K $9W\0!&-[G 1C<^ $8V_\"%]K_ A?:_P(7VO\"%]K_ J"<  "4HP
MAZL  'FS  !LN@  7\$  %+&  !&R@  .\X  #'3   IV0  (=X% ![H#@ =
MZ!4 &^D> !GI)P 8ZC  %NHY !7K0P 4[$X $NQ: !'M9P 0[G< $.Z*  [O
MG@ .\+, #?#-  SO[  ,[?P #.O_  SK_P ,Z_\ #.O_ )>C  ")JP  >[0
M &V\  !?Q   4LH  $7.   YTP  +]@  "7=   =X0  &.P" !;W"P 4]Q$
M$?@7 !#X'@ .^24 #?DM  OZ-0 )^S\ !_M*  3\5P #_68  OYW  #]BP
M_9\  /RU  #\T0  _.T  /S\  #\_0  _/T  /S] (NK  !]M   ;KT  &#&
M  !2S0  1-(  #?8   LW0  (N$  !GE   3Z@  $/H   [_!@ -_PP "O\0
M  ?_%  $_QH  ?\@  #_)P  _S   /\Z  #_10  _U,  /]B  #_=0  _XH
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M'9)(V!V02>\;CTK^&(]+_Q:.2_\4CDS_$HY,_Q*.3/\2CDS_$O]%  #_2P
MZ5,  -Y8  #36P  S5L$ ,I8!P#"6!4 NEHG +-:-P&N6$0$J5=/!Z156 JA
M5& -GE-H$)M1;Q.84'85EE!^%Y1/AAF23HX:CTZ8'(U-HAV+3:X?BDV\((A-
MT""'3>L?AD_\&X90_QB&4/\6AE#_%(91_Q2&4?\4AE'_%/]'  #X3P  Y%<
M -5=  #,8   Q6 " ,%>!0"Z71$ LU\C *Q?,P&F7D #H5Q+!YU:5 J965P.
MEEAD$9-6:Q.057(6CE1Z&(M4@AJ)4XH<AU*4'H52GA^#4:HA@5&X(G]1RR)^
M4N<A?E/Y'7Y4_QI^5?\7?E7_%GY5_Q5^5?\5?E7_%?]*  #N4@  WEL  ,]A
M  #&9   OV4  +IC @"S8@\ K&,@ *9C, &@8CT#FV%(!I9?40J27ED-CUQA
M$8Q;:!.)6F\6AEEV&(18?AJ"5X<<?U>0'WU6FR%[5J<B>5:U(W=6QR1V5N0D
M=E?W'W=8_QMW6?\9=UG_%W=9_Q9W6?\6=UG_%O],  #I5@  V5\  ,ME  #!
M:   NFD  +1H  "M9PT IF@< *!H+0&:9SH#E65%!I!C3@J,8E<-B6%>$(9?
M91.#7FP6@%US&'Y<>QI[7(,=>5N-'W9:F"%T6J0C<EJR)'%:Q"5O6N$E<%OV
M('%<_QQQ7?\:<5W_&'%=_Q=Q7?\7<5W_%_U/  #E60  TV(  ,=H  "];
MMFT  *]L  "G:PL H&P9 )ML*@&5:S<"D&E#!8MH3 F'9E0,@V5;$(!C8A-]
M8FD5>F%P&'AA>!IU8($=<U^+'W!>EB)N7J(D;%ZP)6M>P29I7MXF:E_T(6M@
M_QUK8?\;;&'_&6QA_QAL8?\8;&'_&/51  #B7   SV4  ,-K  "Y;P  L7$
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M&EUM_QE=;?\976W_&>A:  #29@  PV\  +AV  "O>P  IGX  )U^  "1?
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M%\UM  "]>   L8(  *>*  "<C@  DI   (:3  !YE0  ;)<  &:7#@!CF!L
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M##&JL PPJL<,,*GG#"^G^@TOIO\-+Z7_#2^E_PTOI?\-+Z7_#;:$  "JC@
MGI0  )29  "'G@  >Z,  &^H  !CK   5Z\  $NR  !!M08 /K81 #VV'@ [
MMBD .K<T #FW/@ WMT< -K=0 32W6@$RMV0",+=O RZW? 0LMXL%*K><!2FW
MK@8HN,4%*+?F!2>U^0<FL_\')K+_"":R_P@FLO\()K+_"*^-  "BE   EYH
M (N@  !^I@  <:L  &6P  !9M   3;<  $*[   XO@$ +\() "W#$@ LPQX
M*\,I "K$,P IQ#T *,5' "?%40 FQ5P )<9H "/&=@$BQH8!(,:8 1_&JP$>
MQ\$!'L;D 1W$^ (<PO\#','_ QS!_P0<P?\$','_!*64  ":F@  CJ$  (&G
M  !SK@  9[0  %JY  !.O0  0L   #C#   OQP  )LL$ ![0"@ ;T1$ &M(:
M !G2)0 8TR\ &-,Z !?41  6U%  %=5= !35:P 3UGP $M>/ !'8I  0V;L
M$-G> !#5\P 0T_\ $-+_ 1#1_P$0T?\!$-'_ 9R:  "1H0  @Z@  '6P  !H
MMP  6[T  $[!  !"Q0  -\@  "W,   DT   '-4  !7:!0 0X@L $.,1  [D
M&@ .Y", #>4M  SE-P +YD( "N9/  GG70 (YVT !N:   7FE0 $YJL  N;$
M  'FY@  Y_D  .?_  #F_P  YO\  .;_ ).A  "%J0  =[$  &FY  !;P
M3L8  $'*   US@  *M(  "'6   9VP  $M\   WC   +\0@ "?,.  ?S$P $
M\AH  O(B  #R*@  \C0  /(_  #R3   \EP  /)M  #R@@  \I@  /.M  #S
MQ@  ].4  /3V  #T^P  ]/L  /3[ (>I  !YL@  :KH  %S"  !.R0  0,X
M #/3   HV   'MT  !7A   /Y   "N@   7S   #_0$  /P(  #[#0  ^Q$
M /L6  #\'@  _"8  /PP  #]/   _DD  /Y:  #^;0  _X(  /^8  #_K
M_\   /_8  #_Y   _^0  /_D 'NR  !LNP  7<0  $_-  ! T@  ,MD  ";>
M   ;X@  $N8   SJ   %[0   /0   #_    _P   /\   #_!   _PD  /\.
M  #_$@  _Q@  /\A  #_*P  _S<  /]&  #_6   _VL  /^   #_E0  _Z8
M /^S  #_NP  _[L  /^[ /\;)@#_'"0 _QHD /\5)P#_$"T _PHV /\%0P#_
M 5 !_P!> ?\ :P'_ '8!_P"! /\ B@#_ )( _P": /\ H #_ *8 _P"L /\
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M ?\,8@'_"VX!_PMY ?\+@@'_"XL!_PN2 ?\*F0'_"I\ _PJE /\*JP#_"K(
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M";$RY0FM,_4)JS/_":HS_PBH,_\'J#/_!Z<S_P>G,_\'IS/_!_\W!P#_.@
M_SX  /I! 0#Q008 \3\- .8\$@#;.A\ T#LQ ,H\0 #$/$T!P#Q8 KP[80.Y
M.VH%MCIR!K0Z>@>R.8$(L#F(":\YD JM.)@*JSBA"ZDXJ@RH.+8-ICC%#:0X
MW@ZA.?$-GSK_#)XZ_PN=.O\*G#K_"9PZ_PF<.O\)G#K_"?\[ @#_/@  ]T0
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M%8!*_Q* 2_\0@$O_#X!+_PZ 2_\.@$O_#O]#  #L2P  W5,  ,Y8  #$6@
MO5H  +A7 0"Q5 X JE8> *56+@"?5CL!FU5& Y=44 634U@(D%)?"HU19@R+
M4&T.B$]T$(9/?!*$3H43@DZ.%8!-F1=^3:08?$VR&7I-PQIY3=\:>$[T%WA/
M_Q1X3_\2>%#_$'A0_P]X4/\/>%#_#_U&  #G3P  UE<  ,A<  "_7P  MU\
M +%<  "J60P I%H: )Y;*@"96S@!E%I# Y!93 6,6%4(B5=<"H968PR#56H.
M@51Q$']3>1)]4X$4>E*+%GA2E1AV4:$9=%&O&W-1P!MQ4=L<<5+R&7%3_Q5Q
M5/\3<E3_$7)4_Q!R5/\0<E3_$/-(  #C4P  T%L  ,1@  "Z8P  LV,  *QA
M  "D7@D G5\7 )A?)P"37S4!CEY  XI=2@6&7%('@UM9"H!:8 Q]66<.>UAN
M$'A8=1)V5WX4=%:(%W)6DQAO5I\:;E6L&VQ5O1QK5M4=:U;P&FM7_Q=K6/\4
M;%C_$FQ8_Q%L6/\1;%C_$?%+  #?5@  S%X  ,!D  "W9P  KF@  *=F  "?
M8@8 F&,4 ))D) "-8S(!B6(] H1A1P2!8$\'?5]6"7I>70MW760-=5QK$'-<
M<Q)P6WL4;EN%%VQ:D!EJ6IP;:%FJ'&9:NAUE6M$=95KN&V5;_A=F6_\59ES_
M$V=<_Q)G7/\29US_$NU.  #:60  R&$  +QG  "S:@  JVP  *)J  "99P(
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M$]Q<  #'9P  N6\  *]V  "E>P  G'P  )%\  "">   >GD' '5Y% !R>B,
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M%$""KA4_@\(5/H+B%3^!]Q,_@?\20(#_$4" _Q! @/\00(#_$,9K  "W=@
MK'\  **%  "7B0  C(L  (&-  !SC@  98\  %V/"0!:D!0 6) A %:1+0!3
MD#@!49!! DZ020-,D% $2H]8!4>/8 =%CFD)0HYS"T"-?PT^C8T//(V<$#J-
MK!$YC<$1.(WA$#B+]A XBO\/.8G_#SF)_PXYB?\..8G_#K]R  "R?0  IX8
M )R*  "1C@  AI$  'J3  !ME0  7Y<  %29 0!/F0\ 3IH: $R:)P!*FC(
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M B&O\P,@KO\#(*W_!!^L_P0?K/\$'ZS_!*J+  "=D0  DY<  (><  !ZH@
M;:<  &"K  !5KP  2;$  #ZT   SMP  *KH# "2\#0 BO14 (;T@ "&]*@ @
MO3, '[X] !Z^1P =OE( '+]> !J_;  9OWP &+^. !? H0 6P+8 %,#3 !6^
M\0 5O/\!%;O_ 12Z_P(4NO\"%+K_ J&2  "6F   BIX  'VD  !OJ@  8J\
M %:T  !*MP  /KH  #.]   JP   (<0  !G'!0 3RPL $<P2 !',&P 0S"4
M#\TO  [-.@ .S48 #<U2  W.8  ,SG  "\Z#  K.EP )SJP ",[&  C.Z  (
MS?L "<O_  G+_P )R_\ "<O_ )B8  "-G@  ?Z4  '&L  !DLP  5[D  $J]
M   ^P   ,L,  "C&   ?R@  %\T  !'1   ,U@4 "-D,  ;9$@ %VAL !-HD
M  /;+@ !VSD  -Q%  #=4@  WF(  -YS  #>B   WYT  -^S  #?S@  X.X
M -_Z  #?_P  W_\  -__ (^?  "!I@  <ZX  &6U  !8O0  2L(  #W%   Q
MR0  )LP  !W0   4U   #MD   G=   #X0   .,'  #C#0  Y!(  .49  #F
M(@  YRL  .DV  #K0P  [%(  .QB  #M=@  [HP  .ZA  #OMP  []$  ._K
M  #P]@  \/8  /#V (2G  !UKP  9[<  %F_  !+Q@  /,H  "_.   DT@
M&M@  !+<   ,X   !>,   #G    ZP   .L   #M!0  [@L  / 0  #Q%0
M\QX  /0G  #W,P  ^4   /I1  #[8P  _'<  /V-  #]HP  _K8  /[)  #_
MWP  _]\  /_? '>P  !HN0  6L$  $S*   \SP  +M0  "+:   7W@  $.(
M  GF    Z0   .P   #P    ]@   /8   #W    ^    /H'  #[#0  _1$
M /\9  #_(P  _R\  /\^  #_3P  _V(  /]W  #_C0  _Y\  /^N  #_N@
M_[H  /^Z /\6(P#_%2$ _Q(A /\.) #_!BH _P S /\ 00#_ $X _P!< /\
M: #_ '0 _P!^ /\ AP#_ (\ _P"6 /\ G #_ *( _P"H /\ K@#_ +4 _P"]
M /\ QP#_ -8 _P#G /X \P#^ /X _0#_ /P _P#[ /\ ^P#_ /L _P#[ /\
M^P#_ /\:( #_&1X _Q8> /\0( #_"B4 _P0P /\ /0#_ $L _P!8 /\ 9 #_
M '  _P!Z /\ @P#_ (L _P"2 /\ F #_ )X _P"D /\ J@#_ +$ _0"Y /L
MPP#Z -  ^ #C /< \0#V /P ] #_ /0 _P#S /\ \P#_ /, _P#S /\ \P#_
M /\=' #_'!D _QD9 /\4&P#_#B$ _PPL /\).0#_!48 _P)3 /\ 7P#_ &L
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M -P,_P#<#/\ W S_ /\C$@#_(Q  _R$. /\>$ #_'A@ _QPC /\8+P#_%#L
M_Q)) /P050#X#V  ] ]J /$/= #O#GP [0Z$ .L.BP#I#I( YPZ9 .8.H #D
M#J< X@ZO . .N #>#L4 W [: -80[ #2$?H SQ+_ ,T2_P',$O\!RQ/_ <H3
M_P'*$O\!RA+_ ?\G#P#_)PP _R4) /\F#0#_)1, _R,< /\@* #['#4 ]1I"
M .\83P#J%UH YA9E .,6;@#@%G< WA9_ -P6AP#9%HX UA:5 -06G #2%Z,
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M!/\R  #_,P  ^3@  .DY  #B.0  WC4' -XN#0#1+QL R3$L ,,S.P"],T@
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M#8@^Q Z&/^ .A#_T#8- _PN#0/\*@D#_"8)!_PB"0?\(@D'_"/\\  #K0P
MW$H  ,Q/  ##4   O$X  +=) 0"Q1@X JD@< *1)+ "@23H FTE% 9A(3@*4
M1U<#DD=>!8]&90:-1FP'BT5S"8E%>PJ'1(,+A42-#(-$EPZ!0Z(/?T.O$'Y#
MP!!\1-H1>T3Q#WI%_PUZ1O\+>D;_"GI&_PEZ1O\)>D;_"?4^  #F2   TT\
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M%&52^Q%F4_\/9E/_#693_PQF4_\,9E/_#.I)  #54P  Q5H  +I?  "P8@
MJ&(  )]?  "66@  CUH0 (I;'@"%6RP @5LX 7U;00)Z6DH#=UE1!'186 9Q
M6%\';U=F"6U7;0MK5G8-:59_#V=5BA%E59<38U6D%&%5M!5@5<@67U7G%6!6
M^A)@5O\/85?_#F%7_PUA5_\,85?_#.=,  #15@  P5X  +9C  "M9@  I&8
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M#E)B_PU28O\-4F+_#=E6  #$8   MV@  *QN  "C<0  FG,  (]Q  !_:P
M>&L% ')K$@!N;!\ :VPL &AL-P%F;$ "8VM( V!K3P1>:E8&7&I=!UEI90E7
M:6T+56EW#5-H@@]0:(\13F>=$TUGK!1+:, 42VC>%$MG]1),9_\/3&?_#DUG
M_PU-9_\-36?_#=):  # 9   LVP  *ER  "@=@  EG<  (IV  !Y<0  <7$
M &MQ#P!H<1P 9G(H &-R- !@<CT!7G)% EMQ30-9<50%5W!;!E1P8PA2;VL*
M4&]T#$UN@ Y+;HT026Z;$4=MJQ)&;KX316[<$D9M]!%&;?\/1VW_#D=L_PU'
M;/\-1VS_#<Q?  "\:0  L'$  *5W  "<>P  D7P  (9[  !U>   :W<  &5W
M# !A>!< 7W@D %UY, !:>3H!6'E" E9X2@)3>%$$47=8!4]W8 =,=F@(2G9R
M"DAU?0Q%=8H.0W69#T)UJ1! =;P00'79$$!T\P] =/\.07/_#4%S_PQ!<_\,
M07/_#,9D  "W;@  JW8  *)\  "7?P  C($  (&!  !R@   97\  %U_" !9
M?Q, 5X @ %6 *P!3@38 48 ^ 4^ 1@)-@$X"2W]5 TE_705&?V8&1'YP"$)^
M>PD_?H@+/7V7##Q]IPTZ?;H..G[6#3I\\0TZ>_\,.GO_"SIZ_PLZ>O\+.GK_
M"\!I  "R=   IWP  )V!  "2A   AX8  'N'  !NAP  8(<  %6' 0!0B X
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M B:>H0(DGK4"(Y[. B.=[@,CF_X#(IK_!"*9_P0BF?\$(IG_!*R!  "@B
ME8X  (N2  !_E@  <IH  &6=  !9H   3J,  $*D   WI@  +J@% "FI#P H
MJ1@ )ZHB ":J+  EJC4 )*H_ ".J2  BJU, (:M> ""K:@ >JWD ':N+ !NK
MG0 :J[$ &:O* !FJ[ $9J/T!&*?_ ABF_P(8IO\"&*;_ J6)  "9CP  CY0
M (.9  !UG@  :*(  %RF  !0J0  1*P  #FN   OL   )K,  !ZU!@ 9MP\
M&+<7 !>W(0 6MRH %;<T !2X/@ 3N$D $KA4 !*Y8@ 1N7$ $+F#  ^YEP .
MN:P #;G$  VXYP .MOL #K7_  ZT_P .M/\ #K3_ )R0  "2E0  AIL  'F@
M  !KI@  7JL  %*O  !&L@  .K4  "^W   EN@  ';T  !7    0PP8 "\8.
M  K%%0 )Q1X ",4H  ?%,@ &QCT !<9)  7&5P #QF8  L9W  '&BP  QJ
M ,6V  #&T@  Q>\  ,7\  #%_P  Q?\  ,7_ )66  ")G   >Z,  &VI  !@
MKP  4[0  $:X   ZNP  +KX  "3!   ;Q   $\<   [*   (S@$  = *  #0
M$   T!8  -$>  #2)P  TS$  -0\  #520  UE@  -9I  #6?   UI(  -:G
M  #6OP  UN   -;S  #6_@  UO\  -;_ (R=  !^I   ;ZL  &&R  !4N0
M1KT  #G!   MQ   (L<  !G+   1S@  #-(   75    VP   -P#  #="@
MW@\  -\4  #A'   XB0  .0N  #F.@  YTD  .A9  #H:P  Z8$  .F8  #I
MK0  Z<4  .GB  #I\@  Z?4  .GU ("E  !QK0  8[4  %6\  !'P@  .<8
M "S*   @S@  %M(   _6   (VP   -\   #C    Y0   .<   #H 0  Z@<
M .L-  #M$0  [Q@  /$A  #S*P  ]C@  /=(  #X6@  ^6T  /J$  #ZFP
M^J\  /K"  #ZV@  ^M\  /K? '2N  !EM@  5KX  $C&   YRP  *]   !_4
M   4V@  #=\   7C    Y@   .D   #M    [P   /$   #S    ]0   /8"
M  #X"0  ^@X  /T3  #_'   _R@  /\V  #_1P  _UH  /]N  #_A0  _YH
M /^K  #_N0  _[P  /^\ /\1( #_$!X _PP> /\$(0#_ "< _P P /\ /@#_
M $P _P!9 /\ 90#_ '  _P!Z /\ @P#_ (L _P"2 /\ F #_ )X _P"D /\
MJ@#_ +  _P"X /\ P@#_ ,X _P#B /X \ #] /L ^P#_ /L _P#[ /\ ^@#_
M /H _P#Z /\ ^@#_ /\4' #_$AH _PX: /\(' #_ "$ _P M /\ .@#_ $@
M_P!5 /\ 80#_ &P _P!V /\ ?P#_ (< _P". /\ E #_ )H _@"@ /T I@#\
M *P ^P"T /D O0#X ,D ]P#< /4 [ #S /@ \P#_ /( _P#Q /\ \ #_ /
M_P#P /\ \ #_ /\7& #_%18 _Q$5 /\,%P#_!1T _P H /\ -@#_ $, _P!0
M /\ 7 #_ &< _P!Q /\ >@#\ (( ^@") /@ D #W )8 ]0"< /0 H@#S *@
M\0"P /  N #N ,, [ #3 .H YP#I /4 YP#_ .8 _P#E /\ Y0#_ .4 _P#E
M /\ Y0#_ /\:$P#_&!$ _Q00 /\/$0#_#1D _PHD /\%, #_ 3X _P!+ /\
M5P#^ &( ^@!L /4 =0#R 'T \ "$ .X BP#L )$ ZP"7 .D G@#G *0 Y@"L
M .0 M #B +\ X #- -X XP#< /( V@#] -@ _P#6 /\ U0'_ -4!_P#5 O\
MU0+_ /\>$ #_' T _Q<+ /\5#@#_%!4 _Q$? /\.*@#_"S@ _0A% /@&40#T
M!%P [@1F .H$;P#F W< Y 1_ .($A@#@!(P W@23 -T%F@#;!:  V 6H -4%
ML0#2!;L T ;) ,X'X #,"/$ R0K_ ,<+_P#&#/\ Q0S_ ,4,_P#%#/\ Q0S_
M /\A# #_( 8 _QP# /\="@#_&Q  _Q@8 /\4(P#V$3  [PX^ .H.2@#E#58
MX0U@ -T-:0#9#7$ U0UY -,-@0#1#8@ SPV/ ,T.E@#+#IT R@ZE ,@.K@#&
M#[D Q!#( ,(0WP"^$?( NQ+_ +D3_P"W$_\!MA/_ ;83_P&V$_\!MA/_ ?\E
M!@#_(P  _R,  /\D P#_(0H _1T1 /$:&P#H%B< X10U -H30P#3%$\ SA59
M ,L58P#(%FL Q19S ,,7>P#!%X( P!B) +X8D "\&)@ NQF@ +D9J0"W&;0
MM1K" +0:U@"P&^T!K1S\ :L=_P&I'?\!J1W_ :@=_P&H'?\!J!W_ ?\H  #_
M)P  _BH  .\J  #G)P$ YR() .0=$ #9&QT SQTM ,D>/ #$($D OR!3 +PA
M70"Y(64 MR)M +4B= "S(GP L2*# ; BB@&N(I(!K".; :LCI &I(Z\!IR.\
M :8DS@&C).@"H"7Y IXE_P*=)?\"G"7_ ILE_P*;)?\"FR7_ O\L  #_+0
M[3(  .(T  #:,P  TRX# -(E"@#))1< P2<G +LI-@"V*D, LBM. *\K5P"L
M*V  JBMG :@K;P&F*W8!I"M] :,KA *A*XT"GRN5 IXKGP*<*ZH#FBNV YDL
MQP.7+.(#E"WU!)(M_P.1+?\#D"[_ Y M_P.0+?\#D"W_ _\P  #R,P  Y#H
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M2P  M4D  *]#  "I/@L HC\7 )U )@"8030 E$$_ )%!20&.05$!BT!9 HE
M8 .'0&<#A3]M!(,_=06!/WT&?SZ'!WT^D0A[/IP)>CZI"7@^N IW/\T*=3_J
M"G1 _ AT0/\'=$#_!G- _P9S0/\&<T#_!O$[  #?10  S$P  +]/  "V4
MKD\  *=*  "@1 < FD44 )5&(@"01C  C$<\ (E&10&&1DX!@T95 H%%7 -^
M16,$?$1J!'I$<05Y1'D&=T2""'5#C0ES0YD*<4.F"W!#M0QN1,D,;43G#&U%
M^@IL1?\(;$7_!VQ%_P=L1?\';$7_!^P_  #820  QU   +M4  "Q50  J50
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M"5M1_PA;4?\(6U'_"-]*  #)4P  NUH  +!?  "F80  G6$  )1>  "(5P
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M",I8  "Z8@  KFD  *-N  ":<0  D'(  (1Q  !T:P  :6D  &-I"P!?:14
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M!C=XH0<U>+,'-'C+!S1WZP<T=OT'-'7_!S5U_P8U=/\&-73_!KEH  "M<0
MHGD  )A^  "-@   @H$  ':"  !I@0  6X$  %&!  !(@ H 18$3 $.!'@!"
M@BD 08(R $"".P ^@D, /8)+ #N"4P$Y@EP!-X)F C6"<0,S@G\#,8&.!#"!
MGP0N@;$%+8'(!2V!Z00M?_P%+7[_!2U]_P4M??\%+7W_!;-N  "H>   G7\
M )*#  "(A@  ?8<  '"(  !CB0  58H  $N*  !!B@( .XL. #F+%P XC"(
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M !"DX@ 1HO@ $:'_ !&@_P$1H/\!$:#_ :"&  "5C   C)$  '^5  !QF@
M9)X  %BA  !,I   0*8  #6G   JJ0  (JP  !FN   2L D $+$0 !"Q&  .
ML2( #K$K  VQ-0 -L4  #+%+  NQ6  *L6< "+%X  >QBP %L:  !+"U  2P
MT  $L.\ !:_^  :N_P &KO\ !J[_ )B.  "/DP  @I@  '6=  !GH@  6J<
M $ZK  !!K0  -:\  "NQ   AM   &+8  !&Y   -O , ![X,  .]$@ !O1D
M +XB  "^*P  OC8  +Y!  "_3@  OUP  +]M  "_@   OI4  +ZJ  "^P@
MO>0  +WV  "]_P  O?\  +W_ )*4  "%F@  >*   &JF  !<JP  3[   $*S
M   UM@  *K@  ""[   7O@  $,$   O$   $QP   ,D'  #)#0  R1(  ,H9
M  #+(@  RRL  ,TU  #.00  SE   ,]@  #/<@  SX<  ,^=  #/LP  S\X
M ,_K  #.^   SOX  ,[^ (B;  !ZH@  ;*@  %ZO  !0M0  0KD  #6\   I
MOP  'L(  !7&   .R0  ",P   #0    TP   -4   #6!@  V P  -D1  #;
M%@  W!\  -XH  #@-   XD$  .)1  #C8P  XW<  .2.  #DI   Y+H  .74
M  #EZ@  Y?,  .7S 'RC  !NJ@  8+(  %&Y  !#O@  -<(  "C&   <R0
M$\T   S1   $U0   -H   #>    X0   .(   #D    Y0,  .<)  #I#@
MZQ(  .T:  #O)   \C$  /1!  #T4P  ]68  /5\  #VDP  ]JD  />\  #W
MS@  ]]\  /?? '"L  !AM   4[L  $7#   VQP  )\P  !O0   1U0  "ML
M  #?    X@   .4   #I    [    .T   #P    \0   /,   #U!   ]PH
M /H0  #\%@  _R$  /\N  #_0   _U,  /]H  #_@   _Y8  /^H  #_M@
M_[\  /^_ /\-' #_"AL _P(; /\ '@#_ "0 _P N /\ / #_ $H _P!6 /\
M8P#_ &T _P!W /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *P _P"T
M /\ O0#_ ,D _@#= /T [0#\ /H ^P#_ /H _P#Y /\ ^@#_ /H _P#Z /\
M^@#_ /\0&0#_#1< _P86 /\ & #_ !X _P J /\ -P#_ $4 _P!2 /\ 7@#_
M &D _P!R /\ >P#_ (( _P") /\ D #^ )8 _0"< /P H0#[ *@ ^0"O /@
MN #V ,, ] #2 /, YP#R /8 \ #_ .\ _P#P /\ [P#_ .\ _P#N /\ [@#_
M /\2% #_#Q( _PL2 /\ $@#_ !H _P E /\ ,P#_ $  _P!- /\ 60#_ &0
M_0!M /L =@#Y 'T ]P"$ /4 BP#T )$ \P"7 /$ G0#P *, [@"J .P LP#J
M +T Z #+ .< X0#E /$ XP#] ., _P#B /\ X0#_ .$ _P#@ /\ X #_ /\4
M$ #_$0X _PT- /\'#P#_ A4 _P @ /\ +0#_ #H _P!' /D 4P#U %X \@!H
M /  < #M '@ ZP!_ .D A0#H (P Y@"2 .4 F #C )\ X0"F -\ K@#< +@
MV@#% -8 V0#4 .P T@#Y -$ _P#/ /\ S@#_ ,X _P#. /\ S@#_ /\7# #_
M% @ _P\% /\."P#_#!$ _P<: /\!)@#\ #0 ] !! .T 30#I %@ Y@!B .,
M:@#@ '( W@!Y -L @ #9 (8 U@"- -, DP#1 )H SP"A ,T J@#+ +, R0"_
M ,8 T #% .@ PP#V ,$ _P#  O\ OP/_ +\#_P"_ _\ OP/_ /\;!@#_%P
M_Q0  /\3!0#_$0T _PX4 /D*'P#P!BP Y@,Y . #1@#< U$ U@1; -($9 #/
M!6P S 5S ,H%>@#(!8$ Q@6' ,4&C@##!I8 P0:= +\&I@"]!K  NP>\ +D(
MS0"X"N4 M0OW +,-_P"Q#?\ L W_ + ._P"O#O\ KP[_ /\>  #_&P  _QL
M /H:  #U%@4 ]A$- .L.%0#B"R( V LQ - ,/@#+#4H QPU5 ,0.7@#!#F8
MOPYM +T.= "[#WL N0^" +<0B@"V$)$ M!": +(0HP"P$:T KQ&Z *T1R@"J
M$N4 IQ3W *45_P"C%?\ HA7_ *(5_P"B%?\ HA7_ /\B  #_(   \",  .8D
M  #@(0  W!D% -L0# #0$1D R!,I ,(5-P"]%D0 N1=. +475P"S&&  L!AG
M *X8;@"L&74 JQE\ *D9A "H&HP IAJ4 *0:G@"C&Z@ H1NT )\<Q0">'-\
MFAWS 9@>_P&7'O\!EA__ 94?_P&5'_\!E1__ ?\F  #T)P  YBT  -HO  #/
M+0  RB<  ,<?" #!'!, NAXB +0?,0"O(#T JR%( *@B4@"F(EH HR-B *$C
M:0"@(V\ GB-W )PC?@";(X8 F22/ 9<DF0&6)*,!E"2P 9(EOP&1)=8!CB;O
M 8PG_P*+)_\"BB?_ HDG_P*))_\!B2?_ ?HI  #L,   W38  ,TX  #$-P
MOC(  +HK @"U)0X KB<= *@I*P"D*C@ H"I# )TK3 ":*U4 F"M< )8K8P"4
M*VH!DBMQ 9 L> &/+($!C2R* 8LLE **+)\"B"RK H8LN@*%+<X#@R[J X$N
M_ . +O\"?R[_ G\N_P)^+O\"?B[_ O0N  #D-P  TCT  ,4_  "[/P  M#P
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M!&9 _P1F/_\$9C__!.4]  #/1@  OTP  +1/  "J4   HD\  )E*  "11
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M!=!+  "_5   LEH  *=>  "=8   E&   (E=  !\5P  <E0  &Q3#@!H5!D
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M!D->H =!7K$'0%[(!T!>Z = 7?P&05W_!4%=_P5!7/\%05S_!<-6  "T7P
MJ&8  )YJ  "5;0  BFT  ']L  !O9P  9&0  %MB!0!68A  5&(; %)C)0!0
M8R\ 3F0X $UD0 !+9$@ 2F1/ 4AD5P%&9%\"161H D-D<P-!8W\$/V..!3UC
MG@8\8[ &.V3&!CMDY@8[8_H%.V+_!3MB_P4\8?\$/&'_!+Y;  "P8P  I6H
M )MO  "1<@  AG(  'MQ  !L;0  8&L  %5I  !/: T 36D7 $MI(0!):BL
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M B9[X0(F>O<")GC_ B9X_P(G=_\")W?_ JYL  "C=@  F7P  (Y_  "$@@
M>(,  &R$  !?A   480  $>$   \A   ,X0) #"$$0 OA!H +80D "R%+0 K
MA34 *H4^ "F%1P HAE  )X9: ":&9@ DAG, (X:# "&&E0 @AJ<!'H:\ 1Z&
MW@ >A/4!'H+_ 1Z"_P$>@?\!'H'_ :AT  ">?0  DX(  (F%  !^B   <8H
M &6+  !8C   3(T  $".   VC@  +(\  "60#  CD!, (I < "&0)0 @D2X
M'Y$V !Z10  =D4D ')%4 !J18  9D6X &)%^ !:2D  5DJ0 %)&Y !.1V  3
MC_0 %([_ !2-_P 4C/\!%(S_ :-]  "8@P  CH@  (2,  !WCP  :9$  %V3
M  !0E0  19<  #F8   NF0  )9H  !V; @ 6G0P %9T3 !2=&P 3G20 $ITM
M !&>-P 1GD$ $)Y,  ^>6  .GF< #9YW  R>B@ +G9X "IVR  F=S  )G.P
M"IO^  N:_P +F?\ "YG_ )R$  "1B@  B(X  'N2  !ME@  8)D  %2<  !(
MGP  /*   #"A   FHP  ':4  !6G   0J04 "ZL-  BJ$P 'JAL !JHD  6J
M+@ $JC@  JI$  &J4   JEX  *IN  "J@0  JI4  *FJ  "IP0  J.0  *CV
M  "G_P  I_\  *?_ )6+  ",D   ?Y4  '&:  !CG@  5J(  $JF   ]J
M,:H  ":K   =K0  %+    ZR   )M0$  K8*  "V#P  MA4  +<=  "W)0
MMR\  +@Y  "X1@  N%0  +AD  "X=@  N(L  +>@  "WM@  M],  +;O  "V
M_   MO\  +;_ (^2  ""EP  =)T  &:B  !8IP  2ZP  #ZO   QL0  )K,
M !RV   3N   #;L   :^    P0   ,($  #""P  PQ   ,05  #$'   Q20
M ,8N  #(.@  R4<  ,E7  #):0  R7T  ,F4  #(J@  R,,  ,CD  #(]
MR/T  ,C] (69  !WGP  :*8  %JK  !-L0  /[4  #&X   EN@  &KT  !'
M   +PP   \<   #*    S0   ,X   #/ P  T D  -$.  #3$@  U1D  -<B
M  #:+0  W3D  -Y)  #>6@  WVX  -^%  #?G   W[(  -[+  #>Y@  W_0
M -_T 'FA  !KJ   7*\  $ZU  ! NP  ,;X  "3!   9Q0  $,@   G,
MSP   -,   #9    W    -T   #?    X0   .(%  #D"P  YA   .@6  #J
M(   [2L  / Z  #Q2P  \5X  /)S  #SBP  \Z(  /.V  #SR0  \^$  //A
M &VJ  !>L0  4+D  $&_   RQ   ),@  !?,   .T   !M4   #:    W@
M .(   #F    Z0   .H   #L    [@   /    #R    ] 8  /8,  #Y$@
M_!P  /\I  #_.@  _TT  /]B  #_>   _Y   /^C  #_LP  _\$  /_! /\'
M&0#_ 1< _P 7 /\ &@#_ "$ _P K /\ .0#_ $< _P!4 /\ 7P#_ &H _P!S
M /\ >P#_ (, _P"* /\ D #_ )8 _P"; /\ H0#_ *@ _P"O /\ N #_ ,0
M_@#5 /P Z@#[ /@ ^@#_ /D _P#X /\ ^ #_ /8 _P#S /\ \0#_ /\+%0#_
M!1, _P 3 /\ % #_ !H _P G /\ - #_ $( _P!/ /\ 6P#_ &4 _P!N /\
M=@#_ 'X _P"% /X BP#] )$ ^P"7 /H G0#X *, ]P"K /8 LP#T +X \P#,
M /$ XP#O /, [@#_ .T _P#L /\ ZP#_ .P _P#L /\ ZP#_ /\-$0#_"1
M_P / /\ $ #_ !8 _P B /\ +P#_ #T _P!* /\ 50#] &  ^@!I /@ <0#V
M 'D ] !_ /, A@#Q (P [P"2 .X F #L )\ ZP"F .D K@#G +@ Y0#% .,
MV@#A .T WP#[ -X _P#= /\ W0#_ -T _P#= /\ W0#_ /\/#0#_# L _P,)
M /\ # #_ !( _P = /\ *0#[ #< ^ !$ /4 4 #R %H [@!C .P :P#I ',
MYP!Z .4 @ #C (8 X0", -\ DP#= )D VP"A -D J0#5 +( T@"^ -  S@#.
M .8 S #V ,H _P#* /\ R0#_ ,@ _P#( /\ R #_ /\1" #_#0( _P<  /\%
M" #_  X _P 6 /< (@#O #  ZP ] .@ 20#D %0 X != -T 90#9 &T U0!S
M -( >@#0 (  S@"' ,P C0#* )0 R "; ,8 I #$ *T P@"X ,  QP"] -\
MO #Q +L _@"Y /\ N #_ +@ _P"X /\ N #_ /\4  #_#P  _PT  /\,  #_
M!PD ^ $0 .@ &@#C "@ W0 V -@ 0@#2 $T S@!7 ,H 7P#' &8 Q0!M ,,
M= #! 'H OP"! +T B "[ (\ N0"7 +< GP"U *@ LP"S +$ P@"O -@ K@+M
M *P#^P"K!?\ J@;_ *D&_P"I!O\ J0;_ /\6  #_$@  ]Q(  .P1  #F#@
MY08( -T#$@#4 R  S00M ,@$.@##!48 OP50 +P&6 "Y!F  MP=G +4';@"S
M!W4 L0A[ *\(@@"N"8H K F2 *H)FP"H"J4 I@JP *4+OP"C#-0 H0WM )\.
M_@"=#O\ G __ )L/_P";#_\ FP__ /\:  #W&0  ZAX  -\>  #5&@  T!,"
M ,X,"P#'"Q8 P TE +H.,@"V#C\ L@]) *\04@"L$%H JA!A *@1: "F$6\
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M 7@H_P%X*/\!>"C_ >\K  #=,P  RCD  +X[  "T.@  K38  *8O  "A* <
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M M8_  ##1P  M4P  *I0  "@4   ET\  (Y+  "$10  >D & '4_$0!Q0!P
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M TQ+GP1+2[ $2DO%!$E+Y@1)2_H$24O_ TI+_P-*2_\#2DO_ \A)  "X40
MK%<  *%;  "87   CEP  (-9  !V4P  :TX  &1-"@!?3!, 7$T> %I-* !8
M33$ 5DTZ %1-00!33D@ 4DY/ %!.5P%/3E\!34YH 4Q.<P)*3W\"24^- T=/
MG01&3ZX$14_#!$10Y 1$3_D$14__ T5/_P-%3O\#14[_ \1,  "U50  J5L
M )]>  "58   BV   (!>  !R5P  9U,  %Y1!P!941$ 5U$; %11)0!24B\
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M S1?W0,T7O4#-5W_ C5=_P(U7/\"-5S_ KA9  "J80  H&<  )9L  ",;@
M@6X  '9L  !G:0  7&8  %%D  !(8@D 1&(1 $)B&P!!8R0 /V,M #YC-0 ]
M9#T /&1% #MD30 Y9%4 .&1? #9D:0$U9'8!,V2% 3%EE0(P9:<"+V6[ BYE
MV@(N9/0"+F/_ B]C_P(O8O\"+V+_ K->  "G9@  G&T  )-Q  "(<P  ?7,
M ')R  !D<   6&X  $UL  !":@, /&D. #IJ%@ Y:B  .&HH #9K,0 U:SD
M-&M! #-L20 R;%( ,6Q< "]L9@ N;', +&R" 2ILDP$I;*4!*&RY 2=MU@$G
M:_(!)VK_ 2=J_P$H:?\"*&G_ JYD  "C;   F7,  (YV  "$>   >7D  &UX
M  !@=P  4W8  $AU   ^<P  -'(* #%S$0 P<QH +W,C "YS*P M=#0 +'0\
M "MT1  I=$T *'57 "=U8P E=6\ )'5_ ")UD  A=:( ('6W !]UT@ ?=/$
M'W/_ 1]R_P$@<?\!(''_ :EK  "><P  E'D  (I\  " ?@  ='\  &=_  !:
M?P  37X  $-^   X?0  +WT" "A]#0 F?10 )'T< "-^)0 B?BT (7XV "%^
M/P ??T@ 'G]2 !U_7@ <?VL &G]Z !E_C  7?Y\ %G^S !5_S@ 5?N\ %GS_
M !9[_P 6>_\ %WO_ *1R  ":>@  CW\  (6"  ![A   ;88  &"'  !4AP
M2(@  #R(   RB   *(@  ""(!0 :B0X &8D5 !B)'0 7BB8 %HHN !6*-P 4
MBD$ $XI, !*+6  1BV4 $(MU  ^+AP .BIL #8JO  R*R  ,B>H #8?\  Z'
M_P .AO\ #H;_ )][  "4@0  BH4  ("(  !SBP  98T  %F/  !,D   09(
M #22   JD@  (9,  !F4   2E@8 #I<.  V7%0 ,EQT #)<F  N7+P *ESD
M"9=$  B74  &EUX !9=N  .6@  !EI0  )6H  "5O@  E.   )3T  "3_P !
MDO\  9+_ )B"  ".B   A8P  '>/  !JD@  794  %"8  !$F@  .)L  "R<
M   BG0  &9X  !*@   -H@( !Z,+  &C$   HQ<  *,?  "C)P  HS$  *0\
M  "D2   I%8  *1E  "C=P  HXL  *.@  "BM@  H=(  *'P  "@^P  H/\
M *#_ )&*  ")C@  >Y(  &V7  !@FP  4YX  $:A   YHP  +:0  ".F   9
MJ   $:H   RL   %K@   *\'  "O#0  KQ$  + 8  "P(   L2@  +$R  "R
M/@  LDP  +);  "R;   LH$  +&7  "QK   L,8  +#H  "O]P  K_\  *__
M (R0  !_E0  <9H  &.?  !5I   1Z@  #JJ   MK   (JX  !BP   0LP
M"K4   *X    NP   +L   "\!P  O T  +T1  "^%@  OQX  , G  #!,@
MPD   ,-/  ##8   PW0  ,.+  ##H0  P[@  ,+7  #"[P  POH  ,'^ (&7
M  !SG0  9:,  %>H  !)K0  .[$  "VS   AM@  %KD   Z[   'O@   ,$
M  #%    QP   ,@   #)    R@4  ,L+  #-#P  SA0  - <  #3)@  UC(
M -A!  #84P  V68  -E\  #9E   V:L  -G#  #9X0  V?   -GT ':?  !G
MI@  6:P  $NR   \MP  +KH  "&]   5P   #<0   7'    R@   ,X   #2
M    U0   -8   #9    VP   -T   #?!P  X0P  .,1  #F&0  Z20  .PR
M  #M0P  [E8  .]K  #OA   [YP  .^R  #OQ@  []T  ._D &JH  !;KP
M3+8  #Z\   OP   (,0  !3(   ,S    M    #4    V0   -X   #B
MY0   .8   #H    Z0   .P   #N    \ (  /()  #U#P  ^!<  /PC  #_
M,P  _T8  /]:  #_<0  _XD  /^?  #_L0  _\   /_& /\ %0#_ !0 _P 4
M /\ %P#_ !T _P H /\ -P#_ $0 _P!1 /\ 7 #_ &8 _P!O /\ =P#_ 'X
M_P"% /\ BP#_ )$ _P"7 /\ G0#_ *0 _P"K /\ M #^ +\ _0#. /L Y@#Y
M /8 ^ #_ /< _P#W /\ ]P#_ /  _P#L /\ Z0#_ /\#$@#_ !  _P 0 /\
M$0#_ !< _P D /\ ,@#_ #\ _P!, /\ 5P#_ &$ _P!J /\ <@#_ 'D _0"
M /P A@#Z (P ^0"2 /@ F #V )\ ]0"F /0 K@#R +D \ #& .X W@#M /
MZP#^ .H _P#I /\ Z0#_ .< _P#C /\ X #_ /\'#@#_  T _P + /\ # #_
M !, _P ? /\ + #_ #H _P!& /X 4@#[ %P ^ !E /4 ; #S '0 \0!Z .\
M@0#N (< [ "- .H DP#I )H YP"A .8 J0#C +, X0"_ -\ T #= .D V@#Y
M -D _P#7 /\ U0#_ -4 _P#5 /\ U #_ /\)"@#_ 04 _P # /\ "0#_ !
M_P 9 /L )@#W #0 ] !  /( 3 #N %8 Z@!? .< 9P#D &X X@!T .  >P#>
M ($ W "' -H C0#6 )0 U "; -$ HP#/ *T S "X ,H QP#( .  Q@#S ,4
M_P## /\ PP#_ ,, _P## /\ PP#_ /\+ 0#_ P  _P   /\  P#_  L \P 2
M .X 'P#J "T Y@ Z .( 10#> $\ V0!8 -0 8 #1 &@ S@!N ,P = #* 'L
MR "! ,8 AP#$ (X P@"6 ,  G@"^ *< NP"R +D P "W -0 M0#L +, ^P"S
M /\ L@#_ +( _P"Q /\ L0#_ /\-  #_!@  _P,  /<   #T  , YP - .
M& #: "4 TP R ,X /@#* $D Q@!2 ,, 6@#  &$ O@!H +P ;@"Z '0 N ![
M +8 @0"T (@ L@"0 +  F0"N *( K "M *H N@"H ,L I@#F *4 ]P"D /\
MHP#_ *( _P"B /\ H@#_ /\0  #[#   [PX  .8-  #?"0  V@ & -  $0#)
M !T Q  J +\ -P"[ $( MP!+ +0 5 "R %L KP!B *T : "K &X J0!U *@
M>P"F (, I "+ *( E "@ )X G@&H )P"M0"; \8 F07B )@&] "6"/\ E0G_
M )0)_P"4"?\ E G_ /P1  #Q%0  XQD  -89  #,%0  QQ   ,0'"@"] Q0
MMP0A +(&+@"N"#H J@E$ *<)30"D"E4 H@I< * *8@">"VD G MO )L+=@"9
M#'X EPR& )8,D "4#)H D@VF )$-LP"/#<4 C0[B (L0]@")$/\ B!'_ (<1
M_P"'$?\ AQ'_ /89  #G(   UB0  ,@E  "_(@  N1P  +04 0"Q#0X J@X9
M *4/)P"A$#, G1$^ )H11P"8$D\ E1)6 ),27 "1$F, D!-I (X3< ",$W@
MBQ.! (D4BP"'%)8 AA6B (05L "#%L$ @1?= '\8] !]&?\ ?!G_ 'P9_P![
M&?\ >QG_ .\A  #=*0  RBT  +XO  "U+   KB<  *@@  "C%P@ GA83 )D7
M(0"4&2T D1HX (X:00"+&TD B1M0 (<;5P"%'%X A!QD ((<:P" '', ?QU\
M 'T=A@!\'I$ >AZ> '@?JP!W'[P =B#4 '0A\ !R(?\ <2+_ '$A_P!Q(?\
M<2'_ .@H  #2,   PC4  +<W  "M-0  I3$  )XK  "8(P( DAX0 (T@&P")
M(2< AB(R (,C/ "!(T0 ?B-+ 'PD4@![)%D >21? '<D9@!V)6X ="5W ',E
M@0!Q)HT ;R:9 &XFIP!M)[@ ;"?. 6HH[0%I*?\!:"G_ 6@I_P%H*/\!:"C_
M >$N  #+-@  O#L  +$]  "G/0  GSD  )<S  "/+0  B"<, (,G%@!_*"(
M?"DM 'DJ-P!W*C\ =2I' ',K3@!Q*U0 <"M; &XK8@!L*VH :RQR &DL?0!H
M+(D 9BV6 64MI %D+K0!8R[* 6$OZ0%@+_T!8"__ 6 O_P%@+_\!8"[_ =HT
M  #%/   MT$  *Q#  "B0P  F4   ) Z  "(-   @"X( 'HM$@!W+AX <R\I
M '$P,P!O,#L ;3!# &LQ2@!I,5$ 9S%7 &8Q7@!D,68 8S)O &$R>0!@,H4!
M7S*2 5TSH0%<,[$!6S3& 5HTY@%9-?L!637_ 5DT_P%9-/\!633_ =(X  #
M0   LT4  *A(  ">2   E48  (M   "".P  >34$ ',S$ !O-!H ;#0E &DU
M+P!G-3< 938_ &,V1@!B-DT 8#94 %\V6P!=-V, 7#=K %LW=@%9-X(!6#B/
M 58XG@%5.*\"5#G# E,YY )3.OD!4SG_ 5(Y_P%3.?\!4SG_ <T\  "\1
MKTD  *1,  ":3   D4L  (=&  !]0   <SL  &PX#0!H.1< 93DB &,Z*P!@
M.C0 7CH\ %TZ0P!;.DH 6CM0 %@[6 !7.V  5CMH %4\<P%3/'\!4CR- 5 ]
MG %//:P"3C[! DT^X0)-/O@"33[_ 4T^_P%-/?\!33W_ <E   "X2   K$T
M *%0  "740  CD\  (1+  !Y10  ;D   &8]"P!B/10 7ST> %P^* !:/C$
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M CY+V (^2O,"/DK_ CY)_P$_2?\!/TG_ ;U*  "O4@  HU@  )E;  "070
MAEP  'M9  !M4P  8D\  %=, 0!12@T 3DH5 $Q+'P!*2R@ 24LP $=+. !&
M3#\ 14Q& $1,3@!#358 0DU? $!-:@ _378!/4Z$ 3Q.E $[3J4!.4^Y CE/
MU (Y3_(!.4[_ 3E._P$Y3?\!.DW_ ;I.  "L5@  H5L  )=?  "-80  @V$
M 'A>  !I6   7U8  %12  !,3PL 24\2 $=0' !%4"4 0U M $)0-0!!43P
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M 2==_P$H7?\!*%S_ :U<  "B9   F&H  (YN  "#;P  >6\  &YN  !@:P
M5&D  $EG   _90  -6,) #)C$0 P8QD +V0A "YD*0 M9#$ +&0Y "ME0@ J
M94H *&54 "=E7P F9FL )&9Z "-FBP B9IT (&:Q !]FR0 ?9NL (&7^ "!D
M_P @8_\!(6/_ :EB  ">:@  E7   (IS  " =0  =74  &ET  !<<@  3W$
M $1O   Z;@  ,&T# "EL#0 G;!0 )FP< "5M)  D;2P (VTT ")M/0 A;D8
M(&Y0 !YN6P =;F< '&YV !INAP 9;YH &&^N !9OQ@ 6;ND %VW\ !AL_P 8
M:_\ &&O_ *1I  ":<0  D'8  (9Y  !\>P  <7L  &1[  !7>@  2GD  #]X
M   U>   *W<  ")V!P ==@\ ''<6 !MW'@ :=R8 &7<N !AW-P 7>$  %7A*
M !1X5@ 3>&, $GAR !%X@P 0>)< #WBK  YXPP .=^8 #G;Z  ]U_P 0=?\
M$'3_ )]Q  "5>   BWP  ()_  !W@0  :H(  %V"  !0@@  1((  #B"   N
M@@  )((  !R"   4@@D $8,0 !"#%@ 0@QX #H,G  Z#,  -@SD #8-$  R#
M4  +@UT "8-L  B#?@ &@Y$ !8*E  ."NP $@=L !('R  6 _P &?_\ !G__
M )IY  "0?@  AH,  'V%  !OAP  8HD  %6*  !)BP  /8P  #&,   FC
M'8T  !6.   /CP, "I ,  :0$0 $CQ@  X\@  &/*0  CS(  ) ]  "020
MCU8  (]E  "/=@  CXH  (Z?  ".M   C<\  (SN  ",^P  B_\  (O_ )2
M  "+A0  @HD  '2,  !FCP  69$  $R3  ! E0  -)8  "B6   >EP  %9@
M  ^:   *FP   IP)  "<#@  G!,  )P:  "<(@  G2L  )TU  "=0   G4X
M )U<  "=;@  G($  )R7  "<K   F\8  )KH  "9^0  F?\  )C_ (Z(  "&
MC   >)   &J4  !<EP  3YH  $*=   VG@  *9\  !^A   5H@  #J0   BF
M    J    *D$  "I"@  J0X  *D3  "J&@  JB(  *LK  "L-@  K$0  *Q3
M  "L8P  K'<  *N.  "KI   J[P  *K>  "I]   J?T  *G_ (F.  ![DP
M;9<  %^<  !1H   1*0  #:F   JJ   'JD  !2K   -K@  !K    "R
MM0   +4   "U P  M@D  +<.  "X$@  N!D  +HA  "[*P  O#@  +U'  "]
M6   O6L  +V!  "]F0  O;   +W,  "\Z@  O/<  +O^ 'Z5  !PFP  8J
M %.E  !&J@  .*T  "JO   >L0  $[0   RW   #N0   +P   "_    P@
M ,(   ##    Q    ,8&  #'#   R!   ,H6  #,(   SRL  - Z  #12P
MT5X  -)S  #2BP  TJ0  -.[  #3V   T^T  -/V '.=  !DHP  5JD  $>O
M   YLP  *K8  !VY   2O   "K\   ##    Q@   ,D   #-    SP   -
M  #2    U    -8   #9 @  VP@  -X.  #A$P  Y!T  .@J  #H/   Z4\
M .ED  #J?   ZY4  .NL  #KP@  [-4  .SE &:F  !8K   2;,  #NY   K
MO   '<   !'$   )R    ,P   #/    TP   -D   #=    X    .$   #C
M    Y0   .<   #J    [    .X$  #Q"P  ]1(  /@<  #[*P  _3X  /Y3
M  #^:@  _X,  /^;  #_K@  _[X  /_* /\ $@#_ !  _P 1 /\ $P#_ !D
M_P F /\ - #_ $$ _P!- /\ 6 #_ &( _P!K /\ <P#_ 'H _P"! /\ AP#_
M (T _P"3 /\ F0#_ *  _P"G /X KP#\ +H ^@#) /D X0#X /, ]P#_ /8
M_P#U /\ \0#_ .D _P#D /\ X0#_ /\ #P#_  T _P - /\ #@#_ !0 _P A
M /\ +@#_ #P _P!( /\ 4P#_ %T _P!F /X ;0#\ '4 ^P![ /D @@#X (@
M]P". /8 E #T )L \P"B /$ J@#O +0 [0#! .L U0#J .P Z #\ .< _P#E
M /\ Y@#_ .  _P#9 /\ U #_ /\ "P#_  @ _P & /\ "0#_ !  _P < /\
M*0#_ #8 _P!" /L 3@#W %< ] !@ /( : #O &\ [0!V .P ? #J (( Z "(
M .< C@#E )4 XP"< .$ I #? *X W0"Y -H R@#7 .0 U #V -$ _P#0 /\
MT #_ ,\ _P#+ /\ QP#_ /\  P#_    _P   /\ ! #_  T ^@ 6 /8 (P#S
M #  \  \ .T 1P#I %$ Y0!: .( 8@#? &D W0!O -H =@#8 'P U "" -(
MB #0 (\ S0"6 ,L G@#) *@ QP"S ,4 P0#" -@ P #O +\ _@"^ /\ O0#_
M +P _P"\ /\ O #_ /\"  #_    _P   /\   #T  < [0 1 .@ ' #C "D
MWP U -L 00#6 $L T0!4 ,T 7 #* &, R !I ,8 ;P## '4 P0![ +\ @@"^
M (@ O "0 +H F "X *( M0"L +, N0"Q ,L KP#G *X ^ "L /\ JP#_ *P
M_P"L /\ JP#_ /\$  #_    ]@   .X   #G    WP , -8 %0#/ "( R@ N
M ,< .@## $0 P !- +P 50"Y %P MP!C +4 :0"S &\ L0!U *\ >P"M ((
MJP"* *D D@"G )P I0"F *, LP"A ,, GP#> )X \@"= /\ G #_ )P _P";
M /\ FP#_ /\'  #V"0  Z0L  -\*  #5!   S@ % ,8 $ #  !H NP G +<
M,@"S #T L !& *T 3P"J %8 J !< *8 8P"D &@ H@!O *$ =0"? 'P G0"$
M )L C0"9 )< EP"B )4 K@"3 +T D0#3 )  [0"/ /P C@#_ (T!_P"- ?\
MC0'_ /D.  #J$@  W!4  ,T5  #$$0  O@P  +H""@"T !( K@ > *H *@"F
M #4 H@ _ *  2 "= 5  FP)6 )D"7 "7 V, E0-I ),#;P"1!'8 D 1_ (X%
MB ",!9( B@:> (@&J@"&![H A0C/ (0*ZP"""_P @0S_ ( ,_P" #/\ @ S_
M /$5  #@'0  S2   ,$A  "X'0  L1<  *P0  "H"0T H@<6 )T)(P"9"BX
ME0LX ),,00"0#$D C@U0 (P-5P"*#5T B UC (<-:@"%#G$ @PYZ ((.A "
M#H\ ?@^; 'P/J ![$+@ >A#. '@1[ !V$O\ =1+_ '03_P!T$_\ =!/_ .@>
M  #3)@  PRH  +@J  "N*   IR,  * <  ";$P, E@\0 ) 0&P",$2< B1(R
M (83.P"$$T, @A1+ ( 440!^%%< ?!1> 'L590!Y%6P =Q5T '86?@!T%HH
M<A>6 '$7I !O&+0 ;AC) &T9Z !K&OP :AO_ &H;_P!J&_\ :AO_ . F  #*
M+0  O#$  + S  "G,0  GRP  )<F  "0'P  BA<, (48%@"!&2( ?AHL 'L;
M-@!Y&SX =QQ% '4<3 !S'%, <1U9 ' =8 !N'6< ;1YP &L>>@!J'H4 :!^2
M &<?H !E(+  9"'% &,AY !B(OH 82+_ &$B_P!A(O\ 82+_ -<L  ##-
MMC@  *HY  "A.   F#4  ) O  "(*   @"$( 'L@$@!W(1T ="(G '$B,0!O
M(SD ;2-! &LC2 !I(TX :"15 &8D6P!E)&, 8R5K &(E=0!A)8$ 7R:. %XF
MG0!=)ZT 6RC! %LHX !:*?< 62G_ %DI_P!9*?\ 62C_ ,\R  "^.0  L3T
M *8_  "</P  DSP  (HV  "!,   >2H# '(F#P!N)QD :R@C &DH+ !F*34
M92D\ &,I0P!A*DH 8"I1 %XJ5P!=*E\ 7"MH %HK<@!9+'T 6"R+ %8MF@!5
M+:H 5"Z] %,NW !2+_4 4B__ %(N_P!2+O\ 4B[_ ,HV  "Z/0  K4(  *)$
M  "81   CT$  (4\  ![-P  <C$  &LL# !G+14 9"T? &$N* !?+C$ 72XY
M %PO0 !:+T8 6"]- %<O5 !6,%P 53!D %,Q;@!2,7H 43&( % REP!.,J@
M33.[ $TTV !,-/, 3#3_ $PT_P!,,_\ 3#/_ ,8Z  "V0@  J48  )Y)  "5
M20  BT<  (%"  !W/0  ;3<  &0R"0!@,A( 73(< %HR)0!8,RT 5C,U %4S
M/ !3-$, 4C1* %$T40!0-%D 3S5A $TU; !,-G< 2S:% $HWE0!(-Z8 1SBX
M 4<XTP%&./$!1CC_ 48X_P!&./\ 1C?_ ,$^  "R10  IDH  )Q-  "230
MB$L  'Y'  !S0@  :3T  %\W!@!:-A  5S<8 %0W(@!2-RH 4#<R $\X.0!-
M.$  3#A' $LX3@!*.58 23E? $@Z:0!'.G4 13N# $0[DP!#/*0!0CRV 4$]
MT %!/? !03W_ 4$\_P%!//\!03S_ +Y"  "O20  HTX  )E0  "/40  A5
M 'M,  !O1@  94(  %H] @!4.PX 43L5 $\['P!-.R< 2SLO $D\-@!'/#T
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M #)(_P R2/\ ,TC_ +1,  "G5   G%D  ))<  "(70  ?ET  '-:  !E50
M6U(  %!.  !&2@4 0$D. #Y)%@ ]21X .THF #I*+@ Y2C4 .$L] #=+1  V
M2TT -$Q6 #-,8  R3&P ,4UZ #!-BP N39P +4ZO "Q.QP L3ND +$W] "U-
M_P M3/\ +4S_ +!0  "D6   F5T  (]A  "&8@  >V$  '!?  !B6P  6%@
M $Y5  !#40$ .T\, #A/$P V3QL -4\C #10*P S4#( ,E Z #%00@ P44H
M+E%3 "U270 L4FD *U)X "E2B  H4YH )U.M "93Q0 F4^< )E/\ "=2_P G
M4?\ )U'_ *Q5  "@7   EF(  (UF  "#9P  >&8  &UE  !@80  55X  $I;
M   _6   -58( #%5$  P5A< +E8? "U6)P L5B\ *U<V "I7/@ I5T< *%=0
M "986@ E6&< )%AU "-9A@ A69@ (%FK !]9P@ ?6>4 'UCZ "!8_P @5_\
M(5?_ *A:  "=8@  DV<  (IK  !_;   =6P  &IK  !=:   464  $9C   [
M8   ,5X# "I=#0 H71, )ET; "5>(P D7BH (UXR ")>.@ A7D, (%], !]?
M5P >7V, '&!Q !M@@@ 98)4 &&"I !=@P  68.( %U_Y !A>_P 97O\ &5W_
M *1@  "9:   D&X  (9P  !\<@  <G(  &9Q  !8;@  3&P  $%K   V:0
M+6<  "-F"  ?9@\ '685 !QF'0 ;9B4 &F8M !EG-0 89SX %V=( !9G4P 5
M:%\ $VAN !)H?P 1:)( $&BF  ]HO0 .:.  $&?W !!F_P 19?\ $67_ )]G
M  "6;P  C',  ()V  !X>   ;7@  &!W  !3=@  1G0  #MS   Q<@  )W$
M !YQ   6< H $W 0 !-P%P 2<!\ $7$G !!Q+P 0<3@ #G%"  YQ3@ -<5L
M#'%I  MQ>@ *<8T "'&A  9QM@ &<-( !W#O  AO_P );O\ "6[_ )MO  "1
M=0  AWD  'Y\  !T?@  9GX  %E^  !-?@  0'T  #5]   J?   (7P  !A\
M   1? 0 #'P,  I\$0 )?!D "'PA  =\*0 &?#( !'P]  -\2  !?%4  'QC
M  !\=   ?(<  'N<  ![L0  >LL  'GK  !Y^@  >?\  'C_ )9W  ",?
M@X   'F#  !LA   7H4  %&&  !%AP  .8<  "V'   CAP  &H<  !*'   -
MB $ !HD*  &)#P  B10  (@;  "((P  B2P  (DV  ")0@  B$X  (A=  "(
M;0  B($  (>5  "'JP  AL0  (7F  "$^   A/\  (3_ )!^  "'@P  ?H<
M '&)  !CBP  5HT  $F/   \D0  ,)$  "21   :D@  $I,   V4   &E0
M )8&  "6#   E1   )85  "6'0  EB0  )8N  "6.0  ED8  )95  "690
MEG@  )6.  "5I   E+P  )/?  "3]0  DO\  )+_ (N&  "#B@  =8T  &>0
M  !9E   3)<  #^9   RF@  )IL  !N<   2G0  #)\   2@    H@   *,!
M  "C!P  HPP  *,0  "D%0  I!P  *4E  "F+P  ICP  *9+  "F6P  IFX
M *6$  "EFP  I+,  */0  "C[P  HOP  *+_ (:-  !XD0  :I4  %R9  !.
MG0  0:   #.B   FHP  &Z4  !&G   *J0   :L   "M    KP   +    "P
M    L 4  +$+  "R#P  LQ0  +0;  "U)   MS   +<_  "W4   MV(  +=X
M  "WD   MJD  +;"  "VY   MO4  +7^ 'N3  !MF   7YT  %"B  !"I@
M-*D  ":K   :K0  $*\   FR    M    +<   "Z    O    +T   "^
MO@   , "  #!"   P@T  ,02  #&&0  R20  ,HR  #+0P  RU4  ,QJ  #,
M@P  S)P  ,NU  #,S@  S.D  ,SV '";  !AH0  4J8  $2K   VL   )[(
M !JU   0N   ![L   "^    P0   ,0   #(    RP   ,L   #-    S@
M -    #2    U0,  -@*  #;$   WA@  .(D  #C-0  Y$@  .5<  #F<P
MYHT  .:E  #FO   YM,  .?G &.D  !5J@  1K   #BU   HN0  &KP   _
M   %Q    ,<   #+    SP   -0   #8    W    -T   #?    X0   .,
M  #E    Z    .H   #M!@  \0X  /46  #X)0  ^3@  /E-  #Z8P  ^WP
M /R5  #\J@  _+L  /W+ /\ #P#_  X _P . /\ $ #_ !8 _P C /\ , #_
M #T _P!) /\ 5 #_ %X _P!F /\ ;@#_ '8 _P!\ /\ @@#_ (D _P"/ /\
ME0#^ )L _0"C /L JP#Z +4 ^0## /< VP#V /  ] #_ /, _P#R /\ [ #_
M .( _P#< /\ U@#_ /\ # #_  D _P ( /\ "@#_ !( _P > /\ *P#_ #@
M_P!$ /\ 3P#_ %D _@!A /P :0#Z '  ^ !W /< ?0#V (, ] ") /( CP#Q
M )8 [P"= .T I0#L *\ Z@"\ .@ S0#F .@ Y #Z ., _P#B /\ X #_ -4
M_P#. /\ RP#_ /\ !@#_  $ _P   /\ ! #_  X _P 9 /\ )0#] #( ^P ^
M /< 20#S %, \ !< .X 8P#L &H Z@!Q .@ =P#F 'T Y "# .( B0#@ )
MW@"7 -P GP#9 *D U@"T -, Q #0 -X S@#S ,P _P#+ /\ R@#_ ,@ _P#"
M /\ O@#_ /\   #_    _P   /\   #[  L ]@ 3 /$ ( #M "P Z@ X .<
M0P#C $T X !6 -P 70#9 &0 U0!K -( <0#0 '8 S@!\ ,P @P#* (D R "1
M ,8 F0#$ *, P0"M +\ NP"] ,\ NP#K +D _ "W /\ MP#_ +8 _P"T /\
ML0#_ /\   #_    _P   /8   #N  4 YP / .$ &0#; "4 U0 Q -( / #.
M $8 R@!/ ,< 5P#$ %X P0!D +\ :@"] '  NP!V +D ? "X (, M@"* +,
MDP"Q )P KP"G *T LP"K ,4 J0#A *< ]0"F /\ I0#_ *0 _P"D /\ I #_
M /\   #\    \0   .@   #@    U  + ,P $P#' !\ P@ J +\ -0"\ #\
MN !( +4 4 "S %< L !> *X 9 "L &D JP!O *D =0"G 'P I0"$ *, C "A
M )8 GP"A )T K0": +P F #2 )< [@"5 /X E #_ )4 _P"5 /\ E0#_ /P!
M  #P!0  XP<  -4%  #,    Q0 $ +X #@"X !< LP C *\ +@"K #@ J0!!
M *8 2@"C %$ H0!7 )\ 70"= &, FP!I )H ;P"8 '8 E@!] )0 A@"2 )
MD "; (X IP", +8 B@#) (@ YP"' /D AP#_ (8 _P"& /\ A@#_ /0,  #D
M$   T1(  ,41  "]#@  M@@  +$ " "K !$ I@ ; *$ )@"> #$ F@ Z )@
M0P"5 $H DP!1 )$ 5P"/ %T C@!C (P :0"* '  B !W (8 @ "$ (L @@"6
M (  HP!^ +$ ?0#$ 'L"X0!Z _4 >@7_ 'D%_P!X!O\ > ;_ .H3  #6&@
MQAT  +H<  "Q&0  JA,  *0-  "?!0P F0 4 )4 'P"1 BD C0,S (L$/ "(
M!40 A@9+ (0&40""!U< @0== '\'8P!]"&H >PAR 'H(? !X"88 =@F2 '0*
MH !S"J\ <0O! ' ,WP!O#?8 ;@[_ &T._P!M#O\ ;0[_ .$<  #+(P  O"8
M +$F  "H)   H!X  )D8  "3$ ( C@L. (@+%P"$#"( @0TL 'X--0!\#CT
M>@Y% '@.2P!W#E$ =0]8 ',/7@!Q$&4 <!!N &X0=P!L$(( :Q"/ &D1G0!H
M$:T 9A+  &42WP!D$_8 8Q3_ &,4_P!B%/\ 8A3_ -8D  ##*@  M2X  *HO
M  "@+0  F"@  ) B  ")&P  @A,( 'T1$@!Y$AP =A,G ',4, !Q%#@ ;Q4_
M &T51@!L%4P :A93 &@660!G%F$ 919I &07<@!B%WX 81B+ %\8F0!>&:D
M7!F\ %P:V !:&_, 6AS_ %D<_P!9'/\ 61S_ ,TJ  "],0  KS4  *0V  ";
M-   DC$  (DK  "!)0  >1T# ',8#@!O&1@ ;!HB &D;*P!G&S, 91P[ &0<
M00!B'4@ 8!U. %\=50!='5P 7!YD %L>;@!9'WD 6!^' %8@E@!5(*8 5"&X
M %,AT@!2(O$ 4B/_ %(C_P!2(O\ 4B+_ ,@O  "X-@  JSH  * \  "6.P
MC3@  (,R  !Z+0  <B8  &H@# !F(!, 8R$= &$A)@!?(B\ 72(V %LB/0!:
M(T0 6"-* %<C40!5(U@ 5"1A %,D:@!1)78 4"6# $\FDP!.)Z, 3">U $PH
MS@!+*.X 2RG_ $LH_P!+*/\ 2RC_ ,,T  "S.P  IS\  )Q!  "20   B3X
M '\Y  !U,P  ;"T  &,G" !>)A$ 7"89 %DG(@!7)RL 52@R %0H.0!2*$
M42A& % I30!.*54 32E= $PJ9P!+*G, 22N  $@KD !'+*$ 1BVS $4MRP!%
M+NP 1"[_ $0N_P!%+?\ 12W_ +XX  "P/P  I$,  )E%  "/10  A4,  'L^
M  !Q.0  9S0  %XN! !8*PX 52L6 %(L'P!0+"< 3RPO $TM-@!,+3P 2BU#
M $DM2@!(+E( 1RY: $8O9 !%+W  0S!^ $(PC0!!,9X 0#*Q #\RR  _,^H
M/S/^ #\R_P _,O\ /S+_ +L\  "M0P  H4<  )9)  ",20  @T@  'A$  !M
M/@  8SD  %HT  !2, P 3S 3 $PP' !*,"0 23$K $<Q,@!&,3D 1#%  $,R
M1P!",D\ 03-8 $ S8@ _-&T /C1[ #TUBP \-IP .S:O #HWQ@ Y-^@ .3?\
M #HW_P Z-O\ .C;_ +=   "J1@  GDL  )1-  "*3@  @$P  '5(  !J0P
M8#X  %8Y  !--0D 2301 $<U&0!%-2$ 0S4H $$U+P! -38 /S8] #XV10 ]
M-TT /#=5 #LX8  Z.&L .3EY #@YB0 W.IL -3JM #4[Q  T.^8 -#O[ #4[
M_P U.O\ -3K_ +1#  "G2@  G$X  ))1  "(4@  ?E   '--  !G2   7$0
M %(_  !(.@8 1#D/ $$Y%@ _.1X /CDF #PY+0 [.C0 .CH[ #D[0@ X.TH
M-SQ3 #8\70 U/6D -#UW #,^AP Q/ID ,#^K "\_P@ O/^0 +S_Z # __P P
M/O\ ,#[_ +%'  "D30  F5(  (]5  "&5@  ?%4  '%2  !D3   64D  $]%
M  !%0 , /SX- #P^$P Z/AL .3XC #<^*@ V/S$ -3\X #0_0  S0$@ ,D!1
M #%!6P P06< +D)U "U"A0 L0Y< *T.J "I#P  I1.( *D/Y "I#_P K0O\
M*T+_ *Y*  "A40  EU8  (U9  "#6@  >5H  &Y7  !A4@  5TX  $U+  !#
M1P  .D,* #9#$0 T0Q@ ,T,@ #)$)P Q1"\ ,$0V "]%/0 M148 +$5/ "M&
M60 J1F0 *4=R "A'@P F1Y4 )4BH "1(O@ C2.  )$CW "5'_P E1_\ )D?_
M *I/  "?50  E%H  (M>  "!7P  =UX  &M<  !?6   554  $M1  ! 30
M-4H' #!)#@ N214 +4D= "Q))  K2BL *DHS "A*.P G2T, )DM, "5+5@ D
M3&( (TQP "%,@  @39, 'TVF !Y-NP =3MT 'DWV !Y,_P ?3/\ ($O_ *=3
M  "<6@  DE\  (AC  !^9   =&,  &EA  !<7@  4EL  $=8   \50  ,E("
M "I0#  G3Q( )E 9 "50(  D4"@ (U O ")1-P A44  (%%) !Y24P =4E\
M'%)M !I3?0 94Y  &%.D !93N0 54]D %E/T !=2_P 84?\ &5'_ *-9  "8
M8   CV4  (5H  ![:0  <6D  &9G  !99   36$  $)?   X7   +EH  "58
M"  @5PX 'E<4 !U7'  <6", &U@K !I8,P 96#P &%A% !994  565L %%EI
M !-:>@ 26HT $5JA !!:MP .6M4 $%GS !!9_P 16/\ $5C_ )]?  "59@
MC&L  ()M  !X;@  ;F\  &)M  !5:@  2&@  #YF   S90  *6,  "!A 0 8
M8 L %6 0 !1@%P 38!X $F F !)@+@ 183< $&%   ]A2P .85@ #6%F  QB
M=@ +8HD "F&=  EAL@ (8<L "&'K  E@_0 *7_\ "U__ )MF  "2;0  B'$
M 'YS  !U=0  :G0  %QS  !/<@  0W   #AO   M;@  )&P  !MK   3:P0
M#FH,  UJ$@ ,:AD "VHA  IJ*0 ):C( "&H\  =K1P %:U, !&MA  )K<0
M:H0  &J8  !JK0  :<8  &GG  !I^   :/\  &C_ )=M  "-<P  A'<  'MZ
M  !P>P  8WL  %9Z  !)>@  /7D  #%X   G=P  '78  !5V   /=@( "78*
M  1V#P  =A4  '8<  !V)   =2P  '4V  !U00  =4X  '5<  !U;   =7X
M '23  !TJ   <\   '/C  !R]P  <O\  ''_ ))U  ")>@  @'X  ':   !I
M@0  6X(  $Z"  !!@@  -8,  "F"   ?@0  %H$  !""   *@@   H,'  ""
M#0  @A$  ((7  ""'@  @B8  ((O  "".P  @D<  ()5  "!90  @7@  (&-
M  " H@  ?[H  '_=  !^]   ??\  'W_ (U\  "$@0  >X0  &Z&  !@B
M4HH  $6+   YC   +(P  "&,   7C   $(T   F.   "CP   ) #  "/"0
MCPX  (\2  "0&   D!\  ) H  "0,@  D#\  )!-  "070  CW   (^%  ".
MG   CK,  (W0  ",\   B_X  (O_ (B$  " B   <HL  &2-  !6D   2),
M #N5   NE@  (I8  !>7   /F   ")D   ";    G0   )T   "= P  G0D
M )T-  ">$0  GA<  )\?  "?*0  H#4  *!#  "@5   H&8  )][  ">DP
MGJL  )W&  "=Z0  G/D  )S_ (.+  !UC@  9Y(  %F6  !+F0  /9P  #">
M   CGP  %Z    ZB   'I    *8   "H    J@   *H   "J    JP$  *L'
M  "L#   K1   *X6  "O'@  L2D  +$X  "Q2   L5H  +%O  "QB   L:
M +"Z  "OW0  K_(  *_] 'B1  !JE@  7)H  $V?   _HP  ,:8  ".G   7
MJ0  #JL   6N    L    +(   "U    MP   +<   "X    N0   +H   "\
M P  O0D  +X.  # %   PQX  ,4K  #%/   QDX  ,9B  #&>@  QI0  ,:M
M  #&R   Q>4  ,7S &R9  !>G@  3Z0  $&H   RK   )*\  !:Q   -M
M [<   "Z    O0   ,    #$    Q@   ,8   #(    R0   ,L   #,
MS@   - &  #3#0  V!,  -P>  #>+0  WT   .!4  #A:P  X84  .&?  #A
MMP  X<\  .'F &"A  !2IP  0ZT  #2R   EM0  %[D   V\   !OP   ,,
M  #'    R@   ,\   #3    U@   -<   #:    W    -\   #A    XP
M .8   #I 0  [ L  / 2  #S'P  ]#$  /9&  #W7   ^'0  /B/  #YI@
M^;@  /C) /\ #0#_  L _P + /\ #@#_ !, _P ? /\ + #_ #D _P!% /\
M4 #_ %D _P!B /\ :@#_ '$ _P!W /\ ?@#_ (0 _@"* /T D #\ )< ^@">
M /D IP#W +$ ]@"^ /4 T@#S .P \0#^ /  _P#P /\ Y@#_ -P _P#2 /\
MS0#_ /\ !P#_  0 _P " /\ !@#_ !  _P ; /\ )P#_ #, _P _ /\ 2@#^
M %0 ^P!= /D 9 #W &L ]0!R /, > #R 'X \ "$ .\ B@#M )$ [ "9 .H
MH0#H *L Y@"V .0 QP#B ., X #W -X _P#= /\ V0#_ ,P _P#% /\ P0#_
M /\   #_    _P   /\  0#_  T _P 6 /P (@#Y "X ]@ Y /, 10#O $X
M[ !7 .D 7@#F &4 Y !L .( <@#@ '< WP!^ -T A #; (L V "2 -4 FP#2
M *0 SP"O ,T O@#+ -4 R0#O ,< _P#% /\ Q #_ +X _P"X /\ M0#_ /\
M  #_    _P   /X   #W  D \0 1 .L ' #G "@ Y  S .$ /@#= $@ V !1
M -, 6 #0 %\ S@!E ,P :P#* '$ R !W ,8 ?0#$ (0 P@", ,  E "^ )X
MNP"H +D M@"W ,@ M0#F +, ^@"Q /\ L #_ +  _P"L /\ J0#_ /\   #_
M    ^@   /$   #H  , X  - -@ %@#1 "( S0 M ,H -P#& $$ P@!* +\
M4@"] %D N@!? +@ 90"W &H M0!P +, =@"Q 'T KP"% *T C0"K )< J0"A
M *< K@"E +X H@#8 *  \@"? /\ G@#_ )X _P"> /\ G #_ /\   #W
MZP   .$   #6    RP ) ,4 $0"_ !L NP F +< ,0"T #H L0!# *X 2P"K
M %( J0!8 *< 7@"F &0 I !I *( < "@ '8 G@!^ )P A@": )  F "; )8
MIP"4 +8 D@#* )  Z0"/ /P C@#_ (T _P", /\ C0#_ /@   #I @  VP,
M ,P!  #$    O0 " +8 #0"P !4 JP @ *< *@"D #0 H0 \ )X 1 "< $L
MF@!2 )@ 6 "6 %T E0!C ), :0"1 '  CP!W (T @ "+ (H B0"5 (< H0"%
M *\ @P#! ($ X "  /4 ?P#_ '\ _P!_ /\ ?P#_ .X*  #<#@  RA   +X.
M  "U"P  KP,  *D !P"C !  G@ 8 )D (P"6 "P DP U )  /@". $4 C !+
M (H 40"( %< A@!= (4 8P"# &H @0!Q '\ >@!] (0 >P"/ 'D G !W *H
M=0"[ '0 U !R /  <@#_ '( _P!Q /\ <0#_ .,1  #-%P  OQD  +,9  "J
M%0  HQ   )T*  "7 0H D0 2 (T &P") "4 A0 O (, -P"  #X ?@!% 'T
M2P![ %$ >0!7 '@ 70!V &0 = %K '(!= !P G\ ;@*+ &P#F !K Z8 :02W
M &@%S@!G!^P 9@C] &8)_P!E"?\ 90G_ -8:  #$(   MB,  *LC  "A(
MF1L  )(4  ",#@$ A@<- ( $% !\!AX >0<H '8(, !T"#@ <@D_ ' )10!O
M"DP ;0I2 &P*6 !J"U\ : MG &<+< !E#'H 8PR' &(,E0!@#:0 7PVV %X-
MS@!<#NT 7 __ %L0_P!;$/\ 6Q#_ ,TA  "\*   KRL  *0K  ":*0  DB0
M (D?  ""&   >Q$% '4-#P!Q#1< ;@XA &L.*@!I#S( 9Q Y &400 !D$$8
M8Q!- &$04P!?$5H 7A%B %P1:P!;$78 61*# %@2D@!6$Z( 51.T %03RP!3
M%.P 4A7_ %(6_P!2%?\ 4A7_ ,8H  "V+@  J3(  )\R  "5,0  C"T  (,G
M  !Z(0  <AH  &L3"P!G$Q, 9!0< &$4)0!?%2T 714T %P5.P!;%D( 619(
M %@63P!6%U8 51=> %,79P!2&'( 4!A_ $\9C@!.&I\ 3!JP $L;QP!+&^D
M2AS] $H<_P!*'/\ 2AS_ ,$M  "Q-   I3<  )HX  "0-P  AS0  'TO  !T
M*0  ;",  &0<!P!>&1  6QH8 %D;(0!7&RD 51LP %0<-P!2'#T 41Q$ $\=
M2P!.'5( 31U: $L>8P!*'FX 21]\ $<?BP!&()P 12&N $0AQ !#(N8 0R+\
M $,B_P!#(O\ 0R+_ +PR  "M.   H3P  )<^  "-/0  @SH  'DU  !O,
M9BH  %XD @!7( T 5" 4 %$@'0!/(24 3B$L $PA,P!+(CH 22)  $@B1P!'
M(DX 1B-7 $0C8 !#)&L 0B1Y $$EB  _)ID /B:K #TGP0 ])^, /2CZ #TH
M_P ])_\ /2?_ +@V  "J/0  GD   )1"  "*0@  @#\  '8[  !L-@  8C
M %DJ  !1)0L 3241 $LE&0!))2$ 1R8H $4F+P!$)C8 0R8] $(G1 !!)TL
M/RA4 #XH70 ]*6D /"EV #LJA@ Y*Y< ."NI #<LOP W+.  -RSX #<L_P W
M+/\ ."S_ +4Z  "G0   G$0  )%&  "'1@  ?40  '-   !H.P  7S8  %4Q
M  !,*P< 1RD/ $4J%@!#*AX 02HE #\J+  ^*S, /2LY #PK00 [+$@ .BQ1
M #DM6P X+F8 -BYS #4O@P T+Y4 ,S"G #(PO0 Q,=X ,3'W #(Q_P R,/\
M,S#_ +$^  "D1   F4@  (]*  "%2@  >TD  '!%  !E0   6SL  %(V  !(
M,00 0BX- #\N$P ]+AL .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -#%/ #,Q
M60 R,F0 ,3)Q # S@0 O-), +C2F "PUNP L-=L +#7U "TU_P M-/\ +C3_
M *Y!  "B2   ETP  (U.  "#3@  >4T  &Y*  !B10  6$   $X\  !%-P
M/3,+ #DS$0 W,Q@ -C,? #0S)@ S,RT ,C0T #$T/  P-40 +S5, "XV5@ M
M-F( +#=O "LW?P J.)$ *#BD "<YN0 F.=@ )SGT "@Y_P H./\ *3C_ *M%
M  "?2P  E$\  (M2  "!4P  =U(  &Q/  !?20  5D8  $Q"  !"/0  .#@(
M #0X#P R.!4 ,3@= "\X)  N."L +3DR "PY.0 K.D$ *CI* "D[5  H.U\
M)SQM "4\?0 D/8\ (SVB "(]MP A/M0 (3[S "(]_P C/?\ (SS_ *A)  "=
M3P  DE,  (E6  !_5P  =58  &I3  !=3P  4TP  $I(  ! 1   -D % "\]
M#0 M/1, *ST: "H^(0 I/B@ *#XO "<^-P F/S\ )#]( "- 4@ B0%T (4%J
M "!!>@ >08T '4*@ !Q"M0 ;0M$ &T+Q !Q"_P =0?\ 'D'_ *5-  ":4P
MD%@  (9;  !]7   <EL  &=8  !;5   45(  $A.   ]2@  ,T<  "I#"P F
M0Q  )4,6 "1#'@ C1"4 (D0L "%$-  @13P 'D5% !U%3P <1EH &T9H !E&
M>  81XH %T>> !9'LP 42,X %4?O !9'_P 71O\ %T;_ *)2  "76   C5T
M (1@  !Z80  <&   &5>  !96@  3U@  $14   Y40  +TX  "9+!@ @2@X
M'DH3 !U*&@ <2B$ &TLH !I+,  92S@ %TM" !9,3  53%< %$QE !--=0 2
M38@ $4V< !!-L0 .3LP #TWN !!-_P 13/\ $4S_ )Y7  "470  BV(  (%E
M  !W9@  ;68  &-D  !680  2EX  #];   U6   *U8  ")4 0 :4@H %E(0
M !52%@ 44AT $U(D !)2+  14C0 $5(^ !!32  /4U0 #E-B  U4<@ ,5(0
M"U28  E4K0 (5,4 "53G  I3^P +4O\ "U+_ )M=  "19   B&@  'YK  !T
M;   :VP  %]J  !29P  160  #IB   P8   )EX  !U=   56P4 $%H,  Y:
M$0 .6A@ #5L@  Q;)P +6S  "ELZ  E;10 '6U$ !EM>  1;;0 #6X   5N4
M  !;J   6\   %KB  !:]@ !6O\  EG_ )=D  ".:P  A&X  'MP  !R<@
M9W$  %EP  !,;@  0&P  #5K   J:0  (6<  !AF   19@$ #&4*  =E#P $
M910  V0;  )D(P  9"P  &0U  !D0   9$P  &1:  !D:0  9'L  &2/  !C
MI   8[L  &+=  !B]   8O\  &'_ )-L  ")<0  @'4  'AW  !M>   8'<
M %)V  !&=0  .70  "YT   C<@  &G$  !)Q   -<0  !G$(  !P#0  <!(
M ' 7  !O'P  ;R8  &\P  !O.P  ;T<  &]4  !O9   ;W4  &Z*  !MH
M;;8  &S6  !K\@  :_\  &O_ (YS  "%>   ?7L  '-]  !E?@  6'X  $M^
M   ^?@  ,GX  "9]   <?   $WP   U\   &?0   'T%  !\"P  ? \  'P3
M  !\&0  ?"$  'PI  !\-   >T   'M.  ![7@  >V\  'J$  !ZF@  >;$
M 'C.  !W[P  =OX  ';_ (EZ  "!?P  >((  &N#  !=A0  3X8  $*'   U
MB   *8<  !V'   4AP  #8@   :)    B@   (H   ")!@  B0P  (D/  ")
M$P  B1H  (HB  "*+   BC@  (I&  ")5@  B6@  (E\  "(E   AZL  (;&
M  "%Z@  A?L  (3_ (6"  !]A@  ;X@  &&+  !3C0  18\  #B1   KD0
M'Y(  !22   -DP  !)0   "6    EP   )@   "7    EP4  )<+  "8#@
MF!,  )D:  "9(@  FBX  )H]  "930  F5X  )ES  "8BP  F*,  )>\  "6
MX@  EO<  )7_ (")  !RC   9(\  %:3  !(E@  .ID  "R:   ?FP  %)P
M  R>   #GP   *$   "C    I0   *4   "E    I0   *8"  "G"   IPT
M *@1  "I&0  JR,  *LQ  "K00  K%,  *QG  "K@   JIH  *JS  "JT
MJ>\  *G[ '6/  !GE   69@  $J<   \GP  +:(  ""C   3I0  "Z<   &I
M    JP   *X   "Q    L@   +(   "S    M    +4   "V    N 0  +D+
M  "[$   O1@  +\D  "_-0  P$<  ,!;  # <@  P(T  ,&F  # P0  O^,
M +[S &J7  !;G   3:$  #ZE   OJ0  (:L  !.M   +L    +,   "U
MN    +P   "_    P0   ,$   ##    Q    ,8   #'    R0   ,L   #.
M"   T0\  -48  #8)P  V3D  -I-  #;9   VWX  -R9  #<L   W,D  -SC
M %V?  !/I0  0*H  #*O   BL@  %+4   JX    NP   +\   ##    Q@
M ,L   #.    T0   -$   #4    U@   -D   #;    W@   .    #D
MYP8  .L.  #O&0  \"H  /(_  #S50  ]&T  /2(  #TH0  ]+8  /3' /\
M"0#_  8 _P ' /\ # #_ !$ _P < /\ * #_ #0 _P!! /\ 3 #_ %4 _P!=
M /\ 90#_ &P _P!R /X > #\ 'X ^P"$ /H BP#Y )( ]P"9 /8 H@#T *P
M\P"Y /$ RP#P .@ [@#[ .T _P#L /\ X0#_ -( _P#) /\ Q #_ /\  0#_
M    _P   /\ ! #_  X _P 7 /\ (P#_ "\ _P [ /T 1@#Z %  ]P!8 /0
M7P#R &8 \ !L .\ <@#M '@ [ !^ .H A0#I (P YP"3 .4 G #C *8 X0"Q
M -\ P0#= -T VP#T -D _P#6 /\ SP#_ ,0 _P"] /\ N0#_ /\   #_
M_P   /\   #_  L _  3 /< '@#T "H \@ U .X 0 #I $H Y@!2 ., 60#@
M &  W@!F -P ; #: '( UP!X -0 ?@#2 (4 T "- ,X E0#, )\ R0"J ,<
MN #% ,T PP#K ,  _@"_ /\ O@#_ +8 _P"P /\ K0#_ /\   #_    _P
M /D   #R  8 ZP / .8 &0#A "0 W@ O -H .0#3 $, SP!, ,P 4P#) %H
MQP!@ ,4 9@## &L P0!Q +\ =P"] 'X NP"& +D C@"W )@ M0"C +, L "Q
M ,( K@#@ *P ]P"K /\ J@#_ *@ _P"C /\ H #_ /\   #_    ]0   .L
M  #A    U@ , ,\ $P#* !X Q@ I ,( ,P"_ #T NP!% +@ 30"V %0 LP!:
M +$ 7P"P &4 K@!J *P < "K '< J0!_ *< AP"E )$ HP"< *  J0"> +@
MG #. )H [@"9 /\ EP#_ )8 _P"6 /\ DP#_ /T   #Q    Y0   -D   #-
M    Q  & +T #P"W !@ LP B +  + "M #8 J0 ^ *< 1@"D $T H@!3 *
M60"? %X G0!D )L :@": '  F !W )8 @ "4 (H D0"5 (\ H@"- +  BP##
M (D XP"( /D A@#_ (8 _P"& /\ A@#_ /,   #C    T0   ,4   "]
MM@   *X "P"H !( I  < *  )@"< "\ F@ W )< /P"5 $8 D@!, )$ 4@"/
M %@ C0!= (L 8P"* &H B !Q (8 >0"$ (, @@"/ '\ FP!^ *D ? "[ 'H
MU0!X /( > #_ '< _P!W /\ =P#_ .<'  #1#   PPT  +@,  "N"   J
M *( !0";  X E@ 5 )( 'P". "@ BP Q (@ .0"& $  A !& (( 3 "  %(
M?P!7 'T 70![ &, >@!K '@ <P!V 'T = "( '$ E0!P *0 ;@"T &P R@!K
M .H :@#\ &H _P!J /\ :@#_ -H0  #&%   N!8  *T5  "D$@  G X  )8'
M  "0  D B@ 0 (4 & "! "$ ?@ J 'L ,@!Y #D =P!  '4 1@!S $P <@!1
M '  5P!N %X ;0!E &L ;@!I '< 9P"# &4 D0!C )\ 8@"O &  Q !? .0
M7P'X %X"_P!> O\ 7@+_ ,X8  "]'0  L"   *4?  ";'   DQ<  (L1  "$
M#   ?@0+ 'D $@!U !L <@ C &\ *P!M 3, :P$Z &D"0 !G T8 9@-, &0$
M4@!C!%D 801@ %\%:0!>!7, 7 9_ %H&C0!9!YP 5PBM %8(P0!5">$ 5 OV
M %0+_P!4"_\ 5 O_ ,8?  "V)0  J2@  )XH  "4)0  BR$  (,;  ![%
M= X# &X)#0!I"!0 9@D= &0*)0!B"BT 8 LT %X+.@!="T  6PQ' %H,30!8
M#%0 5PU< %4-9 !4#6\ 4@U[ % .B@!/#IH 3@ZL $P/P@!,$., 2Q#Y $L0
M_P!+$?\ 2Q#_ +\F  "P*P  I"\  )DO  "/+0  ABD  'TD  !T'@  ;!<
M &41!P!?#A  7 \7 %H0'P!8$"< 5A N %00-0!3$#L 4A%" % 12 !/$5
M3A%7 $P28 !+$FL 21)X $@3AP!&$Y< 112I $04O@!#%=\ 0Q;X $,6_P!#
M%O\ 0Q;_ +HK  "K,0  H#0  )4U  "+-   @3$  '@K  !O)@  9B   %X9
M 0!7% T 5!03 %$4&P!/%2, 3A4J $P5,0!+%C< 218^ $@61 !'%TP 11=4
M $0770!#&&< 01AT $ 9@P _&I0 /1JF #P;NP [&]L .QSV #P<_P \'/\
M/!S_ +4P  "H-@  G#D  )$[  "'.@  ?C<  ',R  !J+0  82<  %DA  !1
M&PD 3!D0 $H:%P!(&A\ 1AHF $4;+0!#&S, 0ALZ $$<00! '$@ /AQ0 #T=
M60 \'F0 .QYQ #D?@  X'Y( -R"D #8@N  U(=8 -2'T #4B_P U(?\ -B'_
M +(T  "D.@  F3X  (\_  "%/P  >SP  ' X  !G,@  72T  %0H  !,(@4
M1A\. $,?% !!'QL /Q\B #X@*0 ](#  .R V #HA/0 Y(44 .")- #<B5P V
M(V( -"-N #,D?@ R)(\ ,26B "\EM@ O)M( +R;R "\F_P P)O\ ,";_ *\X
M  "B/@  ED(  (Q#  ""0P  >$$  &X]  !C.   6C,  %$N  !(* $ 0"0,
M #TC$0 [)!@ .20? #@D)@ V)"P -24S #0E.@ S)D( ,B9* #$G5  P)U\
M+RAL "XH>P L*8T *RJ@ "HJM  I*L\ *2OP "HK_P J*O\ *RK_ *P\  "?
M0@  E$8  (I'  " 1P  =D4  &Q"  !A/0  5S@  $XS  !$+@  /"D) #<H
M$  U*!4 ,R@< #(H(P P*"D +RDP "\J-P N*C\ +2M( "PK4@ K+%T *BQJ
M "@M>0 G+8L )BZ> "4NLP D+\T )"_N "4O_P E+_\ )B[_ *D_  "=10
MDDD  (A+  !^3   =$H  &I'  !>0@  5#T  $LY  !!-   ."\& #(M#0 P
M+1, +BT9 "TM(  K+2< *BXN "DN-0 I+ST *"]& "<P3P E,%L )#%H ",Q
M=P B,HD (3*= !\SL0 >,\L 'C/M !\S_P @,_\ (3+_ *9#  ":20  D$T
M (9/  !\4   <T\  &A,  !<1@  4D,  $D_   _.P  -C8" "XR#  K,A$
M*3(7 "@R'@ F,B0 )3,K "0S,@ C-#H (C1# "$U30 @-5@ 'S9E !XV=0 <
M-X< &S>; !HWKP 9.,@ &3CK !HX_P ;-_\ &S?_ *-'  "830  CE$  (13
M  ![5   <5,  &90  !:3   4$D  $=%   ]00  ,ST  "HY"0 E-PX (S<4
M "(X&P A."( (#@H !\X,  >.3@ '3E! !PZ2P :.E8 &3MC !@[<@ 6.X4
M%3R9 !0\K0 3/<8 $SWI !0\_0 5//\ %CO_ *!+  "540  BU4  ()8  !Y
M60  ;E@  &16  !840  3D\  $5+   Z1P  ,$,  "= !0 @/@T '3X1 !P^
M%P ;/AX &CXE !D^+0 8/S4 %C\^ !4_2  40%, $T!@ !)!<  108( $$&7
M  ]!K  .0L0 #D+G  ]!_  00?\ $$#_ )U0  "35@  B5H  (!=  !V7@
M;%T  &);  !65P  3%4  $%1   V3@  +$L  "-(   ;10D %T0/ !5$%  4
M11L $T4B !)%*0 113$ $44[ !!&10 /1E  #D=>  U';0 ,1W\ "T>3  E'
MIP (1[X "$?@  E']@ *1O\ "T;_ )I5  "06P  AV   'UB  !S8P  :F(
M &!A  !37@  1UH  #Q7   R50  *%(  !]0   73@0 $4P,  ],$0 .3!<
M#DP>  U-)0 ,32X "TTW  I-0@ )34T !TY:  9.:0 $3GL  DZ/  %.I
M3;H  $W;  %-\@ !3?\  DS_ )9;  "-8@  A&8  'IH  !Q:0  :&D  %QG
M  !/9   0F$  #=?   M7   (UH  !I8   25P$ #58)  E5#@ '51, !E4:
M  15(@ #52H  E4T  !5/@  54H  %97  !690  57<  %6+  !5H   5;8
M %34  !4\0  4_T  %/_ )-B  "*:   @&P  '=N  !O;P  8VX  %9L  !)
M:@  /6@  #)F   G90  '6,  !5B   .80  "6 (  -@#0  7Q$  %\7  !?
M'@  7R8  %\O  !?.@  7T4  %]3  !?80  7G(  %Z'  !=G   7;(  %S/
M  !<[P  6_T  %O_ )!J  "&;P  ?7(  '5T  !J=0  770  $]S  !"<@
M-G   "MO   @;@  %VT  !!L   *;    FL&  !K"P  :@\  &H4  !J&@
M:B$  &DJ  !I-   :4   &E.  !I7   :6T  &B"  !HF   9ZX  &;*  !E
M[0  9?P  &3_ (MQ  ""=@  >GD  '![  !B>P  57L  $AZ   [>@  +WH
M "-Y   9>   $7<   IW   #=P   '<"  !W"   =@T  '80  !V%0  =AL
M '8C  !V+@  =3H  '5'  !U5@  =6@  '1\  !TD@  <ZH  '+$  !QZ0
M</L  '#_ (9Y  !_?0  =G\  &B!  !:@@  3((  #^#   RA   )8,  !J#
M   1@P  "H,   *#    A    (4   "$ P  @P@  (,-  "#$   @Q4  (0<
M  "$)@  A#(  (0_  "#3P  @V   ()U  ""C   @:0  ("]  !_XP  ?OD
M '[_ (*   !ZA   ;(8  %Z(  !0B@  0HL  #6-   GC0  &XT  !&.   *
MC@   (\   "1    D@   )(   "2    D@$  )('  "2#   DA   ),5  "3
M'0  E"@  )0V  "410  DU<  )-K  "3@@  DIP  )&V  "0V   C_,  (__
M 'Z'  !PB@  88T  %.0  !%DP  -Y4  "F6   <EP  $9@   F9    FP
M )P   ">    H    *    "@    H    *$   "A!   H@D  *,.  "D%
MI1T  *8J  "F.@  IDP  *5@  "E>   I9(  *2L  "DR0  H^L  *+Z '..
M  !DD0  5I4  $>9   YG   *IX  !V@   1H0  "*,   "E    IP   *D
M  "L    K@   *X   "N    KP   +    "Q    L@   +,&  "U#0  MQ,
M +D>  "Y+@  ND   +I4  "[:@  NH4  +FA  "YNP  NMX  +GR &>5  !8
MF0  2IX  #NB   LI@  ':@  !&J   'K    *\   "Q    M    +@   "[
M    O    +P   "^    OP   ,    #"    Q    ,8   #( P  RPL  ,\2
M  #1(   T3(  -)&  #370  U'8  -22  #5JP  U<0  -3B %N=  !,H@
M/:<  "^L   ?KP  $;$   >U    N    +L   "^    P@   ,<   #*
MS    ,P   #.    T    -(   #5    V    -L   #?    X@   .8+  #K
M$P  ["0  .TX  #N3@  [V<  /""  #PG   \+(  /'% /\  P#_  $ _P $
M /\ "0#_  \ _P 8 /\ ) #_ #  _P \ /\ 1P#_ %$ _P!9 /\ 8 #] &<
M_ !M /H <P#Y 'D ^ !_ /8 A0#U (P \P"4 /( G0#P *< [@"S .P Q #K
M .$ Z@#X .D _P#G /\ V0#_ ,L _P#" /\ O0#_ /\   #_    _P   /\
M  #_  P _P 4 /\ ( #_ "L _@ W /H 0@#V $L \@!3 /  6P#N &$ [ !G
M .H ;0#H ', YP!Y .4 ?P#C (8 X0". -\ E@#= *  VP"L -@ NP#4 -$
MTP#P -  _P#. /\ R #_ +T _P"V /\ L@#_ /\   #_    _P   /\   #]
M  @ ]P 0 /, &@#O "8 [0 Q .@ .P#C $4 X !- -P 50#9 %L U@!A -,
M9P#1 &P SP!R ,T > #+ '\ R0"' ,< D #% )H PP"E ,  L@"^ ,4 O #E
M +H ^P"X /\ MP#_ +  _P"I /\ I0#_ /\   #_    _@   /4   #L  ,
MY0 - -\ %0#: "  U  J -  -0#+ #X R !' ,4 3@#" %4 P !; +X 80"\
M &8 N@!L +@ <@"V '@ M0"  +, B "Q )( K@"> *P J@"I +L J #5 *8
M\P"D /\ HP#_ *$ _P"; /\ F #_ /\   #[    \    .4   #8    S@ )
M ,< $0#" !H O@ D +L +@"W #@ M !  +$ 2 "N $X K !4 *H 6@"I %\
MIP!E *4 :P"D '$ H@!X *  @0"> (L G "6 )D HP"7 +( E@#' ), Z "2
M /X D0#_ )  _P"- /\ BP#_ /D   #K    W0   ,\   #&    O  $ +4
M#0"P !4 K  > *@ * "E #$ H@ Y )\ 00"= $@ FP!. )D 4P"7 %D E@!>
M )0 9 "2 &H D !Q (X >@", (, B@"/ (@ G "& *H A "\ (( W "! /8
M@ #_ '\ _P!_ /\ ?@#_ .P   #:    R0   +X   "V    K@   *< "0"A
M !  G  8 )@ (@"5 "H D@ R )  .@"- $$ BP!' (D 30"' %( A@!8 (0
M70"" &0 @0!K '\ <P!] 'T >P"( '@ E0!V *, =0"T ', S !Q .T < #_
M '  _P!P /\ < #_ -\%  #*"@  O L  +$)  "H!   H0   )L  P"4  P
MCP 3 (H &P"' "0 A  L ($ ,P!_ #H ?0!! 'L 1P!Y $P =P!2 '8 5P!T
M %T <@!D '  ;0!O '8 ; "" &H CP!I )T 9P"N &4 PP!D .0 8P#Z &,
M_P!B /\ 8P#_ - .  "_$@  LA,  *<2  "=$   E0L  (\#  ")  < @@ .
M 'X %0!Z !X =@ E '0 +0!Q #0 ;P Z &X 0 !L $8 :@!, &D 4@!G %@
M9@!? &0 9P!B '$ 8 !\ %X B0!< )@ 6P"I %D O !8 -P 6 #T %@ _P!7
M /\ 5P#_ ,86  "V&@  JAT  )\<  "5&0  C10  (4/  !^"0  =P$* '(
M$ !N !< :@ ? &@ )P!E "X 9  T &( .P!@ $  7P!& %T 3 !< %, 6@!:
M %@ 8@!7 &P 50!W %, A0!2 )0 4 &E $\!N !. M( 303P $T%_P!-!?\
M307_ +\=  "P(@  HR4  )DE  "/(@  A1T  'T8  !U$@  ;@T" &<&# !C
M Q$ 7P(9 %T#(0!;!"@ 600O %<%-0!6!3L 5 9! %,&1P!1!DX 4 =5 $X'
M7@!-"&< 2PAS $D)@0!("9( 1PJC $4*M@!$"]  1 SO $,-_P!##?\ 1 W_
M +DD  "J*0  GBP  )0L  "**@  @"8  '<A  !N&P  9A0  %\/!0!9"PT
M50H3 %,+&P!1"R( 3PPI $T,+P!,##8 2PT\ $D-0@!(#4D 1@U1 $4.6@!$
M#F0 0@YP $ .?P _#Y  /A"B #P0M@ [$-$ .Q'Q #L1_P [$?\ /!'_ +0I
M  "F+P  FC(  ) R  "&,0  ?"T  '(H  !I(P  81T  %D6  !1$0@ 3 \0
M $H0%@!($!T 1A D $40*P!#$3$ 0A$W $$1/@! $44 /A)- #T25@ \$F$
M.A-M #D3?  W%(T -A2? #45LP T%<T ,Q;N #06_P T%O\ -!;_ *\N  "B
M-   ES<  (PX  ""-@  >#0  &XN  !E*@  7"0  %0>  !,& 0 1A0- $(4
M$@! %!D /Q0@ #T5)P \%2T .Q4T #D6.@ X%D( -Q9* #874P U%UX ,QAJ
M #(9>0 P&8H +QJ= "X:L0 M&\H +1OL "T<_P N&_\ +AO_ *PR  "?.
ME#L  (H\  " /   =CD  &LT  !B+P  62H  % E  !''P  0!H* #P9$  Z
M&18 .!D= #8:(P U&BD -!HP #,:-P R&SX ,1M' "\<4  N'5L +1UG "P>
M=@ J'H@ *1^; "@?K@ G(,< )B#J "<@_@ H(/\ *"#_ *DV  "=/   DC\
M (=!  !]0   =#X  &DZ  !?-0  5C   $TK  !$)0  .R ' #8>#@ S'A,
M,AX9 # >(  O'B8 +A\M "T?-  L(#L *R!$ "HA3@ I(5@ )R)E "8B=  E
M(X4 (R.9 "(DK0 A),4 (27H "(E_0 B)/\ (R3_ *8Z  ":/P  CT,  (5%
M  ![1   <D,  &<_  !=.@  4S8  $HQ  !!+   ."8# #$C#  N(A$ +"(6
M "HB'0 I(B, *",J "<C,0 F)#D )25! "0E2P C)E8 (B9C "$G<@ ?)X,
M'BB7 !THJP ;*<, &RGF !PI^P =*?\ 'BC_ *,^  "80P  C4<  (-)  !Z
M20  <$<  &9$  !:/P  43L  $<W   ^,@  -2T  "PH"0 H)P\ )R<4 "4G
M&@ D)R$ (R@G "(H+@ A*38 ("D_ !\J20 >*E0 '2M@ !LK;P :+($ &2R5
M !<MJ0 6+<$ %BWD !<M^@ 8+?\ &2W_ *%!  "51P  BTL  ()-  !X30
M;DP  &1)  !81   3T   $8]   ].   ,S0  "HO!@ D+ T (2P2 " L&  ?
M+1X 'BTE !TM+  <+C0 &RX\ !HO1@ 8+U$ %S!> !8P;0 5,7\ $S&3 !(Q
MJ  1,K\ $3+B !(R^0 3,?\ $S'_ )Y%  "32P  B4\  (!1  !V4@  ;5
M &).  !620  348  $1#   [/P  ,3H  "<V P ?,@L '#(0 !LR%0 9,AL
M&#(B !<S*0 6,S$ %30Z !0T1  3-$\ $C5< !$U:P 0-GT #S:1  XVI@ -
M-[P #3?=  TV]@ .-O\ #S;_ )M)  "13P  AU,  'Y6  !U5@  :E4  &!3
M  !53P  3$P  $))   X10  +D$  "0]   <.@@ %C@. !4X$@ 4.!@ $SD?
M !(Y)@ 1.2X $#DW  \Z00 ..DP #3M9  T[:  +.WH "CN-  D\H@ '/+@
M!SS5  @\\  )._\ "CO_ )A.  ".5   A5@  'Q;  !R6P  :%H  %Y8  !3
M50  25(  #Y.   T2P  *D<  "%$   80@, $D + ! _$  ./Q4 #C\<  U
M(P ,0"L "T T  I /@ )04H !T%6  9!90 $078  T&*  %!GP  0;0  $'0
M  %![@ !0?P  D#_ )54  ",60  @UX  'E@  !P8   9F   %U>  !16P
M15<  #I4   O40  )4\  !Q,   42@  #D@(  M'#@ (1Q( !T<9  9'(  %
M2"@  T@Q  )(.P  2$<  $A3  !(8@  2',  $B&  !(FP  2+$  $?,  !'
M[0  1_L  $?_ )):  ")8   @&,  '=E  !N9@  968  %ED  !,8   0%T
M #5;   J60  (%<  !=5   04P  "U('  51#0 !4!$  % 6  !0'0  4"4
M % N  !0.   4$,  %!0  !07@  4&\  %"#  !/F   3ZX  $[)  !.ZP
M3?L  $W_ (]A  "&9@  ?6D  '1L  !L;0  86L  %-I  !&9P  .F0  "]C
M   D80  &E\  !)>   ,7   !EP&  !;"P  6@\  %H3  !:&0  62$  %DI
M  !9,P  63\  %E,  !96@  66L  %A^  !8E   5ZL  %?%  !6Z0  5?L
M %7_ (QH  "";0  >G   ')R  !G<@  6G$  $QP   _;@  ,VT  "AK   =
M:@  %&@   UG   '9P   &8#  !F"0  90T  &41  !D%0  9!P  &0D  !D
M+@  9#H  &-'  !C50  8V8  &-Z  !BD   8:<  &#!  !?Y@  7_H  %[_
M (=O  !_=   >'<  &YX  !@>   4G<  $5W   X=@  *W8  "!T   6<P
M#G,   =R    <@   '(   !Q!0  <0H  '$.  !P$0  <!<  ' >  !P)P
M<#,  &]   !O4   ;V   &YT  !NBP  ;:(  &R\  !KX@  :O@  &G_ (-W
M  !\>P  <WT  &5^  !7?P  27\  #Q_   O@   (G\  !=^   /?@  !WX
M  !_    ?P   '\   !^    ?@4  'X*  !^#0  ?A$  'X7  !^(   ?BL
M 'TY  !]2   ?5D  'QM  !\A   >YP  'JV  !YV@  >/4  '?_ (!_  !W
M@@  :8,  %N%  !-A@  /X@  #*)   DB0  &(D   ^)   'B@   (L   ",
M    C0   (T   ",    C    (P#  ","   C0T  (T1  "-%P  CB(  (XO
M  "./P  C5   (UD  ",>P  C)4  (NN  "*S0  B>\  (G_ 'N%  !MB
M7HH  %"-  !"CP  -)$  ":2   9DP  #I0   :5    E@   )@   ":
MFP   )L   ";    FP   )L   "<    G04  )T+  ">$   GQ<  * D  "@
M-   H$8  *!9  "?<   GXH  )ZE  ">P@  G>@  )SY '",  !ACP  4Y(
M $26   VF0  )YL  !F<   /G0  !9\   "A    HP   *4   "H    J0
M *D   "I    J@   *L   "L    K0   *X!  "P"0  L@\  +,8  "T)P
MM#D  +5-  "T9   M'X  +.:  "SM   L]4  +/P &23  !5EP  1YL  #B?
M   IH@  &J0   ZF   $J    *L   "M    L    +0   "V    N    +@
M  "Y    N@   +P   "]    OP   ,    ##    Q0<  ,D/  #*&@  RRP
M ,Q   #-5@  SF\  ,V+  #,J   S,(  ,SB %B;  !)H   .J4  "RI   <
MJP  #ZX   2Q    M    +<   "Z    O@   ,,   #&    R    ,@   #*
M    RP   ,T   #/    T@   -4   #9    W0   .$%  #F#P  YQX  .@R
M  #I2   ZF   .M[  #KEP  [*X  .S" /\   #_    _P   /\ !@#_  T
M_P 5 /\ (0#_ "P _P X /\ 0P#_ $P _@!4 /L 6P#Z &( ^ !H /8 ;@#U
M '0 ] !Z /( @ #Q (< [P"/ .T EP#K *$ Z0"M .< O0#E -@ Y #S .(
M_P#@ /\ T #_ ,0 _P"\ /\ M@#_ /\   #_    _P   /\   #_  D _P 1
M /\ ' #] "< ^0 R /4 /0#Q $8 [0!/ .L 5@#H %P Y@!B .0 : #C &X
MX0!S -\ >0#= (  V@"( -@ D0#4 )L T@"F ,\ M #, ,D R0#I ,@ _P#'
M /\ P0#_ +< _P"O /\ JP#_ /\   #_    _P   /\   #X  4 \@ . .X
M%P#J "( Y@ L .$ -P#= $  V !) -, 4 #0 %8 S@!< ,P 8@#* &< R !M
M ,8 <P#$ 'D P@"! ,  B@"^ )0 O "? +D K "V +X M #= +, ]P"Q /\
ML #_ *@ _P"B /\ G@#_ /\   #_    ^0   .\   #F    WP + -8 $@#0
M !P S  F ,@ , #$ #H P !" +T 2@"[ %  N !6 +8 6P"U &$ LP!F +$
M; "P '( K@!Z *P @@"I (P IP"8 *4 I0"C +0 H #+ )\ [@"= /\ G #_
M )D _P"4 /\ D0#_ /\   #V    Z@   -T   #/    QP & ,  #P"[ !<
MMP @ +, *@"P #, K0 [ *H 0P"G $D I0!/ *, 50"B %H H !? )X 90"=
M &L FP!R )D >P"7 (4 E "0 )( G0"0 *P C@"_ (P X@"+ /H B0#_ (D
M_P"& /\ @P#_ /0   #D    U    ,@   "_    M0 ! *X "P"I !( I0 ;
M *$ (P"> "P FP T )@ / "6 $, E !) )( 3@"0 %, C@!9 (T 7@"+ &0
MB0!K (< <P"% 'T @P"( ($ E0!_ *0 ?0"U 'L SP!Y /$ > #_ '< _P!W
M /\ =0#_ .4   #1    PP   +@   "O    J    *  !@":  X E0 5 )$
M'@". "8 BP M (@ -0"& #P A !" (( 1P"  $T ?P!2 'T 6 ![ %X >0!E
M '@ ;0!V '8 <P"! '$ C@!O )T ;0"N &P Q !J .< :0#] &@ _P!H /\
M:0#_ -4#  ##!P  M@@  *L&  "B    FP   )0   "-  H B  0 (, & !_
M "  ?  G 'H +@!W #4 =0 [ '0 00!R $< < !, &\ 4@!M %@ :P!? &D
M9@!G '  90![ &, B !B )< 8 "G %X NP!= -P 7 #V %P _P!; /\ 6P#_
M ,D-  "Y$   K!$  *$0  "7#0  CP@  (@   ""  4 >P - '< $@!S !H
M;P A &P * !J "\ :  U &< .P!E $$ 8P!& &( 3 !@ %( 7P!9 %T 80!;
M &H 60!U %< @@!5 )$ 5 "B %, M0!1 ,\ 4 #O %  _P!0 /\ 4 #_ +\4
M  "P&   I!H  )D9  "/%@  AQ$  '\-  !W!@  <0 ( &L #@!G !0 9  ;
M &$ (@!> "D 70 O %L -0!9 #L 6 !! %8 1@!5 $T 4P!4 %( 7 !0 &4
M3@!P $P ?0!+ (T 20"> $@ L !' ,< 1@#I $8 ^P!& /\ 10#_ +@;  "J
M(   GB(  ),B  ")'P  @!H  '<5  !O$   : L  &$$"@!= !  60 6 %8
M'0!4 ", 4@ J %  , !/ #4 3@ [ $P 00!+ $@ 20!/ $<!5P!& 6$ 1 )L
M $,">0!! XD 0 .: #X$K0 ]!,0 / 7E #P'^  \!_\ / ?_ +(B  "E)P
MF2D  (XI  "$)P  >R,  '$>  !I&   81(  %H- P!3" P 3P41 $P%%P!*
M!AX 2 8D $<&*@!%!S  1 <V $,(/0!!"$, 0 A+ #X)4P ]"5T .PIH #H*
M=@ X"X< -PN9 #4+K  T#,( ,PSD #,-^0 S#?\ - W_ *TG  "@+   E2\
M (LO  " +@  =RH  &TE  !D(   7!H  %04  !,#P8 1@P- $,,$@!!#!@
M/PP? #X,)0 \#2L .PTR #H-.  X#3\ -PY' #8.4  T#EH ,PYF #$/=  P
M#X4 +A"8 "T0JP L$,, *Q'E "P1^@ L$?\ +1'_ *HL  "=,0  DC0  (<U
M  !]-   =#$  &HK  !@)P  6"$  $\;  !'%@  0!$) #L0#P Y$!0 -Q ;
M #80(0 T$"< ,Q$M #(1-  Q$3L ,!%# "X230 M$E< +!)C "H3<0 I$X(
M)Q25 "84J0 E%<  )!7C "46^@ F%O\ )A7_ *8Q  ":-@  CSD  (4Z  ![
M.0  <38  &<Q  !=+0  5"@  $PB  !#'0  .Q<% #44#0 R$Q$ ,107 "\4
M'0 N%"0 +!0J "L5,0 J%3@ *19  "@62@ G%U0 )A=@ "08;P C&(  (1F3
M " 9IP ?&;X 'AK@ !\:^  @&O\ (!K_ *,T  "8.@  C3T  (,^  !Y/0
M;SL  &4W  !;,@  4BT  $DH  ! (P  .!X! # 9"@ L& \ *A@4 "D8&@ G
M&"  )ADG "49+0 D&C4 (QH^ "(;1P A&U( (!Q> !\=;  ='7X '!V1 !H>
MI0 9'KP &!_= !D?]@ :'_\ &Q[_ *$X  "5/0  BT$  (%"  !W0@  ;4
M &,\  !9-P  3S,  $8N   ]*0  -20  "T@!P G'0T )1T2 ",=%P A'1T
M(1TD " >*P ?'C( 'A\[ !T?10 <($\ &B%< !DA:@ 8(GL %B*/ !4BHP 4
M([H $R/: !0C]0 5(_\ %B/_ )X\  "300  B40  ']&  !U1@  ;$0  &)!
M  !7/   33@  $0T   \,   ,RL  "HF P C(@L ("$0 !XA%0 <(AL &R(A
M !HB*  :(S  &2,X !@D0@ 6)4T %259 !0F:  3)GD $B:- !$GH@ 0)[@
M#B?6 ! H]  1)_\ $2?_ )Q   "110  AT@  'U*  !T2@  :DD  &!&  !5
M00  3#X  $,Z   Z-@  ,3(  "@M   @*0D &R<. !DG$@ 8)Q@ %B<? !4H
M)0 4*"T $R@V !(I0  2*4L $2I7 ! J9@ .*W< #BN+  TLGP ,++4 "RS/
M  PL[P -+/\ #2O_ )E$  "/20  A4P  'Q.  !S3P  :4X  %Y+  !31P
M2D0  $)    Y/0  +S@  "4T   =, 4 %BT, !0L$  3+14 $BT< !$M(P 0
M+2H #RXS  XN/0 -+T@ #2]5  PP8P *,'0 "3"(  @QG  &,;$ !C'+  8Q
MZP ',/P "##_ )=(  "-30  @U$  'I3  !Q5   9U(  %U0  !23   24H
M $!&   U0@  *SX  "(Z   :-P$ $C0)  \S#@ .,Q, #3,9  TS(  ,-"@
M"S0Q  HU.P (-48 !S52  4V8  $-G$  C:$   VF0  -J\  #;(   VZ
M-OD  37_ )1-  "*4@  @58  'A8  !O60  95@  %M5  !14@  1T\  #Q,
M   Q2   )T0  !Y!   6/P  $#P'  LZ#0 ).A$ "#L7  8['@ %.R8 !#LN
M  ([.  !/$,  #Q/   \7@  /&X  #R!   \EP  /*P  #O%   [YP  ._@
M #O_ )%2  "(6   ?UP  '9=  !M7@  8UT  %I<  !.6   0E0  #=1   M
M3@  (TL  !I)   21@  #40&  =##  #0Q   $,5  !#&P  0R,  $,K  !#
M-0  0T   $--  !#6P  0VL  $-^  !#E   0JH  $+#  !!Y@  0?D  $'_
M (Y8  "&7@  ?6$  '-C  !K9   8F,  %=A  !)70  /5H  #)8   G50
M'E,  !51   .3P  "4T%  )-"P  3 X  $P3  !+&   2Q\  $LH  !+,@
M2ST  $M)  !+5P  2V<  $I[  !*D   2:<  $G   !(Y   2/@  $?_ (M?
M  "#9   >F<  '%I  !I:@  7FD  %!F  !#9   -V$  "Q?   A70  &%L
M !!9   *6    U<#  !7"0  5@T  %40  !5%0  5!L  %0C  !4+0  5#D
M %1%  !44P  5&0  %-W  !3C0  4J0  %&]  !0X@  4/@  $__ (AG  !_
M:P  =VX  &]P  !E<   5VX  $IL   ]:P  ,&D  "5H   :9@  $60   MC
M   $8@   &(!  !A!@  8 L  & .  !?$@  7Q<  %\>  !>*   7C,  %Y
M  !>3P  7E\  %UR  !=B   7*   %NY  !:WP  6?<  %C_ (1N  !\<@
M=74  &MV  !==0  3W0  $)S   U<P  *'(  !UP   3;P  #&X   1N
M;@   &X   !L @  ; <  &L+  !K#@  :Q(  &H9  !J(@  :BT  &HZ  !I
M20  :5H  &EL  !H@P  9YL  &:U  !EV   9/4  &3_ (!U  !Z>0  <'L
M &)[  !4?   1GP  #E\   L?   'WL  !1Z   ->@  !'H   !Z    >@
M 'H   !Y    >0$  '@&  !X"P  > X  '@3  !X&@  >"4  '@R  !W00
M=U(  '=E  !V?   =94  '2O  !SS@  <O$  ''_ 'Y]  !U@   9X$  %B"
M  !*@P  /(0  "Z%   AA0  %84   V%   #A0   (8   "'    B    (@
M  "'    AP   (<   "'!   APD  (<.  "($P  B!P  (@I  "(.   ATH
M (==  "&<P  AHT  (6G  "$Q0  @^P  (+^ 'B$  !JA@  7(@  $V*   _
MC   ,8X  "./   6CP  #9    *1    D@   ),   "5    E@   )8   "6
M    E@   )8   "7    EP   )<'  "8#0  F1,  )H?  ":+0  FC\  )I2
M  "::   F8,  )F?  "8N@  E^(  );X &V*  !?C0  4)   $&3   SE@
M))<  !:8   -F0   9L   "=    GP   *$   "D    I0   *0   "E
MI0   *8   "G    J    *D   "J!   K P  *X3  "N(0  KC,  *Y'  "N
M70  KG8  *Z3  "NK@  K<T  *SO &&1  !3E0  1)@  #6<   FGP  %Z$
M  VC    I0   *<   "J    K    +    "R    M    +,   "T    M0
M +<   "X    N0   +L   "]    OP$  ,,+  #%%0  Q24  ,8Y  #'3P
MQV@  ,:%  #&H@  QKP  ,;> %69  !'G0  .*(  "FF   9J   #:L   "M
M    L0   +0   "W    N@   +\   #!    Q    ,,   #%    Q@   ,@
M  #*    S0   ,\   #2    U@   -L   #@#   X1@  .,K  #D00  Y5H
M .9T  #FD0  Y:P  .7$ /\   #_    _P   /\  0#_  H _P 2 /\ '0#_
M "@ _P T /\ /@#] $@ ^@!0 /< 5P#U %T ] !C /( :0#P &\ [P!T .T
M>P#K ($ Z0") .@ D@#F )P Y "H .( MP#? ,T W #N -D _P#9 /\ R@#_
M +X _P"U /\ L #_ /\   #_    _P   /\   #_  8 _P / /P & #X ",
M]  N /  . #K $( Z !* .4 40#B %@ X != -X 8P#< &@ V0!N -8 = #4
M 'L T0"" ,\ BP#- )4 R@"A ,@ KP#% ,$ P@#C ,  ^P#  /\ NP#_ +
M_P"H /\ I #_ /\   #_    _P   /L   #S  $ [0 , .@ $P#C !X X  H
M -H ,@#3 #P SP!$ ,P 2P#) %$ Q@!7 ,0 70#" &( P0!G +\ ;0"] '0
MNP![ +D A "W (X M "9 +( IP"O +< K0#0 *L \@"J /\ J0#_ *$ _P";
M /\ EP#_ /\   #_    ]    .D   #@    U0 ( ,X $ #) !@ Q0 B ,$
M*P"\ #4 N0 ] +8 10"S $L L0!1 *\ 5@"N %L K !A *H 9@"I &T I@!T
M *0 ? "B (8 H "2 )X GP"< *X F0## )< YP"6 /\ E0#_ )( _P"- /\
MB@#_ /P   #P    XP   -0   #(    OP # +D #0"S !, KP < *P )0"I
M "X I0 V *, /@"@ $0 G@!* )T 4 "; %4 F0!: )< 7P"6 &8 E !L )(
M=0"0 'X C@"* (L EP") *8 AP"X (4 U@"$ /8 @@#_ ($ _P!^ /\ ? #_
M .T   #=    S    ,$   "X    K@   *< "0"B !  G@ 7 )H 'P"7 "<
ME  O )$ -P"/ #T C0!# (L 20") $X B !3 (8 60"$ %\ @@!E (  ;0!^
M '< ? "" 'H CP!X )X =0"O ', QP!R .P <0#_ '  _P!P /\ ;@#_ -T
M  #)    O    +$   "I    H0   )D  P"3  P C@ 2 (H &0"' "$ A  I
M ($ , !_ #< ?0 ] 'L 0@!Y $@ > !- '8 4@!T %@ <@!? '$ 9P!O '
M; ![ &H B !H )< 9@"H &4 O !C .$ 8@#Z &$ _P!A /\ 80#_ ,T!  "\
M!0  KP4  *4"  "<    E    (T   "&  @ @0 . 'P % !X !L =0 C '(
M*0!P #  ;@ V &T / !K $$ :0!' &@ 3 !F %( 9 !9 &, 8 !A &D 7P!T
M %T @0!; )  60"A %< M !6 -  50#R %4 _P!4 /\ 50#_ ,$,  "R#@
MI@\  )L.  "2"P  B04  ((   ![  ( =0 + '  $ !L !8 :  = &8 (P!C
M "H 80 P &  -@!> #L 70!! %L 1@!: $P 6 !3 %8 6P!4 &0 4@!N %$
M>P!/ (H 30"; $P K@!+ ,8 2@#J $D _@!) /\ 20#_ +D2  "J%@  GA<
M )06  "*$P  @1   'D+  !Q P  :P & &4 #0!A !$ 70 8 %H '@!8 "0
M5@ J %0 , !3 #8 40 [ %  00!. $< 30!. $L 5@!) %\ 1P!I $8 =@!$
M (4 0P"7 $$ J0!  +\ /P#B #\ ^  ^ /\ /P#_ +(9  "D'@  F!\  (X?
M  "$'   >A@  '(2  !J#@  8@@  %P!" !7  X 4P 3 %  &0!. !\ 3  E
M $H *P!( #  1P V $8 / !$ $( 0P!) $$ 40 _ %H /@!E #P <@ Z ($
M.0"3 #@ I0 V +H -@#; #4 ]  U /\ -0#_ *P@  "?)   E"8  (DF  !_
M)   =2   &P;  !D%0  7!   %0, 0!.!@H 2@(/ $< % !$ !H 0@ @ $
M)0 _ "L /@$Q #P!-P [ CX .0)% #@#30 V U8 -01A #,$;@ Q!7X , 60
M "\%HP M!K@ + ;4 "P'\  L"/\ + C_ *@E  ";*@  D"P  (8M  ![*P
M<B<  &@B  !?'0  5Q<  $\2  !(#@0 00H+ #X'$  [!A4 .0<; #@'(0 V
M""8 -0@L #,(,@ R"3D ,0E! "\)20 N"E, + I> "L+;  I"WP * R/ "8,
MH@ E#+< ) S3 ",-\  D#?\ )0W_ *0J  "8+P  C3(  (,R  !Y,0  ;RX
M &4I  !<)   4Q\  $L9  !#$P  /! & #4-#  S#!$ ,0P6 "\,'  N#2(
M+0TH "L-+@ J#34 *0T] "<.1@ F#E  ) Y< ",/:@ B#WL (!". !\0H@ =
M$+< '!#4 !T1\@ =$?\ 'A'_ *$O  "5,P  BC8  ( W  !V-@  ;3,  &,O
M  !9*@  4"4  $@@   _&@  .!4  # 1"  L$ X *A 2 "@0&  G$!X )1 D
M "00*@ C$3( (A$Z "$10P @$DX 'A): !T3:  ;$W@ &A.+ !@4H  7%+4
M%A31 !85\0 7%?\ &!3_ )XS  "3-P  B#H  'X[  !T.P  :S@  &$T  !7
M+P  3BL  $4F   ](0  -!P  "T7!0 F$PP (Q,0 "(3%0 @$QH 'Q,A !X4
M)P =%"\ '!4W !L500 :%DL &197 !<790 6%W8 %!B) !,8G@ 2&+, $1G.
M !$9[P 2&?\ $QG_ )PV  "1.P  ACX  'P_  !S/P  :3T  %\Y  !5-0
M3#   $,L   Z)P  ,B(  "H> 0 B&0D 'A<. !P7$@ :%Q< &1@> !D8)  8
M&2P %QDT !8:/@ 5&DD $QM5 !(;8P 1''0 $!R'  \=G  .';$ #1W+  T=
M[  .'?\ #QW_ )DZ  "//P  A$(  'M$  !Q0P  :$(  %X^  !3.@  2C8
M $$R   Y+0  ,2D  "@E   @( 8 &AT, !<<$  5'!4 %!T; !0=(@ 3'2D
M$AXR !$?/  0'T8 $"!3  X@80 -(7$ #"&%  LBF0 *(JX "2+'  DBYP *
M(OL "R'_ )<^  ",0P  @T8  'E(  !P2   9T8  %Q$  !2/P  23L  $ X
M   X-   +S   "<L   >)P, %B,* !(A#@ 1(1, $"(9 ! B(  /(B< #B,O
M  TD.0 ,)$0 "R50  HE7@ ))F\ !R:"  8FE@ $)JP  R;$  0FY0 $)O<
M!B;_ )5"  "*1P  @4H  'A,  !O3   94L  %M(  !01   1T$  #\^   W
M.P  +38  "0Q   ;+0  $RH'  \H#0 -)Q$ #2@6  PH'0 +*"4 "BDM  DI
M-P '*D( !BI.  0K7  #*VP  2M_   KE   *ZD  "O!   KXP  *_8  "K_
M ))&  "(2P  ?T\  '91  !M40  8U   %I-  !/2@  1T<  #Y$   S0
M*3P  " X   7-   $3$%  PO#  )+A  !RX5  8O&P %+R,  R\K  (P-0
M,#\  #!,   Q60  ,6D  #%\   QD0  ,:<  #"_   PX0  ,/4  "__ )!+
M  "&4   ?50  '56  !K5@  8E4  %A3  !.4   14T  #I)   O10  )4(
M !P^   4.P  #CD%  DW"P $-@\  383   V&0  -B   #8I   V,@  -ST
M #=)   W5P  -V<  #=Y   WCP  -J4  #:]   VX   -?4  #7_ (U0  "$
M5@  ?%H  ');  !I6P  8%L  %=9  !,5@  0%(  #5.   J2P  ($@  !=&
M   00P  "T$$  1 "@  /PX  #X1   ^%@  /AT  #XF   ^+P  /CH  #Y&
M   ^5   /F0  #YV   ]C   /:,  #R[   \W@  ._4  #O_ (I7  ""7
M>5\  '!A  !H80  7V$  %1>  !'6P  .E<  "]5   E4@  &U   !)-   ,
M2P  !DH#  !)"0  2 T  $<0  !'%   1AH  $8B  !&+   1C<  $9#  !&
M40  1F   $5S  !%B0  1*   $2X  !#W   0O4  $+_ (A=  !_8@  =V4
M &YG  !G:   6V8  $YC  !!80  -%X  "E<   ?6@  %5<   Y6   '5
M %,!  !2!@  40L  %$.  !0$0  3Q8  $\>  !/)P  3S(  $\_  !/30
M3ET  $YO  !.A0  39T  $RU  !+V   2O4  $K_ (5E  !\:0  =&P  &UN
M  !B;0  5&L  $=I   Z9P  +64  ")D   88@  $&    E?    7@   %X
M  != P  7 @  %L,  !:#P  6A,  %D9  !9(@  62T  %DZ  !92   6%@
M %AK  !7@0  5YD  %:R  !5T@  5/0  %/_ (%L  !Y<   <W,  &AS  !:
M<@  3'$  #]P   R;P  )6X  !IL   1:P  "6H   !J    :0   &D   !H
M    9P,  &8(  !F#   9@\  &44  !E'   92<  &0T  !D0P  9%,  &1E
M  !C>P  8I0  &&M  !@S0  7_$  %[_ 'UT  !W=P  ;GD  %]Y  !1>0
M0WD  #9X   I>   ''<  !%V   *=0   '4   !U    =@   '4   !T
M=    ',"  !S!P  <PP  '(0  !R%0  <B   '(L  !R.P  <4P  '%?  !Q
M=   <(X  &^H  !NQ@  ;.T  &O_ 'M[  !R?@  9'X  %5_  !'@   .8$
M "N"   >@0  $H$   J!    @0   ((   "#    @P   (,   ""    @@
M ((   ""    @@4  ((*  ""#P  @A<  ((C  "",@  @D,  (%6  "!;
M@(8  '^A  !^O0  ?>8  'S\ ':"  !H@P  684  $N'   \B0  +HH  ""+
M   3BP  "HL   ",    C0   (\   "1    D@   )$   "1    D0   )$
M  "1    D@   )("  "3"0  E \  )09  "4)P  E#@  )1,  "38@  DWP
M ).8  "2LP  D=@  )#V &J(  !<B@  38T  #^0   PD@  (90  !25   *
ME@   )<   "9    FP   )T   "?    H    *    "@    H    *$   "B
M    HP   *0   "E    I@<  *@0  "H'   J"T  *E   "I5@  J6\  *F+
M  "HJ   I\<  *;L %^/  !0D@  098  #.9   CG   %)T   J?    H0
M *,   "F    J    *P   "N    KP   *\   "P    L    +(   "S
MM    +8   "W    N@   +T'  "_$   OQ\  , S  # 20  P&(  ,!^  #
MFP  P+<  +_8 %.7  !$FP  -9\  ":C   6I0  "Z<   "J    K0   +
M  "S    M@   +L   "]    P    +\   #!    P@   ,0   #&    R
M ,H   #,    SP   -,   #:!P  VQ,  -TE  #>.P  WU,  .!N  #?C
MW:D  -W" /\   #_    _P   /\   #_  < _P 0 /\ &0#_ "0 _P O /P
M.@#Y $, ]0!+ /, 4@#Q %D [P!> .T 9 #K &D Z0!O .< =0#F 'P Y "$
M .( C0#@ )< W0"B -H L0#5 ,4 T@#H -  _P#/ /\ Q #_ +@ _P"O /\
MJ0#_ /\   #_    _P   /\   #_  ( ^P - /< %0#S !\ [P I .H - #F
M #T X@!% -X 3 #; %, V !8 -0 7@#2 &, T !I ,X ;@#, '4 R@!] ,@
MA0#& )  P@"; ,  J0"^ +H NP#9 +D ]P"X /\ M #_ *D _P"B /\ G0#_
M /\   #_    _P   /8   #N    YP * .$ $0#< !H UP C -  +@#+ #<
MQP _ ,0 1@#! $T OP!2 +T 6 "[ %T N0!B +@ : "V &X M !U +$ ?@"O
M (@ K0"3 *H H0"H +$ I@#( *0 [0"B /\ H@#_ )L _P"5 /\ D0#_ /\
M  #\    [@   .,   #8    S0 % ,8 #@#! !4 O0 > +D )P"U #  L@ X
M *\ 0 "L $8 J@!, *@ 40"G %8 I0!; *, 80"A &< GP!N )X =@"; (
MF0", )< F0"4 *@ D@"\ )  WP". /L C@#_ (L _P"& /\ @P#_ /@   #I
M    W    ,P   #!    N    +( "@"L !$ J  8 *4 (0"B "D G@ R )P
M.0"9 #\ EP!% )4 2@"4 %  D@!5 )  6@"/ &  C0!G (L ;P") '@ A@"$
M (0 D0"" *  @ "R 'T S !\ /$ >P#_ 'H _P!W /\ =0#_ .8   #3
MQ@   +L   "Q    IP   *$ !0";  T EP 3 ), &P"0 ", C  K (H ,@"(
M #@ A@ ^ (0 1 "" $D @0!. '\ 4P!] %D >P!@ 'D : !W '$ =0!\ ',
MB0!P )@ ;P"I &T OP!K .8 :@#_ &D _P!I /\ 9P#_ -,   ##    M0
M *L   "C    FP   )(   ",  H AP 0 (, %@!_ !T ?0 D 'H *P!X #(
M=@ X '0 /0!R $( <0!( &\ 30!M %, ; !9 &H 80!H &H 9@!T &0 @0!A
M )$ 7P"B %X M@!< -4 6P#W %L _P!: /\ 6@#_ ,4   "V @  J0(  )\
M  "6    C@   (<   "   4 >@ , '4 $0!Q !@ ;@ > &L )0!I "L 9P Q
M &8 -P!D #P 8P!! &$ 1P!? $T 7@!3 %P 6P!: &0 6 !N %8 >P!4 (H
M4@"; %$ K@!0 ,@ 3P#N $X _P!. /\ 30#_ +L*  "L#0  H T  )4,  ",
M"   @P(  'P   !U    ;@ ( &D #@!E !, 8@ 9 %\ 'P!= "4 6P K %D
M,0!8 #8 5@ [ %4 00!3 $< 40!. %  50!. %X 3 !H $H =0!( (0 1P"5
M $4 J !$ +\ 0P#D $( _ !" /\ 0@#_ +(1  "E%   F14  (X3  "$$0
M>PT  ',(  !L    90 # %\ "P!;  \ 5P 4 %0 &@!1 !\ 3P E $X *P!,
M #  2P V $D / !( $( 1@!( $4 4 !# %D 00!C #\ ;P ^ 'X / "0 #L
MHP Z +@ .0#9 #@ ]0 X /\ . #_ *P7  "?&P  DQT  (D<  !_&0  =14
M &P0  !D#   708  %8 !@!1  P 30 0 $H %0!' !H 10 @ $0 )@!" "L
M00 Q #\ -@ ^ #T / !$ #L 2P Y %0 -P!? #8 :P T 'H ,@", #$ G@ P
M +, +P#. "\ [P N /\ +@#_ *<>  ":(@  CR0  (0D  !Z(0  <1T  &<8
M  !?$P  5PX  % *  !) P@ 10 - $$ $0 ^ !8 /  ; #H (0 Y "8 -P L
M #8 ,@ T #@ ,P _ #$ 1P P %  +@!; "T 9P K '8 *@"( "@ G  G +
M)@#) "4 Z@ E ?L )0'_ *(C  "6*   BRH  ($J  !W*   ;24  &0@  !;
M&P  4A4  $L0  !## ( /0<) #D##@ V 1( ,P$7 #$!'  P 2( +P(G "T"
M+0 L S0 *@,[ "D$0P H!$T )@58 "4%90 C!G0 (@:& " &F@ ?!ZX '@?&
M !T'YP ="/@ '0G_ )\H  "3+0  B"\  'XO  !T+@  :BL  &$F  !8(0
M3QP  $<7   _$@  . X$ #$+"@ N" X *P<2 "D'%P H"!T )P@C "4(*0 D
M"3  (PDW "$*0  @"DH 'PM5 !T+8@ ;#'( &@R% !@,F0 7#*T %@S& !4-
MY@ 5#?D %@W_ )PM  "0,0  AC0  'PT  !R,P  :#$  %\L  !5)P  3",
M $0=   \&   -!,  "T0!@ F#0L ) P/ "(,$P A#!D 'PP? !X-)0 =#2P
M&PTT !H./0 9#D< %PY3 !8.80 4#W$ $Q"$ !(0F  1$*X $!#& ! 0Z  0
M$/L $1#_ )DQ  ".-0  A#@  'HY  !P.   9S8  %TR  !3+0  2B@  $(D
M   Y'P  ,1H  "H5 0 C$0< '1 - !L/$  9#Q4 &! ; !<0(0 6$"D %1 Q
M !01.@ 3$44 $A)1 !$27P 0$F\ #A."  X3E@ -$ZL "Q/"  L4XP ,%/H
M#1/_ )<U  ",.0  @CP  '@]  !O/0  93H  %LW  !2,@  22X  $ J   W
M)0  +R$  "@<   @& , &10* !42#@ 4$A( $Q,8 !(3'P 1%"8 $10N ! 4
M.  /%4( #A9/  T67  ,%VP "Q=_  D8DP (&*@ !AB_  <8X  '&/4 "1C_
M )4X  "*/0  @$   '=!  !M00  9#\  %H\  !0.   1S,  #XP   V*P
M+B<  "<C   ?'P  %QH( !(7#0 0%Q$ #Q<6  X8'  .&", #1DL  P:-0 +
M&D  "AM,  D;6@ ''&D !1Q\  0=D0 "':8  1V\  (<W0 "'/(  QS_ ),\
M  "(00  ?T0  '5%  !L10  8T0  %E!  !//0  1CD  #XV   U,@  +BX
M "4J   =)0  %"$$  \="P -'1  #!T4  L=&@ *'B( "!XJ  <?,P &(#X
M!"!*  ,A5P !(6<  "%Y   AC@  (:0  "&Z   AVP  (?(  "#^ )!   "&
M10  ?4@  '1*  !K2@  8DD  %A&  !.0@  13\  #T\   U.0  *S0  "(O
M   9*P  $B@$  TD"@ )(PX !B,2  4C&0 $)"   B0H  $E,0  )3P  "5(
M   F50  )F4  "9W   FC   )J(  ":Y   FV0  )?(  "7^ (Y%  "$20
M>TT  '-/  !J3P  8$X  %=+  !-2   1$4  #Q"   Q/0  )SD  !XU   5
M,@  #RX#  HL"@ %*PX  2H1   J%@  *AX  "HF   K+P  *SD  "M%   L
M4P  +&(  "QU   LB@  *Z   "NW   KU@  *O(  "K_ (Q)  ""3@  >E(
M '%4  !H5   7U,  %91  !,3@  0TL  #='   M0P  (S\  !H\   2.
M##8#  8S"0  ,@T  #(0   Q%   ,1L  #$C   Q+   ,C<  #)#   R4
M,F   #)R   RAP  ,9X  #&U   PU   ,/(  "__ (E/  " 5   >%<  &]9
M  !F60  7ED  %57  !)4P  /D\  #),   H2   'D4  !5"   .0   "#T"
M  $\"   .PP  #H/   Y$@  .1@  #D@   Y*0  .30  #E    Y3@  .5T
M #EO   XA0  .)P  #>S   WT@  -O(  #7_ (=5  !_6@  =ET  &U?  !E
M7P  75\  %)<  !$6   .%4  "U2   B3P  &$P  !!*   *2    T8!  !%
M!@  1 H  $,-  !"$   014  $$=  !!)@  03$  $$]  !!2@  05H  $%L
M  ! @0  /YD  #^Q   ^T   /?(  #S_ (1<  !\8   <V,  &QE  !D9@
M660  $MA   ^7@  ,EL  "99   <5@  $E0   Q2   $40   $\   !. P
M30@  $P,  !+#@  2Q(  $H9  !*(@  2BP  $HY  !*1P  2E8  $EH  !)
M?@  2)8  $>O  !&S0  1?$  $3_ (%C  !Y9P  <FH  &ML  !@:P  4FD
M $1F   W9   *F(  !]@   57@  #5T   9;    6@   %D   !8    5P0
M %8(  !6#   51   %04  !4'0  5"<  %0T  !40@  4U(  %-D  !2>0
M4I(  %&K  !0R@  3^\  $[_ 'YJ  !W;@  <'$  &9Q  !8<   2F\  #QM
M   O;   (FH  !=I   .9P  !F8   !E    90   &4   !C    8@   &($
M  !A"   80T  & 0  !@%P  8"$  %\N  !?/   7TT  %Y>  !>=   78T
M %RG  !;Q0  6NT  %G_ 'MR  !U=@  :W<  %UV  !/=@  074  #-U   F
M=   &7,  !!R   '<0   '$   !Q    <0   '$   !O    ;P   &X   !N
M @  ;@@  &T,  !M$0  ;1H  &TF  !L-0  ;$8  &M8  !K;0  :H8  &FA
M  !HO@  9^@  &;^ 'EZ  !P?   87P  %-]  !$?0  -GX  "A^   ;?0
M$'T   =]    ?0   'T   !^    ?P   'X   !]    ?0   'P   !\
M?    'P&  !\#   ?!(  'P=  !\+   ?#P  'Q/  ![90  >WX  'J:  !Y
MM@  >-\  '?Z '.   !E@0  5H,  $B$   YA@  *X<  !V'   1AP  !X@
M  "(    B0   (H   ",    C0   (T   ",    C    (P   ",    C
M (T   "-!   C@P  (X3  "/(0  CC(  (Y&  ".6P  C70  (V0  ",K0
MB\X  (KS &B&  !:B   2XL  #R-   MCP  'I   !&1   'D@   ),   "5
M    EP   )D   ";    G    )L   ";    G    )P   "=    G@   )X
M  "?    H0,  *(,  "B%@  HR8  *,Z  "C3P  HV@  **&  "BH@  HL
M *'H %R-  !-D   /Y,  #"6   AF0  $IH   >;    G0   *    "B
MI    *@   "J    JP   *H   "K    K    *T   "N    KP   +$   "R
M    M    +<!  "Y#0  N1H  +HM  "Z0P  NEL  +IW  "[E   N[$  +G2
M %"5  !!F   ,IP  ".@   3H@  "*0   "G    J@   *P   "O    L@
M +<   "Y    NP   +H   "\    O0   +\   #     P@   ,0   #&
MR0   ,T   #2 0  U \  -4?  #7-0  V$T  -AI  #7A@  UZ,  -:] /\
M  #_    _P   /\   #_  , _P - /\ %0#_ "  _  K /@ -0#T #\ \ !'
M .X 3@#K %0 Z0!: .< 7P#E &0 XP!J .$ < #? '8 W0!^ -L AP#8 )$
MTP"= ,\ JP#- +T RP#@ ,D ^P#' /\ O0#_ +$ _P"I /\ HP#_ /\   #_
M    _P   /\   #\    ]@ + /$ $0#M !L Z0 E .0 , #? #D V@!! -4
M2 #1 $X SP!4 ,T 60#+ %X R0!C ,< :0#% &\ PP!W ,  ?P"^ (H NP"5
M +@ HP"V +0 M #- +( \@"P /\ K #_ *, _P"< /\ EP#_ /\   #_
M^@   /$   #H    X  & -D #@#2 !8 S@ ? ,@ *0#$ #( P  Z +T 00"Z
M $@ N !- +8 4P"T %@ L@!= +  8@"N &D K !O *H > "H (( I@". *0
MFP"A *L GP#  )T Y@"; /\ F@#_ )0 _P". /\ B@#_ /\   #V    Z
M -P   #.    Q@ ! +\ "P"Z !$ M@ : +( (@"N "L J@ T *@ .P"E $$
MHP!' *$ 3 "? %$ G@!6 )P 7 ": &( F0!H )< < "5 'H D@"& )  DP"-
M *( BP"U (D TP"' /< A@#_ (0 _P!_ /\ ? #_ /(   #C    T@   ,4
M  "Z    L0   *L !P"E  X H0 4 )X ' ": "4 EP M )0 - "2 #H D !
M (X 10"- $H BP!0 (D 50"( %L A@!A (0 :0"" '( ?P!] 'T BP![ )H
M> "K '8 Q !T .L <P#_ ', _P!P /\ ;@#_ -\   #,    OP   +0   "K
M    H0   )H  @"4  L D  0 (P %P"( !X A0 F (, +0"! #, ?P Y 'T
M/P![ $0 >0!) '@ 3@!V %0 = !: ', 8@!P &L ;@!U &P @P!J )( : "C
M &8 N !D -X 8P#[ &( _P!B /\ 8 #_ ,P   "\    KP   *4   "=
ME    (P   "&  < @0 - 'P $@!X !D =0 ? ', )@!Q "T ;P R &T . !K
M #T :@!" &@ 2 !G $X 90!4 &, 6P!A &0 7P!N %T >P!; (H 60"; %<
MKP!6 ,L 50#R %0 _P!4 /\ 5 #_ +X   "P    I    )D   "0    B
M ($   !Y  ( <P * &\ #P!K !0 9P : &4 ( !C "8 80 L %\ ,@!> #<
M7  \ %L 0@!9 $< 5P!. %8 50!4 %X 4@!H %  = !. (, 3 "5 $H J !)
M ,  2 #H $< _P!' /\ 1P#_ +0)  "F"P  FPP  ) *  "&!0  ?@   '8
M  !O    :  % &, # !? !  6P 5 %@ &@!6 "$ 5  F %, + !1 #$ 4  V
M $X / !- $( 2P!( $D 4 !( %@ 1@!B $0 ;@!" 'T 0 ". #\ H@ ] +@
M/0#= #P ^  \ /\ / #_ *P0  "?$@  E!(  (D1  !_#P  =@P  &X%  !F
M    8  ! %D " !5  T 40 1 $X %@!+ !L 20 A $@ )@!& "L 10 Q $,
M-@!" #P 0 !# #X 2P ] %, .P!= #D :0 W '@ -@") #0 G  S +$ ,@#.
M #( \0 Q /\ ,0#_ *86  ":&0  CAH  (0:  !Z%@  <!(  &@.  !?"@
M6 ,  %$ ! !,  H 2  . $0 $@!! !8 /P ; #T (0 \ "8 .@ L #D ,0 W
M #< -@ ^ #0 1@ S $\ ,0!9 "\ 90 N ', + "% "L F  J *T *0#& "@
MZ@ H /X * #_ *$<  "5(   BB$  '\A  !U'P  ;!H  &,6  !:$0  4@T
M $L'  !$  8 0  + #P #P X !( -@ 7 #0 '  S "$ ,0 G #  +  N #,
M+0 Z "L 0@ J $L * !5 "8 80 E '  ) "! "( E0 A *D ( #! "  Y  ?
M /D 'P#_ )TB  "1)@  AB@  'PG  !R)0  :2(  %\=  !7&   3A,  $8.
M   _"P  . 4' #0 #  Q !  +@ 3 "P &  J !T *0 B "< *  F "X )  V
M ", /@ B $< ( !2 !\ 7@ = &T ' !^ !H D@ 9 *< & "] !< WP 7 ?4
M%P+_ )HG  ".*P  A"T  'DM  !P*P  9B@  %TD  !4'P  2QH  $,4   [
M$   - T" "T)"0 I!0T )@,0 "0!$P B AD (0(> " ")  > RH '0,R !L$
M.@ :!40 &05/ !<&7  6!FH % =\ !,'D  2!Z4 $0>[ ! 'VP 0"/( $ G_
M )<K  ",+P  @3$  '<R  !N,0  9"X  %LJ  !1)0  22   $ ;   X%@
M,1(  "D.!  C# D 'PD- !T'$  ;!Q4 &0@: !@((  7"2< %@DN !4*-P 3
M"D$ $@M- !$+6@ 0"VD #@Q[  X,D  -#*4 # V[  L-V0 +#?$ # W_ )4O
M  "*,P  ?S8  '8V  !L-0  8S,  %DO  !0*P  1R8  #XA   V'0  +A@
M "<3   @$ 4 &0X* !4,#@ 4#!$ $PP6 !(,'  1#2, $ TK  \--  .#C\
M#0Y*  P/6  +#V< "A!Y  @0C0 '$*( !A"X  40U  %$.\ !A#_ )(S  "(
M-P  ?CH  '0[  !K.@  83@  %@U  !.,   12P  #TG   U(P  +1\  "8:
M   >%@$ %Q,& !$0"P .#@X #@\3  T0&0 -$"  #! H  L1,@ *$3P "!)(
M  <250 &$V4 !!-V  ,3BP !%*   !.V   3T0  $^X  !/[ ) V  "&.P
M?#X  ',_  !J/P  8#T  %<Y  !--@  1#$  #PN   T*@  +"8  "4B   >
M'@  %AH" ! 5"0 ,$PX "A,2  D4%P (%!\ !Q4F  85+P $%CH  Q9&  $7
M4P  %V(  !AT   8B0  &)\  !BU   7T   %^T  !?[ (XZ  "$/P  >T(
M ')#  !H0P  7T(  %8_  !,.P  0S<  #LT   S,   +"P  "0I   ;)
M$Q\"  T;"0 )&0T !AD1  09%@ "&1T  1HD   :+0  &S@  !M$   <40
M'&   !UR   =AP  ')T  !RS   <S@  &^T  !O\ (P^  ""0P  >48  '!(
M  !H2   7D8  %5$  !+0   0ST  #LZ   S-P  *C(  " M   7*0  $"4"
M  LB"0 %( T  1\0   ?%   'QL  " B   @*P  (38  "%!   A3P  (5X
M ")P   BA0  (9L  "&R   AS0  (.T  !_\ (I#  " 2   >$L  &],  !F
M30  74L  %1)  !*1@  0D,  #I    O.P  )3<  !PS   3+P  #2P"  <I
M"  !)PP  "8.   E$@  )AD  "8A   F*0  )C,  "<_   G30  )UP  "=M
M   G@@  )YD  ":P   ES   )>X  "3] (A(  !_3   =E   &Y1  !E4@
M7%$  %-/  !*3   04D  #5$   K0   (3P  !<Y   0-@  "C(!  ,P!P
M+PL  "X.   M$0  +18  "T>   M)P  +3$  "T]   M2@  +5D  "UK   M
M@   +)<  "RO   KRP  *NX  "K^ (5-  !]4@  =54  &Q7  !C5P  6U8
M %-5  !'40  .TT  #!)   E1@  '$,  !,_   -/0  !CH    X!0  -PD
M #8-   U#P  -!0  #0;   T)   -"X  #0Z   T1P  -%<  #1H   T?0
M,Y4  #*M   QR@  ,>X  ##_ (-3  ![6   <UL  &I=  !B70  6UT  $]:
M  !"5@  -E(  "I/   @3   %DD   Y'   (1    $(   !! P  /P<  #X+
M   ]#@  /1$  #P8   \(0  /"L  #PW   \1   /%,  #QE   [>@  .I(
M #JK   YR   ..T  #?_ (%:  !Y7@  <6$  &EC  !B9   5V(  $E>   \
M6P  +U@  "15   94P  $%$   I/   !30   $P   !*    200  $@(  !'
M#   1@\  $84  !%'   12<  $4S  !%0   15   $1A  !$=@  0X\  $*H
M  !!Q@  0.P  #__ 'YA  !V90  ;V@  &AJ  !=:0  3V8  $)D   T80
M*%\  !U=   26P  "UD   )8    5@   %8   !4    4P   %($  !1"0
M4 T  % 0  !/&   3R(  $\N  !//   3TL  $Y=  !.<@  38L  $RE  !+
MP@  2>H  $C_ 'MI  !T;   ;F\  &1O  !5;0  1VP  #EJ   L:0  (&<
M !1E   -9    V(   !B    80   &    !?    7@   %T   !<!   7 D
M %L-  !;$@  6QP  %HH  !:-@  6D8  %E8  !9;0  6(4  %>@  !6O0
M5>@  %/^ 'EP  !S=   :74  %MT  !,<P  /G,  #!R   C<0  %F\   UN
M   $;0   &T   !M    ;0   &P   !K    :@   &D   !I    :0,  &@)
M  !H#@  :!4  &<A  !G+P  9S\  &92  !F9@  97\  &2:  !CMP  8N$
M &'\ '=X  !M>@  7WH  %!Z  !">@  ,WL  "5[   8>@  #GD   1Y
M>0   'D   !Z    >@   'H   !X    >    '<   !W    =P   '<!  !W
M"   =PX  '<8  !W)@  =C8  '9)  !U7P  =7<  '23  !SKP  <M,  ''W
M '%^  !C?P  5(   $6"   V@P  *(0  !J$   .@P  !(0   "$    A0
M (8   "(    B0   (@   "'    AP   (<   "'    AP   (@   "(
MB <  (D0  ")'   B2P  (@_  "(50  B&T  (>)  "&IP  A<<  (3O &:$
M  !7A@  2(@  #F*   JC   &XT   ^-   $C@   )    "1    DP   )4
M  "7    F    )8   "7    EP   )<   "8    F    )D   ":    FP
M )T'  "=$0  G2$  )TS  "=20  G&(  )Q_  "<G   G+D  )OB %J+  !+
MC@  /)$  "V3   >E0  $)8   28    F@   )P   ">    H0   *0   "F
M    IP   *8   "G    IP   *@   "I    J@   *P   "M    KP   +$
M  "S"0  LQ4  +0G  "T/0  M54  +5P  "TC@  M*P  +3, $V2   _E@
M+YH  ""=   1GP  !:$   "C    I@   *D   "L    KP   +,   "U
MMP   +8   "W    N    +H   "[    O0   +\   #!    Q    ,<   #+
M    S0P  ,X:  #/+P  ST@  -!B  #0@   T)T  -"X
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MZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q      ,!(0   0
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M____________SW0U"P    I2I_______________________________EC0
M      !/I______________________________V:1T   D,!@E2L?______
M_______________________+.PX3-4Q;34Q>P_______________________
M______^I8#9@AI^VK*FXV?_____________________________@EXV^Y?__
M____________________________________[?G_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^O9RKS'____
M_______________________________/FH%M6D:(ZO__________________
M_____________\1\/B80  !4L/______________________________X(,\
M       NA^W_____________________________K%,0       7;=;_____
M_______________________[@#$        )8<S_____________________
M_______26@(         7<S___________________________^H-0
M    7-/___________________________]]#0          5-;_________
M_________________^Y]10          1-3_________________________
M__RJ9"\"   $(C=)6,[____________________________II&M!*#]C?Y6G
MNMK______________________________]6RK++,Y/K_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^6[EW=BR/_________________________________;
MGF<V"@ "C/_______________________________\A_/P4     7L______
M________________________V8$Y        /*K_____________________
M________GDP         (Y#____________________________<;QH
M    $'WY__________________________^O2            &_N________
M__________________^$$P           &3F________________________
M_^Q1             %?>_________________________[@5
M $C6_________________________W04             #C/____________
M____________^:):$P           "/%_________________________]^;
M7"P           VZ___________________________OL7U5.2(1!P$"$2*R
M_______________________________?OZ69F)J@K+W:________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________COIV ?/O_____
M___________________________RMX17, X ':S_____________________
M_________]**3!4      '+S____________________________UG\V
M     $O)___________________________ZD3X          "^K________
M___________________ 6@           !J5________________________
M__^-)             B$_________________________^=>
M  !W_________________________[0E              !J____________
M_____________WT               !;]/_______________________2L
M              !,Z_______________________I0                 \
MX?______________________, P                MV?______________
M______^9BF$G               GU_______________________[;Z)52<
M           EW/_________________________^RIUV74H\,BTL,#E'WO__
M_____________________________>;=UM+0T]GD____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^_4N];_________________________________Y[B/
M:DLO%6_______________________________^2A9S0'     #S)________
M____________________UH([         !*7________________________
M___MA3$           !O__________________________^F0@
M  !0X?_______________________^QI               WR?__________
M_____________[,O               BMO_______________________WD
M               0I_______________________\C0
MF?______________________J0                  C/______________
M________1@                  ?______________________?
M            =/____________________^7                    :O__
M___________________.                    8___________________
M____*2(!                8?______________________N:. 5S<7
M        :/__________________________^M.NE(9\=7%P<G>!E/______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________;NIV":6G3________________________
M_______(DV4]&0   !V>____________________________VXY,$P
M  !N___________________________;?"P           !%U___________
M______________^+*@             BM/_______________________\)$
M               #E________________________WT!
M?_______________________YS8                 :O______________
M________G0                  6/______________________1@
M            1_C____________________I                    ->G_
M__________________^6                    )=O_________________
M__^\                    &,[____________________K
M        #\+_____________________                    "KG_____
M________________)P                  "K7_____________________
M<                   #;G_____________________X)R,<%5",R8;% \-
M#A(:)K_____________________________YY-C2SLS+S,_6X/S_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________K
MT[SC________________________________TJF%94@L$@&%____________
M________________\:MQ/ \       !/X/_________________________5
M?S4            ?LO_______________________^-U'0
MB?_______________________Y C                9_______________
M________U4,                 2/;_____________________B@
M            +MW_____________________.                   %\C_
M__________________^^                    !+;_________________
M__^<                     *7___________________^Z
M         )/____________________<                     (+_____
M________________                     '3_____________________
M$P                   &C_____________________0@
M     &#_____________________>@                   %W_________
M____________T0                   &'______________________R0
M                 &;______________________\FLF8E]=G%L:6=F9VMP
M>HS_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______BQ:J1>6%W_____________________________]VF=U L#      Q
MQ/_________________________@DDX3            C_______________
M_________])P'0              8/______________________[F\/
M            -^+_____________________EAP                 %,#_
M____________________0                    */_________________
M__^N                     (G___________________^>
M         '+___________________^\                     %______
M_______________:                     $W____________________Z
M                     #O_____________________#@
M     "KY____________________,P                   !OI________
M____________7@                    _;____________________CP
M                  ;0____________________T
M  #*_____________________RL                   #(____________
M_________X                    #+______________________<6 04%
M P$       $&#1C+_______________________\Z^'8S\S-S]#2U-?<XNK_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________\=K&________________
M_______________QQJ.$:$TR&  5J___________________________N7Q&
M&           <?_______________________]=\+P              .^/_
M____________________WV0)                #+7_________________
M____= ,                  (W____________________%%0
M         &K___________________^9                     $O_____
M______________^V                     ##]___________________7
M                     !GG___________________V
M      73____________________#@                    #!________
M____________+P                    "O____________________4@
M                  ">____________________>0
M  ".____________________I0                    " ____________
M________V                     !T_____________________S8
M              !M_____________________WP                   !I
M_____________________]<-                  !H________________
M______]P                  !A________________________4#Q&3E19
M76%D:&QP=GZ)________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________OU;NCBW-:E?__
M________________________^+^.9$$A!0      4OS_________________
M______>=5A@             %\'_____________________Y6P6
M         (W_____________________8P                   %[_____
M______________^=                     #7\__________________^A
M                     !'9___________________*
M      "[___________________N                      "A________
M____________#                     "*____________________+0
M                  !V____________________30
M  !D____________________;P                    !2____________
M________E                     ! ____________________O
M               P____________________Z@X                    B
M_____________________T0                    5________________
M_____X$                    +]?___________________\@+
M           "[/____________________]>                    Y?__
M___________________)'                   VO__________________
M____G0$             !PX7Q?_______________________]6YO,''SM7;
MX>;M]/O_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________C?S______________________________LQJ6(
M;50[(0< ,M[________________________7DEDI             *#_____
M_________________XDV                 &?_____________________
M9@                   #+V__________________^5
M      /(__________________^G                      "@________
M___________7                      !\____________________
M                  !>____________________)0
M  !#____________________2                      L____________
M________:@                     8____________________BP
M               %\___________________KP
MX?__________________U0                      S_______________
M_____R0                     OO___________________U0
M            KO___________________XL                     G___
M_________________\L.                    DO__________________
M__]7                    AO____________________^J"@
M        >?______________________;0                  9O______
M________________]U4                 1?______________________
M__]J(RLU/TI58&IU?H>1G/______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________Z,^VG8-I3KG_____________________
M____[+*#7#H= @       'O______________________\5M*0
M     $#_____________________@QL                   ?+________
M__________^2                      "8__________________^D
M                  !J___________________=
M  !!____________________#@                     =____________
M________.0                      Z/__________________8
M                SO__________________A0
MM___________________J                       H_______________
M____RP                      D/__________________[Q8
M            ??___________________SX                     ;/__
M_________________VD                     6O__________________
M_YD                     2?___________________](6
M        .?____________________]8                    *?______
M______________^B                    &?_____________________U
M5@                  !/______________________NR\
M     /C______________________ZLI                 ,__________
M_______________)1P     '$R N/E)HA.W_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___TU<G____________________________ZTK"2=UU"* P  $K_________
M_______________%?447             !'8____________________Q%
M                  "?__________________^B#
M  !H__________________^4                       V____________
M_______:                       '[/__________________%0
M                Q/__________________2
MHO__________________=0                      @_______________
M____G0                      :?__________________PP
M            4O__________________YP\                     /O__
M_________________S,                     *___________________
M_U@                     &/___________________X$
M        !?___________________ZP                      /______
M_____________]XB                     /+___________________]<
M                     -____________________^?
M     ,S____________________H2@                   +?_________
M____________H!8                  )S______________________WH"
M                 '?_______________________]Z"P
M!4S_________________________HE=H=("-G*N\T.?_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________[>/__________________________]*C>E@Z*2,<%@X&
M  "?_____________________ZQ2#@                !I____________
M_______D0P                     T__________________]Y
M                X__________________-
MLO__________________$P                      A?______________
M____3P                      7?__________________@P
M            .O__________________L@                      '/__
M________________VP,                      O__________________
M_RH                      /O__________________T\
M         .?__________________W0                      -3_____
M_____________YL                      ,#__________________\0'
M                     *W___________________ S
M     )K___________________]G                     (;_________
M__________^C                     '+____________________C1
M                 %S_____________________D08
M $'_____________________ZU\                  !W_____________
M_________\I+                  #________________________+5P
M#!@D,3].8'2+I\?__________________________]?G\O______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________________^O4
MS<?"OKJWL["MJ:BE____________________W7Y3/S C&1$) @
MV_________________]V                        I_______________
M__^Z                        =?__________________!P
M            1O__________________3@                      &O__
M________________C                        /W_________________
MP0                       -O_________________\1D
M         +[__________________T0                      *3_____
M_____________VL                      (W__________________Y$
M                     'G__________________[<
M     &;__________________]XA                     %/_________
M__________]*                     #____________________]W
M                 "O___________________^L"@
M !;____________________G10                    #_____________
M________B@                    #_____________________UDT
M              #]_____________________Z<N                  #5
M______________________^8*@          !A@M16#@________________
M________J&-T@8^<J[O-XOK_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^?+MZF=E8Z)
MA(!\>'1P;&AED/________________^\:D@M&0H                 ,?__
M________________                         ___________________
M0@                       -S_________________C@
M         ++_________________S@                       (W_____
M_____________RD                      &O__________________UH
M                     $[__________________X8
M     #3__________________ZX                      ![_________
M_________]07                      K___________________H]
M                  #___________________]E
M  #___________________^.                      #_____________
M______^\&0                    #O___________________Q3@
M              #8____________________BP                    "_
M____________________S$,                   "A________________
M_____Y$9                  !Z______________________)T"@
M         !%?_______________________H=!,?+#A%4V)RA9NTTO7_____
M_____________________]?H]/__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________^_?S\>[LZ^OL\?__________________V;*9AWEM9%U644M&
M03PX,BTH(\3_________________2R4+                     )+_____
M____________B                        &;_________________UP
M                     #W__________________S,
M     !C__________________VP                       #_________
M_________YT                       #__________________\D,
M                  #V__________________$U
M  #?__________________];                      #+____________
M______^"                      "W__________________^I!@
M              "C___________________3+P                    "-
M____________________7@                    !W________________
M____DP<                   !>____________________S4,
M          ! _____________________X<0                   <____
M_________________]A>                    ____________________
M__^_3@      #APL/E)JAJ7(________________________PGR,FJ>VQ=;H
M_?__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M[N'7S\G#OKJVL:VIIZ:FIZ[_________________OH9M6TQ -R\H(AP6$ L$
M     !3_________________UP4                       #_________
M_________S0                       #V_________________W8
M                  #2_________________[
M  "R_________________^$D                      "6____________
M______]1                      !\__________________]Y
M              !F__________________^@                      !1
M___________________'(P                     \________________
M___N2P                     G____________________=
M           0____________________HQ8                     ____
M________________V$P                     ____________________
M_X@/                    _____________________\M3
M        ______________________^E.           "1TT3FN,________
M________________F3E#45]N?8Z@M<OE____________________________
M_^OY________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^O,N:RA
MF9&+AH%\>'1P:VAF9FCQ_________________V%%,B,8#@8
M  ">_________________WX                       !U____________
M_____\,                       !2__________________LW
M               R__________________]J                       6
M__________________^6                        ________________
M__^_&P                      ___________________F0@
M            ____________________:0                      ____
M________________D (                     ____________________
MN2P                     ]/__________________Z%P
M        V?___________________Y$8                    O/______
M_____________\I3                    G?____________________^8
M+@             0*49FQ/_____________________N?QT,&B@W1E=I?I6O
MS.[_________________________YZ"JN<C8Z?S_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________]]?#KYN+?V]C4TM'0TM?@_________________\Z>BGQQ:6%;
M5E%,2$,^.C8R+RXQ_________________](E$0,
M__________________]"                        ________________
M__]]                        __________________^P"P
M            ]O_________________=.0                      W/__
M________________8@                      Q?__________________
MB0                      K___________________KR(
M        F?__________________UD@                     @O______
M_____________W(                     :?___________________Z$H
M                    3O___________________]-<
M    ,_____________________^6+@              %3)2=___________
M___________@<A,   $/'R]"6'"+J,CL________________________RF]N
M?HZ>L,/8[___________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___YX-+(P+JUL*RHI:*?G9N;G*"G__________________^"9%9+0SPV,"LG
M(AT8$PX)!   U/________________^2                        K?__
M_______________,'@                      B__________________[
M4@                      ;?__________________@
M        4?__________________J1L                     .O______
M____________T$(                     (___________________]6@
M                    #/___________________X\4
M     /___________________[@^                     /__________
M_________^5M P                   /____________________^?-P
M            $"]0=/_____________________=<A0     !A<J05IUE+;:
M________________________O%A$5&1UAIJOR./_____________________
M_________]+-X?'_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________S[^OO]_______________________N
MN:B=EH^*AH)_>WAV=')S=7A_D/_________________K3SHP*"$;%1 +!P(
M        (___________________:0                       /______
M____________FPH                      /__________________R#D
M                     /__________________\&,
M     /___________________XH.                     /__________
M_________[ T                     /___________________]5;
M                 /____________________^%&@
M ^S___________________^Q20              &#E=@?______________
M_______E>QX       PA.%)OC[/9________________________NU@I.4E:
M;("7L,WM_____________________________[.>M,77Z_______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________KOY^'<V=;4TM#0T-'3V>#K]___________________N(I^
M=W%L:&1A7EM96%=765YE<?__________________OS$?%A *!0
M     /__________________[58                      .C_________
M_________X($                     ,S__________________ZLO
M                 +/__________________])7
M )O___________________=\$                    (7_____________
M______^B-P                 %*Y3____________________+80(
M       ,+%!VGM'____________________UC3        TC.U=VF;[E____
M____________________PV,8*CM,7W2-I\;G________________________
M_____ZA_EJB[T.?____________________________________]________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________]W.Q;^\N;:TL[&RLK6YP,G5X____________________Y=L9%Y9
M55%/3$I(1T9(2U!99J'__________________Z<F#@<"
M %;__________________\Y0                     #K_____________
M______1Y"P                   "'___________________^?,@
M              [____________________$6                 @Q6H3_
M___________________I?Q\           8G2W&:PNG_________________
M____ITD      A<O2FB*KM7\________________________TW4>)CA*7G6/
MJ\OO_____________________________ZYRA9BLPMOV________________
M___________________?[_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______^_LJJFHZ&@GY^AHZ:LM,#-W>S___________________^*6E-/2TA&
M1$-"04)#1TY9:7W___________________^>+@8                   #_
M___________________#5@                  %4'_________________
M___G>QH             "31@B[3_____________________GS\
M!"5*<9G"Z_______________________QF8/    $RI$8H.GS?7_________
M________________ZXXU*SY1:(&=O-[_____________________________
M_[YV?Y2IP=SY___________________________________2V//_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________;R\._O[_'S^/W_________________________
M___XL)^:EY:6EIB;GZ2LML+1X>[____________________^CE!*1T5$1$1%
M1D=+45IH@ZG_____________________ID$!           '-F./NN'_____
M________________QF4*       $)TQSG,3L________________________
MY8@O   3*D1B@J;,]/___________________________ZM0-DIA>Y:TUOK_
M_____________________________]*'?)BQR^G_____________________
M_______________4SNW_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^WEX^/DYNCM\?G_____________________________
M_;&4DI*5F9VCJ;*\T.W__________________________YU31TE-459@<XJO
MUOS__________________________[)6 !HU4&V+KM+W________________
M_____________\UO/E][F;?7^?_______________________________^Z?
M@Z;"X?_____________________________________CSNO_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________\
M
M
M                             /______________________________
M____________________________________________________________
M____________________________________________________________
M____________________     /_A0+=H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#<N,BUC,# P(#<Y+C%B
M-C5A-SDL(#(P,C(O,#8O,3,M,3<Z-#8Z,30@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!-
M33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @
M(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E
M9B,B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O
M96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(@H@(" @(" @(" @
M("!X;6QN<SIT:69F/2)H='1P.B\O;G,N861O8F4N8V]M+W1I9F8O,2XP+R(*
M(" @(" @(" @(" @>&UL;G,Z97AI9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]E
M>&EF+S$N,"\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/DUI8W)O<V]F=,*N
M(%=O<F0@,C Q.3PO<&1F.E!R;V1U8V5R/@H@(" @(" @(" \>&UP.D-R96%T
M;W)4;V]L/DUI8W)O<V]F=,*N(%=O<F0@,C Q.3PO>&UP.D-R96%T;W)4;V]L
M/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,BTQ,2TR-E0P,CHP,CHR
M-"LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y
M1&%T93XR,#(S+3 Q+3 X5#$Q.C4U.C(Q*S U.C,P/"]X;7 Z36]D:69Y1&%T
M93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,RTP,2TP.%0Q,3HU
M-3HR,2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<$U-
M.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.C0U9#9B9C$Y+3<P
M-C4M934T9BUA930S+6(U,#-C8V%E-64Y,3PO>&UP34TZ1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HW.3(Y9C=B82TV
M8V0T+3,Y-#8M.6(U9BUC96$Q.&8Q.&1F,V(\+WAM<$U-.DEN<W1A;F-E240^
M"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#I!.4$V
M,#)%1"TX13,Y+30Q1D8M03!!,"TV1#0P1C8U-$9!-38\+WAM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F%C93@Y-3(Y+6,P,S<M-CDT
M-"TY961A+39B,S-C,F-E9&(Y93PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTQ,2TR-E0P,SHS.3HQ-2LP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(S+C4@*%=I;F1O=W,I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#ID968U-38R.2UE,V8S+3,U-#@M8F1B8RUF,F5D
M8V$U8S,S-C<\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C,M,#$M,#A4,3$Z-34Z,C$K,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E(%!H;W1O<VAO<" R,RXU("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R
M<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA
M9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E
M<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D
M;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HW.3(Y9C=B
M82TV8V0T+3,Y-#8M.6(U9BUC96$Q.&8Q.&1F,V(\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#$M,#A4
M,3$Z-34Z,C$K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,RXU("A7
M:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R
M;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12
M968Z:6YS=&%N8V5)1#YX;7 N:6ED.F1E9C4U-C(Y+64S9C,M,S4T."UB9&)C
M+68R961C835C,S,V-SPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M/'-T4F5F.F1O8W5M96YT240^=75I9#I!.4$V,#)%1"TX13,Y+30Q1D8M03!!
M,"TV1#0P1C8U-$9!-38\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @
M(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#I!.4$V,#)%1"TX13,Y
M+30Q1D8M03!!,"TV1#0P1C8U-$9!-38\+W-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @
M/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/E-T97!H96X@36$\+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QD
M8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" @(" \<&AO
M=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @
M(" @(" \<&AO=&]S:&]P.DE#0U!R;V9I;&4^52Y3+B!796(@0V]A=&5D("A3
M5T]0*2!V,CPO<&AO=&]S:&]P.DE#0U!R;V9I;&4^"B @(" @(" @(#QT:69F
M.D]R:65N=&%T:6]N/C$\+W1I9F8Z3W)I96YT871I;VX^"B @(" @(" @(#QT
M:69F.EA297-O;'5T:6]N/C$Q,#(Q,3 O,3 P,# \+W1I9F8Z6%)E<V]L=71I
M;VX^"B @(" @(" @(#QT:69F.EE297-O;'5T:6]N/C$Q,#(Q,3 O,3 P,# \
M+W1I9F8Z65)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.E)E<V]L=71I;VY5
M;FET/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B @(" @(" @(#QE>&EF.D-O
M;&]R4W!A8V4^-C4U,S4\+V5X:68Z0V]L;W)3<&%C93X*(" @(" @(" @/&5X
M:68Z4&EX96Q81&EM96YS:6]N/C8Y.#PO97AI9CI0:7AE;%A$:6UE;G-I;VX^
M"B @(" @(" @(#QE>&EF.E!I>&5L641I;65N<VEO;CXT-C \+V5X:68Z4&EX
M96Q91&EM96YS:6]N/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R
M9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 9$"8 ,!$0 "
M$0$#$0'_Q  >   !! ,! 0$             !08'" $$"0(#"O_$ %L0   &
M 0,"!0($ P0$!@T("P$" P0%!@< "!$2(0D3%#%!%5$6(F%Q%X&1(R0RH1BQ
MP? E-#9"T>$F,S4X149255=B993Q&2A$5')TE;35)T=6=7>"I+6WLO_$ !T!
M 0 " P$! 0$            !! (#!08'" G_Q !7$0 " @$"! ,%!08$ P0&
M A," P$$!0 1!A(3(10Q00<B46'P%7&!D:$((S*QP=$6).'Q)3-"-#9#4A<U
M-V)RM"8G1&-U=K5&4U56=%1D969S@H:2IO_:  P# 0 "$0,1 #\ _?QIIHTT
MT:::---&FFC331IIHTTT:::---&FFC331IIHTTT:::---&FFC331IIHTTT::
M:---&FFC331IIJE.[7=4VV\2%"KC&TXZ87?([>>;4.E7>$R&^?Y LS%>'8P]
M>@9FH,5X&OJ2,O,Q\2J_MSV.CT%I-HZ.X39-GRR7D^)>(QPC*: LT0MWA<-.
MI;3>,[M@)4"D);5 DHEC6@N3LF #+!*2@!.8^]>QCV/-]IM;B/*6,1Q/8P'"
M[,<WB+/8"_PS7K<-XJPN[8O9/(T<W95D<D%6E1LW0K86O:LL75<D5$]M<#K1
M";D_%7=S,2UF?#_I$9$.9-@WE9%/,]+<*,(U9TDF^>D03NZAUCM&QE5RI)D4
M.H9,"%(81 H\%.>]HQ-4+>"ZBU$P!:<96K,@N2B#.(BW,S(CO,1$3,[;;3KZ
MMD/97^QZFC==0_:1S]N\JI994K%P+G5A9M+295T298 (6+FP"Y,B&!@IF9&(
MWTL7W<5XH$->+G$T;8C3+72HJUV*.I]G<Y@I\<YLE68S#QK7YYQ'N;HV<,%I
MB)2:2*K-=LW6:G<&050243,F7;<SGM!5<MJI\'U+%1=EZZM@LG5 GUP:8H<0
M%;$@EJH$Y&1&1DMIB)C;5'ASV8?LE7N'\%=X@_:(SF&SUS#8RUF\2K@C-VE8
MK+V*2'9+'+LJP35V HW#=5!ZVL!PJA@,,2@I?>6\Y>(36H[&"^*MG55R!(6"
MA-)G)3-]D^KPI*1>57[Q%U5&:KVUL2R[9LQ2:.PDFAWC90S@R97)C$$A;F3R
M_&M<,?.-X7K73=2!M\3R%=45+DF4%6"3LA#1$8$NH$F,\VW-KSO!7L^_9IRM
MGBU?&/MPS'#5?&\1OH\*N1PEE[T\0</!70:,R\$8>Q-)K;!/3-5PH:,+$Y5
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M"%(<Q@*/-3GO:,35"W@NHM1, 6G&5JS(+DH@SB(MS,R([S$1$S.VVTZ]E?\
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MX2JUB54:VI Y*L?B+8\O2KERVBY!9N6YERB.W<HWUCQ%[-OV5:+.'QX?]O\
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M!VTG7>HA@WM(W(DD!U^U\[U^B-&FFC331IIHTTT:::P(\ (\"/ "/ =Q'CX
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M=I>1OJJLI8>YG[0F+2E.'Q^_C+Q=-9Q*D<L\PCNR=O< M5L@/$6V56B:B:[
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M"0>+K.WKUTLJY=.555UU#JG,8<5Y[.)6M2LSE%*4 K4M=^T"UK 8$  !; B
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MG4RB@1DZM7!8RO7R"%G)K3>2JJ"[2EF1&"WBP1(I(8B9F=)4/M0VN5V5CYV
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ML@_;L&*#UX@@1PZ19M4UU#D;HE)G&=S8M)XYC)PXP%9MB_:AIK"2D )D-YB
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MW+YEZAU7$ X>OS#'LS=L[T#'$S+OZ9$78HP-O/(-79FT?,+MVZ#UHH@BX;K
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M*,GC7Q 2V!UY\FL# U\MONS.<&9_.4ED$#.(R/#;.%H>6T3M=H9(.*%C6ZT
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M)\]H[[[]O.-_AKT//'/L8 ^/MSWY#OV#_P"/'MJ-1&W-MYC,^OQV[=^W>?\
M;?SUY'@?<1XX]_UXY'YX[_8/D/YC._R^_P"'Y1MMK*-XWVV\_+UVWF-]]MYV
MGOO,;;?'T/DW<>. '[B(=OV^![]A^?YNVWE\8W_T]=HF/6(_7>._;RC:9[?"
M9W^_MO$_/X3&\;' ?OQR <?( /?D?_ZO?V[?KI]3Y?IMZ:F-_NWB//TF8VCM
M/GW'U[]_OU4K?,/_ ,V'(0!_]8IO >_(?C>NA^GZA[=Q]AU[+V?_ />O&_\
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M3%;57<E6.CPQP./NWO'""X*1LW[CWX\K KB)8Q[+%)])I",R!TR0V \/ A+
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M/,(2'8H\XWWC?7AO:/Q73X)X/RG$M_&QF*E J MQ^Z8AY7,C4I!.[@-?[H[
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M10*F@U:I$001(4.  B:1"D* !V  UDQAM8QK)DF-,F&4^9&9213/SDIF=9+
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M%,"+25S"N2F(@IB9F(U[?V9KS#O:1[/E<.V*53B!O&_"B\':R*V-Q];,'GJ
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M<('BG;IP,JF^>/J6!8VY7Q:+<K;9N<,<3Y(K0STY\7P=QMD.&G,,0_R[9S%
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MU[FVR96#NR3#A^[(R,X3; W4>/%7%6K$5 ):>RQI!C::IVZ6,Q\.\2^EC%1
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M)#*RI\UH8@R2:@V62B)<C(S,:16>T[";B#OU:OE/@,O0.2'D.-CA,GTW'<U
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MEF4R0#,.$FS/:*G#FKQ-KVWXD"85S&A2X?H!8LPN8/\ ##@3, @ :F\^M_\
M8^MRD/F0O$6?ED (:AJEOWZRP;N,A/4&#W F4VD,\T3[LMQV/9,>4LI5#GWJ
MZI&%$2)"4E*I7(R$KF0Y)!]ZT$CR[<LC9R>1L#,;2+K]QD;'8;)_=39[M.6=
M$?+;9\"*O"1T%$$=J8DHAW)(JL0[FO5N-*L:"%0&$! O'<+#- -Y$9%.G#!F
M1%JLHD;)PC8.VRQ$/.^V\^\;8AA7'Y2N-3).M2>\V&Y"J U[IMYRM(&%.DPB
M!U$3(A56,R*Z,UII ,S 5)I71R-.:PQM"/"Y  O5^E ]&V(V5\KH@XF>FTJG
MXZK$-2:!5:[2:=769(^OU2IPT?7J[",$S&,FRB86*;M(Z.:$,<QB-VC=)(HF
M,($ 1'6Y[WV62ZPYKVR(!+7,-K)%8"M8R9R13 + 0")G80$1C:(B-:4H37"%
M(4M*X(RA:@%8<S#DV%RA$1S&9$9SMN1%)3,S,SIS:U:VZ---&FFC335#MW0\
M62G\^PPC[]O^/A[\_'OJ?K\]H^MYV_KB4=NWGZ>>_P >WS^I^50N/?Y[<??C
MGG@/?CV]OUX#WT[]_AVWV\OQ^ONU';>/3O,^6TS'KZ;QW[3Y;QO,Z ]@X$?T
M#G^OMW[CQP'Z#^^GU,_?W^&_I.\_4I\]MOT^'EYSMY>OI,Q]T9 1*4>W<1_;
MCVX[<?N(?&GU_M^&WY?=&HVB2^6WIZQWW[[_ !\_7O\ CK(@(=N_?YYYY .>
MW';[\\<CV_8>'PG_ $\OR_3^>D<L[^7KVV\IG;OO.\=MMO*(^7>-P../< YZ
M0]@ ??W#WY_<?80'V^&T^GIW[?Z>6H*=I_\ ]O6?RG?;\H\XF//UP'?GD>_P
M \_' #^O?N \?K]M/C]>>_PGM/R_MJ?+;;R]>_W_ ![3$=MIGXQMMOK/ \"(
M"''SQ^H!U?//\A'O\ZC3>-XB8G?TF>WK.T?#\8CMZ?( !^>W CW]@]OY" =O
M< [\C\Z:3,>G?>([><^?SWWF-_+?M\XUGY > Y'W'W#CN C^G;C@>/OR/OI]
M?7^FHV[3&\[1VB.T3OYQ'EWVF9WC?[HU@P^W?D/Z<#WX'G^O'QP'VU/E\OGY
M?7P_MJ1CM/;OV^?;MO&WR[;^N\_'1R// ![\#WY$ 'WY'D.?M^@?.HTVB8WF
M9[=O2-X[QM'?;X_.?RW9U[PS$[A*^7#T]87-4B[I.5EB\GV2#5RZCDVMAC)$
MJJ2#Q5%NH90[,B(@JJ0.%!, B8"@/9P&59A<I7R24#997!\"DB(8/JUV)+>0
M@BCEADEY=]MIVWUXKV@\(5>.^%,GPO<R#<95R1T29=4M;#3-/(U;P0(.):YZ
MAUQ7.Y1M!SMO,:M#MRVPY"V4TZ7QI@J;_BM5K)97-YE)Z=80#%TQL#V+B8!>
M(22;SR1#-THZO1CPJ@E$WF/52B(@  6UQ-GW<1747'U0J&FJ-:%@1G!"+7-@
MYDQ&8F9<0[1&WN^??7)]E?LYH^S/!7L+C<L[,INY=N4.R]24DMK:=&H28%##
M&1$*8,W(H*99,;1$1O9X+!N3_#!G U2(_$GUU-$K7HB_)^B#'JG4<<?7?*\P
M'X))!_>/,Z1'^RZ>3AYS7T[>>_;[N_G]?6^E:FSF?G1Y\+=68QB5&OR:\$*!
M8X/4SR:)AC6RGD33D?*56Z2G!0$4^!_,LF'<'^G^OUO^'P1OVW^'E'Q^?^GY
M]N[8C+)NB4D6!)&GPR,>=ZU(^4(2)ZTV9ER%='*); <P&(B)S%Z2'-R <%,/
M86HF2](W\_A_?^WW:^TU8]SJ4S+)0]0AEXA.3?)Q2ZA8KK6C2.E2LE5/,L"2
MG6HU!(YA.DF?J$>I,HB)0??J9W]/GV_K_IO'GWF-."WSF?VI*V-4K,6].O7V
MR]A!8L</I9TR[DKELEYTTW $R(%;F*"8K)\F-PL8>0+,[=]OCV^[41S;1\>^
M_P!^_;RGX?#282P;D!JJK@]3B0LX3Z"";0"Q?E&@ACG"BSGCZ[Y/FED 02#E
MP"G08>$1+R<L:3S>FT]_7TC;^_?XZ5*I.9^<LK4>T5F+9/&T&HM6$D2QW#R:
M!4H)MUO)FG!13%(3#PJ=NGR'=8![#,;>L^L?EWW_ *?VT][;;UV\XV\^WQ^M
MO+X0@P-BW-+3<,C.5*';PJLK')RZZ9(KS$(Q1XB6063\N>6/UI,Q6.3H25/U
ME#I3./!1C4[SOY=M_EY;??\ ']/GK[V>P[DV]AET*W4XEW I/5B13E4L6*J[
M,!#RE#^;.MU.H>_/6BF;_P!0--)W]/U^_P"4^L>7ZZ5KI.Y_:.8<M/K$8^;J
MP,:M+&7+&B9&;40*:0;$\^:;"":2_44O055/@/R*J!^87X_7Q_'41S?+RCS]
M/C]=O/64)S/HT)X]6K486\EL9$&D<!8[TQZ^+)N<[DW$P+?S0>&<)\B[*KTE
M#A 2\&,T][:>W??M]WQ\_P"NN>&Z+!64<Z9*P-=,C8JMLQ8,3V!27I3RDSV/
MH>&C7QY^KRQE;0TG[BT?R307L%'*@E#I.%P:HO4Q+YRS<I_'\28/&Y7(X2S=
MJ9.RZ@_J5647TU)0<NK,DK8V7*8P.=03$(%A<@LC;FD8G]$^QKVH<8\"<(^T
MS"<-\0\$X;'\68L:F;J<48WB*[DLE7C&9JI"L"[#8Z[3JV(1>L+(\FZLKQ#J
MI072!QA>5E9=TIWC,CRFPR;0SI CLY2Q'41L94@+J%XL)A 2IB<P<%,;D X*
M(]M>PU^=^_\ ;MY?*>_\NVMR=L6YI&;F4H2I1#F%2E9%.(74)%>8O&$>+%CU
ME!4GTC]:K0$CGZT4C]1AZDR&Y(#4;EOM$1'?SF=^WW>>EVVSF?VS>LFJM9BW
MB[B"26LA%B1P@TFQ76*JW1\Z:;!Y8( D8 2,NGR(\+"/)0:F)G;R[_?V]?O_
M *^>DHEAW)C67+@]3B0L99YFBW: 6*%(T(>/?G=N3!]>\KS"/R,4R\K@ITJ&
M J1B]2A&GO?+T^,1Z[_'Y?S^6E:DSF?G;V4)<JU%L6:<')+1BC<L<!E9I-'F
M/;G\B9=#Y:JOY3]94T^/\2I [ZF-O6?6/R]9^OUU&Y=^VW:?7?OZ1VTU6=EW
M3'>M".Z="D9G=-RNE"DB.HC8RI 7.'%A,/45(3F#I(8>0#@IA[:C3>=IWCOM
M/U_+UUN3UBW,HSTTC!U&(<0:4M))0[A0L5YB\6F\7+'+*>9/I*"=5F")S^8B
MD?J,/4F0>2@U,[[3MMOZ?=^<:7;5.9_;,JL>L5F,>/'$("UF36+'"5G,^><H
MH(^=--R^7Y $-PD=<G(C_:\_EU,[>GQG\O3T]?J-1[W;R\HW^_U]?Z3YZ2D[
M#N2&KNW"E3B LI9Z/1:M +%^2>#/'RAW[@W$Z*0JIOTXU(G+@JG2L?I1.7K.
MF[?7X?Z^OY>L]]_+M_OW]-O3X_CKU V#<BLG-C-U2(;*)0CQ6&!,L9PO,D$G
MI$%/+G50\M0!/U <4B=OS*D[:CT^?;^N_P#32=_AOV_7MM'G]^^O%;L.Y1Q/
M12-AJ<0U@U'J))-PD6+!1%F(_P!JH04IU=3J*'MT(J&^Q!TU&Y=NT?/\_O\
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M59L9)07)U/2R$@7DJH)E#K,F/ CP4P<B$]OK\/\ 7_32)F?.-OU^.JQ;N_\
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M .GZ=^W_ *.L:_;_ 'Y[_.NO[4O_ %[2_P#N2K\?\Y>[^G^VT:\9^R1_[/\
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M*JF=,P@8H@&\UL7TY8!!#4IL*YAD>HBPL7(<&_\ $IRC!BCC<3 A(9D9B=:
M8LY:(&)$A[ZKX$HF56:K3190R([@Y#@-35EL2V"0%$%$QI3F9V%KK+ZE/2L?
M#1_JV#'ULF[19-?6RCU"-C6OGN#II^H?2#ILR:)=76NZ7213 RBA2CB,23%J
M'WF-(A4$=S80K-Q" ^9$*E,9,1$S  9>0S.L_(2*?X0&3,O01B8B2*?2(F8B
M9GMWTJZC32'8K-7:A$N)ZU3D37(1H=NFYEIM^UC(Y!1VX3:M4U7;Q5) BCER
MLDW0(8X&565323 QSE*,;Q+:Z8F)=;L)J5E;_O+%JRR%(KI#^)CG,(06L(DC
M*8@8F=09"M;G', JNEMA[2F!6E"0EC7-.=A!:P&2,RF!$8F9F(TC9 R1C[%%
M8>77)UVJV/JA'K-6[ZSW*=C:Y M%WRY&K)%Q*RSEJR15=.5"(-R'6*994Y2$
M QA -8&Y2V5U,:L&V[ 5:JS,1.Q9,3,$)$IB6.(%L.%AN4B!EML,S&8@9BTQ
M B!"B>XA&9%20V@FLF(F 6,D,29;#$D,;[S&[HC9*/F8]E+1+YI)Q<DU0?1T
MBP<).V+YDZ2*LV=M'2!U$7#=PB<BJ*R1SIJ)F*8AA*(#K>U3$L-3EFIJC(&+
M8,@8&,R) 8E$$)#,3$Q,1,3&TZTJ:MZP<E@-4P8-;%E!@8%&XF!#,B0E$[P4
M3,3'>)VUNZPULT:::H=N['BQU#]81]W^W]_*//;W$/C4_6WK]?K\M8EO\/+O
MWV[^DQO,]NWGVU47M[]Q[!TCP(C\C]N/\_Z:CZ^OKT\HUAW\NT=YYHWB(](^
M._W]OSUCCVXX'GD!'N/(=^>>_;[]A[C^W>?3S_#Z^6F_GOO&VVT=HF/6/3OW
M[=X[1._K.QV >/;G[@''3W_I_/N(@'/N/#TCZ]9_/T\]_EJ>\]^\[?"9WW[?
MAZSY1MMOY]M\![]_?D  1[]P]_G]O]FD[;]O+^7^NG?:(CRVF9]//X=OCOZ=
M_7M.^CC]0 0'GD![\<![<?\ 5\<:><Q^$=_KRU._GVG;:8VV\N\[[[[_ (SW
M]=XT% 0Y'O\ '/;@>/<0#V_K_,-/Q^OY[?A_/4%.^WEZ]MXGOZ;[;_EY?'MH
M#@/O[<\B'[]N.X<#W[\ASW#4?7U/U&D[SW[><1MO]W??M,3$[1,3'PWCM&CW
M#N;XXXX[]N!_U_/R >X=^)[;1\>^_P"?:(_G_7TU/>)G88\XG??X[Q^N_EZ>
MD?$#OV]^.>!]_P!1[#QR/?O[_M\ZC2=O/TG;>/+X;3O&_:-NVWS[^FL^WN81
M#CL(_'V'CGGCGVY#C4[1O\8^6\?SB=MO7S^_6/IY1$Q.WW_+M&V_?OM,3Y[1
MK  /</\ 6' \>PB'(>W\P^>VG;UG]-_3[_/ZG64SY3MO'EYSY[]MXC\_*?3;
MXZJAO>;+O-M-_;-&ZSEPHYII4T&R1UUE.+M71'RTTBG.H(%#JX*41 "B(@
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M;!MDJY1*%8V,"BO9&J]HUFL0_-5TW*ZRI5G5Y;E!%*Z[:ZRZ>[E[#-5';CN
MM=;DG,/8JQA+*MA@)=F8I'<5-0M$GI**DFISE.0KEB^;(.D#&*8I54BB8H@
M@/G,^]M;!9JRAA*?7Q.1>EH]B6U5-S%L&>^Q 8B4=O.(U]%]E.,H9KVH^S;#
MY6JJ]B\MQ]P=C,E2?$RFY0O\18ZK<JNB)B958KM8ID1,3(',1,3WU4;:<YS-
MN'V-[=[>]RW*M;S+QTI,6Z>DTWJSFZ),[;8F*<;)R<')04M&E,U:-VP.V+A1
M(J10]9&R:1 ;GXO!EFYD>','D;S2R#&4KGBD/828NM-[%JEME:VRJ! "5,S7
ML (LED()BUS'O/VE>'\#PA[<?:+PUPUC*^$PV-R^.5C:=)<2BA7/!T'N4A#2
MG>#LV?$S(M4WJ+Y!<"VMB8.M.UC<9&;OJCF2JT^9)%D@*-7E7=6RW 6#&U8Q
MC".K.ZRSC">AL@K4N]V.Q9,^HLGM/FX2OI13*=61)9[!!1D,1P_]91(4.S@7
M$.MT<C%YN120UAG+49X3+&X+#XR!L#T+N%XFA-PGWV8ZB_#E=?%@[]B,=/P#
M)+;93B)K&I-JE--=9\&[J8_(?XF1?RV:MR:"$J.2X:"<6RM3B[>*VI2>BJL4
MWUK3+8X\O5.54F\;7>B-ZMEQG9]MV.K9DN#E9S"<%,QE?97-2W/Z=>+;7)NM
M*V",7M["B0]RM2*9VD2W(N!O.9-H77Z3.'K)V);DZ:,IC;.1 S/PF"?DJV5Q
MU0X=745K(T!Q&-KT'B@PIWO#1XPZM=M^)MC5L*R]3[-@J5AJ+4UB<M:LAFE)
MRE)V5IC -^R:=JGF;-:RD@)MJM%YY4TV+\5%3'M^K6\:BU3<U4L@5&(D8"OF
MDTMMK&$M%2K,[<W#@+0[=N$+5#.Y-W$L9T%JHY_$>1$(ZXM;N]N9G$<%89UZ
M0>5VG;=PI7EU<AXA\6VN=2BX$37Q"J6#37@#EBJ,,KY",_\ 9ZJ]I<V<(G$S
MDFT\K8N C=7&0XC.&/$\,5:J\KKU2Z&Y%M[*,M,:J FV33I_9LY,9KE33<-@
MXJ;=8#F>>%SPOXGMOQI7:?=J)F&^0L=?%K(WKK3-&"V%D%M'9>H60ZVTR,^L
M>89-C=(2%I3*PU**00NCEZ:WQK9^[9LX-TQDVG3PQS5RV!MY(Q>S'-2#K==<
M!0)5;.<55'WFT-@<%^[A'<*Y&D*HN%4K!DZENZW)AM>PAC^3/ CEJJR=?)HK
M*)K#M50R? -#&A55:A;5E03Q*6=')<R$,LC:HV::%UB:BDEQ.%?%#IL5EZ"Q
M%0\TXYC;WDS*-]<I2V2=N<Y'-X>S9YF;@@UQ?$0.XZ"D(6Z6''\X(+?4[718
MI26:+,Y"WPW#5XMRDKM1@^':!N>LL;4PJ;(C"FW%%%/B(+2$'UTUF4J62L8.
MS;2=F0:A5B:JLD4,IV+]QU5^1RU]2=GW?!+KR<PJM*J'#G!N))MP879/Q33P
MN=KU&J0PQ7;QY,92+J/HS_+TSQ(XNKL"1+3<=?;<2I8;5E)Q[=]N>-$PL=:R
M-CU6W,(FH1^Y.]0#L9ZBL[JI>#2E@9(J&4]%!6*VK2J;=A;GK?:BR"0&J'&&
M ML:V!96?ABIW1XB JP@HUX@1D HU5H"[.6?4F* TZC,J''-)GCK0PVP%MO#
M7%%.HD>0(JY)W6GAIQVY>YI9&K=FD3K!3;0[#KNDVVFY*L5<9M^QOXJC]_:W
M46?.0M'%O@UIEK3,Q8+CAL$>.6HN30?X91G<BP*5)KD3A@+'7+Q!7)U#R$Q<
MW5?<5UE+-FCVP)5L>MJZV.7=FP?)D,;XF.LMEN#3AN+U<16WOV6MV!R>1?PB
M?#U-<SDJCD7&7:6/4N3L7KABZSDV5%]"'X7-_9W5Y8K5[-B.'YX9IM0OJG&8
MQUM6;;F[P2>.=CCZ%>UE'V$JJV@EH?/"^UW;I(YTJ=\2F\99JIL]FJN6B1IM
MVMLU0ZY9WZ3.P3+O&]FN4%/(L4#P=FDTV4B\D%D&#@SJ.3=$.@'1L&D>(>%[
MP$H*\4K*K8 I@IK9_(\+W,?1,]U\B>AQ!83,6ER56J9#:%\+7S17LP4T>)45
M&&E,VIL5"MEU'6>'Z^7KW[M"!2-@SL6L,NQ2%)P$F<2N6"!0V:D9<P?OPS'+
M7V.L6.MP#O$T]FK#]TH]?JF?<,J/*Y 5:]7,ESDX:?L^9(9\:O3U.6IUFAH)
M2#K;F-7.K!C5"240H_E^5CJ;6(X87F0D+E/-V;>0*P0O\%C\CPH_&NQ]UB2L
MEDSQV<A_-95XGQ5*^%A"4RRS0I6,M86=?,3B EOB,78K)"!%=?(/H9KAW)8>
MY26XT10.]0#)K96L*1-3(U(BQ?LUSIVM-?&>V/Q)L,Q^(J'37>:(3$%,998:
M3%4JMLPG99UY(25UO[M@ RL_N3Q?$UVMV>M2=:>T2280MYF:?.>:K,5&KF(X
MU6/[<LX4@:TAS"_9EPSBL>)- $5^*,=P4&-N*M7(.V<-J<65Z]FJ]%2Q5M</
M*11/))*6UQFNJI7R1FD$KIN]I&:RMDY634LX>R?&Z<O5L!0@$2=<N&;-VGFJ
M[;*[0Y8KERGB\F44G6>S^T>NY6K.W;%+'.KZX/<S*4V 7R@%VL5?L\NUNY8I
MHUL*"4I5)&7K9X\\@V6=,BPTBZ:"FX\TQR.%5DD_7YH\<>2M?9 P.,ZK#I;@
MP&PBPP[(JL=2(*7UY=-8X&32$)%==KJX*:?)Q@6QK$5Z7>).Q9DA::2@5@]B
MZ_2A!L6*CK@I@QS=6>>2>(/)@#8Q8YDTE5"(J.#IIG.1!(4BJK&*43%23,NH
MBB"B@@!""LLDD!A 5%"%Y,'(,I$#(0)A")%"PD(,YB)F "6&M<$4]ADS -YC
MF(8WF.D,1)#$E Q,Q$D7-(C$SM)% B1;1YSRB1;1V&9VC5%:[O[H=L22:U_$
M^8I"VL,[-MO]]H/F8:9VS%]H?KO&\79+>60S$T@)*C2JC%;Z=.4">N[IT)5D
MBQ8.&4BBS53"W_AUBBB*?$M3*6*N0."BM3L8?&NRU_&9$!$K:;ZL?6MV1A%6
MS4:JO!KMD%S'%<T7F_9XY3K@9/QCL: U5RLG9%&6R"\72NX\Y,:IU3O-77;X
MFQ5LUFRQ5BLIJ+"TV2G,]X8KCFOLY;)U*1=6FZ-\=P:"%AC'RCR[.4U%DZV)
M63AQZ>4*DD=19NY\DS<H%%;R^LG5*9A[ZM9,]1UVO<MU #OXFOCTR^VU)1[K
M 2N-RD9G<I@!W.8&=CS&L#6/GI AM5+Y.)CHLNME%46QYKZ[1( DXB)D2[^[
M.VWD'-F),51$]-Y!R)4JLPK#>/=3_P!3FV";R+;RSQ%A&*NXXJQWZ1)!XX1;
MM#"VX74. )B8 ,(:Y>D22$L'FL7ZF+7$3S;WKK5JKURF-X692T#+GD14GF>R
M02)'&9"0@TY$N5-&[DCB(F3FCCT-L6["PCWVBI26=E"9&<0I8DTA"5 ,K8U5
MAY"<87VE2L=&Q*TVY<QUOK*S<L:DJHW!V9ZI+)1[=JJ\2.R(]>/&S '8"BJZ
M2$IQ*M,*K7<^4M;*Q&02$J!CVM$IK5E%88A$/MD/3K0UR@8<QNP1@BB4C#F@
MH3&),S'?WB@(4(F\BA8FSEKK,6OY (EKF"D=IC>+L/;H\>9AI#;(+9!Y1:V>
M%)+R+B^V3&316 7-8)BN*0\X2M9 M";-V1[#++(2B:SBK2K1TT4@[#*+"Y0:
M[R@!36L=9<JN)Q;ZI>^$N'+XNGEJRX%@ :K((NJ2^H\56UV!.!2:>1QZQ+G;
M84 D<UK.3KL(8B1F,7==1?8"=]SJL8AC$O&-NEM+H2S=<+5HW$42KY:Q'AXQ
M'LY/YC_$@04G7I.G/XF"-7JTZMB1K0Q5M32VMF=AB(^2/7Y6'J\W#KN&"S:1
MD(Q1=AZQ5 [5S)4@$EMQ>(;F+!,C]V2J^4Q.*LU!E?4-5Y#LWCGDFV%8&U7$
MRNUS$N4&-AJZ]:E:(H,+^21C*XK[F1V*62NA:B2Y5G4@,782;$L8T'DD93R&
M3 GC6.MFC331IIHTTT:::---0UEVA7B[HP@5"[#76T8X<+S-<6^J,8^X('(0
M"1KV?@'[*:ADQ JB0N$49AH4C@ZCB%?*)(E+68LY=+9!=M,56J\ UIUE,>9K
M('E96JP0],0(.0JSXF#F0Z9Q!QM$QA1+B22TF"460 6F "M@RN%G(1',PELZ
MBVJ9$K@>8@(P+G/N+VL9BS9.3=8H>-Y#%Z26V[*V+I.TV*^4ZS8=LDW?Z E"
MP;:@"PF%\PC,L)-)K"6J[W;'-#<N:ZR(@Q3F$4VZ0;.<@LY7*2DL@@+_  [:
M'"W%UTVLW'#O$>,SYUZI+?8Q>/QN613M4;2KMD2L6+"&6:H)43(L): %@DG:
MM5'*MV''E<9,NC#U;B<C2>3DVRILN9:D=A&6PXUDOIUFS87XU+7MV2H;9!9<
ME2Z69KAB>3P]E-_EBO2]'AB7NL.38>K%?IE>@7=GM;"AV:9IUNF3256^IT>%
MAI>PMHZ8<5:7G@0293$<T124FSX@;1V7W7<57;ULB<MB*6=\>E>'JP0G*LO<
MIY2]5R.11,5J"LUQ"S'W[=I./;DN(*2FL-1]=3%4<?PICJ5=<AX,,AP_:K7R
MR-9K A[,%7O4L;<11LTJMW+%A:-&W3Q5>VVW1F/#T)O5K&VC/M7OV/6+F\0+
MZRQ&WVGT>[4NBR\W64DBIQ 1MXAI5S'PHN5#'=1,]<'T5;73D7"MG+%+K$=%
MU7"M7,#B29U%9RQ-%>6\+"US1";E)3VK0%BK2,<?7\6Q./HW5(MXVM4J18KV
MWN%70HC",U>%II+% 1,I.<)N&TPTO:1.DDLM=2TZ4^,>^H<IR#K;:R7TE5Y9
M1Z;Q!XEMECL.QV2\>Y;R/#4>UXRLY(V*R]@>,< YI.<%[39GF4(ZQ9@61N,H
M^Q^VJR=!7C;G.@RDHN;3G%(=RX;NI3<N"&VJP\1;8"G*6M5R_9\IL<'9'$NB
MI6E==E?+SQ-9*[;=*1K%@[%=2;K[5:Q2=KJLL!3R=>9A07U<4H5$L.;:IR!J
MG%)L6.5RW8=6,.Q1E8"-N,J),97BDZO>H1A5<%^*_1\:R6.,757-V,X%5O4Y
M=T#_ "#MNMTC&3)+UEM>Z1V)HV(W.TXC!"0@)S%DN6.L%XIL/(*0EE1=/TWB
MJ4?+Y%U&4<(@GM$\;8QRB9T@=9*K'!N,I]-_,]2+&,QW$E*U+$&;G0FU!U*E
M]$D*NA==4L9#+Y!*"AV5RW$MQJC9%>K-&WQ!1R&*F.FJRY.8=C6YRM<>@ 'J
MGC(BZ'38]-R;'6/$+CCR*]?A\^W)^I8,'SJ\L[OV :,BI])LM>;Y(@*U1D,]
M6:!)5'-2CYI[.)2L_!2CB3D4V<:-P4<KR;#)?-%HP5R)3'%'$$UWW8FXJ,5D
MJ7$GV?9N H0>>)Q5V[P^J@E"1R;*N-:]^'IVH+QO!-=N,;)=9SLC_A;%@215
M7K!.3J?83K::[/$M!>;O&G-A9-Y.Q0,N0A6>.BBJ4PG*XQ\555&#]?\ Z1+L
M"7NN?Q12I&;<!,G=E\O\:IW.SX>6G,FUQ&K8JE6KNHC 4ZRGA+C%/6ZQ@@FO
MHC/I'FUPLC6JP0VH@<)>%";%BN^_6S4<+ O;,V5\E:^JSQ8*[&*=4)@+H#9\
M=7QJWA1CM6B05K-E7@!%E\&8P^4QJ?9L\8U;5&NJOM+D6Z?!(W<=FR?$KMY9
MM6:C<B LR"[B/6V:D,3[#KSN(JMG),XRL;17<179->LVB2:79YC*U4VJWN;<
MX_FK= 2$3%Y%D(>35E(EW*$A?J[.S/V\<2&?*Q_9R4IGB^;6+)8ULAP_F\;A
MEKAM55?B++V.';%6H+FA$4&V,?4X@P2+9;5Y=>#'JL,C)*AO.L0(8G(K@W#1
MJ<0U\@\+41:N7>$J-W*352Q:!=XFU0>_AO/7UDQ>ZL!>>+6,4I5FC5^VX;],
MTMVE>RKCO<.K4B;HH&_0,7$;@<*O5Z9C=3&M]K5B0?3\KFHTA8XIM:Y.#D8Q
MBC%(O2Q;]T#6JL%45F1/-LQ[[=?AL70!7:6'XZ1>L6A#H"[-\,#1PE>PM;+;
M+5M-^_8Q[[P0\3QJ,L1M6-RHFSU;%Q2YRQU4'(/?PDU==?(76?A..$Y/(6:1
M..LNNBQ@,<JTFLU=259AN+ H?-6U<2C1^W;Q3L<UJJ4O'<GFN(H=2V]GJU1J
ME<M^#9J5:Y ;5^TQ[V.M=MLFY:AL( %[0M6YNB3U?I>3B1]=:I14FXJAB/(E
M7KBZZZQDK5XF.:PL*=4(E0J*DK%<.BQ'6,WLG+4\E6SWVH)UJU/)+LHA>8O*
M;$4N;30FJO$)4"DK5<NQ?W@FA#"SN785I5813$X>[A'8I=("L.NT7JL-G"5G
MK$K7>3!<);:_B.@QU]>6E[>/PW&N[@>YS,7/V%"S/FY'<VR>2<&\D818C*16
M<-FI(=^]C$&J22+%RLW(F<>IDIJ1=>%"0*DD^C48 MB6UU>XEK)>"WFY@").
M8X!8QDD11O.J>+&T-&O-Z7>,8'5LB\D$:W,]YBX\,;*X@!3(@"3-8C$0)3&I
M8U1UT-4.W=" 62H<AS_P&_X_]^#M_/36)1,[1$[>6_\ ?\-OJ8U40?;[@/''
MW .!^ [ ''(<?/?N&I[;_7^GGZ_IK&//X3&^^_E/>/68F9G?O$SY=HVGO.@!
M$ ^0 0]Q[\#W_3V'^?'//SJ/K^7UY?GI,1)?&?A\?U]-_CWVVVC;6! 1[B'<
M1[#SV'GV[>_';[A[ZF)VWV_6(^N\;[_6SY;[1$;S$>FWGWCM,[[3Y>GIZY^X
M]/P(?< X /?G[<=A^1Y_0=1]?7EIZQ'-ZQ/PF=YGRV^._>/2-OG&@0X[]A$?
MT$1']0#D0^WP ?'(:F-OA,Q'?_?X=]O]>VT;S/:-QV^<1M]\[1/:-_C/K\=8
M#@!Y'N/?D!#WY]N _7GV'[C]M/TCY1OMY_'^_P#+4SO,1$>6T;3$^6WGO/EV
MV\X\NWQUG@>W(<\\=@#VXYX ?;@._P \_P PT[?7ZS]_Z;?/OJ(F.^T[>>\[
M^>^W>.T[^7RW]-M]H , #["' B/ #S\<#]O]_P!-1Z?G_3_74S$S'G$[Q$;S
MV]=X^,[_ .GG.L<A\AV'N''/;OP/V]^.>/Y=M3/U_3OO/W?*(U,1/I/?UW\Y
M]?GY;^??>9F>_;?U[C[AVY ?@0 !Y^>W\^W';N/'=V^OJ/O^N^/E'E.T[3'K
M$S/]X]/7OVC>-O/(<\CS\@ ^_/;[<>WZ?'/?WU&W^W\OSUEM.VT;;=IF/+;:
M>_>)\^W>?7;MWB=,K(.88? -:'+M@K*ERAZ;-UA\^K:*S1NI*)NK%%QQ$BK/
M6[IJ3RE'A%O[5%0H@F(  "("'9P&+;F<K7QR+$56/%\B^8(H#I(:Z=X A*>:
M D>TQWG?RUXCVB<74^!^$LIQ-?QI9:KCCH"R@!+63IN9&K2"8)X,7'(RP+2Y
M@F=@F(]Z8F+88.S+'^(MMJOCG&%=K^$FS3(H4Z4B[]1*YE^L3Z45$5BQR#><
MJ*3ZG(/8R9:33>+7.SFXB;: U,YCI9FY!NLBXSX8L8B]2I6;M;("5<[C!?6>
MQ3!8N]5K#!#;KV4,J711D :AZR,D"@OW;63KG^R'VD8[VAX')9O%8:Q@%U<J
M[$2H+%:7=0*N.MNL@2ZOABZU:W-60L5WAMS$8'$",0A8O"IL[>.QS)U[-]4E
MIV@P4:VLD;8L"$L+6[EJV6I#+E8JU+&0S?!.,?5>+-*2E#@8FS6/(!XJM.(X
MBE@Y8O5)+RF1J]2S<O*6^V)XGAJJ--EA(7LAD.&\!Q/P\>0OY3I*K.N9RCQ'
MM>=./3RMQU,FE9KC-77T154&5_"L:FHUEGB;IV4)<%''U>)<IP_EP57H=2Q9
M%6(R/#U:TD5W2ED6\B*%U76$MKUTQ]X-=]R1@:FM,P7NLX@R/'0];KKK'5?Q
MP^&A!7ZJ6V1OI,EFQ+N.KLOD^SRS*R'5:7B R-C\T<R;1;3\+H+-WJ;CI6JU
M>;:;*W%9E\T[&06R'JK+8O#5,? 8FLIRIQ>14:)._D2=DTY&V/7"NI(H4J_<
MLQ9S&6OH5-5#,MGKF+Y1KS8Z>5XD;GE^.(UO38II@@K4\<NO59123TG<N<_7
M.SS_ ,*>8>SDG-M\T8TAWTKF:.R6>=B-O-B3O,;64L)AA*7I<+>G^XB1FFLK
M)12CJR(75[]351L9VSR6KT^+=8SRO:KQ=KWZSFL6O)UO:15NE3%-1AKX^MLM
MI-8K3-9;,*PAD@\,57(%-B4UL6+X!6NDWP-;'I6I+3QF,X#H59L=>Q7ZO ^1
M3E%V'*>]MEXY%Z0JF#+TV:^-!=4[MMP3;+UC;PHWM'NV$;E+9CQM9"XGRG%W
MZ9KS7;>:NP%PB('$,_AZ-BF4<CFB29U>UR\78G%FOET6;65C;K9'0S].FPC-
MB=@XZE>YTLD>2-*Y.QCN)J[T(W0BM>XCR6!RXNPPGXC[+QF)O\.T2QN*/QK4
MIL9 0R067HMU.>^H+,2W$@92J+'"_AWVI*R]U'ARUD'D&;."1.8REY.096C*
M;T@0*PEU"Z!,4<H[F/#VN&XO-B^5!W!L*/"I5*:J,# 16'BN;7!,+)1)NH3R
M WMADJOM)Y@[DI",LC-K8J7)O(LT<^AF<H6.F!]!P48^4LR[R8#VY2LZKR-3
M)4^C&6X4S5)=ZGU>G=77M<,G7LPHJ3,AC\HZM8;#*E6P/79:$IPD D17B+2+
MA 1<\NLK7G:3FUVP(.I$[%9]]<0@["47:5#(+5L-VI>JK*>#UF"5?)N%MS^W
MQLS82.09R!CH[9%8XYO6YS)$IBR7F)"#29[P46<=],=XHAR0 -62+QFWE9@K
MU_)+JM7+;IX[EQUH+0RUK%]%(&39AP5%\6Y;BQB5NV*5M:[-6\?# "$!476_
MRA$ML/K08BE]<0$T6+M/(/6Z(8+[%'@1W %>7",+%HSCFQDW<XRQF7 ; ,4C
M_+0^*7X1,K1FV2_I^=*/,V"]V!&=B[Q;<-94LMIK2Q+#8;$#Q1A(;L38[EK!
M%.K1*MZU+M\?PC%FS%LVL<';44UTW.K'J"A'#PK$8^P\AC+##3S+;<IXNHJB
M"5L:5CP5^_40I>5O +JUDY:VOC*9>'\-6MI\8>1-_(^+]3(JZ%@635"SE+*[
M=B374;2:[')>$S2IP]5ZJJ%@.7,Q<VPI6[PGK-=;'D.8F-P]-*PR+?KY8WD>
MRV[N&[NLU^^2]7F'KBDR!LW*M:QF:/=51HHRS QB 8@M(RZQL<\N6I&6K"UA
MQ+<"PBET8:ZC(%T(\*PVT^-,EQO5HT',FVS&X1ES*VL1D\84WIOX(*M0+52T
MD[K=F2ZEY.64! ,Y*FJJ$VU#=6)EP=3X-NV;J(FLG(-FM15D\7$#5'&Y.38Z
M,BB81$EX(\-Z3Q3F*_7NXY"PKD3'>1?XG$LN.&6VJ5J4O,(9 M[*VQJ<W='^
M?+K%3"E6<,2))KK4!%1^X7=2+7Z*X5 I,<;2KU<,>(NC-T"Q5''Q"]JE-;JN
M3SN1=:73D;)+%P<06L>I"[0'6H5<>CQ+O#LE^%M9LRJ<G4>VL:[N0L,%Y>+:
MVMD<-A\.ZI-@?"^8X*G98UBF@YMG*0VO,7%%5Z9UJL5VF0476*G"1E<KL*T1
M81,+#,D(^.8,VY 320;-6Y$TDR%*4.1 O4<>3G,8XB8>@][K+3?88;6L*2-A
MSN4R4S,_*(WF=AB(&([1$1VT2E5=2TI 5J4 + !\A!8" 1O.\SR@(CO,S.T1
MO,Z7=:M;=<;O$IO>#ZGN(V01>4\!N\N66PWIPWH%J;Y9L6/28ZD0O&-6YI):
M AH649W,IY!W%20,I-RP2*$09EYGE2*RB7R[CRYB*V;X27D<,63L/MD-*R.2
M?1BB?BZ ]24J2P;7ODMG(P@C]W(;[',Q^Y/V5N'?:!F?9E[?[G!_M'1P7BL9
MP\MG$>';P9C.)CXGK3P_Q4WPJ\C>R%-V"D:R;=7KU563F;L/Y(.J G<=+*V<
M9S,NYW$5?E,01I\=U/$=KQE9;)3[>9E -+^C:D9X,BM&.1$1O0PJ]3<RD<%>
M=XP3>-7R4.\<LSM5)YQ]($FLPMB_+JU9U+BC*8JW9<!E4C%TL3ALREH5NLHP
MMP&6BC8<R_T(Z19$*XQ$8UGXJL5U)/%$M;WQD,<]OAA:(.*\F[X3==@:[8&N
M8&+!K>$<XF*E/B8BQ#J\%W+>W?:AL8ON:I=QANO[F:/BW(F2F>-Y$9.0A[S
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MN;Z,_KV-)3ZHO6)#!EGD;C)).\8#C&1K,/ENP;@K!98BEMF9$IBK0-B87AS
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M%J*TUAE5ALVK0UAE"C<*2(#/J6""?W-<87L3C]V"(![20[J0<\B ?80 1#W
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M[3.\:9;PG*[BZ0[PU#3;"NR5WF*NP:S4HW<.V3 [6S1,D91PW:B#A0IRLC)
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MC5NO _L=ALVV/);VQSTQ8'B&>)QHB[FI1]*N4FI,?8Y5*W27?KN%4T"JK*J
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M%6!HSA+S7*],22+"3;.8_P!?',74>Y>-G#=JY7514*66ST:-?($)E7MT?M%
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MS7,D2UOS([K=/'#%KA9&)ME2F7..X%&4EH?SHE--Y(LXPW2S2ZU1U>KGBLK
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M7%RCH7-JMD@N5Q0U#\;?Q-U3F,4P$VRKV$VZQ IHM;7M54R=9G1!Z38,64'
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M.>WQJ/KZ[3J!CMZ;SWC;TB=H]>_;>?C'GYSMK(\CV^_(_';[>P]QX#M[<_J
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MM;'UN>&5:MQ65\-0>,V):^J[Q*J@S$QQKMF:5>BTH4UUFX=1R5,*028<09#
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M:;N'+N>KJKX^L9 =QU^OA L;D5=-<\C60+;,JL,7T,VEY[DMR^"JGF"7H_\
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M"=9'CCD1YY'\H]Q$>.>W'80_4?U^^H[^GU&GK';;;SCM$1,[=]YWCU[1Y]M
MB/Z=^W?C@!  $>X^_N(=_P!=3Z?U^[T_7^6D1'S[?#?>8F9B.W;;RB>WG&L<
M<_IR(\?/[@'Q[#_4 [A\1J?+UWVVW]-M_+?U\_QVF=]_4$/S?'<3<?(=OO\
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MA0;7"]4&!*Y9EPXF.FG,)MC%.<:[(L4I4JJDKGFEM6IPV%]S OW&4VW9K*7
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M3&%OOL(SM'II4)5*@NB4Q*S75$5G"<F7_@2-$BCL2\IOA*+7NZZ3?E<"'G
M\=8:V3$K,8VD321P&W8E%,QS\DQW"2D8YN7;>1C??:-81(,"9C8P<L(GMN+%
MP,PL2B?X@@"F!&=X@9F(B(F8UNM*_ L'J\DQA(AE(NNOU+]I&LVSUQYA@,IY
M[I%$BZOF& #'\Q0W48 $W(@ Z@8@!Y CD#M[@^Z/:9F/=C:.TS,QV[3,SZSK
M(O?*#+WBB)B"+N41,1$Q!3O,1,",3M/>(B/2-?5Y"P\BY;/)")C'SMD"@,W3
MQ@U<N6@*EZ50;+KI'50!4HB50$C$ZR]C<AVU'*.Y3M&YA*SG:-R7,%$@4_\
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MB !IM&\3M&XB0#.W<0,I(QB?03*9(ACL13,S$S.^H])CT*1DH]"D!Y F8]9
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MB;J\;D\?D&UUVUTKE>R=9L#(/%+19*R@Q,)YH':.<##?;G QW&>4N&?#"LE
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MVCYE=S-RL.;S)=D6;Z:K6 ^T#+C.N6M.MVJ';NPYLE0["/\ P(^]O_OP>_\
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M[*6B7S.3BY)J@^CI&/<HO&+YDZ3*LV=LW;<ZB#ELX1.15%=$YTE4S%.0QBB
MCDQ;%&:F@:V+*0-;!D# AG8A(2B"$HGM,3$3$^>MRFJ>L')8#5,&#6U9B:S
MHW@@,9D2&8[Q,3,3KB9E3Q2;[3<UY)Q; HX,2A*QE*I8_@KED)6QTUF@:3O"
ME'N36?8N+:,XH\I2PI3B\TM!UB#FH0OU* +*0CMM.AR\7;/(TJ]DB0B7WLLH
M6GS"IE"KA.(LG4R$)YR.N,7\&O#VZ]EX7!N7% ZK0-E9;]^7!F->0*K6+8JH
M8:RU21(VC8R-WAU;4"\5]%D%B\V[*K8@'+JIHVEO-S:5T$Q\P\0.Q[@,W[)&
MRDI5<=0Q\L4M6RHP-PN[/^(9K=CS*\9*C$ T?MZ?8L9,;;%0$1Z6T!*R#:UO
M8)N0S205;IO.MA BWECL&BR@;'#&5.IBK43XRF;\'P]FUEE$&(IFU)6K];'.
MKJ4[GPN9A?-";05];;(#A\TB84;Z]RM'C.4H4<8SVA4L7UL6]),;$EA%,O91
M-DAJ_9N9J-.9!E1CN_YS=!#F HG$I3& I>.HW2 CTEY$ Y'C@.1 .1[CJNPI
M!9G D<@!% #MS'(C,P([S$<Q;;1O,1O,=]91&\Q&\1O,1O/E&\^<_*/.=?G?
M>^(9DF,W*7S(R"M)B(YC1ZM3Y[%5FG<G)_@6&:;@'-'F9ZZ5AU)MJW#Y#KT5
M*1UGEY:!CFR0TF6C!F^63B#DW/-Q%A\5<L]AIL)R<\#W(<LB;4IV;6#]I!M1
MCFMCQ*Y/(TN&\%FD\JZQY6*BDK'(L8J)SE<J^4QZ@ZBYQN-]HZ5KYN7[5;CK
M7LWOXYCQ7RJ<NYC3XJMX%D"QPH5DV"^Q4KV!6\8KQ1\B9 HF0K,Z:[>6U8Q_
M1,$W.U%;6R\QLF1WD>[3U3M-8"0C;(P<0DE4E:\VL*RCIP11"'G(UG+,1*N9
MROU1@!FHY[ 2AO%^-X=!IE @*[W#'#7$2LH9D0J*LBWE,OB& 4$I]K#6PY@*
MK95K-L3%MU2E(N8O \8Y(I(883?L/-9G#TU(1 R<#D*E;'V8?!=13+@'7F8=
M6,$J.\8#("M/O$GZ3;5,3K!.P&HZ,%=W#>-<-J[FN4Q>B_LCZV72OUYHVM=<
M:,;M6GDU=J;7U&+HAW=H*W=-%E*!VK'V?C'C6D;UV.$G/K,):EUXXBX<RV4O
MTN=[*PC=PF4Q48Z[#&"2IM@B*K;RUU[4&*@R=Y 3)8RL.:"L[F:U[V8RS@55
MF%-:M:DEV*^:EL@FNZ?\MXAKJU(WVJG8/:ODVX9DP%C?)E]5QDI;K="?4YQ#
M#]G:72@1SXSI=%6)AK3'S5ACIM2+,D+"2>QTR_8'DD'9&CA1$A##WLC553>M
M*B:R)J4G$UBVJ!K+%53S;5%Z*SSI&3)FFYJ%,L5^F^5AU( >?3L'9![#"%"-
MRVI*R))/"NEYJ1-R*[[2%7&+ 76*Z;#UUC9X>'.E4M/G]G_Q$,TXNW/9&P9"
M8IQ_!TNE8VEK:SR;E2Y5J :RCYE3WUJ:R<9539%B,EW.LG?QXU&0)C[&]E/%
M23Y"2?32"#5RP-YVK<?9Q_$%SIJ!V)NJJU*9%)6+C)S.!QZ:IK1-AE9F<1E;
M/V1?O!0H!>KUJY3=&U))ZME JL89"RB0OQSV[3IZ%5"6T<LR7*L/%-9A8FW4
MHMRE8++GSC677#%9J4B^$3>+-G,[G$#!AB#%,@[NTK9F=^>N+Y6J;6L>OH">
MCH=U0EK)DS)]%93]^B8MZ:XNF-))=G,[!J,R0L$5NL>9);)I3=L(5RE47A R
M:+C!,#N,=9X@0WPU%<NOO#!MQ%;'YA"*SI\;:)D6ZB&48N<\6E%&;)P)/^T)
MJ^%7S!()"A@[=9K[%F$4ZR^((REFQAK%NS7)=2H0LIV[*KJJDNX\\0S--X@\
M(24LRVUT,F6J/,W].7NEEN<%4YMO#S)ZY*4&D6 ZSAN[R/7U6;RURT1)&2%Q
M7GT6RCT!60E9AHR1G3?F4C .C&<-XW-K2)R-S(CF*N>NKL8Y8S'BJ.)7C<?2
MR9)*'>*R:K$E22=4+.75G=4P,2NQQ'E\(#^>9KTRQ%W$4E5<DZ D:^0SDW[[
M,6.TK$L/<K$NRSW@8D+XG5_B,.1]QK^/\?WI8^"/QS"46@VN5OUO1M\4[2:W
M)*X+RER-)U"KUIP]\XSF\GBVR[2/>$<W6.5.FBUV7&-4_(I&%R-:UPH%:Y+*
MPTJN(SF/PQ>.REAMBK6!T6[=Q*5-LTB970BY++4.LDBY"I/($LS5(S;XQ\0L
M9,+E^WBLCGBHHQ%!27/:O(U<?3:$X^MD %F46BM22JN@+/1'9MN:7W&XDJEB
MNZ6/ZKEB3CYB7FL?T[)&.[^"5=96>4@86VM%\>7[(\2E#V%NQ;NP01M<X$1(
M+N81U)N'C)4QNC;K+4-<T$9[T,6^\$BPHHW[U,7NIDXD(%R^J%@J5D5B%NH(
M/"-^H(<VO8)AV09 P(7KE>HV.08MUZ_1.60J'.-3:\65UKBFR# L@9]):FIB
M4S?5N9L&UG#B%\I[&OS5QDK 2$K59LD9).F%I?I1$M.KP*$LA8:I#5R3?,(=
MV6+D;'/M&+I\"$3'M)><D(R)>>?NY J=JH I\0N57+MQ(3(6(QU"$%>MH.>?
MGFBE_BGU:U;(9%U9;F4L?9BO8E?8K5@>FTQADJ%>%4ML1S@-FY:75K+:N-IY
M;#F"@'-;5J)<Q17+E=4\T\X(?Q>+VZLMRB7U:PE+QP0V2E*8VJEALCNP1KRE
MN,4J,YN\M"/G:JE5/ Y#L$_*&KS4DD6*QU9I%@*B39PFSZUA A5N =A(O7E,
M=1*WS%%"KCKG&61X2M9*Z2SARDU5IHY&7 Y:EC9*&M6N5OCGUS,Z57(D$S)4
M<59;BAC;)V;F2X*O<4S0H@4$!.J9+&EPZ\&*,OM'*XI,B+RE+[Z>&Y?G>0]O
M,E,R%VCK[(-LPYA8+S,19++:(I-N2]R[F+:0\C<9*5LQ((D2Y8K0#65>**(P
MJ[#TP^C,W$<P608?ADR6\"9P[C>H5H1BRQZ!96L%9, "&V1>ABK!E$MZRSAT
MRWGF="WR[)<0"3%'*LW:B!1,PE:FJKV$"I>\PI1(<MJP'9<@R#7'(0ZB[Q4-
MPMGP_AM>G5U9I5#9%JEZ4')<K,7:N-X*0J\2G*1=>K,[0GD?+L\@V!V)#UM)
MT^;QKE)@_2=$=IB=L?BE:B<[B:;3FNBO;P.6:<% LNJ5Q7@Z5RFF&3X=BJ]"
MW9OY5=D&K^RD6#E< +'HZ9 P,9>L(25A[D9/'*@0A@4V.P.6LHMV(@9,(;9J
MIH46*);1RENG ')R '4BZ^+1DC%"UQJC^-P:X<TE.93K+ZR3MK8.+Q -:AB6
MX4.8*\6E!2=N+G#W:QQR;UB+E"3F:TZD(I%9FW?-"=I<':NTDLA*;%G.IQ.3
MKKW7&/</M&O<&Y4H6<R25U,-]F\5B+HGPV*<;;,S78EX\:RUE3$C9I*?>B>&
M"S%!O*5CQSPX.?G*Z%ROEFT5G,U&X((2?49<,$1,68E9./('B6Y0Q5:K]5W,
MKM16MT'>KI%33Q]=+VC7G4+5\)AE&N.XI@_MCH[!W++HA2E 9E:1\G.NVCM!
M ')SM5>)&08BA:L%3L6/LZIQ/;N54 ?C+V4X>SV!PK<=C@9U36[+A=NAC:;2
M<5>YB[<0MT#9&.BM8NR=, G:IEK7#*:]V&2VK4QF<QG$%V,A;</)6)&,91QY
M6[BEI7:1E:@F22=59$\;>?$"R+G_ '=?P=B6> &&(D:FM/&DBY%AE\LS,D:H
M05B:Q=5I)KTG;I9!LK*OEYZ<6QFSJ;&*BNJ*M$\Y=./IGHJE,B'B6;11,XFY
M8KX\:FSBL5TY@L?&0NPN; TJ?0BMM-QE*VZYDJ@*I^&@'VJ+;>U3A-XP"G9Z
MC3M74V# (J6'8RS<L8Y/.:F.OJ?7:$5DA:E5:E?;<.LU/0U;C>SN!N.V+;W:
MLNT3'RF2;%#25:C&T&+B.9QK!"?GF,.[LL^^F)^IQ#&O5QL\4EIE[+6FN1C5
MBV57?SD8U(J[2X%^XZL[&)4"O^(9 :;+%AJDUJHS7L/$GN<Y"U^):A=%!$S_
M +5:1 K>4BEG=Q]15J;DM88Q4Q]NZ"4@QMBTRLJ3&M76E+VFTY[P()8<B)0(
M[]XYK-_%0S<RDX5.PX^P>*<OC2.N"-<J%S5O]E6ORE+M-D#"K27H%IM]&?VZ
MU)0;.R5"=A+#-U8*XLZB)9\E9585.7NWF>&^VHKB=HL>.0.D,+8GQP5IX7FQ
MRS<&IM/"R\^1\3,9%>I9 Z)X6T^4<0+PG+01-^S(/9<6+ A?:73E=>H=K*TZ
M-U<5W6B,<]:Q5BKC:RXL6J#%.9EU5U%2\;\,>^*=N%N=;J\LMB'$!9V4I^;;
M@I3(*^U^\6FR,<4QD).,$*S'XCR;E=G&RTJVE74-(UF6EGMICI.)7=C#?WIM
M$#G=GPC&"1@*4X7'9*Y;Y6NJ8_QO&%OA<K]BT +K/Q*: U^)WNIN>%:C4R]*
M;;VU9MAI6RPY]52TQ/C<Q./K*,A19,(X<K9KP9JM'7*ME6WPO8:JN\-1+V6,
M5:9X:&6$#(Z&_P R K)1)CV/:#9[!,8<N%WIUCJV7[%&4%92/M]4BRMK"C99
M^)C6$@VBIAPJ^@)1R27;S,5],2L42247!EC8ZE9V75"SY\=4P%FTR"4]+J5K
M(YH+-BC).2EZW4J-2W3<EJQ#QC0:S()JJ.QMJ$-VUAN86BC)/SR:R179"_7M
M(P./OT*>0K=,34\[S+52V#ZYL56K%;150[Q"!V\(>)Q<LA;B6>.[[CNE8XPN
MEC0USFLLVV[T6AJD.2K-; G8X.LW#*2-VL5#=2"CJ ">@*%,5QJH@C+_ (U=
MQCGS$K-40=]N$^9JC1?1KT5-DPMDZ_9Q%6G5R%(TC<H6LD66 Z2LE7Q3Q>K[
M,.LV^P5ZTL><?9 HB+<W;%]-AJUDM$KH+S[+5BHUIPFP-*<* V H/RL,1:+(
M=6O2K,,NQ2;A%9N1T@JFLW51*X171,"R2J*A 4352,F)@534(('(9,3 <H@)
M1$!#6EVZ(;U(("3!\XD!R02N)YH(!B3DAF)B0B).9C:(W[:LK,' MBC%BVB!
MK,"$@,#B" P.)D9$AF)$HF1F)B8G;7!.[^+5DF!NF0ZI"M=OJ,;6LE5^M5BV
M7QS9J@QGJQ,L,IIRJZ\,>XO9UC-4^QXY2B)D)QI65U_JA%@KK!FXB)&2YB,@
MPL30R+*Y&UL<5'8J(F#<VOA>%L#Q-AK=00ERP7G#R5K#(23[#!R7A*["3?7=
MQJK=FN2,J^D(LFN#,!7Z\@<"BU?XBMX7,I>V0 &#B:48_-G84N$3CGS9@VU'
MUK<N6A;Y97<'NSVRH&FZS0JX1\NP&IQMNN"$Q>BW#"+.XDLZ[$L@A1++CMQ8
MWRU;I[H[.2F$K)5YE 'Z#TKZ,;=_&58G)YXC%A\N+XAK5JQ1,G27BL_CJ]1F
M02<$"\CE:$?;V-?7%,MX?O(:OQ"IL-5RO']?!U()4)LFWAN]:80D'[^R^ZB_
M7H.7N1U<6P#Q.:1<,>AEHE#DJ-=([G<W535S5#MW8_\ 9'3P]O\ @5]R/R']
M_ .WQ["/Q^OQV?7U]?SUB7Y]O+S^<;[1OYQ'K$=OSJ&81X$..0#C@WZ?O^O;
MD0_VAI]?7Z:Q';???:9WW'?\^WIMWVC_ %UD.P=A^?S#Q[<AQ[>P@ _;^@Z?
M7U]>ND]YVF/3M&_GM/YQO'W3VVWT#SVX'W#J]OD._/ !_P#'CYU/W_/ZGOV^
MO/2/7MY3R^?:(^$3/^FV_;;1SP7V .KG]/D?CC[?//\ UHVW\]N_GY_C_:-O
MOU&V\[=YV]-_N[3._P ?/;X=OE@. XXY]^!$/;D?C]?;O_UAQ&LIF9WWV\MX
MB?/:/7Y?+UW^Z=9 1#@ #CN/OVYYY$![_8 ^_P#/4_7UV]/7[NVL9VG>9G>=
MO28[;=OUF>W;M\//6/D1X_Q![<"/VY'CD.P_ \^X?RU'U^&IV^<;1/W?&(B9
M[]XB.\;>6CN( (CP'QV[\_[@/ \\_P!=/K^?U^>G:)F(B-_7OM$1/\]]^\>7
MEM$S&@>0'GG@?GCVXYX[AS[A[?(?'.FD;;;;;QZ;[[[S\/E,=]^WK.T1Y ]C
M!^ON >_?X$ '[<?O[]]3O\/3O\?KTTCN,_+RF?A$?&8^._W;[=M'WX'V[<B'
M'Z< (B(\\? <?RU&I^^//OM$[_/>8B(C;?UG?\=,/)63Z=AJK*9*O]0)?JA5
MIFL.YFI*-8M\28;N+)%,DT#-IE-6-6%)PY2<@1RF8H"ER4>L"B';X>Q]K*9:
MM1I6O!V7#8E=GF8'3A==K"V)4PR.<!(.WQVF=IG7A?:1Q)B.$N#LIG\[B8S>
M+I,Q\6<9*JS8LE9R-2HF>E<$D%"7O4[=D3MT^81@X&=7\V2;HL(YZP_;,CXZ
MQ_$X+IL!D%W59:.?HU.M,'<XE7ZQ(C+JGA2LHOK=-)F.CB*N1]6H9F1'J,F5
M H6N*<1>PN1JT\CD/M"Q9K+8@Y8YA3#'/6" Z\RPCYE&< &^_-,Q&^^N1[(N
M-.'^/.'LAE>&N'HX=I4\N^B^F%>DB&6%4:%D[<C0 %;2FTE4F<<\0K:9Y8'9
M^Q>3\%;KJAG/&5OBE4*W4+A;\29*J=VG:_$'FV-?9PSV0L#)Q3KI*+FHDU'S
MC!9A*N9"(>J)'7;2L9&KIJ-A\@(ULAB\9E3[5WML6@6PC4_'7L+Q%E<$2KG(
M4*793E\%;)$J<]#0!#U-.2Y0^K*L-1DLC05!>(I'6I$R !B;J\MP[BLZ!4X*
M"-R3Q6=K Z&)4Y;NNLE0("PYDA+=B2IP-:K\/=J3&P3.%C&%7:GN,4N16%:E
M3BHL&+I[*KN9%#E%-FBZ%PZ.X6+T&657$W/0>YUJVXG%++CVPUH\L0TFVIEH
M%*@@>67[R:X$(@XG<(D=5D)13JJ4F(54K*-2YDR(%JIP(-B6F13,5HY1<1G,
MKF8ZDQ,]UL^1,?I\>9>J<3EM(/ Z[-"%Y:1)E"2KH.I\'+:,.BJ607#^R9&2
M4*Y,F)# %>#"1@X,9"5H;!P42,JLF*ZS8+?:5V&& (/?E:9"*Y(BB)L2)1,C
M,3!0TT2,Q,3#EA+6)F/.&K5$L-<^^ 1)E$#$SI&)E['8OY!HM<*HU9Q_I4QF
ME[G2_ICE\X1<NEHM$B-B5ED'[%HV%VZ3D8M@B=LH19DN[(FY%N&>:2B1D"AI
MJ6)2,R_I0J'&J (_=2UHUVBSIN!W:5<AK8>'-$R,#[XDE+I8,C(#%@V"@"WF
M#DG OK*,1)+%E'(TF"Q:_M'RN+J[8';)C/T^.M-X=MYMPQ-88T)RR.%FB+5D
M]0:.'YGSU(S)J@BS]*D9N""12MR@4!UFL9VFHN"GPI/DTCN1H-A%8?+![F$[
MG+#ZG<1V\@@8B3/> L,/W&@H%-(ME$ ?NU"F9GIP/-O$0O:#81E/,PR*9$U&
MIT:::---&FFF6ZR3CMBL[;/;]2V;B/>!'/T'5I@VZS*0,BLX*Q=I*OR';/#(
M-G"X-EBD6%%!94"="1S%Q$P.!D"$H/J\DB4%!=&0AW+,3,%TI8$-VWZ<F'/M
MS1O)1(ERE$B4=/<2B8*.M,PGM/?][,3"^WOS$P.\Q.F)8\_4>NY5Q5B,2/IJ
M<RVC95825@)"HOX:$&N0)K(0ME:J6AM:VR-ABD'ZM?DXFL3,,NK&N4)&2C%5
MH\KZ:\S9O7Z B2W4,0[,-)D?NF)K9/$XJU6 E]0U7:[LYC'$FV%8&UK$LK->
M:+"U8/($5:MLC$@N9)&,2 ;RR66*>2NA8]Z!6=6 Q5E+&*8Q@/E02KD,F!RZ
M\42SXQ@MRFPME><8N+U-RV0'"-3FD;I+U@E3>!?<7I"\5C8Y!5O.@9VNQ=^G
M>F33 &!D 'H=*"'RCVA6,>G/<'!<QY7&LNE%9PVVU_#%XS'QS2L!D7>](%RG
M,1[G+Y%.OWU^R/B>+<A[*_VBK'#O%JN'J%+AM9YF@S TLL691/#O%IPD+5I@
M-Q\PE=A'40)EO8AFW,H8E(RA@7Q&Z_9]R2NVF5L%1:6Z^WRZ1KF8NN/Y&G6^
M*N$[3Y",+BNM_BB!L=8R/&Q#2U,9Y]>I6@0;EXM%H1=C4;C]78_0<:FY6P^,
MH6.K"J62R(VD+E;;Y(O<:\7Y[Q.-9XFK7#&GC\SB?%5GWJUTK*[H#4,%KFW^
M!["]\K?MUYKP5X*ME+BZBJHG4X)X8X=BKE1\-9<RY&0PEQM%M6I:JIJNJL<\
M6FY*+ 6:C[Y2;7MMI8V?R?9LWT^Y@GFB/C9C%.-;K<:#*PEV@E0D2+96R!CI
M6:KSV2I\X*K/+4FNX+#.I)JX=RR@0JW1S\..S/V7RE%CA/+XV6UV0NM7XE?P
MO(8O,L4^O48A8<2(6RP%.K:BG%I@UT7*BY;K+&0M=/)1;EA/7FL3DL<+QAC3
MH5>-<5?R>)@UM8#46.$YS..K#;97\1(T@MOJ-DWC <G3?%/>XBEV-7')<1EB
M4PCCME)RU]NV%'$?#7^$M5%0OD=CMA3,ON6L[9;/3VEZ=M+%9I/&,:SE746D
M-H_X04/7MV1@67,G-0V#BV<4XNZ@%I#[3/".I9&+U.B!VJU:M5Q]\L0;A?D$
M/N)7D%HKOV4RXJ0 6%&Z2E@8WB6LD&E!8L;1RUG#]N^X5-NF^&2M1"K%7EP@
MY8XTE6&K:UZIB+Q#W^4]MDEFN'R7DVM8XOF+K&YFVEIP73(:,@65=LL9=7F2
M<=CF6ZR,MDN/L<I'/6<G3+M=(EY4TW(MY,\V0\'([:X5_MZM>8 +A$YY;;!D
M3Z8+R'!5G#8UN)2JO7LU"/(6[L9L'UCY7/5-*;M.>M1Y^04Y^$961+"(GX>R
M-0N5=PK.+X[JYFR-FQ+VU[5-F ITPQ,S94WQJ71=JT9(7/DO=AB'Q%7FXF0G
M]M=XN#K#<[%4"8<QZV5:Q6VE>FA<6^F9"JT# RS8KA!J$%+T_)L3*+ ^;A,U
M>4ATRJ.91LD2AC4'U;%;(6'A5G,6)3;B18TL1FZ>*(XB0_>+/AG(X;)&C]W+
MK%?BBO71U54;9)ZM^5%558ID0WPQ]J)IPH(J_:.*-;L8QS#*":OB$+K<?D5#
M(!2'$AD!8+K,(?6 V&?$AQ7;<FAB:@[F)&*M><I:VJR+;+^U)*#LL"TL>*2I
M6Q9K/YIB)U.8NE8K-W1FTGL6Q=NBRL6@]8Q:IE/0;>'R.O\ X?KY!"TXNM9X
MANWJ4[,FI.<]HW'7$JJ2(2; FNO"<28WQJUM8,95#1K->I0N=1M5RAV9<EP,
M==JTDJM"3>LYU#V7<,\+UK3S<M?[]/%&")ZF<@Q]D<C#7XAS*H2=B3%'B0P6
MX&BR:45=,3;>%,ZYEO5LI0+8/N+J3ALAYEO=U44OAH?<E%I1\=)U:RP8,'E6
MB,H6"%FXV01-6VS;RG$EOPD=&<>K)L@ZM/@O$8I58H+H(O4L3<KO5UEA8:-U
M>3&E80U-4ZEFKNAN0K<[A79XB=-R6OQ:VA9;<P,O?,KEK%T,9PIBK)K0;4+.
MJ5?%Y=1PZVMJUOKVDX^S: 41W5UCK'1IIHTTT:::@_<XZBV.VS<(]G(LTY"L
M\'Y8=2\*1ZM&GF(MO0I]60BR2+<IW$>:0:$6:%>H%,LT%8%TBB=,H#R.("6&
M!S9N7+E#B,D350<KEJQINDUPP=R"3&)'GB)D=^:.\:^@>R9-RQ[5/9HC'W(Q
M]]_M X-31OE7"V-&XSB/&A6N%5;(KLQ6<0.FNPA!T!TSF!*9U3S9SGC'% VD
M;*V\=0+/6ZOFN?E,;4]A&2T;98ZE3"KG(UG34M<W8YR%G%HAXWJ<V<K^+BYM
MTW=K-F[AF@T'U9.9P"=>YP_B$5$>!1&$R^6"'/EJ4U\4_FLI)Y;NEQPZ6JDU
M"CE!@M>J87#/??M/8_-4?;7[43S64#B')8O,</KRF1111C&7/M57#N'JVE8]
M)364M%G)X^N]2G$Z0F7J2W9L!:R8W/8LA<IX^Q:XDR.39*KMVG:[?F,[2'&/
M4W5!>UME-U>1E?Q:2;;V=8UKB%8UFA773!VF==,TFB[2],;U=82M-N) 9$ZE
M6A<#G_\ LY60LV:JXHP'.3C2RL9/@Q5$+("23IAD+^#.2::47RY20.47B;,#
M.S*-AV/OY*NRV+.2 KO1C+H :R:8.4(O6D&I8:]D[.]*QA!*SKDKVX)L;;4*
MC.QM)?U61F*TZNDVT@8R2GF,M98,6L8W=O45GI$%'4N+0%%8^)D#IF2UJ!H'
M:Q=:)]W*Y(<2FUV*JFXQ;36%DPDF")M *W[E3R4YZC>"JT.L)K6FC4IY"XS>
M8QM LDVN.WB6U0,!,T <@LI$")L2UJ@,%,%9FWIJ.(,@1NUS$CK*&[-2 BY^
MX5IL[F;@\K%T8.).4F:U!-VWIFT!8[U!8_+=T8**:,61WYXJ84;,VS0CP.E%
M,=86 QE<)K <IR-D@5"I!LF60M;6V5"<>X))SV/NA2*)."<4J89$)7ET3S-^
MG2:2XLHFLI'B)-0HDC8%*+'2"9B#<PU5V60(!84>^ A)!.$CFW&T#3*+>[78
MV=0@LC+U1C5QLB[9BZ>2US205@H<R:3ARA]17]04BI$'#A!(Q%#^H,B3S1O6
M4S6R@8<C!EYUJU40M4D77;44][Y5S"!2 IKM.",0W]T=H,Q&>6JVMN,++R+%
MTE5JUNPPQB9K)M/1743NF3 '9UE0&0F8#$DR2E8$</\ BK'7IU1^C"3T-,K1
M3@S.42BI1C(*1KLO/4U?D:+K&9N"\#U(. 35#@>2]AUI'WEBX?>4<S -'NLY
M';F@3C<2D=XWVF=MXWU:GW62HO=:(B4KGLR!.-P*0GWH$H[C,QL4>4SI+3O]
M#63E54;M454H))1>;43LD,=.'116.W66E3E>B6/22<)G044=BB0BQ#I&$#E$
MH8\X=(7<X]$Y4(-YHZ1D[;HB+-^4I;S#THB9EF\<F^\:F!*6=*!F6_O/W<1,
ML_=;=7W/XOW6\=3M[F\<VVD&'S'C"P9 >XM@[M7Y>]L*;$9 <U^-D$'KHM/G
M9*1B8J<(HW.HW6:.WT4^2(**ISE*F18Y"HKH'4V@LV+M- 2(*5H*=J=O^1:8
MA=H$MCS R0U;(B8B.4Q[[E$:DPE:J;RD(7?*X-0H,)ETT9KQ9D1@I*!";*Q$
MIB!80O%<E-=\+WINV8TDAG*=.6^HF<!'/$[! +VF,:23:,].)GQW[5.10D6+
M<C8PG77." ))&ZS*%*/5JN4)>EA'TVUUE'6*9@DC(M$.5T[R'++>51 SW2*>
MD8SS2,Y#U%,7 \ZVGW3MN+"F0DXE7D4ER01B0=XB),9CEWA(J^4\2/[63$U0
MN%6?V>'I<3;DJO!R31ZHUI;YTO%1$JB#155$6#E=BX1:F(H85"('4 !3#K'<
M+"M-R4Q)L9CG4UY&9&8Z#\BI]BJMDS$1!L37-LA'=2S01P V$<]79-0<>B(%
M0757IH",>XU>+;51=A<QN,=!MM*Y&9@B+JP,%T'<B\.2\< LX;CD"D@NT551
M=(C:X+SFRR#LC!=%PGZ_K151?*)LE4U"E.F[4(V. +'*0<5S#H7*IAL-Z/2E
M<P<,\1S>'Z<CO!]?D/H\N_5Y"Y.;EG;:R85S]685TX83.I/)TQ3',V3YMN6%
M1W9);0$=RVC3?G\Y8AK$C3XF9R)4V\A?;I_#NJM4IIB[4E;H$9)3!Z^3TBRX
M(/TX^)?+*IN11\HR::!Q*NN@FI*/\RU2$3#6NJ6;R1"8*6U*A)&P]4QO#%J.
MP@2()F.9H1YSK=*3%-VP40"L?%:;A,(5RGQEA5:N)"<B4FUCA(0B)+HBU\Q"
M4L,95$> $0 1$ $> XY'] Y$ Y'V#D0#[B :B9F(F8B2F(F8&-MRF(\HYI$=
MY\HYBB-_.8COK5^GU\M5ZH>Y:AWZL3LZR8S$%-0=AO\ 5R8]LTE1(^]3LMCF
M2>Q<RG7F+:ZOX21;O'+(PQ;HT^@@*2R)I0\6?SB(U;%Q:,.C-"++-=V#3Q!-
M>O %<30:MC9AZF&H <H4NAD0TDE*RA+G1M,[5*AN0?CNHM1(RQ8:;+88%1EH
M22/,HX7+35,O5MND7>]',D9D=UO%VX'&65<:5G*45/L*_!V5A%.S1UJFZNRF
MJ^]ET2+-H"QDBY^8B6,\7S"IG8MI=\14_ M'#E(Q%#]*PB:[P1#%/EIPNNQ$
MF2[)R ,D$<X+89B)CSKZ<,"9V((U30\7J-L":X4)FX6Q FE0,8KK-B"* 41*
M.084P,C'G$Q,1&TG9,";HX6_X]R;77<?&8[S(OCEU%76PQU5<RMWKT9#S\3-
MTJ8I=V6?KM)&)L<>_A5$I.+G_*<K-I*%CW*:S4M,*Z[M;!Y+EF&W(RUFE7YS
M&[5;B<ME^&LFIZTG*S)5O&7@.4MM53KDML-GGV"SXLJ[LK2!O[M"L:F\Z(CP
MCU9.AC<Y5"#9$%,"-NI!PQ:IBVDH5U %;F.?&V3,61.3)O;%0H%]&.<=4J,M
MZCUD\KDG5SLIJ9D(]S'B]:VN6MI;2VDVRSJ<+:X..<.S/4WR4A)J+.#IV@>W
M*(OY&2B0I7Z^-.9$ %LLIR]+*D5X*MX58*96E<$EJ')("K N5,97(546TJ.Y
MRRS3;:7!&UIJ578NO 6#L%UI,@)1(F):N:\"(M'DA8O2N9UP];'UBC8+(U2=
MOZK='F/)MJ>;8-%FUT8)H*NJZD1VL@9W(I$<I *#0%S&.)B%ZCD.4NM42Y55
MZ8ZJ[H/;4)<P?B%UFFEYJ@9F3%3%D)E$3 [;S.TQ.K5E1U&&NQ$*-:*UED$0
M[*3; F5R:43,+E@"10)R)1$=XC3ZF[75ZR+4+)9("OB^%8&03<Q'10O!;@0R
MX-0?N6XN!0!1,5@1Z_+!0@GZ0,7G&)@CZ8S$LF!F B=SF#.%A/+'O;$PA6,[
M>\90,;E,1K"8F )LQ,+"8@V3$P S(D401S[HS(@91$S$R(%/D,S#9N>7,8X^
MB;%-7&]U:"8U.!5L]A!Y-,"O(R!2)UC*.(\BYGP-% X*@J5N8KA0Q$T/,4.4
MHZV.4H9)AP(C;K43+O,+MVW+KUZ[)C?IL8UJQ@3Y9B"YBV&)F$1,Q$Q$SS(=
M9#;O+$5U,>YJXCNP%J4PR(.:($"GTG2Z:[4]*ML+BZL\"QJLHR92#&P2,JQC
MXAPSD42.&2Y'[Q=!KTN4E"'2Y5 3=7 !SVUO>,U7%7L;)>#33*F3 GU0F8,(
MB9W(AD9W@=^T;^7?6"3&RH7HGJJ-8M%@1)#TRB)@YF-]AF)CO.W?M/?48VW*
M>W_'K.RYCLUZHL<C"TQ.2G;.%B8R#A"F(.!5;+-FS5XZ54CW3U0A&PQS4PR3
MTZ""8N%_)(&N"%3 K\T+/(Y3$X^ *>6&9+)-31Q:3DIV43RMKY).06*F%99,
M*$VQ+&;I)QD1)I5<E;F1DB!=>@MEC)N@!W@RK+K,ZY0),7TR5O'<)D^4NU-@
MVS![-6VLP[.504<Q;J5GHJ/;2+9)OZM5=@N[=(INT4VH@Y45;F4(1#^V,8$_
MS:R+W&$D_<:'\:B]U@>_"]R"=B&.I,+WF(]^8'^*=M2&[5PU<2:BY=F![P3)
MQ,A$&.XS)1$R.T]XB9C?6K_$3'_")OQU3NER[3CVX_B:%X</UFY7:+) ?7<*
MO%6IBN4FR?4LHW,58A!3$#"+W)Y2W$N1Q\LQ,%R5NU@^7SY43V=.VRI['RSJ
M9B8&3F)@(Y)DYCW8AO-TYDO*.IR%R;S[_*7+ORSM\<>Y)HV5JZ6VX\LT5;*X
M:2EH@LO#N2.F8R,)(+Q<HU!0G;S&KULLB;X-T@H03)G(8V*RAM>I:""Z%ZLJ
MY5.1D>K6?',IL041,041/:8B8VF)B)C;6,S OMUB[/HVG4K2I_B391,0Q1Q\
M8WB8F-X(2$AF1*)EJW_-5;QO?,5T.PQ5@%7+4A9HR%LS0*\6KP3RK5Q[:7I+
M0XD;#'S#))U%1SPS)U&0DNU!9 4Y!9@4Z2ARB%MFS7F85X7%MRIN<0@@DIMU
M:9I H(CBQSVUL&&+6B5B?[_JP"CL>';--MT!ZJTVZ-1JE[RX9OL)*'0!0(FF
M'0*F0LR>), A22X8:T(-R>,QRU XD"0 SRU4QY<ZO=$YJF+T2PI1TZVK[^O1
M4DWM2TVXLS5\\:&,Q&O$9KHK@#61<.$G#='.N)V2O@($!T(H'*V1$':5D M&
MI],0DR8I44VP\F0J1W$EBQ<D8ZGCT*U:V1 :+%RS1,P*/\G9KH59A=OGY(7X
MA3=T=.6[D!"V%22NHHY SY2,?NJ,V4(_MA;ME:M8?5<TU]5)-*FV>U>L)%NK
MFB_LT4^8Q17#3TCL(EI-S+99P@H,,9H#ARWTJ<MMS'4X.!C**S)T[9>]38S!
MX7(9^W7EJ^H4.9C\5?)!=.:_61T;#ZY,5)Z;;(IU+=MD$44GX5-BN&WB1'/9
MS&</TWPMDK'HA?R]*7[G#8KF;4*?($&H-OB^U+;7%Y(W;L:ZSG)ALXD)2R.Z
M3<8Z8EI>7,F6/GU:Y!6R_P -2$[.A$J.E)5*,6C9]Y%-WK- CYPHFP<Y5)BH
M%'&U!(4Y>U5J(@=FQ"LCDZ\$X39)V/LP+S46K84^J$2 .BLPU+@;PTFYB^H3
MY#N4Q,$]4I2*WC58I-<^6!4%JPO>E69;@($G\AO2DVLBR]ER[CNF$H V^TQ=
M87R?-Q];H[.9=(M74]/R<:O+-XEHGYARG=E8-7+A?I.9%$B)Q,KP)1-L9$+R
M XN2$KAQD"!0;SS*Q==MFZ[>8CE2I29_>' 03#2F-W.6!<Y=@#QL9:8,*4CC
MB-IC_P J<K9K4Z0,@9*(-EBTE<P,D(1)L(H4LS%WQ-BK\^@Z=04[#335BY69
MO7,3)LI%!F[;@ KM72S-=9-NY0 0%9!4Q%4@$!.4H"&L9F(4+YF(282P'3,0
MHECOS&+/X" =IW*)D8VG>>VM_P#XA)_\4)$35_X@$7<1(/XADH[C$Q$SZ:1D
M\BX^68/I5*]TU6,C 1&2DD[/"'81X.3"1N+YX5\+=H"YP$B(N%$P5, E)U"
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M B(:G_7Z_7_;STCU*/+X;^4>6\?">TQ'W[1/;;6#<?'OR;GC]N_N =NW^8\
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M+J8R*U15>7<S%LSUB;"PE1S;SW#.9X6L&L)8T*]953*5LB%-/(LLSB:-Z2$
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MTK5G'RA^!21UV6;R75K=RLF*9M\3&&1F;[,Z>Y"&9O4KP@V8;""JY>]DF5K
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M<1]P#OW[_P ^>-1]?S_O_/XZ;]^T=XVGO$3VCUVCRF>V\;?#RB-] =//Q[
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M8$!!(["=&IC#B)F.ICJ%:_2JT&3$Q)U%4\G?J>'+=1UK34,$E%RZK-4MT;,
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M]^_ \?/8?8.?OQ_3D-3'X]O+;[X^OOVUC,E,[=HWC?:?3]/OWCX3.^@P '/
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M&Z<>V*N9<SL"&%P)S<_A'QD\.8KQ]2*%SH,Z]2*<4(046';#X. 7"-PY3D8
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MY1MM^6WX?=K'^CUC?Z&6O>CE?II94\P!/JJ_G>N49D8F-YW3U>6+=,H>7_A
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M8XBD)ALS:2I4IR-&)?@>67.8S,7C-^)4C"7E(_J&+<>LO?I Q?8W.F_U^?\
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MB8GO$ZW-8ZG35O-I"CTVT7$T',V4E7@I.>5@:\>%).2R,4T5>K,HHUCF:]!
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MJL;2(?)00E"E:@O<7]!EG$:F:UL82U6BJ)FC(IE)%E),'3YJ\(U:.VK-J]F
M;Q;BU:6RED48VR$K>S/XCARP<$!HQ]_.9.OA\>RZQ9'(567[=9<N0+RZ38L+
M6Q FP<<?*LDD;%9ZNBW&Y'*5C/JCXM&-QUG)N57$5D9V&(JL6H"$ %\B-AB
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MY+JJ=G =YSL@?0+6.K.J@Y6VJ*9%<W^S1N0!KN1;'=\476FVE_52V*-I)L.
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MNV,-#*5'4[D?\N978Q"\!:?7)7(5'(6\,I>.N92C-;)VZP\MFVV9F9VD]QV
MMF<G9'(EE9>R(-KKIYD.(B*T9Q,VZY9X S$T;4NH_:(Q;\-UO?TWS^%[LD-
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MHK<4IE.:O5=G6J3RV2T6R+7HN4<O'3,&$=3EGD;*?35QABBG.RC&0;'*=8C
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M!>*0Y]=U?EF6@ZM%27*D8C?G"+].8B-Y.'A*^:-YAC2&]JI#E+'E2J8XZO5
MN=SFZ;.WJN9*EG$_17$;A>P9ICI&7I'\-C1SUG,0M<>(H RO0'(R=QLLAZT7
M"\<TR7$B_(IO"5,<?A>),L3^4G+EO"_$O#7#F2QSHF$L194[B-;6\H.Z+*C*
M_(P6A8C0;TE7H.J'%IF1R.!IH2,B'-6S^+S>3J7P/F/F68X@ 0$B$/"R32:B
M:\+>BN?$0P4VRW1:D>W4 <39#H5SGX#,/XTDT3IWNCWFF4N5Q[+4YU2FZ$6*
MREWC736?<7 %2N6KR/>P#,@M'[F:0E:=D:QQ"K"(X7;BE@4-',5N)1XI$#6S
M=<(?4L<*VE>'&+(V1LH(7J>)UM97&!5"HSWS$F9Q62D@D(QI8=6$>'-$=0WC
M;5F.>2Y4P@:TG'76V35KS&_BH1%\;P9C8G<X[?U7,$TWRNCER>"$B+!B.]TJ
MC/:E<(T<1=<"\>N[Q&^N>,)&P!"R;=S%@TE$!0E5=58BL*:R>DN"K<*V<>4L
M*59(>)LKE\: UVRL9@E1C%G3YES%^S9.JSP(H&S8N7Z_A*CK8$3!IY!F.R"G
M!"&TF#PK9XF6\X6=F#K<M"XM[(F#51FEDE+LLLNQ]-PTSQ&]GMS?VN'1S+6X
MB:ID[>("8CY<LDR%POCAR#*WR$*JO'I?58B->E61(Y(FB[7(B+CT":2R!E,Z
MTQ<IUK]>&2BW'.H6AT[ J;G'X&BQR8(^G]HVEUV58@SW5>J"V5O)B5U#ZB;-
MBH\(6ZMX2#,3@ZS)M8"EQ%,H?,!SKKT;DBXV G9M2U(B20!IW;:.F[YJV>M%
M2K-7C=%TV6*!@*JW<)E615*!@*8"J)G*< ,4#  ]P >0UF8$LS6<<IK(@,9V
MW$AF1*)VWCM,3':9C4*8#EK<HH-;0!BSC?8@,8("C?:=B&8F-XB>^MC6.L]&
MFFC337$/Q2L/Y.R/N6V#V&BTR8LT+2<@N'UKD(U%)1M!M#7_ !:]!=\919,Q
M$Q:1KY<.@IQZ&J@_  /R7VAXO(7\]P:^G4;854ND=EBXB12/C<>?,<S,;1RK
M,O7L,Z_?O[(?&_"7"WLJ_:-QG$.=H8F_GN&E5\-5MF8-R#XX;XOK].O @4$7
M7M5U;%(Q!-'X[Q?VZ;4IZW)7)DCNEW(5^'O'UH\O"-)V@S<8U5F5SF,E!IVW
M'U@6A8ADQ44BVU;8+)5Y1H<5'D8Z> 5R7Z@JMRU4U'-.V"!J<C+0(:UC*SDV
M&LLETH&W-QJ?WZK ,0M3&5ZJJZ)A<?@@7<EN;@! -W= BICE*6LT645Q4M;!
M%3*?76Y-H-K;;%6NZV^P?5EO.$WAA[DXJ)QK%QN5\:6A_1\TY7R'#VVQJ*U:
M9H+:\YG1R'$V",B*+B1C6\FF/76YHVRX>LS"GTT9V27>0=T9,8R-0+NQ<,K9
M3A>Y:A8KQ.(PV/RIIZMIEY-'(7K>6Q70N,@;",M5N>&H9MUE&2X>N0.633R5
MA()*KG%Q?H\1U:9'_P 5BM%!-B%5E5G5>$<)@:%V7U%&RO\ 960QAO;C5)L5
M.(\0"<5D64HL6W38+,6P_*2(S-DVC6;'6WJZR&3VL_U0;BP04?(U61CW?XNE
MY*5C:W-/6UQF[,K#6&4AVD0K"V."JC7'SF=AHRPRDXT8L"Q]S!B4P6(J/<%V
MD$>ZB@+$LHU:J2CER5=0KM!8H7+%%+[>13D^O!8#'4K%JQ-5Z\DUZ9M7K%2F
M56P7+4;.2"U5C(-;:7XAE4K&+79QU2^A+FT0L6#72)MZXT^J+!)T@Q9HO7!7
M;U%HW2=NBI@B5RZ31(1PX*D B"15E0.H"8"($ P%Y'CG5AQ+-K34$J43#):Y
M+GE:R*9 )*8B2D!F!YIB.;;?;OJG7!JZZ >V'/!*@<Z Z<-:(##&P&\\D,."
M. WGEB=MYVWUM:UZW:---5*W14FV2\O@3(]8KTA=&V(,J&L=EID6=/ZC(P%@
MJL]3G,Y%M% YD9*J+3:$N#%N8'ZT824&,2>21&K!W56N0S";!<TINX/-\.26
MY0JK9S+<4^G=MD$&U5&&XN:-JRE3CJ!>&TQ45$VG*QMQU,6\!8T&T\AC,T*4
MK@V9%>,\6NQC8YG)"")5Z<D@3ED/MXNM5!4O>EB^5K?P\=]+&SU"S,7V"$7]
M,FF#Z#?%W5[@2*QS1AN<-F#@L<KMJ<Q\BNYQ6ZD,3"A) JW;MW1E1.ZCQ!JG
M<P!?9SL6V[$D2:'#6/R+$2-HC#'<(Y;AS,M2JT"E/.[:N4\@J'=&7E4@K!I<
M(&5_,/K9!N1Z-?=%AG%K:HM_RY0[-T<6K"6&P@CE)83+8\\["5,8)/L%44Q:
MX*PRPFY'99NOO^8:;D:CWBD9"<U.C$@X>[94RQ+8CNU5GG67Z7?G8Q4!A/;.
M_JMB@8VL5F1K<>6?=(/I529,,P )I'<+4*E=R+EUT.BL5FUP<,Y!,%8N6*/#
MR.,%Y2;=)A5Z46<L/%45@37-=:LNG-H2ZK12KFY%4W*ZA!L@88[BVM%(EC%:
MO9XB'A?P1UKPS-[HXU_#462EH$ZPRT$<RQJQ#H7<>&ON[<I3\PKDK&I[.VL=
M)EH]L;,6;1A<K2$5;;I(VR]WUT:BF5QQ8Y:CVQK14ZM48>[0D@VA2/WTVT%6
M.:0FLJCAH^'KL%<MJ7,>-22.*V("SPE?P5G(T+<PRU=LY;-LQ'$EJC8545CK
M&%4JI=LMM6;9](;4%>\2WF@>2RYK@!1.N,/-X++8O%/1 I0JIP_6QF5Q=7)K
M,G9!/$#VNQ5,:05;2[8/#^WF3^,82IQF0\=T2[)8.KF-[;>F&<<F7-2POZDI
M' SA*_'SN!HK\&PME;HR1+%<'[B[O"^O5 ] F55/4I7<E!7,GE;BQVI7\KAL
MN>,EHK\8^O3QU:_7=;\*\*-.M-,V4D+HWHO/*;1_9)V;"HY5!1UZF/2UD^.I
MU<M17D1)K1IJLW,FVM9"E+*\W[=I%FG%LRO8XJ<J&NMN1512RU="*PIDG''A
MT9!PA9G3^W9$8;>\S5ANF-Z+DUV]D)FK6X(.$8W0^+<)_6T&X2#.(BC+8XK)
MVK1)JQ43<^G%\OKXQ.,AALHNF#&LGA<<>,DF%/M6JN""@;71XFU#K5IRI8^U
MU%S<>P[15ZI.)"_>^QA];!>U/V>9+)6%U,?5]J/#F;MO-ILKTZ1\7T\G:9&Z
M0*O60!.8%08<%-(Q62YJU!.H1PCDJ_;,?#-PM99S&;"5L%)A7K:TU:WW1S02
MQK=[=;&NFW2DHFF9%>NK%)E=,V=<B2P"44]DWK8D_9*K$@[FFGD>"_$8W!<(
M8RY6))W; 8Y_,Q86$MLWS!05TM)59SY!I62B[>QE%=2M98_(J:-=%CZ9^T[E
M<5Q1[=/:AGL#D*^1QEB_3M4L@J2C'FE&!QJVVK3]IL)HI:@D-93I9*]+V)%&
M->J7NK] L@;A</XEK-7M&5;[5J SMJU::0Z$_.QB+ET\M,A%Q3%-JF5R)GK1
MO(2[-*1E&A58V/;G,_>.4&)#KE]VT 7D&8T7+98!KEP,STID4Q8+JF#>0T@P
M:KN270$DP>C'[V8#7Y\Q\.R%%=X$RM98]F08)L7,+6BGXZPH6B4J>Y2=^5:"
M,G%RPD3E@032W"9SM^*<8IY5Q?CFO9HKC%LI/61R.46%*9-:BW],*K^KOV]7
MNI;=89 K@0K\&1O#P\DHW63D+9"B=F+NC9>RG<IJM5G!2:Y2+EA8RRY69:MT
MZE4:^.*%S;(BM'8?SVJ@IJ57&LK%@D57;%P-BI8;48%BR"VLK)@HBNT*]2Y<
ML,?;#JRA814&L'1KW',MVZPR@*HV[=6M%(\1%2T9'R_CZ?PG)X]_ ,Y4(FES
M]RN"T-%W-M85YH)=]9'<G28Z)HOX>BH8MI.2/F+VR=U>=K3MU)Q,O)K0;&Y4
M&+%.M8:Q:+#<UDL8^M!045JN/,%^,ZK9KF^Q+F*JV*"T;+N6J=>G<R,O,TZV
M&(&N1%CT,Q%+(C*%R=GKW<=B<@JN22D*XUC+*.JIN%=ADMP/$1V:51-&H>1M
M#FK<C4\,N*0R?ILI)>WDEIQT]7F0C*_6<?52/+-7:^R\NC&RZAHN"AQ!5FU:
M1ZRLR_79LBK,4%EG[6FRVA%MU>TP*J*5-F0REIY0N*%6;"\?4DE%,2QMO*V:
ME* YU@@&-LO: (@&Y\C65DMJ@-JQ;M(IT*JV#SW7&!6;'1*=^8*M!-BX7(!F
MR%@H W;S@AEWP[2#UPEN#/V.BUP\ZA6PE%)@R2(3#EFC(HMCIJ($<)HGCW"#
M\7ZB)8XC%4CP[LK<?,U=Z+/$U*< 4VKUAU2JB(W8VTBPJHVORQ_RW!:>BOTF
M<ARYR5C$DT(+4#5L2^P!P:*U.KD','N(TKR&VJE@=N[%V*Z7.5TX.2!+9V_=
MGR[D]NFQ](8IS'D3"\U4\ORF'8.SR$O74+,^KT:>7JI'QI&OR=E;5BSJ0SHJ
MD:\;F51K\P=%=,@*-/*4!8O+OWXIX@<V"IL4)\*Z6"4KZE)KE19=6Y@F'/35
M)SD5SE"[%E0U'VJ4&RPBQ4%5N^6.AX#:&&A(1$'R/$#Z .V*.FIC^F#&CU#6
M@YL*38Y04R*\J[]\98^IWU:&<U*R7F$98WLM_P ;REQE:O+5*AWF7K\1*VEF
M_2HUB+8SUE:QL!*P18QS.45.FW<S,(HNB)NC<)-3*+J=678\.+:G">0R2P]Z
MA8R+\A3Q]@J9%$LA]R@8$HK"8&N%QZ76&U(JV.6FZ;L&&4A$!=L\+OXGQ^,-
MO:ZFI6HW+E8+<+GDE*+JXAL5CF7'6!B$KL$Y+[GMZVWPD&BI1<I8YNMSL5,L
M=NQW3U+6M"A=!@&TL;T!Y5O!SSB"]4^A9".%1Q"/'Z:S-[Z>)>JLUD H9*V=
M&CE;:D>,9B,9]KV:X-@)*E%.,CS@R :!&6/GQ:P&"GHDIK94AD.CKU%IL6J=
M=U@:P7,L.$AQ#S=/(%=#'2DUR:RB0NL"L<S(QU9E82;(@)V<#;G#Y=G&=5L]
M%#'MDGL74_,-/;H6I"VQEJI%D91Z,NX9O_HM<>M).H6ETI 2[!Y#ID7:K0LV
MS=*$E5V$7UV("&9="V&3\)D$T[RF*A>U7)>.=@<@DQ8T&)R=7'7!<F2"QC\E
M1OU#!],<=E,GQ*&1.W7Q-EE<4JS..9=ID#B= NI^$7E*+^9".FZHZ[6.NP8-
M5ZC838 E60OT*%K=5M=31IIH_P _]_UTGRGMO\OC\M-51PUN4D\EY<SYBNR4
M>#I(X3"INRS3/(:5I5E(ZTC9.$K+%+U2L)U2;BT:\F_?-X:5O5:^GS,:!+?]
M62E(B.PIF%G"3EVL6DE9C(XFPJ)DZRXHT\;;&R%Q@UR(3\>RLT'5*XKLTK,5
MFW41UXSN!X;*KQJR\1#\;7R"&0#5N9#K#J\C""62B61+ JY)M.M2)Q-^ECH;
M1F[)E"S_ (:RI,7"NXVR13;O8J-*K0L_"5ZQQ#^02?HP\-.&%LDD\-ZQAZ.?
MC$C2S858M-\HX8*.R/&3Q%&.9K,?]HU4,M*-=PDB$B$M.G?NXPED3)$$2Z[0
M>NN;Y!;E2JTLBK.4T]?.L;15&L%#0:I1]6"C8F5D7-PB!DG=.O8 VPF#)9"Q
M11#%F T)R;XB>6,1O;-7K=M&>N[96LBXXK3AC3\L/;?7CU#);*3D(F77LD7B
M(56F0&*44NSD,?C"+UXDDNR*GDX\0[1FABFY5EN*4PH5%G-Y# Y5X>]6H6J%
M3 WF7*+7^$G(8L:N?59?9O!A+%>MC\H<TS:BNFUC?(Z:,E86AUD:V!^W:%<(
M5XZR//F%15R%=;7!CV-=B?#UVU'Y==BQ=K*7OR623?;&.9JYE%O;9.'5BT8:
MO2BS>/<$GF;Z4EH-!L10MI>0:*1'D!#R:Y7?X?.^.H>;C&R<TVZ6#UH95U(7
MCQR-CE2F0<\XWDO#5@7#E>+/E$47&5IBVZC[[*E=U<;!A;*Q5JY;[W&5%R)R
M$+$#@QF7NYS59A C)0RO6L#X3Q,'LRVJTJ%B* :^!Z1OWP!8%(Q&X76IXV=7
M&19J8TBK!9/.F+E3YR6=0=/N;ANG%-X^O,+G),7)*^U<2CXRR)V0.739\\+'
MIJK(LJJ[[+N6*RK;:,S,LJ+M4!R]-#S,5Q%]F),+CZ8C)5YDZXF]J7<BSS56
M6Y:!!4JVKM$;3(D.O:Q-H<=FH%.Q$%?'9*9IE8,HAD1%DUIKL2;'L3>SM/4,
M@1+/% 64=VYU0FJ:,HHLHZN+.+6FUJ\V32;G.XD!B&[B1031*<CMH@LLU.L1
M,XEVU=[LTHJ1+YR->S;I0N)F;%>FRJNTT(G:8%!7:DLYH&1782W;I'!ZR9'1
M*R+)@)ILJ*M<TQL@[S7(J09;\L0^Q7=7643(S84:)F'#(:1K9N_I.-,R9-QW
ME@(&@4:@8MQ3DYEE!Y9)%^A+M\G63(E7"(EZXE4FP5H\,^QX[<%D26"=:/V4
MB@LX+$';JI&A$BRO8-Q@BPOB2.'JM;>3BV1X>CE5OEQ0H4N(K3:TU9 PB$K<
M-LR?*$[W56@C%6T1-BMDJN=<PA@A;6;@G8,7!"1AGB$6$<046)<)K=#@LH*I
MR+58>U\8[\\/VVVYHI%^LN/L<V'$URGH]BD2^N+ RN..HVETV_QV1VKZ1J50
M)'@[KEVC%):NH)S(P[Q%PFUFYMD+>06Q2P#PU7*MF4._XPK+4IB3+%V\/QIG
M^"24+(V9<3;R&")M5T5J[)BXBNRLMT1SU#,?M)U)6[$2&*.A</90W@R7#>-X
MB9,A,DNOX5=]B)DK!BT*IV8)?,:4M"[>(/7(6:^K8_J<!EO"T=BR8R_9\G57
M(IFLQ!T^FV\*GD=PC1Y&E$;2+NC]8S+Z-/<X^4>L(^:;-V))9FPCY?;6&#<8
MWI\%6.]PY1J71Y;"63Q.3Z^-M6O>3X:E]H BI8>F;LUPL3;>"DUK/2O#499I
MK=C^:]=98R5%>,!;!M/R./JU;Z\?5@1;+K60I.;X$3!(NN31KB70O>-K]#&;
MML_:-7S-8CAF];H.VCA(>I-=LY2*L@LF;_G$52.0Y!^2F =2Q9I8Q30(&*,E
ML HV(# I$P*/0A*)B8])C7/2Y5A*K"#%J7J6Y+ F)!BFC!K,9CM(F!00S':8
MF)UL:PUMT:::@_/>6)O#=5KUJB*E%6]M(Y"HE-FVLC;'=47BXNZ61A6SSD69
MM4K6G-OXMQ(H.2P3L8%N_1*J49YD<I.O!12S*8?'E$"K*6WTRL1/,RNP,==N
MH(:\P(O!K*D(;,V$$@&R\!L$N$'7OV(I8O(Y"!EIT5U6C7F>F#A?D*=)L2_8
MY42@M2Y<0AL.)?1(DP?6#X57+\W.Y^RCA63I\5%QU$IE"NL!;F%M=R[VRL;F
MYL#!RTF*PXJ$,A5W<0_KS@B LK-:T91HNBY44C%@.S+KI/&VO+<T2I^*R=6D
M2QV8IU>[1*Y7LPZ>F:W;J<I]64$"X%3%VW=0P5:MA-9F(@9ABLI1R=F3G]VQ
M%C%W*=9U>%QU!:EBLA6<JSU5,ED/2=4!6M[E&K[A\(73(5AQ55<HTB>R!5TV
MRDQ6(RQQ3R22]2FZ4%-NB@Z.+Y=F5DY"3;L_/6BC)"20(V.)0&PF/$UO&5YA
M];SZRBA@<FR2AVX3/[@O$*@'_P#*,C$0.9G;65E95/#19Y4E<EPH S"&&=<B
M!JI7,\X-&0.84<"P@6;!&0 BBFV9O$6)CJ=W$P%&PG.906P+0,<7%"0;6=Q#
M1MU?7K(TCCR78M0BZ;<):-K]#6C7$K8K.SB;"X51:R39A75S,?4.**K9.HA>
M%!@IG%=7AL9=) $5[&,1DHRQD"V$*WDV:&.KROEN73J0ZU2KV2L(LG4!=A-4
M[ ]5F#S>88(C$RIN(3+58[WC&#LVXD.;:8\,+!F L,V5-D\ ;EHK/)&YVL"W
MJ2QZ96+ YA)FR-SVQ"P2C7U-F@4JR>-8OW,13EEF<2]MG4BW>3IWT66,:*1R
MJBG7?7!3+\*=UU5+QUE-$0F751 >G><"FNBG%A\/0A#3,G16982QE8T-=RQ=
MO%86!(-<MA&4?]EE@E[B:3FPE]PY1$7'S-2O%:M9HP?-:;<JT&(UWZ8$8SLZ
MTOUPK>-J\%DGJQCZ<M$VLF]R.O29<M;OTW'0R$09")K%?LSAI!LI5[,K.)=8
M'[Y6.BHM"/>RW/H/7?32E9A%S(H1DJ=$3$V%@LDT*V#R;CW %,R]D;4*I##9
MK5_LXK%@+M]F/H[K'-7L7 *!*K1EE9]P3@@^U*55M_,X\%C!%OAZ?1\4TY R
MMAD4!7Z./BU:><EO:VG1$C-Q,CGK'K>1KLVC6YAK]6,L=I.KE=BC%E,@@J1T
MZ.HQ>-@(S.X 'K5=@)@>IF0#96*+D59JSU_&M:FI 1,S8-*V-/IQM$D/24UH
M,VZ;5+8U1F $49%'(9+*1$Q2AY1)#[J;+ZM9)E.^PP3[M1)04Q*V64BR DQW
M]6_<]7Z!E5Q3[FRB(/'2.'BY;#)Y[!).5DVX6)M *Q;ZGH5(3MFX^N9NVLLV
ML3]98%%4%XAF"(+JXBP%QEO&$-6<;<Q=)43,L\2S)!<*884"$5B0=,@B(ZX-
M$I,FIY>0MW0-E;%VJO\ F%Y$\B)1M*R2-&K5N U<3S==;D6"D^::YI)8B(/A
MDRN-*-O_ ,*6?+MOQC-VO'];C$(RIV'%5R3O2\FQRM6K+3W=P<22+9[5(%C7
M'<0RC9,58T)R?]6U9J/$G::A5V;?9N*Z=Q]MBZUC'MR!7*O/!BK&TJ]6W&3A
M_N=53*UH'M!:B%"HAL-<J>I&MPP'V4Q)B^KEURNNZ-P,<H&9M8-N,-.Q<K/'
MUHKI83!EMEGAI2MT"+/C<=\L&>0QXM@>O57<!4;O%9:<NYVOY(4KLK$S&)8B
M)L4I LH)Y2)1A*.)"!=2JR"TA9:Z=&28QK$K5TTF%)6+IMM^&LV5VD-751PR
M7%06E<C)9C:?%'#?#F8YTL)'2;1#B:K?2$,85KPEZFX:+%H:_2PI(: 5"2^U
M=XE5PQ*&-E )NW>%N)^(\8V7@NQSHMGPTRBTX6(("\B\H[8+:B+D46Y0F1*9
M5KW7%5%X&W04988E19,4E_12C1)V@1=(1$4G"15?*73$1\M8AR<CQSKI6$S7
M<Q,F#("?=:N9E;5E$$MRYF(F5M60L7,Q$R!#,Q$]M85W#82#1B1YN:""2 I6
MP");5$2R-9$I@FLB69K*1F0,AF"EUZTZW:---4.W=B/XCJ !\PCX/_[\. _3
MY_WYTUC,1VF?3OZ_C/;\/N^?EKE.:9R&ZSC8JRWMUD;TZ$:UR84\EGCH(>.+
M(-9-TO&21GU8-9G;224CTF315E+-G#)1RHJM(G$$$C>K0G&#PXJXVC49>99N
MU0EAY/K6.G-2%RF$7!JK<H;3&%+$D!BH!A!3U"U\IMW.)G>T2UB*^;S%?!U\
M7BLHT4HX6\!CRL_:L,5<\;AVY>S4M,QZ$A%:ZIZ3>TSN+"4@,*RN9LVNUBJL
MI-2'96"YY BV9&L!39->O16.(V4>N$V7U"20+*A,@D@=X$HH1TW/&.0CGA"2
M""2781A<$M"Y>,/96PU#).DGW51;;E;5.L"V0I9="*DL9*B3_'XI'6 _#NEG
MB;_&?'SKMF*;2Q]:_P 9YCAZH(4<';9BJO#6,RV1<U,V+@1=++C70+UVY@JT
M4;TU7(*]3&O+;O/XJ4Z:4B8^RO9"NTV)EINUMXNO 6,D96(;S#8%H5W*(MCK
MKLUO/3*B<\89<%&:;HRJ(E#FQPX,9! M950BSEV4J]4FV2ZX(M+KO$7BJ6"(
MF?),E$/Y-VB$C$;^KGVCD7#]QE6KEKMVAPJG,Y#)JJXU?@'7,8^_3EU)UP*Q
ML:E!,$5FRC+H&J;X8<Q"B_W.UB.<6)DE7+7+C5I"'AWS]LR;(,'4E).HIBN@
MDY<+I-$EF;F6;F4146*HLF58[0JI$NH=">%K+PJ-\140-^;)(4;"E@J3%N09
M(Q$F0,BFV(D1+DF0ZG+S1M9M^U;$T3RZ)QV7O'@4XV+UI%5:T'9O#B>:N+38
M" >D<O5,ERP89 V(1+.E,$N0F?XJS'@FU;J5CEI&79RKUU'HGBD%8@D3*O8)
M0'BKE^DW6(K+,S-?.9*.$T"K(N%S$2-U:T/X==5&RRQ;KK37"H8-Y7%#_&50
MNK$!A<D)17.2Y60',8RL)(NVNG1]H=3)NQ]6AB<E9NW79=#ZL'3!F/C$90\/
M::\SL MR_' (<U8V\B2A[(%/O0_,>7X,A1BDPA 24&W34.V,22<1JJZ<BV67
M;R$<LBQ=.3(NH]= 4G *=)!,<HIF.'/%')XV,:0!-E5F6B+5DH'!!H:H&)>$
ML 8);(+:(_BB1*)@?/7>X;XC+B)#7QC+>."N;*SPN.IL8J]7L.K7*3!K/=(-
MJFN)(M^F8,62S.)G:0@'CCCX[\=O<1XX^1[ASV]PX^??7+GU]?2/3RV]/N^/
M\XUZ7;?S]?7X1M,_*.Q=]X[3OZ1.VL\=N. YY]A'COQ[@/SS\? #S]N-1]?7
MU_73?OOO,Q\8C?:/A/PV]?68V\M!A^.X\\>X\<"'(?' !\\_'/?V#3]/K?08
M[;_"9CM&^\3M.W?O/\_.//RP4!Y#L/Z#_7[_  /?]?MI^/U'KJ2VF)\M]N_E
M\OAWWC:/E_3T(!QR/'?@/T .W;L(!VXYY^?YZ:QB9WVC?MO/;SF?+?O$SWWV
MV]/PU4[>\Z<M-M.0'+-PNU<INJ<*:S=91%9(WXWKH"*:B0D4((@(AR4P=A$H
M]A$->RX!&"XJQPF,$,A=W$HB8G:C9GRF)CS[_?W\XU\2_:*-B?9#Q0:F&I@M
MP/*U1$!QOQ#BXG8@*)CM.TQO$S$S$]IG>0?"WP^\W*[%LJX]F,L9-QT1?<J6
M64M= -0)"TA^'*CB^<8QQ#Y5H.3:\2//)-FZ[DI*^#LWE"FB\1357*KT/:E7
MY>)\!:2XZY8M%3)*6D*_2=9KVK\UI?#$,.02V0L"*C3)L4L'2Q$L0SQW[*3/
M&^S7BRI>B;J[_$E^@TK#K,M6AF(X?)L),'!(D8B:IYH,1!K"6(.Y&A=QSX5>
M(I9Y(REFS5N%M,Q:+#DZV9'EI64P\R=9*L64:97*#)R<^C7<,P<?73U^M56'
M;5EKC1E0V#=P@=[+M9ERH937S@$@A"*U2)J(J8YU&D"IELT[-GBM?&EG,*9;
MFPUN1?Q"BI;-=IEC%@NJNJG&JK-M*L?J!P39>RS;*;+VVJ;6FP%A#,?2PM[A
M]6%-: 2HL<>-R=Y3G2O[7,[$LC*"2J_1^[SPML822\+(2F>=R,E.,LC1.5K)
M,NYK$ C?KS75*:G6)RT0"6&$J>S>UR(HL)7HUY3*W4WRD.I*A).Y"1E'<@I:
MK-\)D,9D%+5OBBR3J]8A*:YV\U9REK-W63!1:!V59E[@VE5K->F"N@NI5K#6
MKPO781%JA>Q[&,@+M>C2AX<@V:V/Q=>58V@H^65OKTK$SD%%?5<L,NS)6'NK
M3-;4FW+8%C:VU_+-9;Y,S54H?,61BY"L;"M6&GGCX]%TDI^):!"PUDHEB@PQ
MW=9!U)SUI@9F,F7;R?E7DJRE8]R1D9GR&8NN[%4\,TVLHTHS0 !=*#:G,1D.
MDEQBH9F,$>1<SAYJNE9QA*K +VI2*M= ;;0OV\FN!7=MU\4J; <\&AV(;CB3
M=1,G/+8LIQ5&E?6R&4K=%;*[*G+9LRZ(JQX6-,J,U7)B%W2[JFY:NM'.8F.2
M=[=&:*+B*PY)X,8."RD;MT8V5NX;T:8?^6X8SK1<DTHG*$4(H@BF3JVV,N,S
M#FL,7YM'%:;;E3"C7/&.0Q.6RK:_+&RVKRF"Q-ZGSPQ:SIQ7:M]*Q:JOYRZM
M9(45I2"EX]_#KJZXDV#R<-1DDTJS(>;>=#\?EKF,M[_OCJD#D.KY!8WM;$5X
M4V%XR'B857+N?I1NW<WE.S.'TOBE!WD&MY(E*98+G3K:I$8BBTDH:;LE"KT^
MXE*HC6+F1\F];H6I**D'4<IDEL(LUW*2@$UEXH0H"$C2)V RN8S'#]F5@0M
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M5,68T532(I0J@H1NYE':!#U^+,5-W.$!.9<IE%L($6E4BE(_4+P=V4O2N*@
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M1\N_G,S'GZ_&)U4;?,/_ ,V+(8\!V<TWX["(7BN>X_//O[CSSSS\:]E[/_\
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MF\;B'89%/+-Q95WM2TVL72I6R>)(  B""XM<"43.ZYF9VF(BU0'W"_0C"*5
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M/ :?7]]1[WR\_+Y?.>_G\H_&/+6S,'W" LR^B)4 R'TB*%]ZT7P'^M"Q1^L
MAT*<>C!_YP,^K\_D='6(FY'3M]?'ZVT][^7P^6_PG?SGRV^&VAP?<)]'C/3)
M4#ZWZE_]5!07WH@:\H_3O2\*=?F\>?ZCJ'C_  =/SJ>WSW_W_P!/UTGFWG;;
MY;^GUW_3YZ]11]P7E3/UA*@@J$0K]#!H+WI&:]8Q\D'HF4'^Y>A^H"?HX/YX
M(<#T]0#&GO?+?T^'G]V_Q]?P]=%>/N"&:C0LJ5!"!]6G]5&-%[ZX&??S1:@H
MH)/.]NGJY+[\AI]?VU/?[O+^??;Y;;^<;]_PC5DS[C0D7P126.QB_5./IXNA
M?^J%GYIO3BXZ5 +YOE=/F=(<=?/';3Z_OJ/>]-O/U\MOP[[_ )1WU]Y@^X7S
M&/T1+'XI?28WZAZT7W7]8]*3ZJ"'0H >C!WYGI>K\_D]/5WY$6IC?U^OKT\_
MO]-97/N$^CL/3I4#ZWZM[]1!07OH@9="'H/3<* ?SNOU'G]7;CR^GCOIJ/>V
M]-_KS\_GY3\//2C"&SB,191GDZ2$T#-K^%08>L]$+WS5?5_5.M03^3Y/D^5Y
M0@/7U\B/;34]_P"7K^?I^7Z[>6DN&/N(&48!.I8^"(]2G]1%B+[U8->1\P6_
M6H)?-XXZ>H./?33WM_3;Y^?X[;1^6D]8^YGS%/)2QMY76?R^L9#J\OJ'HZN%
M?\73QU?KI]VHCF]=OP_KZ?E_+3BMALYA*E_!R=(&']$SZAF!>>L]?Y(>N /*
M4*3R 7Y\G_G=''(B.FI[]_+TV_KOV_IK27/N"^BL!;I4'Z]ZU[]1!07OH08=
M"'H1;\*=?GB?U'G@8>GCHX^=-1[WR^MOG]_X;=M^VMZ%-G,8JR#.IT@)@&3?
M\+ Q%X+0S_SC^I^J=9Q,"'D]'E^6(&Z^>1$-/KZ_74^]Z[>G^OK^7ZZ2H<^X
MH91A];2QZ$1ZI'ZB+(7WJP:=8>>+?K4$OF]'5Y?4 AU<<]M-._Z_+R[_ .F_
MR\HB=:2Q]S'FJ^0EC;R?-4\GK&0Z_)ZA\OKX5 .OIXZN.W//&FGO?+R_7\8G
MM^&^^WIOIQVTV<0E$PIB=)-$>@:>8,P+SU?U'RQ]:!?*.4OI_-X\GD.KHYYY
M'33O_+MZ_/Y?=Y]Y\]M)RQ]PGT1EY"5 ^O\ U![Z\#B^] $;Y+7T'D<*]?J1
M7]9Y_(B7RP1Z0 >0%IW^/Q\]N_EMY1\-_AW^7?0S/N$^F2XODJ $J ,?HH("
M]]*(BN?ZAZWJ4ZNS?H]/T"'*G/5VT^O[:CWO3;Y[_?\ ?/IY_I/PVJL?/(SC
M(+<G12U_I>^N&)%X+\#>@=>A\CS5!)P,CZ0%^H/^+^;T\&X'34]]_E^OWQY]
MOO[]](C@^Y?SU_3)8W]/YJGI_,%_YGD]8^7YG"O'7T=/5QVZN=-._;R]=]OT
MVW_KI3G3[@@DUPKR=!-%=*'IQ?B]]5U^0GZCS.A0"\>H\WR^ _[7T\]]/J=1
M[W_N_CO_ $]/AZZW9$V=/PW7QC$Z0-H$TA^) <B\^E@3UB_TWZ=TG!7D67IQ
M<>8(_P!MYG3VXX:F=_Y^6WX>?R_7;TWUI,3[@AC)@7Z=!"5 K+Z(" O?2B?S
MS^O];U*";CT_1Y'0(?VG5SR'&GU_;4>]\I_/]>_EY^7?R[:V:J;/ S[$+@G1
M0KG2\^H#$"]^H]7H'/HO(\U0R? R/I06Z@'^[BKQ^;@=-3WV\^_?[OEZ?7?M
MY:0W!]S'GK^F2QMZ?S5/3^8,AY@H]8^7YG"H!U]''5P''5SVTT[]M]H^/U^G
MX[^FE&;/N%"15^@I4 T9Y;;RA?"^!SYOIT_5 ;H4 O3ZGS?*[ /E=//?D=/J
M=._?R^7]-^\?C^GPD?'W"_3H7Z>E0/J@MWGUT' OO2@Y^H./0^AZ5 -Y8QOI
MA7ZQ$?4BIP/3P&FD<V\;[;>OW]_GY>7]H[Z>U!-D<6TC_$8E=([!=#Z9^'A<
M"D+?RS^?ZGSS&'S/,Z/+Z> Z>KGOIV_'U_II&^\_#MM'P^.JF[NN/Q)3^?8(
M1\/L(_\ T\/M\:F-_NW_ )QMZ^GGO^7X8EY;1Y_W_G,[3$;=_/\ &HGOW ..
M>.! 0[??G[=OL'SW^--NV_W_ *?[Q$?TU&^W:9F=O.)CS].V_GW[]_P]=  /
MR(<>X^WSSQW'L//Z]_;4:3,>D3OY1Y^FV_:.\;?+MYZ/;M[<@/<1'D/Y< '(
M\<=N_;G3Z^MM//Y]_*(CO/RG>>T;[]^W?;;TT" \%Y'CD!#]1$?N \?S[^_V
MTGZ_U^&D3'O=H[3$_*-OA,1/EZ=HWCXZ./@.?OQ^X#V_]4??WYY[#WTTF?C$
M=^V_W3'?_P!Z/+MV\IC7GOS\AQ[\>_?@/Y=O8 ]N _4=3\ORGT^I^?EZ[=]I
MG;;?MWW[3\N_SWVG??X[SY]HUZ[!W$??D.1[B';Y_IQQ]A'OIZ;_ %]?I\]1
MWGM$>6T]NT3W]/+X^?K,1VU@?D>. Y$ ^/C[?J ?8/U'XT_UW[_7]=_O[1(S
MZ>?:/G^L?"9^/:(\O6<]^ $0YX]P'CIXX#C@?;]N/D1_87U_3TW_ +_?YS$;
M;S\_+;?FW[S,>DS\YG:-HCU\@!X#CCYX^X\"//V$!Y#^OQ\:??\ +X?AV]>W
M^NDQO.\3/>)GX1O';UG>-I\OA]V^L#P';W^X\]^>_(\<_'/M[C^NGU_?R^7G
M^.D;]I[QW[1MVVGO$;S'K,1W\H[>6JD[Y?\ O8LA_(^IIG<!Y'_EQ7>W ]_U
MXXX'VU[/V?[?XKQV_P#Y+OE_^H6?7Z_IKX?^T=_['^*/.(ZN [;;>?$6*[]N
MWR^,>OKJ;_!NRQB[#.S7*-RR[D:C8NJ1=QDG&FL^0+5!T^OED7^/L;)LF!IB
M??,(\'CQ0!(U;"X\Y<P="1#B'&NC[57H5Q#BDL:M;;>-6FJHS$667#8R+24@
M)F":R%+8R0""* 69[<HS,>/_ &1E,/V><2,!9DNOQ=<:\Q&2!*YQ& 7#&E$;
M+"6, ((YB.8Q'SF(UW$HF0J'E&M,;GC6Z53(%0DS."1UHI=@BK/7WQVBQV[H
MC28A73V/<';.$SH+D2<&,BJ0R:@%.40#Y^U+D2$.4Q4M4MZ^H!!U$M'F4T.:
M(YUL'W@,=Q*.\3.OU MJFRR%,!DI:26P!B4J<&TFID#,\C!@AD@+8AWC>(WC
M7U0O=(=7)]CIM;ZRXO\ %PC6RR5(1G8Q2V,*Z^<J,V4\\KQ'(RS:'=O$56K:
M26:$9K.$U$4UC*$,4-*IAP66)_>KIO55MFOWPK67IFPFO8(=X2]J(ERU,D3-
M42P1D(F=;#_=2@6?NYM YE:#]V7KKF"WL3$[2P$FU8-(-Q6; $IB2&)=>ITT
MU+;>Z306D6_O-NK5.8S<_#52&>6B<C8%K*VBQ/"1T!78YQ*.6J3V<FWZB;*)
MBFYU'TB[4(W:(*JF*08"8.Q7J!,':MDX:M89B7V2KUW7'BA4?O'2FI7?9;"Q
M*5H2UI[ !%&7*71LV.4NA305FV[:>E6KB8+)]AG\*4B;%A+&2(01B,SN4;NO
M4ZQT:::---&FFFY+7"IP*4XO-V:!AT:Q#FL-C6DY9@Q2@8$A'"IIJ94<KI%C
M8HJ;1TH:0>"BU C=<PJ\)'$NEMA"4OL.<I2*Q0%AS#$%(,@%D YA3 +*0,3@
M3F)D2$HC:8G6:@-UA51($VT^!)%=<2;W"3)2)*4.YG!-$EQ(C,2<2/\ %&VM
MROV""M<'$V:KS458ZY/QS27@Y^#D&LK#3,4_1(Y8R47)L55V;]@\;J)KM7;5
M95!=$Y5$E#$, C:<EM=II>IB7+*08IH$MBRCS$P.((2CU@HB=:@,&#S 8F/,
M0\PE!1S 4@8[Q,QN!B0E'G!#,3M,3&DU"\4QU<9#';:VUMQ?HJ!8VJ3I*,W&
MJVR.K,F\<1T=87M>(Y&5:PC^09NV+.46:$9.7;9=NBN=9(Y"ZE3#QM&F8:-%
M]>K=)<P8U+-M#+56O9D=X0ZS64VPA3>4W)6;%P0 4Q+"%1UE-F%LN)LV*BSF
M .TBFU"+;JXEM+E576JRK#%P0I980#)$FK@N6/B+8^V^W#/^RV6S!GE?$MMK
M5W7=8VJR5#M-M)D23&Z8Z<FC5)2!C'S&N@639P\=ZF76:(B$L+@#^4U7.G\T
MXXI82UFN%693,EC;*+<E0KC3L68O,\71*5RQ*S!$0P5!S-(8_>R6^P%,?M;]
MF'B7VEX3V;^W>GP/[.E<9X;*8!:N*<N?$>(PI<,U8P/$ZHM#3R-NO8R>]1]V
MUTJ2WLB:<*D>=RA+J#'9*QW+S=SK45>Z?)6+' ,1R#!,;)#NI>CA)L32<:-N
MCD7AW==+(1Q#OV1I=%H#EF0SE$3HE$X?298L:AWY8$45OLUCN28Q5"S2Y/&(
M.QOTA=5ZB_$*DX-/./4$>:-_Q=*70U*)4R'65 ^NJ0+JO2PR6MJ5[<S5FP26
M)A!"1C(Q,E$QKYP64,:VBE.,DUK(%,L&/&K:6>.;S"V:&E*BW9P)W*<XZ6L;
M)XM$)-X<[-V236.[!-B9LN#DR0I*=*RQ=.O%NV8UJI5UW!L6"A*)J-&#59AK
M)$)0P)@@=!=,AF"$IB=]8(B;3YK5HFQ8&SX,D(_>NBWN,>&E8<QP_<PCI3'4
MW(?=]Z-V)/[H=M=4:4M_9]P&&*ZQR.Q:RF/GLWDVF1;2[QKY9%NRD*FX>S**
M-A9.UW""#9U%'=H+JK))I',=0H#NA3)O?9<+.<E_E_\ A\ 4W=[A<M2/#1'6
MWLE[M>.3=T]E\TZU2Y44RR$M7% "L@=V3'PH%3G:V)6-^D)59B8LQ)Q*)C][
MRZG0I@,4#%$#%, &*8!Y 0$.0$!#L("'<!#W#6'EYZSB8F(F)B8F-XF.\3$^
M4Q/K$ZSIJ=&FFD:P6.OU.*<SMHG(BN0C,4@=R\[(LXF,;"NJ1%$%WSY9!LD*
MJRA$D@.J45%#E(7DQ@ <9(8-"I*(99>JK77O'.^S8.%HKI#^)CG,* 4H((S.
M8$1F9VU!3 K:TI@5(4Q[V%.P)0D9-KFG.PK4H(DV,.8 !B2*8B-]?>*F8B=:
MF?0DI'R[(CMZP.[C7C=\V(^C72S&09F6;**)E<L7K==H[0$P*-W**J*I2*$,
M4,H[B!QW!@0Q9?\ 28%_"83Y$);3L4;Q.W:=9F)+,U,$@8OD@UG$B82Q8.""
M&8@AYU,6T=XCF68'&XE$RDEO%,/<E<=$ME;/D!&NEMRU(+-QHVU*J&D"1);*
MI7@<_5B0)I10D<$N9H# 7QRM//\ /,"8PN8=%HDS#8HMJHNRN>>*CKJGNIJL
MR._09;35LMK WE)ZZ[C7!"HY'6PA4==;"%;+:K+JBSF!.RFDRNJXU EL3EU6
MW*B[!K@A2=FN+)$G+@G1J=9:---0]N&CJ]+X SE$VZ?-5*G*8>R9'6>TDCW<
ML>M5Y[2YMM-3Y8M@DN^DC0T:JYD2Q[-!9V\%L#=NDHLH0AN9FUH;ALNJT[PU
M9F,OKL6( F2A!U6BYT+")-G27)'R#$D7+RC$S,1KV_LRM9.E[2/9]<PF-C,Y
MFIQOPI:Q&(*RFF.5R=?/4&T,;-RP:Z]2+UL%59LO8"40WJM,0 BB*=B-?Q_5
MMI6%J_BR]GR;0(V E4:U>U(*4K)[$T4M,\NX=&@IIJRDX[R'ZKMD"3MLDH<&
MH+% R:I#FYO!Z:5?AK%)QUR<A26ED5[A)97EXS8=)%*6B# V.2#8AB9Y>:.T
MQ.O8_M$9+B7,>V?CS)<7\.CPGQ):R5,\KP\&1J98<8X,/CE+3&1H.?4M=2N"
M;$FAIB,NE<S!@41;?7I=?%]&FFC331IIHTTT:::---&FFC331IIHTTT:::--
M-&FFC331IIHTTT:::---&FFC331IIHTTT:::;EMN-2H%=D[?>K/7Z;5(5$KB
M8LMIF(^ @(IN=5- B\C+RKAJP9)'7521*HY<)D,JH1,!$QR@.)& DD"(1.Q8
M14KA,Q!/M66"FO74,]V/>TA6E01)L80@ R4Q&LA B@Y$2*%*:]DQ$S"TH637
M-.8_A6I0&QASL( )$4Q$3.EIN]9NDVRS5VV<(O4".F:J"Z2J;ML<A5".&QTS
M&*N@=,Y#E52$R9B'*8#"!@$=AB0&:S&0-<S!@42)!,3(S!#.TC,%$C.\1M,;
M>>M8F!B!@8D#(@ED)1(F,QS1(S$[%$CWB8WC;OY:0:E=J;?HQQ-4:UURXP[2
M7EX!U*5>:CIZ/;3L ^6BYV&7>1;ETW1E(:2;KQ\HP44*Z8/$56SI))9,Q P6
M0M15M**&5KM<+=.PN8-%NJV2A=FLT=P<AD@4 U9$!2)1!3(SM,S NL5RF(?4
M=-:TF9B&UK @#)0]?\2G0MJV2MD"< P"VY3&9<^IU.FQ:;M3:/6Y*Y7.UURI
MU&&2%>7M%DFHZ%K\6@"I416D)B1<MX]FD"QBI"HX<)D!0P$$0,/&L#8M<JAA
M@$O>BLF#*!EMBTP$UD+B9CG=8<P%)6.YM88@$$11$S(E$-*1F!0IKWS,3LE*
M%DU[FSY+4E0$QIEL*P$C*8&)G6B3)&/%;7%T1.]5 ]VG*PK=H6H$L<0:S2U.
M0<(M%K7&P8.QDWU<1=.$&RLTV;*QR:ZR21W '4(4<_\ Q+J?_%QHJ/(*_P#$
MH@]C%)*X'\586L4U:Y= 09K,1WD9B,.<>C4L<P]"^PTT7;QTKC5(&TQ55G\#
MV!6,;!@J2(4E#9B GFU\:+E'&N4&\TZQKD"EY :UR8<5ZP.:99H:S(0D\T I
MG4+++0SQXG'RK8IRF78.C).D@,43I% 0T#][7KW%^_4MC)U;(>\BP$0,R:&Q
MN#1B#"9("*-B&=]BC>3F%V'5&3R6J_+XBL?NO1SDP ZJIV8OF-+0'G&-R4P8
MWD"B'WIJ=:SQXTCFCE^_=-V+%F@JZ>/':R;9JU;($,HLX<N%C$20013*9155
M0Y2)D*)C& H".L&M6E9M<P%*6,FQC"$%@,=Y(S*8$1B/.9F(C60 ;#%:P(S,
MH$  9(S(IV$1$8F2*9[1$1,S/:(UKQ,O%3\8QFH.283$/)MDGL;*Q;M!_'/V
M:Y0.BZ9/&JBK=RW6((&3614.F<H@8IA >=;3 UERF) 6PERE$C.QC!C.TQ$[
M$)00SZC,3':=:@8MH\ZS!@<QCS 4$/,!D!CN,S&X&) 4;[B0R,[3$QI1UCK/
M1IIHTTU0[=V'-DI_<0'Z(_'L'/\ ].+^O.I^>WQCU[?TW^'^VL2G;X>GK$;]
M_+RGM\?+^>JA]NWOQV'N/Q\^PCW$?CC]=-NWX[?4^4?S_#?4;S^.T[[?'O$=
MMMYB/+OV^^8C60'[!V[A[?<0$ ]^_/</TY^VFW;T[_G'W^GX>?E\]8S'?;U^
M<[=XCO/EOV[??M/>9VUGOV   OQR(@/\OO\ (<?;G3Y^7]_K;?[^T:=M]YW+
MU\IB/3>?AZ3\IV[SKSW'D._OP/ <A[B(C\<?'Z_R]G;U^OU^Z?+O\8U/:-IC
M;RWCOW[1$1\]_./AZ^?GGL'("(<@(#S[=_GGX]O@/?\ ?4:=YVF(G:8F-O/M
MZ;>OGZSY?=H*(>_'(]Q]@#W^/<1'Y^_'SJ?*?KZ_+\-)B?CL/EWF?2?.>VT3
M\NWP\^VL@(B("(AW]@#X$ 'D?]8?/O\ MIZ?4;QVV[;_ (_U[:QF(C>(CR\Y
M\^^_QB/N^'E/K,Z\@ >X=P'D![#R';W /Z?K]O?C3]-OA]>GY_TRWGO$]I[3
M$3,;3\=_O[]O+Y>N@..2A_+@0'^O'W$>?D0#D.VH_#Z^/IJ9WV*?QWB8_+?X
M1&WI$SM/?1SQSP'80XYY'OVX#X#VX'VX_P!6GGIMY;SWB=_3M'G/K/RG>9G^
M>@0$![<#V$0X#@.._MQWY]N.._Z\:G;^O?RW\NW?;[^V\]]1$[QZQ&\1.\]X
MGXSOZ3Y3$[1V\MYVTQ,DX@A<[U13$]AM):5#7":K#)]9C$:&^E)M[)$R!%1*
M^6;M3>8HT(ARJLF'*OY1YX*/:X>RC<-EJV117FVU O@41S>_U4,44^[!%[@G
M)]HG^'OV[Z\/[1^%:?&_"&5X:OY/[(JY \>3,A^Z*$33R-6Z'9Q@N.JRN"=B
M./\ F=MRVWDDFR*2POL?R?@/ $[<L\S&1,N5RT?6<?3F+ZO8:F8B]#3DW[25
MM]YK-<14@XVJ$E$"EE7,JJZ>-TT(IRD(F+AQEE[W$F<X;ME6=B9IY+&,=;7(
ME%&M0MV+LW#4Z0>_F,H0*:Z7DPR@6"M,L:'%]E7L^QOL]X+XIP>*S-;B:,B>
M1MJAXKA=BW;HXZC&/DJIM2O9=6'RQ[D0(E,P?/"Q.,&F%_$<I)<+XXQ)5K/B
MVHTG)M^GLUY#K\CABYN<\RUKNL-/Q.57D)*;C<;RC0LW!)6)'*,),)NE8FRR
MZ*M/J5VCDD'L=R\>R2R&)9;6FIBZ."QV)1A5A/V=0NTK-N<P8L7+VSALM%A%
MO!/&I<RU<@O+R%3&-);;GU"VL@QV<A!MNY:_D!OIRCCB,@ZC]BJJ8VI964)K
MEE\.Q&/Q=P5WJN,O4L7%A&1D+'@]?%WACQ%QS<OE-W4,P/++%%;QL[8X#,>"
MVM5N=;2S0E,2-9QA 2%^C):M5>0QD=F9M#W-C!+?7HEX#Q^F[!G(3''QH7E8
MX5MAB7WT<.JRP&Y9V&7T<)\88W+73M)@US5J<59;&93$2@8L5\3)].D-I18W
M3+K:^R;*C%E-4\R>+8 DI*Z9<0<.Y#%TW)9$%XVWP_CK^)RA;,JNRC!,[?@V
MQ=0YZS0_%-=XU>M)A[E^NYH88(FH7'<X[R+@">Q<7)9(>V1QOXS1K>YKV27F
M)"35KLY4+;3F$FBF9-FVL1JNF261-9LC:/'D8,'[0.>$)R"5KZ86<<I/"$\4
MHPL"Y T\_+:7%P+EUNAC;,9:F2\N!+!E&PN!7?-6_-C5Y?BEN.>123P!^1XB
M9PQ.5EJG3:P2,==X=5;4NL[)IL8NX(XZVLUMM,&4PKXE]JIV+Z]E*$ROE%A"
M7G#-U-'H6W E"<Q+BA;B:9D*VM,G0[S</DAO>B)T6 !/',E#Y&F'1Y9FL6?8
M5Q9=!=QV*9UT<0XBZSDE%*THCL[3-<:%GA_B#&M*:8I6U&8K97(8]MHTC:2S
M$):=>_<NB>/N:$E:52R:>>8+(83BJB0B>SUY#)X+[/IK"S(&MV!<+KRB D5K
M@7;"^I455)=_&?H)(83$(8Q#)F,4IA3.)!.F(@ B0XIG43$Q1'I,)#G((@/2
M<Q>!&G,;3,1,3$3,;QOM/SC>(G:?.-XB?C$3K9$S,1,Q(S,1,C.VXS,>4\LD
M.\>4\I3&_E,QWUZU&IU&V8VMK?8ER6RHB<XK=W=$M3>H)UF2B8:P'LZT*]3@
M@AI:>D(J%C9'ZF9MZ5[*R3%@V5Z573E%$ICAR,\&2;A\BO#%(98ZQCC6<ZP!
M5V9CP[7$R>6:RF\K+0\K#96%H+4YA"H^ABBIADJ1Y&(*@-E170D3*3JP42\
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MS(.2Q; F1*)UIKO"ROJ + D6/0U3@E3Z]FJYE:U5L*+WE6*ME3:]A1>\MRS
MNXSIWZU:WZ---4:WP8TR]G2K5'"6.ZC 2%3NLN_<9/N5ZBH>TX^@:[%1+Q1E
M!S]+1RSB^]6!S8Y99HDP/6%WC6+5;>OE5$TTDT%^5>JV+CBY&%672QU^W6<
M =EV6-#*V/#&MZX11R5%C)R%:Y<45&'+2IA1)DQ/2I6@HJFR$RRW-[&K6@1B
M1&LNVNW:L6I:'(5*(K ERJ["NLZL"I#%]61@/;5BC=.7).U>Y9MJ&1:L.*L
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M%$Q/Z3I':8GX:X^._"4KRCZS/FF3:JD)'R+_ !RS?8292$<U53RTPS )<WM
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MJ/;'$DVZY365_*<HD3 0]UDP[ZF-MHWGOOW^[X^7U\-1$E/I'K\8[]]O/O\
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MIB8^.V\QO\M?6H6C<2\LD,UM5-BF%?6>%)+/$$6Q56[02G$RA#$GG)@,!ND
MZ4%1_P#4^=/KZ_EI$S,_+YQ/S]=MO3?O\=M)4M;=S:,G(IQE(AEXU-ZZ(P6.
MW;"HJS(L<K90PC84Q$QT0(8>4R"(C_@*/Y0GMO'P[;_UTWGRVG?OWV[?+U_V
MTHV.T[C&SIB2OTR)=ME(.%7>'51;&%*97CT%)=L7JGT!!-N^,LDF  <H%*
MJJ'YS)V]/KO_ &VTWF-M]OPB9[??]_II4=V//1*+%/VM3C%+HM-/$)*-,BW]
M.A#D3$6C@A1FRI@HHIP4P@[4$0]TB^^D;=]_AV^_3<MHG:/GVGM^'G]?#23"
MVG<<NA/FEZ7$-EV\"LX@RD0; #J;"1C4DFJO3/J@*1H]616$#"B7K1)_; (
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MJ/G_ +_7W>6LX\HG:=HWVB(G:8CY;^?KW_#>=IUD1'V$>X!W[#P _?D._/\
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M=8 %)!@+A=,'BRH&**:;?S#G P"4H@(:G:>K"=OWQ<W*K_Q9Y/X]E_Q3R?\
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MI9;7X642&6*R7,07^%^-"YDFP")<\P#.X3$[C$^8QMU(F< 6Z4W;UK<6E;J
MA58#$TWC-2H+8UEW%]<JS<LUEUIEODHN16\2S;ME&2#=M%GQVZ4*@J^ TD8S
MD@H?8J016#B5;9DHSZ\8H3JSX9E<<6-J$2\BZ\6BD[]LH((K<D2@8B949._G
M-=*+%?#J4 K;C+]RVQSMW=95RN*&5D '0FL.ZDM(V'9@V+B>F/;;G=0_"#F\
M<L;RVA,Z5*<E;-D%O=(.X7O%-SMMFKQ$922=@\<LW>=$:3,7=".F'\6UM0T]
M@P,F9$\G6I-$BS1?#!J^QT<'HF1.>&7XZ;3:PS69D:F.1B4$BL33M3C&Y.,/
M7/*O";(N8Q[*Z:S#@ATYA:\M=XAML6L@S:<C"JECG97JOR3\I9.6Q6.F=JM2
M9E&1C%<R'TP2F(MF:DL5VY2*<B29%%!54*F0IU1*4@J'*4 ,H)" !"B<P";I
M* %+SP4   UOF8F9F(VB9F8C>9VC?M&\]YV\MY[SJ1B8$8(N8H&((MHCFF(V
MDMH[1O/?:.T;[1KWJ-9:---&FFC331IIHTTT:::---5^W9+K-MJ^Y=RW64;N
M&^W[,JZ"Z*ATED%DL<V11)9)5,Q3IJ)'*4Y%"&*<AB@8I@$ '7%XDF1X=SY#
M,B0X7*R)1,Q,3%%\Q,3'>)B>\3'>)U])]C*UM]L'LI4T :IOM)X%6Q;!$UL6
M?%&+$P,"B1,#&9$A*)$AF8F)B=<]MIV&K?N#V(;'$_Q?4FT!5)J;MN0XF_4B
M;R XR#6EWN3:5*U1F_:9 J*< N_@K3*)!+R;*UMTE2,NN'7;HK-W/$]GHP[A
M;$E>YK-.U@<OCWJ$B5;EURR?0M+NE+87X9J$LY8K$TN6>E80SD8'U']JRP.)
M]OWM@IXQ"JC;&7X="JQ(@NM3&A7X8S>XU% KF-MK'5QB1<H16;^8#-@&O3M/
MA*FDH)M783.I'D8A9<L+(-\GXZ/D4D-4\H)5!!J:LG3N]97B,I8Z:T]G'T+)
MJRT@,='.G39_69$ZAES>QB'-=1;<LN:Q.+Q5"W?KR-3,'9Q&?N9U61Q]\18O
M'V,D5TZV=B:MD,E":SH\.Q4;_G%]H#1":Z(4I#!.G2<7B,7"?LJQC"H7J<"H
M[N-3-@K./KQ8KG19NL'L3/)'8.%C0AH>)ARN7+TL5&,8T'CQ3S7;L&+5)J#E
MTKV\QRN"7FKGX#J5.8W <ZM6739L6+$@"Y>YKI6N-EKEK".0"/0!YN48]!B(
MURZE>*E6M5AAMBM737AK9W8R$K%<,9,;;F<#S%/J4S.E/6G5C1IIHTTT:::-
M--&FFC331IIHTTUY/U"4P$$H'Z1Z!.43% W ](F*!BB8H#P(E Q1$.0 P#W#
M$N:1* D8/EGEDADA@MO=DA@ADAB=ID8(9F.T%$]XF-MXYHF1WCFB)B)F-^\1
M,Q,1,QY3,3$3WVGRUS3+X?LQ-S=;N]QR[',\AP>6K=<Y2?Q;1).BQURQ[8I6
M7GX?'MKBIS(%Z=/Y*EV":=S=8N#>7:&C7RC@&\$BUD))N[YT8R!KXY 6' *.
M&LC@L@ %LBW>M8'+X"EGJJ9WFCD*%++/1,DRUXNH;JKSG:BVAK,88;Y-:3$>
M(J&<QI,$B?437RV)S%_%V&08KN5,E9Q2);'10*B55:"Y8EQ6G[LXV7O-K$Q?
M)N1OL!:W-L@:;4FK.G8_/CB*7B:0XL3AA;[PP-;;:6XY@L!;$=K<\@H'K[>>
M:14.D2ML#-5%%^RAO1QA4)&.=V2C)NZ<RNA5:.'Q6'BKAJ,\\XR@Q>+&Z^M-
MFU+;]E[NJ(<BQUL1S74V8(I"M4M5%&V9;?LA;R3LB19.[[D7IJ$R$8^8KH*N
MMER2)I6OW5\=:=;]&FFC331IIHTTT:::---&FFC331IIJJVXC;M*Y]LV+"R$
M_2DL95-Y:UK]2K'1IJPS5S:62M/JVBWK]HCK]66=.<1J<@M()/W5:M"_KT&:
M[4&1V_4IJA7,ZT36,%;<?->J=0IK7J60"VBY7R*;9=8(FLZK7-2HK@?.!3+Y
M$N0>BC('5H7*J%C+KKZ768[9M8J59A,?495Y0EGBXGHL,WROPY-62#ED&-'Y
M7PI7SV-Q[#$SV$PVJ<Y>7<K.7C'(VBZ$86W-I\R-9S'MC;W:$)0<I,3^76)&
M_FC;$WF8WSUQK3%14B25BDTZ^5Q>4=RL/'TN#%,BN(U&V+?!U9R8$6C# 1A<
M^=AGV[AX2SQ-?DKJN)Y>IKFY<1R>/R5!9.KKNU<ACT0UOBE5Z.0X?H\/!+ (
M5LLW\-7HKL8&^3@.C9Y3L!=D3EO8G6&IT:::---&FFC331IIHTTT:::---&F
MFC335#MW0C^)*@ ![PC[D?T]>7[]O;GX^=/KZ^O]<"CUF?+R^<]_AW^'UOM4
M/L #Q[]^_P #\#QW']OW'X^'Q^M_OT[[QOMMV[=MX[;QZ1MMY_=$QW]0>1#L
M'(<<>X"/;G@?TY[_ .P>X:GTG].W]?K\/6/*8WGSG>?.([[=OG\_+TWB=IV/
MD/N' <=@#L/MR/O]^/U_34:GX_"=YW[S/>)[Q$1V^&\SZ>F^CWXY .3?("/'
M^WOS[_8>.>0YU/E_K'K^OUZ:1OM.T]H]/.?OW[=MO+O/;RG?;07CYXXY_P 0
M_IQ[![_;]OM[\Q]WW=OKUU!?CY=X].^_G/EV^.V_;S]=9#W[>PB/< ]NP#\A
MQ\!QIJ)\N_G&WG/GM,QZ3O,_'O']_0\AR/Q_(.WZ#W'GG_J^.)[=O3Z_E^OW
MZB-NWQ^[?O$^4QY;3'S^'EWF?'/[#S]_<. _;N(<^_ B.HUEMM\8V^'EWF?G
MO$3MY=MI_&=9_,(\B/'MVX$ Y'V#YY[\<]_8?CN 3VV^?^WK_3ZF.T;QM$^?
M?>)GM,[S^7E/QCUB8U@>XAR/;@1[=Q#MR(?[  1'C3RGT]8[]X_MJ8[#/:8G
MM'K&_?:/*9G[]MM]]H^.LB/(=@[CS^_;OVXXY]NW[:C2(V\YVB-NWIW^,3OM
M/?O'SU4??+VVQ9#[=/\ >*: CW$/^7%=^!Y[_'_1WU[3V?\ _>O'=X_@O?'_
M /8+/R^7Z_?M\/\ VCO_ &/\4=__ !L!Y[;]^(L3\)_+MM]_;6/#KS)DG".P
MVVVC%C.N/[/-;T:K256UHI=UO,8G"7"O8IA)N3/'46;@99DI!Q[I:;&0<.5(
MQ-*/5;.TDRN2NV_1]IQ&SC;A/'Q(C7R=9M>V<K+J I-7/75DI\F->N4V*J5R
M=F"4R&$D9!I@P?(_LDB,>R[C>WRD3<?GLC=K+$QCKV%8KAL0JRN1EC)M09("
M53!)886"%JU&EDER/B<;XH:8N$7:\0XVHK:O94A:&24F,(YBLIVL6YE;A%2T
MVM!4K,,S+2462/B:W<(RP+$K399O*OZLK$>8@RM;OY,JZ]V*KWQKQ%BQ0R=L
M*>YDWQE; V,FC#,@0Z:+2LM6#!39-Q#DIOJO+J8V:;:-G]7%7 +URI!=5:)"
M L08H3-?[;Q-!>1$VC+;*KN-OV\A--==4XTZ*UE>R:[9LIN*A^)YNHN-24=R
MF.J-4GSB.Q).2-Y=[?=Q,I4\9HWRI6:3L-:L]&);(VV765@[3!Q%?--UV?K[
M2,"U-#R<(K]-%63ZN3B:L6YI#XHJF5X@J5 (O_7X5,)ALO@*=(P'_AC\I8OY
M/$ED[(7:I.PK+0T:YVQH5^?7ZG4J _D=-FL@W16CHE0%7$&0PF1R39<3 L(A
M%6IDE8L2190N^*IOW$HF\VQ5:W>;NPBY>4RE0:SC<[/!$;N%7AHO;[E/(DA7
M*\O0WSF9H+A6+S3"EMV0X6_HMB(1<6U@'TQ7#'CP@HV24"8;QE!BC]N"EZWS
MB<U.)6SI3(V8S-G&KX;< B^$FFH3\E3XAM*MG4 Z2LF#:%)\J":$E;;B5<RC
MC);RM@]= .1BK5I>6N#UD%-(,M4#'WL#4M[VZR\B2;0WK%$U6$G9]GVW9QW)
MT^UY,K3RKY#DL#Y-K<ZC&8]OE(J\JC5\JPZE5E#1T[.7>*AGTK7%5I9I%JWR
MP.D47#I)"0< 50A,\>B1CB-@K)$V,;P1<N5&/!\5LI7M<98_**0Z4UA>21+%
MBXJZS&5.K3#;"078+E6++G9# R8SX>O<XTH5'BABIL4[=/@K)8MEA<FZ52[P
MV<Z76E?*=9X$M#SE,]A-8:[&C331IIHTTT:::---&FFN-7BA[J<R;?<H[6*E
MARKXSL\YE*4L4>U;9"JS*< 9UM8J)&0#5A*.73)>"0=O)P4WKIJ\:*%X0< Y
M0.V(J3Y=[0>(\IA,AP[6Q=?'V'9%CP&+U<7?OA?36D09)A*8(G3!D)1/\)<P
MR,3K]S?LD>Q[@;VE<(^U_-<<9?BO%8_A&IC++6\,Y=^/VQ[<9Q%;R+K--:+"
M\BQ*,?!5TN2X9W8J5,%Q!+FA,H^,JM-1",[MMVJ-(-638)S+MG:I([MM%'=I
M%D5VI!S$X SE%F*RB!1;K@94I0%)3GH-N3D/:G+50[!<."F6!#2"PSG%4E'4
M(?\ BA1S0.\CV+OM[L^6N5?X1_89"C=/'>U/VPNR 5+)44OQ%44-N"DYJK<4
M<#+F%&^ %DPQ>P3,\X?Q0L7W)?B],KS=&>/-N^U^8H#2UV-K1I><L\@A-RE/
M;S#Q*LR,P@3+D<1&4?0I&3F02*P8E3=JK$*T;  (DVW+_M-"Y:"EA.'FTALO
M&HUSV"UE46E%=C8C)ALPU0!'$+#8IF.0?X8H\.<*?L46.'L$_B;VG>UJCQ([
M#8MO$%+'XFLRA3S;**#RU6BPN"K)'3KWRL*K'-FQ)) "E[9GJ$_,N7[Q.(N.
MQ@IAK!^WJRR<C0FCW*Z%JL#YJW@,AF?O"/8>M&3R7#"Y@DXXC%9%=165.*ZJ
MP&?F  2)=R=SC]88^<5B<(]C*8GDHLN,11>DR@E5YB^KF3 <DQ,RR9F9]_TC
MSO!7#G[)URUQ:/'7'_M+Q56KQ&]'!K,/C:[F9+AB*Z"KW<K!<*7^ED2LS8!B
MQ"F,+%<Q6C>2)J(9(\6@V,)&17V^[9R973OD*RC( EE?C6E\>K5Z?7G9APY_
MBN90LXULB%=9,T E4BG8/'R@QRXI@Y;UHO>TG[/8<X;A_P"THN*!:8>SPY49
M0Z7,*9R6_6%\($8ZL1($<].9CF'LLX6_8RCBVK57[2O:L7!I<.W[%O)%BJT9
M5?$P9/'+Q]%2O\&P,X]V*9DWO9-,R&RBN,6EP4J8[L'W[Q-9F;M*.>\(;?*E
M MJ+97M1=4NP/7CV0R W:=57B)0JN2Y\J4(_>?V<BN1NU.FEW*_:C^?5K$7.
M/FMLCF<3A*R1IO.L=1QD3+HCO74R"ONV29=F%RC,1Y&/GKB>T#AS]D^CC\.?
MLX]H'M*S.1;Q%BJ^;3GL:A"*O#373&7O5"#A3&R>0K)V*LN6N$SG::S?+440
MF4?&56F8A&>VV[5&D&K)L$YETSM4D=VVBE'219%=H0<Q. ,Y1:"LH@46ZX&5
M*4!24YZ!YJ<A[4I:N'8+AP4RT(:06&28JDHZA#_Q0HDH#>1]V>^WNSY3[+(<
M(_L,A1NGCO:G[879 *EDJ*7X>J*6W!2<U5NF.!UR*F.@!9,,7L$E/./\4+60
M,E^+PQOEU98YV\;8)G'K.W61K1)B>L\@A.2M-;S+U&KR,R@3+<<1&6?0A&+J
M12)'L2)O%5B%9M@ $$]MV_[3 N6QHX3AYM$;5@:3'/8+F51:<5V.B,F$0PTP
M!,B #8YF( 8[10X:X4_8IL<.8"QQ3[3?:U1XF?A<4[B*CCL369CZ>=;00>7J
MT6%P7:(Z=;(%835.;-F30 3-ALSU"?>5[]XF\9!8I6P_@_;W8K!)TA-YEYG:
M; ^:L:[?1?+$4B:N=/)<0+J%+'@@L591Q+G%<QR^O$ Z"V\E=X_6K'3B\1A'
MN93@\F-EQB*+O/,2JO,9!7,J Y9WF6SO,^_Z1Y[@WAS]DZWD>,5\;^T#VE8O
M&U.(#1P2_$8U#;&4X<BN!!=RXGPI>A-Z;,F$K%=*(7$3X;>>:6JWR/XLIL6R
M\DYV_;:"9:2OU=8PU?3LL@-9<XZ7KMH7LTP[<_Q6,H2=965M4F4>@$LB12/D
M)-0T<Y,D5RUKC>]I'V<QA87 1DXNH!2(>?ARHDBP3VD7VEO#@L#6 !ZL1(&R
M>2=H(>NWA?\ 8TCB^E45[2?:L7!9\-Y2Q?R98JM]JJXG7E,0O$T4J_P= EC[
M&);FK%EDTCD;-:H,6U0<I=[H61O%B>H7<V0]O^VF(<,Z/-O*$2"LC]9.6OR/
MI_H,1-"IE:0\F%=]3CUBQ#,#DZ"</T.?S33O>T@XN>.PN!40U&G2Z3S*&78Y
M>BIW_$3V47O<TQTYC:/?C4<1\+_L;5V</QPS[2?:K>4_B"@CB.<ABJZRI<-G
MU?M&[0Y>#JO/?3LKH+*+,%S%O69MVU<:Y)\6V0OM3991V^;9(''CJ;9HW&8K
MMFD'$[&P)U.'SJ*0/EB4(J]23[HD-'O"B;W0.';6./O>TH[M8,CA>'TT2:,6
MFUWL)RT[^\2QG)LW*(\HE9?=/EK;Q7PM^QA5X<S5CA#VE>UC(\3IH//!T<GB
MJRL?:R,#_ETW&#P93D$&79A1:1,1Y,'3$W&9J\56B(YWG(' >V9YA"FIY/EH
M:S3,LZD+(ZQ572SCR.G96"5R>5H]FUZBS1D'T2I7RMW+\RK,\."1Q9!3SF6]
MHU.,PY.&P!XBK&0:JPUA&\L<CK&MS$SD8$FS5&#-<IV(]QZ41/)KT7LPX"_8
M]XB/V>8_(^T?VKHX_P Z7"5*]B:---;%IXQR<X]%K'4\@'").107FGG6KW!R
M4L57@'C>DABQJZ&Q/*$]FC:7A;)]H904=/6ZORCZ295F)0@X)!5M:)Z-(6.B
MFHB@R2,@R2.=-(1*9<RJH]SCKU?"&0=E>&\5D+ )6ZTEAL"NN$I&1L.7$+7$
MS 1L$3,1/>9F?77PC]H;A'&\!^V;CSA+$/R-K'87)4Z]5^6N,R&18#L1CK93
M:N-B&/.&6#$2.(F%P >0ZMMKTFOC&C331IIHTTT:::---&FFC331IIHTTT::
M:---&FFC331IIHTTT:::---&FFC331IIHTTT:::---&FFC331IIHTTT:::--
M-&FFC331IIHTTT:::---&FFHHR)ARK9,>QS^P.YMNM&-56C<(IVS;)F265!8
MXJE<Q[TQC@<."B4Q  O82B/?4Q.WI$_?O_?]?/42,3]1_;Y_=J.PVH8V ./J
M=P__ !.)_K_W"[?RXTW_ /=C]?[ZB1B9WWG]/R\N_P".^C_1/QK[?4KA_P#B
M<3_^@N_\_P"6F_RC]?U[]_QU.WSG]/T[=OPT#M0QL(  R=P'C_VG$\__ ."T
MW^4?K_?40,1,S$S&_P!VW\M'^BAC;_SE<.WM_P )Q/(?S^A<_KJ=_E'Z^OXZ
M<OSG]._Z?#:/N_'0.U#&P^\E</O_ -TXGY]__ 7S[_O[:C?Y1^O]].7;RF8\
MOAWVWVW[?/1_HH8V^).X!^TG$_Y_\!<#_KTW^4=^_K_?3DCXS/;;OM/]/3T_
MWT#M1QN(<#)W#_\ $XG_ /0.F_\ [L?K_?40$1ZSZ_K^&C_10QM_YRN'?_VG
M$_;C_P Q?;MIO'PC]?[ZGE^<]ON^._P^/?60VHXW#VD[A_\ B<3_ /H'3>/A
M'Z_WU$A$^<S]?AK ;4,;!_X2N'[_ %*)Y_\ \%_OWTWCX1^O]]3([^<S]V_;
M^6C_ $4,;<\_4[A]_P#NG$_'Z?0N--X^$?K_ 'TY>VV\_I_/;?49Y?V@RDE0
MI5#!-\4I65$WT ^JUFN\=7[=68U2.GHU](FD:\^JDDSD1<1"#]HU(X8N$DGB
M[=P8@>5U%Z6(LT:F00_(UFVJ80V'(KN:AI\Z6 OE:MJC'E:0&6S!YA&1G>)V
MGRW&>+X@R_#E_'\+92GA\VXJDT\AD*-;(U$"J[7=9AM.U4NH;UJJW)"3KLE;
M&"P9 A@Q9N7<&[]W\]"J;>=S>,\15-&HUUI88!?$]*DC2UY:,_)LMG35<X\E
M3HH3"Q$#H-"+HHMDDBI)-&Y  FN[C\GPH*FQE\+=R%B;#B2T;]D.G5(MTHF(
MN+B97&^Y<LR4S,R1:^?<1\)^U]MNK/!?'>!X<QPXVDJ[4/AW%/FQEEJY+U\2
M9A;$B-DX&17SB"Q&!%01&VMUMB+Q#B8)?59SNPH:V=U<CJ3+')Q<9U(L(VQP
M,'"M4Z@>NEQ^2+4D"3C::DAE#09W@HR*+<9$4D$T$<2R'"$Y07C@;<8J*<+*
ME-VQ+9N]5I38AOB^> E1*#I]6!B0F>3>9F=H<-^VB.$FX\_:)B"XN+.3:5GH
MP.-BJO!^$JKC&S2C#17)T6UVG^(FI+>1XKZ_* B!BW$7B'04)E%ME/=A0KM-
MSE*4C,72,9C*I1"-*NHO4526.2;LJ!&)R[,C(JS;T#U&3;"=0J@LQ.4% 7LA
MP@UM$J&!MUE*M0=X&7;#)LU8&8E 25LY64E,3SA*RB(V@N^VF X;]M%2KGPX
M@]HF(RMJWBR1@'HP..K#B\I+0*+KP5AT#95"H)?1<%@-R@NEO&^F70,(>*'$
MWRDRN0-Z6-K30XRW5N0NU888DI4:^LE193+)S9(%G(M<:,73!U,0R;V/;O6S
MYDX:K."+HNVRB95B6;>3X'95LKJ<.746SKN"J\[]DP38)9"EI 5XQ,5LD#D2
M$H*!F)$HG;7+P_"OM]KY?%6,S[4<'D,.C)4796@GAS%(=>QJK*F7J:G+P*6)
M99K"U -6Y1K)D&#5D,%&SDK"?B=3-^MLMC7>9CFGT&0G'SJI5>1Q-2Y5]!0:
MJG4QC74B\QM(NGJS9/\ (=PN_=JJ>YESC^;6-+)<$KJ5UW>';MBV"A&P\+]D
M :V(]XQ ;H",%/>(@!B/2(UGG.%O;S:S&1L8+VG8/&X=UMS,;CW\.XNPZI4*
M=TH8]N">QI!&T$9N:4]YDIT[,TXB\0ZRS=;<X6W84+'4(RI5;C+)&R^,ZE/+
M3%U9LBIV2QMW$C0)E5JSF'O4X;QZ*S9LT(()HLVY?R!HQN0X02IPY+ V[;2M
M.-)JNV%0NJ1;I1,!;5!$H>TG,$13WDI\]='BCAOVT7;5$^%O:)A\+55BZ*+R
M+6!QULK.44J!O70-^'M$M=EN[ 2) "XG85!';7T9XC\0I/ DG5'FZVAN,]KY
M'&9C,H$QI4R0;/&_T6&;!4%*X6@DBU9 )IM,R/U4\$J\\F01;_4?*0311@K_
M  C.56\<%;C$Q2Z;*4W7RTKO587B(=XN3@.E*PZ?6@=PDN3>9F95PY[9QX0?
MCV^T+#GQ@6<\57S\8+'#45@_"U5_9I4HP\5S?XH+3_$33)G*X ZW* B/G%6(
M_$+@87*+;*VZZAWB:G*.O%XMD8O&=3AT:5>#NDSH66208T&+3EV:34%$#1[U
M&3:G.<#BR$Q0,$W\AP@UM$J&!MU5*M"=X&7;#)LU8&8)"R.VR5E,[3SC(%&W
M\41.VG#W#GMGJ5L^'$/M#Q&5M6\2=? .KX+'5@Q>6E@R%YX)P]>+*H7!!*6B
M]<S._2WC?3#HV#O%'B[M3Y.\[U<:V6DQUJK[^XUQEB.DQ[RP55I+M'%AA&C]
MMC-BY8NI6(3=L$'C=ZT7;*KD71<MU"%6):M9/@9E:R%7ANZBT:'#6<5^R8I>
M2RA+" KQP0K9(E(D)041,2)1.T\C$\*>W^OE<8_+>U+!7\4G(4W9.DKAO%(;
M<QR[2SNU%N7@5,4RQ5%B0:#5FLS@A8$Q!0H9,PIXF\U?[9+8RWEXYIM D)ET
MYJ=6D<3TN5?04*H)?2Q[J2>8WDG3Q9  ,!G#A^[4.(\F5-QK"EDN"5U*Z[O#
MERQ;!0C8>%^R .;'\1B W5B,3Z"(#$?#6[.\+>WBUF<C8P/M.PF,PSK3&8['
MOX=Q=EU.K,_NT,>W!/8TA]3-S"G_ ,T[:=69,1>(;8Y"H*X:W7T/'T?'T:MQ
M=O:R^,ZE.*3]Y9,4TK)9FJLC0)@S)E,/@4<MX]NHT;-2&!-%DW( )AHQN0X0
M2%B,E@;5LSM.97)=VPJ%52.92@H"XJ")8["1S!$7G)S/?71XGX;]L]UV-+AC
MVAXC#)3B:-?)+LX'&VRMY928&]?63\/9E2K+MV @)6M<3R@H(CEUEEB/Q#$\
M#S%5>[KJ&XSRXR*A,0^3B8SJ:<(PQT2&CVR]26KI:"2+7D%9E&0D2RBD&J[*
MBZ30"0*FF5%,60X1G*K>.!MCBHIRME*;MB6G<ZAE%B'3;ED!"Y .G#8'>)GD
MW[R5PY[9QX1LX]OM"PY\7GFPLU<\.#QPU$X2*J5GCBI1AHKFXK0N?%@JAL@6
M"$.@1@1K-+^'%N9SI;(2\;M-T;*^VG$\3)2F Y3'M4I]-&J9%5DH67CI.U,B
MXT)'6.LDD8"+</HU9FJ\4](5%NX207=)K^9XOPO '$UGA^VG!Y.A8PF45=)@
M9)Q>)JBQ;74C%S[(<CC2HI,!4\>39;UP1P7VKV#>U']I;V,8;VI</NX^X1XD
MQ'M)X/N</G3N\*4P^S,LVK<I4L]7?CJ>'LQ8I5LC>4%>PZ[CF^(Y[&-L,4DE
MR/"X&\5]M,Q+F:WR8PD(9O),%I:/1PY14%7T:DZ2._9I+IXN1414<M2JHD5(
MLD=,QP,55,P </:,RO 4K9"^&+PLD"A93D;4P#)B>0IB;\Q,1.TS$Q,;>D^6
MOSK6X1_:("S7.U[6, ZJ+TE92/#.( FH%@RY0&/#X$),7!#!08S$S$P0S&\*
M]YP=XI$I=KA)T7>KC6M4B1M5@?TZMO<14F0>0%5=R[QQ7H1W(.<9O7+US%1"
MC-@N\</7B[E5N==5TX4.94^NKD^!@JU@M<-W76@0D;+@OV0%SQ6,.:(1>$1$
MV01"(@$#$[0,1&T6<OPI[?[&5R;\1[4L%0Q3LA<=C*+>&\4YM/'LLL.G4:YF
M!<QIUZQ+2;3:TV$$F3#DI*7SE?$7B'3T=C1'$^["A4:1A:*UB\F.Y3&=2F4[
MC>DWSM5W9HY)]0)0D4R78J-&Q(YDG&M2*(&4!D4QS'/5H9#A!1W9OX&W9!MH
MF4A7=L+FM5D1@4'(VU]0H*"*3+G*8F(Y]HVUUN(N&_;1<3@AX=]HF'Q+JN)7
M7SK+&!QMD<GEA<PFWT"[#V(KJ-)+7"%0A<2$E"HF9F6LCA3Q-RXTD(5;>5CE
M3):UZAY2/N(8GI98]I16\!.-)BLJ108V!DJ]D)]U!2B4B>-4<H(1BS9-ZBDX
M507WSDN"?&@R.'+L4HJL Z_C[/.5HFJ);H/QO-  H6A(PR(F3B9"9&"CGAPM
M[>(P3ZI^T["%G2RU5Z,G'#N+Z"\2NG;79HE7C!0HFON,J6!=->6 %<@%HB9
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M7Q@Z6<K,F1D6RCA5RNHJ=,5#JJG,)QWHRG 8I4+^&;S'BH!:P<C:$3; C!G
MQ>&(@B@BY8&(B)VB(VU1O\)?M!MOW&T/:K@:M!EJP=*L?#6)8Q%4VF5=!L/
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BC331IIHTTT:::---&FFC331IIHTTT:::---&FFC337__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g428534g03v30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g03v30.jpg
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M P$1  (1 0,1 ?_$ !X  0 " P$! 0$!           '" 4&"00# 0(*_\0
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M%UEIVEIF9]7'L6LIJK1VG+DJV)P8*\@90M:GEK8AGQ=D@[1;3VBT_P"=*O6
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M*V0(QI1]W LN/DL&HA&JFUBK ,.06(1V"('27"\>XM/&E/\ FVZT 2KYDH[
MG*81"8:J]DT(2B)N,<XR%*%@;$%,4Y2%(A(L*6"[TE4@@WJX?*EO#R6AJ=G&
MVVI4K=:OKG+0Q=$YQDN2[/9!.%H9\=;>O=!;# 5L-8!'M0V:?U8:E%&28\G*
M*Q1 1C9[ARX-H#$JZ!DZ=C%).P()^.'-D;2 =#_!^R1X\XU6H 4Q, 38H<K.
M=F!4E<,,!D""'.$1R(5Z+"K.Y(&+'(R'&I(+D% !F)UP9/ 1YE'$L9$'!HEZ
MOH&Z1=.5K5@-@E@=6I#/RMY-FJGHTYZ9A8)F0W(5;9\A3E6['>A MJB&K9+3
M*.K8-(E5K'SU]L^X6CJ+V32B@\_7ZB)T?I*_ JU9H54:)P35VMVZ0IR8B96Y
MQ:0N'+@T@"QD>7*.R8!2&5RU&CQI#/G6Z-<&&I6H3$:P3*9.H4P)'>$A5J^-
M**#Q-$<>*,[17XQP:,X2'O)WB^U<+G\GD-;YW%6 W*6-K:3TIF*=&^+'QL!M
M9;):JJVR,6B:S-Q$%B:<>ILGD0-@=CAA"$X[Q?G<]WA]09C5=]N!;59@IL@+
MG30@[50+FI]R:ICP ,H^,J]\R#E%<[:QC%E40KDVRCID5[ I FO21CKI=G?;
M&U98@=^K6'?$.D5LD41S-?QM^4RQ#.Q5ZV(_@_\ P6@: )QDW6=8:,V8;\!]
M4Y46M+.GLQD[&GK5C.5?X7K6\=4EIS4^GH!J$N5\?F.R$L?Q)LU]ST2WPE'*
M(&K49UY2M1E:%U1T:>P ?9KMW3FQXWVB"RY!KF'6IG3G9RE3OXZ5Y+0MI$J0
M3$2G*XZRZ_ (Q,M.RYHUU>6$<^6"M1D9G-5_D_!7$[2,[/',@'8J3C_(W>,8
M$BQF=FE"6[1C-MG?T(>D'$&A3G"EEF>[_&+"A(-+CB70]\^.S(";7WBQ)V*Q
M'HRC*8CC>,B%!)W@V %=9&M)6!N#U?O-%<LM)I&PJ(W<V*</1?ZM?2XH")FU
MZ:/NA4; D#RYP/$L0ZXS:M/!-$HI.='0(4L@C,33EV/'U1JMI@V;5.T]:5F;
MU#U!D,2!HSK#G-IC$209UHG@5X/",NLV@^I7Z3L$3J&N4\MB)7L5BLUB(Y2&
M,"V9Q^7LUZ=8M(H,I8 &8;-NJ*Z#)EQYJD3CL&'&J[G;)1.JNK%7Z@.!:\VD
M=/725L6&+ #AM-3,:>U8;#A[<Z\1(7B#7)8YM@Z..AC00X7"V,(\AX"1(3W8
MXYZDL">#6)EN40BK1IR(:<[/"[7A$)79H0JS/&;N*8B"*(90E;8L(09YMF'T
MB8^Q/&@IX74%RYE"9P5>F &+8L9Z>M5JV2>1SY8-$H6A;!<JVJENS4O5)M*F
M<QI0!+^M?]0 0P'##1[>P-AW(V3WW*B 'A-"#6QL/IK;1+7MI];;CG0%,9%U
MVQRP=,KDE)=1:R1'1A:8B5*Q8Y\*+>)(,A9S>I3K"ABHR,Q+9:[DR./A<!PN
MXBV7F8,2V3-U75ADTQQ>,>IA.<-K*K9JU0!CFLUD[=C6)!TYUL/5R,:VE]1G
MPN18K#MT\5&O1O$J8NC-K+V;PI LD8A&O&%[Z3U/4O9-GKU;H59OEH:L%'HN
MQ\V.&, 00(2F[ EW<6(*GDFK*+/0WX)[7]@KYL*P#EGQQ5#'_5;\#$R=#I9P
M=FD QK9Z@'#9M4^IE,TBELU(U9D&'J@$%-IBMA,(KEB&8W?^8T^&$LV)U]BL
M[?IT</0R^0C<Q.(SCWA IBIU,7FB9:O6L7&M7Z]P4PW,-=I6ZD*A+H+$8_W>
M06*86K=474$4TBFK%0K@)X16"0B[[GCDGVLD8NFGSD6H&I .)YT/Y.1%F9]\
M@+3GT<H/K"U#<X4_+82K8P>(AE.O&1BL0\"5<:\&?@EDF%*R*)9;.W52ZJ%2
M?C$EX$^31=US^D#6=C2C8^Q5E3E5QYZV6U3 \X]>/2\K8\9:G4'Q-/M0GM&S
M I-\4E7 9$'.9(,^7ZD-X.T76^XV=?K*D-BT[0ENV_"G 8]8(0JJ/BBK$JHV
M$TBS3F!\X:9,5LSB-!'Q#,TA!KYS+,1#C<13^/#8MK5W'/<8<*=C+5\=.)9'
MA(\Y$"U@(G!%YPF(9AO*<Y#C"9A;R=GDS;.N-62Q&#U-'#/9-F\9H_):E$6F
M.@<6/".O=?&W;37S0"8%JU1M,,(!VBF%3M\(XO$;SCVJ=29L!L2^ M@1+58:
MJF\=/%' 6$2(J#0>F&MTTRFMBX]@5@B"/SX9^_V5F"S($B+0\%Q.C**8&BL)
ME<W+&%$6G5+4E7"?LN8M%"0EAR618RS9<CB;@**$A5 /)V(0#%X),/C)O%<;
M'ZYMTLWF*>9'D+N.;+:*Q-.[6K8R-;%VM4XS&0KPNOU].X85S,WX"C.M6R$Z
MK&@]CJ*S,12#(ZO=2QOA!*5D\^! 4ZYW=5K@,@BE=G!Z&5B"3[:I0RP2Y=;F
M>DFL3Q:;U!J<0N%;(&1\Q\<',R!^FVGL@_4QV$Q36*U9@3<HS1);'(@G:,PQ
MB>.T7@3LLK$AD> YQ:9!QGV)])6FX=M([W)TZ>,RN6?(AC3L42U</8%6NLY*
M]TI*)=RP-7;+BQP[-6)[02S!5M3#E#.]*W L>M)Y8I::I6[)7-N6'*'H5')U
M,L#H(R 7EV8S8AI4Z0CC8@1M1^K2JE-D038\QE1CL[';BQ*#Q1YANP&,!S -
MCP[M*T.P,MN<AQ (,QB@\Y%?J3QL1:0IC_E\G>4MBUJVB&]@36+&0QU&_2U)
M<X9"Q-C'6:F'KBLDOVKH+%LT #J1>YCR8TLQ6PV=[7QH1&/%V+JUH%3&2"5D
MK&P1*LZY&;7#C7Q5?>)V:C3K  K4TJ$8AVB2SZU7B=KJZ3X4M(%&X;-@&N1Q
MTQ3CR&;AT_;L$: 3U"?WPE DXD,T VH!*:(R/(#/PF@ _4E'$@I.*;2G'9G?
M7N])&&QM>=B]0S5=WP=?4=4$Z]*1[^(-=I4"V*D1Y"<.LI'R./:[5LDK6Q0N
M E )7E)HRE0-L![\UL)* 5EJQ75]NE4NY +,R$44'E6:K6KO%>8=K)VRAY\
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MEJ]63:(<NEWR/8@.O=N[#' #4$,!E6(=IA0ABT,04RS;DV&Q+DFHF:^<(#F
M%C'LS"U>(EH*(CDW$#!'.X)1LU'"6YCJ<S#D4L0SR76."4N$31D\8BEUPH3<
MP9O$9H#GQM#<R/2#C\>V0$7%Y>%VGA=2YH-.T*K3)=!I=ZT,A 3$MR*.)26A
M]BMF!"G># MFD>R&(Y%_EKJII<2/48YL,?9L)R'K1VPAA#E9+S*?(V@^Q$ N
M$A4:S+/E!K;DF.2*2ZL)L:P%=E,'; T,@-3G8A\#9E*PXB"<(I76"4C''&PU
M%I2*T"2#U(YNT7A")R!8IHN(+DF\&E6/2'BQ#QD+=6Y&[<%@97:M9Z%DF,GJ
M"<!4Y'KCOO<L :4X'L$Q]:\]*D2%R[&N&)9"P[V]B5GW)H 72,FFM;7^;NL<
M2*RX%84$N.=?AGT0IH1_UN9:H<9@["ENPI;D4-#-#T)ELXFP'XKSV5L5 &-R
MT[3">[4CC)P'&9V+6[61GE L>&()2<4HM*+2)(4WX7X9M)FU9ZOL7]4:,KXE
M[4<%F3:J!8L%#0>KD_@:H1A%J38I<@*$+822$20ZHK068D6**8Y2U'J/W+=-
M9[&0+.W UIO5%CUW!A4+<T>H@+1KH3NV><L,%\+NP@5"')=3KF8.:._5YJ7:
MH').RK7%)6E$MH8U!V,-C:MVDY!5Q9*^&Y*5O&RL%!<)BX"#-B8R RB:P?B[
M4QX.U@D&C7D,'#UCSYVN-497 YQJ]S)VM,:=O800L-J@>-IY#"5]5FM7A3J:
MK-8J6RXZCU/P3/'%C+'5;$BY$1\@Q8UHBF8QU&TX :.5\D'M"I];V9I_5):3
M C!9 WX0[L77V*>3A/N'6)4FNHEV4;'*RE0VBD3.7G6@\IAKTJN:/#62B$:!
M <!J61OC:<B1GU.,8KV829A/&)N$,W''B<<N3.2+OLO4V=;XRG;N4CUK[FH9
MW36GK) CJS!VW53TH8PXI2MP(2DQ+X(6"=5&P+>4HUB0CQ/IKG6-K8<\B5::
MWL"ET]5KVY15[$L8VLYIL>YZ31=9-VKTIP';35ACR,#->7 J$(NUY((S&#/1
M8I7VNZP,=V&TY=FW" U2S9[/C[34PS/VF5;)]F:J:+%KB"[<=RL,L&-UHY%:
M4A]6SS;ERZ3L$"3$R%',XO&/D=2XA\U=!0^#(932C94F5I3E4R-J["?483)V
M*AI4FJ6H59C'8[3* )>Y_JSHK#)!2:G?Y<J!=-945N&,C4XL@F5VW-6*ILD6
M;&7675I4-PRT^)-,Y/-&*Y*:P^<$P1TJ#.E5;3]IWA_/J1C.M=M/(DK(W@/'
MQ8EEB"G6B>,F$[$&_5.,T7=A$G.,XQRSZ1\1")G;'9DI!97 XB(JX\998]C4
MAGK8N=>V#*$QY!2M1G7M1[9&S1)%I6ZX0D"4GZ"ZA0C9ZXPS\;8T$^NWZKJ8
MG65B#T&,6"V78="@66#4@<^NGID I);'L%[':IM@M$F((?B&8XLF\)@PT+%Q
M!7%6D&5.86K7[!+H26Y#(&G;F"=@L#"C.$7FXP@B$#2(TA2G!B3D[*FM*L;F
M3%<'FQ7'R6GL=6P%VMAX6:E_-8<-\6-JFHW2AL$B&-F[D"W,A,5:8[,*]B=8
M0F?^I'594O:<&MB:'LVQ727;;[1)-(#CJ>D^)MFN@(ZVG1!-\M=A5=0J743
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MDLF*V.1*<H1N6+.6NL=NK[' 4@BJ5*T 09_9/Z9J[.O)C96;598UUF[-KFV
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M,!N"+,SJ4W"T#!&.O/4AR+L>-JJOPV94>?[/=F6(3'?*#HD0]&>'!&C _+[
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M];FF2Y(ELG9!&&8QU!1'Q$I=,6VV%ZCWH,NZ!\%\U#-AE-B)8P8W49A$M-F
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M@UL!ZT*VJ"H(;7)T-1QQL*>*Z0JNVW:F%FAS>1!&"/I[Q6ZF#-EL:I$2>\9
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MQ'XX^"C&HRNCUZ5\1*9KO(>'5Z<'FTCIX<<H52&EAQ,8!%36+S&EG4B(XJ$
M$$+B[89HZO,(B,+Q-<E$I-GSTWR$,HU#'QN=9,]@D'LLUJQ,<QD+.#GE$76.
M2120KL&,S.\G^*T81Q#Z.0PTW8TF^HM0EPG9AX_&52MBW?#XT%D%FO3K%ACH
M$MM6A7#2K&R<KI0T8,*#];(IR;-LFPRMG$=FDB_33USC7MIZLI.ICB!.OM((
M;'@Z/9[7:X!$/B?M2<IHO-)74^S.7.S/A9A+@-1H4=^&Y)E8*68)1A1@,%>;
M4+]K("ZR97>9;0*]><"<,X[CC"L%X<'!/B:;RD[29H[^=T/5SQ\\>SD<@">H
M=/8K3EMJPZC,&IB+^1R(#U>N ;ALE/E;D3.;K@]4X8P%"8G(21Z5NDQ3+AM*
MYM=*?6J3G[7/UZQFHDN@Z=9@C)]<I8"BQFP^(NWFI*(LD16QK\EN?(G.^T,R
MGF7VH[R(K.G9N2LUJ%9X"A#'B,$4HRD\IP-9-:DY.)W9Y1(:;1>+1;@X6=G=
MGD_<Q>$'B\GJ#*1LV3FU%<I7K8R##$(#4<73Q XU6'")&'.M1!,D3$-+KG)*
M,XPE$<9,_&TL?U..L3[CZK_7+S1X?I1]J[W%]&7L3\;2Q_4XZQ/N/JO]<O'#
M]*/M3B^C+V)^-I8_J<=8GW'U7^N7CA^E'VIQ?1E[$_&TL?U..L3[CZK_ %R\
M</TH^U.+Z,O8GXVEC^IQUB?<?5?ZY>.'Z4?:G%]&7L3\;2Q_4XZQ/N/JO]<O
M'#]*/M3B^C+V)^-I8_J<=8GW'U7^N7CA^E'VIQ?1E[$_&TL?U..L3[CZK_7+
MQP_2C[4XOHR]B?C:6/ZG'6)]Q]5_KEXX?I1]J<7T9>Q/QM+']3CK$^X^J_UR
M\</TH^U.+Z,O8GXVEC^IQUB?<?5?ZY>.'Z4?:G%]&7L3\;2Q_4XZQ/N/JO\
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MF.&<PQ88T2U*EH(<4*GD1S:,.TFOU[%@Q1!L=; HF=\2)0\'0&::Z>^OF8V
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MC!4Q*KQ8/@N1;DN)_P _0SMW;>K_ *[ILWOW?EN^_?X*:A(H:"%# 8:#&&"
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MK?"F,I\&WCQ;;>*W4)UB])EC\B0W4QH>8ZYV\D7\*]'CS5=_D_Z#+-L3,?\
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M>7_R>QK)!\G\'D\O;Z.$XI>;\O3^_P#3P7Y\3WX=B/\ 9- SQ?;]K[$W9U!
MO+_Y/8VUH/D_@\GE[?1VX3B?S_!OT3XH;H21_L=(W<*SC'9.0G6CUK!/)_Y,
M"NH6(E';Z/*G';MC\V.$XI>CR[F?EY=R?%-]*T?_ -S6[K,KO;]I@)X@W7 Q
MZ/\ -A'K6_9G;M]'?O\ P]^$XG\H_<A_2GQ6VJ&/_=74]XCX1/;LEL?XB75F
MZTG&/DQAHILXDVK"?HPM*\8_-PG$_BT7_P#"S>YF7[\66":_V#K?\3"!VQV3
M_P"VKL8OY>WR?_$C!OS9_A<\_?Z>_"<7HC[&3XMTLS_L'B)^)? ^3M_[0]*+
M^7M\G_Q'IPWA7\/I//C/T]^$XOHQ\^Y_R=O9W+\^+RV;'[Y&^*+XDT-6/>G$
MJZ=+!IO&<?)A23/29-<6G\^,N]\^[NK/O[DXF^9'_P W]7NV;T=R_?Q&.IV'
MW]C>+%ULL=L]T>VZ'T26+M^;S^M=*4;TG\/?MC/YN$XF^9'_ ,_]2_/Q/>N>
M/[H/BV;\=1C/Y*#?2_T0$O=^9;D#0P1]?\.<.IS^;MPF\?F-]CR]'F[^GVKY
M*Z3O$&:D-2X_BF%Y4EAI^.Q(.=%?3;-D-QY*X[DAC#P=BNN)9D.1(KDAMI32
M'EQHZUIRIEO*9W?9X[OPN[.[;OL[LSLSNW<[LTI,S][,[[=[JCQ$\XD<4')&
M,X1)M\>,"2A*<(R?>483<8WG%GVD\(.^[PCM]OQ;_$Q8QCU7Q-M?2<X^3)OH
M%H\SS?F\_L;>E<[_ ,/D]'W^CMR.?[;P]OX_@K[Q^;^+K\_ ;XJT/WQ?$(Z8
M"_;Y&S?A[GXOF_-E;H;K+C_+[L9\K*<8]^<8^C!-X_-E]DF_.+IG7GB\PO=&
MZI^@,[C'N_ZZZ,]ZB\KQ_P#B]D=9+N$^;Z>R<XQ]&,\)\3RE]YG_  X6W]JT
MHWIKQ1S^%XLA#PF[MA??SX.=,/4/&]-G/RY<S.WU:\8RK_B[I<]_Y\>[FR*[
M<!MU%NR';NZHY1[>K@FRY5O!8*_Q=NPV,N\7?VO'T[&_IEUP)[[_ &^M0\;Z
M,>M0WY\E^FCP6#KJ^_GE-:EW?4IKF<_+E4X>,-S$9SGOG&?3N93G/?'?/?.>
MB+4FH0\AYO*Q;YKW[4H;?4D64>[T<UYBWT7=&E[=[6@M(DF^^Y&T[B1E??Q<
MH:HB[_\ CY>#K4,]#G6S!SW$],OAL"\I]Z,T;JMZ]=293_\ 833M<OHC^_WI
MPW^2GMCW9[<V/XLU _\ B7HG_P#>J="WOY;]IJEW].^_>_>N:W0YT;0_W;3Y
M<?XQ^"<UG\1P>B'P7EZC0;;NX6BS/W1Y,L!:^DGQ/I]8L58%4?48>$>"DPV6
M*GXK76U*%LMDH3\-2G >R.E^RCYL=.'O^D0I.<M2V?/%=<]$XI7,]?5=L1PG
M-C<#9D$HR;SPF.#-WA-IML6M7#*$N7*3?)?:3,[LM+)=#V$MX^]CZ6JND;%"
MN5+%7A#KK4EVO")Q3%\:IE,G=$8;-+XPI;,2&XY29I.Z@CI\Z%/%+Z4W[8QK
M^I BD&U(!/R7-;]; #4T=<T:S,2^DI6KYT9;O&&5L.2U-###$ROS,Q/3-2H>
M,/I;C^BU/KNCF35>JP5&T&N+=R96!Y'8A8P<@Q/3M5W@*$FVWD0C%DS3:$&9
MN+YCT4?[/F>T/1RW;>D34&(NY&YLU;2!,=#'SJU)F'4LVXYS$Y*)K=@<V)PB
MKUWJ#DX)&LN^X[+_ /[ZD;C_ *'K.Y+PG.>V,=8?1];/=C/?'Y5AZ%ZDISZ<
M?EJ:SGW=_+CW<\O\,XN7^)I;$]__  K>:%[&;)R9O8^R^MOH75@O]UZ7M9Q;
MP:WAM"7'\^;RTJ)W\N_\.;/AMXW4+M_^P^Z3^WR]MI]!YG*NW_\ I-=87A7_
M .1G_P O?W/A3 O\K2X6_P#99?)Q^W^:0W=]J-I+I!@_\OI:N$;_ /JM%Z7)
MW?\ NM>EW^/=Z%^?AG\;@?[U]*]V(83^9'0F8RK./X6>L^AJ5C/_ -IG/YO+
M\F(?(:;EWZ=MQ](L[-MO4Q<>;]O[)_AOI/A_A])V'(_AVOH\"3P[G>KJ6GON
M_BT6Y>"_<=67C*!O]OZ%+T5PGOYO+KOIAGY5V^C'P>\2UK&>^<?*C'O[^[O[
ML<GM.E)?*Q.;%_[/,TR;?_$Q#;^W\.2CX*Z7A?X>L] V]N[M6A<[7W]?9M:2
MV^QG3/7]XJ@_W$_#;V[+4GY<PM/Z[;;SV^7\H3UZVUS&._R90R[G./?Y?S1Q
M:2?_ (.HA_\ YG&&_#L@/?\ ZSU'3+#_ /B'1A9;Q_[*U72W]3/F+SM]K/MW
M\_'\^,M\1R#_ +?X86ZW^V.ZO+K>TQ\Y_@Q\'+7?TXSCZ?(IW\R<JY/#I)_^
M-J,?_P"5QA?_ /K#ZO!0Y.F6#NW8NC"SMW?]K:KI;MZWPEYHOW^?ES5>>H;Q
M'?$FN@:JPZGTC;RZ8D";C6Y)"S2]6[)E_#0Q+*QXU6I,6;:*,*'>IE3&&XI&
MNQVR$NUKECP^'<PG9XXC['1^)T1>->:Q<LV9PID>-?*A!0B,/!)[%D4@6[$"
M%!!N)IN0<J\>(S0D\6(/XATUZOZ?-/T=/OC<+B<:$^9K1+D='7K^HRV;O7"C
MC<5<#?PV,-5JW[$NKD.-6P/(3ZNE.P-IRK6^HG3SXC:]DMZLI6T^E?K5UGMJ
MXOA*[97B/1AU+"M1@K.0DI@.SYFR#^O88&O57+N4399>P$&1@..ZXU),SHT3
MVK*^;Y"%(5ZT/'F+8HP/.-4Y1]60H6?XDI0\-V[I.T'DS-*0Q.[CC^HM.&SE
MK 8FUJ2E4QN>/0KERV/I6>U5JMR4&<PA%DS;M%W;B&TS1#-Y!A9M1&UDM4/'
MT_<$TA]KTW^QAKF$'RW^J_O9=:?<WK_)UTB\/KYDW3%]D-4_J?,<_ER^M+WN
MK1[F]3>Y7$Y52G")PBYH^#A_NONB?[$07]>)\*T_ER^M+WNNEW"JG")PBQA@
M*(L Z2(.C(!@7,1EN4/)1&)L-]'T8<CR$.-*RG/Y2593YD*QA2,X5C&<:&3Q
M6,S5(^-R^/IY3'V8\%BE?K"MU31\&($\)CD[/SB[QXHR9I1=I,SK:I7KN-LB
MNX^W8HVP2X@V:IB ..7G HI1FV_<[,^SMNSL[.[*)/P>W"C?L^J;)AT0W^5G
M75YDS2E?PWCO^P5VQ=Y-@K&<8[X8C.*-!T+SC"1T=O'?'S7^"M3:1_F]'6=Z
MW&#Y_P #ZNL6\AA8C;;<.#SG]XS> =HL[! 666Q<)R9HT0P;=O:?Q+A-0?$U
MABWA=GR_B?3X:]3)O)]OYF4QG\G&9?GS(6+4+TF9WE:+)]GRP3;89\E'K=R'
M$-=6Z0KT<<+:,L(@%W<=L*^#-FCK6"L+>59QAMJ+*:)Y_P#G#&,XRG'1Q/25
MBS7P8+5-&YH?4IWZL&*U X8T\D1MF?X SX92P^;@\I,T!U[ [_/^;0"[/%M*
M_HR\.J7*8.S6U/AA1XRWL1UDK%*#\V^%L41HY'&29OE3,&=3_N[9&YJ6.?2%
MXY.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3.,9]V<=\?FSPBQ<P(%(XRD@(%SD
MYQVSB8/B2L9Q^;.'V5XSC^#/"+49VH]4D_-[2UCKTAYN_F]>I=;E^;O\OF].
M-<[]_I[\(M1F],?383\WM+I[T<0\W?S>NZGH4OS=_E\WIP#G?O\ 3W[]^%.[
M^;^7?X>2T^=T1=%Q/O[2Z0^E\AYO>KU[06J9?FSGY<Y]/4W._P#Z\)N_F_M=
M:A.\.#P\2??)#H.Z,YN5>]2I73!I)Y6>_P"=3E(4K/\ ZYX4\4F[I2;[76H3
M?"E\,N?W]/T ]'[??OW]2Z>]7C?E_-[.K47R_P 'E[=OH[<)QS^=+[S_ *K5
MI'@[>%S(5Y_Q%>G2*OOG/F&4 >(5C.?I3D7F'E.?S93V[?1VX3CE\YW]?/WK
MS_$Z^&DC_9.E"E"_HQ[$L.PP/EQ]&$>QKC \G;Z/)Y>WT=N$XY>;^'X>7E]B
M\D[P</#H(178,C0YY$)_",/0X6_^I09%<PTXAYKS1QVX(C6?1/-MNM_D?L;B
M$K1V4G&<7&0@9Q((DQ$COPS'.4)QW9XOPRB[.V\7=GV?FS[/R6"R"O=!.M<K
M@MUB</65[(!6 $X)1G#C$6$QRX9QC./%%^&<8R;:3,[>KXHKH@:]X^O]0X97
M_"H)UR]<8OR9Q\F4(B=1;;2>W;';'H_+CMV[=N46?CEZ/NQ\MO+R4S&([<3K
MRT]%9])Z&-TA;TCM>E==D.^C9VUT\MH](^^MQ]YSRIQYW7G%NN*[K<6I:LJS
M9OD2^M'W35/%O4_OBKE<JI5._#[^97TV_9>#_ID<F7>_K?WHK26"V5:IQVI5
MJLH"M17\OX8DGS X.P]ZJRJ3)]$\1D1VW/5HR%R)'D5GT#"%O.^1M*E8A%\Y
MURJ R>,%DK57!Y,TF*L..FG!D6<51.E-P8*QL1^4V_.1,FO,PXBHS;J9,MUJ
M.SE;SB$9(MDX1<T>BOYX7BU_I8:-_P"1+I=X5I=T/JO_ ,\ETNX54X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?F
M<8S[LXQG'?&??CO[\9QG&?\ QQG&,XS]&<8SCW\)^_9W+]X1<&?'T_<$TA]K
MTW^QAKF8'RW^J_O94GW-Z_R==(O#Z^9-TQ?9#5/ZGS'/Y<OK2][JT>YO4WN6
M@=3NWKEKO9CHUDR5'T\A1-?+'W*OR9[@70-N(;$L0V7?]Y!1L=[,_7%\$H@"
M*[,+LD@L8K0K-!GQZX*)&KD),V_AOS[O/EW-ZOS]3/#O^3OZ&9]W]/-FVV;\
MUXYNYKVW!.;208))=$]<]>Z>X]12^OV&YK:9M"M:)F#\A^WJ[Q25-,S=GQSR
MT>WL$LPQ:"B:JU@,J=F[O.+RW]+,[^7HVV[OM3GW[^.WHVY;^/AXOYL[=RG7
MJ(ZIJQTVNU)JQZHZF-FYN+9QR&OIZZ<ML[\:#8 J$I?3;'-85JPHJSA#)AG(
M1!K,11I,,LH?A_ J;Z&BR-'??G%MO-V;V;JM'@V+PYX771(YA*TX<T< 7A+B
M%-N)PJ:25A*VUXPI"\=^RD*QA25=TYQC.,\)/Y4OK/[W73'A53A$X1.$3A%B
M3@$)91L@/81(\T*E)\L@>3B,38KO;OY599?0M&'$9SYFW4XPXTO&%MJ2O&%8
MYN6P^*SU ^+S6.I97'68\)Z5^L*U7)W[2<1HSBTX._$,D68@Y;3'*,F9VW*&
M1OXJT*]C;EFA<"^XK-0Q &AYLTQRC+AEW3@[O&<=XR9XN[+G?U(WLGHYZ%0=
M9WVQLI*QV"DZO$)2#::=$C38\@6V#.S_ $IR T15%=;<"2YA",@:E66TQ6)C
M*'?Q)TZ:PO\ 1(6IHW06L<X*.0"'(6\)<LME6TO6KVPGQX\3F+;DR],5Z5<@
MYXFS:N@C0C)X-7#9%$GZ:Z+=.5.D"%C4>J].8LG9"$J5\E6"]!\X<H""MSR&
M.KM#'V)U6+&<;X 52RM.S2<Q DE"Q&M^H,]>*D.M6=36F>/>R[#F3Z>3K)]+
M).%G#4UMX-+,!SL3&5]I+3&8,ISU5^.MMR0EQ#B_MVA>FG,:MTW2U$_1OJ&[
M2*\ZMFYIC(8',L*_5>([8RXNSD\9EZV\G8XP]DL3[.8,X3-&<22^9:IZ-<=I
M_,VL.VLL16M":)PULW4RV.<E4[/,$AW@TKN.-\7<4B=H"SF&6,H">+Q;>\;W
MUY&SA%ADV"EO]\86U=*A:*VVWWSC&,J($!+8G*<YSV\[9!:,X_*PKRYPK/KV
MZ8-$@=H9JQFM*FWVD/56F=08&$/2]V[CH8UX]_QH791Y;[\.SOYU^CS4Q?C8
MT6-SH^?#/ YK$Y64MMWV:M5N3N,^S?)E6C+PVWY+?0=TI]F2E5<M=</85CNG
M <V-)*^3OVRB')>4G./^)*L84GMG&<8SC//8XG56F,^T7P>HL'F.)MV;&9:C
M>EW;\XUCEDSLS\V=F=O%F7G<A@LWB7=LIA\ICG9W9^W4+55N3[;LYQ09VW[G
M9W9_!WW6S<[ZY2<(G")PB<(G")PB<(G")PBK5U<;,O>H='&+WKP/.*EH%VT\
M'L$L8#D68C3M9V[<-$J.W]F0J]%BSG3$K5>JSEQV*Q#<'DH7I:PAXF-(BV9D
M)\I;;Q?;D_MV?9OM?9E0_476#M?>?4U;.E&J7QJ*'J1SJH* ^H,;6ZJ1F; J
M6I*5T5%*7%B090-=*GI@6_K-GA;.:KX&"P8B:;'Y&/PW+04DI*VS,S/MX-RW
M\]_?MOXLV_-837O7;OW8^E*;U'G PS4E4L>C]$7>L"2E6DR-:6^P['U%-N6R
M+-8-G&%,PQM(J=YGB:B#&AK$*L])K=5NFY=B#[-KA24@RAV9G=N_F_K[]F9N
M7V]WHY/W]0M-[$!W;686P-6LK9<!P82-9+?:*28UA,,3_@F#L4BSS*I8P]?>
M 1#HHQ LK<9$!F"/BDTP\9:<AR&&"AVV^WR??]50OI^\1BK66=U@S=PVVAQZ
MGI2F#NJN@EJ//C''OQ/[/4"$P:NRCQ4HC+_"K2K'0KM%V)6FENSA<BP4N*W&
M0DT,0^4O%^7)^;[>7/T;^AV[_2M%V+U?=1=>ZBS-1@!;2, P]\]&-1@:JDP-
M/3+).K.ZM>[S-W8!&L6"C@AF00+4:NYS.)7&-(!DQAJ,,+/ I$240)MR;T\7
MGX=V_?X^7@K%UGQ$-;W&'3':MJ;?MG*'4T=RZURIZ]3<3>I6+QM^[Z.:EWA%
M2+&QSL*M7?6]YFVJ56R)UD;2*P3N451 ?F"U-*-O2WH]/+?E]CMW[=Z_M[K<
MU_> E8.TR7?Q8Q'4[JW0QZ17(^JS)0?<;7L0G09NOMFUFPV&19->*C$X,-5U
M'N!!^P H&R5DQ7&I&9T_(PFS_AO]FV_?W>CUK%V_Q*M,4O7\7:A&E[/(4&SZ
M@VYO#5YX+ ILM.T:/I68(3<E5^-*ND!P.9DU\W!O=9$VY0!T[3,3)#:X]E&D
MJO$)MS9N6[NS>K?S_/R\5:32V\!FYG]MBV:A;:+9=*;4?U'>JU<55=^?$L*M
M?:]VJ)F09].LMK D!1B@[3I1EAZ.75(B29\P5.C1YHY].2.VWIW_ .GCZE-W
M"A4[L/S^]3?HD[Y_O=Z>^6;Y$OK1]TU'BWJ?WQ5Q.54JG?A]_,KZ;?LO!_TR
M.3+O?UO[T6K]7,6T2;OJ_.O+F-UKL./KO>RQUPN<B&QK@Y55M:WQ:M6'')L:
M0B!9;9*17;96+%%P[,JT/7=C-+$V(4P5"3);N?=MVW;DW?X_OT^CO57[V[FY
M/W^7CZ/WXMNRJ\77)GZ9ZJXL.L&:2>V;TS=-B.G:A&)#ZK8+8EZJ6%UW2@ST
MS*9TX_2]S2RL>6EG"IHPY/CE)R(RRL=UZS=\?1)^+P\=WW];*/!^?>S.WGS;
M9N3-NS[^7V>*Z9;>9WJO6TYK0,_5$3;V%AL"YNY!EN*Z[]$F;%^$&20^CE0E
MC6^Z-Q-P)S$(,M-$%1ERT.QDNM*QJZY\>&P"W@.W'XCM@Z@5:XF7V[=3.N#3
MAS4$"SC=8G8('I@TOK[$FI1;B2,61IH:0I9  :P2)25*L@@P]#R@:["1CB87
M46&U$V3EAKX;\</EKF#R+A=W:MDZ'5]JJR=V;>0^MA\:.\)-+>,G;FNIE,1D
M<1V!LC5)5?(8ZODZ;%VW-2MR*X#MMW-/@E\5V:4=OC,RZQ<[:Y:<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(N?'6'U!;"U#
M=!@*!85:LU_+Z;>HK90_;$JL0[$!G[RUN]KMW7.K#THH+*"QH\Y7#-[LSU>;
MR%MM^;KRXE+L@EVMFV"12S;^GFW+?;OY>_;\U6G6O7ON'8>OA'41/%HJ-=QU
MA='?2^3TD\)'NJ:$=1]2Z;0UJ.DS$J#\*F+C5-J=2+Q,?B&4C@ET?7XR!, .
M%#)<KPIV;N]#OOZM_+?OV^QW[_!2!2NJ?=,<GHR'NHX1UQ9]LO5&QW35ZM/%
MY5IIITBB_6"1H#7PF*(G6^TD$CPP@&3N\H!9 =LKNO.H7;%,N=4KU!D00I-N
M_;WMX^/AM]OB[-LNI8<N//B!1X1(];%&QL$N,E>B?C^LCR45J9"D>@E-,R6?
M31GFG/12&6GV_-Y'6FW$J1@JK)<(N#/CZ?N":0^UZ;_8PUS,#Y;_ %7][*D^
MYO7^3KI%X?7S)NF+[(:I_4^8Y_+E]:7O=6CW-ZF]RF>Z:2I%\(6B>;;*(;OM
M,@:[V$-@SDL#+W2!DL_+@5RP1W8\AQN,Q\*[3$S-"/!RT@?8"$"41?BXB-18
MW?EZ'=V];[<_P;V([;_GZ6\E_;FE*&[8G+"J',]&_>HFT9%>Q+QBMR-D0 S
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M1$&P7%)SG"7D9SG//G4^BG#8^4C:,R^H-!6'DY&#IW(//!S*[N[.?3&6AD<
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M*[ S4\W>FG$RW,17Y.71,3I<ASQ\Z5"?D0,UJ 2'-2G&&74X>S;@?[>_;O\
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M];Z6.5WV:N^;QX;6_D]2P<5EGWY;.)G9^7>M"YHG6&/9Y6],YP0VY]=\&6R
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MV8K$PT6(D'/327>STMS"/(WA"$E:3N[0W??XOC]:2Z[\*J<(G"*N%WZ7-=;
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MH=)B8@O1VWQS<+*6T-E/$_F[>IW6)KWA^=-E;MUMM4*NV=;=H':^'Q@2]A[
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MX3@G\V7W7_1/C>O"\^OMTM?ROU+_ %#A."?S9?=?]$^-Z\+SZ^W2U_*_4O\
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M'PBC>5N/44*5/@S=I:ZB311&FB"<.5=:W'E#BNQ3"Z]KX9.CNDD.Q"%Z/MN
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ME&D-AV<7#EC4RK45O[@G\V7W7_11Q-YM[6]/ZJ+$6CI4(Y%DYW6+I 44&(Z
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,4F[.W)V?GY^M?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g428534g04a04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g04a04.jpg
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MG4^AXMAM;.57#L1A3A4JV_M=6,+BA*%2%6VN::2JT9Q]I"C7C5H4MJAP)]#
M
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MT9NM2I5Y4:JHU)PC"HZ<U!O5>6='B/;
M                                                   *XV=[ALOE
M='ZD_&X;WW?-&)[EW_)F8H?O3B?B>_:+P2?O/P^"+#W5X_%DO&30
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MM2C2QFC:4KUO-92L*UW3DGG&<D>K=Z#:2VU&=W;V,<8P^&UXC@%S;XY9J/\
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MBE"M0JTZ]&I'6IU:,XU*52+W2A4@Y1E'MBVCZQD\@
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MW4+G^@/VW;@G^D<*W&"WY<^?_P 'XQYRY?)ET?=+^KH]+F/DWV>3W8]HZ_\
M>,X^4[:+YG[,_:1->_T?=)<,M_\ S:H5?_(Q2MGX9C'&)&%QS<<.7&"VY>?&
M>'>W/,_\(P[[G_Z>8?9V;]W&='9?[XMX?^8H?KO0_:907OZ$=)</_!6(U?\
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MV8R^U@[SGES[.ES^#]@?:"GUZ/Z.O_\ !74?R7T1^SBY7N=(_27#_?F%5/\
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MR;'6FS<AE?(5L6S>ZD1%(N3Y2\'/.26.-;EQC/2-'6=LFB3F8J.<%R4W2YZ
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M.XT9
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M !,_K6X(/XG)7^7'?8U'=/\ "OSQ(]\>_P"3-P!DH
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MFFLTUM33W-/K3.'::;3636QI[T^#.10
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ML[W#9?*Z/U)^-PWON^:,3W+O^3,Q0_>G$_$]^T7@D_>?A\$6'NKQ^+)>,F@
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M>;^]'BVN21E[UM>_=LX/LS/208-
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MZL4O8GL!2X)C7852:<0<1 1+B1Q&1S5-TX8PT<BX5(9;Q8ASFY@WFV^+S+)
M@   5QL[W#9?*Z/U)^-PWON^:,3W+O\ DS,4/WIQ/Q/?M%X)/WGX?!%A[J\?
MBR7C)H           #3_ (F?UK<$'\3DK_+COL:CNG^%?GB1[X]_R9N ,E
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MM:M6&WJ^\=6O<-Q'#:GL<1L+W#ZVU>RO;6O:U,UO6I7ITY;.O9L,N.3/2
M                                        "N-G>X;+Y71^I/QN&]]W
MS1B>Y=_R9F*'[TXGXGOVB\$G[S\/@BP]U>/Q9+QDT           !I_Q,_K6
MX(/XG)7^7'?8U'=/\*_/$CWQ[_DS< 9*
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M:W!!_$Y*_P N.^QJ.Z?X5^>)'OCW_)FX R4
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M?UK<$'\3DK_+COL:CNG^%?GB1[X]_P F;@#)0
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MM8C@V+X1/V6*X7B&&U,VM2^L[BTDVOY57IT];BG'--;4VB0#FCC0
M           "N-G>X;+Y71^I/QN&]]WS1B>Y=_R9F*'[TXGXGOVB\$G[S\/@
MBP]U>/Q9+QDT           !I_Q,_K6X(/XG)7^7'?8U'=/\*_/$CWQ[_DS<
M 9*
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M.^QJ.Z?X5^>)'OCW_)FX R4
M                                                     Q$Q7X&P
MM\M)^$B)QIG&<9;2\:SDF_(WZ6/ O45D^1OA_-[?A'&XG@V#XU0=MC.%8;BU
MLTT[?$[&UOZ.3W_U5U2JPV]?W=I[MEB6(X;5]MAU_>V%99-5;*ZKVM7-;G[2
MA4ISV=6W85J?1>OVYS+5M">HKG)LFPM1;//5A$N<YYYQF*8/RP2I<Y[<D7BU
M29Q^;DN2YSC/0Y=$6AE"4JN!4<8T0KRDY>UT0Q_&, I)MYM/#;.\6#U(Y[7"
MKAU2#RR<6LT^TQZ0=)*L53Q2KA^D-)+)PTAPG#L6J/)9)J]N;=XC"26Z5.\A
M);T\]IUZE;3AL<ZYMP\LBGVI1^PZC$3>#XQ_LE)>L*4^1QC.?]LL5XIC]AA/
MLKTA87MP/I)GB5&GE[.RTVT;PW%E))_NYXG@%31B^R>[VM57519;5)YLKQ[1
M&^_Z3T,C95)^_<Z,XU>X?D_YXV6+0QRUV?Z.#HP?%'/6/=$-^;+ZXK=K1+VY
M>4>Y%8NS%QGM_P"1+C'Q2!#\N9N@6QKX\Q"G/G//#Z\Z5,+V8EH+@6D5);97
M6B6E,;2XE%;\L*TGLL.I1FUFU".-UEGE%3;VCZKT%OMMEI1BF#S>Q4=(,#=Q
M13>[_E^!W-Y4E%/)-O"Z;WR:2V#V:Z\Q[+76M@TC..PRUBI<NO&D-C]+!IRM
MIV"#*4O+.<J'D2)X+CI9-C&<!^U;!+/9I'@6FFB>6QU<;T5Q.M8J2]Y/%L"A
MC6$I+>YSOHPU?O:R0^P>)W.?U-BFC6/]:AAF.V5*Z<>IK#\5GAN(-O=JQM92
MSV),ET!L>@6KH%KETJ\RJ?.,8;1\Y'.'A39\Q%&17'C:1_\ PU42'_[H[+@V
MG.AFD.K' ]*M'\4J3V*A9XO8UKI-_P ,[6-?Z33GL]RI2C/L.%Q+1?23!\WB
MF XO802S]K<X?=4J#2VZT:\J7L9QR_BA.2[2:#M1P1C5YB*;2D?".)!JC+2K
M=^[C8]18I'3UM&9:XD%FR6<X,J5IXZURMT>>2E5P;EDI3Y+Z%;$\.M\0LL*K
MWEO2Q+$:%Y<V-E.I&-Q=T,/=NKVI0IMZU2-M]*MW5U<W%55++)2:]JG97=6T
MN;^G;5IV=G5MZ-U<Q@W1H5;M5G;0JS2R@ZWL*WL\]C<&L\VD\D/?/5  KC9W
MN&R^5T?J3\;AO?=\T8GN7?\ )F8H?O3B?B>_:+P2?O/P^"+#W5X_%DO&314^
M]7J$=J#8+U>1D(?+>N.S-9F,GG-6<0TD8R9(F96LK9XPS QD3)F:2$S+N72<
M='Q#9\ZE<*QB3M%2K>L_'/AU_KD1[GO\-_Q7Q-1[=7-Z%N#:8A]@7F'FH>NL
M6DO/52%H5SF[5KDTA(.6"\]0I&.3J.TV%<DWTVLQLU":ZTV= ^5_)9]<7!K8
MV3R0J:ZTLL]VW?W[UGLW['D]JR)M3W_#/)<5U[WNR>U;&;QT%G'1U%ID=$/Y
M.4BXZJU^/CI*;:*,)F09,HEHU:O9=BJPBE64HY12(M(-%(N-4;.SK(G8,S$R
MW3R][^6[P-&:FG#]I#RSJ*:E>RC:,?N(UD;.<%=OT6JJC-J;.,ES@KAP5-+.
M<&+GD?/+.,]H \;-8V;=NKN&+ATL],M*.P9_BO:7Y&\Q*M:0:W9+=5_U+LS:
M2=X86-HZ\K.Y:IV6FFJEC8SQ)%JE"LF+*&;5M&&:LT_(\G)K<HM9/JR32V]6
M33S62\GF8W1SW9K-]>6:W\=_:_2U:I@F:'^2-S1N7E#"=9ROXK_2=1?:IV_K
M]Y1Y=O@/*7D/$EXUV]8LQF%O^4LMA/Y_UMUEX;LRY9:O%;/)^AZHC!H\W-P*
M\01^(GA")LIAIMOKTO$S9^J3BC2UV>W)57&AMZ8A\6-I/PK"$;IGA/&3R68Q
MZY,G*X02:X5:&46+M9:LLL\]59YY9>]$SMSCGEO?7GU/L1Z1C!H
M
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M/^)G]:W!!_$Y*_RX[[&H[I_A7YXD>^/?\F;@#)0
M
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M
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MX]_R9N ,E
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MQWV-1W3_  K\\2/?'O\ DS< 9*
M
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M=/\ "OSQ(]\>_P"3-P!DH
M
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MB<E?Y<=]C4=T_P *_/$CWQ[_ ),W &2@
M
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M^M-=3XGI(,&@
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M\>_Y,W &2@
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MEQWV-1W3_"OSQ(]\>_Y,W &2@
M
M           5QL[W#9?*Z/U)^-PWON^:,3W+O^3,Q0_>G$_$]^T7@D_>?A\$
M6'NKQ^+)>,F@   XQC&,8QC&,8QC&,8QCEC&,=F,8QCLQC&.S&,>8 <@
M #3_ (F?UK<$'\3DK_+COL:CNG^%?GB1[X]_R9N ,E
M
M                             KC9WN&R^5T?J3\;AO?=\T8GN7?\F9BA
M^].)^)[]HO!)^\_#X(L/=7C\62\9-            :?\3/ZUN"#^)R5_EQWV
M-1W3_"OSQ(]\>_Y,W &2@
M
M       5QL[W#9?*Z/U)^-PWON^:,3W+O^3,Q0_>G$_$]^T7@D_>?A\$6'NK
MQ^+)>,F@           -/^)G]:W!!_$Y*_RX[[&H[I_A7YXD>^/?\F;@#)0
M
M                                             *XV=[ALOE='ZD_&
MX;WW?-&)[EW_ "9F*'[TXGXGOVB\$G[S\/@BP]U>/Q9+QDT           !I
M_P 3/ZUN"#^)R5_EQWV-1W3_  K\\2/?'O\ DS< 9*
M
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M,Z02PV?+)-5<D6.4F=I-1DVFDXK)M/)_>CUF6UFEGMS?P9Z*#!H
M
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MR4
M                                                "N-G>X;+Y71^
MI/QN&]]WS1B>Y=_R9F*'[TXGXGOVB\$G[S\/@BP]U>/Q9+QDT
M!I_Q,_K6X(/XG)7^7'?8U'=/\*_/$CWQ[_DS< 9*
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MH_4GXW#>^[YHQ/<N_P"3,Q0_>G$_$]^T7@D_>?A\$6'NKQ^+)>,F@
M    -/\ B9_6MP0?Q.2O\N.^QJ.Z?X5^>)'OCW_)FX R4
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MMP0?Q.2O\N.^QJ.Z?X5^>)'OCW_)FX R4
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M:CNG^%?GB1[X]_R9N ,E
M
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M)R5_EQWV-1W3_"OSQ(]\>_Y,W &2@
M
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M^%?GB1[X]_R9N ,E
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MY!C#2C?*7C$+*2S1)6)8SS<JR*KB!<O4YE!!5-PJQ(@<JF61,T2D"@
M               86P6*#JL8I,V&3:Q4:FX9,_&71\X\.^DWJ$;%QK-$F#N'
MTI+23II&Q48S27?R<DZ:L&#9P[<(HG _*M6FO6^./*UN5;2K)%\^BW1D?")N
M(^6BW!V<I$2C%P1%]%3$8[34:R45)-VLBP<D.@[;(JER3 &?
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M]GK$\DUI**CG,9I992XY9Y]62>[+BWD1[UPSX9]WSV]3R9NB,E
M            U\XLK+<J;PQ;_M>O3.DKK7M17V7KCIB4QW\?),JY(+IRC A,
M&.=]$D(>29$*4^3.6J1?!J<^@:QR<HI[FUGW9D>Y]S*(TFK9M'[!X>] 05AC
M+[IZ_: MUJA'3>O1T5+U&9UPXUSXU8#2D2IRFZ[L/V1O''3FPEE;$K:>G(N+
M-(9D7*>:]N;W-/MVYY\FLN[NRVELR2W9=>SAU9<_\$;]#)0
M        -=^(W7-VOT/K*4U^>*<V+5FYZ/M7%<G)%Q#Q=QC*XG,1LQ6EI=!E
M)>37JL;/.)6#=N(]TR)8(F)*]PW;'5>-JGEGVIHC6>78\]OZV=Y6/",M.66W
M\5>TE6;>+IFR-XQZM+9L)/,Q$R!Z)JV@ZYN%GB),C)@UD6<M;:O)QJDBQ148
MO7U?>+,'LI'Y:2KZRV:JZTMO4]K;2:S?KM[ L]K?7U<./Z6SKZS=89*
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M[!"XQ&0#-PNNX904?AM$,UUUEFS))150QKF^+)DD340H
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ME\KH_4GXW#>^[YHQ/<N_Y,S%#]Z<3\3W[1>"3]Y^'P18>ZO'XLEXR:
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MR3A!0O8=)0IL=F1"F1
M  !7&SO<-E\KH_4GXW#>^[YHQ/<N_P"3,Q0_>G$_$]^T7@D_>?A\$6'NKQ^+
M)>,F@
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M))YMM;FVUXL)9)+L_7$NL0H
M      5QL[W#9?*Z/U)^-PWON^:,3W+O^3,Q0_>G$_$]^T7@D_>?A\$6'NKQ
M^+)>,F@
M           #YE6;1=PU=K-6RSIEE;+)RJ@DHX:9<)^"<9:K'+E1OE=+_)+9
M2,3PJ?YA^D7L 'T@     #YUVC1T9L9TU;N3,W!7;0RZ*:QFKLB:J)'3;*A3
M90<%2762*LEDJA4UE28-@JA\9 ^@
M              5QL[W#9?*Z/U)^-PWON^:,3W+O^3,Q0_>G$_$]^T7@D_>?
MA\$6'NKQ^+)>,F@
M
M                *XV=[ALOE='ZD_&X;WW?-&)[EW_)F8H?O3B?B>_:+P2?
MO/P^"+#W5X_%DO&30
M
M                  %<;.]PV7RNC]2?C<-[[OFC$]R[_DS,4/WIQ/Q/?M%X
M)/WGX?!%A[J\?BR7C)H
M
M                    "N-G>X;+Y71^I/QN&]]WS1B>Y=_R9F*'[TXGXGOV
MB\$G[S\/@BP]U>/Q9+QDT
M
M                      !7&SO<-E\KH_4GXW#>^[YHQ/<N_P"3,Q0_>G$_
M$]^T7@D_>?A\$6'NKQ^+)>,F@
M
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77!L8YX*8V.?+.0R2W)+P&;>]M^)__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g428534g05a05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g05a05.jpg
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M 0$! 0$! 0'_P  1" 'R EX# 1$  A$! Q$!_\0 '@ !  (" P$! 0
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MKBFFFNJ>]'O<)PJ1C.G.,X268SA)2C)<XRBVFOBFT?L(:
M
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M9+7(R41*29&DR(R,C(R,C+F1D9=1D9=9&749#CSL:::RGE/>FN#7,Y
M
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MPTTUQ333[,]?A.%2*G"49PDLQE"2E%KFI)M-=&?J(:
M
M"L-I>U-=YQ/[,\-PXOI]48GP77Z,E^*>YNE\WQ_J#,N+ZOU-1X+HO0D A0
M       "@^*SWKO$E] >XO\ 'F1"QXKJO4DN#Z/T,QPZ>]\T3]#>L/[)HPEQ
M?5^I2Y!                      !X;\?/[)%KB'V[C.V=(3Z+!;3-,DBP]
MW0YJ.Q5?:;W2<F;,I(+!-E*R0FFE1[NC:<C(R2P?A6IR8,U5Y83?3]E/: ](
MT^O8:I"K=4[:A*6F2COJ>*.%&RJS>?#1R\TJK4G1@I4_#./NH1_DSVQ?R;X;
M;;2V&T>RE:TTBXU2^ITMK*55>&@Z4\NKKUK2AA5+]1BX75I%PC?5ITKASI57
M=UJOHM@/ WPI8#KG%]9HT5J[+:C&*QN FUSO L2RW(KF4I2GI]S=7%S32I,J
MSLICK\M]:%-1XYNE%KX\.!'BQ6.GW>U&O7=Y7O?TI?6]2O/QNG:W=Q;T:<5A
M0I4Z=.JHQIPBE%)Y;QXIN4Y2D_;=&]DWL[T?0]/T&.R.S^HVUA;QHJXU?1]-
MU*]NJCS*M=75S=6M2=6XKU93JS:<80<O=T84J,*=.'5?X">#YQU;\'0^'8V^
ML^D;V$N7>!.DKGS)3;F%6U MHR,_8FVI!I^#ER&H[5[1)8EJMS67*Z5*[7S5
MU3K)_/)B7L?]FCDY4=D-,L)//WM*=UH\DWQ:EI5S9N+Y.+37E@_+P)-5P/<A
MGG$I@">KHM8GQ0;V3$29>+_H^_SJ_KE)+JY-.1%LER(NQ\NH7]9K^?\ K%KH
MUW\;C0]*<O\ ;I6M*>_FI9^)C^:G9ZC_ -V:OMUHR\HZ=M]M=[I=*%[J][0P
MO*+I./\ ='@LYS6<EXIQE<5-,ZC_ &35Y<:CS^"G^1.,YMJ*XG/E_P#FV9F9
M>,S/K)^G;6I_K&S>@U$^+I4]0M)?)VVH4X1^4/B'[/M6H;].]I_M"M9+]F-U
M<[-:Q17^*.J[-7567SK_  '[G>+FN/G3\9D"UZ/\",]X;L#N.R<O$3SF#9+K
M3K5XE*9;:(O&E!>(WZ1V?G_6;-SIY_\ A-:NZ>.GVJA>]GGJ/U9]I%#_ %7V
MGT;C'!:QL/I%UXERG+2;_0N/FXJ/P0[F<?%5R0SF7"5FK:.1$NPP#;NOI;Y%
M\+KL'8.P8K2U%\+4%24GS,D*+D0>/92IOE;;06V?*%WI]W%=%.TM)/YSW\-W
M$OV?VPV^Z.I^SC54N$JVC;2:+4E_B='6=:IQ;YQI86<X>,-W\\<=+[&UX>=
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M5&YMZL9T;BC/$Z56$H/AEV0/B.=
M                    "L-I>U-=YQ/[,\-PXOI]48GP77Z,E^*>YNE\WQ_J
M#,N+ZOU-1X+HO0D A0         "@^*SWKO$E] >XO\ 'F1"QXKJO4DN#Z/T
M,QPZ>]\T3]#>L/[)HPEQ?5^I2Y!
M        1^ZQ+%<E0;>18SC]^VI/1-NZIJVU0:?%T31.C/I-/+X#+D/VI7%>
MB\T:]:D^=*I.F^\)(^*[TW3K]>&^L+*\CC'AN[6A<+'+%:G-8^!2U]PA\*F4
M=-5]PVZ+LGG.?2E/:JPA$[KYF9IGLTC4U!F9F?-#Z3YF9\^8Y*EM#KU#'NM:
MU6"7"*O[KP?[#JN+^:.KWGLV]GFH9=[L-LE<2?&I/9[256^5:-I&JNJFB#^
M1PH,'SIM7/XB9?P'@6P=GZ^[$?C(V4X1FE EGD?61-I2DC+Q#ZOUKU]K%2^5
MPLYQ=VEC>9Z_:K:JW\SB?YG_ &=Q_P!6T">F\GH^M:_HWA_P?HK5+-0X<(I+
MX''@9XK!Y%B^\>+/#VD_[&-6<26R;Z&P1<^1-0L_L\RB$E/5R2MA:3Y$2B47
M,C?K)7E_7Z7H%P_.531;*E)]9VD+:7XH?S7Z?1W:?M9[1M-BOV84-N==O:</
M\-+6;C5*?R<'\=QR7#9N.H]R/&YQ"1$%XF,TQO0.?L=7B2;L_3]99&CX#/ND
M3QES,WNE[(GZ:TZI_K&S.D2^-M6U:T?:&HS@G_Z,? GZC;3VW_=OM6VTIKRA
MJECL=K,./!RK;-6]PTN'^L>+^]D_G-_:Y<+_ !%:[V96;LV;L.UW?A>80J[&
MX&?.8_#QMG#[.L8=-C"IN-TSKU+C\24VF3;T\FN*-$O);]T^\PFV;FN2O8?9
M_KFCWEE/3+*SIZ9<V\IUI6BK2K.XIS:S<QK5$JM:47BG54\RI15))^[<5'^(
M?Y2>P&V^BZ];[5Z]K=QM9I6I4J%C1UAV5.QAI=>A"7@TJK8VLIVMG2JI5+FU
MJ4?!3NZD[J4XJY5257=3]E!PW\;NO]06>RL0V)@>O,)VH]'ML>UGMS!<HS6%
M:1&F6$P]CPH./YM@T[%I%U&3VC",IDA.1T;4.SGP7(S..2T]:V]UG9F[U&%E
M<6=W>7-@G3K7NGW5"VE"3;<K.4ZUM=1KQI/[TONKW-5RA":DZT3U3^3KL-[6
M-%V9KZYINMZ1HFE;0SA<V6@[2:1J&K4Z].,8JGK=*C9ZMI%73JEW37NJ7])4
M5]:QI7%:BZ<;*HO5_N7Q]M<N6<<($XB/_>U9N>M4HOG-.X;1*3_HA1?,?P]#
M]YLF_P#W7:&/2_TV:7?3H9[H_HO[/[8H\-6]FE7=Y[/[44&W\<;37"7R7\#C
ML?'XU_\ 6N#Z;R_^X;IJ^?\ _I6_1Y_^+EX^OQ!G9)\8[11_]>F5/Q\%//7"
MZ;]S'MBC_P")[-*OQ]SM30S\O?W&.[';G'XT7N<X/IQEX_\ TUW15DHN?_Z!
MN.AU?]_D?\P\.R;X5MHH?_UM-J8^?VNEGLA[WVQ1_P#<?9I5_P#JFU-OG=__
M  ]SC?UW')W_ ![L%S7JOA+L.1]91=Y;<@*475UI*3H*2E/P]2EGRZNL^L/=
M;*/A?;00_P 6EZ?/_AU5;OES)]L]L,..SWLXKK_]/:W:2BVOA[S8ZJD^K:^+
M.._SCDC_ .WX<.'ZQY>,Z_B>RZ)TOG24_AU/E\Q*,@^R;+RX:SJT/\>B6\O^
M#6/S\1^F/:S#]K8;8RMS]SM_J5//3WVP_JSG]Z?&:T?)[A%UL^1>-5?Q5,.F
M?SI3/TA6_P#DI:?ZB?8=FWPV@O5\)Z"U_P .IS+^L'M0C^W[-]"G\:'M"C+/
M15ME*&/FSC]\?%PW_MN#&"[R\9U_$G@3_/\ [O;^,57/X?XNAU\O@ZROZ.V?
M?#:2:_QZ+=I_[E>HOQ8_6;VCQ_;]E]*7_P G;G1Y]O?6%O\ C@?OQXH6_P#;
M\$.6.\O'W.WQHV1S^=/=#)*GG_XN@?S!^B]#?#:>W7^/2M4CW\%&I]1^MFW\
M?V_93J,N/]1M?LG/M[Z]MN/QP<^$%Q"L]<O@7W+R(_9'7[4X:)_5_-*5;AB+
M5_3HD?\ /D)^B=(?[.U&G?\ KL-;AZ:=+U#VSVTA_6>R3:A\_<;0["5NREM-
M2;[''A-[48Y=O\$/$ZUU^R[GV7#K:D7SEV#?#?2_X%_07]"6$OV=I]#?^.&L
M4_72G\^1/U]VAA_7>R?;Z*\_<U]B+C\(;8+/R.3XK<I;ZI/!OQ?1^7\1IQ+4
M$])?.1UF[)JEE_W4&?S>(/T#0?[.T>SSSPS<:A#OX],CA]67^<34%_6>S'VE
M0Z:=LU6Y?_#[55<]N"./"ZDM\^V>%;C!C<O'_P"J&JG<O_XG-;#I?^#I<_@Y
M]0?J\G^SKVSLO_J,X9__ -EM!KYX+_.1-?UGL^]I5/G_ .S5"MC_ /YM4KI_
M)LY\,6H1_P!9X=N,"+R/D?\ ]''-YW+Y_P#HENQZ1?.GI!^KE1_LZQL[+_ZS
M:P_^ZX$_G-ME_6;$^TNG_P#X1JM;\;95UV8\-'!6^N;I[BUKR+^)4GA-WPM*
M?G4J%A,M/+YR,R/X#/J$_5NZ?[.H[/S_ ,.OZ4GO^$KF+'\Z6D1_K=F?:/1^
M-3V<[822ZNCI-5'CO^T>_:RY''DQ=,\,;^<:\M8$BMM-@9UDN*7V!YK E,.L
M6=?B--C>75E;>T[+B$Q9E_8V=8PNUA/LU4)M=5(L'9_HNQNP-"49:EK:M;RG
M-3IVEK1N*5U;2BTX3N*M:WG.E5DGXHTH0FU3DG4D_>*"A_,GMR_E&WU.=/9;
M8&6K:+<T9T+C6=8O].O-'U6C4C*->CIEK8:E;T+NVC)*G5O*]Q;P=Q2G&VHQ
M=O.M.MNAP;_M8-3[FU;&<W,[<X;MC%RB5F8L8]K_ #_+<<NEN,K[3RFLD87C
M.1L4<:Y[7D&]37#T-^'/8F-0#FUZ&9)]:VCV"O\ 3;Z2TU4[G3ZWBJ6[K7EI
M;UJ2S]ZA.-S7HRJNEE8JTU)2@XN7AFW$]2]F'\HK9S:G9ZG+:B5UI>T=A[NW
MU.%EHVLZC973<7[O4*$]+L+Z%I"Z\$W.UN94I4JT*D:/O:*A,VW\/CA+3_M]
MLH@_ ?=3"-D5/1Y\OXNZ>'Q.AX^LU<B+X>7(QP'ZI[0>6GN7^"ZLI]O!<2S\
MCTG^>#V=+]O:)4>?VC2M<M\=??Z93Q\SZ3Q^<&?2Z+O$7K:&KQ&FRMGJM2?^
M\5C%BFG_ ,7(1[)[2>6CWLO+[E-3_P""4A_/'[+\XGMMH=)O_P ^XG;]_?TZ
M>/G@RT7CEX-9G+L7%'HA'/ER[:V?B,'Q_P ^W;2/R\?7SY<OA\1C\Y;+[1QX
MZ'JK_P -C<3_ .&G(^BG[6O9?5QX?:!L>L_^9M!IM+O[VXACYDCB\7/"C-Y%
M$XF^'R2:O$EG<VN7%GS\7L$Y&:NO^@_*6SVOQ_:T35UCGIMXOQ]R??3]I'L[
MJ_U6WNQE3/!0VHT23[*^R22+Q$\/T[EVEO33DSI<N7:NS<*D<^?BY=BNU\^?
MP<O&/PEH^KQ_:TO48_XK&Y7K2/NI[:[&U<>ZVMV9J9X>[U[2IYZ>&[>221=K
M:NG<NTMDX#,Z7+EVKF..R.?/Q<NQ6*^?/X.7C'XRL+Z/[5E=Q_Q6U9>L$?=3
MVBV?J_U6NZ/5_P#EZG93_P"&NR11<GQN=R[2R&CF<_%VK;0)'/\ IV*0OG_P
M'XRH5H?M4:L?\5.<?5(^VG?V-7^JO;2IGA[NXHSS_LS9FDK0LNDA:5I/Q*2H
ME$?_ !(S(?EAKBL'U)IK*::YIY7='T!0        H+B2XE-6\*^LK3:.U;A4
M*KBJ.'2TD'L#^1Y=?.-K<AX]C5<\_'*;8R2;6XZXZZQ!KH;;]C9RHD"._(1R
MVC:+?Z[>PL;"GXZDEXJM6>51MZ2:4JU>:3\,(Y222<IR:A",IR47T[;G;K9[
MV>Z#<;0;177N;>F_=6MK2\,[W4KR47*E96-"4H>]KSPY2<I1I4*49UZ]2G1A
M.:D^E-UZXXA-<8_M/5F0,9#B>0L=)IU/1:L*JP:2CM^BO8'36[5WE6ZLF)\!
M\S4A1MOL.2(4B+*?_#4],O-(O*UA?T71N*+WKC"I!Y\%6E/"52E42S":X[TU
M&4917W[*[5:'MIH=EM#L]>PO=-O89C)8C6MZT4O?6EW1RY6]W;R?@K49[T\3
M@YTITZD[6'P'8BL-I>U-=YQ/[,\-PXOI]48GP77Z,E^*>YNE\WQ_J#,N+ZOU
M-1X+HO0D A0         "@^*SWKO$E] >XO\>9$+'BNJ]22X/H_0J3",SWUC
M6DN'F-J?1V+[3IW]$ZPD65K>;F8UK*K[,\3JFCKF*M[7^6]OLE%0Q*[H=OQ2
MZ;ZXQ1>;/97*\9EEXWO=C/G\E^)?E\]W\<_@97]['&271Y\'V"GS_B['Q3U2
MNC_3IZA;Y_-XOGY>(,1_>QU7\&R;^2[_ .7?ZC][?&*1GTN#O$#(O$:.**@5
MTO\ W]7MF7S<_P#CR#$?WO\ =8S+DN_^0_>[Q@D1&?!QC)GSZR3Q/8N?+Y^:
MM=(Y_P#+K/\ XAB/[W^ZR-R_=3^?\4CG]\'%\2N1\&M&:>7\2.)G#SZ_Y<EX
M.V?]?_F&(_O?[K&9?N_BC@MQ\77(S5P8UW,CZB1Q*X(KF7\^:L5;Y?T/X/GZ
M@Q'][_=8S+]W\5^?P'[Y>+8NCSX+XY\_XNAQ(:\/H_SY=.A;Y_-XN?P\@:C^
M\W\OXM%W\EW_ ,N_U'[Y^+(N?/@L4?+Q=#B,UF?2^8NG7(Y<_@Y\OGY!B/[W
MX/\ B,OEV:^N!^^KBO(B,^"B89_"2.(?5)\OGYK:;Y]7S%U]7SAB/[W^ZQE\
MG^'\3G]]G%42N1\$UL:>7\2.(/4)]?\ +DN0V?\ 7_YAB/[W^ZR9E^[^*."W
MAQ3\C-7!%D/,CZB1O[2RN9?SYJMF^7]#^#Y^H,1_>_W67+QP^6?\CG]^/%&7
M+GP094?/Q]#?6CCY?^_D*.?_ "_X>(,1_>_W6,O]U_A_$X_?IQ/ETNEP.YH?
M+Q=#>VA5=+^G3RYOES^#GR^?D&%^\OFG]$QE\G^'\3@]\<3A$1GP,9^HS/D9
M-[QX>CY%U]?-S/6B/J_H?,^7BZPQ''[6_EA_G\\!GX-=OHV?7[^N)8CY'P+[
M+,N7C3NKAP/K_ER5LQ 8C^]_NL;^2[O^!Q^_WB3(C-7 GM0S(_$C<W#0KF7\
M^O:R3_X<O%U_TF%Y279KZ,)OSBU\T_JAX0'$81ETN!/;_7XS1MWAE7R_GRY[
M?3S^;GRY_,&%S7X_P&7R?X?Q'A"<0I<^EP*;HZO^QM3AD7S_ *?^N9/_  ZS
MYAA?O+_>_@,OD_P_B/"(WZDB-? IO,C,^1DC97#&YR\?\MV$?B+QFDBY]7/Q
M<[X5^_'M/_E&7R?X?Q.?",WF1\E<"^_2ZO&G/>&9?_PW@1?\^?S!X5^_'M/_
M )2>)^<7\MYQX2.["(S5P,\0Q<O@1F/#6L^75\!;R)7C\9$1\BZ^?CY/"OWX
M]I_\I<OD_P /XCPE=Q)-/3X'.)$N?CZ&2<-SG+^?\.]2_P"',T\P\*_?CVG_
M ,HR^3_#^(\)K;!&9+X'^)LN7_8MN')SG_/K+?)$?S<C/F'A7[\>T_\ E&7R
M?X?Q'A/;/(B-7!#Q2EU\C),KAV7R_P#+?9'XOYD1<^KF'A7[\>T_^4C>/[,O
MP?HSGPHMC$KDO@DXKB+EXT)X>7/_ (;_ "+_ /MS+^0O@7[\.\O^4>+^[+L<
M%Q3Y[R,U<$_%NGD?B*OT"L_@ZRZ._C,_^!?/XAG"_>3_ -KZQ1<OD_P_B<^%
M3FQ='I<%G%V7/Q]&ET2OE_/GT-]J\7_/X PN:_'^!,O/[.[GE?Y>NX>%9EY=
M+I<&'%^GE_+&])+Y\O'RZ&]SY_-RY\_@#"YK\?X#/PEV^N<?B/"ORCD1JX->
M,%//X.]+3JC+^O8]WK+Y_&?_ )]0OA_O1[_Y#Q?W9=O\SCPL<C)715P=<82>
MKGTN\G52T_TYM;E<Z_\ X?#RZ@\/]Z/<OB^#?R?UP/"UO>1FKA XPT\CY<OW
M?ZZ69_.1-[:7S+__ +XNL3&?[2_%>J&?@_P_C^>Q&,SX@*?8F-66&Y[P1<4^
M6XI=MLMVV/9#J;7]O43D1I+,R.4N%(V6^PXJ-,CQY3"S0:V9##3[2DN-H47T
M6UQ<6=>%S:7$[>XI-NG6HU)4ZD/%%QEX91PUXHMQ:X--IY3/@U32]-UNQN-,
MU?3[;4M.NHQC<65[1I7%M65.I&K352E4\4).%6G"I!M9C.$9IIQ34D;XLYS#
M:66^$CB_898;2VTTWJW$2;;;;224-M(9V,:4H0E))0A!$DDD24ER(B'XM-MM
MRBVWEMRRVWQ;?FV?;'PQBH1AX8Q2C&,8I1C%+"44ONJ*2226$EC&X^_"ZFD1
M&KA0XPT\SY<OW34*S+^I-YZOJ^'GS_Y]0GA_O1[E\7PEV.?"[?(^1\*_&"75
MSY_N?KE%_P":,R5UAX?[T>X\7]V78X\+X^1FKA<XPD\CY<OW*H69^+K(F\I7
MS+K^#KZC,RY=8F/+Q+\?7&"Y?)_A_$>& V1D1\,7&$GG\/[C9*B+^O8[]?\
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M;F2T\,^3P5'RY' X.^)NK4DR^!*J[5<7HF7B]@?5\!\A^BVJVE7_ .<WDO\
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M3WOFB?H;UA_9-&$N+ZOU*7((
M
M      .%)2I)I41*2HC2I*B(TJ29<C(R/J,C+J,CZC+J,"-)III--8:>]-/B
MFO-,Y H %8;2]J:[SB?V9X;AQ?3ZHQ/@NOT9+\4]S=+YOC_4&9<7U?J:CP71
M>A(!"@         %!\5GO7>)+Z ]Q?X\R(6/%=5ZDEP?1^AF.'3WOFB?H;UA
M_9-&$N+ZOU*7((
M
M *PVE[4UWG$_LSPW#B^GU1B?!=?HR7XI[FZ7S?'^H,RXOJ_4U'@NB]"0"%
M        *#XK/>N\27T![B_QYD0L>*ZKU)+@^C]#,<.GO?-$_0WK#^R:,)<7
MU?J4N00
M                                                      5AM+VI
MKO.)_9GAN'%]/JC$^"Z_1DOQ3W-TOF^/]09EQ?5^IJ/!=%Z$@$*
M 4'Q6>]=XDOH#W%_CS(A8\5U7J27!]'Z&8X=/>^:)^AO6']DT82XOJ_4I<@@
M
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M5),ML<F?$
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MJEK.VN(QC4AEQG1N*$UFE<VMQ3<J-U:UH_>I7%"=2E47[,FTTI&.<.+
M
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M-6MH.$K:M+>K'5[1N573+^.5_15G*C<+%2TKW%-MQLP=].J@
M
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M;33RG@Z TXMQDG&46U*+3333PTT]Z:>YI[TSZ&B
M
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MHM\9O#2D8YPXP
M                                                   *PVE[4UWG
M$_LSPW#B^GU1B?!=?HR7XI[FZ7S?'^H,RXOJ_4U'@NB]"0"%          *#
MXK/>N\27T![B_P >9$+'BNJ]22X/H_0S'#I[WS1/T-ZP_LFC"7%]7ZE+D$
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M4\R5ECOIU4
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MH:(
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MHS6:5S:UZ;E1NK:M'[U*XH3J4JBWQF\-*1CG#C
M
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MVC<JNEZA%-?T-9NC<+^DM*]Q3S)66.^'50
M
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M4HM---/#33WII[FGO3/H:(
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MT?O4KBA.I2J+]F;PTI$.<.,
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M[UWB2^@/<7^/,B%CQ75>I)<'T?H9CAT][YHGZ&]8?V31A+B^K]2ER"
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MN%_26=>XIYE&RQWPZJ
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MA8\5U7J27!]'Z&8X=/>^:)^AO6']DT82XOJ_4I<@@
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MII[_ '5Q1=.O2;WN%2.=^42H=B.'
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MIRQF%6#E3FL2A*46F9L<L?
M                                       !6&TO:FN\XG]F>&X<7T^J
M,3X+K]&2_%/<W2^;X_U!F7%]7ZFH\%T7H2 0I"MCX\O,-?YQB#,F+%?R?$,C
MHFG9C\F/$0=M4RJ_I37H*VY[,'I24HF/P7&IK4=;BXCS,DFG$U;FNH-0-?5^
M:3=CZ]KIG#%ISAWQ3!;2:J%E=-GF"Y'=Y"XK&[NL9P_6='AF.5$J!4V2)"IM
MQ/R8Z9T\?K9,5K%>Z$AJ=3W=AXDWGBL->?G^>)-^[=C\K<NO3RZ,WT&2@
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M
M             %8;2]J:[SB?V9X;AQ?3ZHQ/@NOT9+\4]S=+YOC_ %!F7%]7
MZFH\%T7H2 0I3.W\*P:;C&P\TN\(HLGO/W/9U@TU=FMV"Y;X-<0U6=UAL^XB
MPK*9!QZXF08SMD[&K;%^,EHY<>!+?:3&>JXK?C>NB^(?!GG]HFFX=IF]<8RW
M4'#_ ,->'X/199+P37>T\31%I\[V=G\;!KV1L*[TZN!5Q(N7:QQ.!(L,;MK5
MQTV;THN1WE=,-JBCP[+3<L8<I/.,IMM+?NSOW-[FO\S.[.Y+\,[\\/7IGS6#
MUG&#0    !0?%9[UWB2^@/<7^/,B%CQ75>I)<'T?H9CAT][YHGZ&]8?V31A+
MB^K]2ER"                               K[*M88CELQNWE0Y%1DT='
M0AY?C4QZARF(1<B2E-O -MV9'3R_ZA9HGURR,R<AK)1D?2]HM@-FMI+JGJ=Q
M:U]-U^A'PVNTV@W-71]H;98245J5FX5+J@DL?8]0C>6,EE3MI)M'9-(VLUK1
MJ$K*E7I7NDU)>*OHFJT8:CI%=O+;=E<*4*%1O?\ :+25M=)I.->+29%>V=NX
M)S[=C,;>QMKG_KE8W!Q[8D)A/69OU:W(V,90IM!<NG ?QV<\KK1!DN*Y'UWW
M_M+V0?\ I="C[2]!I\;JPIVFB[;VE%;W*MI\IT- V@E""QFSK:)=U9;X6E:H
M\/F/=;%[0_U%6IL5JD^%"[G<:GLS7J/<E3NXQJZMI"E)YQ<T]4H02^]<4HK*
MF>);&Q#-52(U):D5O"+E9XY:1Y%/DU2LN73194%FU%M(I)4?0)]4945TRYL/
MNH,E'VG9O;C9G:J5:AI.HI:E:)+4-#U"C6TS7]-GA>*%_HU_"A?V_A;\/O70
M=O4:;HUJD<2?!:SLQK6A*G5O[-NRN/\ 5-3M*E*^TJ\COQ*UU*TG5M*S:673
M555H)XJ4X2RB<#MIP
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ME]GOZ5K<IY3HIHL8=X.L
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MVE>VM*DI;H5JBQ)VH/0SJ
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MBVI1::::>&FGO33W-/>F?0T0
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M^C]#,<.GO?-$_0WK#^R:,)<7U?J4N00
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MO.5TPT22W-Y?![L[OF;%<.GO?-$_0WK#^R:,9EQ?5^IHN00
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M[SB?V9X;AQ?3ZHQ/@NOT9+\4]S=+YOC_ %!F7%]7ZFH\%T7H2 0H
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MUWG$_LSPW#B^GU1B?!=?HR7XI[FZ7S?'^H,RXOJ_4U'@NB]"0"%
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M5=:3<5+!IN.I6$J6IZ7.*W^*.HZ=4NK/#332E6C+'&*::5BCNYU@
M                                K#:7M37><3^S/#<.+Z?5&)\%U^C)
M?BGN;I?-\?Z@S+B^K]34>"Z+T) (4          H/BL]Z[Q)?0'N+_'F1"QX
MKJO4DN#Z/T,QPZ>]\T3]#>L/[)HPEQ?5^I2Y!
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M;C*+6]2BVFMZ9T^<)TYRIU(2IU(-QG"<7"<9+<XRC)*46GN::31^@V9
M                            "L-I>U-=YQ/[,\-PXOI]48GP77Z,E^*>
MYNE\WQ_J#,N+ZOU-1X+HO0D A0         "@^*SWKO$E] >XO\ 'F1"QXKJ
MO4DN#Z/T,QPZ>]\T3]#>L/[)HPEQ?5^I2Y!
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MPVE[4UWG$_LSPW#B^GU1B?!=?HR7XI[FZ7S?'^H,RXOJ_4U'@NB]"0"%
M      *#XK/>N\27T![B_P >9$+'BNJ]22X/H_0S'#I[WS1/T-ZP_LFC"7%]
M7ZE+D$
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M4DN#Z/T,QPZ>]\T3]#>L/[)HPEQ?5^I2Y!
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M7M37><3^S/#<.+Z?5&)\%U^C)?BGN;I?-\?Z@S+B^K]34>"Z+T) (4
M    H/BL]Z[Q)?0'N+_'F1"QXKJO4DN#Z/T,QPZ>]\T3]#>L/[)HPEQ?5^I2
MY!
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M:[SB?V9X;AQ?3ZHQ/@NOT9+\4]S=+YOC_4&9<7U?J:CP71>A(!"@
M %!\5GO7>)+Z ]Q?X\R(6/%=5ZDEP?1^AF.'3WOFB?H;UA_9-&$N+ZOU*7((
M
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MVE[4UWG$_LSPW#B^GU1B?!=?HR7XI[FZ7S?'^H,RXOJ_4U'@NB]"0"%
M*RV5,VRF+!K-15N%'>S6K&5)R'8;ETYBE,S7]I)CPGJO&W(]W:6ET_-Z,-#4
MVOA0H4"UGRI;TF/ J;2K'G^''\_GXIT-:-<<5&6[(K]#8PG$Z/$MJ[6L-VQL
MICRWK#),3Q2LX>LEG83G&0TR8\C'[#)*_(\N[WX.(-/3Z@DUE_(M94R:NA<K
M[6N*67G*26/CXEE+Y+.>GS43SC=YM=N/RSN+\T;MA6V<;R>1/KX]5E.OMD9U
MJ?-H$)QUZM3E&!73M:]8U+C_ /K!5&152ZG)ZN/*-<N!!NF*^6])DQ'9#L:P
M_@UE=&$\\LK<\<S%\5GO7>)+Z ]Q?X\R((\5U7J)<'T?H9CAT][YHGZ&]8?V
M31A+B^K]2ER"
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M1/T-ZP_LFC&9<7U?J4N00
M
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M0S'#I[WS1/T-ZP_LFC"7%]7ZE+D$
M
M               %8;2]J:[SB?V9X;AQ?3ZHQ/@NOT9+\4]S=+YOC_4&9<7U
M?J:CP71>A(!"@         %!\5GO7>)+Z ]Q?X\R(6/%=5ZDEP?1^AF.'3WO
MFB?H;UA_9-&$N+ZOU*7((
M
M        *PVE[4UWG$_LSPW#B^GU1B?!=?HR7XI[FZ7S?'^H,RXOJ_4U'@NB
M]"0"%          *#XK/>N\27T![B_QYD0L>*ZKU)+@^C]#,<.GO?-$_0WK#
M^R:,)<7U?J4N00
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M/>N\27T![B_QYD0L>*ZKU)+@^C]#,<.GO?-$_0WK#^R:,)<7U?J4N00
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MYH&JVDDJ1,JJ6SCW+R>[?PRGGO\ #=N\PN/GQY/'#M\?)YX\"O,!+>%-KKA
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MO4DN#Z/T,QPZ>]\T3]#>L/[)HPEQ?5^I2Y!
M                          ?)I2:B6:4FM*5)2LR+I)2LTFM)*Y<R2HT(
M-1$?)1H29\^B7)^?SW9,+*>%E)I/&])X;2?'#:65YX7)'T!0      ..1<^?
M(N?47/EU\BY\BY_-S/E_+F?\S '/(N?/D7,R(C/X3(N?(N?\BYGR_ES/^8
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MMMMI2A"4I21%N'%]/JC$^"Z_1DVQ3W-TOF^/]09EQ?5^IJ/!=%Z$@$*
M     4'Q6>]=XDOH#W%_CS(A8\5U7J27!]'Z&8X=/>^:)^AO6']DT82XOJ_4
MI<@@
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M(6/%=5ZDEP?1^AF.'3WOFB?H;UA_9-&$N+ZOU*7((
M
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M^4^"Z_1DOQ3W-TOF^/\ 4&9<7U?J:CP71>A(!"@         %!\5GO7>)+Z
M]Q?X\R(6/%=5ZDEP?1^AF.'3WOFB?H;UA_9-&$N+ZOU*7((
M
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MSLRH9=CUD@GB[*TY!;>FV#AQS:6V2'52W>V"+LZ2:2XEEN%,B
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M5R[*4VA2D(E63K#DZ2AM1MI?D.);]@22!O+;?%MON5;DER+'$
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MQ?3ZHQ/@NOT9+\4]S=+YOC_4&9<7U?J:CP71>A(!"@
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MEM:D<^DE#BFG4H49$2C;<))F:%<@/L
M                5AM+VIKO.)_9GAN'%]/JC$^"Z_1DOQ3W-TOF^/\ 4&9<
M7U?J:CP71>A(!"@
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M[_'I52[+-EVZCSF-[37D\?#&_CTSU_%7?N^6=W/X>6_#^"-VQDH
M                                   !6&TO:FN\XG]F>&X<7T^J,3X+
MK]&2_%/<W2^;X_U!F7%]7ZFH\%T7H2 0H
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MYW/3U?YW_%]-]]"%
M *PVE[4UWG$_LSPW#B^GU1B?!=?HR7XI[FZ7S?'^H,RXOJ_4U'@NB]"0"%
M
M
MK#:7M37><3^S/#<.+Z?5&)\%U^C)?BGN;I?-\?Z@S+B^K]34>"Z+T) (4
M
M                                                          "L
M-I>U-=YQ/[,\-PXOI]48GP77Z,E^*>YNE\WQ_J#,N+ZOU-1X+HO0D A0
M
M                                                         *PV
ME[4UWG$_LSPW#B^GU1B?!=?HR7XI[FZ7S?'^H,RXOJ_4U'@NB]"0"%
M
M                                                        K#:7
MM37><3^S/#<.+Z?5&)\%U^C)?BGN;I?-\?Z@S+B^K]34>"Z+T) (4
M
M                                                      "L-I>U
M-=YQ/[,\-PXOI]48GP77Z,IMNSLFD);:L)K;:")*&VY;Z$(27B2E*7"2DB^
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IB3+DR$I/I)2^^ZZE*N1ETDDXM1$?(S+F1<^1F082X)+Y#+?%M_,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g428534g07q47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g07q47.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[16X4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 6X-D0         IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T#\@      "@  ________   X0DE-! T       0   !:
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@             !/    KD          0
M               !              *Y   !/                      !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   !/     !29VAT;&]N9P   KD
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    &.$))300,      M"
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
M# ,!  (1 Q$ /P#U1SFM$N(:/$F%4&)D3+<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M:FC0R2 <E$'=CZ*,<GM7R4UQTC2)$JJZ@5M-.=-RPYSO@*60$.EX-A$@ ?\
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M-[U-G*)WXT#IZX())#G@=SGF#ITRP!'S]Y;'I%S@Z6-I:K%J<,!EC&;DY!
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MTZRCE(>1(!$#7VMRPG%U+JN"_P H;F2V:)-12Z78TSR1%OH'5VU^+L3P:F:
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M;#$HJ'24=%*=,PD.7P\#!Y@/C[L@(YY"DCU%3D#N0/OKCZRP_P [)Y;^9?\
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M"BL9 P^R8PD* B9-,=_9#.=*ZU<@%E5DYY#(Y4O&P_B1]"ZE/!P/2K%E=%=
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M[0YSF$QSF1*)C&$=Q$1V\1$?,<X#N!@,0!76!Z"N'<,-]&,_W)/Y9.X_UC3
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MU=Z9=)00,8LH4"N4O:Y]LI@9(94CV5N)[>P0N0R"6TW/;Y" J8,WM-KH(/\
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M>_GW_9^%*Y<I=PWY?B(B "/Z!#W[;>7A[\<?ES\,_9]U0.<^7/'V#^7O!Y%
M(78 '8N_CY /@/E[PW#P'SVV_7CCTS^'/Z^S-/QY_7W_ &XY/EP*D.CARHR
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MGN;BT6-FNK1-RY@ S)"F6&J11]$95AD^AJ@J5@CN6!%O,Y2*4\)(Z@$JI\R
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M,51)0!*8HE,8H@(>("(>_)!([&E>?>K7HG> /65-(+1PXZ>Q[E BZ:4C6JW
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M5S&4'SCZLK*WFF:PNQ$JW73KR]NH5X,#K?FS,D;I@'YLV2:&U'(D<:5QS'-
M]%Q?M,:[7F])NVD4#;:#?JM;*Y8V^D9@"U,:L21!FWNC5&[-U7+LJKH%&[DK
MY8&HNI "I*=H]GN2[,B3':BC:^L^J6=Y$J9AT]1]E^<@'AQ)#L,!E3J#CZ.,
M&L/&BRQ+NNFY:RP22OJFC]F]H!C9L>(2B9=;>'F,'2V>)(KOHTIRK3$)%QNJ
M\:OIX\?Z?V.\QSRCF//NK%IN>P!#A6I4+6"4+%OT;=-E<MU&,@HU4;LC$57
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MN+X@VTF?HBJOWA:XC4*RI&D,858P%D6WU;&\-6)##N2A,XP)),?2-6=7T?\
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MTSK\:[!7!-I> /!NHA&"9%N!J8,I!B7.K.5_-?V@V$UJEE\K.GNL74.A.[R
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MQN-Z+\*C'.<G[,\?"J!7FH;_ (9)^6WB['[OSR=QO1?@*FJ>KS;YY)_Q?_\
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ME>>XD>::1BTDDA+.[$Y+,QY)).23R:NBBB@C2&%%BBC4*D: *J*. J@<  <
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M_JM\:<^H^']ZKTK#\[8_PH_K_P!=[\C,?U6\_/X?#]"G/N^']Z=*P?.V/O\
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M6^ J%3OT-85;1#K3->G(IVW=5^63;JM$E6;*135$%GY1?M#]G*GOTUR&YO:
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M\,>/"WH:[-O,&1=I]4EPUJ@QR]RFG5"OK(NI<J.1J'K4=7SC2X;J#38:[O\
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MTU)%3\K)=L%)A$N1'E<N2%:%.HD7Q*5R@/\ 6R][=TBM9&X-VUR(8S]-UM1
M9'4>:CVB,9&>3S4-;RA6<*66-5:4J"1%KU8#GR/A;/EQWJ[4?BTX=M0VU;7J
M^J]1>*VT'PUYB>5:IOY08P(T9 K9L5505#,QEXTK@"F'IF>( /XX9#P2H&8K
MQ'91]0D(Y$5G+N;=Q)]6-MI\-V\)YKB2)XY'B899;E[0$<J\Z$ I&>-1Y&.
M3GM7RIG%IH%?8>_6>NZB0#FG:;N&C:RW(7S<*R@=X234(*4F"ADCE32B72JP
MF G(F*9O'F\,^K$8E=6B1IY((S*-&ZT>C+1Y/C1M8TL._I5S6DPE6",":8P1
MW#1PDNT:2:L+(,#2ZZ3J'(!P,YKFEQ><,*\3+3J.N>G"D/!,V,A,21;&S%I&
MLI(KT[!T[5YN5)%V6-?F1.;P.#1<0_HQSME*+K8:5$RVY8D ;SZM$>?KMH;
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MA:V>CRTXUNC+/'SMED8U:S6JY6Q9\SBTE5T7MN)%$[.H!Y%+M36-[M,*9.9
M7 NC^+<2[GSQ6RQ1PHK$M;-=RV[,"52:Z%O\XR C6(S;J=(92VHC6N!6N6]:
M60.R#2;>QM94#'+PV1N.%;'S;2BX(+:6T:1PV36/,/1^M(+ABC^&"GZR.JL9
M.://VRSQ=-*0EK)(QZ4?)(R%7+;4A0)(BS34!8T\[Z0$42%-;FYRZ^I:>J-9
MB0,MK9VOLCVP?4LBMIT/J(&TZ!'$7@?2'?O7%G<O9M<3%1+-</KAF;PM"8\D
M(.&W$S(#(N4+X7E<&L=IWHPJUI[I\TJ-+U>L4%8HMP[=0]Y1KR9I1BNX0:I)
M<[4MA2%=%$[4BQDBOF_6-L'.GR\QM?6KV3K%Q9W#*MNUM%?Q3*OC2['4/9-T
MRKX.WLBX!U9#L"01DVV]ZL$=Q$81*DTEA(NMQJB-A[6(PAT'.H7;9)'AT]CJ
MX@R?]%4XK5!-4=,=3%[#<G,HGVVPODR5->H-I9%5)Y98AJ1]/F<O$%6:)V40
M9TS!?HJ ,HGR;CR\JR6G3.F+#L=,M[NTDNI3()Y)K2S#K)8-%HB$B72S@ROK
M4H84&W)K\%MM?"(]1N+@&6:Y2[GACP51KVXT%)"_BT*A0C.ER=9QC3S-L9Z,
M:CPMZNDTPU'"-@[:M$N8G3^+I:;"%C6T M,'23DP]:E_6(Y$YPB(+E;0X(D*
MJ/1/VO9"@%VBNM:K,TUV;IV908H=X,-M(<^%7*G)+^((!@ <^?(ZL+(*'B]F
M@$)=7&[<,FG,CR:.X[@:6(+$ZC6?:;< :6G7#O/Z&-M7Y=_(25C"V0EP)5RL
M&%7G$&2[1DM'5(+,[$S5$RYE5VP61 SD$FZ8+H"D*AYNYI+F+HR*QCEZ//%<
M)<,=V2=XM.$D/S9$8QE5!8H6?#'/%D$RPW74YFC#P=4M'LI;4-H2."0MKT/I
M<;C!@&?0 ="^# P87GO1,P-TEVDE=];YN7(XAYR/MBD33$X.:MCN?-&&>N'L
MRI;I8$& !'GZ<6:/=B!G:AQ?#R@!LJP0Q026\*&.,=,M>G6R%M21-9B<17,R
MX7VA_GVRH:'MPX)!%\?4)DF2X.#/^]9^I2R E=2S[.NVC R(H\Q ZCN9R,IA
M>;#5/1)5:EUQ.F06N*C)]-J+K:@ND-/$TEKG&()H)1**#,+R(PJT6+B:%5\H
MXF0>#+I #9KV(1=^U8]0>SO+:\6'<@LY+"X>W+X5KRS:X,,^O2QC602R*T11
MR=(Q+QBLHD":F1-+O'<V\3DY(MKC9WH7&!ND;46EP4T^+P'(T[5ZI<$Y]5>)
M+3C7^=U=G4X_2Z:B;#5]/Q@2N6C248/S/7IDITT^CT64H5*/05:EA#&1!@F<
M5U^<")^=TJ0],GO;DYN9;N"[M07.G:MKLQ%X>SZUC,*;7T- ,@(.H:;;FY$]
MI':+$(555W&1L[DL8(CFTZ1I?#2"7EMP%.4T'7$6OWHS]+>)&/9N$K\K"2['
M46Z749A*N(S[-T6ZEKXSL$]CN_HD5C%-7HX[9\#]/H@=P4S%3J@*==O$UK'T
M^&1=VWM;2&VDBD&/:;>/ CTMD[.H!PQTRAM0X&.9>Y8M?%E82W,ZW$3!\&UE
M7<((&DF109 0N8R"O).>,27]%E6H.6N]G9:U'J\;-6*(LC*(CZ$FSKU=9PYI
MM1=LZ:C=1[T<+EE4"EDP4C0:ILCAV)?M6[>-02"5)W+I,;DW)9M*&*X$>M8U
MP=D@1\L6DR"OA&GG1%U"8';BC#,;,64."3*",B-V;'SI3+:4TKRS88$UE3/@
M5TXO$YZ_:1:V(LDC13.F37=U<0L<4]JJ1W"TC!)@C9HKL3U\"J )R!C.R-"H
M#NP<]7Y/V;OJ4UT\CSPXM;SJ-QU"YC5M+3RMMF%(I]!$0MPTVHF*0RF<$"/;
M(?#%)LVMC;Z=5STRQ2SMKAC]'RDFEA !<RM'&=(E0+MD:FU K&,AZ'O2BXVJ
MOV:8U4>ST7!"XCGT0>HH&,]8-%&BD"T;28V=0(Q]"%-*E5>BP? ^[T2,5HQ[
M$)7?E6[R6YDG!S+<VJD2CPK[2Q8M>*N6S%(<8@U9&D_/G.1KONH/>S%FC$:B
M60/"6U*87*Z[=LJO)T@%R".YT9QB;X?@OJ5*TZNVE.I.MB,]+:US$4*4LO64
MJXLN,"A,MT8Z/AU;3-&>J\UH5,NJ$BEOSH$!$.8#9K@N_P#'6MR8%N)X>HR=
M7FB9O#/,YA,A"A28H]4:XY?&K&2>]<-U);Y>-<01=/BZ7"I/^3 FL1ZI, ,V
M">=*#CRJRW'T9D-,Q3N/J&LDW0W$G+7!W*.6E73D4)6*N980)" ?,PLT89=H
MF,(@*9Q= !@65 42^ YDF._;PVLBAH8[2SM)E(SNK9B<)*#QM3D3N%DP^WR<
M-GC0W5&*S!8@CO<-<Q2*^#%(W=2-/SD;'277*:M(Y'-6^/\ 194R/AJ_%DU5
ML"R\#7H*G%?K5Y(QW%2K!'A8*+!+U@W0=-ADI$7+_K+$===("LF_0$5M=M?R
M6\KS:5=IAJN <@2RJ?F9%[Z!'JDU(=>O6,,FDAJ(KPQ%2(\F,SF'Q8"&[,?M
MFH:3KWO9[;1]':VGSN;@T2#)>CETVDX*1@PM#]JE(PU*B%'32'1(NF6FDLI$
MG)![T$!5D0LB@K@/@EV1+8RO/N3P6L 8MH3.,/'(C$9TM%K &,C*G6<C(/'>
MKOWG)O)*8P2DMQ)IU$ FX,189TY&-H<^>3P*Q='T<<4\CK:_U3UC?7VT6B&D
MXN2MB]/+"E9MY$A!65:1ZELF3(E(H0RO(:1,!MR%YR\G,;WK:\%I-'.D0+)U
MRPZ]*&<8FN+$W),7T/!'.;GGZ130.&!X\QEUDI&&2+]U772(8EYV[>XV=+DX
M&N6$1'2VE0VMCA?.4K3P5TFT58M!]=WT<D:^VO49(K>-2.J![.G"HN&)6XR:
M>[5F$2CTUP4]OKF 42<H<WF7EO[8O1@Q9?W#TN'I8(\1E08T2R=M#OM'"^(<
M-R<5Z5KU-[7]X,D:L.J7BWARV C0[N43 RP_Q R>"OAXY&-3[;Z'S2FX1-MC
M('5J8AW4[<G%R?*GK*$RQ:6MR58KUXO&%L<89=1P)D>J07J)A!N!1./-N6^4
M*\?38Q&JP=.BV($(U!DE$?[P!/ !NA!::?"=C9.=[<&BJ&\, O%$?BOF1[EE
M;2S&WW#88\)P+7?N^#G<W^-K0VY-M9]&=IQ6+=I]:&EQD%&VGLVUF6$":"23
MCG(,U6ZB3(1"8-V9  ;@4.5-;8##[ [!GK?OAS:7MK)")/;(I8A*\A,D1E&!
M(/!XG3NIRO/F,G.6%A#%+$J@+-*\K!?"N9,:@%Y\/ P,_;FHDCO1F:57)!_7
M(#7=[)TB!FR6 ]8C(!LN\A]4$05(G.NY@ME$AHXJ)3)C6ABD5C"F)PG _%#R
M+<W$-G9E9-PV=NUOTB[*92!6$6\TB:C[27VK8\20:=!^EK&G??WQNYKI98!&
M+UU/480W,T*%]F)#H!@9-RX!D(E#ZU\"Z#KRA/T9;1C,EMTMKT^<V&S69K9=
M69)6B$;M+[)1YEE8@D4T&ZJFJ16AY*Q&4ZSNS"Y"41 .@+ XO=45RL+01Q1%
M;:*Y@O4@W/&U_'K#3;H0#1(&4"$19323NOD!<LD\LXF<A?:&Z;-TH3*"!'TY
M].(RF26D0CF76H8$#;7%3O<>"^JZC:BWQ]?6439].[O8:-<Y&OS+0CY!Y-5-
M>XBM%NV)EDRGCW2%H%,' J<Q (H'0/SCRXV19X[,7)5_W9<=1ELT"$!EZJ+(
M7 D;4</#^[H-I@/%N/D#2*NN+YY(H8XAMG8B@F/<XM0PA93QJ$N]+N(0-&A,
M,^HZ8*N?HM:Y+/*0-.OE0@833Y*6CZM 7#1P+^S@X5\,-V"/AC)ZC5,(]2-)
M$\AW8(KE>%52V;->S?+]P23)>M?W$INKA[7IEI)*XTS,G2S>&)MW+D-)[9)N
M'2<E4QP,53-+%)&L*0;,2SWUSM))\T9.H>S"?4F@90"UB$:YR@+@EM7'.,]%
M/0&5KF[:ZU0L;U[/1?97K,(-%O'!+"HLJ>>1;C-KF(\$5C 4HJ&Y2@ =4V7-
M/BV%K"FU$B].6/Q:V5;,70N=1*J'-_OP;A 7;]E3B34"G$DBS8:2-=[?OYGD
M7P[@N_9=F(J0W@LMB79!9@?:9.%_BDJC\(6KM0K^FVGEIUN9ZHT:C6^IS\6H
MK1STZ2KD33B.T4(5 AKI:DY@\TE([K/RC&=W&B$]F3[M_P"!6M<I<]0AZE>)
MJNK=KJZ61/");US ;<NI5B(HVCE+KK)<.!J72=4!E2ROK2)<)>P+8M&3G3:R
MB03R"3RD0;81=&&RV2,"K/;. 1Y;+EJ%<83B F:TG:K)9K; LXRHE66J=NL:
MK95X[6DPM[8)N.3[&Q 8DK.'.H*',,@03[$Q>/V>W@9M0MK9K.$X\+6,X07D
M$J9.[[1L6Y634HC$3923<!39)=AI8V>W7"1V@="W+3V&][)<(VG$;1>TW&5T
MOJUC#+I.K5MAZ+70UM$U!O)\1XK4Q!2PUET,97&L/+VI[82U\'$,%D/;9%-N
MW;I1)11C0B7AA._.H+@.4"*=F.-_\/%&RBZZ1!8VD(D#!DMMT1W4@"K[3C?(
M*#:SGZ8SQR+V>*5KH@":'JTO4YI2" DDQ0R0*/\ @JQB4ZB7QI^CP:SJI^B#
M@*73GE7K^MKE@ZLH2#"_3"&G)$S6JOKI-DXV,29%O7^:G<8)I@W>:CN4*Z[U
M H,&W91%UMM+XVMY8W)CW$M)[.\DMRVE9KVQ:0Q3HQ1]A6$L@DC*RELIB0:,
M-G641LSQH%<)-#"Q.HI;7&C=BDX&Z3M1%'&WI(?*MK&G=K47A"I>HVHB>HTK
M+*HR9+%0I\6XQJ;@IPH2]H7:,!7,_1'H/C6=<%3=(11[.02D5ZFR?F6\?L\5
MS$&9EN1UH-R1I/6A8"0C&>8?8%V^1JW&^CCGMKIV=&(^A'T^,#/&+#VK2>W&
M][4=8 _X:X)\M8DO1UZ5Q:5/IKW5]Z9[0G$K;H%BK#MTGB+I^$.BYE'2(SAS
M+,DAAV902+TA 1. K^(;;KRX@OEN)+J#4BV\]I.4F"".QZCI]KB8F-M+W'LD
M6W,>$V6S')J&GFR>:R>1K88>[NDNEU#4#<VI?8TC(RL/M+ZT&"^XOB3',-Z:
M^B<TQB*S-GTMU^2%];$WT26U,Z*A(%6H#TB8K5APW1O#?M[A(>BHWF^VMDTP
M46 8@_7 4X,MR+(6DF=J>-S?$#0+HR!1!)$,M[.4Q/G)GW-Q<&/:.N8YUBO(
MKP1ZIK*=)+'6P;V:16)G5SI!E$NF $#:*;/);4 FY>IW _I_JC885[*VQTV?
MP->K,,V:!%I.E19UL\J9)<3&DD!+VPTD8%0Y#%(+<GB<1]G:G4F6::Z]F1FE
MZA#>N2W9HC*5ASIY5MPX..,?1/-<02/;]+CZ9R\26E[:)(W!Q=K;))(!]9!;
MICQ$'5W!',%/O11TF15L,,XU6G TZMD@E/V*FHUE)-T[L[+M9(R3:S_K&9-H
MS:(24FD>--".3KBZ3.#]$$!(MY9EEVK--?SG2Q<2=)D()]DNKH6XFGF3/^)1
MO9+?$2M;D:&!E.KP[)[\3=1GZDL"QRWDUN]Z@?4LT-LTS10H="[1'M$P,A$@
M(8?-C2=6'7WT3=.N4E7KIJAK@::LS&QO)6T2[S3])I#V:/D3,E7,.E#JW=T:
M(4449K'[<:3E0Y5@+V'Y$3*S $AG$L$3*SN\LX#Y>6;PF*2-M(VMK,I(*RE]
MP89 GBS/-+(DB)E55$CM0,M[/$NL%9.V^6U)A@(<:#X3J\.TTWP+T2WZ3Z5:
M8O;E+.8/36*DV,;)H,4@<2R<JV@FXN% [>8B I$@TS$ IW',*Y_:+R>WIZS=
M2]2N;F:1!;SO#)$G\8AD<Y$A7":PN3E 4U?76M=EU)[(7BI$K)>7,,[J3IT+
M#OC:7"D>(3GQ8XQ]$YX^?#YP.,]%M3GVL=CU*=ZCZA2\7+Q<O)GJY:TP<)R;
MA@[(JTCQL=A49';+M5S"!GSH%BN2% 4>S[K6&_46=W:);A3>SP7-Q,9-3F>)
M9Q(5&@!8YC,#H))3; UMJ\.-[B22.WA8C;M(DM[90"-$$61&C')ULH)!<!-7
MU1SF$-5?1/Z8ZCRFF<VA<EXM[I\O*C(-7572E6-K8R1H,W8U$@L$<,0X2&(4
M S_FE 5!Y_HB8H;KX'D?$6$640=-L;$1NQ4R/T[VCV:;= ;;)]IE#KMR=P0P
M (/2SZH[B.0MFXOKN[$H.3$M[M;\13'SJG9B*G7'@JV0=0*QC)>B#:ZDZ;0<
M5JEK KZ_03>.:5R4BZ:5U"5:'0;JE=0*\8I;4E+(8Z_8S)RQ)&"*4C0Y1C#"
MY R$1DI%T\$ZY[>#8O)6^C=1^#"1IW@*%9/&7F#;@\"Z/%9/=F2YO&0$6TEY
M+=6D><20R2-DN[X(<$!1H"(5*YUG40)$-Z*J,-;/6H-=)SGA*Q(5+3V,/3"'
M8TN%?*M54V %];RC*,F L&96+5,L4")2N/E![0'13$SS2SRDM)/=1W,KD^.7
M9,AA$C?QR#>EW)<#<++\VFGFHSY@6WT 1K$J$ X\?.XZ#!T*^%PGBTE3EVSQ
MA]4]$!2],I&R6NHZT.86QJRK.2J<^^H*3TU48-S/E7D=()DNK(U@*Z44C#D<
MD<0@-N[E=VR_; %K$Q$MK-:D!%NHWMKLKP)[)AA;<+_"Z9?3*2X\9^:]=,-\
M4N=\0[ATF0)JQINV(+7"L$X1L#5#@EM*_.C3@[;W/@KH=CT\H].G[8N5A0=-
M9[3EC+.(M(PJMI]" 27EC)&DR%;N$BU] Q4065 W5, KEZ8":N^@]NZC/>#5
M#+<;2")<-I$32LJ@^'5DRG/A'853TZ[DLK.&T51.(IEN#)]$NP !X 8 ' .<
MG'P-:Z:E^BNTBLNKT)JRMJ2[KCP9UQ*2T,ZKJ#]"721=-W3!I$NQGV!H1>/%
M1^51Z+64[0#] 0;-NR[.>K'<Z?/<36LSQ3W&Y+%*ATS071(*W$3@_P#"))"8
M!RV=P8YZDG-Q:PV\L"RQVY9/'XHWBF"B6&9"/&)1"H!U# 5AI;/&+N?1(1RD
M1:G4YQ"/9&U6RUUBWV&\O=."=O26K)+$*I8A(U^,,4XE5+"HL]?'=O-C,68=
MF/R"(W:T2/I<"J88>ESW]RJQ.(V>3J L1*$<JPA118IH73)]+N N&[-]+)[2
MB)K%W%% 8Y"94:.'=$.XH";SIO/X\H#J.%7/$N4GT:\) 6>-EIW6.>N=1KTD
MB]IU2>5M-IW.RZA3.6KN8&R/BRKETDW8)"_)%1P%[*8XLU 6 B5=VIO9_:;P
M![S8BM9)D&T3;VYD,,:J2Y0H9923J;.H>$:>9;J4QB,286,R7$X!.L[USM;D
MC'"Z@=E,* //Q'/$)L_0R4*(HEPI4)JN#)6Q6: F8>RNM-TGLW68B 1GDF\,
MW6+>&@/'*@S8*=[ +,J9VA1[M/U?DK;>>6"+I<1<DV,TTURR?-^W;HMPJZ<O
ML!=E]66GU[H^CM^/B:\6:YO;@P+B['@C9M:PN2Y9LZ%W!XETKA-.D\G5X=M-
M9>$6/OLE!]^6M4U+)58Z!NKZ;Y'$F]+5C+]Q+**BX0(X!\E-SII03%)L9%H)
M1'G-RTW5O%U.]OIID"&]O.E7D,,*^%)NFGJ.+95XREQ[< 'R-H18T2:\K%K>
M36EI9V\ URVEMU6S5R='S75QT_>N.S8DMSTV+;CSB0ROET"@/"<;Z*'3UKIX
MAI](:I6F9;F4AEI.6>Q"(OI%:'0?()F$HS!P0(<'ZYB$,HX%$3']M7GW++\O
M)+$%@F?I7[O21!_EW)SJZCC(+3MA,KJ7Z ^<].A>C7&6@5XX^H3WAB9LK)!+
MM:;)SIYCCVV\>/%N'P#'.00'HJ]"$V-1B=070ZJ0]:KIH=Y'VR"04).RJP-"
MN[,Y,,FX!O*N"M"E$>FYY><VZA]O'=+>"9;\/%S=2S/;R!_G;%)L?-P/HYTX
M4ZM*ZBH\(Q6%#LS1RPY0*UNSQ$ZHY?9MW0KKX<I\ZPT^0)&3GBPO/13TB3GH
M2?DM6+*LYB2S;=PFW@4FQ)EA('B3Q;&4$9Y?KI0@L'_2$"E[1WNOL5MTOEO-
M,:LW4Y9%5[CJHO)+B;3@)>7>WINX4R2C0%',:%VYD;QCN=\5^839(D2BVZ>U
M@MM;ZO"MK9;P:V9M.&%P)(P[Z!I$(\#:O#-DMP9)7O3C7>DVZQ'AY'5ITBVA
M[#%-BOG=4:0K>=1K<TV3,[9]>9:&LLFHH'7:AN1("G+S"(67F;VTM878PNG5
M[SKLZH=:"ZOQ:B>V4G3KMP+2,!L*7!.5&.:;.<=/NC)!F6%>D6?12'\!GM[1
MK@[S##;;3"?_ "_&(RN0[9X@:@>B5TVTWJ]KKM<U+L *6!G/QL4^>0**Z=;C
M99-F2.8LV9)Q(7"$.+98Q2=J; [!P!0!J"6ZE[7$BW-A=VRQV\W3YYIXF":P
M^LP&".093*6QB<Q@8R9G/A\X]H$D=S%<QF>.\>WDN,/MNTD8G%RX?2X4W8DC
MUY5M!@4G<SQL=6.#.G4N"-'JV]=1T_H<W0).5"(38C)J6$D<5>5,W&5<\CHH
MQO,DV%PKOUE %Q[.YJX2L%M=6428ANK7HMFB%LF)>C#J0BT\#49AU%]8PNG:
M&-6KP]I=S?O2TZLX$D]E?]4ZD5Y5';J3V#RJWTBJ1&Q32?%G<;(7',5/?1I4
MA_,,I13429 (>4">A6I()+D8S?.4Q7:QQFA[4B I)AV8"-S;%-^$!S>SJO+F
M*^C1+JW9PL-Y9DK*$)LNH"W]NA&8FTO,+6VT2\B/0V8Y-0TV?O&93&8PJ&,0
M,.[$S6NY[/(>1X4W90R#E]0PZZ3F$ZIZ'.HT.'LK6FZS.X>=L)G,0-@4T]3=
M*)T5V0P+55XT)=VII%R4P)';S7;&B:/X0 PY^N I4"XF-G[&[:HYTE6_P"HN
M2ZQK&T0RWLYCQ-JR9S)NK@IMG<SQS+%=PW@C#26<R3V&M@QMI 6,I9M(W1+B
M'( BQM<EM?AGSB1]&]0.(N3T?EW]R=P3O2E@K!+D<5Y*P,[-7U319U(Y5L,W
M#C&.##&AN]ZLD79<0[)[&Y^=>.M2=9TX:?;:6#/=H79[=TEQE#'N3!LQMKUK
M]#1AD%P\/1XNCD!TMV9H)CPRF1%676G(D#[<1 U*5TL,G4"N :G^B>TWU'H:
M=/#426AGS!Y#/H6</6T9-%BO$HR*7X5$]_QXOR.1>I'$I9)D*8-C%YE 7W23
MRM/<R71"AYHHH)0P+JT*&0R*!E<-+K7Q'4%"?1;5QU#<+$ AC+(JR%%5]!65
MM.V^K0PTQ ,-&D:]7TEQSVT?1?0D+%,JU4-7G5=K$)((6>MPIJ,F_P"Y[J!1
M(^FA<$N# KF*>)HQA2P)6S4Z'83",LOV@ 0Z$K"??TJRPRNMI$X+)!83%3/9
MR=M]I-F +< 1"/;;,#ZQH[BO6B32$ :2P6SNF1M!F>+(AN$&EMIH]R?4A,NO
M<7#IH.N3]!^!:'THTVUDH8:H.;7&:Q.RN556%8)7HBME(WE$!)%0_K).=554
MLINNL:10ZA6K4O2+R"8<UU$MSTFPZ6VL+92/,EPS!V<2)$@15 71&NV2!J?E
MO=S7[0R=2N+X(%:9%B>$< ,K2,SLV/$[:P#X1C3GNW&*,O1L5PLT]/+ZH24Q
M3FDM(2],J)ZLFW-6EYLS?OTC^7&R.2SQ'R47!)(<D5#"T[O<&-VGMP%:>C:7
MSVU]9]1*;ES8M81VYU:$%ET]IFBM672^IR9FS."N,?Y)SQBN(EFM)[.,M"ES
M'<&9E.IC<W 0-.G"Z%&CB(ZB<_YHQS.&JG"+%ZI:UTC5M]<EXZ.J+RMR#FFD
M@2NT9IY57;US$J#,#,MNPID+)R"2J?=+P3@N0X*%Z8E4R6ACMFZNSQ[W[VLE
MLVRVAH"-W,\;8?+G=/&% ([D' W>U,(H(U4 PK=H6/(>.Z]GU*5P,:?9Q@Y.
M=9X&.=&(OT/=0K$3?*?4M>I6OM+\[8D<-RT=)P_"E,2RJ3BM2"Q+HT"7.J$L
MF"4OTF!&IB+#W6OVS9"N(,+*TL97,L5LS272I\VMT^F-;24H3)M26H2YVW)E
MS[1)@+H.K3-?[E]<=1%NJ33R/)"Q8OLR.=5PH;2NN*8[.Y%A,[2>+GB4ZIZ,
M2A0L/8::YU2>S\<K6).!C&KBKI)R%<&S%22E9(SGUD7!X=^6(C@21!NRZ8QZ
M@BNL"H CZIZG))U!NI/&K3GK/3>K.%?2A'3&O&AM",,2K&]DUR'/92(^362X
MF:5+:/!CBAZ3==+5=6HNMR+8>T9PH#Q; TKI(.Y](8YQK47T0FE6H.J+K4LU
M_?,#RL[-3D_!N*HA*-G:S]PR7BTXQUZQ,!B30XIR9 6.UD.UA)$$$VG9!!U@
ML9/8-D*I=(K""S"E@&:2'67G9P#Q)K7,.GPZ?\QM7'373-+O!0KF>25A_ T<
MA4F$K@''AY;5A@<:!BMFZ+P40NF^H5)OE1NZ\>:JQZ,3)Q*E<(JE8(Y%=LL"
M0NB3B(QRQQ1.4RXMI -E2CTMTQZD1R:.H]5O\9_>CW[F#.$MS?-"V(S@Y6+:
MP 574&QE,<UWLHO;>Q@= AL?9=$@.2XMA)G4N!S)N DY.G3_ !9R(CN?!'9K
M-2'%'E=78^F4^/NEFF"(R-6]<(FPP\^E%(M#.(D;36BP5@B4HE<&TMVZ5*<L
MHY*+%+H[K=$;\71X7!8V'3[;I@CA&B=4LQB&:UNCJV9I=Q]W,$@RD)&<$5IC
MND@FZA-;0 R7MW)?EY&+J))SF>*:((N_!E8M"AXM/S@_B&F8J7P!</=4BKBV
M=U=I8+#=RR;2;OCQF@C=7,5)D(56/7F-W'7Y#@=8%A0(!EE#&Z)?(<PC MO9
MERB-()91%X%E91A=:\Y"Y;S.=1^_,L\BSB<'4R*%C$GBVP"3X>WJ,<<8SY\=
MO4?@QK-V9%:0MNDZH>+H36EU57NTDP2 <1P. C)Q1$)&*[P5:]H,)V9%6'6Y
M2@#M'SS5-=W<DDMQ'-L74M[9WN\BDZ6M3<$QZ-0RDQN,MXA@H.&R-.NWZ@T%
MI'9B(-$B7T;$MAGCOA:K(,Z3I9!:KI;#?2/'',=5C@GU5K5PIEF#B>7E6$+8
M7=QM]=D=+3JLKC<)16-4E[ V5#4K_P"KSEZ6-33(4[><,W ^XJK 42FZMYXX
M)H&:'=M[3I\73;.%G DMK:/5J"SZ""9!MAL1*/FE[^6"9MV"2(#09;B2YD9?
MH/(P B!CXRL'SN@%R?G6Y'GZ*YFKFF*4Q2F*4Q2M%>.2,UU?5BFK:.%U'=LV
MTC+DM$9I-:'M1NKE==.+]7W",JTAYT!AF8(S191LI'B*JKJ/.1=,$SE/2@F/
M4+?2P6,V]TB.Y)MHKQVM_9I;V/($UN@$NI \9P6 <9S6^V-J+>43A2_M5F[Y
M4&1[%!<B\BMW)S'<2%H-M]+@:3E3C!UXD(?BLTHX0>(FZZCZA7J4UM=GL(UT
MD38I->-A(R.BW:T.M1D5T"NXEP[>.W(**IJ+E4*S8 4@"A[7JWBP-+T*SL$D
MN#=7=C[<(R(YFEF++<6T3@2!81I4H&1B"WN%:>FI:SW^9%C2V2S81I* RAP5
M^<N,A0\H'=L+P3ZUKY<],>. M2LMDJD-K$2RW.,K\+59@=19H-5Z2Q9)3IV2
M5OE4J@52QM6RDF4\DW32@"D<HE.!P[1\CY+QWB23QQS0+-/'8R"XC!%I)[*;
MH)#=1!B3)FX8R2[APO\ PSG-<VLMDT=B;K5)%9OU-3;R*IE!O18[LL$A8! ?
M9$$2&-LD,2_ SV;W3/2</8UVG7[#?6-X)26[M>596BPGHQX[9SU(:-@$XU%5
M74PJO*893O8@'1,DF9B40YA]'J#0;UP;-2(%OV-RN1JF@8YA_=:@ 0PIIE$J
MDRZM<'T0IU8[/;6SMTN6B>Y-M&D#!=.W<(,3R]1?+&59"T)A&(].W<98Z@5Q
MFAZ0^D28S:MA2D[TCJK<:)0&J-VEI"=@:6V]6SVA1_$:GUP$))Q/SB+FPM%H
MV3&PQPI)&G2&C]W'.G=>2Q&)8+<+'"D][=W\43@I/'<^S!_W6 JBTOG$+!7;
M?T )P]7K-;NECOEV2&65(TP&>'.SH]I)QOVN%(*@0Y(8@C("S#IZAQ-UZ8H-
MEM<)JK)NHBXJS$#5K_/R-SU04I,4:-/J0P7EU8B%$[";,O3$X-F2,!$7$=)G
M<** 9(J=UO-90Q;BQ%YATGK@N B!F6.X'3OW)#=-J^<OHS!U/#D)C4^A -6.
M##;SEH)9 @EONDH)]02V%XGMRW%U!'@B*R3<A,JZV.&B\0T@F=^/FN<9UH;:
M7O.$N?GJ\>4"=2O;5*3EHP\21,($8!P5.,25$53BO. \(L*//T&X$/X'V\D)
M):=0G;,=Y%&L5S$C/B!YNG-+IM/HMJAZJ+H"=OX!9QG;ER-N;*:TELXC-#M3
M/*L#;BJ'2UOQ_B+IU)_]1T_V:+V9<@ W,^73(SIRC0?2V$U ;*IZDNVR<_IX
M:21(Z9V:9I$!8'2Z?:8&1-WM' A+-@Z ,9($BJ)H@\WC_'.[N&**+J5K:3RR
MI:Q/'%.Y'M%]%'J$#VDRL=-VWC,K:7U$Q'C3SU;36\C=/GNH(8A->+)<V\8#
M"V!TF:.7.C=M<86$%8M.F3.=?@ZFB^DGI"VM]TBUBU%>6R;2J*4Q#W*$D23D
M+?INMNEJTZ0C5)==26[<BF$?(D5;KQZ23]=R!]VO0$%O4CO+2QAOF:(SI=VO
M1@\,"!WEN;0=2VI9XM0#-:"XD$OB+2&X4 Q!3K\^6%[K9A6X2)H'ZDR/+G:C
M6X]C#QV\N1M>T[";<@1MG9R5FU^#?+C>)Q'W;2+3&>X=SZEU6VKV)J^G:Q6@
M?QLNI&NVJ1^PV1ZP,=6.9LU2&2<@=@\*8S@QN4G1V5\B6.6#JUHL;)/!$TXF
M)?3:R@/!HW6TL,$!]#%3P6/8UKLI;5^G7OM$9269;=K=](-S 0L^L)&=);.I
M-Q1(G*H,G/'GK==#_2&5J%LLYIT\OD-=9]C'C,EKU@G'\:A$19),[AA6&2$;
M'JI65ZM)!R/C.!*L#5 IF@"EN.Z\EC6ZN1;N#:/!TG1HC#3-=1_O'4A(?"VE
MN)%$D?BR94Y7 U:':UGFMIG$>N.&_7YW#(@D]D/B[:II2F(I/!@1R85M7A]+
MI.&UAU3X0-2-*;C#R[K55;2Y2NN9F9A742QM4_+1;YLJLQ:*NI-R8J;EKS.2
MBY<'(#QN',81W'/U2WAN60P-$D8ZC-;N  RF.UVLWB0A@/9KG>.Q'N>(1N-S
MBJ/D]=^P]7L9[O5MPO:W9?C")*S_ ##/V:> 1YE.%_S$\(SSHQJ9P=<17#MI
MA%5SAGF[7,WZ]2Y59^W:7)O]*8>L#7VX$K[>:JD:I=5I>-?KSLNJ_?'LD4+8
ML<BD1LY[0=1ND>0W4$%NZK;QS3W<CW#[MM<%C"#"8 $%OPF8SNSZPS@J-(+5
MVGLYMYYKM5WO9[:VBB11O1C$VN=9R<R-&2@*B)"V0=2XP97IFCO&B-JCK7*7
M.ZUMO#RM*?I4Z&LTNUJ4WV]6=4NQK'$BQ(62.0&-<32$5$A(DN[*K_2DVW_X
M*W7IAA;>TS6ME<P2Z3##TY V[(BYXF&KP-C"\]\C%$>);"\28A+S3UNXBF7B
M6:[9; =-623N8LK=DH%U$D%2,',@\1&DEA6UQD[')<-<9Q(L;]$5R(I4_)29
MV26D<A /)Y225?**5&SEB6,H6P1)TY)NJF9;N-?F:?@R>_B6"21&>'.FY>^G
MO8KUW,2""7;$-KO88K[,4D8+R&W<@)IYW7$L4EO!)NLL,%N8)+!%#,\N%W+A
M%##6;H*!(-"F/:3+2[GS>FK;3OC[F=1'-XLL#K*XJ5:U(JMCK^FJFJ4X9-)S
M&KSJTTC$39Z.*05==(\2W:+IP!!3!(QC(' Q"$VV1C@ADNIY)I[F2TN;>S&H
M1SQB^$6L=1_S#-LFVCR 8\F1^WFN-EY$M86@@MP8WNY4C#I(;4L(WM%#H(VE
M$TN8]3?0C.OBK=6J?Z3$JM26>2>N)&"NIO>;6#EK?87;E"HOA:"M%7>PFB4>
MFTCRH)D04"$.F<7,B?LZ/+R*3;PIN=-AN;B.8$=0BOI0HAC$!-@+.9@6EUW'
M_JB4+*!SASJ.*KF6(KU66"-8RT-@]K& 'D]I47_M<<!!71"VJU&L*2VE<J,
M&0Z7H3QC4_3FU[6'7U)"I2D6P94^$U(F&,[;8%9"5]:'];?A6ENC-*@Q@TH-
MT$8\(U.NY,H1?JD ,TUS)(UI)IN'MY$L('BD8FZMT@$^HNV" K"8"XX&MDC[
M!:UR"T,ERJ-;B8MU"X$RJ#;O-,;?9106!T(8W,:ASI#M@G4<1A7J[QUZH2VI
MVEUBE]4Y-_'U""9+'FKA-.J,QB)4UB;R<)8(L\,(S%Y?BQ:BA*"ZCBI(,WA3
M1RW: ,A=U.RDGL=6+?#R7\%U)&NF*[DB%MM-TI,GV40"24EM=P6WH?H:/G-"
MRVEI>=.N;8/#$9(IH1(0TT4)()]N8:!-G"X4*@!5R#@\2SK%I%QAT"/F8BGO
M^(+4:-:+R$94+14M1Y>.U'C6;LI")NI&62J\P$O&,RM&ZJ,*DG'D6756,,BA
MN 9TT\<D]P\Z3JUQ>6HW+9P%>SM#.<W*:?G;B7VC*SEU"Z&^;?62/#M45%MU
MQ L5O83Y@=/_ /9-LX2W88$$8$1#C1(?H=M/.0)Z.<:;U&6MU9N&K=-5A&3B
M9J-7D[;+BXM,TX#JI$U+32C6H3RJ1FJ":Z2:;<5!=NPZB?4#-L$EK;B62Y,,
MC17MGM1Q(ILULW%T;XI;ELEAHM0")  ,@Y&*ZMUBDN]B74EK+;WBRW3-BY]H
M0P"ST/I(6-@]P3G400,9YK)?1TZO7W7!YKXUFYC4^S1T'#4:*=):A7%Q+L0N
M[PUX"RIUAPI% 6M1ZY6D5U(OL\JJR*FV%1VZW*!,=Y:I)TB]>.,2V]TRQ],5
MY0+B2)%DWTDO-M@YQ+;@S+  "03'R!7;-);=1Z:)2D=Q UZW4F@A_P ,'U6?
MLI2UW%*J&6[T(TQ)&0&!4FM=*GH9Q.41E:3Z4:*VO2BD,'D"QLT?39*0K.M5
ML9, F]TJI>6M<%.<3,BHL#R:4K34#NUXU4(TO4$@:/:@ULPGEE=;F:XDMX;=
M/9E@NW$6Q+>VVY-IM(07#1B7,F7 DCT9?9_AF==+1>T1QZ;B6ZQ<12Q#&OV:
M3YLBYE(RI(.V%SB34 N1V;2ST@FH>J!&3YE;6M)CXE)C)L+;<YRR4V6L+5P<
ML);(=H>N12+90B*DL$NU.+I0B:T8!7X@)ASRKE'D>9XMI9/WC%=6VI28[2>W
M,A?8;5EK-S)'LD+&2(CQSQU#/:0QE!NF*6R:VDP5$T]K/C5%.,'3<@(-PL7!
M+8P, '8KA*9\<E6H7$@\XA+1-R<^Q0;&T^&:BIA1(91%&P&D9"N/'\L*B\&L
M?NGH,4$4A2!,@F=J=4H)VSR0Q_)R$^,7H,[.[N%NHH1'#I29L%F;5JT2$J%(
MD\)+9%>U%)U\+&8FM))44(J@V[*7;3I4'2A SK SJ!09 7G5+A9L7%!Q.05K
MG:!JGKG&5^J,7_=3RUZARDDI+WOD3,R8.I)&*;%7@032$RT:#<%4>H!RK* N
M/(OX;N#?NX5#VD\=\O38E)W3;_,F(2.1B6Y0$".=40$M)B,9Q7<+60:UMY]&
M^K]./47"J$U9N1<F%#S!$Q"ZHF:3(5,N=(J1JJ'I"JNU4=L:_K#.5RWM+-7Z
MW#7K4"=E[K1)(X0XQ]EMLN%3;IK,")KF)&D3CF)B*M94W:!ZG*33?%)+-[2)
MHXIY)[2[@O8HUU6]A;BX$MC. X+W<^[$TCAXU?9&8AQB()+% DCQF5XXEBN8
MVQHGNF!+SVPP3';@I@(=PKK +DYJ?^!A;B:LK.YV>^2>HO<$K!,DV :G6"1G
M325C,#U1&7HR"["/3@J\<BINVLR*RIU>:,V>$!M\M43&WR:4JC+U&YM;:2V+
M,&N4<1S>UM<2!58I,S6WLRA1I,<^2Y8 9YQ%'UN2-@-FTO[N*X$?@MVAUP>S
M)'%@@R1!9]URXR'C 08R;)I?H'JS;:3IA8U[)ZVUV+K3&)O>B4X[=52*->F:
M+528LBD\!+.G)/71%"M.BM56BR14A4,\4!7I)ZIVMH9+F1(1=6=Q9)^Z5=@9
M;&US(4M6325=W#*)&4QC,:C;.>)N7U7<RQNUK(G49WN)-((N6)4!PP9"D:Z2
M8P=P'<;Q#'BTM#A1U9;KRD\ZX62V2H65W>H2G:?.&;B+>Z7S\\, >.N -?5Z
M41+'1B304&<PBBP57,FN!$D 2 #P',G3(>G"[9.H7926VZNR;8Z3X=,XD3=9
MH6G9X'$(G&CV4Y=^"-33VB78NT4+;P-;+>].!$T=_M&9HI(I,1"4P!IE=C$-
M>^I\'9M]>*"I<8!+M0&6D\M>'L=ZK)QD))4^SRL!6HBZH+(A)3&K4:UBY4D]
M770*QAHIJ5[%*HILY\IG2HN2F0XDFAFZI>SK')'%+.LR*[!K86(:0RVL,.$"
MWSZH]N;65 4C9/>LG3TM;?HUC!=$2W$(ECNV0 7,LCI"+66.4LQ$$12YWT,9
M#&6+#KI.OOZE4O7FB\(\,R:1&IVN>LSV28R$BL>W/CV:KS#F,5*O*P2WJ_*N
MS1\6[3 6\4)6IN=8HC()CYT=191?6*]/#PQ0B7_&@[D\:YA\$@41[N\%!+:X
M]!0\/K\%'3F)M[B3J B>5UA#6:^"W=E$A+1DZM!0MI/S;:]0Y0( VG]SX<.(
M?4H:%(.=,Y@VH#'3B05O5[LK-ZW?Z@$E>Z16K\Z\%FY7B9Z/78NEVT4NM. Y
M-,/1Z[86@B\YGCMEN^H30PK':B'<:W@(/ML[LY9M 51(TP0!XL_X==(,DN\
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M!A&9V"'43!.4B,:AU$.T_BEW!HZEFMQ=LT($-O-8W$9B7$BX<Q[,<K (!<*
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M._=F5"L%8CVW6YX(QI&0:T(K52](P&ERK*=?ZW/I ;G,I0+Y*[S\!>^UO&[
M(.3L@&@I8Q:)%F;O1>QZ:AQ>K/@Y'K,&PBXO02.O31K@CN39SI\YX[6.X'LV
M).I'P-+N$_-( AB$=P-<FX=%\K6@NKXX#6PFMV8Q(HDD@S<:X^GIJ*HRC3J?
M6^O5%E4T^+-=*-*?2 6&;BHFY7S5RI1T8^A$]0963U G9%*Q6IJ9T21DM/55
M82++%:>.RJ*F5BUADCFVC^9Z/1$3ZLV36EQ);"6*7V7J;])CNV5Y8[I1:&U7
MJV%7?1B6V441$:+C!.O*TW3QK/;*JQRJ;RW7J$D.$B/3V+ZS9* VW<1X<R$L
MP8- ,)H\<V<!+CC+II[=#\5AKO<75@L\>S@7SR*E#Q\ 9L+XLS)(2DF_<']6
MY 7D<9@@1J@#8(]P8R[CK%!!'[/-;1(GS;&*]N%>90DL4=J+7;M[DY8O<76\
MVP/  8)\!LG3GOR4NV>,H\(>" K;I\V[SF8[T:AL1Q0"+YX^,D31 Z2OBBW4
M:E\>=XXF;J6I2VJ6G>CC]9] .%6M\FUV MCR"G==HHX(U^-:PZP-#/>UM0%\
M#8 C!(_6 PB'E62-(L*W32QQS7UM+.H<;UND6Y[5!'.1XK:;=BVW,2:MHDIX
M0*]&Y>UBBD]G6.:=+%UA9D&V\SX,;21ZO#-&5.HAW)UXR".>C<M%N+Z1NNEE
M7L$AJA>:A 7>$=1$PK<95:*;P]?6Z<I):IM%(1RE8Y:42>QQH9\#N**W*RL(
M'3<=M S;TK"6)Y>DW%Y%"E["O3KF^*H%LT=3*95M8F)9+J,_YCLYU*T8TC'.
M.Y*I:=:AMW8PW,75[.UC! N'6;V86IFE4G7:D+(!$(\*=6';/$CZGZ%\4+_B
M9NC_ $PNNI]5JEK9M)U6=1N$DC3PDV#^3&$A4XQM&))(LVR4E('E&HR"HKIJ
MLBE,B")A4P]*1X>G]=,S1+>1W=[==(BD75'/)<JNWO@E2T:&!0R+G(?Z0/?T
M'FL'GL6G5GA-OTVVN3%I$T<5N;GVT)G4!*XEAV'. I1\H^KPZ>EK?I4%])'4
M&_E-6W>H#NY.SP%BCYFR5Q2 [ V3(<TZ46TPXL%3GEWC<[$I'$*$1W,^ !DQ
ME &.UV^TTG0-7@CA>:2^:9]33VKFTQ:WD6E?\3$$D,4Y=@^[*!"FG+9RL"R=
M1)>-UD$"(BJH$;CVCYZTDU$",@XGB"9X@(DX.90T^X;^-9HQDXM/436ZF$BK
ML@8Z;6_3)&5A:38+EL$PS.$.VW;-0BXP(Y,Q%0; \<\ZYP6*!=<)L9! LQD6
MW"V=HJEP)X[6,S>T2.V#F<AH0DND#*L2IR")OKE#=RR01QS![1[C5* ZF]SF
M&$+P!$,R;RZB9,QXQHRV,2VG/I5275_$-=2KBE7@T^DV,#(-C6-^BHLBLV(U
M[ZF0?-"-KNY(<3)SR;%<R8)+G"/5WV+%C[)+/)'?,JQ3R0//)#IA$,3&08LL
MZ]+1#)FB)\8,/C32-5:-;Q30'0LD*W P'Q(Q5=.LW"X77$XTA!J4+B3EM0(V
M.K.A'%[2=<%)2LZC72>;)Q]M@*Y:]6965OM?;5UN[@C,"V&( 8 '<[)<QE(Z
M2)+MR))LI,H-%^T<R'FV#N9>HFY2&*.4]/0,$S)/!9F^R ^H8G87(R^'U<>
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,IBE,4IBE,4IBE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g428534g30m75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g30m75.jpg
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M">%*MZM0'L>.]VPF!R'@$\*5;U:@/8\=[MA,#D/ )X4JWJU >QX[W;"8'(>
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M+F'5?J81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB814"T_<Y,_T!?\
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M.$;*& !,( "LA(K #&)9 =X\4  226N39796Z;776*UVR/722JJG@^3T5-O
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M5=(  P!@#0 < .2_60B81,(F$3")A%_#%*8HE, &*8!*8I@ 2F*(=! 0'T"
MAZ! ?0(>@<<."* G(7LT.)/(A-Z^F==-*#<G153EO.L"-*C,F=*=XPN92-:M
M5:S8%5%>Z9PXFX1Y(G3**:$@V$PG#(6SO2?MALX61P7)]PHF8!H+H7UD(8,
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M-+F/#F.<T\07)WC??^*VWK%J38+<#NXPQ7U?GVR*B45;ZL\56+$6:(%03_\
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M-#=>+J5Q;'V?,GQ  ECW+=SF#%DA,(F$3")A$PB81,(F$3")A$PB81,(F$5
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MGN"WV9P/?]P*?.<2K3")A$PB81>#K[&<?@%OT9L(J?7_ +0PGS1&_J2.%#>
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M-$_BLI?^"-,/\]WPG>TJ&>:/7[2I Y2JDPB81,(F$3"+6/ROK'"CD;<7&O\
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M1K0QV+IH>U=8;3;RCS66QJ+L1I!O@C)IS1K; VQ"(DC$%4L?*+03]^FP>F3
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MT=/OP-MTYCI9ZN:2.GI8I*29L\+(75$L8>VD;3.W"XAPQD;4   #H = #T
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M4A)1T0S6D)5^RC&#<"BX?2#I!DS0 YRI$%9RY4212 ZAR)E$YR]XYRD#J8P
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MWR3Y*VVFK(K7=G4VY'U#[E1U3XNJB+'-,46Y6ZGH#5%)FZW8J_7'I)6F0\W
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M=S;(OEREB0ZK0D7*M!2B;'&Q4W&SL1YDN]8,9&.<.E4"BP*J1P<XD'0XY]@
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M@C[O%;%MM\'N9T?VG6^>9^I]8Z[OE"Y5=GZ]XRRT1:]O-*#+:<O[UM23*N;
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MG>Q>W@[UE1$:_P  >.##5.[8IGMJ)>2SZ>D-:FUP[/2?.8.-:31(9!!I-O\
MSU>*;+N5W4/%/9%!HA-/R!PW7CZ8@C3D<Z^SBL\]MGK'5_,/1,EQBH6VZ37N
M<FGK1H[DEH6M?#J"-ZKLW*;;@]1UJ<.Q:%5E64/:9&YN:NP>"4C-M9WE8E9
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M5,OL,UDYV&F-@P\;*34=%I2RC9NK>ZFSM\^A!0HR59+*G>LR  M;C(P#QUX
M'3 X8U.FFI4E=A\H^>>JX;7,/=J'IJHV?97.W6''.EV&V0GPOXCT;MJ#?OHC
M8LM1M;[XLJ=1OM2L$)8J])0JMXDH.[-8I"5BE*<:26;0Q &GGHTD]XY:<#IW
M9[<:^^Y.7_)?CPD[0ND]Q_V;-:VOO!K7VP(W6--OK0\F')/=%.U+L>S7()6X
M2<9I!ZDC>HB:TU2%++L6R32,>XL$\S>U6:(K7"  YXC1QUQV D#T\-3@?<.
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M:-K5.=U]6M;J4>&K,]5(F!E'LJN_B'[Z6CK >0<ND&")_@QT%=(W,RC6:?\
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MR;Q3]?5L'C6.&P7BS0M3@PD'QC%9,?A:>>L&'GCPQ#E:M?./+N#$,"1#B40
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M5BR/:W )0$2R;-C$>  _T-TQZN//^_52UC>7>X%^3>C==HVFCW*B;VY*\OM
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M"@!2E      #/GR27$N<27$DDDDDDG)))U))U).I*VC       P -  .  [
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MH6).2<K/3OO\5.20!RX:#/CQQZ,X4*^('"'<&KK!09^ZP,YJBWTYXG([!LU
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MH>-U_>32JI[75Y<R+44"JWCKKQ&#H-0,8SW8&#Q"^N%X#<5Z[$Z_@(:A65C
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MCCC8"Y[WN(:UK07.<0 "2J7O9$Q\DCVQQQM<][WN#6,8T%SG.<2 UK0"220
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MW8R.)8]IRR1AP-Z-[7,=VM*Z,.*7;>4NR)1M1Y5P'@>= J+4NT*BQ>2-/D5
M " YL59;@\G*XNIT*99S#!/1JRZBBOF4$R("9-;=K>@NMIC+6;)5'E]/ESS:
MJQ[(ZR(9SN4U4[<@J6C.&MG\GD:UH'65#SDY;L?213S!E/?(O)I<!OEM.USZ
M=YX9FA:'2PD]KH^M822=V)H6\ZDWRD[)KS&VZ^ME=NM8DB=]E/5B88S<6X'N
ME,=,KR/771*NEW@*NV4,1PW4ZIKI)J )0P-76^NME3)1W&CJ:&JB.)*>JAD@
ME;R)9(UKMTXRUP!:X:M)&JR7355-61-GI)X:F%_FRP2,E8?1O,)&1V@Z@Z$
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MDY0Z'*@TJL0"AN\0[D@'*=/#M[Z!MGJPOELEPK;/(XDB"8"XT;?V+&R/AJV
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MH(6DG<AA8R-I)(;DDG,E!;J*UT[*6@IXZ:!FNZP:N=@ OD><OED( S)(YSR
M 3@ #)V>6NZF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(J!:?N<F?Z
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M,(O!U]C./P"WZ,V$4*V5GLJ;-HFG89PA"-D"$(26?E(0A4B%*4I2N  I2@
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4D\SXE31R%SIA$PB81,(F$3"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g428534g42x62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g42x62.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1/X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $]R^4(0X0DE-! 0      !X< 5H  QLE1QP"   "   < E  "E-T97!H
M96X@36$X0DE-!"4      ! B)R.S>.0!+UE6301,F3\].$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  @"4S,P  0 ".$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!$0      !     "   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              48   *[    !@!G #0 ,@!X #8 ,@
M  $                          0             "NP   48
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   48     4F=H
M=&QO;F<   *[    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   %&     %)G:'1L;VYG   "NP    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$%       !     ,X0DE-! P     "80    !
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M(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     /_B__])0T-?4%)/1DE,10 !";[,_OX>  B <$%$0D4"$   <')T<D--
M64M,86(@!]  !P :  4 *0 U86-S<$%04$P     041"10
M      $  /;6  $     TRU!1$)%
M                               *9&5S8P   /P   !T8W!R=    7
M   K=W1P=    9P    403)",    ;   *(&03)",@   ;   *(&03)",0
MH[@  *(&0C)!,  !1<   CBT0C)!,0 #?G0  CBT0C)!,@ %MR@  CBT9V%M
M=  '[]P  )"19&5S8P         :52Y3+B!796(@0V]A=&5D("A35T]0*2!V
M,@
M                                              !T97AT     $-O
M<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,L($EN8RX  %A96B        "U
M6@  O&<  )(P;69T,@     $ PD   $                    !
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MY^@VZ8;JV.PK[8#NU_ Q\9#R[_1-]:KW!/A:^:OZ]OPZ_7O^N____P"  (
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M-^Z!@X L$GB#(("FWH2!2HVKR4Z X8O>LU& AXHOG&> 48C#A-2 ,H>,;(:
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MACN;:[$I=B*8>*U&94&5JJFN4[23*J<.02^1$J4Z+0Z/?9YV% *0#(V'  "
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M?#2G38T-;1ZCP8NT74&@8HJ!3(F=3(F).HV:P8CL)I29,8C_#3^:7(<]  "
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M<>&UP&YI8[&QO6]Q5*NMZ7" 1)FJ8'&-,P&GDW)X'KNFT7+!!;VG/W-M  "
M (  ?S.Y'W50<<>TR76,8Y&PGG7I5(JLJ79B1':I"7;P,NNF)G=U'L2E,'>2
M!B"E(7C%  "  (  ?OFW\7S^<6^SGWR=8T6O9WQ>5#.K:'Q41"JGPGQK,K:D
MU7R6'KFCM7RA!G*C-GVC  "  (  ?JJVOX22<06R<8.P8L:N/8+Q4\JJ.()F
M0\FFEH(4,G*CI('P'J2B8H(6!K:A?X'D  "  (  ?DRUOXPX<*2Q<HKA8ENM
M/HFP4U6I-XBM0W2EAH?P,C&BDX>>'I"A-(@K!O&?^H2Q  "  (  ??"T_I0&
M<$^PK9) 8@BL<9"74P*H8H\F0R6DJHX2,?ZAG8VU'H&@(XW@!R&>HX32  "
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M9<._L72+6#J[!'352?&VAG5 .I:R=G6_*8VO?W8A%16OQ'6[  ^IZ7CG  "
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M93^Z8I;@5ZZU?Y4*26.PSY.-.C^LD)+"*;:I.),'%F"H+8\A D>AM(&*  "
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M*02"@753!3R#NW:-NDR O72SJ1" C76-EK. 9796@T^ 2W<7;N6 0G?=67"
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MEY:#^I=^AH&#,)5<=&^"@),S88R!\9$P3:J!AH]X.$6!18Y2'K6!6(W=  "
M((  IN*$'*,RELB#1:"(A:V"=IVL<YF!PIK*8,2!-Y@F30" S97R-\> =I2Z
M'E& ;))7  "  (  IDJ#CZT(EB."OJFZA/B!YZ8F<N&!)J*,8!* EY]63%.
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MBH>,6ITP>GF*S9JU:7J)7I@]5ZV((98*1-6'')1;,%Z&5Y/T%O^&LH^-  "
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M@769NGH2<GV7;7I-8F"54WJ543V3:GKI/LN1X7M *EF1''MQ$ :3+WLE  "
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M?B*54J)#;P"3 Y^37O:0S9SQ3AV.W)K4/":-3YG<*&N,.)@:#TN,K(I7  "
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M=)"B.H  9E^?3G^V5TZ<C'^"1QR:&']I-8N8*7]?(:&7=7]8"*Z7BW^3  "
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M<GV>MZ;L9"Z;IJ0R5/J8K:&E10*6#: M,]F3_)Y\()F2V)8*"..1.X8"  "
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M:'^K6(4N6P6GSX2'3+>D;8/S/7*A9(./+)"?,H-K&-F>]X._ NV:.X'[  "
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M7<Z[0&@.4..WEFEP0R.T!6K&-"JPZ&OT(Q^O/FRB#B&Q2&OC  "?!'.P  "
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M71ZU'(G)4$2Q (C<0IZM#8@0,_RID8>2(YVG.H? #^:GJX:X  "9D(    "
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M6G0[-<""?74X&\B#;W5F  "  'JYH(N!V7;5D6:!B'>+@5V!.W@K<!*! WC
M7<" WGE52CB UWGD-06 \WI/&S>!FGHL  "  'XZGV: &8 ED#-_W8 B@!=_
MIX #;Q-_>7_>7-M_9'_"28!_9G^M-'A_?G^4&LI_X7]7  "  (  GCM^L(E]
MCR1^?8C/?P=^4(?_;>1^*X<=6]9^'H9*2)%^,H69,[)^0H4-&CE^684,  "
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MAO*-G67Q=_",>6@@9Y^+B6HG5AN*NVP50SV**FWA+G:**6]'$\B,FV\4  "
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M@E2&2HZR<T.%8(UW8R*$A8PG4B2#S(KP/_*#1(H *]*"_8F>$A^#9X@Z  "
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M><^5'VT":YF3:6YG7$61VV^_2[R0>W$&.;Z/@7(G)7B/=G+("RZ1&')%  "
M (  AB"52'/;>.Z3B'2E:M*1V75D6WN0478>2PR.]7;4.2Z-^G=T)0Z-U'>[
M"QR.R'=]  "  (  A4B3L'P6=_Z1_'Q,:<R077QS6J:.VGR72DN-C'S .)&,
ME'SE))R,6'SF"P&,O'T,  "  (  A&^27819=RJ0L80':/B/&(.A6<:-FH,Q
M2:B,08+). 6+48*')#B*_H)G"NV*\8'N  "  (  @[J11XS(=G*/J(OO:#^.
M#XKT61B,B8GK20:++HC]-YR*)8A;(^N)P(AK"MF)9X84  "  (  @R:0=)5$
M=?&.W9/P9[R-.Y)B6(:+J)#%2&N*38]H-Q2)0HZ8(YZ(LH[&"L:('8=)  "
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M;.Z=0G,A7YV:]'/F42&8T72L08*6\G5H,$25L77^'#:6!77[!%*3Q7=-  "
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M:DN8!IB#7-V5KI;+3G.3894,/QZ199/6+F./^Y/2&S"/C)$]!-6,'(-%  "
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M8*^F WA34_VC+'B<1FJ@>GCO-XF>,WE!)MV<W'EL$I>>,GCU  "4,'QC  "
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M7U:AI)RH4IF>F)KW1-B;HIE6-C.9%YC/)?R7:I;G$JJ7J8R>  N/BH (  "
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M5.FOK'R_2+ZL77RM.[FI-'R<+8ZFE7RB'1FECGR9">JEB'T9  ".P8    "
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ME )S'W-N@^1T#G1T<FAT^'5F7^QUX'933$9VQW<V-Q%WA7?M'9UWDG@'  "
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MCHIKXZ!7?EAM!9V1;35N'9J\6S9O0I@K2#!P4I89,]%PU)4?&SIO-9%Z  "
M (  G51I\:R7C@AK/:ER?<%L5*7R;)=M7Z)K6J5N?9]-1[5OBIT#,U9O_YMX
M&L1N1Y(9  "  (  F%!_EUY:BDE_<&%&>QA_>&/X:I9_GF9V6-A_UVC51<:
M+FL-,.6 OFS>%K6"/6TT  "  '9<EU-]&V>8B49].6FD>@%]9&N':9%]G&U-
M5^U]XV[^1/M^07"/,#E^O7')%C9_LW&[  "  'IGECEZUW"^B %[('(!>.5[
M8G,G:'A[L'0W5OI\"'4Z1"]\<'8I+Y=\VW;8%<5]2':%  "  'WSE05XQ'GG
MAKQY*GIR=Y=YA7K;9WEYX7LY5A!Z3GN.0W%ZP'O<+PE[&WP*%69['7NF  "
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M@KISCZ6*<WUS]**38U5T49^/4E-TQIS]0#-U.9MJ+&QU,YF,$XMTM(TW  "
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M>?V &X"C:\)_WX"67(M_IH!N3&=_>X!).JA_?8 M)MQ_CH 0#5)__G_H  "
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M<=J0D6 :9&F/<6*F5;J.@V4'1;Z-PV<Y-!^-<FD;']*.5FH7!DZ.F6H4  "
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M;;F(%H7[8%Z'*H6'4@N&0H3X0KJ%?(1Q,?*$]X0@'FZ$^80[!I&$/(+;  "
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M96>81V9O6+26HFA 2N&5(VGX.[:3ZFN#*J^3;FRK%C"5%VR4 "^0OFZV  "
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M8?60U8JA552/18GD1[.-OXD5.0:,=HAV*,^+G8A1%76+XX@$ 0.'WX"O  "
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M60R@N&NX31F>E&SQ/_B<FFX>,7^;$6\:(-":P6^5#'V<;&\&  "*>W>B  "
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M5LR:2HZ;2M.8'(V^/=B5_8S;+ZZ41(QV'XN3?HRO#(F3)8AZ  "%(8    "
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M3-^J)F_]05>GJ'"Y-.>E57%M)M^CO''L%@JD3G&K!(2A7'+\  "%07Z*  "
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M3 RD>I(B0*>ANI%5-"Z?(Y"D)F>=+Y"9%B:<]HWD!6J8<(.I  "!@(    "
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MBZ-N[F4/?#%P06=I:Z-QC&FA6>5RT6N^1N9T!VVZ,CAT]6]@&-)TR6_<  "
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MA65D9I#8=D9F-H]F9B%G[8WB50UIDHQ]0M9J](M6+Q5K:HJL%IUK(XG'  "
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M?KUT"6QY<'MTXVX=8.5UNV^B4#)VCW$2/AIW77)=*@MW[7-%$#UY$'++  "
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M><UK6)9$:Y5L?)2!7%UMB9*I3"-NCI$/.JIO6X_V)X!O)X_L#P!Q4(HE  "
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M<@YZ#7+W9)9Z:'0%5BYZNW3W1EM[('73-1=[AW:((71[U';0"+)]<'<+  "
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M;E=S)YK]8/-SFYD04I-S\I<.0S5T296!,G1T>I42'X%SMI+6""QW"H6&  "
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M9;F!'7B160Z ZGDB2UV MWF8/)F DWG\*^B J7I"&$B _WH3 FZ!1'O   "
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M7="32%GW4:Z255S%1%&1E5]B-7F1)6&P)'*1HF-5#T^4C&,G  "("6F:  "
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M6>Z),'U+3@"(9WU[00F'GWV-,MZ'!'V9(MF&S'VC#PN'$GVU  " &X    "
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M4:R;65]51C>9]&%Y.968P&-R*U&8%&4,&E"9$66T!M^8W67C  ""$'(Q  "
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M3I:2/H$[0TR0ZH$C-NV/EX#L*2Z.I8#.&2".J8#K!U",'(#@  "  (    "
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M12VDEF...D&BZV48+A&A?F9Y(!.A!V=6#M&BX6<*  ":WFGN  "  'H\  "
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M0TJ<<X1Q.(&:MH0R+)F9"(/?'PJ8$H/D#JJ8=X-[ +60F8![  "  (    "
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MB'5777M?>4E::GN]:1Y=/GP*6 )?ZGQ618YB*'RD,:UC&WSE&;!C1'SN  "
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M@YYK3%<O=/-L\%K,91MND%XW5!!P(V%X0:QQF&2 +75RI6<)$]%SQF?'  "
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M?-)<:H(';J)>\H'?7V5A1H&@3R=C9X%D/9UE"X$[*DUE)($L$>9H]X$[  "
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M=S=O,%\#:8%PA&'.6J5QS61S2H)S!F;M..%T(FDD)0MTR&JV"XUW]VJJ  "
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M<5YB6H?*9 ]D3(<T5:YF#8:&1CUGF(7K-7!HDX6"(J1GI(6*"LMNSX1#  "
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M:K!T%V747?QU"6?S3_QUZFGK0+EVOVNX+\5W?6TU'!!WRVW6!)Q[Q6ZY  "
M '_O=41P!6O?:7-Q.FU]7+IR3V[^3Q!S17!@/^)T+G&:+R%TWW*6&Z9TNG+B
M!)]YL70H  "  (  =!-M5W0W:$MNL'4Z6Z)OWG8=3@5PYW;>/SQQUG>,+IER
M>W@2&UAQ[G@B!*UX&7FS  "  (  <PYK&'R>9V]LCWT36MIMSWU:33)NXGU^
M/FIOSGV<+@!P4GV]&N%OB'W"!)AX/'Z"  "  (  <CII,X3Y9J%JOH3D6A9L
M"H213'AM)80B/;IN$(/$+6YN=8.7&IAMB(/>!)IX.(*#  "  (  <9)GIXU&
M9@!I0XRQ67AJEHO-2^1KL(K./2ALDXH&+-QLWXFZ&BMK]HG,!)EX.H,<  "
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M7DYZ!&NA4E%ZA6TM14MZ]VZ8-K][:&_.)DQ[VW"A$CE\CW!(  "  '3^  "
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M6KYQ*)#J3NMQX(_;0A-R2XZS- MR?HX")"]R(8XV$1%S/XKP  "  (    "
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M4DZ!$G!Q1O2!''&%.HN!%7)O+,"!)W,M'&>!CG-C"6&!XW.*  "  'RL  "
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M2HR5\5-5/XF53U9*,R:5 ECZ),^5=UL6$N^84ENH 8*4I5V-  "  &T4  "
M (  4YZ3_5<_2;R31%G@/L62IUQ=,HB21%Z;)&>2B&!/$MB4YV"9 =21"F)I
M  "  ''X  "  (  4LN1#%X_2-R0>6!G/@J/[&)M,=B/AV0Y(^2/KV6'$IN1
MI&6. @:-RV=G  "  ';D  "  (  4@".0F5 2 :-R&;Q/2B-2VB!,2^,Z6GA
M(U2- 6K0$DJ.DVJ= A^*\&RD  "  'L\  "  (  43F+R&Q51T2+:6V6/&N*
M]VZU,'2*CV^>(N.*BG ]$?Z+OF_F BV(>'):  "  '\&  "  (  4(*)JW.
M1IF)9W1<.]*(_74-+^J(C'6/(FF(:'77$>*)'W6( D6&57A*  "  (    "
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M/?B>[%=W,WB>&EG%)X^=KUN\&46>H5S8"*>?<UU9  ".W&1^  "  '51  "
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M.L^36G<Y,(*2KG>6)/B2 7>\%VB2'G>9"(*/TGB;  "$LGW*  "  (    "
M (  0\F207V0.FV1]GWM,#*13WWX),.0B'W:%T*0<WW("%*-\'YX  "#18
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M@$=0<VRG<?54 6Y68K174F_R4BE:67%X0&I<KW+G+1-="G08%3AAN'1S  "
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M>QQ##)@6;59'BI7U7H9+DI/R3J!/"I)%/8)119$=*N%0K9$3$]]>:8U   "
M (  B!UA[$X,>L-D!U(=;+%F)E8779MH.5GL359J+EV1.Z1KVF#O)_)LF&.I
M#I-PZV1H  "  '&TAB=<^5<;>4A?BUIW:V-A_EVV7'MD46#33%EF<F/#.LQH
M*69U)T)HAVB4#D-N$6C_  "  '9HA&Y88F!&=[1;6V+?:BU>'&5C6UQ@HV?%
M2VEBZ&H#.@MDH6P-)KEDDFV9#A-KAVW%  "  'J+@KM4,&EI=A=7>6M":)5:
M=&T+6A1=,&ZZ2C]?H'!*.11A57&T)?E@R'*]#;AI>'+/  "  'XC@3)0:W*(
M=*I3]'.J9T%7*72Y6-1:#W6R25Q<GW:=.$Q>2W=Q)6==@W@)#7YI,7@Z  "
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M< 9K#5'\8KILMU725&%N6%F#1,9OW5S[,X]Q*V 3']1QK&(Y!S-WMF,0  "
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M:4)8:7G'7+!;*WI.3Q%=EGJ\0%1?B7LB, =@6'N#'4]@B7N[!M9T<GSJ  "
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M8[MN:ED35U]OW%PN2>EQ-E\A.PUR:F'0*E)S6F0#%D-T"637 ,Y^I&<A  "
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M7>U=XW[T4AM@'W\,139A\G\+-QMC*W\3)T=BWG\O%'%FNW]F 21^$W_Z  "
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M5UUR[E\72^YT$F&0/R]U#V/7,/IUYF70((%V>&<>#'QY06<:  "  &]6  "
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M4J1D;8-!1WUF(8,'.T-G3(*S+:MGLX**'>QFZH*W"XIN7()[  "  (    "
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M2S%XDF/]0%9Y567D-%AY]V>:)HAZ?VCF%=-Z^&DO!'-]W&IO  "  '@@  "
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M1V]L 8;I/-QM089X,3EMSH7S)!%M9(7;%!!NI(6X!%%XM8+K  "  (    "
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M/R=_CV?.-,)__FDW*1Z 3VI7&Y6 P6KX"SN!8&K]  "  '!Y  "  'Z^  "
M (  1[I[XFU,/DU\L&YP,_Y]-F]H*'%]?7 B&OM]IG!L"Q-^AG"'  "  '95
M  "  (    "  (  1OAY,71=/95Z+74=,UQZRW6G)^9[!78#&G)ZYW83"M1\
M-G9L  "  'M'  "  (    "  (  1D]VT'ML/.MX WO0,KUXO'OX)UUX[7P
M&?IXA'O["FUZ;WRM  "  ']X  "  (    "  (  1=-TVX*\/(=V1(+@,F]W
M((*?)SIW.8)+&B1V<H);"LYXM8(&  "  (    "  (    "  (  0)F914BK
M-[*8K4OE+:.8E$[4(:J945$[$GF<,E)3 U*9OE1@  "$LE^*  "  ' -  "
M (  /S>5O$\$-E25CE'9+"R5F51B($N60%9F$6Z8H5<O PF5%5D_  "!KF1
M  "  '4!  "  (  /D&2%E5X-3J2&5?A*QZ2/EH"'SJ2UUN@$*"4PUP? M*0
MSUXN  "  &DC  "  'ET  "  (  /6^.?5O]-%".GUWV*AB.U5^I'F>/9&#H
M#_^0UV$J JJ-!F,Z  "  &Y6  "  'U8  "  (  /)J+%&*:,W2+:60F*42+
MK65T'9F,(F9+#Z>-$&9G IF)Q6B'  "  '0$  "  (    "  (  .\N'\FE=
M,J:(AVJ!*)"(Y6MK'0:)0FOQ#S^)I&O6 J:' VXP  "  'D[  "  (    "
M (  .Q6%*7 I,?2%_G#O)_B&=W%Y'(V&OW&T#N>&KG&& I:$Q713  "  'V8
M  "  (    "  (  .GR"NW<*,5V#SW=\)W:$97>N'"Z$EW>H#J.$27>2 FZ#
M GHK  "  (    "  (    "  (  .@V JGXG,.>!]GY/)PN"K'XQ&^."S'X!
M#I&"7'XN HF!B'[_  "  (    "  (    "  (    #__P  __\  /__  !M
M9G0R      0#"0   0                    $                    !
M   !   "   ") 0=!=H':0C9"C8+A0S'#?\/,1!>$8L2MQ/B%0L6,A=7&'D9
MF!JU&](<[QXE'UD@AR&R(MHC_R4C)D0G9BB&*:<JQROH+0@N*"](,&DQB3*F
M,\(TWC7[-Q@X-3E1.FT[B3RE/<(^WC_X01%"*4-"1%Q%=4:/1ZE(PTG=2O=,
M$DTL3D-/65!O4892G%.R5,E5WU;V6 U9(UHZ6U%<9EUX7HI?FV"M8;YBSV/@
M9/%F F<2:"-I,VI":U)L7FUG;G%O>G"#<8QRE'.<=*-UJG:Q=[=XO7G#>LA[
MS7S.?<U^S'_+@,F!QX+%@\*$OX6[AK>'LXBNB:F*I(N>C)B-D8Z&CWN0<)%D
MDEB33)1 E3.6)I<9F R8_YGRFN2;UIS(G;N>K9^?H(ZA?*)JHU>D1:4SIB"G
M#J?\J.JIUZK%J[.LH:V/KGVO:[!9L4>R-K,DM!*U +7MMMJWR+BUN:.ZD+M^
MO&N]6;Y'OS7 (L$0P?["[,/:Q,?%M<:CQY'(?LELREG+1,PNS1C. <[KS]70
MOM&GTI#3>=1AU4G6,=<8V #8YMG-VK+;F-Q]W6+>1]\LX!#@].'8XKOCGN1[
MY5?F,^<.Y^CHP>F:ZG'K2.P=[/#MP^Z6[W;P5?$S\@_RZO/#])SU<_9)]Q[W
M\_C&^97Z8?LI^^O\I_U<_@O^M/]:__\   'H Z<%+ :$![\(YPH$"Q8,' T>
M#AP/&1 7$102$!,+% 04_!7S%N87V!C,&=8:WAOA'.$=WQ[;']8@T2'+(L0C
MOB2X);,FKB>J**8IHBJ@*YXLG2V:+I4OD3"-,8DRAC.#-($U?S9_-W\X@#F"
M.G\[?CQ\/7P^?#]]0']!@D*%0XE$C4621IA'FDB;29U*GTNC3*9-JDZO3[10
MNE' 4L=3SE355==6V5?;6-Y9X%KC6^=<ZEWM7O%?]6#X8?QC &0#90%E_V;\
M9_IH^&GU:O-K\&SN;>MNZ&_E<.%QWG+:<]9TS77#=KEWKWBE>9MZD'N%?'I]
M;WYD?UB 38%!@C6#*80<A1"%_H;MA]N(RHFXBJ:+E8R#C7&.8(].D#V1+)(;
MDPJ3^I3IE=F6R9>ZF*>9DYJ FVV<6IU(GC:?): 4H02A]:+FH]BDRJ6]IK&G
MIJB;J9&JAZM_K'>M;ZYGKV"P6K%4LD^S3+1)M4:V1;=$N$6Y1KI(NTJ\3KU2
MOE>_7<!CP6K"<L-[Q(3%BL:0QY;(G<FERJW+MLR_S<C.TL_<T.;1\=+[U ;5
M$M8>URK8-]E$VE';7MQKW7G>AM^4X)SAHN*HXZWDLN6VYKKGO>C Z</JU.OE
M[/7N!.\2\"#Q+/(X\T/T3O59]F/W:OAN^6_Z;/MD_%;]1/XO_Q?__P   @4#
MV 5H!L8(!@DR"E(+90QR#7@.>@]Z$'H1>1)U$W 4:!5>%E(711@W&2D:-!L]
M'$ =/QXZ'S0@+"$C(ADC#R0$)/DE[B;C)]@HS"G!*K8KJRR?+9,NAR]\,' Q
M9#)9,TTT034V-BLW(3@6.0LZ #KV.^T\XSW;/M,_RT#$0;U"MT.R1*Q%ID:A
M1YQ(ETF42I!+CDR+38I.B4^(4(A1B5*(4XA4B%6(5HE7BEB+68U:CUN17)-=
MEEZ87YM@G6&?8J!CH62C9:1FIF>G:*AIJ6JJ:ZILJVVK;JMOJW"I<:ARI7.C
M=*!UG7:9=Y5XD7F,>H=[@GQ\?79^;W]I@&&!6H)1@TB$/H4UABN'(8@7B0R*
M HKWB^V,XHW8CLV/PY"YD:^2I9.<E)*5B9: EWB8<)EJFF.;7IQ9G56>4I]0
MH$^A3Z)0HU*D5:59IE^G9JANJ7BJ@JN.K)RMJZZ[K\RPW['SLPFT(+4XME&W
M;+B'N:2ZPKOAO0&^(;]#P&7!A\*JP\[$\<85QSG(7LF"RJ;+RLSMSA#/,M!4
MT732E-.RU,_5Z]<&V![9-MI,VV'<=-V'WIC?I^"SX;[BQ^/-Y-'ETN;0Y\SH
MQ.FZZJSKF^R'[6_N6.]<\%OQ5O),\SWT*O42]?;VUO>S^(WY8OHO^O3[L?QF
M_1']L_Y-_N'_<?__   !V0.-!0D&5 =_")8)H0JD"Y\,DPV"#G /7Q!,$3<2
M(1,)$_ 4UA6[%I\7@QB!&7T:=!MF'%4=01XL'Q<@ "#J(=,BO2.F)) E>B9D
M)TXH.2DE*A J_2OJ+-<MQ"ZQ+YXPC#%Y,F<S531$-3(V(C<1. $X\3GB.M,[
MQ#RU/:8^F#^*0'U!;T)B0U5$244\1C!'(T@720M)_TKS2^A,W$W03L5/N5"M
M4:%2E5.(5'I5;59?5U%80UDU6B9;&%P)7/I=ZU[<7\Q@O6&L8IMCB61X969F
M5&=":#!I'FH+:OAKY6S2;;YNJF^6<()Q;')6<T!T*742=?MVY'?->+9YGGJ&
M>VY\5GT^?B5_#7_T@-N!PH*H@XV$<H57ACN'((@%B.J)SXJSBYB,?8UBCD>/
M+9 2D/B1WI+$DZJ4D95XEF"71Y@OF1B: 9KJF]2<OYVJGI:?@Z!QH5^B3Z,_
MI#"E(J85IPBG_:CSJ>JJXJO;K-6MT*[+K\>PQ+'"LL&SP;3"M<6VR+?-N-.Y
MV[KCN^V\^+X$OQ' (,$PPD##4L1FQ7K&C\>FR+[)ULKQS S-*LY'SV/0@-&?
MTK_3X-4#UB?73-ASV9O:Q-OOW1K>1M]SX*'AS^,"Y$WEF>;GZ#;IANK8["OM
M@.[7\#'QD/+O]$WUJO<$^%KYJ_KV_#K]>_Z[____ (  @ #F3W_.?UC-F7^H
M?LVTVG^9?GF<%'^C?F6#3'_&?H5JA7_^?L!1OX!C?STY ($2@ _\Q7Y\BS3D
MM7YCB6S,0'Y=A\RSFGYNAF::V'Z8A4."&'[9A$]I6G\O@V=0KG^O@J$X%(!V
M@>;ZO'TVEG'B^WTPDY+*RWT^D,^R.GUICEZ9DWVLC"R [WX'BB)H3GYUB!-/
MP7\,A@ W07_H@ZSXXWPNH;?A07PSG;_),WQ-F?"PPGR%EE>817S?DQI_RWU/
MC_-G5GW1C+5.[WY\B4TVAW]GA5SW-WMCK0/?I7MFI^O'JGN'HPJO8'O)GFF6
M^'PKF?A^LGROE;=F;GU#D4%.+GW]C'LUY7[TAN_UO'K*N%7>+WK'LA3&0WKD
MK!2N&7LLIF&5W'N9H-I]I'PDFUEEE7S(E:A-@GV1CX$U6WZ1B%_T=WI2PZK<
M['I&O#+%"7I=M0JL^7JGKCN4Z7L?IYM\V7NVH.ADV'Q@F=U,[7TUDE TZ'X]
MB:?S8WGWSP';V'GCQD##^GGRO>2K]WHZM>R4 GJXKB1\('M;ID!D2'P0G>5,
M;WSJE.,TB7WWBL7R=7FTVEK:ZWF7T#+##WF?QI2K&'GCO6J3.WIDM&I[=WL-
MJT!CPGO,H99,"7ROES,T/7V^B[;N4XC;?C;7AH?$?<+ GX;#?7"IC(7F?562
M4H4J?75[!X2&?<9CQ(/Q?C5,CX-X?NDUDH,H@ #L/8=]B,O6%(9PAT"_:X6#
MA>.H8X2[A,&1'H0;@]]YU(.4@RUBG(,=@HU+DH+#@A8TV(*0@<'J>H9'DV74
M=(5-D-J]_(1OCG.G"X/$C%B/[8,YBG=XRH+*B+UAMH)IAP-*S8(FA4PT,X('
M@V_HVX5/G?[2X(1?FG2\>H..EQ2EJX+GD^B.M()RD0MWNX(5CD%@UH''BV1*
M&(&7B&@SHH&+A03G7(2+J*#1;(.=I!6[$(+4G[JD6X(WFY2-@('"EY5VNH%X
MD[M@"($YC[))=8$:BV4S)($?AGOF (/QLTO0&X,$K;JYS8(ZJ%BC,H&CHRV,
M>X$VGB!UR(#NF11?2H"^D]M(Y("OCCHRN8#!A\_DU8-SO?C.^H*'MU:XM8&\
ML.*B+X$FJJB+GX#$I(IU$8"#GE5>IX!4E]%(:8!3D-DR8(!RB/OCUH,.R*7.
M!8(DP.*WQH%7N5.A2H"_L?J*T(!AJKMT:X NHUQ>*8 'FY5( H 'DSLR%X P
MB?[C (*]TU3--X'6REFV^H$'P9J@B(!NN1.*(X 1L*)SVG_BJ 9=MW_&GOU'
MJW_0E58QW'_[BM?>$I'B?+#([H_Q?&.SL8X8?#J>.XQH?$>(C8K>?(]RQ8EI
M?0I=$8?\?:A'>X:9?I,R484Y?_'<*I"TAI?'E([!A5*RDHSTA#R=-HM7@UN'
MCHGD@K9QTHB(@CU<*X<S@=A&N87I@:(QRX2B@9W:HX^.D)7&.8VHCE>Q<HO=
MC#Z<%8I7BG"&>(CXB-EPT(>UAVA;2(9WA?Q&!85&A)\Q5(09@S390HZ;FI?$
MV(R_EVRP!XL'E&N:R(F"D:2%4H@YCQUOV8<%C*A:@X78BB9%;X2ZAX\P[(.@
MA*_7[HWAI)3#AXP)H(&NNHI;G)N9CXC>F.2$.H>-E4]N\(9KD=59SH5*CC1$
MZ(0]BELPD8,UA@O6M8U+KIS"7(MWJ9VMF8G*I,28@HA2H!>#3(<(FWYN&H7A
MEN)9*X3.DAU$<X/0C/\P18+:AT35IXS0N*/!7(K_LK"LH8E1K-J7FX?=IRJ"
MAH:;H8IM=X5ZF]!8H81BE=!$$H-SCVPP!8*-B%;4PHQJPJ; AHJ=N[*KSXCQ
MM-26T8=[KA*!SH8]IUMLXX4IH()8-H06F4Y#P8,GD9POT8).B4'4!(P3S*F_
MU8I-Q*"K'XBCO*66)X<MM+Z!-X7QK-YL9X3@I-57U(/9G&U#>(+TDX4OIX(;
MB@7.3YL;>X"ZHIA9>U&F[Y6L>T:3"I,G>W-^Z)#&>]IJJ(YU?'=6B(PB?3E"
MEHG"?E O0H="?^+,G9H/A-*Y@9<\@[ZF!I27@M62-)(@@B1^$X_3@:UIVHV8
M@6-5QHM9@3%!_(D1@3<N[X:F@7K+0ID1CB&X1)9%C"ZD^9.=BEJ1+I$WB-5]
M(([ZAWUI HS1ADI5#HJEA1]!=(APA HNI88;@OK*(9@>EXZW&)5CE+FCRY+)
MD@&0&Y!7CXQ\'8XMC5%H((P4BRE46(GYB/E \H?;AL$N986?A%[(_Y=FH/:V
M!Y2MG42BKY(;F;^.^H^]EFE[((V)DS-G48M_D!%3OHEMC,U BH==B6$N+H4T
MA:''[);8JF"T_I0BI=>AKI&2H7"."X\YG3%Z3(T)F0)FEXKXE,Y3-HCPD'1
M,(;OB],M_X38AL'&^Y9DL[^T().NKE:@UY$?J06-08[(H]%YGHRAGJ=F"HJ3
MF6-2QHB"D^(_YX:/C@TMV(2,A[O&+I8#O1FS99-.ML2@(9# L'R,DHYIJD1X
M_HQ&I!%EB8I$G;I2:X@VEQ8_JH9!D LMN(1,B)#%A96OQG&RS9+\OQR?B9!R
MM\:+_HX=L'=X>XO[J2AE((G^H;)2&H?]F>P_<(81D<(MGX0:B4"_(*2'>JVL
MR:#Z>HV:?YU\>I:(%)H?>MAU<I;>>U9BM).E? Q0*I!;?.D]X8SN?B L:HD[
M?].]HJ.<@W"KXI_R@GR9SIQS@;6';ID?@25TQ97O@-)B"I+'@*Y/B8^/@*8]
M;HPU@-PL28B7@5F\@Z*IC#:JW)\&BFZ8[)N%B,^&C)A!AW5S\Y4<AE!A4I(#
MA5!.\X[9A%L]"HN0@X4L+(@%@L2[@J'=E.RIT)Y$DEN7V9K,C_F%E9=^C<)S
M$Y1DB\U@F)%4B>9.9HXTA_H\LHK[AA L$X>$A!&ZI:$:G<.HZ9V.FF66YYHA
MES2$H9;:E"9R/).ID3]?YI"ICFM-X8V4BWT\88IOB'8K_8<5A3VYO*"/IIJH
M'IS]HFF6))F,GF"#WY9)FG]QB),KEJ]?39 BDMI-=HT5CN,\(HG^BK<KZH:W
MAD6X[: @KUJG8)R*JEB5;ID:I7&#-97;H*IP]Y+$F^M>UX^_EQ5-'HRGD@L[
M\(F;C, KVX9HARJX-Y_'N FFP9PMLB>4UIB\K%B"I95^IIQP<Y)KH.1>;8]P
MFPQ,UXQ9E/,[QXE+CHPKSX8HA^NWH)]YP+2F/IO9N=Z45IAJLPZ"*94PK$IP
M")(@I8E>&H\JGJ1,F8P@EX$[GXD<D!0KQ87TB(FPG:XH>B:?BJG->@F.CJ5^
M>AM]@*%(>FIL2ITA>OA;!9CP>\!*"92@?+$Y:I 1??\IT(L<?\2O7*U2@F:>
MU*C9@8*.!J2$@-!\_J!0@%IKOYPR@"):?9@/@!U)C9/*@#8Y(8]+@),IX(IK
M@3FN=ZQKBI^> J?WB/>-4J.=AWM\1Y]SAD=K$YM=A4A9Z9=%A'-)&I,+@ZXX
MY(Z;@Q I[HG/@I&MM*N;DL^=+J<TD&J,<Z+CCC)[>YZQC#5J7)JCBG!95):2
MB,%(L))@AQ(XKXW^A6XI^HE'@\FL[:K]FO6<:J:6E]2+JJ))E.=ZM)X9DBQI
ML)GYCX-8S97RC/A(5)'%BE8X@HUQAZ4J!(C1A."L1*IBHS>;R:7]GU*+"Z&P
MFYEZ&IV$F AI(YEFE(585I51D05( I$PC6LX6HSPB:\J#8ANA=2KGJGOJUZ;
M1*6 IJB*CJ$MHAAYG9T G:]HLYCOF517_93FE.5'Q9"[D$TX/HR(BX<J%(@<
MAJ6K!JF7LVB:PZ4?K=J*&:#*J&QY,9R>HQ]H5)B3G=M7L)25F'Q'DY!JDNPX
M*HPUC24J&8?8AU2J@ZE,NV2:5Z3)M.B)M*!UKH5XU9Q-J$%H!YA&H@E7>)1+
MF[5';I OE3,X%XP#CH(J'H>CA^.BX;?\><>3 ;+,>:.#/*VJ>;AS=:B6>A%C
MF:-]>JQ3OYY(>X-$1IC??(8U2I,<?><G?XS9?[:AY+<M@8V2=['H@+""UJR\
M@ QS$:>C?ZAC*Z*,?X=36)U=?YY#\9?Z?]8U+))$@%4GO(P9@1RA/[9&B4*1
MV[$)A[""3ZO8ADURA*;"A3EBJ*&NA%Q2ZYR&@ZY#I9<J@Q0U%I&#@J@G\HMP
M@F*@M[5RD.:11+ ^CJ6!J:L2C)5Q[*7RBL1B(*#GB2U2@9O&A[%#8)9QACHU
M!9#9A-HH(8K>@XB@++3'F(>0MZ^2E92!&:IIDMEQ6Z5,D$]AIJ SC>E2(YL<
MBYM#)Y7.B4 T^)!#AN0H2(IAA(V?F[1"H"60-Z\$G'F HZG6F0)P[J2ZE;QA
M1)^DDHE1U9I^CU5"^94XC!0T[8^_B,$H:8GWA6Z?+K.ZI["/UJYZHT" 2:E,
MGP-PG*0UFO)@_9\EENY1H9H"DMM"UI2KCJHTY8]&BF8HA8F@AB^>M[-<KQF/
MC:X,J<V #JC2I+1P7J.QG\U@PIZEFOI1<9F:EA%"O)14D04TY8[NB]HHFXE9
MAL^>3;,*MF>//*VNL#1_RZASJC!P**-7I&1@G)Y0GK116YE(F.]"M)00DPTT
MZHZVC1(HK8D@AU&5[,']>7^',KOR>5!XD;7X>6)I_*__><);9ZGK>FA,[*.A
M>T\^ZYT.?&(QA98%?=,E=(YO?ZF5/,$F@-B&T;L8?_EX1;44?UQIKJ\/?P=;
M%:CS?OQ,IJ*G?RP^O9P3?X QDY46@!\EW(V=@0&4V< RB ^&:[HSAHMWZ[0K
MA3MI3:XBA$%:O*@#@X1,8J&\@OH^FILM@HDQI91 @DLF-HSF@CB4D;]0CRZ&
M%+E4C0AW@K-/BQEH[:T\B6U::*<EB ),):#EAK4^?II?A70QN).$A%,FA(Q(
M@TZ40KZ3EDB%QKB2DWEW,[**D.IHF:QZCI-:):98C&5+^* GBE0^:YFLB#PQ
MRY+BAC,FQXO"A$*3Y+W]G5V%>[?PF=QV];'AEIMH9JO2DY)9]J6UD*5+UI]]
MC<$^7YD-BM,QW9)5A^8F_HM2A163B;V#I$Z%.K=HH ]VQ+%1G!!H/ZM!F$M9
MV*4OE*)+Q)[\D/$^6)B#C2TQ[)'<B64G+(KUA<:33;T!JQ.%#K;EI@IVI[#-
MH49H+*J_G+]9R:2SF%)+NIZ1D]4^59@9CT0Q^I%QBJ\G48JIAEJ3 +RBL;6$
M\K9TJ[]VG[!1IA)H)ZHYH+E9S*0LFXY+QYX2EE<^;I>ZD1$R&)$PB\8G;XIN
MAM&)E<PD>7![]<4V>2AN9KYH>2]@[+>.>8]3D+!X>CQ&::D)>RXYVJ$W?$PN
M!IC4?<DCI(_A?YR)2<LJ@&5[O\1B?W9N+[V.?M5@M+:<?HA36Z]P?HM&2:?V
M?M$YV: =?SPN0Y?'?_0D,X[\@.F),\H:AR)[E\-JA:!N"+R3A%=@A[65@W!3
M-*YA@LM&-J;J@F YY9\7@A(N@);6@?PDL(XV@A.)+\D=C;Y[B<)GBZ=MZ+N0
MB<]@:K2(B$!3'ZU<AOI&,*7PA=<Y]YXLA,4NN98%@]TE&XV-@QJ)(\A"E%![
M@L& D9IMYKJ?CRY@7[.:C0)3':QJBP5&.J42B2HZ$9U@AU$N[I51A94E=8S]
MA ")"<>$FMA[>\"VEW=M\+G-E&1@=;+)D953+ZNDCN=&4*1-C$DZ+YROB:LO
M'Y2YAR EP8R%A,6([,;AH2][=L *G1AM_;D:F51@CK(8E=I32ZL DG]&;J.U
MCR<Z4)P9B\@O2Y0YB'DE_XPBA6J(S<94IU![<;]WHG9N#;B"G?A@JK& F<I3
M:ZIPE<)&CZ,YD;8Z<INJC:0O=)/1B:$F,HO2A?.(L<70K3)[<;[QIX=N);?Z
MHCU@TK#YG5=3FZGPF*-&PZ+%D^XZI)M+CS<OH9.'BI8F6HN3AF'RSWMC>;#;
MW7N\>=+$J'P<>@>M)7R#>EZ5<7SW>MU]K7U\>X)E\'X5?#Y.1'[9?30VRW_I
M?GWPLGFYA,_:+7HT@\K#*GJS@NBKSWL[@C*4-'O0@:I\B'QV@4)DX7TN@.--
M57X0@)\V 7\Z@&CNS'A9D +8:GCEC=K!GWEXB]*J7GH9BA"2ZGK)B'U[9'N+
MAP5CY'Q?A89,?7U;@_XU3'Z;@C_M!G<SFS'6KG?(E^^_^'AHE-BHX'D9D?*1
MF'GACU1Z07J[C,-B\GNGBAI+N'RYAT<TK7X,@_WK:79'IE75&W;>H@.^<G>%
MG=ZG=WA!F>R037D6EAUY*'H&DG)B#7L&CI9+ GPLBF\T)'V-A9WJ!'63L6_3
MOW8GK!&]'G;-IM>F-W>/H<^/+WANG.9X'WEIE_UA.7I\DNM*7WNRC6TSKWT?
MAQ?HVG4%O'O2G765M@Z[_W8WK[JE)';[J92./7?DHXUW47CJG7-@@7H&EPQ)
MU'M+D#,S37S"B&CGYW2<QW'1L'4GO^Z[$'7"N'ND-W:"L2N-8'=QJ?AVFWB#
MHJY?\GFJFOQ)7GKVDKLR_'QTB8SG)W15TD'0]G39R9NZ3'5JP/^C;G8DN(",
MHG<3L!5U]'@KIXA?:GE;GHY(^7JQE/HRO'PVBH'BF801>!O-C8.%>'BX'(,.
M>.&B.(*K>62,"8)<>@QUO((?>ME?@('P>\-)58'B?.PS?(($?G7@X8*.@JG,
M7((7@>:W$H&S@3^A*(%E@,&*Z8$K@&MTH($)@#E><X#^@!E(=8$5@!\RX(%:
M@$G?48%!C4'*P8#9BVZUEH""B;B?Q8!-B#Z)LH NAO!SE( IA;Y=CX UA(I'
MNH!D@U@R5H"_@@?=OX HE\7))7_'E/2T 7]\DD*>7']0C[F(=']+C6YRAW]<
MBS%<MW]_B.-'$W_%AG0QW8 T@ZS<1']"HD''LW[BGGNRFGZ@FM*=!WZ ETJ'
M07Z"D]UQB7ZJD)-;[W[@C2!&>W\YB6TQ='^ZA3#:^GZ0K+[&='XQJ 2Q8WWN
MHUB;XWW3GL6&/7W?FDAPGGX,E=!;.7Y6D39%]'["C#LQ&W]1AH[9Z'X"MS+%
M;'VDL7ZP7'U>J\>:Y'U#IB&%7GU:H)%OYGV2FO):GGWAE1=%@7Y<CM$PT'[Y
MA\/9#7V7P9C$EGTZNN*O?WSMM!::!GS-K4V$D7SGIIMO.7TMG]=:&GV'F,-%
M(7X(D2LPDWZOB,[89GU*R^[#[GSNQ">NQ7R8O#691'QOM#N#X'R(K%ANIGS5
MI&!9K'T[G!1$TWW(DSTP8WYTB:W2[XSK=MF_DHM\=U>KO8HM=]V77XC^>'R"
MJ8?F>4-MT8;>>C19&(7>>T9$>X3Q?*$P6H0:?FO1=8N4@,&^9(HU@#RJHXCT
M?]&66H?5?X:!KX;2?V5LZ(7C?V=80(3]?WM#S(0L?[HO[H-N@"K0)HI4BKF]
M%HD%B36I@X?)A\J5-(:_AI. FX70A8-K\83YA)%7;80L@Z)#*X-W@K\OC8+4
M@=+.SHE"E*6[M(?XDC>H$(;.C^*3Z87+C;-_=H3UB[1J^H0SB<)6JH-\A\-"
MG8+;A:\O.8)+@UW-@8AIGH2Z:(<BFS2FR88 E_J2LH4&E-E^9(0QD<YJ%H.%
MCMI5^H+>B\1"'X)0B'DN\8'3A,;,6X>^J&FY3(9ZI#:EM(57H F1K(1BF^U]
M>8.5E]]I1X+ID\Y578)4CYQ!LH'8BQ<NLX%LA@O+9H<SLD2X7H7RK2>DQX3.
MI_^0R8/:HM]\LH,7G<IHI()SF*!4V8'=DSU!5X%RC7XN@($6AR?*H(;'O ^W
MG(6*M@&D (1CK]60!(-JJ:%[_(*JHW=H"X(4G3)4:8&'EJ5!"X$>CZ<N5H#.
MB!K*"H9UQ<VW X4\OL"C6800MWV/68,2L"5[8H)1J-1GC8' H6A4!H$_F;!
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M?LO%LX3AA,JT (0MA *AHH.!@T*.6H+U@IYZQ8)Y@AIG&X(7@:Q3GX'*@41
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MD/98@'5OC4=$/W>UB4HPG'H[A,'14&F!K9>]RVM)J0VIOVT"I%B536[%GYV
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M@M+$SG+<GSFRQW._G"2@)G2AF/&-!'64E;9YIW:GDGYF.G?=CT-3&'DUB_!
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M28]@>\6#AHVC>_YT 8O_?$5D*(ID?*-4/(C5?1A$JH=$?9PUC(7 ?CPGEX1
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MB]0Q\)(GB.4I?8R$AA<BC8<<@YO.H6T89OJ[Z&[L:3VHM7"M:W&4ZG)>;9R
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MAE7$&F'WN>NQ]&1@M%*?&6:?KE>+V&CHJ"UXD6MKH@=E;6XIF]!2IW$5E5Q
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MC7_/=P$K"("Z>E6QQ'L,;TNB:GMI<,^2&WO'<CZ!$WPR<Z=OA'RM=1U=RGU
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M_GX)AN(H:W['@X:?2GPTHLB1!GPDG[N"%'P&G$-RHGO\F(QC WPDE,A3<WR
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MGHT!F#ANX8LQE85ANHE>DI%4A8>OCYI'?(8GC*$[&82BB:4O78-"AHDD_8(
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M7(>I@% C$H3U@#M]?9E^B-UR-);QB!)F>)1/AR)::)&@AA].38[PA1Y"98Q
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M@LW"SV@.8."Q2FI.8[^?46QY9HR,PFZ9:4UYPW##;!-FEG,(;O!3GW5R<?)
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M<R%G/(*-=(%938([=?%+2X']=WD]NH'/>1HPMH'$>N4E 8':?-R,[8'O>'"
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MA'EFI')U@]A8_W07@S1+4W7N@I@^('?U@?\Q?WHZ@5XF.7RC@+.,6FS.C7R
M*6Y4C')S5F_-BR%E^W%:B:=8:7,9B"A*X74.AJ<]Y7<MA20Q:WF7@XTF2GPD
M@>2+P6O"E79_D&U7DZ]RO6[:D8IE;7!RCR]7Y7)&C,]*;G19BFP]FW:2B (Q
M5WD1A7LF6'N\@N:+5&KZG29_'6R9FJ9R06X?EZAD]&^[E&=7@7&7D2)*)'.\
MC=H]6W80BH8Q+WBLAQLF8WMI@[N&\(%M6H1[@H$X7?QO7($R85QB?H%$9+55
M+X%>:"!'SH&(:[8ZX8'';WXN@((R<Z8C;(+/>$&%^7[08KAZJ7[H96ENAW\.
M: MAR7]!:JY4GW^";6-'9G_:<#TZIH!*<T N?(#J=HXCK(&U>BZ$_GQ@:M)Y
MEWRS;,AMH'T";K1@\WU<<)U3\WW(<IE&Z7Y1=+$Z7G[T=N@N<'_%>54CXX"]
M>_:#\WHN<LMXB7JH=!1LCWL>=4U@+GN8=GY32WPT=[I&='SL>0HZ'WV_>FXN
M9W[!>_4D$W_D?9>"\GA$>KUWD'C@>UEKIGEU>]A?57H/?$52R'K'?+I&$WNN
M?3LY[7RM?<@N8WW=?F8D/'\J?PZ"%7:\@IYVV'=Q@I%K '@9@E->J7C)@?52
M)GF<@9A%J7J=@48YJGO#@/DN4'T;@*HD7WZ-@%B!875ZBDYV)G9!B95J5W;V
MB)1>#W>XAVI1G'BCACQ%0GF^A1(Y?'KY@^HN2'QU@K,D>WX+@72 U71YD<!U
MGG5/D%MIT78-CI5=E';7C)A1+'?4BI9$WWD*B)0Y0'I<AI(N07OMA'PDDGVA
M@F2 ;'.WF.]U-'27EN1I8G59E%1=*W8ED7Q0UW<ICJ!$I'ANB\4Y$'G:B.<N
M)GN&A?PDI'U,@RE[>8G!6FEPY(CF7<UEMH@T82E9[8>.9(A-RH;@: %!I88U
M:ZDV!864;X(K!X42<[DA9(2W>$]ZFX=<8AYP+H;!9,YE"H8O9WI98H6?:B]-
M8H40;/U!8X2,;_,U[H06<Q(K(X/"=GPAO8.1>BEYQ(4+:;=O1H2E:[QD3(0V
M;;]8M(/';\=,WH-=<>9!#(,&="4UR8*]=H4K-8*6>1PB"H*/>]UXX8+O<31N
M6X*L<IAC8()?<_)8!((1=4Y,3('2=KE JH&E>#PUFH&)>=4K/8&/>Y4B38&N
M?6IX!X$B>)UMCH#Z>61BFX#'>A9718"3>KU+V8!L>VU 58!L?"\U<H!X?/XK
M1H"G?>$BAH#N?LQW1G^;?_1LW7^/@!YA^W]P@"%6OG]-@ I+;7\^?_1 ,W]0
M?^\U:7^$?_4K57_=?_PBM8!-@ -VIWYHAR)L87YSAK1AC7Y;A@!64'X\A2)+
M 'Y!A$<_W'YO@WDU3'ZU@K,K6G\S@>$BW'_'@0UV*7URCA=KZ'V+C0]A&'UZ
MBZ)5Z7UBB?I*I7UTB%<_B7VZAKTU'7X5A2PK7WZG@XLB_']:@>QUR'RVE,MK
MB'S7DR]@N'S*D015D'RTCHU*8'S+C!L_6WT=B;0U 'V.AU4K5WX[A.XC%7\#
M@J-P=9)>6AYFK)#:77!<;8]S8,I1LXX$9#9&N8QZ9\0[SXKC:X8Q>HE-;W@G
MV8?+<\4?F89Q>%IOJ9 T86!F%([@9 U;Y(V)9L913(PD:9)&=(JN;'T[L8DY
M;Y<QAH?(<MDH%(9P=F4@"84^>B-N]HW^:(!E58S7:I);3(N<;*Q0Q(I1;MA&
M%(C]<1\[?(>O<XPQ@89G=ALH0H4[>.(@:H0Q>\9N.XOP;X)DDXKF<0!:B8G)
M<G]0-XB== I%I8=O=:D[.H9*=V0Q;X4M>3DH8H0K>S4@OH-(?4!MA8HL=G!C
MZ(D]=UY9YH@V>$%/GX<?>2!%288->A(Z_84/>QDQ7(08?# H?8,]?5\A!8*!
M?I%LY(BZ?4UC68?B?:]9:(;I?>]/+87A?AY$[(3A?E4ZYH/Q?J(Q7(,??OPH
MEX)N?UHA0(':?[9L6H>%@_)BU(;"@\!8[(77@UE.O83:@M9$DH/L@E@ZLX,0
M@>8Q;H)&@8,HLH&]@1PA<8%1@+!K[H:8BG5BFH7LB<18OH4!B*I.E(/TAU5$
M=8,&AA,ZBH))A.<Q2X&>@](HPX$J@JLAF8#@@8)KF(7AD+]B284YCXI8;813
MC;I.38-(BYQ$08);B9@Z;8&FAZTQ1H$/A=<HT8"X@_8AN("'@BUEWILQ6:%<
MYYD(7.53F9;G8$%)[92?8[] &9(B9V@V9H^):TPM5XSG;U\E XI7<\<>!X?\
M>&)E(IE'8'U<:Y<_8RE3+I4:9?%)I9+,:-H_]9!8:^DV:HW9;RLMA(M7<I<E
M6XCN=DH>C(:[>AUDE)<G9RQ;U)4_:4Q2MY,S:X!)/9#Y;=8_M(ZA<$HV5HQ$
M<NHMGXGI=:PEI(>L>*8? (6C>[!D!)4:;;=;.)-+;U!2%I%9</=(S8\]<K4_
M9(T*=(XV,HK5=H<MJHBD>)HEW(:1>M@?8X2R?1MC<Y-7=#-:L)&B=4E1FH_
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MPDZ.ER2%(5--E()UXE@0D=IF1%T3CS=6GV)EC(U'A&?[B<\X^6WFANLKO70
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M?!\NMW_<?14FX8!%?A8@:8"\?PUD=GUD?GU;NWW+?M)2LGX!?OM);7XA?Q%
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M;5MF>DM3?6$_>SQ%$V=;?#\W1&W3?6HJXW1J?KV9*D+N@':,&4BO@&5^>$Y
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M_P  __\  &UF=#$      P0A   !                     0
M          $    ! @,$!08'" D*"PP-#@\0$1(3%!46%Q@9&AL<'1X?("$B
M(R0E)B<H*2HK+"TN+S Q,C,T-38W.#DZ.SP]/C] 04)#1$5&1TA)2DM,34Y/
M4%%24U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM;F]P<7)S='5V=WAY>GM\
M?7Y_@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@H:*CI*6FIZBI
MJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-SL_0T=+3U-76
MU]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O\  0$"
M @,#! 0%!@8'!P@("0D*"PL,# T-#@\/$! 1$1(3$Q04%186%Q<8&1D:&AL<
M'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C]
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
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MV8R;GMF,FY[9C)N>V8R;GMF,FY[9C)N>V8R;GMF,FY[9C)N>V?^D."K_H45
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M_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2SQ).+ML*/C[K
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MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
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MCCX=_XY++O^543K_F%1'_YA84_Z87E_VE61J[Y)L=>F.=G[DBH"'WX6'CMN
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MESP>_Z(Z)O^J.2[_LSHT^;T\..[(0SGCU5 WU]I22,C265RZRU]MK<5E?*'
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MH9IZA)J6@8N4DHB1CH^0EHF,F9J$BJ*=@8JMGW^*NY]^BLB>?XG)G8"(RIR
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M2SS_G$P\_Y],//^?3#S_GTP\_Y],//^?3#S_GTP\_Y],//^?3+>\ P"IRP(
MG-L# )+_$ *)_QT(@/\J$'7_,1AK_S@?8O\^)%O_1"E4_THL4/]1+TS_5S))
M_UPS1O]@-43_939"_VDW0?]N.#__<SD]_W<Z//]\.SO_@CPY_X<]./^,/3?_
MDSXV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/JK$  "<T@  C^<"
M (;_$0)\_QL%<?\D"VC_*Q%?_S(75_\Y&U'_/QY,_T8A2/]-(T7_4B5"_U<G
M0/];*#[_7RD\_V,J.O]G*SG_:RPW_V\L-O]T+37_>"XT_WTN,O^"+S'_B# Q
M_XHP,?^*,#'_BC Q_XHP,?^*,#'_BC Q_XHP,?^*,/]J) 3_:3(*_VP^%/]V
M1A[_>TTI_WQ5,_]Z73W_=F9&_W%N3?]M>53_:H1:_F:-7_MCE6+Y89QE^%^B
M:/=>J&KV7*UK]5NS;/1:N6[S6<%N\UC);_)8U'#O6.!PZ5GD<.-:YG#<7>AP
MW%WH<-Q=Z'#<7>APW%WH<-Q=Z'#<7>APW%WH</]J) 3_:3(*_VP^%/]V1A[_
M>TTI_WQ5,_]Z73W_=F9&_W%N3?]M>53_:H1:_F:-7_MCE6+Y89QE^%^B:/=>
MJ&KV7*UK]5NS;/1:N6[S6<%N\UC);_)8U'#O6.!PZ5GD<.-:YG#<7>APW%WH
M<-Q=Z'#<7>APW%WH<-Q=Z'#<7>APW%WH</]J(P3_:3$*_VX^%/]W11[_?$TH
M_WY4,_]\7#S_>61%_W-M3O]O>%7_:X):_6B+7_MEE&/Y8IMF]V"A:?9>IVOU
M7:UL]%RS;O-:NF_R6<%P\EG*<?%8V''L6>%QYEKD<>!<YW'87>AQV%[H<=A>
MZ''87NAQV%[H<=A>Z''87NAQV%[H<?]K(P3_:C$*_W$\%/]Z0QW_@$LH_X%3
M,O^ 6CS_?&)%_W=J3O]Q=%7_;G];_6J)8/IFDF3X9)EH]F&@:_5?IVWS7JUO
M\ERS</);NG'Q6L-R\%G-<^Y9W7/H6N)TX5SE<]E>YG/07^=TT%_G=-!?YW30
M7^=TT%_G=-!?YW307^=TT%_G=/]L(P3_:S$*_W,[%/]]0AW_@DHG_X11,O^#
M63O_@&!%_WMH3?]T<57_<'Q;_&R'8?EHD&;W99AI]6.?;/-AIF_R7ZQQ\5VS
M<O!<NW3O6\5U[UK0=>I:WW;B7.)VVU_E==%@YG;*8>5WRF'E=\IAY7?*8>5W
MRF'E=\IAY7?*8>5WRF'E=_]M(@3_;#$+_W8Z%/^ 01W_A4@G_XA/,?^'5SO_
MA%Y$_W]F3?]X;E7_<WE<_&Z$8OEJC6?V9Y9K]&2>;O)BI7'Q8*QS[UZT=>Y=
MO';N6\=W[5O6>.5<X'C<7^-XTF#D>,MAY'G$8^-ZQ&/C>L1CXWK$8^-ZQ&/C
M>L1CXWK$8^-ZQ&/C>O]N(@3_;3$+_W@X$_^#/QS_B4<F_XM.,/^+53G_B%Q#
M_X-C3/]]:U3_=G5<_'* 8OAMBF?U:91L\V:<</%CI'/O8:QU[E^T=^U=OGGL
M7,MZZ%S<>MY?X7K28>-[RF+B?,1CXGV^9>%]O67A?;UEX7V]9>%]O67A?;UE
MX7V]9>%]O67A??]N(@3_;C +_WLW$_^&/AS_C$4E_X],+O^/4SC_C5I!_XAA
M2_^#:5/Z?'%;]W9\8O-QAVCP;9!M[6F9<>IFH77H8ZEXYF&R>N1@NWOB7\=\
MX%_:?=1BX7W*8^!^PV3@?[UFWX"W9]^ MV??@+=GWX"W9]^ MV??@+=GWX"W
M9]^ MV??@/]O(03_;S +_WXV$O^)/!O_D$0D_Y-,+?^34C;_DEE _XY@2?F(
M9E+T@FY:[WQY8>MW@VCG<HQNY&V5<^!JG7?=9Z9ZVF6N?-9CN'[38L. T6+3
M@<IDWX'!9=Z"NV?=@K5HW8.P:=V#L&G=@[!IW8.P:=V#L&G=@[!IW8.P:=V#
ML&G=@_]P(03_<B\+_X$T$O^,.QK_DT,B_Y=+*_^7433_EE<]^I-=1O..9$_N
MB&M8Z()U8.-\?VC>=XENV7*1=--NF7G0:Z%]S&BI@,EFLH+'9;V#Q67+A,%F
MW(2Y:-N%LVG;A:YKVX6I;-N%J6S;A:ELVX6I;-N%J6S;A:ELVX6I;-N%J6S;
MA?]Q(03_="X*_X0S$?^/.AG_ED,A_YI)*?^:3C+\FE0[]9A;1.Z48DWGCVE5
MX8ES7MN"?&;3?(5OS7>-=<ERE7K%;YU_P6RE@KYJK86[:;B'N6G$B+=IV(BP
M:]F(JVS9B*=MV8BC;]J'HV_:AZ-OVH>C;]J'HV_:AZ-OVH>C;]J'HV_:A_]Q
M( 3_=BP*_X8R$?^2.AC_F4(@_YQ')_^>3"_XGE(X\)U80.F:7TGBE6=2VH]P
M7-&'>&;*@8%OQ7R)=L!WD'R[=)B MW&@A+1OJ8>Q;;.)KFR_BJQLSXNH;M>+
MI&_8BJ!PV(J=<=F)G7'9B9UQV8F=<=F)G7'9B9UQV8F=<=F)G7'9B?]R( 3_
M>"L*_X@P$/^4.1?_FT$>_Y]%)?VA2BWTHE T[*)6/.2@7$7<FV5/TI-M7,J,
M=6;#AGUOO8&%=K=\C7VS>)2!KG6<AJMSI8FG<:Z+I7"ZC:-PR8V@<=6-G'/6
MC)ITUHN7=-B*EW38BI=TV(J7=-B*EW38BI=TV(J7=-B*EW38BO]S( 3_>BH)
M_XLO#_^6.1;_G3\<_Z%#(_JD2"KQIDXQZ*=4..&G7$#5GV).RYAK6\.1<F:\
MBWIOMH6"=["!B7VK?9&"IGF9AJ)WH8J?=:N-G'2VCIITQ8^8==2.E7;5C9-W
MU8V2=]:+DG?6BY)WUHN2=]:+DG?6BY)WUHN2=]:+DG?6B_]S( 3_?"D)_XTO
M#_^8.!7_GST;_Z1!(?>H1B?MJTPMY:U2,]RJ63_0HV%-QIQI6KZ5<&6VCW=O
MKXI_=JF%AGVD@8Z"GWZ6AYM[GHN7>:B.E'BSCY)XP9"0>=.0CWK4CXYZU8V,
M>]:,C'O6C(Q[UHR,>]:,C'O6C(Q[UHR,>]:,C'O6C/]T'P3_?B@)_XXN#O^;
M.!3_H3P9_Z<_'_2K1"3JKTHIXK-1+M:N5S[+IU]-P:!G6KF9;F6QDW5NJHY\
M=J.*@WV>AHN"F8.3AY2 FXN0?J6.C7VPD(I]O9&)?M"1B'[3CXA^U(Z'?M6-
MAW[5C8=^U8V'?M6-AW[5C8=^U8V'?M6-AW[5C?]T'P3_@"<(_Y N#O^=-Q/_
MHSH8_*D]'/&O0B#GM$@DW[=.+-&Q53W'JEY,O:-E6;2=;&2KEW-NI)-Z=IZ.
M@7R8BXB"DH>0AXZ%F8N)@Z*.AH*MD(."NY&"@LR1@H+3D(*"U(^"@=6-@H'5
MC8*!U8V"@=6-@H'5C8*!U8V"@=6-@H'5C?]U'P3_@B8(_Y(M#?^?-A+_I3@6
M^:P[&NZS/QWEN48?VKM+*\VT5#S"KEQ+N*=C6*^A:F.FG'%MGY=W=9B3?GR2
MD(:"C(V.AX>*EHN#B*".?X>KD'V'N)%[A\F1?(?3D'R&U(]]A=6-?875C7V%
MU8U]A=6-?875C7V%U8U]A=6-?875C?]U'P3_A"4(_Y0M#/^@-1#_J#84]J\X
M%^NW/1CBOT49U;Y)*LBX4SN]L5M*LZMB5ZJF:&*AH6]LF9QU=)*8?'N,E8.!
MAI*+AH&0E(M\CIZ.>8VHD':,M9%TC<:1=8W3D':+U(]XB=6->(G5C7B)U8UX
MB=6->(G5C7B)U8UXB=6->(G5C?]V'@/_AB0'_Y<L"_^B,@__JS,1\K,U$^B\
M.A/>Q3\7T,%(*<2[43FYM5E(KK!@5:6J9V&<IFUKE*)T<XV>>GJ&FX& @)B)
MA7N6DHEVE)N-<I.FCV^3LY!ND\.0;I/3CW"1U(YRCM6-<H[5C7*.U8URCM6-
M<H[5C7*.U8URCM6-<H[5C?]W'@/_B2('_YDL"O^E, W\KB\.[[@Q#N3#-PW9
MRCL6R\5&)[^_4#BSNEA'J;5?5)^P95^6K&MICJAR<8:E>'B HG]^>I^'@W2=
MCXAOFYF+;)JDC6F:L(YGF\".9YO5CFF8U8ULE-:,;)36C&R4UHQLE-:,;)36
MC&R4UHQLE-:,;)36C/]X'@/_C"$&_YTK"/^H+ KXLRH+ZK\K">#,,@;1SCD5
MQ<E%);G$3C:NOU9%H[M=4IFV8UV0LFEGAZ]P;X"L=G9YJ7U\<Z>$@6ZEC85I
MI)>(9:.BBF.CKHQAH[Z,8*32BV.@UXMEG-B*99S8BF6<V(IEG-B*99S8BF6<
MV(IEG-B*99S8BO]Z'0/_CR %_Z I!_^L)P?RN"0&Y<<D!-G5)P7+TS<3O\Y#
M([/*3#2GQ51"G,%;3Y*]8EJ)NFAD@;=N;'FT=')SLGMX;;"#?6BOBX%CKI6$
M7ZV@AEVMK8=;K;R'6J[0AURJVH=?I=J'7Z7:AU^EVH=?I=J'7Z7:AU^EVH=?
MI=J'7Z7:A_]^&@/_E!\$_Z4F!?VQ( 3LP1H#W],7 =#<)03$V340N-5!(:S0
M2S&@S%(_E<E93(O%8%>"PV9@>L!L9W.^<VULO'IS9[N"=V*ZBGM>N91^6KB?
M@%BXK(%6N;N!5;K/@5:VWH)8L-V"6*_=@EBOW8)8K]V"6*_=@EBOW8)8K]V"
M6*_=@O^$%P+_F1P"_ZH? _6Y%0+>S0P T-\2 ,7@)@6[WS8.L-U ':3922V8
MU5$[C=%82(//7E)[S&5:<\MK86S)<F=FR'EL8<>!<%W&BG19QI1V5L6?>%/&
MK'E2QKMZ4<?/>5'$XWI3O.)\4[SB?%.\XGQ3O.)\4[SB?%.\XGQ3O.)\4[SB
M?/^*% '_GQ@!_[ 4 =C#"@#.T0H Q.44 ;GD)@BNY#03I.(_()G@1RV/WD\Y
MA=Q61'O:74QSV614;-=K6F;6<E]AU7ED7-2"9UC4BVI5U)5M4M2@;E#4K6].
MU;QP3=;0;TW5Z'!.S.ER3LSI<D[,Z7).S.ER3LSI<D[,Z7).S.ER3LSI<O^2
M$0'_IQ$ V+D) ,O&" #"U0H M^H6 ZSJ)PRBZ308F.@^)(WG1S"#YDXZ>N54
M0W'D6DIIY&%09.-H55_C<%E:XWA<5N. 7U/CB6)0XY-D3>2=94ODJ6=*Y;9G
M2>7&9TCFWV=*X.QG2M_L9TK?[&=*W^QG2M_L9TK?[&=*W^QG2M_L9_^<#0#;
ML08 RKT' +_*!P"UV@H JN\9!:#P* ^6\#4;C/ _)H+P1S%Y\$XY<.]40&CO
M6D9A[V!+7>]G3UCO;E)4[W554?!]5T[PA5E+\(];2/&97$;QHUY$\J]?0_*[
M7T+SS&!!\^=@0?/H8$'SZ&!!\^A@0?/H8$'SZ&!!\^A@0?/H8-ZG @#+M@4
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M;4_"Y&Q/O>QN4+GL;U"Y[&]0N>QO4+GL;U"Y[&]0N>QO4+GL;_^)$ '_G0X
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M23G\XTDY_.-).?SC23G\XTDY_.-).?SC2<>M  "WMP( JL," )[0! "3XPD
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M1$#JS41 ZN1$0.CU1$#G^$- Y_A#0.?X0T#G^$- Y_A#0.?X0\VC  "]K@$
ML+@! *3$ @"9T 4 C^$* (GQ&@&!\2@%>/(R#'#R.Q-I\D,98O)*'USS4"-6
M\U<G4O->*T_S92U,]&PP2?1S,D;T>S1#](0V0?6.-S[UF3D]]J0Z._:P.SKW
MOSPY^,\\./?H/#CW[#PX]^P\./?L/#CW[#PX]^P\./?L/+^J  "QLP  I+\
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M&R'_K1LA_ZT;(?^M&R'_K1LA_ZT;(?^M&YJ^  "+R@  ?M<  '#C  !G_P0
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M5$NYV%1+M^U42K;Y54JS_E9*L_Y62K/^5DJS_E9*L_Y62K/^5OJ' @#6F
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M+S;Q\R\V\?,O-O'S+S;Q\R\V\?,O-O'S+[FG  "KL   G[L  )+&  "&T $
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MFDP?H)=4*9F37#&3D&,XC8UJ/XB*<42#B'A)?H9_37J$B%%V@I%5<X&;6&^
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M6%F4U%=9E.Q769/Y5EN1_E5;D/Y56Y#^55N0_E5;D/Y56Y#^5?]S"0#UA 0
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M04.]_T)#O/]#0[S_0T.\_T-#O/]#0[S_0]:-  #&FP  N*4  *VN  "BM@
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M&RO[ZQLK^^L;*_OK&ZBJ  ":M   C;\  (#)  !TTP  9]X  %[R" !9_A$
M4_\: 4[_(P))_RL#1?\S!$'_.@4^_T$&._]'!SC_3@@U_U0),_]:"3'_80HO
M_VD++/]R#"K_?0TH_X@.)O^5#R7_H1 D_ZX1(_^Z$B+_RA(B_] 2(O_0$B+_
MT!(B_] 2(O_0$IRR  ".O   @<<  '/1  !GW0  6>,  %/]!@!-_PX 2/\6
M $/_'@$__R8".O\M C?_,P,S_SD#,/\_!"[_1 0K_TH%*?]0!2?_5@8D_UT&
M(O]E!R#_;@<=_WD(&_^%"!K_D@D9_YX)&/^H"1?_LPD7_[<)%_^W"1?_MPD7
M_[<)%_^W"9"Z  ""Q0  =-   &?<  !8XP  3?   $?_ @!"_PP //\1 #C_
M& $T_Q\!,/\E 2S_*P(I_S ")?\U B/_.@(@_S\#'O]$ QS_20,9_T\#%_]6
M!!7_7@02_V@$$?]R!0__?@4._XH%#O^4!0W_G@4-_Z(%#?^B!0W_H@4-_Z(%
M#?^B!?\Y+P+_/# #_T$Q _]$- 3_1#H&_T1%"/]%40S_0UT1_T%I%O\^=AG_
M/($<_SJ,'O\YEB#_.)XA_S>E(_\WJR/_-K(D_S:Y)?\VP"7_-<HF_S77)O\U
MY2;_->\F_S7X)O\V_R;^-O\F_#;_)OPV_R?Z-O\H^C;_*/HV_RCZ-O\H^C;_
M*/\Y+P+_/B\#_T0O _]&,@3_2#@&_TA#"/](3PW_1UL2_T1G%O]"<QK_/W\=
M_SV*'_\\DR'_.YLC_SJB)/\YJ27_.; F_SBV)O\XOB?_.,<G_SC3*/\XXRC_
M..TH_CCW*/LX_B?Y.?\G^#C_*?@X_RKV./\J]CC_*O8X_RKV./\J]CC_*O\Z
M+P+_02P#_T8L _]*+P3_3#<%_TU!"/],3 W_2U@2_TAD%_]&<!O_0WP>_T&'
M(/\_D"/_/I@D_SV@)?\]IB;_/*TG_SRT*/\[NRG_.\0I_SO/*?X[X"K[.^LJ
M^#OU*?8\_BGT//\J\SO_*_([_RSO._\M[SO_+>\[_RWO._\M[SO_+?\\+0+_
M1"D"_THI _].+ 3_430%_U(^"/]22@W_4%42_TUA%_]*;1O_2'@?_T6#(O]#
MC23_0I4F_T&=)_] HRC_0*HI_C^Q*OT_N"O\/\$K^C_+*_<_W"SU/^DL\3_T
M*^\__2SM/_\M[#[_+^L^_S#G/_\PYS__,.<__S#G/_\PYS__,/] *@+_2"8"
M_TXF _]2*0/_5C(%_U<\!_]71PS_55$2_U)=%_]0:1S_370@_TI_(_U(B2;[
M1Y$H^D:9*?A%H"KW1*<K]42M+/1#M2WS0[TM\D/(+O!#UR[L0^<NZ43S+>9#
M_##D0O\QXT+_,N%"_S/<0_\TW$/_--Q#_S3<0_\TW$/_-/]#)P+_2R,"_U(B
M O]8)P/_7"\$_UTY!_]>0PS_6TX1_UA8%_Y59!SZ4F\@]U!Z)/1-A"?R3(TI
M\$J5*^])G"WM2:,N[$BJ+^I'L2_I1[HPYT?%,.9'TC#B2.4PWT?R,MM'^S38
M1O\UU4;_-M)&_S?-2/\WS4C_-\U(_S?-2/\WS4C_-_]&) +_3R "_U8? O]=
M) /_82P$_V,U!O]D0 O_8DH0^EY4%O5;7QSQ6&L@[E5U)>M3?RCH48@KYD^1
M+>1.F"_B3: PX4RG,=],KC+=2[<SVTO"--E*SS752^0UT$OP-LU*^SC*2O\Z
MR$K_.L9+_SO!3/\[P4S_.\%,_SO!3/\[P4S_._]*(0+_4QT"_UL< O]B(@+_
M9RD#_VDR!?]J/ GY:$8/\F50%>UA6QKH7F8@Y%MQ)>%8>RG>5H0LVU2,+]A2
ME#+449LTTE"C-=!/JC?.3K(XS$Z\.<I.R3K(3MTZQ$_M.\%.^3V^3O\]O$[_
M/KI/_SZV4/\^ME#_/K90_SZV4/\^ME#_/O]-'@+_5AH!_U\: ?]G( +_;"8"
M_V\N!/EP. ?R;T(,ZVQ+$N5I5QG?96(?VF%L)=1==BK06WXOS5F',LI7CS7(
M5I8WQE2=.<13I3O!4ZT\OU*W/KU2PS^\4M,_N5+H/[52]D&S4O]!L5/_0:]3
M_T&L5/]!K%3_0:Q4_T&L5/]!K%3_0?]0' '_6A<!_V08 ?]L'0'_<2,"_74J
M _-V,P7K=CT*XW-'#]QO4Q?4:UX?SF9G)LIC<2O&8'DPPEZ!-+]<B3>]6I$Z
MNEF8/+A8H#ZV5ZA M%:R0K)6O4.P5<Q#K5;C1*M6\T2H5_Y$IU?_1*58_T2B
M6/]$HEC_1*)8_T2B6/]$HEC_1/]3&0'_710!_V@6 ?]P&@'_=B !]WHF NU\
M+@/D?#@'W'I$#=)U3Q;+<%H>QFQC)L%H;"R]9G4QN6-]-;9AA#FS7XP\L%V4
M/ZY<FT&K6Z1#J5JM1:=:N$:E6<='HUK>1Z%:[T>?6_Q'G5O_1YM<_T::7/]&
MFES_1II<_T::7/]&FES_1O]5%P'_8!(!_VL4 ?]T%P#_>AP!\G\B >>!*0+>
M@C,$TW] #,MZ3!7$=E8>OG%@);EN:"RT:W$RL6AY-JUF@#JJ9(@]IV*/0*5@
MET.B7Z!%GUZI1YU>M$F;7<)*F5W62I=>[$J67_I)E5__29-@_TB28/]'DF#_
M1Y)@_T>28/]'DF#_1_]8%0'_8Q$!_VX2 /]W%0#[?A@ [8,= .*'(P'6ARX#
MS(,]"\5_212]>U,=MW9=);)S92RM;VTRJ6UU-Z9J?#NB:(0^GV:,09QEE$29
M8YQ'EV*F291BL$N28;Y,D&'03(]BZ$R.8_A+C6/_2HQD_TF+9/])BV3_28MD
M_TF+9/])BV3_2?]:$P'_9A  _W$1 /]Z$@#W@A0 Z(<7 -V+' #0BRP#QX@[
M"K^$1Q.X?U$<L7M:)*QW8BNG=&HQHW%R-I]O>3N;;8 _F&N(0I5ID$62:)E(
MCV:B2HQFK4R*9;I-B&7,3H=FYDZ&9_9,AF?_2X5H_TN$:/]*A&C_2H1H_TJ$
M:/]*A&C_2O]<$@'_: \ _W00 /]]$ #SA1  Y(L1 -:/%P#+CBH"PHPX";J(
M1!*SA$\;K']8(Z=\8"NA>&@QG75O-IES=CN5<7T_DF^%0HYMC46+;)9(B&N@
M2X5JJDV#:;=.@6G(3X!JXT^ :_1.?VO_3']K_TM_:_]+?VO_2W]K_TM_:_]+
M?VO_2_]>$ '_:PX _W8. /N #0#JB T VX\, -"2%0#'DB<"OH\V"+:,0A&N
MB$T:J(16(J* 7BJ<?64PEWIL-9-W<SJ/=7L^C'."0HARBT:%<)-)@F^=3']N
MJ$Y];K5/>VW&4'INX%!Y;_).>6_^37EO_TQY;_]+>6__2WEO_TMY;_]+>6__
M2_]@#P#_;0T _WD, .Z#"P#;BPD U)$* ,R5$P#"E24"N9,T![&/01"JC$L9
MHXA4(9V$7"F7@6,ODGYJ-8Y\<3F*>G@]AGB 0H-VB$5_=9%)?'.;3'ERIDYV
M<K-0=7+#4'-RW5!T<_!/='/]371S_TQT<_],='/_3'1S_TQT<_],='/_3/]B
M#@#_;PP _'L* -Z&!@#5C@@ SY0) ,>8$0"^F",!M98R!JV3/P^FD$D8GXQ2
M()B)6BB3AF$NCH-H-(F!;SF%?W8]@7U^07U[AD5Z>8])=GB93'-WI$YQ=[%0
M;W;!4&YWV5!N=^]/;G?\3FYW_TUO=_],;W?_3&]W_TQO=_],;W?_3/]D#0#_
M<@H \'X& -J(!0#0D < RI<( ,*;$ "YFR$!L9HP!JF7/0ZAE$<7FI%0'Y2-
M6">.BU\MB8AF,X2&;3B A'0]>X)[07B A$5T?XU(<7V72VU\HDYK?*]/:7N^
M4&A\U5!H?.U/:7S[3FE\_TUJ>_],:GO_3&I[_TQJ>_],:GO_3/]F"@#_=0@
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M2%&7_T=1EO]'49;_1U&6_T=1EO]'49;_1_9W  #8A0  R9$  +^; 0"TH@
MJZ@  *&P  ":LA$ E+,B 8VR, 6%L3P,?J]&%'BN3AMRK%8A;:M<)VBI8RQD
MJ&HP8*=Q-%RF>3A8I8([5:2,/E&CF$!/HZ5"3:.T0TRCR$-,H^1#2Z'T0TN@
M_T1+H/]$2Z#_1$N@_T1+H/]$2Z#_1.-]  #/BP  PI8  +>?  "MI@  HZT
M )FU  "0N0X B[H> 82Z+0-]N3D)=[A#$'&V3!=KM5,=9K1:(F*S829>LF@K
M6K%O+E:P=S)3L($U3Z^+.$ROESI*KJ0\2*ZS/4>NQSU'KN,\1JWS/4:K_CY%
MJ_\_1:O_/T6K_S]%J_\_1:O_/]J#  #'D0  NYP  *^D  "EJP  FK(  )"Z
M 0"&P0D @<(8 'O"* )UPC4&;\% #&G 21)DOU$77[Y8'%N^7R!7O68D5+QN
M)U&\=BI-NW\M2KN*,$B[EC)%NZ,T0[NR-$*[Q35#N^(T0KGS-4&X_3= M_\W
M0+?_-T"W_S= M_\W0+?_-\Z+  "_F   LJ$  *>I  "<L   D;@  (;  @![
MR < =,L2 '#,(@%KRS #9LL\!V'+10Q<RDX16,I6%53*71E1R60<3LEL'TO)
M=")(R'XD1<B()T/(E2A!R*(J/\BQ*S[)Q"L^R>$J/L?R*SW&_"T\Q?\N/,7_
M+CS%_RX\Q?\N/,7_+L23  "VGP  J:8  )VN  "2MP  AK\  'O' P!PSP<
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M"9BP  "*N@  ?,0  &_-  !BV   5=X  $GD  !$^P4 /_\. #O_%0 X_QP
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M1'9JU$5V:^U#=FO[0G9K_T%V;/] =FS_0'9L_T!V;/] =FS_0/]="@#_:0<
M['0# -I\! #0@P8 R8@' ,.*#P"ZBR !LHHO!*N(/ JDA4<2G8%0&9A^6!^3
M?%\ECGEF*HIW;2Z&=70R@G1\-G]RA#E\<8T]>7"60'9OH4)T;JY$<FZ]17!N
MT45P;^M$<&_Z0W%O_T%Q;_] <7#_0'%P_T!Q</] <7#_0/]?" #_:P0 X78
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M0F!]_T%A??] 87W_0&%]_T!A??] 87W_0/]G  #C=   TG\  ,>( 0"^CP(
MMI4! *Z8!@"FFA4 GYHF IB9,P:1ES\,BY5(%(634!I_D5@@>H]?)7:-92IR
MBVPN;HIS,FJ(>S9FAX0Y8X:./&"%F3]=A*9!6X2T0EJ$QT-:A.-"6H/T05N#
M_T!;@_] 6X/_/UN#_S];@_\_6X/_/_]J  #>>   S8,  ,*,  "YDP  L)@
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M.4F;_SE)F_\Y29O_.=MZ  #(AP  O)(  +&:  "FH   G*8  )&L  "'L0@
M@;(6 'RS)@%VLC,$<;(]"6NQ1PYFL$\38J]6&%ZN71Q:K60@5ZQK(U2L<R90
MJWPI3:J&+$JJDB](J9\P1JFM,D6IOS)$JMHR1*CO,D.G^S-#IO\S0Z7_-$.E
M_S1#I?\T0Z7_--"!  #!C@  M9@  *F?  ">I0  DZP  (BR  !\N0( =KH1
M '*[(0!NNRX":+LZ!F2Z0PI?NDP.6[E3$E>X6A94N&$94;=I'$ZW<1]+MGHB
M2+:$)46VD"=#M9TI0;6L*D"VOBH_MM@J/[3N*CZS^BP]LO\M/;'_+3VQ_RT]
ML?\M/;'_+<>)  "YE0  K)T  *&D  "6JP  BK(  '^X  !SOP, :L0, &?%
M&@!CQ2@!7\4U UO%/P57Q4@)5,10#%#$6 ]-Q%\22L-F%4C#;A=%PW@:0L."
M'$##CAX^PYP?/,.K(#O#O"$ZP]4A.\+N(3G ^2(XO_\D.+__)#B__R0XO_\D
M.+__)+V1  "PFP  I*(  )BJ  ",L0  @+D  '6_  !JQ@0 7LP( %G/$@!7
MT"$ 5= N 5'0.0).T$,$2]!,!DG04PA&T%L+0]!C#4'0:P\^T'41/-& $SK1
MC!0XT9H6-M&I%S71NQ<TTM(7-=#L%C3/]Q@SSO\:,\[_&C/._QHSSO\:,\[_
M&K.9  "FH0  FJD  (ZQ  "!N0  =<   &K'  !>S0, 5-0( $S=#0!*W1@
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M!!G^F 08_Z@$%_^W!!;_R 06_^ $%O_D!!;_Y 06_^0$%O_D!).N  "%MP
M>,   &K)  !=T@  4-D  $3?   ZY   -?<# #+_#  N_Q( *_\: "C_(0 F
M_R< (_\M "#_,P >_SD!'/\_ 1G_10$7_TT!%?]5 1/_7P$1_VH"$/]X @[_
MAP(._Y8"#?^D @S_L (,_[X"#/_" @S_P@(,_\("#/_" H>V  !YOP  :\D
M %[3  !0VP  0^   #CE   O\   *_\  "?_"  D_PX (?\3 ![_&0 ;_QX
M&/\C !7_*  3_RT $?\R !#_.  ._S\ #/]& 0K_3P$'_UD!!/]E 0'_<@$
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M-H=:UC:&6^TVA5O[-85<_S2$7/\SA%S_,X1<_S.$7/\SA%S_,_]3"@#_708
M]68$ -]M P#5<@8 T'4) ,EV$0# =R( N'8Q [%T/@>K<4D.IFY2%*%L6QF=
M:6(=F6=J(I9F<2639'@HD&-_*XUAARZ*8) PB%^9,X5?HS6#7J\V@5Z^.(!>
MT3A_7^HW?E_Z-GY@_S5^8/\T?F#_-'Y@_S1^8/\T?F#_-/]5" #_8 0 Z&D
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M.&UK_S=M:_\V;6O_-FUK_S9M:_\V;6O_-O];  #K9P  V7$  ,QY  ##?@(
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M-5A^_S58?O\U6'[_->EH  #4=   QGX  +N'  "RC0  J)$  )Z4  "6E@X
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M8;0S EZT/01:M$8'5K-."E.S50U0LUP03;)C$TJR:Q9'L7081;%^&D*PBAU
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M#C'+L@\PS,</,,OE#B_)]0\NR/T1+L?_$B['_Q(NQ_\2+L?_$JZ7  "AG@
ME:4  (FM  !\M   <+L  &3!  !9Q@  3LL# $70"  ^U0X /=4: #S6)@ [
MUS$ .=@[ #C910$VV4T!-=E6 C/:7@(QVF@#,-MS!"[;?P4LVXT%*MR=!BG<
MK08HW<$&*-W>!B?;[P<FV?D()MC^"2;8_@DFV/X))MC^":2=  "8I0  BZT
M 'ZT  !QO   9<,  %G)  !-S0  0],! #K9!@ UY T ,^06 #'D(  PY2H
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M 03_K@$$_[P! __' 0/_QP$#_\<! __' 8.T  !UO0  9\8  %K/  !+U0
M/]P  #/A   IY0  (>P  ![]   :_P4 %_\, !7_$  2_Q0 $/\9  [_'@ -
M_R, "_\H  C_+@ &_S4  _\]  #_1@  _U$  /]=  #_:P  _WL  /^+  #_
MF0  _Z4  /^L  #_K   _ZP  /^L /\G+ '_*BH!_RLJ ?\J+@'_)C0"_R4_
M O\C2P/_(5@#_R!D!/\>< 3_'7L$_QV%!?\=C@7_'98%_QV<!O\=H@;_'*@&
M_QRN!_\<M ?_'+L'_QS#!_\<S@?_'=\'_QWK!_P=]0?Y'?X&]Q[_!_<=_PCV
M'?\)]AW_"?8=_PGV'?\)]AW_"?\I*@'_+"<!_RXG ?\M*@'_+#(!_RL] O\I
M20/_)U4#_R5A!/\C;03_(G@%_R*"!?\ABP;_(9,&_R&:!_\AH ?_(:4'_R&K
M"/\AL0C_(;@(_R'!"/\ARPC\(=P(^2'I"/8A] CS(OT'\B+_"?$B_PKQ(?\+
M\"'_"_ A_POP(?\+\"'_"_\L)@'_,"0!_S$C ?\Q)@'_,B\!_S$Z O\O1@/_
M+5(#_RM>!/\I:07_*'4%_R=_!O\GB ?_)I '_R:6"/\FG0C^)J,)_2:I"?PF
MKPG[)K8)^B:^"?@FR GV)MD)\B;H">\G\PGM)_T*ZR;_"^HF_PWI)O\-Z";_
M#N@F_P[H)O\.Z";_#O\O(P'_,R !_S4? ?\W(P'_."P!_S@W O\V0@+_-$X#
M_S):!/\P907_+G &_BU[!_PMA CZ+(P)^"R3"?<LF0KV*Z *]"NF"O,KK OR
M*[,+\2N["^\KQ@ON+-0+ZBSF"^8L\@OD+/P-XBS_#^$L_Q#@+/\0WRS_$=\L
M_Q'?+/\1WRS_$?\S'P'_-QL!_SH: ?\]( '_/R@!_S\R ?\]/@+_.TD#_SE5
M!/LW80;W-6P']31V"/(S?PGP,H<*[S*/"^TRE@OL,9P,ZC&B#.DQJ0SH,; -
MYC&Y#>4QPPWC,M$-WS+E#-PR\0_8,?P1U3'_$M(Q_Q/1,?\4T#'_%- Q_Q30
M,?\4T#'_%/\W&P'_.Q< _S\6 /]#' #_1B0!_T8N ?]$.0+\0D0#]C]0!/$]
M7 ;M/&<'ZCMQ">@Z>@KE.8,+XSB+#.(XD@W@-YD-WS>?#MTWI@[;-ZT/V3:V
M$-<VP1#5-LX0T3?C$<TW\1/*-_L5R#?_%L8W_Q?%-_\8Q#?_&,0W_QC$-_\8
MQ#?_&/\[%P#_0!, _T43 /])& #_3"  _TPI ?I+,P'R2#X"[$9*!.=$5@;C
M0V((WT%L"MQ =0S9/WX-U3Z&#],]C1#1/901SSR;$LT\HA/,/*D4RCNQ%,@[
MNQ7'.\@6Q3S<%L$\[1>^//D9NSS_&KH\_QNY//\;N#S_&[@\_QNX//\;N#S_
M&_\^% #_1!  _TH1 /]/% #_41L ^U(C /%1+0'I3S@!XDU% ]Q+407625P(
MT4=F"\Y&< [+17@0R$2 $L9#AQ3$0HX5PT*5%L%!G!>_0:08O4"L&;Q MAJZ
M0,(:N$#2&[5!Z!NR0?8=L$'_'JY!_QZM0?\>K$'_'JQ!_QZL0?\>K$'_'O]"
M$0#_1PT _T\. /]3$0#_5A4 \U<< .A6)0#@53$!UU,_ L]23 7*4%<)QDYA
M#<-,:A# 2G(2O4EZ%;M(@A:Y1XD8MT>0&;5&EQNS1I\<L46G';!%L1ZN1;P?
MK$7,'ZI%XR"G1O,AI4;_(:-&_R*B1O\AHD;_(:)&_R&B1O\AHD;_(?]%#@#_
M2PH _U,, /]7#0#Y6A  ZUL4 -]:' #46BL S%H[ L982 7!5E,)O%1<#;E2
M91&U4&T4LT]U%[!.?!FN380:K$R+'*I+DAZH2IH?IDJC(:1)K"*C2;@CH4G&
M))]*WB2=2O DFTK])9E+_R292_\DF$O_))A+_R282_\DF$O_)/](# #_3P@
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M+7I<_RQY7/\K>ES_*GI<_RIZ7/\J>ES_*O]1  #R6P  WF0  ,]J  #';@(
MP' $ +IP# "R<1H JW$I :5P-P.?;D('FFQ+#)9J5!&2:%P5CF9C&(ME:1N(
M8W >A6)X(8)A?R2 8(@F?5^1*7M?G"MX7J<M=EZU+G5>QB]T7N$O=%_S+G1?
M_RQT8/\K=&#_*W1@_RMT8/\K=&#_*_]3  #H7@  V6<  ,MM  ##<0$ NW,"
M +5S"0"M=1< IW4G :%T- .;<C\'E7!)"Y%N4A",;%D4B6I@&(5I9QN":&X>
M?V9U(7UE?21Z9(4F=V2/*75CFBMR8J4M<&*S+V]BQ"]N8MXO;F/R+FYC_BUN
M8_\L;F/_*VYC_RMN8_\K;F/_*_]5  #E8   TVD  ,AP  "_=   MW<! +!W
M!P"H>!4 HGDD )QX,@*6=CT&D71'"XQR3P^(<%<3A&]>%X!M9!I];&L=>FMS
M('=J>B-T:8,F<FB-*6]GERQM9Z,N:V:Q+VEFP3!I9MLP:6?P+VEG_2UI9_\L
M:F?_*VIG_RMJ9_\K:F?_*_Y8  #A8P  SVP  ,1S  "[>   LWH  *MZ! "D
M>Q( GGPB )A\+P*2>CL%C'A%"H=W30Z#=542?W-<%GMR8AIX<&D==6]P(')N
M>"-O;8$F;6R+*6ILEBMH:Z$N9FNO+V1JOS!C:]@P8VOO+V1K_"UD:_\M96O_
M+&5K_RQE:_\L96O_+/1;  #=9@  RV\  ,!V  "W>P  KWX  *9^ 0"??Q
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M'3Z?LAX]G\8>/9_C'3V=]!X]G/\?/)O_'SR;_R \F_\@/)O_(,)\  "UB
MJ9   )Z6  "3FP  AY\  'ND  !OJ   8ZP$ %^M$0!<K1\ 6JXK %>N-@%4
MKD #4:U(!4ZM3P=+K5<)2:U>"T:L9@U$K&X/0:QX$3^KA!,\JY$5.JN@%CFK
ML!<XJ\,7.*KA%S>I\Q@WI_X9-J;_&C:F_QHVIO\:-J;_&KJ$  "NCP  HI8
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M B#3ZP(@TO8#']'_!!_1_P0?T?\$']'_!)^;  "4H@  AZD  'FQ  !MN
M8+X  %3#  !)QP  /LL  #70 0 MU08 )=L+ "3>$@ CWAP (M\E "'@+@ @
MX#< '^%  ![A2@ =XE, '.-> !OC:@ :Y'@ &.2( 1?EF@$6YJP!%>;  13G
MW0$3Y>\!$^/Z 1/C^@$3X_H!$^/Z 9:B  ")J0  >[$  &ZY  !AP   5,8
M $C*   ]SP  ,],  "K9   BW@( 'NL* !SL$  ;[1< &>T? !?N)@ 5[BT
M%.\U !/P/0 1\$8 $/%0  _R6P .\FD #?-X  STB@ +]9P "O6N  GVP@ )
M]MD "/7M  CU[0 (]>T "/7M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2
M   QV   )]T  !_A   9Z   %O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI
M  K^,  (_S@ !O]!  /_3   _U@  /]F  #_=P  _XD  /^;  #_JP  _[L
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M#KTVY@ZY-O00MS;_$;4V_Q*T-O\3LS;_$[,V_Q.S-O\3LS;_$_\Y$ #_/0L
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M'HM+_QZ+2_\=BDO_'8I+_QV*2_\=BDO_'?]%  #_30  Y50  -E9  #/6P,
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M(F];_R%O6_\A;UO_(?I/  #A6@  SV(  ,1G  "[:P  LVP  *QJ! "D:Q(
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M($M]L2%*?<0B2GWA(4M\]"%+>_\@2WO_($M[_R!+>_\@2WO_(-!G  # <@
MM'L  *J"  "@A@  E8@  (>(  !\B@  =HP. '*-&@!NCB< :HXR 6:-/ -C
MC40%8(Q,"%R+4PI:BUH-5XIA$%2):!)1B'$53XAZ%TR'A1I*AI(<2(:@'4:&
MKQY%A<(>187?'D6$\AY%@_X>18+_'D6"_QY%@O\>18+_'LIM  "Z>   KX$
M *6'  ":BP  CXT  (&.  !TD0  ;I,* &F4%0!FE2( 8Y4N 6"5. )<E4$$
M691)!E:44 A4DU<*49->#$Z29@],DFX129%X%$:0@Q9$D) 80H^>&4"/K1H_
MC\ :/X_<&C^-\1H_C/T;/XO_&S^+_QL_B_\;/XO_&\)S  "U?@  JH<  )^,
M  "4D   B),  'N5  !LF0  99L$ &"<$ !=G1T 6YXI %B>- %5GCT"4IU%
M U"=305-G50'2YQ;"4B<8PM&G&L-0YMU#T&;@!$^FHT3/)J;%#J:JQ4YFKT5
M.9K9%3F8[Q8YE_P6.);_%SB5_Q<XE?\7.)7_%[MZ  "OA0  I(P  )B1  "-
ME0  @9H  '6=  !HH   6Z0  %:E# !3IA< 4:<C $^G+P!,IS@!2J=! 4BG
M20)&IU $0Z=8!4&G7P8_IF@(/:9R"CJF?0LXIHH--J69#C2EJ0\SI;L/,Z74
M#S.D[@\RHOL0,J'_$3*A_Q$RH?\1,J'_$;2"  "HC   G9(  )*7  "&G
M>:$  &VE  !AJ0  5:P  $NO!0!'L!  1; < $2Q)P!"L3( 0;([ #^R0P$]
MLDL!.[)3 CFR6P,WLF0$-;)N!3.R>08QLH<'+[&6""ZRI@@MLK@)+++0""RP
M[ DKK_D**Z[_"RJM_PLJK?\+*JW_"ZV+  "@D@  E9@  (F=  !]HP  <:@
M &2M  !9L0  3;0  $*X   [N@H .+L3 #>\'@ UO"D -+TR #.].P RO40
M,;Y, "^^50$NOEX!++YH 2J^= (IOH(")[^1 R:_H@,DO[0#([_+ R.^Z ,C
MO/<$(KO_!2*[_P4BN_\%(KO_!:22  "8F   C)X  ("E  !SJP  9[   %NU
M  !/N0  1+P  #K    PQ 0 *L<+ "C($P GR1T )LDG "7),  DRCD (\I"
M "++2P ARU4 (,Q? !_,;  =S7H ',V* !O-G  9SJX!&,[% !C-Y  8S/0!
M&,K\ 1C*_P(8RO\"&,K_ IN9  "/GP  @J8  '6M  !HLP  7+D  %"]  !$
MP0  .<0  ##(   HS $ (- & !G5"P 6UQ  %=@9 !79(@ 4V2L $]HT !/:
M/0 2VT@ $=Q3 !'=7P 0W6T $-Y^  [?D0 .X*0 #>"X  S@T@ +W^T #-[W
M  S=^P ,W?L #-W[ )*?  "%IP  =ZX  &JU  !=O   4,$  $3%   XR0
M+LT  "71   >U0  %MH! !'>!@ 0YPT #N<2  WH&0 ,Z"$ "^DI  KJ,0 )
MZCL !^M%  7K40 $ZUX  ^MN  'K@   ZI0  .JG  #KO   Z](  .OI  #L
M[P  [.\  .SO (>G  !YKP  :[<  %Z^  !1Q0  0\D  #?-   MT0  (]8
M !O;   3WP  #N,   SN @ *]@H !_8.  7V$@ #]A@  /4>  #U)0  ]2X
M /4W  #V0@  ]DX  /9=  #V;@  ]H$  /:5  #WIP  ][<  /C'  #XT
M^-   /C0 'NO  !MN   8,   %+(  !$S0  -]$  "O7   AW   &.   !'D
M   ,YP  !^\   3Z   !_P,  /\(  #_#0  _A   /X4  #_&@  _R$  /\I
M  #_,P  _SX  /]+  #_6P  _VP  /^   #_D@  _Z$  /^M  #_LP  _[,
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M =\:Z '<&_4"V!O_ M4<_P/4'/\#TQS_!-(<_P32'/\$TAS_!/\I%P#_*A,
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M#:4V_PZC-_\.HC?_#J(W_PZB-_\.HC?_#O\W!P#_.P( _T # /)"!0#I0@D
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M%WU+_Q9]2_\6?4O_%O]#  #F3   UE,  ,E8  # 60  NE@! +16"0"L5Q8
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M&U=FL!Q69L,=5F;?'59F\QQ79O\;5V;_&E=F_QI79O\:5V;_&MM9  #'8@
MNFH  *]P  "F<P  FG,  (]P  "'<04 @7(1 'QS'@!X<RH =',U 7!S/P-M
M<D<%:G%.!V=Q50ED<%P+8F]C#E]O:A!=;G(26FU\%5AMAA=6;),95&R@&U)K
MKQQ1:\$<46O<'%%K\1M2:_X:4FK_&E)J_QE2:O\94FK_&=1<  ##9@  MFX
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M%D%_[19!?OL607W_%D%]_Q9!??\607W_%L)J  "U=0  JGT  )^"  "2@P
MA80  'F%  !JB0  9(H# &",$ !=C1L 6XXG %B.,@!5CCL!4XY# E".2@-.
MC5(%3(U9!DF,8 A'C&@*18MR#$*+?0Y BHD//HJ8$3R*IQ([BK@2.HK/$CN(
MZQ([A_H3.X;_$SN&_Q,[AO\3.X;_$[QQ  "O>P  I8,  )F'  ",B   ?XD
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M!26G_P4EI_\%):?_!:>)  ";CP  D90  (29  !XG@  :Z(  %^F  !3J@
M2*T  #VP   TLP, +[4. "VU%@ LM2  *[8I "JV,@ IMSH *+=# ">W3  F
MN%4 )+A? ".X:P BN'@!(+B( 1^XF0$=N:L!'+G  1RXWP$<MO(!&[7\ ANT
M_P(;M/\"&[3_ I^/  "4E0  B)L  'NA  !NI@  8JL  %:P  !*LP  /[8
M #6Y   LO   )+\& !_"#0 =PA0 ',(> !O#)@ :PR\ &<0X !C$00 7Q$H
M%L55 !7%80 4QF\ $\9_ !+&D0 1QZ0 $,>Y  _'U  0QNX $,3Z !##_P 0
MP_\ $,/_ )>6  "+G   ?J(  '&I  !DKP  6+0  $NX  ! NP  -;X  "O!
M   CQ0  &\D! !3,!@ 0T L #M$1  W1&0 -T2$ #-$J  S1-  +TCX "M))
M  G350 )TV( "--R  ;4A  %U)@ !-2K  /5P  !U=P  =7M  '5]@ !U?8
M =7V (Z=  " I   <ZL  &:Q  !9N   3+T  #_    TPP  *L<  "'*   9
MS@  $M(   W6 0 )VP4 !MP-  3<$0 #W1@  =X@  #>*   WS$  . \  #A
M1P  XE0  .-C  #C=   Y(@  .2;  #EK@  Y<$  .75  #FYP  YN<  .;G
M (.D  !UK   :+,  %J[  !-P0  0,0  #/(   HS   ']   !?4   0V0
M"]T   7A    Y    .4'  #F#0  YQ$  .@6  #I'0  ZB4  .LN  #M.0
M[T4  /!3  #Q9   \78  /**  #SG   \ZT  /2[  #TR   ],@  /3( '>M
M  !JM0  7+T  $_$  ! R0  ,\T  "?1   =U@  %-P   [@   (XP   >8
M  #J    [@   .X   #O!   \ H  /$.  #S$@  ]!@  /8@  #X*@  ^C4
M /U#  #^4@  _V,  /]V  #_B0  _YH  /^F  #_L   _[   /^P /\6(P#_
M%2$ _Q$A /\-) #_"2L _P8W /\#1 #_ %$ _P!= /\ : #_ '( _P![ /\
M@P#_ (H _P"1 /\ E@#_ )P _P"A /T I@#[ *P ^0"S /< NP#U ,4 \P#1
M /( Y #Q /$ [P#Z .X _P#N /\ [0#_ .T _P#M /\ [0#_ /\9( #_&!T
M_Q4= /\0'P#_#BD _PPT /\*00#_!TT _P59 /\$9 #_!&X _P-W /\#@ #_
M X< _P.- /T"DP#[ ID ^0*> /<"I #U JH \P&P /$!N #O <( [0'/ .L!
MXP#J >\ Z +[ .<$_P#F!?\ Y@;_ .8&_P#F!O\ Y@;_ /\<&P#_&QD _Q<8
M /\5'0#_$R4 _Q$P /\0/0#_#DD _PQ5 /\+8 #_"VH _0MS /L+? #Y"H,
M]PJ* /4*D #T"I8 \PJ; /$*H0#O":< [0FN .L)M@#H"<  Y@G- .0)X@#B
M"O  WPO[ -X,_P#<#?\ W W_ -L-_P';#?\!VPW_ ?\?%P#_'A, _QL2 /\<
M&0#_&R( _Q@L /\5. #_$T0 _A)0 /D16P#U$&8 \Q!O / 0=P#N$'\ [!"&
M .H0C #I$)( Z!"8 .8/G@#E#Z4 XP^L .$/M #@#[X W@_, -H0X0#5$?
MTA+[ ,\2_P'.$_\!S1/_ <T3_P',$_\!S!/_ ?\B$@#_(@\ _R$/ /\B% #_
M(AP _R G /\=,@#X&SX \AE+ .X85@#J%V  YQ9J .06<@#B%GH X!:" -X6
MB #<%H\ VQ:5 -D6FP#6%J( U!:I -(6L0#0%[L SA?) ,P8W@#(&>X!Q1K[
M <,:_P+!&_\"P!O_ L ;_P+ &_\"P!O_ O\F#@#_)0L _R@, /\I$ #_*!8
M_B8@ /0D*P#L(3@ YB!$ .$?4 #='UL V1YE -4>;0#2'W4 T!]] ,X?@P#,
M'XH!RQ^0 <D?EP'('YX!QA^E <4@K0'#(+<!P2#$ < AU@&\(NH"N2+X [8B
M_P.U(_\#M"/_!+,C_P2S(_\$LR/_!/\I"P#_*@4 _RX( /\O# #_+1  \RL7
M .@H(@#@)B\ V28] -(G2@#-)U4 RBA? ,<H: '%*&\!PR=W <$G?@&_)X0!
MOB>+ KPGD@*[)YD"N2>@ K<GJ0.V*+,#M"B_ [,HSP.P*>8$K2GV!*LJ_P6I
M*O\&J"K_!J@J_P:H*O\&J"K_!O\M!0#_,   _S," /8T!@#O,@H Z"X0 -PL
M& #1+B@ RR\W ,8P1 #!,$\ OC!9 ;LP8@&X,&H"MB]Q K4O> *S+W\#L2^&
M [ OC0.N+I0$K2Z<!*LNI 6I+ZX%J"^Z!:8OR@:D,.(&H3#S!Y\P_PB>,?\(
MG3'_")PQ_PB<,?\(G#'_"/\P  #_-0  [S@  .(Z  #;.00 UC4) ,XT$P#&
M-B( OS@Q +HX/P"V.$H!LSA4 ; W70*M-V0"JS9L ZDV<P2H-GD$IC6 !:0U
MAP6C-8\&H367!Y\UH >>-:H(G#6V")LUQ0F9-=T)EC;O"I0V_0J3-_\*DC?_
M"I(W_PJ2-_\*DC?_"O\S  #V.@  Y#\  -A"  #.0@$ R3X& ,0[#P"[/AT
MM3\L +$_.@"M/T4!J3]/ :8^6 *C/5\#H3UG!)\\;06=/'0&G#M[!IH[@@>8
M.XH(ECN3"94ZG J3.J8+D3JR"Y [P R..]4,C#SL#8H\^PV)//\-B3S_#(@\
M_PR(//\,B#S_#/\W  #J/P  W$4  ,Y)  #%20  OT8" +I## "S1!D K44G
M *A&-0"D14$!H$5+ IU$4P*:0UL#F$-B!99":0:407 'DD%V")! ?@F.0(8*
MC4"."XM F R)0*(-AT"N#H5 O ^$0,\/@D'I#X%!^0^ 0?\/@$+_#H!"_PZ
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M$.Q#  #93   R%,  +U7  "T6   K%<  *52 0">4P\ F%0< )-4*0"/5#4
MBU-  8A32 *%4E $@E%7!7]07@9]4&0(>T]K"7E/<@MW3GL-=4Z$#G--CA!Q
M39D1;TVE$VU-LQ1L3<44:T[A%&M.]!-K3O\2:T[_$FM._Q%K3O\1:T[_$>A&
M  #34   Q%8  +E:  "P7   IEH  )]6  "85@T DE<9 (Y8)@")6#( AE@]
M 8)710)_5DT#?%54!7E46P9W5&$(=5-H"7-3< MQ4G@-;U*!#VU2BQ!K49<2
M:5&C$V=1L11F4<,595+>%652\A1E4O\395+_$F52_Q)E4O\295+_$N1*  #/
M4P  P%H  +5>  "L8   HEX  )I9  "26@L C5L6 (A<(P"$7"\ @%LZ 7U;
M0P)Y6DL#=EE2!'186 9Q6%\';U=F"6U7;0MK5G4-:59^#V=6B1%E59428U6A
M%&)5KQ5A5<$68%7;%F!6\15@5OX48%;_$V%6_Q)A5O\285;_$N!-  #+5@
MO5T  +)A  "H8P  G6$  )5=  "-7@D AUX3 (-?( !_7RP >U\W 7=>0 )T
M7D@#<5U/!&]<5@5L7%P':EMC"6A;:PMF6G,-9%I\#V):AQ%@69,27EF@%%U9
MKA5;6;\66UG8%EM9[Q5;6?T47%G_$UQ9_Q)<6?\27%G_$MQ0  #'60  NF
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M%$QFZQ1-9OL336;_$DYE_Q).9?\23F7_$LQ:  "\8P  L&H  *5O  "8;@
MC&T  (!L  !W;0  <6X+ &UO% !I<"$ 9G$L &1Q-@%A<3X!7G%& EQP30-9
M<%0%5W!;!E5O8@A3;VH*4&YS#$YN?@Y,;8H02FV8$4ELIQ)(;+@31VS-$T=L
MZA-(:_H22&O_$DAJ_Q%(:O\12&K_$<=>  "X9P  K&X  *%R  "3<@  AW$
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M##: _PPV@/\,-H#_#+9O  "J>   GW\  )!^  "#?P  =X   &N"  !>AP
M58H  $Z,!@!*CA  2(\: $>/)0!%D"\ 1) X $*00 ! D$<!/Y!/ 3V05@([
MD%\".9!H S>/<P0UCX %,X^.!C&/G@<PCJ\'+X[#!R^.X0<OC/0(+XO_""^*
M_P@OBO\)+XK_";!V  "E?P  F(0  (J$  !]A0  <(<  &6*  !:C@  3Y(
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M 9J-  "0D@  A)<  '6:  !HGP  6Z,  %"H  !%K   .[   #&R   GM0
M(+@  !BZ!P 4O X $[P5 !*\'@ 1O28 $;TN !"]-P 0OD$ #KY,  Z^5P -
MOF4 #+]T  N_A@ *OID "+ZL  >^P@ 'OM\ "+[P  B]^@ (O?P "+W\ ).4
M  "'F0  >I\  &RE  !@J@  4Z\  $>S   \M@  ,;@  ">[   ?O@  %\$
M !'$ 0 ,R @ ",D.  ?)%  &R1P !<DD  3*+  #RC8  LI   #+3   RUD
M ,MH  #+>0  S(P  ,N?  #+LP  R\@  ,SB  #,[P  S/$  ,SQ (J:  !\
MH0  ;Z<  &*M  !5LP  2+@  #N[   PO@  )L$  !W$   5R   #\L   K.
M   $T@(  -,*  #3#P  U!0  -4:  #6(@  URH  -DT  #:/P  W$L  -Q:
M  #=:@  W7T  -V1  #=I   WK8  -[(  #>W@  WN(  -[B '^B  !QJ0
M9+   %:W  !)O   /,   "_$   DQP  &\L  !//   -T@  !]8   #;
MW@   -\#  #@"0  X0X  .(2  #C%P  Y1X  .8G  #H,0  ZCT  .Q+  #L
M6@  [6P  .Z   #NE   [J4  .ZT  #NP@  [L8  .[& '2J  !FL@  6+D
M $O    ]Q0  +\D  "3-   9T0  $=8   O;   #W@   .$   #E    Z
M .D   #J    ZP8  .T+  #O#P  \!,  /(:  #T(P  ]RX  /D[  #[2@
M_%L  /UM  #]@   _I,  /ZB  #^K0  _J\  /ZO /\0'P#_#AT _PH= /\!
M( #_ "@ _P U /\ 00#_ $X _P!: /\ 90#_ &X _P!W /\ ?P#^ (8 _ ",
M /L D@#Y )< ^ "< /< H@#V *< ]0"M /, M0#R +T \0#) .\ W #N .L
M[0#W .P _P#K /\ Z@#_ .H _P#J /\ Z@#_ /\3' #_$1D _PT9 /\&' #_
M R4 _P Q /\ /@#_ $H _P!6 /\ 80#_ &L _0!S /H >P#W (, ]0") /0
MCP#R )0 \0"9 /  GP#N *0 [0"K .P L@#J +H Z #& .< U@#E .@ Y #U
M ., _@#B /\ X0#_ .$ _P#A /\ X0#_ /\5& #_$Q0 _P\4 /\-&0#_"R(
M_P@M /\$.0#_ 48 _P!1 /X 7 #Z &8 ]@!O /( =P#O 'X [0"% .L BP#J
M )$ Z "6 .< G #F *$ Y "H ., KP#A +@ WP## -T T0#; .8 V0#S -<
M_0#5 O\ U +_ -0#_P#4 _\ U /_ /\8$P#_%1  _Q(/ /\2%0#_$1T _PXH
M /\,- #_"D$ ^0A, /4&5P#Q!F$ [09J .D%<@#F!7H Y 6! .(%AP#@!HT
MWP:2 -T&F #;!IX V0:E -<&K0#4!K4 T@;  - 'SP#.".4 S GT ,H+_P#(
M#/\ QPS_ ,<,_P#&#/\ Q@S_ /\;#@#_&0P _Q@- /\8$0#_%Q@ _Q0B /L1
M+@#S$#H [0Y& .@-4@#E#5P X0UE -X-;0#;#74 V U\ -4-@@#3#8D T0V/
M - -E0#.#9P S0ZC ,L.JP#)#K0 R [  ,8.SP##$.8 P!'U +T2_P"\$O\
MNQ+_ +H2_P&Z$O\!NA+_ ?\?"@#_' 0 _Q\( /\?#0#_'1( ^!H; .X6)@#F
M%#, X!,_ -H32P#4$U8 T!-? ,X4: #+%&\ R11W ,<5?0#&%80 Q!6* ,,5
MD0#!%I@ P!:? +X6IP"\%[  NQ>\ +D7RP"W&.( LQGR ;$:_P&O&_\!KAO_
M :X;_P&M&_\!K1O_ ?\B! #_(@  _R4" /PD!P#W(0P [!T2 .$:' #8&BH
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M!_0R  #C.P  TD$  ,9$  "]0P  MS\  +$["0"J.Q0 I3PB * ], "=/3L
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M"V]$KPQN1, ,;479#6Q%[PQK1?T+:T;_"VM&_PIK1O\*:T;_"N5   #/20
MP4\  +52  "K4@  H4\  )M*  "42@P CTL7 (M,) "'3"\ A$PZ (%,0P%^
M2TL!>TM2 GE*6 -W2E\$=4EF!7-);09Q274';TE^"&U(B EK2),+:DB?#&A(
MK0UG2;T-9DG4#F5)[0UE2OP,94K_"V5*_PME2O\+94K_"^!$  #+30  O5(
M +)6  "F50  G%(  )5.  ".3@D B4\4 (50( "!4"P ?E W 'M00 %X4$@!
M=4]/ G-.50-Q3EP$;TYC!6U-:@9K37(':4U["&=-A0IE39$+9$R=#&)-JPUA
M3;L.8$W1#F!-[ Y@3?L-8$W_#&!-_PM@3?\+8$W_"]Q'  #'4   N58  *Y9
M  "B6   F%8  )!1  ")4@8 @U,1 ']3'0![5"D >%0T '54/0%R4T4!<%-,
M FU24P)K4ED#:5)@!&=19P9E46\'8U%X"&)1@PI@48\+7E";#5U0J0Y;4;D.
M6U'.#UI1Z@Y;4?H-6U'_#%M1_PQ;4?\+6U'_"]9*  ##4P  MED  *M<  ">
M6@  DUD  (M4  "$5@, ?E80 'I7&@!V5R8 <U@Q '!7.@!M5T(!:E=) FA6
M4 )F5E<#9%9>!&)5905@56T'7E5V"%U5@0I;58T+652:#5A4IPY65;@/5E7,
M#U95Z0Y65?D-5E7_#5=4_PQ75/\,5U3_#-%-  # 5@  LUP  *=>  ":70
MCUP  (98  !_60  >5H- '1;%P!Q6R, ;ELN &M;-P!H6T !95M' 6-:3@)A
M6E4#7UI<!%U:8P5<6FL&6EET"%A9?PI668L+5%F8#5-8I@Y26;8.45G*#U%9
MYPY16/@-4EC_#5)8_PQ26/\,4EC_#,U1  "\60  L%\  *-A  "68   BU\
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M"T-E_PM#9?\+0V7_"[]<  "Q9   IFH  )9I  "):0  ?6D  '%I  !G:@
M8FP! %UM#0!9;A8 5V\A %5P*P!3<#4 47 ] %!P10%.<$P!3'!3 DIP6@-(
M<&($1F]K!41O=09";X('0&Z/"3]NG@H];J\*/6[""CQNX H];?0*/6S_"CUK
M_PH^:_\*/FO_"KI@  "M:0  H&X  )%M  "$;0  >&T  &QN  !A<   6W(
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M!*IT  ">>P  CGH  (!Z  !T>P  :'X  %V!  !2A0  28D  $&,   YD 4
M-9$/ #.2%P RDB$ ,9(I #"3,@ NDSH +9-! "R32@ KE%( *I1< "B49P G
ME',!)92" 224DP$BDZ0!(9.W 2"3SP$ADNP!()#Z B"/_P(@C_\"((__ J1\
M  "7@   AW\  'N   !N@@  8H4  %>)  !-C@  0I(  #J6   RF0  *IP)
M "B=$0 FG1D )9TB "2>*@ CGC( (IXZ "&>0@ @GDL 'Y]5 !Z?8  <GVT
M&Y]\ !J?C0 8GY\ %Y^R !:?R0 6GN@ %ISW !:;_P$7F_\!%YO_ 9V#  "/
MA@  @H8  '2'  !GBP  6X\  %"3  !&F   /)P  #.@   KHP  (Z8  !RH
M"P :J1$ &*D8 !>I(0 6JBD %:HQ !2J.0 3JD, $ZM- !*K6  1JV4 $*MT
M  ZKA@ .JYD #:NL  RKP0 ,JM\ #*GR  VH_  -J/\ #:C_ ):*  ")C
M>HT  &R1  !@E0  5)H  $F?   _HP  -:<  "NJ   CK@  &[   !2S 0 /
MM0H #;80  RV%@ +MA\ "K8G  FV+P (MCD ![=#  :W3P $MUL  [=J  *W
M>P  MXX  +>A  "VM   MLL  +;E  "U\0  M?<  +7W (^1  "!E   <I<
M &6<  !8H0  3*8  $&K   WKP  ++(  ".U   :N   $[L   Z]   )P 4
M \$-  #!$0  P1<  ,(>  #")@  PB\  ,,Y  #$1   Q%   ,1>  #%;P
MQ8$  ,65  #%J   Q;P  ,31  #$Y@  Q.X  ,3N (:8  !YG@  :Z,  %VI
M  !0K@  1+,  #>V   LN0  (KP  !F_   1P@  #,4   ;(    RP   ,P'
M  #,#0  S1$  ,T6  #.'0  SR0  - M  #2.   U$0  -12  #580  U7,
M -:'  #6FP  UJT  ->_  #8S@  V-T  -C= 'N@  !NI@  8*T  %.S  !%
MN   .+P  "N_   AP@  %\8  !#)   *S    M    #4    UP   -@   #:
M!0  VPL  -P.  #>$P  WQD  .$A  #C*@  Y38  .=#  #G4P  Z&0  .EW
M  #IC   ZI\  .JN  #JN@  ZL,  .K# '"H  !BKP  5;8  $>\   YP
M+,0  "#(   6S   #M    ?4    V0   -T   #A    XP   .0   #F
MYP$  .D'  #K#   [!   .X5  #P'0  \R<  /8S  #W0P  ^%0  /EF  #Y
M>@  ^HX  /J>  #[J0  ^[   /NP /\+&P#_!QD _P 9 /\ ' #_ "4 _P R
M /\ /P#_ $L _P!7 /\ 8@#_ &L _P!S /T >P#[ (( ^@"( /@ C0#W )(
M]@"8 /4 G0#T *( \P"I /$ L #O +@ [@## .P T0#K .8 Z0#S .@ _@#H
M /\ Z #_ .@ _P#H /\ Z #_ /\.& #_"A4 _P$4 /\ & #_ "( _P N /\
M.P#_ $< _P!3 /T 7@#Z &< ]P!O /4 =P#S 'X \@"$ /  B0#O (\ [@"4
M .P F@#K )\ Z0"E .@ K #F +0 Y "_ ., S #A .( WP#P -X ^P#> /\
MW0#_ -T _P#< /\ W #_ /\0$P#_#1$ _P80 /\"%0#_ !X _P I /\ -@#_
M $( ^@!. /0 60#Q &( [@!K .P <@#J 'D Z !_ .< A0#E (L Y "0 .(
ME@#A )P WP"B -T J0#: +$ V "[ -4 R #2 -T T0#M -  ^0#/ /\ S@#_
M ,T _P#- /\ S0#_ /\1#P#_#@T _PP- /\+$@#_!QD _P(D /\ , #V #P
M[P!) .H 4P#G %T Y !F .$ ;0#? '0 W0![ -L @0#9 (8 U@", -0 D@#2
M )@ T "> ,X I@#, *X R@"X ,@ Q #& -< Q0#J ,, ]P#" /\ P0'_ , "
M_P#  O\ P +_ /\4"P#_$ 8 _Q ) /\0#@#_#A0 _PH> /4&*0#K!#8 XP-"
M -\#3@#;!%< U@1@ -,$: #0!&\ S@5V ,P%? #*!8( R06( ,<%C@#&!90
MQ 6; ,(%HP# !JL O@:U +T&P@"["-0 N@GI +<+^ "U#/\ M S_ +0,_P"T
M#/\ M S_ /\7! #_%   _Q8# /\4"0#_$0X \@X5 .@,(0#>"BX U@L[ - ,
M1P#,#%$ R0Q: ,8-8@#$#6H P@UQ , -=P"_#7T O0Z# +P.B@"Z#I$ N0Z8
M +<.H "V#JD M ^T +(/P0"Q$-0 KA'K *L2^@"I$O\ J!/_ *<3_P"G$_\
MIQ/_ /\:  #_&P  ^1L  .L9  #E% 8 Y1 . -D.%P#/$28 R!(T ,030 "_
M%$L O!14 +D570"W%60 M15K +05<0"R%7@ L19^ *\6A0"N%HP K!:4 *L7
MG "I%Z8 IQBP *88O0"D&,\ HAKG )\:]P"=&_\!G!O_ 9P;_P&;&_\!FQO_
M ?\=  #W(0  Z"0  -TE  #4(0$ SQL( ,H7$0#"&B  O!PM +<=.@"S'D4
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M X,OL@."+\(#@3#: W\P[P-],?X#?3'_ WPQ_P-\,?\#?#'_ ^TO  #;-P
MR3T  +X^  "S/   K#@  *<S! "B,A$ G30= )DU*@"5-34 DC5  (\U20"-
M-5  BS57 (DU7@&'-60!A31K 80T<@*"-'D"@#2" GXTBP-]-)8#>S6A!'DU
MK@1X-;X%=S;4!78V[05T-_P%=#?_!'0W_P1T-_\$=#?_!.<U  #2/0  PT(
M +A$  "L0@  I#X  )\Y  ":. X E#H9 ) Z)@"-.S$ BCL[ (<[1 "$.TP
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M"&!$Y@A?1?@'7T7_!V!%_P9@1/\&8$3_!M9!  ##20  MDX  *=/  ";30
MDDL  (Q'  "%1P0 @$<0 'Q(&@!X2"8 =4DP '-).@!P24( ;DE) 6Q(4 %J
M2%8!:$A= F9(9 )E2&P#8TAU!&%'?P5@1XH&7DB7!UU(I0A;2+0(6TC'"5I(
MY A:2?8(6DG_!UI(_P9:2/\&6DC_!M%%  "_3   LE(  *-1  "74   C4X
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M!TQ3_P=-4_\&35/_!L5.  "V5@  IUH  )A9  "+6   @5<  '=4  !P50
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M!;1>  "G90  E64  (9D  !Z90  ;V4  &1F  !9:   4FH  $UL! !);@X
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M;0  B6P  'QM  !P;0  9FX  %MQ  !0=0  2'@  $%[   Z?@4 -G\. #2
M%@ S@2  ,H$H #"!,  O@C@ +H)  "V"2  L@E  *X): "J"9  H@G  )H)_
M 26"CP$D@J !(X*R 2*"R0$B@><!(G_W 2)^_P(B??\"(GW_ J5Q  "3<0
M@W$  '9Q  !L<@  8'4  %9X  !,?   0X   #N#   SA@  +8D* "J*$0 I
MBQD )XLB ":+*@ EC#$ )(PY ".,0@ BC4H (8U4 ""-7@ ?C6L '8UY !R-
MB@ ;C9P &8VN !B,Q  8C., &8KU !F)_P$9B/\!&8C_ 9UW  ",=@  ?78
M ')W  !E>0  6GP  %"   !&A   /(D  #2,   MD   )9," !^5#  =EA(
M')8: !N7(@ :ERH &9<R !B8.@ 7F$, %IA- !686  4F&0 $YAS !&8A  0
MF)8 $)BI  Z8OP .E]T #Y;R !"5_  0E/\ $)3_ )5]  "%?   >'P  &M^
M  !?@0  5(8  $J*  ! CP  -I,  "V7   FF@  'IT  !>@ P 2H@P $*,2
M !"C&0 /HR$ #J0I  ZD,0 -I#H #*1%  ND4  *I%P ":1J  >D>P &HXX
M!*.A  *CM  #HLL  Z+F  .A\P #H?L  Z'[ (V#  !_@@  <80  &2'  !8
MC   39$  $*6   XF@  +YX  ":B   >I0  %Z@  !&K   ,K@< !Z\-  .O
M$@ "KQD  :\A  "O*0  L#(  + \  "P1P  L%,  +!A  "P<0  L(,  *^7
M  "OJ@  K[\  *[9  "NZP  KO0  *[T (>)  !XB@  :HX  %V3  !1F
M19T  #NB   PI@  )ZH  !ZN   6L0  $+0   NV   %N0,  +H*  "Z#@
MNA,  +L9  "[(0  O"@  +PQ  "]/   OD@  +Y6  "^90  OG<  +Z,  "^
MGP  O;,  +['  "^W@  O>L  +WK '^2  !PE0  8IH  %6?  !)I0  /:L
M #*O   HM   'K8  !6Y   .O   ";\   +"    Q    ,4$  #&"@  Q@X
M ,<2  #(&   R1\  ,HG  #,,   SCP  ,Y)  #/60  SVH  ,]^  #/DP
MSZ8  ,^X  #/R   S]L  ,_; '><  !HH0  6Z<  $ZN  !!M   -+<  "BZ
M   =O0  $\    W$   &QP   ,H   #.    T    -$   #2 @  TP@  -4,
M  #6$   V14  -L<  #=)   X"\  .(\  #C2P  Y%P  .1O  #E@P  Y9@
M .6I  #EM@  Y<,  .7# &RE  !?K   4;(  $2Y   UO   *,   !S$   2
MR   #,L   //    TP   -@   #<    WP   -\   #A    XP   .0#  #F
M"   Z T  .D1  #L&   [B(  /$N  #S/   ]$T  /5?  #V<P  ]X<  />9
M  #XI0  ^+   /BP /\#%P#_ !4 _P 5 /\ & #_ ", _P O /\ / #_ $@
M_P!4 /\ 7@#_ &< _0!O /L =@#Y 'T ^ "# /8 B #U (X ] "3 /( F #Q
M )X \ "D .X JP#M +, ZP"] .H RP#H .$ YP#Q .8 _0#E /\ Y #_ .0
M_P#D /\ Y #_ /\'$P#_ !$ _P 1 /\ %0#_ !\ _P K /\ -P#_ $0 _@!/
M /H 6@#W &, ] !K /( <@#P 'D [P!_ .T A #K (H Z@"/ .@ E #G )H
MY0"@ .0 IP#B *\ X "Y -X Q@#< -H V@#L -@ ^0#6 /\ U@#_ -< _P#8
M /\ V #_ /\*$ #_ PX _P - /\ $@#_ !H _P F /P ,@#W #\ ] !* /$
M50#M %X Z@!F .@ ;@#E '0 XP!Z .( @ #@ (4 W@"+ -P D #; )8 V "<
M -4 HP#3 *L T0"U ,X P0#, -$ RP#G ,D ]0#( /\ R #_ ,@ _P#( /\
MR #_ /\,# #_!@@ _P(* /\ #P#_ !4 _  @ /$ + #L #D Z0!% .4 3P#A
M %D W@!A -L : #7 &\ U !U -( >P#0 (  S@"& ,P C #+ )( R0"8 ,<
MH #% *@ PP"Q ,$ O "_ ,L O0#C +P \@"[ /T NP#_ +H _P"Z /\ N@#_
M /\.!0#_"0  _PD% /\&"P#_ 1  \  9 .8 )0#A #( W  _ -8 20#1 %,
MS@!; ,L 8P#( &H Q@!P ,4 =@## 'L P0"! ,  AP"^ (X O "4 +L G "Y
M *0 MP"N +4 N0"S ,@ L0#? + ![P"O ?L K@+_ *T#_P"M _\ K0/_ /\0
M  #_#@  _PT  /8+ P#R!PH X@$1 -L"'0#2 RL S ,W ,@$0P#$!$T P016
M +X%70"\!60 N@5K +@%<0"W!78 M05\ +,&@P"R!HD L :1 *\'F0"M!Z$
MJP>K *D(MP"H"<8 I@K= *4+\ "C#/T H@W_ *$-_P"A#?\ H W_ /\1  #\
M$@  [!,  .(3  #;#P, U@D+ ,X(% #&"B( P PP +P-/ "X#48 M0U/ +(.
M5P"P#E\ K@YE *T.:P"K#G$ J@YX *@.?@"G#X4 I0^- *0/E@"B$)\ H!"I
M )\0M0"=$<4 FQ'> )D2\0"7$_\ EA3_ )44_P"5%/\ E!3_ /\5  #M&P
MX!\  -(?  #)&P  Q!0% ,$0#@"Z$AL M!,I + 4-0"L%4  J15) *854@"D
M%ED HA9@ *$69@"?%FP GA9R )P6>0";%X  F1>( )@7D0"6&)L E!BF ),9
ML@"1&<$ D!K8 (T;[@"+'/T BAS_ (H<_P")'/\ B1S_ /0=  #D)0  TRD
M ,<J  "\)@  MB   +09"P"N&A4 J!PC *0=+P"A'CH GAY$ )L>3 "9'E0
MEQ]; )4?80"4'V< DA]M )$?= "/('P CB"$ (P@C0"*()< B2&B (<AK@"&
M(KT A2+1 8(CZP&!)/L!@"3_ 7\D_P%_)/\!?R3_ >PE  #;+0  R3$  +PQ
M  "Q+@  JRD  *<D!0"C(Q$ GB0= )HE*@"6)C4 DR8_ )$F1P"/)D\ C296
M (LG7 "))V( B"=I (8G;P"%)W< @R=_ ($GB0& *),!?BB> 7TIJP%[*;D!
M>BG- 7@JZ %W*_D!=BO_ 78K_P%U*_\!=2K_ >4L  #0-   P3@  +,X  "H
M-0  HC$  )TM  "9*@X E"L8 ) L) "-+3  BBTZ (<M0P"%+4H @RU1 ($N
M6 " +EX ?BYD 'TN:P![+G,!>2Y[ 7@NA0%V+H\!="^; 7,OJ )Q+[8"<##)
M F\PY0)N,?<";3'_ FTQ_P)M,?\";3'_ M\R  #).0  NSX  *P]  "A.@
MFC<  )4S  "0,0H C#$4 (<R( "$,RL @3,U '\S/@!],T8 >S-- 'DS5 !W
M,UH =C-A '0S9P%R-&\!<31W 6\T@0%N-(P";#28 FHUI0)I-;,#:#7& V<V
MX@-F-O4#9C;_ F8V_P)F-O\"9C;_ M@W  #$/@  M4(  *9!  ";/P  DSP
M (TX  "(-@< A#<1 ( W' !\."< >C@Q '<Y.@!U.4( <SE) '$Y4 !P.5<
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M U1#_P-40_\#5$/_ \A"  "X20  ITL  )A*  "-20  @T<  'U#  !V0P
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M [I/  "J5   F%0  (E4  !]4P  <U,  &E1  !B4@  7%,  %A4"@!451(
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M 3-CD0(R8Z$",6.S C%CR (Q8N<",6'X C%A_P(R8/\",F#_ JY<  ";70
MBET  'Q=  !P70  9ET  %Q>  !28   3&(  $5E  !!9@H /F<1 #QH&@ [
M:"( .6DK #AI,@ W:CH -FI! #5J20 T:E( ,VI; #%J90 P:G !+FI^ 2UJ
MC@$L:I\!*VJP 2IJQ@$J:>4!*FCV BMG_P(K9_\"*V?_ JEA  "58   A&
M '=@  !L80  8F$  %AC  !.9@  1V@  $!K   Z;@4 -F\. #1P%0 S<!X
M,G$F #!Q+@ O<34 +G(] "UR10 L<DT *W)7 "IR80 I<FT )W)[ "9RBP D
M<IP!(W*N 2-RPP$C<>(!(W#T 2-O_P$C;O\!(V[_ :%E  ".9   ?V0  ')D
M  !H90  7F8  %1I  !);   0F\  #MR   T=0  +G@* "MY$0 J>1@ *7HA
M "=Z*  F>C  )7LX "1[0  C>T@ (GM2 "%[7  @>V@ 'WQV !U\A@ <>Y@
M&WNJ !I[OP :>]X &GGR !MX_@ ;=_\!&W?_ 9EI  "(:0  >6D  &UI  !C
M:@  66P  $]O  !%<P  /7<  #5Z   N?0  )X$# "*##0 @A!( 'X0: !V$
M(@ <A2H &X4Q !J%.0 9A4( &(9, !>&5@ 6AF, %89Q !2&@0 2AI, $8:F
M !&%NP 0A=8 $8/O !&"^P 2@O\ $H'_ )%N  "!;0  =&X  &EN  !=<
M4W,  $EW  ! ?   -X   "^#   GAP  (8H  !J-!@ 5CPT $Y 3 !*0&@ 2
MD"( $9 J !"1,@ 0D3L #Y%$  Z13P -D5P #)%J  N1>@ *D8T ")"?  >0
MLP 'C\D !X_F  >.]  (C?P "(W_ (ES  ![<P  ;W,  &-U  !7>   37T
M $.!   YA@  ,(H  "B.   AD0  &I4  !.7   .F@@ "YP.  F<$P (G!H
M!YPB  :<*@ $G#,  YP]  *=2   G50  )UB  "<<@  G(0  )R7  ";J@
MF[\  )K;  ":[   FO4  )GX ()Y  !V>0  :'H  %Q^  !1@@  1H<  #R,
M   RD0  *94  "&9   9G0  $J    ZC   )I@4  Z<,  "G$   IQ4  *@<
M  "H(P  J"L  *DT  "I/P  J4L  *E9  "I:   J7H  *F.  "IH0  J+4
M *C+  "GY   I^\  *?S 'V   !O@0  880  %6)  !)C@  /I0  #29   J
MG@  (:(  !FF   2J0  #:P   >O    L@   +,'  "S#   LQ   +05  "T
M&P  M2(  +8K  "W-0  MT   +A.  "X70  N&X  +B"  "XEP  N*H  +>^
M  "WT@  M^8  +?J ':(  !GBP  6I   $Z6  !"G   -Z(  "RG   BJP
M&:\  !&S   +M@  !+D   "\    O@   +X   "_!@  P L  ,$/  #"$P
MPQD  ,0@  #%*0  QS0  ,A"  #)40  R6(  ,EU  #)B@  R9\  ,JQ  #*
MP0  R=$  ,G9 &Z3  !@F   4YX  $:D   ZJP  +[   "2U   9N   $+P
M  J_   !P0   ,0   #(    R@   ,H   #,    S0,  ,X(  #0#0  T1
M -,6  #6'@  VB@  -TT  #>0P  WU0  -]G  #@?   X)$  ."D  #@L@
MX+X  .## &:?  !9I@  3*T  #^T   RN   )+P  !B_   0PP  ",<   #*
M    S0   -$   #5    V    -D   #;    W0   -\   #A!   XPH  .4.
M  #G$P  ZAP  .TG  #P-0  \48  /)8  #S:P  \X   /24  #THP  ]*X
M /2R /\ $P#_ !$ _P 1 /\ %0#_ !\ _P L /\ .0#_ $4 _P!0 /\ 6@#^
M &, ^P!K /D <@#W '@ ]0!^ /0 A #R (D \0". /  DP#N )D [0"? .P
MI@#J *X Z "X .8 Q0#E -L XP#M .( ^P#B /\ X0#_ .$ _P#A /\ X0#_
M /\ $ #_  X _P - /\ $@#_ !L _P H /\ - #^ $$ ^P!, /< 5@#T %\
M\0!F .\ ;0#L '0 Z@!Z .D ?P#G (4 Y@"* .4 CP#C )4 X0"; .  H@#>
M *H VP"T -D P #6 -  TP#H -( ]P#1 /\ T0#_ -  _P#0 /\ T #_ /\
M#0#_  D _P * /\ #P#_ !8 ^P B /< +P#T #L \ !' .T 40#I %H Y0!B
M .( :0#@ &\ W@!U -P >@#: (  V "% -4 BP#3 )$ T0"7 ,\ G@#- *8
MRP"O ,D N@#' ,D Q0#B ,0 \@## /X P@#_ ,$ _P#" /\ P@#_ /\#!@#_
M  $ _P & /\ # #Y !$ \0 = .L *0#G #8 XP!! -\ 2P#; %0 U0!< -(
M8P#/ &H S0!P ,L =0#) 'L R "  ,8 A@#% (P PP"3 ,$ F@"_ *( O0"K
M +L M@"Y ,0 MP#: +8 [0"T /H M #_ +0 _P"T /\ M #_ /\$  #_
M_P   /\ !@#L  T Y0 6 -X (@#7 "\ T0 [ ,T 10#* $X Q@!7 ,0 7@#!
M &0 OP!J +T < "\ '4 N@![ +D @0"W (< M0". +, E0"R )X L "G *X
ML@"L +\ J@#1 *@ Z "H /< IP#_ *< _P"F /\ I@#_ /\&  #_!0  \0,
M .@   #A  < U0 0 ,T &P#' "< PP S +\ /@"\ $@ N0!1 +8 6 "T %\
ML@!E +  :@"O '  K0!V *P ? "J (( J0") *< D0"E )H HP"D *$ K@"@
M +L G@'- )T"Y@"<!/0 FP3_ )H%_P":!?\ F07_ /\*  #Q#@  Y!   -D/
M  #."P  R ,+ ,( $P"\ A\ MP,L +,$-P"P!4( K09* *H&4@"H!UD I@=?
M *4'90"C!VL H@AQ * (=P"?"'X G0B% )L)C@":"9< F JA )8*K "5"[H
MDPO, )(,Y0"0#?8 CP[_ (X._P".#O\ C0[_ /81  #F%P  UAL  ,<9  "^
M%0  N1   +<*#0"Q"Q< K TD *@., "E#CL H@Y$ )\/3 "=#U, FP]: )H/
M8 "8$&8 EQ!L )40<@"3$'D DA"! ) 0B@"/$90 C1&? (L1J@"*$K@ B!++
M (83Y@"%%/< @Q7_ (,5_P""%?\ @A7_ .T:  #<(0  RB4  +LB  "Q'P
MJQH  *D4!@"E$A$ H!0> )P5*@"9%34 EA8^ )061P"2%DX D!95 (X76P",
M%V$ BQ=G (D7;0"(%W0 AAA\ (48A@"#&9  @1F; ( :IP!^&K4 ?1O' 'P<
MX@!Z'?4 >1W_ '@=_P!X'?\ >!W_ .4B  #0*0  ORP  + J  "G)P  H",
M )T?  ":&@X E1P8 )$=) ".'B\ C!XY (D>00"''TD A1]0 (,?5@""'UP
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M 5\P_P%?,/\!7S#_ <TT  "\.P  J3H  )LZ  "0.   B34  (,R  !_, $
M>R\. '<P%@!T,"$ <3$K &\Q- !M,3P :S%# &HQ2@!H,E  9S)7 &4R70!D
M,F4 8C)M &$S=P!?,X(!7C.. 5TTG %;-*H!6C6[ 5HUT@%9->T!637\ 5@U
M_P%8-?\!637_ <@X  "W/@  I#X  )8]  "+/   @SH  'TW  !X-   =#0+
M ' U$P!M-1T :C4G &@V, !F-C@ 9#8_ &,V1@!A-DT 8#93 %XW6@!=-V(
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M/A< 7CXA %P^*0!:/C$ 6#XY %<^0 !5/T8 5#]- %,_50!20%P 4$!E $]
M;P%.07H!34&' 4M!E@%*0:4"24*U DE"RP))0N@"24+Y DE!_P))0?\!24'_
M ;U#  "J10  F$4  (I%  !_10  =D,  &]   !H0   8T$! %]!#0!<010
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M 3U-D $\3: !.TZQ CI.Q@(Z3N0".TWV CM-_P$[3/\!/$S_ ;--  ">3
MC4P  '],  !T3   :DP  &!*  !92P  5$P  %!-!0!,3@X 24\5 $=/'@!%
M3R8 1% N $)0-0!!4#T 0%%$ #]12P ^45, /5)< #Q29@ Z4G( .5)_ 3A2
MC@$W4IX!-E*O 352Q $U4N(!-E+U 391_P$V4/\!-U#_ :Y/  "93P  B4\
M 'M/  !P3P  9D\  %Q.  !43P  3U$  $I2 0!&4PP 0U02 $%4&P! 52,
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M "-DO0 B9-H (V/Q "-B_0$D8?\!)&'_ 9Q8  ")6   >ED  &Y9  !C60
M6EH  %!<  !(7@  06   #IC   T9@  +V@* "QI$  J:1< *6H? "AJ)@ G
M:BX )FLU "5K/0 D:T8 (VM/ ")L60 @;&4 'VQR !YL@@ =;)0 '&RF !MK
MN@ ::]0 &VKN !QI_  <:/\ '&C_ )5<  "#7   =5P  &E=  !?70  5EX
M $QA  !#9   /&<  #5J   O;0  *' $ "-R#0 A<A( (',: !]S(0 ><R@
M'70P !QT.  ;=$  &G1* !ET5  7=6  %G5N !5U?@ 4=9  $W2B !)TM@ 1
M=,\ $G/L !)R^@ 3<?\ $W'_ (Y@  !]8   ;V$  &5A  !;8@  460  $AG
M   ^:P  -VX  #!Q   I=0  (G@  !Q[!P 7?0X %GT3 !5]&P 4?B( $WXJ
M !)^,0 1?CH $7Y$ !!_3@ /?UH #G]H  U_>  ,?XH "WZ=  I^L  )?<8
M"GWD  I\]  +>_T "WK_ (9E  !W90  :F4  &%F  !6:   3&L  $)O   Y
M<P  ,7<  "IZ   C?@  '($  !6$   0AP@ #8D.  R)%  ,B1L "XDC  J)
M*P )B3, "(D]  :)2  %B50 !(EA  *)<0 !B8,  (F6  "(J0  A[X  (?:
M  "&[   AO4  (;Z 'YJ  !Q:@  9VL  %ML  !0<   1G0  #QX   S?0
M*H$  ".%   <B   %8P  !"/   ,D@8 !I,,  *3$0  E!8  )0=  "4)
ME2P  )4U  "50   E4P  )99  "6:0  E7H  )6.  "4H0  E+4  )/,  "2
MY@  DO(  )+W 'AP  !M<   8'(  %1U  !)>0  /WX  #6#   LB   (XT
M !N1   4E   #Y<   J:   $G0,  )X)  "?#@  GQ(  * 7  "@'0  H24
M *(M  "B-P  HT,  *-0  "C7P  HW$  *.$  "BF0  HJT  *'"  "AW
MH>L  *#R '-V  !F=P  67L  $V   !"A0  .(L  "Z0   DE0  &YH  !2>
M   .H0  ":0   *G    J@   *L$  "K"@  K T  *T1  "M%@  KAP  *\D
M  "P+0  L3D  +%&  "R50  LF8  +)Y  "RC@  L:,  +*W  "QR@  L>
M +'I &Q^  !?@@  4H<  $:-   [DP  ,)D  ":>   <HP  $Z<   VK   '
MK@   +(   "U    MP   +@   "Y @  N0@  +H,  "[$   O!0  +T;  "_
M(P  P2T  ,(Z  #"20  PUH  ,-L  #$@@  Q)<  ,2K  #$O   Q,L  ,3:
M &6)  !8C@  2Y4  #^;   SH@  **@  !VM   4L0  #;8   :Y    O
M +\   ##    Q    ,4   #&    QP   ,D$  #*"0  RPT  ,T1  #/&
MTB$  -4M  #6/   V$T  -E?  #:<P  VHH  -N>  #;K@  V[H  -S# %Z6
M  !1G   1*,  #BJ   LL0  (+<  !6[   -O@  !,(   #%    R0   ,T
M  #0    T@   -(   #5    U@   -D   #;    W@4  . *  #B#P  Y18
M .@@  #L+0  [3X  .U1  #N90  [WH  .^/  #PGP  \*L  /"S /\ $ #_
M  X _P . /\ $@#_ !T _P I /\ -0#_ $$ _P!- /X 5@#[ %\ ^ !F /8
M;0#T '0 \@!Y /$ ?P#P (0 [@") .T CP#K )4 Z@"; .@ H@#F *H Y0"S
M ., P #A -( X #J -\ ^0#= /\ W0#_ -T _P#> /\ W@#_ /\ #0#_  H
M_P ) /\ #P#_ !@ _P D /X ,0#[ #T ^ !( /0 4@#P %H [0!B .L :0#I
M &\ YP!U .4 >@#C '\ X@"% .  B@#> )  W "6 -H G0#8 *4 U0"O -(
MN@#0 ,H S@#C ,T ] #+ /\ RP#_ ,L _P#+ /\ RP#_ /\ " #_  , _P %
M /\ # #\ !0 ]P ? /( *P#O #< ZP!" .< 3 #D %4 X != -T 9 #: &H
MV !P -4 =0#2 'H T "  ,\ A0#- (L RP"2 ,D F0#' *$ Q0"J ,, M0#!
M ,, OP#: +X [@"] /P O #_ +P _P"\ /\ O #_ /\   #_    _P   /D
M!P#Q !  Z@ : .0 )0#? #$ VP \ -< 1P#2 %  S@!7 ,L 7@#) &4 Q@!J
M ,4 < ## '4 P0!Z ,  @ "^ (8 O "- +H E "Y )P MP"E +4 L "S +T
ML0#/ *\ Z "N /@ K@#_ *T _P"M /\ K0#_ /\   #_    _0   .X  0#C
M  P V@ 4 -$ 'P#, "L R  V ,4 0 #" $H OP!2 +P 60"Z %\ N !E +8
M:@"T &\ LP!U +$ >@"P ($ K@"( *T CP"K )@ J0"A *< JP"E +@ HP#(
M *( X@"A /, H #^ *  _P"@ /\ H #_ /\   #V    Z@   .    #3  8
MR0 / ,( & "] "0 N0 O +8 .@"T $, L0!, *X 4P"L %D J@!? *D 9 "G
M &H I@!O *0 =0"C 'L H0"" *  B@"> ), G "= )H IP"8 +0 E@## )4
MW "4 .\ DP#[ ), _P"3 /\ D@#_ /D%  #J"P  W T  ,L*  #"!0  O  *
M +8 $0"Q !P K@ H *H ,P"G #T I !% *( 30"@ %, G@!9 )P 7P"; &0
MF@!J )@ < "7 '8 E0!^ ), A@"2 8\ D &9 (X"I ", K$ BP/  (D%U@"(
M!NT B ?Z (<(_P"&"/\ A@C_ .\/  #>%   RA4  +P2  "S$   K@P  *L&
M#0"G Q4 H@4@ )\'+ "<"#8 F0@_ )<)1P"5"4X DPE4 )$*6@"0"E\ C@IE
M (T*:P"+"G( B@MY (@+@@"'"XP A0R7 (,,H@"!#;  @ W  '\-V !]#N\
M? _] 'L/_P![$/\ >Q#_ .87  #1'@  O1T  *\<  "F&0  H14  )X0! "=
M#0\ F X9 )0.)0"1#R\ CQ Y (P000"*$$@ B!!/ (<050"%$%L A!%A ((1
M9P" $6X ?Q%U 'T1?@!\$H@ >A*4 '@2H !W$ZX =1.^ '04U0!S%>X <1;]
M '$6_P!Q%O\ <!;_ -P?  #&)0  LR4  *4C  "<(0  EAX  )(9  "1% L
MC104 (D5'P"&%BD @Q8S ($7/ " %T, ?A=* 'P74 !Z%U8 >1A< '<88@!V
M&&D =!AQ ',9>@!Q&80 ;QJ0 &X:G0!L&ZL :QR[ &H<T !I'>P :![[ &@>
M_P!G'O\ 9Q[_ -$F  "]*@  JRH  )TJ  "3*   C24  (@B  "&'08 @QL0
M '\<&@!\'20 >ATN '<>-@!V'CX =!Y% '(?2P!Q'U$ ;Q]8 &X?7@!L'V4
M:R!M &D@=@!H(8$ 9B&- &4BF@!C(J@ 8B.X &$CS0!@).D 8"3Z %\D_P!?
M)/\ 7R3_ ,HL  "V+P  I"\  )8O  ",+0  A2H  ( H  !])   >B(- '8C
M%0!S(R  <20I &\D,@!M)#H :R5! &HE1P!H)4T 9B54 &4E6@!D)F$ 8B9I
M &$F<@!?)WT 7B>* %THEP!;*:4 6BFU %HJR@!9*N< 6"KX %@J_P!8*O\
M6"K_ ,4Q  "O,P  GC,  ) S  "&,@  ?R\  'DM  !U*@  <B@* &\H$@!K
M*1L :2DE &<J+0!E*C4 8RH] &(J0P!@*DH 7RM0 %XK5P!<*UX 6RQF %DL
M;P!8+7H 5RV' %8NE0!4+J, 4R^S %,OQP!2+^4 4B_W %(O_P!2+_\ 4B__
M ,$V  "J-@  F38  (LV  "!-0  >3,  ',Q  !O+P  :RX& &@M$ !D+A@
M8BXA & O*@!>+S$ 7"\Y %LO0 !9+T8 6"]- %<P4P!6,%L 5#%C %,Q; !2
M,G< 43*$ $\SD@!.,Z$ 33.Q $TTQ0%,-.,!3#3V $PT_P!,-/\ 3#/_ +LY
M  "F.0  E3D  (<Y  !\.0  =#<  &XT  !I,P  93(" &$R#0!>,A0 7#,>
M %HS)@!8,RX 5C,U %4T/ !3-$, 4C1* %$T4 !0-5@ 3C5@ $TV:@!,-G4
M2S>" $HWD !).)\ 2#BP 4<XPP%'..$!1SCU 4<X_P%'./\!1SC_ ;<[  "B
M/   D3P  (,\  !X/   <#H  &HW  !D-@  8#8  %PV"P!9-Q( 5C<: %0W
M(P!2-RL 4#<R $\X.0!-.$  3#A' $LX3@!*.54 23E> $@Z: !'.G, 1CN
M $4[C@!$/)X 0SRN 4(\P@%"/=\!0CSS 4(\_P%"//\!0CO_ ;,]  ">/@
MC3X  '\^  !U/@  ;#T  &8Z  !@.0  6SH  %<Z" !3.Q  43L8 $X[( !,
M.R@ 2SLO $D\-@!'/#T 1SQ$ $8]2P!%/5, 1#Y< $,^9@!"/W$ 03]^ $ _
MC0 _0)P /D"M 3U P $]0-T!/4#R 3U _P$^/_\!/C__ :Y   ":0   B4$
M 'Q!  !Q00  :$   &$\  !;/0  5CX  %(^!0!./PX 3#\5 $D_'0!'0"4
M1D L $1 ,P!#0#H 0D%" $%!20! 05$ /T): #Y"8P ]0V\ /$-\ #M#BP Z
M1)L .42K 3E$O@$X1-L!.43Q 3E#_@$Y0_\!.4/_ :I"  "60P  AD,  'A#
M  !N0P  94,  %U   !60   44(  $U" @!)0PP 1D,2 $1$&@!"1"( 040J
M #]%,0 ^13@ /44_ #Q&1P [1D\ .D97 #E'80 X1VP -T=Z #9(B0 U2)D
M-$BJ #1(O0 S2-D -$CP #1'_0 T1_\ -4;_ *9$  "210  @D8  '5&  !J
M1@  844  %E$  !11   3$8  $A'  !$1PH 04@0 #])&  ]22  /$DG #I*
M+@ Y2C8 .$H] #=+1  V2TP -4M5 #1,7P S3&H ,DQW #%,A@ P3)< +TVH
M "Y-NP N3=4 +DSO "],_0 O2_\ ,$O_ *%'  ".2   ?D@  '%(  !F20
M74@  %5(  !,20  1TH  $)+   _3 8 .TT. #E.%0 W3AT -D\D #5/*P S
M3S, ,E Z #%00@ P4$H +U%2 "Y17  M46< +%%U "M1A  J4I4 *5*F "E2
MN0 H4M( *5'N "E0_  J4/\ *D__ )Q*  ")2@  >DL  &U+  !C3   6DP
M %%,  !(30  0T\  #U0   Y4@( -5,, #-4$@ Q5!D ,%4A "Y5*  M52\
M+%8W "M6/@ J5D8 *59/ "A760 G5V0 )E=R "57@0 D5Y( (U>D ")7MP B
M5\\ (E?L "-6^@ C5?\ )%7_ )9-  "$3@  =4X  &E.  !?3P  5D\  $U0
M  !%4@  /U,  #E6   S6   +UH( "M;#P J6Q4 *%P= "=<)  F7"L )5PS
M "1=.@ C74, (EU, "%=5@ @7F$ 'UYN !Y>?@ =7H\ '%ZA !M>M  :7<P
M&UWI !M<^0 <6_\ '%O_ )!1  !^40  <%$  &12  !;4@  4E,  $I4  !!
M5P  .UD  #5;   N7@  *& # "1B#  B8Q$ (6,8 !]D(  >9"< '60N !QD
M-@ ;93X &F5' !EE40 895T %V5J !9E>@ 598L %&6> !-EL0 29<@ $F3G
M !-C]P 48O\ %&+_ (E4  !X50  :U4  &!6  !75@  3U<  $99   ]7
M-E\  #!B   I9   (V<  !UJ!P 9; X &&P3 !9M&@ 5;2$ %&TI !1M,  3
M;3D $FY" !%N3  0;E@ #VYE  YN=0 -;H< #6Z:  QMK0 +;<( "VS@  QK
M\P -:_T #6K_ ()9  !R60  9ED  %Q:  !46@  2EP  $%?   Y8P  ,68
M "II   D;   '6\  !=R   2=0D #W</  YW%  .=QL #7<C  QW*@ +=S,
M"G<\  EW1P (=U( !W=?  5W;P $=X   W>4  %VIP  =KL  775  %TZP "
M=/8  G3\ 'M=  !M70  8EX  %E>  !.8   16,  #QG   S:P  *VX  "1R
M   >=0  %WD  !)\   -?P8 "8$,  6!$0 #@18  H$=  &!)   @2T  ((V
M  ""0   @DP  ()9  "":   @GD  (*-  "!H   @+0  (#+  !_YP  ?O(
M '[Y '1B  !H8@  7F(  %-D  !)9P  /VL  #9P   M=   )7@  !Y\   7
M@   $8,   V&   (B00  HL*  "+#@  BQ,  (P8  ",'P  C28  (TO  ".
M.0  CD0  (Y1  ".8   CG$  (Z%  ".F0  C:T  (S#  ",WP  B^X  (OV
M &YH  !D9P  6&D  $UL  !"<0  .'8  "][   F?P  'H0  !:(   0C
M#(\   :2    E0   )8'  "7#   EP\  )@3  "9&   FA\  )LF  ";,
MG#L  )Q(  "<5P  G&@  )Q[  "<D   FZ4  )NZ  ":T   FN<  )KQ &IM
M  !>;P  47(  $9W   [?   ,8(  ">'   >C   %I$  !"5   *F0  !)P
M  "@    H@   *,!  "C!@  I L  *4.  "F$@  IQ<  *@>  "J)@  JS$
M *L^  "L30  K%T  *QP  "LA0  K)L  *NO  "KPP  J]D  *KH &1U  !7
M>0  2WX  #^$   TB@  *9   !^6   6FP  $)\   FC   !IP   *H   "N
M    L    +    "Q    L@,  +0(  "U#0  MA   +<5  "Y'0  NR8  +PS
M  "]00  O5(  +UD  "^>0  OI   +VD  "]MP  O<8  +W7 %Q_  !0A0
M1(L  #B2   LF0  (9\  !>D   0J0  ":X   "R    M@   +D   "]
MOP   +\   #     P0   ,,   #$!0  Q@H  ,<.  #)$P  RQP  ,XF  #0
M-0  T44  -)7  #2:P  TX(  -.7  #3J0  TK@  -+$ %6,  !)DP  /9H
M #"B   EJ   &JX  !&T   )N0   +T   #!    Q    ,@   #+    S0
M ,T   #/    T    -(   #4    V    -H&  #=#   X!$  .,:  #F)P
MYS@  .A*  #I70  ZG(  .N(  #KFP  [*@  .RR /\ #0#_  L _P + /\
M$ #_ !H _P F /\ ,@#_ #T _P!( /L 4@#X %H ]@!B /, :0#Q &\ \ !U
M .X >@#L '\ ZP"$ .D B@#H )  Y@"6 .0 G0#B *4 X0"O -\ NP#= ,L
MVP#F -D ]P#8 /\ V #_ -< _P#7 /\ U #_ /\ " #_  0 _P $ /\ #0#_
M !4 _@ A /H + #W #@ ] !# /  30#M %4 Z@!= .< 9 #D &H X@!P .
M=0#> 'H W0!_ -L A0#9 (L U0"1 -, F0#1 *  SP"J ,T M0#+ ,0 R0#=
M ,@ \0#' /\ Q@#_ ,8 _P#& /\ QP#_ /\   #_    _P   /\ "@#X !$
M\0 < .P )P#I #( Y@ ] .( 1P#= %  V0!8 -4 7P#2 &4 T !J ,X < #,
M '4 R@!Z ,D ?P#' (4 Q0", ,, E #! )P OP"E +T L "[ +T N@#0 +@
MZP"W /L M@#_ +8 _P"V /\ M@#_ /\   #_    _0   /, !0#I  X X0 6
M -L (0#5 "T T0 W ,X 00#* $H QP!2 ,0 60#" %\ P !E +X :@"\ &\
MNP!T +D >@"W (  M@"' +0 C@"R )< L "@ *X J@"M +< JP#( *D XP"H
M /4 IP#_ *< _P"G /\ I@#_ /\   #^    \0   .4   #7  H S0 1 ,<
M' #" "8 OP Q +P .P"Z $0 MP!, +0 4P"R %D L0!? *\ 9 "M &D K !O
M *H = "I 'H IP"! *8 B0"D )$ H@"; *  I0"> +( G0#! )L V@": .\
MF0#] )@ _P"8 /\ F #_ /T   #P    X0   -$   #&  0 O0 - +< %0"S
M "  L  K *T -0"K #X J !& *8 30"D %0 HP!9 *$ 7P"@ &0 G@!I )T
M;@"; '4 F@![ )@ @P"6 (P E0"6 ), H0"1 *T CP"[ (T SP", .D BP#X
M (P _P", /\ C #_ /,"  #B!P  S <  +\$  "W    L0 ( *L $ "G !D
MI  D *  +@"> #< G !  )H 1P"8 $X E@!4 )4 60"3 %X D@!D )  :0"/
M &\ C0!V (L ?@"* (@ B "2 (8 G0"% *D @P"X ($ R@"  .4 @ #U '\
M_P!_ /\ ?P#_ .@-  #0$   OA   +$.  "H#0  HP@  * "# "< !, F  =
M )4 )P"2 #$ D  Y (X!00", 4@ B@). (D"5 "' ED A@)? (0#9 "# VL
M@0-R ( $>@!^!(0 ?06. 'L%F@!Y!J< > :U '8'R !U"., =0GT '0*_P!S
M"O\ <PK_ -T5  #$%P  L1<  *46  "<$P  EA$  )0-! "3" T C@<5 (L)
M( "("2H A0HS (,+.P"!"T( @ M) 'X+3P!]#%0 >PQ: 'H,8 !X#&< =PQN
M '4-=@!T#8  <@V, ' -F0!O#J8 ;0ZU &P.R0!K#^8 :A#W &D0_P!I$/\
M:1#_ - =  "Y'@  J!X  )L=  "2&P  BQD  (@5  "'$0< A0X0 ($/&@!^
M$"0 >Q M 'D0-@!W$3T =A%$ '012@!S$5  <1%6 ' 17 !N$F( ;1)J &L2
M<P!I$WT :!.) &83E@!E%*, 8Q6S &(5Q@!B%N, 81;V & 7_P!@%_\ 8!?_
M ,<B  "P(P  GR0  )(C  ")(@  @B   'X=  !\&0  >A4- '<5%0!T%A\
M<18H &\7, !N%S@ ;!<_ &L710!I&$L :!A1 &886 !E&%X 8QEF &(9;P!@
M&7D 7QJ% %T;D@!<&Z$ 6QRP %H<PP!9'>  6![T %@>_P!8'O\ 6![_ +\G
M  "I*   F2@  (LH  "")P  >R4  '8C  !S(   <1P) &X<$0!K'!H :1TC
M &<=+ !E'3, 8QXZ &(>00!@'D< 7QY- %X>5 !<'UL 6Q]B %D@:P!8('8
M5B&" %4AD !4(IX 4R*N %(CP !1(]T 423R %$D_P!1)/\ 42/_ +DK  "C
M+   DRP  (8M  !\+   ="H  &\H  !K)0  :2(% &8A#@!C(A8 82(? %\C
M)P!=(R\ 7",V %HC/0!9)$, 5R1* %8D4 !5)%< 4R5? %(E: !1)G, 3R9_
M $XGC0!-*)P 3"BL $LIO@!+*=H 2BGQ $HI_P!+*?\ 2RG_ +,N  ">+P
MCC   ($P  !W+P  ;RX  &HK  !E*@  8R<! %\G# !<)Q, 6B<; %@H) !6
M*"L 52@R %,H.0!2*4  4"E& $\I30!.*50 32I< $PJ90!**W  22M\ $@L
MBP!'+9H 1BVJ $4NO !%+M8 12[O $4N_@!%+O\ 12W_ *XQ  ":,@  B3,
M 'PS  !R,P  :S$  &4O  !@+0  72P  %DL"0!6+!  5"P8 %(L( !0+"@
M3BTO $TM-@!,+3P 2BU# $DM2@!(+E$ 1RY9 $8O8P!%,&T 0S!Z $(QB0!!
M,9@ 03*H $ RNP _,M, /S+N $ R_0! ,O\ 0#+_ *HS  "6-0  AC4  'DV
M  !N-0  9C4  &$R  !<,   5S   %0P!@!1, X 3C 5 $PQ'0!*,24 2#$L
M $<Q,@!&,3D 1#%  $,R1P!",D\ 03-7 $ S8  _-&L /C5X #TUAP \-I8
M.S:G #LVN0 Z-M$ .C;M #LV_  [-O\ .S;_ *8V  "2-P  @C@  '4X  !K
M.   8S<  %TV  !7,P  4S0  $\T P!+- P 2302 $8U&@!%-2( 0S4I $$U
M+P! -38 /S8] #XV1  ]-TP /#=5 #LX7@ Z.&D .3EV #@YA0 W.I4 -SJE
M #8ZN  U.L\ -CKL #8Z^P V.?\ -SG_ *(X  "..0  ?CH  '([  !H.P
M7SH  %DY  !3-@  3C<  $HX  !&. H 1#D0 $$Y%P _.1\ /CDF #PY+0 [
M.C0 .CH[ #D[0@ X.TH -SM3 #8\7  U/&< -#UT #,]@P S/I, ,CZD #$^
MM@ Q/LT ,3[J #$^^@ R/?\ ,CW_ )X[  "+/   >SP  &X]  !D/0  7#T
M %4\  !..@  23L  $4\  !!/0< /CT. #P]%0 Z/AP .3XC #<^*@ V/S$
M-3\X #0_0  S0$@ ,D!0 #% 6@ P064 +T%R "Y"@0 M0I$ +4*B "Q"M0 K
M0LL +$+I "Q"^0 M0?\ +4'_ )D]  "'/@  =S\  &L_  !A0   63\  %(_
M  !)/@  1#\  $!    \000 .4(- #="$@ U0QD ,T,A #)#*  Q1"\ ,$0V
M "]$/0 N144 +45. "Q%6  K1F, *D9O "E&?@ H1H\ )T>A "9'LP F1\D
M)D;G "=&^  H1?\ *$7_ )5   ""00  <T(  &="  !>0@  54(  $Y"  !%
M0@  /T0  #M%   W1@  -$<* #%($  O2!8 +DD> "Q))0 K22P *DDS "E*
M.@ H2D( )TI+ "9+50 E2V  )$MM "-+?  B2XT (4R? "%,L0 @3,< ($OF
M "%+]P B2O\ (DK_ )!#  !^1   ;T0  &1%  !:10  4D4  $I&  !!1P
M/$@  #=)   R2P  +DT' "M.#@ I3A, )T\: "9/(0 E3R@ )$\P "-0-P B
M4#\ (5!( "!04@ ?45T 'E%J !U1>0 <48H &U&< !I1KP 94<4 &5'D !I0
M]@ ;3_\ '$__ (I&  !Y1P  :T<  &!(  !62   3D@  $=)   ^2P  .4P
M #-.   N4   *%," "14"P B51  (%46 !]6'@ >5B0 '58L !Q6,P ;5SL
M&E=$ !E73@ 85UD %UAF !58=0 46(< %%B: !-7K  25\( $E?A !-6]  4
M5?\ %%7_ (1)  !T2@  9DL  %Q+  !32P  2TP  $1-   \3P  -5$  "]4
M   I5@  )%D  !Y;!P :70T &%T2 !==&0 67B  %5XG !1>+@ 37C< $EY
M !%?2@ 17U4 $%]B  ]?<0 .7X, #5^6  U?J0 ,7KX #%[:  U=\  -7/P
M#ES_ 'Y-  !N3@  8DX  %A/  !/3P  2%   $!2   X5   ,%<  "I:   D
M70  'U\  !EB 0 390D $68/ !!F%  /9AL #F<B  UG*0 -9S( #&<[  MG
M10 *9U  "6==  =G;  &9WT !6>0  1FHP "9K<  V7/  1EZ0 $9/4 !&3\
M '=1  !I4@  75(  %12  !,4P  0U4  #M8   S6P  *UX  "5A   ?9
M&6<  !-J   /;08 "W ,  AP$0 '<!8 !7 =  1P)  #<"P  G U  !P/P
M<$H  '!7  !P90  <'8  '"*  !OG@  ;[(  &[(  !MY0  ;?(  &WY '!6
M  !C5@  658  /_B__])0T-?4%)/1DE,10 $"5%7  !'6   /EL  #9?   N
M8@  )F8  !]J   9;0  $W    YS   +=@0 !7@+  %X#P  >1,  'D9  !Y
M'P  >B8  'HO  !Z.0  >D0  'I0  !Z7P  >G   'J#  !ZF   >JP  'G"
M  !XWP  >.\  '?W &I;  !?6P  5EL  $Q<  !"8   .6,  #!H   H;
M('   !ET   3=P  #GL   E^   $@0(  (((  "##0  @Q   (04  "%&0
MAB   (8H  "',0  ASP  (=)  "'5P  AV@  (=[  "'D   AJ4  (6Z  "%
MTP  A.H  (3T &5@  !<8   46$  $9D   \:0  ,FT  "ER   A=P  &7L
M !*    -@P  "(<   **    C0   (X$  "."0  CPT  ) 0  "1%   DAD
M ),@  "4*0  E3,  )5   "63@  EE\  )5R  "5B   E9T  )2R  "4R
MD^(  )/N &%E  !69@  2FH  #]N   U=   *WD  "%_   9A   $8D   R-
M   &D0   )0   "8    F@   )L   "< @  G0<  )X+  "?#@  H1(  *(8
M  "C(   I2D  *8V  "F1   IE4  *9H  "F?0  II0  *6I  "DO0  I-$
M *3D %ML  !/<   0W4  #A[   M@0  (X<  !F-   1D@  "Y<   2<
MH    *,   "F    J    *D   "J    K    *T$  "N"0  L T  +$1  "S
M%P  M2   +8K  "W.@  MTL  +A<  "X<0  N(@  +B=  "XL0  M\(  +?0
M %1V  !(?   /((  #&)   FD   &Y<  !*=   ,H@   Z<   "K    K@
M +(   "V    N    +@   "Z    NP   +T   "^    P 4  ,$+  ##$
MQA8  ,D@  #*+@  RSX  ,Q0  #,9   S7H  ,V1  #-I   S;0  ,W  $V#
M  !!B@  -9$  "F9   >H   $Z8   RL   #L0   +8   "Z    O@   ,(
M  #&    R    ,@   #*    RP   ,T   #.    T    -(!  #5"   V0X
M -T5  #A(0  XC$  .1#  #E5@  YFL  .:"  #GE@  YZ4  .:P /\ "0#_
M  4 _P & /\ #@#_ !8 _P A /\ +0#_ #@ _0!# /D 30#U %4 \@!= /
M8P#N &D [ !O .H = #I 'H YP!_ .8 A0#D (L XP"1 .$ F0#? *$ W "J
M -H M@#7 ,8 U0#A -, ] #2 /\ T0#_ -$ _P#/ /\ R@#_ /\  0#_
M_P ! /\ # #_ !( ^@ = /8 * #S #, \  ^ .P 2 #H %  Y0!8 .( 7@#?
M &0 W0!J -L ;P#9 '0 U@!Z -0 ?P#2 (4 T ", ,X DP#, )P R0"E ,<
ML #& +X Q #4 ,( [@#! /X P #_ ,  _P"_ /\ O@#_ /\   #_    _P
M /H !P#Q  \ ZP 8 .8 (P#B "X X  X -L 0@#5 $L T0!2 ,X 60#+ %\
MR0!E ,< :@#& &\ Q !T ,( >@#! (  OP"& +T C@"[ )8 N0"@ +< J@"V
M +< M #* +( Y@"Q /@ L #_ *\ _P"O /\ L #_ /\   #_    ]P   .H
M @#A  P UP 3 -  '0#, "@ R0 R ,8 / #" $4 OP!- +P 4P"Z %D N !?
M +< 9 "U &D M !N +( = "Q 'H KP"  *T B "L )$ J@": *@ I0"F +$
MI #! *, W "A /( H0#_ *  _P"@ /\ H0#_ /\   #W    Z    -D   #+
M  @ PP 0 +T & "Y "( M@ L +0 -@"R #\ KP!' *P 30"K %0 J0!9 *<
M7@"F &, I0!H *, ;@"B '0 H !Z )X @@"< (L FP"5 )D GP"8 *P E@"Z
M )0 SP"3 .L D@#[ )( _P"2 /\ D0#_ /<   #G    TP   ,8   "[  (
MLP , *T $@"J !P IP F *0 , "C #@ H !  )X 1P"< $X F@!3 )D 6 "7
M %T E@!C )4 : "3 &X D@!T )  ? "/ (4 C0"/ (L F@"* *< B "U (8
MQP"% .0 A #U (0 _P"# /\ @P#_ .P   #3    P0$  +0   "L    I@ '
M *  #@"= !8 F@ @ )< *0"5 #( DP Z )$ 00"/ $@ C0!- (P 4P"+ %@
MB0!= (@ 8P"' &D A0!O (, =P"" (  @ "* 'X E@!] *, >P"P 'H P@!Y
M -T > #Q '< _0!X /\ > #_ -X*  #$"P  L@P  *8+  "="   F00  )4
M"@"1 !$ C@ 9 (L (P") "P AP T (4 .P"# $( @@!( (  3@!_ %, ?0!8
M 'P 7@![ &0 >0!J '@ <@!V 'L = "& ', D@!Q )\ < "M &X O@!M =8
M;0+M &P#^@!L _\ ; /_ ,X0  "W$0  IA(  )H1  "1$   BPX  (D+ P"'
M!0P A $3 ($!' !^ B4 ? ,N 'H#-@!X!#P =P1# '4%2 !T!4X <P54 '$%
M60!P!E\ ;@9F &T&;@!K!W@ :@># &@(D !G"9T 90FL &0)O !C"M0 8POL
M &(,^@!B#/\ 8@S_ ,,6  "M%P  G1@  ) 8  "'%@  @10  'T1  !\#@8
M? H. '@*%@!U"Q\ <@LH ' ,, !O##< ;0P^ &P,1 !K#4H :0U/ &@-50!G
M#5P 90UC &,.:P!B#G4 8 Z! %\.C@!=#YP 7!"K %L0O0!:$-8 61'P %D1
M_0!9$?\ 61'_ +D;  "E'0  E!X  (@>  !^'0  >!L  '08  !Q%0  <1$)
M &\0$0!L$!D :1 B &<1*@!F$3( 9!$Y &,1/P!B$44 8!)+ %\240!=$E@
M7!)? %H3: !9$W( 5Q1] %84BP!4%9D 4Q6I %(6N@!1%M( 41?M %$7_0!1
M%_\ 41?_ +(@  ">(@  CB(  ($C  !W(@  <"$  &P>  !I&P  9Q@$ &85
M#@!C%A4 818> %\6)@!=%BT 7!<T %H7.P!9%T$ 6!A' %8830!5&%0 4QA<
M %(99 !1&6X 3QIZ $X;B !-&Y< 2QRF $H<N !*'<\ 21WK $D=^P!)'?\
M2AW_ *PD  "8)0  B"8  'LG  !Q)@  :B4  &8C  !B(0  8!X  %X<"P!;
M&Q( 61P: %<<(@!5'"D 5!PP %,=-P!1'3T 4!U# $\=2@!-'E$ 3!Y8 $L?
M80!)'VL 2"!W $<@A0!&(90 1"*D $0BM@!#(LP 0R/I $,C^@!#(_\ 0R+_
M *8G  "3*0  @RH  '8J  !M*@  92D  & G  !<)0  62,  %<A!P!5(0\
M4B$6 % A'@!.(24 32(L $PB,P!*(CD 22)  $@B1@!'(TT 12-5 $0D7@!#
M)&D 0B5U $ F@P _)I( /B>C #XGM  ])\H /2CH #TH^0 ])_\ /B?_ *(J
M  ".*P  ?RT  '(M  !H+0  82P  %PK  !8*   5"8  %$F! !.)0T 3"43
M $HF&@!()B( 1R8I $4F+P!$)C8 0R<\ $$G0P! )TL /RA3 #XI7  ]*68
M/"IR #LJ@0 Z*Y  .2NA #@LL@ W+,@ -RSF #@L^  X+/\ ."S_ )TL  "*
M+@  >R\  &\P  !E,   72\  %@N  !3*P  4"H  $PJ  !)*@L 1BH1 $0J
M%P!"*A\ 02HE #\J+  ^*S, /2LY #PK0  [+$@ .BQ0 #DM60 X+F0 -RYP
M #8O?P U+X\ -#"? #,PL0 R,,< ,C#E #,P]P S,/\ -"__ )DO  "',0
M=S(  &LR  !B,@  6C(  %0Q  !/+P  2RT  $<N  !$+@@ 02X. #\N%  ]
M+AP .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -3%. #0Q5P S,F( ,C)N #$S
M?0 P,XT +S2> "XTL  M-,4 +33C "XT]@ O,_\ +S/_ )4Q  "#,P  =#0
M &@U  !>-0  5S0  %$T  !+,@  1C$  $(R   _,@4 /#(- #DS$@ X,QD
M-C,@ #0S)@ S,RT ,C0T #$T.P P-4, ,#5, "\V50 N-F  +3=L "PW>P K
M-XL *CB< "DXK@ H.,, *#CB "DX]0 J-_\ *C?_ )(T  !_-0  <38  &4W
M  !;-P  5#<  $TV  !'-@  0C4  #TV   Z-@( -S<+ #0W$  R-Q8 ,3@=
M "\X)  N."L +3DR "PY.0 K.4$ *CI) "HZ4P I.UX *#MJ "<[>0 F/(D
M)3R; "0\K0 C/,( (SS@ "0\]  E._\ )3O_ (TV  !\.   ;3D  &(Y  !8
M.@  43D  $HY  !$.0  /3D  #DZ   U.P  ,CL( "\\#@ M/10 +#T: "H]
M(0 I/2@ *#XO "<^-@ F/CX )3]' "0_4  C0%L (D!H "% =@ @0(< 'T&9
M !]!JP >0<  'D'> !] \P ?0/X (#__ (DY  !X.@  :3L  %X\  !5/
M33P  $<\  ! /   .#T  #0^   P0   +4$% "I"#  G0A$ )D,8 "1#'@ C
M0R4 (D,L "%$,P @1#L 'T1$ !Y%3@ =15D '$5E !M%=  :184 &4:7 !E&
MJ0 81KX %T7< !A%\0 91/T &D3_ (0\  !S/0  9CX  %L_  !2/P  2C\
M $0_   ]0   -D$  #%#   L1   )T8! "1'"@ A2 \ ($D4 !Y)&P =22(
M'$DI !M*,  :2C@ &4I! !A*2P 72U4 %DMB !5+<0 42X( $TN4 !)+IP 2
M2[P $4O9 !)*\  32OP %$G_ '\_  !O0   84$  %="  !.0@  1T(  $%"
M   Z0P  ,D4  "U'   H20  (TL  !Y-!@ ;3PT &% 1 !=0%P 64!X %5 E
M !10+  3430 $E$] !%11P 145( $%%?  ]2;0 .4GX #5&1  U1I  ,4;@
M#%'1  U0[  -4/H #D__ 'E#  !J1   740  %-%  !+10  1$4  #Y&   V
M2   +TH  "E,   D3P  'U$  !I3   45@D $5<. !!8$P 06!D #U@@  Y8
M*  -6#  #5@Y  Q80P +6$X "EA:  A8:  '6'D !EB,  58GP $6+, !%?*
M  57Y@ %5_, !E;\ '-&  !D1P  64@  %!(  !(2   04D  #I*   R30
M*U   "52   @50  &E@  !5:   0708 #& ,  I@$  )8!4 "& <  =@(P %
M8"L !& T  -@/0 !8$D  &!5  !@8P  8',  &"&  !?F@  7ZX  %_$  !>
MX@  7O   %[X &Q*  !?2P  54L  $Q,  !%3   /4X  #50   N4P  )U8
M "!9   :7   %5\  !!B   -900 "&<+  -G#@  :!,  &@8  !H'P  :28
M &DN  !I.   :4,  &E/  !I70  :6T  &F   !IE   :*D  &B_  !GW
M9NX  &;W &9/  !:3P  44\  $I/  !!40  .%0  #!7   H6P  (5X  !IB
M   490  $&@   QK   ';@,  7 )  !P#0  <1   '$4  !R&@  <R$  ',H
M  !S,0  <SP  '1(  !S5@  <V8  '-Y  !SC@  <Z,  '*Y  !QT@  <>L
M '#T &%3  !64P  3U,  $55   [6   ,EP  "I@   B9   &V@  !1L   /
M;P  "W(   9V    >0   'H&  !Z"@  >PX  'P1  !]%0  ?AL  '\B  "
M*@  @#4  (!!  " 3P  @%\  (!Q  " A@  @)T  '^R  !^R@  ?N4  'WQ
M %Q8  !46   25H  #]=   U80  +&4  "-J   ;;P  %',   YW   )>P
M W\   ""    A    (8!  "&!@  B H  (D-  "*$   BQ4  (P;  ".(@
MCRP  (\X  "/1@  CU8  (]H  "/?@  CY4  (ZK  "-P0  C=P  (SK %E=
M  !.7P  0V(  #AF   N;   )'$  !QW   4?   #H$   B%    B0   (T
M  "0    D@   ),   "4    E@,  )<(  "8#   F@\  )L3  "=&@  GR,
M * N  "@/   H$P  *!>  "@=   GXP  )^B  "?MP  GLL  )[@ %-D  !'
M:   /&T  #%S   G>0  '7\  !2%   -BP  !I    "4    F    )P   "?
M    H0   *(   "D    I0   *<   "H!   J@D  *P-  "M$@  L!D  +(C
M  "R,0  LD(  +)4  "R:0  LH   +*8  "QK   LK\  +'. $QN  ! <P
M-7H  "J!   ?B   %8X   Z5   &F@   )\   "D    J    *P   "O
ML0   +$   "S    M0   +8   "X    N@   +P&  "^#   P!$  ,,9  #%
M)@  Q3<  ,9)  #&70  QW(  ,>*  #(GP  R*\  ,B\ $9Z   Y@0  +HD
M "*0   7F   #Y\   >E    J@   *\   "S    MP   +P   "_    P0
M ,(   #$    Q0   ,<   #)    RP   ,T   #/ P  T@H  -80  #<&@
MW2H  -X\  #?4   X&4  .%[  #AD0  XJ(  .*M /\  @#_    _P # /\
M# #_ !, _P = /\ * #^ #, ^P ^ /< 2 #S %  \ !7 .T 7@#K &0 Z !I
M .< ;P#E '0 XP!Y .( ?P#@ (4 W@", -P DP#9 )P U@"F -, L0#1 ,
MSP#: ,X \0#, /\ RP#_ ,L _P#& /\ P0#_ /\   #_    _P   /\ " #[
M !  ]@ 9 /( ) #O "X [0 Y .@ 0@#C $L X !2 -T 60#9 %\ U@!D -,
M:0#1 &X SP!T ,X >0#, '\ R@"& ,@ C@#& )8 Q "@ ,( JP#  +D O@#-
M +P Z@"[ /P N@#_ +H _P"Z /\ M@#_ /\   #_    _@   /0 ! #K  T
MY  4 -\ 'P#; "D V  S -, /0#. $4 R@!- ,< 4P#% %D PP!? ,$ 9 "_
M &D O0!N +L <P"Z 'D N "  +8 B "T )  L@": +$ I0"O +( K0#$ *P
MX0"K /8 J@#_ *H _P"J /\ J@#_ /\   #]    [@   .(   #5  H S0 1
M ,< &0#$ ", P0 M +\ -P"[ #\ MP!' +4 3@"R %, L !9 *\ 7@"M &,
MK !H *L ;0"I ', J !Z *8 @0"D (H HP"4 *$ GP"? *P G@"[ )P T@";
M .X F@#_ )H _P"9 /\ F0#_ /X   #N    W@   ,L   #!  4 N0 - +0
M% "Q !X K@ G *L , "J #D IP!! *0 2 "B $T H0!3 )\ 6 "> %T G0!B
M )L 9P": &T F !S )< >P"5 (0 E ". )( F0"0 *8 C@"T (T R ", .8
MBP#Y (H _P"* /\ BP#_ /    #;    QP   +H   "P    J  * *0 $ "@
M !@ G0 A )L *@": #, F  [ )8 00"4 $@ D@!- )$ 4@"/ %< C@!< (P
M80"+ &< B@!N (@ =0"' 'X A0"( (, E "" *  @ "O '\ P !^ -T ?0#R
M 'T _P!] /\ ?0#_ .    #&    M0   *H   "B    FP % )4 #0"2 !,
MD  < (T ) "+ "T B@ T (@ .P"& $( A0!' (, 30"" %( @0!7 '\ 7 !^
M &( ?0!H 'L < !Z 'D > "# '8 CP!U )P = "J '( N@!Q -$ < #L '
M^P!P /\ < #_ ,T$  "W!@  IP<  )L&  "3!   C@   (H " "&  \ A  6
M ($ '@!_ "< ?0 N 'P -@!Z #P >0!" '< 1P!V $P =0!2 ', 5P!R %T
M<0!C &\ :P!N '0 ; !^ &L B@!I )@ : "F &< M@!F ,L 90#G &4 ]P!E
M /\ 90#_ , ,  "K#0  FPX  (\.  "&#0  @0L  'X' 0!\ 0L >0 1 '<
M& !U "$ <P I '$ , !O #8 ;@ \ &P 0@!K $< :@!- &D 4@!H %@ 9@!?
M &4 9P!C '  8@%Z & !AP!? I4 7@*C %P#LP!< \< 6P3D %L%] !;!OX
M6P;_ +40  "A$@  D1,  (43  !\$@  =A$  ',.  !R# 0 <0<- &X$$@!L
M!!L :04C &<%*@!F!C$ 9 8W &,&/0!B!T, 80=) %\'3@!>"%4 70A< %L)
M8P!:"6T 6 IX %<*A0!6"Y, 5 NB %,+LP!2#,< 4@SD %$-]0!1#?\ 40W_
M *T5  "9%P  B1@  'T9  !T&   ;1<  &H4  !G$0  9PX' &8,#@!C#!4
M80P= %\,)0!=#2P 7 TS %L-.0!:#3\ 6 U% %<-2P!6#E$ 50Y9 %,.80!2
M#FL 4 ]V $X0@P!-$)( 3!"B $L0L@!*$<@ 21'E $D1]P!)$O\ 21'_ *49
M  "2'   @QT  '8>  !M'0  9AP  &(:  !?%P  7A0! %X1"@!;$!$ 61$8
M %<1( !5$2< 5!$N %,1- !1$3L 4!)! $\21P!.$DX 3!)5 $L37@!)$V<
M2!1S $84@ !%%8\ 1!6? $,6L !"%L4 0A?C $(7]@!"%_\ 0A?_ )\=  ",
M(   ?2$  '$B  !H(@  82$  %P?  !9'   5QD  %46!@!4%0X 4144 $\6
M' !.%B, 3!8J $L6, !*%C< 21<] $<70P!&%TH 11A2 $,86@!"&60 01EP
M #\:?0 ^&XT /1N= #P<K@ [',, .QSA #L=]0 ['/\ /!S_ )HA  "'(P
M>"0  &PE  !C)0  7"0  %<C  !3(   41X  $\< @!-&PP 2QH1 $@;& !'
M&R  11LF $0;+0!#'#, 0APY $ <0  _'4< /AU/ #T>6  \'F( .A]M #D?
M>P X((L -R&; #8AK0 U(<$ -2'? #4A\P V(?\ -B'_ )8C  "#)@  ="<
M &@H  !?*   6"<  %,F  !/)   3"(  $D@  !'( D 1!\/ $(?%0! (!P
M/R C #X@*0 \("\ .R$V #HA/0 Y(40 ."), #<B50 V(U\ -"-K #,D>0 R
M)8D ,26: # EJP P)K\ +R;< # F\@ P)O\ ,27_ )$F  !_*   <2H  &4J
M  !<*@  52H  $\I  !+*   2"4  $0D  !!) 4 /R0- #TD$@ [)!D .20?
M #<D)@ V)"P -24S #0E.@ S)D$ ,B9* #$G4P P)UT +RAI "XI=P M*8<
M+"F8 "LJJ@ J*KT *BK: "LJ\0 K*OX +"G_ (TH  !\*@  ;2P  &(M  !9
M+0  42T  $PL  !'*P  0R@  #\H   \* ( .2@+ #<H$  U*!8 ,R@< #(H
M(P P*"D +RDP "\J-P N*C\ +2M' "PK40 K+%L *BQG "DM=0 H+84 )RV7
M "8NJ  E+KP )2[8 "8N\  F+OT )RW_ (HK  !X+0  :BX  %\O  !6+P
M3B\  $@N  !#+0  /RP  #LL   W+   -"P) #(L#@ P+1, +BT: "TM(  K
M+2< *BXM "HN-0 I+ST *"]% "<P3@ F,%D )3%E "0Q<P C,8, (C*5 "$R
MIP A,KL (#+4 "$R[P B,?P (C'_ (8M  !U+P  9S   %PQ  !3,0  2S$
M $4Q  ! ,   .S   #8P   S,   ,#$& "TQ#0 K,1$ *3(7 "@R'@ G,B0
M)3,K "4S,@ D,SH (S1# "(T3  A-5< (#5C !\U<0 >-H$ '3:3 !PVI0 ;
M-KD &S;2 !PV[0 =-OL '37_ ((P  !Q,@  8S,  %DT  !0-   230  $(S
M   ],P  -S,  #$T   N-0  *S4" "@V"P E-Q  )#<5 "(W&P A."( (#@H
M !\X,  >.#< '3E  !PY20 ;.E0 &CI@ !DZ;@ 8.G\ %SN1 !<[I  6.[<
M%3O0 !8Z[  7.OH &#G_ 'TR  !M-   8#4  %4V  !--@  1C8  $ V   Z
M-@  -#8  "XX   J.0  )CH  ",["  @/ X 'CT2 !T]&  </1\ &SXE !H^
M+0 9/C0 %SX] !8_1P 5/U$ %#]> !0_;  30'P $D"/ !% H@ 10+8 $$#.
M !$_ZP 2/_D $C[_ 'DU  !I-P  7#@  %(Y  !*.0  0SD  #TY   W.0
M,3H  "L\   G/0  (C\  !Y!!  :0@L &$,0 !=#%0 51!L %$0B !-$*0 3
M1#$ $D0Z !%%0P 014X $$5;  Y%:0 .17D #46,  U%GP ,1;( "T7)  Q%
MY0 -1/8 #43_ '0Y  !E.@  6#L  $\[  !'/   0#P  #H\   T/   +CX
M "A    C0@  'T0  !I&   52 @ $DH- !%*$@ 02A@ #TL>  Y+)0 -2RT
M#4LV  Q+0  +2TH "DM6  E+9  (2W0 !TN'  5+F@ $2ZX !$K$  5*X  %
M2O  !DGZ &X\  !@/0  5#X  $L^  !$/@  /3X  #<_   Q0   *D(  "1%
M   ?1P  &DD  !5,   13@4 #E$+  M1$  *410 "5$;  A1(@ '42D !5$R
M  12.P #4D8  5)2  !27P  4F\  %*!  !1E@  4:D  %&_  !0W   4.X
M %#W &A   !;00  4$$  $A!  !!00  .T(  #1#   M10  )D@  "!+   ;
M30  %E   !%3   .500 "E@*  98#@ "6!(  %D7  !9'0  624  %DM  !9
M-@  64$  %E-  !:6@  6FD  %E\  !9D   6:4  %BZ  !8U0  5^P  %?V
M &-$  !610  344  $5%   _10  -T<  "])   H3   (D\  !M2   650
M$5@   U:   )70, !%\)  !@#0  8!   &$4  !A&0  8B   &(G  !B,0
M8CL  &)'  !B50  8V0  &)V  !BBP  8J   &&V  !ASP  8.H  &#U %U(
M  !220  2D@  $-(   Z2@  ,DT  "I0   C4P  '%<  !9:   170  #6
M  AC   #9@$  &<&  !H"P  :0X  &H1  !K%0  ;!L  &TB  !M*@  ;30
M &U   !M3@  ;5T  &UO  !MA   ;)H  &RP  !KR   :^8  &KS %A-  !.
M30  2$P  #Y.   U40  +%0  "18   =7   %F   !!D   ,9P  !VL   %N
M    <    '(#  !R!P  <PL  '4.  !V$0  =Q8  '@<  !Y(P  >BT  'HY
M  !Z1P  >E8  'EH  !Z?   >90  'BJ  !XP0  =]\  '?O %11  !,40
M0E(  #A5   O60  )EX  !YB   69P  $&L   MO   %<P   '<   !Z
M?    'X   !_ @  @ 8  ($*  "##0  A!$  (85  "('   B24  (HP  "*
M/@  B4T  (E?  ")<P  B(L  (BB  "'N0  A]$  (;H %)6  !'5P  /%H
M #)?   H9   'VD  !9O   0=   "GD   )]    @0   (4   "(    B@
M (P   "-    CP   ) $  "2"   DPP  )40  "7%0  F1T  )LG  ";-
MFT0  )I6  "::@  F8(  )J:  "8L   F,<  )?> $M<  ! 8   -64  "MJ
M   A<0  %W<  !!]   )@P   8@   ",    D0   )4   "8    F@   )L
M  "=    GP   *    "B    I 4  *8*  "H#@  JA0  *T=  "M*@  K3D
M *U+  "M7P  K7<  *R0  "KIP  J[H  *O+ $5F   Y:P  +G$  "-X   9
M?P  $(8   F-    DP   )@   "=    H0   *4   "H    JP   *L   "N
M    KP   +$   "S    M0   +<!  "Y!P  O T  +\3  #"'P  PBX  ,)
M  #"5   P6L  ,&#  # FP  P:T  ,&\ #YR   R>   )X   !R(   2D
M"I<   "=    HP   *@   "M    L@   +8   "Y    NP   +P   "^
MP    ,(   #$    Q@   ,@   #+    S@4  -$-  #6%   UR,  -@U  #9
M20  VEX  -MU  #;C   W)\  -RK /\   #_    _P   /\ "0#_ !  _P 9
M /X ) #\ "\ ^0 Y /0 0P#P $L [0!2 .H 60#G %\ Y !D .( :0#@ &X
MW@!S -P >0#: '\ UP"& -0 C@#1 )8 SP"A ,P K #* +L R #2 ,8 [@#&
M /\ Q0#_ ,4 _P"_ /\ N@#_ /\   #_    _P   /X !0#W  X \@ 5 .X
M'P#K "H Z0 T ., /0#> $4 V0!- -0 4P#1 %D S@!> ,P 8P#* &@ R0!M
M ,< <P#% 'D PP"  ,$ B "_ )  O0"; +L I@"Y +0 MP#( +8 Y@"U /L
MM #_ +0 _P"S /\ K@#_ /\   #_    ^    .T   #E  L W0 1 -< &@#2
M "0 SP N ,L -P#' $  PP!' ,  3@"^ %, O !9 +H 7@"X &, M@!H +4
M;0"S ', L0!Y *\ @0"M (H JP"4 *D H "H *T I@"^ *4 VP"D /0 I #_
M *, _P"C /\ H@#_ /\   #V    Y@   -<   #+  8 Q  . +X %0"[ !\
MN0 H +< ,0"T #H L !! *T 2 "K $X J0!3 *< 6 "F %P I !A *, 9P"A
M &P H !S )X >@"= (, FP". )D F0"7 *8 E@"V )4 S "4 .L DP#] ),
M_P"3 /\ DP#_ /<   #D    T    ,$   "W  ( KP + *L $0"G !D I0 B
M *, *P"B #, GP [ )P 0@"; $@ F0!- )< 4@"6 %< E0!; ), 80"2 &8
MD !M (\ = "- 'T C "' (H DP"( *  AP"O (4 P@"% .( A #W (0 _P"$
M /\ A #_ .4   #-    O    *\   "F    G@ ' )H #@"6 !0 E  = )(
M)0"1 "T D  U (T / ", $( B@!' (@ 3 "' %$ A@!6 (0 6P"# &  @0!G
M (  ;@!^ '< ?0"! 'L C0!Z )H > "I '< N@!V -, =@#O '8 _@!U /\
M=0#_ -    "[    JP   )\   "7    D  " (L "P"( !  A@ 7 (0 ( ""
M "< @0 O '\ -0!] #P ? !! 'L 1@!Y $L > !0 '< 50!V %L = !A ',
M:0!Q '$ < ![ &X AP!M )4 :P"C &H M !J ,D :0#H &D ^0!I /\ :0#_
M ,    "L    G (  ) "  "(    @P   '\ !@![  T >0 2 '< &@!V "(
M=  I ', , !Q #8 <  \ &\ 00!M $8 ; !+ &L 4 !J %8 : !< &< 9 !E
M &P 9 !V &, @@!A )  8 "? %\ KP!> ,, 7@#A %X ] != /\ 70#_ +0'
M  "@"0  D L  (0+  !\"@  =P<  '0$  !Q  D ;P / &T %0!K !P :0 C
M &@ *@!G #$ 90 V &0 / !C $$ 8@!& &  3 !? %( 7@!8 %T 7P!; &@
M6@!R %@ ?@!7 (P 5@"; %4 JP!4 +X 5 #: %, [P!4 /L 5 #_ *D-  "6
M#@  AQ   'H0  !R$   ; X  &D,  !G"0, 9@0+ &0 $ !B !< 8  > %X
M)0!= "L 7  Q %H -P!9 #P 6 !" %<!1P!6 4X 50)4 %,"7 !2 V4 40-O
M $\$>P!.!(H 3069 $P%J0!+!;P 2@;4 $H'[0!*!_D 2@?_ *$0  ".$@
M?A0  ',4  !J%   9!,  & 1  !>#P  70T% %T)#0!:!A( 6 <9 %8'( !5
M!R< 4P<M %((,P!1"#@ 4 @^ $\)1 !."4H 3 E1 $L*60!*"F( 2 MM $<+
M>@!&#(@ 1 R8 $,,J0!"#;P 0@W5 $(-[@!"#?L 0@W_ )H4  "'%@  >!@
M &P9  !C&0  71@  %D6  !6$P  5!$  %0." !3#0X 40T4 $\-&P!-#2(
M3 TH $L-+@!*#30 20TZ $<.00!&#D< 10Y/ $0.5P!"#V$ 01!L #\0>0 ^
M$(@ /1&8 #L1J0 [$;P .A'6 #H1\  Z$OT .Q'_ ),8  "!&@  <QP  &<=
M  !>'0  6!P  %,;  !0&   3A8  $P3 P!,$0L 2A 0 $@1%P!&$1X 11$D
M $01*@!"$3  01$W $ 2/0 _$D0 /1), #P35  [$UX .11I #@4=@ W%84
M-A66 #06IP T%KH ,Q;3 #,6[@ T%OP -!;_ (X;  !\'0  ;A\  &,@  !:
M(   4R   $X>  !*'0  2!H  $88  !%%@< 0Q4. $$5$P _%1H /A4@ #T5
M)P [%2T .A8S #D6.@ X%D$ -Q=) #4740 T&%L ,QEF #(9<P P&H, +QJ4
M "X;I0 M&[@ +1O0 "T;[  N&_L +AO_ (H>  !X(   :B(  %\C  !6(P
M3R(  $HA  !&(   0QX  $$;   _&@, /1H, #L9$0 Y&18 -QH= #8:(P U
M&BD -!HP #,;-@ Q&SX ,!Q& "\<3P N'5D +1UD "P><0 K'X$ *A^2 "D?
MI  H(+< )R#. "<@ZP H(/H *1__ (8@  !T(P  9R0  %PE  !3)0  3"4
M $<D  !"(P  /R$  #T?   Z'@  -QX) #4>#@ S'A, ,1X: # >(  O'B8
M+A\M "T?,P L(#L *R!# "HA3  I(58 *")B "8B;P E(W\ )".0 ",CH@ B
M)+4 (B3, "(DZ0 C)/D )"/_ ((C  !Q)0  8R8  %DG  !0*   22<  $,G
M   _)@  .R0  #@B   U(@  ,B(& # B#0 N(A$ +"(7 "HB'0 I(B, *",J
M "<C,0 F)#@ )25! "0E2@ C)E0 (B9@ "$G;0 @)WT 'R>/ !XHH0 >*+0
M'2C* !THZ  >*/@ 'R?_ 'XE  !N)P  8"D  %8I  !-*@  1BH  $$I   \
M*   -R<  #0F   P)@  +28# "LG"P H)Q  )R<4 "4G&@ D)R$ (R@G "(H
M+@ A*38 ("D^ !\J2  >*E( '2M> !PK:P ;*WL &BR- !DLGP 8++( &"S)
M !@LYP 9*_< &BO_ 'HG  !J*@  72L  %,L  !*+   0RP  #XK   Y*P
M-"H  # J   K*@  *2L  "8K"  C+ X (BP2 " L&  ?+!X 'BTE !TM+  <
M+3, &RX\ !HN10 9+U  &"]< !<O:0 6,'D %3"+ !0PG@ 4,+$ $S#' !,P
MY0 4,/8 %2__ '8J  !G+   6BT  % N  !(+@  02X  #LN   V+0  ,2T
M "PM   G+P  )"\  "$P!0 ?,0P '#$0 !LR%0 :,AP &3(B !@R*0 7,S$
M%C,Y !4S0P 4-$T $S19 !(T9P 1-7< $36) ! UG  0-;  #C7&  \TY  0
M-/4 $#3_ '(L  !C+@  5S   $TP  !%,   /C   #@P   S,   +S   "DQ
M   D,@  (3,  !TU @ :-@D %S<. !4W$P 4.!D $S@? !(X)@ 2."X $3DV
M ! Y0  0.4L #CE7  XZ9  -.G0 ##J&  PZF0 +.:P "CG!  HYW@ +.?$
M##C\ &XO  !?,0  4S(  $HS  !",P  .S,  #8S   Q,@  +#,  "<T   A
M-@  '3@  !DY   5.P8 $CT, ! ^$  0/A4 #CX<  X^(P -/BH ##XS  P^
M/  +/T< "C]2  @_8  '/V\ !C^!  4_E  $/Z@  SZ\  0^UP %/NP !3[W
M &DS  !;-   4#4  $<U   _-0  .34  #0U   N-0  *3<  ",X   >.P
M&CP  !8_   2000 #D,*  Q$#@ *1!, "409  A$(  '1"< !D0O  5$.  #
M14(  D5.  !%6P  16H  $5\  !%D   1*0  $2Y  !$T0  1.H  $/U &0V
M  !7-P  3#@  $,X   \.   -S@  #$X   K.0  )3L  " ]   :0   %D(
M !)$   .1P0 "TD)  =*#0 $2Q$  4L6  !+'   2R,  $LK  !+-   2SX
M $Q)  !,5P  3&8  $QW  !+C   2Z$  $NU  !*S@  2ND  $KU %\Z  !2
M.P  2#L  $ [   Z.P  -#L  "X\   G/@  (D$  !Q#   61@  $DD   Y+
M   +3@, !U (  )1#   41   %(3  !3&   4Q\  %,F  !3+P  4SD  %-%
M  !34@  4V$  %-R  !3AP  4IP  %*Q  !1R@  4><  %'T %D^  !./@
M13X  #X^   X/@  ,$   "E"   C1   '4<  !=*   230  #E    M3   &
M50(  %<'  !8"P  60X  %H1  !:%0  6QH  %PA  !<*@  7#0  %P_  !<
M30  7%L  %QL  !<@0  6Y<  %NM  !:Q0  6N0  %GS %1"  !*0@  0D(
M #Q"   T0P  +$8  "5)   >3   %T\  !)3   .5@  "ED   5;    7@
M & $  !A"   8@P  &,.  !D$0  918  &8<  !G(P  9RT  &<Y  !G1@
M9U4  &=F  !G>@  9I$  &6H  !EP   9-X  &3P $]&  !'1@  0$4  #='
M   O2@  )DT  !]1   850  $ED   U<   (8    F,   !F    :    &H
M  !K!   ; @  &T,  !O#@  <!(  '(7  !S'0  ="8  '0R  !T/P  =$X
M '-?  !T<@  <XH  '*A  !QN   <=0  '#L $Q*  !%2@  .TL  #).   I
M4@  (%8  !A;   27P  #60   =H    :P   &\   !R    =0   '8   !W
M    >0(  'H&  !\"@  ?@X  ( 1  ""%@  A!X  (0I  "$-@  A$4  (16
M  "#:@  @X$  (*9  "!L0  @,D  (#E $I.   _4   -5,  "M7   B7
M&6(  !)G   ,;   !7$   !U    >0   'T   "!    @P   (4   "&
MB    (D   "+!   C0@  (\-  "2$   E!8  )8@  "6+   ECL  )9,  "5
M8   E78  )20  "3IP  DKT  )+5 $15   Y60  +UT  "1C   ::0  $F\
M  QU   $>P   (    "%    B0   (T   "1    DP   )0   "6    F
M )H   "<    G@   * &  "B"P  I1   *@7  "I(P  J3$  *E#  "I5@
MJ&T  *:'  "GG@  IK,  *7' #Y>   R8P  )VH  !UP   3>   #'\   .%
M    BP   )$   "6    FP   )\   "B    I    *4   "G    J0   *L
M  "M    L    +(   "U @  MPD  +L0  "^&   OB8  +XX  "^2P  O6$
M +QZ  "[E   NJD  +JY #=J   K<   ('@  !:    -B   !8\   "6
MG    *(   "G    K    +    "S    M@   +<   "Y    NP   +T   "_
M    P@   ,4   #(    R@   ,X(  #2$   U1L  -4L  #40   U%<  --N
M  #4A@  U)L  -.K /\   #_    _P   /\ !0#_  X _P 5 /P ( #Y "H
M]@ T /$ /0#M $8 Z0!- .8 4P#D %D X0!> -X 8P#< &@ V0!N -4 <P#3
M 'D T "  ,X B #+ )$ R0"< ,8 IP#$ +< P@#, ,  [ "_ /\ O@#_ +T
M_P"W /\ L@#_ /\   #_    _P   /H  0#S  L [0 2 .@ &P#E "4 Y  N
M -\ . #8 $  T@!' ,X 3@#+ %0 R !9 ,8 7@#$ &, P@!G ,  ;0"_ ',
MO0!Z +L @0"Y (L M@"5 +0 H0"R *\ L #" *X XP"N /H K #_ *T _P"I
M /\ I@#_ /\   #_    \@   .8   #=  < T@ . ,T %@#* "  R  I ,4
M,@#  #H O !" +D 2 "W $X M0!3 +, 6 "Q %T L !B *X 9P"L &P J@!S
M *D >P"G (0 I0". *, F@"A *@ GP"Y )X T@"= /( G #_ )T _P"< /\
MF0#_ /P   #N    W0   ,P   #!  ( N@ , +8 $@"R !H L  C *\ + "M
M #0 J0 \ *8 0@"D $@ H@!- *  4@"> %< G0!; )P 8 ": &8 F0!L )<
M= "5 'T DP"' )$ DP"0 *$ C@"Q (T Q@", .@ BP#] (P _P", /\ C #_
M .T   #8    Q0   +<   "L    I@ ( *$ #@"? !4 G0 > )L )@": "X
MEP U )4 / "3 $( D0!' )  3 ". %$ C0!5 (L 6@"* &  B0!F (< ;0"%
M '8 A "  (( C "  )H ?P"I 'T O !\ -P ? #U 'P _P!\ /\ ? #_ -D
M  #!    L0   *0   "<    E  # )  # "- !$ BP 8 (D ( ") "@ AP O
M (4 -@"# #P @@!! (  1@!_ $L ?0!/ 'P 5 ![ %H >0!@ '@ 9P!V '
M=0!Z ', A@!Q ), < "B &\ M !N ,P ;@#M &X _@!N /\ ;@#_ ,0   "O
M    H    )0   ",    A@   ($ " !^  X ?  4 'L &P!Y "( >  I '<
M, !U #8 =  [ '( 0 !Q $4 < !* &\ 3P!M %0 ; !; &L 8@!I &H : !T
M &8 @ !E (X 8P"= &( K0!A ,( 80#D &$ ^ !A /\ 80#_ +0   "@
MD0   (8   !^    >0   '4  P!Q  L ;P 0 &T %@!L !T :P D &L *@!I
M #  :  V &8 .P!E $  9 !% &, 2@!A $\ 8 !6 %\ 70!= &4 7 !O %H
M>@!9 (@ 6 "8 %< J !6 +L 5@#8 %8 \0!6 /\ 5@#_ *@!  "4!0  A0<
M 'H'  !R!@  ; 0  &D!  !G  < 9  - &, $0!A !@ 8  ? %\ )0!> "L
M70 P %L -@!: #L 60!  %@ 10!7 $L 5@!1 %4 6 !3 &$ 4@!J %  =@!/
M (0 3@"3 $T I !, +8 3 #- $P ZP!, /H 3 #_ )T)  "+"P  ? T  ' -
M  !H#0  8@P  %\*  !=!@$ 7 $) %H #@!8 !, 5P 9 %8 ( !5 "8 4P K
M %( ,0!1 #8 4  [ $\ 00!. $< 30!- $L 50!* %T 20!G $< <P!& (
M10"0 $0 H0!# +( 0P#( $, Y@!# /4 0P#_ )4-  "##P  =!   &D1  !@
M$0  6A   %8.  !4#0  4PH$ %,&"P!1 Q  3P$5 $X!&P!, 2$ 2P$G $H"
M+ !) C( 2 (W $<#/0!% T, 1 -* $,$40!"!%H 0 5D #\%<  ^!GX /0:.
M #P'GP [![$ .@?& #H'XP Z!_, .@C\ (X0  !\$@  ;A0  &(5  !:%0
M5!0  % 3  !-$0  2PX  $L-!@!*"@P 20@1 $<(%@!%"!T 1 @C $((* !!
M"2X 0 DS #\).0 ^"D  /0I' #P*3P Z"U@ .0MC #@,;P V#'X -0R. #0-
MGP S#;$ ,@W' #(-XP R#?0 ,@W^ (@3  !W%0  :1<  %X8  !5&   3Q@
M $H6  !'%0  11,  $,0 @!##@@ 0@T. $ -$@ _#1@ /0T? #P-)  [#2H
M.0TP #@.-P W#CT -@Y% #4.30 S#U< ,@]B #$0;@ O$'T +A". "T1H  L
M$;( *Q'( "L1Y@ K$?8 +!'_ (,6  !R&0  9!H  %D;  !1&P  2QL  $8:
M  !"&   /Q<  #X4   \$@0 .Q$* #H0$  X$!4 -Q ; #41(0 T$2< ,Q$M
M #(1,P P$3H +Q)" "X22P M$U0 *Q-? "H4;  I%'L *!2, "<5G@ F%;
M)17& "45Y  E%?8 )A7_ 'X9  !N&P  8!T  %8>  !-'@  1QX  $(=   ^
M'   .AH  #@8   W%@  -14' #04#0 R%!( ,!07 "\4'0 M%", +!4J "L5
M,  J%3< *18_ "@62  G%U( )AA= "08:@ C&7D (AF* "$9G  @&:\ 'QG$
M !\9X@ @&?0 (!G_ 'H;  !J'@  71\  %,@  !*(   1"   #X?   Z'@
M-QT  #0<   R&0  ,!D$ "X8"P L&!  *A@4 "D8&@ G&"  )ADF "49+0 D
M&C4 (QH] "(;1@ A&U  (!Q; !\=:  >'7< '1V( !P>FP ;'JT &A[# !H>
MX  :'?, &QW_ '<=  !G(   6B$  % B  !((@  02(  #LB   W(0  ,R
M # ?   M'0  *QT  "@="  F'0X )1T2 ",=%P A'1T (1TD " >*@ ?'C(
M'A\Z !T?0P <($T &R%9 !HA9@ 9(74 &"*' !<BF0 6(JP %2+! !4BWP 5
M(?( %B'^ ',@  !D(@  5R,  $TD  !%)0  /B0  #DD   T(P  ,"(  "PB
M   I(0  )B$  "0A!@ B(0P ("$0 !XA%0 =(AL &R(A !LB*  :(R\ &2,X
M !@D00 7)$L %B57 !4E9  4)G, $R:% !(FF  1)JL $2;  ! FW0 1)?$
M$B7] ' B  !A)   5"8  $HF  !")P  /"8  #8F   Q)0  +24  "DD   F
M)   (B4  !\E P =)@H &R8. !DG$@ 8)Q@ %R<? !8G)0 5*"T %"@U !,I
M/@ 2*4D $2E5 !$J8@ 0*G$ #RJ#  XJE@ .*JD #2J]  TJUP -*NX #BG[
M &PD  !=)@  42@  $@H  ! *0  .2@  #0H   O*   *R<  "<G   B*
M'BD  !LJ   8*P< %BL- !0L$0 3+!8 $BP< !$M(P 0+2H $"TR  \N/  .
M+D8 #2Y2  TN7P ,+VX "R]_  HOD@ )+Z4 "2ZY  @NT  )+ND "B[W &@G
M  !:*0  3BH  $4K   ]*P  -RL  #$J   M*@  *2H  "0J   @*P  &RT
M !@N   5+P0 $C$* ! R#@ /,A, #C(9  TR(  -,B< ##(O  LS.  *,T(
M"3-.  @S6P &-&H !31[  0SC@ #,Z(  C.V  (SS0 #,^< !#+S &0J  !6
M+   2RT  $(M   Z+0  -"T  "\L   K+   )BP  "(M   =+P  &3$  !4R
M   2- , #S8)  PX#0 *.!$ "3@6  @X'0 '."0 !C@L  0X-  #.#X  CE*
M   Y5P  .64  #EW   YBP  .)\  #BS   XR@  ..8  #?R %\M  !2+@
M2"\  #\P   X+P  ,B\  "TO   I+P  )#   !\Q   :,P  %34  !(W   /
M.0, ##L(  @]#0 %/A   SX4   ^&@  /B$  #XH   ^,0  /SL  #]&   _
M4P  /V$  #]S   _AP  /IP  #ZP   ]QP  />0  #WR %HP  !.,@  1#(
M #PR   U,@  ,#$  "LQ   F,@  (#0  !LV   6.   $CL   \]   ,/P,
M"$$(  1##   0PX  $02  !%%@  11T  $4D  !%+0  1C8  $9"  !&3@
M1ET  $9N  !%@@  19@  $2M  !$Q   0^,  $/R %4T  !*-0  034  #DU
M   S-   +C0  "@U   B-P  '3H  !<\   2/P  #T$   Q$   (1@$  T@&
M  !)"@  2@T  $L0  !,%   31D  $X@  !.*   3C(  $T]  !.2@  3E@
M $UI  !-?0  3)0  $RJ  !+P0  2^$  $KR % X  !&.   /3@  #<X   Q
M-P  *CD  "0[   >/0  &$   !-#   /1@  "TD   =+   "3@   % $  !1
M"   4@L  %,.  !4$0  514  %8;  !7(P  5RP  %<X  !71   5U(  %9C
M  !6=P  5HX  %6E  !4O0  4]T  %/P $L\  !"/   .SL  #4[   M/
M)C\  !]"   910  $T@   Y+   +3P  !5$   !4    5P   %@!  !:!0
M6P@  %P,  !=#@  7Q$  & 6  !B'0  8B8  &(Q  !B/@  84P  &%=  !A
M<   8(@  &"@  !?MP  7M0  %WN $=    _/P  .C\  #%    I0P  (48
M !I*   33@  #E$   I5   $6    %L   !>    80   &,   !D 0  900
M &<(  !H"P  :@X  &P2  !N%P  ;R   &\J  !O-@  ;D4  &Y5  !N:
M;7\  &V8  !LL   :\H  &KH $1$   ^0P  -40  "M'   C2P  &T\  !-4
M   .6   "%P   )@    9    &<   !K    ;0   &\   !P    <@   '0"
M  !U!@  =PH  'D.  !\$@  ?A@  '\B  !_+@  ?ST  'Y-  !]80  ?7<
M 'R0  ![J   >L   'G? $-'   Y20  +TP  "50   <50  %%L   Y@   '
M90   &H   !N    <@   '8   !Y    ?    'X   !_    @0   (,   "%
M    AP,  (H(  ",#0  CQ$  )(9  "2)0  DC,  ))$  "15P  D&T  (^&
M  ".GP  C;4  (S- #U.   R40  *%8  !Y<   58@  #F@   =N    =
M 'D   !^    @@   (8   ")    C    (X   "0    D@   )0   "6
MF    )L   ">!@  H0P  *01  "F&P  IBD  *8Z  "E30  I6(  *1[  "C
ME   H:L  *&_ #97   L7   (6(  !=I   /<   !W<   !^    A    (H
M  "/    E    )@   ";    G@   )\   "B    I    *8   "H    JP
M *T   "P    LP0  +<,  "[$@  NQ\  +LP  "[0P  NE@  +EP  "WBP
MMZ$  +>S #!B   E:0  &G   !!X   )@    (@   "/    E@   )L   "A
M    I@   *H   "N    L    +$   "T    M@   +@   "[    O0   ,
M  ##    QP   ,L#  #/#   TQ4  -(E  #2.   T4X  -!E  #/?@  S98
M ,RI /\   #_    _P   /\  P#_  L _  1 /D &P#W "4 \P O .X . #I
M $  Y@!( .( 3@#? %0 W !9 -D 7@#5 &, TP!H -  ;0#. ', RP!Z ,@
M@@#& (P PP"7 ,  HP"^ +( O #( +H Z@"Y /\ N #_ +$ _P"J /\ IP#_
M /\   #_    ^P   /8   #M  < YP / .( %@#? "  W@ I -D ,P#1 #L
MS !" ,@ 2 #% $X P@!3 ,  6 "^ %T O !B +H 9P"Y &T MP!T +4 >P"R
M (4 L "0 *X G "L *H J0"] *< W@"F /D I0#_ *, _P"= /\ FP#_ /T
M  #V    ZP   -\   #1  , R@ , ,4 $@## !L P  D +X + "Y #4 M@ \
M +, 0P"P $@ K@!. *P 4@"K %< J0!< *< 80"F &< I !M *( = "@ 'T
MG@"( )P E0": *, F "T )8 S0"5 /$ E #_ )4 _P"0 /\ C@#_ /,   #F
M    T0   ,(   "X    L0 ( *T #P"J !8 J  > *@ )P"F "\ H@ V )\
M/ "= $( FP!' )D 3 "7 %$ E@!5 )0 6@"3 &  D0!F )  ;@". '8 C "!
M (H C0"( )L A@"L (4 P0"$ .8 @P#] (0 _P"# /\ @0#_ .0   #+
MN@   *P   "B    G  $ )@ # "6 !$ E  9 ), (0"2 "@ CP P (T -@"+
M #P B0!! (@ 1@"& $L A0!/ (0 5 "" %H @0!@ '\ 9P!^ &\ ? !Z 'H
MA@!X )0 =P"D '4 MP!T -0 <P#T '0 _P!T /\ = #_ ,L   "V    I@
M )H   "2    B@   (8 " "#  X @0 4 ($ &P"  ", ?P J 'T , ![ #8
M>@ [ '@ 0 !W $4 =0!) '0 3@!S %0 <0!: '  80!N &D ;0!S &L ?P!I
M (T : "= &< K@!F ,< 90#J &8 _P!F /\ 9P#_ +@   "D    E0   (H
M  "!    ?    '8 ! !T  P <@ 0 '$ %@!P !T <  D &X *@!M #  :P U
M &H .@!I #\ : !$ &< 20!E $X 9 !4 &, 6P!A &, 8 !M %X >0!= (<
M6P"6 %H J !9 +T 60#? %D ^ !: /\ 6@#_ *@   "5    AP   'L   !S
M    ;@   &H  0!G  @ 90 . &0 $@!C !@ 8P ? &( )0!A "H 7P P %X
M-0!= #H 7  ^ %L 1 !9 $D 6 !/ %< 5@!6 %X 5 !H %, <P!1 ($ 4 "1
M $\ H@!. +4 3@#0 $X \ !. /\ 3P#_ )P   ")    >P,  ' #  !H P
M8@$  %\   !=  0 6P + %D #P!8 !0 5P 9 %< ( !6 "4 50 J %, , !2
M #0 40 Y %  /P!/ $0 3@!+ $T 4@!+ %H 2@!C $D ;P!' 'P 1@", $4
MG0!% +  1 #' $0 Z !$ /H 10#_ )($  " !P  <0H  &8*  !>"@  60D
M %4'  !4!   4@ ' %  # !/ !  3@ 5 $T &P!, "  2P F $H *P!) #
M2  U $< .@!& $  10!& $, 3@!" %8 00!? $  :P ^ '@ /0"( #P F0 \
M *L / #! #L X  [ /0 .P#_ (D*  !X#   :@X  %\.  !7#@  40X  $T,
M  !+"P  2@@" $D$"0!(  T 1@ 1 $4 %@!$ !P 0P A $( )@!! "L /P Q
M #X -@ ] #P / !# #L 2@ Z %( .0!< #@ :  V '4 -0"% #0 E@ T *@
M,P"\ #, V  S .\ ,P#[ ((-  !Q#P  9!   %D1  !1$0  2Q$  $<0  !$
M#@  0@T  $$+!0!!!PL /P4. #X#$@ \ A@ .P(= #H#(@ Y R@ . ,M #<#
M,@ V!#D -00_ #0%1P S!5  ,09: # &9@ O!W, +@># "T'E0 L!Z< *P>Z
M "L'T@ K!^L *P?W 'T0  !L$0  7Q,  %04  !,%   1A0  $(3   ^$@
M/!   #H. 0 Z#08 .@H, #@)$  V"!0 -0@9 #0)'P R"20 ,0DI # )+P O
M"C8 +@H] "T*10 L"TX *PM9 "D,90 H#', )PR# "8-E0 E#:< ) V[ ",-
MT@ C#>L (PWW '@2  !H%   6Q8  %$7  !(%P  0A8  #T6   Y%0  -Q,
M #41   S$ , ,PX( #(-#0 P#1$ +PT6 "T-&P L#2$ *PTG "H-+0 I#C0
M* X[ "<.1  E#DX ) ]9 ",090 A$', (!"$ !\0E@ >$*D '1"] !P0V  =
M$.X '1#Y ',4  !D%@  5Q@  $T9  !%&0  /QD  #H8   U%P  ,A8  # 5
M   N$P  +1$$ "P0"@ K$ X *1 2 "@0&  F$!X )1 D "00*@ C$3$ (A$Y
M "$10@ @$DL 'A)6 !T38P <$W$ &A." !D4E0 8%*< %Q2[ !<3U  7$^X
M&!/Z ' 6  !@&0  5!H  $H;  !"'   /!L  #8;   R&@  +QD  "P8   J
M%@  *!0! "83!P E$PP (Q,0 "(3%0 @$QH 'Q,A !X4)P =%"X '!4V !L5
M/P :%DD &194 !@780 6%W  %1B! !08DP 3&*8 $ABZ !(7T@ 2%^P $Q?Z
M &P9  !=&P  41T  $<=   _'@  .1T  #0=   O'   *QL  "@:   F&0
M)!@  "(7!  @%PH 'A<. !P7$@ :%Q< &1@> !D8)  8&2P %QDT !8:/0 5
M&D< %!M2 !,;7P 2'&X $1Q_ ! <D@ 0'*4 #QRY  X<T  .&^H #QOX &D;
M  !:'0  3A\  $4?   ](   -A\  #$?   M'@  *1T  "4=   C'   (!L
M !T; 0 ;&P< &1P- !<<$  6'!4 %1P; !0=(@ 3'2D $AXQ !$>.@ 1'T4
M$!]0  \@70 .(&P #2!\  T@CP ,(*( "R"U  L@R@ +(.4 #!_T &4=  !7
M'P  3"$  $(A   Z(0  -"$  "\A   J(   )A\  ",?   @'@  '1X  !D@
M   6( 0 %" + !(A#@ 1(1, $2(9 ! B'P /(B8 #B,O  XC-P -(T$ #"1-
M  LD60 *)&< "21X  @DBP '))X !R2Q  8DQP &(^, !R/Q &(?  !4(0
M22,  $ C   X(P  ,B,  "PC   H(@  )"$  "$A   >(0  &B$  !8C   3
M) , $24(  \F#0 .)Q$ #2<6  PG'0 +)R, "B<K  DH-  (*#X !RA)  8H
M50 %*60 !"ET  ,IAP "*9L  2BO   HQ0 !*.$  2?P %XB  !1)   1B4
M #TE   U)0  +R4  "HD   F)   (B,  !\C   ;)   &"4  !0F   1* ,
M#RD(  PL#  *+!  ""P4  <L&@ &+"$ !2PH  ,M,  "+3H  2U%   M4@
M+F   "YQ   MA   +9D  "VM   LP@  +.   "SP %HD  !-)@  0R<  #HG
M   S)P  +2<  "@F   D)@  (28  !TF   9)P  %2D  !$K   /+ , #2X'
M  DP#  &,0X  S$2  $R%P  ,AX  #(E   R+0  ,C8  #-"   S3@  ,UT
M #-M   S@0  ,I8  #*K   QP0  ,=\  #'P %8G  !**0  /RH  #<J   P
M*@  *RD  "<H   C*   'BD  !HJ   6+   $BX   \P   -,0( "C0'  4U
M"P "-@X  #<0   X%   .!H  #@B   X*@  .3,  #D^   Y2@  .5D  #EI
M   Y?0  .),  #BH   WOP  -]X  #;P %$K  !&+   /"P  #0L   N+
M*BL  "4K   @+   &RT  !<O   3,0  $#,   TU   )-P( !3H&  $["@
M/ T  #T/   ^$@  /Q<  $ >  ! )0  0"\  $ Z  ! 1@  0%0  $!E   _
M>   /X\  #ZF   ^O0  /=P  #WP $TN  !"+P  .2\  #(O   M+@  *"X
M "(O   =,   &#(  !,U   0-P  ##H   D\   %/@   $$$  !""   0PL
M $0-  !&$   1Q0  $@9  !((0  2"H  $@U  !(00  2$\  $A@  !'<P
M1XH  $:B  !%N0  1=D  $3P $@R   ^,@  -C(  # Q   K,0  )3(  !\T
M   9-@  $SD  ! \   ,/P  "$(   -$    1@   $@"  !*!0  2P@  $P+
M  !.#@  3Q$  %$5  !2'   4B4  %(P  !2/   44H  %%:  !1;0  4(0
M $^=  !.M0  3=(  $WN $,V   [-@  -#4  "\T   G-0  (3@  !H[   4
M/@  $$$   Q$   '1P   DH   !-    3P   %$   !3 @  5 4  %4(  !7
M"P  60X  %L1  !=%P  71\  %TJ  !=-@  7$0  %Q4  !;9P  6WX  %J7
M  !9KP  6,L  %?J #\Y   X.0  ,S@  "LY   C/   '#\  !5#   01P
M"TH   5.    40   %0   !7    6@   %P   !=    7P   & $  !B!P
M9 L  &8.  !H$@  :QD  &LC  !J+@  :CP  &I-  !I7P  :'4  &>/  !F
MJ   9<(  &3C #T]   W/   +CT  "5    =1   %DD  !!-   *40  !%4
M  !:    70   &    !C    9@   &@   !J    :P   &T   !O @  <08
M '0*  !V#@  >1,  'L;  ![)P  >C4  'E%  !X60  >&T  '>&  !VGP
M=;<  '32 #Q!   R0@  *$4  "!*   73@  $%0   I9   "7@   &,   !G
M    :P   &\   !R    =0   '<   !Y    >P   'T   !_    @@   (0#
M  "'"0  B@X  (X3  "/'@  CBL  (X[  "-3@  BV,  (I\  "*E0  B*T
M (?% #9'   L2P  (D\  !E5   06P  "F$   %G    ;0   '(   !W
M>P   '\   "#    A@   (@   "*    C0   (\   "1    E    )<   ":
M 0  G0<  *$-  "E%   I"$  *0Q  "C1   HED  *!P  "?BP  G:(  )VW
M #!0   E50  &UL  !)B   +:0   7    !W    ?0   (,   "(    C0
M )$   "5    F    )H   "<    GP   *$   "C    I@   *D   "L
ML    +0'  "X#@  NA@  +HG  "Y.0  N$X  +=E  "V?@  M98  +.K "E;
M   >8@  %&D   QQ   ">0   ($   ")    CP   )8   ";    H    *0
M  "H    JP   *P   "O    L@   +0   "V    N0   +P   #     Q
M ,@   #-!P  TA   -(=  #1+P  T$0  ,];  #-<P  RXT  ,JA /\   #_
M    ^P   /H   #\  @ ^  / /4 %P#T "  \0 J .L ,P#F #L X@!# -X
M20#: $\ U@!4 -, 60#0 %X S@!C ,L : #) &X Q@!U ,, ?0#! (8 O@"2
M +L G@"Y *X M@## +0 Z "S /\ KP#_ *4 _P"> /\ FP#_ /T   #W
M\@   /    #G  , X0 , -P $@#8 !L U@ D -( +0#, #8 Q@ ] ,( 0P"_
M $D O !. +H 4P"X %@ M@!= +4 8@"S &< L0!N *\ =@"L '\ J@"* *@
MEP"E *8 HP"Y *$ V0"@ /D G@#_ )@ _P"2 /\ CP#_ /,   #L    XP
M -,   #(    P0 ) +T #P"[ !8 N0 ? +< )P"S "\ KP W *P /0"J $,
MJ !( *8 30"D %( HP!6 *$ 6P"? &$ G@!G )P ;P": '@ EP"# )4 D "3
M )X D0"P )  R ". /  C0#_ (H _P"% /\ @@#_ .<   #=    Q@   +@
M  "N    J  $ *4 # "A !( H0 9 *  (@"? "D FP P )@ -P"6 #T DP!"
M )( 1P"0 $L CP!0 (T 50", %H B@!A (@ : "' '  A0![ (, B "! )8
M?P"G 'T O !\ ., ? #] 'P _P!X /\ =@#_ -8   #     KP   *,   "9
M    DP   (\ "0"-  X BP 4 (H ' "* ", B  J (4 , "# #8 @@ [ (
M0 !_ $4 ?@!* 'P 3P![ %0 >@!: '@ 80!V &D =0!S ', @ !Q (X ;P"?
M &X L@!M ,\ ; #T &P _P!K /\ :0#_ ,    "K    FP   (\   "'
M@    'P ! !Z  P >  1 '@ %P!X !X =P D '4 *@!S #  <0 U '  .@!N
M #\ ;0!$ &P 20!K $X :@!4 &@ 6P!G &, 90!M &0 > !B (< 8 "7 %\
MJ@!> ,( 7@#I %X _P!> /\ 70#_ *P   "9    B@   '\   !W    <0
M &T   !J  @ :0 . &@ $@!G !@ 9P ? &< )0!E "H 8P O &( - !A #D
M8  ^ %\ 0P!> $@ 70!. %L 50!: %T 6 !G %< <@!5 ($ 5 "1 %, HP!2
M +@ 40#< %$ ^0!2 /\ 4@#_ )T   "+    ?    '$   !I    9    &
M  !>  4 7  + %L #P!; !0 6@ 9 %H 'P!9 "4 5P J %8 +P!5 #0 5  X
M %, /0!2 $, 4 !) $\ 4 !. %@ 30!B $L ;0!* 'H 20"+ $@ G0!' +$
M1P#, $8 \ !' /\ 1P#_ )    !^    <    &8   !>    60   %8   !3
M  $ 4@ ( %  #0!/ !  3P 5 $X &@!. "  30 E $P *@!* "X 20 S $@
M. !' #X 1@!$ $4 2P!$ %, 0P!= $$ : !  '4 /P"% #X EP ] *L /0##
M #T Y@ ] /L /@#_ (<   !U P  : 8  %T'  !5!@  4 8  $P$  !* 0
M20 $ $< "@!&  X 10 1 $4 %@!$ !L 0P @ $( )0!! "H 0  O #\ -  ^
M #H /0!  #L 1P Z $\ .0!9 #@ 9  W '$ -@"! #4 DP T *8 - "[ #0
MW0 T /4 -0#_ 'X&  !M"0  8 L  %8,  !.#   2 L  $0*  !""   0 4!
M #\!!P ^  L /0 . #P $@ [ !< .P < #H (0 Y "4 -P J #8 ,  U #4
M-  \ #, 0P R $P ,0!5 #  8  O &T +@!] "T CP L *( + "V "P T  L
M .X + #\ '<*  !G#   6@X  % .  !)#@  0PX  #X-   [#   .0L  #@)
M P W!0@ -@(- #4!$  T !, ,P 8 #( '0 Q "( ,  G "\ +  N #( +0 X
M "P 0  K $D *@!2 "D 70 H &L )P%Z "8!C  E )\ )0"R "4 R@ E .@
M)0#W '(-  !B#@  5A   $P1  !$$0  /A$  #D0   V#P  ,PX  #$- 0 P
M"P4 , @* "\&#0 N!1$ + 04 "L#&0 J QX *0,C "@$*0 G!"\ )@4U "4%
M/0 D!48 (P90 "(&7  A!VD ( =Y !\'BP >!YT '@>P !T&Q@ =!N, '07S
M &T.  !>$0  4A(  $@3  ! $P  .A,  #42   Q$0  +A   "P/   J#@,
M*@T' "D+"P H"0X )PD1 "4(%@ D"!L (PD@ "())@ A"2P ( HS !\*.P >
M"T0 '0M/ !P,6P ;#&D &@QY !@,BP 8#)X %PRP !8,Q0 6#.$ %@OP &D0
M  !:$@  3A0  $45   ]%0  -Q4  #$4   M$P  *A(  "@1   F$ $ )! $
M ",."  C#0P (@P/ " ,$P ?#!@ '@T= !T-(P <#2H &PTR !H..@ 8#D0
M%PY0 !8/7  5#VH $Q![ !(0C0 1$*  $1"S ! /R0 0#^0 $0_R &42  !7
M%   2Q8  $(7   Z%P  -!<  "\6   J%0  )Q0  "03   B$P  (!(# !X1
M!@ =$ D '! - !L/$  9$!4 &! ; !<0(0 6$"@ %1$P !01.0 3$4, $A).
M !$26@ 0$FD $!-Y  X3C  .$YX #1.Q  T2Q0 ,$N$ #1+Q &(4  !4%@
M21@  #\9   W&0  ,1D  "P8   H%P  )!8  "$6   ?%0  '!0" !H3!  9
M$@8 %Q(+ !42#@ 4$A( $Q,8 !(3'P 1$R8 $10M ! 4-@ /%4$ #A5,  X6
M5P -%F4 #!=U  L7AP *%YH "1:M  @6P0 (%MT "17N %\6  !1&   1AH
M #T:   U&P  +QH  "H:   E&0  (A@  !\8   <%P  &18! !<6 P 5%@0
M$Q8) !$6#0 0%Q$ #Q<6  X7'  .&", #1@J  P9,P ,&3P "QI'  H:4P )
M&F$ !QMQ  8;@P %&Y< !!JJ  ,:OP #&=H !!GL %P8  !.&@  0QP  #H<
M   S'   +!P  "<<   C&P  (!H  !T9   :&0  %Q@! !48 @ 2&00 $!L'
M  X;#  -'!  #!P3  L<&0 *'!\ "1TG  @=+P ''CD !AY#  0>4  #'UX
M A]N  $?@   'Y4  !ZI   >O0  '=@  !WL %@:  !+'   01X  #@>   P
M'@  *AX  "4=   A'   'AP  !L;   8&P  %AL! !,; @ 1' 0 #AX'  P?
M"P *( X "" 2  8A%P %(1T !"$D  (B+  !(C4  ")    C30  (UH  "-K
M   C?@  (Y,  "*G   BO   (=<  "'M %4=  !('P  /B   #4@   N(
M*"   ",?   @'@  '1T  !H=   6'0  $QX  !$? @ .( 0 #2('  HD"P &
M)0T !"40  (F%   )AH  "8A   G*0  )S(  "<]   G20  *%<  "AG   G
M>P  )Y   ">E   FNP  )M8  "7M %$@  !%(0  .R(  #(B   L(@  )B$
M "(A   >(   &Q\  !@@   4(   $2(   \C   -)0, "B8&  8H"@ #*0T
M "L/   L$@  +!<  "P>   L)@  +2\  "TY   M1@  +50  "UD   M=P
M+(T  "RD   KN@  *]8  "KN $TB  !!)   ."0  # D   I)   )",  "$B
M   =(@  &2(  !4C   2)   #R8   TH   **@( !BP%  (N"0  +PL  # .
M   R$   ,Q4  #,;   S(@  ,RL  #,V   S0@  ,U   #-@   S<P  ,HH
M #*A   QN   ,-8  ##O $DE   ^)@  -"<  "TG   H)@  (R4  !\D   ;
M)0  %B8  !(H   0*@  #2P   HN   &, $  C($   T!P  -0H  #<,   X
M#@  .A(  #H7   Z'P  .B<  #HR   Z/@  .DP  #I<   Z;P  .88  #B>
M   XM@  -]0  #;O $0I   Z*0  ,2D  "LI   F*   (B<  !TH   8*0
M$RL  ! N   -,   "3(   4U   !-P   #D"   [!0  / @  #X+   _#0
M01   $,4  !#&P  0R,  $,N  !#.0  0T<  $)7  !":@  08$  $":   _
ML@  /L\  #[O #\L   V+   +RP  "HK   E*@  'RL  !DM   4+P  $#(
M  TU   (.   !#H    \    /P   $$   !# @  104  $8(  !("P  2@X
M $P1  !-%@  31X  $TH  !--   3$(  $Q1  !+9   2WL  $J4  !)K0
M2,H  $?L #LP   S+P  +2\  "@M   B+P  &S$  !4T   0-P  #3H   @]
M   "0    $,   !&    2    $H   !,    3@$  $\$  !1!P  4PL  %4.
M  !8$@  61D  %@B  !8+@  5SP  %=+  !67@  5G,  %6-  !4IP  4L(
M %+F #@S   Q,@  +#$  "4R   =-0  %C@  !$\   ,0   !T0   !'
M2@   $T   !0    4P   %4   !7    60   %H   !< P  7@<  &$+  !D
M#@  9A,  &<<  !F)P  9C0  &5$  !D5P  9&L  &*%  !AGP  8+D  %[<
M #4W   P-0  *#<  " Z   8/0  $4(   Q&   &2@   $\   !3    5@
M %D   !<    7P   &$   !D    90   &<   !I    ; $  &X&  !Q"P
M= \  '<5  !W(   =BT  '8]  !U3P  =&,  '-[  !RE0  <*\  &_) #4Z
M   K.P  (C\  !I#   22   #$T   52    5P   %P   !@    9    &@
M  !K    ;@   '$   !S    =0   '<   !Z    ?    '\   ""!   A@H
M (H/  ",%P  BR0  (HS  ")10  AUL  (9R  "%BP  @Z4  (*\ "]    E
M1   '$D  !-.   -5   !%H   !A    9@   &L   !O    =    'D   !]
M    @    (,   "%    AP   (H   ",    CP   )(   "6    F0(  )X)
M  "B$   HAH  *$I  "@.P  GU   )UG  ":@0  FID  )FO "E)   ?3@
M%50   Y;   %8@   &D   !P    =P   'T   ""    A@   (L   "/
MDP   )4   "7    F@   )T   "@    HP   *8   "J    K@   +(   "W
M"@  NQ$  +H?  "Y,   MT4  +5<  "T=   L8X  *^D ")4   86P  $&(
M  =J    <P   'L   ""    B0   )    "5    F@   )\   "C    I@
M *@   "K    K@   +    "S    M@   +H   "]    P@   ,<   #, 0
MTPL  -05  #3)@  T3H  -!1  #-:   RX$  ,J6 /P   #V    \@   /$
M  #S  4 ]  , /( $P#P !P [0 E .@ +@#B #8 W@ ^ -D 1 #4 $H T0!/
M ,X 5 #+ %D R0!> ,8 8P#$ &D P0!P +X > "\ ($ N0"- +8 F@"S *L
ML0#  *\ Y@"N /\ I0#_ )H _P"4 /\ CP#_ /0   #L    Z    .<   #?
M    V0 ) -( $ #/ !< SP @ ,P * #& #  P  W +P /@"Y $0 MP!) +4
M3@"S %, L0!7 *\ 70"M &( JP!I *D <0"G 'H I0"% *( DP"@ *( G0"V
M )L U "9 /D E@#_ (T _P"( /\ A #_ .@   #?    V0   ,D   "_
MN  $ +4 #0"S !( L0 : +  (@"M "H J0 Q *8 . "D #T H@!# *  2 ">
M $P G !1 )L 5@"9 %P EP!B )4 :0"3 '( D0!] (\ BP"- )H BP"L (D
MQ0"( .X A@#_ '\ _P!Z /\ > #_ -D   #-    NP   *X   "E    GP
M )P "0"9  \ F0 5 )D '0"8 "0 E  K )$ ,0". #< C  \ (L 00") $8
MB !+ (8 4 "% %4 @P!; (( 8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V
M .  =0#_ '( _P!N /\ ; #_ ,<   "U    I0   )D   "/    B0   (4
M! "$  P @@ 1 (( %P"" !X @  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$
M '4 20!S $\ <@!5 '  7 !O &0 ;0!N &P >@!J (H : "; &< KP!F ,P
M90#U &0 _P!A /\ 8 #_ +0   "@    D    (4   !]    =P   ',   !P
M  @ ;P . &\ $@!O !@ ;P ? &T )0!K "H :0 P &@ - !G #D 9@ ^ &4
M0P!C $@ 8@!. &$ 50!? %X 7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J
M %< _P!6 /\ 5 #_ *$   ".    ?P   '4   !L    :    &0   !A  0
M8  + %\ #P!? !, 7P 9 %\ 'P!= "4 7  J %L +P!9 #, 6  X %< /0!6
M $, 50!) %, 4 !2 %@ 40!A %  ;0!. 'L 30", $P GP!+ +4 2@#< $H
M^@!* /\ 2@#_ )(   "     <@   &<   !?    6@   %<   !5  $ 4P '
M %( # !2 !  4@ 4 %( &@!1 !\ 3P D $X *0!- "X 3  S $L . !* #T
M20!# $@ 2@!& %( 10!< $0 9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!
M /\ 0 #_ (4   !T    9P   %T   !5    3P   $P   !*    2  $ $<
M"@!'  T 1@ 1 $8 %0!& !H 10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^
M #T 10 \ $X .P!7 #H 8@ Y &\ . "  #< DP V *< -@#  #8 Z  V /X
M-@#_ 'P   !K    7@(  %0#  !- P  1P,  $,!  !!    /P ! #X !P ]
M  L /0 . #P $0 \ !8 /  : #H 'P Y "0 .  I #< +@ V #, -0 Z #0
M00 S $D ,@!3 #$ 7@ P &L +P![ "X C@ M *( +0"X "T W0 M /@ +@#_
M ',!  !D!0  5P<  $T(  !&"   0 @  #L'   X!0  -P,  #8 !  U  @
M-  , #0 #P T !( ,P 6 #( &P Q "  ,  D "\ *0 N "\ +0 V "P /0 K
M $4 *@!/ "D 6@ H &< )P!W "8 B0 F )T )0"S "4 SP E /  )@#_ &T&
M  !>"0  4@L  $@,  ! #   .@L  #8+   R"@  , @  "X& @ N P8 +0 *
M "P #0 L !  *P 3 "H %P I !P *  @ "< )0 F "L )0 R "0 .0 C $(
M(@!+ "( 5P A &0 ( !S !\ A0 ? )D '@"N !X QP > .D 'P#Z &@)  !9
M#   30T  $,.   \#@  -@X  #$-   M#0  *@P  "@+   G"00 )@8( "8$
M"P E PX ) $0 "0!%  B 1@ (0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %)
M !L!5  : 6$ &@%P !D!@@ 8 )8 & "J !@ P0 8 .$ & #T &,,  !5#@
M20\  $ 0   X$   ,A   "T/   I#@  )@X  ",-   B# , ( L& " )"0 ?
M!PP '@8. !X%$0 <!14 &P4: !H%'P :!24 &04K !@%,P 7!CP %@9& !8&
M4@ 5!U\ % =N !,'@  2!Y0 $@:G !(%O  2!-D $@/O %\.  !1#P  1A
M #P1   U$0  +Q$  "H1   F$   (A   " /   =#@( ' T% !H-!P :"PH
M&0H- !@)$  7"1( %@D7 !4)'  4"2( % HI !,*,0 2"CH $@M% !$+40 0
M#%\ #PQN  X,@  .#)0 #0NG  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3
M   R$P  +!,  "<2   C$0  'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+
M !,,#0 2#!  $@P4 !$,&@ 1#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX
M"P]M  H/?P )#Y, "0^F  @.N0 (#M  !P[H %@1  !+$@  0!,  #<4   P
M%   *10  "44   A$P  '1(  !H2   7$0( %1$% !,0!P 2$ D $0\* ! .
M#  .#@X #@\2  T0&  -$!X #! E  P0+0 +$38 "A%!  D130 ($EH !Q)J
M  82?  %$I  !!*D  ,1N  #$<\  A'H %42  !)%   /A4  #46   M%@
M)Q8  "(5   >%   &Q0  !@3   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,
M$@X "Q(1  H2%0 )$QL "1,B  @3*@ '%#, !10^  052@ #%5@  A5G  $5
M>@  %8X  !6C   4MP  %,\  !/I %(4  !&%@  .Q<  #(7   K%P  )1<
M "$6   <%@  &14  !84 0 4$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T
M"!80  86$P %%AD !!<?  ,7)P "&#   1@[   91P  &54  !ED   9=P
M&8P  !BB   8MP  %\\  !?J $\6  !#&   .1D  # 9   I&0  (QD  !\8
M   ;%P  &!8  !45 @ 3%04 $10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.
M  (;$@ !&Q8  !L=   <)   '"T  !PX   =1   '5(  !UB   ==0  '8H
M !R@   <M@  &]   !KK $P8  ! &@  -AL  "T;   F&P  (1H  !T9   9
M&0  %Q@  !07 P 2%@0 $!<$  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @
M$   (!0  "$:   A(@  (2H  "$U   B00  (D\  ")?   B<@  (8@  "&?
M   @M@  ']$  !_M $@:   ]'   ,QT  "L=   D'0  (!P  !P;   8&@
M%AD! !,9 0 1&0$ #AH!  P< @ *'0, !Q\%  ,A"   (@H  "0,   F#@
M)A(  "88   G'P  )R<  "<R   G/@  )TL  "=<   G;@  )H4  ":=   E
MM   )-$  "/N $0=   Y'P  ,!\  "@?   C'@  'AT  !L<   8&P  %!P
M !$<   .'0  #1\   HA   &(@$  R0$   F!@  * @  "H+   K#0  +1
M "T5   M'   +20  "XN   N.@  +D@  "U8   M:@  +8$  "R:   KL@
M*M   "GO $ @   V(0  +2$  "8A   A(   '1\  !H>   6'@  $A\   \A
M   -(@  "B0   8F   "*    "L"   M!   +P8  # )   R#   - X  #42
M   U&   -2   #4J   U-@  -4,  #53   T9@  -'P  #.6   RKP  ,<T
M ##O #PC   R)   *B0  "0C   @(@  '"$  !<A   3(P  $"4   TG   )
M*0  !2L   $N    ,    #(    T 0  -@0  #@&   Z"0  / T  #X0   ^
M%   /AP  #XF   ^,0  /C\  #U.   ]80  /'<  #N1   ZJP  .<D  #CM
M #<G   O)P  *"8  ",E   ?)   &24  !0F   0*   #2L   DN   %,
M #,    U    .    #H    \    /@$  $ #  !"!P  1 H  $8-  !)$0
M21<  $@A  !(+   1SH  $=)  !&6P  17$  $2+  !#I0  0L,  $'H #0J
M   L*@  )R@  "(G   <*   %BH  !$M   -,   "3,   ,V    .0   #P
M   ^    00   $,   !&    2    $H   !, P  3@8  % *  !3#@  5!,
M %0<  !3)P  4S0  %-#  !250  46H  %"#  !/G@  3;D  $S@ # M   K
M+   )BL  !\L   8+@  $C(   TU   (.0   CT   !     0P   $8   !)
M    3    $X   !1    4P   %4   !7    60$  %P&  !?"@  8@X  &,5
M  !C'P  8BP  &$\  !@3@  7V(  %Y[  !<E@  6[   %G/ "\P   J+P
M(C   !HS   3-P  #CL   @_   !1    $@   !,    3P   %(   !5
M6    %L   !=    8    &(   !D    9@   &D   !M!0  < L  '00  !T
M&   <R4  '(T  !R10  <%D  &]Q  !MBP  :Z8  &K  "XS   E-0  '3@
M !0\   .00  !T<   !,    40   %4   !9    70   &$   !E    :
M &L   !M    ;P   '(   !T    =P   'H   !^    @@0  (8+  "*$0
MB1P  (@K  "&/0  A%(  (-G  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](
M   (3@   %0   !:    8    &0   !I    ;@   '(   !V    >@   'T
M  "     @@   (4   "(    BP   (X   "2    E@   )L#  "@#   HA,
M * A  "?,P  G4<  )I>  "8=P  EX\  )6G "-#   92   $4X   E5
M7    &,   !J    <0   '8   ![    @    (8   "*    C@   )$   "3
M    E@   )D   "<    H    *,   "G    JP   +    "V!   O T  +H7
M  "Y*   MSP  +12  "R:@  KX4  *V< !Q.   35   "UP   %D    ;
M '0   !\    @P   (D   "/    E    )H   "?    H@   *0   "G
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M____________________________________________________
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M%!46%Q@9&AL<'1X?("$B(R0E)B<H*2HK+"TN+S Q,C,T-38W.#DZ.SP]/C]
M04)#1$5&1TA)2DM,34Y/4%%24U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM
M;F]P<7)S='5V=WAY>GM\?7Y_@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:
MFYR=GI^@H:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'
MR,G*R\S-SL_0T=+3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T
M]?;W^/GZ^_S]_O]M9G0Q      ,$(0   0                    $
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
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M@:>,SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^
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ME7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B
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MKWRHRZ]\J,O_LA<)_[(A'O^O+SK_JCQ9[*1)>MB;6IG&EG&RQ)AXM<*9@;G
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M@:.1U("DF=. IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=&
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M9>J77W[<DVZ3SY)XI<:2@K3$DHFVPY&.N,&.D+K BI*\OX>4O;Z$EK^^@IG
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M&RSET \RR.D/2K3R%6>BXB)]EM8WC8_.3YB,R&&@BL1NIHK!>*J'OWVMA+Z
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MS(R-JL>*D;'$B)2VPX66N,*#F;G"@9NYP7^>NL%]H;O!>Z2[P'JGN\!YJKS
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MLJO+<+:KRV^\J\APP*O$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MA]_&6X[6R&N4QKUQIK6S>+6EJ('#E)^-S8F<HM*'E*?,B)&KQXF/KL.)CK#
MB8VROHJ,L[R*B[2ZBHNTNHJ+M+J*B[2ZBHNTNHJ+M+J*B[2ZBHNTNHJ+M+K_
MG! !_Z$F"O^@-AS_GD(Q_Z5 /O^K0$S_L4!9^K=!9/.]1&_NQ4EWY<Y2?-W6
M8G_,SFB2O,5NI*N[=K2:L7_!BJJ*RW^GG<^ GZC,@IFKQX.5K<2$DZ_!A9&Q
MOX:/L[V'CK2[AXZTNX>.M+N'CK2[AXZTNX>.M+N'CK2[AXZTNX>.M+O_G1 !
M_Z(F"O^@-1S_H#\P_Z<]/?^N/$K_M3Q5^KT]8/#&0F?FT4ILWMY.=LW:5X>^
MT&*6KL5NI:&\>;*5M(.]AJV(QGNJE,IXJZC)>Z*KQWZ<K<2 F:_"@9:PP(*4
MLKZ#DK.\@Y*SO(.2L[R#DK.\@Y*SO(.2L[R#DK.\@Y*SO(.2L[S_GA !_Z(F
M"O^A-!S_HCPN_ZHZ._^R.$?\NS=1\L4Z6.;105S;WD)IS>)&?+[748RNS%^;
MH<-MJ)B\>;*1M82[A;&)PGRND<5XKI_%=:VLQ7BEKL1ZH*_"?)RPP'Z9L;Y_
MEK*]?Y:RO7^6LKU_EK*]?Y:RO7^6LKU_EK*]?Y:RO7^6LKW_GA !_Z,E"?^B
M-!S_I3DM_ZXU./^X,T+TPS-*Y] X3MG>.5K+YCUNON!"@*[44)"ARU^=F,-M
MJ)&]>;&+N(.X@[2(O7VQD,%YL9K!=;&EP7*OK\)UJ*_!=Z.PP'F?L;][G+*]
M>YRRO7N<LKU[G+*]>YRRO7N<LKU[G+*]>YRRO7N<LKW_H! !_Z0D"?^C,AS_
MJ#0K_[,O-/F_+3SIS2] V=XO2LKG-%^]ZCISK]Y!@Z'349&7RV"=D,1NIHR_
M>JV&NX&S?[B'N'JVC;MWM96\=;6?O'*TJ+UNL[*^<:RROG2GLKYVH[*]=J.R
MO7:CLKUVH[*]=J.RO7:CLKUVH[*]=J.RO7:CLKW_H1 !_Z4C"?^D,1S_K2XG
M_[DI+^[()C/:W"8WRN<L3[WR,F.OZ#EUH=U"A);44Y"/S6*:BL=PHH;#>JB
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MA! !_X,: _^+*@S_G#$2_Z4T&O^L-B'^LSHH\[M +>G#2#'ARU$WTL=62\7
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M*2C_HBHG_ZTK)O^Y+";_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+2;_R2VJMP
MFL4  (O3  !]X@  =?\% &G_# %?_Q$"5_\7 U#_'P5)_R8'1/\N"3__-@L[
M_ST--_]##S/_21$P_T\2+O]5$RS_6Q0J_V(5)_]I%B7_<A<C_WL8(?^&&1__
MD1H>_YP;'O^E'!W_L!T=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!V<P   C,X
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M^5;<4_E6W%/Y5MQ3^5;<4_E6W%/Y5MQ3^5;_7AL"_UHE _]4,0;_6#<(_V%
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MDWINCX^#=HB+CGR"B)F!?(:GA7F&N89WA]>%>(7=@WJ#WH%Z@N!_>X'A?7R
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M>&V,Y7AMC.5X;8SE>&V,Y7C_;A,!_WL1 ?^-$ #_G1  ^JP1 -J["P#5R0L
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M1#?_ZD4V_/U%._+_1#[J_T0^YO]&/N;_1C[F_T8^YO]&/N;_1C[F_T;0GP
MO:P  *ZU  "BP@  E<\  (K= P"$_Q(!>_\> W3_*@EL_S,/9/\[%EW_0QM7
M_TH@4?]1)$S_6"=(_V J1/]H+$#_<2X\_WLQ.?^(,C7_EC0S_Z0V,?^V-R__
MT#@N_^\Y+?__.3'__SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.3/\_SG!J   K[$
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M$1/_NA$3_\,2$__#$A/_PQ(3_\,2$__#$A/_PQ*7O@  ALP  '?;  !IYP
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M:7A\\&EX?/!I>'SP:7A\\&G_8!<!_VX2 ?]^$ #_C!$ _YD1 /&D$P#CKA8
MUK8< <NT, C!L#\7MZM+):VF5#.DH5U G)UE2I28;%.,E71;AI%]8G^.AVAY
MC))M=(J><7"(K71MB,%T;8GD<V^'ZG%PA.QO<H/M;7.![FMT@/!I=(#P:72
M\&ET@/!I=(#P:72 \&G_81<!_W$0 ?^"#@#_D X ]9T- ..I# #9M0P S[D:
M ,6X+@>[M#T5L;!)(Z>K4C&>IUL^EJ-C2(Z?:E&&FW)9?YAZ8'B5A&9RDX]L
M;9&<;VF0JG)FD+YS99'A<FB.ZW!JBNQN;(CM;&V&[VMNA/!I;H3P:6Z$\&EN
MA/!I;H3P:6Z$\&G_8Q4!_W4. ?^&#0#XE L W*(( -2M"0#/N H R;T7 +^\
M*P:UN3L3J[9'(:&Q4"^8K5D[CZIA1H>F:$]_HW!7>*!X7G*>@61KFXQI9IJ9
M;6*9J&]?F;QP7IG?;V"6[&YCD>UM9H[N:V>+[VIIB?!H:8GP:&F)\&AIB?!H
M:8GP:&F)\&C_9Q(!_WD, /^*"@#?F@0 TZ8' ,RQ" #'NP@ P<(3 +C"* 2N
MOS@0I;Q$'INX3BR1M5<XB+%>0H"N9DMXJVU3<:EV6FNG?V!EI8ID8*.7:%NC
MIFM9H[IL6*/<:UF@[FM<FN]J7Y;P:6&2\6ACC_%F8X_Q9F./\69CC_%F8X_Q
M9F./\6;_:Q !_WX) /&0! #6G@, S*H& ,2T!@"^O@4 N,@0 +#() .GQC4-
MG<-"&Y/ 3"B*O50S@;I</GFW9$9QM6M.:[-T5&2Q?EI?L(E?6J^68E:NI653
MKKEF4J_;95*K\F95I/)F6)_R9EJ;\V5<E_-D7)?S9%R7\V1<E_-D7)?S9%R7
M\V3_< T _X0$ -V6  #.HP, Q*X$ +NW! "TP@4 KLT, *?.( *>S3$*E<L^
M%HO(22."QE(N>L-:.'+!8D!KP&I'9+YS35Z]?%-9O(A75+N56U"[I5U.N[E>
M3;S;74NY]U].L?9@4:KV8%.E]F!5H?9@5:'V8%6A]F!5H?9@5:'V8%6A]F#_
M=P@ ZXP  -.;  #&J ( N[$" +*[ @"JQP8 HM,* )W6&@&5UBP&C-0Z$8/2
M1AUZT$\G<LY8,6K-8#ADRV@_7LIR15C*?$E4R8A-3\F544S)I5-*R;E42<K<
M4T?(]U5(P/Q82KC[64RR^UI.K?I:3JWZ6DZM^EI.K?I:3JWZ6DZM^EK_?P
MW),  ,JB  "\K $ L;4  *C  P"?RP8 EMD+ )'@&P&*WRP&@M\Y#GG>0Q=Q
MW4T@:MQ6*&/;7R]=VF<U6-EQ.E/9>SY/V8A"2]F614C9ID=&VKI(1=O;1T38
M]$E"T_]-1,G_3T7"_U!'N_]21[O_4D>[_U)'N_]21[O_4D>[_U+FB@  SYL
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M*BS__RHO^?\J+_G_*B_Y_RHO^?\J+_G_*B_Y_RJYI@  JJX  )RY  ".Q0
M@=$  '7>  !M^@D 9?\1 5[_&@)7_R,#4O\L!4S_- =(_SP*0_]$##__3 X\
M_U,0./];$C7_8Q0R_VP6+_]W%RS_A!DI_Y,:)_^B'"7_M!TD_\P>(__M'B+_
M_1\B__\?(O__'R+__Q\B__\?(O__'R+__Q^LJP  G;8  (_"  " S@  <]P
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M&P+_9QL"_VXB _]S*@3_=S4)_WA $/EW2ACR<U0@[&]>*.=K:C#B9W4VWF.
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M6(-O_%B#;_Q8@V_\6(-O_%C_5A@!_V01 ?]R#@#_?A  _X@1 /61% #HF!D
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M75:=ZUQ7FOI;6I7Z6ER1^UE>COQ87XW\5U^-_%=?C?Q77XW\5U^-_%?_:@H
M_WP  -R,  #-F   PZ,# +JJ @"SLP$ K+P* *:]'0&>O"\&EKH\$8VX1QR%
MM5 G?;-9,':Q8#AOKV@_::UP16.K>4I>JH1/6JF04E6HGE52IZ]74:C&5U"G
MZE=0I?Q74Y_]5U6:_597EOY66)7^55B5_E58E?Y56)7^55B5_E7_;P0 YH(
M -*1  #&G0  NZ8! +*N  "JMP$ HL(% )S$& "5PRH$C<(Y#87 1!A]ODXA
M=;Q6*FZZ7C)HN68X8K=N/EVV>$-8M8)'5+2/2U"TG4Y-LZY02[3%4$NSZE!*
ML?]13*O_4DZE_U)0H?]249[_45&>_U%1GO]149[_45&>_U'_=@  W8D  ,J7
M  "^H@  LZH  *FS  "@O ( F,8& )',$@"+S"4"A,LT"7S)0!)UR$H;;<=3
M(V?%7"IAQ&0P7,-M-E?"=CI3PH$_3\&.0DO!G45(P:Y&1\'%1D?!ZD9$OO])
M1;G_2D>S_TM)K?],2JO_3$JK_TQ*J_],2JO_3$JK_TSI?P  T9   ,*>  "U
MIP  JJ\  *"X  "6P0( C,L' (35#0" U1X!>=4N!7+4/ QLTT<49=)0&U_1
M62%:T6(G5=!K+%'0=3!-SX$T2<^.-T;/G3E$T*X[0M#&.T/0ZCI S?T^/LO_
M0$##_T)!O?]#0KG_1$*Y_T1"N?]$0KG_1$*Y_T3=B   QY@  +BC  "KJP
MH+0  )6^  "+R , @-$' 'CA#0!TX1T!;N$K VC@-PAAX$(.7.!-%%?@5AE3
MX%\=3^!I(DO@<R5'X'XH1."+*T+@FBT_X:LO/N+!+S[BY2\\W_HQ.=[_-#G9
M_S8ZT/\X.\S_.3O,_SD[S/\Y.\S_.3O,_SG-D@  O*   *VH  "AL0  E;L
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M$Q[__Q,>__\3'O__$Q[__Q.FJ0  F+,  (J_  ![R@  ;M4  &#?  !4YP
M3O\$ $G_#@!#_Q0 /_\= 3K_)0(V_RP",O\S R__.@,K_T$$*/](!"7_3P4B
M_U<%(/]@!AW_; <:_WD'&/^*"!;_FP@5_ZT)%/_#"1/_XPD3__@)$___"A/_
M_PH3__\*$___"A/__PJ:L0  B[T  'S(  !MU   7^   %'F  !']0  0?\
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M5F=_XU5H@/I3:7[_46I\_T]K>_]-;'G_3&QY_TQL>?],;'G_3&QY_TS_7@P
M_VP! .9Z  #6A@  RX\" ,27! "^G00 N*(. +&C(0&IHC('H9\_$9F<2AN2
MF5,EBY9<+8638S5_D6L[>HYS076,?$9PBH5+:XB13V>'G5)DAJQ48H:_56&&
MX51AAOE28X3_4&6!_T]F?_]-9W[_3&=^_TQG?O],9W[_3&=^_TS_80H _V\
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M25"9_TE2EO](5)+_1U22_T=4DO]'5)+_1U22_T?_;@  WG\  ,J-  "^F
MLZ   *JG  "AK@  E[8  )&Z$ ",NB,!A;DR!GZX/@YWMDD7<;52'FNS6B5E
MLF(K8+%J,%NP<S57KWTY4ZZ)/4^MED!,K:5"2JVY0TFNV$)(J_5#1ZK_1$FE
M_T1+H/]$39S_1$V<_T1-G/]$39S_1$V<_T3J=0  TH8  ,.3  "WG0  K*0
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M+3;*_RTVRO\M-LK_+3;*_RW%D   MIT  *BE  "<K0  C[8  (.^  !WQP
M;,\" &+6!P!:Y X 6.0< %3D*0%0Y#4#3.4_!4CE20=%Y5,*0N9<#3_F9@\\
MYG$2.N=^%#?GC!8UYYP7,^BN&3+IQADRZ.H9,>7^&2_D_QPNY/\>+>+_("WB
M_R MXO\@+>+_("WB_R"ZF@  JJ,  )VK  "0M   @[T  '?&  !KSP  7]8
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M!0[__P65KP  AKH  '?%  !HT   6ML  $SA  ! YP  -_,  #+_   N_P<
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M4@X _UT# /UI  #A<@  UGH" ,Y_!0#*@P@ Q882 +R')@&UAC8&KH-##Z>
M3ABA?%@@FWE@)Y9W:2V2=' SCG)Y-XIP@3R&;HL_@VV50W]LH45\:ZY'>FN_
M2'AKW4AX;/9&>&S_1'=L_T)W:_] =VK_/W=J_SYW:O\^=VK_/G=J_S[_5 P
M_U\  /)L  #==@  T'T" ,F#! #$AP8 OXH0 +>,(P&PBC0%J8A!#J*%3!><
M@54?EG]>)I%\9BV,>6XRB'=V-X1U?SN =(@_?'*20WAQGD9U<*Q(<V^]27%P
MV4EQ</1'<7'_1')P_T)R;_]!<F[_/W)N_SYR;O\^<F[_/G)N_S[_5@H _V(
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M1&!__T)A??]!8GO_/V-Z_S]C>O\_8WK_/V-Z_S__7@  Z6T  -9Y  #(A
MOHP  +:3  "NEP  IIL$ *"=%P":G2D"DYPW"(R:0Q"&F$T8@)95'WJ4729U
MDF4L<)!L,6R.=39GC7XZ8XN)/E^*E4%<B:-$6HFT15B)RT58B.U$6(C_0UF&
M_T%;@_] 78'_/EV _SY=@/\^78#_/EV _S[_8@  Y'$  ,]^  ##B   N9$
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M-TF:_S=)FO\W29K_-TF:_S?B=   RH,  +R/  "PF   I9X  )ND  "0JP
MA;$  'JX! !VN10 <KDE 6VY,P1HN#\(8[A)#EZW4A-:MEH85K9B'%*U:R!.
MM'4D2[2 )TBSCBI%LYTL0K.N+4&SQ2Y!L^DM0+#^+S^O_S$^K?\R0*C_,D&F
M_S)!IO\R0:;_,D&F_S+5?   PHH  +66  "HG0  G:,  )*J  "'L0  ?+<
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M%BC:_Q:SF   I:   )FG  "+L   ?K@  ''   !ER   6<X  $[3  !$VP0
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M 0O_B@(*_Y\""?^U @C_U0('__0"!___ @?__P('__\"!___ @?__P*1K0
M@K@  '/"  !DS   5M4  $C=   [X@  ,.<  "?N   C_P  (/\$ !S_#  9
M_Q$ %O\6 !/_&P 1_R$ #O\G  W_+@ *_S8 !_\^  3_2   _U0  /]B 0#_
M<P$ _X<! /^= 0#_L@$ _\H! /_J 0#_\P$ __,! /_S 0#_\P&$MP  =,$
M &7,  !6V   1]\  #GE   MZ@  (^X  !S]   8_P  %?\  !'_!  /_PL
M#?\.  G_$0 &_Q4  _\:  #_(   _R8  /\N  #_-P  _T$  /]-  #_7
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M4A&L9EP8J&1E':1B;2*A8'4FGEY^*9M=ABV87(\OE5J9,I-9I#206; VCEG
M-HQ9VS>*6?,VB5K_-(A;_S.'6_\QAEO_,(5;_R^%6_\OA5O_+X5;_R__2PP
M_U0  /M>  #B90  V&L! ,]N!0#,< @ QG(2 +YS)@&W<S8$L7!$"JMN3Q&F
M:UD8H6EA'9UG:B*997(GEF-Z*I-B@RZ08(PQC5^5-(I>H#:'7JTXA5V\.8-=
MU#F"7O X@5__-H!?_S2 7_\S?U__,7Y?_S!^7_\P?E__,'Y?_S#_30D _U8
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M.6UL_S=N;/\U;FO_-&YJ_S)N:O\R;FK_,FYJ_S+_4P  ]%\  -YJ  #-<P
MPWH  +M^  "U@0  KH,) *B%&@"BA2L"FX0Z!Y6"10Z0?T\5BGU8&X9[7R"!
M>6<E?7=O*GIV=RYV=( R<W.+-6]RECAL<:,Z:7"R/&APQCQG<.<[9W'\.6AQ
M_S=H</\U:6__-&EN_S-I;O\S:6[_,VEN_S/_5@  ZV(  -AN  #)=@  OWT
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M,UE]_S)9??\R67W_,EE]_S+O8   VVX  ,=Z  "[@P  LHL  *B0  "?DP
ME)8  (V9#@")FAX A)HN GZ9.@=YET4-=)9.$V^55AAJDUX=9I)E(6*1;29>
MCW8J6XZ!+5>-C3!4C)HS48RJ-4^,O35/C-XU3XOW-$^*_S-0B?\R48;_,5*$
M_S%2A/\Q4H3_,5*$_S'J90  TG,  ,)_  "VB   K)   **4  "8F   C)P
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M)CND_R;,>@  NX@  *Z2  "BF0  EYX  (RD  " J@  =:\  &FT  !>N08
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M!2C9L08GVLT&)]?O!B;4_PDETO\+)-'_#"/0_PTCT/\-(]#_#2/0_PVNE@
MH)T  )2D  "&K   >;0  &R[  !@P@  5,8  $C+   ^T   -=4$ "W="@ L
MX1, *^(? "GC*@ HY#4 )^0_ ";E2@ DYE4 (^9A 2'G;@$@YWX"'NB0 AWI
MI (;Z;P"&NKB AKF_ (9Y?\#&>3_!!CC_P48X_\%&./_!1CC_P6CG0  EJ0
M (BL  !ZM0  ;+T  %_$  !3R@  1\X  #S3   RV@  *M\  "7N"0 C\!$
M(?$9 !_Q(@ =\BL &_,T !GT/@ 7]$@ %?52 !/V7P 2]FX!$?>  1#XE $/
M^:H!#OG& 0[Y[0$-]O\!#?3_ 0WS_P$-\_\!#?/_ 0WS_P&9HP  BZP  'RU
M  !MO@  7\8  %+-  !%T@  .=@  "_>   FX@  '^H  !S[!@ 9_PX %_\3
M !3_&@ 2_R$ $/\H  [_,  -_SD "_]#  G_3@ &_UP !/]L  +_@  !_Y8
M /^M  #_R@  __   /__  #__P  __\  /__  #__P"-JP  ?;4  &Z_  !@
MR   4M   $/7   WW0  *^(  "+F   9Z@  %?D  !+_   0_P@ #O\.  S_
M$0 )_Q8 !O\<  /_(@  _RH  /\S  #_/0  _TD  /]7  #_:0  _WX  /^5
M  #_K   _\<  /_H  #_^@  __H  /_Z  #_^@" M0  <+\  &')  !2TP
M0]L  #7A   IY@  'NH  !7N   0^   #O\   O_   (_P  !/\&  #_"@
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M'Z=&X""D1O0@H4;_(9]'_R">1_\@GD?_'YM'_QZ:1_\>FD?_'II'_Q[_0 T
M_T8$ /],  #X4@( Z%4$ .%5" #B50T U549 ,Q7+ #%5SP"OU9*!KI550JV
M4U\.LE)H$J]0<16L3WD8JDZ!&JA-BAVE3)(?HTR<(*%+IB*?2[$CG4O ))M+
MV"692_ EEDS_))5,_R243/\CDTS_(I%-_R&13?\AD4W_(9%-_R'_0@H _TD
M /]1  #F5P  W5L! -5<!0#26PD RUP4 ,->* "\7C@"MEU&!K%;40JM65L/
MJ5AD$Z96;!>C570:H%1]'9Y3A1^;4HXBF5&7))=0H2:54*TGDE"\*)%0T"B.
M4.PHC5'^)XM1_R:+4?\EBE+_)(E2_R.(4O\CB%+_(XA2_R/_10< _TL  /!5
M  #?6P  TV   ,QA P#(808 PV$1 +MD) "U9#0"KV-"!:IA3@JE7U</H5U@
M%)Y<:!B;6W ;F%EX'I58@2&35XHDD%:3)HY5GBB+5:DJB52W*X=4RRN%5>DK
MA%7\*H-6_RB#5O\G@E;_)8%6_R2!5O\D@5;_)(%6_R3_1P, _T\  .=8  #9
M8   S60  ,9F 0#!9@0 NV8. +1I( "N:3$"J&@_!:-F2@J?950/FF-=%)=A
M91B38&T<D%YU'XY=?2*+7(8EB%N0*(5:FBJ#6:8L@%FT+7]9QRY]6>8M?%KZ
M+'M:_RI[6_\H>UO_)WM:_R9Z6O\E>EK_)7I:_R7_20  ^U(  .-<  #28P
MQV@  ,!K  "Z:P( M6L- *YM'0"H;BX!HVT\!9UK2 J9:E$/E&A:%)!F8AB-
M96H<BF-R((=B>B.$88,F@6",*7Y?ERM[7J,M>5ZQ+W==Q"]U7N(O=5[Y+75?
M_RMU7_\I=5__*'5>_R9U7O\F=5[_)G5>_R;_2P  \%4  -Y?  #-9P  PVP
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M*65J_RAE:O\H96K_*&5J_RC]4P  XU\  ,YI  #!<0  MW<  *][  "G?0
MGGT  )A^$0"3@"( CH Q HE_/@:$?4@,?WQ1$7MZ619W>6 :<W=H'F]V<"%L
M=7@E:72"*&9SCBMC<IHN8'&H+UYQNC!=<=0P77'R+EYQ_RQ></\K7W#_*6!O
M_RA@;O\H8&[_*&!N_RCQ50  WF(  ,IM  "]=0  LWL  *N   "B@@  F($
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M)DZ!_R;A8P  R7   +M[  "PA   IHH  )N.  "1D0  A),  'J5 @!UEQ(
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M%SJFKQ@YIL<8.:7J&#BC_QHWH?\;-Z#_'#>?_QPWG_\<-Y__'#>?_QS$>
MM84  *F/  "=E0  DIH  (:?  !ZHP  ;J@  &*L  !5L   4+(. $ZR&P!-
MLR@ 2[,U $FS/P%&LTD"1+-2!$&S6P8_LV0(/+-O"CJS>PPWLXH.-;*:#S.S
MK1 RL\40,K+I$#&P_A(PKO\4+ZW_%2^L_Q8OK/\6+ZS_%B^L_Q:[@0  KHX
M *&5  "6F@  B:   'VF  !QJP  9:\  %FT  !.MP  0[P% $"]$0 _O1X
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M !+@]  2WO\!$=W_ 1';_P(1V_\"$=O_ A';_P*>F@  DJ$  (2I  !VL0
M:+@  %N_  !.Q   0L@  #?,   MT   )-4  !S;   5WP4 %.D. !+J%  1
MZQT $.LF  [L,  .[3H #>Y&  ON4P *[V( "?!T  CQB0 '\J  !?*Z  3Q
MY  "\?T  N__  /M_P #[?\  ^W_  /M_P"5H0  AJD  'BR  !IN@  6\(
M $W(  ! S   --$  "K6   AVP  &>   !+D   /\ $ #?D*  OZ#P )^Q4
M!_L<  3\)  !_"P  /PW  #\0@  _%   /QA  #]=0  _(P  /RD  #\P0
M_.L  /S_  #]_P  _?\  /W_  #]_P")J0  >;(  &J[  !<Q   3LP  #_1
M   RUP  )]T  !WA   5Y0  #N@   KQ   (_0  !?\#  '_"0  _PX  /\2
M  #_%P  _Q\  /\G  #_,0  _SX  /]-  #_7P  _W4  /^-  #_I@  _\(
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M +8 _P"^ /\ R #_ -< _P#G /\ \P#_ /T _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_&RD _QTF /\<)0#_&2< _Q,L /\.- #_"T !_PA.
M ?\%6P'_ V@!_P)T ?\"?P'_ H@!_P*1 ?\"F '_ I\!_P&E /\!K #_ ;(
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M!L@MYP?$+?<)P2W_"K\M_PN]+?\,O"W_#+PL_PR[+/\,NRS_#+LL_PS_,1$
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M&X]'_QJ.1_\9CD?_&(U'_QB-1_\7C4?_%XU'_Q?_/@( _T,  .M+  #=40
MT50  ,I4 0#&4@4 P5$1 +E3(@"S53,!KE1! JI43 6F4U8(HE%?#)]09P^=
M3V\1FDYW%)A.?Q:638@8DTR1&9%,FQN/2Z8=C4NS'HM+Q1Z)2^(>ATSW'H9,
M_QV%3/\<A4W_&H5,_QF%3/\9A4S_&85,_QG_0   _$<  .50  #55@  RED
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M'G!:_QUP6O\<<%K_''!:_QS_2   YU(  --;  #%8@  NV8  +-H  "L:
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M'EMJ_Q[K4P  TV   ,)I  "V<0  K'8  *-Y  "9>0  C7<  (=Y"P"#>Q@
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M'DF!K!](@,$@1X#C'T=_^AY(?O\>2'W_'4E\_QQ)?/\<27S_'$E\_QS680
MPFX  +1X  "J@   GX4  )2'  "(AP  >XD  '",  !KC@T :(\: &:/*0!B
MD#4!7X\_ UR/2 59CE (5HY8"U.-8 Y0C&@038QR$TJ+?19(BHH818J9&D.*
MJAM"BK\;08KA&T&(^1M!AO\;087_&T*%_QI"A/\:0H3_&D*$_QK-9P  O'0
M *]^  "EA@  FHH  (Z,  ""C0  =9   &>4  !AE0@ 7I<4 %R7(P!:F"\
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M""RJ]0HKJ/\+*J;_#"JE_PTJI?\-*J7_#2JE_PVU@   J(L  )R1  "1E@
MA9P  'B@  !KI0  7Z@  %.L  !(KP  /;(  #:U"P TM14 ,[8A #*V+  Q
MMS< ,+=! "^X2P NN%4 ++A@ 2JX;0$IN7L")[F- B6YGP,DN;0#([G2 R.W
M] 0BM?\%(;3_!B&S_P<ALO\'(;+_!R&R_P>MB@  H)$  )67  "(G0  >Z,
M &ZH  !AK0  5;$  $JT   _MP  -+L  "N^ P DP@P (L(4 "+#'P APRH
M(,0T !_$/P >Q4H '<96 !S&8P ;QW, &L>% !G'F0 8R*X %\C+ !?&\0$7
MQ/\!%L/_ A;!_P,6P?\#%L'_ Q;!_P.CD0  F)@  (N>  !]I0  <*L  &*Q
M  !6M@  2KD  #Z]   TP   *L0  "+(   9S 0 $] * !'2$0 0TAH $-,E
M  _3,  .U#P #M1(  W55@ -U64 #-9X  S6C0 +V*0 "MB^  G9Y@ *UOX
M"]3_  O2_P +TO\!"]+_ 0O2_P&:F   CI\  ("F  !RK0  9+0  %>Z  !)
MOP  /<(  #+&   HR0  '\T  !?1   1U@  #-L%  C>"P &WQ$ !=\:  3@
M)  "X2X  >(Z  #C1P  Y%8  .1G  #E>P  YI(  .:J  #GR   Y_   .C_
M  #H_P  Z/\  .C_  #H_P"1GP  @J<  '2O  !EMP  5[X  $G#   \QP
M,,L  "7/   <U   %-D   [=   )X0   N4   #I!@  Z0T  .D1  #J&
MZR$  .TK  #O-P  \44  /)6  #S:   \WX  /27  #UL   ]M   /?S  #W
M_P  ]_\  /?_  #W_P"%IP  =K   &:X  !8P0  2L@  #O,   NT0  (]8
M !G<   1X   #.,   3G    Z@   /4   #T    ]04  /4+  #V#P  ]A0
M /@=  #Z)P  _#0  /]#  #_50  _VD  /^!  #_F@  _[(  /_/  #_[0
M__D  /_Y  #_^0!XL   :+H  %G#  !+RP  .]$  "W8   AW0  %N(   [F
M   (Z@   .T   #P    ^    /\   #_    _P   /\   #_!@  _PP  /\0
M  #_&   _R(  /\P  #_0   _U,  /]I  #_@0  _YD  /^O  #_PP  _]4
M /_5  #_U0#_$R@ _Q,E /\1)0#_#2< _P8M /\ -0#_ $$ _P!/ /\ 7 #_
M &D _P!T /\ ?@#_ (@ _P"0 /\ EP#_ )T _P"D /\ J@#_ +  _P"W /\
MP #_ ,P _P#? /\ [ #_ /@ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_%B4 _Q8B /\4(0#_$", _PHH /\ , #_ #T _P!+ /\ 6 #_ &0
M_P!P /\ >@#_ (0 _P", /\ DP#_ )H _P"@ /\ I@#_ *T _P"T /\ O #^
M ,@ _0#9 /L Z0#Z /8 ^0#_ /@ _P#X /\ ^ #_ /@ _P#Y /\ ^0#_ /D
M_P#_&B( _QH> /\8'0#_$QX _PXB /\*+ #_!SD _P-& /\ 4P#_ &  _P!K
M /\ =@#_ '\ _P"( /\ CP#_ )8 _P"= /\ HP#^ *D _ "P /H N0#W ,0
M]0#2 /, Y@#R /0 \0#_ /  _P#O /\ [P#_ .\ _P#P /\ \ #_ /  _P#_
M'AT _QX9 /\<%P#_%Q@ _Q,> /\1* #_#C0 _PQ! /\*3@#_"%L _P=F /\&
M<0#_!GH _P:# /X&BP#\!I( ^@:9 /@&GP#V!J8 ] :M /(&M0#P!<  [07.
M .L%Y #I!O, Y@C_ .4*_P#D"_\ Y O_ >0+_P'D"_\!Y O_ >0+_P'_(1@
M_R$3 /\@$0#_&Q( _QP: /\:) #_%B\ _Q,\ /\120#_$%4 _ YA /D.:P#V
M#G4 ] Y^ /(.A@#P#HX [@Z5 .T.FP#K#J( Z@ZJ .@.LP#F#[T Y0_, .$/
MXP#=$/, V1'_ =82_P'4$_\!TQ/_ M(3_P+2$_\"TA/_ M(3_P+_)1, _R40
M /\D#0#_(PX _R,4 /\B'@#_'RD _QPU /D90P#T&$\ [Q=; .P79@#I%W
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M!ZLN_PBI+O\(J"[_"*@M_PBH+?\(J"W_"*@M_PC_+P@ _S$  /\U  #V-P
MZC8" .<S" #D+P\ V2X; ,\Q+ #),SP Q#1) , U50&\-5\"NC5H K<U< .U
M-'@$LS2 !;$TB :P-) &KC29!ZPTH@BK-*P)J32Y":<TR@JE->4*H37X"Y\U
M_PR=-?\,G37_"YPU_PN<-?\+G#7_"YPU_PO_,P( _S4  /8Z  #E/@  W$
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M$G]'_Q%_1_\1?T?_$7]'_Q'_.P  [D,  -Q,  #,40  P50  +E4  "T40
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M$@"66R( DEPQ 8Y</0**7$<$AUM0!H-:6 F!66 ,?EEG#GM8;Q!Y5W<3=E:
M%716BQ=R5989;U6C&FU4LAML5,8;:E7F&VI5^QEJ5?\7:E7_%FI5_Q5K5?\4
M:U7_%&M5_Q3R0P  WT\  ,M8  "]70  LV$  *MB  "B8   FUP  )5>$ "0
M8!\ C&$N (AA.@*$8$4$@6!.!GY?5@E[7ET+>%UE#G9<;!!S7'03<%M]%6Y:
MB!=K6I09:5FA&V=9L!QE6<,<9%GC'&19^AID6?\89%G_%V59_Q5E6?\495G_
M%&59_Q3O1@  VE(  ,9;  "Z80  L&4  *9F  "=8P  E6$  (]B#@"+9!P
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M&E9GJAM59[T<5&?<'%1G]AI49O\856;_%U5E_Q969?\55F7_%59E_Q7B40
MRET  +MF  "O;   IG$  )EP  ".;P  @VX  'UP!0!X<A( =7,A ')S+P%O
M<SH";'-$!&ER3 9F<E0(8W%;"V!P8PU=<&L06V]T$UAN?Q55;HL74VV9&5%M
MJ!I/;;L;3FW9&DYL]!E/:_\83VO_%U!J_Q90:O\54&K_%5!J_Q7=50  Q6$
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M$SR"\!(\@?\2/8#_$CU__Q(]?O\1/7[_$3U^_Q'%9@  M7$  *I[  "?@@
MDH(  (6"  !Y@P  ;88  %^*  !8C0$ 5(X/ %*/&P!0CR< 3Y S $V0/0%+
MD$4"29!. T:05@1$CU\%0H]H!S^/<PD]CH +.HZ/##B.H TWCK,.-H[,#C:-
M[PXUB_\.-8G_#S6(_P\VA_\/-H?_#S:'_P^^;0  L'D  *6"  "9AP  C(@
M '^(  !RB@  9HT  %J1  !0E0  29<) $>8$P!%F"  1)DK $.9-@!!FD
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M AJL_P,:J_\#&JO_ QJK_P.HB   FX\  )&4  "$F@  =I\  &BB  !;I0
M3ZD  $2M   YL   +[,  ":V   >N04 &+L. !>[%@ 7O"  %KPJ !6]-0 4
MO4  $[Y+ !*^6  2OF< $;]X !"_C  0P*( #L"Z  [ X0 /O?L #[S_ !"Z
M_P$0NO\!$+K_ 1"Z_P&?CP  E)4  (>;  !YH0  :Z<  %ZL  !2L0  1;0
M #JV   ON0  );P  !V_   5PP  #\8%  O*#0 )RA0 ",H=  ?*)P 'RC(
M!LL^  7+2P $S%H  \QJ  +,?@ !S)0  ,RK  #-R   S.T  ,S_  #+_P !
MRO\  <K_  '*_P"7E@  BIP  'RC  !NJ@  8+   %*V  !%N0  .;P  "Z_
M   CPP  &\8  !/*   -S0  "-$   '4"0  U X  -45  #6'@  V"<  -DQ
M  #;/@  W$L  -U;  #>;@  WH0  -^;  #?M   WMD  -_W  #?_P  W_\
M -__  #?_P"-G0  ?Z4  '"L  !ALP  4[H  $6_   XP@  +,8  "')   8
MS0  $-$   O5   $V@   -X   #@ 0  X0D  .(.  #D$P  Y1L  .<D  #I
M+P  ZSP  .U+  #N70  [G$  .^)  #PH@  \+P  /#C  #O^0  \/\  /#_
M  #P_P"!I0  <JT  &.U  !4O0  1L0  #?(   JS   ']   !75   .V@
M!]X   #B    Y@   .D   #J    [    .X%  #O#   \1   /,7  #U(
M^"L  /LY  #]2@  _EX  /]T  #_C0  _Z8  /_   #_X0  __4  /_U  #_
M]0!TK@  9;<  %;   !'R   .,T  "K2   =V   $]T   SB   #Y@   .D
M  #L    \    /,   #T    ]@   /@   #Z    _0<  /\-  #_$@  _QL
M /\H  #_-P  _TH  /]>  #_=@  _X\  /^F  #_N@  _]$  /_1  #_T0#_
M#R0 _PXB /\+(0#_ R0 _P I /\ ,@#_ #X _P!, /\ 60#_ &4 _P!P /\
M>@#_ (0 _P", /\ D@#_ )D _P"? /\ I0#_ *L _P"R /\ N@#_ ,4 _P#3
M /\ YP#_ /0 _P#_ /X _P#_ /\ _@#_ /X _P#^ /\ _@#_ /X _P#_$2$
M_Q > /\-'0#_!Q\ _P C /\ +0#_ #H _P!( /\ 50#_ &$ _P!L /\ =@#_
M '\ _P"' /\ C@#_ )4 _P"; /\ H0#_ *< _@"N /T M@#\ ,  ^P#- /D
MX@#X /  ]P#\ /8 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#_%1T _Q,:
M /\0&0#_"QD _P = /\ *0#_ #8 _P!# /\ 4 #_ %P _P!G /\ <0#_ 'H
M_@"# /P B@#Z )$ ^0"7 /@ G0#W *, ]0"J /0 L@#R +L \0#( .\ W #N
M .P [0#Z .L _P#J /\ Z@#_ .H _P#J /\ Z@#_ .H _P#_&!D _Q85 /\3
M$P#_#A, _PL: /\') #_ C  _P ^ /\ 2P#_ %< _P!B /P ; #X '4 ]0!^
M /( A0#Q (P [P"3 .X F0#L *  ZP"F .D K@#G +< Y@## .0 U #B .D
MX0#W -\ _P#= /\ W0#_ -T _P#= /\ W0#_ -T _P#_&Q, _QH0 /\6#@#_
M$@X _Q(5 /\/'P#_#"L _PDX /\&10#[ U$ ]P)< /("9@#N G  Z@)X .<"
M@ #F X< Y .. .(#E0#A YP WP2C -T$JP#;!+0 V 7  -8%T #3!N< T CX
M ,X*_P#,"_\ RPS_ ,L,_P#+"_\ RPO_ ,L+_P#_'Q  _QX+ /\:!P#_&0L
M_Q@1 /\6&0#_$B0 ^A P /,./@#N#4H Z0Q6 .4,80#B#&H W@US -L->P#9
M#8, U@V* -0-D0#2#9D T Z@ ,\.J0#-#K, RPZ_ ,H/T #&$>D PA+Y +\3
M_P"]$_\!O!/_ ;P3_P&\$_\!NQ/_ ;L3_P'_(@P _R$$ /\@  #_(04 _Q\,
M /\<$0#V&!P [!4H .43-@#?$D, V1-/ -,46@#0%60 S19M ,L6=0#)%WT
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M!I4N_P65+O\%E2[_!94N_P7_+   _RX  .HU  #=.0  T3D  ,HV  #'+P8
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M//\(@3S_"($\_PC_,P  [#H  -I#  #*1P  OTD  +='  "Q0@  K3X* *9
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M"W%&_POS.0  X$0  ,Q,  "^40  M%,  *I2  "B3@  G4H! )=+$0"332
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M$F)4J1-@5+H47U33%%Y4\A->5/\17U3_#U]4_PY?4_\-7U/_#5]3_PWG1
MSU   +]8  "S70  J%\  )Q=  "26P  BU@  (5:"@"!6Q8 ?5PD 'I=,0!W
M73P!=%U& G%=3@1O7%4%;%Q=!VI<9 EH6VP+95IU#6-:?P]A68L17EF8$EQ8
MIQ1;6+@465G0%%E8\!-96/\16EC_$%I8_PY:5_\-6E?_#5I7_PWC2   RU,
M +M;  "P80  I&(  )=A  ".7P  A5P  ']>!P![7Q, >&$A '5B+@!R8CD!
M;V)# FQA2P-J85,%9V%:!V5@8@EC8&H+8%]S#5Y>?0];7HD165V6$E==I1-5
M7;845%W.%%1=[A-47?\155S_$%5<_PY56_\.5EO_#59;_PW>3   QU8  +A?
M  "M9   H&4  )-D  ")8P  ?V$  'EB P!U9!$ <F4> &]F*P!L9S<!:F=
M F=F20-E9E$$8F58!F!E8 A=9&<*6V1P#%EC>PY68X805&*4$E)BHQ-08K03
M3V+,$T]B[1)/8?\13V'_$%!@_PY08/\.4&#_#5!@_PW93P  PUH  +1C  "I
M:0  FV@  (]G  "$9P  >64  '-G  !O:0X ;&H; &EK* !G;#0 9&P] 6)L
M1@)?:TX$76M6!5IJ70=8:F4)5FEN"U-I> U1:(0/3FB2$$QGH1)+9[(226?)
M$DEGZQ))9O\02F;_#TIE_PY+9?\-2V3_#4MD_PW15   OEX  +%G  "F;0
MEVP  (IK  !_:P  <VL  &UM  !H;@P 97 7 &)Q) !@<3  7G$Z 5QQ0P)9
M<4L#5W%3!%5P6@92<&('4'!K"4YO=0M+;X(-26Z/#T=NGQ!%;K 11&['$4-M
MZA!$;/\/1&O_#D5K_PU%:O\-16K_#45J_PW+6   NF,  *UL  "A<0  DG
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M"#""_P@P@?\(,('_"#"!_PBW:P  JG8  *!_  "0?@  @GX  '9_  !J@
M7H,  %.'  !*BP  08X" #V0#@ [D!@ .I$C #F1+0 XDC< -Y)  #:220 T
MDU( ,Y-< 3&39P$ODW0"+9*# RN2E ,JDJ<#*)*]!"B2X0,GD/H$)X[_!2>-
M_P4GC/\%)XS_!2>,_P6Q=   I7X  )F%  "*A   ?80  &^%  !CB   6(L
M $V/  !#DP  .I<  #*:!P NFQ  +9L: "R<)  KG"X *ITX "F=00 HG4L
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M  FR_P":C0  D),  (28  !TG   9:   %>D  !+J   0*P  #6P   JLP
M(;4  !BX   1NP  #+X"  ; "P "P!$  <$9  #!(@  PBL  ,(V  ##0@
MPU   ,1?  #$<0  Q(<  ,2=  #$M0  Q-H  ,3V  ##_P  P_\  ,/_  ##
M_P"3E   AYH  'B@  !JI@  7*P  $^Q  !!M0  -;<  "FZ   ?O0  %L
M !##   *Q@   \H   #,!0  S P  ,T1  #.&   SB$  - J  #1-0  TT,
M -12  #48P  U7@  -6/  #5IP  UL(  -;I  #6_0  UO\  -;_  #6_P"*
MFP  >Z(  &RI  !>L   4+8  $*Z   TO0  *,$  !W$   4QP  #<L   ;.
M    T@   -<   #9    V@4  -P+  #=$   WQ4  .$=  #C)P  Y3,  .="
M  #H5   Z&<  .E^  #IEP  ZJ\  .K.  #K[P  Z_X  .O_  #K_P!]HP
M;JL  %^R  !1N@  0L   #3#   GQP  &\L  !+/   +TP   M@   #=
MX0   .0   #E    YP   .D   #K!P  [0T  .\1  #Q&0  ]"0  /<Q  #Y
M00  ^E4  /IJ  #[A   ^YT  /RV  #\T@  _>T  /WT  #]] !QK   8;4
M %*]  !$Q   -,D  ";-   :T@  $-@   C=    X0   .4   #H    [
M .\   #Q    \P   /4   #W    ^0$  /L(  #^#@  _Q4  /\A  #_+P
M_T$  /]6  #_;0  _X<  /^@  #_M@  _\H  /_4  #_U #_"R  _P<> /\
M'0#_ "  _P E /\ +@#_ #L _P!) /\ 5@#_ &( _P!M /\ =@#_ '\ _P"'
M /\ C@#_ )0 _P": /\ H #_ *8 _P"M /\ M0#_ +X _P#+ /\ X0#_ /
M_@#] /T _P#] /\ _0#_ /T _P#\ /\ ^0#_ /D _P#_#1T _PL: /\$&0#_
M !H _P ? /\ *@#_ #< _P!% /\ 40#_ %X _P!H /\ <@#_ 'H _P"" /\
MB0#_ )  _P"6 /\ G #^ *( _ "I /L L #Y +D ^ #& /8 V0#U .L ] #Y
M /, _P#R /\ \P#_ /, _P#S /\ \P#_ /, _P#_$!D _PX5 /\(% #_ !0
M_P 9 /\ )0#_ #( _P!  /\ 3 #_ %D _P!C /X ;0#\ '4 ^@!] /D A #W
M (L ]@"1 /0 EP#S )X \@"D /  K #N +0 [0#  .L SP#I .8 Z #U .8
M_P#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#_$A0 _Q 0 /\,#P#_ Q  _P 5
M /\ ( #_ "P _P Z /\ 1P#Z %, ]P!> /0 9P#Q '  [P!X .T ?P#K (8
MZ@", .@ DP#G )D Y0"@ ., IP#A +  WP"Z -T R0#; .  V #P -< _@#5
M /\ U #_ -, _P#3 /\ TP#_ -, _P#_%1  _Q(, /\."0#_"PP _PD2 /\#
M&@#_ "8 _0 S /0 0 #O $T ZP!8 .@ 80#E &H X@!R .  >@#> (  W "'
M -H C@#8 )4 U "< -( HP#0 *P S@"V ,P Q #* -D R #M ,< ^P#% /\
MQ '_ ,,!_P#$ ?\ Q '_ ,0!_P#_& L _Q4% /\0  #_$ 8 _P\- /\,% #\
M!Q\ \0,K .< .0#B $8 W@%1 -H"6P#5 F0 T@-L ,\#= #-!'L RP2" ,H$
MB0#(!9  Q@68 ,0%H #"!JD P0:T +\&P0"]"-4 NPGL +@+_0"V#/\ M0W_
M +0-_P"T#?\ M W_ +0-_P#_&P4 _Q@  /\7  #_%@  ^Q,& /H0#@#N#!8
MXPDB -H), #3"CX S@M* ,H,50#'#5X Q0UG ,(.;P#!#G8 OPY^ +T/A0"\
M#XT NA"5 +@0G0"W$*< M1&R +,1P "R$=4 KA/N *L4_@"I%?\ IQ7_ *<5
M_P"F%/\!IA3_ :84_P'_'P  _QP  /H>  #K'@  XQP  -\5!0#>#@T TPX8
M ,L1* #%$S< P!1$ +P63P"Y%UD MQ=A +08:0"S&7$ L1EX *\:@ "N&H@
MK!N0 *L;F0"I&Z, IQRN *8<O "D'<\ H1[J 9X>_ &<'_\!FQ__ 9H?_P&:
M'O\!F1[_ 9D>_P'_(@  _R$  .PG  #@*@  U"D  ,TD  #*' @ Q!D2 +T<
M(@"W'C$ LR ^ *\A20"M(E, JB-< *@D9 "F)&P I"1S *,D>@"A)8(!H"6+
M 9XEE &=)9X!FR:J 9DFMP&8)LD"E2?F I(G^0*0*/\"CRC_ HXG_P*.)_\"
MCB?_ HXG_P+_)@  \BD  .,Q  #2-   R#0  , P  "[*0( N",. +$F' "L
M*"L J"HX *0K1 "A+$X GRU7 )TM7P";+6<!F2UN 9@N=0&6+GT"E"Z& I,N
MD *1+IH#CRZF XTNLP.,+L4#BB_A!(<O]@2%+_\$A"__ X0O_P.#+_\#@R__
M X,O_P/[*0  ZS$  -DX  #)/   OSP  +8Y  "P,@  K"T+ *<O%P"B,28
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M"'!!J0EO0;D*;4'0"FQ![@EK0O\(:D+_!VI!_P9J0?\&:D'_!6I!_P7M-P
MUD(  ,1)  "W30  JTT  *!*  "81P  DT(  (Y##0")11H AD8H (-'- "
M2#\ ?DA( 7M(4 )Y2%<"=TA? W5(9@1S1VX%<4=V!F]'@ =M1HP):T:8"FE&
MI@MG1K8+9D;,"V5&[ MD1_\)9$;_"&1&_P=D1O\&9$7_!F1%_P;H.P  T$8
M +]-  "S40  I5$  )I.  "22P  C4<  (=("P"#2A8 ?TLD 'U,,0!Z33P
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M#5-3Y@Q34_P+4U/_"512_PA44O\(5%+_!U12_P?:1@  PU   +58  "H6P
MF5H  (U8  "$5P  >U0  '96 0!Q5P\ ;ED; &Q:* !I6C, 9UL] 65;10%C
M6TT"85I5 U]:7 1=6F0%6UEL!EA9=@A668()5%B/"U)8G@Q06*X-3UC##4Y8
MY Q.6/L+3U?_"4]7_PA/5O\(4%;_!U!6_P?32@  P%0  +)<  "C7@  E5T
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M"#]E_P<_9?\'/V3_!S]D_P?#5P  LV$  *=I  "6:   AV<  'MG  !Q9P
M96@  %QJ  !8; $ 5&X. %)O& !0;R0 3G N $UP. !+<4$ 2G%) 4AQ40%&
M<5D"1'!B T)P; 1 <'@%/G"&!CQOE0<Z;Z8(.&^["#AOVP<X;O8'.&W_!SAL
M_P8Y:_\&.6K_!CEJ_P:]7   KV8  *)M  "1;   @FL  '=K  !L;   86X
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M B&%_P*K<@  H7P  (][  " >@  <WH  &9\  !;?P  4((  $:&   \B@
M-(T  "R1   FDPP ))03 ".4'  BE28 (94O ""5.  ?ED( 'I9, !V66  <
MEF0 &I=T !F7A@ 8EYD %Y>N !67R0 6E>X %I/_ 1:2_P$6D?\!%I#_ 1:0
M_P&E>P  F8,  (F!  ![@   ;((  %^$  !4B   28L  #^0   UE   +9<
M "6:   =G@$ %J , !2A$@ 4H1L $Z$E !*A+@ 1HC@ $:)# !"B3P /HEP
M#J-K  VC?0 -HY( #*.G  JBP  +HN8 #*#^  V?_P -GO\ #9W_  V=_P">
MA   DHD  (.(  !SB   98L  %B.  !,D@  09<  #>;   NG@  )*(  !RE
M   5J   #ZL$  JN#  'K1( !JT;  6M)  $KBX  JXY  &N10  KE(  *YA
M  "N<P  KH<  *Z=  "NM   KM4  *WT  "M_P  K/\  *O_  "K_P"6BP
MC)   'N0  !KD@  798  %":  !$GP  .:,  "^G   EJP  '*X  !2Q   .
MM   ";<   &X"0  N X  +D4  "Y'   NB4  +HO  "[.@  O$<  +Q6  "\
M9P  O'L  +R1  "\J0  O,0  +SK  "[_@  N_\  +O_  "[_P"0D@  @Y@
M '.;  !CGP  5:,  $>H   [K0  ,+$  "6T   ;MP  $KH   R]   %OP
M ,,   #$ @  Q0H  ,4.  #&%   QQL  ,@D  #*+@  S#H  ,U)  #-60
MS6P  ,Z#  #.FP  S;4  ,[:  #.]@  S?\  ,W_  #-_P"&F0  =Z   &FF
M  !:K   3+(  #ZV   PN0  )+P  !F_   1P@  "L4   +)    S    -
M  #1    T@$  -,(  #5#0  UQ$  -H8  #<(0  WRP  .$Z  #B2@  XUT
M .1R  #DBP  Y:4  .7   #EY@  Y?@  .7_  #E_P!ZH0  :ZD  %RO  !-
MM@  /[P  #"_   CPP  %\<   _*   'S@   -$   #6    W    -\   #@
M    X@   .0   #F P  Z D  .D.  #L%0  [AX  /$K  #T.@  ]4T  /9A
M  #W>0  ^),  /BM  #YQ@  ^>0  /GS  #Y\P!MJ@  7K(  $^Z  ! P0
M,<4  "+)   6S@  #=(   38    W0   .$   #D    Z    .L   #M
M[P   /$   #S    ]@   /@#  #Z"P  _1$  /\;  #_*0  _SL  /]/  #_
M9@  _W\  /^9  #_KP  _\,  /_6  #_U@#_!!P _P 9 /\ &0#_ !P _P B
M /\ *P#_ #@ _P!& /\ 4P#_ %X _P!I /\ <@#_ 'H _P"" /\ B0#_ (\
M_P"5 /\ FP#_ *$ _P"H /\ KP#_ +D _P#% /\ V0#^ .P _0#[ /L _P#[
M /\ ^P#_ /H _P#T /\ \ #_ /  _P#_!Q@ _P$5 /\ % #_ !8 _P ; /\
M)@#_ #0 _P!" /\ 3@#_ %H _P!D /\ ;0#_ '4 _P!] /\ A #_ (H _0"0
M /P E@#Z )T ^0"C /@ JP#W +0 ]0"_ /0 S@#S .8 \0#V /  _P#O /\
M[P#_ .X _P#N /\ Z@#_ .H _P#_"Q0 _P81 /\ $ #_ !  _P 6 /\ (@#_
M "X _P \ /\ 20#_ %0 _@!? /L : #Y '  ]P!X /4 ?P#S (4 \@"+ /
MD@#O )@ [0"? .P I@#J *X Z "Y .< QP#E -X XP#P .( _@#@ /\ X #_
M .$ _P#A /\ X0#_ .$ _P#_#1  _PD- /\!# #_  P _P 2 /\ ' #_ "@
M_  V /D 0P#V $X \@!9 .\ 8@#L &L Z@!R .@ >0#F (  Y "& .( C #A
M ), WP": -T H0#; *H V "T -4 P #2 -, T #J ,X ^@#- /\ S0#_ ,T
M_P#, /\ S #_ ,P _P#_$ P _PP' /\# @#_  @ _P . /\ %@#V "( \  O
M .P / #I $@ Y0!3 .$ 7 #> &4 VP!L -< <P#4 'H T@"  -  AP#. (X
MS "5 ,H G0#( *4 Q@"O ,0 NP#" ,L P #E +X ]0"] /\ O #_ +P _P"\
M /\ O #_ +P _P#_$04 _PX  /\*  #_" $ _P0* /@ $ #I !H XP H -X
M-0#9 $$ TP!, ,\ 5@#+ %\ R0!F ,8 ;@#$ '0 P@![ ,$ @@"_ (D O0"0
M +P F "Z *$ N "K +8 MP"T ,< L@#@ +$!\@"O O\ K@/_ *T$_P"M!/\
MK03_ *T$_P#_%   _Q   /\/  #R#0  Z@H  .D#"0#= !( U  ? ,T!+0#(
M CH Q -% , #4 "]!%D NP5A +D%: "W!F\ M09V +0'?0"R!X0 L0B, *\(
ME0"M"9X JPFH *H*M0"H"L4 I@O? *0-] "B#O\ H [_ )\._P"?#O\ GP[_
M )\._P#_%P  _Q,  .\8  #D&0  VQ8  -(0 @#/"0L R @6 ,$*) "\##(
MMPT^ +0.20"Q#E, KQ!; *T08P"K$&H J1%Q *@1> "F$8  I1&( *,2D0"A
M$IL H!.F )X3LP"<$\, FQ3> )<6] "5%O\ E!?_ ),7_P"2%_\ DA;_ )(6
M_P#_&@  ]!T  .4C  #5)0  RB0  ,(=  "^%@0 NQ 0 +03'0"O%2L JQ8X
M *<80P"E&4T HAE6 * :70">&V4 G1ML )L<<P":''L F!R# )<=C0"5'9<
MDQZB )(>KP"0'K\ CQ_8 (P@\0&)(/\!B"#_ 8<@_P&'(/\!AB#_ 88@_P'Z
M'@  ZR8  -HM  #*,   OBX  +4H  "P(@  KAL, *@=%P"C'R8 GR$S )PB
M/@"9(T@ ER11 )4D60"3)6  DB5G ) F;@".)G8 C29_ (LFB &*)Y,!B">>
M 88GJP&$)[L!@RC1 8 H[@%^*?\!?2G_ 7PH_P%\*/\!?"C_ 7PH_P'U)
MXRX  ,\U  #!.   M#8  *LQ  "E+   HB8& )XF$P"9*"$ E2HN )(K.0"/
M+$0 C2U, (LM5 ")+EP ARYC (8N:@&$+G(!@BYZ 8$OA %_+X\"?2^: GLO
MIP)Z+[<">"_, G8PZ@)U,/X"<S#_ G,P_P)S+_\"<R__ G,O_P+P*@  W#4
M ,<[  "Z/P  K#P  *(X  "<,P  F"\  )4N$ "0,!P C#(I (DS-0"&-#\
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M!EY!X@9>0?D%74'_!%U _P-=0/\#74#_ UU _P/?.0  R$,  +E*  "I2P
MFTD  )!'  "(1   @T$  'Y!!@!Z0A$ =D,> '1%*@!Q134 ;T8_ &U&1P!K
M1D\!:D96 6A&70)F1F4"9$9M V)&=@1@1H($7D:.!5Q%G 9;1:P&64:_!UA&
MWP981O<%5T7_!%=%_P171/\#6$3_ UA$_P/:/0  Q$<  +5.  "D3@  EDP
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M!4A1_P1)4?\$25#_ TE0_P/*2   N5(  *I7  "85@  BE4  ']4  !V4P
M;%$  &=3  !B5 @ 7U82 %U7'@!;5RD 65@S %A8/ !6640 55E, 5-94P%1
M65L"3UAD DU8;0-+6'@$25B&!4=7E09%5Z4&1%>X!D-8T@9#5_(&0U;_!4-5
M_P1$5?\$1%3_ T14_P/&3   M58  *5:  "460  AE@  'M8  !Q5P  9E8
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M S)D_P.W6P  J60  )9D  "&8P  >&,  &UC  !D9   664  %!H  !):P
M0VT$ $!N#@ ^;Q@ /6\B #QP*P Z<#0 .7$] #AQ10 W<4X -G%7 #1Q80$R
M<6T!,7%Z 2]QB@(M<9P"*W&O BIQR (J<.L"*F__ BIM_P(J;/\"*VS_ BML
M_P*Q80  I&D  )!H  " 9P  =&<  &EG  !?:   56L  $MN  !#<0  /'0
M #=V"@ T=Q( ,W@< #)X)0 Q>2X ,'DW "]Y/P N>4@ +'I2 "MZ7  J>F@
M*'IV "9ZAP$E>ID!(WJL 2)ZQ0$B>>D!(G?_ 2)V_P$B=?\"(G3_ B-T_P*L
M:   G6X  (IM  ![;   ;VP  &5L  !:;@  4'$  $5U   ]>   -GP  "Y_
M @ I@0T )X(4 ":"'@ E@B< )((O ".#.  B@T( (8-+ ""$5@ ?A&( 'H1Q
M !R$@@ ;A)4 &H2I !B$P0 8@^8 &('] !F _P$9?_\!&7[_ 1E^_P&F<
ME7,  (1R  !V<0  :W$  %YS  !4=@  27D  #]]   W@0  +X0  ">(   @
MBP4 &XT. !J-%0 9C1X &(XG !>.,  6CCD %8Y# !2/3P 3CUL $H]J !&/
M>P 0CX\ #X^D  Z/NP -C^  #HWZ  ^+_P 0BO\ $(G_ !")_P"A>@  CGD
M 'YW  !R=P  9'@  %A[  !-?@  0H(  #F&   OB@  )XX  ""1   8E0
M$I@%  Z:#@ -FA0 #)H=  N:)@ +FC  "IH[  F:1@ (FE, !IMA  6:<@ $
MFH8  IJ;  ":L0 !F<\  IGP  *8_P $E_\ !9;_  66_P"9@0  AW\  'I^
M  !K?@  78$  %"%  !%B0  .XT  #&2   HE@  'YD  !B=   1H   #*,"
M  :E"@ !I1   *46  "F'P  IB@  *8R  "G/0  ITH  *=8  "G:   IWP
M *>1  "FJ   IL,  *7I  "E_   I?\  *3_  "D_P"1AP  @H8  '*&  !C
MB   58P  $F1   ]E@  ,IH  "B>   ?H@  %Z8  !"I   +K   !*\   "Q
M!@  L0P  +(1  "R%P  LQ\  +,H  "T,@  M3\  +5-  "U70  M7   +6&
M  "UG0  M;8  +7<  "T]P  M/\  +3_  "T_P"+CP  >HX  &J1  !;E0
M39H  $"?   UI   *J@  ""L   6L   #[0   FW   !N0   +T   "^
MO@8  +\,  # $   P18  ,(=  ##)P  Q3(  ,9   #&40  QV,  ,=X  #'
MD0  QZD  ,?'  #'[   Q_X  ,?_  #'_P"#EP  <9H  &&>  !2HP  1:D
M #BN   LLP  (+<  !:Z   .O0  !L    ##    QP   ,D   #*    S
M ,T#  #."0  T X  -(3  #4&P  V"4  -LR  #=0@  W50  -YI  #>@0
MWIP  -^U  #?V0  W_,  -__  #?_P!WGP  :*8  %FM  !*LP  .[@  "V[
M   ?OP  %,(   S&   #R0   ,P   #0    U0   -D   #:    W    -X
M  #@    X@4  .0+  #G$   ZA@  .TD  #P,@  \40  /)8  #S;P  ](H
M /2D  #TOP  ]-\  /3S  #T] !JJ   6Z\  $RW   ]O0  +<$  !_&   3
MR@  "\X   #2    UP   -P   #@    Y0   .<   #I    ZP   .T   #O
M    \0   /,   #V!P  ^0X  /P6  #_(@  _S,  /]'  #_70  _W8  /^1
M  #_J0  _[X  /_8  #_VP#_ !@ _P 6 /\ %0#_ !@ _P > /\ )P#_ #8
M_P!# /\ 3P#_ %H _P!D /\ ;0#_ '4 _P!] /\ A #_ (H _P"0 /\ E@#_
M )P _P"C /\ JP#_ +0 _@"_ /T SP#[ .< ^@#X /D _P#Y /\ ^0#_ /4
M_P#N /\ Z0#_ .< _P#_ !0 _P 1 /\ $0#_ !( _P 7 /\ (P#_ #$ _P ^
M /\ 2@#_ %8 _P!@ /\ : #_ '  _P!X /T ?@#\ (4 ^@"+ /D D0#X )@
M]P"> /4 I@#T *X \@"Y /$ QP#O .  [@#R .P _P#L /\ [ #_ .L _P#E
M /\ X #_ -X _P#_ Q  _P . /\ #0#_  T _P 3 /\ '@#_ "L _P X /\
M10#^ %  ^P!: /@ 8P#U &L \P!R /$ >0#O '\ [@"& .P C #J )( Z0"9
M .< H #F *D Y "S .$ P #@ -, W@#K -P ^P#; /\ V@#_ -H _P#9 /\
MU #_ -( _P#_!PT _P ) /\ !@#_  D _P / /\ & #[ "4 ^  R /4 /P#R
M $H [0!4 .H 70#G &4 Y !L .( <P#@ 'H W@"  -P A@#: (T UP"4 -0
MFP#2 *0 SP"M ,T N0#+ ,D R0#D ,@ ]@#& /\ Q0#_ ,8 _P#' /\ QP#_
M ,< _P#_"@8 _P$  /\   #_  0 _P + /0 $@#O !\ Z@ L .4 . #B $,
MW0!. -D 5P#4 %\ T0!G ,X ;0#, '0 R@!Z ,@ @ #& (< Q0". ,, E@#!
M )X OP"H +T LP"Z ,( N0#; +< \ "U /\ M@#_ +4 _P"U /\ M0#_ +4
M_P#_#   _P0  /\   #^    ]@ # .@ #0#@ !< V0 D -$ ,0#- #P R@!'
M ,8 40## %D P !@ +X 9P"\ &X N@!T +D >P"W (( M0") +, D0"R )H
ML "D *X KP"L +T J@#0 *@ ZP"G /L I@#_ *8 _P"E /\ I0#_ *4 _P#_
M#0  _P<  /0)  #J"0  X@0  -H !P#/ !$ R  < ,( *0"^ #4 NP!  +<
M2@"T %, L@!; +  8@"N &@ K !O *L =0"I 'T J "$ *8 C0"D )8 HP"@
M *$ JP"? ;D G0/, )P$Z ":!OD F0?_ )@(_P"7"/\ EPC_ )<(_P#_$
M]Q   .@4  #<%0  SA$  ,8-  #"! L O  4 +<!(0"R RX K@4Z *L&1 "H
M"$T I@A5 *0)7 "B"F, H IJ )\+<0"="W@ G N  )H,B0"9#), EPR> )4-
MJ@"4#;@ D@W, ) .Z@".$/P C!#_ (L0_P"+$/\ BQ#_ (H0_P#[$P  [1H
M -T@  #,(0  OQT  +<7  "S$0  L@L- *L-&0"G#B8 HP\S )\0/@"=$4<
MFA%0 )@25P"6$EX E1-E ),3; "2$W, D!1\ (\4A0"-%8\ BQ6: (H5IP"(
M%K4 AA;) (07YP""&/L @!G_ '\9_P!_&?\ ?QC_ '\8_P#U&@  Y",  ,\I
M  # *@  LR8  *HB  "E'   I!4( * 4$P";%B$ EQ@M )09. "1&D( CQM+
M (T<4@"+'%D B1U@ (@=9P"&'F\ A1YW (,?@ ""'XL @!^7 'X@HP!](+(
M>R#% 'DAY !W(OD =B+_ '4B_P!T(?\ ="'_ '0A_P#O(0  VRL  ,<Q  "V
M,0  J2X  * J  ";)@  F"$! )4>$ "0(!L C2$H (DC,P"')#T A21& (,E
M3@"!)E4 ?R9< 'XF8P!\)VL >R=S 'DG? !X*(< =BB3 '0HH %R**\!<2G!
M 6\IX %M*?<!;"G_ 6LI_P%K*?\!:RC_ 6LH_P'H*   T#(  , X  "N-P
MH34  )@R  "2+0  CBD  (LG# "'*!< @RHC ( K+P!^+#D ?"Q" 'HM2@!X
M+E$ =RY8 '4N8 !S+V< <B]O ' O>0%O+X,!;2^0 6LOG0%I+ZP!:#"^ 6<P
MVP%E,/4!9##_ 6,P_P%C+_\!8R__ 6,O_P'B+@  RC@  +H]  "H/   FCH
M )$W  "*,P  AC   (,N"0!_+Q, >S ? '@R*P!V,S4 =#,^ '(T1@!P-$X
M;S55 &TU7 !L-60 :C5L 6@U=0%G-8 !936, 6,UF@)A-JD"8#:[ E\VU@)=
M-O,"73;_ EPV_P%<-?\!7#7_ 5PT_P'<,P  Q3P  +1!  "B0   E3X  (L\
M  "$.0  ?S8  'LT! !W-1  =#<< '$X)P!O.3( ;3D[ &LZ0P!J.DL :#M2
M &<[60!E.V$!8SMI 6([<@%@.WT!7CN* EP[EP);.Z<"63NX U@[T@-7._$"
M5CO_ E8[_P)6.O\!5CK_ 58Y_P'4-P  P$$  *]$  "=0P  D$(  (5   !^
M/@  >3L  '0Z  !Q.@X ;3P8 &L]) !I/B\ 9S\X &4_0 !D0$@ 8D!/ &%
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M T=)R@-&2>P#1DC_ D9(_P)'1_\"1T;_ D=&_P+&0P  MDP  *),  "13
MA$L  'E*  !P20  :48  &1'  !?208 7$H0 %I+&P!83"4 5DPO %5-. !3
M34  4DU( %%.3P!/3E< 3DY? 4Q.:0%*3G,"2$V  D9-CP-%39\#0TVQ T)-
MR -!3>H#04S_ D%,_P)"2_\"0DK_ D)*_P+"1P  LT\  )Y/  "-3@  @$X
M '5-  !L3   8TH  %Y,  !:30( 5DX. %1/& !24"( 45$L $]1-0!.4CT
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M C%:_P(Q6?\",EG_ 3)8_P&V5   I%D  )!8  " 6   <U<  &E7  !@6
M5%D  $Y;  !(70  0U\$ $!@#@ ^81< /6$@ #MB*0 Z8C( .6(Z #AC0@ W
M8TL -F-4 #1C70 S8V@ ,6-V 2]CA0$N8Y8!+&.I 2MCOP$J8^,!*F+[ 2I@
M_P$K7_\!*U__ 2M>_P&Q60  GEP  (M<  ![6P  ;UL  &5;  !<7   45X
M $E@  !#8@  /&4  #AG"@ U:!( -&@; #-I)  R:2T ,6DU "]J/0 N:D8
M+6I/ "QJ60 K:V4 *6MR "AK@@ F:Y, )&NG "-KO0 B:N  (VGY 2-G_P$C
M9O\!(V;_ 21E_P&L8   F&   (5@  !V7P  :E\  &%@  !78   36,  $1F
M   ]:   -FL  #!N!  L< X *G$5 "EQ'@ H<28 )W(O "9R-P E<D  )')*
M ")R5  A<V  ('-M !YS?0 =<Y  &W.C !ISN0 9<]P &G'W !IP_P ;;_\
M&V[_ 1MM_P&F9@  D64  ']D  !Q9   9F0  %UD  !29@  2&D  #]L   W
M;P  ,',  "EV   B>0@ 'WL0 !Y[%P <>Q\ &WLH !I[,  9?#D &'Q# !=\
M3@ 6?%H %7QG !1]>  2?8L $7V? !!]M0 /?=4 $'OU !%Y_P 1>/\ $G?_
M !)W_P">:P  BFH  'II  !M:0  8FD  %=J  !,;0  0W   #ET   Q>
M*7L  ")_   ;@@  %(4) !&&$  1AA< $(<? !"'*  .AS$ #H<[  V'1@ ,
MAU, "X=A  J'<0 )AX0 !X>8  :&K@ %ALD !H7L  >$_P (@_\ "8+_  F"
M_P"5<0  @V\  '1N  !I;@  7&\  %!R  !&=0  /'D  #)]   J@0  (H4
M !N)   4C   #X\#  J2"P &DA$ !)(8  *2(  !DBD  )(S  "3/@  DTL
M )-9  "3:0  DWL  )*0  "2I@  D;\  )'E  "0^@  C_\  (__  "/_P"-
M=P  ?74  '!T  !B=0  57@  $E\   _@   -(0  "N)   BC0  &I$  !.4
M   .EP  "9L   &="   G0X  )T3  ">&@  GB(  )\K  "?-0  H$(  *!0
M  "@7P  H'$  *"'  "?G0  G[4  )[:  "=]@  G?\  )S_  "<_P"&?0
M>'P  &E\  !;?P  3H,  $&(   VC   +)$  ".6   :F@  $IX   VA   &
MI    *<   "I P  J0H  *H.  "K$P  K!D  *TB  "N*P  KS<  *]%  "O
M5   KV8  *][  "NE   KJL  *[)  "N[P  K?\  *W_  "M_P"!A   <80
M &&'  !3BP  1I   #F6   NFP  (Z   !JD   2J   #*P   2O    L@
M +8   "W    MP(  +@(  "Y#0  NA(  +L8  "](0  OBL  , X  # 2
MP%H  ,%N  #!A@  P:   ,&Z  #!XP  P/D  ,#_  # _P!YC0  :)   %F4
M  !+F@  /:   #&E   EJP  &J\  !&S   +N    KL   "^    P0   ,0
M  #%    Q@   ,<   #(!0  R@L  ,P/  #.%0  T!\  -,K  #5.@  U4P
M -9@  #8=P  V)(  -BL  #9R0  V>P  -G[  #8_P!PF0  8)X  %&D  !#
MJ@  -;   "BV   <N@  $;X   G!    Q0   ,@   #+    SP   -(   #3
M    U@   -@   #;    W0   -\'  #B#0  Y1,  .@=  #L*@  [3P  .U1
M  #N9P  [X$  .^<  #PMP  \-,  /#L  #P] !GI@  6*T  $FT   ZN@
M*KX  !S"   0Q@  !\H   #.    T@   -8   #<    X    .,   #D
MY@   .@   #K    [0   .\   #R @  ]0H  /@1  #\'   _RP  /\_  #_
M50  _VX  /^*  #_I   _[H  /_1  #_X0#_ !0 _P 2 /\ $@#_ !0 _P 9
M /\ )0#_ #( _P _ /\ 2P#_ %8 _P!@ /\ : #_ '  _P!X /\ ?P#_ (4
M_P"+ /\ D0#_ )@ _P"> /X I@#] *X _ "Y /H R #Y .( ^ #T /< _P#V
M /\ ]@#_ .\ _P#G /\ X@#_ -X _P#_ !$ _P . /\ #@#_  \ _P 4 /\
M( #_ "T _P Z /\ 1@#_ %$ _P!; /\ 8P#^ &L _ !S /H >0#Y (  ]P"&
M /8 C #U )( \P"9 /( H #P *D [@"S .T P0#K -8 Z@#N .D _@#G /\
MYP#_ .4 _P#= /\ U0#_ -$ _P#_  T _P * /\ " #_  D _P 0 /\ &P#_
M "@ _P U /\ 0 #Z $L ]@!5 /, 7@#Q &8 [@!M .P = #K 'H Z0"  .<
MA@#F (T Y "3 .( FP#@ *, W@"M -P N0#: ,H UP#F -0 ^ #2 /\ T@#_
M -( _P#. /\ R0#_ ,8 _P#_  @ _P # /\   #_  , _P - /P %@#W "(
M\P N .\ .@#L $4 Z !/ .0 6 #A &  W@!G -L ;0#9 '0 U0!Z -, @ #1
M (< SP". ,T E0#+ )X R0"G ,< LP#% ,( PP#< ,$ \0"_ /\ OP#_ +X
M_P"^ /\ O0#_ +L _P#_    _P   /\   #_    ]@ ( .X $0#G !L X0 G
M -T ,P#9 #X TP!) ,\ 4@#+ %D R !A ,8 9P#$ &T P@!S ,  >@"_ (
MO0"( +L D "Y )@ N "B +4 K0"S +L L0#. +  Z@"O /P K0#_ *T _P"N
M /\ K@#_ *X _P#_ @  _P   /T   #R    Z    -X # #3 !4 S  A ,@
M+ #$ #@ P0!" +T 2P"Z %, N !: +8 80"T &< L@!M +  = "O 'H K0""
M *P B@"J ), J "= *8 J "D +4 H@#& *$ XP"? /8 G@#_ )X _P"> /\
MG@#_ )X _P#_!@  ^P   .X%  #B!   U0   ,L !@##  \ O0 9 +@ )0"T
M #$ L0 [ *X 10"L $T J0!5 *< 6P"E &( I !H *( ;@"A '4 GP!\ )X
MA0"< (X F@"8 )@ I "6 +  E0#! ), W "2 /( D0#_ )  _P"0 /\ CP#_
M (\ _P#]"@  \ X  .$1  #.$   P@T  +L'  "W  H L0 2 *P '@"H "D
MI0 T *( /@"? $< G0!/ )L 5@"9 5P EP%C )8":0"4 G  DP-X )$#@ "0
M!(H C@25 (P%H0"*!:X B0:^ (<(V "&"?  A K_ (,+_P"#"_\ @PO_ (,+
M_P#V$   YA<  -(<  # &@  LQ8  *P2  "H#0  I@<- *(%%@"=!R( F0DN
M )8*. "4"T$ D@Q* ) ,40".#5@ C U> (L-90")#6P B YT (8.?0"%#H<
M@PZ3 ($/GP" $*T ?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W$O\ =Q+_ '<2_P#O
M%P  VR$  ,8D  "T(P  J"   * <  ";%P  F1$$ )@.$ "3$!L CQ$G (P2
M,@")$SP AQ-$ (443 "#%%, @15: ( 58 !^%F@ ?19O 'L6> !Y%X, >!>/
M '88G !T&*H <QF[ '(9U !O&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:_P#G(
MT"D  +PK  "K*@  GB@  )8D  "0(   C1P  (P7# "(&!8 A!HB ($;+0!^
M'#< ?!U  'H=2 !Y'D\ =QY5 '8?7 !T'V, <Q]K '$@= !P('\ ;B&+ &PA
MF !K(:< :2*X &@BSP!F(NX 92/_ &0C_P!D(O\ 9"+_ &0A_P#@)@  R"\
M +0Q  "C,   EBX  (TK  "'*   A"0  ((@" !^(!( >R(> '@C*0!U)#,
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M 5$UQ@%0-><!3S7] 4\U_P%/-/\!3S3_ 4\S_P'+-@  N#T  *,\  "2/
MA3L  'LZ  !T-P  ;S4  &PS  !H- H 9343 &(V'@!@-R@ 7C<Q %TX.@!;
M.$$ 6CE( %DY4 !7.5< 5CI? %0Z: !3.G, 43I_ 4\ZC0%..IT!3#JN 4LZ
MPP%*.N4!23K\ 4DY_P%).?\!23C_ 4HX_P''.@  LT   )X_  "./P  @3X
M '<]  !P.P  :C@  &8X  !B.0< 7SH1 %P[&P!:.R4 63PN %<]-P!6/3X
M5#Y& %,^30!2/E4 43Y= $\_9@!-/W  3#]] 4H_BP%(/YL!1S^L 44_P0%$
M/^,!1#[[ 40^_P%$/?\!1#W_ 44\_P'#/@  KT,  )I"  "*0@  ?4$  '-
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M 3I&_P$Z1?\!.T7_ 3M$_P&[10  ID@  ))'  ""1P  =D<  &M'  !C1@
M6T,  %9%  !21P  3D@* $Q)$@!*21P 2$HE $=*+@!&2S8 14L^ $-+1@!"
M3$T 04Q6 $!,7P ^3&H /$QV #M,A0$Y3)4!-TRG 39,O $U3-T!-4OW 35+
M_P$U2O\!-DG_ 39)_P&X20  HDL  (Y*  !^2@  <DH  &A*  !?20  54@
M %!*  !,2P  24P' $9-$ !$3AD 0D\B $%/*P! 4#, /U [ #Y00P \44H
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M "18_P"H50  DE0  (!4  !Q5   9E0  %Q4  !450  2E8  $-8   \6P
M-ET  #!@!0 M80X *V$5 "IB'0 I8B4 *&(N "=C-@ F8SX )6-' "-C40 B
M9%P (61I !]D>0 >9(H '&2> !MDLP 99,X &F/Q !MA_P ;8/\ '&#_ !Q?
M_P"A60  C%@  'M8  !M6   8E@  %E8  !060  1UL  #Y>   W8   ,6,
M "IF   D:0D (6H0 "!J%P ?:B  'FLH !UK,  <:SD &VM" !IL3  9;%@
M%VQE !9L=  4;(8 $VR: !)LKP 1;,H $6OO !)I_P 3:/\ $VC_ !-G_P"9
M70  A5T  '5<  !H7   7EP  %5<  !+7@  0F$  #ED   R9P  *VH  "1M
M   >< $ %W,+ !5T$0 4=!@ $W0A !)U*0 1=3( $74[ !!U1@ /=5( #G5?
M  UU;@ ,=8$ "W65  IUJ@ (=,, "73G  IS_0 +<?\ #''_  QP_P"18@
M?V$  '!A  !D80  6F$  $]B  !%90  /&@  #-L   K;P  )'(  !UV   7
M>0  $7P$  U_#  +?Q( "G\9  E_(@ (?RH !G\T  5_/P $?TL  G]8  %_
M9P  ?WD  '^.  !_HP  ?KL  'W@  !]]P  ?/\  'O_  ![_P")9P  >&<
M &MF  !A9@  5&<  $EI   _;0  -7$  "QU   D>0  '7P  !:    0@P
M#(8"  :)"@ !B0\  (D4  "*&P  BB,  (LL  "+-P  BT,  (M0  "+7P
MBW$  (N&  "+G   BK,  (G3  "(\P  B/\  (?_  "'_P"";0  <VP  &AL
M  !:;0  3F\  $)S   X=P  +GL  "6    =A   %8@  !",   +CP  !)(
M  "4!@  E0P  )40  "6%0  EQP  )@D  "8+@  F3D  )E'  "95@  F6@
M )E]  "9E   F*L  )?(  "6[@  EO\  )7_  "5_P![=   ;W,  &%S  !3
M=@  1GH  #M_   PA   )H@  !V-   4D@  #I8   F9   !G    *    "A
M    H@8  *(,  "D$   I10  *4<  "G)   J"\  *@]  "I3   J5X  *ER
M  "HB0  J*(  *B\  "GY0  IOL  *;_  "E_P!W>P  :'L  %E^  !+@@
M/H<  #*-   GD@  '9<  !2<   .H   !Z0   "H    JP   *X   "O
ML    +$$  "S"@  M X  +43  "V&P  N"0  +HQ  "Z0   NE(  +ME  "[
M?0  NI<  +JQ  "ZT@  NO,  +G_  "Y_P!O@P  7X8  %&+  !#D   -I<
M "J=   ?H@  %:<   VL   %L    +0   "W    NP   +X   "_    P
M ,$   ## 0  Q <  ,4-  #'$0  RAD  ,TD  #.,P  ST0  -!8  #0;@
MT8@  -"D  #0P0  T>8  -'X  #1_P!GCP  5Y0  $F:   [H0  +J<  "&M
M   6LP  #K@   :\    P    ,,   #&    RP   ,T   #.    T    -$
M  #4    U@   -H"  #<"0  WP\  .,7  #F)   YS8  .A)  #I7P  ZG@
M .N4  #KKP  Z\P  .SH  #L]@!?G@  4*0  $*K   TL@  )KD  !F^   .
MP@  !,4   #*    S0   -$   #8    VP   -\   #@    X@   .0   #F
M    Z0   .L   #N    \04  /4-  #Y%@  _"4  /TY  #^3P  _V<  /^"
M  #_G0  _[4  /_+  #_Y #_ !$ _P / /\ #P#_ !$ _P 6 /\ (@#_ "\
M_P [ /\ 1P#_ %( _P!; /\ 9 #_ &P _P!S /\ >@#_ (  _P"& /\ C #^
M ), _0"9 /L H0#Z *D ^ "T /< P@#V -H ]0#Q /0 _P#S /\ \P#_ .D
M_P#@ /\ V #_ -, _P#_  X _P + /\ "@#_  L _P 1 /\ '0#_ "H _P V
M /\ 00#_ $P _P!6 /X 7P#[ &8 ^0!M /< = #U 'H ] "  /( A@#P (T
M[P"4 .T FP#L *0 Z@"N .D N@#G ,T Y0#I .0 ^P#C /\ X@#_ -X _P#1
M /\ S #_ ,@ _P#_  D _P $ /\  0#_  0 _P . /\ & #_ "0 _0 P /L
M.P#W $8 \P!0 .\ 60#L &  Z@!G .< ;@#F '0 Y !Z .( @ #@ (< W@".
M -P E0#: )X U@"H -0 LP#1 ,, SP#? ,X ] #, /\ RP#_ ,L _P#% /\
MOP#_ +P _P#_  ( _P   /\   #_    _0 + /< $P#Q !X [0 J .H -0#G
M $  X@!* -T 4@#9 %H U0!A -( 9P#0 &T S@!S ,P >@#* (  R "' ,8
MCP#$ )@ P@"A ,  K0"^ +L O #0 +H [0"Y /X N #_ +@ _P"W /\ LP#_
M +  _P#_    _P   /\   #Y    [@ % .4 #@#> !@ V  C -( +@#/ #D
MRP!# ,< 3 #$ %0 P0!; +\ 80"\ &< NP!M +D <P"W 'H M0"! +0 B0"R
M )( L "; *\ IP"L +0 JP#& *D Y "G /@ I@#_ *8 _P"E /\ I0#_ *0
M_P#_    _P   /4   #J    W@   -  "@#( !( P@ = +X * "[ #, N0 ]
M +4 1@"R $T L !5 *T 6P"L &$ J@!G *@ ;0"G ', I0!Z *0 @@"B (P
MH "6 )\ H0"= *X FP"^ )D V "7 /$ E@#_ )8 _P"7 /\ EP#_ )< _P#_
M    ]0   .<!  #4    R0   ,  ! "X  X LP 6 *\ (0"K "P J  V *8
M/P"C $< H0!/ )\ 50"= %L FP!A )H 9P"8 &X EP!U )4 ?0"4 (8 D@"1
M )  G ". *D C "X (L S0") .L B #] (@ _P"( /\ B #_ (@ _P#Y!@
MZ0P  -0.  ###   MPD  + "  "K  D I@ 0 *( &@"> "4 FP P )@ .0"6
M $$ E !) )( 4 "0 %8 C@!< (T 8@"+ &D B@!P (@ > "' ($ A0", (0
MF "" *4 @ "T 'X R !] >< ? +Y 'L#_P![!/\ >P3_ 'L$_P#Q#@  WA4
M ,45  "T%   J1$  *$.  ">"@  FP,, )< $P"3 !X D $I (T",P"* SP
MB 1# (8%2P"%!E$ @P97 (('7@" !V0 ?PAL 'T(= !\"'X >@F) '@)E@!W
M"J, =0JS ',+QP!R#.8 < W[ ' -_P!O#?\ ;PW_ &\-_P#H%@  T!X  +D=
M  "I'   G1H  )46  "0$P  CPX# (X*#@")"Q< A@PC (,-+0" #38 ?@X^
M 'P.1@![#DT >0]3 '@06@!V$&$ =1!H ',0<0!Q$7L <!&' &X1E !L$:(
M:Q*R &D2QP!H$^< 9A/] &44_P!E%/\ 91/_ &43_P#?'@  QB0  + D  "@
M(P  E"$  (L?  "&&P  @Q<  ((2" !_$1( ?!(= 'D4* !V%#$ =!4Z '(6
M00!Q%D@ ;Q=/ &X75@!L%UT :QAD &D8;0!H&7< 9AF# &09D !C&I\ 81JO
M & :Q !>&^0 71S[ %P<_P!<&_\ 7!O_ %P;_P#5)0  O2H  *@I  "8*0
MC"@  (,E  !](@  >1\  '@; P!V&0\ <AH8 &\<(P!M'2T :QTU &D>/0!H
M'D0 9A]+ &4?4@!C(%D 8B!A &$@:0!?(7, 72%_ %PAC0!:(IP 62*L %<B
MP !6(^$ 52/Y %0C_P!4(O\ 5"+_ %0B_P#-*P  MBX  *(N  "2+@  A2T
M 'PK  !V*   <B8  &\C  !M(0P :B(5 &<C'P!E)"D 8R0Q &(E.0!@)D$
M7R9( %TF3P!<)U8 6R== %DG9@!8*'  5BA\ %0HB@!3*9D 42FJ % IO@!/
M*=X 3BGW $TI_P!-*?\ 32C_ $XH_P#(,   L#(  )PR  ",,@  @#$  '8P
M  !P+0  :RL  &@I  !F* D 8R@1 & I' !>*B4 7"LN %LK-@!9+#T 6"Q$
M %<M3 !5+5, 5"U; %,M8P!1+FX 4"YZ $XNB !,+Y< 2R^H $DONP!(+]L
M2"_V $<O_P!'+O\ 1RW_ $@M_P#$-   JS4  )<U  "'-0  >S4  '(T  !K
M,@  9B\  &(N  !?+04 7"X0 %HO& !8,"( 5C K %4Q,P!3,3H 4C)" %$R
M20!0,E  3C-8 $TS80!+,VL 2C-W $@TA0!'-)4 132F $,TN0!"--8 0C3T
M $(T_P!",_\ 0C+_ $(R_P# .   IS@  ),X  "#.   =S@  &TW  !F-@
M83,  %TR  !9,@( 5S,- %0T%0!2-1\ 434H $\V, !.-C@ 3#<_ $LW1@!*
M-TX 23A6 $<X7P!&.&D 1#AU $,X@P!!.9, 0#FD #XYN  ].=, /#GS #PX
M_P ]-_\ /3?_ #TV_P"[.P  HCL  (\[  !_.P  <SL  &HZ  !B.0  73<
M %@V  !4-P  43@+ $\Y$P!-.1P 2SHE $HZ+0!(.S4 1SL\ $8\1 !%/$L
M1#Q3 $(\7 !!/6< /SUS #X]@0 \/9$ .CVC #D]M@ X/=$ -SWR #<\_P X
M._\ .#O_ #@Z_P"V/0  GCX  (L^  !\/@  ;SX  &8]  !>/0  6#L  %,Z
M  !/.P  3#P( $D]$0!'/AD 1C\B $0_*@!#/S( 0D Z $% 00! 0$D /D%1
M #U!6@ \060 .D%P #A!?P W08\ -4*A #1"M  R0LX ,D'P #) _P S0/\
M,S__ #0^_P"Q0   FD   (=   !X00  ;$$  &)   !;0   5#\  $X_  !*
M0   1D$% $1"#@!"0Q8 0$,? #]$)P ^1"\ /$0W #M%/@ Z148 .45. #A&
M6  V1F( -49N #-&?  Q1HT ,$:? "Y&LP M1LP +4;O "U%_P N1/\ +D/_
M "Y#_P"L0P  ED,  (-#  !T0P  :$,  %]#  !70P  4$,  $A#  !$10
M048! #Y'#  \2!, .D@< #E))  X22P -DDT #5*.P T2D, ,TI, #)*50 P
M2U\ +TMK "U+>@ L2XL *DN= "A+L0 G2\H )TOM "=*_P H2?\ *$C_ "E'
M_P"G1@  D48  ']&  !P1@  948  %M&  !41@  3$<  $1(   _2@  .TL
M #=,"0 U31  ,TX8 #).(  Q3R@ ,$\P "]/.  N3T  +%!( "M04@ J4%P
M*%!H "=0=P E4(@ )%"; ")0KP A4,@ (%#K "%/_P B3O\ (DW_ "--_P"A
M20  C$D  'I)  !L2@  84H  %A*  !02@  24L  $!,   [3@  -5   #%2
M!  M4PT +%04 "I4'  I520 *%4L "=5,P F53P )59% "163@ B5ED (59E
M !]6=  >5H4 '%:8 !M6K  95L4 &5;I !I5_P ;5/\ &U/_ !Q2_P";30
MADT  '5-  !H30  74T  %1-  !-3@  14\  #Q1   V4P  ,54  "M8   F
M6@D (UL0 ");%P A7!\ (%PG !]<+@ =7#< '%U  !M=2@ :754 &%UA !==
M<  578$ %%V5 !-=J@ 17<( $5WG !);_@ 36O\ $UK_ !19_P"440  @%$
M '!1  !D40  65$  %%1  !)4@  05,  #A6   R60  *UL  "5>   ?80,
M&F,, !AD$0 79!D %F0A !5D*0 493$ $V4Z !)E1  195  $&5=  ]E:P .
M97T #661  QEI0 *9+P "F3@  MC^0 ,8O\ #6'_  UA_P"-50  >E4  &M5
M  !?50  5E4  $Y5  !$5P  /%D  #1<   L7P  )F(  !]E   9:   $VL%
M !!M#0 .;A( #6X:  QN(@ ,;BL "VXT  IN/@ (;DH !VY7  9N90 $;G8
M FZ*  !MGP  ;;8  &S6  !L\P !:_\  FK_  -J_P"%6@  =%H  &9:  !<
M60  4UD  $A:   _70  -F   "YC   F9P  'VH  !EM   3<0  #G0#  IW
M"@ %=Q   7<5  !W'   =R0  '@M  !X-P  >$,  'A0  !X7@  >&\  'B$
M  !XF0  =[   ';-  !U\   =?\  '3_  !T_P!^7P  ;E\  &)>  !97@
M35\  $)B   Y90  ,&@  "=L   ?<   &'0  !)W   ->P  "'X   * "
M@0T  ($1  ""%P  @QX  (,F  "$,   A#L  (1(  "$5P  A&@  (1\  "$
MDP  @ZH  (+%  "!ZP  @?X  (#_  " _P!W90  :60  %]C  !29   1V<
M #QK   Q;P  *',  "!W   8?   $7\   R#   &AP   (H   ", P  C D
M (T.  ".$0  CQ<  ) >  "1)P  DC(  )(_  "23@  DE\  ))S  "2BP
MD:(  )&\  "0Y0  C_P  ([_  "._P!Q:P  9FH  %AK  !+;0  /W$  #1V
M   J>P  ((   !>%   0B0  "XT   21    E0   )@   "9    F@,  )L(
M  "<#0  GA$  )\6  "@'@  HB@  *(U  "C1   HU4  *-I  "B@   HIH
M *&S  "@V   H/8  )__  "?_P!N<0  7W(  %%U  !$>0  -WX  "R$   A
MB@  %X\  !"4   *F0   9T   "@    I    *<   "H    J0   *H   "L
M!@  K0L  *\0  "P%0  LAX  +0I  "T.0  M$H  +5=  "U<P  M8X  +6H
M  "TQ@  L^T  ++_  "R_P!F>@  5WT  $F"   \AP  +XX  ".4   8F@
M$)\   FD    J0   *T   "P    M    +<   "X    N0   +L   "\
MO@(  , (  #"#@  Q!0  ,<>  #(+   R3T  ,I0  #*9@  RG\  ,J;  #*
MN   RMT  ,KU  #*_P!>A@  3XL  $&1   SF   )Y\  !NE   1JP  ";
M  "U    N0   +T   #!    Q@   ,@   #)    RP   ,P   #.    T
M -(   #4!0  V0P  -T2  #A'@  XBX  .-"  #D5P  Y6\  .:,  #FJ
MY<4  .7G  #F]@!6E   2)L  #JB   LJ0  '[   !.V   +O    ,$   #%
M    R0   ,T   #2    U@   -H   #;    W@   .    #B    Y    .<
M  #I    [0   / *  #T$0  ^!\  /DR  #Z2   ^U\  /QZ  #]EP  _:\
M /W'  #]Y #_  X _P - /\ # #_  X _P 3 /\ '@#_ "H _P V /\ 0@#_
M $T _P!7 /\ 7P#_ &< _P!N /\ = #_ 'H _P"! /T AP#\ (T ^@"4 /D
MG #W *4 ]0"O /0 O #S ,\ \0#L /  _@#O /\ [P#_ ., _P#7 /\ S@#_
M ,H _P#_  H _P & /\ ! #_  @ _P 0 /\ &0#_ "4 _P Q /\ /0#_ $<
M_@!1 /L 60#Y &$ ]@!H /0 ;@#S '0 \0!Z .\ @0#N (< [ ". .H E@#H
M )\ Y@"I ., M0#B ,8 X #C -\ ^ #= /\ W0#_ -0 _P#) /\ P@#_ +X
M_P#_  , _P   /\   #_  $ _P - /\ % #] "  ^@ K /< -@#S $$ [P!+
M .P 5 #H %L Y@!B ., : #A &X WP!T -P >@#: ($ V "( -0 D #2 )@
MSP"B ,T K@#+ +P R0#3 ,< \ #& /\ Q #_ ,0 _P"[ /\ M@#_ +, _P#_
M    _P   /\   #_    ]P ( /  $ #K !H YP E .0 , #A #L W !% -4
M30#1 %4 S@!; ,L 8@#) &< QP!M ,4 <P## 'H P0"! +\ B0"] )( NP"<
M +D IP"W +4 M0#( +, Y@"R /L L0#_ +  _P"N /\ J@#_ *< _P#_
M_P   /X   #Q    Y0 " -P #0#3 !0 S0 ? ,H *@#' #0 Q  ^ ,  1P"\
M $X N@!5 +< 6P"U &$ LP!G +( ;0"P ', K@!Z *P @@"J (L J "5 *<
MH "E *T HP"^ *$ VP"@ /0 GP#_ )X _P"? /\ G0#_ )L _P#_    _
M .X   #@    T    ,4 " "^ !  N0 9 +4 (P"S "X L  W *T 0 "J $@
MJ !/ *4 50"C %L H@!@ *  9@"? &P G0!S )L >P": (0 F ". )8 F@"5
M *< DP"W )$ S "0 .P CP#_ (X _P". /\ C@#_ (\ _P#\    [P   -L
M  #)    O0   +4  @"N  P J0 3 *4 '0"B "< H  Q )T .@": $( F !)
M )8 3P"4 %4 DP!; )$ 8 "0 &< C@!M (T =0"+ 'X B0") (@ E0"& *(
MA0"Q (, Q "! .0 @ #Y '\ _P"  /\ @ #_ (  _P#T @  X D  ,<(  "W
M!P  K ,  *8   "@  < FP / )@ %P"5 "$ D@ J (\ ,P"- #P BP!# (D
M20"' %  A@!5 (0 6P"# &$ @0!H (  < !^ 'D ? "$ 'L D !Y )T > "L
M '8 O@!U -T <P#T ', _P!S /\ <P#_ ', _P#I#0  SQ   +D0  "I$
MG@X  )<+  "3!@  D  + (P $0") !H A@ D (, +@"! #8 ?P ^ 'T 1 !\
M $L >@!1 'D 5P!W %T =@!D '0 ; !S 74 <0&  &\"C0!N IH ; .J &L#
MNP!I!-8 : ;Q &@'_P!G!_\ 9P?_ &<'_P#?%   PQ<  *X7  ">%@  DQ4
M (L2  "&$   A P" (,&#0"  Q0 ? 4> 'D'* !W"#  =0@X ',)0 !R"48
M< I, &\*4P!M"UD ; MA &H+:0!I#'( 9PQ^ &8,BP!D#9D 8@VI &$-NP!@
M#=@ 7@[S %T._P!=#O\ 70[_ %T._P#4'   N1T  *0>  "5'0  B1P  ($:
M  ![%P  >!,  '@0!@!W#0\ <PX8 ' .(@!N#RL ;! S &H0.P!I$$( 9Q%)
M &813P!D$58 8Q)= &$29@!@$F\ 7A)[ %P3B !;$Y< 61.G %<4N@!6%-4
M517S %05_P!4%?\ 5!7_ %04_P#*(@  L"(  )TC  "-(P  @2(  'DA  !S
M'@  ;QL  &X7  !M$PP :A04 &<5'@!E%B< 8Q8O &$7-P!@%SX 7AA% %T8
M2P!<&5( 6AE: %D98@!7&FP 5AIW %0:A0!2&Y0 41ND $\;MP!.&]  31SQ
M $P<_P!,'/\ 31S_ $T;_P##)@  JB<  )8G  "'*   >R<  '(F  !L)
M:"$  &8>  !D&P@ 8AL1 %\<&@!='2, 6QXK %H>,P!8'SH 5Q]! %8@2 !4
M($\ 4R!7 %$A7P!0(6D 3B%T $TA@@!+(I$ 22*B $@BM !'(LT 1B/O $4C
M_P!%(O\ 1B+_ $8A_P"\*@  I"L  )$K  ""+   =BL  &TJ  !F*0  8B8
M %\D  !=(@0 6R$. %@B%@!6(Q\ 5"0H %,D, !2)3< 4"4^ $\F10!.)DP
M3"94 $LG7 !))V8 2"=Q $8G?P!%*(\ 0RB@ $$HL@! *,L /RCM #\H_P _
M*/\ 0"?_ $ G_P"W+0  GRX  (PO  !]+P  <2\  &@N  !A+0  72L  %HH
M  !7)P  5"<, %(H$P!0*1P 3BDE $TJ+ !+*C0 2BL[ $DK0@!(+$D 1BQ1
M $4L6@!$+&0 0BUO $ M?0 _+8T /2V> #PML  Z+<@ .BWK #HM_P Z+?\
M.BS_ #HL_P"R,   FS$  (@R  !Y,@  ;3(  &0R  !=,0  6"\  %4L  !1
M+   3RT) $PM$0!*+AD 22\B $<O*@!&,#$ 13 X $,P/P!",4< 03%/ $ Q
M5P ^,6$ /3)M #LR>P Y,HL .#*< #8RKP U,L< -#+I #0R_P U,?\ -3'_
M #4P_P"M,P  EC0  (0U  !U-0  :34  & U  !9-   5#,  % P  !,,0
M23$& $<R#P!%,Q8 0S,? $(T)P! -"X /S4V #XU/0 ]-40 /#9, #HV50 Y
M-E\ -S9K #8V>  T-XD ,C>: #$WK0 O-\4 +S?H "\V_@ P-?\ ,#7_ # T
M_P"I-@  DC8  ( W  !R.   9C@  %TW  !6-P  4#8  $LT  !'-0  1#8#
M $$W#0 _.!0 /C@< #PY)  [.2P .CDS #DZ.@ X.D( -CI* #4Z4P T.UT
M,CMH # [=@ O.X< +3N9 "P[K  J.\, *3OF "HZ_0 J.O\ *SG_ "PX_P"D
M.   CCD  'PZ  !N.@  8SH  %HZ  !3.@  33H  $8X  !".@  /SL  #P\
M"P Z/!$ .#T9 #<](0 V/BD -#XP #,^-P R/S\ ,3]' # _4  N/UH +4!F
M "M =  I0(0 *$"7 "9 J@ E0,$ )$#E "0__  E/O\ )CW_ "8]_P"?.P
MBCP  '@]  !J/0  7ST  %8]  !//0  23T  $(]   \/@  .3\  #9!"  T
M00\ ,D(6 #%"'@ O0R4 +D,M "U#-  L1#P *T1$ "I$30 H1%@ )T5C "5%
M<0 C18( (D65 "!%J  ?1;\ 'D3C !]$^P ?0_\ ($+_ "%!_P":/@  A3\
M '1   !G0   7$   %-   !,0   1D   #Y!   X0P  -$4  #!& P M1PT
M*T@2 "I(&@ I2"( *$DI "=),0 E23D )$E! "-*2@ B2E4 ($IA !]*;P =
M2G\ &TJ2 !I*I@ 82KT %TK@ !A)^@ 92/\ &D?_ !I'_P"50@  @$(  '!#
M  !C0P  6$,  %!#  !)0P  0D0  #M%   U1P  ,$D  "M+   F30D )$X0
M ").%@ A3QT ($\E !]/+  >3S4 '4\] !Q01P :4%$ &5!= !=0:P 64'P
M%%"/ !-0I  14+H $5#> !%/^  23O\ $TW_ !1-_P"/10  >T8  &M&  !?
M1P  54<  $U'  !&1P  /T<  #=*   Q3   *TX  "90   @4P, '%4, !I6
M$0 95A@ %U8@ !96)P 55C  %%8Y !-70@ 25TT $5=9 !!7:  /5WD #E>,
M  U7H  +5[8 "U;4  M6]  ,5?\ #53_  Y3_P"(20  =DH  &=*  !;2@
M44H  $I*  !#2@  .TP  #-.   L40  )E0  "%6   ;60  %5P' !%>#0 0
M7A, $%X:  Y>(@ .7BH #5XS  Q>/0 +7D@ "EY4  A>8@ '7G, !5Z&  ->
MFP "7K$  EW,  )=[@ #7/\ !%O_  5;_P"!3@  <$X  &).  !73@  3DX
M $=.   ^3P  -E$  "Y4   G5P  (5H  !M=   58   $&,#  QF"P (9Q
M!F<5  5G'  $9R0  F<M  %G-P  9T(  &=.  !G7   9VT  &>   !FE0
M9JP  &7'  !EZP  9/P  &3_  !C_P!Z4@  :E,  %U2  !44@  2U(  $)3
M   Y50  ,%@  "A;   A7P  &F(  !1E   0:   #&L!  9N"0  ;PX  &\2
M  !O&   <!\  ' G  !Q,   <3L  '%(  !Q5@  <68  '%Y  !QCP  <*<
M &_!  !OYP  ;OP  &W_  !M_P!S6   95<  %I7  !15@  1E<  #Q:   R
M70  *F$  ")D   ::   %&P   YO   *<@  !'8   !X!0  > L  'D.  !Z
M$P  >QD  'P@  !]*0  ?3,  'U   !]3@  ?5X  'UR  !]B   ?*$  'RZ
M  ![X@  >OH  'G_  !X_P!M70  8%P  %=<  !+70  0%\  #5C   K9P
M(VL  !IO   3<P  #G<   A[   "?@   ((   "# 0  A 8  (4+  "&#P
MB!,  (D9  "*(0  BRL  (LW  ",1@  BU8  (MI  "+@   BYD  (JS  ")
MV   B/<  (C_  "'_P!H8P  7F(  %%B  !$90  .&D  "YN   D<P  &G@
M !-]   -@0  !H4   ")    C0   )    "2    D@   )0%  "5"@  EPX
M )@2  ":&   FR$  )PM  "=/   G4P  )Q?  "<=@  FY$  )NK  ":R0
MFO   )G_  "8_P!E:0  5VD  $EL   ]<0  ,'8  "5\   ;@0  $H<   R,
M   $D0   )4   "9    G0   *    "A    H@   *0   "E 0  IP<  *D,
M  "J$0  K1@  *\B  "O,   KT$  *]4  "O:P  KH4  *ZA  "NO@  K>8
M *S\  "L_P!><0  3W0  $)Y   U?P  *(4  !V,   3D@  #)@   .=
MH@   *8   "J    K@   +    "Q    LP   +0   "V    N    +H$  "\
M"@  OA   ,$7  ##)   PS4  ,1)  #$7@  Q7<  ,63  #%KP  Q=$  ,/R
M  ##_P!6?   1X(  #J(   LCP  ()8  !2=   -HP   ZD   "N    L@
M +<   "[    OP   ,(   #"    Q0   ,8   #(    R@   ,T   #/
MT@@  -4.  #;&   W2<  -XZ  #?4   X&@  ."$  #AH0  X;T  .'B  #@
M] !.BP  0)(  #*9   EH0  &*@   ZO   %M0   +H   "_    Q    ,@
M  #.    T0   -0   #5    V    -H   #=    WP   .(   #D    YP
M .L%  #O#@  ]!D  /4K  #V00  ]U@  /AR  #YD   ^:L  /C$  #XX0#_
M  L _P ( /\ "0#_  P _P 2 /\ &@#_ "8 _P R /\ /@#_ $@ _P!2 /\
M6@#_ &( _P!I /\ ;P#_ '4 _@![ /P @0#[ (@ ^0"/ /< EP#U *  \P"J
M /( MP#O ,D [0#F .P ^P#K /\ ZP#_ -T _P#. /\ Q@#_ ,( _P#_  0
M_P   /\   #_  4 _P - /\ %0#_ "$ _P L /\ . #_ $, _0!, /D 5 #W
M %P ] !C /( :0#P &\ [@!U .P >P#J (( Z ") .< D0#D )H X@"D .
ML #= ,  V@#< -@ ] #5 /\ TP#_ ,L _P#! /\ NP#_ +< _P#_    _P
M /\   #_    _P * /T $0#Y !L ]@ G /0 ,@#P #P [ !& .@ 3@#D %8
MX0!< -X 8P#< &@ V0!N -4 = #2 'L T "" ,T B@#+ ), R "= ,8 J #$
M +< P0#, ,  ZP"^ /\ O0#_ +T _P"T /\ K@#_ *L _P#_    _P   /\
M  #Z    \@ % .H #@#E !8 X  A -T *P#; #8 TP _ ,X 2 #* $\ QP!6
M ,0 7 #" &$ P !G +X ;0"\ ', N@!Z +@ @@"V (L M "6 +( H0"P *\
MK@#! *T X "K /< J@#_ *D _P"F /\ H0#_ )\ _P#_    _P   /<   #H
M    W    -  "@#* !$ Q0 ; ,( )0"_ "\ O  X +@ 00"U $@ L@!/ +
M50"N %L K !A *H 9@"H &P IP!S *4 >P"C (0 H0". )\ F@"= *< FP"X
M )H T "9 .\ F #_ )< _P"6 /\ E #_ )( _P#_    ]@   .0   #2
MQ0   +L !0"U  X L  5 *P 'P"J "D J  R *4 .@"B $( H !) )X 3P"<
M %4 F@!: )@ 8 "6 &8 E0!L ), = "2 'T D "' (X DP", *$ BP"P (H
MQ0"( .8 AP#[ (8 _P"' /\ AP#_ (8 _P#X    Y0   ,T   "]    LP
M *H   "C  H GP 1 )L &0"9 ", EP L )4 - "2 #P D !# (X 20", $\
MB@!4 (D 6@"' &  A@!F (0 ;@"# '< @0"! '\ C0!^ )L ? "J 'L O !Z
M -L > #U '@ _P!X /\ > #_ '@ _P#M    T0(  +L"  "L 0  H@   )L
M  "6  4 D0 - (T % "+ !T B  F (8 +@"$ #8 @@ ] (  0P!^ $D ?0!/
M 'P 50!Z %L >0!A '< :0!U '$ = !\ '( B !Q )8 ;P"E &X M@!M ,X
M; #N &L _P!K /\ :P#_ &L _P#?"P  P@P  *X,  ">#   DPL  (P'  "(
M @  A0 ) ($ $ !_ !< ?  @ 'H * !X #  =@ X '0 /@!S $0 <0!* '
M4 !N %8 ;0!= &P 9 !J &T : !W &< A !E )( 9 "A &, L@!A ,D 8 #I
M &  _ !@ /\ 8 #_ &  _P#0$   MA$  *(2  "3$@  B!$  ( /  !\#0
M>0D! '@#"P!U !$ <P : '  (P!N 2L ; $S &H".0!I T  9P-& &8$3 !E
M!%( 8P59 &(%80!@!6H 7P9T %T&@0!<!X\ 6@>? %D'L !7!\8 5@GG %8*
M^P!5"O\ 50K_ %8*_P#&%0  K1<  )D8  "*&   ?Q<  '86  !Q$P  ;A
M &T-!0!M"0T :@D4 &<*'0!E"B8 8PLN &(,-0!@##P 7PQ" %X-2 !<#4\
M6PU6 %D-7@!8#F@ 5@YS %4.@ !3#H\ 40Z? % .L0!.#L@ 31#J $T0_0!-
M$/\ 31#_ $T0_P"\&P  I1P  )(=  "#'@  =QT  &\<  !I&@  9A<  &04
M  !D$ @ 8@\0 %\0& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^ %8210!4$DP 4Q-3
M %$36P!0$V4 3A1P $P4?0!+%(P 212< $<5K@!&%<4 117H $46_@!%%O\
M117_ $45_P"U'P  GB$  (LB  !\(@  <2(  &@A  !B'P  7QT  %P:  !;
M%P( 6A4- %<6% !5%AT 5!<E %(8+0!1&#0 3Q@[ $X90@!-&4@ 2QI0 $H:
M6 !(&F( 1QIM $4;>@!#&XD 0AN: $ ;K  _&\( /ASE #T<_  ^'/\ /AO_
M #X;_P"O(P  F"0  (8E  !W)@  ;"8  &,E  !=)   62(  %8?  !4'0
M4QP+ %$<$@!.'1H 31TB $L>*0!*'C$ 21\W $<?/@!&($4 12!- $,@50!"
M(%\ 0"%J #\A=P ](8< .R&8 #DAJ@ X(L  -R+C #<B^P W(O\ ."'_ #@A
M_P"J)@  E"<  ($I  !S*0  9RD  %\I  !8*   5"8  %$C  !/(@  3"('
M $HB$ !((A< 1R,? $4D)@!$)"X 0B0T $$E.P! )4, /R5* #TF4P \)EP
M.B9G #DF=0 W)X0 -2>6 #0GJ  R)[X ,2?A #$G^0 R)O\ ,B;_ #,E_P"E
M*0  CRH  'TL  !O+   9"T  %LL  !5*P  4"H  $PH  !*)@  1R<$ $0G
M#0!"*!0 02@< #\I(P ^*2L /2DR #PJ.0 [*D  .2I( #@K4  V*UH -2ME
M #,K<@ Q*X( ,"R4 "XLIP L++P *RS> "PL^  L*_\ +2K_ "TJ_P"A+
MBRT  'DN  !K+P  8"\  %@O  !1+@  3"X  $@L  !%*P  02L  #\L"P ]
M+!$ .RT9 #HN(0 Y+B@ -RXO #8O-@ U+SX -"]% #,O3@ Q,%@ ,#!C "XP
M<  L,(  *C"2 "DPI0 G,+H )C#< "8P]P G+_\ *"__ "@N_P"<+@  AS
M '8Q  !H,@  73(  %4R  !.,0  2#$  $0P  ! +P  /#   #HQ"0 W,1
M-C(6 #4R'@ S,R4 ,C,L #$S,P P-#L +S1# "TT3  L-%8 *C5A "DU;@ G
M-7X )360 ",UHP B-;D (379 "$T]@ B-/\ (S/_ ",R_P"8,0  @S,  '(T
M  !E-   6C4  %$U  !+-   130  $ T   Z,P  -S0  #0U!@ R-@X ,#<3
M "\W&P N-R( +3@I "LX,0 J.#@ *3E  "@Y20 F.5, )3E? ",Y;  A.GP
M(#J. !XZH@ <.K< &SG5 !PY]0 =./\ '3C_ !XW_P"3-   ?S8  &XW  !A
M-P  5S<  $XW  !(-P  0C<  #PW   U.   ,CD  "\Z @ L.PL *CP1 "D\
M&  H/1\ )CTF "4]+@ D/34 (SX] "(^1@ @/E  'SY< !T_:0 ;/WD &C^,
M !@_H  6/[4 %3[2 !8^\P 7/?\ &#S_ !@\_P".-P  >C@  &HY  !>.@
M4SH  $LZ  !%.@  /SH  #DZ   R/   +CX  "E    F00@ )$(. ")"%  A
M0AL ($,C !]#*@ >0S( '$,Z !M$0P :1$T &$19 !=$9P 51'< $T2* !)$
MG@ 11+, $$30 !!#\@ 10O\ $D+_ !-!_P").P  =CP  &8]  !:/0  4#T
M $@]  !"/0  /#T  #8^   O0   *D(  "5$   A1@, '4@, !M)$0 921<
M&$D> !=))@ 622X %4HV !1*0  32DH $4I6 !!*9  /2G0 #DJ'  U*FP ,
M2K  "DK*  M)[  ,2/\ #4?_  U'_P"#/@  <3\  &)   !60   34   $5
M   _0   .4$  #)"   K10  )D<  "%)   <2P  %DX' !-0#@ 24!, $5 9
M !!0(0 /4"D #E Q  U0.P -448 "U%1  I17P )46\ !U"!  50E@ #4*L
M E#%  -/Z  #3_L !4[_  9-_P!]0@  :T,  %U$  !21   2D0  $-#   \
M1   -44  "Y'   G2@  (4P  !Q/   740  $E0#  Y7"@ +6!  "E@5  A8
M'  '6"0 !E@L  58-@ #6$   5A,  !86@  6&D  %A\  !8D0  5Z<  %?
M  !6Y0  5OD  %7_  !5_P!V1P  9D<  %E(  !/1P  1T<  $!'   X2
M,$H  "E-   B4   '%,  !95   16   #5L"  E>"0 $7PX  %\2  !?&
M8!\  & G  !@,   8#L  &!'  !@5   8&,  &!V  !@BP  7Z(  %^[  !?
MX@  7OD  %W_  !=_P!O2P  84P  %5,  !,2P  1$L  #M,   R3@  *U$
M "-4   <5P  %EL  !%>   -8   "&,   )F!P  9PP  &</  !H$P  :1D
M &HA  !J*0  :C0  &I   !J30  :ET  &IO  !JA0  :IT  &FV  !HW0
M:/<  &?_  !F_P!I40  7%   %)0  !*3P  /U   #53   M5@  )%D  !U=
M   68   $&0   QG   &:@   &X   !O P  < @  '$-  !R$   =!0  '4;
M  !V(P  =RP  '<X  !V1@  =E8  '9H  !V?@  =I<  '6Q  !TTP  <_4
M '/_  !R_P!C5@  6%4  %!4  !$50  .5@  "];   F7P  '6,  !5G   0
M;   "G    1S    =@   'H   !\    ? ,  'X(  !_#   @1   ((4  "$
M&P  A20  (8O  "&/0  ADT  (5?  "%=0  A8\  (2I  "#R0  @O$  ('_
M  " _P!?6P  5EH  $E;   ]7@  ,F$  "=F   >:P  %7    YU   )>0
M 7X   "!    A0   (@   "*    BP   (T!  ".!@  D L  )$/  "3%
ME1L  )<F  "7-   ET0  )=6  "6;   E88  )6B  "4P0  D^H  )+_  "2
M_P!=80  3V$  $)D   V:0  *FX  !]T   5>0  #G\   >$    B0   (X
M  "2    E@   )@   ":    FP   )T   "?    H0,  *,(  "E#0  IQ,
M *D<  "J*   JCD  *I+  "J80  J7H  *B9  "HM0  I]T  *?X  "F_P!6
M:   2&P  #IP   N=@  (GT  !>$   .B@  !Y    "6    F@   )\   "C
M    IP   *H   "K    K0   *\   "Q    LP   +4   "X!0  N@P  +T2
M  # '   P"T  ,!   "_50  OVX  +Z+  "^J   OLD  +WO  "\_@!.=
M0'D  #)_   EAP  &8X  !"5   'G    *(   "G    K    +    "U
MN0   +P   "]    OP   ,$   ##    Q@   ,@   #*    S0(  - +  #5
M$@  UB$  -<T  #820  V6   -I\  #:F@  V[4  -O9  #;\@!&@@  .(D
M "N0   =F   $J    JG    K@   +0   "Y    O@   ,(   #(    RP
M ,X   #/    T@   -0   #6    V@   -T   #?    X@   .8   #J"@
M[Q,  / E  #R.@  \U$  /1K  #TB0  ]:4  /6_  #UW0#_  8 _P # /\
M!0#_  L _P 0 /\ %P#_ "( _P M /\ .0#_ $0 _P!- /\ 50#_ %T _P!D
M /\ :@#_ '  _0!V /L ? #Y (, ]P"* /4 D@#S )L \ "F .X LP#K ,0
MZ0#D .< ^0#F /\ Y0#_ -, _P#' /\ OP#_ +L _P#_    _P   /\   #_
M  ( _P + /\ $@#_ !T _P H /\ ,P#_ #X _ !' /@ 3P#T %< \0!= .X
M8P#L &D Z@!O .@ =0#F 'P Y "# .( BP#? )4 W "? -D JP#5 +L T@#4
M ,\ \@#- /\ S #_ ,4 _P"Z /\ M #_ +  _P#_    _P   /\   #_
M_P & /D #P#U !< \P B /$ +0#M #< YP!  .( 20#? %  VP!7 -< 70#4
M &, T0!H ,\ ;@#, '4 R@!\ ,@ A #% (T P@"8 ,  I "] +( NP#& +D
MZ "X /T MP#_ +8 _P"M /\ IP#_ *, _P#_    _P   /\   #U    ZP !
M .0 # #> !, V0 < -, )@#1 #  S  Z ,@ 0@#$ $H P !0 +T 5@"[ %P
MN0!A +< 9P"U &T LP!T +$ ? "O (4 K0"0 *H G "H *H I@"[ *4 V@"C
M /4 HP#_ *( _P"> /\ F@#_ )< _P#_    _@   .\   #?    T    ,<
M!P#!  \ O  7 +D ( "W "H M0 S +  .P"M $, JP!) *@ 3P"F %4 I !:
M *, 8 "A &8 GP!M )T = "< 'T F@"( )@ E "6 *( E "R )( R0"1 .L
MD0#_ )  _P"0 /\ C #_ (H _P#\    [    -D   #'    N@   +$  @"K
M  P IP 2 *0 &P"A "0 H  L )X -0"; #P F !# )8 20"4 $\ D@!4 )
M6@"/ %\ C0!F (L ;0") '8 B "  (8 C "$ )H @@"J ($ O@"  .  @ #Y
M '\ _P!_ /\ ?P#_ 'X _P#Q    V    ,(   "S    J    *    "9  <
ME0 . )( %0"0 !X C@ F (T +@"* #8 AP ] (4 0P"$ $D @@!. ($ 5 !_
M %D ?@!@ 'P 9P!Z &\ >0!Z '< A@!U )0 = "C '( M0!R ,\ <0#Q '
M_P!P /\ < #_ '$ _P#A    Q    +    "B    EP   )$   "+  ( A@ +
M (, $0"! !@ ?P A 'T *0!\ #  >0 W '@ /0!V $, = !) ', 3@!R %0
M< !: &\ 8@!M &H :P!T &H @ !H (X 9P"= &4 KP!E ,8 9 #H &0 _0!C
M /\ 8P#_ &0 _P#/!0  M@<  *,(  "4"   B0<  ((#  !^    >P & '<
M#@!U !, <@ ; '$ (P!O "L ;0 R &P . !J #X :0!$ &< 20!F $\ 90!6
M &, 70!B &4 8 !O %\ >P!= (D 7 "9 %L J@!9 +\ 60#A %@ ^ !8 /\
M6 #_ %D _P#"#   J@T  )<.  ")#@  ?0X  '8-  !Q"@  ;P8  &T "@!K
M !  :0 6 &< '@!E "8 8P M &$ ,P!@ #D 7P _ %T 10!< $L 6P!2 %H
M60!8 &( 5P!L %4 > !3 (8 4@"6 %$ IP!0 +L 3P'; $X"] !. _\ 3@3_
M $X#_P"X$   H1(  (X3  !_$P  =!,  &P2  !G$   90X  &,+ P!C!@P
M8001 %X#&0!<!"$ 6P4H %D&+P!8!C4 5@<[ %4'0@!4!T@ 4PA/ %$(5@!0
M"5\ 3@EI $T)=@!+"H0 20J4 $@*I@!'"KH 1@K8 $4+\P!%#/\ 10S_ $4,
M_P"P%   F18  (<8  !X&0  ;1@  &47  !?%@  7!,  %H1  !:#@8 6@P-
M %<,% !5#!P 4PTD %(-*P!0#3$ 3PXX $X./@!-#D4 2PY- $H.50!(#UX
M1P]H $4/=0!#$(0 01"5 $ 0I@ ^$+L /1#< #T1]@ ]$?\ /1#_ #X0_P"I
M&0  DAL  ($<  !R'0  9QT  %\<  !9&P  51D  %,6  !2$P  4A$* % 0
M$ !.$1@ 3!$@ $H2)P!)$BX 2!,T $<3.P!%$T( 1!-) $,44@!!%%L /Q1E
M #X5<@ \%8$ .A62 #@5I  W%;D -178 #46]0 V%O\ -A;_ #<5_P"C'
MC1X  'L@  !M(0  8B$  %HA  !4'P  4!X  $T;  !,&0  2Q8& $D6#@!'
M%Q4 11<< $08) !"&"H 01@Q $ 9.  _&3\ /1E& #P:3P Z&E@ .1IC #<;
M;P U&WX ,QN0 #(;H@ P&[< +QO3 "\<\P O&_\ ,!O_ # ;_P"='P  B"(
M '<C  !I)   7B0  %8D  !0(P  2R(  $@@  !&'0  11P" $,<# !!'!(
M/QT9 #X=(0 \'B< .QXN #H?-0 Y'SP -Q]$ #8?3  T(%8 ,R!@ #$@;0 O
M('P +2&. "PAH  J(;4 *2'0 "DA\@ I(?\ *B#_ "L@_P"9(@  A"4  ',F
M  !E)P  6R<  %,G  !,)@  1R4  $0D  !"(0  /R$  #TA"0 [(1  .2(6
M #@B'@ V(R4 -2,K #0D,@ S)#D ,B1! # D2@ O)5, +25> "LE:P J)7H
M*"6, "8EGP D);, (R7. ",E\  D)?\ )23_ "4D_P"4)0  @"<  &\I  !B
M*@  5RH  $\J  !)*0  1"@  $ G   ])@  .B4  #<F!@ U)@X -"<4 #(G
M&P Q*"( ,"@I "\H,  M*3< +"D_ "LI1P I*5$ *"I< "8J:0 D*G@ (RJ*
M "$JG0 ?*K( 'BK, !XJ[P ?*?\ ("G_ "$H_P"0*   ?"H  &PK  !?+
M5"P  $PL  !&+   02L  #PK   X*@  -2H  #(K P P*PP +BP1 "TL&  L
M+!\ *BTF "DM+0 H+30 )RX\ "8N10 D+D\ (RY: "$O9P ?+W8 '2^( !PO
MFP :+[  &"_* !@N[0 9+O\ &RW_ !LM_P",*P  >"T  &@N  !;+P  42\
M $DO  !#+P  /BX  #DN   T+@  ,"X  "TO   K, H *3$0 "<Q%0 F,1P
M)3(C "0R*@ C,C$ (3,Y " S0@ ?,TP '3-7 !LS9  :-'0 &#2& !8TF@ 4
M,ZX $S/( !,S[  4,_\ %3+_ !8Q_P"'+@  ="\  &4Q  !8,0  3C(  $8R
M  ! ,0  .S$  #8Q   Q,0  *S,  "@T   E-08 (S8- "$V$@ @-QD 'S<@
M !XW)P =."X &S@V !HX/P 9.$D %SE5 !4Y8@ 4.7$ $CF$ !$YF  0.:T
M#CC'  XXZP 0./\ $#?_ !$V_P"#,0  <#(  &$T  !5-   2S0  $0T   ]
M-   .#0  #,T   M-0  *#<  "0Y   @.@( '3L+ !L\$  9/14 &#T< !<]
M(P 6/2L %3XS !0^/  2/D8 $3Y2 ! ^7P //F\ #CZ!  P^E0 +/JD "C[!
M  H]Y  +/?L ##S_  T[_P!]-   :S8  %TW  !1-P  2#<  $$W   [-P
M-3<  # W   J.0  )3L  " ]   </P  %T$& !1##0 20Q( $4,8 !%#'P 0
M1"< #T0O  Y$.0 -1$, #$1.  M$6P )1&H !T1\  9$D  $0Z4  D.]  -#
MX  #0_8 !$+_  9!_P!X.   9SD  %DZ  !..@  13H  #XZ   X.@  ,SH
M "T[   G/0  (4   !Q"   71   $T8#  ])"@ -2@\ #$H4  M*&P )2B,
M"$HK  =*-  %2CX !$I)  )*5@  2F4  $IW  !*BP  2J$  $FY  !)W0
M2?4  $C_  !(_P!R/   8CT  %4^  !*/@  0CT  #P]   V/0  +SX  "E
M   C0@  '44  !='   32@  #TP"  M/"0 '4 T  U$1  !1%P  41X  %$F
M  !1+P  43D  %%$  !240  4F   %%R  !1AP  49T  %&U  !0V   4/4
M $__  !/_P!L0   74$  %%!  !'00  0$   #E    R00  *D,  "1&   >
M2   %TL  !).   .40  "U,!  96!P  5PP  %@0  !8$P  61D  %HA  !:
M*0  6C,  %H_  !:3   6EH  %IL  !:@0  69D  %FQ  !8T0  6/0  %?_
M  !7_P!E10  6$4  $U%  !%1   /D0  #5%   M1P  )4H  !Y-   84
M$E,   Y6   *60  !%P   !>!   7PD  & -  !A$   8A4  &,;  !D(P
M9"T  &0X  !D10  9%0  &1F  !D>P  8Y,  &.M  !BS   8?(  &'_  !@
M_P!?2@  4TH  $I)  !#2   .4D  "],   G3P  'U(  !A5   260  #5T
M  A@   "8P   &8   !H 0  :04  &H*  !K#0  ;1$  &X6  !P'0  <28
M '$Q  !P/@  <$X  '!?  !P<P  ;XT  &^G  !NQ@  ;>\  &S_  !L_P!:
M3P  4$X  $A-   ]3@  ,U$  "E4   @6   &%P  !%@   ,9   !F@   !K
M    ;P   '(   !T    =0   '<$  !X"0  >@T  'P0  !]%@  ?QX  ( H
M  " -0  @$4  ']6  !_:P  ?X0  'Z@  !]O@  ?.D  'O_  !Z_P!65
M3E,  $)4   W5@  +%H  ")?   88P  $6@   MM   #<@   '8   !Z
M?0   (    "#    A    (8   "' @  B0<  (L,  "-$   D!8  )(?  "2
M+   DCL  ))-  "18@  D7H  (^7  "/M   CN$  (S[  ",_P!560  2%H
M #M=   O80  )&8  !EL   1<@  "G<   )]    @@   (8   "+    C@
M )$   "3    E0   )<   "9    FP   )T$  "?"@  H@\  *06  "F(0
MIC$  *9#  "E5P  I'   *..  "CJP  H=   *#U  "?_P!.80  0&0  #-I
M   G;@  &W4  !%\   +@P   (D   ".    DP   )@   "=    H0   *0
M  "E    IP   *D   "K    K0   +    "R    M0@  +@.  "\%@  O"4
M +PW  "[3   NF0  +F!  "WH@  M\   +?J  "W_ !&:P  .7   "MW   ?
M?P  $X8   N.   !E0   )L   "A    I@   *L   "P    LP   +<   "W
M    N@   +P   "_    P0   ,0   #'    R@   ,T%  #1#@  U!D  -0K
M  #40   TU@  --T  #3D@  TK   -+3  #2\@ ^>0  ,8   ".(   7D0
M#9D   .@    IP   *X   "S    N    +T   #"    Q@   ,H   #*
MS0   ,\   #2    U0   -D   #=    WP   .,   #G!0  ZP\  .P?  #M
M,P  [DL  .]D  #O@@  \)\  /&Y  #QV #_    _P   /\ ! #_  D _P .
M /\ %0#_ !X _P I /\ - #_ #\ _P!( /\ 4 #_ %@ _P!> /\ 90#] &L
M^P!Q /D =P#X 'X ]@"% /, C0#Q )< [@"B .L KP#H ,  Y@#@ ., ^ #B
M /\ VP#_ ,L _P#! /\ N0#_ +0 _P#_    _P   /\   #_    _P ) /\
M$ #_ !D _P C /\ +@#] #D ^0!" /4 2@#R %( [@!8 .L 7@#I &0 Y@!J
M .0 < #B '8 WP!] -T A@#9 (\ U0": -$ IP#. +8 RP#. ,D \ #' /\
MQ0#_ +L _P"T /\ K0#_ *D _P#_    _P   /\   #_    ^P " /8 #0#Q
M !, [0 > .P * #I #( XP [ -T 1 #8 $L TP!1 -  6 #- %T RP!C ,D
M: #& &\ Q !V ,( ?@"_ (< O "2 +H GP"W *T M0#! +( Y "Q /T KP#_
M *P _P"E /\ H #_ )P _P#_    _P   /L   #N    Y    -P " #3 !
MSP 8 ,L (@#) "L Q@ T ,$ /0"] $0 N@!+ +< 40"U %8 L@!< +  80"N
M &< K !N *H =@"H '\ I@"* *, E@"A *4 GP"V )T T0"< /, FP#_ )P
M_P"6 /\ DP#_ )  _P#_    ]@   .<   #3    Q@   +T  P"X  T LP 3
M +$ ' "O "4 K@ N *D -@"F #T HP!$ *$ 2@"? $\ G0!5 )L 6@": &
MF !F )8 ;@"4 '< D@"! )  C@". )P C "M (H PP") .@ B #_ (D _P"'
M /\ A0#_ (( _P#S    XP   ,P   "\    L    *<   "A  @ G@ / )L
M%@"9 !\ F  G )8 +P"3 #< D0 ] (X 0P", $D BP!. (D 5 "' %D A0!@
M (0 9P"" &\ @ !Z 'X A@!\ )0 >@"D 'D N !X -@ =P#W '@ _P!X /\
M=P#_ '4 _P#F    RP   +<   "H    G@   )8   "/  0 BP , (@ $@"'
M !D A0 A (0 *0"" #  ?P W 'T /0!\ $, >@!( 'D 30!W %, =@!9 '0
M80!R &D <0!S &\ ?P!M (T ; "= &H KP!I ,@ : #M &D _P!I /\ :0#_
M &D _P#2    N    *4   "7    C0   (8   "!    ?  ( 'D #@!W !0
M=@ < '0 (P!S "L <0 Q &\ -P!N #T ; !# &L 2 !J $X : !4 &< 6P!E
M &, 8P!M &( > !@ (< 7P"6 %T J != +X 7 #D %P ^P!< /\ 7 #_ %P
M_P#"    J@$  )@#  ")!   ?P(  '@   !T    <  $ &T # !K !$ :0 7
M &@ '@!F "4 90 L &, ,@!B #@ 8  ] %\ 0P!> $D 7 !/ %L 5@!: %X
M6 !H %< <P!5 ($ 5 "1 %( HP!1 +< 40#6 %$ ]0!1 /\ 40#_ %( _P"V
M!P  GPD  (T+  !^#   <PL  &P*  !H!P  90,  &, !P!A  T 7P 3 %T
M&@!< "$ 6P G %D +0!8 #, 5@ Y %4 /P!4 $4 4P!+ %$ 4@!0 %H 3P!D
M $T ;P!, 'T 2@"- $D GP!( +( 1P#, $< [P!& /\ 1P#_ $< _P"L#
ME0X  (,0  !U$   :Q   &,/  !>#@  6PP  %H) @!9! H 5P / %4 %0!3
M !P 4@ C %$ *0!/ "\ 3@ U $T!.P!, 4$ 2@)( $D"3P!( E< 1@-A $4#
M;0!# WH 0@.+ $ #G  _ Z\ /@/( #T$Z@ ]!?P /0;_ #X&_P"D$   CA(
M 'P3  !N%   9!0  %P3  !6$@  4Q$  %$.  !0# 4 4 D, $\'$0!-!Q<
M2P@? $D()0!("2L 1PDQ $8). !$"CX 0PI% $(*30! "U4 /PM? #T+:P \
M"WD .@R* #@,G  W#*\ -0S' #4,Z0 U#?T -0W_ #8,_P"=$P  AQ4  '87
M  !I&   7A@  %88  !0%P  314  $H3  !)$0  20X' $@-#@!&#1, 1 T:
M $,.(0!"#B@ 0 XN #\.-0 ^#SP /0]# #L02P Z$%0 .!!> #80:P T$'D
M,A"* #$0G  O$+  +1#) "T1[  M$?\ +A'_ "\0_P"7%@  @AD  '$;  !D
M'   61P  %$<  !,&P  1QH  $08  !#%0  0A," $$2"P! $1  /A(7 #P2
M'@ [$R4 .A,K #@3,@ W$SD -A1  #042  S%%$ ,11< # 5:  N%7< +!6(
M "H5F@ H%:X )Q7' "85Z@ G%?\ *!7_ "D5_P"1&@  ?1P  &T>  !@'P
M5A\  $X?  !('@  0QT  $ <   ^&@  /1@  #L7!P Y%@X .!<4 #87&P U
M&"( ,Q@H #(8+P Q&38 ,!D] "X91@ M&D\ *QI9 "H:9@ H&G0 )AJ& "0:
MF0 B&JT (1K% " :Z  A&OX (AK_ ",:_P"-'0  >1\  &DA  !<(@  4B(
M $HB  !$(0  /R$  #P@   Y'@  .!L  #4<!  T' T ,AP2 # =&  O'1\
M+ATE "T>+  K'C, *AX[ "D?0P G'TT )A]7 "0?9  B'W( (!^$ !\?EP =
M'ZL &Q_# !L?YP ;'_T '1__ !X>_P")(   =2(  &4C  !9)   3R4  $<E
M  !!)   /",  #@C   U(@  ,R   # @ 0 N(0H +"$0 "LA%0 J(AP *"(C
M "<B*0 F(S  )2,X ",C00 B)$H (215 !\D80 =)'  &R2" !DDE0 7)*H
M%B3! !4DY0 6)/P %R/_ !DC_P"%(@  <20  &(F  !6)P  3"<  $0G   ^
M)P  .28  #4F   Q)0  +B0  "LE   I)0< )R8. "4F$P D)QD (R<@ "(G
M)P A*"X ("@V !XH/@ =*$@ &RE3 !DI7P 8*6X %BF  !0IE  2*:@ $2G
M !$HY  1*/L $RC_ !0G_P" )0  ;B<  %\H  !3*0  22H  $(I   [*0
M-BD  #(H   N*   *B@  "8I   D*@0 (BL, " K$0 ?+!8 '2P= !PL)  ;
M+2L &BTS !@M/  7+44 %BY0 !0N70 2+FP $2Y^ ! ND@ .+J< #2V]  TM
MWP -+?D #BS_ ! L_P!\*   :BH  %LK  !0+   1BP  #\L   Y+   -"L
M "\K   K*P  )BP  "(N   ?+P  '# ) !HQ#@ 9,1, %S$: !8R(0 5,B@
M%#(P !,R.0 2,T, $3-. ! S6P .,VD #3-Z  PSC@ *,Z( "#*Y  @RV0 (
M,O0 "C'_  LQ_P!W*P  9BT  %@N  !-+P  0R\  #PN   V+@  ,2X  "TN
M   I+@  (S   !\R   ;,P  %S4% !0V#  2-Q$ $3<6 !$W'0 0."0 #S@L
M  XX-0 -.#\ ##A*  LX5P ).&4 !SAV  4XB@ #.)\  3>U  $WTP "-_$
M S;_  4V_P!S+@  8C   %0Q  !),0  03$  #DQ   T,0  +S   "LP   E
M,@  (#,  !LV   7.   $SH" ! \"0 -/0X ##T3  L]&0 */2$ "3TI  @]
M,0 &/CL !3Y&  ,^4@ !/F$  #YR   ^A@  /9P  #VR   ]T   //   #S_
M   \_P!M,@  73,  % T  !&-   /C0  #<T   R,P  +3,  "<T   B-@
M'3@  !@Z   4/0  $#\"  U!"  )0PT !D01  -$%@ "1!T  $0D  !$+0
M1#8  $1!  !$3@  1%P  $1M  !$@0  1)@  $.O  !#S0  0O   $+_  !"
M_P!H-@  6#<  $PX  !#.   .S<  #4V   P-@  *3<  ",Y   >.P  &#T
M !-    00@  #44!  A'!P #20P  $D/  !*$P  2QD  $L@  !+*   2S(
M $L]  !,20  3%<  $MH  !+?0  2Y0  $JL  !*R@  2>\  $G_  !)_P!B
M.@  5#L  $D[  ! .P  .3H  #,Y   L.@  )3P  !\_   900  $T0  !!'
M   ,20  "$P   )/!0  4 H  % -  !1$   4A4  %0;  !4(P  5"P  %0W
M  !41   5%(  %1C  !4=P  5(\  %.H  !2Q@  4NT  %'_  !1_P!</P
M3S\  $4_   ^/@  -ST  "\^   G0   ($,  !E&   320  #TP   M/   &
M4@   %0   !7 @  6 <  %D+  !:#@  6Q$  %T6  !>'0  7R8  %\Q  !>
M/0  7DP  %Y=  !><0  78D  %VC  !<P0  6^L  %K_  !:_P!61   2T,
M $-"   \00  ,D(  "E%   A2   &DL  !-.   .4@  "E4   -9    6P
M %X   !@    8@(  &,&  !E"@  9@X  &@1  !J%P  :Q\  &LI  !K-@
M:T4  &M6  !J:@  :H(  &F=  !HNP  9^<  &;_  !E_P!12   2$@  $%&
M   W1P  +$H  "--   ;40  $U4   Y9   (70   6$   !D    9P   &H
M  !L    ;@   '    !R!0  <PD  '4-  !W$0  >A@  'LA  ![+@  >CT
M 'I.  !Y8@  >7D  'B6  !WLP  =>   '3\  !S_P!.30  1TP  #M-   P
M3P  )E,  !Q8   37   #6$   9F    :@   &\   !R    =@   'D   !\
M    ?0   '\   "!    @P(  (8'  "(#   BQ$  (X8  ".)   CC,  (U$
M  ",6   BV\  (J,  ")J@  B,\  (;W  "%_P!-40  05,  #15   I6@
M'E\  !1E   -:@  !7    !V    >P   '\   "#    AP   (H   "-
MC@   )$   "3    E0   )@   ":!0  G0P  * 1  "C&@  HR@  *(Z  "A
M3@  H&4  *"!  ">H   G<$  )ON  ":_P!&60  .5P  "UA   A9P  %FX
M  YU   %>P   ($   "'    C0   )(   "6    F@   )T   "?    H0
M *0   "F    J    *L   "N    L0,  +0+  "X$0  N1X  +DO  "X0P
MMUH  +5V  "TEP  M+4  +'B  "P_  _9   ,6D  "5O   8=P  #W\   :'
M    C@   )0   ":    H    *4   "J    K@   +$   "R    M0   +<
M  "Z    O    +\   ##    Q@   ,D   #."@  TA,  -(C  #1-P  T$\
M ,YJ  #-B@  RJL  ,O+  #+[P W<0  *7@  !V    1B0  ")$   ":
MH0   *<   "M    LP   +D   "^    P@   ,4   #&    R0   ,P   #.
M    T@   -4   #:    W@   .$   #E    Z@L  .L7  #J*P  ZD,  .I>
M  #J>@  ZYD  .NU  #KU0#_    _P   /\  0#_  < _P - /\ $@#_ !L
M_P E /\ +P#_ #H _P!# /\ 2P#_ %, _P!: /T 8 #[ &8 ^@!K /@ <@#V
M '@ ] "  /$ B0#O )( [ "= .D J@#F +P XP#< -\ ]P#= /\ S #_ +X
M_P"U /\ L #_ *T _P#_    _P   /\   #_    _P & /\ #0#_ !0 _P ?
M /\ *0#[ #, ]P ] /, 10#O $T [ !3 .@ 60#E %\ XP!E .  :@#= '$
MV@!X -8 @ #2 (H SP"5 ,P H@#( +( Q0#) ,( [0#  /\ NP#_ +  _P"H
M /\ I #_ *$ _P#_    _P   /T   #Z    ^    /  "0#L !$ Z  9 .<
M(P#E "T W@ V -8 /@#1 $8 S0!, ,H 4@#( %@ Q0!= ,, 8P#  &D O@!P
M +P > "Y ($ MP"- +0 F@"Q *D K@"\ *P X0"J /P J #_ *  _P"9 /\
ME@#_ )0 _P#_    ^0   /(   #G    VP   -$ ! #*  T QP 4 ,0 '0#"
M "8 OP O +L -P"W #\ M !% +$ 2P"N %$ K !6 *H 7 "H &$ I@!H *,
M< "A 'D GP"$ )T D0": *  F "Q )8 S "5 /$ E #_ )$ _P"+ /\ B #_
M (8 _P#W    [    -X   #)    O    +0   "O  H JP 0 *D %P"H "
MIP H *( , "? #@ G  ^ )H 1 "8 $H E@!/ )0 50"3 %H D0!A (\ : "-
M '$ BP![ (D B "' )< A0"H (, O@"! .0 @ #_ (  _P!\ /\ >P#_ 'D
M_P#I    UP   ,$   "Q    I@   )T   "7  4 E  - )( $@"0 !H CP B
M (X *@"+ #$ B0 X (< /@"% $, @P!( ($ 3@!_ %0 ?@!: 'P 80!Z &D
M> !S '8 ?P!U (X <P"? '$ LP!P -  ;P#V &\ _P!O /\ ;0#_ &P _P#:
M    OP   *P   ">    DP   (P   "%    @@ ) '\ #P!^ !4 ?0 < 'P
M) !Z "L =P Q '4 -P!T #T <@!" '$ 2 !O $T ;@!3 &P 6@!K &( :0!L
M &< > !F (8 9 "7 &( J@!A ,( 8 #K &$ _P!A /\ 80#_ &  _P#%
MK0   )L   "-    @P   'P   !W    <@ % '  # !N !$ ;  7 &P '@!K
M "4 :0 L &< ,0!F #< 9  ] &, 0@!B $@ 8 !. %\ 50!= %T 7 !F %H
M<@!9 (  5P"0 %8 HP!5 +D 5 #> %0 ^P!4 /\ 50#_ %4 _P"V    GP
M (T   !_    =0   &X   !I    9@ ! &, "0!A  X 8  3 %\ &0!> "
M70 F %L + !: #( 6  W %< /0!6 $, 50!) %, 4 !2 %@ 40!A $\ ; !.
M 'H 3 "* $L G !* +$ 20#. $D \P!) /\ 20#_ $H _P"J 0  E 4  (('
M  !T"   :@@  &,&  !>!   6P   %D !0!7  P 5@ 0 %0 %0!3 !L 4@ B
M %$ * !0 "T 3@ S $T . !, #X 2P!% $H 3 !( %0 1P!= $8 : !$ '4
M0P"% $$ F !  *L 0 #% #\ Z@ _ /\ 0 #_ $  _P"@"   B@L  'D-  !L
M#0  80T  %H-  !5"P  4@D  % &  !/ @@ 3@ - $P $@!+ !< 2@ > $D
M(P!' "D 1@ O $4 - !$ #H 0@!! $$ 2 !  %  /@!: #T 9  \ '( .@""
M #D E  X *< -P"^ #8 XP V /D -@#_ #< _P"8#0  @PX  '(0  !E$0
M6Q$  %,0  !.$   2@X  $@-  !'"@, 1P<* $4$#@!$ A, 0@(: $$"( !
M R4 /@,K #T$,0 \!#< .P0^ #H%10 Y!4X -P57 #8%8@ T!G  ,@:  #$&
MD@ P!J4 +P6[ "X%W0 N!O4 +0?_ "X'_P"1$   ?1$  &P3  !?%   510
M $X4  !($P  1!(  $$0  ! #@  0 T& $ *#  ^"1  / D6 #L*'  Y"B(
M. HH #<++@ V"S4 -0L[ #,+0P R#$P , Q6 "\,80 M#&\ *PQ_ "H,D@ H
M#*4 )PR[ "4,W0 E#?4 )@W_ "<-_P"+$@  =Q0  &<6  !;%P  41@  $D7
M  !#%P  /Q4  #P4   Z$@  .1$! #D/"  X#@T -PX2 #4.&  T#A\ ,@XE
M #$/+  P#S( +Q Z "T00@ L$$L *A!5 "@080 F$&\ )!"  ",0DP A$*<
M'Q"] !X0X  >$?< 'Q#_ " 0_P"&%   <Q<  &,9  !7&@  31L  $4:  !
M&@  .QD  #@8   U%@  -!0  #,2!  R$@L ,1(0 "\2%0 M$AP +!,B "L3
M*0 J$S  *!,W "<4/P F%$@ )!13 "(47P @%6T 'Q5^ !T5D0 ;%:4 &16[
M !@5W@ 8%?@ &13_ !H4_P""%P  ;QH  %\<  !3'0  2AT  $(=   \'0
M-QP  #0;   Q&@  +QD  "X6   L%P@ *Q8. "D7$P H%QD )Q@@ "48)@ D
M&"T (Q@T "(9/0 @&48 'AE1 !T970 ;&FL &1I\ !<:CP 5&J, %!FZ !(9
MVP 3&?8 %!G_ !48_P!]&@  :QT  %P?  !0(   1R   #\@   Y'P  -!\
M #$>   M'0  *QP  "D;   G&P4 )1L, "0<$0 B'!8 (1P= " =(P ?'2H
M'ATR !P>.@ ;'D0 &1Y. !<>6P 6'FD %!]Z !(>C0 1'J( $!ZX  X>V  /
M'O4 $!W_ !$=_P!Z'0  9Q\  %DA  !-(@  1"(  #PB   V(@  ,B$  "XA
M   J(   )R   "0?   B( ( (" * !XA#P =(10 '"$: !LB(0 9(B< &"(O
M !<B.  5(T$ %"-, !(C6  1(V< $"-X  XCBP -(Y\ #".T  LCT  +(O
M#"+_  TA_P!V'P  9"(  %8C  !+)   020  #HD   T)   +R,  "LC   H
M(P  )",  " C   =)   &R4' !DF#0 7)A$ %B87 !4G'@ 4)R4 $R<L !(G
M-0 1*#\ $"A*  XH5@ -*&0 #"AT  HHAP )*)L !R>Q  4GS  &)^P !R;^
M  @F_P!Q(@  8"0  %,F  !()P  /R<  #<F   Q)@  +28  "DE   E)0
M(B4  !TG   9*   %BH$ !0K"P 2+!  $2P4 ! L&P 0+"( #BPI  XM,@ -
M+3L "RU&  HM4@ (+6  !BUP  0M@P "+9@  "RN   LR0  +.L  2O\  (K
M_P!M)0  72<  $\H  !%*0  /"D  #4I   O*   *R@  "<G   C)P  'R@
M !LJ   7+   $RX" ! P"  .,0T #3$2  PQ%P +,1X "C$F  @R+@ ',C<
M!3)"  ,R3@ !,EP  #)L   R?P  ,I4  #&L   QQP  ,.H  ##\   P_P!H
M*0  6"H  $PK  !!+   .2P  #(K   M*P  *2H  "4J   @*P  '"P  !<N
M   3,   $#("  XT!P *-PP !S<0  4W%  #-QL  C<B   W*@  .#,  #@^
M   X2@  .%@  #AH   X?   -Y(  #>I   VQ0  -NH  #;]   U_P!C+
M5"X  $@O   ^+P  -BX  # N   K+0  )RT  "(M   =+P  &#$  !0S   0
M-0  #C<!  HZ!P &.PL  CP.   ]$@  /A<  #X>   ^)@  /B\  #XZ   ^
M1@  /E0  #YD   ^=P  /H\  #VG   ]PP  /.D  #S]   [_P!>,   4#$
M $0R   [,@  -#$  "XP   I+P  )#   !XR   9-   %#8  ! Y   -.P
M"CT   5 !0  00H  $(-  !#$   1!0  $4:  !&(@  1BL  $8U  !&00
M1D\  $9?  !&<P  18H  $6D  !$P   0^@  $/^  !"_P!8-   2S4  $$U
M   Y-0  ,C0  "TS   F-   (#4  !HX   4.@  $#T   U    )0@  !$4
M  !' P  2 <  $H+  !+#@  3!$  $X5  !/'   3R4  $\O  !//   3TH
M $]:  !.;0  3H4  $V@  !,O   2^<  $O^  !*_P!3.0  1SD  #XY   W
M.   ,3<  "DW   A.0  &SP  !4_   00@  #$4   =(   "2@   $T   !/
M    400  %('  !4"P  50X  %<1  !9%P  6A\  %DI  !9-@  640  %E4
M  !89P  6'\  %>:  !6MP  5>,  %3]  !4_P!./0  0ST  #P\   U.P
M+#P  "0^   <00  %40  !!(   +2P  !4X   !1    5    %<   !9
M6P   %T"  !>!@  8 L  &(.  !D$@  9Q@  &<B  !F+@  9CP  &9-  !E
M8   97<  &23  !CL0  8=T  &#\  !?_P!)0@  04$  #H_   P0   )D,
M !Y&   52@  $$X   I2   #5@   %H   !=    8    &,   !E    9P
M &D   !K 0  ;04  &\*  !R#@  =1(  '<;  !V)@  =C4  '5&  !T60
M=&\  '.+  !RJ0  <,T  &_W  !N_P!&1@  0$4  #5&   J2   ($P  !=1
M   05@  "5H   %?    8P   &@   !K    ;P   '(   !U    =P   'D
M  ![    ?0   ( #  "#"   A@T  (D3  "*'0  BBL  (D\  "(3P  AF8
M (6!  "$H   @L(  ('P  !__P!&2P  .DP  "Y/   C4P  &%@  !!>   )
M9    &D   !O    =    '@   !\    @0   (0   "'    B    (L   ".
M    D    ),   "6    F0<  )T-  "A%   H"$  * Q  ">1   G5L  )QV
M  "9E@  F;4  );E  "5_@ _4@  ,E4  "9:   ;8   $6<   EM    =
M 'L   "!    A@   (L   "0    E    )<   "9    G    )\   "A
MI    *<   "J    K0   +$&  "U#0  N!8  +<F  "V.0  M5   +1J  "R
MB0  L*H  *[/  "M]0 W7   *V$  !YH   3<   "W@   "     AP   (X
M  "5    F@   )\   "D    J    *P   "M    L    +,   "U    N
M +L   "_    PP   ,<   #+!0  T0X  -$;  #0+@  ST4  ,U?  #+?@
MR9X  ,B^  #%Z0 O:0  (W   !9Y   -@0   8L   "3    FP   *(   "H
M    K@   +0   "X    O0   ,    #"    Q0   ,@   #+    S@   -$
M  #6    VP   -\   #D    Z 8  .L1  #J(P  ZCH  .E4  #G<@  Y9,
M ..S  #CU #_    _P   /\   #_  0 _P + /\ $ #_ !< _P A /\ *P#_
M #4 _P ^ /\ 1P#_ $X _P!5 /P 6P#Z &$ ^ !F /8 ;0#T ', \@![ .\
MA #M (X Z@"9 .8 IP#C +D WP#5 -L ]P#6 /\ P #_ +( _P"J /\ I0#_
M *( _P#_    _P   /X   #\    _  # /X "P#_ !$ _P : /T ) #Y "X
M]  X /  0 #L $@ Z0!. .8 5 #B %H WP!? -P 90#8 &L U !R -  >P#-
M (4 R@"1 ,< G@## *X P #% +T ZP"[ /\ L #_ *0 _P"< /\ F #_ )4
M_P#_    ^@   /0   #Q    \@   .H !0#G  X X@ 5 .$ '@#A "@ V  Q
M -  .0#+ $  R !' ,4 30#" %, OP!8 +T 7@"[ &0 N0!K +8 <P"T 'P
ML0"( *X E0"K *0 J "X *8 W "C /L GP#_ )4 _P"/ /\ BP#_ (D _P#Y
M    [P   .<   #?    SP   ,@   #!  H OP 1 +P & "[ "$ N0 J +0
M,@"Q #H K@!  *L 1@"H $P I@!1 *, 5@"A %P GP!C )T :@"; ', F0!^
M )8 C "4 )L D@"M )  QP". /  C0#_ (8 _P"  /\ ?0#_ 'P _P#M
MX    -$   "_    LP   *H   "F  4 H@ - *$ $P"@ !L GP C )L *P"8
M #( E0 Y ), /P"1 $0 CP!* (X 3P", %4 B@!; (@ 8P"& &L A !V ((
M@@"  )( ?@"C 'P N@!Z .$ >0#_ '< _P!R /\ < #_ &\ _P#=    RP
M +8   "G    G0   )0   ".  $ BP * (D $ "( !4 AP = (< )0"$ "P
M@@ R '\ . !] #T >P!# 'D 2 !X $X =@!4 '4 6P!S &, <0!N &\ >@!M
M (D ; ": &H K@!I ,P : #V &< _P!E /\ 9 #_ &, _P#*    M    *$
M  "3    B0   ((   ![    >  % '8 # !U !$ =  8 ', 'P!R "4 <  L
M &X ,@!L #< :@ \ &D 0@!H $@ 9@!. &4 50!C %T 8@!F &  <@!> (
M70"2 %L I0!: +X 60#I %D _P!9 /\ 6 #_ %@ _P"Y    H@   )    "#
M    >0   '$   !M    :0 ! &8 "0!E  X 9  3 &, &0!C "  80 F &
M+ !> #$ 7  W %L / !: $( 6 !( %< 3P!6 %< 5 !@ %, ; !1 'D 4 "*
M $\ G@!. +0 30#: $T ^P!- /\ 30#_ $T _P"J    E    ((   !U
M:P   &0   !@    70   %H !0!8  P 5P 0 %8 %0!6 !L 50 A %, )P!2
M "P 40 Q $\ -P!. #T 30!# $P 2@!* %( 20!; $@ 9@!& ', 10"$ $0
MEP!# *P 0@#) $( \0!" /\ 0P#_ $, _P">    B0   '@#  !J!   800
M %H#  !5 0  4@   %   @!.  D 30 - $P $0!+ !< 2@ < $D (@!( "<
M1P M $4 ,@!$ #@ 0P ^ $( 10!! $T /P!6 #X 80 ] &X .P!^ #H D0 Y
M *8 . "_ #@ Z  X /\ .0#_ #D _P"5 P  @ <  &\)  !B"@  6 L  %$*
M  !,"   208  $<#  !&  8 1  + $, #P!" !, 00 8 $$ '@ _ ", /@ I
M #T +@ [ #0 .@ Z #D 00 X $D -P!2 #8 70 T &H ,P!Z #( C  Q *$
M, "X "\ W@ O /D +P#_ #  _P","0  > P  &@-  !<#@  4@X  $L.  !%
M#0  00P  #\*   ^" ( /00( #P!#0 [ !  .@ 5 #D &@ X "  -@ E #4
M*P T #  ,P W #( /@ Q $8 +P!0 "X 6@ M &< *P!W "H B0 I )T * "S
M "< T0 G /( )P#_ "< _P"&#   <@X  &,0  !6$0  31$  $41  ! $
M/ \  #D.   W#0  -@L$ #8("@ U!@X - 42 #($%P Q!1P , 4B "\%*  N
M!BX +08T "L&/  J!D0 *0=. "<'60 F!V4 ) =U ",'AP B!YL ( :P " &
MRP ?!>T 'P;^ !\'_P" #@  ;1$  %X2  !2$P  2!,  $$3   [$P  -Q(
M #01   R$   , \! # -!@ P"PL +PH0 "T*%  L"QD *@L? "D+)0 H#"L
M)PPR "8,.@ D#$, (PQ- "$-6  @#64 '@UU !P-B  :#9P &0VQ !@,R@ 7
M#.L %PW\ !@,_P![$0  :1,  %H5  !.%@  118  #T6   X%0  ,Q4  # 4
M   M$P  *Q(  "H0 P J#P@ *0X- "@.$0 F#A8 )0\= "0/(P C#RD (1 Q
M " 0.0 >$$( '1!, !L06  9$&8 %Q!V !40B0 4$)X $A"S !$0S@ 1$.X
M$A#^ !(0_P!W$P  914  %<7  !+&   0AD  #H9   T&   ,!<  "P7   I
M%@  )Q4  "84 0 E$@0 (Q(+ "(2#P A$A0 (!(: !X3(  =$R< '!,N !H3
M-@ 9%$  %Q1* !845@ 4%&0 $A1T !$4AP 0%)P #A2Q  T4R@ -%.L #A/^
M  X3_P!S%0  81@  %,:  !(&P  /QL  #<;   R&@  +1H  "D9   F&
M)!@  "(7   @%@$ 'A8( !T6#0 ;%Q( &A<7 !D7'0 8&"0 %A@K !48-  4
M&#T $AE( !$95  0&6( #AER  T9A  ,&9@ "AFM  D8Q@ )&.< "1CZ  H7
M_P!O&   7AH  % <  !%'0  /!T  #4=   O'0  *AP  "8;   C&P  (1H
M !X:   <&@  &AL% !@;#  6'!  %1P5 !0<&P 3'"( $ATI !$=,0 0'3L
M#AU%  T>40 ,'EX "AYM  D>@  ''I0 !1VJ  ,=P@ #'>8 !!SX  4<_P!K
M&@  6QT  $T>  !"'P  .A\  #(?   M'P  *!X  "0>   A'0  'AT  !P=
M   8'@  %1\" !,@"0 2(0X $"$2 ! A&  .(1\ #B(F  TB+@ ,(C< "B)!
M  DB30 '(EH !2)I  ,B?  !(I$  "*H   AP   (>4  "#X   @_P!G'0
M5Q\  $HA  ! (0  -R(  # A   J(0  )B   "(@   ?'P  '!\  !D@   6
M(0  $B," ! D!P .)@P #"80  LF%0 *)AP "28B  @F*@ &)S, !"<]  ,G
M20 !)U8  "=F   G>0  )X\  ":F   FOP  )>0  "7Y   D_P!C(   5"(
M $<C   ])   -"0  "XC   H(P  )"(  "$B   >(0  &B(  !<C   3)
M$"8"  XH!P +*@L ""L.  8K$P $*Q@  BL?  $L)P  +#   "PZ   L10
M+%,  "QC   L=@  +(P  "ND   KO@  *N0  "KZ   I_P!?(P  4"4  $0F
M   Z)@  ,B8  "LF   F)0  (R0  !\D   ;)   %R4  !0G   1*0  #BL"
M  LM!@ '+PL !# .   P$0  ,14  #$<   Q(P  ,BP  #(V   R0@  ,D\
M #)?   R<@  ,8D  #&B   PO   ,.0  "_[   O_P!:)P  3"@  $ I   W
M*0  +RD  "DH   E)P  (28  !PG   8*   %"H  !$L   .+@  "S !  <R
M!0 #- D  #4,   V#P  -Q(  #@8   X(   ."@  #@R   Y/0  .4L  #E;
M   X;@  .(4  #>?   WN@  -N0  #7\   U_P!5*@  2"P  #TL   T+
M+2L  "@J   D*0  'BH  !DK   4+0  $2\   TQ   *-   !S8   (X!
M.@<  #L*   ]#0  /A   $ 4  ! &P  0"0  $ N  ! .0  0$<  $!6  !
M:0  0(   #^;   ^MP  />,  #S\   \_P!0+P  0R\  #DO   R+P  +"T
M "<L   @+0  &B\  !4Q   1,P  #38   DX   %.P   #T   !  0  000
M $,'  !%"P  1@X  $@1  !*%@  2AX  $HH  !*-   24(  $E1  !)9
M2'L  $B7  !'M   1N   $7\  !$_P!*,P  /S,  #8S   P,0  *C   ",Q
M   <,P  %C4  !$X   -.P  "#X   -!    0P   $8   !(    2@   $P$
M  !.!P  3PL  %$.  !4$@  51D  %4B  !4+@  5#P  %1+  !37@  4W0
M %*0  !1K@  4-<  $_[  !._P!%-P  /#<  #4V   O-   )C4  !XW   7
M.@  $3T   Q!   '1    $@   !*    30   %    !3    50   %<   !8
M @  6P8  %T+  !?#@  8A,  &(;  !B)P  8C0  &%%  !@5P  8&T  %^)
M  !=IP  7,P  %KX  !9_P!!/   .CL  #0Y   J.@  (3P  !A    10P
M#$<   9+    3P   %,   !6    60   %P   !?    80   &,   !E
M9P$  &H%  !M"@  < X  ',5  !R(   <BT  '$]  !P3P  ;V4  &Z   !M
MGP  :\$  &GQ  !H_P _0   .3X  "X_   D0@  &D8  !)*   ,3P  !%0
M  !8    70   &$   !E    :    &L   !N    <0   ',   !U    >
M 'L   !^ P  @0H  (4/  "'%P  AB0  (4T  "$1@  @ET  (%V  !_E@
M?K8  'SG  !Z_P _1   ,T4  "A(   =3   $U(   Q7   #70   &,   !H
M    ;0   '$   !V    >@   'X   "!    @P   (8   ")    BP   (X
M  "2    E0$  )D)  ">$   GAH  )TI  "</   FE(  )AL  "6BP  E*H
M )+4  "0^@ X2P  +$X  "!3   560  #6    -G    ;@   '0   !Z
M@    (0   "*    C@   )(   "5    EP   )H   "=    H    *,   "G
M    JP   *\   "T"0  N!   +<>  "U,   LT8  +%@  "O?@  K*   *O!
M  "I[@ Q50  )%L  !AA   .:0  !7$   !Y    @0   (@   "/    E
M )H   "?    I    *@   "I    K    *\   "S    M0   +D   "]
MP0   ,8   #+    T0H  -,4  #1)0  T#L  ,U4  #*<0  R)(  ,6S  ##
MW@ I8@  '&D  !%Q   '>P   (0   "-    E0   )T   "C    J0   *\
M  "T    N0   +P   "^    P@   ,4   #(    S    -    #4    V@
M -\   #D    Z@   .X,  #M&@  ["\  .I)  #H90  YH8  .2E  #BQ@#_
M    _P   /\   #\  $ _  ( /X #@#_ !0 _P = /\ )@#_ #  _P Z /\
M0@#_ $D _@!0 /L 5@#Y %P ]@!B /0 : #R &\ \ !V .T ?P#J (D YP"5
M .0 HP#@ +4 VP#0 -4 ]@#* /\ M@#_ *@ _P"? /\ F@#_ )8 _P#_
M^P   /8   #S    \P   /8 "0#Z  X _0 6 /L ( #W "H \@ S .T .P#I
M $, Y@!) .( 3P#> %4 VP!; -8 8 #2 &< SP!N ,P =@#) (  Q@", ,(
MF@"_ *H NP#! +@ Z0"V /\ IP#_ )H _P"2 /\ C0#_ (H _P#Z    \0
M .H   #G    YP   .0  0#@  L VP 1 -H &@#; ", T0 L ,H - #& #L
MP@!" +\ 2 "\ $X N@!3 +@ 60"V %\ LP!F +$ ;@"N '< K "# *D D0"F
M *$ HP"U *  V "> /L E0#_ (L _P"% /\ @ #_ 'X _P#O    XP   -H
M  #3    Q@   +\   "Y  8 MP . +0 % "T !T LP E *X +0"K #0 IP [
M *0 00"A $8 GP!, )T 40"; %< F0!> )< 90"5 &X DP!Y )  AP". )<
MC "I (D Q "( .\ A0#_ 'P _P!V /\ <P#_ '( _P#@    T    ,8   "V
M    J0   *$   "=  $ F0 * )@ $ "8 !8 EP > )0 )@"1 "T CP T (P
M.@"* #\ B !% (< 2@"% %  @P!6 ($ 7@"  &8 ?@!Q 'P ?0!Y (T =P"@
M '4 M@!S -\ <@#_ &X _P!I /\ 9P#_ &4 _P#,    O@   *L   "=
MDP   (H   "%    @@ % (  #0!_ !$ ?P 8 (  ( !] "8 >@ M '< ,P!U
M #@ =  ^ '( 0P!P $D ;P!/ &T 5@!L %X :@!H &@ =0!G (0 90"6 &0
MJP!B ,D 80#V &  _P!< /\ 6P#_ %H _P"]    J0   )<   ")    ?@
M '@   !S    ;P ! &T "0!L  X :P 3 &L &0!J "  :  F &8 + !E #(
M8P W &( / !@ $( 7P!( %T 3P!< %< 6@!A %D ;0!7 'L 5@". %4 H@!3
M +L 4@#I %( _P!0 /\ 3P#_ $\ _P"M    F    (8   !X    ;@   &<
M  !C    8    %T !0!<  L 6P 0 %L %0!; !L 6@ A %@ )@!6 "P 5  Q
M %, -@!2 #P 40!" $\ 20!. %$ 30!; $L 9@!* '0 20"% $@ F0!' +$
M1@#8 $8 _ !% /\ 10#_ $4 _P"?    B0   '@   !L    8@   %L   !6
M    4P   %$  @!/  @ 3P - $X $0!. !8 30 < $P (0!* "8 20 L $@
M,0!' #< 10 ] $0 1 !# $P 0@!5 $  8  _ &X /@!^ #T D@ \ *D .P#'
M #L \P [ /\ .P#_ #P _P"3    ?@   &X   !A    6    %$   !,
M20   $<   !%  4 1  + $, #@!# !( 0P 7 $( '0!  "( /P G #X +  ]
M #( .P X #H /P Y $< . !0 #< 6P U &@ - !X #, C  R *( ,0"\ #$
MYP Q /\ ,@#_ #, _P")    =@,  &8%  !9!P  4 <  $D&  !#!0  0 ,
M #X!   \  , .P ( #H #0 Z !  .0 4 #D &0 W !X -@ C #4 *  T "X
M,P T #( .P P $, +P!, "X 5P M &0 + !S "L AP J )P *0"U "D W  I
M /L *0#_ "H _P"!!   ;@@  %\*  !3"P  2@L  $(+   ]"@  .0D  #8(
M   U!0  - (& #, "@ R  X ,0 1 #$ %0 P !H +P ? "X )  L "H *P P
M "H -P I #\ * !) "< 5  F &  ) !O ", @@ B )< (0"N "$ S  A /,
M(0#_ "( _P!["0  : P  %H-  !.#@  10X  #T.   X#0  ,PT  # ,   N
M"P  +0D# "T&"  L! P *P(/ "H!$@ I 1< * $< "< (0 F "< )0 M "0
M-  C 3T (@%& "$!40 ? 5T '@%L !P!?P ; )0 &@"J !H Q0 : .L &0#_
M !H _P!U#   9 X  %4/  !*$   0!   #D0   S$   +P\  "P.   I#@
M)PT! "<,!0 G"@H )@@- "4'$  D!A0 (@89 "$&'P @!R0 'P<K !X',@ =
M!SH ' A$ !H(3P 9"%P %PAK !8(?0 5!Y$ % >G !,&OP 2!>0 $@7Z !(%
M_P!Q#@  7Q   %$1  !&$@  /1(  #82   P$@  *Q$  "@1   E$   (Q
M "(.!  A#0< (0P+ " +#@ ?"Q( '0L7 !P,'  ;#"( &@PI !D,,0 8##D
M%@U# !4-3P 3#5P $@UK ! -?@ /#9( #@VG  T,O@ -#.  #0SU  T,_P!M
M$   7!$  $X3  !#%   .A0  #(4   M%   *!,  "43   B$@  (!$  !X1
M P <$ 4 ' \( !L/#  :#A  &0\4 !</&@ 6#R$ %1 H !00,  2$#D $1!$
M ! 04  .$%T #1!K  P0?  +$)  "1"E  @0O  '$-\ !Q#T  </_P!I$0
M6!0  $L5  ! %@  -Q8  # 6   J%@  )A4  "(5   ?%   '1,  !H3 @ 9
M$@0 %Q(& !82"@ 5$@X %!(2 !(2&  1$QX $1,E ! 3+@ .$S< #11   P4
M2P +%%@ "11G  <4>  &%(T !!2C  ,3NP "$]T  1+T  (2_P!E$P  518
M $@7   ]&   -!@  "T8   H&   (Q<  " 7   =%@  &A4  !@5 @ 6%00
M%!4% !(6"  1%@T $!<0  X7%0 .%QL #1<B  P7*0 +&#( "1@\  <81P %
M&%0 !!AC  (8=0 !&(L  !>A   7N0  %]T  !;U   6_P!A%@  4A@  $4:
M   [&@  ,AH  "L:   E&@  (1D  !X8   ;&   &!<  !87 @ 4%P, $A@%
M ! 9!P .&PL #!L/  L;$P *&Q@ "!P?  <<)@ %'"\ !!PX  (<1   '5$
M !U@   =<@  '(@  !R@   ;N0  &]X  !KV   :_P!>&   3QH  $(<   X
M'   +QT  "D<   C'   'QL  !P:   9&0  %QD! !09 @ 2&@, $!L$  X=
M!P ,'@L "1\.  8@$0 %(!8  R <  $A(P  (2L  "$U   A0   (4X  "%=
M   A;P  (88  "">   @N   ']X  ![X   >_P!:&P  2QT  #\>   U'P
M+1\  "<>   B'0  'AT  !L<   8&P  %1L  !(<   0'0( #A\$  PA!@ )
M(@H !2,-  (D$   )1,  "49   F(   )B@  "8R   F/0  )DH  "9:   F
M;   )H,  "6<   EMP  )-\  "/Y   C_P!5'@  1R   #PA   R(0  *R$
M "4@   @'P  '1X  !H=   6'@  $QX  ! @   .(0  #","  @E!0 %)PD
M "@+   J#@  *Q$  "P6   L'0  +"4  "PN   L.@  +$<  "Q6   L:0
M+(   "N:   JM0  *=\  "G[   H_P!1(@  1",  #@D   O)   *",  ",B
M   ?(0  '"   !<@   3(0  $",   XD   +)@  ""@   0J!   + <  "X)
M   P#   ,0\  #,3   S&0  ,R$  #,J   S-0  ,T,  #-2   S90  ,GL
M #*7   QLP  ,-X  "_[   N_P!,)0  /R8  #4G   M)@  )R4  "(D   >
M(P  &2,  !0D   1)@  #B@   LJ   '+    R\    Q @  ,P0  #4'   W
M"@  .0T  #H0   [%0  .QT  #LF   [,0  .SX  #M.   [8   .G<  #F2
M   XL   -]L  #;\   U_P!'*0  .RH  #(J   K*0  )2<  "$F   ;)P
M%2@  !$J   .+   "B\   8Q   !-    #8    X    .P$  #T$   _!P
M00H  $,.  !%$0  11@  $4A  !%+   1#D  $1(  !$6P  0W$  $*-  !!
MJP  0-(  #_Z   ^_P!"+0  ."X  "\M   I*P  )"H  !TJ   7+   $2X
M  TQ   )-   !#<    Z    /    #\   !!    1    $8   !( P  2@<
M $P+  !.#@  4!,  % <  !0)P  3S0  $]#  !/50  3FH  $V&  !,I
M2LH  $GX  !(_P ^,@  -3$  "XO   I+@  ("X  !DQ   2,P  #C<   DZ
M   "/0   $    !$    1P   $D   !,    3P   %$   !3    50$  %@&
M  !:"P  70X  %\5  !>(   7BP  %T\  !<3@  6V,  %I^  !8G0  5\
M %7R  !4_P Z-@  ,S0  "TR   D,P  &S8  !,Y   ./0  "$$   !%
M20   $P   !0    4P   %8   !9    6P   %T   !@    8@   &4   !H
M!0  :PL  &\0  !O&   ;B4  &TT  !M1@  :UL  &IU  !HE   9K8  &3I
M  !B_P X.0  ,C<  "@Y   >.P  %3\   Y$   '20   $T   !2    5@
M %H   !>    8@   &4   !H    :P   &T   !P    <P   '8   !Y
M?00  ($+  "%$0  A!T  ((L  " /@  ?E0  'YK  ![B@  >JH  '?6  !U
M_0 X/0  +#X  ")!   71@  #TL   =1    5P   %P   !B    9@   &L
M  !O    =    '@   ![    ?@   (    "#    A@   (H   "-    D0
M )8#  ";#   G1,  )LA  ":,P  ETD  )1B  "3?P  D*   ([%  ",\P Q
M1   )4@  !I-   04P  "%H   !A    :    &X   !T    >0   '\   "$
M    B0   (T   "1    DP   )8   "9    G0   *    "D    J    *P
M  "R P  MPT  +<7  "U*   LCX  +!6  "L<P  JI0  *FT  "EY0 J3P
M'E0  !);   *8@   &H   !S    >P   ((   ")    C@   )0   ":
MGP   *0   "F    J0   *T   "P    LP   +<   "[    P    ,4   #+
M    T00  -4.  #3'0  T#(  ,U+  #*9@  QH<  ,*I  #!RP B6P  %F(
M  QK   !=    'T   "'    D    )<   ">    I    *L   "Q    M@
M +H   "\    P    ,0   #(    RP   ,\   #4    V@   .    #F
MZP   /$&  #P$P  [B<  .P_  #J6P  YWH  .2;  #@NP#_    ^P   /8
M  #S    ]  % /8 # #Z !$ _P 9 /\ (@#_ "P _P U /\ /0#_ $4 _ !,
M /H 4@#W %@ ]0!> /, 9 #Q &H [@!R .P >@#I (4 Y0"1 .$ H #= +(
MV #. -( ]@#! /\ K0#_ )X _P"6 /\ D #_ (P _P#Z    \@   .P   #I
M    Z0   .P !0#R  P ^  2 /< &P#U "4 \  N .L -P#F #X X@!% -T
M2P#8 %  TP!6 -  7 #- &( R@!J ,@ <@#% 'P P@"( +X E@"Z *@ MP"_
M +0 Z "N /\ G0#_ )  _P"( /\ @P#_ (  _P#P    Y0   -X   #:
MVP   -P   #8  < T0 . -$ %0#2 !X RP G ,4 +P#  #< O0 ] +H 1 "W
M $D M0!/ +( 50"P %L K@!A *P :0"I ', IP!_ *0 C0"A )X G@"R )L
MU0"9 /P C #_ (( _P![ /\ =@#_ '0 _P#B    TP   ,H   #'    O
M +8   "P  $ KP + *P $0"M !@ K0 @ *@ * "D "\ H  V )T / "; $(
MF0!' )< 30"5 %, DP!9 )$ 80"/ &H C !U (H @P"( )0 A@"G (, P@""
M /  ? #_ ', _P!M /\ :@#_ &@ _P#/    P0   +D   "M    H    )@
M  "4    D0 & )  #0"0 !( CP 9 (X (0"+ "@ B  O (8 -0"$ #H @@!
M (  10!^ $L ? !2 'H 60!X &( =@!L '0 >0!R (D <0"= &\ M !M -\
M; #_ &4 _P!@ /\ 7@#_ %P _P"^    L0   *    "2    B0   ((   !\
M    >@ ! '@ "0!W  X >  4 '< &@!T "$ <@ G '  +0!N #, ;  X &L
M/@!I $0 : !* &8 40!D %H 8P!D &$ < !? '\ 7@"3 %T J0!< ,@ 6P#W
M %< _P!4 /\ 4@#_ %$ _P"P    GP   (T   !_    =    &X   !J
M9@   &4 ! !C  L 8P 0 &, %0!C !L 80 A %\ )P!= "P 7  R %H -P!9
M #T 5P!# %8 2P!5 %, 4P!< %( : !0 '< 3P") $X GP!- +H 3 #I $L
M_P!) /\ 1P#_ $< _P"B    C0   'P   !N    90   %X   !9    5P
M %4  0!4  < 4P - %, $0!4 !8 4@ ; %$ (0!/ "8 3@ K $P ,0!+ #<
M2@ ] $D 1 !' $P 1@!6 $0 80!# '  0@"! $$ EP!  *\ /P#7 #\ _P ^
M /\ /0#_ #X _P"4    ?P   &\   !C    60   %$   !-    2@   $@
M  !'  0 1P * $8 #@!& !$ 1P 6 $4 ' !$ "$ 0@ F $$ *P!  #$ /@ W
M #T /@ \ $< .@!0 #D 6P X &D -P!Z #8 CP U *< -0#& #0 ]0 T /\
M- #_ #4 _P"(    =    &4   !8    3P   $@   !#    /P   #T    \
M  ( /  ' #L #  [  \ .P 2 #H %P Y !P -P A #8 )@ U "P -  R #,
M.0 Q $$ , !+ "\ 5@ N &, +0!S "P B  L *  *P"[ "L Z@ K /\ *P#_
M "P _P!_    ;    %T!  !1 @  2 ,  $ #   [ @  -P   #0    S
M,@ % #( "0 R  T ,0 0 #$ $P P !@ +P = "T (@ L "@ *P N "H -0 I
M #T * !& "< 40 F %X )0!N "0 @@ C )D (P"S "( W@ B /\ (P#_ "0
M_P!W    900  %8&  !+!P  0@@  #H(   U!P  , 8  "T%   L P  *P #
M "H !P I  L *0 . "D $0 H !4 )P 9 "8 '@ E "0 )  J ", ,0 B #D
M(0!# "  3@ ? %H '@!I !T ?  < ), &P"L !L S0 ; /8 &P#_ !P _P!P
M!0  7P@  %$*  !&"P  /0L  #4+   P"P  *PH  "@)   E"   ) <" ",$
M!@ C @D (@$, "( #P A !( (  6 !\ &P > "  '0 F !P +@ ; #8 &@ _
M !D 2@ 8 %< %P!F !8 >  5 (\ %0"F !0 PP 4 .X % #_ !4 _P!K"
M6PL  $T,  !"#0  .0T  #$-   L#0  )PT  ",,   A#   'PL! !X*!0 =
M" @ '08+ !P%#0 <!!  &P04 !D$&  9!!X & 0C !<$*P 6!#, %00\ !0$
M1P 3 U0 $@-C !$#=0 0 HH $ &B  \ O  / .4 #P#^ !  _P!G"P  5PT
M $D.   ^#P  -0\  "X/   H#P  ) X  " .   =#@  &PT! !D-!  8# <
M& L) !<)#  7"0X %@D2 !4)%@ 4"1L $PDA !()*  2"3  $0DZ ! )10 /
M"5( #@EA  T)<P ,"(@ "PB?  H'MP *!ML "@7V  H$_P!C#0  4PX  $80
M   [$0  ,A$  "L1   E$   (1   !T0   :#P  & \! !8.!  5#@< % T)
M !,-"P 3# T $@P0 !$,%  0#!D $ P?  \,)P .#2\ #0TY  P-10 +#5$
M"0U@  @-<0 &#88 !0V=  0,M  ##-(  @SQ  (+_P!?#@  4!   $,1   X
M$@  +Q(  "@2   C$@  'A$  !L1   8$0  %1 " !00!0 2$ < $0\) ! /
M"@ 0#@P #@X.  X/$@ -#Q< #! =  P0)  *$"P "1 V  @000 &$$X !1!=
M  ,0;P !$(0  !"<   /M   #M0   [S   ._P!<$   31(  $ 3   V%
M+10  "84   A$P  '!,  !D2   6$@  %!$# !(1!@ 1$0@ $! *  X0"P -
M$0L #!$-  L2$0 *$A4 "1(:  @2(0 &$RD !1,S  ,3/@ "$TL  !-:   3
M;   $X(  !*;   2M   $=<  !'U   1_P!8$@  210  #T5   S%@  *Q8
M "05   ?%0  &A0  !<4   4$P$ $Q($ !$2!P 0$@D #A()  T2"0 +$PH
M"10-  <5#P &%A, !!88  ,6'P "%B<  !<P   7.P  %T@  !=8   7:@
M%H   !:9   5M   %=D  !3W   3_P!5%   1A8  #H7   P&   *!@  "(7
M   =%@  &18  !85   3% , $A,& ! 3!P /$P< #10'  L5"  )%@D !A@,
M  ,:#@ !&A$  !H6   ;'   &R0  !LM   ;.   &T8  !Q5   ;9P  &WT
M !N7   :LP  &=L  !CY   7_P!1%@  0Q@  #<9   N&@  )AH  " 9   ;
M&   &!<  !46 0 3%04 $14$  \5!  -%@0 "Q<%  D9!@ &&@@  AP*   >
M#0  (!   " 3   @&0  ("$  "$J   A-0  (4(  "%2   @9   ('H  !^5
M   ?L0  'ML  !WZ   <_P!-&0  /QL  #0<   K'   )!P  !X;   :&@
M%Q@  !07 @ 2%P( $!@!  T9 0 +&@( "!P#  4=!  "'P8  "$(   C"P
M)0X  "81   F%@  )AX  "<G   G,@  )S\  "9.   F8   )G<  "62   D
MKP  (]H  "+[   A_P!('0  /!X  #$?   H'@  (AX  !T<   9&P  %AH
M !(:   0&P  #1P   L=   ('P  !"$   $C @  )00  "<&   I"0  + P
M "X/   N$P  +AH  "XC   N+@  +CL  "Y*   M7   +7(  "R.   KK
M*M0  "G[   H_P!$(   ."$  "XA   F(0  ("   !P>   8'0  %!T  ! >
M   .'P  "R$   <C   #)0   "<    I    + $  "X#   P!@  ,PH  #4-
M   V$0  -A<  #8?   V*0  -C8  #9%   U5P  -6T  #2)   RJ   ,<\
M ##Z   O_P _)   -"0  "LD   D(P  'R$  !L@   6(   $2$   XC   *
M)0  !B@   (J    +0   "\    R    -    #<    Y P  .P8  #X*  !
M#@  01(  $$:  ! )0  0#$  $!    _4@  /F<  #V"   \H@  .L<  #GX
M   X_P Z*   ,"@  "DG   C)0  'R,  !@D   2)0  #B@   HJ   %+0
M #     S    -@   #@    [    /@   $    !"    10(  $<&  !*"@
M30X  $T5  !,'P  3"L  $LZ  !*3   26$  $A\  !'FP  1;\  $/S  !"
M_P V+   +2L  "<I   C)P  &R@  !0J   .+0  "C    0S    -P   #H
M   ]    0    $,   !&    2    $L   !-    4    %,!  !6!@  60L
M %L0  !;&0  6B4  %DT  !81@  5UH  %5T  !4DP  4K4  %#J  !/_P S
M,   +"X  "<L   >+0  %B\  ! R   *-@   SH    _    0@   $8   !)
M    3    $\   !2    50   %@   !:    70   &    !C    9P8  &L,
M  !L$@  :QX  &LL  !I/0  9U(  &9J  !DB0  8:L  %_<  !=_P Q,P
M+#$  "(R   9-0  $3D   H]   "0@   $<   !,    4    %0   !8
M6P   %\   !B    90   &@   !K    ;@   '$   !U    >0   'T&  ""
M#0  @A8  ( D  !^-0  ?$D  'MA  !X?P  =I\  '/&  !P]P Q-@  )C@
M !P[   20   "T4   )+    40   %8   !;    8    &4   !I    ;@
M '(   !V    >0   'P   !^    @@   (4   ")    C@   ),   "8!@
MG X  )L:  "8*P  ED   ))9  "1<P  C94  (NU  "(Z  K/@  ($$  !5'
M   -30   E0   !;    80   &@   !N    <P   'D   !^    @P   (@
M  ",    CP   )(   "5    F0   )T   "A    I0   *H   "P    MP<
M +@1  "U(0  LC4  *]-  "J:0  J(@  *:H  "BT0 C2   &$X   Y4   $
M7    &0   !M    =0   'P   "#    B0   (\   "5    FP   *    "C
M    I@   *D   "M    L0   +4   "Y    O@   ,0   #*    T@   -H*
M  #6%@  TBD  ,Y!  #*7   Q7P  ,*=  #!O0 <50  $5P   =E    ;@
M '<   !_    B    )    "8    GP   *4   "M    LP   +@   "Z
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M_/[______________________________________________________P
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M8F'VC&)A]HQB\\0/ ,[:"P"]\QT'L?\R%*/_.A^5_S\JB?]&,X#_3SIX_UM
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MC340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R
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M_XLI0_^+*4/_BRE#_XLI0_^+*4/_BRE#_XLI0_^+*4/_BRE#_XLI_X,< _^
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M.!'_N4 9^,)')N[+337DT%1&U<M;6\?#8FZZNVA^KK1NBZ.N<Y::J7J?DJ6
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M44__PU%/_\-13__#44__PU%/_\-13__#44__PU%/_\-1VJ\" ,:\!0"YR04
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M?R<'_XHL"O^3-0[_F3T6_YY&'_^A3BO[H%DX]9QC1N^8;53HD'=BXHA_;]J
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MA966EH*>FI* IYV/?[.>C8#"GHN S)J+@=*2BH#8B8F VX:)@-N&B8#;AHF
MVX:)@-N&B8#;AHF VX:)@-N&_WD: O][(03_BR(%_Y@H!_^C, K_JS@0^;)
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M=4_3YW1/T^=T3]/G=$_3YW1/T^=T3]/G=$_3YW1/T^=T_X\/ ?^D#@#;N @
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M?UZGY7A>I^5X7J?E>%ZGY7A>I^5X7J?E>%ZGY7A>I^5X_WH5 O^.$@'_GQ,
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M9U>O\6=7K_%G5Z_Q9U>O\6=7K_%G_W\. ?^3"P#AI04 TK,' ,F^!P#"RP@
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MAA(E_Y 3)/^9$R/_HQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4G+X
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M7VB2]U]HDO=?:)+W7VB2]U]HDO=?_V\1 ?^!#@#_D0X \J , -JM"0#3N H
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MTRL&F= Z$H_.11^%RTXJ?<E6-'7'73UNQ65$:,1L26/"<TY>P7M36<&$5E7
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MJRH]_+DK._W+*SO]XBLZ_/0K.OSW*SK\]RLZ_/<K.OSW*SK\]RLZ_/<KO:@
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M#AS_H0X;_ZP/&_^N#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/E[P  (C)  !YU@
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M47F!_U%Y@?]1>8'_47F!_U%Y@?]1_V43 ?]U#@#_@PX _Y . /6;#@#HI@X
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MLTA&RLA(1LKF1T?)]T5'R/]#2,?_0DC'_T)(Q_]"2,?_0DC'_T)(Q_]"WHT
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M(C;YXR(V^/,B-O?\(C;W_"(V]_PB-O?\(C;W_"(V]_PBMZ8  *FN  "<N0
MD,0  (//  !WVP  ;_8* &?_$P%@_QT"6O\G U3_, 5/_S@(2O] "D;_2 Q#
M_T\.0/]6#SW_7A [_V42./]N$S;_=Q0T_X(5,O^/%C#_FQ<O_ZD7+O^W&"W_
MR!@L_^$8+/_O&"S_[Q@L_^\8+/_O&"S_[Q@L_^\8JZL  )ZU  "0P0  @LP
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MX&%Y,]Q>@CC87(L\TUJ4/]!8G$+.5Z-$RU6L1LE5M4?'5,!)Q5302<)3YDG
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M1(AT_T.(=/]#B'3_0XAT_T.(=/]#_UT2 ?]K#@#_> X _X,/ /V,$ #ME!(
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MKE-3G\!34I_=4E6?\TY7H/]*6:#_1EF?_T59G_]%69__15F?_T59G_]%_W4
M ."&  #/DP  Q)\! +JG 0"QK@  J;8  *&]#0";O2 !E+PQ!XNZ/1"#MT@:
M?+50(G6S6"IOLE\P:K!F-F6O;3M@K74_7*Q^0UBKAT=5JI-*4:J?3$^JKDU-
MJL!-3:K<34ZJ\DE0JOY&4JG_0U*I_T)2J?]"4JG_0E*I_T)2J?]"\GP  ->,
M  #(F0  O:,  +*K  "IL@  H+L" )?$"0"2Q1L B\0L!(/".@Q[P405=+].
M'6Z]5B1HO%TJ8[MD,%^Z;#1:N70Y5KA\/%.WAS]/MY)"3+:?1$JVK49(ML!&
M2+?=14FV\D-*M?]!2[7_/DNT_SU+M/\]2[3_/4NT_SU+M/\]XH,  ,V2  #!
MGP  M*<  *JO  "@N   EL # (S*!P"&S10 @<TF GK,-0ASRT$/;,I*%V;)
M4QUAR%LC7,=B*%C&:BQ4QG(P4,5\,TW%AC9*Q)(Y1\2?.T7$KCQ$Q<$\0\7?
M/$3$\SM$P_\Y1<+_-T7!_S=%P?\W1<'_-T7!_S=%P?\WU8L  ,6:  "WI
MJZP  *"T  "6O@  B\<$ ('0" !XV0X ==D@ 6_8+P1IV#P)8]9&$%[64!59
MU5@:5=1@'U'4:").U'$F2]-[*4C3A2M%TY(N0M2?+T'4KS _U<(Q/]7A,#_3
M\C _TOTO/]'_+C_0_RX_T/\N/]#_+C_0_RX_T/\NRI0  +NA  "MJ0  HK$
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M$2;_]A$F__81)O_V$2;_]A$F__81IZD  )FS  "+O@  ?LD  '#3  !DW@
M6.<  %+_"0!-_Q$ 1_\9 4/_(@$^_RH".O\R S?_.0,S_S\$,/]&!2W_304K
M_U0&*/];!R;_8P<C_VT((?]Y"1__APD>_Y4*'?^C"AS_L0H;_\ +&O_6"QK_
MWPL:_]\+&O_?"QK_WPL:_]\+F[$  (V\  !^QP  <-(  &/>  !5Y   2_4
M $;_!0! _PX ._\4 #?_&P$S_R,!+_\I BO_, (H_S4")?\[ R+_00,?_T<#
M'?]. QK_5008_UX$%?]H!1/_= 41_X(%$/^0!A#_G08/_ZD&#O^U!@[_N@8.
M_[H&#O^Z!@[_N@8._[H&CKH  '_%  !PT0  8MX  %3E  !&ZP  /_X  #G_
M   T_PD +_\. "O_%  G_QH!(_\A 1__)0$<_RH!&?\O 1;_- (4_SH"$?]
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M'@'_4QP"_UD> O]=)@/_7S $_U\Z!_]=10O_6E 0_5A>%?A5:AGU4W8=\E&
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M-IME_S.;9?\SFV7_,YME_S.;9?\S_U43 ?]@#@#_:PX _W00 /][$@#U@1<
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M1U&;[D13F_Q 59O_/%:;_SI6F_\Z5IO_.E:;_SI6F_\Z\70  -F#  #(D
MOIH  +.A  "JIP  H:X  )>U!@"2MA@ C+4J X6T-PE^LD(1=[!,&'&N5!]L
MK5LE9ZMB*F*J:2]>J7$S6JAZ-U:G@SI3IHX]4*:;0$VEJ4%+I;I"2Z;10DNE
M[3]-I?P\3J3_.4^D_S=/I/\W3Z3_-T^D_S=/I/\WY'H  ,^)  #"E0  MI\
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M)3O*_R4[RO\E.\K_)3O*_R4[RO\EPY,  +6>  "HI@  G:X  )&V  "%OP
M><<  &_.! !DU@D 7MX1 %O>( !7WBT"4]\Z!%#?1 9,WTX)2=]7#$;?7P]#
MWV@10=]Q$S[??!4\WXD7.N"6&3C@I1HWX+<:-N'-&C;?[!HUWOD:--W_&S3<
M_QLTW/\;--S_&S3<_QLTW/\;N9P  *JD  ">JP  DK4  (6^  !YQP  ;<\
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M!A/_Z083_^D&EZ\  (BZ  !ZQ0  ;,\  %[:  !0X   1.8  #SU   W_P0
M,_\- "__$P K_QH */\A "7_)P$A_RT!'O\R 1O_. $9_S\!%O]& A3_30(1
M_U8"$/]@ @[_; (,_WL#"_^+ PK_F@,*_Z@#"?^U PC_P@,(_\(#"/_" PC_
MP@,(_\(#BK@  'O#  !LS@  7ML  $_B  !"YP  -NP  #'_   L_P  )_\'
M "/_#@ @_Q( '/\8 !C_'0 5_R$ $O\F !#_+ $._S$!#?\W 0K_/@$(_T8!
M!?]/ 0'_60$ _V8! /]T 0#_@@( _Y " /^< @#_I@( _Z8" /^F @#_I@(
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M1&!_[$!B@/PZ9(#_-F6!_S-F@?\R9H'_,F:!_S)F@?\R_V0  .5R  #3?@
MQX<  +Z/  "VE0  KID  *:;# "@G!X F9LN!)*9.PJ+ED82A91/&7^15Q]Z
MCUXE=8YE*G&,;"YMBG,R:8E[-F:(A#EBAH\]7X6:/UR%J$%:A;="687,0EJ%
MZC]<AOLZ7H;_-E^'_S)?A_\R7X?_,E^'_S)?A_\R_6@  .!V  #-@@  PHP
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M,$N?_RY+G_\M2Y__+4N?_RU+G_\MW7D  ,F&  "\D@  L9H  *:@  "<I@
MD:P  (:R  !]M@T >;8= '6V+ )OM3D&:K1#"V6S3!%@LE067+%;&EBP8QY5
MKVLA4:]S)4ZN?2A+K8@J2*V5+46MHRY$K;,O0ZW(+T*LYR]#J_DM1*O_*T2J
M_RE$JO\I1*K_*42J_RE$JO\IT8   ,&-  "UF   J9\  )ZE  "3K   B+(
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M$R_4_Q,OU/\3LYH  *:A  ":J0  C;$  ("Z  !TP0  :,D  %S/  !2U0,
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M90$%_W0! _^% 0+_E@$!_Z8! /^U 0#_Q@$ _\H! /_* 0#_R@$ _\H!AK<
M '?!  !HS   6M<  $O>   ^Y   ,ND  "?M   C_P  '_\  !O_!0 7_PP
M%/\0 !'_%  /_Q@ #?\=  O_(@ (_R@ !?\N  +_-0  _ST  /]'  #_4@
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M_Q^95_\?_TT- /]5!@#_704 ^V0' .]I"0#I:PP X6P0 --M'@#);#$"PFI
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M.FUKZS=O;?PQ<&[_+7%N_RIQ;_\H<6__*'%O_RAQ;_\H_UD  .ME  #;<
MS7@  ,1^  "\@@$ MH0! *Z%#@"GAB  H(4P YJ"/0B3@$@/CGU1%8E[61J$
M>6 ?@'=G(WQU;B=Y='4J=G-]+G-RAC%P<9 T;7"<-VIOJ#EH;[<Z9V_+.F=P
MZ3=I<?HR:W+_+6QS_RIL<_\H;'/_*&QS_RAL<_\H_UP  .=H  #5<P  R7L
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M+5N"_RI;@O\I6X+_*5N"_RE;@O\I[&8  -AS  #'?@  O(<  +..  "ID@
MH)4  ):8 0"0F1, BIDD 868,@1_ECX)>91(#G234!1OD5<9:Y!>'6B.92%D
MC6TE8(QU*%V+?BM:BH@N5XF4,52)H3-2B+ T48C#-5"(XC12B/8P4XC_+%2(
M_RE5B/\H58C_*%6(_RA5B/\HYFL  -!X  #"@P  MXP  *V2  "CE@  FIH
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M($"D_R! I/\@RGX  +N+  "OE0  I)L  )FA  ".I@  @JP  '>Q  !JM@
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MCP,CY:$$(N6T!"'ES00@Y.P$(.+[!!_A_P4?X/\%'^#_!1_@_P4?X/\%I)X
M )BE  "+K@  ?;8  '"^  !CQ@  5LL  $O0  ! U0  -MP  "_E!P M[1
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M  #_D   _Z,  /^T  #_Q@  _]8  /_6  #_U@  _]8 @K4  '._  !DR0
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M+GM;["M\7/PF?%W_(GU>_Q]]7O\=?5[_'7U>_QU]7O\=_U   /59  #A8P
MTFH  ,EN  #"< $ O7 # +9P$ "N<2( J' R J%N/P:<;$H+EVI3$))H6Q2.
M9F(8BV5I&XAC<!Z%8G@A@F& )(!@B29]7Y(I>UZ=*WA>J2UV7K@N=5[,+W1>
MZ2UU8/HG=F'_(W=B_R!W8O\>=V+_'G=B_QYW8O\>_U(  .Q<  #<9@  SFT
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M)F9M_R-G;O\@9V[_(&=N_R!G;O\@]ED  .!E  #.;P  PG8  +E\  "Q?P
MJ8   *" !P"9@1< E($H 8Z -0.(?D$(@WQ*#7YZ4A%Z>%D5=G=@&7-V9QQP
M=&X?;7-V(VIR?R9G<8DI9'&5*V)PH2U@<+ O7G#"+UUPWR]?<?4J8''_)F%R
M_R-B<O\@8G+_(&)R_R!B<O\@[UP  -QI  #*<@  OGH  +6   "MA   I(4
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M'U"#_Q]0@_\?WFD  ,EU  "\@   LH@  *B-  "=D0  DY,  (66  !^EPL
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MEA,WKZ84-J^X%#6PT10UKN\4-*W^%#2L_Q0TJ_\4-*O_%#2K_Q0TJ_\4NX4
M *^0  "CEP  F)T  (RC  " J   =*T  &BR  !<M@  4+H! $F\#0!(O!D
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M 1G?Q $8WN<!&-SX 1C;_P(7VO\"%]K_ A?:_P(7VO\"H)P  )2C  "'JP
M>;,  &RZ  !?P0  4L8  $;*   [S@  ,=,  "G9   AW@4 'N@. !WH%0 ;
MZ1X &>DG !CJ,  6ZCD %>M# !3L3@ 2[%H $>UG !#N=P 0[HH #N^>  [P
MLP -\,T #._L  SM_  ,Z_\ #.O_  SK_P ,Z_\ EZ,  (FK  ![M   ;;P
M %_$  !2R@  1<X  #G3   OV   )=T  !WA   8[ ( %O<+ !3W$0 1^!<
M$/@>  [Y)0 -^2T "_HU  G[/P '^TH !/Q7  /]9@ "_G<  /V+  #]GP
M_+4  /S1  #\[0  _/P  /S]  #\_0  _/T BZL  'VT  !NO0  8,8  %+-
M  !$T@  -]@  "S=   BX0  &>4  !/J   0^@  #O\&  W_#  *_Q  !_\4
M  3_&@ !_R   /\G  #_,   _SH  /]%  #_4P  _V(  /]U  #_B@  _Y\
M /^S  #_QP  _^4  /_E  #_Y0  _^4 ?[0  '"]  !AQP  4]   $/6   V
MW0  *N(  !_F   6Z@  $.T   SZ   )_P  !O\   +_!   _PD  /\-  #_
M$   _Q0  /\:  #_(0  _RD  /\T  #_0   _TX  /]>  #_<@  _X<  /^:
M  #_J@  _[D  /^Y  #_N0  _[D _R I ?\B)P'_(B<!_Q\J ?\9, '_$CD!
M_Q!% ?\-4P'_#& !_PIM O\)>0+_"80"_PF. ?\)E@'_"9T!_PFC ?\)J0'_
M"; !_PBW ?\(O@'_",@!_PC6 ?\(Y@'_"/$!_PC[ /\(_P#_"/\ _PG_ ?\)
M_P'_"?\!_PG_ ?\)_P'_"?\!_R,F ?\E) #_)20 _R,G ?\=+ '_&#4!_Q5"
M ?\24 '_$%T"_PYJ O\.=@+_#H "_PZ* O\.D@+_#IH"_PZ@ O\.I@'_#:T!
M_PVS ?\-NP'_#<4!_PW1 ?\-XP'_#>\!_@WZ ?H-_P'Y#O\!^0[_ ?D._P'X
M#O\!^ [_ ?@._P'X#O\!_R8C /\H( #_*"  _R8B /\B* '_(#(!_QP_ ?\9
M3 '_%UD"_Q5E O\3<0+_$WP"_Q.& O\3C@+_$I8"_Q*= O\2HP+_$JD"_Q*P
M O\2MP+_$L$"_Q+, ?T2WP'Y$^T!]1/X ?,3_P'R$_\!\1/_ O 4_P+P%/\"
M\!3_ O 4_P+P%/\"_RH? /\L' #_+!L _RL= /\I) #_*"\!_R4[ ?\B2 '_
M'U0"_QUA O\;;0+_&G<"_QJ! O\:B@+_&I("_QJ9 OT:GP+\&J8"^QJL OD:
MM +X&KT"]AK( O,:VP+O&NH"[!OW ND;_P+H&_\#YQS_ ^8<_P/E'/\#Y1O_
M ^4;_P/E&_\#_RT; /\P%P#_,14 _S 6 /\Q( #_,"H _RXV ?\K0P'_*$\"
M_R9< O\D9P+\(W(#^2-\ _<BA0/U(HT#\R*5 _(BFP/P(J(#[R*I ^TBL0/L
M(KD#ZB+% ^@BU0/D(^D#X"/V!-XC_P3;)/\$V23_!-@D_P37)/\$UB3_!-8D
M_P36)/\$_S$6 /\T$@#_-A$ _S<3 /\Y&P#_."4 _S8Q ?\S/0'],4H!^"Y6
M O0M8@/P+&T#[2MW ^HK@ 3H*H@$YBJ0!.4JEP3C*IX%X2JE!> JK07>*K8%
MW"K"!=HJT@;5*^<&T"OU!\TL_P?++/\'R2S_!\@L_P?'+/\&QRS_!L<L_P;'
M+/\&_S42 /\Y#@#_.@T _SX0 /] %@#_/R  _STJ /D[-P'R.$0![#91 N<U
M7 /C-&<#X#-R!-TS>P7:,H,&UC*+!M0RDP?2,9H(T#&A",XQJ0G,,;()RS&\
M"LDQR@K&,N$+PC+Q"[\S_@N],_\*NS/_"KHS_PFZ,_\)NC/_";HS_PFZ,_\)
M_SD0 /\]"P#_0 D _T0- /]&$0#_11D ]T0C .Y!+P#F/SP!X#Y* =H]5P+3
M/&($SSML!LPZ=0?).GT)QSF%"L4YC O#.)0,P3B;#< XHPV^.*P.O#BV#[HX
MPP^Y.-<0M3CL$+(Y^P^P.O\.KSK_#:XZ_PRM.O\+K3K_"ZTZ_PNM.O\+_SP-
M /] !@#_100 _TD) /]+#0#Y2A$ [4D: .-&)@#:1C8 T49% <M%40/&1%P%
MPD)F"+]";PJ\07<+ND!_#;@_A@ZV/XX0M#Z5$;(^G1*P/J83KSZP%*T^O12K
M/LT5J3[F%:8_]Q.D0/\2HT#_$*) _P^B0/\.HD'_#J)!_PZB0?\._S\) /]$
M  #_2@  ]TX" .Q0!@#J3PL XTP0 -9,'@#-33  QDT_ <!,3 2[2U<&MTEA
M";1(:0RQ1W$.KD9Y$*Q&@!&J18@3J$20%*9$F!:D0Z$7HD.K&*!#MQF?0\<9
MG4/@&IM$\Q>91?\5F$;_$YA&_Q&81O\0ET;_$)=&_Q"71O\0_T(% /]'  #W
M3P  Y5,  -U5 0#7508 U5(+ ,M3&0##5"L O%0[ ;922 2Q45('K5!<"JE.
M9 VF36P/I$QT$:%+>Q.?2H(5G4J*%YM)DQB929P:ETBF&Y5(LAR42,$=DDC8
M'9!)[QN/2OX8CTO_%HY+_Q2.3/\2CDS_$HY,_Q*.3/\2_T4  /]+  #I4P
MWE@  --;  #-6P0 RE@' ,)8%0"Z6B< LUHW :Y81 2I5T\'I%58"J%48 V>
M4V@0FU%O$YA0=A664'X7E$^&&9).CAJ/3I@<C4VB'8M-KA^*3;P@B$W0((=-
MZQ^&3_P;AE#_&(90_Q:&4/\4AE'_%(91_Q2&4?\4_T<  /A/  #D5P  U5T
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M''%=_QIQ7?\8<5W_%W%=_Q=Q7?\7_4\  .59  #38@  QV@  +UL  "V;0
MKVP  *=K"P"@;!D FVPJ 95K-P*0:4,%BVA,"8=F5 R#95L0@&-B$WUB:15Z
M87 8>&%X&G5@@1US7XL?<%Z6(FY>HB1L7K E:U[!)FE>WB9J7_0A:V#_'6MA
M_QML8?\9;&'_&&QA_QAL8?\8]5$  .)<  #/90  PVL  +EO  "Q<0  JG$
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M&5UM_QE=;?\9Z%H  -)F  ##;P  N'8  *][  "F?@  G7X  )%\  "*? \
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ME1M&B*,=1(BT'4.(RAU#A^H<1(;[&D2&_QA%AO\7187_%T6%_Q=%A?\7S6T
M +UX  "Q@@  IXH  )R.  "2D   AI,  'F5  !LEP  9I<. &.8&P!AF"D
M7I@U 5J7/@-7ET<%599/!U*65@E/E5X,3)1F#DJ4;Q!'DWD31).%%4*2DQ=
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M##"JQPPPJ><,+Z?Z#2^F_PTOI?\-+Z7_#2^E_PTOI?\-MH0  *J.  ">E
ME)D  (>>  ![HP  ;Z@  &.L  !7KP  2[(  $&U!@ ^MA$ /;8> #NV*0 Z
MMS0 .;<^ #>W1P VMU !-+=: 3*W9 (PMV\#+K=\!"RWBP4JMYP%*;>N!BBX
MQ04HM^8%)[7Y!R:S_P<FLO\()K+_"":R_P@FLO\(KXT  **4  "7F@  BZ
M 'ZF  !QJP  9;   %FT  !-MP  0KL  #B^ 0 OP@D +<,2 "S#'@ KPRD
M*L0S "G$/0 HQ4< )\51 ";%7  EQF@ (\9V 2+&A@$@QI@!'\:K 1['P0$>
MQN0!'<3X AS"_P,<P?\#','_!!S!_P0<P?\$I90  )J:  ".H0  @:<  '.N
M  !GM   6KD  $Z]  !"P   .,,  "_'   FRP0 'M * !O1$0 :TAH &=(E
M !C3+P 8TSH %]1$ !;44  5U5T %-5K !/6?  2UX\ $=BD !#9NP 0V=X
M$-7S !#3_P 0TO\!$-'_ 1#1_P$0T?\!G)H  )&A  "#J   =;   &BW  !;
MO0  3L$  $+%   WR   +<P  "30   <U0  %=H% !#B"P 0XQ$ #N0:  [D
M(P -Y2T #.4W  OF0@ *YD\ ">==  CG;0 &YH  !>:5  3FJP "YL0  >;F
M  #G^0  Y_\  .;_  #F_P  YO\ DZ$  (6I  !WL0  :;D  %O   !.Q@
M0<H  #7.   JT@  (=8  !G;   2WP  #>,   OQ"  )\PX !_,3  3R&@ "
M\B(  /(J  #R-   \C\  /),  #R7   \FT  /*"  #RF   \ZT  //&  #T
MY0  ]/8  /3[  #T^P  ]/L AZD  'FR  !JN@  7,(  $[)  ! S@  ,],
M "C8   >W0  %>$   _D   *Z   !?,   /] 0  _ @  /L-  #[$0  ^Q8
M /P>  #\)@  _#   /T\  #^20  _EH  /YM  #_@@  _Y@  /^L  #_P
M_]@  /_D  #_Y   _^0 >[(  &R[  !=Q   3\T  $#2   RV0  )MX  !OB
M   2Y@  #.H   7M    ]    /\   #_    _P   /\$  #_"0  _PX  /\2
M  #_&   _R$  /\K  #_-P  _T8  /]8  #_:P  _X   /^5  #_I@  _[,
M /^[  #_NP  _[L _QLF /\<) #_&B0 _Q4G /\0+0#_"C8 _P5# /\!4 '_
M %X!_P!K ?\ =@'_ ($ _P"* /\ D@#_ )H _P"@ /\ I@#_ *P _P"R /\
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M ?\+;@'_"WD!_PN" ?\+BP'_"Y(!_PJ9 ?\*GP#_"J4 _PJK /\*L@#_"KL
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M":TS]0FK,_\)JC/_"*@S_P>H,_\'IS/_!Z<S_P>G,_\'_S<' /\Z  #_/@
M^D$! /%!!@#Q/PT YCP2 -LZ'P#0.S$ RCQ  ,0\30' /%@"O#MA [D[:@6V
M.G(&M#IZ![(Y@0BP.8@)KSF0"JTXF JK.*$+J3BJ#*@XM@VF.,4-I#C>#J$Y
M\0V?.O\,GCK_"YTZ_PJ<.O\)G#K_"9PZ_PF<.O\)_SL" /\^  #W1   YD<
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M$H!+_Q" 2_\/@$O_#H!+_PZ 2_\._T,  .Q+  #=4P  SE@  ,1:  "]6@
MN%<! +%4#@"J5AX I58N )]6.P&;548#EU10!9-36 B04E\*C5%F#(M0;0Z(
M3W00AD]\$H1.A1."3HX5@$V9%WY-I!A\3;(9>DW#&GE-WQIX3O07>$__%'A/
M_Q)X4/\0>%#_#WA0_P]X4/\/_48  .=/  #65P  R%P  +]?  "W7P  L5P
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M$F=<_Q)G7/\2[4X  -I9  #(80  O&<  +-J  "K;   HFH  )EG @"29Q$
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ME!E3;*,;46RS'%!LR!Q/;.<;46SZ&%%L_Q52;/\44FS_$U)L_Q-2;/\3W%P
M ,=G  "Y;P  KW8  *5[  "<?   D7P  ()X  !Z>0< =7D4 ')Z(P!N>B\!
M:WDZ FAY0P-D>$L%87=2"%]W60I<=F ,675H#U=T<!%4='H34G.&%D]SDQA-
M<J$93'*Q&DIRQAI*<N4:2W+Y%TQR_Q5,<O\337+_$DUR_Q)-<O\2U&   ,)K
M  "U=   JWL  *)_  "7@0  C($  'I^  !S?P( ;G\1 &N '@!H@"P 98 W
M 6* 0 -??T@$7'Y0!EE^5PA7?5X+5'QF#5%\;@]/>W@13'N#%$IZD19(>I\7
M1GJO&$5ZQ!A$>N0817GX%D9Y_Q1&>/\21WC_$4=X_Q%'>/\1S64  +UP  "Q
M>0  IX   )R$  "2A@  AH8  '>&  !KA@  9H<- &.'&0!@B"< 7H@S 5N(
M/ )8AT4#5H=-!%.&5 90AEL(3H5C"DN$; Q)A'8/1H.!$42#CQ-"@YT40(*N
M%3^#PA4^@N(5/X'W$S^!_Q) @/\10(#_$$" _Q! @/\0QFL  +=V  "L?P
MHH4  )>)  ",BP  @8T  '..  !ECP  78\) %J0% !8D"$ 5I$M %.0. %1
MD$$"3I!) TR04 1*CU@%1X]@!T6.:0E"CG,+0(U_#3Z-C0\\C9P0.HVL$3F-
MP1$XC>$0.(OV$#B*_P\YB?\/.8G_#CF)_PXYB?\.OW(  +)]  "GA@  G(H
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M R"N_P,@K?\$'ZS_!!^L_P0?K/\$JHL  )V1  "3EP  AYP  'JB  !MIP
M8*L  %6O  !)L0  /K0  #.W   JN@, )+P- "*]%0 AO2  (;TJ ""],P ?
MOCT 'KY' !V^4@ <OUX &K]L !F_?  8OXX %\"A !; M@ 4P-, %;[Q !6\
M_P$5N_\!%+K_ A2Z_P(4NO\"H9(  ):8  "*G@  ?:0  &^J  !BKP  5K0
M $JW   ^N@  ,[T  "K    AQ   &<<% !/+"P 1S!( $<P; !#,)0 /S2\
M#LTZ  [-1@ -S5( #<Y@  S.<  +SH, "LZ7  G.K  (SL8 ",[H  C-^P )
MR_\ "<O_  G+_P )R_\ F)@  (V>  !_I0  <:P  &2S  !7N0  2KT  #[
M   RPP  *,8  !_*   7S0  $=$   S6!0 (V0P !MD2  7:&P $VB0  ]LN
M  ';.0  W$4  -U2  #>8@  WG,  -Z(  #?G0  W[,  -_.  #@[@  W_H
M -__  #?_P  W_\ CY\  (&F  !SK@  9;4  %B]  !*P@  /<4  #')   F
MS   '=   !34   .V0  "=T   /A    XP<  .,-  #D$@  Y1D  .8B  #G
M*P  Z38  .M#  #L4@  [&(  .UV  #NC   [J$  .^W  #OT0  [^L  /#V
M  #P]@  \/8 A*<  '6O  !GMP  6;\  $O&   \R@  +\X  "32   :V
M$MP   S@   %XP   .<   #K    ZP   .T%  #N"P  \!   /$5  #S'@
M]"<  /<S  #Y0   ^E$  /MC  #\=P  _8T  /VC  #^M@  _LD  /_?  #_
MWP  _]\ =[   &BY  !:P0  3,H  #S/   NU   (MH  !?>   0X@  ">8
M  #I    [    /    #V    ]@   /<   #X    ^@<  /L-  #]$0  _QD
M /\C  #_+P  _SX  /]/  #_8@  _W<  /^-  #_GP  _ZX  /^Z  #_N@
M_[H _Q8C /\5(0#_$B$ _PXD /\&*@#_ #, _P!! /\ 3@#_ %P _P!H /\
M= #_ 'X _P"' /\ CP#_ )8 _P"< /\ H@#_ *@ _P"N /\ M0#_ +T _P#'
M /\ U@#_ .< _@#S /X _@#] /\ _ #_ /L _P#[ /\ ^P#_ /L _P#[ /\
M_QH@ /\9'@#_%AX _Q @ /\*)0#_!#  _P ] /\ 2P#_ %@ _P!D /\ < #_
M 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L0#] +D ^P## /H
MT #X ., ]P#Q /8 _ #T /\ ] #_ /, _P#S /\ \P#_ /, _P#S /\ _QT<
M /\<&0#_&1D _Q0; /\.(0#_#"P _PDY /\%1@#_ E, _P!? /\ :P#_ '4
M_P!^ /\ A@#_ (X _P"4 /X FP#\ *$ ^@"G /@ K@#U +4 \P"_ /$ RP#P
M -\ [@#N .P ^0#K /\ Z@#_ .H!_P#I ?\ Z0'_ .D!_P#I ?\ _R 7 /\?
M% #_'!, _Q<5 /\6'0#_$R@ _Q T /\-00#_#$X _PE: /\(9@#_"'  _@=Y
M /P'@0#Z!XD ^ >0 /8&E@#S!IT \0:C .\&J@#M!K( _^+__TE#0U]04D]&
M24Q%  @)Z@:[ .@&R #F!MP Y ;L .((^@#@"O\ W@O_ -T+_P#=#/\ W S_
M -P,_P#<#/\ _R,2 /\C$ #_(0X _QX0 /\>& #_'", _Q@O /\4.P#_$DD
M_!!5 /@/8 #T#VH \0]T .\.? #M#H0 ZPZ+ .D.D@#G#ID Y@Z@ .0.IP#B
M#J\ X ZX -X.Q0#<#MH UA#L -(1^@#/$O\ S1+_ <P2_P'+$_\!RA/_ <H2
M_P'*$O\!_R</ /\G# #_)0D _R8- /\E$P#_(QP _R H /L<-0#U&D( [QA/
M .H76@#F%F4 XQ9N . 6=P#>%G\ W!:' -D6C@#6%I4 U!:< -(7HP#0%ZL
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MM02N*\0$K"O;!*@L[P2F+/X%I"S_!*,M_P2B+?\$HBS_!*(L_P2B+/\$_S(
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M#H8_X Z$/_0-@T#_"X- _PJ"0/\)@D'_"()!_PB"0?\(_SP  .M#  #<2@
MS$\  ,-0  "\3@  MTD! +%&#@"J2!P I$DL *!).@";244!F$A. I1'5P.2
M1UX%CT9E!HU&; >+17,)B45["H=$@PN%1(T,@T27#H%#H@]_0Z\0?D/ $'Q$
MVA%[1/$/>D7_#7I&_PMZ1O\*>D;_"7I&_PEZ1O\)]3X  .9(  #33P  QU0
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M$693_P]F4_\-9E/_#&93_PQF4_\,ZDD  -53  #%6@  NE\  +!B  "H8@
MGU\  )9:  "/6A  BEL> (5;+ "!6S@!?5M! GI:2@-W65$$=%A8!G%87P=O
M5V8);5=M"VM6=@UI5G\/9U6*$655EQ-C5:04856T%6!5R!9?5><58%;Z$F!6
M_P]A5_\.85?_#6%7_PQA5_\,YTP  -%6  #!7@  MF,  *UF  "D9@  FV0
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M#5)B_PU28O\-V58  ,1@  "W:   K&X  *-Q  ":<P  CW$  ']K  !X:P4
M<FL2 &YL'P!K;"P :&PW 69L0 )C:T@#8&M/!%YJ5@9<:ET'66EE"5=I;0M5
M:7<-4VB"#U!HCQ%.9YT336>L%$MHP!1+:-X42V?U$DQG_P],9_\.36?_#4UG
M_PU-9_\-TEH  ,!D  "S;   J7(  *!V  "6=P  BG8  'EQ  !Q<0  :W$/
M &AQ' !F<B@ 8W(T &!R/0%><D4"6W%- UEQ5 57<%L&5'!C"%)O:PI0;W0,
M36Z #DMNC1!);IL11VVK$D9NOA-%;MP21FWT$49M_P]';?\.1VS_#4=L_PU'
M;/\-S%\  +QI  "P<0  I7<  )Q[  "1?   AGL  '5X  !K=P  97<, &%X
M%P!?>"0 77DP %IY.@%8>4("5GA* E-X4011=U@%3W=@!TQV: A*=G(*2'5]
M#$5UB@Y#=9D/0G6I$$!UO!! ==D00'3S#T!T_PY!<_\-07/_#$%S_PQ!<_\,
MQF0  +=N  "K=@  HGP  )=_  ",@0  @8$  '*   !E?P  77\( %E_$P!7
M@"  58 K %.!-@!1@#X!3X!& DV 3@)+?U4#27]=!49_9@9$?G (0GY["3]^
MB L]?9<,/'VG#3I]N@XZ?M8-.GSQ#3I[_PPZ>_\+.GK_"SIZ_PLZ>O\+P&D
M +)T  "G?   G8$  )*$  "'A@  >X<  &Z'  !@AP  58<! %"(#@!.B!H
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M B2>M0(CGLX"(YWN R.;_@,BFO\$(IG_!"*9_P0BF?\$K($  *"(  "5C@
MBY(  '^6  !RF@  99T  %F@  !.HP  0J0  #>F   NJ 4 *:D/ "BI&  G
MJB( )JHL "6J-0 DJC\ (ZI( "*K4P AJUX (*MJ !ZK>0 =JXL &ZN= !JK
ML0 9J\H &:KL 1FH_0$8I_\"&*;_ ABF_P(8IO\"I8D  )F/  "/E   @YD
M '6>  !HH@  7*8  %"I  !$K   .:X  "^P   FLP  'K4& !FW#P 8MQ<
M%[<A !:W*@ 5MS0 %+@^ !.X20 2N%0 $KEB !&Y<0 0N8, #[F7  ZYK  -
MN<0 #;CG  ZV^P .M?\ #K3_  ZT_P .M/\ G)   )*5  "&FP  >:   &NF
M  !>JP  4J\  $:R   ZM0  +[<  "6Z   =O0  %<   !##!@ +Q@X "L45
M  G%'@ (Q2@ !\4R  ;&/0 %QDD !<97  /&9@ "QG<  <:+  #&H   Q;8
M ,;2  #%[P  Q?P  ,7_  #%_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3
MM   1K@  #J[   NO@  ),$  !O$   3QP  #LH   C. 0 !T H  - 0  #0
M%@  T1X  -(G  #3,0  U#P  -5)  #66   UFD  -9\  #6D@  UJ<  -:_
M  #6X   UO,  -;^  #6_P  UO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0
M.<$  "W$   BQP  &<L  !'.   ,T@  !=4   #;    W ,  -T*  #>#P
MWQ0  .$<  #B)   Y"X  .8Z  #G20  Z%D  .AK  #I@0  Z9@  .FM  #I
MQ0  Z>(  .GR  #I]0  Z?4 @*4  '&M  !CM0  5;P  $?"   YQ@  +,H
M "#.   6T@  #]8   C;    WP   .,   #E    YP   .@!  #J!P  ZPT
M .T1  #O&   \2$  /,K  #V.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP
M^L(  /K:  #ZWP  ^M\ =*X  &6V  !6O@  2,8  #G+   KT   ']0  !3:
M   -WP  !>,   #F    Z0   .T   #O    \0   /,   #U    ]@(  /@)
M  #Z#@  _1,  /\<  #_*   _S8  /]'  #_6@  _VX  /^%  #_F@  _ZL
M /^Y  #_O   _[P _Q$@ /\0'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_
M %D _P!E /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\
ML #_ +@ _P#" /\ S@#_ .( _@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_
M /H _P#Z /\ _Q0< /\2&@#_#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4
M_P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[
M +0 ^0"] /@ R0#W -P ]0#L /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /
M_P#P /\ _Q<8 /\5%@#_$14 _PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!<
M /\ 9P#_ '$ _P!Z /P @@#Z (D ^ "0 /< E@#U )P ] "B /, J #Q +
M\ "X .X PP#L -, Z@#G .D ]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E
M /\ _QH3 /\8$0#_%!  _P\1 /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X
M8@#Z &P ]0!U /( ?0#P (0 [@"+ .P D0#K )< Z0"> .< I #F *P Y "T
M .( OP#@ ,T W@#C -P \@#: /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\
M_QX0 /\<#0#_%PL _Q4. /\4%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N
M!&8 Z@1O .8#=P#D!'\ X@2& . $C #>!), W06: -L%H #8!:@ U06Q -(%
MNP#0!LD S@?@ ,P(\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$,
M /\@!@#_' , _QT* /\;$ #_&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6
MW0UI -D-<0#5#7D TPV! -$-B #/#8\ S0Z6 ,L.G0#*#J4 R ZN ,8/N0#$
M$,@ PA#? +X1\@"[$O\ N1/_ +<3_P&V$_\!MA/_ ;83_P&V$_\!_R4& /\C
M  #_(P  _R0# /\A"@#]'1$ \1H; .@6)P#A%#4 VA-# -,43P#.%5D RQ5C
M ,@6:P#%%G, PQ=[ ,$7@@# &(D OAB0 +P8F "[&:  N1FI +<9M "U&L(
MM!K6 + ;[0&M'/P!JQW_ :D=_P&I'?\!J!W_ :@=_P&H'?\!_R@  /\G  #^
M*@  [RH  .<G 0#G(@D Y!T0 -D;'0#/'2T R1X\ ,0@20"_(%, O"%= +DA
M90"W(FT M2)T +,B? "Q(H,!L"** :XBD@&L(YL!JR.D :DCKP&G([P!IB3.
M :,DZ *@)?D"GB7_ ITE_P*<)?\"FR7_ ILE_P*;)?\"_RP  /\M  #M,@
MXC0  -HS  #3+@, TB4* ,DE%P#!)R< NRDV +8J0P"R*TX KRM7 *PK8 "J
M*V<!J"MO :8K=@&D*WT!HRN$ J$KC0*?*Y4"GBN? IPKJ@.:*[8#F2S' Y<L
MX@.4+?4$DBW_ Y$M_P.0+O\#D"W_ Y M_P.0+?\#_S   /(S  #D.@  UCT
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M20  KT,  *D^"P"B/Q< G4 F )A!- "403\ D4%) 8Y!40&+0%D"B4!@ X=
M9P.%/VT$@S]U!8$_?09_/H<'?3Z1"'L^G EZ/JD)>#ZX"G<_S0IU/^H*=$#\
M"'1 _P=T0/\&<T#_!G- _P9S0/\&\3L  -]%  #,3   OT\  +90  "N3P
MITH  *!$!P":110 E48B )!&, ",1SP B49% 89&3@&#1E4"@45< WY%8P1\
M1&H$>D1Q!7E$>09W1(((=4.-"7-#F0IQ0Z8+<$.U#&Y$R0QM1.<,;47Z"FQ%
M_PAL1?\';$7_!VQ%_P=L1?\'[#\  -A)  #'4   NU0  +%5  "I5   H5
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M"%M1_PA;4?\(WTH  ,E3  "[6@  L%\  *9A  "=80  E%X  (A7  " 5@H
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MB I*8Y<+2&.F#$=CN U&8]$-1F/O#$9B_PI'8O\)1V+_"4=B_PA'8O\(RE@
M +IB  "N:0  HVX  )IQ  "0<@  A'$  '1K  !I:0  8VD+ %]I%0!<:B$
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M!S5XLP<T>,L'-'?K!S1V_0<T=?\'-77_!C5T_P8U=/\&N6@  *UQ  "B>0
MF'X  (V   ""@0  =H(  &F!  !;@0  48$  $B "@!%@1, 0X$> $*"*0!!
M@C( 0(([ #Z"0P ]@DL .X)3 3F"7 $W@F8"-8)Q S."?P,Q@8X$,(&?!"Z!
ML04M@<@%+8'I!"U__ 4M?O\%+7W_!2U]_P4M??\%LVX  *AX  "=?P  DH,
M (B&  !]AP  <(@  &.)  !5B@  2XH  $&* @ [BPX .8L7 #B,(@ WC"P
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M !&B^  1H?\ $:#_ 1&@_P$1H/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@
M6*$  $RD  ! I@  -:<  "JI   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .
ML2L #;$U  VQ0  ,L4L "[%8  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P
M[P %K_X !J[_  :N_P &KO\ F(X  (^3  ""F   =9T  &>B  !:IP  3JL
M $&M   UKP  *[$  "&T   8M@  $;D   V\ P 'O@P  [T2  &]&0  OB(
M +XK  "^-@  OD$  +].  "_7   OVT  +^   "^E0  OJH  +["  "]Y
MO?8  +W_  "]_P  O?\ DI0  (6:  !XH   :J8  %RK  !/L   0K,  #6V
M   JN   (+L  !>^   0P0  "\0   3'    R0<  ,D-  #)$@  RAD  ,LB
M  #+*P  S34  ,Y!  #.4   SV   ,]R  #/AP  SYT  ,^S  #/S@  S^L
M ,[X  #._@  SOX B)L  'JB  !LJ   7J\  %"U  !"N0  -;P  "F_   >
MP@  %<8   [)   (S    -    #3    U0   -8&  #8#   V1$  -L6  #<
M'P  WB@  . T  #B00  XE$  .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J
M  #E\P  Y?, ?*,  &ZJ  !@L@  4;D  $.^   UP@  *,8  !S)   3S0
M#-$   35    V@   -X   #A    X@   .0   #E P  YPD  .D.  #K$@
M[1H  .\D  #R,0  ]$$  /13  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #W
MWP  ]]\ <*P  &&T  !3NP  1<,  #;'   GS   &]   !'5   *VP   -\
M  #B    Y0   .D   #L    [0   /    #Q    \P   /4$  #W"@  ^A
M /P6  #_(0  _RX  /]   #_4P  _V@  /^   #_E@  _Z@  /^V  #_OP
M_[\ _PT< /\*&P#_ AL _P > /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\
M;0#_ '< _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"]
M /\ R0#^ -T _0#M /P ^@#[ /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\
M_Q 9 /\-%P#_!A8 _P 8 /\ '@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_
M '( _P![ /\ @@#_ (D _P"0 /X E@#] )P _ "A /L J #Y *\ ^ "X /8
MPP#T -( \P#G /( ]@#P /\ [P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4
M /\/$@#_"Q( _P 2 /\ &@#_ "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T
M^P!V /D ?0#W (0 ]0"+ /0 D0#S )< \0"= /  HP#N *H [ "S .H O0#H
M ,L YP#A .4 \0#C /T XP#_ .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1
M#@#_#0T _P</ /\"%0#_ "  _P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P
M .T > #K '\ Z0"% .@ C #F )( Y0"8 ., GP#A *8 WP"N -P N #: ,4
MU@#9 -0 [ #2 /D T0#_ ,\ _P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_
M#P4 _PX+ /\,$0#_!QH _P$F /P - #T $$ [0!- .D 6 #F &( XP!J .
M<@#> 'D VP"  -D A@#6 (T TP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0
M ,4 Z ## /8 P0#_ , "_P"_ _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%
M_Q,% /\1#0#_#A0 ^0H? / &+ #F SD X -& -P#40#6!%L T@1D ,\%; #,
M!7, R@5Z ,@%@0#&!8< Q0:. ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*
MY0"U"_< LPW_ +$-_P"P#?\ L [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH
M /46!0#V$0T ZPX5 .(+(@#8"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT
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M HLG_P**)_\"B2?_ HDG_P&))_\!^BD  .PP  #=-@  S3@  ,0W  "^,@
MNBL" +4E#@"N)QT J"DK *0J. "@*D, G2M, )HK50"8*UP EBMC )0K:@&2
M*W$!D"QX 8\L@0&-+(H!BRR4 HHLGP*(+*L"ABRZ H4MS@.#+NH#@2[\ X N
M_P)_+O\"?R[_ GXN_P)^+O\"]"X  .0W  #2/0  Q3\  +L_  "T/   KS4
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M!&8__P1F/_\$Y3T  ,]&  "_3   M$\  *I0  "B3P  F4H  )%$  "*00T
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MB 934)8'4E"E"%!0MPE04,X)3U#M"%!0_P=04/\&4%#_!5!0_P504/\%T$L
M +]4  "R6@  IUX  )U@  "48   B5T  'Q7  !R5   ;%,. &A4&0!E5"0
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M!T%>L0= 7L@'0%[H!T!=_ 9!7?\%05W_!4%<_P5!7/\%PU8  +1?  "H9@
MGFH  )5M  "*;0  ?VP  &]G  !D9   6V(% %9B$ !48AL 4F,E %!C+P!.
M9#@ 361  $MD2 !*9$\!2&17 49D7P)%9&@"0V1S T%C?P0_8XX%/6.>!CQC
ML 8[9,8&.V3F!CMC^@4[8O\%.V+_!3QA_P0\8?\$OEL  +!C  "E:@  FV\
M )%R  "&<@  >W$  &QM  !@:P  56D  $]H#0!-:1< 2VDA $EJ*P!(:C0
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M B9Z]P(F>/\")GC_ B=W_P(G=_\"KFP  *-V  "9?   CG\  (2"  !X@P
M;(0  %^$  !1A   1X0  #R$   SA D ,(01 "^$&@ MA"0 +(4M "N%-0 J
MA3X *85' "B&4  GAEH )H9F "2&<P CAH, (8:5 ""&IP$>AKP!'H;> !Z$
M]0$>@O\!'H+_ 1Z!_P$>@?\!J'0  )Y]  "3@@  B84  'Z(  !QB@  98L
M %B,  !,C0  0(X  #:.   LCP  )9 , ".0$P BD!P (9 E ""1+@ ?D38
M'I%  !V120 <D50 &I%@ !F1;@ 8D7X %I*0 !62I  4D;D $Y'8 !./]  4
MCO\ %(W_ !2,_P$4C/\!HWT  )B#  ".B   A(P  '>/  !ID0  79,  %"5
M  !%EP  .9@  "Z9   EF@  '9L" !:=#  5G1, %)T; !.=)  2G2T $9XW
M !&>00 0GDP #YY8  Z>9P -GG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X
M"YK_  N9_P +F?\ G(0  )&*  "(C@  >Y(  &V6  !@F0  5)P  $B?   \
MH   ,*$  ":C   =I0  %:<  !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J
M.  "JD0  :I0  "J7@  JFX  *J!  "JE0  J:H  *G!  "HY   J/8  *?_
M  "G_P  I_\ E8L  (R0  !_E0  <9H  &.>  !6H@  2J8  #VH   QJ@
M)JL  !VM   4L   #K(   FU 0 "M@H  +8/  "V%0  MQT  +<E  "W+P
MN#D  +A&  "X5   N&0  +AV  "XBP  MZ   +>V  "WTP  MN\  +;\  "V
M_P  MO\ CY(  (*7  !TG0  9J(  %BG  !+K   /J\  #&Q   FLP  '+8
M !.X   -NP  !KX   #!    P@0  ,(+  ##$   Q!4  ,0<  #%)   QBX
M ,@Z  #)1P  R5<  ,EI  #)?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0
MR/T A9D  '>?  !HI@  6JL  $VQ   _M0  ,;@  "6Z   :O0  $<    O#
M   #QP   ,H   #-    S@   ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM
M  #=.0  WDD  -Y:  #?;@  WX4  -^<  #?L@  WLL  -[F  #?]   W_0
M>:$  &NH  !<KP  3K4  $"[   QO@  ),$  !G%   0R   "<P   #/
MTP   -D   #<    W0   -\   #A    X@4  .0+  #F$   Z!8  .H@  #M
M*P  \#H  /%+  #Q7@  \G,  /.+  #SH@  \[8  //)  #SX0  \^$ ;:H
M %ZQ  !0N0  0;\  #+$   DR   %\P   [0   &U0   -H   #>    X@
M .8   #I    Z@   .P   #N    \    /(   #T!@  ]@P  /D2  #\'
M_RD  /\Z  #_30  _V(  /]X  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!
M%P#_ !< _P : /\ (0#_ "L _P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![
M /\ @P#_ (H _P"0 /\ E@#_ )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4
M_ #J /L ^ #Z /\ ^0#_ /@ _P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_
M !, _P 4 /\ &@#_ "< _P T /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\
M?@#_ (4 _@"+ /T D0#[ )< ^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C
M .\ \P#N /\ [0#_ .P _P#K /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \
M_P 0 /\ %@#_ "( _P O /\ /0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T
M '\ \P"& /$ C #O )( [@"8 .P GP#K *8 Z0"N .< N #E ,4 XP#: .$
M[0#? /L W@#_ -T _P#= /\ W0#_ -T _P#= /\ _P\- /\,"P#_ PD _P ,
M /\ $@#_ !T _P I /L -P#X $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H
MY0"  ., A@#A (P WP"3 -T F0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#,
M /8 R@#_ ,H _P#) /\ R #_ ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\
M#@#_ !8 ]P B .\ , #K #T Z !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z
M -  @ #. (< S "- ,H E #( )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$
MNP#^ +D _P"X /\ N #_ +@ _P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X
M 1  Z  : ., * #= #8 V !" -( 30#. %< R@!? ,< 9@#% &T PP!T ,$
M>@"_ ($ O0"( +L CP"Y )< MP"? +4 J "S +, L0#" *\ V "N NT K /[
M *L%_P"J!O\ J0;_ *D&_P"I!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@
MW0,2 -0#( #-!"T R 0Z ,,%1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q
M"'L KPB" *X)B@"L"9( J@F; *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T.
M_P"<#_\ FP__ )L/_P";#_\ _QH  /<9  #J'@  WQX  -4:  #0$P( S@P+
M ,<+%@# #24 N@XR +8./P"R#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78
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M 7@H_P%X*/\![RL  -TS  #*.0  OCL  +0Z  "M-@  IB\  *$H!P";)Q,
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M) !\-R\ >3<Y '<X0@!T.$D <CA0 '$X5P!O.%X ;3AE 6PX;0%J.'4!:#B
M F<XC )E.)D#9#FH V(YN0-A.M #8#KN V Z_P-?.O\"7SK_ E\Z_P)?.O\"
MW3L  ,=#  "Y20  KDL  *1,  ";2@  DD4  (D_  "!.@D >SH4 '<[( !T
M/"L <CPU &\]/@!M/48 :SU- &D]4P!H/5H 9CUA 60]:0%C/7(!83U] F ]
MB0)>/98#73ZE UL^M@1:/LP$6C_L!%D__@-9/_\#63__ ED__P)9/O\"UC\
M ,-'  "U3   JE   *!0  "73P  CDL  (1%  !Z0 8 =3\1 '% ' !M0"@
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M!$M+L 1*2\4$24OF!$E+^@1)2_\#2DO_ TI+_P-*2_\#R$D  +A1  "L5P
MH5L  )A<  ".7   @UD  '93  !K3@  9$T* %],$P!<31X 6DTH %A-,0!6
M33H 5$U! %-.2 !23D\ 4$Y7 4].7P%-3F@!3$YS DI/?P))3XT#1T^=!$9/
MK@1%3\,$1%#D!$1/^01%3_\#14__ T5._P-%3O\#Q$P  +55  "I6P  GUX
M )5@  "+8   @%X  ')7  !G4P  7E$' %E1$0!741L 5%$E %)2+P!14C<
M3U(_ $Y21@!-4TT 3%-5 $I370%)4V8!1U-P D53?0)$4XL#0E.; T%4K 1
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M S1>]0,U7?\"-5W_ C5<_P(U7/\"N%D  *IA  "@9P  EFP  (QN  "!;@
M=FP  &=I  !<9@  460  $AB"0!$8A$ 0F(; $%C)  _8RT /F,U #UD/0 \
M9$4 .V1- #ED50 X9%\ -F1I 35D=@$S9(4!,665 C!EIP(O9;L"+F7: BYD
M] (N8_\"+V/_ B]B_P(O8O\"LUX  *=F  "<;0  DW$  (AS  !]<P  <G(
M &1P  !8;@  36P  $)J P \:0X .FH6 #EJ(  X:B@ -FLQ #5K.0 T:T$
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M !9[_P 7>_\ I'(  )IZ  "/?P  A8(  'N$  !MA@  8(<  %2'  !(B
M/(@  #*(   HB   ((@% !J)#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3
MBDP $HM8 !&+90 0BW4 #XN'  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&
M_P .AO\ GWL  )2!  "*A0  @(@  '.+  !EC0  68\  $R0  !!D@  -)(
M "J2   ADP  &90  !*6!@ .EPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0
M")=0  :77@ %EVX  Y:   &6E   E:@  )6^  "4X   E/0  )/_  &2_P !
MDO\ F((  (Z(  "%C   =X\  &J2  !=E0  4)@  $2:   XFP  +)P  "*=
M   9G@  $J    VB @ 'HPL  :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(
M  "D5@  I&4  *-W  "CBP  HZ   **V  "AT@  H?   *#[  "@_P  H/\
MD8H  (F.  ![D@  ;9<  &";  !3G@  1J$  #FC   MI   (Z8  !FH   1
MJ@  #*P   6N    KP<  *\-  "O$0  L!@  + @  "Q*   L3(  +(^  "R
M3   LEL  +)L  "R@0  L9<  +&L  "PQ@  L.@  *_W  "O_P  K_\ C)
M '^5  !QF@  8Y\  %6D  !'J   .JH  "VL   BK@  &+   !"S   *M0
M K@   "[    NP   +P'  "\#0  O1$  +X6  "_'@  P"<  ,$R  #"0
MPT\  ,-@  ##=   PXL  ,.A  ##N   PM<  ,+O  #"^@  P?X @9<  '.=
M  !EHP  5Z@  $FM   [L0  +;,  "&V   6N0  #KL   >^    P0   ,4
M  #'    R    ,D   #*!0  RPL  ,T/  #.%   T!P  -,F  #6,@  V$$
M -A3  #99@  V7P  -F4  #9JP  V<,  -GA  #9\   V?0 =I\  &>F  !9
MK   2[(  #RW   NN@  (;T  !7    -Q   !<<   #*    S@   -(   #5
M    U@   -D   #;    W0   -\'  #A#   XQ$  .89  #I)   [#(  .U#
M  #N5@  [VL  .^$  #OG   [[(  ._&  #OW0  [^0 :J@  %NO  !,M@
M/KP  "_    @Q   %,@   S,   "T    -0   #9    W@   .(   #E
MY@   .@   #I    [    .X   #P @  \@D  /4/  #X%P  _",  /\S  #_
M1@  _UH  /]Q  #_B0  _Y\  /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7
M /\ '0#_ "@ _P W /\ 1 #_ %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4
M_P"+ /\ D0#_ )< _P"= /\ I #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X
M /\ ]P#_ /< _P#W /\ \ #_ .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\
M%P#_ "0 _P R /\ /P#_ $P _P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "&
M /H C #Y )( ^ "8 /8 GP#U *8 ] "N /( N0#P ,8 [@#> .T \ #K /X
MZ@#_ .D _P#I /\ YP#_ ., _P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_
M !\ _P L /\ .@#_ $8 _@!2 /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X
MAP#L (T Z@"3 .D F@#G *$ Y@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_
M -< _P#5 /\ U0#_ -4 _P#4 /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D
M^P F /< - #T $  \@!, .X 5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#<
M (< V@"- -8 E #4 )L T0"C ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,,
M_P## /\ PP#_ ,, _P## /\ _PL! /\#  #_    _P # /\ "P#S !( [@ ?
M .H +0#F #H X@!% -X 3P#9 %@ U !@ -$ : #. &X S !T ,H >P#( ($
MQ@"' ,0 C@#" )8 P "> +X IP"[ +( N0#  +< U "U .P LP#[ +, _P"R
M /\ L@#_ +$ _P"Q /\ _PT  /\&  #_ P  ]P   /0  P#G  T X  8 -H
M)0#3 #( S@ ^ ,H 20#& %( PP!: ,  80"^ &@ O !N +H = "X 'L M@"!
M +0 B "R )  L "9 *X H@"L *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\
MH@#_ *( _P"B /\ _Q   /L,  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$
M "H OP W +L 0@"W $L M !4 +( 6P"O &( K0!H *L ;@"I '4 J ![ *8
M@P"D (L H@"4 *  G@"> :@ G *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_
M )0)_P"4"?\ _!$  /$5  #C&0  UAD  ,P5  #'$   Q <* +T#% "W!"$
ML@8N *X(.@"J"40 IPE- *0*50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7
M#(8 E@R0 )0,F@"2#:8 D0VS (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1
M_P"'$?\ ]AD  .<@  #6)   R"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G
M *$0,P"=$3X FA%' )@23P"5$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$
MB12+ (<4E@"&%:( A!6P (,6P0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![
M&?\ [R$  -TI  #*+0  OB\  +4L  "N)P  J"   *,7" ">%A, F1<A )09
M+0"1&C@ CAI! (L;20")&U  AQM7 (4<7@"$'&0 @AQK ( <<P!_'7P ?1V&
M 'P>D0!Z'IX >!^K '<?O !V(-0 ="'P '(A_P!Q(O\ <2'_ '$A_P!Q(?\
MZ"@  -(P  #"-0  MS<  *TU  "E,0  GBL  )@C @"2'A  C2 ; (DA)P"&
M(C( @R,\ ($C1 !^(TL ?"12 'LD60!Y)%\ =R1F '8E;@!T)7< <R6! '$F
MC0!O)ID ;B:G &TGN !L)\X!:BCM 6DI_P%H*?\!:"G_ 6@H_P%H*/\!X2X
M ,LV  "\.P  L3T  *<]  "?.0  ES,  (\M  "()PP @R<6 '\H(@!\*2T
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M 54XKP)4.<,"4SGD E,Z^0%3.?\!4CG_ 5,Y_P%3.?\!S3P  +Q$  "O20
MI$P  )I,  "12P  AT8  'U   !S.P  ;#@- &@Y%P!E.2( 8SHK & Z- !>
M.CP 73I# %LZ2@!:.U  6#M8 %<[8 !6.V@ 53QS 5,\?P%2/(T!4#V< 4\]
MK )./L$"33[A DT^^ )-/O\!33[_ 4T]_P%-/?\!R4   +A(  "L30  H5
M )=1  ".3P  A$L  'E%  !N0   9CT+ &(]% !?/1X 7#XH %H^,0!8/C@
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M CY*\P(^2O\"/DG_ 3])_P$_2?\!O4H  *]2  "C6   F5L  )!=  "&7
M>UD  &U3  !B3P  5TP! %%*#0!.2A4 3$L? $I+* !)2S  1TLX $9,/P!%
M3$8 1$Q. $--5@!"35\ 0$UJ #]-=@$]3H0!/$Z4 3M.I0$Y3[D".4_4 CE/
M\@$Y3O\!.4[_ 3E-_P$Z3?\!NDX  *Q6  "A6P  EU\  (UA  "#80  >%X
M &E8  !?5@  5%(  $Q/"P!)3Q( 1U < $50)0!#4"T 0E U $%1/ ! 440
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M 2A=_P$H7/\!K5P  *)D  "8:@  CFX  (-O  !Y;P  ;FX  &!K  !4:0
M26<  #]E   U8PD ,F,1 #!C&0 O9"$ +F0I "UD,0 L9#D *V5" "IE2@ H
M950 )V5? "9F:P D9GH (V:+ ")FG0 @9K$ 'V;) !]FZP @9?X (&3_ "!C
M_P$A8_\!J6(  )YJ  "5<   BG,  (!U  !U=0  :70  %QR  !/<0  1&\
M #IN   P;0, *6P- "=L%  F;!P )6TD "1M+  C;30 (FT] "%N1@ @;E
M'FY; !UN9P <;G8 &FZ' !EOF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8
M:_\ I&D  )IQ  "0=@  AGD  'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X
M   K=P  (G8' !UV#P <=Q8 &W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6
M !-X8P 2>'( $7B# !!XEP />*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\
MGW$  )5X  "+?   @G\  '>!  !J@@  78(  %""  !$@@  .((  "Z"   D
M@@  '((  !2""0 1@Q  $(,6 !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#
M70 )@VP "(-^  :#D0 %@J4  X*[  2!VP $@?( !8#_  9__P &?_\ FGD
M )!^  "&@P  ?84  &^'  !BB0  58H  $F+   ]C   ,8P  ":,   =C0
M%8X   ^/ P *D P !I 1  2/&  #CR   8\I  "/,@  D#T  )!)  "/5@
MCV4  (]V  "/B@  CI\  (ZT  "-SP  C.X  (S[  "+_P  B_\ E(   (N%
M  ""B0  =(P  &:/  !9D0  3),  $"5   TE@  *)8  !Z7   5F   #YH
M  J;   "G D  )P.  "<$P  G!H  )PB  "=*P  G34  )U   "=3@  G5P
M )UN  "<@0  G)<  )RL  ";Q@  FN@  )GY  "9_P  F/\ CH@  (:,  !X
MD   :I0  %R7  !/F@  0IT  #:>   IGP  'Z$  !6B   .I   "*8   "H
M    J00  *D*  "I#@  J1,  *H:  "J(@  JRL  *PV  "L1   K%,  *QC
M  "L=P  JXX  *ND  "KO   JMX  *GT  "I_0  J?\ B8X  'N3  !MEP
M7YP  %&@  !$I   -J8  "JH   >J0  %*L   VN   &L    +(   "U
MM0   +4#  "V"0  MPX  +@2  "X&0  NB$  +LK  "\.   O4<  +U8  "]
M:P  O8$  +V9  "]L   O<P  +SJ  "\]P  N_X ?I4  '";  !BH   4Z4
M $:J   XK0  *J\  !ZQ   3M   #+<   .Y    O    +\   #"    P@
M ,,   #$    Q@8  ,<,  #($   RA8  ,P@  #/*P  T#H  -%+  #17@
MTG,  -*+  #2I   T[L  -/8  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS
M   JM@  ';D  !*\   *OP   ,,   #&    R0   ,T   #/    T    -(
M  #4    U@   -D"  #;"   W@X  .$3  #D'0  Z"H  .@\  #I3P  Z60
M .I\  #KE0  ZZP  .O"  #LU0  [.4 9J8  %BL  !)LP  .[D  "N\   =
MP   $<0   G(    S    ,\   #3    V0   -T   #@    X0   .,   #E
M    YP   .H   #L    [@0  /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ
M  #_@P  _YL  /^N  #_O@  _\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8
M_P T /\ 00#_ $T _P!8 /\ 8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_
M ), _P"9 /\ H #_ *< _@"O /P N@#Z ,D ^0#A /@ \P#W /\ ]@#_ /4
M_P#Q /\ Z0#_ .0 _P#A /\ _P / /\ #0#_  T _P . /\ % #_ "$ _P N
M /\ / #_ $@ _P!3 /\ 70#_ &8 _@!M /P =0#[ 'L ^0"" /@ B #W (X
M]@"4 /0 FP#S *( \0"J .\ M #M ,$ ZP#5 .H [ #H /P YP#_ .4 _P#F
M /\ X #_ -D _P#4 /\ _P + /\ " #_  8 _P ) /\ $ #_ !P _P I /\
M-@#_ $( ^P!. /< 5P#T &  \@!H .\ ;P#M '8 [ !\ .H @@#H (@ YP".
M .4 E0#C )P X0"D -\ K@#= +D V@#* -< Y #4 /8 T0#_ -  _P#0 /\
MSP#_ ,L _P#' /\ _P # /\   #_    _P $ /\ #0#Z !8 ]@ C /, , #P
M #P [0!' .D 40#E %H X@!B -\ :0#= &\ V@!V -@ ? #4 (( T@"( -
MCP#- )8 RP"> ,D J #' +, Q0#! ,( V #  .\ OP#^ +X _P"] /\ O #_
M +P _P"\ /\ _P(  /\   #_    _P   /0 !P#M !$ Z  < ., *0#? #4
MVP!! -8 2P#1 %0 S0!< ,H 8P#( &D Q@!O ,, =0#! 'L OP"" +X B "\
M )  N@"8 +@ H@"U *P LP"Y +$ RP"O .< K@#X *P _P"K /\ K #_ *P
M_P"K /\ _P0  /\   #V    [@   .<   #?  P U@ 5 ,\ (@#* "X QP Z
M ,, 1 #  $T O !5 +D 7 "W &, M0!I +, ;P"Q '4 KP![ *T @@"K (H
MJ0"2 *< G "E *8 HP"S *$ PP"? -X G@#R )T _P"< /\ G #_ )L _P";
M /\ _P<  /8)  #I"P  WPH  -4$  #.  4 Q@ 0 ,  &@"[ "< MP R +,
M/0"P $8 K0!/ *H 5@"H %P I@!C *0 : "B &\ H0!U )\ ? "= (0 FP"-
M )D EP"7 *( E0"N ), O0"1 -, D #M (\ _ ". /\ C0'_ (T!_P"- ?\
M^0X  .H2  #<%0  S14  ,01  "^#   N@(* +0 $@"N !X J@ J *8 -0"B
M #\ H !( )T!4 "; E8 F0)< )<#8P"5 VD DP-O )$$=@"0!'\ C@6( (P%
MD@"*!IX B :J (8'N@"%",\ A KK ((+_ "!#/\ @ S_ ( ,_P" #/\ \14
M . =  #-(   P2$  +@=  "Q%P  K!   *@)#0"B!Q8 G0DC )D*+@"5"S@
MDPQ! ) ,20".#5  C U7 (H-70"(#6, APUJ (4.<0"##GH @@Z$ ( .CP!^
M#YL ? ^H 'L0N !Z$,X >!'L '82_P!U$O\ =!/_ '03_P!T$_\ Z!X  -,F
M  ##*@  N"H  *XH  "G(P  H!P  )L3 P"6#Q  D! ; (P1)P")$C( AA,[
M (030P""%$L @!11 'X45P!\%%X >Q5E 'D5; !W%70 =A9^ '06B@!R%Y8
M<1>D &\8M !N&,D ;1GH &L:_ !J&_\ :AO_ &H;_P!J&_\ X"8  ,HM  "\
M,0  L#,  *<Q  "?+   ER8  ) ?  "*%PP A1@6 ($9(@!^&BP >QLV 'D;
M/@!W'$4 =1Q, ',<4P!Q'5D <!U@ &X=9P!M'G  :QYZ &H>A0!H'Y( 9Q^@
M &4@L !D(<4 8R'D &(B^@!A(O\ 82+_ &$B_P!A(O\ URP  ,,T  "V.
MJCD  *$X  "8-0  D"\  (@H  " (0@ >R 2 '<A'0!T(B< <2(Q &\C.0!M
M(T$ :R-( &DC3@!H)%4 9B1; &4D8P!C)6L 8B5U &$E@0!?)HX 7B:= %TG
MK0!;*,$ 6RC@ %HI]P!9*?\ 62G_ %DI_P!9*/\ SS(  +XY  "Q/0  IC\
M )P_  "3/   BC8  ($P  !Y*@, <B8/ &XG&0!K*", :2@L &8I-0!E*3P
M8RE# &$J2@!@*E$ 7BI7 %TJ7P!<*V@ 6BMR %DL?0!8+(L 5BV: %4MJ@!4
M+KT 4R[< %(O]0!2+_\ 4B[_ %(N_P!2+O\ RC8  +H]  "M0@  HD0  )A$
M  "/00  A3P  'LW  !R,0  :RP, &<M%0!D+1\ 82XH %\N,0!=+CD 7"]
M %HO1@!8+TT 5R]4 %8P7 !5,&0 4S%N %(Q>@!1,8@ 4#*7 $XRJ !-,[L
M3338 $PT\P!,-/\ 3#3_ $PS_P!,,_\ QCH  +9"  "I1@  GDD  )5)  "+
M1P  @4(  '<]  !M-P  9#() & R$@!=,AP 6C(E %@S+0!6,S4 53,\ %,T
M0P!2-$H 4311 % T60!/-6$ 335L $PV=P!+-H4 2C>5 $@WI@!'.+@!1SC3
M 48X\0%&./\!1CC_ $8X_P!&-_\ P3X  +)%  "F2@  G$T  ))-  "(2P
M?D<  '-"  !I/0  7S<& %HV$ !7-Q@ 5#<B %(W*@!0-S( 3S@Y $TX0 !,
M.$< 2SA. $HY5@!).5\ 2#II $<Z=0!%.X, 1#N3 $,\I %"/+8!03W0 4$]
M\ %!/?\!03S_ 4$\_P%!//\ OD(  *])  "C3@  F5   (]1  "%4   >TP
M &]&  !E0@  6CT" %0[#@!1.Q4 3SL? $T[)P!+.R\ 23PV $<\/0!'/$0
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M #)(_P S2/\ M$P  *=4  "<60  DEP  (A=  !^70  <UH  &55  !;4@
M4$X  $9*!0! 20X /DD6 #U)'@ [2B8 .DHN #E*-0 X2ST -TM$ #9+30 T
M3%8 ,TQ@ #),;  Q37H ,$V+ "Y-G  M3J\ +$[' "Q.Z0 L3?T +4W_ "U,
M_P M3/\ L%   *18  "970  CV$  (9B  ![80  <%\  &);  !86   3E4
M $-1 0 [3PP .$\3 #9/&P U3R, -% K #-0,@ R4#H ,5!" #!12@ N45,
M+5)= "Q2:0 K4G@ *5*( "A3F@ G4ZT )E/% "93YP F4_P )U+_ "=1_P G
M4?\ K%4  *!<  "68@  C68  (-G  !X9@  ;64  &!A  !57@  2EL  #]8
M   U5@@ ,540 #!6%P N5A\ +58G "Q6+P K5S8 *E<^ "E71P H5U  )EA:
M "589P D6'4 (UF& "%9F  @6:L 'UG" !]9Y0 ?6/H (%C_ "!7_P A5_\
MJ%H  )UB  "39P  BFL  ']L  !U;   :FL  %UH  !190  1F,  #M@   Q
M7@, *ET- "A=$P F71L )5XC "1>*@ C7C( (EXZ "%>0P @7TP 'U]7 !Y?
M8P <8'$ &V"" !E@E0 88*D %V#  !9@X@ 77_D &%[_ !E>_P 97?\ I&
M )EH  "0;@  AG   'QR  !R<@  9G$  %AN  !,;   06L  #9I   M9P
M(V8( !]F#P =9A4 '&8= !MF)0 :9BT &6<U !AG/@ 79T@ %F=3 !5H7P 3
M:&X $FA_ !%HD@ 0:*8 #VB]  YHX  09_< $&;_ !%E_P 19?\ GV<  )9O
M  ",<P  @G8  'AX  !M>   8'<  %-V  !&=   .W,  #%R   G<0  'G$
M !9P"@ 3<!  $W 7 !)P'P 1<2< $'$O !!Q.  .<4( #G%.  UQ6P ,<6D
M"W%Z  IQC0 (<:$ !G&V  9PT@ '<.\ "&__  EN_P );O\ FV\  )%U  "'
M>0  ?GP  '1^  !F?@  67X  $U^  ! ?0  -7T  "I\   A?   &'P  !%\
M!  ,? P "GP1  E\&0 (?"$ !WPI  9\,@ $?#T  WQ(  %\50  ?&,  'QT
M  !\AP  >YP  'NQ  !ZRP  >>L  'GZ  !Y_P  >/\ EG<  (Q\  "#@
M>8,  &R$  !>A0  488  $6'   YAP  +8<  ".'   :AP  $H<   V( 0 &
MB0H  8D/  ")%   B!L  (@C  ")+   B38  (E"  "(3@  B%T  (AM  "(
M@0  AY4  (>K  "&Q   A>8  (3X  "$_P  A/\ D'X  (>#  !^AP  <8D
M &.+  !6C0  28\  #R1   PD0  ))$  !J2   2DP  #90   :5    E@8
M )8,  "5$   EA4  )8=  "6)   EBX  )8Y  "61@  EE4  )9E  "6>
ME8X  )6D  "4O   D]\  )/U  "2_P  DO\ BX8  (.*  !UC0  9Y   %F4
M  !,EP  /YD  #*:   FFP  &YP  !*=   ,GP  !*    "B    HP$  *,'
M  "C#   HQ   *05  "D'   I24  *8O  "F/   IDL  *9;  "F;@  I80
M *6;  "DLP  H]   */O  "B_   HO\ AHT  'B1  !JE0  7)D  $Z=  !!
MH   ,Z(  ":C   ;I0  $:<   JI   !JP   *T   "O    L    +    "P
M!0  L0L  +(/  "S%   M!L  +4D  "W,   MS\  +=0  "W8@  MW@  +>0
M  "VJ0  ML(  +;D  "V]0  M?X >Y,  &V8  !?G0  4*(  $*F   TJ0
M)JL  !JM   0KP  ";(   "T    MP   +H   "\    O0   +X   "^
MP (  ,$(  #"#0  Q!(  ,89  #))   RC(  ,M#  #+50  S&H  ,R#  #,
MG   R[4  ,S.  #,Z0  S/8 <)L  &&A  !2I@  1*L  #:P   GL@  &K4
M !"X   'NP   +X   #!    Q    ,@   #+    RP   ,T   #.    T
M -(   #5 P  V H  -L0  #>&   XB0  .,U  #D2   Y5P  .9S  #FC0
MYJ4  .:\  #FTP  Y^< 8Z0  %6J  !&L   .+4  "BY   :O   #\    7$
M    QP   ,L   #/    U    -@   #<    W0   -\   #A    XP   .4
M  #H    Z@   .T&  #Q#@  ]18  /@E  #Y.   ^4T  /IC  #[?   _)4
M /RJ  #\NP  _<L _P / /\ #@#_  X _P 0 /\ %@#_ ", _P P /\ /0#_
M $D _P!4 /\ 7@#_ &8 _P!N /\ =@#_ 'P _P"" /\ B0#_ (\ _P"5 /X
MFP#] *, ^P"K /H M0#Y ,, ]P#; /8 \ #T /\ \P#_ /( _P#L /\ X@#_
M -P _P#6 /\ _P , /\ "0#_  @ _P * /\ $@#_ !X _P K /\ . #_ $0
M_P!/ /\ 60#^ &$ _ !I /H < #X '< ]P!] /8 @P#T (D \@"/ /$ E@#O
M )T [0"E .P KP#J +P Z #- .8 Z #D /H XP#_ .( _P#@ /\ U0#_ ,X
M_P#+ /\ _P & /\  0#_    _P $ /\ #@#_ !D _P E /T ,@#[ #X ]P!)
M /, 4P#P %P [@!C .P :@#J '$ Z !W .8 ?0#D (, X@") .  D #> )<
MW "? -D J0#6 +0 TP#$ -  W@#. /, S #_ ,L _P#* /\ R #_ ,( _P"^
M /\ _P   /\   #_    _P   /L "P#V !, \0 @ .T + #J #@ YP!# .,
M30#@ %8 W != -D 9 #5 &L T@!Q -  =@#. 'P S "# ,H B0#( )$ Q@"9
M ,0 HP#! *T OP"[ +T SP"[ .L N0#\ +< _P"W /\ M@#_ +0 _P"Q /\
M_P   /\   #_    ]@   .X !0#G  \ X0 9 -L )0#5 #$ T@ \ ,X 1@#*
M $\ QP!7 ,0 7@#! &0 OP!J +T < "[ '8 N0!\ +@ @P"V (H LP"3 +$
MG "O *< K0"S *L Q0"I .$ IP#U *8 _P"E /\ I #_ *0 _P"D /\ _P
M /P   #Q    Z    .    #4  L S  3 ,< 'P#" "H OP U +P /P"X $@
MM0!0 +, 5P"P %X K@!D *P :0"K &\ J0!U *< ? "E (0 HP", *$ E@"?
M *$ G0"M )H O "8 -( EP#N )4 _@"4 /\ E0#_ )4 _P"5 /\ _ $  / %
M  #C!P  U04  ,P   #%  0 O@ . +@ %P"S ", KP N *L . "I $$ I@!*
M *, 40"A %< GP!= )T 8P"; &D F@!O )@ =@"6 'T E "& )( D "0 )L
MC@"G (P M@"* ,D B #G (< ^0"' /\ A@#_ (8 _P"& /\ ] P  .00  #1
M$@  Q1$  +T.  "V"   L0 ( *L $0"F !L H0 F )X ,0": #H F !# )4
M2@"3 %$ D0!7 (\ 70". &, C !I (H < "( '< A@"  (0 BP"" )8 @ "C
M 'X L0!] ,0 >P+A 'H#]0!Z!?\ >07_ '@&_P!X!O\ ZA,  -8:  #&'0
MNAP  +$9  "J$P  I T  )\%# "9 !0 E0 ? )$"*0"- S, BP0\ (@%1 "&
M!DL A 91 (('5P"!!UT ?P=C 'T(:@!["'( >@A\ '@)A@!V"9( = J@ ',*
MKP!Q"\$ < S? &\-]@!N#O\ ;0[_ &T._P!M#O\ X1P  ,LC  "\)@  L28
M *@D  "@'@  F1@  ),0 @"."PX B L7 (0,(@"!#2P ?@TU 'P./0!Z#D4
M> Y+ '<.40!U#U@ <P]> '$090!P$&X ;A!W &P0@@!K$(\ :1&= &@1K0!F
M$L  91+? &03]@!C%/\ 8Q3_ &(4_P!B%/\ UB0  ,,J  "U+@  JB\  * M
M  "8*   D"(  (D;  ""$P@ ?1$2 'D2' !V$R< <Q0P '$4. !O%3\ ;15&
M &P53 !J%E, :!99 &<680!E%FD 9!=R &(7?@!A&(L 7QB9 %X9J0!<&;P
M7!K8 %H;\P!:'/\ 61S_ %D<_P!9'/\ S2H  +TQ  "O-0  I#8  )LT  "2
M,0  B2L  ($E  !Y'0, <Q@. &\9& !L&B( :1LK &<;,P!E'#L 9!Q! &(=
M2 !@'4X 7QU5 %T=7 !<'F0 6QYN %D?>0!8'X< 5B"6 %4@I@!4(;@ 4R'2
M %(B\0!2(_\ 4B/_ %(B_P!2(O\ R"\  +@V  "K.@  H#P  )8[  "-.
M@S(  'HM  !R)@  :B , &8@$P!C(1T 82$F %\B+P!=(C8 6R(] %HC1 !8
M(TH 5R-1 %4C6 !4)&$ 4R1J %$E=@!0)8, 3R:3 $XGHP!,)[4 3"C. $LH
M[@!+*?\ 2RC_ $LH_P!+*/\ PS0  +,[  "G/P  G$$  ))   ")/@  ?SD
M '4S  !L+0  8R<( %XF$0!<)AD 62<B %<G*P!5*#( 5"@Y %(H0 !1*$8
M4"E- $XI50!-*5T 3"IG $LJ<P!)*X  2"N0 $<LH0!&+;, 12W+ $4N[ !$
M+O\ 1"[_ $4M_P!%+?\ OC@  + _  "D0P  F44  (]%  "%0P  >SX  '$Y
M  !G-   7BX$ %@K#@!5*Q8 4BP? % L)P!/+"\ 32TV $PM/ !*+4, 22U*
M $@N4@!'+EH 1B]D $4O< !#,'X 0C"- $$QG@! ,K$ /S+( #\SZ@ _,_X
M/S+_ #\R_P _,O\ NSP  *U#  "A1P  EDD  (Q)  "#2   >$0  &T^  !C
M.0  6C0  %(P# !/,!, 3# < $HP) !),2L 1S$R $8Q.0!$,4  0S)' $(R
M3P!!,U@ 0#-B #\T;0 ^-'L /36+ #PVG  [-J\ .C?& #DWZ  Y-_P .C?_
M #HV_P Z-O\ MT   *I&  ">2P  E$T  (I.  " 3   =4@  &I#  !@/@
M5CD  $TU"0!)-!$ 1S49 $4U(0!#-2@ 034O $ U-@ _-CT /C9% #TW30 \
M-U4 .SA@ #HX:P Y.7D .#F) #<ZFP U.JT -3O$ #0[Y@ T._L -3O_ #4Z
M_P U.O\ M$,  *=*  "<3@  DE$  (A2  !^4   <TT  &=(  !<1   4C\
M $@Z!@!$.0\ 03D6 #\Y'@ ^.28 /#DM #LZ-  Z.CL .3M" #@[2@ W/%,
M-CQ= #4]:0 T/7< ,SZ' #$^F0 P/ZL +S_" "\_Y  O/_H ,#__ # ^_P P
M/O\ L4<  *1-  "94@  CU4  (96  !\50  <5(  &1,  !920  3T4  $5
M P _/@T /#X3 #H^&P Y/B, -SXJ #8_,0 U/S@ -#]  #- 2  R0%$ ,4%;
M #!!9P N0G4 +4*% "Q#EP K0ZH *D/  "E$X@ J0_D *D/_ "M"_P K0O\
MKDH  *%1  "75@  C5D  (-:  !Y6@  ;E<  &%2  !73@  34L  $-'   Z
M0PH -D,1 #1#&  S0R  ,D0G #%$+P P1#8 +T4] "U%1@ L14\ *T99 "I&
M9  I1W( *$># "9'E0 E2*@ )$B^ "-(X  D2/< )4?_ "5'_P F1_\ JD\
M )]5  "46@  BUX  (%?  !W7@  :UP  %]8  !550  2U$  $!-   U2@<
M,$D. "Y)%0 M21T +$DD "M**P J2C, *$H[ "=+0P F2TP )4M6 "1,8@ C
M3'  (4R  "!-DP ?3:8 'DV[ !U.W0 >3?8 'DS_ !],_P @2_\ IU,  )Q:
M  "27P  B&,  'YD  !T8P  :6$  %Q>  !26P  1U@  #Q5   R4@( *E ,
M "=/$@ F4!D )5 @ "10*  C4"\ (E$W "%10  @44D 'E)3 !U27P <4FT
M&E-] !E3D  84Z0 %E.Y !53V0 64_0 %U+_ !A1_P 94?\ HUD  )A@  "/
M90  A6@  'MI  !Q:0  9F<  %ED  !-80  0E\  #A<   N6@  )5@( "!7
M#@ >5Q0 '5<< !Q8(P ;6"L &E@S !E8/  86$4 %EE0 !596P 466D $UIZ
M !):C0 16J$ $%JW  Y:U0 06?, $%G_ !%8_P 16/\ GU\  )5F  ",:P
M@FT  'AN  !N;P  8FT  %5J  !(:   /F8  #-E   I8P  (&$! !A@"P 5
M8!  %& 7 !-@'@ 28"8 $F N !%A-P 084  #V%+  YA6  -868 #&)V  MB
MB0 *89T "6&R  AARP (8>L "6#]  I?_P +7_\ FV8  ))M  "(<0  ?G,
M '5U  !J=   7',  $]R  !#<   .&\  "UN   D;   &VL  !-K!  .:@P
M#6H2  QJ&0 +:B$ "FHI  EJ,@ (:CP !VM'  5K4P $:V$  FMQ  !JA
M:I@  &JM  !IQ@  :><  &GX  !H_P  :/\ EVT  (US  "$=P  >WH  '![
M  !C>P  5GH  $EZ   ]>0  ,7@  "=W   ==@  %78   ]V @ )=@H !'8/
M  !V%0  =AP  '8D  !U+   =38  '5!  !U3@  =5P  '5L  !U?@  =),
M '2H  !SP   <^,  '+W  !R_P  <?\ DG4  (EZ  " ?@  =H   &F!  !;
M@@  3H(  $&"   U@P  *8(  !^!   6@0  $((   J"   "@P<  ((-  ""
M$0  @A<  ((>  "")@  @B\  (([  ""1P  @E4  (%E  "!>   @8T  ("B
M  !_N@  ?]T  '[T  !]_P  ??\ C7P  (2!  ![A   ;H8  &"(  !2B@
M18L  #F,   LC   (8P  !>,   0C0  "8X   */    D ,  (\)  "/#@
MCQ(  ) 8  "0'P  D"@  ) R  "0/P  D$T  )!=  "/<   CX4  (Z<  ".
MLP  C=   (SP  "+_@  B_\ B(0  ("(  !RBP  9(T  %:0  !(DP  .Y4
M "Z6   BE@  %Y<   ^8   (F0   )L   "=    G0   )T#  "="0  G0T
M )X1  ">%P  GQ\  )\I  "@-0  H$,  *!4  "@9@  GWL  )Z3  ">JP
MG<8  )WI  "<^0  G/\ @XL  '6.  !GD@  698  $N9   ]G   ,)X  ".?
M   7H   #J(   >D    I@   *@   "J    J@   *H   "K 0  JP<  *P,
M  "M$   KA8  *\>  "Q*0  L3@  +%(  "Q6@  L6\  +&(  "QH   L+H
M *_=  "O\@  K_T >)$  &J6  !<F@  39\  #^C   QI@  (Z<  !>I   .
MJP  !:X   "P    L@   +4   "W    MP   +@   "Y    N@   +P#  "]
M"0  O@X  , 4  ##'@  Q2L  ,4\  #&3@  QF(  ,9Z  #&E   QJT  ,;(
M  #%Y0  Q?, ;)D  %Z>  !/I   0:@  #*L   DKP  %K$   VT   #MP
M +H   "]    P    ,0   #&    Q@   ,@   #)    RP   ,P   #.
MT 8  -,-  #8$P  W!X  -XM  #?0   X%0  .%K  #AA0  X9\  .&W  #A
MSP  X>8 8*$  %*G  !#K0  -+(  "6U   7N0  #;P   &_    PP   ,<
M  #*    SP   -,   #6    UP   -H   #<    WP   .$   #C    Y@
M .D!  #L"P  \!(  /,?  #T,0  ]D8  /=<  #X=   ^(\  /FF  #YN
M^,D _P - /\ "P#_  L _P . /\ $P#_ !\ _P L /\ .0#_ $4 _P!0 /\
M60#_ &( _P!J /\ <0#_ '< _P!^ /\ A #^ (H _0"0 /P EP#Z )X ^0"G
M /< L0#V +X ]0#2 /, [ #Q /X \ #_ /  _P#F /\ W #_ -( _P#- /\
M_P ' /\ ! #_  ( _P & /\ $ #_ !L _P G /\ ,P#_ #\ _P!* /X 5 #[
M %T ^0!D /< :P#U '( \P!X /( ?@#P (0 [P"* .T D0#L )D Z@"A .@
MJP#F +8 Y #' .( XP#@ /< W@#_ -T _P#9 /\ S #_ ,4 _P#! /\ _P
M /\   #_    _P ! /\ #0#_ !8 _  B /D +@#V #D \P!% .\ 3@#L %<
MZ0!> .8 90#D &P X@!R .  =P#? 'X W0"$ -L BP#8 )( U0"; -( I #/
M *\ S0"^ ,L U0#) .\ QP#_ ,4 _P#$ /\ O@#_ +@ _P"U /\ _P   /\
M  #_    _@   /< "0#Q !$ ZP < .< * #D #, X0 ^ -T 2 #8 %$ TP!8
M -  7P#. &4 S !K ,H <0#( '< Q@!] ,0 A #" (P P "4 +X G@"[ *@
MN0"V +< R "U .8 LP#Z +$ _P"P /\ L #_ *P _P"I /\ _P   /\   #Z
M    \0   .@  P#@  T V  6 -$ (@#- "T R@ W ,8 00#" $H OP!2 +T
M60"Z %\ N !E +< :@"U '  LP!V +$ ?0"O (4 K0"- *L EP"I *$ IP"N
M *4 O@"B -@ H #R )\ _P"> /\ G@#_ )X _P"< /\ _P   /<   #K
MX0   -8   #+  D Q0 1 +\ &P"[ "8 MP Q +0 .@"Q $, K@!+ *L 4@"I
M %@ IP!> *8 9 "D &D H@!P *  =@"> 'X G "& )H D "8 )L E@"G )0
MM@"2 ,H D #I (\ _ ". /\ C0#_ (P _P"- /\ ^    .D"  #; P  S $
M ,0   "]  ( M@ - +  %0"K "  IP J *0 - "A #P G@!$ )P 2P": %(
MF !8 )8 70"5 &, DP!I )$ < "/ '< C0"  (L B@") )4 AP"A (4 KP"#
M ,$ @0#@ (  ]0!_ /\ ?P#_ '\ _P!_ /\ [@H  -P.  #*$   O@X  +4+
M  "O P  J0 ' *, $ "> !@ F0 C )8 + "3 #4 D  ^ (X 10", $L B@!1
M (@ 5P"& %T A0!C (, :@"! '$ ?P!Z 'T A ![ (\ >0"< '< J@!U +L
M= #4 '( \ !R /\ <@#_ '$ _P!Q /\ XQ$  ,T7  "_&0  LQD  *H5  "C
M$   G0H  )<!"@"1 !( C0 ; (D )0"% "\ @P W (  /@!^ $4 ?0!+ 'L
M40!Y %< > != '8 9 !T 6L <@%T ' "?P!N HL ; .8 &L#I@!I!+< : 7.
M &<'[ !F"/T 9@G_ &4)_P!E"?\ UAH  ,0@  "V(P  JR,  *$@  "9&P
MDA0  (P. 0"&!PT @ 04 'P&'@!Y!R@ =@@P '0(. !R"3\ < E% &\*3 !M
M"E( ; I8 &H+7P!H"V< 9PMP &4,>@!C#(< 8@R5 & -I !?#;8 7@W. %P.
M[0!<#_\ 6Q#_ %L0_P!;$/\ S2$  +PH  "O*P  I"L  )HI  "2)   B1\
M ((8  ![$04 =0T/ '$-%P!N#B$ :PXJ &D/,@!G$#D 91!  &001@!C$$T
M81!3 %\16@!>$6( 7!%K %L1=@!9$H, 6!*2 %83H@!5$[0 5!/+ %,4[ !2
M%?\ 4A;_ %(5_P!2%?\ QB@  +8N  "I,@  GS(  )4Q  ",+0  @R<  'HA
M  !R&@  :Q,+ &<3$P!D%!P 810E %\5+0!=%30 7!4[ %L60@!9%D@ 6!9/
M %875@!5%UX 4Q=G %(8<@!0&'\ 3QF. $X:GP!,&K  2QO' $L;Z0!*'/T
M2AS_ $H<_P!*'/\ P2T  +$T  "E-P  FC@  ) W  "'-   ?2\  '0I  !L
M(P  9!P' %X9$ !;&A@ 61LA %<;*0!5&S  5!PW %(</0!1'$0 3QU+ $X=
M4@!-'5H 2QYC $H>;@!)'WP 1Q^+ $8@G !%(:X 1"'$ $,BY@!#(OP 0R+_
M $,B_P!#(O\ O#(  *TX  "A/   ESX  (T]  "#.@  >34  &\P  !F*@
M7B0" %<@#0!4(!0 42 = $\A)0!.(2P 3"$S $LB.@!)(D  2")' $<B3@!&
M(U< 1"-@ $,D:P!")'D 026( #\FF0 ^)JL /2?! #TGXP ]*/H /2C_ #TG
M_P ])_\ N#8  *H]  ">0   E$(  (I"  " /P  =CL  &PV  !B,   62H
M %$E"P!-)1$ 2R49 $DE(0!')B@ 128O $0F-@!#)CT 0B=$ $$G2P _*%0
M/BA= #TI:0 \*78 .RJ& #DKEP X*ZD -RR_ #<LX  W+/@ -RS_ #<L_P X
M+/\ M3H  *=   "<1   D48  (=&  !]1   <T   &@[  !?-@  53$  $PK
M!P!'*0\ 12H6 $,J'@!!*B4 /RHL #XK,P ]*SD /"M! #LL2  Z+%$ .2U;
M #@N9@ V+G, -2^# #0OE0 S,*< ,C"] #$QW@ Q,?< ,C'_ #(P_P S,/\
ML3X  *1$  "92   CTH  (5*  ![20  <$4  &5   !;.P  4C8  $@Q! !"
M+@T /RX3 #TN&P [+B( .2\I #@O+P W+S8 -C ^ #4P1@ T,4\ ,S%9 #(R
M9  Q,G$ ,#.! "\TDP N-*8 +#6[ "PUVP L-?4 +37_ "TT_P N-/\ KD$
M *)(  "73   C4X  (-.  !Y30  ;DH  &)%  !80   3CP  $4W   ],PL
M.3,1 #<S&  V,Q\ -#,F #,S+0 R-#0 ,30\ # U1  O-4P +C96 "TV8@ L
M-V\ *S=_ "HXD0 H.*0 )SFY "8YV  G.?0 *#G_ "@X_P I./\ JT4  )]+
M  "43P  BU(  (%3  !W4@  ;$\  %])  !61@  3$(  $(]   X. @ -#@/
M #(X%0 Q.!T +S@D "XX*P M.3( +#DY "LZ00 J.DH *3M4 "@[7P G/&T
M)3Q] "0]CP C/:( (CVW "$^U  A/O, (CW_ ",]_P C//\ J$D  )U/  "2
M4P  B58  ']7  !U5@  :E,  %U/  !33   2D@  $!$   V0 4 +ST- "T]
M$P K/1H *CXA "D^*  H/B\ )SXW "8_/P D/T@ (T!2 ") 70 A06H ($%Z
M !Y!C0 =0J  '$*U !M"T0 ;0O$ '$+_ !U!_P >0?\ I4T  )I3  "06
MAEL  'U<  !R6P  9U@  %M4  !14@  2$X  #U*   S1P  *D,+ "9#$  E
M0Q8 )$,> "-$)0 B1"P (40T "!%/  >144 '45/ !Q&6@ ;1F@ &49X !A'
MB@ 71YX %D>S !1(S@ 51^\ %D?_ !=&_P 71O\ HE(  )=8  "-70  A&
M 'IA  !P8   95X  %E:  !/6   1%0  #E1   O3@  )DL& "!*#@ >2A,
M'4H: !Q*(0 ;2R@ &DLP !E+.  72T( %DQ, !5,5P 43&4 $TUU !)-B  1
M39P $$VQ  Y.S  /3>X $$W_ !%,_P 13/\ GE<  )1=  "+8@  @64  '=F
M  !M9@  8V0  %9A  !*7@  /UL  #58   K5@  (E0! !I2"@ 64A  %5(6
M !12'0 34B0 $E(L !%2-  14CX $%-(  ]35  .4V( #51R  Q4A  +5)@
M"52M  A4Q0 )5.< "E/[  M2_P +4O\ FUT  )%D  "(:   ?FL  '1L  !K
M;   7VH  %)G  !%9   .F(  #!@   F7@  '5T  !5;!0 06@P #EH1  Y:
M&  -6R  #%LG  M;,  *6SH "5M%  =;40 &6UX !%MM  -;@  !6Y0  %NH
M  !;P   6N(  %KV  %:_P "6?\ EV0  (YK  "$;@  >W   ')R  !G<0
M67   $QN  ! ;   -6L  "II   A9P  &&8  !%F 0 ,90H !V4/  1E%  #
M9!L  F0C  !D+   9#4  &1   !D3   9%H  &1I  !D>P  9(\  &.D  !C
MNP  8MT  &+T  !B_P  8?\ DVP  (EQ  " =0  >'<  &UX  !@=P  4G8
M $9U   Y=   +G0  "-R   :<0  $G$   UQ   &<0@  ' -  !P$@  <!<
M &\?  !O)@  ;S   &\[  !O1P  ;U0  &]D  !O=0  ;HH  &V@  !MM@
M;-8  &OR  !K_P  :_\ CG,  (5X  !]>P  <WT  &5^  !8?@  2WX  #Y^
M   R?@  )GT  !Q\   3?   #7P   9]    ?04  'P+  !\#P  ?!,  'P9
M  !\(0  ?"D  'PT  ![0   >TX  'M>  ![;P  >H0  'J:  !YL0  >,X
M '?O  !V_@  =O\ B7H  (%_  !X@@  :X,  %V%  !/A@  0H<  #6(   I
MAP  '8<  !2'   -B   !HD   "*    B@   (D&  ")#   B0\  (D3  ")
M&@  BB(  (HL  "*.   BD8  (E6  "):   B7P  (B4  "'JP  AL8  (7J
M  "%^P  A/\ A8(  'V&  !OB   88L  %.-  !%CP  .)$  "N1   ?D@
M%)(   V3   $E    )8   "7    F    )<   "7!0  EPL  )@.  "8$P
MF1H  )DB  ":+@  FCT  )E-  "97@  F7,  )B+  "8HP  E[P  );B  "6
M]P  E?\ @(D  '*,  !DCP  5I,  $B6   ZF0  +)H  !^;   4G   #)X
M  .?    H0   *,   "E    I0   *4   "E    I@(  *<(  "G#0  J!$
M *D9  "K(P  JS$  *M!  "L4P  K&<  *N   "JF@  JK,  *K0  "I[P
MJ?L =8\  &>4  !9F   2IP  #R?   MH@  (*,  !.E   +IP   :D   "K
M    K@   +$   "R    L@   +,   "T    M0   +8   "X!   N0L  +L0
M  "]&   OR0  +\U  # 1P  P%L  ,!R  # C0  P:8  ,#!  "_XP  OO,
M:I<  %N<  !-H0  /J4  "^I   AJP  $ZT   NP    LP   +4   "X
MO    +\   #!    P0   ,,   #$    Q@   ,<   #)    RP   ,X(  #1
M#P  U1@  -@G  #9.0  VDT  -MD  #;?@  W)D  -RP  #<R0  W., 79\
M $^E  ! J@  ,J\  "*R   4M0  "K@   "[    OP   ,,   #&    RP
M ,X   #1    T0   -0   #6    V0   -L   #>    X    .0   #G!@
MZPX  .\9  #P*@  \C\  /-5  #T;0  ](@  /2A  #TM@  ],< _P ) /\
M!@#_  < _P , /\ $0#_ !P _P H /\ - #_ $$ _P!, /\ 50#_ %T _P!E
M /\ ; #_ '( _@!X /P ?@#[ (0 ^@"+ /D D@#W )D ]@"B /0 K #S +D
M\0#+ /  Z #N /L [0#_ .P _P#A /\ T@#_ ,D _P#$ /\ _P ! /\   #_
M    _P $ /\ #@#_ !< _P C /\ +P#_ #L _0!& /H 4 #W %@ ] !? /(
M9@#P &P [P!R .T > #L 'X Z@"% .D C #G ), Y0"< ., I@#A +$ WP#!
M -T W0#; /0 V0#_ -8 _P#/ /\ Q #_ +T _P"Y /\ _P   /\   #_
M_P   /\ "P#\ !, ]P > /0 *@#R #4 [@!  .D 2@#F %( XP!9 .  8 #>
M &8 W !L -H <@#7 '@ U !^ -( A0#0 (T S@"5 ,P GP#) *H QP"X ,4
MS0## .L P #^ +\ _P"^ /\ M@#_ +  _P"M /\ _P   /\   #_    ^0
M /( !@#K  \ Y@ 9 .$ ) #> "\ V@ Y -, 0P#/ $P S !3 ,D 6@#' &
MQ0!F ,, :P#! '$ OP!W +T ?@"[ (8 N0". +< F "U *, LP"P +$ P@"N
M .  K #W *L _P"J /\ J #_ *, _P"@ /\ _P   /\   #U    ZP   .$
M  #6  P SP 3 ,H '@#& "D P@ S +\ /0"[ $4 N !- +8 5 "S %H L0!?
M +  90"N &H K !P *L =P"I '\ IP"' *4 D0"C )P H "I )X N "< ,X
MF@#N )D _P"7 /\ E@#_ )8 _P"3 /\ _0   /$   #E    V0   ,T   #$
M  8 O0 / +< & "S "( L  L *T -@"I #X IP!& *0 30"B %, H !9 )\
M7@"= &0 FP!J )H < "8 '< E@"  )0 B@"1 )4 CP"B (T L "+ ,, B0#C
M (@ ^0"& /\ A@#_ (8 _P"& /\ \P   .,   #1    Q0   +T   "V
MK@ + *@ $@"D !P H  F )P +P": #< EP _ )4 1@"2 $P D0!2 (\ 6 "-
M %T BP!C (H :@"( '$ A@!Y (0 @P"" (\ ?P"; 'X J0!\ +L >@#5 '@
M\@!X /\ =P#_ '< _P!W /\ YP<  -$,  ###0  N P  *X(  "H    H@ %
M )L #@"6 !4 D@ ? (X * "+ #$ B  Y (8 0 "$ $8 @@!, (  4@!_ %<
M?0!= 'L 8P!Z &L > !S '8 ?0!T (@ <0"5 '  I !N +0 ; #* &L Z@!J
M /P :@#_ &H _P!J /\ VA   ,84  "X%@  K14  *02  "<#@  E@<  )
M"0"* !  A0 8 ($ (0!^ "H >P R 'D .0!W $  =0!& ', 3 !R %$ < !7
M &X 7@!M &4 :P!N &D =P!G (, 90"1 &, GP!B *\ 8 #$ %\ Y !? ?@
M7@+_ %X"_P!> O\ SA@  +T=  "P(   I1\  )L<  "3%P  BQ$  (0,  !^
M! L >0 2 '4 &P!R ", ;P K &T!,P!K 3H :0)  &<#1@!F TP 9 12 &,$
M60!A!&  7P5I %X%<P!<!G\ 6@:- %D'G !7"*T 5@C! %4)X0!4"_8 5 O_
M %0+_P!4"_\ QA\  +8E  "I*   GB@  )0E  "+(0  @QL  'L4  !T#@,
M;@D- &D(% !F"1T 9 HE &(*+0!@"S0 7@LZ %T+0 !;#$< 6@Q- %@,5 !7
M#5P 50UD %0-;P!2#7L 4 Z* $\.F@!.#JP 3 _" $P0XP!+$/D 2Q#_ $L1
M_P!+$/\ OR8  + K  "D+P  F2\  (\M  "&*0  ?20  '0>  !L%P  91$'
M %\.$ !<#Q< 6A ? %@0)P!6$"X 5! U %,0.P!2$4( 4!%( $\14 !.$5<
M3!)@ $L2:P!)$G@ 2!.' $83EP!%%*D 1!2^ $,5WP!#%O@ 0Q;_ $,6_P!#
M%O\ NBL  *LQ  "@-   E34  (LT  "!,0  >"L  &\F  !F(   7AD! %<4
M#0!4%!, 410; $\5(P!.%2H 3!4Q $L6-P!)%CX 2!9$ $<73 !%%U0 1!==
M $,89P!!&'0 0!F# #\:E  ]&J8 /!N[ #L;VP ['/8 /!S_ #P<_P \'/\
MM3   *@V  "<.0  D3L  (<Z  !^-P  <S(  &HM  !A)P  62$  %$;"0!,
M&1  2AH7 $@:'P!&&B8 11LM $,;,P!"&SH 01Q! $ <2  ^'%  /1U9 #P>
M9  ['G$ .1^  #@?D@ W(*0 -B"X #4AU@ U(?0 -2+_ #4A_P V(?\ LC0
M *0Z  "9/@  CS\  (4_  ![/   <#@  &<R  !=+0  5"@  $PB!0!&'PX
M0Q\4 $$?&P _'R( /B I #T@,  [(#8 .B$] #DA10 X(DT -R)7 #8C8@ T
M(VX ,R1^ #(DCP Q):( +R6V "\FT@ O)O( +R;_ # F_P P)O\ KS@  *(^
M  "60@  C$,  ()#  !X00  ;CT  &,X  !:,P  42X  $@H 0! ) P /2,1
M #LD&  Y)!\ ."0F #8D+  U)3, -"4Z #,F0@ R)DH ,2=4 # G7P O*&P
M+BA[ "PIC0 K*J  *BJT "DJSP I*_  *BO_ "HJ_P K*O\ K#P  )]"  "4
M1@  BD<  (!'  !V10  ;$(  &$]  !7.   3C,  $0N   \*0D -R@0 #4H
M%0 S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T@ +"M2 "LL70 J+&H *"UY
M "<MBP F+IX )2ZS "0OS0 D+^X )2__ "4O_P F+O\ J3\  )U%  "220
MB$L  'Y,  !T2@  :D<  %Y"  !4/0  2SD  $$T   X+P8 ,BT- # M$P N
M+1D +2T@ "LM)P J+BX *2XU "DO/0 H+T8 )S!/ "4P6P D,6@ (S%W "(R
MB0 A,IT 'S.Q !XSRP >,^T 'S/_ " S_P A,O\ ID,  )I)  "030  AD\
M 'Q0  !S3P  :$P  %Q&  !20P  23\  #\[   V-@( +C(, "LR$0 I,A<
M*#(> "8R)  E,RL )#,R ",T.@ B-$, (35- " U6  ?-F4 'C9U !PWAP ;
M-YL &C>O !DXR  9..L &CC_ !LW_P ;-_\ HT<  )A-  ".40  A%,  'M4
M  !Q4P  9E   %I,  !020  1T4  #U!   S/0  *CD) "4W#@ C-Q0 (C@;
M "$X(@ @."@ 'S@P !XY.  =.4$ '#I+ !HZ5@ 9.V, &#MR !8[A0 5/)D
M%#RM !,]Q@ 3/>D %#S] !4\_P 6._\ H$L  )51  "+50  @E@  'E9  !N
M6   9%8  %A1  !.3P  14L  #I'   P0P  )T % " ^#0 =/A$ '#X7 !L^
M'@ :/B4 &3XM !@_-0 6/SX %3]( !1 4P 30&  $D%P !%!@@ 009< #T&L
M  Y"Q  .0N< #T'\ !!!_P 00/\ G5   )-6  ")6@  @%T  '9>  !L70
M8EL  %97  !,50  05$  #9.   L2P  (T@  !M%"0 71 \ %404 !1%&P 3
M12( $D4I !%%,0 113L $$9%  ]&4  .1UX #4=M  Q'?P +1Y, "4>G  A'
MO@ (1^  "4?V  I&_P +1O\ FE4  )!;  "'8   ?6(  '-C  !J8@  8&$
M %->  !'6@  /%<  #)5   H4@  'U   !=.!  13 P #TP1  Y,%P .3!X
M#4TE  Q-+@ +33< "DU"  E-30 '3EH !DYI  1.>P "3H\  4ZD  !-N@
M3=L  4WR  %-_P "3/\ EEL  (UB  "$9@  >F@  '%I  !H:0  7&<  $]D
M  !"80  -U\  "U<   C6@  &E@  !)7 0 -5@D "54.  =5$P &51H !%4B
M  -5*@ "530  %4^  !52@  5E<  %9E  !5=P  58L  %6@  !5M@  5-0
M %3Q  !3_0  4_\ DV(  (IH  " ;   =VX  &]O  !C;@  5FP  $EJ   ]
M:   ,F8  "=E   =8P  %6(   YA   )8 @  V -  !?$0  7Q<  %\>  !?
M)@  7R\  %\Z  !?10  7U,  %]A  !><@  7H<  %V<  !=L@  7,\  %SO
M  !;_0  6_\ D&H  (9O  !]<@  =70  &IU  !==   3W,  $)R   V<
M*V\  "!N   7;0  $&P   IL   ":P8  &L+  !J#P  :A0  &H:  !J(0
M:2H  &DT  !I0   :4X  &E<  !I;0  :((  &B8  !GK@  9LH  &7M  !E
M_   9/\ BW$  ()V  !Z>0  <'L  &)[  !5>P  2'H  #MZ   O>@  (WD
M !EX   1=P  "G<   -W    =P(  '<(  !V#0  =A   '85  !V&P  =B,
M '8N  !U.@  =4<  '56  !U:   ='P  '22  !SJ@  <L0  ''I  !P^P
M</\ AGD  ']]  !V?P  :($  %J"  !,@@  /X,  #*$   E@P  &H,  !&#
M   *@P   H,   "$    A0   (0#  "#"   @PT  (,0  "#%0  A!P  (0F
M  "$,@  A#\  (-/  "#8   @G4  (*,  "!I   @+T  '_C  !^^0  ?O\
M@H   'J$  !LA@  7H@  %"*  !"BP  -8T  ">-   ;C0  $8X   J.
MCP   )$   "2    D@   )(   "2 0  D@<  )(,  "2$   DQ4  ),=  "4
M*   E#8  )1%  "35P  DVL  )."  "2G   D;8  )#8  "/\P  C_\ ?H<
M '"*  !AC0  4Y   $63   WE0  *98  !R7   1F   "9D   ";    G
M )X   "@    H    *    "@    H0   *$$  "B"0  HPX  *04  "E'0
MIBH  *8Z  "F3   I6   *5X  "ED@  I*P  *3)  "CZP  HOH <XX  &21
M  !6E0  1YD  #F<   JG@  ':   !&A   (HP   *4   "G    J0   *P
M  "N    K@   *X   "O    L    +$   "R    LP8  +4-  "W$P  N1X
M +DN  "Z0   NE0  +MJ  "ZA0  N:$  +F[  "ZW@  N?( 9Y4  %B9  !*
MG@  .Z(  "RF   =J   $:H   >L    KP   +$   "T    N    +L   "\
M    O    +X   "_    P    ,(   #$    Q@   ,@#  #+"P  SQ(  -$@
M  #1,@  TD8  --=  #4=@  U)(  -6K  #5Q   U.( 6YT  $RB   ]IP
M+ZP  !^O   1L0  ![4   "X    NP   +X   #"    QP   ,H   #,
MS    ,X   #0    T@   -4   #8    VP   -\   #B    Y@L  .L3  #L
M)   [3@  .Y.  #O9P  \((  /"<  #PL@  \<4 _P # /\  0#_  0 _P )
M /\ #P#_ !@ _P D /\ , #_ #P _P!' /\ 40#_ %D _P!@ /T 9P#\ &T
M^@!S /D >0#X '\ ]@"% /4 C #S )0 \@"= /  IP#N +, [ #$ .L X0#J
M /@ Z0#_ .< _P#9 /\ RP#_ ,( _P"] /\ _P   /\   #_    _P   /\
M# #_ !0 _P @ /\ *P#^ #< ^@!" /8 2P#R %, \ !; .X 80#L &< Z@!M
M .@ <P#G 'D Y0!_ ., A@#A (X WP"6 -T H #; *P V "[ -0 T0#3 /
MT #_ ,X _P#( /\ O0#_ +8 _P"R /\ _P   /\   #_    _P   /T " #W
M !  \P : .\ )@#M #$ Z  [ ., 10#@ $T W !5 -D 6P#6 &$ TP!G -$
M; #/ '( S0!X ,L ?P#) (< QP"0 ,4 F@## *4 P "R +X Q0"\ .4 N@#[
M +@ _P"W /\ L #_ *D _P"E /\ _P   /\   #^    ]0   .P  P#E  T
MWP 5 -H ( #4 "H T  U ,L /@#( $< Q0!. ,( 50#  %L O@!A +P 9@"Z
M &P N !R +8 > "U (  LP"( +$ D@"N )X K "J *D NP"H -4 I@#S *0
M_P"C /\ H0#_ )L _P"8 /\ _P   /L   #P    Y0   -@   #.  D QP 1
M ,( &@"^ "0 NP N +< . "T $  L0!( *X 3@"L %0 J@!: *D 7P"G &4
MI0!K *0 <0"B '@ H "! )X BP"< )8 F0"C )< L@"6 ,< DP#H )( _@"1
M /\ D #_ (T _P"+ /\ ^0   .L   #=    SP   ,8   "\  0 M0 - +
M%0"L !X J  H *4 ,0"B #D GP!! )T 2 "; $X F0!3 )< 60"6 %X E !D
M )( :@"0 '$ C@!Z (P @P"* (\ B "< (8 J@"$ +P @@#< ($ ]@"  /\
M?P#_ '\ _P!^ /\ [    -H   #)    O@   +8   "N    IP ) *$ $ "<
M !@ F  B )4 *@"2 #( D  Z (T 00"+ $< B0!- (< 4@"& %@ A != ((
M9 "! &L ?P!S 'T ?0![ (@ > "5 '8 HP!U +0 <P#, '$ [0!P /\ < #_
M '  _P!P /\ WP4  ,H*  "\"P  L0D  *@$  "A    FP # )0 # "/ !,
MB@ ; (< ) "$ "P @0 S '\ .@!] $$ >P!' 'D 3 !W %( =@!7 '0 70!R
M &0 < !M &\ =@!L (( :@"/ &D G0!G *X 90## &0 Y !C /H 8P#_ &(
M_P!C /\ T X  +\2  "R$P  IQ(  )T0  "5"P  CP,  (D !P""  X ?@ 5
M 'H '@!V "4 =  M '$ - !O #H ;@!  &P 1@!J $P :0!2 &< 6 !F %\
M9 !G &( <0!@ 'P 7@") %P F !; *D 60"\ %@ W !8 /0 6 #_ %< _P!7
M /\ QA8  +8:  "J'0  GQP  )49  "-%   A0\  'X)  !W 0H <@ 0 &X
M%P!J !\ :  G &4 +@!D #0 8@ [ &  0 !? $8 70!, %P 4P!: %H 6 !B
M %< ; !5 '< 4P"% %( E !0 :4 3P&X $X"T@!-!/  307_ $T%_P!-!?\
MOQT  + B  "C)0  F24  (\B  "%'0  ?1@  '42  !N#0( 9P8, &,#$0!?
M AD 70,A %L$* !9!"\ 5P4U %8%.P!4!D$ 4P9' %$&3@!0!U4 3@=> $T(
M9P!+"', 20F! $@)D@!'"J, 10JV $0+T !$#.\ 0PW_ $,-_P!$#?\ N20
M *HI  ">+   E"P  (HJ  " )@  =R$  &X;  !F%   7P\% %D+#0!5"A,
M4PL; %$+(@!/#"D 30PO $P,-@!+#3P 20U" $@-20!&#5$ 10Y: $0.9 !"
M#G  0 Y_ #\/D  ^$*( /!"V #L0T0 [$?$ .Q'_ #L1_P \$?\ M"D  *8O
M  ":,@  D#(  (8Q  !\+0  <B@  &DC  !A'0  618  %$1" !,#Q  2A 6
M $@0'0!&$"0 11 K $,1,0!"$3< 01$^ $ 110 ^$DT /1)6 #P280 Z$VT
M.1-\ #<4C0 V%)\ -16S #05S0 S%NX -!;_ #06_P T%O\ KRX  *(T  "7
M-P  C#@  ((V  !X-   ;BX  &4J  !<)   5!X  $P8! !&% T 0A02 $ 4
M&0 _%"  /14G #P5+0 [%30 .18Z #@60@ W%DH -A=3 #477@ S&&H ,AEY
M # 9B@ O&IT +AJQ "T;R@ M&^P +1S_ "X;_P N&_\ K#(  )\X  "4.P
MBCP  ( \  !V.0  :S0  &(O  !9*@  4"4  $<?  ! &@H /!D0 #H9%@ X
M&1T -AHC #4:*0 T&C  ,QHW #(;/@ Q&T< +QQ0 "X=6P M'6< +!YV "H>
MB  I'YL *!^N "<@QP F(.H )R#^ "@@_P H(/\ J38  )T\  "2/P  AT$
M 'U   !T/@  :3H  %\U  !6,   32L  $0E   [( < -AX. #,>$P R'AD
M,!X@ "\>)@ N'RT +1\T "P@.P K($0 *B%. "DA6  G(F4 )B)T "4CA0 C
M(YD (B2M "$DQ0 A)>@ (B7] "(D_P C)/\ ICH  )H_  "/0P  A44  'M$
M  !R0P  9S\  %TZ  !3-@  2C$  $$L   X)@, ,2,, "XB$0 L(A8 *B(=
M "DB(P H(RH )R,Q "8D.0 E)4$ )"5+ ",F5@ B)F, (2=R !\G@P >*)<
M'2BK !LIPP ;*>8 '"G[ !TI_P >*/\ HSX  )A#  "-1P  @TD  'I)  !P
M1P  9D0  %H_  !1.P  1S<  #XR   U+0  +"@) "@G#P G)Q0 )2<: "0G
M(0 C*"< (B@N "$I-@ @*3\ 'RI) !XJ5  =*V  &RMO !HL@0 9+)4 %RVI
M !8MP0 6+>0 %RWZ !@M_P 9+?\ H4$  )5'  "+2P  @DT  'A-  !N3
M9$D  %A$  !/0   1CT  #TX   S-   *B\& "0L#0 A+!( ("P8 !\M'@ >
M+24 '2TL !PN-  ;+CP &B]& !@O40 7,%X %C!M !4Q?P 3,9, $C&H !$R
MOP 1,N( $C+Y !,Q_P 3,?\ GD4  )-+  ")3P  @%$  '92  !M4   8DX
M %9)  !-1@  1$,  #L_   Q.@  )S8# !\R"P <,A  &S(5 !DR&P 8,B(
M%S,I !8S,0 5-#H %#1$ !,T3P 2-5P $35K ! V?0 /-I$ #C:F  TWO  -
M-]T #3;V  XV_P /-O\ FTD  )%/  "'4P  ?E8  '56  !J50  8%,  %5/
M  !,3   0DD  #A%   N00  )#T  !PZ"  6. X %3@2 !0X&  3.1\ $CDF
M !$Y+@ 0.3< #SI!  XZ3  -.UD #3MH  L[>@ *.XT "3RB  <\N  '/-4
M"#SP  D[_P *._\ F$X  (Y4  "%6   ?%L  ');  !H6@  7E@  %-5  !)
M4@  /DX  #1+   J1P  (40  !A" P 20 L $#\0  X_%0 ./QP #4 C  Q
M*P +0#0 "D ^  E!2@ '058 !D%E  1!=@ #08H  4&?  !!M   0=   4'N
M  %!_  "0/\ E50  (Q9  "#7@  >6   '!@  !F8   75X  %%;  !%5P
M.E0  "]1   E3P  '$P  !1*   .2 @ "T<.  A'$@ '1QD !D<@  5(*  #
M2#$  D@[  !(1P  2%,  $AB  !(<P  2(8  $B;  !(L0  1\P  $?M  !'
M^P  1_\ DEH  (E@  " 8P  =V4  &YF  !E9@  660  $Q@  ! 70  -5L
M "I9   @5P  %U4  !!3   +4@< !5$-  %0$0  4!8  % =  !0)0  4"X
M % X  !00P  4%   %!>  !0;P  4(,  $^8  !/K@  3LD  $[K  !-^P
M3?\ CV$  (9F  !]:0  =&P  &QM  !A:P  4VD  $9G   Z9   +V,  "1A
M   :7P  $EX   Q<   &7 8  %L+  !:#P  6A,  %H9  !9(0  62D  %DS
M  !9/P  64P  %E:  !9:P  6'X  %B4  !7JP  5\4  %;I  !5^P  5?\
MC&@  ()M  !Z<   <G(  &=R  !:<0  3'   #]N   S;0  *&L  !UJ   4
M:   #6<   =G    9@,  &8)  !E#0  91$  &05  !D'   9"0  &0N  !D
M.@  8T<  &-5  !C9@  8WH  &*0  !AIP  8,$  %_F  !?^@  7O\ AV\
M ']T  !X=P  ;G@  &!X  !2=P  17<  #AV   K=@  ('0  !9S   .<P
M!W(   !R    <@   '$%  !Q"@  <0X  ' 1  !P%P  <!X  ' G  !P,P
M;T   &]0  !O8   ;G0  &Z+  !MH@  ;+P  &OB  !J^   :?\ @W<  'Q[
M  !S?0  97X  %=_  !)?P  /'\  "^    B?P  %WX   ]^   '?@   '\
M  !_    ?P   'X   !^!0  ?@H  'X-  !^$0  ?A<  'X@  !^*P  ?3D
M 'U(  !]60  ?&T  'R$  ![G   >K8  'G:  !X]0  =_\ @'\  '>"  !I
M@P  6X4  $V&   _B   ,HD  "2)   8B0  #XD   >*    BP   (P   "-
M    C0   (P   ",    C ,  (P(  "-#0  C1$  (T7  ".(@  CB\  (X_
M  "-4   C60  (Q[  ",E0  BZX  (K-  ")[P  B?\ >X4  &V(  !>B@
M4(T  $*/   TD0  )I(  !F3   .E   !I4   "6    F    )H   ";
MFP   )L   ";    FP   )P   "=!0  G0L  )X0  "?%P  H"0  * T  "@
M1@  H%D  )]P  "?B@  GJ4  )["  "=Z   G/D <(P  &&/  !3D@  1)8
M #:9   GFP  &9P   ^=   %GP   *$   "C    I0   *@   "I    J0
M *D   "J    JP   *P   "M    K@$  + )  "R#P  LQ@  +0G  "T.0
MM4T  +1D  "T?@  LYH  +.T  "SU0  L_  9),  %67  !'FP  .)\  "FB
M   :I   #J8   2H    JP   *T   "P    M    +8   "X    N    +D
M  "Z    O    +T   "_    P    ,,   #%!P  R0\  ,H:  #++   S$
M ,U6  #.;P  S8L  ,RH  #,P@  S.( 6)L  $F@   ZI0  +*D  !RK   /
MK@  !+$   "T    MP   +H   "^    PP   ,8   #(    R    ,H   #+
M    S0   ,\   #2    U0   -D   #=    X04  .8/  #G'@  Z#(  .E(
M  #J8   ZWL  .N7  #LK@  [,( _P   /\   #_    _P & /\ #0#_ !4
M_P A /\ + #_ #@ _P!# /\ 3 #^ %0 ^P!; /H 8@#X &@ ]@!N /4 = #T
M 'H \@"  /$ AP#O (\ [0"7 .L H0#I *T YP"] .4 V #D /, X@#_ .
M_P#0 /\ Q #_ +P _P"V /\ _P   /\   #_    _P   /\ "0#_ !$ _P <
M /T )P#Y #( ]0 ] /$ 1@#M $\ ZP!6 .@ 7 #F &( Y !H ., ;@#A ',
MWP!Y -T @ #: (@ V "1 -0 FP#2 *8 SP"T ,P R0#) .D R #_ ,< _P#!
M /\ MP#_ *\ _P"K /\ _P   /\   #_    _P   /@ !0#R  X [@ 7 .H
M(@#F "P X0 W -T 0 #8 $D TP!0 -  5@#. %P S !B ,H 9P#( &T Q@!S
M ,0 >0#" ($ P "* +X E "\ )\ N0"L +8 O@"T -T LP#W +$ _P"P /\
MJ #_ *( _P"> /\ _P   /\   #Y    [P   .8   #?  L U@ 2 -  ' #,
M "8 R  P ,0 .@#  $( O0!* +L 4 "X %8 M@!; +4 80"S &8 L0!L +
M<@"N 'H K "" *D C "G )@ I0"E *, M "@ ,L GP#N )T _P"< /\ F0#_
M )0 _P"1 /\ _P   /8   #J    W0   ,\   #'  8 P  / +L %P"W "
MLP J +  ,P"M #L J@!# *< 20"E $\ HP!5 *( 6@"@ %\ G@!E )T :P";
M '( F0![ )< A0"4 )  D@"= )  K ". +\ C #B (L ^@") /\ B0#_ (8
M_P"# /\ ]    .0   #4    R    +\   "U  $ K@ + *D $@"E !L H0 C
M )X + "; #0 F  \ )8 0P"4 $D D@!. )  4P". %D C0!> (L 9 ") &L
MAP!S (4 ?0"# (@ @0"5 '\ I !] +4 >P#/ 'D \0!X /\ =P#_ '< _P!U
M /\ Y0   -$   ##    N    *\   "H    H  & )H #@"5 !4 D0 > (X
M)@"+ "T B  U (8 / "$ $( @@!' (  30!_ %( ?0!8 'L 7@!Y &4 > !M
M '8 =@!S ($ <0". &\ G0!M *X ; #$ &H YP!I /T : #_ &@ _P!I /\
MU0,  ,,'  "V"   JP8  *(   ";    E    (T "@"( !  @P 8 '\ ( !\
M "< >@ N '< -0!U #L = !! '( 1P!P $P ;P!2 &T 6 !K %\ :0!F &<
M< !E 'L 8P"( &( EP!@ *< 7@"[ %T W !< /8 7 #_ %L _P!; /\ R0T
M +D0  "L$0  H1   )<-  "/"   B    (( !0![  T =P 2 ', &@!O "$
M;  H &H +P!H #4 9P [ &4 00!C $8 8@!, &  4@!? %D 70!A %L :@!9
M '4 5P"" %4 D0!4 *( 4P"U %$ SP!0 .\ 4 #_ %  _P!0 /\ OQ0  + 8
M  "D&@  F1D  (\6  "'$0  ?PT  '<&  !Q  @ :P . &< % !D !L 80 B
M %X *0!= "\ 6P U %D .P!8 $$ 5@!& %4 30!3 %0 4@!< %  90!. '
M3 !] $L C0!) )X 2 "P $< QP!& .D 1@#[ $8 _P!% /\ N!L  *H@  ">
M(@  DR(  (D?  " &@  =Q4  &\0  !H"P  800* %T $ !9 !8 5@ = %0
M(P!2 "H 4  P $\ -0!. #L 3 !! $L 2 !) $\ 1P%7 $8!80!$ FP 0P)Y
M $$#B0!  YH /@2M #T$Q  \!>4 / ?X #P'_P \!_\ LB(  *4G  "9*0
MCBD  (0G  ![(P  <1X  &D8  !A$@  6@T# %,(# !/!1$ 3 47 $H&'@!(
M!B0 1P8J $4', !$!S8 0P@] $$(0P! "$L /@E3 #T)70 ["F@ .@IV #@+
MAP W"YD -0NL #0,P@ S#.0 ,PWY #,-_P T#?\ K2<  * L  "5+P  BR\
M ( N  !W*@  ;24  &0@  !<&@  5!0  $P/!@!&# T 0PP2 $$,&  _#!\
M/@PE #P-*P [#3( .@TX #@-/P W#D< -@Y0 #0.6@ S#F8 ,0]T # /A0 N
M$)@ +1"K "P0PP K$>4 +!'Z "P1_P M$?\ JBP  )TQ  "2-   AS4  'TT
M  !T,0  :BL  & G  !8(0  3QL  $<6  ! $0D .Q / #D0%  W$!L -A A
M #00)P S$2T ,A$T #$1.P P$4, +A)- "T25P L$F, *A-Q "D3@@ G%)4
M)A2I "45P  D%>, )1;Z "86_P F%?\ IC$  )HV  "/.0  A3H  'LY  !Q
M-@  9S$  %TM  !4*   3"(  $,=   [%P4 -10- #(3$0 Q%!< +Q0= "X4
M)  L%"H *Q4Q "H5.  I%D  *!9* "<75  F%V  )!AO ",8@  A&9, (!FG
M !\9O@ >&N  'QKX " :_P @&O\ HS0  )@Z  "-/0  @SX  'D]  !O.P
M93<  %LR  !2+0  22@  $ C   X'@$ ,!D* "P8#P J&!0 *1@: "<8(  F
M&2< )1DM "0:-0 C&CX (AM' "$;4@ @'%X 'QUL !T=?@ <'9$ &AZE !D>
MO  8']T &1_V !H?_P ;'O\ H3@  )4]  "+00  @4(  '="  !M0   8SP
M %DW  !/,P  1BX  #TI   U)   +2 ' "<=#0 E'1( (QT7 "$='0 A'20
M(!XK !\>,@ >'SL '1]% !P@3P :(5P &2%J !@B>P 6(H\ %2*C !0CN@ 3
M(]H %"/U !4C_P 6(_\ GCP  )-!  ")1   ?T8  '5&  !L1   8D$  %<\
M  !-.   1#0  #PP   S*P  *B8# ",B"P @(1  'B$5 !PB&P ;(B$ &B(H
M !HC,  9(S@ &"1" !8E30 5)5D %"9H !,F>0 2)HT $2>B ! GN  .)]8
M$"CT !$G_P 1)_\ G$   )%%  "'2   ?4H  '1*  !J20  8$8  %5!  !,
M/@  0SH  #HV   Q,@  *"T  " I"0 ;)PX &2<2 !@G&  6)Q\ %2@E !0H
M+0 3*#8 $BE  !(I2P 1*E< $"IF  XK=P .*XL #2R?  PLM0 ++,\ #"SO
M  TL_P -*_\ F40  (])  "%3   ?$X  '-/  !I3@  7DL  %-'  !*1
M0D   #D]   O.   )30  !TP!0 6+0P %"P0 !,M%0 2+1P $2TC ! M*@ /
M+C, #BX]  TO2  -+U4 ##!C  HP=  ),(@ "#&<  8QL0 &,<L !C'K  <P
M_  (,/\ ET@  (U-  "#40  >E,  '%4  !G4@  75   %),  !)2@  0$8
M #5"   K/@  (CH  !HW 0 2- D #S,.  XS$P -,QD #3,@  PT*  +-#$
M"C4[  @U1@ '-5( !39@  0V<0 "-H0  #:9   VKP  -L@  #;H   V^0 !
M-?\ E$T  (I2  "!5@  >%@  &]9  !E6   6U4  %%2  !'3P  /$P  #%(
M   G1   'D$  !8_   0/ < "SH-  DZ$0 (.Q< !CL>  4[)@ $.RX  CLX
M  $\0P  /$\  #Q>   \;@  /($  #R7   \K   .\4  #OG   [^   ._\
MD5(  (A8  !_7   =ET  &U>  !C70  6EP  $Y8  !"5   -U$  "U.   C
M2P  &DD  !)&   -1 8 !T,,  -#$   0Q4  $,;  !#(P  0RL  $,U  !#
M0   0TT  $-;  !#:P  0WX  $.4  !"J@  0L,  $'F  !!^0  0?\ CE@
M (9>  !]80  <V,  &MD  !B8P  5V$  $E=   ]6@  ,E@  "=5   >4P
M%5$   Y/   )304  DT+  !,#@  3!,  $L8  !+'P  2R@  $LR  !+/0
M2TD  $M7  !+9P  2GL  $J0  !)IP  2<   $CD  !(^   1_\ BU\  (-D
M  !Z9P  <6D  &EJ  !>:0  4&8  $-D   W80  +%\  "%=   86P  $%D
M  I8   #5P,  %<)  !6#0  51   %45  !4&P  5",  %0M  !4.0  5$4
M %13  !49   4W<  %.-  !2I   4;T  %#B  !0^   3_\ B&<  ']K  !W
M;@  ;W   &5P  !7;@  2FP  #UK   P:0  )6@  !IF   19   "V,   1B
M    8@$  &$&  !@"P  8 X  %\2  !?%P  7QX  %XH  !>,P  7D   %Y/
M  !>7P  77(  %V(  !<H   6[D  %K?  !9]P  6/\ A&X  'QR  !U=0
M:W8  %UU  !/=   0G,  #5S   H<@  '7   !-O   ,;@  !&X   !N
M;@   &P"  !L!P  :PL  &L.  !K$@  :AD  &HB  !J+0  :CH  &E)  !I
M6@  :6P  &B#  !GFP  9K4  &78  !D]0  9/\ @'4  'IY  !P>P  8GL
M %1\  !&?   .7P  "Q\   ?>P  %'H   UZ   $>@   'H   !Z    >@
M 'D   !Y 0  > 8  '@+  !X#@  >!,  '@:  !X)0  >#(  '=!  !W4@
M=V4  '9\  !UE0  =*\  '/.  !R\0  <?\ ?GT  '6   !G@0  6((  $J#
M   \A   +H4  "&%   5A0  #84   .%    A@   (<   "(    B    (<
M  "'    AP   (<$  "'"0  APX  (@3  "('   B"D  (@X  "'2@  AUT
M (9S  "&C0  A:<  (3%  "#[   @OX >(0  &J&  !<B   38H  #^,   Q
MC@  (X\  !:/   -D    I$   "2    DP   )4   "6    E@   )8   "6
M    E@   )<   "7    EP<  )@-  "9$P  FA\  )HM  ":/P  FE(  )IH
M  "9@P  F9\  )BZ  "7X@  EO@ ;8H  %^-  !0D   09,  #.6   DEP
M%I@   V9   !FP   )T   "?    H0   *0   "E    I    *4   "E
MI@   *<   "H    J0   *H$  "L#   KA,  *XA  "N,P  KD<  *Y=  "N
M=@  KI,  *ZN  "MS0  K.\ 89$  %.5  !$F   -9P  ":?   7H0  #:,
M  "E    IP   *H   "L    L    +(   "T    LP   +0   "U    MP
M +@   "Y    NP   +T   "_ 0  PPL  ,45  #%)0  QCD  ,=/  #':
MQH4  ,:B  #&O   QMX 59D  $>=   XH@  *:8  !FH   -JP   *T   "Q
M    M    +<   "Z    OP   ,$   #$    PP   ,4   #&    R    ,H
M  #-    SP   -(   #6    VP   . ,  #A&   XRL  .1!  #E6@  YG0
M .:1  #EK   Y<0 _P   /\   #_    _P ! /\ "@#_ !( _P = /\ * #_
M #0 _P ^ /T 2 #Z %  ]P!7 /4 70#T &, \@!I /  ;P#O '0 [0![ .L
M@0#I (D Z "2 .8 G #D *@ X@"W -\ S0#< .X V0#_ -D _P#* /\ O@#_
M +4 _P"P /\ _P   /\   #_    _P   /\ !@#_  \ _  8 /@ (P#T "X
M\  X .L 0@#H $H Y0!1 .( 6 #@ %T W@!C -P : #9 &X U@!T -0 >P#1
M (( SP"+ ,T E0#* *$ R "O ,4 P0#" ., P #[ ,  _P"[ /\ L #_ *@
M_P"D /\ _P   /\   #_    ^P   /,  0#M  P Z  3 ., '@#@ "@ V@ R
M -, / #/ $0 S !+ ,D 40#& %< Q != ,( 8@#! &< OP!M +T = "[ 'L
MN0"$ +< C@"T )D L@"G *\ MP"M -  JP#R *H _P"I /\ H0#_ )L _P"7
M /\ _P   /\   #T    Z0   .    #5  @ S@ 0 ,D & #% "( P0 K +P
M-0"Y #T M@!% +, 2P"Q %$ KP!6 *X 6P"L &$ J@!F *D ;0"F '0 I !\
M *( A@"@ )( G@"? )P K@"9 ,, EP#G )8 _P"5 /\ D@#_ (T _P"* /\
M_    /    #C    U    ,@   "_  , N0 - +, $P"O !P K  E *D +@"E
M #8 HP ^ *  1 "> $H G0!0 )L 50"9 %H EP!? )8 9@"4 &P D@!U )
M?@". (H BP"7 (D I@"' +@ A0#6 (0 ]@"" /\ @0#_ 'X _P!\ /\ [0
M -T   #,    P0   +@   "N    IP ) *( $ "> !< F@ ? )< )P"4 "\
MD0 W (\ /0"- $, BP!) (D 3@"( %, A@!9 (0 7P"" &4 @ !M 'X =P!\
M (( >@"/ '@ G@!U *\ <P#' '( [ !Q /\ < #_ '  _P!N /\ W0   ,D
M  "\    L0   *D   "A    F0 # ), # ". !( B@ 9 (< (0"$ "D @0 P
M '\ -P!] #T >P!" 'D 2 !X $T =@!2 '0 6 !R %\ <0!G &\ < !L 'L
M:@"( &@ EP!F *@ 90"\ &, X0!B /H 80#_ &$ _P!A /\ S0$  +P%  "O
M!0  I0(  )P   "4    C0   (8 " "!  X ?  4 '@ &P!U ", <@ I '
M, !N #8 ;0 \ &L 00!I $< : !, &8 4@!D %D 8P!@ &$ :0!? '0 70"!
M %L D !9 *$ 5P"T %8 T !5 /( 50#_ %0 _P!5 /\ P0P  +(.  "F#P
MFPX  )(+  ")!0  @@   'L  @!U  L <  0 &P %@!H !T 9@ C &, *@!A
M #  8  V %X .P!= $$ 6P!& %H 3 !8 %, 5@!; %0 9 !2 &X 40![ $\
MB@!- )L 3 "N $L Q@!* .H 20#^ $D _P!) /\ N1(  *H6  ">%P  E!8
M (H3  "!$   >0L  '$#  !K  8 90 - &$ $0!= !@ 6@ > %@ ) !6 "H
M5  P %, -@!1 #L 4 !! $X 1P!- $X 2P!6 $D 7P!' &D 1@!V $0 A0!#
M )< 00"I $  OP _ .( /P#X #X _P _ /\ LAD  *0>  "8'P  CA\  (0<
M  !Z&   <A(  &H.  !B"   7 $( %< #@!3 !, 4  9 $X 'P!, "4 2@ K
M $@ , !' #8 1@ \ $0 0@!# $D 00!1 #\ 6@ ^ &4 / !R #H @0 Y ),
M. "E #8 N@ V -L -0#T #4 _P U /\ K"   )\D  "4)@  B28  '\D  !U
M(   ;!L  &05  !<$   5 P! $X&"@!* @\ 1P 4 $0 &@!" "  0  E #\
M*P ^ 3$ / $W #L"/@ Y D4 . -- #8#5@ U!&$ ,P1N #$%?@ P!9  +P6C
M "T&N  L!M0 + ?P "P(_P L"/\ J"4  )LJ  "0+   ABT  'LK  !R)P
M:"(  %\=  !7%P  3Q(  $@.! !!"@L /@<0 #L&%0 Y!QL . <A #8()@ U
M""P ,P@R #().0 Q"4$ +PE) "X*4P L"EX *PML "D+?  H#(\ )@RB "4,
MMP D#-, (PWP "0-_P E#?\ I"H  )@O  "-,@  @S(  'DQ  !O+@  92D
M %PD  !3'P  2QD  $,3   \$ 8 -0T, #,,$0 Q#!8 +PP< "X-(@ M#2@
M*PTN "H--0 I#3T )PY& "8.4  D#EP (P]J "(/>P @$(X 'Q"B !T0MP <
M$-0 '1'R !T1_P >$?\ H2\  )4S  "*-@  @#<  '8V  !M,P  8R\  %DJ
M  !0)0  2"   #\:   X%0  ,!$( "P0#@ J$!( *! 8 "<0'@ E$"0 )! J
M ",1,@ B$3H (1%# " 23@ >$EH '1-H !L3>  :$XL &!2@ !<4M0 6%-$
M%A7Q !<5_P 8%/\ GC,  ),W  "(.@  ?CL  '0[  !K.   830  %<O  !.
M*P  128  #TA   T'   +1<% "83#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4
M+P <%3< &Q5! !H62P 9%E< %Q=E !87=@ 4&(D $QB> !(8LP 1&<X $1GO
M !(9_P 3&?\ G#8  )$[  "&/@  ?#\  ',_  !I/0  7SD  %4U  !,,
M0RP  #HG   R(@  *AX! "(9"0 >%PX '!<2 !H7%P 9&!X &1@D !@9+  7
M&30 %AH^ !4:20 3&U4 $AMC !$<=  0'(< #QV<  X=L0 -'<L #1WL  X=
M_P /'?\ F3H  (\_  "$0@  >T0  '%#  !H0@  7CX  %,Z  !*-@  03(
M #DM   Q*0  *"4  " @!@ :'0P %QP0 !4<%0 4'1L %!TB !,=*0 2'C(
M$1\\ ! ?1@ 0(%, #B!A  TA<0 ,(84 "R*9  HBK@ )(L< "2+G  HB^P +
M(?\ ESX  (Q#  "#1@  >4@  '!(  !G1@  7$0  %(_  !).P  0#@  #@T
M   O,   )RP  !XG P 6(PH $B$. !$A$P 0(AD $"(@  \B)P .(R\ #20Y
M  PD1  +)5  "B5>  DF;P ')H( !B:6  0FK  #)L0 !";E  0F]P &)O\
ME4(  (I'  "!2@  >$P  &],  !E2P  6T@  %!$  !'00  /SX  #<[   M
M-@  )#$  !LM   3*@< #R@-  TG$0 -*!8 #"@=  LH)0 **2T "2DW  <J
M0@ &*DX !"M<  ,K;  !*W\  "N4   KJ0  *\$  "OC   K]@  *O\ DD8
M (A+  !_3P  =E$  &U1  !C4   6DT  $]*  !'1P  /D0  #-    I/
M(#@  !<T   1,04 #"\,  DN$  '+A4 !B\;  4O(P #+RL  C U   P/P
M,$P  #%9   Q:0  ,7P  #&1   QIP  ,+\  ##A   P]0  +_\ D$L  (90
M  !]5   =58  &M6  !B50  6%,  $Y0  !%30  .DD  "]%   E0@  '#X
M !0[   ..04 "3<+  0V#P !-A,  #89   V(   -BD  #8R   W/0  -TD
M #=7   W9P  -WD  #>/   VI0  -KT  #;@   U]0  -?\ C5   (16  !\
M6@  <EL  &E;  !@6P  5UD  $Q6  ! 4@  -4X  "I+   @2   %T8  !!#
M   +000 !$ *   _#@  /A$  #X6   ^'0  /B8  #XO   ^.@  /D8  #Y4
M   ^9   /G8  #V,   ]HP  /+L  #S>   []0  ._\ BE<  ()<  !Y7P
M<&$  &AA  !?80  5%X  $=;   Z5P  +U4  "52   ;4   $DT   Q+   &
M2@,  $D)  !(#0  1Q   $<4  !&&@  1B(  $8L  !&-P  1D,  $91  !&
M8   17,  $6)  !$H   1+@  $/<  !"]0  0O\ B%T  ']B  !W90  ;F<
M &=H  !;9@  3F,  $%A   T7@  *5P  !]:   55P  #E8   =4    4P$
M %(&  !1"P  40X  % 1  !/%@  3QX  $\G  !/,@  3S\  $]-  !.70
M3F\  $Z%  !-G0  3+4  $O8  !*]0  2O\ A64  'QI  !T;   ;6X  &)M
M  !4:P  1VD  #IG   M90  (F0  !AB   08   "5\   !>    7@   %T#
M  !<"   6PP  %H/  !:$P  61D  %DB  !9+0  63H  %E(  !86   6&L
M %>!  !7F0  5K(  %72  !4]   4_\ @6P  'EP  !S<P  :',  %IR  !,
M<0  /W   #)O   E;@  &FP  !%K   ):@   &H   !I    :0   &@   !G
M P  9@@  &8,  !F#P  910  &4<  !E)P  9#0  &1#  !D4P  9&4  &-[
M  !BE   8:T  &#-  !?\0  7O\ ?70  '=W  !N>0  7WD  %%Y  !#>0
M-G@  "EX   <=P  $78   IU    =0   '4   !V    =0   '0   !T
M<P(  ','  !S#   <A   '(5  !R(   <BP  '([  !Q3   <5\  '%T  !P
MC@  ;Z@  &[&  !L[0  :_\ >WL  ')^  !D?@  57\  $>    Y@0  *X(
M !Z!   2@0  "H$   "!    @@   (,   "#    @P   ((   ""    @@
M ((   ""!0  @@H  ((/  ""%P  @B,  ((R  ""0P  @58  (%L  " A@
M?Z$  'Z]  !]Y@  ?/P =H(  &B#  !9A0  2X<  #R)   NB@  ((L  !.+
M   *BP   (P   "-    CP   )$   "2    D0   )$   "1    D0   )$
M  "2    D@(  ),)  "4#P  E!D  )0G  "4.   E$P  )-B  "3?   DY@
M )*S  "1V   D/8 :H@  %R*  !-C0  /Y   #"2   AE   %)4   J6
MEP   )D   ";    G0   )\   "@    H    *    "@    H0   *(   "C
M    I    *4   "F!P  J!   *@<  "H+0  J4   *E6  "I;P  J8L  *BH
M  "GQP  INP 7X\  %"2  !!E@  ,YD  ".<   4G0  "I\   "A    HP
M *8   "H    K    *X   "O    KP   +    "P    L@   +,   "T
MM@   +<   "Z    O0<  +\0  "_'P  P#,  ,!)  # 8@  P'X  ,";  #
MMP  O]@ 4Y<  $2;   UGP  )J,  !:E   +IP   *H   "M    L    +,
M  "V    NP   +T   #     OP   ,$   #"    Q    ,8   #(    R@
M ,P   #/    TP   -H'  #;$P  W24  -X[  #?4P  X&X  -^,  #=J0
MW<( _P   /\   #_    _P   /\ !P#_ !  _P 9 /\ ) #_ "\ _  Z /D
M0P#U $L \P!2 /$ 60#O %X [0!D .L :0#I &\ YP!U .8 ? #D (0 X@"-
M .  EP#= *( V@"Q -4 Q0#2 .@ T #_ ,\ _P#$ /\ N #_ *\ _P"I /\
M_P   /\   #_    _P   /\  @#[  T ]P 5 /, 'P#O "D Z@ T .8 /0#B
M $4 W@!, -L 4P#8 %@ U !> -( 8P#0 &D S@!N ,P =0#* 'T R "% ,8
MD #" )L P "I +X N@"[ -D N0#W +@ _P"T /\ J0#_ *( _P"= /\ _P
M /\   #_    ]@   .X   #G  H X0 1 -P &@#7 ", T  N ,L -P#' #\
MQ !& ,$ 30"_ %( O0!8 +L 70"Y &( N !H +8 ;@"T '4 L0!^ *\ B "M
M ), J@"A *@ L0"F ,@ I #M *( _P"B /\ FP#_ )4 _P"1 /\ _P   /P
M  #N    XP   -@   #-  4 Q@ . ,$ %0"] !X N0 G +4 , "R #@ KP!
M *P 1@"J $P J !1 *< 5@"E %L HP!A *$ 9P"? &X G@!V )L @ "9 (P
MEP"9 )0 J "2 +P D #? (X ^P". /\ BP#_ (8 _P"# /\ ^    .D   #<
M    S    ,$   "X    L@ * *P $0"H !@ I0 A *( *0"> #( G  Y )D
M/P"7 $4 E0!* )0 4 "2 %4 D !: (\ 8 "- &< BP!O (D > "& (0 A "1
M (( H "  +( ?0#, 'P \0![ /\ >@#_ '< _P!U /\ Y@   -,   #&
MNP   +$   "G    H0 % )L #0"7 !, DP ; )  (P", "L B@ R (@ . "&
M #X A !$ (( 20"! $X ?P!3 'T 60![ &  >0!H '< <0!U 'P <P") '
MF !O *D ;0"_ &L Y@!J /\ :0#_ &D _P!G /\ TP   ,,   "U    JP
M *,   ";    D@   (P "@"' !  @P 6 '\ '0!] "0 >@ K '@ ,@!V #@
M=  ] '( 0@!Q $@ ;P!- &T 4P!L %D :@!A &@ :@!F '0 9 "! &$ D0!?
M *( 7@"V %P U0!; /< 6P#_ %H _P!: /\ Q0   +8"  "I @  GP   )8
M  ".    AP   (  !0!Z  P =0 1 '$ & !N !X :P E &D *P!G #$ 9@ W
M &0 / !C $$ 80!' %\ 30!> %, 7 !; %H 9 !8 &X 5@![ %0 B@!2 )L
M40"N %  R !/ .X 3@#_ $X _P!- /\ NPH  *P-  "@#0  E0P  (P(  "#
M @  ?    '4   !N  @ :0 . &4 $P!B !D 7P ? %T )0!; "L 60 Q %@
M-@!6 #L 50!! %, 1P!1 $X 4 !5 $X 7@!, &@ 2@!U $@ A !' )4 10"H
M $0 OP!# .0 0@#\ $( _P!" /\ LA$  *44  "9%0  CA,  (01  ![#0
M<P@  &P   !E  , 7P + %L #P!7 !0 5  : %$ 'P!/ "4 3@ K $P , !+
M #8 20 \ $@ 0@!& $@ 10!0 $, 60!! &, /P!O #X ?@ \ )  .P"C #H
MN  Y -D . #U #@ _P X /\ K!<  )\;  "3'0  B1P  '\9  !U%0  ;!
M &0,  !=!@  5@ & %$ # !- !  2@ 5 $< &@!% "  1  F $( *P!! #$
M/P V #X /0 \ $0 .P!+ #D 5  W %\ -@!K #0 >@ R (P ,0"> #  LP O
M ,X +P#O "X _P N /\ IQX  )HB  "/)   A"0  'HA  !Q'0  9Q@  %\3
M  !7#@  4 H  $D#" !%  T 00 1 #X %@ \ !L .@ A #D )@ W "P -@ R
M #0 .  S #\ ,0!' #  4  N %L +0!G "L =@ J (@ * "< "< L  F ,D
M)0#J "4!^P E ?\ HB,  )8H  "+*@  @2H  '<H  !M)0  9"   %L;  !2
M%0  2Q   $,, @ ]!PD .0,. #8!$@ S 1< ,0$< # !(@ O B< +0(M "P#
M-  J SL *01# "@$30 F!5@ )05E ",&=  B!H8 ( :: !\'K@ >!\8 '0?G
M !T(^  ="?\ GR@  ),M  "(+P  ?B\  '0N  !J*P  828  %@A  !/'
M1Q<  #\2   X#@0 ,0L* "X(#@ K!Q( *0<7 "@('0 G"", )0@I "0),  C
M"3< (0I  " *2@ ?"U4 '0MB !L,<@ :#(4 & R9 !<,K0 6#,8 %0WF !4-
M^0 6#?\ G"T  ) Q  "&-   ?#0  '(S  !H,0  7RP  %4G  !,(P  1!T
M #P8   T$P  +1 & "8-"P D# \ (@P3 "$,&0 ?#!\ '@TE !T-+  ;#30
M&@X] !D.1P 7#E, %@YA !0/<0 3$(0 $A"8 !$0K@ 0$,8 $!#H ! 0^P 1
M$/\ F3$  (XU  "$.   >CD  ' X  !G-@  73(  %,M  !**   0B0  #D?
M   Q&@  *A4! ",1!P =$ T &P\0 !D/%0 8$!L %Q A !80*0 5$#$ %!$Z
M !,110 2$E$ $1)? ! 2;P .$X( #A.6  T3JP +$\( "Q3C  P4^@ -$_\
MES4  (PY  ""/   >#T  &\]  !E.@  6S<  %(R  !)+@  0"H  #<E   O
M(0  *!P  " 8 P 9% H %1(. !02$@ 3$Q@ $A,? !$4)@ 1%"X $!0X  \5
M0@ .%D\ #19<  P7;  +%W\ "1B3  @8J  &&+\ !QC@  <8]0 )&/\ E3@
M (H]  " 0   =T$  &U!  !D/P  6CP  % X  !',P  /C   #8K   N)P
M)R,  !\?   7&@@ $A<- ! 7$0 /%Q8 #A@<  X8(P -&2P #!HU  L:0  *
M&TP "1M:  <<:0 %''P !!V1  (=I@ !';P  AS=  (<\@ #'/\ DSP  (A!
M  !_1   =44  &Q%  !C1   64$  $\]  !&.0  /C8  #4R   N+@  )2H
M !TE   4(00 #QT+  T=$  ,'10 "QT:  H>(@ ('BH !Q\S  8@/@ $($H
M R%7  $A9P  (7D  "&.   AI   (;H  "';   A\@  (/X D$   (9%  !]
M2   =$H  &M*  !B20  6$8  $Y"  !%/P  /3P  #4Y   K-   (B\  !DK
M   2* 0 #20*  DC#@ &(Q( !2,9  0D(  ")"@  24Q   E/   )4@  "95
M   F90  )G<  ":,   FH@  )KD  ";9   E\@  )?X CD4  (1)  ![30
M<T\  &I/  !@3@  5TL  $U(  !$10  /$(  #$]   G.0  'C4  !4R   /
M+@, "BP*  4K#@ !*A$  "H6   J'@  *B8  "LO   K.0  *T4  "Q3   L
M8@  +'4  "R*   KH   *[<  "O6   J\@  *O\ C$D  ().  !Z4@  <50
M &A4  !?4P  5E$  $Q.  !#2P  -T<  "U#   C/P  &CP  !(X   ,-@,
M!C,)   R#0  ,A   #$4   Q&P  ,2,  #$L   R-P  ,D,  #)0   R8
M,G(  #*'   QG@  ,;4  ##4   P\@  +_\ B4\  (!4  !X5P  ;UD  &99
M  !>60  55<  $E3   ^3P  ,DP  "A(   >10  %4(   Y    (/0(  3P(
M   [#   .@\  #D2   Y&   .2   #DI   Y-   .4   #E.   Y70  .6\
M #B%   XG   -[,  #?2   V\@  -?\ AU4  ']:  !V70  ;5\  &5?  !=
M7P  4EP  $18   X50  +5(  ")/   83   $$H   I(   #1@$  $4&  !$
M"@  0PT  $(0  !!%0  01T  $$F  !!,0  03T  $%*  !!6@  06P  $"!
M   _F0  /[$  #[0   ]\@  //\ A%P  'Q@  !S8P  ;&4  &1F  !99
M2V$  #Y>   R6P  )ED  !Q6   25   #%(   11    3P   $X#  !-"
M3 P  $L.  !+$@  2AD  $HB  !*+   2CD  $I'  !*5@  26@  $E^  !(
ME@  1Z\  $;-  !%\0  1/\ @6,  'EG  !R:@  :VP  &!K  !2:0  1&8
M #=D   J8@  'V   !5>   -70  !EL   !:    60   %@   !7!   5@@
M %8,  !5$   5!0  %0=  !4)P  5#0  %1"  !34@  4V0  %)Y  !2D@
M4:L  %#*  !/[P  3O\ ?FH  '=N  !P<0  9G$  %AP  !*;P  /&T  "]L
M   B:@  %VD   YG   &9@   &4   !E    90   &,   !B    8@0  &$(
M  !A#0  8!   & 7  !@(0  7RX  %\\  !?30  7EX  %YT  !=C0  7*<
M %O%  !:[0  6?\ >W(  '5V  !K=P  778  $]V  !!=0  ,W4  "9T   9
M<P  $'(   =Q    <0   '$   !Q    <0   &\   !O    ;@   &X"  !N
M"   ;0P  &T1  !M&@  ;28  &PU  !L1@  :U@  &MM  !JA@  ::$  &B^
M  !GZ   9OX >7H  '!\  !A?   4WT  $1]   V?@  *'X  !M]   0?0
M!WT   !]    ?0   'X   !_    ?@   'T   !]    ?    'P   !\
M? 8  'P,  !\$@  ?!T  'PL  !\/   ?$\  'ME  ![?@  >IH  'FV  !X
MWP  =_H <X   &6!  !6@P  2(0  #F&   KAP  '8<  !&'   'B    (@
M  ")    B@   (P   "-    C0   (P   ",    C    (P   ",    C0
M (T$  ".#   CA,  (\A  ".,@  CD8  (Y;  "-=   C9   (RM  "+S@
MBO, :(8  %J(  !+BP  /(T  "V/   >D   $9$   >2    DP   )4   "7
M    F0   )L   "<    FP   )L   "<    G    )T   ">    G@   )\
M  "A P  H@P  *(6  "C)@  HSH  *-/  "C:   HH8  **B  "BP   H>@
M7(T  $V0   _DP  ,)8  "&9   2F@  !YL   "=    H    *(   "D
MJ    *H   "K    J@   *L   "L    K0   *X   "O    L0   +(   "T
M    MP$  +D-  "Y&@  NBT  +I#  "Z6P  NG<  +N4  "[L0  N=( 4)4
M $&8   RG   (Z   !.B   (I    *<   "J    K    *\   "R    MP
M +D   "[    N@   +P   "]    OP   ,    #"    Q    ,8   #)
MS0   -(!  #4#P  U1\  -<U  #830  V&D  ->&  #7HP  UKT _P   /\
M  #_    _P   /\  P#_  T _P 5 /\ ( #\ "L ^  U /0 /P#P $< [@!.
M .L 5 #I %H YP!? .4 9 #C &H X0!P -\ =@#= 'X VP"' -@ D0#3 )T
MSP"K ,T O0#+ .  R0#[ ,< _P"] /\ L0#_ *D _P"C /\ _P   /\   #_
M    _P   /P   #V  L \0 1 .T &P#I "4 Y  P -\ .0#: $$ U0!( -$
M3@#/ %0 S0!9 ,L 7@#) &, QP!I ,4 ;P## '< P !_ +X B@"[ )4 N "C
M +8 M "T ,T L@#R +  _P"L /\ HP#_ )P _P"7 /\ _P   /\   #Z
M\0   .@   #@  8 V0 . -( %@#. !\ R  I ,0 ,@#  #H O0!! +H 2 "X
M $T M@!3 +0 6 "R %T L !B *X :0"L &\ J@!X *@ @@"F (X I "; *$
MJP"? ,  G0#F )L _P": /\ E #_ (X _P"* /\ _P   /8   #H    W
M ,X   #&  $ OP + +H $0"V !H L@ B *X *P"J #0 J  [ *4 00"C $<
MH0!, )\ 40"> %8 G !< )H 8@"9 &@ EP!P )4 >@"2 (8 D "3 (T H@"+
M +4 B0#3 (< ]P"& /\ A #_ '\ _P!\ /\ \@   .,   #2    Q0   +H
M  "Q    JP ' *4 #@"A !0 G@ < )H )0"7 "T E  T )( .@"0 $  C@!%
M (T 2@"+ %  B0!5 (@ 6P"& &$ A !I (( <@!_ 'T ?0"+ 'L F@!X *L
M=@#$ '0 ZP!S /\ <P#_ '  _P!N /\ WP   ,P   "_    M    *L   "A
M    F@ " )0 "P"0 !  C  7 (@ '@"% "8 @P M ($ ,P!_ #D ?0 _ 'L
M1 !Y $D > !. '8 5 !T %H <P!B '  :P!N '4 ; "# &H D@!H *, 9@"X
M &0 W@!C /L 8@#_ &( _P!@ /\ S    +P   "O    I0   )T   "4
MC    (8 !P"!  T ?  2 '@ &0!U !\ <P F '$ +0!O #( ;0 X &L /0!J
M $( : !( &< 3@!E %0 8P!; &$ 9 !? &X 70![ %L B@!9 )L 5P"O %8
MRP!5 /( 5 #_ %0 _P!4 /\ O@   +    "D    F0   )    "(    @0
M 'D  @!S  H ;P / &L % !G !H 90 @ &, )@!A "P 7P R %X -P!< #P
M6P!" %D 1P!7 $X 5@!5 %0 7@!2 &@ 4 !T $X @P!, )4 2@"H $D P !(
M .@ 1P#_ $< _P!' /\ M D  *8+  ";#   D H  (8%  !^    =@   &\
M  !H  4 8P , %\ $ !; !4 6  : %8 (0!4 "8 4P L %$ ,0!0 #8 3@ \
M $T 0@!+ $@ 20!0 $@ 6 !& &( 1 !N $( ?0!  (X /P"B #T N  ] -T
M/ #X #P _P \ /\ K!   )\2  "4$@  B1$  '\/  !V#   ;@4  &8   !@
M  $ 60 ( %4 #0!1 !$ 3@ 6 $L &P!) "$ 2  F $8 *P!% #$ 0P V $(
M/ !  $, /@!+ #T 4P [ %T .0!I #< >  V (D - "< #, L0 R ,X ,@#Q
M #$ _P Q /\ IA8  )H9  ".&@  A!H  'H6  !P$@  : X  %\*  !8 P
M40 $ $P "@!(  X 1  2 $$ %@ _ !L /0 A #P )@ Z "P .0 Q #< -P V
M #X - !& #, 3P Q %D +P!E "X <P L (4 *P"8 "H K0 I ,8 * #J "@
M_@ H /\ H1P  )4@  "*(0  ?R$  '4?  !L&@  8Q8  %H1  !2#0  2P<
M $0 !@!   L /  / #@ $@ V !< -  < #, (0 Q "< ,  L "X ,P M #H
M*P!" "H 2P H %4 )@!A "4 <  D ($ (@"5 "$ J0 @ ,$ ( #D !\ ^0 ?
M /\ G2(  )$F  "&*   ?"<  '(E  !I(@  7QT  %<8  !.$P  1@X  #\+
M   X!0< -  , #$ $  N !, +  8 "H '0 I "( )P H "8 +@ D #8 (P ^
M "( 1P @ %( 'P!> !T ;0 < 'X &@"2 !D IP 8 +T %P#? !<!]0 7 O\
MFB<  (XK  "$+0  >2T  ' K  !F*   720  %0?  !+&@  0Q0  #L0   T
M#0( +0D) "D%#0 F Q  ) $3 "("&0 A AX ( (D !X#*@ = S( &P0Z !H%
M1  9!4\ %P9< !8&:@ 4!WP $P>0 !('I0 1![L $ ?; ! (\@ 0"?\ ERL
M (PO  "!,0  =S(  &XQ  !D+@  6RH  %$E  !)(   0!L  #@6   Q$@
M*0X$ ",,"0 ?"0T '0<0 !L'%0 9"!H & @@ !<))P 6"2X %0HW !,*00 2
M"TT $0M: ! +:0 .#'L #@R0  T,I0 ,#;L "PW9  L-\0 ,#?\ E2\  (HS
M  !_-@  =C8  &PU  !C,P  62\  % K  !')@  /B$  #8=   N&   )Q,
M " 0!0 9#@H %0P. !0,$0 3#!8 $@P< !$-(P 0#2L #PTT  X./P -#DH
M# ]8  L/9P *$'D "!"-  <0H@ &$+@ !1#4  40[P &$/\ DC,  (@W  !^
M.@  =#L  &LZ  !A.   6#4  $XP  !%+   /2<  #4C   M'P  )AH  !X6
M 0 7$P8 $1 +  X.#@ .#Q, #1 9  T0(  ,$"@ "Q$R  H1/  ($D@ !Q)5
M  8390 $$W8  Q.+  $4H   $[8  !/1   3[@  $_L D#8  (8[  !\/@
M<S\  &H_  !@/0  5SD  $TV  !$,0  /"X  #0J   L)@  )2(  !X>   6
M&@( $!4)  P3#@ *$Q( "107  @4'P '%28 !A4O  06.@ #%D8  1=3   7
M8@  &'0  !B)   8GP  &+4  !?0   7[0  %_L CCH  (0_  ![0@  <D,
M &A#  !?0@  5C\  $P[  !#-P  .S0  #,P   L+   )"D  !LD   3'P(
M#1L)  D9#0 &&1$ !!D6  (9'0 !&B0  !HM   ;.   &T0  !Q1   <8
M'7(  !V'   <G0  '+,  !S.   ;[0  &_P C#X  ()#  !Y1@  <$@  &A(
M  !>1@  540  $M   !#/0  .SH  #,W   J,@  ("T  !<I   0)0( "R()
M  4@#0 !'Q   !\4   ?&P  ("(  " K   A-@  (4$  "%/   A7@  (G
M "*%   AFP  (;(  "'-   @[0  '_P BD,  (!(  !X2P  ;TP  &9-  !=
M2P  5$D  $I&  !"0P  .D   "\[   E-P  '#,  !,O   -+ ( !RD(  $G
M#   )@X  "42   F&0  )B$  "8I   F,P  )S\  "=-   G7   )VT  ">"
M   GF0  )K   "7,   E[@  )/T B$@  '],  !V4   ;E$  &52  !<40
M4T\  $I,  !!20  -40  "M    A/   %SD  ! V   *,@$  S '   O"P
M+@X  "T1   M%@  +1X  "TG   M,0  +3T  "U*   M60  +6L  "V    L
MEP  +*\  "O+   J[@  *OX A4T  'U2  !U50  ;%<  &-7  !;5@  4U4
M $=1   [30  ,$D  "5&   <0P  $S\   T]   &.@   #@%   W"0  -@T
M #4/   T%   -!L  #0D   T+@  -#H  #1'   T5P  -&@  #1]   SE0
M,JT  #'*   Q[@  ,/\ @U,  'M8  !S6P  :ET  &)=  !;70  3UH  $)6
M   V4@  *D\  "!,   620  #D<   A$    0@   $$#   _!P  /@L  #T.
M   ]$0  /!@  #PA   \*P  /#<  #Q$   \4P  /&4  #MZ   ZD@  .JL
M #G(   X[0  -_\ @5H  'E>  !Q80  :6,  &)D  !78@  25X  #Q;   O
M6   )%4  !E3   040  "D\   %-    3    $H   !)!   2 @  $<,  !&
M#P  1A0  $4<  !%)P  13,  $5   !%4   1&$  $1V  !#CP  0J@  $'&
M  ! [   /_\ ?F$  '9E  !O:   :&H  %UI  !/9@  0F0  #1A   H7P
M'5T  !);   +60   E@   !6    5@   %0   !3    4@0  %$)  !0#0
M4!   $\8  !/(@  3RX  $\\  !/2P  3ET  $YR  !-BP  3*4  $O"  !)
MZ@  2/\ >VD  '1L  !N;P  9&\  %5M  !';   .6H  "QI   @9P  %&4
M  UD   #8@   &(   !A    8    %\   !>    70   %P$  !<"0  6PT
M %L2  !;'   6B@  %HV  !:1@  65@  %EM  !8A0  5Z   %:]  !5Z
M4_X >7   '-T  !I=0  6W0  $QS   ^<P  ,'(  "-Q   6;P  #6X   1M
M    ;0   &T   !M    ;    &L   !J    :0   &D   !I P  : D  &@.
M  !H%0  9R$  &<O  !G/P  9E(  &9F  !E?P  9)H  &.W  !BX0  8?P
M=W@  &UZ  !?>@  4'H  $)Z   S>P  )7L  !AZ   .>0  !'D   !Y
M>0   'H   !Z    >@   '@   !X    =P   '<   !W    =P$  '<(  !W
M#@  =Q@  '<F  !V-@  =DD  '5?  !U=P  =),  '.O  !RTP  <?< <7X
M &-_  !4@   18(  #:#   HA   &H0   Z#   $A    (0   "%    A@
M (@   ")    B    (<   "'    AP   (<   "'    B    (@   "(!P
MB1   (D<  ")+   B#\  (A5  "(;0  AXD  (:G  "%QP  A.\ 9H0  %>&
M  !(B   .8H  "J,   ;C0  #XT   2.    D    )$   "3    E0   )<
M  "8    E@   )<   "7    EP   )@   "8    F0   )H   ";    G0<
M )T1  "=(0  G3,  )U)  "<8@  G'\  )R<  "<N0  F^( 6HL  $N.   \
MD0  +9,  !Z5   0E@  !)@   ":    G    )X   "A    I    *8   "G
M    I@   *<   "G    J    *D   "J    K    *T   "O    L0   +,)
M  "S%0  M"<  +0]  "U50  M7   +2.  "TK   M,P 39(  #^6   OF@
M()T  !&?   %H0   *,   "F    J0   *P   "O    LP   +4   "W
MM@   +<   "X    N@   +L   "]    OP   ,$   #$    QP   ,L   #-
M#   SAH  ,\O  #/2   T&(  -"   #0G0  T+@
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M[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$      P$A   !
M     0                    $    ! @,$!08'" @)"@L,#0X/$!$2$Q05
M%A<8&1H:&QP='A\@(2(C)"4F)R@I*BLL+2XO,#$Q,C,T-38W.#DZ.SP]/C]
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M_______/=#4+    "E*G______________________________^6-
M $^G______________________________9I'0  "0P&"5*Q____________
M_________________\L[#A,U3%M-3%[#____________________________
M_ZE@-F"&G[:LJ;C9_____________________________^"7C;[E________
M_______________________________M^?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________Z]G*O,?_________
M_________________________\^:@6U:1HCJ________________________
M________Q'P^)A   %2P_______________________________@@SP
M "Z'[?____________________________^L4Q       !=MUO__________
M__________________N ,0        EAS/__________________________
M_]): @        !=S/___________________________Z@U          !<
MT____________________________WT-          !4UO______________
M____________[GU%          !$U/___________________________*ID
M+P(   0B-TE8SO___________________________^FD:T$H/V-_E:>ZVO__
M____________________________U;*LLLSD^O______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________Y;N7=V+(_________________________________]N>9S8*
M  *,________________________________R'\_!0    !>S___________
M___________________9@3D        \JO__________________________
M__^>3          CD/___________________________]QO&@         0
M??G__________________________Z](            ;^[_____________
M_____________X03            9.;_________________________[%$
M            5][_________________________N!4             2-;_
M________________________=!0             .,__________________
M_______YHEH3            (\7_________________________WYM<+
M        #;K__________________________^^Q?54Y(A$' 0(1(K+_____
M_________________________]^_I9F8FJ"LO=K_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^.^G8!\^___________
M______________________*WA%<P#@ =K/__________________________
M____THI,%0      <O/____________________________6?S8
M2\G___________________________J1/@          +ZO_____________
M_____________\!:            &I7__________________________XTD
M            "(3_________________________YUX              '?_
M________________________M"4              &K_________________
M________?0               %OT_______________________]*P
M         $SK______________________^E                 #SA____
M__________________\P#                "W9____________________
M_YF*82<              "?7_______________________MOHE5)P
M     "7<__________________________[*G79=2CPR+2PP.4?>________
M_______________________]YMW6TM#3V>3_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________[]2[UO_________________________________GN(]J2R\5
M;_______________________________Y*%G- <     /,G_____________
M_______________6@CL         $I?__________________________^V%
M,0           &___________________________Z9"             %#A
M________________________[&D              #?)________________
M________LR\              "*V________________________>0
M         !"G_______________________R-                 "9____
M__________________^I                  ",____________________
M__]&                  !______________________]\
M      !T_____________________Y<                   !J________
M_____________\X                   !C______________________\I
M(@$               !A______________________^YHX!7-Q<
M  !H___________________________ZTZZ4AGQU<7!R=X&4____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________]NZG8)I:=/_____________________________
M_\B393T9    '9[____________________________;CDP3         &[_
M_________________________]M\+            $77________________
M_________XLJ             "*T________________________PD0
M          .7________________________?0$               !_____
M___________________G-@                !J____________________
M__^=                  !8______________________]&
M      !'^/___________________^D                    UZ?______
M_____________Y8                    EV____________________[P
M                   8SO___________________^L
M   /PO____________________\                    *N?__________
M__________\G                   *M?____________________]P
M               -N?_____________________@G(QP54(S)AL4#PT.$AHF
MO_____________________________GDV-+.S,O,S];@_/______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^O3O./_
M_______________________________2J85E2"P2 87_________________
M___________QJW$\#P       $_@_________________________]5_-0
M         !^R________________________XW4=              ")____
M____________________D",               !G____________________
M___50P                !(]O____________________^*
M       NW?____________________\X                   7R/______
M_____________[X                    $MO___________________YP
M                    I?___________________[H
M    D____________________]P                     @O__________
M__________\                     =/____________________\3
M                :/____________________]"
M8/____________________]Z                    7?______________
M_______1                    8?______________________)
M            9O______________________R:R9B7UV<6QI9V9G:W!ZC/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^+%JI%Y87?_____________________________W:9W4"P,     #'$____
M_____________________^"23A,           "/____________________
M____TG =              !@_______________________N;P\
M       WXO____________________^6'                  4P/______
M______________]                     H____________________ZX
M                    B?___________________YX
M    <O___________________[P                     7___________
M_________]H                     3?____________________H
M                ._____________________\.
M*OG___________________\S                    &^G_____________
M______]>                    #]O___________________^/
M            !M#____________________0                     ,K_
M____________________*P                   ,C_________________
M____@                    ,O_____________________]Q8!!04# 0
M     08-&,O_______________________SKX=C/S,W/T-+4U]SBZO______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________QVL;_____________________
M__________'&HX1H33(8 !6K__________________________^Y?$88
M      !Q________________________UWPO               [X_______
M_______________?9 D                ,M?____________________]T
M P                  C?___________________\45
M    :O___________________YD                     2___________
M_________[8                     ,/W__________________]<
M                &>?___________________8
M!=/___________________\.                     ,'_____________
M______\O                     *____________________]2
M             )[___________________]Y                     ([_
M__________________^E                     (#_________________
M___8                     '3_____________________-@
M         &W_____________________?                    &G_____
M________________UPT                  &C_____________________
M_W                   &'_______________________]0/$9.5%E=861H
M;'!V?HG_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^_5NZ.+<UJ5________
M___________________XOXYD02$%      !2_/______________________
M]YU6&              7P?_____________________E;!8
M    C?____________________]C                    7O__________
M_________YT                     -?S__________________Z$
M                $=G__________________\H
M +O__________________^X                      *'_____________
M______\,                     (K___________________\M
M             ';___________________]-                     &3_
M__________________]O                     %+_________________
M__^4                     $#___________________^\
M         ##____________________J#@                   "+_____
M________________1                    !7_____________________
M@0                    OU____________________R L
M      +L_____________________UX                   #E________
M_____________\D<                  #:______________________^=
M 0             '#A?%________________________U;F\P<?.U=OAYNWT
M^___________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________^-_/_____________________________^S&I8AM5#LA
M!P RWO_______________________]>262D             H/__________
M____________B38                 9_____________________]F
M                ,O;__________________Y4
M \C__________________Z<                      *#_____________
M_____]<                      'S___________________\
M             %[___________________\E                     $/_
M__________________](                     "S_________________
M__]J                     !C___________________^+
M          7S__________________^O                      #A____
M_______________5                      #/____________________
M)                     "^____________________5
M      "N____________________BP                    "?________
M____________RPX                   "2_____________________U<
M                  "&_____________________ZH*
M  !Y______________________]M                  !F____________
M___________W50                !%_________________________VHC
M*S4_2E5@:G5^AY&<____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________HS[:=@VE.N?_________________________L
MLH-<.AT"        >_______________________Q6TI
M0/____________________^#&P                  !\O_____________
M_____Y(                      )C__________________Z0
M             &K__________________]T                      $'_
M__________________\.                     !W_________________
M__\Y                      #H__________________]@
M          #.__________________^%                      "W____
M______________^H                      "C___________________+
M                      "0___________________O%@
M      !]____________________/@                    !L________
M____________:0                    !:____________________F0
M                  !)____________________TA8
M   Y_____________________U@                    I____________
M_________Z(                    9______________________56
M               $______________________^[+P
M^/______________________JRD                 S_______________
M_________\E'      <3("X^4FB$[?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________35
MR?____________________________K2L))W74(H#   2O______________
M_________\5]11<             $=C____________________$4
M             )___________________Z(,                     &C_
M_________________Y0                      #;_________________
M_]H                       ?L__________________\5
M          #$__________________](                      "B____
M______________]U                      "#__________________^=
M                      !I___________________#
M      !2___________________G#P                     ^________
M____________,P                     K____________________6
M                   8____________________@0
M   %____________________K                       ____________
M________WB(                     \O___________________UP
M                W____________________Y\
MS/___________________^A*                    M_______________
M______^@%@                  G/______________________>@(
M            =________________________WH+               %3/__
M______________________^B5VAT@(V<J[S0Y_______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________MX___________________________TJ-Z6#HI(QP6#@8  )__
M____________________K%(.                 &G_________________
M_^1#                     #3__________________WD
M          #C_________________\T                       "R____
M______________\3                      "%__________________]/
M                      !=__________________^#
M       Z__________________^R                       <________
M___________; P                     "____________________*@
M                    ^___________________3P
M    Y___________________=                       U/__________
M________FP                      P/__________________Q <
M                K?__________________\#,
MFO___________________V<                     AO______________
M_____Z,                     <O___________________^-$
M            7/____________________^1!@                  0?__
M___________________K7P                  '?__________________
M____RDL                  /_______________________\M7   ,&"0Q
M/TY@=(NGQ___________________________U^?R____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________Z]3-Q\*^
MNK>SL*VIJ*7____________________=?E,_,",9$0D"          #;____
M_____________W8                       "G_________________[H
M                      !U__________________\'
M      !&__________________].                       :________
M__________^,                        _?_________________!
M                    V__________________Q&0
M    OO__________________1                       I/__________
M________:P                      C?__________________D0
M                >?__________________MP
M9O__________________WB$                     4_______________
M_____TH                     /____________________W<
M            *____________________ZP*                    %O__
M_________________^=%                     /__________________
M__^*                     /_____________________630
M         /W_____________________IRX                  -7_____
M_________________Y@J           &&"U%8.#_____________________
M__^H8W2!CYRKN\WB^O__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________Y\NWJ9V5CHF$@'QX
M='!L:&60_________________[QJ2"T9"@                 Q________
M__________\                        #__________________]"
M                    W/________________^.
M    LO_________________.                        C?__________
M________*0                      :___________________6@
M                3O__________________A@
M-/__________________K@                      'O______________
M____U!<                     "O__________________^CT
M             /___________________V4                      /__
M_________________XX                      /__________________
M_[P9                     .____________________%.
M         -C___________________^+                     +______
M_______________,0P                   *'_____________________
MD1D                  'K_____________________\G0*
M    $5_______________________^AT$Q\L.$538G*%F[32]?__________
M________________U^CT________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______[]_/Q[NSKZ^SQ___________________9LIF'>6UD75912T9!/#@R
M+2@CQ/________________]+)0L                     DO__________
M______^(                        9O_________________7
M                /?__________________,P
M&/__________________;                        /______________
M____G0                       /__________________R0P
M             /;_________________\34                      -__
M_________________UL                      ,O_________________
M_X(                      +?__________________ZD&
M         */__________________],O                     (W_____
M______________]>                     '?___________________^3
M!P                   %[____________________-0P
M     $#_____________________AQ                   !S_________
M____________V%X                   #______________________[].
M       .'"P^4FJ&I<C________________________"?(R:I[;%UNC]____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________NX=?/
MR<.^NK:QK:FGIJ:GKO________________^^AFU;3$ W+R@B'!80"P0
M%/_________________7!0                       /______________
M____-                        /;_________________=@
M             -+_________________L                        ++_
M________________X20                      );_________________
M_U$                      'S__________________WD
M         &;__________________Z                       %'_____
M_____________\<C                     #S__________________^Y+
M                     "?___________________]T
M     !#___________________^C%@                    #_________
M___________83                     #_____________________B \
M                  #_____________________RU,
M  #______________________Z4X           )'31.:XS_____________
M__________^9.4-17VY]CJ"UR^7_____________________________Z_G_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________Z\RYK*&9D8N&
M@7QX='!K:&9F:/'_________________844R(Q@.!@               )[_
M________________?@                       '7_________________
MPP                       %+_________________^S<
M         #+__________________VH                      !;_____
M_____________Y8                       #__________________[\;
M                      #__________________^9"
M      #___________________]I                      #_________
M__________^0 @                    #___________________^Y+
M                  #T___________________H7
M  #9____________________D1@                   "\____________
M________RE,                   "=_____________________Y@N
M         ! I1F;$_____________________^Y_'0P:*#=&5VE^E:_,[O__
M_______________________GH*JYR-CI_/__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______WU\.OFXM_;V-32T=#2U^#_________________SIZ*?'%I85M644Q(
M0SXZ-C(O+C'_________________TB41 P                    #_____
M_____________T(                       #__________________WT
M                      #__________________[ +
M      #V_________________]TY                      #<________
M__________]B                      #%__________________^)
M                  "O__________________^O(@
M  "9___________________62                     ""____________
M________<@                    !I____________________H2@
M              !.____________________TUP                    S
M_____________________Y8N               5,E)W________________
M_____^!R$P   0\?+T)8<(NHR.S________________________*;VY^CIZP
MP]CO________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________G@
MTLC NK6PK*BEHI^=FYN<H*?__________________X)D5DM#/#8P*R<B'1@3
M#@D$  #4_________________Y(                       "M________
M_________\P>                      "+__________________M2
M                  !M__________________^
M  !1__________________^I&P                     Z____________
M_______00@                     C___________________U:
M               ,____________________CQ0
M____________________N#X                     ________________
M____Y6T#                    _____________________Y\W
M       0+U!T_____________________]UR%      &%RI!6G64MMK_____
M__________________^\6$149'6&FJ_(X___________________________
M____TLWA\?__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________/OZ^_W______________________^ZYJ)V6
MCXJ&@G][>'9T<G-U>'^0_________________^M/.C H(1L5$ L' @
M   C__________________]I                        ____________
M______^;"@                      ___________________(.0
M                ___________________P8P
M____________________B@X                     ________________
M____L#0                     ____________________U5L
M            _____________________X4:                   #[/__
M_________________[%)               8.5V!____________________
M_^5['@      #"$X4F^/L]G_______________________^[6"DY25IL@)>P
MS>W_____________________________LYZTQ=?K____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________^N_GX=S9UM32T-#0T=/9X.OW__________________^XBGYW<6QH
M9&%>6UE85U=97F5Q__________________^_,1\6$ H%
M___________________M5@                      Z/______________
M____@@0                     S/__________________JR\
M            L___________________TE<                     F___
M________________]WP0                    A?__________________
M_Z(W                  4KE/___________________\MA @
M  PL4':>T?____________________6-,       #2,[5W:9ON7_________
M_______________#8Q@J.TQ?=(VGQN?_____________________________
MJ'^6J+O0Y_____________________________________W_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____W<[%O[RYMK2SL;*RM;G R=7C____________________EVQD7EE544],
M2DA'1DA+4%EFH?__________________IR8.!P(                 5O__
M________________SE                      .O__________________
M]'D+                    (?___________________Y\R
M        #O___________________\18                "#%:A/______
M_____________^E_'P          !B=+<9K"Z?____________________^G
M20     "%R]*:(JNU?S________________________3=1XF.$I>=8^KR^__
M____________________________KG*%F*S"V_;_____________________
M_____________]_O____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_[^RJJ:CH:"?GZ&CIJRTP,W=[/___________________XI:4T]+2$9$0T)!
M0D-'3EEI??___________________YXN!@                   /______
M_____________\-6                   50?___________________^=[
M&@             )-&"+M/____________________^?/P         $)4IQ
MF<+K_______________________&9@\    3*D1B@Z?-]?______________
M___________KCC4K/E%H@9V\WO______________________________OG9_
ME*G!W/G__________________________________]+8\_______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________]O+P[^_O\?/X_?____________________________BP
MGYJ7EI:6F)N?I*RVPM'A[O____________________Z.4$I'141$1$5&1TM1
M6FB#J?____________________^F00$           <V8X^ZX?__________
M___________&90H       0G3'.<Q.S________________________EB"\
M !,J1&*"ILST____________________________JU V2F%[EK36^O______
M________________________TH=\F+'+Z?__________________________
M_________]3.[?______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________[>7CX^3FZ.WQ^?_____________________________]L922
MDI69G:.ILKS0[?__________________________G5-'24U15F!SBJ_6_/__
M________________________LE8 &C50;8NNTO?_____________________
M________S6\^7WN9M]?Y________________________________[I^#IL+A
M_____________________________________^/.Z___________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________P
M
M
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MD]?A\1@T1$9'8V:#P?_$ !L! 0 " P$!               $!0$" P8'_\0
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MI&G2,K.,'BLC#7=:#E8*'1\+R;1%JHF)@SZG7C4KSM9MY/?5QU.)70FO3;Q
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M_P!=&?R5WU]'(T5H,J[^'XGB%8$VG.G#T+5FO'EX"QV=1:Z-XH>R@Z7YGM2
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M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1(&4\K5GT@_\
M8LCB)/8B,1(^7\DR?Y_\GO?%^G_%E<1.49Y-C_H+3^H3Q$BY /\ .2NC_P!D
MG@_WIQW[,SU\=_U _P"/?_VFI_B7_>_RDZNB1P@LW4#BFNDHBH ?&)%2"0X?
M[2F'-'4.C(W\+JRG^Y@0?^1G6MVK=+%^&K=74_\ O*0P_P"8$LS7!SC3HALH
MW5:JQH.HE5!9P5VJF>+>.&0@=P1-(J@B"(#QZ9!* @40X@.5?!D_LS-6R-6U
M LSLC6"UE-%KU=%PJ=GI0?X00/@CXEUZD4#F=EBV):NDTZUL2LU*RZJ*[^Q6
M6<K\N?CR(/Y'P>I?&6THHQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1(&2\LUWZ1)>S5_[^+$2>Q$@4OE0_
M] Q/M&:Q$GL1 B ?&(!XP#Q_I'X@_G'\V.P/R>H_\?\ #\QB(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(D#*>5JSZ0?^
MQ9'$2>Q$MNWW*IZ^K4Q<[U98*GU*O,SR$Y9;+*,H6#B628E*9S(2<@LW:-4>
M<Q" =94H&4.1,O,<Y2CSMNJI4/;8E:EE0%V"^3L>E1>_EG8_"HO;,?A03.E5
M5MSBNJMK'(8^* L?%069CU^%5069CT%4%B0 3,1ZP[2W9^[1$#:G>C-QZ[VL
MC ,W*4X%'M$7/+Q!EF[@J R+5FX4=,TW!DU ;+.$2(N!3.")S\AN$DTW"E-!
MK?V+&*);XGP+A0QK+?A; I#%&Z?Q/?77S.'NUBYLY=1>B^;5$@/X>7CYA?RR
M>7V^:]KY?'??Q+^MUEDJE0C3T1$'FWS-E%@DQ KDY1*N9L@JX6*R0<NSHMDU
M#+*%;H**F G   !$Q8EUCUA2E36DEQXJ>B2M-MBJ#T0&M>M*$)^U7M5F[ (,
MFBM+'"N_MJ2@+= ]![:ZV;HE014CM<X[!*5L 0Q$X)3KEZ[I4D[A)5FY>5]S
M(.X\K<5U6+F191BRK YP$@'78J<Z+G@4O*8"C_Z7 )NBM:;[Z4L6U*K[*TM7
M\6K6[*MBC_9<#R']XD'/8]].:ZRIJ7LHKMLJ;Y-3V5JS5D] DHQ*'L ]COH2
MIMFPX:E5N8M=@83[:%@F9W\DX2B5G*B+5,2@HH5NB<RJG+S (E(41X<1X>+,
M9Z+--U=%7B;+6\$#,%4L?P"Q^!^/R9SY#?GXS%IY#677-DJ-US5UM:X12 2M
M: LQ'?X4$]=G]) 4)\C%J76+0@)=L@E=Y>30$A0>B[)9D&-G6>B7KF.S(L_E
MWJ234Y2 0C<#I 9 Z9S>>X:I,S\QEKI-*U<SJO\ FWW/=/(UT<G9< 26K5K]
MEJ>VP4*:V\!X>)/K>?N;57P.QKA>UW 8\[$4FKVCQEVGBJZ">@MS+GQ46&Y2
MWF+5\B'#*,@>&P\TS?J\?M,NYYZ/#8>:9OU>/VF(G4I8D4CH)J1DT0[E4R*!
M1CS<552HJN#$+P4^,$4%5!X\ Y2&\?'@ HG;X:_U3-^KQ^UQ$>&O]4S?U ?M
M<1'AL/-,WZO'[3$1X;#S3-^KQ^TQ$Z5;$B@9 JL;-$,X6!N@ QYORBQB** F
M'!00 1324-Q'@' H^/CPXHG=X;#S3-^KQ^TQ$>&P\TS?J\?M,1'AL/-,WZO'
M[3$1X;#S3-^KQ^TQ$ZEK"BW*4ZT;,IE.JB@418&$#*N%2((IAP4'X2BIR$+^
M;B8.(@'CQ$[?#7^J9OU>/VN(CPV'FF;]7C]IB(\-AYIF_5X_:8B/#8>:9OU>
M/VF(G2O8D6R?57C9I)/G23YS1YN'.NJ1!$OB4$>*BJA"%\7\(P<> >/$3N\-
MAYIF_5X_:8B/#8>:9OU>/VF(CPV'FF;]7C]IB(\-AYIF_5X_:8B=2]A1;(JN
M%XR:311(9150T>;E(0H<3&'@H(\ #] #_)B)V^&P\TS?J\?M,1'AL/-,WZO'
M[3$3[X:_U3-_4!^UQ$^>&P\TS?J\?M,1.I>PHMD%G*\9-)(-TE%UE#1YN5-)
M(AE%#FX*"/ A"F,/ !'@'B <1.P)PI@ P14V(& # /@\?& ^,!_TGYPQ$^^&
MP\TS?J\?M,1/OAK\W@F:^H#_ ./5X8B?/#8>:9OU>/VF(GPTX4A3'-%312E*
M)C"+ > %* B(C^5_, "/Z<1)9LX2=MV[I$1,BY12<)&$!*(I+$*HF(E'Q@(E
M, B ^,!\0XB0\EY9KOTB2]FK_P"_^XXB3V(D E\J'_H")]HS6(DPX<MFB0KN
MW"#5$H@!EG"J:*0"8>!0%10Q2 )A\0 (\1'Q!X\1,:[ L$&6,A7!9=NMW:YT
MTYDXZ2:]42N+"P8"=P!#*F%DAWSO#SX(%!!(YCJ)$ RA:CF24SY; MS>WRG%
M_%'?E^]W4T OXJY-2FX/:.@/!22R@%A?>GNFU;:RV=/<X7F@&T >/=7':-'C
M7VR 7O[/MT_))=@%5F(4WU[X('SW$>LF7VV6\H8]\$#Y[B/63/[;$1[X('SW
M$>LF?VV(CWP0/GN(]9,_ML1'O@@?/<1ZR9?;8B/?! ^>XCUDR^VQ$>^"!\]Q
M'K)E]MB(]\$#Y[B/63/[;$1[X('SW$>LF?VV(CWP0/GN(]9,_ML1'O@@?/<1
MZR9_;8B/?! ^>XCUDR^VQ$>^"!\]Q'K)G]MB(]\$#Y[B/63/[;$1[X('SW$>
MLF7VV(CWP0/GN(]9,_ML1'O@@?/<1ZR9_;8B??#\%Y[B/63/[;$3Y[X('SW$
M>LF?VV(CWP0/GN(]9,OML1'O@@?/<1ZR9_;8B/?! ^>XCUDS^VQ$>^"!\]Q'
MK)E]MB(]\$#Y[B/63/[;$1[X('SW$>LF?VV(CP_ _'X;B.'Z?"3/[;$1[X('
MSW$>LF7VV(GWP_!>>XCUDS^VQ$E"'(H4IR&*<ARE.0Y# 8IR& !*8I@$0,4P
M" E, B @(" \,1(.4\K5GT@_]BR.(D]B)KOVC9)C!5F%L4SI]3<,%!2ZCV0C
MFS-M87M66,R70C[<TI+M-4ML-%.50[TWC$E[''QRKUY7VC]\'<'46ZSVK!9T
M*F&76M.UE:Q,VAEK]M+5K#754:%#UW:J5=J5'A:OT]MSIWJ4V5M6&\E:[.]V
M8.M3:<]9L>P)8Y%=EM3BJRG+<RTW7"NWR6_/09I9[GZ\W#M:K[,VWOBH:?0<
MM+'8V&F;IK-K4F<@ZIB[5^TEHB1<4UP=<8ANX1:)>!;8*$VG)M#GGH1G*130
MR-K76,W$\>UI9.5UTO\ M((Z69]&<_2WY;?<I+9;BUXO:FS+9=3],N=Z[?.V
MT2%<_N<KOJI4'B\[4G$MU;5Z,^H-KKN1J;T33FM3*V=+5N2JX67ZZ2&H(\O4
MV,\FQ_Q#_B+3^;_0)_\ #(D[3%]MV?0ZQL:DU*=LC2.GYI!\FR8J(O5"%/*N
M&$=$!(/6[56/B/"\D'@V(-+NF)922,2/CQ</%4T3;4JU[O52I>Q 6( Z[\:;
MKVK1CTKW+GINT&A"UPSTVWFOVJW==;3[2);8?&MF([[[/7G75[C(O;+2+;:J
MC>RBE;;*ZVL#NJFY-G1836NKQ%]/K"[JTV1-+AQ%18D>NJB0/$/C,JF0 '@(
M@(@(!Q#.V1_#3G?OH"ZOL_R'D 3_ (#YD'EJC=Q?(5*@=GQZ J'KIV%3%5^0
M1\L /D2P-3R;A[)1DBX19I%N6G];V$Z@/BJOW,_%!+1MD!5H9R=0S=FWD*T@
M5XDV*0RQU$W"YU!13)1V(V;U7R](6E:-6#'=2PLZOMOQ[.0SZBU)?XJKSW<8
M$L2L?<[)8Y_=@>DQ7GD/07IS78UQU9=NO/IJ-1;/15OX[B]>9%TBL*UKZZ.7
M+5/:6\45TK4>X6SSEI*N,1+5M5NJ=.1AWMLEF$0G*3T;7X15Z!C*.[!-*&81
MS!B1--58SMV*JJ("F0 (@9<ZQTVX*G OWVU4+\VWLRU(/XG*5O:_7Z +6C,S
M$A0!\GL@')!%=UQ^*L]?NW.?X:T\E3R)_JS*J@=LS, H)/4NK$Q&(C$1B)C/
M86V-:ZS-%>_^?;PYGPN'C$3Q4M+"T;,0(F^G'PQ,=(^ X6-(Z(62L<J+"&C4
MW "]D&Y%.(YJ!NT)FJ^ZZPU!5["CRON3/0K6-XUH]^BQ**$=U:^YUJJ#N0LR
MRLE+7E6-:>?952[DUU/?8$J0-;::Z:WML%:,4K4NW2CN9**8IRE.0Q3D.4#$
M.40,4Q3  E,4P"(&*8! 0$!$! 0$!X8(()!!!!(((Z((^""#\@@_D34$, RD
M%2 000001V""/@@CY!'P1.68F8Q$8B8\>[,H:$O;*](2:J<K18R&L5B9.H&>
M#ND=++.@A)".55BN[3HN7D:Z0:A7U9-P1^U,U$A'@%2' ^ZIKE#.BZOHB$5G
MM^J\*K!2*%!N9G2ZIZRM96Q74ULTV*E7K1O%3;2^A"S*M9IK;QLL:TD5HM;=
MBSS=2G1\@.C)>F7BK[!A?#]2DC24:5\^BW KL).(?L)2,7%M(Q<K#S3..F(F
M38KE%)W'R;%H\0-PZJ)0,41Z-6R+4Y\2EU2W4NCI9794Q8!T>MF1@&5D8!NT
ML1ZW"NC*.88%K$^0]+^W:C*R.C^*V ,KA6Z>MZ[:VZ\;*K*[:RU;JQNS-)M&
M(C$2SG5TJ7OP3UX]>&"SKP1K4A&.XB4!DXAF3TB"KYO,+1X0*ZK%Z"(KM$I$
M\@R,=JX6;))K-U#EZ==+@@+C%;:"Q">VEO?MV?>5+5L0R^XGE6K*Z,P9& RP
M*>P2#UIL>JGH%O.RM?-JSX]^#^'W*K^)=02@8*>NNE;$IVQFC^1I,R6PQ4>_
M6C%)IDQDRP3UVW,)''@2<<,D(BQ-D%2G06?0#V28I."*-SN2KIG3+MX-[5-Q
M4JFA/<J\AX.]9Z\;/:;JU:[ 0U-C(J7(194SI]TU)"VV4DCW*6\+5!#"M_GR
MJ9E[46UD%;:BWN4N"EJHWQ+US69C$1B)CB;VGKR'L[2C3\VFRF)4JR3=.0B9
M<L"X728.916*5LRD:-53F!BV;N1) N9A.768-UGB3!1L0R@80BP7%2#[%5MU
MG9\2:L_A]194&Z-ZY_<0Z#2+/84^5O@H)&65D%98'JRRFI>AY=/H8UYUL"]F
MGZBSJK.;?!;[62NHO8Z*U;1]ET?9"$DXI<\G-)Q#A%L_#N4E'+(BZ2%=DY(W
ME63%PYC9%N!G$7+-4EHN4;E,O'/'*13'#H4<5I:5(2PLH[^&5T6MVKMK/5E-
MJUVTVFJY4L%5U-OA[=M;-J6 L:HG[T4.0/E61K+:A96X[2VOWJ+Z?<J9T%U%
MU18656*M]9I,QB(Q$QY8MFT&OV**I5CEP:R]C.W8LVR\/,N8A5Q*=X281LE.
M(QJ]=BWLQW=T2,C9B29.Y<$' ,&[H$E.7-0-SM76/)T\_@_:':NI;[:ZF;Q6
MZZJATOMHI+W54V5VV(M;HQ/^[K%C_"'Q[(^XHKV&I++%7MJJ7M!J2^P+2UJM
M4KEU91-Q%SJLY/62K0TTRD)VG'CD++&-1.=6%5E&QG<>W=FZ8($67:EZP($5
M.JFD)#*D3!1/F("]7OI]U/OVYQ8/X3=0*VNK!_UC6+4#$=J&)3OR5@,NIK9$
M<>+64B]%/Y:EG9%LZ_169& [Z)Z[ ZZ,NC,3$8B,1+ M>SJ+2Y2)A+3,FC'4
MZY9L6JAXB:=Q*"\H[)'1B4Y.,HUU!UPLL_5)'Q9[%(1:4H^.5DQ.X<CTL5_O
M;117T;6)55)"A[!4]_LUL_BEF@TUO:N=&:]D7R6L@@E9^[J:]_BI%+NW\12M
M6"O<ZKVZT5EA[NAE%-0[-EBA210TW;FM;K/2]/J%A0D)FMH*J/(XD7+QJ(L6
M,@I".7<*ZD(YE'3T8PE4%(EV^KSF28,7Y 8N%T7 D2'9$:S/]2@[I[I!;X#*
M-*6V9G:MNK5JU)1>^6UD%6E:;C0]@J?QQ815<,]A\;6%I5?R&.?V/J$#CM#;
MG^JS?44AO=H^HH-J(+:_*[Y+RS7/I$E[,7S69D]B) I?*=]Z!BO:$SB)72#9
M%T5J198J0(O6SH@&Y."IVY^<J7 XAQYQ\0\.(A^8!Q$PQV@W3F-H\.Z9MU%$
MR;(UB=\DU124<K-6]XA':::!#)J&.J9^V8\J:1146X"C_ 4/E7S69-7%Z%:F
MZ\T7<=NKKH+BTV\=RN'<C*$#%A6<_N.A!6Q$9&Z#$BVX+4V3F,)%^?,FI>1X
MVV[3X>R*N3XCD./:MF=D"-<VE::[ P:NRQ'4,0%.<^BE_%)_T"_LRTE3'12_
MBD_Z!?V8B4<C'H/H]\Q.!$2/&;IJ=8$R"*17"!T3*  \ $2 <3!Q$ XAXQ#X
M\1*HB*/(7@1(P<I>!@(00,' . @( (" AX^(8B<NBE_%)_T"_LQ$=%+^*3_H
M%_9B)Q.BB)# *:10$I@$PD(  ' >(CQ#AP /'X\1*.,9-6D<Q9HF2<ILVC9H
M5<"ICU0;(D1ZAN3F*!C<G,8 $0 1$..(E=T4OXI/^@7]F(CHI?Q2?] O[,1.
M)RMTRB=0J)"!PXF.!"E#B/ .)C  !Q$0 .(_'C_K\#^_^42@9,FC([E(%$5%
M'CQP^ ABI%.4%Q*(D(7B)C$)R^(P!X^(\0#'\_Z?G^G]_P#*/^OX_K)'HI?Q
M2?\ 0+^S$1T4OXI/^@7]F(@4D0 1%-(  .(B)"@  'QB(\/$ 8B1Y&C,CQS*
M=1$2.6;%H(""71(5DO(*E4!3CP$532!B&#Q '2)P$1$0!_U_']>_Q_QC_P#[
M_P OS_P_62'21'XDT_Z!?V8B.BE_%)_T"_LQ$=%+^*3_ *!?V8B1KAHR<.F3
MWK(%",4<F.4O2$AC.&YT!*J;C^3$@'YPX^,1#@(!QXX_3O\ 3^?Z1^O7Z_R_
M62()HF #%32$!#B @0@@(#\0@(!P$!_2&(GWHI?Q2?\ 0+^S$1T4OXI/^@7]
MF(D?(,6D@B+(3I)* NR="!"IF5 &CQN\* I\0,!%!0!,3?F*<1#B(<!?_P!?
MX_RC_K^/ZRO!- W'E(D/*/*;@4@\I@^,!X!XA_D'QXB?>BE_%)_T"_LQ$=%+
M^*3_ *!?V8B=2A&OB1,"!#JE,4A1!,#F\0\1(4> F$ \?B >'Y\?_P!_X?SB
M=4<DBT9M6"2Y5^X-6[03 8G.(-T2(@90A3#R&,!.82C\0CP#']?T_G']/U_E
M(^4\K5GT@_\ 8LCB)/8B>=_ND^CJ_NS2<(G;AVD-5H=SBKO-CJ:IK;'L;5"(
M,"J$F76;)->9MQXU<I'#%6MLY2R5Q^"$[%Q3ONCA5K#8UY^5XKDK3>JXGN >
MI;'5'O:@*6:E7ORN1647?6A7/6]U=[547V6+,J+W8>1P5BIGV5HI6RQ:C96B
M:%MJ#6,M5Z,MOD^"YD7640U,^JG/GOK^S'M_26Q$K430>JMS1K5: :H[%V3L
MO3.R=*,IZ2K\$K%1KUV3:-<J4C>+J_*FFE*24'"/%!;)"O8)I(S>+:NKFPVV
MU7WE:<N.[9JVY\R/4$.K=979>,>16-M&=@/=>PUTY38&*>YINM[J*UJI>FKN
MV_77DS8[+62QF&;&+%I.K0P%)=/)JZZU>W5TU:^VN6KW*=\XOR;'?06G]G3R
M%)<TYW)H^XW/<41)0KZ!1J]N)0U+4[?NGR4["HZKO$1=B$@62#%=I(&G.ZHQ
MPF<OXWP<HJH_#O8I%;FZ87&?0K6AC33R"\M64(+VZ4X^[%7EL!"A*"[57/8&
ML+5+=G%0]WW%QH)>GJOQ]ZSC>2XA@X*JF;E $OTJZ]EKJJ7N6FDJJ^\:;C:!
M6:VW062371505*!DEDSI*%'AP,FH42'*/'B' 2F$/& AF@)!!'Y!!']XA@&!
M4_(8$'^XCH_GX_$U@U" ,XK4B[CN*[^'3V%K!](+JE2>D%I)B[48M4^MR*"J
M\J#(JZ()'63!N4Q>B0JQ30^>KKK]2<;M6NI3?3MQ+8[D6K3MIR[O;J[(#BV[
MCZ68>+, @*E5#^77T8]UGHCE.,MT7VMAT8M=B5UAJ7T<9LW<6UEY52:FHIY*
MU%[95)8JREBGAM'DN<XQ$U8W_HJY;3F:G/5B^>!CUR>ICLD#)1<8ZB6[6%MC
M.?FY5@[5CGK]*:?-6C9N"7$K9R6/:-3JM4579U<Y3]/NHTN Z+H5[.QU8E"9
MKZ_8J(Z[2VZT66H64.P1W+MFSA-[2+,>C.O=;ODV5UL/N5]&BL55V6JW8'M5
M^=:.JEZTNT!1U?8#M*0#%(0IS<YBE*!CB %$Y@  $PE+\$O,/$> >(./ /%@
MD$D@= DD#Y/0_0=GY/7X^?F<QV  3V0!V>NNS^IZ_3O^4Y9B9C$1B)I]VJ-)
M[#VZ>HJT,U737@TI=,7,Y,24$O'OGQV)F;UP#"#GD+?6R@V43GZ#+(L8NQH'
M(DO)-#)E4+G$3GY7/M8^-=38V\E'FP%&ZG3:&I)K6UC763EM]ZNS%K6K52WN
M(.MKO:MPW9G1G-GO]IY>WYK;COSJ$OZ<YV\[0+C[5R7YVLIMK9#T=NVY52-T
M"+G(HN1%(JRB1.FF=4I"@H=-/B;ID,<#&(3F'E*(%XCPXYERI=R@(0LQ0,>V
M"DGQ!/ZD#H$_J9RK#BNL6%6L"('91XJ7"@,57L^*ENR!V>A\=SNS6;QB(Q$U
MM=57;<5N;9^PJ]7:/(Q4[K"IUBI!*W67C7KJQ5B5L$ARS;%M2)%*,BG1;*L0
M'C21E'*8QI.+$P/N+/%9:O#MJ'0T7\M7KJ'YK^G.+-BL+OT&6VL91:E8K=+#
M9[9L0)YOVL:NV[CR?(59LFFBX]#S+W:#I7P7OHJ& K)+*>F-@'8\6O;2]:LM
M9JTBE<(*!@;+-6>;LDRE7K*\M;.0DII1%T]E%)5[6ZHJ55PYZB*+$L2";%@V
M9H Z=&*8X=K#4*\M5)?VZ*#4$=57P/OWV'[E9O=:TV'1=9XU>6BZT"L*H9HR
MFQK=%MH4/=8C%@Q8NM>>C/5VOB/;%5-->:M UG[JA':PL[*N7,Y3>,1&(FJ>
MX-1;"V'L5R[AE8.%J<EI#8&ME[-[X)!*T14[<C)"V?LJ\C7SM'+./[F@)UQL
MS-RH+E04T4Q;%%?@U7N4<M58 1LJXY*4[)KN&+6=5M.GKQ:NG2KOFL\/<85E
MCT2_BLNG0M%G%6*"S8^3LV7?A"E;9'SHU#??Y7H[^Z@=416K7LL">I7LUZJN
M6JX*:C+*HRBXIP:";UFD1%OL5W@ZFSAH5M%N_!$U9X^-DF[28=("_)")M2,8
M<H@V:G5+Q4&UUZETJ&8,U[ZMNE['"^:5:;%>G(;1]V@9P'ZOL5&;W/$(JH.Z
MK/G-'@@*E*<F;-YKVOU-M <6;&I[*9[+O)0U:,X)7R:QV/<V7R#)48B,1-9M
MM439&R[1'0*]:IJFM8]%VX93JUVE6MD86"2A):"5FU*LE27+.0&(8RSD(AH6
MV,"B\6[\Y5,9N@@7FJ!QJ-G[NYLVO-EL0"T(FB@*Q92:O!])!RVOY6"K);>$
M1WL(G86^T<_MK[J_49;]5;GVO+Z775HK16 M\EJLJJUJ/&MK-%%2EZT!): U
M3=J(_GIR]J5U&0<5'7NO8B/J\@_D8\\#KIO.IM)QZK(1D4HA+3:\^X5<,$D%
MT8Y!!!L5^]'F6&?;H%M>ABI6[=RFGEM"?!KHLOP<9A&>E_@V(HX[W38RUEO=
M6OP I#/%*$64@=&G)D.2ER.K;@^[;M>RY?D*5&FNI4#V#R2V[R'OFM-F<B3I
M&(C$37_:5<V;;[95(R,K5.>Z]B9".GW4S(721B[&SL;)=3N;Y"MDH\S'2C2$
M(?O[5HK8(\9"0*@5=1LW1,5?6M2;+F>QL[+3=7CT4JMME+WYK*GT>W9X*+5-
MAJJ'DR(I>UA8Q6M-W95I543WC98GU5-C&JNRBNZJT4BQ/<8JYK#V'P5CX+6C
M+V;);^D-'W#5=]V-.S-W);(*U1]50C3KQD:PFG,A%$E%)63G!CV#5([UT[D#
MK&<)N'!WZJZ[AT5)0I &178BXFS>VJ-^T+M%0K+>U7G;%Q^:M5!)(;O(RLI\
M@%1+/-[+;#-+^[-%-P=F\<C56^8'DUK:[[N@1\>VJ6*$Z"> ZI5%JJK$V@SC
M$8B,1,#;@@=DVU]7:]!5.EV"@!)14S:#S]VE*[*+/H2892T2V1C&E)L3>0BV
MKUDA(/&QI2,6D5&R+$7#5NHNH?;,0NNJZW[%SNMN:Q +6KO*NAT-2WMAWSA_
M<S)[RK[X2UR?!5B[HY+JZQ[EFBJ[/=6Y]M'S6H$LI%P%A4:49Z;G]EBM+N$'
MDP88QT-I#8^N-L[$MMA4JJ%7M#:4*@VAY>2EW#^3=VMU,L9%A%OX.-1H+$D8
MZ51F:]%2LY'S,RH28YF:Z2G>.F9TJXSZ5P3<&P>'7W!!GIV)I[O)#VT6O?2V
M+*]?CQP&I:K;!J8#34&NWUZ5Z\%3:KEOM+#0<!H I'FJWI]-<->M; ^U1D6V
MOO+6PVIDO+-<^D27LQ?.,WD]B) )?*A_Z B?:,UB)ISVLZ;9;)8:TY:5&P7*
M,]X-YA*HC!Q#R:3K&WY-_7%:9;9 C--4((D>Q:3!$+6Z!NTAC&625?-C/R J
MR_;LL*_N]+OPIQZF/A7GSYN1NMYNLW'I:FU9'R?:S+]53GOS+YLXJL[NU7T:
M"P>Y4E^QMF=>C9H2WC;J</C7\FU:=;-\*K^S==1J(1<[6UWMVLB3;+LPV==-
MBO.V&')KQXHR9N ;N9%VRNU4"32:K^,Q5W+;OQ413 ZXJ'*#<IW IE&#ZA\7
MX;U,]6:S4$X+U#IS8Z@_O:;<W%[=63+3X*SK==?5354ZJ6KL97"GQZ.>$MNR
M\SZ28W)0Y]5^CLNG5:]:U9LVWU%Q6'D-5QM9:WHS8].FZ^MF'O5(]8/DXFUQ
M3 8H&*(&*8 ,4P#Q 0$.(" AXA 0\8"'QADX$$=@]@_((_!'\YP(()!!!!Z(
M/P01^01^A$^XF)@3M(1>RIS6$[#:UB(V:>2<?+-9QD[LTC5Y!>&/#/P.V@WD
M96;.X<23MV+9L#,K=B=PBHHDE(-E3E.$'DJS;BUIXV.IR:AX4I[MK6&AQ3XT
M]J+O&PAO8+I[K!4+>)(,_CK$JV9K"RJZZ\A5K&]NI4&BLW%[ODT=5@@7!+/;
M!9_ L%(N+0S.PQVD]31EKA2UZPQ>NJ=&2D*#MP\4CW,= ,&8MW*KN.BG";TI
M$"B^:*L4S,78K,Q4<= '"OH>:MKNY?D[ZG6Q+]VJ[S0AJRUMSV.*K >K:5=F
M6J[I/>K"V^W5Y^VOG^(J>CBN.I=71J<6:KQL4I;U72B*;:SV:K2H!LJ\G]IR
MU?N/X^1RSE9+&,1,7;NC7\QI[9\3%Q4O.2$E1;.Q9Q$ \[A-2*[J(=(IM(MU
M\:;Y43\K<"@8ZJG!$A#F4 HQ=B>=(4@]?48RY%1O"(NNAK+;,P!.JFE UM^0
M G72CY@";1)>!PFNIR57KSZ\W%8+&MPB"XD#.[L0E>DE5S.RWEE%9(PMV-*Y
M*5;6LS%2-9>5U$EMD%HQ1Q2Y76;:98J-&(%D6&MYELR>TY,%"*-G3(&39K(/
MT74LT(9%\4YKC6XLIR'M0X&KSK6X7^ ;9>Z.+.RR57(XLIRN0^2LBDJH"B5&
M9"CVCQ<**L2^XZ>#.Z9:UL6SK[;KJG!2W6I9=) ?S=@S';K(,F1B)@3M21!9
M_L\[?A@KCZV.Y*C3;.)@(RN/K9(OIU=J9."%A"1K&2>KNVTN+)TW<H-##&JH
MEDCJMTVAW"4?2"?IBJL73;BL1E4EJ_#34]EGF ?;"TBWR<E1XDIY=N 9W&NE
M>VAK65: 6.CS("-0$8W5LI^+!96&3V>F-Q(K5'9@IP]-,ZA8+[HQ0-?;%B[C
M"!3I]SL1+4.Q <MV2$.O'IT)>W&K/<:S'/5G)E[A'3<E$1K5HB9-TT7DW8J,
MK<L#S'):*71:RW)JP9UJKWKLHM5&L=RM>BG*EBZJ4\K+?KZ<U>="R6J:2E&7
MA./RWJQL6C %0*7.)\=^>RXJB^35W:6H;)Y*H6S+==9;:*A4+=W,@2;&(E'(
ME;GCWQ7;?O;4S-R5RU[J=\+E 43@L@#)-)91V*R?,F#8B*IU^;I%3.8P%'CI
M ;/>K+YAJK 4"&PMVA'B$ 8MW^/$ D_RF]986(5;Q;S7Q;R">)['1\R0%Z/S
MY$@+^20!W/(F6I>RW^IM-P4)2+Q'TNNN]M+NM=N]26)S&S5W]]"+O6<)>:,_
MB8]VVU^YBW,NNG,.F)*W&OB,%GSEN*+;)M#,-F"ZTBVZOB.&JR"VQ?:JTI>E
M7+6WZ"2N7;ES5UMA>XH6'U!H+6&I;-]1I8<JM;-579S.RS592C>\^.S'HLSG
M&B@'73?N:I=B4^9<%%<"H:73UQAP<EB8LKUJW8O CV8.F30"@U:. ;I@LV;
M7X(((*<R:0%^"!"E /$&:7>/O6^#,Z>X_B[?+.OD?%F)_+,.B?ZDR+2&%58=
M51_;3R51TJMXCM5'Z 'L ?B2.<YTG!02@FH)P,)0(<3 0IS'$H%'B!"I@*AC
M"''E*F G$> % 3<,U?KQ;R!(\6["ABQ'1["A?N)Z_ 7[N_Q\]3*]^0ZZ[['7
M?77??QWY?;U_/R^.OS\3S&L-.@IV>N%@IFK-BPM*4M&O2;(UXKIV^P3>]UFL
M3DZO8;.ZBIBNL4=B3<\K+-R.6$,2Q2\A7H9N:5!95RBQ;],YK2G.="FW(^J^
MY<@"E<%UO&/FPBK)\-6!?6+MUM=8S57_ $9\O*A]-G6T]V:*ZW"[%Q65#6&;
MO6K;<MNBM]9/MLM5%3U85>WWBNC<$4UVA$W0[.\-8(#4E;C;&Q>1+DCNRNHJ
M$D2G3D("JO[1,OZ? OD5!,HV=0U7<Q,<LS./.R,W[F< ,@(!UN+^&)+[!=KJ
MXKB*.0N%@N%W(T<9EIY"SWU9UT%]:7%M"LPT/Y7AF%GD8P]LW;7HK-66WD>0
MMQU&LU>&2W7<] 6DJAHK9"+*LY1#GJ=*"B&LJ,V9PF\8B:47Z.;OM[)2VNM?
MSS#:5>B)P"766U_?XFI7.3DZ]W.+@IC:C>IR5?\ >E!D!-ZHW,_=-RRY4FL7
M'*/3/E$]<WN"O:<Y%2V(<[TV.,WNAME-NK;U:A&C12GG7QQ*6NQ4K]F&JKSZ
M7^T1D73W;U8E];UJ;FH%=-R595-; YJ]#@'8 U2A6]QO+39\W-V4J]L:M,=L
ML]B5<:\[>[3EI6/=*6:2LZLZD\AX4KN33D)&K5<73)5VBJ9L];-"MECF7;HM
M623--,THM4>.XU$/B:AR*>P5\6JK;F.0MJ%G;L_FU=BE6?R:ZKV]+/Y7%$YW
M&UMVAW*N'HX_NU6!1K$Q4I8M8"A552.BB_%3^5/W>W[C[8Y'B,1-2=^QE1G+
MOK>/>4>ZO+8QL]7L$=L6MZSNUH&L,X2?9OCPD=<(. DXFK+6<R0Q,ZL^DHF-
M) .'ZTVXZ!40#./L;ULK/MFI;%N\V-":QHQZLJ9[+;/"M\M)O^JO4N5\JJT2
MM[G!KSI/]@M2P>ZMM;K6J@6OF-=M.A]24)Y6G6!4$Q,B>Y[Q5O+VJVJMQ%V1
M*19*IMO;3R4H5FK[*8;NEE)F<K4K7#A(#<[ Z+$/YEVV;1NT'ZS-VE*,;O$G
M?@SAU6M?=.@%HB0>V5E7A**/)$-38?% OLM81B9+@<9^[/=DL45:M72U\I;8
MNE"Y1R--Q\N6:Q075CN)L_[P(K/C]EETKVMF?2JNV;&3[G&^S=6R5B\!M]93
MRM6?2#_V+(YPFTGL1,<[@>7:.U5L9_K96+;[ 94JR.J8O-@S-$(V5")=*PZL
MB60>QL>9JF]*B=4K^08LC%+P=NV[<5%20N1?17CO?,0MRA#Y=5%EK%B>^U0O
M>NAKQ1[ASK>Z4M>*Q:PK+&2\"T/MS)I5FH:Y%L52ZE@3T%+5)9:JLW0=JJWL
M"%C6C. #HKV =W]IG=5 V>[[1<'"0KBKH0L'7%4[5JZ?M5@=(0+LMHLL[%ZD
ME9NL5B,EY-))6"B3RCUX4"R"@+F9"S*2\N3,V*G54/;LOUWJN=??<9\E63CQ
M6FF^U52S;9K;=>Z4HJU8[<2.#;YN]/4VA-CY;;$N2C%2]M_BE1MW7;^3:P44
M*[LN.G"..HJL=B;=%>IN_P#53;*X7/9T26(:5&E.EV92IM7$DZ:-)=-XS\%Q
M[D)B,0BIP'2";155TQ-'3#2/>/'2 J-2F:%(HXJBUO5C!!V*-3)4Q^XW46UK
MG\F!*&O6&("JXMJ3S>WVF4"6/2>2*26!LSAG#!5*6K;[RKY*62S-XJ[.]9J<
ME:ZR_D66^HJ0FW[RAKV"'&)EW56</I=NFL@JU9S+IA$J2<4AP<*.A[@Z%1+J
MJ)])0@%$BRAN8 FZ4I31H3.YLH2^U*+#^;*5=Q6Y^!\N@5C\#Y/X^/B'0]CU
M9WN7PM>E&L7KQ"V-6I=?$LQ7IB1XEFZZZ\FZ[.1,X21-3:\D6)+>V+1=FU]X
M_:=<OWYY A%BH,[TUKUY=HMS'ZIVRKIIL),C0Z94S) L5,A03^$,/U8+C3P&
MX645"N[BK'LOK#*<U.F[C+40]#QM<5&M+1Y,&/Y^3UM_V=_3+I]9<16E]K&W
MGZC518X9=NW'C]14FP>0#4I]8EQJ8A/#H!1XK-LLF36,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$2!DO+-
M<^D27LU?$2>Q$@$OE0_'_4$3[1FOVXB3^(F"NTTS1?:%V>DX3%5!"MGD5B@<
MR8@E$O&DJHH!BB!N*1&8J@4OPC\G( ")N \M%/U.3=E*>X-?'\AD-8;P-@U8
MKZ#6'^/#W/<\//L>'EY=CKN930N/3Q^YK!2O'\MQ'(FXI[HI_9_*9-GO&H ^
MZ*?8]PU]'W OAXMY='+=;<B]KL \%,B0NX6*<BDF<5$TA78H*]--03'$Y"<_
M*0XG.)B@!A,81XCRPV>]BQV^(7W<N>SQ4^2KYU(WBK=GR [Z![/8^>S^9,Y*
MKV>1WT^3/[6W55YLOBS>W?8GDR@*%9NNRH4=$D=#\2:R5(48B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(D#*>5JSZ0?^Q9'$
M2>Q$U"[<);).=G39VMJUKFY; =;5UULVDJ'I\1!SZM<.ZUW9GK"0D8*=EH=M
M,)2DDS:5Z.C0<@F]F):/;O3MV*CERE6<G4^FA\J(W?A5L2PTU:*S;CY'CFKR
M^S<PKMMO%CV(EP^G->:[WF"]*UKPUZ8^1P;7= *>1PUO6UCTGV=%K5WZ#:B6
M-73F3[[W16M5&!J1W'4\Z_<;M*[.TOKWM#1^RM12NI'$N]K+B+82G9]TUV>S
MS*+.!F&[B0)!:8G9Z'G3E4,1)>7E5T) I^#1- &J*9C>FLMK;B,]8=18.7Y.
MYJ5NM;VJ[<7$*A6AE]NBMFKL"FMF9RA\^O%1/,5U.O+:'\7-7[)XVE;W1";;
M*M?*LZMI)]^VQ5MK9TL K3W ]9+6V=>X<9XXV/\ H+3^H3RLEE(J0^4E<^B3
MW_)'9G]/\1\_\?\ /_I-3_$O^]_E+CS$VFKLVIW38?:&@>DW22<ZTU=M9LX>
M-6[YHO*(JWZMR(BS<).2+*QK76M845$S<W+WYD9'BL3B3EZBJ6WTLUS-6WL#
MD5\;:EN2L85R<C2[5NCJP-MMK( K,'J+ >04GAZ0O-/_ &@Z,(JN6O53Z>U>
M]3<U#7V\I9RW!Z:DMKLKL1ZL^#&+3Y*C5:*T)9?-1LI&/$Y"-8/TE2K)O&39
MT14G'D5*NB14#EX@ \I@-Q#B >(?B#%%JW4TW*P9;:J[%8?A@Z!@1_0@]B3=
M-+9]%]#J4>FZVID;\JU;LA4_U!'1E=G6<8Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B0,EY9KGTB2]F+XB3V
M(D E\J'_ * B?%_[1FO[_P"S$2?Q$PAVF&[YUV<M]HQ8?Y5_P-;,5B!XE+RR
MZ%,F5XL_$_P/R;]-N?@H!DC<O*J4R8F*,_BUI?D^/30H?.^[*FA3WTU#WHMR
MGH@]-66!Z(/S\$'HSS_JMMB>E_4=G&N:N1JX+EK>/M'0-6^K!?9CL'D&7NO2
MM3CR5E)7[E9>P;MU*;FU;KD.DW0%*CU=N9%H]7DFJ)VL*R;G2;OW3AVZ>(IF
M2$B;ETZ<.EB@!W*RJXJ''R_IQ&K]/\)4ZUH]/$\?0ZTWV:JE>G+54ZUZ;7MM
MOK#(0EUMEEMB]-8[N68^_P#5;+9ZG]0VH]MB7\UR>A++Z$RW.FC9=<C6YJZJ
M:Z+&6P%ZJZ:JT8E:ZT0*HR%ES*",1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$2!E/*U9](/_ &+(XB3V(FFO;K[.5([1^@+=
M"VRG!>I>FPMAN6OH!Q=+11HQQ>F$!((P@RTK5;5372K$55A34:OIYE&GZG,Y
M60Y2N4:SDJF"#;GK+[<U;4T,"6*5:KLPU&NDVU577^U2&HKL90]J+4'06,98
M<=8ANKR7N5QZ-.=](4=,WLBY:U]P5VO6O=S>;(C$?#^+> 4Z'>X_4)[2-:;Z
M05T'*Z,1!Y6H=^G9+TXM5AM=LA:R^):)16!=;0VJXI\*BY=-PA&#B<05>(+J
MN"H.$"HO7/I[WK;B<9JM INY#=HRYNB]E><XN)S/;JN]FH?4V;LVVLYO-VST
M4T%Q798ZSSU5=J<G=[RJ]Z\7BJU:D[KJ?0.0YB^O/GI-CAL]&#1B==0'6BZ^
M\*[+6%3VMC/)L?\ 06G]0GE7+&14A\I*Y]$GO^2.S/Z'^78_Z]?]9J?XE_WO
M\I<>8FTP=86QV^_*0NH"0Q5KU3L:KR)% (87$C&3U(FX-/D4YB*)IQB]Q%0A
MT3E-U2\P@4!(I-"UW<5KI=?(KJSMT>BOLVTZ:;PRD$'S;Z<?/8(!'1'<H[&T
M9_5/%Z*V"4V\5R5+D%EL^KSZ^,TXF1E8$!*OKR>AY=LK*R^/S>FKUE5:!6$7
M#XDD\C&!H&1?$9$CB.)2NNG$#*G*P3*1-H 2,<Z*""1"I$Y>"92DY0#S/IYK
M#PO'I;>NF_/0<>B]:1G6W3AL?'I84* M7[^BP>"@*O72@#H3W?JE$3U!RCUT
M'+3IT#?FH:YM)KR\C57OR@WL2]O>;34WFY+MWVQ+=R_<N901B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$@9+
MRS7/I$E[-7Q$GL1(!+Y4/_0$3[1FL1)_$2R]D1@36N[[#F2!<):EVF,% 3],
M%@?P;YJ*0J<Q>0% 5Y!/S%Y>/-S!PXYWS-X:<[@]%+ZF!_EXV*>_\.NY"Y.K
MW^-Y"@KY"[%KJ*]]>7N46)X]]CKOOKOL=?GL2S>SS*(S6E-<2C<[%1!W7$#)
M'CUR.&QBIKN$0XJ$56 CH.GP?MQ.!VC\'+51-)1$R1*;BE"8_9 SK]-KY+(5
MRVK=2C9.1U9FK%BO8"];5%+E\R:[ELK8*RE1Z#EKQJUIL5]-J[N/XC>ENNDT
M7VIOXG%L2YJFKI*I:MXLI;VU#TM78O:L&.9LLI61B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B0,IY6K/I!_[%D<1)[$3 W:
MD4:)=F_>BKZ E+2S2U5>%7%<A99K RLTFG7WQS1[";?(.F40X<<H$+).VKIN
MR 1<+-7*:9D3UG+GQP6,%)9;\3UGW10M5R[<[4Z+;BEHKSYK0FC0YJM HKL[
MJL_@:QXD>7(Y!YA ;@"WM/<2I!\E6JMD>RQU[2M$=&:QE ="?(>1/N*\O'.Z
M#VDH9EI5EI5S 2%9"3C@VR7<$Y;'T]"3MD<7*S6A/7% *[E)M:557277&5<C
M&]R:(]PBF<8W-ZA_G@</BP2JGE>0R5XTH>JO$,G'\+6U0+L"]K-W;I85DOHL
MMMNOMT66A//LQ_;VL$*YOXK#N?1[HL:]M/)\VB^*+6$JSUUT)7F2NUJUJ %=
M52>)L]6+YL79L"[KT73:9*+H#W1N[<OJPXGF,C%&9QZCJPP\G6)]Z=CX,.Y4
M9EA+-%0TC).F[A=J4T<B1RYI5:UC80G?C3I85-]CK92EQS=O]U%J;[EJK1$M
M6[/2;++T2QJJQ9L$"J/RS6YE#AE%;+:X&A""!;2^2D/:]ME39[7-5--CDV%<
MJ1,E,23NAN9V%6AY5W5EW\LWZK55JQEWC"*5D8A(2.E'9E(]T*B1E%&Y4#E*
M44UU3<X%FZ4JKT::Z+/>HKT6I3;^ME2NZUV?@#]X@#?@?G\"0Z'LLJSO<GA:
M]2O8OB5"NR LOBS,Z^))'BQ)'X))$R'D>2)A3:HDC[9I&PG4,D##9)X4P@<"
M%6+;JI8J\DW4 0'J%,[>-E2$ ./612/Q+R\P3\?;4\A4 #YY//\ '9'L756E
MA_+H*03^/$D?RGG^9\*]OI[4]A04\L: /+I;&WX=>-*V'^L"]BLHZ_C12.NN
MY=5%> +[8$**CM0T#>GY"BY9),TNC8(F&MQ>X'2=..^LTUY]RV%ZJFR6.];O
M43-1(@F\=^5X>[N[F\G5W]BYBY0;:DJ1EVY<G)^6<I;9[U*V;;*C:ZTV&^JY
M#40BW6_0N>I/L>GMOC2HY#@<Y/M7/<_GQVO;PY^H5ZJ_8O:OCJK12K7(*+*'
M6WMVIJR#EW/.QB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$@9+RS7/I$E[,7Q$GL1(!+Y4/\ T!$^T9K$2?Q$
MIW:";IJY;+%YD7#=9!4O$0YDUDS)G+Q#@(<2F$.(#Q#CQ#QYD$J01^001_>#
MV)JZAT92.PRLI'\PP((_X&:N]B3OJ?9;TTSDP:!*1],AVTJ#-1)5,94[-%Y*
M'441$R9W2T@[<KO#)B*9G2BQDA%$4Q&+4E%6OFZLR4UYT]2>HVJ2COVU31S6
MW6"?+[A8_P!1YW!OD6LXZ Z$UQ?5GT]Z,LWMH?<_H/T2NU]7B;6U9_3'&9-'
MRG[MJEMSLE+U]H]2HRD@S:K),Z1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B0,IY6K/I!_[%D<1)[$3S4]TY0WC)ZEI,%H^
M([2\Q+2%T6=S"'95L=)J.QDB1$#(/:^O)S]^:/(,E-;V3P:YL,.5,KN?(@WB
MQ,9BL^3/7W?4?M+(:Q;[=6+D+D;[#C7<+N/JS'=4X/U51S6[UKS=>#6$7/\
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M+<Q>5# BS54JMY,[$D4YZSV _BI!!"JH_())^?!%@IX3@LX=E(*8K;'3P5%
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M,1&(D7+343!-R.IB19QJ"JR;9 [QPDAWATKQZ+5L50Q3.'2PE$$FZ('64$!
MA!X#D?1JS9$6S3?50KNM:&UU3W+&[\:ZPQ!>QNCXH@+-T>@>I*R8M>^QJL>:
M[2Z(UMBTUM9[=2?QVVE0174G8\['*HO8[8=RP_#-QN94R5IFI4:ZY1?(NK+.
MMU4+419-7HMSU^KO6"S,$%R<7"4M.. *4H%*2#=%4!=.H^IY/E %PU-QF*Q+
MULWZT9.16Q6\*SBXZZAJO!QW8-.RSH *HQVAO-+\8^&X4NW)WKS'(U/G>GC,
M%BV<2R,OG:O(\K1H2[W*VZJ?)@K)))+;JBIK-R5^F0M>75D$4U9">=MFS:2L
MDHH#N;DRM44T""Z=B4H$*8J13&0:IMVW/Q,5$HCD[%Q>3$[7HK7;+:ZZ]&[0
M?=UZ!4BHILL('0(124K5*_+[O#OYE9R'-;>11,[LF?!39;9FXW*IIPY3;8UC
M"JGMBQ!<@66M9;X] N0)=F6,J8Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B) R7EFN?2)+V8OB)/8B0*7RH?^@(GVC-8B3V(C$34K1+I9KN3M'0+J04
M.H-Y\/L8HR &3:Q4A'1;5)VD^*(@/>7S1^4[$WY1 Q!7$ *X+D;7II//U94N
M)M_T8XS59G]D@*3R'*9_>]_H!B_M>!K^2OMAN^F$Y<'FU+Z=Y71?2/;_ -/N
M<HS:/?5B:3P_ Z5S^P.S6*VN>P.2/+W/'K[9MKDF=8Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1(&4\K5GT@_\ 8LCB)/8B
M8?[05HG*3HS;UPK-@@JG8:QKBX3L)9[.#4:[7Y.+@GKQG,30/CIL?!T>ND1T
MZ%\<K($DC"[,#<%,K^4MMIPW646K39Y4(MA-(*BW154XK;01G6]D=ESMH_<+
M>U9N!J#@S^+H33R.//92^A;KTK-%?N>=I8]!![0-O3-T&%0-GCW[?W]3SN]S
MV[5>Y-OP-AK?:0M^O7%KG*9'6'4C*%N6M;;:+W5(MA)0]LV([<:E:)4=C#3E
MACW PL4U77=IGCYTR ]Q:=W8^BNII?/:U-35Z\UM=VS(JWG]G\?LR81QRZK;
M_B[5JTKOT^5 6NO)HQ(X9R+;:-&OKNH]RU;L=]%M%.LK77]9RF7;LLY$9Z4^
MZK+CQ:>(R]V]LVE;BS>Y9X#UCC/)L?\ 06G]0GE;)LBY ?\ .2NA_P!DGA_W
M)QW[<S^A_O'_ %FI_B7_ 'O\I<68FT8B8/K3<B.V]TP"S<G<K!!T&T@43  /
M7$A&3E4EP,4H%/\ DFE:A4CJ<3")54R@8.0I0F:T2_C<H<^??UF6Q#V *R4L
M5>Q^C>_;^.NOD_D]REXRZW+ZBY=47VE\.(Y*FX%2S:"NC/<P7KONE<67HGL'
MR _ ZEZZQ5$]"K#<R::*D5&A7U44G@2!45ZTNM7UTA>]5<SA1-:-.18ZJAE^
MJ4Y5P*L"A"^;X!PW#<>@"K]-1]"RK<- 5\#OB=3<&<V,KYV5RS%_,,+ KAE'
MN/4Z]<_RE@9W77I/(H[T_3LZ<FB<A6_L^%8K5DTJR*JBOP*FLLA5C?>7$H8Q
M$8B,1&(C$1B(Q$IGKUG&M',A(.VS!@R05=/'KQ=)LT:MD2"HLX<N%C$10123
M*8ZBJIRD(0!,8P  CG.ZZK/59??;7332C66W6NM=55: L]EECD*B*H+,S$*H
M!)($ZT47:;JL^>JV^^^Q:J:*:VMMMM<A4KKK0,[N[$*J*"S$@ $F8X&Y3EJ(
M*>NHYNJR7;HKM;M8$ERUA0BCCIJ&CF""S:6FCD1(JJATQ8,7!@2#PB1!8BXT
M9Y37R(*\)G1JF1'KY;:KCCRK/XL:*4>O3K*J'9/$TT.0O[\(ZO/1CAL/%,&]
M1Z;$O2QTMX/CWK/**RU^2C3?8EN3"K.52P,+]%8+_P!G-B&N3<71HUJ[-*S+
MI[:ILSD7B<C/'3<I1JQD@2%*OQA2$CH)F4@<A$V2 .E2@4\@]?N@,Y/+S\11
M7:=.JR[D=9L]U;]C"Q<[>/CXXLX HQ5 ? 6E!8WPU]MUO=AAZN=TVU#)AIHX
MG"*O9;-QZM4^I WD'Y'46;3R%Q/RS7V&I#VN>C/5U4MZY:RCC$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B) R7EFN?2)+V:OB)/8B0*0_YT/P_U
M!$C_ +Y&:_9B)/8B,1-8-=JD9=H#;T8+UPF9Z#"3)% 3_%#B9C&"I)"J)_&X
M4!1)$R0$^ 5,#"(<WCB:V Y?C^[G[NX1T6CQ 0C-OL)L+=CMA[X0#H_'SW\S
MKQ58/#<]XYT'T_JBBRS3Y?O/[;P]'A4%Z/2GZ9G+>0!;X ^)L_DN<HQ$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1(&4\K5GT
M@_\ 8LCB)/8B:]=K1[58WLP[_D;S'S$M3F&HKZ]LL;7W$.UFWL,TKD@N_0BW
M-B.G (/3H)G!!6;,$20_ TB!F@+%-6<NZUX7L8LK5Z,+TNKYZ_:U+OS-DN=]
M7]F6JG4*;;CH#4^TC^XCIVC6?#56W<KAII9%LMO6M2_N^/3@JR]T$7AG4LJ&
MEEM#E36Z/TP\7?<G:!J_9MCV%O2N);(@+%K^M0=0>Q=AVSV:MFPMH;/66PIJ
M-EB)]G))>O5<[=[<[&Y&*7<LW+I5VBL+/N:#<Q_4@/GXW0_2E-W(69WI=;V;
M-JXWCN*H6]-#$5VELM]M'LJUE=:V^157%1%"VKZC:F9>U7/QM5B6+[2>]CY#
MD;-'L69^A?6RZ.&X^WZAU1K30]9:POH ]C]@SW:#:.:TTUS2X9>ME5;)RTT$
MVR?S2\4:-8G%PVA)%M%-63E%R=XDF@:3?"X%NW4$Z1'!TTJ0&TER0%(JU>VG
M\2M:M=QR,]G:D+9:E"VH%Z1+7_>$H"9Y]L+T!Y,;<?W,60+6UP&U?%5<DUTE
MFKL[/DZA?; /<RK$KV)9W0S65DT:3!ZNNM-=T<@JDG/*,(D9=J@D"8@#5N[Z
MI4%P<* J00^ 7@!C3=(H71I&9F;,-%HH9ATS4!W%+-W\^1KZ)! ^3\R'0;FJ
MS&]0MQI0W#X^+36ON#I2RCI^_A691^ S#YF0\CR1&(F$'QE(WM"P"PJ<C6S:
MNFHL$N4H M(P5A8R::@GX@8QD6+IT0I.!^4JIC!R@(B,]>FXVP=#RJUUOY=_
M(2RID*]?U8 ]_P!.O[O/V"RKU/G?SZIU</?3[?0^Z^C55:K^78)\:G=>NCUY
M=]C];LH"2<82W0X(,62,9<II=!)J\*XXMIH4)TSMT05UE&:[I_(OU#MUNEP
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ME+7K6+65"Q$[C'6O?EL9G0)<I#I;;2RN._;/O45VWU+Y^/G9359:B>35HS@
M^7ON4=/V_2ZOVCX[;5>H,*X4D*JY@76NM=Z)UO!R+):K/EURJQ&D;5:FKN28
M+*E9R#N==(J)O$UV4=WELV.Z5OBR'A\Z$D7U\OR:V#W[K:V09.)5+J%:JNJN
MJUEL\.OW]@467)6KU(*1@_[9O90/IVXCCRK%*5M6[]H<R7JN*N]QL2DT,RDM
MGK\_&FRQO>:>RL9Y-C_H+3^H3R!)LBI#Y25SZ)/?\D;F?T_Q'_7_ ,?^/G4_
MQ+_O?Y2X\Q-HQ$PELHB#'8VC+"J;IF+:K)5$S<W*4ZEGJ4BX(D?X1"GX^ 3F
M3*;F$IBB8A!'B(6&0LV3D:E'8---[?'?2TWH">_T^;1V?U^ 3\SSW++37ROI
MS78Q5QMUX:?N*AWVX;G\".P&/CE9E![Z*D@?DB?D]:MIN?FWDK(J*UN=+$KO
MZRU0[D5_)Q/3*DZE)1!8'KQJ9%%-$T:44&BB8F*Y*X 0 /(:.!KU[==NB]FP
M[!F:[CZT]H77YO'QMT:$876IXJ%]@%*R._<#]]#Z1E]2VX>/PTY,X3D\#:TH
MY.VSWSGRZ_(M3ERV(::;0[LXTGW+58#VC7\F7;9(%&<K<I IE;H [CU6[(5$
M2';LW29.:/< ARB7E9NB(+E(4O .D  'YLLM^-=F'1C 1?<H9*2R!DJL5>Z'
M\".B*K CA>NOMZE3QN]\/)9>09K7-6A++_%R+;JF;K37YD]^5U365EB?]<DF
M4=&GAL58CI!59)=\D+J*EQ1(NF1.<A'B\1,H=)RBW<)BC),G).59!(_  ,!
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M:4(^GVA^*;GG2((K]UB5>[MRBL0QG2W3;%3!1450325,0_/85\?%.0N\[AG
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MR"0?@R^6<5%QX 5A&L&(!\0,V;=L ?! GB!%,@!\ I2^+_T0 OQ  9&9W?\
MB=F_^)B?\R99)557\5UUH!^/!%7KXZ_U0/T^/[I7YK.D8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$2!DO+-<^D27LQ?$2>Q$@4OE0_] Q/M&:Q$GL1&(FIE
MK1=(=JZG/A\)#'A4*NH1-BKP:F?C_AH@G"LPB!%#"Q(A8F IF_)%-(I1XBJ
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MJN9O<6HHUR5CP9Q8?))]&.V6J9$3VVEM$@8.4W*;6B3*S@TH8%@:/&[QS?\
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M?:Y(4JBW;?XG?,HXK1Z!+1,3",P1,]0;NDD7<E%'9QO5*Z7?L'!6DN14'Z;
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M</ZOY3-&0)?QB(Q$8B,1.)C%(4QSF*0A"B8YS"!2E*4!$QC&$0 I2@ B(B(
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M](/_ &+(XF9/8B,1(Z7\DRGHY[_9E<1.<9Y-C_H+3^H3Q$BY#Y25WZ+/>/\
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M?)Z>X_/:NK1[_*;PH!W\I8->C_5+>TO@F;(C.BV&G%GS9U<>5=2?$R\
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M8B1TOY)E/1SW^S*XB<XSR;'_ $%I_4)XB14A\I*Y]$GO^2._/_?_ (9G]/\
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MDE:LH7*/!QHW9[!77;.U;3\7&2S:W7*5?;%OS<H]WL]B31*WAA.!@4)5:\W
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M$$$@CJ<FS9NS01:M$$6K5NF1%NV;I$10013*!4TD44RE333(4 *0A"E*4
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M@\4BGD"*2$N[:2C(PFCG?> ,#%NJ^SJ$K]WPL9:ZSQSW%S8A%.T\'?R-5)8
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>(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g428534g43v59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g43v59.jpg
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M;IB.L3B)]&+1GV;UO[D3-*SSY>LS0\U>WYLD9E"PP!@# & , 8 P!@# & ,
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M(B.?DH$A!;VG:KY!9G]AE$24JCO_ #JK-REPD[ #2_%M_I>RW\&W\>[]._\
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M,T/-7M^;)&90L, 8 P!@# & , UL=D9] G5GVB\I/YL=X8+3\Y^SY(V3X*C
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M8]Z]:^9$NY^I_(XSLWS =8G$3Z,6C/LWK?W(F:5GGR]9FAYJ]OS9(S*%A@#
M& , 8 P!@&MCLC/H$ZL^T7E)_-CO#!:?G/V?)&R?!48 P!@# & , 8 P!@#
M& , 8 P!@$,^;=&F[=K%E*11F)&E*D'MDFC/'(MS^;TXQ=MW&9024\H=*+*I
MIIHB*8&,8/CAF6EI3Z^E;+UMKZ%)]WJ?U,/]GJD9%;; *B5-91"B*%;*=XC@
M4#$M*R;D$SE#O-U4W"1DU"B8# <IAZ%42,>]_P#I_P#>_LB*_3[/[FRS-<R#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M?LUB_P!E9J\0(X;JA\OJ414(</6/J',18]F , 8 P!@# & , 8 P!@# & ,
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M]M.6,E"J<;.3$\A/R4H3%]/.]_\ PN6+WM+_ ,L9Z?\ ^L7:_P#_ &>]<_\
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MD$>^\6,<2]MH_P#IZ^OFEW^S;V$ ^S\DK?%<->)&U)<VC*1;+'Q-M4S4=V;
MVE?[C8[YL]I2VMC:K[=IY6-!7G:JE3HB\W*ZKI7FV2L:>MM';&:B5DA6EA,W
MU:?CU739;>#]#\>GBNIE6'[0C<UMHFK(N-BM)4#?FT(3DZL^J^W LE/I^JMF
M<;GFM8AYHC8*L[<:Y-EN-@3OZ^POV@8BD<NLH"2LE7I%R@2(6ET'+Z]DTOU>
M^_5?IT^/>7@UYM[<:VJX.;C*:*J&MF?+BI\2X>;7KUN=M*M+7C1>H]Z5Z^72
M\O=CPD/(Q+U>XSFFH>&0J]3-8KU8];3@3<*W7DZF^$;=.F_=O[.9K]?T]74_
MLOR/W-5=E;&4AJ=I_;VR8GC7Q@MAWVJ7\PBC?F-EY.[FU[9H2AL[ULZ#JDS)
M,:M#V*R:ZJZ\]7)&P7Z83H[^_P ZQ"#?8&R>W?MN_9T75[+?9>G]%T14=2<Z
MKMN[8U6KU!<:;+6H21T:SV8UOR=JUEL"V06WM8M+*K=]84ZQ3BUIKX,[U*J4
MR)I-HJ5B5<RNO]A0$I<XR1:I/X\0UM\?8T^J?LZFTO!!CW9EKM5.K99>G4-]
ML26&1:M#0+"22BUDF:Z;@RTD9=1H].HDW4210,@@V45,9T14>X@DLH6T4F]G
M+E7CMO["'OMT6[(\+[_WWX*W_P!UFR(_NE/WO[7 /A?$']YT_98.O<_M=.H?
M)\N7Y(?_ $J_;_R5WGX+^>TU\U[DGO<\_!D"]66<$TQ&%\R>5-DO/'>>H!YK
M\4&:@I^<.ODGB 0XD\;O 0W3H.=UPV?1+H^OA^OL*<\O'?V(V%^G_??_ (5;
M)[W!_P K9@Y(?_2K]O\ R7WGX+^>TCYVC]FM$SV?TY;):J&HUQ';?%LK>O2M
MA,U/'+R7+G3M769.++&QZCN/86>OR;Z(EU$(I9<]>GY.*>1D@V<NF+O&TDVD
M]UX]VYDCOZ>CV?=ZGW$<+UOZ\<?^<'*.Z6^LZNJ,J7COV;=.BT@V#.6;5-(]
M-O*3D[JN;V3;9R2IFLE:\"K&/J$5/KDBFK-RA5M?M9JT)12"1H2"VV\5_P"J
M?AW*,7_/@F^AEZP<^-GZ_>:\K=SL7&&PW-S>>.E=OT;K.5LLO"+U/D+S<?<7
MX*\P=AL5D@&<>1K36<C/OH"N!MES7=F4Z]U2S/X^JQ4/;)\1MX)[>AOQ2W:?
M]NO=U_0EOP4V?>]P<=(.\[+MD%;[F\O6X8J5?0$,E (1R5;VU=*[&0;J+1EY
M<K=S%Q<6S12*95LN6.%@F[1<.TUY.0$/H_YU_7V]Y,'!!"SE)R(Y#Z5GJM&:
M8XA6GD;%340\?S%A@KNTK3:OR#=YY.E#+,2UFR/5UU6W=?"[6*Q:F35(BU,Z
M52> VY+H>CZ1J=5\]1XAQ]&LJLC"NF[%E>[H..[L4_+T124OP\J<Y;IN7*G'
MFZL[0>-N->%<O3Z.%NS74..,?+QK;LK-P]6KP(85T+>2.+.I8&=;.<X-6^4D
MJJVI*-;LE&SDB5*\^N>#6,D7*/9?[";*MF#Q=)PKLES*I-U$6ZBA%E(QCK9L
M]DDTC% YV#-P@Z>%*+=NLDLH0Y?OU\)\+2LA%\<8<E*<4XK"C6Y)R2:5D\Z4
M8-KHIRC*,?.DFDT=;Y';'VOUT7V1[ -:A*%-DXSEKT\B,)1A*2G*BK0H6WJ+
M6[IJG"RQ+DA*,I)J&/#'M+N>MR9[*(?C?/\ +!%M:3282=?=FH9M?+S:CMRK
M4#O6]7GV#Z)1\(#P44X22F89NFX3<OW[)5DDQY)Q)P5PKC2PFM9IT!RH\GR7
M1^]K+52C%9"C+(IG"Q[[6V)NNR334(24G/J[LN[>.V'5*==4N!<SM%C7J+O^
M\85CT=Z+/+E;9+3'9#3\RF['AR[X>/.,<K%KC.-EUU4JHU3A2YX\ZSJI$-V7
M.Q0*=0A3#Z6DB="F, "/?5UD1(O0!$>\H<B9?E.8I0$0XN^%>%TF_P#'.%T3
M?_R>_P"V<W[DWX)G;,>U_M=<HI_9^UM)R2;_ ,216R;2;WEH,8KURDHKTM+J
M7YR[J>]'N\-(;>XUS+N,WIJW3.V+P_T=(V=*.I/(JG,[;IAE8]*WWN++Q#29
M78SLT;56QS)*IT39!8MZX<K5&3M$?(<!DDI249*<5)I22:4DGLI)-)I-==FD
MUOLUN>D:9RG37.RMTV3A7*=4I0G.F4H[RK<X.4).N3Y92A)PDUO%M-,PCIOF
M.]4UF9725=AZ&A;=5<\^7+17?E6MD:^7?ZDY,S53<:BF81.R5J0J,O06LFSK
MUZ%9Y+I:\B6=6BX.OOH5ND5"IE:7I?Y5OZ%NN_N[NG3N[BY&7-SDW8H#8NPH
M^#U!2ZY4>6/#7C.UUY<M?WQ_?H\>6S3@+-K2MHL#/:\'&(3FL8_EE>8*0A6U
M203L,W5*X^\IK[8DM%OPY5TZ_P"F3[]_-YOT]/+[F4HG:"[HJ;-U)[*D>/["
M(\G[0^IHS@U#95;B(J]<*N0D3I:J6J:%K?-AR[BJ[':R!GTI0X>&<V*)F56#
M*+NDDBN<2"-O#?\ T^OJMW[GZ>GZEPZYW[9MV\KN-3N<%C$R-4O/:$ZCFV%:
M?G;0T\SU>ZULQK4E*P;*V7&+)*MV#LH+E+8IY!"3-)NXQVS;/QCVPEI)/T](
MM>_KL7KKQ.)W)S7YW4CD2J:2'4P:3;Z"H=@F7T;!P&A+1I^#G)K<U(BTWS!!
M*S3NZW.TJI.;8BT4[17%*'#51G88Q"(13<B.Y+;T[M]W>GW>K;9^'7]#PU;D
M_<*:FTU_K="$N-!TWR:XZ\*V[*SK6"W;<O5,V%I[4,O"\@RW9*T(,)UHT3V0
ME>Y0#5R50M6O*)<[%^U\?*O7!:X&V_7HMTW^BZM;?IW=/U:]9AS57:2;GFXW
M2'I'C=-L'/(?5G""]UJQ0E;M\)6-82O**Z;;I]A879.8V1-K6B-3=ZTC8Z@N
MF4I25'%ON</5Y09 #)2K@''9M=^SDO9'V>OJ1Y;\DMH:BT7M^:ID[2YO8](T
M+_Z1!M:H[(<,[+.OJI9.+_/6,&IP,-"2%]EH!6E2\1<*V>*@; TGI*KL*=5&
MD7.O:Z[E8F4%MES)=R;KWZ]-G%=>Y=>_K^I.-?E';*-R$N.NT(S73N2O>ZN*
MFHW&VFL1;3UZ+=[,TAM&X>?[?75=B2#,Y'LYK*-U12&,'.5A,UMV%6BS+J>>
M(F0DA3;?QZ)M>_T>.W5OV]%MN8DLO:'<D(IG=WB56T['$U%3=SVBV#)5:[OF
MVR0T1S*DN-$J\H;Q'8\7^R$)LNKQI[57W,PVNZE(L)U(IP.P(M D@Y$\OKZ[
M[?MYEU]NW=UZD\-)\A[=?-W[:T]?JZVJ<E375PDZ,5C".GL%?=>0.R)BF1UU
MK.RHZU6"NSKMFFC%P&RZ+,0=!N^M]AI246K"S]7>P5G>B&MMO^WH73;^_<U[
M245K^:UE^H)C\.<Y,>]>M?,K+N?J?R.,[-\P'6)Q$^C%HS[-ZW]R)FE9Y\O6
M9H>:O;\V2,RA88!IJYJ;2F=:\LS!'\F-O\:VDWQWUL*[O1G!B^<LYR\N(W96
MZ01;W^PQ&F]Q5ZHQ532D%E*!#,&,#,OW=HV"^L#J08DJZ3062W7H[WWR27H[
MMVO;[#8'Q%L2MLX]T.Q+[$MFV%I5Q=7"NQ+UK1?3ENM1R[ M2)I">U>Z@JPZ
MI+\@I^1G@G5;K[EL1L0SB$BUE#L4!#Z-^CU=?CZ?7W/T="26"!@# & :V.R,
M^@3JS[1>4G\V.\,%I^<_9\D;)\%1@# & , 8 P!@# & , 8 P!@# & 0XUG_
M %DY;;UL@?O&]4K=<IK8P_&!!1VE&*NB /R <SV D>G3H(%,H7^)NN672N"\
M6Y?3?W_/VT764GX=/Y[F3'S$7(9:-_J%R WSJL_[IA,NVNR:VC_81*VDCIJ2
M:;8/4!@3\\Q[("@'>*6)5_M%(8P99_BA"7A^!^SN]ZW]3*)I-Q_7=>Y="9N8
MBXP!@# & , MYO4JHSFG%D:5FOM;$[*<KJ?;PT<A-.2J!W5 7E$VQ7RP*%Z%
M."BYN^  !NH  9\2CAKAW&U6[7<;0-%Q];R5)9&L4Z7@U:K>IK::NU"%$<NW
MG72?/=+F6RENDCZ5NLZQ=@5:5=JNI6Z92XNG3K<[*LP*G%[Q=>).UX\'%MN+
MC6N5MM;;LN'/MGS2W+#3ZE;BQI+95JY9R0T@E+1!;#"1DT6*E4.H(2<:62:N
M08R"("()/6H).4^H]Q0O7 /%/Z\H%J<N7MHHU/LCQ[$?L^\=S]9A9AR[@?+4
MY+S(Y7D63E5>(\XI)/\ S:J<[+RU)-UX/CD*H %GTK3<75G>QGU@L]DV@[V0
M\=-7Y]@,:,=K!:]3>V%Y6M/P<53Z94(=;75++;+*S@D[,PL=P?-)IZ2V6^RG
M!LHW$M^SW^_JWU?I+N1UUKYNO&N4*)34',,SEX^'<(UB$27BF%@.JK/,8U4C
M$JC%G-J+K*2[9J9)&2.LJ=X18RAQ$04HVG-1'A82M'U7K@U<K2$TUKD :CUD
MT+ -;(T=,+$VA(H8L6,4A/,7SUE-(L$$$Y1H\=-WQ5T7"I#@5V*HE(@FDTPA
M*;58=C9!.:Q,HJO1$>TGC*,RQZAIILT9HHR@G8%*Q.+XBXF9E*V-U1 "8!:4
M;H?1T.HHM$:9U1%+*M562JL;KNH,5%6:YTU%FBBC6'2,=JLHDD=5N8124.FF
M8Y!,0H@)W?B_>5N3U9K":,Y/,ZXH<L=Y8V-P>'DZA7GYG5NC$0;QMI<F=1RH
MKV..;@"#&;5$TFT1 $F[I,@=W!&[\?T]G@?=WK77+^-M,.^H%)>1%Y=F?W6*
M=U6"<1MP?',F8[RTL5F!VM@=F,BD8SB62=K&,DF(G$2%Z ?ESK/6[U8[AYK^
MD.USQ45 G7<U2!76/!P3M!_"0QU%6!SFBH9\U;/8J.$PLX]VV0<-$45D4SE
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M,F)#$,(&S);U:DNZ44_;Z?[;E(=S73H]B8&8RXP!@# & , 8 P!@# & , 8
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MDE.5^[SIJI*$$Q%$U"& Y#D,)3E$#%$0$!P6GYS]GR1LKP5& , 8 P!@# &
M, 8 P!@# & , AOQ9_R];^15^_SB5@V@XAV2WR_T* 4D5VR93>OY&<TR\3NB
M &[J8].@% ,MG15KPAO[_P#M_/16/?)_KM[O^Y,C,188 P!@$,N.G6B[<WYI
MY3]RT;V%*_5IL'J*6*G2H^4^& ^HQ6[-Y6VPG)ZO$34*<"F+W0RSVE"$O3MR
MOV?QOVE(])2C[5[=O^"9N8BXP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!0+7\UK+]03'X<YR8]Z]
M:^9$NY^I_(XSLWS =8G$3Z,6C/LWK?W(F:5GGR]9FAYJ]OS9(S*%A@&CGEKO
MK5-,YJ6]["<Z6G$3:%?T/JZ@WR/E>*R.UWENA@O&V;=50;6:R0RKQK'0IIN6
M=HMX$B=?E L:;PTC,O&I$8(66^W1-]>_KTV_1=/3WO?]-NILLX<W"8O_ !QU
MU<IZ^S^TI"P#;WP;%LM$-K*3N<?^WEH1AK G1A2;A 0TA#I,%JTDFW;(/*X,
M5)-VS=!XFB00^C?_ 'V_3V=QY=ZZ7N>R]R</=B5UW6&T+QRW-=MHV=I-2,JT
ME)YG;..VZ=#HQ,"DQ@I-H#EDIM_]J%7$@[:I+$KWF<A$S2OG.-!/9->*V^*?
M]C'4_J'DM?=TVN0OC;CJ_P!)3\?9==Q:A'FR)#:=8TY9HYNVL\/",SQ454VE
MMV"ZCV2EHFO.*J4>U2B&;8)A"KM4Y8-]O'Q]'?[GT7A\MRDZ(X@6J@6SBQ.;
M"M%?GV_#;C%:>-.L7,"$@#^]!;S:BAY?9]S9O(]BVK$V-0T;56;:J0KRQQB$
MG;KDL::5;LX,H"6^_;TO=_'I^O?WOX>F5.X-$Z2Y"5EE2M]:@UCNNG1TVVLT
M?5=KT2L;"KC&QLF,E&,YYI"VR+EHUM,M(V8EF#:31;$>H,I.0;)K%1>."*"$
MVNYM>I[?(A!V/$7&PG9[:;A8:/91,/$7?DS%Q45&M4&,=&1L?RIW8T8Q[!DV
M(DV9LF35))LU:MTTT&Z"::21")D*4!,_.?\ /0C9K@J, 8 P!@# & , 8 P!
M@# & , H=GF"5ZMV&?5$H)P<'+3"@FZ 4"1C!P].)NOJ[H%0'KU]73KDI;M)
M>E[>\/HF_ C?PPASQNB8206 WE%FG+)/KF/_ )Q0YI-2'(JH(^LQE4(=)0IA
M_M$,0>O00R]NW.TO0DN_?T(K'S5^N^_O)69C+# & , AEM?_ -7_ "?TML(G
M[F,O;)]K:>.7XJ9G*BH)12CD_P A3*.I>-.!C#W11AAZ]T"";,L?Q5RCZ8OG
M7J]/]_XRC6TD_0^GK?7_ ()FYB+C & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@% M?S6LOU!,?ASG)
MCWKUKYD2[GZG\CC.S?,!UB<1/HQ:,^S>M_<B9I6>?+UF:'FKV_-DC,H6& :B
M>;5QVY&<BF,!#; [0.DZZ#2M.F(\."7'#56TCN[HXO.S65B':UXV9I7;JR!?
M,;2J?L)5*]YG3CQ2N<O.>4'F83H+))K_ $[[^EM=.FVR3]>Y.CB4]E9'C[0G
MDW.[ILTFJI;P<SG(JM1=.W9(>%>K,B@IL.KPD17H:#FTFZ:+<C")K\!&)1Z+
M+R&"AFIDHUJ(?>^[V;M>S?=DCL$# & , UL=D9] G5GVB\I/YL=X8+3\Y^SY
M(V3X*C & , 8 P!@# & , 8 P!@# ,#<GIOS!H;9+P#]P[N"+"$#KT,?]H7[
M."4(4/E'JC(*F, ?(F4YA^* CEZUO./KW]W4K+S7_/277I6$_9S4>MX<Q/#5
M:TROG=$Z=.Z]=QR#U\'3U?\ YQROZQ !'Y1]8CD3>\I/]7\R8]R]1D[*DC &
M , BMS&@0E-+OIINNFUEJ5.0EJAUS*)HK Y:N19."-U#B'>5(Q?NGA$2]X55
M&:?0@F*40R5/\>S[I)Q?M*R[M_!IKWF;]?WV"OM:KLU&R<8N\F*]&33J,;/6
MRSQ@9VU;*.D7+4BIET!:.E_)5?$( $5 ""/4Q>M))IM;/HVNI*>Z7ZK<OK()
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@% M?S6LOU!,?ASG)CWKUKYD2[GZG\CC.S?,!UB<1/HQ:,
M^S>M_<B9I6>?+UF:'FKV_-DC,H6& :N^61[G6>5.J]A4BHSW(>S5_55F7C^-
M=>Y&Z_UN=O2"QFRJOL[84]J'9U^I%0N=8G;#L+2<'+;$<Q]VE:0E41AX6)8+
M6EPVL8E=S71=W>O[[-KU=SZDL>'T5LV&XSZ?9[AGZ]9-A+5;SK,/ZG9E[O6V
MC"=DY";J]=A;PZ21<WAA4:I(P=40NK@@KVXL+^T2JBRDD98X/;?IO[>_VDD\
M$# & , UL=D9] G5GVB\I/YL=X8+3\Y^SY(V3X*C & , 8 P!@# & , 8 P!
M@# (><TEE7NO:?3&IQ!W>=DUN#*0O]HS?N/53&*'K[PD?#' !>G3J<!'U@ #
MEJZ2<O1&+92?<EXM+YDOD$4FR*+=$@)HH))HI)E]12))$ B9"_["D*!0_P!@
M9B+]Q]< 8 P!@$6^8-<L%ITR\B:U"2U@E#6*!7+'0L>[DWQD$5EQ66*U9)++
MBDD!@%0X$[I $!,( .9*FE/=M);/JWL5EYK_ )Z2(/"F)E:5O&:@KA%R56FI
M/7<D2.BK Q=1$@],,Y /@!LT?I(+J]YG'/W)1(00,BS<G*(@BIW<MS3@MGOM
M);M=5W/T]WI12'277INOY\C;%FL91@# & , 8 P!@# & , 8 P!@# & , 8
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M41*8H@("(" YA+G[P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MW2[UX2Z[^_\ G>4BVGROT=WZK^?SH3!S$7& , 8 P!@# & , 8 P!@# & ,
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MB\?TW]!1;Q>[73NW\.[P-HU'V'3-D1!)NES["<8B! 7!LH)'C%4Y>\#>28+
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M%^FH<5?>^_V]_M)=X(& , 8!K8[(SZ!.K/M%Y2?S8[PP6GYS]GR1LGP5& ,
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M%"X=CWP2M)E%H[6MAHCQ0PG\MI6P+<W,FIUZE4096&3L<2V$@]!(1".32 0
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M]9TB ID2!3I1+,I7;L" 0\C)KB*\E(JAZS=YX\.JH0AC&\!#P6Q#>$B0 V.
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MZB<L?',(EBTC(MFVCHY@W2:,F+)!-LT:-D" FB@W02*1-)),A0*0A"@4H!T
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M+JV@W^1U#%LHW;5=J_'C7I==ZKH[USZ;-QW5L$TIPA+H>P^#.T#A#M P/O\
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M[^FWP]!)[! P!@# -;'9&?0)U9]HO*3^;'>&"T_.?L^2-D^"HP!@# & , 8
MP!@&,=J[:J.H*VI8+2['Q5O$1AH5J)#RTZ^*4# T8-S&#XA1,073Q7NM6:9R
MF64 ZB*:MHQ<GLO:_0EXLAM+Z>DCG2-3W'=]B8[9W\V%K#MC>4T/4QO$".BV
M:ABJ(/; V5 IEEEBE256:.DP=2)RD\Z$;,$D88+N2@N6#>[\Z6_?MZ$_#P95
M)M[R]B_G_?W$V"$(F4I"%*0A"E(0A"@4I"%  *4I0  *4H  %*       =,Q
M%S]8!H7YH*2G,KM!=,<2JPN=>CZ%9DV'L]PB J,F]IED6,F4KX [S5R,% #7
MR-$53D.=Q.V&+[H*]XH[7&$\_2.R[4,#2+I8O$_:CF?X+T?+A_YNEZ+?5?+B
M37([-3J_I^B4:M;C6[QC+5/Z-0K(V9=._1/+B=H?VBN%]%SJXYG!O8K@_P#4
M/BG&;WQ]2XBC/%EPWH=R>]5WWC4[M#JNH?-/^FY&ORE5*&+=MO1@(*,K$)%5
MV%;%9Q,*P:QL>V)Z_";-$BI)@8W0!45,!>^LJ;J=94QU5!$YS"/PM&TC3] T
MG3M$TJB.+IVE8>/@85$?_F\?&KC57S2V3G9)1Y[;);SMLE.R;<Y2;]!ZCJ&7
MJV?F:GGVN_,S\F[*R;9?Z[KIN<VEW1BF^6$%M&$%&$4HQ2*OGTS2& , 8 P!
M@# & , AAS%U#*7JJ1=AIM7;S%GA9,HRAHYBF>QOH([1PD"*!DB [DDF;L4%
M CR^,L!5#JMD^B:I3^6?M/\ 9IJ/%_#FG:UPOP_3JFOZ5J$7J$L'$KGKF7I$
M\:ZM54NN*R<^O&R73-84?+6J,Y645[0M4N]>P_C7#X=UG,TW7-7LP=)S\22Q
M%E9$XZ7CZC&ZJ?E+%.7D<65]*LB\E\D&XQA;+\4&L):#I_*W7E:D96J5R-"'
M>2)55*)>3+1<H]511 BLE&M'2L:>*%8@E;G.[D&)G1T$%!9ND4DU!ZF['.&/
MM%\$Z#G:CPYH> M,RLU6SX0XN=NGZAEV5U*-F=@XN19@2TYV1:IG+)S<.63*
MFJ<L;(JKKF<^[1M<['>)]6Q<36-4RWFT8KA#B'A]5Y>)1"=C<,7*NJAE++Y)
M;VQ5.-D*F-DXJ^J<YQ,^M.6"=;<(QNY=9W/6KTYP1\Y"Q6F*^N<O]I5%V5!H
MY43-T,8I8]O+ 4"B7QSB'4>Y<;[1T-"OKP.U'@'BG@/*E)5K/^Z6ZIHMLETE
M;7DQJQKYUMIN,<*G4DMFO*R:W?7%W8Y/5:IY7 W%>A<541CS_=/O$,'4X1?=
M"=$YVU0DMTF\FW#WW3\G'?92&J.S*!?4@5J%N@YTPD!0S1H^3+)(D$.H"YBE
MQ1DFOJZ^IRT2'U#ZO4/3NWAGCW@SC&M6<,\2Z1K$G'GEC8V76LZJ.V_-?IUS
MJS\=;=?\_&K[GX/;K/6^%>).')N&MZ+J&G+FY5=?CS>+.6^VU697SXMW79?Y
M5T^]>*+YSEIQ\_)SD2(=10Y4TTRF.HH<P$(0A $QSG,80*4I2@)C&,( 4 $1
M$ #*SG"N,ISE&$(1E.<YR48PA%-RE*3:48Q2;E)M))-M[$QC*4HQC%RE)J,8
MQ3<I2;V48I;MMMI));M]$1?N_*&LQTH-1UC$O]L7A4QT48VLE47AFBI1 IU'
MTP@DNFLD@)@.L,<1RW3*4Y';Y@("<OG_ (L^T%H&%GOAO@'3<SM(XML<JZL'
M0(SNTO&L34969>J55W0MKI<E.UX,,BB"4X9.7AM.<>VM [)-6R<1:UQ9FXW!
MG#\%&<\K5G&O.N@UO&./@V3KG"=B3C#[U*FR3:E31D+:+M%MHW:FX'"$QR"N
M*L=!^(1RVU=35P:QB'=$ITTY9\BHLBHJD8# 82J3#WN''R>;:"'AEXU1V1]H
M?:;=5J?;3Q/9A:3SQOQ^S[A:Y8V!3LU.%>I9=<[:K+*WO%N,]3R^2;\CJV,U
MR+[5O:!PAP379A=FNAPR=0Y956\7:[7Y;+LW3C*>%CSC7.$9)IKFCA4<T?\
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MH6\LG3)]'97=!MS=->ZYG+>=,6G8YU;7R\V=G7:QJ<=8?9KVJXT-#X\Q%&K
MSYJ%6E\5T]8496%<E#'69D*+<(5*-&9-3CCQHRHV8%4FZ]=+KQ;FV-"VJY>6
M?3\@X!E2=CD157<UTH]?!AIY,GBJ%;MT@]383**MFZ9UHDSQ@B=A'\):5F\H
M])>F/YOU7Z^/CT[F^OH--QV3ZKT/P_3^=WJ1.1F\:2+1L_CW3=\Q>H).F;QH
MLFX:NFRY 41<-UTC'26153,4Z:B9C$.0P&*(@(#F$N>G & , 8 P!@# & ,
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M ![E'AO)T 525GZ(^>',9)NDHL=) 6KI8W=()SH1K]8W>,,;)K":1Z_V5O\
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M..RN\E9.Z*L24;<FW+OCS5SH<94YZ(.H!@# & , 8 P!@# & , 8 P!@# &
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MNO&HBN2C%I3[J<>I1KCZ9-.R>]DYR=YYRD^$, 8 P!@# & , 8 P!@# & ,
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M:LBN$Y1IK2P>><WG2MF;GJ4Z+& , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M/JY2DVWZ%W)))(]^;AKC & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M:JQZ(;5U5IOEBES.4G*4KJSD)\@8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M[QD0<,_5,S+LR+*\F56GZ=Y'&Q<G+U?:YGQ3N@8 P!@# & , 8 P!@# & ,
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M;'W @9O/UTTF,1,(&01,E(,W"8I)B42 )?(FTE)[-K?F77]?,])E7S9VP/\
MC7LV/^&'*#_J[@KT\'[U]!YL[8'_ !KV;'_##E!_U=P.G@_>OH4:QJ]L'7Z]
M/3Q;-V<4H:$AI27+&,=7<H#O9$T:Q7>@Q9D#;9A.Z=BCY.W*!3"990@ 4>O0
M0_#X/WKZ%D:0N_;#;FTMJ';ZR_9\4!;:NL*#LA6B6W5/*)K:J4I>*K%692I6
M5L?;"!F]@KAI08>90,@B9*19N4Q23$HD 2^5-I;O9M;[KK^O=Z3*'FSM@?\
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MA*'3_<-Q-_\ OU_^&"/P?[O@?WR;M@_]=]FO[K\H/^;\#\'^[X%(L+WM@X&
MG)T'W9PR7F6'DY;S<PJG*!1\_P#-S)=YY$S3_:\?$=NO!\!N3H/>64(7IZ\#
M\'^[X%CZ1V!VPNYM,ZEV^>-[/J@FVIK2B[&-1KC3>4+&VTPUVK$79!JMH9#;
M2"TL->&2&)FFPD(*$BT<I"4O=Z ):@FU^)[-K?IZ#)_DW;!_Z[[-?W7Y0?\
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MX29$^]W"%  /;@# /PHFFJF=)4A%4E2&3434*4Z:B9RB4Y#D, E.0Y1$IBF
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MR3)D5(&<A=Y%K,7J1AV7>&/@I&]S#%E,WI_"M6#RZ3#-I*V=:5D&R+D@&2\
M8!8DUK*A6*[U+9,W6(V1OE"93<;2[4X*L,Q5X^S T+964(Y*L46#:QDCHU&P
M(H%(G-H1D:A*%=(QS)- "FP.F-5UBSKW&OT6OQ-B6D;/,)OF;04T8^:O#TLE
M>9N%C1.,7 S5ZDB%DKQ,0C*/DKC)!Y?9'4H[$5A R;@# (X; X?<6MK[ 1VK
MLS0.JK[LALG"HH76V4Z(G;"BWKBIEX)LG(R+==8C6)74579-0$&Z"Z[A8J?B
M.%S*"=VNYM>TR6SU)K2/N2^P65*@&UQ</9&5/.),BE7)-S$6Q@YJPMF_463.
MRS<%%QD%-V1HV1G9F$C8^'DY!U&LFK9(09$P!@$<-B\/N+6WKVAL_:6@=5;"
MV$V;1#)O<;A3HB?GD64 NLYA6*;^1;N%2,HQRY<N&;,!!LBX=.EBI>(Y7,H)
MW:[FU[1!</N+58VJIO* T#JJ*W&K.3MF4V:TIT02ZGL5G;R+6PSAK +<TB,K
M,MI>30D'WC^4N$G[I,Z@E6. AN]MMWMX;]"1^"!@$<-B</N+6W+XAM#:.@=5
M;!V&V;P[-O<;?3HB?GT6=?65<PC)-_(MW"I&48Y<.7#-F40;(N'3I8J7BN5S
M*"=WXLS:\J57D+1 W9] 1+NWU>(L<!7+*X8MU9J#A+>YKSRTQ47(G(+EFPL#
MJI5AQ+M4%")/EH").X*<S% 2"/Y_/>RXL 8!;MGJ57ND>TB;= 1-DC&%AJEM
M9,)IBWD&C6ST6SQ-TID^@@Y(HFE+5>VP,+9(-\4H+QLS%,)!J=-RV24*'\]_
M>6HAIG5C:YJ[!;T6OHVY:>5MJDJFT$I#7->N#35[R$:!_-);VXIIC4]Q=R,2
MVM>IF/659@\&8S 0W,FX P"@6OYK67Z@F/PYSDQ[UZU\R)=S]3^1QG9OF ZQ
M.(GT8M&?9O6_N1,TK//EZS-#S5[?FR1F4+# & , 8 P!@# & , 8 P!@# &
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M1QG9OF ZQ.(GT8M&?9O6_N1,TK//EZS-#S5[?FR1F4+# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ! ! 0$
M$!#H(#ZP$!^4!#^(#@# & , 8 Z!UZ] ZB  (_Q$ Z] Z_W!U'I_=U'^_ &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"@6OYK67Z@F
M/PYSDQ[UZU\R)=S]3^1QG9OF ZQ.(GT8M&?9O6_N1,TK//EZS-#S5[?FR1F4
M+# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@% M?S6LOU!,?ASG)CWKUKYD2[GZG\CC.S?,!?D?M/9\2R:Q
MD5L>^1D<Q1(V91\?;["R9,VZ8=U-!JT;2*:#=%,OJ(DDF0A0]12@&1LO!>Y
M]GIDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5
M,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D
M>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'ID
MV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P
M7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G
M_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5
M=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'
MIDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;
M+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_
M-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV]
M[5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N
M0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5
M,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D
M>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'ID
MV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P
M7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G
M_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5
M=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'
MIDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;
M+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_
M-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV]
M[5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N
M0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5
M,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D
M>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'ID
MV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P
M7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0/PIN#;:I#I*[2
LV*HDH0R:B:EWLQR*$. E.0Y#28E,0Q1$IBF 0, B @(#C9>"]R!CK)!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g428534g47j55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g47j55.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1<(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %NR^6&@X0DE-! 0      !X< 5H  QLE1QP"   "   < E  "E-T97!H
M96X@36$X0DE-!"4      ! B)R.S>.0!+UE6301,F3\].$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  @"4S,P  0 ".$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!$0      !     "   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              7<   (O    !@!G #0 -P!J #4 -0
M  $                          0             "+P   7<
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   7<     4F=H
M=&QO;F<   (O    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   %W     %)G:'1L;VYG   "+P    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$%       !     ,X0DE-! P     #)0    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
M A$#$0 _ /4FM!$F>3W/BGV#S^\I,X^9_*A?:OU[[)M_P?J[Y'[VS;L24OD6
M"BL/VN?+FM@$S[G!G_?D+$RVY+7N-;ZPP F2=9'YOW?]M[%;4+?YM_\ 5/Y$
ME*T_==]_^U+3P=]_^U368[]IY3<W[-8QC"YU>,73J6CT[)VC<QOK!S-__7$V
M1(H &1/E_P!TD5U-.AIX.^__ &J!MI;])T?%WGZ?[W[_ +$"O"R',:,G)<YP
M W"OVM)CW?3]1_\ F[$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                              #_XO__24-#7U!23T9)3$4  0F^S/[^
M'@ (@'!!1$)% A   '!R=')#35E+3&%B( ?0  < &@ % "D -6%C<W!!4%!,
M     $%$0D4                    !  #VU@ !     -,M041"10
M                                                        "F1E
M<V,   #\    =&-P<G0   %P    *W=T<'0   &<    %$$R0C    &P  "B
M!D$R0C(   &P  "B!D$R0C$  *.X  "B!D(R03   47   (XM$(R03$  WYT
M  (XM$(R03( !;<H  (XM&=A;70 !^_<  "0D61E<V,         &E4N4RX@
M5V5B($-O871E9" H4U=/4"D@=C(
M
M            =&5X=     !#;W!Y<FEG:'0@,C P,"!!9&]B92!3>7-T96US
M+"!);F,N  !865H@        M5H  +QG  "2,&UF=#(     ! ,)   !
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MJ&ZI>*J"JXZLG*VKKKNOS+#?L?.S";0@M3BV4;=LN(>YI+K"N^&] ;XAOT/
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MG7-ZYCH?FO9[C2 IFIA\<0  E=-_RJS.KRB"@YMHJN2!F8E^IMJ X';[HQ.
M8V.HGYN )D]3G'^ (SETF@6 3!^AF9:!%P  E(Z  *O?KCV++IJ*J?Z)C8B]
MI>V(&G8QHC"&^V+DGKR&($Z?FZ:%CCC5F2R%2Q\NF*N&1@  DW"  *L2K6J3
MYYFJJ3>1FH?,I3"/A'50H6B-O6(2G?R,44WHFNB+.#A!F&J*HA[*E]>+LP
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M:8QBLF&7IGM[K::5-&H&J223&%?MI/"1743AH3^0-3 ^GE*0*A<^GC:.N
MCL2  )P[MK^B[HO9L=&?DGKZK0^<CVF+J(^9^%=YI%J7UD1]H)*6<"_XG9Z6
MI!<GG6>/J   CEZ  )O(MC:KH(MPL42GI7J8K(*D$VDOJ 2A!5<EH]2>ET0Y
MH B=22_$G/"<)Q<5G*B/FP  C@J  )M*M=>TC(LBL-2OVWI7K .KJVCIIWFH
M,5;?HTNEL$/\GY6DGB^<G(:@,1<5G!>/FP  C<6  )K9M8:]ZXK+L'2X@WH.
MJZ&SMFBLIQNOXU:RHN^MH$/?GSBJIR^1G"^@*1<?F[:/H@  C8Z  )'SQ6-Y
M&((?O])XRW(6NGQXN6&CM6EXZE!QL*=Y4SX+K'-YY"FFJ99Z:@]FJUE["P
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M8H!"N[6=-W!-MD":<U_/L0F8+$ZNK":6<3R5I]"5LBC"I):5O! KI..*[@
MC#B  (]FP-6HE'_\NRJDT' 6M:JAAU^BL&^>WTZ)JY.=!SQ]ISJ<K"BXH^":
M;A!.I :+!@  C!F  (\FP%&P]7_,NJ&LDV_VM1^HRU^-K^.EV$YWJPFD&CQO
MIKRB_RBSHU.;A1!LHT2+&P  B_^  ([4O_"YR7^NNBVTFV_MM)NP+5^'KU&L
M^DY[JG"K7#R IB"G]2C<HLB;H!"PHKB+2   B^N  (2TT)]X\W77REEX@V:N
MQ&]X6U<1OM9X?4:SN9-XVC4'M0AY6"#VLG=YK@?KLME[10  B?F  (1BSY^
M;G6;R7Y_9V9PPXQ^K5;.O=9^1$9QN'1^*339L\Q^4"#VL/Y^GPAGL.I_YP
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MSW5*Q.^B.68WOLR?.U:AN.F<_49<LVZ;N34.KIJ;K2'-JS*6VPJ1JA^')0
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M@EUZ2U5@@D][ CDF@IE[TQ/?A)U\CN ?@J""O<KW@BF!][3=@<6!39W?@7F
MS(8C@4. =&VS@2F 0%0>@3" 'C?N@8. +!)X@R" IMZ$@4J-J\E.@.&+WK-1
M@(>*+YQG@%&(PX34@#*'C&R&@"Z&@5,,@$"%CC;G@(V$XA$\@;*$<]SG@"J8
ME\>D?\65U;&J?W:3.IKJ?T:0U(-\?SR.PFM8?TB,WE((?V2+)#7Z?ZR)X1 K
M@'6'P=M@?SVCDL8D?MB?ZK R?I"<:YF!?FF9)((O?F&6%VHZ?GZ3:%$5?J.0
M\S4A?N*/2@] ?V6*4-H-?H6NK<3:?B"J)*[M?=6EO9A+?;&ACX$5?;"=J6DR
M?<N:&U X??F7"S1>?C*57PY[?H")RMCS??.YZL/(?8ZT@:W:?3ZO,9<\?1BJ
M(( C?1ZE;VAA?3^A)T]\?6>=C#.X?9F;9@W8?<.)7-@0?87%6<+K?1^_#JSR
M?,BXUY90?)FRXW]$?*"M;6>=?,NHE4[:?/>DV3,L?1N@6 U3?2B) M=D?371
M%\(\?-#)YZPP?&["QI6"?#2[]WZ$?#BUS6;W?&6PETY4?)>LEC*Z?+>B3 SH
M?*V(NM'!C5%VDKVUB^MW!JD#BJEW?I-^B8YX"7TQB)=XLF8%A\5Y>DV>ARAZ
M23(XAR5[,0S6B21\>= \B_& Q[Q\BIF /J?:B6-_SI)HB%5_?GP?AVY_5V3[
MAJY_44R4AAY_7#$UAAI_F OLAXN 6L[BBJF+&[LAB5^)G*:LB"N(-Y$OAS"'
M#7KRAEB&$V/BA:F%1DN/A2:$EC!$A2&$1 L>AB2#PLU^B8^5=;FQB$F3%Z4F
MAR60VH_-ABZ.SWFQA6R-"V+'A,R+=DJ<A%&*%2]NA$:)60IKA.R&M\PFB+"?
MVKA7AVR<JZ/.ADZ9GHZ!A5V6PGB$A)B4'F'"A B1T4G @Y./T"ZO@WZ.\0G2
M@^&&I,KVB "J:+<OAKVF:J*JA9ZBB(UHA+">VG>"@^^;;V#3@UB87DC[@NJ5
MXRX'@M"5#0E1@P"&3,GYAW*U&;8WAC&P3J&QA0^KEXQUA""G&G:G@V:B]V 7
M@M*?1TA5@EB<=2U[@CB:20CF@D:&!,DLAP.__[5MA<6Z9Z#?A)^TWHNA@ZFO
MDG7>@N^JPE]G@F:FI$?'@>VC^2T$@;J>< B/@:Z%R<B1AJ[+/;3-A73$V* O
MA$F^>HKJ@TNX:'4U@HZS %[5@@:NM4=*@9.JUBR7@5Z>)@A*@36%F\('EKUU
MA*]9E(IV"YP-DH-VEX?PD*YW-G+XCP=W\UT&C91XRT6YC')YIBL#C$YZC :I
MC/]\G,"\E7U_+*Y3DU!^RYL4D5-^?H<!CXA^4W()C>U^3UP<C(A^;43.BV]^
MF2HGBT-^^@8LBVR %[^.E%>(V*T8DC2'G9G[D#:&=87DCGB%B7#_C.J$QELH
MBY*$+T/QBH&#NBECBDV#N06^B@J#)KYODT&2IZODD2B0F9BYCS>.H83(C7",
MXV_KB_2+9EHPBJB*'$,9B9Z)$2BJB66(YP5?B->#H;U'DF><A:K/D$Z9LI>9
MCF&7 X.5C*J4A6[9BRB205E B>N04D)3B.2.QR@(B*".R@4-A]"#:KP\D;^F
MAJG%CZFB^):0C;R?AX*7C ><2FWPBH>945AMB4"6NT&GB#R4WR=\A_"4.P3(
MAO.#/+M;D3FPIZCICR6L7Y6TC36H+(' BWZD-&TLB@2@F%?&B+V=@T$9AZF;
ME2<+AU68O@2/ACR#%;JDD,^[ :@VCKVV )3YC,JQ#X$$BPZL7FQYB92H,%<H
MB%>DUT"=AT"BW":JAM::) 1@A::"]KH:D'S%NJ>GCFW  Y1;C'BZ4H!@BK:T
M\FOBB3>P3E:GA_NM$D MANRHQ"9(AH&9X@0[A2^"W;+#H'ITPZ%(G8AU3H\\
MFL=UXGQHF#UVC&BQE>EW4U/HD]IX,CVADD5Y#"-GDDEYU %*D%E\NK&PGV!]
MYJ!]G&M]F(Y\F:Q]8WNJER1]46?LE-A]9E,DDM)]G3S;D4!]X2*YD3-^5 $L
MCLQ_W;"[GD:'#I]YFUR%](V/F)N$^7JVEB"$,V<%D]V#G%)0D>&#,3P=D%."
M[B(>D#6#.P$1C6^ N:^\G5.0,9YHFFV.8(QNE[2,MGFWE3"+,V83DOJ)^E%^
MD06(\SMNCWB(.2&5CTJ(LP#ZC$" J:[5G'"9BIUVF9.7!(MREN*4IWBSE&62
M<V4QDAN0@E"VD#..[CK*CJ>-W"$7CFV.+P#FBSV G*WSF\RC")RLF.Z?T8JI
MECB<OG?@D[R9Y61CD7V75T__CXJ5/3HXC?Z4$B"IC;>2X #6BF. D:TRFTVL
MH)OLF&^HP8GHE;>D_G<EDSJA?F.ZD/^>9D]NCPJ;\3G"C6J; B!5C1:5W #(
MB:Z AZR0FNNV:IM0F VQXXE(E5&M=7:%DLZI5F,@D).ERT[FCJ>C2CE9C0"A
M6R ,C)"5JP"]B1N @*P4FIS G9K3E[Z[;XB^E0"V5G7WDGBQHF*?D#FMS4YZ
MCDRK73C\C*ZF91^^C#Z5=@"TB*6 >J0)JI%T.9.?INQTO(*QHWQU3W$%H$5U
M_%YSG4IVQ4J\FJAWHC57F+YX:QM F6MX[   C9Y_$:,PJ99\XY,+I>=\FX(D
MHG!\<W!VGS1\<%W:G#E\ETHBF9M\WC2_EZU]+1K0F#5]F   C&R  *)SJ(J%
MB)(_I.2$A8%LH6:#I&^RGC&"_ET?FSR"B$EYF*."1#0LEK*"*QIMEQF"Q@
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M-([FH:2N$'WTGB.J%6Q(FMJF>EGUE^"CE$:^E4RB#C(1DRZ?=!DFDQ"1 0
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M4X3LK<^*PG3[J:2)8&19I;&(/U+6HAB':$ ]GO*&V"O2G+J&P1(KG@:&R@
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M;(+*JQ>S$7+5IM"N\6(JHK^K?%#<GPFI<SZ>F]2FS2J\F62<Y1(&F>:,,
MA>*  (AVO^5S47GANO5SK6K9MD-T*ULGL<ITS$J*K9YUASB3JA1V1B12J"MV
MMPI8J@=W%P  A@R  (@>OP5[+GFYN@AZU&JNM3QZK%KTL*MZMDI/K&YZ[CA?
MJ-5[0R0TIL=[@0J?J"Y\8@  A;:  (?>O?*"Z7EBN/V!]&I>M":!+EJ6KX^
MM4GVJTR =#@:IZR ;"03I8& E K?IH.!)@  A6N  (>7O.>*F'D!M_6)&VGG
MLR*'U%HLKH&&UTF4JD&&+3?/IIV%U2/RI%N&& L7I0>%40  A2F  (<^O J2
M8'BEMQ:08FF$LD&.IEG K9Z-,TD_J4Z,'#>/I:R+EB/7HU:,/@M*H[F'H@
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M_6V9Q;9S-U]8P']SFE!SNX)T)T">MM]TRR]%LR%U9!L&L?AU:P-OL$UWB0
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MY&U4P)J5D%[WNQ^3CE #M=61]D!/L.Z0["]AK-*1 1P5JJ:0"P7DI^&#^P
M@QV  'L7Q82?=6U'O^J<LU[WNF":1U *M0R89D!;L"6772]YK "7>1Q+J:.3
M(08[ILZ$-P  @QV  'KVQ0:G,&T_OUNC_5[\N<&A+% 6M&&?%$!GKW6>62^-
MJU:<TQQXJ."30 :'I>N$:@  @QR  'K<Q)VO/FT^ON&KDU\)N3BH6U JL\RF
M,T"%KM>DSB^YJK"@11RSJ#&39P;(I4:$E@  @QR  .8?=G!S&- ;=TMS\;F
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M")B.F'-P08>EECQQ:76PE#QRC&*UDFASMTZ2D-5TYSC4C\)U]!ZCD(9VA
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MQI0-DR^:48,*D0Z7WG$DCQJ5AEYWC5J3:$K*B]^1KC68BL60QQPCBO*/D0
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M+HJTH*1WA7K#G<%WZ6GDFQ%X7E?\F)MXYT3=EH)Y>B_JE2IY[16FEM1YW
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MCX<8G"B?SW<5F42=#68YEHJ:=%2=E!6804'_D?R6R2VTD&V6A11AD3B-R
M@4N  )7.GK&KEX:=F[VH3G:2F-*D^66VE@ZAUU0>DY6?44&'D8*>$"U8C^F;
MX!0YD(2-K   @."  )5UGF*T\(8[FVNQ*78BF'BM1F5!E:JIKE.TDRJG#D$O
MD1*E.BT.CWV>=A0"D R-AP  @(N  (R<KS1N 'Y7JWMO%V]=J -P+U]YI,!Q
M2TZ,H;MR:#Q!GS=S=R?-G?=T) TOH+ASQ0  @G^  (PLKCEV07X&JGIVCF\
MINUV\E\:HY5W;$XKH(-W^SOHG?1XC">$G)EXY TZGN)XT0  @<6  (NZK0U^
M77USJ5A]_VY\I<)]NUZ+HFE]HDVGGU9]J#MYG,=]QB<SFU=]W@T_G39^.P
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MIWL%I8JDO6OGH>2ASEOXGF*?(TM*FSF=.3F*F)F<K"7SELN9<@U*ESF(_
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MDG$%LG&#L&+&KCV"\5/*JCB"9D/)II:"%#)RHZ2!\!ZDHF*"%@:VH7^!Y
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M1V_0KRNI5F&$JL&F75)DIH*CZT*0HJVBPS&4GX^?\QYVG<F4F0>@F\6%*
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M"V5?O >(R%? MT6'MDEULJB&VCI1KG.&42F>JT>&217MJJ^&D &1I%6!#P
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M6IFDA@^%MXB0A3Z% ':+A(:$4V-Y@^V#PT]<@WF#23FF@SB"XQ_&@YB"N
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M&I6D@F"S,X1>@7RNZW(\@*FJH%]\@!"F[TO7?Z^D>C;-?UBA>1V>?PV4!P
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M+(P C>*,$'OXC%Z*Z6L(BO:)OUDMB;6(LD8<B+Z'W#%9B!>'4!>PB,:'6
M@ "  )I2CJ"648L_C0:4F'LWBWZ2Q&HUBA20\%A>B-6/1D5MA]2-\3#+ARF-
M31=)AZR,!0  @ "  )FDC>^?@HJ'C%J=,'IYBLV:M6EZB5Z8/5>MB"&6"D35
MAQR46S!>AE>3]!;_AK*/C0  @ "  )D<C6BHS(GUB]BEZ7G<BD2BS6C<B,F?
MMU<2AXB=#T1 AHN;22_FA;V:*1:^A>&/80  @ "  )B]C0BR5HF$BWNN\7E6
MB=RK.6A.B%*GD%:1AP:DE$/5A@2B]B^&A3B?'19KA4B/*   @ "  )#8GN%H
MS(+7G$QJC7/?F@)L-&/$E^]MQ5*'E@MO23_LE(9PL2M*D^AQLQ!LEMYQ+P
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M1W\7EGB1RW !E#R00& *DA^.ND\SD#.-8#TECI^,:BDBC;:,70^+CL")D0
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M9W7>I-9Q1V>MH>=R+%B!GR=S%D@PG*MS_C9GFL-TRR(KFD=U'@B FW1U,0
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MAW+WGYF6SF2XG*B5 E6=F=J3346FEU&1\C1WE3R16R$5E!Z0Z CBDPZ& @
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MZ&E@K=AW&UP"JD=W8$V@INMWPSXHH^QX+2T0H<=XA!CNH>EX5 )>G?EZ6
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M F>QJ2V;.UHRI8:95DO8H@:7HSR4GNR6M2OKG).6=AB[F\:0N0.)EE."9
M@ "  '0NK'ZE%V>TJ+ZC&5HNI/R@T$NXH5V>R3Q[GBF=\ROKF[Z;DQC1FO*0
MR .LE8R"?   @ "  &HROP-FM%W.NT!H#E#CMY9I<$,CM 5JQC0JL.AK]",?
MKSYLH@XAL4AKXP  GP1SL   @ "  &GMOCUN,EW/NCENV%#UMD)OG$-%LG=P
M;C1;KRYQ,2-SK4IQG ZUKNAPY@  G<!X*0  @ "  &G-O.=U9%V=N-IU@%#5
MM,]UN$,FL.UV&311K9!V?".1JXAVK@\<K,AV)@  G(E\(@  @ "  &FHNW)\
M:UUAMV9\'E"'LUU[Z4+RKW=[WC0MK!1[\".3J?)[^ ]GJN)[V   FVA_H0
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MZUTCLQ.?25!1KK6=?$*6JIN<)3/IIPN;;B.QI)28(A!6I(.+#   E[*
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M8*T$=8)GOIIL=G%I[X:^=UIK_7(/>$)M^UQ:>2QO[D53>@]QNRL#>M]S&0>
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MT5^XA MLRDOQ@_)NK#:!A"!P2!QEA6%PY@  @$QVNJ&8@[AM@Y*G@T5O"8*
M@NAP;7$U@I]QOE[#@FMS!$L7@EIT.S7 @GUU.!O(@V]U9@  @ !ZN:"+@=EV
MU9%F@8AWBX%=@3MX*W 2@0-XP%W @-YY54HX@-=YY#4%@/-Z3QLW@9IZ+
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M\XRV>]RC57R.>Z>@:VMW>WF=<EF)>W&:R4:/>X.8PS(?>VV7^1D@>L20_0
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M^X0+B+)^)'3RA\%^-63JAN)^.U.IABY^1T$NA:E^52S+A79^5!*YAJ!^!@
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M]X"7A&6H5W%C@V*E16$_@F*B(5!8@9>?F#Y6@0J>92J;@(Z;-1%Q@$6+RP
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M67<JD+&$!VCXCQB#H5G&C9J#,4FHC$&"R3@%BU&"AR0XBOZ"9PKMBO&![@
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M<&X3H"9DE6"KG>YFH%(@F^=HBD)8FAYJ3C#BF/YKPQR!F<%L/P/?F*%LO@
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MWVKZF7.).%V3ES"(=4\ZE0F'K3_BDR*'!R\9D;F&L1N/D9V'%@2HCG:#)@
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M/V&ZJ1MJCU3]ID9KX4= HZ!M*C@WH6!N4R<_H#%O&Q)QHBUNB@  ERUS:0
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M?5^1HM*-KU+?G^>,LD4ZG1Z+NS:&FKR+&R8[F26+2A*EF:B)H0  D-N
M@ "  &LDI0^6$%]4HB:4]5*<GS.3GT3SG%^2639 F?21LR7IF&&1O!*"F*V,
M@P  D">     @ "  &KPI*&=XU]6H:2<J%*9GIB:]T38FZ*95C8SF1>8SR7\
MEVJ6YQ*JEZF,G@ +CXJ "   @ "  &&SN'Q@B57TM7QB4DFALI!D&#QAK\-E
MPRV[K8QG)1R2K41GN A<KJ1G:P  DUARV   @ "  &$PMY%GVU7'M$]I DF2
ML15J.#QOK@MK9BWEJY]L9!SPJPILN@CQK EL:0  DA=W;@  @ "  &#JM@MN
M[%5WLK]ODDE=KW)P13Q#K%%Q!RW6J<YQIQT4J05QR0E<J:5QG0  D.%[@
M@ "  &"JM&1UV%4EL1IV&4C]K=!V83P$JJMVNBVJJ"!W"QT7IS)W!@FHIWIW
M.   C[]_%@  @ "  &!HLO5\TE3IKZQ\OTB^K%U\K3NYJ31\G"V.II5\HAT9
MI8Y\F0GJI8A]&0  CL&     @ "  & NL=J#\53'KH&#ETBCJR2#*CN;I_&"
MP2UOI4B"@QTEI!""H HGH\R".0  C>.     @ "  %_]L/R+%%2UK8V*?4B8
MJA^)O#N+IN&)""U=I#&(MATKHMZ)( IEHDJ&B   C3.     @ "  %_9L%>2
M1E2RK,N1?DB8J4B0=CN%I?F/B2U+HT&/91T8H>R.O I\H1^'%P  C)R
M@ "  %_!K]V9H%2[K"R8O4BCJ)&7@3N'I326A"U2HFV6+1TSH0&33@J2H"*'
M)@  C "     @ "  ,$39Q5?[:[3:3EBM)OM:SYE8(@B;21G[G-I;OAJ:5VW
M<+ELT4;'<D5O$"S/<R9PW0H$=BIQ%+\@9"5JT:U+9HILA9J.:+]N+(;H:M)O
MRW)&;,]Q8%RH;K%RZT7)<$ET4ROH</%U70EM=&AU:[U)895UIZN&9"!V3ID'
M9GUV\X5S:+-WI7#X:M)X7%N!;-!Y$43*;G!YKRL/;MEZ"@CI<MQZ+;MW7TN
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MPY9Z=Z]ANH8T>%QD='2G>11F^V'P>=-I9TX&>IMKMSB+>V9MOQ[+?#MNTP
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M5I @;>^./G_X;Q.,]V[-<"R+G5R]<46*54F-<DR)-C3;<O*(8QOO<<N(2P
M@ "  )YM:X"9$X\\;,B71W\4;>Z5/VWP;PN3)UON<"Z1-$C<<3>/B#19<<6.
M<1N0<%V-6   @ "  )W$:I:BTXZ*:^.@5WY8;06=D6TU;AV:O%LV;T*8*T@P
M<%*6&3/1<-25'QLZ;S61>@  @ "  )U4:?&LEXX(:SVI<GW!;%2E\FR7;5^B
M:UJE;GV?34>U;XJ= S-6;_^;>!K$;D>2&0  @ "  )A0?Y=>6HI)?W!A1GL8
M?WAC^&J6?YYF=EC8?]=HU47&@"YK#3#E@+YLWA:U@CUM-   @ !V7)=3?1MG
MF(E&?3EII'H!?61KAVF1?9QM35?M?>-N_D3[?D%PCS Y?KUQR18V?[-QNP
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MB8/;=0R4(W2W=7V2?&21=>Z0P5-]=FR/*4%!=N*-X2U:=OR-4Q0Y=GZ+%@
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M4WP=@Z1PHVWM@T)QVUYW@O-R^DW?@KMT"SO8@K%T^B>S@O=UAPV>@^=T[P
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MU7?G?/N91&FP?+>77UIY?&^58DI)?$:3LCC3?#22L26">^:22@S+?">(I@
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MZ6]$BNYVJF'>B?EW5%.%B1-W\4/7B%UX>S*CA_9XYQ[=B$9X[09\AY)YOP
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M36Q2A;Z=RU[JA+B;QE""@Z69HD$V@L*8)3"&@B:7MAV!@:^3\P9]@12$8P
M@ "  '&OF]A<LF7QF?=?0ED[F&!AM$M.EOQC^SP*E=IF!RKBE7UGGA8NEX5G
MQP  DPUIOP  @ !_2G#WF@YDC&5GF$=F;UBTEJ)H0$KAE2-I^#NVD^IK@RJO
MDVYLJQ8PE1=LE  OD+YNM@  @ "  '!/F!-L0F2BEFIMCE@.E,MNS$H_DTUO
M^SLTDA%Q"2I6D8)QRA85DMQQA0!SCG!T,P  @ "  &^3EC%SXV/1E)9TK5<K
MDP=U94F-D8]V$CJ9D%MVJ"GEC\%W"17>D-EVK0"BC&MY1   @ "  &[7E)M[
MD&,7DPQ[XE9QD8)\'4C0D E\0SH2CL]\9REUCC%\?!6<CPY\.@##BJI]I@
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ML%H2I!]>%4WPHB-@94"KH%MBC3'RGP5D:"#GGQ-EB@O[H;ME&@  C91MT@
M@ "  &2SI,QC)UFFHHYD\4V3H&UFL$!LGGMH5C'2G/]IOR#SG-5JB@Q/GOII
M_0  B_MRS   @ "  &0KHNAJ=5D,H+AKN$T9GI1L\3_XG)IN'C%_FQ%O&B#0
MFL%OE0Q]G&QO!@  BGMWH@  @ "  &.=H0=QJUAKGN)R>DQHG,ES/#]UFM%S
M]3$1F4ATC2"0F-YTPPR.FAET50  B11[Y0  @ "  &,.GVYX\%?AG5-Y6$O>
MFSMYK3[CF3]Y[#"TEZEZ)R!-ERUZ,0R.F %Z*@  A]%_G   @ "  &*0GBR
M5E=QG!: 84MUF?B 2#Y\E_. &C!5EDY_^B EE:)_^ R5EAZ $0  AK2
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M?4VZK>)C&T(CJVIDN35_J2YF.B<ZI[UG8!7JJ,]G< /2IK]H40  AZ!VL@
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M+4PIIA*$%D"YHW6#QS1!H0*#;"9TGS2#1Q8=GRV#AP4^FR&">@  @JV
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M?E1\9J&H77^!?9)@8!F!78(M8GR!)G#^9+B XE[H9N& I$N7:-2 =S;H:@.
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M#H=G9Z9_/'@S:5Y_1F?X:OE_.5;&;(A_+$0Y;>U_*# :;IY_'A=2;@9^\
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ML8$G>5)<"7*W>>%?*&+^>H1B$U(!>S%DU#^=>^]G7BL\?,5I6Q#>?E!I8
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MMGM';>.%>FT.;O^%#%W'< F$@DU_<0>#_SOC<=N#F2A;<?^#90]:<Z&"^@
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MXG1H?LIC7V;4?NUEM5@7?QYGYT@+?V!I\C9P?\IKN2)G@(1LR0C?@>ELF@
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M:F]F=1"*WF(,=8F*$%.E=?&)*$0T=EB(73-<=J"'V2!*=CN(#PAR>-B%50
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MYV>LA3YILUL+A.EK9DTCA*%L^3WXA'AN9"T'A*%O?1D A9EOH ).A1-Q-@
M@ "  ')P@S]OWV:A@PAQ&5GV@L=R.$Q*@HQS/CTT@G!T(RQM@HYTRAB<@S9T
ML@)=@PIVS0  @ "  '%]@4)WX&6Y@1UXD5D.@.IY(DM=@+=YF#R9@)-Y_"OH
M@*EZ0AA(@/]Z$P)N@41[P   @ "  '"F?Y!_\F3O?W^ (UA2?U6 )TJU?R&
M##P'?OA_\"NS?NE_Y1@S?O-_Z *-?[U_^   @ "  &_V?CF("V1A?CJ'QE?/
M?@V'/4HK?<J&E#MR?9N&"RLI?7V%U!?W?2J&'0*6?G:!P   @ "  &]I?2:0
M)&/7?2^/<E=%?0".9TFJ?+6-/#KU?'R,8"JD?%&,/!>0>[2+6P*??6J!Q@
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MO%M>C)YN_T]BB\EP*D)EBP5Q/#/LBH!R("-OBIARG0\WB\]R#@  @KQXF@
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M&5BMAB&3?$S+A4V24S_AA$^1!C'C@W.0;B("@NV0*@[;@EV*"P  @ "
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M@4^2E01S6T0PD[=T'#?&DGQTMRH"D:MU+1F4DAQU(0<QD"IUW@  @ !_+@
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M349BJ)A6TCM-IPU9/2[LI>1;:2"&I=E<]PZ7J*-="   H A@?   @ !Q+@
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M8$/*GM-V\#CDG2AW52SKFYYWD1]8FM=WG [8FZEW7@!QD]IZ5   @ "
M@ "  $USGQ-]54-_G8-]HCBKF\]]L"RWFC=]GA\FF5U]C [1F>5]M0"PD@E^
MS@  @ "     @ "  $TDG@.$64-*G'.$<3B!FK:$,BR9F0B#WQ\*F!*#Y ZJ
MF'>#>P"UD)F >P  @ "     @ "  $SQG2F+CT,HFY2+ACADF="+""R&F!"*
MCA\3EO.*KP[9EQZ(1 #=CV> E@  @ "     @ "  *G.6NI3J9FM7<=7?(CS
M8(9;-7=08RQ>S&2H9;IB0U#A:!5EE3O":=UHHR,E:7!JZ0/G>6=LRZ?"5J->
M()@46>!@_H>'7.YCQG8-7]AF>&. 8I]I$$_692)KC3K39N=MT")E9=AO; /(
M>9QQ9Z7<4LQHC99'5E5J<X7[6:=L3'257,9N'&(R7[MOWTZV8EYQD#GE9!AS
M%2&Q8K%T&0.M><IV8J/Y3U-RW91Z4R!SVH0\5J%TU',?6?%UR&#A711VNTV9
M7]!WJ#D!87QX>"$*8 1X^0.5>?)Z]:(R3$!]'9+@4$A]1(*^4_Q]:'&O5VU]
MAE_$6K-]JDR>78A]V#@Z7R%^ 2!Z7<E^'0.!>A1^WZ"P2:2'69&+3=V&L(&1
M4;F%_W"=54Z%3E[#6*F$J4O86XF$'C>870V#LR !6_2#H -P>C""*Y]V1W&1
MBI!X2].0#8">3\^.AV_$4W^-"EWW5O&+JDLG6=B*=C<:6T")CQ^D6G6)E@-B
M>DB"29Z$1:R;I(^C2BZ93'_@3C^6\&\:4?^4JUU757^2GTJ.6&R0WS:;6;F/
ML!]564".U0-6>ER"0IWB1%^EAH\/2/"B27]530F?%6Z;4,Z<%ESK5%.9<DHU
M5S^72#9 6&F6(![^6$22_P-->FN"/)V'8B93@(ZD9&576'[V9I5;!FXZ:+=>
MB%QA:L5AYDE1;*EE%S2S;@9G[1O7;8)IFP  @ !M\)O$7A!==(U>8+%@9'W:
M8R=C-6U"97YEYEN$9[=H=TB2:;9JY#07:P-M 1MG:DUN(   @ !RTYH+6EIG
M68N>74-I9GQ/7_5K7&O,8GYM/%H\9.)O"4=W9OMPO#,K:"UR+AJZ9Y%RSP
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M&H5[46V61':(5,6426:15]N24E6=6K>0DT.,7/J/+3 L77B.?!BY7SF,[0
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M;G]386APUW#^8ZMR)6&A9<9S6%#^9\-T>#\;:6-U@"MQ:>MV11*2;$=V#
M@ !^1XM%7 QXN'WR7K5Y:6^M82!Y_&!@8UEZ=5 096QZYCY'9Q=[42K09VA[
MG1(T:GI[;P  @ "  (H16:"""'S27&J"!VZB7O*!WU]E84:!H$\G8V>!9#V=
M90N!.RI-922!+!'F:/>!.P  @ "  (D95YF+3WOG6GV*GFW%71B)O%Z67W^(
MR$YD8:Z'[3SZ8TN'0BGI8R>&_Q&S9["&0P  @ "  (A<5?:4@GLQ6.V3)VT1
M6Y61CEWL7@*/ZDV_8#:.>SQ;8<Z-<2EO86Z-21&"9JJ*8@  @ "  (?95+J=
MF7JJ5[V;GVR"6F>95EU>7-*7"$U%7P.5%COZ8(^3TRD)7^^3:!$D9>^+EP
M@ "  (4P<9)30'AJ<I96\VJE<[-:>%NE=-A=R4M>=?=@YSF7=PYCNR69=_EE
MUPNZ>L1F @  @ !UPH/';=)<#G<W;S!? VF!<(1ASEJE<<UD<TJ"<P9F[3CA
M=")I)"4+=,AJM@N-=_=JJ@  @ !YX8)P:EUDW772; %G%VA8;8-I,EF-;NYK
M*4F8<$!L_S@C<5YNGB2"<;QOL@ME=8)OB@  @ !]@($.9S-ML'1P:0QO-V<
M:K9PH5B5;$!Q\DB];:YS(C=];LQT*R07;N%TRPM.<UYTLP  @ "  '^Z9')V
M@'-(9G-W8V7<:#YX(E=@:=UXP4?/:UIY5#:D;'AYTR-M;#EZ%0L*<9MZ90
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M_FT$>F)6CV ->P!9]E'7>[!=*4)'?&A@'S#_?4%BKASB?FQD(P2$@.ED[0
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MGF=O;(]]$UK:;<]]6DTR;N)]?CYJ;\Y]G"X <%)]O1KA;XA]P@28>#Q^@@
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M3F"0?\%=(51F@ =?T$<0@%5B4SA#@+EDD"=T@6MF1!+7@OMF7P  @0EJ8@
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MLUO+<[V!VT_V=&N!Q4,+=..!C#3I=3F!8R3W=2^!9!&I==J!B0  @ "
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M8U0MAC%BF$C7AA=DKSPOA@1FEBX%AB1H*1UBAO5H_0FCAU%HZP  @ !S9
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MRU!T>_F%SD5&?!N%>#D&>_&$_2MO>[:$PQN->UJ%&PE2?%R#WP  @ "
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M0$@&C<AF\3THC4MH@3$OC.EIX2-4C0%JT!)*CI-JG0(?BO!LI   @ ![/
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M,T5:A4:)0#JYA/.(O2\0A#B(%"'M@X.(&A'D@QV') +7@;2![   @ "
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MZ#O=EPQJ*3%>EEAK0"6HE=)L"A?[EDQL2PAUE0]LKP  A\9T+P  @ "
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M2GEW]6F]3H]XJEC84EQY7D:<56AZ$#,75F9ZLQP*6--[*@&Q?21]B)5G/:F
M?H=K0M2 ;'B;1XN 7&C#2]R 2U?O3\: /D7W4MZ 0S*14Z" 6!NK5RF J &Z
M?12 Y90*.I:*<89*0 ^)B'>Q10:(IV@!28F'U%<[39.'%45<4*V&>S(N436&
M(1MG5<J&D@'"?0B!,)+U. :4/X5E/<"2=G;Y0NV0Q&=N1YB/-5:Y2[N-UD3<
M3M2,MC'#3QB,&QLQ5*^+RP'(?/V!-)(S-@^=M(2^._*;!W9Q04*8AF<$1@F6
M2U9L2C^48T2E35F2XS&)35Z24!KW4\^/\ '-?/6!.).#6KY-[H5#76%2('9;
M7_U6.69]8HI:+U6!9/E=^T,]9Q=ACR]/:$!DL1:J:75F5   @ !MTI%Y59E7
MF8/56+M:_G4M6[9>2F5_7HUA=E2C83%D>$* 8VIG2BZY9%UIMQ9.9F!JV@
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MGGQ^1P:'#6Z72T2&;5^>3QZ%S4^44GZ%0SY85-2$WRN;5$R$Q!157:*$^@
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M1G>T6UMBWVHM7AQE8UM<8*-GQ4MI8NAJ SH+9*%L#2:Y9))MF0X3:X=MQ0
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MI7'23 J,PV2J3[:+LE9W4OB*G$<G5:J)N#:$5PJ)*R0W5L*)8@TE:<B'-@
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MTVN:7MIIOE[D841KEU$[8W)M6$(794MNZS%M9F5P11Y89=YQ 0<.=!-QS@
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MFF<M4>V1HEJP5/602TTO5X*.XCZ866&-TBZ*692->1Q 6YZ-&0:==-.$>0
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M1E^X8V9OI%.[961P[4;*9Q=R%CBC:&YS(BAM:,-SYQ4;:LESV@$3?BYW'@
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M6EG<>KA0^$X'>XA4@D$#?&17W3)T?4Q:VR&4?H!=#0S,@*!=>   @ !EG0
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MLE0&:1ETI$B^:IQU=#QJ:\=V(B[/;'1VL!\#:]MV_0OT<9EW'P  @ !]TP
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M?$V$?]56BD)Y@&!9<38L@/%<&R@3@;%>21;Q@S-?0P2-A A@;@  @ !M\0
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M"DAS;^=XJ3W$</9Y&C'U<99Y:R2A<9MYGQ2B<B9Y@ 20>$I[<P  @ "
M@ "  %&F;"=_=$?O;<Q_N#U8;O=_L3&H;XE_C21E;U)_B11"<#I_L 1<>**
M)P  @ "     @ "  %$E:C^&\D=O; &&Z3S<;4&&>#$Y;<Z%\R01;62%VQ00
M;J2%N 11>+6"ZP  @ "     @ "  $SOC:!*UT-@C6I.-CC5C8-1:2R]C?]4
M1!Y5CU]65PR D=U6]@  B8I<-   @ !LK0  @ "  $N3B<M1E$(XB>94BS>U
MBA=74"O%BG]9OAV9BYA;; PYC15;U@  ADY@WP  @ !QC@  @ "  $J%A?I8
M9T$<ADM:Z3:\AI1=/"K7AO-?.QS<A]1@A ODB)Y@OP  @U1EN@  @ !VB
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M;#SK> -[T#*]>+Q[^"==>.U\ !GZ>(1[^PIM>F]\K0  @ !_>   @ "
M@ "  $73=-N"O#R'=D2"X#)O=R""GR<Z=SF"2QHD=G*"6PK.>+6"!@  @ "
M    @ "     @ "  $"9F45(JS>RF*U+Y2VCF)1.U"&JF5%1.Q)YG#)24P-2
MF;Y48   A+)?B@  @ !P#0  @ "  #\WE;Q/!#94E8Y1V2PLE9E48B!+ED!6
M9A%NF*%7+P,)E159/P  @:YD0   @ !U 0  @ "  #Y!DA95>#4ZDAE7X2L>
MDCY: A\ZDM=;H!"@E,-<'P+2D,]>+@  @ !I(P  @ !Y=   @ "  #UOCGU;
M_310CI]=]BH8CM5?J1YGCV1@Z __D-=A*@*JC09C.@  @ !N5@  @ !]6
M@ "  #R:BQ1BFC-TBVED)BE$BZUE=!V9C")F2P^GC1!F9P*9B<5HAP  @ !T
M!   @ "     @ "  #O+A_)I73*FB(=J@2B0B.5K:QT&B4)K\0\_B:1KU@*F
MAP-N,   @ !Y.P  @ "     @ "  #L5A2EP*3'TA?YP[R?XAG=Q>1R-AK]Q
MM [GAJYQA@*6A,5T4P  @ !]F   @ "     @ "  #I\@KMW"C%=@\]W?"=V
MA&5WKAPNA)=WJ ZCA$EWD@)N@P)Z*P  @ "     @ "     @ "  #H-@*I^
M)S#G@?9^3R<+@JQ^,1OC@LQ^ 0Z1@EQ^+@*)@8A^_P  @ "     @ "
M@ "     __\  /__  #__P  ;69T,@     $ PD   $
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MN____P"  (  YD]_SG]8S9E_J'[-M-I_F7YYG!1_HWYE@TQ_QGZ%:H5__G[
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MT!N#!*VZN<V".JA8HS*!HZ,MC'N!-IX@=<B [ID47TJ OI/;2.2 KXXZ,KF
MP8?/Y-6#<[WXSOJ"A[=6N+6!O+#BHB^!)JJHBY^ Q*2*=1& @YY57J> 5)?1
M2&F 4Y#9,F" <HC[X]:##LBES@6"),#BM\:!5[E3H4J O['ZBM" 8:J[=&N
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M68L\C0R!W(FG>9^!?X@V9B>!.(;.4N*! X5>/]Z [H/8+9V ]H(>PPZ"I)A
ML4Z!]I6^GN"!99,VB]N \I"P>)6 GHXV94N <8O34CN 48E2/VV 4X:@+6:
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M.*2 MH9O*:Z F(-?J;:#ZJ#'FG:#%9W-BGN"2)J*>>Z!EY<9:3F!#I.C6)B
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ME$A_WX @A5-_KH #==Q_AW_B9=I_>G_+5<=_AG^^1@5_IG^U-J9_\7^L*&N
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MBH7#J(=WB& &FBYX,&,;BOAX[V8#>N)YPFC1:C]ZIFNG66U[HVZ>2.5\O7'
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M,+:!Q'KE)0&!VGS<C.V![WAP@**!GGDN<\&!4'G89FJ!"'IY6)B VGLE2L:
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M<\&%JY*0: *$I9"%6]2#EXXT3YR"LXOF0XN" 8F>.""!7H=>+5F [H4!(^^
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MUX0J++R+VX,^)>"($8)7($2$J(%_8%FB&(ZD5].>KXV'3N*:_XOA1=.7%XH
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M]GPC31YNQGS%/'ERZ7V"+0!W8WY;L$%7JX/$H)=;18-$D&!>O(+!?Y]B+X)
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MSWA!A?E^T&*X>JE^Z&5I;H=_#F@+8<E_06JN5)]_@FUC1V9_VG ].J: 2G-
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MB6;&44R,)&F21G2*KFQ].[&).6^7,8:'R'+9*!2&<'9E( F%/GHC;O:-_FB
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M8IJ%[(G$6+Z% 8BJ3I2#](=51'6#!H83.HJ"283G,4N!GH/2*,.!*H*K(9F
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M?8+&C']8?)J5@%E;^9@W<Y!?695V9DIBTI*&6-!FDH^;2V1JHHRR/HIN[(G
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M6[M]RW[24K)^ 7[[26U^(7\10"1^4'\P-RA^F']?+M!^]'^?)P1_B7_<()V
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MV'O2,]5U2WS8*I!XYGWR(K5\8'\/<%-@:W[29L5CG'\97,=FN7\U4F5IX']
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M3)1[N'> 14)\>WAT/=E]#'EN-GM]EWJ#+VM^,GNR*0A^UGSN(T1_JGXA'K"
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M"7H^3'B+$6'01>J*?&2D/S&)KV>/.'N(K&J?,<F'B6W@*V6&;W%&):^%:G3
M(*B$EWA-'*^#^'NJ2]J(7F?.15.($&HA/JZ'>VR(.!"&J&\(,:*%OW&Y*UR$
MXG2*)<^$%W=B(.R#?7I!'1"#$'SL2T&%[VW'1,:%\6^5/D"%F7%N-\2$]G->
M,7.$.75P*V.#B7>D)?""\7G:(2:"C'P)'6&"3GX#2KR#T'.31$R$('3</>2$
M G8B-X:#BW=[,4R"]7CR*UJ";7J")A*!]WP7(5N!P'V<':2!KG[O2DR" 'DO
M0^>"EWGR/96"KWJ?-U:"7GM8,2V!ZGPR*T6!BWT@)AJ!,GX6(82!&7[Y'=J!
M+'^T2?N ?'ZE0Y>!4G[;/56!G7[F-S&!;'[Y,22!#W\P*U2 RG]\)BB EG_1
M(9J GH ;'@6 Q(!4  #__P  __\  /__  !M9G0Q      ,$(0   0
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ML[MMLZNU>+NEL8#!GZZ$QIBKA,J0J(3.B*:&T8*DC-. I)+3@*22TX"DDM.
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MDK*%P(VQAL&)L(?#AJ^(Q(*NBL6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6
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M-6R,Y41ZA-Y3@X#98HI\U6R/>-)QDW70=95SSWB7<<YZF'#-?)EOS7Z:;LR
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M047_KSU0_K@[6?/$/&'FT4-DV=]#<\C<2H6WT%>5JL=EHJ# <*R9NGFTE+:
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MOKY]HK^]>JC O'FOP;1YL,&P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M9UU:^&M?6/=N8%?W<6%6]G1A5?9V8E3U=V-3]7EC4_1\9%+T?F11](!E4?2
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MM'R5N;1\E;FT?)6YM'R5N;3_E2P._Y4]'O^@/2?_J#LP_[ \-_VX/SSQP41
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M8_\Z)%S_0BA6_TDL4?]/+T[_53%+_UHS2/]>-4;_8C9$_V8W0_]I.$'_;#A
M_W Y/_]S.C[_=SH]_WL[//]^/#K_@SPZ_X8].O^&/3K_ACTZ_X8].O^&/3K_
MACTZ_X8].O^&/3K_ACW_=20&_W8U$/]W0QS_@$HG_X52,_^&63[_A6!(_X%H
M4O]\;UK\=WEB]W.#:/1OC&[Q;)-R[VJ:=>UGH'CL9:5ZZV2J?.IBKWWI8;5^
MZ&"[?^A?PX#G7\N!YE[5@>!@VX'78MZ!U&/?@=1CWX'48]^!U&/?@=1CWX'4
M8]^!U&/?@=1CWX'_=20&_W8U$/]W0QS_@$HG_X52,_^&63[_A6!(_X%H4O]\
M;UK\=WEB]W.#:/1OC&[Q;)-R[VJ:=>UGH'CL9:5ZZV2J?.IBKWWI8;5^Z&"[
M?^A?PX#G7\N!YE[5@>!@VX'78MZ!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!
MU&/?@=1CWX'_=20&_W8U$/]W0QS_@$HG_X52,_^&63[_A6!(_X%H4O]\;UK\
M=WEB]W.#:/1OC&[Q;)-R[VJ:=>UGH'CL9:5ZZV2J?.IBKWWI8;5^Z&"[?^A?
MPX#G7\N!YE[5@>!@VX'78MZ!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?
M@=1CWX'_=B0&_W<U$/]Y0AS_@DDG_X=1,O^(6#W_AU](_X-F4?]^;EK[>7=B
M]W6":?1QBF[Q;9)S[FN9=NQHGWGK9J1[ZF2J?>ECKW_H8K6 YV&\@>=@Q(+F
M7\Z"XU_7@]QAVX/28]V#SV3=@\]DW8//9-V#SV3=@\]DW8//9-V#SV3=@\]D
MW8/_=R0&_W@U$/]\01S_A4@G_XI/,O^,5CW_BUU'_X=D4?^";%K[?'1B]WA_
M:?-TB&_P<)!T[6R7>.MJGGOI9Z1^Z&:J@.=DL(+F8K:#Y6&^A.5@QX7E8-.%
MW6+9A=-DW(7,9=N&R67;ALEEVX;)9=N&R67;ALEEVX;)9=N&R67;ALEEVX;_
M>"0&_W@U$/]^0!O_B$<F_XU.,?^/53S_CEM&_XMB4/^&:5G\@'%B]WM[:?-V
MA7#O<HYU[&Z5>>IKG'WH::. YV:I@N5EL(3D8[>%Y&+ A^-ARX??8M6'U63:
MA\UEV8C&9]F)Q&?8B<1GV(G$9]B)Q&?8B<1GV(G$9]B)Q&?8B<1GV(G_>2,&
M_WDT$/^ /QO_BD8F_Y!-,/^24SO_D5I%_X]@3_^*9UG\A&YA]WYX:?)Y@G#O
M=(MVZW"3>^EMFW_G:J*"Y6>IA.1EL(;C9+F(XF+#B>)BT(K89-B*SF;8BL=G
MUXO :-:,OFG6C+YIUHR^:=:,OFG6C+YIUHR^:=:,OFG6C+YIUHS_>2,&_WHT
M$/^#/AO_C44E_Y-,+_^543K_E%=$_Y)=3O^.95C\B&MA]X)T:?)\?W#N=XAV
MZW.1?.AOF8#F:Z&$Y&BIA^)FL8GA9+N+X&/'C-QCU(S/9M:,QVC5C<!IU(ZZ
M:M2.N&O4CKAKU(ZX:]2.N&O4CKAKU(ZX:]2.N&O4CKAKU([_>B,&_WLT$/^%
M/1K_CT0D_Y9*+O^73CC_EU1"_Y5:3/^285;\CFE?]H=P:/*!>G#M>X5WZG:.
M?.9QEX'C;9^&X&JHB=UGL(S:9KN-UF7'CM%FU(_':-./OVK3D+EKTI&S;-*1
MLFW2D;)MTI&R;=*1LFW2D;)MTI&R;=*1LFW2D;)MTI'_>R,&_WPT$?^(/!K_
MDD,D_YA(+?^:3#?_FE)!_YE82OR77U3VDV9=\(UN9NN'=V_F@(%VX7N+?=QU
MDX/7<9R'TFZDB\]KK([,:;61R6C DL=HSY._:]&3N&S0D[)MT)2M;]"3JV_1
MDZMOT9.K;]&3JV_1DZMOT9.K;]&3JV_1DZMOT9/_?",&_WTT$?^*.QG_E$$C
M_YI&+/^<2S7_G5 __YU62/B;75'QF&-;ZY-K9.2-=6W>AGYUV("'?-%ZCX/,
M=I>)QW*?C<1OIY' ;;"3OFR[E;MKR):V;<^6L&_.EJMPSY:F<<^5I7+/E:5R
MSY6E<L^5I7+/E:5RSY6E<L^5I7+/E:5RSY7_?",&_WTT$?^,.AG_ET B_YQ%
M*_^?233_H$X\^Z%41?2@6D[LG6%8Y9EI8=Z3<VK5C'MTSH6#?<A_BX3">I.*
MOG:;C[ISHY.V<:N6LV^VF+%OPIBM<,V8J'+-F*1SS9B@=,Z7GW3.EY]TSI>?
M=,Z7GW3.EY]TSI>?=,Z7GW3.EY]TSI?_?2,&_W\S$?^..1C_F3\A_YY#*?^A
M1S+_HTPZ^*520_"D6$OHHU]4X9]H7=>8<&C.D7ATQHJ ?<"$B(6Z?X^+M7N7
MD+%WGY2M=:>7JG.QF:=SO9NE<\N;H'7+FIUVS)J:=\V9F7?-F)EWS9B9=\V8
MF7?-F)EWS9B9=\V8F7?-F)EWS9C_?B(&_X R$/^0.!C_FS\@_Z!"*/^D1C#^
MIDLX]*A00.RI5T?DJ5U0W*5F6M"=;FC'E75SOXY]?;F)A(6S@XR,K7^3D:E\
MFY6D>:29H7>MFYYWN9R<=\B<F7C*G)=YRYN5>LR:E'K,F91ZS)F4>LR9E'K,
MF91ZS)F4>LR9E'K,F91ZS)G_?B(&_X(R$/^2-Q?_G#T?_Z% )_^F1"[[J4DU
M\:Q//.FN54/AKUU+U:AD6<NA:V?"F7-SN9-Z?;*-@86LB(F,IH20D:& F):=
M?:":F7RJG)9[MIV4>\2>DGS*G9%]RIR/?<N;CWW,FH]]S)J/?<R:CWW,FH]]
MS)J/?<R:CWW,FH]]S)K_?R(&_X0Q$/^3-A?_GCP>_Z,_)?^H0BSXK4<R[[!-
M.>:T5#_=LUM)T*QB6<:D:F:\G7%RM)=W?*R1?H6FC(:,H(B-D9J%E9:6@IZ:
MDH"GG8]_LIZ-@,&>C(#)GHN RIV*@,N;BH#+FXJ RYN*@,N;BH#+FXJ RYN*
M@,N;BH#+FXJ RYO_?R(&_X4P#_^5-A;_GSL=_Z4])/^K02KUL$4O[+5,-..Z
M5#G8MUE(RZ]A6,&H:&:WH6]RKYMU?*>5?(2@D8.+FHV+D92*DY:/AYN:BX6E
MG8B$L)^&A+Z?A87)GH6$R9V%A,J<A83+FX6$RYN%A,N;A83+FX6$RYN%A,N;
MA83+FX6$RYO_@"(&_X<O#_^7-1;_H#H<_Z<\(OZM/R?SLT0LZ;I+,.&_4C73
MNEA'Q[-?5[RL9F6RI6UQJ9]S>Z&:>H2:EH&+E)*(D8Z/D):)C)F:A(JBG8&*
MK9]_BKN??HK(GG^)R9V B,J<@(C+FX"(RYN B,N;@(C+FX"(RYN B,N;@(C+
MFX"(RYO_@2(&_XDN#_^9-17_HC@;_ZDZ(/NP/23PN$(HYK]**MW#3S3.O59&
MPK9>5K>P962MJ6MPI*1Q>IR?>(.4FWZ*CI>&D(B5CI6"DI:9?I"@G'J/JYYX
MC[B?=Y#)GGF.RIUZC,N;>XS+FWN,RYM[C,N;>XS+FWN,RYM[C,N;>XS+FWN,
MRYO_@2(&_XLM#O^;-!3_I#<9_ZPX'OBT.B'MO4 CY,9)(]?'3#/)P55%O;I<
M5;*T8V.HKFEOGZEO>9:E=H*.H7R)AYV#CX&;BY1\F)28=Y>=FW.6J)UQEK6>
M<);&G7*4RIQTDLN;=9'+FG61RYIUD<N:=9'+FG61RYIUD<N:=9'+FG61RYK_
M@B(&_XTL#?^=-!/_IC08_Z\U&_2X-QSIPSX<X,U%']'+2S+$Q51#N+];4ZVY
M86&BM&AMF:]N=Y"K=("(IWJ'@:2!C7NBB9)UH)&6<)Z;F6V=IIMJG;.<:9[#
MG&N<RYMNF,R:;Y?,F6^7S)EOE\R9;Y?,F6^7S)EOE\R9;Y?,F6^7S)G_@R$&
M_Y K#?^@,Q'_J3(5_;,Q%_"^-!?ERSL5VM0_'<O/23"^R5)"LL194:>_8%^<
MNF9KDK9L=8FR<GZ!KWB%>JQ_BW2JAY!OJ(^3:J>9EF>FI)ADIK&98Z?!F62E
MS9AGH,V8:)_-EVB?S9=HG\V7:)_-EVB?S9=HG\V7:)_-EVB?S9?_A"$&_Y,I
M"_^B, __K2X2^+@L$NO&+Q#@U3@+TMH]',742"ZXSU! K,I83Z#%7EV5P61H
MB[UJ<H.Z<'I[MW:!=+5]AVZSA8MHLHZ/9+&8DF&PHY1>L+"57;&_E5VQT)1@
MJM"48:C0E&&HT)1AJ-"48:C0E&&HT)1AJ-"48:C0E&&HT)3_AB$&_Y<H"O^F
M+ W_L2@.\L F#./0* ?4WS(+R=\^&;W;1RRQUD\]I-%63)G-7%F.R6)EA,9H
M;GO$;W9TP75\;<!\@FB^A(9CO8V)7[R7C%N\HHY9O*^/6+V^CE>^U(Y9MM./
M6K33D%JTTY!:M-.06K33D%JTTY!:M-.06K33D%JTTY#_B"$&_YPG"/^J)PK\
MN"$)Z<H;!=7>( 3)Y3 /ON,]';3A1BRHWDXZG-I52)'66U6&TV%@?-!G:73.
M;G!MS75V9\M\>V++A'Y>RHV"6LJ7A%?*HX95RJ^&5,N^AE/,U894Q-F(5<'9
MB57!V8E5P=F)5<'9B57!V8E5P=F)5<'9B57!V8G_C1T%_Z(E!O^P'P7RPA0#
MV=L. <GF( >]Z"\4LN<Z(J?E0S&;XTH^D.%02H;?5U1\WEY==-UE9&S;;&IF
MVW1O8=I\<US9A'99V8YY5=F8>U/:HWQ1VK!]4-N^?5#<TWQ0U.!^4=#@?U'0
MX']1T.!_4=#@?U'0X']1T.!_4=#@?U'0X'__E1H#_ZD? _NZ$@+4S0L R>8/
M KSM( NP[2X9I>PY)YKK0C6/ZDE!A>E02WOH5U-RZ%U::N=C8&3G:F5?YW)I
M6^=Z;%?G@FY3YXMQ4.>5<D[HGW1,Z*IU2^BU=DKGPW9*Z-UV2^3@=4ODX'5+
MY.!U2^3@=4ODX'5+Y.!U2^3@=4ODX'7_G18!_[$2 =/#"0#'T0H N_(1!*_S
M(0^C\RX=F?,Y*H[S0C:$\TI!>_-227+S5U!I\UQ68_-C6EWS:5Y9\W!A5?-W
M8U+S?V9/\H=G3?"/:4OOF&M*[Z!L2>ZI;4CNLVU'[<!N1NW';D;MQVY&[<=N
M1NW';D;MQVY&[<=N1NW';D;MQV[_IP\ T[H' ,7'!P"ZU@D K?H3!J+Z(A*7
M^B\?C?LZ*X/\0S5Z_4P^<?U116C]5DMA_EM/7/YB4U?^:%94_6]84?MU6D[Z
M?%Q,^8-=2OB*7TCWD6!']IEA1O:@8D7UIV-$]+%D0_2U9$/TM61#]+5D0_2U
M9$/TM61#]+5D0_2U9$/TM636L@0 Q+X& +?,!@"LW D!H/\6")7_)12+_S(?
M@O\\*7G_13)O_THY9_]//U__54-:_UM'5?]A2E+_9TQ/_VQ.3?]R3TO_>%%)
M_WY21_^$4T7_BU1#_Y%50OZ85D']GE= _:980/RI6$#\J5A _*E80/RI6$#\
MJ5A _*E80/RI6$#\J5C&N 0 ML0$ *K3!0">\@T"E/\:"8K_*!.!_S0==_\\
M)6W_0BQE_T<R7?]--E?_4SI3_UD]3_]?/TS_9$%*_VE#2/]N1$;_<T5$_WE&
M0O]^1T'_A$@__XI)/O^02CW_E4L\_YQ,//^?3#S_GTP\_Y],//^?3#S_GTP\
M_Y],//^?3#S_GTRWO , J<L" )S; P"2_Q "B?\="(#_*A!U_S$8:_\X'V+_
M/B1;_T0I5/]*+%#_42],_U<R2?]<,T;_8#5$_V4V0O]I-T'_;C@__W,Y/?]W
M.CS_?#L[_X(\.?^'/3C_C#TW_Y,^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^
M-O^5/C;_E3ZJQ   G-(  (_G @"&_Q$"?/\;!7'_) MH_RL17_\R%U?_.1M1
M_S\>3/]&(4C_32-%_U(E0O]7)T#_6R@^_U\I//]C*CK_9RLY_VLL-_]O+#;_
M="TU_W@N-/]]+C+_@B\Q_X@P,?^*,#'_BC Q_XHP,?^*,#'_BC Q_XHP,?^*
M,#'_BC#_:B0$_VDR"O]L/A3_=D8>_WM-*?]\53/_>ET]_W9F1O]Q;DW_;7E4
M_VJ$6OYFC5_[8Y5B^6&<9?A?HFCW7JAJ]ERM:_5;LVST6KEN\UG!;O-8R6_R
M6-1P[UC@<.E9Y'#C6N9PW%WH<-Q=Z'#<7>APW%WH<-Q=Z'#<7>APW%WH<-Q=
MZ'#_:B0$_VDR"O]L/A3_=D8>_WM-*?]\53/_>ET]_W9F1O]Q;DW_;7E4_VJ$
M6OYFC5_[8Y5B^6&<9?A?HFCW7JAJ]ERM:_5;LVST6KEN\UG!;O-8R6_R6-1P
M[UC@<.E9Y'#C6N9PW%WH<-Q=Z'#<7>APW%WH<-Q=Z'#<7>APW%WH<-Q=Z'#_
M:B,$_VDQ"O]N/A3_=T4>_WQ-*/]^5#/_?%P\_WED1?]S;4[_;WA5_VN"6OUH
MBU_[991C^6*;9O=@H6GV7J=K]5VM;/1<LV[S6KIO\EG!</)9RG'Q6-AQ[%GA
M<>9:Y''@7.=QV%WH<=A>Z''87NAQV%[H<=A>Z''87NAQV%[H<=A>Z''_:R,$
M_VHQ"O]Q/!3_>D,=_X!+*/^!4S+_@%H\_WQB1?]W:D[_<715_VY_6_UJB6#Z
M9I)D^&29:/9AH&OU7Z=M\UZM;_)<LW#R6[IQ\5K#<O!9S7/N6=USZ%KB=.%<
MY7/97N9ST%_G=-!?YW307^=TT%_G=-!?YW307^=TT%_G=-!?YW3_;",$_VLQ
M"O]S.Q3_?4(=_X)*)_^$43+_@UD[_X!@1?][:$W_='%5_W!\6_QLAV'Y:)!F
M]V68:?5CGVSS8:9O\E^L<?%=LW+P7+MT[UO%=>]:T'7J6M]VXESB=MM?Y771
M8.9VRF'E=\IAY7?*8>5WRF'E=\IAY7?*8>5WRF'E=\IAY7?_;2($_VPQ"_]V
M.A3_@$$=_X5()_^(3S'_AU<[_X1>1/]_9DW_>&Y5_W-Y7/QNA&+Y:HUG]F>6
M:_1DGF[R8J5Q\6"L<^]>M'7N7;QV[EO'=^U;UGCE7.!XW%_C>-)@Y'C+8>1Y
MQ&/C>L1CXWK$8^-ZQ&/C>L1CXWK$8^-ZQ&/C>L1CXWK_;B($_VTQ"_]X.!/_
M@S\<_XE')O^+3C#_BU4Y_XA<0_^#8TS_?6M4_W9U7/QR@&+X;8IG]6F4;/-F
MG'#Q8Z1S[V&L=>Y?M'?M7;YY[%S+>NA<W'K>7^%ZTF'C>\IBXGS$8^)]OF7A
M?;UEX7V]9>%]O67A?;UEX7V]9>%]O67A?;UEX7W_;B($_VXP"_][-Q/_ACX<
M_XQ%)?^/3"[_CU,X_XU:0?^(84O_@VE3^GQQ6_=V?&+S<8=H\&V0;>UIF7'J
M9J%UZ&.I>.9ALGKD8+M[XE_'?.!?VGW48N%]RF/@?L-DX'^]9M^ MV??@+=G
MWX"W9]^ MV??@+=GWX"W9]^ MV??@+=GWX#_;R$$_V\P"_]^-A+_B3P;_Y!$
M)/^33"W_DU(V_Y)90/^.8$GYB&92]()N6N]\>6'K=X-HYW*,;N1ME7/@:IUW
MW6>F>MIEKGS68[A^TV+#@-%BTX'*9-^!P67>@KMGW8*U:-V#L&G=@[!IW8.P
M:=V#L&G=@[!IW8.P:=V#L&G=@[!IW8/_<"$$_W(O"_^!-!+_C#L:_Y-#(O^7
M2RO_EU$T_Y97/?J374;SCF1/[HAK6.B"=6#C?']HWG>);MERD733;IEYT&NA
M?<QHJ8#)9K*"QV6]@\5ERX3!9MR$N6C;A;-IVX6N:]N%J6S;A:ELVX6I;-N%
MJ6S;A:ELVX6I;-N%J6S;A:ELVX7_<2$$_W0N"O^$,Q'_CSH9_Y9#(?^:22G_
MFDXR_)I4._686T3NE&)-YX]I5>&)<U[;@GQFTWR%;\UWC77)<I5ZQ6^=?\%L
MI8*^:JV%NVFXA[EIQ(BW:=B(L&O9B*MLV8BG;=F(HV_:AZ-OVH>C;]J'HV_:
MAZ-OVH>C;]J'HV_:AZ-OVH?_<2 $_W8L"O^&,A'_DCH8_YE"(/^<1R?_GDPO
M^)Y2./"=6$#IFE])XI5G4MJ/<%S1AWAFRH&!;\5\B7; =Y!\NW28@+=QH(2T
M;ZF'L6VSB:YLOXJL;,^+J&[7BZ1OV(J@<-B*G7'9B9UQV8F=<=F)G7'9B9UQ
MV8F=<=F)G7'9B9UQV8G_<B $_W@K"O^(,!#_E#D7_YM!'O^?127]H4HM]*)0
M-.RB5CSDH%Q%W)ME3]*3;5S*C'5FPX9];[V!A7:W?(U]LWB4@:YUG(:K<Z6)
MIW&NBZ5PNHVC<,F-H''5C9QSUHR:=-:+EW38BI=TV(J7=-B*EW38BI=TV(J7
M=-B*EW38BI=TV(K_<R $_WHJ"?^++P__ECD6_YT_'/^A0R/ZI$@J\:9.,>BG
M5#CAIUQ U9]B3LN8:UO#D7)FO(MZ;[:%@G>P@8E]JWV1@J9YF8:B=Z&*GW6K
MC9QTMHZ:=,6/F'74CI5VU8V3=]6-DG?6BY)WUHN2=]:+DG?6BY)WUHN2=]:+
MDG?6BY)WUHO_<R $_WPI"?^-+P__F#@5_Y\]&_^D02'WJ$8G[:M,+>6M4C/<
MJED_T*-A3<:<:5J^E7!EMH]W;Z^*?W:IA89]I(&.@I]^EH>;>YZ+EWFHCI1X
MLX^2>,&0D'G3D(]ZU(^.>M6-C'O6C(Q[UHR,>]:,C'O6C(Q[UHR,>]:,C'O6
MC(Q[UHS_=!\$_WXH"?^.+@[_FS@4_Z$\&?^G/Q_TJT0DZJ]**>*S42[6KE<^
MRZ=?3<&@9UJYF6YEL9-U;JJ.?':CBH-]GH:+@IF#DX>4@)N+D'ZECHU]L)"*
M?;V1B7[0D8A^TX^(?M2.AW[5C8=^U8V'?M6-AW[5C8=^U8V'?M6-AW[5C8=^
MU8W_=!\$_X G"/^0+@[_G3<3_Z,Z&/RI/1SQKT(@Y[1()-^W3BS1L54]QZI>
M3+VC95FTG6QDJY=S;J23>G:>CH%\F(N(@I*'D(>.A9F+B8.BCH:"K9"#@KN1
M@H+,D8*"TY""@M2/@H'5C8*!U8V"@=6-@H'5C8*!U8V"@=6-@H'5C8*!U8W_
M=1\$_X(F"/^2+0W_GS82_Z4X%OFL.QKNLS\=Y;E&']J[2RO-M%0\PJY<2[BG
M8UBOH6ICIIQQ;9^7=W68DWY\DI"&@HR-CH>'BI:+@XB@CG^'JY!]A[B1>X?)
MD7R'TY!\AM2/?875C7V%U8U]A=6-?875C7V%U8U]A=6-?875C7V%U8W_=1\$
M_X0E"/^4+0S_H#40_Z@V%/:O.!?KMST8XK]%&=6^22K(N%,[O;%;2K.K8E>J
MIFABH:%O;)F<=722F'Q[C)6#@8:2BX:!D)2+?(Z>CGF-J)!VC+61=(W&D76-
MTY!VB]2/>(G5C7B)U8UXB=6->(G5C7B)U8UXB=6->(G5C7B)U8W_=AX#_X8D
M!_^7+ O_HC(/_ZLS$?*S-1/HO#H3WL4_%]#!2"G$NU$YN;592*ZP8%6EJF=A
MG*9M:Y2B='.-GGIZAIN!@("8B85[EI*)=I2;C7*3IH]OD[.0;I/#D&Z3TX]P
MD=2.<H[5C7*.U8URCM6-<H[5C7*.U8URCM6-<H[5C7*.U8W_=QX#_XDB!_^9
M+ K_I3 -_*XO#N^X,0[DPS<-V<H[%LO%1B>_OU XL[I81ZFU7U2?L&5?EJQK
M:8ZH<G&&I7AX@*)_?GJ?AX-TG8^(;YN9BVR:I(UIFK".9YO CF>;U8YIF-6-
M;)36C&R4UHQLE-:,;)36C&R4UHQLE-:,;)36C&R4UHS_>!X#_XPA!O^=*PC_
MJ"P*^+,J"^J_*PG@S#(&T<XY%<7)126YQ$XVKK]61:.[75*9MF-=D+)I9X>O
M<&^ K'9V>:E]?'.GA(%NI8V%::27B&6CHHICHZZ,8:.^C&"DTHMCH->+99S8
MBF6<V(IEG-B*99S8BF6<V(IEG-B*99S8BF6<V(K_>AT#_X\@!?^@*0?_K"<'
M\K@D!N7') 39U2<%R],W$[_.0R.SRDPTI\540IS!6T^2O6):B;IH9(&W;FQY
MM'1R<[)[>&VP@WUHKXN!8ZZ5A%^MH(9=K:V'6ZV\AUJNT(=<JMJ'7Z7:AU^E
MVH=?I=J'7Z7:AU^EVH=?I=J'7Z7:AU^EVH?_?AH#_Y0?!/^E)@7]L2 $[,$:
M ]_3%P'0W"4$Q-DU$+C502&LT$LQH,Q2/Y7)64R+Q6!7@L-F8'K ;&=SOG-M
M;+QZ<V>[@G=BNHI[7KF4?EJXGX!8N*R!5KF[@56ZSX%6MMZ"6+#=@EBOW8)8
MK]V"6*_=@EBOW8)8K]V"6*_=@EBOW8+_A!<"_YD< O^J'P/UN14"WLT, -#?
M$@#%X"8%N]\V#K#=0!VDV4DMF-51.XW16$B#SUY2>\QE6G/+:V%LR7)G9LAY
M;&''@7!=QHIT6<:4=E;%GWA3QJQY4L:[>E''SWE1Q.-Z4[SB?%.\XGQ3O.)\
M4[SB?%.\XGQ3O.)\4[SB?%.\XGS_BA0!_Y\8 ?^P% '8PPH SM$* ,3E% &Y
MY"8(KN0T$Z3B/R"9X$<MC]Y/.87<5D1[VEU,<]ED5&S7:UIFUG)?8=5Y9%S4
M@F=8U(MJ5=25;5+4H&Y0U*UO3M6\<$W6T&]-U>AP3LSI<D[,Z7).S.ER3LSI
M<D[,Z7).S.ER3LSI<D[,Z7+_DA$!_Z<1 -BY"0#+Q@@ PM4* +?J%@.LZB<,
MHNDT&)CH/B2-YT<P@^9..GKE5$-QY%I*:>1A4&3C:%5?XW!96N-X7%;C@%]3
MXXEB4..39$WDG65+Y*EG2N6V9TGEQF=(YM]G2N#L9TK?[&=*W^QG2M_L9TK?
M[&=*W^QG2M_L9TK?[&?_G T V[$& ,J]!P"_R@< M=H* *KO&06@\"@/EO U
M&XSP/R:"\$<Q>?!..7#O5$!H[UI&8>]@2UWO9T]8[VY25.]U55'P?5=.\(59
M2_"/6TCQF5Q&\:->1/*O7T/RNU]"\\Q@0?/G8$'SZ&!!\^A@0?/H8$'SZ&!!
M\^A@0?/H8$'SZ&#>IP( R[8% +W!!0"RSP< I^H- 9WW' >4^"L2BO@V'('Y
M0"9X^D@O;_I--F?Z4SQ@^EA 6_M?1%;[94=2^VQ)3_QR2TO\>4U(_(%/1?V*
M44/]DU)!_IQ3/_ZF5#W_L54]_KQ6//[-5CS^SE8\_LY6//[.5CS^SE8\_LY6
M//[.5CS^SE;.L ( O;H$ +''! "EU@< F_T0 I'_( F(_RT2@/\Y&W;_/R-M
M_T4J9?]+,%[_4358_U<X4_]=.T__8SY,_VA 2?]N04;_=4-#_WQ$0/^$1CW_
MC$<\_Y1(._^=23K_I4HY_ZU+./^Y2SC_N4LX_[E+./^Y2SC_N4LX_[E+./^Y
M2SC_N4N^M0( L, " *3. P"7W@4 C_\4 H;_(PA]_RX0<_\U&&K_/!YB_T(D
M6_](*%7_3BQ0_U0O3/]:,4C_7S-%_V0U0O]J-C__<#<]_W8Y._]\.CG_@SLX
M_XL\-O^3/37_FCXT_Z$^,_^J/S/_JC\S_ZH_,_^J/S/_JC\S_ZH_,_^J/S/_
MJC^QN@$ H\@  );6  "+] D!@_\6 GG_( 9O_R@,9_\P$E__-Q=8_SX;4O]$
M'TS_2B)(_U D1/]5)D'_6B<^_U\I._]D*CK_:2LX_VXL-O]T+33_>BXS_X$O
M,?^(,##_CS N_Y8Q+?^>,BW_GC(M_YXR+?^>,BW_GC(M_YXR+?^>,BW_GC*D
MP@  EL\  (C?  " _PP!=?\2 FK_& -B_R$'6O\I"U/_,0]-_S@22/\^%4/_
M1!<__TH9//]/&CG_4QLW_U@<-?]<'3/_81XQ_V4?,/]J("[_<" M_W8A*_]\
M(BK_@B,H_X@C)_^0)"?_D"0G_Y D)_^0)"?_D"0G_Y D)_^0)"?_D"3_8"4$
M_ULP!O]A.@W_:D$6_V]*'_]Q4BG_;ULR_VMD.O]G;D'_9'I'_V"$3/]=CE#_
M6I93_UB>5O]7I5C_5:M:_U2Q6_]3MUS_4KY=_E''7OQ1T5_[4.!?^%#I7_-1
M[5_N4_!?Z%3Q7^16\E_D5O)?Y%;R7^16\E_D5O)?Y%;R7^16\E__8"4$_ULP
M!O]B.0W_;$ 6_W%)'_]R42G_<5HR_VUC.O]H;4'_97A'_V&#3?]>C5'_6Y94
M_UF=5_]7I%G_5JI;_U6Q7/]4MUW^4[]>_5+'7_Q1TV#Z4.)@]E'I8/%2[F#K
M5.]@Y5;Q8.%7\F#A5_)@X5?R8.%7\F#A5_)@X5?R8.%7\F#_824$_UPP!O]E
M. W_;C\5_W1''_]U4"C_=%@Q_W!A.O]K:D'_9W9(_V.!3?]@BU+_7915_UJ<
M6/]8HUK_5ZI<_E:P7OU4MU_]4[]@_%/)8?I2UF+X4>1B\U+J8NU4[F+F5N]B
MX%CP8MM8\6/;6/%CVUCQ8]M8\6/;6/%CVUCQ8]M8\6/_8B4$_UTO!O]G-@W_
M<3X5_W=&'O]X3BC_=U8Q_W1?.O]N:$'_:G-(_V9^3O]BB5/_7Y)6_UR;6O]:
MHES^6*E>_5>P8/Q5MV'[5,!B^U/*8_E3VF3U4N9D[U3K9.A6[F3A6.]DV5GP
M9=-:\&;36O!FTUKP9M-:\&;36O!FTUKP9M-:\&;_8B0$_UXO!O]J-0W_=#P5
M_WI$'O]\3"?_>U0P_W=<.?]R94'_;&](_VA[3O]DAE/_8)!8_UV96_Y;H5[]
M6:A@_%BP8OM6N&/Z5<%D^53-9?=3WF;R5.=FZE;K9N)9[F;:6NYGT5OO:,Q<
M\&C,7/!HS%SP:,Q<\&C,7/!HS%SP:,Q<\&C_8R0$_U\N!O]M,PS_=SH4_WU"
M'?^ 2B;_?U(P_WQ;./]W8T'_<&Q(_VQW3_]G@E3_8XU9_6"67/Q=GU_Z6Z=B
M^%FN9/=8MF;U5\!G]%;+:/%5W6CM5NEIXUGL:-I;[6G07.YJR5WN:\5>[FO%
M7NYKQ5[N:\5>[FO%7NYKQ5[N:\5>[FO_9",$_V$M!O]P,@S_>S@4_X% '/^$
M227_A%$N_X%9-_]\84#_=FE(_W!S3_ML?U7X:(E:]F227O-AFV'Q7Z-D\%VK
M9NY;LVCL6KQJZEG':^A9V&OD6>AKVEOK;,]=[6W(7NQNPE_L;KY@[&^^8.QO
MOF#L;[Y@[&^^8.QOOF#L;[Y@[&__92,$_V0K!O]S, S_?C83_X4_&_^)2"3_
MB4\M_X97-O^"7C[\?&9&^'9P3O1Q>U7P;85:[6F.7^IEEV/H8I]FYF"G:>->
MKVOA7;ELX%S$;=Y<TV[97>9NSE[K;\9?ZG&_8>IQNF+I<K9CZ7*V8^ERMF/I
M<K9CZ7*V8^ERMF/I<K9CZ7+_9B,$_V<I!O]W+@O_@C42_XD^&O^-1R+_C4XK
M_XQ5,_R(7#SV@V1%\7QL3>QW=U3H<H%:Y&Z*8.%JDV3=9IMHVF2C:]9BK&[3
M8+5PT%^_<<Y?S7++7^)SQ&'H<[UBZ'2W9.=TLF7G=*]FYW2O9N=TKV;G=*]F
MYW2O9N=TKV;G=*]FYW3_9R($_VHG!?]Z+ K_AC01_XT]&?^112#_DDTH_9%3
M,?:.6CKPB6%"ZH-I2^5^=%/@>'U:VG.&8-1NCV;0:Y=JS&B?;LEFIW''9*]S
MQ&.Y=<)BQG; 8MIWNF3F=[-EY7>N9N5WJFCE=ZAHYG>H:.9WJ&CF=ZAHYG>H
M:.9WJ&CF=ZAHYG?_9R($_VTF!?]]*@K_B300_Y$\%_^51![_ETLF^)92+O&4
M6#;JD%X_Y(IG2-V$<5#5?7E:SWB"8<ISBF?&;Y)LPFR:<+]JHG.\:*IVN6>T
M>+9FP'FT9M!ZL6?C>JMHXWJG:N-ZHVOD>:%KY'FA:^1YH6OD>:%KY'FA:^1Y
MH6OD>:%KY'G_:"$$_V\D!?^ *0G_C#,/_Y0[%O^90QS]FTDC])M/*NR953/E
MEEP[WI%E1=2);5#,@W9:QWU^8<%XAFB]=(YMN'&6<K5NG76Q;*9XKFNO>ZQJ
MNWRJ:<I]J&KA?:-LXGR?;>)\G&[B>YINXWN:;N-[FF[C>YINXWN:;N-[FF[C
M>YINXWO_:2$#_W$C!?^"* G_CS(._Y<[%/^<0AKYGD8@\)],)^B?4B[@G5HV
MUI5A1,V.:D_&B')9OX)Z8KE]@FBT>8INL':2<ZQSFG>H<*)ZI6^K?:)NMGZ@
M;<5_GF[;?YMOX'Z8<.%^EG'A?91QXGR4<>)\E''B?)1QXGR4<>)\E''B?)1Q
MXGS_:2$#_W0B!/^%* C_D3$-_YHZ$O^?/Q?UHD0=[*1*(^2D4"G;H5<USYI?
M0\>3:$^_C'!9N(=W8;*"?VBM?H9NJ7J.<Z1WEGB@=9Y[G7.H?IIRLX"7<<"!
MEG+3@9-SWX"1=.!_D'3@?H]TX7V/=.%]CW3A?8]TX7V/=.%]CW3A?8]TX7W_
M:B$#_W8@!/^')P?_E# ,_YTY$?VB/17RI4$:Z:A''^"J3274I%0TRIU=0L&7
M94ZZD6U8LHMU8:R&?&BG@H-NHG^+=)U\DWB9>9M\E7>E?Y)VKX&0=KV"CG;.
M@HUWWH&+=]^ BGC@?XIXX'Z*>.!^BGC@?HIXX'Z*>.!^BGC@?HIXX'[_:B #
M_W@?!/^))@?_EC +_Y\W#_JD.A/OJ3\7YJU%&MRN2B3/J%,SQJ%<0;V;9$VT
ME6M8K8]R8*>+>6BAAX%NFX.(=)> D'B2?IE\CGRB?XMZK8*(>KJ#AWK+@X9[
MWH*%>]Z!A7O?@(5[X'^%>^!_A7O@?X5[X'^%>^!_A7O@?X5[X'__:R #_WH>
M!/^+)@;_F"\*_Z$U#?>G.!#LK3P3X[)"%M>Q1R/+JU(RP:5:0+B?8DRPF6E7
MJ)1P8*&/=V>;BWYNEHB&<Y&%CGB,@I9\B("?@(1_JH*!?[>#@'_(A'^ W8-_
M?]Z!?W_?@(!^X'^ ?N!_@'[@?X!^X'^ ?N!_@'[@?X!^X'__;" #_WP< _^-
M)0;_FBX)_Z,S"_2J- WIL3D/W[<_$M*T1B+'KE QO:A9/[.B8$NKG6=6HYAN
M7YR4=6>6D'QMD(V#<XN*BWB&B)1\@8:=@'Z$J()[A+6#>83%A'B%W8-YA-Z!
M>H/?@'J"X']Z@N!_>H+@?WJ"X']Z@N!_>H+@?WJ"X'__;1\#_WX; _^/) 7_
MG2P'_J8P"?"N,0OEMC4+V[PY$<ZW12##LD\PN*Q7/J^G7TJFH655GIUL7I>9
M<V:0E7ILBI*!<H60B7> C9%\>XN;?W>*I8)TB;*#<HG"@W**VH-SB=Z!=(??
M@'6&X']UAN!_=8;@?W6&X']UAN!_=8;@?W6&X'__;QX#_X ; _^2(P3_H"L&
M^JDL!^VR+ ?BO#$'U< V$,F[0Q^^MDTNM+!6/*JK74FAIF14F:)J79&><66*
MFWAKA)A_<7^6AG9YDX]Z=9&8?G&0HX%ND*^";)"_@VN1U8)MC]Z!;XW?@'"+
MX']PB^!_<(O@?W"+X']PB^!_<(O@?W"+X'__<1P#_X,9 O^5(0/_HRD%]JTG
M!>BW)@3>PRH#T,,U#L2_01VYNDPMKK54.Z6P6T>;K&)2DZAI6XNE;V.%HG9J
M?I]\;WB<A'1SFHQY;YF6?&N7H7]HEZV 9I>\@668T8!FEM]_:)/@?FJ1X7YJ
MD>%^:I'A?FJ1X7YJD>%^:I'A?FJ1X7[_=1H"_X<8 O^8( /_IB4#\K(@ ^2^
M'@+7R2("RL<S#;[#0!RSOTHKJ;I3.9^V6D66LF%0C:]G686L;6!^J71G>*9Z
M;7*D@G)MHHIV:*&4>62@GWQAGZM^7Z"Z?E^@SGY?G^%]8IOA?6.8XGQCF.)\
M8YCB?&.8XGQCF.)\8YCB?&.8XGS_>!@"_XL7 ?^='0+]JQX"[+@7 =[($0#/
MS1\"Q,PP"[C(/AFMQ4@HH\%1-IB]6$*/N5]-AK9E5G^S:UUXL7)D<J]Y:6RM
M@&YGK(ER8JJ2=5^IG7A<J:IZ6JFY>EFJS'I8J>1Z6Z3D>EVAY'E=H>1Y7:'D
M>5VAY'E=H>1Y7:'D>5VAY'G_?14"_Y 4 ?^A& 'VL10 V<$+ -+/"P#(TAP!
MO-$N";'..Q>FRT8EG,A/,Y'$5C^(P5U)@+]C4GB\:EEQNG!?:[EW9&:W?VEA
MMH=M7;61<%FUG')6M*ET5+2X=%.URW13M>1T5+#G=5:LYW56K.=U5JSG=5:L
MYW56K.=U5JSG=5:LYW7_@Q(!_Y81 /^H$0#9N H SL0) ,?2"@"_V1D!M-@K
M!ZG6.12?TT0BE-!-+XK-5#N!REM$>,AB37'':5-KQ6]99<1V7F##?F)<PH=F
M6,&1:%7!G&M2P:AL4,&W;4_"RFU/PN1L3[WL;E"Y[&]0N>QO4+GL;U"Y[&]0
MN>QO4+GL;U"Y[&__B1 !_YT. -JO" #-NP@ Q,<' +S6"P"SWQH!JM\K!Z#>
M.1*6W4,>C-I+*H+84S5YU5H_<=-A1FK2:$QET6]28-!V5EO0?EI7SX==4\^1
M7U#/G&%.SZEC3,^X8TO0RV-,T.5B2L[R94O(\F9+R/)F2\CR9DO(\F9+R/)F
M2\CR9DO(\F;_D@T WJ8$ ,ZT!@#"OP8 N<P( +#=# "GY1T#GN4M"Y3E.1:*
MY$(@@>-**G?B4#-OX5@[:>!?06/@9D9>WVY*6M]U3E;??5%2WX933]^05DW?
MFU=+X*=82>"U64CAQEE(X=]91]_P64;<]5M&W/5;1MSU6T;<]5M&W/5;1MSU
M6T;<]5OMG 0 T:T$ ,*X!0"WPP4 K=$( *3M$ &;[2 %DNTN#HGL.AB [$,A
M=NQ**F[L4#%FZU8W8.M</%OK9$!7ZVM#4^MR1E#K>DE-[(-+2NR,34CLEDY%
M[:%00^VN44+NO%%![\Q20>_E4D#M\5% [?%10.WQ44#M\5% [?%10.WQ44#M
M\5'4I0  Q+(# +:\ P"KR04 H-@( )?T$P&/]20'A_4Q#W[V.QAT]D(@;/9(
M)V7V3RU>]U4Q6?=;-57W8CA1]V@[3?AO/4KX=C]'^'Y!1/F'0T+YD45 ^IM&
M/OJF1SS[L4@[^[Y).OS/23G\XTDY_.-).?SC23G\XTDY_.-).?SC23G\XTG'
MK0  M[<" *K# @">T 0 D^,) (S]& *$_B<'>_\Q#W+_.!9I_T <8O]&(ES_
M3296_U,J4O]9+4[_7S!*_V4R1_]K-$3_<35!_WDW/_^!.#S_BCHZ_Y,[./^=
M/#;_ISTU_[$^-/^^/C/_RC\S_\H_,__*/S/_RC\S_\H_,__*/S/_RC^XL@
MJKT  )W*  "1V ( B/L- 7__&0)V_R0&;O\M#&;_-1)?_SP76/]#&U/_21Y.
M_T\A2O]5)$;_6R9#_V G0/]F*3[_:RH[_W(K.?]Y+3;_@2XT_XHO,?^4,##_
MG#$N_Z4R+?^O,RS_MS,L_[<S+/^W,RS_MS,L_[<S+/^W,RS_MS.KN   GL4
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M6S/Y=F0Z]7!N0?%L>4CM:(--ZF2,4>=AE57E7YU8XUVE6N%;K5S>6K9>W%G
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M<.ERCG'J<8UQZW",<>MPC''K<(QQZW",<>MPC''K<(QQZW#_8R #_W(; _^
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M6DC%^UI(Q?M:2,7[6DC%^UKWD00 U*(" ,>O! "ZN0, L,0% *?0"0"?X1
MF.$A X_@, F&X#L2?=]$&W7>321NW54K9]Q<,F+;9#==VVL[6=IR/U7:>D-2
MVH-%3MJ-2$S:F$I)VJ5+2-NS3$?<Q$Q&W-Y,1MKM3$38^4]#V/M/0]C[3T/8
M^T]#V/M/0]C[3T/8^T_;F@  RJD" +NS @"PO0, I<D% )O6"0"4Z!0!C.DE
M!(3H,PM[Z#P4<^A$&VOH2R)DYU(H7N=9+5GG8#)5YV@U4N=O.$_G=SM,YX ]
M2>>)/T?HE$%$Z)]"0NFL0T'IND1 ZLU$0.KD1$#H]41 Y_A#0.?X0T#G^$-
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M9F^"\F5P@?-D<('S9'"!\V1P@?-D<('S9'"!\V3_:Q0!_WL2 ?^*$@#_EA(
M[:(0 -ZM#@#0L1D Q; K!;NM.0^RJ40;J:5.)Z"A5C*9G5X[DIID0XN7:TJ&
ME')0@))Y57N/@%IWC8E><HR286Z*G&1KB:AG:8FV:&>)R&AGB>-G:(GR9FF'
M\V5JAO-D:H;S9&J&\V1JAO-D:H;S9&J&\V3_;A(!_WX0 /^-$ #WF@X VZ<*
M -.P"P#*M!8 P+0I!+:Q-PZMKD,:I*I,)9NF53"3HUPYC*!C08:=:4B FG!.
M>YAW4W:6?EAQE(9<;)*08&B1FF-ED*9E8Y"T9F&0QF9AD.%F89#R96..\V1D
MC/1C9(ST8V2,]&-DC/1C9(ST8V2,]&/_<1 !_X(/ /^1#0#>GPD TZH) ,RS
M"0#$N!, NK@F [&V-0RGLT$8GJ]*(Y:L4RZ.J5HWAZ9A/X"D9T9ZH6Y,=9]U
M47"=?%5KG(1:9IJ.76.9F&!?F*1B79BR9%N8PV1;F-YC6YCP8UR5]6)>D_5B
M7I/U8EZ3]6)>D_5B7I/U8EZ3]6+_=0X _X8- .N6" #5HP< S*T( ,6V!P"]
MO!$ M+TC JN[,@JAN3\5F+9(()"S42N(L%@T@*Y?/'JK9D-TJ6Q(;ZAS3FJF
M>E)EI8)68:.,6EVBEEQ:HJ)?5Z&P8%:AP6!5HMQ@5:'O8%:?]U]7G/=?5YSW
M7U><]U]7G/=?5YSW7U><]U__>@P _8L) -J;! #.IP8 Q+ & +RY! "UP0X
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M1<+_3D7"_T[?D   S)\  +^J 0"SLP$ J;T" )_'!0"6T@D CMH2 (C;) *
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M(S+^I"0Q_[$E,/^_)B__SR8N_^,F+O_C)B[_XR8N_^,F+O_C)B[_XR:MK0
MG[<  )+"  "&S0  >=H  '#R" !H_Q$ 8?\: 5K_(P-4_RL$3_\S!DK_.PA&
M_T(+0_])#4#_3PX]_U40.O];$3C_81,U_V@4,_]O%3#_>!8N_X(7+/^-&2K_
MF1HI_Z0:*/^O&R?_NAPF_\<<)O_''";_QQPF_\<<)O_''";_QQRAM   D[\
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MX4^[0.!/QT#>3]A!V4_H0=1/]$/03OY%SD[_1LA0_T;"4?]'P%'_1\!1_T?
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M6GQR_%E\<OQ7?'+]5WQR_5=\<OU7?'+]5WQR_5?_8A0!_W$1 ?]]$0#_B!(
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M5V>#_%=G@_Q79X/\5V>#_%?_; X _WL, /*)"0#9E08 SYX( ,FF" #!JQ
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M-4+.N#9!S\TU0<[H-4#-]3<_R_XY/LO_.3[+_SD^R_\Y/LO_.3[+_SG*E@
MO*(  *^J  "CLP  F+P  (W& P""SP< >-D+ '/>& !NWB8":-XS!6+>/@I=
MWD@/6=Y0%%7>6!=1WF ;3MYG'DO=;R!(WG@C1MZ!)4/>C"=!WI@I/]ZF*C[?
MM2H]X,@J/=_C*CS=\2L[W/LM.MS]+CK<_2XZW/TN.MS]+CK<_2[ GP  L:<
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M+?N^&BS[SQLK^^<;*_OK&RO[ZQLK^^L;*_OK&RO[ZQNHJ@  FK0  (V_  "
MR0  =-,  &?>  !>\@@ 6?X1 %/_&@%._R,"2?\K T7_,P1!_SH%/O]!!CO_
M1P<X_TX(-?]4"3/_6@DQ_V$*+_]I"RS_<@PJ_WT-*/^(#B;_E0\E_Z$0)/^N
M$2/_NA(B_\H2(O_0$B+_T!(B_] 2(O_0$B+_T!*<L@  CKP  (''  !ST0
M9]T  %GC  !3_08 3?\. $C_%@!#_QX!/_\F CK_+0(W_S,#,_\Y S#_/P0N
M_T0$*_]*!2G_4 4G_U8&)/]=!B+_90<@_VX''?]Y"!O_A0@:_Y()&?^>"1C_
MJ D7_[,)%_^W"1?_MPD7_[<)%_^W"1?_MPF0N@  @L4  '30  !GW   6.,
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M2XUC_TJ,9/])BV3_28MD_TF+9/])BV3_28MD_TG_6A,!_V80 /]Q$0#_>A(
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M3'1S_TQT<_],='/_3'1S_TS_8@X _V\, /Q["@#>A@8 U8X( ,^4"0#'F!$
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M0DVCM$-,H\A#3*/D0TNA]$-+H/]$2Z#_1$N@_T1+H/]$2Z#_1$N@_T3C?0
MSXL  ,*6  "WGP  K:8  *.M  "9M0  D+D. (NZ'@&$NBT#?;DY"7>X0Q!Q
MMDP7:[53'6:T6B)BLV$F7K)H*UJQ;RY6L'<R4["!-4^OBSA,KY<Z2JZD/$BN
MLSU'KL<]1Z[C/$:M\SU&J_X^1:O_/T6K_S]%J_\_1:O_/T6K_S_:@P  QY$
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M(#G7[R XU?DB-]3_(S?4_R,WU/\C-]3_(S?4_R.YG   JZ0  )^L  "3M0
MA[X  'O&  !PS@, 9=8' %WC#@!:XQL 5N,G 5+D,@).Y#P$2N1$!D?E30A%
MY54*0N5<#$#E9 X^YFP0.^9V$CGF@!0WYXP5->>9%C3GJ!<RZ+@8,NC,&#'H
MY1@QYO08,>7\&#'E_!@QY?P8,>7\&#'E_!BNH@  H:H  )2S  "(O0  >\8
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M!1'_O 41_[P%$?^\!1'_O 6,N   ?<(  &_,  !BV   5-\  $?E   ^\0
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M.:-3_SFB4_\YH53_.*%4_SBA5/\XH53_.*%4_SC_3Q0!_UD0 /]C$@#_:A0
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M$0#9?1@ SGTJ L5[.0:^=T4.MW10%;%P61RM;6(BJ&II)Z5H<2RA9G@OGF2
M,YMBAS:888\XEF"8.Y-?H3V17JL_CUZX0(U>R$&+7N%!BE_S0(E?_S^)8/\^
MB&#_/HA@_SV(8/\]B&#_/8A@_SW_5P\ _V(, /]L# #X= P Z7H, -Y^# #2
M@14 R($G <!_-@:X?$(-LGA-%:QU5ANG<E\BHF]F)YYL;BR;:G4PEVA\,Y1G
MA#:198PYCF25/(QCGCZ)8JA AV*U0H5BQ4*$8MY#@V/Q0H)C_4&"9/] @F3_
M/X)D_S^"9/\_@F3_/X)D_S__60X _V0+ /]N"@#J=P@ VWT( -2""@#,A!(
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M/7EPED!V;Z%"=&ZN1')NO45P;M%%<&_K1'!O^D-Q;_]!<6__0'%P_T!Q</]
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M05N$M$):A,=#6H3C0EJ#]$%;@_] 6X/_0%N#_S];@_\_6X/_/UN#_S__:@
MWG@  ,V#  #"C   N9,  +"8  "GG0( H)\2 )F?(P&3GC$%C)T\"X6;1A)_
MF4X8>I=6'G6672-PE&,H;))J+&B1<3!ED'DT88Z"-UZ-C#I:C)<]6(RD/U:+
MLD!4B\5 5(OA0%2*\S]5BOX_58G_/E6)_SY5B?\^58G_/E6)_S[O;P  UGP
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M,D2H[S)#I_LS0Z;_,T.E_S1#I?\T0Z7_-$.E_S30@0  P8X  +68  "IGP
MGJ4  ).L  "(L@  ?+D" ':Z$0!RNR$ ;KLN FB[.@9DND,*7[I,#ENY4Q)7
MN%H65+AA&5&W:1Q.MW$?2[9Z(DBVA"5%MI G0[6=*4&UK"I MKXJ/[;8*C^T
M[BH^L_HL/;+_+3VQ_RT]L?\M/;'_+3VQ_RW'B0  N94  *R=  "AI   EJL
M (JR  !_N   <[\# &K$# !GQ1H 8\4H 5_%-0-;Q3\%5\5("53$4 Q0Q%@/
M3<1?$DK#9A5(PVX71<-X&D+#@AQ PXX>/L.<'SS#JR [P[PA.L/5(3O"[B$Y
MP/DB.+__)#B__R0XO_\D.+__)#B__R2]D0  L)L  *2B  "8J@  C+$  ("Y
M  !UOP  :L8$ %[," !9SQ( 5] A %70+@%1T#D"3M!#!$O03 9)T%,(1M!;
M"T/08PU!T&L//M!U$3S1@!,ZT8P4.-&:%C;1J1<UT;L7--+2%S70[!8TS_<8
M,\[_&C/._QHSSO\:,\[_&C/._QJSF0  IJ$  )JI  ".L0  @;D  '7   !J
MQP  7LT# %34" !,W0T 2MT8 $C>)@!&WC(!1-\\ D+?10,_WTT$/>!5!3O@
M708YX&8(-^!O"37A>@HSX88,,>&4#3#BHPXNXK,.+N/'#BWCXPXMX/(.+-_[
M#RS?_1 LW_T0+-_]$"S?_1"HH   G*<  (^P  "#N   =L$  &K)  !>SP
M4]4! $G<!@!%Z0\ 0ND9 $#J)  ]ZBX .NLV 3CL/@$V[$8",^U- S'M50,O
M[ET$+>YE!2ON< 4I[WL&*.^)!R;PEP<E\*<()/&X""/QS @B\N4((O#S""+O
M]0@B[_4((N_U""+O]0B>I@  D:\  (2X  !WP0  :LD  %W0  !1UP  1MT
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M(\!!_R2^0?\DO4'_);U!_R6]0?\EO4'_);U!_R7_0A@!_TD3 /]0% #_5AD
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M,)14_S"45/\PE%3_,)14_S#_3PX _U@+ /]@"P#[9@P \&L- .1M#@#6;A8
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M.&EOM3IH;\<Z9V_B.F=O]#AH;_\W:&__-FAO_S9H;_\V:&__-FAO_S;_7@
MY&H  --T  #(?   OX$! +>% 0"OAP< J(D5 *&))0&;B#,$E(8^"8Z$1P^)
M@5 5A']7&G]^7AY[?&4B>'IL)G1Y<RIQ>'LM;G>$,&MVCC-H=9DV9G2E.&1S
MLSEB<\0Z8G/@.F)S\SAC<_\W8W/_-F-S_S9C<_\V8W/_-F-S_S;_80  X&T
M ,]W  #$?P  NX4  +.)  "JBP, HXP3 )R-(P&6C# #D(L\"(J)10Z$ATX3
M?X55&'N#7!UW@F,A<X!J)6]_<2EL?7DL:7R"+V9[BS)C>I<U8'FC-UYYL3A=
M><(Y7'G=.5UY\3A=>/XW7GC_-EYX_S5>>/\U7GC_-5YX_S7U9   W'   ,IZ
M  # @P  MHD  *Z-  "DCP  G9$0 )>2( "1D2X#BI Y!X2.0PQ_C4P2>HM3
M%W6)6AMQB&$@;H9H(VJ%;R=GA'<K8X-_+F""B3%=@90S6X"A-EE_KS=7?\ X
M5W_:-U=_\#=8?OTV6'[_-5A^_S58?O\U6'[_-5A^_S7I:   U'0  ,9^  "[
MAP  LHT  *B1  ">E   EI8. )&7' "+ERL"A98W!7^400IYDTD0=))1%7"0
M6!ELCU\=:(YF(66,;25ABW0H7HI]+%N)AR]8B)(Q58>?,U.'K352A[XU48?6
M-5&&[C52A?LT4H7_-%*%_S-2A?\S4H7_,U*%_S/C;   SGD  ,&#  "VBP
MK)$  **5  "7F0  CYL+ (J=& "$G2<!?IPT!'F;/@ASFD<-;YE/$FJ85A=F
MEUT;8Y5C'E^4:B)<DW(E69)[*%61A2M2D9 N4)"=,$Z0JS%,D+PR3)#3,DR/
M[3),COHR3(W_,4R,_S%,C/\Q3(S_,4R,_S'<<0  R'X  +N(  "QD0  II8
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M(CJL_R,ZK/\C.JS_(SJL_R/ A@  LY(  *>9  "<GP  D*8  (2L  !YL0
M;;<  &&\!0!=O1( 6KX@ %B^+0%4OC@"4;Y"!$Z^2@9,OE((2;Y9"D:^8 Q$
MOF@.0;UQ$3^]?!,\O8@5.KV5%CB]I!<WO;48-KW*&#>\YQ<UN_89-;K_&C2Y
M_QLTN?\;-+G_&S2Y_QNXCP  JI@  )^?  "3I@  AZP  'NS  !ON0  8[X
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M QOI^0.:I   C:P  '^U  !RO0  9<4  %G+  !,T   0=4  #C<   OX0(
M+?$- "OQ$P H\AP )O(D "3S*P B]#( (?0Y !_U00 =]4D &_91 !GW6@$7
M]V4!%?AR 13Y@0$3^9(!$OJB A'ZLP(0^\8"$/O= A#[Z0(0^^D"$/OI A#[
MZ0*/JP  @;0  '.]  !FQ@  6<T  $O3  ! V0  -=X  "SC   F\0  )/X*
M "'_$  ?_Q8 '/\< !G_(@ 7_R@ %?\N !/_-0 2_SP $/]#  [_3  -_U8
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M'JQ!_QZL0?\>K$'_'JQ!_Q[_0A$ _T<- /]/#@#_4Q$ _U85 /-7' #H5B4
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M+79>M2YU7L8O=%[A+W1?\RYT7_\L=&#_*W1@_RMT8/\K=&#_*W1@_RO_4P
MZ%X  -EG  #+;0  PW$! +MS @"U<PD K747 *=U)P&A=#0#FW(_!Y5P20N1
M;E(0C&Q9%(EJ8!B%:6<;@FAN'G]F=2%]97TD>F2%)G=DCREU8YHK<F*E+7!B
MLR]O8L0O;F+>+VYC\BYN8_XM;F/_+&YC_RMN8_\K;F/_*VYC_RO_50  Y6
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M8VO8,&-K[R]D:_PM9&O_+65K_RQE:_\L96O_+&5K_RST6P  W68  ,MO  #
M=@  MWL  *]^  "F?@$ GW\0 )F 'P"3@"T"C7\Y!8A]0PF#>TL-?GI3$GIX
M6A9V=V$9<W5G''!T;A]M<W8B:G)_)FAQB2AE<)0K8G"@+6!OK2]?;[TO7F_4
M+UYO[2]?;_LM7V__+&!O_RQ@;_\L8&__+&!O_RSK7@  V&D  ,=R  "\>0
MLW\  *N"  "A@@  F8,. )2$'0".A"L!B(,V!(."0 A^@$D,>7]1$'5]6!1R
M?%\8;GME&VMZ;!YH>70B97A])6)WAR=@=I(J776>+%MUJRY:=+LO6771+UET
M["Y9=/HM6G3_+%IT_RM:=/\K6G3_*UIT_ROF80  T6T  ,-V  "Y?0  KX,
M *:&  "<A@  E(@, (Z)&0")B2@!@XDT WZ'/@=YAD<+=(5/#W"$5A-M@ET7
M:8%C&F: :AUC?W(@8'YZ(UU]A"9:?(\I6'N<*U9[J2Q4>[DM4WO.+51ZZBU4
M>ODL5'G_*U5Y_RI5>?\J57G_*E5Y_RKA90  S'$  +]Z  "T@@  JX<  *&*
M  "5BP  C8T) (>.%@""CR0!?8\Q GB..P5SC40);XQ,#6N*5!%GB5H59(AA
M&&&':!M>AG >6X5X(5B$@B15A(TF4H.:*5""IRI/@K<K3H+,*TZ"Z"M.@?@J
M3X#_*D^ _RE/@/\I3X#_*4^ _RG;:@  QW4  +I_  "PAP  IHP  )R/  "/
MD0  AI,% ("4$@![E2$ =Y4M 7*5. 1ME$(':9-*"V6240YBD5@27I!?%5N/
M9AA8CFT;58YV'E*-@"%/C(LC38N8)4N+I2=)B[4H2(O**$B*YR=)B?<H28C_
M)TF'_R=)A_\G28?_)TF'_R?1;P  P7L  +6$  "KC   H)   )64  ")EP
M?IH  '>;#@!SG!P ;YTI 6N<-0)FG#\%8IM'"%^:3PM<FE8/6)E<$E688Q53
MF&L74)=S&DV6?1U*E8D?1Y65(465I"-$E+,C0Y3((T.4Y2-#DO4D0Y'_)$.0
M_R1#D/\D0Y#_)$.0_R3*=0  NX$  +"+  "DD0  FI4  (^9  "#G0  =*(
M &ZC"P!JI!< 9J4E &.E,0%?I#L#6Z1$!5BD2PA5HU,+4J-:#4^B81!-HF@3
M2J%Q%4>@>QA$H(8:0I^3'$"?HAT^G[(>/9_&'CV?XQT]G?0>/9S_'SR;_Q\\
MF_\@/)O_(#R;_R#"?   M8@  *F0  ">E@  DYL  (>?  ![I   ;Z@  &.L
M! !?K1$ 7*T? %JN*P!7KC8!5*Y  U&M2 5.K4\'2ZU7"4FM7@M&K&8-1*QN
M#T&L>!$_JX03/*N1%3JKH!8YJ[ 7.*O#%SBJX1<WJ?,8-Z?^&3:F_QHVIO\:
M-J;_&C:F_QJZA   KH\  **6  "7FP  BZ$  '^F  !SJP  9Z\  %JT  !3
MM@P 4;<7 $^W) !-N#  2K@Z 4BX0P)&N$L#1+A2!$&X6@8_N&('/;AK"3JX
M=0LXMX$,-K>.#C2WG0\SMZT/,K?!#S&WW@\QMO(0,+3\$3"S_Q(PL_\3,+/_
M$S"S_Q.RC@  I94  )J;  ".H@  @J@  '6M  !ILP  7K<  %.[  !'P 4
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M !CDB $7Y9H!%N:L 17FP $4Y]T!$^7O 1/C^@$3X_H!$^/Z 1/C^@&6H@
MB:D  'NQ  !NN0  8<   %3&  !(R@  /<\  #/3   JV0  (MX" ![K"@ <
M[!  &^T7 !GM'P 7[B8 %>XM !3O-0 3\#T $?!& !#Q4  /\EL #O)I  WS
M>  ,](H "_6<  KUK@ )]L( "?;9  CU[0 (]>T "/7M  CU[0"+J0  ?;(
M &^Z  !BP@  5<D  $?.   [T@  ,=@  "?=   ?X0  &>@  !;X!@ 4^@T
M$OL2 !#\%P ._!T #?TC  S]*0 *_C  "/\X  ;_00 #_TP  /]8  #_9@
M_W<  /^)  #_FP  _ZL  /^[  #_S@  _\\  /_/  #_SP!_L@  <;H  &/#
M  !6RP  2-$  #K6   OW0  )>$  !SE   4Z0  $?<   __ 0 -_PD "_\-
M  C_$  &_Q0  _\8  #_'@  _R,  /\J  #_,@  _SP  /]'  #_5   _V,
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M2D@"Q$A3!,!'70>\1F8)ND1N"[=#=@VU0WT.LT*$$+%!BQ&P09(2KD":$ZQ
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M'XA.MR"'3L@AA4[B(81/\R"#3_\@@T__'X)0_Q^"4/\>@E#_'H)0_Q[_1P
M\U$  -]8  #170  R6 " ,-@! "]7@T M6 : *YA*@"I8#<"I%Y#!)]=30B;
M6U4+F%E=#I589!&25VL3CU9R%HU5>1B+5($:B%.)'(93DAZ$4IP?@E*G(8!2
MM")_4L0C?5+>(WQ3\2)\4_XA>U3_(7M4_R![5/\@>U3_('M4_R#_2@  Z50
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M)FE>["5J7_LD:E__(VI?_R)J7_\B:E__(FI?_R+P4@  W5T  ,ME  # :P
MMVX  *]O  "G;@$ H&\0 )IP'P"4<"P!CV\X XIM0@:&;$L)@FI2#'YI60][
M:& 2=V9F%'5F;A=R974:<&1^'6UCB!]K8Y(B:6*>)&=BJR5E8KHF9&+/)F1B
MZB9E8OHD96/_(V5C_R)E8_\B96/_(F5C_R+K50  V&   ,AH  "\;@  LW$
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M(U9O_R)7;_\B5V__(E=O_R+?7P  RFD  +QR  "R>   J7T  )]_  "2?@
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M&S^+_QO"<P  M7X  *J'  "?C   E)   (B3  ![E0  ;)D  &6;! !@G!
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M!R^QE@@NLJ8(+;*X"2RRT @LL.P)*Z_Y"BNN_PLJK?\+*JW_"RJM_PNMBP
MH)(  )68  ")G0  ?:,  '&H  !DK0  6;$  $VT  !"N   .[H* #B[$P W
MO!X -;PI #2],@ SO3L ,KU$ #&^3  OOE4!+KY> 2R^: $JOG0"*;Z" B>_
MD0,FOZ(#)+^T R._RP,CON@#([SW!"*[_P4BN_\%(KO_!2*[_P6DD@  F)@
M (R>  " I0  <ZL  &>P  !;M0  3[D  $2\   ZP   ,,0$ "K'"P HR!,
M)\D= ";))P ER3  ),HY "/*0@ BRTL (<M5 "#,7P ?S&P '<UZ !S-B@ ;
MS9P &<ZN 1C.Q0 8S>0 &,ST 1C*_ $8RO\"&,K_ AC*_P*;F0  CY\  (*F
M  !UK0  :+,  %RY  !0O0  1,$  #G$   PR   *,P! "#0!@ 9U0L %M<0
M !78&0 5V2( %-DK !/:-  3VCT $MM( !'<4P 1W5\ $-UM !#>?@ .WY$
M#N"D  W@N  ,X-( "]_M  S>]P ,W?L #-W[  S=^P"2GP  A:<  '>N  !J
MM0  7;P  %#!  !$Q0  .,D  "[-   ET0  'M4  !;: 0 1W@8 $.<-  [G
M$@ -Z!D #.@A  OI*0 *ZC$ ">H[  ?K10 %ZU$ !.M>  /K;@ !ZX   .J4
M  #JIP  Z[P  .O2  #KZ0  [.\  .SO  #L[P"'IP  >:\  &NW  !>O@
M4<4  $/)   WS0  +=$  "/6   ;VP  $]\   [C   ,[@( "O8*  ?V#@ %
M]A(  _88  #U'@  ]24  /4N  #U-P  ]D(  /9.  #V70  ]FX  /:!  #V
ME0  ]Z<  />W  #XQP  ^-   /C0  #XT ![KP  ;;@  &#   !2R   1,T
M #?1   KUP  (=P  !C@   1Y   #.<   ?O   $^@   ?\#  #_"   _PT
M /X0  #^%   _QH  /\A  #_*0  _S,  /\^  #_2P  _UL  /]L  #_@
M_Y(  /^A  #_K0  _[,  /^S  #_LP#_'"8 _QPD /\:)0#_%2< _Q$N /\0
M.@#_#D<!_PU3 ?\+7P'_"FL!_PIU ?\*?P'_"H<!_PJ. ?\*E0'_"IL!_PF@
M ?\)I0#_":L _PFQ /\)N #_"<$ _@G, /P)W@#Y">L ]0GV /,)_P#R"O\
M\0K_ ?$+_P'Q"_\!\0O_ ?$+_P'_'R, _Q\A /\>(0#_&20 _Q<L /\5-P#_
M$T0 _Q%0 ?\07 '_#F<!_PYR ?\.>P'_#H0!_PZ+ ?\.D@'_#I@!_PZ= ?\.
MHP'^#J@!_ ZN ?L.M0#Z#KX ^ [) /4.VP#R#NH [@[U .P._P'K#_\!Z@__
M >H0_P'I$/\!Z1#_ >D0_P'_(A\ _R(< /\A' #_'R  _Q\I /\<- #_&D
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M";DJ_PG_, \ _S(+ /\V#0#_.!  _SD5 /DW'@#O-2@ YS,U . R0@#;,D\
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M-P< _SL" /]  P#R0@4 Z4() .4_#@#8/A8 SD G ,=!-@#"040!O4%/ KE
M60.V/V$$M#YI!K$]<0>O/7@(KCQ_":P\A@JJ.XT+J3N5#*<[G0VE.Z8-HSJP
M#J([O ^@.\T/GCOF$)L\]1&://\1F3S_$9@\_Q&8//\1F#S_$9@\_Q'_.@$
M_T   .]%  #A2   V4@% --&"0#,11( Q$<B +U(,0"X2#\!LT=* K!&5 2L
M15T%JD1D!Z=#; BE0G,*HT)Z"Z%!@0R@08@-GD"0#YQ F!":0*$1F$"L$I=
MN!*50,@3DT#A$Y%!\Q200?\4CT'_%(Y"_Q..0O\3CD+_$XY"_Q/_/   ^40
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M&G=.ZQIW3_H9=D__&79/_QAV3_\7=D__%W9/_Q?X1@  XE   -!7  #$7
MNUX  +1=  "N6@8 IEL3 *!<(@";7"\ EUL[ I):10./64T&BUA5"(A77 J&
M5F,,@U5J#H%4<1!^5'@2?%. %'I2B19X4I08=E*?&712JQIR4KH;<5+-''!2
MZ!MP4_D:<%/_&G!3_QEP4_\8<%/_&'!3_QCO20  W5,  ,M:  # 7P  MV(
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M&V!>_QIA7O\:85[_&F%>_QKD4@  SUP  ,!D  "V:0  K&P  *-L  "9:0
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M&4UO_QG.8   OFH  +)R  "H>   G7L  )!Z  "$>@  >GL  '1\# !O?A<
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M#SZ*F!$\BJ<2.XJX$CJ*SQ([B.L2.X?Z$SN&_Q,[AO\3.X;_$SN&_Q.\<0
MKWL  *6#  "9AP  C(@  '^)  !SC   99   %R3  !7E0P 5)86 %*6(@!0
MERT 39<V $N7/P%)ET<"1Y=. T66501#EET%099E!CZ5;P@\E7H).I6'"SB5
ME0PVE*4--92V#C24S TTD^D--)+X#C20_P\TD/\/-)#_#S20_P^U>   JH(
M )Z(  "3C0  AHX  'F0  !MDP  89<  %6;  !-G@8 29\0 $>?&P!&H"8
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M 1RYP $<N-\!'+;R 1NU_ (;M/\"&[3_ ANT_P*?CP  E)4  (B;  ![H0
M;J8  &*K  !6L   2K,  #^V   UN0  ++P  "2_!@ ?P@T '<(4 !S"'@ ;
MPR8 &L,O !G$.  8Q$$ %\1* !;%50 5Q6$ %,9O !/&?P 2QI$ $<>D !#'
MN0 /Q]0 $,;N !#$^@ 0P_\ $,/_ !##_P"7E@  BYP  'ZB  !QJ0  9*\
M %BT  !+N   0+L  #6^   KP0  (\4  !O) 0 4S 8 $- +  [1$0 -T1D
M#=$A  S1*@ ,T30 "](^  K220 )TU4 "=-B  C3<@ &U(0 !=28  34JP #
MU<   =7<  '5[0 !U?8  =7V  '5]@".G0  @*0  '.K  !FL0  6;@  $R]
M   _P   -,,  "K'   AR@  &<X  !+2   -U@$ "=L%  ;<#0 $W!$  ]T8
M  '>(   WB@  -\Q  #@/   X4<  .)4  #C8P  XW0  .2(  #DFP  Y:X
M .7!  #EU0  YN<  .;G  #FYP"#I   =:P  &BS  !:NP  3<$  $#$   S
MR   *,P  !_0   7U   $-D   O=   %X0   .0   #E!P  Y@T  .<1  #H
M%@  Z1T  .HE  #K+@  [3D  .]%  #P4P  \60  /%V  #RB@  \YP  /.M
M  #TNP  ],@  /3(  #TR !WK0  :K4  %R]  !/Q   0,D  #/-   GT0
M'=8  !3<   .X   ".,   'F    Z@   .X   #N    [P0  / *  #Q#@
M\Q(  /08  #V(   ^"H  /HU  #]0P  _E(  /]C  #_=@  _XD  /^:  #_
MI@  _[   /^P  #_L #_%B, _Q4A /\1(0#_#20 _PDK /\&-P#_ T0 _P!1
M /\ 70#_ &@ _P!R /\ >P#_ (, _P"* /\ D0#_ )8 _P"< /\ H0#] *8
M^P"L /D LP#W +L ]0#% /, T0#R .0 \0#Q .\ ^@#N /\ [@#_ .T _P#M
M /\ [0#_ .T _P#_&2  _Q@= /\5'0#_$!\ _PXI /\,- #_"D$ _P=- /\%
M60#_!&0 _P1N /\#=P#_ X  _P.' /\#C0#] I, ^P*9 /D"G@#W J0 ]0*J
M /,!L #Q ;@ [P'" .T!SP#K >, Z@'O .@"^P#G!/\ Y@7_ .8&_P#F!O\
MY@;_ .8&_P#_'!L _QL9 /\7& #_%1T _Q,E /\1, #_$#T _PY) /\,50#_
M"V  _PMJ /T+<P#["WP ^0J# /<*B@#U"I  ] J6 /,*FP#Q"J$ [PFG .T)
MK@#K";8 Z G  .8)S0#D">( X@KP -\+^P#>#/\ W W_ -P-_P#;#?\!VPW_
M =L-_P'_'Q< _QX3 /\;$@#_'!D _QLB /\8+ #_%3@ _Q-$ /X24 #Y$5L
M]1!F /,0;P#P$'< [A!_ .P0A@#J$(P Z1"2 .@0F #F#YX Y0^E .,/K #A
M#[0 X ^^ -X/S #:$.$ U1'P -(2^P#/$O\!SA/_ <T3_P'-$_\!S!/_ <P3
M_P'_(A( _R(/ /\A#P#_(A0 _R(< /\@)P#_'3( ^!L^ /(92P#N&%8 ZA=@
M .<6:@#D%G( XA9Z . 6@@#>%H@ W!:/ -L6E0#9%IL UA:B -06J0#2%K$
MT!>[ ,X7R0#,&-X R!GN <4:^P'#&O\"P1O_ L ;_P+ &_\"P!O_ L ;_P+_
M)@X _R4+ /\H# #_*1  _R@6 /XF( #T)"L ["$X .8@1 #A'U  W1]; -D>
M90#5'FT TA]U - ??0#.'X, S!^* <L?D ')'Y<!R!^> <8?I0'%(*T!PR"W
M <$@Q ' (=8!O"+J KDB^ .V(O\#M2/_ [0C_P2S(_\$LR/_!+,C_P3_*0L
M_RH% /\N" #_+PP _RT0 /,K%P#H*"( X"8O -DF/0#2)TH S2=5 ,HH7P#'
M*&@!Q2AO <,G=P'!)WX!OR>$ ;XGBP*\)Y("NR>9 KDGH *W)ZD#MBBS [0H
MOP.S*,\#L"GF!*TI]@2K*O\%J2K_!J@J_P:H*O\&J"K_!J@J_P;_+04 _S
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M#(P\[ V*//L-B3S_#8D\_PR(//\,B#S_#(@\_PS_-P  ZC\  -Q%  #.20
MQ4D  +]& @"Z0PP LT09 *U%)P"H1C4 I$5! :!%2P*=1%,"FD-; YA#8@66
M0FD&E$%P!Y)!=@B00'X)CD"&"HU C@N+0)@,B4"B#8= K@Z%0+P/A$#/#X)!
MZ0^!0?D/@$'_#X!"_PZ 0O\.@$+_#H!"_P[Z.P  Y40  --+  #'3@  OD\
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M$FM._Q)K3O\1:T[_$6M._Q'H1@  TU   ,16  "Y6@  L%P  *9:  "?5@
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M$E==_Q+64P  Q%P  +=C  "L:   H&@  )5G  "*8P  @V4" 'UF#P!X9AH
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M$$IMF!%);*<22&RX$T=LS1-';.H32&OZ$DAK_Q)(:O\12&K_$4AJ_Q''7@
MN&<  *QN  "A<@  DW(  (=Q  !Z<0  <7(  &MT!P!F=1$ 8W8= &!W* !>
M=S, 6W@\ 5EW0P)6=TL#5'=2!%)V6050=F '3G5H"$MU<0I)='P,1W2(#D5S
ME@]#<Z400G.V$4%SRQ%"<N@10G+X$4)Q_Q!#</\00W#_$$-P_Q#!8P  LVP
M *AS  ";=@  CG4  (%V  !U=@  :7@  &-Z @!>? X 7'T9 %E^) !7?R\
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M!R^.PP<OCN$'+XST""^+_P@OBO\(+XK_"2^*_PFP=@  I7\  )B$  "*A
M?84  '"'  !EB@  6HX  $^2  !&E0  09@, #Z8%  ]F1\ .YDH #J:,0 Y
MFCH -YI" #::2@ UFE(!,YI: 3&:9 $OFF\"+9I[ BR:B@,JFIH#*9JL!"B:
MP 0GF=X#)Y?R!">6_04GE?\%)Y7_!2>5_P6I?@  GH4  )*)  "$B@  =HP
M &J/  !>DP  5)<  $F;  ! GP  -Z($ #*C#@ QHQ< ,*0A "ZD*@ MI#(
M+*4Z "NE0P JI4L *:54 "BE7@ FI6D ):5V 2.EA0$BI98!(*:H 1^ENP$>
MI=<!'J3O 1ZB^P(>H?\"'J'_ AZA_P*BA@  EXP  (N/  !]D0  ;Y0  &.8
M  !7G0  3:$  $.E   XJ   ,*L  "BN!P DKQ  (Z\7 "&O(0 @L"D '[ Q
M !ZP.@ =L4( '+%, !NQ5@ :L6$ &;)O !BR?@ 6LI  %;*B !2RM@ 3LLX
M$['K !.O^0 3KO\!$Z[_ 1.N_P&:C0  D)(  (27  !UF@  :)\  %NC  !0
MJ   1:P  #NP   QL@  )[4  ""X   8N@< %+P. !.\%0 2O!X $;TF !&]
M+@ 0O3< $+Y!  Z^3  .OE< #;YE  R_=  +OX8 "KZ9  B^K  'OL( ![[?
M  B^\  (O?H "+W\  B]_ "3E   AYD  'J?  !LI0  8*H  %.O  !'LP
M/+8  #&X   GNP  '[X  !?!   1Q $ #,@(  C)#@ 'R10 !LD<  7))  $
MRBP  \HV  +*0   RTP  ,M9  #+:   RWD  ,R,  #+GP  R[,  ,O(  #,
MX@  S.\  ,SQ  #,\0"*F@  ?*$  &^G  !BK0  5;,  $BX   [NP  ,+X
M ";!   =Q   %<@   _+   *S@  !-("  #3"@  TP\  -04  #5&@  UB(
M -<J  #9-   VC\  -Q+  #<6@  W6H  -U]  #=D0  W:0  -ZV  #>R
MWMX  -[B  #>X@!_H@  <:D  &2P  !6MP  2;P  #S    OQ   ),<  !O+
M   3SP  #=(   ?6    VP   -X   #? P  X D  .$.  #B$@  XQ<  .4>
M  #F)P  Z#$  .H]  #L2P  [%H  .UL  #N@   [I0  .ZE  #NM   [L(
M .[&  #NQ@!TJ@  9K(  %BY  !+P   /<4  "_)   DS0  &=$  !'6   +
MVP   ]X   #A    Y0   .@   #I    Z@   .L&  #M"P  [P\  / 3  #R
M&@  ]",  /<N  #Y.P  ^TH  /Q;  #];0  _8   /Z3  #^H@  _JT  /ZO
M  #^KP#_$!\ _PX= /\*'0#_ 2  _P H /\ -0#_ $$ _P!. /\ 6@#_ &4
M_P!N /\ =P#_ '\ _@"& /P C #[ )( ^0"7 /@ G #W *( ]@"G /4 K0#S
M +4 \@"] /$ R0#O -P [@#K .T ]P#L /\ ZP#_ .H _P#J /\ Z@#_ .H
M_P#_$QP _Q$9 /\-&0#_!AP _P,E /\ ,0#_ #X _P!* /\ 5@#_ &$ _P!K
M /T <P#Z 'L ]P"# /4 B0#T (\ \@"4 /$ F0#P )\ [@"D .T JP#L +(
MZ@"Z .@ Q@#G -8 Y0#H .0 ]0#C /X X@#_ .$ _P#A /\ X0#_ .$ _P#_
M%1@ _Q,4 /\/% #_#1D _PLB /\(+0#_!#D _P%& /\ 40#^ %P ^@!F /8
M;P#R '< [P!^ .T A0#K (L Z@"1 .@ E@#G )P Y@"A .0 J #C *\ X0"X
M -\ PP#= -$ VP#F -D \P#7 /T U0+_ -0"_P#4 _\ U /_ -0#_P#_&!,
M_Q40 /\2#P#_$A4 _Q$= /\.* #_##0 _PI! /D(3 #U!E< \09A .T&:@#I
M!7( Y@5Z .0%@0#B!8< X :- -\&D@#=!I@ VP:> -D&I0#7!JT U :U -(&
MP #0!\\ S@CE ,P)] #*"_\ R S_ ,<,_P#'#/\ Q@S_ ,8,_P#_&PX _QD,
M /\8#0#_&!$ _Q<8 /\4(@#[$2X \Q Z .T.1@#H#5( Y0U< .$-90#>#6T
MVPUU -@-? #5#8( TPV) -$-CP#0#94 S@V< ,T.HP#+#JL R0ZT ,@.P #&
M#L\ PQ#F , 1]0"]$O\ O!+_ +L2_P"Z$O\!NA+_ ;H2_P'_'PH _QP$ /\?
M" #_'PT _QT2 /@:&P#N%B8 YA0S . 3/P#:$TL U!-6 - 37P#.%&@ RQ1O
M ,D4=P#'%7T QA6$ ,05B@##%9$ P1:8 , 6GP"^%J< O!>P +L7O "Y%\L
MMQCB +,9\@&Q&O\!KQO_ :X;_P&N&_\!K1O_ :T;_P'_(@0 _R(  /\E @#\
M) < ]R$, .P=$@#A&AP V!HJ - ;. #+'44 QQU0 ,,>6@# 'F( OAYJ +P?
M<0"Z'W@ N1]^ +<?A0"V'XP M!^3 +,?F@&Q(*,!L""L :X@MP&L(<8!JR'=
M :<B[P*E(OT"HR/_ J(C_P*B(_\"H2/_ J$C_P+_)0  _R@  /(J  #E*P
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M"7H\_PAZ//\(>CS_"'H\_PCN-P  W4$  ,M&  "_20  MDD  *Y&  "I000
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M"V!-_PO<1P  QU   +E6  "N60  HE@  )A6  "040  B5(& (-3$0!_4QT
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M"U19F U36*8.4EFV#E%9R@]16><.45CX#5)8_PU26/\,4EC_#%)8_PS-40
MO%D  +!?  "C80  EF   (M?  "!6P  >5T  '-># !O7A4 :U\@ &A?*P!F
M8#4 8V ] 6%?10%?7TP"75]3 UM?6@197F$%5UYI!E5><@A37GT)45V)"U!=
ME@Q.7:0-35VT#DQ=R Y,7>8.35WW#4U<_PQ-7/\,3ES_#$Y<_PS)5   N5P
M *UC  "?8P  DF,  (=B  !\8   =&$  &YB"0!I8Q( 9F,= &-D* !A9#(
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M"CUNP@H\;N */6WT"CUL_PH]:_\*/FO_"CYK_PJZ8   K6D  *!N  "1;0
MA&T  'AM  !L;@  87   %MR  !6= H 4G42 %!V'0!.=R< 3'<Q $MX.0!)
M>$$ 2'A) 49X4 %$=U<"0G=? T!W: ,^=W,$/'9_!CIVC0<Y=IP(-W6M"#=U
MP @V==X(-W3R"#=S_@@W<O\(-W+_"#=R_PBU9@  J6\  )IQ  "+<0  ?G$
M '-R  !H<P  7'8  %1Y  !.>P4 2GT/ $A^& !&?R, 17\L $. -0!"@#T
M08!% #^ 3 $]@%0!/(!< CI_90(X?V\#-G]\!#1_B@0R?YH%,7ZJ!C!^O08P
M?MH&,'WP!C![_08P>_\&,'K_!C!Z_P:P;   I'4  )1U  "&=0  >78  &YW
M  !C>0  5WT  $^!  !'A   0H8, #^'$P ]B!T /(@G #N),  ZB3@ .(E
M #>)2  VB4\ -(E8 3.)80$QB6P!+XEX BV)AP(LB9<#*HBG RF(N@,IB-0#
M*8;N RF%_ 0IA/\$*83_!"F$_P2J=   GGL  (YZ  " >@  ='L  &A^  !=
M@0  4H4  $F)  !!C   .9 % #61#P SDA< ,I(A #&2*0 PDS( +I,Z "V3
M00 LDTH *Y12 "J47  HE&< )Y1S 264@@$DE),!(I.D 2&3MP$@D\\!(9+L
M 2"0^@(@C_\"((__ B"/_P*D?   EX   (=_  ![@   ;H(  &*%  !7B0
M38X  $*2   ZE@  ,ID  "J<"0 HG1$ )IT9 "6=(@ DGBH (YXR "*>.@ A
MGD( ()Y+ !^?50 >GV  ')]M !N??  :GXT &)^? !>?L@ 6G\D %I[H !:<
M]P 6F_\!%YO_ 1>;_P&=@P  CX8  (*&  !TAP  9XL  %N/  !0DP  1I@
M #R<   SH   *Z,  ".F   <J L &JD1 !BI&  7J2$ %JHI !6J,0 4JCD
M$ZI# !.K30 2JU@ $:ME !"K=  .JX8 #JN9  VKK  ,J\$ #*K?  RI\@ -
MJ/P #:C_  VH_P"6B@  B8P  'J-  !LD0  8)4  %2:  !)GP  /Z,  #6G
M   KJ@  (ZX  !NP   4LP$ #[4*  VV$  ,MA8 "[8?  JV)P )MB\ "+8Y
M  >W0P &MT\ !+=;  .W:@ "MWL  +>.  "WH0  MK0  +;+  "VY0  M?$
M +7W  "U]P"/D0  @90  '*7  !EG   6*$  $RF  !!JP  -Z\  "RR   C
MM0  &K@  !.[   .O0  "< %  /!#0  P1$  ,$7  #"'@  PB8  ,(O  ##
M.0  Q$0  ,10  #$7@  Q6\  ,6!  #%E0  Q:@  ,6\  #$T0  Q.8  ,3N
M  #$[@"&F   >9X  &NC  !=J0  4*X  $2S   WM@  ++D  "*\   9OP
M$<(   S%   &R    ,L   #,!P  S T  ,T1  #-%@  SAT  ,\D  #0+0
MTC@  -1$  #44@  U6$  -5S  #6AP  UIL  -:M  #7OP  V,X  -C=  #8
MW0![H   ;J8  &"M  !3LP  1;@  #B\   KOP  (<(  !?&   0R0  "LP
M  +0    U    -<   #8    V@4  -L+  #<#@  WA,  -\9  #A(0  XRH
M .4V  #G0P  YU,  .AD  #I=P  Z8P  .J?  #JK@  ZKH  .K#  #JPP!P
MJ   8J\  %6V  !'O   .<   "S$   @R   %LP   [0   'U    -D   #=
M    X0   .,   #D    Y@   .<!  #I!P  ZPP  .P0  #N%0  \!T  /,G
M  #V,P  ]T,  /A4  #Y9@  ^7H  /J.  #ZG@  ^ZD  /NP  #[L #_"QL
M_P<9 /\ &0#_ !P _P E /\ ,@#_ #\ _P!+ /\ 5P#_ &( _P!K /\ <P#]
M 'L ^P"" /H B #X (T ]P"2 /8 F #U )T ] "B /, J0#Q +  [P"X .X
MPP#L -$ ZP#F .D \P#H /X Z #_ .@ _P#H /\ Z #_ .@ _P#_#A@ _PH5
M /\!% #_ !@ _P B /\ +@#_ #L _P!' /\ 4P#] %X ^@!G /< ;P#U '<
M\P!^ /( A #P (D [P"/ .X E #L )H ZP"? .D I0#H *P Y@"T .0 OP#C
M ,P X0#B -\ \ #> /L W@#_ -T _P#= /\ W #_ -P _P#_$!, _PT1 /\&
M$ #_ A4 _P > /\ *0#_ #8 _P!" /H 3@#T %D \0!B .X :P#L '( Z@!Y
M .@ ?P#G (4 Y0"+ .0 D #B )8 X0"< -\ H@#= *D V@"Q -@ NP#5 ,@
MT@#= -$ [0#0 /D SP#_ ,X _P#- /\ S0#_ ,T _P#_$0\ _PX- /\,#0#_
M"Q( _P<9 /\") #_ #  ]@ \ .\ 20#J %, YP!= .0 9@#A &T WP!T -T
M>P#; ($ V0"& -8 C #4 )( T@"8 -  G@#. *8 S "N ,H N #( ,0 Q@#7
M ,4 Z@## /< P@#_ ,$!_P#  O\ P +_ , "_P#_% L _Q & /\0"0#_$ X
M_PX4 /\*'@#U!BD ZP0V .,#0@#? TX VP17 -8$8 #3!&@ T 1O ,X%=@#,
M!7P R@6" ,D%B #'!8X Q@64 ,0%FP#"!:, P :K +X&M0"]!L( NPC4 +H)
MZ0"W"_@ M0S_ +0,_P"T#/\ M S_ +0,_P#_%P0 _Q0  /\6 P#_% D _Q$.
M /(.%0#H#"$ W@HN -8+.P#0#$< S Q1 ,D,6@#&#6( Q UJ ,(-<0# #7<
MOPU] +T.@P"\#HH N@Z1 +D.F "W#J  M@ZI +0/M "R#\$ L1#4 *X1ZP"K
M$OH J1+_ *@3_P"G$_\ IQ/_ *<3_P#_&@  _QL  /D;  #K&0  Y10& .40
M#@#9#A< SQ$F ,@2- #$$T  OQ1+ +P45 "Y%5T MQ5D +45:P"T%7$ LA5X
M +$6?@"O%H4 KA:, *P6E "K%YP J1>F *<8L "F&+T I!C/ *(:YP"?&O<
MG1O_ 9P;_P&<&_\!FQO_ 9L;_P'_'0  ]R$  .@D  #=)0  U"$! ,\;" #*
M%Q$ PAH@ +P<+0"W'3H LQY% + >3P"M'E< JQY? *D?9@"H'VP IA]S *4?
M>0"C'X  HA^' * @CP"?()@ G2"B )L@K &:(;D!F"'* 98BY &4(_4!DB/_
M 9$C_P&0(_\!D"/_ 9 C_P'_(@  ZRD  -TN  #/+P  QRT  ,$G P"](@T
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M!6P\_P7B.0  S$(  +Y'  "Q2   I48  )U#  "7/P  DCX+ (T_%0")/R$
MA4 M () -P!_0$  ?4!( 'M 3P%Y0%8!=S]= 74_8P)S/VH"<3]R W _>@-N
M/X0$;#^0!6L_G 9I/ZD&:#^X!V= S =F0.@'9D#Y!F5 _P9E0/\&94#_!65
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M!EY(EP==2*4(6TBT"%M(QPE:2.0(6DGV"%I)_P=:2/\&6DC_!EI(_P;110
MOTP  +)2  "C40  EU   (U.  "&2@  @$H! 'I+#@!V3!< <DPC &],+0!M
M338 :DP_ &A,1@!F3$T!9$Q3 6),6@)A3&$"7TQI UY,<@1<3'P%6DR(!EE,
ME0=73*,(5DRR"%5,Q@E53.()54SU"%5,_P=53/\'5DS_!E9,_P;,2   O%
M *]5  "@5   DU,  (E1  "!30  >DX  '5/# !P3Q4 ;5 @ &I0*@!G4#,
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M"$=8P A'6-T(1UCR"$=7_P=(5_\'2%?_!DA7_P;!40  LED  *-<  "46P
MAUL  'U:  !R6   :UD  &5: P!@6PX 75P7 %I<(0!872L 5ETT %1>/ !3
M7D0 45Y+ 5!>4@%.7ED"3%YA DM=:@-)770$1UV !45=C09$79P'0UVL!T)=
MO@A"7=H(0ESQ!T)<_@=#6_\&0UO_!D-;_P:]50  KUT  )]?  "07@  @UX
M 'A=  !M7   95T  %]?  !:8 P 5V$4 %5B'@!28B@ 46,Q $]C.0!.8T$
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M!#%N^P0Q;?\$,6S_!#%L_P2O9   H6D  (]H  "!:   =6D  &MI  !@:P
M56X  $UQ  !&<P  0G4+ #]V$@ ]=QP /'<E #IX+0 Y>#4 .'D] #=Y10 V
M>4T -7E5 #-Y7@ Q>6@!,'ET 2YY@P(M>9("*WBC BIXM0(J>,P"*G?J BIV
M^0,J=?\#*G3_ RIT_P.J:@  FFT  (EL  !\;0  <&T  &9N  !;<0  4'4
M $AX  !!>P  .GX% #9_#@ T@!8 ,X$@ #*!*  P@3  +X(X "Z"0  M@D@
M+()0 "N"6@ J@F0 *()P ":"?P$E@H\!)(*@ 2."L@$B@LD!(H'G 2)_]P$B
M?O\"(GW_ B)]_P*E<0  DW$  (-Q  !V<0  ;'(  &!U  !6>   3'P  $.
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M !"4_P"5?0  A7P  'A\  !K?@  7X$  %2&  !*B@  0(\  #:3   MEP
M)IH  !Z=   7H , $J(, !"C$@ 0HQD #Z,A  ZD*0 .I#$ #:0Z  RD10 +
MI%  "J1<  FD:@ 'I'L !J..  2CH0 "H[0  Z++  .BY@ #H?,  Z'[  .A
M^P"-@P  ?X(  '&$  !DAP  6(P  $V1  !"E@  .)H  "^>   FH@  'J4
M !>H   1JP  #*X'  >O#0 #KQ(  J\9  &O(0  KRD  + R  "P/   L$<
M +!3  "P80  L'$  +"#  "OEP  KZH  *^_  "NV0  KNL  *[T  "N] "'
MB0  >(H  &J.  !=DP  49@  $6=   [H@  ,*8  ">J   >K@  %K$  !"T
M   +M@  !;D#  "Z"@  N@X  +H3  "[&0  NR$  +PH  "\,0  O3P  +Y(
M  "^5@  OF4  +YW  "^C   OI\  +VS  "^QP  OMX  +WK  "]ZP!_D@
M<)4  &*:  !5GP  2:4  #VK   RKP  *+0  !ZV   5N0  #KP   F_   "
MP@   ,0   #%!   Q@H  ,8.  #'$@  R!@  ,D?  #*)P  S#   ,X\  #.
M20  SUD  ,]J  #/?@  SY,  ,^F  #/N   S\@  ,_;  #/VP!WG   :*$
M %NG  !.K@  0;0  #2W   HN@  ';T  !/    -Q   !L<   #*    S@
M -    #1    T@(  -,(  #5#   UA   -D5  #;'   W20  . O  #B/
MXTL  .1<  #D;P  Y8,  .68  #EJ0  Y;8  .7#  #EPP!LI0  7ZP  %&R
M  !$N0  -;P  "C    <Q   $L@   S+   #SP   -,   #8    W    -\
M  #?    X0   .,   #D P  Y@@  .@-  #I$0  [!@  .XB  #Q+@  \SP
M /1-  #U7P  ]G,  />'  #WF0  ^*4  /BP  #XL #_ Q< _P 5 /\ %0#_
M !@ _P C /\ +P#_ #P _P!( /\ 5 #_ %X _P!G /T ;P#[ '8 ^0!] /@
M@P#V (@ ]0". /0 DP#R )@ \0"> /  I #N *L [0"S .L O0#J ,L Z #A
M .< \0#F /T Y0#_ .0 _P#D /\ Y #_ .0 _P#_!Q, _P 1 /\ $0#_ !4
M_P ? /\ *P#_ #< _P!$ /X 3P#Z %H ]P!C /0 :P#R '( \ !Y .\ ?P#M
M (0 ZP"* .H CP#H )0 YP": .4 H #D *< X@"O .  N0#> ,8 W #: -H
M[ #8 /D U@#_ -8 _P#7 /\ V #_ -@ _P#_"A  _P,. /\ #0#_ !( _P :
M /\ )@#\ #( ]P _ /0 2@#Q %4 [0!> .H 9@#H &X Y0!T ., >@#B (
MX "% -X BP#< )  VP"6 -@ G #5 *, TP"K -$ M0#. ,$ S #1 ,L YP#)
M /4 R #_ ,@ _P#( /\ R #_ ,@ _P#_# P _P8( /\""@#_  \ _P 5 /P
M( #Q "P [  Y .D 10#E $\ X0!9 -X 80#; &@ UP!O -0 =0#2 'L T "
M ,X A@#, (P RP"2 ,D F #' *  Q0"H ,, L0#! +P OP#+ +T XP"\ /(
MNP#] +L _P"Z /\ N@#_ +H _P#_#@4 _PD  /\)!0#_!@L _P$0 /  &0#F
M "4 X0 R -P /P#6 $D T0!3 ,X 6P#+ &, R !J ,8 < #% '8 PP![ ,$
M@0#  (< O@". +P E "[ )P N0"D +< K@"U +D LP#( +$ WP"P >\ KP'[
M *X"_P"M _\ K0/_ *T#_P#_$   _PX  /\-  #V"P, \@<* .(!$0#; AT
MT@,K ,P#-P#(!$, Q 1- ,$$5@"^!5T O 5D +H%:P"X!7$ MP5V +4%? "S
M!H, L@:) + &D0"O!YD K0>A *L'JP"I"+< J G& *8*W0"E"_  HPS] *(-
M_P"A#?\ H0W_ * -_P#_$0  _!(  .P3  #B$P  VP\# -8)"P#."!0 Q@HB
M , ,, "\#3P N U& +4-3P"R#E< L Y? *X.90"M#FL JPYQ *H.> "H#GX
MIP^% *4/C0"D#Y8 HA"? * 0J0"?$+4 G1'% )L1W@"9$O$ EQ/_ )84_P"5
M%/\ E13_ )04_P#_%0  [1L  . ?  #2'P  R1L  ,04!0#!$ X NA(; +03
M*0"P%#4 K!5  *D520"F%5( I!99 *(68 "A%F8 GQ9L )X6<@"<%GD FQ>
M )D7B "8%Y$ EAB; )08I@"3&;( D1G! ) :V "-&^X BQS] (H<_P"*'/\
MB1S_ (D<_P#T'0  Y"4  -,I  #'*@  O"8  +8@  "T&0L KAH5 *@<(P"D
M'2\ H1XZ )X>1 ";'DP F1Y4 )<?6P"5'V$ E!]G )(?;0"1'W0 CR!\ (X@
MA ",((T BB"7 (DAH@"'(:X AB*] (4BT0&"(^L!@23[ 8 D_P%_)/\!?R3_
M 7\D_P'L)0  VRT  ,DQ  "\,0  L2X  *LI  "G) 4 HR,1 )XD'0":)2H
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M FPTF )J-:4":36S V@UQ@-G-N(#9C;U V8V_P)F-O\"9C;_ F8V_P+8-P
MQ#X  +5"  "F00  FS\  ),\  "-.   B#8' (0W$0" -QP ?#@G 'HX,0!W
M.3H =3E" ',Y20!Q.5  <#E7 &XY70!L.60!:SEK 6DY= %H.7X"9CF) F0Y
ME0-C.J(#8CJQ V$ZPP-@.^ $7SOS U\[_P-?._\#7SO_ E\[_P+1.P  P$(
M +!%  "A1   E4,  (U   "'/0  @CL" 'T[#@!Y/!@ =3TC ',]+0!P/38
M;CT_ &P]1@!K/4T :3U3 &<]6@!F/6$!9#UH 6,]<0%A/GL"7SZ& EX^DP-<
M/J #6S^O!%H_P01:/]T$63_R!%D__P-9/_\#63__ UD__P/,/P  O$8  *M(
M  "<1P  D48  (A$  ""0   ?#\  '= # !S0!4 ;T$@ &Q!*@!J03, :$$[
M &9"0P!D0DH 8T%0 &%!5P!@0EX!7D)E 5U";@);0G@"6D*$ UA"D -70IX$
M5D.M!%5#OP140]H$5$/Q!%1#_@-40_\#5$/_ U1#_P/(0@  N$D  *=+  "8
M2@  C4D  (-'  !]0P  =D,  '%$"@!M1!( :D4= &=%)P!D13  8D4X &!%
M/P!?14< 745- %M%5 !:1EL!649C 5=&; %61G8"5$:! U-&C@-21YP$4$>K
M!%!'O01/1]8%3T?O!$]'_01/1_\#3T?_ U!'_P/$10  M4T  *--  "53
MB4L  ']*  !X1@  <4<  &Q'!P!H2!  9$@: &%)) !?22T 74DU %M)/0!9
M240 5TE* %9)40!52ED!5$IA 5)*:0%12G0"3TI_ TY*C --2IL$3$NJ!$M+
MO 1*2],%2DON!$M+_01+2O\#2TK_ TM*_P/!2   LE   *!/  "13P  A4X
M 'M-  !S20  ;$H  &=+! !B3 X 7TP7 %Q-(0!:32H 6$TR %9-.@!434$
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M SQ7^@,]5O\#/5;_ SU6_P.V4P  I5<  )17  "%5@  >58  &]6  !E50
M7%8  %=8  !260< 3EH0 $Q:& !*6R$ 2%PJ $=<,@!%7#H 1%U! $-=2 !"
M75  0%U8 #]=80$]76L!/%UV CI=A (Y79,".%VC S==M0,V7<L#-ESH S=<
M^0,W6_\#.%O_ SA:_P.R5P  H%H  (]9  "!60  =5D  &M9  !@6@  5EL
M %%=  !,7@( 2& - $5@% !$81X 0F(F $!B+@ _8C8 /F,^ #UC10 \8TT
M.V-5 #EC7@ X8V@!-F-T 35C@0$S8Y$",F.A C%CLP(Q8\@",6+G C%A^ (Q
M8?\",F#_ C)@_P*N7   FUT  (I=  !\70  <%T  &9=  !<7@  4F   $QB
M  !%90  068* #YG$0 \:!H .V@B #EI*P X:3( -VHZ #9J00 U:DD -&I2
M #-J6P Q:F4 ,&IP 2YJ?@$M:HX!+&J? 2MJL $J:L8!*FGE 2IH]@(K9_\"
M*V?_ BMG_P*I80  E6   (1@  !W8   ;&$  &)A  !88P  3F8  $=H  !
M:P  .FX% #9O#@ T<!4 ,W > #)Q)@ P<2X +W$U "YR/0 M<D4 +')- "MR
M5P J<F$ *7)M "=R>P F<HL )'*< 2-RK@$C<L,!(W'B 2-P] $C;_\!(V[_
M 2-N_P&A90  CF0  ']D  !R9   :&4  %YF  !4:0  26P  $)O   [<@
M-'4  "YX"@ K>1$ *GD8 "EZ(0 G>B@ )GHP "5[.  D>T  (WM( ")[4@ A
M>UP ('MH !]\=@ =?(8 ''N8 !M[J@ :>[\ &GO> !IY\@ ;>/X &W?_ 1MW
M_P&9:0  B&D  'EI  !M:0  8VH  %EL  !/;P  17,  #UW   U>@  +GT
M ">! P B@PT ((02 !^$&@ =A"( '(4J !N%,0 :A3D &85" !B&3  7AE8
M%H9C !6&<0 4AH$ $H:3 !&&I@ 1A;L $(76 !&#[P 1@OL $H+_ !*!_P"1
M;@  @6T  '1N  !I;@  77   %-S  !)=P  0'P  #>    O@P  )X<  "&*
M   :C08 %8\- !.0$P 2D!H $I B !&0*@ 0D3( $)$[  ^11  .D4\ #9%<
M  R1:@ +D7H "I&-  B0GP 'D+, !X_)  >/Y@ 'CO0 "(W\  B-_P")<P
M>W,  &]S  !C=0  5W@  $U]  !#@0  .88  #"*   HC@  (9$  !J5   3
MEP  #IH(  N<#@ )G!, ")P:  ><(@ &G"H !)PS  .</0 "G4@  )U4  "=
M8@  G'(  )R$  "<EP  FZH  )N_  ":VP  FNP  )KU  "9^ "">0  =GD
M &AZ  !<?@  48(  $:'   \C   ,I$  "F5   AF0  &9T  !*@   .HP
M":8%  .G#   IQ   *<5  "H'   J",  *@K  "I-   J3\  *E+  "I60
MJ6@  *EZ  "IC@  J:$  *BU  "HRP  I^0  *?O  "G\P!]@   ;X$  &&$
M  !5B0  28X  #Z4   TF0  *IX  "&B   9I@  $JD   VL   'KP   +(
M  "S!P  LPP  +,0  "T%0  M!L  +4B  "V*P  MS4  +=   "X3@  N%T
M +AN  "X@@  N)<  +BJ  "WO@  M](  +?F  "WZ@!VB   9XL  %J0  !.
ME@  0IP  #>B   LIP  (JL  !FO   1LP  "[8   2Y    O    +X   "^
M    OP8  , +  #!#P  PA,  ,,9  #$(   Q2D  ,<T  #(0@  R5$  ,EB
M  #)=0  R8H  ,F?  #*L0  RL$  ,G1  #)V0!NDP  8)@  %.>  !&I
M.JL  "^P   DM0  &;@  !"\   *OP   <$   #$    R    ,H   #*
MS    ,T#  #."   T T  -$0  #3%@  UAX  -HH  #=-   WD,  -]4  #?
M9P  X'P  ."1  #@I   X+(  ."^  #@PP!FGP  6:8  $RM   _M   ,K@
M "2\   8OP  $,,   C'    R@   ,T   #1    U0   -@   #9    VP
M -T   #?    X00  .,*  #E#@  YQ,  .H<  #M)P  \#4  /%&  #R6
M\VL  /.   #TE   ]*,  /2N  #TL@#_ !, _P 1 /\ $0#_ !4 _P ? /\
M+ #_ #D _P!% /\ 4 #_ %H _@!C /L :P#Y '( ]P!X /4 ?@#T (0 \@")
M /$ C@#P ), [@"9 .T GP#L *8 Z@"N .@ N #F ,4 Y0#; ., [0#B /L
MX@#_ .$ _P#A /\ X0#_ .$ _P#_ !  _P . /\ #0#_ !( _P ; /\ * #_
M #0 _@!! /L 3 #W %8 ] !? /$ 9@#O &T [ !T .H >@#I '\ YP"% .8
MB@#E (\ XP"5 .$ FP#@ *( W@"J -L M #9 ,  U@#0 -, Z #2 /< T0#_
M -$ _P#0 /\ T #_ -  _P#_  T _P ) /\ "@#_  \ _P 6 /L (@#W "\
M]  [ /  1P#M %$ Z0!: .4 8@#B &D X !O -X =0#< 'H V@"  -@ A0#5
M (L TP"1 -$ EP#/ )X S0"F ,L KP#) +H QP#) ,4 X@#$ /( PP#^ ,(
M_P#! /\ P@#_ ,( _P#_ P8 _P ! /\ !@#_  P ^0 1 /$ '0#K "D YP V
M ., 00#? $L VP!4 -4 7 #2 &, SP!J ,T < #+ '4 R0![ ,@ @ #& (8
MQ0", ,, DP#! )H OP"B +T JP"[ +8 N0#$ +< V@"V .T M #Z +0 _P"T
M /\ M #_ +0 _P#_!   _P   /\   #_  8 [  - .4 %@#> "( UP O -$
M.P#- $4 R@!. ,8 5P#$ %X P0!D +\ :@"] '  O !U +H >P"Y ($ MP"'
M +4 C@"S )4 L@"> +  IP"N +( K "_ *H T0"H .@ J #W *< _P"G /\
MI@#_ *8 _P#_!@  _P4  /$#  #H    X0 ' -4 $ #- !L QP G ,, ,P"_
M #X O !( +D 40"V %@ M !? +( 90"P &H KP!P *T =@"L 'P J@"" *D
MB0"G )$ I0": *, I "A *X H "[ )X!S0"= N8 G 3T )L$_P":!?\ F@7_
M )D%_P#_"@  \0X  .00  #9#P  S@L  ,@#"P#" !, O (? +<#+ "S!#<
ML 5" *T&2@"J!E( J =9 *8'7P"E!V4 HP=K *((<0"@"'< GPA^ )T(A0";
M"8X F@F7 )@*H0"6"JP E0NZ ),+S "2#.4 D WV (\._P".#O\ C@[_ (T.
M_P#V$0  YA<  -8;  #'&0  OA4  +D0  "W"@T L0L7 *P-) "H#C  I0X[
M *(.1 "?#TP G0]3 )L/6@":#V  F!!F )<0; "5$'( DQ!Y )(0@0"0$(H
MCQ&4 (T1GP"+$:H BA*X (@2RP"&$^8 A13W (,5_P"#%?\ @A7_ ((5_P#M
M&@  W"$  ,HE  "[(@  L1\  *L:  "I% 8 I1(1 * 4'@"<%2H F14U )86
M/@"4%D< DA9. ) 650".%UL C!=A (L79P")%VT B!=T (88? "%&(8 @QF0
M ($9FP" &J< ?AJU 'T;QP!\'.( >AWU 'D=_P!X'?\ >!W_ '@=_P#E(@
MT"D  +\L  "P*@  IR<  * C  "='P  FAH. )4<& "1'20 CAXO (P>.0")
M'D$ AQ]) (4?4 "#'U8 @A]< ( ?8@!_'VD ?2!P 'P@> !Z(($ >2&, '<A
MEP!U(J0 ="*R ',CPP!R(]\ <"3S &\D_P!O)/\ ;B3_ &XD_P#=*0  R#
M +<R  "H,   GBX  )<J  "3)P  D",* (PC$P"()!\ A"4J ((E- " )CT
M?29$ 'PF2P!Z)E( >"98 '<F7@!U)F4 ="=L '(G= !Q)WT ;RB( &XHE !L
M**$ :RFO 6HIP %I*ML!9RKQ 6<K_P%F*_\!9BK_ 68J_P'4+P  PC8  *\V
M  "A-0  EC0  ) P  "*+0  ARH& (,I$ !_*AH ?"LE 'DK+P!W+#@ =2Q
M ',L1P!Q+$T <"Q4 &XL6@!M+&$ :RUH &HM< !H+7H 9RZ% &4ND0%D+IX!
M8B^L 6$OO0%A,-4!8##O 5\P_0%?,/\!7S#_ 5\P_P'--   O#L  *DZ  ";
M.@  D#@  (DU  "#,@  ?S ! 'LO#@!W,!8 =# A '$Q*P!O,30 ;3$\ &LQ
M0P!J,4H :#)0 &<R5P!E,ET 9#)E &(R;0!A,W< 7S." 5XSC@%=-)P!6S2J
M 5HUNP%:-=(!637M 5DU_ %8-?\!6#7_ 5DU_P'(.   MSX  *0^  "6/0
MBSP  (,Z  !]-P  >#0  '0T"P!P-1, ;34= &HU)P!H-C  9C8X &0V/P!C
M-D8 839- & V4P!>-UH 73=B %PW:@!:.'0!63A_ 5<XC %6.9D!53FH E0Y
MN0)3.L\"4SKK E,Z^P%3.O\!4SG_ 5,Y_P'$/   LD$  *!   "20   AC\
M 'X]  !X.@  <S@  &XY" !J.1$ 9SD: &0Z) !B.BP 8#HT %XZ/ !=.T,
M6SM* %H[4 !8.U< 5SM? %8\9P!4/'$!4SQ\ 5(]B0%1/9<!3SVF DX^MP).
M/LT"3C[I DT^^@)./O\!3CW_ 4X]_P' /P  KD,  )Q#  ".0P  @D(  'I
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M D1%^ )$1?\"147_ D5%_P&Z1@  ID@  )1(  "&2   >T<  ')&  !J0@
M8T,  %Y$  !:10L 5D42 %1&&P!11B, 3T8K $Y&,P!,1SH 2T=! $I'20!)
M2%  2$A8 $=(80!&26L 1$EV 4-)@P%"29(!04FB D!)LP(_2L<"/TKE C])
M]P) 2?\"0$C_ D!(_P&V20  HDH  )%*  "#2@  =TH  &Y)  !E10  7D<
M %E(  !520@ 44H0 $]*& !,2B$ 2DLI $E+,0!'2S@ 1DP_ $5,1@!$3$X
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M 3%5_P&H4@  E5(  (12  !W4@  ;%(  &)2  !84P  3U0  $E6  !$5P
M0%D( #U:$  [6A< .5L@ #A;)P W7"\ -EPV #5</@ T7$8 ,UU. #%=5P P
M76$ +UUL "Y=>@ L78D *UV: 2I=JP$J7;\!*5W> 2I<\@$J6_X!*UO_ 2M:
M_P&C50  CU4  ']5  !R50  9U8  %Y6  !45P  3%D  $5;   _70  .E\$
M #9@#0 T81, ,F(< #%B(P P8BL +V,R "YC.@ M8T( +&-* "ID4P I9%T
M*&1I "=D=@ F9(8 )627 "1DJ0 C9+T (F3: "-C\0 C8OT!)&'_ 21A_P&<
M6   B5@  'I9  !N60  8UD  %I:  !07   2%X  $%@   Z8P  -&8  "]H
M"@ L:1  *FD7 "EJ'P H:B8 )VHN "9K-0 E:ST )&M& "-K3P B;%D (&QE
M !]L<@ >;(( '6R4 !QLI@ ;:[H &FO4 !MJ[@ <:?P '&C_ !QH_P"57
M@UP  '5<  !I70  7UT  %9>  !,80  0V0  #QG   U:@  +VT  "AP!  C
M<@T (7(2 "!S&@ ?<R$ 'G,H !UT,  <=#@ &W1  !IT2@ 9=%0 %W5@ !9U
M;@ 5=7X %'60 !-TH@ 2=+8 $73/ !)S[  2<OH $W'_ !-Q_P".8   ?6
M &]A  !E80  6V(  %%D  !(9P  /FL  #=N   P<0  *74  ")X   <>P<
M%WT. !9]$P 5?1L %'XB !-^*@ 2?C$ $7XZ !%^1  0?TX #W]:  Y_:  -
M?W@ #'^*  M^G0 *?K  "7W&  I]Y  *?/0 "WO]  MZ_P"&90  =V4  &IE
M  !A9@  5F@  $QK  !";P  .7,  #%W   J>@  (WX  !R!   5A   $(<(
M  V)#@ ,B10 #(D;  N)(P *B2L "8DS  B)/0 &B4@ !8E4  2)80 "B7$
M 8F#  ")E@  B*D  (>^  "'V@  ANP  (;U  "&^@!^:@  <6H  &=K  !;
M;   4'   $9T   \>   ,WT  "J!   CA0  '(@  !6,   0CP  #)(&  :3
M#  "DQ$  )06  "4'0  E"0  )4L  "5-0  E4   )5,  "660  EFD  )5Z
M  "5C@  E*$  )2U  "3S   DN8  )+R  "2]P!X<   ;7   &!R  !4=0
M27D  #]^   U@P  +(@  ".-   ;D0  %)0   ^7   *F@  !)T#  ">"0
MGPX  )\2  "@%P  H!T  *$E  "B+0  HC<  *-#  "C4   HU\  *-Q  "C
MA   HID  **M  "AP@  H=P  *'K  "@\@!S=@  9G<  %E[  !-@   0H4
M #B+   ND   ))4  !N:   4G@  #J$   FD   "IP   *H   "K!   JPH
M *P-  "M$0  K18  *X<  "O)   L"T  +$Y  "Q1@  LE4  +)F  "R>0
MLHX  +&C  "RMP  L<H  +'@  "QZ0!L?@  7X(  %*'  !&C0  .Y,  #"9
M   FG@  '*,  !.G   -JP  !ZX   "R    M0   +<   "X    N0(  +D(
M  "Z#   NQ   +P4  "]&P  OR,  ,$M  #".@  PDD  ,-:  ##;   Q((
M ,27  #$JP  Q+P  ,3+  #$V@!EB0  6(X  $N5   _FP  ,Z(  "BH   =
MK0  %+$   VV   &N0   +P   "_    PP   ,0   #%    Q@   ,<   #)
M!   R@D  ,L-  #-$0  SQ@  -(A  #5+0  UCP  -A-  #97P  VG,  -J*
M  #;G@  VZX  -NZ  #<PP!>E@  49P  $2C   XJ@  ++$  ""W   5NP
M#;X   3"    Q0   ,D   #-    T    -(   #2    U0   -8   #9
MVP   -X%  #@"@  X@\  .46  #H(   ["T  .T^  #M40  [F4  .]Z  #O
MCP  \)\  /"K  #PLP#_ !  _P . /\ #@#_ !( _P = /\ *0#_ #4 _P!!
M /\ 30#^ %8 ^P!? /@ 9@#V &T ] !T /( >0#Q '\ \ "$ .X B0#M (\
MZP"5 .H FP#H *( Y@"J .4 LP#C ,  X0#2 .  Z@#? /D W0#_ -T _P#=
M /\ W@#_ -X _P#_  T _P * /\ "0#_  \ _P 8 /\ ) #^ #$ ^P ] /@
M2 #T %( \ !: .T 8@#K &D Z0!O .< =0#E 'H XP!_ .( A0#@ (H W@"0
M -P E@#: )T V "E -4 KP#2 +H T #* ,X XP#- /0 RP#_ ,L _P#+ /\
MRP#_ ,L _P#_  @ _P # /\ !0#_  P _  4 /< 'P#R "L [P W .L 0@#G
M $P Y !5 .  70#= &0 V@!J -@ < #5 '4 T@!Z -  @ #/ (4 S0"+ ,L
MD@#) )D QP"A ,4 J@## +4 P0## +\ V@"^ .X O0#\ +P _P"\ /\ O #_
M +P _P#_    _P   /\   #Y  < \0 0 .H &@#D "4 WP Q -L / #7 $<
MT@!0 ,X 5P#+ %X R0!E ,8 :@#% '  PP!U ,$ >@#  (  O@"& +P C0"Z
M )0 N0"< +< I0"U +  LP"] +$ SP"O .@ K@#X *X _P"M /\ K0#_ *T
M_P#_    _P   /T   #N  $ XP , -H % #1 !\ S  K ,@ -@#% $  P@!*
M +\ 4@"\ %D N@!? +@ 90"V &H M !O +, =0"Q 'H L "! *X B "M (\
MJP"8 *D H0"G *L I0"X *, R "B .( H0#S *  _@"@ /\ H #_ *  _P#_
M    ]@   .H   #@    TP & ,D #P#" !@ O0 D +D +P"V #H M !# +$
M3 "N %, K !9 *H 7P"I &0 IP!J *8 ;P"D '4 HP![ *$ @@"@ (H G@"3
M )P G0": *< F "T )8 PP"5 -P E #O ), ^P"3 /\ DP#_ )( _P#Y!0
MZ@L  -P-  #+"@  P@4  +P "@"V !$ L0 < *X * "J #, IP ] *0 10"B
M $T H !3 )X 60"< %\ FP!D )H :@"8 '  EP!V )4 ?@"3 (8 D@&/ ) !
MF0". J0 C *Q (L#P ")!=8 B ;M (@'^@"'"/\ A@C_ (8(_P#O#P  WA0
M ,H5  "\$@  LQ   *X,  "K!@T IP,5 *(%( "?!RP G @V )D(/P"7"4<
ME0E. ),)5 "1"EH D I? (X*90"-"FL BPIR (H+>0"("X( APN, (4,EP"#
M#*( @0VP ( -P !_#=@ ?0[O 'P/_0![#_\ >Q#_ 'L0_P#F%P  T1X  +T=
M  "O'   IAD  *$5  ">$ 0 G0T/ )@.&0"4#B4 D0\O (\0.0",$$$ BA!(
M (@03P"'$%4 A1!; (0180""$6< @!%N '\1=0!]$7X ?!*( 'H2E !X$J
M=Q.N '43O@!T%-4 <Q7N '$6_0!Q%O\ <1;_ ' 6_P#<'P  QB4  +,E  "E
M(P  G"$  )8>  "2&0  D10+ (T4% ")%1\ AA8I (,6,P"!%SP @!=# 'X7
M2@!\%U  >A=6 'D87 !W&&( =AAI '08<0!S&7H <1F$ &\:D !N&IT ;!NK
M &L<NP!J'-  :1WL &@>^P!H'O\ 9Q[_ &<>_P#1)@  O2H  *LJ  "=*@
MDR@  (TE  "((@  AAT& (,;$ !_'!H ?!TD 'H=+@!W'C8 =AX^ '0>10!R
M'TL <1]1 &\?6 !N'UX ;!]E &L@;0!I('8 :"&! &8AC0!E(IH 8R*H &(C
MN !A(\T 8"3I & D^@!?)/\ 7R3_ %\D_P#*+   MB\  *0O  "6+P  C"T
M (4J  " *   ?20  'HB#0!V(Q4 <R,@ '$D*0!O)#( ;20Z &LE00!J)4<
M:"5- &8E5 !E)5H 9"9A &(F:0!A)G( 7R=] %XGB@!=*)< 6RFE %HIM0!:
M*LH 62KG %@J^ !8*O\ 6"K_ %@J_P#%,0  KS,  )XS  "0,P  AC(  '\O
M  !Y+0  =2H  '(H"@!O*!( :RD; &DI)0!G*BT 92HU &,J/0!B*D, 8"I*
M %\K4 !>*U< 7"M> %LL9@!9+&\ 6"UZ %<MAP!6+I4 5"ZC %,OLP!3+\<
M4B_E %(O]P!2+_\ 4B__ %(O_P#!-@  JC8  )DV  "+-@  @34  'DS  !S
M,0  ;R\  &LN!@!H+1  9"X8 &(N(0!@+RH 7B\Q %PO.0!;+T  62]& %@O
M30!7,%, 5C!; %0Q8P!3,6P 4C)W %$RA !/,Y( 3C.A $TSL0!--,4!3#3C
M 4PT]@!,-/\ 3#3_ $PS_P"[.0  ICD  )4Y  "'.0  ?#D  '0W  !N-
M:3,  &4R @!A,@T 7C(4 %PS'@!:,R8 6#,N %8S-0!5-#P 4S1# %(T2@!1
M-%  4#58 $XU8 !--FH 3#9U $LW@@!*-Y  23B? $@XL %'.,,!1SCA 4<X
M]0%'./\!1SC_ 4<X_P&W.P  HCP  )$\  "#/   >#P  ' Z  !J-P  9#8
M & V  !<-@L 63<2 %8W&@!4-R, 4C<K % W,@!/.#D 33A  $PX1P!+.$X
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M 3E#_P&J0@  ED,  (9#  !X0P  ;D,  &5#  !=0   5D   %%"  !-0@(
M24,, $9#$@!$1!H 0D0B $%$*@ _13$ /D4X #U%/P \1D< .T9/ #I&5P Y
M1V$ .$=L #='>@ V2(D -4B9 #1(J@ T2+T ,TC9 #1(\  T1_T -$?_ #5&
M_P"F1   DD4  ()&  !U1@  :D8  &%%  !91   440  $Q&  !(1P  1$<*
M $%($  _21@ /4D@ #Q))P Z2BX .4HV #A*/0 W2T0 -DM, #5+50 T3%\
M,TQJ #),=P Q3(8 ,$R7 "]-J  N3;L +DW5 "Y,[P O3/T +TO_ #!+_P"A
M1P  CD@  'Y(  !Q2   9DD  %U(  !52   3$D  $=*  !"2P  /TP& #M-
M#@ Y3A4 -TX= #9/)  U3RL ,T\S #)0.@ Q4$( ,%!* "]14@ N45P +5%G
M "Q1=0 K480 *E*5 "E2I@ I4KD *%+2 "E1[@ I4/P *E#_ "I/_P"<2@
MB4H  'I+  !M2P  8TP  %I,  !13   2$T  $-/   ]4   .5(" #53#  S
M5!( ,509 #!5(0 N52@ +54O "Q6-P K5CX *E9& "E63P H5UD )U=D "97
M<@ E5X$ )%>2 "-7I  B5[< (E?/ ")7[  C5OH (U7_ "15_P"630  A$X
M '5.  !I3@  7T\  %9/  !-4   15(  #]3   Y5@  ,U@  "]:"  K6P\
M*EL5 "A<'0 G7"0 )EPK "5<,P D73H (UU# ")=3  A758 (%YA !]>;@ >
M7GX '5Z/ !Q>H0 ;7K0 &EW, !M=Z0 ;7/D '%O_ !Q;_P"040  ?E$  '!1
M  !D4@  6U(  %)3  !*5   05<  #M9   U6P  +EX  "A@ P D8@P (F,1
M "%C&  ?9"  'F0G !UD+@ <9#8 &V4^ !IE1P 995$ &&5= !=E:@ 697H
M%66+ !1EG@ 39;$ $F7( !)DYP 38_< %&+_ !1B_P")5   >%4  &M5  !@
M5@  5U8  $]7  !&60  /5P  #9?   P8@  *60  "-G   =:@< &6P. !AL
M$P 6;1H %6TA !1M*0 4;3  $VTY !)N0@ 1;DP $&Y8  ]N90 .;G4 #6Z'
M  UNF@ ,;:T "VW"  MLX  ,:_, #6O]  UJ_P""60  <ED  &99  !<6@
M5%H  $I<  !!7P  .6,  #%F   J:0  )&P  !UO   7<@  $G4)  ]W#P .
M=Q0 #G<;  UW(P ,=RH "W<S  IW/  )=T< "'=2  =W7P %=V\ !'>   -W
ME  !=J<  ':[  %UU0 !=.L  G3V  )T_ ![70  ;5T  &)>  !97@  3F
M $5C   \9P  ,VL  "MN   D<@  'G4  !=Y   2?   #7\&  F!#  %@1$
M X$6  *!'0 !@20  ($M  ""-@  @D   (),  ""60  @F@  ()Y  ""C0
M@:   ("T  " RP  ?^<  '[R  !^^0!T8@  :&(  %YB  !39   26<  #]K
M   V<   +70  "5X   >?   %X   !&#   -A@  "(D$  *+"@  BPX  (L3
M  ",&   C!\  (TF  "-+P  CCD  (Y$  ".40  CF   (YQ  ".A0  CID
M (VM  ",PP  C-\  (ON  "+]@!N:   9&<  %AI  !-;   0G$  #AV   O
M>P  )G\  !Z$   6B   $(P   R/   &D@   )4   "6!P  EPP  )</  "8
M$P  F1@  )H?  ";)@  FS   )P[  "<2   G%<  )QH  "<>P  G)   )NE
M  ";N@  FM   )KG  ":\0!J;0  7F\  %%R  !&=P  .WP  #&"   GAP
M'HP  !:1   0E0  "ID   2<    H    *(   "C 0  HP8  *0+  "E#@
MIA(  *<7  "H'@  JB8  *LQ  "K/@  K$T  *Q=  "L<   K(4  *R;  "K
MKP  J\,  *O9  "JZ !D=0  5WD  $M^   _A   -(H  "F0   ?E@  %IL
M !"?   )HP   :<   "J    K@   +    "P    L0   +(#  "T"   M0T
M +80  "W%0  N1T  +LF  "\,P  O4$  +U2  "]9   OGD  +Z0  "]I
MO;<  +W&  "]UP!<?P  4(4  $2+   XD@  +)D  "&?   7I   $*D   FN
M    L@   +8   "Y    O0   +\   "_    P    ,$   ##    Q 4  ,8*
M  #'#@  R1,  ,L<  #.)@  T#4  -%%  #25P  TFL  -."  #3EP  TZD
M -*X  #2Q !5C   29,  #V:   PH@  ):@  !JN   1M   ";D   "]
MP0   ,0   #(    RP   ,T   #-    SP   -    #2    U    -@   #:
M!@  W0P  . 1  #C&@  YB<  .<X  #H2@  Z5T  .IR  #KB   ZYL  .RH
M  #LL@#_  T _P + /\ "P#_ !  _P : /\ )@#_ #( _P ] /\ 2 #[ %(
M^ !: /8 8@#S &D \0!O /  =0#N 'H [ !_ .L A #I (H Z "0 .8 E@#D
M )T X@"E .$ KP#? +L W0#+ -L Y@#9 /< V #_ -@ _P#7 /\ UP#_ -0
M_P#_  @ _P $ /\ ! #_  T _P 5 /X (0#Z "P ]P X /0 0P#P $T [0!5
M .H 70#G &0 Y !J .( < #@ '4 W@!Z -T ?P#; (4 V0"+ -4 D0#3 )D
MT0"@ ,\ J@#- +4 RP#$ ,D W0#( /$ QP#_ ,8 _P#& /\ Q@#_ ,< _P#_
M    _P   /\   #_  H ^  1 /$ ' #L "< Z0 R .8 /0#B $< W0!0 -D
M6 #5 %\ T@!E -  :@#. '  S !U ,H >@#) '\ QP"% ,4 C ## )0 P0"<
M +\ I0"] +  NP"] +H T "X .L MP#[ +8 _P"V /\ M@#_ +8 _P#_
M_P   /T   #S  4 Z0 . .$ %@#; "$ U0 M -$ -P#. $$ R@!* ,< 4@#$
M %D P@!? ,  90"^ &H O !O +L = "Y 'H MP"  +8 AP"T (X L@"7 +
MH "N *H K0"W *L R "I ., J #U *< _P"G /\ IP#_ *8 _P#_    _@
M /$   #E    UP * ,T $0#' !P P@ F +\ ,0"\ #L N@!$ +< 3 "T %,
ML@!9 +$ 7P"O &0 K0!I *P ;P"J '0 J0!Z *< @0"F (D I "1 *( FP"@
M *4 G@"R )T P0"; -H F@#O )D _0"8 /\ F #_ )@ _P#]    \    .$
M  #1    Q@ $ +T #0"W !4 LP @ +  *P"M #4 JP ^ *@ 1@"F $T I !4
M *, 60"A %\ H !D )X :0"= &X FP!U )H >P"8 (, E@", )4 E@"3 *$
MD0"M (\ NP"- ,\ C #I (L ^ ", /\ C #_ (P _P#S @  X@<  ,P'  "_
M!   MP   +$ " "K !  IP 9 *0 ) "@ "X G@ W )P 0 ": $< F !. )8
M5 "5 %D DP!> )( 9 "0 &D CP!O (T =@"+ 'X B@"( (@ D@"& )T A0"I
M (, N "! ,H @ #E (  ]0!_ /\ ?P#_ '\ _P#H#0  T!   +X0  "Q#@
MJ T  *,(  "@ @P G  3 )@ '0"5 "< D@ Q )  .0". 4$ C %( (H"3@")
M E0 AP)9 (8"7P"$ V0 @P-K ($#<@" !'H ?@2$ 'T%C@![!9H >0:G '@&
MM0!V!\@ =0CC '4)] !T"O\ <PK_ ',*_P#=%0  Q!<  +$7  "E%@  G!,
M )81  "4#00 DP@- (X'%0"+"2  B DJ (4*,P"#"SL @0M" ( +20!^"T\
M?0Q4 'L,6@!Z#&  > QG '<,;@!U#78 = V  '(-C !P#9D ;PZF &T.M0!L
M#LD :P_F &H0]P!I$/\ :1#_ &D0_P#0'0  N1X  *@>  ";'0  DAL  (L9
M  "(%0  AQ$' (4.$ "!#QH ?A D 'L0+0!Y$#8 =Q$] '811 !T$4H <Q%0
M '$15@!P$5P ;A)B &T2:@!K$G, :1-] &@3B0!F$Y8 912C &,5LP!B%<8
M8A;C &$6]@!@%_\ 8!?_ & 7_P#'(@  L",  )\D  "2(P  B2(  ((@  !^
M'0  ?!D  'H5#0!W%14 =!8? '$6* !O%S  ;A<X &P7/P!K%T4 :1A+ &@8
M40!F&%@ 91A> &,99@!B&6\ 8!EY %\:A0!=&Y( 7!NA %L<L !:',, 61W@
M %@>] !8'O\ 6![_ %@>_P"_)P  J2@  )DH  "+*   @B<  'LE  !V(P
M<R   '$<"0!N'!$ :QP: &D=(P!G'2P 91TS &,>.@!B'D$ 8!Y' %\>30!>
M'E0 7!]; %L?8@!9(&L 6"!V %8A@@!5(9  5"*> %,BK@!2(\  42/= %$D
M\@!1)/\ 423_ %$C_P"Y*P  HRP  ),L  "&+0  ?"P  '0J  !O*   :R4
M &DB!0!F(0X 8R(6 &$B'P!?(R< 72,O %PC-@!:(ST 621# %<D2@!6)%
M5217 %,E7P!2)6@ 429S $\F?P!.)XT 32B< $PHK !+*;X 2RG: $HI\0!*
M*?\ 2RG_ $LI_P"S+@  GB\  (XP  "!,   =R\  &\N  !J*P  92H  &,G
M 0!?)PP 7"<3 %HG&P!8*"0 5B@K %4H,@!3*#D 4BE  % I1@!/*4T 3BE4
M $TJ7 !,*F4 2BMP $DK? !(+(L 1RV: $8MJ@!%+KP 12[6 $4N[P!%+OX
M12[_ $4M_P"N,0  FC(  (DS  !\,P  <C,  &LQ  !E+P  8"T  %TL  !9
M+ D 5BP0 %0L& !2+"  4"PH $XM+P!-+38 3"T\ $HM0P!)+4H 2"Y1 $<N
M60!&+V, 13!M $,P>@!",8D 03&8 $$RJ ! ,KL /S+3 #\R[@! ,OT 0#+_
M $ R_P"J,P  EC4  (8U  !Y-@  ;C4  &8U  !A,@  7#   %<P  !4, 8
M43 . $XP%0!,,1T 2C$E $@Q+ !',3( 1C$Y $0Q0 !#,D< 0C)/ $$S5P!
M,V  /S1K #XU>  ]-8< /#:6 #LVIP [-KD .C;1 #HV[0 [-OP .S;_ #LV
M_P"F-@  DC<  ((X  !U.   :S@  &,W  !=-@  5S,  %,T  !/- , 2S0,
M $DT$@!&-1H 134B $,U*0!!-2\ 0#4V #\V/0 ^-D0 /3=, #PW50 [.%X
M.CAI #DY=@ X.84 -SJ5 #<ZI0 V.K@ -3K/ #8Z[  V.OL -CG_ #<Y_P"B
M.   CCD  'XZ  !R.P  :#L  %\Z  !9.0  4S8  $XW  !*.   1C@* $0Y
M$ !!.1< /SD? #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<[4P V/%P -3QG
M #0]=  S/8, ,SZ3 #(^I  Q/K8 ,3[- #$^Z@ Q/OH ,CW_ #(]_P">.P
MBSP  'L\  !N/0  9#T  %P]  !5/   3CH  $D[  !%/   03T' #X]#@ \
M/14 .CX< #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 4  Q0%H ,$%E "]!
M<@ N0H$ +4*1 "U"H@ L0K4 *T++ "Q"Z0 L0OD +4'_ "U!_P"9/0  ASX
M '<_  !K/P  84   %D_  !2/P  23X  $0_  ! 0   /$$$ #E"#0 W0A(
M-4,9 #-#(0 R0R@ ,40O #!$-@ O1#T +D5% "U%3@ L15@ *T9C "I&;P I
M1GX *$:/ "='H0 F1[, )D?) "9&YP G1O@ *$7_ "A%_P"50   @D$  '-"
M  !G0@  7D(  %5"  !.0@  14(  #]$   [10  -T8  #1'"@ Q2!  +T@6
M "Y)'@ L224 *TDL "I),P I2CH *$I" "=*2P F2U4 )4M@ "1+;0 C2WP
M(DN- "%,GP A3+$ ($S' "!+Y@ A2_< (DK_ ")*_P"00P  ?D0  &]$  !D
M10  6D4  %)%  !*1@  04<  #Q(   W20  ,DL  "Y-!P K3@X *4X3 "=/
M&@ F3R$ )4\H "1/,  C4#< (E _ "%02  @4%( 'U%= !Y1:@ =47D '%&*
M !M1G  :4:\ &5'% !E1Y  :4/8 &T__ !Q/_P"*1@  >4<  &M'  !@2
M5D@  $Y(  !'20  /DL  #E,   S3@  +E   "A3 @ D5 L (E40 "!5%@ ?
M5AX 'E8D !U6+  <5C, &U<[ !I71  95TX &%=9 !=89@ 56'4 %%B' !18
MF@ 35ZP $E?" !)7X0 35O0 %%7_ !15_P"$20  =$H  &9+  !<2P  4TL
M $M,  !$30  /$\  #51   O5   *58  "19   >6P< &ET- !A=$@ 771D
M%EX@ !5>)P 47BX $UXW !)>0  17TH $5]5 !!?8@ /7W$ #E^#  U?E@ -
M7ZD #%Z^  Q>V@ -7?  #5S\  Y<_P!^30  ;DX  &).  !83P  3T\  $A0
M  ! 4@  .%0  #!7   J6@  )%T  !]?   98@$ $V4) !%F#P 09A0 #V8;
M  YG(@ -9RD #6<R  QG.P +9T4 "F=0  EG70 '9VP !F=]  5GD  $9J,
M F:W  -ESP $9>D !&3U  1D_ !W40  :5(  %U2  !44@  3%,  $-5   [
M6   ,UL  "M>   E80  'V0  !EG   3:@  #VT&  MP#  (<!$ !W 6  5P
M'0 $<"0  W L  )P-0  <#\  '!*  !P5P  <&4  '!V  !PB@  ;YX  &^R
M  !NR   ;>4  &WR  !M^0!P5@  8U8  %E6  #_XO__24-#7U!23T9)3$4
M! E15P  1U@  #Y;   V7P  +F(  "9F   ?:@  &6T  !-P   .<P  "W8$
M  5X"P !> \  'D3  !Y&0  >1\  'HF  !Z+P  >CD  'I$  !Z4   >E\
M 'IP  !Z@P  >I@  'JL  !YP@  >-\  'CO  !W]P!J6P  7UL  %9;  !,
M7   0F   #EC   P:   *&P  "!P   9=   $W<   Y[   )?@  !($"  ""
M"   @PT  (,0  "$%   A1D  (8@  "&*   AS$  (<\  "'20  AU<  (=H
M  "'>P  AY   (:E  "%N@  A=,  (3J  "$] !E8   7&   %%A  !&9
M/&D  #)M   I<@  (7<  !E[   2@   #8,   B'   "B@   (T   ".!
MC@D  (\-  "0$   D10  )(9  "3(   E"D  )4S  "50   EDX  )9?  "5
M<@  E8@  )6=  "4L@  E,@  )/B  "3[@!A90  5F8  $IJ   _;@  -70
M "MY   A?P  &80  !&)   ,C0  !I$   "4    F    )H   ";    G (
M )T'  ">"P  GPX  *$2  "B&   HR   *4I  "F-@  ID0  *95  "F:
MIGT  *:4  "EJ0  I+T  *31  "DY !;;   3W   $-U   X>P  +8$  ".'
M   9C0  $9(   N7   $G    *    "C    I@   *@   "I    J@   *P
M  "M!   K@D  + -  "Q$0  LQ<  +4@  "V*P  MSH  +=+  "X7   N'$
M +B(  "XG0  N+$  +?"  "WT !4=@  2'P  #R"   QB0  )I   !N7   2
MG0  #*(   .G    JP   *X   "R    M@   +@   "X    N@   +L   "]
M    O@   , %  #!"P  PQ   ,86  #)(   RBX  ,L^  #,4   S&0  ,UZ
M  #-D0  S:0  ,VT  #-P !-@P  08H  #61   IF0  'J   !.F   ,K
M [$   "V    N@   +X   #"    Q@   ,@   #(    R@   ,L   #-
MS@   -    #2 0  U0@  -D.  #=%0  X2$  .(Q  #D0P  Y58  .9K  #F
M@@  YY8  .>E  #FL #_  D _P % /\ !@#_  X _P 6 /\ (0#_ "T _P X
M /T 0P#Y $T ]0!5 /( 70#P &, [@!I .P ;P#J '0 Z0!Z .< ?P#F (4
MY "+ ., D0#A )D WP"A -P J@#: +8 UP#& -4 X0#3 /0 T@#_ -$ _P#1
M /\ SP#_ ,H _P#_  $ _P   /\  0#_  P _P 2 /H '0#V "@ \P S /
M/@#L $@ Z !0 .4 6 #B %X WP!D -T :@#; &\ V0!T -8 >@#4 '\ T@"%
M -  C #. ), S "< ,D I0#' +  Q@"^ ,0 U #" .X P0#^ ,  _P#  /\
MOP#_ +X _P#_    _P   /\   #Z  < \0 / .L & #F ", X@ N .  . #;
M $( U0!+ -$ 4@#. %D RP!? ,D 90#' &H Q@!O ,0 = #" 'H P0"  +\
MA@"] (X NP"6 +D H "W *H M@"W +0 R@"R .8 L0#X +  _P"O /\ KP#_
M +  _P#_    _P   /<   #J  ( X0 , -< $P#0 !T S  H ,D ,@#& #P
MP@!% +\ 30"\ %, N@!9 +@ 7P"W &0 M0!I +0 ;@"R '0 L0!Z *\ @ "M
M (@ K "1 *H F@"H *4 I@"Q *0 P0"C -P H0#R *$ _P"@ /\ H #_ *$
M_P#_    ]P   .@   #9    RP ( ,, $ "] !@ N0 B +8 + "T #8 L@ _
M *\ 1P"L $T JP!4 *D 60"G %X I@!C *4 : "C &X H@!T *  >@"> ((
MG "+ )L E0"9 )\ F "L )8 N@"4 ,\ DP#K )( ^P"2 /\ D@#_ )$ _P#W
M    YP   -,   #&    NP " +, # "M !( J@ < *< )@"D #  HP X *
M0 "> $< G !. )H 4P"9 %@ EP!= )8 8P"5 &@ DP!N )( = "0 'P CP"%
M (T CP"+ )H B@"G (@ M0"& ,< A0#D (0 ]0"$ /\ @P#_ (, _P#L
MTP   ,$!  "T    K    *8 !P"@  X G0 6 )H ( "7 "D E0 R ), .@"1
M $$ CP!( (T 30", %, BP!8 (D 70"( &, AP!I (4 ;P"# '< @@"  (
MB@!^ )8 ?0"C 'L L !Z ,( >0#= '@ \0!W /T > #_ '@ _P#>"@  Q L
M +(,  "F"P  G0@  )D$  "5  H D0 1 (X &0"+ ", B0 L (< - "% #L
M@P!" (( 2 "  $X ?P!3 'T 6 !\ %X >P!D 'D :@!X '( =@![ '0 A@!S
M )( <0"? '  K0!N +X ;0'6 &T"[0!L _H ; /_ &P#_P#.$   MQ$  *82
M  ":$0  D1   (L.  ")"P, AP4, (0!$P"! 1P ?@(E 'P#+@!Z S8 > 0\
M '<$0P!U!4@ = 5. ',%5 !Q!5D < 9? &X&9@!M!FX :P=X &H'@P!H")
M9PF= &4)K !D";P 8PK4 &,+[ !B#/H 8@S_ &(,_P##%@  K1<  )T8  "0
M&   AQ8  ($4  !]$0  ? X& 'P*#@!X"A8 =0L? '(+* !P##  ;PPW &T,
M/@!L#$0 :PU* &D-3P!H#54 9PU< &4-8P!C#FL 8@YU & .@0!?#HX 70^<
M %P0JP!;$+T 6A#6 %D1\ !9$?T 61'_ %D1_P"Y&P  I1T  )0>  "('@
M?AT  '@;  !T&   <14  '$1"0!O$!$ ;! 9 &D0(@!G$2H 9A$R &01.0!C
M$3\ 8A%% & 22P!?$E$ 71)8 %P27P!:$V@ 61-R %<4?0!6%(L 5!69 %,5
MJ0!2%KH 41;2 %$7[0!1%_T 41?_ %$7_P"R(   GB(  (XB  "!(P  =R(
M ' A  !L'@  :1L  &<8! !F%0X 8Q85 &$6'@!?%B8 718M %P7- !:%SL
M61=! %@81P!6&$T 51A4 %,87 !2&60 41EN $\:>@!.&X@ 31N7 $L<I@!*
M'+@ 2AW/ $D=ZP!)'?L 21W_ $H=_P"L)   F"4  (@F  ![)P  <28  &HE
M  !F(P  8B$  & >  !>' L 6QL2 %D<&@!7'"( 51PI %0<, !3'3< 41T]
M % =0P!/'4H 31Y1 $P>6 !+'V$ 21]K $@@=P!'((4 1B&4 $0BI !$(K8
M0R+, $,CZ0!#(_H 0R/_ $,B_P"F)P  DRD  (,J  !V*@  ;2H  &4I  !@
M)P  7"4  %DC  !7(0< 52$/ %(A%@!0(1X 3B$E $TB+ !,(C, 2B(Y $DB
M0 !((D8 1R-- $4C50!$)%X 0R1I $(E=0! )H, /R:2 #XGHP ^)[0 /2?*
M #THZ  ]*/D /2?_ #XG_P"B*@  CBL  '\M  !R+0  :"T  &$L  !<*P
M6"@  %0F  !1)@0 3B4- $PE$P!*)AH 2"8B $<F*0!%)B\ 1"8V $,G/ !!
M)T, 0"=+ #\H4P ^*5P /2EF #PJ<@ [*H$ .BN0 #DKH0 X++( -RS( #<L
MY@ X+/@ ."S_ #@L_P"=+   BBX  'LO  !O,   93   %TO  !8+@  4RL
M % J  !,*@  22H+ $8J$0!$*A< 0BH? $$J)0 _*BP /BLS #TK.0 \*T
M.RQ( #HL4  Y+5D ."YD #<N<  V+W\ -2^/ #0PGP S,+$ ,C#' #(PY0 S
M,/< ,S#_ #0O_P"9+P  AS$  '<R  !K,@  8C(  %HR  !4,0  3R\  $LM
M  !'+@  1"X( $$N#@ _+A0 /2X< #LN(@ Y+RD ."\O #<O-@ V,#X -3!&
M #4Q3@ T,5< ,S)B #(R;@ Q,WT ,#.- "\TG@ N-+  +33% "TTXP N-/8
M+S/_ "\S_P"5,0  @S,  '0T  !H-0  7C4  %<T  !1-   2S(  $8Q  !"
M,@  /S(% #PR#0 Y,Q( .#,9 #8S(  T,R8 ,S,M #(T-  Q-#L ,#5# # U
M3  O-E4 +C9@ "TW;  L-WL *S>+ "HXG  I.*X *#C# "@XX@ I./4 *C?_
M "HW_P"2-   ?S4  '$V  !E-P  6S<  %0W  !--@  1S8  $(U   ]-@
M.C8" #<W"P T-Q  ,C<6 #$X'0 O."0 +C@K "TY,@ L.3D *SE! "HZ20 J
M.E, *3M> "@[:@ G.WD )CR) "4\FP D/*T (SS" ",\X  D//0 )3O_ "4[
M_P"--@  ?#@  &TY  !B.0  6#H  %$Y  !*.0  1#D  #TY   Y.@  -3L
M #(["  O/ X +3T4 "P]&@ J/2$ *3TH "@^+P G/C8 )CX^ "4_1P D/U
M(T!; ") :  A0'8 ($"' !]!F0 ?0:L 'D'  !Y!W@ ?0/, 'T#^ " __P")
M.0  >#H  &D[  !>/   53P  $T\  !'/   0#P  #@]   T/@  ,$   "U!
M!0 J0@P )T(1 "9#&  D0QX (T,E ")#+  A1#, ($0[ !]$1  >14X '459
M !Q%90 ;170 &D6% !E&EP 91JD &$:^ !=%W  81?$ &43] !I$_P"$/
M<ST  &8^  !;/P  4C\  $H_  !$/P  /4   #9!   Q0P  +$0  "=& 0 D
M1PH (4@/ "!)%  >21L '4DB !Q)*0 ;2C  &DHX !E*00 82DL %TM5 !9+
M8@ 52W$ %$N" !-+E  22Z< $DN\ !%+V0 22O  $TK\ !1)_P!_/P  ;T
M &%!  !70@  3D(  $="  !!0@  .D,  #)%   M1P  *$D  "-+   >308
M&T\- !A0$0 74!< %E > !50)0 44"P $U$T !)1/0 144< $5%2 !!17P /
M4FT #E)^  U1D0 -4:0 #%&X  Q1T0 -4.P #5#Z  Y/_P!Y0P  :D0  %U$
M  !310  2T4  $1%   ^1@  -D@  "]*   I3   )$\  !]1   :4P  %%8)
M !%7#@ 06!, $%@9  ]8(  .6"@ #5@P  U8.0 ,6$, "UA.  I86@ (6&@
M!UAY  98C  %6)\ !%BS  17R@ %5^8 !5?S  96_ !S1@  9$<  %E(  !0
M2   2$@  $%)   Z2@  ,DT  "M0   E4@  (%4  !I8   56@  $%T&  Q@
M#  *8!  "6 5  A@'  '8", !6 K  1@-  #8#T  6!)  !@50  8&,  &!S
M  !@A@  7YH  %^N  !?Q   7N(  %[P  !>^ !L2@  7TL  %5+  !,3
M14P  #U.   U4   +E,  "=6   @60  &EP  !5?   08@  #64$  AG"P #
M9PX  &@3  !H&   :!\  &DF  !I+@  :3@  &E#  !I3P  :5T  &EM  !I
M@   :90  &BI  !HOP  9]P  &;N  !F]P!F3P  6D\  %%/  !*3P  05$
M #A4   P5P  *%L  "%>   :8@  %&4  !!H   ,:P  !VX#  %P"0  < T
M '$0  !Q%   <AH  ',A  !S*   <S$  ',\  !T2   <U8  '-F  !S>0
M<XX  '.C  !RN0  <=(  ''K  !P] !A4P  5E,  $]3  !%50  .U@  #)<
M   J8   (F0  !MH   4;   #V\   MR   &=@   'D   !Z!@  >@H  'L.
M  !\$0  ?14  'X;  !_(@  @"H  ( U  " 00  @$\  (!?  " <0  @(8
M ("=  !_L@  ?LH  '[E  !]\0!<6   5%@  $E:   _70  -6$  "QE   C
M:@  &V\  !1S   .=P  "7L   -_    @@   (0   "& 0  A@8  (@*  ")
M#0  BA   (L5  ",&P  CB(  (\L  "/.   CT8  (]6  "/:   CWX  (^5
M  ".JP  C<$  (W<  ",ZP!970  3E\  $-B   X9@  +FP  "1Q   <=P
M%'P   Z!   (A0   (D   "-    D    )(   "3    E    )8#  "7"
MF P  )H/  ";$P  G1H  )\C  "@+@  H#P  *!,  "@7@  H'0  )^,  "?
MH@  G[<  )[+  ">X !39   1V@  #QM   Q<P  )WD  !U_   4A0  #8L
M  :0    E    )@   "<    GP   *$   "B    I    *4   "G    J 0
M *H)  "L#0  K1(  + 9  "R(P  LC$  +)"  "R5   LFD  +*   "RF
ML:P  +*_  "QS@!,;@  0',  #5Z   J@0  'X@  !6.   .E0  !IH   "?
M    I    *@   "L    KP   +$   "Q    LP   +4   "V    N    +H
M  "\!@  O@P  , 1  ##&0  Q28  ,4W  #&20  QET  ,=R  #'B@  R)\
M ,BO  #(O !&>@  .8$  "Z)   BD   %Y@   ^?   'I0   *H   "O
MLP   +<   "\    OP   ,$   #"    Q    ,4   #'    R0   ,L   #-
M    SP,  -(*  #6$   W!H  -TJ  #>/   WU   .!E  #A>P  X9$  .*B
M  #BK0#_  ( _P   /\  P#_  P _P 3 /\ '0#_ "@ _@ S /L /@#W $@
M\P!0 /  5P#M %X ZP!D .@ :0#G &\ Y0!T ., >0#B '\ X "% -X C #<
M ), V0"< -8 I@#3 +$ T0#  ,\ V@#. /$ S #_ ,L _P#+ /\ Q@#_ ,$
M_P#_    _P   /\   #_  @ ^P 0 /8 &0#R "0 [P N .T .0#H $( XP!+
M .  4@#= %D V0!? -8 9 #3 &D T0!N ,\ = #. 'D S !_ ,H A@#( (X
MQ@"6 ,0 H #" *L P "Y +X S0"\ .H NP#\ +H _P"Z /\ N@#_ +8 _P#_
M    _P   /X   #T  0 ZP - .0 % #? !\ VP I -@ ,P#3 #T S@!% ,H
M30#' %, Q0!9 ,, 7P#! &0 OP!I +T ;@"[ ', N@!Y +@ @ "V (@ M "0
M +( F@"Q *4 KP"R *T Q "L .$ JP#V *H _P"J /\ J@#_ *H _P#_
M_0   .X   #B    U0 * ,T $0#' !D Q  C ,$ +0"_ #< NP _ +< 1P"U
M $X L@!3 +  60"O %X K0!C *P : "K &T J0!S *@ >@"F ($ I "* *,
ME "A )\ GP"L )X NP"< -( FP#N )H _P": /\ F0#_ )D _P#^    [@
M -X   #+    P0 % +D #0"T !0 L0 > *X )P"K #  J@ Y *< 00"D $@
MH@!- *$ 4P"? %@ G@!= )T 8@"; &< F@!M )@ <P"7 'L E0"$ )0 C@"2
M )D D "F (X M "- ,@ C #F (L ^0"* /\ B@#_ (L _P#P    VP   ,<
M  "Z    L    *@ "@"D !  H  8 )T (0"; "H F@ S )@ .P"6 $$ E !(
M )( 30"1 %( CP!7 (X 7 ", &$ BP!G (H ;@"( '4 AP!^ (4 B "# )0
M@@"@ (  KP!_ ,  ?@#= 'T \@!] /\ ?0#_ 'T _P#@    Q@   +4   "J
M    H@   )L !0"5  T D@ 3 )  ' "- "0 BP M (H - "( #L A@!" (4
M1P"# $T @@!2 ($ 5P!_ %P ?@!B 'T : ![ '  >@!Y '@ @P!V (\ =0"<
M '0 J@!R +H <0#1 '  [ !P /L < #_ '  _P#-!   MP8  *<'  ";!@
MDP0  (X   "*  @ A@ / (0 %@"! !X ?P G 'T +@!\ #8 >@ \ 'D 0@!W
M $< =@!, '4 4@!S %< <@!= '$ 8P!O &L ;@!T &P ?@!K (H :0"8 &@
MI@!G +8 9@#+ &4 YP!E /< 90#_ &4 _P# #   JPT  )L.  "/#@  A@T
M ($+  !^!P$ ? $+ 'D $0!W !@ =0 A ', *0!Q #  ;P V &X / !L $(
M:P!' &H 30!I %( : !8 &8 7P!E &< 8P!P &(!>@!@ 8< 7P*5 %X"HP!<
M [, 7 /' %L$Y !;!?0 6P;^ %L&_P"U$   H1(  )$3  "%$P  ?!(  '81
M  !S#@  <@P$ '$'#0!N!!( ; 0; &D%(P!G!2H 9@8Q &0&-P!C!CT 8@=#
M &$'20!?!TX 7@A5 %T(7 !;"6, 6@EM %@*> !7"H4 5@N3 %0+H@!3"[,
M4@S' %(,Y !1#?4 40W_ %$-_P"M%0  F1<  (D8  !]&0  =!@  &T7  !J
M%   9Q$  &<.!P!F# X 8PP5 &$,'0!?#"4 70TL %P-,P!;#3D 6@T_ %@-
M10!7#4L 5@Y1 %4.60!3#F$ 4@YK % /=@!.$(, 31"2 $P0H@!+$+( 2A'(
M $D1Y0!)$?< 21+_ $D1_P"E&0  DAP  (,=  !V'@  ;1T  &8<  !B&@
M7Q<  %X4 0!>$0H 6Q 1 %D1& !7$2  51$G %01+@!3$30 41$[ % 200!/
M$D< 3A). $P250!+$UX 21-G $@4<P!&%(  116/ $05GP!#%K  0A;% $(7
MXP!"%_8 0A?_ $(7_P"?'0  C"   'TA  !Q(@  :"(  &$A  !<'P  61P
M %<9  !5%@8 5!4. %$5% !/%AP 3A8C $P6*@!+%C  2A8W $D7/0!'%T,
M1A=* $484@!#&%H 0AED $$9<  _&GT /AN- #T;G0 \'*X .QS# #L<X0 [
M'?4 .QS_ #P<_P":(0  AR,  '@D  !L)0  8R4  %PD  !7(P  4R   %$>
M  !/' ( 31L, $L:$0!(&Q@ 1QL@ $4;)@!$&RT 0QPS $(<.0! '$  /QU'
M #X=3P ]'E@ /!YB #H?;0 Y'WL .""+ #<AFP V(:T -2'! #4AWP U(?,
M-B'_ #8A_P"6(P  @R8  '0G  !H*   7R@  %@G  !3)@  3R0  $PB  !)
M(   1R ) $0?#P!"'Q4 0" < #\@(P ^("D /" O #LA-@ Z(3T .2%$ #@B
M3  W(E4 -B-? #0C:P S)'D ,B6) #$EF@ P):L ,":_ "\FW  P)O( ,";_
M #$E_P"1)@  ?R@  '$J  !E*@  7"H  %4J  !/*0  2R@  $@E  !$)
M020% #\D#0 ])!( .R09 #DD'P W)"8 -B0L #4E,P T)3H ,R9! #(F2@ Q
M)U, ,"== "\H:0 N*7< +2F' "PIF  K*JH *BJ] "HJV@ K*O$ *RK^ "PI
M_P"-*   ?"H  &TL  !B+0  62T  %$M  !,+   1RL  $,H   _*   /"@"
M #DH"P W*!  -2@6 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK1P L*U$
M*RQ; "HL9P I+74 *"V% "<MEP F+J@ )2Z\ "4NV  F+O  )B[] "<M_P"*
M*P  >"T  &HN  !?+P  5B\  $XO  !(+@  0RT  #\L   [+   -RP  #0L
M"0 R+ X ,"T3 "XM&@ M+2  *RTG "HN+0 J+C4 *2\] "@O10 G,$X )C!9
M "4Q90 D,7, (S&# "(RE0 A,J< (3*[ " RU  A,N\ (C'\ "(Q_P"&+0
M=2\  &<P  !<,0  4S$  $LQ  !%,0  0#   #LP   V,   ,S   # Q!@ M
M,0T *S$1 "DR%P H,AX )S(D "4S*P E,S( )#,Z ",T0P B-$P (357 " U
M8P ?-7$ 'C:! !TVDP <-J4 &S:Y !LVT@ <-NT '3;[ !TU_P"",   <3(
M &,S  !9-   4#0  $DT  !",P  /3,  #<S   Q-   +C4  "LU @ H-@L
M)3<0 "0W%0 B-QL (3@B " X*  ?.#  'C@W !TY0  <.4D &SI4 !HZ8  9
M.FX &#I_ !<[D0 7.Z0 %CNW !4[T  6.NP %SKZ !@Y_P!],@  ;30  & U
M  !5-@  338  $8V  ! -@  .C8  #0V   N.   *CD  "8Z   C.P@ (#P.
M !X]$@ =/1@ '#T? !L^)0 :/BT &3XT !<^/0 6/T< %3]1 !0_7@ 4/VP
M$T!\ !) CP 10*( $4"V !! S@ 1/^L $C_Y !(^_P!Y-0  :3<  %PX  !2
M.0  2CD  $,Y   ].0  -SD  #$Z   K/   )ST  "(_   >000 &D(+ !A#
M$  70Q4 %40; !1$(@ 31"D $T0Q !)$.@ 114, $$5. !!%6P .16D #D5Y
M  U%C  -19\ #$6R  M%R0 ,1>4 #43V  U$_P!T.0  93H  %@[  !/.P
M1SP  $ \   Z/   -#P  "X^   H0   (T(  !]$   :1@  %4@( !)*#0 1
M2A( $$H8  ]+'@ .2R4 #4LM  U+-@ ,2T  "TM*  I+5@ )2V0 "$MT  =+
MAP %2YH !$NN  1*Q  %2N  !4KP  9)^@!N/   8#T  %0^  !+/@  1#X
M #T^   W/P  ,4   "I"   D10  'T<  !I)   53   $4X%  Y1"P +41
M"E$4  E1&P (42( !U$I  51,@ $4CL  U)&  %24@  4E\  %)O  !2@0
M498  %&I  !1OP  4-P  %#N  !0]P!H0   6T$  %!!  !(00  04$  #M"
M   T0P  +44  "9(   @2P  &TT  !90   14P  #E4$  I8"@ &6 X  E@2
M  !9%P  61T  %DE  !9+0  638  %E!  !930  6EH  %II  !9?   69
M %FE  !8N@  6-4  %?L  !7]@!C1   5D4  $U%  !%10  /T4  #='   O
M20  *$P  ")/   ;4@  %E4  !%8   -6@  "5T#  1?"0  8 T  & 0  !A
M%   81D  &(@  !B)P  8C$  &([  !B1P  8E4  &-D  !B=@  8HL  &*@
M  !AM@  8<\  &#J  !@]0!=2   4DD  $I(  !#2   .DH  #)-   J4
M(U,  !Q7   66@  $5T   U@   (8P   V8!  !G!@  : L  &D.  !J$0
M:Q4  &P;  !M(@  ;2H  &TT  !M0   ;4X  &U=  !M;P  ;80  &R:  !L
ML   :\@  &OF  !J\P!830  3DT  $A,   ^3@  -5$  "Q4   D6   '5P
M !9@   09   #&<   =K   !;@   '    !R P  <@<  ',+  !U#@  =A$
M '<6  !X'   >2,  'HM  !Z.0  >D<  'I6  !Y:   >GP  'F4  !XJ@
M>,$  '??  !W[P!440  3%$  $)2   X50  +UD  "9>   >8@  %F<  !!K
M   +;P  !7,   !W    >@   'P   !^    ?P(  ( &  "!"@  @PT  (01
M  "&%0  B!P  (DE  "*,   BCX  (E-  ")7P  B7,  (B+  "(H@  A[D
M (?1  "&Z !25@  1U<  #Q:   R7P  *&0  !]I   6;P  $'0   IY   "
M?0   ($   "%    B    (H   ",    C0   (\   "0!   D@@  ),,  "5
M$   EQ4  )D=  ";)P  FS0  )M$  ":5@  FFH  )F"  ":F@  F+   )C'
M  "7W@!+7   0&   #5E   K:@  (7$  !=W   0?0  "8,   &(    C
M )$   "5    F    )H   ";    G0   )\   "@    H@   *0%  "F"@
MJ X  *H4  "M'0  K2H  *TY  "M2P  K5\  *UW  "LD   JZ<  *NZ  "K
MRP!%9@  .6L  "YQ   C>   &7\  !"&   )C0   ),   "8    G0   *$
M  "E    J    *L   "K    K@   *\   "Q    LP   +4   "W 0  N0<
M +P-  "_$P  PA\  ,(N  #"0   PE0  ,%K  #!@P  P)L  ,&M  #!O  ^
M<@  ,G@  ">    <B   $I    J7    G0   *,   "H    K0   +(   "V
M    N0   +L   "\    O@   ,    #"    Q    ,8   #(    RP   ,X%
M  #1#0  UA0  -<C  #8-0  V4D  -I>  #;=0  VXP  -R?  #<JP#_
M_P   /\   #_  D _P 0 /\ &0#^ "0 _  O /D .0#T $, \ !+ .T 4@#J
M %D YP!? .0 9 #B &D X !N -X <P#< 'D V@!_ -< A@#4 (X T0"6 ,\
MH0#, *P R@"[ ,@ T@#& .X Q@#_ ,4 _P#% /\ OP#_ +H _P#_    _P
M /\   #^  4 ]P . /( %0#N !\ ZP J .D - #C #T W@!% -D 30#4 %,
MT0!9 ,X 7@#, &, R@!H ,D ;0#' ', Q0!Y ,, @ #! (@ OP"0 +T FP"[
M *8 N0"T +< R "V .8 M0#[ +0 _P"T /\ LP#_ *X _P#_    _P   /@
M  #M    Y0 + -T $0#7 !H T@ D ,\ +@#+ #< QP!  ,, 1P#  $X O@!3
M +P 60"Z %X N !C +8 : "U &T LP!S +$ >0"O ($ K0"* *L E "I *
MJ "M *8 O@"E -L I #T *0 _P"C /\ HP#_ *( _P#_    ]@   .8   #7
M    RP & ,0 #@"^ !4 NP ? +D * "W #$ M  Z +  00"M $@ JP!. *D
M4P"G %@ I@!< *0 80"C &< H0!L *  <P"> 'H G0"# )L C@"9 )D EP"F
M )8 M@"5 ,P E #K ), _0"3 /\ DP#_ ), _P#W    Y    -    #!
MMP " *\ "P"K !$ IP 9 *4 (@"C "L H@ S )\ .P"< $( FP!( )D 30"7
M %( E@!7 )4 6P"3 &$ D@!F )  ;0"/ '0 C0!] (P AP"* ), B "@ (<
MKP"% ,( A0#B (0 ]P"$ /\ A #_ (0 _P#E    S0   +P   "O    I@
M )X !P":  X E@ 4 )0 '0"2 "4 D0 M )  -0"- #P C !" (H 1P"( $P
MAP!1 (8 5@"$ %L @P!@ ($ 9P"  &X ?@!W 'T @0![ (T >@": '@ J0!W
M +H =@#3 '8 [P!V /X =0#_ '4 _P#0    NP   *L   "?    EP   )
M @"+  L B  0 (8 %P"$ "  @@ G ($ +P!_ #4 ?0 \ 'P 00![ $8 >0!+
M '@ 4 !W %4 =@!; '0 80!S &D <0!Q '  >P!N (< ;0"5 &L HP!J +0
M:@#) &D Z !I /D :0#_ &D _P#     K    )P"  "0 @  B    (,   !_
M  8 >P - 'D $@!W !H =@ B '0 *0!S #  <0 V '  / !O $$ ;0!& &P
M2P!K %  :@!6 &@ 7 !G &0 90!L &0 =@!C (( 80"0 &  GP!? *\ 7@##
M %X X0!> /0 70#_ %T _P"T!P  H D  ) +  "$"P  ? H  '<'  !T!
M<0 ) &\ #P!M !4 :P < &D (P!H "H 9P Q &4 -@!D #P 8P!! &( 1@!@
M $P 7P!2 %X 6 != %\ 6P!H %H <@!8 'X 5P", %8 FP!5 *L 5 "^ %0
MV@!3 .\ 5 #[ %0 _P"I#0  E@X  (<0  !Z$   <A   &P.  !I#   9PD#
M &8$"P!D !  8@ 7 &  '@!> "4 70 K %P ,0!: #< 60 \ %@ 0@!7 4<
M5@%. %4"5 !3 EP 4@-E %$#;P!/!'L 3@2* $T%F0!,!:D 2P6\ $H&U !*
M!^T 2@?Y $H'_P"A$   CA(  'X4  !S%   :A0  &03  !@$0  7@\  %T-
M!0!="0T 6@82 %@'&0!6!R  50<G %,'+0!2"#, 40@X % (/@!/"40 3@E*
M $P)40!+"ED 2@IB $@+;0!'"WH 1@R( $0,F !##*D 0@V\ $(-U0!"#>X
M0@W[ $(-_P":%   AQ8  '@8  !L&0  8QD  %T8  !9%@  5A,  %01  !4
M#@@ 4PT. %$-% !/#1L 30TB $P-* !+#2X 2@TT $D-.@!'#D$ 1@Y' $4.
M3P!$#E< 0@]A $$0;  _$'D /A"( #T1F  [$:D .Q&\ #H1U@ Z$?  .A+]
M #L1_P"3&   @1H  ',<  !G'0  7AT  %@<  !3&P  4!@  $X6  !,$P,
M3!$+ $H0$ !($1< 1A$> $41) !$$2H 0A$P $$1-P! $CT /Q)$ #T23  \
M$U0 .Q-> #D4:0 X%'8 -Q6% #85E@ T%J< -!:Z #,6TP S%NX -!;\ #06
M_P".&P  ?!T  &X?  !C(   6B   %,@  !.'@  2AT  $@:  !&&   118'
M $,5#@!!%1, /Q4: #X5(  ]%2< .Q4M #H6,P Y%CH .!9! #<720 U%U$
M-!A; #,99@ R&7, ,!J# "\:E  N&Z4 +1NX "T;T  M&^P +AO[ "X;_P"*
M'@  >"   &HB  !?(P  5B,  $\B  !*(0  1B   $,>  !!&P  /QH# #T:
M#  [&1$ .1D6 #<:'0 V&B, -1HI #0:,  S&S8 ,1L^ # <1@ O'$\ +AU9
M "T=9  L'G$ *Q^! "H?D@ I'Z0 *""W "<@S@ G(.L *"#Z "D?_P"&(
M=",  &<D  !<)0  4R4  $PE  !')   0B,  #\A   ]'P  .AX  #<>"0 U
M'@X ,QX3 #$>&@ P'B  +QXF "X?+0 M'S, +" [ "L@0P J(4P *2%6 "@B
M8@ F(F\ )2-_ "0CD  C(Z( (B2U "(DS  B).D (R3Y "0C_P""(P  <24
M &,F  !9)P  4"@  $DG  !#)P  /R8  #LD   X(@  -2(  #(B!@ P(@T
M+B(1 "PB%P J(AT *2(C "@C*@ G(S$ )B0X "4E00 D)4H (R94 "(F8  A
M)VT ("=] !\GCP >**$ 'BBT !THR@ =*.@ 'BCX !\G_P!^)0  ;B<  & I
M  !6*0  32H  $8J  !!*0  /"@  #<G   T)@  ,"8  "TF P K)PL *"<0
M "<G%  E)QH )"<A ",H)P B*"X (2DV " I/@ ?*D@ 'BI2 !TK7@ <*VL
M&RM[ !HLC0 9+)\ &"RR !@LR0 8+.< &2OW !HK_P!Z)P  :BH  %TK  !3
M+   2BP  $,L   ^*P  .2L  #0J   P*@  *RH  "DK   F*P@ (RP. "(L
M$@ @+!@ 'RP> !XM)0 =+2P '"TS !LN/  :+D4 &2]0 !@O7  7+VD %C!Y
M !4PBP 4,)X %#"Q !,PQP 3,.4 %##V !4O_P!V*@  9RP  %HM  !0+@
M2"X  $$N   [+@  -BT  #$M   L+0  )R\  "0O   A, 4 'S$, !PQ$  ;
M,A4 &C(< !DR(@ 8,BD %S,Q !8S.0 5,T, %#1- !,T60 2-&< $35W !$U
MB0 0-9P $#6P  XUQ@ /-.0 $#3U ! T_P!R+   8RX  %<P  !-,   13
M #XP   X,   ,S   "\P   I,0  )#(  "$S   =-0( &C8) !<W#@ 5-Q,
M%#@9 !,X'P 2."8 $C@N !$Y-@ 0.4  $#E+  XY5P ..F0 #3IT  PZA@ ,
M.ID "SFL  HYP0 *.=X "SGQ  PX_ !N+P  7S$  %,R  !*,P  0C,  #LS
M   V,P  ,3(  "PS   G-   (38  !TX   9.0  %3L& !(]#  0/A  $#X5
M  X^'  ./B, #3XJ  P^,P ,/CP "S]'  H_4@ (/V  !S]O  8_@0 %/Y0
M!#^H  ,^O  $/M< !3[L  4^]P!I,P  6S0  % U  !'-0  /S4  #DU   T
M-0  +C4  "DW   C.   'CL  !H\   6/P  $D$$  Y#"@ ,1 X "D03  E$
M&0 (1"  !T0G  9$+P %1#@  T5"  )%3@  15L  $5J  !%?   19   $2D
M  !$N0  1-$  $3J  !#]0!D-@  5S<  $PX  !#.   /#@  #<X   Q.
M*SD  "4[   @/0  &D   !9"   21   #D<$  M)"0 '2@T !$L1  %+%@
M2QP  $LC  !+*P  2S0  $L^  !,20  3%<  $QF  !,=P  2XP  $NA  !+
MM0  2LX  $KI  !*]0!?.@  4CL  $@[  ! .P  .CL  #0[   N/   )SX
M ")!   <0P  %D8  !))   .2P  "TX#  =0"  "40P  %$0  !2$P  4Q@
M %,?  !3)@  4R\  %,Y  !310  4U(  %-A  !3<@  4X<  %*<  !2L0
M4<H  %'G  !1] !9/@  3CX  $4^   ^/@  .#X  #!    I0@  (T0  !U'
M   72@  $DT   Y0   +4P  !E4"  !7!P  6 L  %D.  !:$0  6A4  %L:
M  !<(0  7"H  %PT  !</P  7$T  %Q;  !<;   7($  %N7  !;K0  6L4
M %KD  !9\P!40@  2D(  $)"   \0@  -$,  "Q&   E20  'DP  !=/   2
M4P  #E8   I9   %6P   %X   !@!   80@  &(,  !C#@  9!$  &46  !F
M'   9R,  &<M  !G.0  9T8  &=5  !G9@  9WH  &:1  !EJ   9<   &3>
M  !D\ !/1@  1T8  $!%   W1P  +TH  "9-   ?40  &%4  !)9   -7
M"&    )C    9@   &@   !J    :P0  &P(  !M#   ;PX  ' 2  !R%P
M<QT  '0F  !T,@  =#\  '1.  !S7P  ='(  '.*  !RH0  <;@  ''4  !P
M[ !,2@  14H  #M+   R3@  *5(  "!6   86P  $E\   UD   ':    &L
M  !O    <@   '4   !V    =P   'D"  !Z!@  ? H  'X.  " $0  @A8
M (0>  "$*0  A#8  (1%  "$5@  @VH  (.!  ""F0  @;$  (#)  " Y0!*
M3@  /U   #53   K5P  (EP  !EB   29P  #&P   5Q    =0   'D   !]
M    @0   (,   "%    A@   (@   ")    BP0  (T(  "/#0  DA   )06
M  "6(   EBP  )8[  "63   E6   )5V  "4D   DZ<  )*]  "2U0!$50
M.5D  "]=   D8P  &FD  !)O   ,=0  !'L   "     A0   (D   "-
MD0   ),   "4    E@   )@   ":    G    )X   "@!@  H@L  *40  "H
M%P  J2,  *DQ  "I0P  J58  *AM  "FAP  IYX  *:S  "EQP ^7@  ,F,
M "=J   =<   $W@   Q_   #A0   (L   "1    E@   )L   "?    H@
M *0   "E    IP   *D   "K    K0   +    "R    M0(  +<)  "[$
MOA@  +XF  "^.   ODL  +UA  "\>@  NY0  +JI  "ZN0 W:@  *W   "!X
M   6@   #8@   6/    E@   )P   "B    IP   *P   "P    LP   +8
M  "W    N0   +L   "]    OP   ,(   #%    R    ,H   #."   TA
M -4;  #5+   U$   -17  #3;@  U(8  -2;  #3JP#_    _P   /\   #_
M  4 _P . /\ %0#\ "  ^0 J /8 - #Q #T [0!& .D 30#F %, Y !9 .$
M7@#> &, W !H -D ;@#5 ', TP!Y -  @ #. (@ RP"1 ,D G #& *< Q "W
M ,( S #  .P OP#_ +X _P"] /\ MP#_ +( _P#_    _P   /\   #Z  $
M\P + .T $@#H !L Y0 E .0 +@#? #@ V !  -( 1P#. $X RP!4 ,@ 60#&
M %X Q !C ,( 9P#  &T OP!S +T >@"[ ($ N0"+ +8 E0"T *$ L@"O +
MP@"N ., K@#Z *P _P"M /\ J0#_ *8 _P#_    _P   /(   #F    W0 '
M -( #@#- !8 R@ @ ,@ *0#% #( P  Z +P 0@"Y $@ MP!. +4 4P"S %@
ML0!= +  8@"N &< K !L *H <P"I 'L IP"$ *4 C@"C )H H0"H )\ N0">
M -( G0#R )P _P"= /\ G #_ )D _P#\    [@   -T   #,    P0 " +H
M# "V !( L@ : +  (P"O "P K0 T *D / "F $( I !( *( 30"@ %( G@!7
M )T 6P"< &  F@!F )D ; "7 '0 E0!] ), AP"1 ), D "A (X L0"- ,8
MC #H (L _0", /\ C #_ (P _P#M    V    ,4   "W    K    *8 " "A
M  X GP 5 )T '@"; "8 F@ N )< -0"5 #P DP!" )$ 1P"0 $P C@!1 (T
M50"+ %H B@!@ (D 9@"' &T A0!V (0 @ "" (P @ ": '\ J0!] +P ? #<
M 'P ]0!\ /\ ? #_ 'P _P#9    P0   +$   "D    G    )0  P"0  P
MC0 1 (L & ") "  B0 H (< +P"% #8 @P \ (( 00"  $8 ?P!+ 'T 3P!\
M %0 >P!: 'D 8 !X &< =@!P '4 >@!S (8 <0"3 '  H@!O +0 ;@#, &X
M[0!N /X ;@#_ &X _P#$    KP   *    "4    C    (8   "!  @ ?@ .
M 'P % ![ !L >0 B '@ *0!W #  =0 V '0 .P!R $  <0!% '  2@!O $\
M;0!4 &P 6P!K &( :0!J &@ = !F (  90". &, G0!B *T 80#" &$ Y !A
M /@ 80#_ &$ _P"T    H    )$   "&    ?@   'D   !U  , <0 + &\
M$ !M !8 ;  = &L ) !K "H :0 P &@ -@!F #L 90!  &0 10!C $H 80!/
M &  5@!? %T 70!E %P ;P!: 'H 60"( %@ F !7 *@ 5@"[ %8 V !6 /$
M5@#_ %8 _P"H 0  E 4  (4'  !Z!P  <@8  &P$  !I 0  9P ' &0 #0!C
M !$ 80 8 &  'P!? "4 7@ K %T , !; #8 6@ [ %D 0 !8 $4 5P!+ %8
M40!5 %@ 4P!A %( :@!0 '8 3P"$ $X DP!- *0 3 "V $P S0!, .L 3 #Z
M $P _P"="0  BPL  'P-  !P#0  : T  &(,  !?"@  708! %P!"0!:  X
M6  3 %< &0!6 "  50 F %, *P!2 #$ 40 V %  .P!/ $$ 3@!' $T 30!+
M %4 2@!= $D 9P!' ', 1@"  $4 D !$ *$ 0P"R $, R !# .8 0P#U $,
M_P"5#0  @P\  '00  !I$0  8!$  %H0  !6#@  5 T  %,*! !3!@L 40,0
M $\!%0!. 1L 3 $A $L!)P!* BP 20(R $@"-P!' ST 10-# $0#2@!#!%$
M0@1: $ %9  _!7  /@9^ #T&C@ \!Y\ .P>Q #H'Q@ Z!^, .@?S #H(_ ".
M$   ?!(  &X4  !B%0  6A4  %04  !0$P  31$  $L.  !+#08 2@H, $D(
M$0!'"!8 10@= $0((P!"""@ 00DN $ ),P _"3D /@I  #T*1P \"D\ .@M8
M #D+8P X#&\ -@Q^ #4,C@ T#9\ ,PVQ #(-QP R#>, ,@WT #(-_@"($P
M=Q4  &D7  !>&   51@  $\8  !*%@  1Q4  $43  !#$ ( 0PX( $(-#@!
M#1( /PT8 #T-'P \#20 .PTJ #D-,  X#C< -PX] #8.10 U#DT ,P]7 #(/
M8@ Q$&X +Q!] "X0C@ M$:  +!&R "L1R  K$>8 *Q'V "P1_P"#%@  <AD
M &0:  !9&P  41L  $L;  !&&@  0A@  #\7   ^%   /!($ #L1"@ Z$!
M.! 5 #<0&P U$2$ -!$G #,1+0 R$3, ,!$Z "\20@ N$DL +1-4 "L37P J
M%&P *11[ "@4C  G%9X )A6P "45Q@ E%>0 )17V "85_P!^&0  ;AL  & =
M  !6'@  31X  $<>  !"'0  /AP  #H:   X&   -Q8  #45!P T% T ,A02
M # 4%P O%!T +10C "P5*@ K%3  *A4W "D6/P H%D@ )Q=2 "8870 D&&H
M(QEY "(9B@ A&9P (!FO !\9Q  ?&>( (!GT " 9_P!Z&P  :AX  %T?  !3
M(   2B   $0@   ^'P  .AX  #<=   T'   ,AD  # 9!  N& L +!@0 "H8
M%  I&!H )Q@@ "89)@ E&2T )!HU ",:/0 B&T8 (1M0 " <6P ?'6@ 'AUW
M !T=B  <'IL &QZM !H>PP :'N  &AWS !L=_P!W'0  9R   %HA  !0(@
M2"(  $$B   [(@  -R$  #,@   P'P  +1T  "L=   H'0@ )AT. "4=$@ C
M'1< (1T= "$=)  @'BH 'QXR !X?.@ ='T, '"!- !LA60 :(68 &2%U !@B
MAP 7(ID %B*L !4BP0 5(M\ %2'R !8A_@!S(   9"(  %<C  !-)   124
M #XD   Y)   -",  # B   L(@  *2$  "8A   D(08 (B$, " A$  >(14
M'2(; !LB(0 ;(B@ &B,O !DC.  8)$$ %R1+ !8E5P 5)60 %"9S !,FA0 2
M)I@ $2:K !$FP  0)MT $27Q !(E_0!P(@  820  %0F  !*)@  0B<  #PF
M   V)@  ,24  "TE   I)   )B0  "(E   ?)0, '28* !LF#@ 9)Q( &"<8
M !<G'P 6)R4 %2@M !0H-0 3*3X $BE) !$I50 1*F( $"IQ  \J@P .*I8
M#BJI  TJO0 -*M< #2KN  XI^P!L)   728  %$H  !(*   0"D  #DH   T
M*   +R@  "LG   G)P  (B@  !XI   ;*@  &"L' !8K#0 4+!$ $RP6 !(L
M'  1+2, $"TJ ! M,@ /+CP #BY&  TN4@ -+E\ #"]N  LO?P *+Y( "2^E
M  DNN0 (+M  "2[I  HN]P!H)P  6BD  $XJ  !%*P  /2L  #<K   Q*@
M+2H  "DJ   D*@  ("L  !LM   8+@  %2\$ !(Q"@ 0,@X #S(3  XR&0 -
M,B  #3(G  PR+P +,S@ "C-"  DS3@ (,UL !C1J  4T>P $,XX  S.B  (S
MM@ ",\T  S/G  0R\P!D*@  5BP  $LM  !"+0  .BT  #0M   O+   *RP
M "8L   B+0  '2\  !DQ   5,@  $C0#  \V"0 ,. T "C@1  DX%@ (.!T
M!S@D  8X+  $.#0  S@^  (Y2@  .5<  #EE   Y=P  .8L  #B?   XLP
M.,H  #CF   W\@!?+0  4BX  $@O   _,   ."\  #(O   M+P  *2\  "0P
M   ?,0  &C,  !4U   2-P  #SD#  P["  (/0T !3X0  ,^%   /AH  #XA
M   ^*   /C$  #\[   _1@  /U,  #]A   _<P  /X<  #Z<   ^L   /<<
M #WD   ]\@!:,   3C(  $0R   \,@  -3(  # Q   K,0  )C(  " T   ;
M-@  %C@  !([   //0  ##\#  A!"  $0PP  $,.  !$$@  118  $4=  !%
M)   12T  $8V  !&0@  1DX  $9=  !&;@  18(  $68  !$K0  1,0  $/C
M  !#\@!5-   2C4  $$U   Y-0  ,S0  "XT   H-0  (C<  !TZ   7/
M$C\   ]!   ,1   "$8!  -(!@  20H  $H-  !+$   3!0  $T9  !.(
M3B@  $XR  !-/0  3DH  $Y8  !-:0  37T  $R4  !,J@  2\$  $OA  !*
M\@!0.   1C@  #TX   W.   ,3<  "HY   D.P  'CT  !A    30P  #T8
M  M)   '2P   DX   !0!   40@  %(+  !3#@  5!$  %45  !6&P  5R,
M %<L  !7.   5T0  %=2  !68P  5G<  %:.  !5I0  5+T  %/=  !3\ !+
M/   0CP  #L[   U.P  +3P  "8_   ?0@  &44  !-(   .2P  "T\   51
M    5    %<   !8 0  6@4  %L(  !<#   70X  %\1  !@%@  8AT  &(F
M  !B,0  8CX  &%,  !A70  87   &"(  !@H   7[<  %[4  !=[@!'0
M/S\  #H_   Q0   *4,  "%&   :2@  $TX   Y1   *50  !%@   !;
M7@   &$   !C    9 $  &4$  !G"   : L  &H.  !L$@  ;A<  &\@  !O
M*@  ;S8  &Y%  !N50  ;F@  &U_  !MF   ;+   &O*  !JZ !$1   /D,
M #5$   K1P  (TL  !M/   35   #E@   A<   "8    &0   !G    :P
M &T   !O    <    '(   !T @  =08  '<*  !Y#@  ?!(  'X8  !_(@
M?RX  '\]  !^30  ?6$  'UW  !\D   >Z@  'K   !YWP!#1P  .4D  "],
M   E4   '%4  !1;   .8   !V4   !J    ;@   '(   !V    >0   'P
M  !^    ?P   ($   "#    A0   (<#  "*"   C T  (\1  "2&0  DB4
M )(S  "21   D5<  )!M  "/A@  CI\  (VU  ",S0 ]3@  ,E$  "A6   >
M7   %6(   YH   ';@   '0   !Y    ?@   ((   "&    B0   (P   ".
M    D    )(   "4    E@   )@   ";    G@8  *$,  "D$0  IAL  *8I
M  "F.@  I4T  *5B  "D>P  HY0  *&K  "AOP V5P  +%P  "%B   7:0
M#W    =W    ?@   (0   "*    CP   )0   "8    FP   )X   "?
MH@   *0   "F    J    *L   "M    L    +,$  "W#   NQ(  +L?  "[
M,   NT,  +I8  "Y<   MXL  +>A  "WLP P8@  )6D  !IP   0>   "8
M  "(    CP   )8   ";    H0   *8   "J    K@   +    "Q    M
M +8   "X    NP   +T   #     PP   ,<   #+ P  SPP  -,5  #2)0
MTC@  -%.  #090  SWX  ,V6  #,J0#_    _P   /\   #_  , _P + /P
M$0#Y !L ]P E /, +P#N #@ Z0!  .8 2 #B $X WP!4 -P 60#9 %X U0!C
M -, : #0 &T S@!S ,L >@#( (( Q@", ,, EP#  *, O@"R +P R "Z .H
MN0#_ +@ _P"Q /\ J@#_ *< _P#_    _P   /L   #V    [0 ' .< #P#B
M !8 WP @ -X *0#9 #, T0 [ ,P 0@#( $@ Q0!. ,( 4P#  %@ O@!= +P
M8@"Z &< N0!M +< = "U 'L L@"% +  D "N )P K "J *D O0"G -X I@#Y
M *4 _P"C /\ G0#_ )L _P#]    ]@   .L   #?    T0 # ,H # #% !(
MPP ; ,  ) "^ "P N0 U +8 / "S $, L !( *X 3@"L %( JP!7 *D 7 "G
M &$ I@!G *0 ;0"B '0 H !] )X B "< )4 F@"C )@ M "6 ,T E0#Q )0
M_P"5 /\ D #_ (X _P#S    Y@   -$   #"    N    +$ " "M  \ J@ 6
M *@ '@"H "< I@ O *( -@"? #P G0!" )L 1P"9 $P EP!1 )8 50"4 %H
MDP!@ )$ 9@"0 &X C@!V (P @0"* (T B "; (8 K "% ,$ A #F (, _0"$
M /\ @P#_ ($ _P#D    RP   +H   "L    H@   )P ! "8  P E@ 1 )0
M&0"3 "$ D@ H (\ , "- #8 BP \ (D 00"( $8 A@!+ (4 3P"$ %0 @@!:
M ($ 8 !_ &< ?@!O 'P >@!Z (8 > "4 '< I !U +< = #4 ', ] !T /\
M= #_ '0 _P#+    M@   *8   ":    D@   (H   "&  @ @P . ($ % "!
M !L @  C '\ *@!] #  >P V 'H .P!X $  =P!% '4 20!T $X <P!4 '$
M6@!P &$ ;@!I &T <P!K '\ :0"- &@ G0!G *X 9@#' &4 Z@!F /\ 9@#_
M &< _P"X    I    )4   "*    @0   'P   !V  0 =  , '( $ !Q !8
M<  = '  ) !N "H ;0 P &L -0!J #H :0 _ &@ 1 !G $D 90!. &0 5 !C
M %L 80!C &  ;0!> 'D 70"' %L E@!: *@ 60"] %D WP!9 /@ 6@#_ %H
M_P"H    E0   (<   ![    <P   &X   !J  $ 9P ( &4 #@!D !( 8P 8
M &, 'P!B "4 80 J %\ , !> #4 70 Z %P /@!; $0 60!) %@ 3P!7 %8
M5@!> %0 : !3 ', 40"! %  D0!/ *( 3@"U $X T !. /  3@#_ $\ _P"<
M    B0   'L#  !P P  : ,  &(!  !?    70 $ %L "P!9  \ 6  4 %<
M&0!7 "  5@ E %4 *@!3 #  4@ T %$ .0!0 #\ 3P!$ $X 2P!- %( 2P!:
M $H 8P!) &\ 1P!\ $8 C !% )T 10"P $0 QP!$ .@ 1 #Z $4 _P"2!
M@ <  '$*  !F"@  7@H  %D)  !5!P  5 0  %( !P!0  P 3P 0 $X %0!-
M !L 3  @ $L )@!* "L 20 P $@ -0!' #H 1@!  $4 1@!# $X 0@!6 $$
M7P!  &L /@!X #T B  \ )D / "K #P P0 [ .  .P#T #L _P")"@  > P
M &H.  !?#@  5PX  %$.  !-#   2PL  $H( @!)! D 2  - $8 $0!% !8
M1  < $, (0!" "8 00 K #\ ,0 ^ #8 /0 \ #P 0P [ $H .@!2 #D 7  X
M &@ -@!U #4 A0 T )8 - "H #, O  S -@ ,P#O #, ^P""#0  <0\  &00
M  !9$0  41$  $L1  !'$   1 X  $(-  !!"P4 00<+ #\%#@ ^ Q( / (8
M #L"'0 Z R( .0,H #@#+0 W S( -@0Y #4$/P T!4< ,P50 #$&6@ P!F8
M+P=S "X'@P M!Y4 + >G "L'N@ K!]( *P?K "L']P!]$   ;!$  %\3  !4
M%   3!0  $84  !"$P  /A(  #P0   Z#@$ .@T& #H*#  X"1  -@@4 #4(
M&0 T"1\ ,@DD #$)*0 P"2\ +PHV "X*/0 M"D4 + M. "L+60 I#&4 * QS
M "<,@P F#94 )0VG "0-NP C#=( (PWK ",-]P!X$@  :!0  %L6  !1%P
M2!<  $(6   ]%@  .14  #<3   U$0  ,Q # #,."  R#0T , T1 "\-%@ M
M#1L + TA "L-)P J#2T *0XT "@..P G#D0 )0Y. "0/60 C$&4 (1!S " 0
MA  ?$)8 'A"I !T0O0 <$-@ '1#N !T0^0!S%   9!8  %<8  !-&0  11D
M #\9   Z&   -1<  #(6   P%0  +A,  "T1!  L$ H *Q . "D0$@ H$!@
M)A > "40)  D$"H (Q$Q "(1.0 A$4( (!)+ !X25@ =$V, '!-Q !H3@@ 9
M%)4 &!2G !<4NP 7$]0 %Q/N !@3^@!P%@  8!D  %0:  !*&P  0AP  #P;
M   V&P  ,AH  "\9   L&   *A8  "@4 0 F$P< )1,, ",3$  B$Q4 (!,:
M !\3(0 >%"< '10N !P5-@ ;%3\ &A9) !D65  8%V$ %A=P !48@0 4&),
M$QBF !(8N@ 2%]( $A?L !,7^@!L&0  71L  %$=  !''0  /QX  #D=   T
M'0  +QP  "L;   H&@  )AD  "08   B%P0 (!<* !X7#@ <%Q( &A<7 !D8
M'@ 9&"0 &!DL !<9-  6&CT %1I' !0;4@ 3&U\ $AQN !$<?P 0')( $!RE
M  \<N0 .'-  #AOJ  \;^ !I&P  6AT  $X?  !%'P  /2   #8?   Q'P
M+1X  "D=   E'0  (QP  " ;   =&P$ &QL' !D<#0 7'!  %AP5 !4<&P 4
M'2( $QTI !(>,0 1'CH $1]% ! ?4  /(%T #B!L  T@?  -((\ #""B  L@
MM0 +(,H "R#E  P?] !E'0  5Q\  $PA  !"(0  .B$  #0A   O(0  *B
M "8?   C'P  (!X  !T>   9(   %B $ !0@"P 2(0X $2$3 !$B&0 0(A\
M#R(F  XC+P .(S< #2-!  PD30 +)%D "B1G  DD>  ()(L !R2>  <DL0 &
M),< !B/C  <C\0!B'P  5"$  $DC  ! (P  .",  #(C   L(P  *"(  "0A
M   A(0  'B$  !HA   6(P  $R0# !$E"  /)@T #B<1  TG%@ ,)QT "R<C
M  HG*P )*#0 ""@^  <H20 &*%4 !2ED  0I=  #*8<  BF;  $HKP  *,4
M 2CA  $G\ !>(@  420  $8E   ])0  -24  "\E   J)   )B0  "(C   ?
M(P  &R0  !@E   4)@  $2@#  \I"  ,+ P "BP0  @L%  '+!H !BPA  4L
M*  #+3   BTZ  $M10  +5(  "Y@   N<0  +80  "V9   MK0  +,(  "S@
M   L\ !:)   328  $,G   Z)P  ,R<  "TG   H)@  )"8  "$F   =)@
M&2<  !4I   1*P  #RP#  TN!P ), P !C$.  ,Q$@ !,A<  #(>   R)0
M,BT  #(V   S0@  ,TX  #-=   S;0  ,X$  #*6   RJP  ,<$  #'?   Q
M\ !6)P  2BD  #\J   W*@  ,"H  "LI   G*   (R@  !XI   :*@  %BP
M !(N   /,   #3$"  HT!P %-0L  C8.   W$   .!0  #@:   X(@  ."H
M #DS   Y/@  .4H  #E9   Y:0  .7T  #B3   XJ   -[\  #?>   V\ !1
M*P  1BP  #PL   T+   +BP  "HK   E*P  ("P  !LM   7+P  $S$  ! S
M   --0  "3<"  4Z!@ !.PH  #P-   ]#P  /A(  #\7  ! '@  0"4  $ O
M  ! .@  0$8  $!4  ! 90  /W@  #^/   ^I@  /KT  #W<   ]\ !-+@
M0B\  #DO   R+P  +2X  "@N   B+P  '3   !@R   3-0  $#<   PZ   )
M/   !3X   !!!   0@@  $,+  !$#0  1A   $<4  !(&0  2"$  $@J  !(
M-0  2$$  $A/  !(8   1W,  $>*  !&H@  1;D  $79  !$\ !(,@  /C(
M #8R   P,0  *S$  "4R   ?-   &38  !,Y   0/   ##\   A"   #1
M $8   !( @  2@4  $L(  !,"P  3@X  $\1  !1%0  4AP  %(E  !2,
M4CP  %%*  !16@  46T  %"$  !/G0  3K4  $W2  !-[@!#-@  .S8  #0U
M   O-   )S4  "$X   :.P  %#X  !!!   ,1   !T<   )*    30   $\
M  !1    4P(  %0%  !5"   5PL  %D.  !;$0  71<  %T?  !=*@  738
M %Q$  !<5   6V<  %M^  !:EP  6:\  %C+  !7Z@ _.0  .#D  #,X   K
M.0  (SP  !P_   50P  $$<   M*   %3@   %$   !4    5P   %H   !<
M    70   %\   !@!   8@<  &0+  !F#@  :!(  &L9  !K(P  :BX  &H\
M  !J30  :5\  &AU  !GCP  9J@  &7"  !DXP ]/0  -SP  "X]   E0
M'40  !9)   030  "E$   15    6@   %T   !@    8P   &8   !H
M:@   &L   !M    ;P(  '$&  !T"@  =@X  'D3  ![&P  >R<  'HU  !Y
M10  >%D  'AM  !WA@  =I\  '6W  !TT@ \00  ,D(  "A%   @2@  %TX
M !!4   *60   EX   !C    9P   &L   !O    <@   '4   !W    >0
M 'L   !]    ?P   ((   "$ P  APD  (H.  ".$P  CQX  (XK  "..P
MC4X  (MC  "*?   BI4  (BM  "'Q0 V1P  +$L  ")/   950  $%L   IA
M   !9P   &T   !R    =P   'L   !_    @P   (8   "(    B@   (T
M  "/    D0   )0   "7    F@$  )T'  "A#0  I10  *0A  "D,0  HT0
M *)9  "@<   GXL  )VB  "=MP P4   )54  !M;   28@  "VD   %P
M=P   'T   "#    B    (T   "1    E0   )@   ":    G    )\   "A
M    HP   *8   "I    K    +    "T!P  N X  +H8  "Z)P  N3D  +A.
M  "W90  MGX  +66  "SJP I6P  'F(  !1I   ,<0   GD   "!    B0
M (\   "6    FP   *    "D    J    *L   "L    KP   +(   "T
MM@   +D   "\    P    ,0   #(    S0<  -(0  #2'0  T2\  -!$  #/
M6P  S7,  ,N-  #*H0#_    _P   /L   #Z    _  ( /@ #P#U !< ]  @
M /$ *@#K #, Y@ [ .( 0P#> $D V@!/ -8 5 #3 %D T !> ,X 8P#+ &@
MR0!N ,8 =0## 'T P0"& +X D@"[ )X N0"N +8 PP"T .@ LP#_ *\ _P"E
M /\ G@#_ )L _P#]    ]P   /(   #P    YP # .$ # #< !( V  ; -8
M) #2 "T S  V ,8 /0#" $, OP!) +P 3@"Z %, N !8 +8 70"U &( LP!G
M +$ ;@"O '8 K !_ *H B@"H )< I0"F *, N0"A -D H #Y )X _P"8 /\
MD@#_ (\ _P#S    [    .,   #3    R    ,$ "0"]  \ NP 6 +D 'P"W
M "< LP O *\ -P"L #T J@!# *@ 2 "F $T I !2 *, 5@"A %L GP!A )X
M9P"< &\ F@!X )< @P"5 )  DP"> )$ L "0 ,@ C@#P (T _P"* /\ A0#_
M (( _P#G    W0   ,8   "X    K@   *@ ! "E  P H0 2 *$ &0"@ "(
MGP I )L , "8 #< E@ ] ), 0@"2 $< D !+ (\ 4 "- %4 C !: (H 80"(
M &@ AP!P (4 >P"# (@ @0"6 '\ IP!] +P ? #C 'P _0!\ /\ > #_ '8
M_P#6    P    *\   "C    F0   ),   "/  D C0 . (L % "* !P B@ C
M (@ *@"% #  @P V (( .P"  $  ?P!% 'X 2@!\ $\ >P!4 'H 6@!X &$
M=@!I '4 <P!S (  <0". &\ GP!N +( ;0#/ &P ] !L /\ :P#_ &D _P#
M    JP   )L   "/    AP   (    !\  0 >@ , '@ $0!X !< >  > '<
M) !U "H <P P '$ -0!P #H ;@ _ &T 1 !L $D :P!. &H 5 !H %L 9P!C
M &4 ;0!D '@ 8@"' &  EP!? *H 7@#" %X Z0!> /\ 7@#_ %T _P"L
MF0   (H   !_    =P   '$   !M    :@ ( &D #@!H !( 9P 8 &< 'P!G
M "4 90 J &, +P!B #0 80 Y &  /@!? $, 7@!( %T 3@!; %4 6@!= %@
M9P!7 '( 50"! %0 D0!3 *, 4@"X %$ W !1 /D 4@#_ %( _P"=    BP
M 'P   !Q    :0   &0   !@    7@ % %P "P!;  \ 6P 4 %H &0!: !\
M60 E %< *@!6 "\ 50 T %0 . !3 #T 4@!# %  20!/ %  3@!8 $T 8@!+
M &T 2@!Z $D BP!( )T 1P"Q $< S !& /  1P#_ $< _P"0    ?@   '
M  !F    7@   %D   !6    4P ! %( " !0  T 3P 0 $\ %0!. !H 3@ @
M $T )0!, "H 2@ N $D ,P!( #@ 1P ^ $8 1 !% $L 1 !3 $, 70!! &@
M0 !U #\ A0 ^ )< /0"K #T PP ] .8 /0#[ #X _P"'    =0,  &@&  !=
M!P  508  % &  !,!   2@$  $D ! !'  H 1@ . $4 $0!% !8 1  ; $,
M( !" "4 00 J $  +P _ #0 /@ Z #T 0  [ $< .@!/ #D 60 X &0 -P!Q
M #8 @0 U ), - "F #0 NP T -T - #U #4 _P!^!@  ;0D  & +  !6#
M3@P  $@+  !$"@  0@@  $ % 0 _ 0< /@ + #T #@ \ !( .P 7 #L '  Z
M "$ .0 E #< *@ V #  -0 U #0 /  S $, ,@!, #$ 50 P &  +P!M "X
M?0 M (\ + "B "P M@ L -  + #N "P _ !W"@  9PP  %H.  !0#@  20X
M $,.   ^#0  .PP  #D+   X"0, -P4( #8"#0 U 1  -  3 #, &  R !T
M,0 B #  )P O "P +@ R "T .  L $  *P!) "H 4@ I %T * !K "<!>@ F
M 8P )0"? "4 L@ E ,H )0#H "4 ]P!R#0  8@X  %80  !,$0  1!$  #X1
M   Y$   -@\  #,.   Q#0$ , L% # ("@ O!@T +@41 "P$%  K QD *@,>
M "D#(P H!"D )P0O "8%-0 E!3T ) 5& ",&4  B!EP (0=I " '>0 ?!XL
M'@>= !X'L  =!L8 '0;C !T%\P!M#@  7A$  %(2  !($P  0!,  #H3   U
M$@  ,1$  "X0   L#P  *@X# "H-!P I"PL * D. "<)$0 E"!8 ) @; ",)
M(  B"28 (0DL " *,P ?"CL '@M$ !T+3P <#%L &PQI !H,>0 8#(L & R>
M !<,L  6#,4 %@SA !8+\ !I$   6A(  $X4  !%%0  /14  #<5   Q%
M+1,  "H2   H$0  )A ! "00!  C#@@ (PT, "(,#P @#!, 'PP8 !X-'0 =
M#2, ' TJ !L-,@ :#CH & Y$ !<.4  6#UP %0]J !,0>P 2$(T $1"@ !$0
MLP 0#\D $ _D !$/\@!E$@  5Q0  $L6  !"%P  .A<  #07   O%@  *A4
M "<4   D$P  (A,  " 2 P >$08 '1 ) !P0#0 ;#Q  &1 5 !@0&P 7$"$
M%A H !41,  4$3D $Q%# !(23@ 1$EH $!)I ! 3>0 .$XP #A.>  T3L0 -
M$L4 #!+A  T2\0!B%   5!8  $D8   _&0  -QD  #$9   L&   *!<  "06
M   A%@  'Q4  !P4 @ :$P0 &1(& !<2"P 5$@X %!(2 !,3&  2$Q\ $1,F
M !$4+0 0%#8 #Q5!  X53  .%E< #19E  P7=0 +%X< "A>:  D6K0 (%L$
M"!;=  D5[@!?%@  41@  $8:   ]&@  -1L  "\:   J&@  )1D  "(8   ?
M&   '!<  !D6 0 7%@, %18$ !,6"0 1%@T $!<1  \7%@ .%QP #A@C  T8
M*@ ,&3, #!D\  L:1P *&E, "1IA  <;<0 &&X, !1N7  0:J@ #&K\  QG:
M  09[ !<&   3AH  $,<   Z'   ,QP  "P<   G'   (QL  " :   =&0
M&AD  !<8 0 5& ( $AD$ ! ;!P .&PP #1P0  P<$P +'!D "AP?  D=)P (
M'2\ !QXY  8>0P $'E   Q]>  (?;@ !'X   !^5   >J0  'KT  !W8   =
M[ !8&@  2QP  $$>   X'@  ,!X  "H>   E'0  (1P  !X<   ;&P  &!L
M !8; 0 3&P( $1P$  X>!P ,'PL "B .  @@$@ &(1< !2$=  0A)  "(BP
M 2(U   B0   (TT  "-:   C:P  (WX  ".3   BIP  (KP  "'7   A[0!5
M'0  2!\  #X@   U(   +B   "@@   C'P  (!X  !T=   :'0  %AT  !,>
M   1'P( #B $  TB!P *) L !B4-  0E$  ")A0  "8:   F(0  )RD  "<R
M   G/0  )TD  "A7   H9P  )WL  ">0   GI0  )KL  ";6   E[0!1(
M12$  #LB   R(@  +"(  "8A   B(0  'B   !L?   8(   %"   !$B   /
M(P  #24#  HF!@ &* H  RD-   K#P  +!(  "P7   L'@  +"8  "TO   M
M.0  +48  "U4   M9   +7<  "R-   LI   *[H  "O6   J[@!-(@  020
M #@D   P)   *20  "0C   A(@  '2(  !DB   5(P  $B0   \F   -*
M"BH"  8L!0 "+@D  "\+   P#@  ,A   #,5   S&P  ,R(  #,K   S-@
M,T(  #-0   S8   ,W,  #**   RH0  ,;@  ##6   P[P!))0  /B8  #0G
M   M)P  *"8  ",E   ?)   &R4  !8F   2*   $"H   TL   *+@  !C !
M  (R!   - <  #4*   W#   . X  #H2   Z%P  .A\  #HG   Z,@  .CX
M #I,   Z7   .F\  #F&   XG@  .+8  #?4   V[P!$*0  .BD  #$I   K
M*0  )B@  "(G   =*   &"D  !,K   0+@  #3    DR   %-0   3<    Y
M @  .P4  #P(   ^"P  /PT  $$0  !#%   0QL  $,C  !#+@  0SD  $-'
M  !"5P  0FH  $&!  ! F@  /[(  #[/   ^[P _+   -BP  "\L   J*P
M)2H  !\K   9+0  %"\  ! R   --0  "#@   0Z    /    #\   !!
M0P(  $4%  !&"   2 L  $H.  !,$0  318  $T>  !-*   330  $Q"  !,
M40  2V0  $M[  !*E   2:T  $C*  !'[  [,   ,R\  "TO   H+0  (B\
M !LQ   5-   $#<   TZ   (/0   D    !#    1@   $@   !*    3
M $X!  !/!   40<  %,+  !5#@  6!(  %D9  !8(@  6"X  %<\  !72P
M5EX  %9S  !5C0  5*<  %+"  !2Y@ X,P  ,3(  "PQ   E,@  '34  !8X
M   1/   #$    =$    1P   $H   !-    4    %,   !5    5P   %D
M  !:    7 ,  %X'  !A"P  9 X  &83  !G'   9B<  &8T  !E1   9%<
M &1K  !BA0  89\  &"Y  !>W  U-P  ,#4  "@W   @.@  &#T  !%"   ,
M1@  !DH   !/    4P   %8   !9    7    %\   !A    9    &4   !G
M    :0   &P!  !N!@  <0L  '0/  !W%0  =R   '8M  !V/0  =4\  '1C
M  !S>P  <I4  '"O  !OR0 U.@  *SL  "(_   :0P  $D@   Q-   %4@
M %<   !<    8    &0   !H    :P   &X   !Q    <P   '4   !W
M>@   'P   !_    @@0  (8*  "*#P  C!<  (LD  "*,P  B44  (=;  "&
M<@  A8L  (.E  ""O  O0   )40  !Q)   33@  #50   1:    80   &8
M  !K    ;P   '0   !Y    ?0   (    "#    A0   (<   "*    C
M (\   "2    E@   )D"  ">"0  HA   *(:  "A*0  H#L  )]0  "=9P
MFH$  )J9  "9KP I20  'TX  !54   .6P  !6(   !I    <    '<   !]
M    @@   (8   "+    CP   ),   "5    EP   )H   "=    H    *,
M  "F    J@   *X   "R    MPH  +L1  "Z'P  N3   +=%  "U7   M'0
M +&.  "OI  B5   &%L  !!B   ':@   ',   ![    @@   (D   "0
ME0   )H   "?    HP   *8   "H    JP   *X   "P    LP   +8   "Z
M    O0   ,(   #'    S $  -,+  #4%0  TR8  -$Z  #040  S6@  ,N!
M  #*E@#\    ]@   /(   #Q    \P % /0 # #R !, \  < .T )0#H "X
MX@ V -X /@#9 $0 U !* -$ 3P#. %0 RP!9 ,D 7@#& &, Q !I ,$ < "^
M '@ O "! +D C0"V )H LP"K +$ P "O .8 K@#_ *4 _P": /\ E #_ (\
M_P#T    [    .@   #G    WP   -D "0#2 !  SP 7 ,\ ( #, "@ Q@ P
M ,  -P"\ #X N0!$ +< 20"U $X LP!3 +$ 5P"O %T K0!B *L :0"I '$
MIP!Z *4 A0"B ), H "B )T M@"; -0 F0#Y )8 _P"- /\ B #_ (0 _P#H
M    WP   -D   #)    OP   +@ ! "U  T LP 2 +$ &@"P "( K0 J *D
M,0"F #@ I  ] *( 0P"@ $@ G@!, )P 40"; %8 F0!< )< 8@"5 &D DP!R
M )$ ?0"/ (L C0": (L K ") ,4 B #N (8 _P!_ /\ >@#_ '@ _P#9
MS0   +L   "N    I0   )\   "<  D F0 / )D %0"9 !T F  D )0 *P"1
M #$ C@ W (P / "+ $$ B0!& (@ 2P"& %  A0!5 (, 6P"" &( @ !K 'X
M=0!\ (( >@"2 '@ HP!W +D =@#@ '4 _P!R /\ ;@#_ &P _P#'    M0
M *4   "9    CP   (D   "%  0 A  , (( $0"" !< @@ > (  )0!^ "L
M?  Q 'H -@!Y #L =P!  '8 1 !U $D <P!/ '( 50!P %P ;P!D &T ;@!L
M 'H :@"* &@ FP!G *\ 9@#, &4 ]0!D /\ 80#_ &  _P"T    H    )
M  "%    ?0   '<   !S    <  ( &\ #@!O !( ;P 8 &\ 'P!M "4 :P J
M &D , !H #0 9P Y &8 /@!E $, 8P!( &( 3@!A %4 7P!> %X 9P!< ',
M6P"" %D DP!8 *8 5P"_ %< Z@!7 /\ 5@#_ %0 _P"A    C@   '\   !U
M    ;    &@   !D    80 $ &  "P!?  \ 7P 3 %\ &0!? !\ 70 E %P
M*@!; "\ 60 S %@ . !7 #T 5@!# %4 20!3 %  4@!8 %$ 80!0 &T 3@![
M $T C !, )\ 2P"U $H W !* /H 2@#_ $H _P"2    @    '(   !G
M7P   %H   !7    50 ! %, !P!2  P 4@ 0 %( % !2 !H 40 ? $\ ) !.
M "D 30 N $P ,P!+ #@ 2@ ] $D 0P!( $H 1@!2 $4 7 !$ &< 0P!U $(
MA@!! )@ 0 "N $  RP _ /( 0 #_ $  _P"%    =    &<   !=    50
M $\   !,    2@   $@ ! !'  H 1P - $8 $0!& !4 1@ : $4 'P!$ "0
M0P I $( +0!! #, /P X #X /@ ] $4 / !. #L 5P Z &( .0!O #@ @  W
M ), -@"G #8 P  V .@ -@#^ #8 _P!\    :P   %X"  !4 P  30,  $<#
M  !# 0  00   #\  0 ^  < /0 + #T #@ \ !$ /  6 #P &@ Z !\ .0 D
M #@ *0 W "X -@ S #4 .@ T $$ ,P!) #( 4P Q %X , !K "\ >P N (X
M+0"B "T N  M -T +0#X "X _P!S 0  9 4  %<'  !-"   1@@  $ (   [
M!P  . 4  #<#   V  0 -0 ( #0 #  T  \ -  2 #, %@ R !L ,0 @ #
M)  O "D +@ O "T -@ L #T *P!% "H 3P I %H * !G "< =P F (D )@"=
M "4 LP E ,\ )0#P "8 _P!M!@  7@D  %(+  !(#   0 P  #H+   V"P
M,@H  # (   N!@( +@,& "T "@ L  T +  0 "L $P J !< *0 < "@ (  G
M "4 )@ K "4 ,@ D #D (P!" "( 2P B %< (0!D "  <P ? (4 'P"9 !X
MK@ > ,< '@#I !\ ^@!H"0  60P  $T-  !##@  / X  #8.   Q#0  +0T
M "H,   H"P  )PD$ "8&"  F! L )0,. "0!$  D 10 (@$8 "$!'0 A "(
M(  H !\ +@ > 38 '0$_ !P!20 ; 50 &@%A !H!<  9 8( & "6 !@ J@ 8
M ,$ & #A !@ ] !C#   50X  $D/  ! $   .!   #(0   M#P  *0X  "8.
M   C#0  (@P# " +!@ @"0D 'P<, !X&#@ >!1$ ' 45 !L%&@ :!1\ &@4E
M !D%*P 8!3, %P8\ !8&1@ 6!E( %0=? !0';@ 3!X  $@>4 !(&IP 2!;P
M$@39 !(#[P!?#@  40\  $80   \$0  -1$  "\1   J$0  )A   "(0   @
M#P  '0X" !P-!0 :#0< &@L* !D*#0 8"1  %PD2 !8)%P 5"1P % DB !0*
M*0 3"C$ $@HZ !(+10 1"U$ $ Q?  \,;@ .#(  #@R4  T+IP -"[H #0K2
M  T*Z@!<#P  3A$  $,2   Z$P  ,A,  "P3   G$@  (Q$  !\1   <$
M&A " !@/!  6#@< %0X) !0-"P 3# T $@P0 !(,%  1#!H $0T@ ! -*  /
M#3  #@X[  T.1@ -#E$ # ]>  L/;0 *#W\ "0^3  D/I@ (#KD " [0  <.
MZ !8$0  2Q(  $ 3   W%   ,!0  "D4   E%   (1,  !T2   :$@  %Q$"
M !41!0 3$ < $A ) !$/"@ 0#@P #@X.  X/$@ -$!@ #1 >  P0)0 ,$"T
M"Q$V  H100 )$4T "!):  <2:@ &$GP !1*0  02I  #$;@  Q'/  (1Z !5
M$@  210  #X5   U%@  +18  "<6   B%0  'A0  !L4   8$P  %1(# !,2
M!0 2$0< $!$)  \1"@ -$0L #!(.  L2$0 *$A4 "1,;  D3(@ ($RH !Q0S
M  44/@ $%4H  Q58  (59P !%7H  !6.   5HP  %+<  !3/   3Z0!2%
M1A8  #L7   R%P  *Q<  "47   A%@  '!8  !D5   6% $ %!,$ !(3!@ 1
M$@@ #Q((  X3"0 ,% H "A4-  @6$  &%A, !189  07'P #%R<  A@P  $8
M.P  &4<  !E5   99   &7<  !F,   8H@  &+<  !?/   7Z@!/%@  0Q@
M #D9   P&0  *1D  ",9   ?&   &Q<  !@6   5%0( $Q4% !$4!@ 0% 8
M#A4'  P6"  *%PH !QD,  0:#@ "&Q(  1L6   ;'0  '"0  !PM   <.
M'40  !U2   =8@  '74  !V*   <H   '+8  !O0   :ZP!,&   0!H  #8;
M   M&P  )AL  "$:   =&0  &1D  !<8   4%P, $A8$ ! 7!  .%P0 #!D%
M  H:!P '' D  QT+   ?#0  (!   " 4   A&@  (2(  "$J   A-0  (D$
M ")/   B7P  (G(  "&(   AGP  (+8  !_1   ?[0!(&@  /1P  #,=   K
M'0  )!T  " <   <&P  &!H  !89 0 3&0$ $1D!  X: 0 ,' ( "AT#  <?
M!0 #(0@  "(*   D#   )@X  "82   F&   )Q\  "<G   G,@  )SX  "=+
M   G7   )VX  ":%   FG0  );0  "31   C[@!$'0  .1\  # ?   H'P
M(QX  !X=   ;'   &!L  !0<   1'   #AT   T?   *(0  !B(!  ,D!
M)@8  "@(   J"P  *PT  "T0   M%0  +1P  "TD   N+@  +CH  "Y(   M
M6   +6H  "V!   LF@  *[(  "K0   I[P! (   -B$  "TA   F(0  (2
M !T?   :'@  %AX  !(?   /(0  #2(   HD   &)@   B@    K @  +00
M "\&   P"0  ,@P  #0.   U$@  -1@  #4@   U*@  -38  #5#   U4P
M-&8  #1\   SE@  ,J\  #'-   P[P \(P  ,B0  "HD   D(P  ("(  !PA
M   7(0  $R,  ! E   -)P  "2D   4K   !+@   #     R    - $  #8$
M   X!@  .@D  #P-   ^$   /A0  #X<   ^)@  /C$  #X_   ]3@  /6$
M #QW   [D0  .JL  #G)   X[0 W)P  +R<  "@F   C)0  'R0  !DE   4
M)@  $"@   TK   )+@  !3     S    -0   #@    Z    /    #X!  !
M P  0@<  $0*  !&#0  21$  $D7  !((0  2"P  $<Z  !'20  1EL  $5Q
M  !$BP  0Z4  $+#  !!Z  T*@  +"H  "<H   B)P  '"@  !8J   1+0
M#3    DS   #-@   #D    \    /@   $$   !#    1@   $@   !*
M3 ,  $X&  !0"@  4PX  %03  !4'   4R<  %,T  !30P  4E4  %%J  !0
M@P  3YX  $VY  !,X  P+0  *RP  "8K   ?+   &"X  !(R   --0  "#D
M  (]    0    $,   !&    20   $P   !.    40   %,   !5    5P
M %D!  !<!@  7PH  &(.  !C%0  8Q\  &(L  !A/   8$X  %]B  !>>P
M7)8  %NP  !9SP O,   *B\  "(P   :,P  $S<   X[   (/P   40   !(
M    3    $\   !2    50   %@   !;    70   &    !B    9    &8
M  !I    ;04  ' +  !T$   =!@  ',E  !R-   <D4  '!9  !O<0  ;8L
M &NF  !JP  N,P  )34  !TX   4/   #D$   ='    3    %$   !5
M60   %T   !A    90   &@   !K    ;0   &\   !R    =    '<   !Z
M    ?@   (($  "&"P  BA$  (D<  "(*P  ACT  (12  "#9P  @8$  '^;
M  !^L@ I.@  (#T  !9"   /2   "$X   !4    6@   &    !D    :0
M &X   !R    =@   'H   !]    @    ((   "%    B    (L   ".
MD@   )8   "; P  H P  *(3  "@(0  GS,  )U'  ":7@  F'<  )>/  "5
MIP C0P  &4@  !%.   )50   %P   !C    :@   '$   !V    >P   (
M  "&    B@   (X   "1    DP   )8   "9    G    *    "C    IP
M *L   "P    M@0  +P-  "Z%P  N2@  +<\  "T4@  LFH  *^%  "MG  <
M3@  $U0   M<   !9    &P   !T    ?    (,   ")    CP   )0   ":
M    GP   *(   "D    IP   *H   "N    L0   +0   "X    O    ,$
M  #'    S0   -0%  #8$   U1X  -,Q  #02   S5\  ,MV  #(C@
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M^_S^______________________________________________________\
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MXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     #!"$   $
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M@K&+PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ 0%?C
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MP(JL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
MBZQQP(NL<<"+K'' BZQQP(NL_[@4#O^X'B?_M"I&]Z\V:=ZG0H_'FV*QQ)MR
MML*;?[G FXB]OIF)P+R5BL.ZD8O&N(V-R+>*C\JVB)',M863S;2#EL^S@9G0
MLX"=T;)_H]&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P
M?J31L'ZDT;!^I-&P?J31_[@4#O^X'B?_M"I&]Z\V:=ZG0H_'FV*QQ)MRML*;
M?[G FXB]OIF)P+R5BL.ZD8O&N(V-R+>*C\JVB)',M863S;2#EL^S@9G0LX"=
MT;)_H]&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31
ML'ZDT;!^I-&P?J31_[@4#O^X'B?_M"I&]Z\V:=ZG0H_'FV*QQ)MRML*;?[G
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MB9#.LX>2T+*$E=*Q@IG3L8&>U*Z HM2L@*/2K("CTJR H]*L@*/2K("CTJR
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MUI.2H-:3DJ#6_;L1#?V\&2;^N21&]K0N:MRK.I+'H%RQQ*%HML&E<;J^IWK
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MB:N&RH>KALJ%JHC*@ZJ)RX&JB\N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N
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M"?^Q(Q[_KC$Z_ZD^6>VB2WG9FER7R)5RL,65?;7#EX6XP9>+N[^3C+V^CX[
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MQ+%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$_ZL:!?^K)1?_J30O_Z1"2OF?3V;HF5R
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M[))I>N&1<XK8CWR8T(Z$I,J.C*W&C9"TQ(J3M\.&E;C"A)BYP8&;NL%_G;O
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MO+R;B,*YE8K'M8V-SK"&EM2I@J#6H8*DT)V"J,N:@ZK(F8.MQ9>$K\*6A+#
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M\[8Y<.J_-WWCRC6'U-$WE;["2ZFPN6"UJ+1PO:.P?L*=K83'DJJ$RXBGALZ
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MHJ;-=*:HS7*IJ<QQK:K,<+*KRW"VJ\MOO*O(<,"KQ'' JL1QP*K$<<"JQ''
MJL1QP*K$<<"JQ'' JL1QP*K$<<"J_Y$2 ?^5)PO_E3L<_Y-++_^/64/_C&14
M^XQK8_**<G'JB'Q]XX:$A]Z"BH_:?X^6UGV4F]-ZF)_1>)RBT'>?I,YUHJ;-
M=*:HS7*IJ<QQK:K,<+*KRW"VJ\MOO*O(<,"KQ'' JL1QP*K$<<"JQ'' JL1Q
MP*K$<<"JQ'' JL1QP*K$<<"J_Y$2 ?^5)PO_E3L<_Y-++_^/64/_C&14^XQK
M8_**<G'JB'Q]XX:$A]Z"BH_:?X^6UGV4F]-ZF)_1>)RBT'>?I,YUHJ;-=*:H
MS7*IJ<QQK:K,<+*KRW"VJ\MOO*O(<,"KQ'' JL1QP*K$<<"JQ'' JL1QP*K$
M<<"JQ'' JL1QP*K$<<"J_Y(2 ?^6)PK_ECL<_Y1+,/^064/_CV-4^HYI9/&-
M<'+IBWI^XHF"B=R%B9+8@HZ9U'^3GM%]EZ+/>YNFS7F>J,QWHJK+=J6LRG2I
MK<ESK:[)<K*OR7&WK\AQO*_"<[VNOG2]K[YTO:^^=+VOOG2]K[YTO:^^=+VO
MOG2]K[YTO:^^=+VO_Y,2 ?^7)PK_F#L<_Y5+,/^1643_D6!5^I!F9/"/;7/H
MC7> X8R B]N(AY35A8V<TH*1H<]_EJ;,?9FIRWN=K,EYH:[(=Z6PQW:IL<9U
MK;+&=+*SQG.YL\)UNK.\=;JSN':ZL[AVNK.X=KJSN':ZL[AVNK.X=KJSN':Z
ML[AVNK.X=KJS_Y01 ?^8)PK_F3L<_Y9+,/^2643_DEY5^I)D9?"1:G3GCW.!
MX(Y]C-F+A9;4B(N>T(60I,V"E*G*?YBMR'V<L,=[H++&>:2TQ7BHM<1VKK;$
M=;2VP7:WMKQWM[:W=[>VLWBWMK-XM[:S>+>VLWBWMK-XM[:S>+>VLWBWMK-X
MM[:S>+>V_Y41 ?^9)PK_F3L<_Y=*,/^36$3_E%Q5^I1A9?"39W3GD7""WX]Z
MCMB-@YC2BXJ@SH>/I\N$DZS(@9>PQG^;L\1]G[7#>Z2WPGFIN<)WK[G"=K6Y
MO'BVN+AXMKBS>+:WL'FWM[!YM[>P>;>WL'FWM[!YM[>P>;>WL'FWM[!YM[>P
M>;>W_Y81 ?^:)PK_FCL<_Y=*,?^4543_EEE5^I9>9?"59'3GDVR"WI%VCMB/
M?YG1C8BBS8J.J<F'DJ[&A):SQ(&:ML)^G[G">Z2ZP7FJNL%WL;J]>+6ZMWBU
MN;-YM;FO>;:XK'JVMZQZMK>L>K:WK'JVMZQZMK>L>K:WK'JVMZQZMK>L>K:W
M_Y<1 ?^;)@K_FSL<_YA),?^64T3_F%=5^IA;9?"7873GEFB"WI-RC]:1>YK0
MCX2CRXV,J\>*D;'$AI6VPX.9N,%_GKK!>Z2[P'FKO+]WL[RX>+.[LGFTNZYY
MM;JK>K6YJ'NVN*A[MKBH>[:XJ'NVN*A[MKBH>[:XJ'NVN*A[MKBH>[:X_Y<1
M ?^;)@K_G#H<_YA),?^8443_FE14^IM89/":773GF&."WI9MC]:3=YK0D8"D
MRH^)K,:-C[/#B92WPH28NL!_GKR_>Z6^OWFNOKEXLKZR>;*]K7JSO*E[M+JF
M>[6YI'RVN*1\MKBD?+:XI'RVN*1\MKBD?+:XI'RVN*1\MKBD?+:X_Y@1 ?^<
M)@K_G#D<_YE(,?^93T3_G%)4^YU58_&=6G/GFU^!WIEIC]:6<IK/DWRERI&%
MK<60C;3#BY*XP866N[^ G;Z]>Z7!NWFOP;)ZL,"L>[&^J'NSO:5\M+NB?;6Y
MH'VVN*!]MKB@?;:XH'VVN*!]MKB@?;:XH'VVN*!]MKB@?;:X_YD1 ?^=)@K_
MG3D<_YE',?^;34/_GD]3^Y]28_&@5G+HGUN WYUDCM>:;9K0EW>DRI2!K<62
MBK7"CI"YOX>5O;V G,&[>Z?$LWJMQ*M[K\*F?+&_HWVRO:!^M+N>?[6YG'^V
MN)Q_MKB<?[:XG'^VN)Q_MKB<?[:XG'^VN)Q_MKB<?[:X_YD1 ?^>)@K_G3@<
M_YI',?^<2T+_H$U2_*)08O*C4W'IHU=_X*%>C-B>9YC0FW&CRIA[K<65A;3"
MDHVZOHJ2O[J!F\6W?*G)JWRKQZ1]KL.@?K# G7^RO9N L[N9@;6ZF(&VN)B!
MMKB8@;:XF(&VN)B!MKB8@;:XF(&VN)B!MKB8@;:X_YH1 ?^>)@K_GC@<_YI&
M,O^>24+_HDI1_:1-8/.F4&_JIU1]X:98BMJD8I;2H6NARYUUJ\::@+/"F(JZ
MO(Z/PK:#F<NL?:;.HG^JR9V K<2:@;# F(*ROI>#L[R5@[6ZE(.VN)2#MKB4
M@[:XE(.VN)2#MKB4@[:XE(.VN)2#MKB4@[:X_YH1 ?^?)@K_GC<<_YM&,O^?
M1T'_I$A0_J=*7_2I3&WKJU![XZQ4A]RK7)/4J66=SJ9OI\BC>K##GX2XNY:+
MQ+",F<Z@@Z31F82IRI:%K<64A:_!DX6QOI*%L[R1A;2ZD86UN9&%M;F1A;6Y
MD86UN9&%M;F1A;6YD86UN9&%M;F1A;6Y_YL1 ?^?)@K_GS<<_YM%,O^A14#_
MID9/_ZI'7?:M26OML$QXYK-/@]^T58[9M5^7T[5IH,ZU=J?!JWRVL)^%Q*&5
MDLZ4CJ/2D(NHRX^*K,:.BJ_"CHFQOXZ)LKV.B+2[CHBUN8Z(M;F.B+6YCHBU
MN8Z(M;F.B+6YCHBUN8Z(M;F.B+6Y_YL1 ?^@)@K_GS8<_YQ$,?^C0S__J$-.
M_ZU$6_BQ16CPMDATZ;M,?N/ 48??QEN.ULAKE,:]<::ULWBUI:B!PY2?C<V)
MG*+2AY2GS(B1J\>)CZ[#B8ZPP(F-LKZ*C+.\BHNTNHJ+M+J*B[2ZBHNTNHJ+
MM+J*B[2ZBHNTNHJ+M+J*B[2Z_YP0 ?^A)@K_H#8<_YY",?^E0#[_JT!,_[%
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M;,R:_X82 ?^((0;_B#44_X9&)?^'4S7_BUM#_XQB4?Z*:E[VAW%J\(1Z=.J
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M2CO_HTL[_Z-+._^C2SO_HTL[_Z-+._^C2SO_HTL[_Z-+MKH" *;*  "8W
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M9T7NYV=&Z^AG1NOH9T;KZ&=&Z^AG1NOH9T;KZ&=&Z^AG[J(  ,VT @"\O@0
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M2X#48%=VT6AA;<]P:67->G!>S(9U6,R5>53,IGM1S;Q\4,SB?%/!X']5M]^
M6+'>@5JKWH%<IM^!7*;?@5RFWX%<IM^!7*;?@5RFWX%<IM^!_X / ?^.#@'_
MH@T V[4( ,[!" #&T D OND2 K3I)0JJZ#,7H.8^)9;E1S*+XTX_@.%527;@
M75-MWF9;9=UO85[=>F=8W(9K4]R5;U#=IG%-WKMR3=_A<4[1YW10QN9W4K[D
M>%.XY'E5LN-Z5;+C>E6RXWI5LN-Z5;+C>E6RXWI5LN-Z_X,. ?^6"P#=JP0
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MYW68;N=UF&[G=9ANYW68;N=U_V<6 ?]D( /_<!X#_WXB!?^++ G_DS<0_YA
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M@(#;A8" W8. ?]Z!@'[@?X!]X7V ?>-[@'SD>H!\Y'J ?.1Z@'SD>H!\Y'J
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M>F.7Y'EFE.5W9I+F=V:2YG=FDN9W9I+F=V:2YG=FDN9W_W 2 ?^ #@'_D@X
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M8$N]]F!+O?9@2[WV8$N]]F!+O?9@_XD  -F>  #'K $ N;8" *[! P"ES@8
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M;W*#[6US@>YK=(#P:72 \&ET@/!I=(#P:72 \&ET@/!I_V$7 ?]Q$ '_@@X
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M9%R7\V1<E_-D7)?S9%R7\V1<E_-D_W - /^$! #=E@  SJ,# ,2N! "[MP0
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MD@\;_Z(0&O^R$1G_R!(8_^43%__Z%!?_^A07__H4%__Z%!?_^A07__H4G[,
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M8']S^%Y^<_E<?G+Z6GYR^UE^<OM9?G+[67YR^UE^<OM9_U@7 ?]G$ '_=0X
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M6FN!^UIK@?M::X'[6FN!^UIK@?M:_V(0 /]R!P#X@@, VX\" ,^:!0#)HP8
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M45&>_U%1GO]1_W8  -V)  #*EP  OJ(  +.J  "ILP  H+P" )C&!@"1S!(
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MMB8U\=(F-._S)C3L_R8RZ_\H,N?_*S/D_RPSY/\L,^3_+#/D_RPSY/\LP9P
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M"13_PPD3_^,)$__X"1/__PH3__\*$___"A/__PH3__\*FK$  (N]  !\R
M;=0  %_@  !1Y@  1_4  $'_   \_PD -_\0 #+_%0$N_QT!*O\C 2;_*0$B
M_R\"'_\U AS_.P(9_T(#%O]) Q/_40,1_UH##_]F! W_= 0+_X4$"O^6!0G_
MJ 4(_[D%!__0!0?_XP4'_^,%!__C!0?_XP4'_^,%C;H  'W'  !MTP  7^
M %#G  !"[0  .O\  #7_   O_P( *O\* ";_#P B_Q0 'O\: 1K_'P$6_R,!
M$_\H 1#_+0$._S,!#/\Y @K_00('_TD" _]3 @#_7@( _VP" /]\ P#_C0,
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M3I!C_TR.9/]+C&3_2HMD_TB+9/](BV3_2(MD_TB+9/](_U 6 ?]<$ #_: T
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M379Q_TQV<?],=G'_3'9Q_TQV<?],_UD0 /]F!P#_<P0 X7\! -:(! #/D 8
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M2V&#_TMA@_]+_V0% /5T  #:@@  RXX  ,&7  "XG@$ L:4  *FK!P"CK1H
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MN#I$NM<Y0[CU.T*V_SU"L_\^1*[_/D6I_SY%J?\^1:G_/D6I_SY%J?\^X'T
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M&3'E_ADOY/\<+N3_'BWB_R MXO\@+>+_("WB_R MXO\@NIH  *JC  "=JP
MD+0  (.]  !WQ@  :\\  %_6  !4W@0 4? 0 $WP&P!*\"8!1O$P D+R.@,^
M\D,$._-+!3CS5 <V]%T(,_1H"3#U= LN]8$,+/:1#BKVH@\H][<0)_C6$2?V
M]!$F\_\1)O'_$27Q_Q,E\?\3)?'_$R7Q_Q,E\?\3K:$  *"I  "2LP  A+P
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M P#_[ , _^P# /_L P#_[ , _^P#B+D  'C$  !IT   6]T  $OC   ^Z0
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M.*Q0_SBG4?\WHU+_-J!3_S6?4_\UGU/_-9]3_S6?4_\U_T87 ?]0$0#_6 T
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M/H)C_SV"8_\\@F/_/()C_SR"8_\\_U / /];!P#_9@, [&\" -QV P#4? <
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M/VUR_S]M<O\__UD' /]E  #B<@  T7P  ,>$  # B@( N8\" +.2# "LE!T
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MLD%2DLE"4I'K05*0_T!2C_\_58O_/E:(_SU7A_\]5X?_/5>'_SU7A_\]^6<
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M+4"P_B\_K_\Q/JW_,D"H_S)!IO\R0:;_,D&F_S)!IO\RU7P  ,**  "UE@
MJ)T  )VC  "2J@  A[$  'RW  !PO@, :,(. &;#'0!CPRT!7L,Y!%K#1 A6
MPDX,4L)7$$_!7Q1+P6D72,%S&D7 ?AU"P(P@/\";(CW K2,\P<0C/,#I(SJ^
M_B8XO/\H-[O_*3BX_RHXMO\K.+;_*SBV_RLXMO\KR84  +F3  "LG   H*(
M )2J  "(L0  ?+@  '&^  !FQ0, 6\L( %?-$P!6SB, 4\XR 5#./@--ST@%
M2<]2"$;/6PM#SV4.0,]O$#[/>Q,[SXD5.<^9%S?/JQ@VT,,8-L_H&#3-^QLR
MR_\=,<K_'S#)_R$OR/\A+\C_(2_(_R$OR/\AOH\  *^:  "BH0  EJD  (JP
M  !]N   <;\  &;&  !;S ( 4-(' $?:# !&W!@ 1=PG $3=-0%!W4 "/]Y+
M SW>500ZWU\&.-]I!S7?=@DSX(0+,>"4#"_AI@TNX;P.+>+@#BW>^ \KW?\2
M*MS_%"G:_Q8HVO\6*-K_%BC:_Q8HVO\6LY@  *6@  "9IP  B[   'ZX  !Q
MP   9<@  %G.  !.TP  1-L$ #_I#0 ]Z1< .^HC #GJ+@ VZS@!-.M" 3'L
M2P(O[54#+>U? RKN:P0H[G@%)N^(!B7OF@<C\*X'(O'(!R+P[0<A[/\'(>O_
M""#K_PH?ZO\+'^K_"Q_J_PL?ZO\+J)\  )NF  "-KP  ?[@  ''!  !DR@
M6-   $S6  !!W0  ..0  #7V#  S]Q0 ,/<> "[X)P K^3  */DX 2;Z0 $C
M^TD!(?M2 1[\70(<_6D"&OUY QC^BP,7_YX#%?^S!!3_TP04_O0$$_S_ Q/Z
M_P,3^?\#$_G_ Q/Y_P,3^?\#G:4  (^N  " N   <L(  &3+  !6TP  2=H
M #[?   TY   +O0  "O_"@ H_Q  )?\7 "+_'P ?_R8 '/\M !G_-  7_SP
M%/]$ 1+_3@$0_UD!#O]G 0S_=P$+_XH""O^? @G_M0((_]4"!__T @?__P('
M__\"!___ @?__P('__\"D:T  (*X  !SP@  9,P  %;5  !(W0  .^(  ##G
M   G[@  (_\  "#_!  <_PP &?\1 !;_%@ 3_QL $?\A  [_)P -_RX "O\V
M  ?_/@ $_T@  /]4  #_8@$ _W,! /^' 0#_G0$ _[(! /_* 0#_Z@$ __,!
M /_S 0#_\P$ __,!A+<  '3!  !ES   5M@  $??   YY0  +>H  "/N   <
M_0  &/\  !7_   1_P0 #_\+  W_#@ )_Q$ !O\5  /_&@  _R   /\F  #_
M+@  _S<  /]!  #_30  _UP  /]M  #_@@  _Y8  /^H  #_N@  _\,  /_#
M  #_PP  _\, _R0O ?\E+P'_*"\!_R<Q ?\D-@+_(#X"_QI) _\75@/_%60#
M_Q-R!/\2?P3_$HH$_Q*4!/\2G07_$J0%_Q*L!O\2LP;_$KH&_Q+#!O\3S@?_
M$]\'_Q/K!_\3]@?_$_\'_Q/_!O\3_P;_%/\'_Q3_"/\3_PC_%?\)_Q7_"?\5
M_PG_%?\)_R4N ?\I+0'_*RP!_RLN ?\I,P+_)#L"_Q]& _\=4P/_&V$$_QEN
M!/\7>P3_%X<%_Q>1!?\7F@;_%Z$&_Q>I!_\7L ?_%[<(_Q? "/\8R@C_&-L(
M_QCH"/\8] C_&/T(_QG_"/\9_PC_&?\)_QG_"O\8_PO_&O\+_QK_"_\:_PO_
M&O\+_R8M ?\L*0'_+B@!_R\J ?\M+P+_*3<"_R=# _\D4 /_(ET$_R!J!?\>
M=P7_'H,&_QZ-!_\>E@?_'IX(_QZE"?\>K G_'K,)_QZ\"O\>Q@K_'M,*_Q[E
M"O\>\0K_'_P*_A__"OT?_PO\'_\,_![_#?P?_P[W(?\.]R'_#O<A_P[W(?\.
M_RHJ ?\O)@'_,B0!_S,E ?\R*@'_,30"_R\_ _\M3 /_*ED$_RAF!?\F<@;_
M)7X'_R6)"/\ED@G_)9H*_R6A"_\EJ O_)+ ,_R2X#/\EP0S_)<X-_R7A#?PE
M[PWY)OH,]B;_#?4F_P_T)?\0]"7_$?(F_Q+M)_\2[2?_$NTG_Q+M)_\2_RXF
M ?\T(@'_-R !_SDA ?\X)0'_.2\"_S@[ O\U1P/_,U0%_S%A!O\O;0?_+GD)
M_RV$"O\MC0S_+)8-_RR=#?\LI0[]+*P/_"RT#_LLO0_Y+,D0]BS=$/,M[ _O
M+?@/[2W_$NLL_Q3J+/\5Z2S_%N4M_Q;@+O\6X"[_%N N_Q;@+O\6_S(C ?\X
M'0'_/!L!_SX; ?] (@'_02L!_T V O\^0@/_/$\%_SE<!O\X: C]-G,+^S5^
M#/@UB [W-)$/]329$/,TH!'R,Z@2\#.P$N\SN1/N,\43ZS37$^<TZA+C-/<4
MX33_%]XS_QG<,_\:VS/_&M0T_QK.-?\:SC7_&LXU_QK.-?\:_S8? ?\\&0'_
M018 _T06 /]''@'_22<!_T@R O]&/0/_1$D%^D)6!_9 8@GR/VX,[SUY#^T\
M@Q#J/(P2Z#N4$^<[G!3E.Z05XSJM%>(ZMA;@.\(6WSO2%MH[Z!?4.O8:T#K_
M',TZ_Q[+.O\>RCK_'\0[_Q_ //\>P#S_'L \_Q[ //\>_SD; ?] %0#_11$
M_TH3 /].&0#_4"(!_U L ?U.-P+V2T,$\$E0!^M(70KG1FD-XT5T$.!$?A/=
M0X<5VT*0%]A!F!C50* 9TT"I&]% LAS/0+T=S4#,'<I!Y![&0/0@PD#_(K]
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M+992_RR44O\KE%+_*Y12_RN44O\K_T80 /]."0#_5@4 _EX& .]B!P#G90H
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M,7EB_S%Y8O\Q_T\' /]9  #F9   UVP  ,QS  #$=P( OWD$ +EZ#@"R?"
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ML#MA=L0\87;E.V%V^SEB=O\W8W7_-6-S_S1D<O\S9'+_,V1R_S-D<O\S_U@
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M-4^+]S1/BO\S4(G_,E&&_S%2A/\Q4H3_,5*$_S%2A/\QZF4  -)S  #"?P
MMH@  *R0  "BE   F)@  (R<  "$GPH @* 9 'RA*0%WH#8%<I]!"FV>2P]H
MG5,49)Q;&6";8QU<FFLA6)ET)568?BE1EXHL3I:8+DN6J#!*EKPQ29;<,$F4
M]C!)D_\P29+_,$J0_R]+C?\O2XW_+TN-_R]+C?\OXFL  ,IY  "\A0  L8\
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M'C.S_Q\SLO\@,[+_(#.R_R SLO\@P8,  +21  "FF   FYX  (^E  ""JP
M=K$  &NV  !?O   5,$# $S%#0!+Q1D 2<8H $C&-0!%QT !0\=* T#'4P0^
MQUT&.\=G"#G'<PHWQX ,-,>0#3+'H0XQR+4/,,C3#S#&]! NQ/\3+<+_%2S!
M_Q8KP/\7*\#_%RO _Q<KP/\7N(T  *J7  ">G@  D:4  (2L  !XL@  :[D
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M 0WS_P$-\_\!F:,  (NL  !\M0  ;;X  %_&  !2S0  1=(  #G8   OW@
M)N(  !_J   <^P8 &?\. !?_$P 4_QH $O\A !#_*  ._S  #?\Y  O_0P )
M_TX !O]<  3_;  "_X   ?^6  #_K0  _\H  /_P  #__P  __\  /__  #_
M_P  __\ C:L  'VU  !NOP  8,@  %+0  !#UP  -]T  "OB   BY@  &>H
M !7Y   2_P  $/\(  [_#@ ,_Q$ "?\6  ;_'  #_R(  /\J  #_,P  _ST
M /])  #_5P  _VD  /]^  #_E0  _ZP  /_'  #_Z   __H  /_Z  #_^@
M__H @+4  '"_  !AR0  4M,  $/;   UX0  *>8  ![J   5[@  $/@   [_
M   +_P  "/\   3_!@  _PH  /\.  #_$0  _Q4  /\;  #_(P  _RL  /\V
M  #_0P  _U,  /]E  #_>@  _Y$  /^F  #_N   _\\  /_/  #_SP  _\\
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M!?$<_P;P'/\'[QW_".\=_PGO'/\)[AS_">X<_PGN'/\)_RHB ?\N'0#_,!L
M_S < /\P(@#_,"P!_RXW ?\K1 +_*%$"_R9= _\D:0/_(W4$_R-_!/XCB 3]
M(Y$%^R.8!?HCH 7X(Z<&]R.N!O4CMP;T(\$&\B3/!NXDY ;J)?(&Z"7^".8D
M_PKD)?\+XR7_#.,D_PSB)/\,X23_#>$D_PWA)/\-_RX> /\S& #_-18 _S45
M /\X'0#_."<!_S<S ?\T/P'_,DL"_R]8 _LN9 3X+6\$]2QZ!?,L@P;Q+(P&
M[RR4!^TLG CL+*,(ZBRK".DLLPCG++X)YBS,">(MX@C>+?$*VRS^#-8M_P[4
M+/\/TBS_$-$L_Q#/+/\0SBW_$,XM_Q#.+?\0_S(9 /\W% #_.A$ _SP2 /\_
M&0#_0"( _SXM ?\\.0'Z.D4"]#A2 _ W7@3L-FH%Z35T!N8U?@CD-(<(XC20
M"> TF K>-)\*W#.G"]HSL S8,[L,U3/)#=(TWPW.-/ /RC3]$L<T_Q/%-/\4
MPS3_%<,S_Q7 -/\5OS3_%+\T_Q2_-/\4_S85 /\[$ #_/@T _T,/ /]&% #_
M1AP _T8F /9$,@'O0C\!Z4!, ^0_603?/F0&VSUO"-@\>0K4/((,T3N+#<\[
MDP_-.IH0RSJB$<DZJQ+(.K43QCK"$\0ZU13 .^L5O#K[%[DZ_QBW.O\9MCK_
M&;4Z_QBR._\8L3O_&+$[_QBQ._\8_SD2 /\_#0#_0PD _T@, /]+$ #_3!4
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M(XA2_R.(4O\C_T4' /]+  #P50  WUL  --@  #,80, R&$& ,-A$0"[9"0
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MKR]P8L$P;V+?,&YC]RYO8_\L;V/_*F]C_RAO8O\G;V+_)V]B_R=O8O\G_TT
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M,%UQ\BY><?\L7G#_*U]P_RE@;_\H8&[_*&!N_RA@;O\H\54  -YB  #*;0
MO74  +-[  "K@   HH(  )B!  "1@P\ C84? (B%+@*#A#L%?H-%"GJ!3@]U
M@%84<7]>&&Y]9AQJ?&T@9WMV(V-Z@"=@>8LJ77B8+%IWIBY8=[@O5W?1+U=W
M\2Y8=O\L6';_*EEU_RE:=/\H6G3_)UIT_R=:=/\G[5D  -=F  #%<0  N7H
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M)4:+_R1&BO\D1HK_)$:*_R1&BO\DV&D  ,-V  "U@0  JXH  )^/  "5DP
MBI8  'Z:  !PG0  :Y\. &B?' !FH"H!8J W E^?005;GTH(6)Y2"U2>6@Y1
MG6(23IQK%4N<=1A(FX$:19N/'4*:GQ] FK @/YK((#^9ZQ\_F/\@/I;_(3Z5
M_R$_E/\A/Y3_(3^4_R$_E/\AS7   +Q]  "PB   I(\  )F4  ".F   @YT
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MM   3K<  $.\!0! O1$ /[T> #Z^*P \OC8 .[]! #F_2P$WOU0"-<!? C/
M:@0QP'<%+\"&!BW EP<KP*H(*L'"""K YP<IO?T**+S_#">Z_PTGN?\.)[G_
M#B>Y_PXGN?\.LHP  *64  "9F@  C:$  '^G  !RK0  9K,  %JX  !/NP
M1+\  #K$ @ PR0@ +LH1 "W*'0 LRRD *\LU "O,0  JS4H *,U6 "?.80 F
MSF\!),Y_ 2//D0(ASZ4"(-"] B#/Y (?S?H#'LO_!![*_P4=R?\&'<G_!AW)
M_P8=R?\&J)0  )R:  "0H0  @J@  '2O  !GM@  6[P  $[   !#PP  .<<
M "_,   GT 0 ']8* !O:$  ;VQH &MLF !K<,0 9W3P &-U( !C>50 7WV(
M%N!R !7@A0 4X9H $^*Q !+CSP 2X/0 $M[_ 1'=_P$1V_\"$=O_ A';_P(1
MV_\"GIH  )*A  "$J0  =K$  &BX  !;OP  3L0  $+(   WS   +=   "35
M   <VP  %=\% !3I#@ 2ZA0 $>L= !#K)@ .[#  #NTZ  WN1@ +[E, "N]B
M  GP=  (\8D !_*@  7RN@ $\>0  O']  +O_P #[?\  ^W_  /M_P #[?\
ME:$  (:I  !XL@  :;H  %O"  !-R   0,P  #31   JU@  (=L  !G@   2
MY   #_ !  WY"@ +^@\ "?L5  ?['  $_"0  ?PL  #\-P  _$(  /Q0  #\
M80  _74  /R,  #\I   _,$  /SK  #\_P  _?\  /W_  #]_P  _?\ B:D
M 'FR  !JNP  7,0  $[,   _T0  ,M<  "?=   =X0  %>4   [H   *\0
M"/T   7_ P !_PD  /\.  #_$@  _Q<  /\?  #_)P  _S$  /\^  #_30
M_U\  /]U  #_C0  _Z8  /_"  #_YP  __P  /__  #__P  __\ ?+,  &R\
M  !=Q@  3L\  #_6   QW0  )>(  !KF   1Z@  #.X   7R    _P   /\
M  #_    _P   /\%  #_"@  _PX  /\2  #_&   _R$  /\K  #_.0  _TH
M /]=  #_<P  _XP  /^D  #_N0  _]0  /_>  #_W@  _]X _Q@L /\9*0#_
M&2@ _Q4K /\0, #_"S@!_P-$ ?\ 40'_ %X!_P!L ?\ > '_ ((!_P", ?\
ME '_ )P _P"B /\ J #_ *\ _P"V /\ O@#_ ,@ _P#7 /\ YP#_ /, _P#]
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _QLI /\=)@#_'"4
M_QDG /\3+ #_#C0 _PM  ?\(3@'_!5L!_P-H ?\"= '_ G\!_P*( ?\"D0'_
M I@!_P*? ?\!I0#_ :P _P&R /\!N@#_ <0 _P'1 /\ Y #_ /$ _P#\ /P!
M_P#\ O\ _ /_ /P$_P'\!?\!_ 7_ ?P%_P'\!?\!_Q\F /\A(@#_("$ _QXC
M /\8)P#_$S  _Q$\ ?\.2@'_#5<!_PMC ?\*;P'_"GH!_PJ$ ?\*C0'_"I0!
M_PJ; ?\*H@'_"J@!_PJO ?\*MP'_"L  _PK, /\*X #["N\ ]PKZ /4+_P'U
M#/\!] W_ ?0-_P+T#?\"] W_ O0-_P+T#?\"_R(B /\D'0#_)!P _R(= /\>
M(@#_'"P _QDX /\610'_$U(!_Q)> ?\0:@'_$'4!_Q!_ ?\0B '_$) !_Q"7
M ?\0G@'_$*4!_1"L ?P0LP'Z$+T!^1') ?41W0'Q$>T![A'Y >P2_P+K$_\"
MZA/_ ^D3_P/I$_\#Z1/_ ^D3_P/I$_\#_R8= /\H& #_*!8 _R86 /\F'0#_
M)B@ _R,T /\@0 #_'4T!_QM9 ?\990'^&7 !_!AZ ?D8@P'W&(P!]AB3 ?08
MF@'S&*$!\1FH ? 9L +N&;H"[1G& NH:V0+F&NL!XAOY N ;_P/>'/\$W1S_
M!=P<_P7<'/\%VQS_!=L<_P7;'/\%_RH9 /\M$P#_+1$ _RT1 /\N&0#_+2(
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M$J([_Q*B._\2_S@* /\\  #_00  ]44  .9& @#A10< XT(- -5#&0#,12P
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ML"""4,$A@%#=(7Y1]"!]4?\??5'_'7U1_QQ]4?\;?5'_&GU1_QI]4?\:_T(
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M)FE>[B1I7O\B:E[_(&I>_Q]J7O\>:E[_'6I>_QUJ7O\=^4H  .-5  #/7P
MP64  +=J  "O;   IVP  )]J 0"9:Q$ E&TB )!N,0&+;3T$AVQ'!X-K4 M_
M:E@/?&A@$WAG9Q9V9V\9<V9X''!E@1YM9(PA:F.8(VABIB5F8K8F9&+,)F1B
M["5D8O\C9&+_(65B_Q]E8O\>96+_'65B_QUE8O\=\DP  -]8  #*8@  O6D
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M(%1P_Q]5</\>56__'55O_QU5;_\=Y5<  ,UD  "^;0  LG4  *A[  "??@
MDWT  (=]  " ?P< ?( 5 'B!) !U@C(!<8$]!&V 1@=I@$\*9G]6#6-^7A%@
M?68477QN%UI[=QI7>H(=5'J/'U%YG2%/>:XB3GG#(DUXY2)-=_LA3G?_'TYV
M_QY/=?\=3W7_'4]U_QU/=?\=WUP  ,AH  "Y<@  KGH  *6   ":@@  CH(
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M%SJ._Q<ZCO\7Q6X  +9[  "JA0  GHL  )2/  "(D@  >Y0  &Z7  !BFP
M5YX  %*@#@!1H!L 3Z$H $VA- !+H3X!2:%' D>A4 -$H5@%0J%A!S^@:PD]
MH'<+.J"%#3B@E XVH*8/-:"[$#2@W0\TG?<0,YS_$C.:_Q(SF?\3,YG_$S.9
M_Q,SF?\3O7<  *^#  "CBP  F)$  (V5  "!F0  <YP  &>?  !;H@  3Z8
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MA0 9QYD &,BN !?(RP 7QO$!%\3_ 1;#_P(6P?\#%L'_ Q;!_P,6P?\#HY$
M )B8  "+G@  ?:4  '"K  !BL0  5K8  $JY   ^O0  -,   "K$   BR
M&<P$ !/0"@ 1TA$ $-(: !#3)0 /TS  #M0\  [42  -U58 #=5E  S6>  ,
MUHT "]BD  K8O@ )V>8 "M;^  O4_P +TO\ "]+_ 0O2_P$+TO\!FI@  (Z?
M  " I@  <JT  &2T  !7N@  2;\  #W"   RQ@  *,D  !_-   7T0  $=8
M  S;!0 (W@L !M\1  7?&@ $X"0  N$N  'B.@  XT<  .16  #D9P  Y7L
M .:2  #FJ@  Y\@  .?P  #H_P  Z/\  .C_  #H_P  Z/\ D9\  (*G  !T
MKP  9;<  %>^  !)PP  /,<  ##+   ESP  '-0  !39   .W0  ">$   +E
M    Z08  .D-  #I$0  ZA@  .LA  #M*P  [S<  /%%  #R5@  \V@  /-^
M  #TEP  ];   /;0  #W\P  ]_\  /?_  #W_P  ]_\ A:<  ':P  !FN
M6,$  $K(   [S   +M$  "/6   9W   $>    SC   $YP   .H   #U
M]    /4%  #U"P  ]@\  /84  #X'0  ^B<  /PT  #_0P  _U4  /]I  #_
M@0  _YH  /^R  #_SP  _^T  /_Y  #_^0  __D >+   &BZ  !9PP  2\L
M #O1   MV   (=T  !;B   .Y@  ".H   #M    \    /@   #_    _P
M /\   #_    _P8  /\,  #_$   _Q@  /\B  #_,   _T   /]3  #_:0
M_X$  /^9  #_KP  _\,  /_5  #_U0  _]4 _Q,H /\3)0#_$24 _PTG /\&
M+0#_ #4 _P!! /\ 3P#_ %P _P!I /\ = #_ 'X _P"( /\ D #_ )< _P"=
M /\ I #_ *H _P"P /\ MP#_ ,  _P#, /\ WP#_ .P _P#X /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _Q8E /\6(@#_%"$ _Q C /\** #_
M #  _P ] /\ 2P#_ %@ _P!D /\ < #_ 'H _P"$ /\ C #_ ), _P": /\
MH #_ *8 _P"M /\ M #_ +P _@#( /T V0#[ .D ^@#V /D _P#X /\ ^ #_
M /@ _P#X /\ ^0#_ /D _P#Y /\ _QHB /\:'@#_&!T _Q,> /\.(@#_"BP
M_P<Y /\#1@#_ %, _P!@ /\ :P#_ '8 _P!_ /\ B #_ (\ _P"6 /\ G0#_
M *, _@"I /P L #Z +D ]P#$ /4 T@#S .8 \@#T /$ _P#P /\ [P#_ .\
M_P#O /\ \ #_ /  _P#P /\ _QX= /\>&0#_'!< _Q<8 /\3'@#_$2@ _PXT
M /\,00#_"DX _PA; /\'9@#_!G$ _P9Z /\&@P#^!HL _ :2 /H&F0#X!I\
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M \,<_P/#'/\#_R@0 /\I"P#_* 8 _RL+ /\K$ #_*1< _28B /0C+@#L(3L
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MM Z;.\4.F3O@#I8[] ^4//\/DCS_#Y(\_PZ1//\-D3S_#9$\_PV1//\-_S4
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M&'E,ZQAX3/X7=TS_%7=,_Q1W3/\3=TS_$G=,_Q)W3/\2_SX  .A'  #54
MQE8  +Q8  "T60  K58  *=3!P"A5!4 G%8E )A7- &45T "D%=*!(U64P:*
M55L)AU1C"X14:@Z"4W(0@%)Z$GU2@Q1[48X6>%"9&'90IAET4+4:<U#)&G%0
MZ!IP4?P8<%'_%W!1_Q5P4?\4<5#_$W%0_Q-Q4/\3]4   .1+  #/5   P5H
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M&%]=_Q=@7?\68%W_%6!=_Q5@7?\5ZTH  -16  ##7@  MF4  *QI  "B:0
MF&<  (]E  ")9@P A6@9 (%I* !^:C4!>FD_ W9I205S:%$(<&=9"FUG8 UK
M9F<0:&5P$F5D>15C9(,78&./&5YBG1M<8JP<6F*_'%EBWQQ98O<:6F+_&5IA
M_Q=;8?\66V'_%5MA_Q5;8?\5YTT  ,]9  "_8@  LV@  *EM  ">;0  DVL
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M%$MP_Q1+</\4U%H  ,!F  "S;P  J'8  )UY  "/>   A'@  '=Y  !O?
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M#P!2CQL 4(\G $^0,P!-D#T!2Y!% DF03@-&D%8$1(]?!4*/: <_CW,)/8Z
M"SJ.CPPXCJ --XZS#C:.S XVC>\.-8O_#C6)_P\UB/\/-H?_#S:'_P\VA_\/
MOFT  +!Y  "E@@  F8<  (R(  !_B   <HH  &:-  !:D0  4)4  $F7"0!'
MF!, 19@@ $29*P!#F38 09I  $":2 $^FE$"/)I: CJ:9 ,WFF\%-9E]!C.9
MC <QF9T(+YFP""Z9R@@NF.T(+I;_"BV4_PHMD_\++9+_"RV2_PLMDO\+MG4
M *J!  ">B   DXT  (:.  !XCP  :Y(  %^5  !4F0  29T  $"@   ZH@T
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M  [ N@ .P.$ #[W[  ^\_P 0NO\!$+K_ 1"Z_P$0NO\!GX\  )25  "'FP
M>:$  &NG  !>K   4K$  $6T   ZM@  +[D  "6\   =OP  %<,   _&!0 +
MR@T "<H4  C*'0 'RB< !\HR  ;+/@ %RTL !,Q:  /,:@ "S'X  <R4  #,
MJP  S<@  ,SM  #,_P  R_\  <K_  '*_P !RO\ EY8  (J<  !\HP  ;JH
M &"P  !2M@  1;D  #F\   NOP  (\,  !O&   3R@  #<T   C1   !U D
M -0.  #5%0  UAX  -@G  #9,0  VSX  -Q+  #=6P  WFX  -Z$  #?FP
MW[0  -[9  #?]P  W_\  -__  #?_P  W_\ C9T  '^E  !PK   8;,  %.Z
M  !%OP  .,(  "S&   AR0  &,T  !#1   +U0  !-H   #>    X $  .$)
M  #B#@  Y!,  .4;  #G)   Z2\  .L\  #M2P  [ET  .YQ  #OB0  \*(
M /"\  #PXP  [_D  /#_  #P_P  \/\ @:4  '*M  !CM0  5+T  $;$   W
MR   *LP  !_0   5U0  #MH   ?>    X@   .8   #I    Z@   .P   #N
M!0  [PP  /$0  #S%P  ]2   /@K  #[.0  _4H  /Y>  #_=   _XT  /^F
M  #_P   _^$  /_U  #_]0  __4 =*X  &6W  !6P   1\@  #C-   JT@
M'=@  !/=   ,X@   ^8   #I    [    /    #S    ]    /8   #X
M^@   /T'  #_#0  _Q(  /\;  #_*   _S<  /]*  #_7@  _W8  /^/  #_
MI@  _[H  /_1  #_T0  _]$ _P\D /\.(@#_"R$ _P,D /\ *0#_ #( _P ^
M /\ 3 #_ %D _P!E /\ < #_ 'H _P"$ /\ C #_ )( _P"9 /\ GP#_ *4
M_P"K /\ L@#_ +H _P#% /\ TP#_ .< _P#T /\ _P#^ /\ _P#_ /X _P#^
M /\ _@#_ /X _P#^ /\ _Q$A /\0'@#_#1T _P<? /\ (P#_ "T _P Z /\
M2 #_ %4 _P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"5 /\ FP#_ *$ _P"G
M /X K@#] +8 _ #  /L S0#Y .( ^ #P /< _ #V /\ ]0#_ /4 _P#U /\
M]0#_ /4 _P#U /\ _Q4= /\3&@#_$!D _PL9 /\ '0#_ "D _P V /\ 0P#_
M %  _P!< /\ 9P#_ '$ _P!Z /X @P#\ (H ^@"1 /D EP#X )T ]P"C /4
MJ@#T +( \@"[ /$ R #O -P [@#L .T ^@#K /\ Z@#_ .H _P#J /\ Z@#_
M .H _P#J /\ _Q@9 /\6%0#_$Q, _PX3 /\+&@#_!R0 _P(P /\ /@#_ $L
M_P!7 /\ 8@#\ &P ^ !U /4 ?@#R (4 \0", .\ DP#N )D [ "@ .L I@#I
M *X YP"W .8 PP#D -0 X@#I .$ ]P#? /\ W0#_ -T _P#= /\ W0#_ -T
M_P#= /\ _QL3 /\:$ #_%@X _Q(. /\2%0#_#Q\ _PPK /\). #_!D4 ^P-1
M /<"7 #R F8 [@)P .H"> #G H  Y@.' .0#C@#B Y4 X0.< -\$HP#=!*L
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M /\E  #_)@  ^R<  /$E P#P(0L Z!P2 -X9'0#4&RT S1T\ ,@?20#%(%4
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M") U[ B.-OX(C#;_"(LV_PB+-O\'BC7_!XHU_P>*-?\'_R\  /(T  #B/
MTD$  ,="  # 0   NSH! +8V#@"P.1P JCLL *8\.@"C/48 GSU0 9T]60*:
M/6$#F#UH!)8\< 64/'<&DCR !Y$\B >/.Y((C3N="8L[J0J).[<+B#O*"X4\
MZ N#//L+@CS_"H$\_PJ!//\)@3S_"($\_PB!//\(_S,  .PZ  #:0P  RD<
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M#VI,_PYJ2_\-:DO_#&I+_PQJ2_\,\#T  -M(  #'4   NE4  +!8  "E5@
MG%,  )=/  "14 X C%(< (E4*P"%5#< @E1" 7]42P-\5%,$>E-:!GA38@AU
M4FD)<U)Q"W%1>@UN480/;%"0$&I0G!)H4*L39E"\$V50V!-D4/,29%#_$&10
M_P]D4/\.94__#65/_PQE3_\,[$$  -1,  ##5   MED  *Q<  "@6@  EU<
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M#E9;_PU66_\-WDP  ,=6  "X7P  K60  *!E  "39   B6,  ']A  !Y8@,
M=601 ')E'@!O9BL ;&<W 6IG0 )G9DD#9691!&)E6 9@96 (761G"EMD< Q9
M8WL.5F.&$%1BE!)28J,34&*T$T]BS!-/8NT23V'_$4]A_Q!08/\.4&#_#E!@
M_PU08/\-V4\  ,-:  "T8P  J6D  )MH  "/9P  A&<  'EE  !S9P  ;VD.
M &QJ&P!I:R@ 9VPT &1L/0%B;$8"7VM.!%UK5@5::ET'6&IE"59I;@M3:7@-
M46B$#TYHDA!,9Z$22V>R$DEGR1))9^L226;_$$IF_P]*9?\.2V7_#4MD_PU+
M9/\-T50  +Y>  "Q9P  IFT  )=L  "*:P  ?VL  '-K  !M;0  :&X, &5P
M%P!B<20 8'$P %YQ.@%<<4,"67%+ U=Q4P15<%H&4G!B!U!P:PE.;W4+2V^"
M#4ENCP]';I\016ZP$41NQQ%#;>H01&S_#T1K_PY%:_\-16K_#45J_PU%:O\-
MRU@  +IC  "M;   H7$  ))P  "%;P  >F\  &YP  !E<P  8'4' %UV$@!;
M=Q\ 67@K %=X-@!5>#\!4WA( E%X3P-/=U<$3'=?!4IW: =(=G,)179_"T-U
MC0Q!=9T./W6N#CYUQ0X]=>@./G/]#3YR_PT^<?\,/W'_##]P_PP_</\,Q5X
M +5I  "I<0  G'4  (UT  " =   =70  &EV  !>>0  6'P! %1]#@!2?AH
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M RB2O00HDN$#)Y#Z!">._P4GC?\%)XS_!2>,_P4GC/\%L70  *5^  "9A0
MBH0  'V$  !OA0  8X@  %B+  !-CP  0Y,  #J7   RF@< +IL0 "V;&@ L
MG"0 *YPN "J=.  IG4$ *)U+ ">>50 FGF$ )9YN ".>?@$BGI !()ZC 1^>
MN0$>GMT!'ISX AZ:_P(>F?\#'I?_ QZ7_P,>E_\#JGT  )Z%  "3BP  A8H
M '6+  !HC@  6Y$  %"5  !&F0  .YT  #*@   JHP  (J8) !^G$0 >IQH
M':@D !RH+0 ;J#< &JE! !FI3  8J5@ %ZIF !:J=@ 5JHD %*J> !.KM  2
MJ], $JCU !.G_P$3I?\!$Z7_ 1.D_P$3I/\!HX8  )>,  "-D0  ?9(  &V5
M  !@F   5)P  $B@   ^I   -*<  "JK   AK@  &;$  !*S!P /M1  #K47
M  ZU(0 -M2L #;4V  RV00 +MDX "K9<  FV;  (MG\ ![:4  :VJ@ %ML4
M!K;J  >U_P (M/\ "+/_  FR_P )LO\ FHT  )"3  "$F   =)P  &6@  !7
MI   2Z@  $"L   UL   *K,  "&U   8N   $;L   R^ @ &P L  L 1  '!
M&0  P2(  ,(K  #"-@  PT(  ,-0  #$7P  Q'$  ,2'  #$G0  Q+4  ,3:
M  #$]@  P_\  ,/_  ##_P  P_\ DY0  (>:  !XH   :J8  %RL  !/L0
M0;4  #6W   IN@  '[T  !;    0PP  "L8   /*    S 4  ,P,  #-$0
MSA@  ,XA  #0*@  T34  --#  #44@  U&,  -5X  #5CP  U:<  -;"  #6
MZ0  UOT  -;_  #6_P  UO\ BIL  'NB  !LJ0  7K   %"V  !"N@  -+T
M "C!   =Q   %,<   W+   &S@   -(   #7    V0   -H%  #<"P  W1
M -\5  #A'0  XR<  .4S  #G0@  Z%0  .AG  #I?@  Z9<  .JO  #JS@
MZ^\  .O^  #K_P  Z_\ ?:,  &ZK  !?L@  4;H  $+    TPP  )\<  !O+
M   2SP  "],   +8    W0   .$   #D    Y0   .<   #I    ZP<  .T-
M  #O$0  \1D  /0D  #W,0  ^4$  /I5  #Z:@  ^X0  /N=  #\M@  _-(
M /WM  #]]   _?0 <:P  &&U  !2O0  1,0  #3)   FS0  &M(  !#8   (
MW0   .$   #E    Z    .P   #O    \0   /,   #U    ]P   /D!  #[
M"   _@X  /\5  #_(0  _R\  /]!  #_5@  _VT  /^'  #_H   _[8  /_*
M  #_U   _]0 _PL@ /\''@#_ !T _P @ /\ )0#_ "X _P [ /\ 20#_ %8
M_P!B /\ ;0#_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K0#_
M +4 _P"^ /\ RP#_ .$ _P#P /X _0#] /\ _0#_ /T _P#] /\ _ #_ /D
M_P#Y /\ _PT= /\+&@#_!!D _P : /\ 'P#_ "H _P W /\ 10#_ %$ _P!>
M /\ : #_ '( _P!Z /\ @@#_ (D _P"0 /\ E@#_ )P _@"B /P J0#[ +
M^0"Y /@ Q@#V -D ]0#K /0 ^0#S /\ \@#_ /, _P#S /\ \P#_ /, _P#S
M /\ _Q 9 /\.%0#_"!0 _P 4 /\ &0#_ "4 _P R /\ 0 #_ $P _P!9 /\
M8P#^ &T _ !U /H ?0#Y (0 ]P"+ /8 D0#T )< \P"> /( I #P *P [@"T
M .T P #K ,\ Z0#F .@ ]0#F /\ YP#_ .8 _P#E /\ Y0#_ .4 _P#E /\
M_Q(4 /\0$ #_# \ _P,0 /\ %0#_ "  _P L /\ .@#_ $< ^@!3 /< 7@#T
M &< \0!P .\ > #M '\ ZP"& .H C #H ), YP"9 .4 H #C *< X0"P -\
MN@#= ,D VP#@ -@ \ #7 /X U0#_ -0 _P#3 /\ TP#_ -, _P#3 /\ _Q40
M /\2# #_#@D _PL, /\)$@#_ QH _P F /T ,P#T $  [P!- .L 6 #H &$
MY0!J .( <@#@ 'H W@"  -P AP#: (X V "5 -0 G #2 *, T "L ,X M@#,
M ,0 R@#9 ,@ [0#' /L Q0#_ ,0!_P## ?\ Q '_ ,0!_P#$ ?\ _Q@+ /\5
M!0#_$   _Q & /\/#0#_#!0 _ <? /$#*P#G #D X@!& -X!40#: EL U0)D
M -(#; #/ W0 S01[ ,L$@@#*!(D R 60 ,8%F #$!:  P@:I ,$&M "_!L$
MO0C5 +L)[ "X"_T M@S_ +4-_P"T#?\ M W_ +0-_P"T#?\ _QL% /\8  #_
M%P  _Q8  /L3!@#Z$ X [@P6 .,)(@#:"3  TPH^ ,X+2@#*#%4 QPU> ,4-
M9P#"#F\ P0YV +\.?@"]#X4 O ^- +H0E0"X$)T MQ"G +41L@"S$<  LA'5
M *X3[@"K%/X J17_ *<5_P"G%?\ IA3_ :84_P&F%/\!_Q\  /\<  #Z'@
MZQX  .,<  #?%04 W@X- -,.& #+$2@ Q1,W , 41 "\%D\ N1=9 +<780"T
M&&D LQEQ +$9> "O&H  KAJ( *P;D "K&YD J1NC *<<K@"F'+P I!W/ *$>
MZ@&>'OP!G!__ 9L?_P&:'_\!FA[_ 9D>_P&9'O\!_R(  /\A  #L)P  X"H
M -0I  #-)   RAP( ,09$@"]'"( MQXQ +,@/@"O(4D K2)3 *HC7 "H)&0
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M!7LV_P5Z-O\$>C;_!'HU_P1Z-?\$]2T  .0W  #0/P  PD,  +=$  "M0
MISH  *,V!@"=-Q, F3DB )4Z+P"2/#L CSQ& (P\3P&*/%<!B#Q> H8\90*$
M/&T#@CQU!( \?01_/(<%?3R2!GL[G@=Y.ZP'=SN\"'8\U0AT//$(<SS_!W(\
M_P9R//\%<CS_!7([_P5R._\%\3(  -X]  #)1   O$@  +!)  "F1@  GT$
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M!UY*_P=>2O\'XS\  ,M)  "\40  L%4  *%4  "64@  C5   (=,  "!30@
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MC0I-79P+2UVL#$I=P0Q)7>,,25SZ"DE;_PE*6_\(2EK_"$I:_P=*6O\'SDX
M +Q8  "N8   GV$  )%@  "%7P  >U\  '!=  !J7P  96$* &)B% !@8R$
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M"#AONP@X;]L'.&[V!SAM_P<X;/\&.6O_!CEJ_P8Y:O\&O5P  *]F  "B;0
MD6P  ()K  !W:P  ;&P  &%N  !7<   4',  $QU"@!)=A, 1W<? $9W*0!%
M>#, 0W@\ $)X1 !!>$T!/WA5 3UX7@([>&@".7AT S=X@@0U>),%,W>D!3)W
MN04Q>-<%,7;U!3%T_P4Q<_\%,7+_!3)R_P4R<O\%MV,  *IM  "<<0  BW
M 'UP  !R<   9W$  %QS  !1=P  2GH  $)] P _?@X /7\8 #Q_(P [@"T
M.H V #F!/P X@4@ -H%0 #6!6@$S@60!,8%P 2^!?P(M@8\#+(&A RJ!M@,I
M@=(#*7_S RE]_P,I?/\#*7O_ RE[_P,I>_\#L6H  *5T  "5=@  A74  'AU
M  !M=0  87<  %=Z  !,?@  0X$  #N%   UB D ,HD1 #&)&P PB24 +XHO
M "Z*.  MBT$ +(M* "J+5  IBU\ *(MK ":+>@$DBXL!(XN> 2*+LP$AC,X!
M(8KQ 2"(_P(@AO\"((7_ B&%_P(AA?\"JW(  *%\  "/>P  @'H  '-Z  !F
M?   6W\  %""  !&A@  /(H  #2-   LD0  )I,, "24$P CE!P (I4F "&5
M+P @E3@ 'Y9" !Z63  =EE@ ')9D !J7=  9EX8 &)>9 !>7K@ 5E\D %I7N
M !:3_P$6DO\!%I'_ 1:0_P$6D/\!I7L  )F#  ")@0  >X   &R"  !?A
M5(@  $F+   _D   -90  "V7   EF@  '9X! !:@#  4H1( %*$; !.A)0 2
MH2X $:(X !&B0P 0HD\ #Z)<  ZC:P -HWT #:.2  RCIP *HL  "Z+F  R@
M_@ -G_\ #9[_  V=_P -G?\ GH0  )*)  "#B   <X@  &6+  !8C@  3)(
M $&7   WFP  +IX  "2B   <I0  %:@   ^K!  *K@P !ZT2  :M&P %K20
M!*XN  *N.0 !KD4  *Y2  "N80  KG,  *Z'  "NG0  KK0  *[5  "M]
MK?\  *S_  "K_P  J_\ EHL  (R0  ![D   :Y(  %V6  !0F@  1)\  #FC
M   OIP  ):L  !RN   4L0  #K0   FW   !N D  +@.  "Y%   N1P  +HE
M  "Z+P  NSH  +Q'  "\5@  O&<  +Q[  "\D0  O*D  +S$  "\ZP  N_X
M +O_  "[_P  N_\ D)(  (.8  !SFP  8Y\  %6C  !'J   .ZT  #"Q   E
MM   &[<  !*Z   ,O0  !;\   ##    Q (  ,4*  #%#@  QA0  ,<;  #(
M)   RBX  ,PZ  #-20  S5D  ,UL  #.@P  SIL  ,VU  #.V@  SO8  ,W_
M  #-_P  S?\ AID  '>@  !II@  6JP  $RR   ^M@  ,+D  "2\   9OP
M$<(   K%   "R0   ,P   #0    T0   -(!  #3"   U0T  -<1  #:&
MW"$  -\L  #A.@  XDH  .-=  #D<@  Y(L  .6E  #EP   Y>8  .7X  #E
M_P  Y?\ >J$  &NI  !<KP  3;8  #^\   POP  (\,  !?'   /R@  !\X
M  #1    U@   -P   #?    X    .(   #D    Y@,  .@)  #I#@  [!4
M .X>  #Q*P  ]#H  /5-  #V80  ]WD  /B3  #XK0  ^<8  /GD  #Y\P
M^?, ;:H  %ZR  !/N@  0,$  #'%   BR0  %LX   W2   $V    -T   #A
M    Y    .@   #K    [0   .\   #Q    \P   /8   #X P  ^@L  /T1
M  #_&P  _RD  /\[  #_3P  _V8  /]_  #_F0  _Z\  /_#  #_U@  _]8
M_P0< /\ &0#_ !D _P < /\ (@#_ "L _P X /\ 1@#_ %, _P!> /\ :0#_
M '( _P!Z /\ @@#_ (D _P"/ /\ E0#_ )L _P"A /\ J #_ *\ _P"Y /\
MQ0#_ -D _@#L /T ^P#[ /\ ^P#_ /L _P#Z /\ ] #_ /  _P#P /\ _P<8
M /\!%0#_ !0 _P 6 /\ &P#_ "8 _P T /\ 0@#_ $X _P!: /\ 9 #_ &T
M_P!U /\ ?0#_ (0 _P"* /T D #\ )8 ^@"= /D HP#X *L ]P"T /4 OP#T
M ,X \P#F /$ ]@#P /\ [P#_ .\ _P#N /\ [@#_ .H _P#J /\ _PL4 /\&
M$0#_ !  _P 0 /\ %@#_ "( _P N /\ / #_ $D _P!4 /X 7P#[ &@ ^0!P
M /< > #U '\ \P"% /( BP#P )( [P"8 .T GP#L *8 Z@"N .@ N0#G ,<
MY0#> ., \ #B /X X #_ .  _P#A /\ X0#_ .$ _P#A /\ _PT0 /\)#0#_
M 0P _P , /\ $@#_ !P _P H /P -@#Y $, ]@!. /( 60#O &( [ !K .H
M<@#H 'D Y@"  .0 A@#B (P X0"3 -\ F@#= *$ VP"J -@ M #5 ,  T@#3
M -  Z@#. /H S0#_ ,T _P#- /\ S #_ ,P _P#, /\ _Q , /\,!P#_ P(
M_P ( /\ #@#_ !8 ]@ B /  +P#L #P Z0!( .4 4P#A %P W@!E -L ; #7
M ', U !Z -( @ #0 (< S@". ,P E0#* )T R "E ,8 KP#$ +L P@#+ ,
MY0"^ /4 O0#_ +P _P"\ /\ O #_ +P _P"\ /\ _Q$% /\.  #_"@  _P@!
M /\$"@#X !  Z0 : ., * #> #4 V0!! -, 3 #/ %8 RP!? ,D 9@#& &X
MQ !T ,( >P#! (( OP") +T D "\ )@ N@"A +@ JP"V +< M #' +( X "Q
M ?( KP+_ *X#_P"M!/\ K03_ *T$_P"M!/\ _Q0  /\0  #_#P  \@T  .H*
M  #I PD W0 2 -0 'P#- 2T R (Z ,0#10#  U  O019 +L%80"Y!6@ MP9O
M +4&=@"T!WT L@>$ +$(C "O")4 K0F> *L)J "J"K4 J K% *8+WP"D#?0
MH@[_ * ._P"?#O\ GP[_ )\._P"?#O\ _Q<  /\3  #O&   Y!D  -L6  #2
M$ ( SPD+ ,@(%@#!"B0 O PR +<-/@"T#DD L0Y3 *\06P"M$&, JQ!J *D1
M<0"H$7@ IA&  *41B "C$I$ H1*; * 3I@">$[, G!/# )L4W@"7%O0 E1;_
M )07_P"3%_\ DA?_ )(6_P"2%O\ _QH  /0=  #E(P  U24  ,HD  #"'0
MOA8$ +L0$ "T$QT KQ4K *L6. "G&$, I1E- *(95@"@&ET GAME )T;; ";
M'', FAQ[ )@<@P"7'8T E1V7 ),>H@"2'J\ D!Z_ (\?V ",(/$!B2#_ 8@@
M_P&'(/\!AR#_ 88@_P&&(/\!^AX  .LF  #:+0  RC   +XN  "U*   L"(
M *X;# "H'1< HQ\F )\A,P"<(CX F2-( )<D40"5)%D DR5@ )(E9P"0)FX
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M FHU_P)J-?\"ZC   -,Z  #"00  LT,  *5!  ";/@  E3H  ) V  ",-0T
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MC 572IH&54JJ!U1*O0=32MP'4DKV!E)*_P522?\$4DG_ U)(_P-32/\#U$$
M ,!+  "R40  H%   ))/  "'3@  ?DP  'A(  !R2@  ;DL- &M-& !H3B0
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M!D17N 9#6-(&0U?R!D-6_P5#5?\$1%7_!$14_P-$5/\#QDP  +56  "E6@
ME%D  (98  ![6   <5<  &96  !A6   75D$ %E:$ !76QL 55PF %-=, !2
M73D 45Y! $]>20!-7E$!3%Y8 4I>80)(76L#1EUV T1=@P1"79(%0%VC!C]=
MM@8^7= &/5SQ!3Y;_P0^6O\$/EK_ SY9_P,_6?\#P5   +%:  "A70  D%P
M ();  !V6P  ;5L  &%;  !;70  5EX  %)@#0!081< 3F(B $UB+ !,8S4
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M BIO_P(J;?\"*FS_ BML_P(K;/\"L6$  *1I  "0:   @&<  '1G  !I9P
M7V@  %5K  !+;@  0W$  #QT   W=@H -'<2 #-X'  R>"4 ,7DN #!Y-P O
M>3\ +GE( "QZ4@ K>EP *GIH "AZ=@ F>H<!)7J9 2-ZK $B>L4!(GGI 2)W
M_P$B=O\!(G7_ B)T_P(C=/\"K&@  )UN  "*;0  >VP  &]L  !E;   6FX
M %!Q  !%=0  /7@  #9\   N?P( *8$- ">"%  F@AX )8(G "2"+P C@S@
M(H-" "&#2P @A%8 'X1B !Z$<0 <A(( &X25 !J$J0 8A,$ &(/F !B!_0 9
M@/\!&7__ 1E^_P$9?O\!IG   )5S  "$<@  =G$  &MQ  !><P  5'8  $EY
M   _?0  -X$  "^$   GB   ((L% !N-#@ :C14 &8T> !B.)P 7CC  %HXY
M !6.0P 4CT\ $X]; !*/:@ 1CWL $(^/  ^/I  .C[L #8_@  Z-^@ /B_\
M$(K_ !")_P 0B?\ H7H  (YY  !^=P  <G<  &1X  !8>P  37X  $*"   Y
MA@  +XH  ">.   @D0  &)4  !*8!0 .F@X #9H4  R:'0 +FB8 "YHP  J:
M.P )FD8 ")I3  :;80 %FG( !)J&  *:FP  FK$  9G/  *9\  "F/\ !)?_
M  66_P %EO\ F8$  (=_  !Z?@  :WX  %V!  !0A0  18D  #N-   QD@
M*)8  !^9   8G0  $:    RC @ &I0H  :40  "E%@  IA\  *8H  "F,@
MIST  *=*  "G6   IV@  *=\  "GD0  IJ@  *;#  "EZ0  I?P  *7_  "D
M_P  I/\ D8<  (*&  !RA@  8X@  %6,  !)D0  /98  #*:   HG@  'Z(
M !>F   0J0  "ZP   2O    L08  +$,  "R$0  LA<  +,?  "S*   M#(
M +4_  "U30  M5T  +5P  "UA@  M9T  +6V  "UW   M/<  +3_  "T_P
MM/\ BX\  'J.  !JD0  6Y4  $V:  ! GP  -:0  "JH   @K   %K    ^T
M   )MP   ;D   "]    O@   +X&  "_#   P!   ,$6  #"'0  PR<  ,4R
M  #&0   QE$  ,=C  #'>   QY$  ,>I  #'QP  Q^P  ,?^  #'_P  Q_\
M@Y<  '&:  !AG@  4J,  $6I   XK@  ++,  ""W   6N@  #KT   ;
MPP   ,<   #)    R@   ,P   #- P  S@D  - .  #2$P  U!L  -@E  #;
M,@  W4(  -U4  #>:0  WH$  -Z<  #?M0  W]D  -_S  #?_P  W_\ =Y\
M &BF  !9K0  2K,  #NX   MNP  '[\  !3"   ,Q@   \D   #,    T
M -4   #9    V@   -P   #>    X    .(%  #D"P  YQ   .H8  #M)
M\#(  /%$  #R6   \V\  /2*  #TI   ]+\  /3?  #T\P  ]/0 :J@  %NO
M  !,MP  /;T  "W!   ?Q@  $\H   O.    T@   -<   #<    X    .4
M  #G    Z0   .L   #M    [P   /$   #S    ]@<  /D.  #\%@  _R(
M /\S  #_1P  _UT  /]V  #_D0  _ZD  /^^  #_V   _]L _P 8 /\ %@#_
M !4 _P 8 /\ '@#_ "< _P V /\ 0P#_ $\ _P!: /\ 9 #_ &T _P!U /\
M?0#_ (0 _P"* /\ D #_ )8 _P"< /\ HP#_ *L _P"T /X OP#] ,\ ^P#G
M /H ^ #Y /\ ^0#_ /D _P#U /\ [@#_ .D _P#G /\ _P 4 /\ $0#_ !$
M_P 2 /\ %P#_ ", _P Q /\ /@#_ $H _P!6 /\ 8 #_ &@ _P!P /\ > #]
M 'X _ "% /H BP#Y )$ ^ "8 /< G@#U *8 ] "N /( N0#Q ,< [P#@ .X
M\@#L /\ [ #_ .P _P#K /\ Y0#_ .  _P#> /\ _P,0 /\ #@#_  T _P -
M /\ $P#_ !X _P K /\ . #_ $4 _@!0 /L 6@#X &, ]0!K /, <@#Q 'D
M[P!_ .X A@#L (P Z@"2 .D F0#G *  Y@"I .0 LP#A ,  X #3 -X ZP#<
M /L VP#_ -H _P#: /\ V0#_ -0 _P#2 /\ _P<- /\ "0#_  8 _P ) /\
M#P#_ !@ ^P E /@ ,@#U #\ \@!* .T 5 #J %T YP!E .0 ; #B ', X !Z
M -X @ #< (8 V@"- -< E #4 )L T@"D ,\ K0#- +D RP#) ,D Y #( /8
MQ@#_ ,4 _P#& /\ QP#_ ,< _P#' /\ _PH& /\!  #_    _P $ /\ "P#T
M !( [P ? .H + #E #@ X@!# -T 3@#9 %< U !? -$ 9P#. &T S !T ,H
M>@#( (  Q@"' ,4 C@## )8 P0"> +\ J "] +, N@#" +D VP"W /  M0#_
M +8 _P"U /\ M0#_ +4 _P"U /\ _PP  /\$  #_    _@   /8  P#H  T
MX  7 -D ) #1 #$ S0 \ ,H 1P#& %$ PP!9 ,  8 "^ &< O !N +H = "Y
M 'L MP"" +4 B0"S )$ L@": +  I "N *\ K "] *H T "H .L IP#[ *8
M_P"F /\ I0#_ *4 _P"E /\ _PT  /\'  #T"0  Z@D  .($  #:  < SP 1
M ,@ ' #" "D O@ U +L 0 "W $H M !3 +( 6P"P &( K@!H *P ;P"K '4
MJ0!] *@ A "F (T I "6 *, H "A *L GP&Y )T#S "<!.@ F@;Y )D'_P"8
M"/\ EPC_ )<(_P"7"/\ _Q   /<0  #H%   W!4  ,X1  #&#0  P@0+ +P
M% "W 2$ L@,N *X%.@"K!D0 J A- *8(50"D"5P H@IC * *:@"?"W$ G0MX
M )P+@ ":#(D F0R3 )<,G@"5#:H E VX )(-S "0#NH CA#\ (P0_P"+$/\
MBQ#_ (L0_P"*$/\ ^Q,  .T:  #=(   S"$  +\=  "W%P  LQ$  +(+#0"K
M#1D IPXF *,/,P"?$#X G1%' )H14 "8$E< EA)> )4390"3$VP DA-S ) 4
M? "/%(4 C16/ (L5F@"*%:< B!:U (86R0"$%^< @AC[ ( 9_P!_&?\ ?QG_
M '\8_P!_&/\ ]1H  .0C  #/*0  P"H  +,F  "J(@  I1P  *05" "@%!,
MFQ8A )<8+0"4&3@ D1I" (\;2P"-'%( BQQ9 (D=8 "('6< AAYO (4>=P"#
M'X  @A^+ ( ?EP!^(*, ?2"R 'L@Q0!Y(>0 =R+Y '8B_P!U(O\ ="'_ '0A
M_P!T(?\ [R$  -LK  #',0  MC$  *DN  "@*@  FR8  )@A 0"5'A  D" ;
M (TA* ")(S, AR0] (4D1@"#)4X @295 '\F7 !^)F, ?"=K 'LG<P!Y)WP
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MC %C-9H"83:I F VNP)?-M8"73;S ETV_P)<-O\!7#7_ 5PU_P%<-/\!W#,
M ,4\  "T00  HD   )4^  "+/   A#D  '\V  ![- 0 =S40 '0W' !Q."<
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M E$^_P%1/O\!SSL  +U%  "J1P  F48  (M%  "!1   >4(  '0^  !O/P
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M?@)!4HT"/U*= SY2KP,]4L8#/%+I CQ1_@(\4/\"/4__ CU/_P(]3O\"ODL
M *Y3  ":4@  B5$  'Q1  !Q4   :%   %Y.  !840  5%(  %%3# !.5!0
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M 2QCJ0$K8[\!*F/C 2IB^P$J8/\!*U__ 2M?_P$K7O\!L5D  )Y<  "+7
M>UL  &];  !E6P  7%P  %%>  !)8   0V(  #QE   X9PH -6@2 #1H&P S
M:20 ,FDM #%I-0 O:CT +FI& "UJ3P L:ED *VME "EK<@ H:X( )FN3 "1K
MIP C:[T (FK@ "-I^0$C9_\!(V;_ 2-F_P$D9?\!K&   )A@  "%8   =E\
M &I?  !A8   5V   $UC  !$9@  /6@  #9K   P;@0 +' . "IQ%0 I<1X
M*'$F "=R+P F<C< )7)  "1R2@ B<E0 (7-@ "!S;0 ><WT '7.0 !MSHP :
M<[D &7/< !IQ]P :</\ &V__ !MN_P$;;?\!IF8  )%E  !_9   <60  &9D
M  !=9   4F8  $AI   _;   -V\  #!S   I=@  (GD( !][$  >>Q< ''L?
M !M[*  :>S  &7PY !A\0P 7?$X %GQ: !5\9P 4?7@ $GV+ !%]GP 0?;4
M#WW5 !![]0 1>?\ $7C_ !)W_P 2=_\ GFL  (IJ  !Z:0  ;6D  &)I  !7
M:@  3&T  $-P   Y=   ,7@  "E[   B?P  &X(  !2%"0 1AA  $887 !"'
M'P 0AR@ #H<Q  Z'.P -AT8 #(=3  N'80 *AW$ "8>$  >'F  &AJX !8;)
M  :%[  'A/\ "(/_  F"_P )@O\ E7$  (-O  !T;@  :6X  %QO  !0<@
M1G4  #QY   R?0  *H$  "*%   ;B0  %(P   ^/ P *D@L !I(1  22&  "
MDB   9(I  "2,P  DSX  )-+  "360  DVD  )-[  "2D   DJ8  )&_  "1
MY0  D/H  (__  "/_P  C_\ C7<  'UU  !P=   8G4  %5X  !)?   /X
M #2$   KB0  (HT  !J1   3E   #I<   F;   !G0@  )T.  "=$P  GAH
M )XB  "?*P  GS4  *!"  "@4   H%\  *!Q  "@AP  GYT  )^U  ">V@
MG?8  )W_  "<_P  G/\ AGT  'A\  !I?   6W\  $Z#  !!B   -HP  "R1
M   CE@  &IH  !*>   -H0  !J0   "G    J0,  *D*  "J#@  JQ,  *P9
M  "M(@  KBL  *\W  "O10  KU0  *]F  "O>P  KI0  *ZK  "NR0  KN\
M *W_  "M_P  K?\ @80  '&$  !AAP  4XL  $:0   YE@  +IL  ".@   :
MI   $J@   RL   $KP   +(   "V    MP   +<"  "X"   N0T  +H2  "[
M&   O2$  +XK  # .   P$@  ,!:  #!;@  P88  ,&@  #!N@  P>,  ,#Y
M  # _P  P/\ >8T  &B0  !9E   2YH  #V@   QI0  ):L  !JO   1LP
M"[@   *[    O@   ,$   #$    Q0   ,8   #'    R 4  ,H+  #,#P
MSA4  - ?  #3*P  U3H  -5,  #68   V'<  -B2  #8K   V<D  -GL  #9
M^P  V/\ <)D  &">  !1I   0ZH  #6P   HM@  '+H  !&^   )P0   ,4
M  #(    RP   ,\   #2    TP   -8   #8    VP   -T   #?!P  X@T
M .43  #H'0  ["H  .T\  #M40  [F<  .^!  #OG   \+<  /#3  #P[
M\/0 9Z8  %BM  !)M   .KH  "J^   <P@  $,8   ?*    S@   -(   #6
M    W    .    #C    Y    .8   #H    ZP   .T   #O    \@(  /4*
M  #X$0  _!P  /\L  #_/P  _U4  /]N  #_B@  _Z0  /^Z  #_T0  _^$
M_P 4 /\ $@#_ !( _P 4 /\ &0#_ "4 _P R /\ /P#_ $L _P!6 /\ 8 #_
M &@ _P!P /\ > #_ '\ _P"% /\ BP#_ )$ _P"8 /\ G@#^ *8 _0"N /P
MN0#Z ,@ ^0#B /@ ] #W /\ ]@#_ /8 _P#O /\ YP#_ .( _P#> /\ _P 1
M /\ #@#_  X _P / /\ % #_ "  _P M /\ .@#_ $8 _P!1 /\ 6P#_ &,
M_@!K /P <P#Z 'D ^0"  /< A@#V (P ]0"2 /, F0#R *  \ "I .X LP#M
M ,$ ZP#6 .H [@#I /X YP#_ .< _P#E /\ W0#_ -4 _P#1 /\ _P - /\
M"@#_  @ _P ) /\ $ #_ !L _P H /\ -0#_ $  ^@!+ /8 50#S %X \0!F
M .X ;0#L '0 ZP!Z .D @ #G (8 Y@"- .0 DP#B )L X "C -X K0#< +D
MV@#* -< Y@#4 /@ T@#_ -( _P#2 /\ S@#_ ,D _P#& /\ _P ( /\  P#_
M    _P # /\ #0#\ !8 ]P B /, +@#O #H [ !% .@ 3P#D %@ X0!@ -X
M9P#; &T V0!T -4 >@#3 (  T0"' ,\ C@#- )4 RP"> ,D IP#' +, Q0#"
M ,, W #! /$ OP#_ +\ _P"^ /\ O@#_ +T _P"[ /\ _P   /\   #_
M_P   /8 " #N !$ YP ; .$ )P#= #, V0 ^ -, 20#/ %( RP!9 ,@ 80#&
M &< Q !M ,( <P#  'H OP"  +T B "[ )  N0"8 +@ H@"U *T LP"[ +$
MS@"P .H KP#\ *T _P"M /\ K@#_ *X _P"N /\ _P(  /\   #]    \@
M .@   #>  P TP 5 ,P (0#( "P Q  X ,$ 0@"] $L N@!3 +@ 6@"V &$
MM !G +( ;0"P '0 KP!Z *T @@"L (H J@"3 *@ G0"F *@ I "U *( Q@"A
M ., GP#V )X _P"> /\ G@#_ )X _P"> /\ _P8  /L   #N!0  X@0  -4
M  #+  8 PP / +T &0"X "4 M  Q +$ .P"N $4 K !- *D 50"G %L I0!B
M *0 : "B &X H0!U )\ ? "> (4 G ". )H F "8 *0 E@"P )4 P0"3 -P
MD@#R )$ _P"0 /\ D #_ (\ _P"/ /\ _0H  / .  #A$0  SA   ,(-  "[
M!P  MP * +$ $@"L !X J  I *4 - "B #X GP!' )T 3P"; %8 F0%< )<!
M8P"6 FD E )P ),#> "1 X  D 2* (X$E0",!:$ B@6N (D&O@"'"-@ A@GP
M (0*_P"#"_\ @PO_ (,+_P"#"_\ ]A   .87  #2'   P!H  +,6  "L$@
MJ T  *8'#0"B!18 G0<B )D)+@"6"C@ E M! )(,2@"0#%$ C@U8 (P-7@"+
M#64 B0UL (@.= "&#GT A0Z' (,.DP"!#Y\ @!"M 'X0O@!]$-L >A'T '@2
M_P!W$O\ =Q+_ '<2_P!W$O\ [Q<  -LA  #&)   M",  *@@  "@'   FQ<
M )D1! "8#A  DQ ; (\1)P",$C( B1,\ (<31 "%%$P @Q13 ($56@" %6
M?A9H 'T6;P![%G@ >1># '@7CP!V&)P =!BJ ',9NP!R&=0 ;QKQ &X;_P!M
M&_\ ;1K_ &T:_P!M&O\ YR   - I  "\*P  JRH  )XH  "6)   D"   (T<
M  ",%PP B!@6 (0:(@"!&RT ?APW 'P=0 !Z'4@ >1Y/ '<>50!V'UP =!]C
M ',?:P!Q('0 <"!_ &XABP!L(9@ :R&G &DBN !H(L\ 9B+N &4C_P!D(_\
M9"+_ &0B_P!D(?\ X"8  ,@O  "T,0  HS   )8N  "-*P  AR@  (0D  ""
M( @ ?B 2 'LB'@!X(RD =20S ',E/ !Q)4, <"9+ &XF4@!M)UD :R=@ &HG
M: !I*'$ 9RA[ &4HB !D*94 8BFD & IM0!?*<L 7BKL %PJ_P!<*?\ 7"G_
M %PI_P!<*/\ V"P  ,,U  "M-0  G30  ) S  "&,0  @"T  'PK  !Y* ,
M=B<0 '(I&@!P*B4 ;2LO &LL. !J+$  :"U' &<M3@!E+E4 9"Y= &,N90!A
M+VX 7R]X %XOA !<+Y( 6B^A 5DOL@%8,,@!5C#I 54P_@%5+_\ 52__ %4N
M_P!5+O\ T#$  +TZ  "H.0  ES@  (HW  " -@  >C(  '4P  !R+@  ;BX-
M &LO%@!I,"$ 9C$K &0R- !C,CT 83-$ & S2P!?-%( 731: %PT8@!:-&L
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M?0%*/XL!2#^; 4<_K %%/\$!1#_C 40^^P%$/O\!1#W_ 40]_P%%//\!PSX
M *]#  ":0@  BD(  'U!  !S0   :S\  &4\  !@/   7#X$ %D^#P!7/Q@
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M 3=,IP$V3+P!-4S= 35+]P$U2_\!-4K_ 39)_P$V2?\!N$D  *)+  ".2@
M?DH  ')*  !H2@  7TD  %5(  !02@  3$L  $E,!P!&31  1$X9 $)/(@!!
M3RL 0% S #]0.P ^4$, /%%* #M14P Z45P .%%G #=1<P U48( ,U&3 3)1
MI0$P4;H!+U': 2]0]@$O3_\!,$[_ 3!._P$P3?\!M$T  )U-  "*30  >DT
M &Y-  !D30  6TT  %%-  !+3P  1E   $)2 P _4PT /505 #Q4'@ Z52<
M.54O #A5-P W5C\ -E9' #564  S5ED ,E=D #!7<0 O5X  +5>1 "M7HP J
M5[@ *5?6 "E6]0 I5?\ *E3_ 2I3_P$J4O\!KU$  )A1  "%40  =E   &I0
M  !@4   6%$  $Y2  !'4P  054  #M8   X60H -5H1 #1:&@ S6R( ,ELK
M #%;,P O7#L +EQ# "U<3  L7%8 *UU@ "E=;0 H77P )EV. "1=H0 C7;4
M(EW2 ")<\P B6_\ (UK_ "-9_P D6/\ J%4  ))4  " 5   <50  &94  !<
M5   5%4  $I6  !#6   /%L  #9=   P8 4 +6$. "MA%0 J8AT *6(E "AB
M+@ G8S8 )F,^ "5C1P C8U$ (F1< "%D:0 ?9'D 'F2* !QDG@ ;9+, &63.
M !IC\0 ;8?\ &V#_ !Q@_P <7_\ H5D  (Q8  ![6   ;5@  &)8  !96
M4%D  $=;   ^7@  -V   #%C   J9@  )&D) "%J$  @:A< 'VH@ !YK*  =
M:S  '&LY !MK0@ :;$P &6Q8 !=L90 6;'0 %&R& !-LF@ 2;*\ $6S* !%K
M[P 2:?\ $VC_ !-H_P 39_\ F5T  (5=  !U7   :%P  %Y<  !57   2UX
M $)A   Y9   ,F<  "MJ   D;0  'G ! !=S"P 5=!$ %'08 !-T(0 2=2D
M$74R !%U.P 0=48 #W52  YU7P -=6X #'6!  MUE0 *=:H "'3#  ETYP *
M<_T "W'_  QQ_P ,</\ D6(  ']A  !P80  9&$  %IA  !/8@  164  #QH
M   S;   *V\  "1R   ==@  %WD  !%\!  -?PP "W\2  I_&0 )?R( "'\J
M  9_-  %?S\ !']+  )_6  !?V<  ']Y  !_C@  ?Z,  'Z[  !]X   ??<
M 'S_  ![_P  >_\ B6<  'AG  !K9@  868  %1G  !):0  /VT  #5Q   L
M=0  )'D  !U\   6@   $(,   R& @ &B0H  8D/  ")%   BAL  (HC  "+
M+   BS<  (M#  "+4   BU\  (MQ  "+A@  BYP  (JS  ")TP  B/,  (C_
M  "'_P  A_\ @FT  '-L  !H;   6FT  $YO  !"<P  .'<  "Y[   E@
M'80  !6(   0C   "X\   22    E 8  )4,  "5$   EA4  )<<  "8)
MF"X  )DY  "91P  F58  )EH  "9?0  F90  )BK  "7R   ENX  );_  "5
M_P  E?\ >W0  &]S  !A<P  4W8  $9Z   [?P  ,(0  ":(   =C0  %)(
M  Z6   )F0   9P   "@    H0   *(&  "B#   I!   *44  "E'   IR0
M *@O  "H/0  J4P  *E>  "I<@  J(D  *BB  "HO   I^4  *;[  "F_P
MI?\ =WL  &A[  !9?@  2X(  #Z'   RC0  )Y(  !V7   4G   #J    >D
M    J    *L   "N    KP   +    "Q!   LPH  +0.  "U$P  MAL  +@D
M  "Z,0  ND   +I2  "[90  NWT  +J7  "ZL0  NM(  +KS  "Y_P  N?\
M;X,  %^&  !1BP  0Y   #:7   JG0  'Z(  !6G   -K   !;    "T
MMP   +L   "^    OP   ,    #!    PP$  ,0'  #%#0  QQ$  ,H9  #-
M)   SC,  ,]$  #06   T&X  -&(  #0I   T,$  -'F  #1^   T?\ 9X\
M %>4  !)F@  .Z$  "ZG   AK0  %K,   ZX   &O    ,    ##    Q@
M ,L   #-    S@   -    #1    U    -8   #: @  W D  -\/  #C%P
MYB0  .<V  #H20  Z5\  .IX  #KE   ZZ\  .O,  #LZ   [/8 7YX  %"D
M  !"JP  -+(  ":Y   9O@  #L(   3%    R@   ,T   #1    V    -L
M  #?    X    .(   #D    Y@   .D   #K    [@   /$%  #U#0  ^18
M /PE  #].0  _D\  /]G  #_@@  _YT  /^U  #_RP  _^0 _P 1 /\ #P#_
M  \ _P 1 /\ %@#_ "( _P O /\ .P#_ $< _P!2 /\ 6P#_ &0 _P!L /\
M<P#_ 'H _P"  /\ A@#_ (P _@"3 /T F0#[ *$ ^@"I /@ M #W ,( ]@#:
M /4 \0#T /\ \P#_ /, _P#I /\ X #_ -@ _P#3 /\ _P . /\ "P#_  H
M_P + /\ $0#_ !T _P J /\ -@#_ $$ _P!, /\ 5@#^ %\ ^P!F /D ;0#W
M '0 ]0!Z /0 @ #R (8 \ "- .\ E #M )L [ "D .H K@#I +H YP#- .4
MZ0#D /L XP#_ .( _P#> /\ T0#_ ,P _P#( /\ _P ) /\ ! #_  $ _P $
M /\ #@#_ !@ _P D /T , #[ #L ]P!& /, 4 #O %D [ !@ .H 9P#G &X
MY@!T .0 >@#B (  X "' -X C@#< )4 V@"> -8 J #4 +, T0## ,\ WP#.
M /0 S #_ ,L _P#+ /\ Q0#_ +\ _P"\ /\ _P " /\   #_    _P   /T
M"P#W !, \0 > .T *@#J #4 YP!  .( 2@#= %( V0!: -4 80#2 &< T !M
M ,X <P#, 'H R@"  ,@ AP#& (\ Q "8 ,( H0#  *T O@"[ +P T "Z .T
MN0#^ +@ _P"X /\ MP#_ +, _P"P /\ _P   /\   #_    ^0   .X !0#E
M  X W@ 8 -@ (P#2 "X SP Y ,L 0P#' $P Q !4 ,$ 6P"_ &$ O !G +L
M;0"Y ', MP!Z +4 @0"T (D L@"2 +  FP"O *< K "T *L Q@"I .0 IP#X
M *8 _P"F /\ I0#_ *4 _P"D /\ _P   /\   #U    Z@   -X   #0  H
MR  2 ,( '0"^ "@ NP S +D /0"U $8 L@!- +  50"M %L K !A *H 9P"H
M &T IP!S *4 >@"D (( H@", *  E@"? *$ G0"N )L O@"9 -@ EP#Q )8
M_P"6 /\ EP#_ )< _P"7 /\ _P   /4   #G 0  U    ,D   #   0 N  .
M +, %@"O "$ JP L *@ -@"F #\ HP!' *$ 3P"? %4 G0!; )L 80": &<
MF !N )< =0"5 'T E "& )( D0"0 )P C@"I (P N "+ ,T B0#K (@ _0"(
M /\ B #_ (@ _P"( /\ ^08  .D,  #4#@  PPP  +<)  "P @  JP ) *8
M$ "B !H G@ E )L , "8 #D E@!! )0 20"2 %  D !6 (X 7 "- &( BP!I
M (H < "( '@ AP"! (4 C "$ )@ @@"E (  M !^ ,@ ?0'G 'P"^0![ _\
M>P3_ 'L$_P![!/\ \0X  -X5  #%%0  M!0  *D1  "A#@  G@H  )L## "7
M !, DP > ) !*0"- C, B@,\ (@$0P"&!4L A091 (,&5P""!UX @ =D '\(
M; !]"'0 ? A^ 'H)B0!X"98 =PJC '4*LP!S"\< <@SF ' -^P!P#?\ ;PW_
M &\-_P!O#?\ Z!8  - >  "Y'0  J1P  )T:  "5%@  D!,  (\. P"."@X
MB0L7 (8,(P"##2T @ TV 'X./@!\#D8 >PY- 'D/4P!X$%H =A!A '40: !S
M$'$ <1%[ ' 1AP!N$90 ;!&B &L2L@!I$L< :!/G &83_0!E%/\ 913_ &43
M_P!E$_\ WQX  ,8D  "P)   H",  )0A  "+'P  AAL  (,7  ""$@@ ?Q$2
M 'P2'0!Y%"@ =A0Q '05.@!R%D$ <19( &\73P!N%U8 ;!== &L89 !I&&T
M:!EW &89@P!D&9  8QJ? &$:KP!@&L0 7AOD %T<^P!<'/\ 7!O_ %P;_P!<
M&_\ U24  +TJ  "H*0  F"D  (PH  "#)0  ?2(  'D?  !X&P, =AD/ '(:
M& !O'", ;1TM &L=-0!I'CT :!Y$ &8?2P!E'U( 8R!9 &(@80!A(&D 7R%S
M %TA?P!<(8T 6B*< %DBK !7(L  5B/A %4C^0!4(_\ 5"+_ %0B_P!4(O\
MS2L  +8N  "B+@  DBX  (4M  !\*P  =B@  '(F  !O(P  ;2$, &HB%0!G
M(Q\ 920I &,D,0!B)3D 8"9! %\F2 !=)D\ 7"=6 %LG70!9)V8 6"AP %8H
M? !4*(H 4RF9 %$IJ@!0*;X 3RG> $XI]P!-*?\ 32G_ $TH_P!.*/\ R#
M + R  "<,@  C#(  ( Q  !V,   <"T  &LK  !H*0  9B@) &,H$0!@*1P
M7BHE %PK+@!;*S8 62P] %@L1 !7+4P 52U3 %0M6P!3+6, 42YN % N>@!.
M+H@ 3"^7 $LOJ !)+[L 2"_; $@O]@!'+_\ 1R[_ $<M_P!(+?\ Q#0  *LU
M  "7-0  AS4  'LU  !R-   :S(  &8O  !B+@  7RT% %PN$ !:+Q@ 6# B
M %8P*P!5,3, 4S$Z %(R0@!1,DD 4#)0 $XS6 !-,V$ 2S-K $HS=P!(-(4
M1S25 $4TI@!#-+D 0C36 $(T] !"-/\ 0C/_ $(R_P!",O\ P#@  *<X  "3
M.   @S@  '<X  !M-P  9C8  &$S  !=,@  63(" %<S#0!4-!4 4C4? %$U
M* !/-C  3C8X $PW/P!+-T8 2C=. $DX5@!'.%\ 1CAI $0X=0!#.(, 03F3
M $ YI  ^.;@ /3G3 #PY\P \./\ /3?_ #TW_P ]-O\ NSL  *([  "/.P
M?SL  ',[  !J.@  8CD  %TW  !8-@  5#<  %$X"P!/.1, 33D< $LZ)0!*
M.BT 2#LU $<[/ !&/$0 13Q+ $0\4P!"/%P 03UG #\]<P ^/8$ /#V1 #H]
MHP Y/;8 .#W1 #<]\@ W//\ .#O_ #@[_P X.O\ MCT  )X^  "+/@  ?#X
M &\^  !F/0  7CT  %@[  !3.@  3SL  $P\" !)/1$ 1SX9 $8_(@!$/RH
M0S\R $) .@!!0$$ 0$!) #Y!40 ]05H /$%D #I!<  X07\ -T&/ #5"H0 T
M0K0 ,D+. #)!\  R0/\ ,T#_ #,__P T/O\ L4   )I   "'0   >$$  &Q!
M  !B0   6T   %0_  !./P  2D   $9!!0!$0@X 0D,6 $!#'P _1"< /D0O
M #Q$-P [13X .D5& #E%3@ X1E@ -D9B #5&;@ S1GP ,4:- #!&GP N1K,
M+4;, "U&[P M1?\ +D3_ "Y#_P N0_\ K$,  )9#  "#0P  =$,  &A#  !?
M0P  5T,  %!#  !(0P  1$4  $%& 0 ^1PP /$@3 #I('  Y220 .$DL #9)
M-  U2CL -$I# #-*3  R2E4 ,$M? "]+:P M2WH +$N+ "I+G0 H2[$ )TO*
M "=+[0 G2O\ *$G_ "A(_P I1_\ IT8  )%&  !_1@  <$8  &5&  !;1@
M5$8  $Q'  !$2   /TH  #M+   W3 D -4T0 #-.&  R3B  ,4\H #!/,  O
M3S@ +D]  "Q02  K4%( *E!< "A0:  G4'< )5"( "10FP B4*\ (5#( "!0
MZP A3_\ (D[_ ")-_P C3?\ H4D  (Q)  !Z20  ;$H  &%*  !82@  4$H
M $E+  ! 3   .TX  #50   Q4@0 +5,- "Q4%  J5!P *54D "A5+  G53,
M)E4\ "5610 D5DX (E99 "%690 ?5G0 'E:% !Q6F  ;5JP &5;% !E6Z0 :
M5?\ &U3_ !M3_P <4O\ FTT  (9-  !U30  :$T  %U-  !430  34X  $5/
M   \40  -E,  #%5   K6   )EH) "-;$  B6Q< (5P? "!<)P ?7"X '5PW
M !Q=0  ;74H &EU5 !A=80 777  %5V! !1=E0 37:H $5W" !%=YP 26_X
M$UK_ !-:_P 46?\ E%$  (!1  !P40  9%$  %E1  !140  25(  $%3   X
M5@  ,ED  "M;   E7@  'V$# !IC#  89!$ %V09 !9D(0 59"D %&4Q !-E
M.@ 2940 $650 !!E70 /96L #F5]  UED0 ,9:4 "F2\  IDX  +8_D #&+_
M  UA_P -8?\ C54  'I5  !K50  7U4  %95  !.50  1%<  #Q9   T7
M+%\  "9B   ?90  &6@  !-K!0 0;0T #FX2  UN&@ ,;B( #&XK  MN-  *
M;CX "&Y*  =N5P &;F4 !&YV  )NB@  ;9\  &VV  !LU@  ;/,  6O_  )J
M_P #:O\ A5H  '1:  !F6@  7%D  %-9  !(6@  /UT  #9@   N8P  )F<
M !]J   9;0  $W$   YT P *=PH !7<0  %W%0  =QP  '<D  !X+0  >#<
M 'A#  !X4   >%X  'AO  !XA   >)D  '>P  !VS0  =?   '7_  !T_P
M=/\ ?E\  &Y?  !B7@  65X  $U?  !"8@  .64  #!H   G;   'W   !AT
M   2=P  #7L   A^   "@ @  ($-  "!$0  @A<  (,>  "#)@  A#   (0[
M  "$2   A%<  (1H  "$?   A),  (.J  ""Q0  @>L  ('^  " _P  @/\
M=V4  &ED  !?8P  4F0  $=G   \:P  ,6\  "AS   @=P  &'P  !%_   ,
M@P  !H<   "*    C ,  (P)  "-#@  CA$  (\7  "0'@  D2<  )(R  "2
M/P  DDX  ))?  "2<P  DHL  )&B  "1O   D.4  (_\  "._P  CO\ <6L
M &9J  !8:P  2VT  #]Q   T=@  *GL  ""    7A0  $(D   N-   $D0
M )4   "8    F0   )H#  ";"   G T  )X1  "?%@  H!X  *(H  "B-0
MHT0  *-5  "C:0  HH   **:  "ALP  H-@  *#V  "?_P  G_\ ;G$  %]R
M  !1=0  1'D  #=^   LA   (8H  !>/   0E   "ID   &=    H    *0
M  "G    J    *D   "J    K 8  *T+  "O$   L!4  +(>  "T*0  M#D
M +1*  "U70  M7,  +6.  "UJ   M,8  +/M  "R_P  LO\ 9GH  %=]  !)
M@@  /(<  "^.   CE   &)H  !"?   )I    *D   "M    L    +0   "W
M    N    +D   "[    O    +X"  # "   P@X  ,04  #''@  R"P  ,D]
M  #*4   RF8  ,I_  #*FP  RK@  ,K=  #*]0  RO\ 7H8  $^+  !!D0
M,Y@  ">?   ;I0  $:L   FP    M0   +D   "]    P0   ,8   #(
MR0   ,L   #,    S@   -    #2    U 4  -D,  #=$@  X1X  .(N  #C
M0@  Y%<  .5O  #FC   YJ@  .7%  #EYP  YO8 5I0  $B;   ZH@  +*D
M !^P   3M@  "[P   #!    Q0   ,D   #-    T@   -8   #:    VP
M -X   #@    X@   .0   #G    Z0   .T   #P"@  ]!$  /@?  #Y,@
M^D@  /M?  #\>@  _9<  /VO  #]QP  _>0 _P . /\ #0#_  P _P . /\
M$P#_ !X _P J /\ -@#_ $( _P!- /\ 5P#_ %\ _P!G /\ ;@#_ '0 _P!Z
M /\ @0#] (< _ "- /H E #Y )P ]P"E /4 KP#T +P \P#/ /$ [ #P /X
M[P#_ .\ _P#C /\ UP#_ ,X _P#* /\ _P * /\ !@#_  0 _P ( /\ $ #_
M !D _P E /\ ,0#_ #T _P!' /X 40#[ %D ^0!A /8 : #T &X \P!T /$
M>@#O ($ [@"' .P C@#J )8 Z "? .8 J0#C +4 X@#& .  XP#? /@ W0#_
M -T _P#4 /\ R0#_ ,( _P"^ /\ _P # /\   #_    _P ! /\ #0#_ !0
M_0 @ /H *P#W #8 \P!! .\ 2P#L %0 Z !; .8 8@#C &@ X0!N -\ = #<
M 'H V@"! -@ B #4 )  T@"8 ,\ H@#- *X RP"\ ,D TP#' /  Q@#_ ,0
M_P#$ /\ NP#_ +8 _P"S /\ _P   /\   #_    _P   /< " #P !  ZP :
M .< )0#D #  X0 [ -P 10#5 $T T0!5 ,X 6P#+ &( R0!G ,< ;0#% ',
MPP!Z ,$ @0"_ (D O0"2 +L G "Y *< MP"U +4 R "S .8 L@#[ +$ _P"P
M /\ K@#_ *H _P"G /\ _P   /\   #^    \0   .4  @#<  T TP 4 ,T
M'P#* "H QP T ,0 /@#  $< O !. +H 50"W %L M0!A +, 9P"R &T L !S
M *X >@"L (( J@"+ *@ E0"G *  I0"M *, O@"A -L H #T )\ _P"> /\
MGP#_ )T _P"; /\ _P   /P   #N    X    -    #%  @ O@ 0 +D &0"U
M ", LP N +  -P"M $  J@!( *@ 3P"E %4 HP!; *( 8 "@ &8 GP!L )T
M<P"; 'L F@"$ )@ C@"6 )H E0"G ), MP"1 ,P D #L (\ _P". /\ C@#_
M (X _P"/ /\ _    .\   #;    R0   +T   "U  ( K@ , *D $P"E !T
MH@ G *  ,0"= #H F@!" )@ 20"6 $\ E !5 ), 6P"1 &  D !G (X ;0"-
M '4 BP!^ (D B0"( )4 A@"B (4 L0"# ,0 @0#D (  ^0!_ /\ @ #_ (
M_P"  /\ ] (  . )  #'"   MP<  *P#  "F    H  ' )L #P"8 !< E0 A
M )( *@"/ #, C0 \ (L 0P") $D AP!0 (8 50"$ %L @P!A ($ : "  '
M?@!Y 'P A ![ )  >0"= '@ K !V +X =0#= ', ] !S /\ <P#_ ', _P!S
M /\ Z0T  ,\0  "Y$   J1   )X.  "7"P  DP8  )  "P", !$ B0 : (8
M) "# "X @0 V '\ /@!] $0 ? !+ 'H 40!Y %< =P!= '8 9 !T &P <P%U
M '$!@ !O HT ;@*: &P#J@!K [L :036 &@&\0!H!_\ 9P?_ &<'_P!G!_\
MWQ0  ,,7  "N%P  GA8  ),5  "+$@  AA   (0, @"#!@T @ ,4 'P%'@!Y
M!R@ =P@P '4(. !S"4  <@E& ' *3 !O"E, ;0M9 &P+80!J"VD :0QR &<,
M?@!F#(L 9 V9 &(-J0!A#;L 8 W8 %X.\P!=#O\ 70[_ %T._P!=#O\ U!P
M +D=  "D'@  E1T  (D<  "!&@  >Q<  '@3  !X$ 8 =PT/ ',.& !P#B(
M;@\K &P0,P!J$#L :1!" &<120!F$4\ 9!%6 &,270!A$F8 8!)O %X2>P!<
M$X@ 6Q.7 %D3IP!7%+H 5A35 %45\P!4%?\ 5!7_ %05_P!4%/\ RB(  + B
M  "=(P  C2,  ($B  !Y(0  <QX  &\;  !N%P  ;1,, &H4% !G%1X 918G
M &,6+P!A%S< 8!<^ %X810!=&$L 7!E2 %H96@!9&6( 5QIL %8:=P!4&H4
M4AN4 %$;I !/&[< 3AO0 $T<\0!,'/\ 3!S_ $T<_P!-&_\ PR8  *HG  "6
M)P  AR@  'LG  !R)@  ;"0  &@A  !F'@  9!L( &(;$0!?'!H 71TC %L>
M*P!:'C, 6!\Z %<?00!6($@ 5"!/ %,@5P!1(5\ 4"%I $XA= !-(8( 2R*1
M $DBH@!((K0 1R+- $8C[P!%(_\ 12+_ $8B_P!&(?\ O"H  *0K  "1*P
M@BP  '8K  !M*@  9BD  &(F  !?)   72($ %LA#@!8(A8 5B,? %0D* !3
M)#  4B4W % E/@!/)D4 3B9, $PF5 !+)UP 22=F $@G<0!&)W\ 12B/ $,H
MH !!*+( 0"C+ #\H[0 _*/\ /RC_ $ G_P! )_\ MRT  )\N  ",+P  ?2\
M '$O  !H+@  82T  %TK  !:*   5R<  %0G# !2*!, 4"D< $XI)0!-*BP
M2RHT $HK.P!)*T( 2"Q) $8L40!%+%H 1"QD $(M;P! +7T /RV- #TMG@ \
M+;  .BW( #HMZP Z+?\ .BW_ #HL_P Z+/\ LC   )LQ  "(,@  >3(  &TR
M  !D,@  73$  %@O  !5+   42P  $\M"0!,+1$ 2BX9 $DO(@!'+RH 1C Q
M $4P. !#,#\ 0C%' $$Q3P! ,5< /C%A #TR;0 [,GL .3*+ #@RG  V,J\
M-3+' #0RZ0 T,O\ -3'_ #4Q_P U,/\ K3,  )8T  "$-0  =34  &DU  !@
M-0  630  %0S  !0,   3#$  $DQ!@!',@\ 13,6 $,S'P!"-"< 0#0N #\U
M-@ ^-3T /35$ #PV3  Z-E4 .39? #<V:P V-G@ -#>) #(WF@ Q-ZT +S?%
M "\WZ  O-OX ,#7_ # U_P P-/\ J38  )(V  " -P  <C@  &8X  !=-P
M5C<  % V  !+-   1S4  $0V P!!-PT /S@4 #XX'  \.20 .SDL #HY,P Y
M.CH .#I" #8Z2@ U.E, -#M= #([:  P.W8 +SN' "T[F0 L.ZP *CO# "D[
MY@ J.OT *CK_ "LY_P L./\ I#@  (XY  !\.@  ;CH  &,Z  !:.@  4SH
M $TZ  !&.   0CH  #\[   \/ L .CP1 #@]&0 W/2$ -CXI #0^,  S/C<
M,C\_ #$_1P P/U  +C]: "U 9@ K0'0 *4"$ "A EP F0*H )4#! "1 Y0 D
M/_P )3[_ "8]_P F/?\ GSL  (H\  !X/0  :CT  %\]  !6/0  3ST  $D]
M  !"/0  /#X  #D_   V00@ -$$/ #)"%@ Q0AX +T,E "Y#+0 M0S0 +$0\
M "M$1  J1$T *$18 "=%8P E17$ (T6" ")%E0 @1:@ 'T6_ !Y$XP ?1/L
M'T/_ "!"_P A0?\ FCX  (4_  !T0   9T   %Q   !30   3$   $9    ^
M00  .$,  #1%   P1@, +4<- "M($@ J2!H *4@B "A)*0 G23$ )4DY "1)
M00 C2DH (DI5 "!*80 ?2F\ '4I_ !M*D@ :2J8 &$J] !=*X  82?H &4C_
M !I'_P :1_\ E4(  (!"  !P0P  8T,  %A#  !00P  24,  $)$   [10
M-4<  #!)   K2P  )DT) "1.$  B3A8 (4\= "!/)0 ?3RP 'D\U !U//0 <
M4$< &E!1 !E070 74&L %E!\ !10CP 34*0 $5"Z !%0W@ 13_@ $D[_ !--
M_P 43?\ CT4  'M&  !K1@  7T<  %5'  !-1P  1D<  #]'   W2@  ,4P
M "M.   F4   (%,# !Q5#  :5A$ &588 !=6(  65B< %58P !16.0 35T(
M$E=- !%760 05V@ #U=Y  Y7C  -5Z  "U>V  M6U  +5O0 #%7_  U4_P .
M4_\ B$D  '9*  !G2@  6TH  %%*  !*2@  0TH  #M,   S3@  +%$  "94
M   A5@  &UD  !5<!P 17@T $%X3 !!>&@ .7B( #EXJ  U>,P ,7CT "UY(
M  I>5  (7F( !UYS  5>A@ #7IL  EZQ  )=S  "7>X  US_  1;_P %6_\
M@4X  '!.  !B3@  5TX  $Y.  !'3@  /D\  #91   N5   )U<  "%:   ;
M70  %6   !!C P ,9@L "&<0  9G%0 %9QP !&<D  )G+0 !9S<  &="  !G
M3@  9UP  &=M  !G@   9I4  &:L  !EQP  9>L  &3\  !D_P  8_\ >E(
M &I3  !=4@  5%(  $M2  !"4P  .54  #!8   H6P  (5\  !IB   490
M$&@   QK 0 &;@D  &\.  !O$@  ;Q@  ' ?  !P)P  <3   '$[  !Q2
M<58  '%F  !Q>0  <8\  '"G  !OP0  ;^<  &[\  !M_P  ;?\ <U@  &57
M  !:5P  458  $97   \6@  ,ET  "IA   B9   &F@  !1L   .;P  "G(
M  1V    > 4  '@+  !Y#@  >A,  'L9  !\(   ?2D  'TS  !]0   ?4X
M 'U>  !]<@  ?8@  'RA  !\N@  >^(  'KZ  !Y_P  >/\ ;5T  &!<  !7
M7   2UT  $!?   U8P  *V<  "-K   :;P  $W,   YW   (>P   GX   ""
M    @P$  (0&  "%"P  A@\  (@3  ")&0  BB$  (LK  "+-P  C$8  (M6
M  "+:0  BX   (N9  "*LP  B=@  (CW  "(_P  A_\ :&,  %YB  !18@
M1&4  #AI   N;@  )',  !IX   3?0  #8$   :%    B0   (T   "0
MD@   )(   "4!0  E0H  )<.  "8$@  FA@  )LA  "<+0  G3P  )U,  "<
M7P  G'8  )N1  ";JP  FLD  )KP  "9_P  F/\ 96D  %=I  !);   /7$
M #!V   E?   &X$  !*'   ,C   !)$   "5    F0   )T   "@    H0
M *(   "D    I0$  *<'  "I#   JA$  *T8  "O(@  KS   *]!  "O5
MKVL  *Z%  "NH0  KKX  *WF  "L_   K/\ 7G$  $]T  !">0  -7\  "B%
M   =C   $Y(   R8   #G0   *(   "F    J@   *X   "P    L0   +,
M  "T    M@   +@   "Z!   O H  +X0  #!%P  PR0  ,,U  #$20  Q%X
M ,5W  #%DP  Q:\  ,71  ##\@  P_\ 5GP  $>"   ZB   +(\  ""6   4
MG0  #:,   .I    K@   +(   "W    NP   +\   #"    P@   ,4   #&
M    R    ,H   #-    SP   -((  #5#@  VQ@  -TG  #>.@  WU   .!H
M  #@A   X:$  .&]  #AX@  X/0 3HL  $"2   RF0  ):$  !BH   .KP
M!;4   "Z    OP   ,0   #(    S@   -$   #4    U0   -@   #:
MW0   -\   #B    Y    .<   #K!0  [PX  /09  #U*P  ]D$  /=8  #X
M<@  ^9   /FK  #XQ   ^.$ _P + /\ " #_  D _P , /\ $@#_ !H _P F
M /\ ,@#_ #X _P!( /\ 4@#_ %H _P!B /\ :0#_ &\ _P!U /X >P#\ ($
M^P"( /D CP#W )< ]0"@ /, J@#R +< [P#) .T Y@#L /L ZP#_ .L _P#=
M /\ S@#_ ,8 _P#" /\ _P $ /\   #_    _P % /\ #0#_ !4 _P A /\
M+ #_ #@ _P!# /T 3 #Y %0 ]P!< /0 8P#R &D \ !O .X =0#L 'L Z@""
M .@ B0#G )$ Y ": .( I #@ +  W0#  -H W #8 /0 U0#_ -, _P#+ /\
MP0#_ +L _P"W /\ _P   /\   #_    _P   /\ "@#] !$ ^0 ; /8 )P#T
M #( \  \ .P 1@#H $X Y !6 .$ 7 #> &, W !H -D ;@#5 '0 T@![ -
M@@#- (H RP"3 ,@ G0#& *@ Q "W ,$ S #  .L O@#_ +T _P"] /\ M #_
M *X _P"K /\ _P   /\   #_    ^@   /( !0#J  X Y0 6 .  (0#= "L
MVP V -, /P#. $@ R@!/ ,< 5@#$ %P P@!A ,  9P"^ &T O !S +H >@"X
M (( M@"+ +0 E@"R *$ L "O *X P0"M .  JP#W *H _P"I /\ I@#_ *$
M_P"? /\ _P   /\   #W    Z    -P   #0  H R@ 1 ,4 &P#" "4 OP O
M +P . "X $$ M0!( +( 3P"P %4 K@!; *P 80"J &8 J !L *< <P"E 'L
MHP"$ *$ C@"? )H G0"G )L N ": -  F0#O )@ _P"7 /\ E@#_ )0 _P"2
M /\ _P   /8   #D    T@   ,4   "[  4 M0 . +  %0"L !\ J@ I *@
M,@"E #H H@!" *  20"> $\ G !5 )H 6@"8 &  E@!F )4 ; "3 '0 D@!]
M )  AP". ), C "A (L L "* ,4 B #F (< ^P"& /\ AP#_ (< _P"& /\
M^    .4   #-    O0   +,   "J    HP * )\ $0"; !D F0 C )< + "5
M #0 D@ \ )  0P". $D C !/ (H 5 ") %H AP!@ (8 9@"$ &X @P!W ($
M@0!_ (T ?@"; 'P J@![ +P >@#; '@ ]0!X /\ > #_ '@ _P!X /\ [0
M -$"  "[ @  K $  *(   ";    E@ % )$ #0"- !0 BP = (@ )@"& "X
MA  V (( /0"  $, ?@!) 'T 3P!\ %4 >@!; 'D 80!W &D =0!Q '0 ? !R
M (@ <0"6 &\ I0!N +8 ;0#. &P [@!K /\ :P#_ &L _P!K /\ WPL  ,(,
M  "N#   G@P  ),+  ",!P  B (  (4 "0"! !  ?P 7 'P ( !Z "@ >  P
M '8 . !T #X <P!$ '$ 2@!P %  ;@!6 &T 70!L &0 :@!M &@ =P!G (0
M90"2 &0 H0!C +( 80#) &  Z0!@ /P 8 #_ &  _P!@ /\ T!   +81  "B
M$@  DQ(  (@1  " #P  ? T  'D) 0!X PL =0 1 ', &@!P ", ;@$K &P!
M,P!J CD :0-  &<#1@!F!$P 9012 &,%60!B!6$ 8 5J %\&= !=!H$ 7 >/
M %H'GP!9![  5P?& %8)YP!6"OL 50K_ %4*_P!6"O\ QA4  *T7  "9&
MBA@  '\7  !V%@  <1,  &X0  !M#04 ;0D- &H)% !G"AT 90HF &,++@!B
M##4 8 P\ %\,0@!>#4@ 7 U/ %L-5@!9#5X 6 YH %8.<P!5#H  4PZ/ %$.
MGP!0#K$ 3@[( $T0Z@!-$/T 31#_ $T0_P!-$/\ O!L  *4<  "2'0  @QX
M '<=  !O'   :1H  &87  !D%   9! ( &(/$ !?$!@ 71 A %L1*0!:$3$
M6!(X %<2/@!6$D4 5!), %,34P!1$UL 4!-E $X4< !,%'T 2Q2, $D4G !'
M%:X 1A7% $45Z !%%OX 11;_ $45_P!%%?\ M1\  )XA  "+(@  ?"(  '$B
M  !H(0  8A\  %\=  !<&@  6Q<" %H5#0!7%A0 518= %07)0!2&"T 41@T
M $\8.P!.&4( 31E( $L:4 !*&E@ 2!IB $<:;0!%&WH 0QN) $(;F@! &ZP
M/QO" #X<Y0 ]'/P /AS_ #X;_P ^&_\ KR,  )@D  "&)0  =R8  &PF  !C
M)0  720  %DB  !6'P  5!T  %,<"P!1'!( 3AT: $T=(@!+'BD 2AXQ $D?
M-P!''SX 1B!% $4@30!#(%4 0B!? $ A:@ _(7< /2&' #LAF  Y(:H ."+
M #<BXP W(OL -R+_ #@A_P X(?\ JB8  )0G  "!*0  <RD  &<I  !?*0
M6"@  %0F  !1(P  3R(  $PB!P!*(A  2"(7 $<C'P!%)"8 1"0N $(D- !!
M)3L 0"5# #\E2@ ])E, /"9< #HF9P Y)G4 -R>$ #4GE@ T)Z@ ,B>^ #$G
MX0 Q)_D ,B;_ #(F_P S)?\ I2D  (\J  !]+   ;RP  &0M  !;+   52L
M % J  !,*   2B8  $<G! !$)PT 0B@4 $$H'  _*2, /BDK #TI,@ \*CD
M.RI  #DJ2  X*U  -BM: #4K90 S*W( ,2N" # LE  N+*< +"R\ "LLW@ L
M+/@ +"O_ "TJ_P M*O\ H2P  (LM  !Y+@  :R\  & O  !8+P  42X  $PN
M  !(+   12L  $$K   _+ L /2P1 #LM&0 Z+B$ .2XH #<N+P V+S8 -2\^
M #0O10 S+TX ,3!8 # P8P N,'  +#"  "HPD@ I,*4 )S"Z "8PW  F,/<
M)R__ "@O_P H+O\ G"X  (<P  !V,0  :#(  %TR  !5,@  3C$  $@Q  !$
M,   0"\  #PP   Z,0D -S$0 #8R%@ U,AX ,S,E #(S+  Q,S, ,#0[ "\T
M0P M-$P +#16 "HU80 I-6X )S5^ "4UD  C-:, (C6Y "$UV0 A-/8 (C3_
M ",S_P C,O\ F#$  (,S  !R-   930  %HU  !1-0  2S0  $4T  ! -
M.C,  #<T   T-08 ,C8. # W$P O-QL +C<B "TX*0 K.#$ *C@X "DY0  H
M.4D )CE3 "4Y7P C.6P (3I\ " ZC@ >.J( '#JW !LYU0 <.?4 '3C_ !TX
M_P >-_\ DS0  '\V  !N-P  83<  %<W  !.-P  2#<  $(W   \-P  -3@
M #(Y   O.@( +#L+ "H\$0 I/!@ *#T? "8])@ E/2X )#TU ",^/0 B/D8
M(#Y0 !\^7  =/VD &S]Y !H_C  8/Z  %C^U !4^T@ 6/O, %SW_ !@\_P 8
M//\ CC<  'HX  !J.0  7CH  %,Z  !+.@  13H  #\Z   Y.@  ,CP  "X^
M   I0   )D$( "1"#@ B0A0 (4(; "!#(P ?0RH 'D,R !Q#.@ ;1$, &D1-
M !A$60 71&< %41W !-$B@ 21)X $42S !!$T  00_( $4+_ !)"_P 30?\
MB3L  '8\  !F/0  6CT  % ]  !(/0  0CT  #P]   V/@  +T   "I"   E
M1   (48# !U(#  ;21$ &4D7 !A)'@ 7228 %DDN !5*-@ 42D  $TI* !%*
M5@ 02F0 #TIT  Y*AP -2IL #$JP  I*R@ +2>P #$C_  U'_P -1_\ @SX
M '$_  !B0   5D   $U   !%0   /T   #E!   R0@  *T4  "9'   A20
M'$L  !9.!P 34 X $E 3 !%0&0 04"$ #U I  Y0,0 -4#L #5%&  M140 *
M45\ "5%O  =0@0 %4)8  U"K  )0Q0 #3^@  T_[  5._P &3?\ ?4(  &M#
M  !=1   4D0  $I$  !#0P  /$0  #5%   N1P  )TH  "%,   <3P  %U$
M !)4 P .5PH "U@0  I8%0 (6!P !U@D  98+  %6#8  UA   %83   6%H
M %AI  !8?   6)$  %>G  !7P   5N4  %;Y  !5_P  5?\ =D<  &9'  !9
M2   3T<  $='  ! 1P  .$@  #!*   I30  (E   !Q3   650  $5@   U;
M @ )7@D !%\.  !?$@  7Q@  & ?  !@)P  8#   & [  !@1P  8%0  &!C
M  !@=@  8(L  %^B  !?NP  7^(  %[Y  !=_P  7?\ ;TL  &%,  !53
M3$L  $1+   [3   ,DX  "M1   C5   '%<  !9;   17@  #6    AC   "
M9@<  &<,  !G#P  :!,  &D9  !J(0  :BD  &HT  !J0   :DT  &I=  !J
M;P  :H4  &J=  !IM@  :-T  &CW  !G_P  9O\ :5$  %Q0  !24   2D\
M #]0   U4P  +58  "19   =70  %F   !!D   ,9P  !FH   !N    ;P,
M ' (  !Q#0  <A   '04  !U&P  =B,  '<L  !W.   =D8  '96  !V:
M=GX  ':7  !UL0  =-,  '/U  !S_P  <O\ 8U8  %A5  !05   1%4  #E8
M   O6P  )E\  !UC   59P  $&P   IP   $<P   '8   !Z    ?    'P#
M  !^"   ?PP  ($0  ""%   A!L  (4D  "&+P  ACT  (9-  "%7P  A74
M (6/  "$J0  @\D  (+Q  "!_P  @/\ 7UL  %9:  !)6P  /5X  #)A   G
M9@  'FL  !5P   .=0  "7D   %^    @0   (4   "(    B@   (L   "-
M 0  C@8  ) +  "1#P  DQ0  )4;  "7)@  ES0  )=$  "75@  EFP  )6&
M  "5H@  E,$  )/J  "2_P  DO\ 76$  $]A  !"9   -FD  "IN   ?=
M%7D   Y_   'A    (D   ".    D@   )8   "8    F@   )L   "=
MGP   *$#  "C"   I0T  *<3  "I'   JB@  *HY  "J2P  JF$  *EZ  "H
MF0  J+4  *?=  "G^   IO\ 5F@  $AL   Z<   +G8  ")]   7A   #HH
M  >0    E@   )H   "?    HP   *<   "J    JP   *T   "O    L0
M +,   "U    N 4  +H,  "]$@  P!P  , M  # 0   OU4  +]N  "^BP
MOJ@  +[)  "][P  O/X 3G0  $!Y   R?P  )8<  !F.   0E0  !YP   "B
M    IP   *P   "P    M0   +D   "\    O0   +\   #!    PP   ,8
M  #(    R@   ,T"  #0"P  U1(  -8A  #7-   V$D  -E@  #:?   VIH
M -NU  #;V0  V_( 1H(  #B)   KD   '9@  !*@   *IP   *X   "T
MN0   +X   #"    R    ,L   #.    SP   -(   #4    U@   -H   #=
M    WP   .(   #F    Z@H  .\3  #P)0  \CH  /-1  #T:P  ](D  /6E
M  #UOP  ]=T _P & /\  P#_  4 _P + /\ $ #_ !< _P B /\ +0#_ #D
M_P!$ /\ 30#_ %4 _P!= /\ 9 #_ &H _P!P /T =@#[ 'P ^0"# /< B@#U
M )( \P"; /  I@#N +, ZP#$ .D Y #G /D Y@#_ .4 _P#3 /\ QP#_ +\
M_P"[ /\ _P   /\   #_    _P " /\ "P#_ !( _P = /\ * #_ #, _P ^
M /P 1P#X $\ ] !7 /$ 70#N &, [ !I .H ;P#H '4 Y@!\ .0 @P#B (L
MWP"5 -P GP#9 *L U0"[ -( U #/ /( S0#_ ,P _P#% /\ N@#_ +0 _P"P
M /\ _P   /\   #_    _P   /\ !@#Y  \ ]0 7 /, (@#Q "T [0 W .<
M0 #B $D WP!0 -L 5P#7 %T U !C -$ : #/ &X S !U ,H ? #( (0 Q0"-
M ,( F #  *0 O0"R +L Q@"Y .@ N #] +< _P"V /\ K0#_ *< _P"C /\
M_P   /\   #_    ]0   .L  0#D  P W@ 3 -D ' #3 "8 T0 P ,P .@#(
M $( Q !* ,  4 "] %8 NP!< +D 80"W &< M0!M +, = "Q 'P KP"% *T
MD "J )P J "J *8 NP"E -H HP#U *, _P"B /\ G@#_ )H _P"7 /\ _P
M /X   #O    WP   -    #'  < P0 / +P %P"Y "  MP J +4 ,P"P #L
MK0!# *L 20"H $\ I@!5 *0 6@"C &  H0!F )\ ;0"= '0 G !] )H B "8
M )0 E@"B )0 L@"2 ,D D0#K )$ _P"0 /\ D #_ (P _P"* /\ _    .P
M  #9    QP   +H   "Q  ( JP , *< $@"D !L H0 D *  + "> #4 FP \
M )@ 0P"6 $D E !/ )( 5 "0 %H CP!? (T 9@"+ &T B0!V (@ @ "& (P
MA ": (( J@"! +X @ #@ (  ^0!_ /\ ?P#_ '\ _P!^ /\ \0   -@   #"
M    LP   *@   "@    F0 ' )4 #@"2 !4 D  > (X )@"- "X B@ V (<
M/0"% $, A !) (( 3@"! %0 ?P!9 'X 8 !\ &< >@!O 'D >@!W (8 =0"4
M '0 HP!R +4 <@#/ '$ \0!P /\ < #_ '  _P!Q /\ X0   ,0   "P
MH@   )<   "1    BP " (8 "P"# !$ @0 8 '\ (0!] "D ?  P 'D -P!X
M #T =@!# '0 20!S $X <@!4 '  6@!O &( ;0!J &L = !J (  : ". &<
MG0!E *\ 90#& &0 Z !D /T 8P#_ &, _P!D /\ SP4  +8'  "C"   E @
M (D'  "" P  ?@   'L !@!W  X =0 3 '( &P!Q ", ;P K &T ,@!L #@
M:@ ^ &D 1 !G $D 9@!/ &4 5@!C %T 8@!E &  ;P!? 'L 70") %P F0!;
M *H 60"_ %D X0!8 /@ 6 #_ %@ _P!9 /\ P@P  *H-  "7#@  B0X  'T.
M  !V#0  <0H  &\&  !M  H :P 0 &D %@!G !X 90 F &, +0!A #, 8  Y
M %\ /P!= $4 7 !+ %L 4@!: %D 6 !B %< ; !5 '@ 4P"& %( E@!1 *<
M4 "[ $\!VP!. O0 3@/_ $X$_P!. _\ N!   *$2  ".$P  ?Q,  '03  !L
M$@  9Q   &4.  !C"P, 8P8, &$$$0!> QD 7 0A %L%* !9!B\ 6 8U %8'
M.P!5!T( 5 =( %,(3P!1"%8 4 E? $X):0!-"78 2PJ$ $D*E !("J8 1PJZ
M $8*V !%"_, 10S_ $4,_P!%#/\ L!0  )D6  "'&   >!D  &T8  !E%P
M7Q8  %P3  !:$0  6@X& %H,#0!7#!0 50P< %,-) !2#2L 4 TQ $\.. !.
M#CX 30Y% $L.30!*#E4 2 ]> $</: !%#W4 0Q"$ $$0E0! $*8 /A"[ #T0
MW  ]$?8 /1'_ #T0_P ^$/\ J1D  )(;  "!'   <AT  &<=  !?'   61L
M %49  !3%@  4A,  %(1"@!0$!  3A$8 $P1( !*$B< 21(N $@3- !'$SL
M11-" $0320!#%%( 011; #\490 ^%7( /!6! #H5D@ X%:0 -Q6Y #45V  U
M%O4 -A;_ #86_P W%?\ HQP  (T>  ![(   ;2$  &(A  !:(0  5!\  % >
M  !-&P  3!D  $L6!@!)%@X 1Q<5 $47' !$&"0 0A@J $$8,0! &3@ /QD_
M #T91@ \&D\ .AI8 #D:8P W&V\ -1M^ #,;D  R&Z( ,!NW "\;TP O'/,
M+QO_ # ;_P P&_\ G1\  (@B  !W(P  :20  %XD  !6)   4",  $LB  !(
M(   1AT  $4< @!#' P 01P2 #\=&0 ^'2$ /!XG #L>+@ Z'S4 .1\\ #<?
M1  V'TP -"!6 #,@8  Q(&T +R!\ "TAC@ L(:  *B&U "DAT  I(?( *2'_
M "H@_P K(/\ F2(  (0E  !S)@  92<  %LG  !3)P  3"8  $<E  !$)
M0B$  #\A   ](0D .R$0 #DB%@ X(AX -B,E #4C*P T)#( ,R0Y #(D00 P
M)$H +R53 "TE7@ K)6L *B5Z "@EC  F)9\ )"6S ",ES@ C)?  )"7_ "4D
M_P E)/\ E"4  ( G  !O*0  8BH  %<J  !/*@  22D  $0H  ! )P  /28
M #HE   W)@8 -28. #0G%  R)QL ,2@B # H*0 O*#  +2DW "PI/P K*4<
M*2E1 "@J7  F*FD )"IX ",JB@ A*IT 'RJR !XJS  >*N\ 'RG_ " I_P A
M*/\ D"@  'PJ  !L*P  7RP  %0L  !,+   1BP  $$K   \*P  ."H  #4J
M   R*P, ,"L, "XL$0 M+!@ +"P? "HM)@ I+2T *"TT "<N/  F+D4 )"Y/
M ",N6@ A+V< 'R]V !TOB  <+YL &B^P !@OR@ 8+NT &2[_ !LM_P ;+?\
MC"L  '@M  !H+@  6R\  %$O  !)+P  0R\  #XN   Y+@  -"X  # N   M
M+P  *S * "DQ$  G,14 )C$< "4R(P D,BH (S(Q "$S.0 @,T( 'S-, !TS
M5P ;,V0 &C1T !@TA@ 6-)H %#.N !,SR  3,^P %#/_ !4R_P 6,?\ ARX
M '0O  !E,0  6#$  $XR  !&,@  0#$  #LQ   V,0  ,3$  "LS   H-
M)34& ",V#0 A-A( (#<9 !\W(  >-R< '3@N !LX-@ :.#\ &3A) !<Y50 5
M.6( %#EQ !(YA  1.9@ $#FM  XXQP ...L $#C_ ! W_P 1-O\ @S$  ' R
M  !A-   530  $LT  !$-   /30  #@T   S-   +34  "@W   D.0  (#H"
M !T["P ;/!  &3T5 !@]'  7/2, %CTK !4^,P 4/CP $CY& !$^4@ 0/E\
M#SYO  X^@0 ,/I4 "SZI  H^P0 */>0 "SW[  P\_P -._\ ?30  &LV  !=
M-P  43<  $@W  !!-P  .S<  #4W   P-P  *CD  "4[   @/0  '#\  !=!
M!@ 40PT $D,2 !%#&  10Q\ $$0G  ]$+P .1#D #41#  Q$3@ +1%L "41J
M  =$?  &1)  !$.E  )#O0 #0^   T/V  1"_P &0?\ >#@  &<Y  !9.@
M3CH  $4Z   ^.@  .#H  #,Z   M.P  )ST  "%    <0@  %T0  !-& P /
M20H #4H/  Q*%  +2AL "4HC  A**P '2C0 !4H^  1*20 "2E8  $IE  !*
M=P  2HL  $JA  !)N0  2=T  $GU  !(_P  2/\ <CP  &(]  !5/@  2CX
M $(]   \/0  -CT  "\^   I0   (T(  !U%   71P  $TH   ], @ +3PD
M!U -  -1$0  41<  %$>  !1)@  42\  %$Y  !11   4E$  %)@  !1<@
M48<  %&=  !1M0  4-@  %#U  !/_P  3_\ ;$   %U!  !100  1T$  $!
M   Y0   ,D$  "I#   D1@  'D@  !=+   23@  #E$   M3 0 &5@<  %<,
M  !8$   6!,  %D9  !:(0  6BD  %HS  !:/P  6DP  %I:  !:;   6H$
M %F9  !9L0  6-$  %CT  !7_P  5_\ 944  %A%  !-10  140  #Y$   U
M10  +4<  "5*   >30  &%   !)3   .5@  "ED   1<    7@0  %\)  !@
M#0  81   &(5  !C&P  9",  &0M  !D.   9$4  &14  !D9@  9'L  &.3
M  !CK0  8LP  &'R  !A_P  8/\ 7TH  %-*  !*20  0T@  #E)   O3
M)T\  !]2   850  $ED   U=   (8    F,   !F    : $  &D%  !J"@
M:PT  &T1  !N%@  <!T  '$F  !Q,0  <#X  '!.  !P7P  <',  &^-  !O
MIP  ;L8  &WO  !L_P  ;/\ 6D\  %!.  !(30  /4X  #-1   I5   (%@
M !A<   18   #&0   9H    :P   &\   !R    =    '4   !W!   > D
M 'H-  !\$   ?18  '\>  " *   @#4  (!%  !_5@  ?VL  '^$  !^H
M?;X  'SI  ![_P  >O\ 5E0  $Y3  !"5   -U8  "Q:   B7P  &&,  !%H
M   +;0   W(   !V    >@   'T   "     @P   (0   "&    AP(  (D'
M  "+#   C1   ) 6  "2'P  DBP  )([  "230  D6(  )%Z  "/EP  C[0
M ([A  ",^P  C/\ 55D  $A:   [70  +V$  "1F   9;   $7(   IW   "
M?0   ((   "&    BP   (X   "1    DP   )4   "7    F0   )L   "=
M!   GPH  *(/  "D%@  IB$  *8Q  "F0P  I5<  *1P  "CC@  HZL  *'0
M  "@]0  G_\ 3F$  $!D   S:0  )VX  !MU   1?   "X,   ")    C@
M ),   "8    G0   *$   "D    I0   *<   "I    JP   *T   "P
ML@   +4(  "X#@  O!8  +PE  "\-P  NTP  +ID  "Y@0  MZ(  +?   "W
MZ@  M_P 1FL  #EP   K=P  'W\  !.&   +C@   94   ";    H0   *8
M  "K    L    +,   "W    MP   +H   "\    OP   ,$   #$    QP
M ,H   #-!0  T0X  -09  #4*P  U$   --8  #3=   TY(  -*P  #2TP
MTO( /GD  #&    CB   %Y$   V9   #H    *<   "N    LP   +@   "]
M    P@   ,8   #*    R@   ,T   #/    T@   -4   #9    W0   -\
M  #C    YP4  .L/  #L'P  [3,  .Y+  #O9   [X(  /"?  #QN0  \=@
M_P   /\   #_  0 _P ) /\ #@#_ !4 _P > /\ *0#_ #0 _P _ /\ 2 #_
M %  _P!8 /\ 7@#_ &4 _0!K /L <0#Y '< ^ !^ /8 A0#S (T \0"7 .X
MH@#K *\ Z #  .8 X #C /@ X@#_ -L _P#+ /\ P0#_ +D _P"T /\ _P
M /\   #_    _P   /\ "0#_ !  _P 9 /\ (P#_ "X _0 Y /D 0@#U $H
M\@!2 .X 6 #K %X Z0!D .8 :@#D '  X@!V -\ ?0#= (8 V0"/ -4 F@#1
M *< S@"V ,L S@#) /  QP#_ ,4 _P"[ /\ M #_ *T _P"I /\ _P   /\
M  #_    _P   /L  @#V  T \0 3 .T '@#L "@ Z0 R ., .P#= $0 V !+
M -, 40#0 %@ S0!= ,L 8P#) &@ Q@!O ,0 =@#" 'X OP"' +P D@"Z )\
MMP"M +4 P0"R .0 L0#] *\ _P"L /\ I0#_ *  _P"< /\ _P   /\   #[
M    [@   .0   #<  @ TP 0 ,\ & #+ "( R0 K ,8 - #! #T O0!$ +H
M2P"W %$ M0!6 +( 7 "P &$ K@!G *P ;@"J '8 J !_ *8 B@"C )8 H0"E
M )\ M@"= -$ G #S )L _P"< /\ E@#_ ), _P"0 /\ _P   /8   #G
MTP   ,8   "]  , N  - +, $P"Q !P KP E *X +@"I #8 I@ ] *, 1 "A
M $H GP!/ )T 50"; %H F@!@ )@ 9@"6 &X E !W )( @0"0 (X C@"< (P
MK0"* ,, B0#H (@ _P") /\ AP#_ (4 _P"" /\ \P   .,   #,    O
M +    "G    H0 ( )X #P"; !8 F0 ? )@ )P"6 "\ DP W )$ /0". $,
MC !) (L 3@") %0 AP!9 (4 8 "$ &< @@!O (  >@!^ (8 ? "4 'H I !Y
M +@ > #8 '< ]P!X /\ > #_ '< _P!U /\ Y@   ,L   "W    J    )X
M  "6    CP $ (L # "( !( AP 9 (4 (0"$ "D @@ P '\ -P!] #T ? !#
M 'H 2 !Y $T =P!3 '8 60!T &$ <@!I '$ <P!O '\ ;0"- &P G0!J *\
M:0#( &@ [0!I /\ :0#_ &D _P!I /\ T@   +@   "E    EP   (T   "&
M    @0   'P " !Y  X =P 4 '8 ' !T ", <P K '$ ,0!O #< ;@ ] &P
M0P!K $@ :@!. &@ 5 !G %L 90!C &, ;0!B '@ 8 "' %\ E@!= *@ 70"^
M %P Y !< /L 7 #_ %P _P!< /\ P@   *H!  "8 P  B00  '\"  !X
M=    '  ! !M  P :P 1 &D %P!H !X 9@ E &4 + !C #( 8@ X &  /0!?
M $, 7@!) %P 3P!; %8 6@!> %@ : !7 ', 50"! %0 D0!2 *, 40"W %$
MU@!1 /4 40#_ %$ _P!2 /\ M@<  )\)  "-"P  ?@P  ',+  !L"@  : <
M &4#  !C  < 80 - %\ $P!= !H 7  A %L )P!9 "T 6  S %8 .0!5 #\
M5 !% %, 2P!1 %( 4 !: $\ 9 !- &\ 3 !] $H C0!) )\ 2 "R $< S !'
M .\ 1@#_ $< _P!' /\ K P  )4.  "#$   =1   &L0  !C#P  7@X  %L,
M  !:"0( 600* %< #P!5 !4 4P < %( (P!1 "D 3P O $X -0!- 3L 3 %!
M $H"2 !) D\ 2 )7 $8#80!% VT 0P-Z $(#BP!  YP /P.O #X#R  ]!.H
M/07\ #T&_P ^!O\ I!   (X2  !\$P  ;A0  &04  !<$P  5A(  %,1  !1
M#@  4 P% % )# !/!Q$ 30<7 $L('P!)""4 2 DK $<),0!&"3@ 1 H^ $,*
M10!""DT 0 M5 #\+7P ]"VL / MY #H,B@ X#)P -PRO #4,QP U#.D -0W]
M #4-_P V#/\ G1,  (<5  !V%P  :1@  %X8  !6&   4!<  $T5  !*$P
M21$  $D.!P!(#0X 1@T3 $0-&@!##B$ 0@XH $ .+@ _#C4 /@\\ #T/0P [
M$$L .A!4 #@07@ V$&L -!!Y #(0B@ Q$)P +Q"P "T0R0 M$>P +1'_ "X1
M_P O$/\ EQ8  ((9  !Q&P  9!P  %D<  !1'   3!L  $<:  !$&   0Q4
M $(3 @!!$@L 0!$0 #X2%P \$AX .Q,E #H3*P X$S( -Q,Y #840  T%$@
M,Q11 #$47  P%6@ +A5W "P5B  J%9H *!6N "<5QP F%>H )Q7_ "@5_P I
M%?\ D1H  'T<  !M'@  8!\  %8?  !.'P  2!X  $,=  ! '   /AH  #T8
M   [%P< .18. #@7%  V%QL -1@B #,8*  R&"\ ,1DV # 9/0 N&48 +1I/
M "L:60 J&F8 *!IT "8:A@ D&ID (AJM "$:Q0 @&N@ (1K^ "(:_P C&O\
MC1T  'D?  !I(0  7"(  %(B  !*(@  1"$  #\A   \(   .1X  #@;   U
M' 0 -!P- #(<$@ P'1@ +QT? "X=)0 M'BP *QXS "H>.P I'T, )Q]- "8?
M5P D'V0 (A]R " ?A  ?'Y< '1^K !L?PP ;'^< &Q_] !T?_P >'O\ B2
M '4B  !E(P  620  $\E  !')0  020  #PC   X(P  -2(  #,@   P( $
M+B$* "PA$  K(14 *B(< "@B(P G(BD )B,P "4C.  C(T$ (B1* "$D50 ?
M)&$ '21P !LD@@ 9))4 %R2J !8DP0 5).4 %B3\ !<C_P 9(_\ A2(  '$D
M  !B)@  5B<  $PG  !$)P  /B<  #DF   U)@  ,24  "XD   K)0  *24'
M "<F#@ E)A, )"<9 ",G(  B)R< (2@N " H-@ >*#X '2A( !LI4P 9*5\
M&"EN !8I@  4*90 $BFH !$IP  1*.0 $2C[ !,H_P 4)_\ @"4  &XG  !?
M*   4RD  $DJ  !"*0  .RD  #8I   R*   +B@  "HH   F*0  )"H$ "(K
M#  @*Q$ 'RP6 !TL'0 <+"0 &RTK !HM,P 8+3P %RU% !8N4  4+ET $BYL
M !$N?@ 0+I( #BZG  TMO0 -+=\ #2WY  XL_P 0+/\ ?"@  &HJ  !;*P
M4"P  $8L   _+   .2P  #0K   O*P  *RL  "8L   B+@  'R\  !PP"0 :
M,0X &3$3 !<Q&@ 6,B$ %3(H !0R,  3,CD $C-# !$S3@ 0,UL #C-I  TS
M>@ ,,XX "C.B  @RN0 (,MD "#+T  HQ_P +,?\ =RL  &8M  !8+@  32\
M $,O   \+@  -BX  #$N   M+@  *2X  ",P   ?,@  &S,  !<U!0 4-@P
M$C<1 !$W%@ 1-QT $#@D  \X+  ..#4 #3@_  PX2@ +.%< "3AE  <X=@ %
M.(H  SB?  $WM0 !-],  C?Q  ,V_P %-O\ <RX  &(P  !4,0  23$  $$Q
M   Y,0  -#$  "\P   K,   )3(  " S   ;-@  %S@  !,Z @ 0/ D #3T.
M  P]$P +/1D "CTA  D]*0 (/3$ !CX[  4^1@ #/E(  3YA   ^<@  /H8
M #V<   ]L@  /=   #SP   \_P  //\ ;3(  %TS  !0-   1C0  #XT   W
M-   ,C,  "TS   G-   (C8  !TX   8.@  %#T  ! _ @ -00@ "4,-  9$
M$0 #1!8  D0=  !$)   1"T  $0V  !$00  1$X  $1<  !$;0  1($  $28
M  !#KP  0\T  $+P  !"_P  0O\ :#8  %@W  !,.   0S@  #LW   U-@
M,#8  "DW   C.0  'CL  !@]   30   $$(   U% 0 (1P<  TD,  !)#P
M2A,  $L9  !+(   2R@  $LR  !+/0  3$D  $Q7  !+:   2WT  $N4  !*
MK   2LH  $GO  !)_P  2?\ 8CH  %0[  !).P  0#L  #DZ   S.0  +#H
M "4\   ?/P  &4$  !-$   01P  #$D   A,   "3P4  % *  !0#0  41
M %(5  !4&P  5",  %0L  !4-P  5$0  %12  !48P  5'<  %2/  !3J
M4L8  %+M  !1_P  4?\ 7#\  $\_  !%/P  /CX  #<]   O/@  )T   "!#
M   91@  $TD   ],   +3P  !E(   !4    5P(  %@'  !9"P  6@X  %L1
M  !=%@  7AT  %\F  !?,0  7CT  %Y,  !>70  7G$  %V)  !=HP  7,$
M %OK  !:_P  6O\ 5D0  $M#  !#0@  /$$  #)"   I10  (4@  !I+   3
M3@  #E(   I5   #60   %L   !>    8    &("  !C!@  90H  &8.  !H
M$0  :A<  &L?  !K*0  :S8  &M%  !K5@  :FH  &J"  !IG0  :+L  &?G
M  !F_P  9?\ 44@  $A(  !!1@  -T<  "Q*   C30  &U$  !-5   .60
M"%T   %A    9    &<   !J    ;    &X   !P    <@4  ',)  !U#0
M=Q$  'H8  ![(0  >RX  'H]  !Z3@  >6(  'EY  !XE@  =[,  '7@  !T
M_   <_\ 3DT  $=,   [30  ,$\  "93   <6   $UP   UA   &9@   &H
M  !O    <@   '8   !Y    ?    'T   !_    @0   (,"  "&!P  B P
M (L1  ".&   CB0  (XS  "-1   C%@  (MO  "*C   B:H  (C/  "&]P
MA?\ 35$  $%3   T50  *5H  !Y?   490  #6H   5P    =@   'L   !_
M    @P   (<   "*    C0   (X   "1    DP   )4   "8    F@4  )T,
M  "@$0  HQH  *,H  "B.@  H4X  *!E  "@@0  GJ   )W!  ";[@  FO\
M1ED  #E<   M80  (6<  !9N   .=0  !7L   "!    AP   (T   "2
ME@   )H   "=    GP   *$   "D    I@   *@   "K    K@   +$#  "T
M"P  N!$  +D>  "Y+P  N$,  +=:  "U=@  M)<  +2U  "QX@  L/P /V0
M #%I   E;P  &'<   ]_   &AP   (X   "4    F@   *    "E    J@
M *X   "Q    L@   +4   "W    N@   +P   "_    PP   ,8   #)
MS@H  -(3  #2(P  T3<  -!/  #.:@  S8H  ,JK  #+RP  R^\ -W$  "EX
M   =@   $8D   B1    F@   *$   "G    K0   +,   "Y    O@   ,(
M  #%    Q@   ,D   #,    S@   -(   #5    V@   -X   #A    Y0
M .H+  #K%P  ZBL  .I#  #J7@  ZGH  .N9  #KM0  Z]4 _P   /\   #_
M  $ _P ' /\ #0#_ !( _P ; /\ )0#_ "\ _P Z /\ 0P#_ $L _P!3 /\
M6@#] &  ^P!F /H :P#X '( ]@!X /0 @ #Q (D [P"2 .P G0#I *H Y@"\
M ., W #? /< W0#_ ,P _P"^ /\ M0#_ +  _P"M /\ _P   /\   #_
M_P   /\ !@#_  T _P 4 /\ 'P#_ "D ^P S /< /0#S $4 [P!- .P 4P#H
M %D Y0!? ., 90#@ &H W0!Q -H > #6 (  T@"* ,\ E0#, *( R "R ,4
MR0#" .T P #_ +L _P"P /\ J #_ *0 _P"A /\ _P   /\   #]    ^@
M /@   #P  D [  1 .@ &0#G ", Y0 M -X -@#6 #X T0!& ,T 3 #* %(
MR !8 ,4 70## &, P !I +X < "\ '@ N0"! +< C0"T )H L0"I *X O "L
M .$ J@#\ *@ _P"@ /\ F0#_ )8 _P"4 /\ _P   /D   #R    YP   -L
M  #1  0 R@ - ,< % #$ !T P@ F +\ +P"[ #< MP _ +0 10"Q $L K@!1
M *P 5@"J %P J !A *8 : "C '  H0!Y )\ A "= )$ F@"@ )@ L0"6 ,P
ME0#Q )0 _P"1 /\ BP#_ (@ _P"& /\ ]P   .P   #>    R0   +P   "T
M    KP * *L $ "I !< J  @ *< * "B #  GP X )P /@": $0 F !* )8
M3P"4 %4 DP!: )$ 80"/ &@ C0!Q (L >P") (@ AP"7 (4 J "# +X @0#D
M (  _P"  /\ ? #_ 'L _P!Y /\ Z0   -<   #!    L0   *8   "=
MEP % )0 #0"2 !( D  : (\ (@". "H BP Q (D . "' #X A0!# (, 2 "!
M $X ?P!4 'X 6@!\ &$ >@!I '@ <P!V '\ =0". ', GP!Q +, < #0 &\
M]@!O /\ ;P#_ &T _P!L /\ V@   +\   "L    G@   ),   ",    A0
M (( "0!_  \ ?@ 5 'T ' !\ "0 >@ K '< ,0!U #< =  ] '( 0@!Q $@
M;P!- &X 4P!L %H :P!B &D ; !G '@ 9@"& &0 EP!B *H 80#" &  ZP!A
M /\ 80#_ &$ _P!@ /\ Q0   *T   ";    C0   (,   !\    =P   '(
M!0!P  P ;@ 1 &P %P!L !X :P E &D + !G #$ 9@ W &0 /0!C $( 8@!(
M &  3@!? %4 70!= %P 9@!: '( 60"  %< D !6 *, 50"Y %0 W@!4 /L
M5 #_ %4 _P!5 /\ M@   )\   "-    ?P   '4   !N    :0   &8  0!C
M  D 80 . &  $P!? !D 7@ @ %T )@!; "P 6@ R %@ -P!7 #T 5@!# %4
M20!3 %  4@!8 %$ 80!/ &P 3@!Z $P B@!+ )P 2@"Q $D S@!) /, 20#_
M $D _P!* /\ J@$  )0%  ""!P  = @  &H(  !C!@  7@0  %L   !9  4
M5P , %8 $ !4 !4 4P ; %( (@!1 "@ 4  M $X ,P!- #@ 3  ^ $L 10!*
M $P 2 !4 $< 70!& &@ 1 !U $, A0!! )@ 0 "K $  Q0 _ .H /P#_ $
M_P!  /\ H @  (H+  !Y#0  ; T  &$-  !:#0  50L  %()  !0!@  3P((
M $X #0!, !( 2P 7 $H '@!) ", 1P I $8 +P!% #0 1  Z $( 00!! $@
M0 !0 #X 6@ ] &0 / !R #H @@ Y )0 . "G #< O@ V ., -@#Y #8 _P W
M /\ F T  (,.  !R$   91$  %L1  !3$   3A   $H.  !(#0  1PH# $<'
M"@!%! X 1 (3 $("&@!! B  0 ,E #X#*P ]!#$ / 0W #L$/@ Z!44 .05.
M #<%5P V!6( - 9P #(&@  Q!I( , :E "\%NP N!=T +@;U "T'_P N!_\
MD1   'T1  !L$P  7Q0  %44  !.%   2!,  $02  !!$   0 X  $ -!@!
M"@P /@D0 #P)%@ ["AP .0HB #@**  W"RX -@LU #4+.P S"T, ,@Q, # ,
M5@ O#&$ +0QO "L,?P J#)( * RE "<,NP E#-T )0WU "8-_P G#?\ BQ(
M '<4  !G%@  6Q<  %$8  !)%P  0Q<  #\5   \%   .A(  #D1 0 Y#P@
M. X- #<.$@ U#A@ - X? #(.)0 Q#RP , \R "\0.@ M$$( +!!+ "H050 H
M$&$ )A!O "00@  C$), (1"G !\0O0 >$.  'A'W !\0_P @$/\ AA0  ',7
M  !C&0  5QH  $T;  !%&@  0!H  #L9   X&   -18  #04   S$@0 ,A(+
M #$2$  O$A4 +1(< "P3(@ K$RD *A,P "@3-P G%#\ )A1( "044P B%%\
M(!5M !\5?@ =%9$ &Q6E !D5NP 8%=X &!7X !D4_P :%/\ @A<  &\:  !?
M'   4QT  $H=  !"'0  /!T  #<<   T&P  ,1H  "\9   N%@  +!<( "L6
M#@ I%Q, *!<9 "<8(  E&"8 )!@M ",8-  B&3T (!E& !X940 =&5T &QIK
M !D:?  7&H\ %1JC !09N@ 2&=L $QGV !09_P 5&/\ ?1H  &L=  !<'P
M4"   $<@   _(   .1\  #0?   Q'@  +1T  "L<   I&P  )QL% "4;#  D
M'!$ (AP6 "$<'0 @'2, 'QTJ !X=,@ <'CH &QY$ !D>3@ 7'EL %AYI !0?
M>@ 2'HT $1ZB ! >N  .'M@ #Q[U ! =_P 1'?\ >AT  &<?  !9(0  32(
M $0B   \(@  -B(  #(A   N(0  *B   "<@   D'P  (B " " @"@ >(0\
M'2$4 !PA&@ ;(B$ &2(G !@B+P 7(C@ %2-! !0C3  2(U@ $2-G ! C>  .
M(XL #2.?  PCM  +(]  "R+P  PB_P -(?\ =A\  &0B  !6(P  2R0  $$D
M   Z)   -"0  "\C   K(P  *",  "0C   @(P  '20  !LE!P 9)@T %R81
M !8F%P 5)QX %"<E !,G+  2)S4 $2@_ ! H2@ .*%8 #2AD  PH=  **(<
M"2B;  <GL0 %)\P !B?L  <F_@ ()O\ <2(  & D  !3)@  2"<  #\G   W
M)@  ,28  "TF   I)0  )24  "(E   =)P  &2@  !8J!  4*PL $BP0 !$L
M%  0+!L $"PB  XL*0 .+3( #2T[  LM1@ *+5( ""U@  8M<  $+8,  BV8
M   LK@  +,D  "SK  $K_  "*_\ ;24  %TG  !/*   12D  #PI   U*0
M+R@  "LH   G)P  (R<  !\H   ;*@  %RP  !,N @ 0, @ #C$-  TQ$@ ,
M,1< "S$>  HQ)@ (,BX !S(W  4R0@ #,DX  3)<   R;   ,G\  #*5   Q
MK   ,<<  ##J   P_   ,/\ :"D  %@J  !,*P  02P  #DL   R*P  +2L
M "DJ   E*@  ("L  !PL   7+@  $S   ! R @ .- < "C<,  <W$  %-Q0
M S<;  (W(@  -RH  #@S   X/@  .$H  #A8   X:   .'P  #>2   WJ0
M-L4  #;J   V_0  -?\ 8RP  %0N  !(+P  /B\  #8N   P+@  *RT  "<M
M   B+0  '2\  !@Q   4,P  $#4   XW 0 *.@< !CL+  (\#@  /1(  #X7
M   ^'@  /B8  #XO   ^.@  /D8  #Y4   ^9   /G<  #Z/   ]IP  /<,
M #SI   \_0  ._\ 7C   % Q  !$,@  .S(  #0Q   N,   *2\  "0P   >
M,@  &30  !0V   0.0  #3L   H]   %0 4  $$*  !"#0  0Q   $04  !%
M&@  1B(  $8K  !&-0  1D$  $9/  !&7P  1G,  $6*  !%I   1,   $/H
M  !#_@  0O\ 6#0  $LU  !!-0  .34  #(T   M,P  )C0  " U   :.
M%#H  ! ]   -0   "4(   1%    1P,  $@'  !*"P  2PX  $P1  !.%0
M3QP  $\E  !/+P  3SP  $]*  !/6@  3FT  $Z%  !-H   3+P  $OG  !+
M_@  2O\ 4SD  $<Y   ^.0  -S@  #$W   I-P  (3D  !L\   5/P  $$(
M  Q%   '2    DH   !-    3P   %$$  !2!P  5 L  %4.  !7$0  61<
M %H?  !9*0  638  %E$  !95   6&<  %A_  !7F@  5K<  %7C  !4_0
M5/\ 3CT  $,]   \/   -3L  "P\   D/@  '$$  !5$   02   "TL   5.
M    40   %0   !7    60   %L   != @  7@8  & +  !B#@  9!(  &<8
M  !G(@  9BX  &8\  !F30  96   &5W  !DDP  8[$  &'=  !@_   7_\
M24(  $%!   Z/P  ,$   "9#   >1@  %4H  !!.   *4@   U8   !:
M70   &    !C    90   &<   !I    :P$  &T%  !O"@  <@X  '42  !W
M&P  =B8  '8U  !U1@  =%D  '1O  !SBP  <JD  '#-  !O]P  ;O\ 1D8
M $!%   U1@  *D@  "!,   740  $%8   E:   !7P   &,   !H    :P
M &\   !R    =0   '<   !Y    >P   'T   "  P  @P@  (8-  ")$P
MBAT  (HK  ")/   B$\  (9F  "%@0  A*   (+"  "!\   ?_\ 1DL  #I,
M   N3P  (U,  !A8   07@  "60   !I    ;P   '0   !X    ?    ($
M  "$    AP   (@   "+    C@   )    "3    E@   )D'  "=#0  H10
M * A  "@,0  GD0  )U;  "<=@  F98  )FU  "6Y0  E?X /U(  #)5   F
M6@  &V   !%G   );0   '0   ![    @0   (8   "+    D    )0   "7
M    F0   )P   "?    H0   *0   "G    J@   *T   "Q!@  M0T  +@6
M  "W)@  MCD  +50  "T:@  LHD  +"J  "NSP  K?4 -UP  "MA   >:
M$W    MX    @    (<   ".    E0   )H   "?    I    *@   "L
MK0   +    "S    M0   +@   "[    OP   ,,   #'    RP4  -$.  #1
M&P  T"X  ,]%  #-7P  RWX  ,F>  #(O@  Q>D +VD  "-P   6>0  #8$
M  &+    DP   )L   "B    J    *X   "T    N    +T   #     P@
M ,4   #(    RP   ,X   #1    U@   -L   #?    Y    .@&  #K$0
MZB,  .HZ  #I5   YW(  .63  #CLP  X]0 _P   /\   #_    _P $ /\
M"P#_ !  _P 7 /\ (0#_ "L _P U /\ /@#_ $< _P!. /\ 50#\ %L ^@!A
M /@ 9@#V &T ] !S /( >P#O (0 [0". .H F0#F *< XP"Y -\ U0#; /<
MU@#_ ,  _P"R /\ J@#_ *4 _P"B /\ _P   /\   #^    _    /P  P#^
M  L _P 1 /\ &@#] "0 ^0 N /0 . #P $  [ !( .D 3@#F %0 X@!: -\
M7P#< &4 V !K -0 <@#0 'L S0"% ,H D0#' )X PP"N ,  Q0"] .L NP#_
M +  _P"D /\ G #_ )@ _P"5 /\ _P   /H   #T    \0   /(   #J  4
MYP . .( %0#A !X X0 H -@ ,0#0 #D RP!  ,@ 1P#% $T P@!3 +\ 6 "]
M %X NP!D +D :P"V ', M !\ +$ B "N )4 JP"D *@ N "F -P HP#[ )\
M_P"5 /\ CP#_ (L _P") /\ ^0   .\   #G    WP   ,\   #(    P0 *
M +\ $0"\ !@ NP A +D *@"T #( L0 Z *X 0 "K $8 J !, *8 40"C %8
MH0!< )\ 8P"= &H FP!S )D ?@"6 (P E "; )( K0"0 ,< C@#P (T _P"&
M /\ @ #_ 'T _P!\ /\ [0   .    #1    OP   +,   "J    I@ % *(
M#0"A !, H  ; )\ (P"; "L F  R )4 .0"3 #\ D0!$ (\ 2@". $\ C !5
M (H 6P"( &, A@!K (0 =@"" (( @ "2 'X HP!\ +H >@#A 'D _P!W /\
M<@#_ '  _P!O /\ W0   ,L   "V    IP   )T   "4    C@ ! (L "@")
M !  B  5 (< '0"' "4 A  L (( ,@!_ #@ ?0 ] 'L 0P!Y $@ > !. '8
M5 !U %L <P!C '$ ;@!O 'H ;0") &P F@!J *X :0#, &@ ]@!G /\ 90#_
M &0 _P!C /\ R@   +0   "A    DP   (D   ""    >P   '@ !0!V  P
M=0 1 '0 & !S !\ <@ E '  + !N #( ;  W &H / !I $( : !( &8 3@!E
M %4 8P!= &( 9@!@ '( 7@"  %T D@!; *4 6@"^ %D Z0!9 /\ 60#_ %@
M_P!8 /\ N0   *(   "0    @P   'D   !Q    ;0   &D  0!F  D 90 .
M &0 $P!C !D 8P @ &$ )@!@ "P 7@ Q %P -P!; #P 6@!" %@ 2 !7 $\
M5@!7 %0 8 !3 &P 40!Y %  B@!/ )X 3@"T $T V@!- /L 30#_ $T _P!-
M /\ J@   )0   ""    =0   &L   !D    8    %T   !:  4 6  , %<
M$ !6 !4 5@ ; %4 (0!3 "< 4@ L %$ ,0!/ #< 3@ ] $T 0P!, $H 2@!2
M $D 6P!( &8 1@!S $4 A !$ )< 0P"L $( R0!" /$ 0@#_ $, _P!# /\
MG@   (D   !X P  :@0  &$$  !: P  50$  %(   !0  ( 3@ ) $T #0!,
M !$ 2P 7 $H ' !) "( 2  G $< +0!% #( 1  X $, /@!" $4 00!- #\
M5@ ^ &$ /0!N #L ?@ Z )$ .0"F #@ OP X .@ . #_ #D _P Y /\ E0,
M ( '  !O"0  8@H  %@+  !1"@  3 @  $D&  !' P  1@ & $0 "P!#  \
M0@ 3 $$ & !! !X /P C #X *0 ] "X .P T #H .@ Y $$ . !) #< 4@ V
M %T - !J #, >@ R (P ,0"A #  N  O -X +P#Y "\ _P P /\ C D  '@,
M  !H#0  7 X  %(.  !+#@  10T  $$,   _"@  /@@" #T$"  \ 0T .P 0
M #H %0 Y !H .  @ #8 )0 U "L -  P #, -P R #X ,0!& "\ 4  N %H
M+0!G "L =P J (D *0"= "@ LP G -$ )P#R "< _P G /\ A@P  '(.  !C
M$   5A$  $T1  !%$0  0!   #P/   Y#@  -PT  #8+!  V" H -08. #0%
M$@ R!!< ,04< # %(@ O!2@ +@8N "T&-  K!CP *@9$ "D'3@ G!UD )@=E
M "0'=0 C!X< (@>; " &L  @!LL 'P7M !\&_@ ?!_\ @ X  &T1  !>$@
M4A,  $@3  !!$P  .Q,  #<2   T$0  ,A   # / 0 P#08 , L+ "\*$  M
M"A0 + L9 "H+'P I"R4 * PK "<,,@ F##H ) Q# ",,30 A#5@ ( UE !X-
M=0 <#8@ &@V< !D-L0 8#,H %PSK !<-_  8#/\ >Q$  &D3  !:%0  3A8
M $46   ]%@  .!4  #,5   P%   +1,  "L2   J$ , *@\( "D.#0 H#A$
M)@X6 "4/'0 D#R, (P\I "$0,0 @$#D 'A!" !T03  ;$%@ &1!F !<0=@ 5
M$(D %!"> !(0LP 1$,X $1#N !(0_@ 2$/\ =Q,  &45  !7%P  2Q@  $(9
M   Z&0  -!@  # 7   L%P  *18  "<5   F% $ )1($ ",2"P B$@\ (1(4
M " 2&@ >$R  '1,G !P3+@ :$S8 &11  !<42@ 6%%8 %!1D !(4=  1%(<
M$!2<  X4L0 -%,H #13K  X3_@ .$_\ <Q4  &$8  !3&@  2!L  #\;   W
M&P  ,AH  "T:   I&0  )A@  "08   B%P  (!8! !X6"  =%@T &Q<2 !H7
M%P 9%QT &!@D !88*P 5&#0 %!@] !(92  1&50 $!EB  X9<@ -&80 #!F8
M  H9K0 )&,8 "1CG  D8^@ *%_\ ;Q@  %X:  !0'   11T  #P=   U'0
M+QT  "H<   F&P  (QL  "$:   >&@  '!H  !H;!0 8&PP %AP0 !4<%0 4
M'!L $QPB !(=*0 1'3$ $!T[  X=10 -'E$ #!Y>  H>;0 )'H  !QZ4  4=
MJ@ #'<(  QWF  0<^  %'/\ :QH  %L=  !-'@  0A\  #H?   R'P  +1\
M "@>   D'@  (1T  !X=   <'0  &!X  !4? @ 3( D $B$. ! A$@ 0(1@
M#B$?  XB)@ -(BX #"(W  HB00 )(DT !R):  4B:0 #(GP  2*1   BJ
M(<   "'E   @^   (/\ 9QT  %<?  !*(0  0"$  #<B   P(0  *B$  "8@
M   B(   'Q\  !P?   9(   %B$  !(C @ 0) < #B8,  PF$  +)A4 "B8<
M  DF(@ ()BH !B<S  0G/0 #)TD  2=6   G9@  )WD  ">/   FI@  )K\
M "7D   E^0  )/\ 8R   %0B  !'(P  /20  #0D   N(P  *",  "0B   A
M(@  'B$  !HB   7(P  $R0  ! F @ .* < "RH+  @K#@ &*Q, !"L8  (K
M'P !+"<  "PP   L.@  +$4  "Q3   L8P  +'8  "R,   KI   *[X  "KD
M   J^@  *?\ 7R,  % E  !$)@  .B8  #(F   K)@  )B4  ",D   ?)
M&R0  !<E   4)P  $2D   XK @ ++08 !R\+  0P#@  ,!$  #$5   Q'
M,2,  #(L   R-@  ,D(  #)/   R7P  ,G(  #&)   QH@  ,+P  ##D   O
M^P  +_\ 6B<  $PH  ! *0  -RD  "\I   I*   )2<  "$F   <)P  &"@
M !0J   1+   #BX   LP 0 ',@4  S0)   U#   -@\  #<2   X&   ."
M #@H   X,@  .3T  #E+   Y6P  .&X  #B%   WGP  -[H  #;D   U_
M-?\ 52H  $@L   ]+   -"P  "TK   H*@  )"D  !XJ   9*P  %"T  !$O
M   -,0  "C0   <V   ". 0  #H'   ["@  /0T  #X0  ! %   0!L  $ D
M  ! +@  0#D  $!'  ! 5@  0&D  $"    _FP  /K<  #WC   \_   //\
M4"\  $,O   Y+P  ,B\  "PM   G+   ("T  !HO   5,0  $3,   TV   )
M.   !3L    ]    0 $  $$$  !#!P  10L  $8.  !($0  2A8  $H>  !*
M*   2C0  $E"  !)40  260  $A[  !(EP  1[0  $;@  !%_   1/\ 2C,
M #\S   V,P  ,#$  "HP   C,0  '#,  !8U   1.   #3L   @^   #00
M $,   !&    2    $H   !,!   3@<  $\+  !1#@  5!(  %49  !5(@
M5"X  %0\  !42P  4UX  %-T  !2D   4:X  %#7  !/^P  3O\ 13<  #PW
M   U-@  +S0  "8U   >-P  %SH  !$]   ,00  !T0   !(    2@   $T
M  !0    4P   %4   !7    6 (  %L&  !="P  7PX  &(3  !B&P  8B<
M &(T  !A10  8%<  &!M  !?B0  7:<  %S,  !:^   6?\ 03P  #H[   T
M.0  *CH  "$\   80   $4,   Q'   &2P   $\   !3    5@   %D   !<
M    7P   &$   !C    90   &<!  !J!0  ;0H  ' .  !S%0  <B   '(M
M  !Q/0  <$\  &]E  !N@   ;9\  &O!  !I\0  :/\ /T   #D^   N/P
M)$(  !I&   22@  #$\   14    6    %T   !A    90   &@   !K
M;@   '$   !S    =0   '@   ![    ?@,  ($*  "%#P  AQ<  (8D  "%
M-   A$8  ()=  "!=@  ?Y8  'ZV  !\YP  >O\ /T0  #-%   H2   '4P
M !-2   ,5P   UT   !C    :    &T   !Q    =@   'H   !^    @0
M (,   "&    B0   (L   ".    D@   )4!  "9"0  GA   )X:  "=*0
MG#P  )I2  "8;   EHL  )2J  "2U   D/H .$L  "Q.   @4P  %5D   U@
M   #9P   &X   !T    >@   (    "$    B@   (X   "2    E0   )<
M  ":    G0   *    "C    IP   *L   "O    M D  +@0  "W'@  M3
M +-&  "Q8   KWX  *R@  "KP0  J>X ,54  "1;   880  #FD   5Q
M>0   ($   "(    CP   )0   ":    GP   *0   "H    J0   *P   "O
M    LP   +4   "Y    O0   ,$   #&    RP   -$*  #3%   T24  - [
M  #-5   RG$  ,B2  #%LP  P]X *6(  !QI   1<0  !WL   "$    C0
M )4   "=    HP   *D   "O    M    +D   "\    O@   ,(   #%
MR    ,P   #0    U    -H   #?    Y    .H   #N#   [1H  .PO  #J
M20  Z&4  .:&  #DI0  XL8 _P   /\   #_    _  ! /P " #^  X _P 4
M /\ '0#_ "8 _P P /\ .@#_ $( _P!) /X 4 #[ %8 ^0!< /8 8@#T &@
M\@!O /  =@#M '\ Z@") .< E0#D *, X "U -L T #5 /8 R@#_ +8 _P"H
M /\ GP#_ )H _P"6 /\ _P   /L   #V    \P   /,   #V  D ^@ . /T
M%@#[ "  ]P J /( ,P#M #L Z0!# .8 20#B $\ W@!5 -L 6P#6 &  T@!G
M ,\ ;@#, '8 R0"  ,8 C #" )H OP"J +L P0"X .D M@#_ *< _P": /\
MD@#_ (T _P"* /\ ^@   /$   #J    YP   .<   #D  $ X  + -L $0#:
M !H VP C -$ + #* #0 Q@ [ ,( 0@"_ $@ O !. +H 4P"X %D M@!? +,
M9@"Q &X K@!W *P @P"I )$ I@"A *, M0"@ -@ G@#[ )4 _P"+ /\ A0#_
M (  _P!^ /\ [P   .,   #:    TP   ,8   "_    N0 & +< #@"T !0
MM  = +, )0"N "T JP T *< .P"D $$ H0!& )\ 3 "= %$ FP!7 )D 7@"7
M &4 E0!N ), >0"0 (< C@"7 (P J0") ,0 B #O (4 _P!\ /\ =@#_ ',
M_P!R /\ X    -    #&    M@   *D   "A    G0 ! )D "@"8 !  F  6
M )< '@"4 "8 D0 M (\ - ", #H B@ _ (@ 10"' $H A0!0 (, 5@"! %X
M@ !F 'X <0!\ 'T >0"- '< H !U +8 <P#? '( _P!N /\ :0#_ &< _P!E
M /\ S    +X   "K    G0   ),   "*    A0   (( !0"   T ?P 1 '\
M& "  "  ?0 F 'H +0!W #, =0 X '0 /@!R $, < !) &\ 3P!M %8 ; !>
M &H : !H '4 9P"$ &4 E@!D *L 8@#) &$ ]@!@ /\ 7 #_ %L _P!: /\
MO0   *D   "7    B0   'X   !X    <P   &\  0!M  D ;  . &L $P!K
M !D :@ @ &@ )@!F "P 90 R &, -P!B #P 8 !" %\ 2 != $\ 7 !7 %H
M80!9 &T 5P![ %8 C@!5 *( 4P"[ %( Z0!2 /\ 4 #_ $\ _P!/ /\ K0
M )@   "&    >    &X   !G    8P   &    !=  4 7  + %L $ !; !4
M6P ; %H (0!8 "8 5@ L %0 ,0!3 #8 4@ \ %$ 0@!/ $D 3@!1 $T 6P!+
M &8 2@!T $D A0!( )D 1P"Q $8 V !& /P 10#_ $4 _P!% /\ GP   (D
M  !X    ;    &(   !;    5@   %,   !1  ( 3P ( $\ #0!. !$ 3@ 6
M $T ' !, "$ 2@ F $D + !( #$ 1P W $4 /0!$ $0 0P!, $( 50!  &
M/P!N #X ?@ ] )( / "I #L QP [ /, .P#_ #L _P \ /\ DP   'X   !N
M    80   %@   !1    3    $D   !'    10 % $0 "P!#  X 0P 2 $,
M%P!" !T 0  B #\ )P ^ "P /0 R #L .  Z #\ .0!' #@ 4  W %L -0!H
M #0 >  S (P ,@"B #$ O  Q .< ,0#_ #( _P S /\ B0   '8#  !F!0
M60<  % '  !)!@  0P4  $ #   ^ 0  /  # #L "  Z  T .@ 0 #D %  Y
M !D -P > #8 (P U "@ -  N #, -  R #L , !# "\ 3  N %< +0!D "P
M<P K (< *@"< "D M0 I -P *0#[ "D _P J /\ @00  &X(  !?"@  4PL
M $H+  !""P  /0H  #D)   V"   -04  #0"!@ S  H ,@ . #$ $0 Q !4
M,  : "\ 'P N "0 +  J "L ,  J #< *0 _ "@ 20 G %0 )@!@ "0 ;P C
M (( (@"7 "$ K@ A ,P (0#S "$ _P B /\ >PD  &@,  !:#0  3@X  $4.
M   ]#@  . T  #,-   P#   +@L  "T) P M!@@ + 0, "L"#P J 1( *0$7
M "@!'  G "$ )@ G "4 +0 D #0 (P$] "(!1@ A 5$ 'P%= !X!;  < 7\
M&P"4 !H J@ : ,4 &@#K !D _P : /\ =0P  &0.  !5#P  2A   $ 0   Y
M$   ,Q   "\/   L#@  *0X  "<- 0 G# 4 )PH* "8(#0 E!Q  ) 84 "(&
M&0 A!A\ ( <D !\'*P >!S( '0<Z !P(1  :"$\ &0A< !<(:P 6"'T %0>1
M !0'IP 3!K\ $@7D !(%^@ 2!?\ <0X  %\0  !1$0  1A(  #T2   V$@
M,!(  "L1   H$0  )1   ",0   B#@0 (0T' "$,"P @"PX 'PL2 !T+%P <
M#!P &PPB !H,*0 9##$ & PY !8-0P 5#4\ $PU< !(-:P 0#7X #PV2  X-
MIP -#+X #0S@  T,]0 -#/\ ;1   %P1  !.$P  0Q0  #H4   R%   +10
M "@3   E$P  (A(  " 1   >$0, '! % !P/"  ;#PP &@X0 !D/%  7#QH
M%@\A !40*  4$#  $A Y !$01  0$%  #A!=  T0:P ,$'P "Q"0  D0I0 (
M$+P !Q#?  <0]  '#_\ :1$  %@4  !+%0  0!8  #<6   P%@  *A8  "85
M   B%0  'Q0  !T3   :$P( &1($ !<2!@ 6$@H %1(. !02$@ 2$A@ $1,>
M !$3)0 0$RX #A,W  T40  ,%$L "Q18  D49P '%'@ !A2-  04HP #$[L
M A/=  $2]  "$O\ 91,  %46  !(%P  /1@  #08   M&   *!@  ",7   @
M%P  '18  !H5   8%0( %A4$ !05!0 2%@@ $18- ! 7$  .%Q4 #A<;  T7
M(@ ,%RD "Q@R  D8/  '&$< !1A4  088P "&'4  1B+   7H0  %[D  !?=
M   6]0  %O\ 818  %(8  !%&@  .QH  #(:   K&@  )1H  "$9   >&
M&Q@  !@7   6%P( %!<# !(8!0 0&0< #AL+  P;#P +&Q, "AL8  @<'P '
M'"8 !1PO  0<.  "'$0  !U1   =8   '7(  !R(   <H   &[D  !O>   :
M]@  &O\ 7A@  $\:  !"'   .!P  "\=   I'   (QP  !\;   <&@  &1D
M !<9 0 4&0( $AH# ! ;!  .'0< #!X+  D?#@ &(!$ !2 6  ,@'  !(2,
M "$K   A-0  (4   "%.   A70  (6\  "&&   @G@  (+@  !_>   >^
M'O\ 6AL  $L=   _'@  -1\  "T?   G'@  (AT  !X=   ;'   &!L  !4;
M   2'   $!T"  X?!  ,(08 "2(*  4C#0 ")!   "43   E&0  )B   "8H
M   F,@  )CT  "9*   F6@  )FP  ":#   EG   );<  "3?   C^0  (_\
M51X  $<@   \(0  ,B$  "LA   E(   (!\  !T>   :'0  %AX  !,>   0
M(   #B$   PC @ ()04 !2<)   H"P  *@X  "L1   L%@  +!T  "PE   L
M+@  +#H  "Q'   L5@  +&D  "R    KF@  *K4  "G?   I^P  */\ 42(
M $0C   X)   +R0  "@C   C(@  'R$  !P@   7(   $R$  ! C   .)
M"R8   @H   $*@0  "P'   N"0  , P  #$/   S$P  ,QD  #,A   S*@
M,S4  #-#   S4@  ,V4  #)[   REP  ,;,  ##>   O^P  +O\ 3"4  #\F
M   U)P  +28  "<E   B)   'B,  !DC   4)   $28   XH   +*@  !RP
M  ,O    ,0(  #,$   U!P  -PH  #D-   Z$   .Q4  #L=   [)@  .S$
M #L^   [3@  .V   #IW   YD@  .+   #?;   V_   -?\ 1RD  #LJ   R
M*@  *RD  "4G   A)@  &R<  !4H   1*@  #BP   HO   &,0   30    V
M    .    #L!   ]!   /P<  $$*  !##@  11$  $48  !%(0  12P  $0Y
M  !$2   1%L  $-Q  !"C0  0:L  $#2   _^@  /O\ 0BT  #@N   O+0
M*2L  "0J   =*@  %RP  !$N   -,0  "30   0W    .@   #P    _
M00   $0   !&    2 ,  $H'  !,"P  3@X  % 3  !0'   4"<  $\T  !/
M0P  3U4  $YJ  !-A@  3*0  $K*  !)^   2/\ /C(  #4Q   N+P  *2X
M " N   9,0  $C,   XW   ).@   CT   !     1    $<   !)    3
M $\   !1    4P   %4!  !8!@  6@L  %T.  !?%0  7B   %XL  !=/
M7$X  %MC  !:?@  6)T  %?   !5\@  5/\ .C8  #,T   M,@  )#,  !LV
M   3.0  #CT   A!    10   $D   !,    4    %,   !6    60   %L
M  !=    8    &(   !E    : 4  &L+  !O$   ;Q@  &XE  !M-   ;48
M &M;  !J=0  :)0  &:V  !DZ0  8O\ .#D  #(W   H.0  'CL  !4_   .
M1   !TD   !-    4@   %8   !:    7@   &(   !E    :    &L   !M
M    <    ',   !V    >0   'T$  "!"P  A1$  (0=  ""+   @#X  'Y4
M  !^:P  >XH  'JJ  !WU@  =?T .#T  "P^   B00  %T8   ]+   '40
M %<   !<    8@   &8   !K    ;P   '0   !X    >P   'X   "
M@P   (8   "*    C0   )$   "6 P  FPP  )T3  ";(0  FC,  )=)  "4
M8@  DW\  )"@  ".Q0  C/, ,40  "5(   :30  $%,   A:    80   &@
M  !N    =    'D   !_    A    (D   "-    D0   ),   "6    F0
M )T   "@    I    *@   "L    L@,  +<-  "W%P  M2@  +(^  "P5@
MK',  *J4  "IM   I>4 *D\  !Y4   26P  "F(   !J    <P   'L   ""
M    B0   (X   "4    F@   )\   "D    I@   *D   "M    L    +,
M  "W    NP   ,    #%    RP   -$$  #5#@  TQT  - R  #-2P  RF8
M ,:'  #"J0  P<L (EL  !9B   ,:P   70   !]    AP   )    "7
MG@   *0   "K    L0   +8   "Z    O    ,    #$    R    ,L   #/
M    U    -H   #@    Y@   .L   #Q!@  \!,  .XG  #L/P  ZEL  .=Z
M  #DFP  X+L _P   /L   #V    \P   /0 !0#V  P ^@ 1 /\ &0#_ "(
M_P L /\ -0#_ #T _P!% /P 3 #Z %( ]P!8 /4 7@#S &0 \0!J .X <@#L
M 'H Z0"% .4 D0#A *  W0"R -@ S@#2 /8 P0#_ *T _P"> /\ E@#_ )
M_P", /\ ^@   /(   #L    Z0   .D   #L  4 \@ , /@ $@#W !L ]0 E
M /  +@#K #< Y@ ^ .( 10#= $L V !0 -, 5@#0 %P S0!B ,H :@#( '(
MQ0!\ ,( B "^ )8 N@"H +< OP"T .@ K@#_ )T _P"0 /\ B #_ (, _P"
M /\ \    .4   #>    V@   -L   #<    V  ' -$ #@#1 !4 T@ > ,L
M)P#% "\ P  W +T /0"Z $0 MP!) +4 3P"R %4 L !; *X 80"L &D J0!S
M *< ?P"D (T H0"> )X L@"; -4 F0#\ (P _P"" /\ >P#_ '8 _P!T /\
MX@   -,   #*    QP   +P   "V    L  ! *\ "P"L !$ K0 8 *T ( "H
M "@ I  O *  -@"= #P FP!" )D 1P"7 $T E0!3 ), 60"1 &$ CP!J (P
M=0"* (, B "4 (8 IP"# ,( @@#P 'P _P!S /\ ;0#_ &H _P!H /\ SP
M ,$   "Y    K0   *    "8    E    )$ !@"0  T D  2 (\ &0". "$
MBP H (@ +P"& #4 A  Z (( 0 "  $4 ?@!+ 'P 4@!Z %D > !B '8 ; !T
M 'D <@") '$ G0!O +0 ;0#? &P _P!E /\ 8 #_ %X _P!< /\ O@   +$
M  "@    D@   (D   ""    ?    'H  0!X  D =P . '@ % !W !H =  A
M '( )P!P "T ;@ S &P . !K #X :0!$ &@ 2@!F %$ 9 !: &, 9 !A '
M7P!_ %X DP!= *D 7 #( %L ]P!7 /\ 5 #_ %( _P!1 /\ L    )\   "-
M    ?P   '0   !N    :@   &8   !E  0 8P + &, $ !C !4 8P ; &$
M(0!? "< 70 L %P ,@!: #< 60 ] %< 0P!6 $L 50!3 %, 7 !2 &@ 4 !W
M $\ B0!. )\ 30"Z $P Z0!+ /\ 20#_ $< _P!' /\ H@   (T   !\
M;@   &4   !>    60   %<   !5  $ 5  ' %, #0!3 !$ 5  6 %( &P!1
M "$ 3P F $X *P!, #$ 2P W $H /0!) $0 1P!, $8 5@!$ &$ 0P!P $(
M@0!! )< 0 "O #\ UP _ /\ /@#_ #T _P ^ /\ E    '\   !O    8P
M %D   !1    30   $H   !(    1P $ $< "@!&  X 1@ 1 $< %@!% !P
M1  A $( )@!! "L 0  Q #X -P ] #X / !' #H 4  Y %L . !I #< >@ V
M (\ -0"G #4 Q@ T /4 - #_ #0 _P U /\ B    '0   !E    6    $\
M  !(    0P   #\    ]    /  " #P !P [  P .P / #L $@ Z !< .0 <
M #< (0 V "8 -0 L #0 ,@ S #D ,0!! #  2P O %8 +@!C "T <P L (@
M+ "@ "L NP K .H *P#_ "L _P L /\ ?P   &P   != 0  40(  $@#  !
M P  .P(  #<    T    ,P   #( !0 R  D ,@ - #$ $  Q !, ,  8 "\
M'0 M "( +  H "L +@ J #4 *0 ] "@ 1@ G %$ )@!> "4 ;@ D (( (P"9
M ", LP B -X (@#_ ", _P D /\ =P   &4$  !6!@  2P<  $((   Z"
M-0<  # &   M!0  + ,  "L  P J  < *0 + "D #@ I !$ *  5 "< &0 F
M !X )0 D "0 *@ C #$ (@ Y "$ 0P @ $X 'P!: !X :0 = 'P ' "3 !L
MK  ; ,T &P#V !L _P < /\ < 4  %\(  !1"@  1@L  #T+   U"P  , L
M "L*   H"0  )0@  "0' @ C! 8 (P() "(!#  B  \ (0 2 "  %@ ? !L
M'@ @ !T )@ < "X &P V !H /P 9 $H & !7 !< 9@ 6 '@ %0"/ !4 I@ 4
M ,, % #N !0 _P 5 /\ :P@  %L+  !-#   0@T  #D-   Q#0  + T  "<-
M   C#   (0P  !\+ 0 >"@4 '0@( !T&"P <!0T ' 00 !L$%  9!!@ &00>
M !@$(P 7!"L %@0S !4$/  4!$< $P-4 !(#8P 1 W4 $ ** ! !H@ / +P
M#P#E  \ _@ 0 /\ 9PL  %<-  !)#@  /@\  #4/   N#P  * \  "0.   @
M#@  '0X  !L- 0 9#00 & P' !@+"0 7"0P %PD. !8)$@ 5"18 % D; !,)
M(0 2"2@ $@DP !$).@ 0"44 #PE2  X)80 -"7, # B(  L(GP *![< "@;;
M  H%]@ *!/\ 8PT  %,.  !&$   .Q$  #(1   K$0  )1   "$0   =$
M&@\  !@/ 0 6#@0 %0X' !0-"0 3#0L $PP- !(,$  1#!0 $ P9 ! ,'P /
M#"< #@TO  T-.0 ,#44 "PU1  D-8  (#7$ !@V&  4-G0 $#+0  PS2  (,
M\0 ""_\ 7PX  % 0  !#$0  .!(  "\2   H$@  (Q(  !X1   ;$0  &!$
M !40 @ 4$ 4 $A ' !$/"0 0#PH $ X,  X.#@ .#Q( #0\7  P0'0 ,$"0
M"A L  D0-@ ($$$ !A!.  4070 #$&\  1"$   0G   #[0   [4   .\P
M#O\ 7!   $T2  ! $P  -A0  "T4   F%   (1,  !P3   9$@  %A(  !01
M P 2$08 $1$( ! 0"@ .$ L #1$+  P1#0 +$A$ "A(5  D2&@ ($B$ !A,I
M  43,P #$SX  A-+   36@  $VP  !."   2FP  $K0  !'7   1]0  $?\
M6!(  $D4   ]%0  ,Q8  "L6   D%0  'Q4  !H4   7%   %!,! !,2!  1
M$@< $!()  X2"0 -$@D "Q,*  D4#0 '%0\ !A83  06&  #%A\  A8G   7
M,   %SL  !=(   76   %VH  !:    6F0  %;0  !79   4]P  $_\ 510
M $86   Z%P  ,!@  "@8   B%P  '18  !D6   6%0  $Q0# !(3!@ 0$P<
M#Q,'  T4!P +%0@ "18)  88#  #&@X  1H1   :%@  &QP  !LD   ;+0
M&S@  !M&   <50  &V<  !M]   ;EP  &K,  !G;   8^0  %_\ 418  $,8
M   W&0  +AH  "8:   @&0  &Q@  !@7   5%@$ $Q4% !$5!  /%00 #18$
M  L7!0 )&08 !AH(  (<"@  '@T  " 0   @$P  (!D  " A   A*@  (34
M "%"   A4@  (&0  "!Z   ?E0  '[$  ![;   =^@  '/\ 31D  #\;   T
M'   *QP  "0<   >&P  &AH  !<8   4%P( $A<" ! 8 0 -&0$ "QH"  @<
M P %'00  A\&   A"   (PL  "4.   F$0  )A8  "8>   G)P  )S(  "<_
M   F3@  )F   "9W   ED@  )*\  "/:   B^P  (?\ 2!T  #P>   Q'P
M*!X  "(>   ='   &1L  !8:   2&@  $!L   T<   +'0  "!\   0A   !
M(P(  "4$   G!@  *0D  "P,   N#P  +A,  "X:   N(P  +BX  "X[   N
M2@  +5P  "UR   LC@  *ZP  "K4   I^P  */\ 1"   #@A   N(0  )B$
M " @   <'@  &!T  !0=   0'@  #A\   LA   '(P   R4    G    *0
M "P!   N P  , 8  #,*   U#0  -A$  #87   V'P  -BD  #8V   V10
M-5<  #5M   TB0  ,J@  #'/   P^@  +_\ /R0  #0D   K)   )",  !\A
M   ;(   %B   !$A   .(P  "B4   8H   "*@   "T    O    ,@   #0
M   W    .0,  #L&   ^"@  0 X  $$2  !!&@  0"4  $ Q  ! 0   /U(
M #YG   ]@@  /*(  #K'   Y^   ./\ .B@  # H   I)P  (R4  !\C   8
M)   $B4   XH   **@  !2T    P    ,P   #8    X    .P   #X   !
M    0@   $4"  !'!@  2@H  $T.  !-%0  3!\  $PK  !+.@  2DP  $EA
M  !(?   1YL  $6_  !#\P  0O\ -BP  "TK   G*0  (R<  !LH   4*@
M#BT   HP   $,P   #<    Z    /0   $    !#    1@   $@   !+
M30   %    !3 0  5@8  %D+  !;$   6QD  %HE  !9-   6$8  %=:  !5
M=   5),  %*U  !0Z@  3_\ ,S   "PN   G+   'BT  !8O   0,@  "C8
M  ,Z    /P   $(   !&    20   $P   !/    4@   %4   !8    6@
M %T   !@    8P   &<&  !K#   ;!(  &L>  !K+   :3T  &=2  !F:@
M9(D  &&K  !?W   7?\ ,3,  "PQ   B,@  &34  !$Y   */0   D(   !'
M    3    %    !4    6    %L   !?    8@   &4   !H    :P   &X
M  !Q    =0   'D   !]!@  @@T  ((6  " )   ?C4  'Q)  ![80  >'\
M ':?  !SQ@  </< ,38  "8X   <.P  $D    M%   "2P   %$   !6
M6P   &    !E    :0   &X   !R    =@   'D   !\    ?@   ((   "%
M    B0   (X   "3    F 8  )P.  ";&@  F"L  )9   "260  D7,  (V5
M  "+M0  B.@ *SX  "!!   51P  #4T   )4    6P   &$   !H    ;@
M ',   !Y    ?@   (,   "(    C    (\   "2    E0   )D   "=
MH0   *4   "J    L    +<'  "X$0  M2$  +(U  "O30  JFD  *B(  "F
MJ   HM$ (T@  !A.   .5   !%P   !D    ;0   '4   !\    @P   (D
M  "/    E0   )L   "@    HP   *8   "I    K0   +$   "U    N0
M +X   #$    R@   -(   #:"@  UA8  -(I  #.00  REP  ,5\  #"G0
MP;T '%4  !%<   '90   &X   !W    ?P   (@   "0    F    )\   "E
M    K0   +,   "X    N@   +X   #"    Q@   ,H   #.    TP   -H
M  #@    YP   .T   #S    ] X  /(>  #O-@  [%$  .AN  #DD   W[$
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M_________________________________________P
M   ! P0%!@@)"@L-#@\1$A,4%A<8&AL<'1\@(2(D)28H*2HK+2XO,#(S-#8W
M.#D[/#T^0$%"1$5&1TE*2TU.3U!24U155UA96UQ=7F!A8F-E9F=I:FML;F]P
M<7-T=7=X>7I\?7Z @8*#A8:'B(J+C(Z/D)&3E)66F)F:G)V>GZ&BHZ2FIZBJ
MJZRMK["QL[2UMKBYNKN]OK_!PL/$QL?(R<O,S<_0T=+4U=;7V=K;W=[?X.+C
MY.;GZ.GK[.WN\/'R]/7V]_GZ^_S^________________________________
M______________________\                      0,$!08("0H+#0X/
M$1(3%!87&!H;'!T?("$B)"4F*"DJ*RTN+S R,S0V-S@Y.SP]/D!!0D1%1D=)
M2DM-3D]04E-455=865M<75Y@86)C969G:6IK;&YO<'%S='5W>'EZ?'U^@(&"
M@X6&AXB*BXR.CY"1DY25EIB9FIR=GI^AHJ.DIJ>HJJNLK:^PL;.TM;:XN;J[
MO;Z_P<+#Q,;'R,G+S,W/T-'2U-76U]G:V]W>W^#BX^3FY^CIZ^SM[O#Q\O3U
M]O?Y^OO\_O__________________________________________________
M____  $" P0%!@<("0H+# T.#Q 1$A,4%187&!D:&QP='A\@(2(C)"4F)R@I
M*BLL+2XO,#$R,S0U-C<X.3H[/#T^/T!!0D-$149'2$E*2TQ-3D]045)35%56
M5UA96EM<75Y?8&%B8V1E9F=H:6IK;&UN;W!Q<G-T=79W>'EZ>WQ]?G^ @8*#
MA(6&AXB)BHN,C8Z/D)&2DY25EI>8F9J;G)V>GZ"AHJ.DI::GJ*FJJZRMKJ^P
ML;*SM+6VM[BYNKN\O;Z_P,'"P\3%QL?(R<K+S,W.S]#1TM/4U=;7V-G:V]S=
MWM_@X>+CY.7FY^CIZNOL[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$      P0A
M   !                     0                    $    ! @,$!08'
M" D*"PP-#@\0$1(3%!46%Q@9&AL<'1X?("$B(R0E)B<H*2HK+"TN+S Q,C,T
M-38W.#DZ.SP]/C] 04)#1$5&1TA)2DM,34Y/4%%24U155E=865I;7%U>7V!A
M8F-D969G:&EJ:VQM;F]P<7)S='5V=WAY>GM\?7Y_@(&"@X2%AH>(B8J+C(V.
MCY"1DI.4E9:7F)F:FYR=GI^@H:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[
MO+V^O\#!PL/$Q<;'R,G*R\S-SL_0T=+3U-76U]C9VMO<W=[?X.'BX^3EYN?H
MZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O\  0$" @,#! 0%!@8'!P@("0D*"PL,
M# T-#@\/$! 1$1(3$Q04%186%Q<8&1D:&AL<'!T>'A\@("$B(B,D)"4F)B<H
M*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C] 0D-$149(24I,34]04E-55UA:
M7%Y@8F1F:&IM;W%T=GE\?H&#AHF+CI"2E9>9FYV?H:.EIZBJK*VOL+*SM;:W
MN;J[O+V_P,'"P\3%QL?(R<K+S,W-SL_0T=+2T]35UM;7V-G9VMO;W-W=WM_?
MX.'AXN/CY.7EYN;GZ.CIZ>KKZ^SL[>[N[^_P\/'R\O/S]/3U]O;W]_CX^?GZ
M^_O\_/W]_O[_  $! @(# P0$!08&!P<(" D)"@L+# P-#0X/#Q 0$1$2$Q,4
M%!46%A<7&!D9&AH;'!P='AX?(" A(B(C)"0E)B8G*"DI*BLL+2TN+S Q,C(S
M-#4V-S@Y.CL\/3X_0$)#1$5&2$E*3$U/4%)355=86EQ>8&)D9FAJ;6]Q='9Y
M?'Z!@X:)BXZ0DI67F9N=GZ&CI:>HJJRMK["RL[6VM[FZN[R]O\#!PL/$Q<;'
MR,G*R\S-S<[/T-'2TM/4U=;6U]C9V=K;V]S=W=[?W^#AX>+CX^3EY>;FY^CH
MZ>GJZ^OL[.WN[N_O\/#Q\O+S\_3T]?;V]_?X^/GY^OO[_/S]_?[^__^E)0;_
MI# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF
M><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# .
M_Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*W
MH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z
M&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+
ML9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q
M0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"
MTZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_
MNTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:
MB=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR
M_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=RE
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%5
M1?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#
M7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKR
MQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5P
MY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)L
MAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z
M<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,
MLG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2J
MPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E
M)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMV
MM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_
MI# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF
M><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# .
M_Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*W
MH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^F)0;_I# ._Z<Z
M&/^R0R+_O$LR_\-41?S&75KQR&1QX\9JA]; ;YO+N'*LPK%TNKNM=\2TJ7O-
MJZ-_U**>A=N9FH[AF9J.X9F:CN&9FH[AF9J.X9F:CN&9FH[AF9J.X9F:CN&9
MFH[AF9J.X9F:CN&9FH[AF9J.X9F:CN&9FH[AF9J.X?^F)0;_I3 ._Z@Z%_^S
M0R+_ODLQ_\541?G)7%OOS6-QX\QIB-7&;9S)OW"NO;9RNK2P=<.KJGC*HJ5\
MT9FA@=B0G8G=D)V)W9"=B=V0G8G=D)V)W9"=B=V0G8G=D)V)W9"=B=V0G8G=
MD)V)W9"=B=V0G8G=D)V)W9"=B=V0G8G=D)V)W?^F)0;_I3 ._ZHZ%_^U0R+_
MP$LQ_<A31?;-6UOMT6%RX=!GB='+:YW"P&ZMMK=QN*RQ<\&CK';(FJAYSI*D
M?M2)H(78B:"%V(F@A=B)H(78B:"%V(F@A=B)H(78B:"%V(F@A=B)H(78B:"%
MV(F@A=B)H(78B:"%V(F@A=B)H(78B:"%V/^G)0;_I3 ._ZLZ%_^V0R'_P4LQ
M^LM21//16EKJV6!RWM9EB<O,:IR[P6VKK[EPMJ6T<KZ<KW3$E*MWRHNG>\^$
MI('4A*2!U(2D@=2$I('4A*2!U(2D@=2$I('4A*2!U(2D@=2$I('4A*2!U(2D
M@=2$I('4A*2!U(2D@=2$I('4A*2!U/^G)0;_IC ._ZTZ%O^X0B'^Q$HP]\Y2
M1/#66%KGX%YRUMIDB,3-:9JTPVRHJ+MOLIZV<+J6LG+ CJYVQH:J>LI_IW_.
M?Z=_SG^G?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_SG^G?\Y_
MIW_.?Z=_SG^G?\Y_IW_.?Z=_SO^H)0;_IS ._ZXY%O^Z0B#[QDHO]--10^O=
M5UKCYEQQSMMDA[W/:9BNQ6NEHKYNKYBY;[:0M7&\B+%TP8&N>,5[K'W)>ZQ]
MR7NL?<E[K'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<E[K'W)
M>ZQ]R7NL?<E[K'W)>ZQ]R?^H) ;_IS -_[ Y%?^]0A_WR4HO[]A00N;C55G<
MZ%MPQMUCA;;1:)6GR&NAG,%MJI.\;[&*N7&VA+5TNWVR=[]WL'S"=[!\PG>P
M?,)WL'S"=[!\PG>P?,)WL'S"=[!\PG>P?,)WL'S"=[!\PG>P?,)WL'S"=[!\
MPG>P?,)WL'S"=[!\PO^I) 7_J# -_[,Y%/[ 0A[SS4HMZ=U/0.'I4UG3ZEMO
MO]]C@J_39Y&ARVJ=EL5MI8W ;ZN&O7&P?[ISM7JW=[ATM7N[=+5[NW2U>[MT
MM7N[=+5[NW2U>[MTM7N[=+5[NW2U>[MTM7N[=+5[NW2U>[MTM7N[=+5[NW2U
M>[MTM7N[=+5[N_^J) 7_J2\-_[8X$_G$01WMTDDKXN--0-OO4EC*[5IMM^%B
M?ZC69XV;SVJ7D<EMGXC%;Z6"PG&I>[]TK7:]=[!QNWNS<;M[LW&[>[-QNWNS
M<;M[LW&[>[-QNWNS<;M[LW&[>[-QNWNS<;M[LW&[>[-QNWNS<;M[LW&[>[-Q
MNWNS<;M[L_^K) 7_JR\-_[HX$O/)01ODVDDHV.A,0,[S45? [UEKKN1A>J#<
M9X:4U&N0B\]NEX3,<)Q]R7.@>,9UHW/$>*9NPGRI;L)\J6["?*ENPGRI;L)\
MJ6["?*ENPGRI;L)\J6["?*ENPGRI;L)\J6["?*ENPGRI;L)\J6["?*ENPGRI
M;L)\J?^M) 7_L"\+^\ X#^K001?:XD8HS.Y,0</Y4%6U\UAFI>EA=)?A9WZ-
MVVN&A==OC'_4<I%ZT764=<]XEW'->YILS'Z<;,Q^G&S,?IQLS'Z<;,Q^G&S,
M?IQLS'Z<;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<;,Q^
MG/^O(P3_MBT)\<@V#-W</1/-ZD8JP?9+0+;_3U&J]UA@F^]A:X_H:'2%Y&U[
M?^!Q@'G>=(-UW'B&<MI[B6[8?HMKUH*-:]:"C6O6@HUKUH*-:]:"C6O6@HUK
MUH*-:]:"C6O6@HUKUH*-:]:"C6O6@HUKUH*-:]:"C6O6@HUKUH*-:]:"C?^Q
M(P3ZORP&X]0O!\[F.Q;!\T4KM/])/:C_3DR>_5=8D?9A88;Q:6E_[6]N>>IT
M<G7H=W5QYWIW;N5]>6OD@'MIXX1\:>.$?&GCA'QIXX1\:>.$?&GCA'QIXX1\
M:>.$?&GCA'QIXX1\:>.$?&GCA'QIXX1\:>.$?&GCA'QIXX1\:>.$?/^U(@/K
MRR("T.,G!\+Q.AFT_D(JIO]&.9O_3462_U9/AOYB5G[Z:EQW]W!@<_5U8V_S
M>&5M\GQG:O%_:&CP@FIF[X5K9N^%:V;OA6MF[X5K9N^%:V;OA6MF[X5K9N^%
M:V;OA6MF[X5K9N^%:V;OA6MF[X5K9N^%:V;OA6MF[X5K9N^%:_;"&P'4WQ$!
MPN\F"[7\.AJG_SXGF?]$,XW_2SV%_U5%?/]A2W7_:D]P_W!2;/]U5&K^>59H
M_7Q79OQ_6&3\@EIC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[
MAEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6]3/"@#$[1("M?LF
M#:C_-AF9_SLCC/]!+(#_2C1X_U,Z<?]?/VS_:4-H_V]%9?]T1V/_=TAB_WM)
M8?]^2E__@4I>_X1+7O^$2U[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$2U[_A$M>
M_X1+7O^$2U[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$2_^?(@7_G2T,_YXX%?^H
M01[_L4DK_[93//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,
MO[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_
ML4DK_[93//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#
MD<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK
M_[93//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W
M?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93
M//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+
MM'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X
M74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@
MSZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[
MMF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C
M[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C[K1O
M=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C[K1O=^*L
M=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C[K1O=^*L=8G8
MI'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C[K1O=^*L=8G8I'N9
MSIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?
M(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_
MILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_
MG2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3
MA+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,
M_Y\X%?^J0![_LTDK_[E2//^[7$_ZNF5D[;AM>.&P<XO5J'F<S)]]JL67@;6_
MD86^NHR)Q;:'C\RR@Y;2KX&@UJ=^HM.G?J+3IWZBTZ=^HM.G?J+3IWZBTZ=^
MHM.G?J+3IWZBTZ=^HM.G?J+3IWZBTZ=^HM.G?J+3IWZBT_^?(@7_GBT,_Z W
M%/^K0![_M$DK_[M2//^]6U#ZOF1D[+QL>>"U<HW3K7>>RJ1ZK<*<?KF\EH+#
MMY"'RK*+C-*NAY78IH.=VJ&"H=6A@J'5H8*AU:&"H=6A@J'5H8*AU:&"H=6A
M@J'5H8*AU:&"H=6A@J'5H8*AU:&"H=6A@J'5H8*AU?^@(@7_GBT,_Z$W%/^L
M0!W_MD@K_[U1//_ 6E#ZP6-E[,%J>MZY<(_2L76AR*AXL,"A>[RYFW_'M):$
MS["4C=6KD9?:H(F<W)J(H->:B*#7FHB@UYJ(H->:B*#7FHB@UYJ(H->:B*#7
MFHB@UYJ(H->:B*#7FHB@UYJ(H->:B*#7FHB@U_^@(@7_GBT,_Z(W%/^M0!W_
MMT@J_[]1//_"6E#YQ&)EZ\5I>]Z^;I#1MG.CQJYVL[ZG><"XHW_)M*&&SZR<
MC=6CEI3:FI&<W)6.G]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5CI_8E8Z?
MV)6.G]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V/^@(@7_GRT,_Z,W%/^N0!W_N$@J
M_\%0//[%65#WR&!FZ\IG?-W#;9'/O'&EQ;1TM;VP><"VK'_(KJ>%SZ6ABM6<
MG)':E9F<W(^4G]B/E)_8CY2?V(^4G]B/E)_8CY2?V(^4G]B/E)_8CY2?V(^4
MG]B/E)_8CY2?V(^4G]B/E)_8CY2?V/^A(@7_GRT,_Z0W%/^P/QS_ND@J_\-0
M._O(6%#URU]FZ<]F?-S):Y+.PV^FP;IRM;:R=L"LK'O(I*A_SIRDA=24H(W8
MC9^9VXJ<G]B*G)_8BIR?V(J<G]B*G)_8BIR?V(J<G]B*G)_8BIR?V(J<G]B*
MG)_8BIR?V(J<G]B*G)_8BIR?V/^A(@7_H"T,_Z8V$_^Q/QS_NT@I_L9/._C+
M5U#RT%YFY]1D?=K/:9/(Q6VFNKMPM*VS<[^CK7;'FJAZS9*E?]**HH;7A*"1
MV82BG->$HIS7A**<UX2BG->$HIS7A**<UX2BG->$HIS7A**<UX2BG->$HIS7
MA**<UX2BG->$HIS7A**<U_^A(@7_H"T,_Z<V$_^S/QS_O4<I_,A.._7.5D_N
MU5UFY-IB?=/2:)+!QFRDL[QOL::U<KR<KW3$DZMWRHNG>\^#I('4?:*+UGNC
ME=5[HY75>Z.5U7NCE=5[HY75>Z.5U7NCE=5[HY75>Z.5U7NCE=5[HY75>Z.5
MU7NCE=5[HY75>Z.5U?^B(07_H"T,_Z@V$O^T/QO_OT<H^<M..O+354_JW%MF
MX.!A?<S39Y&[R&NBK+YNKZ"W<+B5LG/ C:YVQ86J>LI^J'_.>*:'T76EC])U
MI8_2=:6/TG6EC])UI8_2=:6/TG6EC])UI8_2=:6/TG6EC])UI8_2=:6/TG6E
MC])UI8_2=:6/TO^B(07_H2P+_ZHV$O^V/AO]PD<H]<U..>[95$[FXUEEV.)@
M>\759H^TRFJ?I<%MJYFZ;[20M7*[B+%UP(&N>,5ZK'W)=*J$RW&IB\QQJ8O,
M<:F+S'&IB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+S'&IB\QQ
MJ8O,<:F+S/^C(07_HBP+_ZPU$?^Y/AKYQ4<G\-%-..G@4DSBZ5=DSN1?>KW7
M9HRMS&J;G\1LIY.^;Z^*N7&U@[9TNGRS=[YVL7S"<:^"Q&ZNA\9NKH?&;JZ'
MQFZNA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'QFZNA\9NKH?&
M;JZ'QO^D(07_HRP+_Z\U$/^\/ACTR48EZMA--N+G3TS<[U5CQN9?>+3:98FE
MT&F6F,ALH8W#;ZB%OW&N?KMTLGBY=[9SMWNY;K6 O&NTA;YKM(6^:[2%OFNT
MA;YKM(6^:[2%OFNTA;YKM(6^:[2%OFNTA;YKM(6^:[2%OFNTA;YKM(6^:[2%
MOO^E(03_I"P+_[,U#_O!/A?MST8BX=]+--CK3TS/\U1BO.A>=*O>9(2=U&F0
MD<YMF8?);Z" Q7*E>L)TJ73 >*QPOGNO:[R LFB[A+-HNX2S:+N$LVB[A+-H
MNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$L_^F
M(03_J"L*_[@T#?/'/13DV$4>UN9)-<OQ3DS$]U-?L>Q=<*'B9'V5VVF'BM5N
MCX+0<95[S72:=LMWG7')>:!MQWVB:<6!I6;$A:9FQ(6F9L2%IF;$A:9FQ(6F
M9L2%IF;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IO^H( 3_
MKBH(_+\S"^G//!#7X4(>RNU)-;_X34JW^U);IO%=:9CI972,XFI]@]UOA'S:
M<XEWUW>,<]5ZCV_3?9%LT8"4:-"$EF7/AY=ESX>79<^'EV7/AY=ESX>79<^'
MEV7/AY=ESX>79<^'EV7/AY=ESX>79<^'EV7/AY=ESX>79<^'E_^J( /_M2D&
M\,@Q!]K=,PS+ZD(AOO9(-;+_3$:I_U%5F_==8([P96J%ZVQQ?>=Q=G?D=GIS
MXGE];^%\?VS?@(%IWH.#9]V'A67<B89EW(F&9=R)AF7<B89EW(F&9=R)AF7<
MB89EW(F&9=R)AF7<B89EW(F&9=R)AF7<B89EW(F&9=R)AO^M'P/YOR4#W]8B
M LOH,@^^]$$BL/]%,Z3_2D&<_U%-C_Y=5H7Y9EY]]&YD=O)S:'+O>&MN[GQM
M;.U_;VKL@G!GZH5R9>J)<V/IC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,=&/IC'1C
MZ8QT8^F,=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,=/^V' +HS10!S.8=!+[S
M,1*Q_SXBH_]"+Y;_2#J-_U!$A/]<2WO_9U%T_FY6;_QS66S[>%MI^7Q=9_A_
M7F;X@U]D]X9@8O:)86'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&)A]HQB
M8?:,8F'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,8O/$#P#.V@L O?,=!['_,A2C
M_SH?E?\_*HG_1C. _T\Z>/];0''_9D5L_VU(:/]S2F;_=TQD_WM-8O]_3F'_
M@D]@_X507O^)45[_BU%>_XM17O^+45[_BU%>_XM17O^+45[_BU%>_XM17O^+
M45[_BU%>_XM17O^+45[_BU%>_XM17O^+4<S+"0"^Y@P!K_\>":3_,!.5_S4<
MA_\\)'S_1"MS_TTQ;/]8-6?_8SEC_VL[8?]Q/5__=3Y=_WD_7/]\0%O_?T%:
M_X)!6?^&0EC_B$)8_XA"6/^(0EC_B$)8_XA"6/^(0EC_B$)8_XA"6/^(0EC_
MB$)8_XA"6/^(0EC_B$)8_XA"6/^(0O^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1
M-/^O6T7_K657^*EO:.VC>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZU
MPG:CN<!TJKR]<;*^N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&_N6^QO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O
M6T7_K657^*EO:.VC>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:C
MN<!TJKR]<;*^N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_
MN6^QO[EOL;^Y;[&_N6^QO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_
MK657^*EO:.VC>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!T
MJKR]<;*^N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657
M^*EO:.VC>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]
M<;*^N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EO
ML;^Y;[&_N6^QO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657^*EO
M:.VC>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]<;*^
MN6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y
M;[&_N6^QO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657^*EO:.VC
M>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]<;*^N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_
MN6^QO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657^*EO:.VC>'GC
MFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]<;*^N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657^*EO:.VC>'GCFW^'
MVY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]<;*^N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO_^9
M'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657^*EO:.VC>'GCFW^'VY*%
ME-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]<;*^N6^QO[EOL;^Y;[&_
MN6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO_^9'P7_
MEBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657^*EO:.VC>'GCFW^'VY*%E-2+
MC)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]<;*^N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO_^9'P7_ERL+
M_Y<V$O^A/AK_JD8E_[!0-/^Q6D7_L&17]ZQM:>RG=WOAGGV*V9:#E]&.B:++
MB(ZKQX*3L<1^E[?!>IR[OG>BO[QUJL*U<:[#LW*OP;-RK\&S<J_!LW*OP;-R
MK\&S<J_!LW*OP;-RK\&S<J_!LW*OP;-RK\&S<J_!LW*OP?^9'P7_ERH*_Y@U
M$O^C/1K_K$8E_[-/-/^T64;_M&-8]K%L:^JM=7W?HWN-U9N!G,V2AJC'BXJQ
MPH6/N;^ E+Z[?)K#N7FAQ[5VJ<JM=:S&JW:MQ*MVK<2K=JW$JW:MQ*MVK<2K
M=JW$JW:MQ*MVK<2K=JW$JW:MQ*MVK<2K=JW$JW:MQ/^:'P3_F"H*_YHT$O^E
M/1G_KD8E_[5.-/^W6$;_MV%9];5J;.FR<W_=J'B0TY]^H,J6@JS$CH>WOHB,
MO[J#D<6W?YC+M'RASZMXI<^E>:K(I'FLQJ1YK,:D>:S&I'FLQJ1YK,:D>:S&
MI'FLQJ1YK,:D>:S&I'FLQJ1YK,:D>:S&I'FLQO^:'P3_F"H*_YLT$?^F/1G_
MKT4E_[=.-/^Z5T;_NV!9]+EI;>>V<8'<K':3T*1[H\B:?[' DX2\NXR)Q;>(
MD,NTAIG.LH:DT:1\I-&??:G*GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJ
MR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJR/^;'P3_F2H*_YPT$?^G/!G_L44D
M_[E--/^\5T;^OE]9]+UG;N>Z;X+:L725SZAYIL6??;2^EX' N92*QK61DLNO
MC9C/JHJATIZ"H].9@:C,F(*IRIB"J<J8@JG*F(*IRIB"J<J8@JG*F(*IRIB"
MJ<J8@JG*F(*IRIB"J<J8@JG*F(*IRO^;'P3_F2H*_YTT$?^I/!C_LD4D_[M-
M,_^_5D;]P5Y:\\%F;^:_;8/9MG.7S:UWJ,2E>[>^H8/ MIN)QJZ5C\RHD97/
MHHZ>TIF'HM.4AJ?-DX:HRY.&J,N3AJC+DX:HRY.&J,N3AJC+DX:HRY.&J,N3
MAJC+DX:HRY.&J,N3AJC+DX:HR_^;'P3_F2H*_YXS$?^J/!C_LT4D_[Q,,__!
M54;[Q%U:\\5E;^7#;(38NW&8S+)UJ\.M?+:YI8&_L)Z&QJB9C,NAE9+0FY*;
MTY2.HM2/BJ;.CXJHRX^*J,N/BJC+CXJHRX^*J,N/BJC+CXJHRX^*J,N/BJC+
MCXJHRX^*J,N/BJC+CXJHR_^;'P3_FBH*_Y\S$/^K/!C_M40C_[Y,,_[#547Y
MQUQ:\<ED;^7(:H76P6^:RKETJKZP>K:SJ7^_JJ*$QJ*=BLN;FI#/E9>9TH^4
MHM2*D*;.BH^HS(J/J,R*CZC,BH^HS(J/J,R*CZC,BH^HS(J/J,R*CZC,BH^H
MS(J/J,R*CZC,BH^HS/^<'P3_FBH*_Z S$/^L/!C_MD0C_[],,OS&5$7VREQ:
M[\UB<.3-:(;3Q6V:Q;QSJKFT>+6NK7V^I:>"Q9VBB,N5GX[/CYR6THN<HM.&
ME:;.AI2GS(:4I\R&E*?,AI2GS(:4I\R&E*?,AI2GS(:4I\R&E*?,AI2GS(:4
MI\R&E*?,AI2GS/^<'P3_FBD*_Z(S$/^M.Q?_MT0C_\%,,OG)4T7SS5I:[-)@
M<.#09H;.R&R:P+]QJ;2X=[6IL7R^GZR!Q9>HALJ0I(S.BJ*5T86BH=*!G*;.
M@9JGS(&:I\R!FJ?,@9JGS(&:I\R!FJ?,@9JGS(&:I\R!FJ?,@9JGS(&:I\R!
MFJ?,@9JGS/^<'@3_FRD*_Z,S$/^O.Q?_N40B_<-+,?;,4D3PTEE9Z-I?<-O5
M9(;)S&J9NL-OJ*V[=+2BM'F]F*]]PY"L@\B)J8G,@Z>1SWZFG-!]I*;-?**H
MRWRBJ,M\HJC+?**HRWRBJ,M\HJC+?**HRWRBJ,M\HJC+?**HRWRBJ,M\HJC+
M?**HR_^='@3_FRD*_Z4R#_^Q.Q;_O$0A^L9+,?/144/KVE=9X]]=;]/;8X7"
MSVF7L<1MIZ2\<+*8M72[CK%XPH:M?<: JX+*>JF*S7:HE,YVJ:/,=ZNHRG>K
MJ,IWJZC*=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,IWJZC*=ZNH
MRO^='@3_G"D*_Z<R#_^S.Q;_OD,@]<I++^[64$+FX597W.1;;LO>8X.ZT6B4
MJ<=LHYN^;JZ0N'&WAK1TO7ZP>,)WKGS&<JR#R6VKC,IMJYG);JR?QVZLG\=N
MK)_';JR?QVZLG\=NK)_';JR?QVZLG\=NK)_';JR?QVZLG\=NK)_';JR?Q_^>
M'@3_G2D)_ZDR#O^V.A3ZPD,?\,Y*+N?=3T#BZ5)7TNA:;<'@8H"QU&>1H<IK
MGI3#;JB)O7&P@+ETMGFV=[ITM'N];K*!P&JPB,)GL)+#9K"6PV:PEL-FL);#
M9K"6PV:PEL-FL);#9K"6PV:PEL-FL);#9K"6PV:PEL-FL);#9K"6P_^?'@3_
MGBD)_ZTQ#?^Z.A/TQT(=Z-5**]_D3#_7[%%6R>Y9:[?C87RHV&>+FL]KEXW)
M;J"#Q'&G>\!TK'6]>+!PNWNS;+F MFBXAKADMX^Y8[:1NF.VD;ICMI&Z8[:1
MNF.VD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1NO^@'@3_H2@(
M_[$P"_O .1'LSD(9W]]'*-/I3$#*\5%5OO)8:*WF87>>W6>$DM5LCX?/;Y9^
MRW.<>,AVH7+&>:1NQ'RG:<*!J6; AJQBOXVM8;^/KF&_CZYAOX^N8;^/KF&_
MCZYAOX^N8;^/KF&_CZYAOX^N8;^/KF&_CZYAOX^N8;^/KO^B'0/_IB<'_[<O
M"?+'. WAV$$4TN9&*L?P3$"^^%!3LO578Z+K87"5XV=[BMUMA('8<8MZU'60
M=-)YDW#0?)9LSG^9:,R#FV3+B)UARHV?8,F/GV#)CY]@R8^?8,F/GV#)CY]@
MR8^?8,F/GV#)CY]@R8^?8,F/GV#)CY]@R8^?8,F/G_^D'0/_K28%^[XM!N;0
M- C3XCP6Q^Y&*[OY2CZP_D]/IOI77)CQ86B,ZVAQ@^9N>'OB<WUUWWB!<=U[
MA&W;?X=JVH.)9]F&BF37BXQAUI".8-61CF#5D8Y@U9&.8-61CF#5D8Y@U9&.
M8-61CF#5D8Y@U9&.8-61CF#5D8Y@U9&.8-61CO^G' /_M2,#[LDF ]7?*0?'
M[#P9NOA$*ZW_2#NC_TU)FO]75(WY85V$]&IE?/!P:G;M=FYQZWIQ;>E^=&OH
M@G9HYH5W9N6(>6/DC'IAXY%\8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2
M?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2?/^K&P+WP!T!V=P2 <?K* JZ]SL:
MK/]!*:#_1C:5_TQ!C?]62X/_85)[_6M7=/IQ7&_X=E]L]GMA:?5_8V?T@V1E
M\X9F8_**9V'QCFA?\))I7_"3:E_PDVI?\)-J7_"3:E_PDVI?\)-J7_"3:E_P
MDVI?\)-J7_"3:E_PDVI?\)-J7_"3:O^W%0'6SPL Q^H3 KGW*0VL_SD:GO\^
M)I+_1#"'_TLY@/]40'C_849R_VI*;/]P36G_=E!F_WM19/]_4V/_@U1A_X95
M8/Z)5E[^C5==_9)87/V36%S]DUA<_9-87/V36%S]DUA<_9-87/V36%S]DUA<
M_9-87/V36%S]DUA<_9-87/V36-;$" #&U D N/<4!*O_*0Z>_S08D/\Z(83_
M02EZ_TDP<O]2-FS_7CIH_V@]9/]O0&'_=$%?_WE#7O]]1%W_@$5<_X1%6_^'
M1EK_BD=8_X]'6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(
M6/^02%C_D$A8_Y!(6/^02,3'!P"WVP<!J?\6!I__*@V0_S 5@_\V''?_/B)N
M_T<H9O]0+&'_6B]=_V0Q6_]L,UG_<358_W4V5O]Y-E;_?#=5_W\W5/^".%/_
MA3E2_XDY4O^*.5+_BCE2_XHY4O^*.5+_BCE2_XHY4O^*.5+_BCE2_XHY4O^*
M.5+_BCE2_XHY4O^*.?^2'03_D"D)_XTU$/^8.Q?_H$0A_Z9.+?^G63S_I61,
M_Z%N6_>;>&KNE8%WYXZ)@N&&CXO<@)63V'R;F=1XH)[1=:2BSW.II<UQKJC,
M;[6JRFV^K<-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-I
MO:[#:;VNPVF]KO^2'03_D"D)_XTU$/^8.Q?_H$0A_Z9.+?^G63S_I61,_Z%N
M6_>;>&KNE8%WYXZ)@N&&CXO<@)63V'R;F=1XH)[1=:2BSW.II<UQKJC,;[6J
MRFV^K<-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#
M:;VNPVF]KO^2'03_D"D)_XTU$/^8.Q?_H$0A_Z9.+?^G63S_I61,_Z%N6_>;
M>&KNE8%WYXZ)@N&&CXO<@)63V'R;F=1XH)[1=:2BSW.II<UQKJC,;[6JRFV^
MK<-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN
MPVF]KO^2'03_D"D)_XTU$/^8.Q?_H$0A_Z9.+?^G63S_I61,_Z%N6_>;>&KN
ME8%WYXZ)@N&&CXO<@)63V'R;F=1XH)[1=:2BSW.II<UQKJC,;[6JRFV^K<-I
MO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]
MKO^2'03_D"D)_XTU$/^8.Q?_H$0A_Z9.+?^G63S_I61,_Z%N6_>;>&KNE8%W
MYXZ)@N&&CXO<@)63V'R;F=1XH)[1=:2BSW.II<UQKJC,;[6JRFV^K<-IO:[#
M:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KO^2
M'03_D"D)_XTU$/^8.Q?_H$0A_Z9.+?^G63S_I61,_Z%N6_>;>&KNE8%WYXZ)
M@N&&CXO<@)63V'R;F=1XH)[1=:2BSW.II<UQKJC,;[6JRFV^K<-IO:[#:;VN
MPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KO^2'03_
MD"D)_XTU$/^8.Q?_H$0A_Z9.+?^G63S_I61,_Z%N6_>;>&KNE8%WYXZ)@N&&
MCXO<@)63V'R;F=1XH)[1=:2BSW.II<UQKJC,;[6JRFV^K<-IO:[#:;VNPVF]
MKL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KO^2'03_D"D)
M_XTU$/^8.Q?_H$0A_Z9.+?^G63S_I61,_Z%N6_>;>&KNE8%WYXZ)@N&&CXO<
M@)63V'R;F=1XH)[1=:2BSW.II<UQKJC,;[6JRFV^K<-IO:[#:;VNPVF]KL-I
MO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KO^3'03_D"D)_X\T
M$/^:.Q?_HD0@_ZE-+?^J6#S_J&),_Z1L7/6?=FSLF7]ZY)&'AMZ)C9#8@Y.8
MTWZ9G]!ZG:3-=J*IRW2GK,EQK:_';[2RP6RYM+QLN[&\;+NQO&R[L;QLN[&\
M;+NQO&R[L;QLN[&\;+NQO&R[L;QLN[&\;+NQO&R[L?^4'03_D2@)_Y$S$/^<
M.A;_I$,@_ZQ,+?^M5CW_K6!-_JEJ7O2E=&[JGWU]X9:#B]F.BI;3AY"@SH&5
MI\I\FJW'>)^RQ'6EML)RJ[G <+2[MVZUN;-ON+6S;[BULV^XM;-ON+6S;[BU
MLV^XM;-ON+6S;[BULV^XM;-ON+6S;[BULV^XM?^4'03_DB@)_Y,R#_^>.A;_
MIT,@_ZY++?^Q53W_L%]._:YH7_*J<G#GI'J!WIJ C]62AYS.BXRFR821K\1^
ME[7!>9R[OG:CO[QTJ\*T;Z[#KG*SO*MSMKBK<[:XJW.VN*MSMKBK<[:XJW.V
MN*MSMKBK<[:XJW.VN*MSMKBK<[:XJW.VN/^5' 3_DB@)_Y4R#_^@.A;_J4(?
M_[!*+?^T5#W_M%Y._;-G8/&O<'+FJ7B#VY]^D]*7@Z'+CHFLQ(:.M<" E+V\
M>YK#NGJCQ;=YJ\>L<ZS&IW6QOZ5WM;JE=[6ZI7>UNJ5WM;JE=[6ZI7>UNJ5W
MM;JE=[6ZI7>UNJ5WM;JE=[6ZI7>UNO^5' 3_DR@)_Y8Q#_^A.17_JD(?_[)*
M+/^V4SS_MUU.^[9E8?"T;G3DK76&V:1[EL^;@*7'DH6QP8J+N[V'E,"[A9W$
MMH*DQ[!^JLBE=ZK(H7FPP9]ZL[R?>K.\GWJSO)]ZL[R?>K.\GWJSO)]ZL[R?
M>K.\GWJSO)]ZL[R?>K.\GWJSO/^5' 3_DR@)_Y<Q#_^C.17_K$(?_[1*+/^Y
M4SS_NEQ.^+ID8N^X;'7CLG.(V*EYF<V??JG%F(2TOY.,O+B-D\&SB9G%KH:A
MR*J$J<F??*G*FWVNPIE^LKV9?K*]F7ZRO9E^LKV9?K*]F7ZRO9E^LKV9?K*]
MF7ZRO9E^LKV9?K*]F7ZRO?^6' 3_DR@)_Y@P#O^D.17_K4$>_[5)+/^[4CS]
MO5M.]KUC8NZ]:W;BMG&)U:YWF\NE?*K"G8.TN9:)O+*1D,&LC);&IXF=R*.'
MILJ9@*C+EH&NQ)6!L;Z5@;&^E8&QOI6!L;Z5@;&^E8&QOI6!L;Z5@;&^E8&Q
MOI6!L;Z5@;&^E8&QOO^6' 3_E"<)_YDP#O^E.13_KD$>_[=)*_^]43S\OUI.
M],%B8NS!:7?ANW"+TK%TG<>H>ZJ\H(&TM)J'O*R4C<*FD)3&H(V;R9R+I,N5
MAJC+D86MQ9"%L;^0A;&_D(6QOY"%L;^0A;&_D(6QOY"%L;^0A;&_D(6QOY"%
ML;^0A;&_D(6QO_^6' 3_E"<(_YHP#O^F.!3_L$$=_[A)*_^_43SZPEE.\L1A
M8^G%:'?=OFV,S;1SG<*K>:JWI'ZTKIV$O*:8BL&@E)'&FI&8R9:/H<N0BZC,
MC(FLQ8R)L,",B;# C(FPP(R)L,",B;# C(FPP(R)L,",B;# C(FPP(R)L,",
MB;# C(FPP/^7' 3_E2<(_YLP#O^G.!3_L4$=_[I)*__"4#OXQEA.\,A?8^;(
M9GC8P6N-R;=QG;VO=ZFRIWRSJ:&"NZ&<B,&:F(_&E):6R9"4G\N+D:C,AXZL
MQH>-L,&'C;#!AXVPP8>-L,&'C;#!AXVPP8>-L,&'C;#!AXVPP8>-L,&'C;#!
MAXVPP?^7&P/_E2<(_YTO#?^I.!/_LT =_[Q(*OS%3SOVR5=.[<U>8^++9'C2
MQ&J,Q+MOG+BR=:FMJWNSHZ: NYNAAL&4G8W%CIN4R(J9G<J&F:C+@I.LQH*2
MK\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\&"DJ_!@I*O
MP?^7&P/_E2<(_YXO#?^J.!/_M4 <_[Y(*?G(3CKSS59-ZM-<8M[/8GC-QVB+
MO[YNF[*W<ZBGL'FRGJM^NI6GA,".HXO$B*&2QX.?FLF H*?*?9JLQGV8K\%]
MF*_!?9BOP7V8K\%]F*_!?9BOP7V8K\%]F*_!?9BOP7V8K\%]F*_!?9BOP?^8
M&P/_EB<(_Z O#?^L-Q+_MT ;_<%(*/;+3CGOTU1,YME:8MC487?'RV>*N<-L
MFJV\<J>AMG>QF+%]N(^M@KZ(JHG#@JB0QGVGF<AZIZ7)=Z*LQ7B?L,%XG[#!
M>)^PP7B?L,%XG[#!>)^PP7B?L,%XG[#!>)^PP7B?L,%XG[#!>)^PP?^8&P/_
MER8(_Z(O#/^N-Q+_N3\:^<1')_'.33CJVU-+X-]98-#:7W;!T&6)L\EKF:;"
M<*6;O76OD;A[MHBU@+R!LH; >["-PW:NEL5SKJ'&<JVMQ'*IL,!RJ;# <JFP
MP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFPP/^9&P/_F"8(
M_Z0N"_^Q-A'^O3\9],A')>O433;EXU!)V>-77\G?7G2ZUV2&K,]IEIW';:.1
MP'&LAKMULWZW>KEWM'^]<K*%OVVQC<%JL)?":;&EP6RTLKULM+*];+2RO6RT
MLKULM+*];+2RO6RTLKULM+*];+2RO6RTLKULM+*];+2RO?^:&P/_F28(_Z<M
M"O^U-@_YP3\7[LY&(^3<3#+=YT])S^A67L#D77*RWF2"H]1ID97+;9R)Q7"E
M?\!SK'>\=[%PN7RU:[>!N&>VA[ICM9"[8;6;O&.WIKECMZ:Y8[>FN6.WIKEC
MMZ:Y8[>FN6.WIKECMZ:Y8[>FN6.WIKECMZ:Y8[>FN?^;&P/_FR4'_ZLM"?^Y
M-0WRQSX5Y=5&']KC23//ZTY)QNU47;?J7&ZHXF-]FMEIBH[2;92$S'&;>\AU
MH7/$>*9NPGRI:<"!K&6^AZYBO8ZP7[V7L5Z\GK%>O)ZQ7KR>L5Z\GK%>O)ZQ
M7KR>L5Z\GK%>O)ZQ7KR>L5Z\GK%>O)ZQ7KR>L?^<&@/_H"0&_[ L"/G - OI
MSST0VM]"'<[I23/$\4Y(N_)26JWP6VF>YV-VDN!I@8?:;XE^U'.0=]%WE7'.
M>YELS'^<:,J#GF3)B*!AQXZB7L:5I%S&FZ1<QIND7,:;I%S&FZ1<QIND7,:;
MI%S&FZ1<QIND7,:;I%S&FZ1<QIND7,:;I/^>&@/_I2,%_[<J!?#(,@?<VS4,
MSN="'\+Q2#2X^4Q&K_=15:+U6V*5[61MBN=K=H#B<'UYWG6"<]MZAV[9?HIK
MUX*,9]6&CF34BY!ATY"27M&6E%S1FY5<T9N57-&;E5S1FY5<T9N57-&;E5S1
MFY5<T9N57-&;E5S1FY5<T9N57-&;E?^A&0+_K2$#^+\F ^+4)0/.Y3,/PO!"
M(;;Z1S.K_DM"HOY03Y?[6UJ+]65C@O!L:GKL<G!TZ7AT;^=\=VSE@7IHXX1\
M9N*(?6/AC']@X)&!7M^6@ES>FH-<WIJ#7-Z:@US>FH-<WIJ#7-Z:@US>FH-<
MWIJ#7-Z:@US>FH-<WIJ#7-Z:@_^C&0+_MAT!Z<P7 <_C'@/"\#,2M?I (JG_
M1#"=_TD]E?]02(O_6U""_657>OEM773V<V%O]'ED:_)^9VCQ@FEF\(9J9.^*
M;&+NCFU@[9)N7>R7<%SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ
M7.N;<5SKFW%<ZYMQ7.N;<?^L%0'SPQ  T=H+ ,'O'P:T^S,3J/\\()O_0BR0
M_T@VA_]//W__6D9X_V5+<?]M3VS_<U)I_WE59OY^5V3]@EAB_(998?N*6E_Z
MCEM>^I)<7/F775OXFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>6_B;
M7EOXFUY;^)M>6_B;7OJY#@#-RPD P.8- ;+\( BG_S,3FO\Y'8W_/R:"_T8N
M>O].-7/_6#IM_V,_:?]L0F7_<D1B_W=&8/]\1U__@4A=_X5)7/^(2EO_C$M:
M_Y!,6/^535?_F4U7_YE-5_^935?_F4U7_YE-5_^935?_F4U7_YE-5_^935?_
MF4U7_YE-5_^93<W!!@"^T < L?8. J7_(0F9_RX2C/\T&8#_.R!V_T,G;?],
M+&;_5#!B_V S7O]I-5S_;S=:_W0X6?]Y.5C_?3I7_X [5O^$.U7_ASQ4_XL]
M4_^0/5+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSY2
M_Y,^4O^3/KW%!0"PUP4 H_\0 YG_(@F+_RD/?O\P%7/_.!II_T ?8O])(UO_
M4297_UHH5?]B*E+_:2M1_V\L4/]S+4__=RY._WHN3O]]+TW_@"],_X0P2_^(
M,$O_BS!+_XLP2_^+,$O_BS!+_XLP2_^+,$O_BS!+_XLP2_^+,$O_BS!+_XLP
M2_^+,/^+' 3_B"@(_X0T#O^/.A3_ET(<_YY+)_^>5S3_G6)"_YEM3_^3>%SX
MC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.W6^ND=MMLY3:;+F6V&O"F-5I
MS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+
MF_^+' 3_B"@(_X0T#O^/.A3_ET(<_YY+)_^>5S3_G6)"_YEM3_^3>%SXC8)G
M\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.W6^ND=MMLY3:;+F6V&O"F-5IS)K,
M9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F_^+
M' 3_B"@(_X0T#O^/.A3_ET(<_YY+)_^>5S3_G6)"_YEM3___XO__24-#7U!2
M3T9)3$4 !PF3>%SXC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.W6^ND=MM
MLY3:;+F6V&O"F-5IS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+
MF\QERYO,9<N;S&7+F_^+' 3_B"@(_X0T#O^/.A3_ET(<_YY+)_^>5S3_G6)"
M_YEM3_^3>%SXC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.W6^ND=MMLY3:
M;+F6V&O"F-5IS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QE
MRYO,9<N;S&7+F_^+' 3_B"@(_X0T#O^/.A3_ET(<_YY+)_^>5S3_G6)"_YEM
M3_^3>%SXC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.W6^ND=MMLY3:;+F6
MV&O"F-5IS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,
M9<N;S&7+F_^+' 3_B"@(_X0T#O^/.A3_ET(<_YY+)_^>5S3_G6)"_YEM3_^3
M>%SXC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.W6^ND=MMLY3:;+F6V&O"
MF-5IS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;
MS&7+F_^+' 3_B2@(_X4S#O^0.13_F$(<_YY+)_^?5C3_GF%"_YIM4/^5=UWW
MCX%H\8F+<NN#DGOG?9B"XWB=B.!THXS=<JB0VV^MD]INLY;8;+J8UFO"F]%I
MRIS*9LJ<RF;*G,IFRIS*9LJ<RF;*G,IFRIS*9LJ<RF;*G,IFRIS*9LJ<RF;*
MG/^,' /_B2<(_X@R#O^3.!3_FT$<_Z)*)_^D5#3_HE]#_Y]J4?V:=%_UE'YL
M[8Z(>.>'CX'B@)6*W7N:D-IWH);6=*::U'&LGM)OLJ'0;;FCSVS#IL5GPZ;
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MBI6[IH>=OJ*%I<"?A*_!EGZPP91_MKB3@+NRDX"[LI. N[*3@+NRDX"[LI.
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M-1EQ_ST>:?]%(V+_329;_U8I6/]?+%;_:"U4_VXO4_]S,%+_>#%1_WPQ4/^
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MC"(&_YTG!_^J+@G_MC8.]\$^%NW,1B#DV$LNV=Q01,G46%B[S5YKKL9E>J+
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M*3S_L"H\_[0J//^T*CS_M"H\_[0J//^T*CS_M"H\_[0J//^T*K.X 0"EQ@
ME]4  (OO! &$_Q,"=_\:!&W_(@=D_RH+7/\R#E7_.1%0_T$32_](%4C_3Q=%
M_U880O]<&4#_81H^_V<://]M&SO_<QPY_WD<./^ '3;_B!TU_X\>-/^7'C+_
MH!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'Z;   "7S@  B=X
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M34GXX$U(]_--2/?T34CW]$U(]_1-2/?T34CW]$U(]_1-2/?T3=JC  #'L0(
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M:D_%[6A0P/-D4;WU85&]]6%1O?5A4;WU85&]]6%1O?5A4;WU8?^&"@#PF@0
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M-3__[S4__^\U/__O-3__[S4__^\U/__O-<2J  "SLP  I[\  )K+  "/V@(
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M<%^?ZVMAG?)E8IKV8&*9]UYBF?=>8IGW7F*9]UYBF?=>8IGW7O]S$ '_A0P
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M3DK*_TU*RO]-2LK_34K*_TU*RO]-2LK_3>>/  #1GP  PZL! +>T @"MOP,
MH\L& )O9"@"4Y1H!C>4K!H3D-0U[XS\6<^)('FSA4B9FX5HL8.!B,EO@:C97
MX'(Z4]][/5#?A4!-WX]#2N";14C@J$9&X+A'1>',1T7@Z$=%W_9&1=[_1$7>
M_T1%WO]$1=[_1$7>_T1%WO]$1=[_1-F7  #'I@  N+   *RY 0"BQ0( F-$&
M (_K#0")[A\"@.XK!GCM- QP[3T3:.U&&6+M3AY=[5<C6>U@)U7M:"I2[7$M
M3^UY+TSM@S)*[HTT1^Z8-47NI3=#[[,X0O#$.$'PWSE![^\X0.W].$#L_SA
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M:6^&ZV-RA_E<<X;]5G.%_U)SA?]2<X7_4G.%_U)SA?]2<X7_4O]H$0'_> T
M_X8- /:3# #>H D UJD* -*R#0#'LB("O:\S"K.K01>JITPDH:)5,)F>73J2
MFF1"BY=K2864<E" DGE5>X^!6G:-B5YRC))B;HJ=96N)J6=HB;AH9XG+:&F+
MZ6-LC?E<;8S]5VV*_U)MBO]2;8K_4FV*_U)MBO]2;8K_4O]K$ '_>PL _XH*
M .*8!@#6HP@ T*P) ,NU"P#!MA\!N+0Q":ZP/Q:DK$HBG*A3+I2D6SB,H&)
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M5%NA_U!;H?]06Z'_4%NA_U!;H?]06Z'_4/]W!P#PB0  UI@  ,ND P#!K00
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M.4/8_SE#V/\Y0]C_.="6  #!HP  LJP  *>U  "<P   D<H# (?6!P" Z1$
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M7']S[%:!=OM/@WC_2H-X_T6">/]$@GC_1()X_T2">/]$@GC_1/]?$0'_;0P
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M36R*_TALB?]';(G_1VR)_T=LB?]';(G_1_]I"P#_> 0 Y8<  -:2 P#-G 4
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M0E*I_T)2J?]"4JG_0O)\  #7C   R)D  +VC  "RJP  J;(  *"[ @"7Q D
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M"AW_HPH<_[$*&__ "QK_U@L:_]\+&O_?"QK_WPL:_]\+&O_?"YNQ  "-O
M?L<  '#2  !CW@  5>0  $OU  !&_P4 0/\. #O_%  W_QL!,_\C 2__*0(K
M_S "*/\U B7_.P,B_T$#'_]' QW_3@,:_U4$&/]>!!7_: 43_W0%$?^"!1#_
MD 80_YT&#_^I!@[_M08._[H&#O^Z!@[_N@8._[H&#O^Z!HZZ  !_Q0  <-$
M &+>  !4Y0  1NL  #_^   Y_P  -/\) "__#@ K_Q0 )_\: 2/_(0$?_R4!
M'/\J 1G_+P$6_S0"%/\Z A'_0 (0_T8"#O]. @S_5@()_V #!_]L P3_> ,#
M_X8# O^1 P'_G0,!_Z$# ?^A P'_H0,!_Z$# ?^A _\V+0+_.2X"_SXN _]
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M3)%C[T>29?U!DF?_/)-I_SB3:O\UDVK_-9-J_S63:O\UDVK_-?]7$0'_8PT
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M0GIX_SY[>?\Z>WG_.GMY_SI[>?\Z>WG_.O]?# #_; 0 ]7D" -Z# @#3BP4
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M/&.,_SQCC/\\8XS_//]J  #F>@  U88  ,F1  # F0$ N)\! +"E  "HJ0X
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M&C;AS1HVW^P:-=[Y&C3=_QLTW/\;--S_&S3<_QLTW/\;--S_&[F<  "JI
MGJL  )*U  "%O@  ><<  &W/  !BU@, 6.$( %7J$P!1ZR  3>LK 4GK-0)%
M[#X$0NQ'!3_L3P<][5@).NU@"CCM:@PV[G0-,^Z #C+NC@\P[YT0+N^M$2WP
MP!$M\-X1+.[Q$2SL_A$LZ_\0+.O_$"SK_Q LZ_\0+.O_$*VB  "@J0  D[,
M (:]  !YQ@  ;,\  &#8  !5W@  3O,* $KW$P!&^!T 0_@G 3_X, ([^3@"
M./E  S7Z1P0S^D\%,/M7!2[[7P8K_&D'*?QT""?\@@DE_9 ))/V@"B/^L HB
M_L0+(?_@"R']\@H@_/P*(/S\"B#\_ H@_/P*(/S\"J*G  "5L0  A[L  'G&
M  !LSP  7]D  %+?  !(Z   0_\( #__$  [_QD -_\A #3_*0$P_S !+?\W
M BK_/@(G_T0")?]+ R+_4P,@_UP#'?]F!!O_<@09_X %%_^/!1;_GP85_Z\&
M%/_ !A3_U@83_^D&$__I!A/_Z083_^D&$__I!I>O  "(N@  >L4  &S/  !>
MV@  4.   $3F   \]0  -_\$ #/_#0 O_Q, *_\: "C_(0 E_R<!(?\M 1[_
M,@$;_S@!&?\_ 1;_1@(4_TT"$?]6 A#_8 (._VP"#/][ PO_BP,*_YH#"O^H
M PG_M0,(_\(#"/_" PC_P@,(_\(#"/_" XJX  ![PP  ;,X  %[;  !/X@
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M-ZI2]#.I5/\NJ%;_*ZA7_RBH5_\EJ%?_):A7_R6H5_\EJ%?_)?]-$P#_5@X
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M-8=G_S&':/\NAVG_+8=I_RV':?\MAVG_+?]7# #_800 _FP# .1U 0#;>P4
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M,7%X_S%Q>/\Q<7C_,?]? @#W;   WG<  -"!  #'B $ P(T# +F1 P"RDQ$
MJY,C :.1,P:<CD -E8M*%8^(4QR)AELBA(-B*("!:2U\?W Q>'YW-71\@#AQ
M>XD\;GJ3/VMYGD)H>*M$9GB[161XT45F>>Y :'O].FI[_S9K?/\R:WS_,FM\
M_S)K?/\R:WS_,O]A  #J;P  V7H  ,R$  ##BP  NY$! +25 0"LEPX I9<A
M 9Z6,067DSX,D)!(%(J.41N$BUDA?XE@)WN'9RMWA6XP<X1U-&^"?3=K@8<[
M:("1/F5_G$%B?JE#8'ZY1%]^ST1@?^Q 8H#\.F2 _S9E@?\S9H'_,F:!_S)F
M@?\R9H'_,O]D  #E<@  TWX  ,>'  "^CP  MI4  *Z9  "FFPP H)P> )F;
M+@22F3L*BY9&$H643QE_D5<?>H]>)76.92IQC&PN;8IS,FF)>S9FB(0Y8H:/
M/5^%FC]<A:A!6H6W0EF%S$):A>H_7(;[.EZ&_S9?A_\R7X?_,E^'_S)?A_\R
M7X?_,OUH  #@=@  S8(  ,*,  "YDP  L)D  *B=  "?H D F:$: ).@*P.,
MGS@(A9U#$'^:3!=YF%0==)=<(G"58R=KDVHL9Y)Q,&21>3-@CX(W7(Z-.EF-
MF3U7C:8_5(VV0%.-RT!4C>D]5HWZ.5>-_S59CO\R68[_,5F._S%9CO\Q68[_
M,>UM  #9>P  R(<  +V0  "TF   JIT  *&A  "7I@0 D:<5 (RG)P*%IC4&
M?Z1 #7FB2A1SH%(:;I]9'VF=8"1EG&<H89MO+%Z:=S!:F( S5I>+-E.7ESE1
MEJ4[3Y:T/$Z6R3Q.EN@Z3Y;Y-E&6_S-2EO\P4I;_,%*6_S!2EO\P4I;_,.9R
M  #0@   PHP  +B6  "MG   HZ$  )FF  ".K0  B*X1 (.N(@%]K3$$=ZP]
M"G*J1Q!LJ4\69ZA7&V.G7A]?IF4D6Z1M)UBD=2M4HW\N4:*),4ZAEC1+H:0V
M2:&T-DBAR#=(H.<U2:#Y,DJ?_S!+G_\N2Y__+4N?_RU+G_\M2Y__+=UY  #)
MA@  O)(  +&:  "FH   G*8  )&L  "&L@  ?;8- 'FV'0!UMBP";[4Y!FJT
M0PMELTP18+)4%ERQ6QI8L&,>5:]K(5&O<R5.KGTH2ZV(*DBME2U%K:,N1*VS
M+T.MR"]"K.<O0ZOY+42K_RM$JO\I1*K_*42J_RE$JO\I1*K_*=&   #!C0
MM9@  *F?  ">I0  DZP  (BR  !]N   <;X& &Z_%0!JOR8!9K\S V&^/P==
MOD@+6;U1#U6]61-1O& 73KQH&DN[<1U(NWL?1;J'(D*ZE"1 NJ(F/KJS)CVZ
MR"8]NN@F/;CY)3VW_R0]MO\C/;;_(SVV_R,]MO\C/;;_(\>(  "YE0  K)T
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M,-CV$C#6_Q,OU/\3+]3_$R_4_Q,OU/\3+]3_$[.:  "FH0  FJD  (VQ  "
MN@  =,$  &C)  !<SP  4M4# $C<" !%Y1( 0^4> $'F*@ ^YC4!.^<^ 3GG
M1P(WYU #-.A9!#+H8@4PZ&T&+NEY!RSIAP@KZI8)*>JG"BCJN@HGZ]8*)^GP
M"B?G_0DFYO\*)N;_"B;F_PHFYO\*)N;_"JB@  "<IP  C[   (*Y  !TP@
M:,H  %O1  !/UP  1=T  #[N"0 \\A$ .?,; #;S)0 T]"X ,?0W 2[U/P$L
M]4<!*?9/ B?V5P(E]V$#(_=L R'X>@0?^(D$'OF:!1SYJP4;^L %&OK>!1KY
M\@4:]_T%&?;_!1GV_P49]O\%&?;_!9ZF  "1KP  @[D  '7"  !GRP  6M,
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M&\L_^QK)0/\8QT#_%\9!_Q7%0?\4Q$'_%,1!_Q3$0?\4Q$'_%/]!%P#_1Q(
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M)IE6_R.95O\AF5?_'YE7_Q^95_\?F5?_'_]-#0#_508 _UT% /MD!P#O:0D
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M"0#$=A< O'8J ;1T.@6N<48,IVY1$J)K6AB>:6(=FF=I(99E<2639'@HD&*
M*XUAB"Z+8)$QB%^:,X9>I36#7K(W@E["-X!>W#B 7_(S@6'_+8)B_RF"8_\F
M@F3_)8)D_R6"9/\E@F3_)?]3!@#_70  YV<  -MO  #0= ( RG@% ,9Y!P"^
M>A4 MGHH :]X-P6H=D0+HG-.$IQP5QB8;5\=E&MG(9!J;B6-:'4HBF=]*X=E
MA2Z$9(XQ@6.7-']BHC9\8J\X>F*^.7EBU3EY8^\T>F7^+WMF_RM\9_\H?&?_
M)GQG_R9\9_\F?&?_)O]5 P#_8   XVH  -5R  #,> $ Q7L# ,!]!0"Y?A(
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M-%&(PS50B.(T4HCV,%.(_RQ4B/\I58C_*%6(_RA5B/\H58C_*.9K  #0>
MPH,  +>,  "MD@  HY8  )J:  ".G@  AY\0 (.?( !^GR\">)T[!W.<10QN
MFTT1:9E5%F687!IAEV,>7I9J(5N5<B57E'PH5).&*U&2DBY.DJ P3)*O,4N2
MPC%*D> Q3)'U+4V1_RI.D/\H3I#_)DZ0_R9.D/\F3I#_)MYP  #)?0  O(D
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M'#FR_QPYL?\;.;#_&SFP_QLYL/\;.;#_&\&&  "TDP  IYH  )R@  "1IP
MA:T  'FS  !MN   8KT! %;"!P!3PQ0 4L,C %#$, %-Q#L"2L1% T?$3@5%
MQ%<'0L-?"4##: L]PW(-.\-^#SC#C!$VPYL2-<.K$S/#P!,SP^ 3,\'U$S+
M_Q0RO_\4,;[_%#&^_Q0QOO\4,;[_%+B0  "KF0  GZ   ).G  "'K@  >[0
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M A+P_P(2\/\"$O#_ IJD  "-K0  ?[8  '&_  !CQP  5LX  $G3   ]V@
M,]\  "KC   F] 4 )/L- "'\$P >_1L '/TB !G^*0 7_C$ %?\Y !/_00 1
M_TH $/]5  [_80 ,_V\!#/^  0K_DP$)_Z8!"/^Z 0?_U $'_^L!!O_V 0;_
M]@$&__8!!O_V 8^L  " M@  <K\  &/)  !6T0  2-@  #O=   PX@  )N8
M !_P   <_P  &?\) !;_#@ 4_Q, $?\9  __'@ -_R0 "_\K  G_,@ &_SL
M _]$  #_3P  _UP  /]K  #_?0  _Y   /^C  #_M   _\8  /_6  #_U@
M_]8  /_6 (*U  !SOP  9,D  %;3  !'VP  .N   "[E   CZ0  &NT  !7]
M   2_P  $/\"  [_"0 +_PT "/\0  3_$P !_Q@  /\>  #_)   _RL  /\S
M  #_/0  _TD  /]6  #_9@  _W@  /^*  #_FP  _Z@  /^Q  #_L0  _[$
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M)@'_+B,!_R\B ?\O)0'_+"L!_RHU O\G00+_)$X#_R); _\@: 3_'G0$_QV
M!/\=B@3_'9(%_QV:!?\=H07_':<%_QVM!?\=M 3_';T$_QW'!/\=U 3^'>8$
M^QWR!/<>^P/U'O\$]![_!/,>_P3S'O\$\A[_!/(>_P3R'O\$\A[_!/\N(@'_
M,A\!_S0> ?\S( '_,B8!_S(R ?\O/@+_+$H#_RI7 _\G9 3_)G %_R5[!?\D
MA07_)(X&_R26!O\DG0;_)*,&_R2J!OTDL0;\)+D&^R3#!ODDSP;V).,&\B3P
M!>XE^@7M)?\&ZR7_!NHE_P;I)?\&Z27_!NDE_P;I)?\&Z27_!O\R'@'_-AL
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M3A8 _T\? /U.*0'T3#0![$A! N9'3@3@15L&VT1F"=9"< S207D.ST""$,U
MBA'*/Y$3R3^9%,<^H!7%/J@6PSZQ%\$^O!? /LL8O3[B&+H^\A>W/_\6M4#_
M%+1 _Q.S0?\1LT'_$+-!_Q"S0?\0LT'_$/] $ #_1@P _TL* /]1#0#_4Q$
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M&HM6_QJ+5O\:BU;_&O],! #_4P  [%P  -]B  #49@$ SF@% ,MG" #"9Q8
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M+UYPPB]=<-\O7W'U*F!Q_R9A<O\C8G+_(&)R_R!B<O\@8G+_(.]<  #<:0
MRG(  +YZ  "U@   K80  *2%  ":A0, E(44 (Z&)0&)A#,#@X,^!WZ!2 MY
M?U 0=7Y7%'%]7AAN>V4;:WIL'FAY=")E>'TE8G>'*%]VDRI<=I\L6G6N+EEU
MP"Y8==TN67;S*EMV_R9<=_\C7'?_(%QW_R!<=_\@7'?_(.I@  #5;   Q78
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M)$B,_R))B_\@2HO_'DJ+_QY*B_\>2HO_'M5N  ##>P  MX4  *R-  "BD@
MEY8  (R9  !_G   =9X% '"?$P!MGR, :9\P 66>.P1AGD4'79U-"EJ<5 U7
MFUP15)IC%%&::Q=.F7092YA_'$B8BQY%EYD@0Y>H(4*7NB)!E],B09;O($*5
M_AY"E?\=0Y3_'$.4_QQ#E/\<0Y3_',QU  "\@0  L8P  *:2  ";EP  D9L
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M#BRX_PXLN/\.++C_#K./  "FEP  FYT  (^C  "#J@  =K   &JU  !>N@
M4KX  $?" 0 ]QP8 .,D0 #?)&P VRB< -<HS #3+/0 SRT< ,<M1 3#+6P$N
MS&4"+,QQ BK,?P,IS) $)\RA!";-M 0ES<X$)<ON!"3)_ 8CR/\'(\?_!R/'
M_P<CQ_\'(\?_!ZF6  ">G0  DJ,  (6K  !XL@  :[@  %^^  !2P@  1\8
M #W*   TSP0 *]0) ";9#P EV1D )=HE "3:,  CVSL (]M% "+<4  AW5L
M(-UH ![>=@ =WH<!'-^9 1K?K $9W\0!&-[G 1C<^ $8V_\"%]K_ A?:_P(7
MVO\"%]K_ J"<  "4HP  AZL  'FS  !LN@  7\$  %+&  !&R@  .\X  #'3
M   IV0  (=X% ![H#@ =Z!4 &^D> !GI)P 8ZC  %NHY !7K0P 4[$X $NQ:
M !'M9P 0[G< $.Z*  [OG@ .\+, #?#-  SO[  ,[?P #.O_  SK_P ,Z_\
M#.O_ )>C  ")JP  >[0  &V\  !?Q   4LH  $7.   YTP  +]@  "7=   =
MX0  &.P" !;W"P 4]Q$ $?@7 !#X'@ .^24 #?DM  OZ-0 )^S\ !_M*  3\
M5P #_68  OYW  #]BP  _9\  /RU  #\T0  _.T  /S\  #\_0  _/T  /S]
M (NK  !]M   ;KT  &#&  !2S0  1-(  #?8   LW0  (N$  !GE   3Z@
M$/H   [_!@ -_PP "O\0  ?_%  $_QH  ?\@  #_)P  _S   /\Z  #_10
M_U,  /]B  #_=0  _XH  /^?  #_LP  _\<  /_E  #_Y0  _^4  /_E '^T
M  !PO0  8<<  %/0  !#U@  -MT  "KB   ?Y@  %NH  !#M   ,^@  "?\
M  ;_   "_P0  /\)  #_#0  _Q   /\4  #_&@  _R$  /\I  #_-   _T
M /].  #_7@  _W(  /^'  #_F@  _ZH  /^Y  #_N0  _[D  /^Y /\@*0'_
M(B<!_R(G ?\?*@'_&3 !_Q(Y ?\010'_#5,!_PQ@ ?\*;0+_"7D"_PF$ O\)
MC@'_"98!_PF= ?\)HP'_":D!_PFP ?\(MP'_"+X!_PC( ?\(U@'_".8!_PCQ
M ?\(^P#_"/\ _PC_ /\)_P'_"?\!_PG_ ?\)_P'_"?\!_PG_ ?\C)@'_)20
M_R4D /\C)P'_'2P!_Q@U ?\50@'_$E !_Q!= O\.:@+_#G8"_PZ  O\.B@+_
M#I("_PZ: O\.H +_#J8!_PVM ?\-LP'_#;L!_PW% ?\-T0'_#>,!_PWO ?X-
M^@'Z#?\!^0[_ ?D._P'Y#O\!^ [_ ?@._P'X#O\!^ [_ ?\F(P#_*"  _R@@
M /\F(@#_(B@!_R R ?\</P'_&4P!_Q=9 O\590+_$W$"_Q-\ O\3A@+_$XX"
M_Q*6 O\2G0+_$J,"_Q*I O\2L +_$K<"_Q+! O\2S ']$M\!^1/M ?43^ 'S
M$_\!\A/_ ?$3_P+P%/\"\!3_ O 4_P+P%/\"\!3_ O\J'P#_+!P _RP; /\K
M'0#_*20 _R@O ?\E.P'_(D@!_Q]4 O\=80+_&VT"_QIW O\:@0+_&HH"_QJ2
M O\:F0+]&I\"_!JF OL:K +Y&K0"^!J] O8:R +S&ML"[QKJ NP;]P+I&_\"
MZ!O_ ^<<_P/F'/\#Y1S_ ^4;_P/E&_\#Y1O_ _\M&P#_,!< _S$5 /\P%@#_
M,2  _S J /\N-@'_*T,!_RA/ O\F7 +_)&<"_"-R _DC? /W(H4#]2*- _,B
ME0/R(IL#\"*B ^\BJ0/M(K$#["*Y ^HBQ0/H(M4#Y"/I ^ C]@3>(_\$VR3_
M!-DD_P38)/\$UR3_!-8D_P36)/\$UB3_!/\Q%@#_-!( _S81 /\W$P#_.1L
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M#J)!_PZB0?\.HD'_#O\_"0#_1   _TH  /=. @#L4 8 ZD\+ .-,$ #63!X
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M)6M>P29I7MXF:E_T(6M@_QUK8?\;;&'_&6QA_QAL8?\8;&'_&/51  #B7
MSV4  ,-K  "Y;P  L7$  *IQ  "B;P@ FV\7 )9P)P"0;S4"BVY !89L20B"
M:E(,?FE9#WMH8!)W9F84=69N%W)E=AIP9'X=;6.('VMCDR)I8J D9F*N)65B
MOR9D8MHF9&/R(F5D_QYF9/\;9V3_&6=E_QAG9?\89V7_&/!3  #=7P  RV@
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M(E9Q_AY7<?\<5W'_&EAQ_QE8<?\96''_&>->  #-:0  OW,  +1Z  "K?P
MHH(  )B#  "+@0  A($- '^"&@![@BD!=H$V G*!0 5N?TD(:GY0"V=]5PYD
M?%X187MF%%YZ;1=;>G8967F '%9XBQ]3>)@A47>F(E!WMR-/=\XC3W?L(5!W
M_1Y1=_\;4G?_&5)W_QE2=_\94G?_&=YB  #(;@  NW<  +!_  "GA   G8<
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M%3Z/_Q4^C_\5/H__%<5S  "W?P  K(D  *&/  "6DP  BY8  '^9  !SG
M9)\  %R@"0!9H!0 5Z$B %6A+P!2H3D!4*%# DV@2P1*H%,%2*!:!T6?8PE#
MGVP+0)YV#CZ>@Q [GI$1.9V@$CB=LA,WGL@3-YWH$C:;^A(VFO\2-IG_$3>9
M_Q$WF?\1-YG_$;Y[  "QAP  I8\  )N4  "0F   A)P  '>@  !KI   7Z<
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M!*64  ":F@  CJ$  (&G  !SK@  9[0  %JY  !.O0  0L   #C#   OQP
M)LL$ ![0"@ ;T1$ &M(: !G2)0 8TR\ &-,Z !?41  6U%  %=5= !35:P 3
MUGP $M>/ !'8I  0V;L $-G> !#5\P 0T_\ $-+_ 1#1_P$0T?\!$-'_ 9R:
M  "1H0  @Z@  '6P  !HMP  6[T  $[!  !"Q0  -\@  "W,   DT   '-4
M !7:!0 0X@L $.,1  [D&@ .Y", #>4M  SE-P +YD( "N9/  GG70 (YVT
M!N:   7FE0 $YJL  N;$  'FY@  Y_D  .?_  #F_P  YO\  .;_ ).A  "%
MJ0  =[$  &FY  !;P   3L8  $'*   US@  *M(  "'6   9VP  $M\   WC
M   +\0@ "?,.  ?S$P $\AH  O(B  #R*@  \C0  /(_  #R3   \EP  /)M
M  #R@@  \I@  /.M  #SQ@  ].4  /3V  #T^P  ]/L  /3[ (>I  !YL@
M:KH  %S"  !.R0  0,X  #/3   HV   'MT  !7A   /Y   "N@   7S   #
M_0$  /P(  #[#0  ^Q$  /L6  #\'@  _"8  /PP  #]/   _DD  /Y:  #^
M;0  _X(  /^8  #_K   _\   /_8  #_Y   _^0  /_D 'NR  !LNP  7<0
M $_-  ! T@  ,MD  ";>   ;X@  $N8   SJ   %[0   /0   #_    _P
M /\   #_!   _PD  /\.  #_$@  _Q@  /\A  #_*P  _S<  /]&  #_6
M_VL  /^   #_E0  _Z8  /^S  #_NP  _[L  /^[ /\;)@#_'"0 _QHD /\5
M)P#_$"T _PHV /\%0P#_ 5 !_P!> ?\ :P'_ '8!_P"! /\ B@#_ )( _P":
M /\ H #_ *8 _P"L /\ L@#_ +D _P#" /\ S0#_ -\ _P#L /\ ^ #_ /\
M_0#_ /T _P#] /\ _0#_ /T _P#] /\ _0#_ /\?(P#_'R$ _QXA /\9(P#_
M$RD _PXR /\,0 #_"4T!_P=: ?\$9P'_ W,!_P-] ?\#AP'_ X\ _P*6 /\"
MG #_ J( _P*H /\"KP#_ ;8 _P&^ /\!R0#_ =L _P#J /P ]@#X /\ ]P+_
M /<#_P#V!/\ ]@3_ /8%_P#V!?\ ]@7_ /\B'P#_(AP _R$< /\>'P#_&"0
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M \$D_P/!)/\#P23_ _\P#P#_,@L _S,( /\V#0#_-A( _S4: /TR)0#T,#(
M[2T_ .<L3 #B*U@!W2MC =DJ;0'5*G8"TBI_ M JA@+.*HX#S"J5 \HJG /)
M*J,$QRJL!,4JM@3#*L,%PBK5!;XKZP6Z*_D&N"S_!K8L_P6U+/\%M"S_!;0L
M_P6T+/\%M"S_!?\T# #_-@4 _SD# /\\" #_/ T _3L3 /$X'0#H-2D X#0W
M -DS1@#1-%(!S3-= <DS9P+&,W #Q#)X!,$R@ 2_,H<%OC*/!KPRE@:Z,9X'
MN#&F![<QL BU,KP(LS+,";$RY0FM,_4)JS/_":HS_PBH,_\'J#/_!Z<S_P>G
M,_\'IS/_!_\W!P#_.@  _SX  /I! 0#Q008 \3\- .8\$@#;.A\ T#LQ ,H\
M0 #$/$T!P#Q8 KP[80.Y.VH%MCIR!K0Z>@>R.8$(L#F(":\YD JM.)@*JSBA
M"ZDXJ@RH.+8-ICC%#:0XW@ZA.?$-GSK_#)XZ_PN=.O\*G#K_"9PZ_PF<.O\)
MG#K_"?\[ @#_/@  ]T0  .9'  #?2 $ VD8& -E "P#-0AD Q40K +Y$.P"Y
M1$@!M4-3 [%"7 2N0F4&JT%L!ZE = FF0'L*I#^#"Z,_B@VA/I,.GSZ<#YT^
MI1";/K$1FCZ_$9@^U!*6/^T1E#_\#Y- _PZ20/\,DD'_"Y)!_PN20?\+DD'_
M"_\]  #_0P  Z4D  -Y.  #33P  S4X# ,I)" #"210 NTHF +5+-@"O2T,"
MJTI. Z=)5P6D2& 'H4=G"9Y&;PJ<1G8,FD5]#IA%A0^61(X0E$27$I)#H1.0
M0ZP4CT.Z%8U#S16+1.@5BD7Z$HE&_Q")1O\.B$;_#8A&_PV(1O\-B$;_#?]
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M&7I-PQIY3=\:>$[T%WA/_Q1X3_\2>%#_$'A0_P]X4/\/>%#_#_U&  #G3P
MUE<  ,A<  "_7P  MU\  +%<  "J60P I%H: )Y;*@"96S@!E%I# Y!93 6,
M6%4(B5=<"H968PR#56H.@51Q$']3>1)]4X$4>E*+%GA2E1AV4:$9=%&O&W-1
MP!MQ4=L<<5+R&7%3_Q5Q5/\3<E3_$7)4_Q!R5/\0<E3_$/-(  #C4P  T%L
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M&V!?_1AA7_\585__$V)?_Q)B7_\28E__$NI1  #47   Q&0  +EJ  "P;@
MIW   )YN  "4:P  C6H0 (=K'@"#:RP ?FLX GIJ0@-V:4H&<VA2"'!G60IM
M9F -:V5G#VAD;A%F9'<49&.!%F%CC!A?8I@:76*F'%MBMAU:8LP=6F+J'%MC
M_!A<8_\67&/_%%UC_Q-=8_\376/_$^95  #/7P  P6@  +9N  "L<@  I'0
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M$TUR_Q)-<O\237+_$M1@  #":P  M70  *M[  "B?P  EX$  (R!  !Z?@
M<W\" &Y_$0!K@!X :( L &6 -P%B@$ #7W](!%Q^4 99?E<(5WU>"U1\9@U1
M?&X/3WMX$4Q[@Q1*>I$62'J?%T9ZKQA%>L081'KD&$5Y^!9&>?\41GC_$D=X
M_Q%'>/\11WC_$<UE  "]<   L7D  *>   "<A   DH8  (:&  !WA@  :X8
M &:'#0!CAQD 8(@G %Z(,P%;B#P"6(=% U:'3013AE0&4(9;"$Z%8PI+A&P,
M281V#T:#@1%$@X\30H.=%$""KA4_@\(5/H+B%3^!]Q,_@?\20(#_$4" _Q!
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M"[AZ  "LA0  H8L  ):0  "+E   ?Y<  '*;  !FG0  6J   $ZB  !%I D
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M !? H0 6P+8 %,#3 !6^\0 5O/\!%;O_ 12Z_P(4NO\"%+K_ J&2  "6F
MBIX  'VD  !OJ@  8J\  %:T  !*MP  /KH  #.]   JP   (<0  !G'!0 3
MRPL $<P2 !',&P 0S"4 #\TO  [-.@ .S48 #<U2  W.8  ,SG  "\Z#  K.
MEP )SJP ",[&  C.Z  (S?L "<O_  G+_P )R_\ "<O_ )B8  "-G@  ?Z4
M '&L  !DLP  5[D  $J]   ^P   ,L,  "C&   ?R@  %\T  !'1   ,U@4
M"-D,  ;9$@ %VAL !-HD  /;+@ !VSD  -Q%  #=4@  WF(  -YS  #>B
MWYT  -^S  #?S@  X.X  -_Z  #?_P  W_\  -__ (^?  "!I@  <ZX  &6U
M  !8O0  2L(  #W%   QR0  )LP  !W0   4U   #MD   G=   #X0   .,'
M  #C#0  Y!(  .49  #F(@  YRL  .DV  #K0P  [%(  .QB  #M=@  [HP
M .ZA  #OMP  []$  ._K  #P]@  \/8  /#V (2G  !UKP  9[<  %F_  !+
MQ@  /,H  "_.   DT@  &M@  !+<   ,X   !>,   #G    ZP   .L   #M
M!0  [@L  / 0  #Q%0  \QX  /0G  #W,P  ^4   /I1  #[8P  _'<  /V-
M  #]HP  _K8  /[)  #_WP  _]\  /_? '>P  !HN0  6L$  $S*   \SP
M+M0  "+:   7W@  $.(   GF    Z0   .P   #P    ]@   /8   #W
M^    /H'  #[#0  _1$  /\9  #_(P  _R\  /\^  #_3P  _V(  /]W  #_
MC0  _Y\  /^N  #_N@  _[H  /^Z /\6(P#_%2$ _Q(A /\.) #_!BH _P S
M /\ 00#_ $X _P!< /\ : #_ '0 _P!^ /\ AP#_ (\ _P"6 /\ G #_ *(
M_P"H /\ K@#_ +4 _P"] /\ QP#_ -8 _P#G /X \P#^ /X _0#_ /P _P#[
M /\ ^P#_ /L _P#[ /\ ^P#_ /\:( #_&1X _Q8> /\0( #_"B4 _P0P /\
M/0#_ $L _P!8 /\ 9 #_ '  _P!Z /\ @P#_ (L _P"2 /\ F #_ )X _P"D
M /\ J@#_ +$ _0"Y /L PP#Z -  ^ #C /< \0#V /P ] #_ /0 _P#S /\
M\P#_ /, _P#S /\ \P#_ /\=' #_'!D _QD9 /\4&P#_#B$ _PPL /\).0#_
M!48 _P)3 /\ 7P#_ &L _P!U /\ ?@#_ (8 _P". /\ E #^ )L _ "A /H
MIP#X *X ]0"U /, OP#Q ,L \ #? .X [@#L /D ZP#_ .H _P#J ?\ Z0'_
M .D!_P#I ?\ Z0'_ /\@%P#_'Q0 _QP3 /\7%0#_%AT _Q,H /\0- #_#4$
M_PQ. /\)6@#_"&8 _PAP /X'>0#\!X$ ^@>) /@'D #V!I8 \P:= /$&HP#O
M!JH [0:R /_B__])0T-?4%)/1DE,10 (">H&NP#H!L@ Y@;< .0&[ #B"/H
MX K_ -X+_P#="_\ W0S_ -P,_P#<#/\ W S_ /\C$@#_(Q  _R$. /\>$ #_
M'A@ _QPC /\8+P#_%#L _Q)) /P050#X#V  ] ]J /$/= #O#GP [0Z$ .L.
MBP#I#I( YPZ9 .8.H #D#J< X@ZO . .N #>#L4 W [: -80[ #2$?H SQ+_
M ,T2_P',$O\!RQ/_ <H3_P'*$O\!RA+_ ?\G#P#_)PP _R4) /\F#0#_)1,
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M!I8T_P66-/\%EC3_!?\U  #_.   ZCX  -]"  #50@  SS\# ,TX" #%.!4
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M"O)"  #@3   SE,  ,%8  "X6@  L%D  *E6  "B4@< FU(5 )93) "14S(
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M%&%5M!5@5<@67U7G%6!6^A)@5O\/85?_#F%7_PUA5_\,85?_#.=,  #15@
MP5X  +9C  "M9@  I&8  )MD  "07@  B5X. (1?&P" 7RD ?%\U 7A?/P)T
M7D<#<5U/!&]<5@5L7%P':EMC"6A;:PMF6G,-9%I]#V):B!%?69037EFB%%Q9
MLA5;6<866EGE%5M:^1);6O\07%K_#EQ:_PU<6O\-7%K_#>-/  #-60  OF$
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M%$MG]1),9_\/3&?_#DUG_PU-9_\-36?_#=):  # 9   LVP  *ER  "@=@
MEG<  (IV  !Y<0  <7$  &MQ#P!H<1P 9G(H &-R- !@<CT!7G)% EMQ30-9
M<50%5W!;!E1P8PA2;VL*4&]T#$UN@ Y+;HT026Z;$4=MJQ)&;KX316[<$D9M
M]!%&;?\/1VW_#D=L_PU';/\-1VS_#<Q?  "\:0  L'$  *5W  "<>P  D7P
M (9[  !U>   :W<  &5W# !A>!< 7W@D %UY, !:>3H!6'E" E9X2@)3>%$$
M47=8!4]W8 =,=F@(2G9R"DAU?0Q%=8H.0W69#T)UJ1! =;P00'79$$!T\P]
M=/\.07/_#4%S_PQ!<_\,07/_#,9D  "W;@  JW8  *)\  "7?P  C($  (&!
M  !R@   97\  %U_" !9?Q, 5X @ %6 *P!3@38 48 ^ 4^ 1@)-@$X"2W]5
M TE_705&?V8&1'YP"$)^>PD_?H@+/7V7##Q]IPTZ?;H..G[6#3I\\0TZ>_\,
M.GO_"SIZ_PLZ>O\+.GK_"\!I  "R=   IWP  )V!  "2A   AX8  'N'  !N
MAP  8(<  %6' 0!0B X 3H@: $V))@!+B3  28DZ $B)0@%&B4H!1(E2 D*)
M6@- B&,$/8AM!3N(> 8YAX8(-X>5"36'I@HTA[D*,X?3"C.&\ DSA?\),X3_
M"3.#_PDS@_\),X/_";EP  "M>@  HH(  )>'  "-B@  @8P  '6.  !HCP
M6I   $^1  !'D@H 1)(3 $.3'P!!DRH 0),T #^3/0 ]DT4 .Y-- 3J35@$X
MDU\"-I-I S23=0,RDH,$,)*3!2Z2I 8MDK<&+)+1!BR1[P8KC_\&*X[_!BN-
M_P<KC?\'*XW_![-X  "G@@  G(@  )&,  "'D   >I,  &V5  !AEP  59D
M $F;   _G $ .9T. #>=%P VGB( -)XL #.>-0 RGCX ,9Y' #"?4  NGUH
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M )R0  "2E0  AIL  'F@  !KI@  7JL  %*O  !&L@  .K4  "^W   EN@
M';T  !7    0PP8 "\8.  K%%0 )Q1X ",4H  ?%,@ &QCT !<9)  7&5P #
MQF8  L9W  '&BP  QJ   ,6V  #&T@  Q>\  ,7\  #%_P  Q?\  ,7_ )66
M  ")G   >Z,  &VI  !@KP  4[0  $:X   ZNP  +KX  "3!   ;Q   $\<
M  [*   (S@$  = *  #0$   T!8  -$>  #2)P  TS$  -0\  #520  UE@
M -9I  #6?   UI(  -:G  #6OP  UN   -;S  #6_@  UO\  -;_ (R=  !^
MI   ;ZL  &&R  !4N0  1KT  #G!   MQ   (L<  !G+   1S@  #-(   75
M    VP   -P#  #="@  W@\  -\4  #A'   XB0  .0N  #F.@  YTD  .A9
M  #H:P  Z8$  .F8  #IK0  Z<4  .GB  #I\@  Z?4  .GU ("E  !QK0
M8[4  %6\  !'P@  .<8  "S*   @S@  %M(   _6   (VP   -\   #C
MY0   .<   #H 0  Z@<  .L-  #M$0  [Q@  /$A  #S*P  ]C@  /=(  #X
M6@  ^6T  /J$  #ZFP  ^J\  /K"  #ZV@  ^M\  /K? '2N  !EM@  5KX
M $C&   YRP  *]   !_4   4V@  #=\   7C    Y@   .D   #M    [P
M /$   #S    ]0   /8"  #X"0  ^@X  /T3  #_'   _R@  /\V  #_1P
M_UH  /]N  #_A0  _YH  /^K  #_N0  _[P  /^\ /\1( #_$!X _PP> /\$
M(0#_ "< _P P /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z /\ @P#_ (L _P"2
M /\ F #_ )X _P"D /\ J@#_ +  _P"X /\ P@#_ ,X _P#B /X \ #] /L
M^P#_ /L _P#[ /\ ^@#_ /H _P#Z /\ ^@#_ /\4' #_$AH _PX: /\(' #_
M "$ _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_ (< _P". /\
ME #_ )H _@"@ /T I@#\ *P ^P"T /D O0#X ,D ]P#< /4 [ #S /@ \P#_
M /( _P#Q /\ \ #_ /  _P#P /\ \ #_ /\7& #_%18 _Q$5 /\,%P#_!1T
M_P H /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#\ (( ^@") /@ D #W
M )8 ]0"< /0 H@#S *@ \0"P /  N #N ,, [ #3 .H YP#I /4 YP#_ .8
M_P#E /\ Y0#_ .4 _P#E /\ Y0#_ /\:$P#_&!$ _Q00 /\/$0#_#1D _PHD
M /\%, #_ 3X _P!+ /\ 5P#^ &( ^@!L /4 =0#R 'T \ "$ .X BP#L )$
MZP"7 .D G@#G *0 Y@"L .0 M #B +\ X #- -X XP#< /( V@#] -@ _P#6
M /\ U0'_ -4!_P#5 O\ U0+_ /\>$ #_' T _Q<+ /\5#@#_%!4 _Q$? /\.
M*@#_"S@ _0A% /@&40#T!%P [@1F .H$;P#F W< Y 1_ .($A@#@!(P W@23
M -T%F@#;!:  V 6H -4%L0#2!;L T ;) ,X'X #,"/$ R0K_ ,<+_P#&#/\
MQ0S_ ,4,_P#%#/\ Q0S_ /\A# #_( 8 _QP# /\="@#_&Q  _Q@8 /\4(P#V
M$3  [PX^ .H.2@#E#58 X0U@ -T-:0#9#7$ U0UY -,-@0#1#8@ SPV/ ,T.
ME@#+#IT R@ZE ,@.K@#&#[D Q!#( ,(0WP"^$?( NQ+_ +D3_P"W$_\!MA/_
M ;83_P&V$_\!MA/_ ?\E!@#_(P  _R,  /\D P#_(0H _1T1 /$:&P#H%B<
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M!/PS  #K.@  W$$  ,U$  ##1   O4$  +@[ 0"R-PX JS@< *4Y*P"A.C@
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M"W!#M0QN1,D,;43G#&U%^@IL1?\(;$7_!VQ%_P=L1?\';$7_!^P_  #820
MQU   +M4  "Q50  J50  *%0  "92@( DDD1 (U*'P")2RP A4PX ()+0@%_
M2TH!?$I2 GE*6 -W2E\$=4EF!7-);09Q278';TA_"&U(B@EL2)8+:DBC#&A(
ML@UG2,4-9DGD#69)^ MF2?\)9DK_"&9)_P=F2?\'9DG_!^A#  #230  PE,
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M#U55\PU55?\+5E7_"595_PE65?\(5E7_"-M-  #%5P  N%X  *UB  "C90
MFF4  )!C  "#7   >UL& '5;$@!Q6Q\ ;EPK &M<-@!H6S\!95M' 6-;3@)A
M6E4#7UI<!%U:8P5;6FL&65EU"%=9@ I568P+5%F:#5)9J@Y16;P.4%G8#E!9
M\@U16?\+45G_"E%9_PE16?\(45G_"-11  #"6@  M&$  *IF  "@:   EVD
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M"4%G_PA"9_\(0F?_",5=  "V9@  JFT  *!S  "6=@  BW<  (!V  !P<@
M97$  %QP!P!8<!$ 5G = %1Q* !2<3, 4'$\ $]R1 %-<4L!2W%3 DEQ6@-'
M<6($17!L!4-P=P9!<(0'/W"3"#UOHPD[<+4*.W#-"CIO[ D[;OX(.V[_"#MM
M_P<[;?\'.VW_![]B  "Q:P  IG,  )UY  "2>P  AWP  'M\  !M>@  8'@
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M ZUV  "C@   EX4  (V)  ""C   =HX  &F0  !<D@  4),  $24   ZE0
M,98( "V7$0 LEQH *Y<D "J7+0 IES8 *)@_ ">82  FF%( )9A< ".8:  B
MF'< ()B' !^8F0$=F*P!')C# 1R7Y0$<E?H!&Y3_ 1N3_P(;D_\"&Y/_ J=_
M  "<A@  D8L  (>/  !ZD@  ;94  &&8  !5FP  29T  #V>   SGP  *J$
M "&C"@ ?HQ$ 'J,: !VD)  <I"T &Z0V !JD/P 9I$H &*15 !:E80 5I7
M%*6! !.EE  2I:@ $:6_ !"DX@ 1HO@ $:'_ !&@_P$1H/\!$:#_ :"&  "5
MC   C)$  '^5  !QF@  9)X  %BA  !,I   0*8  #6G   JJ0  (JP  !FN
M   2L D $+$0 !"Q&  .L2( #K$K  VQ-0 -L4  #+%+  NQ6  *L6< "+%X
M  >QBP %L:  !+"U  2PT  $L.\ !:_^  :N_P &KO\ !J[_ )B.  "/DP
M@I@  '6=  !GH@  6J<  $ZK  !!K0  -:\  "NQ   AM   &+8  !&Y   -
MO , ![X,  .]$@ !O1D  +XB  "^*P  OC8  +Y!  "_3@  OUP  +]M  "_
M@   OI4  +ZJ  "^P@  O>0  +WV  "]_P  O?\  +W_ )*4  "%F@  >*
M &JF  !<JP  3[   $*S   UM@  *K@  ""[   7O@  $,$   O$   $QP
M ,D'  #)#0  R1(  ,H9  #+(@  RRL  ,TU  #.00  SE   ,]@  #/<@
MSX<  ,^=  #/LP  S\X  ,_K  #.^   SOX  ,[^ (B;  !ZH@  ;*@  %ZO
M  !0M0  0KD  #6\   IOP  'L(  !7&   .R0  ",P   #0    TP   -4
M  #6!@  V P  -D1  #;%@  W!\  -XH  #@-   XD$  .)1  #C8P  XW<
M .2.  #DI   Y+H  .74  #EZ@  Y?,  .7S 'RC  !NJ@  8+(  %&Y  !#
MO@  -<(  "C&   <R0  $\T   S1   $U0   -H   #>    X0   .(   #D
M    Y0,  .<)  #I#@  ZQ(  .T:  #O)   \C$  /1!  #T4P  ]68  /5\
M  #VDP  ]JD  />\  #WS@  ]]\  /?? '"L  !AM   4[L  $7#   VQP
M)\P  !O0   1U0  "ML   #?    X@   .4   #I    [    .T   #P
M\0   /,   #U!   ]PH  /H0  #\%@  _R$  /\N  #_0   _U,  /]H  #_
M@   _Y8  /^H  #_M@  _[\  /^_ /\-' #_"AL _P(; /\ '@#_ "0 _P N
M /\ / #_ $H _P!6 /\ 8P#_ &T _P!W /\ ?P#_ (< _P". /\ E #_ )H
M_P"@ /\ I@#_ *P _P"T /\ O0#_ ,D _@#= /T [0#\ /H ^P#_ /H _P#Y
M /\ ^@#_ /H _P#Z /\ ^@#_ /\0&0#_#1< _P86 /\ & #_ !X _P J /\
M-P#_ $4 _P!2 /\ 7@#_ &D _P!R /\ >P#_ (( _P") /\ D #^ )8 _0"<
M /P H0#[ *@ ^0"O /@ N #V ,, ] #2 /, YP#R /8 \ #_ .\ _P#P /\
M[P#_ .\ _P#N /\ [@#_ /\2% #_#Q( _PL2 /\ $@#_ !H _P E /\ ,P#_
M $  _P!- /\ 60#_ &0 _0!M /L =@#Y 'T ]P"$ /4 BP#T )$ \P"7 /$
MG0#P *, [@"J .P LP#J +T Z #+ .< X0#E /$ XP#] ., _P#B /\ X0#_
M .$ _P#@ /\ X #_ /\4$ #_$0X _PT- /\'#P#_ A4 _P @ /\ +0#_ #H
M_P!' /D 4P#U %X \@!H /  < #M '@ ZP!_ .D A0#H (P Y@"2 .4 F #C
M )\ X0"F -\ K@#< +@ V@#% -8 V0#4 .P T@#Y -$ _P#/ /\ S@#_ ,X
M_P#. /\ S@#_ /\7# #_% @ _P\% /\."P#_#!$ _P<: /\!)@#\ #0 ] !!
M .T 30#I %@ Y@!B ., :@#@ '( W@!Y -L @ #9 (8 U@"- -, DP#1 )H
MSP"A ,T J@#+ +, R0"_ ,8 T #% .@ PP#V ,$ _P#  O\ OP/_ +\#_P"_
M _\ OP/_ /\;!@#_%P  _Q0  /\3!0#_$0T _PX4 /D*'P#P!BP Y@,Y . #
M1@#< U$ U@1; -($9 #/!6P S 5S ,H%>@#(!8$ Q@6' ,4&C@##!I8 P0:=
M +\&I@"]!K  NP>\ +D(S0"X"N4 M0OW +,-_P"Q#?\ L W_ + ._P"O#O\
MKP[_ /\>  #_&P  _QL  /H:  #U%@4 ]A$- .L.%0#B"R( V LQ - ,/@#+
M#4H QPU5 ,0.7@#!#F8 OPYM +T.= "[#WL N0^" +<0B@"V$)$ M!": +(0
MHP"P$:T KQ&Z *T1R@"J$N4 IQ3W *45_P"C%?\ HA7_ *(5_P"B%?\ HA7_
M /\B  #_(   \",  .8D  #@(0  W!D% -L0# #0$1D R!,I ,(5-P"]%D0
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M H8LN@*%+<X#@R[J X$N_ . +O\"?R[_ G\N_P)^+O\"?B[_ O0N  #D-P
MTCT  ,4_  "[/P  M#P  *\U  "I+PL HR\7 )XQ)@"9,C, EC(^ )(S2 "0
M,U  C3-8 (LS7@&),V4!AS-L 88S<P&$,WP"@C.% H SCP-_,YH#?3.G WPS
MM01Z,\D$>33F!'<U^01V-?\#=37_ W4U_P-U-?\#=37_ _ S  #=/0  RD,
M +Y%  "U1@  K4,  *8]  "@-@8 F383 )0X(0"0.2X C#DY (DY0P"'.4P
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M"&!$\P=@1/\&7T3_!5]$_P1@1/\$8$3_!.!!  #*2@  NU   +!3  "G50
MGE,  )5/  "+20  @T<+ 'U'%0!Y1R( =D@N '-(. !Q2$$ ;DA) 6Q(4 %J
M2%8!:$A= F9'9 )E1VP#8T=V!&%'@ 5@1XT&7D>:!UQ'J0A;2+L(6DC4"%I(
M\0=:2?\&6DG_!5I(_P5:2/\$6DC_!-M$  #&30  N%,  *U7  "C60  FE@
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M!DM4_P5+5/\%2U3_!<Q.  "[5P  KEX  *1B  ":9   D60  (9B  !W6P
M;5@  &98# !B6!8 7U@B %U9+ !;638 65D^ %=91@!664T!5%E4 5)96P)1
M66,#3UEL TU9=P1+6(0%25B2!TA8H@='6;,(1EG*"$59Z@A&6?T&1EC_!D98
M_P5'6/\%1UC_!<=2  "X6P  JV$  *%F  "8:   CFD  (-G  !R8   :%X
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M!+E@  "L:0  H7   )AU  "-=P  @G<  '=W  !I=   7',  %%Q  !(< H
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M "&&E0 @AJ<!'H:\ 1Z&W@ >A/4!'H+_ 1Z"_P$>@?\!'H'_ :AT  ">?0
MDX(  (F%  !^B   <8H  &6+  !8C   3(T  $".   VC@  +(\  "60#  C
MD!, (I < "&0)0 @D2X 'Y$V !Z10  =D4D ')%4 !J18  9D6X &)%^ !:2
MD  5DJ0 %)&Y !.1V  3C_0 %([_ !2-_P 4C/\!%(S_ :-]  "8@P  CH@
M (2,  !WCP  :9$  %V3  !0E0  19<  #F8   NF0  )9H  !V; @ 6G0P
M%9T3 !2=&P 3G20 $ITM !&>-P 1GD$ $)Y,  ^>6  .GF< #9YW  R>B@ +
MG9X "IVR  F=S  )G.P "IO^  N:_P +F?\ "YG_ )R$  "1B@  B(X  'N2
M  !ME@  8)D  %2<  !(GP  /*   #"A   FHP  ':4  !6G   0J04 "ZL-
M  BJ$P 'JAL !JHD  6J+@ $JC@  JI$  &J4   JEX  *IN  "J@0  JI4
M *FJ  "IP0  J.0  *CV  "G_P  I_\  *?_ )6+  ",D   ?Y4  '&:  !C
MG@  5J(  $JF   ]J   ,:H  ":K   =K0  %+    ZR   )M0$  K8*  "V
M#P  MA4  +<=  "W)0  MR\  +@Y  "X1@  N%0  +AD  "X=@  N(L  +>@
M  "WM@  M],  +;O  "V_   MO\  +;_ (^2  ""EP  =)T  &:B  !8IP
M2ZP  #ZO   QL0  )K,  !RV   3N   #;L   :^    P0   ,($  #""P
MPQ   ,05  #$'   Q20  ,8N  #(.@  R4<  ,E7  #):0  R7T  ,F4  #(
MJ@  R,,  ,CD  #(]   R/T  ,C] (69  !WGP  :*8  %JK  !-L0  /[4
M #&X   EN@  &KT  !'    +PP   \<   #*    S0   ,X   #/ P  T D
M -$.  #3$@  U1D  -<B  #:+0  W3D  -Y)  #>6@  WVX  -^%  #?G
MW[(  -[+  #>Y@  W_0  -_T 'FA  !KJ   7*\  $ZU  ! NP  ,;X  "3!
M   9Q0  $,@   G,    SP   -,   #9    W    -T   #?    X0   .(%
M  #D"P  YA   .@6  #J(   [2L  / Z  #Q2P  \5X  /)S  #SBP  \Z(
M /.V  #SR0  \^$  //A &VJ  !>L0  4+D  $&_   RQ   ),@  !?,   .
MT   !M4   #:    W@   .(   #F    Z0   .H   #L    [@   /    #R
M    ] 8  /8,  #Y$@  _!P  /\I  #_.@  _TT  /]B  #_>   _Y   /^C
M  #_LP  _\$  /_! /\'&0#_ 1< _P 7 /\ &@#_ "$ _P K /\ .0#_ $<
M_P!4 /\ 7P#_ &H _P!S /\ >P#_ (, _P"* /\ D #_ )8 _P"; /\ H0#_
M *@ _P"O /\ N #_ ,0 _@#5 /P Z@#[ /@ ^@#_ /D _P#X /\ ^ #_ /8
M_P#S /\ \0#_ /\+%0#_!1, _P 3 /\ % #_ !H _P G /\ - #_ $( _P!/
M /\ 6P#_ &4 _P!N /\ =@#_ 'X _P"% /X BP#] )$ ^P"7 /H G0#X *,
M]P"K /8 LP#T +X \P#, /$ XP#O /, [@#_ .T _P#L /\ ZP#_ .P _P#L
M /\ ZP#_ /\-$0#_"1  _P / /\ $ #_ !8 _P B /\ +P#_ #T _P!* /\
M50#] &  ^@!I /@ <0#V 'D ] !_ /, A@#Q (P [P"2 .X F #L )\ ZP"F
M .D K@#G +@ Y0#% ., V@#A .T WP#[ -X _P#= /\ W0#_ -T _P#= /\
MW0#_ /\/#0#_# L _P,) /\ # #_ !( _P = /\ *0#[ #< ^ !$ /4 4 #R
M %H [@!C .P :P#I ', YP!Z .4 @ #C (8 X0", -\ DP#= )D VP"A -D
MJ0#5 +( T@"^ -  S@#. .8 S #V ,H _P#* /\ R0#_ ,@ _P#( /\ R #_
M /\1" #_#0( _P<  /\%" #_  X _P 6 /< (@#O #  ZP ] .@ 20#D %0
MX != -T 90#9 &T U0!S -( >@#0 (  S@"' ,P C0#* )0 R "; ,8 I #$
M *T P@"X ,  QP"] -\ O #Q +L _@"Y /\ N #_ +@ _P"X /\ N #_ /\4
M  #_#P  _PT  /\,  #_!PD ^ $0 .@ &@#C "@ W0 V -@ 0@#2 $T S@!7
M ,H 7P#' &8 Q0!M ,, = #! 'H OP"! +T B "[ (\ N0"7 +< GP"U *@
MLP"S +$ P@"O -@ K@+M *P#^P"K!?\ J@;_ *D&_P"I!O\ J0;_ /\6  #_
M$@  ]Q(  .P1  #F#@  Y08( -T#$@#4 R  S00M ,@$.@##!48 OP50 +P&
M6 "Y!F  MP=G +4';@"S!W4 L0A[ *\(@@"N"8H K F2 *H)FP"H"J4 I@JP
M *4+OP"C#-0 H0WM )\._@"=#O\ G __ )L/_P";#_\ FP__ /\:  #W&0
MZAX  -\>  #5&@  T!," ,X,"P#'"Q8 P TE +H.,@"V#C\ L@]) *\04@"L
M$%H JA!A *@1: "F$6\ I!%V *(1?0"A$84 GQ*. )T2EP"<$J( FA.M )@3
MO "7%-  E!7L )(6_0"0%_\ CQ?_ (X7_P".%_\ CA?_ /H=  #N(P  WR@
M - J  #')P  P2$  +T9!0"Y$A  LA4> *T6+ "H%S@ I!A# *$93 "?&50
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M G$N] )P+_\";R__ F\O_P%N+_\!;B__ >@Q  #3.@  PS\  +=!  "N00
MICX  )XX  "7,0$ D2X0 (PO' "(,"@ A#$S ($R/0!_,D8 ?3)- 'LR5 !Y
M,EL =S)A '4R:0%T,G !<C)Y 7 SA %O,Y ";3.= FPSJP)J-+P":335 V@U
M\0)G-?\"9S7_ F8U_P)F-?\"9C3_ N(V  #,/P  O40  +)'  "H1P  H$0
M )@_  "0.0  B#0- (,U%P!_-B0 ?#<O 'DW.0!W.$( =#A) '(X4 !Q.%<
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M U1#_P-40_\"5$/_ M!"  "_2@  LE   *=3  "=5   E%,  (I0  !_2@
M=44" &Y##@!K1!D 9T4D &5%+@!B13< 844_ %]%1@!=14T 6T54 %I&6P%9
M1F,!5T9L E9&=P)41H,#4T:1 U%&H0101[$$3T?'!$Y'YP1.1_L$3D?_ TY'
M_P-/1_\#3T?_ \Q&  "[3@  KU0  *17  ":6   D5<  (94  ![3@  <$H
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M \!0  "R6   IEX  )QB  "290  B&4  'UB  !N7   8UD  %E6 P!45@X
M4588 $]6(@!-5RP 3%<T $I7/ !)6$0 2%A+ $=84P!%6%L!1%AD 4)8;@%
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M 3%EE0(P9:<"+V6[ BYEV@(N9/0"+F/_ B]C_P(O8O\"+V+_ K->  "G9@
MG&T  )-Q  "(<P  ?7,  ')R  !D<   6&X  $UL  !":@, /&D. #IJ%@ Y
M:B  .&HH #9K,0 U:SD -&M! #-L20 R;%( ,6Q< "]L9@ N;', +&R" 2IL
MDP$I;*4!*&RY 2=MU@$G:_(!)VK_ 2=J_P$H:?\"*&G_ JYD  "C;   F7,
M (YV  "$>   >7D  &UX  !@=P  4W8  $AU   ^<P  -'(* #%S$0 P<QH
M+W,C "YS*P M=#0 +'0\ "MT1  I=$T *'57 "=U8P E=6\ )'5_ ")UD  A
M=:( ('6W !]UT@ ?=/$ 'W/_ 1]R_P$@<?\!(''_ :EK  "><P  E'D  (I\
M  " ?@  ='\  &=_  !:?P  37X  $-^   X?0  +WT" "A]#0 F?10 )'T<
M "-^)0 B?BT (7XV "%^/P ??T@ 'G]2 !U_7@ <?VL &G]Z !E_C  7?Y\
M%G^S !5_S@ 5?N\ %GS_ !9[_P 6>_\ %WO_ *1R  ":>@  CW\  (6"  ![
MA   ;88  &"'  !4AP  2(@  #R(   RB   *(@  ""(!0 :B0X &8D5 !B)
M'0 7BB8 %HHN !6*-P 4BD$ $XI, !*+6  1BV4 $(MU  ^+AP .BIL #8JO
M  R*R  ,B>H #8?\  Z'_P .AO\ #H;_ )][  "4@0  BH4  ("(  !SBP
M98T  %F/  !,D   09(  #22   JD@  (9,  !F4   2E@8 #I<.  V7%0 ,
MEQT #)<F  N7+P *ESD "9=$  B74  &EUX !9=N  .6@  !EI0  )6H  "5
MO@  E.   )3T  "3_P !DO\  9+_ )B"  ".B   A8P  '>/  !JD@  794
M %"8  !$F@  .)L  "R<   BG0  &9X  !*@   -H@( !Z,+  &C$   HQ<
M *,?  "C)P  HS$  *0\  "D2   I%8  *1E  "C=P  HXL  *.@  "BM@
MH=(  *'P  "@^P  H/\  *#_ )&*  ")C@  >Y(  &V7  !@FP  4YX  $:A
M   YHP  +:0  ".F   9J   $:H   RL   %K@   *\'  "O#0  KQ$  + 8
M  "P(   L2@  +$R  "R/@  LDP  +);  "R;   LH$  +&7  "QK   L,8
M +#H  "O]P  K_\  *__ (R0  !_E0  <9H  &.?  !5I   1Z@  #JJ   M
MK   (JX  !BP   0LP  "K4   *X    NP   +L   "\!P  O T  +T1  "^
M%@  OQX  , G  #!,@  PD   ,-/  ##8   PW0  ,.+  ##H0  P[@  ,+7
M  #"[P  POH  ,'^ (&7  !SG0  9:,  %>H  !)K0  .[$  "VS   AM@
M%KD   Z[   'O@   ,$   #%    QP   ,@   #)    R@4  ,L+  #-#P
MSA0  - <  #3)@  UC(  -A!  #84P  V68  -E\  #9E   V:L  -G#  #9
MX0  V?   -GT ':?  !GI@  6:P  $NR   \MP  +KH  "&]   5P   #<0
M  7'    R@   ,X   #2    U0   -8   #9    VP   -T   #?!P  X0P
M .,1  #F&0  Z20  .PR  #M0P  [E8  .]K  #OA   [YP  .^R  #OQ@
M[]T  ._D &JH  !;KP  3+8  #Z\   OP   (,0  !3(   ,S    M    #4
M    V0   -X   #B    Y0   .8   #H    Z0   .P   #N    \ (  /()
M  #U#P  ^!<  /PC  #_,P  _T8  /]:  #_<0  _XD  /^?  #_L0  _\
M /_& /\ %0#_ !0 _P 4 /\ %P#_ !T _P H /\ -P#_ $0 _P!1 /\ 7 #_
M &8 _P!O /\ =P#_ 'X _P"% /\ BP#_ )$ _P"7 /\ G0#_ *0 _P"K /\
MM #^ +\ _0#. /L Y@#Y /8 ^ #_ /< _P#W /\ ]P#_ /  _P#L /\ Z0#_
M /\#$@#_ !  _P 0 /\ $0#_ !< _P D /\ ,@#_ #\ _P!, /\ 5P#_ &$
M_P!J /\ <@#_ 'D _0"  /P A@#Z (P ^0"2 /@ F #V )\ ]0"F /0 K@#R
M +D \ #& .X W@#M /  ZP#^ .H _P#I /\ Z0#_ .< _P#C /\ X #_ /\'
M#@#_  T _P + /\ # #_ !, _P ? /\ + #_ #H _P!& /X 4@#[ %P ^ !E
M /4 ; #S '0 \0!Z .\ @0#N (< [ "- .H DP#I )H YP"A .8 J0#C +,
MX0"_ -\ T #= .D V@#Y -D _P#7 /\ U0#_ -4 _P#5 /\ U #_ /\)"@#_
M 04 _P # /\ "0#_ !  _P 9 /L )@#W #0 ] !  /( 3 #N %8 Z@!? .<
M9P#D &X X@!T .  >P#> ($ W "' -H C0#6 )0 U "; -$ HP#/ *T S "X
M ,H QP#( .  Q@#S ,4 _P## /\ PP#_ ,, _P## /\ PP#_ /\+ 0#_ P
M_P   /\  P#_  L \P 2 .X 'P#J "T Y@ Z .( 10#> $\ V0!8 -0 8 #1
M &@ S@!N ,P = #* 'L R "! ,8 AP#$ (X P@"6 ,  G@"^ *< NP"R +D
MP "W -0 M0#L +, ^P"S /\ L@#_ +( _P"Q /\ L0#_ /\-  #_!@  _P,
M /<   #T  , YP - .  & #: "4 TP R ,X /@#* $D Q@!2 ,, 6@#  &$
MO@!H +P ;@"Z '0 N ![ +8 @0"T (@ L@"0 +  F0"N *( K "M *H N@"H
M ,L I@#F *4 ]P"D /\ HP#_ *( _P"B /\ H@#_ /\0  #[#   [PX  .8-
M  #?"0  V@ & -  $0#) !T Q  J +\ -P"[ $( MP!+ +0 5 "R %L KP!B
M *T : "K &X J0!U *@ >P"F (, I "+ *( E "@ )X G@&H )P"M0"; \8
MF07B )@&] "6"/\ E0G_ )0)_P"4"?\ E G_ /P1  #Q%0  XQD  -89  #,
M%0  QQ   ,0'"@"] Q0 MP0A +(&+@"N"#H J@E$ *<)30"D"E4 H@I< * *
M8@">"VD G MO )L+=@"9#'X EPR& )8,D "4#)H D@VF )$-LP"/#<4 C0[B
M (L0]@")$/\ B!'_ (<1_P"'$?\ AQ'_ /89  #G(   UB0  ,@E  "_(@
MN1P  +04 0"Q#0X J@X9 *4/)P"A$#, G1$^ )H11P"8$D\ E1)6 ),27 "1
M$F, D!-I (X3< ",$W@ BQ.! (D4BP"'%)8 AA6B (05L "#%L$ @1?= '\8
M] !]&?\ ?!G_ 'P9_P![&?\ >QG_ .\A  #=*0  RBT  +XO  "U+   KB<
M *@@  "C%P@ GA83 )D7(0"4&2T D1HX (X:00"+&TD B1M0 (<;5P"%'%X
MA!QD ((<:P" '', ?QU\ 'T=A@!\'I$ >AZ> '@?JP!W'[P =B#4 '0A\ !R
M(?\ <2+_ '$A_P!Q(?\ <2'_ .@H  #2,   PC4  +<W  "M-0  I3$  )XK
M  "8(P( DAX0 (T@&P")(2< AB(R (,C/ "!(T0 ?B-+ 'PD4@![)%D >21?
M '<D9@!V)6X ="5W ',E@0!Q)HT ;R:9 &XFIP!M)[@ ;"?. 6HH[0%I*?\!
M:"G_ 6@I_P%H*/\!:"C_ >$N  #+-@  O#L  +$]  "G/0  GSD  )<S  "/
M+0  B"<, (,G%@!_*"( ?"DM 'DJ-P!W*C\ =2I' ',K3@!Q*U0 <"M; &XK
M8@!L*VH :RQR &DL?0!H+(D 9BV6 64MI %D+K0!8R[* 6$OZ0%@+_T!8"__
M 6 O_P%@+_\!8"[_ =HT  #%/   MT$  *Q#  "B0P  F4   ) Z  "(-
M@"X( 'HM$@!W+AX <R\I '$P,P!O,#L ;3!# &LQ2@!I,5$ 9S%7 &8Q7@!D
M,68 8S)O &$R>0!@,H4!7S*2 5TSH0%<,[$!6S3& 5HTY@%9-?L!637_ 5DT
M_P%9-/\!633_ =(X  # 0   LT4  *A(  ">2   E48  (M   "".P  >34$
M ',S$ !O-!H ;#0E &DU+P!G-3< 938_ &,V1@!B-DT 8#94 %\V6P!=-V,
M7#=K %LW=@%9-X(!6#B/ 58XG@%5.*\"5#G# E,YY )3.OD!4SG_ 5(Y_P%3
M.?\!4SG_ <T\  "\1   KTD  *1,  ":3   D4L  (=&  !]0   <SL  &PX
M#0!H.1< 93DB &,Z*P!@.C0 7CH\ %TZ0P!;.DH 6CM0 %@[6 !7.V  5CMH
M %4\<P%3/'\!4CR- 5 ]G %//:P"3C[! DT^X0)-/O@"33[_ 4T^_P%-/?\!
M33W_ <E   "X2   K$T  *%0  "740  CD\  (1+  !Y10  ;D   &8]"P!B
M/10 7ST> %P^* !:/C$ 6#XX %<^0 !5/T8 5#]- %,_50!20%T 4$!F $]
M< %.0'P!3$&* 4M!F@)*0:L"24*^ DA"W@)(0O8"2$+_ DA"_P%(0?\!2$'_
M <5$  "U2P  J5   )Y4  "55   BU,  (!0  !U2@  :D8  &%"" !<01$
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M 3Q.E $[3J4!.4^Y CE/U (Y3_(!.4[_ 3E._P$Y3?\!.DW_ ;I.  "L5@
MH5L  )=?  "-80  @V$  'A>  !I6   7U8  %12  !,3PL 24\2 $=0' !%
M4"4 0U M $)0-0!!43P 0%%$ #]13  ^4E0 /%)= #M29P Z4G, .%." 3=3
MD@$U4Z0!-%.W 3-4T0$S4_$!-%/_ 312_P$T4O\!-%+_ ;92  "I6@  GF
M )1D  "+9@  @&4  '1C  !F7@  7%P  %%8  !'50< 0E40 $!5&  _5B$
M/58J #Q6,@ [5CD .E=! #E720 X5U$ -UA: #5890 T6'$ ,EB  3%8D $O
M6:(!+EFU 2U9SP$M6>\!+EC_ 2Y7_P$N5_\!+E;_ ;)7  "E7P  FV4  )%I
M  "':@  ?&H  '%H  !C90  6&(  $U?  !#70( /%L- #I<%  X7!T -UPF
M #5=+@ T738 ,UT^ #)=1@ Q7DX ,%Y7 "]>8@ M7FX +%]] "I?C@ I7Z
M*%^S 2=?S  G7^T!)U[_ 2==_P$H7?\!*%S_ :U<  "B9   F&H  (YN  "#
M;P  >6\  &YN  !@:P  5&D  $EG   _90  -6,) #)C$0 P8QD +V0A "YD
M*0 M9#$ +&0Y "ME0@ J94H *&54 "=E7P F9FL )&9Z "-FBP B9IT (&:Q
M !]FR0 ?9NL (&7^ "!D_P @8_\!(6/_ :EB  ">:@  E7   (IS  " =0
M=74  &ET  !<<@  3W$  $1O   Z;@  ,&T# "EL#0 G;!0 )FP< "5M)  D
M;2P (VTT ")M/0 A;D8 (&Y0 !YN6P =;F< '&YV !INAP 9;YH &&^N !9O
MQ@ 6;ND %VW\ !AL_P 8:_\ &&O_ *1I  ":<0  D'8  (9Y  !\>P  <7L
M &1[  !7>@  2GD  #]X   U>   *W<  ")V!P ==@\ ''<6 !MW'@ :=R8
M&7<N !AW-P 7>$  %7A* !1X5@ 3>&, $GAR !%X@P 0>)< #WBK  YXPP .
M=^8 #G;Z  ]U_P 0=?\ $'3_ )]Q  "5>   BWP  ()_  !W@0  :H(  %V"
M  !0@@  1((  #B"   N@@  )((  !R"   4@@D $8,0 !"#%@ 0@QX #H,G
M  Z#,  -@SD #8-$  R#4  +@UT "8-L  B#?@ &@Y$ !8*E  ."NP $@=L
M!('R  6 _P &?_\ !G__ )IY  "0?@  AH,  'V%  !OAP  8HD  %6*  !)
MBP  /8P  #&,   FC   '8T  !6.   /CP, "I ,  :0$0 $CQ@  X\@  &/
M*0  CS(  ) ]  "020  CU8  (]E  "/=@  CXH  (Z?  ".M   C<\  (SN
M  ",^P  B_\  (O_ )2   "+A0  @HD  '2,  !FCP  69$  $R3  ! E0
M-)8  "B6   >EP  %9@   ^:   *FP   IP)  "<#@  G!,  )P:  "<(@
MG2L  )TU  "=0   G4X  )U<  "=;@  G($  )R7  "<K   F\8  )KH  "9
M^0  F?\  )C_ (Z(  "&C   >)   &J4  !<EP  3YH  $*=   VG@  *9\
M !^A   5H@  #J0   BF    J    *D$  "I"@  J0X  *D3  "J&@  JB(
M *LK  "L-@  K$0  *Q3  "L8P  K'<  *N.  "KI   J[P  *K>  "I]
MJ?T  *G_ (F.  ![DP  ;9<  %^<  !1H   1*0  #:F   JJ   'JD  !2K
M   -K@  !K    "R    M0   +4   "U P  M@D  +<.  "X$@  N!D  +HA
M  "[*P  O#@  +U'  "]6   O6L  +V!  "]F0  O;   +W,  "\Z@  O/<
M +O^ 'Z5  !PFP  8J   %.E  !&J@  .*T  "JO   >L0  $[0   RW   #
MN0   +P   "_    P@   ,(   ##    Q    ,8&  #'#   R!   ,H6  #,
M(   SRL  - Z  #12P  T5X  -)S  #2BP  TJ0  -.[  #3V   T^T  -/V
M '.=  !DHP  5JD  $>O   YLP  *K8  !VY   2O   "K\   ##    Q@
M ,D   #-    SP   -    #2    U    -8   #9 @  VP@  -X.  #A$P
MY!T  .@J  #H/   Z4\  .ED  #J?   ZY4  .NL  #KP@  [-4  .SE &:F
M  !8K   2;,  #NY   KO   '<   !'$   )R    ,P   #/    TP   -D
M  #=    X    .$   #C    Y0   .<   #J    [    .X$  #Q"P  ]1(
M /@<  #[*P  _3X  /Y3  #^:@  _X,  /^;  #_K@  _[X  /_* /\ $@#_
M !  _P 1 /\ $P#_ !D _P F /\ - #_ $$ _P!- /\ 6 #_ &( _P!K /\
M<P#_ 'H _P"! /\ AP#_ (T _P"3 /\ F0#_ *  _P"G /X KP#\ +H ^@#)
M /D X0#X /, ]P#_ /8 _P#U /\ \0#_ .D _P#D /\ X0#_ /\ #P#_  T
M_P - /\ #@#_ !0 _P A /\ +@#_ #P _P!( /\ 4P#_ %T _P!F /X ;0#\
M '4 ^P![ /D @@#X (@ ]P". /8 E #T )L \P"B /$ J@#O +0 [0#! .L
MU0#J .P Z #\ .< _P#E /\ Y@#_ .  _P#9 /\ U #_ /\ "P#_  @ _P &
M /\ "0#_ !  _P < /\ *0#_ #8 _P!" /L 3@#W %< ] !@ /( : #O &\
M[0!V .P ? #J (( Z "( .< C@#E )4 XP"< .$ I #? *X W0"Y -H R@#7
M .0 U #V -$ _P#0 /\ T #_ ,\ _P#+ /\ QP#_ /\  P#_    _P   /\
M! #_  T ^@ 6 /8 (P#S #  \  \ .T 1P#I %$ Y0!: .( 8@#? &D W0!O
M -H =@#8 'P U "" -( B #0 (\ S0"6 ,L G@#) *@ QP"S ,4 P0#" -@
MP #O +\ _@"^ /\ O0#_ +P _P"\ /\ O #_ /\"  #_    _P   /\   #T
M  < [0 1 .@ ' #C "D WP U -L 00#6 $L T0!4 ,T 7 #* &, R !I ,8
M;P## '4 P0![ +\ @@"^ (@ O "0 +H F "X *( M0"L +, N0"Q ,L KP#G
M *X ^ "L /\ JP#_ *P _P"L /\ JP#_ /\$  #_    ]@   .X   #G
MWP , -8 %0#/ "( R@ N ,< .@## $0 P !- +P 50"Y %P MP!C +4 :0"S
M &\ L0!U *\ >P"M (( JP"* *D D@"G )P I0"F *, LP"A ,, GP#> )X
M\@"= /\ G #_ )P _P"; /\ FP#_ /\'  #V"0  Z0L  -\*  #5!   S@ %
M ,8 $ #  !H NP G +< ,@"S #T L !& *T 3P"J %8 J !< *8 8P"D &@
MH@!O *$ =0"? 'P G0"$ )L C0"9 )< EP"B )4 K@"3 +T D0#3 )  [0"/
M /P C@#_ (T!_P"- ?\ C0'_ /D.  #J$@  W!4  ,T5  #$$0  O@P  +H"
M"@"T !( K@ > *H *@"F #4 H@ _ *  2 "= 5  FP)6 )D"7 "7 V, E0-I
M ),#;P"1!'8 D 1_ (X%B ",!9( B@:> (@&J@"&![H A0C/ (0*ZP"""_P
M@0S_ ( ,_P" #/\ @ S_ /$5  #@'0  S2   ,$A  "X'0  L1<  *P0  "H
M"0T H@<6 )T)(P"9"BX E0LX ),,00"0#$D C@U0 (P-5P"*#5T B UC (<-
M:@"%#G$ @PYZ ((.A " #H\ ?@^; 'P/J ![$+@ >A#. '@1[ !V$O\ =1+_
M '03_P!T$_\ =!/_ .@>  #3)@  PRH  +@J  "N*   IR,  * <  ";$P,
ME@\0 ) 0&P",$2< B1(R (83.P"$$T, @A1+ ( 440!^%%< ?!1> 'L590!Y
M%6P =Q5T '86?@!T%HH <A>6 '$7I !O&+0 ;AC) &T9Z !K&OP :AO_ &H;
M_P!J&_\ :AO_ . F  #*+0  O#$  + S  "G,0  GRP  )<F  "0'P  BA<,
M (48%@"!&2( ?AHL 'L;-@!Y&SX =QQ% '4<3 !S'%, <1U9 ' =8 !N'6<
M;1YP &L>>@!J'H4 :!^2 &<?H !E(+  9"'% &,AY !B(OH 82+_ &$B_P!A
M(O\ 82+_ -<L  ##-   MC@  *HY  "A.   F#4  ) O  "(*   @"$( 'L@
M$@!W(1T ="(G '$B,0!O(SD ;2-! &LC2 !I(TX :"15 &8D6P!E)&, 8R5K
M &(E=0!A)8$ 7R:. %XFG0!=)ZT 6RC! %LHX !:*?< 62G_ %DI_P!9*?\
M62C_ ,\R  "^.0  L3T  *8_  "</P  DSP  (HV  "!,   >2H# '(F#P!N
M)QD :R@C &DH+ !F*34 92D\ &,I0P!A*DH 8"I1 %XJ5P!=*E\ 7"MH %HK
M<@!9+'T 6"R+ %8MF@!5+:H 5"Z] %,NW !2+_4 4B__ %(N_P!2+O\ 4B[_
M ,HV  "Z/0  K4(  *)$  "81   CT$  (4\  ![-P  <C$  &LL# !G+14
M9"T? &$N* !?+C$ 72XY %PO0 !:+T8 6"]- %<O5 !6,%P 53!D %,Q;@!2
M,7H 43&( % REP!.,J@ 33.[ $TTV !,-/, 3#3_ $PT_P!,,_\ 3#/_ ,8Z
M  "V0@  J48  )Y)  "520  BT<  (%"  !W/0  ;3<  &0R"0!@,A( 73(<
M %HR)0!8,RT 5C,U %4S/ !3-$, 4C1* %$T40!0-%D 3S5A $TU; !,-G<
M2S:% $HWE0!(-Z8 1SBX 4<XTP%&./$!1CC_ 48X_P!&./\ 1C?_ ,$^  "R
M10  IDH  )Q-  "230  B$L  'Y'  !S0@  :3T  %\W!@!:-A  5S<8 %0W
M(@!2-RH 4#<R $\X.0!-.$  3#A' $LX3@!*.58 23E? $@Z:0!'.G4 13N#
M $0[DP!#/*0!0CRV 4$]T %!/? !03W_ 4$\_P%!//\!03S_ +Y"  "O20
MHTX  )E0  "/40  A5   'M,  !O1@  94(  %H] @!4.PX 43L5 $\['P!-
M.R< 2SLO $D\-@!'/#T 1SQ$ $8]2P!%/50 1#Y< $,^9P!"/W, 0#^! #\_
MD0 ^0*( /4"U 3Q!S@$\0>X!/$'_ 3Q _P$\0/\!/3__ ;I%  "L3   H5$
M )=4  "-50  @U0  'A1  !L2P  84<  %9"  !/0 P 3#\3 $E ' !'0"0
M1D L $1 ,P!#0#H 0D%" $%!20! 0E$ /T): #Y#90 ]0W$ .T-_ #I$CP Y
M1*  .$6S 3=%RP$W1>P!-T7_ 3=$_P$X1/\!.$/_ +=)  "I4   GE4  )18
M  "+60  @%@  '96  !H4   74P  %-(  !*10D 1D01 $1$&0!"1"( 044I
M #]%,0 ^13@ /44_ #Q&1P [1D\ .D=8 #E'8@ X2&X -DA\ #5(C0 T29X
M,TFQ #))R0 Q2>L ,DG^ #)(_P R2/\ ,TC_ +1,  "G5   G%D  ))<  "(
M70  ?ET  '-:  !E50  6U(  %!.  !&2@4 0$D. #Y)%@ ]21X .THF #I*
M+@ Y2C4 .$L] #=+1  V2TT -$Q6 #-,8  R3&P ,4UZ #!-BP N39P +4ZO
M "Q.QP L3ND +$W] "U-_P M3/\ +4S_ +!0  "D6   F5T  (]A  "&8@
M>V$  '!?  !B6P  6%@  $Y5  !#40$ .T\, #A/$P V3QL -4\C #10*P S
M4#( ,E Z #%00@ P44H +E%3 "U270 L4FD *U)X "E2B  H4YH )U.M "93
MQ0 F4^< )E/\ "=2_P G4?\ )U'_ *Q5  "@7   EF(  (UF  "#9P  >&8
M &UE  !@80  55X  $I;   _6   -58( #%5$  P5A< +E8? "U6)P L5B\
M*U<V "I7/@ I5T< *%=0 "986@ E6&< )%AU "-9A@ A69@ (%FK !]9P@ ?
M6>4 'UCZ "!8_P @5_\ (5?_ *A:  "=8@  DV<  (IK  !_;   =6P  &IK
M  !=:   464  $9C   [8   ,5X# "I=#0 H71, )ET; "5>(P D7BH (UXR
M ")>.@ A7D, (%], !]?5P >7V, '&!Q !M@@@ 98)4 &&"I !=@P  68.(
M%U_Y !A>_P 97O\ &5W_ *1@  "9:   D&X  (9P  !\<@  <G(  &9Q  !8
M;@  3&P  $%K   V:0  +6<  "-F"  ?9@\ '685 !QF'0 ;9B4 &F8M !EG
M-0 89SX %V=( !9G4P 5:%\ $VAN !)H?P 1:)( $&BF  ]HO0 .:.  $&?W
M !!F_P 19?\ $67_ )]G  "6;P  C',  ()V  !X>   ;7@  &!W  !3=@
M1G0  #MS   Q<@  )W$  !YQ   6< H $W 0 !-P%P 2<!\ $7$G !!Q+P 0
M<3@ #G%"  YQ3@ -<5L #'%I  MQ>@ *<8T "'&A  9QM@ &<-( !W#O  AO
M_P );O\ "6[_ )MO  "1=0  AWD  'Y\  !T?@  9GX  %E^  !-?@  0'T
M #5]   J?   (7P  !A\   1? 0 #'P,  I\$0 )?!D "'PA  =\*0 &?#(
M!'P]  -\2  !?%4  'QC  !\=   ?(<  'N<  ![L0  >LL  'GK  !Y^@
M>?\  'C_ )9W  ",?   @X   'F#  !LA   7H4  %&&  !%AP  .8<  "V'
M   CAP  &H<  !*'   -B $ !HD*  &)#P  B10  (@;  "((P  B2P  (DV
M  ")0@  B$X  (A=  "(;0  B($  (>5  "'JP  AL0  (7F  "$^   A/\
M (3_ )!^  "'@P  ?H<  '&)  !CBP  5HT  $F/   \D0  ,)$  "21   :
MD@  $I,   V4   &E0   )8&  "6#   E1   )85  "6'0  EB0  )8N  "6
M.0  ED8  )95  "690  EG@  )6.  "5I   E+P  )/?  "3]0  DO\  )+_
M (N&  "#B@  =8T  &>0  !9E   3)<  #^9   RF@  )IL  !N<   2G0
M#)\   2@    H@   *,!  "C!P  HPP  *,0  "D%0  I!P  *4E  "F+P
MICP  *9+  "F6P  IFX  *6$  "EFP  I+,  */0  "C[P  HOP  *+_ (:-
M  !XD0  :I4  %R9  !.G0  0:   #.B   FHP  &Z4  !&G   *J0   :L
M  "M    KP   +    "P    L 4  +$+  "R#P  LQ0  +0;  "U)   MS
M +<_  "W4   MV(  +=X  "WD   MJD  +;"  "VY   MO4  +7^ 'N3  !M
MF   7YT  %"B  !"I@  -*D  ":K   :K0  $*\   FR    M    +<   "Z
M    O    +T   "^    O@   , "  #!"   P@T  ,02  #&&0  R20  ,HR
M  #+0P  RU4  ,QJ  #,@P  S)P  ,NU  #,S@  S.D  ,SV '";  !AH0
M4J8  $2K   VL   )[(  !JU   0N   ![L   "^    P0   ,0   #(
MRP   ,L   #-    S@   -    #2    U0,  -@*  #;$   WA@  .(D  #C
M-0  Y$@  .5<  #F<P  YHT  .:E  #FO   YM,  .?G &.D  !5J@  1K
M #BU   HN0  &KP   _    %Q    ,<   #+    SP   -0   #8    W
M -T   #?    X0   .,   #E    Z    .H   #M!@  \0X  /46  #X)0
M^3@  /E-  #Z8P  ^WP  /R5  #\J@  _+L  /W+ /\ #P#_  X _P . /\
M$ #_ !8 _P C /\ , #_ #T _P!) /\ 5 #_ %X _P!F /\ ;@#_ '8 _P!\
M /\ @@#_ (D _P"/ /\ E0#^ )L _0"C /L JP#Z +4 ^0## /< VP#V /
M] #_ /, _P#R /\ [ #_ .( _P#< /\ U@#_ /\ # #_  D _P ( /\ "@#_
M !( _P > /\ *P#_ #@ _P!$ /\ 3P#_ %D _@!A /P :0#Z '  ^ !W /<
M?0#V (, ] ") /( CP#Q )8 [P"= .T I0#L *\ Z@"\ .@ S0#F .@ Y #Z
M ., _P#B /\ X #_ -4 _P#. /\ RP#_ /\ !@#_  $ _P   /\ ! #_  X
M_P 9 /\ )0#] #( ^P ^ /< 20#S %, \ !< .X 8P#L &H Z@!Q .@ =P#F
M 'T Y "# .( B0#@ )  W@"7 -P GP#9 *D U@"T -, Q #0 -X S@#S ,P
M_P#+ /\ R@#_ ,@ _P#" /\ O@#_ /\   #_    _P   /\   #[  L ]@ 3
M /$ ( #M "P Z@ X .< 0P#C $T X !6 -P 70#9 &0 U0!K -( <0#0 '8
MS@!\ ,P @P#* (D R "1 ,8 F0#$ *, P0"M +\ NP"] ,\ NP#K +D _ "W
M /\ MP#_ +8 _P"T /\ L0#_ /\   #_    _P   /8   #N  4 YP / .$
M&0#; "4 U0 Q -( / #. $8 R@!/ ,< 5P#$ %X P0!D +\ :@"] '  NP!V
M +D ? "X (, M@"* +, DP"Q )P KP"G *T LP"K ,4 J0#A *< ]0"F /\
MI0#_ *0 _P"D /\ I #_ /\   #\    \0   .@   #@    U  + ,P $P#'
M !\ P@ J +\ -0"\ #\ N !( +4 4 "S %< L !> *X 9 "L &D JP!O *D
M=0"G 'P I0"$ *, C "A )8 GP"A )T K0": +P F #2 )< [@"5 /X E #_
M )4 _P"5 /\ E0#_ /P!  #P!0  XP<  -4%  #,    Q0 $ +X #@"X !<
MLP C *\ +@"K #@ J0!! *8 2@"C %$ H0!7 )\ 70"= &, FP!I )H ;P"8
M '8 E@!] )0 A@"2 )  D "; (X IP", +8 B@#) (@ YP"' /D AP#_ (8
M_P"& /\ A@#_ /0,  #D$   T1(  ,41  "]#@  M@@  +$ " "K !$ I@ ;
M *$ )@"> #$ F@ Z )@ 0P"5 $H DP!1 )$ 5P"/ %T C@!C (P :0"* '
MB !W (8 @ "$ (L @@"6 (  HP!^ +$ ?0#$ 'L"X0!Z _4 >@7_ 'D%_P!X
M!O\ > ;_ .H3  #6&@  QAT  +H<  "Q&0  JA,  *0-  "?!0P F0 4 )4
M'P"1 BD C0,S (L$/ "(!40 A@9+ (0&40""!U< @0== '\'8P!]"&H >PAR
M 'H(? !X"88 =@F2 '0*H !S"J\ <0O! ' ,WP!O#?8 ;@[_ &T._P!M#O\
M;0[_ .$<  #+(P  O"8  +$F  "H)   H!X  )D8  "3$ ( C@L. (@+%P"$
M#"( @0TL 'X--0!\#CT >@Y% '@.2P!W#E$ =0]8 ',/7@!Q$&4 <!!N &X0
M=P!L$(( :Q"/ &D1G0!H$:T 9A+  &42WP!D$_8 8Q3_ &,4_P!B%/\ 8A3_
M -8D  ##*@  M2X  *HO  "@+0  F"@  ) B  ")&P  @A,( 'T1$@!Y$AP
M=A,G ',4, !Q%#@ ;Q4_ &T51@!L%4P :A93 &@660!G%F$ 919I &07<@!B
M%WX 81B+ %\8F0!>&:D 7!F\ %P:V !:&_, 6AS_ %D<_P!9'/\ 61S_ ,TJ
M  "],0  KS4  *0V  ";-   DC$  (DK  "!)0  >1T# ',8#@!O&1@ ;!HB
M &D;*P!G&S, 91P[ &0<00!B'4@ 8!U. %\=50!='5P 7!YD %L>;@!9'WD
M6!^' %8@E@!5(*8 5"&X %,AT@!2(O$ 4B/_ %(C_P!2(O\ 4B+_ ,@O  "X
M-@  JSH  * \  "6.P  C3@  (,R  !Z+0  <B8  &H@# !F(!, 8R$= &$A
M)@!?(B\ 72(V %LB/0!:(T0 6"-* %<C40!5(U@ 5"1A %,D:@!1)78 4"6#
M $\FDP!.)Z, 3">U $PHS@!+*.X 2RG_ $LH_P!+*/\ 2RC_ ,,T  "S.P
MIS\  )Q!  "20   B3X  '\Y  !U,P  ;"T  &,G" !>)A$ 7"89 %DG(@!7
M)RL 52@R %0H.0!2*$  42A& % I30!.*54 32E= $PJ9P!+*G, 22N  $@K
MD !'+*$ 1BVS $4MRP!%+NP 1"[_ $0N_P!%+?\ 12W_ +XX  "P/P  I$,
M )E%  "/10  A4,  'L^  !Q.0  9S0  %XN! !8*PX 52L6 %(L'P!0+"<
M3RPO $TM-@!,+3P 2BU# $DM2@!(+E( 1RY: $8O9 !%+W  0S!^ $(PC0!!
M,9X 0#*Q #\RR  _,^H /S/^ #\R_P _,O\ /S+_ +L\  "M0P  H4<  )9)
M  ",20  @T@  'A$  !M/@  8SD  %HT  !2, P 3S 3 $PP' !*,"0 23$K
M $<Q,@!&,3D 1#%  $,R1P!",D\ 03-8 $ S8@ _-&T /C1[ #TUBP \-IP
M.S:O #HWQ@ Y-^@ .3?\ #HW_P Z-O\ .C;_ +=   "J1@  GDL  )1-  "*
M3@  @$P  '5(  !J0P  8#X  %8Y  !--0D 2301 $<U&0!%-2$ 0S4H $$U
M+P! -38 /S8] #XV10 ]-TT /#=5 #LX8  Z.&L .3EY #@YB0 W.IL -3JM
M #4[Q  T.^8 -#O[ #4[_P U.O\ -3K_ +1#  "G2@  G$X  ))1  "(4@
M?E   '--  !G2   7$0  %(_  !(.@8 1#D/ $$Y%@ _.1X /CDF #PY+0 [
M.C0 .CH[ #D[0@ X.TH -SQ3 #8\70 U/6D -#UW #,^AP Q/ID ,#^K "\_
MP@ O/^0 +S_Z # __P P/O\ ,#[_ +%'  "D30  F5(  (]5  "&5@  ?%4
M '%2  !D3   64D  $]%  !%0 , /SX- #P^$P Z/AL .3XC #<^*@ V/S$
M-3\X #0_0  S0$@ ,D!1 #%!6P P06< +D)U "U"A0 L0Y< *T.J "I#P  I
M1.( *D/Y "I#_P K0O\ *T+_ *Y*  "A40  EU8  (U9  "#6@  >5H  &Y7
M  !A4@  5TX  $U+  !#1P  .D,* #9#$0 T0Q@ ,T,@ #)$)P Q1"\ ,$0V
M "]%/0 M148 +$5/ "M&60 J1F0 *4=R "A'@P F1Y4 )4BH "1(O@ C2.
M)$CW "5'_P E1_\ )D?_ *I/  "?50  E%H  (M>  "!7P  =UX  &M<  !?
M6   554  $M1  ! 30  -4H' #!)#@ N214 +4D= "Q))  K2BL *DHS "A*
M.P G2T, )DM, "5+5@ D3&( (TQP "%,@  @39, 'TVF !Y-NP =3MT 'DWV
M !Y,_P ?3/\ ($O_ *=3  "<6@  DE\  (AC  !^9   =&,  &EA  !<7@
M4EL  $=8   \50  ,E(" "I0#  G3Q( )E 9 "50(  D4"@ (U O ")1-P A
M44  (%%) !Y24P =4E\ '%)M !I3?0 94Y  &%.D !93N0 54]D %E/T !=2
M_P 84?\ &5'_ *-9  "88   CV4  (5H  ![:0  <6D  &9G  !99   36$
M $)?   X7   +EH  "58"  @5PX 'E<4 !U7'  <6", &U@K !I8,P 96#P
M&%A% !994  565L %%EI !-:>@ 26HT $5JA !!:MP .6M4 $%GS !!9_P 1
M6/\ $5C_ )]?  "59@  C&L  ()M  !X;@  ;F\  &)M  !5:@  2&@  #YF
M   S90  *6,  "!A 0 88 L %6 0 !1@%P 38!X $F F !)@+@ 183< $&%
M  ]A2P .85@ #6%F  QB=@ +8HD "F&=  EAL@ (8<L "&'K  E@_0 *7_\
M"U__ )MF  "2;0  B'$  'YS  !U=0  :G0  %QS  !/<@  0W   #AO   M
M;@  )&P  !MK   3:P0 #FH,  UJ$@ ,:AD "VHA  IJ*0 ):C( "&H\  =K
M1P %:U, !&MA  )K<0  :H0  &J8  !JK0  :<8  &GG  !I^   :/\  &C_
M )=M  "-<P  A'<  'MZ  !P>P  8WL  %9Z  !)>@  /7D  #%X   G=P
M'78  !5V   /=@( "78*  1V#P  =A4  '8<  !V)   =2P  '4V  !U00
M=4X  '5<  !U;   =7X  '23  !TJ   <\   '/C  !R]P  <O\  ''_ ))U
M  ")>@  @'X  ':   !I@0  6X(  $Z"  !!@@  -8,  "F"   ?@0  %H$
M !""   *@@   H,'  ""#0  @A$  ((7  ""'@  @B8  ((O  "".P  @D<
M ()5  "!90  @7@  (&-  " H@  ?[H  '_=  !^]   ??\  'W_ (U\  "$
M@0  >X0  &Z&  !@B   4HH  $6+   YC   +(P  "&,   7C   $(T   F.
M   "CP   ) #  "/"0  CPX  (\2  "0&   D!\  ) H  "0,@  D#\  )!-
M  "070  CW   (^%  ".G   CK,  (W0  ",\   B_X  (O_ (B$  " B
M<HL  &2-  !6D   2),  #N5   NE@  (I8  !>7   /F   ")D   ";
MG0   )T   "= P  G0D  )T-  ">$0  GA<  )\?  "?*0  H#4  *!#  "@
M5   H&8  )][  ">DP  GJL  )W&  "=Z0  G/D  )S_ (.+  !UC@  9Y(
M %F6  !+F0  /9P  #">   CGP  %Z    ZB   'I    *8   "H    J@
M *H   "J    JP$  *L'  "L#   K1   *X6  "O'@  L2D  +$X  "Q2
ML5H  +%O  "QB   L:   +"Z  "OW0  K_(  *_] 'B1  !JE@  7)H  $V?
M   _HP  ,:8  ".G   7J0  #JL   6N    L    +(   "U    MP   +<
M  "X    N0   +H   "\ P  O0D  +X.  # %   PQX  ,4K  #%/   QDX
M ,9B  #&>@  QI0  ,:M  #&R   Q>4  ,7S &R9  !>G@  3Z0  $&H   R
MK   )*\  !:Q   -M    [<   "Z    O0   ,    #$    Q@   ,8   #(
M    R0   ,L   #,    S@   - &  #3#0  V!,  -P>  #>+0  WT   .!4
M  #A:P  X84  .&?  #AMP  X<\  .'F &"A  !2IP  0ZT  #2R   EM0
M%[D   V\   !OP   ,,   #'    R@   ,\   #3    U@   -<   #:
MW    -\   #A    XP   .8   #I 0  [ L  / 2  #S'P  ]#$  /9&  #W
M7   ^'0  /B/  #YI@  ^;@  /C) /\ #0#_  L _P + /\ #@#_ !, _P ?
M /\ + #_ #D _P!% /\ 4 #_ %D _P!B /\ :@#_ '$ _P!W /\ ?@#_ (0
M_@"* /T D #\ )< ^@"> /D IP#W +$ ]@"^ /4 T@#S .P \0#^ /  _P#P
M /\ Y@#_ -P _P#2 /\ S0#_ /\ !P#_  0 _P " /\ !@#_ !  _P ; /\
M)P#_ #, _P _ /\ 2@#^ %0 ^P!= /D 9 #W &L ]0!R /, > #R 'X \ "$
M .\ B@#M )$ [ "9 .H H0#H *L Y@"V .0 QP#B ., X #W -X _P#= /\
MV0#_ ,P _P#% /\ P0#_ /\   #_    _P   /\  0#_  T _P 6 /P (@#Y
M "X ]@ Y /, 10#O $X [ !7 .D 7@#F &4 Y !L .( <@#@ '< WP!^ -T
MA #; (L V "2 -4 FP#2 *0 SP"O ,T O@#+ -4 R0#O ,< _P#% /\ Q #_
M +X _P"X /\ M0#_ /\   #_    _P   /X   #W  D \0 1 .L ' #G "@
MY  S .$ /@#= $@ V !1 -, 6 #0 %\ S@!E ,P :P#* '$ R !W ,8 ?0#$
M (0 P@", ,  E "^ )X NP"H +D M@"W ,@ M0#F +, ^@"Q /\ L #_ +
M_P"L /\ J0#_ /\   #_    ^@   /$   #H  , X  - -@ %@#1 "( S0 M
M ,H -P#& $$ P@!* +\ 4@"] %D N@!? +@ 90"W &H M0!P +, =@"Q 'T
MKP"% *T C0"K )< J0"A *< K@"E +X H@#8 *  \@"? /\ G@#_ )X _P">
M /\ G #_ /\   #W    ZP   .$   #6    RP ) ,4 $0"_ !L NP F +<
M,0"T #H L0!# *X 2P"K %( J0!8 *< 7@"F &0 I !I *( < "@ '8 G@!^
M )P A@": )  F "; )8 IP"4 +8 D@#* )  Z0"/ /P C@#_ (T _P", /\
MC0#_ /@   #I @  VP,  ,P!  #$    O0 " +8 #0"P !4 JP @ *< *@"D
M #0 H0 \ )X 1 "< $L F@!2 )@ 6 "6 %T E0!C ), :0"1 '  CP!W (T
M@ "+ (H B0"5 (< H0"% *\ @P#! ($ X "  /4 ?P#_ '\ _P!_ /\ ?P#_
M .X*  #<#@  RA   +X.  "U"P  KP,  *D !P"C !  G@ 8 )D (P"6 "P
MDP U )  /@". $4 C !+ (H 40"( %< A@!= (4 8P"# &H @0!Q '\ >@!]
M (0 >P"/ 'D G !W *H =0"[ '0 U !R /  <@#_ '( _P!Q /\ <0#_ .,1
M  #-%P  OQD  +,9  "J%0  HQ   )T*  "7 0H D0 2 (T &P") "4 A0 O
M (, -P"  #X ?@!% 'T 2P![ %$ >0!7 '@ 70!V &0 = %K '(!= !P G\
M;@*+ &P#F !K Z8 :02W &@%S@!G!^P 9@C] &8)_P!E"?\ 90G_ -8:  #$
M(   MB,  *LC  "A(   F1L  )(4  ",#@$ A@<- ( $% !\!AX >0<H '8(
M, !T"#@ <@D_ ' )10!O"DP ;0I2 &P*6 !J"U\ : MG &<+< !E#'H 8PR'
M &(,E0!@#:0 7PVV %X-S@!<#NT 7 __ %L0_P!;$/\ 6Q#_ ,TA  "\*
MKRL  *0K  ":*0  DB0  (D?  ""&   >Q$% '4-#P!Q#1< ;@XA &L.*@!I
M#S( 9Q Y &400 !D$$8 8Q!- &$04P!?$5H 7A%B %P1:P!;$78 61*# %@2
MD@!6$Z( 51.T %03RP!3%.P 4A7_ %(6_P!2%?\ 4A7_ ,8H  "V+@  J3(
M )\R  "5,0  C"T  (,G  !Z(0  <AH  &L3"P!G$Q, 9!0< &$4)0!?%2T
M714T %P5.P!;%D( 619( %@63P!6%U8 51=> %,79P!2&'( 4!A_ $\9C@!.
M&I\ 3!JP $L;QP!+&^D 2AS] $H<_P!*'/\ 2AS_ ,$M  "Q-   I3<  )HX
M  "0-P  AS0  'TO  !T*0  ;",  &0<!P!>&1  6QH8 %D;(0!7&RD 51LP
M %0<-P!2'#T 41Q$ $\=2P!.'5( 31U: $L>8P!*'FX 21]\ $<?BP!&()P
M12&N $0AQ !#(N8 0R+\ $,B_P!#(O\ 0R+_ +PR  "M.   H3P  )<^  "-
M/0  @SH  'DU  !O,   9BH  %XD @!7( T 5" 4 %$@'0!/(24 3B$L $PA
M,P!+(CH 22)  $@B1P!'(DX 1B-7 $0C8 !#)&L 0B1Y $$EB  _)ID /B:K
M #TGP0 ])^, /2CZ #TH_P ])_\ /2?_ +@V  "J/0  GD   )1"  "*0@
M@#\  '8[  !L-@  8C   %DJ  !1)0L 3241 $LE&0!))2$ 1R8H $4F+P!$
M)C8 0R8] $(G1 !!)TL /RA4 #XH70 ]*6D /"EV #LJA@ Y*Y< ."NI #<L
MOP W+.  -RSX #<L_P W+/\ ."S_ +4Z  "G0   G$0  )%&  "'1@  ?40
M '-   !H.P  7S8  %4Q  !,*P< 1RD/ $4J%@!#*AX 02HE #\J+  ^*S,
M/2LY #PK00 [+$@ .BQ1 #DM6P X+F8 -BYS #4O@P T+Y4 ,S"G #(PO0 Q
M,=X ,3'W #(Q_P R,/\ ,S#_ +$^  "D1   F4@  (]*  "%2@  >TD  '!%
M  !E0   6SL  %(V  !(,00 0BX- #\N$P ]+AL .RXB #DO*0 X+R\ -R\V
M #8P/@ U,$8 -#%/ #,Q60 R,F0 ,3)Q # S@0 O-), +C2F "PUNP L-=L
M+#7U "TU_P M-/\ +C3_ *Y!  "B2   ETP  (U.  "#3@  >4T  &Y*  !B
M10  6$   $X\  !%-P  /3,+ #DS$0 W,Q@ -C,? #0S)@ S,RT ,C0T #$T
M/  P-40 +S5, "XV5@ M-F( +#=O "LW?P J.)$ *#BD "<YN0 F.=@ )SGT
M "@Y_P H./\ *3C_ *M%  "?2P  E$\  (M2  "!4P  =U(  &Q/  !?20
M5D8  $Q"  !"/0  .#@( #0X#P R.!4 ,3@= "\X)  N."L +3DR "PY.0 K
M.D$ *CI* "D[5  H.U\ )SQM "4\?0 D/8\ (SVB "(]MP A/M0 (3[S "(]
M_P C/?\ (SS_ *A)  "=3P  DE,  (E6  !_5P  =58  &I3  !=3P  4TP
M $I(  ! 1   -D % "\]#0 M/1, *ST: "H^(0 I/B@ *#XO "<^-P F/S\
M)#]( "- 4@ B0%T (4%J "!!>@ >08T '4*@ !Q"M0 ;0M$ &T+Q !Q"_P =
M0?\ 'D'_ *5-  ":4P  D%@  (9;  !]7   <EL  &=8  !;5   45(  $A.
M   ]2@  ,T<  "I#"P F0Q  )4,6 "1#'@ C1"4 (D0L "%$-  @13P 'D5%
M !U%3P <1EH &T9H !E&>  81XH %T>> !9'LP 42,X %4?O !9'_P 71O\
M%T;_ *)2  "76   C5T  (1@  !Z80  <&   &5>  !96@  3U@  $14   Y
M40  +TX  "9+!@ @2@X 'DH3 !U*&@ <2B$ &TLH !I+,  92S@ %TM" !9,
M3  53%< %$QE !--=0 238@ $4V< !!-L0 .3LP #TWN !!-_P 13/\ $4S_
M )Y7  "470  BV(  (%E  !W9@  ;68  &-D  !680  2EX  #];   U6
M*U8  ")4 0 :4@H %E(0 !52%@ 44AT $U(D !)2+  14C0 $5(^ !!32  /
M4U0 #E-B  U4<@ ,5(0 "U28  E4K0 (5,4 "53G  I3^P +4O\ "U+_ )M=
M  "19   B&@  'YK  !T;   :VP  %]J  !29P  160  #IB   P8   )EX
M !U=   56P4 $%H,  Y:$0 .6A@ #5L@  Q;)P +6S  "ELZ  E;10 '6U$
M!EM>  1;;0 #6X   5N4  !;J   6\   %KB  !:]@ !6O\  EG_ )=D  ".
M:P  A&X  'MP  !R<@  9W$  %EP  !,;@  0&P  #5K   J:0  (6<  !AF
M   19@$ #&4*  =E#P $910  V0;  )D(P  9"P  &0U  !D0   9$P  &1:
M  !D:0  9'L  &2/  !CI   8[L  &+=  !B]   8O\  &'_ )-L  ")<0
M@'4  'AW  !M>   8'<  %)V  !&=0  .70  "YT   C<@  &G$  !)Q   -
M<0  !G$(  !P#0  <!(  ' 7  !O'P  ;R8  &\P  !O.P  ;T<  &]4  !O
M9   ;W4  &Z*  !MH   ;;8  &S6  !K\@  :_\  &O_ (YS  "%>   ?7L
M '-]  !E?@  6'X  $M^   ^?@  ,GX  "9]   <?   $WP   U\   &?0
M 'T%  !\"P  ? \  'P3  !\&0  ?"$  'PI  !\-   >T   'M.  ![7@
M>V\  'J$  !ZF@  >;$  'C.  !W[P  =OX  ';_ (EZ  "!?P  >((  &N#
M  !=A0  3X8  $*'   UB   *8<  !V'   4AP  #8@   :)    B@   (H
M  ")!@  B0P  (D/  ")$P  B1H  (HB  "*+   BC@  (I&  ")5@  B6@
M (E\  "(E   AZL  (;&  "%Z@  A?L  (3_ (6"  !]A@  ;X@  &&+  !3
MC0  18\  #B1   KD0  'Y(  !22   -DP  !)0   "6    EP   )@   "7
M    EP4  )<+  "8#@  F!,  )D:  "9(@  FBX  )H]  "930  F5X  )ES
M  "8BP  F*,  )>\  "6X@  EO<  )7_ (")  !RC   9(\  %:3  !(E@
M.ID  "R:   ?FP  %)P   R>   #GP   *$   "C    I0   *4   "E
MI0   *8"  "G"   IPT  *@1  "I&0  JR,  *LQ  "K00  K%,  *QG  "K
M@   JIH  *JS  "JT   J>\  *G[ '6/  !GE   69@  $J<   \GP  +:(
M ""C   3I0  "Z<   &I    JP   *X   "Q    L@   +(   "S    M
M +4   "V    N 0  +D+  "[$   O1@  +\D  "_-0  P$<  ,!;  # <@
MP(T  ,&F  # P0  O^,  +[S &J7  !;G   3:$  #ZE   OJ0  (:L  !.M
M   +L    +,   "U    N    +P   "_    P0   ,$   ##    Q    ,8
M  #'    R0   ,L   #."   T0\  -48  #8)P  V3D  -I-  #;9   VWX
M -R9  #<L   W,D  -SC %V?  !/I0  0*H  #*O   BL@  %+4   JX
MNP   +\   ##    Q@   ,L   #.    T0   -$   #4    U@   -D   #;
M    W@   .    #D    YP8  .L.  #O&0  \"H  /(_  #S50  ]&T  /2(
M  #TH0  ]+8  /3' /\ "0#_  8 _P ' /\ # #_ !$ _P < /\ * #_ #0
M_P!! /\ 3 #_ %4 _P!= /\ 90#_ &P _P!R /X > #\ 'X ^P"$ /H BP#Y
M )( ]P"9 /8 H@#T *P \P"Y /$ RP#P .@ [@#[ .T _P#L /\ X0#_ -(
M_P#) /\ Q #_ /\  0#_    _P   /\ ! #_  X _P 7 /\ (P#_ "\ _P [
M /T 1@#Z %  ]P!8 /0 7P#R &8 \ !L .\ <@#M '@ [ !^ .H A0#I (P
MYP"3 .4 G #C *8 X0"Q -\ P0#= -T VP#T -D _P#6 /\ SP#_ ,0 _P"]
M /\ N0#_ /\   #_    _P   /\   #_  L _  3 /< '@#T "H \@ U .X
M0 #I $H Y@!2 ., 60#@ &  W@!F -P ; #: '( UP!X -0 ?@#2 (4 T "-
M ,X E0#, )\ R0"J ,< N #% ,T PP#K ,  _@"_ /\ O@#_ +8 _P"P /\
MK0#_ /\   #_    _P   /D   #R  8 ZP / .8 &0#A "0 W@ O -H .0#3
M $, SP!, ,P 4P#) %H QP!@ ,4 9@## &L P0!Q +\ =P"] 'X NP"& +D
MC@"W )@ M0"C +, L "Q ,( K@#@ *P ]P"K /\ J@#_ *@ _P"C /\ H #_
M /\   #_    ]0   .L   #A    U@ , ,\ $P#* !X Q@ I ,( ,P"_ #T
MNP!% +@ 30"V %0 LP!: +$ 7P"P &4 K@!J *P < "K '< J0!_ *< AP"E
M )$ HP"< *  J0"> +@ G #. )H [@"9 /\ EP#_ )8 _P"6 /\ DP#_ /T
M  #Q    Y0   -D   #-    Q  & +T #P"W !@ LP B +  + "M #8 J0 ^
M *< 1@"D $T H@!3 *  60"? %X G0!D )L :@": '  F !W )8 @ "4 (H
MD0"5 (\ H@"- +  BP## (D XP"( /D A@#_ (8 _P"& /\ A@#_ /,   #C
M    T0   ,4   "]    M@   *X "P"H !( I  < *  )@"< "\ F@ W )<
M/P"5 $8 D@!, )$ 4@"/ %@ C0!= (L 8P"* &H B !Q (8 >0"$ (, @@"/
M '\ FP!^ *D ? "[ 'H U0!X /( > #_ '< _P!W /\ =P#_ .<'  #1#
MPPT  +@,  "N"   J    *( !0";  X E@ 5 )( 'P". "@ BP Q (@ .0"&
M $  A !& (( 3 "  %( ?P!7 'T 70![ &, >@!K '@ <P!V 'T = "( '$
ME0!P *0 ;@"T &P R@!K .H :@#\ &H _P!J /\ :@#_ -H0  #&%   N!8
M *T5  "D$@  G X  )8'  "0  D B@ 0 (4 & "! "$ ?@ J 'L ,@!Y #D
M=P!  '4 1@!S $P <@!1 '  5P!N %X ;0!E &L ;@!I '< 9P"# &4 D0!C
M )\ 8@"O &  Q !? .0 7P'X %X"_P!> O\ 7@+_ ,X8  "]'0  L"   *4?
M  ";'   DQ<  (L1  "$#   ?@0+ 'D $@!U !L <@ C &\ *P!M 3, :P$Z
M &D"0 !G T8 9@-, &0$4@!C!%D 801@ %\%:0!>!7, 7 9_ %H&C0!9!YP
M5PBM %8(P0!5">$ 5 OV %0+_P!4"_\ 5 O_ ,8?  "V)0  J2@  )XH  "4
M)0  BR$  (,;  ![%   = X# &X)#0!I"!0 9@D= &0*)0!B"BT 8 LT %X+
M.@!="T  6PQ' %H,30!8#%0 5PU< %4-9 !4#6\ 4@U[ % .B@!/#IH 3@ZL
M $P/P@!,$., 2Q#Y $L0_P!+$?\ 2Q#_ +\F  "P*P  I"\  )DO  "/+0
MABD  'TD  !T'@  ;!<  &41!P!?#A  7 \7 %H0'P!8$"< 5A N %00-0!3
M$#L 4A%" % 12 !/$5  3A%7 $P28 !+$FL 21)X $@3AP!&$Y< 112I $04
MO@!#%=\ 0Q;X $,6_P!#%O\ 0Q;_ +HK  "K,0  H#0  )4U  "+-   @3$
M '@K  !O)@  9B   %X9 0!7% T 5!03 %$4&P!/%2, 3A4J $P5,0!+%C<
M218^ $@61 !'%TP 11=4 $0770!#&&< 01AT $ 9@P _&I0 /1JF #P;NP [
M&]L .QSV #P<_P \'/\ /!S_ +4P  "H-@  G#D  )$[  "'.@  ?C<  ',R
M  !J+0  82<  %DA  !1&PD 3!D0 $H:%P!(&A\ 1AHF $4;+0!#&S, 0ALZ
M $$<00! '$@ /AQ0 #T=60 \'F0 .QYQ #D?@  X'Y( -R"D #8@N  U(=8
M-2'T #4B_P U(?\ -B'_ +(T  "D.@  F3X  (\_  "%/P  >SP  ' X  !G
M,@  72T  %0H  !,(@4 1A\. $,?% !!'QL /Q\B #X@*0 ](#  .R V #HA
M/0 Y(44 .")- #<B5P V(V( -"-N #,D?@ R)(\ ,26B "\EM@ O)M( +R;R
M "\F_P P)O\ ,";_ *\X  "B/@  ED(  (Q#  ""0P  >$$  &X]  !C.
M6C,  %$N  !(* $ 0"0, #TC$0 [)!@ .20? #@D)@ V)"P -24S #0E.@ S
M)D( ,B9* #$G5  P)U\ +RAL "XH>P L*8T *RJ@ "HJM  I*L\ *2OP "HK
M_P J*O\ *RK_ *P\  "?0@  E$8  (I'  " 1P  =D4  &Q"  !A/0  5S@
M $XS  !$+@  /"D) #<H$  U*!4 ,R@< #(H(P P*"D +RDP "\J-P N*C\
M+2M( "PK4@ K+%T *BQJ "@M>0 G+8L )BZ> "4NLP D+\T )"_N "4O_P E
M+_\ )B[_ *D_  "=10  DDD  (A+  !^3   =$H  &I'  !>0@  5#T  $LY
M  !!-   ."\& #(M#0 P+1, +BT9 "TM(  K+2< *BXN "DN-0 I+ST *"]&
M "<P3P E,%L )#%H ",Q=P B,HD (3*= !\SL0 >,\L 'C/M !\S_P @,_\
M(3+_ *9#  ":20  D$T  (9/  !\4   <T\  &A,  !<1@  4D,  $D_   _
M.P  -C8" "XR#  K,A$ *3(7 "@R'@ F,B0 )3,K "0S,@ C-#H (C1# "$U
M30 @-5@ 'S9E !XV=0 <-X< &S>; !HWKP 9.,@ &3CK !HX_P ;-_\ &S?_
M *-'  "830  CE$  (13  ![5   <5,  &90  !:3   4$D  $=%   ]00
M,ST  "HY"0 E-PX (S<4 "(X&P A."( (#@H !\X,  >.3@ '3E! !PZ2P :
M.E8 &3MC !@[<@ 6.X4 %3R9 !0\K0 3/<8 $SWI !0\_0 5//\ %CO_ *!+
M  "540  BU4  ()8  !Y60  ;E@  &16  !840  3D\  $5+   Z1P  ,$,
M "= !0 @/@T '3X1 !P^%P ;/AX &CXE !D^+0 8/S4 %C\^ !4_2  40%,
M$T!@ !)!<  108( $$&7  ]!K  .0L0 #D+G  ]!_  00?\ $$#_ )U0  "3
M5@  B5H  (!=  !V7@  ;%T  &);  !65P  3%4  $%1   V3@  +$L  "-(
M   ;10D %T0/ !5$%  411L $T4B !)%*0 113$ $44[ !!&10 /1E  #D=>
M  U';0 ,1W\ "T>3  E'IP (1[X "$?@  E']@ *1O\ "T;_ )I5  "06P
MAV   'UB  !S8P  :F(  &!A  !37@  1UH  #Q7   R50  *%(  !]0   7
M3@0 $4P,  ],$0 .3!< #DP>  U-)0 ,32X "TTW  I-0@ )34T !TY:  9.
M:0 $3GL  DZ/  %.I   3;H  $W;  %-\@ !3?\  DS_ )9;  "-8@  A&8
M 'IH  !Q:0  :&D  %QG  !/9   0F$  #=?   M7   (UH  !I8   25P$
M#58)  E5#@ '51, !E4:  15(@ #52H  E4T  !5/@  54H  %97  !690
M57<  %6+  !5H   5;8  %34  !4\0  4_T  %/_ )-B  "*:   @&P  '=N
M  !O;P  8VX  %9L  !):@  /6@  #)F   G90  '6,  !5B   .80  "6 (
M  -@#0  7Q$  %\7  !?'@  7R8  %\O  !?.@  7T4  %]3  !?80  7G(
M %Z'  !=G   7;(  %S/  !<[P  6_T  %O_ )!J  "&;P  ?7(  '5T  !J
M=0  770  $]S  !"<@  -G   "MO   @;@  %VT  !!L   *;    FL&  !K
M"P  :@\  &H4  !J&@  :B$  &DJ  !I-   :4   &E.  !I7   :6T  &B"
M  !HF   9ZX  &;*  !E[0  9?P  &3_ (MQ  ""=@  >GD  '![  !B>P
M57L  $AZ   [>@  +WH  "-Y   9>   $7<   IW   #=P   '<"  !W"
M=@T  '80  !V%0  =AL  '8C  !V+@  =3H  '5'  !U5@  =6@  '1\  !T
MD@  <ZH  '+$  !QZ0  </L  '#_ (9Y  !_?0  =G\  &B!  !:@@  3((
M #^#   RA   )8,  !J#   1@P  "H,   *#    A    (4   "$ P  @P@
M (,-  "#$   @Q4  (0<  "$)@  A#(  (0_  "#3P  @V   ()U  ""C
M@:0  ("]  !_XP  ?OD  '[_ (*   !ZA   ;(8  %Z(  !0B@  0HL  #6-
M   GC0  &XT  !&.   *C@   (\   "1    D@   )(   "2    D@$  )('
M  "2#   DA   ),5  "3'0  E"@  )0V  "410  DU<  )-K  "3@@  DIP
M )&V  "0V   C_,  (__ 'Z'  !PB@  88T  %.0  !%DP  -Y4  "F6   <
MEP  $9@   F9    FP   )P   ">    H    *    "@    H    *$   "A
M!   H@D  *,.  "D%   I1T  *8J  "F.@  IDP  *5@  "E>   I9(  *2L
M  "DR0  H^L  *+Z '..  !DD0  5I4  $>9   YG   *IX  !V@   1H0
M"*,   "E    IP   *D   "L    K@   *X   "N    KP   +    "Q
ML@   +,&  "U#0  MQ,  +D>  "Y+@  ND   +I4  "[:@  NH4  +FA  "Y
MNP  NMX  +GR &>5  !8F0  2IX  #NB   LI@  ':@  !&J   'K    *\
M  "Q    M    +@   "[    O    +P   "^    OP   ,    #"    Q
M ,8   #( P  RPL  ,\2  #1(   T3(  -)&  #370  U'8  -22  #5JP
MU<0  -3B %N=  !,H@  /:<  "^L   ?KP  $;$   >U    N    +L   "^
M    P@   ,<   #*    S    ,P   #.    T    -(   #5    V    -L
M  #?    X@   .8+  #K$P  ["0  .TX  #N3@  [V<  /""  #PG   \+(
M /'% /\  P#_  $ _P $ /\ "0#_  \ _P 8 /\ ) #_ #  _P \ /\ 1P#_
M %$ _P!9 /\ 8 #] &< _ !M /H <P#Y 'D ^ !_ /8 A0#U (P \P"4 /(
MG0#P *< [@"S .P Q #K .$ Z@#X .D _P#G /\ V0#_ ,L _P#" /\ O0#_
M /\   #_    _P   /\   #_  P _P 4 /\ ( #_ "L _@ W /H 0@#V $L
M\@!3 /  6P#N &$ [ !G .H ;0#H ', YP!Y .4 ?P#C (8 X0". -\ E@#=
M *  VP"L -@ NP#4 -$ TP#P -  _P#. /\ R #_ +T _P"V /\ L@#_ /\
M  #_    _P   /\   #]  @ ]P 0 /, &@#O "8 [0 Q .@ .P#C $4 X !-
M -P 50#9 %L U@!A -, 9P#1 &P SP!R ,T > #+ '\ R0"' ,< D #% )H
MPP"E ,  L@"^ ,4 O #E +H ^P"X /\ MP#_ +  _P"I /\ I0#_ /\   #_
M    _@   /4   #L  , Y0 - -\ %0#: "  U  J -  -0#+ #X R !' ,4
M3@#" %4 P !; +X 80"\ &8 N@!L +@ <@"V '@ M0"  +, B "Q )( K@">
M *P J@"I +L J #5 *8 \P"D /\ HP#_ *$ _P"; /\ F #_ /\   #[
M\    .4   #8    S@ ) ,< $0#" !H O@ D +L +@"W #@ M !  +$ 2 "N
M $X K !4 *H 6@"I %\ IP!E *4 :P"D '$ H@!X *  @0"> (L G "6 )D
MHP"7 +( E@#' ), Z "2 /X D0#_ )  _P"- /\ BP#_ /D   #K    W0
M ,\   #&    O  $ +4 #0"P !4 K  > *@ * "E #$ H@ Y )\ 00"= $@
MFP!. )D 4P"7 %D E@!> )0 9 "2 &H D !Q (X >@", (, B@"/ (@ G "&
M *H A "\ (( W "! /8 @ #_ '\ _P!_ /\ ?@#_ .P   #:    R0   +X
M  "V    K@   *< "0"A !  G  8 )@ (@"5 "H D@ R )  .@"- $$ BP!'
M (D 30"' %( A@!8 (0 70"" &0 @0!K '\ <P!] 'T >P"( '@ E0!V *,
M=0"T ', S !Q .T < #_ '  _P!P /\ < #_ -\%  #*"@  O L  +$)  "H
M!   H0   )L  P"4  P CP 3 (H &P"' "0 A  L ($ ,P!_ #H ?0!! 'L
M1P!Y $P =P!2 '8 5P!T %T <@!D '  ;0!O '8 ; "" &H CP!I )T 9P"N
M &4 PP!D .0 8P#Z &, _P!B /\ 8P#_ - .  "_$@  LA,  *<2  "=$
ME0L  (\#  ")  < @@ . 'X %0!Z !X =@ E '0 +0!Q #0 ;P Z &X 0 !L
M $8 :@!, &D 4@!G %@ 9@!? &0 9P!B '$ 8 !\ %X B0!< )@ 6P"I %D
MO !8 -P 6 #T %@ _P!7 /\ 5P#_ ,86  "V&@  JAT  )\<  "5&0  C10
M (4/  !^"0  =P$* '( $ !N !< :@ ? &@ )P!E "X 9  T &( .P!@ $
M7P!& %T 3 !< %, 6@!: %@ 8@!7 &P 50!W %, A0!2 )0 4 &E $\!N !.
M M( 303P $T%_P!-!?\ 307_ +\=  "P(@  HR4  )DE  "/(@  A1T  'T8
M  !U$@  ;@T" &<&# !C Q$ 7P(9 %T#(0!;!"@ 600O %<%-0!6!3L 5 9!
M %,&1P!1!DX 4 =5 $X'7@!-"&< 2PAS $D)@0!("9( 1PJC $4*M@!$"]
M1 SO $,-_P!##?\ 1 W_ +DD  "J*0  GBP  )0L  "**@  @"8  '<A  !N
M&P  9A0  %\/!0!9"PT 50H3 %,+&P!1"R( 3PPI $T,+P!,##8 2PT\ $D-
M0@!(#4D 1@U1 $4.6@!$#F0 0@YP $ .?P _#Y  /A"B #P0M@ [$-$ .Q'Q
M #L1_P [$?\ /!'_ +0I  "F+P  FC(  ) R  "&,0  ?"T  '(H  !I(P
M81T  %D6  !1$0@ 3 \0 $H0%@!($!T 1A D $40*P!#$3$ 0A$W $$1/@!
M$44 /A)- #T25@ \$F$ .A-M #D3?  W%(T -A2? #45LP T%<T ,Q;N #06
M_P T%O\ -!;_ *\N  "B-   ES<  (PX  ""-@  >#0  &XN  !E*@  7"0
M %0>  !,& 0 1A0- $(4$@! %!D /Q0@ #T5)P \%2T .Q4T #D6.@ X%D(
M-Q9* #874P U%UX ,QAJ #(9>0 P&8H +QJ= "X:L0 M&\H +1OL "T<_P N
M&_\ +AO_ *PR  "?.   E#L  (H\  " /   =CD  &LT  !B+P  62H  % E
M  !''P  0!H* #P9$  Z&18 .!D= #8:(P U&BD -!HP #,:-P R&SX ,1M'
M "\<4  N'5L +1UG "P>=@ J'H@ *1^; "@?K@ G(,< )B#J "<@_@ H(/\
M*"#_ *DV  "=/   DC\  (=!  !]0   =#X  &DZ  !?-0  5C   $TK  !$
M)0  .R ' #8>#@ S'A, ,AX9 # >(  O'B8 +A\M "T?-  L(#L *R!$ "HA
M3@ I(5@ )R)E "8B=  E(X4 (R.9 "(DK0 A),4 (27H "(E_0 B)/\ (R3_
M *8Z  ":/P  CT,  (5%  ![1   <D,  &<_  !=.@  4S8  $HQ  !!+
M."8# #$C#  N(A$ +"(6 "HB'0 I(B, *",J "<C,0 F)#D )25! "0E2P C
M)E8 (B9C "$G<@ ?)X, 'BB7 !THJP ;*<, &RGF !PI^P =*?\ 'BC_ *,^
M  "80P  C4<  (-)  !Z20  <$<  &9$  !:/P  43L  $<W   ^,@  -2T
M "PH"0 H)P\ )R<4 "4G&@ D)R$ (R@G "(H+@ A*38 ("D_ !\J20 >*E0
M'2M@ !LK;P :+($ &2R5 !<MJ0 6+<$ %BWD !<M^@ 8+?\ &2W_ *%!  "5
M1P  BTL  ()-  !X30  ;DP  &1)  !81   3T   $8]   ].   ,S0  "HO
M!@ D+ T (2P2 " L&  ?+1X 'BTE !TM+  <+C0 &RX\ !HO1@ 8+U$ %S!>
M !8P;0 5,7\ $S&3 !(QJ  1,K\ $3+B !(R^0 3,?\ $S'_ )Y%  "32P
MB4\  (!1  !V4@  ;5   &).  !620  348  $1#   [/P  ,3H  "<V P ?
M,@L '#(0 !LR%0 9,AL &#(B !<S*0 6,S$ %30Z !0T1  3-$\ $C5< !$U
M:P 0-GT #S:1  XVI@ --[P #3?=  TV]@ .-O\ #S;_ )M)  "13P  AU,
M 'Y6  !U5@  :E4  &!3  !53P  3$P  $))   X10  +D$  "0]   <.@@
M%C@. !4X$@ 4.!@ $SD? !(Y)@ 1.2X $#DW  \Z00 ..DP #3M9  T[:  +
M.WH "CN-  D\H@ '/+@ !SS5  @\\  )._\ "CO_ )A.  ".5   A5@  'Q;
M  !R6P  :%H  %Y8  !350  25(  #Y.   T2P  *D<  "%$   80@, $D +
M ! _$  ./Q4 #C\<  U (P ,0"L "T T  I /@ )04H !T%6  9!90 $078
M T&*  %!GP  0;0  $'0  %![@ !0?P  D#_ )54  ",60  @UX  'E@  !P
M8   9F   %U>  !16P  15<  #I4   O40  )4\  !Q,   42@  #D@(  M'
M#@ (1Q( !T<9  9'(  %2"@  T@Q  )(.P  2$<  $A3  !(8@  2',  $B&
M  !(FP  2+$  $?,  !'[0  1_L  $?_ )):  ")8   @&,  '=E  !N9@
M968  %ED  !,8   0%T  #5;   J60  (%<  !=5   04P  "U('  51#0 !
M4!$  % 6  !0'0  4"4  % N  !0.   4$,  %!0  !07@  4&\  %"#  !/
MF   3ZX  $[)  !.ZP  3?L  $W_ (]A  "&9@  ?6D  '1L  !L;0  86L
M %-I  !&9P  .F0  "]C   D80  &E\  !)>   ,7   !EP&  !;"P  6@\
M %H3  !:&0  62$  %DI  !9,P  63\  %E,  !96@  66L  %A^  !8E
M5ZL  %?%  !6Z0  5?L  %7_ (QH  "";0  >G   ')R  !G<@  6G$  $QP
M   _;@  ,VT  "AK   =:@  %&@   UG   '9P   &8#  !F"0  90T  &41
M  !D%0  9!P  &0D  !D+@  9#H  &-'  !C50  8V8  &-Z  !BD   8:<
M &#!  !?Y@  7_H  %[_ (=O  !_=   >'<  &YX  !@>   4G<  $5W   X
M=@  *W8  "!T   6<P  #G,   =R    <@   '(   !Q!0  <0H  '$.  !P
M$0  <!<  ' >  !P)P  <#,  &]   !O4   ;V   &YT  !NBP  ;:(  &R\
M  !KX@  :O@  &G_ (-W  !\>P  <WT  &5^  !7?P  27\  #Q_   O@
M(G\  !=^   /?@  !WX   !_    ?P   '\   !^    ?@4  'X*  !^#0
M?A$  'X7  !^(   ?BL  'TY  !]2   ?5D  'QM  !\A   >YP  'JV  !Y
MV@  >/4  '?_ (!_  !W@@  :8,  %N%  !-A@  /X@  #*)   DB0  &(D
M  ^)   'B@   (L   ",    C0   (T   ",    C    (P#  ","   C0T
M (T1  "-%P  CB(  (XO  "./P  C5   (UD  ",>P  C)4  (NN  "*S0
MB>\  (G_ 'N%  !MB   7HH  %"-  !"CP  -)$  ":2   9DP  #I0   :5
M    E@   )@   ":    FP   )L   ";    FP   )L   "<    G04  )T+
M  ">$   GQ<  * D  "@-   H$8  *!9  "?<   GXH  )ZE  ">P@  G>@
M )SY '",  !ACP  4Y(  $26   VF0  )YL  !F<   /G0  !9\   "A
MHP   *4   "H    J0   *D   "I    J@   *L   "L    K0   *X!  "P
M"0  L@\  +,8  "T)P  M#D  +5-  "T9   M'X  +.:  "SM   L]4  +/P
M &23  !5EP  1YL  #B?   IH@  &J0   ZF   $J    *L   "M    L
M +0   "V    N    +@   "Y    N@   +P   "]    OP   ,    ##
MQ0<  ,D/  #*&@  RRP  ,Q   #-5@  SF\  ,V+  #,J   S,(  ,SB %B;
M  !)H   .J4  "RI   <JP  #ZX   2Q    M    +<   "Z    O@   ,,
M  #&    R    ,@   #*    RP   ,T   #/    T@   -4   #9    W0
M .$%  #F#P  YQX  .@R  #I2   ZF   .M[  #KEP  [*X  .S" /\   #_
M    _P   /\ !@#_  T _P 5 /\ (0#_ "P _P X /\ 0P#_ $P _@!4 /L
M6P#Z &( ^ !H /8 ;@#U '0 ] !Z /( @ #Q (< [P"/ .T EP#K *$ Z0"M
M .< O0#E -@ Y #S .( _P#@ /\ T #_ ,0 _P"\ /\ M@#_ /\   #_
M_P   /\   #_  D _P 1 /\ ' #] "< ^0 R /4 /0#Q $8 [0!/ .L 5@#H
M %P Y@!B .0 : #C &X X0!S -\ >0#= (  V@"( -@ D0#4 )L T@"F ,\
MM #, ,D R0#I ,@ _P#' /\ P0#_ +< _P"O /\ JP#_ /\   #_    _P
M /\   #X  4 \@ . .X %P#J "( Y@ L .$ -P#= $  V !) -, 4 #0 %8
MS@!< ,P 8@#* &< R !M ,8 <P#$ 'D P@"! ,  B@"^ )0 O "? +D K "V
M +X M #= +, ]P"Q /\ L #_ *@ _P"B /\ G@#_ /\   #_    ^0   .\
M  #F    WP + -8 $@#0 !P S  F ,@ , #$ #H P !" +T 2@"[ %  N !6
M +8 6P"U &$ LP!F +$ ; "P '( K@!Z *P @@"I (P IP"8 *4 I0"C +0
MH #+ )\ [@"= /\ G #_ )D _P"4 /\ D0#_ /\   #V    Z@   -T   #/
M    QP & ,  #P"[ !< MP @ +, *@"P #, K0 [ *H 0P"G $D I0!/ *,
M50"B %H H !? )X 90"= &L FP!R )D >P"7 (4 E "0 )( G0"0 *P C@"_
M (P X@"+ /H B0#_ (D _P"& /\ @P#_ /0   #D    U    ,@   "_
MM0 ! *X "P"I !( I0 ; *$ (P"> "P FP T )@ / "6 $, E !) )( 3@"0
M %, C@!9 (T 7@"+ &0 B0!K (< <P"% 'T @P"( ($ E0!_ *0 ?0"U 'L
MSP!Y /$ > #_ '< _P!W /\ =0#_ .4   #1    PP   +@   "O    J
M *  !@":  X E0 5 )$ '@". "8 BP M (@ -0"& #P A !" (( 1P"  $T
M?P!2 'T 6 ![ %X >0!E '@ ;0!V '8 <P"! '$ C@!O )T ;0"N &P Q !J
M .< :0#] &@ _P!H /\ :0#_ -4#  ##!P  M@@  *L&  "B    FP   )0
M  "-  H B  0 (, & !_ "  ?  G 'H +@!W #4 =0 [ '0 00!R $< < !,
M &\ 4@!M %@ :P!? &D 9@!G '  90![ &, B !B )< 8 "G %X NP!= -P
M7 #V %P _P!; /\ 6P#_ ,D-  "Y$   K!$  *$0  "7#0  CP@  (@   ""
M  4 >P - '< $@!S !H ;P A &P * !J "\ :  U &< .P!E $$ 8P!& &(
M3 !@ %( 7P!9 %T 80!; &H 60!U %< @@!5 )$ 5 "B %, M0!1 ,\ 4 #O
M %  _P!0 /\ 4 #_ +\4  "P&   I!H  )D9  "/%@  AQ$  '\-  !W!@
M<0 ( &L #@!G !0 9  ; &$ (@!> "D 70 O %L -0!9 #L 6 !! %8 1@!5
M $T 4P!4 %( 7 !0 &4 3@!P $P ?0!+ (T 20"> $@ L !' ,< 1@#I $8
M^P!& /\ 10#_ +@;  "J(   GB(  ),B  ")'P  @!H  '<5  !O$   : L
M &$$"@!= !  60 6 %8 '0!4 ", 4@ J %  , !/ #4 3@ [ $P 00!+ $@
M20!/ $<!5P!& 6$ 1 )L $,">0!! XD 0 .: #X$K0 ]!,0 / 7E #P'^  \
M!_\ / ?_ +(B  "E)P  F2D  (XI  "$)P  >R,  '$>  !I&   81(  %H-
M P!3" P 3P41 $P%%P!*!AX 2 8D $<&*@!%!S  1 <V $,(/0!!"$, 0 A+
M #X)4P ]"5T .PIH #H*=@ X"X< -PN9 #4+K  T#,( ,PSD #,-^0 S#?\
M- W_ *TG  "@+   E2\  (LO  " +@  =RH  &TE  !D(   7!H  %04  !,
M#P8 1@P- $,,$@!!#!@ /PP? #X,)0 \#2L .PTR #H-.  X#3\ -PY' #8.
M4  T#EH ,PYF #$/=  P#X4 +A"8 "T0JP L$,, *Q'E "P1^@ L$?\ +1'_
M *HL  "=,0  DC0  (<U  !]-   =#$  &HK  !@)P  6"$  $\;  !'%@
M0!$) #L0#P Y$!0 -Q ; #80(0 T$"< ,Q$M #(1-  Q$3L ,!%# "X230 M
M$E< +!)C "H3<0 I$X( )Q25 "84J0 E%<  )!7C "46^@ F%O\ )A7_ *8Q
M  ":-@  CSD  (4Z  ![.0  <38  &<Q  !=+0  5"@  $PB  !#'0  .Q<%
M #44#0 R$Q$ ,107 "\4'0 N%"0 +!0J "L5,0 J%3@ *19  "@62@ G%U0
M)A=@ "08;P C&(  (1F3 " 9IP ?&;X 'AK@ !\:^  @&O\ (!K_ *,T  "8
M.@  C3T  (,^  !Y/0  ;SL  &4W  !;,@  4BT  $DH  ! (P  .!X! # 9
M"@ L& \ *A@4 "D8&@ G&"  )ADG "49+0 D&C4 (QH^ "(;1P A&U( (!Q>
M !\=;  ='7X '!V1 !H>I0 9'KP &!_= !D?]@ :'_\ &Q[_ *$X  "5/0
MBT$  (%"  !W0@  ;4   &,\  !9-P  3S,  $8N   ]*0  -20  "T@!P G
M'0T )1T2 ",=%P A'1T (1TD " >*P ?'C( 'A\[ !T?10 <($\ &B%< !DA
M:@ 8(GL %B*/ !4BHP 4([H $R/: !0C]0 5(_\ %B/_ )X\  "300  B40
M ']&  !U1@  ;$0  &)!  !7/   33@  $0T   \,   ,RL  "HF P C(@L
M("$0 !XA%0 <(AL &R(A !HB*  :(S  &2,X !@D0@ 6)4T %259 !0F:  3
M)GD $B:- !$GH@ 0)[@ #B?6 ! H]  1)_\ $2?_ )Q   "110  AT@  'U*
M  !T2@  :DD  &!&  !500  3#X  $,Z   Z-@  ,3(  "@M   @*0D &R<.
M !DG$@ 8)Q@ %B<? !4H)0 4*"T $R@V !(I0  2*4L $2I7 ! J9@ .*W<
M#BN+  TLGP ,++4 "RS/  PL[P -+/\ #2O_ )E$  "/20  A4P  'Q.  !S
M3P  :4X  %Y+  !31P  2D0  $)    Y/0  +S@  "4T   =, 4 %BT, !0L
M$  3+14 $BT< !$M(P 0+2H #RXS  XN/0 -+T@ #2]5  PP8P *,'0 "3"(
M  @QG  &,;$ !C'+  8QZP ',/P "##_ )=(  "-30  @U$  'I3  !Q5
M9U(  %U0  !23   24H  $!&   U0@  *SX  "(Z   :-P$ $C0)  \S#@ .
M,Q, #3,9  TS(  ,-"@ "S0Q  HU.P (-48 !S52  4V8  $-G$  C:$   V
MF0  -J\  #;(   VZ   -OD  37_ )1-  "*4@  @58  'A8  !O60  95@
M %M5  !14@  1T\  #Q,   Q2   )T0  !Y!   6/P  $#P'  LZ#0 ).A$
M"#L7  8['@ %.R8 !#LN  ([.  !/$,  #Q/   \7@  /&X  #R!   \EP
M/*P  #O%   [YP  ._@  #O_ )%2  "(6   ?UP  '9=  !M7@  8UT  %I<
M  !.6   0E0  #=1   M3@  (TL  !I)   21@  #40&  =##  #0Q   $,5
M  !#&P  0R,  $,K  !#-0  0T   $--  !#6P  0VL  $-^  !#E   0JH
M $+#  !!Y@  0?D  $'_ (Y8  "&7@  ?6$  '-C  !K9   8F,  %=A  !)
M70  /5H  #)8   G50  'E,  !51   .3P  "4T%  )-"P  3 X  $P3  !+
M&   2Q\  $LH  !+,@  2ST  $M)  !+5P  2V<  $I[  !*D   2:<  $G
M  !(Y   2/@  $?_ (M?  "#9   >F<  '%I  !I:@  7FD  %!F  !#9
M-V$  "Q?   A70  &%L  !!9   *6    U<#  !7"0  5@T  %40  !5%0
M5!L  %0C  !4+0  5#D  %1%  !44P  5&0  %-W  !3C0  4J0  %&]  !0
MX@  4/@  $__ (AG  !_:P  =VX  &]P  !E<   5VX  $IL   ]:P  ,&D
M "5H   :9@  $60   MC   $8@   &(!  !A!@  8 L  & .  !?$@  7Q<
M %\>  !>*   7C,  %Y   !>3P  7E\  %UR  !=B   7*   %NY  !:WP
M6?<  %C_ (1N  !\<@  =74  &MV  !==0  3W0  $)S   U<P  *'(  !UP
M   3;P  #&X   1N    ;@   &X   !L @  ; <  &L+  !K#@  :Q(  &H9
M  !J(@  :BT  &HZ  !I20  :5H  &EL  !H@P  9YL  &:U  !EV   9/4
M &3_ (!U  !Z>0  <'L  &)[  !4?   1GP  #E\   L?   'WL  !1Z   -
M>@  !'H   !Z    >@   'H   !Y    >0$  '@&  !X"P  > X  '@3  !X
M&@  >"4  '@R  !W00  =U(  '=E  !V?   =94  '2O  !SS@  <O$  ''_
M 'Y]  !U@   9X$  %B"  !*@P  /(0  "Z%   AA0  %84   V%   #A0
M (8   "'    B    (@   "'    AP   (<   "'!   APD  (<.  "($P
MB!P  (@I  "(.   ATH  (==  "&<P  AHT  (6G  "$Q0  @^P  (+^ 'B$
M  !JA@  7(@  $V*   _C   ,8X  "./   6CP  #9    *1    D@   ),
M  "5    E@   )8   "6    E@   )8   "7    EP   )<'  "8#0  F1,
M )H?  ":+0  FC\  )I2  "::   F8,  )F?  "8N@  E^(  );X &V*  !?
MC0  4)   $&3   SE@  ))<  !:8   -F0   9L   "=    GP   *$   "D
M    I0   *0   "E    I0   *8   "G    J    *D   "J!   K P  *X3
M  "N(0  KC,  *Y'  "N70  KG8  *Z3  "NK@  K<T  *SO &&1  !3E0
M1)@  #6<   FGP  %Z$   VC    I0   *<   "J    K    +    "R
MM    +,   "T    M0   +<   "X    N0   +L   "]    OP$  ,,+  #%
M%0  Q24  ,8Y  #'3P  QV@  ,:%  #&H@  QKP  ,;> %69  !'G0  .*(
M "FF   9J   #:L   "M    L0   +0   "W    N@   +\   #!    Q
M ,,   #%    Q@   ,@   #*    S0   ,\   #2    U@   -L   #@#
MX1@  .,K  #D00  Y5H  .9T  #FD0  Y:P  .7$ /\   #_    _P   /\
M 0#_  H _P 2 /\ '0#_ "@ _P T /\ /@#] $@ ^@!0 /< 5P#U %T ] !C
M /( :0#P &\ [P!T .T >P#K ($ Z0") .@ D@#F )P Y "H .( MP#? ,T
MW #N -D _P#9 /\ R@#_ +X _P"U /\ L #_ /\   #_    _P   /\   #_
M  8 _P / /P & #X ", ]  N /  . #K $( Z !* .4 40#B %@ X != -X
M8P#< &@ V0!N -8 = #4 'L T0"" ,\ BP#- )4 R@"A ,@ KP#% ,$ P@#C
M ,  ^P#  /\ NP#_ +  _P"H /\ I #_ /\   #_    _P   /L   #S  $
M[0 , .@ $P#C !X X  H -H ,@#3 #P SP!$ ,P 2P#) %$ Q@!7 ,0 70#"
M &( P0!G +\ ;0"] '0 NP![ +D A "W (X M "9 +( IP"O +< K0#0 *L
M\@"J /\ J0#_ *$ _P"; /\ EP#_ /\   #_    ]    .D   #@    U0 (
M ,X $ #) !@ Q0 B ,$ *P"\ #4 N0 ] +8 10"S $L L0!1 *\ 5@"N %L
MK !A *H 9@"I &T I@!T *0 ? "B (8 H "2 )X GP"< *X F0## )< YP"6
M /\ E0#_ )( _P"- /\ B@#_ /P   #P    XP   -0   #(    OP # +D
M#0"S !, KP < *P )0"I "X I0 V *, /@"@ $0 G@!* )T 4 "; %4 F0!:
M )< 7P"6 &8 E !L )( =0"0 'X C@"* (L EP") *8 AP"X (4 U@"$ /8
M@@#_ ($ _P!^ /\ ? #_ .T   #=    S    ,$   "X    K@   *< "0"B
M !  G@ 7 )H 'P"7 "< E  O )$ -P"/ #T C0!# (L 20") $X B !3 (8
M60"$ %\ @@!E (  ;0!^ '< ? "" 'H CP!X )X =0"O ', QP!R .P <0#_
M '  _P!P /\ ;@#_ -T   #)    O    +$   "I    H0   )D  P"3  P
MC@ 2 (H &0"' "$ A  I ($ , !_ #< ?0 ] 'L 0@!Y $@ > !- '8 4@!T
M %@ <@!? '$ 9P!O '  ; ![ &H B !H )< 9@"H &4 O !C .$ 8@#Z &$
M_P!A /\ 80#_ ,T!  "\!0  KP4  *4"  "<    E    (T   "&  @ @0 .
M 'P % !X !L =0 C '( *0!P #  ;@ V &T / !K $$ :0!' &@ 3 !F %(
M9 !9 &, 8 !A &D 7P!T %T @0!; )  60"A %< M !6 -  50#R %4 _P!4
M /\ 50#_ ,$,  "R#@  I@\  )L.  "2"P  B04  ((   ![  ( =0 + '
M$ !L !8 :  = &8 (P!C "H 80 P &  -@!> #L 70!! %L 1@!: $P 6 !3
M %8 6P!4 &0 4@!N %$ >P!/ (H 30"; $P K@!+ ,8 2@#J $D _@!) /\
M20#_ +D2  "J%@  GA<  )06  "*$P  @1   'D+  !Q P  :P & &4 #0!A
M !$ 70 8 %H '@!8 "0 5@ J %0 , !3 #8 40 [ %  00!. $< 30!. $L
M5@!) %\ 1P!I $8 =@!$ (4 0P"7 $$ J0!  +\ /P#B #\ ^  ^ /\ /P#_
M +(9  "D'@  F!\  (X?  "$'   >A@  '(2  !J#@  8@@  %P!" !7  X
M4P 3 %  &0!. !\ 3  E $H *P!( #  1P V $8 / !$ $( 0P!) $$ 40 _
M %H /@!E #P <@ Z ($ .0"3 #@ I0 V +H -@#; #4 ]  U /\ -0#_ *P@
M  "?)   E"8  (DF  !_)   =2   &P;  !D%0  7!   %0, 0!.!@H 2@(/
M $< % !$ !H 0@ @ $  )0 _ "L /@$Q #P!-P [ CX .0)% #@#30 V U8
M-01A #,$;@ Q!7X , 60 "\%HP M!K@ + ;4 "P'\  L"/\ + C_ *@E  ";
M*@  D"P  (8M  ![*P  <B<  &@B  !?'0  5Q<  $\2  !(#@0 00H+ #X'
M$  [!A4 .0<; #@'(0 V""8 -0@L #,(,@ R"3D ,0E! "\)20 N"E, + I>
M "L+;  I"WP * R/ "8,H@ E#+< ) S3 ",-\  D#?\ )0W_ *0J  "8+P
MC3(  (,R  !Y,0  ;RX  &4I  !<)   4Q\  $L9  !#$P  /! & #4-#  S
M#!$ ,0P6 "\,'  N#2( +0TH "L-+@ J#34 *0T] "<.1@ F#E  ) Y< ",/
M:@ B#WL (!". !\0H@ =$+< '!#4 !T1\@ =$?\ 'A'_ *$O  "5,P  BC8
M ( W  !V-@  ;3,  &,O  !9*@  4"4  $@@   _&@  .!4  # 1"  L$ X
M*A 2 "@0&  G$!X )1 D "00*@ C$3( (A$Z "$10P @$DX 'A): !T3:  ;
M$W@ &A.+ !@4H  7%+4 %A31 !85\0 7%?\ &!3_ )XS  "3-P  B#H  'X[
M  !T.P  :S@  &$T  !7+P  3BL  $4F   ](0  -!P  "T7!0 F$PP (Q,0
M "(3%0 @$QH 'Q,A !X4)P =%"\ '!4W !L500 :%DL &197 !<790 6%W8
M%!B) !,8G@ 2&+, $1G. !$9[P 2&?\ $QG_ )PV  "1.P  ACX  'P_  !S
M/P  :3T  %\Y  !5-0  3#   $,L   Z)P  ,B(  "H> 0 B&0D 'A<. !P7
M$@ :%Q< &1@> !D8)  8&2P %QDT !8:/@ 5&DD $QM5 !(;8P 1''0 $!R'
M  \=G  .';$ #1W+  T=[  .'?\ #QW_ )DZ  "//P  A$(  'M$  !Q0P
M:$(  %X^  !3.@  2C8  $$R   Y+0  ,2D  "@E   @( 8 &AT, !<<$  5
M'!4 %!T; !0=(@ 3'2D $AXR !$?/  0'T8 $"!3  X@80 -(7$ #"&%  LB
MF0 *(JX "2+'  DBYP *(OL "R'_ )<^  ",0P  @T8  'E(  !P2   9T8
M %Q$  !2/P  23L  $ X   X-   +S   "<L   >)P, %B,* !(A#@ 1(1,
M$"(9 ! B(  /(B< #B,O  TD.0 ,)$0 "R50  HE7@ ))F\ !R:"  8FE@ $
M)JP  R;$  0FY0 $)O< !B;_ )5"  "*1P  @4H  'A,  !O3   94L  %M(
M  !01   1T$  #\^   W.P  +38  "0Q   ;+0  $RH'  \H#0 -)Q$ #2@6
M  PH'0 +*"4 "BDM  DI-P '*D( !BI.  0K7  #*VP  2M_   KE   *ZD
M "O!   KXP  *_8  "K_ ))&  "(2P  ?T\  '91  !M40  8U   %I-  !/
M2@  1T<  #Y$   S0   *3P  " X   7-   $3$%  PO#  )+A  !RX5  8O
M&P %+R,  R\K  (P-0  ,#\  #!,   Q60  ,6D  #%\   QD0  ,:<  #"_
M   PX0  ,/4  "__ )!+  "&4   ?50  '56  !K5@  8E4  %A3  !.4
M14T  #I)   O10  )4(  !P^   4.P  #CD%  DW"P $-@\  383   V&0
M-B   #8I   V,@  -ST  #=)   W5P  -V<  #=Y   WCP  -J4  #:]   V
MX   -?4  #7_ (U0  "$5@  ?%H  ');  !I6P  8%L  %=9  !,5@  0%(
M #5.   J2P  ($@  !=&   00P  "T$$  1 "@  /PX  #X1   ^%@  /AT
M #XF   ^+P  /CH  #Y&   ^5   /F0  #YV   ]C   /:,  #R[   \W@
M._4  #O_ (I7  ""7   >5\  '!A  !H80  7V$  %1>  !'6P  .E<  "]5
M   E4@  &U   !)-   ,2P  !DH#  !)"0  2 T  $<0  !'%   1AH  $8B
M  !&+   1C<  $9#  !&40  1F   $5S  !%B0  1*   $2X  !#W   0O4
M $+_ (A=  !_8@  =V4  &YG  !G:   6V8  $YC  !!80  -%X  "E<   ?
M6@  %5<   Y6   '5    %,!  !2!@  40L  %$.  !0$0  3Q8  $\>  !/
M)P  3S(  $\_  !/30  3ET  $YO  !.A0  39T  $RU  !+V   2O4  $K_
M (5E  !\:0  =&P  &UN  !B;0  5&L  $=I   Z9P  +64  ")D   88@
M$&    E?    7@   %X   != P  7 @  %L,  !:#P  6A,  %D9  !9(@
M62T  %DZ  !92   6%@  %AK  !7@0  5YD  %:R  !5T@  5/0  %/_ (%L
M  !Y<   <W,  &AS  !:<@  3'$  #]P   R;P  )6X  !IL   1:P  "6H
M  !J    :0   &D   !H    9P,  &8(  !F#   9@\  &44  !E'   92<
M &0T  !D0P  9%,  &1E  !C>P  8I0  &&M  !@S0  7_$  %[_ 'UT  !W
M=P  ;GD  %]Y  !1>0  0WD  #9X   I>   ''<  !%V   *=0   '4   !U
M    =@   '4   !T    =    ',"  !S!P  <PP  '(0  !R%0  <B   '(L
M  !R.P  <4P  '%?  !Q=   <(X  &^H  !NQ@  ;.T  &O_ 'M[  !R?@
M9'X  %5_  !'@   .8$  "N"   >@0  $H$   J!    @0   ((   "#
M@P   (,   ""    @@   ((   ""    @@4  ((*  ""#P  @A<  ((C  ""
M,@  @D,  (%6  "!;   @(8  '^A  !^O0  ?>8  'S\ ':"  !H@P  684
M $N'   \B0  +HH  ""+   3BP  "HL   ",    C0   (\   "1    D@
M )$   "1    D0   )$   "1    D@   )("  "3"0  E \  )09  "4)P
ME#@  )1,  "38@  DWP  ).8  "2LP  D=@  )#V &J(  !<B@  38T  #^0
M   PD@  (90  !25   *E@   )<   "9    FP   )T   "?    H    *
M  "@    H    *$   "B    HP   *0   "E    I@<  *@0  "H'   J"T
M *E   "I5@  J6\  *F+  "HJ   I\<  *;L %^/  !0D@  098  #.9   C
MG   %)T   J?    H0   *,   "F    J    *P   "N    KP   *\   "P
M    L    +(   "S    M    +8   "W    N@   +T'  "_$   OQ\  , S
M  # 20  P&(  ,!^  # FP  P+<  +_8 %.7  !$FP  -9\  ":C   6I0
M"Z<   "J    K0   +    "S    M@   +L   "]    P    +\   #!
MP@   ,0   #&    R    ,H   #,    SP   -,   #:!P  VQ,  -TE  #>
M.P  WU,  .!N  #?C   W:D  -W" /\   #_    _P   /\   #_  < _P 0
M /\ &0#_ "0 _P O /P .@#Y $, ]0!+ /, 4@#Q %D [P!> .T 9 #K &D
MZ0!O .< =0#F 'P Y "$ .( C0#@ )< W0"B -H L0#5 ,4 T@#H -  _P#/
M /\ Q #_ +@ _P"O /\ J0#_ /\   #_    _P   /\   #_  ( ^P - /<
M%0#S !\ [P I .H - #F #T X@!% -X 3 #; %, V !8 -0 7@#2 &, T !I
M ,X ;@#, '4 R@!] ,@ A0#& )  P@"; ,  J0"^ +H NP#9 +D ]P"X /\
MM #_ *D _P"B /\ G0#_ /\   #_    _P   /8   #N    YP * .$ $0#<
M !H UP C -  +@#+ #< QP _ ,0 1@#! $T OP!2 +T 6 "[ %T N0!B +@
M: "V &X M !U +$ ?@"O (@ K0"3 *H H0"H +$ I@#( *0 [0"B /\ H@#_
M )L _P"5 /\ D0#_ /\   #\    [@   .,   #8    S0 % ,8 #@#! !4
MO0 > +D )P"U #  L@ X *\ 0 "L $8 J@!, *@ 40"G %8 I0!; *, 80"A
M &< GP!N )X =@"; (  F0", )< F0"4 *@ D@"\ )  WP". /L C@#_ (L
M_P"& /\ @P#_ /@   #I    W    ,P   #!    N    +( "@"L !$ J  8
M *4 (0"B "D G@ R )P .0"9 #\ EP!% )4 2@"4 %  D@!5 )  6@"/ &
MC0!G (L ;P") '@ A@"$ (0 D0"" *  @ "R 'T S !\ /$ >P#_ 'H _P!W
M /\ =0#_ .8   #3    Q@   +L   "Q    IP   *$ !0";  T EP 3 ),
M&P"0 ", C  K (H ,@"( #@ A@ ^ (0 1 "" $D @0!. '\ 4P!] %D >P!@
M 'D : !W '$ =0!\ ', B0!P )@ ;P"I &T OP!K .8 :@#_ &D _P!I /\
M9P#_ -,   ##    M0   *L   "C    FP   )(   ",  H AP 0 (, %@!_
M !T ?0 D 'H *P!X #( =@ X '0 /0!R $( <0!( &\ 30!M %, ; !9 &H
M80!H &H 9@!T &0 @0!A )$ 7P"B %X M@!< -4 6P#W %L _P!: /\ 6@#_
M ,4   "V @  J0(  )\   "6    C@   (<   "   4 >@ , '4 $0!Q !@
M;@ > &L )0!I "L 9P Q &8 -P!D #P 8P!! &$ 1P!? $T 7@!3 %P 6P!:
M &0 6 !N %8 >P!4 (H 4@"; %$ K@!0 ,@ 3P#N $X _P!. /\ 30#_ +L*
M  "L#0  H T  )4,  ","   @P(  'P   !U    ;@ ( &D #@!E !, 8@ 9
M %\ 'P!= "4 6P K %D ,0!8 #8 5@ [ %4 00!3 $< 40!. %  50!. %X
M3 !H $H =0!( (0 1P"5 $4 J !$ +\ 0P#D $( _ !" /\ 0@#_ +(1  "E
M%   F14  (X3  "$$0  >PT  ',(  !L    90 # %\ "P!;  \ 5P 4 %0
M&@!1 !\ 3P E $X *P!, #  2P V $D / !( $( 1@!( $4 4 !# %D 00!C
M #\ ;P ^ 'X / "0 #L HP Z +@ .0#9 #@ ]0 X /\ . #_ *P7  "?&P
MDQT  (D<  !_&0  =14  &P0  !D#   708  %8 !@!1  P 30 0 $H %0!'
M !H 10 @ $0 )@!" "L 00 Q #\ -@ ^ #T / !$ #L 2P Y %0 -P!? #8
M:P T 'H ,@", #$ G@ P +, +P#. "\ [P N /\ +@#_ *<>  ":(@  CR0
M (0D  !Z(0  <1T  &<8  !?$P  5PX  % *  !) P@ 10 - $$ $0 ^ !8
M/  ; #H (0 Y "8 -P L #8 ,@ T #@ ,P _ #$ 1P P %  +@!; "T 9P K
M '8 *@"( "@ G  G +  )@#) "4 Z@ E ?L )0'_ *(C  "6*   BRH  ($J
M  !W*   ;24  &0@  !;&P  4A4  $L0  !## ( /0<) #D##@ V 1( ,P$7
M #$!'  P 2( +P(G "T"+0 L S0 *@,[ "D$0P H!$T )@58 "4%90 C!G0
M(@:& " &F@ ?!ZX '@?& !T'YP ="/@ '0G_ )\H  "3+0  B"\  'XO  !T
M+@  :BL  &$F  !8(0  3QP  $<7   _$@  . X$ #$+"@ N" X *P<2 "D'
M%P H"!T )P@C "4(*0 D"3  (PDW "$*0  @"DH 'PM5 !T+8@ ;#'( &@R%
M !@,F0 7#*T %@S& !4-Y@ 5#?D %@W_ )PM  "0,0  AC0  'PT  !R,P
M:#$  %\L  !5)P  3",  $0=   \&   -!,  "T0!@ F#0L ) P/ "(,$P A
M#!D 'PP? !X-)0 =#2P &PTT !H./0 9#D< %PY3 !8.80 4#W$ $Q"$ !(0
MF  1$*X $!#& ! 0Z  0$/L $1#_ )DQ  ".-0  A#@  'HY  !P.   9S8
M %TR  !3+0  2B@  $(D   Y'P  ,1H  "H5 0 C$0< '1 - !L/$  9#Q4
M&! ; !<0(0 6$"D %1 Q !01.@ 3$44 $A)1 !$27P 0$F\ #A."  X3E@ -
M$ZL "Q/"  L4XP ,%/H #1/_ )<U  ",.0  @CP  '@]  !O/0  93H  %LW
M  !2,@  22X  $ J   W)0  +R$  "@<   @& , &10* !42#@ 4$A( $Q,8
M !(3'P 1%"8 $10N ! 4.  /%4( #A9/  T67  ,%VP "Q=_  D8DP (&*@
M!AB_  <8X  '&/4 "1C_ )4X  "*/0  @$   '=!  !M00  9#\  %H\  !0
M.   1S,  #XP   V*P  +B<  "<C   ?'P  %QH( !(7#0 0%Q$ #Q<6  X8
M'  .&", #1DL  P:-0 +&D  "AM,  D;6@ ''&D !1Q\  0=D0 "':8  1V\
M  (<W0 "'/(  QS_ ),\  "(00  ?T0  '5%  !L10  8T0  %E!  !//0
M1CD  #XV   U,@  +BX  "4J   =)0  %"$$  \="P -'1  #!T4  L=&@ *
M'B( "!XJ  <?,P &(#X !"!*  ,A5P !(6<  "%Y   AC@  (:0  "&Z   A
MVP  (?(  "#^ )!   "&10  ?4@  '1*  !K2@  8DD  %A&  !.0@  13\
M #T\   U.0  *S0  "(O   9*P  $B@$  TD"@ )(PX !B,2  4C&0 $)"
M B0H  $E,0  )3P  "5(   F50  )F4  "9W   FC   )J(  ":Y   FV0
M)?(  "7^ (Y%  "$20  >TT  '-/  !J3P  8$X  %=+  !-2   1$4  #Q"
M   Q/0  )SD  !XU   5,@  #RX#  HL"@ %*PX  2H1   J%@  *AX  "HF
M   K+P  *SD  "M%   L4P  +&(  "QU   LB@  *Z   "NW   KU@  *O(
M "K_ (Q)  ""3@  >E(  '%4  !H5   7U,  %91  !,3@  0TL  #='   M
M0P  (S\  !H\   2.   ##8#  8S"0  ,@T  #(0   Q%   ,1L  #$C   Q
M+   ,C<  #)#   R4   ,F   #)R   RAP  ,9X  #&U   PU   ,/(  "__
M (E/  " 5   >%<  &]9  !F60  7ED  %57  !)4P  /D\  #),   H2
M'D4  !5"   .0   "#T"  $\"   .PP  #H/   Y$@  .1@  #D@   Y*0
M.30  #E    Y3@  .5T  #EO   XA0  .)P  #>S   WT@  -O(  #7_ (=5
M  !_6@  =ET  &U?  !E7P  75\  %)<  !$6   .%4  "U2   B3P  &$P
M !!*   *2    T8!  !%!@  1 H  $,-  !"$   014  $$=  !!)@  03$
M $$]  !!2@  05H  $%L  ! @0  /YD  #^Q   ^T   /?(  #S_ (1<  !\
M8   <V,  &QE  !D9@  660  $MA   ^7@  ,EL  "99   <5@  $E0   Q2
M   $40   $\   !. P  30@  $P,  !+#@  2Q(  $H9  !*(@  2BP  $HY
M  !*1P  2E8  $EH  !)?@  2)8  $>O  !&S0  1?$  $3_ (%C  !Y9P
M<FH  &ML  !@:P  4FD  $1F   W9   *F(  !]@   57@  #5T   9;
M6@   %D   !8    5P0  %8(  !6#   51   %04  !4'0  5"<  %0T  !4
M0@  4U(  %-D  !2>0  4I(  %&K  !0R@  3^\  $[_ 'YJ  !W;@  <'$
M &9Q  !8<   2F\  #QM   O;   (FH  !=I   .9P  !F8   !E    90
M &4   !C    8@   &($  !A"   80T  & 0  !@%P  8"$  %\N  !?/
M7TT  %Y>  !>=   78T  %RG  !;Q0  6NT  %G_ 'MR  !U=@  :W<  %UV
M  !/=@  074  #-U   F=   &7,  !!R   '<0   '$   !Q    <0   '$
M  !O    ;P   &X   !N @  ;@@  &T,  !M$0  ;1H  &TF  !L-0  ;$8
M &M8  !K;0  :H8  &FA  !HO@  9^@  &;^ 'EZ  !P?   87P  %-]  !$
M?0  -GX  "A^   ;?0  $'T   =]    ?0   'T   !^    ?P   'X   !]
M    ?0   'P   !\    ?    'P&  !\#   ?!(  'P=  !\+   ?#P  'Q/
M  ![90  >WX  'J:  !YM@  >-\  '?Z '.   !E@0  5H,  $B$   YA@
M*X<  !V'   1AP  !X@   "(    B0   (H   ",    C0   (T   ",
MC    (P   ",    C    (T   "-!   C@P  (X3  "/(0  CC(  (Y&  ".
M6P  C70  (V0  ",K0  B\X  (KS &B&  !:B   2XL  #R-   MCP  'I
M !&1   'D@   ),   "5    EP   )D   ";    G    )L   ";    G
M )P   "=    G@   )X   "?    H0,  *(,  "B%@  HR8  *,Z  "C3P
MHV@  **&  "BH@  HL   *'H %R-  !-D   /Y,  #"6   AF0  $IH   >;
M    G0   *    "B    I    *@   "J    JP   *H   "K    K    *T
M  "N    KP   +$   "R    M    +<!  "Y#0  N1H  +HM  "Z0P  NEL
M +IW  "[E   N[$  +G2 %"5  !!F   ,IP  ".@   3H@  "*0   "G
MJ@   *P   "O    L@   +<   "Y    NP   +H   "\    O0   +\   #
M    P@   ,0   #&    R0   ,T   #2 0  U \  -4?  #7-0  V$T  -AI
M  #7A@  UZ,  -:] /\   #_    _P   /\   #_  , _P - /\ %0#_ "
M_  K /@ -0#T #\ \ !' .X 3@#K %0 Z0!: .< 7P#E &0 XP!J .$ < #?
M '8 W0!^ -L AP#8 )$ TP"= ,\ JP#- +T RP#@ ,D ^P#' /\ O0#_ +$
M_P"I /\ HP#_ /\   #_    _P   /\   #\    ]@ + /$ $0#M !L Z0 E
M .0 , #? #D V@!! -4 2 #1 $X SP!4 ,T 60#+ %X R0!C ,< :0#% &\
MPP!W ,  ?P"^ (H NP"5 +@ HP"V +0 M #- +( \@"P /\ K #_ *, _P"<
M /\ EP#_ /\   #_    ^@   /$   #H    X  & -D #@#2 !8 S@ ? ,@
M*0#$ #( P  Z +T 00"Z $@ N !- +8 4P"T %@ L@!= +  8@"N &D K !O
M *H > "H (( I@". *0 FP"A *L GP#  )T Y@"; /\ F@#_ )0 _P". /\
MB@#_ /\   #V    Z    -P   #.    Q@ ! +\ "P"Z !$ M@ : +( (@"N
M "L J@ T *@ .P"E $$ HP!' *$ 3 "? %$ G@!6 )P 7 ": &( F0!H )<
M< "5 'H D@"& )  DP"- *( BP"U (D TP"' /< A@#_ (0 _P!_ /\ ? #_
M /(   #C    T@   ,4   "Z    L0   *L !P"E  X H0 4 )X ' ": "4
MEP M )0 - "2 #H D !  (X 10"- $H BP!0 (D 50"( %L A@!A (0 :0""
M '( ?P!] 'T BP![ )H > "K '8 Q !T .L <P#_ ', _P!P /\ ;@#_ -\
M  #,    OP   +0   "K    H0   )H  @"4  L D  0 (P %P"( !X A0 F
M (, +0"! #, ?P Y 'T /P![ $0 >0!) '@ 3@!V %0 = !: ', 8@!P &L
M;@!U &P @P!J )( : "C &8 N !D -X 8P#[ &( _P!B /\ 8 #_ ,P   "\
M    KP   *4   "=    E    (P   "&  < @0 - 'P $@!X !D =0 ? ',
M)@!Q "T ;P R &T . !K #T :@!" &@ 2 !G $X 90!4 &, 6P!A &0 7P!N
M %T >P!; (H 60"; %< KP!6 ,L 50#R %0 _P!4 /\ 5 #_ +X   "P
MI    )D   "0    B    ($   !Y  ( <P * &\ #P!K !0 9P : &4 ( !C
M "8 80 L %\ ,@!> #< 7  \ %L 0@!9 $< 5P!. %8 50!4 %X 4@!H %
M= !. (, 3 "5 $H J !) ,  2 #H $< _P!' /\ 1P#_ +0)  "F"P  FPP
M ) *  "&!0  ?@   '8   !O    :  % &, # !? !  6P 5 %@ &@!6 "$
M5  F %, + !1 #$ 4  V $X / !- $( 2P!( $D 4 !( %@ 1@!B $0 ;@!"
M 'T 0 ". #\ H@ ] +@ /0#= #P ^  \ /\ / #_ *P0  "?$@  E!(  (D1
M  !_#P  =@P  &X%  !F    8  ! %D " !5  T 40 1 $X %@!+ !L 20 A
M $@ )@!& "L 10 Q $, -@!" #P 0 !# #X 2P ] %, .P!= #D :0 W '@
M-@") #0 G  S +$ ,@#. #( \0 Q /\ ,0#_ *86  ":&0  CAH  (0:  !Z
M%@  <!(  &@.  !?"@  6 ,  %$ ! !,  H 2  . $0 $@!! !8 /P ; #T
M(0 \ "8 .@ L #D ,0 W #< -@ ^ #0 1@ S $\ ,0!9 "\ 90 N ', + "%
M "L F  J *T *0#& "@ Z@ H /X * #_ *$<  "5(   BB$  '\A  !U'P
M;!H  &,6  !:$0  4@T  $L'  !$  8 0  + #P #P X !( -@ 7 #0 '  S
M "$ ,0 G #  +  N #, +0 Z "L 0@ J $L * !5 "8 80 E '  ) "! "(
ME0 A *D ( #! "  Y  ? /D 'P#_ )TB  "1)@  AB@  'PG  !R)0  :2(
M %\=  !7&   3A,  $8.   _"P  . 4' #0 #  Q !  +@ 3 "P &  J !T
M*0 B "< *  F "X )  V ", /@ B $< ( !2 !\ 7@ = &T ' !^ !H D@ 9
M *< & "] !< WP 7 ?4 %P+_ )HG  ".*P  A"T  'DM  !P*P  9B@  %TD
M  !4'P  2QH  $,4   [$   - T" "T)"0 I!0T )@,0 "0!$P B AD (0(>
M " ")  > RH '0,R !L$.@ :!40 &05/ !<&7  6!FH % =\ !,'D  2!Z4
M$0>[ ! 'VP 0"/( $ G_ )<K  ",+P  @3$  '<R  !N,0  9"X  %LJ  !1
M)0  22   $ ;   X%@  ,1(  "D.!  C# D 'PD- !T'$  ;!Q4 &0@: !@(
M(  7"2< %@DN !4*-P 3"D$ $@M- !$+6@ 0"VD #@Q[  X,D  -#*4 # V[
M  L-V0 +#?$ # W_ )4O  "*,P  ?S8  '8V  !L-0  8S,  %DO  !0*P
M1R8  #XA   V'0  +A@  "<3   @$ 4 &0X* !4,#@ 4#!$ $PP6 !(,'  1
M#2, $ TK  \--  .#C\ #0Y*  P/6  +#V< "A!Y  @0C0 '$*( !A"X  40
MU  %$.\ !A#_ )(S  "(-P  ?CH  '0[  !K.@  83@  %@U  !.,   12P
M #TG   U(P  +1\  "8:   >%@$ %Q,& !$0"P .#@X #@\3  T0&0 -$"
M#! H  L1,@ *$3P "!)(  <250 &$V4 !!-V  ,3BP !%*   !.V   3T0
M$^X  !/[ ) V  "&.P  ?#X  ',_  !J/P  8#T  %<Y  !--@  1#$  #PN
M   T*@  +"8  "4B   >'@  %AH" ! 5"0 ,$PX "A,2  D4%P (%!\ !Q4F
M  85+P $%CH  Q9&  $74P  %V(  !AT   8B0  &)\  !BU   7T   %^T
M !?[ (XZ  "$/P  >T(  ')#  !H0P  7T(  %8_  !,.P  0S<  #LT   S
M,   +"P  "0I   ;)   $Q\"  T;"0 )&0T !AD1  09%@ "&1T  1HD   :
M+0  &S@  !M$   <40  '&   !UR   =AP  ')T  !RS   <S@  &^T  !O\
M (P^  ""0P  >48  '!(  !H2   7D8  %5$  !+0   0ST  #LZ   S-P
M*C(  " M   7*0  $"4"  LB"0 %( T  1\0   ?%   'QL  " B   @*P
M(38  "%!   A3P  (5X  ")P   BA0  (9L  "&R   AS0  (.T  !_\ (I#
M  " 2   >$L  &],  !F30  74L  %1)  !*1@  0D,  #I    O.P  )3<
M !PS   3+P  #2P"  <I"  !)PP  "8.   E$@  )AD  "8A   F*0  )C,
M "<_   G30  )UP  "=M   G@@  )YD  ":P   ES   )>X  "3] (A(  !_
M3   =E   &Y1  !E4@  7%$  %-/  !*3   04D  #5$   K0   (3P  !<Y
M   0-@  "C(!  ,P!P  +PL  "X.   M$0  +18  "T>   M)P  +3$  "T]
M   M2@  +5D  "UK   M@   +)<  "RO   KRP  *NX  "K^ (5-  !]4@
M=54  &Q7  !C5P  6U8  %-5  !'40  .TT  #!)   E1@  '$,  !,_   -
M/0  !CH    X!0  -PD  #8-   U#P  -!0  #0;   T)   -"X  #0Z   T
M1P  -%<  #1H   T?0  ,Y4  #*M   QR@  ,>X  ##_ (-3  ![6   <UL
M &I=  !B70  6UT  $]:  !"5@  -E(  "I/   @3   %DD   Y'   (1
M $(   !! P  /P<  #X+   ]#@  /1$  #P8   \(0  /"L  #PW   \1
M/%,  #QE   [>@  .I(  #JK   YR   ..T  #?_ (%:  !Y7@  <6$  &EC
M  !B9   5V(  $E>   \6P  +U@  "15   94P  $%$   I/   !30   $P
M  !*    200  $@(  !'#   1@\  $84  !%'   12<  $4S  !%0   15
M $1A  !$=@  0X\  $*H  !!Q@  0.P  #__ 'YA  !V90  ;V@  &AJ  !=
M:0  3V8  $)D   T80  *%\  !U=   26P  "UD   )8    5@   %8   !4
M    4P   %($  !1"0  4 T  % 0  !/&   3R(  $\N  !//   3TL  $Y=
M  !.<@  38L  $RE  !+P@  2>H  $C_ 'MI  !T;   ;F\  &1O  !5;0
M1VP  #EJ   L:0  (&<  !1E   -9    V(   !B    80   &    !?
M7@   %T   !<!   7 D  %L-  !;$@  6QP  %HH  !:-@  6D8  %E8  !9
M;0  6(4  %>@  !6O0  5>@  %/^ 'EP  !S=   :74  %MT  !,<P  /G,
M #!R   C<0  %F\   UN   $;0   &T   !M    ;0   &P   !K    :@
M &D   !I    :0,  &@)  !H#@  :!4  &<A  !G+P  9S\  &92  !F9@
M97\  &2:  !CMP  8N$  &'\ '=X  !M>@  7WH  %!Z  !">@  ,WL  "5[
M   8>@  #GD   1Y    >0   'D   !Z    >@   'H   !X    >    '<
M  !W    =P   '<!  !W"   =PX  '<8  !W)@  =C8  '9)  !U7P  =7<
M '23  !SKP  <M,  ''W '%^  !C?P  5(   $6"   V@P  *(0  !J$   .
M@P  !(0   "$    A0   (8   "(    B0   (@   "'    AP   (<   "'
M    AP   (@   "(    B <  (D0  ")'   B2P  (@_  "(50  B&T  (>)
M  "&IP  A<<  (3O &:$  !7A@  2(@  #F*   JC   &XT   ^-   $C@
M )    "1    DP   )4   "7    F    )8   "7    EP   )<   "8
MF    )D   ":    FP   )T'  "=$0  G2$  )TS  "=20  G&(  )Q_  "<
MG   G+D  )OB %J+  !+C@  /)$  "V3   >E0  $)8   28    F@   )P
M  ">    H0   *0   "F    IP   *8   "G    IP   *@   "I    J@
M *P   "M    KP   +$   "S"0  LQ4  +0G  "T/0  M54  +5P  "TC@
MM*P  +3, $V2   _E@  +YH  ""=   1GP  !:$   "C    I@   *D   "L
M    KP   +,   "U    MP   +8   "W    N    +H   "[    O0   +\
M  #!    Q    ,<   #+    S0P  ,X:  #/+P  ST@  -!B  #0@   T)T
M -"X                       ! P0%!@@)"@L-#@\1$A,4%A<8&AL<'1\@
M(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&1TE*2TU.3U!24U155UA9
M6UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z @8*#A8:'B(J+C(Z/D)&3
ME)66F)F:G)V>GZ&BHZ2FIZBJJZRMK["QL[2UMKBYNKN]OK_!PL/$QL?(R<O,
MS<_0T=+4U=;7V=K;W=[?X.+CY.;GZ.GK[.WN\/'R]/7V]_GZ^_S^________
M______________________________________________\
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MVMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q
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M__________^H-0          7-/___________________________]]#0
M        5-;__________________________^Y]10          1-3_____
M______________________RJ9"\"   $(C=)6,[_____________________
M_______II&M!*#]C?Y6GNMK______________________________]6RK++,
MY/K_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^6[EW=BR/______________
M___________________;GF<V"@ "C/______________________________
M_\A_/P4     7L______________________________V8$Y        /*K_
M____________________________GDP         (Y#_________________
M___________<;QH         $'WY__________________________^O2
M         &_N__________________________^$$P           &3F____
M_____________________^Q1             %?>____________________
M_____[@5             $C6_________________________W04
M     #C/________________________^:):$P           "/%________
M_________________]^;7"P           VZ________________________
M___OL7U5.2(1!P$"$2*R_______________________________?OZ69F)J@
MK+W:________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______COIV ?/O________________________________RMX17, X ':S_
M_____________________________]**3!4      '+S________________
M____________UG\V         $O)___________________________ZD3X
M         "^K___________________________ 6@           !J5____
M______________________^-)             B$____________________
M_____^=>              !W_________________________[0E
M      !J_________________________WT               !;]/______
M_________________2L               !,Z_______________________
MI0                 \X?______________________, P
M   MV?____________________^9BF$G               GU___________
M____________[;Z)52<            EW/_________________________^
MRIUV74H\,BTL,#E'WO_______________________________>;=UM+0T]GD
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^_4N];_________________
M________________Y[B/:DLO%6_______________________________^2A
M9S0'     #S)____________________________UH([         !*7____
M_______________________MA3$           !O____________________
M______^F0@            !0X?_______________________^QI
M       WR?_______________________[,O               BMO______
M_________________WD                0I_______________________
M\C0                 F?______________________J0
M    C/______________________1@                  ?___________
M___________?                    =/____________________^7
M                :O_____________________.
M8_______________________*2(!                8?______________
M________N:. 5S<7            :/__________________________^M.N
ME(9\=7%P<G>!E/______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________;NIV":6G3____
M___________________________(DV4]&0   !V>____________________
M________VXY,$P        !N___________________________;?"P
M      !%U_________________________^+*@             BM/______
M_________________\)$               #E_______________________
M_WT!                ?_______________________YS8
M    :O______________________G0                  6/__________
M____________1@                  1_C____________________I
M                ->G___________________^6
M)=O___________________^\                    &,[_____________
M_______K                    #\+_____________________
M            "KG_____________________)P                  "K7_
M____________________<                   #;G_________________
M____X)R,<%5",R8;% \-#A(:)K_____________________________YY-C2
MSLS+S,_6X/S_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________KT[SC________________________________TJF%
M94@L$@&%____________________________\:MQ/ \       !/X/______
M___________________5?S4            ?LO______________________
M_^-U'0              B?_______________________Y C
M    9_______________________U4,                 2/;_________
M____________B@                  +MW_____________________.
M                %\C___________________^^
M!+;___________________^<                     *7_____________
M______^Z                     )/____________________<
M             (+_____________________                     '3_
M____________________$P                   &C_________________
M____0@                   &#_____________________>@
M         %W_____________________T0                   &'_____
M_________________R0                  &;_____________________
M_\FLF8E]=G%L:6=F9VMP>HS_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________BQ:J1>6%W________________________
M_____]VF=U L#      QQ/_________________________@DDX3
M    C________________________])P'0              8/__________
M____________[F\/                -^+_____________________EAP
M                %,#_____________________0
M */___________________^N                     (G_____________
M______^>                     '+___________________^\
M             %_____________________:                     $W_
M___________________Z                     #O_________________
M____#@                   "KY____________________,P
M         !OI____________________7@                    _;____
M________________CP                    ;0____________________
MT                     #*_____________________RL
M      #(_____________________X                    #+________
M______________<6 04% P$       $&#1C+_______________________\
MZ^'8S\S-S]#2U-?<XNK_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M\=K&_______________________________QQJ.$:$TR&  5J___________
M________________N7Q&&           <?_______________________]=\
M+P              .^/_____________________WV0)
M#+7_____________________= ,                  (W_____________
M_______%%0                   &K___________________^9
M             $O___________________^V                     ##]
M___________________7                     !GG________________
M___V                      73____________________#@
M          #!____________________+P                    "O____
M________________4@                    ">____________________
M>0                    ".____________________I0
M      " ____________________V                     !T________
M_____________S8                   !M_____________________WP
M                  !I_____________________]<-
M  !H______________________]P                  !A____________
M____________4#Q&3E1976%D:&QP=GZ)____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______OU;NCBW-:E?__________________________^+^.9$$A!0
M4OS_______________________>=5A@             %\'_____________
M________Y6P6                 (W_____________________8P
M             %[___________________^=                     #7\
M__________________^A                     !'9________________
M___*                      "[___________________N
M          "A____________________#                     "*____
M________________+0                    !V____________________
M30                    !D____________________;P
M      !2____________________E                     ! ________
M____________O                      P____________________Z@X
M                   B_____________________T0
M   5_____________________X$                    +]?__________
M_________\@+                   "[/____________________]>
M                Y?_____________________)'
MVO______________________G0$             !PX7Q?______________
M_________]6YO,''SM7;X>;M]/O_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________C?S_______________
M_______________LQJ6(;50[(0< ,M[________________________7DEDI
M             *#______________________XDV                 &?_
M____________________9@                   #+V________________
M__^5                      /(__________________^G
M          "@___________________7                      !\____
M________________                      !>____________________
M)0                    !#____________________2
M       L____________________:@                     8________
M____________BP                     %\___________________KP
M                    X?__________________U0
M    S____________________R0                     OO__________
M_________U0                     KO___________________XL
M                G____________________\L.
MDO____________________]7                    AO______________
M______^J"@                  >?______________________;0
M            9O______________________]U4                 1?__
M______________________]J(RLU/TI58&IU?H>1G/__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________Z,^VG8-I3KG_
M________________________[+*#7#H= @       'O_________________
M_____\5M*0               $#_____________________@QL
M          ?+__________________^2                      "8____
M______________^D                      !J___________________=
M                      !!____________________#@
M       =____________________.0                      Z/______
M____________8                       SO__________________A0
M                    M___________________J
M    H___________________RP                      D/__________
M________[Q8                     ??___________________SX
M                ;/___________________VD
M6O___________________YD                     2?______________
M_____](6                    .?____________________]8
M            *?____________________^B                    &?__
M___________________U5@                  !/__________________
M____NR\                  /C______________________ZLI
M         ,_________________________)1P     '$R N/E)HA.W_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________TU<G____________________________ZTK"2
M=UU"* P  $K________________________%?447             !'8____
M________________Q%                    "?__________________^B
M#                     !H__________________^4
M       V___________________:                       '[/______
M____________%0                      Q/__________________2
M                    HO__________________=0
M    @___________________G0                      :?__________
M________PP                      4O__________________YP\
M                /O___________________S,
M*____________________U@                     &/______________
M_____X$                     !?___________________ZP
M             /___________________]XB                     /+_
M__________________]<                     -__________________
M__^?                     ,S____________________H2@
M         +?_____________________H!8                  )S_____
M_________________WH"                 '?_____________________
M__]Z"P              !4S_________________________HE=H=("-G*N\
MT.?_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________[>/_____________________
M_____]*C>E@Z*2,<%@X&  "?_____________________ZQ2#@
M      !I___________________D0P                     T________
M__________]Y                        X__________________-
M                    LO__________________$P
M    A?__________________3P                      7?__________
M________@P                      .O__________________L@
M                '/__________________VP,
M O___________________RH                      /O_____________
M_____T\                      .?__________________W0
M             -3__________________YL                      ,#_
M_________________\0'                     *W_________________
M__ S                     )K___________________]G
M         (;___________________^C                     '+_____
M_______________C1                    %S_____________________
MD08                  $'_____________________ZU\
M     !W______________________\I+                  #_________
M_______________+5P  #!@D,3].8'2+I\?_________________________
M_]?G\O______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^O4S<?"OKJWL["MJ:BE____________________W7Y3
M/S C&1$) @          V_________________]V
M    I_________________^Z                        =?__________
M________!P                      1O__________________3@
M                &O__________________C
M /W_________________P0                       -O_____________
M____\1D                      +[__________________T0
M             *3__________________VL                      (W_
M_________________Y$                      'G_________________
M_[<                      &;__________________]XA
M         %/___________________]*                     #______
M______________]W                     "O___________________^L
M"@                   !;____________________G10
M      #_____________________B@                    #_________
M____________UDT                   #]_____________________Z<N
M                  #5______________________^8*@          !A@M
M16#@________________________J&-T@8^<J[O-XOK_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________^?+MZF=E8Z)A(!\>'1P;&AED/________________^\:D@M&0H
M                ,?__________________
M ___________________0@                       -S_____________
M____C@                       ++_________________S@
M             (W__________________RD                      &O_
M_________________UH                      $[_________________
M_X8                      #3__________________ZX
M         ![__________________]07                      K_____
M______________H]                      #___________________]E
M                      #___________________^.
M      #___________________^\&0                    #O________
M___________Q3@                    #8____________________BP
M                  "_____________________S$,
M  "A_____________________Y$9                  !Z____________
M__________)T"@               !%?_______________________H=!,?
M+#A%4V)RA9NTTO7__________________________]?H]/______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________^_?S\>[LZ^OL\?______________
M____V;*9AWEM9%U644M&03PX,BTH(\3_________________2R4+
M             )+_________________B                        &;_
M________________UP                       #W_________________
M_S,                      !C__________________VP
M          #__________________YT                       #_____
M_____________\D,                      #V__________________$U
M                      #?__________________];
M      #+__________________^"                      "W________
M__________^I!@                    "C___________________3+P
M                  "-____________________7@
M  !W____________________DP<                   !>____________
M________S4,                   ! _____________________X<0
M               <_____________________]A>
M______________________^_3@      #APL/E)JAJ7(________________
M________PGR,FJ>VQ=;H_?______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________[N'7S\G#OKJVL:VIIZ:FIZ[_________________
MOH9M6TQ -R\H(AP6$ L$     !3_________________UP4
M          #__________________S0                       #V____
M_____________W8                       #2_________________[
M                      "R_________________^$D
M      "6__________________]1                      !\________
M__________]Y                      !F__________________^@
M                  !1___________________'(P
M   \___________________N2P                     G____________
M________=                      0____________________HQ8
M                ____________________V$P
M_____________________X@/                    ________________
M_____\M3                    ______________________^E.
M    "1TT3FN,________________________F3E#45]N?8Z@M<OE________
M_____________________^OY____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^O,N:RAF9&+AH%\>'1P:VAF9FCQ_________________V%%
M,B,8#@8               ">_________________WX
M      !U_________________\,                       !2________
M__________LW                       R__________________]J
M                   6__________________^6
M    __________________^_&P                      ____________
M_______F0@                      ____________________:0
M                ____________________D (
M____________________N2P                     ]/______________
M____Z%P                     V?___________________Y$8
M            O/___________________\I3                    G?__
M__________________^8+@             0*49FQ/__________________
M___N?QT,&B@W1E=I?I6OS.[_________________________YZ"JN<C8Z?S_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________]]?#KYN+?V]C4TM'0TM?@________
M_________\Z>BGQQ:6%;5E%,2$,^.C8R+RXQ_________________](E$0,
M                    __________________]"
M    __________________]]                        ____________
M______^P"P                      ]O_________________=.0
M                W/__________________8@
MQ?__________________B0                      K_______________
M____KR(                     F?__________________UD@
M            @O___________________W(                     :?__
M_________________Z$H                    3O__________________
M_]-<                    ,_____________________^6+@
M    %3)2=______________________@<A,   $/'R]"6'"+J,CL________
M________________RF]N?HZ>L,/8[_______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________YX-+(P+JUL*RHI:*?G9N;G*"G____________
M______^"9%9+0SPV,"LG(AT8$PX)!   U/________________^2
M                K?_________________,'@
MB__________________[4@                      ;?______________
M____@                       4?__________________J1L
M            .O__________________T$(                     (___
M________________]6@                     #/__________________
M_X\4                     /___________________[@^
M         /___________________^5M P                   /______
M______________^?-P              $"]0=/_____________________=
M<A0     !A<J05IUE+;:________________________O%A$5&1UAIJOR./_
M_____________________________]+-X?'_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________S[^OO]____
M___________________NN:B=EH^*AH)_>WAV=')S=7A_D/______________
M___K3SHP*"$;%1 +!P(         (___________________:0
M             /__________________FPH                      /__
M________________R#D                      /__________________
M\&,                      /___________________XH.
M         /___________________[ T                     /______
M_____________]5;                     /____________________^%
M&@                   ^S___________________^Q20
M&#E=@?_____________________E>QX       PA.%)OC[/9____________
M____________NU@I.4E:;("7L,WM_____________________________[.>
MM,77Z_______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________KOY^'<V=;4TM#0T-'3V>#K]___
M________________N(I^=W%L:&1A7EM96%=765YE<?__________________
MOS$?%A *!0               /__________________[58
M         .C__________________X($                     ,S_____
M_____________ZLO                     +/__________________])7
M                     )O___________________=\$
M     (7___________________^B-P                 %*Y3_________
M___________+80(            ,+%!VGM'____________________UC3
M      TC.U=VF;[E________________________PV,8*CM,7W2-I\;G____
M_________________________ZA_EJB[T.?_________________________
M___________]________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________]W.Q;^\N;:TL[&RLK6YP,G5X_______
M_____________Y=L9%Y955%/3$I(1T9(2U!99J'__________________Z<F
M#@<"                 %;__________________\Y0
M     #K___________________1Y"P                   "'_________
M__________^?,@                    [____________________$6
M              @Q6H3____________________I?Q\           8G2W&:
MPNG_____________________ITD      A<O2FB*KM7\________________
M________TW4>)CA*7G6/J\OO_____________________________ZYRA9BL
MPMOV___________________________________?[___________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________^_LJJFHZ&@GY^AHZ:LM,#-W>S_________
M__________^*6E-/2TA&1$-"04)#1TY9:7W___________________^>+@8
M                  #____________________#5@
M%4'____________________G>QH             "31@B[3_____________
M________GS\         !"5*<9G"Z_______________________QF8/
M$RI$8H.GS?7_________________________ZXXU*SY1:(&=O-[_________
M_____________________[YV?Y2IP=SY____________________________
M_______2V//_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________;R\._O[_'S^/W_____
M_______________________XL)^:EY:6EIB;GZ2LML+1X>[_____________
M_______^CE!*1T5$1$1%1D=+45IH@ZG_____________________ID$!
M       '-F./NN'_____________________QF4*       $)TQSG,3L____
M____________________Y8@O   3*D1B@J;,]/______________________
M_____ZM0-DIA>Y:TUOK______________________________]*'?)BQR^G_
M___________________________________4SNW_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^WEX^/DYNCM\?G_________
M_____________________;&4DI*5F9VCJ;*\T.W_____________________
M_____YU31TE-459@<XJOUOS__________________________[)6 !HU4&V+
MKM+W_____________________________\UO/E][F;?7^?______________
M_________________^Z?@Z;"X?__________________________________
M___CSNO_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________\
M
M
M                                                 /__________
M____________________________________________________________
M____________________________________________________________
M________________________________________     /_A0,9H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I
M9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL
M;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E
M(#DN,"UC,# P(#<Y+C$W,6,R-V8L(#(P,C(O,#@O,38M,3@Z,#(Z-#,@(" @
M(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO
M<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @
M(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @
M(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P
M.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIT:69F/2)H='1P.B\O;G,N861O8F4N
M8V]M+W1I9F8O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z97AI9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]E>&EF+S$N,"\B/@H@(" @(" @(" \<&1F.E!R;V1U
M8V5R/DUI8W)O<V]F=,*N(%=O<F0@,C Q.3PO<&1F.E!R;V1U8V5R/@H@(" @
M(" @(" \>&UP.D-R96%T;W)4;V]L/DUI8W)O<V]F=,*N(%=O<F0@,C Q.3PO
M>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R
M,BTQ,2TR-E0P,CHP,CHR-"LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @
M(" @(#QX;7 Z36]D:69Y1&%T93XR,#(S+3 Q+3 X5#$S.C0S.C4P*S U.C,P
M/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^
M,C R,RTP,2TP.%0Q,SHT,SHU,"LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*
M(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S
M:&]P.F0Y-3-F865F+34W9#4M-C,T8BUB.3(R+6%B,64V-S8X,3(W,3PO>&UP
M34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP
M+FEI9#ID8S)E.&(V.2TS.#<U+6(P-#(M8C T."UE-&0R8V%E8V%F,3 \+WAM
M<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^=75I9#I!.4$V,#)%1"TX13,Y+30Q1D8M03!!,"TV1#0P1C8U-$9!
M-38\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-
M.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C)E
M83<U.#<T+68U-F8M9C,T,RTY.30V+3!E,C%B.6(S-V(Y-3PO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTQ
M,2TR-E0P-#HQ,#HU,RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(S
M+C4@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HS,&0U93@U."TP,S T
M+64Q-#@M.3 W.2TR8C(X,C4R968S-3 \+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#$M,#A4,3,Z-#,Z
M-3 K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R-"XQ("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#ID8S)E.&(V.2TS.#<U+6(P-#(M8C T."UE-&0R8V%E8V%F,3 \
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C,M,#$M,#A4,3,Z-#,Z-3 K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H
M;W1O<VAO<" R-"XQ("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \
M>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C,P9#5E.#4X
M+3 S,#0M93$T."TY,#<Y+3)B,C@R-3)E9C,U,#PO<W12968Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^861O8F4Z9&]C:60Z
M<&AO=&]S:&]P.F-F,#(W-V8R+6$U-V,M-6$T8BUB-S$W+3(R96$U-F5E-31F
M93PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#YU=6ED.D$Y038P,D5$+3A%,SDM-#%&1BU!,$$P+39$
M-#!&-C4T1D$U-CPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @
M(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \9&,Z8W)E871O<CX*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^
M4W1E<&AE;B!-83PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G
M92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-
M;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(" @(#QP:&]T;W-H
M;W Z24-#4')O9FEL93Y5+E,N(%=E8B!#;V%T960@*%-73U I('8R/"]P:&]T
M;W-H;W Z24-#4')O9FEL93X*(" @(" @(" @/'1I9F8Z3W)I96YT871I;VX^
M,3PO=&EF9CI/<FEE;G1A=&EO;CX*(" @(" @(" @/'1I9F8Z6%)E<V]L=71I
M;VX^.38P,C,P+S$P,# P/"]T:69F.EA297-O;'5T:6]N/@H@(" @(" @(" \
M=&EF9CI94F5S;VQU=&EO;CXY-C R,S O,3 P,# \+W1I9F8Z65)E<V]L=71I
M;VX^"B @(" @(" @(#QT:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S
M;VQU=&EO;E5N:70^"B @(" @(" @(#QE>&EF.D-O;&]R4W!A8V4^-C4U,S4\
M+V5X:68Z0V]L;W)3<&%C93X*(" @(" @(" @/&5X:68Z4&EX96Q81&EM96YS
M:6]N/C4U.3PO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B @(" @(" @(#QE>&EF
M.E!I>&5L641I;65N<VEO;CXS-S4\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP
M;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C
M:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( 7<"+P,!$0 "$0$#$0'_Q  >  $  @,!
M 0$! 0          !@@!!PD%! ,""O_$ %@0   & @ !!P8("@8'!@4%   "
M P0%!@$'"!$2%!465M8357:4E98A,34V4521U DB06&!M;:WU? 7(W&AP>$D
M)C)$A;'Q&"4S-&;10D928L93A*:TQ?_$ !T! 0 !!0$! 0             $
M @,%!@<!" G_Q !#$0 " @(! P,# 00(! 0%!0$" P$$  4&$1(3!Q0A%2(Q
M(R0R,T$(%E%A<G2RM"4T0G$70U*11%1DDJ%3@;'1TO#_V@ , P$  A$#$0 _
M /\ >W)R<@WD6$9&L&3Q=ZSDGQSOI)>-211C5XIN8I3-XJ4.JHJ>53R4N4T2
ME*D?.3FR;& QGY=)MGF2N^]$EX0#&.DVSS)7?>B2\(!C'2;9YDKOO1)>$ QC
MI-L\R5WWHDO" 8QTFV>9*[[T27A ,8Z3;/,M=]Z)+]'_ ,H?S^<,9GI-L\RU
MWWGDO" 8S'2;9YDKOO1)>$ QCI-L\R5WWHDO" 8QTFV>9*[[T27A ,8Z3;/,
MM=]Z)+P@&,=)MGF2N^]$EX0#&.DVSS)7?>B2\(!C,Y<VS\D+7?TV>2Q_^(9#
M&8Z3;/,M=]Z)+P@&,=)MGF2N^]$EX0#&.DVSS)7?>B2\(!C'2;9YEKO)Z427
M_+LA_B&,=)MGF2N^]$EX0#&9Z3;/,M=^/O/)?%[H?'^;^\,8Z3;/RPM=]YY+
M/_XA@,9CI-L\R5WWHDO" 8QTFV>9*[[T27A ,8Z3;/,E=]Z)+P@&,STFV>9:
M][SR7A$,9CI-L\R5WWHDO" 8QTFV>9:[[T27A ,8Z3;/,E=]Z)+P@&,=)MGF
M2N^]$EX0#&.DVSS)7?>B2\(!C'2;9YDKOO1)>$ QCI-L\R5WWHDO" 8QTFV>
M9:[[T27A#Z?_ '_,&,=)MGF6N^]$EX0#&.DVSS)7?>B2\(!C'2;9YEKOO1)?
M'[H?W_W!C'2;9YDKOO1)>$ QF>DVSS+7?>>2\(!C,=)MGF2N^]$EX0#&.DVS
MS)7?>B2\(!C'2;9YDKOO1)>$ QCI-L\R5WWHDO" 8QTFV?DA:[[T27A#(8QT
MFV>9:[[T27A ,8Z3;/,M=]Z)+P@&,=)MGF2N^]$EX0#&.DVSS)7?>B2\(!C,
M])MGF6O>\\EX1#&8Z3;/,E=]Z)+P@&,=)MGF2N^]$EX0#&.DVSS)7?>B2\(!
MC'2;9YDKOO1)>$ QCI-L\RUWWHDOT_\ RA_U_,&,=)MGF2N^]$EX0#&.DVSS
M)7?>B2\(!C'2;9YDKOO1)>$ QCI-L\R5WWHDO" 8QTFV>9*[[T27A ,9GI-L
M\RUWWGDO" 8QTFV>9:[[SR7A ,9CI-L\R5WWHDO" 8QTFV>9:[^?_6B2\(?#
M_<&,=)MGF6N^]$EX0#&9Z3;/,M=]YY+P@&,=)MGF6N_G_P!9Y+PA\/\ <&,Q
MTFV>9*[[T27A ,9GI-L\RU[WGDO"/]O\_$QF.DVSS)7?>B2\(!C/IAY)V_S*
M(OF;9DZBY$K!4C1\K(-U?*1D;)D537681JF.5.2(D=,S;'-.D;.#G*;&<,9\
M[GYV0OT]G;/^LJA_D&,D(8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,
M!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8
MP&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,C
ML)\I6_TB;?LG5PQAS\[(3Z>SMH_650_R#&2(,8#& Q@,8#& Q@,8#&4-X\8"
M.>PG#[85SR99*#XGM*-(_#><FV<89"8N<:5]B1@F<BA!S2O(Q;Y9.)F.?N(L
MV%5(M5F=PY,K7JY\?*= 8].YZ^1U6240R(2/$>0V>BA9W"@R<I4L<B%N8 "E
MC"3U7-Y\=_'N3++]U>MKVAZ?:4.7M=?6&9,>AD'AMO&4D4I(R!I+EJ4FN&;L
M@ZULS>7$'#;1PW<P&H.&2O6_6R#]14A*I/SKF^NYW9M?-A4IXRV1#FMPD>PL
M\;Y"4B$6V4&CMOTQQA?$N>ZEH>6;RDPE[K7;I%/76E]/<4DTN/Z[;ZZLB>DS
M"MQMKMP+B)B5;1=%=*T%A""5$Q2%V-OQ#5. 'ZW:U]@[8TFC!HV+7;>MJ7!9
M#]UHZ_7=(KB<$=0]R^PHE&]1Y7I@_7W/2-U[ W<[RK==2\(>GKEKEU(Y,WD*
M-9IO7D[=IC:-9P0R9H:UR%OCVK%Q-Q:+9TLA"H0QE#M.D-%<WOX^D3R78ZD8
M3M*WJ&_5TR7'<RO6H5N-'K-"OO[YBALK&UNC;I',HV,6"79!P*"%XW2 &Q=Q
M/4W^MG3W./A8M2\^Y>RF[O-QK;VS>?Q,V=?J=7KK->X)0[6G<9<K,KN?+BZX
M:OEI>>UIKR<L&#EGIFCU25F\*)E24Q+2$"P=R.%$BE(5,^'BRW.3P0N"&Y2X
M+CDY,2MRA%7<;6M6B(KU]E>0B(F9B$JLM6J(DIF9B $8B9F9GIUF9_.8S2/=
M9TVILV"DWOUM%SCF(B3:VJHV',1$1$D124Q$1$=?B(C/<LDRK!197Z#1-\NK
M*U^)1;+.C,DC*S\_&02:JKDC5Z=--L>2PY/@C54RA4<I%P7)\'+!4OR%(]>W
MHMS.O3K_  E&WITZQ^]V=O7^77KTGITG*1'6>GX^"G_VB9__ #TZ?W?GY_&?
MQTFU^9:][SR7A$6\\QTFU^9:][S27A(,8Z3:_,M>]YY+PD&,=)M?F6O>\\EX
M1#&9Z3:O,U?]YI+PD&,QTFU^9:][S27A+^W^?B8QTFU^9:][SR7A$,8Z3:_,
MM>]YY+PD&,=)M?F6O>\\EX1#&.DVOS+7O>:2^+W2_N_O#&.DVOS+7O>>2\(A
MC,])M7F:O^\TEX2#&?BE(65?RGD8NLK>15,BKY*UOU/)+$Y,G14YE3SS%28,
M7)DS<AR\N.7&.7 MK:IO?XFK;XV$IGC,3\;0Z22S[9GL8,3$D!="CK'6(ZQE
M9K-?;W@8=X0P.\9'O NO:8]8CN ND]"CK$])Z3\9\;2PRK][)QC)"GNY*%.V
M2EX]M<G2[V+4>(=):$D&J=5,NSRZ;_US;#A,GETL&.ESBE-G$6MM-;<MWZ%3
M84K5[5&A>SIU[276M>=I,6*PW:ZS)M6;")AR(< >5?4U]PQ,Q?=2N5T5;3ZE
ME-:\+3I6&I8M%L4,\3BK-(86^$M_3;*R+QG,"?29CKYC6\JO;1)4MJ6JKV>'
MCVLK)0Y+-+]):1[PY2(.#FS3L(&P8RB.3IIK'61*X:G733(Z;F5@5^3:&UR"
M_P 6K[.NWD&LHU]C?U8^3W%:E:* 0\YD(5,%)+D@!A-4+JYM  LH)DIVEVJ-
M35WKJ3EZF[9;3JWB[?$ZRB))BQB"ED=($^TB 09*VBLB)+8"1Y=VG!L$ZGKO
M.SC)L%S:)'!LE+DN#&P7LERYP7)BXSG'+C&3%QG/PXY<YUCK ]8[IB9@>L=9
M@9B"F(_,Q$D,3/XB2CK^8S&=)Z3/2>D3$3/3XB9ZS$3/XB9B)F(_GTGI^)S\
MSR%D3511/%UDBR_/\@D>U/RJK>2+@ZOD4\U/!U?)E_&/S,9YA>0QN3&1035
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MLUMAE96O.E6[AW6K6:"G8S-UK+UPU0<OJY;^O(1ZY)EPZ8++**'-ZOHNTRX
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M@,9'83Y2M_I$V_9.K_S\/_(,9ES\[(7T=L_ZRJ'Y?Y_N#&2$,8#& Q@,8#&
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MU&,!_>$B2R 6^14!+0E5)(&FT)LR=>K>M+52#R7+;*M*Q9"C47UZ'9ODJ*2
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MB5\$X@!<>XL5:# "4G:)JV^12J([89NSGN,I)A]#!F<S> Q@,8#& Q@,8#&
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MJPUULS:,I)/IC>-A)J$64EV;U=FX8*N%G*+8Q%'*3?#U%JNC CS#;JM"5BL
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M8O4DS*JND7.''E6Q$E<U65,IO+]NQE>IK#8DA?VHI-+;:9 L\$1($34L<@9
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M8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#&
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MP/1(A*"$I$AF)$AF8(9B>L3$QTF)B?F)CYB<H8M;5FIH Q3!(&+8,&!@42)
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M<':J$98=$QBON*X1\S!TY*8M0$2(RZD;H,I_AAUZ0K>I+M*]&M]2=*SB-MK
MKIWRF%?X9L7%/:,HW(C!:HW%!&-3=*JDH(Z38;T[YMY,UZF;#@T$IF-@[9 R
M#<CMBLJFUDV:R#I'!D'\8]3RI@F5$3E4;/V*Y#\TQ5$%L?BF'/N0\8T7):;-
M7R734=K5@B[JVQJ+<2&Q$A+$DP?+5LA'6!<@E/7/R!B41,=GTN^V.J:K9:+:
M/J&P -=FA9F%V$ET,.Z5E*K-<XZ3V'#$L&?D2&<XJV;8<E';6Q:JR\ENC4N=
MRUI2$_)24RO'04+)N5(^+74DW*K[H*N#KF<1QU_ZDKQRV*?_ .,WY/;_ )O>
MH^HT<BT-K9>WXIMYK\43NK][:.I:C5WGE3U[FWW';FHV#>3J9NGQ!;=7@YB.
MZ?OK4\8JVN'3I]LBE+M]KX;OFZVI4HKL["]54-BXL*JAK^X7(JA5D5]3)"G2
M/7XSM=2[0TNM2KML8I*MVUAB&,HFW7(<BK8SI BBK8_/(GD^6RV5$/+$+E!Q
MA/"[<ZB"B:AOU;XIR"OROC6CY)46Q*-WJZ>Q!#@,&(FRD6,07D )/PLDU0T1
ME3X"'()B6+,O@O?:EVAW.TTSS!K=;=L4R:LA(&PEA"#1[2*!\H0+)64^14E*
MVB+!(8DXV#,3D>A?E*W^D3;]DZQ_/P_\@QF'7SLA/1VT?K*H!C)$&,!C 8R!
MV77^M)EZZM-PJ%-E7J$6BT=SEEA8=\=M$1BCYXDFJ\E&ZI6[-FH^?N,YR=--
M/RZQS&QC.<XHDEH%A3(* S\S3F1""9XUI\C#GIU+QK4ON*?W0 ?P(Q%<>1LK
M7'>R1DH4N.XIB62/= #'7Y.1'XB/F8B>G7(#47G#,O:8=/7[O3#BXX,_-$DH
M[BG+SI2XC7>) Q2UTYWA&W5V7)7!U^:VY,E*;/EC(XS?7YNK_'Y/^4/W$CW=
MOL_=T>[R3^[XYN>PZ1/S+85(_B>EADIZIALK[O/^SP<CW>YBO9^%=?GR^U]W
M\#]WA\W_ $0>;8L%OJU3/!IV>PPT >S3C2LUXLO(M8\TU89!-=5C"QF'*B?3
M)-VFV<';LT.>NJ5%3)"9YN1;"):X:RX\CV*LO!(?<TD5%2ZTV C[I775'>X^
MG:L9B2F.X>MPOL4QY_:E4IAK2^ ";#UUD013\1+7N6H(_,D<1'QUF.7%YV'7
MHQ>SZ4C.,?A6J^D7<E;&%ICSMTGV^HQG-2TBYME(8G0N"M<?2:[E]*1329-5
MB65MA5+E8RDTAEZYJTP^YG1"8G?11#0U]2&MF8';(U@4D:55DYA\K@UUZ@67
M43 ;7:QB0H@^!1<N&VF^Z^J0T=@^W?NVF['L(-;L+;W6K=M8G*EF*K;G/74O
MC**T=J6DY"Y7/6!D1!-FT3;&R9L1L@1N8V39,9 J1"I&-D_X^<Y3P7.<F_&S
MGX3?#RCUDE)G)_OR9273IT[I*>[\?'YZ_CX_LR.H0%2A7,RL5@(3,S,R$#$#
M,S/S,R/3K,_/7\_.?2*,N8#&5(W_ 'W9](V_PMQ]7M<7&T38NT75'NM:-5VC
MV8FB&J%GL#=<EF?/'&(Q@@>&0)EE&PS6167-Y8TZ5M@[!5K>CMZ=*Q^I79QK
M?;)"Q_3\-K4A6Z,8<1)N\A7T$L(-*U>V9#0LQ8CP4;$I1I"N(^RRO>\?HL87
MWP5;:;%*3%03T%9PI-E;#.'28V0),5F5X8RVX97D'V&J5"NMUCX4R1&W:\5/
MA)%5PKDJ>P*P<V$D$"*+K*9QC."(HIJ*J&Y")D.<V"YD5?XI?Y>W_M794/YG
M_"?^@L]?M/&_5Y_W4M/\&$?*<YG<3\LQNG&!I.MG;21VM,U)*SJ.58N3:ND9
M78N]-/UU'"+%PT;OSY=1%+FR(.,M'K)95#+1)+IQTL&T[U;ZSZ3LUHS]W*?4
MWTRT)#TB)-:N2TKQ0#&1*A*#\7Q,%/:4R0ROOD<=PD/<>OFFMF(DOAWI%ZF<
MA67E7W*M;6M5U0$2!.+)@=:M;#N@)3UCI!"V Z],<6:-QC&,MY_X,8^*J6G/
M_P#C#<(^(C_MF1QVGC/J\_[J6G^##W&.T\9]7G_=2T_P8,8[3QGU>?\ =2T_
MP8,8[3QGU>?]U+3_  8,8[3QGU>?]T[3_!@QCM/&?5Y_W4M/\&#&.T\;C_=Y
M_P!U+3G_ )0P8S/::-^KS_NI:?X,&,=IHWZO/^ZEI_@P8QVFC?J\_P"ZEI_@
MP8QVFC?J\_[J6G^#!C,=IXSZO/\ NI:?X,&,=IXWZO/^ZEI_@P8S/::-^KS_
M ,/_ *4M/]__ '-\'Z0QF.T\9]7G_=.T_P &#&.T\9]7G_=2T_P8,9GM-&_5
MY_W4M/\ !@QF.T\;]7G_ '4M/\&#&.T\;]7G_=2T_P &#&.T\;]7G_H^:EI_
M@W]_Q!C':>,^KS_NI:?X,&,=IXSZO/\ NI:?X,&,SVFC?J\_[J6G^#!C,=IX
MSZO/^ZEI_@P8QVGC/J\_[J6G^#!C':>,^KS_ +IVG^#!C':>-^+H\_[J6G_G
MU-R!C':>,^KS_NI:?X,&,=IXSZO/^ZEI_@P8QVGC/J\_[J6G^#!C':>,^KS_
M +J6G^#!C':>,^KS_NI:?X,&,=IXSZO/^ZEI_@P8QVGC/J\_[J6G^#!C':>,
M^KS_ +J6G^#!C':>,^KS_NI:?X,&,SVFC?J\_P"ZEI_@P8S':>,^KS_NI:?X
M,&,=IXWZO/\ NI:?R_\ !O\ I^4,8[3QGU>?]U+3_!@QF>TT;]7G_=2T_P &
M#&8[3QGU>?\ =2T_P8,8[3QGU>?]T[3_  8,8[3QGU>?]U+3_!@QF>TT;]7G
MO=2T_P '#&8[3QOU>?\ =2TY_P"4,&,=IXSZO/\ NI:?X,&,\R:>5.QQ;^"L
M,"]G864;*LY*(F*+8).,D&BQ>:LU>L7D"LU=-U2\I5$5TE$SE^ Q<X%:VL2P
M6I8:FA,$#%D0&!1^)$AF"&8_E,3$Y8M5:UVNVI<KHMU7A*WU[*@>ARRCH0-4
MP2!@%'Q(D,Q,?F,I$_X;IO4,@M:.#._SVJ,F7<OI/1EWJ5_MO#U:'"YC*JIM
MH'#+KW6#ITN?"B\Q072*)"(HM\0*J'E"'V8=^C8!".1T_?\ 01!>TK2NOMT1
M'2(DF]OBO",=>B[8S,S,S#1GI,<L;Z=['CCBO^F>Z_J_U,VOXIM8L;#AU\SZ
MS(A4AONM$PSGN.SJ#$>@B'M"'K$\C[C^&XW0QW/ .(_7-.C=:5)PK"WJA(N'
M+]_=7Z6>A34DQMTO!Q<Q7L-G:2SBKM>HFJC4F2$L[.8-DS9#H=;TPU3-:V#M
M..]8&&U;1K  KB7WK T+8Q;9(9B'%+2[OF4DOX*?FW9_TIN5*Y-3-&GUR='K
MF'4VVH%K'/VCAZ*M.3L;-:O9J0IL&=!<5%R$3$7EV>O8/^D'56RJON+7-.VA
M2CR)ZK=X-I/0F9:+=PTD5F[+G'DGD<\3(JBLBJ11+*B65V3K!,.XUX^CUVKQ
M?CMZD[76[%&Q 0ZJTDLA9BP.X9_(D/Q,3'28Z]"CKT,1*"&/M70;NCR33:W?
M:V7S1VM15RM[E#*[X6V.O:U+8@A,2B1F8[EGT\B6,40,+8 BYE\CL)\I6_TB
M;?LG5PQAS\[(3T=M'P_\2J'\_H#&2(,8#& QFA.*"I/;QH+9]:CD:RY?/:XH
MNV0N<F>'J2RD8Z;2G,LLB0Q2-X0Q69NLNE8.Q5:^51?I*LU%TS0[GVS0=(U2
M&KN=);9%Z>E24UMK3:[W ]"ABH4)R:H S;$2M,0\E$,FK\S95$VX*UK=M2#V
M'3WLLO:RW45%4B^%O)CAA;I_@G,.^>SI-%.&Q.&9;YH;1O4/P=$(^<L+<ND_
MX4)G+_81D&E<=)N&[\R5;A&V8)0[Q [IHL^<NUEDD7C:.608/7L?FJLS,;6(
M*\,1IYDA7'[*<%N])V^Z^Z(Z#(S*3%9=C>T"8KS NQA[ S$ZPBBD739BON84
M"\6%J=P??2#N(_)(J,63,R U3<)$3"")ZAVF(7EHE3JUK75[!'&S)5=S9XI2
M8BHRP-TE2,)!5LW=,7I,I9543RNP>M'B22JF45L<N2'QC?,,>6M"_<@)PN6R
M81(,'QO3Y5Q)JBPB303(%D")S)I>$$H\D'CGJMW?*#[?((=L]968N2<@?V,\
M%A:; @4C,FH9!BC@6AQIGI;:L9!6BN;(?_@U:387,Y9C6F5GKD\E=IPCF;M#
M]^YD7%59UATC(R&"/L.F\8Y7QE['J(EF#ME57QDIFIE)LXT($^5H9Q>L8:\0
M:YMBF6M38I3*R6A-M]I3*EUR&A6I6&6'5+ (0EXVKA6%3MV2!,DAW;Z\VI\)
M>T,+AT7)B LM)2:7MV:X20^V]*ZP-KMML-1=L&>,89M<8416QALAC"K<N"(*
MXPD7&%$"X.?!43_[29<'/C!,EQ@YL8Y<VV?OG]I#]Y?:7R0_,_:4](^Z/Q/Q
M'SU^(_&4ICHI4=P%T6$=RXZ++[8^X(ZST"?R,=9Z#T^9_.?2*,N8#&5NWAI:
MY[3N6E+17+Y6*DTT]>#7W$9-T"5MKBP2AH>4KW1<R+'8=02BV&(F:D,\S$=(
M.>L<,G?2>C-UV#M1_9=N.S9^LL=7?U/M@GPG*-J2/J#)L%#A\TKJ51I%[?LK
MG%@WA<%JUHHO#-K5-URYA3&7Z&QBP<>4!?JFQ8UXR@941*\Y,FX/G$["2!:6
M5# FLLB&5Y"[[\A,O3+7/[PJN)%7^(7^7M_[1V5#^9_PG_H+)H(^4YR]E5"V
MWCXV*Y/DBRM'<\*VMV>.3)\I-RPFY-SS26<84RD15!66K;G&%<86\B]RHFCC
MD364TSU>$ITGHCJES/=MO5]>W8';/4DZ35;%_D&9[0Z S7#!=Q%\=TK&6#$A
MB_2O]I]3O7;;',]./^D^AXV@Q+X!NYNLO.20Q,E$D&T4<=('KWQ)] F)9U"&
MYYE,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,
M!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C.=
M^SOP9G#;M+B2K?$;-P7D7S1VK,WFAI-FRU,V59&V&N82;L4:O@Z*9D%43KV.
M.;H]7W%4C8\V@<ZLV:<V^ES7=4=,[3*;U QA=:U)%%FFDN[RJ2<?,Q,3^B<S
MWUNI>*8Z+\7&MYZ&\(WW-J7-;53M<MDV=KJ1 "UF[NK\?M;-U)=1'MD)*ZD
ME.RF!]T$]UKW70M!!%LBDW;I)-VZ"9$4$$4RI(HHIEP1-)),F"D333)C!2$(
M7!2EQ@I<8QC&!J,S,S,S,S,S,S,SUF9GYF9F?F9F?F9G\YV,1$!$ $0 !@0
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MXU''5-@IZE6U+=30$(.>IS'?I+JB4)2F! AZ!,2N.H0W+,K@,8#& Q@,8#&
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MR@ODV$CQK4!(HAQV0J>[J>_*G#)M11BPN;4)E(D\>Y4$+CK@RVNO+F4UG;%
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M<=K:KWE@/;$?]X#&.UM5[RP'MB/^\!C':ZJ]Y8#VQ'_> QCM;5>\L![8C_O
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M!B(B(B(C)Z-QS7<!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C
M8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,
M!C 8P&,!C 8P&,!C(]"_*5N_-86W[)UC(8PY^=<+Z/6?]95$,9(0Q@,8#&:<
MN]FW+#+7M2FZUKEJ80U,C)6CG>7<T*^MMP4?O23-9?-,0+_$&S9QB+1TSES*
M/"/73C#7R">/*JM[7<[Q,GQC#OJVOJH#R?IGJ[ UQN[%Q]OZ+*3F-_9H@Y<A
M)-@Q+M6=?1<-3$D4IFAL7V#$>K%WT1,Z^DI76(:N[$=&698N*YEVDLACR%K3
M7>Q.*:6O-?B-IZ2UW0*=(FE$WD[7]M%O,KETVAG[Y@S0B,5RN^1(NY;%RN^P
MN^\DDF9'H6/+]+:RU @IM0QQ"2Z!OK@*NOE>-_6HD3/OGL6-:S9/I"Y[V"OJ
MU?;"WQFFX2K0M8&++/CL%+.V55_:7&>0!D?U"FRNJJ1[HD0:9]I0,R-KA9R]
M@,8#& Q@,8#& QD+OWR$R],M<_O"JXD5?XI?Y>W_ +5V5#^9_P )_P"@LJ#8
M.%+0O#]7N(S:NJJ$PJ]OVG6'$7+FC_ZIC',Y++5FZ@ZE'(IE2@(F;E5$I61A
MX_!6KZ3PU1(FBP91K)EH?KKRG;V/2#E]6W;:]2..WJ*![B%KF;,8UJX:8]3L
M.D;?MU0423!.5SU)ID5'HKZ:</XWZIT-YI-2BC>W&WJ6;9@(RBJFC,7VIHIF
M(71J-?5&Y96KHN' #!@%H0M=Y(QF6/C8]@3F\QDR:M"<TO,+S6Z!$2\TG+GF
MEY"8Y"\N>3')CE&U4:PTJ5.F';V5:M>L/:/:/:A0*CM'Y[8Z#'0>L](^.N2+
M3ILVK-@NLE8>YQ=9[IZM83)ZE\=T]2^9Z1UGYS[A*RQ@,8#& Q@,8#& Q@,8
M#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q
M@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,9'83Y2M_I$V_9.KA
MC#GYV0GH[:/UE4 QDB#& Q@,973BU6<H<.NTSL\6H[LU?31;MJ8]4C)Z06<R
M3%NG%)2R+N/5AX^6,KB-FIA-\T/$PSI_(%<)&;8-B):"6MU281-N'[[05RI^
M;VZ[H/V]-1TWV.X/"FT!D@CDIB",8D&Q/B.36.%#><5@:D(T^[?-R4Q9.EX-
M/>=[Y%>?BQ;IR'N::.H2ZRI2X8N2A@TZX<M/XH^Z:3-YX,[CH4QDK(S[<3/$
MWC<;)?*]8ECYA5:QV\MN6JK[R72$YC+!GEN=IT7+TG3,M7.9K,@?J819 /)J
M&#")K]TV('=:$^U;O'/A\4Q#)'S#Y1&8[&]L&K#V EAZPRKDV5W_ "RP;$P-
M4IU>T5YS7,A-B"AI58'QSV3:ALP$AG5 0<GX#& Q@,8#& Q@,9"[[\A,O3+7
M/[PJN)%7^(7^7M_[1V5#^9_PG_H+(3O_ #Y;71HG'PJ6&WZ^@4R\[.#*=.O,
M!E9(I"YPHKY5LDNF=-+^LRF8YB\F"YR.0^L_ZW!RUD=._=\FX5IPCKTDO><O
MTOE" C[V2Q"W!(+^^1(BB8[9G-Z].([.3Q<GKVZS2\EV)ST^!]OQ_9=AR4_:
M'8TUE!']O=$#/[T9NG'Q8_LP.JQ'2(C^R.F:'F1[C 8P&,!C 8P&,!C 8P&,
M!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8
MP&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8R.PGRE;_2)M^R=7#&'
M7SMA/1VT?K.H!C)$&,!C 8S0_$XA!O=$[%C+%6WMNBYJ(;P!JXPFE:TO*O9Z
M481$4W4LB/*>O,L2CUFI(SG-4+%,".7ITE2(F2/$MJ)\TD@L&.9M-5X!:XT)
MAX;"NU<O:K]7P]P=&)1,6+<3[2M/N'KR739*2LO\Q5UU]9M[#W "C:%5&KN-
MM2@72*?<37!L5R<0J!\K,R@1F8HKPXU#1^O=S:#2B]=YJNR]DZXOMC23@=M;
M/O;6LNZR3J6RQ<[$WVRS[-:N3&'2RM9M#1I$2&9*)4CE$S(+K85S%-_N)W(U
M'$:1XSQ[;&;4)&&Z_?NU%N$,F()M785KJZS%K!S%6:3K'E$&U4F_"V% $:]E
MA0K-/*M[I$J!ISVW=.OD%6+*9'M79JEKZ[E6H8H"JVGTV)AH6BBGUB$+)^ Q
M@,8#& Q@,8#&0N^_(3+TRUS^\*KB15_B%_E[?^T=E0_F?\)_Z"R$[H_KS:GC
MN7/^G[FI9LEP;!>4L.C,6+G&Y,9/S2GAT\_B8Y#*93(IDJ1SYQQ_U5ZM+TUI
M1/S<]5>*'(=>D&&K5M-W/=TB2D1+6!,=L=)9XQ.161S&]<%_3'F=G_Y?@F^B
M)Z=>A764=;TCKT'K(W2C[OP/<0Q)B,9NH=8S0\!C 8P&,!C 8P&,!C 8P&,!
MC 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P
M&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8R.PGRE;_2)MR>Z=7_QY
M0QAS\[(3Z.SMH_650_S#&2(,8#& QE+-_;[A=9VB\M-BVBCQ.JJGJ)A9YRDV
M*"0E;-M5[992SPW9JK].G63-PWR2':Q3YCB$G%'3V?8)*X9(<XSB$TA92VG=
M6C96"O5]1K=2KJ-AEQ]-%E-FQ BYDU'OMK"LU:E^.=7MVDR8JS 2U*9YM5X+
M$T)([ENWL604J35I'2[AK=A+GW-=9O;;'O)D#:U8(4UEN(&NG!AJ&RZ=MU/O
M4]5=55&2XDV%CE5M85BBXB;7J2N1L7FQPK9*Y.I=[+RT.1+JJ+M$0\CVC1E8
M)J'Z&JEA#+978.V:(6N.-M'<=0U@[2WL%3XT-V-:_K-:[7FH9:+TC.ULEKK3
M'FX1UESM*RNR;DX,VA=95WE:O[:G9V4ZNC78(G)4+-';[&O?@Q@1K6[4:H6M
M2I:TN19[FC7>E=:>KPQF9' 8P&,!C 8P&,!C(7??D)EZ9:Y_>%5Q(J_Q"_R]
MO_:.RH?S/^$_]!9"-B?Z5L[1,:;X4^T5SFU"\XI>7JBDR;=(Q<_^)DQ7$LCG
M)"XYAD\J<\V,X(4W(.;E#_4'T>H%,]D[OE>V./B(GZ7Q+8)5]W[_ '0_9*GM
MB.P@\G?,3 06]<9CQ<2]0[4?O?3=#0&>DST][OZK#ZQ^[$2NF<=TSW07;VQ,
M24CNL=7S0\!C 8P&,<N,?'GX_@Q^?/T!C 8SYGCQI'-'4@_=-V+!BV7>/7KM
M9-LT9M&R1EG+ITX6,1%!NW1(=5994Y$TDR&.<Q2ESG%#&+2LVM,%J4!,8QA0
M +6 R1F9E,"( ,21$4Q Q$S,Q$96M9M,%* V,88K6M8R9L,Y@0  &)(C(I@1
M$8F2F8B(F9R(TC9>N=F1SR7UQ?J9?XF.=F8/Y.EV>$M$>Q?%13<&9.WD(]>M
MVSHJ"J2QFZRA%<)*)J9)S#ESF\Q9I4#F@:TL$R!K!(%F*YZ,(#*($A7/P<C,
MP,_!=,LPQ9,)0F$M 0,UP428BR3$"((GN$3E;(&9B(*0*(ZR,]/[DMD:\AZR
MTNLO>Z=%TY^NS;,;9(V:&95MXYD7.&4>@UG'+U.,76?/,X:M$DG1CN'.<((E
M.K^**8B2=4KC$D^^:5T4C$RVX=A,V*X55QU.P3Z\2](J$Y:G]0((/NRHYA86
MVG, O7^X]\P_M"E[1TUK7NR+I%?VUB)0_P LAX71*V=IQVY,\9QG&,XSC.,X
MQG&<9Y<9QGX<9QG'P9QG'Q9'GX_.>_G\9D,9YK:9B'DC)0[24CG4M#$9*2\6
MW>MEI"+3DB+J1RDBR34,X9$?D;.3LCN4TRNBMUC(9/A(^2A^X"8/W +CK$8_
M(#86I#V(DH^V'+1:JN-4SW@JPAA# M7)>3,"<+*8ADJ!\!,]#E#&.2MT#/S*
MC=6L*!G3L)B'!$R2SB/2#/<UK>MSZ@U>ZCV.RMJ:YUZ]ED5G$6TN]VK=5=23
M=N<B;A=@A.23%5XB@HHF191N10B9SD*?)<FQC-(F!M-(&).6"V,4)03 6TF"
MHS")DA!A):*RF(@Y4R!F9 NE4@8@+2$H69& ,F)@"-< 3 $ICM(@%BY,8F9&
M#"9B(*.L\C)2-FXYC+PT@QEHF3:HOHZ3C72#Z/?LG*956[MD\:J*MW39=(Q5
M$5T%#I*$-@Q#9+G&1=8MB3)35FIH3(FM@$!@4?D2 H@AF/YQ,1,9:6Q;0%BC
M!BRCJ)K*# HB9CJ)#,C,=8F.L3,?&?;DQ<8R;)L8+C&<Y-G..3&,<O+G.?BQ
MC')GEY?BY,\HMS,1$S,Q$1$S,S/2(B/F9F9^(B(_,Y7^?B/F?QT_O_LR/5BW
MU.[1RLO3;/7[9%(/WL4M)UN9CIR/1E(U7R$C'*O(QPY;IOV"^,HO&AU,.&RN
M/)K)D/\  *HB94A\1,IM)&S5='RJQ7,B 'H9'V-21 8BU<D!$!1!3(ST\F8A
MMA$S$.JNFO:3,]&UK @#"0]<_>EP@Q9DID"<"8%(]"B9^@]CKR<^A55)V')9
MW,:O,MJX>39%G7$0U71:NI5&)RMA^K'-W+ENW7>D;F;)+N$4E%2G5(4W@?J0
MZ5_?%>5"^0^Z$$^#E,-F.L+ET+9*H/I+(6?9U["Z5%$B(&42(,,EK(HF!8P1
MDR "GX(Q"),A&9*!B2F.D=<\6T[(UY1GL%&W6]TZH2-H>=75IC9[+#0+RPR&
M5$4N@PC:4>M5I5YY5RW3Z,Q(NMSUT2\SG*DP8J)>^*J8\UH@\@UE?J/E<3TD
MX2'5DAUB8[H'MZQTZ]<I9,)0RTV8565/1MAGV(7/:1]&-+HL)[ ,^A%$]HD7
MX&9CZ8^]TB5L4Y4(NX5>1ME80;.K)6&,_%.[!7VSPA5&CB;AT'2DA%H.B'(=
MNJ^;H)K%,4R9C8SC.?!(30RT$P=9+20ZP,]R%/"#DTL;'4 :,+9)+(H.( YD
M>@ST]/\ 38I+/L<Y4O2H_M8U D $Y0%T)BH-BQE@1(01@,SU(8GWHZ3CI=@T
ME8E^SDXM^W3=L9&/<HO&+QJJ7!TG+5VW.H@X05)G!TUDE#IG+G!BFSC/**B$
M@F1,9$HZ3,%$C,1,1,3,3TF.L3$Q_;$Q/XSV8F"(9B8(#-9C/P0,6<K8LH_(
MF!B0&,Q!"8R)1$Q,9J2?XD.'FJ.B,;1O;3M<>JD<J)M)W9=,B7*A&<B]B'9R
M(/YENJ8K66C9&,<&*7.$9!@\9J9*X:K)DH P9_#(3^U1_9,%]CTKL(+XZ_:Y
M#E.47X8IBV!,@8S-1K8N9A@&N8(@F#$@F# 0(@F"B.A"+ (A_(B83,1!1,_#
M(\4?#/#NBL9;B&TA&/3MF+TC20VK16;D[.39(2,<[*@XG4U3-G\>Z;/F2^"Y
M2=,W"#E QT52'-7(E!,"1F#4QJ6A,3W+<@Y6Y3!_(,2P26T"B"68R!Q!1,9;
MB8D%LB8E;0ABC_Z6+F2&# OP820D,$,S'42CKUB>DVA-L:MLS<SRN;(H<^T)
M,1=>.YA;= 2C<L].((.86$,LRD%TRRTNV=-7$9'9-AV_1<H*M452+)F-5*FP
M2QE;()K;R%#(%W,?K%N;LDA'3J;=>JO89=6/4Z@(<3X6*SD:/,KH<^1?1:J;
MV3WC]B-@T$4''\_:JZY@*J,GH-AA@"9,BB)]O%SJ&;7FAXM-=S=\0V+%FG8F
MHW-HQ7\N<LL3F8#I/6N(C+S&6N)++7H>7.,H>6\K^**%Q+1>:HE@56K39-<=
MXUW.7Y4J>0]84QJOU%@R1(U]3&)&.N73B5PJ61(18[X1)QVPZ5?Q(5)=/)X_
M^OL[NS_JZ9Z2\W#-I5A N9:-;S<JV?/8R'7?-DI219QAFI9)VQ8'5*Z=MH\S
MYD5ZN@DHFUR[;87,GE=+GAB3ED!'=*06QL#]TJ!IDM1LB.O8## P61=(,Q(1
MF9&8CPOM$2+[1-L) I^!)TK8V%#,_$LE26L@(GNE:F'$=H%,>F&,!C 8P&,!
MC 8R U;:VK[S-SM:I6QZ);K%5U%4;+ UBVP,],UY5!T=BNE-QD6_=/8I1%ZF
MHS5(^00,FZ(= ^,*ER3!42^L-Q$>:H?A[+2OU*Y>X6;4=KAZK+S+6QBNA3Y
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MC$T[V%-U6NJ %S74&_2*<B)1.R+C2-MIZ+:TB(+M5[ENIKKFOGR@F\A]3O:
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MVB8:::U()(S2@NR3L2*A]S$K%C!DD[FUK>.*#8M0C;/#?T((M%S.&1TK"QV
MSF"N(]8S54[U%DHJRPHXRF5U@S-0S<R:Q>:5$^#H)=3X'RW^D%SCC-#D&K_\
M)DUG2ZJ2]W3YG5V@NILFNP[:JILJ>1W9%B"JG*9%H]!44$E>B\JT'I)QC=V]
M3=_K^QRX6\3UECC;Z,KLA#0&NQX#8[%=TIF'C#()<]9,9%A[?J)>(C%@89OB
MFF<U7&'76F*F6[8G^7H3GH70,S&>KN3K'HF772,?^2Z1A+^O\GD=.XU'K=&Z
MISS _2V>.]+/U"..#RN-S_RK_:>SG9_L7_.^V]QY_P#X7S^/];QYI.ZGTRG6
MV?ZO#SJ-Q^C[2=R6@G6_QU>X]Q[*(L_\MYO#X_\ S_%W_I]^54UMQ'Z"I6ZN
M+M>S;CUQ&*.]E4[$;']KH1W.3*\-J^JPDHS@(%D[=34_),IMD[A5HN&8/Y L
MPV7B\-<ODSM\=6U,39T>M17B;#;?(=X59:8EI-7L[>O&@\8#N_9K7=!JM3TK
MRJ#=+82!F.B[+HG9@;Y%"ZO%M:FRQY"A==U3=<ML6DN8V0!3:Z'):U1D)@#D
MD0Q#5]VDIOBBL$P2W5!_O\L!3B;?WU47.TD8;7\A(QR5<K,/(ZUU<Z+FHFK+
M0MJ=O+,W:/'\-BTSB5:7@XN7Q.JY?)XBV$W.,@PXBPQW"^065)'IV<DV%3D=
M_7")FD@^\>-'K=FVMJ2I2X+]79)A5*#6^=6**^\M /58HY1Q91=TQ!Z/4;+C
MH7[EN!:)2M=;DE5^I&QM0M+JG[FM;AEA,&F':0XAM@MJ-INN4[8C9G*UFM\-
M%=H6F6L/6)AENRIV&/AHG:5@S(KQ3FVG?T9^>QLGJ]4L,5&TQ>G+J6U@[3>*
M$2W._P#M7(]@PA]V-GD>Y1?1$]L:C1#I5['4;Q+%2$DJ\QD6EW+16-??!BM9
M24%WHQ^O]P(U92!^&1T]F_2LQ(_MW(0W^V07'V"SRKF6IJZRM-5 (V%?ZL>P
M8^:RP\&U77$=;D=?;!N<EQ)/(>ZH2BM>L^H&U!UL>4T7)GVY'52-<'F)UE&$
MJ40YKSDC-6S[=+;X=X9Z>[P31_'Q*M7>ZXGN91T'A.;D[4=&9[#R!5!>R;IK
M]W<Z>P[Q6:]:!V(14K48H-W0QJVT0.U;V2[=/+M#LO[837"1UQ\@77I0++!W
M]>GQSI-U6KB87+<%2!6QL6J]E6F\FV2BU- $ )Z,D.-#936A-UI7B/C*[>$^
M'S>\H]8D1U$NN3:6M-HM8BA*Y;R5$:F6FK=")2D2[B.JXV/G6;5:0@*S!221
MW"4HB6<2Q,"4&CTJN#U P6']8 ;7Y=6\?G:8)K3[:[86=E]K4O=VG<&I(IRN
MJM/GKI>7<LM]S.B;C:!D6NITBNZ6Q+$0I)PI3!=5L*6I.P4*I,;,,F3ET_Q;
M[83;6BJ4_?-+FF;3;=+A9'<=AF->UMC0JM;=0M+8B24L,#JV^5"#@7>Q\N:K
M&6&Q:ZG"D(FK6G\X6;53GF/C5&PT*6:Z4+M<WI*L62F!V%O1WJ2=+5L0P14Z
MU8I6=E=;3ILU+-DO3F5)J"!RWP*C>VLBP\&6G6='Q38NJ+7/?4+96=FC=6$
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M^W 8QRX^G'VX#&.7'TX^W 8QRX^G'VX#&.7'TX^W 8QRX^G'VX#&.7'TX^W
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M>,K<.*=MC&Y+R.PGRE;_ $B;?LG5PQAS\[(3/_IVT?K*H?\ L&,D08P&,!C
M8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,
M!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8
MP&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,CL)\I6_TB;?LG5_Y_+_@&,.?G9">C
MMH^'_B50_G] 8R1!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C
M8P&,!C 8P&,!C 8P&,!C 8P&,!C*9\4&Q>(S5$#;]AT63T\SHU=;4IK&1-NH
M5PM=EG)FP6-.$FE5Y6$VI28^&C8Q)_&KL$>I91R^6*[35<-D\I*%\IB;KVOI
M/,1+:\CH:>MXUS^ST;T:] W7$32A[QNNO1[8 KCX$(F7032**GR(5KMA0E,:
M[C^UV[Y,XZ.M:RMLKTTU# 1*ELK5*PS8(FR++!E"CA4KR2+;$L- G*K4>(#<
M-'A+#<;]$L-6GUG4'-84V2U*P0ZTJ\]4[=)[AD(MFA)N2DDYV(L41A)FK&JE
MFX90ZY%KB30URT@!S=2C<VK54VBRJ6MJ:\K ;-K057.G[8!MM6EMF!;:H@'6
MXIQ5#LO\BDMLF0C0*=-6&U 2+T;6]M7*BB RQP6 MI535Y/;]03<O% UV5EW
M4_TSXU>&61=-FL;LU*33>6>1I324C:I>)&NN;A&-#/5:NA:&5:7KBM@>MBF/
M!Q!)3+^QF+E*OMY-;'DQ0KN>M+%+:<6J+MC4"$M\]RI6:2;!TZTA%BVQ!#!-
MKUU,L+0VO9)45[*&LN/Z5F656"!)TK*JEWR& A2:_L\1W627CJ53,Y5%VP:Z
M46$VJ\V(?3MK3(DN*?2#BJ-[@VM$R[8.K-,TU&&9Z^V.[OG:FND45GX-363:
MI*[&0?PC9%1[+(KU9/JZ/+U@[RBRR5QGQI"H:QD0$JW0=M$/48OKSK:[O;OO
M-L)EB$5$69&LY[V+6JR:T,(6L "]")8=E<1(,J6*]1P.B:Y^ZM5UVZM=0O\
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M9E-6'1*I)I*-2>C7:5R*,#'N"+5@$R:XK,9NVDG3K5=DHI-9LC _9 NP1V
MVK@E 1Q23UA6*T<D"P.Z!@:V#:"=:*CV),I$,7 7K@L(9?::(736])V24+0D
MO:>\1FG(^^MM;/+:JA9W<^A4T5#5NV&JV;<Z9XD&]/4OQ((U$0MZS(Z;A.K+
MV1.?,FJCG$=_6IX-:J1-V9&M'D+QWFK$NBBLJUA&&Q92%O9-Y=$UM"V=2'C7
M-+Q;(REL!=L3%48-_P!H]U03D8EDUYOR$4O>0OO*E%OR*FL5N$B\6I)4F+E2
M?G;FO]ABY[6VIZ(_;Q%[VU*S"#:PN6;:2+4*C58S,Q;[2WBW?*TDI1LW.QB(
M)J^36C<3<RP=23=XQ:N&+JFN,VKQUX.5HHZ]NXV+ B";-9=NIKZE-,D)@MVP
MV%Y 2PQ*%4$;%RXFPI '6TQK5)M2 -:^[6U=%+)9"CNVJ]RZ3;/B);)K5-?K
M=A:):FJ99L*JTX=7&R=I&B](\3!&MFV1K[=FQB2EK;\0]@U31I)C09*(@4D"
M0L$\K4#*2L)&2M<K\O*G</SQ9+A8D'UC>IO"Q'ED4B,&EVF,;'6:::X]-C9H
M[YEP@F0!]C3[O>5[)4XL]4D=?74$VYUR3LVJM,D,M39EL6[-JW$T;VS6PS.I
M3'CYJDQ$["Z^ZU^M*NZV-<!*5MV%LZC-@**U K0LA84PCVR=V:FV#93W[8^D
M[_(HSMNU\VK]HA;6C'MXDUPU]<3R:4+(R4:R*G'-+##2L/+P$WF+2;1;[+1C
M+-&4=UBK&,J:TQ9UTVH$0L4+YZ;:+"9E16UTZE^M>1!$9K1LJ5M;)09G->]7
MV"0,JZT3-=K]"\"X_P"6V55NTUT3TDD+"ZVK=UAE'\6=8[VY)>4"UM"]1&QY
M;2[%JQ884XP&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,CL)\I
M6_TB;<GNG5_\>4,8=?.V$]';1^LZ@&,D08P&,!C 8P&,!C 8P&,!C 8P&,!C
M 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8RM'%CKC9>W-0R.O=
M8-J,>6G9>OK/WU\L\_6XZ-CX.;83QE6>*]2[DYDWCM>,288:K)Q2#=)TH_Z8
ML=J1BZI3+%;727NT"1JMI3VS1[Y%KF:^REZ:JX\9  /D3\MDB(DP @%=WF(T
M5' '1VE:2*&;#5[/5#/9$@M>UUUN@VP4]\$1UX>)K3 P+I[NYRNR(9&M\ZTW
M7L_'#S)UV%U:VEM:[/KNT+M&S6Q+:TCLNH&/?,^S]6EV.J)1S+H.CRSM3KF6
MAJ\H@1DW)U.ME\J9A=1V5=ZK8!)-IHU>YUX=XPJRP]S0.@335!-4 U!/RB,6
M&39+].2K1'?-EO>W3WJDP W+%C5FL8*9K>+5[FIMQ[W=L-!EF=?71,#78*(L
M.9!/\ !8KY$<-/$]'-(U%2+T,=1GQ>27$NIS-I[!R3,3).'#D]4(8VCRF/)(
MG<>3+*&(FU4*G@^6A,GR0E6N(*8\5!DD8Z'1;W362"(B7EMT[-06D"1=(A$;
MFT15V'$G[1 P\?=,*K5?B;$\FE$1/U9_''4?-/C[?H)Z(B&WV0WQ^XCC5&(E
M/G[)V-J9B8H)B]$#\$.YY.UNKU;*OPU7A=GO+9&RF.M;O,62W4&RU7:D=$QT
MQ$3CN9T\JI 6FL]GHQ]79YE6;(U<KNGJ*[*/(BFJYM4("G7U2V*78-&DOZ6]
MW1 RB7[M_(:FPU=B180M&Y;L4+E9J5Q8H"!A:4QAI&1?9[INR\#6UUNNZ&]4
M9^\3BTVF/C[:NPK :URBW3.;JS"PZ:MX5A"WBL;,=$ZU4)>DZJ6K-2I6K*]-
MMX^:/"4BGD<T76<>^D7#MVUBB/XRM2;MNV(=P4DK8FE,26E'?299.KL#.<1J
M-O<"V]6?72]E@FU5TO<79()%4K&NQHI [,@"$R9U:/N#&86NL5M8%+PLU( #
MACE"CJ4M)=:8?,M$([8)Q+J>3RL 8-TI E++I"GDJ/+H;AUX4X76^ETZ?;=<
MZ=J>TG=2F*19-BZH8MGDU8HZ3:J-SS;VVR%$I5D/)NLN#JNF#U*1136;(+=9
M.\J93;W=RM6QUMC6U&MI(O:I-&TH0$4 ]-7VD.A2VB%H3[!N3Y024.>Y$P<!
M[E]=1[E;@]O94FR]>\O;:F;")K 3=OLV$5I-@=Z81YIH#"C,65JZ6QXO)[9&
MNJIPI[<6B-.539"NGI2!X<:M<H&@/XMS:GKC9+B9JCZDU_M_ .J[#(TV%;0+
MK"EFBH"QW(\[(9*HW>1J38I%[MYH[)NVV5I"AV.VT3=*ZD)&S7 5ZQK[.RNS
M9B:]AD,+6@NE4&JGV<6GL&T9J0,451]E[6BE[YUJ>15]ZRU$+3L@"DVX^E30
MH>^MY4OO&;+S&SY@J*4=3]J>Q<<<<'N[_P"CBZT>(M55BX)*[ZAM>JM:3>R-
MA; J%9SK>W,;%-X;72ST[%RJ41:6K!JVCZ2T87"+JJS;)FTW(E>*G0J788-O
MCU]QG:MZGD5C:M99[3L!K'ZE^N7KBO+%3-P^LZRZRN[<128:I"K,# ^68K:H
M-J;>@$+IHVG&F:ILU%E%9FT;:&U-Y6J-O@UE>/$*2KU+3?+YV/.(*NI3+XV;
M6[+84) L[W)VMM)QB2:[Q?6>R]J:H:KR:K9--]R*T"ZUR5?QN%<'RR9S;Z1*
M@7D5*4BYCGS8:M/N2:F7=@PQ:H:91U49@4$U '->73XPZ'VF:HDUK9V&SOE+
M8WP]C 4!&0,,0@72LQ@XA:[1I4XUC#"$I@$!8(0<RN! L%*/JBL:[<R#VNR6
MQY!Q(MB-ED[SN;;^S&A")*>5)EDSV3=[>SBEC'_%5>1C5L[42_JE%%$OZL>D
MUD)-0"J>XA9'<M8GWK%@@/N(43UKGR%Y%A/C.8 S69J5(T>,9:+9ED$ &N(A
MC(7VL)9%))@X2;(E0]C#"6+&6 LP%K8.I-*UEQ?4.5WT_KL%PZM'NZ=CN+M'
M3\AM'9$SBD(+5^$K29%JHEI&$);';=K#8D"H]K:RW5=+X:'7*@CEPM86LYTE
M'3G8*I-=VZ>ZY74-ED3NMI:VC0JK<RNL3K%:FNE[O(!^,;#*DQ,ULDV"26YM
M;0%394RCJJ*JKC]KY(T]5E9+7M5%@EC:DA8]"H(DCW*79,NCX^&M\'UWTMG1
M=ET]8ZQ=+EJ]KLIE=F.RWLI4H38RNW';*9MT^VF:W7KH[J<NVG8YHXBT$JY,
MME8S&8QTL3F=)4E^:$6; 4JZU:MW&];QE%8VF3M?6TMD[NML+. F+1MLNL%L
M4,) NAT$EJ22OI#8HK2C=;?/U0N1.Y*QZ4C%:S:NTSUERLY$,7*UKUQ"NA87
M,DAZ?(VNX++@B'O."C9\1"P[JAS=.KFTSS5IM+O:E>O.Q*)*4^>V#=Y"XV>,
MCH"*@I^N[.UY&%4C6$=1;FP@$YQ5%](.9B ,\6;*TTX70?J*]9C0UNKU^AU3
MC-:W,VVOT[;+K*;^K:<TY9=.[;FC85;!VD[P@"V,",#<L]+0[.S80#;>QN[G
M9#6\QI"C<NT-7KZ#*.X0L+R"!&N&=N?M#C:MA;(55[9')KK[A"EZ+MJZ6.3H
M'#5L>'M&S#[1A]M7:H$<;MI\C)O6DI.0C-@2FN&LDW0?-US5"90V- JUA1T1
MT>'EL,\,G-6M8%2G5J]I4BUX[&NA^O.?)>HV76G55W2*4DJVL;AU;ER"N#<J
M(6N*R9;,I\N>6P^7DSWGN:>M1:3;CL6BU0UM?6,L58&'@RM8&DBW.O\ '4$+
M#[(C9_\ -;M;?D5V2VGI#B&=-G;JMZSS>JG?%6:#IXK 5+8L2Q;=KUF;-%PY
M5C*].0L0:=6114S'0;V0EUR=%CEU$[% XJ[+801 M>_TJ]/#VE )3L:6VJ;3
M5@]LSVUZ]V!V%&;#.BPO6-<+2!+&M5<LJ.U1K H#:_5[E&X6A0R;K%8M9M-3
ML%5EC]S[*E[)&P% P37HH64U09;:A#Z\N>';B1?HS;IFQT.HTFN+&!XE&#G.
MU+]S,UN+)'*$@%3)Z34)F2=)Q;50C](ZC),KQ;."*8:)9=W=>4:Z>+1?B4_U
M?7RM6SA<=TP7(9WT%->'2B#BE/);_<-CV_EG6U8GQ^_;]/IN,7>'D#*<PQ6[
MJ<=7084P,3&FC3R#W>.&P(VPTE0A!).\<7G_ *S8J+FY8'3L;V^WUM7B%8(.
M$J?)TJFZCI$@NBX;IVMO5):P3]FM441R1!5S6UIF<0A8*5,V12F,0TA(Q_EH
MMPQ>._*(S5U5V#@@9OMVK=BA@]CDZZGJ:NLU9O7/4D/O%.PNQ7/HP*+=<QH@
MQQJ7Y=CR[&BN(CKHM?L-=9,9D@G:;'9+?L:8%(C#(UB];00YH001>;>J$4.I
MM6%N11E6 Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& QD=A/E*W^
MD3;]DZN&,.?G9"8_].VC^Z2J'_N&,D08P&,!C 8P&,!C 8P&,!C 8P&,!C 8
MP&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!
MC 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P
M&,!C 8P&,CL)\I6_TB;?LG5PQAS\[(3T=M'ZRJ'Z/Y_M#&2(,8#& Q@,8#&
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(YSFR;X&,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g428534g47l56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g47l56.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1K24&AO=&]S:&]P(#,N,  X0DE-! 0
M    &K:^:#@X0DE-! 0      !X< 5H  QLE1QP"   "   < E  "E-T97!H
M96X@36$X0DE-!"4      ! B)R.S>.0!+UE6301,F3\].$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  @"4S,P  0 ".$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!$0      !     "   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              5(   )Y    !@!G #0 -P!L #4 -@
M  $                          0             ">0   5(
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   5(     4F=H
M=&QO;F<   )Y    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   %2     %)G:'1L;VYG   ">0    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$%       !     ,X0DE-! P     $%T    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
M A$#$0 _ /0W,LZE9D4OMLQF46;:S0XUV$;?=ZGT_9N_FOWT3&J<Z_,'K6^V
M\;?=( -5#]K0_=M9N=]%5:\?%S,CJF/:YWIBZO<6VN!!%;'QO:[V;7_X)6L2
MEGVC-U=_2 ?IN[TX_P#*240V/1M[7O\ F&?^DTMF2.+6G^LR?^I>Q2]!GB__
M #W_ /DDO09XO_SW?^2213&,L<.K=_9<W_OSU&VS.;637378\1#386@Z^[W>
MD_\ -1/09XO_ ,]__DDO09XO_P ]W_DDK57B6.[*_P!&S_//_I)+=E?Z.O\
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M:TO_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M    _^+__TE#0U]04D]&24Q%  $)OLS^_AX "(!P041"10(0  !P<G1R0TU9
M2TQA8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M     0  ]M8  0    #3+4%$0D4
M                              ID97-C    _    '1C<')T   !<
M "MW='!T   !G    !1!,D(P   !L   H@9!,D(R   !L   H@9!,D(Q  "C
MN   H@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W*  ".+1G86UT
M  ?OW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@*%-73U I('8R
M
M                                             '1E>'0     0V]P
M>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:(        +5:
M  "\9P  DC!M9G0R      0#"0   0                    $
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M 9 GE@L#KXW(@GVVRZ%7LKVD;9WAKAZ1;)J=J<9]RI>@I=%IEI3KHE)4EI*
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MVGX@JB2N[7W5I;V82WVQH8^!%7VPG:EI,GW+FAM0.'WYEPLT7GXRE5\.>WZ
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M:)IMCF",;I>TC+9YMY4PBS-F$Y+ZB?I1?I$%B/,[;H]XB#DAE8]*B+, ^HQ
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M'YL\@HA)>9BC@D0T+):R@BL:;9<9@L8  (M@@ "AL*>5CB^18Z/VC(. ?:"
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MI \CPJ!@F"T+\: =B!,  (1A@ ![;LLQ<OUMF<6V<S=?6,!_<YI0<[N"="=
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MBJP;WZO0BS %@:DD@[D  (,>@ ![.<8EE^1M5,":E9!>][L?DXY0 [75D?9
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MX;7 ;FECL;&];W%4JZWI<(!$F:I@<8TS :>3<G@>NZ;1<L$%O:<_<VT  (
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M3["MDD!B"*QQD)=3 JABCR9#):2JCA(Q_J&=C;4>@: CC> '(9ZCA-(  (
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MP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_=B$5%:_$=;L #ZGI>.<  (
M@ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR>S@5;JW>>P0
MHZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ@4))J+/2@,PZ9J^M@)8IG*R*
M@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME7[P'B,A7P+=%A[9)=;*HAMHZ
M4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (  @ !R4;_YD6AE2KL?C\M7LK9.
MCE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5   (  @ !R,+]0F--E
M/[IBEN!7KK5_E0I)8[#/DXTZ/ZR0DL(IMJDXDP<68*@MCR$"1Z&T@8H  (
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MAXQ:G3!Z>8K-FK5I>HE>F#U7K8@AE@I$U8<<E%LP7H97D_06_X:RCXT  (
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M=9FZ>A)R?9=M>DUB8)53>I51/9-J>ND^RY'A>T J69$<>W$0!I,O>R4  (
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M(I52HD-O ),#GY->]I#-G/%.'8[<FM0\)HU/F=PH:XPXF!H/2XRLBE<  (
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MD*(Z@ !F7Y].?[973IR,?X)'')H8?VDUBY@I?U\AH9=U?U@(KI>+?Y,  (
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M?9ZWINQD+INFI#)4^IBMH:5% I8-H"TSV9/\GGP@F9+8E@H(XY$[A@(  (
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M?ZM8A2Y;!:?/A(=,MZ1M@_,]<J%D@X\LD)\R@VL8V9[W@[\"[9H[@?L  (
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MSKM : Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,  )\$<[   (
M@ !I[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*<9P.M:[H<.8
M )W >"D  (  @ !IS;SG=61=G;C:=8!0U;3/=;A#)K#M=ADT4:V0=GPCD:N(
M=JX/'*S(=B8  )R)?"(  (  @ !IJ+MR?&M=8;=F?!Y0A[-=>^E"\J]W>]XT
M+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (  @ !I>KHQ@W]=-;8C@MI05K(5
M@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@    (  @ !I3KD\BKM=
M'K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<ZA\ /YJ>KAK@  )F0@    (
M@ !I*;A_D?Y=%+1'D,A0/[ 8CX)"E*P;CFPS\:B;C>$CIZ8RCD40(J99BND
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M)'Y]B,]_!WY0A_]MY'XKAQU;UGX>ADI(D7XRA9DSLGY"A0T:.7Y9A0P  (
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M\HV=9?%W\(QY:"!GGXN):B=6&XJ[;!5#/8HJ;>$N=HHI;T<3R(R;;Q0  (
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M5(9*CK)S0X5@C7=C(H2%C"=2)(/,BO _\H-$B@ KTH+]B9X2'X-GB#H  (
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MSY4?;0)KF9-I;F=<19';;[]+O)![<08YOH^!<B<E>(]V<L@++I$8<D4  (
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M\8[=D_!GO(T[DF)8AHNHD,5(:XI-CV@W%(E"CI@CGHBRCL8*QH@=ATD  (
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M[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q=?X<-I8%=?L$4I/%=TT  (
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M2Y@&F(-<W96NELM.<Y-AE0P_'I%ED]8N8X_[D](;,(^,D3T$U8P<@T4  (
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MKZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4  )0P?&,  (
M@ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP?O(2DIR&?N,
M )+H@    (  @ !KO::'AO)?V:.EAG=3):#'A>1%A9X+A5 VV)NKA.4F;YHH
MA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?D:+2C:]2WY_GC+)%.IT>B[LV
MAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (  @ !K)*4/EA!?5*(FE/52G)\S
MDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,  ) G@    (  @ !J\*2AG>-?
M5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=JEN<2JI>IC)X "X^*@ @  (
M@ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$9[@(7*ZD9VL
M )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5:C@\;ZX+:V8MY:N?;&0<\*L*
M;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5=[*_;Y))7:]R<$4\0ZQ1<0<M
MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (  @ !@JK1D==A5);$:=AE(_:W0
M=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@  (^_?Q8  (  @ !@:++U?-)4
MZ:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.?)D)ZJ6(?1D  ([!@    (
M@ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00@J *)Z/,@CD
M (WC@    (  @ !?_;#\BQ14M:V-BGU(F*H?B;P[BZ;AB0@M7:0QB+8=*Z+>
MB2 *9:)*AH@  (TS@    (  @ !?V;!7DD94LJS+D7Y(F*E(D'8[A:7YCXDM
M2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@    (  @ !?P:_=F:!4NZPLF+U(HZB1
MEX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8  (P @    (  @ #!$V<57^VN
MTVDY8K2;[6L^96"((FTD9^YS:6[X:FE=MW"Y;-%&QW)%;Q LSW,F<-T*!'8J
M<12_(&0E:M&M2V:*;(6:CFB_;BR&Z&K2;\MR1FS/<6!<J&ZQ<NM%R7!)=%,K
MZ'#Q=5T);71H=6N]26&5=:>KAF0@=DZ9!V9]=O.%<VBS=Z5P^&K2>%Q;@6S0
M>1%$RFYP>:\K#V[9>@H(Z7+<>BV[=U]+@%VIN&'U@ ^70V1L?\B#[F;!?XUO
MEVD!?VE:4FL8?TU#SVR^?RDJ0FSD?NT(=G&S?H:YS%U5BP2H(& 7B=R5LF*F
MB+6":64,AY=N4F=BAHY9-6F0A:="YVLYA,TIB6L9A!H(%')9@C^X<5O E;.F
MU%Z2D[N4<&$MD;6!,6.BC[9M+68#C=18/&@WC!U"&FGCBJ HY6E^B;$'P7+E
MA3ZW7%IYH&.ES%U6G9Z3:E_UFKJ ,6)PE]YL/63>E3%7:F<:DL!!<6B[D*\H
M8&@7C\H'?'-9A1"VCEE_JPZE!5QBIWR2G%[^H[Y_7V%VH AK;F/GG)E6K68L
MF8] UF?)ER<G[&;BE2('1'.XA.JV"EC4M:RD?ENUL3^2 UY$K*5^NF"QJ"%J
MSV,=I -6'V5@H'Y 36;PGA\G;F7(F5\'&'0#A,RS-V[L7T>BF7!/8C&1#G&G
M9.E^:'+V9W=JM'0_:>U5Z76!;$T_O':D;G<F G=:;_P$,GL)<1*QPFPL::NA
M>VW/:XR0 &]0;5!]:W"];O]IPW(@<)]5#G-X<C(^^'2@<YHE5W4/='@#X7ER
M=<FP,6FU<_2?S6M^=-^.>VT@=;A[]FZM=HQH>G P=V!3[7&A>"X]_G+)>-PD
MAW+F>28#F7GK>D:NDF>"?A^>)FEF?BV,VFLA?BYZE6S'?BEG.&YI?C!2V6_N
M?CL]''$7?CPCTG#A?A #6WI3?BNM$&6?B$><LV>8AXN+;&EIAKIY+FL@A>%F
M$VS1A151UVYLA&<\2V^2@\<C,&\&@U,#)GJM@8*KUF08DGV;@&8?D/R*06?Z
MCUEX#FF_C:]E!6MZC!I0]FT6BJ\[E&XZB8@BH&U=B1\"^GKY@@.JW&+<G+6:
MB63LFG*)2V;+E_YW'VB5E85D)6I<DS50-FO^D28Z_VT2CX\B+VOJCMP"U7LW
M@>JJ(V'LINV9S&/^H^F(A&79H*AV5F>?G6)C8&EJFF%/@&L4E]$Z;FPAEA8A
MR6JJDY "MWMJ@=:IK6%%L1^91F-4K5N'Z&4BJ4UUL6;<I45BQ6BBH:1.^FI*
MGK8YZVM*G/HA3VF*EH4"GWN3@<6EI'<57L.6>G>O8;J&-'A<9'1TIWD49OMA
M\'G3:6=.!GJ;:[<XBWMF;;\>RWP[;M,  (  <F"D>'1Y:(V56G54:HZ% 78E
M;&ESBW;V;B=@[G?+;]5-(GBC<6PWPWEF<L<>*'G8<U$  (  =P6C-G(7<E"4
M G,?<VZ#Y'0.='1R:'3X=69?['7@=E-,1G;'=S8W$7>%=^T=G7>2> <  (
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MBFOCH%=^6&T%G9%M-6X=FKQ;-F]"F"M(,'!2EADST7#4E1\;.F\UD7H  (
M@ "=5&GQK)>."&L]J7)]P6Q4I?)LEVU?HFM:I6Y]GTU'M6^*G0,S5F__FW@:
MQ&Y'DAD  (  @ "84'^77EJ*27]P849[&']X8_AJEG^>9G98V'_7:-5%QH N
M:PTPY8"^;-X6M8(];30  (  =ER74WT;9YB)1GTY::1Z 7UD:X=ID7V<;4U7
M[7WC;OY$^WY!<(\P.7Z]<<D6-G^S<;L  (  >F>6.7K7<+Z( 7L@<@%XY7MB
M<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5Q7U(=H4  (  ??.5!7C$>>>&
MO'DJ>G)WEWF%>MMG>7GA>SE6$'I.>XY#<7K >]PO"7L;? H59GL=>Z8  (
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MNG./I8IS?7/THI-C5711GX]24W3&G/U ,W4YFVHL;'4SF8P3BW2TC3<  (
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M_8 ;@*-KPG_?@)9<BW^F@&Y,9W][@$DZJ']]@"TFW'^.@! -4G_^?^@  (
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MVI"18!ID:8]Q8J95NHZ#90=%OHW#9SDT'XUR:1L?THY6:A<&3HZ9:A0  (
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MN8@6A?M@7H<JA8=2"X9"A/A"NH5\A'$Q\H3WA" >;H3YA#L&D80\@ML  (
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M9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0 +Y"^;K8  (
M@ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"<<H6%9+<<84
M<XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'=65)C9&/=A(ZF9!;=J@IY8_!
M=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C%Y,,>^)6<9&"?!U(T) )?$,Z
M$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (  @ !N,I-;@UIB?)'6@SY5W)!(
M@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<  (  @ !MK))/BR=A
M]9#5BJ%55(]%B>1'LXV_B14Y!HQVB'8HSXN=B%$5=8OCB 0! X??@*\  (
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M#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!;Y4,?9QL;P8  (I[=Z(  (
M@ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>=,,,CIH9=%4
M (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[>:T^XYD_>>PPM)>I>B<@39<M
M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97<9P6@&%+=9GX@$@^?)?S@!HP
M599.?_H@)96B?_@,E98>@!$  (:T@    (  @ !B)ITMA[]7&9L8AWE+))CP
MAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T  (7.@    (  @ !AU9Q>CRM6
MS)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^C*\,B9,EB'H  (4A@    (
M@ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);D>\,OY'LB)\
M (2<@    (  @ !9([&M6F1.&J]27(U"9*T97JHUG*L88)XG+*GC8B,5DZMA
M8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-NJWB8QM"(ZMJ9+DU?ZDN9CHG
M.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (  @ !8"*Z2:&A-2JP+:9!!T*F)
M:K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@  (9G>MT  (  @ !7KJRG;SI,
MWZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.<:L$A*%<<OP  (5!?HH  (
M@ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)==RD$PI\&>.$
M (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\FDJ!T?3,6&Z"7
M?18$_YSO?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U@\<T0:$"@VPF
M=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,$Z4RBOU JJ*#
MBF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (  @ !68J<TDGY,
M#*1ZDB) IZ&ZD54T+I\CD*0F9YTOD)D6)ISVC>0%:IAP@ZD  (& @    (
M@ "U)F%36;*C_F/170.2-F8O8#=_AFAQ8TQKWFJ?9D97*&RN:25!*FYB:\\G
MZV[:;=T&N72C;L6S*EW.9&&B<6":9JR0U&,V:.9^2V6N:Q!JNF@-;2A6'FI
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MHV[N90]\,7!!9VEKHW&,::%9Y7+1:[Y&YG0';;HR.'3U;V 8TG3);]P  (
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M961FD-AV1F8VCV9F(6?MC>)5#6F2C'U"UFKTBU8O%6MJBJP6G6LCB<<  (
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MO70);'EP>W3C;AU@Y76[;Z)0,G:/<1(^&G==<ETJ"W?M<T40/7D0<LL  (
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MS6M8ED1KE6Q\E(%<76V)DJE,(VZ.D0\ZJF];C_8G@&\GC^P/ '%0BB4  (
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M#GH-<O=DEGIH= 56+GJ[=/=&6WL@==,U%WN'=H@A='O4=M (LGUP=PL  (
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M5W,GFOU@\W.;F1!2DW/REPY#-71)E8$R='1ZE1(?@7.VDM8(+'<*A88  (
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MN8$=>)%9#H#J>2)+78"W>9@\F8"3>?PKZ("I>D(82(#_>A,";H%$>\   (
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MT)-(6?=1KI)57,5$49&57V(U>9$E8; D<I&B8U4/3Y2,8R<  (@):9H  (
M?M1H'9(C7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<:%L/:9%M9_H
M (8B;F0  (  @ !G48^V9C=<0([,9_U04(WG::U#'(T;:STTC8R1;)4CXHS"
M;6X/7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)<"I"98L%<3PS
M[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:EHJ\=A5.FXGQ
M=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (  @ !D]XGB?/!9
M[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"X<2?;4  ( ;@    (
M@ !D6HB(A(M94H?FA'=-:(<@A"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<
M (  @    (  @ !CWH> C$59#8;OB^5-+X8?BR1 /X4LBCLR+X1GB; B-H0&
MB@$.Y8.@A_(  (  @    (  @ !C?(:QE!E8K88ADWQ,RX5-DE,_X81/D08Q
MXX-SD&XB H+MD"H.VX)=B@L  (  @    (  @ !<X)[Q5=]20IU96)]&P)P(
M6T4Y^9K[7;@KB9I]7[X:29O-8+@&A)Q*800  (.C;4D  (  @ !<!IS=71U1
MK)M97U5&-YGT87DYE9C 8W(K49@490P:4)D19;0&WYC=9>,  ((0<C$  (
M@ !;7YJ%9$-0]9D;9?Q%GY>]9Z(Y!9:$:28JZI7%:E8:)I:':K4'%Y6<:N0
M ("7=Q0  (  @ !:MIA :UI0.);G;)Y$T967;<XX:I1A;N,J:I.?;[$9W90S
M;\X'+I*Q<",  (  >V4  (  @ !:#)9,<H%/DI4$<UM$,).W=!PWQI)\=+<J
M I&K=2T9E)(<=2$',9 J==X  (  ?RX  (  @ !9<Y2W><A/!I-]>D-#L9(N
M>I4W49#I>L,IF) $>M\9<9 M>LP'.XWX>]$  (  @    (  @ !8\)-K@1-.
MEI(^@3M#3)#J@2,V[8^7@.PI+HZE@,X9((ZI@.L'4(P<@.   (  @    (
M@ !8B))<B&!.+Y$ZB#M"YX_FA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D
M (  @    (  @ !8-Y&.C^5."9!RCZ-"PX\5CLXV;XV0C=LHXHQ7C<(8^8P(
MC*$'<HE4A0D  (  @    (  @ !0IJIA5$U&8JB85M([3:<-63TN[*7D6VD@
MAJ797/<.EZBC70@  * (8'P  (  <2X  (  @ !/QJB46RI%Q*;,73<ZOZ4>
M7S(NA:/!8/<@6Z-M8BL.QZ6R8@<  )UL914  (  =?@  (  @ !//:938>]%
M+:268XXZ0:+K91@N$:%^9GD@$Z$'9U8.T:+A9PH  )K>:>X  (  >CP  (
M@ !.QZ0+:*=$HZ)9:=XYI*"V:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL
M (  ??\  (  @ !.2Z(+;W%$*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9
M<8X -98 =0D  (  @    (  @ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?
M6)K7=YP.V)NI=UX <9/:>E0  (  @    (  @ !-<Y\3?55#?YV#?:(XJYO/
M?; LMYHW?9X?)IE=?8P.T9GE?;4 L)()?LX  (  @    (  @ !-))X#A%E#
M2IQSA'$X@9JVA#(LF9D(@]\?"I@2@^0.JIAW@WL M9"9@'L  (  @    (
M@ !,\9TIBX]#*)N4BX8X9)G0BP@LAI@0BHX?$Y;SBJ\.V9<>B$0 W8]G@)8
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M=5==>U]Y25IJ>[UI'ET^? I8 E_J?%9%CF(H?*0QK6,;?.49L&-$?.X  (
M?Q*59%&"A+6'/%4!A&1X*U@Q@_IH%5LE@X)7#%WC@Q)$U6 D@KDQ&F#T@H$9
M2&&E@J$  (  @ "444]HCG.&/U,&C5]W0U9/C"MG/UE:BO)60EPKB=1$*UYN
MB.8PJ5\4B%(8_&!-B$D  (  @ "3@4VXF!J%>U%MED1VB%3%E$EFD5?;DE)5
MG5JWD)-#C%SZCRTP+%UXCGP8N5\YC.T  (  @ "2]$QWH9>$[5 WGP1U]U.3
MG$1F!U:KF9E5)5F(ETE#+%O&E8TOR5P3E/L865YFD'8  (  @ "16&FL4V*#
MGFM,5R]T\VSP6LQE&VZ07C=4$' C87A!K'&89( M=7*E9PD3T7/&9\<  (
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MTEQJ@@=NHE[R@=]?96%&@:!/)V-G@60]G64+@3LJ364D@2P1YFCW@3L  (
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M-V\P7P-I@7"$8<Y:I7'-9'-*@G,&9NTXX70B:20E"W3(:K8+C7?W:JH  (
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M7F):A\ID#V1,AS15KF8-AH9&/6>8A>LU<&B3A8(BI&>DA8H*RV[/A$,  (
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ML'079=1=_'4)9_-/_'7J:>M N7:_:[@OQ7=];34<$'?+;=8$G'O%;KD  (
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M &E#C+%9>&J6B\U+Y&NPBLX]*&R3B@8LW&S?B;H:*VOVB<P$F7@Z@QP  (
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M3GH$:Z%247J%;2U%2WKW;I@VOWMH;\XF3'O;<*$2.7R/<$@  (  =/X  (
M@ !H8W;5<=-=5'>0<O5177@E<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X
M (  >>(  (  @ !G<W2@><5<<'5X>F)0B'8>>M5#FG:=>R4U?W;_>V0E?7<?
M>Y(1UW>Y>V   (  ?@D  (  @ !FKG+(@;-;RW.]@=M/]G1K@<5#"W3C@8PT
MZ74Y@6,D]W4O@601J77:@8D  (  @    (  @ !F$G%)B9I;-')-B55/8G,!
MB+U"@G-TB 4T9W.[AXLD<G.)AYL12W1JAL$  (  @    (  @ !EF' 6D89:
MOG$HD.I.ZW'@C]M"$W)+CK,T"W)^C@(D+W(ACC81$7,_BO   (  @    (
M@ !@IHQO49A6!XOM5-Q*=XNI5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD
M (  :6D  (  ?G!?CXE26/Y5*XD16[M)JHC>7E4\]8C$8+PNH8CN8L8=R8GY
M8_@)I(JH8_T  (  ;BD  (  @ !>GX9!8&-4+88Q8IA(UX879*\\+X8$9I8N
M!88D:"D=8H;U:/T)HX=1:.L  (  <V0  (  @ !=L(-H9\E3,H-W:7I'U8-Q
M:PT[9X-J;'HM58.);9P<XX0D;A@)AH1G;@P  (  >%L  (  @ !<QH#H;SU2
M3H$2<'%&]($<<84ZBX$5<F\LP($G<RT<9X&.<V,)88'C<XH  (  ?*P  (
M@ !;]'['=L11B'\*=X5&/7\?>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D
M (  @    (  @ !;/'SP?CU0UWU/?I)%F7UO?K0Y1WUD?K<KFWU/?KH;T7TD
M?L0)C7W2?S,  (  @    (  @ !:K'MYA<M0='OYA<Y%1GP;A7@Y!GOQA/TK
M;WNVA,,;C7M:A1L)4GQ<@]\  (  @    (  @ !:.WI*C6Q0!7K7C2M$V7K_
MC&TXIWK-BY(K)WIUBT@;8GG9BS()3'LJADD  (  @    (  @ !4I9;<4#U*
MC)7Q4U4_B95/5DHS)I4"6/HDSY5W6Q82[YA26Z@!@I2E78T  (  ;10  (
M@ !3GI/]5S])O)-$6> ^Q9*G7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD
M (  <?@  (  @ !2RY$,7C](W)!Y8&<^"H_L8FTQV(^'9#DCY(^O98<2FY&D
M98X"!HW+9V<  (  =N0  (  @ !2 (Y"94!(!HW(9O$]*(U+:($Q+XSI:>$C
M5(T!:M 22HZ3:IT"'XKP;*0  (  >SP  (  @ !1.8O(;%5'1(MI;98\:XKW
M;K4P=(J/;YXBXXJ*<#T1_HN^;^8"+8AX<EH  (  ?P8  (  @ !0@HFK<X!&
MF8EG=%P[THC]=0TOZHB,=8\B:8AH==<1XHD?=8@"1895>$H  (  @    (
M@ !/XH?B>JE&#(>X>RT[6(=4>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<
M (  @    (  @ !/8(9C@<1%B(92@? ZV(7V@=<O#(5P@:<AFX41@:81+X48
M@<,"88,1@74  (  @    (  @ !.^(4TB3-%6H5&B4 ZN83SB+TO$(0XB!0A
M[8.#B!H1Y(,=AR0"UX&T@>P  (  @    (  @ !(6*)Q3E\^WZ$\44(T::!G
M4_8H6: H5DX9PZ%S5[\(HZ,;6&4  )&47^0  (  <'H  (  @ !'1Y_F5/X]
M^)[L5W<S>)X:6<4GCYVO6[P919ZA7-@(IY]S75D  ([<9'X  (  =5$  (
M@ !&FYT-6YT]-)PM7:PRPIMO7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$
M (  >:D  (  @ !&!YH\8CH\A)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,
M9U\  (G>;GP  (  ?8   (  @ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7
M^Y9,;$L(=94/;*\  (?&="\  (  @    (  @ !$Q963;[X[2I4*<*<PY)1;
M<5\E3).^<=,7N)0 <= (DI(I<F0  (80>6<  (  @    (  @ !$.Y/"=IPZ
MSY-:=SDP@I*N=Y8D^)(!=[P7:)(>=YD(@H_2>)L  (2R?<H  (  @    (
M@ !#R9)!?9 Z;9'V?>TP,I%/??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@
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M9E!D EK/:*]35EVE:O)!8U_Q;1 MT6"=;MH5L6/@;XH  (  =V*-RDR3:NN
M1U!S;*=Q]50!;E9BM%=2;_)2*5I9<7A :ERO<N<M$UT*=!@5.&&X=',  (
M>W:,'$BN=(9^Q4S;=7MPDE"M=F-A8%0L=SQ1-%=<> T_E%F[>-0L<5FZ>7L4
MU5_G>:P  (  ?O.*L45(?AM]A$FX?DUO>DW$?G)@9E%V?HQ03E2_?JD^]%<=
M?M0K]5; ?PD4AUYD?U@  (  @ ")B$);AYY\?D<&APUNETM$AFU?GD\>A<U/
ME%)^A4,^6%34A-\KFU1,A,0455VBA/H  (  @ "(H3_PD/][LD3*CZUMXDDP
MCDI? 4TFC/-/ U"5B] ]RU+<BODK+5)'BL84*EWKB9L  (  @ "'_SX1FAY[
M'$,,F!9M5D>*E?5>ADN2D_).H$\*DD4]@E%%D1TJX5"MD1,3WUYIC4   (
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MJE/T<ZIG05<I=+E8U%H/=;))7%R?=ITX3%Y+=W$E9UV#> D-?FDQ>#H  (
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M!FL-4?QBNFRW5=)486Y868-$QF_=7/LSCW$K8!,?U'&L8CD',W>V8Q   (
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M0EAI><=<L%LK>DY/$5V6>KQ 5%^)>R(P!V!8>X,=3V")>[L&UG1R?.H  (
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MNVYJ61-77V_<7"Y)Z7$V7R$[#7)J8= J4G-:9 ,60W0)9-< SGZD9R$  (
M?(1MEFBG7?=B4FIX8)%6-FPC8Q%(V&V=96DZ)F[=9X@IFF^?:3<5QW!]::T
MX'Z&;"H  (  ?[QL-62T9A=@^&;$:!)4XFB<:?='WFHV:[TY1FN$;4TH\&P1
M;H(576UN;JD \WYE<98  (  @ !JXV$C;D9?N&-F;Z13NV5D<.U&RF<7<A8X
MHVAN<R(H;6C#<^<5&VK)<]H!$WXN=QX  (  @ !IQ5X#=H!>R&!V=U!2YV*6
M=_]%]&1<>) WS66C>1$GV66J>7@4KFB:>6<!$GXP>_0  (  @ !HW%M+?JM=
M[5WC?O12&V ??PQ%-F'R?PLW&V,K?Q,G1V+>?R\4<6:[?V8!)'X3?_H  (
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M77+N7Q=+[G0289 _+W4/8]<P^G7F9= @@79X9QX,?'E!9QH  (  ;U8  (
M@ !@L&W59#)6&V]19C1*L'"7:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"
M (  =-$  (  @ !?A&I<:^A5 VP$;5])I&UI;KP]+&Z+;_,O>&]/</D?2V\=
M<8@+_G/0<6X  (  >;(  (  @ !>=F=&<[)4!FD9=*1(OFJ<=70\:FO'=B(N
MSVQT=K ? VO;=OT+]'&9=Q\  (  ?=,  (  @ !=F&23>WA32V:5>_-(&V@S
M?#H[TFE??&(N,VGH?(L>>FD=?*P+UV_"?3T  (  @    (  @ !<YV)*@S)2
MI&1M@T%'?68A@P<[0V=,@K,MJV>S@HH=[&;J@K<+BFY<@GL  (  @    (
M@ !<8F!MBNQ2)F*JBJ5&_V1NB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH
M (  @    (  @ !8\X-<3&!.JX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)
M6EP$<8?56Z(  (  :34  (  ?AI7>'].4WQ-A'_55HI">8!@67$V+(#Q7!LH
M$X&Q7DD6\8,S7T,$C80(8&X  (  ;?$  (  @ !62'M:6K-,5'P?74!!>WS)
M7ZHU/GU?8=<G4WX"8Y$6:W[[9"\$BH"V958  (  <R0  (  @ !5*W>B8?5+
M,7B28_U 5GE59>0T6'GW9YHFB'I_:.85TWKX:2\$<WW<:F\  (  >"   (
M@ !4&G0Y:4=**752:LX_578O;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,
M (  ?'(  (  @ !3)G$L<*M)0W)O<;L^A'-D<J8RH70&<V<E-W0]<^L5!72'
M<],$8GE#==\  (  @    (  @ !246YW> I(<V_G>*D]Q'#V>1HQ]7&6>6LD
MH7&;>9\4HG(F>8 $D'A*>W,  (  @    (  @ !1IFPG?W1'[VW,?[@]6&[W
M?[$QJ&^)?XTD96]2?XD40G Z?[ $7'BB@"<  (  @    (  @ !1)6H_AO)'
M;VP!AND\W&U!AG@Q.6W.A?,D$6UDA=L4$&ZDA;@$47BU@NL  (  @    (
M@ !,[XV@2M=#8(UJ3C8XU8V#46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0
M (  ;*T  (  @ !+DXG+491".(GF5(LWM8H75U KQ8I_6;X=F8N86VP,.8T5
M6]8  (9.8-\  (  <8X  (  @ !*A87Z6&=!'(9+6NDVO(:473PJUX;S7SL<
MW(?48(0+Y(B>8+\  (-49;H  (  =H@  (  @ !)C8)47T= %X+(84\UJX,C
M8RLJ 8.!9+\<((0Q9:L+B(2W9<(  ("J:MX  (  >NL  (  @ !(FW[Q9CP_
M)W^/9\XTPG_^:3<I'H!/:E<;E8#!:O@+.X%@:OT  (  <'D  (  ?KX  (
M@ !'NGOB;4P^37RP;G S_GTV;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4
M (  @    (  @ !&^'DQ=%T]E7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV
M=FP  (  >T<  (  @    (  @ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9
M^GB$>_L*;7IO?*T  (  ?W@  (  @    (  @ !%TW3;@KP\AW9$@N R;W<@
M@I\G.G<Y@DL:)'9R@EL*SGBU@@8  (  @    (  @    (  @ ! F9E%2*LW
MLIBM2^4MHYB43M0AJIE143L2>9PR4E,#4IF^5&   (2R7XH  (  < T  (
M@  _-Y6\3P0V5)6.4=DL+)695&(@2Y9 5F81;IBA5R\#"94563\  (&N9$
M (  =0$  (  @  ^09(657@U.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/
M7BX  (  :2,  (  >70  (  @  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/
M_Y#782H"JHT&8SH  (  ;E8  (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM
M970=F8PB9DL/IXT09F<"F8G%:(<  (  = 0  (  @    (  @  [RX?R:5TR
MIHB':H$HD(CE:VL=!HE":_$//XFD:]8"IH<#;C   (  >3L  (  @    (
M@  [%84I<"DQ](7^<.\G^(9W<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@
M (  @    (  @  Z?(*[=PHQ78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,"
M>BL  (  @    (  @    (  @  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.
MD8)<?BX"B8&(?O\  (  @    (  @    (  @    /__  #__P  __\  &UF
M=#(     ! ,)   !                     0                    $
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MO]/@U0/6)]=,V'/9F]K$V^_=&MY&WW/@H>'/XP+D3>69YN?H-NF&ZMCL*^V
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MHWUZK%._GDA[@T1&F-]\AC5*DQQ]YR=_C-E_MJ'DMRV!C9)WL>B L(+6K+R
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M@A>!YK<2@;.!/Z$H@66 P8KI@2N :W2@@0F .5YS@/Z &4AU@16 'S+@@5J
M2=]1@4&-0<K!@-F+;K66@(*)N)_%@$V(/HFR@"Z&\'.4@"F%OEV/@#6$BD>Z
M@&2#6#)6@+^"!]V_@"B7Q<DE?\>4]+0!?WR20IY<?U"/N8AT?TN-;G*'?UR+
M,5RW?W^(XT<3?\6&=#'=@#2#K-Q$?T*B0<>S?N*>>[*:?J":TIT'?H"72H=!
M?H*3W7&)?JJ0DUOO?N"-($9[?SF);3%T?[J%,-KZ?I"LOL9T?C&H!+%C?>ZC
M6)OC?=.>Q88]?=^:2'">?@R5T%LY?E:1-D7T?L*,.S$;?U&&CMGH?@*W,L5L
M?:2Q?K!<?5ZKQYKD?4.F(85>?5J@D6_F?9*:\EJ>?>&5%T6!?ER.T3#0?OF'
MP]D-?9?!F,26?3JZXJ]_?.VT%IH&?,VM3821?.>FFV\Y?2V?UUH:?8>8PT4A
M?@B1*S"3?J^(SMAF?4K+[L/N?.[$)Z[%?)B\-9E$?&^T.X/@?(BL6&ZF?-6D
M8%FL?3N<%$33?<B3/3!C?G2)K=+OC.MVV;^2BWQW5ZN]BBUWW9=?B/YX?(*I
MA^9Y0VW1AMYZ-%D8A=Y[1D1[A/%\H3!:A!I^:]%UBY2 P;YDBC6 /*JCB/1_
MT99:A]5_AH&OAM)_96SHA>-_9UA A/U_>T/,A"Q_NB_N@VZ *M FBE2*N;T6
MB06)-:F#A\F'RI4TAK^&DX";A="%@VOQA/F$D5=MA"R#HD,K@W>"OR^-@M2!
MTL[.B4*4I;NTA_B2-Z@0ALZ/XI/IA<N-LW]VA/6+M&KZA#.)PE:J@WR'PT*=
M@MN%KR\Y@DN#7<V!B&F>A+IHAR*;-*;)A@"7^I*RA0:4V7YDA#&1SFH6@X6.
MVE7Z@MZ+Q$(?@E"(>2[Q@=.$QLQ;A[ZH:;E,AGJD-J6TA5>@"9&LA&*;[7UY
M@Y67WVE'@NF3SE5=@E2/G$&R@=B+%RZS@6R&"\MFAS.R1+A>A?*M)Z3'A,ZG
M_Y#)@]JBWWRR@Q>=RFBD@G.8H%39@=V3/4%7@7*-?BZ @1:')\J@AL>\#[><
MA8JV :0 A&.OU9 $@VJIH7O\@JJC=V@+@A2=,E1I@8>6I4$+@1Z/IRY6@,Z(
M&LH*AG7%S;<#A3R^P*-9A!"W?8]9@Q*P)7MB@E&HU&>-@<"A:%0&@3^9L$#%
M@.&1B"XT@)6(Y,.[E?AUWK'*D[)V<I]OD9!W$(R4CY%WR7E<C:EXJF7^B\MY
MN%++B>MZZC_$B U\:RUIAB1^8,)\E,%_-+#0DH-^V)Z$D&U^DXNVCGI^<GB%
MC*)^>64UBME^I5(4B0]^YS\[AT=_6RTKA72 #,%9DZ*(?Z^BD6^'0)U[CUJ&
M$HJOC7>%&W>6B["$1&1EB?R#BE%HB$:"US[!AI2"-BSTA->!G<!%DI.1V*Y\
MD&R/NIQ+CF6-JHFGC'V+QW:>BLR*#6.1B2F(8E#"AX>&KSY0A>^$\BS%A$N#
M$+\GD;Z;)JUTCYB8,9L\C9>548B+B\"2B76HB@Z/UV+%B("--5 IANV*=CWM
MA62'D"R<@]*$8KXGD1ND<ZQVCOB@JYI"C/B<Z(>ABR69-737B7B5BV(2A^>1
MW$^FAF*.#CV9A.N)_BQY@VN%CKU.D)BMKJNECGBI#9ESC':D8(;:BJ2?MG0H
MB/Z;$F&%AW.66$\YA>F1;#U5A(*,-2Q<@Q6&DKR?D#&VV:KZCA.Q5YC#C!"K
MM88MBCFF!W.(B):@6F#_AQ>:E$[;A924CCT;A"R.+BQ%@LZ'<+P9C]^_]ZIR
MC<:YAI@NB\"RVX66B>6L%W,!B$&E4V"3AL:>=$Z&A4^753SA@_./WRPR@I6(
M)[4.GSUU,J1CG"AUSI-BF3=V>H'QEF5W17 LDZ-X.EY&D.%Y7DR=CA%ZJ#LV
MBRQ\1"JMB!Y^5+0'GBE]_*.CFQ1]MY*NF"=]CH%$E5M]BF]^DJ1]LEVCC_)^
M 4P*C3)^:CK4BF!_"RJ=AV5_[K,=G1>&O**MF@V%H)'1ER"$H(!DE&*#T6ZR
MD;F#*5SSCQF"GTM^C&F"'SI]B:F!NRJ/AL&!:[(IG"F/8J&JF26-?Y#"ED&+
MO'][DWZ*%&W=D.2(G%Q%CE&'+4K]B[&%O#HQB02$2BJ#AC&"R+%,FTN8'Z#%
MF%&5=(_7E7:2XGZ/DKN08FT7D!2-^UN@C92+I4J%BP.).#GLB&R&LBIYA;2$
M [!TFJN@VJ &E["=98\=E-*9^GW.DAF6H6QBCX"34EL*C/R/_TH;BG>,D3FP
MA^^(\BIPA4J%&*^[FBZI>9]1ES6E.HYIE%6@\WTED9V<LFO.CPF8=5J3C(F4
M)DG%B?V/K#F"AX2*^2IIA/*&"*\AF<ZQ_IZ]EM2LZXW4D_*GOGR3D3:BB&M(
MCJ2=5%HCC"Z8!TEZB:62ASE;ARN,Q"ICA*J&TJZJF8&Z=IY&EHBT@8U4DZ.N
M67P2D..H'&K7CE"AX5G+B]V;CDDVB6&5"CDPAO*.22I>A'"'>*<!J+ITP9=^
MI-QU6X>XH1YV#'>;G75VXF<YF<YWYE;$EAEY'$:ADD5Z>#;@CD1\*B@OB?Y^
M2*8RI\1]"I;SH^!\SX<VH!U\MW<:G'-\R6:UF-%]"U9)E2=]>$8WD5Y^ 3:H
MC6U^R"A+B3A_T:5_IK^%/98SHN2$.H:-GQZ#6'9JFWR"K&84E^."*E7!E$>!
MRD71D(R!>C9XC*N!3"ADB(J!.Z3&I<^-6Y5FH?R+GH6QGCZ* '6JFIF(CF5G
MEPZ'1E4WDWV&$$5QC]"$VS9,B_^#KRAZA_*"A:0$I1&5:I2FH3^2^(3NG860
MI73GF>..<63(EDJ,2E2YDLB*.T4=CR6(&#8HBV2%ZBB-AW"#JZ-CI&.=CY0'
MH)B:8(1/G-Z70W1.F3R4.60\E::1-U1*DAF..$34CH.+)S8(BMF']2B<AP&$
MK*+/H^6EEI.*H!>AI(/4G%:=M'//F*^9SF/&E2*5\E/MD9^2"427C@*. #7O
MBF>)SRBIAJ:%B:).HXBM>I,1G[>HP(-=F_*C]7-=F$:?*V-?E+J:9U.8D4&5
MD$1@C:>0EC7;B@N+;BBTAEN&0J'HHS^U2)*NGVJON(+VFZ&I_W+XE_*D/F,)
ME&6>AU-7D.Z8OT0SC5^2US7$B<^,RBB\AA^&V9FLLFQT:8L\K<=T^GR=J3IU
MK6V^I+-VC%ZPH!IWG4^BFV!XXD#^EG9Z3S+<D41\%"7VB[=^/)D:L8M\/(KE
MK-Q\ 7Q*J$)[]&UIH[%\&%Y6GQ=\<D]1FF-\^T"_E8!]HS+1D%M^C"8\BN-_
MMIBAL(F#ZHI=J^*"]GO2IT*"*FSHHK2!G5WAGB"!/D[SF7>!!D""E)^ XC+'
MCXJ YR9ZBBF!$)@BKY:+>XG)JO2)VWLNIEJ(8FQ9H<>'&UUBG3^& TZ2F*&%
M 4!'D]2$!C*_CM*#'R:OB8B"1Y>8KLZ3 XD\JB^0NGJ<I9>.EVO'H0:,EESM
MG'6*L4XZE^2(X4 3DR&'!S*XCBZ%+R;<B/Z#6Y<0KC6:AHB^J9.7D'HCI/>4
MM&M5H&61]%R'F]2/0DWPES6,D3_JDGV)V#*SC9Z'$"<"B(J$2Y:KK:6A\(A:
MJ0:>17G"I&J:J&KYG]B7'5PXFTJ3F4VXEJZ0"S_-D>:,:C*PC1R(NB<AB"J%
M%Y9'K4:I-X@:J*"DS'F&H_6@66JUGU&;\5OUFL*7F4U^ECJ3.#^KD8..P3*O
MC+N*,B<[A]R%PI7TK/RP88?0J$VK*7D]HYREU&IQGO6@AEN_FF6;44U:E=Z6
M%#^8D320QS*OC'F+;"=/AYV&3(T1O%)T''^BMN-TH'(6L81U461DK!=V-U:<
MIG]W5$CKH*YXJSN\FIAZ*B\PE"-\ B0!C4E^,(R_NWA[@G]]M@%[0G'PL(U[
M.V0YJPU[;U9MI6Q[WTC&GYU\A3NKF8M]3"]2DR-^5R1NC&1_GHR$NFZ"LG\N
MM/^!QW&IKX2!#&/IJ@* FE8FI&. 74B4GIR 33N8F)6 5"]PDC^ C"3-BYV
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MJ]Q[7D*+I-Q\'3;CG8=] "P:E<E^*B+7C<!_AX$0Q&"!L'2'OCN P6?PM^R
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MC&."/Y7[BN&!MH0LB86!2W(+B#N ^5_-AP2 ODW,A=" C#P=A*Z :BM:@Y.
M5+9HC,6, *7;BSF*G93#B<B)-H,FB'"'Z7$:ASV&ME\&AAJ%CTTTA/^$8CN[
M@_F#+"LZ@OF!U[5.B\R5)J37BD.2]I.[B-F0P8(2AX^.CW LAF2,:%X^A5N*
M3TR@A%*('3MA@UZ%R"L@@G.#-K1:BPV>2:/@B8F;39+(B""8.8$MAMN5'&]@
MA;:2 5V4A*V.X4PD@[>+J3L5@MF(-"L)@@"$;;.2BG:G5:,8B/>CAY'_AXR?
MC(!JAD:;?&ZRA2F7:ET)A"F31DN_@S*.^CK8@F:*:"KV@:&%?++VB@*P2*)W
MB(BKI)%4AQFFN7_ A<RAIFX4A+&<D5R @\"79TM=@M*2"SJB@@B,7BKG@5*&
M8K*(B:ZY(:'ZB#BSGY#"AL*MLW\IA6RGCVV.A$ZA:EP6@V&;,$L)@H&4Q#IK
M@<2."RK:@1.''ZM:F<!ONYPCERMQ"HQ.E,=R47O2DH%SHFKKD$-U$5G?C@)V
MJ4D:B[9X9CB:B61Z<RD&AP-\[*J3F']X@9MQE@%XYXN/DZ=Y6'L:D65YWFHZ
MCR]ZA%E!C/Y[2TB4BL)\+#A(B(1]0BD'AC5^F:G#ET.!+)I_E-B OHJRDH*
M7GHZD$^ &FERCBE_\UB9C M_Y4@2B>-_XC?^A[I_^2D(A7^ )ZC5EBN)M)F
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MEJZ!M7@-E"V!4VGKD;6 _UMPCTJ P$T#C-V D3\-BF& :#&UA^" 3"6YA52
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M<(*#_IGI<=V#7H?;<SV"P750=+J".V*P=E.!O%!0> N!/#Y!>?N MBT=?#"
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MNXH>DE=\77WID'Q\GG$GCJ=\U6/VC-1]$E9IBPM]7DCJB49]O#OGAWY^)B^
MA<)^I21YA Y_,8E5D1:$ GTICT>#I7!KC7N#,6,WB[6"L57GB?*",TB%B$F!
MQSNMAIN!6"]WA/J ["2D@V6 ?HBMD ^+JGR"CDZ*J6_(C(F)?6*DBL.(,E5F
MB0F&Y$@[AV.%GSN!A<Z$6B]MA$V# R3(@M:!HH@ECT>3+7P,C9*1C&]4B\>/
MGF(GB?N-@53KB$J+8D?:AK2)13M5A2.'(R]D@[J$Y"3E@F""G8>YCK.:?GN>
MC0&8.&[ABS&5A6&ZB5Z2D52%AZ^/FD=\AB>,H3L9A**)I2]=@T*&B23]@@"#
M;X=HCD:AGGM&C)6>LFY_BKR;,F%9B-^7750TARR3AT="A:F/L3KQA#.+V"]-
M@N>'ZB40@;.$&X!"H QD6W3VG3AFOVDDFH)I(5S+E\)KC5 ME-UN%4.4D=MP
MRS> CK]SJRP#BY5VWB'8B&YZ9'^ZGKIK_720F_1MF6B]F3)O05QVEF1P_T_K
MDW]RW$-JD(ITXC=SC8!W"BPDBFUY<R(XAU]\$G\VG3)S8W/QFH-T4V@ZE\=U
M3EOXE0)V84^)DBQWD4,KCTUXXS=;C%MZ3BP^B6-[Y2*,AG)]G'Z>F[5ZFW-)
MF1-Z\V>'EFA[3%MPD[![M4\7D/)\-$+@CBM\R3<[BU-];RQ/B'A^,"+5A:1^
M_WX$FG:!P7*QE^"!B&;OE3V!0EK<DHV ]DZSC]F NT*6C2J D#<:BFF :BQ<
MAZF 4",2A/6 .WU]F7Z(W7(TEO&($F9XE$^'(EIHD:"&'TY-CO"%'D)EC$"$
M*#<'B9>#."QIAO6"02-&A&&!3GT2F*Z/SG''EBJ.;&8+DXF,S5H D-N+#$WU
MCC*)2$(MBXR'AC<"B-^%QRQYAEF#_2-P@^>".7R]F!V6E7&7E9Z4J&7;DN^2
M3EG&D"J/M4VZC7V-(D'NBNV*F#;8B%6(%2R A=N%@2.2@X2"_7Q\E[2=*'%7
ME2R:IF65DG.7C%E_CZ:4(4V!C/:0OD''BFJ-93;#A^**%RR!A7V&PR.N@S6#
MG73KJ5!CZ&I/I>-F/5]@HG)HH50?GM!K'DBYFNYMOCUOEMEPD#*^DI]SC"C
MCDAVV2 BB?AZ8G1UJ#5K(VH0I+ALNE\MH21N;E/_G6IP1$BIF8-R0CUTE7ET
M;C+=D4]VO2D'C0YY3"">B-M\ W05IKQR%&F?HTES#5[9G[5T'%.QF_UU4TAT
MF"-VK3U?E"YX,#+KD!IYSBE"B_9[FR$*A^)]?G.LI3QXT6DGH=1Y/UY7GDQY
MN5-6FJ)Z3T@MEMQ[!3TZDOY[UC+NCP1\O"EPBOU]P2%GAPM^TW- H_9_?&C
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MC[Z"SU_IC>.">U3%B_:"$$F9B@Z!JCZBB"^!530KAF2!"RIUA*Z P"(U@Q2
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MD--[[CE^C=I\I3 YBM5]:B>]A]Y^12"IA1-_(FK*FM: 2V$]F$R 4E=8E9*
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M[S5I?X1_]2M5?]U__"*U@$V  W:G?FB'(FQA?G.&M&&-?EN& %90?CR%(DL
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ME\]^)TC\E1U^44#9DB%^<3C?CPQ^J3%"B_I^^RI<B/A_8"0BACY_PA\F@]F
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M9UY_I&S,:<)_MV!D;#=_LE/#;ME_KD<<<;=_MSKV=,I_RR]P>!M_Y25/>WV
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M;9.$16-\;UJ#V5@J<2R#2TRO<RF"P$%/=5R"0#:-=[*!R"QB>DB!3".>?.&
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M6V9Z2U-]83][/$439UM\/S=$;=-]:BKC=&I^O9DJ0NZ =HP92*^ 97YX3D"
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M=@A^A22">F]_8WI(6 Z!CF_E6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!:
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M<@=_QTQG<]%_QD09=7-_LCO'=QQ_NS.F>.Q_W2Q">L& %"6/?+R 0" /?J2
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M>/:"%T2@>A^!OSUQ>NV!6#95>Z.!&B]H?'R ^"DG?6. Z".*?GZ SA\(?YB
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M  #__P  ;69T,0     #!"$   $                    !
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M_Z,X*O^@14#_H$Q4^Z1+8_&H2W/FJTR#W:U0D=2L6)[,JF*IQZILL<2J=K;
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M14#_H4I3^Z9(8O*K2''HKTB W[-*CM:U49K0MEJDS+AEJ\J]<:[!N7NVM[*
MP*ZLA,BFJ(7.G:2'U)2@CMB.GYG;C)N>V8R;GMF,FY[9C)N>V8R;GMF,FY[9
MC)N>V8R;GMF,FY[9C)N>V8R;GMF,FY[9C)N>V8R;GMF,FY[9_Z0X*O^A14#_
MHDE3_*='8?*M1G#ILD9_X+='C-F[3I?3OU>?T,5CI,7 <*VZN'FWL+* P*FM
MA<>@J(3-EZ6%THZAB=>'H)+9AZ&<V(>AG-B'H9S8AZ&<V(>AG-B'H9S8AZ&<
MV(>AG-B'H9S8AZ&<V(>AG-B'H9S8AZ&<V(>AG-B'H9S8_Z0W*O^A1$#_HTA2
M_*E%8?.N1&_JM4-]XKQ$B=S"2I/8RE29RL9BI+R];K"RMGBYJK& P:2MA<>;
MJ83,DZ:$T(JCA]2#HH[6@J*6UH*BEM:"HI;6@J*6UH*BEM:"HI;6@J*6UH*B
MEM:"HI;6@J*6UH*BEM:"HI;6@J*6UH*BEM:"HI;6_Z4W*O^A1$'_I$92_:I$
M8/2Q0F[KN$%[Y,%"AM_,1HW3SU*7P<1AI[.[;;.KM7B[I;& P9^NA,:8JX3*
MD*B$SHBFAM&"I(S3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM.
MI)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3_Z4W*O^A1$'_I451_JQ"7_6T
M/VSMO#YXY\= @>#61H?)S5&:N,)@JJRZ;;6EM7B\H+& P9NNA,65K(3(CJJ$
MRX>HALZ"IXO/?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0
M?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0_Z4V*O^B0T'_IT-0_ZX_7?>W/&GP
MPCMSYM _>=/9/XJ^RU&=K\!AK*6Y;K:@M7F\G+*!P)BOA,.2KH3&C*R%R(>J
MA\J"J8K,?ZF.S7^ICLU_J8[-?ZF.S7^ICLU_J8[-?ZF.S7^ICLU_J8[-?ZF.
MS7^ICLU_J8[-?ZF.S7^ICLU_J8[-_Z8V*O^B0D'_J4!/_[([6_F].&7LRSAM
MW-PU>,?6/HZSR5*@I\!CK9^Y<+::M7J\F+*!OY2QA<*/KX7$BZZ&Q8:MA\>"
MK(K(?ZN-R7^KC<E_JXW)?ZN-R7^KC<E_JXW)?ZN-R7^KC<E_JXW)?ZN-R7^K
MC<E_JXW)?ZN-R7^KC<E_JXW)_Z<U*O^C0D'_K#Q-_[<V5_+%,U_AUC9CS>,Q
M?+K3/Y&IR%2AG\!EK9FZ<K66MGNZE+."OI*RA<"-L8;!B;"'PX:OB,2"KHK%
M@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6
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MP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M=F)4]7=C4_5Y8U/T?&12]'YD4?2 95'T@&51](!E4?2 95'T@&51](!E4?2
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MA(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O
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MDIK4>YB>TG>>H=!TI*3.<JJFS7"QJ,UON:G+;\&IPW'!J;QRP*JW<\"JMW/
MJK=SP*JW<\"JMW/ JK=SP*JW<\"JMW/ JK=SP*JW<\"J_X\M#O^//A[_DDHM
M_YA-.?^;3T7_G5-1_YU87/B;7FCQF65RZI5M?.21=X;?C(&.VX>)E=:!D)K3
M?9:?T'F=H\YUHZ;-<JNIS'"SJLMOO:O%<K^KO7._K+9TOJRQ=;ZML76^K;%U
MOJVQ=;ZML76^K;%UOJVQ=;ZML76^K;%UOJVQ=;ZM_Y M#O^0/A[_DTDM_YE,
M.?^=3D3_GU%0_Y]66_F>7&;RG&)QZYAI>^64<X3@CWV-VXJ&E-:$C9O2?Y6@
MSWJ<I<UVHZC+<ZNKRG&UK<9QOJV^=+VNMG6]KK!VO:ZL=[VNK'>]KJQWO:ZL
M=[VNK'>]KJQWO:ZL=[VNK'>]KJQWO:ZL=[VN_Y M#O^0/A[_E4DL_YM*./^>
M3$/_H4]/_Z)46OJA667SH%]O[)UF>>:8;X/@DWF,VXZ"D]:'BIO2@9*ASWR:
MILIXHJK'=:NMPW.TK[]SO+"W=;RPL'>[L*IXN["G>;RPIWF\L*=YO+"G>;RP
MIWF\L*=YO+"G>;RPIWF\L*=YO+"G>;RP_Y$M#O^1/A[_ED@L_YQ(-_^@2D+_
MHTU-_Z126/NE5V/TI%UM[J%C=^B>:X#BF'6)W))^DM.,AYK,AH^AQH"7I\%\
MGJR]>::ON7:OL;=VNK*O=[JRJGFZLJ5ZNK*B>[NQHGN[L:)[N[&B>[NQHGN[
ML:)[N[&B>[NQHGN[L:)[N[&B>[NQ_Y$M#O^1/A[_F$<L_YU'-_^A2$'_I4M,
M_Z=05ORH56'UJ%MK[:=A=.6D:7[>GW.'U)A]D,N1A)K$BHRBOH23J+B FJVT
M?**PL'JKLZUYM;2H>KFTI'NYM*!]N;.=?;JSG7VZLYU]NK.=?;JSG7VZLYU]
MNK.=?;JSG7VZLYU]NK.=?;JS_Y(M#O^2/A[_F$8K_YY&-O^C1T'_ITE+_ZI.
M5?JK4U[RK%EHZ:Q@<>*I:'K9I7.#S9QZC\65@9J]CHBBMXB0J;&$EZZL@)^Q
MJ'ZGM*5]L;6A?;BVG7ZXM9I_N;29@+JSF8"ZLYF NK.9@+JSF8"ZLYF NK.9
M@+JSF8"ZLYF NK.9@+JS_Y(M#O^2/A[_F44K_Y]$-?^D14#_J4A)_ZQ,4_BN
M4ESOL%AEYK%?;=ZP:7;2J7&"R*!XC[^8?IJWDH6BL(R,J:J(E*ZDA9RRH(*D
MM9V!KK::@+>WEX&WMI6"N;24@KFSE(*YLY2"N;.4@KFSE(*YLY2"N;.4@KFS
ME(*YLY2"N;.4@KFS_Y,M#O^2/1[_FD0J_Z!#-?^F1#[_JT9(_ZY+4?6R4%GL
MM5=AY+=>:=JT:7/-K&^"PJ1VC[F<?)FQEH.BJI&*J:.,D:Z>B9FRF8>AM9:%
MJ[>3A;:WD82WMY"%N+60A;FTD(6YM)"%N;20A;FTD(6YM)"%N;20A;FTD(6Y
MM)"%N;20A;FT_Y,M#O^3/1[_FT,J_Z)"-/^H0CW_K45&_+%*3_*U3U;INE9=
MX;U@9-2X9W+(KVV!O:=TCK2@>IFKFH"BI)6'J9V1CJZ7CI:RDHN?M8^*J+>,
MBK.XBXFWMXN(N+6+B+FTBXBYM(N(N;2+B+FTBXBYM(N(N;2+B+FTBXBYM(N(
MN;2+B+FT_Y,M#O^3/1[_G$$J_Z- ,_^I03S_KT1%^K1(3/"Z3E/GOU99WL)@
M8,^[9G'#LVR!N*MRCJZD>)BEGGZAGIJ$J)>6C*Z1DY2RC)&<M8B/IK>%C[&X
MA8ZVMX:-N+:'C+BUAXRXM8>,N+6'C+BUAXRXM8>,N+6'C+BUAXRXM8>,N+6'
MC+BU_Y0L#O^4/1[_G4 I_Z0^,O^K/SO_L4)"^+A'2>V^3D_EQE=3VL9>7\N^
M9'&^MFJ LZ]PC:FI=IB@HWRAF)^"J)&;B:V*F9*RA9::M8&5I+=_E:ZW?I2W
MMX&1M[:"D+BU@I"XM8*0N+6"D+BU@I"XM8*0N+6"D+BU@I"XM8*0N+6"D+BU
M_Y0L#O^4/1[_GC\H_Z8],?^M/CG_M$% ]+Q&1>O$34GBSEA+T\I<7L;"8W"Y
MNFA_KK1NC*.N=)>:J7J?DJ6 IXJAAZR$GX^Q?YV7M'N<H;9XFZRW=YNWMGJ7
MN+5\E;FT?)6YM'R5N;1\E;FT?)6YM'R5N;1\E;FT?)6YM'R5N;1\E;FT_Y4L
M#O^5/1[_H#TG_Z@[,/^P/#?]N#\\\<%$0.C+3D+>TU5*SLU;7<#&86ZTOV=^
MJ+EMBIVT<I64KWB>BZM^I82HA:I]IHRO>*25LG2CG[1QHZJU<*.XM7.>N;1V
MF[FS=INYLW:;N;-VF[FS=INYLW:;N;-VF[FS=INYLW:;N;-VF[FS_Y8L#O^7
M/![_HCHF_ZHY+O^S.C3YO3PX[LA#.>/54#?7VE)(R-)97+K+7VVMQ65\H<!K
MB9>Z<).-MG:<A+-\HGVP@ZAWKHJL<JV3KVZLG;%KK*BR::VVLFRHN[%OH[NQ
M;Z.[L6^CN[%OH[NQ;Z.[L6^CN[%OH[NQ;Z.[L6^CN[%OH[NQ_Y<L#O^:.QW_
MI#<E_ZTV*_^W-S#SPSHQYM!#,-S?2C7/WU)'P=A86K/17FNFRV-ZFL=IAH_"
M;I"&OW28?;QZGW:Z@:1PN(FH:[>2JVBWG*UEMZ>N9+>TKF6SO:YHK;VN:*V]
MKFBMO:YHK;VN:*V]KFBMO:YHK;VN:*V]KFBMO:YHK;VN_Y@L#O^=.1S_IS0C
M_[$S*/F],BKJRS<IW-T^*=#C1CK%XDU+N-Y56JS97&B>TV)WDL]G@HC+;8Q^
MR7.4=L=YFG#%@9]JQ(FB9L.2I6+#G*=@PZ:H7\.TJ%_!PJAANL&I8;K!J6&Z
MP:EANL&I8;K!J6&ZP:EANL&I8;K!J6&ZP:EANL&I_YDL#O^@-1K_JC$@_[8N
M(_#%+2+?V#,<T.,Z+L3H0D"XY4E0J^%.7Y[>56R2VUQWA]AC@7[5:HEVU'&/
M;]%YE&O.@)AGS(B;9,J0G6+)F)]@R:&@7\FKH%_)N9]<R,.B7,C#HES(PZ)<
MR,.B7,C#HES(PZ)<R,.B7,C#HES(PZ)<R,.B_YLL#O^D,!C_KRP;^+XG&^31
M)A?1XBT@Q.LW,[?K/D6JZ454GN=,8I+E4FZ&XUAX?>!@?W;<:89PV'&+:]5X
MCVC3?Y)ET8:48L^-EF#.E)A>SIN97<VCFES-K9I;S;>:6\VWFEO-MYI;S;>:
M6\VWFEO-MYI;S;>:6\VWFEO-MYI;S;>:_YTL#O^H*Q3_MR05Z\H<$=/@'A/$
MZRLFM_$T.*KP/$F=[T17D>Y+8X;M4FU]Z%MU=>-B?'#@:X%KW7*%:-IXB&39
M?HMBUX2-7]6*CE[4D)!<TY616M.<DEG2I)-8TJR36-*LDUC2K)-8TJR36-*L
MDUC2K)-8TJR36-*LDUC2K)-8TJR3_Z$K#?^O(P_TPA<,UMT0!\7K'ABW]BDK
MJ?<S/)WV/$N1]T18AO9-8GWP5FIVZUYQ;N=D=FKD:WIFXG)]9.!W@&'??8)?
MWH*$7=V'A5O<C(9:VY&'6-J6B%?9G8E6V:.*5MFCBE;9HXI6V:.*5MFCBE;9
MHXI6V:.*5MFCBE;9HXI6V:.*_Z@C"?VY%@?6T0L#QNH0"[;W'AVI_2DNG/XT
M/I#_/DN&_D=6??A17G;S665N\%]J:.UE;F3J:W)AZ7%T7^=V=EWF>WA;Y7]Y
M6>2$>ECCB'Q7XXQ]5N*1?E3AEW]3X9Q_4^&<?U/AG']3X9Q_4^&<?U/AG']3
MX9Q_4^&<?U/AG']3X9Q__[$5 ]3'"0'&U@H#MO<2#ZC_'R";_RLPD/\V/87_
M0$A]_TM1=?U46&WY6EUG]F!B8_-F95_R:V=<\'!I6N]T:UCN>&Q7[7QN5>R
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M/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^JL0  )S2  "/YP(
MAO\1 GS_&P5Q_R0+:/\K$5__,A=7_SD;4?\_'DS_1B%(_TTC1?]2)4+_5R=
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M,:#,4C^5R5E,B\5@5X+#9F!ZP&QG<[YS;6R\>G-GNX)W8KJ*>UZYE'Y:N)^
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M5CS^S58\_LY6//[.5CS^SE8\_LY6//[.5CS^SE8\_LY6SK " +VZ! "QQP0
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MC(*6?(B GX"$?ZJ"@7^W@X!_R(1_@-V#?W_>@7]_WX" ?N!_@'[@?X!^X'^
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M8DK.\F5+R/)F2\CR9DO(\F9+R/)F2\CR9DO(\F9+R/)F_Y(- -ZF! #.M 8
MPK\& +G," "PW0P I^4= Y[E+0N4Y3D6BN1"(('C2BIWXE S;^%8.VG@7T%C
MX&9&7M]N2EK?=4Y6WWU14M^&4T_?D%9-WYM72^"G6$G@M5E(X<992.'?64??
M\%E&W/5;1MSU6T;<]5M&W/5;1MSU6T;<]5M&W/5;[9P$ -&M! #"N 4 M\,%
M *W1" "D[1 !F^T@!9+M+@Z)[#H8@.Q#(7;L2BIN[% Q9NM6-V#K7#Q;ZV1
M5^MK0U/K<D90ZWI)3>R#2TKLC$U([)9.1>VA4$/MKE%"[KQ10>_,4D'OY5)
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M;%>D[6Q:G^UL6I[M;%J>[6Q:GNUL6I[M;%J>[6Q:GNUL_WP0 ?^.$ #VG@T
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M/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH  +&S  "DOP
MF,H! (S8! "$^@X ?/L; G3[)@5L_# *9?PX$%[]0!58_D<94_Y-'4__5"!+
M_UHB2/]A)47_9R9"_VTH0/]U*CW_?2LZ_X8M./^1+C;_FR\T_Z8P,_^R,3+_
MOC(Q_] R,?_6,C'_UC(Q_]8R,?_6,C'_UC(Q_]8RLJ\  *6Z  "8Q@  B](
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M)P/UE2X%ZYDU".&<.PS6F$,6S)-/(L2-6"Z]AV$XMH)I0;!^<4BK>GE.IW>
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M=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8 U:X; <JM+0;
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M2T?%[4M&P_E-1<+_3D7"_TY%PO].1<+_3D7"_TY%PO].WY   ,R?  "_J@$
ML[,! *F] @"?QP4 EM() ([:$@"(VR0"@-HR"'C9/A!QV$@8:M=0'V366"5?
MU5\J6]1G+U?4;C-3TW8V4--_.4S3B#M*TY0^1].@/T74KD!$U+]!0]780$33
M[$!"TO9"0='^1$'1_D1!T?Y$0='^1$'1_D1!T?Y$T9@  ,.E  "UK@  J;@
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M)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@  ALT  'G:  !P\@@
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M O]X* /_?#$'^'XZ"_!]0Q'I>DP8XG97']QR82C4;6LOSVET-LME?3O'8H5
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M5%.=ZU-3G/A35)K_4U29_U-4F?]35)G_4U29_U-4F?]3_W@& .&)  #0E@(
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M.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@  H[,  )B\  "-Q@,
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M$B+_T!(B_] 2G+(  (Z\  "!QP  <]$  &?=  !9XP  4_T& $W_#@!(_Q8
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M3V*!ZTYC@?E-8X'_3&2 _TMD@/]+9(#_2V2 _TMD@/]+_VD( /MX! #<A $
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M1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\  *VF  "CK0
MF;4  )"Y#@"+NAX!A+HM WVY.0EWN$,0<;9,%VNU4QUFM%HB8K-A)EZR:"M:
ML6\N5K!W,E.P@35/KXLX3*^7.DJNI#Q(KK,]1Z['/4>NXSQ&K?,]1JO^/D6K
M_S]%J_\_1:O_/T6K_S]%J_\_VH,  ,>1  "[G   KZ0  *6K  ":L@  D+H!
M (;!"0"!PA@ >\(H G7"-09OP4 ,:<!)$F2_41=?OE@<6[Y?(%>]9B14O&XG
M4;QV*DV[?RU*NXHP2+N6,D6[HS1#N[(T0KO%-4.[XC1"N?,U0;C]-T"W_S=
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M(S?4_R,WU/\CN9P  *ND  "?K   D[4  (>^  ![Q@  <,X# &76!P!=XPX
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M<@05_W\$%/^,!1/_F@42_Z8%$?^R!1'_O 41_[P%$?^\!1'_O 41_[P%C+@
M 'W"  !OS   8M@  %3?  !'Y0  /O$  #G_ 0 T_PL ,/\0 "S_%@ I_QP
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M17!OZT1P;_I#<6__07%O_T!Q</] <7#_0'%P_T!Q</] _U\( /]K! #A=@
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M0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P  PHP  +F3  "PF
MIYT" *"?$@"9GR,!DYXQ!8R=/ N%FT82?YE.&'J75AYUEETC<)1C*&R2:BQH
MD7$P99!Y-&&.@C=>C8PZ6HR7/5B,I#]6B[) 5(O%0%2+X4!4BO,_58K^/U6)
M_SY5B?\^58G_/E6)_SY5B?\^[V\  -9\  #(AP  O9$  +28  "JG   H*(
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M-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K   B+(  'RY @!VNA$
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ME TPXJ,.+N*S#B[CQPXMX^,.+>#R#BS?^P\LW_T0+-_]$"S?_1 LW_T0J*
M )RG  "/L   @[@  ';!  !JR0  7L\  %/5 0!)W 8 1>D/ $+I&0! ZB0
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M @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8  'F_  !KR0
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M_QKC,O\:XS+_&N,R_QKC,O\:_S@C ?\]( '_01\!_T4C ?]'+ +_1S8#_T9
M!/]$3 ;_05@(_S]D"_L^;P[Y/'D0]CN#$?0ZBQ/S.9,4\3F9%/ XH!7N.*86
M[3BM%NPXM!;J.+T6Z3C)%N<XVQ;C.>H6X#CU&-TX_QK;-_\<V3?_'=<W_QW6
M-_\>UC?_'M8W_Q[6-_\>_SL@ ?]!' '_11H!_TL@ ?]-* '_3C("_TT\!/]*
M1P;Z2%,(]D9?"_)$:@[O0G01[$%^$^I AQ3H/XX5YCZ6%N4^G!?C/:,8XCVJ
M&. ]LAC?/;L9W3W&&=L]V!K6/>D:TCWU'<X]_A_,//\@RSS_(<D\_R')//\A
MR3S_(<D\_R')//\A_S\< ?]%%P'_2Q<!_U = ?]3) '_5"T"_U,W _=10@7Q
M3DT([$Q:"^A*90_E2&\1XD=Y%-]%@A;=1(H7VD.1&=A"F1K50I\;TT&F'-%!
MKAW/0;<>SD'!'LQ!T!_)0N4?Q4+S(<)!_B/ 0?\DOD'_)+U!_R6]0?\EO4'_
M);U!_R6]0?\E_T(8 ?])$P#_4!0 _U89 /]9( '_6B@!]UHR N]8/03H54D'
MXU-5"MY18 [93FH2U$QT%M!+?!C.280;S$B,',I'DQ[(1YH?QD:A(<1&J2+"
M1;$CP46\([]%R22]1M\EN4;O)K9&^R>T1O\HLT;_*+)&_RBQ1O\HL4;_*+%&
M_RBQ1O\H_T85 /]-$0#_51( _UL6 /]>&P#Y8",![V L >9>-@/?7$0%V%E0
M"M%76P_,5&44R%)N&,50=QO#3W\=P$Z&'[Y-CB&\3)4CNDN<)+A*I":V2JPG
MM$JV*+-)PRFQ2=8IKDKJ*JM*^"NI2O\KJ$O_*Z=+_RNG2_\KITO_*Z=+_RNG
M2_\K_TD2 /]0#@#_61  _U\2 /]C%@#R91T YV4E -YD,0'48C\%S6!+"L==
M5@_"6F 5OEAI&;M6<1RX5'D?ME.!(K-2B"2Q4) FKU"7**U/GRFK3J@KJ4ZR
M+*=.OBVF3LXNHT[F+J%/]2Z?3_\NGD__+IU/_RZ=4/\NG5#_+IU0_RZ=4/\N
M_TP0 /]4#0#_70X _V,/ /EG$0#K:14 WVH< --J+ '+:#L$Q65'";]B4@^Z
M8%P5MEUE&;);;1VO674AK%A\(ZI6@R:G58LHI523*J-3FRRA4Z,NGU*M+YU2
MN3";4LDQF5+B,9=3\C&64_\QE53_,914_S"45/\PE%3_,)14_S"45/\P_T\.
M /]8"P#_8 L ^V8, /!K#0#D;0X UFX6 ,QO* '$;3<$O6M$";=H3P^R95@5
MKF)A&JI@:1ZG7G AI%UX):%;?R>?6H<JG%F.+)I8ERZ85Z PE5:J,I-6M3.1
M5L4TD%;=-(Y7\#2-5_TSC%C_,XQ8_S*,6/\QC%C_,8Q8_S&,6/\Q_U$, /];
M"0#_8P@ ZVH' -UN" #8<0H SW(3 ,9S)0&^<C0#MW!!"+%M3 ZL:E44IV=>
M&:-E91Z@8VTBG&%T)9I@>RB77H,KE%V++9)<DS"/6YPRC5JF-(M:LC6)6L$V
MAUK6-H9;[3:%6_LUA5S_-(1<_S.$7/\SA%S_,X1<_S.$7/\S_U,* /]=!@#U
M9@0 WVT# -5R!@#0=0D R781 ,!W(@"X=C$#L70^!ZMQ20ZF;E(4H6Q;&9UI
M8AV99VHBEF9Q)9-D>"B08W\KC6&'+HI@D#"(7YDSA5^C-8->KS:!7KXX@%[1
M.']?ZC=^7_HV?F#_-7Y@_S1^8/\T?F#_-'Y@_S1^8/\T_U4( /]@! #H:0
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M-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=   R'P  +^! 0"WA0$
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M,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0  EYD  (^;"P"*G1@
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MEQX^L*8@/+"W(#RPS" \K^@@.Z[W(3JM_R(ZK/\C.JS_(SJL_R,ZK/\CP(8
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M!BC=P08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T  )BE  "+K0
M?K0  '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8 ,>0@ ##E*@ N
MYC, +>8\ "OG1  JYTP!*.A4 2?H70$EZ6<"(^ES B+J@0(@ZI$#'^NA QWK
ML@,<[,<#'.SA QOJ\0,;Z?D#&^GY QOI^0,;Z?D#FJ0  (VL  !_M0  <KT
M &7%  !9RP  3-   $'5   XW   +^$" "WQ#0 K\1, */(< ";R)  D\RL
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M1V8+SD9P#LM%>!#(1( 2QD.'%,1"CA7#0I46P4&<%[]!I!B]0*P9O$"V&KI
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M)Y-.[">13_LGD$__)Y!0_R:/4/\FCU#_)H]0_R:/4/\F_TH) /]3!0#X6@0
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M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9   SVH  ,=N @#
M< 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.9F,8BV5I&XAC
M<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>X2]T7_,N=%__
M+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT  ,-Q 0"[<P(
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M+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@  H8(  )F##@"4A!T
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MF"5+BZ4G28NU*$B+RBA(BN<G28GW*$F(_R=)A_\G28?_)TF'_R=)A_\GT6\
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M%SBKPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0  *Z/  "BE@
MEYL  (NA  !_I@  <ZL  &>O  !:M   4[8, %&W%P!/MR0 3;@P $JX.@%(
MN$,"1KA+ T2X4@1!N%H&/[AB!SVX:PDZN'4+.+>!##:WC@XTMYT/,[>M#S*W
MP0\QM]X/,;;R$#"T_!$PL_\2,+/_$S"S_Q,PL_\3LHX  *65  ":FP  CJ(
M (*H  !UK0  :;,  %ZW  !3NP  1\ % $/"$ !"PAL 0,,G #_#,@ ^Q#P
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M 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@
M2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4
M[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GV
MV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](
M #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D
M"OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP
M_\X  /_/  #_SP  _\\ ?[(  '&Z  !CPP  5LL  $C1   ZU@  +]T  "7A
M   <Y0  %.D  !'W   /_P$ #?\)  O_#0 (_Q  !O\4  /_&   _QX  /\C
M  #_*@  _S(  /\\  #_1P  _U0  /]C  #_<P  _X4  /^7  #_I   _[(
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M$ZX\\12K//T5J3S_%J@\_Q:H//\6ISS_%J<\_Q:G//\6_ST- /]"" #_2 H
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M((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T  ,E@ @##8 0
MO5X- +5@&@"N82H J6 W J1>0P2?74T(FUM5"YA970Z56&01DE=K$X]6<A:-
M57D8BU2!&HA3B1R&4Y(>A%*<'X)2IR& 4K0B?U+$(WU2WB-\4_$B?%/^(7M4
M_R%[5/\@>U3_('M4_R![5/\@_TH  .E4  #:7   S&$  ,-D  "\9 ( MF,*
M *]D%P"I92< HV0T IYC0 2984H'E5]2"Y%>6@Z.76$1BUMH$XE:;Q:&6788
MA%A]&H%8AAQ_5X\>?5:9('M6I")Y5K$C=U;!)'96VB1U5^\D=5?](W58_R)U
M6/\A=5C_(758_R%U6/\A_TT  .57  #37P  R&0  +]G  "W:   L6<' *EH
M% "C:20 GF@R 9EG/02494<'D&1/"HQB5PV(85X0A5]E$X->;!: 77,8?5UZ
M&GM<@QUY6XP?=EN7(71:HB-R6J\D<5J_)7!:U25O6^TE;UO\(V];_R)O6_\B
M;UO_(6];_R%O6_\A^D\  .%:  #/8@  Q&<  +MK  "S;   K&H$ *1K$@">
M;"$ F6PO 91K.@./:40&BFA-"89F50V#95P0@&1B$WUB:15Z8G 8>&%X&G5@
M@!US7XH?<%^4(6Y>H"-L7JTE:UZ\)FI>T29I7NPE:E_[)&I?_R-J7_\B:E__
M(FI?_R)J7_\B\%(  -U=  #+90  P&L  +=N  "O;P  IVX! *!O$ ":<!\
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MF")8<*8D5G"U)55PR"55<.4E57#V)%9O_R-6;_\B5V__(E=O_R)7;_\BWU\
M ,II  "\<@  LG@  *E]  "??P  DGX  (I_!P"$@!, @($A 'N!+@%W@#D#
M<H!"!6Y_2@AK?E$+:'U8#F1\7Q%B>V847WIM%UQY=1E9>'\<5WB*'E1WEB%2
M=J0B47:S(U!VQB10=N,C4'7U(U%U_R)1=/\A473_(5%T_R%1=/\AV&,  ,5M
M  "X=@  KGT  *6"  ":@P  C8,  (2$ P!]A1  >88> '6'*P%QAS8";88_
M!&F%1P=EA$\*8H-6#5^#7 ]<@F,26H%K%5> <QA4?WT:47^('$]^E!]-?J(@
M2WVQ(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_($M[_R!+>_\@T&<  ,!R  "T
M>P  JH(  *"&  "5B   AX@  'R*  !VC X <HT: &Z.)P!JCC(!9HT\ V.-
M1 5@C$P(7(M3"EJ+6@U7BF$05(EH$E&(<15/B'H73(>%&DJ&DAQ(AJ =1H:O
M'D6%PAY%A=\>183R'D6#_AY%@O\>18+_'D6"_QY%@O\>RFT  +IX  "O@0
MI8<  )J+  "/C0  @8X  '21  !NDPH :905 &:5(@!CE2X!8)4X ER50019
ME$D&5I10"%235PI1DUX,3I)F#TR2;A%)D7@41I"#%D20D!A"CYX90(^M&C^/
MP!H_C]P:/XWQ&C^,_1L_B_\;/XO_&S^+_QL_B_\;PG,  +5^  "JAP  GXP
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M"2NO^0HKKO\+*JW_"RJM_PLJK?\+K8L  *"2  "5F   B9T  'VC  !QJ
M9*T  %FQ  !-M   0K@  #NZ"@ XNQ, -[P> #6\*0 TO3( ,[T[ #*]1  Q
MODP +[Y5 2Z^7@$LOF@!*KYT BF^@@(GOY$#)K^B R2_M ,CO\L#([[H R.\
M]P0BN_\%(KO_!2*[_P4BN_\%I)(  )B8  ",G@  @*4  '.K  !GL   6[4
M $^Y  !$O   .L   ##$!  JQPL *,@3 "?)'0 FR2< )<DP "3*.0 CRD(
M(LM+ "'+50 @S%\ '\QL !W->@ <S8H &\V< !G.K@$8SL4 &,WD !C,] $8
MROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@  =:T  &BS  !<N0  4+T  $3!
M   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5V!D %=DB !39*P 3VC0 $]H]
M !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@I  -X+@ #.#2  O?[0 ,WO<
M#-W[  S=^P ,W?L DI\  (6G  !WK@  :K4  %V\  !0P0  1,4  #C)   N
MS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ( #>@9  SH(0 +Z2D "NHQ  GJ
M.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE   ZJ<  .N\  #KT@  Z^D  .SO
M  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%  !#R0  -\T  "W1   CU@
M&]L  !/?   .XP  #.X"  KV"@ ']@X !?82  /V&   ]1X  /4E  #U+@
M]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4  />G  #WMP  ^,<  /C0  #X
MT   ^-  >Z\  &VX  !@P   4L@  $3-   WT0  *]<  "'<   8X   $>0
M  SG   '[P  !/H   '_ P  _P@  /\-  #^$   _A0  /\:  #_(0  _RD
M /\S  #_/@  _TL  /];  #_;   _X   /^2  #_H0  _ZT  /^S  #_LP
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M LTB] /*(_\$R"/_!<<C_P;&(_\&QB/_!L8C_P;&(_\&_RP2 /\N#P#_,!
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M$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]   #O10  X4@  -E(!0#31@D
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M%W9/_Q=V3_\7^$8  .)0  #05P  Q%P  +M>  "T70  KEH& *9;$P"@7"(
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MF!IC7J4<85ZT'6!>QQU@7N,=8%[U'&!>_QM@7O\:85[_&F%>_QIA7O\:Y%(
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M'%%KP1Q1:]P<46OQ&U)K_AI2:O\:4FK_&5)J_QE2:O\9U%P  ,-F  "V;@
MK'0  *)W  "6=@  B74  (%V 0!Z=P\ =G@; ')Y)P!O>3(!:W@\ FAX1 1E
M=TP&8G=3"%]V6@I==6$,6G5H#UAT<!%5<WD34W.$%E%RD!A/<IX937&M&DQQ
MOQM+<=D;3''P&DQP_1I-</\936__&4UO_QE-;_\9SF   +YJ  "R<@  J'@
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M$CN'^A,[AO\3.X;_$SN&_Q,[AO\3O'$  *][  "E@P  F8<  (R(  !_B0
M<XP  &60  !<DP  5Y4, %26%@!2EB( 4)<M $V7-@!+ES\!29=' D>73@-%
MEE4$0Y9=!4&6908^E6\(/)5Z"3J5APLXE94,-I2E#364M@XTE,P--)/I#322
M^ XTD/\/-)#_#S20_P\TD/\/M7@  *J"  ">B   DXT  (:.  !YD   ;9,
M &&7  !5FP  39X& $F?$ !'GQL 1J F $2@, !#H3H 0:%" 3^A20$]H5$"
M.Z%9 CFA80,WH&L$-:!V!3.@@P8QH)(',*"B""Z@LP@NH,D(+I_G""V=]PDM
MG/\*+9O_"BV;_PHMF_\*KX   *.)  "7C@  C9,  '^5  !RF   9IP  %N@
M  !/I   1:<  #ZI#  \JA0 .JH? #FJ*0 XJS( -ZL[ #6K0P TK$L ,JQ3
M 3&L7 $OK&8"+:QQ BNL?P,JK(X#**R>!">LL 0FK,4$)JOD R6I]00EJ/\%
M):?_!26G_P4EI_\%IXD  )N/  "1E   A)D  'B>  !KH@  7Z8  %.J  !(
MK0  /;   #2S P OM0X +;46 "RU(  KMBD *K8R "FW.@ HMT, )[=, ":X
M50 DN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<N< !'+C? 1RV\@$;M?P"&[3_
M ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF  !BJP  5K   $JS   _M@
M-;D  "R\   DOP8 '\(- !W"%  <PAX &\,F !K#+P 9Q#@ &,1! !?$2@ 6
MQ54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D #\?4 !#&[@ 0Q/H $,/_ !##
M_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8M   2[@  $"[   UO@  *\$
M "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1(0 ,T2H #-$T  O2/@ *TDD
M"=-5  G38@ (TW( !M2$  74F  $U*L  ]7   '5W  !U>T  =7V  '5]@ !
MU?8 CIT  ("D  !SJP  9K$  %FX  !,O0  /\   #3#   JQP  (<H  !G.
M   2T@  #=8!  G;!0 &W T !-P1  /=&  !WB   -XH  #?,0  X#P  .%'
M  #B5   XV,  .-T  #DB   Y)L  .6N  #EP0  Y=4  .;G  #FYP  YN<
M@Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@  "C,   ?T   %]0  !#9   +
MW0  !>$   #D    Y0<  .8-  #G$0  Z!8  .D=  #J)0  ZRX  .TY  #O
M10  \%,  /%D  #Q=@  \HH  /.<  #SK0  ]+L  /3(  #TR   ],@ =ZT
M &JU  !<O0  3\0  $#)   SS0  )]$  !W6   4W   #N    CC   !Y@
M .H   #N    [@   .\$  #P"@  \0X  /,2  #T&   ]B   /@J  #Z-0
M_4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8  /^P  #_L   _[  _Q8C /\5
M(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_ %T _P!H /\ <@#_ 'L _P"#
M /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L K #Y +, ]P"[ /4 Q0#S -$
M\@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_ .T _P#M /\ _QD@ /\8'0#_
M%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D _P1D /\$;@#_ W< _P.  /\#
MAP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S ;  \0&X .\!P@#M <\ ZP'C
M .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&_P#F!O\ _QP; /\;&0#_%Q@
M_Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@ /\+:@#]"W, ^PM\ /D*@P#W
M"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X ZPFV .@)P #F"<T Y GB .(*
M\ #?"_L W@S_ -P-_P#<#?\ VPW_ =L-_P';#?\!_Q\7 /\>$P#_&Q( _QP9
M /\;(@#_&"P _Q4X /\31 #^$E  ^1%; /409@#S$&\ \!!W .X0?P#L$(8
MZA", .D0D@#H$)@ Y@^> .4/I0#C#ZP X0^T . /O@#>#\P VA#A -41\ #2
M$OL SQ+_ <X3_P'-$_\!S1/_ <P3_P',$_\!_R(2 /\B#P#_(0\ _R(4 /\B
M' #_("< _QTR /@;/@#R&4L [AA6 .H78 #G%FH Y!9R .(6>@#@%H( WA:(
M -P6CP#;%I4 V1:; -86H@#4%JD TA:Q - 7NP#.%\D S!C> ,@9[@'%&OL!
MPQK_ L$;_P+ &_\"P!O_ L ;_P+ &_\"_R8. /\E"P#_* P _RD0 /\H%@#^
M)B  ]"0K .PA. #F($0 X1]0 -T?6P#9'F4 U1YM -(?=0#0'WT SA^# ,P?
MB@'+'Y !R1^7 <@?G@'&'Z4!Q2"M <,@MP'!(,0!P"'6 ;PBZ@*Y(O@#MB+_
M [4C_P.T(_\$LR/_!+,C_P2S(_\$_RD+ /\J!0#_+@@ _R\, /\M$ #S*Q<
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M#(@\_PR(//\,_S<  .H_  #<10  SDD  ,5)  "_1@( ND,, +-$&0"M12<
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MF1%O3:43;4VS%&Q-Q11K3N$4:T[T$VM._Q)K3O\2:T[_$6M._Q%K3O\1Z$8
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M%5M9OQ9;6=@66UGO%5M9_11<6?\37%G_$EQ9_Q)<6?\2W%   ,=9  "Z8
MKV0  *1E  "99   D&   (AA!@""8A$ ?F,= 'IC*@!V8S0!<V(] 6]B1@)L
M84T$:F%4!6=@6@=E8&$(8U]I"F%?<0Q?7GH.75Z%$%M>D1)979X46%VL%5==
MO1967=465EWN%5==_!177?\35UW_$E==_Q)77?\2UE,  ,1<  "W8P  K&@
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M$TAK^A)(:_\22&K_$4AJ_Q%(:O\1QUX  +AG  "L;@  H7(  )-R  "'<0
M>G$  '%R  !K= < 9G41 &-V'0!@=R@ 7G<S %MX/ %9=T,"5G=+ U1W4@12
M=ED%4'9@!TYU: A+=7$*271\#$=TB Y%<Y8/0W.E$$)SMA%!<\L10G+H$4)R
M^!%"<?\00W#_$$-P_Q!#</\0P6,  +-L  "H<P  FW8  (YU  "!=@  =78
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M""^*_PDOBO\)L'8  *5_  "8A   BH0  'V%  !PAP  98H  %J.  !/D@
M1I4  $&8#  ^F!0 /9D? #N9*  ZFC$ .9HZ #>:0@ VFDH -9I2 3.:6@$Q
MFF0!+YIO BV:>P(LFHH#*IJ: RF:K 0HFL $)YG> R>7\@0GEOT%)Y7_!2>5
M_P4GE?\%J7X  )Z%  "2B0  A(H  ':,  !JCP  7I,  %27  !)FP  0)\
M #>B!  RHPX ,:,7 #"D(0 NI"H +:0R "RE.@ KI4, *J5+ "FE5  HI5X
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M90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (OO  "+WZ  B]_  (O?P DY0
M (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV   QN   )[L  !^^   7P0
M$<0!  S("  (R0X !\D4  ;)'  %R20 !,HL  /*-@ "RD   ,M,  #+60
MRV@  ,MY  #,C   RY\  ,NS  #+R   S.(  ,SO  #,\0  S/$ BIH  'RA
M  !OIP  8JT  %6S  !(N   .[L  #"^   FP0  '<0  !7(   /RP  "LX
M  32 @  TPH  -,/  #4%   U1H  -8B  #7*@  V30  -H_  #<2P  W%H
M -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>  #>X@  WN( ?Z(  '&I  !D
ML   5K<  $F\   \P   +\0  "3'   ;RP  $\\   W2   'U@   -L   #>
M    WP,  . )  #A#@  XA(  .,7  #E'@  YB<  .@Q  #J/0  [$L  .Q:
M  #M;   [H   .Z4  #NI0  [K0  .["  #NQ@  [L8 =*H  &:R  !8N0
M2\   #W%   OR0  ),T  !G1   1U@  "]L   />    X0   .4   #H
MZ0   .H   #K!@  [0L  .\/  #P$P  \AH  /0C  #W+@  ^3L  /M*  #\
M6P  _6T  /V   #^DP  _J(  /ZM  #^KP  _J\ _Q ? /\.'0#_"AT _P$@
M /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\ ;@#_ '< _P!_ /X A@#\ (P
M^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U /( O0#Q ,D [P#< .X ZP#M
M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\ _Q,< /\1&0#_#1D _P8< /\#
M)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#] ', ^@![ /< @P#U (D ] "/
M /( E #Q )D \ "? .X I #M *L [ "R .H N@#H ,8 YP#6 .4 Z #D /4
MXP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48 /\3% #_#Q0 _PT9 /\+(@#_
M""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\ \@!W .\ ?@#M (4 ZP"+ .H
MD0#H )8 YP"< .8 H0#D *@ XP"O .$ N #? ,, W0#1 -L Y@#9 /, UP#]
M -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5$ #_$@\ _Q(5 /\1'0#_#B@
M_PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R .8%>@#D!8$ X@6' . &C0#?
M!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L  T ?/ ,X(Y0#,"?0 R@O_ ,@,
M_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_& T _Q@1 /\7& #_%"( ^Q$N
M /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-=0#8#7P U0V" -,-B0#1#8\
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M J$C_P*A(_\"_R4  /\H  #R*@  Y2L  -\H!0#<(0L TB$4 ,DD) ##)3(
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MG >!.J@(@#JU"7X[Q@E].^$)>SSS"7L\_PEZ//\(>CS_"'H\_PAZ//\([C<
M -U!  #+1@  OTD  +9)  "N1@  J4$$ *-!$0"=0AX F$,K )5#-P"10T$
MCD)* 8Q"4@&)05D"AT%? X5!9@.#0&T$@4!T!8! >P9^/X0'?#^."'H_F0EX
M/Z4*=T"R"G5 PPMT0-T+<T'Q"W)!_PIR0?\*<D'_"7)!_PER0?\)Z3P  -5%
M  #%2P  NDX  +!.  "G2P  HD8  )M&#@"61QH D4@G (Y(,P"*2#T AT=&
M 81'3@&"1E4"@$9< WY%8@1\16D$>D5P!7A$> 9V1($(=$2+"7)$E@IP1*(+
M;T2O#&Y$P QM1=D-;$7O#&M%_0MK1O\+:T;_"FM&_PIK1O\*Y4   ,])  #!
M3P  M5(  *M2  "A3P  FTH  )1*# "/2Q< BTPD (=,+P"$3#H @4Q# 7Y+
M2P%[2U(">4I8 W=*7P1U268%<TEM!G%)=0=O27X(;4B("6M(DPMJ2)\,:$BM
M#6=)O0UF2=0.94GM#65*_ QE2O\+94K_"V5*_PME2O\+X$0  ,M-  "]4@
MLE8  *95  "<4@  E4X  (Y."0")3Q0 A5 @ (%0+ !^4#< >U!  7A02 %U
M3T\"<TY5 W%.7 1O3F,%;4UJ!FM-<@=I37L(9TV%"F5-D0MD3)T,8DVK#6%-
MNPY@3=$.8$WL#F!-^PU@3?\,8$W_"V!-_PM@3?\+W$<  ,=0  "Y5@  KED
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M#E%8^ U26/\-4EC_#%)8_PQ26/\,S5$  +Q9  "P7P  HV$  )9@  "+7P
M@5L  'E=  !S7@P ;UX5 &M?( !H7RL 9F U &-@/0%A7T4!7U], EU?4P-;
M7UH$65YA!5=>:0957G((4UY]"5%=B0M0798,3EVD#4U=M Y,7<@.3%WF#DU=
M]PU-7/\,35S_#$Y<_PQ.7/\,R50  +E<  "M8P  GV,  ))C  "'8@  ?&
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M"CYK_PH^:_\*NF   *UI  "@;@  D6T  (1M  !X;0  ;&X  &%P  !;<@
M5G0* %)U$@!0=AT 3G<G $QW,0!+>#D 27A! $AX20%&>% !1'=7 D)W7P-
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M<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@D/H"((__ B"/_P(@C_\"I'P
M )>   "'?P  >X   &Z"  !BA0  5XD  $V.  !"D@  .I8  #*9   JG D
M*)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y" "">2P ?GU4 'I]@ !R?;0 ;
MGWP &I^- !B?GP 7G[( %I_) !:>Z  6G/< %IO_ 1>;_P$7F_\!G8,  (^&
M  ""A@  =(<  &>+  !;CP  4),  $:8   \G   ,Z   "NC   CI@  '*@+
M !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J0P 3JTT $JM8 !&K90 0JW0
M#JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\  VH_P -J/\ EHH  (F,  !Z
MC0  ;)$  &"5  !4F@  29\  #^C   UIP  *ZH  ".N   ;L   %+,!  ^U
M"@ -MA  #+86  NV'P *MB< ";8O  BV.0 'MT, !K=/  2W6P #MVH  K=[
M  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U]P  M?< CY$  (&4  !REP
M99P  %BA  !,I@  0:L  #>O   LL@  ([4  !JX   3NP  #KT   G !0 #
MP0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD  ,1$  #$4   Q%X  ,5O  #%
M@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@  Q.X AI@  'F>  !KHP  7:D
M %"N  !$LP  -[8  "RY   BO   &;\  !'"   ,Q0  !L@   #+    S <
M ,P-  #-$0  S18  ,X=  #/)   T"T  -(X  #41   U%(  -5A  #5<P
MUH<  -:;  #6K0  U[\  -C.  #8W0  V-T >Z   &ZF  !@K0  4[,  $6X
M   XO   *[\  "'"   7Q@  $,D   K,   "T    -0   #7    V    -H%
M  #;"P  W X  -X3  #?&0  X2$  .,J  #E-@  YT,  .=3  #H9   Z7<
M .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@  &*O  !5M@  1[P  #G    L
MQ   (,@  !;,   .T   !]0   #9    W0   .$   #C    Y    .8   #G
M 0  Z0<  .L,  #L$   [A4  / =  #S)P  ]C,  /=#  #X5   ^68  /EZ
M  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'&0#_ !D _P < /\ )0#_ #(
M_P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![ /L @@#Z (@ ^ "- /< D@#V
M )@ ]0"= /0 H@#S *D \0"P .\ N #N ,, [ #1 .L Y@#I /, Z #^ .@
M_P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_ 10 _P 8 /\ (@#_ "X _P [
M /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /, ?@#R (0 \ ") .\ CP#N )0
M[ ": .L GP#I *4 Z "L .8 M #D +\ XP#, .$ X@#? /  W@#[ -X _P#=
M /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A  _P(5 /\ '@#_ "D _P V /\
M0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H '\ YP"% .4 BP#D )  X@"6
M .$ G #? *( W0"I -H L0#8 +L U0#( -( W0#1 .T T #Y ,\ _P#. /\
MS0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2 /\'&0#_ B0 _P P /8 / #O
M $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L VP"! -D A@#6 (P U "2 -(
MF #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#% .H PP#W ,( _P#! ?\ P +_
M , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.% #_"AX ]08I .L$-@#C T(
MWP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\ ,H%@@#)!8@ QP6. ,8%E #$
M!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D MPOX +4,_P"T#/\ M S_ +0,
M_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R#A4 Z PA -X*+@#6"SL T Q'
M ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-?0"]#H, O Z* +H.D0"Y#I@
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MH@";(*P!FB&Y 9@AR@&6(N0!E"/U 9(C_P&1(_\!D"/_ 9 C_P&0(_\!_R(
M .LI  #=+@  SR\  ,<M  #!)P, O2(- +8C&@"P)2@ K"8T *@F0 "E)TD
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M!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W_P1T-_\$YS4  -(]  ##0@
MN$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF (T[,0"*.SL ASM$ (0[3 ""
M.U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#=CJ(!'0ZDP1R.IX%<3JK!6\[
MNP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L//\%XCD  ,Q"  "^1P  L4@
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M"%I)]@A:2?\'6DC_!EI(_P9:2/\&T44  +],  "R4@  HU$  )=0  "-3@
MADH  (!* 0!Z2PX =DP7 '),(P!O3"T ;4TV &I,/P!H3$8 9DQ- 61,4P%B
M3%H"84QA E],:0->3'($7$Q\!5I,B 993)4'5TRC"%9,L@A53,8)54SB"55,
M]0A53/\'54S_!U9,_P963/\&S$@  +Q0  "O50  H%0  )-3  ")40  @4T
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M!TA7_P9(5_\&P5$  +)9  "C7   E%L  (=;  !]6@  <E@  &M9  !E6@,
M8%L. %U<%P!:7"$ 6%TK %9=- !47CP 4UY$ %%>2P%07E(!3EY9 DQ>80)+
M76H#25UT!$==@ 5%78T&1%V<!T-=K ="7;X(0EW:"$)<\0="7/X'0UO_!D-;
M_P9#6_\&O54  *]=  "?7P  D%X  (->  !X70  ;5P  &5=  !?7P  6F ,
M %=A% !58AX 4F(H %%C,0!/8SD 3F-! $QC2 !+8T\!26-6 4=C7@)%8V<"
M1&-Q T)C?01 8HL%/V*:!CYBJ@8]8KP'/&+6!SUA[P8]8?T&/F#_!CY@_P8^
M8/\&N5D  *MA  ":80  BV$  ']A  !T80  :6$  %]B  !99   5&8) %%G
M$0!.9QH 3&@D $MI+0!):38 2&D^ $9J10!%:DP 0VI4 4)J7 % :64"/FEO
M CQI>P,[:8D$.6F8!3AHJ 4W:+H%-VG3!3=H[@4W9_P%.&;_!3AF_P4X9O\%
MM%X  *=E  "590  AF0  'IE  !O90  9&8  %EH  !2:@  36P$ $EN#@!'
M;A8 16\@ $1P*0!"<#( 07 Z $!Q0@ _<4D /7%1 #QQ60$Z<6(!.'%L C9P
M> (U<(8#,W"5 S)PI@0Q<+@$,'#0!#%O[ 0Q;OL$,6W_!#%L_P0Q;/\$KV0
M *%I  "/:   @6@  '5I  !K:0  8&L  %5N  !-<0  1G,  $)U"P _=A(
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M !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(_P$9B/\!G7<  (QV  !]=@
M<G<  &5Y  !:?   4(   $:$   \B0  -(P  "V0   EDP( 'Y4, !V6$@ <
MEAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T %9A8 !289  3F', $9B$ !"8
ME@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0E/\ E7T  (5\  !X?   :WX
M %^!  !4A@  2HH  $"/   VDP  +9<  "::   >G0  %Z # !*B#  0HQ(
M$*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10  JD7  )I&H !Z1[  :CC@ $
MHZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L C8,  '^"  !QA   9(<  %B,
M  !-D0  0I8  #B:   OG@  )J(  !ZE   7J   $:L   RN!P 'KPT  Z\2
M  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P4P  L&$  +!Q  "P@P  KY<
M *^J  "OOP  KMD  *[K  "N]   KO0 AXD  'B*  !JC@  79,  %&8  !%
MG0  .Z(  #"F   GJ@  'JX  !:Q   0M   "[8   6Y P  N@H  +H.  "Z
M$P  NQD  +LA  "\*   O#$  +T\  "^2   OE8  +YE  "^=P  OHP  +Z?
M  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5  !BF@  59\  $FE   ]JP
M,J\  "BT   >M@  %;D   Z\   )OP   L(   #$    Q00  ,8*  #&#@
MQQ(  ,@8  #)'P  RB<  ,PP  #./   SDD  ,]9  #/:@  SWX  ,^3  #/
MI@  S[@  ,_(  #/VP  S]L =YP  &BA  !;IP  3JX  $&T   TMP  *+H
M !V]   3P   #<0   ;'    R@   ,X   #0    T0   -("  #3"   U0P
M -80  #9%0  VQP  -TD  #@+P  XCP  .-+  #D7   Y&\  .6#  #EF
MY:D  .6V  #EPP  Y<, ;*4  %^L  !1L@  1+D  #6\   HP   ',0  !+(
M   ,RP   \\   #3    V    -P   #?    WP   .$   #C    Y ,  .8(
M  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T30  ]5\  /9S  #WAP  ]YD
M /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8 /\ (P#_ "\ _P \ /\ 2 #_
M %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (, ]@"( /4 C@#T ), \@"8 /$
MG@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G /$ Y@#] .4 _P#D /\ Y #_
M .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\ 'P#_ "L _P W /\ 1 #^ $\
M^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$ .L B@#J (\ Z "4 .< F@#E
M *  Y "G .( KP#@ +D W@#& -P V@#: .P V #Y -8 _P#6 /\ UP#_ -@
M_P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_ "8 _  R /< /P#T $H \0!5
M .T 7@#J &8 Z !N .4 = #C 'H X@"  .  A0#> (L W "0 -L E@#8 )P
MU0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U ,@ _P#( /\ R #_ ,@ _P#(
M /\ _PP, /\&" #_ @H _P / /\ %0#\ "  \0 L .P .0#I $4 Y0!/ .$
M60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #. (8 S ", ,L D@#) )@ QP"@
M ,4 J ## +$ P0"\ +\ RP"] ., O #R +L _0"[ /\ N@#_ +H _P"Z /\
M_PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E .$ ,@#< #\ U@!) -$ 4P#.
M %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($ P "' +X C@"\ )0 NP"< +D
MI "W *X M0"Y +, R "Q -\ L 'O *\!^P"N O\ K0/_ *T#_P"M _\ _Q
M /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#*P#, S< R 1# ,0$30#!!%8
MO@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:# +(&B0"P!I$ KP>9 *T'H0"K
M!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\ H0W_ *$-_P"@#?\ _Q$  /P2
M  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@# ##  O T\ +@-1@"U#4\ L@Y7
M + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</A0"E#XT I ^6 *(0GP"@$*D
MGQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_ )44_P"4%/\ _Q4  .T;  #@
M'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD L!0U *P50 "I%4D IA52 *06
M60"B%F  H19F )\6; ">%G( G!9Y )L7@ "9%X@ F!>1 )88FP"4&*8 DQFR
M )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<_P")'/\ ]!T  .0E  #3*0
MQRH  +PF  "V(   M!D+ *X:%0"H'", I!TO *$>.@">'D0 FQY, )D>5 "7
M'UL E1]A )0?9P"2'VT D1]T (\@? ".((0 C""- (H@EP")(:( AR&N (8B
MO0"%(M$!@B/K 8$D^P& )/\!?R3_ 7\D_P%_)/\!["4  -LM  #),0  O#$
M +$N  "K*0  IR0% *,C$0">)!T FB4J )8F-0"3)C\ D29' (\F3P"-)E8
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M V8V]0-F-O\"9C;_ F8V_P)F-O\"V#<  ,0^  "U0@  ID$  )L_  "3/
MC3@  (@V!P"$-Q$ @#<< 'PX)P!Z.#$ =SDZ '4Y0@!S.4D <3E0 ' Y5P!N
M.5T ;#ED 6LY:P%I.70!:#E^ F8YB0)D.94#8SJB V(ZL0-A.L,#8#O@!%\[
M\P-?._\#7SO_ U\[_P)?._\"T3L  ,!"  "P10  H40  )5#  "-0   AST
M (([ @!].PX >3P8 '4](P!S/2T <#TV &X]/P!L/48 :SU- &D]4P!G/5H
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M T]'_P-01_\#Q$4  +5-  "C30  E4P  (E+  !_2@  >$8  '%'  !L1P<
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M>0) 6(8"/EB5 SU8I0,\6+<$/%C-!#Q7Z@,\5_H#/5;_ SU6_P,]5O\#ME,
M *57  "45P  A58  'E6  !O5@  954  %Q6  !76   4ED' $Y:$ !,6A@
M2ELA $A<*@!'7#( 15PZ $1=00!#74@ 0EU0 $!=6  _76$!/5UK 3Q==@(Z
M780".5V3 CA=HP,W7;4#-EW+ S9<Z ,W7/D#-UO_ SA;_P,X6O\#LE<  *!:
M  "/60  @5D  '59  !K60  8%H  %9;  !170  3%X" $A@#0!%8!0 1&$>
M $)B)@! 8BX /V(V #YC/@ ]8T4 /&-- #MC50 Y8UX .&-H 39C= $U8X$!
M,V.1 C)CH0(Q8[,",6/( C%BYP(Q8?@",6'_ C)@_P(R8/\"KEP  )M=  "*
M70  ?%T  '!=  !F70  7%X  %)@  !,8@  164  $%F"@ ^9Q$ /&@: #MH
M(@ Y:2L .&DR #=J.@ V:D$ -6I) #1J4@ S:EL ,6IE #!J< $N:GX!+6J.
M 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG_P(K9_\"J6$  )5@  "$8
M=V   &QA  !B80  6&,  $YF  !':   0&L  #IN!0 V;PX -' 5 #-P'@ R
M<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E< *G)A "ER;0 G<GL )G*+ "1R
MG $C<JX!(W+# 2-QX@$C</0!(V__ 2-N_P$C;O\!H64  (YD  !_9   <F0
M &AE  !>9@  5&D  $EL  !";P  .W(  #1U   N> H *WD1 "IY&  I>B$
M)WHH "9Z,  E>S@ )'M  "-[2  B>U( (7M< "![:  ??'8 '7R& !Q[F  ;
M>ZH &GN_ !I[W@ :>?( &WC^ !MW_P$;=_\!F6D  (AI  !Y:0  ;6D  &-J
M  !9;   3V\  $5S   ]=P  -7H  "Y]   G@0, (H,- ""$$@ ?A!H '80B
M !R%*@ ;A3$ &H4Y !F%0@ 8ADP %X96 !:&8P 5AG$ %(:! !*&DP 1AJ8
M$86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X  (%M  !T;@  :6X  %UP  !3
M<P  27<  $!\   W@   +X,  ">'   AB@  &HT& !6/#0 3D!, $I : !*0
M(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,D6H "Y%Z  J1C0 (D)\ !Y"S
M  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS  !O<P  8W4  %=X  !-?0
M0X$  #F&   PB@  *(X  "&1   :E0  $Y<   Z:"  +G X "9P3  B<&@ '
MG"( !IPJ  2<,P #G#T  IU(  "=5   G6(  )QR  "<A   G)<  )NJ  ";
MOP  FML  )KL  ":]0  F?@ @GD  '9Y  !H>@  7'X  %&"  !&AP  /(P
M #*1   IE0  (9D  !F=   2H   #J,   FF!0 #IPP  *<0  "G%0  J!P
M *@C  "H*P  J30  *D_  "I2P  J5D  *EH  "I>@  J8X  *FA  "HM0
MJ,L  *?D  "G[P  I_, ?8   &^!  !AA   58D  $F.   ^E   -)D  "J>
M   AH@  &:8  !*I   -K   !Z\   "R    LP<  +,,  "S$   M!4  +0;
M  "U(@  MBL  +<U  "W0   N$X  +A=  "X;@  N((  +B7  "XJ@  M[X
M +?2  "WY@  M^H =H@  &>+  !:D   3I8  $*<   WH@  +*<  "*K   9
MKP  $;,   NV   $N0   +P   "^    O@   +\&  # "P  P0\  ,(3  ##
M&0  Q"   ,4I  #'-   R$(  ,E1  #)8@  R74  ,F*  #)GP  RK$  ,K!
M  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK   OL   )+4  !FX   0O
M"K\   '!    Q    ,@   #*    R@   ,P   #- P  S@@  - -  #1$
MTQ8  -8>  #:*   W30  -Y#  #?5   WV<  .!\  #@D0  X*0  ."R  #@
MO@  X,, 9I\  %FF  !,K0  /[0  #*X   DO   &+\  !##   (QP   ,H
M  #-    T0   -4   #8    V0   -L   #=    WP   .$$  #C"@  Y0X
M .<3  #J'   [2<  / U  #Q1@  \E@  /-K  #S@   ])0  /2C  #TK@
M]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P _P Y /\ 10#_ %  _P!: /X
M8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q (X \ "3 .X F0#M )\ [ "F
M .H K@#H +@ Y@#% .4 VP#C .T X@#[ .( _P#A /\ X0#_ .$ _P#A /\
M_P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T /X 00#[ $P ]P!6 /0 7P#Q
M &8 [P!M .P = #J 'H Z0!_ .< A0#F (H Y0"/ ., E0#A )L X "B -X
MJ@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1 /\ T #_ -  _P#0 /\ _P -
M /\ "0#_  H _P / /\ %@#[ "( ]P O /0 .P#P $< [0!1 .D 6@#E &(
MX@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+ -, D0#1 )< SP"> ,T I@#+
M *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\ P0#_ ,( _P#" /\ _P,& /\
M 0#_  8 _P , /D $0#Q !T ZP I .< -@#C $$ WP!+ -L 5 #5 %P T@!C
M ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4 C ## ), P0": +\ H@"] *L
MNP"V +D Q "W -H M@#M +0 ^@"T /\ M #_ +0 _P"T /\ _P0  /\   #_
M    _P & .P #0#E !8 W@ B -< +P#1 #L S0!% ,H 3@#& %< Q !> ,$
M9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U (X LP"5 +( G@"P *< K@"R
M *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8 _P"F /\ _P8  /\%  #Q P
MZ    .$ !P#5 !  S0 ; ,< )P## #, OP ^ +P 2 "Y %$ M@!8 +0 7P"R
M &4 L !J *\ < "M '8 K !\ *H @@"I (D IP"1 *4 F@"C *0 H0"N *
MNP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9!?\ _PH  /$.  #D$   V0\
M ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %0@"M!DH J@92 *@'60"F!U\
MI0=E *,':P"B"'$ H AW )\(?@"="(4 FPF. )H)EP"8"J$ E@JL )4+N@"3
M"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\ ]A$  .87  #6&P  QQD  +X5
M  "Y$   MPH- +$+%P"L#20 J XP *4..P"B#D0 GP], )T/4P";#UH F@]@
M )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1E "-$9\ BQ&J (H2N "($LL
MAA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H  -PA  #*)0  NR(  +$?  "K
M&@  J10& *42$0"@%!X G!4J )D5-0"6%CX E!9' )(63@"0%E4 CA=; (P7
M80"+%V< B1=M (@7= "&&'P A1B& (,9D "!&9L @!JG 'X:M0!]&\< ?!SB
M 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I  "_+   L"H  *<G  "@(P
MG1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y! (<?20"%'U  @Q]6 ((?7 "
M'V( ?Q]I 'T@< !\('@ >B"! 'DAC !W(9< =2*D '0BL@!S(\, <B/? ' D
M\P!O)/\ ;R3_ &XD_P!N)/\ W2D  ,@P  "W,@  J#   )XN  "7*@  DR<
M ) C"@",(Q, B"0? (0E*@"")30 @"8] 'TF1 !\)DL >B92 '@F6 !W)EX
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M 5@U_P%9-?\!R#@  +<^  "D/@  ECT  (L\  "#.@  ?3<  '@T  !T- L
M<#43 &TU'0!J-2< :#8P &8V. !D-C\ 8S9& &$V30!@-E, 7C=: %TW8@!<
M-VH 6CAT 5DX?P%7.(P!5CF9 54YJ )4.;D"4SK/ E,ZZP)3.OL!4SK_ 5,Y
M_P%3.?\!Q#P  +)!  "@0   DD   (8_  !^/0  >#H  ',X  !N.0@ :CD1
M &<Y&@!D.B0 8CHL & Z- !>.CP 73M# %L[2@!:.U  6#M7 %<[7P!6/&<
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M> %(184!1T64 45%HP)%1K0"1$;) D1&YP)$1?@"1$7_ D5%_P)%1?\!ND8
M *9(  "42   AD@  'M'  !R1@  :D(  &-#  !>1   6D4+ %9%$@!41AL
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M 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390_P$W4/\!KD\  )E/  ")3P
M>T\  '!/  !F3P  7$X  %1/  !/40  2E(! $93# !#5!( 050; $!5(P ^
M52L /58R #Q6.@ [5D$ .E9) #E740 X5UH -E=C #57;P T5WP!,U>, 3%7
MG $P5ZT!,%?" 3!7X $P5O0!,5;_ 3%5_P$Q5?\!J%(  )52  "$4@  =U(
M &Q2  !B4@  6%,  $]4  !)5@  1%<  $!9"  ]6A  .UH7 #E;(  X6R<
M-UPO #9<-@ U7#X -%Q& #-=3@ Q75< ,%UA "]=;  N77H +%V) "M=F@$J
M7:L!*EV_ 2E=W@$J7/(!*EO^ 2M;_P$K6O\!HU4  (]5  !_50  <E4  &=6
M  !>5@  5%<  $Q9  !%6P  /UT  #I?!  V8 T -&$3 #)B'  Q8B, ,&(K
M "]C,@ N8SH +6-" "QC2@ J9%, *61= "AD:0 G9'8 )F2& "5DEP D9*D
M(V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@  (E8  !Z60  ;ED  &-9  !:
M6@  4%P  $A>  !!8   .F,  #1F   O: H +&D0 "II%P I:A\ *&HF "=J
M+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?;'( 'FR" !ULE  <;*8 &VNZ
M !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<  !U7   :5T  %]=  !67@
M3&$  $-D   \9P  -6H  "]M   H< 0 (W(- "%R$@ @<QH 'W,A !YS*  =
M=#  ''0X !MT0  :=$H &714 !=U8  6=6X %75^ !1UD  3=*( $G2V !%T
MSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O80  96$  %MB  !19   2&<
M #YK   W;@  ,'$  "EU   B>   ''L' !=]#@ 6?1, %7T; !1^(@ 3?BH
M$GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X  Q_B@ +?IT "GZP  E]Q@ *
M?>0 "GST  M[_0 +>O\ AF4  '=E  !J90  868  %9H  !,:P  0F\  #ES
M   Q=P  *GH  "-^   <@0  %80  !"'"  -B0X #(D4  R)&P +B2, "HDK
M  F),P (B3T !HE(  6)5  $B6$  HEQ  &)@P  B98  (BI  "'O@  A]H
M (;L  "&]0  AOH ?FH  '%J  !G:P  6VP  %!P  !&=   /'@  #-]   J
M@0  (X4  !R(   5C   $(\   R2!@ &DPP  I,1  "4%@  E!T  )0D  "5
M+   E34  )5   "53   EED  )9I  "5>@  E8X  )2A  "4M0  D\P  )+F
M  "2\@  DO< >'   &UP  !@<@  5'4  $EY   _?@  -8,  "R(   CC0
M&Y$  !24   /EP  "IH   2= P  G@D  )\.  "?$@  H!<  * =  "A)0
MHBT  *(W  "C0P  HU   *-?  "C<0  HX0  **9  "BK0  H<(  *'<  "A
MZP  H/( <W8  &9W  !9>P  38   $*%   XBP  +I   "25   ;F@  %)X
M  ZA   )I    J<   "J    JP0  *L*  "L#0  K1$  *T6  "N'   KR0
M + M  "Q.0  L48  +)5  "R9@  LGD  +*.  "QHP  LK<  +'*  "QX
ML>D ;'X  %^"  !2AP  1HT  #N3   PF0  )IX  !RC   3IP  #:L   >N
M    L@   +4   "W    N    +D"  "Y"   N@P  +L0  "\%   O1L  +\C
M  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$EP  Q*L  ,2\  #$RP  Q-H
M98D  %B.  !+E0  /YL  #.B   HJ   ':T  !2Q   -M@  !KD   "\
MOP   ,,   #$    Q0   ,8   #'    R00  ,H)  #+#0  S1$  ,\8  #2
M(0  U2T  -8\  #830  V5\  -IS  #:B@  VYX  -NN  #;N@  W,, 7I8
M %&<  !$HP  .*H  "RQ   @MP  %;L   V^   $P@   ,4   #)    S0
M -    #2    T@   -4   #6    V0   -L   #>!0  X H  .(/  #E%@
MZ"   .PM  #M/@  [5$  .YE  #O>@  [X\  /"?  #PJP  \+, _P 0 /\
M#@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_ $T _@!6 /L 7P#X &8 ]@!M
M /0 = #R 'D \0!_ /  A #N (D [0"/ .L E0#J )L Z "B .8 J@#E +,
MXP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_ -X _P#> /\ _P - /\ "@#_
M  D _P / /\ & #_ "0 _@ Q /L /0#X $@ ] !2 /  6@#M &( ZP!I .D
M;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #< )8 V@"= -@ I0#5 *\ T@"Z
M -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L _P#+ /\ _P ( /\  P#_  4
M_P , /P % #W !\ \@ K .\ -P#K $( YP!, .0 50#@ %T W0!D -H :@#8
M '  U0!U -( >@#0 (  SP"% ,T BP#+ )( R0"9 ,< H0#% *H PP"U ,$
MPP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\ /\ _P   /\   #_    ^0 '
M /$ $ #J !H Y  E -\ ,0#; #P UP!' -( 4 #. %< RP!> ,D 90#& &H
MQ0!P ,, =0#! 'H P "  +X A@"\ (T N@"4 +D G "W *4 M0"P +, O0"Q
M ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\ _P   /\   #]    [@ ! .,
M# #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_ %( O !9 +H 7P"X &4 M@!J
M +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L F "I *$ IP"K *4 N "C ,@
MH@#B *$ \P"@ /X H #_ *  _P"@ /\ _P   /8   #J    X    -, !@#)
M  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P K@!3 *P 60"J %\ J0!D *<
M:@"F &\ I !U *, >P"A (( H "* )X DP"< )T F@"G )@ M "6 ,, E0#<
M )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+  #<#0  RPH  ,(%  "\  H
MM@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!- *  4P"> %D G !? )L 9 ":
M &H F !P )< =@"5 'X DP"& )(!CP"0 9D C@*D (P"L0"+ \  B076 (@&
M[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*%0  O!(  +,0  "N#   JP8-
M *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)3@"3"50 D0I: ) *7P"."F4
MC0IK (L*<@"*"WD B N" (<+C "%#)< @PRB ($-L " #<  ?PW8 'T.[P!\
M#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0  KQP  *89  "A%0  GA $ )T-
M#P"8#AD E XE )$/+P"/$#D C!!! (H02 "($$\ AQ!5 (406P"$$6$ @A%G
M ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3K@!U$[X =!35 ',5[@!Q%OT
M<1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,  )PA  "6'@  DAD  )$4"P"-
M%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH ?!=0 'H75@!Y&%P =QAB '88
M:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K'+L :AS0 &D=[ !H'OL :![_
M &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H  "-)0  B"(  (8=!@"#&Q
M?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+ '$?40!O'U@ ;A]> &P?90!K
M(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@ 82/- & DZ0!@)/H 7R3_ %\D
M_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%*@  @"@  'TD  !Z(@T =B,5
M ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E30!F)50 925: &0F80!B)FD
M829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK* %DJYP!8*O@ 6"K_ %@J_P!8
M*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P  >2T  '4J  !R* H ;R@2 &LI
M&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?*U  7BM7 %PK7@!;+&8 62QO
M %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(OY0!2+_< 4B__ %(O_P!2+_\
MP38  *HV  "9-@  BS8  ($U  !Y,P  <S$  &\O  !K+@8 :"T0 &0N& !B
M+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT 5S!3 %8P6P!4,6, 4S%L %(R
M=P!1,H0 3S.2 $XSH0!-,[$ 333% 4PTXP%,-/8 3#3_ $PT_P!,,_\ NSD
M *8Y  "5.0  ASD  'PY  !T-P  ;C0  &DS  !E,@( 83(- %XR% !<,QX
M6C,F %@S+@!6,S4 530\ %,T0P!2-$H 4310 % U6 !.-6  339J $PV=0!+
M-X( 2C>0 $DXGP!(.+ !1SC# 4<XX0%'./4!1SC_ 4<X_P%'./\!MSL  *(\
M  "1/   @SP  '@\  !P.@  :C<  &0V  !@-@  7#8+ %DW$@!6-QH 5#<C
M %(W*P!0-S( 3S@Y $TX0 !,.$< 2SA. $HY50!).5X 2#IH $<Z<P!&.X
M13N. $0\G@!#/*X!0CS" 4(]WP%"//,!0CS_ 4(\_P%"._\!LST  )X^  "-
M/@  ?SX  '4^  !L/0  9CH  & Y  !;.@  5SH( %,[$ !1.Q@ 3CL@ $P[
M* !+.R\ 23PV $<\/0!'/$0 1CU+ $4]4P!$/EP 0SYF $(_<0!!/WX 0#^-
M #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X__P$^/_\!KD   )I   ")00
M?$$  '%!  !H0   83P  %L]  !6/@  4CX% $X_#@!,/Q4 23\= $= )0!&
M0"P 1$ S $- .@!"04( 04%) $!!40 _0EH /D)C #U#;P \0WP .T.+ #I$
MFP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y0_\!JD(  )9#  "&0P  >$,
M &Y#  !E0P  74   %9   !10@  34(" $E## !&0Q( 1$0: $)$(@!!1"H
M/T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A #A';  W1WH -DB) #5(F0 T
M2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\ ID0  ))%  ""1@  =48  &I&
M  !A10  640  %%$  !,1@  2$<  $1'"@!!2!  /TD8 #U)(  \22< .DHN
M #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,:@ R3'< ,4R& #!,EP O3:@
M+DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<  (Y(  !^2   <4@  &9)  !=
M2   54@  $Q)  !'2@  0DL  #],!@ [30X .4X5 #=.'0 V3R0 -4\K #-/
M,P R4#H ,5!" #!02@ O45( +E%< "U19P L474 *U&$ "I2E0 I4J8 *5*Y
M "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*  !Z2P  ;4L  &-,  !:3
M44P  $A-  !#3P  /5   #E2 @ U4PP ,U02 #%4&0 P52$ +E4H "U5+P L
M5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W( )5>! "17D@ C5Z0 (E>W ")7
MSP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U3@  :4X  %]/  !63P  35
M $52   _4P  .58  #-8   O6@@ *UL/ "I;%0 H7!T )UPD "9<*P E7#,
M)%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^ !U>CP <7J$ &UZT !I=S  ;
M7>D &USY !Q;_P <6_\ D%$  'Y1  !P40  9%(  %M2  !24P  2E0  $%7
M   [60  -5L  "Y>   H8 , )&(, ")C$0 A8Q@ 'V0@ !YD)P =9"X '&0V
M !ME/@ :94< &651 !AE70 796H %F5Z !5EBP 499X $V6Q !)ER  29.<
M$V/W !1B_P 48O\ B50  'A5  !K50  8%8  %=6  !/5P  1ED  #U<   V
M7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!, %FT: !5M(0 4;2D %&TP !-M
M.0 2;D( $6Y, !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS
M  UK_0 -:O\ @ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@
M*FD  "1L   =;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *
M=SP "7='  AW4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T
M]@ "=/P >UT  &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(
M !YU   7>0  $GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8
M ()   ""3   @ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@
M?OD =&(  &AB  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>
M   1@P  #88   B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY
M  ".1   CE$  (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8
M;F@  &1G  !8:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,
MCP  !I(   "5    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<
M.P  G$@  )Q7  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT
M %YO  !1<@  1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G
M *    "B    HP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0
MJSX  *Q-  "L70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y
M  !+?@  /X0  #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X
M  "P    L    +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,
M +U!  "]4@  O60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$
MBP  .)(  "R9   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_
M    OP   ,    #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U
M  #110  TE<  -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@
M,*(  "6H   :K@  $;0   FY    O0   ,$   #$    R    ,L   #-
MS0   ,\   #0    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G
M.   Z$H  .E=  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0
M /\ &@#_ "8 _P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4
M[@!Z .P ?P#K (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#;
M .8 V0#W -@ _P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\
M%0#^ "$ ^@ L /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U
M -X >@#= '\ VP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T
MR #Q ,< _P#& /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q
M !P [  G .D ,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P
M=0#* 'H R0!_ ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K
M +< ^P"V /\ M@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8
MVP A -4 +0#1 #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[
M '0 N0!Z +< @ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@
M]0"G /\ IP#_ *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP <
M ,( )@"_ #$ O  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\
MJ@!T *D >@"G ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9
M /T F #_ )@ _P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +,
M( "P "L K0 U *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N
M )L =0": 'L F "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@
MC #_ (P _P", /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D
M "0 H  N )X -P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\
M;P"- '8 BP!^ (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_
M '\ _P!_ /\ Z T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T
ME0 G )( ,0"0 #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"!
M W( @ 1Z 'X$A !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*
M_P!S"O\ W14  ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@
M (@)*@"%"C, @PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X
M=0UV '0-@ !R#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I
M$/\ T!T  +D>  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0
M) ![$"T >1 V '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S
M &D3?0!H$XD 9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\
MQR(  + C  "?)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q
M%B@ ;Q<P &X7. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9
M>0!?&H4 71N2 %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<
M *DH  "9*   BR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2,
M9QTL &4=,P!C'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6
M(8( 52&0 %0BG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L
M  "3+   ABT  'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G
M %TC+P!<(S8 6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\
M3B>- $THG !,**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".
M,   @3   '<O  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H
M*P!5*#( 4R@Y %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+
M $<MF@!&+:H 12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P
M?#,  '(S  !K,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.
M+2\ 32TV $PM/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$Q
MF !!,J@ 0#*[ #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38
M &XU  !F-0  83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P
M1S$R $8Q.0!$,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [
M-J< .S:Y #HVT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX
M  !C-P  738  %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O
M $ U-@ _-CT /C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4
M-CJX #4ZSP V.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?
M.@  63D  %,V  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ
M-  Z.CL .3M" #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV
M #$^S0 Q/NH ,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0
M53P  $XZ  !).P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U
M/S@ -#]  #- 2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"
MRP L0ND +$+Y "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\
M $D^  !$/P  0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8
M+T0] "Y%10 M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F
M1N< )T;X "A%_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"
M   _1   .T4  #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ
M "A*0@ G2DL )DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8
M(4OW ")*_P B2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \
M2   -TD  #)+   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0
M/P A4$@ (%!2 !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V
M !M/_P <3_\ BD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3
M,TX  "Y0   H4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :
M5T0 &5=. !A760 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15
M_P 45?\ A$D  '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0
M "E6   D60  'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D
M$5]* !%?50 07V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .
M7/\ ?DT  &Y.  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=
M   ?7P  &6(! !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%
M  IG4  )9UT !V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P
M=U$  &E2  !=4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   9
M9P  $VH   ]M!@ +< P "' 1  =P%@ %<!T !' D  -P+  "<#4  ' _  !P
M2@  <%<  '!E  !P=@  <(H  &^>  !OL@  ;L@  &WE  !M\@  ;?D <%8
M &-6  !95@  _^+__TE#0U]04D]&24Q%  0)45<  $=8   ^6P  -E\  "YB
M   F9@  'VH  !EM   3<   #G,   MV!  %> L  7@/  !Y$P  >1D  'D?
M  !Z)@  >B\  'HY  !Z1   >E   'I?  !Z<   >H,  'J8  !ZK   ><(
M 'C?  !X[P  =_< :EL  %];  !66P  3%P  $)@   Y8P  ,&@  "AL   @
M<   &70  !-W   .>P  "7X   2! @  @@@  (,-  "#$   A!0  (49  "&
M(   AB@  (<Q  "'/   ATD  (=7  "':   AWL  (>0  "&I0  A;H  (73
M  "$Z@  A/0 96   %Q@  !180  1F0  #QI   R;0  *7(  "%W   9>P
M$H    V#   (AP   HH   "-    C@0  (X)  "/#0  D!   )$4  "2&0
MDR   )0I  "5,P  E4   )9.  "67P  E7(  )6(  "5G0  E+(  )3(  "3
MX@  D^X 864  %9F  !*:@  /VX  #5T   K>0  (7\  !F$   1B0  #(T
M  :1    E    )@   ":    FP   )P"  "=!P  G@L  )\.  "A$@  HA@
M *,@  "E*0  IC8  *9$  "F50  IF@  *9]  "FE   I:D  *2]  "DT0
MI.0 6VP  $]P  !#=0  .'L  "V!   CAP  &8T  !&2   +EP  !)P   "@
M    HP   *8   "H    J0   *H   "L    K00  *X)  "P#0  L1$  +,7
M  "U(   MBL  +<Z  "W2P  N%P  +AQ  "XB   N)T  +BQ  "WP@  M]
M5'8  $A\   \@@  ,8D  ":0   ;EP  $IT   RB   #IP   *L   "N
ML@   +8   "X    N    +H   "[    O0   +X   # !0  P0L  ,,0  #&
M%@  R2   ,HN  #+/@  S%   ,QD  #->@  S9$  ,VD  #-M   S<  38,
M $&*   UD0  *9D  !Z@   3I@  #*P   .Q    M@   +H   "^    P@
M ,8   #(    R    ,H   #+    S0   ,X   #0    T@$  -4(  #9#@
MW14  .$A  #B,0  Y$,  .56  #F:P  YH(  .>6  #GI0  YK  _P ) /\
M!0#_  8 _P . /\ %@#_ "$ _P M /\ . #] $, ^0!- /4 50#R %T \ !C
M .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0 BP#C )$ X0"9 -\ H0#< *H
MV@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_ ,\ _P#* /\ _P ! /\   #_
M  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X [ !( .@ 4 #E %@ X@!> -\
M9 #= &H VP!O -D = #6 'H U !_ -( A0#0 (P S@"3 ,P G #) *4 QP"P
M ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\ _P"^ /\ _P   /\   #_
M^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!" -4 2P#1 %( S@!9 ,L 7P#)
M &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8 O0". +L E@"Y *  MP"J +8
MMP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P /\ _P   /\   #W    Z@ "
M .$ # #7 !, T  = ,P * #) #( Q@ \ ,( 10"_ $T O !3 +H 60"X %\
MMP!D +4 :0"T &X L@!T +$ >@"O (  K0"( *P D0"J )H J "E *8 L0"D
M ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\ _P   /<   #H    V0   ,L
M" ## !  O0 8 +D (@"V "P M  V +( /P"O $< K !- *L 5 "I %D IP!>
M *8 8P"E &@ HP!N *( = "@ 'H G@"" )P BP"; )4 F0"? )@ K "6 +H
ME #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P   .<   #3    Q@   +L  @"S
M  P K0 2 *H ' "G "8 I  P *, . "@ $  G@!' )P 3@": %, F0!8 )<
M70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"- (\ BP": (H IP"( +4 A@#'
M (4 Y "$ /4 A #_ (, _P"# /\ [    -,   #! 0  M    *P   "F  <
MH  . )T %@": "  EP I )4 ,@"3 #H D0!! (\ 2 "- $T C !3 (L 6 ")
M %T B !C (< :0"% &\ @P!W (( @ "  (H ?@"6 'T HP![ +  >@#" 'D
MW0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R#   I@L  )T(  "9!   E0 *
M )$ $0". !D BP C (D + "' #0 A0 [ (, 0@"" $@ @ !. '\ 4P!] %@
M? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2 '$ GP!P *T ;@"^ &T!U@!M
M NT ; /Z &P#_P!L _\ SA   +<1  "F$@  FA$  )$0  "+#@  B0L# (<%
M# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W!$, =05( '0%3@!S!50 <059
M ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)G0!E":P 9 F\ &,*U !C"^P
M8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@  (<6  "!%   ?1$  'P.!@!\
M"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X ; Q$ &L-2@!I#4\ : U5 &<-
M7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<$*L 6Q"] %H0U@!9$?  61']
M %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=  !X&P  =!@  '$5  !Q$0D
M;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_ &(110!@$DL 7Q)1 %T26 !<
M$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D 4A:Z %$6T@!1%^T 41?] %$7
M_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P(0  ;!X  &D;  !G& 0 9A4.
M &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D700!8&$< 5AA- %485 !3&%P
M4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX $H=SP!)'>L 21W[ $D=_P!*
M'?\ K"0  )@E  "()@  >R<  '$F  !J)0  9B,  &(A  !@'@  7AP+ %L;
M$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0'4, 3QU* $T>40!,'E@ 2Q]A
M $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,BS !#(^D 0R/Z $,C_P!#(O\
MIB<  ),I  "#*@  =BH  &TJ  !E*0  8"<  %PE  !9(P  5R$' %4A#P!2
M(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D  2")& $<C30!%(U4 1"1> $,D
M:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]*.@ /2CY #TG_P ^)_\ HBH
M (XK  !_+0  <BT  &@M  !A+   7"L  %@H  !4)@  428$ $XE#0!,)1,
M2B8: $@F(@!')BD 128O $0F-@!#)SP 02=# $ G2P _*%, /BE< #TI9@ \
M*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8 ."SX #@L_P X+/\ G2P  (HN
M  ![+P  ;S   &4P  !=+P  6"X  %,K  !0*@  3"H  $DJ"P!&*A$ 1"H7
M $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL2  Z+%  .2U9 #@N9  W+G
M-B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W #,P_P T+_\ F2\  (<Q  !W
M,@  :S(  &(R  !:,@  5#$  $\O  !++0  1RX  $0N" !!+@X /RX4 #TN
M'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U,4X -#%7 #,R8@ R,FX ,3-]
M # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S_P O,_\ E3$  (,S  !T-
M:#4  %XU  !7-   430  $LR  !&,0  0C(  #\R!0 \,@T .3,2 #@S&0 V
M,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P +S95 "XV8  M-VP +#=[ "LW
MBP J.)P *3BN "@XPP H..( *3CU "HW_P J-_\ DC0  '\U  !Q-@  93<
M %LW  !4-P  338  $<V  !"-0  /38  #HV @ W-PL -#<0 #(W%@ Q.!T
M+S@D "XX*P M.3( +#DY "LY00 J.DD *CI3 "D[7@ H.VH )SMY "8\B0 E
M/)L )#RM ",\P@ C/.  )#ST "4[_P E._\ C38  'PX  !M.0  8CD  %@Z
M  !1.0  2CD  $0Y   ].0  .3H  #4[   R.P@ +SP. "T]%  L/1H *CTA
M "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "- 6P B0&@ (4!V "! AP ?09D
M'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D  '@Z  !I.P  7CP  %4\  !-
M/   1SP  $ \   X/0  -#X  #!    M004 *D(, "="$0 F0Q@ )$,> "-#
M)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <164 &T5T !I%A0 91I< &4:I
M !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]  !F/@  6S\  %(_  !*/P
M1#\  #U    V00  ,4,  "Q$   G1@$ )$<* "%(#P @210 'DD; !U)(@ <
M22D &THP !I*.  92D$ &$I+ !=+50 62V( %4MQ !1+@@ 32Y0 $DNG !)+
MO  12]D $DKP !-*_  42?\ ?S\  &]   !A00  5T(  $Y"  !'0@  04(
M #I#   R10  +4<  "A)   C2P  'DT& !M/#0 84!$ %U 7 !90'@ 54"4
M%% L !-1-  243T $5%' !%14@ 045\ #U)M  Y2?@ -49$ #5&D  Q1N  ,
M4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1   4T4  $M%  !$10  /D8  #9(
M   O2@  *4P  "1/   ?40  &E,  !16"0 15PX $%@3 !!8&0 /6"  #E@H
M  U8,  -6#D #%A#  M83@ *6%H "%AH  =8>0 &6(P !5B?  18LP $5\H
M!5?F  57\P &5OP <T8  &1'  !92   4$@  $A(  !!20  .DH  #)-   K
M4   )5(  "!5   :6   %5H  !!=!@ ,8 P "F 0  E@%0 (8!P !V C  5@
M*P $8#0  V ]  %@20  8%4  &!C  !@<P  8(8  %^:  !?K@  7\0  %[B
M  !>\   7O@ ;$H  %]+  !52P  3$P  $5,   ]3@  -5   "Y3   G5@
M(%D  !I<   57P  $&(   UE!  (9PL  V<.  !H$P  :!@  &@?  !I)@
M:2X  &DX  !I0P  :4\  &E=  !I;0  :8   &F4  !HJ0  :+\  &?<  !F
M[@  9O< 9D\  %I/  !13P  2D\  $%1   X5   ,%<  "A;   A7@  &F(
M !1E   0:   #&L   =N P !< D  ' -  !Q$   <10  '(:  !S(0  <R@
M ',Q  !S/   =$@  '-6  !S9@  <WD  '..  !SHP  <KD  ''2  !QZP
M</0 85,  %93  !/4P  154  #M8   R7   *F   ")D   ;:   %&P   ]O
M   +<@  !G8   !Y    >@8  'H*  ![#@  ?!$  'T5  !^&P  ?R(  ( J
M  " -0  @$$  (!/  " 7P  @'$  ("&  " G0  ?[(  '[*  !^Y0  ??$
M7%@  %18  !)6@  /UT  #5A   L90  (VH  !MO   4<P  #G<   E[   #
M?P   ((   "$    A@$  (8&  "("@  B0T  (H0  "+%0  C!L  (XB  "/
M+   CS@  (]&  "/5@  CV@  (]^  "/E0  CJL  (W!  "-W   C.L 65T
M $Y?  !#8@  .&8  "YL   D<0  ''<  !1\   .@0  "(4   ")    C0
M )    "2    DP   )0   "6 P  EP@  )@,  ":#P  FQ,  )T:  "?(P
MH"X  * \  "@3   H%X  *!T  "?C   GZ(  )^W  ">RP  GN  4V0  $=H
M   \;0  ,7,  "=Y   =?P  %(4   V+   &D    )0   "8    G    )\
M  "A    H@   *0   "E    IP   *@$  "J"0  K T  *T2  "P&0  LB,
M +(Q  "R0@  LE0  +)I  "R@   LI@  +&L  "ROP  L<X 3&X  $!S   U
M>@  *H$  !^(   5C@  #I4   ::    GP   *0   "H    K    *\   "Q
M    L0   +,   "U    M@   +@   "Z    O 8  +X,  # $0  PQD  ,4F
M  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(KP  R+P 1GH  #F!   NB0
M(I   !>8   /GP  !Z4   "J    KP   +,   "W    O    +\   #!
MP@   ,0   #%    QP   ,D   #+    S0   ,\#  #2"@  UA   -P:  #=
M*@  WCP  -]0  #@90  X7L  .&1  #BH@  XJT _P " /\   #_  , _P ,
M /\ $P#_ !T _P H /X ,P#[ #X ]P!( /, 4 #P %< [0!> .L 9 #H &D
MYP!O .4 = #C 'D X@!_ .  A0#> (P W "3 -D G #6 *8 TP"Q -$ P #/
M -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\ _P   /\   #_    _P ( /L
M$ #V !D \@ D .\ +@#M #D Z !" ., 2P#@ %( W0!9 -D 7P#6 &0 TP!I
M -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8 E@#$ *  P@"K ,  N0"^ ,T
MO #J +L _ "Z /\ N@#_ +H _P"V /\ _P   /\   #^    ]  $ .L #0#D
M !0 WP ? -L *0#8 #, TP ] ,X 10#* $T QP!3 ,4 60## %\ P0!D +\
M:0"] &X NP!S +H >0"X (  M@"( +0 D "R )H L0"E *\ L@"M ,0 K #A
M *L ]@"J /\ J@#_ *H _P"J /\ _P   /T   #N    X@   -4 "@#- !$
MQP 9 ,0 (P#! "T OP W +L /P"W $< M0!. +( 4P"P %D KP!> *T 8P"L
M &@ JP!M *D <P"H 'H I@"! *0 B@"C )0 H0"? )\ K "> +L G #2 )L
M[@": /\ F@#_ )D _P"9 /\ _@   .X   #>    RP   ,$ !0"Y  T M  4
M +$ '@"N "< JP P *H .0"G $$ I !( *( 30"A %, GP!8 )X 70"= &(
MFP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9 )  I@". +0 C0#( (P Y@"+
M /D B@#_ (H _P"+ /\ \    -L   #'    N@   +    "H  H I  0 *
M& "= "$ FP J )H ,P"8 #L E@!! )0 2 "2 $T D0!2 (\ 5P". %P C !A
M (L 9P"* &X B !U (< ?@"% (@ @P"4 (( H "  *\ ?P#  'X W0!] /(
M?0#_ 'T _P!] /\ X    ,8   "U    J@   *(   ";  4 E0 - )( $P"0
M !P C0 D (L +0"* #0 B  [ (8 0@"% $< @P!- (( 4@"! %< ?P!< 'X
M8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T *H <@"Z '$ T0!P .P < #[
M '  _P!P /\ S00  +<&  "G!P  FP8  ),$  ".    B@ ( (8 #P"$ !8
M@0 > '\ )P!] "X ?  V 'H / !Y $( =P!' '8 3 !U %( <P!7 '( 70!Q
M &, ;P!K &X = !L 'X :P"* &D F !H *8 9P"V &8 RP!E .< 90#W &4
M_P!E /\ P P  *L-  ";#@  CPX  (8-  "!"P  ?@<! 'P!"P!Y !$ =P 8
M '4 (0!S "D <0 P &\ -@!N #P ; !" &L 1P!J $T :0!2 &@ 6 !F %\
M90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S %P#QP!;!.0 6P7T %L&_@!;
M!O\ M1   *$2  "1$P  A1,  'P2  !V$0  <PX  '(,! !Q!PT ;@02 &P$
M&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A!TD 7P=. %X(50!="%P 6PEC
M %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,QP!2#.0 40WU %$-_P!1#?\
MK14  )D7  ")&   ?1D  '08  !M%P  :A0  &<1  !G#@< 9@P. &,,%0!A
M#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44 5PU+ %8.40!5#ED 4PYA %(.
M:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)$>4 21'W $D2_P!)$?\ I1D
M )(<  "#'0  =AX  &T=  !F'   8AH  %\7  !>% $ 7A$* %L0$0!9$1@
M5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)' $X23@!,$E4 2Q-> $D39P!(
M%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^, 0A?V $(7_P!"%_\ GQT  (P@
M  !](0  <2(  &@B  !A(0  7!\  %D<  !7&0  518& %05#@!1%10 3Q8<
M $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $872@!%&%( 0QA: $(99 !!&7
M/QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU #L<_P \'/\ FB$  (<C  !X
M)   ;"4  &,E  !<)   5R,  %,@  !1'@  3QP" $T;# !+&A$ 2!L8 $<;
M( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^'4\ /1Y8 #P>8@ Z'VT .1][
M #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A_P V(?\ EB,  (,F  !T)P
M:"@  %\H  !8)P  4R8  $\D  !,(@  22   $<@"0!$'P\ 0A\5 $ @'  _
M(", /B I #P@+P [(38 .B$] #DA1  X(DP -R)5 #8C7P T(VL ,R1Y #(E
MB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q)?\ D28  '\H  !Q*@  92H
M %PJ  !5*@  3RD  $LH  !()0  1"0  $$D!0 _) T /202 #LD&0 Y)!\
M-R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3 # G70 O*&D +BEW "TIAP L
M*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\ C2@  'PJ  !M+   8BT  %DM
M  !1+0  3"P  $<K  !#*   /R@  #PH @ Y* L -R@0 #4H%@ S*!P ,B@C
M # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL6P J+&< *2UU "@MA0 G+9<
M)BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL  '@M  !J+@  7R\  %8O  !.
M+P  2"X  $,M   _+   .RP  #<L   T+ D ,BP. # M$P N+1H +2T@ "LM
M)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E,64 )#%S ",Q@P B,I4 (3*G
M "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O  !G,   7#$  %,Q  !+,0
M13$  $ P   [,   -C   #,P   P,08 +3$- "LQ$0 I,A< *#(> "<R)  E
M,RL )3,R "0S.@ C-$, (C1, "$U5P @-6, 'S5Q !XV@0 =-I, '#:E !LV
MN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C,P  630  % T  !)-   0C,
M #TS   W,P  ,30  "XU   K-0( *#8+ "4W$  D-Q4 (C<; "$X(@ @."@
M'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN !@Z?P 7.Y$ %SND !8[MP 5
M.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0  538  $TV  !&-@  0#8  #HV
M   T-@  +C@  "HY   F.@  (SL( " \#@ >/1( '3T8 !P]'P ;/B4 &CXM
M !D^-  7/CT %C]' !4_40 4/UX %#]L !- ?  20(\ $4"B !% M@ 00,X
M$3_K !(_^0 2/O\ >34  &DW  !<.   4CD  $HY  !#.0  /3D  #<Y   Q
M.@  *SP  "<]   B/P  'D$$ !I""P 80Q  %T,5 !5$&P 41"( $T0I !-$
M,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -18P #46?  Q%L@ +1<D #$7E
M  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\  ! /   .CP  #0\   N/@
M*$   "-"   ?1   &D8  !5("  22@T $4H2 !!*&  /2QX #DLE  U++0 -
M2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X< !4N:  1+K@ $2L0 !4K@  5*
M\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]/@  -S\  #%    J0@  )$4
M !]'   :20  %4P  !%.!0 .40L "U$0  I1%  )41L "%$B  =1*0 %43(
M!%([  -21@ !4E(  %)?  !2;P  4H$  %&6  !1J0  4;\  %#<  !0[@
M4/< :$   %M!  !000  2$$  $%!   [0@  -$,  "U%   F2   ($L  !M-
M   64   $5,   Y5!  *6 H !E@.  )8$@  61<  %D=  !9)0  62T  %DV
M  !900  64T  %I:  !::0  67P  %F0  !9I0  6+H  %C5  !7[   5_8
M8T0  %9%  !-10  144  #]%   W1P  +TD  "A,   B3P  &U(  !95   1
M6   #5H   E= P $7PD  & -  !@$   810  &$9  !B(   8B<  &(Q  !B
M.P  8D<  &)5  !C9   8G8  &*+  !BH   8;8  &'/  !@Z@  8/4 74@
M %))  !*2   0T@  #I*   R30  *E   "-3   <5P  %EH  !%=   -8
M"&,   -F 0  9P8  &@+  !I#@  :A$  &L5  !L&P  ;2(  &TJ  !M-
M;4   &U.  !M70  ;6\  &V$  !LF@  ;+   &O(  !KY@  :O, 6$T  $Y-
M  !(3   /DX  #51   L5   )%@  !U<   68   $&0   QG   ':P   6X
M  !P    <@,  '('  !S"P  =0X  '81  !W%@  >!P  'DC  !Z+0  >CD
M 'I'  !Z5@  >6@  'I\  !YE   >*H  'C!  !WWP  =^\ 5%$  $Q1  !"
M4@  .%4  "]9   F7@  'F(  !9G   0:P  "V\   5S    =P   'H   !\
M    ?@   '\"  " !@  @0H  (,-  "$$0  AA4  (@<  "))0  BC   (H^
M  ")30  B5\  (ES  "(BP  B*(  (>Y  "'T0  AN@ 4E8  $=7   \6@
M,E\  "AD   ?:0  %F\  !!T   *>0   GT   "!    A0   (@   "*
MC    (T   "/    D 0  )((  "3#   E1   )<5  "9'0  FR<  )LT  ";
M1   FE8  )IJ  "9@@  FIH  )BP  "8QP  E]X 2UP  $!@   U90  *VH
M "%Q   7=P  $'T   F#   !B    (P   "1    E0   )@   ":    FP
M )T   "?    H    *(   "D!0  I@H  *@.  "J%   K1T  *TJ  "M.0
MK4L  *U?  "M=P  K)   *NG  "KN@  J\L 168  #EK   N<0  (W@  !E_
M   0A@  "8T   "3    F    )T   "A    I0   *@   "K    JP   *X
M  "O    L0   +,   "U    MP$  +D'  "\#0  OQ,  ,(?  #"+@  PD
M ,)4  #!:P  P8,  ,";  #!K0  P;P /G(  #)X   G@   '(@  !*0   *
MEP   )T   "C    J    *T   "R    M@   +D   "[    O    +X   #
M    P@   ,0   #&    R    ,L   #.!0  T0T  -84  #7(P  V#4  -E)
M  #:7@  VW4  -N,  #<GP  W*L _P   /\   #_    _P ) /\ $ #_ !D
M_@ D /P +P#Y #D ] !# /  2P#M %( Z@!9 .< 7P#D &0 X@!I .  ;@#>
M ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$ S "L ,H NP#( -( Q@#N ,8
M_P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_    _@ % /< #@#R !4 [@ ?
M .L *@#I #0 XP ] -X 10#9 $T U !3 -$ 60#. %X S !C ,H : #) &T
MQP!S ,4 >0## (  P0"( +\ D "] )L NP"F +D M "W ,@ M@#F +4 ^P"T
M /\ M #_ +, _P"N /\ _P   /\   #X    [0   .4 "P#= !$ UP : -(
M) #/ "X RP W ,< 0 ## $< P !. +X 4P"\ %D N@!> +@ 8P"V &@ M0!M
M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@ K0"F +X I0#; *0 ] "D /\
MHP#_ *, _P"B /\ _P   /8   #F    UP   ,L !@#$  X O@ 5 +L 'P"Y
M "@ MP Q +0 .@"P $$ K0!( *L 3@"I %, IP!8 *8 7 "D &$ HP!G *$
M; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6 +8 E0#, )0 ZP"3 /T DP#_
M ), _P"3 /\ ]P   .0   #0    P0   +<  @"O  L JP 1 *< &0"E "(
MHP K *( ,P"? #L G !" )L 2 "9 $T EP!2 )8 5P"5 %L DP!A )( 9@"0
M &T CP!T (T ?0", (< B@"3 (@ H "' *\ A0#" (4 X@"$ /< A #_ (0
M_P"$ /\ Y0   ,T   "\    KP   *8   ">  < F@ . )8 % "4 !T D@ E
M )$ +0"0 #4 C0 \ (P 0@"* $< B !, (< 40"& %8 A !; (, 8 "! &<
M@ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z '8 TP!V .\ =@#^ '4 _P!U
M /\ T    +L   "K    GP   )<   "0  ( BP + (@ $ "& !< A  @ ((
M)P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X %  =P!5 '8 6P!T &$ <P!I
M '$ <0!P 'L ;@"' &T E0!K *, :@"T &H R0!I .@ :0#Y &D _P!I /\
MP    *P   "< @  D (  (@   "#    ?P & 'L #0!Y !( =P : '8 (@!T
M "D <P P '$ -@!P #P ;P!! &T 1@!L $L :P!0 &H 5@!H %P 9P!D &4
M; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!> .$ 7@#T %T _P!= /\ M <
M * )  "0"P  A L  'P*  !W!P  = 0  '$ "0!O  \ ;0 5 &L ' !I ",
M:  J &< ,0!E #8 9  \ &, 00!B $8 8 !, %\ 4@!> %@ 70!? %L : !:
M '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H 4P#O %0 ^P!4 /\ J0T  )8.
M  "'$   >A   '(0  !L#@  :0P  &<) P!F! L 9  0 &( %P!@ !X 7@ E
M %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!3@!5 E0 4P)< %(#90!1 V\
M3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M $H'^0!*!_\ H1   (X2  !^
M%   <Q0  &H4  !D$P  8!$  %X/  !=#04 70D- %H&$@!8!QD 5@<@ %4'
M)P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,"5$ 2PI9 $H*8@!("VT 1PMZ
M $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-^P!"#?\ FA0  (<6  !X&
M;!D  &,9  !=&   618  %83  !4$0  5 X( %,-#@!1#10 3PT; $T-(@!,
M#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\ 1 Y7 $(/80!!$&P /Q!Y #X0
MB  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [$?\ DQ@  ($:  !S'   9QT
M %X=  !8'   4QL  % 8  !.%@  3!,# $P1"P!*$!  2!$7 $81'@!%$20
M1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4 #L37@ Y%&D .!1V #<5A0 V
M%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\ CAL  'P=  !N'P  8R   %H@
M  !3(   3AX  $H=  !(&@  1A@  $46!P!#%0X 0143 #\5&@ ^%2  /14G
M #L5+0 Z%C, .18Z #@600 W%TD -1=1 #086P S&68 ,AES # :@P O&I0
M+ANE "T;N  M&]  +1OL "X;^P N&_\ BAX  '@@  !J(@  7R,  %8C  !/
M(@  2B$  $8@  !#'@  01L  #\: P ]&@P .QD1 #D9%@ W&AT -AHC #4:
M*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M'60 +!YQ "L?@0 J'Y( *1^D
M "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C  !G)   7"4  %,E  !,)0
M1R0  $(C   _(0  /1\  #H>   W'@D -1X. #,>$P Q'AH ,!X@ "\>)@ N
M'RT +1\S "P@.P K($, *B%, "DA5@ H(F( )B)O "4C?P D(Y  (R.B "(D
MM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C)@  62<  % H  !))P  0R<
M #\F   [)   ."(  #4B   R(@8 ,"(- "XB$0 L(A< *B(= "DB(P H(RH
M)R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M " G?0 ?)X\ 'BBA !XHM  =
M*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0  5BD  $TJ  !&*@  02D  #PH
M   W)P  -"8  # F   M)@, *R<+ "@G$  G)Q0 )2<: "0G(0 C*"< (B@N
M "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK>P :+(T &2R? !@LL@ 8+,D
M&"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP  $HL  !#+   /BL  #DK   T
M*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!( ("P8 !\L'@ >+24 '2TL !PM
M,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5,(L %#"> !0PL0 3,,< $S#E
M !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N  !!+@  .RX  #8M   Q+0
M+"T  "<O   D+P  (3 % !\Q#  <,1  &S(5 !HR'  9,B( &#(I !<S,0 6
M,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D $#6< ! UL  .-<8 #S3D ! T
M]0 0-/\ <BP  &,N  !7,   33   $4P   ^,   .#   #,P   O,   *3$
M "0R   A,P  '34" !HV"0 7-PX %3<3 !0X&0 3.!\ $C@F !(X+@ 1.38
M$#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9  LYK  *.<$ "CG>  LY\0 ,
M./P ;B\  %\Q  !3,@  2C,  $(S   [,P  -C,  #$R   L,P  )S0  "$V
M   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 ./AP #CXC  T^*@ ,/C, ##X\
M  L_1P */U( "#]@  <_;P &/X$ !3^4  0_J  #/KP !#[7  4^[  %/O<
M:3,  %LT  !0-0  1S4  #\U   Y-0  -#4  "XU   I-P  (S@  !X[   :
M/   %C\  !)!!  .0PH #$0.  I$$P )1!D "$0@  =$)P &1"\ !40X  -%
M0@ "14X  $5;  !%:@  17P  $60  !$I   1+D  $31  !$Z@  0_4 9#8
M %<W  !,.   0S@  #PX   W.   ,3@  "LY   E.P  (#T  !I    60@
M$D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<  !+(P  2RL  $LT  !+/@
M3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4  $K.  !*Z0  2O4 7SH  %([
M  !(.P  0#L  #H[   T.P  +CP  "<^   B00  '$,  !9&   220  #DL
M  M. P '4 @  E$,  !1$   4A,  %,8  !3'P  4R8  %,O  !3.0  4T4
M %-2  !380  4W(  %.'  !2G   4K$  %'*  !1YP  4?0 63X  $X^  !%
M/@  /CX  #@^   P0   *4(  "-$   =1P  %TH  !)-   .4   "U,   95
M @  5P<  %@+  !9#@  6A$  %H5  !;&@  7"$  %PJ  !<-   7#\  %Q-
M  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:Y   6?, 5$(  $I"  !"0@
M/$(  #1#   L1@  )4D  !Y,   73P  $E,   Y6   *60  !5L   !>
M8 0  &$(  !B#   8PX  &01  !E%@  9AP  &<C  !G+0  9SD  &=&  !G
M50  9V8  &=Z  !FD0  9:@  &7   !DW@  9/  3T8  $=&  ! 10  -T<
M "]*   F30  'U$  !A5   260  #5P   A@   "8P   &8   !H    :@
M &L$  !L"   ;0P  &\.  !P$@  <A<  ',=  !T)@  =#(  '0_  !T3@
M<U\  '1R  !SB@  <J$  '&X  !QU   <.P 3$H  $5*   [2P  ,DX  "E2
M   @5@  &%L  !)?   -9   !V@   !K    ;P   '(   !U    =@   '<
M  !Y @  >@8  'P*  !^#@  @!$  ((6  "$'@  A"D  (0V  "$10  A%8
M (-J  "#@0  @ID  (&Q  " R0  @.4 2DX  #]0   U4P  *U<  ")<   9
M8@  $F<   QL   %<0   '4   !Y    ?0   ($   "#    A0   (8   "(
M    B0   (L$  "-"   CPT  )(0  "4%@  EB   )8L  "6.P  EDP  )5@
M  "5=@  E)   ).G  "2O0  DM4 1%4  #E9   O70  )&,  !II   2;P
M#'4   1[    @    (4   ")    C0   )$   "3    E    )8   "8
MF@   )P   ">    H 8  *(+  "E$   J!<  *DC  "I,0  J4,  *E6  "H
M;0  IH<  *>>  "FLP  I<< /EX  #)C   G:@  '7   !-X   ,?P   X4
M  "+    D0   )8   ";    GP   *(   "D    I0   *<   "I    JP
M *T   "P    L@   +4"  "W"0  NQ   +X8  "^)@  OC@  +Y+  "]80
MO'H  +N4  "ZJ0  NKD -VH  "MP   @>   %H    V(   %CP   )8   "<
M    H@   *<   "L    L    +,   "V    MP   +D   "[    O0   +\
M  #"    Q0   ,@   #*    S@@  -(0  #5&P  U2P  -1   #45P  TVX
M -2&  #4FP  TZL _P   /\   #_    _P % /\ #@#_ !4 _  @ /D *@#V
M #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X W@!C -P : #9 &X U0!S -,
M>0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#" ,P P #L +\ _P"^ /\ O0#_
M +< _P"R /\ _P   /\   #_    ^@ ! /, "P#M !( Z  ; .4 )0#D "X
MWP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!> ,0 8P#" &< P !M +\ <P"]
M 'H NP"! +D BP"V )4 M "A +( KP"P ,( K@#C *X ^@"L /\ K0#_ *D
M_P"F /\ _P   /\   #R    Y@   -T !P#2  X S0 6 ,H ( #( "D Q0 R
M ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$ 70"P &( K@!G *P ; "J ',
MJ0![ *< A "E (X HP": *$ J "? +D G@#2 )T \@"< /\ G0#_ )P _P"9
M /\ _    .X   #=    S    ,$  @"Z  P M@ 2 +( &@"P ", KP L *T
M- "I #P I@!" *0 2 "B $T H !2 )X 5P"= %L G !@ )H 9@"9 &P EP!T
M )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P Z "+ /T C #_ (P _P", /\
M[0   -@   #%    MP   *P   "F  @ H0 . )\ %0"= !X FP F )H +@"7
M #4 E0 \ ), 0@"1 $< D !, (X 40"- %4 BP!: (H 8 ") &8 AP!M (4
M=@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\ /4 ? #_ 'P _P!\ /\ V0
M ,$   "Q    I    )P   "4  , D  , (T $0"+ !@ B0 @ (D * "' "\
MA0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4 'L 6@!Y &  > !G '8 < !U
M 'H <P"& '$ DP!P *( ;P"T &X S !N .T ;@#^ &X _P!N /\ Q    *\
M  "@    E    (P   "&    @0 ( 'X #@!\ !0 >P ; 'D (@!X "D =P P
M '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T 5 !L %L :P!B &D :@!H '0
M9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X &$ _P!A /\ M    *    "1
M    A@   'X   !Y    =0 # '$ "P!O !  ;0 6 &P '0!K "0 :P J &D
M, !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@ %8 7P!= %T 90!< &\ 6@!Z
M %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8 _P!6 /\ J $  )0%  "%!P
M>@<  '(&  !L!   :0$  &< !P!D  T 8P 1 &$ & !@ !\ 7P E %X *P!=
M #  6P V %H .P!9 $  6 !% %< 2P!6 %$ 50!8 %, 80!2 &H 4 !V $\
MA !. ), 30"D $P M@!, ,T 3 #K $P ^@!, /\ G0D  (L+  !\#0  < T
M &@-  !B#   7PH  %T& 0!< 0D 6@ . %@ $P!7 !D 5@ @ %4 )@!3 "L
M4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5 $H 70!) &< 1P!S $8 @ !%
M )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\ E0T  (,/  !T$   :1$  & 1
M  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/ 14 3@$; $P!(0!+ 2< 2@(L
M $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($6@! !60 /P5P #X&?@ ]!HX
M/ >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA   'P2  !N%   8A4  %H5  !4
M%   4!,  $T1  !+#@  2PT& $H*# !)"!$ 1P@6 $4('0!$"", 0@@H $$)
M+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y"V, . QO #8,?@ U#(X - V?
M #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5  !I%P  7A@  %48  !/&
M2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2 #\-&  ]#1\ / TD #L-*@ Y
M#3  . XW #<./0 V#D4 -0Y- #,/5P R#V( ,1!N "\0?0 N$(X +1&@ "P1
ML@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D&@  61L  %$;  !+&P  1AH
M $(8   _%P  /A0  #P2!  [$0H .A 0 #@0%0 W$!L -1$A #01)P S$2T
M,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L "D4>P H%(P )Q6> "85L  E
M%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0  5AX  $T>  !''@  0AT  #X<
M   Z&@  .!@  #<6   U%0< -!0- #(4$@ P%!< +Q0= "T4(P L%2H *Q4P
M "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9>0 B&8H (1F< " 9KP ?&<0
M'QGB " 9]  @&?\ >AL  &H>  !='P  4R   $H@  !$(   /A\  #H>   W
M'0  -!P  #(9   P&00 +A@+ "P8$  J&!0 *1@: "<8(  F&28 )1DM "0:
M-0 C&CT (AM& "$;4  @'%L 'QUH !X==P ='8@ '!Z; !L>K0 :'L, &A[@
M !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B  !!(@  .R(  #<A   S(
M,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7 "$='0 A'20 (!XJ !\>,@ >
M'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H< %R*9 !8BK  5(L$ %2+? !4A
M\@ 6(?X <R   &0B  !7(P  320  $4E   ^)   .20  #0C   P(@  +"(
M "DA   F(0  )"$& "(A#  @(1  'B$5 !TB&P ;(B$ &R(H !HC+P 9(S@
M&"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8 !$FJP 1)L  $";= !$E\0 2
M)?T <"(  &$D  !4)@  2B8  $(G   \)@  -B8  #$E   M)0  *20  "8D
M   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7)Q\ %B<E !4H+0 4*#4 $RD^
M !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJJ0 -*KT #2K7  TJ[@ .*?L
M;"0  %TF  !1*   2"@  $ I   Y*   -"@  "\H   K)P  )R<  "(H   >
M*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P $2TC ! M*@ 0+3( #RX\  XN
M1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )+KD ""[0  DNZ0 *+O< :"<
M %HI  !.*@  12L  #TK   W*P  ,2H  "TJ   I*@  )"H  " K   ;+0
M&"X  !4O!  2,0H $#(.  \R$P .,AD #3(@  TR)P ,,B\ "S,X  HS0@ )
M,TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8  C/-  ,SYP $,O, 9"H  %8L
M  !++0  0BT  #HM   T+0  +RP  "LL   F+   (BT  !TO   9,0  %3(
M !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X)  &."P !#@T  ,X/@ ".4H
M #E7   Y90  .7<  #F+   XGP  .+,  #C*   XY@  -_( 7RT  %(N  !(
M+P  /S   #@O   R+P  +2\  "DO   D,   'S$  !HS   5-0  $C<   \Y
M P ,.P@ "#T-  4^$  #/A0  #X:   ^(0  /B@  #XQ   _.P  /T8  #]3
M   _80  /W,  #^'   ^G   /K   #W'   ]Y   /?( 6C   $XR  !$,@
M/#(  #4R   P,0  *S$  "8R   @-   &S8  !8X   2.P  #ST   P_ P (
M00@ !$,,  !##@  1!(  $46  !%'0  120  $4M  !&-@  1D(  $9.  !&
M70  1FX  $6"  !%F   1*T  $3$  !#XP  0_( 530  $HU  !!-0  .34
M #,T   N-   *#4  "(W   =.@  %SP  !(_   /00  #$0   A& 0 #2 8
M $D*  !*#0  2Q   $P4  !-&0  3B   $XH  !.,@  33T  $Y*  !.6
M36D  $U]  !,E   3*H  $O!  !+X0  2O( 4#@  $8X   ].   -S@  #$W
M   J.0  )#L  !X]   80   $T,   ]&   +20  !TL   ).    4 0  %$(
M  !2"P  4PX  %01  !5%0  5AL  %<C  !7+   5S@  %=$  !74@  5F,
M %9W  !6C@  5:4  %2]  !3W0  4_  2SP  $(\   [.P  -3L  "T\   F
M/P  'T(  !E%   32   #DL   M/   %40   %0   !7    6 $  %H%  !;
M"   7 P  %T.  !?$0  8!8  &(=  !B)@  8C$  &(^  !A3   85T  &%P
M  !@B   8*   %^W  !>U   7>X 1T   #\_   Z/P  ,4   "E#   A1@
M&DH  !-.   .40  "E4   18    6P   %X   !A    8P   &0!  !E!
M9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH  &\V  !N10  ;E4  &YH  !M
M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U1   *T<  "-+   ;3P  $U0
M  Y8   (7    F    !D    9P   &L   !M    ;P   '    !R    = (
M '4&  !W"@  >0X  'P2  !^&   ?R(  '\N  !_/0  ?DT  'UA  !]=P
M?)   'NH  !ZP   >=\ 0T<  #E)   O3   )5   !Q5   46P  #F    =E
M    :@   &X   !R    =@   'D   !\    ?@   '\   "!    @P   (4
M  "' P  B@@  (P-  "/$0  DAD  )(E  "2,P  DD0  )%7  "0;0  CX8
M (Z?  "-M0  C,T /4X  #)1   H5@  'EP  !5B   .:   !VX   !T
M>0   'X   ""    A@   (D   ",    C@   )    "2    E    )8   "8
M    FP   )X&  "A#   I!$  *8;  "F*0  ICH  *5-  "E8@  I'L  *.4
M  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P   '=P   'X   "$    B@
M (\   "4    F    )L   ">    GP   *(   "D    I@   *@   "K
MK0   +    "S!   MPP  +L2  "['P  NS   +M#  "Z6   N7   +>+  "W
MH0  M[, ,&(  "5I   :<   $'@   F     B    (\   "6    FP   *$
M  "F    J@   *X   "P    L0   +0   "V    N    +L   "]    P
M ,,   #'    RP,  ,\,  #3%0  TB4  -(X  #13@  T&4  ,]^  #-E@
MS*D _P   /\   #_    _P # /\ "P#\ !$ ^0 ; /< )0#S "\ [@ X .D
M0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3 &@ T !M ,X <P#+ 'H R ""
M ,8 C ## )< P "C +X L@"\ ,@ N@#J +D _P"X /\ L0#_ *H _P"G /\
M_P   /\   #[    ]@   .T !P#G  \ X@ 6 -\ ( #> "D V0 S -$ .P#,
M $( R !( ,4 3@#" %, P !8 +X 70"\ &( N@!G +D ;0"W '0 M0![ +(
MA0"P )  K@"< *P J@"I +T IP#> *8 ^0"E /\ HP#_ )T _P"; /\ _0
M /8   #K    WP   -$  P#*  P Q0 2 ,, &P#  "0 O@ L +D -0"V #P
MLP!# +  2 "N $X K !2 *L 5P"I %P IP!A *8 9P"D &T H@!T *  ?0">
M (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\ E0#_ )  _P". /\ \P   .8
M  #1    P@   +@   "Q  @ K0 / *H %@"H !X J  G *8 +P"B #8 GP \
M )T 0@"; $< F0!, )< 40"6 %4 E !: ), 8 "1 &8 D !N (X =@", ($
MB@"- (@ FP"& *P A0#! (0 Y@"# /T A #_ (, _P"! /\ Y    ,L   "Z
M    K    *(   "<  0 F  , )8 $0"4 !D DP A )( * "/ #  C0 V (L
M/ ") $$ B !& (8 2P"% $\ A !4 (( 6@"! &  ?P!G 'X ;P!\ 'H >@"&
M '@ E !W *0 =0"W '0 U !S /0 = #_ '0 _P!T /\ RP   +8   "F
MF@   )(   "*    A@ ( (, #@"! !0 @0 ; (  (P!_ "H ?0 P 'L -@!Z
M #L > !  '< 10!U $D = !. ', 5 !Q %H < !A &X :0!M ', :P!_ &D
MC0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G /\ N    *0   "5    B@
M ($   !\    =@ $ '0 # !R !  <0 6 '  '0!P "0 ;@ J &T , !K #4
M:@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!; &$ 8P!@ &T 7@!Y %T AP!;
M )8 6@"H %D O0!9 -\ 60#X %H _P!: /\ J    )4   "'    >P   ',
M  !N    :@ ! &< " !E  X 9  2 &, & !C !\ 8@ E &$ *@!? #  7@ U
M %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8 7@!4 &@ 4P!S %$ @0!0 )$
M3P"B $X M0!. -  3@#P $X _P!/ /\ G    (D   ![ P  < ,  &@#  !B
M 0  7P   %T ! !;  L 60 / %@ % !7 !D 5P @ %8 )0!5 "H 4P P %(
M- !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!* &, 20!O $< ? !& (P 10"=
M $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '  !Q"@  9@H  %X*  !9"0
M50<  %0$  !2  < 4  , $\ $ !. !4 30 ; $P ( !+ "8 2@ K $D , !(
M #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\ 0 !K #X >  ] (@ / "9 #P
MJP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J#@  7PX  %<.  !1#@  30P
M $L+  !*" ( 200) $@ #0!& !$ 10 6 $0 ' !# "$ 0@ F $$ *P _ #$
M/@ V #T /  \ $, .P!* #H 4@ Y %P . !H #8 =0 U (4 - "6 #0 J  S
M +P ,P#8 #, [P S /L @@T  '$/  !D$   61$  %$1  !+$0  1Q   $0.
M  !"#0  00L% $$'"P _!0X /@,2 #P"&  [ AT .@,B #D#*  X RT -P,R
M #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'<P N!X, +0>5 "P'IP K![H
M*P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0  $P4  !&%   0A,  #X2   \
M$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D - D? #())  Q"2D , DO "\*
M-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G#(, )@V5 "4-IP D#;L (PW2
M ",-ZP C#?< >!(  &@4  !;%@  41<  $@7  !"%@  /18  #D5   W$P
M-1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T; "P-(0 K#2< *@TM "D.-  H
M#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0 'Q"6 !X0J0 =$+T '!#8 !T0
M[@ =$/D <Q0  &06  !7&   31D  $49   _&0  .A@  #47   R%@  ,!4
M "X3   M$00 +! * "L0#@ I$!( *! 8 "80'@ E$"0 )! J ",1,0 B$3D
M(1%" " 22P >$E8 '1-C !P3<0 :$X( &125 !@4IP 7%+L %Q/4 !<3[@ 8
M$_H <!8  & 9  !4&@  2AL  $(<   \&P  -AL  #(:   O&0  +!@  "H6
M   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4+@ <%38 &Q4_
M !H620 9%E0 &!=A !87<  5&($ %!B3 !,8I@ 2&+H $A?2 !(7[  3%_H
M;!D  %T;  !1'0  1QT  #\>   Y'0  -!T  "\<   K&P  *!H  "89   D
M&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X &1@D !@9+  7&30 %AH] !4:
M1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /'+D #AS0  X;Z@ /&_@ :1L
M %H=  !.'P  11\  #T@   V'P  ,1\  "T>   I'0  )1T  ",<   @&P
M'1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB !,=*0 2'C$ $1XZ !$?10 0
M'U  #R!=  X@;  -('P #2"/  P@H@ +(+4 "R#*  L@Y0 ,'_0 91T  %<?
M  !,(0  0B$  #HA   T(0  +R$  "H@   F'P  (Q\  " >   ='@  &2
M !8@!  4( L $B$. !$A$P 1(AD $"(?  \B)@ .(R\ #B,W  TC00 ,)$T
M"R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'  8CXP '(_$ 8A\  %0A  !)
M(P  0",  #@C   R(P  +",  "@B   D(0  (2$  !XA   :(0  %B,  !,D
M P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *)RL "2@T  @H/@ '*$D !BA5
M  4I9  $*70  RF'  (IFP !**\  "C%  $HX0 !)_  7B(  %$D  !&)0
M/24  #4E   O)0  *B0  "8D   B(P  'R,  !LD   8)0  %"8  !$H P /
M*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@  RTP  (M.@ !+44  "U2   N
M8   +G$  "V$   MF0  +:T  "S"   LX   +/  6B0  $TF  !#)P  .B<
M #,G   M)P  *"8  "0F   A)@  '28  !DG   5*0  $2L   \L P -+@<
M"3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M   R-@  ,T(  #-.   S70
M,VT  #.!   RE@  ,JL  #'!   QWP  ,?  5B<  $HI   _*@  -RH  # J
M   K*0  )R@  ",H   >*0  &BH  !8L   2+@  #S    TQ @ *- < !34+
M  (V#@  -Q   #@4   X&@  ."(  #@J   Y,P  .3X  #E*   Y60  .6D
M #E]   XDP  .*@  #>_   WW@  -O  42L  $8L   \+   -"P  "XL   J
M*P  )2L  " L   ;+0  %R\  !,Q   0,P  #34   DW @ %.@8  3L*   \
M#0  /0\  #X2   _%P  0!X  $ E  ! +P  0#H  $!&  ! 5   0&4  #]X
M   _CP  /J8  #Z]   ]W   /?  32X  $(O   Y+P  ,B\  "TN   H+@
M(B\  !TP   8,@  $S4  ! W   ,.@  "3P   4^    000  $((  !#"P
M1 T  $80  !'%   2!D  $@A  !(*@  2#4  $A!  !(3P  2&   $=S  !'
MB@  1J(  $6Y  !%V0  1/  2#(  #XR   V,@  ,#$  "LQ   E,@  'S0
M !DV   3.0  $#P   P_   (0@   T0   !&    2 (  $H%  !+"   3 L
M $X.  !/$0  414  %(<  !2)0  4C   %(\  !12@  45H  %%M  !0A
M3YT  $ZU  !-T@  3>X 0S8  #LV   T-0  +S0  "<U   A.   &CL  !0^
M   000  #$0   ='   "2@   $T   !/    40   %,"  !4!0  50@  %<+
M  !9#@  6Q$  %T7  !='P  72H  %TV  !<1   7%0  %MG  !;?@  6I<
M %FO  !8RP  5^H /SD  #@Y   S.   *SD  ",\   </P  %4,  !!'   +
M2@  !4X   !1    5    %<   !:    7    %T   !?    8 0  &('  !D
M"P  9@X  &@2  !K&0  :R,  &HN  !J/   :DT  &E?  !H=0  9X\  &:H
M  !EP@  9., /3T  #<\   N/0  )4   !U$   620  $$T   I1   $50
M %H   !=    8    &,   !F    :    &H   !K    ;0   &\"  !Q!@
M= H  '8.  !Y$P  >QL  'LG  !Z-0  >44  'A9  !X;0  =X8  ':?  !U
MMP  =-( /$$  #)"   H10  ($H  !=.   05   "ED   )>    8P   &<
M  !K    ;P   '(   !U    =P   'D   ![    ?0   '\   ""    A ,
M (<)  "*#@  CA,  (\>  ".*P  CCL  (U.  "+8P  BGP  (J5  "(K0
MA\4 -D<  "Q+   B3P  &54  !!;   *80   6<   !M    <@   '<   ![
M    ?P   (,   "&    B    (H   "-    CP   )$   "4    EP   )H!
M  "=!P  H0T  *44  "D(0  I#$  *-$  "B60  H'   )^+  "=H@  G;<
M,%   "55   ;6P  $F(   MI   !<    '<   !]    @P   (@   "-
MD0   )4   "8    F@   )P   "?    H0   *,   "F    J0   *P   "P
M    M <  +@.  "Z&   NB<  +DY  "X3@  MV4  +9^  "UE@  LZL *5L
M !YB   4:0  #'$   )Y    @0   (D   "/    E@   )L   "@    I
M *@   "K    K    *\   "R    M    +8   "Y    O    ,    #$
MR    ,T'  #2$   TAT  -$O  #01   SUL  ,US  #+C0  RJ$ _P   /\
M  #[    ^@   /P " #X  \ ]0 7 /0 ( #Q "H ZP S .8 .P#B $, W@!)
M -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D ;@#& '4 PP!] ,$ A@"^ )(
MNP"> +D K@"V ,, M #H +, _P"O /\ I0#_ )X _P"; /\ _0   /<   #R
M    \    .<  P#A  P W  2 -@ &P#6 "0 T@ M ,P -@#& #T P@!# +\
M20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q &X KP!V *P ?P"J (H J "7
M *4 I@"C +D H0#9 *  ^0"> /\ F #_ )( _P"/ /\ \P   .P   #C
MTP   ,@   #!  D O0 / +L %@"Y !\ MP G +, +P"O #< K  ] *H 0P"H
M $@ I@!- *0 4@"C %8 H0!; )\ 80"> &< G !O )H > "7 (, E0"0 ),
MG@"1 +  D #( (X \ "- /\ B@#_ (4 _P"" /\ YP   -T   #&    N
M *X   "H  0 I0 , *$ $@"A !D H  B )\ *0"; #  F  W )8 /0"3 $(
MD@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H (< < "% 'L @P"( ($ E@!_
M *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\ U@   ,    "O    HP   )D
M  "3    CP ) (T #@"+ !0 B@ < (H (P"( "H A0 P (, -@"" #L @ !
M '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8 :0!U ', <P"  '$ C@!O )\
M;@"R &T SP!L /0 ; #_ &L _P!I /\ P    *L   ";    CP   (<   "
M    ?  $ 'H # !X !$ >  7 '@ '@!W "0 =0 J ', , !Q #4 <  Z &X
M/P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E &T 9 !X &( AP!@ )< 7P"J
M %X P@!> .D 7@#_ %X _P!= /\ K    )D   "*    ?P   '<   !Q
M;0   &H " !I  X :  2 &< & !G !\ 9P E &4 *@!C "\ 8@ T &$ .0!@
M #X 7P!# %X 2 != $X 6P!5 %H 70!8 &< 5P!R %4 @0!4 )$ 4P"C %(
MN !1 -P 40#Y %( _P!2 /\ G0   (L   !\    <0   &D   !D    8
M %X !0!<  L 6P / %L % !: !D 6@ ? %D )0!7 "H 5@ O %4 - !4 #@
M4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M $H >@!) (L 2 "= $< L0!'
M ,P 1@#P $< _P!' /\ D    'X   !P    9@   %X   !9    5@   %,
M 0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !- "4 3  J $H +@!) #, 2  X
M $< /@!& $0 10!+ $0 4P!# %T 00!H $  =0 _ (4 /@"7 #T JP ] ,,
M/0#F #T ^P ^ /\ AP   '4#  !H!@  70<  %4&  !0!@  3 0  $H!  !)
M  0 1P * $8 #@!% !$ 10 6 $0 &P!# "  0@ E $$ *@!  "\ /P T #X
M.@ ] $  .P!' #H 3P Y %D . !D #< <0 V ($ -0"3 #0 I@ T +L - #=
M #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,  !("P  1 H  $((  ! !0$
M/P$' #X "P ]  X /  2 #L %P [ !P .@ A #D )0 W "H -@ P #4 -0 T
M #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T +0"/ "P H@ L +8 + #0 "P
M[@ L /P =PH  &<,  !:#@  4 X  $D.  !##@  /@T  #L,   Y"P  . D#
M #<%"  V @T -0$0 #0 $P S !@ ,@ = #$ (@ P "< +P L "X ,@ M #@
M+ !  "L 20 J %( *0!= "@ :P G 7H )@&, "4 GP E +( )0#* "4 Z  E
M /< <@T  &(.  !6$   3!$  $01   ^$0  .1   #8/   S#@  ,0T! # +
M!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I R, * 0I "<$+P F!34 )04]
M "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'G0 >![  '0;& !T&XP =!?,
M;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(  #$1   N$   + \  "H. P J
M#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2  (@DF "$)+  @"C, 'PH[ !X+
M1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7#+  %@S% !8,X0 6"_  :1
M %H2  !.%   114  #T5   W%0  ,10  "T3   J$@  *!$  "80 0 D$ 0
M(PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC !P-*@ ;#3( &@XZ !@.1  7
M#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+, $ _) ! /Y  1#_( 91(  %<4
M  !+%@  0A<  #H7   T%P  +Q8  "H5   G%   )!,  "(3   @$@, 'A$&
M !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80*  5$3  %!$Y !,10P 2$DX
M$1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%  P2X0 -$O$ 8A0  %06  !)
M&   /QD  #<9   Q&0  +!@  "@7   D%@  (18  !\5   <% ( &A,$ !D2
M!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1%"T $!0V  \500 .%4P #A97
M  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6W0 )%>X 7Q8  %$8  !&&@
M/1H  #4;   O&@  *AH  "49   B&   'Q@  !P7   9%@$ %Q8# !46!  3
M%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H #!DS  P9/  +&D< "AI3  D:
M80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $&>P 7!@  $X:  !#'   .AP
M #,<   L'   )QP  ",;   @&@  '1D  !H9   7& $ %1@" !(9!  0&P<
M#AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO  <>.0 &'D, !!Y0  ,?7@ "
M'VX  1^    ?E0  'JD  !Z]   =V   '>P 6!H  $L<  !!'@  .!X  # >
M   J'@  )1T  "$<   >'   &QL  !@;   6&P$ $QL" !$<!  .'@< #!\+
M  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B-0  (D   "--   C6@  (VL
M "-^   CDP  (J<  "*\   AUP  (>T 51T  $@?   ^(   -2   "X@   H
M(   (Q\  " >   ='0  &AT  !8=   3'@  $1\"  X@!  -(@< "B0+  8E
M#0 $)1   B84   F&@  )B$  "<I   G,@  )ST  "=)   H5P  *&<  "=[
M   GD   )Z4  ":[   FU@  )>T 42   $4A   [(@  ,B(  "PB   F(0
M(B$  !X@   ;'P  &"   !0@   1(@  #R,   TE P *)@8 !B@*  ,I#0
M*P\  "P2   L%P  +!X  "PF   M+P  +3D  "U&   M5   +60  "UW   L
MC0  +*0  "NZ   KU@  *NX 32(  $$D   X)   ,"0  "DD   D(P  (2(
M !TB   9(@  %2,  !(D   /)@  #2@   HJ @ &+ 4  BX)   O"P  , X
M #(0   S%0  ,QL  #,B   S*P  ,S8  #-"   S4   ,V   #-S   RB@
M,J$  #&X   PU@  ,.\ 224  #XF   T)P  +2<  "@F   C)0  'R0  !LE
M   6)@  $B@  ! J   -+   "BX   8P 0 ",@0  #0'   U"@  -PP  #@.
M   Z$@  .A<  #H?   Z)P  .C(  #H^   Z3   .EP  #IO   YA@  .)X
M #BV   WU   -N\ 1"D  #HI   Q*0  *RD  "8H   B)P  '2@  !@I   3
M*P  $"X   TP   ),@  !34   $W    .0(  #L%   \"   /@L  #\-  !!
M$   0Q0  $,;  !#(P  0RX  $,Y  !#1P  0E<  $)J  !!@0  0)H  #^R
M   ^SP  /N\ /RP  #8L   O+   *BL  "4J   ?*P  &2T  !0O   0,@
M#34   @X   $.@   #P    _    00   $,"  !%!0  1@@  $@+  !*#@
M3!$  $T6  !-'@  32@  $TT  !,0@  3%$  $MD  !+>P  2I0  $FM  !(
MR@  1^P .S   #,O   M+P  *"T  "(O   ;,0  %30  ! W   -.@  "#T
M  )     0P   $8   !(    2@   $P   !. 0  3P0  %$'  !3"P  50X
M %@2  !9&0  6"(  %@N  !7/   5TL  %9>  !6<P  58T  %2G  !2P@
M4N8 .#,  #$R   L,0  )3(  !TU   6.   $3P   Q    '1    $<   !*
M    30   %    !3    50   %<   !9    6@   %P#  !>!P  80L  &0.
M  !F$P  9QP  &8G  !F-   940  &17  !D:P  8H4  &&?  !@N0  7MP
M-3<  # U   H-P  (#H  !@]   10@  #$8   9*    3P   %,   !6
M60   %P   !?    80   &0   !E    9P   &D   !L 0  ;@8  '$+  !T
M#P  =Q4  '<@  !V+0  =CT  '5/  !T8P  <WL  '*5  !PKP  ;\D -3H
M "L[   B/P  &D,  !)(   ,30  !5(   !7    7    &    !D    :
M &L   !N    <0   ',   !U    =P   'H   !\    ?P   (($  "&"@
MB@\  (P7  "+)   BC,  (E%  "'6P  AG(  (6+  "#I0  @KP +T   "5$
M   <20  $TX   U4   $6@   &$   !F    :P   &\   !T    >0   'T
M  "     @P   (4   "'    B@   (P   "/    D@   )8   "9 @  G@D
M *(0  "B&@  H2D  * [  "?4   G6<  )J!  ":F0  F:\ *4D  !].   5
M5   #EL   5B    :0   '    !W    ?0   ((   "&    BP   (\   "3
M    E0   )<   ":    G0   *    "C    I@   *H   "N    L@   +<*
M  "[$0  NA\  +DP  "W10  M5P  +1T  "QC@  KZ0 (E0  !A;   08@
M!VH   !S    >P   ((   ")    D    )4   ":    GP   *,   "F
MJ    *L   "N    L    +,   "V    N@   +T   #"    QP   ,P!  #3
M"P  U!4  -,F  #1.@  T%$  ,UH  #+@0  RI8 _    /8   #R    \0
M /, !0#T  P \@ 3 /  ' #M "4 Z  N .( -@#> #X V0!$ -0 2@#1 $\
MS@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X +P @0"Y (T M@": +, JP"Q
M ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\ ]    .P   #H    YP   -\
M  #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #  #< O  ^ +D 1 "W $D M0!.
M +, 4P"Q %< KP!= *T 8@"K &D J0!Q *< >@"E (4 H@"3 *  H@"= +8
MFP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z    -\   #9    R0   +\   "X
M  0 M0 - +, $@"Q !H L  B *T *@"I #$ I@ X *0 /0"B $, H !( )X
M3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1 'T CP"+ (T F@"+ *P B0#%
M (@ [@"& /\ ?P#_ 'H _P!X /\ V0   ,T   "[    K@   *4   "?
MG  ) )D #P"9 !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"(
M $L A@!0 (4 50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8
MX !U /\ <@#_ &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $
M (0 # "" !$ @@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0
M=0!) ', 3P!R %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E
M /4 9 #_ &$ _P!@ /\ M    *    "0    A0   'T   !W    <P   '
M" !O  X ;P 2 &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!#
M &, 2 !B $X 80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H
M5P#_ %8 _P!4 /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@
M  L 7P / %\ $P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8
M0P!5 $D 4P!0 %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z
M $H _P!* /\ D@   (    !R    9P   %\   !:    5P   %4  0!3  <
M4@ , %( $ !2 !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!)
M $, 2 !* $8 4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $
M_P!  /\ A0   '0   !G    70   %4   !/    3    $H   !(  0 1P *
M $< #0!& !$ 1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X
M/0!% #P 3@ [ %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V
M /\ ?    &L   !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T
M"P ]  X /  1 #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !!
M #, 20 R %, ,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\
M<P$  &0%  !7!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T
M  P -  / #0 $@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L
M10 J $\ *0!: "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08
M %X)  !2"P  2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H
M+  - "P $  K !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B
M $L (@!7 "$ 9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,
M  !-#0  0PX  #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+
M "4##@ D 1  ) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D
M&P%4 !H!80 : 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)
M#P  0!   #@0   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'
M#  >!@X '@41 !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92
M !4'7P 4!VX $P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$
M/!$  #41   O$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9
M"@T & D0 !<)$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,
M7P /#&X #@R   X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,
M #(3   L$P  )Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L
M$PP- !(,$  2#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +
M#VT "@]_  D/DP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4
M   I%   )10  "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,
M  X.#@ .#Q( #1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH
M!A)\  42D  $$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G
M%@  (A4  !X4   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2
M#@ +$A$ "A(5  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z
M   5C@  %:,  !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P
M(18  !P6   9%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (
M%A  !A83  46&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9
MC   &*(  !BW   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@
M !L7   8%@  %14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X
M AL2  $;%@  &QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@
M'*   !RV   ;T   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9
M   7&   %!<# !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0
M   @%   (1H  "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\
M ""V   ?T0  '^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6
M&0$ $QD! !$9 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F
M$@  )A@  "<?   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T
M   DT0  (^X 1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'
M$1P   X=   -'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$
M+14  "T<   M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   J
MT   *>\ 0"   #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$
M  TB   *)   !B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(
M #48   U(   -2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0
M,.\ /",  #(D   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI
M   %*P   2X    P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4
M   ^'   /B8  #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T
M-R<  "\G   H)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P
M,P   #4    X    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)
M%P  2"$  $@L  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H
M "PJ   G*   (B<  !PH   6*@  $2T   TP   ),P   S8    Y    /
M #X   !!    0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P
M5!P  %,G  !3-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL
M   F*P  'RP  !@N   2,@  #34   @Y   "/0   $    !#    1@   $D
M  !,    3@   %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4
M &,?  !B+   83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B
M,   &C,  !,W   ..P  "#\   %$    2    $P   !/    4@   %4   !8
M    6P   %T   !@    8@   &0   !F    :0   &T%  !P"P  =!   '08
M  !S)0  <C0  ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.
M%#P   Y!   '1P   $P   !1    50   %D   !=    80   &4   !H
M:P   &T   !O    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")
M'   B"L  (8]  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@
M  A.    5    %H   !@    9    &D   !N    <@   '8   !Z    ?0
M (    ""    A0   (@   "+    C@   )(   "6    FP,  * ,  "B$P
MH"$  )\S  "=1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<
M    8P   &H   !Q    =@   'L   "     A@   (H   ".    D0   ),
M  "6    F0   )P   "@    HP   *<   "K    L    +8$  "\#0  NA<
M +DH  "W/   M%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L
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M__________________________________________________\
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M]O?X^?K[_/W^_VUF=#$      P0A   !                     0
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MT]35UM?8V=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_Q\O/T]?;W^/GZ^_S]_O\
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M@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO?
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MGH_<BYZ/W(N>C]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W.;%"Q/QQA$O\L074NK
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
MG=&R?Z/1L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZD
MT;!^I-&P?J31L'ZDT?^X% [_N!TG_[4I1O>P-6G>J$&0QYQAL<2<<;;"FWZY
MOYV&O;V:B<&[EXG$N9.*Q[>/C,JUC([,M(F0SK.'DM"RA)72L8*9T[&!GM2N
M@*+4K("CTJR H]*L@*/2K("CTJR H]*L@*/2K("CTJR H]*L@*/2K("CTJR
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M@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N
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MCK.&OHRRAK^*LH? B+*(P(:QB,&%L8G!A+&*P8*QB\&!L8S"@+&,PH"QC,*
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MRO&]# ;YOA(:^KX;-_RZ)5KGSA-HR-D+B:W#,J>AN%:XG;5HNYNS=;Z9LG_
MF+&$P9.PA<*/KX7#C*^&Q(FNAL6&KH?%A*Z(QH.MBL:!K8O&?ZV.QWVMD,=]
MK9#'?:V0QWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0Q]_
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MD(S%N(R/R+:'DLNT@Y?.LX"=T+)_I-&L?J7/J'ZGS*1_J<FA@*S&H8"LQJ&
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MV8Y^E]&-AZ+,C(VJQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O
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M@IC+M7ZAS:]\I\VI?:G*I7ZKQZ)_K<2??Z_"G8"QOYV L;^=@+&_G8"QOYV
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MUJ&"I-"=@JC+FH.JR)F#K<67A*_"EH2PP):$L,"6A+# EH2PP):$L,"6A+#
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ML+E@M:BT<+VCL'["G:V$QY*JA,N(IX;.@*:-T'VGF-!]J*3.?J2HRW^?JLF
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M)#'JRQHUT.(70[_P'5ZOZ"5UH-LQAY;12)20RER>C<5JI8O!=JJ)OGVOA;R
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MMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MM*O(<+^LOW.^K+=TOJVR=;ZLKG:_K*IVOZNH=\"JJ'? JJAWP*JH=\"JJ'?
MJJAWP*JH=\"JJ'? JO^+$0'_C2 &_XXT%/^-12;_EDTS_YE00?^:54__FEI=
M]YA@:>^5:'7HDG" X8][BMR+A)/6AHR:TH"3H<Y[FJ;,=Z*JRG2KKLARN*_
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M:_-KDW#P:9ES[F>?=^QEI7GK9*I[ZF*O?>EAM7[H8+U_Z%_%@.A>T('B7]J
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MZZ%G1^RS:4;MT&E(YNAI2]GK:DS/[&U.Q^MO3\#J<$_ ZG!/P.IP3\#J<$_
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M&A[_G!L>_Z4<'?^P'1W_L!T=_[ ='?^P'1W_L!T=_[ ='?^P'9S   ",S@
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MA^1Y<H?D>7*'Y'ERA^1Y<H?D>?]M$P'_=A,!_X@2 ?^8$P#_IQD![[,6 >+
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M=V:2YG=FDN9W9I+F=_]P$@'_@ X!_Y(. /*C"P#9LPD S[X) ,O,"0#$TQ<
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M."[_[SDM__\Y,?__.3/\_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.<&H  "OL0
MHKT  )3*  "'V   ??,' ';_$@%M_QH#9?\D!5[_+0I8_S8/4O\]$TS_119(
M_TP90_]3&S__6AX\_V$@./]I(37_<B,Q_WTE+O^*)BO_F2@I_Z<I)_^Y*R;_
MTBPE_^\L)/__+23__RTD__\M)/__+23__RTD__\M)/__+;&N  "CN0  E,8
M (;3  !YX0  <?\( &?_#P%?_Q4"5_\> U'_)@5+_RX'1O\V"D'_/0P]_T0.
M.?]+$#;_41(R_U@3+_]?%2S_9Q8I_W$7)O]\&"/_B1H@_Y@;'_^F'!W_MQT<
M_\H>'/_F'QO_\!\;__ ?&__P'QO_\!\;__ ?&__P'Z2U  "5P@  AL\  '?>
M  !K]   8O\# %G_"P%1_Q$!2O\7 D3_'P,__R8$.O\M!3;_- 8R_SH'+O]
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M:72 \&ET@/!I=(#P:?]A%P'_<1 !_X(. /^0#@#UG0T XZD, -FU# #/N1H
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M24+3_TU$R?]/1<+_4$>[_U)'N_]21[O_4D>[_U)'N_]21[O_4N:*  #/FP
MOZ<  +*P  "GNP  G,8# )/1!@"+Z@X A>@? G[H+09VZ#@.;NA!%F;G2AU?
MYU(C6>=;*57G9"U0YVTQ3.=X-4GGA#A&Z)$Z0^B@/$#ILCX_ZLL^/NCO/CWF
M_S\]X/]"/]?_1$#._T9 SO]&0,[_1D#._T9 SO]&0,[_1M:3  #$HP  M*P
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M'R+__Q\B__\?(O__'R+__Q\B__\?(O__'ZRK  "=M@  C\(  (#.  !SW
M9^D  %__!@!8_PX 4?\5 4O_'0)&_R8#0?\M!#S_-04X_SP&-/]"!S'_20@N
M_U )*_]7"BC_7PHE_VD,(_]T#2#_@@X=_Y(/&_^B$!K_LA$9_\@2&/_E$Q?_
M^A07__H4%__Z%!?_^A07__H4%__Z%)^S  "0OP  @,P  '+:  !DY   6/4
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M67YR^UE^<OM9?G+[6?]8%P'_9Q !_W4. /^!#@#_C X \940 ..=$0#6HQL
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M5U"E_%=3G_U759K]5E>6_E98E?Y56)7^55B5_E58E?Y56)7^5?]O! #F@@
MTI$  ,:=  "[I@$ LJX  *JW 0"BP@4 G,08 )7#*@2-PCD-A<!$&'V^3B%U
MO%8J;KI>,FBY9CABMVX^7;9X0UBU@D=4M(]+4+2=3DVSKE!+M,502[/J4$JQ
M_U%,J_]23J7_4E"A_U)1GO]149[_45&>_U%1GO]149[_4?]V  #=B0  RI<
M +ZB  "SJ@  J;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)?,E $G7(2AMMQU,C
M9\5<*F'$9#!<PVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'P<5&1\'J1D2^_TE%
MN?]*1[/_2TFM_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1D   PIX  +6G
M  "JKP  H+@  );! @",RP< A-4- (#5'@%YU2X%<M0\#&S31Q1ETE ;7]%9
M(5K18B=5T&LL4=!U,$W/@31)SXXW1L^=.430KCM"T,8[0]#J.D#-_3X^R_]
M0,/_0D&]_T-"N?]$0KG_1$*Y_T1"N?]$0KG_1-V(  #'F   N*,  *NK  "@
MM   E;X  (O( P" T0< >.$- '3A'0%NX2L#:. W"&'@0@Y<X$T45^!6&5/@
M7QU/X&DB2^!S)4?@?BA$X(LK0N":+3_AJR\^XL$O/N+E+SS?^C$YWO\T.=G_
M-CK0_S@[S/\Y.\S_.3O,_SD[S/\Y.\S_.<V2  "\H   K:@  *&Q  "5NP
MB<4  '[/ @!TV@8 ;NL1 &CK'@%BZRH#7>PU!E?L/PM2[$@/3>Q1$TKM6A9&
M[6,90^UM'$#M>!X][H4A.NZ3(SCOHR0V\+8F-?'2)C3O\R8T[/\F,NO_*#+G
M_RLSY/\L,^3_+#/D_RPSY/\L,^3_+,&<  "PI@  HZX  ):X  ")PP  ?<T
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M"A/__PH3__\*$___"IJQ  "+O0  ?,@  &W4  !?X   4>8  $?U  !!_P
M//\) #?_$  R_Q4!+O\= 2K_(P$F_RD!(O\O A__-0(<_SL"&?]" Q;_20,3
M_U$#$?]: P__9@0-_W0$"_^%! K_E@4)_Z@%"/^Y!0?_T 4'_^,%!__C!0?_
MXP4'_^,%!__C!8VZ  !]QP  ;=,  %_@  !0YP  0NT  #K_   U_P  +_\"
M "K_"@ F_P\ (O\4 ![_&@$:_Q\!%O\C 1/_* $0_RT!#O\S 0S_.0(*_T$"
M!_]) @/_4P( _UX" /]L @#_? , _XT# /^= P#_K , _[4# /^U P#_M0,
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MBFJJ4X=JN52%:L]4A&ON4X-L_U&";/]/@6O_38!K_TR :_]*@&O_2H!K_TJ
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M5&&&^5)CA/]098'_3V9__TUG?O],9W[_3&=^_TQG?O],9W[_3/]A"@#_;P
MX'X  -")  #&DP$ OYL# +BA @"QI@L JJ@> :.G+P6;I3T/E*)(&8R?42*%
MG%DK?YIA,GF8:3ETE7$_;Y-Y1&J2@TAED(Y,88^;3UZ.JE);CKU26H[>4EN-
M^%!<B_]/7HC_3F"%_TQA@_]+88/_2V&#_TMA@_]+88/_2_]D!0#U=   VH(
M ,N.  #!EP  N)X! +&E  "IJP< HZT: )RL+ 25JSH,C:A%%H:F3Q]_I%<H
M>:)?+W.@9C5MGFX[:)QW0&.:@45?F8Q)6YB93%>7J$Y5E[M/5)?<3E26]DY5
ME/]-6)#_3%F-_TM;BO]*6XK_2EN*_TI;BO]*6XK_2O]H  #E>0  T8<  ,62
M  "[G   L:(  *FI  "AL0( F[,5 )6S* *.LC8)AK!"$G^N3!MXK%0C<JI<
M*FRH9#%GIVPV8J5U.UVD?T!9HXI#5:*71U&AITE/H;I*3J+924Z@]4E.G_])
M4)G_25*6_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P  RHT  +Z8  "S
MH   JJ<  *&N  "7M@  D;H0 (RZ(P&%N3(&?K@^#G>V21=QM5(>:[-:)66R
M8BM@L6HP6[!S-5>O?3E3KHD]3ZV60$RMI4)*K;E#2:[80DBK]4-'JO]$2:7_
M1$N@_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,  +>=  "LI
MHJL  )BS  ".NP$ A<$, ('"'0![PBT#=<$Z"6_ 11%IOT\88[Y7'EZ]7R-9
MO&@H5;MQ+5&[>S!-NH<T2KJ5-T>ZI3E%NK@Z1+K7.4.X]3M"MO\]0K/_/D2N
M_SY%J?\^1:G_/D6I_SY%J?\^1:G_/N!]  #)C0  NYH  *ZB  "CJ0  F+$
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M("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0  =\8  &O/  !?U@
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M XBY  !XQ   :=   %O=  !+XP  /ND  #+N   K_P  )O\  "'_   =_P@
M&O\- !;_$0 3_Q8 $/\:  [_'P +_R0 "?\J  ;_,  "_S<! /]  0#_2@$
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M+?\:^2W_'/,O_QSM,?\=ZC+_'>HR_QWJ,O\=ZC+_'?\S*0'_."8!_STD ?]
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M27%P]$=Q<?]$<G#_0G)O_T%R;O\_<F[_/G)N_SYR;O\^<F[_/O]6"@#_8@
MYF\  -=Y  #,@0$ Q8<# +^+! "YC@X LI @ :N/,06DC#\-G8I*%I:'4QZ1
MA%PEBX%D+(9_:S&"?7,V?GM\.WIYAC]V=Y!"<G:<16]UJ4AL=;I):W7426MU
M\D=K=?]%;'7_0VUS_T%M<O\_;7+_/VUR_S]M<O\_;7+_/_]9!P#_90  XG(
M -%\  #'A   P(H" +F/ @"SD@P K)0= *:3+P2>D3P+F(](%)&,41R+B5HD
MAH=B*H&%:3!\@G$U>(%Z.G1_@SYP?8Y";'R:16E[IT=F>KA(9'O02&1[\$=E
M>_]$9GK_0V=X_T%H=O\_:';_/VAV_S]H=O\_:';_/_];! #W:0  W78  ,V
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M05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX  ,.(  "YD0
ML)<  *>;  ">H0  F*,3 ).C)0&-HC0&AJ% #8"?2A5YG5,<=)M:(V^98BAJ
MF&HN9I9R,F&5?#==E(8Z69*3/E:2H4!3D;)!4I+)0E*1ZT%2D/] 4H__/U6+
M_SY6B/\]5X?_/5>'_SU7A_\]5X?_/?EG  #==@  R8,  +V-  "SE0  J9L
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M,D&F_S)!IO\R0:;_,M5\  #"B@  M98  *B=  "=HP  DJH  (>Q  !\MP
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M"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T  #CD   U]@P
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M 0#_AP$ _YT! /^R 0#_R@$ _^H! /_S 0#_\P$ __,! /_S 82W  !TP0
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M+?\6X"[_%N N_Q;@+O\6X"[_%O\R(P'_.!T!_SP; ?\^&P'_0"(!_T$K ?]
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M.8)>\#B!7_\V@%__-(!?_S-_7_\Q?E__,'Y?_S!^7_\P?E__,/]-"0#_5@
M[F$  -UI  #1;P  RG,# ,5U!@# =A  N'@C +%X,P.K=D$)I7-,$)]P5A>;
M;E\=EFQG(I-J;R>/:'<KC&=_+XEEB#*%9)(U@F.=-X!BJCE]8KDZ>V+/.WIB
M[CEZ8_\X>F/_-GEC_S1Y8_\R>6+_,7EB_S%Y8O\Q>6+_,?]/!P#_60  YF0
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M-VAP_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X  ,EV  "_?0
MMX(  +"%  "HAP8 HHD7 )R**0&6B3<&D(=##(N%31.%@E49@(!='WQ_921X
M?6TI='MU+7!Z?C%M>8@T:7>4-V9VH3IC=K [87;$/&%VY3MA=OLY8G;_-V-U
M_S5C<_\T9'+_,V1R_S-D<O\S9'+_,_]8  #F9@  TG$  ,5Z  "[@0  LH<
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M,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\  +:(  "LD   HI0  )B8  ",G
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M(,&#  "TD0  II@  )N>  "/I0  @JL  ':Q  !KM@  7[P  %3! P!,Q0T
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M AOIO (:ZN("&N;\ AGE_P,9Y/\$&./_!1CC_P48X_\%&./_!:.=  "6I
MB*P  'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP  )>X) "/P$0 A
M\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1]X !$/B4 0_Y
MJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC  "+K   ?+4
M &V^  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L& !G_#@ 7_Q,
M%/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP  O^   '_E@
M_ZT  /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]M0  ;K\  &#(
M  !2T   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_"  ._PX #/\1
M  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I  #_?@  _Y4
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M)9E+\"663/\DE4S_))1,_R.33/\BD4W_(9%-_R&13?\AD4W_(?]""@#_20
M_U$  .97  #=6P$ U5P% -);"0#+7!0 PUXH +Q>. *V748&L5M1"JU96P^I
M6&03IE9L%Z-5=!J@5'T=GE.%'YM2CB*949<DEU"A)I50K2>24+PHD5#0*(Y0
M["B-4?XGBU'_)HM1_R6*4O\DB5+_(XA2_R.(4O\CB%+_(_]%!P#_2P  \%4
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M*W5?_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\  ,UG  ##;
MNV\  +5P  "O;PH J'$: *-R*P&=<CD$F'!%"9-N3PZ/;5@4BVM@&(=I9QR$
M:&\@@6=W(WUF@"9Z9(HI=V.4+'5CH2YR8J\O<&+!,&]BWS!N8_<N;V/_+&]C
M_RIO8_\H;V+_)V]B_R=O8O\G;V+_)_]-  #K6   V6,  ,EJ  "_<   MW,
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M*&!N_RA@;O\H8&[_*/%5  #>8@  RFT  +UU  "S>P  JX   **"  "8@0
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M)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6  !^F@  <)T  &N?#@!HGQP
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M$#*SQ1 RLND0,;#^$C"N_Q0OK?\5+ZS_%B^L_Q8OK/\6+ZS_%KN!  "NC@
MH94  )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4 0+T1 #^]'@ ^
MOBL /+XV #N_00 YOTL!-[]4 C7 7P(SP&H$,<!W!2_ A@8MP)<'*\"J""K!
MP@@JP.<'*;W]"BB\_PPGNO\-)[G_#B>Y_PXGN?\.)[G_#K*,  "EE   F9H
M (VA  !_IP  <JT  &:S  !:N   3[L  $2_   ZQ ( ,,D( "[*$0 MRAT
M+,LI "O+-0 KS$  *LU* "C-5@ GSF$ )LYO 23.?P$CSY$"(<^E B#0O0(@
MS^0"'\WZ Q[+_P0>RO\%'<G_!AW)_P8=R?\&'<G_!JB4  "<F@  D*$  (*H
M  !TKP  9[8  %N\  !.P   0\,  #G'   OS   )] $ !_6"@ ;VA  &]L:
M !K;)@ :W#$ &=T\ !C=2  8WE4 %]]B !;@<@ 5X(4 %.&: !/BL0 2X\\
M$N#T !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0  A*D  ':Q  !H
MN   6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4Z0X $NH4 !'K
M'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?RH  %\KH !/'D
M  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(  &FZ  !;P@
M3<@  $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H "_H/  G[%0 '
M^QP !/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C   _*0  /S!  #\
MZP  _/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$  !.S   /]$
M #+7   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)  #_#@  _Q(
M /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT  /^F  #_P@
M_^<  /_\  #__P  __\  /__ 'RS  !LO   7<8  $[/   _U@  ,=T  "7B
M   :Y@  $>H   SN   %\@   /\   #_    _P   /\   #_!0  _PH  /\.
M  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,  #_I   _[D
M /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#  _PLX ?\#1 '_
M %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_ *@ _P"O /\
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M"[<T\PVT-/\/L33_#[ T_Q"O-/\0KC3_#ZXT_P^N-/\/KC3_#_\U#@#_. <
M_SP" /] !@#_00L ^D$/ .T_%@#C/"( VCTQ -(^00#,/D\"R#Y: \0]9 7!
M/6X'OSQV"+P\?@JZ.X<+N#N/#+<[EPVU.I\.LSJI#[$ZM!"O.L(1KCK9$:H[
M[Q*G._\3I3O_%*0[_Q.C._\3HCO_$Z([_Q*B._\2HCO_$O\X"@#_/   _T$
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M'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5   -56  #*60
MPEH  +U8 P"X5PX L5D> *Q:+P&G6CT"HEE)!9Y84PF;5UL,EU9D$)55:Q*2
M5',5CU-[%XU2A!J+48T<B%&7'H90HQ^$4+ @@E#!(8!0W2%^4?0@?5'_'WU1
M_QU]4?\<?5'_&WU1_QI]4?\:?5'_&O]"  #P2@  WU0  ,Y:  #$7@  O%\
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M'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E  "W:@  KVP  *=L  "?:@$
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M'>57  #-9   OFT  +)U  "H>P  GWX  )-]  "'?0  @'\' 'R %0!X@20
M=8(R 7&!/01M@$8':8!/"F9_5@UC?EX18'UF%%U\;A=:>W<:5WJ"'51ZCQ]1
M>9TA3WFN(DYYPR)->.4B37?[(4YW_Q].=O\>3W7_'4]U_QU/=?\=3W7_'=]<
M  #(:   N7(  *YZ  "E@   FH(  (Z"  " @P  >84" '2&$0!QB"  ;H@N
M 6J(.0)GAT,%8X=,"&"&4PM=A5L.6H1C$5>$:Q14@W4748* &DZ!C1Q+@9L>
M28&L'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<27S_'-9A  #"
M;@  M'@  *J   "?A0  E(<  (B'  ![B0  <(P  &N.#0!HCQH 9H\I &*0
M-0%?CS\#7(](!5F.4 A6CE@+4XU@#E",:!!-C'(32HM]%DB*BAA%BID:0XJJ
M&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_&LUG  "\=
MKWX  *6&  ":B@  CHP  (*-  !UD   9Y0  &&5" !>EQ0 7)<C %J8+P!7
MF#H!5)A$ U*73 5/EU0'3)=<"4F690Q'EF\.1)5Z$4&5B!,_E)<5/92H%CN4
MO18[E-\6.I+X%SJ0_Q<ZC_\7.H[_%SJ._Q<ZCO\7.H[_%\5N  "V>P  JH4
M )Z+  "4CP  B)(  'N4  !NEP  8IL  %>>  !2H X 4: ; $^A* !-H30
M2Z$^ 4FA1P)'H5 #1*%8!4*A80<_H&L)/:!W"SJ@A0TXH)0.-J"F#S6@NQ T
MH-T/-)WW$#.<_Q(SFO\2,YG_$S.9_Q,SF?\3,YG_$[UW  "O@P  HXL  )B1
M  "-E0  @9D  '.<  !GGP  6Z(  $^F  !'J0@ 1*H2 $.J'P!!JRL 0*LW
M #^L00 ]K$H!.ZQ3 CFL7 ,WK&<$-:QS!3*L@08PK)$'+JRC""VLN DLK-D(
M+*KU"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP  G)$  )&6  "%
MG   >*   &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 SMB$ ,K8L #&W
M-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(GN8T");F? R2YM ,CN=(#([?T
M!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<  (B=  ![HP
M;J@  &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0 (L,? "'#*@ @
MQ#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7R,L %\;Q 1?$
M_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE  !PJP  8K$
M %:V  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1 !#2&@ 0TR4
M#],P  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X "=GF  K6_@ +
MU/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !DM   5[H  $F_
M   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?$0 %WQH !. D
M  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(  #G\   Z/\
M .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@  2<,  #S'   P
MRP  )<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0  Z1$  .H8  #K
M(0  [2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #VT   ]_,  /?_
M  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P  "[1   CU@
M&=P  !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L  /8/  #V%
M^!T  /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@  _\\  /_M  #_
M^0  __D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=   6X@  #N8
M  CJ    [0   /    #X    _P   /\   #_    _P   /\&  #_#   _Q
M /\8  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\  /_#  #_U0
M_]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_ $\ _P!< /\
M:0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\ L #_ +< _P#
M /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L _P!8 /\ 9 #_
M '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_ +0 _P"\ /X
MR #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D _P#Y /\ ^0#_
M /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3 /\ 8 #_ &L
M_P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +  ^@"Y /< Q #U
M -( \P#F /( ] #Q /\ \ #_ .\ _P#O /\ [P#_ /  _P#P /\ \ #_ /\>
M'0#_'AD _QP7 /\7& #_$QX _Q$H /\.- #_#$$ _PI. /\(6P#_!V8 _P9Q
M /\&>@#_!H, _@:+ /P&D@#Z!ID ^ :? /8&I@#T!JT \@:U / %P #M!<X
MZP7D .D&\P#F"/\ Y0K_ .0+_P#D"_\!Y O_ >0+_P'D"_\!Y O_ ?\A& #_
M(1, _R 1 /\;$@#_'!H _QHD /\6+P#_$SP _Q%) /\050#\#F$ ^0YK /8.
M=0#T#GX \@Z& / .C@#N#I4 [0Z; .L.H@#J#JH Z ZS .8/O0#E#\P X0_C
M -T0\P#9$?\!UA+_ =03_P'3$_\"TA/_ M(3_P+2$_\"TA/_ O\E$P#_)1
M_R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL [!=F .D7< #F
M%WD Y!>! .(7B0#@%Y$ WQ>8 -T7GP#;%Z< V1BQ -88NP#4&<H T!KA <P;
M\P')'/\"QAS_ L0<_P/#'/\#PQS_ \,<_P/#'/\#PQS_ _\H$ #_*0L _R@&
M /\K"P#_*Q  _RD7 /TF(@#T(RX ["$[ .8@20#B(%4 WB!@ -HA:@#6(70
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M#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S @#_-0  ]CH  .4^  #<0
MU#T$ -(W"0#+.!4 PSHF +T]-@"X/D0!M#Y0 ;$]6@.N/6,$K#UK!:D\<P:G
M/'L(ICR#":0[BPJB.Y0+H#N=#)X[J V=.[0.FSO%#ID[X Z6._0/E#S_#Y(\
M_P^2//\.D3S_#9$\_PV1//\-D3S_#?\U  #_.0  ZD$  -U&  #01P  R48
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M$W=,_Q)W3/\2=TS_$O\^  #H1P  U5   ,96  "\6   M%D  *U6  "G4P<
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M%>M*  #45@  PUX  +9E  "L:0  HFD  )AG  "/90  B68, (5H&0"!:2@
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M&D]MNQM.;=D:3FST&4]K_QA/:_\74&K_%E!J_Q50:O\54&K_%=U5  #%80
MMVH  *QQ  "B=0  E'0  (ET  !\<P  =G4  '%W$ !O>!T ;'DK &EY-P%F
M>4 #8WE)!6!X40===U@)6W=@#%AV: Y5=7$14G5\$U!TB!9-=)<72W.F&$ES
MN1E(<]4927+S&$EQ_Q=*<?\62G#_%4MP_Q1+</\42W#_%-1:  # 9@  LV\
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M#C6+_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(  )F'  ",B
M?X@  '**  !FC0  6I$  %"5  !)EPD 1Y@3 $68( !$F2L 0YDV $&:0 !
MFD@!/II1 CR:6@(ZFF0#-YIO!369?08SF8P',9F=""^9L @NF<H(+ICM""Z6
M_PHME/\*+9/_"RV2_PLMDO\++9+_"[9U  "J@0  GH@  ).-  "&C@  >(\
M &N2  !?E0  5)D  $F=  ! H   .J(- #BC%P WHR( -J0M #6D-P TI$$
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M 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP  %*Q  !%M
M.K8  "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT !\HG  ?*,@ &
MRSX !<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0  S/\  ,O_  '*
M_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y   YO   +K\
M "/#   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>  #8)P  V3$
M -L^  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<  -__  #?_P
MW_\  -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   LQ@  (<D  !C-
M   0T0  "]4   3:    W@   . !  #A"0  X@X  .03  #E&P  YR0  .DO
M  #K/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y  #P_P  \/\
M /#_ (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T   %=4   [:   '
MW@   .(   #F    Z0   .H   #L    [@4  .\,  #Q$   \Q<  /4@  #X
M*P  ^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_]0  __4  /_U
M '2N  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(   /F    Z0
M .P   #P    \P   /0   #V    ^    /H   #]!P  _PT  /\2  #_&P
M_R@  /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0  _]$  /_1 /\/
M) #_#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z
M /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z /\ Q0#_ -,
M_P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\ _@#_ /\1(0#_
M$!X _PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\
M?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P P #[ ,T ^0#B
M /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /\5'0#_$QH
M_Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#^
M (, _ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q ,@ [P#< .X
M[ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8&0#_%A4 _Q,3
M /\.$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L /@ =0#U 'X
M\@"% /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,, Y #4 .( Z0#A
M /< WP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_&A  _Q8. /\2
M#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"< #J G@ YP*
M .8#AP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70 -,&YP#0"/@
MS@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L _QH' /\9"P#_
M&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>#7, VPU[ -D-
M@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81Z0#"$OD OQ/_
M +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R   /\A!0#_'PP
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M!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!  #'0@  P$   +LZ 0"V-@X
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M#/ ]  #;2   QU   +I5  "P6   I58  )Q3  "73P  D5 . (Q2' ")5"L
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M%%M8N!196= 465CP$UE8_Q%:6/\06EC_#EI7_PU:5_\-6E?_#>-(  #+4P
MNUL  +!A  "D8@  EV$  (Y?  "%7   ?UX' 'M?$P!X82$ =6(N ')B.0%O
M8D,";&%+ VIA4P5G85H'96!B"6-@:@M@7W,-7EY]#UM>B1%979825UVE$U5=
MMA147<X45%WN$U1=_Q%57/\055S_#E5;_PY66_\-5EO_#=Y,  #'5@  N%\
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M$$1L_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P  *%Q  "2<
MA6\  'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7>#8 57@_ 5-X2 )1
M>$\#3W=7!$QW7P5*=V@'2'9S"45V?PM#=8T,076=#C]UK@X^=<4./77H#CYS
M_0T^<O\-/G'_##]Q_PP_</\,/W#_#,5>  "U:0  J7$  )QU  "-=   @'0
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M!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4  &.(  !8BP
M38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@ *9U! "B=2P G
MGE4 )IYA "6>;@ CGGX!(IZ0 2">HP$?GKD!'I[= 1Z<^ (>FO\"'IG_ QZ7
M_P,>E_\#'I?_ ZI]  ">A0  DXL  (6*  !UBP  :(X  %N1  !0E0  1ID
M #N=   RH   *J,  "*F"0 ?IQ$ 'J<: !VH)  <J"T &Z@W !JI00 9J4P
M&*E8 !>J9@ 6JG8 %:J) !2JG@ 3J[0 $JO3 !*H]0 3I_\!$Z7_ 1.E_P$3
MI/\!$Z3_ :.&  "7C   C9$  'V2  !ME0  8)@  %2<  !(H   /J0  #2G
M   JJP  (:X  !FQ   2LP< #[40  ZU%P .M2$ #;4K  VU-@ ,MD$ "[9.
M  JV7  )MFP "+9_  >VE  &MJH !;;%  :VZ@ 'M?\ "+3_  BS_P )LO\
M";+_ )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K   -;   "JS   A
MM0  &+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P  PC8  ,-"  ##
M4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##_P  P_\  ,/_
M ).4  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H  !^]   6P
M$,,   K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H  -$U  #30P
MU%(  -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P  UO\  -;_ (J;
M  ![H@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'   -RP  !LX
M  #2    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G  #E,P  YT(
M .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\  .O_ 'VC  !N
MJP  7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "V    -T   #A
M    Y    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T)   ]S$  /E!
M  #Z50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT '&L  !AM0
M4KT  $3$   TR0  )LT  !K2   0V   "-T   #A    Y0   .@   #L
M[P   /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0  _R$  /\O  #_
M00  _U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+( #_!QX _P =
M /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V /\ ?P#_ (<
M_P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L _P#A /\ \ #^
M /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_"QH _P09 /\
M&@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\ >@#_ (( _P")
M /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9 /4 ZP#T /D
M\P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4 _P@4 /\ % #_
M !D _P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z 'T ^0"$ /<
MBP#V )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D Y@#H /4 Y@#_
M .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/ /\#$ #_ !4
M_P @ /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@ [0!_ .L A@#J
M (P Z "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8 /  UP#^ -4
M_P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+# #_"1( _P,:
M /\ )@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z -X @ #< (<
MV@". -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T QP#[ ,4 _P#$
M ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_#PT _PP4 /P'
M'P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$>P#+!(( R@2)
M ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O] +8,_P"U#?\
MM W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8 ^A . .X,%@#C
M"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_#GX O0^% +P/
MC0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5_P"G%?\ IQ7_
M *84_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4% -X.#0#3#A@
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M!/4M  #D-P  T#\  ,)#  "W1   K4   *<Z  "C-@8 G3<3 )DY(@"5.B\
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M"V=&M@MF1LP+94;L"V1'_PED1O\(9$;_!V1&_P9D1?\&9$7_!N@[  #01@
MOTT  +-1  "E40  FDX  ))+  "-1P  AT@+ (-*%@!_2R0 ?4PQ 'I-/ !W
M344!=4U- G--50)Q35P#;TUC!&U,:P5K3',':4M]"&9+B0ED2Y8*8DND"V%+
MM Q?2\H,7DOJ"UY+_@I>2_\)7DK_"%Y*_P=>2O\'7DK_!^,_  #+20  O%$
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M#$Y8^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP  *->  "570
MB5P  '];  !V60  <%H  &M<#0!H71@ 9EXD &1?, !B7SH 8%]# 5Y?2P)<
M7U("6E]: UA?80557FH&4UYT!U%=?PE/78T*35V<"TM=K Q*7<$,25WC#$E<
M^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.  "\6   KF   )]A  "18   A5\
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M!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL  &QL  !A;@
M5W   %!S  !,=0H 2783 $=W'P!&=RD 17@S $-X/ !">$0 07A- 3]X50$]
M>%X".WAH CEX= ,W>(($-7B3!3-WI 4R=[D%,7C7!3%V]04Q=/\%,7/_!3%R
M_P4R<O\%,G+_!;=C  "J;0  G'$  (MP  !]<   <G   &=Q  !<<P  47<
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M :5[  "9@P  B8$  'N   !L@@  7X0  %2(  !)BP  /Y   #64   MEP
M)9H  !V> 0 6H P %*$2 !2A&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .
MHVL #:-]  VCD@ ,HZ< "J+   NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$
M  "2B0  @X@  '.(  !EBP  6(X  $R2  !!EP  -YL  "Z>   DH@  '*4
M !6H   /JP0 "JX,  >M$@ &K1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$
M *YS  "NAP  KIT  *ZT  "NU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",
MD   >Y   &N2  !=E@  4)H  $2?   YHP  +Z<  "6K   <K@  %+$   ZT
M   )MP   ;@)  "X#@  N10  +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG
M  "\>P  O)$  +RI  "\Q   O.L  +O^  "[_P  N_\  +O_ )"2  "#F
M<YL  &.?  !5HP  1Z@  #NM   PL0  );0  !NW   2N@  #+T   6_
MPP   ,0"  #%"@  Q0X  ,84  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-
M;   SH,  ,Z;  #-M0  SMH  ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8
M %JL  !,L@  /K8  #"Y   DO   &;\  !'"   *Q0   LD   #,    T
M -$   #2 0  TP@  -4-  #7$0  VA@  -PA  #?+   X3H  .)*  #C70
MY'(  .2+  #EI0  Y<   .7F  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV
M   _O   ,+\  "/#   7QP  #\H   ?.    T0   -8   #<    WP   .
M  #B    Y    .8#  #H"0  Z0X  .P5  #N'@  \2L  /0Z  #U30  ]F$
M /=Y  #XDP  ^*T  /G&  #YY   ^?,  /GS &VJ  !>L@  3[H  $#!   Q
MQ0  (LD  !;.   -T@  !-@   #=    X0   .0   #H    ZP   .T   #O
M    \0   /,   #V    ^ ,  /H+  #]$0  _QL  /\I  #_.P  _T\  /]F
M  #_?P  _YD  /^O  #_PP  _]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "(
M_P K /\ . #_ $8 _P!3 /\ 7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_
M )4 _P"; /\ H0#_ *@ _P"O /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L
M_P#[ /\ ^@#_ /0 _P#P /\ \ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F
M /\ - #_ $( _P!. /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )
M_ "6 /H G0#Y *, ^ "K /< M #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O
M /\ [@#_ .X _P#J /\ Z@#_ /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\
M+@#_ #P _P!) /\ 5 #^ %\ ^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2
M .\ F #M )\ [ "F .H K@#H +D YP#' .4 W@#C /  X@#^ .  _P#@ /\
MX0#_ .$ _P#A /\ X0#_ /\-$ #_"0T _P$, /\ # #_ !( _P < /\ * #\
M #8 ^0!# /8 3@#R %D [P!B .P :P#J '( Z !Y .8 @ #D (8 X@", .$
MDP#? )H W0"A -L J@#8 +0 U0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_
M ,P _P#, /\ S #_ /\0# #_# < _P," /\ " #_  X _P 6 /8 (@#P "\
M[  \ .D 2 #E %, X0!< -X 90#; &P UP!S -0 >@#2 (  T "' ,X C@#,
M )4 R@"= ,@ I0#& *\ Q "[ ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P
M_P"\ /\ O #_ /\1!0#_#@  _PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U
M -D 00#3 $P SP!6 ,L 7P#) &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )
MO "8 +H H0"X *L M@"W +0 QP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M
M!/\ K03_ /\4  #_$   _P\  /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@"
M.@#$ T4 P -0 +T$60"[!6$ N05H +<&;P"U!G8 M =] +('A "Q"(P KPB5
M *T)G@"K":@ J@JU *@*Q0"F"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\
MGP[_ /\7  #_$P  [Q@  .09  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W
M#3X M Y) +$.4P"O$%L K1!C *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2
MFP"@$Z8 GA.S )P3PP";%-X EQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_
M /\:  #T'0  Y2,  -4E  #*)   PAT  +X6! "[$!  M!,= *\5*P"K%C@
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M GHOMP)X+\P"=C#J G4P_@)S,/\"<S#_ G,O_P)S+_\"<R__ O J  #<-0
MQSL  +H_  "L/   HC@  )PS  "8+P  E2X0 ) P' ",,BD B3,U (8T/P"$
M-4D @C51 ( U6 !^-5\!?35F 7LV;@%Y-78">#6  G8UBP-T-9<#<C:D W V
MM 1O-L@$;3;G!&PV_ -K-O\#:S;_ FHV_P)J-?\":C7_ NHP  #3.@  PD$
M +-#  "E00  FSX  )4Z  "0-@  C#4- (@W& "$."4 @3HQ '\[/ !\.T4
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M!EA&]P571?\$5T7_!%=$_P-81/\#6$3_ ]H]  #$1P  M4X  *1.  "63
MBTL  (-)  !]10  >$8" '1'$ !P2!L ;DDG &M*,@!J2SP :$M$ &9+3 %D
M2U,!8DM: F!+8@)?2VH#74MT!%M*?P592HP%5TJ:!E5*J@=42KT'4TK<!U)*
M]@922O\%4DG_!%))_P-22/\#4TC_ ]1!  # 2P  LE$  *!0  "23P  ATX
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M!$15_P1$5/\#1%3_ \9,  "U5@  I5H  )19  "&6   >U@  '%7  !F5@
M85@  %U9! !96A  5UL; %5<)@!373  4ETY %%>00!/7DD 35Y1 4Q>6 %*
M7F$"2%UK T9==@-$78,$0EV2!4!=HP8_7;8&/EW0!CU<\04^6_\$/EK_!#Y:
M_P,^6?\#/UG_ \%0  "Q6@  H5T  )!<  ""6P  =EL  &U;  !A6P  6UT
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M K%A  "D:0  D&@  (!G  !T9P  :6<  %]H  !5:P  2VX  $-Q   \=
M-W8* #1W$@ S>!P ,G@E #%Y+@ P>3< +WD_ "YY2  L>E( *WI< "IZ:  H
M>G8 )GJ' 25ZF0$C>JP!(GK% 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH
M  "=;@  BFT  'ML  !O;   96P  %IN  !0<0  174  #UX   V?   +G\"
M "F!#0 G@A0 )H(> "6")P D@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$
M'(2" !N$E0 :A*D &(3! !B#Y@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5
M<P  A'(  '9Q  !K<0  7G,  %1V  !)>0  /WT  #>!   OA   )X@  ""+
M!0 ;C0X &HT5 !F-'@ 8CB< %XXP !:..0 5CD, %(]/ !./6P 2CVH $8][
M !"/CP /CZ0 #H^[  V/X  .C?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0
M?G<  ')W  !D>   6'L  $U^  !"@@  .88  "^*   GC@  ()$  !B5   2
MF 4 #IH.  V:%  ,FAT "YHF  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:
MA@ "FIL  )JQ  &9SP "F?   IC_  27_P %EO\ !9;_ )F!  "'?P  >GX
M &M^  !=@0  4(4  $6)   [C0  ,9(  "B6   ?F0  &)T  !&@   ,HP(
M!J4*  &E$   I18  *8?  "F*   IC(  *<]  "G2@  IU@  *=H  "G?
MIY$  *:H  "FPP  I>D  *7\  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(
M  !5C   29$  #V6   RF@  *)X  !^B   7I@  $*D   NL   $KP   +$&
M  "Q#   LA$  +(7  "S'P  LR@  +0R  "U/P  M4T  +5=  "U<   M88
M +6=  "UM@  M=P  +3W  "T_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-
MF@  0)\  #6D   JJ   (*P  !:P   /M   ";<   &Y    O0   +X   "^
M!@  OPP  , 0  #!%@  PAT  ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1
M  #'J0  Q\<  ,?L  #'_@  Q_\  ,?_ (.7  !QF@  89X  %*C  !%J0
M.*X  "RS   @MP  %KH   Z]   &P    ,,   #'    R0   ,H   #,
MS0,  ,X)  #0#@  TA,  -0;  #8)0  VS(  -U"  #=5   WFD  -Z!  #>
MG   W[4  -_9  #?\P  W_\  -__ '>?  !HI@  6:T  $JS   [N   +;L
M !^_   4P@  #,8   /)    S    -    #5    V0   -H   #<    W@
M .    #B!0  Y L  .<0  #J&   [20  / R  #Q1   \E@  /-O  #TB@
M]*0  /2_  #TWP  ]/,  /3T &JH  !;KP  3+<  #V]   MP0  '\8  !/*
M   +S@   -(   #7    W    .    #E    YP   .D   #K    [0   .\
M  #Q    \P   /8'  #Y#@  _!8  /\B  #_,P  _T<  /]=  #_=@  _Y$
M /^I  #_O@  _]@  /_; /\ & #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_
M $, _P!/ /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\
MG #_ *, _P"K /\ M #^ +\ _0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_
M .X _P#I /\ YP#_ /\ % #_ !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X
M_P!* /\ 5@#_ &  _P!H /\ < #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W
M )X ]0"F /0 K@#R +D \0#' .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4
M_P#@ /\ W@#_ /\#$ #_  X _P - /\ #0#_ !, _P > /\ *P#_ #@ _P!%
M /X 4 #[ %H ^ !C /4 :P#S '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D
MYP"@ .8 J0#D +, X0#  .  TP#> .L W #[ -L _P#: /\ V@#_ -D _P#4
M /\ T@#_ /\'#0#_  D _P & /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /(
M2@#M %0 Z@!= .< 90#D &P X@!S .  >@#> (  W "& -H C0#7 )0 U ";
M -( I #/ *T S0"Y ,L R0#) .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\
MQP#_ /\*!@#_ 0  _P   /\ ! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#=
M $X V0!7 -0 7P#1 &< S@!M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$
MG@"_ *@ O0"S +H P@"Y -L MP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_
M /\,  #_!   _P   /X   #V  , Z  - .  %P#9 "0 T0 Q ,T / #* $<
MQ@!1 ,, 60#  &  O@!G +P ;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P
M *0 K@"O *P O0"J -  J #K *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-
M  #_!P  ] D  .H)  #B!   V@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!*
M +0 4P"R %L L !B *X : "L &\ JP!U *D ?0"H (0 I@"- *0 E@"C *
MH0"K )\!N0"= \P G 3H )H&^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W
M$   Z!0  -P5  #.$0  Q@T  ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(
M30"F"%4 I E< *(*8P"@"FH GPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ
M )0-N "2#<P D [J (X0_ ",$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@
MW2   ,PA  "_'0  MQ<  +,1  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":
M$5  F!)7 )827@"5$V4 DQ-L )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6
MM0"&%LD A!?G ((8^P" &?\ ?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD
M , J  "S)@  JB(  *4<  "D%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL
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M 64P]0%D,/\!8S#_ 6,O_P%C+_\!8R__ >(N  #*.   NCT  *@\  ":.@
MD3<  (HS  "&,   @RX) '\O$P![,!\ >#(K '8S-0!T,SX <C1& ' T3@!O
M-54 ;35< &PU9 !J-6P!:#5U 6<U@ %E-8P!8S6: F$VJ0)@-KL"7S;6 ETV
M\P)=-O\"7#;_ 5PU_P%<-?\!7#3_ =PS  #%/   M$$  *)   "5/@  BSP
M (0Y  !_-@  >S0$ '<U$ !T-QP <3@G &\Y,@!M.3L :SI# &HZ2P!H.U(
M9SM9 &4[80%C.VD!8CMR 6 [?0%>.XH"7#N7 EL[IP)9.[@#6#O2 U<[\0)6
M._\"5CO_ E8Z_P%6.O\!5CG_ =0W  # 00  KT0  )U#  "00@  A4   'X^
M  !Y.P  =#H  '$Z#@!M/!@ :STD &D^+P!G/S@ 93]  &1 2 !B0$\ 84!7
M %] 7@%=0&8!7$!O 5I >@)80(<"5D"5 E1 I -30+8#4D#/ U% [P-00/_B
M__])0T-?4%)/1DE,10 &"?\"4#__ E __P)1/O\!43[_ <\[  "]10  JD<
M )E&  "+10  @40  'E"  !T/@  ;S\  &M # !G014 94(A &-#*P!A0S4
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M T%-Z@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\  (U.  " 3@
M=4T  &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P 3U$U $Y2/0!-
M4D4 3%)- $I25 !)4ET!1U)F 452<0%#4GX"05*- C]2G0,^4J\#/5+& SQ2
MZ0(\4?X"/%#_ CU/_P(]3_\"/4[_ KY+  "N4P  FE(  (E1  !\40  <5
M &A0  !>3@  6%$  %12  !14PP 3E04 $Q5'P!+5BD 258R $A6.@!'5T(
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M 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L  %Q<  !17@
M26   $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34 +VH] "YJ1@ M
M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")JX  C:?D!(V?_ 2-F
M_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86   %=@  !-8P  1&8
M #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W "5R0  D<DH
M(G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :<?< &G#_ !MO_P ;
M;O\!&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F  !(:0  /VP  #=O
M   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\.0 8?$, %WQ.
M !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_ !%X_P 2=_\
M$G?_ )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<   .70  #%X   I
M>P  (G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .ASL #8=&  R'
M4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#_P )@O\ "8+_
M )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT  "J!   BA0
M&XD  !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,  ),^  "32P
MDUD  )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P  C_\  (__ (UW
M  !]=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-   :D0  $Y0
M  Z7   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U  "@0@  H%
M *!?  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\  )S_ (9]  !X
M?   :7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2G@  #:$   :D
M    IP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O-P  KT4  *]4
M  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_ (&$  !QA
M88<  %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K   !*\   "R
MM@   +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P  P#@  ,!(  #
M6@  P6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-  !HD   690
M $N:   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X   #!    Q
M ,4   #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL  -4Z  #53
MUF   -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@G@  4:0  $.J
M   UL   *+8  !RZ   1O@  "<$   #%    R    ,L   #/    T@   -,
M  #6    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ  #M/   [5$
M .YG  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0  2;0  #JZ   J
MO@  ',(  !#&   'R@   ,X   #2    U@   -P   #@    XP   .0   #F
M    Z    .L   #M    [P   /("  #U"@  ^!$  /P<  #_+   _S\  /]5
M  #_;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2 /\ % #_ !D
M_P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@ _P!_ /\ A0#_
M (L _P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X /0 ]P#_ /8
M_P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\ #P#_ !0 _P @
M /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y /D @ #W (8
M]@", /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X Z0#^ .< _P#G
M /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_ !  _P ; /\
M* #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L >@#I (  YP"&
M .8 C0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X -( _P#2 /\
MT@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T _  6 /< (@#S
M "X [P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5 'H TP"  -$
MAP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\ _P"_ /\ O@#_
M +X _P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1 .< &P#A "<
MW0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ', P !Z +\ @ "]
M (@ NP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M /\ K0#_ *X
M_P"N /\ K@#_ /\"  #_    _0   /(   #H    W@ , -, %0#, "$ R  L
M ,0 . #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T *\ >@"M ((
MK "* *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\ G@#_ )X _P">
M /\ G@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"] !D N  E +0
M,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$ =0"? 'P G@"%
M )P C@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_ )  _P"/ /\
MCP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !( K  > *@ *0"E
M #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3 W@ D0.  ) $
MB@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+_P"#"_\ @PO_
M /80  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46 )T'(@"9"2X
ME@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0 A@Y] (4.AP"#
M#I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W$O\ =Q+_ .\7
M  #;(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0&P"/$2< C!(R
M (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X 'D7@P!X%X\
M=AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\ ;1K_ .<@  #0
M*0  O"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$&B( @1LM 'X<
M-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @?P!N(8L ;"&8
M &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_ . F  #(+P
MM#$  *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX >",I '4D,P!S
M)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E*(@ 9"F5 &(I
MI !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L  ##-0  K34
M )TT  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE &TK+P!K+#@
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M 4HZY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\  (X_  "!/@
M=ST  ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X 5STW %8]/@!4
M/D8 4SY- %(^50!1/ET 3S]F $T_< !,/WT!2C^+ 4@_FP%'/ZP!13_! 40_
MXP%$/OL!1#[_ 40]_P%$/?\!13S_ <,^  "O0P  FD(  (I"  !]00  <T
M &L_  !E/   8#P  %P^! !9/@\ 5S\8 %5 (@!302L 4D$T %!"/ !/0D,
M3D)+ $U#4@!+0UH 2D-D $A#;@!'0WL!14.) 4-#F0%"0ZL!0$/  3]#X0$_
M0_D!/T+_ 3]!_P% 0?\!0$#_ ;]!  "J10  ED4  (9%  !Y1   ;T0  &="
M  !@/P  6T$  %="  !40PT 4405 $]%'P!.12@ 3$8Q $M&.0!*1T$ 24=(
M $A'4 !&1U@ 14=A $-(; !"2'@!0$B' 3Y(EP$\2*D!.TB^ 3I(WP$Z1_@!
M.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P  :T<  &-&  !;
M0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%2SX 0TM& $),
M30!!3%8 0$Q? #Y,:@ \3'8 .TR% 3E,E0$W3*<!-DR\ 35,W0$U2_<!-4O_
M 35*_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H  %])  !52
M4$H  $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L /E!# #Q12@ [
M45, .E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O4/8!+T__ 3!.
M_P$P3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T  %M-  !130  2T\
M $90  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53< -U8_ #961P U5E
M,U99 #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I5O4 *57_ "I4_P$J
M4_\!*E+_ :]1  "840  A5$  '90  !J4   8%   %A1  !.4@  1U,  $%5
M   [6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<0P M7$P +%Q6
M "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_ "-:_P C6?\
M)%C_ *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@  0U@  #Q;   V
M70  ,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E8T< (V-1 ")D
M7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@_P <8/\ '%__
M *%9  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX  #=@   Q8P
M*F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T( &FQ, !EL6  7
M;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3:/\ $V?_ )E=
M  "%70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G   K:@  )&T
M !YP 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&  ]U4@ .=5\
M#75N  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\ #'#_ )%B  !_
M80  <&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D<@  '78  !=Y
M   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_2P "?U@  7]G
M  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_ (EG  !X9P
M:V8  &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?   %H   !"#   ,
MA@( !HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P  BU   (M?  "+
M<0  BX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M  !S;   :&P
M %IM  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P   N/   $D@
M )0&  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<  )E6  "9:
MF7T  )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O<P  87,  %-V
M  !&>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<    H    *$
M  "B!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,  "I7@  J7(
M *B)  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P  67X  $N"   ^
MAP  ,HT  ">2   =EP  %)P   Z@   'I    *@   "K    K@   *\   "P
M    L00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z4@  NV4  +M]
M  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L  $.0   VEP
M*IT  !^B   5IP  #:P   6P    M    +<   "[    O@   +\   #
MP0   ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1   T%@  -!N  #1
MB   T*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA   NIP  (:T
M !:S   .N   !KP   #     PP   ,8   #+    S0   ,X   #0    T0
M -0   #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D  .E?  #J>
MZY0  .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   FN0  &;X   ["
M   $Q0   ,H   #-    T0   -@   #;    WP   .    #B    Y    .8
M  #I    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/  #_9P  _X(
M /^=  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8 _P B /\ +P#_
M #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_ (8 _P", /X
MDP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /, _P#S /\ Z0#_
M .  _P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P = /\ *@#_ #8
M_P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (  \@"& /  C0#O
M )0 [0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B /\ W@#_ -$
M_P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\ ) #] #  ^P [
M /< 1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"  .  AP#> (X
MW "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\ RP#_ ,4 _P"_
M /\ O #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M "H Z@ U .<
M0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H @ #( (< Q@"/
M ,0 F #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_ +< _P"S /\
ML #_ /\   #_    _P   /D   #N  4 Y0 . -X & #8 ", T@ N ,\ .0#+
M $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U ($ M ") +(
MD@"P )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4 _P"E /\ I #_
M /\   #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H +L ,P"Y #T
MM0!& +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H I "" *( C "@
M )8 GP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7 /\ EP#_ /\
M  #U    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L + "H #8 I@ _
M *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!] )0 A@"2 )$
MD "< (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\ B #_ /D&  #I
M#   U X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0"; #  F  Y )8
M00"4 $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (< @0"% (P A "8
M (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_ /$.  #>%0
MQ14  +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D C0(S (H#/ "(
M!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z"8D > F6 '<*
MHP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6  #0'@  N1T
M *D<  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM ( --@!^#CX
M? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8< ;A&4 &P1H@!K
M$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&)   L"0  * C
M  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84,0!T%3H <A9!
M '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0 &,:GP!A&J\
M8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@  J"D  )@I  ",
M*   @R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K'34 :1X] &@>
M1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HBG !9(JP 5R+
M %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX  )(N  "%+0
M?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$ 8B4Y & F00!?
M)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1*:H 4"F^ $\I
MW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR  " ,0  =C
M ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV %DL/0!8+$0
M5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@ 22^[ $@OVP!(
M+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![-0  <C0  &LR
M  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q.@!2,D( 43))
M % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y $(TU@!"-/0
M0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.   ;3<  &8V  !A
M,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,-S\ 2S=& $HW
M3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TYTP \.?, /#C_
M #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH  &(Y  !=-P
M6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP 1CQ$ $4\2P!$
M/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W/?( -SS_ #@[
M_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]  !8.P  4SH
M $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!! $! 20 ^05$
M/4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?  ,D#_ #- _P S
M/_\ -#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4/P  3C\  $I
M  !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%1@ Y14X .$98
M #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_ "Y$_P N0_\
M+D/_ *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P  2$,  $1%  !!
M1@$ /D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S2DP ,DI5 #!+
M7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)_P H2/\ *4?_
M *=&  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@  #]*   [2P
M-TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@ *U!2 "I07  H
M4&@ )U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B3?\ (TW_ *%)
M  ",20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.   U4   ,5($
M "U3#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9. ")660 A5F4
M'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\ '%+_ )M-  "&
M30  =4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q50  *U@  "9:
M"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=50 876$ %UUP
M !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_ )11  " 40
M<%$  &11  !940  45$  $E2  !!4P  .%8  #)9   K6P  )5X  !]A P :
M8PP &&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  095T #V5K  YE
M?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5  !Z50  :U4
M %]5  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4  !EH   3:P4
M$&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E< !FYE  1N=@ "
M;HH  &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T6@  9EH  %Q9
M  !360  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q   .= , "G<*
M  5W$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>  !X;P  >(0
M 'B9  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P  8EX  %E>  !-
M7P  0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (?@   H (  "!
M#0  @1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$:   A'P  (23
M  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,  %)D  !'9P
M/&L  #%O   H<P  ('<  !A\   1?P  #(,   :'    B@   (P#  ","0
MC0X  (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P  DG,  )*+  "1
MH@  D;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM   _<0  -'8
M "I[   @@   %X4  !")   +C0  !)$   "5    F    )D   ": P  FP@
M )P-  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD  **   "BF@
MH;,  *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W?@  +(0  "&*
M   7CP  $)0   J9   !G0   *    "D    IP   *@   "I    J@   *P&
M  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S  "UC@  M:@
M +3&  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@  (Y0  !B:   0
MGP  ":0   "I    K0   +    "T    MP   +@   "Y    NP   +P   "^
M @  P @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*?P  RIL  ,JX
M  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4  !&K   )L
M +4   "Y    O0   ,$   #&    R    ,D   #+    S    ,X   #0
MT@   -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P  YHP  .:H  #E
MQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\    P0   ,4
M  #)    S0   -(   #6    V@   -L   #>    X    .(   #D    YP
M .D   #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H  /V7  #]KP
M_<<  /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_ #8 _P!" /\
M30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P C0#Z )0 ^0"<
M /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_ -< _P#. /\
MR@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$ _P ] /\ 1P#^
M %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L (X Z@"6 .@
MGP#F *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D _P#" /\ O@#_
M /\  P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V /, 00#O $L
M[ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@ U "0 -( F #/
M *( S0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V /\ LP#_ /\
M  #_    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$ .P#< $4 U0!-
M -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP") +T D@"[ )P
MN0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\ IP#_ /\   #_
M    _@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$ #X P !' +P
M3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H BP"H )4 IP"@
M *4 K0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_ /\   #\
M[@   .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #< K0!  *H 2 "H
M $\ I0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8 (X E@": )4
MIP"3 +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P   #O    VP
M ,D   "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z )H 0@"8 $D
ME@!/ )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D B "5 (8 H@"%
M +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@"0  QP@  +<'
M  "L P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T / "+ $, B0!)
M (< 4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0 'D G0!X *P
M=@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$   N1   *D0  ">
M#@  EPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_ #X ?0!$ 'P
M2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"F@!L ZH :P.[
M &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<  )X6  "3%0
MBQ(  (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@ <PE  '()1@!P
M"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B#:D 80V[ & -
MV !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=  ")'   @1H
M 'L7  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [ &D00@!G$4D
M9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z< 5Q2Z %84U0!5
M%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!(@  >2$  ',>
M  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7/@!>&$4 71A+
M %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW $X;T !-'/$
M3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P  <B8  &PD  !H
M(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7'T$ 5B!( %0@
M3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<BS0!&(^\ 12/_
M $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H  &8I  !B)@
M7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X 3R9% $XF3 !,
M)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _*.T /RC_ #\H
M_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M  !=*P  6B@
M %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M" $@L20!&+%$
M12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L .BW_ #HM_P Z
M+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8+P  52P  %$L
M  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q1P!!,4\ 0#%7
M #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_ #4Q_P U,?\
M-3#_ *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P  4#   $PQ  !)
M,08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \-DP .C95 #DV
M7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U_P P-?\ ,#3_
M *DV  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0  $<U  !$-@,
M03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH -3I3 #0[70 R
M.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K.?\ +#C_ *0X
M  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z   _.P  /#P+
M #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0 "X_6@ M0&8
M*T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\ )CW_ )\[  "*
M/   >#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y/P  -D$( #1!
M#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$6  G16, )45Q
M "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_ )H^  "%/P
M=$   &=   !<0   4T   $Q   !&0   /D$  #A#   T10  ,$8# "U'#0 K
M2!( *D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @2F$ 'TIO !U*
M?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"  " 0@  <$,
M &-#  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL  "9-"0 D3A
M(DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T %U!K !90?  4
M4(\ $U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![1@  :T8  %]'
M  !51P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3 P <50P &E81
M !E6&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H  ]7>0 .5XP
M#5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@  9TH  %M*  !1
M2@  2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   57 < $5X- !!>
M$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =><P %7H8  UZ;
M  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX  %=.  !.3@
M1TX  #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P, #&8+  AG$  &
M9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0  9X   &:5  !F
MK   9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12  !+4@  0E,
M #E5   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)  !O#@  ;Q(
M &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D  '&/  !PIP
M;\$  &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&5P  /%H  #)=
M   J80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X"P  >0X  'H3
M  ![&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(  !\H0  ?+H
M 'OB  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P  -6,  "MG   C
M:P  &F\  !-S   .=P  "'L   )^    @@   (,!  "$!@  A0L  (8/  "(
M$P  B1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+F0  BK,  (G8
M  "(]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX  "1S   :>
M$WT   V!   &A0   (D   "-    D    )(   "2    E 4  )4*  "7#@
MF!(  )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0  FZL  )K)  ":
M\   F?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!   2AP  #(P
M  21    E0   )D   "=    H    *$   "B    I    *4!  "G!P  J0P
M *H1  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$  *Z^  "MY@
MK/P  *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,F    YT   "B
M    I@   *H   "N    L    +$   "S    M    +8   "X    N@0  +P*
M  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O  #%T0  P_(
M ,/_ %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0   *X   "R
MMP   +L   "_    P@   ,(   #%    Q@   ,@   #*    S0   ,\   #2
M"   U0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #AO0  X>(  .#T
M $Z+  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\   #$    R
M ,X   #1    U    -4   #8    V@   -T   #?    X@   .0   #G
MZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP  ^,0  /CA /\
M"P#_  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\ 2 #_ %( _P!:
M /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7 /4 H #S *H
M\@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\ P@#_ /\ ! #_
M    _P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#] $P ^0!4 /<
M7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0 F@#B *0 X "P
M -T P #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_ /\   #_
M_P   /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8 Z !. .0 5@#A
M %P W@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#( )T Q@"H ,0
MMP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\   #_    _P
M /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!( ,H 3P#' %8
MQ !< ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8 L@"A +  KP"N
M ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_    ]P   .@
M  #<    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4 2 "R $\ L !5
M *X 6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP": )T IP"; +@
MF@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V    Y    -(   #%
M    NP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@ $D G@!/ )P
M50": %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P H0"+ +  B@#%
M (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0   +T   "S
MJ@   *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $, C@!) (P 3P"*
M %0 B0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\ *H >P"\ 'H
MVP!X /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!  "B    FP
M )8 !0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !# 'X 20!] $\
M? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4 ;@"V &T S@!L
M .X :P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3"P  C <  (@"
M  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ', 1 !Q $H < !0
M &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R &$ R0!@ .D
M8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0  @ \  'P-  !Y
M"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G T8 9@1, &4$
M4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'Q@!6">< 5@K[
M %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8  '$3  !N$
M;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$( 7@U( %P-3P!;
M#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-$.H 31#] $T0
M_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:  !F%P  9!0
M &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)% %023 !3$U,
M41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@ 11;^ $46_P!%
M%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?'0  7!H  %L7
M @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T92 !+&E  2AI8
M $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\ #X<_P ^&_\
M/AO_ *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@  5A\  %0=  !3
M' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%($T 0R!5 $(@
M7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B_P X(?\ ."'_
M *HF  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,  $\B  !,(@<
M2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H /293 #PF7  Z
M)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R)O\ ,R7_ *4I
M  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF  !')P0 1"<-
M $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0 #8K6@ U*V4
M,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\ +2K_ *$L  "+
M+0  >2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!*P  /RP+ #TL
M$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P6  P,&, +C!P
M "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_ )PN  "',
M=C$  &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,   .C$) #<Q$  V
M,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J-6$ *35N "<U
M?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q  "#,P  <C0
M &4T  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4& #(V#@ P-Q,
M+S<; "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\ (SEL "$Z?  @
M.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_-@  ;C<  &$W
M  !7-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P["P J/!$ *3P8
M "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I !L_>0 :/XP
M&#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.   :CD  %XZ  !3
M.@  2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D0@X (D(4 "%"
M&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$=P 31(H $D2>
M !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT  %H]  !0/0
M2#T  $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P &TD1 !E)%P 8
M21X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .2H< #4J;  Q*
ML  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9   !-0   14
M #]    Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U . !)0$P 14!D
M$% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($ !5"6  -0JP "
M4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*1   0T,  #Q$
M   U10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8$  *6!4 "%@<
M  =8)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1  !7IP  5\
M %;E  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P  0$<  #A(   P
M2@  *4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@  7Q(  %\8  !@
M'P  8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?H@  7[L  %_B
M  !>^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP  #).   K40
M(U0  !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\  &@3  !I&0
M:B$  &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0  :;8  &C=  !H
M]P  9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6   D60  '5T
M !9@   09   #&<   9J    ;@   &\#  !P"   <0T  '(0  !T%   =1L
M '8C  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$  '33  !S]0
M<_\  '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =8P  %6<  !!L
M   *<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!$   @A0  (0;
M  "%)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)  ""\0  @?\
M (#_ %];  !66@  25L  #U>   R80  )V8  !YK   5<   #G4   EY   !
M?@   ($   "%    B    (H   "+    C0$  (X&  "0"P  D0\  ),4  "5
M&P  ER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3Z@  DO\  )+_
M %UA  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0   ")    C@
M )(   "6    F    )H   ";    G0   )\   "A P  HP@  *4-  "G$P
MJ1P  *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0  I_@  *;_ %9H
M  !(;   .G   "YV   B?0  %X0   Z*   'D    )8   ":    GP   *,
M  "G    J@   *L   "M    KP   +$   "S    M0   +@%  "Z#   O1(
M , <  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\  +S^ $YT  !
M>0  ,G\  "6'   9C@  $)4   ><    H@   *<   "L    L    +4   "Y
M    O    +T   "_    P0   ,,   #&    R    ,H   #- @  T L  -42
M  #6(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR $:"   XB0
M*Y   !V8   2H   "J<   "N    M    +D   "^    P@   ,@   #+
MS@   ,\   #2    U    -8   #:    W0   -\   #B    Y@   .H*  #O
M$P  \"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\ !@#_  , _P %
M /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5 /\ 70#_ &0
M_P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8 [@"S .L Q #I
M .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_    _P   /\
M @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0 5P#Q %T [@!C
M .P :0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K -4 NP#2 -0
MSP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_    _P   /\   #_
M  8 ^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #; %< UP!= -0
M8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T L@"[ ,8 N0#H
M +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P   /4   #K  $
MY  , -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %  O0!6 +L 7 "Y
M &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F +L I0#: *,
M]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\   #0    QP '
M ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/ *8 50"D %H
MHP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +( D@#) )$ ZP"1
M /\ D #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z    L0 " *L
M# "G !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0 3P"2 %0 D !:
M (\ 7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^ (  X "  /D
M?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H    H    )D !P"5
M  X D@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20"" $X @0!4 '\
M60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '( SP!Q /$ < #_
M '  _P!P /\ <0#_ .$   #$    L    *(   "7    D0   (L  @"&  L
M@P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D <P!. '( 5 !P
M %H ;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D .@ 9 #] &,
M_P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X   ![  8 =P .
M '4 $P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!) &8 3P!E %8
M8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$ 6 #X %@ _P!8
M /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O!@  ;0 * &L
M$ !I !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P 2P!; %( 6@!9
M %@ 8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T $X#_P!.!/\
M3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@  8PL# &,&# !A
M!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3"$\ 40A6 % )
M7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,_P!%#/\ 10S_
M + 4  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$  %H.!@!:# T
M5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT 2@Y5 $@/7@!'
M#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]$/\ /A#_ *D9
M  "2&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3  !2$0H 4! 0
M $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12 $$46P _%&4
M/A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\ -Q7_ *,<  "-
M'@  >R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+%@8 218. $<7
M%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:6  Y&F, -QMO
M #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_ )T?  "((@
M=R,  &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' ( 0QP, $$<$@ _
M'1D /ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S(&  ,2!M "\@
M?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB  "$)0  <R8
M &4G  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$) #LA$  Y(A8
M."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X *R5K "HE>@ H
M)8P )B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  " )P  ;RD  &(J
M  !7*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F#@ T)Q0 ,B<;
M #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII "0J>  C*HH
M(2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@  ;"L  %\L  !4
M+   3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N+!$ +2P8 "PL
M'P J+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O=@ =+X@ '"^;
M !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X  %LO  !1+P
M22\  $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1  )S$5 "8Q'  E
M,B, )#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8-(8 %C2: !0S
MK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q  !.,@  1C(
M $ Q   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382 " W&0 ?-R
M'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80 $3F8 ! YK0 .
M.,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+-   1#0  #TT
M   X-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]%0 8/1P %STC
M !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5  L^J0 */L$
M"CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P  03<  #LW   U
M-P  ,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 10Q@ $4,? !!$
M)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#I0 "0[T  T/@
M  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH  #@Z   S.@
M+3L  "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0 "TH;  E*(P (
M2BL !THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0  2;D  $G=  !)
M]0  2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]   O/@  *4
M "-"   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7  !1'@  428
M %$O  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4  %#8  !0]0
M3_\  $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J0P  )$8  !Y(
M   72P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9&0  6B$  %HI
M  !:,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1  !8]   5_\
M %?_ &5%  !810  344  $5$   ^1   -44  "U'   E2@  'DT  !A0   2
M4P  #E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0  8QL  &0C  !D
M+0  9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A\@  8?\  &#_
M %]*  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4  !)9   -70
M"&    )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8  ' =  !Q)@
M<3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P  ;/\  &S_ %I/
M  !03@  2$T  #U.   S40  *50  "!8   87   $6    QD   &:    &L
M  !O    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6  !_'@  @"@
M ( U  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\  'K_ %94  !.
M4P  0E0  #=6   L6@  (E\  !AC   1:   "VT   -R    =@   'H   !]
M    @    (,   "$    A@   (<"  ")!P  BPP  (T0  "0%@  DA\  )(L
M  "2.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_ %59  !(6@
M.UT  "]A   D9@  &6P  !%R   *=P   GT   ""    A@   (L   ".
MD0   ),   "5    EP   )D   ";    G00  )\*  "B#P  I!8  *8A  "F
M,0  ID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA  ! 9   ,VD
M "=N   ;=0  $7P   N#    B0   (X   "3    F    )T   "A    I
M *4   "G    J0   *L   "M    L    +(   "U"   N X  +P6  "\)0
MO#<  +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y<   *W<  !]_
M   3A@  "XX   &5    FP   *$   "F    JP   +    "S    MP   +<
M  "Z    O    +\   #!    Q    ,<   #*    S04  -$.  #4&0  U"L
M -1   #36   TW0  -.2  #2L   TM,  -+R #YY   Q@   (X@  !>1   -
MF0   Z    "G    K@   +,   "X    O0   ,(   #&    R@   ,H   #-
M    SP   -(   #5    V0   -T   #?    XP   .<%  #K#P  [!\  .TS
M  #N2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $ /\ "0#_  X
M_P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X _P!E /T :P#[
M '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F .  XP#X .(
M_P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\   #_  D _P 0
M /\ &0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!> .D 9 #F &H
MY !P .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X R0#P ,< _P#%
M /\ NP#_ +0 _P"M /\ J0#_ /\   #_    _P   /\   #[  ( ]@ - /$
M$P#M !X [  H .D ,@#C #L W0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H
M ,8 ;P#$ '8 P@!^ +\ AP"\ )( N@"? +< K0"U ,$ L@#D +$ _0"O /\
MK #_ *4 _P"@ /\ G #_ /\   #_    ^P   .X   #D    W  ( -, $ #/
M !@ RP B ,D *P#& #0 P0 ] +T 1 "Z $L MP!1 +4 5@"R %P L !A *X
M9P"L &X J@!V *@ ?P"F (H HP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_
M )8 _P"3 /\ D #_ /\   #V    YP   -,   #&    O0 # +@ #0"S !,
ML0 < *\ )0"N "X J0 V *8 /0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8
M &8 E@!N )0 =P"2 ($ D ". (X G ", *T B@## (D Z "( /\ B0#_ (<
M_P"% /\ @@#_ /,   #C    S    +P   "P    IP   *$ " ">  \ FP 6
M )D 'P"8 "< E@ O ), -P"1 #T C@!# (P 20"+ $X B0!4 (< 60"% &
MA !G (( ;P"  'H ?@"& 'P E !Z *0 >0"X '@ V !W /< > #_ '@ _P!W
M /\ =0#_ .8   #+    MP   *@   ">    E@   (\ ! "+  P B  2 (<
M&0"% "$ A  I (( , !_ #< ?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A
M '( :0!Q ', ;P!_ &T C0!L )T :@"O &D R !H .T :0#_ &D _P!I /\
M:0#_ -(   "X    I0   )<   "-    A@   ($   !\  @ >0 . '< % !V
M !P =  C ', *P!Q #$ ;P W &X /0!L $, :P!( &H 3@!H %0 9P!; &4
M8P!C &T 8@!X &  AP!? )8 70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_
M ,(   "J 0  F ,  (D$  !_ @  >    '0   !P  0 ;0 , &L $0!I !<
M:  > &8 )0!E "P 8P R &( . !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8
M &@ 5P!S %4 @0!4 )$ 4@"C %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'
M  "?"0  C0L  'X,  !S"P  ; H  &@'  !E P  8P ' &$ #0!? !, 70 :
M %P (0!; "< 60 M %@ ,P!6 #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0
M30!O $P ?0!* (T 20"? $@ L@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5
M#@  @Q   '40  !K$   8P\  %X.  !;#   6@D" %D$"@!7  \ 50 5 %,
M' !2 ", 40 I $\ +P!. #4 30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M
M $,#>@!" XL 0 .< #\#KP ^ \@ /03J #T%_  ]!O\ /@;_ *00  ".$@
M?!,  &X4  !D%   7!,  %82  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+
M"!\ 20@E $@)*P!'"3$ 1@DX $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+
M>0 Z#(H . R< #<,KP U#,< -0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<
M &D8  !>&   5A@  % 7  !-%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H
M0PXA $(.* ! #BX /PXU #X//  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R
M$(H ,1"< "\0L  M$,D +1'L "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<
M  !9'   41P  $P;  !'&@  1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(>
M #L3)0 Z$RL .!,R #<3.0 V%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@
M*A6: "@5K@ G%<< )A7J "<5_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6
M'P  3A\  $@>  !#'0  0!P  #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48
M(@ S&"@ ,A@O #$9-@ P&3T +AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9
M "(:K0 A&L4 (!KH "$:_@ B&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@
M2B(  $0A   _(0  /"   #D>   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N
M'24 +1XL "L>,P J'CL *1]# "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?
MJP ;'\, &Q_G !L?_0 ='_\ 'A[_ (D@  !U(@  92,  %DD  !/)0  1R4
M $$D   \(P  .",  #4B   S(   ," ! "XA"@ L(1  *R$5 "HB'  H(B,
M)R(I "8C,  E(S@ (R-! "(D2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6
M),$ %23E !8D_  7(_\ &2/_ (4B  !Q)   8B8  %8G  !,)P  1"<  #XG
M   Y)@  -28  #$E   N)   *R4  "DE!P G)@X )283 "0G&0 C)R  (B<G
M "$H+@ @*#8 'B@^ !TH2  ;*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<
M$2CD !$H^P 3*/\ %"?_ ( E  !N)P  7R@  %,I  !)*@  0BD  #LI   V
M*0  ,B@  "XH   J*   )BD  "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM
M*P :+3, &"T\ !<M10 6+E  %"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?
M  TM^0 .+/\ $"S_ 'PH  !J*@  6RL  % L  !&+   /RP  #DL   T*P
M+RL  "LK   F+   (BX  !\O   <, D &C$. !DQ$P 7,1H %C(A !4R*  4
M,C  $S(Y !(S0P 1,TX $#-;  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R
M]  *,?\ "S'_ '<K  !F+0  6"X  $TO  !#+P  /"X  #8N   Q+@  +2X
M "DN   C,   'S(  !LS   7-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P
M#C@U  TX/P ,.$H "SA7  DX90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #
M-O\ !3;_ ',N  !B,   5#$  $DQ  !!,0  .3$  #0Q   O,   *S   "4R
M   @,P  &S8  !<X   3.@( $#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ
M  8^.P %/D8  SY2  $^80  /G(  #Z&   ]G   /;(  #W0   \\   //\
M #S_ &TR  !=,P  4#0  $8T   ^-   -S0  #(S   M,P  )S0  "(V   =
M.   &#H  !0]   0/P( #4$(  E##0 &1!$  T06  )$'0  1"0  $0M  !$
M-@  1$$  $1.  !$7   1&T  $2!  !$F   0Z\  $/-  !"\   0O\  $+_
M &@V  !8-P  3#@  $,X   [-P  -38  # V   I-P  (SD  !X[   8/0
M$T   !!"   -10$ "$<'  -)#   20\  $H3  !+&0  2R   $LH  !+,@
M2ST  $Q)  !,5P  2V@  $M]  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z
M  !4.P  23L  $ [   Y.@  ,SD  "PZ   E/   'S\  !E!   31   $$<
M  Q)   (3    D\%  !0"@  4 T  %$0  !2%0  5!L  %0C  !4+   5#<
M %1$  !44@  5&,  %1W  !4CP  4Z@  %+&  !2[0  4?\  %'_ %P_  !/
M/P  13\  #X^   W/0  +SX  "=    @0P  &48  !-)   /3   "T\   92
M    5    %<"  !8!P  60L  %H.  !;$0  718  %X=  !?)@  7S$  %X]
M  !>3   7ET  %YQ  !=B0  7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P
M0T(  #Q!   R0@  *44  "%(   :2P  $TX   Y2   *50   UD   !;
M7@   &    !B @  8P8  &4*  !F#@  :!$  &H7  !K'P  :RD  &LV  !K
M10  :U8  &IJ  !J@@  :9T  &B[  !GYP  9O\  &7_ %%(  !(2   048
M #='   L2@  (TT  !M1   350  #ED   A=   !80   &0   !G    :@
M &P   !N    <    '(%  !S"0  =0T  '<1  !Z&   >R$  'LN  !Z/0
M>DX  'EB  !Y>0  >)8  '>S  !UX   =/P  '/_ $Y-  !'3   .TT  #!/
M   F4P  '%@  !-<   -80  !F8   !J    ;P   '(   !V    >0   'P
M  !]    ?P   ($   "# @  A@<  (@,  "+$0  CA@  (XD  ".,P  C40
M (Q8  "+;P  BHP  (FJ  "(SP  AO<  (7_ $U1  !!4P  -%4  "E:   >
M7P  %&4   UJ   %<    '8   ![    ?P   (,   "'    B@   (T   ".
M    D0   ),   "5    F    )H%  "=#   H!$  *,:  "C*   HCH  *%.
M  "@90  H($  )Z@  "=P0  F^X  )K_ $99   Y7   +6$  "%G   6;@
M#G4   5[    @0   (<   "-    D@   )8   ":    G0   )\   "A
MI    *8   "H    JP   *X   "Q P  M L  +@1  "Y'@  N2\  +A#  "W
M6@  M78  +27  "TM0  L>(  +#\ #]D   Q:0  )6\  !AW   /?P  !H<
M  ".    E    )H   "@    I0   *H   "N    L0   +(   "U    MP
M +H   "\    OP   ,,   #&    R0   ,X*  #2$P  TB,  -$W  #03P
MSFH  ,V*  #*JP  R\L  ,OO #=Q   I>   '8   !&)   (D0   )H   "A
M    IP   *T   "S    N0   +X   #"    Q0   ,8   #)    S    ,X
M  #2    U0   -H   #>    X0   .4   #J"P  ZQ<  .HK  #J0P  ZEX
M .IZ  #KF0  Z[4  .O5 /\   #_    _P ! /\ !P#_  T _P 2 /\ &P#_
M "4 _P O /\ .@#_ $, _P!+ /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8
M> #T (  \0") .\ D@#L )T Z0"J .8 O #C -P WP#W -T _P#, /\ O@#_
M +4 _P"P /\ K0#_ /\   #_    _P   /\   #_  8 _P - /\ % #_ !\
M_P I /L ,P#W #T \P!% .\ 30#L %, Z !9 .4 7P#C &4 X !J -T <0#:
M '@ U@"  -( B@#/ )4 S "B ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@
M_P"D /\ H0#_ /\   #_    _0   /H   #X    \  ) .P $0#H !D YP C
M .4 +0#> #8 U@ ^ -$ 1@#- $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '
MO !X +D @0"W (T M ": +$ J0"N +P K #A *H _ "H /\ H #_ )D _P"6
M /\ E #_ /\   #Y    \@   .<   #;    T0 $ ,H #0#' !0 Q  = ,(
M)@"_ "\ NP W +< /P"T $4 L0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P
M *$ >0"? (0 G0"1 )H H "8 +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\
MA@#_ /<   #L    W@   ,D   "\    M    *\ "@"K !  J0 7 *@ ( "G
M "@ H@ P )\ . "< #X F@!$ )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T
M<0"+ 'L B0"( (< EP"% *@ @P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_
M .D   #7    P0   +$   "F    G0   )< !0"4  T D@ 2 )  &@"/ "(
MC@ J (L ,0") #@ AP ^ (4 0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X
M ', =@!_ '4 C@!S )\ <0"S '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H
M  "_    K    )X   "3    C    (4   ""  D ?P / 'X %0!] !P ?  D
M 'H *P!W #$ =0 W '0 /0!R $( <0!( &\ 30!N %, ; !: &L 8@!I &P
M9P!X &8 A@!D )< 8@"J &$ P@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M
M    FP   (T   "#    ?    '<   !R  4 <  , &X $0!L !< ;  > &L
M)0!I "P 9P Q &8 -P!D #T 8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R
M %D @ !7 )  5@"C %4 N0!4 -X 5 #[ %0 _P!5 /\ 50#_ +8   "?
MC0   '\   !U    ;@   &D   !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( !=
M "8 6P L %H ,@!8 #< 5P ] %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X
M>@!, (H 2P"< $H L0!) ,X 20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<
M '0(  !J"   8P8  %X$  !;    60 % %< # !6 !  5  5 %, &P!2 "(
M40 H %  +0!. #, 30 X $P /@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!#
M (4 00"8 $  JP!  ,4 /P#J #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-
M  !A#0  6@T  %4+  !2"0  4 8  $\"" !.  T 3  2 $L %P!* !X 20 C
M $< *0!& "\ 10 T $0 .@!" $$ 00!( $  4  ^ %H /0!D #P <@ Z ((
M.0"4 #@ IP W +X -@#C #8 ^0 V /\ -P#_ )@-  "##@  <A   &41  !;
M$0  4Q   $X0  !*#@  2 T  $<* P!'!PH 100. $0"$P!" AH 00(@ $ #
M)0 ^ RL /00Q #P$-P [!#X .@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2
M # &I0 O!;L +@7= "X&]0 M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%
M3A0  $@3  !$$@  01   $ .  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X
M"B@ -PLN #8+-0 U"SL ,PM# #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,
MI0 G#+L )0S= "4-]0 F#?\ )PW_ (L2  !W%   9Q8  %L7  !1&   21<
M $,7   _%0  /!0  #H2   Y$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4
M,0\L # /,@ O$#H +1!" "P02P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?
M$+T 'A#@ !X1]P ?$/\ (!#_ (84  !S%P  8QD  %<:  !-&P  11H  $ :
M   [&0  .!@  #46   T%   ,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I
M "H3,  H$S< )Q0_ "842  D%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L
M&!7> !@5^  9%/\ &A3_ ((7  !O&@  7QP  %,=  !*'0  0AT  #P=   W
M'   -!L  #$:   O&0  +A8  "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08
M+0 C&#0 (AD] " 91@ >&5$ '1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG;
M !,9]@ 4&?\ %1C_ 'T:  !K'0  7!\  % @  !'(   /R   #D?   T'P
M,1X  "T=   K'   *1L  "<;!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >
M'3( '!XZ !L>1  9'DX %QY; !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>
M]0 0'?\ $1W_ 'H=  !G'P  62$  $TB  !$(@  /"(  #8B   R(0  +B$
M "H@   G(   )!\  "(@ @ @( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\
M%R(X !4C00 4(TP $B-8 !$C9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,
M(O\ #2'_ '8?  !D(@  5B,  $LD  !!)   .B0  #0D   O(P  *R,  "@C
M   D(P  (",  !TD   ;)0< &28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U
M !$H/P 0*$H #BA6  TH9  ,*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX
M"";_ '$B  !@)   4R8  $@G   _)P  -R8  #$F   M)@  *24  "4E   B
M)0  '2<  !DH   6*@0 %"L+ !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM
M.P ++48 "BU2  @M8  &+7  !"V#  (MF   +*X  "S)   LZP !*_P  BO_
M &TE  !=)P  3R@  $4I   \*0  -2D  "\H   K*   )R<  ",G   ?*
M&RH  !<L   3+@( $# (  XQ#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %
M,D(  S).  $R7   ,FP  #)_   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I
M  !8*@  3"L  $$L   Y+   ,BL  "TK   I*@  )2H  " K   <+   %RX
M !,P   0,@( #C0'  HW#  '-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X
M #A*   X6   .&@  #A\   WD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4
M+@  2"\  #XO   V+@  ,"X  "LM   G+0  (BT  !TO   8,0  %#,  ! U
M   .-P$ "CH'  8["P "/ X  #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&
M   ^5   /F0  #YW   ^CP  /:<  #W#   \Z0  //T  #O_ %XP  !0,0
M1#(  #LR   T,0  +C   "DO   D,   'C(  !DT   4-@  $#D   T[   *
M/0  !4 %  !!"@  0@T  $,0  !$%   11H  $8B  !&*P  1C4  $9!  !&
M3P  1E\  $9S  !%B@  1:0  $3   !#Z   0_X  $+_ %@T  !+-0  034
M #DU   R-   +3,  "8T   @-0  &C@  !0Z   0/0  #4    E"   $10
M $<#  !(!P  2@L  $L.  !,$0  3A4  $\<  !/)0  3R\  $\\  !/2@
M3UH  $YM  !.A0  3:   $R\  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X
M   Q-P  *3<  "$Y   ;/   %3\  !!"   ,10  !T@   )*    30   $\
M  !1!   4@<  %0+  !5#@  5Q$  %D7  !:'P  62D  %DV  !91   650
M %AG  !8?P  5YH  %:W  !5XP  5/T  %3_ $X]  !#/0  /#P  #4[   L
M/   )#X  !Q!   51   $$@   M+   %3@   %$   !4    5P   %D   !;
M    70(  %X&  !@"P  8@X  &02  !G&   9R(  &8N  !F/   9DT  &5@
M  !E=P  9),  &.Q  !AW0  8/P  %__ $E"  !!00  .C\  #!    F0P
M'D8  !5*   03@  "E(   -6    6@   %T   !@    8P   &4   !G
M:0   &L!  !M!0  ;PH  '(.  !U$@  =QL  '8F  !V-0  =48  '19  !T
M;P  <XL  '*I  !PS0  ;_<  &[_ $9&  ! 10  -48  "I(   @3   %U$
M !!6   )6@   5\   !C    :    &L   !O    <@   '4   !W    >0
M 'L   !]    @ ,  (,(  "&#0  B1,  (H=  "**P  B3P  (A/  "&9@
MA8$  (2@  ""P@  @?   '__ $9+   Z3   +D\  "-3   86   $%X   ED
M    :0   &\   !T    >    'P   "!    A    (<   "(    BP   (X
M  "0    DP   )8   "9!P  G0T  *$4  "@(0  H#$  )Y$  "=6P  G'8
M )F6  "9M0  EN4  )7^ #]2   R50  )EH  !M@   19P  "6T   !T
M>P   ($   "&    BP   )    "4    EP   )D   "<    GP   *$   "D
M    IP   *H   "M    L08  +4-  "X%@  MR8  +8Y  "U4   M&H  +*)
M  "PJ@  KL\  *WU #=<   K80  'F@  !-P   +>    (    "'    C@
M )4   ":    GP   *0   "H    K    *T   "P    LP   +4   "X
MNP   +\   ##    QP   ,L%  #1#@  T1L  - N  #/10  S5\  ,M^  #)
MG@  R+X  ,7I "]I   C<   %GD   V!   !BP   ),   ";    H@   *@
M  "N    M    +@   "]    P    ,(   #%    R    ,L   #.    T0
M -8   #;    WP   .0   #H!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP
MX[,  ./4 /\   #_    _P   /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\
M-0#_ #X _P!' /\ 3@#_ %4 _ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$
M .T C@#J )D Y@"G ., N0#? -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\
MH@#_ /\   #_    _@   /P   #\  , _@ + /\ $0#_ !H _0 D /D +@#T
M #@ \ !  .P 2 #I $X Y@!4 .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T
MA0#* )$ QP"> ,, K@#  ,4 O0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_
M /\   #Z    ]    /$   #R    Z@ % .< #@#B !4 X0 > .$ * #8 #$
MT  Y ,L 0 #( $< Q0!- ,( 4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q
M (@ K@"5 *L I "H +@ I@#< *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D
M  #O    YP   -\   #/    R    ,$ "@"_ !$ O  8 +L (0"Y "H M  R
M +$ .@"N $  JP!& *@ 3 "F %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X
ME@", )0 FP"2 *T D #' (X \ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@
M    T0   +\   "S    J@   *8 !0"B  T H0 3 *  &P"? ", FP K )@
M,@"5 #D DP _ )$ 1 "/ $H C@!/ (P 50"* %L B !C (8 :P"$ '8 @@""
M (  D@!^ *, ? "Z 'H X0!Y /\ =P#_ '( _P!P /\ ;P#_ -T   #+
MM@   *<   "=    E    (X  0"+  H B0 0 (@ %0"' !T AP E (0 + ""
M #( ?P X 'T /0![ $, >0!( '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T
MB0!L )H :@"N &D S !H /8 9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0
M ),   ")    @@   'L   !X  4 =@ , '4 $0!T !@ <P ? '( )0!P "P
M;@ R &P -P!J #P :0!" &@ 2 !F $X 90!5 &, 70!B &8 8 !R %X @ !=
M )( 6P"E %H O@!9 .D 60#_ %D _P!8 /\ 6 #_ +D   "B    D    (,
M  !Y    <0   &T   !I  $ 9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L
M %X ,0!< #< 6P \ %H 0@!8 $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H
M3P"> $X M !- -H 30#[ $T _P!- /\ 30#_ *H   "4    @@   '4   !K
M    9    &    !=    6@ % %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %(
M+ !1 #$ 3P W $X /0!- $, 3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7
M $, K !" ,D 0@#Q $( _P!# /\ 0P#_ )X   ")    > ,  &H$  !A!
M6@,  %4!  !2    4  " $X "0!-  T 3  1 $L %P!* !P 20 B $@ )P!'
M "T 10 R $0 . !# #X 0@!% $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D
MI@ X +\ . #H #@ _P Y /\ .0#_ )4#  " !P  ;PD  &(*  !8"P  40H
M $P(  !)!@  1P,  $8 !@!$  L 0P / $( $P!! !@ 00 > #\ (P ^ "D
M/0 N #L -  Z #H .0!! #@ 20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P
M +@ +P#> "\ ^0 O /\ , #_ (P)  !X#   : T  %P.  !2#@  2PX  $4-
M  !!#   /PH  #X( @ ]! @ / $- #L $  Z !4 .0 : #@ (  V "4 -0 K
M #0 ,  S #< ,@ ^ #$ 1@ O %  +@!: "T 9P K '< *@") "D G0 H +,
M)P#1 "< \@ G /\ )P#_ (8,  !R#@  8Q   %81  !-$0  11$  $ 0   \
M#P  .0X  #<-   V"P0 -@@* #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&
M+@ M!C0 *P8\ "H&1  I!TX )P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+
M !\%[0 ?!OX 'P?_ ( .  !M$0  7A(  %(3  !($P  01,  #L3   W$@
M-!$  #(0   P#P$ , T& # +"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G
M##( )@PZ "0,0P C#$T (0U8 " -90 >#74 ' V( !H-G  9#;$ & S* !<,
MZP 7#?P & S_ 'L1  !I$P  6A4  $X6  !%%@  /18  #@5   S%0  ,!0
M "T3   K$@  *A # "H/"  I#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$
M(! Y !X00@ =$$P &Q!8 !D09@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2
M$/X $A#_ '<3  !E%0  5Q<  $L8  !"&0  .AD  #08   P%P  +!<  "D6
M   G%0  )A0! "42!  C$@L (A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V
M !D40  7%$H %A16 !049  2%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X
M#A/_ ',5  !A&   4QH  $@;   _&P  -QL  #(:   M&@  *1D  "88   D
M&   (A<  " 6 0 >%@@ '18- !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08
M/0 2&4@ $1E4 ! 98@ .&7( #1F$  P9F  *&:T "1C&  D8YP )&/H "A?_
M &\8  !>&@  4!P  $4=   \'0  -1T  "\=   J'   )AL  ",;   A&@
M'AH  !P:   :&P4 &!L, !8<$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .
M'44 #1Y1  P>7@ *'FT "1Z   <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:
M  !;'0  31X  $(?   Z'P  ,A\  "T?   H'@  )!X  "$=   >'0  '!T
M !@>   5'P( $R ) !(A#@ 0(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$
M"2)-  <B6@ %(FD  R)\  $BD0  (J@  "'    AY0  (/@  "#_ &<=  !7
M'P  2B$  $ A   W(@  ,"$  "HA   F(   (B   !\?   <'P  &2   !8A
M   2(P( $"0'  XF#  ,)A  "R85  HF'  ))B( ""8J  8G,P $)ST  R=)
M  $G5@  )V8  "=Y   GCP  )J8  ":_   EY   )?D  "3_ &,@  !4(@
M1R,  #TD   T)   +B,  "@C   D(@  (2(  !XA   :(@  %R,  !,D   0
M)@( #B@'  LJ"P (*PX !BL3  0K&  "*Q\  2PG   L,   +#H  "Q%   L
M4P  +&,  "QV   LC   *Z0  "N^   JY   *OH  "G_ %\C  !0)0  1"8
M #HF   R)@  *R8  "8E   C)   'R0  !LD   7)0  %"<  !$I   .*P(
M"RT&  <O"P $, X  # 1   Q%0  ,1P  #$C   R+   ,C8  #)"   R3P
M,E\  #)R   QB0  ,:(  #"\   PY   +_L  "__ %HG  !,*   0"D  #<I
M   O*0  *2@  "4G   A)@  '"<  !@H   4*@  $2P   XN   +, $ !S(%
M  ,T"0  -0P  #8/   W$@  .!@  #@@   X*   .#(  #D]   Y2P  .5L
M #AN   XA0  -Y\  #>Z   VY   -?P  #7_ %4J  !(+   /2P  #0L   M
M*P  *"H  "0I   >*@  &2L  !0M   1+P  #3$   HT   '-@   C@$   Z
M!P  .PH  #T-   ^$   0!0  $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I
M  ! @   /YL  #ZW   ]XP  //P  #S_ % O  !#+P  .2\  #(O   L+0
M)RP  " M   :+P  %3$  !$S   --@  "3@   4[    /0   $ !  !!!
M0P<  $4+  !&#@  2!$  $H6  !*'@  2B@  $HT  !)0@  25$  $ED  !(
M>P  2)<  $>T  !&X   1?P  $3_ $HS   _,P  -C,  # Q   J,   (S$
M !PS   6-0  $3@   T[   (/@   T$   !#    1@   $@   !*    3 0
M $X'  !/"P  40X  %02  !5&0  52(  %0N  !4/   5$L  %->  !3=
M4I   %&N  !0UP  3_L  $[_ $4W   \-P  -38  "\T   F-0  'C<  !<Z
M   1/0  #$$   =$    2    $H   !-    4    %,   !5    5P   %@"
M  !;!@  70L  %\.  !B$P  8AL  &(G  !B-   844  &!7  !@;0  7XD
M %VG  !<S   6O@  %G_ $$\   Z.P  -#D  "HZ   A/   &$   !%#   ,
M1P  !DL   !/    4P   %8   !9    7    %\   !A    8P   &4   !G
M 0  :@4  &T*  !P#@  <Q4  '(@  !R+0  <3T  '!/  !O90  ;H   &V?
M  !KP0  :?$  &C_ #]    Y/@  +C\  "1"   :1@  $DH   Q/   $5
M %@   !=    80   &4   !H    :P   &X   !Q    <P   '4   !X
M>P   'X#  "!"@  A0\  (<7  "&)   A30  (1&  ""70  @78  '^6  !^
MM@  ?.<  'K_ #]$   S10  *$@  !U,   34@  #%<   -=    8P   &@
M  !M    <0   '8   !Z    ?@   ($   "#    A@   (D   "+    C@
M )(   "5 0  F0D  )X0  ">&@  G2D  )P\  ":4@  F&P  ):+  "4J@
MDM0  )#Z #A+   L3@  (%,  !59   -8    V<   !N    =    'H   "
M    A    (H   ".    D@   )4   "7    F@   )T   "@    HP   *<
M  "K    KP   +0)  "X$   MQX  +4P  "S1@  L6   *]^  "LH   J\$
M *GN #%5   D6P  &&$   YI   %<0   'D   "!    B    (\   "4
MF@   )\   "D    J    *D   "L    KP   +,   "U    N0   +T   #!
M    Q@   ,L   #1"@  TQ0  -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/>
M "EB   <:0  $7$   =[    A    (T   "5    G0   *,   "I    KP
M +0   "Y    O    +X   #"    Q0   ,@   #,    T    -0   #:
MWP   .0   #J    [@P  .T:  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\
M  #_    _P   /P  0#\  @ _@ . /\ % #_ !T _P F /\ , #_ #H _P!"
M /\ 20#^ %  ^P!6 /D 7 #V &( ] !H /( ;P#P '8 [0!_ .H B0#G )4
MY "C .  M0#; -  U0#V ,H _P"V /\ J #_ )\ _P": /\ E@#_ /\   #[
M    ]@   /,   #S    ]@ ) /H #@#] !8 ^P @ /< *@#R #, [0 [ .D
M0P#F $D X@!/ -X 50#; %L U@!@ -( 9P#/ &X S !V ,D @ #& (P P@":
M +\ J@"[ ,$ N #I +8 _P"G /\ F@#_ )( _P"- /\ B@#_ /H   #Q
MZ@   .<   #G    Y  ! .  "P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#"
M $( OP!( +P 3@"Z %, N !9 +8 7P"S &8 L0!N *X =P"L (, J0"1 *8
MH0"C +4 H #8 )X ^P"5 /\ BP#_ (4 _P"  /\ ?@#_ .\   #C    V@
M -,   #&    OP   +D !@"W  X M  4 +0 '0"S "4 K@ M *L - "G #L
MI !! *$ 1@"? $P G0!1 )L 5P"9 %X EP!E )4 ;@"3 'D D "' (X EP",
M *D B0#$ (@ [P"% /\ ? #_ '8 _P!S /\ <@#_ .    #0    Q@   +8
M  "I    H0   )T  0"9  H F  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z
M (H /P"( $4 AP!* (4 4 "# %8 @0!> (  9@!^ '$ ? !] 'D C0!W *
M=0"V ', WP!R /\ ;@#_ &D _P!G /\ 90#_ ,P   "^    JP   )T   "3
M    B@   (4   ""  4 @  - '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4
M. !T #X <@!# '  20!O $\ ;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K
M &( R0!A /8 8 #_ %P _P!; /\ 6@#_ +T   "I    EP   (D   !^
M>    ',   !O  $ ;0 ) &P #@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C
M #< 8@ \ &  0@!? $@ 70!/ %P 5P!: &$ 60!M %< >P!6 (X 50"B %,
MNP!2 .D 4@#_ %  _P!/ /\ 3P#_ *T   "8    A@   '@   !N    9P
M &,   !@    70 % %P "P!; !  6P 5 %L &P!: "$ 6  F %8 + !4 #$
M4P V %( / !1 $( 3P!) $X 40!- %L 2P!F $H = !) (4 2 "9 $< L0!&
M -@ 1@#\ $4 _P!% /\ 10#_ )\   ")    >    &P   !B    6P   %8
M  !3    40 " $\ " !/  T 3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q
M $< -P!% #T 1 !$ $, 3 !" %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,<
M.P#S #L _P [ /\ / #_ ),   !^    ;@   &$   !8    40   $P   !)
M    1P   $4 !0!$  L 0P . $, $@!# !< 0@ = $  (@ _ "< /@ L #T
M,@ [ #@ .@ _ #D 1P X %  -P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G
M #$ _P R /\ ,P#_ (D   !V P  9@4  %D'  !0!P  208  $,%  !  P
M/@$  #P  P [  @ .@ - #H $  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S
M #0 ,@ [ #  0P O $P +@!7 "T 9  L ', *P"' "H G  I +4 *0#< "D
M^P I /\ *@#_ ($$  !N"   7PH  %,+  !*"P  0@L  #T*   Y"0  -@@
M #4%   T @8 ,P * #( #@ Q !$ ,0 5 #  &@ O !\ +@ D "P *@ K #
M*@ W "D /P H $D )P!4 "8 8  D &\ (P"" "( EP A *X (0#, "$ \P A
M /\ (@#_ 'L)  !H#   6@T  $X.  !%#@  /0X  #@-   S#0  , P  "X+
M   M"0, +08( "P$#  K @\ *@$2 "D!%P H 1P )P A "8 )P E "T )  T
M ",!/0 B 48 (0%1 !\!70 > 6P ' %_ !L E  : *H &@#% !H ZP 9 /\
M&@#_ '4,  !D#@  50\  $H0  ! $   .1   #,0   O#P  + X  "D.   G
M#0$ )PP% "<*"@ F" T )0<0 "0&%  B!AD (08? " ')  ?!RL '@<R !T'
M.@ <"$0 &@A/ !D(7  7"&L %@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_
M '$.  !?$   41$  $82   ]$@  -A(  # 2   K$0  *!$  "40   C$
M(@X$ "$-!P A# L ( L. !\+$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6
M#4, %0U/ !,-7  2#6L $ U^  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0
M  !<$0  3A,  $,4   Z%   ,A0  "T4   H$P  )1,  "(2   @$0  'A$#
M !P0!0 <#P@ &P\, !H.$  9#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0
M$!!0  X070 -$&L #!!\  L0D  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8
M%   2Q4  $ 6   W%@  ,!8  "H6   F%0  (A4  !\4   =$P  &A," !D2
M!  7$@8 %A(* !42#@ 4$A( $A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+
M  L46  )%&< !Q1X  84C0 $%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@
M2!<  #T8   T&   +1@  "@8   C%P  (!<  !T6   :%0  &!4" !85!  4
M%04 $A8( !$6#0 0%Q  #A<5  X7&P -%R( #!<I  L8,@ )&#P !QA'  48
M5  $&&,  AAU  $8BP  %Z$  !>Y   7W0  %O4  !;_ &$6  !2&   11H
M #L:   R&@  *QH  "4:   A&0  'A@  !L8   8%P  %A<" !07 P 2& 4
M$!D'  X;"P ,&P\ "QL3  H;&  ('!\ !QPF  4<+P $'#@  AQ$   =40
M'6   !UR   <B   '*   !NY   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<
M   O'0  *1P  ",<   ?&P  '!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'
M  P>"P )'PX !B 1  4@%@ #(!P  2$C   A*P  (34  "%    A3@  (5T
M "%O   AA@  ()X  ""X   ?W@  'O@  ![_ %H;  !+'0  /QX  #4?   M
M'P  )QX  "(=   >'0  &QP  !@;   5&P  $AP  ! = @ .'P0 #"$&  DB
M"@ %(PT  B00   E$P  )1D  "8@   F*   )C(  "8]   F2@  )EH  "9L
M   F@P  )9P  "6W   DWP  (_D  "/_ %4>  !'(   /"$  #(A   K(0
M)2   " ?   ='@  &AT  !8>   3'@  $"    XA   ,(P( ""4%  4G"0
M* L  "H.   K$0  +!8  "P=   L)0  +"X  "PZ   L1P  +%8  "QI   L
M@   *YH  "JU   IWP  *?L  "C_ %$B  !$(P  ."0  "\D   H(P  (R(
M !\A   <(   %R   !,A   0(P  #B0   LF   (*   !"H$   L!P  +@D
M # ,   Q#P  ,Q,  #,9   S(0  ,RH  #,U   S0P  ,U(  #-E   R>P
M,I<  #&S   PW@  +_L  "[_ $PE   _)@  -2<  "TF   G)0  (B0  !XC
M   9(P  %"0  !$F   .*   "RH   <L   #+P   #$"   S!   -0<  #<*
M   Y#0  .A   #L5   ['0  .R8  #LQ   [/@  .TX  #M@   Z=P  .9(
M #BP   WVP  -OP  #7_ $<I   [*@  ,BH  "LI   E)P  (28  !LG   5
M*   $2H   XL   *+P  !C$   $T    -@   #@    [ 0  /00  #\'  !!
M"@  0PX  $41  !%&   12$  $4L  !$.0  1$@  $1;  !#<0  0HT  $&K
M  ! T@  /_H  #[_ $(M   X+@  +RT  "DK   D*@  '2H  !<L   1+@
M#3$   DT   $-P   #H    \    /P   $$   !$    1@   $@#  !*!P
M3 L  $X.  !0$P  4!P  % G  !/-   3T,  $]5  !.:@  388  $RD  !*
MR@  2?@  $C_ #XR   U,0  +B\  "DN   @+@  &3$  !(S   .-P  "3H
M  (]    0    $0   !'    20   $P   !/    40   %,   !5 0  6 8
M %H+  !=#@  7Q4  %X@  !>+   73P  %Q.  !;8P  6GX  %B=  !7P
M5?(  %3_ #HV   S-   +3(  "0S   ;-@  $SD   X]   (00   $4   !)
M    3    %    !3    5@   %D   !;    70   &    !B    90   &@%
M  !K"P  ;Q   &\8  !N)0  ;30  &U&  !K6P  :G4  &B4  !FM@  9.D
M &+_ #@Y   R-P  *#D  !X[   5/P  #D0   =)    30   %(   !6
M6@   %X   !B    90   &@   !K    ;0   '    !S    =@   'D   !]
M!   @0L  (41  "$'0  @BP  ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7]
M #@]   L/@  (D$  !=&   /2P  !U$   !7    7    &(   !F    :P
M &\   !T    >    'L   !^    @    (,   "&    B@   (T   "1
ME@,  )L,  "=$P  FR$  )HS  "720  E&(  )-_  "0H   CL4  (SS #%$
M   E2   &DT  !!3   (6@   &$   !H    ;@   '0   !Y    ?P   (0
M  ")    C0   )$   "3    E@   )D   "=    H    *0   "H    K
M +(#  "W#0  MQ<  +4H  "R/@  L%8  *QS  "JE   J;0  *7E "I/   >
M5   $EL   IB    :@   ',   ![    @@   (D   ".    E    )H   "?
M    I    *8   "I    K0   +    "S    MP   +L   #     Q0   ,L
M  #1!   U0X  -,=  #0,@  S4L  ,IF  #&AP  PJD  ,'+ ");   68@
M#&L   %T    ?0   (<   "0    EP   )X   "D    JP   +$   "V
MN@   +P   #     Q    ,@   #+    SP   -0   #:    X    .8   #K
M    \08  / 3  #N)P  [#\  .I;  #G>@  Y)L  ."[ /\   #[    ]@
M /,   #T  4 ]@ , /H $0#_ !D _P B /\ + #_ #4 _P ] /\ 10#\ $P
M^@!2 /< 6 #U %X \P!D /$ :@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8
M ,X T@#V ,$ _P"M /\ G@#_ )8 _P"0 /\ C #_ /H   #R    [    .D
M  #I    [  % /( # #X !( ]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+
M -@ 4 #3 %8 T !< ,T 8@#* &H R !R ,4 ? #" (@ O@"6 +H J "W +\
MM #H *X _P"= /\ D #_ (@ _P"# /\ @ #_ /    #E    W@   -H   #;
M    W    -@ !P#1  X T0 5 -( '@#+ "< Q0 O ,  -P"] #T N@!$ +<
M20"U $\ L@!5 +  6P"N &$ K !I *D <P"G '\ I "- *$ G@"> +( FP#5
M )D _ ", /\ @@#_ 'L _P!V /\ = #_ .(   #3    R@   ,<   "\
MM@   +   0"O  L K  1 *T & "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9
M $< EP!- )4 4P"3 %D D0!A (\ :@", '4 B@"# (@ E "& *< @P#" ((
M\ !\ /\ <P#_ &T _P!J /\ : #_ ,\   #!    N0   *T   "@    F
M )0   "1  8 D  - )  $@"/ !D C@ A (L * "( "\ A@ U (0 .@"" $
M@ !% 'X 2P!\ %( >@!9 '@ 8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L
M /\ 90#_ &  _P!> /\ 7 #_ +X   "Q    H    )(   ")    @@   'P
M  !Z  $ >  ) '< #@!X !0 =P : '0 (0!R "< <  M &X ,P!L #@ :P ^
M &D 1 !H $H 9@!1 &0 6@!C &0 80!P %\ ?P!> ), 70"I %P R !; /<
M5P#_ %0 _P!2 /\ 40#_ +    "?    C0   '\   !T    ;@   &H   !F
M    90 $ &, "P!C !  8P 5 &, &P!A "$ 7P G %T + !< #( 6@ W %D
M/0!7 $, 5@!+ %4 4P!3 %P 4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_
M $D _P!' /\ 1P#_ *(   "-    ?    &X   !E    7@   %D   !7
M50 ! %0 !P!3  T 4P 1 %0 %@!2 !L 40 A $\ )@!. "L 3  Q $L -P!*
M #T 20!$ $< 3 !& %8 1 !A $, < !" ($ 00"7 $  KP _ -< /P#_ #X
M_P ] /\ /@#_ )0   !_    ;P   &,   !9    40   $T   !*    2
M $< ! !'  H 1@ . $8 $0!' !8 10 < $0 (0!" "8 00 K $  ,0 ^ #<
M/0 ^ #P 1P Z %  .0!; #@ :0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T
M /\ -0#_ (@   !T    90   %@   !/    2    $,    _    /0   #P
M @ \  < .P , #L #P [ !( .@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y
M #$ 00 P $L +P!6 "X 8P M ', + "( "P H  K +L *P#J "L _P K /\
M+ #_ '\   !L    70$  %$"  !( P  0 ,  #L"   W    -    #,    R
M  4 ,@ ) #( #0 Q !  ,0 3 #  &  O !T +0 B "P *  K "X *@ U "D
M/0 H $8 )P!1 "8 7@ E &X ) "" ", F0 C +, (@#> "( _P C /\ ) #_
M '<   !E!   5@8  $L'  !""   .@@  #4'   P!@  +04  "P#   K  ,
M*@ ' "D "P I  X *0 1 "@ %0 G !D )@ > "4 )  D "H (P Q "( .0 A
M $, ( !. !\ 6@ > &D '0!\ !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %
M  !?"   40H  $8+   ]"P  -0L  # +   K"@  * D  "4(   D!P( (P0&
M ",""0 B 0P (@ / "$ $@ @ !8 'P ; !X (  = "8 '  N !L -@ : #\
M&0!* !@ 5P 7 &8 %@!X !4 CP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;
M"P  30P  $(-   Y#0  ,0T  "P-   G#0  (PP  "$,   ?"P$ '@H% !T(
M"  =!@L ' 4- !P$$  ;!!0 &008 !D$'@ 8!", %P0K !8$,P 5!#P % 1'
M !,#5  2 V, $0-U ! "B@ 0 :( #P"\  \ Y0 / /X $ #_ &<+  !7#0
M20X  #X/   U#P  +@\  "@/   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8
M"PD %PD, !<)#@ 6"1( %0D6 !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)
M4@ ."6$ #0ES  P(B  +")\ "@>W  H&VP *!?8 "@3_ &,-  !3#@  1A
M #L1   R$0  *Q$  "40   A$   '1   !H/   8#P$ %@X$ !4.!P 4#0D
M$PT+ !,,#0 2#!  $0P4 ! ,&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )
M#6  " UQ  8-A@ %#9T ! RT  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2
M   O$@  *!(  ",2   >$0  &Q$  !@1   5$ ( %! % !(0!P 1#PD $ \*
M ! .#  .#@X #@\2  T/%P ,$!T #! D  H0+  )$#8 "!!!  803@ %$%T
M Q!O  $0A   $)P   ^T   .U   #O,   [_ %P0  !-$@  0!,  #84   M
M%   )A0  "$3   <$P  &1(  !82   4$0, $A$& !$1"  0$ H #A +  T1
M"P ,$0T "Q(1  H2%0 )$AH "!(A  83*0 %$S,  Q,^  (32P  $UH  !-L
M   3@@  $IL  !*T   1UP  $?4  !'_ %@2  !)%   /14  #,6   K%@
M)!4  !\5   :%   %Q0  !03 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )
M% T !Q4/  86$P $%A@  Q8?  (6)P  %S   !<[   72   %U@  !=J   6
M@   %ID  !6T   5V0  %/<  !/_ %44  !&%@  .A<  # 8   H&   (A<
M !T6   9%@  %A4  !,4 P 2$P8 $!,'  \3!P -% < "Q4(  D6"0 && P
M QH.  $:$0  &A8  !L<   ;)   &RT  !LX   ;1@  '%4  !MG   ;?0
M&Y<  !JS   9VP  &/D  !?_ %$6  !#&   -QD  "X:   F&@  (!D  !L8
M   8%P  %18! !,5!0 1%00 #Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-
M   @$   (!,  " 9   @(0  (2H  "$U   A0@  (5(  "!D   @>@  'Y4
M !^Q   >VP  '?H  !S_ $T9   _&P  -!P  "L<   D'   'AL  !H:   7
M&   %!<" !(7 @ 0& $ #1D!  L: @ (' , !1T$  (?!@  (0@  ",+   E
M#@  )A$  "86   F'@  )R<  "<R   G/P  )DX  "9@   F=P  )9(  "2O
M   CV@  (OL  "'_ $@=   \'@  ,1\  "@>   B'@  '1P  !D;   6&@
M$AH  ! ;   -'   "QT   @?   $(0   2,"   E!   )P8  "D)   L#
M+@\  "X3   N&@  +B,  "XN   N.P  +DH  "U<   M<@  +(X  "NL   J
MU   *?L  "C_ $0@   X(0  +B$  "8A   @(   '!X  !@=   4'0  $!X
M  X?   +(0  !R,   ,E    )P   "D    L 0  +@,  # &   S"@  -0T
M #81   V%P  -A\  #8I   V-@  -D4  #57   U;0  -(D  #*H   QSP
M,/H  "__ #\D   T)   *R0  "0C   ?(0  &R   !8@   1(0  #B,   HE
M   &*    BH    M    +P   #(    T    -P   #D#   [!@  /@H  $ .
M  !!$@  01H  $ E  ! ,0  0$   #]2   ^9P  /8(  #RB   ZQP  .?@
M #C_ #HH   P*   *2<  ",E   ?(P  &"0  !(E   .*   "BH   4M
M,    #,    V    .    #L    ^    0    $(   !% @  1P8  $H*  !-
M#@  314  $P?  !,*P  2SH  $I,  !)80  2'P  $>;  !%OP  0_,  $+_
M #8L   M*P  )RD  ",G   ;*   %"H   XM   *,   !#,    W    .@
M #T   !     0P   $8   !(    2P   $T   !0    4P$  %8&  !9"P
M6Q   %L9  !:)0  630  %A&  !76@  570  %23  !2M0  4.H  $__ #,P
M   L+@  )RP  !XM   6+P  $#(   HV   #.@   #\   !"    1@   $D
M  !,    3P   %(   !5    6    %H   !=    8    &,   !G!@  :PP
M &P2  !K'@  :RP  &D]  !G4@  9FH  &2)  !AJP  7]P  %W_ #$S   L
M,0  (C(  !DU   1.0  "CT   )"    1P   $P   !0    5    %@   !;
M    7P   &(   !E    :    &L   !N    <0   '4   !Y    ?08  ((-
M  ""%@  @"0  'XU  !\20  >V$  'A_  !VGP  <\8  '#W #$V   F.
M'#L  !)    +10   DL   !1    5@   %L   !@    90   &D   !N
M<@   '8   !Y    ?    'X   ""    A0   (D   ".    DP   )@&  "<
M#@  FQH  )@K  "60   DED  )%S  "-E0  B[4  (CH "L^   @00  %4<
M  U-   "5    %L   !A    :    &X   !S    >0   'X   "#    B
M (P   "/    D@   )4   "9    G0   *$   "E    J@   +    "W!P
MN!$  +4A  "R-0  KTT  *II  "HB   IJ@  *+1 "-(   83@  #E0   1<
M    9    &T   !U    ?    (,   ")    CP   )4   ";    H    *,
M  "F    J0   *T   "Q    M0   +D   "^    Q    ,H   #2    V@H
M -86  #2*0  SD$  ,I<  #%?   PIT  ,&] !Q5   17   !V4   !N
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M_O______________________________________________________
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M\O/T]?;W^/GZ^_S]_O]M9G0Q      ,$(0   0                    $
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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MNF.VD;ICMI&Z8[:1NF.VD;K_H!X$_Z$H"/^Q, O[P#D1[,Y"&=_?1RC3Z4Q
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M2%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$C$QP<
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MM*Z=A+RFF(K!H)21QIJ1F,F6CZ'+D(NHS(R)K,6,B;# C(FPP(R)L,",B;#
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MK\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\'_EQL#_Y4G"/^>+PW_JC@3_[5
M'/^^2"GYR$XZ\\U63>K37&+>SV)XS<=HB[^^;INRMW.HI[!YLIZK?KJ5IX3
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MUG2FFM1QK)[2;[*AT&VYH\]LPZ;%9\.FP&G'H<!IQZ' :<>AP&G'H<!IQZ'
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M?[:XDX"[LI. N[*3@+NRDX"[LI. N[*3@+NRDX"[LI. N[*3@+NRDX"[LI.
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MJZMXIJ*E?JZ9H(2UDIV+NHR:D[Z'F)O A)>EPH"6K\)_DK.\@)&XM8"1N+6
MD;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+7_DAH#_Y E!_^;
M+ K_IS0/_[(\%O^[1"'YQ4LP\<Y10>?26%3:SEYIRL9E?+V]:XRPMG":I;!V
MI9RJ?*V3IH*TC*.)N8:@D+V!GIF_?9ZBP7N>K\%YF;.\>I>XM7J7N+5ZE[BU
M>I>XM7J7N+5ZE[BU>I>XM7J7N+5ZE[BU>I>XM7J7N+7_DAD#_Y E!_^=*PK_
MJC,._[4\%?R_1"#TR$HN[=-0/^/85E/3TEUHQ<IC>[?":8NJNV^8G[9THY6Q
M>JR-K8"RA:J'MW^GCKMZII>^=Z:@OW2FK;]SH;2[=)ZXM72>N+5TGKBU=)ZX
MM72>N+5TGKBU=)ZXM72>N+5TGKBU=)ZXM72>N+7_DQD#_Y$D!_^?*PG_K#,-
M_[@[%/C#0Q[OS4HLY]I//=W>55'-V%MGOL]B>K#(9XFDPFV7F;QRH8^X>*F&
MM7ZP?[*%M7FPC+ATKY6[<*^?O&ZOK+QMJ[6Y;J>YM&ZGN;1NI[FT;J>YM&ZG
MN;1NI[FT;J>YM&ZGN;1NI[FT;J>YM&ZGN;3_E!D#_Y(D!_^B*@C_L#(,_KPZ
M$O+'0ASHTTDIX>%,.]3C4U'&W5IEM]5@>*G/9H>=R6N4D<5PGH?!=J9_OGRL
M>+R$L7*ZB[1MN9.V:KB<N&>WI[AGM[>V:+*[L6BRN[%HLKNQ:+*[L6BRN[%H
MLKNQ:+*[L6BRN[%HLKNQ:+*[L6BRN['_E1@#_Y4C!O^E*0?_M#$*^,$Z$.O.
M0AC@W4<EU>5+.\OG45"]XUECK]Y?=*+898.6TVJ/BLYOF7_(<Z%UQ'BG;L%]
MJVF^A*YEO8NQ8;R3LE^\G;)?O*RQ8K^^K6*_OJUBO[ZM8K^^K6*_OJUBO[ZM
M8K^^K6*_OJUBO[ZM8K^^K6*_OJW_EA@#_YDA!?^J* ;_N3 (\,@X#>'80!/4
MXT4FRNM+.\'L3T^SZ%=@IN5?;YKB9GR.W&R&A-5QCWK0=95SS7J;;,I_GV?'
MA*)CQHJD7\21IES$F:=:PZ2G6L2PIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G6L2P
MIUK$L*=:Q+"G6L2PIUK$L*?_F!<"_YX@!/^O)@7XP"X&YM S"-7A/!3)ZD4H
MO_)*.[7Q3DRI[U9;G>U?:)+J9W.'XVU\?MYR@G;:>(APUWV,:]2"D&;2AY)C
MT8R57\^2EES.F9A9SJ*96,VKFEC-JYI8S:N:6,VKFEC-JYI8S:N:6,VKFEC-
MJYI8S:N:6,VKFEC-JYK_FA<"_Z4> _^W(P/MR28#UMXI!LGI.Q>^\T0IL_A)
M.JCW34B?]E55E/5?8(GQ:&B [&]P>.AU=7+E>GEMXG]]:>"$@&7?B8)BW8Z$
M7]R3AEW;F8=:VJ&)6-FHB5C9J(E8V:B)6-FHB5C9J(E8V:B)6-FHB5C9J(E8
MV:B)6-FHB5C9J(G_G!8"_ZT; O;!'0';VA,!R>@I";WS.QFR_4,HIOY'-IS]
M3$.3_55-BOU?5H'Y:5UY]7!B<_)V9V[P?&IJ[H%M9^R&;V3KBW%AZH]R7^F4
M=%WHF75:YZ!W6.:F>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X
M6.:F>%CFIGC_HA4!_[<5 -C/"P#*YQ,"O/,I"['].QFD_T FF?]%,H__2SR'
M_U1$?_]?2WC_:5!Q_W!4;/UV6&G[?%IF^H%<8_B&7F'WBU]?]I!A7O:58ESU
MFF-:]*!D6/.E95CSI658\Z5E6/.E95CSI658\Z5E6/.E95CSI658\Z5E6/.E
M95CSI67_K1  UL,( ,C3"@"[]!4#K_\J#:/_-QB7_STBB_]#+('_2C1Z_U(Z
M<_]>/V[_:$-I_V]'9O]U26/_>TMA_X%,7_^%3EW_BD]<_X]06O^345G_F%)7
M_YY35O^C5%;_HU16_Z-45O^C5%;_HU16_Z-45O^C5%;_HU16_Z-45O^C5%;_
MHU39N@4 Q<<' +G9" "L_Q<%HO\K#97_,Q:)_SD>?O] )77_2"MM_U P9_]:
M-&/_93=@_VTY7O]S.US_>#U:_WT^6/^"/U?_AD!6_XM 5?^/053_E$)3_YI#
M4?^?0U'_GT-1_Y]#4?^?0U'_GT-1_Y]#4?^?0U'_GT-1_Y]#4?^?0U'_GT/&
MO@4 M\T% *KD" &?_QD&E/\H#(?_+A-[_S49<?\]'FG_12-B_TTF6_]6*5C_
M7RQ6_V@M5/]N+U/_<S!2_W@Q4?]\,5#_@#)/_X0S3O^(,TW_C#1,_Y(T2_^6
M-4O_EC5+_Y8U2_^6-4O_EC5+_Y8U2_^6-4O_EC5+_Y8U2_^6-4O_EC6WQ ,
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MVH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][,PW_AC@1_XY
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M6E3[L5M4^[%;5/NQ6U3[L5M4^[%;5/NQ6U3[L5M4^[%;5/NQ6U3[L5OPKP@
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MB723V(G_?!@"_X0< _^5'P/_HR4$_Z\L!O>Z,PGLQ#L/XLY"&-/.2"S&QU)
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M:$WHZ&A-Z.AH3>CH:$WHZ&A-Z.AH3>CH:$WHZ&C_F0L W:X$ ,R\!@#!R0<
MN-L* *WX' 2D^"\-F?@Y%X_X/R&%^$8J?/A-,G7W5SEN]V _:?=I0V3X<4=A
M^'E*7?B!3%KXB4]8^))15OF;4E/YI511^J]54/J[5D[ZRE=-^^-73/OI5TS[
MZ5=,^^E73/OI5TS[Z5=,^^E73/OI5TS[Z5?EI0  SK0$ +^_!0"TS@8 JNL-
M :#_'P:7_R\-C/\V%8+_/1UX_T0D</],*FK_5"]E_UXS8?]G-UW_;SE:_W8\
M6/]^/E;_AC]3_XY!4?^70E#_H$-._ZE%3?^S14O_OD9*_]!'2?_<1TG_W$=)
M_]Q'2?_<1TG_W$=)_]Q'2?_<1TG_W$?1K@  O[D# ++% P"GU04 G/T/ I3_
M(@:)_RL,?O\R$G7_.AAL_T(=9?])(E__425:_UHH5_]C*U3_:RU2_W(O4/]Y
M,$__@#%-_X@R2_^0-$K_F#5(_Z$U1_^J-D;_LS=$_[\X1/_%.$3_Q3A$_\4X
M1/_%.$3_Q3A$_\4X1/_%.$3_Q3C!LP  LKX" *7, 0"9W0, D/\2 H;_'P5[
M_R<*<?\N#FC_-A-A_SX76O]&&E7_31U1_U4?3O]=($O_9"))_VLC1_]Q)$;_
M>"5$_W\F0_^&)T'_CBA _Y8H/_^>*3W_IRD\_[ J//^T*CS_M"H\_[0J//^T
M*CS_M"H\_[0J//^T*CS_M"JSN $ I<8  )?5  "+[P0!A/\3 G?_&@1M_R('
M9/\J"US_,@Y5_SD14/]!$TO_2!5(_T\71?]6&$+_7!E _V$:/O]G&CS_;1L[
M_W,<.?]Y'#C_@!TV_X@=-?^/'C3_EQXR_Z ?,O^D'S+_I!\R_Z0?,O^D'S+_
MI!\R_Z0?,O^D'S+_I!^FP   E\X  (G>  !__P<!=/\0 FG_%0-?_QP%5_\D
M"%#_+ I*_S,,1?\[#D'_00\]_T<0.O]-$3C_4A$V_U<2-/]<$S+_81,Q_V84
M+_]K%"[_<14M_W<5+/]]%2K_@Q8I_XL6*?^.%BG_CA8I_XX6*?^.%BG_CA8I
M_XX6*?^.%BG_CA;_9B #_V$J!?]A,PC_:38+_VX]#_]Q1A7_<U$<_W->(_]P
M;2G_;GPP_VN)-?]IECG_9Z$]_V:J0/]DLD+_8[E$_V'"1O]@R$?_7LU(_US4
M2O];WDO[6>1,]UCJ3/17[TWP5O--[%7X3>Q5^$WL5?A-[%7X3>Q5^$WL5?A-
M[%7X3>Q5^$W_9B #_V$J!?]A,PC_:38+_VX]#_]Q1A7_<U$<_W->(_]P;2G_
M;GPP_VN)-?]IECG_9Z$]_V:J0/]DLD+_8[E$_V'"1O]@R$?_7LU(_US42O];
MWDO[6>1,]UCJ3/17[TWP5O--[%7X3>Q5^$WL5?A-[%7X3>Q5^$WL5?A-[%7X
M3>Q5^$W_9B #_V(J!?]C,0C_:S4+_W \#_]S117_=4\<_W9=(_]S;"K_<'HQ
M_VV'-O]KE#O_:9\__VBH0O]FL$7_9+A'_V/ 2?]AQTK_7\Q,_UW33?Q<WD[Y
M6N1/]5GJ4/%8[U'M5_11Z5?Y4.E7^5#I5_E0Z5?Y4.E7^5#I5_E0Z5?Y4.E7
M^5#_9Q\#_V,J!?]E, C_;C,+_W0Z#_]W0Q7_>4X<_WI:)/]W:"O_='8S_W&$
M.?]ND#__;)M#_VJE1_]HK4K_9[9,_V6^3O]CQ5#_8<M2_5_25/E=W57T6^16
M\%KJ5^M8\%CG6/57XUGZ5.-9^E3C6?I4XUGZ5.-9^E3C6?I4XUGZ5.-9^E3_
M:!\#_V,I!?]H+@?_<3(*_W<X#_][0A7_?4P<_WY8)/][9BW_=W,U_W2 //]Q
MC$+_;Y='_VRA2_]JJD__:+)2_V>[5/]EQ%;^8LI8^6#16O5>W%SP7.1=ZEKK
M7N99\5_B6O5;W%OY5]Q;^5?<6_E7W%OY5]Q;^5?<6_E7W%OY5]Q;^5?_:1X#
M_V0I!?]K+0?_=# *_WLW#O]_017_@4H<_X)5)?]_8R[_>W V_WA\/O]UB47_
M<91+_V^>4/]LIE3_:JY8_6BW6_QFP%WZ9,E@]6'08O!>W&/J7.5EY5OL9MY:
M\&/86_1@T5WX6]%=^%O17?A;T5WX6]%=^%O17?A;T5WX6]%=^%O_:1X#_V4H
M!?]N*P?_>"X*_W\V#O^#/Q3_A4@<_X=3)?^$8"__@&PX_WQY0?]XA4G^=)!0
M^W&95OENHEKX:ZI?]FBR8O1FNV7S9,5H\&+0:^I?W6WC7>=NVUOJ;=-<[VC-
M7O-DR%_W7\A?]U_(7_=?R%_W7\A?]U_(7_=?R%_W7\A?]U__:AX#_V8H!?]Q
M*0?_>RP)_X,U#?^'/A3_BD<;_XQ0)?^)72__A6DZ_8%U1/I\@$WW>(M5]'.5
M7/%OG6+O;*5G[6FM:^MFMF_H8\!RYF',=>-@WW?67.1XSE[I<LE?[6W$8/!H
MOV+T8[]B]&._8O1COV+T8[]B]&._8O1COV+T8[]B]&/_:QT#_V<G!?]T)P;_
M?RL(_X<S#?^,/!/_CT4;_Y%.)?^/6C#\BV8[^(9Q1O.!?%'O?(=:[':08NAQ
MF&GE;*!PX6BH==YDL'K;8KI^V&''?]1AVG_+7^%^Q&'E=[]BZ7*[8^UMMF3Q
M9[9D\6>V9/%GMF3Q9[9D\6>V9/%GMF3Q9[9D\6?_;!T#_VHF!?]W)@;_@BH(
M_XHR#/^0.Q+_DT,:_Y9,)/V55S#WD6(\\HQM2>R&>%3G?X%?XGB*:=QRDG+6
M;9IXTFJB?,YGJW_+9K2!R66_@\=DSH3!8]V#NF3B?+9FYG:R9^IQKFCO:JYH
M[VJN:.]JKFCO:JYH[VJN:.]JKFCO:JYH[VK_;1P#_VPD!?]Z) 7_A2D'_XXQ
M"_^4.1'_F$(9_YM*)/B;5##REU\]ZY)J2^6*<UC>@GQDU7R%;L]VC77*<I5Z
MQFZ=?L-LI8*_:J^$O6FYAKIHQX>W:-J'L6C>@:UIXWJI:^ATIFOL;:9L[6VF
M;.UMIFSM;:9L[6VF;.UMIFSM;:9L[6W_;1P#_VXC!/]](@7_B"@'_Y$P"O^8
M.!#_G$ 8^Y])(_2A4B_MG5P]Y99F3-V.;UK3AWAES(&!;L9[B7;!=Y%[O'.9
M@+APH82U;JJ'LFVTB:]LP8JM;-**J&S<A:5MX7ZB;N5WGV_K<)]OZW"?;^MP
MGV_K<)]OZW"?;^MPGV_K<)]OZW#_;AP#_W$B!/]_(07_BR<&_Y0O"?^;-P__
MH#\7^*1'(?"G3R[HHEH]WYMC3=24;%K+C'5EQ(9];[Z A7:X?(U\LWB5@:]U
MG86K<J6)J'&OBZ5PNXRC<,N-H''9B)UQWX&;<N1ZF7/I<IESZ7*9<^ERF7/I
M<IESZ7*9<^ERF7/I<IESZ7+_;QL#_W,@!/^"( 3_CB8&_Y<N"/^?-@[]I#X5
M]*A&(.RL32WCIU@\V:!A3,V8:EG%D7)EO8MZ;K:%@G:P@(E]JWV1@J=YF8:C
M=Z**GW6KC9QTMXZ:=,:/F'76BY9VW8.4=N)\DW;G=))VZ'22=NATDG;H=))V
MZ'22=NATDG;H=))VZ'3_;QL"_W4?!/^$'P3_D"4%_YHM"/^B-0SZJ#T4\:Q%
M'NBP3"O?JU<[TJ1?2\B<:%F_E6]DMX]W;K"*?W:JA89]I(&.@I]^EH>;>YZ+
MEWFHCI1XLX^2>,*0D7K5C8]ZVX6.>N%^C7KF=HUZYG:->N9VC7KF=HUZYG:-
M>N9VC7KF=HUZYG;_<!L"_W8> _^&'@3_DR4%_YTL!_^E- OWJSP2[K%#'.6T
M2RG:KU4ZS:A>2L*@9EBYFFUDL9-U;JJ.?':CBH-]GH:+@IF"DX>4@)N+D'ZE
MCHU]L)"*?;Z1BG_3CXE^VH>(?M]_AW[E=X=^Y7>'?N5WAW[E=X=^Y7>'?N5W
MAW[E=X=^Y7?_<!L"_W@= _^('@/_E20$_Z K!O^H,@KTKSH1Z[5"&N&X2B?4
MLU,YR*M<2;ZD9%>TGFMCK)AR;:23>76>CH%\F(N(@I*'D(>-A9F+B8.BCH:"
MKI&#@KR1@H/.D8.#V8B"@M^!@H+D>8*"Y'B"@N1X@H+D>(*"Y'B"@N1X@H+D
M>(*"Y'C_<1H"_WH< _^*'0/_ER,$_Z(I!?RL,0GQLSD/Z+I %]V\2"7/ME(X
MPZ];2+FH8E:OHFIBIYQP;)^7=W68DWY\DI"&@HR-CH>'BI>+@XB@CG^'JY%\
MA[F1>X?+D7R(V(E]A]Z"?8;D>GV&Y'E]AN1Y?8;D>7V&Y'E]AN1Y?8;D>7V&
MY'G_<1H"_WP: _^-' /_FB(#_Z4H!/FO+P?NN#<,Y+\_%-C 1B3*NE WO[-9
M1[2L856JIFAAH:%N:YF<=722F'Q[C)6#@8:2BX:!D)2+?(Z>CGB-J9!VC+:1
M=(W(D7:.V(IWC-V"=XKC>G>*XWIWBN-Z=XKC>G>*XWIWBN-Z=XKC>G>*XWK_
M<AH"_W\9 O^/&P+_G2 #_ZDF _:S+07JO34)X,8\$-+$1"/%O4\UNK=81J^Q
M7U2EJV9@G*9M:I2B<W.,GGIZAIN!@("8B85ZEI*)=92;C7*3IH]OD[20;93%
MD'"5V(IPDMV#<9#C>W&0XWMQD.-[<9#C>W&0XWMQD.-[<9#C>W&0XWO_<QD"
M_X(7 O^2&@+_H!\"_ZTD O*X*@3FPS$&V\PU#\S(0B' PDTTM+Q61*FV7E*?
ML61>EJQK:(ZI<7&&I7AX?Z)_?GF@AX-TG8^(;YR9BVN;I(UHF[*.9YO"CFF=
MV(IJF=V":Y;C>VN6XWMKEN-[:Y;C>VN6XWMKEN-[:Y;C>VN6XWO_=!D"_X45
M O^6& '_I!P!^[(@ >V_)0+AS"H#U-$R#<?,01^ZQTPQKL%40J.\7%"9MV)<
MD+-I9H>P;VZ K79U>:I]>W.HA(!MIHV%:*67B&6DHXIBI+"+8*3!BV*FV8AC
MHMZ!99[C>F6>XWIEGN-Z99[C>F6>XWIEGN-Z99[C>F6>XWK_=A@"_XD3 ?^:
M%@'_J1@!]K@; >?'&@';V1P!S=8P"\#2/QVTS4HOJ,A2/YW#6DV2OV%8B;MG
M8H"X;6MYMG1Q<K-[=VRQ@WQGL(R 8J^6@UZNH89<KJ^'6J^_AUNPVH1=K.!_
M7J?E>%ZGY7A>I^5X7J?E>%ZGY7A>I^5X7J?E>%ZGY7C_>A4"_XX2 ?^?$P#_
ML!, [\ 0 -G4# #.WQP!Q-TO";G9/1JMTT@LH<]0.Y7+6$F+QU]4@L1E7GG"
M;&9RP')L:[YZ<F:]@G9ANXMZ7+N5?5FZH7]7NJ^ 5;N_@%6\V7]6N.-Z6++G
M=5BRYW18LN=T6++G=%BRYW18LN=T6++G=%BRYW3_@!(!_Y00 /^F#P#CN L
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M, U=_S@05_] $U'_1Q9-_TX82O]6&4?_7!I$_V,<0O]I'4#_<!X__W@>/?^
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M<6J4[6QJE.UL:I3M;&J4[6QJE.UL:I3M;&J4[6S_<18"_X,1 ?^4$P'_HA0
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M85&]]6%1O?5A4;WU85&]]6'_A@H \)H$ -2J! #(M@8 OL$% +?/"0"PXQ$
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M$B7_D!,D_YD3(_^C%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ2<O@
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M9GJ"]U]Z@OA>>H+X7GJ"^%YZ@OA>>H+X7GJ"^%[_9Q<"_W<1 ?^'$P'_E!4
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M7F*9]UYBF?=>8IGW7F*9]U[_<Q !_X4, /J6"@#;I08 T;$( ,N[" #&QPL
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M*CW\N2L[_<LK._WB*SK\]"LZ_/<K.OSW*SK\]RLZ_/<K.OSW*SK\]RN]J
MKK   *&\  "5R   B=0  '[H!0!W_Q(!;_\< F?_)@5@_R\(6?\W"U3_/PY/
M_T<12_].$T?_5A5$_UT60O]D&$#_;!D]_W4:._]^&SG_B1PW_Y0=-O^@'C7_
MK!\S_[D?,__('S+_XB R_^<@,O_G(#+_YR R_^<@,O_G(#+_YR"PK0  HK<
M )7$  "'T   >]T  '+]"0!J_Q$!8?\9 EK_(@-4_RH%3O\R!TG_.@E%_T$+
M0?](##[_3@X[_U4/./];$#;_8A$T_VD1,O]R$B__>Q,M_X84*_^2%2K_GA4I
M_ZD6*/^S%B?_PA8G_\<6)__'%B?_QQ8G_\<6)__'%B?_QQ:DM   EL   (?,
M  !ZV@  ;>L  &3_!0!<_PX!5/\4 4W_' )(_R0$0O\L!3[_,P8Z_SD'-O]
M"#/_10@P_TL)+O]1"BO_5PHI_UT+)_]D"R3_; PB_W8-(/^ #1[_C X=_Y<.
M'/^A#AO_K \;_ZX/&_^N#QO_K@\;_ZX/&_^N#QO_K@^7O   B,D  'G6  !K
MXP  7_8  %;_  !._PH 1_\0 4'_%@(\_QT"-_\D S+_*@,O_S $*_\V!2?_
M.P4E_T %(O]%!B#_2@8>_U &&_]6!QG_7 <7_V0(%?]M"!/_=P@1_X$)$/^+
M"1#_E0D/_Y@)#_^8"0__F D/_Y@)#_^8"0__F G_22<"_T0Q!/]+,03_4#0&
M_U(Z"/]20PO_44X/_T]<$_]-:Q;_3'D9_TN'&_])DQW_2)T?_TBF(/]'KB'_
M1[4B_T:](_]&QB/_1M D_T;@)/]&ZB7_1O,E_T;Z)?]&_R7_1O\E_T;_)?]&
M_R3]1O\C_4;_(_U&_R/]1O\C_4;_(_U&_R/_22<"_T8O _]-+P3_4C(&_U4Y
M"/]50@O_5$T/_U)9$_]0:!?_3W<:_TZ$'?],D1__2YLA_TJD(O]*K"/_2;,D
M_TF[)?](Q";_2,TF_TC=)_](Z"?_2/$H_TCY*/](_RC_2/\H_DC_*/M(_R?Y
M2/\F^4C_)OE(_R;Y2/\F^4C_)OE(_R;_2B<"_T@M _]0+03_53 &_U@V"/]9
M0 O_6$L/_U56$_]49AC_4G0;_U&!'O]/CB'_3I@C_TVA)?]-J2;_3+$G_TNX
M*/]+P2G_2\HJ_TK9*O]*YBO_2O K_TKX+/]*_RS]2O\L^DK_*_=*_RGU2O\H
M]4K_*/5*_RCU2O\H]4K_*/5*_RC_2R8"_TLK _]2*P3_6"X%_ULT"/]=/@O_
M74D/_UI4%/]98AC_5W$=_U5^(/]3BB/_4I4F_U&>*/]0IBK_3ZXK_TZU+/].
MO2W_3<<N_TW3+_],XS#_3.TP_$SV,?I,_C'W3/\Q]4W_+_)-_RWP3?\K\$W_
M*_!-_ROP3?\K\$W_*_!-_RO_2R8"_TXI _]6*03_7"L%_V Q!_]B.PO_8D8/
M_V!1%/]>7QG_7&T>_UIZ(_]8AB;_5I$I_U6:+/]3HB[_4JHP_U&Q,?]1N3/_
M4,,T_D_.-?M/WS;X3NLW]4[U./)._3CP3_\U[E#_,^M1_S'I4?\OZ5'_+^E1
M_R_I4?\OZ5'_+^E1_R__3"4"_U$G _]:)@/_8"@%_V4O!_]H.0K_:$,/_V=.
M%?]E6AK_8F@@_U]V)?]=@2K_6HPN_EB6,?Q7GC3[5:8V^52M./A3M3KW4KX[
M]5')/?-1VC[P4.@_[%#S0.E1_3[H4_\[YE3_..-5_S7A5?\SX57_,^%5_S/A
M5?\SX57_,^%5_S/_320"_U0D _]=(P/_924$_VHM!O]M-@K_;D ._VU+%/]K
M5AO_:&0A_F5Q*/MB?2WX7X<R]ER1-O-:F3KR6*$]\%>I0.Y5L4+L5+E$ZU/$
M1NE2TDCE4>5)XE+R2-]4_$3=5O] VUC_/=99_SK26?\XTEG_.-)9_SC26?\X
MTEG_.-)9_SC_3B0"_U@A _]A( /_:B,$_W K!?]S- G_=#X._W1(%/]R4AO[
M;U\C]FML*O)G=S'O8X(W[&"+/>E=E$'F6IQ%Y%BD2>)6K$S@5+1.W52_4-M4
MS5#74^)1TE3P3M!7^TK.6O]%S5S_0LE<_S[%7/\\Q5S_/,5<_SS%7/\\Q5S_
M/,5<_SS_3R,"_UL? O]E'0+_;B$#_W4I!?]Y,0C_>CL,_WI$$_IY3AOT=ELC
M[G%G+.EL<C7E:'P\X6.%0]U@CDC979=,U5R?3]):IU'/6;!3S5BZ5,M8QE7)
M5]I6Q5?L5<-;^4_"7O]*P%__1KU@_T*Z8/] NF#_0+I@_T"Z8/] NF#_0+I@
M_T#_4B$"_UX= O]I&@+_<Q\#_WHF!/]^+P;_@3@+^X%!$O. 2QKL?%<CYG=C
M+>!Q;3C:;7= TVF 1L]EB4O+8Y%/R&"94L5?H57"7:I7P%RS6;Y<OUJ\6\Y;
MN%OE6[=>]56W8O]/M6/_2K)D_T:P9/]#L&3_0[!D_T.P9/]#L&3_0[!D_T/_
M51\"_V$: O]M& +_=QT"_WXD _^$+ 7^AS4)]8@^$.V'2!CE@U0BWGY?+M1X
M:3C.<W- R6Y\1\1KA$S :(Q1O6645+ICG%>W8J5:M&"N7+)@N5ZP7\=>K5_?
M7ZQB\5FL9?Y3JF?_3JAG_TJF9_]&IF?_1J9G_T:F9_]&IF?_1J9G_T;_5QT"
M_V08 O]P%@+_>QP"_X,B O^)*@3YC#('[XX[#>>.1!;>BE$AU(1<+<Q^9CC%
M>&]!P'1W2+MP@$VW;8A2LVJ05K!HF%FL9J!<JF6I7Z=DM&"E8\)AHV/58J)E
M[5VB:?M7H6K_49]K_TR>:_])GFO_29YK_TF>:_])GFO_29YK_TG_61P"_V<6
M ?]S%0'_?AH!_X<@ O^-)P/TDB\&ZI0X"^&40A/6CTX@S(E9+<6#8S>^?6M
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M6(IV_U*)=O].B7;_3HEV_TZ)=O].B7;_3HEV_T[_7Q<!_VX1 ?][$@'_AQ0
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M4G.%_U)SA?]2<X7_4G.%_U+_:!$!_W@- /^&#0#VDPP WJ ) -:I"@#2L@T
MQ[(B KVO,PJSJT$7JJ=,)*&B53"9GETZDIID0HN7:TF%E')0@))Y57N/@5IV
MC8E><HR28FZ*G65KB:EG:(FX:&>)RVAIB^EC;(WY7&V,_5=MBO]2;8K_4FV*
M_U)MBO]2;8K_4FV*_U+_:Q !_WL+ /^*"@#BF 8 UJ,( -"L"0#+M0L P;8?
M ;BT,0FNL#\6I*Q*(IRH4RZ4I%LXC*!B0(:>:4B FW!.>IEW4W66?EAPE(=<
M;).08&B2FV-DD:=E8I"V9F"1R69BDN=B993X7&>2_5=GD?]29Y'_4F>1_U)G
MD?]29Y'_4F>1_U+_;@X _W\) /&.!0#9FP4 SZ8' ,FO!P#$N0@ N[H< ;*X
M+P>HM3T3G[%(():N42N.JEDUAJ=@/H"E9T5ZHFY+=*!U46^>?%5JG(599IN.
M76*:F6!>F:9B7)FT8UJ9QV-;FN5@7YOW6V":_E9AF/]289C_4F&8_U)AF/]2
M89C_4F&8_U+_<@L _X,% -^3 0#1GP0 R:H& ,&R!0"[O00 M+\8 *N^+ 6B
MNSH1F;A%'9"U3RB'LE<R@*]>.GFM94)SJVQ(;JES36FG>E%DIH-67Z2-65RC
MF%Q8HZ1>5J.S7U6CQE]5I.1=6*3V6%JC_U1;H?]06Z'_4%NA_U!;H?]06Z'_
M4%NA_U#_=P< \(D  -:8  #+I , P:T$ +FV P"RP 0 J\44 */%* 2;PC<.
MD<!#&8F]3"2 NE4N>;A<-G*V8SUMM&I#9[-Q2&*Q>4Q>L(%06J^+5%:OEU93
MKJ-84*ZR64^NQEE/KN184:[V5%.N_U!4K/]-5*S_352L_TU4K/]-5*S_352L
M_TW_?0  WX\  ,Z=  ##J ( N; " +"Z @"HQ 4 H<P/ )O,(P*2RC,*B<@_
M%8'&21]YQ%(H<L):,&O!83=FOV@\8;YP05R]>$58O(%)5+R+3%&[ED].NZ-1
M3+NS4DJ[QE)*N^113+OV3DVZ_TM.N?])3KG_24ZY_TE.N?])3KG_24ZY_TGO
MA0  U)4  ,>C  "ZK $ L+0  *>_ P">R08 E=0+ )#5'0&)U"X&@-(\$'C0
M1AEQST\A:LY8*63-7R]?S&<T6LMN.5;*=SU2RH! 3\F+0TS)ET5)R:1'1\FS
M2$;*R$A&RN9'1\GW14?(_T-(Q_]"2,?_0DC'_T)(Q_]"2,?_0DC'_T+>C0
MRYP  +VG  "QL   IKH  )S$ P"3SP< BMT, (7?'0%^WRP%=MXW"V_>0Q-H
MW4T:8MQ5(%W;7298VV4J5-IM+E#:=C)-VH U2MJ+-T?:ESE%VJ0[0]NT/$+<
MR#Q"V^4[0MKT.D+9_CI#V/\Y0]C_.4/8_SE#V/\Y0]C_.4/8_SG0E@  P:,
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M&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4  )#!  ""S
M==D  &GD  !A_PD 6_\1 %3_&0%._R("2?\K!$3_,@5 _SH&//]!!SG_1P@V
M_TX),_]4"C'_6PLN_V(,+/]K#"G_=0TG_X .)?^-#B3_F@\C_Z80(O^S$"'_
MP1 A_] 0(?_0$"'_T! A_] 0(?_0$"'_T!"?L@  D;X  (/*  !UU@  9^(
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M/\D=_S_6'?\_Y1W_/^\=_S_W'O\__AW_/_\=_S__'?] _QS^0/\;_D#_&_Y
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M1()X_T2">/]$@GC_1()X_T3_7Q$!_VT, /]Z#0#_A0T \H\- .>8#0#;GPX
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M4U.?P%-2G]U259_S3E>@_TI9H/]&69__15F?_T59G_]%69__15F?_T7_=0
MX(8  ,^3  #$GP$ NJ<! +&N  "IM@  H;T- )N]( &4O#$'B[H]$(.W2!I\
MM5 B=;-8*F^R7S!JL&8V9:]M.V"M=3]<K'Y#6*N'1U6JDTI1JI],3ZJN34VJ
MP$U-JMQ-3JKR25"J_D92J?]#4JG_0E*I_T)2J?]"4JG_0E*I_T+R?   UXP
M ,B9  "]HP  LJL  *FR  "@NP( E\0) )+%&P"+Q"P$@\(Z#'O!1!5TOTX=
M;KU6)&B\72ICNV0P7[IL-%JY=#E6N'P\4[>'/T^WDD),MI]$2K:M1DBVP$9(
MM]U%2;;R0TJU_T%+M?\^2[3_/4NT_SU+M/\]2[3_/4NT_SWB@P  S9(  ,&?
M  "TIP  JJ\  *"X  "6P , C,H' (;-% "!S28">LPU"'/+00]LRDH79LE3
M'6'(6R-<QV(H6,9J+%3&<C!0Q7PS3<6&-DK$DCE'Q)\[1<2N/$3%P3Q#Q=\\
M1,3S.T3#_SE%PO\W1<'_-T7!_S=%P?\W1<'_-T7!_S?5BP  Q9H  +>D  "K
MK   H+0  ):^  "+QP0 @= ( 'C9#@!UV2 !;]@O!&G8/ ECUD807M90%5G5
M6!I5U& ?4=1H(D[4<29+TWLI2-.%*T73DBY"U)\O0=2O,#_5PC$_U>$P/]/R
M,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$  *VI  "BL0
MEKL  (O$  " S0, ==@( &_D$0!JY" !9.0M U[D. =9Y$$+5>1+#U'D5!)-
MY%T62N1E&$?D;AM%Y'<=0N2"'T#DCB$^Y9LC/.6J)#OFO"0ZYM,D.>7N)#GC
M^B,YXO\D.>+_)#GB_R0YXO\D.>+_)#GB_R2_G@  KZ8  *.N  "7N   BL(
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M"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X  %7D  !+]0
M1O\% $#_#@ [_Q0 -_\; 3/_(P$O_RD"*_\P BC_-0(E_SL#(O]! Q__1P,=
M_TX#&O]5!!C_7@05_V@%$_]T!1'_@@40_Y &$/^=!@__J08._[4&#O^Z!@[_
MN@8._[H&#O^Z!@[_N@:.N@  ?\4  '#1  !BW@  5.4  $;K   __@  .?\
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M-9-J_S63:O\UDVK_-9-J_S7_5Q$!_V,- /]N# #_=PX _W\/ /"%$0#CB18
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M3V*"OT]A@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0
M]G8  -R"  #.C0  Q94" +Z< P"WH0( KZ01 *BD) *@HC0(F)] $9&<2AJ*
MF5,BA)=;*7Z58C!YDFDU=9!P.G"/=SYLC7]":(R)1F6*DTEAB9]+7HFL35V)
MO4Y<B=9-7HKP2&"+_D-BB_\_8XS_/&.,_SQCC/\\8XS_/&.,_SS_:@  YGH
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M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD  ,*5  "VGP
MK*4  **L  "8LP  CKL" (B]$@"#O24!?+PS!G:[/PUONDD4:KA1&F6W61]@
MMF D7+5G*5BT;RQ4LW@P4;.",TVRC39*LIHX2+&H.D:RN3I%LM$Z1K'M.4>P
M_#9'L/\T2*__,TBO_S-(K_\S2*__,TBO_S/;@@  QY   +N<  "NHP  I*H
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M&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X  'G'  !MSP
M8M8# %CA" !5ZA, 4>L@ $WK*P%)ZS4"1>P^!$+L1P4_[$\'/>U8"3KM8 HX
M[6H,-NYT#3/N@ XR[HX/,.^=$"[OK1$M\, 1+?#>$2SN\1$L[/X1+.O_$"SK
M_Q LZ_\0+.O_$"SK_Q"MH@  H*D  ).S  "&O0  ><8  &S/  !@V   5=X
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M PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\  "S_   G_P<
M(_\. "#_$@ <_Q@ &/\= !7_(0 2_R8 $/\L 0[_,0$-_S<!"O\^ 0C_1@$%
M_T\! ?]9 0#_9@$ _W0! /^" @#_D ( _YP" /^F @#_I@( _Z8" /^F @#_
MI@+_+B\"_S,L O\W+0+_.# "_S<V _\T/P3_,4L&_R]8!_\L9@C_*G0)_RF!
M"O\HC0O_*)<+_RB?"_\HI@S_)ZT,_R>T#/\GNPS_)\0,_R?.#/\HW@O_*.D+
M_RCS"_\H^PO_*/\*_RG_"O\I_PK_*?\*_RC_"O\H_PK_*/\*_RC_"O\H_PK_
M,"T"_S8J O\Y*@+_.RX"_SHT _\X/ 3_-DD&_S-6!_\Q8PG_+W$*_RU^"_\M
MB@S_+)0,_RR<#?\LI W_+*L-_RRQ#?\LN0W_*\$-_RS+#?\LV@W_+.<-_RSQ
M#?\L^@W_+/\,_BW_#/TM_PS]+?\,_2S_"_TL_PO]+/\+_2S_"_TL_PO_,BL!
M_SDH O\]* +_/RH"_SXP _\].@3_/$8&_SE3"/\W8 G_-6T+_S-Z#/\RA@W_
M,9 ._S&9#O\QH0__,:@/_S"N#_\PM0__,+T0_S#'$/\PU!#_,.00_S'O$/XQ
M^0_[,?\/^3'_#_@Q_P[W,?\.]S'_#O8Q_P[V,?\.]C'_#O8Q_P[_-2@!_SPE
M ?] ) +_0R<"_T,L _]$-P3_0D,&_T!/"/\]7 K_.VD,_SEV#?\X@@__-XP0
M_S>5$?\VG1'_-J02_S:K$O\VLA/_-;H3_S7#$_\USQ/\->$3^3;M$_8V]Q/S
M-O\3\3;_$O V_Q+P-_\1[S?_$>\W_Q#O-_\0[S?_$.\W_Q#_.24!_T A ?]%
M( '_1R("_TDI O]*- 3_23\%_T9+"/]$6 K_0F4-_T!Q#_\^?1'_/8<2_SV1
M%/X\F17]/* 5_#NG%OH[KA?Y.[87^#N_%_8[RACT.]P8\#OJ&.T[]ACJ._\7
MZ#S_%^<\_Q;F/?\5Y3W_%.4]_Q3E/?\4Y3W_%.4]_Q3_/2(!_T0> ?])' '_
M31X!_U F O]1, /_4#L%_TY&"/]+4PO_2& ._T9L$?M%>!/X1((5]D.,%_1"
ME!CS09P9\4&C&^] JAON0+(<[3^['>L_QA[I/]4>Y3_H'^) ]![?0/X=W4'_
M&]M"_QK90O\8V$+_%]A"_Q?80O\7V$+_%]A"_Q?_0!\!_T@: ?].& '_4AL!
M_U8C O]8+ /_5S<$_U5"!_]230OY4%H.]4UG$O%,<A;N2GT8ZTB&&^E'CQWG
M1I<?Y46>(.-$IB+A1*XCX$.W)-Y#PB7<0] FUT/E)M-$\R301?XBS4;_(,Q'
M_Q[*1_\<R4C_&\E(_QO)2/\;R4C_&\E(_QO_1!L!_TP6 ?]2% '_6!@!_UT?
M ?]?* +_7C(#_5T]!O9:20KP5U4/ZE5B$^92;1CB4'<<WTZ!']Q,BB+92Y(D
MU4J:)M-)H2C12:DISTBR*LU(O"O+2,DLR$C?+,5([RO"2OPHP$O_);],_R*^
M3?\@O4W_'[U-_QZ]3?\>O4W_'KU-_Q[_1Q@!_T\3 ?]6$0#_7A4 _V(< ?]E
M) '^92T"]&0X!>UA0PGF7U$.X%Q=%-I8:!K45G(>T%1[(LQ2A";*4(PHQT^4
M*L5.FRS#3J,NP4VL+[],MC"]3,(QNTS3,KA,Z3&V3O@MM%#_*K-1_R>S4O\D
MLE+_(K)2_R*R4O\BLE+_(K)2_R+_2A4!_U,1 /];#P#_8A( _V@7 /]J'P'V
M:R@![&LR ^1I/@?<9DP-TV)8%,U?8QO(7&T@Q%IV),%8?BB^5H8KNU6.+KE3
MEC"V4IXRM%*F,[)1L#6P4;PVKE#+-ZQ0XS>J4O0SJ53_+JA6_RNH5_\HJ%?_
M):A7_R6H5_\EJ%?_):A7_R7_31, _U8. /]?#0#_9Q  _VP3 /MP&0#O<2(!
MY'$L MMP.@71;$@,R6A4%,-E7QN^8F@ANE]Q)K9=>2JS6X$ML%J),*Y8D3.K
M5YDUJ5:A-Z=6JSBE5;8ZHU7%.Z%5W3N?5O WGUC^,I]:_RZ>6_\KGES_*)Y<
M_RB>7/\HGES_*)Y<_RC_4!$ _UD, /]C# #_:PT _W 0 /5T$P#H=AH W7<E
M =%V-@3(<D0,P6Y0%+MK6QNV9V0AL65M)ZUB=2NJ8'POIU^$,J1=C#2B7)0W
MGUN=.9U:ICN:6;$]F%F_/I=9TSZ56NP[E5W[-99>_S&67_\MEF#_*I9@_RJ6
M8/\JEF#_*I9@_RK_4@\ _UP* /]F"0#_;@H ]G0, .]X#@#A>Q( U'P@ ,I[
M,P3!=T$+NG1-$[1P6!NN;&$AJ6II)Z9G<2NB97@OGV2 ,YQBB#:989 XEE^9
M.Y1>HCV17JT_CUV[0(U=S4&,7N@_C6'Y.(UB_S..9/\PCF3_+(YE_RR.9?\L
MCF7_+(YE_RS_50X _U\& /]I!@#T<@8 XG@& -M\"0#9?PP S8$= ,1_, .[
M?#\*M'A+$JUU51JH<5XAHVYF)I]L;BN;:G4OF&A],Y5GA#:298PYCV25/(QC
MGSZ)8JI AV&W0H5AR4*$8N1!A63W.X9F_S6'9_\QAVC_+H=I_RV':?\MAVG_
M+8=I_RW_5PP _V$$ /YL P#D=0$ VWL% -. " #0@PH QX4: +Z$+0.V@3P)
MKWU($JAY4AFB=EL@G7-C)IEP:RN5;G(OD6UY,XYK@3:+:8DZB&B2/(5GG#^"
M9J=!@&:T0WYFQ41\9N%#?FCU/']J_S> :_\S@6S_+X%L_R^!;/\O@6S_+X%L
M_R__60L _V,! /1O  #?>   U'\$ ,Z#!@#*AP@ PH@8 +F'*P*QA3H(JH%&
M$:-^4!B=>ED?F'=A)9-U:"J/<V\OBW%W,XAO?C:%;H8Z@FR//7]KF4!\:J5"
M>6JQ1'=JPD1V:MU$>&SS/GEN_SAZ;_\T>W#_,'QP_S!\</\P?'#_,'QP_S#_
M6P@ _V8  .=R  #:>P  SX(# ,F'!0#$B@8 O(P5 +2+* *LB3@'I85$$)Z"
M3AB8?U<>DWQ?)(YY9BJ*=VTNAG5T,H)T?#9_<H0Y?'&-/7EPET!V;Z)"<VZO
M1'%NP$5P;ME%<G#Q/W-R_SEU<_\U=G3_,79T_S%V=/\Q=G3_,79T_S'_708
M_VD  .)T  #4?0  RX4" ,2*! "_C04 MX\3 +"/)@&HC34'H(I"#IJ&3!:3
M@U4=CH%=)(E^9"F%?&LM@7IR,GUX>35Z=X(Y=G:+/'-UE4!P=*!";7.M1&MS
MO45J<]5%;'3O0&YV_CIO=_\V<7C_,G%X_S%Q>/\Q<7C_,7%X_S'_7P( ]VP
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M/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8  ,V"  #"C
MN9,  +"9  "HG0  GZ ) )FA&@"3H"L#C)\X"(6=0Q!_FDP7>9A4'7277")P
ME6,G:Y-J+&>2<3!DD7DS8(^"-UR.C3I9C9D]5XVF/U2-MD!3C<M 5(WI/5:-
M^CE7C?\U68[_,EF._S%9CO\Q68[_,5F._S'M;0  V7L  ,B'  "]D   M)@
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M*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4  ).L  "(L@
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M"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<  $7=   ^[@D
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M 07_= $#_X4! O^6 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP
M=\$  &C,  !:UP  2]X  #[D   RZ0  )^T  "/_   ?_P  &_\% !?_#  4
M_Q  $?\4  __&  -_QT "_\B  C_*  %_RX  O\U  #_/0  _T<  /]2  #_
M7@  _VT  /]^ 0#_C@$ _YL! /^I 0#_JP$ _ZL! /^K 0#_JP'_*BT!_RXK
M ?\P*P'_,"X"_RXU O\I/0/_)4D$_R-7!/\A9 7_'W(&_QU_!O\=B@;_'90&
M_QV<!_\<HP?_'*H'_QRQ!_\<N ;_'+\&_QS)!O\<U@;_'>4&_QWO!O\=^07_
M'?\%_QW_!?\=_P7_'?\%_QW_!?\=_P7_'?\%_QW_!?\=_P7_+"L!_S H ?\S
M* '_,RL"_S$Q O\M.@/_*T<$_RA4!?\F807_)&\&_R)\!_\BAP?_(I$'_R&9
M!_\AH0C_(:<(_R&N"/\AM0C_(;P(_R'&!_\AT0?_(>('_R+M!_\B]P?_(O\&
M_2+_!OPB_P;\(O\&_"+_!OLB_P;[(O\&^R+_!OLB_P;_+B@!_S,E ?\V)0'_
M-R<!_S4M O\T. /_,D0$_R]1!?\L7@;_*FL'_REW!_\H@PC_)XT(_R>6"?\G
MG0G_)Z0)_R>K"?\GL@G_)[D)_R?""?\GS0G_)]X)_R?K"?PG]@CY*/X(]RC_
M"/8H_PCU*/\(]2C_"/4H_PCU*/\(]2C_"/4H_PC_,B4!_S<B ?\Z(0'_.R,!
M_SLI O\[- +_.4 $_S9-!?\T6@;_,68'_S!S"/\N?PG_+HD*_RZ2"O\MF0O_
M+:$+_RVG"_\MK@O_+;4,_RV^#/XMR0S[+=D,^"WH"_0N] OQ+OX+[R[_"^XN
M_POM+O\+["[_"NPN_PKL+O\*["[_"NPN_PK_-2(!_SL> ?\_'0'_0!\!_T(F
M ?]",0+_0#P#_SY(!?\[50;_.6((_S=N"O\V>0O_-80,_32-#?PTE0WZ-)P.
M^3.C#O<SJ@_V,[(/]3.Z#_,SQ0_R,](/[C/E#^HT\@_G-/T/Y33_#^0T_P[B
M-?\.XC7_#>$U_PWA-?\-X37_#>$U_PW_.1X!_S\: ?]#& '_1AH!_TDC ?])
M+0+_2#@#_T5$!?]#4 ?_0%T)^SYI"_@]= WU/'\.\SN(#_$[D!#O.I@1[3J?
M$NPYIA/J.:X3Z3FV%.<YP13F.<X5XCGC%=XY\17;.OP4V#K_$]4[_Q+3._\2
MTCO_$=([_Q#2._\0TCO_$-([_Q#_/1L!_T,6 /](% #_3!<!_T\? ?]0* '_
M3S,"_TT_!/M*2@;U1U<)\49D#.U$;P[I0WD1YT*#$^1!BQ3B0),6X#^;%]\_
MHAC=/JH9VSZS&M@^O1K6/LH;TC[?&\X^[QO+/_L:R4#_&,= _Q?&0?\5Q4'_
M%,1!_Q3$0?\4Q$'_%,1!_Q3_01< _T<2 /],$ #_4A0 _U8; /]7) '_5BX"
M^%0Y _%110;K3U()YDU>#.%+:1#=2703V4A]%M5&AAC218X:T$66',Y$G1W,
M1*4>RD.M'\A#MB#&0\,AQ4/3(<%#Z2&^1/<?O$7_';I&_QNY1_\9N$?_&+A'
M_Q>X1_\7N$?_%[A'_Q?_1!0 _TL0 /]1#@#_5Q$ _UL6 /]='@#Y72@![ULS
M N=9/P3@5TT(VE19#=-29!+.4&X6RDYW&<=,@!S%2X@>PDJ0(,!*ER&^29\C
MO$BG)+I(L"6X2+PFMTC+)[1'XR>R2?,EL$K_(JY+_Q^N3/\=K4S_&ZU-_QJM
M3?\:K4W_&JU-_QK_1Q$ _T\- /]6# #_7 X _V 2 /UB& #P8R$ YF(L =Y@
M.@/47D@'S5M4#<=87Q/#5FD7OU1R&[Q2>AZY48(AME"*([1/D26R3IDGL$VB
M**Y-JRJL3+8KJDS$+*A,VRRF3>\JI$_])J10_R.C4?\@HU+_'J)2_QVB4O\=
MHE+_':)2_QW_2@\ _U(* /]:"0#_8 L _V4. /5G$0#H:!@ W6<D -)F-0+*
M9$0'PV%0#;U>6Q.Y7&08M5IM'+%8=2"N5WTCK%6$):E4C"BG4Y0JI5*=+*-2
MIBVA4;$OGU&^,)U1T3";4>HOFE/Z*II5_R:95O\CF5;_(9E7_Q^95_\?F5?_
M'YE7_Q__30T _U4& /]=!0#[9 < [VD) .EK# #A;!  TVT> ,EL,0+":D '
MNV=,#;5D5Q.P86 9K%]I':A=<2&E7'@DHEJ )Z!9ARJ=6) LFU>8+IE6HC"6
M5:PRE%6Y,Y-5RC.15>4SD5?W+9%9_RF16O\ED5O_(Y%;_R&16_\AD5O_(9%;
M_R'_3PL _U<" /]A @#J: $ WFT$ -AP" #5< L RW(; ,)Q+@*Z;ST&M&Q)
M#:YI5!.I9UT9I&1E':%B;2&=870EFE]\*)A>@RN578LMDEN4,)!;GC*-6J@T
MBUFU-8I9QC:(6>$VB%ST,(A=_RN)7O\HB5__)8E?_R.)7_\CB5__(XE?_R/_
M40D _UH  /5D  #@;   UW$# -!T!@#-=0D Q'87 +QV*@&T=#H%KG%&#*=N
M41*B:UH8GFEB'9IG:2&697$EDV1X*)!B@"N-88@NBV"1,8A?FC.&7J4U@UZR
M-X)>PC> 7MPX@%_R,X%A_RV"8O\I@F/_)H)D_R6"9/\E@F3_)8)D_R7_4P8
M_UT  .=G  #;;P  T'0" ,IX!0#&>0< OGH5 +9Z* &O>#<%J'9$"Z)S3A*<
M<%<8F&U?'91K9R&0:FXEC6AU*(IG?2N'984NA&2.,8%CES1_8J(V?&*O.'IB
MOCEY8M4Y>6/O-'IE_B][9O\K?&?_*'QG_R9\9_\F?&?_)GQG_R;_50, _V
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M-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@  -5S  #)>P
MP((  +B&  "QB   J8D- ***'0"<B2X"E8<[!X^%10Z)@D\4A(!7&7]^7AY[
M?&4B>'ML)G1Y<RIQ>'LM;G>$,&MVCC-H=9HV972F.&-TM3EA=,DZ873G.&-V
M^3)E=O\N9G?_*V=W_REG=_\I9W?_*6=W_RG_7P  XVP  -!V  #%?P  O(4
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M*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(  *.6  ":F@
MCIX  (>?$ "#GR  ?I\O GB=.P=SG$4,;IM-$6F9519EF%P:89=C'EZ6:B%;
ME7(E5Y1\*%23ABM1DI(N3I*@,$R2KS%+DL(Q2I'@,4R1]2U-D?\J3I#_*$Z0
M_R9.D/\F3I#_)DZ0_R;><   R7T  +R)  "RD@  IY<  )V;  "3GP  AJ0
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M&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@  &*] 0!6P@<
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M R/EH00BY;0$(>7-!"#D[ 0@XOL$'^'_!1_@_P4?X/\%'^#_!1_@_P6DG@
MF*4  (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW   +^4' "WM$  K
M[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9\W$!&/.! 1?T
MD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P_P*:I   C:T
M '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0% "3[#0 A_!,
M'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$ #/]O 0S_@ $*
M_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/K   @+8  '*_
M  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_"0 6_PX %/\3
M !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<  #_:P  _WT
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M)9E,R":63.(FE4[U(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_&)11_QC_20@
M_U   /M8  #E7@  W6(# -9C!P#480H RF(9 ,)C+ &[8CL#M&!("*]=4PRJ
M6UP1IEID%:-8;!B@5W0;G55['9M4@R"95(LBEE.3))12G2624:<GD%&S*(Y1
MPRF-4=TJC%+R)HM4_R*+5?\>BU;_'(M6_QJ+5O\:BU;_&HM6_QK_3 0 _U,
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M+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P  -QF  #.;0
MQ'(  +UT  "W= $ L'0. *EU'P"B="\"G'(]!9=P1PJ1;E$/C6Q9%(EJ8!>%
M:6<;@FAN'G]F=2%]97TD>F2&)W=CD"EU8YLL<F*G+G!BMB]O8LDO;F+F+F]D
M^2AP9?\D<6;_(7%F_Q]Q9O\?<6;_'W%F_Q__5   Z%\  -=I  #*<   P'4
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M(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@  M8   *V$  "DA0
MFH4# )2%% ".AB4!B80S X.#/@=^@4@+>7]0$'5^5Q1Q?5X8;GME&VMZ;!YH
M>70B97A])6)WARA?=I,J7':?+%IUKBY9=< N6'7=+EEV\RI;=O\F7'?_(UQW
M_R!<=_\@7'?_(%QW_R#J8   U6P  ,5V  "Z?@  L80  *B(  "?B0  E(H
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M'DJ+_Q[5;@  PWL  +>%  "LC0  HI(  )>6  ",F0  ?YP  '6>!0!PGQ,
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M$S>OIA0VK[@4-;#1%#6N[Q0TK?X4-*S_%#2K_Q0TJ_\4-*O_%#2K_Q2[A0
MKY   *.7  "8G0  C*,  ("H  !TK0  :+(  %RV  !0N@$ 2;P- $B\&0!&
MO2< 1;TS $.]/0%!O4<!/[U0 CV]6 ,ZO6$%.+UK!C:]=P@TO80),KV3"C"]
MI LOO;<,+K[0"RZ\[@PMNOX-++G_#2RX_PXLN/\.++C_#BRX_PZSCP  II<
M )N=  "/HP  @ZH  ':P  !JM0  7KH  %*^  !'P@$ /<<& #C)$  WR1L
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M  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK_P"7HP  B:L  'NT  !MO
M7\0  %+*  !%S@  .=,  "_8   EW0  '>$  !CL @ 6]PL %/<1 !'X%P 0
M^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<  _UF  +^=P  _8L  /V?  #\
MM0  _-$  /SM  #\_   _/T  /S]  #\_0"+JP  ?;0  &Z]  !@Q@  4LT
M $32   WV   +-T  "+A   9Y0  $^H  !#Z   ._P8 #?\,  K_$  '_Q0
M!/\:  '_(   _R<  /\P  #_.@  _T4  /]3  #_8@  _W4  /^*  #_GP
M_[,  /_'  #_Y0  _^4  /_E  #_Y0!_M   <+T  &''  !3T   0]8  #;=
M   JX@  '^8  !;J   0[0  #/H   G_   &_P   O\$  #_"0  _PT  /\0
M  #_%   _QH  /\A  #_*0  _S0  /]   #_3@  _UX  /]R  #_AP  _YH
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M#[DXUQ"U..P0LCG[#[ Z_PZO.O\-KCK_#*TZ_PNM.O\+K3K_"ZTZ_PO_/ T
M_T & /]%! #_20D _TL- /E*$0#M21H XT8F -I&-@#11D4!RT51 \9$7 7"
M0F8(OT)O"KQ!=PNZ0'\-N#^&#K8_CA"T/I41LCZ=$K ^IA.O/K 4K3Z]%*L^
MS16I/N85IC_W$Z1 _Q*C0/\0HD#_#Z) _PZB0?\.HD'_#J)!_P[_/PD _T0
M /]*  #W3@( [% & .I/"P#C3!  UDP> ,U-, #&33\!P$Q,!+M+5P:W26$)
MM$AI#+%'<0ZN1GD0K$: $:I%B!.H1) 4ID28%J1#H1>B0ZL8H$.W&9]#QQF=
M0^ :FT3S%YE%_Q681O\3F$;_$9A&_Q"71O\0ET;_$)=&_Q#_0@4 _T<  /=/
M  #E4P  W54! -=5!@#54@L RU,9 ,-4*P"\5#L!ME)(!+%14@>M4%P*J4YD
M#:9-; ^D3'01H4M[$Y]*@A6=2HH7FTF3&)E)G!J72*8;E4BR')1(P1V22-@=
MD$GO&X]*_AB/2_\6CDO_%(Y,_Q*.3/\2CDS_$HY,_Q+_10  _TL  .E3  #>
M6   TUL  ,U;! #*6 < PE@5 +I:)P"S6C<!KEA$!*E73P>D55@*H51@#9Y3
M:!";46\3F%!V%990?A>43X89DDZ.&H].F!R-3:(=BTVN'XI-O""(3= @ATWK
M'X9/_!N&4/\8AE#_%H90_Q2&4?\4AE'_%(91_Q3_1P  ^$\  .17  #570
MS&   ,5@ @#!7@4 NET1 +-?(P"L7S,!IEY  Z%<2P>=6E0*F5E<#I989!&3
M5FL3D%5R%HY4>AB+5((:B5.*'(=2E!Z%4IX?@U&J(8%1N")_4<LB?E+G(7Y3
M^1U^5/\:?E7_%WY5_Q9^5?\5?E7_%7Y5_Q7_2@  [E(  -Y;  #/80  QF0
M +]E  "Z8P( LV(/ *QC( "F8S !H&(] YMA2 :67U$*DEY9#8]<81&,6V@3
MB5IO%H99=AB$6'X:@E>''']7D!]]5ILA>U:G(GE6M2-W5L<D=E;D)'97]Q]W
M6/\;=UG_&7=9_Q=W6?\6=UG_%G=9_Q;_3   Z58  -E?  #+90  P6@  +II
M  "T:   K6<- *9H' "@:"T!FF<Z Y5E10:08TX*C&)7#8EA7A"&7V43@UYL
M%H!=<QA^7'L:>UR#'7E;C1]V6I@A=%JD(W):LB1Q6L0E;UKA)7!;]B!Q7/\<
M<5W_&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D  --B  #':   O6P  +9M  "O
M;   IVL+ *!L&0";;"H!E6LW I!I0P6+:$P)AV94#(-E6Q" 8V(3?6)I%7IA
M<!AX87@:=6"!'7-?BQ]P7I8B;EZB)&Q>L"5K7L$F:5[>)FI?]"%K8/\=:V'_
M&VQA_QEL8?\8;&'_&&QA_QCU40  XEP  ,]E  ##:P  N6\  +%Q  "J<0
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M&5AQ_QGC7@  S6D  +]S  "T>@  JW\  **"  "8@P  BX$  (2!#0!_@AH
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M&T:(HQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&_Q=%A?\7187_%T6%_Q?-;0
MO7@  +&"  "GB@  G(X  )*0  "&DP  >94  &R7  !FEPX 8Y@; &&8*0!>
MF#4!6I<^ U>71P55ED\'4I96"4^57@Q,E&8.2I1O$$>3>1-$DX450I*3%T"2
MHA@^DK,9/9+)&3V1Z1@]D/H7/H__%CZ/_Q4^C_\5/H__%3Z/_Q7%<P  MW\
M *R)  "ACP  EI,  (N6  !_F0  <YP  &2?  !<H D 6: 4 %>A(@!5H2\
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M!2BWY@4GM?D')K/_!R:R_P@FLO\()K+_"":R_PBOC0  HI0  )>:  "+H
M?J8  '&K  !EL   6;0  $VW  !"NP  .+X! "_""0 MPQ( +,,> "O#*0 J
MQ#, *<0] "C%1P GQ5$ )L5< "7&:  CQG8!(L:& 2#&F $?QJL!'L?! 1[&
MY $=Q/@"',+_ QS!_P,<P?\$','_!!S!_P2EE   FIH  (ZA  "!IP  <ZX
M &>T  !:N0  3KT  $+    XPP  +\<  ";+!  >T H &]$1 !K2&@ 9TB4
M&-,O !C3.@ 7U$0 %M10 !7570 4U6L $]9\ !+7CP 1V*0 $-F[ !#9W@ 0
MU?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@  D:$  (.H  !UL   :+<  %N]
M  !.P0  0L4  #?(   MS   )-   !S5   5V@4 $.(+ !#C$0 .Y!H #N0C
M  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F@  %YI4 !.:K  +FQ  !YN8
M .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D  '>Q  !IN0  6\   $[&  !!
MR@  -<X  "K2   AU@  &=L  !+?   -XP  "_$(  GS#@ '\Q, !/(:  +R
M(@  \BH  /(T  #R/P  \DP  /)<  #R;0  \H(  /*8  #SK0  \\8  /3E
M  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ  !<P@  3LD  $#.   STP
M*-@  ![=   5X0  #^0   KH   %\P   _T!  #\"   ^PT  /L1  #[%@
M_!X  /PF  #\,   _3P  /Y)  #^6@  _FT  /^"  #_F   _ZP  /_   #_
MV   _^0  /_D  #_Y ![L@  ;+L  %W$  !/S0  0-(  #+9   FW@  &^(
M !+F   ,Z@  !>T   #T    _P   /\   #_    _P0  /\)  #_#@  _Q(
M /\8  #_(0  _RL  /\W  #_1@  _U@  /]K  #_@   _Y4  /^F  #_LP
M_[L  /^[  #_NP#_&R8 _QPD /\:) #_%2< _Q M /\*-@#_!4, _P%0 ?\
M7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_ *  _P"F /\ K #_ +( _P"Y
M /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T _P#] /\ _0#_ /T _P#] /\
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M ?\1= '_$7T!_Q"& ?T0C@'\$)4!^A"; ?D0H0'W$*@!]A"O ?00MP#S$,(
M\1#0 .T0Y0#H$?( YA'^ >02_P'C$O\!XA+_ >(2_P'A$O\!X1+_ >$2_P'_
M*18 _RH3 /\I$@#_)Q, _R@< /\G)P#_(S, _R _ /\=3 #_&U@!_!ED ?@9
M;@'V&'@!\QB! ?$8B0'O&) ![AB7 >P8G@'J&*0!Z1BL ><8M 'F&+\!Y!C-
M > 9XP'<&O$!V!K^ M0;_P+2&_\"T1O_ M ;_P+0&_\"T!O_ M ;_P+_+1(
M_RX/ /\N#0#_+Q  _R\7 /\N(0#_+"T _RDY /DF1@#T)%,![R)> >LB:0'H
M(7,!YB%\ >,AA 'A(8P!X"&3 =XAF@'<(:$!VB&I =@AL0+5(;P"TR+) M B
MWP+,(_ #R"/] \8D_P/$)/\#PR3_ \(D_P/!)/\#P23_ \$D_P/_, \ _S(+
M /\S" #_-@T _S82 /\U&@#],B4 ]# R .TM/P#G+$P XBM8 =TK8P'9*FT!
MU2IV M(J?P+0*H8"SBJ. \PJE0/**IP#R2JC!,<JK 3%*K8$PRK#!<(JU06^
M*^L%NBOY!K@L_P:V+/\%M2S_!;0L_P6T+/\%M"S_!;0L_P7_- P _S8% /\Y
M P#_/ @ _SP- /T[$P#Q.!T Z#4I . T-P#9,T8 T312 <TS70'),V<"QC-P
M \0R> 3!,H $OS*'!;XRCP:\,I8&NC&>![@QI@>W,; (M3*\"+,RS FQ,N4)
MK3/U":LS_PFJ,_\(J#/_!Z@S_P>G,_\'IS/_!Z<S_P?_-P< _SH  /\^  #Z
M00$ \4$& /$_#0#F/!( VSH? - [,0#*/$  Q#Q- < \6 *\.V$#N3MJ!;8Z
M<@:T.GH'LCF!"+ YB FO.9 *K3B8"JLXH0NI.*H,J#BV#:8XQ0VD.-X.H3GQ
M#9\Z_PR>.O\+G3K_"IPZ_PF<.O\)G#K_"9PZ_PG_.P( _SX  /=$  #F1P
MWT@! -I&!@#90 L S4(9 ,5$*P"^1#L N41( ;5#4P.Q0EP$KD)E!JM!; >I
M0'0)ID!["J0_@PNC/XH-H3Z3#I\^G ^=/J40FSZQ$9H^OQ&8/M02EC_M$90_
M_ ^30/\.DD#_#))!_PN20?\+DD'_"Y)!_PO_/0  _T,  .E)  #>3@  TT\
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M$GA0_Q!X4/\/>%#_#WA0_P_]1@  YT\  -97  #(7   OU\  +=?  "Q7
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M$F)?_Q+J40  U%P  ,1D  "Y:@  L&X  *=P  ">;@  E&L  (UJ$ "':QX
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M&5-LHQM1;+,<4&S('$]LYQM1;/H846S_%5)L_Q12;/\34FS_$U)L_Q/<7
MQV<  +EO  "O=@  I7L  )Q\  "1?   @G@  'IY!P!U>10 <GHC &YZ+P%K
M>3H":'E# V1X2P5A=U((7W=9"EQV8 Q9=6@/5W1P$51T>A-2<X863W.3&$UR
MH1E,<K$:2G+&&DIRY1I+<OD73'+_%4QR_Q--<O\237+_$DUR_Q+48   PFL
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M$3B-X1 XB_80.(K_#SF)_P\YB?\..8G_#CF)_PZ_<@  LGT  *>&  "<B@
MD8X  (:1  !ZDP  ;94  %^7  !4F0$ 3YD/ $Z:&@!,FB< 2IHR $B:/ %&
MFD0!1)I, D*:5 - F5P$/IEF!3N9< <YF'P(-YB*"C68F@LSF*L+,IB_##*8
MWPLQEO4+,97_"S&4_PLQD_\+,9/_"S&3_PNX>@  K(4  *&+  "6D   BY0
M '^7  !RFP  9IT  %J@  !.H@  1:0) $*D$P! I!\ /Z0J #ZE-  \I3X
M.Z5' 3FE3P$WI5@"-:5A C.E; ,QI7D$+Z2'!2VDEP8LI*D&*Z2]!BJDW@8J
MHO4'*:'_!RF@_P@IG_\(*9__""F?_PBQ@@  I8L  )J1  "0E@  @YH  ':?
M  !JH@  7J8  %*I  !&JP  /*T  #6O#  SL!4 ,K A #&P*P OL#4 +K$^
M "VQ2  LL5$ *[%; "FQ9P$GL70!)K&# 22QE (CL:8"(K*[ B&RVP(AK_,#
M(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$  ).7  "'G   >J(  &VG  !@
MJP  5:\  $FQ   ^M   ,[<  "JZ P DO T (KT5 "&](  AO2H (+TS !^^
M/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7P*$ %L"V !3 TP 5OO$ %;S_
M 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>  !]I   ;ZH  &*O  !6M
M2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+ !',$@ 1S!L $,PE  _-+P .
MS3H #LU&  W-4@ -SF  #,YP  O.@P *SI< "<ZL  C.Q@ (SN@ ",W[  G+
M_P )R_\ "<O_  G+_P"8F   C9X  '^E  !QK   9+,  %>Y  !*O0  /L
M #+#   HQ@  '\H  !?-   1T0  #-8%  C9#  &V1( !=H;  3:)  #VRX
M =LY  #<10  W5(  -YB  #><P  WH@  -^=  #?LP  W\X  .#N  #?^@
MW_\  -__  #?_P"/GP  @:8  '.N  !EM0  6+T  $K"   ]Q0  ,<D  ";,
M   =T   %-0   [9   )W0   ^$   #C!P  XPT  .02  #E&0  YB(  .<K
M  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #NH0  [[<  ._1  #OZP  \/8
M /#V  #P]@"$IP  =:\  &>W  !9OP  2\8  #S*   OS@  )-(  !K8   2
MW   #.    7C    YP   .L   #K    [04  .X+  #P$   \14  /,>  #T
M)P  ]S,  /E   #Z40  ^V,  /QW  #]C0  _:,  /ZV  #^R0  _]\  /_?
M  #_WP!WL   :+D  %K!  !,R@  /,\  "[4   BV@  %]X  !#B   )Y@
M .D   #L    \    /8   #V    ]P   /@   #Z!P  ^PT  /T1  #_&0
M_R,  /\O  #_/@  _T\  /]B  #_=P  _XT  /^?  #_K@  _[H  /^Z  #_
MN@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_ $$ _P!. /\ 7 #_ &@ _P!T
M /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\ J #_ *X _P"U /\ O0#_ ,<
M_P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_ /L _P#[ /\ ^P#_ /L _P#_
M&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T _P!+ /\ 6 #_ &0 _P!P /\
M>@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"Q /T N0#[ ,, ^@#0
M /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /, _P#S /\ \P#_ /, _P#_'1P
M_QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5& /\"4P#_ %\ _P!K /\ =0#_
M 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *< ^ "N /4 M0#S +\ \0#+ /
MWP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I ?\ Z0'_ .D!_P#_(!< _Q\4
M /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,3@#_"5H _PAF /\(< #^!WD
M_ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J .T&L@#_XO__24-#7U!23T9)
M3$4 " GJ!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_ -T,_P#<#/\
MW S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\ _Q0[ /\220#\
M$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.
MKP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_
M <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\
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M!*XKQ 2L*]L$J"SO!*8L_@6D+/\$HRW_!*(M_P2B+/\$HBS_!*(L_P3_,@
M_S,  /DX  #I.0  XCD  -XU!P#>+@T T2\; ,DQ+ ##,SL O3-( +DT4P&V
M,UP!LS-E K S;0*N,W0#K#)[ ZLR@P2I,HH$IS*3!:4RFP:D,J4&HC*P!Z R
MO@>?,M$'G#/J!YHS^P>8-/\'ES3_!I8T_P:6-/\%EC3_!98T_P7_-0  _S@
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M$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@  --/  #'5
MO54  +94  "P4   J4P+ *)-& "=3B@ F$XV )1.00&034L"C4U3!(I,6@6'
M2V$&A4MH"(-*;PF 2G<+?DE_#'Q)B0YZ2),/>$B?$'=(K!)U2+P2=$G2$W-)
M[A%R2O\/<DK_#7)*_PMR2O\+<DK_"G)*_PKR0@  X$P  ,Y3  #!6   N%H
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M#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68  *1F  ";9
MD%X  (E>#@"$7QL @%\I 'Q?-0%X7S\"=%Y' W%=3P1O7%8%;%Q<!VI;8PEH
M6VL+9EIS#61:?0]B6H@17UF4$UY9HA1<6;(56UG&%EI9Y15;6OD26UK_$%Q:
M_PY<6O\-7%K_#5Q:_PWC3P  S5D  +YA  "S9@  J6D  *!J  "7:   BV(
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M#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$  '%Q  !K<0\
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M9   MVX  *MV  "B?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %>
M( !5@"L 4X$V %& /@%/@$8"38!. DM_50-)?UT%1G]F!D1^< A"?GL)/WZ(
M"SU]EPP\?:<-.GVZ#CI^U@TZ?/$-.GO_##I[_PLZ>O\+.GK_"SIZ_PO :0
MLG0  *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$ 4(@. $Z(&@!-
MB28 2XDP $F).@!(B4(!1HE* 42)4@)"B5H#0(AC!#V(;04[B'@&.8>&"#>'
ME0DUAZ8*-(>Y"C.'TPHSAO ),X7_"3.$_PDS@_\),X/_"3.#_PFY<   K7H
M **"  "7AP  C8H  (&,  !UC@  :(\  %J0  !/D0  1Y(* $22$P!#DQ\
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M !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0
M=9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7
MMR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VY
MQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8
M %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14
M"<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@
MQM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T
M  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6
M  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\
M -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   Y
MP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?
M%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%
M  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@
M(,X  !;2   /U@  "-L   #?    XP   .4   #G    Z $  .H'  #K#0
M[1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #Z
MP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H
M  W?   %XP   .8   #I    [0   .\   #Q    \P   /4   #V @  ^ D
M /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP
M_[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\
M60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P
M /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\
M^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_
M &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L
MM #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_
M /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P
M_P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P
M +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4
M_P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B
M /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0
MX@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_
M'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$
M9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[
M - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P
M_R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=
M#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00
MR #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,
M /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6,
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M Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,  .0Z  #6/0
MS#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U( H3-: 9\S8@&<
M,VD"FC-P IDS=P*7,G\#E3*' Y,RD 22,IH$D#*E!8XRL06-,\(&BS/<!HDT
M\@:'-/\%AC3_!88T_P2%-/\$A33_!(4T_P3\,P  ZSH  -Q!  #-1   PT0
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M"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5   L54  *E4  "A4
MF4H" )))$0"-2A\ B4LL (5,. ""2T(!?TM* 7Q*4@)Y2E@#=TI?!'5)9@5S
M26T&<4EV!V](?PAM2(H);$B6"VI(HPQH2+(-9TC%#69)Y UF2?@+9DG_"69*
M_PAF2?\'9DG_!V9)_P?H0P  TDT  ,)3  "W6   K5D  *18  "<50  DTX
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M"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P  @UP  'M;!@!U6Q(
M<5L? &Y<*P!K7#8 :%L_ 65;1P%C6TX"85I5 U]:7 1=6F,%6UIK!EE9=0A7
M68 *55F,"U19F@U26:H.45F\#E!9V Y06?(-45G_"U%9_PI16?\)45G_"%%9
M_PC440  PEH  +1A  "J9@  H&@  )=I  ",9P  ?6   '5? P!O7Q  :U\<
M &A@* !F8#, 8V \ 6%@1 %?7TP"7%]3 UM?6@197V$%5UYI!E5><PA37GX)
M45V*"T]=F0Q-7:@-3%ZZ#DM>U Y+7O$,3%[_"TQ=_PI,7?\)3%W_"$Q=_PC/
M5   OEX  +%E  "G:@  G6T  )1M  ");   >&4  &]D  !I9 X 9609 &)D
M)0!@93  7F4Z %QE0@%:94H"6&11 E9D6 -49%\$4F1G!5!C<0=.8WL)3&.(
M"DICEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B_PE'8O\)1V+_"$=B_PC*6
MNF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L 7VD5 %QJ(0!:
M:BT 6&LV %9K/P%5:T<!4VI. E%J50-/:ET$36IE!4II;@9(:7D'1FF&"41I
ME0I#:*4+06FW#$!ISPQ :.X+06C_"D%G_PE!9_\(0F?_"$)G_PC%70  MF8
M *IM  "@<P  EG8  (MW  " =@  <'(  &5Q  !<< < 6' 1 %9P'0!4<2@
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M!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@  )U_  "2@P
MB(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ< .(PB #>,+  V
MC#4 -(P] #.,1@ RC4\ ,8U8 "^-8@$MC&X!*XQ[ 2J,BP(HC)P")HRO B6,
MQ@(EB^@")8K[ R6(_P,EB/\#)8?_ R6'_P.M=@  HX   )>%  "-B0  @HP
M ':.  !ID   7)(  %"3  !$E   .I4  #&6"  MEQ$ +)<: "N7)  JERT
M*9<V "B8/P GF$@ )IA2 "687  CF&@ (IAW ""8AP ?F)D!'9BL 1R8PP$<
ME^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G?P  G(8  )&+  "'CP  >I(  &V5
M  !AF   59L  $F=   ]G@  ,Y\  "JA   AHPH 'Z,1 !ZC&@ =I"0 '*0M
M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P !2E@0 3I90 $J6H !&EOP 0I.(
M$:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0  <9H  &2>  !8
MH0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0L1@ #K$B  ZQ
M*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2PM0 $L-  !+#O
M  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP
M0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@
MOBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]
M]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8
M "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(
M ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP
MSO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["
M   5Q@  #LD   C,    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?
M  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H
M .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,
MT0  !-4   #:    W@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M
M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??
M  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP
M .(   #E    Z0   .P   #M    \    /$   #S    ]00  /<*  #Z$
M_!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_
MOP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M
M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T
M_P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_
M$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\
M<@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@##
M /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0
M_P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[
M '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@
MRP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$.
M /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '
M[0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6
M -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/
M!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R
M -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -
MQ0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_
M$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%
M<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE
M +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@
M]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]
M#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M$<H JA+E *<4
M]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C  #F)   X"$
M -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@ + 89P"N&&X
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M G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P  NS\  +0\  "O-0
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M!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P  BTD  (-'"P!]1Q4
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M!E-0E@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0_P904/\%4%#_!5!0_P702P
MOU0  +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX :%09 &54) !B
M5"\ 8%0X %Y40 !<5$@!6E1/ 5E45@%75%T"551E U14;@125'D%4%2&!DY4
ME =-5*0(2U2U"$M4S E*5.L(2U3^!TM4_P9+5/\%2U3_!4M4_P7,3@  NU<
M *Y>  "D8@  FF0  )%D  "&8@  =UL  &U8  !F6 P 8E@6 %]8(@!=62P
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M!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,  *5J  ";;P
MD7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$ 26HK $AJ- !'
M:CT 16M$ $1K3 !":U0!06M< 3]J90(]:G ".VI] SEJC 0W:IP$-FJN!35J
MQ 4U:N4%-6GY!#5I_P0U:/\$-6C_!#5H_P2Y8   K&D  *%P  "8=0  C7<
M ()W  !W=P  :70  %QS  !1<0  2' * $5P$@!#<1T 0G$G $!R,  _<C@
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M 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP
M6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >
MD4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2.
M_P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4
M $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC<
M$9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +
MFO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@
M   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX
M  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\
M *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   F
MJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X
M.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_
M  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@
M$[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@
MR#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(
M_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,
M  /'    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT
M -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !Y
MH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3
M    V0   -P   #=    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK
M  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@
M7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@   -X   #B
MY@   .D   #J    [    .X   #P    \@   /0&  #V#   ^1(  /P<  #_
M*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7
M /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L
M_P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\
M .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\
M$P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^
M /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q .,
M[P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_
M !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0
M?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M
M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P
M_P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E
M (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P
M]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P .
M /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H
MT "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[
M /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!
M$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z
M +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L
MJP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #=
M Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(
M>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_
M )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L
MQPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B
M$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2%OT D!?_ (\7
M_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A  "]&04 N1(0
M +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II )<;< "5&W<
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M 6XO_P'H,0  TSH  ,,_  "W00  KD$  *8^  ">.   ES$! )$N$ ",+QP
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M EX]E@-=/J4#6SZV!%H^S 1:/^P$63_^ UD__P-9/_\"63__ ED^_P+6/P
MPT<  +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$ <4 < &U * !K
M03( :4$[ &=!0@!E04D 8T%0 &%!5P!@05X!7D%F 5U";P);0GH"6D*& UA"
ME -70J,$54.S!%1#R0140^D$4T/] U-#_P-40_\#5$/_ E1#_P+00@  OTH
M +)0  "G4P  G50  )13  "*4   ?TH  '5% @!N0PX :T09 &=%) !E12X
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M!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54  *E;  "?7@
ME6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424 4E(O %%2-P!/
M4C\ 3E)& $U330!,4U4 2E-= 4E39@%'4W "15-] D13BP-"4YL#052L!$!4
MP00_5.($/U3X T!3_P- 4_\#0%/_ T!2_P/ 4   LE@  *9>  "<8@  DF4
M (AE  !]8@  ;EP  &-9  !95@, 5%8. %%6& !/5B( 35<L $Q7- !*5SP
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M BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',  'US  !R<@
M9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$ -6LY #1K00 S
M;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G;=8!)VOR 2=J
M_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@  'EY  !M>   8'<
M %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL +70T "QT/  K=$0
M*71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?==( 'W3Q !]S_P$?
M<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G?P  6G\  $U^
M  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^-@ A?C\ 'W](
M !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O !9\_P 6>_\
M%GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \
MB   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*
M3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_
M  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@
M*I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (
MEU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2
M_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT
M !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@
M *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1
MB@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J
M   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),
M  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D
M?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "
MN    +L   "[    O <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##
M3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT
M &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0
M ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800
MV%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL
M  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.    T@   -4
M  #6    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,
M .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^
MO   +\   "#$   4R   #,P   +0    U    -D   #>    X@   .4   #F
M    Z    .D   #L    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&
M  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !<
M_P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_
M (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@
M_P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7
M /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8
M^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J
M /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\
M'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"'
M .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\
MUP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[
M "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P
MAP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_
M ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\
MZ@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#&
M (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +(
M_P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E
M -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($
MM "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B
M /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0
M*@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"#
M *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\
ME G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R
M!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,
MA@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_
M (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R<
MH1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")
M%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9
M_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM
M )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88
M?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H
M*   TC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B
M,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E=P!S)8$ <2:-
M &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_ 6@H_P'A+@
MRS8  +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8 ?R@B 'PI+0!Y
M*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I+'T :"R) &8M
ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N_P':-   Q3P
M +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1( =RX> ',O*0!Q,#,
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M DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4
MEU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7
M/D  53]& %0_30!3/U4 4D!= %! 9@!/0' !3D!\ 4Q!B@%+09H"2D&K DE"
MO@)(0MX"2$+V DA"_P)(0O\!2$'_ 4A!_P'%1   M4L  *E0  ">5   E50
M (M3  " 4   =4H  &I&  !A0@@ 7$$1 %E"&P!70B4 54(N %-"-0!10CT
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M 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$  (-A  !X7@
M:5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4 05$\ $!11  _
M44P /E)4 #Q270 [4F< .E)S #A3@@$W4Y(!-5.D 313MP$S5-$!,U/Q 313
M_P$T4O\!-%+_ 312_P&V4@  J5H  )Y@  "49   BV8  (!E  !T8P  9EX
M %Q<  !16   1U4' $)5$ ! 51@ /U8A #U6*@ \5C( .U8Y #I700 Y5TD
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M 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P
M.FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >
M;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK
M_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@
M "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8
M$WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?
M<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"
M   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=
M  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0
MD'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5
MC@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/
M90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4
M (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@
M"IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7
MG6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0
M  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@
M  "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,
M *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?
MG   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U
M    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK
M  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0
M1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\    OP   ,(   #"
MPP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2
M<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,
M "JV   =N0  $KP   J_    PP   ,8   #)    S0   ,\   #0    T@
M -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9
MZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W
M   1Q   "<@   #,    SP   -,   #9    W0   .    #A    XP   .4
M  #G    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH
M /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_
M #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\
MDP#_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y .$ ^ #S /< _P#V /\ ]0#_
M /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\ #0#_  X _P 4 /\ (0#_ "X
M_P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U /L >P#Y (( ^ "( /< C@#V
M )0 ] "; /, H@#Q *H [P"T .T P0#K -4 Z@#L .@ _ #G /\ Y0#_ .8
M_P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_  D _P 0 /\ ' #_ "D _P V
M /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T =@#L 'P Z@"" .@ B #G (X
MY0"5 ., G #A *0 WP"N -T N0#: ,H UP#D -0 ]@#1 /\ T #_ -  _P#/
M /\ RP#_ ,< _P#_  , _P   /\   #_  0 _P - /H %@#V ", \P P /
M/ #M $< Z0!1 .4 6@#B &( WP!I -T ;P#: '8 V !\ -0 @@#2 (@ T "/
M ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,  [P"_ /X O@#_ +T _P"\ /\
MO #_ +P _P#_ @  _P   /\   #_    ]  ' .T $0#H !P XP I -\ -0#;
M $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\ PP!U ,$ >P"_ (( O@"( +P
MD "Z )@ N "B +4 K "S +D L0#+ *\ YP"N /@ K #_ *L _P"L /\ K #_
M *L _P#_!   _P   /8   #N    YP   -\ # #6 !4 SP B ,H +@#' #H
MPP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O +$ =0"O 'L K0"" *L B@"I
M )( IP"< *4 I@"C +, H0## )\ W@"> /( G0#_ )P _P"< /\ FP#_ )L
M_P#_!P  ]@D  .D+  #?"@  U00  ,X !0#& !  P  : +L )P"W #( LP ]
M +  1@"M $\ J@!6 *@ 7 "F &, I !H *( ;P"A '4 GP!\ )T A "; (T
MF0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\ (X _P"- ?\ C0'_ (T!_P#Y
M#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H M  2 *X '@"J "H I@ U *(
M/P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3 V\ D01V ) $?P".!8@ C 62
M (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,_P" #/\ @ S_ ( ,_P#Q%0
MX!T  ,T@  #!(0  N!T  +$7  "L$   J D- *('%@"="2, F0HN )4+. "3
M#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H A0YQ (,.>@""#H0 @ Z/ 'X/
MFP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T$_\ =!/_ '03_P#H'@  TR8
M ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/$ "0$!L C!$G (D2,@"&$SL
MA!-# ((42P" %%$ ?A17 'P47@![%64 >15L '<5= !V%GX =!:* '(7E@!Q
M%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\ :AO_ &H;_P#@)@  RBT  +PQ
M  "P,P  IS$  )\L  "7)@  D!\  (H7# "%&!8 @1DB 'X:+ ![&S8 >1L^
M '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>< !K'GH :AZ% &@?D@!G'Z
M92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_ &$B_P#7+   PS0  +8X  "J
M.0  H3@  )@U  "0+P  B"@  ( A" ![(!( =R$= '0B)P!Q(C$ ;R,Y &TC
M00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B)74 826! %\FC@!>)IT 72>M
M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH_P#/,@  OCD  +$]  "F/P
MG#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9 &LH(P!I*"P 9BDU &4I/ !C
M*4, 82I* & J40!>*E< 72I? %PK: !:*W( 62Q] %@LBP!6+9H 52VJ %0N
MO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*-@  NCT  *U"  "B1   F$0
M (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M'P!A+B@ 7RXQ %TN.0!<+T
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M 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.  "94   CU$  (50  ![3
M;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG $L[+P!)/#8 1SP] $<\1 !&
M/4L 13U4 $0^7 !#/F< 0C]S $ _@0 _/Y$ /D"B #U M0$\0<X!/$'N 3Q!
M_P$\0/\!/$#_ 3T__P&Z10  K$P  *%1  "75   C54  (-4  !X40  ;$L
M &%'  !60@  3T , $P_$P!)0!P 1T D $9 + !$0#, 0T Z $)!0@!!04D
M0$)1 #]"6@ ^0V4 /4-Q #M#?P Z1(\ .42@ #A%LP$W1<L!-T7L 3=%_P$W
M1/\!.$3_ 3A#_P"W20  J5   )Y5  "46   BUD  (!8  !V5@  :%   %U,
M  !32   2D4) $9$$0!$1!D 0D0B $%%*0 _13$ /D4X #U%/P \1D< .T9/
M #I'6  Y1V( .$AN #9(?  U2(T -$F> #-)L0 R2<D ,4GK #))_@ R2/\
M,DC_ #-(_P"T3   IU0  )Q9  "27   B%T  'Y=  !S6@  954  %M2  !0
M3@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX .4HU #A+/0 W2T0 -DM- #1,
M5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L3L< +$[I "Q-_0 M3?\ +4S_
M "U,_P"P4   I%@  )E=  "/80  AF(  'MA  !P7P  8EL  %A8  !.50
M0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R #)0.@ Q4$( ,%%* "Y14P M
M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4 )E/G "93_  G4O\ )U'_ "=1
M_P"L50  H%P  )9B  "-9@  @V<  'AF  !M90  8&$  %5>  !*6P  /U@
M #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7-@ J5SX *5=' "A74  F6%H
M)5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE !]8^@ @6/\ (%?_ "%7_P"H
M6@  G6(  )-G  "*:P  ?VP  '5L  !J:P  76@  %%E  !&8P  .V   #%>
M P J70T *%T3 "9=&P E7B, )%XJ "->,@ B7CH (5Y# "!?3  ?7U< 'E]C
M !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?^0 87O\ &5[_ !E=_P"D8
MF6@  )!N  "&<   ?'(  ')R  !F<0  6&X  $QL  !!:P  -FD  "UG   C
M9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4 &&<^ !=G2  69U, %6A? !-H
M;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 09O\ $67_ !%E_P"?9P  EF\
M (QS  ""=@  >'@  &UX  !@=P  4W8  $9T   [<P  ,7(  "=Q   ><0
M%G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X  YQ0@ .<4X #7%;  QQ:0 +
M<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\ "6[_  EN_P";;P  D74  (=Y
M  !^?   ='X  &9^  !9?@  37X  $!]   U?0  *GP  "%\   8?   $7P$
M  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\/0 #?$@  7Q5  !\8P  ?'0
M 'R'  ![G   >[$  'K+  !YZP  >?H  'G_  !X_P"6=P  C'P  (.   !Y
M@P  ;(0  %Z%  !1A@  18<  #F'   MAP  (X<  !J'   2AP  #8@!  :)
M"@ !B0\  (D4  "(&P  B",  (DL  ")-@  B4(  (A.  "(70  B&T  (B!
M  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$_P"0?@  AX,  'Z'  !QB0
M8XL  %:-  !)CP  /)$  #"1   DD0  &I(  !*3   -E   !I4   "6!@
ME@P  )40  "6%0  EAT  )8D  "6+@  ECD  )9&  "650  EF4  )9X  "5
MC@  E:0  )2\  "3WP  D_4  )+_  "2_P"+A@  @XH  '6-  !GD   690
M $R7   _F0  ,IH  ":;   ;G   $IT   R?   $H    *(   "C 0  HP<
M *,,  "C$   I!4  *0<  "E)0  IB\  *8\  "F2P  IEL  *9N  "EA
MI9L  *2S  "CT   H^\  *+\  "B_P"&C0  >)$  &J5  !<F0  3IT  $&@
M   SH@  )J,  !NE   1IP  "JD   &K    K0   *\   "P    L    + %
M  "Q"P  L@\  +,4  "T&P  M20  +<P  "W/P  MU   +=B  "W>   MY
M +:I  "VP@  MN0  +;U  "U_@![DP  ;9@  %^=  !0H@  0J8  #2I   F
MJP  &JT  !"O   )L@   +0   "W    N@   +P   "]    O@   +X   #
M @  P0@  ,(-  #$$@  QAD  ,DD  #*,@  RT,  ,M5  #,:@  S(,  ,R<
M  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F  !$JP  -K   ">R   :M0
M$+@   >[    O@   ,$   #$    R    ,L   #+    S0   ,X   #0
MT@   -4#  #8"@  VQ   -X8  #B)   XS4  .1(  #E7   YG,  .:-  #F
MI0  YKP  .;3  #GYP!CI   5:H  $:P   XM0  *+D  !J\   /P   !<0
M  #'    RP   ,\   #4    V    -P   #=    WP   .$   #C    Y0
M .@   #J    [08  /$.  #U%@  ^"4  /DX  #Y30  ^F,  /M\  #\E0
M_*H  /R[  #]RP#_  \ _P . /\ #@#_ !  _P 6 /\ (P#_ #  _P ] /\
M20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_ (( _P") /\ CP#_ )4 _@";
M /T HP#[ *L ^@"U /D PP#W -L ]@#P /0 _P#S /\ \@#_ .P _P#B /\
MW #_ -8 _P#_  P _P ) /\ " #_  H _P 2 /\ '@#_ "L _P X /\ 1 #_
M $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T ]@"# /0 B0#R (\ \0"6 .\
MG0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C /\ X@#_ .  _P#5 /\ S@#_
M ,L _P#_  8 _P ! /\   #_  0 _P . /\ &0#_ "4 _0 R /L /@#W $D
M\P!3 /  7 #N &, [ !J .H <0#H '< Y@!] .0 @P#B (D X "0 -X EP#<
M )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\ RP#_ ,H _P#( /\ P@#_ +X
M_P#_    _P   /\   #_    ^P + /8 $P#Q "  [0 L .H . #G $, XP!-
M .  5@#< %T V0!D -4 :P#2 '$ T !V ,X ? #, (, R@") ,@ D0#& )D
MQ "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_ +< _P"V /\ M #_ +$ _P#_
M    _P   /\   #V    [@ % .< #P#A !D VP E -4 ,0#2 #P S@!& ,H
M3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y 'P N "# +8 B@"S ), L0"<
M *\ IP"M +, JP#% *D X0"G /4 I@#_ *4 _P"D /\ I #_ *0 _P#_
M_    /$   #H    X    -0 "P#, !, QP ? ,( *@"_ #4 O  _ +@ 2 "U
M %  LP!7 +  7@"N &0 K !I *L ;P"I '4 IP!\ *4 A "C (P H0"6 )\
MH0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5 /\ E0#_ )4 _P#\ 0  \ 4
M .,'  #5!0  S    ,4 ! "^  X N  7 +, (P"O "X JP X *D 00"F $H
MHP!1 *$ 5P"? %T G0!C )L :0": &\ F !V )8 ?0"4 (8 D@"0 )  FP".
M *< C "V (H R0"( .< AP#Y (< _P"& /\ A@#_ (8 _P#T#   Y!   -$2
M  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A "8 G@ Q )H .@"8 $, E0!*
M ), 40"1 %< CP!= (X 8P", &D B@!P (@ =P"& (  A "+ (( E@"  *,
M?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_ '@&_P#J$P  UAH  ,8=  "Z
M'   L1D  *H3  "D#0  GP4, )D % "5 !\ D0(I (T#,P"+!#P B 5$ (8&
M2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z"'P > F& '8)D@!T"J  <PJO
M '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T._P#A'   RR,  +PF  "Q)@
MJ"0  * >  "9&   DQ " (X+#@"("Q< A PB ($-+ !^#34 ? X] 'H.10!X
M#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'< ;!"" &L0CP!I$9T :!&M &82
MP !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6)   PRH  +4N  "J+P  H"T
M )@H  "0(@  B1L  ((3" !]$1( >1(< '83)P!S%#  <10X &\5/P!M%48
M;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^ &$8BP!?&)D 7AFI %P9O !<
M&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@  O3$  *\U  "D-@  FS0  )(Q
M  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I&RL 9QLS &4<.P!D'$$ 8AU(
M & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?AP!6()8 52"F %0AN !3(=(
M4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8  *LZ  "@/   ECL  (TX  "#
M,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28 7R(O %TB-@!;(CT 6B-$ %@C
M2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/)I, 3B>C $PGM0!,*,X 2RCN
M $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_  "<00  DD   (D^  !_.0
M=3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K %4H,@!4*#D 4BA  %$H1@!0
M*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y  1RRA $8MLP!%+<L 12[L $0N
M_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "910  CT4  (5#  ![/@  <3D
M &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L+P!-+38 3"T\ $HM0P!)+4H
M2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&> $ RL0 _,L@ /S/J #\S_@ _
M,O\ /S+_ #\R_P"[/   K4,  *%'  "620  C$D  (-(  !X1   ;3X  &,Y
M  !:-   4C , $\P$P!,,!P 2C D $DQ*P!',3( 1C$Y $0Q0 !#,D< 0C)/
M $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LVKP Z-\8 .3?H #DW_  Z-_\
M.C;_ #HV_P"W0   JD8  )Y+  "430  BDX  (!,  !U2   :D,  & ^  !6
M.0  334) $DT$0!'-1D 134A $,U* !!-2\ 0#4V #\V/0 ^-D4 /3=- #PW
M50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U.\0 -#OF #0[^P U._\ -3K_
M #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0  !S30  9T@  %Q$  !2/P
M2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<\4P V
M/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\( +S_D "\_^@ P/_\ ,#[_ # ^
M_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q4@  9$P  %E)  !/10  14 #
M #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 40 Q05L
M,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B "I#^0 J0_\ *T+_ "M"_P"N
M2@  H5$  )=6  "-60  @UH  'E:  !N5P  85(  %=.  !-2P  0T<  #I#
M"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O13T +45& "Q%3P K1ED *D9D
M "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(]P E1_\ )4?_ "9'_P"J3P
MGU4  )1:  "+7@  @5\  '=>  !K7   7U@  %55  !+40  0$T  #5*!P P
M20X +DD5 "U)'0 L220 *THK "I*,P H2CL )TM# "9+3  E2U8 )$QB "-,
M<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >3/\ 'TS_ "!+_P"G4P  G%H
M ))?  "(8P  ?F0  '1C  !I80  7%X  %);  !'6   /%4  #)2 @ J4 P
M)T\2 "90&0 E4"  )% H "-0+P B43< (5%  "!120 >4E, '5)? !Q2;0 :
M4WT &5.0 !A3I  64[D %5/9 !93]  74O\ &%'_ !E1_P"C60  F&   (]E
M  "%:   >VD  '%I  !F9P  660  $UA  !"7P  .%P  "Y:   E6 @ (%<.
M !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A810 665  %5E; !19:0 36GH
M$EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_ !%8_P"?7P  E68  (QK  ""
M;0  >&X  &YO  !B;0  56H  $AH   ^9@  ,V4  "EC   @80$ && + !5@
M$  48!< $V > !)@)@ 28"X $6$W !!A0  /84L #F%8  UA9@ ,8G8 "V*)
M  IAG0 )8;( "&'+  AAZP )8/T "E__  M?_P";9@  DFT  (AQ  !^<P
M=74  &IT  !<<P  3W(  $-P   X;P  +6X  "1L   ;:P  $VL$  YJ#  -
M:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T< !6M3  1K80 ":W$  &J$  !J
MF   :JT  &G&  !IYP  :?@  &C_  !H_P"7;0  C7,  (1W  ![>@  <'L
M &-[  !6>@  27H  #UY   Q>   )W<  !UV   5=@  #W8"  EV"@ $=@\
M '85  !V'   =B0  '4L  !U-@  =4$  '5.  !U7   =6P  '5^  !TDP
M=*@  '/   !SXP  <O<  '+_  !Q_P"2=0  B7H  (!^  !V@   :8$  %N"
M  !.@@  08(  #6#   I@@  'X$  !:!   0@@  "H(   *#!P  @@T  ((1
M  ""%P  @AX  ((F  ""+P  @CL  ()'  ""50  @64  (%X  "!C0  @*(
M '^Z  !_W0  ?O0  'W_  !]_P"-?   A($  'N$  !NA@  8(@  %**  !%
MBP  .8P  "R,   AC   %XP  !"-   )C@   H\   "0 P  CPD  (\.  "/
M$@  D!@  ) ?  "0*   D#(  ) _  "030  D%T  (]P  "/A0  CIP  (ZS
M  "-T   C/   (O^  "+_P"(A   @(@  '*+  !DC0  5I   $B3   [E0
M+I8  "*6   7EP  #Y@   B9    FP   )T   "=    G0,  )T)  "=#0
MGA$  )X7  "?'P  GRD  * U  "@0P  H%0  *!F  "?>P  GI,  )ZK  "=
MQ@  G>D  )SY  "<_P"#BP  =8X  &>2  !9E@  2YD  #V<   PG@  (Y\
M !>@   .H@  !Z0   "F    J    *H   "J    J@   *L!  "K!P  K P
M *T0  "N%@  KQX  +$I  "Q.   L4@  +%:  "Q;P  L8@  +&@  "PN@
MK]T  *_R  "O_0!XD0  :I8  %R:  !-GP  /Z,  #&F   CIP  %ZD   ZK
M   %K@   +    "R    M0   +<   "W    N    +D   "Z    O ,  +T)
M  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&8@  QGH  ,:4  #&K0  QL@
M ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP  "2O   6L0  #;0   .W
MN@   +T   #     Q    ,8   #&    R    ,D   #+    S    ,X   #0
M!@  TPT  -@3  #<'@  WBT  -]   #@5   X6L  .&%  #AGP  X;<  .'/
M  #AY@!@H0  4J<  $.M   TL@  );4  !>Y   -O    ;\   ##    QP
M ,H   #/    TP   -8   #7    V@   -P   #?    X0   .,   #F
MZ0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP  /AT  #XCP  ^:8  /FX  #X
MR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_ "P _P Y /\ 10#_ %  _P!9
M /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X B@#] )  _ "7 /H G@#Y *<
M]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_ .8 _P#< /\ T@#_ ,T _P#_
M  < _P $ /\  @#_  8 _P 0 /\ &P#_ "< _P S /\ /P#_ $H _@!4 /L
M70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O (H [0"1 .P F0#J *$ Z "K
M .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D _P#, /\ Q0#_ ,$ _P#_
M_P   /\   #_  $ _P - /\ %@#\ "( ^0 N /8 .0#S $4 [P!. .P 5P#I
M %X Y@!E .0 ; #B '( X !W -\ ?@#= (0 VP"+ -@ D@#5 )L T@"D ,\
MKP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^ /\ N #_ +4 _P#_    _P
M /\   #^    ]P ) /$ $0#K !P YP H .0 ,P#A #X W0!( -@ 40#3 %@
MT !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$ ,( C #  )0 O@"> +L J "Y
M +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\ K #_ *D _P#_    _P   /H
M  #Q    Z  # .  #0#8 !8 T0 B ,T +0#* #< Q@!! ,( 2@"_ %( O0!9
M +H 7P"X &4 MP!J +4 < "S '8 L0!] *\ A0"M (T JP"7 *D H0"G *X
MI0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_ )P _P#_    ]P   .L   #A
M    U@   ,L "0#% !$ OP ; +L )@"W #$ M  Z +$ 0P"N $L JP!2 *D
M6 "G %X I@!D *0 :0"B '  H !V )X ?@"< (8 F@"0 )@ FP"6 *< E "V
M )( R@"0 .D CP#\ (X _P"- /\ C #_ (T _P#X    Z0(  -L#  #, 0
MQ    +T  @"V  T L  5 *L ( "G "H I  T *$ / "> $0 G !+ )H 4@"8
M %@ E@!= )4 8P"3 &D D0!P (\ =P"- (  BP"* (D E0"' *$ A0"O (,
MP0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N"@  W X  ,H0  "^#@  M0L
M *\#  "I  < HP 0 )X & "9 ", E@ L ), -0"0 #X C@!% (P 2P"* %$
MB !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$ 'L CP!Y )P =P"J '4 NP!T
M -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0  S1<  +\9  "S&0  JA4  *,0
M  "="@  EP$* )$ $@"- !L B0 E (4 +P"# #< @  ^ 'X 10!] $L >P!1
M 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"BP!L Y@ :P.F &D$MP!H!<X
M9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"   +8C  "K(P  H2   )D;  "2
M%   C X! (8'#0" !!0 ? 8> 'D'* !V"#  = @X '()/P!P"44 ;PI, &T*
M4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B#)4 8 VD %\-M@!>#<X 7 [M
M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K  "D*P  FBD  )(D  ")'P
M@A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R &<0.0!E$$  9!!& &,030!A
M$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I( 5A.B %43M !4$\L 4Q3L %(5
M_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?,@  E3$  (PM  "#)P  >B$
M '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5- !<%3L 6Q9" %D62 !8%D\
M5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ? $P:L !+&\< 2QOI $H<_0!*
M'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.   D#<  (<T  !]+P  ="D  &PC
M  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4'#< 4AP] %$<1 !/'4L 3AU2
M $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4AK@!$(<0 0R+F $,B_ !#(O\
M0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T  (,Z  !Y-0  ;S   &8J  !>
M) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3, 2R(Z $DB0 !((D< 1R). $8C
M5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ])\$ /2?C #TH^@ ]*/\ /2?_
M #TG_P"X-@  JCT  )Y   "40@  BD(  ( _  !V.P  ;#8  &(P  !9*@
M424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V $,F/0!")T0 02=+ #\H5  ^
M*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\ -RS@ #<L^  W+/\ -RS_ #@L
M_P"U.@  IT   )Q$  "11@  AT8  'U$  !S0   :#L  %\V  !5,0  3"L'
M $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK.0 \*T$ .RQ( #HL40 Y+5L
M."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'> #$Q]P R,?\ ,C#_ #,P_P"Q
M/@  I$0  )E(  "/2@  A4H  'M)  !P10  94   %L[  !2-@  2#$$ $(N
M#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V,#X -3!& #0Q3P S,5D ,C)D
M #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU]0 M-?\ +33_ "XT_P"N00
MHD@  )=,  "-3@  @TX  'E-  !N2@  8D4  %A   !./   13<  #TS"P Y
M,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P ,#5$ "\U3  N-E8 +39B "PW
M;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H.?\ *#C_ "DX_P"K10  GTL
M )1/  "+4@  @5,  '=2  !L3P  7TD  %9&  !,0@  0CT  #@X"  T. \
M,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI! "HZ2@ I.U0 *#M? "<\;0 E
M/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\ (SW_ ",\_P"H20  G4\  ))3
M  ")5@  ?U<  '56  !J4P  74\  %-,  !*2   0$0  #9 !0 O/0T +3T3
M "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_2  C0%( (D!= "%!:@ @07H
M'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_ !Y!_P"E30  FE,  )!8  "&
M6P  ?5P  ');  !G6   6U0  %%2  !(3@  /4H  #-'   J0PL )D,0 "5#
M%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =14\ '$9: !M&:  91G@ &$>*
M !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&_P"B4@  EU@  (U=  "$8
M>F$  '!@  !E7@  65H  $]8  !$5   .5$  "].   F2P8 ($H. !Y*$P =
M2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P %4Q7 !1,90 3374 $DV( !%-
MG  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">5P  E%T  (MB  "!90  =V8
M &UF  !C9   5F$  $I>   _6P  -5@  "M6   B5 $ &E(* !92$  54A8
M%%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4  Y38@ -5'( #%2$  M4F  )
M5*T "%3%  E4YP *4_L "U+_  M2_P";70  D60  (AH  !^:P  =&P  &ML
M  !?:@  4F<  $5D   Z8@  ,&   "9>   =70  %5L% !!:#  .6A$ #EH8
M  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;7@ $6VT  UN   %;E   6Z@
M %O   !:X@  6O8  5K_  )9_P"79   CFL  (1N  ![<   <G(  &=Q  !9
M<   3&X  $!L   U:P  *FD  "%G   89@  $68!  QE"@ '90\ !&44  -D
M&P "9",  &0L  !D-0  9$   &1,  !D6@  9&D  &1[  !DCP  8Z0  &.[
M  !BW0  8O0  &+_  !A_P"3;   B7$  (!U  !X=P  ;7@  &!W  !2=@
M1G4  #ET   N=   (W(  !IQ   2<0  #7$   9Q"   < T  ' 2  !P%P
M;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0  &]U  !NB@  ;:   &VV  !L
MU@  :_(  &O_  !K_P".<P  A7@  'U[  !S?0  97X  %A^  !+?@  /GX
M #)^   F?0  ''P  !-\   -?   !GT   !]!0  ? L  'P/  !\$P  ?!D
M 'PA  !\*0  ?#0  'M   ![3@  >UX  'MO  !ZA   >IH  'FQ  !XS@
M=^\  ';^  !V_P")>@  @7\  'B"  !K@P  784  $^&  !"AP  -8@  "F'
M   =AP  %(<   V(   &B0   (H   "*    B08  (D,  ")#P  B1,  (D:
M  "*(@  BBP  (HX  "*1@  B58  (EH  ")?   B)0  (>K  "&Q@  A>H
M (7[  "$_P"%@@  ?88  &^(  !ABP  4XT  $6/   XD0  *Y$  !^2   4
MD@  #9,   24    E@   )<   "8    EP   )<%  "7"P  F X  )@3  "9
M&@  F2(  )HN  ":/0  F4T  )E>  "9<P  F(L  )BC  "7O   EN(  );W
M  "5_P" B0  <HP  &2/  !6DP  2)8  #J9   LF@  'YL  !2<   ,G@
M Y\   "A    HP   *4   "E    I0   *4   "F @  IP@  *<-  "H$0
MJ1D  *LC  "K,0  JT$  *Q3  "L9P  JX   *J:  "JLP  JM   *GO  "I
M^P!UCP  9Y0  %F8  !*G   /)\  "VB   @HP  $Z4   NG   !J0   *L
M  "N    L0   +(   "R    LP   +0   "U    M@   +@$  "Y"P  NQ
M +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-  #!I@  P,$  +_C  "^\P!J
MEP  6YP  $VA   ^I0  +ZD  "&K   3K0  "[    "S    M0   +@   "\
M    OP   ,$   #!    PP   ,0   #&    QP   ,D   #+    S@@  -$/
M  #5&   V"<  -DY  #:30  VV0  -M^  #<F0  W+   -S)  #<XP!=GP
M3Z4  $"J   RKP  (K(  !2U   *N    +L   "_    PP   ,8   #+
MS@   -$   #1    U    -8   #9    VP   -X   #@    Y    .<&  #K
M#@  [QD  / J  #R/P  \U4  /1M  #TB   ]*$  /2V  #TQP#_  D _P &
M /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\ 00#_ $P _P!5 /\ 70#_ &4
M_P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2 /< F0#V *( ] "L /, N0#Q
M ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\ R0#_ ,0 _P#_  $ _P   /\
M  #_  0 _P . /\ %P#_ ", _P O /\ .P#] $8 ^@!0 /< 6 #T %\ \@!F
M /  ; #O '( [0!X .P ?@#J (4 Z0", .< DP#E )P XP"F .$ L0#? ,$
MW0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_ +D _P#_    _P   /\   #_
M    _P + /P $P#W !X ]  J /( -0#N $  Z0!* .8 4@#C %D X !@ -X
M9@#< &P V@!R -< > #4 'X T@"% -  C0#. )4 S "? ,D J@#' +@ Q0#-
M ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T _P#_    _P   /\   #Y
M\@ & .L #P#F !D X0 D -X +P#: #D TP!# ,\ 3 #, %, R0!: ,< 8 #%
M &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X MP"8 +4 HP"S +  L0#" *X
MX "L /< JP#_ *H _P"H /\ HP#_ *  _P#_    _P   /4   #K    X0
M -8 # #/ !, R@ > ,8 *0#" #, OP ] +L 10"X $T M@!4 +, 6@"Q %\
ML !E *X :@"L '  JP!W *D ?P"G (< I0"1 *, G "@ *D G@"X )P S@":
M .X F0#_ )< _P"6 /\ E@#_ ), _P#]    \0   .4   #9    S0   ,0
M!@"]  \ MP 8 +, (@"P "P K0 V *D /@"G $8 I !- *( 4P"@ %D GP!>
M )T 9 "; &H F@!P )@ =P"6 (  E "* )$ E0"/ *( C0"P (L PP") .,
MB #Y (8 _P"& /\ A@#_ (8 _P#S    XP   -$   #%    O0   +8   "N
M  L J  2 *0 ' "@ "8 G  O )H -P"7 #\ E0!& )( 3 "1 %( CP!8 (T
M70"+ &, B@!J (@ <0"& 'D A "# (( CP!_ )L ?@"I 'P NP!Z -4 > #R
M '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-  "X#   K@@  *@   "B  4
MFP . )8 %0"2 !\ C@ H (L ,0"( #D A@!  (0 1@"" $P @ !2 '\ 5P!]
M %T >P!C 'H :P!X ', =@!] '0 B !Q )4 < "D &X M !L ,H :P#J &H
M_ !J /\ :@#_ &H _P#:$   QA0  +@6  "M%0  I!(  )P.  "6!P  D  )
M (H $ "% !@ @0 A 'X *@![ #( >0 Y '< 0 !U $8 <P!, '( 40!P %<
M;@!> &T 90!K &X :0!W &< @P!E )$ 8P"? &( KP!@ ,0 7P#D %\!^ !>
M O\ 7@+_ %X"_P#.&   O1T  + @  "E'P  FQP  ),7  "+$0  A P  'X$
M"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I D  9P-& &8#3 !D!%( 8P19
M &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(K0!6",$ 50GA %0+]@!4"_\
M5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4  (LA  "#&P  >Q0  '0. P!N
M"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH 70M  %L,1P!:#$T 6 Q4 %<-
M7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,#\( 3!#C $L0^0!+$/\ 2Q'_
M $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I  !])   =!X  &P7  !E$0<
M7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [ %(10@!0$4@ 3Q%0 $X15P!,
M$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X 0Q7? $,6^ !#%O\ 0Q;_ $,6
M_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X*P  ;R8  &8@  !>&0$ 5Q0-
M %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6/@!(%D0 1Q=, $475 !$%UT
M0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO; #L<]@ \'/\ /!S_ #P<_P"U
M,   J#8  )PY  "1.P  ASH  'XW  !S,@  :BT  &$G  !9(0  41L) $P9
M$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!'$$ 0!Q( #X<4  ]'5D /!YD
M #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A]  U(O\ -2'_ #8A_P"R-
MI#H  )D^  "//P  A3\  'L\  !P.   9S(  %TM  !4*   3"(% $8?#@!#
M'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T .2%% #@B30 W(E< -B-B #0C
M;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O)O\ ,";_ # F_P"O.   HCX
M )9"  ",0P  @D,  'A!  !N/0  8S@  %HS  !1+@  2"@! $ D#  ](Q$
M.R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9" #(F2@ Q)U0 ,"=? "\H;  N
M*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\ *BK_ "LJ_P"L/   GT(  )1&
M  "*1P  @$<  '9%  !L0@  83T  %<X  !.,P  1"X  #PI"0 W*!  -2@5
M #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK2  L*U( *RQ= "HL:@ H+7D
M)RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__ "8N_P"I/P  G44  )))  "(
M2P  ?DP  '1*  !J1P  7D(  %0]  !+.0  030  #@O!@ R+0T ,"T3 "XM
M&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G,$\ )3!; "0Q:  C,7< (C*)
M "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R_P"F0P  FDD  )!-  "&3P
M?%   '-/  !H3   7$8  %)#  !)/P  /SL  #8V @ N,@P *S(1 "DR%P H
M,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T (#58 !\V90 >-G4 '#>' !LW
MFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C1P  F$T  (Y1  "$4P  >U0
M '%3  !F4   6DP  %!)  !'10  /4$  #,]   J.0D )3<. ",W%  B.!L
M(3@B " X*  ?.#  'CDX !TY00 <.DL &CI6 !D[8P 8.W( %CN% !4\F0 4
M/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P  E5$  (M5  ""6   >5D  &Y8
M  !D5@  6%$  $Y/  !%2P  .D<  #!#   G0 4 (#X- !T^$0 </A< &SX>
M !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !- 8  207  $4&" !!!EP /0:P
M#D+$  Y"YP /0?P $$'_ !! _P"=4   DU8  (E:  " 70  =EX  &Q=  !B
M6P  5E<  $Q5  !!40  -DX  "Q+   C2   &T4) !=$#P 51!0 %$4; !-%
M(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -1VT #$=_  M'DP )1Z< "$>^
M  A'X  )1_8 "D;_  M&_P":50  D%L  (=@  !]8@  <V,  &IB  !@80
M4UX  $=:   \5P  ,E4  "A2   ?4   %TX$ !%,#  /3!$ #DP7  Y,'@ -
M324 #$TN  M--P *34( "4U-  =.6@ &3FD !$Y[  ).CP !3J0  $VZ  !-
MVP !3?(  4W_  ),_P"66P  C6(  (1F  !Z:   <6D  &AI  !<9P  3V0
M $)A   W7P  +5P  "-:   :6   $E<!  U6"0 )50X !U43  95&@ $52(
M U4J  )5-   53X  %5*  !65P  5F4  %5W  !5BP  5:   %6V  !4U
M5/$  %/]  !3_P"38@  BF@  (!L  !W;@  ;V\  &-N  !6;   26H  #UH
M   R9@  )V4  !UC   58@  #F$   E@"  #8 T  %\1  !?%P  7QX  %\F
M  !?+P  7SH  %]%  !?4P  7V$  %YR  !>AP  79P  %VR  !<SP  7.\
M %O]  !;_P"0:@  AF\  'UR  !U=   :G4  %UT  !/<P  0G(  #9P   K
M;P  (&X  !=M   0;   "FP   )K!@  :PL  &H/  !J%   :AH  &HA  !I
M*@  :30  &E   !I3@  :5P  &EM  !H@@  :)@  &>N  !FR@  9>T  &7\
M  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[  !(>@  .WH  "]Z   C>0
M&7@  !%W   *=P   W<   !W @  =P@  '8-  !V$   =A4  '8;  !V(P
M=BX  '4Z  !U1P  =58  '5H  !T?   =)(  '.J  !RQ   <>D  '#[  !P
M_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _@P  ,H0  "6#   :@P  $8,
M  J#   "@P   (0   "%    A ,  (,(  "##0  @Q   (,5  "$'   A"8
M (0R  "$/P  @T\  (-@  ""=0  @HP  (&D  " O0  ?^,  '[Y  !^_P""
M@   >H0  &R&  !>B   4(H  $*+   UC0  )XT  !N-   1C@  "HX   "/
M    D0   )(   "2    D@   )(!  "2!P  D@P  )(0  "3%0  DQT  )0H
M  "4-@  E$4  )-7  "3:P  DX(  )*<  "1M@  D-@  (_S  "/_P!^AP
M<(H  &&-  !3D   19,  #>5   IE@  ')<  !&8   )F0   )L   "<
MG@   *    "@    H    *    "A    H00  *()  "C#@  I!0  *4=  "F
M*@  ICH  *9,  "E8   I7@  *62  "DK   I,D  */K  "B^@!SC@  9)$
M %:5  !'F0  .9P  "J>   =H   $:$   BC    I0   *<   "I    K
M *X   "N    K@   *\   "P    L0   +(   "S!@  M0T  +<3  "Y'@
MN2X  +I   "Z5   NVH  +J%  "YH0  N;L  +K>  "Y\@!GE0  6)D  $J>
M   [H@  +*8  !VH   1J@  !ZP   "O    L0   +0   "X    NP   +P
M  "\    O@   +\   #     P@   ,0   #&    R ,  ,L+  #/$@  T2
M -$R  #21@  TUT  -1V  #4D@  U:L  -7$  #4X@!;G0  3*(  #VG   O
MK   'Z\  !&Q   'M0   +@   "[    O@   ,(   #'    R@   ,P   #,
M    S@   -    #2    U0   -@   #;    WP   .(   #F"P  ZQ,  .PD
M  #M.   [DX  .]G  #P@@  \)P  /"R  #QQ0#_  , _P ! /\ ! #_  D
M_P / /\ & #_ "0 _P P /\ / #_ $< _P!1 /\ 60#_ &  _0!G /P ;0#Z
M ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T \ "G .X LP#L ,0 ZP#A .H
M^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_    _P   /\   #_    _P ,
M /\ % #_ "  _P K /X -P#Z $( ]@!+ /( 4P#P %L [@!A .P 9P#J &T
MZ !S .< >0#E '\ XP"& .$ C@#? )8 W0"@ -L K #8 +L U #1 -, \ #0
M /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_    _P   /\   #_    _0 ( /<
M$ #S !H [P F .T ,0#H #L XP!% .  30#< %4 V0!; -8 80#3 &< T0!L
M ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,, I0#  +( O@#% +P Y0"Z /L
MN #_ +< _P"P /\ J0#_ *4 _P#_    _P   /X   #U    [  # .4 #0#?
M !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X P@!5 ,  6P"^ &$ O !F +H
M; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L *H J0"[ *@ U0"F /, I #_
M *, _P"A /\ FP#_ )@ _P#_    ^P   /    #E    V    ,X "0#' !$
MP@ : +X ) "[ "X MP X +0 0 "Q $@ K@!. *P 5 "J %H J0!? *< 90"E
M &L I !Q *( > "@ ($ G@"+ )P E@"9 *, EP"R )8 QP"3 .@ D@#^ )$
M_P"0 /\ C0#_ (L _P#Y    ZP   -T   #/    Q@   +P ! "U  T L  5
M *P '@"H "@ I0 Q *( .0"? $$ G0!( )L 3@"9 %, EP!9 )8 7@"4 &0
MD@!J )  <0". 'H C "# (H CP"( )P A@"J (0 O "" -P @0#V (  _P!_
M /\ ?P#_ 'X _P#L    V@   ,D   "^    M@   *X   "G  D H0 0 )P
M& "8 "( E0 J )( ,@"0 #H C0!! (L 1P") $T AP!2 (8 6 "$ %T @@!D
M ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4 M !S ,P <0#M '  _P!P /\
M< #_ '  _P#?!0  R@H  +P+  "Q"0  J 0  *$   ";  , E  , (\ $P"*
M !L AP D (0 + "! #, ?P Z 'T 00![ $< >0!, '< 4@!V %< = != '(
M9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E ,, 9 #D &, ^@!C /\ 8@#_
M &, _P#0#@  OQ(  +(3  "G$@  G1   )4+  "/ P  B0 ' (( #@!^ !4
M>@ > '8 )0!T "T <0 T &\ .@!N $  ; !& &H 3 !I %( 9P!8 &8 7P!D
M &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P 6 #< %@ ] !8 /\ 5P#_ %<
M_P#&%@  MAH  *H=  "?'   E1D  (T4  "%#P  ?@D  '<!"@!R !  ;@ 7
M &H 'P!H "< 90 N &0 - !B #L 8 !  %\ 1@!= $P 7 !3 %H 6@!8 &(
M5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2 $T$\ !-!?\ 307_ $T%_P"_
M'0  L"(  *,E  "9)0  CR(  (4=  !]&   =1(  &X- @!G!@P 8P,1 %\"
M&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3!D< 409. % '50!.!UX 30AG
M $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,[P!##?\ 0PW_ $0-_P"Y)
MJBD  )XL  "4+   BBH  ( F  !W(0  ;AL  &84  !?#P4 60L- %4*$P!3
M"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4( 2 U) $8-40!%#EH 1 YD $(.
M< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [$?\ .Q'_ #P1_P"T*0  IB\
M )HR  "0,@  AC$  'PM  !R*   :2,  &$=  !9%@  41$( $P/$ !*$!8
M2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%% #X230 ]$E8 /!)A #H3;0 Y
M$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\ -!;_ #06_P"O+@  HC0  )<W
M  ",.   @C8  '@T  !N+@  92H  %PD  !4'@  3!@$ $84#0!"%!( 0!09
M #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<62@ V%U, -1=> #,8:@ R&7D
M,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_ "X;_P"L,@  GS@  )0[  "*
M/   @#P  '8Y  !K-   8B\  %DJ  !0)0  1Q\  $ :"@ \&1  .AD6 #@9
M'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O'%  +AU; "T=9P L'G8 *AZ(
M "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@_P"I-@  G3P  )(_  "'00
M?4   '0^  !I.@  7S4  %8P  !-*P  1"4  #L@!P V'@X ,QX3 #(>&0 P
M'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X *2%8 "<B90 F(G0 )2.% ",C
MF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F.@  FC\  (]#  "%10  >T0
M ')#  !G/P  73H  %,V  !*,0  02P  #@F P Q(PP +B(1 "PB%@ J(AT
M*2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96 "(F8P A)W( 'R># !XHEP =
M**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@  F$,  (U'  "#20  >DD  '!'
M  !F1   6C\  %$[  !'-P  /C(  #4M   L* D *"</ "<G%  E)QH )"<A
M ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK8  ;*V\ &BR! !DLE0 7+:D
M%BW! !8MY  7+?H &"W_ !DM_P"A00  E4<  (M+  ""30  >$T  &Y,  !D
M20  6$0  $]   !&/0  /3@  #,T   J+P8 )"P- "$L$@ @+!@ 'RT> !XM
M)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6,&T %3%_ !,QDP 2,:@ $3*_
M !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/  " 40  =E(  &U0  !B3@
M5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+ !PR$  ;,A4 &3(; !@R(@ 7
M,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L $#9]  \VD0 .-J8 #3>\  TW
MW0 --O8 #C;_  \V_P";20  D4\  (=3  !^5@  =58  &I5  !@4P  54\
M $Q,  !"20  .$4  "Y!   D/0  '#H( !8X#@ 5.!( %#@8 !,Y'P 2.28
M$3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ  H[C0 )/*( !SRX  <\U0 (
M//  "3O_  H[_P"83@  CE0  (58  !\6P  <EL  &A:  !>6   4U4  $E2
M   ^3@  -$L  "I'   A1   &$(# !) "P 0/Q  #C\5  X_'  -0", #$ K
M  M -  *0#X "4%*  =!5@ &064 !$%V  -!B@ !09\  $&T  !!T  !0>X
M 4'\  ) _P"55   C%D  (->  !Y8   <&   &9@  !=7@  45L  $57   Z
M5   +U$  "5/   <3   %$H   Y("  +1PX "$<2  ='&0 &1R  !4@H  -(
M,0 "2#L  $A'  !(4P  2&(  $AS  !(A@  2)L  $BQ  !'S   1^T  $?[
M  !'_P"26@  B6   (!C  !W90  ;F8  &5F  !99   3&   $!=   U6P
M*ED  "!7   750  $%,   M2!P %40T  5 1  !0%@  4!T  % E  !0+@
M4#@  %!#  !04   4%X  %!O  !0@P  3Y@  $^N  !.R0  3NL  $W[  !-
M_P"/80  AF8  'UI  !T;   ;&T  &%K  !3:0  1F<  #ID   O8P  )&$
M !I?   27@  #%P   9<!@  6PL  %H/  !:$P  6AD  %DA  !9*0  63,
M %D_  !93   65H  %EK  !8?@  6)0  %>K  !7Q0  5ND  %7[  !5_P",
M:   @FT  'IP  !R<@  9W(  %IQ  !,<   /VX  #-M   H:P  '6H  !1H
M   -9P  !V<   !F P  9@D  &4-  !E$0  9!4  &0<  !D)   9"X  &0Z
M  !C1P  8U4  &-F  !C>@  8I   &&G  !@P0  7^8  %_Z  !>_P"';P
M?W0  'AW  !N>   8'@  %)W  !%=P  .'8  "MV   @=   %G,   YS   '
M<@   '(   !R    <04  '$*  !Q#@  <!$  ' 7  !P'@  <"<  ' S  !O
M0   ;U   &]@  !N=   ;HL  &VB  !LO   :^(  &KX  !I_P"#=P  ?'L
M '-]  !E?@  5W\  $E_   \?P  +X   ")_   7?@  #WX   =^    ?P
M '\   !_    ?@   'X%  !^"@  ?@T  'X1  !^%P  ?B   'XK  !].0
M?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H  'CU  !W_P" ?P  =X(  &F#
M  !;A0  388  #^(   RB0  )(D  !B)   /B0  !XH   "+    C    (T
M  "-    C    (P   ", P  C @  (T-  "-$0  C1<  (XB  ".+P  CC\
M (U0  "-9   C'L  (R5  "+K@  BLT  (GO  ")_P![A0  ;8@  %Z*  !0
MC0  0H\  #21   FD@  &9,   Z4   &E0   )8   "8    F@   )L   ";
M    FP   )L   ";    G    )T%  "="P  GA   )\7  "@)   H#0  *!&
M  "@60  GW   )^*  ">I0  GL(  )WH  "<^0!PC   88\  %.2  !$E@
M-ID  ">;   9G   #YT   6?    H0   *,   "E    J    *D   "I
MJ0   *H   "K    K    *T   "N 0  L D  +(/  "S&   M"<  +0Y  "U
M30  M&0  +1^  "SF@  L[0  +/5  "S\ !DDP  59<  $>;   XGP  *:(
M !JD   .I@  !*@   "K    K0   +    "T    M@   +@   "X    N0
M +H   "\    O0   +\   #     PP   ,4'  #)#P  RAH  ,LL  #,0
MS58  ,YO  #-BP  S*@  ,S"  #,X@!8FP  2:   #JE   LJ0  '*L   ^N
M   $L0   +0   "W    N@   +X   ##    Q@   ,@   #(    R@   ,L
M  #-    SP   -(   #5    V0   -T   #A!0  Y@\  .<>  #H,@  Z4@
M .I@  #K>P  ZY<  .RN  #LP@#_    _P   /\   #_  8 _P - /\ %0#_
M "$ _P L /\ . #_ $, _P!, /X 5 #[ %L ^@!B /@ : #V &X ]0!T /0
M>@#R (  \0"' .\ CP#M )< ZP"A .D K0#G +T Y0#8 .0 \P#B /\ X #_
M -  _P#$ /\ O #_ +8 _P#_    _P   /\   #_    _P ) /\ $0#_ !P
M_0 G /D ,@#U #T \0!& .T 3P#K %8 Z !< .8 8@#D &@ XP!N .$ <P#?
M 'D W0"  -H B #8 )$ U "; -( I@#/ +0 S #) ,D Z0#( /\ QP#_ ,$
M_P"W /\ KP#_ *L _P#_    _P   /\   #_    ^  % /( #@#N !< Z@ B
M .8 + #A #< W0!  -@ 20#3 %  T !6 ,X 7 #, &( R@!G ,@ ;0#& ',
MQ !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^ +0 W0"S /< L0#_ +  _P"H
M /\ H@#_ )X _P#_    _P   /D   #O    Y@   -\ "P#6 !( T  < ,P
M)@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V %L M0!A +, 9@"Q &P L !R
M *X >@"L (( J0", *< F "E *4 HP"T *  RP"? .X G0#_ )P _P"9 /\
ME #_ )$ _P#_    ]@   .H   #=    SP   ,< !@#   \ NP 7 +< ( "S
M "H L  S *T .P"J $, IP!) *4 3P"C %4 H@!: *  7P"> &4 G0!K )L
M<@"9 'L EP"% )0 D "2 )T D "L (X OP", .( BP#Z (D _P") /\ A@#_
M (, _P#T    Y    -0   #(    OP   +4  0"N  L J0 2 *4 &P"A ",
MG@ L )L - "8 #P E@!# )0 20"2 $X D !3 (X 60"- %X BP!D (D :P"'
M ', A0!] (, B "! )4 ?P"D 'T M0![ ,\ >0#Q '@ _P!W /\ =P#_ '4
M_P#E    T0   ,,   "X    KP   *@   "@  8 F@ . )4 %0"1 !X C@ F
M (L +0"( #4 A@ \ (0 0@"" $< @ !- '\ 4@!] %@ >P!> 'D 90!X &T
M=@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G &D _0!H /\ : #_ &D _P#5
M P  PP<  +8(  "K!@  H@   )L   "4    C0 * (@ $ "# !@ ?P @ 'P
M)P!Z "X =P U '4 .P!T $$ <@!' '  3 !O %( ;0!8 &L 7P!I &8 9P!P
M &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P ]@!< /\ 6P#_ %L _P#)#0
MN1   *P1  "A$   EPT  (\(  "(    @@ % 'L #0!W !( <P : &\ (0!L
M "@ :@ O &@ -0!G #L 90!! &, 1@!B $P 8 !2 %\ 60!= &$ 6P!J %D
M=0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0 /\ 4 #_ %  _P"_%   L!@
M *0:  "9&0  CQ8  (<1  !_#0  =P8  '$ " !K  X 9P 4 &0 &P!A "(
M7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!- %, 5 !2 %P 4 !E $X < !,
M 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L 1@#_ $4 _P"X&P  JB   )XB
M  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A! H 70 0 %D %@!6 !T 5  C
M %( *@!0 #  3P U $X .P!, $$ 2P!( $D 3P!' 5< 1@%A $0"; !# GD
M00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_ #P'_P"R(@  I2<  )DI  ".
M*0  A"<  'LC  !Q'@  :1@  &$2  !:#0, 4P@, $\%$0!,!1< 2@8> $@&
M) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^"5, /0E= #L*:  Z"G8 . N'
M #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-_P"M)P  H"P  )4O  "++P
M@"X  '<J  !M)0  9"   %P:  !4%   3 \& $8,#0!##!( 00P8 #\,'P ^
M#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E  - Y: #,.9@ Q#W0 , ^% "X0
MF  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J+   G3$  )(T  "'-0  ?30
M '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1"0 [$ \ .1 4 #<0&P V$"$
M-! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7 "P28P J$W$ *1." "<4E0 F
M%*D )17  "05XP E%OH )A;_ "85_P"F,0  FC8  (\Y  "%.@  >SD  '$V
M  !G,0  72T  %0H  !,(@  0QT  #L7!0 U% T ,A,1 #$4%P O%!T +A0D
M "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "878  D&&\ (QB  "$9DP @&:<
M'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H  (T]  "#/@  >3T  &\[  !E
M-P  6S(  %(M  !)*   0",  #@> 0 P&0H +!@/ "H8%  I&!H )Q@@ "89
M)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?'6P '1U^ !P=D0 :'J4 &1Z\
M !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!  "!0@  =T(  &U   !C/
M63<  $\S  !&+@  /2D  #4D   M( < )QT- "4=$@ C'1< (1T= "$=)  @
M'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H &")[ !8BCP 5(J, %".Z !,C
MV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_1@  =48  &Q$  !B00  5SP
M $TX  !$-   /#   #,K   J)@, (R(+ " A$  >(14 '"(; !LB(0 :(B@
M&B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y !(FC0 1)Z( $">X  XGU@ 0
M*/0 $2?_ !$G_P"<0   D44  (=(  !]2@  =$H  &I)  !@1@  54$  $P^
M  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9)Q( &"<8 !8G'P 5*"4 %"@M
M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XKBP -+)\ #"RU  LLSP ,+.\
M#2S_  TK_P"91   CTD  (5,  !\3@  <T\  &E.  !>2P  4T<  $I$  !"
M0   .3T  "\X   E-   '3 % !8M#  4+!  $RT5 !(M'  1+2, $"TJ  \N
M,P .+CT #2](  TO50 ,,&, "C!T  DPB  (,9P !C&Q  8QRP &,>L !S#\
M  @P_P"72   C4T  (-1  !Z4P  <50  &=2  !=4   4DP  $E*  ! 1@
M-4(  "L^   B.@  &C<! !(T"0 /,PX #C,3  TS&0 -,R  ##0H  LT,0 *
M-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID  #:O   VR   -N@  #;Y  $U
M_P"430  BE(  (%6  !X6   ;UD  &58  !;50  45(  $=/   \3   ,4@
M "=$   >00  %C\  ! \!P +.@T "3H1  @[%P &.QX !3LF  0[+@ ".S@
M 3Q#   \3P  /%X  #QN   \@0  /)<  #RL   [Q0  .^<  #OX   [_P"1
M4@  B%@  ']<  !V70  ;5X  &-=  !:7   3E@  $)4   W40  +4X  "-+
M   :20  $D8   U$!@ '0PP  T,0  !#%0  0QL  $,C  !#*P  0S4  $-
M  !#30  0UL  $-K  !#?@  0Y0  $*J  !"PP  0>8  $'Y  !!_P".6
MAEX  'UA  !S8P  :V0  &)C  !780  25T  #U:   R6   )U4  !Y3   5
M40  #D\   E-!0 "30L  $P.  !,$P  2Q@  $L?  !+*   2S(  $L]  !+
M20  2U<  $MG  !*>P  2I   $FG  !)P   2.0  $CX  !'_P"+7P  @V0
M 'IG  !Q:0  :6H  %YI  !09@  0V0  #=A   L7P  (5T  !A;   060
M"E@   -7 P  5PD  %8-  !5$   514  %0;  !4(P  5"T  %0Y  !410
M5%,  %1D  !3=P  4XT  %*D  !1O0  4.(  %#X  !/_P"(9P  ?VL  '=N
M  !O<   97   %=N  !*;   /6L  #!I   E:   &F8  !%D   +8P  !&(
M  !B 0  808  & +  !@#@  7Q(  %\7  !?'@  7B@  %XS  !>0   7D\
M %Y?  !=<@  78@  %R@  !;N0  6M\  %GW  !8_P"$;@  ?'(  '5U  !K
M=@  774  $]T  !"<P  -7,  "AR   =<   $V\   QN   $;@   &X   !N
M    ; (  &P'  !K"P  :PX  &L2  !J&0  :B(  &HM  !J.@  :4D  &E:
M  !I;   :(,  &>;  !FM0  9=@  &3U  !D_P" =0  >GD  '![  !B>P
M5'P  $9\   Y?   +'P  !][   4>@  #7H   1Z    >@   'H   !Z
M>0   'D!  !X!@  > L  '@.  !X$P  >!H  '@E  !X,@  =T$  '=2  !W
M90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^?0  =8   &>!  !8@@  2H,
M #R$   NA0  (84  !6%   -A0   X4   "&    AP   (@   "(    AP
M (<   "'    AP0  (<)  "'#@  B!,  (@<  "(*0  B#@  (=*  "'70
MAG,  (:-  "%IP  A,4  (/L  ""_@!XA   :H8  %R(  !-B@  /XP  #&.
M   CCP  %H\   V0   "D0   )(   "3    E0   )8   "6    E@   )8
M  "6    EP   )<   "7!P  F T  )D3  ":'P  FBT  )H_  ":4@  FF@
M )F#  "9GP  F+H  )?B  "6^ !MB@  7XT  %"0  !!DP  ,Y8  "27   6
MF   #9D   &;    G0   )\   "A    I    *4   "D    I0   *4   "F
M    IP   *@   "I    J@0  *P,  "N$P  KB$  *XS  "N1P  KET  *YV
M  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28   UG   )I\  !>A   -HP
M *4   "G    J@   *P   "P    L@   +0   "S    M    +4   "W
MN    +D   "[    O0   +\!  ##"P  Q14  ,4E  #&.0  QT\  ,=H  #&
MA0  QJ(  ,:\  #&W@!5F0  1YT  #BB   II@  &:@   VK    K0   +$
M  "T    MP   +H   "_    P0   ,0   ##    Q0   ,8   #(    R@
M ,T   #/    T@   -8   #;    X P  .$8  #C*P  Y$$  .5:  #F=
MYI$  .6L  #EQ #_    _P   /\   #_  $ _P * /\ $@#_ !T _P H /\
M- #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R &D \ !O .\ = #M 'L ZP"!
M .D B0#H )( Y@"< .0 J #B +< WP#- -P [@#9 /\ V0#_ ,H _P"^ /\
MM0#_ +  _P#_    _P   /\   #_    _P & /\ #P#\ !@ ^  C /0 +@#P
M #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &, W !H -D ;@#6 '0 U ![ -$
M@@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#  /L P #_ +L _P"P /\ J #_
M *0 _P#_    _P   /\   #[    \P ! .T # #H !, XP > .  * #: #(
MTP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B ,$ 9P"_ &T O0!T +L >P"Y
M (0 MP". +0 F0"R *< KP"W *T T "K /( J@#_ *D _P"A /\ FP#_ )<
M_P#_    _P   /0   #I    X    -4 " #. !  R0 8 ,4 (@#! "L O  U
M +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P 80"J &8 J0!M *8 = "D 'P
MH@"& *  D@"> )\ G "N )D PP"7 .< E@#_ )4 _P"2 /\ C0#_ (H _P#\
M    \    .,   #4    R    +\  P"Y  T LP 3 *\ ' "L "4 J0 N *4
M-@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7 %\ E@!F )0 ; "2 '4 D !^
M (X B@"+ )< B0"F (< N "% -8 A #V (( _P"! /\ ?@#_ 'P _P#M
MW0   ,P   #!    N    *X   "G  D H@ 0 )X %P": !\ EP G )0 +P"1
M #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D A !? (( 90"  &T ?@!W 'P
M@@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P /\ < #_ &X _P#=    R0
M +P   "Q    J0   *$   "9  , DP , (X $@"* !D AP A (0 *0"! #
M?P W 'T /0![ $( >0!( '@ 30!V %( = !8 '( 7P!Q &< ;P!P &P >P!J
M (@ : "7 &8 J !E +P 8P#A &( ^@!A /\ 80#_ &$ _P#- 0  O 4  *\%
M  "E @  G    )0   "-    A@ ( ($ #@!\ !0 >  ; '4 (P!R "D <  P
M &X -@!M #P :P!! &D 1P!H $P 9@!2 &0 60!C &  80!I %\ = != ($
M6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_ %4 _P#!#   L@X  *8/  ";
M#@  D@L  (D%  ""    >P " '4 "P!P !  ;  6 &@ '0!F ", 8P J &$
M, !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6 %L 5 !D %( ;@!1 'L 3P"*
M $T FP!, *X 2P#& $H Z@!) /X 20#_ $D _P"Y$@  JA8  )X7  "4%@
MBA,  ($0  !Y"P  <0,  &L !@!E  T 80 1 %T & !: !X 6  D %8 *@!4
M #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8 20!? $< :0!& '8 1 "% $,
MEP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R&0  I!X  )@?  ".'P  A!P
M 'H8  !R$@  :@X  &((  !< 0@ 5P . %, $P!0 !D 3@ ? $P )0!* "L
M2  P $< -@!& #P 1 !" $, 20!! %$ /P!: #X 90 \ '( .@"! #D DP X
M *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(   GR0  )0F  "))@  ?R0  '4@
M  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!' !0 1  : $( ( !  "4 /P K
M #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$80 S!&X ,05^ # %D  O!:,
M+0:X "P&U  L!_  + C_ "P(_P"H)0  FRH  ) L  "&+0  >RL  '(G  !H
M(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q  .P85 #D'&P X!R$ -@@F #4(
M+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K"VP *0M\ "@,CP F#*( )0RW
M "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR  "#,@  >3$  &\N  !E*0
M7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1 #$,%@ O#!P +@TB "T-*  K
M#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH (@][ " 0C@ ?$*( '1"W !P0
MU  =$?( '1'_ !X1_P"A+P  E3,  (HV  " -P  =C8  &TS  !C+P  62H
M % E  !((   /QH  #@5   P$0@ +! . "H0$@ H$!@ )Q > "40)  D$"H
M(Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X !H3BP 8%*  %Q2U !84T0 6
M%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P  =#L  &LX  !A-   5R\  $XK
M  !%)@  /2$  #0<   M%P4 )A,, ",3$  B$Q4 (!,: !\3(0 >%"< '10O
M !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08B0 3&)X $ABS !$9S@ 1&>\
M$AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\  &D]  !?.0  534  $PP  !#
M+   .B<  #(B   J'@$ (AD) !X7#@ <%Q( &A<7 !D8'@ 9&"0 &!DL !<9
M-  6&CX %1I) !,;50 2&V, $1QT ! <AP /'9P #AVQ  T=RP -'>P #AW_
M  \=_P"9.@  CS\  (1"  ![1   <4,  &A"  !>/@  4SH  $HV  !!,@
M.2T  #$I   H)0  (" & !H=#  7'!  %1P5 !0=&P 4'2( $QTI !(>,@ 1
M'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID "B*N  DBQP )(N< "B+[  LA
M_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<1   4C\  $D[  ! .   .#0
M "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B&0 0(B  #R(G  XC+P -)#D
M#"1$  LE4  *)5X "29O  <F@@ &)I8 !":L  ,FQ  $)N4 !";W  8F_P"5
M0@  BD<  (%*  !X3   ;TP  &5+  !;2   4$0  $=!   _/@  -SL  "TV
M   D,0  &RT  !,J!P /* T #2<1  TH%@ ,*!T "R@E  HI+0 )*3< !RI"
M  8J3@ $*UP  RML  $K?P  *Y0  "NI   KP0  *^,  "OV   J_P"21@
MB$L  ']/  !V40  ;5$  &-0  !:30  3TH  $='   ^1   ,T   "D\   @
M.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL !2\C  ,O*P ",#4  # _   P
M3   ,5D  #%I   Q?   ,9$  #&G   POP  ,.$  ##U   O_P"02P  AE
M 'U4  !U5@  :U8  &)5  !84P  3E   $5-   Z20  +T4  "5"   </@
M%#L   XY!0 )-PL !#8/  $V$P  -AD  #8@   V*0  -C(  #<]   W20
M-U<  #=G   W>0  -X\  #:E   VO0  -N   #7U   U_P"-4   A%8  'Q:
M  !R6P  :5L  &!;  !760  3%8  $!2   U3@  *DL  "!(   71@  $$,
M  M!!  $0 H  #\.   ^$0  /A8  #X=   ^)@  /B\  #XZ   ^1@  /E0
M #YD   ^=@  /8P  #VC   \NP  /-X  #OU   [_P"*5P  @EP  'E?  !P
M80  :&$  %]A  !47@  1UL  #I7   O50  )5(  !M0   230  #$L   9*
M P  20D  $@-  !'$   1Q0  $8:  !&(@  1BP  $8W  !&0P  1E$  $9@
M  !%<P  18D  $2@  !$N   0]P  $+U  !"_P"(70  ?V(  '=E  !N9P
M9V@  %MF  !.8P  06$  #1>   I7   'UH  !57   .5@  !U0   !3 0
M4@8  %$+  !1#@  4!$  $\6  !/'@  3R<  $\R  !//P  3TT  $Y=  !.
M;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%90  ?&D  '1L  !M;@  8FT
M %1K  !':0  .F<  "UE   B9   &&(  !!@   )7P   %X   !>    70,
M %P(  !;#   6@\  %H3  !9&0  62(  %DM  !9.@  64@  %A8  !8:P
M5X$  %>9  !6L@  5=(  %3T  !3_P"!;   >7   '-S  !H<P  6G(  $QQ
M   _<   ,F\  "5N   :;   $6L   EJ    :@   &D   !I    :    &<#
M  !F"   9@P  &8/  !E%   91P  &4G  !D-   9$,  &13  !D90  8WL
M &*4  !AK0  8,T  %_Q  !>_P!]=   =W<  &YY  !?>0  47D  $-Y   V
M>   *7@  !QW   1=@  "G4   !U    =0   '8   !U    =    '0   !S
M @  <P<  ',,  !R$   <A4  '(@  !R+   <CL  '%,  !Q7P  <70  '".
M  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^  !5?P  1X   #F!   K@@
M'H$  !*!   *@0   ($   ""    @P   (,   "#    @@   ((   ""
M@@   ((%  """@  @@\  ((7  ""(P  @C(  ()#  "!5@  @6P  ("&  !_
MH0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+AP  /(D  "Z*   @BP  $XL
M  J+    C    (T   "/    D0   )(   "1    D0   )$   "1    D0
M )(   "2 @  DPD  )0/  "4&0  E"<  )0X  "43   DV(  )-\  "3F
MDK,  )'8  "0]@!JB   7(H  $V-   _D   ,)(  "&4   4E0  "I8   "7
M    F0   )L   "=    GP   *    "@    H    *    "A    H@   *,
M  "D    I0   *8'  "H$   J!P  *@M  "I0   J58  *EO  "IBP  J*@
M *?'  "F[ !?CP  4)(  $&6   SF0  (YP  !2=   *GP   *$   "C
MI@   *@   "L    K@   *\   "O    L    +    "R    LP   +0   "V
M    MP   +H   "]!P  OQ   +\?  # ,P  P$D  ,!B  # ?@  P)L  ,"W
M  "_V !3EP  1)L  #6?   FHP  %J4   NG    J@   *T   "P    LP
M +8   "[    O0   ,    "_    P0   ,(   #$    Q@   ,@   #*
MS    ,\   #3    V@<  -L3  #=)0  WCL  -]3  #@;@  WXP  -VI  #=
MP@#_    _P   /\   #_    _P ' /\ $ #_ !D _P D /\ +P#\ #H ^0!#
M /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D ;P#G '4 Y@!\ .0 A #B (T
MX "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_ ,0 _P"X /\ KP#_ *D _P#_
M    _P   /\   #_    _P " /L #0#W !4 \P ? .\ *0#J #0 Y@ ] .(
M10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#. &X S !U ,H ?0#( (4 Q@"0
M ,( FP#  *D O@"Z +L V0"Y /< N #_ +0 _P"I /\ H@#_ )T _P#_
M_P   /\   #V    [@   .< "@#A !$ W  : -< (P#0 "X RP W ,< /P#$
M $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@ M@!N +0 =0"Q 'X KP"( *T
MDP"J *$ J "Q *8 R "D .T H@#_ *( _P"; /\ E0#_ )$ _P#_    _
M .X   #C    V    ,T !0#&  X P0 5 +T '@"Y "< M0 P +( . "O $
MK !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G )\ ;@"> '8 FP"  )D C "7
M )D E "H )( O "0 -\ C@#[ (X _P"+ /\ A@#_ (, _P#X    Z0   -P
M  #,    P0   +@   "R  H K  1 *@ & "E "$ H@ I )X ,@"< #D F0 _
M )< 10"5 $H E !0 )( 50"0 %H CP!@ (T 9P"+ &\ B0!X (8 A "$ )$
M@@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_ '4 _P#F    TP   ,8   "[
M    L0   *<   "A  4 FP - )< $P"3 !L D  C (P *P"* #( B  X (8
M/@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y &@ =P!Q '4 ? !S (D < "8
M &\ J0!M +\ :P#F &H _P!I /\ :0#_ &< _P#3    PP   +4   "K
MHP   )L   "2    C  * (< $ "# !8 ?P = 'T ) !Z "L >  R '8 . !T
M #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$ : !J &8 = !D ($ 80"1 %\
MH@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%    M@(  *D"  "?    E@
M (X   "'    @  % 'H # !U !$ <0 8 &X '@!K "4 :0 K &< ,0!F #<
M9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D %@ ;@!6 'L 5 "* %( FP!1
M *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@  K T  * -  "5#   C @  (,"
M  !\    =0   &X " !I  X 90 3 &( &0!? !\ 70 E %L *P!9 #$ 6  V
M %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P : !* '4 2 "$ $< E0!% *@
M1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10  )D5  ".$P  A!$  'L-  !S
M"   ;    &4  P!?  L 6P / %< % !4 !H 40 ? $\ )0!. "L 3  P $L
M-@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _ &\ /@!^ #P D  [ *, .@"X
M #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=  ")'   ?QD  '45  !L$
M9 P  %T&  !6  8 40 , $T $ !* !4 1P : $4 ( !$ "8 0@ K $$ ,0 _
M #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L - !Z #( C  Q )X , "S "\
MS@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$)   >B$  '$=  !G&   7Q,
M %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P &P Z "$ .0 F #< +  V #(
M-  X #, /P Q $< , !0 "X 6P M &< *P!V "H B  H )P )P"P "8 R0 E
M .H )0'[ "4!_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5
M  !+$   0PP" #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T
M "H#.P I!$, * 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^<
M'0CX !T)_P"?*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'
M%P  /Q(  #@.!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)
M-P A"D  ( I* !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY
M !8-_P"<+0  D#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0
M/!@  #03   M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :
M#CT &0Y' !<.4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0
M_P"9,0  CC4  (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\
M #$:   J%0$ (Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H
M$Q%% !(240 1$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7
M-0  C#D  ((\  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A
M   H'   (!@# !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"
M  X63P -%EP #!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.
MBCT  (!   !W00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G
M(P  'Q\  !<:"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;
M3  )&UH !QQI  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$
M ']$  !U10  ;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@
M'24  !0A!  /'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #
M(5<  2%G   A>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(
M  !T2@  :TH  &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L
M !(H!  -) H "2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4
M "9E   F=P  )HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S
M3P  :D\  &!.  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N
M P *+ H !2L.  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB
M   L=0  +(H  "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5
M:%0  %]3  !640  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &
M,PD  #(-   R$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R
M<@  ,H<  #&>   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED
M %Y9  !55P  25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @
M #L,   Z#P  .1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P
M.(4  #B<   WLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?
M  !27   1%@  #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*
M  !##0  0A   $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($
M #^9   _L0  /M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+
M80  /EX  #);   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,
M#   2PX  $L2  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6
M  !'KP  1LT  $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@
M-V0  "IB   ?8   %5X   U=   &6P   %H   !9    6    %<$  !6"
M5@P  %40  !4%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1
MJP  4,H  $_O  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP
M ")J   7:0  #F<   9F    90   &4   !E    8P   &(   !B!   80@
M &$-  !@$   8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP
M6\4  %KM  !9_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES
M   0<@  !W$   !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(
M  !M#   ;1$  &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X
M &?H  !F_@!Y>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '
M?0   'T   !]    ?@   '\   !^    ?0   'T   !\    ?    'P   !\
M!@  ? P  'P2  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?
M  !W^@!S@   98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B
M (D   "*    C    (T   "-    C    (P   ",    C    (P   "-
MC00  (X,  ".$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*
M\P!HA@  6H@  $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<
M  "9    FP   )P   ";    FP   )P   "<    G0   )X   ">    GP
M *$#  "B#   HA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<
MC0  39   #^3   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H
M    J@   *L   "J    JP   *P   "M    K@   *\   "Q    L@   +0
M  "W 0  N0T  +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0
M09@  #*<   CH   $Z(   BD    IP   *H   "L    KP   +(   "W
MN0   +L   "Z    O    +T   "_    P    ,(   #$    Q@   ,D   #-
M    T@$  -0/  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P
M /\   #_    _P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X
MZP!4 .D 6@#G %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/
M *L S0"] ,L X #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\
M  #_    _    /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!.
M ,\ 5 #- %D RP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *,
MM@"T +0 S0"R /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q
M    Z    .  !@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@
M30"V %, M !8 +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K
M )\ P "= .8 FP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<
MS@   ,8  0"_  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A
M $P GP!1 )X 5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L
MM0") -, AP#W (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@
M +$   "K  < I0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4
MC0!* (L 4 ") %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V
M ,0 = #K ', _P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$
M  ":  ( E  + )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$
M 'D 20!X $X =@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@
M9 #> &, ^P!B /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",
M    A@ ' ($ #0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H
M0@!H $@ 9P!. &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+
M %4 \@!4 /\ 5 #_ %0 _P"^    L    *0   "9    D    (@   "!
M>0 " ', "@!O  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !;
M $( 60!' %< 3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@
MZ !' /\ 1P#_ $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P
M &@ !0!C  P 7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P
M30!" $L 2 !) %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \
M /@ / #_ #P _P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &
M 0!9  @ 50 - %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \
M $  0P ^ $L /0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$
M,0#_ #$ _P"F%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1
M  0 3  * $@ #@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8
M/@ T $8 ,P!/ #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^
M "@ _P"A'   E2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P
M1  & $  "P \  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K
M $( *@!+ "@ 50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\
M_P"=(@  D28  (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL
M #@%!P T  P ,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X
M(@!' "  4@ ? %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":
M)P  CBL  (0M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0-
M @ M"0D *04- "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$
M !D%3P 7!EP %@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P
MC"\  ($Q  !W,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I
M#@0 (PP) !\)#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+
M30 1"UH $ MI  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,
M '\V  !V-@  ;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P
M(! % !D."@ 5# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,
M#U@ "P]G  H0>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ
M  !T.P  :SH  &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8!
M !<3!@ 1$ L #@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4
M!A-E  03=@ #$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S
M/P  :C\  & ]  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8:
M @ 0%0D #!,.  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B
M   8=   &(D  !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P
M:$,  %]"  !6/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -
M&PD "1D-  89$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =
M<@  '8<  !R=   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@
M %Y&  !51   2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D
M!2 -  $?$   'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<
M(H4  "&;   AL@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+
M  !420  2D8  $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,
M   F#@  )1(  "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(
M ">9   FL   )<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !3
M3P  2DP  $%)   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N
M#@  +1$  "T6   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7
M   LKP  *\L  "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350
M1U$  #M-   P20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0
M-0\  #04   T&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   R
MK0  ,<H  #'N   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8
M #92   J3P  ($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X
M #T1   \&   /"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP
M.<@  #CM   W_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8
M   D50  &5,  !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/
M  !&%   11P  $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8
M $#L   __P!^80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =
M70  $EL   M9   "6    %8   !6    5    %,   !2!   40D  % -  !0
M$   3Q@  $\B  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ
M  !(_P![:0  =&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490
M#60   -B    8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0
M6Q(  %L<  !:*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3
M_@!Y<   <W0  &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T
M  !M    ;0   &T   !L    :P   &H   !I    :0   &D#  !H"0  : X
M &@5  !G(0  9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W
M>   ;7H  %]Z  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y
M    >@   'H   !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.
M  !W&   =R8  '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@
M8W\  %2   !%@@  -H,  "B$   :A   #H,   2$    A    (4   "&
MB    (D   "(    AP   (<   "'    AP   (<   "(    B    (@'  ")
M$   B1P  (DL  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8
M $B(   YB@  *HP  !N-   /C0  !(X   "0    D0   ),   "5    EP
M )@   "6    EP   )<   "7    F    )@   "9    F@   )L   "=!P
MG1$  )TA  "=,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1
M   MDP  'I4  !"6   $F    )H   "<    G@   *$   "D    I@   *<
M  "F    IP   *<   "H    J0   *H   "L    K0   *\   "Q    LPD
M +,5  "T)P  M#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @
MG0  $9\   6A    HP   *8   "I    K    *\   "S    M0   +<   "V
M    MP   +@   "Z    NP   +T   "_    P0   ,0   #'    RP   ,T,
M  #.&@  SR\  ,](  #08@  T(   -"=  #0N
M 0,$!08("0H+#0X/$1(3%!87&!H;'!T?("$B)"4F*"DJ*RTN+S R,S0V-S@Y
M.SP]/D!!0D1%1D=)2DM-3D]04E-455=865M<75Y@86)C969G:6IK;&YO<'%S
M='5W>'EZ?'U^@(&"@X6&AXB*BXR.CY"1DY25EIB9FIR=GI^AHJ.DIJ>HJJNL
MK:^PL;.TM;:XN;J[O;Z_P<+#Q,;'R,G+S,W/T-'2U-76U]G:V]W>W^#BX^3F
MY^CIZ^SM[O#Q\O3U]O?Y^OO\_O__________________________________
M____________________                      $#! 4&" D*"PT.#Q$2
M$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y 04)$149'24I+
M34Y/4%)35%576%E;7%U>8&%B8V5F9VEJ:VQN;W!Q<W1U=WAY>GQ]?H"!@H.%
MAH>(BHN,CH^0D9.4E9:8F9J<G9Z?H:*CI*:GJ*JKK*VOL+&SM+6VN+FZN[V^
MO\'"P\3&Q\C)R\S-S]#1TM35UM?9VMO=WM_@XN/DYN?HZ>OL[>[P\?+T]?;W
M^?K[_/[_____________________________________________________
M_P                     ! P0%!@@)"@L-#@\1$A,4%A<8&AL<'1\@(2(D
M)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&1TE*2TU.3U!24U155UA96UQ=
M7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z @8*#A8:'B(J+C(Z/D)&3E)66
MF)F:G)V>GZ&BHZ2FIZBJJZRMK["QL[2UMKBYNKN]OK_!PL/$QL?(R<O,S<_0
MT=+4U=;7V=K;W=[?X.+CY.;GZ.GK[.WN\/'R]/7V]_GZ^_S^____________
M__________________________________________\  0(#! 4&!P@)"@L,
M#0X/$!$2$Q05%A<8&1H;'!T>'R A(B,D)28G*"DJ*RPM+B\P,3(S-#4V-S@Y
M.CL\/3X_0$%"0T1%1D=(24I+3$U.3U!14E-455976%E:6UQ=7E]@86)C9&5F
M9VAI:FML;6YO<'%R<W1U=G=X>7I[?'U^?X"!@H.$A8:'B(F*BXR-CH^0D9*3
ME)66EYB9FIN<G9Z?H*&BHZ2EIJ>HJ:JKK*VNK["QLK.TM;:WN+FZN[R]OK_
MP<+#Q,7&Q\C)RLO,S<[/T-'2T]35UM?8V=K;W-W>W^#AXN/DY>;GZ.GJZ^SM
M[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     # 2$   $
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M_____\]T-0L    *4J?______________________________Y8T
M3Z?_____________________________]FD=   )# 8)4K'_____________
M________________RSL.$S5,6TU,7L/_____________________________
MJ6 V8(:?MJRIN-G_____________________________X)>-ON7_________
M_____________________________^WY____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________KV<J\Q___________
M________________________SYJ!;5I&B.K_________________________
M_______$?#XF$   5+#______________________________^"#/
M+H?M_____________________________ZQ3$       %VW6____________
M________________^X Q        "6',____________________________
MTEH"         %W,____________________________J#4          %S3
M____________________________?0T          %36________________
M___________N?44          $34___________________________\JF0O
M @  !"(W25C.____________________________Z:1K02@_8W^5I[K:____
M___________________________5LJRRS.3Z________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________ENY=W8LC_________________________________VYYG-@H
M HS________________________________(?S\%     %[/____________
M_________________]F!.0       #RJ____________________________
M_YY,         ".0____________________________W&\:         !!]
M^?__________________________KT@           !O[O______________
M____________A!,           !DYO_________________________L40
M          !7WO________________________^X%0            !(UO__
M______________________]T%              XS___________________
M______FB6A,            CQ?_________________________?FUPL
M       -NO__________________________[[%]53DB$0<! A$BLO______
M________________________W[^EF9B:H*R]VO______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________X[Z=@'S[____________
M____________________\K>$5S . !VL____________________________
M___2BDP5      !R\____________________________]9_-@        !+
MR?__________________________^I$^           OJ_______________
M____________P%H            :E?__________________________C20
M           (A/_________________________G7@              =___
M______________________^T)0              :O__________________
M______]]                6_3_______________________TK
M        3.O______________________Z4                 /.'_____
M_________________S ,                +=G_____________________
MF8IA)P              )]?______________________^V^B54G
M    )=S__________________________LJ==EU*/#(M+# Y1][_________
M______________________WFW=;2T-/9Y/__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________OU+O6_________________________________^>XCVI++Q5O
M_______________________________DH6<T!P     \R?______________
M_____________]:".P         2E___________________________[84Q
M            ;___________________________ID(             4.'_
M_______________________L:0              -\G_________________
M______^S+P              (K;_______________________]Y
M        $*?_______________________(T                 )G_____
M_________________ZD                  (S_____________________
M_T8                  '______________________WP
M     '3_____________________EP                   &K_________
M____________S@                   &/______________________RDB
M 0               &'______________________[FC@%<W%P
M &C___________________________K3KI2&?'5Q<')W@93_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________V[J=@FEIT_______________________________
MR)-E/1D    =GO___________________________]N.3!,         ;O__
M________________________VWPL            1=?_________________
M________BRH             (K3________________________"1
M         Y?_______________________]] 0               '______
M_________________^<V                 &K_____________________
M_YT                  %C______________________T8
M     $?X____________________Z0                   #7I________
M____________E@                   "7;____________________O
M                 !C.____________________ZP
M  _"_____________________P                    JY____________
M_________R<                   JU_____________________W
M              VY_____________________^"<C'!50C,F&Q0/#0X2&B:_
M____________________________^>38TL[,R\S/UN#\________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________Z].\X___
M_____________________________]*IA65(+!(!A?__________________
M__________&K<3P/        3^#_________________________U7\U
M        '[+________________________C=1T              (G_____
M__________________^0(P               &?_____________________
M_]5#                 $CV_____________________XH
M     "[=_____________________S@                  !?(________
M____________O@                    2V____________________G
M                  "E____________________N@
M  "3____________________W                     ""____________
M_________P                    !T_____________________Q,
M              !H_____________________T(                   !@
M_____________________WH                   !=________________
M_____]$                   !A______________________\D
M          !F_______________________)K)F)?79Q;&EG9F=K<'J,____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
MXL6JD7EA=______________________________=IG=0+ P     ,<3_____
M____________________X)).$P           (______________________
M___2<!T              &#______________________^YO#P
M     #?B_____________________Y8<                 !3 ________
M_____________T                    "C____________________K@
M                  ")____________________G@
M  !R____________________O                     !?____________
M________V@                    !-____________________^@
M               [_____________________PX                    J
M^?___________________S,                    ;Z?______________
M_____UX                    /V____________________X\
M           &T/___________________]                      RO__
M__________________\K                    R/__________________
M__^                     R______________________W%@$%!0,!
M   !!@T8R________________________.OAV,_,S<_0TM37W.+J________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________':QO______________________
M________\<:CA&A-,A@ %:O__________________________[E\1A@
M     ''________________________7?"\              #OC________
M_____________]]D"0                RU_____________________W0#
M                  "-____________________Q14
M  !J____________________F0                    !+____________
M________M@                     P_?__________________UP
M               9Y___________________]@                     %
MT____________________PX                     P?______________
M_____R\                     K____________________U(
M            GO___________________WD                     CO__
M_________________Z4                     @/__________________
M_]@                     =/____________________\V
M        ;?____________________]\                    :?______
M_______________7#0                  :/______________________
M<                   8?_______________________U \1DY465UA9&AL
M<'9^B?______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________[]6[HXMS6I7_________
M__________________B_CF1!(04      %+\_______________________W
MG588             !?!_____________________^5L%@
M  "-_____________________V,                   !>____________
M________G0                     U_/__________________H0
M               1V?__________________R@
MN___________________[@                      H?______________
M_____PP                     BO___________________RT
M            =O___________________TT                     9/__
M_________________V\                     4O__________________
M_Y0                     0/___________________[P
M        ,/___________________^H.                    (O______
M______________]$                    %?____________________^!
M                    "_7____________________("P
M     NS_____________________7@                   .7_________
M____________R1P                  -K______________________YT!
M              <.%\7________________________5N;S!Q\[5V^'F[?3[
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________XW\______________________________[,:EB&U4.R$'
M #+>________________________UY)9*0            "@____________
M__________^)-@                !G_____________________V8
M               R]O__________________E0                     #
MR/__________________IP                      H/______________
M____UP                      ?/___________________P
M            7O___________________R4                     0___
M_________________T@                     +/__________________
M_VH                     &/___________________XL
M        !?/__________________Z\                      .'_____
M_____________]4                      ,____________________\D
M                     +[___________________]4
M     *[___________________^+                     )__________
M___________+#@                   )+_____________________5P
M                 (;_____________________J@H
M 'G______________________VT                  &;_____________
M__________=5                 $7_________________________:B,K
M-3]*56!J=7Z'D9S_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^C/MIV#:4ZY_________________________^RR
M@UPZ'0(       ![_______________________%;2D               !
M_____________________X,;                   'R_______________
M____D@                      F/__________________I
M            :O__________________W0                      0?__
M_________________PX                     '?__________________
M_SD                      .C__________________V
M         ,[__________________X4                      +?_____
M_____________Z@                      */__________________\L
M                     )#__________________^\6
M     'W___________________\^                     &S_________
M__________]I                     %K___________________^9
M                 $G____________________2%@
M #G_____________________6                    "G_____________
M________H@                   !G_____________________]58
M              3______________________[LO                  #X
M______________________^K*0                #/________________
M________R4<     !Q,@+CY2:(3M________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________]-7)
M____________________________^M*PDG==0B@,  !*________________
M________Q7U%%P             1V/___________________\10
M            G___________________H@P                     :/__
M________________E                       -O__________________
MV@                      !^S__________________Q4
M         ,3__________________T@                      *+_____
M_____________W4                      (/__________________YT
M                     &G__________________\,
M     %+__________________^</                     #[_________
M__________\S                     "O___________________]8
M                 !C___________________^!
M  7___________________^L                      #_____________
M_______>(@                    #R____________________7
M              #?____________________GP                    #,
M____________________Z$H                   "W________________
M_____Z 6                  "<______________________]Z @
M          !W________________________>@L               5,____
M_____________________Z)7:'2 C9RKO-#G________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________^WC___________________________2HWI8.BDC'!8.!@  G___
M__________________^L4@X                 :?__________________
MY$,                     -/__________________>0
M         ./_________________S0                       ++_____
M_____________Q,                      (7__________________T\
M                     %W__________________X,
M     #K__________________[(                      !S_________
M_________]L#                      +___________________\J
M                  #[__________________]/
M  #G__________________]T                      #4____________
M______^;                      # ___________________$!P
M              "M___________________P,P                    ":
M____________________9P                    "&________________
M____HP                    !R____________________XT0
M          !<_____________________Y$&                  !!____
M_________________^M?                   =____________________
M___*2P                  ________________________RU<   P8)#$_
M3F!TBZ?'___________________________7Y_+_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________KU,W'PKZZ
MM[.PK:FHI?___________________]U^4S\P(QD1"0(          -O_____
M____________=@                       *?_________________N@
M                     '7__________________P<
M     $;__________________TX                      !K_________
M_________XP                       #]_________________\$
M                  #;__________________$9
M  "^__________________]$                      "D____________
M______]K                      "-__________________^1
M              !Y__________________^W                      !F
M___________________>(0                    !3________________
M____2@                     _____________________=P
M           K____________________K H                    6____
M________________YT4                     ____________________
M_XH                     _____________________]9-
M        _?____________________^G+@                  U?______
M________________F"H           88+45@X/______________________
M_ZAC=(&/G*N[S>+Z____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________GR[>IG96.B82 ?'AT
M<&QH99#_________________O&I(+1D*                 #'_________
M_________P                        /__________________T(
M                  #<_________________XX
M  "R_________________\X                       "-____________
M______\I                      !K__________________]:
M              !.__________________^&                       T
M__________________^N                       >________________
M___4%P                     *___________________Z/0
M            ____________________90                      ____
M________________C@                      ____________________
MO!D                     [___________________\4X
M        V/___________________XL                     O_______
M_____________\Q#                    H?____________________^1
M&0                  >O_____________________R= H
M   17_______________________Z'03'RPX15-B<H6;M-+U____________
M_______________7Z/3_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______OW\_'N[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M
M*"/$_________________TLE"P                    "2____________
M_____X@                       !F_________________]<
M               ]__________________\S                       8
M__________________]L                        ________________
M__^=                        ___________________)#
M            ]O_________________Q-0                      W___
M________________6P                      R___________________
M@@                      M___________________J08
M        H___________________TR\                     C?______
M_____________UX                     =____________________Y,'
M                    7O___________________\U#
M    0/____________________^'$                   '/__________
M___________87@                   /______________________OTX
M      X<+#Y2:H:ER/_______________________\)\C)JGML76Z/W_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^[AU\_)
MP[ZZMK&MJ:>FIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4
M_________________]<%                        ________________
M__\T                        ]O________________]V
M            TO________________^P                        LO__
M_______________A)                       EO__________________
M40                      ?/__________________>0
M        9O__________________H                       4?______
M____________QR,                     //__________________[DL
M                    )____________________W0
M    $/___________________Z,6                     /__________
M_________]A,                     /____________________^(#P
M                 /_____________________+4P
M /______________________I3@           D=-$YKC/______________
M_________YDY0U%?;GV.H+7+Y?_____________________________K^?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________KS+FLH9F1BX:!
M?'AT<&MH9F9H\?________________]A13(C& X&                GO__
M______________]^                        =?_________________#
M                        4O_________________[-P
M        ,O__________________:@                      %O______
M____________E@                       /__________________OQL
M                     /__________________YD(
M     /___________________VD                      /__________
M_________Y "                     /___________________[DL
M                 /3__________________^A<
M -G___________________^1&                    +S_____________
M_______*4P                   )W_____________________F"X
M        $"E&9L3_____________________[G\=#!HH-T97:7Z5K\SN____
M_____________________^>@JKG(V.G\____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____?7PZ^;BW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#
M/CHV,B\N,?_________________2)1$#                     /______
M____________0@                       /__________________?0
M                     /__________________L L
M     /;_________________W3D                      -S_________
M_________V(                      ,7__________________XD
M                 *___________________Z\B
M )G__________________]9(                     (+_____________
M______]R                     &G___________________^A*
M             $[____________________37                    #/_
M____________________EBX              !4R4G?_________________
M____X'(3   !#Q\O0EAPBZC([/_______________________\IO;GZ.GK##
MV.__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________^>#2
MR,"ZM;"LJ*6BGYV;FYR@I___________________@F162T,\-C K)R(=&!,.
M"00  -3_________________D@                       *W_________
M________S!X                      (O_________________^U(
M                 &W__________________X
M %'__________________ZD;                     #K_____________
M_____]!"                     "/___________________5H
M              S___________________^/%                     #_
M__________________^X/@                    #_________________
M___E;0,                   #_____________________GS<
M     ! O4'3_____________________W7(4      87*D%:=92VVO______
M_________________[Q81%1D=8::K\CC____________________________
M___2S>'Q____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________\^_K[_?______________________[KFHG9:/
MBH:"?WMX=G1R<W5X?Y#_________________ZT\Z,"@A&Q40"P<"
M "/__________________VD                       #_____________
M_____YL*                      #__________________\@Y
M              #___________________!C                      #_
M__________________^*#@                    #_________________
M__^P-                     #____________________56P
M          #_____________________A1H                   /L____
M________________L4D              !@Y78'_____________________
MY7L>       ,(3A2;X^SV?_______________________[M8*3E)6FR E[#-
M[?____________________________^SGK3%U^O_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______Z[^?AW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD
M85Y;65A75UE>97'__________________[\Q'Q80"@4               #_
M_________________^U6                      #H________________
M__^"!                     #,__________________^K+P
M          "S___________________25P                    ";____
M_______________W?!                    "%____________________
MHC<                 !2N4____________________RV$"
M#"Q0=I[1____________________]8TP       -(SM7=IF^Y?__________
M_____________\-C&"H[3%]TC:?&Y_____________________________^H
M?Y:HN]#G_____________________________________?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___=SL6_O+FVM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*
M2$=&2$M066:A__________________^G)@X' @                !6____
M_______________.4                      Z___________________T
M>0L                    A____________________GS(
M       .____________________Q%@                (,5J$________
M____________Z7\?           &)TMQFL+I_____________________Z=)
M      (7+TIHBJ[5_/_______________________]-U'B8X2EYUCZO+[___
M__________________________^N<H68K,+;]O______________________
M____________W^______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
MO[*JIJ.AH)^?H:.FK+3 S=WL____________________BEI33TM(1D1#0D%"
M0T=.66E]____________________GBX&                    ________
M____________PU8                  !5!____________________YWL:
M              DT8(NT_____________________Y\_          0E2G&9
MPNO______________________\9F#P   !,J1&*#I\WU________________
M_________^N.-2L^46B!G;S>______________________________^^=G^4
MJ<'<^?__________________________________TMCS________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________V\O#O[^_Q\_C]____________________________^+"?
MFI>6EI:8FY^DK+;"T>'N_____________________HY02D=%1$1$149'2U%:
M:(.I_____________________Z9! 0          !S9CC[KA____________
M_________\9E"@      !"=,<YS$[/_______________________^6(+P
M$RI$8H*FS/3___________________________^K4#9*87N6M-;Z________
M_______________________2AWR8L<OI____________________________
M________U,[M________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________MY>/CY.;H[?'Y______________________________VQE)*2
ME9F=HZFRO-#M__________________________^=4T=)35%68'.*K];\____
M______________________^R5@ :-5!MBZ[2]_______________________
M_______-;SY?>YFWU_G________________________________NGX.FPN'_
M____________________________________X\[K____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________
M
M
M                      #_____________________________________
M____________________________________________________________
M____________________________________________________________
M_____________P    #_X4#&:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.
M5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O
M(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 Y+C M8S P," W.2XQ-S%C,C=F
M+" R,#(R+S X+S$V+3$X.C R.C0S(" @(" @(" B/@H@(" \<F1F.E)$1B!X
M;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y
M;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO
M<&1F+S$N,R\B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM
M;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@
M(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(*(" @(" @(" @(" @>&UL
M;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\B"B @(" @
M(" @(" @('AM;&YS.F5X:68](FAT=' Z+R]N<RYA9&]B92YC;VTO97AI9B\Q
M+C O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY-:6-R;W-O9G3"KB!7;W)D
M(#(P,3D\+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O
M;#Y-:6-R;W-O9G3"KB!7;W)D(#(P,3D\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C(M,3$M,C94,#(Z,#(Z,C0K,#4Z
M,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^
M,C R,RTP,2TP.%0Q,SHT,SHS,BLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @
M(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C,M,#$M,#A4,3,Z-#,Z,S(K
M,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7!-33I$;V-U
M;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#IC9#0X864Y8BTT8SAC+65D
M-#8M830R8RUC9C<R,6%B.#=C,C4\+WAM<$U-.D1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z.3<T96(R.&(M968P."TT
M.#0S+3EF9# M-S5A-CEE93<X-S4T/"]X;7!-33I);G-T86YC94E$/@H@(" @
M(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z03E!-C R140M
M.$4S.2TT,49&+4$P03 M-D0T,$8V-31&034V/"]X;7!-33I/<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#HU-F$U9F$X."UB9#8Y+3%E-#@M86)C
M-2TS,6(T-S(S-# Q-C,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IW:&5N/C(P,C(M,3$M,C94,#0Z,3(Z,3DK,#4Z,S \
M+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R
M94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,RXU("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z-#<W.3EF.&8M8F4P8BTV930U+6)A,S,M-31D.&,T-V0W
M96(V/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(S+3 Q+3 X5#$S.C0S.C,R*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @,C0N,2 H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O
M;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P
M<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A
M;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.3<T96(R.&(M968P
M."TT.#0S+3EF9# M-S5A-CEE93<X-S4T/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 Q+3 X5#$S.C0S
M.C,R*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C0N,2 H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN
M<W1A;F-E240^>&UP+FEI9#HT-S<Y.68X9BUB93!B+39E-#4M8F$S,RTU-&0X
M8S0W9#=E8C8\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E
M9CID;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#HV,F8Q-3 W92TY
M93DP+6,Q-#8M.3@X-2TU,35D93 W9#$W-SD\+W-T4F5F.F1O8W5M96YT240^
M"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#I!
M.4$V,#)%1"TX13,Y+30Q1D8M03!!,"TV1#0P1C8U-$9!-38\+W-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O
M;3X*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/E-T97!H96X@36$\+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^
M"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@
M(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L
M;W)-;V1E/@H@(" @(" @(" \<&AO=&]S:&]P.DE#0U!R;V9I;&4^52Y3+B!7
M96(@0V]A=&5D("A35T]0*2!V,CPO<&AO=&]S:&]P.DE#0U!R;V9I;&4^"B @
M(" @(" @(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I9F8Z3W)I96YT871I;VX^
M"B @(" @(" @(#QT:69F.EA297-O;'5T:6]N/CDY.30W,"\Q,# P,#PO=&EF
M9CI84F5S;VQU=&EO;CX*(" @(" @(" @/'1I9F8Z65)E<V]L=71I;VX^.3DY
M-#<P+S$P,# P/"]T:69F.EE297-O;'5T:6]N/@H@(" @(" @(" \=&EF9CI2
M97-O;'5T:6]N56YI=#XR/"]T:69F.E)E<V]L=71I;VY5;FET/@H@(" @(" @
M(" \97AI9CI#;VQO<E-P86-E/C8U-3,U/"]E>&EF.D-O;&]R4W!A8V4^"B @
M(" @(" @(#QE>&EF.E!I>&5L6$1I;65N<VEO;CXV,S,\+V5X:68Z4&EX96Q8
M1&EM96YS:6]N/@H@(" @(" @(" \97AI9CI0:7AE;%E$:6UE;G-I;VX^,S,X
M/"]E>&EF.E!I>&5L641I;65N<VEO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" %% F # 1$  A$! Q$!_\0 'P !  $% 0$! 0$           @!!08'"00#
M @H+_\0 =Q    8" 0$$! 8'#P@2#@D% 0(#! 4&  <($0D2$R$4%3%!%A<9
M46&7&")6<974UR,W.%=867=X@9&6H;&VMR0G,C:4P=7P)28H*3,U.4)&1TEG
M@Y.GT];A-$-25&1E=':'IL?1X_%$14A356-UA;1FA+7#Q?_$ !T! 0 " P$!
M 0$            !! (#!08'" G_Q !T$0 " @$"! ($!@D,"0X* Q$" P$$
M!0 1!A(3(10Q!Q5!40@6%R)A<2,R55:!D932\!@D)517DY6AL='3U3,T-39"
M4Y+!X28G-T1%1E)B9826U-;Q0T=R<X*%IK*TM61V=Z2V8V9T=8.BI;/$Q<;C
MAJ/D_]H # ,!  (1 Q$ /P#^_C&FF--00VSS'F]177>M3G=<P3Y'75<T=)ZX
M?,+V^*YOLYO>\K:QK$#:63NDH-Z,1K=R((NY*-D;JGZB<!*>CD=IGBPFJJQ>
MJ+FJ"RR3^+V\+)JM9*ZLBO#8S/ED3MB!N@$8N\Y]FL%-C!.F:JQ6B:O?="H\
M:22D_")X3R/%3W@(38%6*];^+IJKL8M)M9.)D*;&6T@YME0NBO$$6M/5[M()
M67MYZ<\U#!M'VM+1#TKDLJSV:J])KNPV;;=HTY6E==E6H['XR860G:C*V!PZ
MFS:ZDV-348N#0ZLZX/ ([:(HR$TK*&,'%99M;&XNVU4#8;Q U%LK6*M55M8*
M%T;E4<>Z\NQ84U]JNVN#:D6+"<\A4;C:]@WDB;%5&3R+069RCU3C,3P[G3L"
MTE@[Q=C%\34F(K%5%/B:UZNRV'22Q^^^97./5_#2M1<A;4'%HMT^<AX*A0SY
MDUG'T:#CT9W-J"\.!&\2S6_,%'0D/WW!BHID,?KT['#V L\172IUVJ1TU2UC
M6P4B(Q,1$0(Q)213VCV1MWG7S/TD^D;%^C3!JS>3J6KT6+:Z=>I3Z4.8PXDB
M*3<8+$%C',4R7-/:!&9GMZ](\[N.FZ:'6;BC?Z[2Y*P,S+KTVVSD;'6*)<(B
M8KIJY;G7 BQ$C$,*;MN)VSA( 51.8@YED^&<OC++Z[*K7@DX&+*%F2&1.W*0
MEMO&^_D404>4Q$ZPX4]*?!W%>*H9&OE:E%]Y'6+%WK*%7ZQ1]NMJX.8F0F/M
MPD@*.XE,3J0;+<.J)'PO0MD4ASXQ4SH^'9HCJJ54 %,Q %V'> X&*("'7VA\
MX9R9HW8WWJ6/F^?V%D[=]O8.O8QG<*7+MEL=\^((-[B(YHGO$QNR-_./QQ[]
M9:VLM<> !FD_".BF 1 S:58K@(![1 4ES (![^GL]^:24T>Q*8,^X@*/Y8C5
MU=RHV(E5JNR)[Q*WJ.)CWQ(E,3^#5W3525+WDE$U2_\ =)G*<OS^THB'L\\U
M[3'G&VM\3$^4Q/U3$_R:_>-3IC33&FF--,::8TTQIIC33&FF--,::8TTQIIC
M33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,:
M:8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC3
M3&FF--,::8TTQIIC33&FF--,::8TTQIK"[]>HK7=:>V259S,J5L )LX2N1B\
MS89M\IU!O&0T6WZ*O7SDP=U-,#$(4 ,HJHFF4QPTM;*X&!4QS#G8%*'F,IB)
M(I[S$0(C!$1%,1$1.V\[1.U*NK,[FM0!',QK2Y5K'>!B2F(F>Y$(C$1,R4Q$
M1WU&[6W+9]<;,A7KOQVWQIII(B4L39M@59LE75UE3%*V9R;V,>O#0;YUWOS!
MN_3 IC )!6*;H VTJZL$/44#QC?HD7]DF(F2!#=N1K!&)(@B1GE[QOY:K-.5
M[$*V,3);2P!WE8^4,8K?G!<EL,%$%WGO$1WU>;MP_P!:;#O&U+W:[!L&2=;:
MIE-IDM!^OHQ&NUQ#7TW\)J7/TUJE %D(BSUZRF4GX^4=2DDD235,H=HHB1%!
M*NH315;62UJB/.U^(E6@*(MU,I7KUZ8MK,Y>05-IU*M6PAJVJ?70*F"0-L0Z
MR3>:S7LR ?8<+D>'W(CG%%[%Y0K,VT7($X81$-VXL&):@P"RS:><5&O%(?@1
MHV%FJC84'=_<RU?D"3-I=/;0BH?;\\A=)38S"<VSX42A\(9"*ODW,6B,)%#7
MV#1[).F1&0PQB1A+*'>&L"ZLI25*K5:]6D E-*DRG5L4DWJR#(Y'(^'M6(=<
M8;&6&LBR_J65(<J+#GVD,18<;9:5N&/+DAQUKZ<;5MT)D0A7@W4\/BZ4A"H:
M%:BI:W#).)N2<YZ#3;[Q-Y (W&O1\^G6=/[,N,!Z<F<5(FS5JD3LM!S#)5(Z
M2J+IA(-&[A/H?PE13\)PFLB8Z9M]#(W<98BU0L,K/&)&&+Y=^4O.)@H(2B?=
M(S[XUP<_PY@^*<<S$\0XVOE,<T@,ZUB#B.<)YA,#6:VK,9\B68S[)G:9C6Q-
M(T*DQ&D]5P<=5*^WB&^OZ@HC'A%,E&Q5%X%BX64\-5%0#**KJJ*G4-WC&.<Q
MA'J.:W7+5A[++K#6/:4FQLF7.13.\S,Q,><^R-H]T:LTL/BL92KXRA0JUJ%1
M8IK55I#I*6OL C!04SM[YF9F>\S,ZODSHS2EB 0GM0ZQF!$%NAY&B5=VJ07
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M 'VYKV_59C3[$VE_ID<A?KXV-_AK'KVQMMX+$?7ZJI[_ /[O3X@8[[N\9_\
M2W-?@_VS[/9I]B;2_P!,CD+]?.Q_\-8]>V-]_!8C^"J?OW]J_;Y3]&GQ!Q_W
M>XS_ .EV:]W_ .5?A^OZ.VGV)M+_ $R.0OU\['_O36/7UC]I8CW?W*I_T?\
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MRI*H.0=BBO >EE\4\<I*&*5P9,K98&KM=% _>N<!9RICD9 0"T3N3>I5YW6
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ME,00\<$_5?BCYI][_7=&FOTBCNCU@P%=WKH8L*RN23*D2P>G&N H'!LHR$R
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MLY)Q)#&\1.V\1Y3K6J/%V<"$BC!HKB/$616Z %C"LJ;!K\037Y5BF([A74-
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MT8JDPK&UV-=L$MG*14655>1RN R8 P_$^&CAWARAPM2K07*CJB[&XVNVVV8
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MX9_A2O\ G:?*$<)_U2NK?PZ/XOCXJ<2?<3(?DY_S:3Z7?1A'GQWPS'UY2O\
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MM_#H_B^/BGQ+]Q,C^3G_ #:CY7?1A]_?#/\ "E?\[5?E!^%'ZI75OX='[_\
M]QD?%3B3[BY#\G/3Y7?1A]_?#/\ "E?\[Z)U3Y0GA/\ JE=6_AT?Q?'Q4XD^
MXN0_)ST^5WT8;[?'OAG?W>M*^_\ [VGRA/"?]4KJW\.C^+Y/Q4XDGRPF1G_F
MY_S:?*[Z,)WVX[X9G;S_ &4K]OK^=JORA'"?]4KJW\.C^+X^*G$D^6$R,_\
M-S_FT^5WT8??WPS_  I7_.^F-/E".$_G_FE=6^7M_P G1]__  &/BIQ)]Q,C
M^3G_ #:?*[Z,/O[X9_A2O^=JGRA/"?\ 5*ZM\_\ QZ/_ #&1\5.)(\\)D/R<
M_P";4_*[Z,?/X]<-;>_UI7_.U7Y0CA1^J5U;[>G^GH^WYO\ L?'Q4XD^XN0_
M)SU'RN^C#[^^&>WG^RE?M_\ K:?*$<*/U2NK?P]\_P#P'M^CVX^*G$GW%R'Y
M.>GRN^C#[^^&?X4K_G:!VA'"@?9R5U;^'O\ X'M^CVX^*G$GW$R'?R_6Y_S:
M?*[Z,/O[X9_A2O\ G:?*$<)_U2NK?/\ \>C]'_@_TACXJ<2?<7(?DYZ?*]Z,
M/O[X9[=I_92OVGW?;:?*$<)_U2NK?PZ/W_\ O?YO/[V/BIQ)]Q<A^3GI\KWH
MP^_OAG^%*_YVGRA'"?\ 5*ZM_<G1']SR0]OT8^*G$GW%R'Y.>GRN^C#;?X]\
M,[>_UI7V_P#>T^4(X4>?^:5U;Y>W_)T?Q?'Q4XD^XN0_)ST^5WT8??WPS_"E
M?\[5/E">$_ZI75OX='\7Q\5.)/N+D/R<]/E>]&'W]\,_PI7_ #M/E">$_P"J
M5U;^'1_YC)^*G$GW$R/Y.?\ -I\KOHP^_OAGW_W4K^7O^VT^4(X3_JE=6_AT
M?Q?(^*G$GW%R'Y.>GRN^C"?+COAF?_6E?\[5?E".%'ZI75OS_P"GH_B_TACX
MJ<2?<3(?DY_S:?*]Z,/O[X9_A2O^=H':$<)Q]G)75OX='_F,?%3B3[BY#\G/
M3Y7O1A]_?#/\*5_SM/E".%'7I]DKJWK_ /KH_P#,8^*G$GW%R'Y.>GRN^C#[
M^^&?X4K_ )VGRA'"?IU^R5U;T^?UZ/XOCXJ<2?<7(?DYZ?*[Z,/O[X9_A2O^
M=I\H1PG_ %2NK?9U_P!/1]G_ !&/BIQ)]Q<A^3GI\KOHP^_OAG^%*_YVGRA'
M"C]4KJW\.C\W7_[CYOW_ '8^*G$GW%R'Y.>GRO>C#[^^&?X4K_G:I\H3PG_5
M*ZM^;_3T?^8Q\5.)/N+D/R<]/E>]&'W]\,_PI7_.U7Y0CA0(=?LE=6]//_Z]
M^;V_]HQ\5.)/+U)D-_=X<_YM/E>]&'W]\,_PI7_.T^4(X4?JE=6_/_IZ/WO^
M]\GXI\2^?J3([>_PY_S:GY7?1C]_7#7\*5_SM/E".$_ZI;5OX=_^!^]\_NR/
MBIQ)]Q,A^3G_ #:CY7?1A]_?#/\ "E?\[5/E">$X_P#VEM6_/_IZ/_,8^*G$
MGW%R'Y.>GRN^C#[^^&?X4K_G:K\H1PH_5*ZM\O\ QZ/O_P#[?'Q4XD^XF0_)
MS_FT^5WT8;[?'OAG?W>M*^__ +VGRA'"?]4KJW\.CT]G7V^!T]F/BIQ)]Q<A
M^3GJ?E=]&/W]<->_^ZE?R]_VV@=H1PH'KTY*ZM\O_'O_ ,#'Q4XD^XN0_)SU
M'RN^C#[^^&?X4K_G:?*$<*.G7[)75O3Y_7H_\QD_%3B3[B9'\G/^;3Y7?1A]
M_?#/\*5_SM/E".$_ZI75OX='\7R/BIQ)]Q,A^3G_ #:?*[Z,/O[X9_A2O^=J
MGRA/"?\ 5*ZM_#H_B^3\5.)/N)D?R<_YM/E>]&&^WQ[X9W]WK2OO_P"]K]?*
M#\* _P#M*ZM^;_3W_P"!D?%3B3S]29#;W^'/^;3Y7O1A]_?#/\*5_P [7Y^4
M(X3_ *I75OG[/\G1_%\?%3B3[B9#\G/^;3Y7O1A]_?#/\*5_SM>MCS[X92;Y
MG&Q_(W63M_(.F[%DT0FQ.LY=NEB(-FZ) 0ZG5664(FF4/[(Q@#WY!\+<1+$C
M/#7P$!DR(JYQ B,3)%,SY1$1,S/NC6U/I7]&MAJD(XWX<:Y[ 2E2\D@C:UIP
MM:P&"W(S,H$1CO)3$1WU+I-0BR::J9@.FJ0JB9P]AB'*!B&#Z#%$!#Z!S@3&
MTS$^<=IU] B8F(F)WB8B8GWQ/>)U^\:G3&FF--,::8TTQIIC33&FF--,::8T
MTQIIC33&FF--62RO&4?7IU_),QD(YE$2+M\P*D18SQHW:*JN&Q451!-05TB'
M3 B@@0PFZ&$"]1"K=8M52PQRNLH%$1J^;\^(_P 'Y\B,;S_A%,0/VTS&V^M]
M8#;82M9P#&,  .9F($B*(B9VB9]OE$3,^6T[ZYE<,-FZ_N>PV<?1^)Q-&PRU
M?L=EA+.&V-46L),LRNP4>J+TW7FQ;=*14O+-TV?IKZS1,<]:M6C>(](*5L1D
MEU$BZ46H8V%E6I8^O"(DK$37\2]H)"RN&5X4M[&6#D';V7M)Y=4IEDU+DB-X
M D9>17<A++$_89%Z "L9DELK?/."H2L>G,(6$# JB=IZH95ULTQIJ/7+CRXI
M<G/VO6Z/Z-[+C3RUL+47GJC6/['E*_FW&XT\]?PU<PQ_S7'*7S'RY&;N\A'W
MALVS= Z![O8/TAU]X9^J^'>^ P/G'[#XSV[]XHIB//M$SMM'?ZO+7\B/27M\
MHO'^TSO\=N*NT3,^6<O]Y\MNW;M[/+?:=1QZ?QAU#IT#V^?VWGY 'M_O^6=F
M/=M.^TQ':/?Y3/E,>_M$3W\YVUXB-OIW]FW:=_/O[-H_'VWWB-HU7W>X 'IU
MZ= ]W4.H=0]@]?H$!\O8&1MM^"8W\MHW]N_?W>[:-]N\>;O/M\N7:=_+_3[9
M^J9U4!]G3W]?W1Z^T>OG]\>@>P?;TZ CZMYF/;OY>^/KCM'Z;QO,SO$;[Q[N
MT_1&WLVC;S[Q$_3J@=X?8/O'VCT'KTZ>_J/4 \Q_BZ9EMO/E';;W3_'VGV>V
M)^K;;4[3/;MO]/G[O;W^F8C?7Z 0 >@C] >0AY=.G7K]_P!_7W?O8QO.\]IF
M/KG?V=OHF-_;/T1&F^V_E[H\YW\HGO[IC?ZO9MJ@B'3_ *QZCY=1Z^8^7OZ]
M?Y1$8^CSB=M]MO/M,^7NCM'X=O;&F\QV\]IG^*-OK\OJV]GT4'S /H\^H>77
MV>?7]_J/M\O, Z>67?>/?MVGW1/OW\IW\_/W1[I3/?MO'M\_?]/T^W^/;;3R
M$/?T#R\@\Q\A\^G7YPZ^SW 'N'(F=XW\ICSV\HGWS/MWVVC;Z._?29W';;M$
MQ]7U^?OW]FW\6G7S 0^CV>70/,//V] \@Z]0'V]!'IT#(G;O.WN[>[M[X[1'
MMCW]O9/=/E&\;>W>(B8B/H]V\S';M[-]Y[S0??TZ#Y"/7KY^?MZC[!Z?1[A]
M_GDSM$1MOO,1/;MM'EOV]_T[[3,_A3^#;OW[Q$;_ %>W;V=_Y=5]H=/;T !_
MB\OO^WH !TZCU$?;B>WO\O;[MNXQ/T>7EY^R)CO/X8\HV\_*(WGR[Q]7;??M
M':-JB(=1Z"'7V@(^SK[P#KY>[J ]?F#V9$^?EW]WT;>SW[3Y3OY;;=H[)G;S
MCOY;?1._MCR\]HC?R[[:H8#"/7S$.O4/?[>@^[_Y?,.3M.TSOMO[/+R]GGVV
M\HCV[=H[:B9F(YH_PMX[1/;ZOY_*._?50'R\^OEU$/:(_N^?L]W[ONZ".3O,
M[=Y]\3$QVB(GM/OVGVSY[SY3OJ8GM&\SM,SO.V_:/*-_=OM[-N\_A>73V_-U
M\OY.H>T?;[?:(FR/+MVWV\XVG>=_;VF9]G;Z/=.F\3OR[>78M]NV\?1';RB/
M=[]M?D?,/=[/W>GT?>[H]1]GF.-YG:8[=MM^VVWU^S>8G;?;Z/;J"GOW^GR]
ML>S;\/GM]/;??=U#Z/=T]P@ #[QZ^7EY>_W>_P \CS[SVW[?1VV\N\>WW]OI
MWB-(GSGV^S>=OY?/;M&TSWC4LN&VA*_R$W)#TZZOIV'H_P"9)3\Q7T!4D&SR
M873AJTW34.QD$6Q'EA?1Y';A=JHDWCR/' B4$>^7C\0Y!V+PURU4A!9"5-#&
MKL1,H;:56L7B%VQKF1&G4LL !.):T%($H)@SKZ'Z+^$J7&7%M#%Y4[B<&)K9
MF;-"(FU6JN>C'UI7)I>(PS)W:-9C92P4+<;V#*EEM?M></KU.[OMFOIR".K5
M-77II6MBRRMGB*8FWCWDV6+:#'3<\W=-!E)1%1-W&-"1[UPZ 0(1L/7[6I6X
MEH/PF-RA.E1Y>N44E EEIGCQKFUB?#+^R,A#%&MLP0P,1)2R(COVP]$V;CCO
MB#AJ:96,=PODAG+VG9"KBA'#.M*"M:B[:!E=;[-:PAJEPIA&PND*^;>!FSNG
MLSJJE7K='Z );)C8D)O=[K:&B[E>*LBPEZXSJ+FSK>""T%7@6L)01,":2#\W
MI:*"HI,@-U[GC,9Q[=*,9;RXU0QKL'ELGD#J4[!.KG0R::*S 1>XN@4,DFQ*
MRD3((Y]OMOLG%OP><,NIFJ7!7K6SQ!2XDX>P^/3E\SC!J6J^4P+\O:DY.A0
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MFE4XAX@H8QC.%\3>R(ILOMUINLQM+)LQH7IK#*W.0+A%;'K0*^IWV$=M18Z
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M:+$'QFJ@@8H' .F4$^CVHJN=2<C;-3,(S!S$J2)^&.^[(K;!#']D59=/LF#
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M?KC6?:I(HOM/6J*":BJRM_IR:*213'4544L4:1-)),H=XYU#&*4I2E,8PB
M ^0#1R4Q&.O;S$1X*U)%,S_B#F9GR[1Y^[V[^>N[PM$EQ-PZ(Q,D6=P\1M$R
M4S.0K[0,;1WGV1YSY1OVU_H,113%BXTIRF*<L>S*8I@$#%,#=,#%, ]! P"
M@("'4!\A\\_)9_;%_P"5/\LZ_L:KLI<3Y],/_=C7OS'6S3&FF--,::8TTQII
MC33&FF--,::8TTQIIC33&FF--:VVC5&-EKP/':MI\>JJKV6-9U6R3%;=24@Q
M8.R(,':L0<%'S1?QC +)RW>-S+ DL+191),@T[L])3+(@UIIK7%BI;""#&Y5
M;4;,P(G\\%/,TMY".NT0>K9BQ*-Z/GE""D16Y]0S*0@BCPMM%M<#,R,\IL0
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M=!V96NM66,5I X-=V\"5,R$^EN8_!U FN5C7"L'8[3C(B8JDNVU;='<"TC;
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MQXH3P=6S!N(%*N\0QRXE;7,D$THR3.4*RK3H(#8A360QZ89KMXO'57/$\;6
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M8N<Y9  0A/4Y"*&$(R0 4QK.?@M>BP5\YJSBPY8F#/,3$G$'"]P&*TFS[),
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M,7HIL*6Y09XU. &+,<Q/*2S&" AWK;[2)1,>7GWC7J^17X3?_A^T/O?#\_\
M@GZ _>S#Y2N)MMN>C[/]J1[/+_PGZ=_?.L_U+OHLWF>EG^__ "Q__P W:=/D
M5^$W_P"'[0_A^I_@G$^DKB:?,Z/Y)_\ W._X??/OU/ZEWT6?XG/^>\_LQ/>>
M_OK?3/;RU7Y%CA-Y?Y'[0\OFOQP_DB,CY2>)?^%1_)/_ .YJ/U+GHL_Q.?\
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MQ+R3#:_QGW;5\[J=R\C!8O['5&%+C'LO<R/BG.V>4U_;JO&OFA4TI&4>I =
M^DZP-O&8-;2KMHW:+K ;67NHW-@?CVU9Z%9PN3W&R[J+K6!!T4F[<NK=6U*,
M>]3A7;=+*5@*A*Z=1MRJ?45:\1)ML5/#LW(!1!/8LB5%I,SU8B!;.S:OU*J=
MFU!H64JCW6N]- 5_CON2<OD_*LK54HR.EY]Q/;"JC-O 3R5RF[!#6R=CB0,M
M+5MO'218^6&7>II+QZ_35:$LD/72M6)5Q3PWQ8B$QS6 9PTO#)##2J.DJ49!
M6 QP3>$P.E)VR&M8ZBH35YF*4&06XW9X,5Q#BS:Z/UO99G"NO1D3.2,EGC+N
M2N/.M*V>L4]!!6*I*)S)<7+A=49BYS%EJ%;HM(DY36Z41,7^+A4@V#=[Q%1S
M:&I3JT2:2#<PUVDMXB,F46I'"[B:G$H=586*%;23D^9;&PRIGETW%2=DSL6*
MJD3TZJ\C>FV=S*O@8@SM[6W(J0.RT1:OVS%UIU8ZFZD5>MZC&PN;B\9":KNM
M DR<33"L*<<@RYH%5HE[VYY1.4U4U!*:MFRLL*X$\<]_<6M$7RK7I>G3]T>2
MJDM2Z=%7BP2=/3?L:RPC%W[VW2]52EXQQL.RLW5KLB;>NR*,([EETFQ9=5-5
MT[Z>5N=?'5UX^NM=I4WC37:4#6QZ+5B#I8A#EA)V*6(5S"EQJ2Q_.0=- <G)
M2KICUK:?9<<U7#76;E@)6+CDLMG8RCDS(BJW?!]=34R]XJBJ!0YD3 1%F6X,
M<HXNS<=.4E090\IROINWK;;]MTNV<K=G.M%'I-^;/F-W@*&R<:LDX^/<SR1*
M^]0%E1J^5C(0C8[E622[Y#X8TU8K*4E5R8[!V^'WX7.ON"-C*KZK:5Q#*6\Q
M#II9)3K(3+ZBW(YZTI45B'UK-]I9:CD8MC%:ZK,8_(8-50IBFL<=%BFHK<;+
MDI/#O=2E9 ]JV68<-HHKR#[9L;@ES%E-Q1]JJ+'C;*1=<YA7#E-%['NLS;C;
M(FZ]=]<6BJFT[*,HJLI),6U+<3B4#7+4E87K->N-8E9>HH.8=RWFN/40ZO3J
MJ+D)F+P''F! %&2HSD<5Y/)WZN2MN(&1C[*E9,D7%=') RPA5I+%*_68V[5A
M-AF6D0A49D. ;.YKZPXBYP>OA6O9157U%S91D&</'D^O#*9P5R]0),G<7D*<
M=V/9?<SIFBP]#?5?0^K$H[01-?3=AU[O6\KR=RM\=MH=EMTI(\=IJFR<="2S
M7OP2TPVFUI>(.N+YNW>D2%FKV":GIIB :44;G!%M%4&S6"W'"_#SL#<4VRJ"
M*K-N7S>48(L1!+BNT#$^J-1<Q(6UM*.I?L<9,9=-(6&U XFRI92K*TLF!L30
MV"H8$Q0M"):LDEL,2<I/9UWNK7SB#8X_2^KXV$U;>]KW#:2-LY&;#W%:(-?9
M, K%*KU"QW;5Y%+F8DLLO8/5\@WIC)J=P#%'OJ)'?+ZQG:[=Y7G6JNX%R7#5
M2W62L+M6Y;RU;*4BY.;9@XZ*IH5<*Q#)*\QP5U @4'3M U]&!+9UN>+,/F;"
M7-9-2UC\=B;6*LJF9WZ!7(LUK)U5I()]5I4U[3LD].L=?=E-NBE:_P!I5\CJ
M"?;/)73U:H;;M._]L7:O[AK*6UXG9OP:N^FI2 :UO5+"P$A48.T+5V:NPKIR
M,BO$H1358\>IKJ/;4QV&Z5:O#Z%_A"UD<,9DZGDIX3&%):K*N!EFH#%LNMKU
M"J6?#NL*%UJTJO(MZ>0-&0RN;<PC"OE?CG-*XE((?B XMIVT]$:26 JVVDZQ
M3+Q/B:RW1C%M\(M[Q96GEPPXV;TU.\Y7R^V&&FJ4UY W]&ZU2E:=6GY5O214
MH</57C9]8Y9A6VDJ)7,:*[<6-2A_8*ZAA%8&Z&FS7 N%9P06'OM];B!HVC"$
M* ,R<L4F%]1QR2)@()L, 2*&'"AZ@BO4-B9S=+*S70E2,7A:3ZP;D3'XFS<9
M+>IL D+EV9F>9?-$2I/?PY.LQ=@M ;0V)Q6UWI>EUJL,]W\;7]YI$XRM]HFZ
M*RC)F:ZLV-F(@>G7F OM,FX1\>97B92NO8VR%2;-6,S"N 4?(]*Y;F_DL7Q#
M3$45[5&A1M"\(<RAX8J99&C8I3R"QX,QZ1"$V:+X58)M>\"RF&D@&.G*XRPZ
MW8D<J.:H6 :"'9-$E?FE?7;63IJ-F+K1 VJN+KOKFNYCF- 15GK3A+O9SL!1
ME;8#2=DJT3O.2Y"P>ZV\[,0^UWZDO6S1SS1[^JA3GK!A4@6<.JJWMB%R=-TM
M=%;08T0\FF:8/SB!<U  5;GC*/&N,158R3K\1UN*BXA.NW+.Y!.DVDW.(MV1
MZ62BWD,35M)*F!0A6OF:1'S/Z49&> W6F5U=.<-9X05PVJX>/7+#BVO*_%LF
M N"Q\URS=Z&%8%>SH,UOLR.8<#58"NHZ#XELQ@=%\@=7MS,]]6PR0S&V;Q(V
MNJR"8*\<P.1G4&3Q"* ZHN'!O1@79 T$W<+N8;6H<!-*7,P/ N,ZOES7>%+-
M)UVZ4Q.XSD8J,*)C=@%:,288A\^\%JO%D72B! .+<_G8"-B*<=E<0[&UZ,E.
MT<R6/%IQ(DJ1JJ$1DCYER7T9V<>YZ[R)INX=R0\'931;JBW..F83DYMA!IJZ
MUUBD)4J3KC'5[.DP=3V=$/&7I_JVP2S^HK-4I,4I" E?0R'7Z-6PBG=RKT-?
M^N+_ !':59<L7E<J\0NFR5)E1C.ECRJM(!FP#+8N&JMBT5W,ZJ>+<4VS5J5]
ME]/P>%J6JRYFL*V85L&NX%I4$VSXCI+8=5@*Y#8T"L-1]B/;_-/@-=>1/)JH
M;;20-L#6CS5\%J^T:_<[^V3H@M+>U^]R=P;[!B/@! 6%OL0\@G, UEJ?.!71
M5/7H@S&T,"N'9<X^'7-#+9&XPN6;-O Y3'9 >:PW&W<$%N$USQK"77N5C>Y5
MU#/$5V5WS;%HVE6 !/6O6AL8G&4A6$S19Q(%NM*P#UG5X@K85$A-^88RH2 Q
M3JYCX:RIRKHG +96W=H&^<)>3-6V%';!D&V@GNMM2[8WCNB4V4[+L"Q[?OE*
MV+1)B)&D/:K 1+)\VD*R#DD7'232XS?I<8BT6)%-W+10KJJ1A7QC2O\ *D:W
M#/$'#TJK3(KO,S&2=:K92P\07%*0\2(W!\/9 #7-@6K1NI>Q(]6R::D#)W<I
MP?E%,<'--!O#U?'U[=5 ,:PK 6(I-MJ.6 UK'G6E1L9#M1:X^<;)#DMI;=5(
MUG9-:RMWO-6UB:-VAJ[D+"WB'A(S4MYCK9%:6V0;6>C=43^HYN:;IK1CMQ,3
MNP-EQXJJK3KEZ,4V]8=J5/1CZ)<D$5#.8[-7!!Q+H\0L/#LP3O 9JI'A&3CE
M5PL0NE0FM#1JO?#3M/B><E]4<Q8(C: 7,3G<(B87^O\ !)LW&9$'OQ=R3N1%
MUM]@G%^VHVHBQ4K&J%1T9L,NS[W!5==4!MK"@4>G7IE;=C3LTWN/)39.Y8ZM
MN-GR.OE+7(O)F^:V=-=I0DL2F*RKZDN:E1%D72S5I!VV#<'EI>4RK.76RF(D
M6$.+HJP"F].NH'#5H9W-\07:D)DBEMM=C(+KXG,KM5+-2+=UQ(-*:M$<(&'4
M\N%L6'9NO=9@0L%R6+:,+7P&-L0T@D*:8I#,VJ+*N0K,.E5DX:T^NF;7++2.
MVMB6+3UWUU6]7[.^ 9;A$VO56V9J0J]1L<?=J^,$M/,9MA5[L+&:KQSG=LVS
MJM/DG[<ZS$CN,55(^2Y)IYW9-<@,U<OAG8B7$7,[%F5VO<5>KJVCQ![(FNY,
M.JD:SW&P$QM-I11%>G).<NUCL@C) "8CP^1E==M=M*US3NI4]3KUW<KX2\ )
ME=X[CKE);>S Y00$W;3ZYUEQRNA)C6G'*KQ-OM^W[34YQG8M.[:)LZ5=A%MM
M+7 6;(K J5,KRS:<,Z3CVB#UP4I!&.#M5LA*;('"Y6M/&6.SL.4?V>QCZ>$K
MXBU#!F!A=O(,2ZXU?4:N)ML2;&\DM8YU,Y2:A,0WAKBO%MJK"?"5KO$(/"I%
M=9F4LJXZ7J<+"E33;15*UIZ@]'>6T]+[!J;'F-;=UJ:3UE=]S;LU1MSA>XBM
MAN]@W"4W5J/5-1KU<JK*G2E&HTG,S<L\UJ60>0%.?S<A+UB;F8Q9)LVC7$BZ
MYB9<NKA*.,F&<1T^+.*<M4K0L2"Y@N(KZJ^3!S.:65:?JK(LI9>VQ?@\8%A>
M1?:4"0D;#V5;#@;D9Z6!+@?!\,9>TV(VH92D_-92O;K#(."S:K93*,=A1@1N
M6GXA'0J,=<*NCH>^TC;H3AU<]0TR,JLCM*WZSN;61&1>*4^M3>SMAL)-Y9Y>
M2D8V'L#J-8N;)-R#D%4XJ4<(M"(MRD4 A3!CQ"H;:64<7N52L%+'X_Q3.0XQ
M^.Z"$-=*U2,V&HKPY\ I8,LM:<0'-MK7PW<8B]0RN9DXLE8'(7XKCUY6XYET
M5$=1HR=>IN%*M)N(@JI7N1D,\W,.*X-\Q&&OM^58=+<:"RVVN%E X[I/3;ZM
MCQN_V!5(61KBEGG2+\?R@E%,64N=_%G;I+OCK1+=H8K87GIK*]=<#UY05#,#
M9XYP_%%1)Q'376J)QXWQ,HF9&S99C![",@476D11".2QAC;$T<WA,HP.L&-Q
MN0IV1@N6;!.R5C(4P$)$HE0#;)#)8<R,( A$NILNFT^STY+VV%W&\@M0<9/7
MVWN-_%#7B4 ^V98(V.H^S-!W.]2TQ)QECC=-"M)Q;AO88*PQLL:!CG3Z3B1A
MGL2W(FA-%L3>%5Y%A D2ZOI4QOI 3,ST6E1'#\)U+^*+EZ@CTYX;R&+7MS+M
M5N(#O[5"HMH9"A*C=BJ])Q0#!X*XEX1LP,=11G?MY)F,R2BF1*&'.3&\]9 1
M5&XT:H-M^,&W2_55X6\K:3N&6VTKQ^XRUZ(><L&7(N8?P&];E-6:+IJ>ND:Q
M:H.+9(<=V#F5F9"22DY[T5N^9-Y1:56:B1)?HNIRJQU\90IJ<38IX[&^D&O:
MA"C:;D\2B_P'*@#$V1462I:J&07.D82<?-(;.7BSF# Z_+%YZN EQ#W0I<V^
M%[0N>3+$BR(!PG%1+I4/(BNLV!L1 -I[,>.KWV0L]:6".L;T\5B[Y58Y_KW=
M-=N=HT] J7:2LH5_9FKV>CZ?==?R$RZDS*H!M/:=TM *)*,8L@QR"B;3H8R9
MC#/Y3DAMT,*3,@AB[M"W&/KRJO2&]6BE4"TH+$[J3CSL'"V!?:!I4;\N('Q:
MS<,"#A:,E?,<?:B*=]#;ZE*M9"*30:YU,F8\5]8;"ZR>JIE5)>*9RRTVWPTW
M+>MY['>MVFKYO6NT=QZ+W;';6GYR8:;>TF^TZTIK.0HU+K;>LOF$Y$VE*G**
M1<R6YU8E<=6F>7DX&U)&*W5JX=DTSH%8&$G@\OF,O6M4YCK9Y>5E[(Q.7$QV
M2E8VF8JS9$K0V<%7K45TZM@9NQORCPMUFI6$L&_PLSA=]9O*M6,.2R+$YJBR
M(85AR;-Y>4548"#7EJ\V!O=)@(3I6:XB<N'M#VI7FW'WBTI*W#F/#;[AO2=W
M3A62E%CW40NXCY-8O'515M8#D@2$3:I(.V(FFW9C.P!F8LAIH#*:WH^4_P"Q
M'PU:N6,H*-F!(V<OE\J 4R+I];HCEHI[L!$$%$&1 "Z%(PMRHW<;L0QAQQ#B
MUTL?+0@"%ZL?BL9SV>4SZ2VQCBOET^L0N;T9YYCKS-GEEQ^V/N-;BW;Z'7=;
MJV?1>VV.PI:JV^8>,X(8]2FSL$[C8:?8U62754C)*19+LP-!1Z;U)J"W6/53
M3($[LK9:S>K[65MX>XBPHFZ9KNEF3/'.J6)@>OR24T#0R>H<UO%R\8LPHD.Q
M$X=AK6/=,UG/MXBX$+CQ"!.BUW64?SJY$'3L$8S C+NC"9A/5ZJN2C3LQN:D
MY38C7KVK\?\ 597''7DOJ.W;(H>[+I)V*5L>W]VTW<]5D#Q2&FJB]<PS+X#&
MITL 6QK*,F5WF9:(>%6C"LY3;3Z=3%Q2Y3.:=7T.'70MA("_;]%[\AXVM8LK
MV.DK/HRU@QN*4]M-M1(FBT+YE&YS@LW;=AG:<AGO2)?98E2W-HTN.Z3::(0M
MFZ[#\')5V@ELA7NS56,^&DN8>L'#3C!*:%TQL*K2E(94RS['E)">L->5WUL;
M?\<]L+FNM:\O*'OMV@*?--&4FU8,$C1$; ,O5J+83>G2#E0%R;,D06L:K'J,
MF)7-^5J8H4%7"\_K,05A1DVR74EKY?L@8-\BNNJ1,VT*4N3D/'6)B6@&.3UE
M&4PX,?!R# JL@EU8B6DL5<]@I  ZKF1 B'/':79[\S;11*W0:*35%0C(#D+2
M-BQ<B7;DXO::]4JG49N!=K(6A?3+B1LR\B^GECM*I: ?^KX)LI!JVY\D]!=I
MH%C2;B+#@0P\?4SBV):'/6L1;K)11QU]*O#KO4K'A@5DWK"B\ZCV+@6V BRS
MIB]2TY^NMUN%Y.O4KUS@OLJ63F!RMR_389,9C;:.F!4Q)E]/K#EN0*4A%*?1
MN_A5S&V^^K\@'&/A[ N$N'&]^,MM;Q.^[=&PTY-;-?Z_G:A8VT0UXZ 5K#5.
M?I,@_&+6<N7QUK2X71DR&8"1]KRR0R%/C*JB65_C(GA@J)L+K,QMWA_-7[D6
M)9'3@YBK?%M<E@J1LTTK,2$^LO+$W1QZ.'565C;]1\2V<JX1&$A?QUKAX\-<
MJR,RSHMR/7A5KJ>( *U)?)S>)($Y51],[UXW4?D*&R]1:BKD-MCCWI;1VOZS
MJ+8MAV)8+7M&G5.6I2BCBM+:BH:!4IY2?!ZK)A(+GCHZ"(I(&,B<5F?0S=E6
M93D\?6 EY#B#C[(Y_'52A<5J]#)IQ$O78M$8 @<8G"G8-\J%!BTB*%$O[+S<
M$J,.'#MBRP&UN&.%J^+RMTQ9!W+%5]DU-%*@>UDY"Q;&N-8>J_J.* ZD=M=A
MM)T^3U]I_5]%FER.I>HT*JUV473$3)J/XB%9LG8IF,8XF3!=$Y4S"8W4@ /7
MSS=F+2KN5R%I.\I?;>Q1%V(P)A<IE';8F1L91["*8U3QRF)I5P:L5-Y)-B0F
M)!!-,FR@)CM((D^D,QVD0B8[3K9^<W5W3&FF--,::8TTQIIC33&FN>G:1?G5
M:4_;;\=/YY#[/\?(.H^[/7\&?V_D]_O?S'_PWT_]_N[Z^,^F_P#O?X6_^T;@
MKV;_ .Z<_IO[_P 6NA>>0U]FTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQ
MIIC33&FM(<B&.[G^I[,CQ[O>O-<;-*W35A[7M"L/;74H]!-0IGPNX]E.P0MW
M)F@*@RD'2L@Q9N?#6>13YN4Z(U+77B$DIPJ4+AFWV"'LK[3!!5:[GKI?S2,B
M3TN66T@0CS=0;52:_.<6$L=)+(40!3RB_P#P"<L.5KE=I@UJ<EFT\PG,CR%
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M5FBHL6CK"(WGW?R_@CSG\&I6ZC_.HUC^QY2_;[?[6XWVXU$^<_Y_/\.OY_\
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M\,4_ZJU,^@?CV8_V?N.X^H\S_GXMGZ//?V^_M'?D/PLW;HAOI&^7WF_NC?L
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M #167=+@^V98=1X\,B@J^9Z(B];))@V!98F>JT'G((2$#T1%92/SH*9ZC+6
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M3/9=_$M6,,\ !CK<XZ,#/G2$/)A(-&CAN)H]105")[4U^O;NU1/;PM:E861
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M28@.=66);#99!+-52@FH*P"%,8J(5:8THGGZC!'K3,CL1L+YTSVU1.&BX)7
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MBUBHM)!!Q&2OJI1TFJ9)L]!LL3T&5PN9;PKPPA-#)KLU<AEGN6K'M8\ )R9
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MDK]0G+(2FM;>B)A9R.MC[5MO K<PZ^^'6^]&.QUA8VUII_JS?-+AA8OV[0S
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MBBMF.Q$DO E+"N+];J43 9)N0! B"8%K_%[.2HTSALN2SK8&H0EC[A1T.&1
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M$8//565&(P>35-*KPI4JP&+M0"U<#W[60X6*!Z'++<.=M]:JV8DQH2-*9FN
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MH=3\H? 'W\\'_P#2;"_]=T^ROXM?JE- _7'KO_I'CU!G?N+EOX.N?T.GRA<
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M&I+.%#*N%4V,<@V:D475,958Y4@,JH8QSB8PB.;)(B@((B* & ")F9@ C>8
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M.<,B ")F!B3+U;RC$E,#$E,1,S$1WG5S^Q3[5+]<!K/U?1G[_P#:E^[D^O\
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M]R?&CM/X1BM)S7:*4F(CFP%,YD).E0C!BW Q@(45G;NK(H) 8Y@*45%"@)A
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MVSK*?1[\((1ZA>F*A 00!)3AD0/.<\H!)3C=H(R[".^Y3V&-]7'[%/M4NO\
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M;-K+,E63E:*F&)TWD;(HI+G,T?M#D7:KE(LB8IR%$.1=IHOU7TK$$5>R$J<
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MW(_A*GDO$JW>C,W0R\C853YHY#]7!479@J4S*HM"32<IB)+^@N\[3EJ=8Z3
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MO9C66L'Y%.:?"7;6M^:0^L)8(5"D=IMR(YYK4-NTDF352,6J.T*;7ZAK$'*
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MD0-384U3 *88HHVUM7\*W@58M4?"W'+J]A,HLUF8K%0EZ#V*5,Z7$2V#W$2
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MJ'=?Y;\:CM[/Y=_\T:IZI[03],#AQ]4&[/RX8TU7U3V@?OO_  Y^J#=8?^W
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'IC33&FO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g428534g56j49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g56j49.jpg
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MU2,W.4%9=7:1D[?8)"4U-E&T)C(S56%Q<_"AL;/_Q  > 0$   <! 0$
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MIF2XV.WY/$TX#2Q2N2$,?)2>$+K<F&)* Z\XO)F66(HFB.)DR^V\KJY*KLV
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MFB-DIM4W_9 XUC"_*79\LIEB-+$+5%&Z+>)\AK9_C;&,.=$1&'4Z&W.7A"'
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M% B72$=LM68)DNK)./!:Y/ME]F#M0VY80#!6+[5@F%:0N\*](]A^U7F'/Y7
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MMDFWGP?V7>0,3>N5/D_72CZ<=C_MQKWX3\=3+#ONUT\9C_1*>V2;>?!_9=Y
MQ-ZY5([0O@FNM?7:O[RK=&L^XY\#L#JBP:=NKEFLU2GRH-6LD*; GRZVX-H8
MAJ";;9GO*BRR#):$VXEM3HYY*5(7E;;@JT6IJXM1G9RC<X3L"1O7F34671(2
M)I1C@@N(A+I(D,47G%:Y?M%]F5M3VFW+9_=,06G \:3LVQE;<<6$;5:;U'9D
M7>U2&)$9FZ#*Q'-.1;R<CMH\S&.&^0J2!*;545(X_)^NE'TX['_;C7OPGYBN
MIEAWW:Z>,Q_HE=0]LDV\^#^R[R!B;URI\GZZ4?3CL?\ ;C7OPGXZF6'?=KIX
MS'^B4]LDV\^#^R[R!B;URI\GZZ4?3CL?]N->_"?CJ98=]VNGC,?Z)3VR3;SX
M/[+O(&)O7*GR?KI1]..Q_P!N->_"?CJ98=]VNGC,?Z)3VR3;SX/[+O(&)O7*
MGR?KI1]..Q_VXU[\)^.IEAWW:Z>,Q_HE/;)-O/@_LN\@8F]<JD=J+P376O2V
MI.PFF*G9]QRZIV5!U(!?I9VS5&6='PJ9(L4D4NK2X5"&PA\EYRS$,3EDQIEM
MU#<7##4;+;JGLK!P5:+?!ND!AV<K%V;8:E*X\R3@C'5U0W))'$05=\:$I">:
M99:53->7XU]F3M3QWC39ICJ\VG [-XV5W"]7+#C%OM-Z9M\E^^M6QJ8-W9D8
MCE2)+38VJ,L<8DJ"0$3RN&ZA C<<?D_72CZ<=C_MQKWX3\Q74RP[[M=/&8_T
M2NH>V2;>?!_9=Y Q-ZY4^3]=*/IQV/\ MQKWX3\=3+#ONUT\9C_1*>V2;>?!
M_9=Y Q-ZY4^3]=*/IQV/^W&O?A/QU,L.^[73QF/]$I[9)MY\']EWD#$WKE3Y
M/UTH^G'8_P"W&O?A/QU,L.^[73QF/]$I[9)MY\']EWD#$WKE3Y/UTH^G'8_[
M<:]^$_'4RP[[M=/&8_T2GMDFWGP?V7>0,3>N528HG@I>N&O.M^Y>K@.S;@?U
MYO(U63MO)$K+4W[;#F50F$+#45\C'HD05#CNR0$)$Q$\&3<=9<DI9=86MMQK
M+QL&6F+:9]G:=G<DN+C3CY$\RKR$R39BC9I'0!15:%"U-FJHJY*BJBIRK$/L
MQ-J.)=J.!MKD^TX);Q-L_@7:W62+%M5Y;LS[%YB7"%**Y17<0OS'W0:N3ZL%
M'N$00<%I3!P1(3C/\GZZ4?3CL?\ ;C7OPGYB.IEAWW:Z>,Q_HE=5]LDV\^#^
MR[R!B;URI\GZZ4?3CL?]N->_"?CJ98=]VNGC,?Z)3VR3;SX/[+O(&)O7*GR?
MKI1]..Q_VXU[\)^.IEAWW:Z>,Q_HE/;)-O/@_LN\@8F]<J?)^NE'TX['_;C7
MOPGXZF6'?=KIXS'^B4]LDV\^#^R[R!B;URI\GZZ4?3CL?]N->_"?CJ98=]VN
MGC,?Z)3VR3;SX/[+O(&)O7*GR?KI1]..Q_VXU[\)^.IEAWW:Z>,Q_HE/;)-O
M/@_LN\@8F]<J?)^NE'TX['_;C7OPGXZF6'?=KIXS'^B4]LDV\^#^R[R!B;UR
MI\GZZ4?3CL?]N->_"?CJ98=]VNGC,?Z)3VR3;SX/[+O(&)O7*GR?KI1]..Q_
MVXU[\)^.IEAWW:Z>,Q_HE/;)-O/@_LN\@8F]<J?)^NE'TX['_;C7OPGXZF6'
M?=KIXS'^B4]LDV\^#^R[R!B;URI\GZZ4?3CL?]N->_"?CJ98=]VNGC,?Z)3V
MR3;SX/[+O(&)O7*GR?KI1]..Q_VXU[\)^.IEAWW:Z>,Q_HE/;)-O/@_LN\@8
MF]<J?)^NE'TX['_;C7OPGXZF6'?=KIXS'^B4]LDV\^#^R[R!B;URI\GZZ4?3
MCL?]N->_"?CJ98=]VNGC,?Z)3VR3;SX/[+O(&)O7*GR?KI1]..Q_VXU[\)^.
MIEAWW:Z>,Q_HE/;)-O/@_LN\@8F]<J?)^NE'TX['_;C7OPGXZF6'?=KIXS'^
MB4]LDV\^#^R[R!B;URI\GZZ4?3CL?]N->_"?CJ98=]VNGC,?Z)3VR3;SX/[+
MO(&)O7*GR?KI1]..Q_VXU[\)^.IEAWW:Z>,Q_HE/;)-O/@_LN\@8F]<J[E\Z
M)7S\IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2H&]F/\8,+_9<=_2!?F N?[I'^*'^T
M==[V8_8](^ZLG\VA5'GF.KHM.*5D#=5L+WFL-"93GGWGH[/D)0KSLB/EA+\=
M'B7GRI#*I,?#K&/\*C+S6%(QE:?'/NG/^0N*JB<.=4RS3[:9IFG.F:=U*QY7
M6W!KURVAW8 Z>I511:<1Q6W514S1HT:<47/K"T%D2Y+5#*#DX3*)$J&\RPZE
MM;3R\)\VXAUQ]IM;:\*RE:''(LA*%ISE*LM*SC.<>+.8*!"B*HJB*F:+VLE5
M43\J+5=J9&?,FVG@-P5(2!%76) +9F)"J(HD(NMJ2*B*FM,TY\O&!!)1'(C$
M)_)+#BFLP_)QA_#B496I'DYSXO*PG&<^+Q_/\V,>/.<8RT%JT9+JYM/;S1,\
MJ++C)&Y9O@Y-I0]]GV&E5TH6>7-FN2KEP[>5>ER!-:8=DN17T1F9?H#DC+2O
M,)FX2XO,7+WB\WE_"&G%Y;PK*L(3E6<>3G&<P421%547)%TJN7#5Q7+/FSR1
M>%5!D,&8M"ZVKAL\H%M"3>$QF@[U SU;O42#JRRU+EGG5;FOF\+RWZJG*7C"
M<Y2B.XO.,J=?8PWG"$J\3V'XDMI;.?$\AR)*0M"51G\-S;L\\M!9KQRR[JJG
M]:+FG.F2Y\RY44N$)4U<K805SR4G!%%1 ;<4D4E3,%!YDT-.P(7FE$E1UO5:
M,X\6<XS_  XSG&?%G&<?-_\ G'CQG_\ >,^+/^;DE7=>.*59W=P5;3]QUZ5L
M\.R$$$K*E$.%5@,NPDG<"HSA6>O$*'G#F&V(4=UU2\YQC.<83C]]G&.6<FZQ
MK4[#.2,@]\_I ([)/FJMBKIJHAQ1$ 57/[U7H8.NN,;-B*+:WK9'*-;%5YZZ
MSV;=&%9CB1(X[][L5)Q]P11.TBY\R5*?V@^EOHCO'[I;!_:Y?=.EJ][7;R:_
M7*>MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW6ZGM!]
M+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM
M=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW6ZG
MM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6
MKWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW
M6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQ
MTZ6KWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP
M-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#
M^UQTZ6KWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQO
MWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W
M2V#^UQTZ6KWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].M
MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW6ZGM!]+?1'
M>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K
M].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW6ZGM!]+
M?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM=
MO)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW6ZGM
M!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6K
MWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW6
MZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQT
MZ6KWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-
MYW6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^
MUQTZ6KWM=O)K].MYQOWVP-YW6ZGM!]+?1'>/W2V#^UQTZ6KWM=O)K].MYQOW
MVP-YW6ZO8SX0G0:'F/74#:U6%K?8:FV.RZPL@ZNA&'G4,Y)'2;;4E(H/%RO#
MI$K);3!%Q$NSR+\:#'D26HIC2S9IO0N,=O-$-^1 ?;8:151-;KF1;ML<\S<5
M-#8YF:B D22G['?: H.<B?PI=90MN&Q;;9BBV2;C., 4TC0(JFV4N8Z@J$:(
MT2R)3RA'CMNON-MG-V',B$(D6? E1IT"=&8F0IL-]J3$F1)+27HTJ+)94MF1
M&D,K0ZP^TM;3K2TN-J4A6,YVL2$Q$P(3 Q0@,50A(23,2$D54(2145%15147
M-%RKASS+T=YV/(:<8D,..,OL/-DT\R\T2@ZTZT:";;C9B0.-F*$!(HDB*BI5
M1R:J=.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI4#>S'^,&%_LN._I OS 7/]TC_%#_:.N][,?L>D
M?=63^;0JT N+*;:2^Y&?0POQ80\MEQ+2LY\?BPEQ2<(5X_%GQ>+.?'XL^+^#
MF/R7+/)<N[DN7RUT)'6B,FQ<;)P?K@0Q4QYOKA1=2<Z<Z=M*].,95G"<8RK.
M<XQA.,>/.<YSXL8QC'CSG.<_-C&,9^?D*G541%55R1.*JO,B=U:SU5O8C&P9
M!D+(BM5M33$,2X2QEF.Q&2YYQG&?5K3B)4N<X_.)2GD/.R)+B\)0PC"4IN-\
MB&!("HC>2"&K@B(G%/K4R4B52)5S525>"5@$LYNP9T<YK;I7,3-Z8,94-PW=
M*":_ZR8DTRP+;$5H% &V@',G"S)?(V[M0!,04X'Q)3%COQL2,SL-.IP_FR>*
M1'_["YZ-,CJL2GXDC&7,,RQ\21YM?SMX"^@@@:,\D5,U+N[WBG8\"3>9HO'(
M@1<NU239#?EO2PF*TKK@.JWN%,54.A>;;OU<-ZRZEL1MYO(%-F2ZVA"N1K[#
M-[E%6I+L89B ZN0TO,UN1E]33BI1.7EUQ7HS6%D)2)KL%V4I2?/#(C43,=6&
MU.<'(4\\A05S1<T7/+B:]SZY=2IJ_P"5$3+AG4L*Q-1";!R2L@!;--P3: A#
MNHK.D1WAZ8S1,"^#2(NB4\;R.(I(-6&,34X'>%R!TR=B<<;(YEM25(6[+9@3
M8S<=.,PY/G'<N3\27<^<RXXE*6\(1YSSN*:%V"BHDNHT+4B\ZH)(B<RYKF6:
M\<UYNWG5^Y&09@2FY#+&X@G'1DFD409.0RZ3BY/-:008ZM FE!%54M2H.BLA
MF["F3"4:7('-K8BX90X/>>PMN1B-/GOL-ON>C(<7F-")SAK3SN')BFWU/3)4
MMW&<9JE(5215%-*<%!5X+D1*B*N2+P$E%%7CVR4ESSQS&'F6(KK+<DD-U7"&
M0 :2;WL>.V:MCO"$=Z_%CRG !18U-HVRRR'-@;RUS92E-,8PY(<QAMAAI.,Y
M4KQ)2E#3#:$9<7GQ>/#32$J<5G*&T8SA&+=5U+GEQ5>9/\JSX(C+2(1]BV*J
M1F2\$3-24B,B)!%,^)F2H*)J)<E5?1AM>?.>)"\^:QY3OB3G/FT^6EORG/F_
M>8\XM#?C5XL>6M*?_F5C&8?X<]3J0IIS)$UKD.:IV2Z5+(?^9=(D629KI%5Y
MD5:CSN'_ ,_:0_U[=_ZC%.:U?_W39_X^9^9G71<&_8_CG^0V+].1JO?+2K.G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*SY[71J.MMMZ8'0X@$Y8RK>);[CM?%MI@92
MX;8:B+?C.O/$HD5AB.W*<<DN9;QC"4Y7R\6$ZF2*329,J^XFHE5EM-&2NB@J
M0JJF(H(H2J2Y9=NL &(X+B$0,S%%9XVV(2LMB-QE$K^8P3-X0<  C/.FXX30
MBT.K/-42OP1UW81$,I))^@0GAAQ^O)&NR5*)$R<9V(T\V'CLLNH(M(]-9=P\
MT]A#C/EN->6E&>0<A/-"X3F@%;=5C=J2[QQP5%%1H414-$U(N:+DJ<4SRJ,;
M$=NF/16HN_?;E06[CRH&D2+%BN@\;93'#,"C$6X,5 PU">D3TJM4A.CG!0I)
MA]##T1!@L"F>AJ?E*&D0C0IPDW.4W'RPAEA1F&PF2R^_'>?\ZAEQ>$H4N5R(
M\VWO21%%'762TYENS91M7$/),D1%=%-2*HJN:(J\%6M%OD&7+6&V1@\L.'/9
MWR TDF-.*8,8F!)S>$9I">,FC;;<!O01BF:H-,Y4#3'EKDMQXL9+XJ.U.DR$
M,P92C<;T\:Y&DJ_>+CO#/*)N2%>0S%AH\J6MAYQEEV58SJ9ZD$116Q0R)$ M
MZ.MM1)><5;S<4ER013LE0E$5JA=X3FE&B<==5N6X;#39&^TD%WD\H7&T[(7&
MY6486TU&Z\JHR+@"9C5&Z.9"9DY6X/(L1A0P]Z6*E9E1W@99QJ/$+,Y6TP[F
M)B8\S!D>=::?C2W6FWV4)<0M4[L1UK5FH&(M-O:FRU"K+JH(N)FB+IUD(%FB
M*)JB*B9U1A7R%.1I!&1&<=ERK?N9;6Z<"=#$W'HAY$8;[<-G(;T&;;K($8&2
MB0IAW+6LS3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE>,XPK&4J
MQA258SA2<XQG&<9QXLXSC/S9QG'S9QGYLXXY^>HHJHJ*BJBHN:*G!45.947M
M*E9AI/=EKZP3$CXD,I<= RI"WBU @-N3[%JU<AW+DNP:KBXRIXA6<+6Y+.ZM
M:SG+>,O$]?)CDDOU2RW5JNTFP$C8@Y*LQ*JN0P13?MZDN9/V\>*N1\U4GK>G
M-FKD/(]4=_"XXP/:=J+*R77HEEV@M-H$3$$@ACVW%2-B@LV_%;JY!&NFD1:@
M8J/Z]4"+B%7(RMW:V=C:?<:ML"L!;I23PRSU6Q06B00Z'E-S!Y"&[XTX<9>;
MSGQ+;<2XQ)CNX;D1)33T64TS)9=:1T^-)CS([4J*\W(CO@CC3S1(0&*]M%3M
MHJ*)(N1"2*)(A(J)XSO-FNN'KI.LM[@2K7=K:^4:= F-$S)C/!DNDP).(D*B
MXTX*DV\T8/-&;1@99)RO6,IQ2O&5)QE*<JQA2O'Y*<YQC*O)^?/DX_ASXL?/
MGQ?P?Y^*44I*<8RI24XRI*<95G&,94M6$H3C.?%XU*5G"4X_A4K.,8\><XQQ
M2O/CQGQ^+.,^+/BS_P#C/_IG_P!,_/CBE>,J3C*4Y5C"E>/R4YSC&5>3\^?)
MQ_#GQ8^?/B_@_P _%*\\4KQE24X\:LX3CQXQX\YQC'C5G"4X\>?\ZE9PG&/X
M<YSC&/GSQ2GCQ\WSX^?^#Y_X?FSGYO\ U^;&<_-_FQG/%**4E.,J4K"4IQG.
M5*SC&,8Q_#G.<^+&,8_SYSQ2O/%*\>4G"L(RK&%*PI6$^/'E92G*<*5C'\.<
M)RM&%9QCQ8RI.,^+RL>-2O/%*_.%)SXO$I.?'Y7B\6<9\?DY\2O%\_S^3GYE
M>+^#/S9XI7GRD^/"?*3Y6<9SC'CQX\X3G&%9QC^'.$Y5C&<_P8SG&,_/G'%*
M\\4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2H,=B7V(VT LF2QB5&C@@K\
MB-GQ>*0PT6*..L9\?S>)UM*F\^/YO$KY_FY@;DJ)*!53-$;!53NHAGFGWZ[M
MLY!QS"\YMIQ6G7+A-!MU.=MPH<00<3+CF!*A?>K7R[Q#9:C#\1\DHBE&&##T
MAC&<SHDXZD[#RPT\^IOQLS684M]I^.RMUR+F'F1Z)(D)7;J^*(@HFI%UHXJH
MG9HKF\3)%SYB055%3BHY9H*KGL26-XR<D;SDSR)#<AMMN*B,/,6\H#R.&V"'
MD;#C[ $VX8@#J/(WOFFU'\8M541%D-1P/HDIX>Y#Q+9'CEJ\ZKS*G):D/.K4
MV])<:<SCT-V*U 8F+BM,RL1F7G(;UK)40-*J.2J@BO'@N?%>"JJ?\.G2BJ*(
MN6:S="KJKK9.3]\T$D7E9.1)%-":T%E";$4,&A,/]N+QR'&!=,VMZ8#6S[G4
M)\MR<[74JE2"?IDUUX6.=S-CKL1HDMK*42V6XTE(R:,BKE81(S/7!<8F(4TX
MF1B8GF2)25OLE+4N8"N:;PRRYT1%TD**62ZE%4)%SS2WCV6\1V1CC<EW3<7<
M, $F0&X=&VP8J&BJT9.M+*8E.BTI-I'%\7&50Q5NO7BQU%N&-5+#0)KLJ,2]
M*Q%#BXSPR5F;8&ATMQ#'HB9CC$.6(=4,4ZW!E(C(\[*3)1Y;<-XT@CJ 2S0L
M\@!%%=3B"2Y99JB*"Z572J)Q7.IUMMW)Z0C,R0P+3L96E=FRG0E,HQ;CDL"3
MF^5D7'F9@)*0"D-$ZNEI6R42]*K;5WXV(T@.MI.6V$HQ$%C$LQ'F$6S")#<=
MR2K$Q#;YP9,3$F.92XH>Y&=D9PI,E;?-*F2@J9HG,(Y(J;[BB9]DB*X!:27G
M%4SYEJ=+1=&W%=;FH:ZG%+?2I*F\!E:%5LG!;165)N!*85YD<Q22+HM<%:2V
M ;=%$Y4Q)AJGBY1MPC.'I98B)2EOT=8Z>.<;6K$ H->;=5'0VWZ,J,^_!<<7
M%DO-YE;>$."CJ%7-1#DB9(F6DAR^M,5SR3++)5%<T5:NKA:'9B(XT\D>4U"2
M,Q)4S>5=6\&3'DB8HLB+* @1PB+>HZVW($1>: DK8]DIR$1VWJZGR&H@S"O(
M&P7GLRHL+T6<VY(>FXS*9FR%.3\2E-1WVUJ1'<COX9:D(BCC/#-O@@AS"*KF
MB9$BKJ3-"7,M7!>9%1<D5*#EMO*DX07%<R>E*B+)? $:>?WL<A;!E=V;#:"P
MK.MQLD0G!<;UFVM6/M]3B3$S' CF%QI AR!B,)#,*CI&O!Y:WD/L.QWTRWY4
M4HEUUUV5E^/,CMYRRAA3:XB\TBY[OF4%'( 3+2H$JHJ*BZE5#1555S0DYLLJ
MHR+/=W6=P,X5%QN8,C>RYCB.K*"8R($#@N@K(-.Q% 0%K=N,NDB.$X)#5NGZ
M3&AQD^CIE9FQ!WK!N"%A-RVGFY]5GS,.3)DA?I6%-ABC#L:3&\TL@3E.(7(&
MN1_-3*XPB)PSU".K2 ZD74R19JI+FG8%P)/KB7+L53*D-OO;KSI*XK2,O2>3
MD_.?)HP./=F&=++#8[G(IL0P=:<UI'BM HM2A=UPUW_+'3MH:3DBHOH419.S
M-^CX8;C)Q*CZUDQY[R&&GI"&T2IS4B6E&'592E_"<Y\>,\U'$2B4NSJ":4WT
ME,LD3LD@DA*B(J\%)%7G[==HV?,R6,+8W:E/;]Y(UL+>*9.+NG,3 Y' C(&U
M,F8YM,D6@<U!51,LJ_7+&E.*4XI3BE.*4XI3BE.*4XI3BE.*5N=W:+;D!^OO
M*/% TD$=KZ29N3&GV.$-+SJX5ACVY&/--3(00C6T.Q&G'8R7$%226FX*5--I
MRBW!%;)A=\XT3+K.\=)#?!MPV'1!"X(0,N,(HHJBBHXYD@9HB:4&%5&0W<02
M!%FMSX%Q6+!:<8MK\J&Q<XCT@FU4C9>G1KFHO$(N*)1(JF4A1(EN2MT.9+E#
M7F"SS9JPCS,NLS9S,JNPU"+(),C9@U"FD+:*MC16 TE_S"%2/3)4KSZ&58'\
MGZ*+O7'=+BHZ^#I1S-"9'=/MNMF'!%1U ;W1%I35J(LT%=W5LF"A2'$A;R(!
M0;=(A,W-A@V;B\DRV3(,IF22&HE$*3+Y:TWO"1M66FMV1CRBJ-G9,0(*+ 1O
MI<]J03V$_%?R]Y@>3@W\ ,!M^MXKN$N(D@VX2IZ6%)D-.D5-I2\RU&\_)E2>
M+3;C+>HT5R:HKJ40<":RVRF]%<ES905-$[)%<5.R1!S*NYAIZ?+ASY.YCFW&
MPX#H(&\D17\/7"5/+D;PYBK4\GTCD:*V81D)5 S<T-?@[<:R:KM:K4O,MV%3
MY0?+SL/_ +-)L,-8B)".)A/R6%IBNQ)L1+8I<YC&7!KRY*V&WVO07#TJ.ZQ'
MCEJ48I-9D'8D^*MB#VA2%4%1(<FE,>+:ZE%%106,"S7.#<;I<V=T#]Y:F: ?
M^JM6YX9CS\%7VVG!5T7F'E*6,=W(9("V+A-GOQM\NWUW,BU$1;)5AHG3D5,:
M+*RH\UYM;TR"A.6EPX<.-$#!PL%#$1IS#TUR>B,XMR3EV6_%IE)8SD&VCHHY
M%2.#;A":HJF"<%$ 06FF01!1=1J:"JJ69J-RS9[EN[5&E.0W#BWDKM)E1&76
M (09?54)'GWW7ILR:^3CQBH,#'5T4!K0RV]J7F.K;:<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2K*0*34DPM7K8,E<;Y:I#L*H4@%AE1@[*8
M2A4J0MR0MJ&&KXEMQN38;.8?B P,)27ITM+KT6/)ID9JXU'8:.3,D*HQHK66
M]>(<E(E4E06F6T5">?=46F0XF2*HH5ZQ%8Y+-NMSG1K-8+2V#UXOD_6D* VX
MJHTT(MB3TVXRR$FK=:X8.SI[R*##2@#KC74?J7UR)=?ZK:7K)8DF+KLHXS;K
M@' O2XVN*T8Q"3$R.I(60EGQN.-81FS7"=$CG;R5:P6)1AL-D2"#]!PW8W+-
M&?5]_>RISHR9+;*D,)AS3IW<1I<N.7^WDFB/2W$1UP0%&VF_*VUW:3&VAW6U
MC;;:L.R89@'9[-,N ,N8DN<+?J\DB^36U/L1)52V6=AUR!8HAK#BNR7CESYD
M.!?7/OEK?K'KK1FCI>CM>V>G6G9UH)7.-L^Y,1ISMJL^U;;6!T8+$TWZ/(@#
MR%DJ"C3)A4T<0DL3(DD(0%P4ND-CKDB99\<U3A^W[?D[5LLW7GPHA1FQQP_8
M"FB<QP%OB4R<SL^UMNR+2S7NQD?7MBL$;&GW,,#6;3:.NA0^#]*.1I(W7UDB
M3V3C4R4.M*HYCGS+E]KM9IS<>YGQX+QJ\W+J[W@M=_H>U$7^E"]B:]D;B'P+
M!'VG9G1DX+=]PZ!L(1 NM9T_'Q6:\9U=JPX'N>NI1JU V+.^.2/)DH\\G8,*
M9IEE]KM=Q%SYU7+BN6:=KCEVJM0OJIWVLTO02-V;/HFP8FO]DZ-V;<52=DFO
M18=VUE<*B0V/::@+%Z/K;A,/LH8'-GJ70;63F-ZM/&"X$7:LU0V+'4A15'+@
MF7/\F>:=OG[2\.;\NQIO7?NH/WO8[K2ME4FLZS+[V@;#56QEG("7CM2D;/ZV
M.V9JVAX&M/0CUA(:0I6^J9#26+E,,E+;2,^N6%B1YZGJ@F62Y]OXD[BY<<^[
MEG_CS5B>S>HW;DWV$.[FH>PJT->%WS89C6Q4KM&\J(BJ7>L=*U.4U^MOT<R#
M$US+>B]OQS%:'SI8@N]8JU*?;\N;/<"JCFF67VL^;M9_YHF?[+FTKK)V?N_5
M.GT7<UPJ.R-]T[L)U@WC-G&[8X2HUC=T)M/2M^O(VM%8^IJX7HPW9[FO;Z8
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M3=BF8@1)GJ+AFB*F?%.%=LV=76V0K$^S,N,"(ZMSD.(U)F1V'% H\04- =<
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M!55,^5RQ5%3G14(T5%XHO-Q145."U1?E";/_ /N\'\SC?U?D.B,K_G'\ ?\
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M"F/O$!<:4-GQQRG/,QDH\Q$=C6B3V$G/S$A-B#P/(D='.Q9<?;42=8(FR$2
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M7BY7T>F0?>;&$"EPE!)4B :@QQC,R2(B9KX]"6()89+D85,\Y-0E]M$>JMU
MFHK;D1'.22Y4QO-Y4;-R4;)$#P"VA$T.X!,@=;(NRS-,T1+(<%269MWEQ;X4
M7HU8K-A^23=O I4>+9F9K+<B"^Y+-EJ8\EPD$KC\.4RVJ,Z6%4")RZ >Q9T5
M9&[*0"0#TDJ6OIF]QI^!F6[C*V'%6..Q\2E WB-?%O"_,CW1PJ9YEQAG&6U1
MUN.9549OCS;Z/FT#Q.NS'9HFC>4HIPJ#PZMRIL-DWDVK;1:51.&G-:M;ALV@
M3+85LCSGX#42)8(5@<C<J0K*UAUY),!U6DGA&N,L)>N2,F6QK%QQ=2.((HD>
M'LM*==4PVMIA3B\LM.NI><;:RK.6VW'DM,)=6A'B2MU++*7%8RO#3>,^1C"+
MEFN2*B9KDBKFJ)VD541$543G5$3/GR3FKHX(: ".$)N((H9 *@!&B)J(04W%
M 5+-1%7#445$4R5-2^OD*FIQ2G%*<4IQ2O&<X3C*E9QA.,9SG.<XQC&,8\><
MYSGYL8QCY\YS\V,<41%5<D3-5X(B<ZKW*ESU.Z<V;L_*AW*T+*U#KY'D>4LS
M%6^-LNW5,.>2Z)H\E/FY0BE*6E3!C8#&42B:/.CJ,YYY;UH#;1AK"S]_(94K
M>1K,)?[05)N1<LEXMQ23(FHBY*+LQ.R<3,(BH2E(:X_M<VS6O9<T]9;4D2\;
M0W&\DA.BW*MF#T,<PEWUI=34R^(BHY#P\XA-12TR;\.A M4WZ$*K5*U1JX%J
M%.!"ZS5ZZ/CB@8$+#9'BQ8^*CR&(L.)'0AIIM./&I7B3Y3CBENN*6ZM:U=JC
MQV(C#4:*RVQ'8 6V66A0&VP%,D$1%$1$3\JYJN:JJU\[[M=KG?;E-O%YGRKI
M=;E(<ES[A->.1*ER75U..O/.*1F2KP3-<A%$$4011$R#E:L?3BE.*4XI3BE.
M*4XI3BE.*4XI3BE<_)OA%])%Z[L]_6P^R[#N&M:Q<[/-J4.&PS'4,JE$U]>H
MUA)'1[QUB#2R3.UM>#Y9X;"/$Z[)-$'#5<C8K-@0/5'++BO,O;_;M_)_56'@
M/";ZBGD*\+)TV[1#IBNNY52 -=,6_9$S9$5A@R0I%6J]:%$1UG;13DS+A#(P
M;*@N1@1V!<:MKL+K@J.IDJY]Q.VO#]EK:'M -!9,X"*@;*68C6J[U4O!B:\*
M%R58DZRN6:3L8Q9A@59(L#!4?)"IVZP$)D)MR/K785)V%&CRJB8D%(*FE?ZO
MBSSYLL_VX+5#0N]U1MM*W#L<I1;2+J% [":&T/2VARQY>T7]SLIK?JK;M2'I
M 65($0JPY8[+VJJ=8?$S#,O 2%%2</3QOG"@X*IES?&BK\F?^58$0\*+HENO
MP+L$ 7R3KZ 9+C;M9B]<F!,@T ^F5\[L$A  2AHC-.W09J^H1%D0!/%8#L*F
M%(\>T2[ .&5RP*CI7/+A\7%/^;3][CW:HY'?CJ!KX]N;:QL!>J;;1H&9$V42
M+!X2R9L'HLGO(47A#(T6WDA9)VA2=8[4=2-#X;*GD/1UUN+99)-EI"H9+P3N
MKP^^B?\ C]N?>M:[M:DMETK=(@5_8L<C<[[N;7-))$ZV-A!;?;>OFUA^G=N0
MJ]-6?6],<J5CDF"ZVEQ6)Q6DTN]V\'$)!:F5D,J*BI^3/+M9IFG_ )[G,O&L
M2V/X1'KMK"W6ZD%D7,Q:*7.>@$A]7!B"F7UP:YN.T%E193E@AQ8Z@PW1FQ?6
M$$N^**^>B#%0Q\N*=&RI"F2_M][N?;2JJC]ZZ#L.\[0A56OFS&J]9Z4L>V5[
M%&QYQ O:Y]"VEM+5&QJI6M>Q1R[%)DU2SZHL >.X]YDG9#C3\,,$=')&&#*B
MHJ<.W_GDJ+GS9+GW:IJUX0_KQ>Y>(-(B[ O4J:5G5>OOT^F_A2 N%V$ZOB;J
M*:_J=Y#$9U!-W.-J<DU>1P1BTX7:Q.",6DNV4P),"X*F2_M_7]I5[OW\LTJR
MV;PF76"L39H^2]>2*X@4S;)2Q52;>8SKP"2W &G["QF44AJ>K'I6@MP(B14M
MJM,YFDOKAUIY)VJ8/*9+_A]_N?U?%QYZLJO"9:7'6/8KMD&%!6L*D+U>5IU^
MC/0R$Z]#KXO>F#-BAU)2X9*%7*[#T@8(1?1'BUG-#)R9B*S$2A#+JHZ>;NYJ
MF7QIEPSYNW6XZ!W5U/LF[4NB!Z]L4>;V-G8KFO9%BK8P6.N4#4=I&5/9A0!*
M6?><D0:8;(P\%\.L1YBHV$3H$2:P[#7(5!47+/[6?Q9\4SK#3_A&.O\ 7IJF
M)(S:TD9BQ7T U:8^NR+%2(,:ON2Z#?K"$L)62-@V(+6+1%)CR;5>64L#:!N9
M: 2XIBL/'5,E^+FS_J_S3XOCX+6N5>%'T\/(7HJ:J-TSK$,)KEFH-WK<./8I
MU\I<[2NRM^V.\.5C#P^<! "-:ZJMMC%0E/DK,?@P&HK(&+928NM2E,ESR_;G
MR^_QX?;^+C5\LGA.^O@4H,;'J.F KE>-W4G,;%$6"TFB1WKT*J]OJ K$%^&<
M&6VQ:SO@V'%.F:D8BQ*S,(O#5IG XY532O<_;A_FG#GK(!/A&]'$C,X;)"7X
M&.@6&BTB18#D&L0!,2_W>X[MH2*>3E*M:XPR8+MNA[=6DE)$G(2S66;6JY2R
M%C,VBLPS2HZ5^WS\V?:3/N=Q<_Z\LEJ?W%2TXI5+.@PBD*8,)PXI$:1BR()
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M!*6RP:8@"YDK B&03DE>A$XTZN>I#!74S?)!'6)+R<T(#['(T5'T)40T$")
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M<XS))J9_M^W<JRR^LO6^?*+SI_7[24Z;8"MA.'9<W55%ER3)JW26)EK+%'Y
M)QV>2L\R-'F6&;*4[)-2V6Y1)R2^A+F%,U[J_+6$F>EG6,N>IQ]C36NZ^NH7
M(M>UBJS1:4&!W ^8HM^UW(<OHUBNJ1:XK%<V==FX4:>O&(TPY+EH5E3KJ'%,
MUX_&F7WLT7_"L[)]:^NIMV4\:T)I<P].F%R$QTKJZD$7)4ZP*E+/3'US ;ZG
M9)M<Z:LN\O.7"2YLM<Q3RI+^7%,U[JUY:ZV]=V)V2;&A]-L$526YJI[&LJ6Q
M,5,9-VNRMRE2&@J'52$V*^7@]YY2\N*,7&TDU*S,/E7I:H9KW?V_9$^2MT\4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*X\]]=;;%MVZ112J4&ZV<8WK\'#<(UZ
MJG34%$MHU9778JY8V!)CIDMM/L..,*<PZAMYI:DX2XC.=,O\:2].$VH[[H\G
M;34VTX8YH;JJF8BJ9HBIFF>?%*]G^Q\Q1AFS8'F1+QB*Q6F46(Y[XQKE=[?!
MD$R<"U #PLRI#3BM$;;@BX@J!$!BBJHDB0G_ !&[K]S^TON_MG]T<PG(9OO.
M5XN[^I7=.G[ GAKA+SCL_P!,I^(W=?N?VE]W]L_NCCD,WWG*\7=_4IT_8$\-
M<)><=G^F4_$;NOW/[2^[^V?W1QR&;[SE>+N_J4Z?L">&N$O..S_3*?B-W7[G
M]I?=_;/[HXY#-]YRO%W?U*=/V!/#7"7G'9_IE/Q&[K]S^TON_MG]T<<AF^\Y
M7B[OZE.G[ GAKA+SCL_TRGXC=U^Y_:7W?VS^Z..0S?><KQ=W]2G3]@3PUPEY
MQV?Z93\1NZ_<_M+[O[9_=''(9OO.5XN[^I3I^P)X:X2\X[/],I^(W=?N?VE]
MW]L_NCCD,WWG*\7=_4IT_8$\-<)><=G^F4_$;NOW/[2^[^V?W1QR&;[SE>+N
M_J4Z?L">&N$O..S_ $RMP]?=/[:#[NU85+ZNV**%C[N!E3R1*DV6# A169S:
MW9,N9*&-1XS#2<94X\\XAM"<9RI6,8\?+RW0Y83HAG%DB(OMJ1$PZ(BB$BJJ
MJHHB(B<ZJN25I>T7&F#IN!,60X6+,,RY<FQ7!F/%BWZUR)#[IL$@-,L-2C==
M<-> @ D1+P1%6N_O.A5\\*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4KYE_#!>$J[;]1.TU>U?HR\@JY3B&F:G<94 E1JE9)"SQ6TWL
M7-DIGG!4V8AIR&#'-IC)>PPVII;B$)6ZYE7*L;8IO-EN[42WR&VF"@LOD)QV
M755PWI($NIP")$46P3+/),L\LU6OHQ[$_P!COLLVJ[-+AB7&EFG7"[1\7W2T
M-/QKU=+>VD&+;+))9;5B%)9:4A>FR"5Q04R0D%25 %$Y5>W/\(Y[V*E]T^NO
MV?YJ'5 Q/[\9\3B_-5Z;ZRSV/W@Q=?.B_P#TZGMS_".>]BI?=/KK]G^.J!B?
MWXSXG%^:IUEGL?O!BZ^=%_\ IU/;G^$<][%2^Z?77[/\=4#$_OQGQ.+\U3K+
M/8_>#%U\Z+_].K>59\)_X8"WQZ-(!6^B/)V7 FE:*Q/K&@@<ZR"AQ"VBIQ2$
M...#2"!D4G1;3 >(2HT>&B6-0QE[SA$6F;D&L68U?2.K;\=>5"1QT)JVMDZ
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M:<=<2UDNMT'6P64V@1Q%\9(,M(,)/J;1B0,$YK<;95&Q+2.2WEPV+XFN$&!
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M.47$[#G);/%N8/@J;RX,2WM\CT-R1&F+&C-6]YA@A=.2 .O AN$)M-./(8-
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M9G(Y>TN27X\RH;5UQK:="$21*U@-/B,>==A21XH(IFG#AS+G]O@GQ?$J_?\
MEUZ_X.7=,6U%#%4[+/TVN639FP;]<:6 ;V$- 6J-?KQV#L;8[+0F_"IU8)TZ
M-NX$:K5DK1*&;:N^IZL<:FP)KT0H 5'/XN/#CW,LOB[>7[<<]O[_ .FV[-M;
M?FW^H=E#= I9 @.=,ZW2BQNC3PM.OW*))@,'*W8:G;J>\*GS']E!7PEEEP8.
MPZ_2K+316M[4SL.W;,5!%X99)GVE^^B_?_\ *YY\,L6G]&M_$H@I,CM06C&H
M<YQ96Q!$;"%2[$]"VCINYQ[M-&R=C& XJ]W#7>JC6D[_ (K<(+6WZ]M&Y6(*
M,B9GV&KVY3-.Y^V2_P">:=OASKPRP -X.'>,5JAB[!V<7<:S4-E===D8 VV'
M>;,W#-Z-NG2G8)HT$DEKP\KU]L2T=7]E2R$HNT0P$>WX=GBW4RXEHQ?51S3M
M)ES_ )<_B[BI\GVLKWLSJ#VNMO:4U;P>[I4+6!5)J\B"DB0>8@"B2;=HQD3J
M*SU<=L*&^:&QJA6-F_@Z=! A >%$.$(9QF2:LYN>55#-,N;C_P#/'_-.;[54
M-6\'QV-CV:C2[_VV+7"H@HFI!-SK@AW9]0D7P?K432Q,V85+P]DSRKI*RQ M
MD;(HFSYL5R4>D$6_1?3IL!"HJJ=SN_ES^+M<%3M]KN94X7P<&Z0H>/6T=GR"
MZ]"@:_A0AX96S*8]&8J^]9&S;S#5.K>RV%3F=O59QH+:)A)B9.'GLSYK+A09
M+@PPZH9IW./WLN;).UFBY\57/CW*ZZP(,89!A#8:7$1!\2-!BH>D2);J8T1E
M##"794MU^5)<2TVG"Y$E]Z0\K&7'G7'%*7E4*J^*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI7R*>&9V=!U)X2:JVZ?YMZ.KJ8  /"Y=?=/BST.R7'9X8N#,*'6FEV
M4! ( Y91O\)Z;9!ML"3$PY(EQ6<O(SQG'$L86*67R5,N@S;:B32N@X+K\MLV
MSTO,.M"39&F^8=%YLLE#/BE?5+V(V&W\5>QYNEJCZ@<3:E.G!):GC DP7K?:
M,-RXDV(DBV7BW3GV)K49>AMWM\BUS&5>;E(.0$G,NS;:ZH/VB(8,ZY,E1ME_
M&03*$\RZG<MA3!I?9QFQ:OL5D*O37Q4/:::992]?V@/+MF8QW%6J:HV*S8S,
MC8 ;5'9EF)T3<BN$#O*C,\V7Y1"<MQV(ZZ:FH#,W#IM2Q/>([N651&G7%DM^
MB[=A7:B%L=B0\0Q(LBW+AZ-%C(W=+1869$3#<2WXEM]OB@R$E[#/1>W1)^&G
MXBPW(71.Z(XMRM\0+#+J#>^>FI*=+*LZBF*E2W+BM4>7JNK-(A*=U$Q6]9X"
MX#[1% AXZJ7A/EG@T^KFXQV!$9M>7\FY60\&+EQL9$1I!52+?\"ALHB9PD:B
M;O=S ; 69&:N-DRXC@BCRKK7=C)"P/M>C,-12Q6RC30VI$<:Q/<R)[3BL[CB
M+EBR\-2ILB1=+*N4*8Q<X3D)]T[9HY&WRM_![-O710K<>K]FZ/K!'7#E&,WH
MO*=>H S#:ENSIQ/7B60H#9(UYV9 7+4.EGH-D!':PUZ&3 324H$)BMT';A;@
MG1)<!DHO)W)#BJL8<LU(CC9-MR@52%5TDX+K;C29&V1JV UF;;@G&TG".)<-
MXTN4?$(WJ'8XC0A?9*DB PQ&OZG,G8>D@+3Z-)(:A/6Z;"N1;V-.9CMS93I5
MM5[&Z*J5A[&VS%%V!:;#NX)L9^M3K*3"EDTHS8KN8,5ZKV=VVJNY_8H*6.8K
M)F[7219@%J-35EZI*'%(^';@8BS=+>PY='N3R7G9[<I6B=)L]P;L@S:9=5[?
MN26B!&CD/JZV\X6ME0-$5]RE=-GN-KM V?6I;W8K9;\&3,/MW%BW1ID5;Q#M
M]EB1)]SMJ6I+-!P_.9?.XP[-9V[=.MD-D8MT;D1G%"TQ,3V)OW6NRB6JSEKK
M5G/& >P(EDV6DA+FY%':_(FCG[*%K<25;2;,=DQ%@L0FED8*33<. .B3;#.8
MC-(:I2KE$EE#<>:><<;DB[+U$NAQM2#>MLBKQ(B&(HB:QUH(B*N$B5D\/X%Q
M'AR/B>%;+C;8,2=87;?AQ6&F4E0IX,R MTRXNM6J,9G$<?-XTCO+#)Y^0ZS
M9-PR+9M<[7A]:*C,A[E<BQVO;_.[N%G@(EQJND(V1.Q06=?N!CUT?#OTG9(P
MK36CC[-)J)  %,WL!:*E??5U;B1[IJ\!%5$!]\W&KDY/!UL%W1INY3:1MVX^
MK:QY0''1Q4CL$VV<AIYB1H:%-=N&RZ7B)#.7:+1%@S\"0L&28,Z4)3X[B2L/
MS>CPRX-F"6%YP])BW<H0'>;LQ/EQ+)/MMTL?*+BXY8+=NC0)TW/..#;99:21
MWGUYN +7=LB0EE*#K:EU:U1-P:OKLM@P4B8HB<%:?2*.I<H7-M=;J84A8Q8D
MC6VVG*;T^VN.$XH/.QSN%L?;BO".N-%89>&;#;)#,>3]FQ'C]D)/-,-DZ $W
MQOK5@_'4&$Q"&1:[=>8^"L>VF=?[6Z\D:^XAO%SMCN$\27!LXD9Y;VJQKM>;
MUDU)9MEPNDQBWR9,>XD0_NM;FZZ#J]?=>;8"7+9 ^U['!;:+6ZK0P4!PY;*G
ML;T:'7AJYDT0>@4JQ:1+WL>V4>(0"E>M]XQYZCNHKL:4LU/M@-28LQMZ4#TI
MN:;S*-BKCS,K(6@U$VX+#L Y ZU(3:?D<6%W2*LMQP?M D3['?\ "TVT8=D6
MO#TW"L6U7-Z:^,*UW3#RF]<)",LRX+]X@8SBV2048([\:?:K+F%Z%;@XV.2:
MWW9TPJ9@"7MVNSEN(5JZUZ2F?#T[2@L.R5<-L_K(>>)DJR]M0L*&G9FO*%O\
M 0",K(!2)G94&0W(%0'6V:M4BS[&R;9O1G'R:D-+J&"PV+K(2[4XIDTLLP!Q
M8T>Y-DVBDV;DL50@')&<?B'!NV"Z1)T6UW^%:F+C:)[:L/8NO,QVW7*7AO:-
M"&-'N(88BR9$)J_WS TYB88L2X\/#KS9MRGA([G'7:%NT[95:NB:IK#H&2'!
M1V[I,GU2-7BI:SYK%7''Y3D\;>;$),!RUL#VBZ@8;%8JTNH1KF_3\S;"%# ,
M!M?OKT)V$V,-K=J#+:/D3*-&;NF.+A*02' -LW@=?;%&6B91]6=3C;;>CI6#
M;3BVW2K\[BBY#.;EW$RL[+%U<N$6+;4N5SD06A8DV6WRXDN):Y=ML\YYRY7-
MN[.6@+KN8$R7-698N:!72Z<4IQ2G%*WE)[$[-D7'2]\3.#QK/H 52@FLIT>O
MBO-"1>O3+A^I12$%^._!.^K"KTB2N08CS)4_TAQH@]*92RVUEROD\I5JF(3(
MR+,W%:@&+#>3;<)U7HPN J*#V[<4B4G1(CU*AD29(FB-[.,+MV;&M@6/-<M>
MT&7>YV*&'+C+URY6(H8V^[NQY#;@/P.51 ;:%N&XRU'W8G'!HU,CS25W%W7)
M7">:F5(7+$TPEKX%.!4FN 9P.HEY^R"!$(/E"(4-UP?-=VO=,3X1',^$3<F#
MR!2-.+A1)&'=EBBZDH*A1FR:BN0F39B,LFU&<.<9M 38BJ@2W&5K!S6#BF!N
M";K39CA&MC."&Q? V;Q*9EWJ+B&?'GWRY3V)UXAQ\-1XTZ0U+?>$9# 82LG)
MWXR,/Q19D1XCK$.;+C/:>V3M*V;:MJ+M>'!)"P8$5T+*E008L&V2B5@3#"#G
MBC(6- 1.(.#X$=F:2?\ *FR4MH;R^AEF,TSBY]QDW*2DN7NC>W3#1$#+;*.#
M';%H%<1H0UFH *&XO9EDB9HB"B;GAG"MHPA:"L=B&9'MW++E-::D3I4\HSUT
MF/SI(13G.R%8CC(D.&Q&#)AI2(MVIFX1YY;>S6U+M,VP0L$P"_+W96Z75-AN
M1JX+A8*A]?S*[/JK<-J*RTT&?'RJE67'9 I$1R=ZG83.S(3)(8F7DF_W&6=Q
M-\F2*ZL18TU18 -XW#)DX^E!1$:("C,*I-H*GNDUZM3FO 6C9AA2QLX2CVYF
MX-LX(N5ZNV'1<N4M_DDS$+-Q8NQ/$Z9E-;D-7>YB+<LGA8Y:XL?=*W'5G8LS
MO=V%(KDXG$Z-+AE)MDG6,2_K&A+#VQ=QI]9I%H8M(W('T8S$,A*=65NQY*/(
MA$P@HF*]7RQ@YR)?%C"]&I:SAD+AR#?;*WPU:DK*BL1) R W6ET76HT=5$DR
M!QELV]!-AIUMG8+L[CBUN(U^9>BL6QBVRV\4W\9EH&S7FYWRU.6J2D_>PGH<
MZ\W-!<;+4_%G2XLOE#4J2+V%9[6[?SKLGJA4RL9U^8#6,'.JZ*;76 V8UFM<
M2ZR)409&@,#AQ4-8X3,RIEAT2+/J+"Y0ZN/C1L^=$D6G3'<^0N6[5'Y$ZT^T
M<?DK"-:7Y RE(6T! ;<:?!#C. (G&34#"M@9B6<39-@Y,1Q<6HQ=.F&'-MLY
MBZ%>;DY-WMLM+MD;:>E.R#DR8DRVO&Q=H<EYV/>#1J3<FY,F.P\W&[F"KI5.
M*4XI3BE2)ZQ=6]O]N-FP=8ZA YG3,^8EV:S3\/,56B@7'O-.G[23;:=Q%CI\
M3B8,!A#Q4S)1F&*ARG_*2C/8>P[<L2SP@VYG4O GWSS&/%:SR5U]Q$72/.@B
MB*XZ2:&Q(L\N9[5=K.$-C^&7\2XLG(T*ZVK9:V%!RZ7N<@:@@VV,IBKAKF*O
M/F018C1;Z4\TWDJ_;7TMZ/ZAZ3ZZ35*#$P:N1IF*]L+9Q6(PW9;J483G.$J\
MA3WJ:MP'5NI!5B&^Y#'-+4_)?)&))$M.]688PK;<+0DC0PWDAQ!69.<%$?DF
M/=RSW;(*J[I@5401<R4W%-POA_MGVW8PVUXC*\8A?6):8ANC8,-17C*VV6,:
MHG8HJ DNXO@(<NN3K8O2"1 ;"/$;CQ&)F<V:N-TXI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4__7_]_P#]<4KEIIWKCVTF;XT7LGM#;:QL
ML-JS7MV@RV8LZ$_$9W'8:%UO@$MA! &00R&R&*[)HV\K%1XZFD']>5^Y@!L)
MV# (S*O35154RX)DN?\ G_FGVZT6]T7[%F+@F[@ZS1M)Q2&V)FP)FOJ9MLN9
M U\JG>'1V]2+=4LQ:15V01BYZ=ZP[%HUS6UF>0LFTMHVBUD7HE:VI>D!%1U<
M_;X99]M<T5.//VU1?M)SHN5;7TWU6V?6+SH T9ZV:@U]$U]M[;VW2A6C;NER
MU:_D;+%6H*NB:["1]0 F(^LWXMU,$K)20[E7A6^U5^CV>PS77VS,!"H*O/\
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M98Q4*<WK,W>GWV7&7+>[$NB@A1GD49+\.:$8-TZPZ#9C,-@H[C32M,M(RX:
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MO?)_^G?O-[+_ &QUC\'^=3ZCN%_?E[\9@>C:^8/M@&VCO!LW\C8E];Z?)_\
MIW[S>R_VQUC\'^.H[A?WY>_&8'HVGM@&VCO!LW\C8E];Z?)_^G?O-[+_ &QU
MC\'^.H[A?WY>_&8'HVGM@&VCO!LW\C8E];Z?)_\ IW[S>R_VQUC\'^.H[A?W
MY>_&8'HVGM@&VCO!LW\C8E];Z?)_^G?O-[+_ &QUC\'^.H[A?WY>_&8'HVGM
M@&VCO!LW\C8E];Z?)_\ IW[S>R_VQUC\'^.H[A?WY>_&8'HVGM@&VCO!LW\C
M8E];Z?)_^G?O-[+_ &QUC\'^.H[A?WY>_&8'HVGM@&VCO!LW\C8E];Z?)_\
MIW[S>R_VQUC\'^.H[A?WY>_&8'HVGM@&VCO!LW\C8E];Z?)_^G?O-[+_ &QU
MC\'^.H[A?WY>_&8'HVGM@&VCO!LW\C8E];Z?)_\ IW[S>R_VQUC\'^.H[A?W
MY>_&8'HVGM@&VCO!LW\C8E];Z?)_^G?O-[+_ &QUC\'^.H[A?WY>_&8'HVGM
M@&VCO!LW\C8E];Z?)_\ IW[S>R_VQUC\'^.H[A?WY>_&8'HVGM@&VCO!LW\C
M8E];Z?)_^G?O-[+_ &QUC\'^.H[A?WY>_&8'HVGM@&VCO!LW\C8E];Z?)_\
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MV(V<824>32C;+LI QNN/3;!:MW!O9]*(QB]5+1;;K&-LZI*IU"VB/ZW!;.8
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ME21"DN7&UQRM)V:7!L_+R)=3SL^,K4AJ.3C;W,7FOUV"IB^#XNU6UMW?ZL[
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&%*<4K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g428534g64p61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g64p61.jpg
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M 0$! 0$! 0$! 0'_P  1" $+ F8# 1$  A$! Q$!_\0 'P !  (" P$! 0$
M          <(!@D$!0H# @$+_\0 7A    8" 0 $"08(" @+!P4  @,$!08'
M  $("1,85Q$2%!<9E9;5UA4A4U:8U!8T-5ATD[/7(B,Q=7B4M+<V-SA4=Y>V
MTPHD)3(S.4%1<G.R)F%C<7:UN"="0T1B_\0 '0$!   ' 0$
M  $"! 4&!P@#"?_$ &@1   % @$%!@X)#PH$! 4%   ! @,$!081!Q(3(3$7
M05%6E=,4%1884E5789&6H='4U0@B-51Q@9*4UB,R,S13='63E[&SM+72\"0V
M-T)S=G>RML$F1'+A)2=B\3A&1Z*W0V>#A*;_V@ , P$  A$#$0 _ /?Q@ P
M8 , & # #19PPZ4!.KO*Q>+_ ",?"4RQ+:\[CM168YG )(6IR9>[(VF!3!69
ML)92XHL)*&+R \00.  D,SH9IQTB5N6T;DL<TTN'7*.T:DJ@17JA"01FI)G'
M;4Y+CI+$S29XK?9+$T'BZV69G)1R/DNR_H=NVMV!>\M+;K=QU>#;5>?42$/(
M14Y+4:CU-Q6"4O)226J?,69$^1(BR#)\FG']Z>:N'7 8 , & # !@ P \WW
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M9E:6W7T16E.*:;6LC0E2R+ E*(R(]9C2MZ?>I?S?K%]J8U]WS96Y14.VT/\
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M91K]*WXTHTQOC<;;S#2MKW9?LH>]:V,I(A2%*7-S4HVQ&K5DW2CT>=7)S4"
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M5<R;V]S=1RIF)=G&OHRW3"8-C5IUM5()>Y,T=>&E?MO(T)6XF.:)N:"7!S/
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M<VD,1'6(\TGCBNJ?J,.&HG28=9=,B;D+4G,=0>>E.)FG$C\]/IZ^2O=#1O\
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M?R?R9<!C(VUM/23OL_X+7+Q1O)6XODL'%XRDJ>PCM'+ESTB9)M%7,Z(S$_\
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M'BJA&J-';Z+>(JSRN\7)YX^-=:.\K'.WQWG2^9;<'P4C<)=7S4-*A8'J$+)
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M+E5E;3[W0ZT1WY$"'(=AMOZ(I)I)+:L5)QAO+B,6# !@ P 8 , & # !@ P
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M !@ P 8 , & # !@ P 8 6.IOD4]TO75SPJ-H'$EYMLB DDR]MD6VA5%_P
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MH[A)=9IK+U1DNQJK-3[9#E0<;4AV&P><F E27G,9QH3"W59K4=3A@ P 8 ,
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MJ)Z/7\@V;_.\:_L3MFBW]J?@/\X^A:-A_#_L0V*YX"<, & # !@ P 8 , &
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M1LMFI28D1"C9BM*-*36ZMYY[SN7_ $2R76E))4N!K&_LBM>)G>BDP5@ %*S
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MZ!.CU_(-F_SO&O[$[9K=_:GX#_..GT;#^'_8AL5SP$X8 , & # !@ P 8 ,
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M$0&T/H]?R#9O\[QK^Q.V4S^U/P'^<>J-A_#_ +$-BN> G# !@ P 8 , & #
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M .#[_C'+'_R:._\ 7;N8?E:V4#X:I^:G#=_L,=N4;X+2_/<H](V::'<H8 ,
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MWHF-IYN1M*>22<0TOZQI;UR97L(-E/ %A9WC(1(ULBU&G-/5@9D1ZC,]>S#
MR^#XR$Z$DHS(S,CS3-)<)D6.'PGO",:/Y03:W9'8L,U'(PEF5;V=-6)4PA^5
M6\,CJMOAC-)ZVL=N<%BY5\EDV09+H8)&0K0KM(&YU<C]%K-LXAJI"6LSPP+'
M$]6!E[7 C(\3/?,RQWR+7@(J022(\3P,BU\!XF2BP+L<#W]>KA$M\>;1L>R"
M+306;#HY&7JMK4>J]2N\+>75\ADR1-K,PNPW9A7/;4S.6S6A:\JXG(21HQIT
MLF8'=&6HTH3*T2&="C5CB1$:3S=1ZC,MH@M*4YN:9GBDC,C+ R\&K7M^,6)R
M<2!@ P 8 0-R=LN:TU1%DVQ 8RVS%^KN/'RXZ,NABP@ASC[*86KE&R5"$83R
MEK='@.3ND#XAP%9S>% ,).E?E:>59FE)FG S+7@?!O[Y;"UB9!$I1$9X$9X8
M\'PX[P@*#\O'>>W5+:F94L6/2*H]3,\I:3%(7@:>T:_G2U438SZ05MX"02=6
M@&IZ3J2DJM04K6HM /,2';VBWYDX9JPU8'FYIX;<=O\ 6WL#+X2WQ.;9$G.,
M^R)1$9:C+86S^MJPW\.$2[77((ZP^05J5&CCQ22,0&NJVFS'*QJS#%4M_#E\
MGK2>L3(] "2GCX P\HUC6:&<-Z2J/E@@S;:M0;%.E><HR+81;>'_ +<&W';W
MA*:,$$K'6:C+#@P(O+K^(69R<2!@ P 8 8_+5$C21>1*H>C;G&5I61T4QMN=
MC#B6MQ?$Z(XUK;UYZ<99R9(N6 )2'JBA"&E+.$HT6=U?5#@>.!X88[V.P1+#
M$L=F_@-;$!Z0"03971P/P9C2-)>%$S>4,YP4SV,QMY$P<XY*Z4.>$QR++,6Z
M/2.0DQQ@TSTLTW +TS)M.9*A+XZ4]6.:6*3WCU*UZMN_AX<2WA[*:).=K/VJ
MB+>UI/\ K=[X/SZQ+D&Y=N\EY3OG&1VC#2SR&-N4I)="%JA2U."V(,D,B;^P
MV7%U2Y2:UREME+Z^+V11"6;:J2Q%$0F>WQ8-(4K#J9*U&O,/#5CC@1[Q%@9&
M9[YX_!AAB)3;(D9Y8X&18;-IGL,MI8%KQV'K(L<!>O/4>08 , & #?A\&_!_
M+_V>'7AUX?\ WZ\.O#_\O#K_ .> &L ?.V;,;J@9IE$XBU.$>Y=+>.-M%IPO
M>BH=#5JJ+HH/;A"A4Y +TPRI3-(85KY1ZD"3\+2C"MK"X\Y[5^&E41X'FZE&
ME6HSP(C(L[#'9B?DQX</;1D9&9&?UA++O\*=AZRP/AV;PL0OY"2UDL'BA"'"
M+1]:BY)N%D;.D*9R<VU9'&N)UY([&CP"HR>C<0'K79I0LJ=V-.DN@-JXQS3I
MT:LK2=4";/5BC$D^WU[^.&TM7#@98GCMU8:L1*2",G#Q,LPBU;<3,\-NK5\7
M_;(JIM:U)/<=PUC8$"C+(UP1H@DCC<JA\C=) A.(F^Y%O4+E1CFR,Q*6=L:)
MC1/;DF9A+6\+/(V53L11*UO4N4R5*-2DF1:M>)=_81]_#@\P@I*22DR,S,\2
M,C+@WR[W!CK%E<G$@8 , & %:^5MTR3CW58;89F5H>F".S*$H[%VZ>7;-8*^
MD<E;HY()>VE(3R!+5<5TZIG<]O/&4G4MR=:,U8B 1L[)%J-)8D6.O7JQU<.T
MO]Q.A)*5FF9EJ/##?,B,\/CX=X1Q4W)Z4V1;UJ5">TQEO>ZXM5N9T8TZ=V.+
MDE-.\0?Y"T64D&-S_@ =GIC/B9:I.4N94;B%,=H]PTZIDZ:5*U*,RU;2P/ R
M(TZ\3+6>W#5\..O8(J024I5B>M)GKPU*QPP[_#B,.%SM TPN6/<E@11,M3<L
M9SQ8A<58'9Z?T;LYP@PXQTF+PZ(8J8^)V!N9&F0RAXTT0]S<B$*),U-[8Y.2
MDH9K28$9GACG&DB+9JU:SU?#CJ^ 1T6)E@>)9B5F9X$>O5@6)X8XZBQ/#OB\
M4'E#3-X=&9@PO[-*F63,C<]M4CCH1A9'I XIBU29P; &JEII:1048$999RHX
MXOYP';"8$0 ^B3Q(CQ(\2VEL\NOPZQYF6!F6!E@>&![?C&59$0# !@ P KKR
MMMV6T+1LPN&(QUNE1D!^27N2,SAI=L6X5IU2)):[(-(#R#!KHVS*E,EZ@XP)
M"Q&T+$6S$YJDI41(LS2G$L-6W'@W\-9:_C$Z$DM1),\,<</APU%KX=@B. <J
MW^=W99U/)$$6T;&Y'7"RMGDE.Z"2V35\J1RY;*I4B$>[DZ3J(RK@,RBI1Y99
MS8KD30@,V+3?($XT,A.*,S(L#/'VNHRQ+7CM5MU8>7 RV3&@B22L3UYQ&6KV
MJB,L"/#:1D9'PX#&E_+JTHC-Y%75A5K$6QY5WS0M+5_)HK(GN2Q!0NNUK>Y,
MX(9"8O9XXM-E%:Q)A$\/3<W[1I7L4BBQ9)[*E<O+=1TBB,R,DXYR4D9&>&*N
M'OD6WX.^0:-)EB1G]:I1D>!'@G BX=IGY#U"SG&ZZ$G(6D*^N)&TC8M3)J5F
MK682C:P+6\LKNXQQ_0IU@B4PEJ),^,[@4@6&)DQBM$$A08F3F&")!.A6<DE<
M/_L8D6G-4:=N'YCUEY-HF_)A*& # !@!6CDE=<BHHFH9$E9V9?!Y=<T(K"QG
MERVM"?"6>?K_ )%9I>3M.I3I1(4LB&W,KEI:+0"-OJ->$0BT)Z95(M1IP,L,
M#41'B6.!'O[2_C>$Z$DK.+7B23,B(L<3(L</!YA&%#<H9S<RV<1TN-Q9+-:_
ML.QF!RC@A.[40]P=BC,9?JVF:%R6*UZAG(L<J=PIT3!7,Z[R)F<'L(2%"Z/B
M XRH6I6\6HU8X%AJ+##7G']=B6'>\(BI!)P/$\#(CQU;YF1E@7!@>_KU<(Q-
M[YCV1!>/G(:R)S6,<-L*E93:$;8&J)2!V706?-U=M#,X.$T1.[JU-[NBCC$Z
M/)D0DVQHS.KF+0='4RPIS<B$R2&D,DF9D6)&9%AL/#:>O>+AW][6(DV1K2DE
M'@K#'$B(RQ,RPPQUGJQ^#7WAOLX=\I38FF8X1/UGBPU\3HSV9T/,$,$0<'$L
ML\24TTS>Q!CJH\X76"%OQ6M0+:O?BI358RH.-YQ9Y%[; C,BW_\ O^<02>!F
MG>Q/69[/X^(;?M;UO6MZWK>MZ\.MZ^?6];_DWK?_ &ZWE,/0, & # !@ P 8
M , /%%TN?_6#WY_X*K_N7KO.E<GW\T:5\,_]I3!\J_9*?TT7C_TV[_I:B#8O
M_P 'W_&.6/\ Y-'?^NW<P_*ULH'PU3\U.&[_ &&.W*-\%I?GN4>D;--#N4,
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M">I3Q1_.BRAT,<S>I+$X/!ZB*DG:<1=5LLQZD@@DZV\'>)*2$EF_^DL"^/\
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M? \8H8FELZB#7/>449BLH65Y-I-7[^Y1XVJ;B>#F@4AB3FTNY:$YR9VM8<F
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M@]<2;WWC2+[(PS$\'E/SAV4./G=N@]<2;WWC2+[(PS$\'E/SB@_,ZK8%6+I
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M\K<1OZ8=:_[$V=F16_\ 8[A_N[,_6X UGE(^V<F_^)E"_95?%P\QT;,# !@
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MD18$1XF=O\Z:&D@P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
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M<1OZ8=:_[$V=F16_]CN'^[LS];@#6>4C[9R;_P")E"_95?%P\QT;,# !@ P
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MFV0]5RT@'$5Y)$[-:5W9&AV;IA9,=D0F$#J[.[6VD/L;G26#3EE51K8"29^
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MB\980;6$Q=HIJ.&M9[IU\D&O'*3GE>J)/;$S<!22+8>/ME)^3AK\HW!8$H8
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MW #\A65_.T;_ +&[9WS[#'W)OW\(T+]6J0Y.]DC[HVK]Y53]/#&PK.UQS0&
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M!W*,H'XVR?IB/D?RELI*2:I4\)^3J=.06,X\\]?QU*))*+#L9AIIIE]! 66
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M)H$ZA5UBOP*A%B0IRT2F*?4J<3:XT]MV*MM353>4>D;7@I","VF(Y\Q7)_\
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M[9WS[#'W)OW\(T+]6J0Y.]DC[HVK]Y53]/#&PK.UQS0& # !@ P 8 , & #
M!@ P 8 , & $<7'_ (HK4_T<3C_9ATRLIWNA!^_(OZ= L=S_ ,VKA_ =6_4)
M POBI_DO<;O] E/?W>1W*JO^[M:_"U1_7'A:\GG\P+&_N?;/[%A">\M(S ,
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MGH6KXL!TD=IWA%#U38MB/%;GI%E;)()A)&=4P5?RJ:UC8OG=.02A)&2D7)E
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M & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@
MP 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ><=7
M^-JOT@[]H+/AO+^VY7WP]^D4/J&Q]@9_LF_\B1Q\IQZC9MP _(5E?SM&_P"Q
MNV=\^PQ]R;]_"-"_5JD.3O9(^Z-J_>54_3PQL*SM<<T!@ P 8 , & # !@ P
M 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
M !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
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M B>CO$1FA9$1D9*;<2AU#C:<RS*!8PP 8 , & # !@ P 8 , & # !@ P 8
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M4S)949Z*5%=P(GH[Q$9H61$9&2FW$H=0XVG,<R@6,, & # !@ P 8 , & #
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M5>>1(K+<",FI/-YAI7+)M.E/.;2EM2B5J6MM)(6LE+01)40Q/,<%Y# !@ P
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M49XF9F>LS,]9F>LSUF/UDP@& # !@ P 8 , & # !@ P 8 , & # !@ P 8
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MC,U*49XF9F>LS,]9F>LSUF/UDP@& # !@ P 8 , & # !@ P 8 , & # !@
MP 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , &
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F+ 8ZI2E*-2C-2E&:E*49FI2C/$S,SUF9GK,SUF>LQ^LF$ P _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g428534g73e11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g73e11.jpg
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M 0$! 0$! 0$! ?_  !$(  T D0,!$0 "$0$#$0'_Q  :   " P$!
M       '" 4&"@0)_\0 )Q   @,! 0$   4% 0$     !08#! <" 0@3%!46
M%P 1$E>7UAG_Q  6 0$! 0                   0+_Q  J$0 ! P($!@("
M P         ! !$A,4%187&1@:&QP>'P M$2\2*RTO_:  P# 0 "$0,1 #\
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MADX(#*;&(#GZD-0X(%$J)'8#7Y#D%TH&>O(?CY[W@@Y)!-\.*J)G+YS7RO\
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DH:A/9%7Y:E3JN03&)'O5>,O_ ,R^/]U]?\Y\_P#=_P!%%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g428534g89q11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g89q11.jpg
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M 0$! 0$! 0$! 0'_P  1" &H AX# 1$  A$! Q$!_\0 '@ !  (" P$! 0
M          8'!0@#! D" 0K_Q !2$  !! ("  $)! 8'!04&! <% @,$!@$'
M  @1"1(3%!475973%B%6E"(Q4U32U",V06&6M-4R4723M20U<7-U&#-"=H&S
M)31B@B9C<H6AP='_Q  = 0$  04! 0$             ! $" P4&!P@)_\0
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M^M>ZFP;3W6[-:3DE$)U'JWKXWMFK2;'J:Y!-@!#DMJB27HMHJGL\3<2$ /\
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MW&C/SZ^BL35-E:DDAB- K&8C-!RT[2(I#R&011QA"Q#L_P!\;M6/N!)&@O\
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M"7D42<'W05)5F]U26\LR6^J-)1>Y'8MN)-=6@M[%(JER=Z%:RI>&6XD%>1X
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MIQ'5^KO)P4S,P<=/U;M1JV-+F.NO!0Y>Q-,N2B4E+F6"<H0&F&GI"VE9C$I
MT>ZWA;4UUG*7=CT],MFSU!-PR)+K;)  #NL9/"CCE0[A..?-0S?C'/.<]Z0*
MDFMUO0-3OCFGK=2:U6<EH89; !:1N>)6BA>8L0>V1HXR.0Y'!G.P?)^[E[%;
MC[I[FN<D'IY>\-!P=$:MK#%BQ9YV71JZ,5<M-\( HB8,401+T.&/;&CG"Q#
M0Q-7*C-2AL9F?A@WM37U-13A#VQ3O&[9E*>$.&$Z>%"KGN+JDY8LP5>]  >U
MF*S+W0^VWVVZMVUQX=4=QI4TVMKK/ZR_,?J<AL79(4[%B>6DD8CC,LG@RN65
M6C57C\KJ!VTM OR:0R=KK7E=STAL -5T?D[09D-W&#5W*)#9(UMH76)ZH[9<
M74<S6L$LM3O:DR5%FP8,>-'($;QM=7$W4++8L2?=F-_! K$&%I!.2LA:5>>Q
MI>/=Y7M4$,22JX6Z6ZGLQ^CZ-Z%"#V/GA-MFV086DK&D@DKB.LY42QU2X$G#
M^*[*ZQJJR28?L?TT[H[N"]Y:?(JVKL#-N7"FG-+$JG>8FMP4VNU2\P3^4WZI
MUZKQY.QMCE@(P5$EV+;!@A$#$X\QVL$8$1F U)OH;?44WTLHDL]U6&:.XLL)
ML.))8"G,$LDI%>NLC,1'512R%1(K$DC#O^D^K=Q#UC5:OK?#VENI-J7K75H0
MO7JW4F_NVK!6#7]A+!'$K3[.5UAD5S7DC4('ND]U6[(P^SG1/L)7*G13#.C>
MOTS46P:T0V L2H,=F4VSUIHLV416I^2X>.[96I4E(@?*G*R/EQH\=Q#D6:["
MCV6O.MW-"269#<O+:@D6#N[T66*3M*^(O:Y$9 [F"^\"6\B,VTW3>_7J+HW>
MP5:<HT^C;5WJ[WO"\*9JMFN)1)ZN_BQ V0S>%&S^XRA2"K&%:_Z%;-H&T>T%
M/NNK*'V&T/V'VM+VY7RUHVW:*H-JI4J8F&I<'8NN8D*:S;Y0V6Z.>&D!T:9(
M>E HLCU\:HGGV!GGWE>>MK98;,U"[0K"K(D=6*5I$5%0-7L,08@P#!E8@ .0
M58+S)%H]%;&CLNHZEO74M[I-[LFVD$EG:6:T=:669YF2_05'6T\;&,QR1J[,
MT"MWQF3B#*.]-.PVN-@^4?;H]?JFQ:CWDH1-FJ6<E=VZQ.H%CFUK8(F2!L@R
M>+)SI0]$B_3< WP[A"._'$!8Q22'1,G3!-HV]"Q!T^9I):\NEG4RQK#XBSQK
M) P>-E95#$0+W]_:06<J'(56O;I/>T+W7XIP5;]7K&C(*MF2X*[T;#U[T;06
M(WB=V3NNN(3$9%98H%E>(,[Q;L](-2;$Z[]2-8:BV"+#2;OKD"<'OPZJ>26'
MF5NFS!R F&2)0 3,:1+21;AK;E(3%C2$96N<MA7I4Z?<VJ]_:6;4#N(;#HP:
M5"K)PB(W<JER0.WN\O,CR[>?+.OZ/U=_1=,:[5WHXFN4(9D9*TWBI*3-+,@2
M21(0K,) A##M5AR7*^>4!MKIU8^P/63=M;V<-M3&X-M%+';9%;&WT1*I,._M
M+BLZO(07EKC1':Y10@:EUF1(DL#CA,/5YREBW9)+QFS:NV2CL:<E=HS4JK'$
M':!A,T!Y-E6'!(DF=YI  617D7W@%]W1[/I2QO.G=O!L8[*[79R3VFKQW8FI
MK>!4:Z1#RJM7IPQ5*[,PCFEBK.3&6D]^@[)Y/SL!V2Z$Z^ZY;]+URG[XT"6A
M2=4;(''EVJL6,0(@3A (3:%QHC!N!Z.O2(X K*:'2I+,@-7['&<,.K+A>3H]
M[1U^[GV%%)):5Y"+5=D$4L;NP=VBY)1O?!=06 (>2,]@[7S2V.A]YU!T51T&
M[EKU-UI)4;67XYS9K6(HD>*&.SVH)DX@98)&$;L&B@L*9298<](*E>.SA*JB
M0MET<!K>R4#XT([;9FQ:^5U'@DVRAB=8 S8-Q>Q2D5UY+A*#5Y]0K"W\*;#2
MK2+QE9MKGY8=<LK/'<=Z_<62(5Y%M=I)(C8O]X4@<*91+( >6$;<=I[ZM<ZA
M>M%#8T\,&P"*DUI[\$NK\0* \\0B)ORH6YD2M)5KEO*)K,?)F&D'<KJ%N3?W
M;WJ]MR#0J?<-6:2CX@[$%V(X&@+O4(J21,.1057(Y+Q7('J:W8Z(5C*1/69'
MGQ77<14H)/[G4[6I1U.QJ---%9N$M \:,PA95[4+R*4(/(!+1J>!Y@<^Z./Z
MLZ6VV[ZIZ=VB4JMK6ZA>R_'/-"ANI)('F6&M(95*=A*A+$B=S<J2%XD;,]3.
MJ'8;I7OV^T[7+P2Y]'=C%%6D)6S-I4Q?=.V4FTCUA(F%,CNQC0R&ME HNV@O
ME\N&9$&FG7; .(0C5FTVE#<48); >'<UU\-Y$BY@MQK\.]@048^;I[G".70_
M>V4IEZ8Z9WO2.[NU*!BM]'7Y/68:\UGMNZJQ(!W")'!6:-"!%*/%+2PK%,"9
MXW2:SO*$=7-D]A(?7FZ:G="DK?UVW?6MKMT:QE5 Q%Z%BYPZ7/$ME\Q9D2 9
M0L5%0.>(L(@9B2RC;LEEQ;*'H^BV5>@U^&T'6*_3DJF:->]X68,%;MY!9/>/
M<%/=R%(!\^-CUSTYL-XFBMZPPR6]%N*^R%*Q+X,-V.-XW>+Q>UU24&)1&7'9
MV/*"P/;S5=8ZV=C<=UNRW:$W1*D*J6Y>NF-65ZL1]B1B5K@'8P.FLP%$DI Q
M@?HWYE8=BDU,F%1QRI?I(,HVQ'2]*DR;#7_<C7:Y)Y6EI[#UEY#7*Q,A>4MV
M\R%^0).5Y3EN.&$9/ UU?0;X=7=0=1S4ZL=7:Z$:V"NMY9+*3+#4">(/!6'@
MO7*R$2]L?=RC3!>6U^UUTQ[IZGZK]7-,U^K:J)F=6]@#MWVEXGJTJT/4TC96
M#T"7J+8)^N%7-?G7!TT\(+60+!$W<7*R.?K<_$7,U3TZQM]1:V>RMR2652S1
M2&M[DGAB98^PBU!'(HG3N5'6-V:%P&$B\]O&CH=)]6ZSIOIS4P5M;)+K=Y-<
MV7,U<V#4>P)T?5WIZ\IHS&-YHI;$*17(F,;5W[._FO=C=9-EZ"TEY3L[N/75
M M56['W?7!S5P<CMVSG,D+).V#(;K@V58WQPRY3SH,M;!\V"2-2@[]B/!&8$
M]Y LO,)1L]?8U[USIQ*EB>*37PV$LNM6).V,0 R,(PS1+&ZQ,K*@?PXW+*.Y
M I@W^G=AI-1Z1)]K0HVJV_N4)M=#)M+,WB6'OL*\;6#'':>:&2U&\<DS1&>>
M%8Y"(I7E6Z>O<\[3NTVGK/OCJIV-K^XK/J![0&J[W<]E:6NX&$%U[5RMRGB$
M@M9"*6R)49;@DLR;;88Q5+$TJU%<DC!\I]Z/$OA)=;;CI;/7R5([?KUF"&O<
MA=GL2+$K&2R\W?V$KVPH5)"$@.RC-OHWGJ]1ZJSNNFM]#M;&J.DUMVWL-/<A
M2*C6EMO%X.NBIB+Q@DG=:G63AY0A,<;$K2+GDV^U+OD\K!U3]@4E.QBO9I>W
MHY'[;P\U1-4>#1F,LN$?4<$L&6YL7+&820ZHRF742$S\YPME$Q>H=:N^BVG?
M,:\>O%4KX)\4RAR>0O=V]A!YY[^>?+M_'FE/0'4IZ$GZ:\"F+\G4)VBR>N(:
MWJQ@5>#)V>()0Z\=GA%2"&#_ ! W5*=3]P5#L3VXWE40T:ZB^VV@(M,B5Z;8
M@XP]K;9$*J#JS&'V202EH&$*&XB/F2^9K,XT8'*;4.B5@E&8C3Y.G39U9=?J
MZ4KF%M7>,QD6-V2Q7,K2%H@H[EG\^.R141O)C(I) Z^3IG:U=[U1N*L*VX^I
M](M1('GBCFH7TK)65+!=A')2(4,TU>266/@QK6D55=J.$^3#+5G2>G-6'QED
M/WG3&MSDJB=@-%[)3KO9U.VQ=;Q=;98*T-;LY(,(+ZI@X* TQ2$Q,&R1)"#$
MP6-R]9R#(.<_4:27+=J-XTAMV$6>C=K^/7FJPPPQ)(QC5V2RW;)RH[HR.Q6;
MB-3)IHO1W+7U&JUL\<\US4Z^9J>[TVP%'8U-G<N7+4]=!8DABEUB"6$+(W98
M5A*\<7-AQ#.K'U)[>)VOY._=)6;2-QWKKI2K;6=RRB%N<J&2IVT!Y0V.9C%'
M:S.<+0(""2FRA-H,HV5>&+(9#KD%%^@P1[35>J[ZH@FJ0WYHI*@6+Q>U(V#%
M"HD 5F[?=4OV+W =X"Y-GZ8ZI&SZ%V\KT]K=T-.U7VS/:-7Q)K,3QK*LIKN9
M402D22"'QI3$7\+NE]W#V3H/N[9FY?*(F[ \#IE2[;ZTJ]2H=C@G6B,T2=I4
M&ML1W+,%BIQ+C5^PS@2_3(@RB,U 24Y'E,(E.*:3='O*=>IH4C$DLNKL22SQ
MLG:KI*9.1&Y/!= _EW!5+CD'CSS'8Z*V^QVW7<TYAJ5>I]?6JTK"3"1XIJ:5
MU4V(5]Y8)WA/<$:1Q"Q5@&/&;B=.*7OBCZXU)KO>.G=:@[!I2@#]61-H@KK"
MLLRPU>N"H@4([5H#=5CF!#16&)$+LD0P5%-JD1%2V8<M<AN,.U6VFI36+5BG
M;L.ER=K+5GA:,1R2,7?Q6,I1BK,_AE%;R/!(XY;JNE*FZIZ_5T-QJM?#/J*,
M>M38PW$L//6KQ)#":R"LLL0E2*+UA998@63O"N6"QU_W(ZV;MN'83JSVKT0W
M6K;9NNY&SPCFK+=8'*O$M=7N,7 XL_6[ N"1'"K D=((Q%K*1TQG//&3$N.J
M%9'D,^IV-.*AL]9=\2*.^L;1V8D\0Q2Q'N021@JS1]P4CM/(X9>!W]RP>J]!
MN+6\Z;ZDTHKVK&BDLI-K;4YK+9KVU$<K5YRDD<4_AM(I,BA3S&X),7AR03O'
MUDW?V7TSI^JZ_P!4Z]HI^M=DZ]O*R5]JYBV1J!80#8X9)!0G"KH^,0NMC+VA
MZ1(5 @D1OH(#K\VP2)+[2%YM-LJ>NMVY)[-B>.37O3CD\%N[N>1"O:K2,5AC
M2, =S*W+<+& .<A=8]/;CJ#5:JM1UE&G-7Z@@W%B 6XQ&(X8)TD$DBP1K);L
M2V2S=D<D85"7G9F R<^4LZW;8[6Z#H^O=35\0Q9H^V:=LDZBT'AH.*.@5T&=
MARA\J9#]JXG&G7S46*QZBF9 RU E+620VB%B7AZ>V%7679I[3N8S5EKIX:,Y
M9I)$8, W;VH A)[B&Y8<*?>XE^D'0;/J;24Z.L@B6P-G5V$XLSQPK&D$$Z,C
M.GB=\Q:95'9W)PC$R<!.['S^NN]Q?E)6NUU;K54+:VN77X;JDY@M<L!3M))X
M-B"9*9*%Q!)?)Y<:((\P=%#R\12$Z2EF47$QFE3E7#84FZ>^YDDDJV(;S64[
M8>])E['50&+KV<E_>+CE5!(1R0N6/H=U'U^.I8*]677V])'K)A+;\&:I)XL4
MDCM&D4OC%5BXC6)^UW8!I8E!?*(ZG]"=FZ-AE=&[3U90MSZZ ;O5MK5>X#>V
M[3$'@6\*@^H%)^H6XCJ%;&!IC3)\&="]4CRB)::,>M,<<T@G*F[/>5KA2Y6L
MS5+#TO5;-1*L19SPW*+;)Y%=R0K*>XA4#"(N2HTW3/16QTR2Z;9:VEMJ$&X^
MZ>MVDVSLK'"/<"2OJ@I'K\(5W1T[0TDKQFRL:B1]A.KG7#;6K^X7='<MYK(9
MJ@]C#51(TQ^)8!94H,8IV#C66[**QA'JBRR"<>1%P-D%DQW6/12LM^"7DP-E
ML*MG5:BI#(_CT$E68%&56,O9_>V\^>WM(/<$Y!\N?AF\Z<T&SUW575NVN5XA
M2WTM62H5GBEDC%7Q@18B\NTR"163PVD[2O#\?$4>_P!2^TP?;?E'=G4VL:M>
ME=G*M6ANHHFP)8.V 5R*UE@61BWJJD!Y(,O)D*Z0D@HI".= I)HA,V:/B!F2
MTN:-KK7JZ"M-)9 UTKM:: /$X$G+*89%97]Q^T.5*2=O)C/=QQIVZ8ZDBVG7
MNQJ5M:6ZBJP1:M;SPV828.V*1;E9TDB/BPF1H5D6:#Q BV%[.X'#:@Z>]I0O
M:WIGOV[56O,#-4Z+)ZQVDV]M]RRSH=BDUZU")9D  ;K8VM5BNR9-C;76Z!KZ
M*FLA!T)N'EP6IQ;F+K>VUKZS;T89).ZU=6S6(J^&IC$D3A)',C2R2 1D23SD
MRNS<GNS%J^E>I(NI>DMW<K5UCUFFDU^R!VIL.L[5[4+2P0"O'7KP,U@&O1HJ
M*\,:!.8_CFS7E/NMVUNU?7P)JG4(T)+L36SJQ<IDJQG6 (B(*KD$TT\TN1EF
M9+>G37RL=$1J/!=9PVS*<DR(ZD1VY.NZ<V-;67WM6F<1^KR1 1H7<M(R$'CE
M0  AYY8'S' /GQT/I$T&SZDT<.MU4<+SC8U[;M8G6")(ZZ3 @MVNQ=VD4*%0
M@ ,68<*&Q\OKCM2H=Y+-W0J]?5<!.SNN4G4Q_6LJP !EII=Q@S:E.#3(DR>1
M15R-0(-U"/'+KA',%A\XC+(1115MQ3#=PV%:731ZB1_":ML!:2P(W:.:$K,K
MJRJ/$65?&)4,A5@BJ73CDXVT&RK=8V.K:\'K46QT+:R?7M/#'9J6D>J\+H[N
M*SUG%55E*3>)&\CNL<H)4:1%?)B;\JO2[K=U[J\RJ7:]T7LY![%[$F2+'D-4
M1K$467&O5"KR24')(BXMHC!4U)>$P8;\UDU,?]43)B,O;E>I*,NWV-^1988)
M]<U"N!&&E8EE82R*K=JCD-R [,!V*.>"1R$GH\W=7I+0:.LU:Y=I=0IOK[-8
M\*K&JQRQFI6:1#(Y(="&,2(SB9V"]R@^_L'/I(S4E<%8V1,;9E2X;WJJI+$E
MUAK#C,MV"])B/2H^$IC.NQY4EA66<88D/,X;7GACY$@'N ) (YX(Y/F 0" ?
MCP0#Y^8!SVU/-0Q0QLX#.A[2RL5'(8H65F7@*2K,#Q[K$<'/+"G]9]Y5CN)W
MBWM*IXV72>Q>MQE/H+4.V _;<4K6J8(KL9^R09+T=@<--2A3SL=^%-*2X;4F
M)Z[ ;RJ5F)TLNQIRZG3T1*RS4+#33EHG["LDSR$1D EF0..0P120>&/ESYO5
MZ?W-;JOK#=-4C>GO=?'4I!+4/C+)7JPP*UA&91'',T1*E&D=0R=Z#WNW5R)Y
M.#LE,Z"]>.L[[-!&[&U!VC<W&<DS;8\Y5R56APMEE8S0PH.#3Y_M*<0M(D$F
M-)$,ICR52)KSF![&9"MB=_KQO-AL09VKV];ZH@$0\596-9"65G5>U5B=^0YY
M'  [CQG.#H'J!^B=%T\12COZOJ,[69GM$UY*RIL)%$<D<3OXCR68H>UHE[6[
MG)\,=V;C1>KVS;1W6VAW'.A&ZL*:Z_N::UOKE1P)*M]I+RHZG2-@MLL3/GU0
M(+;?=>'!X35@+RI:,1"A#(A4!(^3JSLJ\6GK:F-_%?UX6[%@(XBC4-PJ1!U6
M5V( 9R8T \U4,6[AU:].[&QU=LNJYX16B&C.IU]#QH6M6967F2>TT3O6AC#%
MHXD$\K,.V5_"[ C1GI[TKV30N@.P.H&X,#:I:+4*VW7V;?5BL2R#F(>T!Q*"
MP4@J1[/GYDBD3E,E!TN/":FQL(CQYSS4F1B)DVNXKS[R#:U.Z6.)JKF*53&Q
M-=E)5OPEX;CE6!8@^94$#F/TMTCL*71%[I;:^'5LV8MI +5:5+$838QR()$X
M\-^Z,/VRQL$#K[JN0Q[:J#]!]WV;7O0'2UO0!J OIULJ3?;Y?Q5@C$HET8KE
MC25J4'6D.,ANP(EV!A+>3LNW"JHFMN>D=@HL3K++4B2^[IQS[RY"7E;;5Q!#
M7="IA,D?;*UAB?#XC)/8L3R^)Y ^&">-9%T5N;-'HC4VQ!5CZ5V#7;MZ*=9%
MM+7L>+537HH$_?. /&>U'5]7/+()R #'WNC?9&31?*>U_-8K3)'N7L&';-68
M7<A:F!0[[:6(T^Q=7D-JR+FL"R\9S#8A!YAV4A^,F1A"&Y#MXW.O$W3C^)(5
MU$!BL_>FY=O"C0&$<^\I93YOX9XX/'/EF ]'=0-2](D'JU<2=5WDM:WFW%Q%
M'ZY/,RVR ?#=8Y5/$7C*6[E#< ,9\-Z>;^9VQY,:Z/UH"V&Z@::A:ZVI_P#Q
M8+7,EF,4B-1GYE383C*"HQAR DSZ2:\*E.#Y3;*(F2#;L1&%]M1-;J.(22%]
MM<:S6^]-VJAG,X64\^ZQ[BGNAAW#GGM/.3H^E=VNS]'EMJ\(BZ6U*4-E_=,1
M=I146FS5E^$L8*";ES&QC8 +X@*#NT[4FO=U]]H?9?KQM*O6?2.R=8>TNPH2
MJR,2QUAV!J2_ HNKWR"?0(P/>-V*N(),/>C:67AZPN<=QV2-M<S,NV6U8IZ0
MZ^_6DCN5[/;0>4%6C@M02&QV^?O!(Y"OXPALQ$ -$.+ZNLH[?K5.H-#LH+&G
MV&N\3>Q5F[XY[NKO0+KF?R'AM-/ )%/ ,JZZVI+1VG[NIV4ZN]N=O;5[<L#:
MWK-W66VM(8I.JS0"Y,ZP+.GV:_%B)<V])KU5D7;9DMJ1[3& @=K.3->"X+\7
M+<2%EUZ1 NU^RU56MJR9+(LU;GC6EDA-A.PR$D5 \O@UQQVL[QQK88AARW #
M6[_ISJC:;+JA8Z^O.NV>G]4ULL%M==*9Q J [5H*QM[%@WB100V9GHQ1E>%0
MEF2)#NEG9/,GR5\J;4:O$3TS@EFMJLMW@;*?EI+R*=!;;K.,1&6",Z+"J;Y.
M6R\_&@XP0A0XI.6^F6J-D;;Z\CJ51+*?NNR&L3"P [/%;F3WB54F0*" 6]UB
M4 XYBQ=)=0!O1NSU:R^RB3#9 7(V+"9JR 5_= D=4K&1P2J>^B)([=_;J:3K
MI.UC^XL-OJ7M*\]4+5V?N.PK4K2>[M8@: >]U17S+"2))OX%W9C! B<"2C%E
M'5.P58(TN*/#5F)!9@2IQC:*ZQ-J3]U*T.SBUL,$?KM.R\\?K"\QHO@.*Y4(
MX2-I8Y7(+.Y8L%7F9*\EF/JM1TQLKG35GJ*W>L_<C<:Z"C-]S9>+$C^NP'8K
M(\T32V(ZL]:$%8X:R1JC/+OB&TKN'9W<.E]V=9TT( U7:.E\*AT<3L*<S"."
MK!9JY.LU6^V%,B*DR&*\/E&1H2PPHQ)\HA,><J+&?9PRZYI'N5:VIFT]B9WM
M1;=IYG@!,;)'((Y/!F/'+L$9XV*!?->2#SG9Q:C:['JJIU?KJD4&ML=)I3IQ
M7G5)HY[%=[%;UJHA9E@C::.&=%D:0=K]JL."=<1_1WNF9C]*#UPI.O6;5UW[
M)O[&NXT'LX97J5+JJ[R+L\#W>ZOJE/$ZVUZ(@#!>(4QNO0G[,>,2Y!8M"DK=
MSZ+8-N=.C;A(IK!BOZX5X6>NTDPE\!HF\>S+*UB=V9NX>(1'&@"JPX\]"G1W
M5TJ](S6JE 6=#OVOW(X=C'7J-6]=BLQBCKJU2+7T8DCB[&\!&L32NTDJ'D\?
MT'<X7/<<<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,AEJU
MSKV]N07KO0Z9<G1F'4C7;55PEA<'I>4A3V(*R\&8J)AU3;:G<,9;PXIM&5^.
M4)SC-%8G@#"&>:$-QW"*1XPW'P[NQASQR>.<B6:%&Z4-RE4MF/GPS9K0SF/G
M@GL,J.4Y('/;QSP.?ADNCQV(K#,6*RU&C1FFX\>/';0RPPPRA+;++++:4MM-
M--I2AMM"4H0A*4I3A.,8YB))))))))))Y))\R23YDD_$Y*5550J@*J@*JJ %
M50.  !Y  >0 \@/(9R\IE<<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8SI$A
MHXQ!E"R\"$5&3F5QYHXE%8G09D=?W+8E1)+;L>0RO'W+:>;6A7]J<\N5F1@R
M,R,IY5E)5@?R@@@@_P X.621QRHT<J)+&X*O'(JNCJ?BK(P*L#^,$$'(_6Z!
M1*<Z\]4:54JJ](93&?=K=;# W7XZ%86AAYP9"BJ=90O&%I:7E2$JQA6$XSC&
M>7R3SS "6:64 D@22.X!/Q(#$\$_C/QS!!2I526JU*M8D!28*\4)*CX*3&BD
M@?B!\ADMYBR5CC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQ
MCC&.,8XQCC&.,8XQF! U6L55N<S6*X!KC12>^5)M 0X\.V1*2?#UDE.0/CQT
MRY\CS4^GF2,.2'?-QZ1Q7ACE\DLDI!ED>0JH53([.54?!06)X4?B \A^(9AA
MK5ZP<5Z\-<2.TL@ABCB$DC?A2.(U4,[?Y3MRQ_&3F>Y9F;'&,@LG5VLYIEZQ
MS-=42789$EN9(.R:C7WS+\ME6%-2GBCH]<YV2TK&%-OK?4ZA6,92K&<<SBS9
M5!&+$X0#M""60(%/Q 4-P ?R<<9#;7:]Y3.]&F\Y8.9FJP-*7'P8R%"Y8?B8
MGD?B.3KF#)F.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.
M,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQ
MCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.
M,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQ
MCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.
M,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQ
MCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.
M,9&[):A-6BID$759==\[$6&QC"Y4E2<??YB,J2E#:<YQY[SBDMI\<)\<K4E"
MN&ZZ](?3?H^UZ7=Y8=K%CO%#5U0DNPONG'?X,3.B1PQEE\:S.\<$?*IW-,\<
M3[#7ZVULI"E=!VKQXDK\B.,'X=Q )+'_ "44%CYG@*"12L[<IMQU7L\8-BL>
M.?-3)]8F/>']GG.(>BM_?^O.,,_=G[O.S_;\J[7^RBZKGL,=-H=%KZG)[$O^
MO;*UP/@7GAM:Z#S'F5%7R^ <\<GK8>DZ:J/'L6)'_&8_#B3_ %*R2M_K[_\
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MG^NQ[R+K\<<_)#?Y/C^WIZ5OUMF^JM%_"\>S^G^9CZ:S_78]Y%U^..?DAO\
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MY;C'&,D%3_K17/\ UP5_GF.=EZ.O\8'0_P#[W=.?_-Z>0=G_ (-O_P#<[/\
MY+YNAS]3L\EQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,PEF_JY8/_1"
MO^0D<Y/KW_["]:?^Z?4?_P GN9+H?].I?][K?^<F:5<_*O/7<<8RG^P=TOFM
M]$[CV!JVE.;'V32M9W:TT.A--RGUV^V@JZ0) *^F- 4@A-]IDH\>-F -6DE/
MPO,,<K$U]C/-OT_2H;'>Z?7[2Z-;K;NSHU+]\E%%.I8LQQ6+):0&-/!B9G\2
M4>%'QWR>XK9BG>2.":2)/$D2-VCC\_?=5)5>!YGD@#@>9^ \SGGOU)[)W'M%
M3]-[&T=VUK>Y2,2P5;/:_2=PHM J%WH40D.DB[<&K  1 JENUW]CK;*;E(9O
M>=BKM(,#-AURWSI[C$DKZ!U;TW4Z7N;C7;SI*SIHW@M>R>ZIWK]NC?:*59:D
M]JQ-);I[(7*:%"U :[U6>PDEFG'&"L.OJV'LI#)!;68AD]:A=(T= 1PZJH"O
M'V,>??,G>JD*Y/'/0/\ <HPYWDW1U<VMOA'4.4!A4!WJI!L%+IJJCV+@'ZK$
M(6>T$;OL(1/A6E\9=IJZC%UY0[1K<_AH<]&8,%S:R.062OT;%[#Z;JC4Z+VN
M2=]@O5;U[MSUOIR2"VT52K'1U\T<E19:*"XVPOU=E7+2JS0PP"(6*-</KLU6
M6?U0J(_5>Y$[)PR LQ>0$.1(>P1HT3>[P&9B>WTGTNWM5G5]/C;PD@9VV(0Y
MX?>"E6BH@5LV8'SYD+[0 1R94U8L18(D>,:'BI,IZ>,C3VX!%6)\>2E/F^Y.
MJ;9W&TBV(]2\@DHQ6W\2S!#(B2"M8D[4$LU9F:"25%$<K1F2/E&4G8P^+X2"
M<J90"'*#A6()'<HY/ 8<$ GD \'S!S!M]AM4OV"?7(9LN2D"=B1-2EBPFFW,
MO51.RIJ!RFJ@4MPP!+K0\BVZ6&P)LB649%CC4QBO$"$4^KV9C.>G]JM>.P\$
M,2S:Y]M#%-=I0VIM:AE!MQ4Y;"6I(R(99$5(FED@1K,<;5QXN4]8B[BH9B1(
M(B0DA42$ A"X4H#[P!)/ 8]I(;RR*7WM_P!>]91K"4N=YD"ZQ3KD)U[<[U'J
M-U+Z[IMU-E1@*#7+3?PU=(5 '/:.&108SZ\9:8K!2?%@VAX-(>;;5*H=(]0;
M-Z\5*@);5RG-L*5%K=*'8W*4$,MB2Q5U\UB.[8C,$$LT'A0,UJ*-I*JS*I(M
MDMUXPQ=^%1Q&[]KF-'8A0KR!2BGN8*>6X4D!NTG,_;^RNHJ46O0,B9L!DIJ\
M4/-[+B4:@7_8JZ".*CW# ]5KS0ZS8DB2$H*W@ZV!=5FPYK[T8_[*]BR6)[D>
MITYMKL5&>.""&+9S20:U[U_7ZX7Y(9!#)ZKZ_:K&:-)R8&L+_<XL*]?Q?'1H
MQ5[,2,ZDLQB :0)'))X8([AW]BMP2OO=OX7:0W;VGG(79>[G6&K9U)B7LS!K
M&^ZU8;=I9='I]]V*UM )5JZ]:CJZ2_0:O9&+ 3A!6D/8KX]QZP2I4P:-ABWR
M1.!$D3:W174]K[K]FL,/W LUZ>[%ZY0UIU<]NP*M<7EV%JJ:\4DY*^L2 5T5
M)9'E6**5TL>[63PN90?'5GA[$>3Q54=Q[/#5NX@?Y(]X\@ $D _9?NAU]!T9
MW8\VPW!RI#Z&#V?9YPW4>W#$V@T.PC7S(VP[)"":/-.:\;R&BRC,L=<1P8S!
M#1)9B6.9%Q9$QJD/1N_GO#71UZ8MR7Y]7623;ZB%+]^O*():^MGEO)!L3X[+
M DE*2>&2=TACD:5T1C7*ZIXA9^P1K*Q$,Q,<;*6#2*(RT?N@L0X5@O)( !.;
M#A[ +NE2%VJC'PQ@-:Z["/T^T0E).5\H,.#6R( ]$5!FQ$%P\V+*B$&,Q",9
M,^$XGT$UG#J'T\_-7EIVY:MZ":&:K8>O<JR P6(I8)#'8@<2(YAFC=7C8/&Q
MC<'N1N"ID*P=0Z,&5U#(P]Y2&'*L.".0001P?,?CS4XEO_>6D1TXCV3THT<I
M(6.[+*[MZVS9MVKXX7%1ER2;N.E[#ZCMRJ-I0EQ:A>OL[X3&:1AV4:;PM26N
MJCT.DW4B1].;HP79F5(=)U&D=*Q)*_ 2"GNJ_?J+9+'@3;'[@=Q/:L!/!:*U
MB: $V(>Y .3/6)=0!SRSPMQ,G^B/UCC\;?'C6GN!WI) J;I6YZ)M.Q:[H_8E
M4)[1LW;6B]5;KV<U_5*BQF)!K88Y7Q$ROO5YBPYF&; 9L,W$F?6(54@CG0+J
M[6B6-Z7I'H:.>YNJ>]JZZQN]=;CU5;I*_P!54NF-A;N-XCV9H+$Z3K8:MX<-
M>&LG8EI[;RK8 J%)8UN\52%X'D6&13(UM*KVHD0<!595*E0W)8L3RO8!VGO\
MM[>L-H<O.C:%=L[SK_9"/;AT@^/W#5*J)I-;M(V=/E9@)$U81/*H"I$1D(#D
M84\K/+LF8)))/,&5A8H?PW4U44=YL*7W#L=.-4E6O)I[=J:[9J2QQH)/%M31
MPF?QGYFCD2)(FADC,7B)Q+).K-WP1OXZV.\%A,B!%8$GCM0%NWM_!(+%@P//
M!\A?G-#F?'&,V_U__4T#_P (O_,O\_3+T,_XL.C_ /PV3_C;6>6;S_"MW_M1
M_P"6F3'GIV:K'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC*3W5_P!W
M@O\ C)G_ -AKGRC_ &5/^!^D/_$MI_PM7.OZ1_O]W_LHO_WOFO?/BW.YQQC/
M+WRA>F>PEPN_6S>>C:%0.Q8[KH6V$8O_ %)V.:@ 16UX-[!#@8:VU8D;CSJG
M#V30$C#F:9*M\%Z"S[=+K%R&9R7X93T[T?;GIZG2ZET>\OW^G9.HX=?#K^K=
M=!)8EU+T)Y;$]2U% \=R36[$R5Q=2FXD;U>$2JR=KPZS80V'>M/!''8%=I&D
MJR,%$H=0JNA;W/$CX;L[_+WB00?(UKUI+Z%[.ZC[PU?JHU=.G.\KW6DZWW%J
M*T5?- MG6_=QFD6FI5>\,5,:ZQ%'?:)M^!,@E:=/BC[ ]5?; ](NWRCCBMEU
M+#ONF-OT19ZK:CUCHJ-K[I:?;5;0V%3J31P7ZMNW1-N0,\H@*R1R0W8WDK"W
MX$AEIK7465S!9BNK5[ZD\B^'-$R^&]>=D=$?L'D.[R(*$!NSD</W9KAI$Y0=
M/WOJ=U?[R=3@75?L'1KI10G7+M#J$6&)Z.[ 7"L-H$^P(NP X^$; V/:@V01
MB%M<[)B//DR9?)Y,D;9W*VAKH]W7O[BCU7U1T/U9/U3T]=I7I^I.E]O+-%O.
MGZ=H^+X\FOFED@L5M5(L;P[/62!8HX?5RLE46NZ- T<+U:MVHM6='1:UF$ P
M3NON]H=0&5I02#'*/,GN\G*#/;KL#LBRZ?TGLW:%/U\;VI9J-42MC#Z^KC<A
MXW9Y0]GTOJ,"/#C39\MQMKTDQR$,A3BLUB,[%%0IA%Z-&=\3T&NK;?=:S67-
MA!JJUZW%6FV%DJL%5)&X\21G9(T4GA!)*Z0QE@\SI&KL-U/(T4,DJ1M*R(6$
M:\]S<?B  ))X\^ "3QP 21FFH[RAE'E:9LFZ:E<M6[YK,JX:<U9K-6NYA:BE
MR6XMPW1&OH.N]J5&TR[19M0R0)\G7RIN=8(KY*/59A,BQ6Y1$4D5.[&7T?7D
MW-;2VZ>TT-I*>XVNS&Q2*]#%IM/2.QDV6JN55JU=PD]>*Q% E9UB>VD436DC
ME,T<,7T,+3(\4Z]\,4?AL4)FF<1B.5&+M"58J6[@2$);M)'!LK;G8K;W5^O[
MIVGO6E4^S:$U9H>=M9K8VMIDH#8I-_%%'84G3+FO+$:L<R:X6AN#B '8Z#HH
M)EY]\:8 C%M(EN:W4=.ZGJ>QI=7H[MNKOMKOH]2=;L46Q76A-$KKN1L:\-9$
M$,@DCGUIKRS]JK+#8E!,:Y)K$M99I9T1H(H#*)(SVL9 >/!\-F8GN'!63N"\
MGAE'QR)[#[9;4T3#ZMWK;E1H9?6W9/96L]/G&J!(/-6+2MXW)%6K7\I\D7DS
MANUZ9@[AJK60["$:W*#U28=D'UXG&??#096OZ4U>];JBEJ;EZ'8]-ZS9[F!M
M@D!K;NAIF'W018H5274W?5^ZW6KO+LXI.R2K)8B=5GDMDM2P"J\RHT=F6.$^
M'SW0O,/O9Y8D2IW>ZQ C(Y#!6!*BLZ?WJW>=$=J]JV36FGJCI+I5OK?VN=V2
M6[Y=K%?CE#TGJ@)?'3NMH+=&#!IUIEDB\5M0RQO!1TV!,7!C/Q)HI,XUL[G0
MVEKR]*ZJMLMQ<W?6NAZ?V.D4T*5:A!?W>WGUXK[)_7IYXZJ10L1+66>1)%$C
M(\<IC@Q)>G86I6BA2&E/8CF^^.TC1P1+)W1#PU4N2?P6*@\\ @CEK5UQV;["
MVS9>CXDK1,TWJ+<E;*%;;; =2OE4?Z^E<5R+8JJP?/7AN,(W!6K,\Z_6_M-4
MA%,EC22(A1RN2!,SSF-5L>FNGZFMWCKNT@V^FLPPU*L]NA;7J&(V6K6GKUZ)
M>;36:JA;1K7)[J21%XA969/>RQV9WD@^\%HIE)=E21?5SVAD#,X"S*WFO<@0
M@\'M(/EL1V* :B)T1)W<FQR&H*]32&#\'9@S;QG2DFHE,19,-N<NX"[#7H3\
M5R/)?9D@;*LM63#:LQRX0DQCT/.>Z>GVT=_P-/KH]O9N1FN^LDU$.[%N+O20
MQK3EK67#AD5EGJB*U"1W0SQ-[V2+"Q%.Z:0Q*A[A()FA[#P1SWAE''!(*MRI
M^!4C-+]:[C[4G+9#J>E)A_L[I4K",PU=A=R:NCZ"GT5_(B;D"='VKU>KANR(
M]PK@<U&QK;KW7*](AXFS9VS)C_HH[W9;+3]+P5)+6Z2#IG=1/"XZ>TVT;?QW
MU\9!/!)5[K4W3<BQ&0O]U.HK-D.$1-9&O+B)'-99PD):S"P8&Q-%X!C/:>U@
MW""R"W''A5U7@D^*?(9YA;-MMMU1Y+.FI*ZSV_KORD&IMMZM4/M5GU/?HUHM
M?9([V& B[ 6@[L76U4G9@K<U8,V"*^V*O1X9;*D;D5QV,^R.?'0O3M93I;7T
MI7/"V>HV/HXVVIVOB5:NUU[5J?34'3MB:O#)I!9]?U<NELPUV4RT*\U2Y72R
MK*9%E?62N\6K3[U-'L8IHNUVAD[GLM81683=OARK,K$<!V5T8J00I _J(3YV
M4IRK&,*\,>=C&<JQA7A]^,9SC&<XQG[L9SC&<X^_PQ^KGS%G2Y^\8R05/^M%
M<_\ 7!7^>8YV7HZ_Q@=#_P#O=TY_\WIY!V?^#;__ '.S_P"2^;H<_4[/)<<8
MQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC,)9OZN6#_ -$*_P"0D<Y/KW_[
M"]:?^Z?4?_R>YDNA_P!.I?\ >ZW_ )R9I5S\J\]=QQC*KW8_MJ+K*RS=%P*^
M7VK R%(U,):IR!5<L#H^PB9I:N&"ZHTU0:%8@+!4(Z:CPY<P/Z_@G!C/S(K#
M2]II5U+[.LF\DL0ZN3QH[<]6/Q;%<25Y4BLPP]\8F>O.T4X@9T2;PS$[*CL1
MBF\41L8 IE'!0.>%;A@2K'@]H905[@"5YY Y&>:VZNHMNWKVGZH]A]=:)7U>
MVUJ7;H.Y[WWSFU:^:F[,U",&SF;7I*+ UG9S9K9J;_.4+&(L.RP=1Q7*I'GN
M,)7)(NUW'I&EZNJZ+I;JOIW8[P=3ZC;ZBQ3T6@%6^T>LW$LJ-4WCR;.K!!K#
MKT$LIKZR>X;-MXPWN1"SFNFJ//:JV(X/5IHI5>>?NCYEA (> "-F,GB'@=TB
MIVIS^,]F7+NG7-TWK1=RZ<[/=.PG9"CS+A<_<Z2K]KU7"<E5$FMV349UA=NM
MCIQS55NK6)_V?8M5"5:SCXH,BQ+:8-2G0\S3Z795-%>TVXZ7ZPGZ;O)3I_=A
M+%7:.$N1\+;CKBE6NP;6G9\/UEJM\5(%EF-;EH4$Z9IHWGCFALU%L(7?P2KQ
M@E#YH6+LC1.G/;WQ][%1W?A'M-O]#=);4ZX=0]%Z1W9?T[.V=KVI/![/;FYI
M G%=4^<+$Q  >3+,QB1,52P4\73!)&;%B2)PT!%E+AP_2XBM:CKO=ZKJ/J[>
M[O2:_P"Y>KV-L35:9CBB90((8IIY(H6>**6[8CENS1QNZQRV'0._'<<U&&6O
M4@AGD\66-"K/R2#[Q*J"P!(12$!(!(4'@?#-7C_57;D??[6\M&CK5H#89_L0
M*)[J2%OP$WUHW]I 7;6&2%HONHRA<N1'[J*ZL'Q!PBR5*L5XW'OJ6IA2QM"I
M+Y(9TT'5.I?I]M'O)*N_U]?IZ:+2&>A/!U+T_NY:C-%5H;>**&.321;61I9J
MMNU8@;7]R0UC,JQ21FJRBP)X0T$C6%,X6136GA#<%I(B21.8@ &15(?S+<$D
M=CK7K?N1UO:V!UP=U%K7:.JB.Y=M[&UEV'+;/C#V(-7W#LNQ;3FP-K:PD 95
MP/W>HG[284TJN3<!KAZ,:.78:<VAT\S;U+L>CNH_N?U$NWV6LVL>ET^MV?3L
M6K:0O:TVLK:E)=5LUL+3KT;=>I!R+$9GI<RRBO=)6N5:.Y7\2OX4<D1FEDBL
M&4#A)I&E(EB[2[.C.WX)X?R'<GX63[3VG=U=9M\=P[")IZMR:Q[,['';VI<P
M-9JR#LU+V#(I06FVZCWN/<BH9'V/?S6 $VGV&J.V>8.&*)#2-9;>A0WBD'<;
MC2]3:+H^O-;&GV?36MDT-U)JUF>K=URW9[M2]1:G%.?7%];LI<K6Q6223PI8
MK)#NL5\,,U:>VP3QHK,@G0AE#I(45'23O*CL]U2C)W$#D%?($ZMZ;Z&;BZ[V
MGR6H,0&CWVK]1T]MC.Y;0#-UX4*B'>S@4Z]%#:]"V,R*-E:[4+18IL#"Y8\.
M]BI0A\^-%EF)$H-&ZG<=>:?J&IZ4YYIFH6NKCTE#IJD\-B:9X.F)JZM-L)ZT
M,M>&S<J5D<A9)5-UY8V=(%2=XT-&:NVK50)%J>M&9E*J UE6\HU8@E4=B/,
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M"[K[4].U"WQCL5I6AE3\7(#H>"/)AP1Y$9[!%(DT<<L9[HY461&'XU<!E/\
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M1C"$N*QEMQ.$(<RWYOI,?.WIA]"*=;3/U'TW)7I]2")$N5ISX53<I"H2)GF
M/JVPCB584F=3#.B113M"$$XZ72[XT%%:T&DJ\DHR^;P%CRW"D^]&22Q4>\I)
M*AN>TT#-K-A'.J:F!232DY\/.Q$==:5G_P#EOLI<8=Q_>VXK']_/C;:] ]:Z
M2=Z^SZ6WE9T)7O&NL6*SD'@F&Y62:I.O/EW0SR+_ #YV\.QHV%#0VX'!'/'B
M*KC_ *R.5=?]#*#G1]E%/AL_\G(^GS4^SV__ $'N/JR[_49F]8K_ )^'Z5/M
M8]E%/AL_\G(^GQ[/;_\ 0>X^K+O]1CUBO^?A^E3[6/913X;/_)R/I\>SV_\
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M9QC.,XSCPSC.,_=G&<?=G&?NSCE&565E90RL"K*P!5E(X*L#R"""001P1Y'
M)!Y!X(\P1\0?RY15KU*XZ^]/K*V4I=4IQP2^OT24+5GQSB$^KQ;2A6<YSAA_
M+:&OOPA[S/-;1\A>D;^QOFL7+&WZ!DJQI8=YING+<@K)#(Q+,-3;8&%878^Y
M3MM!'7'<(K7A>'7B[36=3JJ+#L58E0%%I!W%@/@9D'O%A^-T[BWXT!Y9JS<H
M=P;5E"@$[.<9\,Y;PTZG_P"BVG%H5C^_"LXYX--Z'_2;7D:*3HW;LRD@F%(+
M,9(/'NRUYY8F'Y"KD'X@D9T"[O5, 1=A /\ *[U/^M64,/\ 6!GQ]AK=^'R/
M_)Q_%S%_:E])7ZF;S]E_^O*_=G5_/H/_ (C_ $8^PUN_#Y'_ )./XN/[4OI*
M_4S>?LO_ ->/NSJ_GT'_ ,1_HQ]AK=^'R/\ R<?Q<?VI?25^IF\_9?\ Z\?=
MG5_/H/\ XC_1C[#6[\/D?^3C^+C^U+Z2OU,WG[+_ /7C[LZOY]!_\1_HQ]AK
M=^'R/_)Q_%Q_:E])7ZF;S]E_^O'W9U?SZ#_XC_1GPY2;8TA;K@$@AMM"G%JR
MUCP2A&,J4K/Z7ZL)QG.?[L<QS>BKTBUX99YNC]U'#!&\TLCUN%CBC4O(['N\
ME1%+$_B .57;ZQF55NP%F(50&/))/  \OB2>,XHE1LT^+&G0PLZ1$F1V9460
MTWA3;\>0VEUAYO/G?>AQM:5IS_:E6.1=9Z-^N]SK=?M]7TMM[VLVM*KL===@
MK]T%NC=@2S4M0MW#NBG@DCEC;@<HX/'GE\NTU\$LD$UN&.6&1XI8V)#))&Q1
MT8<>3*P*D?E&=C[#6[\/D?\ DX_BY._M2^DK]3-Y^R__ %YC^[.K^?0?_$?Z
M,?8:W?A\C_R<?Q<?VI?25^IF\_9?_KQ]V=7\^@_^(_T8^PUN_#Y'_DX_BX_M
M2^DK]3-Y^R__ %X^[.K^?0?_ !'^C'V&MWX?(_\ )Q_%Q_:E])7ZF;S]E_\
MKQ]V=7\^@_\ B/\ 1C[#6[\/D?\ DX_BX_M2^DK]3-Y^R_\ UX^[.K^?0?\
MQ'^C'V&MWX?(_P#)Q_%Q_:E])7ZF;S]E_P#KQ]V=7\^@_P#B/]&9X1JRTD74
MXF1VQ$;QQY[\MQM;OF_V^BBL+6ZI>,?J2[EA&?VF.=ATU_8]>D+=V(QLZ4/3
M= L/%M[*>"6<)R._P-?4FEL22@'E$LFG$Y!!L+D.UU)K:ZGPG:U)^)(E8+S^
M+NE=0H7\I3O(_DYL17*V.K ], >C.?.SAR3)<\,ORW_#&,N.JQC&,8QC]%MM
M.,(:3]R<95E:E?;70_0VCZ!TJ:?2Q,>]A-?OS]IN;&UV]IGL.H"A5'N00(!%
M!'[J@NTDDG!W[]C8SF>=AY#MCC7GLB3^2H)/Q^+,?-CYD\  9_G99"QQC'&,
M<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,@AW^
MO5!_X:W_ .1&\\<ZQ_QP^AC_ +AZ3_\ Y/H<W='_  +O?^OJO^(GR=\]CS28
MXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC
M&.,8XQCC&.,8XQCC&.,8XQCC&=$I_P!VD?\ @9?^7<YI^H?\ ;S_ ,'V?_!3
MYGJ_])K_ /;P_P#F+F H/]1:7_\ *E>_Z1$YQ?H6_P 3OHH__+?HC_TSK,G;
MW_#FY_\ %=C_ ,7-DMYZ9FJQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&
M,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC((=_KU0?\ AK?_
M )$;SQSK'_'#Z&/^X>D__P"3Z'-W1_P+O?\ KZK_ (B?)WSV/-)CC&.,8XQC
MC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,
M8XQCC&.,8XQCC&.,9T2G_=I'_@9?^7<YI^H?\ ;S_P 'V?\ P4^9ZO\ TFO_
M -O#_P"8N8"@_P!1:7_\J5[_ *1$YQ?H6_Q.^BC_ /+?HC_TSK,G;W_#FY_\
M5V/_ !<V2WGIF:K'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8
MQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,@AW^O5!_X:W_Y$;SQSK'_'
M#Z&/^X>D_P#^3Z'-W1_P+O?^OJO^(GR=\]CS28XQCC&.,8XQCC&.,8XQCC&.
M,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQ
MCC&=$I_W:1_X&7_EW.:?J'_ &\_\'V?_  4^9ZO_ $FO_P!O#_YBY@*#_46E
M_P#RI7O^D1.<7Z%O\3OHH_\ RWZ(_P#3.LR=O?\ #FY_\5V/_%S9+>>F9JL<
M8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC
M'&,<8QQC'&,<8QQC'&,<8R"'?Z]4'_AK?_D1O/'.L?\ '#Z&/^X>D_\ ^3Z'
M-W1_P+O?^OJO^(GR=\]CS28XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&
M.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&=$I_W:1_X&7_
M )=SFGZA_P  ;S_P?9_\%/F>K_TFO_V\/_F+F H/]1:7_P#*E>_Z1$YQ?H6_
MQ.^BC_\ +?HC_P!,ZS)V]_PYN?\ Q78_\7-DMYZ9FJQQC'&,<8QQC'&,<8QQ
MC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,
M<8QQC(A9*X2+D 942;:"S0F":$+?%)*M/H*-1F74J:5.A8;RVF/XI5YR_'*_
MU)\W]+S'KSH7?=3;OI'J/IKJVOTIM^DEZ@CAEM=.1]25[D/4-:C5L(]:3;:H
M0M"E(%'$DI8R?@KV>]MM=L*U2"[6MTWN0W/5BRQVC59&K.[J0X@G[@Q?@CA>
M./B>?+I^Q+]^.AG^#&O]?YJO9+TS_P">+0?[J:W_ #EF;US0_H2U]<M_#\>Q
M+]^.AG^#&O\ 7^/9+TS_ .>+0?[J:W_.6/7-#^A+7URW\/Q[$OWXZ&?X,:_U
M_CV2],_^>+0?[J:W_.6/7-#^A+7URW\/Q[$OWXZ&?X,:_P!?X]DO3/\ YXM!
M_NIK?\Y8]<T/Z$M?7+?P_'L2_?CH9_@QK_7^/9+TS_YXM!_NIK?\Y8]<T/Z$
MM?7+?P_'L2_?CH9_@QK_ %_CV2],_P#GBT'^ZFM_SECUS0_H2U]<M_#\>Q+]
M^.AG^#&O]?X]DO3/_GBT'^ZFM_SECUS0_H2U]<M_#\>Q+]^.AG^#&O\ 7^/9
M+TS_ .>+0?[J:W_.6/7-#^A+7URW\/Q[$OWXZ&?X,:_U_CV2],_^>+0?[J:W
M_.6/7-#^A+7URW\/Q[$OWXZ&?X,:_P!?X]DO3/\ YXM!_NIK?\Y8]<T/Z$M?
M7+?P_'L2_?CH9_@QK_7^/9+TS_YXM!_NIK?\Y8]<T/Z$M?7+?P_'L2_?CH9_
M@QK_ %_CV2],_P#GBT'^ZFM_SECUS0_H2U]<M_#\>Q+]^.AG^#&O]?X]DO3/
M_GBT'^ZFM_SECUS0_H2U]<M_#\>Q+]^.AG^#&O\ 7^/9+TS_ .>+0?[J:W_.
M6/7-#^A+7URW\/Q[$OWXZ&?X,:_U_CV2],_^>+0?[J:W_.6/7-#^A+7URW\/
MQ[$OWXZ&?X,:_P!?X]DO3/\ YXM!_NIK?\Y8]<T/Z$M?7+?P_,#9OM_70DLO
MBY"Y>8KD)&(^:BTQA?K<^+"\?2X-.^;Z/UGTGAZ-7G>9YGBGSO.QQ?I"_MU=
M#=);/J=/2IT]LVU\VIB%)O1E7J++]T]SK]26-@=5V2G@B\9P/!;Q#$(^4[^]
M9VN^X.PN15/N1:A\59CXGW6:3M\*"2;CL]23GN\/M_"''//GQP<][$OWXZ&?
MX,:_U_G:>R7IG_SQ:#_=36_YRR#ZYH?T):^N6_A^/8E^_'0S_!C7^O\ 'LEZ
M9_\ /%H/]U-;_G+'KFA_0EKZY;^'X]B7[\=#/\&-?Z_Q[)>F?_/%H/\ =36_
MYRQZYH?T):^N6_A^/8E^_'0S_!C7^O\ 'LEZ9_\ /%H/]U-;_G+'KFA_0EKZ
MY;^'X]B7[\=#/\&-?Z_Q[)>F?_/%H/\ =36_YRQZYH?T):^N6_A^/8E^_'0S
M_!C7^O\ 'LEZ9_\ /%H/]U-;_G+'KFA_0EKZY;^'X]B7[\=#/\&-?Z_Q[)>F
M?_/%H/\ =36_YRQZYH?T):^N6_A^/8E^_'0S_!C7^O\ 'LEZ9_\ /%H/]U-;
M_G+'KFA_0EKZY;^'X]B7[\=#/\&-?Z_Q[)>F?_/%H/\ =36_YRQZYH?T):^N
M6_A^/8E^_'0S_!C7^O\ 'LEZ9_\ /%H/]U-;_G+'KFA_0EKZY;^'X]B7[\=#
M/\&-?Z_Q[)>F?_/%H/\ =36_YRQZYH?T):^N6_A^/8E^_'0S_!C7^O\ 'LEZ
M9_\ /%H/]U-;_G+'KFA_0EKZY;^'X]B7[\=#/\&-?Z_Q[)>F?_/%H/\ =36_
MYRQZYH?T):^N6_A^/8E^_'0S_!C7^O\ 'LEZ9_\ /%H/]U-;_G+'KFA_0EKZ
MY;^'X]B7[\=#/\&-?Z_Q[)>F?_/%H/\ =36_YRQZYH?T):^N6_A^/8E^_'0S
M_!C7^O\ 'LEZ9_\ /%H/]U-;_G+'KFA_0EKZY;^'YQO5^]OLNL.7H;Z-YIQI
M?A3&L9\QQ.4*\,^WONSYN<^&?[,\CV^B?3'<JV:<_IBT1AMUYJTP7T55E8Q3
MQM%(%;VR/:W8QX/!X/GER7]'&Z2+I+7<C*Z\[EB.5((Y'W/\QR,E($7@&##!
M</YDX$"AXS$G+?H<R,0(C,7#V6L+<PUEW#7GY;](YYGG>;YZO#SL^C=&=.KT
MATATKTFMLWUZ8Z<TG3ZWF@%9KHTVMK:X6S6$LXKFP*WC& 3S"(OV>+)V]YU=
MZUZ[=N7"GAFW:L6O#[N_P_'F>7L[^U>[L[^WN[5[N.>T<\9EN=+D7'&,<8QQ
MC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,
M<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQ
MC()LO^I9;_SPW_71G/&_3_\ XI^I/^^=*?\ K'I_-WT[_ABK_P!2Y_P5G)WS
MV3-)CC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQ
MCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.
M,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQ
MD$V7_4LM_P">&_ZZ,YXWZ?\ _%/U)_WSI3_UCT_F[Z=_PQ5_ZES_ (*SD[Y[
M)FDQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8Q
MQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&
M,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,9SX
M8SG[_NQX_=C.<_=_NQCQSG/]V,9SG^SE"> 2>> "?($GR_( "2?R  D_ #G'
M_P#'Y/\ _.4=L+8U)EUHL+CV&&LCB2-1F%EN4W(2N*9@NR4+;=CH4A;+;+JG
M$+\U2?,5C./.QX<^0?3?Z=_1'M.@>I>G*/7&KFWHV&AA?5-%L(+L<VMZKT]B
M_#+#8I1-%+4AJ67GBE[)$,+H5[QVYVN@Z>W46QJVGU\PK^'883!HFC*R5)UC
M(99""'9U"D<@\C\66$&OM0L4W X(<BDIN6UN^@BMR5J2TWC&5NN*RQA#3:<Y
M2GSW%)3E:D(QG*UI3GV_I/TT^B[KK;+HND.L-?O]LT$UHT]?#L)'CK0 &6Q,
M[4TAKP(61/%GDC1I9(H58RRQHVAN:+;Z^$V+M*6M"&"]\K1 %F^"J.\LS'S/
M"@G@%B. 2)?SU#-1CC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.
M,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQ
MCC&.,9&#-SK !>6BAB*Q(3CQ5%;])*E)\?U>?'BH>>;\[^S+B$8SC[_'P\<\
MX'J?TH= ]'2M6Z@ZFH4[B %Z$/C[#81]PY3QJ6NBM68 X/*-/'$C#DANT$C9
M5-1LKR]]:I+(A^$C=L<9_+VR2LB-Q^,*21^3(W[W*/\ $9/RZ=]'G#?*1]$_
MZ:OG_P#LFU__ -ULV'LKNOF\?[1#]O'O<H_Q&3\NG?1X^4CZ)_TU?^I-I^[8
M]E=U\WC_ &B'[>/>Y1_B,GY=.^CQ\I'T3_IJ_P#4FT_=L>RNZ^;Q_M$/V\>]
MRC_$9/RZ=]'CY2/HG_35_P"I-I^[8]E=U\WC_:(?MX][E'^(R?ET[Z/'RD?1
M/^FK_P!2;3]VQ[*[KYO'^T0_;Q[W*/\ $9/RZ=]'CY2/HG_35_ZDVG[MCV5W
M7S>/]HA^WCWN4?XC)^73OH\?*1]$_P"FK_U)M/W;'LKNOF\?[1#]O'O<H_Q&
M3\NG?1X^4CZ)_P!-7_J3:?NV/97=?-X_VB'[>/>Y1_B,GY=.^CQ\I'T3_IJ_
M]2;3]VQ[*[KYO'^T0_;Q[W*/\1D_+IWT>/E(^B?]-7_J3:?NV/97=?-X_P!H
MA^WCWN4?XC)^73OH\?*1]$_Z:O\ U)M/W;'LKNOF\?[1#]O'O<H_Q&3\NG?1
MX^4CZ)_TU?\ J3:?NV/97=?-X_VB'[>/>Y1_B,GY=.^CQ\I'T3_IJ_\ 4FT_
M=L>RNZ^;Q_M$/V\>]RC_ !&3\NG?1X^4CZ)_TU?^I-I^[8]E=U\WC_:(?MX]
M[E'^(R?ET[Z/'RD?1/\ IJ_]2;3]VQ[*[KYO'^T0_;Q[W*/\1D_+IWT>/E(^
MB?\ 35_ZDVG[MCV5W7S>/]HA^WCWN4?XC)^73OH\?*1]$_Z:O_4FT_=L>RNZ
M^;Q_M$/V\>]RC_$9/RZ=]'CY2/HG_35_ZDVG[MCV5W7S>/\ :(?MX][E'^(R
M?ET[Z/'RD?1/^FK_ -2;3]VQ[*[KYO'^T0_;Q[W*/\1D_+IWT>/E(^B?]-7_
M *DVG[MCV5W7S>/]HA^WCWN4?XC)^73OH\?*1]$_Z:O_ %)M/W;'LKNOF\?[
M1#]O'O<H_P 1D_+IWT>/E(^B?]-7_J3:?NV/97=?-X_VB'[>/>Y1_B,GY=.^
MCQ\I'T3_ *:O_4FT_=L>RNZ^;Q_M$/V\H;:T>@7):38 EZA8O.:1+P\.GM0R
MC'G)1ER0IN,O+<R.C]),A*%9?:1Z!U*E89<;^,?[)/2^AOTK2KU;T3NQI>N_
M$KP[,6M+MJVJZBJ=R0FQ?>"C*\&THP^_'=2&1KE>+U.RCNM6:#N>EIM[IP:5
M^OX^OX9HNRQ TU9^"0L8,@[HI#Y%"1V,>]2!W*9[0#NL*"(3!@D)$B?(PA90
MHL5,2_.?3C/AC&/0JRS$9SE28T9*LI;3G*UY<><==7[1Z$^I?0!Z%>F$T^GV
M]V]NKRPS=1]1S=/;)+FXN(IX51ZN[5=959W37Z]'9(49Y97GMSV;,VBWU/J7
M?6S// D<$99:M5;,)2%"?B?? >5^ 9)".6/  5%51//>Y1_B,GY=.^CSV;Y2
M/HG_ $U?^I-I^[9H_97=?-X_VB'[>/>Y1_B,GY=.^CQ\I'T3_IJ_]2;3]VQ[
M*[KYO'^T0_;Q[W*/\1D_+IWT>/E(^B?]-7_J3:?NV/97=?-X_P!HA^WCWN4?
MXC)^73OH\?*1]$_Z:O\ U)M/W;'LKNOF\?[1#]O'O<H_Q&3\NG?1X^4CZ)_T
MU?\ J3:?NV/97=?-X_VB'[>/>Y1_B,GY=.^CQ\I'T3_IJ_\ 4FT_=L>RNZ^;
MQ_M$/V\>]RC_ !&3\NG?1X^4CZ)_TU?^I-I^[8]E=U\WC_:(?MX][E'^(R?E
MT[Z/'RD?1/\ IJ_]2;3]VQ[*[KYO'^T0_;Q[W*/\1D_+IWT>/E(^B?\ 35_Z
MDVG[MCV5W7S>/]HA^WCWN4?XC)^73OH\?*1]$_Z:O_4FT_=L>RNZ^;Q_M$/V
M\>]RC_$9/RZ=]'CY2/HG_35_ZDVG[MCV5W7S>/\ :(?MX][E'^(R?ET[Z/'R
MD?1/^FK_ -2;3]VQ[*[KYO'^T0_;Q[W*/\1D_+IWT>/E(^B?]-7_ *DVG[MC
MV5W7S>/]HA^WCWN4?XC)^73OH\?*1]$_Z:O_ %)M/W;'LKNOF\?[1#]O'O<H
M_P 1D_+IWT>/E(^B?]-7_J3:?NV/97=?-X_VB'[>/>Y1_B,GY=.^CQ\I'T3_
M *:O_4FT_=L>RNZ^;Q_M$/V\>]RC_$9/RZ=]'CY2/HG_ $U?^I-I^[8]E=U\
MWC_:(?MX][E'^(R?ET[Z/'RD?1/^FK_U)M/W;'LKNOF\?[1#]O'O<H_Q&3\N
MG?1X^4CZ)_TU?^I-I^[8]E=U\WC_ &B'[>/>Y1_B,GY=.^CQ\I'T3_IJ_P#4
MFT_=L>RNZ^;Q_M$/V\>]RC_$9/RZ=]'CY2/HG_35_P"I-I^[8]E=U\WC_:(?
MMX][E'^(R?ET[Z/'RD?1/^FK_P!2;3]VQ[*[KYO'^T0_;SZ3MJC*5C&2CZ,9
MSX><H:0\W']^?,CJ5X?^"<\OC_LCO1+(ZHV^N0ACP9)-'N"B_P [>%3D?C_J
MHQ_FRAZ6W0!(K(W'XA8@Y/\ HYD _P#UR:"C@@XSE\21BSVT^'G^KNX4XUG/
MZL/,Y\'6<Y_L2ZA&<X^_&.>I]/=6=-=65FN=.;O7[B!.T2^IV$>:N6\U6U6/
M;9JNP'*I8BB=AY@$>>:>S3M4G[+5>6!CSQXBD*W'Q*-YJX'Y48C^?,KSH<C8
MXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQE+;4OL@&E  ,]EDE)9
MP[-EHS_20HSGCAMIG/\ \$J1C&5>D^Y;#/FK;QAQUMQOY9_LA?3#<Z32/HWI
MBRU;>WJRV=KLX6XGU-"?N6&O4<><6PN!6D,_E)3J^'+"!-:AGK]?TSHX[I-Z
MVO=7B?LAB/X,TB\%F<?CB3D#M^#ORI\D96UB6I2U*6M2EK6K*EK7G*E*4K.<
MJ4I6<YRI2LYSG.<YSG.<YSG/CSX(DD>61Y97>261VDDDD8O)([DL[N[$LSLQ
M+,S$EB2223GI          '  'D  /( #R 'PSYY9E<<8QQC'&,AEWV/KS60
MR,:V1?*9KX/,FM#(A:[V@'4QDHD\AQQD?&GGIT"*_-=;:=<:B-.J?<0VXI+>
M4H5G$ZAK-EM97@UFOO;*=(S*\-"I8N2I$I :1XZ\<CK&I8 N0%!(!/)&8Y)8
MH@&EDCB4G@-(ZH"?R L0"?YOCG;J=XI=]'OEJ-;ZO=!<62W"DDJF?$V(?'F/
M#H!=J(_,#RYD=J2Z)*BRC;#CB75CB4":E&8TR.ZY9<H7M?(L.PI6Z,S(9%BN
M5IJTC(LLD#.L<R(Q030S0E@"!+%)&3WHP%4DCD'=&Z2*#P2C*X!X#<<J2.>U
ME;C\A!^!&2CD3+\<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8R,V
MRZTVA"5G[U;:S2P3:UMN&K8>%UT2AQN+)G.-K(F)4.&E:(4*9,6C+V%)BQ),
MA6,,L.K1*IT;NPF%>A3M7K! (@IUYK4Q!=(P1% CN09)$0$+YNZ*/>90;'DC
MB7ND=(U^'<[*B\\$\<L0/@"?] )^ SMUNS5RY 1%JJ%@"6NKGX+!0%9*V5@'
M )L9*1AR*1$&!<B4.)09+><+8EPY#T=Y&<*;<4G/CRRU5M4;$U.[6GIVZTC1
M6*MJ&2O8@E0\/%-!*J2Q2*?)D=593Y$#*HZ2*KQLKHP!5T8,K _ JP)!!_$0
M2,S?,&78XQCC&.,9$(NP:%.N,S7<*[U"9L <)</D*+%LH:1<8 )J3"ANFIE8
M:FK-Q1+<PD.BN$GX*(:))"$PI[#LIA#DQ]=L$I)LGH7$UTDPK1[!ZLZTI+!6
M1Q EHH('F*12N(ED+E8Y&"\(Q%@EB,AB$D9E"EC&'4R!00"Q0'N"@D DCCD@
M?C&2_D/+\<8QQC'&,A5]V3KK50%5IVA?J5K>L(DM0UV.^VH%3P*9C^%J8BJ+
MV&>.'IDO):<4TQF1AUS#:\H0K"%>$[7:O9[>P*FIUU[:6RI<5==4L7;!12 S
MB&M'+(54D MV\ D<GS&8Y)8H5[YI8XDYX[I'6->3\!W,0.?YN<SP"P ;6%&6
M2KFQ%DKIJ(U/#G@!*$8"EH#^/.8FC"@YZ3!GQ'D_I-28K[K+F/O0O..1[%:Q
M3GEJVX)JMF!S'/7L1/!/#(ODT<L,JK)&ZGR*NH8?C&7*RNH=&5U8 JRD,K _
M A@2"#^(@\9E^8<NQQC'&,<8QQC(IF^4?%P1KS-RJF+^X(?L#=&S8A&+@X!B
MNQ6))M%9]<]M*$1WIT)E\DF%F&T[,BMN/)7(:PN9]S[_ *D=EZC<^YPF6L=A
MZM-ZD+#AV2N;79X F98Y&6(R>(P1R%(5N+/$C[_"\1/$*EA'W+WE1QRW9SW=
MHY')XX'(_+DKY#R_'&,<8QQC'&,<8S(#"A --9(#)3L26PK&4.M*\/''CC*F
MW$Y\4.M+\/!QIQ*FUI^Y2<XYN-#U!N>F-I6W.AV%C6[&HP:*Q7?M++R"\,T9
MYCL5Y0 LU>9)(9D]V1&'EF"S6@MQ-!9B26)QP5<<\'\3*?BK#XJRD,I\P1FX
M]'M;-N"-S_-2U-85ZL2CISGS6I24X5Z1O&<Y5Z"0C*76O'.?-\5LY4M32E9_
M3OT4>D2MZ2>E8-OV1UMK4D]1W=&,GL@OHBN)H Y+^J7(F6Q7[BYCYDK-)+)7
MD<^2;G6/JKC0<EX7'B5Y#\6C)(X;CR[T8%6XXYX#\ ,!DQYZ;FIQQC'&,<8Q
MQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8S1VYS'9ULL,AW.<JR7FLI\<^.4LQ7
MUQ6$_P#[&&6T_P#TY^3?I1V5C;>D7K6[98M(>I-K53N/)6MKK4FOIQGG\U4J
MP1\? !>!Y 9[-IXE@U="->./587/'P+RH)7/^MW8_P _.1GG!YLL<8QQC'&,
M<8SS/[EZ2[$'-[:6[/\ 4NQZPM>Y.NM-NP YUYVY.>A5V^:]VY*@XESJ_81Z
MWINM[V0DT.:*KMHG04A3F1\@<2)L"0ID:7]2Z(WO35?I_>]*=8U=M4TG4U[7
MV(.I=-&LEK7;+2K(4CLUI0L>TU\:;%)K52.3UBOXBRQ1--/!+#JKU>TUFO;I
M-"\]:.16K3'A9(IB.2K#SBD/AL%<@!N""W:K*U==>MZSMRZF[G&^J.GHW7+O
M!5K;[4W5UZW,#:*UN+OZ/2(<0-(GRJF8JL(Z&VL!JPX9"V,**#?:JQS%JGB'
M$>ER9V74O3R:/<]#U^K]VW4W05ND(M'U)HYS%9?IMK\C3I$MR"Y)7GT]BW+,
M^KFAF\$2M3BF4D>!BK6#/!?:E *M]'YGK3KW*+ C ')0H&$RH%$@(Y([ROGR
MUX=;NV%A[3">O!G6\X)"8.:EL%^[%P3E7FK+4"VP2:]>#-:NC46 ?(K5D<VH
M#V3$<3/]K-R 6J;1'3ZK))ARR=!U/T?7Z2GZD@VB6)&K[BMKNFI*]J,0[&G)
M%]TY=J)36E6U5&HGU;#PO!9;&XJ/[Z13PYGJW7N"JT)4!H7EM!D):-P?"6+M
M[E*.9EE'GR"L+_ E3FFI+OCVX&=/+OV\?DZ'E-ZB[6E])6#6D775V'L;!J4/
MM*)Z\HG0[=(VD7DT0QB =C&F,^P;DPR0&O29/K\0D@*-[F+T>]&S=:T.BU7J
M%#NND(=]6VC[.A*VMN2=)3=2^')2340KL(/$KO W]T46:*557PWB,\L$[&Z*
M,ETFN? N- \0BD D06UK<AS,3&P# CW7'()/// V\@;W[ UON+=NKEML>K;3
M'*]0RW9C7]L$ZSLE834CM=V;%UP2J=A!N[4/O6X#-29$&8DN,<K15AZ,3ANR
M%M2(CD;BY>G^G+/1-'JVG6VU1H.LX>EME2FVM6V;E>SJGVD5NM8745EI6$,$
M\#J]>U"5>%PG<D@>:+-E+TE1VA?NHM;B<1,@1DE$3(Z^,Q=3W*P(*'XCG-0@
M7>GN/#Z6=:_* 69W1%AUY?#^K!VX-'UG6MU"6>'6=J;3@ZM9/Z^V'.VL?1*L
MH8V;!RXE9)TAR!*&2)<&06?F0$F9_:6.@.B7ZZZI]'-4=0UMEKZ^XDTF_M[2
MA/4>UI]3+MVK[/6QZ>L4JSUZ]A'MPWQ(DJ)(L*I(8(X2["^*-79.:[12/")Z
MZ12*X2:80]T4AF;EPS*0C)QQY%B1W-**WVXVWIN1Y6G>&TK:[M&D]4MCN#:3
MK>)7T W$#X.GZ-9JU70YB.4FL 0ZS5F>8/3Y(,V2D+E3;%,G/^@;&IAV>C=-
MNU]#NAU%,:B_U?JUDO[1[!L RR;O8T[5J>!HHVL3""HKUXTL5XE")51%[C+E
MR79X#N;$TGC1TY>$B"]OD(49$4@D(O<Q[B59B26+'@#-@=I=E=Y: &]0MC7&
M;KS9M#[$;<T_I/8H.IU0O6R=-L&\XZHU.NFMC#UL/^V*J"/YC0;!7;' *FS8
MR<T8$'A#D1X5*YS4=+Z'J*7K/64DV6KV'36FW6^UEBY;AM17JO3[=]ZCM(%J
M5O!N6*W?)6M59(8*\L9@GK3AQ,DJ:W8K"C+(8IH[4T->540H4:P/O<D3%VY1
M6\F5@68$%64@@T!;NYG;>-IWRC6U@AK1 ]?1;=&Q*V!#R=5W6<WLBH:\USK[
M8"@YJ0K<#*ZX2)1K$4@2#H_!/TLQ^)(BBQ,8:Y%*]'2Z(Z-;>>C/3SP=0R#K
M_1ZNU8F7;T(SJ[NSVFSU@F@4:1O6HHGJPR+7D\'M175YIFE#PQGO71#M)E:L
M/N?/(JJ89#XJ1Q1R=K'Q_=)#$%ASR2. H'#;"C.RF\@':'J!KNZ3-<'M=]Q]
M3[CN8X)7:<= 6/5-AU94]?7J%$S;9]V.Q;V+*B+E."$GWJK57W"0V&:@Q1<6
M1("(YN7I?06.D^M-G139U]ET3N-)1EGLW:]FKN*VWN;*A(_J<="N^OEAFHQS
MQ*MRXHBED@D:9U2P9*V["VZ,4AB:*_#/(%6-E:%H8XI .\R,)%*R%22BDL P
M"@]HZ/6SN7:=F[>&:7V[,%Z:WM'5L"1=.N=_H)^KFR@0-+FJJ=OZ\['>,RJI
MN&FLBHJ)%I)"73TTFU(<L;4.@CQKP";?U1T14U6FEWFE27>=/-]S5H]3:[8U
MK<$,]A$]<I=2ZQ8%N:6\9F*U(YEK1Q%%K%]E),+,=*E]YIU@G(@L??3)5DB9
M&*J3V/6F[BDZ=HY<KR2#W\1@=ILGO5O[;?7T#UV(:F3K]Z;MOMCHGK]8&;]7
MK ;8C@]N6I 227#O@+;6E#R(QMA[_P#.133,A$KSFV8SL9*GM9T!T[INH['4
ML>X^Z033]']0=1UFUUFM79K&FIFPL,ZV:5H212EA^ \#(4\V<.0N;869ZRU3
M!X7,]VO6;Q59N%G?M[E*NG!''XPW//XB//7:]]J^UFB=N]A])7R?I?8I*N]*
M=B]RM+;& ZSN%/$Q%ZO-( 6C6&R:*K;-CF38LR;.%2*Y: UT$O-PWI3)",2F
MMI0CI=?TATCU!INFM]KX]YK8K/76LZ(WNLL[2E=G?[K0&S4VVKV T]6.-DCC
MF2U4GH3*9%1HWB1CS%ENW*TUJ"4P2E-?+?@E6)XP/!;M>&6/QG)!)':ZR+\?
M/D^0^ O;OLS7]/=2MIWF3JJW%.[\3KC6-84>C:^(5^5KR[; U-9ML[!)&CMV
MW2,!WF'-"5Q4"F@5$M?O,6,E!&O$2D6&[)+)^C.EK.[ZQU&O7;THN@WZGM[:
M_L-C%939:_6[BIIM;'7KT-%+8U\D=BT)+UCPMDIJQ22K%$SA(0NVT@I2R&%V
MV JI#''$5\*22%II"S23JL@*KQ&O,1[R!R0.3:,O<7?2ET7L\4-Z!'7$A1HE
M//\ 6Y^$JEQ;QLT(1>@L[+#63651W!<84JVZZ0[-(59@/<J[%V>VL0 :8K)J
M0M^1J4TGH]O;#I2&#J.6C'L'NUNIQ(+ST-58B#G53U=I<TE*1*6S(CBMM/1M
M/J6$UAFMUU"KE,^RCCMEJPD,81JA'AB293P)5:%)Y 7B\RG$B";E5X1CR:]3
MY1D(_JZ;;]=VP'M<_8M_Z/ZZU2E&J23U=M75=_VX6:"D06^]>76QU!40V%7%
M/%ZPC$W78*ZJC0*I'.#\(FWM[9?VL["[9*6SJ6-17K=.;[J:W?@OP[;3[?7:
M:)IXK'3NRH5KO?!8#5X;9,>SL4 TEQJ\O*:]<7W4'@F2-UF9K->JD;1M#-#)
M,W:RV8I&3AEX8H08DDX"!APTAG-BW7W8UO4^V=JN>NZ; IFL]!V7;VC;_<1U
M58)D[E2ZX7-VC7%_UWKC>MM?+"G4CXTP#;PEBJF8T&1*@%8$R?%BRB,"MHNA
M-G<Z.J4=G>DN[7J*KINH-=2DMM%%1O688*FSUNSVG3])89E\1TL4K%6YWR*D
MD,B1NZ196L7X4NO)%&$BK//7D<("SQHS/%)%%9<L/(%75DX!(() Y@FM.VG9
M%_8GDWF[^0U*;I??;4=G/E*]6:'9JZ<UE;:YU]@;RA$H%I(;#/QK6,*Y]I 2
M8N36@"HB7($F!*RJ/)S+V&UZ.Z836^D\ZV/<07?1YN:E:&S;V%6S!M:=KJ23
MI]XI:<6LK-3EA^]68IDMV0Y$B2( R%,<-VT9-5XI@9-E [E4C=6B=*PL AS*
MW>#YJ047CD<'R\Y[Y-F_[HV=6>RMBV[LEN_.U_N+V2UF'2NM("OC1>M+PFG!
M&8"XIB0/A V0H>*U$!11+*X\A4F?.*E2,V;,DZ_TGZW1ZJUTM6TVK.N6UT3T
MOMI^+1G66;:Z_P!>G:0/"LLEAIYG+V'F(9 D<<,,4:(N3523RI:>>7Q>V[:B
M7W.W@12=B@<,0%[5 "A?+S)9B23".V2ME.^4A\G  KMY$!@QZL]TBD :0J,D
MW#@%*YJ[7,1X@5CMVL0V=DOP;"3AB'$I%+!LSR2//)(GN(1.Z/&K'HQ])UBS
M0FGGKV^AHI)8[B0/)#9VNT<10L:<QKJ)*T4DX/C"PT<7 B,8)QW?%.UU2K(J
MJZ7R 4[@&6&,$L.\=Q(8A?P>WD_'G+#TYN#9F[\=K:KURQJK4 7JKN.S=;]=
M5 WK^43%V.\4&H5>Q'#=L'@K/56Z[KLT<MB:_61%1:@%HL$/.L\@\1439KHS
M6[O2ZO0^R%OJ8[?=3]7:2IU1L[M?8I%-6H;&[<JP5Z<MBI<-G9P04_6;4UTR
M0M)-'46M$(FM398)YK'KB5?!@6G.]6*-HN0\D:(S,X5T[(F9^U%3A@%+ESSV
MC72A>4$W]V*F>3S;U&,U;J^#W>U%V;LA[W@4ZUWLIK&]=>800;+6)R(V!28=
MQJQ6SF)*H$*3'KDYX3!A$5F\XE/#'.FV/HXZ=Z:3TDG<S;?:R=!;KI2K7^YM
MVGKXMKK^I9+$J";Q];?>E<AJP+WR*UF-9I)(O5^4$HBQ[*U:^YO@"&$;"&VS
M>+&\AADK!0>.V5 Z%V) (4\ <MYD9ZM2"-ZJ&FY!>TEJ 8V76-:ODK <E.3=
M>:N)W8+6%RB924_/EVDA2*'+.1GI4F1,FV"77 #CCK[Y-Z&I3WD2Q:^[NUAJ
M0[&'5V]HL5:N@CV6VBH3VPD4*+&E2*_L$KLJ*J)62S9 55B5P%W),B0%G:-I
M4B)9CS%"9%3DDDES'&6'))+%5\R3QFA^K>V.WK!OOK[ID\1I%BA=@.JU_P!M
M/7BM4JRB*G7MH4*1KEF8O6,JP%X)/8FG"35\=D BA(=&D&X<,.8%7,A$*380
MWT#;='Z:OT[U)O*T=^M)TYU=KM,M"U>J3V[.IV*;-D^ZJ5H9(M;NXFUP6Q#%
M*Z0.\\$U&-X8Y)=;#<G:Q6@9HV%FI+-XBQNJ)-'X7/A%F!F@/B'M) + *PD(
M) SWDI=A[>V]TRH6T]R;!]X5FNEKW7*61D D"B<9T9V VT'>:E2HQ)\?*@)C
MP8$0 ,&!P0^LA8,0'"C/Q(S"VX_I=UFETO6^QU.CUWW-J4:>B41+8,T+";IS
M3SAD1HEE20O)(]F6:>S+:GD>Q(ZN[ W::6>>C'-/+XK2/8/)7AAVVIU/)!((
MX "@*H10% ( RLMD7(1K3RK5OV4:C2'Q-#\DI=[F:;@,H<(2152['LGID>*A
M648>DJBQ)*8K2UI3EYWP\4^>K/-MJZ,VT]$%/5P,BS;#TQT*4!D8K$LUWIAZ
MZ.Y /:O>Z%V )[1SP>!F.601;B25N2L>E>1@/B0EHL>/Y^!Y9/-1;][F[.=Z
MO[5%:EKQ'2&Z0@*R;58F2=<@D:[J=[JL,_3[1KBX0-ZV<[>4!II"$.L \]KD
M00MT!Y1<,,I4W&*WC6[GIWHC5+U9J9MU9BWVBL6*NH*)L[!V=S7W'K7JFTI2
M=/U*^O,\<<DE:2OLYHZ4@\">78)_=69(;-Z4U)EA1J]A5:;DQ+X22(&C>)Q8
M=I.TD!@T2E^>56,^Z(G;.YVX:78=/3Y<K5=Q#['[X0^J9X/KL=9#])K5%M!V
MX5NL$8VVY[P6$6W(!F@ATK8 (- .@@<Y!^DD@M?-06S")M/H?2WJV[C1-O2F
MUGH]?J^O/LY*M:_:V%2"C9MQ-IHA8>'26([,BZV>>2O8L1FO?BL68)# <;WY
MXW@),+K+L13*Q*[1I&[.B$3GM#3KV@R*H95/<A56'(ELKN7::]V;)Z&VQ,%Z
M(,%]R@:SHYG8=!/N:O[":IFQP.)BZ!N\>936D;SDSY)S$2D%LCWXDF.)J+=.
M-3IKEM:A)T14L]*Q=0Z=)NH8(-)8M;]M;L:PVW3>WC>QV?='0R0&T>GUC6OW
MWX1(LB-/>-ZO'&*1O-]UMFO,5K%IU2N)8V\*S">WGP[ ;L%@DMQ&W!!"Q]A8
ME\YNAE_W5L3:7?=6S-E,W$#KCN3>-65,(JL)%Y @Z_K/3LT)"!RHYIZ*- PF
M"4_#PA0N7/(F9T^PD3\F=.DH<>D+6Z+6:GT=_<K5M1L;3HBAM[LXM>-ZS8L[
M7=QSR6%:!7EL.T4?;,)DBB@CCK15DCC0AK9;$LVR\:;Q%BNR0HO9V]JK'"5"
M\,0% )Y7@EF)<L23FZFS:C(GP9ENJFO=?; V@'KQ0-3(FRSD^O5UEDJIITD/
M58(5.V%,K<,RY%A8.2 ]2F2C+(X;%(Y>8'P<Q.%U=Q8Y(Z=S8['7:F:S%/>?
M5UX[-HM"&$4HK27=;':D@#R>KI/=C2!I97B[6ED[]A,A(,B112S*K+&)6*J.
M[XCN"2E W [BJ$L  ?(#C1_R4;T<1URNNJYNNI^JK_I+L1N>@[>I7MB"=J(W
M9QP]&VV<>U9-&0!0]C5,X=LT-+H8=D;%?!!760Y)XN3AS#Y;O/2\'FZGH[=-
MG'M]=O>FM'L=+?\  DKW9=37KMIJZ[:.62:1MQ'+JITV,QE=;$ZM/$(8I$K0
MZ_3>[5DA,1AE@M3QSQ]P9!*Q$S>"5  A(E7PUXY5> >3[QEMOW=V$*=\#74N
MCV'5-5IZ^HT+L$*N!S7%FM=J$GY>VY>M7Q$J&QLZN!CD/$>#[4@24M!/4G9#
ML>;#-)2TXW#IZ'IN+T?0=8WZVWMW1UG)TY-2K[.K3J35DTR;19D=M5:G@?OD
M\&1"T_B*H:.2 \AKWL6CLFI1M"D?J0M!VB=W5C.8BI F56'ER#PO')Y#>6:C
MUOOEVEE=1]#]NSSVF,#BW9"M:"V=K4/0+8AZSCW^QY#KA9;C6KA-V0[FIDGI
MT#[8U\$_7;#"&H4H24)&T.I?B]E9]'G2:]9]0]&5QO/%@Z8M=1:K:3[&F5J2
MKTQ%U/5I6J4>K'KD0CE%*S82U5DE(\:&* KVO#38VS2K76\#AK2UY8EB?EU-
MEJK.CF8]AY'B*I1P/P26YY&X]!WYMGL;L/MW3]0FZ/KEGK+L=C3%=^V50*7&
M9<-A1:0#MY>R7&+#M59>':Z=FV.+70HJO.1+!/;"E;%]J6T3HH*!Q.QZ=T_3
M.MZ,N[F#8;-NJM8V\L^HW(:24M:]^Q2AJT7DJ6EEV:I5>U8FLAZT1L0U?4R8
MWLR38[,]J6[' T<7JD@@7Q(RY>7PU<NX#IQ$2P50OO$*S]_F%&J^N_*&;UWL
MKR;[]#KNM-<([E2>T52V0,N-:L]VE46[];:U=/:A"IDQ-YJ$8W5R5FJ$YR",
MF0F)\L;Z@ARR07'9F$=;L_1OH.G_ .V<FPM;3:'HE.D[FKFI6JE!+]#JBU0,
M4=R&:A=>"W%4O1B25)&C242$59%$9R'%L[%G[E>$L47KQN)*'1Y#')423DH1
M(@9&="0I'/' +@\Y5^_.W_9Z7T=[L$$WNL53;763NE5>KTC8VOZ?,!,WFA6+
M86B0RRT4$7M-BD4>R2Z[N1V 2F"CI%R.^%7) 2A$L@S-%[;IWHOI1>ONA(CK
M[=S3=5]"W.K%UFQNI8;7["MK>H9Q"]B&I62_52UHQ)%'-7C#+.$LK.D3)-BL
MWK9U]\^(B35+ZU#+$A7Q(VEKCD*SL8V*S=I(9OP>5()Y%X[7#[1>\J7US&5B
MXTL;?7NB&_XY&[FJ(2*AF(B-S:D=<DP:/"NHA^1-\51XD./,N:(4-;T@H^DB
MEC :;H-1-J5]$O4TMNE>EUZ^D'IQHJ$&PBAG9SHMT LE]Z,RK'P&=VCHF1PJ
M0KX7=X\<B99ONO55)(Q+]S[(,C1DKQXT1Y$8D')^  ,G Y+>?':>S2>[O8DK
MU7,;0(:V1L*YZE[=[+ZZ;R*Z6HI@Z29UGJJ]V>JV+<NOM/R;.3/&#/J8ZO+F
M5&*?L;PG!$W:(XTZ-"9K<BV_T'TU#U;!JHMH=;1W/1FJZFZ?BWVP@KQ-M-QK
MZERMH]ENDJ15X( \MD)=>M56;PH*C2UY;'K2H]A:-,S&+Q9(;LM6P:\3,?!A
MD=&GC@,A8MP%Y0._;RS\,%[3O7U;W;7^P.K<;%JVS:-MFO2[/8AHBU4<.8K.
M61T"6C,$#=:E8)<DW5-B XC[,&X!R30MU1%&"D<"!A$XHB'Y_P!6:*STYMON
M9<U6PT]E*M:6>I?G@MAI)$/?9H7:R)7N:RPRF2E/$TP$9\%K%B2)YGV-.PMF
M'Q4ECF4NP5XU*>0/DLB,2R2J"!(IX\_>"JK!1L9SFLE8XQCC&.,8XQEV:.F.
MH/%H&,Y]#)$^M+3X_=Z6'+CM-*SC_?A$U['C_?X<^JO[$[9SQ=8=1Z<,WJM[
MIS[H2IR>WUC6;*E7@<K\.1%M;*AOQ=W'/F >.ZSA5J-6?@=\=KP@?Q]DT4C,
M.?R<PH>/_P"#LYS[VSSC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC
M--=EA70UO*94C.(Y-Y96*YX9\UQ,Q:G'\8SX>'BU+R^WE.,^.$X0KPQA:>?F
M#Z=^EK'3'I*WY>)EI;ZS)U#KYNTB.:/9R-/<53QV]U?8FW R E@BQ2$*LJ<^
MM].7$MZJL >9*R"M*O/FIB 5#^7AHNQ@?ASR!^"<@//'<WN.,8XQCC&.,90]
MOZ_5JT;0;W2-MNQ:'LUJBP=<(L5)LS46"_4QQPU8HL$Q2[ ,L6O[._'*6 F]
M G6NJ')@3$F3]GWA*YY-<[H*74=JIJ3HY:>LV&J:_)LS5OU2\BW)((*SR0WJ
MTM;95%:&M$LD=.Y7CG[5]96;PX1'&DJH\WK >6.81B+OC?@% S. T;!HGX9B
M071BO)[>.3S7;6JV.J5&VO?=!Z<M?8+<>R;@(NFPHY#8-4![(VZ?>>%UU\L3
MNU]F@*8+C5"JH6L!587V;JPT<-6'K8D:_/<R]LSMVZOOZ?7=1;NITYI-72FH
MZUH];<L:O2U@LME88J&NCL7I6NW"!9MR>M6Y991/:FE6,=N/P13CFDK0/9GE
M=7E#2HLLS<A>3)*50"-/P4'8@4<* 3Y]_JYH6)J8'M6XS*>#UWLOL;M&S[KV
M6&K$F$58KI^RM1H H$T7Q%5 *D0@:!#FV2;&8> E]B%;K8A;"H![&',?5G4+
M[FQJ*27;&RU?3&IJ:+53VUDA:S6JL\DMAH>_Q(8YYY'CJHS+8AUD-"K,WB5N
M16I6$"S.46*6U,\\JH0>QGX"KW<$$JH!8@%#*TC*.&R$R_)]Z+G:%MO6N62V
M.[JB\;-?V[917VKC-%I]WE;"B;7E3T6%D,V7B17]C#X-L5 B2F(S<V*B"PAD
M*Y(&/3D](_4$?4-+JA(]8NXU^J7359O4V:&.@FM?3I&:S3F!W75R24_$=&8H
MYD8F<+,,9UE<UY*I:7P9)3,Z]X!,AD$I/<%# &4!^ 0.1P.%\LL*T]=JRQM@
MAV<BO7^U;D&:,+:/'Q(A:KQHARB32<6TR:Y@--AU^MMD3%Q'0K \;?(");,Q
M'J+!0?7L8$IUE7J6VVF3I1AKJFDFW\.^D=X;;O7V"0O32R9XWLVS%!2EDK+
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MGE?2'95O6)=6)Y1/+#"ZO%ZS2:<";[G[(7=>LA?LJJLTRR6FG%XDLJ-)"U@
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M2&(/-- D:F261(HPS O(Z(O+, ;DM5I&"1V('<\\*DL;,> 2>%5B3P 2>!Y
M$_ 9R^PS7P<I\OE_1Y(]D^JOU9Z@^IMC^[9;Z[3^=UOIXOMX]AFO@Y3Y?+^C
MQ[)]5?JSU!]3;']VQZ[3^=UOIXOMX]AFO@Y3Y?+^CQ[)]5?JSU!]3;']VQZ[
M3^=UOIXOMX]AFO@Y3Y?+^CQ[)]5?JSU!]3;']VQZ[3^=UOIXOMX]AFO@Y3Y?
M+^CQ[)]5?JSU!]3;']VQZ[3^=UOIXOMX]AFO@Y3Y?+^CQ[)]5?JSU!]3;']V
MQZ[3^=UOIXOMX]AFO@Y3Y?+^CQ[)]5?JSU!]3;']VQZ[3^=UOIXOMX]AFO@Y
M3Y?+^CQ[)]5?JSU!]3;']VQZ[3^=UOIXOMX]AFO@Y3Y?+^CQ[)]5?JSU!]3;
M']VQZ[3^=UOIXOMX]AFO@Y3Y?+^CQ[)]5?JSU!]3;']VQZ[3^=UOIXOMX]AF
MO@Y3Y?+^CQ[)]5?JSU!]3;']VQZ[3^=UOIXOMX]AFO@Y3Y?+^CQ[)]5?JSU!
M]3;']VQZ[3^=UOIXOMX]AFO@Y3Y?+^CQ[)]5?JSU!]3;']VQZ[3^=UOIXOMX
M]AFO@Y3Y?+^CQ[)]5?JSU!]3;']VQZ[3^=UOIXOMX]AFO@Y3Y?+^CQ[)]5?J
MSU!]3;']VQZ[3^=UOIXOMX]AFO@Y3Y?+^CQ[)]5?JSU!]3;']VQZ[3^=UOIX
MOMX]AFO@Y3Y?+^CQ[)]5?JSU!]3;']VQZ[3^=UOIXOMX]AFO@Y3Y?+^CQ[)]
M5?JSU!]3;']VQZ[3^=UOIXOMX]AFO@Y3Y?+^CQ[)]5?JSU!]3;']VQZ[3^=U
MOIXOMX]AFO@Y3Y?+^CQ[)]5?JSU!]3;']VQZ[3^=UOIXOMX]AFO@Y3Y?+^CQ
M[)]5?JSU!]3;']VQZ[3^=UOIXOMX]AFO@Y3Y?+^CQ[)]5?JSU!]3;']VQZ[3
M^=UOIXOMX]AFO@Y3Y?+^CQ[)]5?JSU!]3;']VQZ[3^=UOIXOMY]( '7%80V%
M++5G[L)0.F*5G/\ NPG#.<Y_^F.7Q]'=72NL<72W4<LC'A8X]'LW=B?@%1:I
M9B?Q  DY0WJ2@EKE50/B38A '^DE^,L2KZD/%GVWC33@4;A6%.8>\WV@^G'A
MG+;$;]++&5?[.796$>C\?.2R]X93SVOT?_V-_6'4=N"UU37FZ6T2LKSBSV#=
MVXP03#5H'O:HSCE&L;%8O!Y$B5;7!CS0;+JJC51DIL+E@@A2G/JZ'\3/)Y=_
M'Q"Q=W=\"Z?'-HAP^&*A1AT!A$>'$:2RPRCQ\$IQ]^<YSGQ4M:U9RMQQ6<K<
M<4I:U94K.<_?VETVMZ>U5'2Z>K'2UNN@6M4K1\]L<:\DLS,2\DLKLTLTTC-)
M-,[RR,TCLQ\UGGELS23SN9)96+NY^))_F'   X"J  J@    9W.;3,6.,8XQ
MCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.
M,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9!-E_U++?\ GAO^NC.>
M-^G_ /Q3]2?]\Z4_]8]/YN^G?\,5?^I<_P""LY.^>R9I,<8QQC'&,<8QQC'&
M,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8Q
MQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&
M,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,@FR_P"I9;_SPW_71G/&
M_3__ (I^I/\ OG2G_K'I_-WT[_ABK_U+G_!6<G?/9,TF.,8XQCC&.,8XQCC&
M.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8X
MQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&
M.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&039?]2RW_GAO^NC.>-^G
M_P#Q3]2?]\Z4_P#6/3^;OIW_  Q5_P"I<_X*SD[Y[)FDQQC'&,<8QQC'&,<8
MQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'
M&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8
MQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,9\?#/A^O\ L\<^&/'^_/AG
MP_\ 'PS_ .'*'G@\ $\'@$\ G\0) ) Y^)X/'Y#\,?Z?_P"/_P#&:M;-V[(B
M-%:<6J$P;.R["<1(42:>C/L1B,:8W*C*Q#;]/'E)BJ0VXG*<H4I2'4)=:<:3
M^=7]D)_9/7=77ZC]%G4WHPVVAW#6=//%???5K>ON4M?O:&UAV.N==7!ZY1V$
M>N>*"961X96>*S%%9KV*T?IO372<<S5=O5VT-B +,K1BNZ2QO)!)"T<@,S=D
MD9D!93R& !4E65C96O=GR]@R9'J=4ECQ</&4RB\DBVY'3(RG"FXC#:8;:I,E
M6,I6XA"TI89SAQY:<N,(>]^]!_\ 9";'TWW;K:OT;[/1].:P,E_J;8;NO/3%
MTH'AUM*"/6Q/?O.&26PD<J1TJS":S*CS5(+7.;_IJ+0)&)MI#8M3><=2*!ED
M\/GAI9&,I$<8(*J2"9'Y5%(5V2V^?3&<KCC&.,8XQCC&.,8XQCC&.,8XQCC&
M.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8X
MQCC&.,8XQCC&.,8XQCC&<3[[$5EV1)>;8CLH4X\\\M+;33:,>*EN+7G"4I3C
M'CE2LXQCD>W;JT*T]V[9@J4ZL3SV;5F5(*\$,:EI)9II&6..-%!+.[!0!R3E
MR(\CJD:L[N0J(@+,S$\ *H!))/P ')RF3FZPT)U; 8>^7RC.4YE.N^HQ%9QG
MP\YGSFGI#R<?[ULL85^M*LI\,Y^7^J_[*CIC5V9:G3&FM]2F)BC;">Q]R-<[
M D=];OK6KME 1\9*U,-\49DX8]=2Z/MS(KVYTJ!@"(E7QI0/R/PZ1H?]#N1^
M, CC(S[]"/\ 97X7YU_Z..<'\K?=?BZ,U?UK;_=1FR]BJ_S^;Z%/MX]^A'\/
MPOSK_P!'CY6^Z_4S5_6MO]UQ[%5_GTWT*?;Q[]"/X?A?G7_H\?*WW7ZF:OZU
MM_NN/8JO\^F^A3[>/?H1_#\+\Z_]'CY6^Z_4S5_6MO\ =<>Q5?Y]-]"GV\>_
M0C^'X7YU_P"CQ\K?=?J9J_K6W^ZX]BJ_SZ;Z%/MX]^A'\/POSK_T>/E;[K]3
M-7]:V_W7'L57^?3?0I]O'OT(_A^%^=?^CQ\K?=?J9J_K6W^ZX]BJ_P ^F^A3
M[>/?H1_#\+\Z_P#1X^5ONOU,U?UK;_=<>Q5?Y]-]"GV\>_0C^'X7YU_Z/'RM
M]U^IFK^M;?[KCV*K_/IOH4^WCWZ$?P_"_.O_ $>/E;[K]3-7]:V_W7'L57^?
M3?0I]O'OT(_A^%^=?^CQ\K?=?J9J_K6W^ZX]BJ_SZ;Z%/MX]^A'\/POSK_T>
M/E;[K]3-7]:V_P!UQ[%5_GTWT*?;Q[]"/X?A?G7_ */'RM]U^IFK^M;?[KCV
M*K_/IOH4^WCWZ$?P_"_.O_1X^5ONOU,U?UK;_=<>Q5?Y]-]"GV\>_0C^'X7Y
MU_Z/'RM]U^IFK^M;?[KCV*K_ #Z;Z%/MX]^A'\/POSK_ -'CY6^Z_4S5_6MO
M]UQ[%5_GTWT*?;Q[]"/X?A?G7_H\?*WW7ZF:OZUM_NN/8JO\^F^A3[>/?H1_
M#\+\Z_\ 1X^5ONOU,U?UK;_=<>Q5?Y]-]"GV\>_0C^'X7YU_Z/'RM]U^IFK^
MM;?[KCV*K_/IOH4^WCWZ$?P_"_.O_1X^5ONOU,U?UK;_ '7'L57^?3?0I]O'
MOT(_A^%^=?\ H\?*WW7ZF:OZUM_NN/8JO\^F^A3[>/?H1_#\+\Z_]'CY6^Z_
M4S5_6MO]UQ[%5_GTWT*?;Q[]"/X?A?G7_H\?*WW7ZF:OZUM_NN/8JO\ /IOH
M4^WD(N]U@WV S#,5N,V]%=PY#(Q)JT3HN,J3EYIMQR,XA3,A"?,=:=0MO.?,
M=PG#K3:T^1^EWTG:7TSZ:KJNJNA*,-K7V4L:O>:[;2P[?7 R1FW7KSRT)HWJ
MWX4\&S6GBE@+>%96-;->"6/<Z73SZ*=YJ>QD99%*RUY85:"7R/8S*LBD/&3R
MK*RM\5)[68&2!]N8 #8@@151L(?":PTPPU,D>&,??E2UJRUE;KSJ\J<>><4I
MQUQ2G'%*6K.<][TO_9(1]&:'6],],^CO1ZG2ZFNM:E2K;.V%102SRRNU8R3V
M9Y"\UJU.\D]F>22::1Y'9CK[?2IO6);=O9V)IYF+R2/%'R3\   P"HH 5$4!
M44!5   S)^_0C^'X7YU_Z/-_\K?=?J9J_K6W^ZY&]BJ_SZ;Z%/MX]^A'\/PO
MSK_T>/E;[K]3-7]:V_W7'L57^?3?0I]O'OT(_A^%^=?^CQ\K?=?J9J_K6W^Z
MX]BJ_P ^F^A3[>/?H1_#\+\Z_P#1X^5ONOU,U?UK;_=<>Q5?Y]-]"GV\>_0C
M^'X7YU_Z/'RM]U^IFK^M;?[KCV*K_/IOH4^WCWZ$?P_"_.O_ $>/E;[K]3-7
M]:V_W7'L57^?3?0I]O'OT(_A^%^=?^CQ\K?=?J9J_K6W^ZX]BJ_SZ;Z%/MX]
M^A'\/POSK_T>/E;[K]3-7]:V_P!UQ[%5_GTWT*?;Q[]"/X?A?G7_ */'RM]U
M^IFK^M;?[KCV*K_/IOH4^WCWZ$?P_"_.O_1X^5ONOU,U?UK;_=<>Q5?Y]-]"
MGV\>_0C^'X7YU_Z/'RM]U^IFK^M;?[KCV*K_ #Z;Z%/MX]^A'\/POSK_ -'C
MY6^Z_4S5_6MO]UQ[%5_GTWT*?;Q[]"/X?A?G7_H\?*WW7ZF:OZUM_NN/8JO\
M^F^A3[>/?H1_#\+\Z_\ 1X^5ONOU,U?UK;_=<>Q5?Y]-]"GV\>_0C^'X7YU_
MZ/'RM]U^IFK^M;?[KCV*K_/IOH4^WCWZ$?P_"_.O_1X^5ONOU,U?UK;_ '7'
ML57^?3?0I]O'OT(_A^%^=?\ H\?*WW7ZF:OZUM_NN/8JO\^F^A3[>/?H1_#\
M+\Z_]'CY6^Z_4S5_6MO]UQ[%5_GTWT*?;Q[]"/X?A?G7_H\?*WW7ZF:OZUM_
MNN/8JO\ /IOH4^WCWZ$?P_"_.O\ T>/E;[K]3-7]:V_W7'L57^?3?0I]O'OT
M(_A^%^=?^CQ\K?=?J9J_K6W^ZX]BJ_SZ;Z%/MX]^A'\/POSK_P!'CY6^Z_4S
M5_6MO]UQ[%5_GTWT*?;SZ1O6=A6,N5V(I/\ :E$]Y"LX_N5F,YC'_CE&?_#E
M\?\ 9<;8.IEZ*USQ@^\L>YLQ.P_&%D:C,JG^<QOQ^0_#*'HJ'@]M^4'\1,",
M/]8$BD_[1EB5?:5>L;S<)W#H@B[G"6H\Q2%,2%Y_4W'EH\U"G,Y^Y+;R&%N*
MSA+27%9\.>U= ?V071?6]J#56!/TWN[#+'7I;.2)ZER5B L-+9Q]D4DS,0L<
M-J&G-,Y"5XYF/&:#9=-7]>C3+VVJZ@EI(00\8'^5)$>6"_C+(751YL5&67SW
M?.=QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC-9-PVU^83S6(CJ
MD0!_HED,(5G&)<Y:4NI;<SC[ELQ&U-^:C_9]94XI>,J9:RCX+_LF?2/;V6^;
MH+6V'BU&E%>7<B)R!L=M+&EE()BIXDK:V&2'MB)[?7GG:5#)5KM'Z-TGJDBK
MC92H#//W"OW#GPH02I9?R/*P;S^/AA>#P[ TESY3SLLUH[6=J*%T[U;)W1M2
MNWPGK@24#C+.>HH<187:G@\6@ Q1$P&E6 2<E#I)4E%B*<KHX[)C*7EV7%88
M\UU74](=);#K7;IHM19U\6SGBFEJ5]A/-66X:\,EB:*&=:\U=)4AB=P+,M=7
M X1V;W<B7+D=&$SS+(8E(#M&JMV=Q"J64LK$$D#W0W'XP!F2NW9C7%6Z\3NT
M5=28VUJ&#27=DJ-:J]@'I,R@Q14@W/M R,8/UYHE$'#8SK\P?"E/'4K0Y&:$
MO2F9#+6*CTML[?4L?2=GP=/NI+ZZL0;?UBNJ;%YEKQU)7AKV3$\LKJJ2R(M?
M@AVF5&5C=);B2J;B]TT C\7NA[6)C"EBX#,O( 'F >[GR[>0>+P!D91<0/)S
M0A6MRIL9$A\"<<#NEQ:U^.<Q""P!8Z&5);QX97[.+D(^/'&$R%*PK"=#8B2&
M:2*.Q#:2-BJV*XG6&8#_ "XQ9AKSA3^+Q8(G_*HR0I+*"59"1R5;M[E_F/:S
M+S_H8C^?,KS#E<C5SL[-*J5DM\D85,Q:P$)'I@P(D>LO+ABHKLV6V/;*D1(]
MV4F,RZXVU)(Q4NY1Z-#F7%(0J51JM>N5:2RPP/;GBKI+.91"CS.(T,IABFE"
M=S $I$Y'//' )RR1Q&CR$,P12Q"\=Q"CD\=Q4<\#\9&4;K;L]7]MT3KALN@:
MWVR?I/908T<"'8]?KWJNM@4JKR[2.,;9S]K,YKL$FW%0%@K!?:EQ9^;"@.-M
M-O>LIW^TZ4LZ78=3ZK8[/3U[_2\IKV*[6;/?M+"VTJ2PZ?\ N/\ NF2$N9Y!
M8]4 K1R2*6*]ACQ6UFCJRQQ3-':'<K!4XB4H7#3>_P"Z#QV@KW^\0#P#SFR_
M.6R7CC&.,9!-H7\;JG7-XV:9%FC(2@5<W<#@^N-#9!MT)78#Y4PZ.C%B@:#*
MD1!L65,Q%<(L/24L*8B)?EN,1W=AJM=+M]G0U4$L$$^QMP4H);)E6!9[,BPP
M"5H8IY$5Y71.\1,$+!G[4#,N.:00Q22LK,L2,[!>"Q506;@,5!( )XY'/' Y
M/ S@U'LH#N?5&L=PU6,5AU?:^O:7LJMQ#L>+$-Q0-[K8VT!XQB+"FD848JP/
M*QVB$>(0GQ69:7FX\V4TE#[EVYU5G1[C:Z2XT+V]/LKVJM/79W@>SK[4M2=H
M'D2)WA:6%C&SQ1NR%2R(25%()5GAAG0,$FBCE0, &"R('4, 2 P##D D _ G
MXY87-;F7'&,UNWAVFUIHF@@]F'&3MQIYS:5;T_@IKW%=/(%W.S7YO6$:.4Q/
ML89*(PV\+= 'E0%SY@B;$FLRH27(SB,=/H.DMIU#L+&KKM7I7:^IM;KPMEZS
M7,U&IKCMG:'PZLY+2T +%?Q!&D\;HR2$.#D6Q<BKQ+,P:2-IE@[HNUN)&D\(
M \NOD).5;CD@@\C-D><QDK'&,Q0<Z%L$>3,!%1QB)#*F <J2,F,38\<S7R<H
M*=%//1UN-MD QB#-%%(BE8?@$8<J%)0U)CNMHRS5YZ[*EB&6!WAAL(LJ-&S0
M68DGKS*& )BG@DCFB<#MDB='0E6!-%96!*L& 9E)!!X92593Q\"K @CX@@@Y
ME>8LKCC&.,8XQCC&8HP="UZ+'FG2HX/#EE0H*+))S&(3$@U9"\(!7Q3#LA;:
M'2)HX2'B!<-&5/SB,V+#CH<?>;0K+#!/9=DKPR3.D4\[)$C2,L%:&2Q8F8*"
M1'!!%)-,Y]V.*-W8A5)%K,J %F"@LJ@D\ L[!54<_C9B% _&2 ,IBN=B:=9>
MQ&P^LS 2W#]@:VU]4-G%R!*$%352=4NY8R$!209&"?GD9$I9"OEVI40B'%N1
MDQ?.5E6'6?/WEKIJ[5Z:UO533TY-=M-E=U4$<4DYN17-?#!/86Q%)7CB5!'9
MA*/'/*'[^.!VMQA2RCV9:O:XDBC25B0O84D9E4J0Q))*MR"H(XR_.<]DC'&,
M<8QQC*_'WN5/V59-=*H-_'Q*]5Z]9FMD$!0EK6UC=/S2L-RLUPRR=?,S+0!P
M*Q,L$"77X$2%")"WF"$M4OT;>QDUZ1ZNKLQL==(]FW9JG5QS3-M*PK1PN+=J
M!JZP1U+'C=E:1+,CR213*T2!.3B$I,SQ>%* B*_BE0(G[B1V(W<6+KQRP*@
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M:$I0A.$XQC&%V9V9W9G=V+.[DLS,Q)9F8DEF8DDDDDDDD\Y<      !P /(
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M.41X*ID1[,1A&4(REJ/EMM.4ISA.,IQX5AOWZPD%>[;@$K%I1#9FB$K'D%I
MCJ'8@GDMR?,^?GAHXVX[HT;M' [D4\#\@Y'D/YADHQC&,8QC&,8QC&,8QCPQ
MC&/NQC&,?=C&,?=C&/U<B9?D(=UCK9]F7'?U[1WH\\O*/SF':F!<9FGIJ<(F
MFY;2X&422\M&,(E$GDKF2$XPEUY>,8QR>-KM%9'797U>.%*T;"Y8#1UXR3'
MC"3E84))2)2$4DE5'.8_!A\_O47FQ8_>U\V/Q8^7FQ_&?B<[\>C4J(5P<BT^
MK1C>&/5<&(]?$LE<1?5,0/5L$&XB9>&/4<8A>A]-Z/U3&(WF^AQA',;7[SP^
MKM=MM7+=Y@:S,82_?XG=X1<IW>)]\[NWGO\ >Y[O/*B*,'N$:!N..X(H/'''
M'/'/''E_H\OAG6':ZU\(;"-":+31;5:FSB5<;'5@)"; $2;>6B4\(B-!:2*F
MD&E*;G2H.&'Y;:LH?<<3G..72[+8SF=IMA=F:TD<5HRVIY#9CB(,4<Y>0F9(
MR 8TD[E0@%0#E!%$O;VQ1KV$E.$4=I;XE>![I/XR."?QYF!-;KH&07E @ 4+
M*/D%ECLD2*@CI!LJXGS7"9=Z&PRX2(.)QA*YDQ3TE:<>"G,XYAFM6;"PI/8G
MG2M&(:Z32R2K!"#R(H5=F$48/F(T"J#\!ERHBEBJJI8]S%5 +-^5B!YG^<\G
M.L<IU1L\D3-LM6KEAF )?KX*6<!C"TD+.\49]=$OSXLAT;+\6F\^L0ULO>+:
M,^?XH3X707;E5)HZMNS62RGAV$@GEA2>/@CPYEC=1*G#,.QPR\$^7F<HT:.5
M+HC%3RI90Q4_E4D'@_SC.8C5ZR7*ASI:N@B9RO+D.5\R1$#YI4&N6E*)2PY&
M3'=EC%R4(0B0J$\QEY*$I<RK"<8Q2*W:AAGKPV;$4%D*+,$4TD<-@(24$\2L
M$E"$DJ)%;M))''.5*(S*S(K,G/:Q4%EY^/:2.1S^/@C,(WK'6K*(#;6O:.TV
M*D2)8MMNI@$(&RI<Q1"5)@)2/PF'(DSU*G2'H^&W'IBE27%*>SE><YVNT8RE
MME?8S*J3$W+!,J(@B1)29/OBI&!&JMR%0!  HXRWP81QQ%&.TDCW%\B3R2/+
MR)/F>/Q^?QS+B*C5 $R<1 UBO!"!3.5$YX@*-&S"*E.J?4J=*AQF7Y>5/+6]
MG,A;F<NJ4YG]-6<YPS7+=B..*Q:LSQ0CB*.:>66.(<!>(T=F5!V@+[H'D /@
M,N5$4DJBJ3\2J@$_C\R "?/\N?MCJ=5N,%L9;JU7[2-:DMS&A]C##CD%J6SA
M6&I3<0G&E,(DM86O#;Z6\.HPI6$JQA6?&E:Y;I2&6G:L5)2I0R5IY8)"C<=R
M%XF1BK<#E2>#P.1Y8=$D'#HKCGGAU##G\O!!'/\ /GV6JU9/!%5HY701JN*;
MBLJKY80/(A%,P5M.0FE"ID=Z!EN&XPRY%1ECS8ZV6E-80IM&<(;=JO/ZU7LV
M(+(+L+$,TD4X:0,)&\9&63EPS!SW<L&8-SR<,B.O8R*R>7NLH*^7P]T@CRX'
M'EY<9C5Z^H+DV8272*@LB0C/0I\]=:"JFSH<B/B)(B3)6867Y,9^+C$9YAYQ
M;3L?&&5H4WC">9!L=@(TB%^X(HW62.(6IQ'&ZMWJZ('[4=7]Y64 AO>!!\\M
M\*+DGPX^2"">Q>2#Y$$\>8(\B#\<^'=<Z]>KTFI/42FNU6;(Q+F5EVKA'*]+
MEX]%G$J2%7!R-?D8RPQX/.QEN8]"U^E_1H\+AL]DME+@V%X7(U[$MBW.+*)[
MWN).)/%5?>;W0X'O-Y>9QX47:4\./L)Y*=B]I/Y2O'!/\_&<T^A44J/%B2E+
MJ9(4#9]7"#)]<#S!X=C+;366!<.1#<C#V?1,,M^CB-LH]&RTCS?-;1C%L>QV
M$,DTT-ZY%-8;NGECLSQR3-R3W3.KAI&Y9CRY8\L3\2<J8HV 4QH57\$%%(7_
M $ C@?ZLSS@P:\.4'='P71*HF("A;D2.L<J!AK#&(2H2F\QLQ,,8PSB-EK+/
MHL8;\SS,>'(PEE$@F$D@F#^()0["02=W=X@D![N_N][NY[N[SYYR[@<=O [>
M...!QQ^3CX<?S9RJAQ%3&B"HL94]B,_#9G*8:S,9B2G8[\F*U)RG+S<:0]#B
M//L(7AIYV+'<<2I;#64T#N$,8=A&S*[1ACV,Z!U1RO/:657<*Q'*AW (#'EP
M.>>!SP1SQY\'@D<_'@D#D?S#(_\ 8:D^UY-@^QU6]O3$R42S?V>$^UY2)L=<
M28B22]4]<?3+BN.1I*77E8?CK6R[A;:LIS)]?O\ @K6]=M^KH5*5_69O!0HP
M="L7?X:E' 92%':P##@CG+?#C[BWAIW'GENQ>X\C@\GCD\CR/Y1G.#J%3K#L
MUZM5>NUYXEEM1%X&$&B72"F5.J95-<@1HZY66E/OJ;R_ES*%/.Y3X9<7E5MB
M[<MB-;5NS96+D1"Q/+,(PP4,(Q([!.X*H/;QR%7GX#*K&B<]B(O/Q[5"\_Z>
M .?]>? *ETZKRRT^LU.LUV<?D^N'9H("+$2S4OSEJ]:+21\6.\1D^<XXKT\Q
M;SOG.+SYWBM6<UL7KMM(8[5RU9CKKV5X[%B:9($X [(5D=EB7@ =J!1P!Y>0
MRBQQH6*1HA8\L555+'X\L0 2>?/SS)F P>PC)@4^*&G Y%G,<@),08I,9.8R
MK"LL3($UI^+)9RI*59;?:6C*DXSYOCC',4,TU:5)Z\TL$\3=T4T,CQ2QMP1W
M)(A5T;@D<J0>"1SYY<RJP*L RGR(8 @C\A!\CF'11:0V(%5]NG55 $"^W*!A
M$5X0D0&DLJ<4S(%#<0\0AS[2GG5-O0V67$*=<RE6,K5G.8W[QGFLF[;-FPK+
M8L&S,9YU8 ,LTO?XDJL%4,'9@0!R/(9;X<?:J^&G:OFJ]B]JG\JCC@?Z@,Q5
MJH @S'L!(*)J(F^%@I 5"NQ*IQ3,^"[-&N"D/S%1)@(R1C,Q'/0+A-6 <IZ,
MG$;$IEK/W9JFQF@:O%/-<FU\,\<TE"*X\$<@243%4[X[$$3LX[A(U:4*Y[RC
M'+7B5@Q4(LC*5$A0,1R.WSX*L1QY<=P\O+G-?^E_4T5U)T=K?4\LC3;[:==5
M*/2$;5$:VC4.R6.OP9#CT%@VEVR7$BZXPA;;2T8L"H2L1V5,PHV$)0GHNN.L
M)NLM_M-PL5W75-G=>_\ <B;:/L:M6S(H61H"*M&(!B"0?5A(.YNZ1N><CT*2
MTJ\4)*2/$@C\81"-V4$D!O?D)XY_E<?#RS9./0J-#EDI\2F5.+.-,3(IB9'K
MH=B66C$,YS/CDI#4-+TYB=E6<S&I2W6Y.<YR\E?CGG,/L+[I%&]ZX\<#(\"/
M9F9(7C_O;1*7*QM'_D,@!7_)(R4(HP21&@+ AB$4$@_$$\>8/XP?C^/.M'UM
MKJ(P)BQ:#2HT8! *"P4:/503+ 48<3YAH<)9;@);'0#"/T"D2&EF.03^C+;>
MQ]W+FV>R=IG?8WF:Q)#-89K=AFGEK^<$LQ,A,LD!_O+N6:/_ ""N4$,0[>(H
MQV@A>$7W0WX07R\@WXP/(_CSA]UNLLPL#<ZZHF1R9.9J8'V1K_J29F6L,9EX
MB^S_ $&).6<89R_AOTN6L8;ROS,8QR[[K;7Q#+]T]AXI3PS)ZY9\0Q\]W87\
M3N*=WGV\]O/GQSCP8>./"CXYYX\->.?ASQQQSQ^/,O"IE/'%UV ?5*U /.->
M@<-P@0N*7<8RTVSEE9)B*W,4UEEIIKT:GLH]$TVWYOF(3C&%[MV2$5I+=J2N
M&[A7>Q*T(;DMW")G,8;N9CR%YY)//).5$<8;N"(&^'<%4-QQQQR!S\/+_1G:
M-UJN65N"S8P 6P,C",8P-:-BH)5L>6A95F&4@HGL/IB$8F5KS&G1\-R6,K5Z
M)U'G9\;(+5FJ9#6L3US+$\$I@FDA,L,G'?#(8V4O$_ [XVY1N!R#QE61'X#H
MK@$, RAN&'P(Y!X(_$1YC,+G6^N\Y*9S0J7G)OQ]M9S5@><E_&6B?GVIGU'_
M +?XSFFYN?6_2_\ :VT2/_?(2O&?[I[(>"!L;P%?^\#UNQ]X]PQ_>?OGWO[V
M2GN=ON$K^"2,M\*+S^]1^]^%[B^]Y\^?EY^?GY_C\\_2&N->%@D"M%:%2R=<
M%2O718 A5@<P(-F>D=>];@"I,%R##E>F?>=]8CL-N^D>=7Y_G.+SE'L]E#8D
MM1;"]%:F3PY;,=N=+$J<*O9),L@D=.U57M9B.%4<< 8,43*$:*,HIY52BE0?
MCR%(X!Y)/('X\F#;:&D(::0AMIM"6VVVTX0AM",82A"$)QA*4)3C"4I3C&$X
MQC&,8QCD(DDDDDDDDDGDDGS))/F23\3F3X?#-(] =.DZCVMV%VA=;%K_ &?+
MW=NF7NP&VO4> )S61V55JG4,C@=E+7FZ.RXWLRH#Y#TR&. 3'B+CK_G(CH9B
M-=WU%UJ=SI^F]32J['5)H=$FAL$;GUFOM:ZW+EWQ+%6'740C>+=D54>6RBQ
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M^2[Z3/SO37UK9_AV/:_4_P FW]"G];CW,7#]H'_.O?RG'R7?29^=Z:^M;/\
M#L>U^I_DV_H4_K<>YBX?M _YU[^4X^2[Z3/SO37UK9_AV/:_4_R;?T*?UN/<
MQ</V@?\ .O?RG'R7?29^=Z:^M;/\.Q[7ZG^3;^A3^MQ[F+A^T#_G7OY3CY+O
MI,_.]-?6MG^'8]K]3_)M_0I_6X]S%P_:!_SKW\IQ\EWTF?G>FOK6S_#L>U^I
M_DV_H4_K<>YBX?M _P"=>_E./DN^DS\[TU]:V?X=CVOU/\FW]"G];CW,7#]H
M'_.O?RG'R7?29^=Z:^M;/\.Q[7ZG^3;^A3^MQ[F+A^T#_G7OY3CY+OI,_.]-
M?6MG^'8]K]3_ ";?T*?UN/<Q</V@?\Z]_*<?)=])GYWIKZUL_P .Q[7ZG^3;
M^A3^MQ[F+A^T#_G7OY3CY+OI,_.]-?6MG^'8]K]3_)M_0I_6X]S%P_:!_P Z
M]_*<?)=])GYWIKZUL_P['M?J?Y-OZ%/ZW'N8N'[0/^=>_E./DN^DS\[TU]:V
M?X=CVOU/\FW]"G];CW,7#]H'_.O?RG'R7?29^=Z:^M;/\.Q[7ZG^3;^A3^MQ
M[F+A^T#_ )U[^4X^2[Z3/SO37UK9_AV/:_4_R;?T*?UN/<Q</V@?\Z]_*<?)
M=])GYWIKZUL_P['M?J?Y-OZ%/ZW'N8N'[0/^=>_E./DN^DS\[TU]:V?X=CVO
MU/\ )M_0I_6X]S%P_:!_SKW\IQ\EWTF?G>FOK6S_  ['M?J?Y-OZ%/ZW'N8N
M'[0/^=>_E./DN^DS\[TU]:V?X=CVOU/\FW]"G];CW,7#]H'_ #KW\IQ\EWTF
M?G>FOK6S_#L>U^I_DV_H4_K<^DZ6MZE8PIX,C&<_>I4V1G&,?[\X1"4K/_TQ
MGE\?]BUZ2G=5>STO"I/G))M+K*H_*1%JY'/_ /2ARAZPU0!(2XQ_((8P3_MF
M _\ URQ*OIP:+?:FG9*2\AI6%MPVVLMCD+3GQQEW#F<NS/-SC&<)7AEG/WX<
M9=QSVSH#^QCT73]J#:]7WX^I;L#K+!K(H&@TD4JD%6LK*S6-GVL R)*M6LP)
M2>I87-!LNK;-E&AI1FI&P(:5F#6&4_R2 %AY'D2I=Q\5=3ESXQC&,8QC&,8Q
MC&,8QX8QC'W8QC&/NQC&/U8Y]1@         <  >0  \@ /( ?#.0^/QS]Y7
M&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8
MXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9!-E_U++?^>&_
MZZ,YXWZ?_P#%/U)_WSI3_P!8]/YN^G?\,5?^I<_X*SD[Y[)FDQQC'&,<8QQC
M'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<
M8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC
M'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8R";+_J66_\ /#?]
M=&<\;]/_ /BGZD_[YTI_ZQZ?S=]._P"&*O\ U+G_  5G)WSV3-)CC&.,8XQC
MC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,
M8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQC
MC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQD$V7_ %++?^>&
M_P"NC.>-^G__ !3]2?\ ?.E/_6/3^;OIW_#%7_J7/^"LY.^>R9I,<8QQC'&,
M<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQ
MC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,
M<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC&<>.,X^_P"_'A]V
M<XS]_P#NSCPSC/\ ?C.,X_LY0CD$'G@@CR)!\_R$$$'\A!!'Q!YQ_P#Q^7__
M #FGNY16PJUEZ3'LAPK32#[6<(>D*>6,?2^A^/$FYPGSEM8?;;5#EJS^FI*6
M7L^GPE3_ .6_]E;TYZ<N@&M;"CU[U=U)Z*MW<KD0VKKVY.GKJW(;=+5[<^&7
MEJK=A@;4;-S]]DCBJ7&]=6*6]ZUT?:Z?V/9%+KJ57;P(_OJ@C6S&49))8O,!
M7[&831#X ET'9R$M;4P.]^JHL-XL!E]R4UXC@,F0K"([+B?NEDF_!.<R7$9\
M6(B_NC)SZ1].9.4MQOI/^QHZ/],GW.BZW]+_ %OU3<L;*MW:+HO8776*C4L)
MY;+?0!49MA-&W-362<+KXV\:XAOLD.OY?JF]I#*U#24*D:1-Q/>CC!:5U/\
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M\RJ?LT/V,?: ]\;+_,IOUN/;+J_]:NI/KS:?O6/4*/S*I^S0_8Q]H#WQLO\
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M924=DT4<<:D78F/$H5O$  C9BH3AA\,L]K26YX7=/M9O2)0@!*E[1ZN4/45
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MF&M&EAC7>$RI+,]N-)I/>4>LN/&=7K6EV$5IX0B&BU:3NL>+(LGC))W,2OO
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M%CE;;5<3JRQ)LC(R5.@Q9(T1'E&')$R.W"'R_/\ '%LNHO1 %XX^?6Q191/
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M?##*2Z]L<<P2P. 29H82>8U>.35BQ]":L1<[1#ZO=I-$I?:NGAZI=:. JP_
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M26X;TFNJO90HT[,TICL-''X8<PEC'&[<*[,JD>(H957W@UD?2,L&IN:.OO\
M9P:V5)DHQQI52?7I//XYB6VL0L6(4)>&.-W0^KR/$[R<1LD55Y/,%AR^O1]E
MR1_O!V=U_P!L$1X?7]3 @15BZ^L"T@((,& R*B0 1F2%'+)1,Y=FIB^NH42D
MDYF3#.7[O/\ > :X;U>M>JHSSRN[1WRW>SN_<6= [!3Y+SV\*JKV&-["P\WF
M78,GKVQT>SDCBHUH((I]&L0@CAA@,:I!,T,9D7S<+WCQ&D;Q1M'IS2$741W=
MYMBPOG_?=M8CMHK$E#&8380P3KP"L21<%QN7)S*%X&5@0IK$E&)29F2#SC[K
M$J/%A:RW=:VE-#&$]3JK54AB>]%=Y S @<-W2-SP>..T  @ENDU6G75S;B99
MS/\ =C9/LY5:,((99((*[1(0[=T?AUXB.X=W?XA+$,JI -3]8RNB $[6^HML
M%JSIQXV>,U^ED:J$L![7+5E*RSA8#KNWS'V8T$ @N0GS1<.XU:\R1F9CK+<U
MUA+*&L]K9+>D%BW522WV(DDRRO&E@QH$62Q$.2TG:JAFAE@#< E0>>86LZ=D
MTL#Z_5[.6OJC--+!4DK0SS4!8E>:6"C:8A4@\61WC2W6N-'W$!RO $?L_26C
M66=L6 [9ST?7NW]G:RV]LNE.-HGS#ESU;FK.#/9]LER%$182RR:159=RA28I
M8H1?@2U!C=?P3DXQ?'N)HUKL(T-BI7L5:\P]U4AL^*&[H@O:[QB:41,"JJ&'
M>DG:#D>STA3L/?C-B9:.TV.OVNPJ$!WFMZXUC'X=IF\2*&PU.LUM&2620HQA
MF@\1LP WHR*@DJU/D;&(3FZ]VEV7VK<B.5F(RV2MFTX9Z!8*NZMLOE<>L1HU
MH.X&>C\XLRXZ/7)(2DPGD3LC[IV611752^LK:L$2$]L54H8Y>"OG*?"3N^"?
MA<*.X=N&+HZ.-Z[F^[B#J/8=2E374"2SLDG2>L2)?=KJMF;P^.902A9V"$/6
M5JZ06;7G6"\Z3U=:SNR0:QPJK4"F%J[I\<?K]+F;#KYLXTJUV$##BWFR5:N1
MB::2BV&:R.??8B1YY8>70)M0*3%N8Y]E#<LQI7;N:6>5)+;1O,M>1$(B21C#
M'+*5,WA+(P!)52G=$^NM='V*/3ES4:ZS/L(3''6I5)8-4D\--[T$TP]9G@1+
MEBM7644Q9EK1LP57ECE$5F#ITGI9?+<.A%;U:I]&MU'VA!VQK6XS-;ZEC[!E
MVXI6#5.V+C;86JV[9=#V,!LU6D@10XE,/QKC&4.DLN2H \>(;D5FW$,3%8(Q
M-%-6:K8A%BT:XB61):YJ/+%7GKO'*)&90AB/<" S,Q%E3I*[:C26Y9DIVJ>Q
M39Z^T^OUBWFM25Y:EX;6*M:V%+80V*S011R-,EI>Q@61$B!W*V-UXKFU]#$]
M$7<^;GCBK0J2_:A\6OA3<:Q K3 NX,^.'BP\:N0\B;0,'S8@M(A8]R'$0.G-
MS&W9+K^I@OR5KRWH4164L!&QD=#&\30NC,SF0]T3,"_?W!CW*00 .LV&BK[/
M2R:6Y/,\<HC8V8U@AF6>&RER&:-(XEKKX5F.-UC\(QE%".'!8M2]UZ1C+V6N
M-P,;"EL7_8&U-$;1MA\?6([(EUWKCEA[6=6"UY\U*6, M3432%A=F&"Y@M*,
M$TQ20J)[.BCI<.X:!8HD@!@@K7:T4;2DL!?Y%F5Y @[I".U8^U$1 B\JQ[BV
MIM]'QW);=N6\RWK^RTNQM3QUP(B=!P==6A@:9C'"'#R3EII996ED"R1)X:QW
M#V4T UV0H >@$[9(JD,9=Z7>WB(P.R1ERBM$.PK&&BMMS)[;$8>^4@L^T6U)
ME2'H?G1X\F*[G,G,37WCKYVG6(2EH9H0K.5 6=#&Y)"\E@K'M^ #>9!'EFUZ
M@T@W]**C)9:LD=RI=+QQ"1VDI3)8B4!W"JC2(/$!#,5\E93[V5"2Z/@4"^QE
M5INP#-(UYV@J9P5L'6PX+!F4T#<[6*D!K=L?6\"1,;DU W984E;A02J86 22
M*&2$F!(=892W*7</WT)9H$FGUTJ-7L,Y69X8F#Q5[+!2)DC(X5^U) I*A@"<
MU4G1\(CWU:I>EIT>HJTT5[7QPH]2"W9C:*U?UZ,X:K-81B9(BTL+2<.4)4 1
MV[^3YJ>PG[))L&Q;%&EFM5:/UN)G @PN%-K)+K_9,V^B72![2>,P9I%RP/S%
MG!)2!*$SQ;S(]EJ&ZPY.DY8=]- (PD$9"6KEAE=V*RK>C,4T+=H5@H3CL96#
M*P+'NY &"[T/6OFPT]^=&FUNGU\;P0QH]>326#:I6T\0S(TAG9S-%)&T3QD(
M I4NUBDNJ1,H8TK=I.WRZ-E:6M5TL8NS0Z)1A@,E'V!2%4"RB/L8)'0!L)O(
M7#<P40=EDIT0SEZ3-<*#EQQ42.NT55N0^JH:]R*&-HS/.SJ8)A/&_C.S,Q[Q
MPR@*I3@ *W+&?)TU))+J+C;247]39MV(["4J<<,BW:9HV(O5(XTC0>%P\<A:
M1UFY9S)'VQ+ Z#T+%:\AZ4ABMH&R*-'Z^WKK^O.%ZV+<=*Q=^$VR]E(&/9TT
M:WEX/-BP<@V(;<9*66Y;4]V9F4RY"SS[QYVN,U9%-V>E/)VR-PIHKVQJG<K'
MAP3WDD^?':%X/,&ET5%034)%L9I!IZ.YHP&6O&3*F[D$MAY?#>,<PNJ>"$"^
M0<.7[E*85GR>L"#6ZC7PV[;U6GZ7U8.]4@MDK(^&&LK%3,V$)8TVALFS/6J-
M9FI%:#P)*H;<>#+&.&668\&21B2Q=QWI:261Z<,@FV<>S>.1B\9E2-X_"*E?
M.,B1V')+!NPDL%8/B'0R)7JP1;>Y7:ITW-TU#8KQK#86M+-#.+(D60]MA6KQ
M(Q0!&C,RA4:1'BXI7DZJY+!;I$IV>2%/;G?Z_EIJZY0J570]8L?7H["/UHB#
MKHN*Q 4/+2H*&RPN8MU]U+\MYPK(E.MOLU&_D$E-Q65A3%Y5\2>:1Y([R&.1
M7D<ENY Q*,/(< =@4<&C=!UVAV\0V,D9VYT<C^!2J015K&BF2:O)#!&BIX<K
M(!+$Y+$,Q,K,0PL2T](ZC;G=FCBUTL$BH;QN.I-@[D .CQ2)UMMVH5U=X?,%
M&8+8]FK#;>_2ZTY=1<,-,S)Q"DIK,RK9GR%<P1;F6+U9EAC$U**U!4<,W;%%
M:$@971NXRM$)I/!9G''(\02]HR?9Z/JVCL8Y;<[5=Q;U=[;0%(@]FUJS7:-H
MI4"+6CM-4KFY&L+]P1A7>MWL<ZM;Z2!ZI;H>QQ5^FKV&#W[NG?U8,SJ['?##
MRF_@2Z[L2G$P#)>*Z7JC\'$20%4R8%6 80&P7W3<YC$N),K)N7EB-=X%]7>C
M3HR()"'9*+]]>59.PA)0>0_*-&RLP"*>"+*_1\5:TFPBNN;\.[V^[K3/75HH
MY-W!ZO?J20"53+6*!&B*RQ3QO&A,SKWH^K&Q>C=SK%AH]4U:,M9K7XC5UR!G
M[2FOZ&O3UVMFSMJE=B[$&;/J>RK7K!U^H$"6!)0>+"D+37W429HE=9#*&XFV
M+95]S#(D\MEHDL/9BDCB[[L'@Q5JRP5VK2UXK $JKW(6=8Y!P&\5N_A.<O\
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MQ"U-QH[DF&M_$EV7)??2%K$D=6**>S;J7Y) \C*+51VD5TC;R".[%F1F?S)
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MX)2G&"SSHH5)I44<\*LCJHY/)X ('F22?+S.4DI4Y7,DM2K+(>.9)*\3N>
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ME.^E]+)+9AQF?:,AST[_ *1Z9Z9Q?IG?.5GTB_&K2ROV=\DC]@X3N=F[ ..
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M0YYY8'\C<C!J566)&K5V2!@\"F&,K"X\PT2E>(V!\PR!2/RYB<:YJ:+>=NS
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MBO<"K<$CN4D$J>/B"0"0?+D#\F9&1'[2Z*Y1@Z=RANQP" Z\@]K ,0&'! )
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MTZK",KSG.,YA,C(S*1^ Q0D<\=P)''/\_!X_'QFXCE25(W4\>+&LJ*W ?L8
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M$=F:IOF[!K6S ]L%%9NA::8?I3M=K( * KPF*0V0/UA+:GPHKILP%IRL6V'
MD# RY=MK8P'U@I9-AUKVH*;>K/$RK>F03^)))))(W%=K*]I(5'F^]%@SA<NN
MZ>O T$FUJZ^&38ZR[N(QL8;,4CZ2I,:9@KP0PP1K)L(]:P=$,TL-3^ZEC:*'
MNJ*!TMW,YK;>U/N=)@VW9I6B=KJA4MQIV:,8&;+8W[-/&*N[9*CD%!*.D0AF
M95I!+-Y,$HE,75/:-"DSGGH\#$H[BF+-&6*8Q5DGU<LM7U9B]<T1&DHCE\1E
M"N@E"^ BF82]LX'FV:M.D=L==NJENHEK8RTNIJE7:_=&,1[!=Y)-+7:Q5\!)
M#)#*U9I/7)95J&L'I.Y(06[IWJGM*A[**%*FAC0@@_U%T/JXC;J+!UL4GL[A
MUW9C!BVGI%4(PCE=..%0AC[/LV4T%(3'V\D%I3$6R-FNQ;>SK35U27F\R;:[
M96*9K"KZI/$B1()5*2(%=?$,:.H![>0P+ ;34]-;*EL))*P7213]+:76R6J2
M:^1QM:%B66U.U:1)H)C)#+ZN)Y89&8>(1V$1N8AV Z@]B+_>ML$J;:&)I.W]
M,*[I%O:MB>J]8GW6_@]RXV"8B6<+2X$)L:"N%'2JAS2@^OH9CIE/L*$K&,-O
M/Y*.UH00U5FB*I%MY+AJH)95A@>IX"-&\Q/<\4WW\*TG)*@ANX\"+O.EM]>N
M[.2I95I;724&G&RG->O);O0[;UZ5;$-1$$<-JG_<3R)" O<RF+PU!:UM9]>;
MBBY:U(EM:>[*C1=D6C?.P:S,V2'NS+VS ^O(>N:5%C"@ @%6A$">]8B]Q6W6
M1V(#Q2@![!8%QK$<7 1&L7X3#85)_6)C7BI5Y5KO"17><V)B6D:21V 18N9&
M[@L[I'S&O)V>OT5L6]?)+K_N?36_8W5^NVPBMJ=A%02A358H(H*\2.T\MHBO
M'X;2489YRL\WAC2OJ;HTCLBN4;8.H:E2JS;=,=L.VMED[.3-!PLW"IR3.V 0
M#4,MRLNNVW-=L5B.UI\O&)Q(H894@2R@*5,)2X,'FWVEQ:\D\%J6:2*WK-7&
M*W#D12A*KO;42#PN^...0(58NTLG8X"AFSD>FM-)?@IWM55IU[6IZEZGL/L>
M^%/6JK3;.&#5,:Q-KP)YYJYE615ABJPF2!GD9$S.1.F79*95=E#)NMZX'QL+
MH$6Z]KK,&TT!BO#-SHL\@H F1(0B%#<>J()\K/GUBS6DW=;]#'9E2"YV2>?1
M ?M.WURRUF6Q(W@;Q;XE:.<R&GX06126)XED[562.)(8"> B",$C,G26_>ML
M(WH5XA>Z(ET1K)9I"O'MA9,D#HD:*35@,LCU[%F:Y=6/N,LS3$(V5V?T8VQ=
M@/9IR%J^J*N6QNO_ %1I.JSI$G3,$J[L;3S<MJZETF42Y$^NN91+'(''!;CD
MLDT%4AS#&&1R)-M;<U(9-=W69!#7O[.>TBI-VR5[9!B3L[0).>&#(WDI?GSY
M;C)LNC=G<K]0]FNJFW?T?3-/6SR25!)!?U087)1*&9ZYX= DT1+2"$@\<1]V
MX7;#KWN3<6D^P]6#;#-W3.U]?R %$TU:06JP=8HEBFSP4N&4Q<1@&-9I3P/$
M";A;A*SGF<9FR'H;4R3'&.,ZG5WZE2YKY7@2#U6<23W(GLO)-&JN"OA,YC ?
MN7\&-#Y 'M!8'JNIM%MMKJ-[6AOS6_NE2:"EJ;,.MAKTIWD@=9?6XX5L,80C
M@E[$P]]BJNRQD:N[CZ6;0OLSMS8P^K*SBV[7@=/Y.GC\\C2F3M9/Z<E"Y6QY
MV33<Y^=6)TI$3#$.>(DO.FUQD)DNLLX96K8U-O6A751O:D\*JVU%N,+.4DCM
MAA77L[>V11SRRL $Y\@?/.<VW2.QNOU18BUM?UK9ITJVJG>2F)J\VJ:)M@_B
M]Y>N[!.U'B8F8KPQ"\$R/:74W=%N/=A9E<J<.2$V[1NRL# #84G7)UP->-AU
M9RI:]L>L;^/?B7D) -I;!%KY1[P@O5ZED2^_2)LJ>.K\?..MM*D4=!9)2'JS
MZ]N^ 6$[X8)1+/'9@8&!RG,BP30=LLH<"=0&<Y(V73&VM3[UJ]5&AVE/J!/
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I;#84PLT,H]4N>%(H[8(H(HF$HE:2..&*/Q'9D0!N3N;S49UF.,9__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
